id	compound_id	pk_adm_other_routes	pk_age_group	pk_analyte_cid	pk_analyte_mw	pk_analyte_pt	pk_analyte_query	pk_analyte_smiles	pk_analyte_tissue	pk_analyte_unii	pk_application_cid	pk_application_mw	pk_application_pt	pk_application_query	pk_application_smiles	pk_application_unii	pk_auc_hours	pk_auc_other_units	pk_auc_type	pk_auc_units	pk_auc_value	pk_cmax_other_units	pk_cmax_units	pk_cmax_value	pk_dose_other_types	pk_dose_other_units	pk_dose_type	pk_dose_units	pk_dose_value	pk_exp_other_types	pk_experiment_type	pk_food_status	pk_frequency_other_period	pk_frequency_period	pk_frequency_times	pk_funbound_comment	pk_funbound_value	pk_health_status	pk_routes	pk_sex	pk_source_type	pk_source_uri	pk_species	pk_thalf_other_units	pk_thalf_units	pk_thalf_value	pk_application_comment	pk_population_comment	pk_application_combo_comment	pk_population_size	pk_annotated_form	pk_analyte_other_tissue	pkappcombo
1	3		ADULT	2160	277.4033	AMITRIPTYLINE	AMITRIPTYLINE	CN(C)CCC=C1C2=CC=CC=C2CCC3=C1C=CC=C3	PLASMA	1806D8D52K									∞	ng × h/mL	593		ng/mL	15.3			RECOMMENDED	mg	75		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10383563	Homo sapiens		h	20.4							false
2	3		ADULT	2160	277.4033	AMITRIPTYLINE	amitriptyline	CN(C)CCC=C1C2=CC=CC=C2CCC3=C1C=CC=C3	PLASMA	1806D8D52K																	RECOMMENDED	mg	150		MULTIPLE	FASTED		day	1		7.7	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6125396	Homo sapiens										false
3	4			214348	373.3615	DEFERASIROX	DEFERASIROX	OC(=O)C1=CC=C(C=C1)N2N=C(N=C2C3=C(O)C=CC=C3)C4=C(O)C=CC=C4	PLASMA	V8G4MOF2V9							24		t	μM × h	6.513							mg/kg	10		STEADY-STATE			day	1				Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01709838	Homo sapiens										false
4	4			214348	373.3615	DEFERASIROX	DEFERASIROX	OC(=O)C1=CC=C(C=C1)N2N=C(N=C2C3=C(O)C=CC=C3)C4=C(O)C=CC=C4	PLASMA	V8G4MOF2V9							2		t	μM × h	48.556							mg/kg	10		STEADY-STATE			day	1				Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01709838	Homo sapiens										false
5	4			214348	373.3615	DEFERASIROX	DEFERASIROX	OC(=O)C1=CC=C(C=C1)N2N=C(N=C2C3=C(O)C=CC=C3)C4=C(O)C=CC=C4	PLASMA	V8G4MOF2V9							4		t	μM × h	44.652							mg/kg	10		STEADY-STATE			day	1				Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01709838	Homo sapiens										false
6	4		ADULT	214348	373.3615	DEFERASIROX	DEFERASIROX	OC(=O)C1=CC=C(C=C1)N2N=C(N=C2C3=C(O)C=CC=C3)C4=C(O)C=CC=C4	PLASMA	V8G4MOF2V9							24		t	μM × h	688		μM	46.5			UNKNOWN	mg	1000		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/20097723	Homo sapiens		h	9.4							false
7	4		ADULT	214348	373.3615	DEFERASIROX	DEFERASIROX	OC(=O)C1=CC=C(C=C1)N2N=C(N=C2C3=C(O)C=CC=C3)C4=C(O)C=CC=C4	PLASMA	V8G4MOF2V9							24		t	μM × h	3172		μM	220			UNKNOWN	mg/kg	30		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26093827	Homo sapiens		h	12							false
8	5		ADULT	154234|86310107	328.4072	PERAMIVIR ANHYDROUS	PERAMIVIR ANHYDROUS	CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O	SERUM	9ZS94HQO3B									∞	ng × h/mL	102700		ng/mL	46800			RECOMMENDED	mg	600		SINGLE	UNKNOWN				In vitro binding of peramivir to human plasma proteins is less than 30%.	70	HEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206426lbl.pdf	Homo sapiens		h	20							false
9	6		ADULT	53234134	666.7	Ceftolozane	CC(C)(C(=O)O)ON=C(C1=NSC(=N1)N)C(=O)NC2C3N(C2=O)C(=C(CS3)C[N+]4=CC(=C(N4C)N)NC(=O)NCCN)C(=O)[O-]	CC(C)(C(=O)O)ON=C(C1=NSC(=N1)N)C(=O)NC2C3N(C2=O)C(=C(CS3)C[N+]4=CC(=C(N4C)N)NC(=O)NCCN)C(=O)[O-]	PLASMA	37A4IES95Q	123630		TAZOBACTAM	tazobactam	C[C@]2(CN1C=CN=N1)[C@@H](N3[C@@H](CC3=O)S2(=O)=O)C(O)=O	SE10G96M8W	8		t	μg × h/mL	182		μg/mL	74.4			RECOMMENDED	g	1		STEADY-STATE	UNKNOWN		day	3		81.5	HEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206829lbl.pdf	Homo sapiens		h	3.12							true
10	6		ADULT	53234134	666.7	Ceftolozane	CC(C)(C(=O)O)ON=C(C1=NSC(=N1)N)C(=O)NC2C3N(C2=O)C(=C(CS3)C[N+]4=CC(=C(N4C)N)NC(=O)NCCN)C(=O)[O-]	CC(C)(C(=O)O)ON=C(C1=NSC(=N1)N)C(=O)NC2C3N(C2=O)C(=C(CS3)C[N+]4=CC(=C(N4C)N)NC(=O)NCCN)C(=O)[O-]	PLASMA	37A4IES95Q	123630		TAZOBACTAM	tazobactam	C[C@]2(CN1C=CN=N1)[C@@H](N3[C@@H](CC3=O)S2(=O)=O)C(O)=O	SE10G96M8W	8		t	μg × h/mL	172		μg/mL	69.1			RECOMMENDED	g	1		SINGLE	UNKNOWN					81.5	HEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206829lbl.pdf	Homo sapiens		h	2.77							true
11	7		ADULT	56640146	493.575	DASABUVIR	DASABUVIR	COC1=C(C=C(C=C1C2=CC3=C(C=C2)C=C(NS(C)(=O)=O)C=C3)N4C=CC(=O)NC4=O)C(C)(C)C	PLASMA	DE54EQW8T1							12		t	ng × h/mL	2620		ng/mL	320			UNKNOWN	mg	200		MULTIPLE	UNKNOWN		day	2	Dasabuvir is >99.9% bound to human plasma proteins over a concentration range of 0.1–10 uM (0.05–5 ug/mL)	0.1	HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/28258380/	Homo sapiens										false
12	7		ADULT	56640146	493.575	DASABUVIR	DASABUVIR	COC1=C(C=C(C=C1C2=CC3=C(C=C2)C=C(NS(C)(=O)=O)C=C3)N4C=CC(=O)NC4=O)C(C)(C)C	PLASMA	DE54EQW8T1							12		t	ng × h/mL	7050		ng/mL	912			UNKNOWN	mg	400		MULTIPLE	UNKNOWN		day	2	Dasabuvir is >99.9% bound to human plasma proteins over a concentration range of 0.1–10 uM (0.05–5 ug/mL)	0.1	HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/28258380/	Homo sapiens		h	6.87							false
13	7		ADULT	56640146	493.575	DASABUVIR	DASABUVIR	COC1=C(C=C(C=C1C2=CC3=C(C=C2)C=C(NS(C)(=O)=O)C=C3)N4C=CC(=O)NC4=O)C(C)(C)C	PLASMA	DE54EQW8T1							12		t	ng × h/mL	8800		ng/mL	1130			UNKNOWN	mg	600		MULTIPLE	UNKNOWN		day	2	Dasabuvir is >99.9% bound to human plasma proteins over a concentration range of 0.1–10 uM (0.05–5 ug/mL)	0.1	HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/28258380/	Homo sapiens		h	6.87							false
14	7		ADULT	56640146	493.575	DASABUVIR	DASABUVIR	COC1=C(C=C(C=C1C2=CC3=C(C=C2)C=C(NS(C)(=O)=O)C=C3)N4C=CC(=O)NC4=O)C(C)(C)C	PLASMA	DE54EQW8T1							12		t	ng × h/mL	15800		ng/mL	2110			UNKNOWN	mg	1000		MULTIPLE	UNKNOWN		day	2	Dasabuvir is >99.9% bound to human plasma proteins over a concentration range of 0.1–10 uM (0.05–5 ug/mL)	0.1	HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/28258380/	Homo sapiens		h	6.52							false
15	8			23725625	434.4628	OLAPARIB	OLAPARIB	FC1=C(C=C(CC2=NNC(=O)C3=C2C=CC=C3)C=C1)C(=O)N4CCN(CC4)C(=O)C5CC5	PLASMA	WOH1JD9AR8							12		t	μg × h/mL	43.95							mg	300		SINGLE			day	2			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02430311	Homo sapiens										false
16	8			23725625	434.4628	OLAPARIB	OLAPARIB	FC1=C(C=C(CC2=NNC(=O)C3=C2C=CC=C3)C=C1)C(=O)N4CCN(CC4)C(=O)C5CC5	PLASMA	WOH1JD9AR8							12		t	μg × h/mL	43.91							mg	300		SINGLE			day	2			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02430311	Homo sapiens										false
17	8			23725625	434.4628	OLAPARIB	OLAPARIB	FC1=C(C=C(CC2=NNC(=O)C3=C2C=CC=C3)C=C1)C(=O)N4CCN(CC4)C(=O)C5CC5	PLASMA	WOH1JD9AR8													μg/mL	6.875				mg	300		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02430311	Homo sapiens										false
18	8			23725625	434.4628	OLAPARIB	OLAPARIB	FC1=C(C=C(CC2=NNC(=O)C3=C2C=CC=C3)C=C1)C(=O)N4CCN(CC4)C(=O)C5CC5	PLASMA	WOH1JD9AR8							12		t	μg × h/mL	31.68							mg	300		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02430311	Homo sapiens										false
19	8			23725625	434.4628	OLAPARIB	OLAPARIB	FC1=C(C=C(CC2=NNC(=O)C3=C2C=CC=C3)C=C1)C(=O)N4CCN(CC4)C(=O)C5CC5	PLASMA	WOH1JD9AR8							48		t	μg × h/mL	36.37							mg	300		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02430311	Homo sapiens										false
20	8			23725625	434.4628	OLAPARIB	OLAPARIB	FC1=C(C=C(CC2=NNC(=O)C3=C2C=CC=C3)C=C1)C(=O)N4CCN(CC4)C(=O)C5CC5	PLASMA	WOH1JD9AR8									?	μg × h/mL	36.53							mg	300		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02430311	Homo sapiens										false
21	8		UNKNOWN	23725625	434.4628	OLAPARIB	OLAPARIB	FC1=C(C=C(CC2=NNC(=O)C3=C2C=CC=C3)C=C1)C(=O)N4CCN(CC4)C(=O)C5CC5	PLASMA	WOH1JD9AR8																						UNKNOWN				The in vitro protein binding of olaparib is approximately 82%	18	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208558s001lbl.pdf	Homo sapiens										false
22	8		ADULT	23725625	434.4628	OLAPARIB	OLAPARIB	FC1=C(C=C(CC2=NNC(=O)C3=C2C=CC=C3)C=C1)C(=O)N4CCN(CC4)C(=O)C5CC5	BLOOD	WOH1JD9AR8							12		t	μg × h/mL	31.7		μg/mL	6.88			UNKNOWN	mg	300		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/30887180	Homo sapiens		h	6.52							false
23	8		ADULT	23725625	434.4628	OLAPARIB	OLAPARIB	FC1=C(C=C(CC2=NNC(=O)C3=C2C=CC=C3)C=C1)C(=O)N4CCN(CC4)C(=O)C5CC5	BLOOD	WOH1JD9AR8							12		t	μg × h/mL	10.9		μg/mL	2.97			UNKNOWN	mg	100		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/30887180	Homo sapiens		h	7.17							false
24	8		ADULT	23725625	434.4628	OLAPARIB	OLAPARIB	FC1=C(C=C(CC2=NNC(=O)C3=C2C=CC=C3)C=C1)C(=O)N4CCN(CC4)C(=O)C5CC5	BLOOD	WOH1JD9AR8									∞	μg × h/mL	44		μg/mL	8.27			UNKNOWN	mg	300		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/30887180	Homo sapiens										false
25	8		ADULT	23725625	434.4628	OLAPARIB	OLAPARIB	FC1=C(C=C(CC2=NNC(=O)C3=C2C=CC=C3)C=C1)C(=O)N4CCN(CC4)C(=O)C5CC5	BLOOD	WOH1JD9AR8									∞	μg × h/mL	16.7		μg/mL	3.75			UNKNOWN	mg	100		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/30887180	Homo sapiens										false
26	9		ADULT	11567473	398.3877	FINAFLOXACIN	FINAFLOXACIN	OC(=O)C1=CN(C2CC2)C3=C(C#N)C(N4C[C@@H]5NCCO[C@H]5C4)=C(F)C=C3C1=O	PLASMA	D26OSN9Q4R									∞	mg × h/L	1.26		mg/L	0.44			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21709093/	Homo sapiens		h	3.8							false
27	9		ADULT	11567473	398.3877	FINAFLOXACIN	FINAFLOXACIN	OC(=O)C1=CN(C2CC2)C3=C(C#N)C(N4C[C@@H]5NCCO[C@H]5C4)=C(F)C=C3C1=O	PLASMA	D26OSN9Q4R									∞	mg × h/L	4.08		mg/L	1.9			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21709093/	Homo sapiens		h	4.06							false
28	9		ADULT	11567473	398.3877	FINAFLOXACIN	FINAFLOXACIN	OC(=O)C1=CN(C2CC2)C3=C(C#N)C(N4C[C@@H]5NCCO[C@H]5C4)=C(F)C=C3C1=O	PLASMA	D26OSN9Q4R									∞	mg × h/L	29.2		mg/L	11.1			UNKNOWN	mg	800		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21709093/	Homo sapiens		h	10.5							false
29	9		ADULT	11567473	398.3877	FINAFLOXACIN	FINAFLOXACIN	OC(=O)C1=CN(C2CC2)C3=C(C#N)C(N4C[C@@H]5NCCO[C@H]5C4)=C(F)C=C3C1=O	PLASMA	D26OSN9Q4R							24		t	mg × h/L	3.76		mg/L	1.69			UNKNOWN	mg	150		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21709093/	Homo sapiens										false
30	9		ADULT	11567473	398.3877	FINAFLOXACIN	FINAFLOXACIN	OC(=O)C1=CN(C2CC2)C3=C(C#N)C(N4C[C@@H]5NCCO[C@H]5C4)=C(F)C=C3C1=O	PLASMA	D26OSN9Q4R							24		t	mg × h/L	4.01		mg/L	1.5			UNKNOWN	mg	150		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21709093/	Homo sapiens		h	5.3							false
31	9		ADULT	11567473	398.3877	FINAFLOXACIN	FINAFLOXACIN	OC(=O)C1=CN(C2CC2)C3=C(C#N)C(N4C[C@@H]5NCCO[C@H]5C4)=C(F)C=C3C1=O	PLASMA	D26OSN9Q4R							24		t	mg × h/L	8.75		mg/L	2.96			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21709093/	Homo sapiens										false
32	9		ADULT	11567473	398.3877	FINAFLOXACIN	FINAFLOXACIN	OC(=O)C1=CN(C2CC2)C3=C(C#N)C(N4C[C@@H]5NCCO[C@H]5C4)=C(F)C=C3C1=O	PLASMA	D26OSN9Q4R							24		t	mg × h/L	9.09		mg/L	4.15			UNKNOWN	mg	300		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21709093/	Homo sapiens		h	6.5							false
33	9		ADULT	11567473	398.3877	FINAFLOXACIN	FINAFLOXACIN	OC(=O)C1=CN(C2CC2)C3=C(C#N)C(N4C[C@@H]5NCCO[C@H]5C4)=C(F)C=C3C1=O	PLASMA	D26OSN9Q4R							24		t	mg × h/L	18.7		mg/L	7.67			UNKNOWN	mg	600		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21709093/	Homo sapiens										false
34	9		ADULT	11567473	398.3877	FINAFLOXACIN	FINAFLOXACIN	OC(=O)C1=CN(C2CC2)C3=C(C#N)C(N4C[C@@H]5NCCO[C@H]5C4)=C(F)C=C3C1=O	PLASMA	D26OSN9Q4R							24		t	mg × h/L	19.2		mg/L	6.76			UNKNOWN	mg	600		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21709093/	Homo sapiens		h	8.8							false
35	9		ADULT	11567473	398.3877	FINAFLOXACIN	FINAFLOXACIN	OC(=O)C1=CN(C2CC2)C3=C(C#N)C(N4C[C@@H]5NCCO[C@H]5C4)=C(F)C=C3C1=O	PLASMA	D26OSN9Q4R							24		t	mg × h/L	20.8		mg/L	8.68			UNKNOWN	mg	800		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21709093/	Homo sapiens										false
36	9		ADULT	11567473	398.3877	FINAFLOXACIN	FINAFLOXACIN	OC(=O)C1=CN(C2CC2)C3=C(C#N)C(N4C[C@@H]5NCCO[C@H]5C4)=C(F)C=C3C1=O	PLASMA	D26OSN9Q4R							24		t	mg × h/L	26.1		mg/L	8.95			UNKNOWN	mg	800		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21709093/	Homo sapiens		h	14							false
37	9		ADULT	11567473	398.3877	FINAFLOXACIN	FINAFLOXACIN	OC(=O)C1=CN(C2CC2)C3=C(C#N)C(N4C[C@@H]5NCCO[C@H]5C4)=C(F)C=C3C1=O	PLASMA	D26OSN9Q4R									∞	mg × h/L	6.85		mg/L	2.56			UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28784673/	Homo sapiens		h	10.6							false
38	9		ADULT	11567473	398.3877	FINAFLOXACIN	FINAFLOXACIN	OC(=O)C1=CN(C2CC2)C3=C(C#N)C(N4C[C@@H]5NCCO[C@H]5C4)=C(F)C=C3C1=O	PLASMA	D26OSN9Q4R									∞	mg × h/L	14.7		mg/L	6			UNKNOWN	mg	400		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28784673/	Homo sapiens		h	12.1							false
39	9		ADULT	11567473	398.3877	FINAFLOXACIN	FINAFLOXACIN	OC(=O)C1=CN(C2CC2)C3=C(C#N)C(N4C[C@@H]5NCCO[C@H]5C4)=C(F)C=C3C1=O	PLASMA	D26OSN9Q4R									∞	mg × h/L	21.8		mg/L	8			UNKNOWN	mg	600		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28784673/	Homo sapiens		h	11.7							false
40	9		ADULT	11567473	398.3877	FINAFLOXACIN	FINAFLOXACIN	OC(=O)C1=CN(C2CC2)C3=C(C#N)C(N4C[C@@H]5NCCO[C@H]5C4)=C(F)C=C3C1=O	PLASMA	D26OSN9Q4R									∞	mg × h/L	31.7		mg/L	13.3			UNKNOWN	mg	800		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28784673/	Homo sapiens		h	15.3							false
41	9		ADULT	11567473	398.3877	FINAFLOXACIN	FINAFLOXACIN	OC(=O)C1=CN(C2CC2)C3=C(C#N)C(N4C[C@@H]5NCCO[C@H]5C4)=C(F)C=C3C1=O	PLASMA	D26OSN9Q4R									∞	mg × h/L	46.9		mg/L	20.2			UNKNOWN	mg	1000		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28784673/	Homo sapiens		h	17.1							false
42	9		ADULT	11567473	398.3877	FINAFLOXACIN	FINAFLOXACIN	OC(=O)C1=CN(C2CC2)C3=C(C#N)C(N4C[C@@H]5NCCO[C@H]5C4)=C(F)C=C3C1=O	PLASMA	D26OSN9Q4R							24		t	mg × h/L	21.8		mg/L	8.84			UNKNOWN	mg	600		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28784673/	Homo sapiens										false
43	9		ADULT	11567473	398.3877	FINAFLOXACIN	FINAFLOXACIN	OC(=O)C1=CN(C2CC2)C3=C(C#N)C(N4C[C@@H]5NCCO[C@H]5C4)=C(F)C=C3C1=O	PLASMA	D26OSN9Q4R							24		t	mg × h/L	24.3		mg/L	9.15			UNKNOWN	mg	600		MULTIPLE	UNKNOWN		day	1			HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28784673/	Homo sapiens		h	11.9							false
44	9		ADULT	11567473	398.3877	FINAFLOXACIN	FINAFLOXACIN	OC(=O)C1=CN(C2CC2)C3=C(C#N)C(N4C[C@@H]5NCCO[C@H]5C4)=C(F)C=C3C1=O	PLASMA	D26OSN9Q4R							24		t	mg × h/L	32		mg/L	11.5			UNKNOWN	mg	800		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28784673/	Homo sapiens										false
45	9		ADULT	11567473	398.3877	FINAFLOXACIN	FINAFLOXACIN	OC(=O)C1=CN(C2CC2)C3=C(C#N)C(N4C[C@@H]5NCCO[C@H]5C4)=C(F)C=C3C1=O	PLASMA	D26OSN9Q4R							24		t	mg × h/L	35.4		mg/L	37.8			UNKNOWN	mg	800		MULTIPLE	UNKNOWN		day	1			HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28784673/	Homo sapiens		h	15							false
46	9		ADULT	11567473	398.3877	FINAFLOXACIN	FINAFLOXACIN	OC(=O)C1=CN(C2CC2)C3=C(C#N)C(N4C[C@@H]5NCCO[C@H]5C4)=C(F)C=C3C1=O	PLASMA	D26OSN9Q4R							24		t	mg × h/L	49.8		mg/L	17.1			UNKNOWN	mg	1000		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28784673/	Homo sapiens										false
47	9		ADULT	11567473	398.3877	FINAFLOXACIN	FINAFLOXACIN	OC(=O)C1=CN(C2CC2)C3=C(C#N)C(N4C[C@@H]5NCCO[C@H]5C4)=C(F)C=C3C1=O	PLASMA	D26OSN9Q4R							24		t	mg × h/L	64.1		mg/L	18.1			UNKNOWN	mg	1000		MULTIPLE	UNKNOWN		day	1			HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28784673/	Homo sapiens		h	16.9							false
48	10		UNKNOWN	40632	185.2218	PIRFENIDONE	PIRFENIDONE	CC1=CN(C(=O)C=C1)C2=CC=CC=C2	PLASMA	D7NLD2JX7U																						UNKNOWN				binds to human plasma proteins, primarily to serum albumin, in a concentration-independent manner over the range of concentrations observed in clinical trials. The overall mean binding was 58% at concentrations observed in clinical studies (1 to 10 ug/mL).	42	HEALTHY		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022535s000lbl.pdf	Homo sapiens		h	3							false
49	10		ADULT	40632	185.2218	PIRFENIDONE	PIRFENIDONE	CC1=CN(C(=O)C=C1)C2=CC=CC=C2	PLASMA	D7NLD2JX7U									∞	ng × h/mL	98000		ng/mL	6560			RECOMMENDED	mg	801		SINGLE	HIGH-FAT						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/28808905	Homo sapiens		h	2.75							false
50	11		UNKNOWN	9809715	539.6248	NINTEDANIB	NINTEDANIB	COC(=O)C1=CC2=C(C=C1)\\C(C(=O)N2)=C(\\NC3=CC=C(C=C3)N(C)C(=O)CN4CCN(C)CC4)C5=CC=CC=C5	PLASMA	G6HRD2P839																						UNKNOWN				The in vitro protein binding of nintedanib in human plasma was high, with a bound fraction of 97.8%	2.2	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205832s000lbl.pdf	Homo sapiens										false
51	11		ADULT	9809715	539.2533	NINTEDANIB	NINTEDANIB	COC(=O)C1=CC2=C(C=C1)\\C(C(=O)N2)=C(\\NC3=CC=C(C=C3)N(C)C(=O)CN4CCN(C)CC4)C5=CC=CC=C5	PLASMA	G6HRD2P839									∞	ng × h/mL	56.2		ng/mL	8.4			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/27093880	Homo sapiens		h	11.7							false
52	13		CHILD	66621102	888.9999	[NO STEREO] LEDIPASVIR	CC(C)C(C(=O)N1CC2(CC2)CC1C3=NC=C(N3)C4=CC5=C(C=C4)C6=C(C5(F)F)C=C(C=C6)C7=CC8=C(C=C7)N=C(N8)C9C1CCC(C1)N9C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC	COC(=O)NC(C(C)C)C(=O)N1CC2(CC2)CC1C3=NC=C(N3)C4=CC5=C(C=C4)C6=C(C=C(C=C6)C7=CC8=C(C=C7)N=C(N8)C9C%10CCC(C%10)N9C(=O)C(NC(=O)OC)C(C)C)C5(F)F	PLASMA	[NO STEREO] 013TE6E4WV	91302628		[NO STEREO] PSI-7851|[NO STEREO] SOFOSBUVIR	CC(C)OC(=O)C(C)NP(=O)(OCC1C(C(C(O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3	CC(C)OC(=O)C(C)NP(=O)(OCC1OC(N2C=CC(=O)NC2=O)C(C)(F)C1O)OC3=CC=CC=C3	[NO STEREO] 3S5S1851OV|[NO STEREO] WJ6CA3ZU8B	24		t	ng × h/mL	9320		ng/mL	531			INVESTIGATIONAL	mg	45		MULTIPLE	FED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31220349/	Homo sapiens										true
53	13		ADULT	66621102	888.9999	[NO STEREO] LEDIPASVIR	CC(C)C(C(=O)N1CC2(CC2)CC1C3=NC=C(N3)C4=CC5=C(C=C4)C6=C(C5(F)F)C=C(C=C6)C7=CC8=C(C=C7)N=C(N8)C9C1CCC(C1)N9C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC	COC(=O)NC(C(C)C)C(=O)N1CC2(CC2)CC1C3=NC=C(N3)C4=CC5=C(C=C4)C6=C(C=C(C=C6)C7=CC8=C(C=C7)N=C(N8)C9C%10CCC(C%10)N9C(=O)C(NC(=O)OC)C(C)C)C5(F)F	PLASMA	[NO STEREO] 013TE6E4WV	91302628		[NO STEREO] PSI-7851|[NO STEREO] SOFOSBUVIR	CC(C)OC(=O)C(C)NP(=O)(OCC1C(C(C(O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3	CC(C)OC(=O)C(C)NP(=O)(OCC1OC(N2C=CC(=O)NC2=O)C(C)(F)C1O)OC3=CC=CC=C3	[NO STEREO] 3S5S1851OV|[NO STEREO] WJ6CA3ZU8B	24		t	ng × h/mL	7290		ng/mL	323			RECOMMENDED	mg	90		STEADY-STATE	UNKNOWN		day	1		0.2	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212477s000lbl.pdf	Homo sapiens		h	47							true
54	14		ADULT	56959086	741.8196	NALOXEGOL OXALATE	NALOXEGOL OXALATE	OC(=O)C(O)=O.COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3CC4=C5C(O[C@@H]1[C@@]25CCN3CC=C)=C(O)C=C4	PLASMA	65I14TNM33							24		t	ng × h/mL	39		ng/mL	8			UNKNOWN	mg	5		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23726675	Homo sapiens		h	17.4							false
55	14		ADULT	56959086	741.8196	NALOXEGOL OXALATE	NALOXEGOL OXALATE	OC(=O)C(O)=O.COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3CC4=C5C(O[C@@H]1[C@@]25CCN3CC=C)=C(O)C=C4	PLASMA	65I14TNM33							24		t	ng × h/mL	334.8		ng/mL	81.1			UNKNOWN	mg	25		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23726675	Homo sapiens		h	14.1							false
56	14		ADULT	56959086	741.8196	NALOXEGOL OXALATE	NALOXEGOL OXALATE	OC(=O)C(O)=O.COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3CC4=C5C(O[C@@H]1[C@@]25CCN3CC=C)=C(O)C=C4	PLASMA	65I14TNM33							24		t	ng × h/mL	403.6		ng/mL	100			UNKNOWN	mg	50		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23726675	Homo sapiens		h	20.3							false
57	14		UNKNOWN	56959086	741.8196	NALOXEGOL OXALATE	NALOXEGOL OXALATE	OC(=O)C(O)=O.COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3CC4=C5C(O[C@@H]1[C@@]25CCN3CC=C)=C(O)C=C4	PLASMA	65I14TNM33																	UNKNOWN				UNKNOWN	UNKNOWN				Plasma protein binding of naloxegol in humans was low (~4.2%).	95.8	UNKNOWN	UNKNOWN	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204760s009lbl.pdf	Homo sapiens		h	6							false
58	15		ADULT		959.1727	ELIGLUSTAT TARTRATE	ELIGLUSTAT TARTRATE	O[C@@H]([C@@H](O)C(O)=O)C(O)=O.CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)C2=CC3=C(OCCO3)C=C2.CCCCCCCC(=O)N[C@H](CN4CCCC4)[C@H](O)C5=CC6=C(OCCO6)C=C5	BLOOD	N0493335P3							12		t	ng × h/mL	21.7		ng/mL	4.83			UNKNOWN	mg	50		STEADY-STATE	FASTED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20864621	Homo sapiens		h	4.32							false
59	15		ADULT		959.1727	ELIGLUSTAT TARTRATE	ELIGLUSTAT TARTRATE	O[C@@H]([C@@H](O)C(O)=O)C(O)=O.CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)C2=CC3=C(OCCO3)C=C2.CCCCCCCC(=O)N[C@H](CN4CCCC4)[C@H](O)C5=CC6=C(OCCO6)C=C5	BLOOD	N0493335P3							12		t	ng × h/mL	556		ng/mL	130			UNKNOWN	mg	200		STEADY-STATE	FASTED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20864621	Homo sapiens		h	6.19							false
60	15		ADULT		959.1727	ELIGLUSTAT TARTRATE	ELIGLUSTAT TARTRATE	O[C@@H]([C@@H](O)C(O)=O)C(O)=O.CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)C2=CC3=C(OCCO3)C=C2.CCCCCCCC(=O)N[C@H](CN4CCCC4)[C@H](O)C5=CC6=C(OCCO6)C=C5	BLOOD	N0493335P3							12		t	ng × h/mL	1042		ng/mL	265			UNKNOWN	mg	350		STEADY-STATE	FASTED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20864621	Homo sapiens		h	5.64							false
61	15		ADULT		959.1727	ELIGLUSTAT TARTRATE	ELIGLUSTAT TARTRATE	O[C@@H]([C@@H](O)C(O)=O)C(O)=O.CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)C2=CC3=C(OCCO3)C=C2.CCCCCCCC(=O)N[C@H](CN4CCCC4)[C@H](O)C5=CC6=C(OCCO6)C=C5	BLOOD	N0493335P3							12		t	ng × h/mL	62.1		ng/mL	10.5			UNKNOWN	mg	50		STEADY-STATE	FASTED		day	2			HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20864621	Homo sapiens		h	7.28							false
62	15		ADULT		959.1727	ELIGLUSTAT TARTRATE	ELIGLUSTAT TARTRATE	O[C@@H]([C@@H](O)C(O)=O)C(O)=O.CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)C2=CC3=C(OCCO3)C=C2.CCCCCCCC(=O)N[C@H](CN4CCCC4)[C@H](O)C5=CC6=C(OCCO6)C=C5	BLOOD	N0493335P3							12		t	ng × h/mL	1000		ng/mL	158			UNKNOWN	mg	200		STEADY-STATE	FASTED		day	2			HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20864621	Homo sapiens		h	5.77							false
63	15		ADULT		959.1727	ELIGLUSTAT TARTRATE	ELIGLUSTAT TARTRATE	O[C@@H]([C@@H](O)C(O)=O)C(O)=O.CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)C2=CC3=C(OCCO3)C=C2.CCCCCCCC(=O)N[C@H](CN4CCCC4)[C@H](O)C5=CC6=C(OCCO6)C=C5	BLOOD	N0493335P3							12		t	ng × h/mL	1776		ng/mL	303			UNKNOWN	mg	350		STEADY-STATE	FASTED		day	2			HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20864621	Homo sapiens		h	5.44							false
64	15		ADULT		959.1727	ELIGLUSTAT TARTRATE	ELIGLUSTAT TARTRATE	O[C@@H]([C@@H](O)C(O)=O)C(O)=O.CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)C2=CC3=C(OCCO3)C=C2.CCCCCCCC(=O)N[C@H](CN4CCCC4)[C@H](O)C5=CC6=C(OCCO6)C=C5	BLOOD	N0493335P3									∞	ng × h/mL	28.1		ng/mL	2.7			UNKNOWN	mg/kg	0.3		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20864621	Homo sapiens		h	4.8							false
65	15		ADULT		959.1727	ELIGLUSTAT TARTRATE	ELIGLUSTAT TARTRATE	O[C@@H]([C@@H](O)C(O)=O)C(O)=O.CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)C2=CC3=C(OCCO3)C=C2.CCCCCCCC(=O)N[C@H](CN4CCCC4)[C@H](O)C5=CC6=C(OCCO6)C=C5	BLOOD	N0493335P3									∞	ng × h/mL	151		ng/mL	10.4			UNKNOWN	mg/kg	1		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20864621	Homo sapiens		h	6.5							false
66	15		ADULT		959.1727	ELIGLUSTAT TARTRATE	ELIGLUSTAT TARTRATE	O[C@@H]([C@@H](O)C(O)=O)C(O)=O.CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)C2=CC3=C(OCCO3)C=C2.CCCCCCCC(=O)N[C@H](CN4CCCC4)[C@H](O)C5=CC6=C(OCCO6)C=C5	BLOOD	N0493335P3									∞	ng × h/mL	112		ng/mL	13.3			UNKNOWN	mg/kg	2		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20864621	Homo sapiens		h	6.4							false
67	15		ADULT		959.1727	ELIGLUSTAT TARTRATE	ELIGLUSTAT TARTRATE	O[C@@H]([C@@H](O)C(O)=O)C(O)=O.CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)C2=CC3=C(OCCO3)C=C2.CCCCCCCC(=O)N[C@H](CN4CCCC4)[C@H](O)C5=CC6=C(OCCO6)C=C5	BLOOD	N0493335P3									∞	ng × h/mL	692		ng/mL	91.1			UNKNOWN	mg/kg	5		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20864621	Homo sapiens		h	6.2							false
68	15		ADULT		959.1727	ELIGLUSTAT TARTRATE	ELIGLUSTAT TARTRATE	O[C@@H]([C@@H](O)C(O)=O)C(O)=O.CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)C2=CC3=C(OCCO3)C=C2.CCCCCCCC(=O)N[C@H](CN4CCCC4)[C@H](O)C5=CC6=C(OCCO6)C=C5	BLOOD	N0493335P3									∞	ng × h/mL	1562		ng/mL	267			UNKNOWN	mg/kg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20864621	Homo sapiens		h	6.1							false
69	15		ADULT		959.1727	ELIGLUSTAT TARTRATE	ELIGLUSTAT TARTRATE	O[C@@H]([C@@H](O)C(O)=O)C(O)=O.CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)C2=CC3=C(OCCO3)C=C2.CCCCCCCC(=O)N[C@H](CN4CCCC4)[C@H](O)C5=CC6=C(OCCO6)C=C5	BLOOD	N0493335P3									∞	ng × h/mL	10528		ng/mL	1852			UNKNOWN	mg/kg	30		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20864621	Homo sapiens		h	6.8							false
70	15		ADULT		959.1727	ELIGLUSTAT TARTRATE	ELIGLUSTAT TARTRATE	O[C@@H]([C@@H](O)C(O)=O)C(O)=O.CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)C2=CC3=C(OCCO3)C=C2.CCCCCCCC(=O)N[C@H](CN4CCCC4)[C@H](O)C5=CC6=C(OCCO6)C=C5	BLOOD	N0493335P3									∞	ng × h/mL	696		ng/mL	79.1			UNKNOWN	mg	300		SINGLE	HIGH-FAT						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20864621	Homo sapiens										false
71	15		ADULT		959.1727	ELIGLUSTAT TARTRATE	ELIGLUSTAT TARTRATE	O[C@@H]([C@@H](O)C(O)=O)C(O)=O.CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)C2=CC3=C(OCCO3)C=C2.CCCCCCCC(=O)N[C@H](CN4CCCC4)[C@H](O)C5=CC6=C(OCCO6)C=C5	BLOOD	N0493335P3									∞	ng × h/mL	623		ng/mL	88.3			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20864621	Homo sapiens										false
72	15		UNKNOWN		959.1727	ELIGLUSTAT TARTRATE	ELIGLUSTAT TARTRATE	O[C@@H]([C@@H](O)C(O)=O)C(O)=O.CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)C2=CC3=C(OCCO3)C=C2.CCCCCCCC(=O)N[C@H](CN4CCCC4)[C@H](O)C5=CC6=C(OCCO6)C=C5	PLASMA	N0493335P3									?	ng × h/mL	76.3		ng/mL	12.1			RECOMMENDED	mg	84		MULTIPLE	UNKNOWN		day	2	Eliglustat is moderately bound to human plasma proteins (76 to 83%).	17	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205494Orig1s000lbl.pdf	Homo sapiens		h	6.5							false
73	16			24965990	450.921	SUVOREXANT	SUVOREXANT	C[C@@H]1CCN(CCN1C(=O)C2=C(C=CC(C)=C2)N3N=CC=N3)C4=NC5=C(O4)C=CC(Cl)=C5	PLASMA	081L192FO9													μM	0.854				mg	20		SINGLE	FASTED						HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01043926	Homo sapiens										false
74	16		ADULT	24965990	450.921	SUVOREXANT	SUVOREXANT	C[C@@H]1CCN(CCN1C(=O)C2=C(C=CC(C)=C2)N3N=CC=N3)C4=NC5=C(O4)C=CC(Cl)=C5	PLASMA	081L192FO9							24		t	μM × h	3.43		μM	0.356			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29705869	Homo sapiens		h	7.7							false
75	16		ADULT	24965990	450.921	SUVOREXANT	SUVOREXANT	C[C@@H]1CCN(CCN1C(=O)C2=C(C=CC(C)=C2)N3N=CC=N3)C4=NC5=C(O4)C=CC(Cl)=C5	PLASMA	081L192FO9							24		t	μM × h	5.03		μM	0.572			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29705869	Homo sapiens		h	8.4							false
76	16		ADULT	24965990	450.921	SUVOREXANT	SUVOREXANT	C[C@@H]1CCN(CCN1C(=O)C2=C(C=CC(C)=C2)N3N=CC=N3)C4=NC5=C(O4)C=CC(Cl)=C5	PLASMA	081L192FO9							24		t	μM × h	8.53		μM	0.802			UNKNOWN	mg	40		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29705869	Homo sapiens		h	8.6							false
77	16		ADULT	24965990	450.921	SUVOREXANT	SUVOREXANT	C[C@@H]1CCN(CCN1C(=O)C2=C(C=CC(C)=C2)N3N=CC=N3)C4=NC5=C(O4)C=CC(Cl)=C5	PLASMA	081L192FO9							24		t	μM × h	11.48		μM	1.329			UNKNOWN	mg	80		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29705869	Homo sapiens		h	10							false
78	16		ADULT	24965990	450.921	SUVOREXANT	SUVOREXANT	C[C@@H]1CCN(CCN1C(=O)C2=C(C=CC(C)=C2)N3N=CC=N3)C4=NC5=C(O4)C=CC(Cl)=C5	PLASMA	081L192FO9							24		t	μM × h	18.1		μM	1.425			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29705869	Homo sapiens		h	12.6							false
79	16		ADULT	24965990	450.921	SUVOREXANT	SUVOREXANT	C[C@@H]1CCN(CCN1C(=O)C2=C(C=CC(C)=C2)N3N=CC=N3)C4=NC5=C(O4)C=CC(Cl)=C5	PLASMA	081L192FO9							24		t	μM × h	4.36		μM	0.414			UNKNOWN	mg	10		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29705869	Homo sapiens		h	8.1							false
80	16		ADULT	24965990	450.921	SUVOREXANT	SUVOREXANT	C[C@@H]1CCN(CCN1C(=O)C2=C(C=CC(C)=C2)N3N=CC=N3)C4=NC5=C(O4)C=CC(Cl)=C5	PLASMA	081L192FO9							24		t	μM × h	6.08		μM	0.574			UNKNOWN	mg	20		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29705869	Homo sapiens		h	9.2							false
81	16		ADULT	24965990	450.921	SUVOREXANT	SUVOREXANT	C[C@@H]1CCN(CCN1C(=O)C2=C(C=CC(C)=C2)N3N=CC=N3)C4=NC5=C(O4)C=CC(Cl)=C5	PLASMA	081L192FO9							24		t	μM × h	10.64		μM	1.08			UNKNOWN	mg	40		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29705869	Homo sapiens		h	9.4							false
82	16		ADULT	24965990	450.921	SUVOREXANT	SUVOREXANT	C[C@@H]1CCN(CCN1C(=O)C2=C(C=CC(C)=C2)N3N=CC=N3)C4=NC5=C(O4)C=CC(Cl)=C5	PLASMA	081L192FO9							24		t	μM × h	18.32		μM	1.488			UNKNOWN	mg	80		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29705869	Homo sapiens		h	11.2							false
83	16		ADULT	24965990	450.921	SUVOREXANT	SUVOREXANT	C[C@@H]1CCN(CCN1C(=O)C2=C(C=CC(C)=C2)N3N=CC=N3)C4=NC5=C(O4)C=CC(Cl)=C5	PLASMA	081L192FO9							24		t	μM × h	27.62		μM	2.085			UNKNOWN	mg	100		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29705869	Homo sapiens		h	14.5							false
84	16		UNKNOWN	24965990	450.921	SUVOREXANT	SUVOREXANT	C[C@@H]1CCN(CCN1C(=O)C2=C(C=CC(C)=C2)N3N=CC=N3)C4=NC5=C(O4)C=CC(Cl)=C5	PLASMA	081L192FO9																						UNKNOWN				Suvorexant is extensively bound (>99%) to human plasma proteins and does not preferentially distribute into red blood cells.	1	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204569Orig1s007lbl.pdf	Homo sapiens		h	12							false
85	17		UNKNOWN	11949646	450.909	EMPAGLIFLOZIN	EMPAGLIFLOZIN	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C2=CC(CC3=CC=C(O[C@H]4CCOC4)C=C3)=C(Cl)C=C2	PLASMA	HDC1R2M35U									?	nM × h	1870		nM	259			UNKNOWN	mg	10		STEADY-STATE	UNKNOWN		day	1	Following administration of an oral [14C]-empagliflozin solution to healthy subjects, the red blood cell partitioning was approximately 36.8% and plasma protein binding was 86.2%.	13.8	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204629s023lbl.pdf	Homo sapiens		h	12.4							false
86	17		UNKNOWN	11949646	450.909	EMPAGLIFLOZIN	EMPAGLIFLOZIN	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C2=CC(CC3=CC=C(O[C@H]4CCOC4)C=C3)=C(Cl)C=C2	PLASMA	HDC1R2M35U									?	nM × h	4740		nM	687			UNKNOWN	mg	25		STEADY-STATE	UNKNOWN		day	1			UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204629s023lbl.pdf	Homo sapiens										false
87	18		ADULT	11711522	422.902	OLODATEROL HYDROCHLORIDE	OLODATEROL HYDROCHLORIDE	Cl.COC1=CC=C(CC(C)(C)NC[C@H](O)C2=C3OCC(=O)NC3=CC(O)=C2)C=C1	PLASMA	65R445W3V9							24		t	pg × h/mL	104		pg/mL	5.92			UNKNOWN	μg	5		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Respiratory	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26316741	Homo sapiens										false
88	18		ADULT	11711522	422.902	OLODATEROL HYDROCHLORIDE	OLODATEROL HYDROCHLORIDE	Cl.COC1=CC=C(CC(C)(C)NC[C@H](O)C2=C3OCC(=O)NC3=CC(O)=C2)C=C1	PLASMA	65R445W3V9							24		t	pg × h/mL	160		pg/mL	13.1			UNKNOWN	μg	10		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Respiratory	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26316741	Homo sapiens										false
89	18		UNKNOWN	11711522	422.902	OLODATEROL HYDROCHLORIDE	OLODATEROL HYDROCHLORIDE	Cl.COC1=CC=C(CC(C)(C)NC[C@H](O)C2=C3OCC(=O)NC3=CC(O)=C2)C=C1	PLASMA	65R445W3V9																	UNKNOWN	μg	5		UNKNOWN	UNKNOWN		day	1	In vitro binding of [14C] olodaterol to human plasma proteins is independent of concentration and is approximately 60%.	40	UNHEALTHY	UNKNOWN	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/203108s008lbl.pdf	Homo sapiens		h	7.5							false
90	19			11625818	415.423	IDELALISIB	IDELALISIB	CC[C@H](NC1=C2N=CNC2=NC=N1)C3=NC4=C(C(=O)N3C5=CC=CC=C5)C(F)=CC=C4	PLASMA	YG57I8T5M0							12		t	ng × h/mL	9293.39		ng/mL	2258.8				mg	150		MULTIPLE			day	2			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01282424	Homo sapiens										false
91	19			11625818	415.423	IDELALISIB	IDELALISIB	CC[C@H](NC1=C2N=CNC2=NC=N1)C3=NC4=C(C(=O)N3C5=CC=CC=C5)C(F)=CC=C4	PLASMA	YG57I8T5M0							12		t	ng × h/mL	9094.76		ng/mL	2647.5				mg	150		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01282424	Homo sapiens										false
92	19		ADULT	11625818	415.423	IDELALISIB	IDELALISIB	CC[C@H](NC1=C2N=CNC2=NC=N1)C3=NC4=C(C(=O)N3C5=CC=CC=C5)C(F)=CC=C4	PLASMA	YG57I8T5M0									∞	ng × h/mL	10.439		ng/mL	1.953			DEFINED DAILY	mg	150		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.ema.europa.eu/en/documents/product-information/zydelig-epar-product-information_en.pdf	Homo sapiens		h	8.2							false
93	20		ADOLESCENT	11499245	151.931	TAVABOROLE	TAVABOROLE	OB1OCC2=C1C=CC(F)=C2	BLOOD	K124A4EUQ3							24		t	ng × h/mL	76		ng/mL	5.9			RECOMMENDED	%	5		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Topical	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204427s006lbl.pdf	Homo sapiens										false
94	20		ADULT	11499245	151.931	TAVABOROLE	TAVABOROLE	OB1OCC2=C1C=CC(F)=C2	BLOOD	K124A4EUQ3									?	ng × h/mL	75.8		ng/mL	5.2			RECOMMENDED	%	5		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Topical	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204427s006lbl.pdf	Homo sapiens										false
95	20		ADULT	11499245	151.931	TAVABOROLE	TAVABOROLE	OB1OCC2=C1C=CC(F)=C2	PLASMA	K124A4EUQ3																	RECOMMENDED	%	5		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Topical	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000ClinPharmR.pdf	Homo sapiens		h	28.5							false
96	21		ADULT	91800105	494.5	BELINOSTAT GLUCURONIDE	BELINOSTAT GLUCURONIDE	C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)C=CC(=O)NOC3C(C(C(C(O3)C(=O)O)O)O)O	PLASMA	7W03E88X74									∞	mg × min/mL	15.1		μg/mL	80.8				mg/m²	400		SINGLE							UNHEALTHY	Intravenous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01273155	Homo sapiens		min	280							false
97	21		ADULT	69620795	302.4	BELINOSTAT AMIDE	BELINOSTAT METABOLITE M21	C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)C=CC(=O)N	PLASMA	40EYG848GW									∞	μg × min/mL	647		μg/mL	1.26				mg/m²	400		SINGLE							UNHEALTHY	Intravenous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01273155	Homo sapiens		min	305							false
98	21		ADULT	759339	277.3	3-(PHENYLSULFAMOYL)BENZOIC ACID	BELINOSTAT METABOLITE M24	O=S(NC1=CC=CC=C1)(C2=CC=CC(C(O)=O)=C2)=O	PLASMA	RA8T70956T									∞	μg × min/mL	1009		μg/mL	2.56				mg/m²	400		SINGLE							UNHEALTHY	Intravenous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01273155	Homo sapiens		min	264							false
99	21		ADULT	22492441	303.3	BELINOSTAT ACID	BELINOSTAT METABOLITE M26	C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)/C=C/C(=O)O	PLASMA	D342E3PX5U									∞	μg × min/mL	361		μg/mL	1.68				mg/m²	400		SINGLE							UNHEALTHY	Intravenous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01273155	Homo sapiens		min	131							false
100	21		ADULT	72376230	332.4	METHYL BELINOSTAT	METHYL BELINOSTAT	CONC(=O)C=CC1=CC(=CC=C1)S(=O)(=O)NC2=CC=CC=C2	PLASMA	KF5Y5X84T9									∞	μg × min/mL	354		μg/mL	2.1				mg/m²	400		SINGLE							UNHEALTHY	Intravenous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01273155	Homo sapiens		min	79.6							false
101	21		ADULT	6918638	318.348	BELINOSTAT	BELINOSTAT	ONC(=O)\\C=C\\C1=CC=CC(=C1)S(=O)(=O)NC2=CC=CC=C2	PLASMA	F4H96P17NZ									∞	μg × min/mL	719		μg/mL	21.9				mg/m²	400		SINGLE							UNHEALTHY	Intravenous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01273155	Homo sapiens		min	118							false
102	21		UNKNOWN	6918638	318.348	BELINOSTAT	BELINOSTAT	ONC(=O)\\C=C\\C1=CC=CC(=C1)S(=O)(=O)NC2=CC=CC=C2	PLASMA	F4H96P17NZ																						UNKNOWN				In vitro plasma studies have shown that between 92.9% and 95.8% of belinostat is bound to protein in an equilibrium dialysis assay, and was independent of belinostat plasma concentrations from 500 to 25,000 ng/mL.	5.65	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206256lbl.pdf	Homo sapiens										false
103	21		ADULT	6918638	318.348	BELINOSTAT	BELINOSTAT	ONC(=O)\\C=C\\C1=CC=CC(=C1)S(=O)(=O)NC2=CC=CC=C2	PLASMA	F4H96P17NZ									∞	μM × h	8.7		ng/mL	681			DEFINED DAILY	mg/m²	1000		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/20706839	Homo sapiens		h	1.5							false
104	22		ADULT	11234049	370.3378	TEDIZOLID	Tedizolid	CN1N=NC(=N1)C2=NC=C(C=C2)C3=C(F)C=C(C=C3)N4C[C@H](CO)OC4=O	PLASMA	97HLQ82NGL									∞	μg × h/mL	56.1		μg/mL	3.77			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205435Orig1s000ClinPharmR.pdf#page=27	Homo sapiens		h	10.8	Capsules				Tedizolid Phosphate Disodium		false
105	22		ADULT	11234049	370.3378	TEDIZOLID	Tedizolid	CN1N=NC(=N1)C2=NC=C(C=C2)C3=C(F)C=C(C=C3)N4C[C@H](CO)OC4=O	PLASMA	97HLQ82NGL							24		t	μg × h/mL	16.7		μg/mL	1.8			UNKNOWN	mg	200		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205435Orig1s000ClinPharmR.pdf#page=27	Homo sapiens		h	11.1	Capsules	Day 1 PK			Tedizolid Phosphate Disodium		false
106	22		ADULT	11234049	370.3378	TEDIZOLID	Tedizolid	CN1N=NC(=N1)C2=NC=C(C=C2)C3=C(F)C=C(C=C3)N4C[C@H](CO)OC4=O	PLASMA	97HLQ82NGL							24		t	μg × h/mL	22.5		μg/mL	1.8			UNKNOWN	mg	200		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205435Orig1s000ClinPharmR.pdf#page=27	Homo sapiens		h	10.2	Capsule	Day 15 PK			Tedizolid Phosphate Disodium		false
107	22		ADULT	11234049	370.3378	TEDIZOLID	Tedizolid	CN1N=NC(=N1)C2=NC=C(C=C2)C3=C(F)C=C(C=C3)N4C[C@H](CO)OC4=O	PLASMA	97HLQ82NGL							24		t	μg × h/mL	24.1		μg/mL	2.1			UNKNOWN	mg	300		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205435Orig1s000ClinPharmR.pdf#page=27	Homo sapiens		h	10.1	Capsules	Day 1 PK			Tedizolid Phosphate Disodium		false
108	22		ADULT	11234049	370.3378	TEDIZOLID	Tedizolid	CN1N=NC(=N1)C2=NC=C(C=C2)C3=C(F)C=C(C=C3)N4C[C@H](CO)OC4=O	PLASMA	97HLQ82NGL							24		t	μg × h/mL	31.2		μg/mL	2.7			UNKNOWN	mg	300		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205435Orig1s000ClinPharmR.pdf#page=27	Homo sapiens		h	11.9	Capsules	Day 15 PK			Tedizolid Phosphate Disodium		false
109	22		ADULT	11234049	370.3378	TEDIZOLID	Tedizolid	CN1N=NC(=N1)C2=NC=C(C=C2)C3=C(F)C=C(C=C3)N4C[C@H](CO)OC4=O	PLASMA	97HLQ82NGL							24		t	μg × h/mL	46		μg/mL	4.2			UNKNOWN	mg	400		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205435Orig1s000ClinPharmR.pdf#page=27	Homo sapiens		h	8.01	Capsules	Day 1 PK			Tedizolid Phosphate Disodium		false
110	22		ADULT	11234049	370.3378	TEDIZOLID	Tedizolid	CN1N=NC(=N1)C2=NC=C(C=C2)C3=C(F)C=C(C=C3)N4C[C@H](CO)OC4=O	PLASMA	97HLQ82NGL									∞	μg × h/mL	25.35		μg/mL	1.99			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205435Orig1s000ClinPharmR.pdf#page=27	Homo sapiens		h	11.2	Capsules				Tedizolid Phosphate Di sodium		false
111	22		ADULT	11234049	370.3378	TEDIZOLID	Tedizolid	CN1N=NC(=N1)C2=NC=C(C=C2)C3=C(F)C=C(C=C3)N4C[C@H](CO)OC4=O	PLASMA	97HLQ82NGL									∞	μg × h/mL	79.26		μg/mL	5.21			UNKNOWN	mg	800		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205435Orig1s000ClinPharmR.pdf#page=27	Homo sapiens		h	11.4	Capsules				Tedizolid Phosphate Disodium		false
112	22		ADULT	11234049	370.3378	TEDIZOLID	Tedizolid	CN1N=NC(=N1)C2=NC=C(C=C2)C3=C(F)C=C(C=C3)N4C[C@H](CO)OC4=O	PLASMA	97HLQ82NGL									∞	μg × h/mL	91.8		μg/mL	5.52			UNKNOWN	mg	800		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205435Orig1s000ClinPharmR.pdf#page=27	Homo sapiens		h	10.6	Capsule				Tedizolid Phosphate Disodium		false
113	22		ADULT	11234049	370.3378	TEDIZOLID	Tedizolid	CN1N=NC(=N1)C2=NC=C(C=C2)C3=C(F)C=C(C=C3)N4C[C@H](CO)OC4=O	PLASMA	97HLQ82NGL									∞	μg × h/mL	123.1		μg/mL	9.49			UNKNOWN	mg	1200		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205435Orig1s000ClinPharmR.pdf#page=27	Homo sapiens		h	10.4	Capsule				Tedizolid Phosphate Disodium		false
114	22		ADULT	11234049	370.3378	TEDIZOLID	Tedizolid	CN1N=NC(=N1)C2=NC=C(C=C2)C3=C(F)C=C(C=C3)N4C[C@H](CO)OC4=O	PLASMA	97HLQ82NGL							24		t	μg × h/mL	52		μg/mL	4.7			UNKNOWN	mg	400		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205435Orig1s000ClinPharmR.pdf#page=27	Homo sapiens		h	12.8	Capsules	Day 15 PK			Tedizolid Phosphate Disodium		false
115	22		ADULT	11234049	370.3378	TEDIZOLID	Tedizolid	CN1N=NC(=N1)C2=NC=C(C=C2)C3=C(F)C=C(C=C3)N4C[C@H](CO)OC4=O	PLASMA	97HLQ82NGL									∞	μg × h/mL	58.7		μg/mL	5.13			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205435Orig1s000ClinPharmR.pdf#page=28	Homo sapiens		h	11.3							false
116	22		ADULT	11234049	370.3378	TEDIZOLID	Tedizolid	CN1N=NC(=N1)C2=NC=C(C=C2)C3=C(F)C=C(C=C3)N4C[C@H](CO)OC4=O	PLASMA	97HLQ82NGL							24		t	μg × h/mL	29.18		μg/mL	3.01			UNKNOWN	mg	200		STEADY-STATE	FASTED		day	1			HEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205435Orig1s000ClinPharmR.pdf#page=28	Homo sapiens		h	12.4		Day 7					false
117	22		ADULT	11234049	370.3378	TEDIZOLID	Tedizolid	CN1N=NC(=N1)C2=NC=C(C=C2)C3=C(F)C=C(C=C3)N4C[C@H](CO)OC4=O	PLASMA	97HLQ82NGL									∞	μg × h/mL	17.36		μg/mL	1.16			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205435Orig1s000ClinPharmR.pdf#page=28	Homo sapiens		h	13.4							false
118	22		ADULT	11234049	370.3378	TEDIZOLID	Tedizolid	CN1N=NC(=N1)C2=NC=C(C=C2)C3=C(F)C=C(C=C3)N4C[C@H](CO)OC4=O	PLASMA	97HLQ82NGL									∞	μg × h/mL	32.58		μg/mL	2.62			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205435Orig1s000ClinPharmR.pdf#page=28	Homo sapiens		h	11							false
119	22		ADULT	11234049	370.3378	TEDIZOLID	Tedizolid	CN1N=NC(=N1)C2=NC=C(C=C2)C3=C(F)C=C(C=C3)N4C[C@H](CO)OC4=O	PLASMA	97HLQ82NGL									∞	μg × h/mL	51.9		μg/mL	4.53			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205435Orig1s000ClinPharmR.pdf#page=28	Homo sapiens		h	9.3							false
120	22		ADULT	11234049	370.3378	TEDIZOLID	Tedizolid	CN1N=NC(=N1)C2=NC=C(C=C2)C3=C(F)C=C(C=C3)N4C[C@H](CO)OC4=O	PLASMA	97HLQ82NGL							24		t	μg × h/mL	22.29		μg/mL	2.34			UNKNOWN	mg	200		MULTIPLE	FASTED		day	1			HEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205435Orig1s000ClinPharmR.pdf#page=29	Homo sapiens		h	9.33		Day 1					false
121	22			11234049	370.3378	TEDIZOLID	Tedizolid	CN1N=NC(=N1)C2=NC=C(C=C2)C3=C(F)C=C(C=C3)N4C[C@H](CO)OC4=O	PLASMA	97HLQ82NGL																										The mean plasma protein binding of Tedizolid in human EDTA-treated plasma at the concentration ranges of 0.1-50 µg/mL was 84.6%.	15.4				OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205435Orig1s000ClinPharmR.pdf#page=58	Homo sapiens										false
122	22		ADULT	11234049	370.3378	TEDIZOLID	Tedizolid	CN1N=NC(=N1)C2=NC=C(C=C2)C3=C(F)C=C(C=C3)N4C[C@H](CO)OC4=O	PLASMA	97HLQ82NGL									∞	μg × h/mL	23.8		μg/mL	2			UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205435Orig1s000ClinPharmR.pdf#page=9	Homo sapiens										false
123	22		ADULT	11234049	370.3378	TEDIZOLID	Tedizolid	CN1N=NC(=N1)C2=NC=C(C=C2)C3=C(F)C=C(C=C3)N4C[C@H](CO)OC4=O	PLASMA	97HLQ82NGL							24		t	μg × h/mL	25.6		μg/mL	2.2			UNKNOWN	mg	200		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205435Orig1s000ClinPharmR.pdf#page=9	Homo sapiens										false
124	22		ADULT	11234049	370.3378	TEDIZOLID	Tedizolid	CN1N=NC(=N1)C2=NC=C(C=C2)C3=C(F)C=C(C=C3)N4C[C@H](CO)OC4=O	PLASMA	97HLQ82NGL									∞	μg × h/mL	26.6		μg/mL	2.3			UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205435Orig1s000ClinPharmR.pdf#page=9	Homo sapiens										false
125	22		ADULT	11234049	370.3378	TEDIZOLID	Tedizolid	CN1N=NC(=N1)C2=NC=C(C=C2)C3=C(F)C=C(C=C3)N4C[C@H](CO)OC4=O	PLASMA	97HLQ82NGL							24		t	μg × h/mL	29.2		μg/mL	3			UNKNOWN	mg	200		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205435Orig1s000ClinPharmR.pdf#page=9	Homo sapiens										false
126	23		UNKNOWN	489181	348.3903	EFINACONAZOLE	EFINACONAZOLE	C[C@@H](N1CCC(=C)CC1)[C@](O)(CN2C=NC=N2)C3=C(F)C=C(F)C=C3	PLASMA	J82SB7FXWB																						UNKNOWN				Efinaconazole in vitro binding to human plasma proteins is high, 95.8% - 96.5%. Because of low systemic levels, efinaconazole plasma protein binding is not expected to be clinically relevant.	3.85	UNKNOWN		UNKNOWN	OTHER GOV'T	https://pdf.hres.ca/dpd_pm/00054721.PDF	Homo sapiens										false
127	23		ADULT	489181	348.3903	EFINACONAZOLE	EFINACONAZOLE	C[C@@H](N1CCC(=C)CC1)[C@](O)(CN2C=NC=N2)C3=C(F)C=C(F)C=C3	PLASMA	J82SB7FXWB									?	ng × h/mL	12.15		ng/mL	0.67			RECOMMENDED	mg	42		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Topical	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203567s009lbl.pdf	Homo sapiens										false
128	23		ADULT	489181	348.3903	EFINACONAZOLE	EFINACONAZOLE	C[C@@H](N1CCC(=C)CC1)[C@](O)(CN2C=NC=N2)C3=C(F)C=C(F)C=C3	PLASMA	J82SB7FXWB																	RECOMMENDED	mg	42		MULTIPLE	UNKNOWN		day	1			HEALTHY	Topical	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203567s009lbl.pdf	Homo sapiens		h	29.9							false
129	23		ADOLESCENT	489181	348.3903	EFINACONAZOLE	EFINACONAZOLE	C[C@@H](N1CCC(=C)CC1)[C@](O)(CN2C=NC=N2)C3=C(F)C=C(F)C=C3	PLASMA	J82SB7FXWB							24		t	ng × h/mL	11.4		ng/mL	0.55			RECOMMENDED	mg	42		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Topical	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203567s009lbl.pdf	Homo sapiens										false
130	24		ADULT	10077130	492.6	VORAPAXAR	VORAPAXAR	CCOC(=O)N[C@@H]1CC[C@@H]2[C@H](C[C@@H]3[C@@H]([C@@H](C)OC3=O)[C@H]2\\C=C\\C4=CC=C(C=N4)C5=CC=CC(F)=C5)C1	PLASMA	ZCE93644N2									∞	ng × h/mL	18400		ng/mL	262			UNKNOWN	mg	40		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/27121783	Homo sapiens		h	240							false
131	25		ADULT	57379345	558.135	CERITINIB	CERITINIB	CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC3=NC(NC4=C(C=CC=C4)S(=O)(=O)C(C)C)=C(Cl)C=N3	PLASMA	K418KG2GET							24		t	ng × h/mL	16500		ng/mL	800			MAX TOLERATED	mg	750		SINGLE	UNKNOWN				Ceritinib is highly bound to plasma protein (about 97%), independent of the drug concentration. Changed PK ref1 to https://www.ncbi.nlm.nih.gov/pubmed/28740365	3	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/28740365	Homo sapiens		h	40							false
132	27		ADULT	3599	407.568	MILTEFOSINE	MILTEFOSINE	CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C	PLASMA	53EY29W7EC							12		t	μg × h/mL	636		μg/mL	66.2			RECOMMENDED	mg	50		MULTIPLE	UNKNOWN		day	2	Human plasma protein binding of miltefosine was 98% over the drug concentration range from 0.1 to 10 µg/mL.	2	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204684s000lbl.pdf	Homo sapiens		day	6.4							false
133	27		ADULT	3599	407.568	MILTEFOSINE	MILTEFOSINE	CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C	PLASMA	53EY29W7EC							8		t	μg × h/mL	295		μg/mL	37.3			RECOMMENDED	mg	50		MULTIPLE	UNKNOWN		day	3	Human plasma protein binding of miltefosine was 98% over the drug concentration range from 0.1 to 10 µg/mL.	2	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204684s000lbl.pdf	Homo sapiens		day	6.8							false
134	29		UNKNOWN	439260	169.1778	NOREPINEPHRINE	NOREPINEPHRINE	NC[C@H](O)C1=CC=C(O)C(O)=C1	PLASMA	X4W3ENH1CV																	UNKNOWN				UNKNOWN	UNKNOWN					75	UNKNOWN	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/007513s038lbl.pdf	Homo sapiens		min	2.4							false
135	30		ADULT	10220503	245.3169	TASIMELTEON	TASIMELTEON	CCC(=O)NC[C@@H]1C[C@H]1C2=C3CCOC3=CC=C2	PLASMA	SHS4PU80D9									∞	ng × h/mL	2304		ng/mL	445			UNKNOWN	mg	100		SINGLE	HIGH-FAT						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205677Orig1s000ClinPharmR.pdf	Homo sapiens		h	2.06							false
136	30		ADULT	10220503	245.3169	TASIMELTEON	TASIMELTEON	CCC(=O)NC[C@@H]1C[C@H]1C2=C3CCOC3=CC=C2	PLASMA	SHS4PU80D9									∞	ng × h/mL	2269		ng/mL	786			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205677Orig1s000ClinPharmR.pdf	Homo sapiens		h	2.75							false
137	30		ADULT	10220503	245.3169	TASIMELTEON	TASIMELTEON	CCC(=O)NC[C@@H]1C[C@H]1C2=C3CCOC3=CC=C2	PLASMA	SHS4PU80D9									?	ng × h/mL	8		ng/mL	5			UNKNOWN	mg	1		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205677Orig1s000ClinPharmR.pdf	Homo sapiens		h	1.75							false
138	30		ADULT	10220503	245.3169	TASIMELTEON	TASIMELTEON	CCC(=O)NC[C@@H]1C[C@H]1C2=C3CCOC3=CC=C2	PLASMA	SHS4PU80D9									?	ng × h/mL	59		ng/mL	33			UNKNOWN	mg	10		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205677Orig1s000ClinPharmR.pdf	Homo sapiens		h	1.29							false
139	30		ADULT	10220503	245.3169	TASIMELTEON	TASIMELTEON	CCC(=O)NC[C@@H]1C[C@H]1C2=C3CCOC3=CC=C2	PLASMA	SHS4PU80D9									?	ng × h/mL	426		ng/mL	173			UNKNOWN	mg	50		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205677Orig1s000ClinPharmR.pdf	Homo sapiens		h	2.37							false
140	30		ADULT	10220503	245.3169	TASIMELTEON	TASIMELTEON	CCC(=O)NC[C@@H]1C[C@H]1C2=C3CCOC3=CC=C2	PLASMA	SHS4PU80D9									?	ng × h/mL	1823		ng/mL	394			UNKNOWN	mg	150		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205677Orig1s000ClinPharmR.pdf	Homo sapiens		h	2.78							false
141	30		ADULT	10220503	245.3169	TASIMELTEON	TASIMELTEON	CCC(=O)NC[C@@H]1C[C@H]1C2=C3CCOC3=CC=C2	PLASMA	SHS4PU80D9									?	ng × h/mL	17		ng/mL	12			UNKNOWN	mg	1		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205677Orig1s000ClinPharmR.pdf	Homo sapiens		h	1.49							false
142	30		ADULT	10220503	245.3169	TASIMELTEON	TASIMELTEON	CCC(=O)NC[C@@H]1C[C@H]1C2=C3CCOC3=CC=C2	PLASMA	SHS4PU80D9									?	ng × h/mL	96		ng/mL	51			UNKNOWN	mg	10		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205677Orig1s000ClinPharmR.pdf	Homo sapiens		h	1.44							false
143	30		ADULT	10220503	245.3169	TASIMELTEON	TASIMELTEON	CCC(=O)NC[C@@H]1C[C@H]1C2=C3CCOC3=CC=C2	PLASMA	SHS4PU80D9									?	ng × h/mL	611		ng/mL	261			UNKNOWN	mg	50		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205677Orig1s000ClinPharmR.pdf	Homo sapiens		h	2.57							false
144	30		ADULT	10220503	245.3169	TASIMELTEON	TASIMELTEON	CCC(=O)NC[C@@H]1C[C@H]1C2=C3CCOC3=CC=C2	PLASMA	SHS4PU80D9									?	ng × h/mL	3797		ng/mL	873			UNKNOWN	mg	150		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205677Orig1s000ClinPharmR.pdf	Homo sapiens		h	2.63							false
145	31		ADULT	11519070	428.6	Umeclidinium	C1C[N+]2(CCC1(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)CCOCC5=CC=CC=C5	C1C[N+]2(CCC1(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)CCOCC5=CC=CC=C5	PLASMA	GE2T1418SV									∞	pg × h/mL	575.7		pg/mL	995.9			INVESTIGATIONAL	μg	500		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23284643/	Homo sapiens		h	1.56							false
146	31		ADULT	11519070	428.5858	UMECLIDINIUM	UMECLIDINIUM	OC(C1=CC=CC=C1)(C2=CC=CC=C2)C34CC[N+](CCOCC5=CC=CC=C5)(CC3)CC4	PLASMA	GE2T1418SV							24		t	pg × h/mL	298		pg/mL	258			RECOMMENDED	μg	62.5		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25816315/	Homo sapiens										false
147	31		ADULT	11519070	428.5858	UMECLIDINIUM	UMECLIDINIUM	OC(C1=CC=CC=C1)(C2=CC=CC=C2)C34CC[N+](CCOCC5=CC=CC=C5)(CC3)CC4	PLASMA	GE2T1418SV	10184665		VILANTEROL	VILANTEROL	OCC1=C(O)C=CC(=C1)[C@@H](O)CNCCCCCCOCCOCC2=C(Cl)C=CC=C2Cl	028LZY775B	24		t	pg × h/mL	304		pg/mL	245			RECOMMENDED	μg	62.5		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25816315/	Homo sapiens										true
148	31		UNKNOWN	11519070	428.6	Umeclidinium	C1C[N+]2(CCC1(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)CCOCC5=CC=CC=C5	C1C[N+]2(CCC1(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)CCOCC5=CC=CC=C5	PLASMA	GE2T1418SV	10184665		Vilanterol		C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl	GW642444x											UNKNOWN				UNKNOWN	UNKNOWN		UNKNOWN			11	UNKNOWN	UNKNOWN	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/203975Orig1s010lbl.pdf	Homo sapiens										true
149	32		ADULT	45375808	529.5	Sofosbuvir		CC(C)OC(=O)C(C)NP(=O)(OCC1C(C(C(O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3	PLASMA	WJ6CA3ZU8B									∞	ng × h/mL	861		ng/mL	1001.7			RECOMMENDED	mg	400		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30185395/	Homo sapiens		h	0.38							false
150	32		ADULT	45375808	529.4525	SOFOSBUVIR	Sofosbuvir	CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC3=CC=CC=C3	PLASMA	WJ6CA3ZU8B							24		t	ng × h/mL	872.2		ng/mL	922.3			RECOMMENDED	mg	400		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30185395/	Homo sapiens		h	0.35							false
151	32		ADULT	45375808	529.5	Sofosbuvir	Sofosbuvir	CC(C)OC(=O)C(C)NP(=O)(OCC1C(C(C(O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3	PLASMA	WJ6CA3ZU8B	37542		Ribavirin	ribavirin	C1=NC(=NN1C2C(C(C(O2)CO)O)O)C(=O)N	49717AWG6K	24		t	ng × h/mL	969						RECOMMENDED	mg	400		STEADY-STATE	UNKNOWN		day	1		63	UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204671s002lbl.pdf	Homo sapiens		h	0.4							true
152	33		ADULT	118984465	749.939	SIMEPREVIR	SIMEPREVIR	COC1=CC=C2C(O[C@@H]3C[C@@H]4[C@@H](C3)C(=O)N(C)CCCCC=CC5C[C@]5(NC4=O)C(=O)NS(=O)(=O)C6CC6)=CC(=NC2=C1C)C7=NC(=CS7)C(C)C	PLASMA	9WS5RD66HZ							24		t	ng × h/mL	24630		ng/mL	2304			UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19852962/	Homo sapiens										false
153	33		ADULT	118984465	749.939	SIMEPREVIR	SIMEPREVIR	COC1=CC=C2C(O[C@@H]3C[C@@H]4[C@@H](C3)C(=O)N(C)CCCCC=CC5C[C@]5(NC4=O)C(=O)NS(=O)(=O)C6CC6)=CC(=NC2=C1C)C7=NC(=CS7)C(C)C	PLASMA	9WS5RD66HZ							24		t	ng × h/mL	79710		ng/mL	6172			UNKNOWN	mg	200		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19852962/	Homo sapiens		h	16.04							false
154	33		ADULT	118984465	749.939	SIMEPREVIR	SIMEPREVIR	COC1=CC=C2C(O[C@@H]3C[C@@H]4[C@@H](C3)C(=O)N(C)CCCCC=CC5C[C@]5(NC4=O)C(=O)NS(=O)(=O)C6CC6)=CC(=NC2=C1C)C7=NC(=CS7)C(C)C	PLASMA	9WS5RD66HZ							24		t	ng × h/mL	56430		ng/mL	4067			UNKNOWN	mg	200		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19852962/	Homo sapiens										false
155	33		ADULT	118984465	749.939	SIMEPREVIR	SIMEPREVIR	COC1=CC=C2C(O[C@@H]3C[C@@H]4[C@@H](C3)C(=O)N(C)CCCCC=CC5C[C@]5(NC4=O)C(=O)NS(=O)(=O)C6CC6)=CC(=NC2=C1C)C7=NC(=CS7)C(C)C	PLASMA	9WS5RD66HZ							24		t	ng × h/mL	206000		ng/mL	11470			UNKNOWN	mg	200		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19852962/	Homo sapiens		h	41.32							false
156	34			91971609	474.5117	PCI-45227	PCI-45227	NC1=C2C(=NC=N1)N(N=C2C3=CC=C(OC4=CC=CC=C4)C=C3)[C@@H]5CCCN(C5)C(=O)C(O)CO	PLASMA	29446230GA							24		t	ng × h/mL	1485							mg	560		MULTIPLE			day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01325701	Homo sapiens										false
157	34			91971609	474.5117	PCI-45227	PCI-45227	NC1=C2C(=NC=N1)N(N=C2C3=CC=C(OC4=CC=CC=C4)C=C3)[C@@H]5CCCN(C5)C(=O)C(O)CO	PLASMA	29446230GA							24		t	ng × h/mL	1671							mg	840		MULTIPLE			day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01325701	Homo sapiens										false
158	34			24821094	440.4971	IBRUTINIB	IBRUTINIB	NC1=NC=NC2=C1C(=NN2[C@@H]3CCCN(C3)C(=O)C=C)C4=CC=C(OC5=CC=CC=C5)C=C4	PLASMA	1X70OSD4VX							24		t	ng × h/mL	1285							mg	560		MULTIPLE			day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01325701	Homo sapiens										false
159	34			24821094	440.4971	IBRUTINIB	IBRUTINIB	NC1=NC=NC2=C1C(=NN2[C@@H]3CCCN(C3)C(=O)C=C)C4=CC=C(OC5=CC=CC=C5)C=C4	PLASMA	1X70OSD4VX							24		t	ng × h/mL	1337							mg	840		MULTIPLE			day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01325701	Homo sapiens										false
160	34			24821094	440.4971	IBRUTINIB	IBRUTINIB	NC1=NC=NC2=C1C(=NN2[C@@H]3CCCN(C3)C(=O)C=C)C4=CC=C(OC5=CC=CC=C5)C=C4	PLASMA	1X70OSD4VX							4		t	ng × h/mL	561.6							mg	560		STEADY-STATE			day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01646021	Homo sapiens										false
161	34			24821094	440.4971	IBRUTINIB	IBRUTINIB	NC1=NC=NC2=C1C(=NN2[C@@H]3CCCN(C3)C(=O)C=C)C4=CC=C(OC5=CC=CC=C5)C=C4	PLASMA	1X70OSD4VX																										Reversible binding of ibrutinib to human plasma protein in vitro was 97.3% with no concentration dependence in the range of 50 to 1000 ng/mL	2.7				EXPERIMENT	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5391303/	Homo sapiens										false
162	34		ADULT	24821094	440.4971	IBRUTINIB	IBRUTINIB	NC1=NC=NC2=C1C(=NN2[C@@H]3CCCN(C3)C(=O)C=C)C4=CC=C(OC5=CC=CC=C5)C=C4	PLASMA	1X70OSD4VX							24		t	ng × h/mL	236		ng/mL	38.5			UNKNOWN	mg	420		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/25724156	Homo sapiens		h	9.7							false
163	34		ADULT	24821094	440.4971	IBRUTINIB	IBRUTINIB	NC1=NC=NC2=C1C(=NN2[C@@H]3CCCN(C3)C(=O)C=C)C4=CC=C(OC5=CC=CC=C5)C=C4	PLASMA	1X70OSD4VX							24		t	ng × h/mL	864		ng/mL	120			UNKNOWN	mg	420		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/25724156	Homo sapiens		h	4.5							false
164	34		ADULT	24821094	440.4971	IBRUTINIB	IBRUTINIB	NC1=NC=NC2=C1C(=NN2[C@@H]3CCCN(C3)C(=O)C=C)C4=CC=C(OC5=CC=CC=C5)C=C4	PLASMA	1X70OSD4VX							24		t	ng × h/mL	485		ng/mL	51.7			UNKNOWN	mg	420		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/25724156	Homo sapiens		h	11							false
165	34		ADULT	24821094	440.4971	IBRUTINIB	IBRUTINIB	NC1=NC=NC2=C1C(=NN2[C@@H]3CCCN(C3)C(=O)C=C)C4=CC=C(OC5=CC=CC=C5)C=C4	PLASMA	1X70OSD4VX							24		t	ng × h/mL	611		ng/mL	147			UNKNOWN	mg	420		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/25724156	Homo sapiens		h	5.2							false
166	35		ADULT	9881504	254.28	Eslicarbazepine	C1C(C2=CC=CC=C2N(C3=CC=CC=C31)C(=O)N)O	C1C(C2=CC=CC=C2N(C3=CC=CC=C31)C(=O)N)O	PLASMA	S5VXA428R4							24		t	μg × h/mL	132.5		μg/mL	9.7			RECOMMENDED	mg	400		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21680153/	Homo sapiens		h	12.8							false
167	35		ADULT	9881504	254.28	Eslicarbazepine	C1C(C2=CC=CC=C2N(C3=CC=CC=C31)C(=O)N)O	C1C(C2=CC=CC=C2N(C3=CC=CC=C31)C(=O)N)O	PLASMA	S5VXA428R4																	UNKNOWN				UNKNOWN	UNKNOWN		day	1		60	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022416s009lbl.pdf	Homo sapiens		h	16.5							false
168	37		ADULT	16004692	588.273	MACITENTAN	MACITENTAN	CCCNS(=O)(=O)NC1=NC=NC(OCCOC2=NC=C(Br)C=N2)=C1C3=CC=C(Br)C=C3	BLOOD	Z9K9Y9WMVL									∞	ng × h/mL	5759		ng/mL	227			DEFINED DAILY	mg	10		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/23568224	Homo sapiens		h	14.1							false
169	37		ADULT	25099191	546.2	Aprocitentan	ACT-132577		BLOOD	MZI81HV01P									∞	ng × h/mL	19749		ng/mL	178			DEFINED DAILY	mg	10		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/23568224	Homo sapiens		h	46.7							false
170	38			11304743	422.4157	RIOCIGUAT	RIOCIGUAT	COC(=O)N(C)C1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=C2C=CC=N4	PLASMA	RU3FE2Y4XI																										Plasma protein binding in humans is approximately 95%, with serum albumin and α1–acidic glycoprotein being the main binding components.	5				DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204819s006lbl.pdf	Homo sapiens										false
171	38		ADULT	11304743	422.4157	RIOCIGUAT	RIOCIGUAT	COC(=O)N(C)C1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=C2C=CC=N4	PLASMA	RU3FE2Y4XI									∞	μg × h/L	158		μg/L	29.7			RECOMMENDED	mg	1		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26507720	Homo sapiens		h	3.67							false
172	39		ADULT	154257	470.6026	BAZEDOXIFENE	BAZEDOXIFENE	CC1=C(N(CC2=CC=C(OCCN3CCCCCC3)C=C2)C4=C1C=C(O)C=C4)C5=CC=C(O)C=C5	PLASMA	Q16TT9C5BK			ESTROGENS, CONJUGATED	conjugated estrogens		IU5QR144QX			?	ng × h/mL	71		ng/mL	6.9			RECOMMENDED	mg	20		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022247Orig1s001lbl.pdf	Homo sapiens		h	30							true
173	40			91936922	314.4	LU-AA39835	Lu AA39835	CC1=CC(=C(C=C1)SC2=C(C=CC(=C2)O)N3CCNCC3)C	PLASMA	C459W0B337							240		t	ng × h/mL	0.078		ng/mL	0.008				mg	5		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02170220	Homo sapiens										false
174	40			118753351	328.429	LU-AA34443	Lu AA34443	CC1=C(C=CC(=C1)C(=O)O)SC2=CC=CC=C2N3CCNCC3	PLASMA								240		t	ng × h/mL	88.614							mg	5		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02170220	Homo sapiens										false
175	40			118753351	328.429	LU-AA34443	Lu AA34443	CC1=C(C=CC(=C1)C(=O)O)SC2=CC=CC=C2N3CCNCC3	PLASMA										∞	ng × h/mL	122.899							mg	5		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02170220	Homo sapiens										false
176	40			118753351	328.429	LU-AA34443	Lu AA34443	CC1=C(C=CC(=C1)C(=O)O)SC2=CC=CC=C2N3CCNCC3	PLASMA														ng/mL	2.654				mg	5		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02170220	Homo sapiens										false
177	40			91936922	314.4	LU-AA39835	Lu AA39835	CC1=CC(=C(C=C1)SC2=C(C=CC(=C2)O)N3CCNCC3)C	PLASMA	C459W0B337							240		t	ng × h/mL	1.143		ng/mL	0.029				mg	5		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02170220	Homo sapiens										false
178	40			9966051	298.446	VORTIOXETINE	VORTIOXETINE	CC1=CC(C)=C(SC2=C(C=CC=C2)N3CCNCC3)C=C1	PLASMA	3O2K1S3WQV							240		t	ng × h/mL	166.955							mg	5		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02170220	Homo sapiens										false
179	40			9966051	298.446	VORTIOXETINE	VORTIOXETINE	CC1=CC(C)=C(SC2=C(C=CC=C2)N3CCNCC3)C=C1	PLASMA	3O2K1S3WQV									∞	ng × h/mL	187.202							mg	5		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02170220	Homo sapiens										false
180	40			9966051	298.446	VORTIOXETINE	VORTIOXETINE	CC1=CC(C)=C(SC2=C(C=CC=C2)N3CCNCC3)C=C1	PLASMA	3O2K1S3WQV													ng/mL	2.078				mg	5		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02170220	Homo sapiens										false
181	40			118753351	328.429	LU-AA34443	Lu AA34443	CC1=C(C=CC(=C1)C(=O)O)SC2=CC=CC=C2N3CCNCC3	PLASMA								240		t	ng × h/mL	71.942							mg	5		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02170220	Homo sapiens										false
182	40			118753351	328.429	LU-AA34443	Lu AA34443	CC1=C(C=CC(=C1)C(=O)O)SC2=CC=CC=C2N3CCNCC3	PLASMA										∞	ng × h/mL	124.708							mg	5		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02170220	Homo sapiens										false
183	40			118753351	328.429	LU-AA34443	Lu AA34443	CC1=C(C=CC(=C1)C(=O)O)SC2=CC=CC=C2N3CCNCC3	PLASMA														ng/mL	1.374				mg	5		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02170220	Homo sapiens										false
184	40			9966051	298.446	VORTIOXETINE	VORTIOXETINE	CC1=CC(C)=C(SC2=C(C=CC=C2)N3CCNCC3)C=C1	PLASMA	3O2K1S3WQV							240		t	ng × h/mL	188.663							mg	5		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02170220	Homo sapiens										false
185	40			9966051	298.446	VORTIOXETINE	VORTIOXETINE	CC1=CC(C)=C(SC2=C(C=CC=C2)N3CCNCC3)C=C1	PLASMA	3O2K1S3WQV									∞	ng × h/mL	288.053							mg	5		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02170220	Homo sapiens										false
186	40			9966051	298.446	VORTIOXETINE	VORTIOXETINE	CC1=CC(C)=C(SC2=C(C=CC=C2)N3CCNCC3)C=C1	PLASMA	3O2K1S3WQV													ng/mL	1.67				mg	5		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02170220	Homo sapiens										false
187	40		ADULT	9966051	298.446	VORTIOXETINE	CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C	CC1=CC(C)=C(SC2=CC=CC=C2N3CCNCC3)C=C1	PLASMA	3O2K1S3WQV									∞	ng × h/mL	273.42		ng/mL	4.6			RECOMMENDED	mg	10		SINGLE	UNKNOWN					1	HEALTHY	Oral	FEMALE / MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/29189941/	Homo sapiens		h	60.62							false
188	40		ADULT	9966051	298.446	VORTIOXETINE	CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C	CC1=CC(C)=C(SC2=CC=CC=C2N3CCNCC3)C=C1	PLASMA	3O2K1S3WQV							24		t	ng × h/mL	344		ng/mL	17.92			RECOMMENDED	mg	10		MULTIPLE	UNKNOWN		day	1		1	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29189941/	Homo sapiens		h	58.84							false
189	40		ADULT	9966051	298.446	VORTIOXETINE	CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C	CC1=CC(C)=C(SC2=CC=CC=C2N3CCNCC3)C=C1	PLASMA	3O2K1S3WQV													ng/mL	33			RECOMMENDED	mg	20		STEADY-STATE	UNKNOWN		day	1		2	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204447s013lbl.pdf	Homo sapiens		h	66							false
190	41		ADULT	54726191	419.4	Dolutegravir	CC1CCOC2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O	CC1CCOC2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O	PLASMA	DKO1W9H7M1							24		t	μg × h/mL	53.6		μg/mL	3.67			RECOMMENDED	mg	50		STEADY-STATE	UNKNOWN		day	1		1.1	UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204790lbl.pdf	Homo sapiens		h	14							false
191	41		ADULT	57414794	419.3788	[NO STEREO] DOLUTEGRAVIR	CC1CCOC2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O	CC1CCOC2CN3C=C(C(=O)NCC4=C(F)C=C(F)C=C4)C(=O)C(O)=C3C(=O)N12	PLASMA	[NO STEREO] DKO1W9H7M1							24		t	μg × h/mL	75.1		μg/mL	4.15			RECOMMENDED	mg	50		STEADY-STATE	UNKNOWN		day	2		1.1	UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204790lbl.pdf	Homo sapiens		h	14							false
192	42		UNKNOWN	10184653	485.938	AFATINIB	AFATINIB	CN(C)C\\C=C\\C(=O)NC1=C(O[C@H]2CCOC2)C=C3N=CN=C(NC4=CC(Cl)=C(F)C=C4)C3=C1	PLASMA	41UD74L59M																						UNKNOWN				In vitro binding of afatinib to human plasma proteins is approximately 95%.	5	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/201292s014lbl.pdf	Homo sapiens										false
193	42		ADULT	10184653	485.163	AFATINIB	AFATINIB	CN(C)C\\C=C\\C(=O)NC1=C(O[C@H]2CCOC2)C=C3N=CN=C(NC4=CC(Cl)=C(F)C=C4)C3=C1	PLASMA	41UD74L59M									∞	ng × h/mL	886		ng/mL	33.7			UNKNOWN	mg	50		SINGLE	FASTED						UNHEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/24906422	Homo sapiens		h	74.9							false
194	42		ADULT	10184653	485.163	AFATINIB	AFATINIB	CN(C)C\\C=C\\C(=O)NC1=C(O[C@H]2CCOC2)C=C3N=CN=C(NC4=CC(Cl)=C(F)C=C4)C3=C1	PLASMA	41UD74L59M									∞	ng × h/mL	956		ng/mL	30.7			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/24906422	Homo sapiens		h	60.3							false
195	42		ADULT	10184653	485.163	AFATINIB	AFATINIB	CN(C)C\\C=C\\C(=O)NC1=C(O[C@H]2CCOC2)C=C3N=CN=C(NC4=CC(Cl)=C(F)C=C4)C3=C1	PLASMA	41UD74L59M							24		t	ng × h/mL	683		ng/mL	42.7			MAX TOLERATED	mg	40		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/29337963	Homo sapiens										false
196	43		ADULT	11707110	615.4	TRAMETINIB	TRAMETINIB	CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC4=C(F)C=C(I)C=C4)C5=CC(NC(C)=O)=CC=C5	PLASMA	33E86K87QN									∞	ng × h/mL	498		ng/mL	9.5			DEFINED DAILY	mg	2		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/23893461	Homo sapiens		h	127							false
197	43		ADULT	11707110	615.4	TRAMETINIB	TRAMETINIB	CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC4=C(F)C=C(I)C=C4)C5=CC(NC(C)=O)=CC=C5	PLASMA	33E86K87QN									∞	ng × h/mL	525		ng/mL	8.03			DEFINED DAILY	mg	2		SINGLE	FASTED				Trametinib is greater than 95% protein bound. Trametinib was highly bound to plasma protein in all species, including humans (96-98% in mouse, rat, dog, monkey and human plasma). https://www.tga.gov.au/sites/default/files/auspar-trametinib-140317.pdf	5	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/24606567	Homo sapiens		h	264							false
198	44		ADULT	44462760	519.101	DABRAFENIB	DABRAFENIB	CC(C)(C)C1=NC(=C(S1)C2=NC(N)=NC=C2)C3=C(F)C(NS(=O)(=O)C4=C(F)C=CC=C4F)=CC=C3	PLASMA	QGP4HA4G1B									∞	μg × h/mL	4341		ng/mL	1478			RECOMMENDED	mg	150		MULTIPLE	FASTED		day	2	Dabrafenib binds to human plasma protein and is 99.7% bound.	0.3	UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf	Homo sapiens		h	8							false
199	44		ADULT	44462760	519.101	DABRAFENIB	DABRAFENIB	CC(C)(C)C1=NC(=C(S1)C2=NC(N)=NC=C2)C3=C(F)C(NS(=O)(=O)C4=C(F)C=CC=C4F)=CC=C3	PLASMA	QGP4HA4G1B							12		t	ng × h/mL	2619		ng/mL	806			RP2D	mg	150		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4109288/	Homo sapiens		h	5.2							false
200	44		ADULT	44462760	519.101	DABRAFENIB	DABRAFENIB	CC(C)(C)C1=NC(=C(S1)C2=NC(N)=NC=C2)C3=C(F)C(NS(=O)(=O)C4=C(F)C=CC=C4F)=CC=C3	PLASMA	QGP4HA4G1B	11707110		TRAMETINIB	trametinib	CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC4=C(F)C=C(I)C=C4)C5=CC(NC(C)=O)=CC=C5	33E86K87QN			∞	ng × h/mL	13485.6		ng/mL	2497.4			DEFINED DAILY	mg	300		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947742/pdf/JDE-45-397.pdf	Homo sapiens		h	4.9							true
201	46		ADULT	21880659	486.429	[NO STEREO] VILANTEROL	C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl	OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCOCC2=C(Cl)C=CC=C2Cl	PLASMA	[NO STEREO] 028LZY775B									∞	pg × h/mL	251.4		pg/mL	495.9			INVESTIGATIONAL	μg	50		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23284643/	Homo sapiens		h	0.42							false
202	46		ADULT	21880659	486.429	[NO STEREO] VILANTEROL	C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl	OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCOCC2=C(Cl)C=CC=C2Cl	PLASMA	[NO STEREO] 028LZY775B							24		t	pg × h/mL	214		pg/mL	239			RECOMMENDED	μg	25		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25816315/	Homo sapiens										false
203	46		ADULT	21880659	486.429	[NO STEREO] VILANTEROL	C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl	OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCOCC2=C(Cl)C=CC=C2Cl	PLASMA	[NO STEREO] 028LZY775B	11519070		UMECLIDINIUM	umeclidinium	OC(C1=CC=CC=C1)(C2=CC=CC=C2)C34CC[N+](CCOCC5=CC=CC=C5)(CC3)CC4	GE2T1418SV	24		t	pg × h/mL	118		pg/mL	205			RECOMMENDED	μg	25		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25816315/	Homo sapiens		h	1.84							true
204	46		UNKNOWN	21880659	486.429	[NO STEREO] VILANTEROL	C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl	OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCOCC2=C(Cl)C=CC=C2Cl	PLASMA	[NO STEREO] 028LZY775B	11519070		Umeclidinium	C1C[N+]2(CCC1(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)CCOCC5=CC=CC=C5	C1C[N+]2(CCC1(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)CCOCC5=CC=CC=C5	GE2T1418SV											UNKNOWN				UNKNOWN	UNKNOWN		UNKNOWN			6	UNKNOWN	UNKNOWN	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203975s000lbl.pdf	Homo sapiens										true
205	47		ADULT	24812758	444.5	CANAGLIFLOZIN	CANAGLIFLOZIN	CC1=C(CC2=CC=C(S2)C3=CC=C(F)C=C3)C=C(C=C1)[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O	PLASMA	6S49DGR869									∞	ng × h/mL	10521		ng/mL	1178			RECOMMENDED	mg	100		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26048186	Homo sapiens		h	16							false
206	51		ADULT	3036505	378.891	OSPEMIFENE	OSPEMIFENE	OCCOC1=CC=C(C=C1)C(=C(\\CCCl)C2=CC=CC=C2)\\C3=CC=CC=C3	PLASMA	B0P231ILBK									∞	ng × h/mL	4165		ng/mL	533			RECOMMENDED	mg	60		SINGLE	FASTED						HEALTHY	Oral	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203505s000lbl.pdf	Homo sapiens		h	26							false
207	53		ADULT	134780	273.24	POMALIDOMIDE	POMALIDOMIDE	NC1=C2C(=O)N(C3CCC(=O)NC3=O)C(=O)C2=CC=C1	PLASMA	D2UX06XLB5									?	ng × h/mL	860		ng/mL	75			RECOMMENDED	mg	4		STEADY-STATE	UNKNOWN		day	1	Human plasma protein binding ranges from 12% to 44% and is not concentration dependent.	72	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204026s019lbl.pdf	Homo sapiens		h	7.5							false
208	54		ADULT	11450633	339.3916	ALOGLIPTIN	ALOGLIPTIN	CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC3=C(C=CC=C3)C#N)C1=O	PLASMA	JHC049LO86							24		t	ng × h/mL	842.17		ng/mL	75.38				mg	12.5		MULTIPLE			day	1			HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01391663	Homo sapiens										false
209	54		ADULT	11450633	339.3916	ALOGLIPTIN	ALOGLIPTIN	CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC3=C(C=CC=C3)C#N)C1=O	PLASMA	JHC049LO86							24		t	ng × h/mL	1625.58		ng/mL	154.83				mg	25		MULTIPLE			day	1			HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01391663	Homo sapiens										false
210	54		ADULT	11450633	339.3916	ALOGLIPTIN	ALOGLIPTIN	CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC3=C(C=CC=C3)C#N)C1=O	PLASMA	JHC049LO86							24		t	ng × h/mL	3389.21		ng/mL	335.36				mg	50		MULTIPLE			day	1			HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01391663	Homo sapiens										false
211	54		ADULT	11450633	339.3916	ALOGLIPTIN	ALOGLIPTIN	CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC3=C(C=CC=C3)C#N)C1=O	PLASMA	JHC049LO86													ng/mL	55.28				mg	12.5		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01391663	Homo sapiens										false
212	54		ADULT	11450633	339.3916	ALOGLIPTIN	ALOGLIPTIN	CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC3=C(C=CC=C3)C#N)C1=O	PLASMA	JHC049LO86									∞	ng × h/mL	895.28							mg	12.5		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01391663	Homo sapiens										false
213	54		ADULT	11450633	339.3916	ALOGLIPTIN	ALOGLIPTIN	CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC3=C(C=CC=C3)C#N)C1=O	PLASMA	JHC049LO86							24		t	ng × h/mL	601.65							mg	12.5		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01391663	Homo sapiens										false
214	54		ADULT	11450633	339.3916	ALOGLIPTIN	ALOGLIPTIN	CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC3=C(C=CC=C3)C#N)C1=O	PLASMA	JHC049LO86																		mg	12.5		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01391663	Homo sapiens		h	20.67							false
215	54		ADULT	11450633	339.3916	ALOGLIPTIN	ALOGLIPTIN	CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC3=C(C=CC=C3)C#N)C1=O	PLASMA	JHC049LO86													ng/mL	114.08				mg	25		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01391663	Homo sapiens										false
216	54		ADULT	11450633	339.3916	ALOGLIPTIN	ALOGLIPTIN	CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC3=C(C=CC=C3)C#N)C1=O	PLASMA	JHC049LO86									∞	ng × h/mL	1674.88							mg	25		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01391663	Homo sapiens										false
217	54		ADULT	11450633	339.3916	ALOGLIPTIN	ALOGLIPTIN	CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC3=C(C=CC=C3)C#N)C1=O	PLASMA	JHC049LO86							24		t	ng × h/mL	1174.76							mg	25		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01391663	Homo sapiens										false
218	54		ADULT	11450633	339.3916	ALOGLIPTIN	ALOGLIPTIN	CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC3=C(C=CC=C3)C#N)C1=O	PLASMA	JHC049LO86																		mg	25		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01391663	Homo sapiens		h	19.45							false
219	54		ADULT	11450633	339.3916	ALOGLIPTIN	ALOGLIPTIN	CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC3=C(C=CC=C3)C#N)C1=O	PLASMA	JHC049LO86													ng/mL	246				mg	50		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01391663	Homo sapiens										false
220	54		ADULT	11450633	339.3916	ALOGLIPTIN	ALOGLIPTIN	CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC3=C(C=CC=C3)C#N)C1=O	PLASMA	JHC049LO86									∞	ng × h/mL	3306.68							mg	50		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01391663	Homo sapiens										false
221	54		ADULT	11450633	339.3916	ALOGLIPTIN	ALOGLIPTIN	CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC3=C(C=CC=C3)C#N)C1=O	PLASMA	JHC049LO86							24		t	ng × h/mL	2488.48							mg	50		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01391663	Homo sapiens										false
222	54		ADULT	11450633	339.3916	ALOGLIPTIN	ALOGLIPTIN	CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC3=C(C=CC=C3)C#N)C1=O	PLASMA	JHC049LO86																		mg	50		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01391663	Homo sapiens		h	17							false
223	54		ADULT	11163584	339.3916	[NO STEREO] ALOGLIPTIN	CN1C(=O)C=C(N(C1=O)CC2=CC=CC=C2C#N)N3CCCC(C3)N	CN1C(=O)C=C(N2CCCC(N)C2)N(CC3=CC=CC=C3C#N)C1=O	PLASMA	[NO STEREO] JHC049LO86							24		t	ng × h/mL	1511		ng/mL	165			RECOMMENDED	mg	25		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25936384/	Homo sapiens		h	16.9							false
224	54		ADULT	11163584	339.3916	[NO STEREO] ALOGLIPTIN	CN1C(=O)C=C(N(C1=O)CC2=CC=CC=C2C#N)N3CCCC(C3)N	CN1C(=O)C=C(N2CCCC(N)C2)N(CC3=CC=CC=C3C#N)C1=O	PLASMA	[NO STEREO] JHC049LO86																	RECOMMENDED	mg	25		SINGLE	UNKNOWN					80	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022271s011lbl.pdf	Homo sapiens		h	21							false
225	56		ADULT	5388906	555.505	BEDAQUILINE	BEDAQUILINE	COC1=C(C=C2C=C(Br)C=CC2=N1)[C@@H](C3=CC=CC=C3)[C@@](O)(CCN(C)C)C4=C5C=CC=CC5=CC=C4	PLASMA	78846I289Y							144		t	mg × h/L	38.737		mg/L	2.547			UNKNOWN	mg	300		SINGLE	UNKNOWN				In human plasma samples, bedaquiline is >99.9% bound to protein at concentrations of ≥5 mg/L.	0.01	HEALTHY	Oral	FEMALE / MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/24860154/	Homo sapiens		h	24							false
226	56		ADULT	5388906	555.505	BEDAQUILINE	BEDAQUILINE	COC1=C(C=C2C=C(Br)C=CC2=N1)[C@@H](C3=CC=CC=C3)[C@@](O)(CCN(C)C)C4=C5C=CC=CC5=CC=C4	PLASMA	78846I289Y							144		t	mg × h/L	64.53		mg/L	3.755			UNKNOWN	mg	450		SINGLE	UNKNOWN				In human plasma samples, bedaquiline is >99.9% bound to protein at concentrations of ≥5 mg/L.	0.01	HEALTHY	Oral	FEMALE / MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/24860154/	Homo sapiens		h	24							false
227	56		UNKNOWN	5388906	555.505	BEDAQUILINE	BEDAQUILINE	COC1=C(C=C2C=C(Br)C=CC2=N1)[C@@H](C3=CC=CC=C3)[C@@](O)(CCN(C)C)C4=C5C=CC=CC5=CC=C4	PLASMA	78846I289Y																	UNKNOWN	mg	400		UNKNOWN	UNKNOWN		day	1	The plasma protein binding of bedaquiline is > 99.9%.	0.01	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/204384s000lbl.pdf	Homo sapiens										false
228	57		ADULT	10182969	459.5	Apixaban	COC1=CC=C(C=C1)N2C3=C(CCN(C3=O)C4=CC=C(C=C4)N5CCCCC5=O)C(=N2)C(=O)N	COC1=CC=C(C=C1)N2C3=C(CCN(C3=O)C4=CC=C(C=C4)N5CCCCC5=O)C(=N2)C(=O)N	PLASMA	3Z9Y7UWC1J									∞	ng × h/mL	2024		ng/mL	207			DEFINED DAILY	mg	10		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23488672/	Homo sapiens		h	12							false
229	57		ADULT	10182969	459.5	Apixaban		COC1=CC=C(C=C1)N2C3=C(CCN(C3=O)C4=CC=C(C=C4)N5CCCCC5=O)C(=N2)C(=O)N	PLASMA	3Z9Y7UWC1J																	UNKNOWN				UNKNOWN	UNKNOWN		UNKNOWN			13	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202155s000lbl.pdf	Homo sapiens		h	12							false
230	58			9853053	693.7204	LOMITAPIDE	LOMITAPIDE	FC(F)(F)CNC(=O)C4(CCCCN1CCC(CC1)NC(=O)C2=C(C=CC=C2)C3=CC=C(C=C3)C(F)(F)F)C5=CC=CC=C5C6=C4C=CC=C6	PLASMA	82KUB0583F							168		t	ng × h/mL	43.6		ng/mL	1.13				mg	20		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02044419	Homo sapiens		h	48.8							false
231	58			9853053	693.7204	LOMITAPIDE	LOMITAPIDE	FC(F)(F)CNC(=O)C4(CCCCN1CCC(CC1)NC(=O)C2=C(C=CC=C2)C3=CC=C(C=C3)C(F)(F)F)C5=CC=CC=C5C6=C4C=CC=C6	PLASMA	82KUB0583F							168		t	ng × h/mL	38.3		ng/mL	0.986				mg	20		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02044419	Homo sapiens		h	52.4							false
232	58			9853053	693.7204	LOMITAPIDE	LOMITAPIDE	FC(F)(F)CNC(=O)C4(CCCCN1CCC(CC1)NC(=O)C2=C(C=CC=C2)C3=CC=C(C=C3)C(F)(F)F)C5=CC=CC=C5C6=C4C=CC=C6	PLASMA	82KUB0583F							168		t	ng × h/mL	40.2		ng/mL	1.03				mg	20		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02044419	Homo sapiens		h	47.7							false
233	58			9928271	348.4	LOMITAPIDE metabolite M1	LOMITAPIDE metabolite M1	C1CNCCC1NC(=O)C2=CC=CC=C2C3=CC=C(C=C3)C(F)(F)F	PLASMA	BP7YFS63H2							168		t	ng × h/mL	75.2		ng/mL	2.74				mg	20		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02044419	Homo sapiens		h	39.1							false
234	58			9928271	348.4	LOMITAPIDE metabolite M1	LOMITAPIDE metabolite M1	C1CNCCC1NC(=O)C2=CC=CC=C2C3=CC=C(C=C3)C(F)(F)F	PLASMA	BP7YFS63H2							168		t	ng × h/mL	70.4		ng/mL	2.52				mg	20		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02044419	Homo sapiens		h	38.7							false
235	58			9928271	348.4	LOMITAPIDE metabolite M1	LOMITAPIDE metabolite M1	C1CNCCC1NC(=O)C2=CC=CC=C2C3=CC=C(C=C3)C(F)(F)F	PLASMA	BP7YFS63H2							168		t	ng × h/mL	72.9		ng/mL	2.65				mg	20		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02044419	Homo sapiens		h	37							false
236	58			54158214	377.4	LOMITAPIDE metabolite M3	LOMITAPIDE metabolite M3	C1=CC=C2C(=C1)C3=CC=CC=C3C2(CCCC(=O)O)C(=O)NCC(F)(F)F	PLASMA	EA4GAV9AYU							168		t	ng × h/mL	460		ng/mL	28.6				mg	20		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02044419	Homo sapiens		h	44							false
237	58			54158214	377.4	LOMITAPIDE metabolite M3	LOMITAPIDE metabolite M3	C1=CC=C2C(=C1)C3=CC=CC=C3C2(CCCC(=O)O)C(=O)NCC(F)(F)F	PLASMA	EA4GAV9AYU							168		t	ng × h/mL	443		ng/mL	30.2				mg	20		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02044419	Homo sapiens		h	46							false
238	58			54158214	377.4	LOMITAPIDE metabolite M3	LOMITAPIDE metabolite M3	C1=CC=C2C(=C1)C3=CC=CC=C3C2(CCCC(=O)O)C(=O)NCC(F)(F)F	PLASMA	EA4GAV9AYU							168		t	ng × h/mL	450		ng/mL	31				mg	20		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02044419	Homo sapiens		h	45.7							false
239	58		ADULT	9853053	693.7204	LOMITAPIDE	LOMITAPIDE	FC(F)(F)CNC(=O)C4(CCCCN1CCC(CC1)NC(=O)C2=C(C=CC=C2)C3=CC=C(C=C3)C(F)(F)F)C5=CC=CC=C5C6=C4C=CC=C6	PLASMA	82KUB0583F							24		t	ng × h/mL	241		ng/mL	5.75			RECOMMENDED	mg	60		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26686567/	Homo sapiens		h	51.5							false
240	58		ADULT	9853053	693.7204	LOMITAPIDE	LOMITAPIDE	FC(F)(F)CNC(=O)C4(CCCCN1CCC(CC1)NC(=O)C2=C(C=CC=C2)C3=CC=C(C=C3)C(F)(F)F)C5=CC=CC=C5C6=C4C=CC=C6	PLASMA	82KUB0583F							24		t	ng × h/mL	403		ng/mL	24.6			RECOMMENDED	mg	60		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26686567/	Homo sapiens		h	46.5							false
241	58		UNKNOWN	9853053	693.7204	LOMITAPIDE	LOMITAPIDE	FC(F)(F)CNC(=O)C4(CCCCN1CCC(CC1)NC(=O)C2=C(C=CC=C2)C3=CC=C(C=C3)C(F)(F)F)C5=CC=CC=C5C6=C4C=CC=C6	PLASMA	82KUB0583F																	UNKNOWN	mg	60		UNKNOWN	UNKNOWN		day	1	Lomitapide is 99.8% plasma-protein bound.	0.2	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/203858s019lbl.pdf	Homo sapiens										false
242	60		ADULT	24826799	532.5595	PONATINIB	PONATINIB	CN1CCN(CC2=C(C=C(NC(=O)C3=CC(C#CC4=CN=C5C=CC=NN45)=C(C)C=C3)C=C2)C(F)(F)F)CC1	BLOOD	4340891KFS							24		t	nM × h	2856		nM	183.1			UNKNOWN	mg	60		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23190221	Homo sapiens		h	19.7							false
243	60		ADULT	24826799	532.5595	PONATINIB	PONATINIB	CN1CCN(CC2=C(C=C(NC(=O)C3=CC(C#CC4=CN=C5C=CC=NN45)=C(C)C=C3)C=C2)C(F)(F)F)CC1	PLASMA	4340891KFS									?	ng × h/mL	1253		ng/mL	73			UNKNOWN	mg	45		STEADY-STATE	UNKNOWN		day	1	Ponatinib is greater than 99% bound to plasma proteins in vitro	1	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203469lbl.pdf	Homo sapiens										false
244	60		ADULT	24826799	532.5595	PONATINIB	PONATINIB	CN1CCN(CC2=C(C=C(NC(=O)C3=CC(C#CC4=CN=C5C=CC=NN45)=C(C)C=C3)C=C2)C(F)(F)F)CC1	PLASMA	4340891KFS							24		t	ng × h/mL	1253		ng/mL	73			DEFINED DAILY	mg	45		STEADY-STATE	UNKNOWN		day	1	Ponatinib is greater than 99% bound to plasma proteins in vitro.	1	UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203469lbl.pdf	Homo sapiens		h	24							false
245	62			9926791	312.3696	TOFACITINIB	TOFACITINIB	C[C@@H]1CCN(C[C@@H]1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N	PLASMA	87LA6FU830							24		t	ng × h/mL	2670.2		ng/mL	565				mg	100		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01743677	Homo sapiens		h	3.32							false
246	62			9926791	312.3696	TOFACITINIB	TOFACITINIB	C[C@@H]1CCN(C[C@@H]1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N	PLASMA	87LA6FU830							24		t	ng × h/mL	3114.3		ng/mL	647.4				mg	100		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01743677	Homo sapiens		h	3.005							false
247	62			9926791	312.3696	TOFACITINIB	TOFACITINIB	C[C@@H]1CCN(C[C@@H]1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N	PLASMA	87LA6FU830							24		t	ng × h/mL	1673.1		ng/mL	346.9				mg	100		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01743677	Homo sapiens		h	3.201							false
248	62			9926791	312.3696	TOFACITINIB	TOFACITINIB	C[C@@H]1CCN(C[C@@H]1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N	PLASMA	87LA6FU830							24		t	ng × h/mL	2669.7							mg	100		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01743677	Homo sapiens		h	3.284							false
249	62		ADULT	9926791	312.3696	TOFACITINIB	TOFACITINIB	C[C@@H]1CCN(C[C@@H]1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N	PLASMA	87LA6FU830																	RECOMMENDED	mg	5		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203214s000lbl.pdf	Homo sapiens		h	3							false
250	62		UNKNOWN	9926791	312.3696	TOFACITINIB	TOFACITINIB	C[C@@H]1CCN(C[C@@H]1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N	PLASMA	87LA6FU830																						UNKNOWN				The mean fraction unbound in human plasma of tofacitinib was determined to be 0.61	61	UNKNOWN		UNKNOWN	OTHER GOV'T	https://www.ema.europa.eu/en/documents/assessment-report/xeljanz-epar-public-assessment-report_en.pdf	Homo sapiens										false
251	62		ADULT	9926791	312.3696	TOFACITINIB	TOFACITINIB	C[C@@H]1CCN(C[C@@H]1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N	PLASMA	87LA6FU830									∞	ng × h/mL	259.8		ng/mL	36.7			UNKNOWN	mg	11		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26970526	Homo sapiens		h	5.9							false
252	62		ADULT	9926791	312.3696	TOFACITINIB	TOFACITINIB	C[C@@H]1CCN(C[C@@H]1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N	PLASMA	87LA6FU830							24		t	ng × h/mL	272.9		ng/mL	38.7			UNKNOWN	mg	11		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26970526	Homo sapiens										false
253	62		ADULT	9926791	312.3696	TOFACITINIB	TOFACITINIB	C[C@@H]1CCN(C[C@@H]1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N	PLASMA	87LA6FU830									∞	ng × h/mL	247.9		ng/mL	41.2			UNKNOWN	mg	5		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26970526	Homo sapiens		h	3.2							false
254	62		ADULT	9926791	312.3696	TOFACITINIB	TOFACITINIB	C[C@@H]1CCN(C[C@@H]1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N	PLASMA	87LA6FU830							24		t	ng × h/mL	266.1		ng/mL	44.1			UNKNOWN	mg	5		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26970526	Homo sapiens										false
255	63		ADULT	45356872	545.6213	[NO STEREO] OMACETAXINE MEPESUCCINATE	COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2C3=C(CCN4CCCC24C=C1OC)C=C5OCOC5=C3	COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2C3=C(CCN4CCCC24C=C1OC)C=C5OCOC5=C3	PLASMA	[NO STEREO] 6FG8041S5B									∞	ng × h/mL	136.2		ng/mL	25.1			DEFINED DAILY	mg/m²	1.25		SINGLE	UNKNOWN						UNHEALTHY	Subcutaneous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/23053254	Homo sapiens		h	6.96							false
256	64		ADULT	9924495	349.4	Perampanel		C1=CC=C(C=C1)N2C=C(C=C(C2=O)C3=CC=CC=C3C#N)C4=CC=CC=N4	PLASMA	H821664NPK									∞	μg × h/L	8.092		μg/L	123.3			RECOMMENDED	mg	4		SINGLE	UNKNOWN					4.5	HEALTHY	Oral	FEMALE / MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/25495693/	Homo sapiens		h	117.4							false
257	64		ADULT	9924495	349.3847	PERAMPANEL	C1=CC=C(C=C1)N2C=C(C=C(C2=O)C3=CC=CC=C3C#N)C4=CC=CC=N4	O=C1N(C=C(C=C1C2=CC=CC=C2C#N)C3=CC=CC=N3)C4=CC=CC=C4	PLASMA	H821664NPK									∞	μg × h/L	7352		μg/L	371.9			RECOMMENDED	mg	4		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/25495693/	Homo sapiens		h	98.1							false
258	64		ADULT	9924495	349.4	Perampanel		C1=CC=C(C=C1)N2C=C(C=C(C2=O)C3=CC=CC=C3C#N)C4=CC=CC=N4	PLASMA	H821664NPK																	UNKNOWN				UNKNOWN	UNKNOWN		UNKNOWN			4.5	HEALTHY	UNKNOWN	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202834lbl.pdf	Homo sapiens		h	105							false
259	65		UNKNOWN	11167602	482.815	REGORAFENIB	REGORAFENIB	CNC(=O)C1=NC=CC(OC2=CC(F)=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1	PLASMA	24T2A1DOYB																						UNKNOWN				Regorafenib is highly bound (99.5%) to human plasma proteins.	0.5	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203085lbl.pdf	Homo sapiens										false
260	65		ADULT	11167602	482.07687	REGORAFENIB	Regorafenib	CNC(=O)C1=NC=CC(OC2=CC(F)=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1	PLASMA	24T2A1DOYB							24		t	μg × h/mL	33042.8		μg/L	2522.2			UNKNOWN	mg	160		STEADY-STATE	FED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/23553067	Homo sapiens		h	30.4							false
261	66		UNKNOWN	54684141	270.2073	TERIFLUNOMIDE	TERIFLUNOMIDE	C\\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F	PLASMA	1C058IKG3B																						UNKNOWN				Teriflunomide is extensively bound to plasma protein (>99%) and is mainly distributed in plasma.	1	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202992s000lbl.pdf	Homo sapiens										false
262	66		ADULT	54684141	270.2073	TERIFLUNOMIDE	TERIFLUNOMIDE	C\\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F	PLASMA	1C058IKG3B							168		t	μg × h/mL	100		μg/mL	1.06			UNKNOWN	mg	7		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202992Orig1s000ClinpharmR.pdf	Homo sapiens		h	243							false
263	67		ADULT	5328940	530.446	BOSUTINIB	BOSUTINIB	COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl	PLASMA	5018V4AEZ0									?	ng × h/mL	3650		ng/mL	200			RECOMMENDED	mg	500		STEADY-STATE	FED		day	1	Bosutinib was highly bound to human plasma proteins in vitro (94%) and ex vivo in healthy subjects (96%), and binding was not concentration-dependent.	4	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203341lbl.pdf	Homo sapiens		h	22.5							false
264	67		ADULT	5328940	530.4	BOSUTINIB	BOSUTINIB	COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl	PLASMA	5018V4AEZ0									∞	ng × h/mL	3650		ng/mL	200			RECOMMENDED	mg	500		MULTIPLE	FED		day	1	Bosutinib was highly bound to human plasma proteins in vitro (94%) and ex vivo in healthy subjects (96%), and binding was not concentration-dependent. Species info here https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203341Orig1s000PharmR.pdf Bosutinib was highly bound to plasma proteins in all species tested: mouse, rat, rabbit, dog, and human plasma with mean unbound fractions (fu) of 0.059, 0.061, 0.028, 0.041, and 0.063 in the respective species.	4	UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203341lbl.pdf	Homo sapiens										false
265	67		ADULT	5328940	530.446	BOSUTINIB	BOSUTINIB	COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl	PLASMA	5018V4AEZ0									?	ng × h/mL	4084.7		ng/mL	278.12			UNKNOWN	mg	600		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203341Orig1s000ClinPharmR.pdf	Homo sapiens		h	15.4				2	BOSUTINIB		false
266	67		ADULT	5328940	530.446	BOSUTINIB	BOSUTINIB	COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl	PLASMA	5018V4AEZ0									?	ng × h/mL	2900		ng/mL	190			UNKNOWN	mg	400		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203341Orig1s000ClinPharmR.pdf	Homo sapiens		h	19.89				69	BOSUTINIB		false
267	67		ADULT	5328940	530.446	BOSUTINIB	BOSUTINIB	COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl	PLASMA	5018V4AEZ0									?	ng × h/mL	1170		ng/mL	76.6			UNKNOWN	mg	300		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203341Orig1s000ClinPharmR.pdf	Homo sapiens		h	19.4				5	BOSUTINIB		false
268	67		ADULT	5328940	530.446	BOSUTINIB	BOSUTINIB	COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl	PLASMA	5018V4AEZ0									?	ng × h/mL	1670		ng/mL	95.4			UNKNOWN	mg	200		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203341Orig1s000ClinPharmR.pdf	Homo sapiens		h	30				5	BOSUTINIB		false
269	67		ADULT	5328940	530.446	BOSUTINIB	BOSUTINIB	COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl	PLASMA	5018V4AEZ0									?	ng × h/mL	2340		ng/mL	117			UNKNOWN	mg	400		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203341Orig1s000ClinPharmR.pdf	Homo sapiens		h	18.6				54			false
270	67		ADULT	5328940	530.446	BOSUTINIB	BOSUTINIB	COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl	PLASMA	5018V4AEZ0									?	ng × h/mL	1200		ng/mL	63.7			UNKNOWN	mg	300		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203341Orig1s000ClinPharmR.pdf	Homo sapiens		h	17.1				7			false
271	67		ADULT	5328940	530.446	BOSUTINIB	BOSUTINIB	COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl	PLASMA	5018V4AEZ0									?	ng × h/mL	2950		ng/mL	125			UNKNOWN	mg	500		SINGLE	FED						UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203341Orig1s000ClinPharmR.pdf	Homo sapiens		h	21.9					BOSUTINIB		false
272	67		ADULT	5328940	530.446	BOSUTINIB	BOSUTINIB	COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl	PLASMA	5018V4AEZ0									?	ng × h/mL	3580		ng/mL	273			UNKNOWN	mg	500		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203341Orig1s000ClinPharmR.pdf	Homo sapiens		h	23.3				10	BOSUTINIB		false
273	67		ADULT	5328940	530.446	BOSUTINIB	BOSUTINIB	COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl	PLASMA	5018V4AEZ0									?	ng × h/mL	129		ng/mL	4.89			UNKNOWN	mg	50		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203341Orig1s000ClinPharmR.pdf	Homo sapiens		h	12.9				4			false
274	67		ADULT	5328940	530.446	BOSUTINIB	BOSUTINIB	COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl	PLASMA	5018V4AEZ0									?	ng × h/mL	329		ng/mL	19.6			UNKNOWN	mg	100		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203341Orig1s000ClinPharmR.pdf	Homo sapiens		h	64.7				4	BOSUTINIB		false
275	67		ADULT	5328940	530.446	BOSUTINIB	BOSUTINIB	COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl	PLASMA	5018V4AEZ0									?	ng × h/mL	114		ng/mL	6.9			UNKNOWN	mg	50		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203341Orig1s000ClinPharmR.pdf	Homo sapiens		h	25.8				3	BOSUTINIB		false
276	67		ADULT	5328940	530.446	BOSUTINIB	BOSUTINIB	COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl	PLASMA	5018V4AEZ0									?	ng × h/mL	284		ng/mL	17			UNKNOWN	mg	100		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203341Orig1s000ClinPharmR.pdf	Homo sapiens		h	18.6				4			false
277	67		ADULT	5328940	530.446	BOSUTINIB	BOSUTINIB	COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl	PLASMA	5018V4AEZ0									?	ng × h/mL	920		ng/mL	43.1			UNKNOWN	mg	200		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203341Orig1s000ClinPharmR.pdf	Homo sapiens		h	20.79				6			false
278	67		ADULT	5328940	530.446	BOSUTINIB	BOSUTINIB	COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl	PLASMA	5018V4AEZ0									?	ng × h/mL	2950		ng/mL	125			UNKNOWN	mg	500		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203341Orig1s000ClinPharmR.pdf	Homo sapiens		h	21.9				13			false
279	67		ADULT	5328940	530.446	BOSUTINIB	BOSUTINIB	COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl	PLASMA	5018V4AEZ0									?	ng × h/mL	4300		ng/mL	206			UNKNOWN	mg	600		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203341Orig1s000ClinPharmR.pdf	Homo sapiens		h	19.9				10			false
280	67		ADULT	5328940	530.446	BOSUTINIB	BOSUTINIB	COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl	PLASMA	5018V4AEZ0									?	ng × h/mL	4000		ng/mL	216			UNKNOWN	mg	800		SINGLE	HIGH-FAT						HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203341Orig1s000ClinPharmR.pdf	Homo sapiens		h	33.8					BOSUTINIB		false
281	67		ADULT	5328940	530.4	BOSUTINIB	BOSUTINIB	COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl	PLASMA	5018V4AEZ0									∞	ng × h/mL	1150		ng/mL	62.1			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/27113346	Homo sapiens		h	39.1							false
282	67		ADULT	5328940	530.4	BOSUTINIB	BOSUTINIB	COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl	PLASMA	5018V4AEZ0									∞	ng × h/mL	1768		ng/mL	88			UNKNOWN	mg	400		SINGLE	FED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/27113346	Homo sapiens		h	32.4							false
283	68		ADULT	15951529	464.4	ENZALUTAMIDE	ENZALUTAMIDE	CNC(=O)C1=CC=C(C=C1F)N2C(=S)N(C(=O)C2(C)C)C3=CC(=C(C=C3)C#N)C(F)(F)F	PLASMA	93T0T9GKNU									∞	μg × h/mL	340		μg/mL	3.4			UNKNOWN	mg	150		SINGLE	FED				The mean unbound fraction for enzalutamide ranged from 1.49 to 2.39 %, from 2.62 to 3.63 % for N-desmethyl enzalutamide, and from 1.43 to 2.28 % for the carboxylic acid metabolite.	1.94	UNHEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/25917876	Homo sapiens		day	6							false
284	70		ADULT	11434515	484.7	Aclidinium		C1C[N+]2(CCC1C(C2)OC(=O)C(C3=CC=CS3)(C4=CC=CS4)O)CCCOC5=CC=CC=C5	PLASMA	K17VY42F6C							12		t	pg × h/mL	468.4		pg/mL	240.5			RECOMMENDED	μg	400		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22366196/	Homo sapiens		h	17							false
285	70		ADULT	11434515	484.7	Aclidinium	C1C[N+]2(CCC1C(C2)OC(=O)C(C3=CC=CS3)(C4=CC=CS4)O)CCCOC5=CC=CC=C5	C1C[N+]2(CCC1C(C2)OC(=O)C(C3=CC=CS3)(C4=CC=CS4)O)CCCOC5=CC=CC=C5	PLASMA	K17VY42F6C									∞	pg × h/mL	386.7		pg/mL	194.2			RECOMMENDED	μg	400		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://pubmed.ncbi.nlm.nih.gov/22366196/	Homo sapiens		h	5.9							false
286	70		UNKNOWN	11434515	484.7	Aclidinium		C1C[N+]2(CCC1C(C2)OC(=O)C(C3=CC=CS3)(C4=CC=CS4)O)CCCOC5=CC=CC=C5	PLASMA	K17VY42F6C																	UNKNOWN				UNKNOWN	UNKNOWN		UNKNOWN				UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202450s012lbl.pdf	Homo sapiens		h	6.5							false
287	71		UNKNOWN	11556711	719.9099	CARFILZOMIB	CARFILZOMIB	CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN2CCOCC2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]4(C)CO4	PLASMA	72X6E3J5AR																						UNKNOWN				When tested in vitro, the binding of carfilzomib to human plasma proteins averaged 97% over the concentration range of 0.4 to 4 micromolar.	3	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202714lbl.pdf	Homo sapiens										false
288	71		ADULT	11556711	719.9099	CARFILZOMIB	CARFILZOMIB	CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN2CCOCC2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]4(C)CO4	PLASMA	72X6E3J5AR	5743		DEXAMETHASONE	Dexamethasone	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO	7S5I7G3JQL			∞	ng × h/mL	563		ng/mL	1389			RECOMMENDED	mg/m²	56		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/28424963	Homo sapiens		h	0.34							true
289	72		ADULT	9865528	396.506	MIRABEGRON	MIRABEGRON	NC1=NC(CC(=O)NC2=CC=C(CCNC[C@H](O)C3=CC=CC=C3)C=C2)=CS1	PLASMA	MVR3JL3B2V									∞	ng × h/mL	177		ng/mL	12.8			MAX DAILY	mg	50		SINGLE	FASTED				The plasma protein binding is 71%.	29	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202611Orig1s000ClinPharmR.pdf	Homo sapiens		h	41.5							false
290	72		ADULT	9865528	396.506	MIRABEGRON	MIRABEGRON	NC1=NC(CC(=O)NC2=CC=C(CCNC[C@H](O)C3=CC=CC=C3)C=C2)=CS1	PLASMA	MVR3JL3B2V									∞	ng × h/mL	46.82		ng/mL	29.4			MAX DAILY	mg	50		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/25791612	Homo sapiens		h	28.1							false
291	73		ADULT	11658860	195.689	LORCASERIN	LORCASERIN	C[C@H]1CNCCC2=CC=C(Cl)C=C12	PLASMA	637E494O0Z							24		t	ng × h/mL	611		ng/mL	38.5			DEFINED DAILY	mg	20		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27692638/	Homo sapiens		h	13							false
292	73		ADULT	11658860	195.689	LORCASERIN	LORCASERIN	C[C@H]1CNCCC2=CC=C(Cl)C=C12	PLASMA	637E494O0Z							24		t	ng × h/mL	808		ng/mL	56.1			DEFINED DAILY	mg	20		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27692638/	Homo sapiens		h	12.4							false
293	73		ADULT	11658860	195.689	LORCASERIN	LORCASERIN	C[C@H]1CNCCC2=CC=C(Cl)C=C12	PLASMA	637E494O0Z							24		t	ng × h/mL	1216		ng/mL	69.5			RECOMMENDED	mg	20		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27692638/	Homo sapiens		h	12.4							false
294	73		ADULT	11658860	195.689	LORCASERIN	LORCASERIN	C[C@H]1CNCCC2=CC=C(Cl)C=C12	PLASMA	637E494O0Z							24		t	ng × h/mL	1318		ng/mL	78.7			RECOMMENDED	mg	20		STEADY-STATE	FED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27692638/	Homo sapiens		h	12							false
295	73		ADULT	11658860	195.689	LORCASERIN	LORCASERIN	C[C@H]1CNCCC2=CC=C(Cl)C=C12	PLASMA	637E494O0Z									∞	ng × h/mL	172		ng/mL	11.16			UNKNOWN	mg	3		SINGLE	UNKNOWN					30	HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022529Orig1s000ClinPharmR.pdf	Homo sapiens		h	11.38							false
296	73		ADULT	11658860	195.689	LORCASERIN	LORCASERIN	C[C@H]1CNCCC2=CC=C(Cl)C=C12	PLASMA	637E494O0Z							24		t	ng × h/mL	172.2		ng/mL	13.7			UNKNOWN	mg	3		STEADY-STATE	UNKNOWN		day	1		30	HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022529Orig1s000ClinPharmR.pdf	Homo sapiens		h	10.23							false
297	73		ADULT	11658860	195.689	LORCASERIN	LORCASERIN	C[C@H]1CNCCC2=CC=C(Cl)C=C12	PLASMA	637E494O0Z									∞	ng × h/mL	516.9		ng/mL	39.7			UNKNOWN	mg	10		SINGLE	UNKNOWN					30	HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022529Orig1s000ClinPharmR.pdf	Homo sapiens		h	8.87							false
298	73		ADULT	11658860	195.689	LORCASERIN	LORCASERIN	C[C@H]1CNCCC2=CC=C(Cl)C=C12	PLASMA	637E494O0Z							24		t	ng × h/mL	593.8		ng/mL	50.85			UNKNOWN	mg	10		STEADY-STATE	UNKNOWN		day	1		30	HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022529Orig1s000ClinPharmR.pdf	Homo sapiens		h	10.28							false
299	73		ADULT	11658860	195.689	LORCASERIN	LORCASERIN	C[C@H]1CNCCC2=CC=C(Cl)C=C12	PLASMA	637E494O0Z									∞	ng × h/mL	1086.2		ng/mL	83.77			DEFINED DAILY	mg	20		SINGLE	UNKNOWN					30	HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022529Orig1s000ClinPharmR.pdf	Homo sapiens		h	9.55							false
300	73		ADULT	11658860	195.689	LORCASERIN	LORCASERIN	C[C@H]1CNCCC2=CC=C(Cl)C=C12	PLASMA	637E494O0Z							24		t	ng × h/mL	899.2		ng/mL	85.02			RECOMMENDED	mg	20		STEADY-STATE	UNKNOWN		day	1		30	HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022529Orig1s000ClinPharmR.pdf	Homo sapiens		h	11.26							false
301	74		ADULT	9869929	483.9	Avanafil		COC1=C(C=C(C=C1)CNC2=NC(=NC=C2C(=O)NCC3=NC=CC=N3)N4CCCC4CO)Cl	PLASMA	DR5S136IVO									∞	ng × h/mL	7148.67		ng/mL	2630			RECOMMENDED	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20637970/	Homo sapiens		h	7.53							false
302	74		ADULT	18762634	483.951	[NO STEREO] AVANAFIL	COC1=C(C=C(C=C1)CNC2=NC(=NC=C2C(=O)NCC3=NC=CC=N3)N4CCCC4CO)Cl	COC1=C(Cl)C=C(CNC2=NC(=NC=C2C(=O)NCC3=NC=CC=N3)N4CCCC4CO)C=C1	PLASMA	[NO STEREO] DR5S136IVO									∞	ng × h/mL	7339.13		ng/mL	2231.63			RECOMMENDED	mg	100		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20637970/	Homo sapiens		h	8.66							false
303	74		ADULT	9869929	483.9	Avanafil		COC1=C(C=C(C=C1)CNC2=NC(=NC=C2C(=O)NCC3=NC=CC=N3)N4CCCC4CO)Cl	PLASMA	DR5S136IVO																	UNKNOWN				SINGLE	UNKNOWN					1	UNKNOWN	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202276s000lbl.pdf	Homo sapiens		h	5							false
304	77		ADULT	9978917	410.4515	TAFLUPROST ACID	TAFLUPROST ACID	O[C@H]1C[C@@H](O)[C@H](\\C=C\\C(F)(F)COC2=CC=CC=C2)[C@H]1C\\C=C/CCCC(O)=O	PLASMA	WTV8EPZ396									?	pg × min/mL	405.9		pg/mL	24.4			RECOMMENDED	drop	1		SINGLE	UNKNOWN						HEALTHY	Topical	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18752509	Homo sapiens										false
305	77		ADULT	9978917	410.4515	TAFLUPROST ACID	TAFLUPROST ACID	O[C@H]1C[C@@H](O)[C@H](\\C=C\\C(F)(F)COC2=CC=CC=C2)[C@H]1C\\C=C/CCCC(O)=O	PLASMA	WTV8EPZ396									∞	pg × min/mL	394		pg/mL	26			RECOMMENDED	drop	1		SINGLE	UNKNOWN						HEALTHY	Topical	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202514s000lbl.pdf	Homo sapiens										false
306	78		ADULT	16220172	392.4907	IVACAFTOR	IVACAFTOR	CC(C)(C)C1=CC(=C(NC(=O)C2=CNC3=C(C=CC=C3)C2=O)C=C1O)C(C)(C)C	PLASMA	1Y740ILL1Z									∞	ng × h/mL	44916		ng/mL	2212			UNKNOWN	mg	150		SINGLE	HIGH-FAT						HEALTHY	Oral	UNKNOWN	EXPERIMENT	http://www.concertpharma.com/wp-content/uploads/2015/10/CTP656-Ph1SAD-NACFC-08OCT2015.pdf	Homo sapiens		h	15							false
307	79		ADULT	24776445	421.297	VISMODEGIB	vismodegib	CS(=O)(=O)C1=CC(Cl)=C(C=C1)C(=O)NC2=CC(=C(Cl)C=C2)C3=NC=CC=C3	PLASMA	25X868M3DS									∞	μM × h	2850		μM	5.95			DEFINED DAILY	mg	150		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22458643	Homo sapiens		day	11.3							false
308	79		UNKNOWN	24776445	421.297	VISMODEGIB	VISMODEGIB	CS(=O)(=O)C1=CC(Cl)=C(C=C1)C(=O)NC2=CC(=C(Cl)C=C2)C3=NC=CC=C3	PLASMA	25X868M3DS																						UNKNOWN				The mean (±SD) fraction unbound increases from 0.00253 ± 0.00144 (single dose) to 0.00653 ± 0.00286 (steady state).	0.45	UNKNOWN		UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/21753154/	Homo sapiens										false
309	80		ADULT	6450551	386.47	AXITINIB	AXITINIB	CNC(=O)C1=C(SC2=CC3=C(C=C2)C(\\C=C\\C4=NC=CC=C4)=NN3)C=CC=C1	PLASMA	C9LVQ0YUXG							24		t	ng × h/mL	2171		ng/mL	162			UNKNOWN	mg	20		STEADY-STATE	FED		day	2			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16027439	Homo sapiens		h	4.8							false
310	80		ADULT	6450551	386.47	AXITINIB	AXITINIB	CNC(=O)C1=C(SC2=CC3=C(C=C2)C(\\C=C\\C4=NC=CC=C4)=NN3)C=CC=C1	PLASMA	C9LVQ0YUXG							24		t	μg × h/mL	717		ng/mL	82			UNKNOWN	mg	15		STEADY-STATE	FED		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16027439	Homo sapiens		h	4.6							false
311	80		ADULT	6450551	386.47	AXITINIB	AXITINIB	CNC(=O)C1=C(SC2=CC3=C(C=C2)C(\\C=C\\C4=NC=CC=C4)=NN3)C=CC=C1	PLASMA	C9LVQ0YUXG							24		t	ng × h/mL	265		ng/mL	27.8			UNKNOWN	mg	5		SINGLE	HIGH-FAT				Axitinib is highly bound (>99%) to human plasma proteins with preferential binding to albumin and moderate binding to α1-acid glycoprotein.	1	UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202324lbl.pdf	Homo sapiens										false
312	80		ADULT	6450551	386.47	AXITINIB	AXITINIB	CNC(=O)C1=C(SC2=CC3=C(C=C2)C(\\C=C\\C4=NC=CC=C4)=NN3)C=CC=C1	PLASMA	C9LVQ0YUXG							24		t	ng × h/mL	265		ng/mL	27.8			RECOMMENDED	mg	5		STEADY-STATE	FED		day	2	Axitinib is highly bound (>99%) to human plasma proteins with preferential binding to albumin and moderate binding to α1-acid glycoprotein.	1	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202324lbl.pdf	Homo sapiens										false
313	80		ADULT	6450551	386.12012	AXITINIB	AXITINIB	CNC(=O)C1=C(SC2=CC3=C(C=C2)C(\\C=C\\C4=NC=CC=C4)=NN3)C=CC=C1	PLASMA	C9LVQ0YUXG									∞	ng × h/mL	187		ng/mL	51.1			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/19603168	Homo sapiens		h	9.4							false
314	80		ADULT	6450551	386.12012	AXITINIB	AXITINIB	CNC(=O)C1=C(SC2=CC3=C(C=C2)C(\\C=C\\C4=NC=CC=C4)=NN3)C=CC=C1	BLOOD	C9LVQ0YUXG									∞	ng × h/mL	160.3		ng/mL	32.2			UNKNOWN	mg	5		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/22644797	Homo sapiens		h	5.4							false
315	80		ADULT	6450551	386.12012	AXITINIB	AXITINIB	CNC(=O)C1=C(SC2=CC3=C(C=C2)C(\\C=C\\C4=NC=CC=C4)=NN3)C=CC=C1	BLOOD	C9LVQ0YUXG									∞	ng × h/mL	206.8		ng/mL	52.7			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/22644797	Homo sapiens		h	7							false
316	80		ADULT	6450551	386.12012	AXITINIB	AXITINIB	CNC(=O)C1=C(SC2=CC3=C(C=C2)C(\\C=C\\C4=NC=CC=C4)=NN3)C=CC=C1	BLOOD	C9LVQ0YUXG									∞	ng × h/mL	162		ng/mL	28.8			UNKNOWN	mg	5		SINGLE	HIGH-FAT						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/22644797	Homo sapiens		h	3							false
317	81		ADULT	6918670	430.5339	INGENOL MEBUTATE	INGENOL MEBUTATE	C\\C=C(\\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C	BLOOD	7686S50JAH									?	ng × h/mL	1.43		nM	0.332			UNKNOWN	mg	0.127		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Topical	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/28524709	Homo sapiens										false
318	83		ADULT	25126798	306.365	RUXOLITINIB	RUXOLITINIB	N#CC[C@H](C1CCCC1)N2C=C(C=N2)C3=NC=NC4=C3C=CN4	PLASMA	82S8X8XX8H									∞	nM × h	21500		nM	5300			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://doi.org/10.1182/blood.V118.21.5162.5162	Homo sapiens		h	3.28							false
319	83		ADULT	25126798	306.365	RUXOLITINIB	RUXOLITINIB	N#CC[C@H](C1CCCC1)N2C=C(C=N2)C3=NC=NC4=C3C=CN4	PLASMA	82S8X8XX8H									∞	nM × h	2160		nM	613			UNKNOWN	mg	10		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://doi.org/10.1182/blood.V118.21.5162.5162	Homo sapiens		h	2.98							false
320	83		ADULT	25126798	306.365	RUXOLITINIB	RUXOLITINIB	N#CC[C@H](C1CCCC1)N2C=C(C=N2)C3=NC=NC4=C3C=CN4	PLASMA	82S8X8XX8H									∞	nM × h	2190		nM	562			UNKNOWN	mg	10		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://doi.org/10.1182/blood.V118.21.5162.5162	Homo sapiens		h	2.96							false
321	83		UNKNOWN	25126798	306.365	RUXOLITINIB	RUXOLITINIB	N#CC[C@H](C1CCCC1)N2C=C(C=N2)C3=NC=NC4=C3C=CN4	PLASMA	82S8X8XX8H																						UNKNOWN				The mean fraction unbound in vitro in human plasma and serum as determined by equilibrium dialysis is 3.3% and 3.2%, respectively, and similar at 3 and 10 uM of ruxolitinib concentrations (study INCYTE-DMB-07.11.1). There are also data from https://www.ncbi.nlm.nih.gov/pubmed/27128228 (In the pooled plasma from subjects with normal, mild, moderate, and severe hepatic impairment, the fraction unbound was 3.5%, 3.4%, 3.3%, and 4.1%, respectively. The ex vivo protein binding of ruxolitinib was determined in pooled samples from patients; The unbound fraction of ruxolitinib was quantified using LC/MS/MS with the percent fraction unbound calculated as final compound concentration in post-dialysis buffer divided by final compound concentration in post-dialysis plasma from the incubation.)	3.3	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202192Orig1s000ClinPharmR.pdf	Homo sapiens										false
322	83		ADULT	25126798	306.365	RUXOLITINIB	RUXOLITINIB	N#CC[C@H](C1CCCC1)N2C=C(C=N2)C3=NC=NC4=C3C=CN4	PLASMA	82S8X8XX8H									∞	nM × h	4350		nM	1100			UNKNOWN	mg	25		MULTIPLE	FASTED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/30105794	Homo sapiens		h	2.8							false
323	83		ADULT	25126798	306.365	RUXOLITINIB	RUXOLITINIB	N#CC[C@H](C1CCCC1)N2C=C(C=N2)C3=NC=NC4=C3C=CN4	PLASMA	82S8X8XX8H									∞	nM × h	3180		nM	333			UNKNOWN	mg	25		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/30105794	Homo sapiens		h	5.3							false
324	84		ADULT	2789	300.74	CLOBAZAM	CLOBAZAM	CN1C2=C(C=C(Cl)C=C2)N(C3=CC=CC=C3)C(=O)CC1=O	PLASMA	2MRO291B4U									∞	μg × h/L	13741		μg/L	641			RECOMMENDED	mg	30		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6529527/	Homo sapiens										false
325	84		ADULT	2789	300.74	CLOBAZAM	CLOBAZAM	CN1C2=C(C=C(Cl)C=C2)N(C3=CC=CC=C3)C(=O)CC1=O	PLASMA	2MRO291B4U																	UNKNOWN	mg	30		UNKNOWN	UNKNOWN		day	1	The in vitro plasma protein binding of clobazam and N-desmethylclobazam is approximately 80-90% and 70%, respectively.	10	UNKNOWN	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202067s005,203993s007lbl.pdf	Homo sapiens		h	36							false
326	85			2972	139.1519	DEFERIPRONE	DEFERIPRONE	CN1C=CC(=O)C(O)=C1C	SERUM	2BTY8KH53L																		mg/kg	33		SINGLE								Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01770652	Homo sapiens		h	1.77							false
327	85			2972	139.1519	DEFERIPRONE	DEFERIPRONE	CN1C=CC(=O)C(O)=C1C	SERUM	2BTY8KH53L													μg/mL	33.4				mg/kg	33		SINGLE								Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01770652	Homo sapiens										false
328	85			2972	139.1519	DEFERIPRONE	DEFERIPRONE	CN1C=CC(=O)C(O)=C1C	SERUM	2BTY8KH53L																		mg/kg	33		SINGLE								Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01770652	Homo sapiens		h	2.03							false
329	85			2972	139.1519	DEFERIPRONE	DEFERIPRONE	CN1C=CC(=O)C(O)=C1C	SERUM	2BTY8KH53L													μg/mL	43.3				mg/kg	33		SINGLE								Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01770652	Homo sapiens										false
330	85			2972	139.1519	DEFERIPRONE	DEFERIPRONE	CN1C=CC(=O)C(O)=C1C	SERUM	2BTY8KH53L																		mg/kg	33		SINGLE								Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01770652	Homo sapiens		h	2.2							false
331	85			2972	139.1519	DEFERIPRONE	DEFERIPRONE	CN1C=CC(=O)C(O)=C1C	SERUM	2BTY8KH53L													μg/mL	30.6				mg/kg	33		SINGLE								Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01770652	Homo sapiens										false
332	85			10064278	315.276	Deferiprone 3-O-beta-D-Glucuronide	DEFERIPRONE 3-O-.BETA.-D-GLUCURONIDE	CC1=C(C(=O)C=CN1C)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C(=O)O)O)O)O	SERUM	1QOS5ADQ2R																		mg/kg	33		SINGLE								Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01770652	Homo sapiens		h	2.58							false
333	85			10064278	315.276	Deferiprone 3-O-beta-D-Glucuronide	DEFERIPRONE 3-O-.BETA.-D-GLUCURONIDE	CC1=C(C(=O)C=CN1C)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C(=O)O)O)O)O	SERUM	1QOS5ADQ2R													μg/mL	60.8				mg/kg	33		SINGLE								Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01770652	Homo sapiens										false
334	85			10064278	315.276	Deferiprone 3-O-beta-D-Glucuronide	DEFERIPRONE 3-O-.BETA.-D-GLUCURONIDE	CC1=C(C(=O)C=CN1C)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C(=O)O)O)O)O	SERUM	1QOS5ADQ2R																		mg/kg	33		SINGLE								Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01770652	Homo sapiens		h	2.58							false
335	85			10064278	315.276	Deferiprone 3-O-beta-D-Glucuronide	DEFERIPRONE 3-O-.BETA.-D-GLUCURONIDE	CC1=C(C(=O)C=CN1C)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C(=O)O)O)O)O	SERUM	1QOS5ADQ2R													μg/mL	118.8				mg/kg	33		SINGLE								Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01770652	Homo sapiens										false
336	85			10064278	315.276	Deferiprone 3-O-beta-D-Glucuronide	DEFERIPRONE 3-O-.BETA.-D-GLUCURONIDE	CC1=C(C(=O)C=CN1C)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C(=O)O)O)O)O	SERUM	1QOS5ADQ2R																		mg/kg	33		SINGLE								Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01770652	Homo sapiens		h	3.35							false
337	85			10064278	315.276	Deferiprone 3-O-beta-D-Glucuronide	DEFERIPRONE 3-O-.BETA.-D-GLUCURONIDE	CC1=C(C(=O)C=CN1C)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C(=O)O)O)O)O	SERUM	1QOS5ADQ2R													μg/mL	150.8				mg/kg	33		SINGLE								Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01770652	Homo sapiens										false
338	85			2972	139.1519	DEFERIPRONE	DEFERIPRONE	CN1C=CC(=O)C(O)=C1C	PLASMA	2BTY8KH53L									∞	μg × h/mL	95.4		μg/mL	34.1				mg/kg	33		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01860703	Homo sapiens		h	1.8							false
339	85			10064278	315.276	Deferiprone 3-O-beta-D-Glucuronide	DEFERIPRONE 3-O-glucuronide	CC1=C(C(=O)C=CN1C)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C(=O)O)O)O)O	PLASMA	1QOS5ADQ2R									∞	μg × h/mL	205.5		μg/mL	35.2				mg/kg	33		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01860703	Homo sapiens		h	2.5							false
340	85			2972	139.1519	DEFERIPRONE	DEFERIPRONE	CN1C=CC(=O)C(O)=C1C	PLASMA	2BTY8KH53L									∞	μg × h/mL	152.1		μg/mL	54.4				mg/kg	50		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01860703	Homo sapiens		h	1.8							false
341	85			10064278	315.276	Deferiprone 3-O-beta-D-Glucuronide	DEFERIPRONE 3-O-glucuronide	CC1=C(C(=O)C=CN1C)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C(=O)O)O)O)O	PLASMA	1QOS5ADQ2R									∞	μg × h/mL	331.2		μg/mL	51.4				mg/kg	50		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01860703	Homo sapiens		h	2.6							false
342	85		ADULT		139.15	DEFERIPRONE	CC1=C(C(=O)C=CN1C)O	CC1=C(C(=O)C=CN1C)O	PLASMA										∞	μM × min	15001		μM	64.8			RECOMMENDED	mg/kg	25		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27975237/	Homo sapiens		min	168							false
343	86		ADULT	11626560	450.337	CRIZOTINIB	CRIZOTINIB	C[C@@H](OC1=C(N)N=CC(=C1)C2=CN(N=C2)C3CCNCC3)C4=C(Cl)C(F)=CC=C4Cl	PLASMA	53AH36668S									?	ng × h/mL	3240		ng/mL	475			UNKNOWN	mg	300		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31778074	Homo sapiens										false
344	86		ADULT	11626560	450.337	CRIZOTINIB	CRIZOTINIB	C[C@@H](OC1=C(N)N=CC(=C1)C2=CN(N=C2)C3CCNCC3)C4=C(Cl)C(F)=CC=C4Cl	PLASMA	53AH36668S									?	ng × h/mL	3084		ng/mL	327			RECOMMENDED	mg	250		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202570Orig1s000ClinPharmR.pdf	Homo sapiens										false
345	86		ADULT	11626560	450.337	CRIZOTINIB	CRIZOTINIB	C[C@@H](OC1=C(N)N=CC(=C1)C2=CN(N=C2)C3CCNCC3)C4=C(Cl)C(F)=CC=C4Cl	PLASMA	53AH36668S									?	ng × h/mL	3054		ng/mL	328			RECOMMENDED	mg	250		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202570Orig1s000ClinPharmR.pdf	Homo sapiens										false
346	86		ADULT	11626560	450.337	CRIZOTINIB	CRIZOTINIB	C[C@@H](OC1=C(N)N=CC(=C1)C2=CN(N=C2)C3CCNCC3)C4=C(Cl)C(F)=CC=C4Cl	PLASMA	53AH36668S									∞	ng × h/mL	1817		ng/mL	87			RECOMMENDED	mg	250		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202570Orig1s000ClinPharmR.pdf	Homo sapiens		h	47.1							false
347	86		UNKNOWN	11626560	450.3	CRIZOTINIB	CRIZOTINIB	C[C@@H](OC1=C(N)N=CC(=C1)C2=CN(N=C2)C3CCNCC3)C4=C(Cl)C(F)=CC=C4Cl	PLASMA	53AH36668S																						UNKNOWN				Unbound fraction (fu) of PF-02341066 (CRIZOTINIB) in plasma from preclinical species and humans determined using equilibrium dialysis. Original data are from in vitro exp. https://www.ncbi.nlm.nih.gov/pubmed/?21098644	9.3	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202570Orig1s000PharmR.pdf	Homo sapiens										false
348	86		ADULT	11626560	450.337	CRIZOTINIB	CRIZOTINIB	C[C@@H](OC1=C(N)N=CC(=C1)C2=CN(N=C2)C3CCNCC3)C4=C(Cl)C(F)=CC=C4Cl	PLASMA	53AH36668S									∞	ng × h/mL	2321		ng/mL	99.6			DEFINED DAILY	mg	250		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/24990113	Homo sapiens		h	29							false
349	87		ADULT	6918173	1304.522	ICATIBANT	ICATIBANT	N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC(=O)N[C@@H](CC3=CC=CS3)C(=O)N[C@@H](CO)C(=O)N4CC5=C(C[C@@H]4C(=O)N6[C@H]7CCCC[C@H]7C[C@H]6C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C=CC=C5	PLASMA	7PG89G35Q7													ng/mL	1190				mg	30		SINGLE							HEALTHY	Subcutaneous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02045264	Homo sapiens										false
350	87		ADULT	6918173	1304.522	ICATIBANT	ICATIBANT	N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC(=O)N[C@@H](CC3=CC=CS3)C(=O)N[C@@H](CO)C(=O)N4CC5=C(C[C@@H]4C(=O)N6[C@H]7CCCC[C@H]7C[C@H]6C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C=CC=C5	PLASMA	7PG89G35Q7																		mg	30		SINGLE							HEALTHY	Subcutaneous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02045264	Homo sapiens		h	1.77							false
351	87		ADULT	6918173	1304.522	ICATIBANT	ICATIBANT	N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC(=O)N[C@@H](CC3=CC=CS3)C(=O)N[C@@H](CO)C(=O)N4CC5=C(C[C@@H]4C(=O)N6[C@H]7CCCC[C@H]7C[C@H]6C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C=CC=C5	PLASMA	7PG89G35Q7									∞	ng × h/mL	2320							mg	30		SINGLE							HEALTHY	Subcutaneous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02045264	Homo sapiens										false
352	87		ADULT	6918173	1304.522	ICATIBANT	ICATIBANT	N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC(=O)N[C@@H](CC3=CC=CS3)C(=O)N[C@@H](CO)C(=O)N4CC5=C(C[C@@H]4C(=O)N6[C@H]7CCCC[C@H]7C[C@H]6C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C=CC=C5	PLASMA	7PG89G35Q7							48		t	ng × h/mL	2320							mg	30		SINGLE							HEALTHY	Subcutaneous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02045264	Homo sapiens										false
353	87			6918173	1304.522	ICATIBANT	ICATIBANT	N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC(=O)N[C@@H](CC3=CC=CS3)C(=O)N[C@@H](CO)C(=O)N4CC5=C(C[C@@H]4C(=O)N6[C@H]7CCCC[C@H]7C[C@H]6C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C=CC=C5	PLASMA	7PG89G35Q7													ng/mL	405				mg	30		SINGLE							UNHEALTHY	Subcutaneous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT03888755	Homo sapiens										false
354	87			6918173	1304.522	ICATIBANT	ICATIBANT	N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC(=O)N[C@@H](CC3=CC=CS3)C(=O)N[C@@H](CO)C(=O)N4CC5=C(C[C@@H]4C(=O)N6[C@H]7CCCC[C@H]7C[C@H]6C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C=CC=C5	PLASMA	7PG89G35Q7									?	ng × h/mL	611							mg	30		SINGLE							UNHEALTHY	Subcutaneous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT03888755	Homo sapiens										false
355	87			6918173	1304.522	ICATIBANT	ICATIBANT	N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC(=O)N[C@@H](CC3=CC=CS3)C(=O)N[C@@H](CO)C(=O)N4CC5=C(C[C@@H]4C(=O)N6[C@H]7CCCC[C@H]7C[C@H]6C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C=CC=C5	PLASMA	7PG89G35Q7									?	ng × h/mL	1198							mg	30		SINGLE							UNHEALTHY	Subcutaneous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT03888755	Homo sapiens										false
356	87			6918173	1304.522	ICATIBANT	ICATIBANT	N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC(=O)N[C@@H](CC3=CC=CS3)C(=O)N[C@@H](CO)C(=O)N4CC5=C(C[C@@H]4C(=O)N6[C@H]7CCCC[C@H]7C[C@H]6C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C=CC=C5	PLASMA	7PG89G35Q7									?	ng × h/mL	1506							mg	30		SINGLE							UNHEALTHY	Subcutaneous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT03888755	Homo sapiens										false
357	87		ADULT		1304.5	Icatibant		C1CCC2C(C1)CC(N2C(=O)C3CC4=CC=CC=C4CN3C(=O)C(CO)NC(=O)C(CC5=CC=CS5)NC(=O)CNC(=O)C6CC(CN6C(=O)C7CCCN7C(=O)C(CCCN=C(N)N)NC(=O)C(CCCN=C(N)N)N)O)C(=O)NC(CCCN=C(N)N)C(=O)O	PLASMA																		RECOMMENDED	mg	30		UNKNOWN	UNKNOWN		day	1	Icatibant is 44% plasma protein bound and has a volume of distribution of ≈20–25 L	56	UNKNOWN	Subcutaneous	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/20030426/	Homo sapiens										false
358	87		ADULT	6918173	1304.522	ICATIBANT	ICATIBANT	N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC(=O)N[C@@H](CC3=CC=CS3)C(=O)N[C@@H](CO)C(=O)N4CC5=C(C[C@@H]4C(=O)N6[C@H]7CCCC[C@H]7C[C@H]6C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C=CC=C5	PLASMA	7PG89G35Q7									∞	ng × h/mL	2165		ng/mL	974			RECOMMENDED	mg	30		SINGLE	UNKNOWN						HEALTHY	Subcutaneous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022150s012s013lbl.pdf	Homo sapiens		h	1.4							false
359	88		ADULT	42611257	489.07254	VEMURAFENIB	VEMURAFENIB	CCCS(=O)(=O)NC1=C(F)C(C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(Cl)C=C4)=C(F)C=C1	PLASMA	207SMY3FQT							12		t	μg × h/mL	601		μg/mL	62			MAX TOLERATED	mg	960		MULTIPLE	UNKNOWN		day	2	Vemurafenib is highly bound (> 99%) to human albumin and alpha-1 acid glycoprotein plasma proteins.	1	UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202429s000lbl.pdf	Homo sapiens										false
360	88		ADULT	42611257	489.07254	VEMURAFENIB	VEMURAFENIB	CCCS(=O)(=O)NC1=C(F)C(C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(Cl)C=C4)=C(F)C=C1	PLASMA	207SMY3FQT							168		t	μg × h/mL	920.3		μg/mL	17.2			UNKNOWN	mg	240		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/24178368	Homo sapiens		h	31.5							false
361	88		ADULT	42611257	489.07254	VEMURAFENIB	VEMURAFENIB	CCCS(=O)(=O)NC1=C(F)C(C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(Cl)C=C4)=C(F)C=C1	PLASMA	207SMY3FQT							168		t	μg × h/mL	3530.3		μg/mL	61.4			MAX TOLERATED	mg	960		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/24178368	Homo sapiens		h	34.1							false
362	89			9871419	522.568	TICAGRELOR	TICAGRELOR	CCCSC1=NC2=C(N=NN2[C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)C(N[C@@H]4C[C@H]4C5=CC(F)=C(F)C=C5)=N1	PLASMA	GLH0314RVC							24		t	ng × h/mL	12379		ng/mL	1208				mg	270		SINGLE								Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01898442	Homo sapiens										false
363	89			9871419	522.568	TICAGRELOR	TICAGRELOR	CCCSC1=NC2=C(N=NN2[C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)C(N[C@@H]4C[C@H]4C5=CC(F)=C(F)C=C5)=N1	PLASMA	GLH0314RVC							24		t	ng × h/mL	12381		ng/mL	1208				mg	360		SINGLE								Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01898442	Homo sapiens										false
364	89		ADULT	9871419	522.568	TICAGRELOR	TICAGRELOR	CCCSC1=NC2=C(N=NN2[C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)C(N[C@@H]4C[C@H]4C5=CC(F)=C(F)C=C5)=N1	PLASMA	GLH0314RVC							12		t	ng × h/mL	10160		ng/mL	1583			UNKNOWN	mg	200		MULTIPLE	FASTED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20642549/	Homo sapiens										false
365	89		ADULT	9871419	522.568	TICAGRELOR	TICAGRELOR	CCCSC1=NC2=C(N=NN2[C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)C(N[C@@H]4C[C@H]4C5=CC(F)=C(F)C=C5)=N1	PLASMA	GLH0314RVC																	RECOMMENDED	mg	90		SINGLE	UNKNOWN				Ticagrelor and the active metabolite are extensively bound to human plasma proteins (>99%).	1	UNKNOWN	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022433s028lbl.pdf	Homo sapiens		h	7							false
366	90		ADULT	9875401	435.881	RIVAROXABAN	RIVAROXABAN	ClC1=CC=C(S1)C(=O)NC[C@H]2CN(C(=O)O2)C3=CC=C(C=C3)N4CCOCC4=O	PLASMA	9NDF7JZ4M3							24		t	μg × h/L	1.114		μg/L	138.4			RECOMMENDED	mg	10		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23999929/	Homo sapiens		h	10.77							false
367	90		ADULT	9875401	435.881	RIVAROXABAN	RIVAROXABAN	ClC1=CC=C(S1)C(=O)NC[C@H]2CN(C(=O)O2)C3=CC=C(C=C3)N4CCOCC4=O	PLASMA	9NDF7JZ4M3																	RECOMMENDED	mg	20		UNKNOWN	UNKNOWN		day	1	Plasma protein binding of rivaroxaban in human plasma is approximately 92% to 95%, with albumin being the main binding component.	5	HEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202439s031,022406s035lbl.pdf	Homo sapiens		h	9							false
368	91		ADULT	121892	303.3314	EZOGABINE	EZOGABINE	CCOC(=O)NC1=C(N)C=C(NCC2=CC=C(F)C=C2)C=C1	PLASMA	12G01I6BBU									?	ng × h/mL	1831		ng/mL	414			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022345Orig1s000ClinPharmR.pdf	Homo sapiens		h	8.4							false
369	91		ADULT	121892	303.3314	EZOGABINE	EZOGABINE	CCOC(=O)NC1=C(N)C=C(NCC2=CC=C(F)C=C2)C=C1	PLASMA	12G01I6BBU									?	ng × h/mL	1914		ng/mL	498			UNKNOWN	mg	100		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022345Orig1s000ClinPharmR.pdf	Homo sapiens		h	7.2							false
370	91		ADULT	121892	303.3314	EZOGABINE	EZOGABINE	CCOC(=O)NC1=C(N)C=C(NCC2=CC=C(F)C=C2)C=C1	PLASMA	12G01I6BBU									?	ng × h/mL	5134		ng/mL	819			UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022345Orig1s000ClinPharmR.pdf	Homo sapiens		h	7.4							false
371	91		ADULT	121892	303.3314	EZOGABINE	EZOGABINE	CCOC(=O)NC1=C(N)C=C(NCC2=CC=C(F)C=C2)C=C1	PLASMA	12G01I6BBU									?	ng × h/mL	5279		ng/mL	978			UNKNOWN	mg	200		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022345Orig1s000ClinPharmR.pdf	Homo sapiens		h	7							false
372	91		ADULT	121892	303.3314	EZOGABINE	EZOGABINE	CCOC(=O)NC1=C(N)C=C(NCC2=CC=C(F)C=C2)C=C1	PLASMA	12G01I6BBU									?	ng × h/mL	5136		ng/mL	842			UNKNOWN	mg	250		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022345Orig1s000ClinPharmR.pdf	Homo sapiens		h	7.9							false
373	91		ADULT	121892	303.3314	EZOGABINE	EZOGABINE	CCOC(=O)NC1=C(N)C=C(NCC2=CC=C(F)C=C2)C=C1	PLASMA	12G01I6BBU									?	ng × h/mL	5184		ng/mL	993			UNKNOWN	mg	250		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022345Orig1s000ClinPharmR.pdf	Homo sapiens		h	6.8							false
374	91		ADULT	121892	303.3314	EZOGABINE	EZOGABINE	CCOC(=O)NC1=C(N)C=C(NCC2=CC=C(F)C=C2)C=C1	PLASMA	12G01I6BBU									?	ng × h/mL	3972.5		ng/mL	551.9			UNKNOWN	mg	200		SINGLE	HIGH-FAT						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022345Orig1s000ClinPharmR.pdf	Homo sapiens										false
375	91		ADULT	121892	303.3314	EZOGABINE	EZOGABINE	CCOC(=O)NC1=C(N)C=C(NCC2=CC=C(F)C=C2)C=C1	PLASMA	12G01I6BBU									?	ng × h/mL	4393.8		ng/mL	561			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022345Orig1s000ClinPharmR.pdf	Homo sapiens										false
376	91		ADULT	121892	303.3314	EZOGABINE	EZOGABINE	CCOC(=O)NC1=C(N)C=C(NCC2=CC=C(F)C=C2)C=C1	PLASMA	12G01I6BBU									∞	ng × h/mL	7895.9		ng/mL	938.7			UNKNOWN	mg	400		SINGLE	HIGH-FAT						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022345Orig1s000ClinPharmR.pdf	Homo sapiens		h	6.28							false
377	91		ADULT	121892	303.3314	EZOGABINE	EZOGABINE	CCOC(=O)NC1=C(N)C=C(NCC2=CC=C(F)C=C2)C=C1	PLASMA	12G01I6BBU									∞	ng × h/mL	7355.9		ng/mL	728.8			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022345Orig1s000ClinPharmR.pdf	Homo sapiens		h	7.57							false
378	92		ADULT		1058	FIDAXOMICIN	FIDAXOMICIN	CCC1C=C(C(CC=CC=C(C(=O)OC(CC=C(C=C(C1OC2C(C(C(C(O2)(C)C)OC(=O)C(C)C)O)O)C)C)C(C)O)COC3C(C(C(C(O3)C)OC(=O)C4=C(C(=C(C(=C4O)Cl)O)Cl)CC)O)OC)O)C	PLASMA										∞	ng × h/mL	62.9		ng/mL	5.2			RECOMMENDED	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201699s000lbl.pdf	Homo sapiens		h	11.7							false
379	93		ADULT	3010818	679.8493	TELAPREVIR	TELAPREVIR	CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C3=NC=CN=C3)C4CCCCC4)C(C)(C)C)C(=O)C(=O)NC5CC5	PLASMA	655M5O3W0U									∞	ng × h/mL	3146.52		ng/mL	539.79			UNKNOWN	mg	375		SINGLE	FED				Telaprevir is approximately 59% to 76% bound to human plasma proteins	32.5	HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201917Orig1s000ClinPharmR.pdf	Homo sapiens		h	3.23							false
380	93		ADULT	3010818	679.8493	TELAPREVIR	TELAPREVIR	CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C3=NC=CN=C3)C4CCCCC4)C(C)(C)C)C(=O)C(=O)NC5CC5	PLASMA	655M5O3W0U									∞	ng × h/mL	11749.1		ng/mL	1740.84			RECOMMENDED	mg	750		SINGLE	FED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201917Orig1s000ClinPharmR.pdf	Homo sapiens		h	3.96							false
381	93		ADULT	3010818	679.8493	TELAPREVIR	TELAPREVIR	CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C3=NC=CN=C3)C4CCCCC4)C(C)(C)C)C(=O)C(=O)NC5CC5	PLASMA	655M5O3W0U									∞	ng × h/mL	24250.23		ng/mL	3232.22			UNKNOWN	mg	1500		SINGLE	FED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201917Orig1s000ClinPharmR.pdf	Homo sapiens		h	6.49							false
382	93		ADULT	3010818	679.8493	TELAPREVIR	TELAPREVIR	CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C3=NC=CN=C3)C4CCCCC4)C(C)(C)C)C(=O)C(=O)NC5CC5	PLASMA	655M5O3W0U							8		t	ng × h/mL	19809.27		ng/mL	3090			RECOMMENDED	mg	750		STEADY-STATE	UNKNOWN		day	3			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201917Orig1s000ClinPharmR.pdf	Homo sapiens										false
383	93		ADULT	15940245	679.8493	VRT-127394	VRT-127394	CCC[C@@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C3=NC=CN=C3)C4CCCCC4)C(C)(C)C)C(=O)C(=O)NC5CC5	PLASMA	52YTW6K39W							8		t	ng × h/mL	13274.77		ng/mL	1940			RECOMMENDED	mg	750		STEADY-STATE	UNKNOWN		day	3			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201917Orig1s000ClinPharmR.pdf	Homo sapiens										false
384	93		ADULT	15940245	679.8493	VRT-127394	VRT-127394	CCC[C@@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C3=NC=CN=C3)C4CCCCC4)C(C)(C)C)C(=O)C(=O)NC5CC5	PLASMA	52YTW6K39W									∞	ng × h/mL	5203		ng/mL	511			RECOMMENDED	mg	750		SINGLE	FED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201917Orig1s000ClinPharmR.pdf	Homo sapiens		h	4.77							false
385	94		ADOLESCENT		366.4	RILPIVIRINE	RILPIVIRINE		PLASMA								24		t	μg × h/mL	2.38		μg/mL	0.14			RECOMMENDED	mg	25		MULTIPLE	FED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27187753/	Homo sapiens										false
386	94		ADULT		366.4	RILPIVIRINE			PLASMA								24		t	ng × h/mL	1792		ng/mL	121			RECOMMENDED	mg	25		MULTIPLE	UNKNOWN		day	1	Rilpivirine is approximately 99.7% bound to plasma proteins, primarily albumin	0.3	PREGNANT	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29335895/	Homo sapiens										false
387	95		ADULT	10324367	519.6767	BOCEPREVIR	BOCEPREVIR	CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC3CCC3)C(=O)C(N)=O)C2(C)C)C(C)(C)C	PLASMA	89BT58KELH							8		t	ng × h/mL	5408		ng/mL	1723			RECOMMENDED	mg	800		STEADY-STATE	UNKNOWN		day	3		25	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202258lbl.pdf	Homo sapiens		h	3.4							false
388	95		ADULT	10324367	519.6767	BOCEPREVIR	BOCEPREVIR	CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC3CCC3)C(=O)C(N)=O)C2(C)C)C(C)(C)C	PLASMA	89BT58KELH									?	ng × h/mL	994		ng/mL	339			UNKNOWN	mg	200		SINGLE	HIGH-FAT						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202258Orig1s000ClinPharmR.pdf	Homo sapiens		h	2.1							false
389	95		ADULT	10324367	519.6767	BOCEPREVIR	BOCEPREVIR	CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC3CCC3)C(=O)C(N)=O)C2(C)C)C(C)(C)C	PLASMA	89BT58KELH									?	ng × h/mL	2100		ng/mL	698			UNKNOWN	mg	400		SINGLE	HIGH-FAT						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202258Orig1s000ClinPharmR.pdf	Homo sapiens		h	1.9							false
390	95		ADULT	10324367	519.6767	BOCEPREVIR	BOCEPREVIR	CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC3CCC3)C(=O)C(N)=O)C2(C)C)C(C)(C)C	PLASMA	89BT58KELH									?	ng × h/mL	6350		ng/mL	1710			UNKNOWN	mg	800		SINGLE	HIGH-FAT						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202258Orig1s000ClinPharmR.pdf	Homo sapiens		h	3							false
391	95		ADULT	10324367	519.6767	BOCEPREVIR	BOCEPREVIR	CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC3CCC3)C(=O)C(N)=O)C2(C)C)C(C)(C)C	PLASMA	89BT58KELH							8		t	ng × h/mL	1330		ng/mL	505			UNKNOWN	mg	200		STEADY-STATE	UNKNOWN		day	3			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202258Orig1s000ClinPharmR.pdf	Homo sapiens		h	3.5							false
392	95		ADULT	10324367	519.6767	BOCEPREVIR	BOCEPREVIR	CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC3CCC3)C(=O)C(N)=O)C2(C)C)C(C)(C)C	PLASMA	89BT58KELH							8		t	ng × h/mL	2620		ng/mL	881			UNKNOWN	mg	400		STEADY-STATE	UNKNOWN		day	3			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202258Orig1s000ClinPharmR.pdf	Homo sapiens		h	5.1							false
393	95		ADULT	10324367	519.6767	BOCEPREVIR	BOCEPREVIR	CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC3CCC3)C(=O)C(N)=O)C2(C)C)C(C)(C)C	PLASMA	89BT58KELH							8		t	ng × h/mL	4830		ng/mL	1680			RECOMMENDED	mg	800		STEADY-STATE	UNKNOWN		day	3			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202258Orig1s000ClinPharmR.pdf	Homo sapiens		h	10.2							false
394	95		ADULT	10324367	519.6767	BOCEPREVIR	BOCEPREVIR	CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC3CCC3)C(=O)C(N)=O)C2(C)C)C(C)(C)C	PLASMA	89BT58KELH							8		t	ng × h/mL	6500		ng/mL	1940			UNKNOWN	mg	1200		STEADY-STATE	UNKNOWN		day	3			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202258Orig1s000ClinPharmR.pdf	Homo sapiens		h	3							false
395	96		ADULT	10096344	472.5422	LINAGLIPTIN	LINAGLIPTIN	CC#CCN1C(=NC2=C1C(=O)N(CC3=NC4=C(C=CC=C4)C(C)=N3)C(=O)N2C)N5CCC[C@@H](N)C5	PLASMA	3X29ZEJ4R2									?	nM × h	139		nM	8.9			DEFINED DAILY	mg	5		SINGLE	UNKNOWN				Plasma protein binding of linagliptin is concentration-dependent, decreasing from about 99% at 1 nmol/L to 75%-89% at ≥30 nmol/L, reflecting saturation of binding to DPP-4 with increasing concentration of linagliptin. At high concentrations, where DPP-4 is fully saturated, 70% to 80% of linagliptin remains bound to plasma proteins and 20% to 30% is unbound in plasma.	25	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201280lbl.pdf	Homo sapiens										false
396	96		ADULT	10096344	472.5422	LINAGLIPTIN	LINAGLIPTIN	CC#CCN1C(=NC2=C1C(=O)N(CC3=NC4=C(C=CC=C4)C(C)=N3)C(=O)N2C)N5CCC[C@@H](N)C5	PLASMA	3X29ZEJ4R2							336		t	nM × h	194		nM	16.4			DEFINED DAILY	mg	5		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/23331248	Homo sapiens		h	119							false
397	97		ADULT	132971	349.509	ABIRATERONE	ABIRATERONE	C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2C5=CN=CC=C5	PLASMA	G819A456D0									∞	ng × h/mL	365		ng/mL	71.9			RECOMMENDED	mg	1000		SINGLE	UNKNOWN				Mild hepatic impairment		UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24374856/	Homo sapiens		h	17.7							false
398	97		ADULT	132971	349.509	ABIRATERONE	ABIRATERONE	C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2C5=CN=CC=C5	PLASMA	G819A456D0									∞	ng × h/mL	1562		ng/mL	297			RECOMMENDED	mg	1000		SINGLE	UNKNOWN				Moderate hepatic impairment		UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24374856/	Homo sapiens		h	18.6							false
399	97		ADULT	132971	349.509	ABIRATERONE	ABIRATERONE	C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2C5=CN=CC=C5	PLASMA	G819A456D0									∞	ng × h/mL	330		ng/mL	85.7			RECOMMENDED	mg	1000		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24374856/	Homo sapiens		h	13.1							false
400	97		ADULT	132971	349.509	ABIRATERONE	ABIRATERONE	C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2C5=CN=CC=C5	PLASMA	G819A456D0									∞	ng × h/mL	177		ng/mL	12.5			MIN EFFICACIOUS	mg	125		SINGLE	UNKNOWN				Severe hepatic impairment		UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24374856/	Homo sapiens		h	18.2							false
401	97		ADULT	132971	349.509	ABIRATERONE	ABIRATERONE	C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2C5=CN=CC=C5	PLASMA	G819A456D0									∞	ng × h/mL	461		ng/mL	64.5			MAX DAILY	mg	2000		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24374856/	Homo sapiens		h	15.4							false
402	97		ADULT	132971	349.509	ABIRATERONE	ABIRATERONE	C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2C5=CN=CC=C5	PLASMA	G819A456D0									∞	ng × h/mL	315		ng/mL	50.2			RECOMMENDED	mg	1000		SINGLE	UNKNOWN				end‐stage renal disease		UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24374856/	Homo sapiens		h	18.2							false
403	97		ADULT	132971	349.509	ABIRATERONE	ABIRATERONE	C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2C5=CN=CC=C5	PLASMA	G819A456D0									∞	ng × h/mL	315		ng/mL	60.6			RECOMMENDED	mg	1000		SINGLE	UNKNOWN				Study 3		HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24374856/	Homo sapiens		h	18.2							false
404	97		ADULT	132971	349.509	ABIRATERONE	ABIRATERONE	C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2C5=CN=CC=C5	PLASMA	G819A456D0									?	ng × h/mL	1173		ng/mL	226			RECOMMENDED	mg	1000		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202379s005lbl.pdf	Homo sapiens										false
405	97		ADULT	132971	349.509	ABIRATERONE	ABIRATERONE	C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2C5=CN=CC=C5	PLASMA	G819A456D0							24		t	ng × h/mL	993		ng/mL	226			RECOMMENDED	mg	1000		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202379s027s028lbl.pdf	Homo sapiens		h	12							false
406	98		ADULT	3081361	474.1067	VANDETANIB	VANDETANIB	COC1=CC2=C(NC3=CC=C(Br)C=C3F)N=CN=C2C=C1OCC4CCN(C)CC4	PLASMA	YO460OQ37K							24		t	ng × h/mL	38611		ng/mL	2024			UNKNOWN	mg	300		STEADY-STATE	UNKNOWN		day	1	Vandetanib is 94% bound to human serum albumin and α1-acid-glycoprotein.	6	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000ClinPharmR.pdf	Homo sapiens		day	7.6							false
407	98		ADULT	3081361	474.1067	VANDETANIB	VANDETANIB	COC1=CC2=C(NC3=CC=C(Br)C=C3F)N=CN=C2C=C1OCC4CCN(C)CC4	PLASMA	YO460OQ37K									∞	ng × h/mL	22030		ng/mL	130			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000ClinPharmR.pdf	Homo sapiens		h	204							false
408	99		ADULT	3446	171.24	GABAPENTIN	GABAPENTIN	NCC1(CC(O)=O)CCCCC1	PLASMA	6CW7F3G59X									∞	ng × h/mL	23574		ng/mL	3223.69			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/25214768	Homo sapiens		h	4.69							false
409	99		ADULT	3446	171.24	GABAPENTIN	GABAPENTIN	NCC1(CC(O)=O)CCCCC1	PLASMA	6CW7F3G59X									∞	μg × h/mL	41.79		μg/mL	3.98			UNKNOWN	mg	600		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/9562133	Homo sapiens										false
410	101		UNKNOWN	449193	403.207	ROFLUMILAST	ROFLUMILAST	FC(F)OC1=CC=C(C=C1OCC2CC2)C(=O)NC3=C(Cl)C=NC=C3Cl	PLASMA	0P6C6ZOP5U																						UNKNOWN				Plasma protein binding of roflumilast and its N-oxide metabolite is approximately 99% and 97%, respectively.	1	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022522s003lbl.pdf	Homo sapiens		h	17							false
411	101		ADULT	449193	403.207	ROFLUMILAST	ROFLUMILAST	FC(F)OC1=CC=C(C=C1OCC2CC2)C(=O)NC3=C(Cl)C=NC=C3Cl	PLASMA	0P6C6ZOP5U									∞	ng × h/mL	65.1		ng/mL	12.5			DEFINED DAILY	mg	0.5		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/30538429	Homo sapiens		h	19.9							false
412	103		ADULT	6918314	441.5249	VILAZODONE	VILAZODONE	NC(=O)C1=CC2=C(O1)C=CC(=C2)N3CCN(CCCCC4=CNC5=CC=C(C=C45)C#N)CC3	PLASMA	S239O2OOV3							24		t	ng × h/mL	1645		ng/mL	156			RECOMMENDED	mg	40		STEADY-STATE	FED		day	1	Vilazodone is widely distributed and approximately 96-99% protein-bound.	1	UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022567s021lbl.pdf	Homo sapiens		h	25							false
413	105		ADULT	446598	424.983	CLINDAMYCIN	CLINDAMYCIN	CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O	PLASMA	3U02EL437C									∞	μg × h/mL	12.2		μg/mL	3.1			RECOMMENDED	mg	600		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10475141/	Homo sapiens		h	2.3							false
414	105		CHILD	446598	424.983	CLINDAMYCIN	CLINDAMYCIN	CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O	PLASMA	3U02EL437C							24		t	ng × h/mL	13.54		ng/mL	0.92			RECOMMENDED	g	0.03		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Topical	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/050803Orig1s000ClinPharmR.pdf	Homo sapiens										false
415	106		ADULT	2528	627.9402	METRIZOIC ACID	METRIZOIC ACID	CN(C(C)=O)C1=C(I)C(C(O)=O)=C(I)C(NC(C)=O)=C1I	SERUM	CM1N99QR1M							4		t	μg × h/mL	250		μg/mL	300			UNKNOWN	mg	2310		SINGLE	UNKNOWN					100	HEALTHY	Intravenous	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3375780/	Homo sapiens		min	75.1							false
416	107		ADULT	3454|5273896|135398740	255.2306	GANCICLOVIR	GANCICLOVIR	NC1=NC2=C(N=CN2COC(CO)CO)C(=O)N1	PLASMA	P9G3CKZ4P5							8		t	mg × h/L	35.4		mg/L	4.8			UNKNOWN	g	1		MULTIPLE	FED		day	3			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/10747829	Homo sapiens										false
417	107		ADULT		255.2306	GANCICLOVIR	GANCICLOVIR	NC1=NC2=C(N=CN2COC(CO)CO)C(=O)N1	PLASMA	P9G3CKZ4P5									∞	μg × h/mL	53.8		μg/mL	13.3			UNKNOWN	mg/kg	5		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/16737936	Homo sapiens		h	5.2							false
418	108		ADULT	46245300|132940384|140552216	410.299	EDETATE CALCIUM DISODIUM	EDETATE CALCIUM DISODIUM	O.O.[Na+].[Na+].[Ca++].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O	SERUM	25IH6R4SGF													μg/mL	51			UNKNOWN	g	1		SINGLE	UNKNOWN						UNKNOWN	Intramuscular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3096624	Homo sapiens										false
419	108		UNKNOWN	46245300|132940384|140552216	410.299	EDETATE CALCIUM DISODIUM	EDETATE CALCIUM DISODIUM	O.O.[Na+].[Na+].[Ca++].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O	PLASMA	25IH6R4SGF																	UNKNOWN				UNKNOWN	UNKNOWN						UNKNOWN	UNKNOWN	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/008922s016lbl.pdf	Homo sapiens		min	60							false
420	110		ADULT	460612|6918992	305.2	MELPHALAN	N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O	N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O	PLASMA	Q41OR9510P									?	ng × h/mL	498		ng/mL	212			INVESTIGATIONAL	mg/kg	0.25		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/014691s030lbl.pdf	Homo sapiens		h	1							false
421	110		UNKNOWN	460612|6918992	305.2	MELPHALAN	N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O	N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O	PLASMA	Q41OR9510P																						UNKNOWN				Average melphalan binding to plasma proteins ranges from approximately 50% to 90%. Serum albumin is the major binding protein, accounting for approximately 40% to 60% of the plasma protein binding, while α1­ acid glycoprotein accounts for about 20% of the plasma protein binding. Approximately 30% of melphalan is (covalently) irreversibly bound to plasma proteins.	70	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207155s000lbl.pdf	Homo sapiens										false
422	110		ADULT	460612|6918992	305.2	MELPHALAN	N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O	N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O	PLASMA	Q41OR9510P							8		t	mg × h/L	12.84						RECOMMENDED	mg/m²	200		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26879446	Homo sapiens										false
423	114		UNKNOWN	22420	279.101	CYCLOPHOSPHAMIDE	CYCLOPHOSPHAMIDE	O.ClCCN(CCCl)P1(=O)NCCCO1	PLASMA	8N3DW7272P																						UNKNOWN				Approximately 20% of cyclophosphamide is protein bound, with no dose dependent changes. Some metabolites are protein bound to an extent greater than 60%	80	UNKNOWN		UNKNOWN	DRUG LABEL	https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/0e1cb955-99c8-4fe5-89d1-399c8e52174e/spl-doc?hl=cyclophosphamide	Homo sapiens										false
424	114		ADULT	2907	261.079	CYCLOPHOSPHAMIDE	CYCLOPHOSPHAMIDE	ClCCN(CCCl)P1(=O)NCCCO1	PLASMA	6UXW23996M	5291 | 47208066		Imatinib | Bevacizumab	Imatinib | Bevacizumab	CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5 | NA	BKJ8M8G5HI | 2S9ZZM9Q9V			∞	μg × h/L	17587		μg/L	1234			MAX TOLERATED	mg	50		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/24022191	Homo sapiens		h	10.8							true
425	116		ADULT	36294	467.5145	TOBRAMYCIN	TOBRAMYCIN	NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O	PLASMA	VZ8RRZ51VK							12		t	μg × h/mL	11.6		μg/mL	3.7			RECOMMENDED	mg	80		SINGLE	UNKNOWN						HEALTHY	Intramuscular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4208289/	Homo sapiens		h	1.6							false
426	116		UNKNOWN	36294	467.5145	TOBRAMYCIN	TOBRAMYCIN	NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O	SPUTUM	VZ8RRZ51VK													μg/mL	814			RECOMMENDED	mg	300		SINGLE	UNKNOWN				Binding of tobramycin to serum proteins is negligible.	100	UNKNOWN	Respiratory	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201820s005lbl.pdf	Homo sapiens		h	4.4							false
427	118		ADULT	4649	153.1354	AMINOSALICYLIC ACID	AMINOSALICYLIC ACID	NC1=CC=C(C(O)=O)C(O)=C1	PLASMA	5B2658E0N2							12		t	mg × h/L	690.35		mg/L	82.69			RECOMMENDED	g	8		MULTIPLE	FED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31682027/	Homo sapiens										false
428	118		ADULT	4649	153.1354	AMINOSALICYLIC ACID	AMINOSALICYLIC ACID	NC1=CC=C(C(O)=O)C(O)=C1	PLASMA	5B2658E0N2							12		t	mg × h/L	414.07		mg/L	53.63			RECOMMENDED	g	4		MULTIPLE	FED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31682027/	Homo sapiens										false
429	118		ADULT	65509	195.1721	4-ACETAMIDOSALICYLIC ACID	4-ACETAMIDOSALICYLIC ACID	CC(=O)NC1=CC(O)=C(C=C1)C(O)=O	PLASMA	I7C1010RKE							12		t	mg × h/L	142.49		mg/L	16.36			RECOMMENDED	g	8		MULTIPLE	FED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31682027/	Homo sapiens										false
430	118		ADULT	65509	195.1721	4-ACETAMIDOSALICYLIC ACID	4-ACETAMIDOSALICYLIC ACID	CC(=O)NC1=CC(O)=C(C=C1)C(O)=O	PLASMA	I7C1010RKE							12		t	mg × h/L	145.02		mg/L	14.59			RECOMMENDED	g	4		MULTIPLE	FED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31682027/	Homo sapiens										false
431	118		ADULT	4649	153.1354	AMINOSALICYLIC ACID	AMINOSALICYLIC ACID	NC1=CC=C(C(O)=O)C(O)=C1	PLASMA	5B2658E0N2													μg/mL	20			UNKNOWN	g	4		SINGLE	UNKNOWN				Plasma protein binding is about 50 to 60%	45	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.ema.europa.eu/en/documents/product-information/granupas-epar-product-information_en.pdf	Homo sapiens		h	1.62							false
432	119		ADULT	24841|21844680	127.91241	HYDROGEN IODIDE	I	I	PLASMA	694C0EFT9Q													mg/mL	7			UNKNOWN	mg/kg	7.2		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6706519	Homo sapiens		min	102							false
433	119		ADULT	24841|21844680	127.91241	HYDROGEN IODIDE	I	I	PLASMA	694C0EFT9Q													mg/mL	3.6			UNKNOWN	mg/kg	3.36		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6706519	Homo sapiens		min	110							false
434	121		ADULT	37768	585.6025	AMIKACIN	AMIKACIN	NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O	SERUM	84319SGC3C							24		t	μg × h/mL	23.5		μg/mL	2.8			RECOMMENDED	mg	590		STEADY-STATE	UNKNOWN		day	1	The protein binding of amikacin in serum is ≤ 10%.	90	UNHEALTHY	Respiratory	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207356s000lbl.pdf	Homo sapiens		h	5.9							false
435	122		ADULT	135398508	277.28	Entecavir		C=C1C(CC(C1CO)O)N2C=NC3=C2N=C(NC3=O)N	PLASMA	NNU2O4609D							24		t	ng × h/mL	14.78		ng/mL	4.23			RECOMMENDED	mg	0.5		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17050790/	Homo sapiens		h	129.9							false
436	122		ADULT	135398508	277.28	Entecavir		C=C1C(CC(C1CO)O)N2C=NC3=C2N=C(NC3=O)N	PLASMA	NNU2O4609D							24		t	ng × h/mL	26.38		ng/mL	8.24			RECOMMENDED	mg	1		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17050790/	Homo sapiens		h	148.89							false
437	122		ADULT	135398508	277.28	Entecavir		C=C1C(CC(C1CO)O)N2C=NC3=C2N=C(NC3=O)N	PLASMA	NNU2O4609D													ng/mL	4.2			RECOMMENDED	mg	0.5		STEADY-STATE	UNKNOWN		day	1		87	HEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021797s018,021798s019lbl.pdf	Homo sapiens		h	138.5							false
438	122		ADULT	135398508	277.28	Entecavir		C=C1C(CC(C1CO)O)N2C=NC3=C2N=C(NC3=O)N	PLASMA	NNU2O4609D									?	ng × h/mL	27.9		ng/mL	8.1			RECOMMENDED	mg	1		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021797s018,021798s019lbl.pdf	Homo sapiens										false
439	123		ADULT	14052	204.3098	ETHAMBUTOL	ETHAMBUTOL	CC[C@@H](CO)NCCN[C@@H](CC)CO	SERUM	8G167061QZ									∞	μg × h/mL	28		μg/mL	4.5			RECOMMENDED	mg/kg	25		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10049268/	Homo sapiens										false
440	123		ADULT	14052	204.3098	ETHAMBUTOL	ETHAMBUTOL	CC[C@@H](CO)NCCN[C@@H](CC)CO	SERUM	8G167061QZ			aluminum-magnesium antacid	aluminum-magnesium antacid					∞	μg × h/mL	27.5		μg/mL	3.3			RECOMMENDED	mg/kg	25		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10049268/	Homo sapiens										true
441	123		ADULT	14052	204.3098	ETHAMBUTOL	ETHAMBUTOL	CC[C@@H](CO)NCCN[C@@H](CC)CO	SERUM	8G167061QZ									∞	μg × h/mL	29.6		μg/mL	3.8			RECOMMENDED	mg/kg	25		SINGLE	HIGH-FAT						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10049268/	Homo sapiens										false
442	124		NEWBORN	441306	475.5795	NETILMICIN	NETILMICIN	CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O	SERUM	4O5J85GJJB									?	mg × h/L	76.9						UNKNOWN	mg/kg	4.5		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11450885	Homo sapiens		h	6.1							false
443	125		ADULT	165580	615.6285	PAROMOMYCIN	PAROMOMYCIN	NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O	PLASMA	61JJC8N5ZK							24		t	ng × h/mL	2180		ng/mL	331			UNKNOWN	mg	150		SINGLE	UNKNOWN						UNHEALTHY	Topical	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23877689	Homo sapiens		h	5.04							false
444	125		ADULT	165580	615.6285	PAROMOMYCIN	paromomycin	NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O	PLASMA	61JJC8N5ZK							24		t	ng × h/mL	8575		ng/mL	1000			UNKNOWN	mg	150		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Topical	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23877689	Homo sapiens		h	5.96							false
445	125		UNKNOWN	165580	615.6285	PAROMOMYCIN	PAROMOMYCIN	NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O	PLASMA	61JJC8N5ZK																						UNKNOWN					100	UNKNOWN		UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28756612	Homo sapiens										false
446	126		ADULT	5311236	382.5341	UNOPROSTONE	Unoprostone	CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\\C=C/CCCC(O)=O	PLASMA	6X4F561V3W													ng/mL	1.5			RECOMMENDED	drop	1		MULTIPLE	UNKNOWN		day	2			HEALTHY	Ocular	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021214s006s007lbl.pdf	Homo sapiens		min	14							false
447	131		ADULT	5388937	1022.218	QUINUPRISTIN	QUINUPRISTIN	CC[C@H]1NC(=O)[C@@H](NC(=O)C2=NC=CC=C2O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@@H]3CC(=O)[C@H](CS[C@@H]4CN5CCC4CC5)CN3C(=O)[C@H](CC6=CC=C(C=C6)N(C)C)N(C)C(=O)[C@@H]7CCCN7C1=O)C8=CC=CC=C8	PLASMA	23OW28RS7P			DALFOPRISTIN			R9M4FJE48E			?	μg × h/mL	7.2		μg/mL	3.2			RECOMMENDED	mg/kg bw	2.25		STEADY-STATE	UNKNOWN		day	3			HEALTHY	Intravenous	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050747s015,050748s014lbl.pdf	Homo sapiens		h	3.07							true
448	132		ADULT	44564	311.635	LODOXAMIDE	LODOXAMIDE	OC(=O)C(=O)NC1=CC(=CC(NC(=O)C(O)=O)=C1Cl)C#N	URINE	SPU695OD73																	INVESTIGATIONAL	mg	3		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.visioninstitutecanada.com/storage/app/media/ALOMIDE-ALCON.pdf	Homo sapiens		h	8.5							false
449	133		ADULT	3767|6064144|6064145	137.1393	ISONIAZID	isoniazid	NNC(=O)C1=CC=NC=C1	PLASMA	V83O1VOZ8L							6		t	mg × h/L	71.52		mg/L	16.6			RECOMMENDED	mg/kg bw	15		MULTIPLE	FASTED		week	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25224007/	Homo sapiens										false
450	133		ADULT	3767|6064144|6064145	137.1393	ISONIAZID	ISONIAZID	NNC(=O)C1=CC=NC=C1	PLASMA	V83O1VOZ8L							6		t	mg × h/L	6.96		mg/L	2.1			RECOMMENDED	mg/kg bw	5		MULTIPLE	FED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25224007/	Homo sapiens										false
451	133		ADULT	3767|6064144|6064145	137.1393	ISONIAZID	ISONIAZID	NNC(=O)C1=CC=NC=C1	PLASMA	V83O1VOZ8L							6		t	mg × h/L	53.17		mg/L	7.7			RECOMMENDED	mg/kg bw	15		MULTIPLE	FED		week	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25224007/	Homo sapiens										false
452	133		ADULT	3767|6064144|6064145	137.1393	ISONIAZID	isoniazid	NNC(=O)C1=CC=NC=C1	PLASMA	V83O1VOZ8L							6		t	mg × h/L	11.06		mg/L	3.1			RECOMMENDED	mg/kg bw	5		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25224007/	Homo sapiens										false
453	133		ADULT	3767|6064144|6064145	137.1393	ISONIAZID	ISONIAZID	NNC(=O)C1=CC=NC=C1	PLASMA	V83O1VOZ8L							6		t	mg × h/L	9.71		mg/L	2.8			RECOMMENDED	mg/kg bw	5		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25224007/	Homo sapiens										false
454	133		ADULT	3767|6064144|6064145	137.1393	ISONIAZID	ISONIAZID	NNC(=O)C1=CC=NC=C1	PLASMA	V83O1VOZ8L							6		t	mg × h/L	37.81		mg/L	8.7			RECOMMENDED	mg/kg bw	15		MULTIPLE	UNKNOWN		week	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25224007/	Homo sapiens										false
455	133		UNKNOWN	3767|6064144|6064145	137.1393	ISONIAZID	ISONIAZID	NNC(=O)C1=CC=NC=C1	PLASMA	V83O1VOZ8L																	UNKNOWN				UNKNOWN	UNKNOWN					86	UNHEALTHY	UNKNOWN	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29735566/	Homo sapiens										false
456	134		UNKNOWN	2123	210.2794	ALTRETAMINE	ALTRETAMINE	CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C	PLASMA	Q8BIH59O7H																						UNKNOWN				The free fractions of altretamine, pentamethylmelamine and tetramethylmelamine are 6%, 25% and 50%, respectively.	6	UNKNOWN		UNKNOWN	OTHER GOV'T	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8456a8db-a7f6-4bc0-86be-e9c8c374140b	Homo sapiens										false
457	134		ADULT	2123	210.28	ALTRETAMINE	ALTRETAMINE	CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C	PLASMA	Q8BIH59O7H							24		t	ng × h/mL	1147		ng/mL	790			UNKNOWN	mg	200		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/2515524	Homo sapiens		h	2.2							false
458	135			5280965	924.079	AMPHOTERICIN B	amphotericin b	C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\\C=C\\C=C\\C=C\\C=C\\C=C\\C=C\\C=C\\2)[C@@H](O)[C@@H](N)[C@@H]1O	PLASMA	7XU7A7DROE																										Plasma, ultrafiltration method (protein binding ranges 96.3 (1.34 mcg/mL AMB) to 99.5 (74.3 mcg/mL AMB) %	2.1				EXPERIMENT	https://aac.asm.org/content/46/3/834.long	Homo sapiens										false
459	135		ADULT	5280965	924.079	AMPHOTERICIN B	amphotericin b	C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\\C=C\\C=C\\C=C\\C=C\\C=C\\C=C\\C=C\\2)[C@@H](O)[C@@H](N)[C@@H]1O	SERUM	7XU7A7DROE							24		t	μg × h/mL	27		μg/mL	7.3			UNKNOWN	mg/kg	1		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050740Orig1s031lbl.pdf	Homo sapiens		h	10.7							false
460	135		ADULT	5280965	924.079	AMPHOTERICIN B	amphotericin b	C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\\C=C\\C=C\\C=C\\C=C\\C=C\\C=C\\C=C\\2)[C@@H](O)[C@@H](N)[C@@H]1O	SERUM	7XU7A7DROE							24		t	μg × h/mL	65		μg/mL	17.2			UNKNOWN	mg/kg	2.5		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050740Orig1s031lbl.pdf	Homo sapiens		h	8.1							false
461	135		ADULT	5280965	924.079	AMPHOTERICIN B	amphotericin b	C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\\C=C\\C=C\\C=C\\C=C\\C=C\\C=C\\C=C\\2)[C@@H](O)[C@@H](N)[C@@H]1O	SERUM	7XU7A7DROE							24		t	μg × h/mL	269		μg/mL	57.6			UNKNOWN	mg/kg	5		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050740Orig1s031lbl.pdf	Homo sapiens		h	6.4							false
462	135		ADULT	5280965	924.079	AMPHOTERICIN B	amphotericin b	C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\\C=C\\C=C\\C=C\\C=C\\C=C\\C=C\\C=C\\2)[C@@H](O)[C@@H](N)[C@@H]1O	SERUM	7XU7A7DROE							24		t	μg × h/mL	60		μg/mL	12.2			UNKNOWN	mg/kg	1		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050740Orig1s031lbl.pdf	Homo sapiens		h	7							false
463	135		ADULT	5280965	924.079	AMPHOTERICIN B	amphotericin b	C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\\C=C\\C=C\\C=C\\C=C\\C=C\\C=C\\C=C\\2)[C@@H](O)[C@@H](N)[C@@H]1O	SERUM	7XU7A7DROE							24		t	μg × h/mL	197		μg/mL	31.4			UNKNOWN	mg/kg	2.5		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050740Orig1s031lbl.pdf	Homo sapiens		h	6.3							false
464	135		ADULT	5280965	924.079	AMPHOTERICIN B	amphotericin b	C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\\C=C\\C=C\\C=C\\C=C\\C=C\\C=C\\C=C\\2)[C@@H](O)[C@@H](N)[C@@H]1O	SERUM	7XU7A7DROE							24		t	μg × h/mL	555		μg/mL	83			UNKNOWN	mg/kg	5		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050740Orig1s031lbl.pdf	Homo sapiens		h	6.8							false
465	135		ADULT	5280965	924.079	AMPHOTERICIN B	amphotericin b	C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\\C=C\\C=C\\C=C\\C=C\\C=C\\C=C\\C=C\\2)[C@@H](O)[C@@H](N)[C@@H]1O	SERUM	7XU7A7DROE							24		t	μg × h/mL	476		μg/mL	83.7			UNKNOWN	mg/kg	7.5		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	REVIEW	https://www.pmda.go.jp/drugs/2006/P200600024/40009300_21800AMY10095_K254_2.pdf	Homo sapiens		h	8.5							false
466	135		ADULT	5280965	924.079	AMPHOTERICIN B	amphotericin b	C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\\C=C\\C=C\\C=C\\C=C\\C=C\\C=C\\C=C\\2)[C@@H](O)[C@@H](N)[C@@H]1O	SERUM	7XU7A7DROE							24		t	μg × h/mL	382		μg/mL	62.4			UNKNOWN	mg/kg	7.5		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	REVIEW	https://www.pmda.go.jp/drugs/2006/P200600024/40009300_21800AMY10095_K254_2.pdf	Homo sapiens		h	6.9							false
467	136		ADULT		298.37	ARTEMETHER			PLASMA								24		t	ng × h/mL	146		ng/mL	60			RECOMMENDED	mg	80		SINGLE	UNKNOWN				Artemether is highly bound to human serum proteins in vitro (95.4% ).	4.6	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022268s021lbl.pdf	Homo sapiens		h	1.6							false
468	139		ADULT	2478	246.302	BUSULFAN	BUSULFAN	CS(=O)(=O)OCCCCOS(C)(=O)=O	PLASMA	G1LN9045DK									∞	μM × min	1167		ng/mL	1222			RECOMMENDED	mg/kg	0.8		STEADY-STATE	UNKNOWN		day	4	Busulfan primarily binds to albumin (Mean ± standard deviation=32.4 ± 2.2%).	67.6	UNHEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014lbl.pdf	Homo sapiens										false
469	139		ADULT	2478	246.302	BUSULFAN	busulfan	CS(=O)(=O)OCCCCOS(C)(=O)=O	PLASMA	G1LN9045DK																	RECOMMENDED	mg/kg	0.8		STEADY-STATE	UNKNOWN		day	4			UNHEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.ema.europa.eu/en/documents/product-information/busilvex-epar-product-information_en.pdf	Homo sapiens		h	3.35							false
470	140		ADULT	2576	260.33	CARISOPRODOL	CARISOPRODOL	CCCC(C)(COC(N)=O)COC(=O)NC(C)C	SERUM	21925K482H													μM	13.3			UNKNOWN	mg	700		SINGLE	FASTED				Protein binding of carisoprodol was in the range of 41-67%	46	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7974621	Homo sapiens		min	99							false
471	140		ADULT	2576	260.33	CARISOPRODOL	CARISOPRODOL	CCCC(C)(COC(N)=O)COC(=O)NC(C)C	PLASMA	21925K482H									∞	μg × h/mL	4.5		μg/mL	1.2			RECOMMENDED	mg	250		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/011792s048lbl.pdf	Homo sapiens		h	1.7							false
472	140		ADULT	2576	260.33	CARISOPRODOL	CARISOPRODOL	CCCC(C)(COC(N)=O)COC(=O)NC(C)C	PLASMA	21925K482H									∞	μg × h/mL	7		μg/mL	1.8			RECOMMENDED	mg	350		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011792s050lbl.pdf	Homo sapiens		h	2							false
473	141		UNKNOWN	2708	304.212	CHLORAMBUCIL	CHLORAMBUCIL	OC(=O)CCCC1=CC=C(C=C1)N(CCCl)CCCl	PLASMA	18D0SL7309																						UNKNOWN				In vitro, chlorambucil is 99% bound to plasma proteins, specifically albumin.	1	UNKNOWN		UNKNOWN	DRUG LABEL	https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/967ed3ff-d99b-41e8-b768-dfb586d3d9a6/spl-doc?hl=chlorambucil	Homo sapiens										false
474	141		ADULT	2708	304.2	CHLORAMBUCIL	CHLORAMBUCIL	OC(=O)CCCC1=CC=C(C=C1)N(CCCl)CCCl	PLASMA	18D0SL7309									∞	μg × h/mL	1.99		μg/mL	1.46			UNKNOWN	mg	40		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/6489421	Homo sapiens		h	0.94							false
475	141		ADULT	2708	304.2	CHLORAMBUCIL		OC(=O)CCCC1=CC=C(C=C1)N(CCCl)CCCl	PLASMA	18D0SL7309									∞	ng × h/mL	380		ng/mL	259			MAX DAILY	mg	10		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/6840176	Homo sapiens										false
476	142		ADULT	2713|5353524|5360566|9552079|88536661	505.447	CHLORHEXIDINE	CHLORHEXIDINE	ClC1=CC=C(NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC2=CC=C(Cl)C=C2)C=C1	SALIVA	R4KO0DY52L							4		t	ng × h/mL	148287.6						UNKNOWN	%	0.2		SINGLE	UNKNOWN						UNHEALTHY	Dental	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26271869	Homo sapiens										false
477	142		ADULT	2713|5353524|5360566|9552079|88536661	505.447	CHLORHEXIDINE	CHLORHEXIDINE	ClC1=CC=C(NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC2=CC=C(Cl)C=C2)C=C1	SALIVA	R4KO0DY52L							4		t	ng × h/mL	180892.9						UNKNOWN	%	0.2		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Dental	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26271869	Homo sapiens										false
478	142		UNKNOWN	2713|5353524|5360566|9552079|88536661	505.447	CHLORHEXIDINE	CHLORHEXIDINE	ClC1=CC=C(NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC2=CC=C(Cl)C=C2)C=C1	SERUM	R4KO0DY52L																						UNKNOWN					17	UNKNOWN		UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4269593	Homo sapiens										false
479	142		UNKNOWN		505.447	CHLORHEXIDINE			SALIVA	R4KO0DY52L																						UNKNOWN					73	UNKNOWN		UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4269593/	Homo sapiens										false
480	142		ADULT	2713|5353524|5360566|9552079|88536661	505.447	CHLORHEXIDINE	CHLORHEXIDINE	ClC1=CC=C(NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC2=CC=C(Cl)C=C2)C=C1	INFLAMMATORY EXUDATE	R4KO0DY52L									?	μg × h/mL	187083.4		μg/mL	2007			UNKNOWN	mg	2.5		SINGLE	UNKNOWN						UNHEALTHY	Dental	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9869352	Homo sapiens										false
481	142		ADULT	2713|5353524|5360566|9552079|88536661	505.447	CHLORHEXIDINE	CHLORHEXIDINE	ClC1=CC=C(NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC2=CC=C(Cl)C=C2)C=C1	PLASMA	R4KO0DY52L													μg/g	0.206			UNKNOWN	mg	300		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019028s022lbl.pdf	Homo sapiens										false
482	143		ADULT	2724	245.66	CHLORPHENESIN CARBAMATE	CHLORPHENESIN CARBAMATE	NC(=O)OCC(O)COC1=CC=C(Cl)C=C1	SERUM	57U5YI11WP	4107		METHOCARBAMOL	methocarbamol	COC1=C(OCC(O)COC(N)=O)C=CC=C1	125OD7737X	12		t	μg × h/mL	84		μg/mL	14.9			UNKNOWN	g	2		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/5133920/	Homo sapiens		h	0.44							true
483	144		ADULT	2762	262.2182	CINOXACIN	CINOXACIN	CCN1N=C(C(O)=O)C(=O)C2=C1C=C3OCOC3=C2	SERUM	LMK22VUH23									∞	μg × h/mL	78.4		μg/mL	14			UNKNOWN	mg	500		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3665628	Homo sapiens		h	2.27							false
484	144		ADULT	2762	262.2182	CINOXACIN	CINOXACIN	CCN1N=C(C(O)=O)C(=O)C2=C1C=C3OCOC3=C2	SERUM	LMK22VUH23							12		t	μg × h/mL	80.62		μg/mL	15.27			UNKNOWN	mg	500		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3665628	Homo sapiens		h	2.23							false
485	144		ADULT	2762	262.2182	CINOXACIN	CINOXACIN	CCN1N=C(C(O)=O)C(=O)C2=C1C=C3OCOC3=C2	SERUM	LMK22VUH23													μg/mL	12.7			UNKNOWN	mg	500		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/507797	Homo sapiens		h	1.1							false
486	144		ADULT	2762	262.2182	CINOXACIN	CINOXACIN	CCN1N=C(C(O)=O)C(=O)C2=C1C=C3OCOC3=C2	SERUM	LMK22VUH23									∞	μg × h/mL	45.19		μg/mL	15.1			UNKNOWN	mg	500		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6653617	Homo sapiens		h	2.08							false
487	145		UNKNOWN	20279	285.687	CLADRIBINE	cladribine	NC1=NC(Cl)=NC2=C1N=CN2[C@H]3C[C@H](O)[C@@H](CO)O3	PLASMA	47M74X9YT5									∞	ng × h/mL	99.17		ng/mL	29.05			UNKNOWN	mg	10		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	REVIEW	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/022561Orig1s000ClinPharmR.pdf	Homo sapiens		h	19.7							false
488	145		UNKNOWN	20279	285.687	CLADRIBINE	CLADRIBINE	NC1=NC(Cl)=NC2=C1N=CN2[C@H]3C[C@H](O)[C@@H](CO)O3	PLASMA	47M74X9YT5									∞	ng × h/mL	69.4		ng/mL	20.57			UNKNOWN	mg	3		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	REVIEW	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/022561Orig1s000ClinPharmR.pdf	Homo sapiens		h	18.4							false
489	146		ADULT	2788	305.5	CLIOQUINOL	CLIOQUINOL	OC1=C(I)C=C(Cl)C2=CC=CN=C12	PLASMA	7BHQ856EJ5									?	μg × h/mL	1600		μg/mL	42			MAX TOLERATED	mg	1600		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22683301/	Homo sapiens		h	41							false
490	147		ADULT	6253	243.2166	CYTARABINE	CYTARABINE	NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O	PLASMA	04079A1RDZ	30323		DAUNORUBICIN	daunorubicin	COC1=CC=CC2=C1C(=O)C3=C(C2=O)C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O)C(C)=O	ZS7284E0ZP			?	μg × h/mL	1900		μg/mL	62.2			RECOMMENDED	mg/m²	100		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209401s000lbl.pdf	Homo sapiens		h	40.4							true
491	147		ADULT	6253	243.2166	CYTARABINE	Cytarabine	NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O	CEREBROSPINAL FLUID	04079A1RDZ																	UNKNOWN	mg	50		SINGLE	UNKNOWN						UNKNOWN	Intrathecal	UNKNOWN	REVIEW	https://www.ncbi.nlm.nih.gov/pubmed/12162758	Homo sapiens		h	80							false
492	148		ADULT	83952	735	Erythromycylamine	erythromycylamine		PLASMA	YX9KV1OMA4							24		t	μg × h/mL	0.9		μg/mL	0.3			UNKNOWN	mg	500		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/050678Orig1s000rev.pdf	Homo sapiens		h	8							false
493	148		ADULT	83952	735	Erythromycylamine	Erythromycylamine		PLASMA	YX9KV1OMA4							24		t	μg × h/mL	1.8		μg/mL	0.4			UNKNOWN	mg	500		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/050678Orig1s000rev.pdf	Homo sapiens		h	8							false
494	149		ADULT	73303|6918242	420.504	DORIPENEM	DORIPENEM	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N2C1=O)C(O)=O	PLASMA	BHV525JOBH							8		t	μg × h/mL	52.98		μg/mL	16.87			RECOMMENDED	mg	500		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28920154/	Homo sapiens		h	2.93							false
495	149		ADULT	73303|6918242	420.504	DORIPENEM	DORIPENEM	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N2C1=O)C(O)=O	PLASMA	BHV525JOBH							8		t	μg × h/mL	70.64		μg/mL	12.94			RECOMMENDED	mg	500		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28920154/	Homo sapiens		h	4.04							false
496	149		ADULT	73303|6918242	420.504	DORIPENEM	DORIPENEM	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N2C1=O)C(O)=O	PLASMA	BHV525JOBH									∞	mg × h/L	13.8		mg/L	10.2			UNKNOWN	mg	250		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29746394/	Homo sapiens		h	0.91							false
497	149		ADULT	73303|6918242	420.504	DORIPENEM	DORIPENEM	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N2C1=O)C(O)=O	PLASMA	BHV525JOBH									∞	μg × h/mL	36.3		μg/mL	23			RECOMMENDED	mg	500		SINGLE	UNKNOWN					91.9	HEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022106s002s005lbl.pdf	Homo sapiens		h	1							false
498	150		ADULT	448812	831.962	EPTIFIBATIDE	EPTIFIBATIDE	NC(=N)NCCCC[C@@H]1NC(=O)CCSSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC3=CNC4=C3C=CC=C4)NC(=O)[C@H](CC(O)=O)NC(=O)CNC1=O)C(N)=O	PLASMA	NA8320J834									∞	mg × h/L	43.08		mg/L	2.59			UNKNOWN	μg/kg bw	2880	infusion, 24 hour	OTHER	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15110131/	Homo sapiens		h	4.18							false
499	151		ADULT	3287|2761171	166.243	ETHIONAMIDE	ETHIONAMIDE	CCC1=NC=CC(=C1)C(N)=S	PLASMA	OAY8ORS3CQ									?	μg × h/mL	7.67		μg/mL	2.16			RECOMMENDED	mg	250		SINGLE	FASTED				approximately 30% bound to proteins	70	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/013026s024lbl.pdf	Homo sapiens		h	1.92							false
500	152		UNKNOWN	3366|5282376	129.0925	FLUCYTOSINE	FLUCYTOSINE	NC1=NC(=O)NC=C1F	PLASMA	D83282DT06																						UNKNOWN				In vitro studies have shown that 2.9% to 4% of flucytosine is protein-bound over the range of therapeutic concentrations found in the blood.	96.6	UNKNOWN		UNKNOWN	DRUG LABEL	https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/5721b46a-4a9f-46c2-8804-a9bad4d5f80a/spl-doc?hl=flucytosine	Homo sapiens										false
501	152		ADULT	3366	129.09	FLUCYTOSINE	FLUCYTOSINE	NC1=NC(=O)NC=C1F	PLASMA	D83282DT06									∞	mg × h/L	506		mg/L	57.3			UNKNOWN	mg	1500		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/20038612	Homo sapiens		h	8.11							false
502	153		ADULT	37393	500.424	HALOFANTRINE	HALOFANTRINE	CCCCN(CCCC)CCC(O)C1=C2C=CC(=CC2=C3C=C(Cl)C=C(Cl)C3=C1)C(F)(F)F	PLASMA	Q2OS4303HZ									?	mg × h/L	7.86		μg/L	345			UNKNOWN	mg	500		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2775616/	Homo sapiens		h	98							false
503	153		ADULT	37393	500.424	HALOFANTRINE	HALOFANTRINE	CCCCN(CCCC)CCC(O)C1=C2C=CC(=CC2=C3C=C(Cl)C=C(Cl)C3=C1)C(F)(F)F	PLASMA	Q2OS4303HZ									?	mg × h/L	9.36		μg/L	546			UNKNOWN	mg	1000		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2775616/	Homo sapiens		h	72							false
504	153		ADULT	115076	444.317	DESBUTYLHALOFANTRINE	DESBUTYLHALOFANTRINE	CCCCNCCC(O)C1=CC2=C(Cl)C=C(Cl)C=C2C3=CC(=CC=C13)C(F)(F)F	PLASMA	7K35DDV85X									?	mg × h/L	8.76		μg/L	79			UNKNOWN	mg	250		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2775616/	Homo sapiens										false
505	153		ADULT	115076	444.317	DESBUTYLHALOFANTRINE	DESBUTYLHALOFANTRINE	CCCCNCCC(O)C1=CC2=C(Cl)C=C(Cl)C=C2C3=CC(=CC=C13)C(F)(F)F	PLASMA	7K35DDV85X									?	mg × h/L	17.33		μg/L	114			UNKNOWN	mg	500		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2775616/	Homo sapiens										false
506	153		ADULT	115076	444.317	DESBUTYLHALOFANTRINE	DESBUTYLHALOFANTRINE	CCCCNCCC(O)C1=CC2=C(Cl)C=C(Cl)C=C2C3=CC(=CC=C13)C(F)(F)F	PLASMA	7K35DDV85X									?	mg × h/L	24.46		μg/L	191			UNKNOWN	mg	1000		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2775616/	Homo sapiens										false
507	153		ADULT	37393	500.424	HALOFANTRINE	HALOFANTRINE	CCCCN(CCCC)CCC(O)C1=C2C=CC(=CC2=C3C=C(Cl)C=C(Cl)C3=C1)C(F)(F)F	PLASMA	Q2OS4303HZ									?	mg × h/L	11.3		μg/L	1218			UNKNOWN	mg	250		SINGLE	HIGH-FAT						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2775616/	Homo sapiens										false
508	153		ADULT	37393	500.424	HALOFANTRINE	HALOFANTRINE	CCCCN(CCCC)CCC(O)C1=C2C=CC(=CC2=C3C=C(Cl)C=C(Cl)C3=C1)C(F)(F)F	PLASMA	Q2OS4303HZ									?	mg × h/L	3.92		μg/L	185			UNKNOWN	mg	250		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2775616/	Homo sapiens		h	81							false
509	153		ADULT	37393	500.424	HALOFANTRINE	HALOFANTRINE	CCCCN(CCCC)CCC(O)C1=C2C=CC(=CC2=C3C=C(Cl)C=C(Cl)C3=C1)C(F)(F)F	PLASMA	Q2OS4303HZ													ng/mL	3200			RECOMMENDED	mg	500		MULTIPLE	FED		day	3			HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20250s7s8lbl.pdf	Homo sapiens		day	8							false
510	154		ADULT	5905	354.0985	IDOXURIDINE	IDOXURIDINE	OC[C@H]1O[C@H](C[C@@H]1O)N2C=C(I)C(=O)NC2=O	PLASMA	LGP81V5245									?	μM × h	139.03						UNKNOWN	mg/m²	4538		MULTIPLE	UNKNOWN		day	1			HEALTHY	Intraperitoneal	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9661893/	Homo sapiens										false
511	155		ADULT	3730	821.1379	IOHEXOL	IOHEXOL	CC(=O)N(CC(O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I	SERUM	4419T9MX03																	UNKNOWN	mg/kg	269.63		SINGLE	FED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6408018	Homo sapiens		min	119							false
512	155		ADULT	3730	821.1379	IOHEXOL	IOHEXOL	CC(=O)N(CC(O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I	PLASMA	4419T9MX03									∞	μg × min/mL	6365.609		μg/mL	16.395			UNKNOWN	mg	647.11		SINGLE	FASTED						HEALTHY	Subcutaneous	FEMALE / MALE	OTHER	https://scholarscompass.vcu.edu/cgi/viewcontent.cgi?article=1278&context=etd&httpsredir=1&referer=	Homo sapiens		min	139.132							false
513	155		UNKNOWN	3730	821.1379	IOHEXOL	IOHEXOL	CC(=O)N(CC(O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I	BLOOD	4419T9MX03																						UNKNOWN				Iohexol displays a low affinity for serum or plasma proteins and is poorly bound to serum albumin.	100	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018956s099lbl.pdf	Homo sapiens		min	20							false
514	156		ADULT	65492	777.0853	IOPAMIDOL	IOPAMIDOL	C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I	PLASMA	JR13W81H44							24		t	μg × h/mL	931		μg/mL	112.7			UNKNOWN	mL	15		SINGLE	UNKNOWN						UNHEALTHY	Intrathecal	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3096110	Homo sapiens										false
515	156		UNKNOWN	65492	777.0853	IOPAMIDOL	IOPAMIDOL	C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I	PLASMA	JR13W81H44																						UNKNOWN				Iopamidol does not bind to plasma proteins	100	UNKNOWN		UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9084958	Homo sapiens										false
516	156		ADULT	65492	777.0853	IOPAMIDOL	IOPAMIDOL	C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I	PLASMA	JR13W81H44																	UNKNOWN				SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/018735s054lbl.pdf	Homo sapiens		h	2							false
517	157		ADULT	3736	791.1119	IOPROMIDE	IOPROMIDE	COCC(=O)NC1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I	PLASMA	712BAC33MZ									∞	mg × h/mL	2.3						UNKNOWN	g	15		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7957519	Homo sapiens		h	1.95							false
518	157		ADULT	3736	791.1119	IOPROMIDE	IOPROMIDE	COCC(=O)NC1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I	PLASMA	712BAC33MZ									∞	mg × h/mL	13.2						UNKNOWN	g	80		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7957519	Homo sapiens		h	1.9							false
519	157		UNKNOWN	3736	791.1119	IOPROMIDE	IOPROMIDE	COCC(=O)NC1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I	PLASMA	712BAC33MZ																	UNKNOWN				UNKNOWN	UNKNOWN				Plasma protein binding of iopromide is 1%.	99	UNKNOWN	UNKNOWN	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021425s030lbl.pdf	Homo sapiens										false
520	158		ADULT	24841|21844680	127.91241	HYDROGEN IODIDE	I	I	PLASMA	694C0EFT9Q									∞	mg × h/mL	1.74		mg/mL	1.45			UNKNOWN	mL	50		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2793391	Homo sapiens		h	2.06							false
521	158		ADULT	24841|21844680	127.91241	HYDROGEN IODIDE	I	I	PLASMA	694C0EFT9Q									∞	mg × h/mL	4.43		mg/mL	2.36			UNKNOWN	mL	150		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2793391	Homo sapiens		h	2.04							false
522	158		UNKNOWN	3741	807.1113	IOVERSOL	IOVERSOL	OCCN(C(=O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I	PLASMA	N3RIB7X24K																						UNKNOWN				In an in vitro human plasma study, ioversol did not bind to protein.	100	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019710s054,020923s019lbl.pdf	Homo sapiens										false
523	159		ADULT	60825	229.256	LAMIVUDINE	LAMIVUDINE	NC1=NC(=O)N(C=C1)[C@@H]2CS[C@H](CO)O2	PLASMA	2T8Q726O95							12		t	μg × h/mL	5.53		μg/mL	1.4			UNKNOWN	mg	150		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020564s039,020596s038lbl.pdf	Homo sapiens										false
524	159		ADULT	60825	229.256	LAMIVUDINE	LAMIVUDINE	NC1=NC(=O)N(C=C1)[C@@H]2CS[C@H](CO)O2	BLOOD	2T8Q726O95							24		t	μg × h/mL	12.4		μg/mL	3.3			DEFINED DAILY	mg	300		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/29150845	Homo sapiens		h	13.9							false
525	161			3950	233.695	LOMUSTINE	LOMUSTINE	ClCCN(N=O)C(=O)NC1CCCCC1	PLASMA	7BRF0Z81KG																											50				REVIEW	http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Lomustine_monograph.pdf	Homo sapiens										false
526	161		UNKNOWN	3950	233.69	LOMUSTINE	LOMUSTINE	ClCCN(N=O)C(=O)NC1CCCCC1	PLASMA	7BRF0Z81KG													ng/mL	2			UNKNOWN	mg/m²	100		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.medicines.org.uk/emc/product/1401/smpc	Homo sapiens										false
527	164		ADULT	29769|23662354|139072523	164.179	MESNA	MESNA	[Na+].[O-]S(=O)(=O)CCS	PLASMA	NR7O1405Q9									?	μM × h	110		μM	33			UNKNOWN	g	1.2		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/8462128	Homo sapiens										false
528	164		ADULT	29769|23662354|139072523	164.179	MESNA	MESNA	[Na+].[O-]S(=O)(=O)CCS	PLASMA	NR7O1405Q9									?	μM × h	201		μM	511			UNKNOWN	g	1.2		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/8462128	Homo sapiens										false
529	164		ADULT	29769|23662354|139072523	164.179	MESNA	MESNA	[Na+].[O-]S(=O)(=O)CCS	BLOOD	NR7O1405Q9									?	μM × h	49		μM	79			UNKNOWN	g/m²	0.24		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/9469350	Homo sapiens		min	92							false
530	165		ADULT	15459	221.2524	METAXALONE	METAXALONE	CC1=CC(OCC2CNC(=O)O2)=CC(C)=C1	PLASMA	1NMA9J598Y									?	ng × h/mL	7479		ng/mL	983			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/013217s046lbl.pdf	Homo sapiens		h	9							false
531	165		ADULT	15459	221.2524	METAXALONE	METAXALONE	CC1=CC(OCC2CNC(=O)O2)=CC(C)=C1	PLASMA	1NMA9J598Y									?	ng × h/mL	15044		ng/mL	1816			RECOMMENDED	mg	800		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/013217s046lbl.pdf	Homo sapiens		h	8							false
532	165		ADULT	15459	221.2524	METAXALONE	METAXALONE	CC1=CC(OCC2CNC(=O)O2)=CC(C)=C1	PLASMA	1NMA9J598Y									∞	ng × h/mL	15045		ng/mL	1816			RECOMMENDED	mg	800		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/013217s046lbl.pdf	Homo sapiens										false
533	165		ADULT	15459	221.2524	METAXALONE	METAXALONE	CC1=CC(OCC2CNC(=O)O2)=CC(C)=C1	PLASMA	1NMA9J598Y									∞	ng × h/mL	20833		ng/mL	3510			RECOMMENDED	mg	800		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/013217s046lbl.pdf	Homo sapiens										false
534	166		UNKNOWN	5746	334.3272	MITOMYCIN	MITOMYCIN C	CO[C@]12[C@H]3N[C@H]3CN1C4=C([C@H]2COC(N)=O)C(=O)C(N)=C(C)C4=O	PLASMA	50SG953SK6																						UNKNOWN				Plasma protein binding of mitomycin C was 24±4%	76	UNKNOWN		UNKNOWN	EXPERIMENT	https://scialert.net/fulltextmobile/?doi=ijp.2006.293.297	Homo sapiens										false
535	166		ADULT	5746	334.3272	MITOMYCIN	mitomycin c	CO[C@]12[C@H]3N[C@H]3CN1C4=C([C@H]2COC(N)=O)C(=O)C(N)=C(C)C4=O	PLASMA	50SG953SK6									∞	μg × h/L	773						UNKNOWN	mg/m²	10		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/3097025	Homo sapiens		min	54							false
536	166		ADULT	5746	334.3272	MITOMYCIN	mitomycin c	CO[C@]12[C@H]3N[C@H]3CN1C4=C([C@H]2COC(N)=O)C(=O)C(N)=C(C)C4=O	PLASMA	50SG953SK6									∞	μg × h/L	630						UNKNOWN	mg/m²	10		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/6411336	Homo sapiens		min	50							false
537	168		ADULT	3011155	297.2673	NELARABINE	NELARABINE	COC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3O)C2=NC(N)=N1	PLASMA	60158CV180																	UNKNOWN	mg/kg	75		MULTIPLE	UNKNOWN		hour	2			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/10694549	Homo sapiens		min	16.5							false
538	169		ADULT	4612	279.3348	OXAMNIQUINE	OXAMNIQUINE	CC(C)NCC1CCC2=C(N1)C=C(C(CO)=C2)[N+]([O-])=O	PLASMA										?	ng × min/mL	417900		ng/mL	1983			UNKNOWN	g	1		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3104279	Homo sapiens		min	111							false
539	169		ADULT	4612	279.3348	OXAMNIQUINE	OXAMNIQUINE	CC(C)NCC1CCC2=C(N1)C=C(C(CO)=C2)[N+]([O-])=O	PLASMA										?	ng × min/mL	339097		ng/mL	1267			UNKNOWN	g	1		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3104279	Homo sapiens		min	151.2							false
540	170		CHILD	4723|137628477	176.172	PEMOLINE	PEMOLINE	NC1=NC(=O)C(O1)C2=CC=CC=C2	PLASMA	7GAQ2332NK							8		t	μg × h/mL	46.2		μg/mL	2.76			UNKNOWN	mg/kg	2		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4017397/	Homo sapiens		h	7.28							false
541	171		ADULT	4735	340.4195	PENTAMIDINE	PENTAMIDINE	NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1	BLOOD	673LC5J4LQ							28		t	nM × h	6734		nM	751			DEFINED DAILY	mg/kg	3.9		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8056699	Homo sapiens										false
542	171		ADULT	4735	340.4195	PENTAMIDINE	PENTAMIDINE	NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1	PLASMA	673LC5J4LQ													ng/mL	18.8			UNKNOWN	mg/kg	4		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Irrigation	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019887s014lbl.pdf	Homo sapiens										false
543	171		ADULT	4735	340.4195	PENTAMIDINE	PENTAMIDINE	NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1	PLASMA	673LC5J4LQ													ng/mL	612			UNKNOWN	mg/kg	4		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019887s014lbl.pdf	Homo sapiens		h	6.4							false
544	172		ADULT	163659	1085.1454	PLICAMYCIN	PLICAMYCIN	CO[C@@H]([C@@H]1CC2=CC3=CC(O[C@H]4C[C@@H](O[C@H]5C[C@@H](O)[C@H](O)[C@@H](C)O5)[C@H](O)[C@@H](C)O4)=C(C)C(O)=C3C(O)=C2C(=O)[C@H]1O[C@H]6C[C@@H](O[C@H]7C[C@@H](O[C@H]8C[C@](C)(O)[C@H](O)[C@@H](C)O8)[C@@H](O)[C@@H](C)O7)[C@H](O)[C@@H](C)O6)C(=O)[C@@H](O)[C@@H](C)O	PLASMA	NIJ123W41V									∞	ng × h/mL	1489		ng/mL	350			UNKNOWN	mg/m²	1		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1412612/	Homo sapiens		h	10.6							false
545	173		ADULT	4891	312.4061	PRAZIQUANTEL	PRAZIQUANTEL	O=C(C1CCCCC1)N2CC3N(CCC4=C3C=CC=C4)C(=O)C2	PLASMA	6490C9U457									?	μg × h/mL	3.02		μg/mL	0.83			UNKNOWN	mg/kg	40		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/018714s018lbl.pdf	Homo sapiens		h	2.99							false
546	174		ADULT	1046	123.11	PYRAZINAMIDE	PYRAZINAMIDE	NC(=O)C1=CN=CC=N1	PLASMA	2KNI5N06TI	3767 | 135398735 | 14052		Isoniazid | Rifampicin | Ethambutol	Isoniazid | Rifampicin | Ethambutol	C1=CN=CC=C1C(=O)NN | CC1C=CC=C(C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)C(O4)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C=NN5CCN(CC5)C)C | CCC(CO)NCCNC(CC)CO	V83O1VOZ8L | VJT6J7R4TR | 8G167061QZ			∞	mg × h/mL	344		mg/L	38.2			UNKNOWN	mg/kg bw	27.8		STEADY-STATE	UNKNOWN		day	3			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/23629715	Homo sapiens		h	5.5							true
547	174		ADULT	1046	123.11	PYRAZINAMIDE	PYRAZINAMIDE	NC(=O)C1=CN=CC=N1	PLASMA	2KNI5N06TI									∞	mg × h/L	520		mg/L	38.7			UNKNOWN	mg/kg bw	27		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/2737233	Homo sapiens										false
548	175		ADULT		877.0307	RIFAPENTINE	RIFAPENTINE	CO[C@H]1\\C=C\\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)C(C)=C\\C=C\\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(\\C=N\\N5CCN(CC5)C6CCCC6)=C(O)C4=C3C2=O	PLASMA	XJM390A33U							72		t	μg × h/mL	319.54		μg/mL	15.05			RECOMMENDED	mg	600		STEADY-STATE	UNKNOWN		3 days	1	In healthy volunteers, rifapentine and 25-desacetyl rifapentine were 97.7% and 93.2% bound to plasma proteins, respectively. Rifapentine was mainly bound to albumin.	2.3	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021024s017s018lbl.pdf	Homo sapiens		h	13.19							false
549	175		ADULT		877.0307	RIFAPENTINE	RIFAPENTINE	CO[C@H]1\\C=C\\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)C(C)=C\\C=C\\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(\\C=N\\N5CCN(CC5)C6CCCC6)=C(O)C4=C3C2=O	PLASMA	XJM390A33U	3767|6064144|6064145		ISONIAZID	Isoniazid	NNC(=O)C1=CC=NC=C1	V83O1VOZ8L			?	μg × h/mL	817		μg/mL	25.8			UNKNOWN	mg	900		SINGLE	FED						HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021024s017s018lbl.pdf	Homo sapiens		h	16.6							true
550	176		UNKNOWN	23615975	265.2206	STREPTOZOCIN	STREPTOZOCIN	CN(N=O)C(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO	PLASMA	5W494URQ81									?	mM × min	5.3		mM	0.03			UNKNOWN	g	1		SINGLE	UNKNOWN						UNHEALTHY	Intraperitoneal	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/1458714	Homo sapiens										false
551	177		ADULT	159269	242.2286	TELBIVUDINE	TELBIVUDINE	CC1=CN([C@@H]2C[C@@H](O)[C@H](CO)O2)C(=O)NC1=O	PLASMA	2OC4HKD3SF							24		t	μg × h/mL	0.56		μg/mL	0.2			UNKNOWN	mg	25		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16495245/	Homo sapiens										false
552	177		ADULT	159269	242.2286	TELBIVUDINE	TELBIVUDINE	CC1=CN([C@@H]2C[C@@H](O)[C@H](CO)O2)C(=O)NC1=O	PLASMA	2OC4HKD3SF							24		t	μg × h/mL	0.75		μg/mL	0.22			UNKNOWN	mg	25		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16495245/	Homo sapiens										false
553	177		ADULT	159269	242.2286	TELBIVUDINE	TELBIVUDINE	CC1=CN([C@@H]2C[C@@H](O)[C@H](CO)O2)C(=O)NC1=O	PLASMA	2OC4HKD3SF							24		t	μg × h/mL	2.91		μg/mL	0.61			UNKNOWN	mg	100		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16495245/	Homo sapiens										false
554	177		ADULT	159269	242.2286	TELBIVUDINE	TELBIVUDINE	CC1=CN([C@@H]2C[C@@H](O)[C@H](CO)O2)C(=O)NC1=O	PLASMA	2OC4HKD3SF							24		t	μg × h/mL	4.14		μg/mL	0.82			UNKNOWN	mg	100		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16495245/	Homo sapiens										false
555	177		ADULT	159269	242.2286	TELBIVUDINE	TELBIVUDINE	CC1=CN([C@@H]2C[C@@H](O)[C@H](CO)O2)C(=O)NC1=O	PLASMA	2OC4HKD3SF							24		t	μg × h/mL	5.02		μg/mL	0.99			UNKNOWN	mg	200		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16495245/	Homo sapiens										false
556	177		ADULT	159269	242.2286	TELBIVUDINE	TELBIVUDINE	CC1=CN([C@@H]2C[C@@H](O)[C@H](CO)O2)C(=O)NC1=O	PLASMA	2OC4HKD3SF							24		t	μg × h/mL	6.67		μg/mL	1.24			UNKNOWN	mg	200		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16495245/	Homo sapiens										false
557	177		ADULT	159269	242.2286	TELBIVUDINE	TELBIVUDINE	CC1=CN([C@@H]2C[C@@H](O)[C@H](CO)O2)C(=O)NC1=O	PLASMA	2OC4HKD3SF							24		t	μg × h/mL	20.94		μg/mL	3.97			UNKNOWN	mg	800		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16495245/	Homo sapiens										false
558	177		ADULT	159269	242.2286	TELBIVUDINE	TELBIVUDINE	CC1=CN([C@@H]2C[C@@H](O)[C@H](CO)O2)C(=O)NC1=O	PLASMA	2OC4HKD3SF							24		t	μg × h/mL	29.73		μg/mL	5.46			UNKNOWN	mg	800		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16495245/	Homo sapiens										false
559	177		ADULT	159269	242.2286	TELBIVUDINE	TELBIVUDINE	CC1=CN([C@@H]2C[C@@H](O)[C@H](CO)O2)C(=O)NC1=O	PLASMA	2OC4HKD3SF									?	μg × h/mL	26.1		μg/mL	3.69			RECOMMENDED	mg	600		STEADY-STATE	UNKNOWN		day	1		96.7	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022011s013lbl.pdf	Homo sapiens		h	44.5							false
560	178		ADULT	3002190	812.0037	TELITHROMYCIN	TELITHROMYCIN	CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]3N(CCCCN4C=NC(=C4)C5=CN=CC=C5)C(=O)O[C@]13C)OC	PLASMA	KI8H7H19WL							24		t	mg × h/L	2.57		mg/L	0.8			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11120961/	Homo sapiens		h	6.68							false
561	178		ADULT	3002190	812.0037	TELITHROMYCIN	TELITHROMYCIN	CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]3N(CCCCN4C=NC(=C4)C5=CN=CC=C5)C(=O)O[C@]13C)OC	PLASMA	KI8H7H19WL							24		t	mg × h/L	8.25		mg/L	1.9			DEFINED DAILY	mg	800		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11120961/	Homo sapiens		h	7.16							false
562	178		ADULT	3002190	812.0037	TELITHROMYCIN	TELITHROMYCIN	CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]3N(CCCCN4C=NC(=C4)C5=CN=CC=C5)C(=O)O[C@]13C)OC	PLASMA	KI8H7H19WL							24		t	mg × h/L	23.1		mg/L	4.07			UNKNOWN	mg	1600		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11120961/	Homo sapiens		h	10.13							false
563	178		ADULT	3002190	812.0037	TELITHROMYCIN	TELITHROMYCIN	CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]3N(CCCCN4C=NC(=C4)C5=CN=CC=C5)C(=O)O[C@]13C)OC	PLASMA	KI8H7H19WL							24		t	mg × h/L	3.5		mg/L	0.829			UNKNOWN	mg	400		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11120961/	Homo sapiens		h	7.7							false
564	178		ADULT	3002190	812.0037	TELITHROMYCIN	TELITHROMYCIN	CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]3N(CCCCN4C=NC(=C4)C5=CN=CC=C5)C(=O)O[C@]13C)OC	PLASMA	KI8H7H19WL							24		t	mg × h/L	12.5		mg/L	2.27			RECOMMENDED	mg	800		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11120961/	Homo sapiens		h	9.81							false
565	178		ADULT	3002190	812.0037	TELITHROMYCIN	TELITHROMYCIN	CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]3N(CCCCN4C=NC(=C4)C5=CN=CC=C5)C(=O)O[C@]13C)OC	PLASMA	KI8H7H19WL							24		t	mg × h/L	30.2		mg/L	4.48			UNKNOWN	mg	1600		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11120961/	Homo sapiens		h	18.7							false
566	178		ADULT	3002190	812.0037	TELITHROMYCIN	TELITHROMYCIN	CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]3N(CCCCN4C=NC(=C4)C5=CN=CC=C5)C(=O)O[C@]13C)OC	PLASMA	KI8H7H19WL							24		t	μg × h/mL	8.25		μg/mL	1.9			DEFINED DAILY	mg	800		SINGLE	UNKNOWN				Total in vitro protein binding is approximately 60% to 70% and is primarily due to human serum albumin.	35	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021144s012lbl.pdf	Homo sapiens		h	7.16							false
567	178		ADULT	3002190	812.0037	TELITHROMYCIN	TELITHROMYCIN	CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]3N(CCCCN4C=NC(=C4)C5=CN=CC=C5)C(=O)O[C@]13C)OC	PLASMA	KI8H7H19WL							24		t	μg × h/mL	12.5		μg/mL	2.27			RECOMMENDED	mg	800		STEADY-STATE	UNKNOWN		day	1	Total in vitro protein binding is approximately 60% to 70% and is primarily due to human serum albumin.		HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021144s012lbl.pdf	Homo sapiens		h	9.81							false
568	179			5394	194.1508	TEMOZOLOMIDE	TEMOZOLOMIDE	CN1N=NC2=C(N=CN2C1=O)C(N)=O	PLASMA	YF1K15M17Y																		mg/m²	200		SINGLE								Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02343081	Homo sapiens		h	1.89							false
569	179			5394	194.1508	TEMOZOLOMIDE	TEMOZOLOMIDE	CN1N=NC2=C(N=CN2C1=O)C(N)=O	PLASMA	YF1K15M17Y																		mg/m²	200		SINGLE								Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02343081	Homo sapiens		h	1.87							false
570	179		ADULT	5394	194.1508	TEMOZOLOMIDE	TEMOZOLOMIDE	CN1N=NC2=C(N=CN2C1=O)C(N)=O	PLASMA	YF1K15M17Y									?	μg × h/mL	23.4		μg/mL	7.5			RECOMMENDED	mg/m²	150		SINGLE	UNKNOWN				It is weakly bound to human plasma proteins; the mean percent bound of drug-related total radioactivity is 15%.	85	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021029s031lbl.pdf	Homo sapiens		h	1.8							false
571	180		ADULT	5453	189.218	THIOTEPA	THIOTEPA	S=P(N1CC1)(N2CC2)N3CC3	PLASMA	905Z5W3GKH																	UNKNOWN	mg/m²	20		UNKNOWN	UNKNOWN				The binding of thiotepa to plasma proteins is approximately 10% to 20%	85	UNKNOWN	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208264s000lbl.pdf	Homo sapiens		h	2.55							false
572	180		ADULT	5453	189.218	THIOTEPA	THIOTEPA	S=P(N1CC1)(N2CC2)N3CC3	PLASMA	905Z5W3GKH							48		t	μg × h/mL	28.24		μg/mL	8.91			RECOMMENDED	mg/m²	200		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/11249051	Homo sapiens		h	4.15							false
573	181				585.6487	TIGECYCLINE	TIGECYCLINE	CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C(=O)C3=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O)C(O)=C(NC(=O)CNC(C)(C)C)C=C4N(C)C	SERUM	70JE2N95KR							96		t	mg × h/L	7.64							mg	100		SINGLE								Intravenous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01560143	Homo sapiens										false
574	181		ADULT	54686904	585.6	Tigecycline		CC(C)(C)NCC(=O)NC1=CC(=C2CC3CC4C(C(=O)C(=C(C4(C(=O)C3=C(C2=C1O)O)O)O)C(=O)N)N(C)C)N(C)C	PLASMA	70JE2N95KR							24		t	μg × h/mL	4.7		μg/mL	0.63			RECOMMENDED	mg	50		MULTIPLE	UNKNOWN		day	2	at concentrations observed in clinical studies 1.0 ug/mL	11	UNHEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021821s026s031lbl.pdf	Homo sapiens		h	42.4							false
575	182		ADULT	5479	247.272	TINIDAZOLE	TINIDAZOLE	CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O	PLASMA	033KF7V46H									∞	μg × h/mL	901.6		μg/mL	47.7			DEFINED DAILY	g	2		SINGLE	FASTED				Plasma protein binding of tinidazole is 12%.	88	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021618s003lbl.pdf	Homo sapiens		h	13.2							false
576	183		ADULT	5483	163.195	TIOPRONIN	TIOPRONIN	CC(S)C(=O)NCC(O)=O	PLASMA	C5W04GO61S							48		t	μg × h/mL	29		μg/mL	3.6			UNKNOWN	mg	500		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/1505618	Homo sapiens		h	18.7							false
577	184		UNKNOWN	6256	296.1999	TRIFLURIDINE	TRIFLURIDINE	OC[C@H]1O[C@H](C[C@@H]1O)N2C=C(C(=O)NC2=O)C(F)(F)F	PLASMA	RMW9V5RW38																						UNKNOWN				Trifluridine mainly binds to human serum albumin. The in vitro protein binding of trifluridine in human plasma is >96%, independent of drug concentration and presence of tipiracil.	6	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/207981s008lbl.pdf	Homo sapiens										false
578	184		ADULT	6256	296.1999	TRIFLURIDINE	TRIFLURIDINE	OC[C@H]1O[C@H](C[C@@H]1O)N2C=C(C(=O)NC2=O)C(F)(F)F	BLOOD	RMW9V5RW38									∞	ng × h/mL	248		ng/mL	96			UNKNOWN	mg/m²	35		SINGLE	HIGH-FAT						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/28111727	Homo sapiens										false
579	184		ADULT	6256	296.1999	TRIFLURIDINE	TRIFLURIDINE	OC[C@H]1O[C@H](C[C@@H]1O)N2C=C(C(=O)NC2=O)C(F)(F)F	BLOOD	RMW9V5RW38	5287953|6323266		TIPIRACIL	tipiracil	ClC1=C(CN2CCCC2=N)NC(=O)NC1=O	NGO10K751P			∞	μg × h/mL	6694		ng/mL	2155			UNKNOWN	mg/m²	35		SINGLE	HIGH-FAT						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/28111727	Homo sapiens										true
580	185		ADULT	71616	349.31	Voriconazole	Voriconazole	CC(C1=NC=NC=C1F)C(CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O	PLASMA	JFU09I87TR									∞	μg × h/mL	27.9		μg/mL	3.1			RECOMMENDED	mg	200		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19933807	Homo sapiens		h	15.5							false
581	185		ADULT	71616	349.31	VORICONAZOLE	VORICONAZOLE	CC(C1=NC=NC=C1F)C(CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O	PLASMA	JFU09I87TR							12		t	μg × h/mL	13.9		μg/mL	3.13			RECOMMENDED	mg/kg	6		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021266s039,021267s050,021630s029lbl.pdf	Homo sapiens										false
582	185		ADULT	71616	349.31	Voriconazole	Voriconazole	CC(C1=NC=NC=C1F)C(CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O	PLASMA	JFU09I87TR							12		t	μg × h/mL	13.7		μg/mL	3.03			RECOMMENDED	mg/kg	3		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021266s039,021267s050,021630s029lbl.pdf	Homo sapiens										false
583	185		ADULT	71616	349.31	Voriconazole	Voriconazole	CC(C1=NC=NC=C1F)C(CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O	PLASMA	JFU09I87TR							12		t	μg × h/mL	33.9		μg/mL	4.77			RECOMMENDED	mg/kg	4		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021266s039,021267s050,021630s029lbl.pdf	Homo sapiens										false
584	185		ADULT	71616	349.31	Voriconazole	Voriconazole	CC(C1=NC=NC=C1F)C(CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O	PLASMA	JFU09I87TR							12		t	μg × h/mL	9.31		μg/mL	2.3			DEFINED DAILY	mg	400		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021266s039,021267s050,021630s029lbl.pdf	Homo sapiens										false
585	185		ADULT	71616	349.31	Voriconazole	Voriconazole	CC(C1=NC=NC=C1F)C(CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O	PLASMA	JFU09I87TR							12		t	μg × h/mL	12.4		μg/mL	2.31			RECOMMENDED	mg	200		MULTIPLE	UNKNOWN		day	2	Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9-15 ug/mL)	42	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021266s039,021267s050,021630s029lbl.pdf	Homo sapiens										false
586	185		ADULT	71616	349.31	Voriconazole	Voriconazole	CC(C1=NC=NC=C1F)C(CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O	PLASMA	JFU09I87TR							12		t	μg × h/mL	34		μg/mL	4.74			UNKNOWN	mg	300		MULTIPLE	UNKNOWN		day	2	Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9-15 ug/mL)	42	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021266s039,021267s050,021630s029lbl.pdf	Homo sapiens										false
587	186		ADULT	6439900	562.695	ECAMSULE	ECAMSULE	CC1(C)C2CCC1(CS(O)(=O)=O)C(=O)C2=CC3=CC=C(C=C4C5CCC(CS(O)(=O)=O)(C4=O)C5(C)C)C=C3	PLASMA	M94R1PM439													ng/mL	1.5			RECOMMENDED	g	0.576		MULTIPLE	UNKNOWN		day	4			HEALTHY	Topical	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31058986/	Homo sapiens										false
588	188		ADULT	153921|24847884|101673418	573.66	GADODIAMIDE	GADODIAMIDE	[Gd+3].CNC(=O)CN(CCN(CCN(CC([O-])=O)CC(=O)NC)CC([O-])=O)CC([O-])=O	PLASMA	84F6U3J2R6																	RECOMMENDED	mmol/kg	0.1		SINGLE	UNKNOWN				human serum proteins	100	HEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022066lbl.pdf	Homo sapiens		min	77.8							false
589	189		ADULT	9873	498.962	PERFLUBRON	PERFLUBRON	FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br	SERUM	Q1D0Q7R4D9													mg/dL	0.16			INVESTIGATIONAL	mL/kg	14		SINGLE	UNKNOWN						UNHEALTHY	Respiratory	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11171732	Homo sapiens										false
590	190		UNKNOWN	2724354	182.218	SUCCIMER	Succimer	OC(=O)[C@@H](S)[C@@H](S)C(O)=O	PLASMA	DX1U2629QE																	UNKNOWN				UNKNOWN	UNKNOWN		UNKNOWN		Most of the DMSA in the plasma (92-95%) was found to be bound to plasma proteins, mainly albumin.	6.5	UNKNOWN	UNKNOWN	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2166796/	Homo sapiens										false
591	190		ADULT	92908|11947774|101332025|129634980	784.126	STIBOCAPTATE	STIBOCAPTATE	OC(=O)C(S[Sb]1SC(C(S1)C(O)=O)C(O)=O)C(S[Sb]2SC(C(S2)C(O)=O)C(O)=O)C(O)=O	PLASMA	9WCI9N7UUQ													μM	55			RECOMMENDED	mg/kg bw	10		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7588486/	Homo sapiens		h	3.3							false
592	190		ADULT	2724354	182.218	SUCCIMER	Succimer	OC(=O)[C@@H](S)[C@@H](S)C(O)=O	PLASMA	DX1U2629QE							24		t	μM × h	318		μM	25.3			INVESTIGATIONAL	mg	300		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7716789/	Homo sapiens		h	9.9							false
593	190		ADULT	2724354	182.218	SUCCIMER	Succimer	OC(=O)[C@@H](S)[C@@H](S)C(O)=O	BLOOD	DX1U2629QE																	UNKNOWN				SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019998s013lbl.pdf	Homo sapiens		day	2							false
594	193		ADULT	244	108.1378	BENZYL ALCOHOL	BENZYL ALCOHOL	OCC1=CC=CC=C1	SERUM	LKG8494WBH	9677		NANDROLONE DECANOATE	nandrolone decanoate	CCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C	H45187T098	840		t	μM × h	397.3		μM	34.8			UNKNOWN	mmol	0.46		SINGLE	UNKNOWN						HEALTHY	Subcutaneous	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27019966/	Homo sapiens										true
595	193		ADULT	243|20144841	122.1213	BENZOIC ACID	Benzoic acid	OC(=O)C1=CC=CC=C1	SERUM	8SKN0B0MIM	9677		NANDROLONE DECANOATE	nandrolone decanoate	CCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C	H45187T098	840		t	μM × h	417.4		μM	1.8			UNKNOWN	mmol	0.46		SINGLE	UNKNOWN						HEALTHY	Subcutaneous	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27019966/	Homo sapiens										true
596	193		ADULT	464	179.1727	HIPPURIC ACID	Hippuric acid	OC(=O)CNC(=O)C1=CC=CC=C1	SERUM	TE0865N2ET	9677		NANDROLONE DECANOATE	nandrolone decanoate	CCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C	H45187T098	840		t	μM × h	7113.6		μM	16.6			UNKNOWN	mmol	0.46		SINGLE	UNKNOWN						HEALTHY	Subcutaneous	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27019966/	Homo sapiens										true
597	196		ADULT		203.28	CROTAMITON	CROTAMITON		PLASMA	D6S4O4XD0H							24		t	ng × h/mL	344		ng/mL	24.5			UNKNOWN	mg	500		SINGLE	UNKNOWN						HEALTHY	Topical	MALE	EXPERIMENT	https://www.tandfonline.com/doi/abs/10.3109/09546639209089058	Homo sapiens				5 g of crotamiton ointment (Crotamitex\n10%)			6	CROTAMITON		false
598	198		ADULT	5323714	225.1583	FURAZOLIDONE	furazolidone	[O-][N+](=O)C1=CC=C(O1)C=NN2CCOC2=O	SERUM	5J9CPU3RE0							24		t	μg × h/mL	0.89		μg/mL	0.34			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1046/j.0306-5251.2001.01435.x	Homo sapiens		h	4.87							false
599	199		CHILD	6419706	195.1473	GLUCONATE ION	gluconate	OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O	PLASMA	W552L9Y4VZ									∞	μg × h/mL	95		μg/mL	12.9			RECOMMENDED	mg/kg	1.5		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020955s017lbl.pdf	Homo sapiens		h	2							false
600	200		ADULT	3516	198.2158	GUAIFENESIN	GUAIFENESIN	COC1=CC=CC=C1OCC(O)CO	PLASMA	495W7451VQ									∞	μg × h/mL	4.2		μg/mL	3.7			RECOMMENDED	mg	400		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/205474s005lbl.pdf	Homo sapiens		h	1							false
601	202		ADULT	1054	169.1778	PYRIDOXINE	PYRIDOXINE	CC1=NC=C(CO)C(CO)=C1O	PLASMA	KV2JZ1BI6Z	3162		DOXYLAMINE	doxylamine	CN(C)CCOC(C)(C1=CC=CC=C1)C2=CC=CC=N2	95QB77JKPL			∞	ng × h/mL	43.4		ng/mL	32.6			RECOMMENDED	mg	10		SINGLE	UNKNOWN				Pyridoxine is highly protein bound, primarily to albumin. Its main active metabolite, pyridoxal 5’-phosphate (PLP) accounts for at least 60% of circulating vitamin B6 concentrations.	20	HEALTHY	Oral	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021876s013lbl.pdf	Homo sapiens		h	0.4							true
602	203		UNKNOWN	3690	261.086	IFOSFAMIDE	IFOSFAMIDE	ClCCNP1(=O)OCCCN1CCCl	PLASMA	UM20QQM95Y																						UNKNOWN				Ifosfamide shows little plasma protein binding.	100	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019763s017lbl.pdf	Homo sapiens										false
603	203		ADULT	3690	261.086	IFOSFAMIDE	IFOSFAMIDE	ClCCNP1(=O)OCCCN1CCCl	BLOOD	UM20QQM95Y							24		t	μM × h	1360		μM	200			UNKNOWN	g/m²	1.5		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/1795004	Homo sapiens		h	5							false
604	203		ADULT	3690	261.086	IFOSFAMIDE	IFOSFAMIDE	ClCCNP1(=O)OCCCN1CCCl	BLOOD	UM20QQM95Y							24		t	μM × h	1520		μM	203			UNKNOWN	g/m²	1.5		SINGLE	FASTED						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/1795004	Homo sapiens		h	5.6							false
605	203		CHILD	3690	261.086	IFOSFAMIDE	IFOSFAMIDE	ClCCNP1(=O)OCCCN1CCCl	BLOOD	UM20QQM95Y									?	mM × h	7.54						UNKNOWN	g/m²	3		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/8339288	Homo sapiens		h	2.12							false
606	204		UNKNOWN	27648	613.9566	IOCETAMIC ACID	IOCETAMIC ACID	CC(CN(C(C)=O)C1=C(I)C(N)=C(I)C=C1I)C(O)=O	PLASMA	FA675Q0E3E																	RECOMMENDED	mg	750		SINGLE	UNKNOWN				High, to plasma albumin	1	UNKNOWN	Oral	UNKNOWN	OTHER	https://www.drugs.com/mmx/iocetamic-acid.html#citec00114201	Homo sapiens		h	20							false
607	205		ADULT	3723	627.9402	IODAMIDE	IODAMIDE	CC(=O)NCC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I	PLASMA	4RII332O0R									?	g × h/L	2.58						UNKNOWN	g	24.75		SINGLE	UNKNOWN				The mean plasma protein binding in normal subjects at 10 minutes after drug administration was less than 5 per cent	95	HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/338644	Homo sapiens		h	1.29							false
608	205		ADULT	3723	627.9402	IODAMIDE	IODAMIDE	CC(=O)NCC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I	PLASMA	4RII332O0R									?	g × h/L	6.69						UNKNOWN	g	61.82		SINGLE	UNKNOWN				The mean plasma protein binding in normal subjects at 10 minutes after drug administration was less than 5 per cent	95	HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/338644	Homo sapiens		h	1.02							false
609	205		ADULT	3723	627.9402	IODAMIDE	IODAMIDE	CC(=O)NCC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I	PLASMA	4RII332O0R									?	g × h/L	14.02						UNKNOWN	g	9.8		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/338644	Homo sapiens		h	16.4							false
610	207		ADULT	3743	791.1119	IOXILAN	IOXILAN	CC(=O)N(CC(O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCCO)=C1I	PLASMA	A4YJ7J11TG																	UNKNOWN	g	72.8		SINGLE	UNKNOWN				Binding of ioxilan to plasma protein is negligible.	100	HEALTHY	Intravascular	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020316s029lbl.pdf	Homo sapiens		min	23.5							false
611	207		ADULT	3743	791.1119	IOXILAN	IOXILAN	CC(=O)N(CC(O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCCO)=C1I	PLASMA	A4YJ7J11TG																	UNKNOWN	g	72.8		SINGLE	UNKNOWN				Binding of ioxilan to plasma protein is negligible	100	HEALTHY	Intravascular	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020316s029lbl.pdf	Homo sapiens		min	13.1							false
612	208		ADULT	12597	146.1412	ISOSORBIDE	ISOSORBIDE	O[C@H]1CO[C@@H]2[C@H](O)CO[C@H]12	PLASMA	WXR179L51S													μg/mL	2.16			UNKNOWN	mg	100		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4695381/	Homo sapiens		h	9							false
613	210		ADULT	4101	140.1863	METHENAMINE	METHENAMINE	C1N2CN3CN1CN(C2)C3	SERUM	J50OIX95QV							12		t	μg × h/mL	177		μg/mL	34			RECOMMENDED	g	1		MULTIPLE	FASTED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7076604/	Homo sapiens		h	4.8							false
614	211		ADULT	20056604	789.096	METRIZAMIDE	METRIZAMIDE	CN(C(C)=O)C1=C(I)C(C(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO)=C(I)C(NC(C)=O)=C1I	SERUM	RHH3W8F1CO							24		t	μg × h/mL	208		μg/mL	15.6			UNKNOWN	mg	1700		SINGLE	UNKNOWN						UNKNOWN	Intrathecal	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1151624/	Homo sapiens		h	0.75							false
615	212		ADULT	4421	232.2353	NALIDIXIC ACID	NALIDIXIC ACID	CCN1C=C(C(O)=O)C(=O)C2=C1N=C(C)C=C2	PLASMA	3B91HWA56M									∞	μg × h/mL	327.7		μg/mL	27.8			UNKNOWN	g	1		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7174858/	Homo sapiens		h	11.5							false
616	214		ADULT	5355130	290.3972	OCTINOXATE	octinoxate	CCCCC(CC)COC(=O)\\C=C\\C1=CC=C(OC)C=C1	PLASMA	4Y5P7MUD51	51040	310.3869	AVOBENZONE	Avobenzone	COC1=CC=C(C=C1)C(=O)CC(=O)C2=CC=C(C=C2)C(C)(C)C	G63QQF2NOX	22		t	ng × h/mL	103.4		ng/mL	7.9			UNKNOWN	mg/cm²	2		MULTIPLE	UNKNOWN		day	4	AUC(73-95), Day 4 PK		HEALTHY	Topical	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31961417/	Homo sapiens				Applied at 2mg/cm2 to 75% of the body surface area (area outside of normal swimwear) except for the antecubital area (q8h)		Octocrylene, Homosalate Octisalate	12	Supergoop (Non-Aerosol Spray), Sunscreen Mist with Vitamin C SPF 50		true
617	214		ADULT	5355130	290.3972	OCTINOXATE	Octinoxate	CCCCC(CC)COC(=O)\\C=C\\C1=CC=C(OC)C=C1	PLASMA	4Y5P7MUD51	51040	310.3869	AVOBENZONE	Avobenzone	COC1=CC=C(C=C1)C(=O)CC(=O)C2=CC=C(C=C2)C(C)(C)C	G63QQF2NOX	22		t	ng × h/mL	79.5		ng/mL	6.1			UNKNOWN	mg/cm²	2		MULTIPLE	UNKNOWN		day	4	AUC(73-95h), Day 4 PK		HEALTHY	Topical	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31961417/	Homo sapiens				Applied at 2mg/cm2 to 75% of the body surface area (area outside of normal swimwear) except for the antecubital area (q8h)		Homosalate, Octisalate	12	Supergoop (Pump Spray), Sun Defying Sunscreen Oil with Meadowfoam SPF 50		true
618	214		ADULT	5355130	290.3972	OCTINOXATE	Octinoxate	CCCCC(CC)COC(=O)\\C=C\\C1=CC=C(OC)C=C1	PLASMA	4Y5P7MUD51	51040	310.3869	AVOBENZONE	Avobenzone	COC1=CC=C(C=C1)C(=O)CC(=O)C2=CC=C(C=C2)C(C)(C)C	G63QQF2NOX	23		t	ng × h/mL	21.6		ng/mL	2			UNKNOWN	mg/cm²	2		SINGLE	UNKNOWN						HEALTHY	Topical	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31961417/	Homo sapiens		h	50.6	Applied at 2mg/cm2 to 75% of the body surface area (area outside of normal swimwear) except for the antecubital area (qd)		Octocrylene, Homosalate, Octisalate	12	Supergoop (Non-Aerosol Spray), Sunscreen Mist with Vitamin C SPF 50		true
619	214		ADULT	5355130	290.3972	OCTINOXATE	Octinoxate	CCCCC(CC)COC(=O)\\C=C\\C1=CC=C(OC)C=C1	PLASMA	4Y5P7MUD51	51040	310.3869	AVOBENZONE	Avobenzone	COC1=CC=C(C=C1)C(=O)CC(=O)C2=CC=C(C=C2)C(C)(C)C	G63QQF2NOX	23		t	ng × h/mL	9.9		ng/mL	1.1			UNKNOWN	mg/cm²	2		SINGLE	UNKNOWN						HEALTHY	Topical	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31961417/	Homo sapiens		h	157.4	Applied at 2mg/cm2 to 75% of the body surface area (area outside of normal swimwear) except for the antecubital area (qd)		Homasalate, Octisalate	12	Supergoop (Pump Spray), Sun Defying Sunscreen Oil with Meadowfoam SPF 50		true
620	215		ADULT	22571	361.4767	OCTOCRYLENE	OCTOCRYLENE	CCCCC(CC)COC(=O)C(C#N)=C(C1=CC=CC=C1)C2=CC=CC=C2	PLASMA	5A68WGF6WM													ng/mL	7.8			RECOMMENDED	g	2.7		STEADY-STATE	UNKNOWN		day	4			HEALTHY	Topical	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/31058986	Homo sapiens		h	43.3							false
621	215		ADULT	22571	361.4767	OCTOCRYLENE	OCTOCRYLENE	CCCCC(CC)COC(=O)C(C#N)=C(C1=CC=CC=C1)C2=CC=CC=C2	PLASMA	5A68WGF6WM													ng/mL	3.7			RECOMMENDED	g	2.7		SINGLE	UNKNOWN						HEALTHY	Topical	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/31058986	Homo sapiens										false
622	216		ADULT	4632	228.2433	OXYBENZONE	oxybenzone	COC1=CC(O)=C(C=C1)C(=O)C2=CC=CC=C2	PLASMA	95OOS7VE0Y	51040	310.3869	AVOBENZONE	Avobenzone	COC1=CC=C(C=C1)C(=O)CC(=O)C2=CC=C(C=C2)C(C)(C)C	G63QQF2NOX	22		t	ng × h/mL	3443.7		ng/mL	258.1			UNKNOWN	mg/cm²	2		MULTIPLE	UNKNOWN		day	4	Day 4, AUC(73-95h)		HEALTHY	Topical	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31961417/	Homo sapiens				Applied at 2mg/cm2 to 75% of the body surface area (area outside of normal swimwear) except for the antecubital area (q8h)		Octocrylene	12	Hawaiian Tropic (Lotion), Island Sport Ultra-Light High Performance Sunscreen, SPF 50		true
623	216		ADULT	4632	228.2433	OXYBENZONE	oxybenzone	COC1=CC(O)=C(C=C1)C(=O)C2=CC=CC=C2	PLASMA	95OOS7VE0Y							22		t	ng × h/mL	2757.3		ng/mL	180.1			UNKNOWN	mg/cm²	2		MULTIPLE	UNKNOWN		day	4	Day 4, AUC(73-95h)		HEALTHY	Topical	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31961417/	Homo sapiens				Applied at 2mg/cm2 to 75% of the body surface area (area outside of normal swimwear) except for the antecubital area (q8h)			12	Neutrogene (Aerosol Spray), Ultra Sheer Body Mist SPF 100		false
624	216		ADULT	4632	228.2433	OXYBENZONE	oxybenzone	COC1=CC(O)=C(C=C1)C(=O)C2=CC=CC=C2	PLASMA	95OOS7VE0Y	51040	310.3869	AVOBENZONE	Avobenzone	COC1=CC=C(C=C1)C(=O)CC(=O)C2=CC=C(C=C2)C(C)(C)C	G63QQF2NOX	23		t	ng × h/mL	1204		ng/mL	94.2			UNKNOWN	mg/cm²	2		SINGLE	UNKNOWN						HEALTHY	Topical	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31961417/	Homo sapiens		h	78.5	Applied at 2mg/cm2 to 75% of the body surface area (area outside of normal swimwear) except for the antecubital area (qd)	M6/F6	Octocrylene,	12	Hawaiian Tropic (Lotion), Island Sport Ultra-Light High Performance Sunscreen, SPF 50		true
625	216		ADULT	4632	228.2433	OXYBENZONE	oxybenzone	COC1=CC(O)=C(C=C1)C(=O)C2=CC=CC=C2	PLASMA	95OOS7VE0Y	51040	310.3869	AVOBENZONE	Avobenzone	COC1=CC=C(C=C1)C(=O)CC(=O)C2=CC=C(C=C2)C(C)(C)C	G63QQF2NOX	23		t	ng × h/mL	1159.6		ng/mL	85.4			UNKNOWN	mg/cm²	2		SINGLE	UNKNOWN						HEALTHY	Topical	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31961417/	Homo sapiens		h	79.2	Applied at 2mg/cm2 to 75% of the body surface area (area outside of normal swimwear) except for the antecubital area (qd)		Octocrylene, Homosalate, Octisalate	12	Neutrogena (Aerosol Spray), Ultra Sheer Body Mist SPF 100		true
626	218		ADULT	9639	338.0418	PERFLEXANE	PERFLEXANE	FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F	PLASMA	FX3WJ41CMX																	RECOMMENDED	μg/kg bw	20		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21191lbl.pdf	Homo sapiens		h	5.3							false
627	218		ADULT	9639	338.0418	PERFLEXANE	PERFLEXANE	FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F	BLOOD	FX3WJ41CMX									∞	ng × h/mL	11.3		ng/mL	26.3			RECOMMENDED	μg/kg bw	20		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-191_Imagent_medr_P4.pdf	Homo sapiens		h	5.7							false
628	219		ADULT	6839	189.2105	PHENSUXIMIDE	PHENSUXIMIDE	CN1C(=O)CC(C1=O)C2=CC=CC=C2	PLASMA	6WVL9C355G																	UNKNOWN	mg	20		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/116142/	Homo sapiens		h	7.8							false
629	221		ADULT	999	136.1479	PHENYLACETIC ACID	PHENYLACETIC ACID	OC(=O)CC1=CC=CC=C1	PLASMA	ER5I1W795A	10759|517055		SODIUM BENZOATE	sodium benzoate	[Na+].[O-]C(=O)C1=CC=CC=C1	OJ245FE5EU			∞	μM × h	15004		μM	2225			UNKNOWN	g/m²	3.75		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15050977/	Homo sapiens										true
630	221		ADULT	999	136.1479	PHENYLACETIC ACID	PHENYLACETIC ACID	OC(=O)CC1=CC=CC=C1	PLASMA	ER5I1W795A	10759|517055		SODIUM BENZOATE	sodium benzoate	[Na+].[O-]C(=O)C1=CC=CC=C1	OJ245FE5EU			∞	μM × h	28156		μM	3022			UNKNOWN	g/m²	5.5		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15050977/	Homo sapiens										true
631	221		ADULT		264.28	PHENYLACETYLGLUTAMINE	PHENYLACETYLGLUTAMINE		PLASMA	92358I79RG	10759|517055		SODIUM BENZOATE	sodium benzoate	[Na+].[O-]C(=O)C1=CC=CC=C1	OJ245FE5EU			∞	μM × h	2047		μM	281			UNKNOWN	g/m²	3.75		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15050977/	Homo sapiens										true
632	221		UNKNOWN	8243|23690424	158.1297	SODIUM PHENYLACETATE	sodium phenylacetate	[Na+].[O-]C(=O)CC1=CC=CC=C1	PLASMA	48N6U1781G																						UNKNOWN					0.44	UNKNOWN		UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8946671/	Homo sapiens										false
633	225		UNKNOWN	9046	364.5204	QUINESTROL	QUINESTROL	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OC5CCCC5)=C4)[C@@H]1CC[C@@]2(O)C#C	PLASMA	JR0N7XD5GZ																	UNKNOWN				SINGLE	UNKNOWN						UNKNOWN	Intralymphatic	UNKNOWN	REVIEW	https://books.google.ru/books?id=ja2nBgAAQBAJ&pg=PA381&redir_esc=y#v=onepage&q&f=false	Homo sapiens		h	120							false
634	227		ADULT	130313	233.242	SULBACTAM	SULBACTAM	CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O	PLASMA	S4TF6I2330	6249|7048611		AMPICILLIN	ampicillin	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O	7C782967RD			∞	μg × h/mL	83.79						DEFINED DAILY	g	1		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2338029	Homo sapiens		h	1.14							true
635	227		ADULT	130313	233.242	SULBACTAM	SULBACTAM	CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O	PLASMA	S4TF6I2330	6249|7048611		AMPICILLIN	ampicillin	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O	7C782967RD			∞	μg × h/mL	40.71						RECOMMENDED	g	0.5		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2338029	Homo sapiens		h	1.15							true
636	227		ADULT	130313	233.242	SULBACTAM	SULBACTAM	CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O	PLASMA	S4TF6I2330	6249|7048611		AMPICILLIN	ampicillin	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O	7C782967RD			∞	μg × h/mL	40.33		μg/mL	15.36			UNKNOWN	g	0.5		SINGLE	UNKNOWN						HEALTHY	Intramuscular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2338029	Homo sapiens		h	1.26							true
637	227		UNKNOWN	130313	233.242	SULBACTAM	SULBACTAM	CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O	SERUM	S4TF6I2330																						UNKNOWN				sulbactam approximately 38% reversibly bound to human serum protein	62	HEALTHY		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050608s040lbl.pdf	Homo sapiens		h	1							false
638	228		ADULT	5326	280.303	SULFAMETER	SULFAMETER	COC1=CN=C(NS(=O)(=O)C2=CC=C(N)C=C2)N=C1	PLASMA	3L179F09D6							60		t	μg × h/mL	1599		μg/mL	44.2			UNKNOWN	g	1		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/5072410/	Homo sapiens		h	24							false
639	229		ADULT	5411	264.3633	TETRACAINE	TETRACAINE	CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C	PLASMA	0619F35CGV	4636		OXYMETAZOLINE	oxymetazoline	CC1=C(CC2=NCCN2)C(C)=C(O)C(=C1)C(C)(C)C	8VLN5B44ZY							ng/mL	0.24			INVESTIGATIONAL	mg	18		SINGLE	UNKNOWN						HEALTHY	Nasal	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22855901/	Homo sapiens										true
640	229		ADULT	5411	264.3633	TETRACAINE	TETRACAINE	CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C	PLASMA	0619F35CGV	4636		OXYMETAZOLINE	oxymetazoline	CC1=C(CC2=NCCN2)C(C)=C(O)C(=C1)C(C)(C)C	8VLN5B44ZY							ng/mL	1.15			INVESTIGATIONAL	mg	36		SINGLE	UNKNOWN						HEALTHY	Nasal	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22855901/	Homo sapiens										true
641	229		ADULT	95946	193.2423	4-(BUTYLAMINO)BENZOIC ACID	4-(BUTYLAMINO)BENZOIC ACID	CCCCNC1=CC=C(C=C1)C(O)=O	PLASMA	KGL80FSD2F	4636		OXYMETAZOLINE	oxymetazoline	CC1=C(CC2=NCCN2)C(C)=C(O)C(=C1)C(C)(C)C	8VLN5B44ZY			∞	ng × h/mL	862		ng/mL	492			RECOMMENDED	mg	18		SINGLE	UNKNOWN						HEALTHY	Nasal	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22855901/	Homo sapiens		h	1							true
642	229		ADULT	95946	193.2423	4-(BUTYLAMINO)BENZOIC ACID	4-(BUTYLAMINO)BENZOIC ACID	CCCCNC1=CC=C(C=C1)C(O)=O	PLASMA	KGL80FSD2F	4636		OXYMETAZOLINE	oxymetazoline	CC1=C(CC2=NCCN2)C(C)=C(O)C(=C1)C(C)(C)C	8VLN5B44ZY			∞	ng × h/mL	1773		ng/mL	886			INVESTIGATIONAL	mg	36		SINGLE	UNKNOWN						HEALTHY	Nasal	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22855901/	Homo sapiens		h	1.01							true
643	230		ADULT	5564	289.542	TRICLOSAN	TRICLOSAN	OC1=CC(Cl)=CC=C1OC2=C(Cl)C=C(Cl)C=C2	PLASMA	4NM5039Y5X									∞	ng × h/mL	2.6		ng/mL	218			UNKNOWN	mg	4		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16952905/	Homo sapiens		h	21							false
644	231		UNKNOWN	5585	228.2433	TRIOXSALEN	TRIOXSALEN	CC1=CC2=CC3=C(OC(=O)C=C3C)C(C)=C2O1	PLASMA	Y6UY8OV51T													ng/mL	3			UNKNOWN	mg	40		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6155034/	Homo sapiens										false
645	231			5585	228.2433	TRIOXSALEN	TRIOXSALEN	CC1=CC2=CC3=C(OC(=O)C=C3C)C(C)=C2O1	SERUM	Y6UY8OV51T																										The percentage of binding to human serum proteins is 98%	2				REVIEW	https://www.ncbi.nlm.nih.gov/pubmed/3512141	Homo sapiens										false
646	232		ADULT	49849894	392.572	URSODIOL	URSODIOL	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	PLASMA	724L30Y2QR							24		t	μM × h	49.8		μM	15.2			UNKNOWN	mg/kg bw	15		MULTIPLE	FED		day	1			HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22414767	Homo sapiens										false
647	235		ADULT	60714|21881518|24838311|44144429	558.68	GADOTERIDOL	GADOTERIDOL	[Gd+3].CC(O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1	SERUM	0199MV609F																	UNKNOWN	mmol/kg	0.3		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1506147/	Homo sapiens		h	1.57							false
648	237		UNKNOWN	50108|146673010	566.665	ISOSULFAN BLUE	ISOSULFAN BLUE	[Na+].CCN(CC)C1=CC=C(C=C1)C(=C2C=CC(C=C2)=[N+](CC)CC)C3=C(C=CC(=C3)S([O-])(=O)=O)S([O-])(=O)=O	PLASMA	39N9K8S2A4																	UNKNOWN				UNKNOWN	UNKNOWN				Following subcutaneous administration, Lymphazurin 1% binds to serum proteins and is picked up by the lymphatic vessels.	99	UNKNOWN	Subcutaneous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018310s011lbl.pdf	Homo sapiens										false
649	240		UNKNOWN	6194|5281966	252.098	URACIL MUSTARD	URACIL MUSTARD	ClCCN(CCCl)C1=CNC(=O)NC1=O	PLASMA	W7KQ46GJ8U																	UNKNOWN				SINGLE	UNKNOWN					95	UNKNOWN		UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/14088966/	Homo sapiens										false
650	245		ADULT	16850	332.3063	FLUORESCEIN	FLUORESCEIN	OC1=CC2=C(C=C1)C3(OC(=O)C4=C3C=CC=C4)C5=CC=C(O)C=C5O2	BLOOD	TPY09G7XIR									?	μg × min/mL	1350		μg/mL	10.9			RECOMMENDED	mg	188		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	DRUG LABEL	https://gp2u.com.au/static/pdf/F/FLUORESCEIN_NOVARTIS-PI.pdf	Homo sapiens										false
651	245		ADULT	16850	332.3063	FLUORESCEIN	FLUORESCEIN	OC1=CC2=C(C=C1)C3(OC(=O)C4=C3C=CC=C4)C5=CC=C(O)C=C5O2	BLOOD	TPY09G7XIR													μg/mL	10.9			RECOMMENDED	mg	188		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4039592/	Homo sapiens		min	286							false
652	245		ADULT	16850	332.3063	FLUORESCEIN	FLUORESCEIN	OC1=CC2=C(C=C1)C3(OC(=O)C4=C3C=CC=C4)C5=CC=C(O)C=C5O2	BLOOD	TPY09G7XIR													μg/mL	3.5			RECOMMENDED	mg	188		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4039592/	Homo sapiens		min	267							false
653	246		ADULT	4114	216.19	METHOXSALEN	METHOXSALEN	COC1=C2OC(=O)C=CC2=CC3=C1OC=C3	PLASMA	U4VJ29L7BQ							12		t	ng × h/mL	521		ng/mL	129			RECOMMENDED	mg/kg	0.6		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/3729509	Homo sapiens		h	2.38							false
654	248		ADULT	785	110.11	HYDROQUINONE	HYDROQUINONE	C1=CC(=CC=C1O)O	PLASMA	XV74C1N1AE	444795|91488		Tretinoin|Fluocinolone	Tretinoin|Fluocinolone	CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C|CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CC(C4=CC(=O)C=CC43C)F)F)O	5688UTC01R|CT1IX58L9S							ng/mL	56.035			RECOMMENDED	g	1		SINGLE	UNKNOWN						HEALTHY	Topical	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021112s006lbl.pdf	Homo sapiens										true
655	252			9832912	639.8186	MOXIDECTIN	MOXIDECTIN	CO\\N=C1/C[C@]2(C[C@@H]3C[C@@H](C\\C=C(C)\\C[C@@H](C)\\C=C\\C=C4/CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)O[C@@H]([C@H]1C)C(\\C)=C\\C(C)C	PLASMA	NGU5H31YO9													ng/mL	133				mg	16		SINGLE								Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT03012828	Homo sapiens										false
656	252			9832912	639.8186	MOXIDECTIN	MOXIDECTIN	CO\\N=C1/C[C@]2(C[C@@H]3C[C@@H](C\\C=C(C)\\C[C@@H](C)\\C=C\\C=C4/CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)O[C@@H]([C@H]1C)C(\\C)=C\\C(C)C	PLASMA	NGU5H31YO9													ng/mL	176				mg	24		SINGLE								Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT03012828	Homo sapiens										false
657	252			9832912	639.8186	MOXIDECTIN	MOXIDECTIN	CO\\N=C1/C[C@]2(C[C@@H]3C[C@@H](C\\C=C(C)\\C[C@@H](C)\\C=C\\C=C4/CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)O[C@@H]([C@H]1C)C(\\C)=C\\C(C)C	PLASMA	NGU5H31YO9													ng/mL	247				mg	36		SINGLE								Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT03012828	Homo sapiens										false
658	252			9832912	639.8186	MOXIDECTIN	MOXIDECTIN	CO\\N=C1/C[C@]2(C[C@@H]3C[C@@H](C\\C=C(C)\\C[C@@H](C)\\C=C\\C=C4/CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)O[C@@H]([C@H]1C)C(\\C)=C\\C(C)C	PLASMA	NGU5H31YO9													ng/mL	27.2				mg	4		SINGLE								Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT03012828	Homo sapiens										false
659	252			9832912	639.8186	MOXIDECTIN	MOXIDECTIN	CO\\N=C1/C[C@]2(C[C@@H]3C[C@@H](C\\C=C(C)\\C[C@@H](C)\\C=C\\C=C4/CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)O[C@@H]([C@H]1C)C(\\C)=C\\C(C)C	PLASMA	NGU5H31YO9													ng/mL	56.7				mg	8		SINGLE								Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT03012828	Homo sapiens										false
660	252		ADULT	9832912	639.8186	MOXIDECTIN	MOXIDECTIN	CO\\N=C1/C[C@]2(C[C@@H]3C[C@@H](C\\C=C(C)\\C[C@@H](C)\\C=C\\C=C4/CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)O[C@@H]([C@H]1C)C(\\C)=C\\C(C)C	PLASMA	NGU5H31YO9									∞	ng × h/mL	3387		ng/mL	58.9			RECOMMENDED	mg	8		SINGLE	FASTED				The plasma protein binding in humans is unknown.		HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210867lbl.pdf	Homo sapiens		h	784							false
661	252		ADULT	9832912	639.8186	MOXIDECTIN	MOXIDECTIN	CO\\N=C1/C[C@]2(C[C@@H]3C[C@@H](C\\C=C(C)\\C[C@@H](C)\\C=C\\C=C4/CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)O[C@@H]([C@H]1C)C(\\C)=C\\C(C)C	PLASMA	NGU5H31YO9									∞	ng × h/mL	2738		ng/mL	63.1			RECOMMENDED	mg	8		SINGLE	FASTED				The plasma protein binding in humans is unknown.		UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210867lbl.pdf	Homo sapiens		h	559							false
662	252		ADULT	9832912	639.8186	MOXIDECTIN	MOXIDECTIN	CO\\N=C1/C[C@]2(C[C@@H]3C[C@@H](C\\C=C(C)\\C[C@@H](C)\\C=C\\C=C4/CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)O[C@@H]([C@H]1C)C(\\C)=C\\C(C)C	PLASMA	NGU5H31YO9									?	ng × h/mL	3387		ng/mL	58.9			RECOMMENDED	mg	8		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210867Orig1s000ClinPharmR.pdf	Homo sapiens										false
663	252		ADULT	9832912	639.8186	MOXIDECTIN	MOXIDECTIN	CO\\N=C1/C[C@]2(C[C@@H]3C[C@@H](C\\C=C(C)\\C[C@@H](C)\\C=C\\C=C4/CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)O[C@@H]([C@H]1C)C(\\C)=C\\C(C)C	PLASMA	NGU5H31YO9									?	ng × h/mL	7885		ng/mL	79.1			RECOMMENDED	mg	8		SINGLE	HIGH-FAT						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210867Orig1s000ClinPharmR.pdf	Homo sapiens										false
664	252		ADULT	9832912	639.8186	MOXIDECTIN	MOXIDECTIN	CO\\N=C1/C[C@]2(C[C@@H]3C[C@@H](C\\C=C(C)\\C[C@@H](C)\\C=C\\C=C4/CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)O[C@@H]([C@H]1C)C(\\C)=C\\C(C)C	PLASMA	NGU5H31YO9							24		t	ng × h/mL	632.6		ng/mL	56.7			RECOMMENDED	mg	8		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210867Orig1s000ClinPharmR.pdf	Homo sapiens										false
665	252		ADULT	9832912	639.8186	MOXIDECTIN	MOXIDECTIN	CO\\N=C1/C[C@]2(C[C@@H]3C[C@@H](C\\C=C(C)\\C[C@@H](C)\\C=C\\C=C4/CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)O[C@@H]([C@H]1C)C(\\C)=C\\C(C)C	PLASMA	NGU5H31YO9							24		t	ng × h/mL	2613		ng/mL	247			MAX TOLERATED	mg	36		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210867Orig1s000ClinPharmR.pdf	Homo sapiens										false
666	256		ADULT	5282203	258.315	PELUBIPROFEN		CC(C(=O)O)c1ccc(\\C=C\\2/CCCCC2=O)cc1	PLASMA	1619C79FVJ									∞	ng × h/mL	484.31		ng/mL	453.04			UNKNOWN	mg	45		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27989618/	Homo sapiens		h	0.37				23			false
667	257		ADULT	164486	247.2053	PR-69	PR-69	OC[C@@H](O)[C@H](CO)OCN1C=CN=C1[N ]([O-])=O	SERUM	4BLU68P76A									?	μg × h/mL	101		μg/mL	38			UNKNOWN	mg/m²	400		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11272282/	Homo sapiens		h	3.5				3	Doranidazole		false
668	257		ADULT	164486	247.2053	PR-69	PR-69	OC[C@@H](O)[C@H](CO)OCN1C=CN=C1[N ]([O-])=O	SERUM	4BLU68P76A									?	μg × h/mL	502		μg/mL	172			UNKNOWN	mg/m²	2000		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11272282/	Homo sapiens		h	4.2				3	Doranidazole		false
669	257		ADULT	164486	247.2053	PR-69	Doranidazole	OC[C@@H](O)[C@H](CO)OCN1C=CN=C1[N ]([O-])=O	SERUM	4BLU68P76A									?	μg × h/mL	248		μg/mL	89			UNKNOWN	mg/m²	800		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11272282/	Homo sapiens		h	4.4				3	Doranidazole		false
670	257		ADULT	164486	247.2053	PR-69	PR-69	OC[C@@H](O)[C@H](CO)OCN1C=CN=C1[N ]([O-])=O	SERUM	4BLU68P76A									?	μg × h/mL	319		μg/mL	117			UNKNOWN	mg/m²	1300		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11272282/	Homo sapiens		h	4.9				1	Doranidazole		false
671	259		ADULT	472335	393.3496	RUBITECAN	RUBITECAN	CC[C@@]1(O)C(=O)OCC2=C1C=C3N(CC4=CC5=C(C=CC=C5[N ]([O-])=O)N=C34)C2=O	PLASMA	H19C446XXB							24		t	ng × h/mL	557		ng/mL	52.9			MAX TOLERATED	mg/m²	1.5		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16205924	Homo sapiens							9	RUBITECAN		false
672	259		ADULT	472335	393.3496	RUBITECAN	RUBITECAN	CC[C@@]1(O)C(=O)OCC2=C1C=C3N(CC4=CC5=C(C=CC=C5[N ]([O-])=O)N=C34)C2=O	PLASMA	H19C446XXB							24		t	ng × h/mL	330		ng/mL	26.1			MAX TOLERATED	mg/m²	1.5		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16205924	Homo sapiens							9	RUBITECAN		false
673	259		ADULT	472335	393.3496	RUBITECAN	RUBITECAN	CC[C@@]1(O)C(=O)OCC2=C1C=C3N(CC4=CC5=C(C=CC=C5[N ]([O-])=O)N=C34)C2=O	PLASMA	H19C446XXB									∞	ng × h/mL	1047.35		ng/mL	115.56			MAX TOLERATED	mg/m²	1.5		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21191594	Homo sapiens		h	9.17				7	RUBITECAN		false
674	259		ADULT	472335	393.3496	RUBITECAN	RUBITECAN	CC[C@@]1(O)C(=O)OCC2=C1C=C3N(CC4=CC5=C(C=CC=C5[N ]([O-])=O)N=C34)C2=O	PLASMA	H19C446XXB									∞	ng × h/mL	2214.92		ng/mL	85.98			MAX TOLERATED	mg	1.5		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21191594	Homo sapiens		h	21.25	The 8 patients for a multiple-dose pharmacokinetic study were orally administered 9-nitrocamptothecin 1.5 mg/m(2) for 5 consecutive days.			8	RUBITECAN		false
675	260		ADULT	176873	588.6559	CILENGITIDE	cilengitide	CC(C)[C@@H]1N(C)C(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC1=O	PLASMA	4EDF46E4GI									?	ng × h/mL	168674		ng/mL	59487			UNKNOWN	mg/m²	600		MULTIPLE	UNKNOWN		week	2			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12706360/	Homo sapiens		h	3.56				4	cilengitide		false
676	260		ADULT	176873	588.6559	CILENGITIDE	cilengitide	CC(C)[C@@H]1N(C)C(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC1=O	PLASMA	4EDF46E4GI									?	ng × h/mL	11533		ng/mL	3334			UNKNOWN	mg/m²	30		MULTIPLE	UNKNOWN		week	2			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12706360/	Homo sapiens		h	3.51				3	cilengitide		false
677	260		ADULT	176873	588.6559	CILENGITIDE	cilengitide	CC(C)[C@@H]1N(C)C(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC1=O	PLASMA	4EDF46E4GI									?	ng × h/mL	32406		ng/mL	11101			UNKNOWN	mg/m²	120		MULTIPLE	UNKNOWN		week	2			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12706360/	Homo sapiens		h	3.95				3	cilengitide		false
678	260		ADULT	176873	588.6559	CILENGITIDE	cilengitide	CC(C)[C@@H]1N(C)C(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC1=O	PLASMA	4EDF46E4GI									?	ng × h/mL	161051		ng/mL	43418			UNKNOWN	mg/m²	400		MULTIPLE	UNKNOWN		week	2			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12706360/	Homo sapiens		h	3.66				3	cilengitide		false
679	260		ADULT	176873	588.6559	CILENGITIDE	cilengitide	CC(C)[C@@H]1N(C)C(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC1=O	PLASMA	4EDF46E4GI									?	ng × h/mL	524688		ng/mL	123902			UNKNOWN	mg/m²	1200		MULTIPLE	UNKNOWN		week	2			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12706360/	Homo sapiens		h	4.48				6	cilengitide		false
680	260		ADULT	176873	588.6559	CILENGITIDE	cilengitide	CC(C)[C@@H]1N(C)C(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC1=O	PLASMA	4EDF46E4GI									?	ng × h/mL	521472		ng/mL	161619			HIGHEST STUDIED	mg/m²	1600		MULTIPLE	UNKNOWN		week	2			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12706360/	Homo sapiens		h	3.14				6	cilengitide		false
681	263		ADULT	108189|135400184	284.336	NOLATREXED	NOLATREXED	CC1=C(SC2=CC=NC=C2)C3=C(C=C1)N=C(N)NC3=O	PLASMA	K75ZUN743Q									?	mg × min/mL	107						MAX TOLERATED	mg/m²	904		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9508200	Homo sapiens		min	298	904 mg/m2/d for 5 days			5	NOLATREXED		false
682	263		ADULT	108189|135400184	284.336	NOLATREXED	NOLATREXED	CC1=C(SC2=CC=NC=C2)C3=C(C=C1)N=C(N)NC3=O	PLASMA	K75ZUN743Q									?	mg × min/mL	131		μg/mL	24			UNKNOWN	mg/m²	1040		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9508200	Homo sapiens		min	203	1040 mg/m2/d for 5 days			1	NOLATREXED		false
683	263		ADULT	108189|135400184	284.336	NOLATREXED	NOLATREXED	CC1=C(SC2=CC=NC=C2)C3=C(C=C1)N=C(N)NC3=O	PLASMA	K75ZUN743Q																	UNKNOWN	mg/m²	1350		SINGLE	UNKNOWN				Over the concentration range 2-18 ug/ml, unbound AG337 constituted between 2.2 and 3.3% of the total AG337 in plasma. There was no significant difference in the extent of protein binding in individual patients at the high and low AG337 concentrations.	2.75	UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9815922	Homo sapiens		min	97	24-h i.v. infusion			3	NOLATREXED		false
684	263		ADULT	108189|135400184	284.336	NOLATREXED	NOLATREXED	CC1=C(SC2=CC=NC=C2)C3=C(C=C1)N=C(N)NC3=O	PLASMA	K75ZUN743Q									?	μg × min/mL	3.1		μg/mL	19.2			MAX TOLERATED	mg/m²	250		MULTIPLE	UNKNOWN		day	4			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9918208	Homo sapiens				5 days of oral administration every 6 h			5	NOLATREXED		false
685	275		ADULT	5320|5969238|6456071	214.242	SULFACETAMIDE	SULFACETAMIDE	CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1	PLASMA	4965G3J0F5									∞	μg × h/mL	1803		μg/mL	99.2			UNKNOWN	mg	750		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6663474/	Homo sapiens		h	10.3							false
686	275		ADULT	5320|5969238|6456071	214.242	SULFACETAMIDE	SULFACETAMIDE	CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1	PLASMA	4965G3J0F5																	UNKNOWN				SINGLE	UNKNOWN				It is bound to plasma protein to the extent of 15 to 18%	82	UNKNOWN	Ocular	UNKNOWN	REVIEW	https://www.sciencedirect.com/science/article/pii/S0099542808606103	Homo sapiens		h	13							false
687	285		ADULT	6438378	380.5	limaprost	limaprost		PLASMA	L02U804092							6		t	pg × h/mL	0.779		pg/mL	1.26			UNKNOWN	μg	5		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18218297/	Homo sapiens		min	27				116	limaprost alfadex		false
688	285		ADULT	6438378	380.5	limaprost	limaprost		PLASMA	L02U804092							12		t	pg × h/mL	18.6		pg/mL	13.37			RECOMMENDED	μg	30		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19825922/	Homo sapiens		h	1.64				5	limaprost		false
689	285		ADULT	6438378	380.5	Limaprost	Limaprost		PLASMA	L02U804092							6		t	pg × min/mL	70.68		pg/mL	2.56			UNKNOWN	μg	5		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25586152/	Homo sapiens		min	21.7				12	Limaprost		false
690	285		ADULT	6438378	380.5	Limaprost	Limaprost		PLASMA	L02U804092							6		t	pg × min/mL	45.33		pg/mL	1.56			UNKNOWN	μg	5		STEADY-STATE	FASTED		day	3			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25586152/	Homo sapiens		min	18.31				12	Limaprost		false
691	286		ADULT	275196	413.4205	NOSCAPINE	NOSCAPINE	COC1=C(OC)C2=C(C=C1)[C@H](OC2=O)[C@@H]3N(C)CCC4=C3C(OC)=C5OCOC5=C4	SERUM	8V32U4AOQU																						UNKNOWN				The binding in serum pooled from volunteers was 93 +/- 0.2% (at 100 ng mL-1). After incubation for 24 h the binding decreased to about 85% (ultrafiltration 87.0 +/- 1.0%; equilibrium dialysis 84.3 +/- 1.2%), because of the conversion of noscapine to noscapinic acid.	7	HEALTHY		UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/1972403	Homo sapiens										false
692	286		ADULT	275196	413.4	NOSCAPINE	NOSCAPINE	COC1=C(OC)C2=C(C=C1)[C@@H](OC2=O)[C@@H]3N(C)CCC4=C3C(OC)=C5OCOC5=C4	PLASMA	8V32U4AOQU|A4C6WE7BZN|Z4241U523E									∞	μg × h/L	794		μg/L	394			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/2257866	Homo sapiens		h	4.5							false
693	291		ADULT	904	135.1632	ACETANILIDE	acetanilide	CC(=O)NC1=CC=CC=C1	PLASMA	SP86R356CC													μg/mL	3.1			UNKNOWN	mg/kg m.a.m.	50		SINGLE	FASTED				Cmax reported in article (3.1 mg/mL) is unusually high, and most likely is an error		HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://bpspubs.onlinelibrary.wiley.com/doi/abs/10.1111/j.1365-2125.1978.tb00878.x	Homo sapiens		h	1.57	m.a.m. (metabolically active mass) is subject weight in kilos raised to the power of 0.7						false
694	291			904	135.1632	ACETANILIDE	acetanilide	CC(=O)NC1=CC=CC=C1	PLASMA	SP86R356CC																										solvent extraction method	90				EXPERIMENT	https://jpet.aspetjournals.org/content/94/1/22	Homo sapiens										false
695	291		CHILD	904	135.1632	ACETANILIDE	acetanilide	CC(=O)NC1=CC=CC=C1	PLASMA	SP86R356CC																	UNKNOWN	mg/kg m.a.m.	50		SINGLE	FASTED						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1429951/	Homo sapiens		h	4.78							false
696	303		ADULT	3100	255.3547	DIPHENHYDRAMINE	diphenhydramine	CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2	PLASMA	8GTS82S83M							24		t	ng × h/mL	155.2		ng/mL	14.5			UNKNOWN	mg	25		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12851661/	Homo sapiens		h	10							false
697	303		UNKNOWN	10660	469.964	DIMENHYDRINATE	dimenhydrinate	CN1C2=C(N=C(Cl)N2)C(=O)N(C)C1=O.CN(C)CCOC(C3=CC=CC=C3)C4=CC=CC=C4	PLASMA	JB937PER5C									∞	ng × h/mL	788.43		ng/mL	80.07			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17442639/	Homo sapiens		h	7.44							false
698	303		ADULT	3100	255.3547	DIPHENHYDRAMINE	diphenhydramine	CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2	PLASMA	8GTS82S83M									∞	ng × h/mL	528						UNKNOWN	mg	50		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2328304/	Homo sapiens		h	4.7							false
699	303		ADULT	3100	255.3547	DIPHENHYDRAMINE	Diphenhydramine	CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2	PLASMA	8GTS82S83M									∞	ng × h/mL	270		ng/mL	47.8			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2328304/	Homo sapiens		h	5.3							false
700	303		ADULT	3100	255.3547	DIPHENHYDRAMINE	Diphenhydramine	CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2	PLASMA	8GTS82S83M									∞	ng × h/mL	221		ng/mL	38.3			UNKNOWN	mg	50		SINGLE	UNKNOWN						HEALTHY	Sublingual	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2328304/	Homo sapiens		h	5.4							false
701	326		ADULT	8362	262.3441	HOMOSALATE	HOMOSALATE	CC1CC(CC(C)(C)C1)OC(=O)C2=C(O)C=CC=C2	PLASMA	V06SV4M95S							23		t	ng × h/mL	104		ng/mL	7.6			RECOMMENDED	mg/cm²	2		SINGLE	UNKNOWN						HEALTHY	Topical	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31961417/	Homo sapiens		h	67.9	Aerosol Spray			11	HOMOSALATE		false
702	326		ADULT	8362	262.3441	HOMOSALATE	HOMOSALATE	CC1CC(CC(C)(C)C1)OC(=O)C2=C(O)C=CC=C2	PLASMA	V06SV4M95S							23		t	ng × h/mL	62.3		ng/mL	4.6			RECOMMENDED	mg/cm²	2		SINGLE	UNKNOWN						HEALTHY	Topical	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31961417/	Homo sapiens		h	78.4	Nonaerosol Spray			12	HOMOSALATE		false
703	326		ADULT	8362	262.3441	HOMOSALATE	HOMOSALATE	CC1CC(CC(C)(C)C1)OC(=O)C2=C(O)C=CC=C2	PLASMA	V06SV4M95S							95		t	ng × h/mL	267.4		ng/mL	17.9			RECOMMENDED	mg/cm²	2		MULTIPLE	UNKNOWN		day	4			HEALTHY	Topical	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31961417/	Homo sapiens				Nonaerosol Spray			10	HOMOSALATE		false
704	326		ADULT	8362	262.3441	HOMOSALATE	HOMOSALATE	CC1CC(CC(C)(C)C1)OC(=O)C2=C(O)C=CC=C2	PLASMA	V06SV4M95S							95		t	ng × h/mL	199		ng/mL	14.3			RECOMMENDED	mg/cm²	2		MULTIPLE	UNKNOWN		day	4			HEALTHY	Topical	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31961417/	Homo sapiens				Pump Spray			10	HOMOSALATE		false
705	326		ADULT	8362	262.3441	HOMOSALATE	HOMOSALATE	CC1CC(CC(C)(C)C1)OC(=O)C2=C(O)C=CC=C2	PLASMA	V06SV4M95S							23		t	ng × h/mL	47.6		ng/mL	3.8			RECOMMENDED	mg/cm²	2		SINGLE	UNKNOWN						HEALTHY	Topical	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31961417/	Homo sapiens		h	46.9	Pump Spray			12	HOMOSALATE		false
706	326		ADULT	8362	262.3441	HOMOSALATE	HOMOSALATE	CC1CC(CC(C)(C)C1)OC(=O)C2=C(O)C=CC=C2	PLASMA	V06SV4M95S							95		t	ng × h/mL	350.8		ng/mL	23.1			RECOMMENDED	mg/cm²	2		MULTIPLE	UNKNOWN		day	4			HEALTHY	Topical	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31961417/	Homo sapiens				Aerosol Spray			12	HOMOSALATE		false
707	329		ADULT	6032	484.4986	KANAMYCIN A	KANAMYCIN A	NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O	PLASMA	EQK9Q303C5							12		t	μg × h/mL	44.2		μg/mL	11.9			UNKNOWN	mg	250		SINGLE	UNKNOWN						HEALTHY	Intramuscular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4790604/	Homo sapiens		h	2.1							false
708	337		ADULT	8364	250.3334	OCTISALATE	Octisalate	CCCCC(CC)COC(=O)C1=C(O)C=CC=C1	PLASMA	4X49Y0596W	51040	310.3869	AVOBENZONE	Avobenzone	COC1=CC=C(C=C1)C(=O)CC(=O)C2=CC=C(C=C2)C(C)(C)C	G63QQF2NOX	23		t	ng × h/mL	67.9		ng/mL	5.1			RECOMMENDED	mg/cm²	2		MULTIPLE	UNKNOWN		day	4	n=11 for t1/2		HEALTHY	Transdermal	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31961417/	Homo sapiens		h	37.4	Day 4 (qid on Days 2-4), Aerosol spray (Neutrogena, Ultra Sheer Body Mist with Vitamin C, SPF50), 5% Octisalate; 2mg/cm2 to 75% of body surface		Avobenzone 3%, Homosalate, 15%, Octocrylene 10%, Oxybenzone 6%	12			true
709	337		ADULT	8364	250.3334	OCTISALATE	Octisalate	CCCCC(CC)COC(=O)C1=C(O)C=CC=C1	PLASMA	4X49Y0596W	51040	310.3869	AVOBENZONE	Avobenzone	COC1=CC=C(C=C1)C(=O)CC(=O)C2=CC=C(C=C2)C(C)(C)C	G63QQF2NOX	23		t	ng × h/mL	76.9		ng/mL	5.8			RECOMMENDED	mg/cm²	2		MULTIPLE	UNKNOWN		day	4	n=5 for t1/2		HEALTHY	Transdermal	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31961417/	Homo sapiens		h	27.3	Day 4 (qid on Days 2-4), Nonaerosol spray (Supergoop, Sunscreen Mist with Vitamin C, SPF50), 5% Octisalate; 2mg/cm2 to 75% of body surface		Avobenzone 3%, Homosalate, 10%, Octocrylene 10%, Octinoxate 7.5%	10			true
710	337		ADULT	8364	250.3334	OCTISALATE	Octisalate	CCCCC(CC)COC(=O)C1=C(O)C=CC=C1	PLASMA	4X49Y0596W	51040	310.3869	AVOBENZONE	Avobenzone	COC1=CC=C(C=C1)C(=O)CC(=O)C2=CC=C(C=C2)C(C)(C)C	G63QQF2NOX	23		t	ng × h/mL	54		ng/mL	4.6			RECOMMENDED	mg/cm²	2		MULTIPLE	UNKNOWN		day	4	n=5 for t1/2		HEALTHY	Transdermal	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31961417/	Homo sapiens		h	77.1	Day 4 (qid on Days 2-4), Pump spray (Supergoop, Sun Defying Sunscreen Oil with Meadowfoam, SPF50), 5% Octisalate; 2mg/cm2 to 75% of body surface		Avobenzone 3%, Homosalate, 10%, Octinoxate 7.5%	10			true
711	337		ADULT	8364	250.3334	OCTISALATE	Octisalate	CCCCC(CC)COC(=O)C1=C(O)C=CC=C1	PLASMA	4X49Y0596W	51040	310.3869	AVOBENZONE	Avobenzone	COC1=CC=C(C=C1)C(=O)CC(=O)C2=CC=C(C=C2)C(C)(C)C	G63QQF2NOX	23		t	ng × h/mL	14.7		ng/mL	1.4			RECOMMENDED	mg/cm²	2		SINGLE	UNKNOWN				n=5 for t1/2		HEALTHY	Transdermal	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31961417/	Homo sapiens		h	27.3	Day 1, Nonaerosol spray (Supergoop, Sunscreen Mist with Vitamin C, SPF50), 5% Octisalate; 2mg/cm2 to 75% of body surface		Avobenzone 3%, Homosalate, 10%, Octocrylene 10%, Octinoxate 7.5%	12			true
712	337		ADULT	8364	250.3334	OCTISALATE	Octisalate	CCCCC(CC)COC(=O)C1=C(O)C=CC=C1	PLASMA	4X49Y0596W	51040	310.3869	AVOBENZONE	Avobenzone	COC1=CC=C(C=C1)C(=O)CC(=O)C2=CC=C(C=C2)C(C)(C)C	G63QQF2NOX	23		t	ng × h/mL	12		ng/mL	1.3			RECOMMENDED	mg/cm²	2		SINGLE	UNKNOWN				n=11 for t1/2		HEALTHY	Transdermal	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31961417/	Homo sapiens		h	37.4	Day 1, Aerosol spray (Neutrogena, Ultra Sheer Body Mist with Vitamin C, SPF50), 5% Octisalate		Avobenzone 3%, Homosalate, 15%, Octocrylene 10%, Oxybenzone 6%	12			true
713	337		ADULT	8364	250.3334	OCTISALATE	Octisalate	CCCCC(CC)COC(=O)C1=C(O)C=CC=C1	PLASMA	4X49Y0596W	51040	310.3869	AVOBENZONE	Avobenzone	COC1=CC=C(C=C1)C(=O)CC(=O)C2=CC=C(C=C2)C(C)(C)C	G63QQF2NOX	23		t	ng × h/mL	4.5		ng/mL	0.7			RECOMMENDED	mg/cm²	2		SINGLE	UNKNOWN				n=5 for t1/2		HEALTHY	Transdermal	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31961417/	Homo sapiens		h	77.1	Day 1, Pump spray (Supergoop, Sun Defying Sunscreen Oil with Meadowfoam, SPF50), 5% Octisalate; 2mg/cm2 to 75% of body surface		Avobenzone 3%, Homosalate, 10%, Octinoxate 7.5%	12			true
714	346		ADULT	7175	180.2005	PROPYLPARABEN	PROPYLPARABEN	CCCOC(=O)C1=CC=C(O)C=C1	SERUM	Z8IX2SC1OH									∞	nM × h	8757		nM	2777			UNKNOWN	mg/kg	0.6		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31234001/	Homo sapiens		h	2.9				12			false
715	346			7175	180.2005	PROPYLPARABEN	PROPYLPARABEN	CCCOC(=O)C1=CC=C(O)C=C1	PLASMA	Z8IX2SC1OH																											8.5				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33188879/	Homo sapiens				In vitro human plasma protein binding assay	In vitro study					false
716	348		ADULT	5147	137.136	SALICYLAMIDE	SALICYLAMIDE	NC(=O)C1=C(O)C=CC=C1	PLASMA	EM8BM710ZC									∞	μg × min/mL	76		μg/mL	30.9			RECOMMENDED	mg	500		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6689276/	Homo sapiens		min	12							false
717	354		ADULT	5323	310.329	SULFADIMETHOXINE	sulfadimethoxine	COC1=NC(OC)=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1	PLASMA	30CPC5LDEX																						UNKNOWN				healthy adults w/o other drugs; equilibrium dialysis; sulfa drug concentration - 100 mcg/mL	3	HEALTHY		UNKNOWN	EXPERIMENT	https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1002/cpt196895561	Homo sapiens										false
718	354		ADULT	5323	310.329	SULFADIMETHOXINE	sulfadimethoxine	COC1=NC(OC)=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1	PLASMA	30CPC5LDEX																						UNKNOWN				healthy adults w/o other drugs; equilibrium dialysis; sulfa drug concentration - 200 mcg/mL	7	HEALTHY		UNKNOWN	EXPERIMENT	https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1002/cpt196895561	Homo sapiens										false
719	361		ADULT	7547	315.582	TRICLOCARBAN	Triclocarban	ClC1=CC=C(NC(=O)NC2=CC(Cl)=C(Cl)C=C2)C=C1	BLOOD	BGG1Y1ED0Y																	UNKNOWN	μg	103		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1109279/	Homo sapiens		h	8.6							false
720	368		UNKNOWN	73415770	891.91	GADOFOSVESET	Gadofosveset	[H ].[H ].[H ].[Gd 3].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)C[C@H](COP([O-])(=O)OC1CCC(CC1)(C2=CC=CC=C2)C3=CC=CC=C3)N(CC([O-])=O)CC([O-])=O	PLASMA	E65RW73PHS																	UNKNOWN	mmol/kg	0.03		SINGLE	UNKNOWN				At 0.05, 0.5, 1 and 4 hours after injection of 0.03 mmol/kg the plasma protein binding of gadofosveset ranges from\n79.8 to 87.4%.	12.6	UNKNOWN	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021711s004lbl.pdf#page=7	Homo sapiens								Gadofosveset trisodium		false
721	368		UNKNOWN	73415770	891.91	GADOFOSVESET	Gadofosveset	[H ].[H ].[H ].[Gd 3].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)C[C@H](COP([O-])(=O)OC1CCC(CC1)(C2=CC=CC=C2)C3=CC=CC=C3)N(CC([O-])=O)CC([O-])=O	PLASMA	E65RW73PHS									?	μg × h/mL	962		μg/mL	98.3			UNKNOWN	mmol/kg	0.05		SINGLE	UNKNOWN						UNKNOWN	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021711s000_ClinPharmR.pdf#page=27	Homo sapiens		h	13.9					Gadofosveset trisodium		false
722	368		UNKNOWN	73415770	891.91	GADOFOSVESET	Gadofosveset	[H ].[H ].[H ].[Gd 3].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)C[C@H](COP([O-])(=O)OC1CCC(CC1)(C2=CC=CC=C2)C3=CC=CC=C3)N(CC([O-])=O)CC([O-])=O	PLASMA	E65RW73PHS									?	μg × h/mL	1327		μg/mL	129			UNKNOWN	mmol/kg	0.075		SINGLE	UNKNOWN						UNKNOWN	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021711s000_ClinPharmR.pdf#page=27	Homo sapiens		h	15					Gadofosveset trisodium		false
723	368		UNKNOWN	73415770	891.91	GADOFOSVESET	Gadofosveset	[H ].[H ].[H ].[Gd 3].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)C[C@H](COP([O-])(=O)OC1CCC(CC1)(C2=CC=CC=C2)C3=CC=CC=C3)N(CC([O-])=O)CC([O-])=O	PLASMA	E65RW73PHS									?	μg × h/mL	1435		μg/mL	151			UNKNOWN	mmol/kg	0.1		SINGLE	UNKNOWN						UNKNOWN	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021711s000_ClinPharmR.pdf#page=27	Homo sapiens		h	14.9					Gadofosveset trisodium		false
724	377		ADULT	5479539	514.577	CEFPIROME	Cefpirome	CO\\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[N ]3=C4CCCC4=CC=C3)=C(N2C1=O)C([O-])=O)C5=CSC(N)=N5	PLASMA	S72Q2F09HY	2764|4011971	331.3415	CIPROFLOXACIN	Ciprofloxacin	OC(=O)C1=CN(C2CC2)C3=CC(N4CCNCC4)=C(F)C=C3C1=O	5E8K9I0O4U			∞	mg × h/L	306		mg/L	150			UNKNOWN	g	2		MULTIPLE	UNKNOWN		day	2			HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10401943/	Homo sapiens		h	2.1	1st infusion			9			true
725	377		ADULT	5479539	514.577	CEFPIROME	Cefpirome	CO\\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[N ]3=C4CCCC4=CC=C3)=C(N2C1=O)C([O-])=O)C5=CSC(N)=N5	PLASMA	S72Q2F09HY	2764|4011971	331.3415	CIPROFLOXACIN	Ciprofloxacin	OC(=O)C1=CN(C2CC2)C3=CC(N4CCNCC4)=C(F)C=C3C1=O	5E8K9I0O4U			∞	mg × h/L	242		mg/L	131			UNKNOWN	g	2		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10401943/	Homo sapiens		h	2.2	1st infusion	Trauma patients		9			true
726	377		ADULT	5479539	514.577	CEFPIROME	Cefpirome	CO\\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[N ]3=C4CCCC4=CC=C3)=C(N2C1=O)C([O-])=O)C5=CSC(N)=N5	PLASMA	S72Q2F09HY									∞	μg × h/mL	138		μg/mL	59.7			UNKNOWN	mg	1000		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1564130/	Homo sapiens		h	1.7		Healthy Japanese males		6			false
727	377		ADULT	5479539	514.577	CEFPIROME	Cefpirome	CO\\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[N ]3=C4CCCC4=CC=C3)=C(N2C1=O)C([O-])=O)C5=CSC(N)=N5	PLASMA	S72Q2F09HY									∞	μg × h/mL	259		μg/mL	119			UNKNOWN	mg	2000		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1564130/	Homo sapiens		h	1.71	IV-infusion	Healthy Japanese males		6			false
728	377		ADULT	5479539	514.577	CEFPIROME	Cefpirome	CO\\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[N ]3=C4CCCC4=CC=C3)=C(N2C1=O)C([O-])=O)C5=CSC(N)=N5	PLASMA	S72Q2F09HY									∞	μg × h/mL	77.8		μg/mL	57.2			UNKNOWN	mg	500		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1564130/	Homo sapiens		h	1.72	IV-3 min	Healthy Japanese males		6			false
729	377		ADULT	5479539	514.577	CEFPIROME	Cefpirome	CO\\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[N ]3=C4CCCC4=CC=C3)=C(N2C1=O)C([O-])=O)C5=CSC(N)=N5	PLASMA	S72Q2F09HY									∞	μg × h/mL	84		μg/mL	36.6			UNKNOWN	mg	500		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1564130/	Homo sapiens		h	1.65	IV-infusion	Healthy Japanese male		6			false
730	377		ADULT	5479539	514.577	CEFPIROME	Cefpirome	CO\\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[N ]3=C4CCCC4=CC=C3)=C(N2C1=O)C([O-])=O)C5=CSC(N)=N5	PLASMA	S72Q2F09HY									∞	μg × h/mL	119		μg/mL	86.7			UNKNOWN	mg	1000		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1564130/	Homo sapiens		h	1.72	IV-3 min	Healthy Japanese males		6			false
731	377		ADULT	5479539	514.577	CEFPIROME	Cefpirome	CO\\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[N ]3=C4CCCC4=CC=C3)=C(N2C1=O)C([O-])=O)C5=CSC(N)=N5	PLASMA	S72Q2F09HY									∞	μg × h/mL	117		μg/mL	85.9			UNKNOWN	mg	1000		MULTIPLE	UNKNOWN		day	2			HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1564130/	Homo sapiens		h	1.76	IV-3 min, 9th administration	Healthy Japanese males		6			false
732	377		ADULT	5479539	514.577	CEFPIROME	Cefpirome	CO\\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[N ]3=C4CCCC4=CC=C3)=C(N2C1=O)C([O-])=O)C5=CSC(N)=N5	PLASMA	S72Q2F09HY									∞	μg × h/mL	124		μg/mL	91			UNKNOWN	mg	1000		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1564130/	Homo sapiens		h	1.78	IV-3 min, 1st administration	Healthy Japanese males		6			false
733	377		ADULT	5479539	514.577	CEFPIROME	Cefpirome	CO\\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[N ]3=C4CCCC4=CC=C3)=C(N2C1=O)C([O-])=O)C5=CSC(N)=N5	PLASMA	S72Q2F09HY									∞	μg × h/mL	128		μg/mL	58.4			UNKNOWN	mg	1000		MULTIPLE	UNKNOWN		day	2			HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1564130/	Homo sapiens		h	1.84	IV-infusion, 1st administration	Healthy Japanese males		6			false
734	377		ADULT	5479539	514.577	CEFPIROME	Cefpirome	CO\\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[N ]3=C4CCCC4=CC=C3)=C(N2C1=O)C([O-])=O)C5=CSC(N)=N5	PLASMA	S72Q2F09HY									∞	μg × h/mL	127		μg/mL	63			UNKNOWN	mg	1000		MULTIPLE	UNKNOWN		day	2			HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1564130/	Homo sapiens		h	1.71	IV-infusion, 9th administration	Healthy Japanese males		6			false
735	377			5479539	514.577	CEFPIROME	Cefpirome	CO\\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[N ]3=C4CCCC4=CC=C3)=C(N2C1=O)C([O-])=O)C5=CSC(N)=N5	PLASMA	S72Q2F09HY																										10% plasma protein binding	90				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9506005/	Homo sapiens										false
736	390		ADULT	71771	354.185	ACECLOFENAC	Aceclofenac	OC(=O)COC(=O)CC1=C(NC2=C(Cl)C=CC=C2Cl)C=CC=C1	PLASMA	RPK779R03H									∞	ng × h/mL	20814.17		ng/mL	10700.18			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://mhraproducts4853.blob.core.windows.net/docs/b3d28f88fd5c2a58da9fe9c222d07115029b119b	Homo sapiens				Film-coated tablets			35			false
737	390		ADULT	71771	354.185	ACECLOFENAC	Aceclofenac	OC(=O)COC(=O)CC1=C(NC2=C(Cl)C=CC=C2Cl)C=CC=C1	PLASMA	RPK779R03H									∞	μg × h/mL	43.2		μg/mL	10.3			UNKNOWN	mg	100		MULTIPLE	FASTED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22149151/	Homo sapiens		h	2.1	Immediate-release tablets			41			false
738	390		ADULT	71771	354.185	ACECLOFENAC	Aceclofenac	OC(=O)COC(=O)CC1=C(NC2=C(Cl)C=CC=C2Cl)C=CC=C1	PLASMA	RPK779R03H									∞	μg × h/mL	43.3		μg/mL	10.6			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22149151/	Homo sapiens		h	5	Controlled-release tablets			41			false
739	390		ADULT	71771	354.185	ACECLOFENAC	Aceclofenac	OC(=O)COC(=O)CC1=C(NC2=C(Cl)C=CC=C2Cl)C=CC=C1	PLASMA	RPK779R03H									∞	μg × h/mL	43.2		μg/mL	10.3			UNKNOWN	mg	200		SINGLE	HIGH-FAT						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22149151/	Homo sapiens		h	3.9	Controlled-release tablets			41			false
740	390		ADULT	71771	354.185	ACECLOFENAC	Aceclofenac	OC(=O)COC(=O)CC1=C(NC2=C(Cl)C=CC=C2Cl)C=CC=C1	PLASMA	RPK779R03H									∞	μg × h/mL	23.272		μg/mL	8.629			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32898192/	Homo sapiens		h	3.841	Immediate release tablets			12			false
741	390			71771	354.185	ACECLOFENAC	Aceclofenac	OC(=O)COC(=O)CC1=C(NC2=C(Cl)C=CC=C2Cl)C=CC=C1	PLASMA	RPK779R03H																										Aceclofenac is highly protein-bound (>99%).	1				OTHER	https://www.medicines.org.uk/emc/product/4240/smpc#PHARMACOKINETIC_PROPS	Homo sapiens										false
742	391		ADULT	1981	415.824	ACEMETACIN	ACEMETACIN	COC1=CC2=C(C=C1)N(C(=O)C3=CC=C(Cl)C=C3)C(C)=C2CC(=O)OCC(O)=O	PLASMA	5V141XK28X									∞	ng × h/mL	589		ng/mL	245			UNKNOWN	mg	60		SINGLE	FED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1888622/	Homo sapiens		h	1.03		young volunteers, mean age 30.9 years (22-44 years)		10	ACEMETACIN		false
743	391		ADULT	3715	357.788	INDOMETHACIN	indoMETACIN	COC1=CC2=C(C=C1)N(C(=O)C3=CC=C(Cl)C=C3)C(C)=C2CC(O)=O	PLASMA	XXE1CET956									∞	ng × h/mL	6349		ng/mL	705			UNKNOWN	mg	60		STEADY-STATE	FED		day	2			HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1888622/	Homo sapiens		h	7.07	7 days dosing	young volunteers, mean age 30.9 years (22-44 years)		10	ACEMETACIN		false
744	391		ADULT	1981	415.824	ACEMETACIN	ACEMETACIN	COC1=CC2=C(C=C1)N(C(=O)C3=CC=C(Cl)C=C3)C(C)=C2CC(=O)OCC(O)=O	PLASMA	5V141XK28X									∞	ng × h/mL	483		ng/mL	187			UNKNOWN	mg	60		STEADY-STATE	FED		day	2			HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1888622/	Homo sapiens		h	1.1	7 days dosing	young volunteers, mean age 30.9 years (22-44 years)		10	ACEMETACIN		false
745	391		ADULT	1981	415.824	ACEMETACIN	aceMETACIN	COC1=CC2=C(C=C1)N(C(=O)C3=CC=C(Cl)C=C3)C(C)=C2CC(=O)OCC(O)=O	PLASMA	5V141XK28X									∞	ng × h/mL	664		ng/mL	268			UNKNOWN	mg	60		SINGLE	FED						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1888622/	Homo sapiens		h	1.03		elderly patients with osteoarthritis, mean age 75.9 years (68-80 years)		10	ACEMETACIN		false
746	391		ADULT	3715	357.788	INDOMETHACIN	indoMETACIN	COC1=CC2=C(C=C1)N(C(=O)C3=CC=C(Cl)C=C3)C(C)=C2CC(O)=O	PLASMA	XXE1CET956									∞	ng × h/mL	4596		ng/mL	632			UNKNOWN	mg	60		SINGLE	FED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1888622/	Homo sapiens		h	6.01		young volunteers, mean age 30.9 years (22-44 years)		10	ACEMETACIN		false
747	391		ADULT	1981	415.824	ACEMETACIN	aceMETACIN	COC1=CC2=C(C=C1)N(C(=O)C3=CC=C(Cl)C=C3)C(C)=C2CC(=O)OCC(O)=O	PLASMA	5V141XK28X									∞	ng × h/mL	712		ng/mL	277			UNKNOWN	mg	60		STEADY-STATE	FED		day	2			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1888622/	Homo sapiens		h	2.27	7 days dosing	elderly patients with osteoarthritis, mean age 75.9 years (68-80 years)		10	ACEMETACIN		false
748	391		ADULT	3715	357.788	INDOMETHACIN	indoMETACIN	COC1=CC2=C(C=C1)N(C(=O)C3=CC=C(Cl)C=C3)C(C)=C2CC(O)=O	PLASMA	XXE1CET956									∞	ng × h/mL	4296		ng/mL	555			UNKNOWN	mg	60		SINGLE	FED						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1888622/	Homo sapiens		h	6.12		elderly patients with osteoarthritis, mean age 75.9 years (68-80 years)		10	ACEMETACIN		false
749	391		ADULT	3715	357.788	INDOMETHACIN	INDOMETHACIN	COC1=CC2=C(C=C1)N(C(=O)C3=CC=C(Cl)C=C3)C(C)=C2CC(O)=O	PLASMA	XXE1CET956									∞	ng × h/mL	7586		ng/mL	804			UNKNOWN	mg	60		STEADY-STATE	FED		day	2			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1888622/	Homo sapiens		h	7.2	7 days dosing	elderly patients with osteoarthritis, mean age 75.9 years (68-80 years)		10	ACEMETACIN		false
750	393		ADULT	2018	193.2009	ACTARIT		CC(=O)Nc1ccc(CC(=O)O)cc1	PLASMA	HW5B6351RZ									∞	μg × h/mL	4.56		μg/mL	2.24			RECOMMENDED	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/530263_1149031F1030_1_14F_1F.pdf#page=17	Homo sapiens		h	0.862							false
751	393		ADULT	2018	193.2009	ACTARIT	Actarit	CC(=O)Nc1ccc(CC(=O)O)cc1	PLASMA	HW5B6351RZ									∞	μg × h/mL	7.66		μg/mL	3.87			UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/530263_1149031F1030_1_14F_1F.pdf#page=17	Homo sapiens		h	0.803							false
752	393		ADULT	2018	193.2009	ACTARIT		CC(=O)Nc1ccc(CC(=O)O)cc1	PLASMA	HW5B6351RZ									∞	μg × h/mL	16		μg/mL	7.91			UNKNOWN	mg	400		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/530263_1149031F1030_1_14F_1F.pdf#page=17	Homo sapiens		h	0.909							false
753	393		ADULT	2018	193.2009	ACTARIT		CC(=O)Nc1ccc(CC(=O)O)cc1	PLASMA	HW5B6351RZ									∞	μg × h/mL	28.7		μg/mL	14.1			UNKNOWN	mg	800		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/530263_1149031F1030_1_14F_1F.pdf#page=17	Homo sapiens		h	0.851							false
754	393		ADULT	2018	193.2009	ACTARIT		CC(=O)Nc1ccc(CC(=O)O)cc1	PLASMA	HW5B6351RZ									∞	μg × h/mL	4.56		μg/mL	2.24			RECOMMENDED	mg	100		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/530263_1149031F1030_1_14F_1F.pdf#page=18	Homo sapiens		h	0.86				4			false
755	393		ADULT	2018	193.2009	ACTARIT		CC(=O)Nc1ccc(CC(=O)O)cc1	PLASMA	HW5B6351RZ									∞	μg × h/mL	4.16		μg/mL	2.09			RECOMMENDED	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/530263_1149031F1030_1_14F_1F.pdf#page=18	Homo sapiens		h	1.13				16			false
756	393			2018	193.2009	ACTARIT		CC(=O)Nc1ccc(CC(=O)O)cc1	PLASMA	HW5B6351RZ																										Plasma protein binding: 17~20%	80				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/530263_1149031F1030_1_14F_1F.pdf#page=19	Homo sapiens										false
757	395		ADULT	2194	240.365	ANETHOLTRITHION	ANETHOLTRITHION	COC1=CC=C(C=C1)C2=CC(=S)SS2	PLASMA	QUY32964DJ													ng/mL	0.98			UNKNOWN	mg	75		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17586125/	Homo sapiens		h	3.78	test tablet			22	ANETHOLTRITHION		false
758	395		ADULT	2194	240.365	ANETHOLTRITHION	ANETHOLTRITHION	COC1=CC=C(C=C1)C2=CC(=S)SS2	PLASMA	QUY32964DJ													ng/mL	0.96			UNKNOWN	mg	75		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17586125/	Homo sapiens		h	4.03	reference tablet			22	ANETHOLTRITHION		false
759	395		ADULT	2194	240.365	ANETHOLTRITHION	ANETHOLTRITHION	COC1=CC=C(C=C1)C2=CC(=S)SS2	PLASMA	QUY32964DJ									∞	ng × h/mL	1035.2		ng/mL	279.6			UNKNOWN	mg	75		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20980118/	Homo sapiens		h	4.5				19	ANETHOLTRITHION		false
760	399		ADULT	65948	582.6463	AZELNIDIPINE	AZELNIDIPINE	CC(C)OC(=O)C1=C(C)NC(N)=C(C1C2=CC(=CC=C2)[N ]([O-])=O)C(=O)OC3CN(C3)C(C4=CC=CC=C4)C5=CC=CC=C5	PLASMA	PV23P19YUG							24		t	ng × h/mL	426		ng/mL	48.3			UNKNOWN	mg	16		STEADY-STATE	FED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12675275/	Homo sapiens		h	8.68	6 weeks dosing	essential hypertension		22	AZELNIDIPINE		false
761	399		UNKNOWN	65948	582.6463	AZELNIDIPINE	AZELNIDIPINE	CC(C)OC(=O)C1=C(C)NC(N)=C(C1C2=CC(=CC=C2)[N ]([O-])=O)C(=O)OC3CN(C3)C(C4=CC=CC=C4)C5=CC=CC=C5	PLASMA	PV23P19YUG																	UNKNOWN				SINGLE	UNKNOWN					10	UNKNOWN	UNKNOWN	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/14636080/	Homo sapiens				there are no data on application				AZELNIDIPINE		false
762	399		ADULT	65948	582.6463	AZELNIDIPINE	AZELNIDIPINE	CC(C)OC(=O)C1=C(C)NC(N)=C(C1C2=CC(=CC=C2)[N ]([O-])=O)C(=O)OC3CN(C3)C(C4=CC=CC=C4)C5=CC=CC=C5	PLASMA	PV23P19YUG							96		t	ng × h/L	53.6		ng/mL	5.1			UNKNOWN	mg	8		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16920318/	Homo sapiens		h	25				12	AZELNIDIPINE		false
763	399		ADULT	65948	582.6463	AZELNIDIPINE	AZELNIDIPINE	CC(C)OC(=O)C1=C(C)NC(N)=C(C1C2=CC(=CC=C2)[N ]([O-])=O)C(=O)OC3CN(C3)C(C4=CC=CC=C4)C5=CC=CC=C5	PLASMA	PV23P19YUG							96		t	ng × h/mL	186		ng/mL	8.66			UNKNOWN	mg	8		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18771003/	Homo sapiens		h	22.8				8	AZELNIDIPINE		false
764	399		ADULT	65948	582.6463	AZELNIDIPINE	AZELNIDIPINE	CC(C)OC(=O)C1=C(C)NC(N)=C(C1C2=CC(=CC=C2)[N ]([O-])=O)C(=O)OC3CN(C3)C(C4=CC=CC=C4)C5=CC=CC=C5	PLASMA	PV23P19YUG							96		t	ng × h/mL	429		ng/mL	19.17			UNKNOWN	mg	16		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18771003/	Homo sapiens		h	23.5				8	AZELNIDIPINE		false
765	399		ADULT	65948	582.6463	AZELNIDIPINE	AZELNIDIPINE	CC(C)OC(=O)C1=C(C)NC(N)=C(C1C2=CC(=CC=C2)[N ]([O-])=O)C(=O)OC3CN(C3)C(C4=CC=CC=C4)C5=CC=CC=C5	PLASMA	PV23P19YUG							96		?	ng × h/mL	169.19		ng/mL	15.04			UNKNOWN	mg	8		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18771003/	Homo sapiens							8	AZELNIDIPINE		false
766	402		ADULT	6042|23423984	300.808	THIAMINE	Thiamine	[Cl-].CC1=C(CCO)SC=[N ]1CC2=C(N)N=C(C)N=C2	PLASMA	X66NSO3N35									?	μg × h/L	3034.8		μg/L	679.4			UNKNOWN	mg	300		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24399744/	Homo sapiens		h	2.1	Day 14			12			false
767	402		ADULT	6042|23423984	300.808	THIAMINE	Thiamine	[Cl-].CC1=C(CCO)SC=[N ]1CC2=C(N)N=C(C)N=C2	BLOOD	X66NSO3N35									?	μg × h/L	4968.3		μg/L	668.6			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24399744/	Homo sapiens		h	4.5				12			false
768	402		ADULT	6042|23423984	300.808	THIAMINE	Thiamine	[Cl-].CC1=C(CCO)SC=[N ]1CC2=C(N)N=C(C)N=C2	BLOOD	X66NSO3N35									?	μg × h/L	6841.9		μg/L	837			UNKNOWN	mg	300		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24399744/	Homo sapiens		h	4.8	Day 14			12			false
769	402		ADULT	6042|23423984	300.808	THIAMINE	Thiamine	[Cl-].CC1=C(CCO)SC=[N ]1CC2=C(N)N=C(C)N=C2	RED BLOOD CELLS	X66NSO3N35									?	μg × h/L	8742.1		μg/L	985.3			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24399744/	Homo sapiens		h	5				12			false
770	402		ADULT	6042|23423984	300.808	THIAMINE	Thiamine	[Cl-].CC1=C(CCO)SC=[N ]1CC2=C(N)N=C(C)N=C2	RED BLOOD CELLS	X66NSO3N35									?	μg × h/L	11517.9		μg/L	1106			UNKNOWN	mg	300		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24399744/	Homo sapiens		h	5.5	Day 14			12			false
771	402		ADULT	6042|23423984	300.808	THIAMINE	Thiamine	[Cl-].CC1=C(CCO)SC=[N ]1CC2=C(N)N=C(C)N=C2	PLASMA	X66NSO3N35									?	μg × h/L	1819.9		μg/L	520.5			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24399744/	Homo sapiens		h	1.6				12			false
772	402		ADULT	5431|644169|71586757	424.306	COCARBOXYLASE	Thiamine diphosphate	[H ].CC1=C(CCOP([O-])(=O)OP(O)([O-])=O)SC=[N ]1CC2=CN=C(C)N=C2N	BLOOD	Q57971654Y									?	ng × h/mL	2002.9		ng/mL	79.7			UNKNOWN	mg	150		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33727798/	Homo sapiens		h	46.4				10			false
773	402		ADULT	10761|131664207	380.787	MONOPHOSPHOTHIAMINE	Thiamine monophosphate	[Cl-].CC1=C(CCOP(O)(O)=O)SC=[N ]1CC2=C(N)N=C(C)N=C2	BLOOD	P712T71Q3T									?	ng × h/mL	380		ng/mL	12.6			UNKNOWN	mg	1200		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33727798/	Homo sapiens		h	44.9				10			false
774	402		ADULT	5431|644169|71586757	424.306	COCARBOXYLASE	Thiamine diphosphate	[H ].CC1=C(CCOP([O-])(=O)OP(O)([O-])=O)SC=[N ]1CC2=CN=C(C)N=C2N	BLOOD	Q57971654Y									?	ng × h/mL	2785.2		ng/mL	99.3			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33727798/	Homo sapiens		h	18.6				10			false
775	402		ADULT	5431|644169|71586757	424.306	COCARBOXYLASE	Thiamine diphosphate	[H ].CC1=C(CCOP([O-])(=O)OP(O)([O-])=O)SC=[N ]1CC2=CN=C(C)N=C2N	BLOOD	Q57971654Y									?	ng × h/mL	3130.5		ng/mL	89.1			UNKNOWN	mg	600		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33727798/	Homo sapiens		h	24.5				10			false
776	402		ADULT	5431|644169|71586757	424.306	COCARBOXYLASE	Thiamine diphosphate	[H ].CC1=C(CCOP([O-])(=O)OP(O)([O-])=O)SC=[N ]1CC2=CN=C(C)N=C2N	BLOOD	Q57971654Y									?	ng × h/mL	3804.3		ng/mL	101			UNKNOWN	mg	900		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33727798/	Homo sapiens		h	42.5				10			false
777	402		ADULT	5431|644169|71586757	424.306	COCARBOXYLASE	Thiamine diphosphate	[H ].CC1=C(CCOP([O-])(=O)OP(O)([O-])=O)SC=[N ]1CC2=CN=C(C)N=C2N	BLOOD	Q57971654Y									?	ng × h/mL	4601.3		ng/mL	120			UNKNOWN	mg	1200		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33727798/	Homo sapiens		h	48.2				10			false
778	402		ADULT	6042|23423984	300.808	THIAMINE	Thiamine	[Cl-].CC1=C(CCO)SC=[N ]1CC2=C(N)N=C(C)N=C2	BLOOD	X66NSO3N35									?	ng × h/mL	1639.8		ng/mL	276			UNKNOWN	mg	150		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33727798/	Homo sapiens		h	37.2	Day 1 (single dose)			12			false
779	402		ADULT	6042|23423984	300.808	THIAMINE	Thiamine	[Cl-].CC1=C(CCO)SC=[N ]1CC2=C(N)N=C(C)N=C2	BLOOD	X66NSO3N35									?	ng × h/mL	3795.1		ng/mL	439			UNKNOWN	mg	150		MULTIPLE	FASTED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33727798/	Homo sapiens		h	36.48	Day 10 (13th dose, no doses on Days 2 and 3)			12			false
780	402		ADULT	6042|23423984	300.808	THIAMINE	Thiamine	[Cl-].CC1=C(CCO)SC=[N ]1CC2=C(N)N=C(C)N=C2	BLOOD	X66NSO3N35									?	ng × h/mL	4902.9		ng/mL	624			UNKNOWN	mg	300		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33727798/	Homo sapiens		h	29	Day 1 (single dose)			12			false
781	402		ADULT	6042|23423984	300.808	THIAMINE	Thiamine	[Cl-].CC1=C(CCO)SC=[N ]1CC2=C(N)N=C(C)N=C2	BLOOD	X66NSO3N35									?	ng × h/mL	11081.3		ng/mL	1089			UNKNOWN	mg	300		MULTIPLE	FASTED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33727798/	Homo sapiens		h	25.97	Day 10 (13th dose, no doses on Days 2 and 3)			12			false
782	402		ADULT	6042|23423984	300.808	THIAMINE	Thiamine	[Cl-].CC1=C(CCO)SC=[N ]1CC2=C(N)N=C(C)N=C2	BLOOD	X66NSO3N35									?	ng × h/mL	1983.4		ng/mL	344			UNKNOWN	mg	150		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33727798/	Homo sapiens		h	13.9				10			false
783	402		ADULT	6042|23423984	300.808	THIAMINE	Thiamine	[Cl-].CC1=C(CCO)SC=[N ]1CC2=C(N)N=C(C)N=C2	BLOOD	X66NSO3N35									?	ng × h/mL	13493.8		ng/mL	1485			UNKNOWN	mg	600		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33727798/	Homo sapiens		h	16.8	Day 1 (single dose)			12			false
784	402		ADULT	6042|23423984	300.808	THIAMINE	Thiamine	[Cl-].CC1=C(CCO)SC=[N ]1CC2=C(N)N=C(C)N=C2	BLOOD	X66NSO3N35									?	ng × h/mL	4823.6		ng/mL	674			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33727798/	Homo sapiens		h	10				10			false
785	402		ADULT	6042|23423984	300.808	THIAMINE	Thiamine	[Cl-].CC1=C(CCO)SC=[N ]1CC2=C(N)N=C(C)N=C2	BLOOD	X66NSO3N35									?	ng × h/mL	14399.1		ng/mL	1601			UNKNOWN	mg	600		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33727798/	Homo sapiens		h	6.6				10			false
786	402		ADULT	6042|23423984	300.808	THIAMINE	Thiamine	[Cl-].CC1=C(CCO)SC=[N ]1CC2=C(N)N=C(C)N=C2	BLOOD	X66NSO3N35									?	ng × h/mL	31855		ng/mL	2783			UNKNOWN	mg	600		MULTIPLE	FASTED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33727798/	Homo sapiens		h	16.46	Day 10 (13th dose, no doses on Days 2 and 3)			12			false
787	402		ADULT	6042|23423984	300.808	THIAMINE	Thiamine	[Cl-].CC1=C(CCO)SC=[N ]1CC2=C(N)N=C(C)N=C2	BLOOD	X66NSO3N35									?	ng × h/mL	25841.3		ng/mL	2607			UNKNOWN	mg	900		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33727798/	Homo sapiens		h	6.3				10			false
788	402		ADULT	6042|23423984	300.808	THIAMINE	Thiamine	[Cl-].CC1=C(CCO)SC=[N ]1CC2=C(N)N=C(C)N=C2	BLOOD	X66NSO3N35									?	ng × h/mL	39155.3		ng/mL	3730			UNKNOWN	mg	1200		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33727798/	Homo sapiens		h	6.3				10			false
789	402		ADULT	5431|644169|71586757	424.306	COCARBOXYLASE	Thiamine diphosphate	[H ].CC1=C(CCOP([O-])(=O)OP(O)([O-])=O)SC=[N ]1CC2=CN=C(C)N=C2N	BLOOD	Q57971654Y									?	ng × h/mL	2984		ng/mL	79			UNKNOWN	mg	300		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33727798/	Homo sapiens		h	34.3	Day 1 (single dose)			12			false
790	402		ADULT	5431|644169|71586757	424.306	COCARBOXYLASE	Thiamine diphosphate	[H ].CC1=C(CCOP([O-])(=O)OP(O)([O-])=O)SC=[N ]1CC2=CN=C(C)N=C2N	BLOOD	Q57971654Y									?	ng × h/mL	5617.7		ng/mL	126			UNKNOWN	mg	600		MULTIPLE	FASTED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33727798/	Homo sapiens		h	41.7	Day 10 (13th dose, no doses on Days 2 and 3)			12			false
791	402		ADULT	5431|644169|71586757	424.306	COCARBOXYLASE	Thiamine diphosphate	[H ].CC1=C(CCOP([O-])(=O)OP(O)([O-])=O)SC=[N ]1CC2=CN=C(C)N=C2N	BLOOD	Q57971654Y									?	ng × h/mL	2198.9		ng/mL	68			UNKNOWN	mg	150		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33727798/	Homo sapiens		h	67.4	Day 1 (single dose)			12			false
792	402		ADULT	10761|131664207	380.787	MONOPHOSPHOTHIAMINE	Thiamine monophosphate	[Cl-].CC1=C(CCOP(O)(O)=O)SC=[N ]1CC2=C(N)N=C(C)N=C2	BLOOD	P712T71Q3T									?	ng × h/mL	164.6		ng/mL	7.99			UNKNOWN	mg	150		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33727798/	Homo sapiens		h	35.3				10			false
793	402		ADULT	5431|644169|71586757	424.306	COCARBOXYLASE	Thiamine diphosphate	[H ].CC1=C(CCOP([O-])(=O)OP(O)([O-])=O)SC=[N ]1CC2=CN=C(C)N=C2N	BLOOD	Q57971654Y									?	ng × h/mL	4009.8		ng/mL	111			UNKNOWN	mg	150		MULTIPLE	FASTED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33727798/	Homo sapiens		h	51.2	Day 10 (13th dose, no doses on Days 2 and 3)			12			false
794	402		ADULT	10761|131664207	380.787	MONOPHOSPHOTHIAMINE	Thiamine monophosphate	[Cl-].CC1=C(CCOP(O)(O)=O)SC=[N ]1CC2=C(N)N=C(C)N=C2	BLOOD	P712T71Q3T									?	ng × h/mL	271.5		ng/mL	9.24			UNKNOWN	mg	600		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33727798/	Homo sapiens		h	36				10			false
795	402		ADULT	10761|131664207	380.787	MONOPHOSPHOTHIAMINE	Thiamine monophosphate	[Cl-].CC1=C(CCOP(O)(O)=O)SC=[N ]1CC2=C(N)N=C(C)N=C2	BLOOD	P712T71Q3T									?	ng × h/mL	214.4		ng/mL	8.51			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33727798/	Homo sapiens		h	31.8				10			false
796	402		ADULT	5431|644169|71586757	424.306	COCARBOXYLASE	Thiamine diphosphate	[H ].CC1=C(CCOP([O-])(=O)OP(O)([O-])=O)SC=[N ]1CC2=CN=C(C)N=C2N	BLOOD	Q57971654Y									?	ng × h/mL	5141.4		ng/mL	126			UNKNOWN	mg	300		MULTIPLE	FASTED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33727798/	Homo sapiens		h	37.4	Day 10 (13th dose, no doses on Days 2 and 3)			12			false
797	402		ADULT	5431|644169|71586757	424.306	COCARBOXYLASE	Thiamine diphosphate	[H ].CC1=C(CCOP([O-])(=O)OP(O)([O-])=O)SC=[N ]1CC2=CN=C(C)N=C2N	BLOOD	Q57971654Y									?	ng × h/mL	3588.6		ng/mL	77			UNKNOWN	mg	600		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33727798/	Homo sapiens		h	28.7	Day 1 (single dose)			12			false
798	402		ADULT	10761|131664207	380.787	MONOPHOSPHOTHIAMINE	Thiamine monophosphate	[Cl-].CC1=C(CCOP(O)(O)=O)SC=[N ]1CC2=C(N)N=C(C)N=C2	BLOOD	P712T71Q3T									?	ng × h/mL	311.1		ng/mL	12			UNKNOWN	mg	900		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33727798/	Homo sapiens		h	74.8				10			false
799	403		ADULT	16363	381.4433	BENPERIDOL	BENPERIDOL	FC1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)N3C(=O)NC4=C3C=CC=C4	PLASMA	97O6X78C53									∞	ng × h/mL	79.4		ng/mL	10.2			UNKNOWN	mg	6		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	doi:10.1007/bf02247478	Homo sapiens		h	5.53	Glianimon liquid form	Schizophrenic patients		12	Benperidol		false
800	403		ADULT	16363	381.4433	BENPERIDOL	BENPERIDOL	FC1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)N3C(=O)NC4=C3C=CC=C4	PLASMA	97O6X78C53									∞	ng × h/mL	157.9		ng/mL	105.5			UNKNOWN	mg	6		SINGLE	FASTED						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	doi:10.1007/bf02247478	Homo sapiens		h	5.8		Schizophrenic patients		13	Benperidol		false
801	403		ADULT	16363	381.4433	BENPERIDOL	BENPERIDOL	FC1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)N3C(=O)NC4=C3C=CC=C4	PLASMA	97O6X78C53									∞	ng × h/mL	64.5		ng/mL	7.3			UNKNOWN	mg	6		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	doi:10.1007/bf02247478	Homo sapiens		h	4.65	Glianimon tablet form	Schizophrenic patients		13	Benperidol		false
802	404		ADULT	2333	424.083	BENZBROMARONE	benzbromarone	CCC1=C(C(=O)C2=CC(Br)=C(O)C(Br)=C2)C3=C(O1)C=CC=C3	SERUM	4POG0RL69O									?	mg × h/L	10.32		mg/L	1.84			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7250176/	Homo sapiens		h	2.77				7	benzbromarone		false
803	405		ADULT	71339	350.393	BIAPENEM	Biapenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN4C=NC=[N ]4C3)=C(N2C1=O)C([O-])=O	PLASMA	YR5U3L9ZH1							8		t	mg × h/L	70		mg/L	20.8			UNKNOWN	mg	750		MULTIPLE	UNKNOWN		day	3			HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33685898/	Homo sapiens		h	1.2				5			false
804	405		ADULT	71339	350.393	BIAPENEM	Biapenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN4C=NC=[N ]4C3)=C(N2C1=O)C([O-])=O	PLASMA	YR5U3L9ZH1							8		t	mg × h/L	115		mg/L	38.2			UNKNOWN	mg	1000		MULTIPLE	UNKNOWN		day	3			HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33685898/	Homo sapiens		h	1.42	Day 7			6			false
805	405		ADULT	71339	350.393	BIAPENEM	Biapenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN4C=NC=[N ]4C3)=C(N2C1=O)C([O-])=O	PLASMA	YR5U3L9ZH1							8		t	mg × h/L	148		mg/L	52.3			UNKNOWN	mg	1250		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33685898/	Homo sapiens		h	1.31				6			false
806	405		ADULT	71339	350.393	BIAPENEM	Biapenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN4C=NC=[N ]4C3)=C(N2C1=O)C([O-])=O	PLASMA	YR5U3L9ZH1							8		t	mg × h/L	146		mg/L	44.8			UNKNOWN	mg	1250		MULTIPLE	UNKNOWN		day	3			HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33685898/	Homo sapiens		h	1.63	Day 7			5			false
807	405		ADULT	71339	350.393	BIAPENEM	Biapenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN4C=NC=[N ]4C3)=C(N2C1=O)C([O-])=O	PLASMA	YR5U3L9ZH1							8		t	mg × h/L	17.5		mg/L	5.43			UNKNOWN	mg	250		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33685898/	Homo sapiens		h	1.1				3			false
808	405		ADULT	71339	350.393	BIAPENEM	Biapenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN4C=NC=[N ]4C3)=C(N2C1=O)C([O-])=O	PLASMA	YR5U3L9ZH1							8		t	mg × h/L	18.4		mg/L	5.71			UNKNOWN	mg	250		MULTIPLE	UNKNOWN		day	3			HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33685898/	Homo sapiens		h	1.06	Day 7			3			false
809	405		ADULT	71339	350.393	BIAPENEM	Biapenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN4C=NC=[N ]4C3)=C(N2C1=O)C([O-])=O	PLASMA	YR5U3L9ZH1							8		t	mg × h/L	52.4		mg/L	16.3			UNKNOWN	mg	500		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33685898/	Homo sapiens		h	1.3				6			false
810	405		ADULT	71339	350.393	BIAPENEM	Biapenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN4C=NC=[N ]4C3)=C(N2C1=O)C([O-])=O	PLASMA	YR5U3L9ZH1							8		t	mg × h/L	49.4		mg/L	16.6			UNKNOWN	mg	500		MULTIPLE	UNKNOWN		day	3			HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33685898/	Homo sapiens		h	1.13	Day 7			6			false
811	405		ADULT	71339	350.393	BIAPENEM	Biapenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN4C=NC=[N ]4C3)=C(N2C1=O)C([O-])=O	PLASMA	YR5U3L9ZH1							8		t	mg × h/L	68.3		mg/L	22.6			UNKNOWN	mg	750		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33685898/	Homo sapiens		h	1.03				6			false
812	405		ADULT	71339	350.393	BIAPENEM	Biapenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN4C=NC=[N ]4C3)=C(N2C1=O)C([O-])=O	PLASMA	YR5U3L9ZH1							8		t	mg × h/L	123		mg/L	39.8			UNKNOWN	mg	1000		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33685898/	Homo sapiens		h	1.21				6			false
813	405			71339	350.393	BIAPENEM	Biapenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN4C=NC=[N ]4C3)=C(N2C1=O)C([O-])=O	PLASMA	YR5U3L9ZH1																										Human plasma protein binding (ultrafiltration): 6.6% (10μg/mL), 4.3% (50μg/mL)	93.4				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/780009_6139401D1020_2_1F.pdf#page=29	Homo sapiens										false
814	405		ADULT	71339	350.393	BIAPENEM	Biapenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN4C=NC=[N ]4C3)=C(N2C1=O)C([O-])=O	PLASMA	YR5U3L9ZH1									?	μg × h/mL	14.7		μg/mL	8.8			UNKNOWN	mg	150		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2001/P200100035/53039600_21300AMZ00761_Q101_1.pdf#page=3 | https://www.pmda.go.jp/drugs/2001/P200100035/53039600_21300AMZ00761_W103_1.pdf#page=1 | https://www.info.pmda.go.jp/go/interview/2/780009_6139401D1020_2_1F.pdf#page=24	Homo sapiens		h	0.97				5			false
815	405		ADULT	71339	350.393	BIAPENEM	Biapenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN4C=NC=[N ]4C3)=C(N2C1=O)C([O-])=O	PLASMA	YR5U3L9ZH1									?	μg × h/mL	29.2		μg/mL	17.3			UNKNOWN	mg	300		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2001/P200100035/53039600_21300AMZ00761_Q101_1.pdf#page=3 | https://www.pmda.go.jp/drugs/2001/P200100035/53039600_21300AMZ00761_W103_1.pdf#page=1 | https://www.info.pmda.go.jp/go/interview/2/780009_6139401D1020_2_1F.pdf#page=24	Homo sapiens		h	1.03				5			false
816	405		ADULT	71339	350.393	BIAPENEM	Biapenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN4C=NC=[N ]4C3)=C(N2C1=O)C([O-])=O	PLASMA	YR5U3L9ZH1									?	μg × h/mL	55.4		μg/mL	32.4			UNKNOWN	mg	600		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2001/P200100035/53039600_21300AMZ00761_Q101_1.pdf#page=3 | https://www.pmda.go.jp/drugs/2001/P200100035/53039600_21300AMZ00761_W103_1.pdf#page=1 | https://www.info.pmda.go.jp/go/interview/2/780009_6139401D1020_2_1F.pdf#page=24	Homo sapiens		h	1.04				5			false
817	405		ADULT	71339	350.393	BIAPENEM	Biapenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN4C=NC=[N ]4C3)=C(N2C1=O)C([O-])=O	PLASMA	YR5U3L9ZH1									?	μg × h/mL	23.4		μg/mL	14.7			UNKNOWN	mg	300		MULTIPLE	UNKNOWN		day	2			HEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.pmda.go.jp/drugs/2001/P200100035/53039600_21300AMZ00761_Q101_1.pdf#page=3 | https://www.pmda.go.jp/drugs/2001/P200100035/53039600_21300AMZ00761_W103_1.pdf#page=2 | https://www.info.pmda.go.jp/go/interview/2/780009_6139401D1020_2_1F.pdf#page=25	Homo sapiens		h	0.85	Day 6 (11th dose)			5			false
818	405		ADULT	71339	350.393	BIAPENEM	Biapenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN4C=NC=[N ]4C3)=C(N2C1=O)C([O-])=O	PLASMA	YR5U3L9ZH1									?	μg × h/mL	26.2		μg/mL	15.6			UNKNOWN	mg	300		MULTIPLE	UNKNOWN		day	2			HEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.pmda.go.jp/drugs/2001/P200100035/53039600_21300AMZ00761_Q101_1.pdf#page=3 | https://www.pmda.go.jp/drugs/2001/P200100035/53039600_21300AMZ00761_W103_1.pdf#page=2 | https://www.info.pmda.go.jp/go/interview/2/780009_6139401D1020_2_1F.pdf#page=25	Homo sapiens		h	0.96	Day 1 (1st dose)			5			false
819	405		ADULT	71339	350.393	BIAPENEM	Biapenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN4C=NC=[N ]4C3)=C(N2C1=O)C([O-])=O	PLASMA	YR5U3L9ZH1									?	μg × h/mL	56.7		μg/mL	32.6			UNKNOWN	mg	600		MULTIPLE	UNKNOWN		day	2			HEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.pmda.go.jp/drugs/2001/P200100035/53039600_21300AMZ00761_Q101_1.pdf#page=3 | https://www.pmda.go.jp/drugs/2001/P200100035/53039600_21300AMZ00761_W103_1.pdf#page=3 | https://www.info.pmda.go.jp/go/interview/2/780009_6139401D1020_2_1F.pdf#page=25	Homo sapiens		h	1.03	Day 1 (1st dose)			5			false
820	405		ADULT	71339	350.393	BIAPENEM	Biapenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN4C=NC=[N ]4C3)=C(N2C1=O)C([O-])=O	PLASMA	YR5U3L9ZH1									?	μg × h/mL	57.1		μg/mL	35.3			UNKNOWN	mg	600		MULTIPLE	UNKNOWN		day	2			HEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.pmda.go.jp/drugs/2001/P200100035/53039600_21300AMZ00761_Q101_1.pdf#page=3 | https://www.pmda.go.jp/drugs/2001/P200100035/53039600_21300AMZ00761_W103_1.pdf#page=3 | https://www.info.pmda.go.jp/go/interview/2/780009_6139401D1020_2_1F.pdf#page=25	Homo sapiens		h	1.01	Day 5 (9th dose)			5			false
821	405		ADULT	71339	350.393	BIAPENEM	Biapenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN4C=NC=[N ]4C3)=C(N2C1=O)C([O-])=O	PLASMA	YR5U3L9ZH1									?	μg × h/mL	34.5		μg/mL	17.4			UNKNOWN	mg	300		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.pmda.go.jp/drugs/2001/P200100035/53039600_21300AMZ00761_Q101_1.pdf#page=3 | https://www.pmda.go.jp/drugs/2001/P200100035/53039600_21300AMZ00761_W103_1.pdf#page=7 | https://www.info.pmda.go.jp/go/interview/2/780009_6139401D1020_2_1F.pdf#page=26	Homo sapiens		h	1.82		Elderly subjects (65~74 y)		5			false
822	405		ADULT	71339	350.393	BIAPENEM	Biapenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN4C=NC=[N ]4C3)=C(N2C1=O)C([O-])=O	PLASMA	YR5U3L9ZH1									?	μg × h/mL	44.6		μg/mL	20.2			UNKNOWN	mg	300		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.pmda.go.jp/drugs/2001/P200100035/53039600_21300AMZ00761_Q101_1.pdf#page=3 | https://www.pmda.go.jp/drugs/2001/P200100035/53039600_21300AMZ00761_W103_1.pdf#page=7 | https://www.info.pmda.go.jp/go/interview/2/780009_6139401D1020_2_1F.pdf#page=26	Homo sapiens		h	1.75		Elderly subjects (75~84 y)		5			false
823	405		ADULT	71339	350.393	BIAPENEM	Biapenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN4C=NC=[N ]4C3)=C(N2C1=O)C([O-])=O	PLASMA	YR5U3L9ZH1									?	μg × h/mL	26.6		μg/mL	14.2			UNKNOWN	mg	300		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.pmda.go.jp/drugs/2001/P200100035/53039600_21300AMZ00761_Q101_1.pdf#page=3 | https://www.pmda.go.jp/drugs/2001/P200100035/53039600_21300AMZ00761_W103_1.pdf#page=7 | https://www.info.pmda.go.jp/go/interview/2/780009_6139401D1020_2_1F.pdf#page=26	Homo sapiens		h	1.51		non-Elderly subjects		5			false
824	405		ADULT	71339	350.393	BIAPENEM	Biapenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN4C=NC=[N ]4C3)=C(N2C1=O)C([O-])=O	PLASMA	YR5U3L9ZH1									?	μg × h/mL	52.7		μg/mL	24.8			UNKNOWN	mg	300		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.pmda.go.jp/drugs/2001/P200100035/53039600_21300AMZ00761_Q101_1.pdf#page=3 | https://www.pmda.go.jp/drugs/2001/P200100035/53039600_21300AMZ00761_W104_1.pdf#page=1 | https://www.info.pmda.go.jp/go/interview/2/780009_6139401D1020_2_1F.pdf#page=27	Homo sapiens		h	3.33		Renal impairment patients in hemodialysis (started dialysis right after biapenem administration)		5			false
825	405		ADULT	71339	350.393	BIAPENEM	Biapenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN4C=NC=[N ]4C3)=C(N2C1=O)C([O-])=O	PLASMA	YR5U3L9ZH1									?	μg × h/mL	120		μg/mL	19			UNKNOWN	mg	300		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.pmda.go.jp/drugs/2001/P200100035/53039600_21300AMZ00761_Q101_1.pdf#page=3 | https://www.pmda.go.jp/drugs/2001/P200100035/53039600_21300AMZ00761_W104_1.pdf#page=1 | https://www.info.pmda.go.jp/go/interview/2/780009_6139401D1020_2_1F.pdf#page=27	Homo sapiens		h	3.92		Renal impairment patients after hemodialysis		5			false
826	405		ADULT	71339	350.393	BIAPENEM	Biapenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN4C=NC=[N ]4C3)=C(N2C1=O)C([O-])=O	PLASMA	YR5U3L9ZH1									?	μg × h/mL	68		μg/mL	25.6			UNKNOWN	mg	300		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.pmda.go.jp/drugs/2001/P200100035/53039600_21300AMZ00761_Q101_1.pdf#page=3 | https://www.pmda.go.jp/drugs/2001/P200100035/53039600_21300AMZ00761_W104_1.pdf#page=2 | https://www.info.pmda.go.jp/go/interview/2/780009_6139401D1020_2_1F.pdf#page=27	Homo sapiens		h	2.28		Renal impairment (CLcr=23.1 mL/min)		1			false
827	405		ADULT	71339	350.393	BIAPENEM	Biapenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN4C=NC=[N ]4C3)=C(N2C1=O)C([O-])=O	PLASMA	YR5U3L9ZH1									?	μg × h/mL	61.1		μg/mL	24			UNKNOWN	mg	300		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.pmda.go.jp/drugs/2001/P200100035/53039600_21300AMZ00761_Q101_1.pdf#page=3 | https://www.pmda.go.jp/drugs/2001/P200100035/53039600_21300AMZ00761_W104_1.pdf#page=2 | https://www.info.pmda.go.jp/go/interview/2/780009_6139401D1020_2_1F.pdf#page=27	Homo sapiens		h	1.82		Renal impairment (CLcr=40.6 mL/min)		1			false
828	405		ADULT	71339	350.393	BIAPENEM	Biapenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN4C=NC=[N ]4C3)=C(N2C1=O)C([O-])=O	PLASMA	YR5U3L9ZH1									?	μg × h/mL	46.6		μg/mL	12.8			UNKNOWN	mg	300		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.pmda.go.jp/drugs/2001/P200100035/53039600_21300AMZ00761_Q101_1.pdf#page=3 | https://www.pmda.go.jp/drugs/2001/P200100035/53039600_21300AMZ00761_W104_1.pdf#page=2 | https://www.info.pmda.go.jp/go/interview/2/780009_6139401D1020_2_1F.pdf#page=27	Homo sapiens		h	1.95		Renal impairment (CLcr=49.4 mL/min)		1			false
829	405		ADULT	71339	350.393	BIAPENEM	Biapenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN4C=NC=[N ]4C3)=C(N2C1=O)C([O-])=O	PLASMA	YR5U3L9ZH1									?	μg × h/mL	66.1		μg/mL	33.2			UNKNOWN	mg	600		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.pmda.go.jp/drugs/2001/P200100035/53039600_21300AMZ00761_W103_1.pdf#page=8	Homo sapiens		h	2.19		non-Elderly subjects		5			false
830	405		ADULT	71339	350.393	BIAPENEM	Biapenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN4C=NC=[N ]4C3)=C(N2C1=O)C([O-])=O	PLASMA	YR5U3L9ZH1									?	μg × h/mL	91.9		μg/mL	40.2			UNKNOWN	mg	600		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.pmda.go.jp/drugs/2001/P200100035/53039600_21300AMZ00761_W103_1.pdf#page=8	Homo sapiens		h	1.59		Elderly subjects (75~84 y)		5			false
831	405		ADULT	71339	350.393	BIAPENEM	Biapenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN4C=NC=[N ]4C3)=C(N2C1=O)C([O-])=O	PLASMA	YR5U3L9ZH1									?	μg × h/mL	70.1		μg/mL	33.8			UNKNOWN	mg	600		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.pmda.go.jp/drugs/2001/P200100035/53039600_21300AMZ00761_W103_1.pdf#page=8	Homo sapiens		h	1.45		Elderly subjects (65~74 y)		5			false
832	406		ADULT	2448	420.315	BROMPERIDOL	Bromperidol	OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C3=CC=C(Br)C=C3	PLASMA	LYH6F7I22E									∞	ng × h/mL	150		ng/mL	8.5			UNKNOWN	mg/kg bw	0.18		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16915578/	Homo sapiens		h	20.4				13			false
833	406		ADULT	2448	420.315	BROMPERIDOL	Bromperidol	OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C3=CC=C(Br)C=C3	PLASMA	LYH6F7I22E							96		t	ng × h/mL	54.69		ng/mL	2.38			RECOMMENDED	mg	6		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/300119_1179028C1104_1_101_1F.pdf#page=24	Homo sapiens		h	38.7				12			false
834	406		ADULT	2448	420.315	BROMPERIDOL	Bromperidol	OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C3=CC=C(Br)C=C3	PLASMA	LYH6F7I22E							72		t	ng × h/mL	11.78		ng/mL	0.53			RECOMMENDED	mg	3		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/672173_1179028C1090_2_002_1F.pdf#page=33	Homo sapiens		h	24.1				16			false
835	407		ADULT	2451	393.689	BROTIZOLAM	Brotizolam	CC1=NN=C2CN=C(C3=C(SC(Br)=C3)N12)C4=C(Cl)C=CC=C4	PLASMA	5XZM1R3DKF									?	ng × min/mL	3397		ng/mL	7.3			UNKNOWN	mg	0.5		SINGLE	FASTED					8.4	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6140948/	Homo sapiens		h	5				8			false
836	407		ADULT	2451	393.689	BROTIZOLAM	Brotizolam	CC1=NN=C2CN=C(C3=C(SC(Br)=C3)N12)C4=C(Cl)C=CC=C4	SERUM	5XZM1R3DKF																	UNKNOWN	mg	0.25		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6661376/	Homo sapiens		h	7.37	Day 1	Patients with mild renal impairment		4			false
837	407		ADULT	2451	393.689	BROTIZOLAM	Brotizolam	CC1=NN=C2CN=C(C3=C(SC(Br)=C3)N12)C4=C(Cl)C=CC=C4	SERUM	5XZM1R3DKF																	UNKNOWN	mg	0.25		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6661376/	Homo sapiens		h	7.61	Day 1	Patients with moderate renal impairment		4			false
838	407		ADULT	2451	393.689	BROTIZOLAM	Brotizolam	CC1=NN=C2CN=C(C3=C(SC(Br)=C3)N12)C4=C(Cl)C=CC=C4	SERUM	5XZM1R3DKF																	UNKNOWN	mg	0.25		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6661376/	Homo sapiens		h	6.9		Patients with severe renal impairment		6			false
839	407		ADULT	2451	393.689	BROTIZOLAM	Brotizolam	CC1=NN=C2CN=C(C3=C(SC(Br)=C3)N12)C4=C(Cl)C=CC=C4	PLASMA	5XZM1R3DKF									?	ng × min/mL	5488						UNKNOWN	mg	0.5		SINGLE	FASTED					12.4	UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6661377/	Homo sapiens					Patients with cirrhosis		8			false
840	407		ADULT	2451	393.689	BROTIZOLAM	Brotizolam	CC1=NN=C2CN=C(C3=C(SC(Br)=C3)N12)C4=C(Cl)C=CC=C4	PLASMA	5XZM1R3DKF									?	ng × min/mL	3852						UNKNOWN	mg	0.5		SINGLE	FASTED					9.2	UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6661377/	Homo sapiens					Patients with normal liver function		8			false
841	408		ADULT	656604	223.313	BUCILLAMINE	BUCILLAMINE	CC(C)(S)C(=O)N[C@@H](CS)C(O)=O	BLOOD	R80LRA5WTF									∞	μg × h/L	116.43		μg/mL	39.47			UNKNOWN	mg/kg	42		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/12847560/	Homo sapiens		h	0.41	3-h long intravenous infusion				BUCILLAMINE		false
842	408		ADULT	656604	223.313	BUCILLAMINE	BUCILLAMINE	CC(C)(S)C(=O)N[C@@H](CS)C(O)=O	BLOOD	R80LRA5WTF									∞	μg × h/L	76.99		μg/mL	45.81			UNKNOWN	mg/kg	42		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/12847560/	Homo sapiens		h	0.4	3-h long intravenous infusion				BUCILLAMINE		false
843	408		ADULT	656604	223.313	BUCILLAMINE	BUCILLAMINE	CC(C)(S)C(=O)N[C@@H](CS)C(O)=O	PLASMA	R80LRA5WTF									∞	μg × min/mL	1410.9		μg/mL	4.5			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19546034/	Homo sapiens		min	229.5				20	BUCILLAMINE		false
844	410		ADULT	2515	283.3268	CADRALAZINE	CADRALAZINE	CCOC(=O)NNC1=NN=C(C=C1)N(CC)CC(C)O	PLASMA	8T96I3U713							24		t	ng × h/g	621		ng/g	210			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	10.1007/BF03189745	Homo sapiens		h	2.4				6	cadralazine		false
845	410		ADULT	2515	283.3268	CADRALAZINE	CADRALAZINE	CCOC(=O)NNC1=NN=C(C=C1)N(CC)CC(C)O	PLASMA	8T96I3U713							24		t	ng × h/g	1168		ng/g	379			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	10.1007/BF03189745	Homo sapiens		h	2.3				5	cadralazine		false
846	410		ADULT	2515	283.3268	CADRALAZINE	CADRALAZINE	CCOC(=O)NNC1=NN=C(C=C1)N(CC)CC(C)O	PLASMA	8T96I3U713							24		t	ng × h/g	330		ng/g	130			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	10.1007/BF03189745	Homo sapiens		h	2.4				6	cadralazine		false
847	410		ADULT	2515	283.3268	CADRALAZINE	CADRALAZINE	CCOC(=O)NNC1=NN=C(C=C1)N(CC)CC(C)O	PLASMA	8T96I3U713									∞	pmol × h/mL	1884		pmol/mL	749			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	10.1111/j.1365-2125.1990.tb03672.x	Homo sapiens		h	2.38		slow acetylator phenotype		6	cadralazine		false
848	410		ADULT	2515	283.3268	CADRALAZINE	CADRALAZINE	CCOC(=O)NNC1=NN=C(C=C1)N(CC)CC(C)O	PLASMA	8T96I3U713									∞	pmol × h/mL	1884		pmol/mL	611			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	10.1111/j.1365-2125.1990.tb03672.x	Homo sapiens					fast acetylator phenotype		6	cadralazine		false
849	410		ADULT	2515	283.3268	CADRALAZINE	CADRALAZINE	CCOC(=O)NNC1=NN=C(C=C1)N(CC)CC(C)O	PLASMA	8T96I3U713									∞	μg × h/L	632		μg/L	224			UNKNOWN	mg	15		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	REVIEW	10.2165/00003495-199040040-00005	Homo sapiens		h	1.7		essential hypertension		5	cadralazine		false
850	410		ADULT	2515	283.3268	CADRALAZINE	CADRALAZINE	CCOC(=O)NNC1=NN=C(C=C1)N(CC)CC(C)O	PLASMA	8T96I3U713									∞	μg × h/L	2888		μg/L	568			UNKNOWN	mg	30		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	REVIEW	10.2165/00003495-199040040-00005	Homo sapiens		h	3.1		essential hypertension		6	cadralazine		false
851	415		ADULT	6537431	479.493	CEFTERAM	CEFTERAM	CO\\N=C(/C(=O)N[C@H]1[C@H]2SCC(CN3N=NC(C)=N3)=C(N2C1=O)C(O)=O)C4=CSC(N)=N4	PLASMA	74CQ4Q3N63							6		t	μg × h/mL	2.79		μg/mL	1.32			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18498914/	Homo sapiens		h	1.16	powder suspension [test] Simcere Pharmaceutical Group, Nanjing, China			24	CEFTERAM PIVOXIL		false
852	415		ADULT	6537431	479.493	CEFTERAM	CEFTERAM	CO\\N=C(/C(=O)N[C@H]1[C@H]2SCC(CN3N=NC(C)=N3)=C(N2C1=O)C(O)=O)C4=CSC(N)=N4	PLASMA	74CQ4Q3N63							6		t	μg × h/mL	2.7		μg/mL	1.22			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18498914/	Homo sapiens		h	1.1	tablet [reference] Tomiron ® (Toyama Chemical Co. Ltd., Toyama, Japan)			24	CEFTERAM PIVOXIL		false
853	415		ADULT	6537431	479.493	CEFTERAM	CEFTERAM	CO\\N=C(/C(=O)N[C@H]1[C@H]2SCC(CN3N=NC(C)=N3)=C(N2C1=O)C(O)=O)C4=CSC(N)=N4	PLASMA	74CQ4Q3N63									∞	μg × h/mL	4.76		μg/mL	1.73			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20166432/	Homo sapiens		h	1.33	reference preparation cefteram pivoxil tablets (containing 50mg cefteram pivoxil, Batch NO. LB200l) were purchased from Toyama Chemical Co. Ltd.			24	CEFTERAM PIVOXIL		false
854	415		ADULT	6537431	479.493	CEFTERAM	CEFTERAM	CO\\N=C(/C(=O)N[C@H]1[C@H]2SCC(CN3N=NC(C)=N3)=C(N2C1=O)C(O)=O)C4=CSC(N)=N4	PLASMA	74CQ4Q3N63									∞	μg × h/mL	4.89		μg/mL	1.65			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20166432/	Homo sapiens		h	1.32	test preparation cefteram pivoxil capsules (containing 50mg cefteram pivoxil, Batch NO. 070501) were all provided by Suzhou Dawnrays Pharmaceutical Co. Ltd.			24	CEFTERAM PIVOXIL		false
855	416		ADULT	5284533	362.89	CHLORMADINONE	CHLORMADINONE	CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C	PLASMA	SDS4N642GG	5991		ETHINYL ESTRADIOL	ethinylestradiol	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@]2(O)C#C	423D2T571U	24		t	pg × h/mL	9685		pg/mL	1597.3			RECOMMENDED	mg	2		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16904418/	Homo sapiens		h	25.3							true
856	417		ADULT	2747	262.3489	CIFENLINE	CIFENLINE	C1C(C2=NCCN2)C1(C3=CC=CC=C3)C4=CC=CC=C4	PLASMA	Z7489237QT									?	ng × h/mL	3278		ng/mL	419			UNKNOWN	mg	160		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3783460/	Homo sapiens		h	7.8				18	Cibenzoline		false
857	417		ADULT	2747	262.3489	CIFENLINE	CIFENLINE	C1C(C2=NCCN2)C1(C3=CC=CC=C3)C4=CC=CC=C4	SERUM	Z7489237QT									?	ng × h/mL	3929		ng/mL	1150			UNKNOWN	mg	160		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3783460/	Homo sapiens		h	7.5				18	CIFENLINE		false
858	418		ADULT	2787	468.5818	CLINOFIBRATE	Clinofibrate	CCC(C)(OC1=CC=C(C=C1)C2(CCCCC2)C3=CC=C(OC(C)(CC)C(O)=O)C=C3)C(O)=O	PLASMA	0374EZJ8CU									∞	μg × h/mL	410		μg/mL	22			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23319135/	Homo sapiens		h	18.19				12			false
859	418		ADULT	2787	468.5818	CLINOFIBRATE	Clinofibrate	CCC(C)(OC1=CC=C(C=C1)C2(CCCCC2)C3=CC=C(OC(C)(CC)C(O)=O)C=C3)C(O)=O	PLASMA	0374EZJ8CU									∞	μg × h/mL	580		μg/mL	27			UNKNOWN	mg	600		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23319135/	Homo sapiens		h	21.51				12			false
860	418		ADULT	2787	468.5818	CLINOFIBRATE	Clinofibrate	CCC(C)(OC1=CC=C(C=C1)C2(CCCCC2)C3=CC=C(OC(C)(CC)C(O)=O)C=C3)C(O)=O	PLASMA	0374EZJ8CU									∞	μg × h/mL	240		μg/mL	11			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23319135/	Homo sapiens		h	20.47				12			false
861	418		ADULT	2787	468.5818	CLINOFIBRATE	Clinofibrate	CCC(C)(OC1=CC=C(C=C1)C2(CCCCC2)C3=CC=C(OC(C)(CC)C(O)=O)C=C3)C(O)=O	PLASMA	0374EZJ8CU									∞	μg × h/mL	342.24		μg/mL	17.85			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23849436/	Homo sapiens							12			false
862	418		ADULT	2787	468.5818	CLINOFIBRATE	Clinofibrate	CCC(C)(OC1=CC=C(C=C1)C2(CCCCC2)C3=CC=C(OC(C)(CC)C(O)=O)C=C3)C(O)=O	PLASMA	0374EZJ8CU									∞	μg × h/mL	351.8		μg/mL	11.25			UNKNOWN	mg	400		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23849436/	Homo sapiens							12			false
863	419		ADULT	12492	345.8	clopamide	clopamide		PLASMA	17S83WON0I									?	ng × h/mL	862		ng/mL	91			UNKNOWN	mg	10		MULTIPLE	FED		UNKNOWN				HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3621784/	Homo sapiens		h	10				8	clopamide		false
864	419		ADULT	12492	345.8	clopamide	clopamide		PLASMA	17S83WON0I									?	ng × h/mL	1538		ng/mL	175			UNKNOWN	mg	20		SINGLE	FED		UNKNOWN				HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3621784/	Homo sapiens		h	8.1				8	clopamide		false
865	419		ADULT	12492	345.8	clopamide	clopamide		PLASMA	17S83WON0I									?	ng × h/mL	543		ng/mL	63			UNKNOWN	mg	5		SINGLE	FED		UNKNOWN	0			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3621784/	Homo sapiens		h	11.6				8	clopamide		false
866	421		ADULT	5362116	452.5	Delapril	Delapril		PLASMA	W77UAL9THI									∞	ng × h/mL	206		ng/mL	173			UNKNOWN	mg	30		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/13677245/	Homo sapiens							18	Delapril		false
867	421		ADULT	5362116	452.5	delapril hydrochloride	delapril		PLASMA	W77UAL9THI									∞	ng × h/mL	218		ng/mL	136			UNKNOWN	mg	30		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/13677245/	Homo sapiens					Adults = elderly aged 65-73 years		16	delapril hydrochloride		false
868	421		ADULT	5362116	452.5	Delapril	Delapril		PLASMA	W77UAL9THI									∞	ng × h/mL	206		ng/mL	221			UNKNOWN	mg	30		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/14558436/	Homo sapiens		h	0.45				18	Delapril hydrochloride		false
869	421		ADULT	5362116	452.5	delapril	delapril		PLASMA	W77UAL9THI									?	ng × h/mL	572		ng/mL	489			UNKNOWN	mg	30		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3802709/	Homo sapiens		h	0.3				9	delapril hydrochloride		false
870	422		ADULT	3037918	255.3978	DIMEMORFAN	DIMEMORFAN	CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C)C=C4	PLASMA	623OAC38YU									∞	μg × h/L	28.46		μg/L	2.19			RECOMMENDED	mg	20		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25262813/	Homo sapiens		h	11				12	DIMEMORFAN		false
871	422		ADULT	3037918	255.3978	DIMEMORFAN	DIMEMORFAN	CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C)C=C4	PLASMA	623OAC38YU									∞	μg × h/L	57.26		μg/L	5.3			HIGHEST STUDIED	mg	40		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25262813/	Homo sapiens		h	10.8				12	DIMEMORFAN		false
872	422		ADULT	3037918	255.3978	DIMEMORFAN	DIMEMORFAN	CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C)C=C4	PLASMA	623OAC38YU									∞	μg × h/L	12.14		μg/L	0.94			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25262813/	Homo sapiens		h	10.4				12	DIMEMORFAN		false
873	422		ADULT	3037918	255.3978	DIMEMORFAN	DIMEMORFAN	CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C)C=C4	PLASMA	623OAC38YU									∞	ng × h/mL	46.9		ng/mL	2.71			RECOMMENDED	mg	20		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28243685/	Homo sapiens		h	10.6				12	DIMEMORFAN PHOSPHATE		false
874	422		ADULT	3037918	255.3978	DIMEMORFAN	DIMEMORFAN	CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C)C=C4	PLASMA	623OAC38YU									∞	ng × h/mL	117		ng/mL	6.19			HIGHEST STUDIED	mg	40		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28243685/	Homo sapiens		h	10.8				12	DIMEMORFAN PHOSPHATE		false
875	422		ADULT	3037918	255.3978	DIMEMORFAN	DIMEMORFAN	CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C)C=C4	PLASMA	623OAC38YU									∞	ng × h/mL	49.3		ng/mL	2.95			RECOMMENDED	mg	20		SINGLE	HIGH-FAT						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28243685/	Homo sapiens		h	11.6				12	DIMEMORFAN PHOSPHATE		false
876	422		ADULT	3037918	255.3978	DIMEMORFAN	DIMEMORFAN	CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C)C=C4	PLASMA	623OAC38YU									∞	ng × h/mL	124		ng/mL	6.52			RECOMMENDED	mg	20		STEADY-STATE	HIGH-FAT		day	3			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28243685/	Homo sapiens		h	10.7	4 days dosing			12	DIMEMORFAN PHOSPHATE		false
877	422		ADULT	3037918	255.3978	DIMEMORFAN	DIMEMORFAN	CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C)C=C4	PLASMA	623OAC38YU									∞	ng × h/mL	21.5		ng/mL	1.03			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28243685/	Homo sapiens		h	11.4				12	DIMEMORFAN PHOSPHATE		false
878	423		ADULT	55483	356.5017	DOPEXAMINE	DOPEXAMINE	OC1=C(O)C=C(CCNCCCCCCNCCC2=CC=CC=C2)C=C1	PLASMA	398E7Z7JB5													mg/L	124			UNKNOWN	μg/kg	180		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/1970288/	Homo sapiens		min	7	1.0 to 4.0 ug/kg/min over 60 minutes (total dose 180 ug/kg)			10	DOPEXAMINE HYDROCHLORIDE		false
879	423		ADULT	55483	356.5017	DOPEXAMINE	DOPEXAMINE	OC1=C(O)C=C(CCNCCCCCCNCCC2=CC=CC=C2)C=C1	BLOOD	398E7Z7JB5													ng/mL	236			UNKNOWN	μg/kg/min	2		SINGLE	UNKNOWN				anhepatic period of liver transplantation		UNHEALTHY	Intravenous	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8148227/	Homo sapiens				48h infusion	orthotopic liver transplantation		5	DOPEXAMINE HYDROCHLORIDE		false
880	425		ADULT	3191	469.6576	EBASTINE	Ebastine	CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)OC(C3=CC=CC=C3)C4=CC=CC=C4	PLASMA	TQD7Q784P1							24		t	ng × h/mL	25.9		ng/mL	5.97			UNKNOWN	mg	20		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17518511/	Homo sapiens		h	37.3	Day 5	Severe renal imparment		8			false
881	425		ADULT	3191	469.6576	EBASTINE	Ebastine	CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)OC(C3=CC=CC=C3)C4=CC=CC=C4	PLASMA	TQD7Q784P1							24		t	ng × h/mL	30.3		ng/mL	5.98			UNKNOWN	mg	20		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17518511/	Homo sapiens		h	24.8	Day 5			12			false
882	425		ADULT	3191	469.6576	EBASTINE	Ebastine	CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)OC(C3=CC=CC=C3)C4=CC=CC=C4	PLASMA	TQD7Q784P1							24		t	ng × h/mL	21.5		ng/mL	5.58			UNKNOWN	mg	20		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17518511/	Homo sapiens		h	23.6	Day 5			8			false
883	425		ADULT	3191	469.6576	EBASTINE	Ebastine	CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)OC(C3=CC=CC=C3)C4=CC=CC=C4	PLASMA	TQD7Q784P1							24		t	ng × h/mL	16.8		ng/mL	3.71			UNKNOWN	mg	20		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17518511/	Homo sapiens		h	5.3	Day 1			12			false
884	425		ADULT	3191	469.6576	EBASTINE	Ebastine	CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)OC(C3=CC=CC=C3)C4=CC=CC=C4	PLASMA	TQD7Q784P1							24		t	ng × h/mL	28.8		ng/mL	5.49			UNKNOWN	mg	20		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17518511/	Homo sapiens		h	24.3	Day 5	Mild renal impairment		8			false
885	425			3191	469.6576	EBASTINE	Ebastine	CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)OC(C3=CC=CC=C3)C4=CC=CC=C4	PLASMA	TQD7Q784P1							24		t	ng × h/mL	21.5		ng/mL	4.15			UNKNOWN	mg	20		SINGLE	UNKNOWN						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17518511/	Homo sapiens		h	5.2		Severe renal impairment		8			false
886	425		ADULT	3191	469.6576	EBASTINE	Ebastine	CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)OC(C3=CC=CC=C3)C4=CC=CC=C4	PLASMA	TQD7Q784P1							24		t	ng × h/mL	16.5		ng/mL	3.91			UNKNOWN	mg	20		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17518511/	Homo sapiens		h	4.4	Day 1	Moderate renal impairment		8			false
887	425		ADULT	3191	469.6576	EBASTINE	Ebastine	CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)OC(C3=CC=CC=C3)C4=CC=CC=C4	PLASMA	TQD7Q784P1							24		t	ng × h/mL	14.9		ng/mL	3.31			UNKNOWN	mg	20		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17518511/	Homo sapiens		h	5.8	Day 1	Mild renal impairment		8			false
888	425		ADULT	65820|40479695	499.6405	CAREBASTINE	Carebastine	CC(C)(C(O)=O)C1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)OC(C3=CC=CC=C3)C4=CC=CC=C4	PLASMA	75DLN707DO							72		t	ng × h/mL	1417		ng/mL	53.4			DEFINED DAILY	mg	5		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400093_4490019F1028_1_023_1F.pdf#page=26	Homo sapiens		h	18.1		PMDA Drug information page 26		23	Ebastel		false
889	425		ADULT	65820|40479695	499.6405	CAREBASTINE	Carebastine	CC(C)(C(O)=O)C1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)OC(C3=CC=CC=C3)C4=CC=CC=C4	PLASMA	75DLN707DO							72		t	ng × h/mL	2630		ng/mL	97.7			DEFINED DAILY	mg	10		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400093_4490019F1028_1_023_1F.pdf#page=26	Homo sapiens		h	17.6		PMDA Drug information page 26		24	Ebastel		false
890	425			3191	469.6576	EBASTINE	Ebastine	CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)OC(C3=CC=CC=C3)C4=CC=CC=C4	SERUM	TQD7Q784P1																										Human serum protein binding: >99.9% (in vitro, Human serum, equilibrium dialysis)	0.1				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400093_4490019F1028_1_023_1F.pdf#page=29	Homo sapiens										false
891	425			65820|40479695	499.6405	CAREBASTINE	Carebastine	CC(C)(C(O)=O)C1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)OC(C3=CC=CC=C3)C4=CC=CC=C4	PLASMA	75DLN707DO																										Human plasma protein binding: 97.4~97.7% (in vitro, Human plasma, ultrafiltration)	2.3				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400093_4490019F1028_1_023_1F.pdf#page=29	Homo sapiens										false
892	426		ADULT	4021	174.1992	EDARAVONE	CC1=NN(C(=O)C1)C2=CC=CC=C2	CC1=NN(C(=O)C1)C2=CC=CC=C2	PLASMA	S798V6YJRP									∞	mg × h/L	5.24		μg/mL	2.48			RECOMMENDED	mg	30		MULTIPLE	FASTED		day	2			HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22762844/	Homo sapiens		h	2.52							false
893	426		ADULT	4021	174.2	Edaravone		CC1=NN(C(=O)C1)C2=CC=CC=C2	PLASMA	S798V6YJRP							24		t	ng × h/mL	1373.5		ng/mL	1049.3			RECOMMENDED	mg	60		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28872908/	Homo sapiens		h	0.86							false
894	426		ADULT	4021	174.1992	EDARAVONE	CC1=NN(C(=O)C1)C2=CC=CC=C2	CC1=NN(C(=O)C1)C2=CC=CC=C2	PLASMA	S798V6YJRP									∞	ng × h/mL	5576.72		ng/mL	2030.2			RECOMMENDED	mg	30		SINGLE	FASTED						HEALTHY	Sublingual	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30241688/	Homo sapiens		h	2.83							false
895	426		ADULT	4021	174.1992	EDARAVONE	CC1=NN(C(=O)C1)C2=CC=CC=C2	CC1=NN(C(=O)C1)C2=CC=CC=C2	PLASMA	S798V6YJRP									∞	ng × h/mL	5981.91		ng/mL	2354			RECOMMENDED	mg	30		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30241688/	Homo sapiens		h	3.04							false
896	426		UNKNOWN	4021	174.1992	EDARAVONE	CC1=NN(C(=O)C1)C2=CC=CC=C2	CC1=NN(C(=O)C1)C2=CC=CC=C2	PLASMA	S798V6YJRP																	UNKNOWN				UNKNOWN	UNKNOWN		UNKNOWN			8	UNKNOWN	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209176lbl.pdf	Homo sapiens		h	5.25							false
897	427		ADULT	119171	631.6552	EFONIDIPINE	Efonidipine	CC1=C(C(C2=CC=CC(=C2)[N ]([O-])=O)C(=C(C)N1)P3(=O)OCC(C)(C)CO3)C(=O)OCCN(CC4=CC=CC=C4)C5=CC=CC=C5	PLASMA	40ZTP2T37Q							24		t	ng × h/mL	4.1		ng/mL	1.7			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/3/380077_2149034F1020_3_1F.pdf#page=22	Homo sapiens		h	2.9	Efonidipine hydrochloride ethanolate	PMDA Drug information page 22		6	Landel tablets		false
898	427		ADULT	119171	631.6552	EFONIDIPINE	Efonidipine	CC1=C(C(C2=CC=CC(=C2)[N ]([O-])=O)C(=C(C)N1)P3(=O)OCC(C)(C)CO3)C(=O)OCCN(CC4=CC=CC=C4)C5=CC=CC=C5	PLASMA	40ZTP2T37Q							24		t	ng × h/mL	25.4		ng/mL	11.7			DEFINED DAILY	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/3/380077_2149034F1020_3_1F.pdf#page=22	Homo sapiens		h	1.4	Efonidipine hydrochloride ethanolate	PMDA Drug information page 22		5	Landel tablets		false
899	427		ADULT	119171	631.6552	EFONIDIPINE	Efonidipine	CC1=C(C(C2=CC=CC(=C2)[N ]([O-])=O)C(=C(C)N1)P3(=O)OCC(C)(C)CO3)C(=O)OCCN(CC4=CC=CC=C4)C5=CC=CC=C5	PLASMA	40ZTP2T37Q							24		t	ng × h/mL	57.6		ng/mL	17.9			DEFINED DAILY	mg	40		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/3/380077_2149034F1020_3_1F.pdf#page=22	Homo sapiens		h	2.2		PMDA Drug information page 22		6			false
900	427		ADULT	119171	631.6552	EFONIDIPINE	Efonidipine	CC1=C(C(C2=CC=CC(=C2)[N ]([O-])=O)C(=C(C)N1)P3(=O)OCC(C)(C)CO3)C(=O)OCCN(CC4=CC=CC=C4)C5=CC=CC=C5	PLASMA	40ZTP2T37Q							8		t	ng × h/mL	31.5		ng/mL	12.9			DEFINED DAILY	mg	20		SINGLE	UNKNOWN				PMDA Drug information page 23		UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/3/380077_2149034F1020_3_1F.pdf#page=23	Homo sapiens		h	2.1		Resistant hypertension (RH) patients		6			false
901	427		ADULT	119171	631.6552	EFONIDIPINE	Efonidipine	CC1=C(C(C2=CC=CC(=C2)[N ]([O-])=O)C(=C(C)N1)P3(=O)OCC(C)(C)CO3)C(=O)OCCN(CC4=CC=CC=C4)C5=CC=CC=C5	PLASMA	40ZTP2T37Q							8		t	ng × h/mL	34.7		ng/mL	10.8			DEFINED DAILY	mg	20		SINGLE	UNKNOWN				PMDA Drug information page 23		UNKNOWN	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/3/380077_2149034F1020_3_1F.pdf#page=23	Homo sapiens		h	2		Essential hypertension (EH) patients		6			false
902	427		ADULT	119171	631.6552	EFONIDIPINE	Efonidipine	CC1=C(C(C2=CC=CC(=C2)[N ]([O-])=O)C(=C(C)N1)P3(=O)OCC(C)(C)CO3)C(=O)OCCN(CC4=CC=CC=C4)C5=CC=CC=C5	PLASMA	40ZTP2T37Q							8		t	ng × h/mL	61.7		ng/mL	19.7			DEFINED DAILY	mg	30		SINGLE	UNKNOWN				PMDA Drug information page 23		UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/3/380077_2149034F1020_3_1F.pdf#page=23	Homo sapiens		h	1.8		Essential hypertension (EH) patients		5			false
903	427		ADULT	119171	631.6552	EFONIDIPINE	Efonidipine	CC1=C(C(C2=CC=CC(=C2)[N ]([O-])=O)C(=C(C)N1)P3(=O)OCC(C)(C)CO3)C(=O)OCCN(CC4=CC=CC=C4)C5=CC=CC=C5	PLASMA	40ZTP2T37Q							8		t	ng × h/mL	68.8		ng/mL	26.1			DEFINED DAILY	mg	30		SINGLE	UNKNOWN				PMDA Drug information page 23		UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/3/380077_2149034F1020_3_1F.pdf#page=23	Homo sapiens		h	1.7		Resistant hypertension (RH) patients		5			false
904	427			119171	631.6552	EFONIDIPINE	Efonidipine	CC1=C(C(C2=CC=CC(=C2)[N ]([O-])=O)C(=C(C)N1)P3(=O)OCC(C)(C)CO3)C(=O)OCCN(CC4=CC=CC=C4)C5=CC=CC=C5	SERUM	40ZTP2T37Q																										Protein binding in human serum: 99.4~99.8% (200~2000ng/mL, 14C-efonidipine hydrochloride ethanolate, gel-filtration)	0.2				DRUG LABEL	https://www.info.pmda.go.jp/go/interview/3/380077_2149034F1020_3_1F.pdf#page=25	Homo sapiens					PMDA Drug information page 25					false
905	428		ADULT	1549120	319.399	EPALRESTAT	epalrestat	CC(=C/C1=CC=CC=C1)\\C=C2/SC(=S)N(CC(O)=O)C2=O	PLASMA	424DV0807X									∞	μg × h/mL	6.4		μg/mL	3.9			DEFINED DAILY	mg	50		SINGLE	FASTED				Epalrestat is highly protein-bound, with a protein-binding rate of 90.1%	9.9	HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/18447661/	Homo sapiens								epalrestat		false
906	429		ADULT	3236	259.3865	EPERISONE	Eperisone	CCC1=CC=C(C=C1)C(=O)C(C)CN2CCCCC2	PLASMA	2M2P0551D3									?	ng × h/mL	21.08		ng/mL	7.9			DEFINED DAILY	mg	150		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	http://www.info.pmda.go.jp/go/interview/1/170033_1249009D1030_1_008_1F.pdf#page=24	Homo sapiens		h	1.75	Day 14			8	Eperisone hydrochloride		false
907	429		ADULT	3236	259.3865	EPERISONE	Eperisone	CCC1=CC=C(C=C1)C(=O)C(C)CN2CCCCC2	PLASMA	2M2P0551D3									?	ng × h/mL	19.68		ng/mL	7.5			DEFINED DAILY	mg	150		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	http://www.info.pmda.go.jp/go/interview/1/170033_1249009D1030_1_008_1F.pdf#page=24	Homo sapiens		h	1.6	Day 1			8	Eperisone hydrochloride		false
908	429		ADULT	3236	259.3865	EPERISONE	Eperisone	CCC1=CC=C(C=C1)C(=O)C(C)CN2CCCCC2	PLASMA	2M2P0551D3									?	ng × h/mL	20.29		ng/mL	7.8			DEFINED DAILY	mg	150		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	http://www.info.pmda.go.jp/go/interview/1/170033_1249009D1030_1_008_1F.pdf#page=24	Homo sapiens		h	1.68	Day 8			8	Eperisone hydrochloride		false
909	429		ADULT	3236	259.3865	EPERISONE	Eperisone	CCC1=CC=C(C=C1)C(=O)C(C)CN2CCCCC2	PLASMA	2M2P0551D3																						UNKNOWN				Human plasma protein binding: 95.8% (109ng/mL eperisone hydrochloride)	4.2	HEALTHY		MALE	OTHER GOV'T	http://www.info.pmda.go.jp/go/interview/1/170033_1249009D1030_1_008_1F.pdf#page=25	Homo sapiens							5			false
910	429		ADULT	3236	259.3865	EPERISONE	Eperisone	CCC1=CC=C(C=C1)C(=O)C(C)CN2CCCCC2	PLASMA	2M2P0551D3							8		∞	ng × h/mL	8.86		ng/mL	2			UNKNOWN	mg	50		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	http://www.info.pmda.go.jp/go/interview/1/470007_1249009F1473_1_V09_1F.pdf#page=20	Homo sapiens		h	3.37				6			false
911	429		ADULT	3236	259.3865	EPERISONE	Eperisone	CCC1=CC=C(C=C1)C(=O)C(C)CN2CCCCC2	PLASMA	2M2P0551D3							8		∞	ng × h/mL	13.2		ng/mL	4.21			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	http://www.info.pmda.go.jp/go/interview/1/470007_1249009F1473_1_V09_1F.pdf#page=20	Homo sapiens		h	2.55				6			false
912	429		ADULT	3236	259.3865	EPERISONE	Eperisone	CCC1=CC=C(C=C1)C(=O)C(C)CN2CCCCC2	PLASMA	2M2P0551D3							8		∞	ng × h/mL	20.27		ng/mL	7.18			UNKNOWN	mg	150		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	http://www.info.pmda.go.jp/go/interview/1/470007_1249009F1473_1_V09_1F.pdf#page=20	Homo sapiens		h	2.93				6			false
913	429		ADULT	3236	259.3865	EPERISONE	Eperisone	CCC1=CC=C(C=C1)C(=O)C(C)CN2CCCCC2	PLASMA	2M2P0551D3									∞	ng × h/mL	22.91		ng/mL	3.46			DEFINED DAILY	mg	150		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32024955/	Homo sapiens		h	1.99	Osmotic tablets			12			false
914	429		ADULT	3236	259.3865	EPERISONE	Eperisone	CCC1=CC=C(C=C1)C(=O)C(C)CN2CCCCC2	PLASMA	2M2P0551D3									∞	ng × h/mL	20.88		ng/mL	7.65			DEFINED DAILY	mg	150		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32024955/	Homo sapiens		h	1.81	Immediate-release tablets			12			false
915	430		ADULT	65632	249.307	ERDOSTEINE	Erdosteine	OC(=O)CSCC(=O)NC1CCSC1=O	PLASMA	76J0853EKA	91268	198.1793	THEOPHYLLINE	Theophylline	O.CN1C2=C(N=CN2)C(=O)N(C)C1=O	C137DTR5RG	24		t	μg × h/mL	3.55		μg/mL	1.15			UNKNOWN	mg	300		MULTIPLE	FASTED		day	3			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2126836/	Homo sapiens		h	1.36	Day 15, 900mg single dose PK	Patients with chronic hypersecretive obstructive bronchitis		20			true
916	430		ADULT	10199236	267.323	Homocysteine,N-[[(carboxymethyl)thio]acetyl]-		C(CS)C(C(=O)O)NC(=O)CSCC(=O)O	PLASMA		91268	198.1793	THEOPHYLLINE	Theophylline	O.CN1C2=C(N=CN2)C(=O)N(C)C1=O	C137DTR5RG	24		t	μg × h/mL	12.32		μg/mL	3.45			UNKNOWN	mg	900		SINGLE	FASTED						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2126836/	Homo sapiens		h	1.68		Patients with chronic hypersecretive obstructive bronchitis		20			true
917	430		ADULT	65632	249.307	ERDOSTEINE	Erdosteine	OC(=O)CSCC(=O)NC1CCSC1=O	PLASMA	76J0853EKA	91268	198.1793	THEOPHYLLINE	Theophylline	O.CN1C2=C(N=CN2)C(=O)N(C)C1=O	C137DTR5RG	24		t	μg × h/mL	3.71		μg/mL	1.34			UNKNOWN	mg	900		SINGLE	FASTED						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2126836/	Homo sapiens		h	1.29		Patients with chronic hypersecretive obstructive bronchitis		20			true
918	430		ADULT	10199236	267.323	Homocysteine,N-[[(carboxymethyl)thio]acetyl]-		C(CS)C(C(=O)O)NC(=O)CSCC(=O)O	PLASMA		91268	198.1793	THEOPHYLLINE	Theophylline	O.CN1C2=C(N=CN2)C(=O)N(C)C1=O	C137DTR5RG	24		t	μg × h/mL	12.23		μg/mL	3.17			UNKNOWN	mg	300		MULTIPLE	FASTED		day	3			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2126836/	Homo sapiens		h	1.49	Day 15, 900mg single dose PK	Patients with chronic hypersecretive obstructive bronchitis		20			true
919	430		ADULT	65632	249.307	ERDOSTEINE	Erdosteine	OC(=O)CSCC(=O)NC1CCSC1=O	PLASMA	76J0853EKA									∞	μg × h/mL	3.492		μg/mL	1.419			UNKNOWN	mg	600		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ingentaconnect.com/content/jpa/cjpa/2007/00000027/00000010/art00010	Homo sapiens		h	2.478	Tablets			20			false
920	430		ADULT	65632	249.307	ERDOSTEINE	Erdosteine	OC(=O)CSCC(=O)NC1CCSC1=O	PLASMA	76J0853EKA									∞	μg × h/mL	3.523		μg/mL	1.594			UNKNOWN	mg	600		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ingentaconnect.com/content/jpa/cjpa/2007/00000027/00000010/art00010	Homo sapiens		h	2.603				20			false
921	431		ADULT	3307	342.846	ETIZOLAM	Etizolam	CCC1=CC2=C(S1)N3C(C)=NN=C3CN=C2C4=C(Cl)C=CC=C4	PLASMA	A76XI0HL37							24		t	ng × h/mL	105		ng/mL	17.3			UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16261363/	Homo sapiens		h	10.5		CYP2C19 EM		12			false
922	431		ADULT	3307	342.846	ETIZOLAM	Etizolam	CCC1=CC2=C(S1)N3C(C)=NN=C3CN=C2C4=C(Cl)C=CC=C4	PLASMA	A76XI0HL37							24		t	ng × h/mL	158		ng/mL	20.7			UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16261363/	Homo sapiens		h	14.8		CYP2C19 PM		9			false
923	431		ADULT	3307	342.846	ETIZOLAM	Etizolam	CCC1=CC2=C(S1)N3C(C)=NN=C3CN=C2C4=C(Cl)C=CC=C4	PLASMA	A76XI0HL37							24		t	ng × h/mL	158		ng/mL	20.7			UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16261363/	Homo sapiens		h	14.8		CYP2C19 PM		9			false
924	431		ADULT	3307	342.846	ETIZOLAM	Etizolam	CCC1=CC2=C(S1)N3C(C)=NN=C3CN=C2C4=C(Cl)C=CC=C4	PLASMA	A76XI0HL37							24		t	ng × h/mL	59.4		ng/mL	15.4			UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16261363/	Homo sapiens		h	8.3		No CYP2C19 alleles mutated		5			false
925	431		ADULT	3307	342.846	ETIZOLAM	Etizolam	CCC1=CC2=C(S1)N3C(C)=NN=C3CN=C2C4=C(Cl)C=CC=C4	PLASMA	A76XI0HL37							24		t	ng × h/mL	158		ng/mL	20.7			UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16261363/	Homo sapiens		h	14.8		Two CYP2C19 alleles mutated		9			false
926	431		ADULT	3307	342.846	ETIZOLAM	Etizolam	CCC1=CC2=C(S1)N3C(C)=NN=C3CN=C2C4=C(Cl)C=CC=C4	PLASMA	A76XI0HL37							24		t	ng × h/mL	138		ng/mL	18.7			UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16261363/	Homo sapiens		h	12		One CYP2C19 allele mutated		7			false
927	431		ADULT	3307	342.846	ETIZOLAM	Etizolam	CCC1=CC2=C(S1)N3C(C)=NN=C3CN=C2C4=C(Cl)C=CC=C4	PLASMA	A76XI0HL37													ng/mL	8.3			UNKNOWN	mg	0.5		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2065698/	Homo sapiens		h	3.4				6			false
928	431		ADULT	3307	342.846	ETIZOLAM	Etizolam	CCC1=CC2=C(S1)N3C(C)=NN=C3CN=C2C4=C(Cl)C=CC=C4	PLASMA	A76XI0HL37									?	ng × h/mL	46.1		ng/mL	9.3			UNKNOWN	mg	0.5		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2065698/	Homo sapiens		h	3.5	Day 8 (15th dose)			6			false
929	431		ADULT	3307	342.846	ETIZOLAM	Etizolam	CCC1=CC2=C(S1)N3C(C)=NN=C3CN=C2C4=C(Cl)C=CC=C4	PLASMA	A76XI0HL37							24		t	ng × h/mL	266.66		ng/mL	35.25			UNKNOWN	mg	0.5		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400061_1179025F1352_1_902_1F.pdf#page=22	Homo sapiens		h	12.24				12			false
930	431		ADULT	3307	342.846	ETIZOLAM	Etizolam	CCC1=CC2=C(S1)N3C(C)=NN=C3CN=C2C4=C(Cl)C=CC=C4	PLASMA	A76XI0HL37							24		t	ng × h/mL	277.07		ng/mL	40.39			RECOMMENDED	mg	1		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400061_1179025F1352_1_902_1F.pdf#page=23	Homo sapiens		h	13.26				12			false
931	431			3307	342.846	ETIZOLAM	Etizolam	CCC1=CC2=C(S1)N3C(C)=NN=C3CN=C2C4=C(Cl)C=CC=C4	PLASMA	A76XI0HL37																										Human plasma protein binding: 93%	7				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400061_1179025F1352_1_902_1F.pdf#page=24	Homo sapiens										false
932	434		ADULT	134669|36689154	179.237	FUDOSTEINE	fudosteine	N[C@@H](CSCCCO)C(O)=O	PLASMA	UR9VPI71PT									∞	mg × h/mL	24.91		mg/mL	11.75			RECOMMENDED	mg	400		MULTIPLE	FASTED		day	3			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16898073/	Homo sapiens		h	2.4				9	fudosteine		false
933	434		ADULT	134669|36689154	179.237	FUDOSTEINE	fudosteine	N[C@@H](CSCCCO)C(O)=O	PLASMA	UR9VPI71PT									∞	μg × h/mL	23.95		μg/mL	10.13			UNKNOWN	mg	400		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16898073/	Homo sapiens		h	2.33				10	fudosteine		false
934	435		ADULT	1234	484.6276	GALLOPAMIL	Gallopamil	COC1=CC(=CC(OC)=C1OC)C(CCCN(C)CCC2=CC(OC)=C(OC)C=C2)(C#N)C(C)C	SERUM	39WPC8JHR8																						UNKNOWN				6.3~8.75%, 10ng/mL gallopamil, equilibrium dialysis	7.5	HEALTHY		MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3443143/	Homo sapiens							20			false
935	435		ADULT	12883723	484.6276	GALLOPAMIL, (R)-	Gallopamil, (R)-	COC1=CC(=CC(OC)=C1OC)[C@](CCCN(C)CCC2=CC(OC)=C(OC)C=C2)(C#N)C(C)C	SERUM	V8KE5XTM0I																										Human serum protein binding: 96% (2h after a single 50mg pseudo racemate (25mg each of (R)-/(S)- forms) dose,  equilibrium dialysis)	4	HEALTHY		UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8398599/	Homo sapiens							6			false
936	435		ADULT	6603929	484.6276	GALLOPAMIL, (S)-	Gallopamil, (S)-	COC1=CC(=CC(OC)=C1OC)[C@@](CCCN(C)CCC2=CC(OC)=C(OC)C=C2)(C#N)C(C)C	SERUM	5X7S7C93QM																						UNKNOWN				Human serum protein binding:  94.3% (2h after a single 50mg pseudo racemate (25mg each of (R)-/(S)- forms) dose,  equilibrium dialysis)	5.7	HEALTHY		UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8398599/	Homo sapiens							6			false
937	435		ADULT	1234	484.6276	GALLOPAMIL	Gallopamil	COC1=CC(=CC(OC)=C1OC)C(CCCN(C)CCC2=CC(OC)=C(OC)C=C2)(C#N)C(C)C	PLASMA	39WPC8JHR8							12		t	ng × h/mL	206		ng/mL	61.1			UNKNOWN	mg	80		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8981554/	Homo sapiens		h	4.4	Day 1			10			false
938	435		ADULT	1234	484.6276	GALLOPAMIL	Gallopamil	COC1=CC(=CC(OC)=C1OC)C(CCCN(C)CCC2=CC(OC)=C(OC)C=C2)(C#N)C(C)C	PLASMA	39WPC8JHR8							12		t	ng × h/mL	295.2		ng/mL	77			UNKNOWN	mg	80		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8981554/	Homo sapiens		h	3.6	Day 28			10			false
939	435		ADULT	12883723	484.6276	GALLOPAMIL, (R)-	Gallopamil, (R)-	COC1=CC(=CC(OC)=C1OC)[C@](CCCN(C)CCC2=CC(OC)=C(OC)C=C2)(C#N)C(C)C	SERUM	V8KE5XTM0I									?	nM × h	196.9		nM	117.8			UNKNOWN	mg	50		SINGLE	FASTED					3.9	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9190842/	Homo sapiens		h	4.7				6	50mg [RS]-gallopamil HCl (25mg (R)- and 25mg (S)-forms)		false
940	435		ADULT	6603929	484.6276	GALLOPAMIL, (S)-	Gallopamil, (S)-	COC1=CC(=CC(OC)=C1OC)[C@@](CCCN(C)CCC2=CC(OC)=C(OC)C=C2)(C#N)C(C)C	SERUM	5X7S7C93QM									?	nM × h	187.8		nM	96.4			UNKNOWN	mg	50		SINGLE	FASTED					5.6	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9190842/	Homo sapiens		h	5.8				6	50mg [RS]-gallopamil HCl (25mg (R)- and 25mg (S)-forms)		false
941	435		ADULT	12883723	484.6276	GALLOPAMIL, (R)-	Gallopamil, (R)-	COC1=CC(=CC(OC)=C1OC)[C@](CCCN(C)CCC2=CC(OC)=C(OC)C=C2)(C#N)C(C)C	SERUM	V8KE5XTM0I									?	nM × h	79.5		nM	36.8			UNKNOWN	mg	25		SINGLE	FASTED					4	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9190842/	Homo sapiens		h	6				6	25mg [R]-gallopamil HCl		false
942	435		ADULT	6603929	484.6276	GALLOPAMIL, (S)-	Gallopamil, (S)-	COC1=CC(=CC(OC)=C1OC)[C@@](CCCN(C)CCC2=CC(OC)=C(OC)C=C2)(C#N)C(C)C	SERUM	5X7S7C93QM									?	nM × h	111.9		nM	50.9			UNKNOWN	mg	25		SINGLE	FASTED					5.9	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9190842/	Homo sapiens		h	6.7				6	25mg [S]-gallopamil HCl		false
943	435		ADULT	12883723	484.6276	GALLOPAMIL, (R)-	Gallopamil, (R)-	COC1=CC(=CC(OC)=C1OC)[C@](CCCN(C)CCC2=CC(OC)=C(OC)C=C2)(C#N)C(C)C	SERUM	V8KE5XTM0I									?	nM × h	574.8		nM	249.1			UNKNOWN	mg	100		SINGLE	FASTED					4.5	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9190842/	Homo sapiens		h	5				6	100mg [R]-gallopamil HCl		false
944	437		ADULT	124093|40461170	426.4127	GARENOXACIN	Garenoxacin	C[C@H]1NCC2=C1C=CC(=C2)C3=C(OC(F)F)C4=C(C=C3)C(=O)C(=CN4C5CC5)C(O)=O	PLASMA	V72H9867WB									∞	μg × h/mL	118.1		μg/mL	8.86			DEFINED DAILY	mg	400		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/400022_6241017F1022_2_007_1F.pdf#page=41	Homo sapiens		h	12.4	circular tablets			19			false
945	437		ADULT	124093|40461170	426.4127	GARENOXACIN	Garenoxacin	C[C@H]1NCC2=C1C=CC(=C2)C3=C(OC(F)F)C4=C(C=C3)C(=O)C(=CN4C5CC5)C(O)=O	PLASMA	V72H9867WB									?	μg × h/mL	75.3		μg/mL	8.36			DEFINED DAILY	mg	400		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/400022_6241017F1022_2_007_1F.pdf#page=43	Homo sapiens		h	11.66	Day 1 PK			6			false
946	437		ADULT	124093|40461170	426.4127	GARENOXACIN	Garenoxacin	C[C@H]1NCC2=C1C=CC(=C2)C3=C(OC(F)F)C4=C(C=C3)C(=O)C(=CN4C5CC5)C(O)=O	PLASMA	V72H9867WB									?	μg × h/mL	110.9		μg/mL	11.06			DEFINED DAILY	mg	400		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/400022_6241017F1022_2_007_1F.pdf#page=43	Homo sapiens		h	9.76	Day 7 PK			6			false
947	437		ADULT	124093|40461170	426.4127	GARENOXACIN	Garenoxacin	C[C@H]1NCC2=C1C=CC(=C2)C3=C(OC(F)F)C4=C(C=C3)C(=O)C(=CN4C5CC5)C(O)=O	PLASMA	V72H9867WB									?	μg × h/mL	114.9		μg/mL	10.9			DEFINED DAILY	mg	400		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/400022_6241017F1022_2_007_1F.pdf#page=43	Homo sapiens		h	10.67	Day 14 PK			6			false
948	437		ADULT	124093|40461170	426.4127	GARENOXACIN	Garenoxacin	C[C@H]1NCC2=C1C=CC(=C2)C3=C(OC(F)F)C4=C(C=C3)C(=O)C(=CN4C5CC5)C(O)=O	SERUM	V72H9867WB																	DEFINED DAILY	mg	400		SINGLE	FASTED				human serum protein binding: 79~80% (400mg single oral dose, after 3 or 12 h)	20	HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/400022_6241017F1022_2_007_1F.pdf#page=49	Homo sapiens							14			false
949	437		ADULT	124093|40461170	426.4127	GARENOXACIN	Garenoxacin	C[C@H]1NCC2=C1C=CC(=C2)C3=C(OC(F)F)C4=C(C=C3)C(=O)C(=CN4C5CC5)C(O)=O	PLASMA	V72H9867WB									?	μg × h/mL	21.5		μg/mL	2.09			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700040/480297000_21900AMX01088000_A100_1.pdf#page=25	Homo sapiens		h	14.46		Japanese		6			false
950	437		ADULT	124093|40461170	426.4127	GARENOXACIN	Garenoxacin	C[C@H]1NCC2=C1C=CC(=C2)C3=C(OC(F)F)C4=C(C=C3)C(=O)C(=CN4C5CC5)C(O)=O	PLASMA	V72H9867WB									?	μg × h/mL	100.7		μg/mL	7.43			DEFINED DAILY	mg	400		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700040/480297000_21900AMX01088000_A100_1.pdf#page=25	Homo sapiens		h	12.36		Japanese		6			false
951	437		ADULT	124093|40461170	426.4127	GARENOXACIN	Garenoxacin	C[C@H]1NCC2=C1C=CC(=C2)C3=C(OC(F)F)C4=C(C=C3)C(=O)C(=CN4C5CC5)C(O)=O	PLASMA	V72H9867WB									?	μg × h/mL	48.9		μg/mL	4.89			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700040/480297000_21900AMX01088000_A100_1.pdf#page=25	Homo sapiens		h	12.65		Japanese		6			false
952	437		ADULT	124093|40461170	426.4127	GARENOXACIN	Garenoxacin	C[C@H]1NCC2=C1C=CC(=C2)C3=C(OC(F)F)C4=C(C=C3)C(=O)C(=CN4C5CC5)C(O)=O	PLASMA	V72H9867WB									?	μg × h/mL	165.5		μg/mL	12.34			HIGHEST STUDIED	mg	600		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700040/480297000_21900AMX01088000_A100_1.pdf#page=25	Homo sapiens		h	12.39		Japanese		6			false
953	437		ADULT	124093|40461170	426.4127	GARENOXACIN	Garenoxacin	C[C@H]1NCC2=C1C=CC(=C2)C3=C(OC(F)F)C4=C(C=C3)C(=O)C(=CN4C5CC5)C(O)=O	PLASMA	V72H9867WB									?	μg × h/mL	149.1		μg/mL	10.67			HIGHEST STUDIED	mg	800		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700040/480297000_21900AMX01088000_A100_1.pdf#page=27	Homo sapiens		h	13.2		Non-Japanese (caucasian, black, hispanic/latino, asian/pacific islander, middle eastern)		6			false
954	437		ADULT	124093|40461170	426.4127	GARENOXACIN	Garenoxacin	C[C@H]1NCC2=C1C=CC(=C2)C3=C(OC(F)F)C4=C(C=C3)C(=O)C(=CN4C5CC5)C(O)=O	PLASMA	V72H9867WB									?	μg × h/mL	71.7		μg/mL	5.76			DEFINED DAILY	mg	400		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700040/480297000_21900AMX01088000_A100_1.pdf#page=27	Homo sapiens		h	14.1		Non-Japanese		13			false
955	437		ADULT	124093|40461170	426.4127	GARENOXACIN	Garenoxacin	C[C@H]1NCC2=C1C=CC(=C2)C3=C(OC(F)F)C4=C(C=C3)C(=O)C(=CN4C5CC5)C(O)=O	PLASMA	V72H9867WB									?	μg × h/mL	14.3		μg/mL	1.16			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700040/480297000_21900AMX01088000_A100_1.pdf#page=27	Homo sapiens		h	11.7		Non-Japanese (caucasian, black, hispanic/latino, asian/pacific islander, middle eastern)		6			false
956	437		ADULT	124093|40461170	426.4127	GARENOXACIN	Garenoxacin	C[C@H]1NCC2=C1C=CC(=C2)C3=C(OC(F)F)C4=C(C=C3)C(=O)C(=CN4C5CC5)C(O)=O	PLASMA	V72H9867WB									?	μg × h/mL	6.9		μg/mL	0.6			UNKNOWN	mg	50		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700040/480297000_21900AMX01088000_A100_1.pdf#page=27	Homo sapiens		h	10.5		Non-Japanese (caucasian, black, hispanic/latino, asian/pacific islander, middle eastern)		6			false
957	437		ADULT	124093|40461170	426.4127	GARENOXACIN	Garenoxacin	C[C@H]1NCC2=C1C=CC(=C2)C3=C(OC(F)F)C4=C(C=C3)C(=O)C(=CN4C5CC5)C(O)=O	PLASMA	V72H9867WB									?	μg × h/mL	38.6		μg/mL	2.81			UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700040/480297000_21900AMX01088000_A100_1.pdf#page=27	Homo sapiens		h	15.4		Non-Japanese (caucasian, black, hispanic/latino, asian/pacific islander, middle eastern)		6			false
958	437		ADULT	124093|40461170	426.4127	GARENOXACIN	Garenoxacin	C[C@H]1NCC2=C1C=CC(=C2)C3=C(OC(F)F)C4=C(C=C3)C(=O)C(=CN4C5CC5)C(O)=O	PLASMA	V72H9867WB									?	μg × h/mL	83.5		μg/mL	6.15			DEFINED DAILY	mg	400		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700040/480297000_21900AMX01088000_A100_1.pdf#page=27	Homo sapiens		h	12.6		Non-Japanese (caucasian, black, hispanic/latino, asian/pacific islander, middle eastern)		6			false
959	437		ADULT	124093|40461170	426.4127	GARENOXACIN	Garenoxacin	C[C@H]1NCC2=C1C=CC(=C2)C3=C(OC(F)F)C4=C(C=C3)C(=O)C(=CN4C5CC5)C(O)=O	PLASMA	V72H9867WB									?	μg × h/mL	102.8		μg/mL	6.95			UNKNOWN	mg	600		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700040/480297000_21900AMX01088000_A100_1.pdf#page=27	Homo sapiens		h	13.4		Non-Japanese (caucasian, black, hispanic/latino, asian/pacific islander, middle eastern)		6			false
960	437		ADULT	124093|40461170	426.4127	GARENOXACIN	Garenoxacin	C[C@H]1NCC2=C1C=CC(=C2)C3=C(OC(F)F)C4=C(C=C3)C(=O)C(=CN4C5CC5)C(O)=O	PLASMA	V72H9867WB									?	μg × h/mL	63.8		μg/mL	4.69			DEFINED DAILY	mg	400		SINGLE	HIGH-FAT						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700040/480297000_21900AMX01088000_A100_1.pdf#page=27	Homo sapiens		h	14.9		Non-Japanese		13			false
961	437		ADULT	124093|40461170	426.4127	GARENOXACIN	Garenoxacin	C[C@H]1NCC2=C1C=CC(=C2)C3=C(OC(F)F)C4=C(C=C3)C(=O)C(=CN4C5CC5)C(O)=O	PLASMA	V72H9867WB									?	μg × h/mL	113.9		μg/mL	7			UNKNOWN	mg	600		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700040/480297000_21900AMX01088000_A100_1.pdf#page=28	Homo sapiens		h	16.3		Severe hepatic impairment, non-Japanese		2			false
962	437		ADULT	124093|40461170	426.4127	GARENOXACIN	Garenoxacin	C[C@H]1NCC2=C1C=CC(=C2)C3=C(OC(F)F)C4=C(C=C3)C(=O)C(=CN4C5CC5)C(O)=O	PLASMA	V72H9867WB									?	μg × h/mL	136.4		μg/mL	12.6			UNKNOWN	mg	600		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700040/480297000_21900AMX01088000_A100_1.pdf#page=28	Homo sapiens		h	14.4		CLcr>80mL/min, normal renal function, non-Japanese		6			false
963	437		ADULT	124093|40461170	426.4127	GARENOXACIN	Garenoxacin	C[C@H]1NCC2=C1C=CC(=C2)C3=C(OC(F)F)C4=C(C=C3)C(=O)C(=CN4C5CC5)C(O)=O	PLASMA	V72H9867WB									?	μg × h/mL	156.5		μg/mL	9.2			UNKNOWN	mg	600		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700040/480297000_21900AMX01088000_A100_1.pdf#page=28	Homo sapiens		h	24.5		HD subject, dosed immediately after HD, non-Japanese		6			false
964	437		ADULT	124093|40461170	426.4127	GARENOXACIN	Garenoxacin	C[C@H]1NCC2=C1C=CC(=C2)C3=C(OC(F)F)C4=C(C=C3)C(=O)C(=CN4C5CC5)C(O)=O	PLASMA	V72H9867WB									?	μg × h/mL	113.9		μg/mL	9.8			UNKNOWN	mg	600		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700040/480297000_21900AMX01088000_A100_1.pdf#page=28	Homo sapiens		h	16.7		Mild hepatic impairment, non-Japanese		5			false
965	437		ADULT	124093|40461170	426.4127	GARENOXACIN	Garenoxacin	C[C@H]1NCC2=C1C=CC(=C2)C3=C(OC(F)F)C4=C(C=C3)C(=O)C(=CN4C5CC5)C(O)=O	PLASMA	V72H9867WB									?	μg × h/mL	108.6		μg/mL	8.3			UNKNOWN	mg	600		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700040/480297000_21900AMX01088000_A100_1.pdf#page=28	Homo sapiens		h	20.2		Moderate hepatic impairment, non-Japanese		6			false
966	437		ADULT	124093|40461170	426.4127	GARENOXACIN	Garenoxacin	C[C@H]1NCC2=C1C=CC(=C2)C3=C(OC(F)F)C4=C(C=C3)C(=O)C(=CN4C5CC5)C(O)=O	PLASMA	V72H9867WB									?	μg × h/mL	113		μg/mL	11			UNKNOWN	mg	600		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700040/480297000_21900AMX01088000_A100_1.pdf#page=28	Homo sapiens		h	11.8		Non-Japanese, normal liver function		6			false
967	437		ADULT	124093|40461170	426.4127	GARENOXACIN	Garenoxacin	C[C@H]1NCC2=C1C=CC(=C2)C3=C(OC(F)F)C4=C(C=C3)C(=O)C(=CN4C5CC5)C(O)=O	PLASMA	V72H9867WB									?	μg × h/mL	205.4		μg/mL	10.1			UNKNOWN	mg	600		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700040/480297000_21900AMX01088000_A100_1.pdf#page=28	Homo sapiens		h	26.5		Severe renal impairment, CLcr<30mL/min, no dialysis, non-Japanese		6			false
968	437		ADULT	124093|40461170	426.4127	GARENOXACIN	Garenoxacin	C[C@H]1NCC2=C1C=CC(=C2)C3=C(OC(F)F)C4=C(C=C3)C(=O)C(=CN4C5CC5)C(O)=O	PLASMA	V72H9867WB									?	μg × h/mL	138		μg/mL	6			UNKNOWN	mg	600		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700040/480297000_21900AMX01088000_A100_1.pdf#page=28	Homo sapiens		h	32.7		HD subjects, dosed 3 h prior to HD, non-Japanese		7			false
969	437		ADULT	124093|40461170	426.4127	GARENOXACIN	Garenoxacin	C[C@H]1NCC2=C1C=CC(=C2)C3=C(OC(F)F)C4=C(C=C3)C(=O)C(=CN4C5CC5)C(O)=O	PLASMA	V72H9867WB									?	μg × h/mL	165		μg/mL	7.1			UNKNOWN	mg	600		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700040/480297000_21900AMX01088000_A100_1.pdf#page=28	Homo sapiens		h	28.5		CAPD subjects, non-Japanese		6			false
970	438		ADULT	27812	308.4141	GESTRINONE	Gestrinone	CC[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C#C	PLASMA	1421533RCM													ng/mL	19			RECOMMENDED	mg	2.5		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE	OTHER GOV'T	https://gp2u.com.au/static/pdf/D/DIMETRIOSE-PI.pdf	Homo sapiens								Gestrinone		false
971	442		ADULT	124246	374.368	IGURATIMOD	IGURATIMOD	CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C3C(=O)C(NC=O)=COC3=C1	PLASMA	4IHY34Y2NV							48		t	μg × h/mL	20.93		μg/mL	1.24			DEFINED DAILY	mg	25		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29051989/	Homo sapiens		h	8.55				8	Iguratimod		false
972	442		ADULT	124246	374.368	IGURATIMOD	IGURATIMOD	CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C3C(=O)C(NC=O)=COC3=C1	PLASMA	4IHY34Y2NV							48		t	μg × h/mL	56.81		μg/mL	3.59			HIGHEST STUDIED	mg	75		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29051989/	Homo sapiens		h	7.3				8	Iguratimod		false
973	442		ADULT	124246	374.368	IGURATIMOD	IGURATIMOD	CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C3C(=O)C(NC=O)=COC3=C1	PLASMA	4IHY34Y2NV							48		t	μg × h/mL	31.88		μg/mL	1.88			RECOMMENDED	mg	50		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29051989/	Homo sapiens		h	10.25				8	Iguratimod		false
974	442		ADULT	124246	374.368	IGURATIMOD	IGURATIMOD	CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C3C(=O)C(NC=O)=COC3=C1	PLASMA	4IHY34Y2NV							48		t	μg × h/mL	34.89		μg/mL	2.13			RECOMMENDED	mg	50		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29051989/	Homo sapiens		h	6.31				8	Iguratimod		false
975	443		ADULT	6433090	319.4002	IMIDAFENACIN	imidafenacin	CC1=NC=CN1CCC(C(N)=O)(C2=CC=CC=C2)C3=CC=CC=C3	PLASMA	XJR8Y07LJO									∞	ng × eq × h/mL	83.06		ng × eq/mL	3.86			UNKNOWN	mg	0.25		SINGLE	FASTED				[14C]imidafenacin		HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17567733/	Homo sapiens		h	72.11				6	[14C]imidafenacin		false
976	443		ADULT	6433090	319.4002	IMIDAFENACIN	IMIDAFENACIN	CC1=NC=CN1CCC(C(N)=O)(C2=CC=CC=C2)C3=CC=CC=C3	PLASMA	XJR8Y07LJO									∞	pg × h/mL	2060		pg/mL	416			UNKNOWN	mg	0.1		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18251758/	Homo sapiens		h	3				14	IMIDAFENACIN		false
977	443		ADULT	6433090	319.4002	IMIDAFENACIN	IMIDAFENACIN	CC1=NC=CN1CCC(C(N)=O)(C2=CC=CC=C2)C3=CC=CC=C3	PLASMA	XJR8Y07LJO									∞	pg × h/mL	993		pg/mL	476			UNKNOWN	mg	0.028		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18251758/	Homo sapiens		h	3.2				14	IMIDAFENACIN		false
978	443		ADULT	6433090	319.4002	IMIDAFENACIN	IMIDAFENACIN	CC1=NC=CN1CCC(C(N)=O)(C2=CC=CC=C2)C3=CC=CC=C3	PLASMA	XJR8Y07LJO													pg/mL	1940			HIGHEST STUDIED	mg	0.5		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/23372610/	Homo sapiens							32	IMIDAFENACIN		false
979	443		ADULT	6433090	319.4002	IMIDAFENACIN	IMIDAFENACIN	CC1=NC=CN1CCC(C(N)=O)(C2=CC=CC=C2)C3=CC=CC=C3	PLASMA	XJR8Y07LJO							12		t	pg × h/mL	5580		pg/mL	1240			UNKNOWN	mg	0.25		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/23372610/	Homo sapiens		h	2.8				6	IMIDAFENACIN		false
980	443		ADULT	6433090	319.4002	IMIDAFENACIN	IMIDAFENACIN	CC1=NC=CN1CCC(C(N)=O)(C2=CC=CC=C2)C3=CC=CC=C3	PLASMA	XJR8Y07LJO													pg/mL	1240			UNKNOWN	mg	0.25		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/23372610/	Homo sapiens		h	2.7				6	IMIDAFENACIN		false
981	443		ADULT	6433090	319.4002	IMIDAFENACIN	IMIDAFENACIN	CC1=NC=CN1CCC(C(N)=O)(C2=CC=CC=C2)C3=CC=CC=C3	PLASMA	XJR8Y07LJO													pg/mL	109			UNKNOWN	mg	0.025		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/23372610/	Homo sapiens							32	IMIDAFENACIN		false
982	443		ADULT	6433090	319.4002	IMIDAFENACIN	IMIDAFENACIN	CC1=NC=CN1CCC(C(N)=O)(C2=CC=CC=C2)C3=CC=CC=C3	PLASMA	XJR8Y07LJO													pg/mL	180			UNKNOWN	mg	0.05		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/23372610/	Homo sapiens							32	IMIDAFENACIN		false
983	443		ADULT	6433090	319.4002	IMIDAFENACIN	IMIDAFENACIN	CC1=NC=CN1CCC(C(N)=O)(C2=CC=CC=C2)C3=CC=CC=C3	PLASMA	XJR8Y07LJO													pg/mL	1010			UNKNOWN	mg	0.25		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/23372610/	Homo sapiens							32	IMIDAFENACIN		false
984	443		ADULT	6433090	319.4002	IMIDAFENACIN	IMIDAFENACIN	CC1=NC=CN1CCC(C(N)=O)(C2=CC=CC=C2)C3=CC=CC=C3	PLASMA	XJR8Y07LJO													pg/mL	382			UNKNOWN	mg	0.1		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/23372610/	Homo sapiens							32	IMIDAFENACIN		false
985	444		ADULT	3731	777.0853	IOMEPROL	IOMEPROL	CN(C(=O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I	PLASMA	17E17JBP8L																	RECOMMENDED	g	65		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10507822/	Homo sapiens		h	32.6		continuous ambulatory peritoneal dialysis patients with variable degrees of residual renal function		14	IOMEPROL		false
986	444		ADULT	3731	777.0853	IOMEPROL	IOMEPROL	CN(C(=O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I	PLASMA	17E17JBP8L									∞	mg × h/mL	7.7						RECOMMENDED	g	40.8		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11410750/	Homo sapiens		h	2.34	50 mL of iomeprol 400 containing iomeprol 816 mg/mL (equivalent to 400 mg iodine per mL)			5	IOMEPROL		false
987	444		ADULT	3731	777.0853	IOMEPROL	IOMEPROL	CN(C(=O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I	PLASMA	17E17JBP8L									∞	mg × h/mL	22.1						RECOMMENDED	g	40.8		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11410750/	Homo sapiens		h	6.9		moderate renal impairment		6	IOMEPROL		false
988	444		ADULT	3731	777.0853	IOMEPROL	IOMEPROL	CN(C(=O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I	PLASMA	17E17JBP8L									∞	mg × h/mL	10.3						RECOMMENDED	g	40.8		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11410750/	Homo sapiens		h	3.67	50 mL of iomeprol 400 containing iomeprol 816 mg (equivalent to 400 mg iodine per mL)	mild renal impairment		6	IOMEPROL		false
989	444		ADULT	3731	777.0853	IOMEPROL	IOMEPROL	CN(C(=O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I	PLASMA	17E17JBP8L									∞	mg × h/mL	46.4						RECOMMENDED	g	40.8		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11410750/	Homo sapiens		h	15.1	50 mL of iomeprol 400 containing iomeprol 816 mg (equivalent to 400 mg iodine per mL)	severe renal impairment		4	IOMEPROL		false
990	447		ADULT	5282136	431.548	LAFUTIDINE	Lafutidine	[O-][S ](CC(=O)NC\\C=C/COC1=NC=CC(CN2CCCCC2)=C1)CC3=CC=CO3	PLASMA	49S4O7ADLC							24		t	ng × h/mL	793		ng/mL	174			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400107_2325006F1036_1_04F_1F.pdf#page=37 | https://www.pmda.go.jp/drugs/2000/g000103/65ctdp_1-249.pdf#page=165	Homo sapiens		h	3.3				6			false
991	447		ADULT	5282136	431.548	LAFUTIDINE	Lafutidine	[O-][S ](CC(=O)NC\\C=C/COC1=NC=CC(CN2CCCCC2)=C1)CC3=CC=CO3	PLASMA	49S4O7ADLC							24		t	ng × h/mL	849		ng/mL	167			UNKNOWN	mg	10		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400107_2325006F1036_1_04F_1F.pdf#page=37 | https://www.pmda.go.jp/drugs/2000/g000103/65ctdp_1-249.pdf#page=165	Homo sapiens		h	3.79				6			false
992	447		ADULT	5282136	431.548	LAFUTIDINE	Lafutidine	[O-][S ](CC(=O)NC\\C=C/COC1=NC=CC(CN2CCCCC2)=C1)CC3=CC=CO3	PLASMA	49S4O7ADLC									∞	ng × h/mL	895		ng/mL	178			UNKNOWN	mg	10		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400107_2325006F1036_1_04F_1F.pdf#page=38 | https://www.pmda.go.jp/drugs/2000/g000103/65ctdp_1-249.pdf#page=165	Homo sapiens		h	2.99	1st dose			6			false
993	447		ADULT	5282136	431.548	LAFUTIDINE	Lafutidine	[O-][S ](CC(=O)NC\\C=C/COC1=NC=CC(CN2CCCCC2)=C1)CC3=CC=CO3	PLASMA	49S4O7ADLC							14		t	ng × h/mL	1004		ng/mL	203			UNKNOWN	mg	10		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400107_2325006F1036_1_04F_1F.pdf#page=38 | https://www.pmda.go.jp/drugs/2000/g000103/65ctdp_1-249.pdf#page=165	Homo sapiens		h	3.54	14th dose			6			false
994	447			5282136	431.548	LAFUTIDINE	Lafutidine	[O-][S ](CC(=O)NC\\C=C/COC1=NC=CC(CN2CCCCC2)=C1)CC3=CC=CO3	PLASMA	49S4O7ADLC																										Human plasma protein binding (ultrafiltration): 88.6% (0.3μg/mL), 87.7% (1μg/mL), 88.0% (3μg/mL)	1.4				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400107_2325006F1036_1_04F_1F.pdf#page=42	Homo sapiens										false
995	447		ADULT	5282136	431.548	LAFUTIDINE	Lafutidine	[O-][S ](CC(=O)NC\\C=C/COC1=NC=CC(CN2CCCCC2)=C1)CC3=CC=CO3	PLASMA	49S4O7ADLC							24		t	ng × h/mL	1089		ng/mL	231			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2000/g000103/65ctdp_1-249.pdf#page=164	Homo sapiens		h	4.37				5			false
996	447		ADULT	5282136	431.548	LAFUTIDINE	Lafutidine	[O-][S ](CC(=O)NC\\C=C/COC1=NC=CC(CN2CCCCC2)=C1)CC3=CC=CO3	PLASMA	49S4O7ADLC							24		t	ng × h/mL	2295		ng/mL	610			UNKNOWN	mg	40		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2000/g000103/65ctdp_1-249.pdf#page=164	Homo sapiens		h	4.14				5			false
997	447		ADULT	5282136	431.548	LAFUTIDINE	Lafutidine	[O-][S ](CC(=O)NC\\C=C/COC1=NC=CC(CN2CCCCC2)=C1)CC3=CC=CO3	PLASMA	49S4O7ADLC							24		t	ng × h/mL	3808		ng/mL	834			UNKNOWN	mg	80		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2000/g000103/65ctdp_1-249.pdf#page=164	Homo sapiens		h	4.28				5			false
998	447		ADULT	5282136	431.548	LAFUTIDINE	Lafutidine	[O-][S ](CC(=O)NC\\C=C/COC1=NC=CC(CN2CCCCC2)=C1)CC3=CC=CO3	PLASMA	49S4O7ADLC							24		t	ng × h/mL	6513		ng/mL	1666			UNKNOWN	mg	160		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2000/g000103/65ctdp_1-249.pdf#page=164	Homo sapiens		h	4.03				5			false
999	447		ADULT	5282136	431.548	LAFUTIDINE	Lafutidine	[O-][S ](CC(=O)NC\\C=C/COC1=NC=CC(CN2CCCCC2)=C1)CC3=CC=CO3	PLASMA	49S4O7ADLC							12		t	ng × h/mL	1208		ng/mL	251			UNKNOWN	mg	20		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2000/g000103/65ctdp_1-249.pdf#page=166	Homo sapiens		h	3.37	1st dose			5			false
1000	447		ADULT	5282136	431.548	LAFUTIDINE	Lafutidine	[O-][S ](CC(=O)NC\\C=C/COC1=NC=CC(CN2CCCCC2)=C1)CC3=CC=CO3	PLASMA	49S4O7ADLC							12		t	ng × h/mL	1658		ng/mL	339			UNKNOWN	mg	20		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2000/g000103/65ctdp_1-249.pdf#page=166	Homo sapiens		h	2.4	7th dose			5			false
1001	447		ADULT	5282136	431.548	LAFUTIDINE	Lafutidine	[O-][S ](CC(=O)NC\\C=C/COC1=NC=CC(CN2CCCCC2)=C1)CC3=CC=CO3	PLASMA	49S4O7ADLC							12		t	ng × h/mL	1584		ng/mL	344			UNKNOWN	mg	20		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2000/g000103/65ctdp_1-249.pdf#page=166	Homo sapiens		h	3.12	15th dose			5			false
1002	447		ADULT	5282136	431.548	LAFUTIDINE	Lafutidine	[O-][S ](CC(=O)NC\\C=C/COC1=NC=CC(CN2CCCCC2)=C1)CC3=CC=CO3	PLASMA	49S4O7ADLC							12		t	ng × h/mL	3027		ng/mL	698			UNKNOWN	mg	60		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2000/g000103/65ctdp_1-249.pdf#page=166	Homo sapiens		h	2.08	1st dose			5			false
1003	447		ADULT	5282136	431.548	LAFUTIDINE	Lafutidine	[O-][S ](CC(=O)NC\\C=C/COC1=NC=CC(CN2CCCCC2)=C1)CC3=CC=CO3	PLASMA	49S4O7ADLC							12		t	ng × h/mL	3845		ng/mL	726			UNKNOWN	mg	60		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2000/g000103/65ctdp_1-249.pdf#page=166	Homo sapiens		h	2.01	7th dose			5			false
1004	447		ADULT	5282136	431.548	LAFUTIDINE	Lafutidine	[O-][S ](CC(=O)NC\\C=C/COC1=NC=CC(CN2CCCCC2)=C1)CC3=CC=CO3	PLASMA	49S4O7ADLC							12		t	ng × h/mL	3664		ng/mL	804			UNKNOWN	mg	60		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2000/g000103/65ctdp_1-249.pdf#page=166	Homo sapiens		h	2.41	15th dose			5			false
1005	448		ADULT	114905	509.5925	LANDIOLOL	LANDIOLOL	CC1(C)OC[C@@H](COC(=O)CCC2=CC=C(OC[C@@H](O)CNCCNC(=O)N3CCOCC3)C=C2)O1	PLASMA	62NWQ924LH									∞	μg × h/mL	0.1		μg/mL	1.14			UNKNOWN	mg/kg	0.3		SINGLE	UNKNOWN				Protein binding of landiolol is low (<10%) and dose dependent. https://www.amomed.com/wp-content/uploads/2017/10/ALL_LDL3_Landiolol300mg_SPC.pdf	90	HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27373605/	Homo sapiens		min	3.63				12	LANDIOLOL		false
1006	448		ADULT	114905	509.5925	LANDIOLOL	LANDIOLOL	CC1(C)OC[C@@H](COC(=O)CCC2=CC=C(OC[C@@H](O)CNCCNC(=O)N3CCOCC3)C=C2)O1	PLASMA	62NWQ924LH									∞	μg × h/mL	0.03		μg/mL	0.29			UNKNOWN	mg/kg	0.1		SINGLE	UNKNOWN				Protein binding of landiolol is low (<10%) and dose dependent. https://www.amomed.com/wp-content/uploads/2017/10/ALL_LDL3_Landiolol300mg_SPC.pdf	90	HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27373605/	Homo sapiens		min	3.2				12	LANDIOLOL		false
1007	448		ADULT	114905	509.5925	LANDIOLOL	LANDIOLOL	CC1(C)OC[C@@H](COC(=O)CCC2=CC=C(OC[C@@H](O)CNCCNC(=O)N3CCOCC3)C=C2)O1	PLASMA	62NWQ924LH									∞	μg × h/mL	0.06		μg/mL	0.79			UNKNOWN	mg/kg	0.2		SINGLE	UNKNOWN				Protein binding of landiolol is low (<10%) and dose dependent. https://www.amomed.com/wp-content/uploads/2017/10/ALL_LDL3_Landiolol300mg_SPC.pdf	90	HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27373605/	Homo sapiens		min	3.43				12	LANDIOLOL		false
1008	451		ADULT	3949	468.5355	LOMERIZINE	Lomerizine	COC1=C(OC)C(OC)=C(CN2CCN(CC2)C(C3=CC=C(F)C=C3)C4=CC=C(F)C=C4)C=C1	PLASMA	DEE37CY4VO									∞	ng × h/mL	74.22		ng/mL	9.06			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24412691/	Homo sapiens		h	5.48				18			false
1009	451		ADULT	3949	468.5355	LOMERIZINE	Lomerizine	COC1=C(OC)C(OC)=C(CN2CCN(CC2)C(C3=CC=C(F)C=C3)C4=CC=C(F)C=C4)C=C1	PLASMA	DEE37CY4VO							12		t	ng × h/mL	40.7		ng/mL	7.3			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/5/672212_2190023F1037_5_1F.pdf#page=29	Homo sapiens		h	3.3					Lomerizine hydrochloride		false
1010	451		ADULT	3949	468.5355	LOMERIZINE	Lomerizine	COC1=C(OC)C(OC)=C(CN2CCN(CC2)C(C3=CC=C(F)C=C3)C4=CC=C(F)C=C4)C=C1	PLASMA	DEE37CY4VO							12		t	ng × h/mL	45.5		ng/mL	7.7			UNKNOWN	mg	10		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/5/672212_2190023F1037_5_1F.pdf#page=29	Homo sapiens		h	3.4					Lomerizine hydrochloride		false
1011	451		ADULT	3949	468.5355	LOMERIZINE	Lomerizine	COC1=C(OC)C(OC)=C(CN2CCN(CC2)C(C3=CC=C(F)C=C3)C4=CC=C(F)C=C4)C=C1	PLASMA	DEE37CY4VO							12		t	ng × h/mL	183.1		ng/mL	31.3			UNKNOWN	mg	40		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/5/672212_2190023F1037_5_1F.pdf#page=29	Homo sapiens		h	3.6					Lomerizine hydrochloride		false
1012	451		ADULT	3949	468.5355	LOMERIZINE	Lomerizine	COC1=C(OC)C(OC)=C(CN2CCN(CC2)C(C3=CC=C(F)C=C3)C4=CC=C(F)C=C4)C=C1	PLASMA	DEE37CY4VO							12		t	ng × h/mL	83.9		ng/mL	15.7			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/5/672212_2190023F1037_5_1F.pdf#page=29	Homo sapiens		h	4							false
1013	451			3949	468.5355	LOMERIZINE	Lomerizine	COC1=C(OC)C(OC)=C(CN2CCN(CC2)C(C3=CC=C(F)C=C3)C4=CC=C(F)C=C4)C=C1	PLASMA	DEE37CY4VO																										Human plasma protein binding: 78% (in vitro)	22				EXPERIMENT	https://www.info.pmda.go.jp/go/interview/5/672212_2190023F1037_5_1F.pdf#page=30	Homo sapiens										false
1014	452		ADULT	3965	246.3016	LOXOPROFEN	LOXOPROFEN	CC(C(O)=O)C1=CC=C(CC2CCCC2=O)C=C1	PLASMA	3583H0GZAP							6		t	μg × h/mL	3.54		μg/mL	3.58			UNKNOWN	mg	60		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17915642/	Homo sapiens		h	1.92				24	LOXOPROFEN		false
1015	452		ADULT	3965	246.3016	LOXOPROFEN	LOXOPROFEN	CC(C(O)=O)C1=CC=C(CC2CCCC2=O)C=C1	PLASMA	3583H0GZAP							6		t	μg × h/mL	11.5		μg/mL	6.6			UNKNOWN	mg	60		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27121671/	Homo sapiens		h	1.6				24	LOXOPROFEN		false
1016	453		ADULT	13605986	354.277	[NO STEREO] LULICONAZOLE, (+/-)-|[NO STEREO] LULICONAZOLE, (+)-|[NO STEREO] LULICONAZOLE	C1C(SC(=C(C#N)N2C=CN=C2)S1)C3=C(C=C(C=C3)Cl)Cl	ClC1=CC(Cl)=C(C=C1)C2CSC(S2)=C(C#N)N3C=CN=C3	PLASMA	[NO STEREO] 5JA16R08FJ|[NO STEREO] 757AJC6576|[NO STEREO] RE91AN4S8G							24		t	ng × h/mL	1.72		ng/mL	0.1			INVESTIGATIONAL	mg	20		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Topical	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23545529/	Homo sapiens		h	19.9							false
1017	453		ADULT	13605986	354.277	[NO STEREO] LULICONAZOLE, (+/-)-|[NO STEREO] LULICONAZOLE, (+)-|[NO STEREO] LULICONAZOLE	C1C(SC(=C(C#N)N2C=CN=C2)S1)C3=C(C=C(C=C3)Cl)Cl	ClC1=CC(Cl)=C(C=C1)C2CSC(S2)=C(C#N)N3C=CN=C3	PLASMA	[NO STEREO] 5JA16R08FJ|[NO STEREO] 757AJC6576|[NO STEREO] RE91AN4S8G							24		t	ng × h/mL	18.74		ng/mL	0.93			RECOMMENDED	mg	35		STEADY-STATE	UNKNOWN		day	1		1	UNHEALTHY	Topical	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204153s000lbl.pdf	Homo sapiens										false
1018	454		ADULT	4008	610.6994	MANIDIPINE	Manidipine	COC(=O)C1=C(C)NC(C)=C(C1C2=CC=CC(=C2)[N ]([O-])=O)C(=O)OCCN3CCN(CC3)C(C4=CC=CC=C4)C5=CC=CC=C5	PLASMA	6O4754US88							24		t	ng × h/mL	13.02		ng/mL	3.15			RECOMMENDED	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400813_2149027F1101_1_004_1F.pdf#page=28	Homo sapiens		h	4.92				20	Manidipine hydrochloride		false
1019	454		ADULT	4008	610.6994	MANIDIPINE	Manidipine	COC(=O)C1=C(C)NC(C)=C(C1C2=CC=CC(=C2)[N ]([O-])=O)C(=O)OCCN3CCN(CC3)C(C4=CC=CC=C4)C5=CC=CC=C5	PLASMA	6O4754US88							24		t	ng × h/mL	35.08		ng/mL	6.94			RECOMMENDED	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400813_2149027F1101_1_004_1F.pdf#page=29	Homo sapiens		h	7.31				30	Manidipine hydrochloride		false
1020	454		ADULT	4008	610.6994	MANIDIPINE	Manidipine	COC(=O)C1=C(C)NC(C)=C(C1C2=CC=CC(=C2)[N ]([O-])=O)C(=O)OCCN3CCN(CC3)C(C4=CC=CC=C4)C5=CC=CC=C5	PLASMA	6O4754US88							24		t	ng × h/mL	42.9		ng/mL	7.1			RECOMMENDED	mg	20		SINGLE	FED						UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400813_2149027F1101_1_004_1F.pdf#page=31	Homo sapiens		h	7.25		Essential hypertension patients with normal renal function		7	Manidipine hydrochloride		false
1021	454		ADULT	4008	610.6994	MANIDIPINE	Manidipine	COC(=O)C1=C(C)NC(C)=C(C1C2=CC=CC(=C2)[N ]([O-])=O)C(=O)OCCN3CCN(CC3)C(C4=CC=CC=C4)C5=CC=CC=C5	PLASMA	6O4754US88							24		t	ng × h/mL	60.2		ng/mL	11.6			RECOMMENDED	mg	20		MULTIPLE	FED		day	1			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400813_2149027F1101_1_004_1F.pdf#page=31	Homo sapiens		h	8.3	Day 1			6	Manidipine hydrochloride		false
1022	454		ADULT	4008	610.6994	MANIDIPINE	Manidipine	COC(=O)C1=C(C)NC(C)=C(C1C2=CC=CC(=C2)[N ]([O-])=O)C(=O)OCCN3CCN(CC3)C(C4=CC=CC=C4)C5=CC=CC=C5	PLASMA	6O4754US88							24		t	ng × h/mL	85.2		ng/mL	15.1			RECOMMENDED	mg	20		MULTIPLE	FED		day	1			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400813_2149027F1101_1_004_1F.pdf#page=31	Homo sapiens		h	11.2	Day 7			6	Manidipine hydrochloride		false
1023	454		ADULT	4008	610.6994	MANIDIPINE	Manidipine	COC(=O)C1=C(C)NC(C)=C(C1C2=CC=CC(=C2)[N ]([O-])=O)C(=O)OCCN3CCN(CC3)C(C4=CC=CC=C4)C5=CC=CC=C5	PLASMA	6O4754US88							24		t	ng × h/mL	45.3		ng/mL	9			RECOMMENDED	mg	20		MULTIPLE	FED		day	1			UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400813_2149027F1101_1_004_1F.pdf#page=31	Homo sapiens		h	8.9	Day 1	Renal impairment (serum CR: 1.4~6.5mg/dL)		10	Manidipine hydrochloride		false
1024	454		ADULT	4008	610.6994	MANIDIPINE	Manidipine	COC(=O)C1=C(C)NC(C)=C(C1C2=CC=CC(=C2)[N ]([O-])=O)C(=O)OCCN3CCN(CC3)C(C4=CC=CC=C4)C5=CC=CC=C5	PLASMA	6O4754US88							24		t	ng × h/mL	69.4		ng/mL	12.2			RECOMMENDED	mg	20		MULTIPLE	FED		day	1			UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400813_2149027F1101_1_004_1F.pdf#page=31	Homo sapiens		h	15.5	Day 8	Manidipine hydrochloride		10	Manidipine hydrochloride		false
1025	454		ADULT	4008	610.6994	MANIDIPINE	Manidipine	COC(=O)C1=C(C)NC(C)=C(C1C2=CC=CC(=C2)[N ]([O-])=O)C(=O)OCCN3CCN(CC3)C(C4=CC=CC=C4)C5=CC=CC=C5	PLASMA	6O4754US88							24		∞	ng × h/mL	29.1		ng/mL	8.6			RECOMMENDED	mg	20		SINGLE	FED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400813_2149027F1101_1_004_1F.pdf#page=31	Homo sapiens		h	3.9		Manidipine hydrochloride		12	Manidipine hydrochloride		false
1026	454		ADULT	4008	610.6994	MANIDIPINE	Manidipine	COC(=O)C1=C(C)NC(C)=C(C1C2=CC=CC(=C2)[N ]([O-])=O)C(=O)OCCN3CCN(CC3)C(C4=CC=CC=C4)C5=CC=CC=C5	PLASMA	6O4754US88							24		∞	ng × h/mL	74.5		ng/mL	11.7			RECOMMENDED	mg	20		SINGLE	FED						UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400813_2149027F1101_1_004_1F.pdf#page=31	Homo sapiens		h	8.4		Moderate hepatic impairment (Child-Pugh B)		3	Manidipine hydrochloride		false
1027	454		ADULT	4008	610.6994	MANIDIPINE	Manidipine	COC(=O)C1=C(C)NC(C)=C(C1C2=CC=CC(=C2)[N ]([O-])=O)C(=O)OCCN3CCN(CC3)C(C4=CC=CC=C4)C5=CC=CC=C5	PLASMA	6O4754US88							24		∞	ng × h/mL	33.5		ng/mL	6.5			RECOMMENDED	mg	20		SINGLE	FED						UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400813_2149027F1101_1_004_1F.pdf#page=31	Homo sapiens		h	4.8		Mild hepatic impairment (Child-Pugh A)		5	Manidipine hydrochloride		false
1028	454			4008	610.6994	MANIDIPINE	Manidipine	COC(=O)C1=C(C)NC(C)=C(C1C2=CC=CC(=C2)[N ]([O-])=O)C(=O)OCCN3CCN(CC3)C(C4=CC=CC=C4)C5=CC=CC=C5	PLASMA	6O4754US88																										Human plasma protein binding: 99.6~100% (manidipine hydrochloride: 99.0~99.7% (0.1, 0.5, 2.5μg/mL, ultrafiltration))	0				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400813_2149027F1101_1_004_1F.pdf#page=32	Homo sapiens										false
1029	455		ADULT	5282367	444.6481	MENATETRENONE	Menatetrenone	CC(C)=CCC\\C(C)=C\\CC\\C(C)=C\\CC\\C(C)=C\\CC1=C(C)C(=O)C2=C(C=CC=C2)C1=O	PLASMA	27Y876D139							24		t	ng × h/mL	370.6		ng/mL	133.4			RECOMMENDED	mg	15		SINGLE	LOW-FAT						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8877895/	Homo sapiens							6	Menatetrenone		false
1030	455		ADULT	5282367	444.6481	MENATETRENONE	Menatetrenone	CC(C)=CCC\\C(C)=C\\CC\\C(C)=C\\CC\\C(C)=C\\CC1=C(C)C(=O)C2=C(C=CC=C2)C1=O	PLASMA	27Y876D139							24		t	ng × h/mL	1024.4		ng/mL	409.4			UNKNOWN	mg	15		SINGLE	HIGH-FAT						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8877895/	Homo sapiens							6	Menatetrenone		false
1031	455		ADULT	5282367	444.6481	MENATETRENONE	Menatetrenone	CC(C)=CCC\\C(C)=C\\CC\\C(C)=C\\CC\\C(C)=C\\CC1=C(C)C(=O)C2=C(C=CC=C2)C1=O	PLASMA	27Y876D139							24		t	ng × h/mL	485.2		ng/mL	139.7			RECOMMENDED	mg	15		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8877895/	Homo sapiens							6	Menatetrenone		false
1032	457		ADULT	65906|5282132	432.4933	MIZOLASTINE	mizolastine	CN(C1CCN(CC1)C2=NC3=C(C=CC=C3)N2CC4=CC=C(F)C=C4)C5=NC=CC(=O)N5	PLASMA	244O1F90NA									∞	ng × h/mL	2636.8		ng/mL	351.6			UNKNOWN	mg	10		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29702735/	Homo sapiens		h	5.13				24	mizolastine		false
1033	458		ADULT	104762	259.216	MIZORIBINE	MIZORIBINE	NC(=O)C1=C(O)N(C=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O	SERUM	4JR41A10VP									?	μg × h/mL	31.2		μg/mL	4.6			UNKNOWN	mg/kg	6		MULTIPLE	FASTED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17096684/	Homo sapiens		h	3.1				5	MIZORIBINE		false
1034	458		ADULT	104762	259.216	MIZORIBINE	MIZORIBINE	NC(=O)C1=C(O)N(C=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O	SERUM	4JR41A10VP									∞	μg × h/mL	18.1		μg/mL	2.7			UNKNOWN	mg/kg	3		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17096684/	Homo sapiens		h	2.9				6	MIZORIBINE		false
1035	458		ADULT	104762	259.216	MIZORIBINE	MIZORIBINE	NC(=O)C1=C(O)N(C=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O	SERUM	4JR41A10VP									?	μg × h/mL	35.5		μg/mL	4.7			UNKNOWN	mg/kg	6		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17096684/	Homo sapiens		h	3				5	MIZORIBINE		false
1036	458		ADULT	104762	259.216	MIZORIBINE	MIZORIBINE	NC(=O)C1=C(O)N(C=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O	SERUM	4JR41A10VP									∞	μg × h/mL	38.3		μg/mL	5.5			UNKNOWN	mg/kg	6		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17096684/	Homo sapiens		h	2.7				6	MIZORIBINE		false
1037	458		ADULT	104762	259.216	MIZORIBINE	MIZORIBINE	NC(=O)C1=C(O)N(C=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O	SERUM	4JR41A10VP									∞	μg × h/mL	61.9		μg/mL	9.6			HIGHEST STUDIED	mg/kg	12		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17096684/	Homo sapiens		h	2.9				6	MIZORIBINE		false
1038	458		ADULT	104762	259.216	MIZORIBINE	MIZORIBINE	NC(=O)C1=C(O)N(C=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O	SERUM	4JR41A10VP									∞	μg × h/mL	46.4		μg/mL	6.6			UNKNOWN	mg/kg	9		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17096684/	Homo sapiens		h	2.8				6	MIZORIBINE		false
1039	458		ADULT	104762	259.216	MIZORIBINE	MIZORIBINE	NC(=O)C1=C(O)N(C=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O	SERUM	4JR41A10VP							12		t	μg × h/mL	13.2		μg/mL	2.3			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18661478/	Homo sapiens		h	3.1				24	MIZORIBINE		false
1040	460		ADULT	4238|5353788|5360788|15730296	242.2319	MOLSIDOMINE	Molsidomine	CCOC(=O)[N-]C1=C[N ](=NO1)N2CCOCC2	PLASMA	D46583G77X							24		t	ng × h/mL	423		μg/L	37			UNKNOWN	mg	16		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://link.springer.com/article/10.2165/00137696-200402020-00005	Homo sapiens		h	12				36			false
1041	460		ADULT	5219	170.1692	LINSIDOMINE	Linsidomine	[NH-]C1=C[N ](=NO1)N2CCOCC2	PLASMA	5O5U71P6VQ							24		t	ng × h/mL	61		μg/L	8			UNKNOWN	mg	16		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://link.springer.com/article/10.2165/00137696-200402020-00005	Homo sapiens		h	12				36			false
1042	460		ADULT	5219	170.1692	LINSIDOMINE	Linsidomine	[NH-]C1=C[N ](=NO1)N2CCOCC2	PLASMA	5O5U71P6VQ							24		t	ng × h/mL	49		μg/L	8			UNKNOWN	mg	16		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://link.springer.com/article/10.2165/00137696-200402020-00005	Homo sapiens		h	6.6		n=10 for t1/2 and AUC		12			false
1043	460		ADULT	5219	170.1692	LINSIDOMINE	Linsidomine	[NH-]C1=C[N ](=NO1)N2CCOCC2	PLASMA	5O5U71P6VQ							24		t	ng × h/mL	60		μg/L	8			UNKNOWN	mg	16		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://link.springer.com/article/10.2165/00137696-200402020-00005	Homo sapiens		h	10				36			false
1044	460		ADULT	4238|5353788|5360788|15730296	242.2319	MOLSIDOMINE	Molsidomine	CCOC(=O)[N-]C1=C[N ](=NO1)N2CCOCC2	PLASMA	D46583G77X							24		t	ng × h/mL	311		μg/L	32			UNKNOWN	mg	16		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://link.springer.com/article/10.2165/00137696-200402020-00005	Homo sapiens		h	12				36			false
1045	460		ADULT	4238|5353788|5360788|15730296	242.2319	MOLSIDOMINE	Molsidomine	CCOC(=O)[N-]C1=C[N ](=NO1)N2CCOCC2	PLASMA	D46583G77X							24		t	ng × h/mL	335		μg/L	32			UNKNOWN	mg	16		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://link.springer.com/article/10.2165/00137696-200402020-00005	Homo sapiens		h	9.7		n=10 for t1/2 and AUC		12			false
1046	460		ADULT	4238|5353788|5360788|15730296	242.2319	MOLSIDOMINE	Molsidomine	CCOC(=O)[N-]C1=C[N ](=NO1)N2CCOCC2	PLASMA	D46583G77X							24		t	ng × h/mL	310		μg/L	34			UNKNOWN	mg	16		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://link.springer.com/article/10.2165/00137696-200402020-00005	Homo sapiens		h	8.2		n=10 for t1/2 and AUC		12			false
1047	460		ADULT	5219	170.1692	LINSIDOMINE	Linsidomine	[NH-]C1=C[N ](=NO1)N2CCOCC2	PLASMA	5O5U71P6VQ							24		t	ng × h/mL	70		μg/L	10			UNKNOWN	mg	16		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://link.springer.com/article/10.2165/00137696-200402020-00005	Homo sapiens		h	5.8		n=10 for t1/2 and AUC		12			false
1048	460		ADULT	4238|5353788|5360788|15730296	242.2319	MOLSIDOMINE	Molsidomine	CCOC(=O)[N-]C1=C[N ](=NO1)N2CCOCC2	PLASMA	D46583G77X									?	ng × h/mL/kg	17.54		ng/mL/kg	0.89			UNKNOWN	mg	2		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1777378/	Homo sapiens		h	13.1		Cirrhotic patients		7			false
1049	460		ADULT	5219	170.1692	LINSIDOMINE	Linsidomine	[NH-]C1=C[N ](=NO1)N2CCOCC2	PLASMA	5O5U71P6VQ									?	ng × h/mL/kg	0.5		ng/mL/kg	0.03			UNKNOWN	mg	2		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1777378/	Homo sapiens		h	7.5		Cirrhotic patients		7			false
1050	460		ADULT	4238|5353788|5360788|15730296	242.2319	MOLSIDOMINE	Molsidomine	CCOC(=O)[N-]C1=C[N ](=NO1)N2CCOCC2	PLASMA	D46583G77X									?	ng × h/mL/kg	0.46		ng/mL/kg	0.26			UNKNOWN	mg	2		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1777378/	Homo sapiens		h	1.2				6			false
1051	460		ADULT	5219	170.1692	LINSIDOMINE	Linsidomine	[NH-]C1=C[N ](=NO1)N2CCOCC2	PLASMA	5O5U71P6VQ									?	ng × h/mL/kg	0.11		ng/mL/kg	0.08			UNKNOWN	mg	2		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1777378/	Homo sapiens		h	1				6			false
1052	460		ADULT	5219	170.1692	LINSIDOMINE	LINSIDOMINE	[NH-]C1=C[N ](=NO1)N2CCOCC2	PLASMA	5O5U71P6VQ									∞	μg × h/L	12.2		ng/mL	4.4			UNKNOWN	mg	2		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1955198/	Homo sapiens		h	1.8		Elderly subjects		6			false
1053	460		ADULT	5219	170.1692	LINSIDOMINE	LINSIDOMINE	[NH-]c1on[n ](c1)N2CCOCC2	PLASMA	5O5U71P6VQ									∞	μg × h/L	7.4		ng/mL	5.3			UNKNOWN	mg	2		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1955198/	Homo sapiens		h	1		Young subjects		6			false
1054	460		ADULT	4238|5353788|5360788|15730296	242.2319	MOLSIDOMINE	Molsidomine	CCOC(=O)[N-]C1=C[N ](=NO1)N2CCOCC2	PLASMA	D46583G77X									∞	μg × h/L	106.5		ng/mL	29.7			UNKNOWN	mg	2		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1955198/	Homo sapiens		h	1.9		Elderly subjects		6			false
1055	460		ADULT	4238|5353788|5360788|15730296	242.2319	MOLSIDOMINE	Molsidomine	CCOC(=O)[N-]C1=C[N ](=NO1)N2CCOCC2	PLASMA	D46583G77X									∞	μg × h/L	31.7		ng/mL	17.9			UNKNOWN	mg	2		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1955198/	Homo sapiens		h	1.2		Young subjects		6			false
1056	460		ADULT	4238|5353788|5360788|15730296	242.2319	MOLSIDOMINE	Molsidomine	CCOC(=O)[N-]C1=C[N ](=NO1)N2CCOCC2	PLASMA	D46583G77X													ng/mL	15			UNKNOWN	mg	2		SINGLE	UNKNOWN					100	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3838399/	Homo sapiens		h	1.6				2			false
1057	463		UNKNOWN	9850038	360.3794	LEVONADIFLOXACIN	LEVONADIFLOXACIN	C[C@H]1CCC2=C(N3CCC(O)CC3)C(F)=CC4=C2N1C=C(C(O)=O)C4=O	UNKNOWN	8WHH66L098													μg/mL	4			UNKNOWN	mg	600		SINGLE	UNKNOWN						UNKNOWN	Intravenous	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/17020421/	Homo sapiens		h	6	LEVONADIFLOXACIN (WCK 771), active (-)-(S)-isomer of NADIFLOXACIN	size is unknown			LEVONADIFLOXACIN		false
1058	464		ADULT	4418	392.4907	NAFTOPIDIL	NAFTOPIDIL	COC1=C(C=CC=C1)N2CCN(CC(O)COC3=CC=CC4=C3C=CC=C4)CC2	PLASMA	R9PHW59SFN																	UNKNOWN	mg	5		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8016009/	Homo sapiens		h	3.6		liver-impaired		10	NAFTOPIDIL		false
1059	464		ADULT	4418	392.4907	NAFTOPIDIL	NAFTOPIDIL	COC1=C(C=CC=C1)N2CCN(CC(O)COC3=CC=CC4=C3C=CC=C4)CC2	PLASMA	R9PHW59SFN																	UNKNOWN	mg	5		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8016009/	Homo sapiens		h	3.3				12	NAFTOPIDIL		false
1060	464		ADULT	4418	392.4907	NAFTOPIDIL	NAFTOPIDIL	COC1=C(C=CC=C1)N2CCN(CC(O)COC3=CC=CC4=C3C=CC=C4)CC2	PLASMA	R9PHW59SFN																	UNKNOWN	mg	50		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8016009/	Homo sapiens		h	16.6		liver-impaired		10	NAFTOPIDIL		false
1061	464		ADULT	4418	392.4907	NAFTOPIDIL	NAFTOPIDIL	COC1=C(C=CC=C1)N2CCN(CC(O)COC3=CC=CC4=C3C=CC=C4)CC2	PLASMA	R9PHW59SFN																	UNKNOWN	mg	50		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8016009/	Homo sapiens		h	5.4				12	NAFTOPIDIL		false
1062	464		ADULT	4418	392.4907	NAFTOPIDIL	NAFTOPIDIL	COC1=C(C=CC=C1)N2CCN(CC(O)COC3=CC=CC4=C3C=CC=C4)CC2	PLASMA	R9PHW59SFN									?	μg × h/L	298.3		μg/L	114.3			UNKNOWN	mg	75		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://tcpharm.org/pdf/10.12793/jkscpt.2010.18.2.127	Homo sapiens							8	NAFTOPIDIL		false
1063	464		ADULT	4418	392.4907	NAFTOPIDIL	NAFTOPIDIL	COC1=C(C=CC=C1)N2CCN(CC(O)COC3=CC=CC4=C3C=CC=C4)CC2	PLASMA	R9PHW59SFN									?	μg × h/L	178.7		μg/L	88.9			UNKNOWN	mg	50		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://tcpharm.org/pdf/10.12793/jkscpt.2010.18.2.127	Homo sapiens							8	NAFTOPIDIL		false
1064	464		ADULT	4418	392.4907	NAFTOPIDIL	NAFTOPIDIL	COC1=C(C=CC=C1)N2CCN(CC(O)COC3=CC=CC4=C3C=CC=C4)CC2	PLASMA	R9PHW59SFN									?	μg × h/L	342.6		μg/L	179.5			HIGHEST STUDIED	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://tcpharm.org/pdf/10.12793/jkscpt.2010.18.2.127	Homo sapiens							8	NAFTOPIDIL		false
1065	464		ADULT	4418	392.4907	NAFTOPIDIL	NAFTOPIDIL	COC1=C(C=CC=C1)N2CCN(CC(O)COC3=CC=CC4=C3C=CC=C4)CC2	PLASMA	R9PHW59SFN									?	μg × h/L	71.1		μg/L	44			UNKNOWN	mg	25		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://tcpharm.org/pdf/10.12793/jkscpt.2010.18.2.127	Homo sapiens							8	NAFTOPIDIL		false
1066	465		ADULT	4593|5282233	250.2554	OLPRINONE	Olprinone	CC1=C(C=C(C#N)C(=O)N1)C2=CN3C=CN=C3C=C2	PLASMA	4Y8BMI9YGC									∞	ng × h/mL	8.6		ng/mL	13.1			UNKNOWN	μg/kg bw	5		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23690065/	Homo sapiens		h	0.55				8			false
1067	465		ADULT	4593|5282233	250.2554	OLPRINONE	Olprinone	CC1=C(C=C(C#N)C(=O)N1)C2=CN3C=CN=C3C=C2	PLASMA	4Y8BMI9YGC																	UNKNOWN	μg/kg bw	50		SINGLE	FASTED				Human plasma protein binding: 81.3% (5, 30, and 120 min after 50mcg/kg iv administration, equilibrium dialysis)	18.7	HEALTHY	Intravenous	MALE	EXPERIMENT	https://www.jstage.jst.go.jp/article/jscpt1970/21/3/21_3_613/_article/-char/en	Homo sapiens							4			false
1068	466		ADULT	9417	363.4959	OPIPRAMOL	Opipramol	OCCN1CCN(CCCN2C3=C(C=CC=C3)C=CC4=C2C=CC=C4)CC1	PLASMA	D23ZXO613C									?	ng × h/mL	170		ng/mL	15			UNKNOWN	mg	50		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12642963/	Homo sapiens		h	11		Sugar-coated tablets		20			false
1069	466		ADULT	9417	363.4959	OPIPRAMOL	Opipramol	OCCN1CCN(CCCN2C3=C(C=CC=C3)C=CC4=C2C=CC=C4)CC1	PLASMA	D23ZXO613C									?	ng × h/mL	320		ng/mL	28			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12642963/	Homo sapiens		h	11		Film-coated tablets		18			false
1070	466			9417	363.4959	OPIPRAMOL	Opipramol	OCCN1CCN(CCCN2C3=C(C=CC=C3)C=CC4=C2C=CC=C4)CC1	PLASMA	D23ZXO613C																										The plasma protein binding amounts to approximately 91%.	9				REVIEW	https://www.researchgate.net/profile/Satyakam-Mohapatra/publication/259936188_OPIPRAMOL_A_NOVEL_DRUG/links/0deec52ea4beabb2e0000000/OPIPRAMOL-A-NOVEL-DRUG.pdf	Homo sapiens										false
1071	467		ADULT	4615|1385580	426.5533	OXATOMIDE	Oxatomide	O=C1NC2=C(C=CC=C2)N1CCCN3CCN(CC3)C(C4=CC=CC=C4)C5=CC=CC=C5	PLASMA	J31IL9Z2EE							24		t	ng × h/mL	84.6		ng/mL	13.6			DEFINED DAILY	mg	60		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/300119_4490005F1603_1_071_1F.pdf#paage=19	Homo sapiens		h	7.6	30mg x 2 tablets						false
1072	467		ADULT	4615|1385580	426.5533	OXATOMIDE	Oxatomide	O=C1NC2=C(C=CC=C2)N1CCCN3CCN(CC3)C(C4=CC=CC=C4)C5=CC=CC=C5	PLASMA	J31IL9Z2EE							24		t	ng × h/mL	92.1		ng/mL	13.2			DEFINED DAILY	mg	60		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/300119_4490005F1603_1_071_1F.pdf#paage=20	Homo sapiens		h	7.3	2% Dry syrup						false
1073	467			4615|1385580	426.5533	OXATOMIDE	Oxatomide	O=C1NC2=C(C=CC=C2)N1CCCN3CCN(CC3)C(C4=CC=CC=C4)C5=CC=CC=C5	SERUM	J31IL9Z2EE																										Human serum albumin (4%) binding: 93.3~98.7% (27~2400ng/mL)	1.3				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/331552_4490005F1433_2_005_1F.pdf#page=17	Homo sapiens										false
1074	468		ADULT	5282440	228.2466	OZAGREL	Ozagrel	OC(=O)\\C=C\\C1=CC=C(CN2C=CN=C2)C=C1	PLASMA	L256JB984D									?	ng × h/mL	281		ng/mL	97			UNKNOWN	μg/kg/min	1		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/230034_3999411H2038_1_005_1F.pdf#page=25	Homo sapiens		h	0.79	3h infusion			8	Ozagrel sodium		false
1075	468		ADULT	5282440	228.2466	OZAGREL	Ozagrel	OC(=O)\\C=C\\C1=CC=C(CN2C=CN=C2)C=C1	PLASMA	L256JB984D									?	ng × h/mL	4659.2		ng/mL	1657.3			UNKNOWN	μg/kg/min	15		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/230034_3999411H2038_1_005_1F.pdf#page=25	Homo sapiens		h	0.66	3h infusion			4	Ozagrel sodium		false
1076	468		ADULT	5282440	228.2466	OZAGREL	Ozagrel	OC(=O)\\C=C\\C1=CC=C(CN2C=CN=C2)C=C1	PLASMA	L256JB984D									?	ng × h/mL	197.4		ng/mL	576.5			UNKNOWN	mg	5		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/230034_3999411H2038_1_005_1F.pdf#page=26	Homo sapiens		h	2.09				4	Ozagrel sodium		false
1077	468		ADULT	5282440	228.2466	OZAGREL	Ozagrel	OC(=O)\\C=C\\C1=CC=C(CN2C=CN=C2)C=C1	PLASMA	L256JB984D									?	ng × h/mL	3913.2		ng/mL	1928.8			UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/230034_4490012F1026_1_003_1F.pdf#page=19	Homo sapiens		h	1.45					Ozagrel hydrochloride		false
1078	468		ADULT	5282440	228.2466	OZAGREL	Ozagrel	OC(=O)\\C=C\\C1=CC=C(CN2C=CN=C2)C=C1	PLASMA	L256JB984D									?	ng × h/mL	3360		ng/mL	2020			UNKNOWN	mg	200		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/230034_4490012F1026_1_003_1F.pdf#page=19	Homo sapiens		h	0.74	Day 1				Ozagrel hydrochloride		false
1079	468		ADULT	5282440	228.2466	OZAGREL	Ozagrel	OC(=O)\\C=C\\C1=CC=C(CN2C=CN=C2)C=C1	PLASMA	L256JB984D									?	ng × h/mL	3500		ng/mL	1940			UNKNOWN	mg	200		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/230034_4490012F1026_1_003_1F.pdf#page=19	Homo sapiens		h	0.76	Day 3				Ozagrel hydrochloride		false
1080	468			5282440	228.2466	OZAGREL	Ozagrel	OC(=O)\\C=C\\C1=CC=C(CN2C=CN=C2)C=C1	SERUM	L256JB984D																										Human serum protein binding: 54% (62.5 mcM)	46				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/230034_4490012F1026_1_003_1F.pdf#page=19	Homo sapiens								Ozagrel hydrochloride		false
1081	469		ADULT	65957|40466872	318.2997	PAZUFLOXACIN	Pazufloxacin	C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2C4(N)CC4	SERUM	4CZ1R38NDI									∞	μg × h/mL	13.3		μg/mL	8.99			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/400022_6241401G1020_2_006_1F.pdf#page=48	Homo sapiens		h	1.65				5	Pazufloxacin mesilate		false
1082	469		ADULT	65957|40466872	318.2997	PAZUFLOXACIN	Pazufloxacin	C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2C4(N)CC4	SERUM	4CZ1R38NDI									∞	μg × h/mL	21.7		μg/mL	11			UNKNOWN	mg	500		SINGLE	FASTED						HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/400022_6241401G1020_2_006_1F.pdf#page=48	Homo sapiens		h	1.88				6	Pazufloxacin mesilate		false
1083	469		ADULT	65957|40466872	318.2997	PAZUFLOXACIN	Pazufloxacin	C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2C4(N)CC4	SERUM	4CZ1R38NDI									∞	μg × h/mL	59.42		μg/mL	18.45			UNKNOWN	mg	1000		SINGLE	FASTED						HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/400022_6241401G1020_2_006_1F.pdf#page=48	Homo sapiens		h	3				8	Pazufloxacin mesilate		false
1084	469		ADULT	65957|40466872	318.2997	PAZUFLOXACIN	Pazufloxacin	C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2C4(N)CC4	SERUM	4CZ1R38NDI													μg/mL	13			UNKNOWN	mg	500		MULTIPLE	FASTED		day	2			HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/400022_6241401G1020_2_006_1F.pdf#page=49	Homo sapiens				Day 2			6	Pazufloxacin mesilate		false
1085	469		ADULT	65957|40466872	318.2997	PAZUFLOXACIN	Pazufloxacin	C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2C4(N)CC4	SERUM	4CZ1R38NDI													μg/mL	11.6			UNKNOWN	mg	500		MULTIPLE	FASTED		day	2			HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/400022_6241401G1020_2_006_1F.pdf#page=49	Homo sapiens				Day 4			6	Pazufloxacin mesilate		false
1086	469		ADULT	65957|40466872	318.2997	PAZUFLOXACIN	Pazufloxacin	C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2C4(N)CC4	SERUM	4CZ1R38NDI													μg/mL	12.3			UNKNOWN	mg	500		MULTIPLE	FASTED		day	2			HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/400022_6241401G1020_2_006_1F.pdf#page=49	Homo sapiens				Day 5			6	Pazufloxacin mesilate		false
1087	469		ADULT	65957|40466872	318.2997	PAZUFLOXACIN	Pazufloxacin	C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2C4(N)CC4	SERUM	4CZ1R38NDI													μg/mL	11.2			UNKNOWN	mg	500		MULTIPLE	FASTED		day	2			HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/400022_6241401G1020_2_006_1F.pdf#page=49	Homo sapiens				Day 3			6	Pazufloxacin mesilate		false
1088	469		ADULT	65957|40466872	318.2997	PAZUFLOXACIN	Pazufloxacin	C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2C4(N)CC4	SERUM	4CZ1R38NDI							12		t	μg × h/mL	57.1		μg/mL	18.45			RECOMMENDED	mg	1000		MULTIPLE	FASTED		day	2			HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/400022_6241401G1020_2_006_1F.pdf#page=49	Homo sapiens		h	3	Day 1			8	Pazufloxacin mesilate		false
1089	469		ADULT	65957|40466872	318.2997	PAZUFLOXACIN	Pazufloxacin	C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2C4(N)CC4	SERUM	4CZ1R38NDI							12		t	μg × h/mL	57.81		μg/mL	23.38			RECOMMENDED	mg	1000		STEADY-STATE	FASTED		day	2			HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/400022_6241401G1020_2_006_1F.pdf#page=49	Homo sapiens		h	2.9	Day 6			6	Pazufloxacin mesilate		false
1090	469		ADULT	65957|40466872	318.2997	PAZUFLOXACIN	Pazufloxacin	C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2C4(N)CC4	SERUM	4CZ1R38NDI									∞	μg × h/mL	21.7		μg/mL	11			UNKNOWN	mg	500		MULTIPLE	FASTED		day	2			HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/400022_6241401G1020_2_006_1F.pdf#page=49 | https://www.pmda.go.jp/drugs/2002/P200200014/48029700_21400AMZ00456_X100_1.pdf#page=28	Homo sapiens		h	1.88	Day 1 (single dose)			6	Pazufloxacin mesilate		false
1091	469		ADULT	65957|40466872	318.2997	PAZUFLOXACIN	Pazufloxacin	C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2C4(N)CC4	SERUM	4CZ1R38NDI													μg/mL	10.9			UNKNOWN	mg	500		MULTIPLE	FASTED		day	2			HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/400022_6241401G1020_2_006_1F.pdf#page=49 | https://www.pmda.go.jp/drugs/2002/P200200014/48029700_21400AMZ00456_X100_1.pdf#page=28	Homo sapiens				Day 6 (single dose, last)			6	Pazufloxacin mesilate		false
1092	469		ADULT	65957|40466872	318.2997	PAZUFLOXACIN	Pazufloxacin	C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2C4(N)CC4	SERUM	4CZ1R38NDI									∞	μg × h/mL	37.2		μg/mL	18.3			UNKNOWN	mg	500		SINGLE	FASTED						HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/400022_6241401G1020_2_006_1F.pdf#page=50	Homo sapiens		h	2.04		Elderly subjects		10	Pazufloxacin mesilate		false
1093	469		ADULT	65957|40466872	318.2997	PAZUFLOXACIN	Pazufloxacin	C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2C4(N)CC4	SERUM	4CZ1R38NDI									∞	μg × h/mL	21.7		μg/mL	11			UNKNOWN	mg	500		SINGLE	FASTED						HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/400022_6241401G1020_2_006_1F.pdf#page=50	Homo sapiens		h	1.88		non-Elderly subjects		6	Pazufloxacin mesilate		false
1094	469		ADULT	65957|40466872	318.2997	PAZUFLOXACIN	Pazufloxacin	C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2C4(N)CC4	SERUM	4CZ1R38NDI									∞	μg × h/mL	59.42		μg/mL	18.45			RECOMMENDED	mg	1000		SINGLE	FASTED						HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/400022_6241401G1020_2_006_1F.pdf#page=50	Homo sapiens		h	3		non-Elderly subjects		8	Pazufloxacin mesilate		false
1095	469		ADULT	65957|40466872	318.2997	PAZUFLOXACIN	Pazufloxacin	C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2C4(N)CC4	SERUM	4CZ1R38NDI									∞	μg × h/mL	73.18		μg/mL	25.74			RECOMMENDED	mg	1000		SINGLE	FASTED						HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/400022_6241401G1020_2_006_1F.pdf#page=50	Homo sapiens		h	3		Elderly subjects		10	Pazufloxacin mesilate		false
1096	469		ADULT	65957|40466872	318.2997	PAZUFLOXACIN	Pazufloxacin	C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2C4(N)CC4	SERUM	4CZ1R38NDI									t	μg × h/mL	69.21		μg/mL	25.74			RECOMMENDED	mg	1000		MULTIPLE	FASTED		day	2			HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/400022_6241401G1020_2_006_1F.pdf#page=51	Homo sapiens		h	3	Day 1	Elderly subjects		10	Pazufloxacin mesilate		false
1097	469		ADULT	65957|40466872	318.2997	PAZUFLOXACIN	Pazufloxacin	C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2C4(N)CC4	SERUM	4CZ1R38NDI							12		t	μg × h/mL	71.33		μg/mL	25.44			RECOMMENDED	mg	1000		MULTIPLE	FASTED		day	2			HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/400022_6241401G1020_2_006_1F.pdf#page=51	Homo sapiens		h	3.6	Day 6	Elderly subjects		9	Pazufloxacin mesilate		false
1098	469		ADULT	65957|40466872	318.2997	PAZUFLOXACIN	Pazufloxacin	C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2C4(N)CC4	SERUM	4CZ1R38NDI									∞	μg × h/mL	241		μg/mL	13			RECOMMENDED	mg	1000		MULTIPLE	FASTED		day	2			UNHEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/400022_6241401G1020_2_006_1F.pdf#page=52	Homo sapiens		h	21.2		Chronic renal failure patients in dialysis (24-h after administration)		9	Pazufloxacin mesilate		false
1099	469		ADULT	65957|40466872	318.2997	PAZUFLOXACIN	Pazufloxacin	C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2C4(N)CC4	SERUM	4CZ1R38NDI									∞	μg × h/mL	421		μg/mL	10.47			UNKNOWN	mg	300		SINGLE	FASTED						UNHEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/400022_6241401G1020_2_006_1F.pdf#page=53 | https://www.jstage.jst.go.jp/article/chemotherapy1995/56/4/56_4_462/_article/-char/en	Homo sapiens		h	31.9		ESRD undergoing dialysis with renal cyst infection (administered right after dialysis)		9	Pazufloxacin mesilate		false
1100	469			65957|40466872	318.2997	PAZUFLOXACIN	Pazufloxacin	C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2C4(N)CC4	SERUM	4CZ1R38NDI																										Human serum protein binding: 30.7% (ultrafiltration)	69.3				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/400022_6241401G1020_2_006_1F.pdf#page=57	Homo sapiens										false
1101	470		ADULT	6451293	226.1415	PENTAERYTHRITOL DINITRATE	Pentaerythritol dinitrate	OCC(CO)(CO[N+]([O-])=O)CO[N+]([O-])=O	PLASMA	1U685G1XE6													ng/mL	17			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8573222/	Homo sapiens		h	4.5							false
1102	470		ADULT	6451293	226.1415	PENTAERYTHRITOL DINITRATE	Pentaerythritol dinitrate	OCC(CO)(CO[N+]([O-])=O)CO[N+]([O-])=O	PLASMA	1U685G1XE6													ng/mL	7.5			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8573222/	Homo sapiens		h	4.5							false
1103	470		ADULT	150933	181.1439	PENTAERYTHRITOL MONONITRATE	Pentaerythritol mononitrate	OCC(CO)(CO)CO[N+]([O-])=O	PLASMA	959217Q3I8													ng/mL	79			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8573222/	Homo sapiens		h	10.5							false
1104	470		ADULT	150933	181.1439	PENTAERYTHRITOL MONONITRATE	Pentaerythritol mononitrate	OCC(CO)(CO)CO[N+]([O-])=O	PLASMA	959217Q3I8													ng/mL	35			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8573222/	Homo sapiens		h	10.5							false
1105	473		ADULT	124225|74685708	349.38	ULIFLOXACIN	ULIFLOXACIN	CC1SC2=C(C(O)=O)C(=O)C3=CC(F)=C(C=C3N12)N4CCNCC4	PLASMA	C38638H76Y									∞	μg × h/mL	5		μg/mL	1.03			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12705176/	Homo sapiens		h	12.1				11	PRULIFLOXACIN		false
1106	473		ADULT	124225|74685708	349.38	ULIFLOXACIN	ULIFLOXACIN	CC1SC2=C(C(O)=O)C(=O)C3=CC(F)=C(C=C3N12)N4CCNCC4	PLASMA	C38638H76Y									∞	μg × h/mL	6.6		μg/mL	1.4			UNKNOWN	mg	450		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12705176/	Homo sapiens		h	10.6				11	PRULIFLOXACIN		false
1107	473		ADULT	124225|74685708	349.38	ULIFLOXACIN	ULIFLOXACIN	CC1SC2=C(C(O)=O)C(=O)C3=CC(F)=C(C=C3N12)N4CCNCC4	PLASMA	C38638H76Y									∞	μg × h/mL	7.3		μg/mL	1.6			HIGHEST STUDIED	mg	600		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12705176/	Homo sapiens		h	10.7				11	PRULIFLOXACIN		false
1108	473		ADULT	124225|74685708	349.38	ULIFLOXACIN	ULIFLOXACIN	CC1SC2=C(C(O)=O)C(=O)C3=CC(F)=C(C=C3N12)N4CCNCC4	PLASMA	C38638H76Y									∞	μg × h/mL	9.72		μg/mL	1.88			HIGHEST STUDIED	mg	400		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7983237/	Homo sapiens		h	7.94				6	PRULIFLOXACIN		false
1109	473		ADULT	124225|74685708	349.38	ULIFLOXACIN	ULIFLOXACIN	CC1SC2=C(C(O)=O)C(=O)C3=CC(F)=C(C=C3N12)N4CCNCC4	PLASMA	C38638H76Y									∞	μg × h/mL	3.99		μg/mL	0.68			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7983237/	Homo sapiens		h	7.72				6	PRULIFLOXACIN		false
1110	473		ADULT	124225|74685708	349.38	ULIFLOXACIN	ULIFLOXACIN	CC1SC2=C(C(O)=O)C(=O)C3=CC(F)=C(C=C3N12)N4CCNCC4	PLASMA	C38638H76Y									?	μg × h/mL	9.67		μg/mL	1.41			UNKNOWN	mg	300		STEADY-STATE	FED		day	2	Serum protein binding	54.8	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7983237/	Homo sapiens		h	8.3	7 days dosing			6	PRULIFLOXACIN		false
1111	473		ADULT	124225|74685708	349.38	ULIFLOXACIN	ULIFLOXACIN	CC1SC2=C(C(O)=O)C(=O)C3=CC(F)=C(C=C3N12)N4CCNCC4	PLASMA	C38638H76Y									∞	μg × h/mL	6.13		μg/mL	0.81			UNKNOWN	mg	200		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7983237/	Homo sapiens		h	7.44				6	PRULIFLOXACIN		false
1112	473		ADULT	124225|74685708	349.38	ULIFLOXACIN	ULIFLOXACIN	CC1SC2=C(C(O)=O)C(=O)C3=CC(F)=C(C=C3N12)N4CCNCC4	PLASMA	C38638H76Y									∞	μg × h/mL	6.41		μg/mL	1.09			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7983237/	Homo sapiens		h	8.92				6	PRULIFLOXACIN		false
1113	475		ADULT	2449	354.4394	SERATRODAST	SERATRODAST	CC1=C(C)C(=O)C(C(CCCCCC(O)=O)C2=CC=CC=C2)=C(C)C1=O	PLASMA	4U58JM421N							24		t	μg × h/mL	231		μg/mL	25.3			UNKNOWN	mg	160		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	FEMALE	EXPERIMENT	https://link.springer.com/article/10.2165/00044011-199714060-00008	Homo sapiens		h	40.6				6	SERATRODAST		false
1114	475		ADULT	2449	354.4394	SERATRODAST	SERATRODAST	CC1=C(C)C(=O)C(C(CCCCCC(O)=O)C2=CC=CC=C2)=C(C)C1=O	PLASMA	4U58JM421N							24		t	μg × h/mL	334		μg/mL	23.2			UNKNOWN	mg	240		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://link.springer.com/article/10.2165/00044011-199714060-00008	Homo sapiens		h	34.1				6	SERATRODAST		false
1115	475		ADULT	2449	354.4394	SERATRODAST	SERATRODAST	CC1=C(C)C(=O)C(C(CCCCCC(O)=O)C2=CC=CC=C2)=C(C)C1=O	PLASMA	4U58JM421N							24		t	μg × h/mL	351		μg/mL	22.9			HIGHEST STUDIED	mg	320		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://link.springer.com/article/10.2165/00044011-199714060-00008	Homo sapiens		h	42				6	SERATRODAST		false
1116	475		ADULT	2449	354.4394	SERATRODAST	SERATRODAST	CC1=C(C)C(=O)C(C(CCCCCC(O)=O)C2=CC=CC=C2)=C(C)C1=O	PLASMA	4U58JM421N									∞	μg × h/mL	192		μg/mL	11.4			UNKNOWN	mg	160		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://link.springer.com/article/10.2165/00044011-199714060-00008	Homo sapiens		h	18.5				6	SERATRODAST		false
1117	475		ADULT	2449	354.4394	SERATRODAST	SERATRODAST	CC1=C(C)C(=O)C(C(CCCCCC(O)=O)C2=CC=CC=C2)=C(C)C1=O	PLASMA	4U58JM421N									∞	μg × h/mL	385		μg/mL	16.8			UNKNOWN	mg	240		SINGLE	FASTED			-1			HEALTHY	Oral	FEMALE	EXPERIMENT	https://link.springer.com/article/10.2165/00044011-199714060-00008	Homo sapiens		h	20.4				6	SERATRODAST		false
1118	475		ADULT	2449	354.4394	SERATRODAST	SERATRODAST	CC1=C(C)C(=O)C(C(CCCCCC(O)=O)C2=CC=CC=C2)=C(C)C1=O	PLASMA	4U58JM421N									∞	μg × h/mL	271		μg/mL	11.6			HIGHEST STUDIED	mg	320		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://link.springer.com/article/10.2165/00044011-199714060-00008	Homo sapiens		h	16.5				5	SERATRODAST		false
1119	475		ADULT	2449	354.4394	SERATRODAST	SERATRODAST	CC1=C(C)C(=O)C(C(CCCCCC(O)=O)C2=CC=CC=C2)=C(C)C1=O	PLASMA	4U58JM421N									∞	μg × h/mL	302		μg/mL	13.8			UNKNOWN	mg	240		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://link.springer.com/article/10.2165/00044011-199714060-00008	Homo sapiens		h	26.2				6	SERATRODAST		false
1120	475		ADULT	2449	354.4394	SERATRODAST	SERATRODAST	CC1=C(C)C(=O)C(C(CCCCCC(O)=O)C2=CC=CC=C2)=C(C)C1=O	PLASMA	4U58JM421N							24		t	μg × h/mL	435		μg/mL	39.9			UNKNOWN	mg	240		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	FEMALE	EXPERIMENT	https://link.springer.com/article/10.2165/00044011-199714060-00008	Homo sapiens		h	40.3				6	SERATRODAST		false
1121	475		ADULT	2449	354.4394	SERATRODAST	SERATRODAST	CC1=C(C)C(=O)C(C(CCCCCC(O)=O)C2=CC=CC=C2)=C(C)C1=O	PLASMA	4U58JM421N							24		t	μg × h/mL	582		μg/mL	37.4			HIGHEST STUDIED	mg	320		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	FEMALE	EXPERIMENT	https://link.springer.com/article/10.2165/00044011-199714060-00008	Homo sapiens		h	27.9				4	SERATRODAST		false
1122	475		ADULT	2449	354.4394	SERATRODAST	SERATRODAST	CC1=C(C)C(=O)C(C(CCCCCC(O)=O)C2=CC=CC=C2)=C(C)C1=O	PLASMA	4U58JM421N							24		t	μg × h/mL	166		μg/mL	15.7			UNKNOWN	mg	160		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://link.springer.com/article/10.2165/00044011-199714060-00008	Homo sapiens		h	34.3				5	SERATRODAST		false
1123	475		ADULT	2449	354.4394	SERATRODAST	SERATRODAST	CC1=C(C)C(=O)C(C(CCCCCC(O)=O)C2=CC=CC=C2)=C(C)C1=O	PLASMA	4U58JM421N									∞	μg × h/mL	197		μg/mL	10.4			UNKNOWN	mg	160		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://link.springer.com/article/10.2165/00044011-199714060-00008	Homo sapiens		h	19.7				6	SERATRODAST		false
1124	475		ADULT	2449	354.4394	SERATRODAST	SERATRODAST	CC1=C(C)C(=O)C(C(CCCCCC(O)=O)C2=CC=CC=C2)=C(C)C1=O	PLASMA	4U58JM421N									∞	μg × h/mL	350		μg/mL	14.7			HIGHEST STUDIED	mg	320		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://link.springer.com/article/10.2165/00044011-199714060-00008	Homo sapiens		h	18				5	SERATRODAST		false
1125	476		ADULT	5282219	450.5	Sofalcone	Sofalcone		PLASMA	2B668TJX8E							12		t	μg × h/mL	1.26		μg/mL	0.39			UNKNOWN	mg	50		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17586104/	Homo sapiens		h	3.29				30	solfacone		false
1126	476		ADULT	5282219	450.5	solfacone	solfacone		PLASMA	2B668TJX8E							12		t	μg × h/mL	3.99		μg/mL	1.27			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17586104/	Homo sapiens		h	2.77				30	solfacone		false
1127	476		ADULT	5282219	450.5	solfacone	solfacone		PLASMA	2B668TJX8E							12		t	μg × h/mL	5.48		μg/mL	2.11			UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17586104/	Homo sapiens		h	3.38				30	solfacone		false
1128	477		ADULT	5311454	234.2909	STIRIPENTOL	STIRIPENTOL	CC(C)(C)C(O)C=CC1=CC2=C(OCO2)C=C1	PLASMA	R02XOT8V8I									∞	mg × h/L	8.3		mg/L	2.1			UNKNOWN	mg	500		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24725808/	Homo sapiens		h	2							false
1129	477		ADULT	5311454	234.2909	STIRIPENTOL	STIRIPENTOL	CC(C)(C)C(O)C=CC1=CC2=C(OCO2)C=C1	PLASMA	R02XOT8V8I									∞	mg × h/L	31		mg/L	6.5			UNKNOWN	mg	1000		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24725808/	Homo sapiens		h	7.7							false
1130	477		ADULT	5311454	234.2909	STIRIPENTOL	STIRIPENTOL	CC(C)(C)C(O)C=CC1=CC2=C(OCO2)C=C1	PLASMA	R02XOT8V8I									∞	mg × h/L	88		mg/L	14			UNKNOWN	mg	2000		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24725808/	Homo sapiens		h	10							false
1131	479		CHILD	71774|101611567	328.447	SUPLATAST	Suplatast	CCOCC(O)COC1=CC=C(NC(=O)CC[S ](C)C)C=C1	PLASMA	4T0HO29O56							24		t	ng × h/mL	407.4		ng/mL	59.6			RECOMMENDED	mg/kg bw	3		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400107_4490016R1020_1_03B_1F.pdf#page=17	Homo sapiens		h	3		Asthma patients		10	Suplatast tosilate		false
1132	479		CHILD	71774|101611567	328.447	SUPLATAST	Suplatast	CCOCC(O)COC1=CC=C(NC(=O)CC[S ](C)C)C=C1	PLASMA	4T0HO29O56									?	ng × h/mL	230.5		ng/mL	27.6			RECOMMENDED	mg/kg bw	2		SINGLE	FED				AUC: n=6 for AUC(0-24h), n=1 for AUC(0-12h)		UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400107_4490016R1020_1_03B_1F.pdf#page=17	Homo sapiens		h	3.1		Asthma patients		7	Suplatast tosilate		false
1133	479		ADULT	71774|101611567	328.447	SUPLATAST	Suplatast	CCOCC(O)COC1=CC=C(NC(=O)CC[S ](C)C)C=C1	PLASMA	4T0HO29O56							24		t	ng × h/mL	257		ng/mL	39.6			RECOMMENDED	mg/kg bw	100		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400107_4490016R1020_1_03B_1F.pdf#page=17 | https://www.info.pmda.go.jp/go/interview/1/400107_4490016R1020_1_03B_1F.pdf#page=32	Homo sapiens		h	2.8					Suplatast tosilate		false
1134	479			71774|101611567	328.447	SUPLATAST	Suplatast	CCOCC(O)COC1=CC=C(NC(=O)CC[S ](C)C)C=C1	SERUM	4T0HO29O56																										Human serum protein binding: 2.13% (10 mcg/mL, equilibrium dialysis)	97.87				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400107_4490016R1020_1_03B_1F.pdf#page=34	Homo sapiens										false
1135	480		ADULT	5374	209.311	TALIPEXOLE	Talipexole	NC1=NC2=C(CCN(CC=C)CC2)S1	PLASMA	7AM2J46Z1Y									∞	ng × h/mL	10.9		ng/mL	0.95			UNKNOWN	mg	0.4		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19646081/	Homo sapiens		h	12.29				12	Talipexole hydrochloride		false
1136	480		ADULT	5374	209.311	TALIPEXOLE	Talipexole	NC1=NC2=C(CCN(CC=C)CC2)S1	PLASMA	7AM2J46Z1Y	6047|6971033	197.1879	LEVODOPA	L-dopa	N[C@@H](CC1=CC=C(O)C(O)=C1)C(O)=O	46627O600J			∞	ng × h/mL	10.42		ng/mL	0.89			UNKNOWN	mg	0.4		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19646081/	Homo sapiens		h	10.65			and Benserazide	12	Talipexole hydrochloride		true
1137	480		ADULT	5374	209.311	TALIPEXOLE	Talipexole	NC1=NC2=C(CCN(CC=C)CC2)S1	PLASMA	7AM2J46Z1Y									?	pg × h/mL	4949		pg/mL	658			UNKNOWN	mg	0.2		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/650168_1169009F1020_1_198_1F.pdf#page=26	Homo sapiens		h	5.1				6			false
1138	480			5374	209.311	TALIPEXOLE	Talipexole	NC1=NC2=C(CCN(CC=C)CC2)S1	PLASMA	7AM2J46Z1Y																										Human plasma protein binding: 33.3~39.4%	60.6				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/650168_1169009F1020_1_198_1F.pdf#ppage=28	Homo sapiens										false
1139	482		ADULT	5282199	330.5472	TETRAPRENYLACETONE	TETRAPRENYLACETONE	CC(=O)CC\\C=C(/C)CC\\C=C(/C)CC\\C=C(/C)CCC=C(C)C	PLASMA	57B67OXM8F							24		t	ng × h/mL	851.7		ng/mL	246.9			UNKNOWN	mg	50		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17482416/	Homo sapiens		h	3.38				20	TETRAPRENYLACETONE		false
1140	483		ADULT	5467	328.427	TIAPRIDE	Tiapride	CCN(CC)CCNC(=O)C1=C(OC)C=CC(=C1)S(C)(=O)=O	SERUM	LAH70H9JPH							7		t	μg × h/mL	5.89		μg/mL	1.47			UNKNOWN	mg	100		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2948825/	Homo sapiens		min	229		5 patients with tardive dyskinesia (TD) and 2 patients with Huntington's disease (HD)		7			false
1141	483			5467	328.427	TIAPRIDE	Tiapride	CCN(CC)CCNC(=O)C1=C(OC)C=CC(=C1)S(C)(=O)=O	SERUM	LAH70H9JPH																										No protein binding could be detected using an in vitro dialysis technique. (equilibrium dialysis)	100				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2948825/	Homo sapiens										false
1142	483		ADULT	5467	328.427	TIAPRIDE	Tiapride	CCN(CC)CCNC(=O)C1=C(OC)C=CC(=C1)S(C)(=O)=O	SERUM	LAH70H9JPH							24		t	ng × h/mL	1332		ng/mL	213.4			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400813_1190004F1161_1_007_1F.pdf#page=17	Homo sapiens		h	3.5	25mg tablets			14			false
1143	483		ADULT	5467	328.427	TIAPRIDE	Tiapride	CCN(CC)CCNC(=O)C1=C(OC)C=CC(=C1)S(C)(=O)=O	SERUM	LAH70H9JPH													ng/mL	720			RECOMMENDED	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/4/530169_1190004C1025_4_016_1F.pdf#page=22	Homo sapiens		h	3.91				6			false
1144	483		ADULT	5467	328.427	TIAPRIDE	Tiapride	CCN(CC)CCNC(=O)C1=C(OC)C=CC(=C1)S(C)(=O)=O	SERUM	LAH70H9JPH									?	μg × h/mL	5.89		μg/mL	0.876			RECOMMENDED	mg	100		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/4/530169_1190004C1025_4_016_1F.pdf#page=22	Homo sapiens		h	3.91		Elderly patients (60~79 y, average 67 y)		6			false
1145	483		ADULT	5467	328.427	TIAPRIDE	Tiapride	CCN(CC)CCNC(=O)C1=C(OC)C=CC(=C1)S(C)(=O)=O	SERUM	LAH70H9JPH																	RECOMMENDED	mg	100		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/4/530169_1190004C1025_4_016_1F.pdf#page=23	Homo sapiens		h	21.6		Severe renal impairment, CLcr: 0~10		5			false
1146	483		ADULT	5467	328.427	TIAPRIDE	Tiapride	CCN(CC)CCNC(=O)C1=C(OC)C=CC(=C1)S(C)(=O)=O	SERUM	LAH70H9JPH																	RECOMMENDED	mg	100		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/4/530169_1190004C1025_4_016_1F.pdf#page=23	Homo sapiens		h	8.63		Severe renal impairment, CLcr: 11~30		1			false
1147	483		ADULT	5467	328.427	TIAPRIDE	Tiapride	CCN(CC)CCNC(=O)C1=C(OC)C=CC(=C1)S(C)(=O)=O	SERUM	LAH70H9JPH																	RECOMMENDED	mg	100		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/4/530169_1190004C1025_4_016_1F.pdf#page=23	Homo sapiens		h	7.54		Moderate renal impairment, CLcr: 31~60		3			false
1148	483		ADULT	5467	328.427	TIAPRIDE	Tiapride	CCN(CC)CCNC(=O)C1=C(OC)C=CC(=C1)S(C)(=O)=O	SERUM	LAH70H9JPH																	RECOMMENDED	mg	100		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/4/530169_1190004C1025_4_016_1F.pdf#page=23	Homo sapiens		h	4.24		Moderate renal impairment, CLcr: 61~90		4			false
1149	483			5467	328.427	TIAPRIDE	Tiapride	CCN(CC)CCNC(=O)C1=C(OC)C=CC(=C1)S(C)(=O)=O	PLASMA	LAH70H9JPH																										Human plasma protein binding: <10% (equilibrium dialysis)	90				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/4/530169_1190004C1025_4_016_1F.pdf#page=24	Homo sapiens										false
1150	484		ADULT	73951793	312.4458	TIBOLONE	TIBOLONE	C[C@@H]1CC2=C(CCC(=O)C2)[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(O)C#C)[C@H]13	PLASMA	FF9X0205V2													ng/mL	1.47			DEFINED DAILY	mg	2.5		SINGLE	HIGH-FAT						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11899948/	Homo sapiens							26	TIBOLONE		false
1151	484		ADULT		314.5	3.BETA.-HYDROXYTIBOLONE	3.BETA.-HYDROXYTIBOLONE		PLASMA	TEP8IU9GMR									∞	ng × h/mL	15.36		ng/mL	3.77			DEFINED DAILY	mg	2.5		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11899948/	Homo sapiens		h	5.61				22	TIBOLONE		false
1152	484		ADULT		314.5	3.BETA.-HYDROXYTIBOLONE	3.BETA.-HYDROXYTIBOLONE		PLASMA	TEP8IU9GMR									∞	ng × h/mL	17.38		ng/mL	3.22			DEFINED DAILY	mg	2.5		SINGLE	HIGH-FAT						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11899948/	Homo sapiens		h	5.08				24	TIBOLONE		false
1153	484		ADULT		314.4617	3.ALPHA.-HYDROXYTIBOLONE	3.ALPHA.-HYDROXYTIBOLONE	C[C@@H]1CC2=C(CC[C@@H](O)C2)[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(O)C#C)[C@H]13	PLASMA	37T303O94A									∞	ng × h/mL	47.78		ng/mL	9.6			DEFINED DAILY	mg	2.5		SINGLE	HIGH-FAT						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11899948/	Homo sapiens		h	4.96				24	TIBOLONE		false
1154	484		ADULT	73951793	312.4458	TIBOLONE	TIBOLONE	C[C@@H]1CC2=C(CCC(=O)C2)[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(O)C#C)[C@H]13	PLASMA	FF9X0205V2													ng/mL	1.44			DEFINED DAILY	mg	2.5		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11899948/	Homo sapiens							24	TIBOLONE		false
1155	484		ADULT		314.4617	3.ALPHA.-HYDROXYTIBOLONE	3.ALPHA.-HYDROXYTIBOLONE	C[C@@H]1CC2=C(CC[C@@H](O)C2)[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(O)C#C)[C@H]13	PLASMA	37T303O94A									∞	ng × h/mL	45.04		ng/mL	12.97			DEFINED DAILY	mg	2.5		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11899948/	Homo sapiens		h	5.32				24	TIBOLONE		false
1156	484		ADULT	73951793	312.4458	TIBOLONE	TIBOLONE	C[C@@H]1CC2=C(CCC(=O)C2)[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(O)C#C)[C@H]13	PLASMA	FF9X0205V2													ng/mL	1.5			DEFINED DAILY	mg	2.5		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12207627/	Homo sapiens					early (age 45-55 years) postmenopausal women		16	TIBOLONE		false
1157	484		ADULT	73951793	312.4458	TIBOLONE	TIBOLONE	C[C@@H]1CC2=C(CCC(=O)C2)[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(O)C#C)[C@H]13	PLASMA	FF9X0205V2													ng/mL	1.6			DEFINED DAILY	mg	2.5		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12207627/	Homo sapiens					late (65-75 years) postmenopausal women		16	TIBOLONE		false
1158	484		ADULT		314.4617	3.ALPHA.-HYDROXYTIBOLONE	3.ALPHA.-HYDROXYTIBOLONE	C[C@@H]1CC2=C(CC[C@@H](O)C2)[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(O)C#C)[C@H]13	PLASMA	37T303O94A							16		t	ng × h/mL	29.2		ng/mL	10.9			UNKNOWN	mg	1.25		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12207627/	Homo sapiens		h	5.9		late (65-75 years) postmenopausal women		16	TIBOLONE		false
1159	484		ADULT		314.4617	3.ALPHA.-HYDROXYTIBOLONE	3.ALPHA.-HYDROXYTIBOLONE	C[C@@H]1CC2=C(CC[C@@H](O)C2)[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(O)C#C)[C@H]13	PLASMA	37T303O94A							16		t	ng × h/mL	45.4		ng/mL	14.6			DEFINED DAILY	mg	2.5		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12207627/	Homo sapiens		h	5.7		early (age 45-55 years) postmenopausal women		16	TIBOLONE		false
1160	484		ADULT	73951793	312.4458	TIBOLONE	TIBOLONE	C[C@@H]1CC2=C(CCC(=O)C2)[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(O)C#C)[C@H]13	PLASMA	FF9X0205V2													ng/mL	0.9			UNKNOWN	mg	1.25		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12207627/	Homo sapiens					early (age 45-55 years) postmenopausal women		16	TIBOLONE		false
1161	484		ADULT		314.5	3.BETA.-HYDROXYTIBOLONE	3.BETA.-HYDROXYTIBOLONE		PLASMA	TEP8IU9GMR							8		t	ng × h/mL	5.7		ng/mL	2.1			UNKNOWN	mg	1.25		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12207627/	Homo sapiens		h	6.2		late (65-75 years) postmenopausal women		16	TIBOLONE		false
1162	484		ADULT		314.5	3.BETA.-HYDROXYTIBOLONE	3.BETA.-HYDROXYTIBOLONE		PLASMA	TEP8IU9GMR							8		t	ng × h/mL	5.7		ng/mL	2.1			DEFINED DAILY	mg	2.5		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12207627/	Homo sapiens		h	6.2		early (age 45-55 years) postmenopausal women		16	TIBOLONE		false
1163	484		ADULT		314.4617	3.ALPHA.-HYDROXYTIBOLONE	3.ALPHA.-HYDROXYTIBOLONE	C[C@@H]1CC2=C(CC[C@@H](O)C2)[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(O)C#C)[C@H]13	PLASMA	37T303O94A							16		t	ng × h/mL	24.6		ng/mL	8.3			UNKNOWN	mg	1.25		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12207627/	Homo sapiens		h	6.4		early (age 45-55 years) postmenopausal women		16	TIBOLONE		false
1164	484		ADULT		314.5	3.BETA.-HYDROXYTIBOLONE	3.BETA.-HYDROXYTIBOLONE		PLASMA	TEP8IU9GMR							8		t	ng × h/mL	6.2		ng/mL	2.1			UNKNOWN	mg	1.25		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12207627/	Homo sapiens		h	6.2		early (age 45-55 years) postmenopausal women		16	TIBOLONE		false
1165	484		ADULT	73951793	312.4458	TIBOLONE	TIBOLONE	C[C@@H]1CC2=C(CCC(=O)C2)[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(O)C#C)[C@H]13	PLASMA	FF9X0205V2													ng/mL	1.1			UNKNOWN	mg	1.25		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12207627/	Homo sapiens					late (65-75 years) postmenopausal women		16	TIBOLONE		false
1166	484		ADULT		314.5	3.BETA.-HYDROXYTIBOLONE	3.BETA.-HYDROXYTIBOLONE		PLASMA	TEP8IU9GMR							8		t	ng × h/mL	10.9		ng/mL	3.7			DEFINED DAILY	mg	2.5		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12207627/	Homo sapiens		h	5.9		late (65-75 years) postmenopausal women		16	TIBOLONE		false
1167	484		ADULT		314.4617	3.ALPHA.-HYDROXYTIBOLONE	3.ALPHA.-HYDROXYTIBOLONE	C[C@@H]1CC2=C(CC[C@@H](O)C2)[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(O)C#C)[C@H]13	PLASMA	37T303O94A							16		t	ng × h/mL	55.7		ng/mL	16.7			DEFINED DAILY	mg	2.5		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12207627/	Homo sapiens		h	6		late (65-75 years) postmenopausal women		16	TIBOLONE		false
1168	486		ADULT	5531	205.2596	TRAPIDIL	trapidil	CCN(CC)C1=CC(C)=NC2=NC=NN12	PLASMA	EYG5Y6355E									?	μg × h/mL	20.5		μg/mL	5.14			RECOMMENDED	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8904615/	Homo sapiens		h	1.31				12	trapidil		false
1169	486		ADULT	5531	205.2596	TRAPIDIL	TRAPIDIL	CCN(CC)C1=CC(C)=NC2=NC=NN12	PLASMA	EYG5Y6355E									?	μg × h/mL	13.2		μg/mL	5.01			RECOMMENDED	mg	200		STEADY-STATE	UNKNOWN		day	3			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8904615/	Homo sapiens		h	1.14				12	TRAPIDIL		false
1170	486		ADULT	40136	177.21	desethyltrapidil	desethyltrapidil		PLASMA										?	μg × h/mL	16.2		μg/mL	1.5			RECOMMENDED	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8904615/	Homo sapiens							12	trapidil		false
1171	486		ADULT	40136	177.21	desethyltrapidil	desethyltrapidil		PLASMA										?	μg × h/mL	34.5		μg/mL	4.74			RECOMMENDED	mg	200		STEADY-STATE	UNKNOWN		day	3			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8904615/	Homo sapiens							10	trapidil		false
1172	486		ADULT	5531	205.2596	TRAPIDIL	trapidil	CCN(CC)C1=CC(C)=NC2=NC=NN12	PLASMA	EYG5Y6355E									?	μg × h/mL	20.8		μg/mL	5.67			RECOMMENDED	mg	200		STEADY-STATE	UNKNOWN		day	3			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8904615/	Homo sapiens		h	2.41				10	trapidil		false
1173	486		ADULT	40136	177.21	desethyltrapidil	desethyltrapidil		PLASMA										?	μg × h/mL	16.9		μg/mL	2.7			RECOMMENDED	mg	200		STEADY-STATE	UNKNOWN		day	3			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8904615/	Homo sapiens							12	trapidil		false
1174	487		ADULT	9882105	278.301	TREOSULFAN	TREOSULFAN	CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O	PLASMA	CO61ER3EPI									?	μg × h/mL	5980		μg/mL	1297			MAX TOLERATED	g/m²	47		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11106234/	Homo sapiens		h	2.16				3	TREOSULFAN		false
1175	487		ADULT	9882105	278.301	TREOSULFAN	TREOSULFAN	CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O	PLASMA	CO61ER3EPI									?	μg × h/mL	8040		μg/mL	1520			HIGHEST STUDIED	g/m²	56		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11106234/	Homo sapiens		h	3.06				1	TREOSULFAN		false
1176	487		ADULT	9882105	278.301	TREOSULFAN	TREOSULFAN	CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O	PLASMA	CO61ER3EPI									∞	μg × h/mL	708		μg/mL	465			UNKNOWN	g/m²	8		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9654108/	Homo sapiens		h	1.94	0.5-h intravenous infusion			14	TREOSULFAN		false
1177	487		ADULT	9882105	278.301	TREOSULFAN	TREOSULFAN	CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O	PLASMA	CO61ER3EPI									∞	μg × h/mL	977		μg/mL	597			UNKNOWN	g/m²	10		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9654108/	Homo sapiens		h	1.87	0.5-h intravenous infusion			7	TREOSULFAN		false
1178	487		ADULT	9882105	278.301	TREOSULFAN	TREOSULFAN	CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O	PLASMA	CO61ER3EPI									∞	μg × h/mL	940		μg/mL	306			UNKNOWN	g/m²	10		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9654108/	Homo sapiens		h	1.99	2-h intravenous infusion			3	TREOSULFAN		false
1179	487		ADULT	9882105	278.301	TREOSULFAN	TREOSULFAN	CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O	PLASMA	CO61ER3EPI									∞	μg × h/mL	541		μg/mL	181			UNKNOWN	g/m²	8		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9654108/	Homo sapiens		h	1.75	2-h intravenous infusion			4	TREOSULFAN		false
1180	487		ADULT	9882105	278.301	TREOSULFAN	TREOSULFAN	CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O	PLASMA	CO61ER3EPI													μg/mL	494			RECOMMENDED	g/m²	14		SINGLE	UNKNOWN				Treosulfan does not bind to plasma proteins.	100	UNHEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.ema.europa.eu/en/documents/product-information/trecondi-epar-product-information_en.pdf	Homo sapiens				2-hour intravenous infusion	size is unknown			TREOSULFAN		false
1181	487		ADULT	9882105	278.301	TREOSULFAN	TREOSULFAN	CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O	PLASMA	CO61ER3EPI													μg/mL	461			RECOMMENDED	g/m²	12		SINGLE	UNKNOWN				Treosulfan does not bind to plasma proteins.	100	UNHEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.ema.europa.eu/en/documents/product-information/trecondi-epar-product-information_en.pdf	Homo sapiens				2-hour intravenous infusion	size is unknown			TREOSULFAN		false
1182	487		ADULT	9882105	278.301	TREOSULFAN	TREOSULFAN	CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O	PLASMA	CO61ER3EPI													μg/mL	306			RECOMMENDED	g/m²	10		SINGLE	UNKNOWN				Treosulfan does not bind to plasma proteins.	100	UNHEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.ema.europa.eu/en/documents/product-information/trecondi-epar-product-information_en.pdf	Homo sapiens				2-hour intravenous infusion	size is unknown			TREOSULFAN		false
1183	489		ADULT	5597	294.3462	TROXIPIDE	Troxipide	COC1=CC(=CC(OC)=C1OC)C(=O)NC2CCCNC2	PLASMA	W6QJX1Q00Z							24		t	μg × h/mL	7.13		μg/mL	0.84			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/230109_2329015C1100_1_013_1F.pdf#page=16	Homo sapiens		h	7.4	Tablets			18			false
1184	489		ADULT	5597	294.3462	TROXIPIDE	Troxipide	COC1=CC(=CC(OC)=C1OC)C(=O)NC2CCCNC2	PLASMA	W6QJX1Q00Z							24		t	μg × h/mL	7.94		μg/mL	1.09			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/230109_2329015C1100_1_013_1F.pdf#page=16	Homo sapiens		h	7	Fine granules			20			false
1185	489			5597	294.3462	TROXIPIDE	Troxipide	COC1=CC(=CC(OC)=C1OC)C(=O)NC2CCCNC2	SERUM	W6QJX1Q00Z																										Human serum albumin binding: no (equilibrium dialysis)	100				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/230109_2329015C1100_1_013_1F.pdf#page=17	Homo sapiens										false
1186	490		ADULT	5639	387.476	URAPIDIL	Urapidil	COC1=C(C=CC=C1)N2CCN(CCCNC3=CC(=O)N(C)C(=O)N3C)CC2	PLASMA	A78GF17HJS									∞	ng × h/mL	6084.7484		ng/mL	976.0297			UNKNOWN	mg	60		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://innovareacademics.in/journals/index.php/ijpps/article/view/2902	Homo sapiens		h	4.1779				9			false
1187	490		ADULT	5639	387.476	URAPIDIL	Urapidil	COC1=C(C=CC=C1)N2CCN(CCCNC3=CC(=O)N(C)C(=O)N3C)CC2	PLASMA	A78GF17HJS									∞	ng × h/mL	6374.4837		ng/mL	1005.6091			UNKNOWN	mg	60		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://innovareacademics.in/journals/index.php/ijpps/article/view/2902	Homo sapiens		h	4.6332				10			false
1188	490			5639	387.476	URAPIDIL	Urapidil	COC1=C(C=CC=C1)N2CCN(CCCNC3=CC(=O)N(C)C(=O)N3C)CC2	PLASMA	A78GF17HJS																										The plasma protein binding is 80%.	20				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25838996/	Homo sapiens										false
1189	490		ADULT	5639	387.476	URAPIDIL	Urapidil	COC1=C(C=CC=C1)N2CCN(CCCNC3=CC(=O)N(C)C(=O)N3C)CC2	PLASMA	A78GF17HJS									∞	ng × h/mL	849		ng/mL	143.6			RECOMMENDED	mg	15		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/200022_2149020N1031_1_120_1F.pdf#page=32 | https://www.jstage.jst.go.jp/article/jscpt1970/18/2/18_2_407/_article/-char/en	Homo sapiens		h	2.66				6			false
1190	490		ADULT	5639	387.476	URAPIDIL	Urapidil	COC1=C(C=CC=C1)N2CCN(CCCNC3=CC(=O)N(C)C(=O)N3C)CC2	PLASMA	A78GF17HJS													ng/mL	271.4			DEFINED DAILY	mg	30		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/200022_2149020N1031_1_120_1F.pdf#page=32 | https://www.jstage.jst.go.jp/article/jscpt1970/18/2/18_2_407/_article/-char/en	Homo sapiens		h	3.8				14			false
1191	490		ADULT	5639	387.476	URAPIDIL	Urapidil	COC1=C(C=CC=C1)N2CCN(CCCNC3=CC(=O)N(C)C(=O)N3C)CC2	PLASMA	A78GF17HJS									?	ng × h/mL	1624		ng/mL	200.9			RECOMMENDED	mg	30		MULTIPLE	FED		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/200022_2149020N1031_1_120_1F.pdf#page=32 | https://www.jstage.jst.go.jp/article/jscpt1970/18/3/18_3_579/_article/-char/en	Homo sapiens		h	3.7	Day 1 (single dose)			6			false
1192	490		ADULT	5639	387.476	URAPIDIL	Urapidil	COC1=C(C=CC=C1)N2CCN(CCCNC3=CC(=O)N(C)C(=O)N3C)CC2	PLASMA	A78GF17HJS									?	ng × h/mL	1709		ng/mL	268.1			RECOMMENDED	mg	30		MULTIPLE	FED		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/200022_2149020N1031_1_120_1F.pdf#page=32 | https://www.jstage.jst.go.jp/article/jscpt1970/18/3/18_3_579/_article/-char/en	Homo sapiens		h	3.8	Day 7 (single dose)			6			false
1193	490		ADULT	5639	387.476	URAPIDIL	Urapidil	COC1=C(C=CC=C1)N2CCN(CCCNC3=CC(=O)N(C)C(=O)N3C)CC2	SERUM	A78GF17HJS																						UNKNOWN				Human serum protein binding: 87.4%	12.6	HEALTHY		UNKNOWN	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/200022_2149020N1031_1_120_1F.pdf#page=33	Homo sapiens										false
1194	490		ADULT	5639	387.476	URAPIDIL	Urapidil	COC1=C(C=CC=C1)N2CCN(CCCNC3=CC(=O)N(C)C(=O)N3C)CC2	PLASMA	A78GF17HJS									?	ng × h/mL	1593		ng/mL	164.1			RECOMMENDED	mg	15		MULTIPLE	FED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.jstage.jst.go.jp/article/jscpt1970/17/4/17_4_637/_article/-char/en	Homo sapiens		h	7.2	Day 1 (single dose)	Hypertensive Patients with Impaired Renal Function		7			false
1195	490		ADULT	5639	387.476	URAPIDIL	Urapidil	COC1=C(C=CC=C1)N2CCN(CCCNC3=CC(=O)N(C)C(=O)N3C)CC2	PLASMA	A78GF17HJS													ng/mL	205.5			RECOMMENDED	mg	15		MULTIPLE	FED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.jstage.jst.go.jp/article/jscpt1970/17/4/17_4_637/_article/-char/en	Homo sapiens		h	8.4	Day 7 (single dose)	Hypertensive Patients with Impaired Renal Function		7			false
1196	490		ADULT	5639	387.476	URAPIDIL	Urapidil	COC1=C(C=CC=C1)N2CCN(CCCNC3=CC(=O)N(C)C(=O)N3C)CC2	PLASMA	A78GF17HJS									∞	ng × h/mL	2386		ng/mL	243.3			DEFINED DAILY	mg	30		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.jstage.jst.go.jp/article/jscpt1970/18/2/18_2_407/_article/-char/en	Homo sapiens		h	5.92				6			false
1197	490		ADULT	5639	387.476	URAPIDIL	Urapidil	COC1=C(C=CC=C1)N2CCN(CCCNC3=CC(=O)N(C)C(=O)N3C)CC2	PLASMA	A78GF17HJS									∞	ng × h/mL	4523		ng/mL	487.4			DEFINED DAILY	mg	60		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.jstage.jst.go.jp/article/jscpt1970/18/2/18_2_407/_article/-char/en	Homo sapiens		h	4.37				6			false
1198	492		ADULT	26618	354.809	XIPAMIDE	XIPAMIDE	CC1=CC=CC(C)=C1NC(=O)C2=C(O)C=C(Cl)C(=C2)S(N)(=O)=O	URINE	4S9EY0NUEC																	MIN EFFICACIOUS	mg	20		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22197154/	Homo sapiens		h	10.031				6	XIPAMIDE		false
1199	492		ADULT	26618	354.809	XIPAMIDE	XIPAMIDE	CC1=CC=CC(C)=C1NC(=O)C2=C(O)C=C(Cl)C(=C2)S(N)(=O)=O	PLASMA	4S9EY0NUEC									∞	μg × min/mL	943						UNKNOWN	mg	20		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6734710/	Homo sapiens							14	XIPAMIDE		false
1200	492		ADULT	26618	354.809	XIPAMIDE	https://pubmed.ncbi.nlm.nih.gov/6734710/	CC1=CC=CC(C)=C1NC(=O)C2=C(O)C=C(Cl)C(=C2)S(N)(=O)=O	PLASMA	4S9EY0NUEC									∞	μg × min/mL	690		μg/mL	3			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6734710/	Homo sapiens		h	7				19	XIPAMIDE		false
1201	493		ADULT	5720	298.356	ZALTOPROFEN	Zaltoprofen	CC(C(O)=O)C1=CC2=C(SC3=C(C=CC=C3)C(=O)C2)C=C1	PLASMA	H8635NG3PY									∞	μg × h/mL	15.57		μg/mL	5.37			UNKNOWN	mg	80		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23554672/	Homo sapiens		h	4.83				12			false
1202	493		ADULT	5720	298.356	ZALTOPROFEN	Zaltoprofen	CC(C(O)=O)C1=CC2=C(SC3=C(C=CC=C3)C(=O)C2)C=C1	PLASMA	H8635NG3PY									∞	μg × h/mL	53.41		μg/mL	16.41			UNKNOWN	mg	240		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23554672/	Homo sapiens		h	4.83				12			false
1203	493		ADULT	5720	298.356	ZALTOPROFEN	Zaltoprofen	CC(C(O)=O)C1=CC2=C(SC3=C(C=CC=C3)C(=O)C2)C=C1	PLASMA	H8635NG3PY									∞	μg × h/mL	16.54		μg/mL	4.9			UNKNOWN	mg	80		STEADY-STATE	UNKNOWN		day	3			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23554672/	Homo sapiens		h	6.49	Day 7 (19th dose)			12			false
1204	493		ADULT	5720	298.356	ZALTOPROFEN	Zaltoprofen	CC(C(O)=O)C1=CC2=C(SC3=C(C=CC=C3)C(=O)C2)C=C1	PLASMA	H8635NG3PY									∞	μg × h/mL	41.61		μg/mL	12.32			UNKNOWN	mg	160		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23554672/	Homo sapiens		h	5.04				12			false
1205	493		ADULT	5720	298.356	ZALTOPROFEN	Zaltoprofen	CC(C(O)=O)C1=CC2=C(SC3=C(C=CC=C3)C(=O)C2)C=C1	PLASMA	H8635NG3PY									∞	μg × h/mL	19.66		μg/mL	4.85			UNKNOWN	mg	80		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29092729/	Homo sapiens		h	4.89	Capsules			24			false
1206	493		ADULT	5720	298.356	ZALTOPROFEN	Zaltoprofen	CC(C(O)=O)C1=CC2=C(SC3=C(C=CC=C3)C(=O)C2)C=C1	PLASMA	H8635NG3PY									∞	μg × h/mL	20.35		μg/mL	4.46			UNKNOWN	mg	80		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29092729/	Homo sapiens		h	4.95	Tablets			24			false
1207	493		ADULT	5720	298.356	ZALTOPROFEN	Zaltoprofen	CC(C(O)=O)C1=CC2=C(SC3=C(C=CC=C3)C(=O)C2)C=C1	PLASMA	H8635NG3PY									∞	μg × h/mL	20.14		μg/mL	3.71			UNKNOWN	mg	80		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29092729/	Homo sapiens		h	4.89	Capsules			24			false
1208	493		ADULT	5720	298.356	ZALTOPROFEN	Zaltoprofen	CC(C(O)=O)C1=CC2=C(SC3=C(C=CC=C3)C(=O)C2)C=C1	PLASMA	H8635NG3PY									∞	μg × h/mL	20.09		μg/mL	3.52			UNKNOWN	mg	80		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29092729/	Homo sapiens		h	4.87	Tablets			24			false
1209	493		ADULT	5720	298.356	ZALTOPROFEN	Zaltoprofen	CC(C(O)=O)C1=CC2=C(SC3=C(C=CC=C3)C(=O)C2)C=C1	PLASMA	H8635NG3PY									?	μg × h/mL	12.77		μg/mL	5			RECOMMENDED	mg	80		SINGLE	UNKNOWN				Human plasma protein binding: >98%	2	HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/530213_1149029F1025_1_1F.pdf#page=16	Homo sapiens		h	9.08				6			false
1210	495		ADULT	2169	380.459	AMOSULALOL	Amosulalol	COC1=C(OCCNCC(O)C2=CC=C(C)C(=C2)S(N)(=O)=O)C=CC=C1	PLASMA	C69JI1BAU8									∞	μg × h/mL	1.67		μg/mL	0.2			UNKNOWN	mg	12.5		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/171911_2149018F1021_1_LWT_2F.pdf#page=21 | https://pubmed.ncbi.nlm.nih.gov/6478731/	Homo sapiens		h	4.4				2	Amosulalol hydrochloride		false
1211	495		ADULT	2169	380.459	AMOSULALOL	Amosulalol	COC1=C(OCCNCC(O)C2=CC=C(C)C(=C2)S(N)(=O)=O)C=CC=C1	PLASMA	C69JI1BAU8									∞	μg × h/mL	3.64		μg/mL	0.49			RECOMMENDED	mg	25		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/171911_2149018F1021_1_LWT_2F.pdf#page=21 | https://pubmed.ncbi.nlm.nih.gov/6478731/	Homo sapiens		h	5.2				2	Amosulalol hydrochloride		false
1212	495		ADULT	2169	380.459	AMOSULALOL	Amosulalol	COC1=C(OCCNCC(O)C2=CC=C(C)C(=C2)S(N)(=O)=O)C=CC=C1	PLASMA	C69JI1BAU8									∞	μg × h/mL	6.07		μg/mL	1.11			RECOMMENDED	mg	50		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/171911_2149018F1021_1_LWT_2F.pdf#page=21 | https://pubmed.ncbi.nlm.nih.gov/6478731/	Homo sapiens		h	4.8				4	Amosulalol hydrochloride		false
1213	495		ADULT	2169	380.459	AMOSULALOL	Amosulalol	COC1=C(OCCNCC(O)C2=CC=C(C)C(=C2)S(N)(=O)=O)C=CC=C1	PLASMA	C69JI1BAU8									∞	μg × h/mL	12.58		μg/mL	1.87			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/171911_2149018F1021_1_LWT_2F.pdf#page=21 | https://pubmed.ncbi.nlm.nih.gov/6478731/	Homo sapiens		h	5.6				4	Amosulalol hydrochloride		false
1214	495		ADULT	2169	380.459	AMOSULALOL	Amosulalol	COC1=C(OCCNCC(O)C2=CC=C(C)C(=C2)S(N)(=O)=O)C=CC=C1	PLASMA	C69JI1BAU8									∞	μg × h/mL	22.09		μg/mL	4.09			UNKNOWN	mg	150		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/171911_2149018F1021_1_LWT_2F.pdf#page=21 | https://pubmed.ncbi.nlm.nih.gov/6478731/	Homo sapiens		h	5.7				6	Amosulalol hydrochloride		false
1215	495		ADULT	2169	380.459	AMOSULALOL	Amosulalol	COC1=C(OCCNCC(O)C2=CC=C(C)C(=C2)S(N)(=O)=O)C=CC=C1	PLASMA	C69JI1BAU8							24		t	μg × h/mL	2.661		μg/mL	0.311			RECOMMENDED	mg	30		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/171911_2149018F1021_1_LWT_2F.pdf#page=22	Homo sapiens		h	3.6				6	Amosulalol hydrochloride		false
1216	495		ADULT	2169	380.459	AMOSULALOL	Amosulalol	COC1=C(OCCNCC(O)C2=CC=C(C)C(=C2)S(N)(=O)=O)C=CC=C1	PLASMA	C69JI1BAU8							24		t	μg × h/mL	3.287		μg/mL	0.498			RECOMMENDED	mg	30		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/171911_2149018F1021_1_LWT_2F.pdf#page=22	Homo sapiens		h	3.1				6	Amosulalol hydrochloride		false
1217	495		ADULT	2169	380.459	AMOSULALOL	Amosulalol	COC1=C(OCCNCC(O)C2=CC=C(C)C(=C2)S(N)(=O)=O)C=CC=C1	PLASMA	C69JI1BAU8																						UNKNOWN				Human plasma protein binding: 96~98% (1~4h after administration of amosulalol hydrochloride)	2	HEALTHY		UNKNOWN	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/171911_2149018F1021_1_LWT_2F.pdf#page=23	Homo sapiens										false
1218	498		ADULT		436.3	[3H]-11-bromovincamine			PLASMA														ng × eq/mL	1900			UNKNOWN	mg	40		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4085521/	Homo sapiens		h	11				2	[3H]-11-bromovincamine fumarate		false
1219	499		ADULT	5284529	365.404	CEFROXADINE	CEFROXADINE	COC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C3=CCC=CC3)C2=O)C(O)=O	PLASMA	B908C4MV2R							6		t	μg × h/mL	46.25		μg/mL	17.62			UNKNOWN	mg	500		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16137854/	Homo sapiens		h	1				9	CEFROXADINE		false
1220	499		ADULT	5284529	365.404	CEFROXADINE	CEFROXADINE	COC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C3=CCC=CC3)C2=O)C(O)=O	PLASMA	B908C4MV2R									?	μg × h/mL	21.3		μg/mL	16			UNKNOWN	mg	424		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7069577/	Homo sapiens		h	1.03				4	CEFROXADINE		false
1221	499		ADULT	5284529	365.404	CEFROXADINE	CEFROXADINE	COC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C3=CCC=CC3)C2=O)C(O)=O	PLASMA	B908C4MV2R									?	μg × h/mL	2.55						UNKNOWN	mg	50		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7069577/	Homo sapiens		h	0.74				4	CEFROXADINE		false
1222	499		ADULT	5284529	365.404	CEFROXADINE	CEFROXADINE	COC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C3=CCC=CC3)C2=O)C(O)=O	PLASMA	B908C4MV2R									?	μg × h/mL	10.1		μg/mL	7.6			UNKNOWN	mg	212		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7069577/	Homo sapiens		h	1.03				4	CEFROXADINE		false
1223	499		ADULT	5284529	365.404	CEFROXADINE	CEFROXADINE	COC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C3=CCC=CC3)C2=O)C(O)=O	PLASMA	B908C4MV2R									?	μg × h/mL	44.4		μg/mL	28.8			HIGHEST STUDIED	mg	847		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7069577/	Homo sapiens		h	1.03				4	CEFROXADINE		false
1224	499		ADULT	5284529	365.404	CEFROXADINE	CEFROXADINE	COC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C3=CCC=CC3)C2=O)C(O)=O	SERUM	B908C4MV2R									?	μg × h/mL	12.07		μg/mL	7.7			UNKNOWN	mg	250		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7389422/	Homo sapiens		h	0.85				11	CEFROXADINE		false
1225	499		ADULT	5284529	365.404	CEFROXADINE	CEFROXADINE	COC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C3=CCC=CC3)C2=O)C(O)=O	SERUM	B908C4MV2R									?	μg × h/mL	23.59		μg/mL	12.3			HIGHEST STUDIED	mg	500		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7389422/	Homo sapiens		h	0.92				11	CEFROXADINE		false
1226	499		ADULT	5284529	365.404	CEFROXADINE	CEFROXADINE	COC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C3=CCC=CC3)C2=O)C(O)=O	SERUM	B908C4MV2R									?	μg × h/mL	6.1		μg/mL	4.5			UNKNOWN	mg	125		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7389422/	Homo sapiens		h	1.13				11	CEFROXADINE		false
1227	501		CHILD	3081431	399.5	21-Desacetyldeflazacort	21-desDFZ		PLASMA	T1LWN33J2P									∞	ng × h/mL	400		ng/mL	206			UNKNOWN	mg/kg	0.9		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf	Homo sapiens										false
1228	501		ADOLESCENT	3081431	399.5	21-Desacetyldeflazacort	21-desDFZ		PLASMA	T1LWN33J2P									∞	ng × h/mL	655		ng/mL	381			UNKNOWN	mg/kg	0.9		SINGLE	UNKNOWN				It is 40% protein bound and has no affinity for corticosteroid binding globulin (transcortin) and binds to plasma protein and blood cells instead	60	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf	Homo sapiens										false
1229	502		ADULT	681	153.1784	DOPAMINE	Dopamine	NCCC1=CC=C(O)C(O)=C1	PLASMA	VTD58H1Z2X							5		t	ng × h/mL	100.6		ng/mL	53.1			UNKNOWN	mg	750		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10484011/	Homo sapiens		h	0.8		Cirrhotic patients		7			false
1230	502		ADULT	681	153.1784	DOPAMINE	Dopamine	NCCC1=CC=C(O)C(O)=C1	PLASMA	VTD58H1Z2X							5		t	ng × h/mL	100		ng/mL	62.6			UNKNOWN	mg	750		MULTIPLE	FED		day	3			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10484011/	Homo sapiens		h	0.8	7 day administration	Cirrhotic patients		7			false
1231	502		ADULT	681	153.1784	DOPAMINE	Dopamine	NCCC1=CC=C(O)C(O)=C1	PLASMA	VTD58H1Z2X							5		t	ng × h/mL	97.5		ng/mL	76.8			UNKNOWN	mg	750		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10484011/	Homo sapiens		h	0.8		Cirrhotic patients		6			false
1232	502		ADULT	681	153.1784	DOPAMINE	Dopamine	NCCC1=CC=C(O)C(O)=C1	PLASMA	VTD58H1Z2X							24		t	ng × h/mL	97		ng/mL	63			UNKNOWN	mg	750		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400315_2119007D1031_1_08A_1F.pdf#page=20	Homo sapiens		h	0.7				9			false
1233	502		ADULT	71137	470.537	DOCARPAMINE	Docarpamine	CCOC(=O)OC1=C(OC(=O)OCC)C=C(CCNC(=O)[C@H](CCSC)NC(C)=O)C=C1	SERUM	RPQ57D8S72																										Human plasma protein binding: 40.5% (5 mcg/mL)	59.5	HEALTHY		MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400315_2119007D1031_1_08A_1F.pdf#page=21 | https://www.jstage.jst.go.jp/article/dmpk1986/6/2/6_2_277/_article/-char/en	Homo sapiens										false
1234	503		ADULT	65858	278.367	EGUALEN	Egualen	CCC1=C2C=CC=C(C=C2C(=C1)S(O)(=O)=O)C(C)C	PLASMA	17VM9WN49U									?	ng × h/mL	10744.1		ng/mL	1272			RECOMMENDED	mg	15		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/270139_2323002D1032_2_006_1F.pdf#page=23	Homo sapiens		h	7.8	Tablets			16	Egualen sodium hydrate		false
1235	503		ADULT	65858	278.367	EGUALEN	Egualen	CCC1=C2C=CC=C(C=C2C(=C1)S(O)(=O)=O)C(C)C	PLASMA	17VM9WN49U									?	ng × h/mL	11710.9		ng/mL	1417.7			RECOMMENDED	mg	15		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/270139_2323002D1032_2_006_1F.pdf#page=23	Homo sapiens		h	7.9	Granules			16	Egualen sodium hydrate		false
1236	503		ADULT	65858	278.367	EGUALEN	Egualen	CCC1=C2C=CC=C(C=C2C(=C1)S(O)(=O)=O)C(C)C	PLASMA	17VM9WN49U									?	μg × h/mL	6		μg/mL	0.6			UNKNOWN	mg	10		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/270139_2323002D1032_2_006_1F.pdf#page=24	Homo sapiens		h	4.6				6	Egualen sodium hydrate		false
1237	503		ADULT	65858	278.367	EGUALEN	Egualen	CCC1=C2C=CC=C(C=C2C(=C1)S(O)(=O)=O)C(C)C	PLASMA	17VM9WN49U									?	μg × h/mL	7.2		μg/mL	0.58			RECOMMENDED	mg	15		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/270139_2323002D1032_2_006_1F.pdf#page=24	Homo sapiens		h	5.9				6	Egualen sodium hydrate		false
1238	503		ADULT	65858	278.367	EGUALEN	Egualen	CCC1=C2C=CC=C(C=C2C(=C1)S(O)(=O)=O)C(C)C	PLASMA	17VM9WN49U									?	μg × h/mL	18.2		μg/mL	1.84			MAX DAILY	mg	30		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/270139_2323002D1032_2_006_1F.pdf#page=24	Homo sapiens		h	4.4				6	Egualen sodium hydrate		false
1239	503		ADULT	65858	278.367	EGUALEN	Egualen	CCC1=C2C=CC=C(C=C2C(=C1)S(O)(=O)=O)C(C)C	PLASMA	17VM9WN49U																						UNKNOWN				Plasma protein binding: 98.3% (0.3mcg/mL), 98.3% (1.0mcg/mL), 98.3% (.03mcg/mL), 98.2% (10.0mcg/mL); equilibrium dialysis	1.7	HEALTHY		MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/270139_2323002D1032_2_006_1F.pdf#page=25 | https://www.jstage.jst.go.jp/article/dmpk1986/5/3/5_3_375/_article/-char/en	Homo sapiens								Egualen sodium hydrate		false
1240	503		ADULT	65858	278.367	EGUALEN	Egualen	CCC1=C2C=CC=C(C=C2C(=C1)S(O)(=O)=O)C(C)C	PLASMA	17VM9WN49U																	RECOMMENDED	mg	15		SINGLE	FASTED				Plasma protein binding: 99.8% (4 and 8h after egualen sodium hydrate administration); equilibrium dialysis	0.2	HEALTHY	Oral	MALE	OTHER GOV'T	https://www.jstage.jst.go.jp/article/dmpk1986/5/3/5_3_375/_article/-char/en	Homo sapiens							3	Egualen sodium hydrate		false
1241	504		ADULT	3042090	231.3333	EPTAZOCINE	Eptazocine	CN1CC[C@]2(C)C[C@@H](CC3=CC=C(O)C=C23)C1	PLASMA	2208ZLI77S									?	ng × h/mL	82.34		ng/mL	29.97			UNKNOWN	mg	15		SINGLE	UNKNOWN						HEALTHY	Subcutaneous	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/530169_1149405A1025_1_004_1F.pdf#page-16	Homo sapiens		h	1.77				12			false
1242	504		ADULT	3042090	231.3333	EPTAZOCINE	Eptazocine	CN1CC[C@]2(C)C[C@@H](CC3=CC=C(O)C=C23)C1	PLASMA	2208ZLI77S									?	ng × h/mL	95.64		ng/mL	34.86			UNKNOWN	mg	15		SINGLE	UNKNOWN						HEALTHY	Intramuscular	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/530169_1149405A1025_1_004_1F.pdf#page=16	Homo sapiens		h	1.66				12			false
1243	504		ADULT	3042090	231.3333	EPTAZOCINE	Eptazocine	CN1CC[C@]2(C)C[C@@H](CC3=CC=C(O)C=C23)C1	PLASMA	2208ZLI77S	948	44.0128	NITROUS OXIDE	Nitrous oxide	[O-][N ]#N	K50XQU1029			?	μg × min/mL	119.1						UNKNOWN	mg	60		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.jstage.jst.go.jp/article/jscpt1970/22/4/22_4_731/_article/-char/en	Homo sapiens		min	108.9			Nitrous oxide, oxygen and enflurane anesthesia	5			true
1244	504		ADULT	3042090	231.3333	EPTAZOCINE	Eptazocine	CN1CC[C@]2(C)C[C@@H](CC3=CC=C(O)C=C23)C1	PLASMA	2208ZLI77S									?	μg × min/mL	143.6						UNKNOWN	mg	90		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	MALE	EXPERIMENT	https://www.jstage.jst.go.jp/article/jscpt1970/22/4/22_4_731/_article/-char/en	Homo sapiens		min	110.3				5			false
1245	505			155667	332.714	LOFLAZEPIC ACID	Loflazepic acid	OC(=O)C1N=C(C2=CC=CC=C2F)C3=C(NC1=O)C=CC(Cl)=C3	SERUM	Y3R871DUQ5																										Human serum protein binding (ultrafiltration): >99% (100ng/mL Loflazepic acid), 96.0% (500ng/mL Loflazepic acid)	1				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/780009_1124029C1038_1_1F.pdf#page=23	Homo sapiens										false
1246	505			4540	288.704	NORFLURAZEPAM	Norflurazepam	FC1=C(C=CC=C1)C2=NCC(=O)NC3=CC=C(Cl)C=C23	SERUM	X9U41NXR6M																										Human serum protein binding (ultrafiltration): 98.6% (100ng/mL Norflurazepam), 94.3% (500ng/mL Norflurazepam)	1.4				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/780009_1124029C1038_1_1F.pdf#page=23	Homo sapiens										false
1247	506		ADULT	5282190	524.5792	FALECALCITRIOL	FALECALCITRIOL	C[C@H](CCCC(O)(C(F)(F)F)C(F)(F)F)[C@H]1CC[C@H]2\\C(CCC[C@]12C)=C\\C=C3\\C[C@@H](O)C[C@H](O)C3=C	SERUM	G70A8514T8													pg/mL	28			UNKNOWN	μg	2		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8155746/	Homo sapiens		h	15				12	FALECALCITRIOL		false
1248	509		ADULT	178039	313.3974	INDISETRON	Indisetron	CN1C[C@@H]2C[C@@H](C[C@H](C1)N2C)NC(=O)C3=NNC4=C3C=CC=C4	PLASMA	89RBZ66NVC									∞	ng × h/mL	277.3		ng/mL	34.7			UNKNOWN	mg	4		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2004/P200400003/53011600_21600AMZ00038_X100_1.pdf#page=17	Homo sapiens		h	5.93				6			false
1249	509		ADULT	178039	313.3974	INDISETRON	Indisetron	CN1C[C@@H]2C[C@@H](C[C@H](C1)N2C)NC(=O)C3=NNC4=C3C=CC=C4	PLASMA	89RBZ66NVC									∞	ng × h/mL	438.4		ng/mL	59			UNKNOWN	mg	8		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2004/P200400003/53011600_21600AMZ00038_X100_1.pdf#page=17	Homo sapiens		h	4.4				6			false
1250	509		ADULT	178039	313.3974	INDISETRON	Indisetron	CN1C[C@@H]2C[C@@H](C[C@H](C1)N2C)NC(=O)C3=NNC4=C3C=CC=C4	PLASMA	89RBZ66NVC									∞	ng × h/mL	1208.34		ng/mL	164.59			UNKNOWN	mg	16		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2004/P200400003/53011600_21600AMZ00038_X100_1.pdf#page=17	Homo sapiens		h	6.25				6			false
1251	509		ADULT	178039	313.3974	INDISETRON	Indisetron	CN1C[C@@H]2C[C@@H](C[C@H](C1)N2C)NC(=O)C3=NNC4=C3C=CC=C4	PLASMA	89RBZ66NVC									∞	ng × h/mL	2488.7		ng/mL	339.1			UNKNOWN	mg	32		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2004/P200400003/53011600_21600AMZ00038_X100_1.pdf#page=17	Homo sapiens		h	6.09				6			false
1252	509		ADULT	178039	313.3974	INDISETRON	Indisetron	CN1C[C@@H]2C[C@@H](C[C@H](C1)N2C)NC(=O)C3=NNC4=C3C=CC=C4	PLASMA	89RBZ66NVC									∞	ng × h/mL	1103.6		ng/mL	128.5			UNKNOWN	mg	16		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2004/P200400003/53011600_21600AMZ00038_X100_1.pdf#page=18	Homo sapiens		h	6.04				6			false
1253	509		ADULT	178039	313.3974	INDISETRON	Indisetron	CN1C[C@@H]2C[C@@H](C[C@H](C1)N2C)NC(=O)C3=NNC4=C3C=CC=C4	PLASMA	89RBZ66NVC							24		t	ng × h/mL	1229.7		ng/mL	185.6			UNKNOWN	mg	16		MULTIPLE	FASTED		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2004/P200400003/53011600_21600AMZ00038_X101_1.pdf#page=2	Homo sapiens		h	5.1	Day 1 (single dose)			6			false
1254	509		ADULT	178039	313.3974	INDISETRON	Indisetron	CN1C[C@@H]2C[C@@H](C[C@H](C1)N2C)NC(=O)C3=NNC4=C3C=CC=C4	PLASMA	89RBZ66NVC							24		t	ng × h/mL	1664.3		ng/mL	200.6			UNKNOWN	mg	16		MULTIPLE	FASTED		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2004/P200400003/53011600_21600AMZ00038_X101_1.pdf#page=2	Homo sapiens		h	6.71	Day 7 (single dose)			6			false
1255	509		ADULT	178039	313.3974	INDISETRON	Indisetron	CN1C[C@@H]2C[C@@H](C[C@H](C1)N2C)NC(=O)C3=NNC4=C3C=CC=C4	PLASMA	89RBZ66NVC																	UNKNOWN	mg	16		MULTIPLE	FASTED		day	2	Human plasma protein binding (day 7): 76.5% (1h after dose), 75.4% (8h after dose)	23.5	HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2004/P200400003/53011600_21600AMZ00038_X101_1.pdf#page=3	Homo sapiens				Day 7 (single dose)			6			false
1256	509		ADULT	178039	313.3974	INDISETRON	Indisetron	CN1C[C@@H]2C[C@@H](C[C@H](C1)N2C)NC(=O)C3=NNC4=C3C=CC=C4	PLASMA	89RBZ66NVC																	UNKNOWN	mg	16		MULTIPLE	FASTED		day	2	Human plasma protein binding (day 1): 78.5% (1h after dose), 76.2% (8h after dose)	21.5	HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2004/P200400003/53011600_21600AMZ00038_X101_1.pdf#page=3	Homo sapiens				Day 1 (single dose)			6			false
1257	510		ADULT	13314	335.185	LORMETAZEPAM	LORMETAZEPAM	CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C3=C(Cl)C=CC=C3	PLASMA	GU56C842ZA							24		t	ng × h/mL	64						UNKNOWN	mg/kg	0.015		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1974495/	Homo sapiens							5	LORMETAZEPAM		false
1258	510		ADULT	13314	335.185	LORMETAZEPAM	LORMETAZEPAM	CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C3=C(Cl)C=CC=C3	PLASMA	GU56C842ZA							24		t	ng × h/mL	85						UNKNOWN	mg/kg	0.015		SINGLE	FASTED						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1974495/	Homo sapiens							5	LORMETAZEPAM		false
1259	510		ADULT	13314	335.185	LORMETAZEPAM	LORMETAZEPAM	CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C3=C(Cl)C=CC=C3	PLASMA	GU56C842ZA							24		t	ng × h/mL	84		ng/mL	13.9			UNKNOWN	mg/kg	0.03		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1974495/	Homo sapiens							5	LORMETAZEPAM		false
1260	510		ADULT	13314	335.185	LORMETAZEPAM	LORMETAZEPAM	CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C3=C(Cl)C=CC=C3	PLASMA	GU56C842ZA							24		t	ng × h/mL	167		ng/mL	27.2			UNKNOWN	mg/kg	0.03		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1974495/	Homo sapiens							5	LORMETAZEPAM		false
1261	510		ADULT	13314	335.185	LORMETAZEPAM	LORMETAZEPAM	CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C3=C(Cl)C=CC=C3	PLASMA	GU56C842ZA																	UNKNOWN	mg	2		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/43806/	Homo sapiens		h	13.1	lormetazepam-5-14C			5	LORMETAZEPAM		false
1262	510		ADULT	13314	335.185	LORMETAZEPAM	LORMETAZEPAM	CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C3=C(Cl)C=CC=C3	PLASMA	GU56C842ZA																	UNKNOWN	mg	0.2		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/43806/	Homo sapiens		h	13.3	lormetazepam-5-14C			5	LORMETAZEPAM		false
1263	512		ADULT	135168	281.35	Denitronipradilol			PLASMA										∞	μg × h/L	195.93		μg/L	16.63			UNKNOWN	mg	6		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18370546/	Homo sapiens		h	7.52		33.2 years old		6	NIPRADILOL		false
1264	512		ADULT	135168	281.35	Denitronipradilol			PLASMA										∞	μg × h/L	217.11		μg/L	11.19			UNKNOWN	mg	6		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18370546/	Homo sapiens		h	11.49		liver cirrhosis		8	NIPRADILOL		false
1265	512		ADULT	135168	281.35	Denitronipradilol			PLASMA										∞	μg × h/L	169.89		μg/L	12.5			UNKNOWN	mg	6		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18370546/	Homo sapiens		h	8.36		55.5 years		6	NIPRADILOL		false
1266	512		ADULT	72006	326.345	NIPRADILOL	NIPRADILOL	CC(C)NCC(O)COC1=C2OCC(CC2=CC=C1)O[N ]([O-])=O	PLASMA	FVM336I71Y									∞	μg × h/L	47.32		μg/L	6.07			UNKNOWN	mg	6		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18370546/	Homo sapiens		h	4.33		55.5 years old		6	NIPRADILOL		false
1267	512		ADULT	72006	326.345	NIPRADILOL	NIPRADILOL	CC(C)NCC(O)COC1=C2OCC(CC2=CC=C1)O[N ]([O-])=O	PLASMA	FVM336I71Y									∞	μg × h/L	31.12		μg/L	5.72			UNKNOWN	mg	6		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18370546/	Homo sapiens		h	3.34		33.2 years old		6	NIPRADILOL		false
1268	512		ADULT	72006	326.345	NIPRADILOL	NIPRADILOL	CC(C)NCC(O)COC1=C2OCC(CC2=CC=C1)O[N ]([O-])=O	PLASMA	FVM336I71Y									∞	μg × h/L	73.89		μg/L	8.43			UNKNOWN	mg	6		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18370546/	Homo sapiens		h	4.43		liver cirrhosis		8	NIPRADILOL		false
1269	515		ADULT		332.414	OXITROPIUM	Oxitropium	CC[N ]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]3O[C@@H]23)OC(=O)[C@H](CO)C4=CC=CC=C4	PLASMA	8G15T83E6I									?	ng × h/mL	8.9						UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2598990/	Homo sapiens		min	142				12	Oxitropium bromide		false
1270	516		ADULT	4823	334.3718	PIMOBENDAN	PIMOBENDAN	COC1=CC=C(C=C1)C2=NC3=C(N2)C=CC(=C3)C4=NNC(=O)CC4C	PLASMA	34AP3BBP9T							6		t	ng × h/mL	47.4						UNKNOWN	mg	5		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2060537/	Homo sapiens		h	0.9				5	PIMOBENDAN		false
1271	516		ADULT	4823	334.3718	PIMOBENDAN	PIMOBENDAN	COC1=CC=C(C=C1)C2=NC3=C(N2)C=CC(=C3)C4=NNC(=O)CC4C	PLASMA	34AP3BBP9T							6		t	ng × h/mL	22.2						UNKNOWN	mg	2.5		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2060537/	Homo sapiens		h	0.71				5	PIMOBENDAN		false
1272	516		ADULT		334.4	PIMOBENDAN, ( )-			PLASMA	613JXV89SU									∞	ng × h/mL	55.5		ng/mL	69.1			UNKNOWN	mg	5		SINGLE	FASTED					2.4	HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7768258/	Homo sapiens		h	1.81				8	PIMOBENDAN		false
1273	516		ADULT		334.4	PIMOBENDAN, (-)-			PLASMA	9HTU209Z0N									∞	ng × h/mL	50.8		ng/mL	74			UNKNOWN	mg	5		SINGLE	FASTED					2.4	HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7768258/	Homo sapiens		h	1.86				8	PIMOBENDAN		false
1274	516		ADULT		334.4	PIMOBENDAN, (-)-			PLASMA	9HTU209Z0N									∞	ng × h/mL	53.7		ng/mL	16.8			UNKNOWN	mg	7.5		SINGLE	FASTED					2.4	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7768258/	Homo sapiens		h	2.86				8	PIMOBENDAN		false
1275	516		ADULT		334.4	PIMOBENDAN, ( )-			PLASMA	613JXV89SU									∞	ng × h/mL	52.9		ng/mL	15.8			UNKNOWN	mg	7.5		SINGLE	FASTED					2.4	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7768258/	Homo sapiens		h	2.59				8	PIMOBENDAN		false
1276	516		ADULT		334.4	PIMOBENDAN, ( )-			PLASMA	613JXV89SU									∞	ng × h/mL	34.4		ng/mL	14.6			UNKNOWN	mg	2.5		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7781260/	Homo sapiens		h	3.07				8	PIMOBENDAN		false
1277	516		ADULT		334.4	PIMOBENDAN, (-)-			PLASMA	9HTU209Z0N									∞	ng × h/mL	37.5		ng/mL	15.9			UNKNOWN	mg	2.5		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7781260/	Homo sapiens		h	2.62				8	PIMOBENDAN		false
1278	516		ADULT		334.4	PIMOBENDAN, ( )-	PIMOBENDAN, ( )-		PLASMA	613JXV89SU									∞	ng × h/mL	44		ng/mL	16.3			UNKNOWN	mg	5		SINGLE	FASTED						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7781260/	Homo sapiens		h	2.56				7	PIMOBENDAN		false
1279	516		ADULT		334.4	PIMOBENDAN, (-)-			PLASMA	9HTU209Z0N									∞	ng × h/mL	48.3		ng/mL	17			UNKNOWN	mg	5		SINGLE	FASTED						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7781260/	Homo sapiens		h	2.93				7	PIMOBENDAN		false
1280	521		ADULT	171758	414.453	TEMOCILLIN	Temocillin	CO[C@]2(NC(=O)C(C(O)=O)C1=CSC=C1)[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O	SERUM	03QB156W6I									∞	mg × h/L	1749						UNKNOWN	g	1		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26603304/	Homo sapiens		h	22.5	1g q24h	ESRD w/hemodialysis, under the treatment of G(-) infection		16			false
1281	521		ADULT	171758	414.453	TEMOCILLIN	Temocillin	CO[C@]2(NC(=O)C(C(O)=O)C1=CSC=C1)[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O	SERUM	03QB156W6I									∞	mg × h/L	5088						UNKNOWN	g	2		MULTIPLE	UNKNOWN		2 days	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26603304/	Homo sapiens		h	26	2g q48h	ESRD w/hemodialysis, under the treatment of G(-) infection		16			false
1282	521		ADULT	171758	414.453	TEMOCILLIN	Temocillin	CO[C@]2(NC(=O)C(C(O)=O)C1=CSC=C1)[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O	SERUM	03QB156W6I									∞	mg × h/L	7621						UNKNOWN	g	3		MULTIPLE	UNKNOWN		3 days	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26603304/	Homo sapiens		h	35.8	3g q72h	ESRD w/hemodialysis, under the treatment of G(-) infection		16			false
1283	521		ADULT	171758	414.453	TEMOCILLIN	Temocillin	CO[C@]2(NC(=O)C(C(O)=O)C1=CSC=C1)[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O	PLASMA	03QB156W6I									∞	mg × h/mL	1197.1		mg/L	233.5			UNKNOWN	g	2		SINGLE	UNKNOWN				fu: 6.8% (2h post-dose), 5.5% (12h post-dose)	15	HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32433753/	Homo sapiens		h	5.3				8			false
1284	521		ADULT	171758	414.453	TEMOCILLIN	Temocillin	CO[C@]2(NC(=O)C(C(O)=O)C1=CSC=C1)[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O	PLASMA	03QB156W6I									∞	mg × h/mL	1314		mg/L	100			UNKNOWN	g	2		SINGLE	UNKNOWN						HEALTHY	Subcutaneous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32433753/	Homo sapiens		h	6.6				8			false
1285	521		ADULT	171758	414.453	TEMOCILLIN	Temocillin	CO[C@]2(NC(=O)C(C(O)=O)C1=CSC=C1)[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O	SERUM	03QB156W6I									?	mg × h/L	344.1		mg/L	77.9			UNKNOWN	g	0.5		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4029032/ | https://pubmed.ncbi.nlm.nih.gov/28849402/	Homo sapiens		h	5.2				10			false
1286	521		ADULT	171758	414.453	TEMOCILLIN	Temocillin	CO[C@]2(NC(=O)C(C(O)=O)C1=CSC=C1)[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O	SERUM	03QB156W6I									?	mg × h/L	573.3		mg/L	160.8			UNKNOWN	g	1		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4029032/ | https://pubmed.ncbi.nlm.nih.gov/28849402/	Homo sapiens		h	5				10			false
1287	521		ADULT	171758	414.453	TEMOCILLIN	Temocillin	CO[C@]2(NC(=O)C(C(O)=O)C1=CSC=C1)[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O	SERUM	03QB156W6I									?	mg × h/L	784.5		mg/L	236.1			UNKNOWN	g	2		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4029032/ | https://pubmed.ncbi.nlm.nih.gov/28849402/	Homo sapiens		h	5				10			false
1288	521		ADULT	171758	414.453	TEMOCILLIN	Temocillin	CO[C@]2(NC(=O)C(C(O)=O)C1=CSC=C1)[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O	SERUM	03QB156W6I													mg/L	31.33			UNKNOWN	mg/kg	3.75		SINGLE	FASTED						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6619046/	Homo sapiens		h	4.75				5			false
1289	521		ADULT	171758	414.453	TEMOCILLIN	Temocillin	CO[C@]2(NC(=O)C(C(O)=O)C1=CSC=C1)[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O	SERUM	03QB156W6I													mg/L	75.08			UNKNOWN	mg/kg	7.5		SINGLE	FASTED						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6619046/	Homo sapiens		h	5.88				5			false
1290	521		ADULT	171758	414.453	TEMOCILLIN	Temocillin	CO[C@]2(NC(=O)C(C(O)=O)C1=CSC=C1)[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O	SERUM	03QB156W6I													mg/L	75.08			UNKNOWN	mg/kg	15		SINGLE	FASTED						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6619046/	Homo sapiens		h	5.18				5			false
1291	521		ADULT	171758	414.453	TEMOCILLIN	Temocillin	CO[C@]2(NC(=O)C(C(O)=O)C1=CSC=C1)[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O	SERUM	03QB156W6I													mg/L	26.71			UNKNOWN	mg/kg	7.5		SINGLE	FASTED						HEALTHY	Intramuscular	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6619046/	Homo sapiens		h	5.53				5			false
1292	521		ADULT	171758	414.453	TEMOCILLIN	Temocillin	CO[C@]2(NC(=O)C(C(O)=O)C1=CSC=C1)[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O	SERUM	03QB156W6I													mg/L	69.8			UNKNOWN	mg/kg	7.5		SINGLE	FASTED						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6619046/	Homo sapiens		h	13.57		Mild renal impairment		5			false
1293	521		ADULT	171758	414.453	TEMOCILLIN	Temocillin	CO[C@]2(NC(=O)C(C(O)=O)C1=CSC=C1)[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O	SERUM	03QB156W6I													mg/L	49.41			UNKNOWN	mg/kg	7.5		SINGLE	FASTED						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6619046/	Homo sapiens		h	18.86		Moderate renal impairment		5			false
1294	521		ADULT	171758	414.453	TEMOCILLIN	Temocillin	CO[C@]2(NC(=O)C(C(O)=O)C1=CSC=C1)[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O	SERUM	03QB156W6I													mg/L	49.52			UNKNOWN	mg/kg	7.5		SINGLE	FASTED						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6619046/	Homo sapiens		h	28.22		Severe renal impairment		5			false
1295	521		ADULT	171758	414.453	TEMOCILLIN	Temocillin	CO[C@]2(NC(=O)C(C(O)=O)C1=CSC=C1)[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O	SERUM	03QB156W6I									?	mg × h/L	1553		mg/L	118			UNKNOWN	mg	15		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6853404/	Homo sapiens		h	17.5		Renal impairment, CLcr <20 mL/min/1.73m2		5			false
1296	521		ADULT	171758	414.453	TEMOCILLIN	Temocillin	CO[C@]2(NC(=O)C(C(O)=O)C1=CSC=C1)[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O	SERUM	03QB156W6I									?	mg × h/L	418		mg/L	127			UNKNOWN	mg	15		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6853404/	Homo sapiens		h	3.5		Renal impairment, CLcr >70 mL/min/1.73m2		6			false
1297	521		ADULT	171758	414.453	TEMOCILLIN	Temocillin	CO[C@]2(NC(=O)C(C(O)=O)C1=CSC=C1)[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O	SERUM	03QB156W6I									?	mg × h/L	1301		mg/L	122			UNKNOWN	mg	15		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6853404/	Homo sapiens		h	12.7		Renal impairment, CLcr 20-70 mL/min/1.73m2		5			false
1298	521		ADULT	171758	414.453	TEMOCILLIN	Temocillin	CO[C@]2(NC(=O)C(C(O)=O)C1=CSC=C1)[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O	SERUM	03QB156W6I													mg/L	281.2			UNKNOWN	g	2		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	OTHER	https://www.medicines.org.uk/emc/product/466#PHARMACOKINETIC_PROPS	Homo sapiens		h	4.2				6			false
1299	521		ADULT	171758	414.453	TEMOCILLIN	Temocillin	CO[C@]2(NC(=O)C(C(O)=O)C1=CSC=C1)[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O	SERUM	03QB156W6I													mg/L	482.9			UNKNOWN	g	4		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	OTHER	https://www.medicines.org.uk/emc/product/466#PHARMACOKINETIC_PROPS	Homo sapiens		h	4.2				8			false
1300	521		ADULT	171758	414.453	TEMOCILLIN	Temocillin	CO[C@]2(NC(=O)C(C(O)=O)C1=CSC=C1)[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O	SERUM	03QB156W6I													mg/L	72.7			UNKNOWN	g	1		SINGLE	UNKNOWN						HEALTHY	Intramuscular	UNKNOWN	OTHER	https://www.medicines.org.uk/emc/product/466#PHARMACOKINETIC_PROPS	Homo sapiens		h	5.4				6			false
1301	521		ADULT	171758	414.453	TEMOCILLIN	Temocillin	CO[C@]2(NC(=O)C(C(O)=O)C1=CSC=C1)[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O	SERUM	03QB156W6I													mg/L	93.2			UNKNOWN	g	1		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	OTHER	https://www.medicines.org.uk/emc/product/466#PHARMACOKINETIC_PROPS	Homo sapiens		h	11.7		Elderly patients		10			false
1302	521		ADULT	171758	414.453	TEMOCILLIN	Temocillin	CO[C@]2(NC(=O)C(C(O)=O)C1=CSC=C1)[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O	SERUM	03QB156W6I													mg/L	49.5			UNKNOWN	mg/kg	7.5		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	OTHER	https://www.medicines.org.uk/emc/product/466#PHARMACOKINETIC_PROPS	Homo sapiens		h	28.2		Renally impaired patients		5			false
1303	521		ADULT	171758	414.453	TEMOCILLIN	Temocillin	CO[C@]2(NC(=O)C(C(O)=O)C1=CSC=C1)[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O	SERUM	03QB156W6I													mg/L	173.1			UNKNOWN	g	1		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	OTHER	https://www.medicines.org.uk/emc/product/466#PHARMACOKINETIC_PROPS	Homo sapiens		h	4.2				6			false
1304	521		ADULT	171758	414.453	TEMOCILLIN	Temocillin	CO[C@]2(NC(=O)C(C(O)=O)C1=CSC=C1)[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O	SERUM	03QB156W6I																						UNKNOWN				The protein serum binding rate is 85% in healthy volunteers.	15	HEALTHY		FEMALE / MALE	OTHER	https://www.medicines.org.uk/emc/product/466#PHARMACOKINETIC_PROPS	Homo sapiens										false
1305	526		ADULT	9811353	862.9114	BIMOSIAMOSE	BIMOSIAMOSE	OC[C@H]1O[C@H](OC2=C(C=C(CCCCCCC3=CC(C4=CC(CC(O)=O)=CC=C4)=C(O[C@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]5O)C=C3)C=C2)C6=CC(CC(O)=O)=CC=C6)[C@@H](O)[C@@H](O)[C@@H]1O	PLASMA	97B5KCW80W									∞	μg × h/mL	1360		μg/mL	675			UNKNOWN	mg/kg	30		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16240703	Homo sapiens		h	4.1					BIMOSIAMOSE		false
1306	526		ADULT	9811353	862.9114	BIMOSIAMOSE	BIMOSIAMOSE	OC[C@H]1O[C@H](OC2=C(C=C(CCCCCCC3=CC(C4=CC(CC(O)=O)=CC=C4)=C(O[C@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]5O)C=C3)C=C2)C6=CC(CC(O)=O)=CC=C6)[C@@H](O)[C@@H](O)[C@@H]1O	PLASMA	97B5KCW80W									t	ng × h/mL	7378		ng/mL	64.4			UNKNOWN	mg	70		MULTIPLE	UNKNOWN		day	2			HEALTHY	Respiratory	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17067318	Homo sapiens							1	BIMOSIAMOSE		false
1307	526		ADULT	9811353	862.9114	BIMOSIAMOSE	BIMOSIAMOSE	OC[C@H]1O[C@H](OC2=C(C=C(CCCCCCC3=CC(C4=CC(CC(O)=O)=CC=C4)=C(O[C@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]5O)C=C3)C=C2)C6=CC(CC(O)=O)=CC=C6)[C@@H](O)[C@@H](O)[C@@H]1O	PLASMA	97B5KCW80W									?	ng × h/mL	952		ng/mL	49.8			UNKNOWN	mg	140		SINGLE	UNKNOWN						HEALTHY	Respiratory	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17067318	Homo sapiens							1	BIMOSIAMOSE		false
1308	526		ADULT	9811353	862.9114	BIMOSIAMOSE	BIMOSIAMOSE	OC[C@H]1O[C@H](OC2=C(C=C(CCCCCCC3=CC(C4=CC(CC(O)=O)=CC=C4)=C(O[C@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]5O)C=C3)C=C2)C6=CC(CC(O)=O)=CC=C6)[C@@H](O)[C@@H](O)[C@@H]1O	PLASMA	97B5KCW80W									∞	μg × h/mL	10.8		μg/mL	1.69			UNKNOWN	mg	300		STEADY-STATE	FASTED		day	1			HEALTHY	Subcutaneous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17876866	Homo sapiens		h	4.2	day 7			6	BIMOSIAMOSE		false
1309	526		ADULT	9811353	862.9114	BIMOSIAMOSE	BIMOSIAMOSE	OC[C@H]1O[C@H](OC2=C(C=C(CCCCCCC3=CC(C4=CC(CC(O)=O)=CC=C4)=C(O[C@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]5O)C=C3)C=C2)C6=CC(CC(O)=O)=CC=C6)[C@@H](O)[C@@H](O)[C@@H]1O	PLASMA	97B5KCW80W									∞	μg × h/mL	11.1		μg/mL	2.17			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Subcutaneous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17876866	Homo sapiens		h	3.7				6	BIMOSIAMOSE		false
1310	527		ADULT	5282459	417.4986	CINEPAZIDE	Cinepazide	COC1=CC(=CC(OC)=C1OC)\\C=C\\C(=O)N2CCN(CC(=O)N3CCCC3)CC2	PLASMA	67Y4P5C84X													μg/mL	3.7			UNKNOWN	mg	200		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.jstage.jst.go.jp/article/jscpt1970/10/2/10_2_203/_article/-char/en	Homo sapiens		h	1.07				7			false
1311	527		ADULT	5282459	417.4986	CINEPAZIDE	Cinepazide	COC1=CC(=CC(OC)=C1OC)\\C=C\\C(=O)N2CCN(CC(=O)N3CCCC3)CC2	PLASMA	67Y4P5C84X													μg/mL	3.7			UNKNOWN	mg	400		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.jstage.jst.go.jp/article/jscpt1970/10/2/10_2_203/_article/-char/en	Homo sapiens		h	1.64				7			false
1312	531		ADULT	3033968	310.4299	GESTODENE	Gestodene	CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1C=C[C@@]2(O)C#C	SERUM	1664P6E6MI	5991	296.4034	ETHINYL ESTRADIOL	Ethinylestradiol	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@]2(O)C#C	423D2T571U	24		t	ng × h/mL	1.03		ng/mL	0.11			MAX DAILY	mg	0.1		MULTIPLE	FASTED		day	1	At the end of cycle one, the free fraction was only 0.6% and the fractions bound to SHBG and albumin were 81.4% and 18.0%, respectively.	0.6	HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8222659/	Homo sapiens		h	20	After Cycle 1 (Days 1~6: 0.05mg GEST, 0.03mg EE2; Days 7~11: 0.07mg GEST, 0.04mg EE2; Days 12~21: 0.1mg GEST, 0.03mg EE2)		0.03 mg	14			true
1313	531		ADULT	3033968	310.4299	GESTODENE	Gestodene	CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1C=C[C@@]2(O)C#C	SERUM	1664P6E6MI	5991	296.4034	ETHINYL ESTRADIOL	Ethinylestradiol	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@]2(O)C#C	423D2T571U	24		t	ng × h/mL	0.3		ng/mL	0.07			MAX DAILY	mg	0.1		SINGLE	FASTED				After single dose administration, the free fraction of GEST was 1.3% and the fractions bound to SHBG and albumin were 69.4% and 29.3%, respectively.	1.3	HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8222659/	Homo sapiens		h	18			0.03 mg	14			true
1314	531		ADULT	3033968	310.4299	GESTODENE	Gestodene	CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1C=C[C@@]2(O)C#C	SERUM	1664P6E6MI	5991	296.4034	ETHINYL ESTRADIOL	Ethinylestradiol	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@]2(O)C#C	423D2T571U	24		t	ng × h/mL	0.98		ng/mL	0.1			MAX DAILY	mg	0.1		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8222659/	Homo sapiens		h	21.9	After Cycle 3 (Days 1~6: 0.05mg GEST, 0.03mg EE2; Days 7~11: 0.07mg GEST, 0.04mg EE2; Days 12~21: 0.1mg GEST, 0.03mg EE2), one-week wash out between cycles		0.03 mg	14			true
1315	533		ADULT	101524	669.552	BECATECARIN	BECATECARIN	CCN(CC)CCN1C(=O)C2=C(C1=O)C3=C(N([C@@H]4O[C@H](CO)[C@@H](OC)[C@H](O)[C@H]4O)C5=C3C=CC=C5Cl)C6=C2C7=C(N6)C(Cl)=CC=C7	PLASMA	A60X6MBU6G									∞	μg × h/mL	83.7		μg/mL	5.3			UNKNOWN	mg/m²	744		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11387367	Homo sapiens		h	73.2	30-minute  IV  infusion			4	BECATECARIN		false
1316	533		ADULT	101524	669.552	BECATECARIN	BECATECARIN	CCN(CC)CCN1C(=O)C2=C(C1=O)C3=C(N([C@@H]4O[C@H](CO)[C@@H](OC)[C@H](O)[C@H]4O)C5=C3C=CC=C5Cl)C6=C2C7=C(N6)C(Cl)=CC=C7	PLASMA	A60X6MBU6G									∞	μg × min/mL	5262		μg/mL	14.5			MAX TOLERATED	mg/m²	572		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12114420	Homo sapiens		h	28.8				12	BECATECARIN		false
1317	557		UNKNOWN	71961	493.533	ASPOXICILLIN	ASPOXICILLIN	CNC(=O)C[C@@H](N)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)C3=CC=C(O)C=C3	UNKNOWN	0745KNO26J							1.82										UNKNOWN	g	2		SINGLE	UNKNOWN						UNKNOWN	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3851864/	Homo sapiens		h	1.4	drip infusion for 60 minutes						false
1318	557		UNKNOWN	71961	493.533	ASPOXICILLIN	ASPOXICILLIN	CNC(=O)C[C@@H](N)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)C3=CC=C(O)C=C3	UNKNOWN	0745KNO26J													μg/g	40.3			UNKNOWN	g	2		SINGLE	UNKNOWN						UNKNOWN	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3851864/	Homo sapiens				drip infusion for 30 minutes						false
1319	557		UNKNOWN	71961	493.533	ASPOXICILLIN	ASPOXICILLIN	CNC(=O)C[C@@H](N)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)C3=CC=C(O)C=C3	UNKNOWN	0745KNO26J							0.44						μg/g	73.6			UNKNOWN	g	2		SINGLE	UNKNOWN						UNKNOWN	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3851864/	Homo sapiens		h	1.3							false
1320	559		ADULT	71310	212.2902	ATIPAMEZOLE	ATIPAMEZOLE	CCC1(CC2=C(C1)C=CC=C2)C3=CN=CN3	PLASMA	03N9U5JAF6									?	mg × h/L	0.333						UNKNOWN	mg	30		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1975199/	Homo sapiens		h	1.975				6	ATIPAMEZOLE		false
1321	559		ADULT	71310	212.2902	ATIPAMEZOLE	ATIPAMEZOLE	CCC1(CC2=C(C1)C=CC=C2)C3=CN=CN3	PLASMA	03N9U5JAF6									?	mg × h/L	0.095						UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1975199/	Homo sapiens		h	1.655				6	ATIPAMEZOLE		false
1322	559		ADULT	71310	212.2902	ATIPAMEZOLE	ATIPAMEZOLE	CCC1(CC2=C(C1)C=CC=C2)C3=CN=CN3	PLASMA	03N9U5JAF6									?	mg × h/L	1.191						UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1975199/	Homo sapiens		h	1.806				6	ATIPAMEZOLE		false
1323	559		UNKNOWN	71310	212.2902	ATIPAMEZOLE	ATIPAMEZOLE	CCC1(CC2=C(C1)C=CC=C2)C3=CN=CN3	PLASMA	03N9U5JAF6																	UNKNOWN				UNKNOWN	UNKNOWN				in vitro binding study	6.7	UNKNOWN	UNKNOWN	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31699808/	Homo sapiens				in vitro binding study				ATIPAMEZOLE		false
1324	559		ADULT	71310	212.2902	ATIPAMEZOLE	ATIPAMEZOLE	CCC1(CC2=C(C1)C=CC=C2)C3=CN=CN3	SERUM	03N9U5JAF6									?	ng × h/mL	4.2		ng/mL	1.2			UNKNOWN	mg	20		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7586944/	Homo sapiens		h	2				9	ATIPAMEZOLE		false
1325	559		ADULT	71310	212.2902	ATIPAMEZOLE	ATIPAMEZOLE	CCC1(CC2=C(C1)C=CC=C2)C3=CN=CN3	SERUM	03N9U5JAF6									?	ng × h/mL	74		ng/mL	26			UNKNOWN	mg	20		SINGLE	UNKNOWN						HEALTHY	Buccal	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7586944/	Homo sapiens		h	1.6				6	ATIPAMEZOLE		false
1326	559		ADULT	71310	212.2902	ATIPAMEZOLE	ATIPAMEZOLE	CCC1(CC2=C(C1)C=CC=C2)C3=CN=CN3	SERUM	03N9U5JAF6									?	ng × h/mL	44		ng/mL	15			UNKNOWN	mg	10		SINGLE	UNKNOWN						HEALTHY	Buccal	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7586944/	Homo sapiens		h	1.5				6	ATIPAMEZOLE		false
1327	559		ADULT	71310	212.2902	ATIPAMEZOLE	ATIPAMEZOLE	CCC1(CC2=C(C1)C=CC=C2)C3=CN=CN3	SERUM	03N9U5JAF6									?	ng × h/mL	112		ng/mL	38			UNKNOWN	mg	40		SINGLE	UNKNOWN						HEALTHY	Buccal	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7586944/	Homo sapiens		h	1.6				6	ATIPAMEZOLE		false
1328	559		ADULT	71310	212.2902	ATIPAMEZOLE	ATIPAMEZOLE	CCC1(CC2=C(C1)C=CC=C2)C3=CN=CN3	SERUM	03N9U5JAF6									?	ng × h/mL	231		ng/mL	145			UNKNOWN	mg	20		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7586944/	Homo sapiens		h	1.8				9	ATIPAMEZOLE		false
1329	559		ADULT	71310	212.2902	ATIPAMEZOLE	ATIPAMEZOLE	CCC1(CC2=C(C1)C=CC=C2)C3=CN=CN3	SERUM	03N9U5JAF6									?	ng × h/mL	26		ng/mL	11			UNKNOWN	mg	5		SINGLE	UNKNOWN						HEALTHY	Buccal	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7586944/	Homo sapiens		h	1.5				6	ATIPAMEZOLE		false
1330	559		ADULT	71310	212.2902	ATIPAMEZOLE	ATIPAMEZOLE	CCC1(CC2=C(C1)C=CC=C2)C3=CN=CN3	SERUM	03N9U5JAF6									?	ng × h/mL	85		ng/mL	23			UNKNOWN	mg	22.8		SINGLE	UNKNOWN						HEALTHY	Buccal	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7586944/	Homo sapiens		h	2				9	ATIPAMEZOLE		false
1331	560		ADULT	65958|74689674	389.4207	BALOFLOXACIN	Balofloxacin	CNC1CCCN(C1)C2=C(OC)C3=C(C=C2F)C(=O)C(=CN3C4CC4)C(O)=O	PLASMA	Q022B63JPM									∞	μg × h/mL	7.41		μg/mL	1.39			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17161665/	Homo sapiens		h	7.57				6			false
1332	560		ADULT	65958|74689674	389.4207	BALOFLOXACIN	Balofloxacin	CNC1CCCN(C1)C2=C(OC)C3=C(C=C2F)C(=O)C(=CN3C4CC4)C(O)=O	PLASMA	Q022B63JPM									∞	μg × h/mL	18.66		μg/mL	2.31			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17161665/	Homo sapiens		h	6.66				6			false
1333	560		ADULT	65958|74689674	389.4207	BALOFLOXACIN	Balofloxacin	CNC1CCCN(C1)C2=C(OC)C3=C(C=C2F)C(=O)C(=CN3C4CC4)C(O)=O	PLASMA	Q022B63JPM									∞	μg × h/mL	15.91		μg/mL	1.46			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17161665/	Homo sapiens		h	6.65				6			false
1334	560		ADULT	65958|74689674	389.4207	BALOFLOXACIN	Balofloxacin	CNC1CCCN(C1)C2=C(OC)C3=C(C=C2F)C(=O)C(=CN3C4CC4)C(O)=O	PLASMA	Q022B63JPM													μg/mL	1.05			UNKNOWN	mg	100		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17161665/	Homo sapiens		h	7.67	Day 6 (single dose)			6			false
1335	560		ADULT	65958|74689674	389.4207	BALOFLOXACIN	Balofloxacin	CNC1CCCN(C1)C2=C(OC)C3=C(C=C2F)C(=O)C(=CN3C4CC4)C(O)=O	PLASMA	Q022B63JPM									∞	μg × h/mL	6.86		μg/mL	0.89			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17161665/	Homo sapiens		h	6.94				6			false
1336	560		ADULT	65958|74689674	389.4207	BALOFLOXACIN	Balofloxacin	CNC1CCCN(C1)C2=C(OC)C3=C(C=C2F)C(=O)C(=CN3C4CC4)C(O)=O	PLASMA	Q022B63JPM									∞	μg × h/mL	13.21		μg/mL	2.09			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17161665/	Homo sapiens		h	9.24				6			false
1337	560		ADULT	65958|74689674	389.4207	BALOFLOXACIN	Balofloxacin	CNC1CCCN(C1)C2=C(OC)C3=C(C=C2F)C(=O)C(=CN3C4CC4)C(O)=O	PLASMA	Q022B63JPM									∞	μg × h/mL	6.56		μg/mL	1.07			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17161665/	Homo sapiens		h	7.89				12			false
1338	560		ADULT	65958|74689674	389.4207	BALOFLOXACIN	Balofloxacin	CNC1CCCN(C1)C2=C(OC)C3=C(C=C2F)C(=O)C(=CN3C4CC4)C(O)=O	PLASMA	Q022B63JPM													μg/mL	0.99			UNKNOWN	mg	100		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17161665/	Homo sapiens		h	7.02	Day 6 (single dose)			6			false
1339	560		ADULT	65958|74689674	389.4207	BALOFLOXACIN	Balofloxacin	CNC1CCCN(C1)C2=C(OC)C3=C(C=C2F)C(=O)C(=CN3C4CC4)C(O)=O	PLASMA	Q022B63JPM									∞	μg × h/mL	19.67		μg/mL	2.73			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17161665/	Homo sapiens		h	7.16				6			false
1340	560		ADULT	65958|74689674	389.4207	BALOFLOXACIN	Balofloxacin	CNC1CCCN(C1)C2=C(OC)C3=C(C=C2F)C(=O)C(=CN3C4CC4)C(O)=O	PLASMA	Q022B63JPM									∞	μg × h/mL	5.53		μg/mL	0.64			UNKNOWN	mg	100		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17161665/	Homo sapiens		h	7.72				12			false
1341	560		ADULT	65958|74689674	389.4207	BALOFLOXACIN	Balofloxacin	CNC1CCCN(C1)C2=C(OC)C3=C(C=C2F)C(=O)C(=CN3C4CC4)C(O)=O	PLASMA	Q022B63JPM									∞	μg × h/mL	17.1		μg/mL	2.17			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9124849/	Homo sapiens		h	7.8		Young subjects		6			false
1342	560		ADULT	65958|74689674	389.4207	BALOFLOXACIN	Balofloxacin	CNC1CCCN(C1)C2=C(OC)C3=C(C=C2F)C(=O)C(=CN3C4CC4)C(O)=O	PLASMA	Q022B63JPM									∞	μg × h/mL	22.9		μg/mL	1.72			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9124849/	Homo sapiens		h	13.3		Elderly subjects (65 y, one 64.75 y)		10			false
1343	563			2313|152743127	282.294	BENDAZAC	Bendazac	OC(=O)COC1=NN(CC2=CC=CC=C2)C3=C1C=CC=C3	PLASMA	G4AG71204O																										Bendazac is highly bound to plasma proteins (>99%).	1				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3197747/	Homo sapiens										false
1344	563		ADULT	2313|152743127	282.294	BENDAZAC	Bendazac	OC(=O)COC1=NN(CC2=CC=CC=C2)C3=C1C=CC=C3	PLASMA	G4AG71204O									?	mg × h/L	159		mg/L	41.9			UNKNOWN	mg	500		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3197747/	Homo sapiens		h	3.5				10	Bendazac lysine		false
1345	563		ADULT	2313|152743127	282.294	BENDAZAC	Bendazac	OC(=O)COC1=NN(CC2=CC=CC=C2)C3=C1C=CC=C3	PLASMA	G4AG71204O									?	mg × h/L	339		mg/L	36.4			UNKNOWN	mg	500		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3197747/	Homo sapiens		h	8		Cirrhosis patients		11	Bendazac lysine		false
1346	563		ADULT	2313|152743127	282.294	BENDAZAC	Bendazac	OC(=O)COC1=NN(CC2=CC=CC=C2)C3=C1C=CC=C3	PLASMA	G4AG71204O									∞	mg × h/L	159		mg/L	41.9			UNKNOWN	mg	500		SINGLE	FASTED				Plasma protein binding: 99.6%	0.4	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3691618/	Homo sapiens		h	3.5				10	Bendazac lysine		false
1347	563		ADULT	2313|152743127	282.294	BENDAZAC	Bendazac	OC(=O)COC1=NN(CC2=CC=CC=C2)C3=C1C=CC=C3	PLASMA	G4AG71204O									∞	mg × h/L	84		mg/L	25.5			UNKNOWN	mg	500		SINGLE	FASTED				Plasma protein binding: 99.0%	1	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3691618/	Homo sapiens		h	3.1		Renal failure (hemodialysis)		5	Bendazac lysine		false
1348	563		ADULT	2313|152743127	282.294	BENDAZAC	Bendazac	OC(=O)COC1=NN(CC2=CC=CC=C2)C3=C1C=CC=C3	PLASMA	G4AG71204O									∞	mg × h/L	150		mg/L	27.6			UNKNOWN	mg	500		SINGLE	FASTED				Plasma protein binding: 99.2%	0.8	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3691618/	Homo sapiens		h	4.7		Moderate renal impairment		5	Bendazac lysine		false
1349	563		ADULT	2313|152743127	282.294	BENDAZAC	Bendazac	OC(=O)COC1=NN(CC2=CC=CC=C2)C3=C1C=CC=C3	PLASMA	G4AG71204O									∞	mg × h/L	149		mg/L	31.2			UNKNOWN	mg	500		SINGLE	FASTED				Plasma protein binding: 99.3%	0.7	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3691618/	Homo sapiens		h	3.8		Severe renal impairment		5	Bendazac lysine		false
1350	567		ADULT	71651	193.1992	BETAMIPRON	Betamipron	OC(=O)CCNC(=O)C1=CC=CC=C1	PLASMA	3W0M245736	72015|40466880	339.41	PANIPENEM	Panipenem	C[C@@H](O)[C@@H]1[C@H]2CC(S[C@H]3CCN(C3)C(C)=N)=C(N2C1=O)C(O)=O	W9769W09JF			∞	μg × h/mL	32.96		μg/mL	25.69			UNKNOWN	mg	1000		MULTIPLE	UNKNOWN		day	2	Human serum protein bining: 73.1%, ultrafiltration	26.9	HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=40 | https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=51 | https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_265/_article/-char/en	Homo sapiens		h	0.79	9th dose, 60-min infusion		1000mg	4			true
1351	567		ADULT	71651	193.1992	BETAMIPRON	Betamipron	OC(=O)CCNC(=O)C1=CC=CC=C1	PLASMA	3W0M245736	72015|40466880	339.41	PANIPENEM	Panipenem	C[C@@H](O)[C@@H]1[C@H]2CC(S[C@H]3CCN(C3)C(C)=N)=C(N2C1=O)C(O)=O	W9769W09JF			∞	μg × h/mL	31.29		μg/mL	23.68			UNKNOWN	mg	1000		SINGLE	FASTED						HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=40 | https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_242/_article/-char/en	Homo sapiens		h	0.76	60-min infusion		1000mg	5			true
1352	567		ADULT	71651	193.1992	BETAMIPRON	Betamipron	OC(=O)CCNC(=O)C1=CC=CC=C1	PLASMA	3W0M245736	72015|40466880	339.41	PANIPENEM	Panipenem	C[C@@H](O)[C@@H]1[C@H]2CC(S[C@H]3CCN(C3)C(C)=N)=C(N2C1=O)C(O)=O	W9769W09JF			∞	μg × h/mL	8.9		μg/mL	7.25			UNKNOWN	mg	250		SINGLE	FASTED						HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=40 | https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_242/_article/-char/en	Homo sapiens		h	0.65	60-min infusion		250mg	5			true
1353	567		ADULT	71651	193.1992	BETAMIPRON	Betamipron	OC(=O)CCNC(=O)C1=CC=CC=C1	PLASMA	3W0M245736	72015|40466880	339.41	PANIPENEM	Panipenem	C[C@@H](O)[C@@H]1[C@H]2CC(S[C@H]3CCN(C3)C(C)=N)=C(N2C1=O)C(O)=O	W9769W09JF			∞	μg × h/mL	19.7		μg/mL	15.59			UNKNOWN	mg	500		SINGLE	FASTED						HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=40 | https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_242/_article/-char/en	Homo sapiens		h	0.67	60-min infusion		500mg	5			true
1354	567		ADULT	71651	193.1992	BETAMIPRON	Betamipron	OC(=O)CCNC(=O)C1=CC=CC=C1	PLASMA	3W0M245736	72015|40466880	339.41	PANIPENEM	Panipenem	C[C@@H](O)[C@@H]1[C@H]2CC(S[C@H]3CCN(C3)C(C)=N)=C(N2C1=O)C(O)=O	W9769W09JF			∞	μg × h/mL	42.09		μg/mL	33.23			UNKNOWN	mg	1000		MULTIPLE	UNKNOWN		day	2			HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=40 | https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_265/_article/-char/en	Homo sapiens		h	0.78	1st dose, 60-min infusion		1000mg	4			true
1355	567		ADULT	71651	193.1992	BETAMIPRON	Betamipron	OC(=O)CCNC(=O)C1=CC=CC=C1	PLASMA	3W0M245736	72015|40466880	339.41	PANIPENEM	Panipenem	C[C@@H](O)[C@@H]1[C@H]2CC(S[C@H]3CCN(C3)C(C)=N)=C(N2C1=O)C(O)=O	W9769W09JF			∞	μg × h/mL	19.47		μg/mL	16.19			UNKNOWN	mg	500		MULTIPLE	UNKNOWN		day	2			HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=40 | https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_265/_article/-char/en	Homo sapiens		h	0.71	9th dose, 60-min infusion		500mg	5			true
1356	567		ADULT	71651	193.1992	BETAMIPRON	Betamipron	OC(=O)CCNC(=O)C1=CC=CC=C1	PLASMA	3W0M245736	72015|40466880	339.41	PANIPENEM	Panipenem	C[C@@H](O)[C@@H]1[C@H]2CC(S[C@H]3CCN(C3)C(C)=N)=C(N2C1=O)C(O)=O	W9769W09JF			∞	μg × h/mL	17.7		μg/mL	14.1			UNKNOWN	mg	500		MULTIPLE	UNKNOWN		day	2			HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=40 | https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_265/_article/-char/en	Homo sapiens		h	0.81	1st dose, 60-min infusion		500mg	5			true
1357	567		CHILD	71651	193.1992	BETAMIPRON	Betamipron	OC(=O)CCNC(=O)C1=CC=CC=C1	PLASMA	3W0M245736	72015|40466880	339.41	PANIPENEM	Panipenem	C[C@@H](O)[C@@H]1[C@H]2CC(S[C@H]3CCN(C3)C(C)=N)=C(N2C1=O)C(O)=O	W9769W09JF							μg/mL	38.74			UNKNOWN	mg/kg	20		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=41 | https://www.jstage.jst.go.jp/article/antibiotics1968b/45/2/45_208/_article/-char/en	Homo sapiens		h	0.47	30-min infusion	Pediatric patients with bacterial infection	20mg/kg	27			true
1358	567		CHILD	71651	193.1992	BETAMIPRON	Betamipron	OC(=O)CCNC(=O)C1=CC=CC=C1	PLASMA	3W0M245736	72015|40466880	339.41	PANIPENEM	Panipenem	C[C@@H](O)[C@@H]1[C@H]2CC(S[C@H]3CCN(C3)C(C)=N)=C(N2C1=O)C(O)=O	W9769W09JF							μg/mL	18.33			UNKNOWN	mg/kg	10		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=41 | https://www.jstage.jst.go.jp/article/antibiotics1968b/45/2/45_208/_article/-char/en	Homo sapiens		h	0.51	30-min infusion	Pediatric patients with bacterial infection	10mg/kg	24			true
1359	567		CHILD	71651	193.1992	BETAMIPRON	Betamipron	OC(=O)CCNC(=O)C1=CC=CC=C1	PLASMA	3W0M245736	72015|40466880	339.41	PANIPENEM	Panipenem	C[C@@H](O)[C@@H]1[C@H]2CC(S[C@H]3CCN(C3)C(C)=N)=C(N2C1=O)C(O)=O	W9769W09JF							μg/mL	50.08			UNKNOWN	mg/kg	30		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=41 | https://www.jstage.jst.go.jp/article/antibiotics1968b/45/2/45_208/_article/-char/en	Homo sapiens		h	0.63	30-min infusion	Pediatric patients with bacterial infection	30mg/kg	4			true
1360	567		ADULT	71651	193.1992	BETAMIPRON	Betamipron	OC(=O)CCNC(=O)C1=CC=CC=C1	PLASMA	3W0M245736	72015|40466880	339.41	PANIPENEM	Panipenem	C[C@@H](O)[C@@H]1[C@H]2CC(S[C@H]3CCN(C3)C(C)=N)=C(N2C1=O)C(O)=O	W9769W09JF			∞	μg × h/mL	37.61		μg/mL	20.46			UNKNOWN	mg	500		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=55 | https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_372/_pdf/-char/en	Homo sapiens		h	1.31	60-min infusion	Patients with renal impairment, 30=< CLcr <60 mL/min (ave. 42.9 mL/min)	500mg	5			true
1361	567		ADULT	71651	193.1992	BETAMIPRON	Betamipron	OC(=O)CCNC(=O)C1=CC=CC=C1	PLASMA	3W0M245736	72015|40466880	339.41	PANIPENEM	Panipenem	C[C@@H](O)[C@@H]1[C@H]2CC(S[C@H]3CCN(C3)C(C)=N)=C(N2C1=O)C(O)=O	W9769W09JF			∞	μg × h/mL	20.4		μg/mL	18.08			UNKNOWN	mg	500		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=55 | https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_372/_pdf/-char/en	Homo sapiens		h	0.71	60-min infusion	Patients with renal impairment, CLcr >=60 mL/min (ave. 76.1 mL/min)	500mg	5			true
1362	567		ADULT	71651	193.1992	BETAMIPRON	Betamipron	OC(=O)CCNC(=O)C1=CC=CC=C1	PLASMA	3W0M245736	72015|40466880	339.41	PANIPENEM	Panipenem	C[C@@H](O)[C@@H]1[C@H]2CC(S[C@H]3CCN(C3)C(C)=N)=C(N2C1=O)C(O)=O	W9769W09JF			∞	μg × h/mL	194.67		μg/mL	25.81			UNKNOWN	mg	500		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=55 | https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_372/_pdf/-char/en	Homo sapiens		h	5.77	60-min infusion	Patients with renal impairment, CLcr <30 mL/min (ave. 7.5 mL/min)	500mg	6			true
1363	567		ADULT	71651	193.1992	BETAMIPRON	Betamipron	OC(=O)CCNC(=O)C1=CC=CC=C1	PLASMA	3W0M245736	72015|40466880	339.41	PANIPENEM	Panipenem	C[C@@H](O)[C@@H]1[C@H]2CC(S[C@H]3CCN(C3)C(C)=N)=C(N2C1=O)C(O)=O	W9769W09JF			∞	μg × h/mL	630		μg/mL	53			UNKNOWN	mg	500		SINGLE	UNKNOWN				Human plasma protein binding: 49.7%, ultrafiltration	50.3	UNHEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=56 | https://pubmed.ncbi.nlm.nih.gov/15729484/ | https://www.jstage.jst.go.jp/article/jscpt1970/34/1/34_1_17S/_article/-char/en	Homo sapiens		h	2.24	HD day (right after infusion), 60-min infusion	ESRD patients underwent hemodialysis, HD day	500mg	8			true
1364	567		ADULT	71651	193.1992	BETAMIPRON	Betamipron	OC(=O)CCNC(=O)C1=CC=CC=C1	PLASMA	3W0M245736	72015|40466880	339.41	PANIPENEM	Panipenem	C[C@@H](O)[C@@H]1[C@H]2CC(S[C@H]3CCN(C3)C(C)=N)=C(N2C1=O)C(O)=O	W9769W09JF			∞	μg × h/mL	1898		μg/mL	54.3			UNKNOWN	mg	500		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=56 | https://pubmed.ncbi.nlm.nih.gov/15729484/ | https://www.jstage.jst.go.jp/article/jscpt1970/34/1/34_1_17S/_article/-char/en	Homo sapiens		h	30.8	non-HD day, 60-min infusion	ESRD patients underwent hemodialysis, non-HD day	500mg	8			true
1365	567		ADULT	71651	193.1992	BETAMIPRON	Betamipron	OC(=O)CCNC(=O)C1=CC=CC=C1	PLASMA	3W0M245736	72015|40466880	339.41	PANIPENEM	Panipenem	C[C@@H](O)[C@@H]1[C@H]2CC(S[C@H]3CCN(C3)C(C)=N)=C(N2C1=O)C(O)=O	W9769W09JF			∞	μg × h/mL	5.31		μg/mL	4.47			UNKNOWN	mg	125		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_242/_article/-char/en	Homo sapiens		h	0.65	60-min infusion		125mg	2			true
1366	573			6917974	384.5085	BUFOGENIN	Bufogenin	C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@]15O[C@@H]5C[C@@H]2C6=COC(=O)C=C6	PLASMA	3K654P2M4J																										The average plasma protein binding rate with resibufogenin was 84.51%.	15.49				EXPERIMENT	https://europepmc.org/article/med/23227551 | http://www.yxxb.com.cn:8081/aps/CN/abstract/abstract14301.shtml	Homo sapiens										false
1367	574			2468	157.2168	BUFORMIN	Buformin	CCCCNC(=N)NC(N)=N	PLASMA	W2115E9C7B																										Human plasma protein binding: 7.7% (0-300μM), ultrafiltration	92.3				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/5068947/	Homo sapiens										false
1368	577		ADULT	5360410	236.2273	CARBAZOCHROME	CARBAZOCHROME	CN1CC(O)C2=C\\C(=N\\NC(N)=O)C(=O)C=C12	PLASMA	81F061RQS4									∞	ng × h/mL	77.94		ng/mL	19.4			UNKNOWN	mg	90		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24487058/	Homo sapiens		h	1.64							false
1369	579		UNKNOWN	2577	257.2614	CARMOFUR	CARMOFUR	CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O	PLASMA	HA82M3RAB2									?	μg × h/mL	6.51						UNKNOWN	mg	100		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/2948036	Homo sapiens		h	1.05							false
1370	583		ADULT	65755	440.481	CEFTEZOLE	CEFTEZOLE	OC(=O)C1=C(CSC2=NN=CS2)CS[C@@H]3[C@H](NC(=O)CN4C=NN=N4)C(=O)N13	SERUM	2Z86SYP11W													μg/mL	22.5			UNKNOWN	g	1		SINGLE	UNKNOWN						HEALTHY	Intramuscular	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3802300/	Homo sapiens		h	1.5		size is unknown			CEFTEZOLE		false
1371	583		ADULT	65755	440.481	CEFTEZOLE	CEFTEZOLE	OC(=O)C1=C(CSC2=NN=CS2)CS[C@@H]3[C@H](NC(=O)CN4C=NN=N4)C(=O)N13	SERUM	2Z86SYP11W													μg/mL	73.5			UNKNOWN	g	2		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7389424/	Homo sapiens		h	0.64	2-hour intravenous drip infusion	normal renal function		4	CEFTEZOLE		false
1372	583		ADULT	65755	440.481	CEFTEZOLE	CEFTEZOLE	OC(=O)C1=C(CSC2=NN=CS2)CS[C@@H]3[C@H](NC(=O)CN4C=NN=N4)C(=O)N13	SERUM	2Z86SYP11W													μg/mL	135.4			UNKNOWN	g	2		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7389424/	Homo sapiens		h	7.389	2-hour intravenous drip infusion	moderate renal impairment		5	CEFTEZOLE		false
1373	583		ADULT	65755	440.481	CEFTEZOLE	CEFTEZOLE	OC(=O)C1=C(CSC2=NN=CS2)CS[C@@H]3[C@H](NC(=O)CN4C=NN=N4)C(=O)N13	SERUM	2Z86SYP11W													μg/mL	146.7			UNKNOWN	g	2		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7389424/	Homo sapiens		h	10.73	2-hour intravenous drip infusion	severe renal impairment		3	CEFTEZOLE		false
1374	583		ADULT	65755	440.481	CEFTEZOLE	CEFTEZOLE	OC(=O)C1=C(CSC2=NN=CS2)CS[C@@H]3[C@H](NC(=O)CN4C=NN=N4)C(=O)N13	SERUM	2Z86SYP11W													μg/mL	100.7			UNKNOWN	g	2		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7389424/	Homo sapiens		h	1.06	2-hour intravenous drip infusion	mild renal impairment		3	CEFTEZOLE		false
1375	586		ADULT	5773	415.486	CEPHALORIDINE	CEPHALORIDINE	[O-]C(=O)C1=C(C[N+]2=CC=CC=C2)CS[C@@H]3[C@H](NC(=O)CC4=CC=CS4)C(=O)N13	PLASMA	LVZ1VC61HB									∞	μg × h/mL	40		μg/mL	38			UNKNOWN	g	1		SINGLE	UNKNOWN					69	UNHEALTHY	Intramuscular	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/278145/	Homo sapiens		h	1.5							false
1376	590		ADULT	9064	290.2681	CIANIDANOL	Cianidanol	O[C@H]1CC2=C(O[C@@H]1C3=CC=C(O)C(O)=C3)C=C(O)C=C2O	PLASMA	8R1V1STN48							8		t	nM × h	306		nM	78.3			UNKNOWN	mg	35		SINGLE	FASTED				Total ( )-catechin		HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10617953/	Homo sapiens		h	3.17				9			false
1377	590			9064	290.2681	CIANIDANOL	Cianidanol	O[C@H]1CC2=C(O[C@@H]1C3=CC=C(O)C(O)=C3)C=C(O)C=C2O	PLASMA	8R1V1STN48																										Human plasma protein binding: 95.9% (ultrafiltration), 100% (HPAC)	4.1				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20732774/	Homo sapiens										false
1378	591		ADULT	151170	343.4168	CILOMILAST	Cilomilast	COC1=CC=C(C=C1OC2CCCC2)[C@]3(CC[C@@H](CC3)C(O)=O)C#N	PLASMA	8ATB1C1R6X																						UNKNOWN				The ex vivo plasma protein binding of cilomilast (approximately 99.5%) was similar in healthy young and elderly subjects. The principal binding protein was albumin, and binding was not saturable at therapeutic concentrations.	0.5	HEALTHY		MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11549099/	Homo sapiens										false
1379	591		ADULT	151170	343.4168	CILOMILAST	Cilomilast	COC1=CC=C(C=C1OC2CCCC2)[C@]3(CC[C@@H](CC3)C(O)=O)C#N	PLASMA	8ATB1C1R6X									∞	μg × h/mL	2.91		μg/mL	0.463			UNKNOWN	mg	4		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16509757/	Homo sapiens		h	6.76				9			false
1380	591		ADULT	151170	343.4168	CILOMILAST	Cilomilast	COC1=CC=C(C=C1OC2CCCC2)[C@]3(CC[C@@H](CC3)C(O)=O)C#N	PLASMA	8ATB1C1R6X									∞	μg × h/mL	6.78		μg/mL	0.122			UNKNOWN	mg	10		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16509757/	Homo sapiens		h	7				9			false
1381	591		ADULT	151170	343.4168	CILOMILAST	Cilomilast	COC1=CC=C(C=C1OC2CCCC2)[C@]3(CC[C@@H](CC3)C(O)=O)C#N	PLASMA	8ATB1C1R6X									∞	μg × h/mL	12.2		μg/mL	0.186			UNKNOWN	mg	15		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16509757/	Homo sapiens		h	7.19							false
1382	591		ADULT	151170	343.4168	CILOMILAST	Cilomilast	COC1=CC=C(C=C1OC2CCCC2)[C@]3(CC[C@@H](CC3)C(O)=O)C#N	PLASMA	8ATB1C1R6X									∞	μg × h/mL	13.4		μg/mL	1.68			UNKNOWN	mg	20		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16509757/	Homo sapiens		h	7.04				9			false
1383	591		ADULT	151170	343.4168	CILOMILAST	Cilomilast	COC1=CC=C(C=C1OC2CCCC2)[C@]3(CC[C@@H](CC3)C(O)=O)C#N	PLASMA	8ATB1C1R6X							12		t	μg × h/mL	1.43		μg/mL	0.281			UNKNOWN	mg	2		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16509757/	Homo sapiens		h	6.16				9			false
1384	591		ADULT	151170	343.4168	CILOMILAST	Cilomilast	COC1=CC=C(C=C1OC2CCCC2)[C@]3(CC[C@@H](CC3)C(O)=O)C#N	PLASMA	8ATB1C1R6X									∞	μg × h/mL	1.08		μg/mL	0.248			UNKNOWN	mg	2		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16509757/	Homo sapiens		h	3.27				9			false
1385	591		ADULT	151170	343.4168	CILOMILAST	Cilomilast	COC1=CC=C(C=C1OC2CCCC2)[C@]3(CC[C@@H](CC3)C(O)=O)C#N	PLASMA	8ATB1C1R6X									∞	pmol × h/mL	5.04		μg/mL	0.872			UNKNOWN	mg	7		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16509757/	Homo sapiens		h	6.69				9			false
1386	591		ADULT	151170	343.4168	CILOMILAST	Cilomilast	COC1=CC=C(C=C1OC2CCCC2)[C@]3(CC[C@@H](CC3)C(O)=O)C#N	PLASMA	8ATB1C1R6X							12		t	μg × h/mL	3.06		μg/mL	0.596			UNKNOWN	mg	4		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16509757/	Homo sapiens		h	8.11				9			false
1387	591		ADULT	151170	343.4168	CILOMILAST	Cilomilast	COC1=CC=C(C=C1OC2CCCC2)[C@]3(CC[C@@H](CC3)C(O)=O)C#N	PLASMA	8ATB1C1R6X							12		t	μg × h/mL	13.9		μg/mL	2.66			UNKNOWN	mg	15		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16509757/	Homo sapiens		h	8.24				9			false
1388	591		ADULT	151170	343.4168	CILOMILAST	Cilomilast	COC1=CC=C(C=C1OC2CCCC2)[C@]3(CC[C@@H](CC3)C(O)=O)C#N	PLASMA	8ATB1C1R6X							12		t	μg × h/mL	6.01		μg/mL	1.09			UNKNOWN	mg	7		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16509757/	Homo sapiens		h	8.2				9			false
1389	591		ADULT	151170	343.4168	CILOMILAST	Cilomilast	COC1=CC=C(C=C1OC2CCCC2)[C@]3(CC[C@@H](CC3)C(O)=O)C#N	PLASMA	8ATB1C1R6X							12		t	μg × h/mL	6.94		μg/mL	1.48			UNKNOWN	mg	10		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16509757/	Homo sapiens		h	7.2				9			false
1390	610		UNKNOWN	3242	234.2545	EPIRIZOLE	EPIRIZOLE	COC1=CC(C)=NN1C2=NC(OC)=CC(C)=N2	SERUM	3B46O2FH8I													μg/mL	0.8			HIGHEST STUDIED	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://www.jstage.jst.go.jp/article/cpb1958/24/6/24_6_1305/_pdf/-char/en	Homo sapiens							2			false
1391	613		ADULT	68741	399.5662	EPRISTERIDE	EPRISTERIDE	CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C=C(CC[C@]4(C)[C@H]3CC[C@]12C)C(O)=O	PLASMA	39517A04PS									∞	ng × h/mL	3358		ng/mL	149			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8983399	Homo sapiens		h	26.2				12	EPRISTERIDE		false
1392	613		ADULT	68741	399.5662	EPRISTERIDE	epristeride	CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C=C(CC[C@]4(C)[C@H]3CC[C@]12C)C(O)=O	PLASMA	39517A04PS									∞	ng × h/mL	3194		ng/mL	283			UNKNOWN	mg	4.5		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8983399	Homo sapiens		h	27.3				12	epristeride		false
1393	615			3282	165.1891	ETHENZAMIDE	Ethenzamide	CCOC1=C(C=CC=C1)C(N)=O	UNKNOWN	L929ZCK4BF																											100				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16394537/	Homo sapiens										false
1394	618		ADULT	198695	196.2462	FASORACETAM	Fasoracetam	O=C([C@H]1CCC(=O)N1)N2CCCCC2	PLASMA	42O8UF5CJB									?	μg × h/mL	24.6		μg/mL	3.06			UNKNOWN	mg	100		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10450537/	Homo sapiens					Elderly males		7			false
1395	618		ADULT	198695	196.2462	FASORACETAM	Fasoracetam	O=C([C@H]1CCC(=O)N1)N2CCCCC2	PLASMA	42O8UF5CJB									?	μg × h/mL	14.4		μg/mL	2.13			UNKNOWN	mg	100		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10450537/	Homo sapiens					Young adult males		6			false
1396	618		ADOLESCENT	198695	196.2462	FASORACETAM	Fasoracetam	O=C([C@H]1CCC(=O)N1)N2CCCCC2	PLASMA	42O8UF5CJB									∞	μg × h/mL	136.46		μg/mL	20.52			UNKNOWN	mg	800		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29339723/	Homo sapiens		h	4.06		ADHD subjects		6			false
1397	618		ADOLESCENT	198695	196.2462	FASORACETAM	Fasoracetam	O=C([C@H]1CCC(=O)N1)N2CCCCC2	PLASMA	42O8UF5CJB									∞	μg × h/mL	15.68		μg/mL	1.72			UNKNOWN	mg	100		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29339723/	Homo sapiens		h	6.99		ADHD subjects		6			false
1398	618		ADOLESCENT	198695	196.2462	FASORACETAM	Fasoracetam	O=C([C@H]1CCC(=O)N1)N2CCCCC2	PLASMA	42O8UF5CJB									∞	μg × h/mL	30.2		μg/mL	5.07			UNKNOWN	mg	200		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29339723/	Homo sapiens		h	4.48		ADHD subjects		6			false
1399	618		ADOLESCENT	198695	196.2462	FASORACETAM	Fasoracetam	O=C([C@H]1CCC(=O)N1)N2CCCCC2	PLASMA	42O8UF5CJB									∞	μg × h/mL	6.87		μg/mL	1.19			UNKNOWN	mg	50		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29339723/	Homo sapiens		h	4.44		ADHD subjects		6			false
1400	618		ADOLESCENT	198695	196.2462	FASORACETAM	Fasoracetam	O=C([C@H]1CCC(=O)N1)N2CCCCC2	PLASMA	42O8UF5CJB									∞	μg × h/mL	58.11		μg/mL	10.77			UNKNOWN	mg	400		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29339723/	Homo sapiens		h	4.11		ADHD subjects		6			false
1401	621		ADULT	28871	329.801	FENTIAZAC	FENTIAZAC	OC(=O)CC1=C(N=C(S1)C2=CC=CC=C2)C3=CC=C(Cl)C=C3	PLASMA	0YHF6E6NLS							12		t	ng × h/mL	5200		ng/mL	3450			DEFINED DAILY	mg	200		STEADY-STATE	FASTED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	doi:10.3109/00498258409151493	Homo sapiens				tablet with 150ml water	day 8		10	fentiazac		false
1402	621		ADULT	28871	329.801	FENTIAZAC	FENTIAZAC	OC(=O)CC1=C(N=C(S1)C2=CC=CC=C2)C3=CC=C(Cl)C=C3	PLASMA	0YHF6E6NLS							12		t	ng × h/mL	5670		ng/mL	4080			DEFINED DAILY	mg	200		STEADY-STATE	FASTED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	doi:10.3109/00498258409151493	Homo sapiens				tablet with 150ml water	day 15		10	fentiazac		false
1403	621		ADULT	28871	329.801	FENTIAZAC	FENTIAZAC	OC(=O)CC1=C(N=C(S1)C2=CC=CC=C2)C3=CC=C(Cl)C=C3	PLASMA	0YHF6E6NLS							12		t	ng × h/mL	5770		ng/mL	1990			DEFINED DAILY	mg	200		STEADY-STATE	FASTED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	doi:10.3109/00498258409151493	Homo sapiens				tablet with 150ml water	day 15 active metabolite		10	fentiazac		false
1404	621		ADULT	28871	329.801	FENTIAZAC	FENTIAZAC	OC(=O)CC1=C(N=C(S1)C2=CC=CC=C2)C3=CC=C(Cl)C=C3	PLASMA	0YHF6E6NLS							12		t	ng × h/mL	5510		ng/mL	1500			DEFINED DAILY	mg	200		STEADY-STATE	FASTED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	doi:10.3109/00498258409151493	Homo sapiens				tablet with 150ml water	day 8 active metabolite		10	fentiazac		false
1405	621		ADULT	28871	329.801	FENTIAZAC	FENTIAZAC	OC(=O)CC1=C(N=C(S1)C2=CC=CC=C2)C3=CC=C(Cl)C=C3	PLASMA	0YHF6E6NLS							12		t	ng × h/mL	3400		ng/mL	1240			DEFINED DAILY	mg	200		STEADY-STATE	FASTED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	doi:10.3109/00498258409151493	Homo sapiens				tablet with 150ml water	day 1 active metabolite		10	fentiazac		false
1406	621		ADULT	28871	329.801	FENTIAZAC	FENTIAZAC	OC(=O)CC1=C(N=C(S1)C2=CC=CC=C2)C3=CC=C(Cl)C=C3	PLASMA	0YHF6E6NLS							12		t	ng × h/mL	4490		ng/mL	2670			DEFINED DAILY	mg	200		STEADY-STATE	FASTED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	doi:10.3109/00498258409151493	Homo sapiens				tablet with 150ml water	day 1		10	fentiazac		false
1407	621		ADULT	28871	329.801	FENTIAZAC	FENTIAZAC	OC(=O)CC1=C(N=C(S1)C2=CC=CC=C2)C3=CC=C(Cl)C=C3	PLASMA	0YHF6E6NLS													mg/L	5.4			DEFINED DAILY	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8447848/	Homo sapiens		h	7		elderly (> 76 years)		12	fentiazac		false
1408	622		ADULT	35455	320.385	FEPRAZONE	FEPRAZONE	CC(C)=CCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3	PLASMA	7BVX6J0CGR									∞	mg × h/L	694						UNKNOWN	mg	400		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	http://dx.doi.org/10.3109/00498259309059434	Homo sapiens		h	24.6		non-rheumatoid patients with renal impairment		10	feprazone		false
1409	622		ADULT	35455	320.385	FEPRAZONE	FEPRAZONE	CC(C)=CCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3	PLASMA	7BVX6J0CGR										mg × h/L	1640						UNKNOWN	mg	400		SINGLE	UNKNOWN						UNKNOWN	Oral	FEMALE / MALE	EXPERIMENT	http://dx.doi.org/10.3109/00498259309059434	Homo sapiens		h	22.6		Elderly patients		10	feprazone		false
1410	622		ADULT	35455	320.385	FEPRAZONE	FEPRAZONE	CC(C)=CCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3	PLASMA	7BVX6J0CGR									∞	mg × h/L	1370						UNKNOWN	mg	400		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	http://dx.doi.org/10.3109/00498259309059434	Homo sapiens		h	23.3				10	feprazone		false
1411	622		ADULT	35455	320.385	FEPRAZONE	FEPRAZONE	CC(C)=CCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3	PLASMA	7BVX6J0CGR									∞	mg × h/L	854						UNKNOWN	mg	400		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	http://dx.doi.org/10.3109/00498259309059434	Homo sapiens		h	20.9		rheumatoid arthritis		10	feprazone		false
1412	622		ADULT	35455	320.385	FEPRAZONE	FEPRAZONE	CC(C)=CCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3	PLASMA	7BVX6J0CGR									∞	mg × h/L	1370		μg/mL	9.5			UNKNOWN	mg	400		SINGLE	FED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://doi.org/10.3109/00498258809041724	Homo sapiens		h	23				10	feprazone		false
1413	624		ADULT	3357|40466912	369.3383	FLEROXACIN	FLEROXACIN	CN1CCN(CC1)C2=C(F)C3=C(C=C2F)C(=O)C(=CN3CCF)C(O)=O	PLASMA	N804LDH51K									?	mg × h/L	99		mg/L	8.7			DEFINED DAILY	mg	400		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10606835/	Homo sapiens					acute infective exacerbation of bronchitis or bronchiectasis		6	FLEROXACIN		false
1414	624		ADULT	3357|40466912	369.3383	FLEROXACIN	FLEROXACIN	CN1CCN(CC1)C2=C(F)C3=C(C=C2F)C(=O)C(=CN3CCF)C(O)=O	PLASMA	N804LDH51K									?	mg × h/L	149		mg/L	11.7			RECOMMENDED	mg	400		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10606835/	Homo sapiens				3 days dosing	acute infective exacerbation of bronchitis or bronchiectasis		6	FLEROXACIN		false
1415	624		ADULT	3357|40466912	369.3383	FLEROXACIN	FLEROXACIN	CN1CCN(CC1)C2=C(F)C3=C(C=C2F)C(=O)C(=CN3CCF)C(O)=O	SPUTUM	N804LDH51K									?	mg × h/L	10		mg/L	2.5			RECOMMENDED	mg	400		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10606835/	Homo sapiens				3 days dosing	acute infective exacerbation of bronchitis or bronchiectasis		6	FLEROXACIN		false
1416	624		ADULT	3357|40466912	369.3383	FLEROXACIN	FLEROXACIN	CN1CCN(CC1)C2=C(F)C3=C(C=C2F)C(=O)C(=CN3CCF)C(O)=O	SPUTUM	N804LDH51K									?	mg × h/L	10		mg/L	2.3			DEFINED DAILY	mg	400		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10606835/	Homo sapiens					acute infective exacerbation of bronchitis or bronchiectasis		6	FLEROXACIN		false
1417	624		ADULT	3357|40466912	369.3383	FLEROXACIN	FLEROXACIN	CN1CCN(CC1)C2=C(F)C3=C(C=C2F)C(=O)C(=CN3CCF)C(O)=O	SERUM	N804LDH51K							24		t	μg × h/mL	96.5		μg/mL	8.5			RECOMMENDED	mg	400		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8203844/	Homo sapiens		h	8.9	3 days dosing			20	FLEROXACIN		false
1418	624		ADULT	3357|40466912	369.3383	FLEROXACIN	FLEROXACIN	CN1CCN(CC1)C2=C(F)C3=C(C=C2F)C(=O)C(=CN3CCF)C(O)=O	SERUM	N804LDH51K							24		t	μg × h/mL	83.1		μg/mL	6.4			RECOMMENDED	mg	400		MULTIPLE	FED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8203844/	Homo sapiens		h	9.7	3 days dosing			20	FLEROXACIN		false
1419	624		ADULT	3357|40466912	369.3383	FLEROXACIN	FLEROXACIN	CN1CCN(CC1)C2=C(F)C3=C(C=C2F)C(=O)C(=CN3CCF)C(O)=O	SERUM	N804LDH51K							24		∞	μg × h/mL	86.3		μg/mL	6.3			DEFINED DAILY	mg	400		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8203844/	Homo sapiens		h	10.7				20	FLEROXACIN		false
1420	624		ADULT	3357|40466912	369.3383	FLEROXACIN	FLEROXACIN	CN1CCN(CC1)C2=C(F)C3=C(C=C2F)C(=O)C(=CN3CCF)C(O)=O	SERUM	N804LDH51K							24		∞	μg × h/mL	77.7		μg/mL	4.6			DEFINED DAILY	mg	400		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8203844/	Homo sapiens		h	10.6				20	FLEROXACIN		false
1421	624		ADULT	3357|40466912	369.3383	FLEROXACIN	FLEROXACIN	CN1CCN(CC1)C2=C(F)C3=C(C=C2F)C(=O)C(=CN3CCF)C(O)=O	SERUM	N804LDH51K									∞	μg × h/mL	90		μg/mL	6.5			DEFINED DAILY	mg	400		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8851614/	Homo sapiens							10	FLEROXACIN		false
1422	624		ADULT	3357|40466912	369.3383	FLEROXACIN	FLEROXACIN	CN1CCN(CC1)C2=C(F)C3=C(C=C2F)C(=O)C(=CN3CCF)C(O)=O	SERUM	N804LDH51K									∞	μg × h/mL	82.6		μg/mL	6			DEFINED DAILY	mg	400		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8851614/	Homo sapiens							10	FLEROXACIN		false
1423	624		ADULT	3357|40466912	369.3383	FLEROXACIN	FLEROXACIN	CN1CCN(CC1)C2=C(F)C3=C(C=C2F)C(=O)C(=CN3CCF)C(O)=O	SERUM	N804LDH51K							24		t	μg × h/mL	104		μg/mL	9			RECOMMENDED	mg	400		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8851614/	Homo sapiens				3 days dosing			10	FLEROXACIN		false
1424	624		ADULT	3357|40466912	369.3383	FLEROXACIN	FLEROXACIN	CN1CCN(CC1)C2=C(F)C3=C(C=C2F)C(=O)C(=CN3CCF)C(O)=O	SERUM	N804LDH51K							24		t	μg × h/mL	89		μg/mL	8			RECOMMENDED	mg	400		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8851614/	Homo sapiens				3 days dosing			10	FLEROXACIN		false
1425	625		ADULT	3362	182.174	FLOPROPIONE		CCC(=O)c1c(O)cc(O)cc1O	PLASMA	05V5NVB5Y1													μg/mL	9			UNKNOWN	mg	240		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/170033_1249007F1032_1_008_1F.pdf#page=18	Homo sapiens							12			false
1426	633		ADULT	71793	303.765	GLYCLOPYRAMIDE	GLYCLOPYRAMIDE	ClC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CCCC2	PLASMA	KE474IKG1W							8		t	μg × h/L	8.64						UNKNOWN	μg/kg	6		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://onlinelibrary.wiley.com/doi/epdf/10.1111/j.1399-6576.1989.tb02956.x	Homo sapiens		h	0.83		elderly with mild systemic disease		6	glycopyrrolate		false
1427	633		ADULT	71793	303.765	GLYCLOPYRAMIDE	GLYCLOPYRAMIDE	ClC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CCCC2	PLASMA	KE474IKG1W							8		t	μg × h/L	5.2		μg/L	0.76			UNKNOWN	mg	4		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://onlinelibrary.wiley.com/doi/epdf/10.1111/j.1399-6576.1989.tb02956.x	Homo sapiens							6	glycopyrrolate		false
1428	633		ADULT	71793	303.765	GLYCLOPYRAMIDE	GLYCLOPYRAMIDE	ClC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CCCC2	PLASMA	KE474IKG1W							12		t	μg × h/L	5.2		μg/L	3.47			UNKNOWN	μg/kg	8		SINGLE	UNKNOWN						UNHEALTHY	Intramuscular	UNKNOWN	EXPERIMENT	https://onlinelibrary.wiley.com/doi/epdf/10.1111/j.1399-6576.1989.tb02956.x	Homo sapiens							6	glycopyrrolate		false
1429	633		CHILD	71793	303.765	GLYCLOPYRAMIDE	GLYCLOPYRAMIDE	ClC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CCCC2	PLASMA	KE474IKG1W									∞	μg × min/L	276.3						UNKNOWN	μg/kg	5		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://onlinelibrary.wiley.com/doi/epdf/10.1111/j.1600-0773.1998.tb01456.x	Homo sapiens		min	139				6	glycopyrrolate		false
1430	633		CHILD	71793	303.765	GLYCLOPYRAMIDE	GLYCLOPYRAMIDE	ClC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CCCC2	PLASMA	KE474IKG1W									∞	μg × min/L	106.6		μg/L	0.37			UNKNOWN	μg/kg	50		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://onlinelibrary.wiley.com/doi/epdf/10.1111/j.1600-0773.1998.tb01456.x	Homo sapiens							6	glycopyrrolate		false
1431	637		ADULT	5280567	176.1687	HYMECROMONE	HYMECROMONE	CC1=CC(=O)OC2=C1C=CC(O)=C2	PLASMA	3T5NG4Q468																	UNKNOWN	mg	400		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8427942/	Homo sapiens		min	306				8	HYMECROMONE SODIUM		false
1432	637		ADULT	5280567	176.1687	HYMECROMONE	HYMECROMONE	CC1=CC(=O)OC2=C1C=CC(O)=C2	PLASMA	3T5NG4Q468																	UNKNOWN	mg	800		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8427942/	Homo sapiens		min	385				6	HYMECROMONE SODIUM		false
1433	641			3740	1215.8131	IOTROXIC ACID	Iotroxic acid	OC(=O)C1=C(I)C=C(I)C(NC(=O)COCCOCCOCC(=O)NC2=C(I)C(C(O)=O)=C(I)C=C2I)=C1I	PLASMA	84C5PTP9X6																										Human plasma protein binding (equilibrium dialysis): 56.17% (1.6μg/mL), 69.69% (1.2μg/mL), 78.24% (0.8μg/mL), 87.89% (0.4μg/mL), 91.81% (0.2μg/mL), 90.83% (0.1μg/mL)	8.19				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/630004_7219403A1038_1_002_1F.pdf#page=15	Homo sapiens										false
1434	641		ADULT	3740	1215.8131	IOTROXIC ACID	Iotroxic acid	OC(=O)C1=C(I)C=C(I)C(NC(=O)COCCOCCOCC(=O)NC2=C(I)C(C(O)=O)=C(I)C=C2I)=C1I	BLOOD	84C5PTP9X6																	UNKNOWN	mg/kg	70		SINGLE	UNKNOWN				t1/2 (0.5-6)		UNHEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/630004_7219403A1038_1_002_1F.pdf#page=15	Homo sapiens		h	1.4		Patients with normal renal and hepatic function					false
1435	641		ADULT	3740	1215.8131	IOTROXIC ACID	Iotroxic acid	OC(=O)C1=C(I)C=C(I)C(NC(=O)COCCOCCOCC(=O)NC2=C(I)C(C(O)=O)=C(I)C=C2I)=C1I	BLOOD	84C5PTP9X6																	UNKNOWN	mg/kg	112		SINGLE	UNKNOWN				t1/2 (0.5-6)		UNHEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/630004_7219403A1038_1_002_1F.pdf#page=15	Homo sapiens		h	1.8		Patients with normal renal and hepatic function					false
1436	649		ADULT	5857	284.4357	LYNESTRENOL	Lynestrenol	C[C@]12CC[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C	PLASMA	N2Z8ALG4U5	5991	296.4034	ETHINYL ESTRADIOL	Ethinylestradiol	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@]2(O)C#C	423D2T571U			∞	ng × h/mL	47		ng/mL	3.7			UNKNOWN	μg	150		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23570863/	Homo sapiens		h	28.9				20			true
1437	649		ADULT	6230	298.4192	NORETHINDRONE	Norethisterone	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C	SERUM	T18F433X4S							12		t	ng × h/mL	64.1		ng/mL	14.6			UNKNOWN	mg	1		SINGLE	UNKNOWN				follicular phase		HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7172676/	Homo sapiens		h	2.5				6			false
1438	649		ADULT	6230	298.4192	NORETHINDRONE	Norethisterone	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C	SERUM	T18F433X4S							12		t	ng × h/mL	114.4		ng/mL	19.5			UNKNOWN	mg	2		SINGLE	UNKNOWN				follicular phase		HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7172676/	Homo sapiens		h	4				6			false
1439	649		ADULT	6230	298.4192	NORETHINDRONE	Norethisterone	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C	SERUM	T18F433X4S							12		t	ng × h/mL	164.2		ng/mL	26.3			UNKNOWN	mg	5		SINGLE	UNKNOWN				follicular phase		HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7172676/	Homo sapiens		h	4.3				6			false
1440	651		ADULT	4006	288.383	MALOTILATE	Malotilate	CC(C)OC(=O)C(C(=O)OC(C)C)=C1SC=CS1	PLASMA	RV59PND975													μg/mL	0.7			UNKNOWN	mg	500		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3743616/	Homo sapiens					Patients in cirrhosis		9			false
1441	651		ADULT	4006	288.383	MALOTILATE	Malotilate	CC(C)OC(=O)C(C(=O)OC(C)C)=C1SC=CS1	PLASMA	RV59PND975													μg/mL	0.019			UNKNOWN	mg	600		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3743616/	Homo sapiens							4			false
1442	651		ADULT	4006	288.383	MALOTILATE	Malotilate	CC(C)OC(=O)C(C(=O)OC(C)C)=C1SC=CS1	PLASMA	RV59PND975									∞	μg × h/mL	0.052		μg/mL	0.035			UNKNOWN	mg	200		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.jstage.jst.go.jp/article/jscpt1970/13/4/13_4_559/_article/-char/en	Homo sapiens		h	1.069				5			false
1443	651		ADULT	4006	288.383	MALOTILATE	Malotilate	CC(C)OC(=O)C(C(=O)OC(C)C)=C1SC=CS1	PLASMA	RV59PND975									∞	μg × h/mL	0.044		μg/mL	0.028			UNKNOWN	mg	100		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.jstage.jst.go.jp/article/jscpt1970/13/4/13_4_559/_article/-char/en	Homo sapiens							5			false
1444	651		ADULT	4006	288.383	MALOTILATE	Malotilate	CC(C)OC(=O)C(C(=O)OC(C)C)=C1SC=CS1	PLASMA	RV59PND975									?	μg × h/mL	0.035		μg/mL	0.024			UNKNOWN	mg	200		MULTIPLE	FED		day	3			HEALTHY	Oral	MALE	EXPERIMENT	https://www.jstage.jst.go.jp/article/jscpt1970/13/4/13_4_559/_article/-char/en	Homo sapiens				Day 7 PK			5			false
1445	651		ADULT	4006	288.383	MALOTILATE	Malotilate	CC(C)OC(=O)C(C(=O)OC(C)C)=C1SC=CS1	PLASMA	RV59PND975									?	μg × h/mL	0.02		μg/mL	0.015			UNKNOWN	mg	200		MULTIPLE	FED		day	3			HEALTHY	Oral	MALE	EXPERIMENT	https://www.jstage.jst.go.jp/article/jscpt1970/13/4/13_4_559/_article/-char/en	Homo sapiens				Day 1 PK			5			false
1446	651		ADULT	4006	288.383	MALOTILATE	Malotilate	CC(C)OC(=O)C(C(=O)OC(C)C)=C1SC=CS1	PLASMA	RV59PND975									∞	μg × h/mL	0.1		μg/mL	0.058			UNKNOWN	mg	400		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.jstage.jst.go.jp/article/jscpt1970/13/4/13_4_559/_article/-char/en	Homo sapiens		h	0.91				5			false
1447	655		ADULT	4047	382.883	MEFRUSIDE	Mefruside	CN(CC1(C)CCCO1)S(=O)(=O)C2=CC(=C(Cl)C=C2)S(N)(=O)=O	PLASMA	X1NS9SNS92									?	ng × h/mL	5929		ng/mL	861			RECOMMENDED	mg	25		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/530169_2135001F1136_1_009_1F.pdf#page=15	Homo sapiens		h	5.85				14			false
1448	658		ADULT	25382	291.4299	MELITRACEN	Melitracen	CN(C)CCC=C1C2=CC=CC=C2C(C)(C)C3=C1C=CC=C3	PLASMA	Q7T0Y1109Z	5281881	434.518	FLUPENTIXOL	Flupentixol	OCCN1CCN(CC\\C=C2\\C3=C(SC4=C2C=C(C=C4)C(F)(F)F)C=CC=C3)CC1	FA0UYH6QUO			∞	ng × h/mL	453.7055		ng/mL	9.7926			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31571834/	Homo sapiens		h	72.793			0.5 mg	23			true
1449	658		ADULT	25382	291.4299	MELITRACEN	Melitracen	CN(C)CCC=C1C2=CC=CC=C2C(C)(C)C3=C1C=CC=C3	PLASMA	Q7T0Y1109Z	5281881	434.518	FLUPENTIXOL	Flupentixol	OCCN1CCN(CC\\C=C2\\C3=C(SC4=C2C=C(C=C4)C(F)(F)F)C=CC=C3)CC1	FA0UYH6QUO			∞	ng × h/mL	477.9061		ng/mL	10.6205			UNKNOWN	mg	10		SINGLE	HIGH-FAT						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31571834/	Homo sapiens		h	67.1625			0.5 mg	22			true
1450	658			25382	291.4299	MELITRACEN	Melitracen	CN(C)CCC=C1C2=CC=CC=C2C(C)(C)C3=C1C=CC=C3	PLASMA	Q7T0Y1109Z																										flupentixol/melitracen (reported 99%/89%\nplasma protein binding)	11				EXPERIMENT	https://www.tandfonline.com/doi/abs/10.1080/09674845.2020.1819632?journalCode=tbbs20	Homo sapiens										false
1451	671		ADULT	4486	405.4482	NIFEKALANT	NIFEKALANT	CN1C(=O)C=C(NCCN(CCO)CCCC2=CC=C(C=C2)[N ]([O-])=O)N(C)C1=O	PLASMA	5VZ7GZM43E									∞	mg × h/L	4.616		mg/L	1.943			HIGHEST STUDIED	mg/kg/h	0.6		STEADY-STATE	UNKNOWN		hour	1			HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	doi:10.1016/j.jchromb.2013.09.003	Homo sapiens		h	1.3	loading dosage of 0.4 mg/kg Nifekalant through a\nbolus infusion over a period of 5 min, a continuing maintenance dosage at a flow rate of 0.6 mg/kg h starting immediately after the first dosage and continuing for a period of 6 h, and a second loading dosage of 0.2 mg/kg over a period of 5 min starting 1.5 h after the start of the maintenance dosage			8	Nifekalant		false
1452	671		ADULT	4486	405.4482	NIFEKALANT	NIFEKALANT	CN1C(=O)C=C(NCCN(CCO)CCCC2=CC=C(C=C2)[N ]([O-])=O)N(C)C1=O	PLASMA	5VZ7GZM43E									∞	ng × h/mL	302.44		ng/mL	358.62			DEFINED DAILY	mg/kg	0.4		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.aidic.it/cet/15/46/230.pdf	Homo sapiens		h	1.34	constant speed pump over 5 minutes			8	hydrochloric acid nifekalant		false
1453	671		ADULT	4486	405.4482	NIFEKALANT	NIFEKALANT	CN1C(=O)C=C(NCCN(CCO)CCCC2=CC=C(C=C2)[N ]([O-])=O)N(C)C1=O	PLASMA	5VZ7GZM43E									∞	ng × h/mL	209.9		ng/mL	230.95			DEFINED DAILY	mg/kg	0.3		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.aidic.it/cet/15/46/230.pdf	Homo sapiens		h	1.54	constant speed pump over 5 minutes			8	hydrochloric acid nifekalant		false
1454	671		ADULT	4486	405.4482	NIFEKALANT	NIFEKALANT	CN1C(=O)C=C(NCCN(CCO)CCCC2=CC=C(C=C2)[N ]([O-])=O)N(C)C1=O	PLASMA	5VZ7GZM43E									∞	ng × h/mL	2627.33		ng/mL	444.3			HIGHEST STUDIED	mg/kg/h	0.4		STEADY-STATE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.aidic.it/cet/15/46/230.pdf	Homo sapiens		h	1.35	constant speed pump over 5 minutes  then intravenous drip at 0.4 mg/kg/h for 6 hours			8	hydrochloric acid nifekalant		false
1455	680		UNKNOWN	72493	687.8583	OLEANDOMYCIN	OLEANDOMYCIN	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@@H](C)C[C@@]4(CO4)C(=O)[C@H](C)[C@@H](O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1O	SERUM	P8ZQ646136													mg/L	0.8			UNKNOWN	mg	500		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/2656049	Homo sapiens										false
1456	680		UNKNOWN	72493	687.8583	OLEANDOMYCIN	OLEANDOMYCIN	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@@H](C)C[C@@]4(CO4)C(=O)[C@H](C)[C@@H](O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1O	SERUM	P8ZQ646136																	UNKNOWN				UNKNOWN	UNKNOWN						UNKNOWN	UNKNOWN	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4067847	Homo sapiens		min	63							false
1457	686		UNKNOWN	4621	467.6434	OXETHAZAINE	oxethazaine	CN(C(=O)CN(CCO)CC(=O)N(C)C(C)(C)CC1=CC=CC=C1)C(C)(C)CC2=CC=CC=C2	PLASMA	IP8QT76V17				Alumina|Magnesium hydroxide									ng/mL	20			UNKNOWN	mg	20		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	REVIEW	https://www.msjonline.org/index.php/ijrms/article/viewFile/4410/3655	Homo sapiens		h	1							true
1458	689		NEWBORN	31264	132.1577	PARALDEHYDE	PARALDEHYDE	C[C@H]1OC(C)O[C@@H](C)O1	PLASMA	S6M3YBG8QA													μg/mL	247			UNKNOWN	mg/kg/h	150	infusion, 3 hour	OTHER	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6694030	Homo sapiens		h	10.2							false
1459	692		ADULT	12675	288.031	PERFLENAPENT		FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F	BLOOD	483AU1Y5CZ									?	mg × min/L	10						UNKNOWN	mL/kg	0.02		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11368867/	Homo sapiens		min	2.1	31.6 mg administered			6			false
1460	692		ADULT	12675	288.031	PERFLENAPENT		FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F	BLOOD	483AU1Y5CZ									?	mg × min/L	21.8						UNKNOWN	mL/kg	0.05		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11368867/	Homo sapiens		min	1.8	75.1 mg administered			6			false
1461	692		ADULT	12675	288.031	PERFLENAPENT		FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F	BLOOD	483AU1Y5CZ									?	mg × min/L	42.6						UNKNOWN	mL/kg	0.1		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11368867/	Homo sapiens		min	2.3	160.2 mg administered			6			false
1462	692		ADULT	12675	288.031	PERFLENAPENT		FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F	BLOOD	483AU1Y5CZ									?	mg × min/L	8.3						UNKNOWN	mL/kg	0.01		SINGLE							HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11368867/	Homo sapiens		min	2.5	14.9 mg administered						false
1463	699		ADULT	4820	272.3853	PILSICAINIDE	PILSICAINIDE	CC1=CC=CC(C)=C1NC(=O)CC23CCCN2CCC3	PLASMA	AV0X7V6CSE									?	ng × h/mL	3470		ng/mL	409			UNKNOWN	mg	50		SINGLE	FED					73.2	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2050177/	Homo sapiens		h	3.4		normal renal function		6	PILSICAINIDE HYDROCHLORIDE		false
1464	699		ADULT	4820	272.3853	PILSICAINIDE	PILSICAINIDE	CC1=CC=CC(C)=C1NC(=O)CC23CCCN2CCC3	PLASMA	AV0X7V6CSE									?	ng × h/mL	7870		ng/mL	505			UNKNOWN	mg	50		SINGLE	FED					63.3	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2050177/	Homo sapiens		h	9.3		moderate renal imparment		8	PILSICAINIDE HYDROCHLORIDE		false
1465	699		ADULT	4820	272.3853	PILSICAINIDE	PILSICAINIDE	CC1=CC=CC(C)=C1NC(=O)CC23CCCN2CCC3	PLASMA	AV0X7V6CSE									?	ng × h/mL	4760		ng/mL	459			UNKNOWN	mg	50		SINGLE	FED					65.5	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2050177/	Homo sapiens		h	5.7		mild renal impairment		10	PILSICAINIDE HYDROCHLORIDE		false
1466	699		ADULT	4820	272.3853	PILSICAINIDE	PILSICAINIDE	CC1=CC=CC(C)=C1NC(=O)CC23CCCN2CCC3	PLASMA	AV0X7V6CSE									?	ng × h/mL	23800		ng/mL	630			UNKNOWN	mg	50		SINGLE	FED					63	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2050177/	Homo sapiens		h	23.7		severe renal impairment		8	PILSICAINIDE HYDROCHLORIDE		false
1467	699		ADULT	4820	272.3853	PILSICAINIDE	PILSICAINIDE	CC1=CC=CC(C)=C1NC(=O)CC23CCCN2CCC3	PLASMA	AV0X7V6CSE									∞	μg × h/mL	1.71		μg/mL	0.54			UNKNOWN	mg/kg	0.5		SINGLE	FED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24480637/	Homo sapiens		h	5.98				10	PILSICAINIDE HYDROCHLORIDE		false
1468	699		ADULT	4820	272.3853	PILSICAINIDE	PILSICAINIDE	CC1=CC=CC(C)=C1NC(=O)CC23CCCN2CCC3	PLASMA	AV0X7V6CSE									∞	μg × h/mL	2.72		μg/mL	1.05			UNKNOWN	mg/kg	0.75		SINGLE	FED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24480637/	Homo sapiens		h	5.46				10	PILSICAINIDE HYDROCHLORIDE		false
1469	699		ADULT	4820	272.3853	PILSICAINIDE	PILSICAINIDE	CC1=CC=CC(C)=C1NC(=O)CC23CCCN2CCC3	PLASMA	AV0X7V6CSE									∞	μg × h/mL	0.79		μg/mL	0.34			UNKNOWN	mg/kg	0.25		SINGLE	FED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24480637/	Homo sapiens		h	5.19				10	PILSICAINIDE HYDROCHLORIDE		false
1470	704			4888	255.272	PRANOPROFEN		CC(C(=O)O)c1ccc2Oc3ncccc3Cc2c1	SERUM	2R7O1ET613																										Human serum protein binding: 99.3% (ultracentrifuge)	0.7				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1494108/	Homo sapiens										false
1471	704		ADULT	4888	255.272	PRANOPROFEN		CC(C(=O)O)c1ccc2Oc3ncccc3Cc2c1	PLASMA	2R7O1ET613									∞	ng × h/mL	9295		ng/mL	3590			RECOMMENDED	mg	75		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2231310/	Homo sapiens		h	5.4				5			false
1472	704		ADULT	4888	255.272	PRANOPROFEN		CC(C(=O)O)c1ccc2Oc3ncccc3Cc2c1	PLASMA	2R7O1ET613							10		t	μg × h/mL	16.3		μg/mL	6.59			RECOMMENDED	mg	75		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2787808/	Homo sapiens		h	3		Elderly patients, afebrile period		9			false
1473	704		ADULT	4888	255.272	PRANOPROFEN		CC(C(=O)O)c1ccc2Oc3ncccc3Cc2c1	PLASMA	2R7O1ET613							10		t	μg × h/mL	19.4		μg/mL	7.37			RECOMMENDED	mg	75		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2787808/	Homo sapiens		h	4.2		Elderly patients, febrile period		9			false
1474	704			4888	255.272	PRANOPROFEN		CC(C(=O)O)c1ccc2Oc3ncccc3Cc2c1	PLASMA	2R7O1ET613																	RECOMMENDED	mg	75		SINGLE					Human plasma protein binding: 99.5% (1h and 3h after the oral administration of 75mg drug)	0.5		Oral		OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400315_1149010F1136_1_110_1F.pdf#page=22	Homo sapiens										false
1475	706		ADULT	4938	306.3602	PROPENTOFYLLINE	Propentofylline	CCCN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C	PLASMA	5RTA398U4H									∞	ng × h/mL	508.5		ng/mL	828.4			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9868540/	Homo sapiens		h	0.74				10			false
1476	706		ADULT	128535	322.3628	Hydroxypropentofylline		CC(O)Cn1cnc2N(C)C(=O)N(CCCCC(=O)C)C(=O)c12	PLASMA										∞	ng × h/mL	460.1		ng/mL	269.2			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9868540/	Homo sapiens		h	0.79				10			false
1477	708		ADULT	4942	367.4813	PROPIVERINE	Propiverine	CCCOC(C(=O)OC1CCN(C)CC1)(C2=CC=CC=C2)C3=CC=CC=C3	PLASMA	468GE2241L							72		t	ng × h/mL	1886.4		ng/mL	97.58			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=28	Homo sapiens		h	25.87				13	Propiverine hydrochloride		false
1478	708		ADULT	4942	367.4813	PROPIVERINE	Propiverine	CCCOC(C(=O)OC1CCN(C)CC1)(C2=CC=CC=C2)C3=CC=CC=C3	PLASMA	468GE2241L							72		t	ng × h/mL	1799.67		ng/mL	102.18			RECOMMENDED	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=29	Homo sapiens		h	28.21				14	Propiverine hydrochloride		false
1479	708		ADULT	4942	367.4813	PROPIVERINE	Propiverine	CCCOC(C(=O)OC1CCN(C)CC1)(C2=CC=CC=C2)C3=CC=CC=C3	SERUM	468GE2241L									∞	ng × h/mL	558		ng/mL	56			UNKNOWN	mg	15		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=29	Homo sapiens		h	16.3	Liquid			10	Propiverine hydrochloride		false
1480	708		ADULT	4942	367.4813	PROPIVERINE	Propiverine	CCCOC(C(=O)OC1CCN(C)CC1)(C2=CC=CC=C2)C3=CC=CC=C3	SERUM	468GE2241L									∞	ng × h/mL	615		ng/mL	62.9			UNKNOWN	mg	15		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=29	Homo sapiens		h	12.8	Tablets			10	Propiverine hydrochloride		false
1481	708		ADULT	4942	367.4813	PROPIVERINE	Propiverine	CCCOC(C(=O)OC1CCN(C)CC1)(C2=CC=CC=C2)C3=CC=CC=C3	SERUM	468GE2241L									∞	ng × h/mL	1348		ng/mL	136			UNKNOWN	mg	30		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=29	Homo sapiens		h	14.1	Tablets			10	Propiverine hydrochloride		false
1482	708		ADULT	4942	367.4813	PROPIVERINE	Propiverine	CCCOC(C(=O)OC1CCN(C)CC1)(C2=CC=CC=C2)C3=CC=CC=C3	SERUM	468GE2241L									∞	ng × h/mL	1403		ng/mL	196			UNKNOWN	mg	15		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=29	Homo sapiens		h	13.9				10	Propiverine hydrochloride		false
1483	708		ADULT	4942	367.4813	PROPIVERINE	Propiverine	CCCOC(C(=O)OC1CCN(C)CC1)(C2=CC=CC=C2)C3=CC=CC=C3	SERUM	468GE2241L									∞	ng × h/mL	483		ng/mL	48.5			UNKNOWN	mg	10		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=29	Homo sapiens		h	11.4	Tablets			10	Propiverine hydrochloride		false
1484	708		ADULT	6337695	384.493	PROPIVERINE N-OXIDE		CCCOC(C(=O)OC1CC[NH](C)([O-])CC1)(c2ccccc2)c3ccccc3	SERUM										∞	ng × h/mL	5107		ng/mL	281			UNKNOWN	mg	15		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=30	Homo sapiens		h	13.2				10	Propiverine hydrochloride		false
1485	708		ADULT	6337695	384.493	PROPIVERINE N-OXIDE		CCCOC(C(=O)OC1CC[NH](C)([O-])CC1)(c2ccccc2)c3ccccc3	SERUM										∞	ng × h/mL	3578		ng/mL	393			UNKNOWN	mg	10		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=30	Homo sapiens		h	11.1	Tablets			10	Propiverine hydrochloride		false
1486	708		ADULT	6337695	384.493	PROPIVERINE N-OXIDE		CCCOC(C(=O)OC1CC[NH](C)([O-])CC1)(c2ccccc2)c3ccccc3	SERUM										∞	ng × h/mL	4557		ng/mL	562			UNKNOWN	mg	15		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=30	Homo sapiens		h	11.7	Tablets			10	Propiverine hydrochloride		false
1487	708		ADULT	6337695	384.493	PROPIVERINE N-OXIDE		CCCOC(C(=O)OC1CC[NH](C)([O-])CC1)(c2ccccc2)c3ccccc3	SERUM										∞	ng × h/mL	4058		ng/mL	508			UNKNOWN	mg	15		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=30	Homo sapiens		h	10.3	Liquid			10	Propiverine hydrochloride		false
1488	708		ADULT	6337695	384.493	PROPIVERINE N-OXIDE		CCCOC(C(=O)OC1CC[NH](C)([O-])CC1)(c2ccccc2)c3ccccc3	SERUM										∞	ng × h/mL	9519		ng/mL	1100			UNKNOWN	mg	30		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=30	Homo sapiens		h	13.3	Tablets			10	Propiverine hydrochloride		false
1489	708		ADULT	4942	367.4813	PROPIVERINE	Propiverine	CCCOC(C(=O)OC1CCN(C)CC1)(C2=CC=CC=C2)C3=CC=CC=C3	SERUM	468GE2241L							5		t	ng × h/mL	630						UNKNOWN	mg	15		STEADY-STATE	FED		day	3	AUCinf (120-inf) = 3890 ng x h/mL		UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=31 | https://pubmed.ncbi.nlm.nih.gov/9923582/	Homo sapiens				Last dose (16th)	Control subjects		12	Propiverine hydrochloride		false
1490	708		ADULT	4942	367.4813	PROPIVERINE	Propiverine	CCCOC(C(=O)OC1CCN(C)CC1)(C2=CC=CC=C2)C3=CC=CC=C3	SERUM	468GE2241L							5		t	ng × h/mL	209		ng/mL	221			UNKNOWN	mg	15		MULTIPLE	FED		day	3			UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=31 | https://pubmed.ncbi.nlm.nih.gov/9923582/	Homo sapiens				1st dose	Fatty liver disease		12	Propiverine hydrochloride		false
1491	708		ADULT	4942	367.4813	PROPIVERINE	Propiverine	CCCOC(C(=O)OC1CCN(C)CC1)(C2=CC=CC=C2)C3=CC=CC=C3	SERUM	468GE2241L							5		t	ng × h/mL	177		ng/mL	155			UNKNOWN	mg	15		MULTIPLE	FED		day	3			UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=31 | https://pubmed.ncbi.nlm.nih.gov/9923582/	Homo sapiens				1st dose	Control subjects		12	Propiverine hydrochloride		false
1492	708		ADULT	4942	367.4813	PROPIVERINE	Propiverine	CCCOC(C(=O)OC1CCN(C)CC1)(C2=CC=CC=C2)C3=CC=CC=C3	SERUM	468GE2241L							5		t	ng × h/mL	657						UNKNOWN	mg	15		STEADY-STATE	FED		day	3	AUCinf (120-inf) = 7187 ng x h/mL		UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=31 | https://pubmed.ncbi.nlm.nih.gov/9923582/	Homo sapiens				Last dose (16th)	Fatty liver disease		12	Propiverine hydrochloride		false
1493	708		ADULT	6337695	384.493	PROPIVERINE N-OXIDE		CCCOC(C(=O)OC1CC[NH](C)([O-])CC1)(c2ccccc2)c3ccccc3	SERUM								5		t	ng × h/mL	1345		ng/mL	645			UNKNOWN	mg	15		MULTIPLE	FED		day	3			UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=32 | https://pubmed.ncbi.nlm.nih.gov/9923582/	Homo sapiens				1st dose	Control subjects		12	Propiverine hydrochloride		false
1494	708		ADULT	6337695	384.493	PROPIVERINE N-OXIDE		CCCOC(C(=O)OC1CC[NH](C)([O-])CC1)(c2ccccc2)c3ccccc3	SERUM								5		t	ng × h/mL	2512						UNKNOWN	mg	15		STEADY-STATE	FED		day	3	AUCinf (120-inf) = 11920 ng x h/mL		UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=32 | https://pubmed.ncbi.nlm.nih.gov/9923582/	Homo sapiens				Last dose (16th)	Control subjects		12	Propiverine hydrochloride		false
1495	708		ADULT	6337695	384.493	PROPIVERINE N-OXIDE		CCCOC(C(=O)OC1CC[NH](C)([O-])CC1)(c2ccccc2)c3ccccc3	SERUM								5		t	ng × h/mL	3200						UNKNOWN	mg	15		STEADY-STATE	FED		day	3	AUCinf (120-inf) = 17005 ng x h/mL		UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=32 | https://pubmed.ncbi.nlm.nih.gov/9923582/	Homo sapiens				Last dose (16th)	Fatty liver disease		12	Propiverine hydrochloride		false
1496	708		ADULT	6337695	384.493	PROPIVERINE N-OXIDE		CCCOC(C(=O)OC1CC[NH](C)([O-])CC1)(c2ccccc2)c3ccccc3	SERUM								5		t	ng × h/mL	1139		ng/mL	819			UNKNOWN	mg	15		MULTIPLE	FED		day	3			UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=32 | https://pubmed.ncbi.nlm.nih.gov/9923582/	Homo sapiens				1st dose	Fatty liver disease		12	Propiverine hydrochloride		false
1497	708			4942	367.4813	PROPIVERINE	Propiverine	CCCOC(C(=O)OC1CCN(C)CC1)(C2=CC=CC=C2)C3=CC=CC=C3	SERUM	468GE2241L																										Human serum protein binding: 90~95% (ultrafiltration)	5				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=33 | https://pubmed.ncbi.nlm.nih.gov/9231343/	Homo sapiens										false
1498	708			6337695	384.493	PROPIVERINE N-OXIDE		CCCOC(C(=O)OC1CC[NH](C)([O-])CC1)(c2ccccc2)c3ccccc3	SERUM																											Human serum protein binding: 60% (ultrafiltration)	40				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=33 | https://pubmed.ncbi.nlm.nih.gov/9231343/	Homo sapiens										false
1499	708			6337695	384.493	Propiverine N-oxide		CCCOC(C(=O)OC1CC[NH](C)([O-])CC1)(c2ccccc2)c3ccccc3	SERUM	468GE2241L																										Human serum protein binding: 82.81% (84.9 mcg/mL)	17.19				EXPERIMENT	https://www.jstage.jst.go.jp/article/dmpk1986/6/1/6_1_3/_article/-char/en	Homo sapiens										false
1500	708			4942	367.4813	PROPIVERINE	Propiverine	CCCOC(C(=O)OC1CCN(C)CC1)(C2=CC=CC=C2)C3=CC=CC=C3	SERUM	468GE2241L																										Human serum protein binding: 91.2% (84.9 mcg/mL)	15.1				EXPERIMENT	https://www.jstage.jst.go.jp/article/dmpk1986/6/1/6_1_3/_article/-char/en	Homo sapiens										false
1501	709		ADULT	3778	230.3055	PROPYPHENAZONE	Propyphenazone	CC(C)C1=C(C)N(C)N(C1=O)C2=CC=CC=C2	PLASMA	OED8FV75PY	3100	255.3547	DIPHENHYDRAMINE	Diphenhydramine	CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2	8GTS82S83M							μg/L	3320			UNKNOWN	mg	220		STEADY-STATE	UNKNOWN		day	3			HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://en.cnki.com.cn/Article_en/CJFDTotal-DSDX200818007.htm	Homo sapiens							12			true
1502	709		ADULT	3778	230.3055	PROPYPHENAZONE	Propyphenazone	CC(C)C1=C(C)N(C)N(C1=O)C2=CC=CC=C2	PLASMA	OED8FV75PY	3100	255.3547	DIPHENHYDRAMINE	Diphenhydramine	CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2	8GTS82S83M			?	μg × h/L	6522.007		μg/L	3220			UNKNOWN	mg	220		MULTIPLE	UNKNOWN		day	3			HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://en.cnki.com.cn/Article_en/CJFDTotal-DSDX200818007.htm	Homo sapiens		h	3.029	every 8 h for 10 times			12			true
1503	709		ADULT	3778	230.3055	PROPYPHENAZONE	Propyphenazone	CC(C)C1=C(C)N(C)N(C1=O)C2=CC=CC=C2	PLASMA	OED8FV75PY	3100	255.3547	DIPHENHYDRAMINE	Diphenhydramine	CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2	8GTS82S83M			?	μg × h/L	8055.037		μg/L	3252.083			UNKNOWN	mg	220		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://en.cnki.com.cn/Article_en/CJFDTotal-DSDX200818007.htm	Homo sapiens		h	2.826				12			true
1504	709			3778	230.3055	PROPYPHENAZONE	Propyphenazone	CC(C)C1=C(C)N(C)N(C1=O)C2=CC=CC=C2	UNKNOWN	OED8FV75PY																										Protein binding: 10-20 %	80				REVIEW	https://link.springer.com/chapter/10.1007/978-3-319-33889-7_1	Homo sapiens										false
1505	710		ADULT	4967|666418	180.27	PROTIONAMIDE	Protionamide	CCCC1=NC=CC(=C1)C(N)=S	PLASMA	76YOO33643							12		t	μg × h/mL	10.4		μg/mL	1.8			UNKNOWN	mg/kg bw	6.5		STEADY-STATE	FED		day	2			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19723408/	Homo sapiens		h	2.2		MDR-TB patients, BMI<18.5		6			false
1506	710		ADULT	4967|666418	180.27	PROTIONAMIDE	Protionamide	CCCC1=NC=CC(=C1)C(N)=S	PLASMA	76YOO33643							12		t	μg × h/mL	11.3		μg/mL	2.5			UNKNOWN	mg/kg bw	5.9		STEADY-STATE	FED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19723408/	Homo sapiens		h	3		MDR-TB patients, 18.5=<BMI<23		11			false
1507	712		ADULT	4977	238.2432	PROXYPHYLLINE	Proxyphylline	CC(O)CN1C=NC2=C1C(=O)N(C)C(=O)N2C	PLASMA	13G1DMN4P0	3182	254.2426	DYPHYLLINE	Diprophylline	CN1C2=C(N(CC(O)CO)C=N2)C(=O)N(C)C1=O	263T0E9RR9							mg/L	6.87			UNKNOWN	mg	300		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6630383/	Homo sapiens		h	8.69			Diprophylline (300mg), Theophylline (200mg) and Proxyphylline (300mg)	4			true
1508	712			4977	238.2432	PROXYPHYLLINE	Proxyphylline	CC(O)CN1C=NC2=C1C(=O)N(C)C(=O)N2C	PLASMA	13G1DMN4P0																										Human plasma protein binding: almost 0%	100				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/530169_2115008F1038_1_005_1F.pdf#page=18	Homo sapiens										false
1509	712		ADULT	4977	238.2432	PROXYPHYLLINE	Proxyphylline	CC(O)CN1C=NC2=C1C(=O)N(C)C(=O)N2C	PLASMA	13G1DMN4P0	65326|11790256|60208008	201.693	EPHEDRINE HYDROCHLORIDE	Ephedrine hydrochloride	Cl.CN[C@@H](C)[C@H](O)C1=CC=CC=C1	NLJ6390P1Z			∞	μg × h/mL	59.57		μg/mL	3.946			UNKNOWN	mg	150		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/730155_2229112F1033_1_011_1F.pdf#page=17	Homo sapiens				Gastric-disintegrable tablets		Proxyphylline, ephedrine hydrochloride, and phenobarbital	13			true
1510	712		ADULT	4977	238.2432	PROXYPHYLLINE	Proxyphylline	CC(O)CN1C=NC2=C1C(=O)N(C)C(=O)N2C	PLASMA	13G1DMN4P0	65326|11790256|60208008	201.693	EPHEDRINE HYDROCHLORIDE	Ephedrine hydrochloride	Cl.CN[C@@H](C)[C@H](O)C1=CC=CC=C1	NLJ6390P1Z			∞	μg × h/mL	46.38		μg/mL	3.588			UNKNOWN	mg	150		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/730155_2229112F1033_1_011_1F.pdf#page=18	Homo sapiens				Enteric-coated tablets		Proxyphylline, ephedrine hydrochloride, and phenobarbital	14			true
1511	713		ADULT	4990	253.2545	PYRICARBATE	PYRICARBATE	CNC(=O)OCC1=CC=CC(COC(=O)NC)=N1	PLASMA	81R511UV73									?	μg × h/mL	142.28		μg/mL	15.8			UNKNOWN	g	1		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/501551/	Homo sapiens		h	4.8	Angioxine, Roussel Laboratories, Paris, France			10	PYRICARBATE		false
1512	713		ADULT	4990	253.2545	PYRICARBATE	PYRICARBATE	CNC(=O)OCC1=CC=CC(COC(=O)NC)=N1	PLASMA	81R511UV73									?	μg × h/mL	132.77		μg/mL	14.5			UNKNOWN	g	1		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/501551/	Homo sapiens		h	4.8	Medoxal, Allard Laboratories, Paris, France			10	PYRICARBATE		false
1513	713		ADULT	4990	253.2545	PYRICARBATE	PYRICARBATE	CNC(=O)OCC1=CC=CC(COC(=O)NC)=N1	SERUM	81R511UV73									?	μg × h/mL	187.36		μg/mL	18.28			UNKNOWN	g	1		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6745304/	Homo sapiens		h	5.86				10	PYRICARBATE		false
1514	713		ADULT	4990	253.2545	PYRICARBATE	PYRICARBATE	CNC(=O)OCC1=CC=CC(COC(=O)NC)=N1	SERUM	81R511UV73									?	μg × h/mL	249.6		μg/mL	21.8			UNKNOWN	g	1		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6745304/	Homo sapiens		h	6.56		chronic renal insufficiency		14	PYRICARBATE		false
1515	722		ADULT	36119	447.5264	SISOMICIN	SISOMICIN	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3OC(CN)=CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O	SERUM	X55XSL74YQ							8		t	μg × h/mL	5.39						UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7334458	Homo sapiens		h	2.34							false
1516	722		ADULT	36119	447.5264	SISOMICIN	SISOMICIN	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3OC(CN)=CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O	SERUM	X55XSL74YQ							8		t	μg × h/mL	11.3						UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7334458	Homo sapiens		h	2.68							false
1517	722		ADULT	36119	447.5264	SISOMICIN	SISOMICIN	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3OC(CN)=CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O	SERUM	X55XSL74YQ							8		t	μg × h/mL	17.76						UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7334458	Homo sapiens		h	2.75							false
1518	722		ADULT	36119	447.5264	SISOMICIN	SISOMICIN	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3OC(CN)=CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O	SERUM	X55XSL74YQ							8		t	μg × h/mL	3.98						UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Intramuscular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7334458	Homo sapiens		h	1.89							false
1519	722		ADULT	36119	447.5264	SISOMICIN	SISOMICIN	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3OC(CN)=CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O	SERUM	X55XSL74YQ							8		t	μg × h/mL	10.15						UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Intramuscular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7334458	Homo sapiens		h	2.7							false
1520	722		ADULT	36119	447.5264	SISOMICIN	SISOMICIN	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3OC(CN)=CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O	SERUM	X55XSL74YQ							8		t	μg × h/mL	21.52						UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Intramuscular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7334458	Homo sapiens		h	3.44							false
1521	723		ADULT	72734323	873.674	SITAFLOXACIN	Sitafloxacin	O.O.O.N[C@@H]1CN(CC12CC2)C3=C(F)C=C4C(=O)C(=CN([C@@H]5C[C@@H]5F)C4=C3Cl)C(O)=O.N[C@@H]6CN(CC67CC7)C8=C(F)C=C9C(=O)C(=CN([C@@H]\u0010C[C@@H]\u0010F)C9=C8Cl)C(O)=O	SERUM	9TD681796G									∞	μg × h/mL	1.52		μg/mL	0.29			UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_A100_2.pdf#page=35	Homo sapiens		h	5.2				6			false
1522	723		ADULT	72734323	873.674	SITAFLOXACIN	Sitafloxacin	O.O.O.N[C@@H]1CN(CC12CC2)C3=C(F)C=C4C(=O)C(=CN([C@@H]5C[C@@H]5F)C4=C3Cl)C(O)=O.N[C@@H]6CN(CC67CC7)C8=C(F)C=C9C(=O)C(=CN([C@@H]\u0010C[C@@H]\u0010F)C9=C8Cl)C(O)=O	SERUM	9TD681796G									∞	μg × h/mL	2.62		μg/mL	0.51			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_A100_2.pdf#page=35	Homo sapiens		h	6.2				6			false
1523	723		ADULT	72734323	873.674	SITAFLOXACIN	Sitafloxacin	O.O.O.N[C@@H]1CN(CC12CC2)C3=C(F)C=C4C(=O)C(=CN([C@@H]5C[C@@H]5F)C4=C3Cl)C(O)=O.N[C@@H]6CN(CC67CC7)C8=C(F)C=C9C(=O)C(=CN([C@@H]\u0010C[C@@H]\u0010F)C9=C8Cl)C(O)=O	SERUM	9TD681796G									∞	μg × h/mL	5.55		μg/mL	1			DEFINED DAILY	mg	100		SINGLE	FASTED				Human serum protein binding: 46~55% (1, 4, and 8 h after 100mg administration at the fasted condition, ultrafiltration)	45	HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_A100_2.pdf#page=35 | https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K101_2.pdf#page=6	Homo sapiens		h	5.7				6			false
1524	723		ADULT	72734323	873.674	SITAFLOXACIN	Sitafloxacin	O.O.O.N[C@@H]1CN(CC12CC2)C3=C(F)C=C4C(=O)C(=CN([C@@H]5C[C@@H]5F)C4=C3Cl)C(O)=O.N[C@@H]6CN(CC67CC7)C8=C(F)C=C9C(=O)C(=CN([C@@H]\u0010C[C@@H]\u0010F)C9=C8Cl)C(O)=O	SERUM	9TD681796G									∞	μg × h/mL	12.04		μg/mL	1.86			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_A100_2.pdf#page=36	Homo sapiens		h	5.3				6			false
1525	723		ADULT	72734323	873.674	SITAFLOXACIN	Sitafloxacin	O.O.O.N[C@@H]1CN(CC12CC2)C3=C(F)C=C4C(=O)C(=CN([C@@H]5C[C@@H]5F)C4=C3Cl)C(O)=O.N[C@@H]6CN(CC67CC7)C8=C(F)C=C9C(=O)C(=CN([C@@H]\u0010C[C@@H]\u0010F)C9=C8Cl)C(O)=O	SERUM	9TD681796G									∞	μg × h/mL	5.81		μg/mL	0.88			DEFINED DAILY	mg	100		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K101_2.pdf#page=4	Homo sapiens		h	5.5				6			false
1526	723		ADULT	72734323	873.674	SITAFLOXACIN	Sitafloxacin	O.O.O.N[C@@H]1CN(CC12CC2)C3=C(F)C=C4C(=O)C(=CN([C@@H]5C[C@@H]5F)C4=C3Cl)C(O)=O.N[C@@H]6CN(CC67CC7)C8=C(F)C=C9C(=O)C(=CN([C@@H]\u0010C[C@@H]\u0010F)C9=C8Cl)C(O)=O	SERUM	9TD681796G									∞	μg × h/mL	4.66		μg/mL	0.63			UNKNOWN	mg	50		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K102_2.pdf#pag3=7	Homo sapiens		h	7.5		Mild renal impairment		6			false
1527	723		ADULT	72734323	873.674	SITAFLOXACIN	Sitafloxacin	O.O.O.N[C@@H]1CN(CC12CC2)C3=C(F)C=C4C(=O)C(=CN([C@@H]5C[C@@H]5F)C4=C3Cl)C(O)=O.N[C@@H]6CN(CC67CC7)C8=C(F)C=C9C(=O)C(=CN([C@@H]\u0010C[C@@H]\u0010F)C9=C8Cl)C(O)=O	SERUM	9TD681796G									∞	μg × h/mL	8.04		μg/mL	0.75			UNKNOWN	mg	50		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K102_2.pdf#pag3=7	Homo sapiens		h	11.5		Moderate renal impairment		3			false
1528	723		ADULT	72734323	873.674	SITAFLOXACIN	Sitafloxacin	O.O.O.N[C@@H]1CN(CC12CC2)C3=C(F)C=C4C(=O)C(=CN([C@@H]5C[C@@H]5F)C4=C3Cl)C(O)=O.N[C@@H]6CN(CC67CC7)C8=C(F)C=C9C(=O)C(=CN([C@@H]\u0010C[C@@H]\u0010F)C9=C8Cl)C(O)=O	SERUM	9TD681796G									∞	μg × h/mL	9.95		μg/mL	0.6			UNKNOWN	mg	50		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K102_2.pdf#pag3=7	Homo sapiens		h	16.3		Severe renal impairment		3			false
1529	723		ADULT	72734323	873.674	SITAFLOXACIN	Sitafloxacin	O.O.O.N[C@@H]1CN(CC12CC2)C3=C(F)C=C4C(=O)C(=CN([C@@H]5C[C@@H]5F)C4=C3Cl)C(O)=O.N[C@@H]6CN(CC67CC7)C8=C(F)C=C9C(=O)C(=CN([C@@H]\u0010C[C@@H]\u0010F)C9=C8Cl)C(O)=O	SERUM	9TD681796G							12		t	μg × h/mL	2.2		μg/mL	0.38			RECOMMENDED	mg	50		MULTIPLE	FED		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K102_2.pdf#page=1	Homo sapiens				Day 1 PK (1st dose)			6			false
1530	723		ADULT	72734323	873.674	SITAFLOXACIN	Sitafloxacin	O.O.O.N[C@@H]1CN(CC12CC2)C3=C(F)C=C4C(=O)C(=CN([C@@H]5C[C@@H]5F)C4=C3Cl)C(O)=O.N[C@@H]6CN(CC67CC7)C8=C(F)C=C9C(=O)C(=CN([C@@H]\u0010C[C@@H]\u0010F)C9=C8Cl)C(O)=O	SERUM	9TD681796G							12		t	μg × h/mL	2.71		μg/mL	0.5			RECOMMENDED	mg	50		MULTIPLE	FED		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K102_2.pdf#page=1	Homo sapiens		h	5.1	Day 7 PK			6			false
1531	723		ADULT	72734323	873.674	SITAFLOXACIN	Sitafloxacin	O.O.O.N[C@@H]1CN(CC12CC2)C3=C(F)C=C4C(=O)C(=CN([C@@H]5C[C@@H]5F)C4=C3Cl)C(O)=O.N[C@@H]6CN(CC67CC7)C8=C(F)C=C9C(=O)C(=CN([C@@H]\u0010C[C@@H]\u0010F)C9=C8Cl)C(O)=O	SERUM	9TD681796G							12		t	μg × h/mL	4.34		μg/mL	0.84			UNKNOWN	mg	100		MULTIPLE	FED		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K102_2.pdf#page=3	Homo sapiens				Day 1 PK (1st dose)			6			false
1532	723		ADULT	72734323	873.674	SITAFLOXACIN	Sitafloxacin	O.O.O.N[C@@H]1CN(CC12CC2)C3=C(F)C=C4C(=O)C(=CN([C@@H]5C[C@@H]5F)C4=C3Cl)C(O)=O.N[C@@H]6CN(CC67CC7)C8=C(F)C=C9C(=O)C(=CN([C@@H]\u0010C[C@@H]\u0010F)C9=C8Cl)C(O)=O	SERUM	9TD681796G							12		t	μg × h/mL	5.9		μg/mL	1.09			UNKNOWN	mg	100		MULTIPLE	FED		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K102_2.pdf#page=3	Homo sapiens		h	4.6	Day 7 PK			6			false
1533	723		ADULT	72734323	873.674	SITAFLOXACIN	Sitafloxacin	O.O.O.N[C@@H]1CN(CC12CC2)C3=C(F)C=C4C(=O)C(=CN([C@@H]5C[C@@H]5F)C4=C3Cl)C(O)=O.N[C@@H]6CN(CC67CC7)C8=C(F)C=C9C(=O)C(=CN([C@@H]\u0010C[C@@H]\u0010F)C9=C8Cl)C(O)=O	SERUM	9TD681796G							24		t	μg × h/mL	6.35		μg/mL	0.61			DEFINED DAILY	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K102_2.pdf#page=5	Homo sapiens		h	6		Elderly subjects (65~80 y)		5			false
1534	723		ADULT	72734323	873.674	SITAFLOXACIN	Sitafloxacin	O.O.O.N[C@@H]1CN(CC12CC2)C3=C(F)C=C4C(=O)C(=CN([C@@H]5C[C@@H]5F)C4=C3Cl)C(O)=O.N[C@@H]6CN(CC67CC7)C8=C(F)C=C9C(=O)C(=CN([C@@H]\u0010C[C@@H]\u0010F)C9=C8Cl)C(O)=O	SERUM	9TD681796G							24		t	μg × h/mL	4.86		μg/mL	0.91			DEFINED DAILY	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K102_2.pdf#page=5	Homo sapiens		h	3.3		Non-elderly subjects (25~25 y)		6			false
1535	723		ADULT	72734323	873.674	SITAFLOXACIN	Sitafloxacin	O.O.O.N[C@@H]1CN(CC12CC2)C3=C(F)C=C4C(=O)C(=CN([C@@H]5C[C@@H]5F)C4=C3Cl)C(O)=O.N[C@@H]6CN(CC67CC7)C8=C(F)C=C9C(=O)C(=CN([C@@H]\u0010C[C@@H]\u0010F)C9=C8Cl)C(O)=O	PLASMA	9TD681796G							12		t	μg × h/mL	27.32		μg/mL	5.08			UNKNOWN	mg	600		MULTIPLE	UNKNOWN		day	2			HEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K128_2.pdf#page=10	Homo sapiens				Day 1 (1st dose)			28			false
1536	723		ADULT	72734323	873.674	SITAFLOXACIN	Sitafloxacin	O.O.O.N[C@@H]1CN(CC12CC2)C3=C(F)C=C4C(=O)C(=CN([C@@H]5C[C@@H]5F)C4=C3Cl)C(O)=O.N[C@@H]6CN(CC67CC7)C8=C(F)C=C9C(=O)C(=CN([C@@H]\u0010C[C@@H]\u0010F)C9=C8Cl)C(O)=O	PLASMA	9TD681796G							12		t	μg × h/mL	17.23		μg/mL	3.44			UNKNOWN	mg	400		MULTIPLE	UNKNOWN		day	2			HEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K128_2.pdf#page=10	Homo sapiens				Day 1 PK (1st dose)			28			false
1537	723		ADULT	72734323	873.674	SITAFLOXACIN	Sitafloxacin	O.O.O.N[C@@H]1CN(CC12CC2)C3=C(F)C=C4C(=O)C(=CN([C@@H]5C[C@@H]5F)C4=C3Cl)C(O)=O.N[C@@H]6CN(CC67CC7)C8=C(F)C=C9C(=O)C(=CN([C@@H]\u0010C[C@@H]\u0010F)C9=C8Cl)C(O)=O	PLASMA	9TD681796G							12		t	μg × h/mL	24.16		μg/mL	4.2			UNKNOWN	mg	400		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K128_2.pdf#page=10	Homo sapiens				Day 4 (8th dose)			28			false
1538	723		ADULT	72734323	873.674	SITAFLOXACIN	Sitafloxacin	O.O.O.N[C@@H]1CN(CC12CC2)C3=C(F)C=C4C(=O)C(=CN([C@@H]5C[C@@H]5F)C4=C3Cl)C(O)=O.N[C@@H]6CN(CC67CC7)C8=C(F)C=C9C(=O)C(=CN([C@@H]\u0010C[C@@H]\u0010F)C9=C8Cl)C(O)=O	PLASMA	9TD681796G							12		t	μg × h/mL	39.12		μg/mL	6.44			UNKNOWN	mg	600		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K128_2.pdf#page=10	Homo sapiens				Day 4 (8th dose)			28			false
1539	723		ADULT	72734323	873.674	SITAFLOXACIN	Sitafloxacin	O.O.O.N[C@@H]1CN(CC12CC2)C3=C(F)C=C4C(=O)C(=CN([C@@H]5C[C@@H]5F)C4=C3Cl)C(O)=O.N[C@@H]6CN(CC67CC7)C8=C(F)C=C9C(=O)C(=CN([C@@H]\u0010C[C@@H]\u0010F)C9=C8Cl)C(O)=O	PLASMA	9TD681796G							12		t	μg × h/mL	56.36		μg/mL	9.07			UNKNOWN	mg	800		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K128_2.pdf#page=10	Homo sapiens				Day 4 (8th dose)			28			false
1540	723		ADULT	72734323	873.674	SITAFLOXACIN	Sitafloxacin	O.O.O.N[C@@H]1CN(CC12CC2)C3=C(F)C=C4C(=O)C(=CN([C@@H]5C[C@@H]5F)C4=C3Cl)C(O)=O.N[C@@H]6CN(CC67CC7)C8=C(F)C=C9C(=O)C(=CN([C@@H]\u0010C[C@@H]\u0010F)C9=C8Cl)C(O)=O	PLASMA	9TD681796G							12		t	μg × h/mL	38.09		μg/mL	7.18			UNKNOWN	mg	800		MULTIPLE	UNKNOWN		day	2			HEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K128_2.pdf#page=10	Homo sapiens				Day 1 (1st dose)			28			false
1541	724		ADULT	72760	254.2426	1,2-BIS(3,5-DIOXOPIPERAZIN-1-YL)ETHANE	1,2-BIS(3,5-DIOXOPIPERAZIN-1-YL)ETHANE	O=C1CN(CCN2CC(=O)NC(=O)C2)CC(=O)N1	PLASMA	QML51S42CD							24		t	μg × h/mL	66.04		μg/mL	4.38			UNKNOWN	mg/m²	560		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/380101_4291004C1030_1_A01_1F.pdf#page=24	Homo sapiens		h	7.56	Day 5 PK			1			false
1542	724		ADULT	72760	254.2426	1,2-BIS(3,5-DIOXOPIPERAZIN-1-YL)ETHANE	1,2-BIS(3,5-DIOXOPIPERAZIN-1-YL)ETHANE	O=C1CN(CCN2CC(=O)NC(=O)C2)CC(=O)N1	PLASMA	QML51S42CD							24		t	μg × h/mL	20.59		μg/mL	2.7			UNKNOWN	mg/m²	600		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/380101_4291004C1030_1_A01_1F.pdf#page=24	Homo sapiens		h	4.58				2			false
1543	724		ADULT	72760	254.2426	1,2-BIS(3,5-DIOXOPIPERAZIN-1-YL)ETHANE	1,2-BIS(3,5-DIOXOPIPERAZIN-1-YL)ETHANE	O=C1CN(CCN2CC(=O)NC(=O)C2)CC(=O)N1	PLASMA	QML51S42CD							24		t	μg × h/mL	35.46		μg/mL	4.47			UNKNOWN	mg/m²	750		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/380101_4291004C1030_1_A01_1F.pdf#page=24	Homo sapiens		h	5.28				3			false
1544	724		ADULT	72760	254.2426	1,2-BIS(3,5-DIOXOPIPERAZIN-1-YL)ETHANE	1,2-BIS(3,5-DIOXOPIPERAZIN-1-YL)ETHANE	O=C1CN(CCN2CC(=O)NC(=O)C2)CC(=O)N1	PLASMA	QML51S42CD							24		t	μg × h/mL	61.85		μg/mL	7.42			UNKNOWN	mg/m²	1500		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/380101_4291004C1030_1_A01_1F.pdf#page=24	Homo sapiens		h	4.99				1			false
1545	724		ADULT	72760	254.2426	1,2-BIS(3,5-DIOXOPIPERAZIN-1-YL)ETHANE	1,2-BIS(3,5-DIOXOPIPERAZIN-1-YL)ETHANE	O=C1CN(CCN2CC(=O)NC(=O)C2)CC(=O)N1	PLASMA	QML51S42CD							24		t	μg × h/mL	74		μg/mL	11.46			UNKNOWN	mg/m²	1000		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/380101_4291004C1030_1_A01_1F.pdf#page=24	Homo sapiens		h	2.64	Day 5 PK			1			false
1546	724		ADULT	72760	254.2426	1,2-BIS(3,5-DIOXOPIPERAZIN-1-YL)ETHANE	1,2-BIS(3,5-DIOXOPIPERAZIN-1-YL)ETHANE	O=C1CN(CCN2CC(=O)NC(=O)C2)CC(=O)N1	PLASMA	QML51S42CD							24		t	μg × h/mL	51.64		μg/mL	6.16			UNKNOWN	mg/m²	800		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/380101_4291004C1030_1_A01_1F.pdf#page=24	Homo sapiens		h	4.15	Day 5 PK			3			false
1547	724		ADULT	72760	254.2426	1,2-BIS(3,5-DIOXOPIPERAZIN-1-YL)ETHANE	1,2-BIS(3,5-DIOXOPIPERAZIN-1-YL)ETHANE	O=C1CN(CCN2CC(=O)NC(=O)C2)CC(=O)N1	PLASMA	QML51S42CD							24		t	μg × h/mL	8.31		μg/mL	0.93			UNKNOWN	mg/m²	270		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/380101_4291004C1030_1_A01_1F.pdf#page=24	Homo sapiens		h	3.6	Day 5 PK			1			false
1548	724		ADULT	72760	254.2426	1,2-BIS(3,5-DIOXOPIPERAZIN-1-YL)ETHANE	1,2-BIS(3,5-DIOXOPIPERAZIN-1-YL)ETHANE	O=C1CN(CCN2CC(=O)NC(=O)C2)CC(=O)N1	PLASMA	QML51S42CD							24		t	μg × h/mL	62.81		μg/mL	8.41			UNKNOWN	mg/m²	1200		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/380101_4291004C1030_1_A01_1F.pdf#page=24	Homo sapiens		h	3.47	Day 5 PK			1			false
1549	724		ADULT	72760	254.2426	1,2-BIS(3,5-DIOXOPIPERAZIN-1-YL)ETHANE	1,2-BIS(3,5-DIOXOPIPERAZIN-1-YL)ETHANE	O=C1CN(CCN2CC(=O)NC(=O)C2)CC(=O)N1	PLASMA	QML51S42CD							24		t	μg × h/mL	9.37		μg/mL	1.15			UNKNOWN	mg/m²	200		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/380101_4291004C1030_1_A01_1F.pdf#page=24	Homo sapiens		h	3.99	Day 5 PK			2			false
1550	724		ADULT	72760	254.2426	1,2-BIS(3,5-DIOXOPIPERAZIN-1-YL)ETHANE	1,2-BIS(3,5-DIOXOPIPERAZIN-1-YL)ETHANE	O=C1CN(CCN2CC(=O)NC(=O)C2)CC(=O)N1	PLASMA	QML51S42CD							24		t	μg × h/mL	6.84						UNKNOWN	mg/m²	320		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/380101_4291004C1030_1_A01_1F.pdf#page=24	Homo sapiens				Day 5 PK			1			false
1551	724			5233	514.5262	SOBUZOXANE	Sobuzoxane	CC(C)COC(=O)OCN1C(=O)CN(CCN2CC(=O)N(COC(=O)OCC(C)C)C(=O)C2)CC1=O	PLASMA	R1308VH37P																										Plasma protein binding: <=2%	98				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/380101_4291004C1030_1_A01_1F.pdf#page=25	Homo sapiens										false
1552	728		ADULT	20055036	414.453	SULBENICILLIN	SULBENICILLIN	CC1(C)S[C@@H]2[C@H](NC(=O)[C@@H](C3=CC=CC=C3)S(O)(=O)=O)C(=O)N2[C@H]1C(O)=O	SERUM	Q2VYF0562D																	UNKNOWN	g	4		SINGLE	UNKNOWN				in vitro incubation at different concentrations from 50 to 400 ug/ml with a 4% solution of human albumin. the bound fraction was in the order of 70%.	30	HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1120400/	Homo sapiens		min	70				5	SULBENICILLIN		false
1553	728		ADULT	20055036	414.453	SULBENICILLIN	SULBENICILLIN	CC1(C)S[C@@H]2[C@H](NC(=O)[C@@H](C3=CC=CC=C3)S(O)(=O)=O)C(=O)N2[C@H]1C(O)=O	SERUM	Q2VYF0562D													μg/mL	252			UNKNOWN	g	2		SINGLE	UNKNOWN				only ranges are given: the peak concentration ranged from 104 to 252 ug/ml, serum half-lives ranged from 71 to 97 min.		HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1120400/	Homo sapiens		min	97				5	SULBENICILLIN		false
1554	732			5330	280.303	SULFAMETHOXYPYRIDAZINE	SULFAMETHOXYPYRIDAZINE	COC1=NN=C(NS(=O)(=O)C2=CC=C(N)C=C2)C=C1	PLASMA	T034E4NS2Z																										at 5 mg% of sulfamethoxypyridazine in human plasma. Funbound is 8.5, 12, 16.3 and 20.3% at 10, 15, 20 and 25 mg% of sulfamethoxypyridazine, respectively.	6.5				REVIEW	https://pubmed.ncbi.nlm.nih.gov/4981614/	Homo sapiens										false
1555	732		ADULT	5330	280.303	SULFAMETHOXYPYRIDAZINE	SULFAMETHOXYPYRIDAZINE	COC1=NN=C(NS(=O)(=O)C2=CC=C(N)C=C2)C=C1	PLASMA	T034E4NS2Z													mg/L	0.85			UNKNOWN	g	1		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6081878/	Homo sapiens										false
1556	732		ADULT	5330	280.303	SULFAMETHOXYPYRIDAZINE	SULFAMETHOXYPYRIDAZINE	COC1=NN=C(NS(=O)(=O)C2=CC=C(N)C=C2)C=C1	PLASMA	T034E4NS2Z													mg/L	0.75			UNKNOWN	g	1		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6081878/	Homo sapiens										false
1557	732			5330	280.303	SULFAMETHOXYPYRIDAZINE	SULFAMETHOXYPYRIDAZINE	COC1=NN=C(NS(=O)(=O)C2=CC=C(N)C=C2)C=C1	UNKNOWN	T034E4NS2Z																															OTHER	https://www.karger.com/Article/Abstract/414199	Homo sapiens		h	38							false
1558	734			5332	280.303	SULFAMONOMETHOXINE	Sulfamonomethoxine	COC1=NC=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1	SERUM	U700P169W2																										Human serum protein binding 8equilibrium dialysis): 79.7% (10 mcg/mL), 61.8% (50 mcg/mL), 42.2% (250 mcg/mL), 18.8% (500 mcg/mL)	20.3				EXPERIMENT	https://link.springer.com/article/10.1007/BF00779111	Homo sapiens										false
1559	734		ADULT	5332	280.303	SULFAMONOMETHOXINE	Sulfamonomethoxine	COC1=NC=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1	PLASMA	U700P169W2									∞	mg × h/L	2130.6						UNKNOWN	mg/kg bw	10		SINGLE	UNKNOWN				Human plasma protein binding: 91.9% (ultrafiltration)	8.1	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1981528/	Homo sapiens		h	25		Fast acetylators		5			false
1560	734		ADULT	5332	280.303	SULFAMONOMETHOXINE	Sulfamonomethoxine	COC1=NC=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1	PLASMA	U700P169W2									∞	mg × h/L	2489.4						UNKNOWN	mg/kg bw	10		SINGLE	UNKNOWN				Human plasma protein binding: 92.6% (ultrafiltration)	7.4	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1981528/	Homo sapiens		h	29.8		Slow acetylators		5			false
1561	742		ADULT	2006	233.1836	ACITAZANOLAST	ACITAZANOLAST	OC(=O)C(=O)NC1=CC(=CC=C1)C2=NN=NN2	PLASMA	99Y8VJ356G									?	μg × h/mL	2.18		μg/mL	1.18			UNKNOWN	mg	75		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://en.cnki.com.cn/Article_en/CJFDTotal-LCZZ200103013.htm	Homo sapiens		h	2.48				12			false
1562	742			2006	233.1836	ACITAZANOLAST	Acitazanolast	OC(=O)C(=O)NC1=CC(=CC=C1)C2=NN=NN2	PLASMA	99Y8VJ356G																										Plasma protein binding of Acitazanolast: 95.6% (2.1 mcM), 95.8% (8.6 mcM), 95.5% (21 mcM)	4				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/890016_1319745Q1024_2_009_1F.pdf#page=26	Homo sapiens										false
1563	743		UNKNOWN	5386	200.1671	TEGAFUR	TEGAFUR	FC1=CN(C2CCCO2)C(=O)NC1=O	SERUM	1548R74NSZ																						UNKNOWN				Oteracil, gimeracil, 5-FU, and tegafur were 8.4%, 32.2%, 18.4%, and 52.3% protein bound, respectively. The protein binding in human serum was not concentration-dependent over a range of 0.1 to 1.0 µg/ml for oteracil, gimeracil, and 5-FU and 1.2 to 11.8 µg/ml for tegafur.	47.7	UNKNOWN		UNKNOWN	OTHER GOV'T	https://www.ema.europa.eu/en/documents/product-information/teysuno-epar-product-information_en.pdf	Homo sapiens										false
1564	743		ADULT	5386	200.1671	TEGAFUR	TEGAFUR	FC1=CN(C2CCCO2)C(=O)NC1=O	PLASMA	1548R74NSZ	3472|5282202|54679224		GIMERACIL	gimeracil	OC1=CC(=O)NC=C1Cl	UA8SE1325T	8		t	ng × h/mL	10786		ng/mL	2046.2			UNKNOWN	mg	80		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/31011915	Homo sapiens		h	8.5							true
1565	744		ADULT	636411	346.404	TENATOPRAZOLE, (S)-	S-tenatoprazole	COC1=NC2=C(NC(=N2)[S ]([O-])CC3=C(C)C(OC)=C(C)C=N3)C=C1	PLASMA	C96SM5K071									∞	mg × h/mL	44716		ng/mL	3570.7			UNKNOWN	mg	30		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20015104/	Homo sapiens		h	8.21	Day 5 PK			31			false
1566	744		ADULT	636411	346.404	TENATOPRAZOLE, (S)-	S-tenatoprazole	COC1=NC2=C(NC(=N2)[S ]([O-])CC3=C(C)C(OC)=C(C)C=N3)C=C1	PLASMA	C96SM5K071									∞	ng × h/mL	105391		ng/mL	7206.71			UNKNOWN	mg	60		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20015104/	Homo sapiens		h	8.7	Day 5 PK			31			false
1567	744		ADULT	636411	346.404	TENATOPRAZOLE, (S)-	S-tenatoprazole	COC1=NC2=C(NC(=N2)[S ]([O-])CC3=C(C)C(OC)=C(C)C=N3)C=C1	PLASMA	C96SM5K071									∞	ng × h/mL	157431		ng/mL	11475.3			HIGHEST STUDIED	mg	90		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20015104/	Homo sapiens		h	9.01	Day 5 PK			31			false
1568	744		ADULT	636411	346.404	TENATOPRAZOLE	Tenatoprazole	COC1=CC=C2NC(=NC2=N1)[S ]([O-])CC3=NC=C(C)C(OC)=C3C	PLASMA	RE0689TX2K									?	ng × h/mL	218372		ng/mL	11819			HIGHEST STUDIED	mg	80		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://www.sciencedirect.com/science/article/pii/S0016508503811599	Homo sapiens		h	9.2				6			false
1569	744		ADULT	636411	346.404	TENATOPRAZOLE	Tenatoprazole	COC1=CC=C2NC(=NC2=N1)[S ]([O-])CC3=NC=C(C)C(OC)=C3C	PLASMA	RE0689TX2K									?	ng × h/mL	75240		ng/mL	5494			UNKNOWN	mg	40		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://www.sciencedirect.com/science/article/pii/S0016508503811599	Homo sapiens		h	8.7				6			false
1570	744		ADULT	636411	346.404	TENATOPRAZOLE	Tenatoprazole	COC1=CC=C2NC(=NC2=N1)[S ]([O-])CC3=NC=C(C)C(OC)=C3C	PLASMA	RE0689TX2K									?	ng × h/mL	12675		ng/mL	1284			UNKNOWN	mg	10		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://www.sciencedirect.com/science/article/pii/S0016508503811599	Homo sapiens		h	5.2				6			false
1571	744		ADULT	636411	346.404	TENATOPRAZOLE	Tenatoprazole	COC1=CC=C2NC(=NC2=N1)[S ]([O-])CC3=NC=C(C)C(OC)=C3C	PLASMA	RE0689TX2K									?	ng × h/mL	35910		ng/mL	2990			UNKNOWN	mg	20		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://www.sciencedirect.com/science/article/pii/S0016508503811599	Homo sapiens		h	7.8				6			false
1572	745		ADULT	208901	408.465	TESAGLITAZAR	Tesaglitazar	CCO[C@@H](CC1=CC=C(OCCC2=CC=C(OS(C)(=O)=O)C=C2)C=C1)C(O)=O	PLASMA	6734037O3L							192		t	μM × h	14.9						UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15319332/	Homo sapiens		h	45				8			false
1573	745		ADULT	208901	408.465	TESAGLITAZAR	Tesaglitazar	CCO[C@@H](CC1=CC=C(OCCC2=CC=C(OS(C)(=O)=O)C=C2)C=C1)C(O)=O	PLASMA	6734037O3L																										The mean value of the free fraction of tesaglitazar was 0.11% and ranged from 0.10 to 0.13%.	0.11	HEALTHY		MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15319332/	Homo sapiens							5			false
1574	745		ADULT	208901	408.465	TESAGLITAZAR	Tesaglitazar	CCO[C@@H](CC1=CC=C(OCCC2=CC=C(OS(C)(=O)=O)C=C2)C=C1)C(O)=O	PLASMA	6734037O3L							192		t	μM × h	14.5		μM	0.65			UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15319332/	Homo sapiens		h	46				8			false
1575	745		ADULT	208901	408.465	TESAGLITAZAR	Tesaglitazar	CCO[C@@H](CC1=CC=C(OCCC2=CC=C(OS(C)(=O)=O)C=C2)C=C1)C(O)=O	PLASMA	6734037O3L									∞	μM × h	13.1		μM	0.41			UNKNOWN	mg	1		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16920896/	Homo sapiens		h	36.9				20			false
1576	745		ADULT	208901	408.465	TESAGLITAZAR	Tesaglitazar	CCO[C@@H](CC1=CC=C(OCCC2=CC=C(OS(C)(=O)=O)C=C2)C=C1)C(O)=O	PLASMA	6734037O3L									∞	μM × h	13.2		μM	0.5			UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16920896/	Homo sapiens		h	37.5				20			false
1577	749		ADULT	5477|3033151	397.509	TIMIPERONE	Timiperone	FC1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)N3C(=S)NC4=C3C=CC=C4	PLASMA	626DQ7N19L									?	ng × h/mL	175.3		ng/mL	13.6			RECOMMENDED	mg	4		SINGLE	UNKNOWN						UNHEALTHY	Intramuscular	UNKNOWN	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/4/530258_1179405A1032_4_004_1F.pdf#page=19	Homo sapiens		h	15.7		Schizophrenia patients		7			false
1578	749		ADULT	5477|3033151	397.509	TIMIPERONE	Timiperone	FC1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)N3C(=S)NC4=C3C=CC=C4	PLASMA	626DQ7N19L									?	ng × h/mL	39.321		ng/mL	5.947			RECOMMENDED	mg	6		SINGLE	FED						UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/6/530258_1179026C1040_6_003_1F.pdf#page=22	Homo sapiens		h	5.906		Schizophrenia patients		7			false
1579	749			5477|3033151	397.509	TIMIPERONE	Timiperone	FC1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)N3C(=S)NC4=C3C=CC=C4	PLASMA	626DQ7N19L																										Human plasma protein binding: >95% (ultracentrifugation), 90~96% (equilibrium dialysis), 77~79% (gel filtration)	5				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/6/530258_1179026C1040_6_003_1F.pdf#page=24 | https://www.jstage.jst.go.jp/article/cpb1958/31/4/31_4_1411/_article/-char/en	Homo sapiens										false
1580	750		ADULT	5480	316.418	TINORIDINE	TINORIDINE	CCOC(=O)C1=C(N)SC2=C1CCN(CC3=CC=CC=C3)C2	PLASMA	C9Z9ICZ7YR																	UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://europepmc.org/article/med/6605310	Homo sapiens		h	8.2				6	tinoridine		false
1581	750		ADULT	5480	316.418	TINORIDINE	TINORIDINE	CCOC(=O)C1=C(N)SC2=C1CCN(CC3=CC=CC=C3)C2	PLASMA	C9Z9ICZ7YR																	UNKNOWN	mg	200		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://europepmc.org/article/med/6605310	Homo sapiens		h	8.2		renal failure			tinoridine		false
1582	751		ADULT	60790	384.4257	TOBORINONE	Toborinone	COC1=CC=C(CNCC(O)COC2=CC3=C(NC(=O)C=C3)C=C2)C=C1OC	PLASMA	1U1N0YXM99									?	ng × h/mL	483		ng/mL	102			UNKNOWN	μg/kg/min	1		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12017343/	Homo sapiens				Over 6h infusion	CYP2D6 poor metabolizers		11			false
1583	751		ADULT	60790	384.4257	TOBORINONE	Toborinone	COC1=CC=C(CNCC(O)COC2=CC3=C(NC(=O)C=C3)C=C2)C=C1OC	PLASMA	1U1N0YXM99									?	ng × h/mL	488		ng/mL	108			UNKNOWN	μg/kg/min	1		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12017343/	Homo sapiens				Over 6h infusion	CYP2D6 extensive metabolizers		11			false
1584	751		ADULT	60790	384.4257	TOBORINONE	Toborinone	COC1=CC=C(CNCC(O)COC2=CC3=C(NC(=O)C=C3)C=C2)C=C1OC	PLASMA	1U1N0YXM99									∞	ng × h/mL	735		ng/mL	125			UNKNOWN	μg/kg/min	1		SINGLE	UNKNOWN				ultrafiltration	25.61	UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12463726/	Homo sapiens		h	4.34	4-h infusion	Congestive heart failure w/hepatic impairment		5			false
1585	751		ADULT	60790	384.4257	TOBORINONE	Toborinone	COC1=CC=C(CNCC(O)COC2=CC3=C(NC(=O)C=C3)C=C2)C=C1OC	PLASMA	1U1N0YXM99									∞	ng × h/mL	498		ng/mL	104			UNKNOWN	μg/kg/min	1		SINGLE	UNKNOWN				ultrafiltration	19.59	UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12463726/	Homo sapiens		h	2.06	4-h infusion	Congestive heart failure w/o renal or hepatic impairment		10			false
1586	751		ADULT	60790	384.4257	TOBORINONE	Toborinone	COC1=CC=C(CNCC(O)COC2=CC3=C(NC(=O)C=C3)C=C2)C=C1OC	PLASMA	1U1N0YXM99									∞	ng × h/mL	694		ng/mL	130			UNKNOWN	μg/kg/min	1		SINGLE	UNKNOWN				ultrafiltration	23.57	UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12463726/	Homo sapiens		h	3.74	4-h infusion	Congestive heart failure w/renal and hepatic impairment		6			false
1587	751		ADULT	60790	384.4257	TOBORINONE	Toborinone	COC1=CC=C(CNCC(O)COC2=CC3=C(NC(=O)C=C3)C=C2)C=C1OC	PLASMA	1U1N0YXM99									∞	ng × h/mL	623		ng/mL	102			UNKNOWN	μg/kg/min	1		SINGLE	UNKNOWN				ultrafiltration	22.32	UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12463726/	Homo sapiens		h	2.77	4-h infusion	Congestive heart failure w/renal impairment		11			false
1588	751		ADULT		384.4257	(R)-(plus)-Toborinone		COC1=C(C=C(C=C1)CNC[C@H](COC2=CC3=C(C=C2)NC(=O)C=C3)O)OC	PLASMA								6		t	ng × h/mL	297.7		ng/mL	211.6			UNKNOWN	μg/kg/min	5		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8106598/	Homo sapiens		h	3.63	1-h infusion			3	Toborinone		false
1589	751		ADULT		384.4257	(S)-(-)-Toborinone		COC1=C(OC)C=C(CNC[C@H](O)COC2=CC3=C(NC(C=C3)=O)C=C2)C=C1	PLASMA								6		t	ng × h/mL	261		ng/mL	180.3			UNKNOWN	μg/kg/min	5		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8106598/	Homo sapiens		h	3.78	1-h infusion			3			false
1590	751		ADULT	60790	384.4257	TOBORINONE	Toborinone	COC1=CC=C(CNCC(O)COC2=CC3=C(NC(=O)C=C3)C=C2)C=C1OC	PLASMA	1U1N0YXM99									∞	ng × h/mL	52.38		ng/mL	244.26			UNKNOWN	mg/kg bw	0.05		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8163718/	Homo sapiens		h	1.22	Rapid administration (5 min)			6			false
1591	751		ADULT	60790	384.4257	TOBORINONE	Toborinone	COC1=CC=C(CNCC(O)COC2=CC3=C(NC(=O)C=C3)C=C2)C=C1OC	PLASMA	1U1N0YXM99									∞	ng × h/mL	189.57		ng/mL	447.32			UNKNOWN	mg/kg bw	0.1		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8163718/	Homo sapiens		h	4.27	Rapid administration (5 min)			6			false
1592	751		ADULT	60790	384.4257	TOBORINONE	Toborinone	COC1=CC=C(CNCC(O)COC2=CC3=C(NC(=O)C=C3)C=C2)C=C1OC	PLASMA	1U1N0YXM99									∞	ng × h/mL	445.44		ng/mL	1093.56			UNKNOWN	mg/kg bw	0.2		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8163718/	Homo sapiens		h	3.84	Rapid administration (5 min)			6			false
1593	751		ADULT	60790	384.4257	TOBORINONE	Toborinone	COC1=CC=C(CNCC(O)COC2=CC3=C(NC(=O)C=C3)C=C2)C=C1OC	PLASMA	1U1N0YXM99									∞	ng × h/mL	835.86		ng/mL	2334.14			UNKNOWN	mg/kg bw	0.4		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8163718/	Homo sapiens		h	3.79	Rapid administration (5 min)			6			false
1594	751		ADULT	60790	384.4257	TOBORINONE	Toborinone	COC1=CC=C(CNCC(O)COC2=CC3=C(NC(=O)C=C3)C=C2)C=C1OC	PLASMA	1U1N0YXM99									∞	ng × h/mL	42.4		ng/mL	33.57			UNKNOWN	mg/kg bw	0.5		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8163718/	Homo sapiens		h	2.47	1-h infusion			3			false
1595	751		ADULT	60790	384.4257	TOBORINONE	Toborinone	COC1=CC=C(CNCC(O)COC2=CC3=C(NC(=O)C=C3)C=C2)C=C1OC	PLASMA	1U1N0YXM99									∞	ng × h/mL	136.9		ng/mL	91.77			UNKNOWN	mg/kg bw	1		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8163718/	Homo sapiens		h	2.3	1-h infusion			3			false
1596	751		ADULT	60790	384.4257	TOBORINONE	Toborinone	COC1=CC=C(CNCC(O)COC2=CC3=C(NC(=O)C=C3)C=C2)C=C1OC	PLASMA	1U1N0YXM99									∞	ng × h/mL	336.87		ng/mL	205.97			UNKNOWN	mg/kg bw	2.5		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8163718/	Homo sapiens		h	3.5	1-h infusion			3			false
1597	751		ADULT	60790	384.4257	TOBORINONE	Toborinone	COC1=CC=C(CNCC(O)COC2=CC3=C(NC(=O)C=C3)C=C2)C=C1OC	PLASMA	1U1N0YXM99									∞	ng × h/mL	752.33		ng/mL	435.43			UNKNOWN	mg/kg bw	5		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8163718/	Homo sapiens		h	3.54	1-h infusion			3			false
1598	751		ADULT	60790	384.4257	TOBORINONE	Toborinone	COC1=CC=C(CNCC(O)COC2=CC3=C(NC(=O)C=C3)C=C2)C=C1OC	PLASMA	1U1N0YXM99									∞	ng × h/mL	2044.13		ng/mL	1206.26			UNKNOWN	mg/kg bw	15		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8163718/	Homo sapiens		h	4.32	1-h infusion			5			false
1599	751		ADULT	60790	384.4257	TOBORINONE	Toborinone	COC1=CC=C(CNCC(O)COC2=CC3=C(NC(=O)C=C3)C=C2)C=C1OC	PLASMA	1U1N0YXM99									∞	ng × h/mL	1399.3		ng/mL	851.17			UNKNOWN	mg/kg bw	10		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8163718/	Homo sapiens		h	3.42	1-h infusion			3			false
1600	754		ADULT	5536	310.3423	TREPIBUTONE	Trepibutone	CCOC1=CC(OCC)=C(OCC)C=C1C(=O)CCC(O)=O	SERUM	H1187LU49Q									?	μg × h/mL	6.45		μg/mL	2.9			UNKNOWN	mg	40		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/180095_2369003C1030_2_001_1F.pdf#page=17	Homo sapiens		h	1.4		Tablets		10			false
1601	754		ADULT	5536	310.3423	TREPIBUTONE	Trepibutone	CCOC1=CC(OCC)=C(OCC)C=C1C(=O)CCC(O)=O	SERUM	H1187LU49Q									?	μg × h/mL	5.1		μg/mL	3.6			UNKNOWN	mg	40		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/180095_2369003C1030_2_001_1F.pdf#page=17	Homo sapiens		h	1.79		Fine granules 10%		10			false
1602	754			5536	310.344	TREPIBUTONE		CCOc1cc(OCC)c(cc1OCC)C(=O)CCC(=O)O	SERUM	H1187LU49Q																										Human serum protein binding: >=94% (equilibrium dialysis)	6				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/180095_2369003C1030_2_001_1F.pdf#page=18	Homo sapiens										false
1603	754		ADULT	5536	310.344	TREPIBUTONE		CCOc1cc(OCC)c(cc1OCC)C(=O)CCC(=O)O	SERUM	H1187LU49Q													μg/mL	1.4			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/180095_2369003C1030_2_001_1F.pdf#page=18 | https://www.jstage.jst.go.jp/article/jscpt1970/8/4/8_4_485/_article/-char/en	Homo sapiens							2			false
1604	754		ADULT	5536	310.344	TREPIBUTONE		CCOc1cc(OCC)c(cc1OCC)C(=O)CCC(=O)O	SERUM	H1187LU49Q													μg/mL	3.1			UNKNOWN	mg	40		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/180095_2369003C1030_2_001_1F.pdf#page=18 | https://www.jstage.jst.go.jp/article/jscpt1970/8/4/8_4_485/_article/-char/en	Homo sapiens							2			false
1605	754		ADULT	5536	310.344	TREPIBUTONE		CCOc1cc(OCC)c(cc1OCC)C(=O)CCC(=O)O	SERUM	H1187LU49Q													μg/mL	3.9			UNKNOWN	mg	60		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/180095_2369003C1030_2_001_1F.pdf#page=18 | https://www.jstage.jst.go.jp/article/jscpt1970/8/4/8_4_485/_article/-char/en	Homo sapiens							1			false
1606	754		ADULT	5536	310.344	TREPIBUTONE		CCOc1cc(OCC)c(cc1OCC)C(=O)CCC(=O)O	SERUM	H1187LU49Q													μg/mL	0.3			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.jstage.jst.go.jp/article/jscpt1970/8/4/8_4_485/_article/-char/en	Homo sapiens							3			false
1607	754		ADULT	5536	310.344	TREPIBUTONE		CCOc1cc(OCC)c(cc1OCC)C(=O)CCC(=O)O	SERUM	H1187LU49Q													μg/mL	5.1			UNKNOWN	mg	80		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.jstage.jst.go.jp/article/jscpt1970/8/4/8_4_485/_article/-char/en	Homo sapiens							1			false
1608	754		ADULT	5536	310.344	TREPIBUTONE		CCOc1cc(OCC)c(cc1OCC)C(=O)CCC(=O)O	SERUM	H1187LU49Q													μg/mL	12.1			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.jstage.jst.go.jp/article/jscpt1970/8/4/8_4_485/_article/-char/en	Homo sapiens							1			false
1609	757		ADULT	454194	213.1906	TROXACITABINE	TROXACITABINE	NC1=NC(=O)N(C=C1)[C@@H]2CO[C@H](CO)O2	PLASMA	60KQZ0388Y									∞	ng × h/mL	3306		ng/mL	1028			MAX TOLERATED	mg/m²	12.5		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12011137	Homo sapiens		h	30				2	TROXACITABINE		false
1610	762			2040	283.3003	AFLOQUALONE	Afloqualone	CC1=C(C=CC=C1)N2C(=O)C3=C(C=CC(N)=C3)N=C2CF	SERUM	CO4U2C8ORZ																										Human serum albumin binding: 54% (equilibrium dialysis)	46				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/430920_1249008F1215_2_080_1F.pdf#page=17	Homo sapiens										false
1611	762		ADULT	2040	283.3003	AFLOQUALONE	Afloqualone	CC1=C(C=CC=C1)N2C(=O)C3=C(C=CC(N)=C3)N=C2CF	PLASMA	CO4U2C8ORZ									∞	ng × h/mL	245		ng/mL	37.9			RECOMMENDED	mg	20		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.jstage.jst.go.jp/article/jscpt1970/16/4/16_4_649/_article/-char/en	Homo sapiens		h	3.34				5			false
1612	763		ADULT	2097	219.2796	ALMINOPROFEN	ALMINOPROFEN	CC(C(O)=O)C1=CC=C(NCC(C)=C)C=C1	PLASMA	0255AHR9GJ									?	μg × h/mL	58.5		μg/mL	16.1			UNKNOWN	mg	200		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1491485/	Homo sapiens		h	2.45				5	ALMINOPROFEN		false
1613	763		ADULT	2097	219.2796	ALMINOPROFEN	ALMINOPROFEN	CC(C(O)=O)C1=CC=C(NCC(C)=C)C=C1	PLASMA	0255AHR9GJ									?	μg × h/mL	58.1		μg/mL	21.6			UNKNOWN	mg	200		STEADY-STATE	UNKNOWN		day	3	day 5		UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1491485/	Homo sapiens		h	2.49				5	ALMINOPROFEN		false
1614	763		ADULT	2097	219.2796	ALMINOPROFEN	ALMINOPROFEN	CC(C(O)=O)C1=CC=C(NCC(C)=C)C=C1	PLASMA	0255AHR9GJ													mg/L	39.2			UNKNOWN	mg	300		SINGLE	FASTED						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7439265/	Homo sapiens		h	2.8				4	ALMINOPROFEN		false
1615	763		ADULT	2097	219.2796	ALMINOPROFEN	ALMINOPROFEN	CC(C(O)=O)C1=CC=C(NCC(C)=C)C=C1	PLASMA	0255AHR9GJ													mg/L	24.2			UNKNOWN	mg	300		STEADY-STATE	UNKNOWN		day	3			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8573683/	Homo sapiens							7	ALMINOPROFEN		false
1616	763		ADULT	2097	219.2796	ALMINOPROFEN	ALMINOPROFEN	CC(C(O)=O)C1=CC=C(NCC(C)=C)C=C1	UNKNOWN	0255AHR9GJ													mg/L	9.3			UNKNOWN	mg	300		STEADY-STATE	UNKNOWN		day	3			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8573683/	Homo sapiens				analyte in synovial fluid			7	ALMINOPROFEN		false
1617	766		ADULT	2326	309.4452	BENPROPERINE	Benproperine	CC(COC1=CC=CC=C1CC2=CC=CC=C2)N3CCCCC3	PLASMA	3AA6IZ48YK									∞	ng × h/mL	5234.31		ng/mL	146.4			UNKNOWN	mg	80		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	EXPERIMENT	https://en.cnki.com.cn/Article_en/CJFDTotal-YWYY200902004.htm	Homo sapiens		h	24.7	80 mg benproperine phosphate sustained-release capsule						false
1618	766		ADULT	14456346	309.4503	BENPROPERINE, (R)-		C[C@H](COc1ccccc1Cc2ccccc2)N3CCCCC3	PLASMA	A867ZCR5CE									∞	ng × h/mL	2010		ng/mL	153			DEFINED DAILY	mg	60		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12567913/	Homo sapiens		h	14	60mg racemate dose			6			false
1619	766		ADULT	14456347	309.4452	BENPROPERINE, (S)-		C[C@@H](COc1ccccc1Cc2ccccc2)N3CCCCC3	PLASMA	9P1NT3465X									∞	ng × h/mL	4257		ng/mL	333			DEFINED DAILY	mg	60		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12567913/	Homo sapiens		h	17	60mg racemate dose			6			false
1620	770		ADULT	6419536	240.3036	BUDRALAZINE	Budralazine	CC(C)=CC(C)=NNC1=NN=CC2=CC=CC=C12	PLASMA	S0177QHV2B													ng/mL	50			UNKNOWN	mg	60		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3429588/	Homo sapiens										false
1621	771		ADULT	2465	323.4272	BUFETOLOL	Bufetolol	CC(C)(C)NCC(O)COC1=C(OCC2CCCO2)C=CC=C1	BLOOD	WS1467RT9Z																	UNKNOWN	mg	10		SINGLE	UNKNOWN						UNKNOWN	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400315_2123006F1030_1_090_1F.pdf#page=17	Homo sapiens		h	1.48		Healthy and Unhealthy subjects		5			false
1622	777		UNKNOWN	127527	627.651	CEFBUPERAZONE	CEFBUPERAZONE	CCN1CCN(C(=O)N[C@H]([C@H](C)O)C(=O)N[C@@]2(OC)[C@H]3SCC(CSC4=NN=NN4C)=C(N3C2=O)C(O)=O)C(=O)C1=O	SERUM	T0785J3X40																	UNKNOWN	g	1		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	REVIEW	10.2165/00003495-198700342-00008	Homo sapiens		h	1.6					CEFBUPERAZONE		false
1623	777		ADULT	127527	627.651	CEFBUPERAZONE	CEFBUPERAZONE	CCN1CCN(C(=O)N[C@H]([C@H](C)O)C(=O)N[C@@]2(OC)[C@H]3SCC(CSC4=NN=NN4C)=C(N3C2=O)C(O)=O)C(=O)C1=O	PLASMA	T0785J3X40									∞	μg × h/mL	116		μg/mL	44.7			UNKNOWN	g	0.5		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://doi.org/10.1016/j.jpba.2016.06.029	Homo sapiens		h	1.9	served with light breakfast before drip intravenous infusion at constant speed for 1 h			12	cefbuperazone		false
1624	777		ADULT	127527	627.651	CEFBUPERAZONE	CEFBUPERAZONE	CCN1CCN(C(=O)N[C@H]([C@H](C)O)C(=O)N[C@@]2(OC)[C@H]3SCC(CSC4=NN=NN4C)=C(N3C2=O)C(O)=O)C(=O)C1=O	PLASMA	T0785J3X40									∞	μg × h/mL	224		μg/mL	86.7			UNKNOWN	g	1		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://doi.org/10.1016/j.jpba.2016.06.029	Homo sapiens		h	1.8	served with light breakfast before drip intravenous infusion at constant speed for 1 h			12	cefbuperazone		false
1625	777		ADULT	127527	627.651	CEFBUPERAZONE	CEFBUPERAZONE	CCN1CCN(C(=O)N[C@H]([C@H](C)O)C(=O)N[C@@]2(OC)[C@H]3SCC(CSC4=NN=NN4C)=C(N3C2=O)C(O)=O)C(=O)C1=O	PLASMA	T0785J3X40									∞	μg × h/mL	427		μg/mL	168			UNKNOWN	g	2		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://doi.org/10.1016/j.jpba.2016.06.029	Homo sapiens		h	1.9	served with light breakfast before drip intravenous infusion at constant speed for 1 h			12	cefbuperazone		false
1626	777		ADULT	127527	627.651	CEFBUPERAZONE	CEFBUPERAZONE	CCN1CCN(C(=O)N[C@H]([C@H](C)O)C(=O)N[C@@]2(OC)[C@H]3SCC(CSC4=NN=NN4C)=C(N3C2=O)C(O)=O)C(=O)C1=O	PLASMA	T0785J3X40									∞	μg × h/mL	240		μg/mL	94.9			UNKNOWN	g	1		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://doi.org/10.1016/j.jpba.2016.06.029	Homo sapiens		h	1.9	1.0 g cefbuperazone sodium injections for 5 consecutive days at 12 h interval			12	cefbuperazone		false
1627	777		UNKNOWN	127527	627.651	CEFBUPERAZONE	CEFBUPERAZONE	CCN1CCN(C(=O)N[C@H]([C@H](C)O)C(=O)N[C@@]2(OC)[C@H]3SCC(CSC4=NN=NN4C)=C(N3C2=O)C(O)=O)C(=O)C1=O	SERUM	T0785J3X40													μg/g	21.9			UNKNOWN	g	1		SINGLE	UNKNOWN						UNKNOWN	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3165475/	Homo sapiens		h	2.03	intravenous drip infusion of 1 g of cefbuperazone over a period of 1 hour						false
1628	778		CHILD	6536774	556.591	CEFLUPRENAM	Cefluprenam	CC[N ](C)(C\\C=C\\C1=C(N2[C@H](SC1)[C@H](NC(=O)C(=N/OCF)\\C3=NSC(N)=N3)C2=O)C([O-])=O)CC(N)=O	SERUM	098633Q42P									?	μg × h/mL	111.7		μg/mL	155.3			UNKNOWN	mg/kg bw	20		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9743906/	Homo sapiens		h	1.43		>= 1 yr		9			false
1629	778		NEWBORN	6536774	556.591	CEFLUPRENAM	Cefluprenam	CC[N ](C)(C\\C=C\\C1=C(N2[C@H](SC1)[C@H](NC(=O)C(=N/OCF)\\C3=NSC(N)=N3)C2=O)C([O-])=O)CC(N)=O	SERUM	098633Q42P									?	μg × h/mL	81		μg/mL	153			UNKNOWN	mg/kg bw	20		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9743906/	Homo sapiens		h	1.6				2			false
1630	782		ADULT	17925	305.159	DELORAZEPAM	DELORAZEPAM	ClC1=CC=C2NC(=O)CN=C(C2=C1)C3=C(Cl)C=CC=C3	PLASMA	O91W32476G									∞	ng × h/mL	2002.4		ng/mL	15.9			UNKNOWN	mg	4		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19488979/	Homo sapiens		h	138.7	Olcadil® (reference)			24	CLOXAZOLAM		false
1631	782		ADULT	17925	305.159	DELORAZEPAM	DELORAZEPAM	ClC1=CC=C2NC(=O)CN=C(C2=C1)C3=C(Cl)C=CC=C3	PLASMA	O91W32476G									∞	ng × h/mL	1920.1		ng/mL	17			UNKNOWN	mg	4		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19488979/	Homo sapiens		h	136.9	Cloxazolam (test)			24	CLOXAZOLAM		false
1632	793		ADULT	37541	332.2766	FLOCTAFENIC ACID	FLOCTAFENIC ACID	OC(=O)C1=C(NC2=C3C=CC=C(C3=NC=C2)C(F)(F)F)C=CC=C1	BLOOD	K9D19L5WTV													μg/mL	1.57			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33200/	Homo sapiens							6	FLOCTAFENINE		false
1633	794		UNKNOWN	3398	376.809	FLUTAZOLAM	flutazolam	OCCN1C2=CC=C(Cl)C=C2C3(OCCN3CC1=O)C4=CC=CC=C4F	SERUM	5G2K7O5D8S									?	μg × h/mL	0.068		μg/mL	0.014			UNKNOWN	mg	12		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/300119_1124024C1035_2_070_1F.pdf#page=23	Homo sapiens										false
1634	795		ADULT	4540	288.704	NORFLURAZEPAM	Norfludiazepam	FC1=C(C=CC=C1)C2=NCC(=O)NC3=CC=C(Cl)C=C23	SERUM	X9U41NXR6M									∞	μg × h/mL	2.34		ng/mL	24.9			UNKNOWN	mg	2		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2633923/	Homo sapiens		h	87.2				8			false
1635	795		ADULT	3400	342.795	FLUTOPRAZEPAM	Flutoprazepam	FC1=C(C=CC=C1)C2=NCC(=O)N(CC3CC3)C4=CC=C(Cl)C=C24	SERUM	2GHY1101MM													ng/mL	2.7			UNKNOWN	mg	2		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2633923/	Homo sapiens							8			false
1636	795			4540	288.704	NORFLURAZEPAM	Norfludiazepam	FC1=C(C=CC=C1)C2=NCC(=O)NC3=CC=C(Cl)C=C23	PLASMA	X9U41NXR6M																										Norfludiazepam	1.4				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9158878/	Homo sapiens										false
1637	795		ADULT	4540	288.704	NORFLURAZEPAM	Norfludiazepam	FC1=C(C=CC=C1)C2=NCC(=O)NC3=CC=C(Cl)C=C23	PLASMA	X9U41NXR6M													ng/mL	163.3			UNKNOWN	mg	8		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/5/580591_1124027F1035_5_006_1F.pdf#page=19	Homo sapiens		h	215.5				15			false
1638	795		ADULT	4540	288.704	NORFLURAZEPAM	Norfludiazepam	FC1=C(C=CC=C1)C2=NCC(=O)NC3=CC=C(Cl)C=C23	PLASMA	X9U41NXR6M													ng/mL	273			UNKNOWN	mg	12		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/5/580591_1124027F1035_5_006_1F.pdf#page=19	Homo sapiens		h	134.2				15			false
1639	795		ADULT	4540	288.704	NORFLURAZEPAM	Norfludiazepam	FC1=C(C=CC=C1)C2=NCC(=O)NC3=CC=C(Cl)C=C23	PLASMA	X9U41NXR6M													ng/mL	38.7			UNKNOWN	mg	2		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/5/580591_1124027F1035_5_006_1F.pdf#page=19	Homo sapiens		h	186.7				15			false
1640	795		ADULT	4540	288.704	NORFLURAZEPAM	Norfludiazepam	FC1=C(C=CC=C1)C2=NCC(=O)NC3=CC=C(Cl)C=C23	PLASMA	X9U41NXR6M													μg/mL	93.3			UNKNOWN	mg	4		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/5/580591_1124027F1035_5_006_1F.pdf#page=19	Homo sapiens		h	132.9				15			false
1641	795		ADULT	4540	288.704	NORFLURAZEPAM	Norfludiazepam	FC1=C(C=CC=C1)C2=NCC(=O)NC3=CC=C(Cl)C=C23	PLASMA	X9U41NXR6M													ng/mL	370.3			UNKNOWN	mg	16		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/5/580591_1124027F1035_5_006_1F.pdf#page=19	Homo sapiens		h	243.6				15			false
1642	795			3400	342.795	FLUTOPRAZEPAM	Flutoprazepam	FC1=C(C=CC=C1)C2=NCC(=O)N(CC3CC3)C4=CC=C(Cl)C=C24	PLASMA	2GHY1101MM																										Plasma protein binding: 95%	5				EXPERIMENT	https://www.jstage.jst.go.jp/article/jsdt1994/29/10/29_10_1393/_article/-char/en	Homo sapiens										false
1643	797		ADULT	5282237	394.5448	GEMEPROST	Gemeprost	CCCCC(C)(C)[C@H](O)\\C=C\\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\\C=C\\C(=O)OC	PLASMA	45KZB1FOLS													ng/mL	6			RECOMMENDED	mg	1		SINGLE	UNKNOWN						PREGNANT	Vaginal	FEMALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/180188_2499700H1036_1_002_2F.pdf#page=21	Homo sapiens							6			false
1644	798			443881	414.5775	GESTONORONE CAPROATE	Gestonorone caproate	CCCCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O	PLASMA	U38E620NS6																										Plasma protein binding (Gestonorone caproate): 95.3%	4.7				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/670109_2479401A1035_1_001_1F.pdf#page=10	Homo sapiens										false
1645	799		ADULT	9577124	447.4831	GIMATECAN	GIMATECAN	CC[C@@]1(O)C(=O)OCC2=C1C=C3N(CC4=C(\\C=N\\OC(C)(C)C)C5=C(C=CC=C5)N=C34)C2=O	PLASMA	7KKS9R192F									∞	ng × h/mL	8568		ng/mL	75.4			MAX TOLERATED	mg/m²	2.4		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19118068	Homo sapiens		h	79.8	It was taken orally in the morning, either 1 h before or after eating, once every 7 days for 3 consecutive weeks; dose 3			10	GIMATECAN		false
1646	799		ADULT	9577124	447.4831	GIMATECAN	GIMATECAN	CC[C@@]1(O)C(=O)OCC2=C1C=C3N(CC4=C(\\C=N\\OC(C)(C)C)C5=C(C=CC=C5)N=C34)C2=O	PLASMA	7KKS9R192F									?	ng × h/mL	7364		ng/mL	66.3			UNKNOWN	mg/m²	3.2		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19118068	Homo sapiens		h	67.3	It was taken orally in the morning, either 1 h before or after eating, once every 7 days for 3 consecutive weeks; dose 1			6	GIMATECAN		false
1647	799		ADULT	9577124	447.4831	GIMATECAN	GIMATECAN	CC[C@@]1(O)C(=O)OCC2=C1C=C3N(CC4=C(\\C=N\\OC(C)(C)C)C5=C(C=CC=C5)N=C34)C2=O	PLASMA	7KKS9R192F									?	ng × h/mL	10825		ng/mL	86.1			UNKNOWN	mg/m²	3.2		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19118068	Homo sapiens		h	88.5	It was taken orally in the morning, either 1 h before or after eating, once every 7 days for 3 consecutive weeks; dose 3			6	GIMATECAN		false
1648	799		ADULT	9577124	447.4831	GIMATECAN	GIMATECAN	CC[C@@]1(O)C(=O)OCC2=C1C=C3N(CC4=C(\\C=N\\OC(C)(C)C)C5=C(C=CC=C5)N=C34)C2=O	PLASMA	7KKS9R192F									?	ng × h/mL	7757		ng/mL	66.9			MAX TOLERATED	mg/m²	2.4		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19118068	Homo sapiens		h	80.6	It was taken orally in the morning, either 1 h before or after eating, once every 7 days for 3 consecutive weeks; dose 1			11	GIMATECAN		false
1649	799		ADULT	9577124	447.4831	GIMATECAN	GIMATECAN	CC[C@@]1(O)C(=O)OCC2=C1C=C3N(CC4=C(\\C=N\\OC(C)(C)C)C5=C(C=CC=C5)N=C34)C2=O	PLASMA	7KKS9R192F									?	ng × h/mL	910		ng/mL	13.3			UNKNOWN	mg/m²	0.27		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19118068	Homo sapiens		h	51.2	It was taken orally in the morning, either 1 h before or after eating, once every 7 days for 3 consecutive weeks; dose 1			3	GIMATECAN		false
1650	799		ADULT		447.4831	GIMATECAN	GIMATECAN	CC[C@@]1(O)C(=O)OCC2=C1C=C3N(CC4=C(\\C=N\\OC(C)(C)C)C5=C(C=CC=C5)N=C34)C2=O	PLASMA	7KKS9R192F									?	ng × h/mL	3327		ng/mL	27.6			UNKNOWN	mg/m²	0.88		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19118068	Homo sapiens		h	88.3	It was taken orally in the morning, either 1 h before or after eating, once every 7 days for 3 consecutive weeks; dose 1			3	GIMATECAN		false
1651	799		ADULT		447.4831	GIMATECAN	GIMATECAN	CC[C@@]1(O)C(=O)OCC2=C1C=C3N(CC4=C(\\C=N\\OC(C)(C)C)C5=C(C=CC=C5)N=C34)C2=O	PLASMA	7KKS9R192F									?	ng × h/mL	5992		ng/mL	46.4			UNKNOWN	mg/m²	1.33		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19118068	Homo sapiens		h	84.3	It was taken orally in the morning, either 1 h before or after eating, once every 7 days for 3 consecutive weeks; dose 1			3	GIMATECAN		false
1652	799		ADULT		447.4831	GIMATECAN	GIMATECAN	CC[C@@]1(O)C(=O)OCC2=C1C=C3N(CC4=C(\\C=N\\OC(C)(C)C)C5=C(C=CC=C5)N=C34)C2=O	PLASMA	7KKS9R192F									?	ng × h/mL	2212		ng/mL	28.8			UNKNOWN	mg/m²	0.53		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19118068	Homo sapiens		h	113.8	It was taken orally in the morning, either 1 h before or after eating, once every 7 days for 3 consecutive weeks; dose 1			3	GIMATECAN		false
1653	799		ADULT		447.4831	GIMATECAN	GIMATECAN	CC[C@@]1(O)C(=O)OCC2=C1C=C3N(CC4=C(\\C=N\\OC(C)(C)C)C5=C(C=CC=C5)N=C34)C2=O	PLASMA	7KKS9R192F									?	ng × h/mL	3078		ng/mL	36.4			UNKNOWN	mg/m²	1.87		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19118068	Homo sapiens		h	65.2	It was taken orally in the morning, either 1 h before or after eating, once every 7 days for 3 consecutive weeks; dose 1			3	GIMATECAN		false
1654	799		ADULT	9577124	447.4831	GIMATECAN	GIMATECAN	CC[C@@]1(O)C(=O)OCC2=C1C=C3N(CC4=C(\\C=N\\OC(C)(C)C)C5=C(C=CC=C5)N=C34)C2=O	PLASMA	7KKS9R192F									?	ng × h/mL	6726		ng/mL	44.9			UNKNOWN	mg/m²	0.88		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19118068	Homo sapiens		h	123	It was taken orally in the morning, either 1 h before or after eating, once every 7 days for 3 consecutive weeks; dose 3			3	GIMATECAN		false
1655	799		ADULT	9577124	447.4831	GIMATECAN	GIMATECAN	CC[C@@]1(O)C(=O)OCC2=C1C=C3N(CC4=C(\\C=N\\OC(C)(C)C)C5=C(C=CC=C5)N=C34)C2=O	PLASMA	7KKS9R192F									?	ng × h/mL	3499		ng/mL	27.9			UNKNOWN	mg/m²	0.53		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19118068	Homo sapiens		h	110.8	It was taken orally in the morning, either 1 h before or after eating, once every 7 days for 3 consecutive weeks; dose 3			3	GIMATECAN		false
1656	799		ADULT	9577124	447.4831	GIMATECAN	GIMATECAN	CC[C@@]1(O)C(=O)OCC2=C1C=C3N(CC4=C(\\C=N\\OC(C)(C)C)C5=C(C=CC=C5)N=C34)C2=O	PLASMA	7KKS9R192F									?	ng × h/mL	904		ng/mL	9.6			UNKNOWN	mg/m²	0.27		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19118068	Homo sapiens		h	70	It was taken orally in the morning, either 1 h before or after eating, once every 7 days for 3 consecutive weeks; dose 3			3	GIMATECAN		false
1657	799		ADULT	9577124	447.4831	GIMATECAN	GIMATECAN	CC[C@@]1(O)C(=O)OCC2=C1C=C3N(CC4=C(\\C=N\\OC(C)(C)C)C5=C(C=CC=C5)N=C34)C2=O	PLASMA	7KKS9R192F									?	ng × h/mL	5270		ng/mL	59.6			UNKNOWN	mg/m²	1.87		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19118068	Homo sapiens		h	59.6	It was taken orally in the morning, either 1 h before or after eating, once every 7 days for 3 consecutive weeks; dose 3			3	GIMATECAN		false
1658	799		ADULT	9577124	447.4831	GIMATECAN	GIMATECAN	CC[C@@]1(O)C(=O)OCC2=C1C=C3N(CC4=C(\\C=N\\OC(C)(C)C)C5=C(C=CC=C5)N=C34)C2=O	PLASMA	7KKS9R192F									?	ng × h/mL	8539		ng/mL	59			UNKNOWN	mg/m²	1.33		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19118068	Homo sapiens		h	100.8	It was taken orally in the morning, either 1 h before or after eating, once every 7 days for 3 consecutive weeks; dose 3			3	GIMATECAN		false
1659	800		UNKNOWN	3472|5282202|54679224	145.544	GIMERACIL	GIMERACIL	OC1=CC(=O)NC=C1Cl	PLASMA	UA8SE1325T																						UNKNOWN				Oteracil, gimeracil, 5-FU, and tegafur are 8.4%, 32.2%, 18.4%, and 52.3% protein bound, respectively	67.8	UNKNOWN		UNKNOWN	OTHER GOV'T	https://www.ema.europa.eu/en/documents/product-information/teysuno-epar-product-information_en.pdf	Homo sapiens										false
1660	800		ADULT	3472|5282202|54679224	145.544	GIMERACIL	GIMERACIL	OC1=CC(=O)NC=C1Cl	PLASMA	UA8SE1325T	5386		TEGAFUR	tegafur	FC1=CN(C2CCCO2)C(=O)NC1=O	1548R74NSZ			?	mg × h/L	3						UNKNOWN	mg/m²	25		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/14650374	Homo sapiens										true
1661	800		UNKNOWN	3472|5282202|54679224	145.544	GIMERACIL	GIMERACIL	OC1=CC(=O)NC=C1Cl	PLASMA	UA8SE1325T	5386		TEGAFUR	tegafur	FC1=CN(C2CCCO2)C(=O)NC1=O	1548R74NSZ							ng/mL	374.9			UNKNOWN	mg	60		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/23289150	Homo sapiens		h	7.8							true
1662	801		ADULT	12947024	333.155	FLUBROMAZEPAM	Flubromazepam	FC1=C(C=CC=C1)C2=NCC(=O)NC3=CC=C(Br)C=C23	PLASMA	GKX573279U													ng/mL	48.3			UNKNOWN	mg	5		SINGLE	FASTED				t1/2 = 42~123 h		HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/530258_1124005C1032_2_003_1F.pdf#page=22	Homo sapiens		h	42				1	Haloxazolam		false
1663	801		ADULT	12947024	333.155	FLUBROMAZEPAM	Flubromazepam	FC1=C(C=CC=C1)C2=NCC(=O)NC3=CC=C(Br)C=C23	PLASMA	GKX573279U													ng/mL	58.6			UNKNOWN	mg	5		MULTIPLE	UNKNOWN		day	1	Cmax = 37.7~69.8 ng/mL		UNHEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/530258_1124005C1032_2_003_1F.pdf#page=23	Homo sapiens				Day 7			3	Haloxazolam		false
1664	801		ADULT	12947024	333.155	FLUBROMAZEPAM	Flubromazepam	FC1=C(C=CC=C1)C2=NCC(=O)NC3=CC=C(Br)C=C23	PLASMA	GKX573279U													ng/mL	14.3			UNKNOWN	mg	5		MULTIPLE	UNKNOWN		day	1	Cmax = 5.3~30.1 ng/mL		UNHEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/530258_1124005C1032_2_003_1F.pdf#page=23	Homo sapiens				Day 1			3	Haloxazolam		false
1665	801		ADULT	12947024	333.155	FLUBROMAZEPAM	Flubromazepam	FC1=C(C=CC=C1)C2=NCC(=O)NC3=CC=C(Br)C=C23	PLASMA	GKX573279U																	UNKNOWN	mg	5		MULTIPLE	UNKNOWN		day	1	t1/2 = 43.2~144 h		UNHEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/530258_1124005C1032_2_003_1F.pdf#page=23	Homo sapiens		h	43.2	Day 10			3	Haloxazolam		false
1666	804			65985	835.1644	IOBITRIDOL	Iobitridol	CN(CC(O)CO)C(=O)C1=C(I)C(C(=O)N(C)CC(O)CO)=C(I)C(NC(=O)C(CO)CO)=C1I	UNKNOWN	182ECH14UH																										The binding of iobitridol at a concentration of 10-2 M to\nhuman albumin (40 g/L solution) in vitro was 2.1 %.	97.9				REVIEW	https://pubmed.ncbi.nlm.nih.gov/23341290/	Homo sapiens										false
1667	808		ADULT	6249|7048611	349.405	AMPICILLIN	Ampicillin	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O	SERUM	7C782967RD							6		t	mg × h/L	21.8		mg/L	12			UNKNOWN	mg	800		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2759930/	Homo sapiens		h	0.9				6	Lenampicillin hydrochloride		false
1668	808		ADULT	6249|7048611	349.405	AMPICILLIN	Ampicillin	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O	SERUM	7C782967RD							6		t	μg × h/mL	9		μg/mL	4.9			UNKNOWN	mg	400		MULTIPLE	UNKNOWN		day	4			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3729355/	Homo sapiens		h	0.7	Day 7			6			false
1669	808		ADULT	6249|7048611	349.405	AMPICILLIN	Ampicillin	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O	SERUM	7C782967RD							6		t	μg × h/mL	9.3		μg/mL	4.9			UNKNOWN	mg	400		MULTIPLE	UNKNOWN		day	4			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3729355/	Homo sapiens		h	0.67	Day 1			6			false
1670	808		ADULT	6249|7048611	349.405	AMPICILLIN	Ampicillin	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O	SERUM	7C782967RD							6		t	μg × h/mL	10.8		μg/mL	5.8			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3729355/	Homo sapiens		h	0.61				5			false
1671	808		ADULT	6249|7048611	349.405	AMPICILLIN	Ampicillin	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O	SERUM	7C782967RD							6		t	μg × h/mL	19.7		μg/mL	10.4			UNKNOWN	mg	800		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3729355/	Homo sapiens		h	0.83				5			false
1672	808		ADULT	6249|7048611	349.405	AMPICILLIN	Ampicillin	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O	SERUM	7C782967RD							6		t	μg × h/mL	9.6		μg/mL	6.7			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3729355/	Homo sapiens		h	0.68				11			false
1673	808		ADULT	6249|7048611	349.405	AMPICILLIN	Ampicillin	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O	SERUM	7C782967RD							6		t	μg × h/mL	7.4		μg/mL	3.6			UNKNOWN	mg	400		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3729355/	Homo sapiens		h	0.85				11			false
1674	808			65646	461.488	LENAMPICILLIN	Lenampicillin	CC1=C(COC(=O)[C@@H]2N3[C@H](SC2(C)C)[C@H](NC(=O)[C@H](N)C4=CC=CC=C4)C3=O)OC(=O)O1	SERUM	8M568DM08K																										Human serum protein binding: 30.0% (15 mcg/mL), ultrafiltration	70				EXPERIMENT	https://www.jstage.jst.go.jp/article/chemotherapy1953/32/Supplement8/32_Supplement8_181/_article/-char/ja/	Homo sapiens								Lenampicillin hydrochloride		false
1675	809		ADULT	216262	399.505	LENAPENEM	Lenapenem	CNCC[C@@H](O)[C@@H]1C[C@@H](CN1)SC2=C(N3[C@@H]([C@@H]([C@@H](C)O)C3=O)[C@H]2C)C(O)=O	PLASMA	D6NBQ3H12U									∞	mg × h/L	31.98		mg/L	17.75			UNKNOWN	mg	250		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8089072/	Homo sapiens		h	1.54				6			false
1676	809		ADULT	216262	399.505	LENAPENEM	Lenapenem	CNCC[C@@H](O)[C@@H]1C[C@@H](CN1)SC2=C(N3[C@@H]([C@@H]([C@@H](C)O)C3=O)[C@H]2C)C(O)=O	PLASMA	D6NBQ3H12U									∞	mg × h/L	66.31		mg/L	38.8			UNKNOWN	mg	500		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8089072/	Homo sapiens		h	1.5				6			false
1677	809		ADULT	216262	399.505	LENAPENEM	Lenapenem	CNCC[C@@H](O)[C@@H]1C[C@@H](CN1)SC2=C(N3[C@@H]([C@@H]([C@@H](C)O)C3=O)[C@H]2C)C(O)=O	PLASMA	D6NBQ3H12U									∞	mg × h/L	120.21		mg/L	71.88			UNKNOWN	mg	1000		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8089072/	Homo sapiens		h	1.41				6			false
1678	809		ADULT	216262	399.505	LENAPENEM	Lenapenem	CNCC[C@@H](O)[C@@H]1C[C@@H](CN1)SC2=C(N3[C@@H]([C@@H]([C@@H](C)O)C3=O)[C@H]2C)C(O)=O	PLASMA	D6NBQ3H12U									∞	mg × h/L	65.34		mg/L	39			UNKNOWN	mg	500		MULTIPLE	UNKNOWN		day	2			HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8089072/	Homo sapiens		h	1.43	1st dose			6			false
1679	809		ADULT	216262	399.505	LENAPENEM	Lenapenem	CNCC[C@@H](O)[C@@H]1C[C@@H](CN1)SC2=C(N3[C@@H]([C@@H]([C@@H](C)O)C3=O)[C@H]2C)C(O)=O	PLASMA	D6NBQ3H12U									∞	mg × h/L	68.25		mg/L	40.05			UNKNOWN	mg	500		MULTIPLE	UNKNOWN		day	2			HEALTHY	Intravenous	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8089072/	Homo sapiens		h	1.46				6			false
1680	811		ADULT	3033860	464.904	LOPRAZOLAM	Loprazolam	CN1CCN(CC1)\\C=C2/N=C3CN=C(C4=C(Cl)C=CC=C4)C5=C(C=CC(=C5)[N ]([O-])=O)N3C2=O	SERUM	759N8462G8									?	ng × h/mL	35.5		ng/mL	4.1			UNKNOWN	mg	1		MULTIPLE	FED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2860916/	Homo sapiens		h	8				6			false
1681	811		ADULT	3033860	464.904	LOPRAZOLAM	Loprazolam	CN1CCN(CC1)\\C=C2/N=C3CN=C(C4=C(Cl)C=CC=C4)C5=C(C=CC(=C5)[N ]([O-])=O)N3C2=O	SERUM	759N8462G8									?	ng × h/mL	50		ng/mL	4.6			UNKNOWN	mg	1		MULTIPLE	FED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2860916/	Homo sapiens		h	3.3	Day 7 PK			6			false
1682	811		ADULT	3033860	464.904	LOPRAZOLAM	Loprazolam	CN1CCN(CC1)\\C=C2/N=C3CN=C(C4=C(Cl)C=CC=C4)C5=C(C=CC(=C5)[N ]([O-])=O)N3C2=O	PLASMA	759N8462G8									?	ng × h/mL	46.6		ng/mL	4.3			UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2864049/	Homo sapiens		h	11.22		Young subjects (23-39 y)		10			false
1683	811		ADULT	3033860	464.904	LOPRAZOLAM	Loprazolam	CN1CCN(CC1)\\C=C2/N=C3CN=C(C4=C(Cl)C=CC=C4)C5=C(C=CC(=C5)[N ]([O-])=O)N3C2=O	PLASMA	759N8462G8									?	ng × h/mL	74.5		ng/mL	4.2			UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2864049/	Homo sapiens		h	19.77		Elderly subjects (67-83 y)		9			false
1684	811			3033860	464.904	LOPRAZOLAM	Loprazolam	CN1CCN(CC1)\\C=C2/N=C3CN=C(C4=C(Cl)C=CC=C4)C5=C(C=CC(=C5)[N ]([O-])=O)N3C2=O	PLASMA	759N8462G8																										Less than 85% of loprazolam was protein bound in rat, dog or human plasma in vitro.	15				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6140793/	Homo sapiens										false
1685	820		ADULT	5282433	302.434	NETICONAZOLE	Neticonazole	CCCCCOC1=C(C=CC=C1)C(=C/SC)\\N2C=CN=C2	PLASMA	KVL61ZF9UO							120		t	ng × h/mL	63.3		ng/mL	5.9			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Topical	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/4/650034_2655711M1039_4_111_1F.pdf#page=26	Homo sapiens		h	7.63	Cream, 10h-application (covered)			5	Neticonazole hydrochloride		false
1686	827		ADULT	4617	328.793	OXAZOLAM	Oxazolam	CC1CN2CC(=O)NC3=C(C=C(Cl)C=C3)C2(O1)C4=CC=CC=C4	SERUM	1V2WI2NA1C									?	μg × h/mL	10.37		ng/mL	115			UNKNOWN	mg	40		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6150943/	Homo sapiens		h	61.2				12			false
1687	827			4617	328.793	OXAZOLAM	Oxazolam	CC1CN2CC(=O)NC3=C(C=C(Cl)C=C3)C2(O1)C4=CC=CC=C4	PLASMA	1V2WI2NA1C									∞	ng × h/mL	8535		ng/mL	97.96			MAX DAILY	mg	20		SINGLE	FASTED							Oral		OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/3/530258_1124013B1031_3_004_1F.pdf#page=29	Homo sapiens		h	55.86				7			false
1688	828		ADULT	72015|40466880	339.41	PANIPENEM	Panipenem	C[C@@H](O)[C@@H]1[C@H]2CC(S[C@H]3CCN(C3)C(C)=N)=C(N2C1=O)C(O)=O	PLASMA	W9769W09JF	71651	193.1992	BETAMIPRON	Betamipron	OC(=O)CCNC(=O)C1=CC=CC=C1	3W0M245736			∞	μg × h/mL	45.21		μg/mL	27.51			UNKNOWN	mg	500		SINGLE	FASTED						HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=39 | https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_242/_article/-char/en	Homo sapiens		h	1.19			500mg	5			true
1689	828		ADULT	72015|40466880	339.41	PANIPENEM	Panipenem	C[C@@H](O)[C@@H]1[C@H]2CC(S[C@H]3CCN(C3)C(C)=N)=C(N2C1=O)C(O)=O	PLASMA	W9769W09JF	71651	193.1992	BETAMIPRON	Betamipron	OC(=O)CCNC(=O)C1=CC=CC=C1	3W0M245736			∞	μg × h/mL	23.2		μg/mL	14.26			UNKNOWN	mg	250		SINGLE	FASTED						HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=39 | https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_242/_article/-char/en	Homo sapiens		h	1.14			250mg	5			true
1690	828		ADULT	72015|40466880	339.41	PANIPENEM	Panipenem	C[C@@H](O)[C@@H]1[C@H]2CC(S[C@H]3CCN(C3)C(C)=N)=C(N2C1=O)C(O)=O	PLASMA	W9769W09JF	71651	193.1992	BETAMIPRON	Betamipron	OC(=O)CCNC(=O)C1=CC=CC=C1	3W0M245736			∞	μg × h/mL	84.8		μg/mL	49.27			UNKNOWN	mg	1000		SINGLE	FASTED						HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=39 | https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_242/_article/-char/en	Homo sapiens		h	1.23			1000mg	5			true
1691	828		ADULT	72015|40466880	339.41	PANIPENEM	Panipenem	C[C@@H](O)[C@@H]1[C@H]2CC(S[C@H]3CCN(C3)C(C)=N)=C(N2C1=O)C(O)=O	PLASMA	W9769W09JF	71651	193.1992	BETAMIPRON	Betamipron	OC(=O)CCNC(=O)C1=CC=CC=C1	3W0M245736			∞	μg × h/mL	85.88		μg/mL	50.01			UNKNOWN	mg	1000		MULTIPLE	FASTED		day	2			HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=40 | https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_265/_article/-char/en	Homo sapiens		h	1.11	1st dose		1000mg	4			true
1692	828		ADULT	72015|40466880	339.41	PANIPENEM	Panipenem	C[C@@H](O)[C@@H]1[C@H]2CC(S[C@H]3CCN(C3)C(C)=N)=C(N2C1=O)C(O)=O	PLASMA	W9769W09JF	71651	193.1992	BETAMIPRON	Betamipron	OC(=O)CCNC(=O)C1=CC=CC=C1	3W0M245736			∞	μg × h/mL	39.42		μg/mL	23.32			UNKNOWN	mg	500		MULTIPLE	FASTED		day	2			HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=40 | https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_265/_article/-char/en	Homo sapiens		h	1.07	1st dose		500mg	5			true
1693	828		ADULT	72015|40466880	339.41	PANIPENEM	Panipenem	C[C@@H](O)[C@@H]1[C@H]2CC(S[C@H]3CCN(C3)C(C)=N)=C(N2C1=O)C(O)=O	PLASMA	W9769W09JF	71651	193.1992	BETAMIPRON	Betamipron	OC(=O)CCNC(=O)C1=CC=CC=C1	3W0M245736			∞	μg × h/mL	40.27		μg/mL	26.24			UNKNOWN	mg	500		MULTIPLE	FASTED		day	2			HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=40 | https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_265/_article/-char/en	Homo sapiens		h	1.27	9th dose (last dose, single dose on Day 5)		500mg	5			true
1694	828		ADULT	72015|40466880	339.41	PANIPENEM	Panipenem	C[C@@H](O)[C@@H]1[C@H]2CC(S[C@H]3CCN(C3)C(C)=N)=C(N2C1=O)C(O)=O	PLASMA	W9769W09JF	71651	193.1992	BETAMIPRON	Betamipron	OC(=O)CCNC(=O)C1=CC=CC=C1	3W0M245736			∞	μg × h/mL	71.07		μg/mL	44.58			UNKNOWN	mg	1000		MULTIPLE	FASTED		day	2			HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=40 | https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_265/_article/-char/en	Homo sapiens		h	1.35	9th dose (last dose, single dose on Day 5)		1000mg	4			true
1695	828		ADULT	72015|40466880	339.41	PANIPENEM	Panipenem	C[C@@H](O)[C@@H]1[C@H]2CC(S[C@H]3CCN(C3)C(C)=N)=C(N2C1=O)C(O)=O	SERUM	W9769W09JF																	UNKNOWN	mg	500		MULTIPLE	FASTED		day	2	Human serum protein binding: 7.0% (1h after 9th administration, ultrailtration)	93	HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/430574_6139503D1027_2_C11_1F.pdf#page=51 | https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_265/_article/-char/en#page=18	Homo sapiens				9th dose (last dose, single dose on Day 5)			5			false
1696	828		ADULT	72015|40466880	339.41	PANIPENEM	Panipenem	C[C@@H](O)[C@@H]1[C@H]2CC(S[C@H]3CCN(C3)C(C)=N)=C(N2C1=O)C(O)=O	PLASMA	W9769W09JF	71651	193.1992	BETAMIPRON	Betamipron	OC(=O)CCNC(=O)C1=CC=CC=C1	3W0M245736			∞	μg × h/mL	11.72		μg/mL	6.8			UNKNOWN	mg	125		SINGLE	FASTED						HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.jstage.jst.go.jp/article/chemotherapy1953/39/Supplement3/39_Supplement3_242/_article/-char/en	Homo sapiens		h	1.13			125mg	2			true
1697	831		UNKNOWN	9829523	570.6371	MIDOSTAURIN	MIDOSTAURIN	CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N3C4=C(C=CC=C4)C5=C3C6=C(C7=C(C=CC=C7)N26)C8=C5CNC8=O)N(C)C(=O)C9=CC=CC=C9	PLASMA	ID912S5VON																						UNKNOWN				Midostaurin, CGP62221, and CGP52421 are greater than 99.8% bound to plasma protein in vitro.	0.2	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997s000lbl.pdf	Homo sapiens										false
1698	831		UNKNOWN	9829523	570.2267	MIDOSTAURIN	MIDOSTAURIN	CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N3C4=C(C=CC=C4)C5=C3C6=C(C7=C(C=CC=C7)N26)C8=C5CNC8=O)N(C)C(=O)C9=CC=CC=C9	PLASMA	ID912S5VON									∞	ng × h/mL	15700		ng/mL	1210			UNKNOWN	mg	50		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.ema.europa.eu/en/documents/assessment-report/rydapt-epar-public-assessment-report_en.pdf	Homo sapiens		h	20							false
1699	832		ADULT	5311356	398.4953	PHOLCODINE	PHOLCODINE	CN1CC[C@@]23[C@H]4OC5=C2C(C[C@@H]1[C@@H]3C=C[C@@H]4O)=CC=C5OCCN6CCOCC6	PLASMA	LPP64AWZ7L							168		t	mg × h/L	0.72		mg/L	12.8			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3190994/	Homo sapiens		h	45.4				6	PHOLCODINE		false
1700	832		ADULT	5311356	398.4953	PHOLCODINE	PHOLCODINE	CN1CC[C@@]23[C@H]4OC5=C2C(C[C@@H]1[C@@H]3C=C[C@@H]4O)=CC=C5OCCN6CCOCC6	SALIVA	LPP64AWZ7L							168		t	mg × h/L	6.61						UNKNOWN	mg	60		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3190994/	Homo sapiens		h	46.7				6	PHOLCODINE		false
1701	832		ADULT	5311356	398.4953	PHOLCODINE	PHOLCODINE	CN1CC[C@@]23[C@H]4OC5=C2C(C[C@@H]1[C@@H]3C=C[C@@H]4O)=CC=C5OCCN6CCOCC6	SALIVA	LPP64AWZ7L							168		t	mg × h/L	2.91						UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3190994/	Homo sapiens		h	55.6				6	PHOLCODINE		false
1702	832		ADULT	5311356	398.4953	PHOLCODINE	PHOLCODINE	CN1CC[C@@]23[C@H]4OC5=C2C(C[C@@H]1[C@@H]3C=C[C@@H]4O)=CC=C5OCCN6CCOCC6	PLASMA	LPP64AWZ7L							168		?	mg × h/L	0.55						UNKNOWN	mg	20		MULTIPLE	UNKNOWN		day	3			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3190994/	Homo sapiens				10 days dosing			6	PHOLCODINE		false
1703	832		ADULT	5311356	398.4953	PHOLCODINE	PHOLCODINE	CN1CC[C@@]23[C@H]4OC5=C2C(C[C@@H]1[C@@H]3C=C[C@@H]4O)=CC=C5OCCN6CCOCC6	SALIVA	LPP64AWZ7L							168		?	mg × h/L	1.97						UNKNOWN	mg	20		MULTIPLE	UNKNOWN		day	3			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3190994/	Homo sapiens		h	53.5	10 days dosing			6	PHOLCODINE		false
1704	832		ADULT	5311356	398.4953	PHOLCODINE	PHOLCODINE	CN1CC[C@@]23[C@H]4OC5=C2C(C[C@@H]1[C@@H]3C=C[C@@H]4O)=CC=C5OCCN6CCOCC6	PLASMA	LPP64AWZ7L							168		t	mg × h/L	1.67		mg/L	26.3			UNKNOWN	mg	60		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3190994/	Homo sapiens		h	51.9				6	PHOLCODINE		false
1705	832		ADULT	5311356	398.4953	PHOLCODINE	PHOLCODINE	CN1CC[C@@]23[C@H]4OC5=C2C(C[C@@H]1[C@@H]3C=C[C@@H]4O)=CC=C5OCCN6CCOCC6	PLASMA	LPP64AWZ7L							8		t	ng × h/mL	162		ng/mL	27			UNKNOWN	mg	60		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3741728/	Homo sapiens							4	PHOLCODINE		false
1706	832		ADULT	5311356	398.4953	PHOLCODINE	PHOLCODINE	CN1CC[C@@]23[C@H]4OC5=C2C(C[C@@H]1[C@@H]3C=C[C@@H]4O)=CC=C5OCCN6CCOCC6	PLASMA	LPP64AWZ7L							121		t	ng × h/mL	933		ng/mL	50.7			UNKNOWN	mg	60		SINGLE	FASTED				Model-independent pharmacokinetic parameters free (unconjugated) pholcodine		HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3741728/	Homo sapiens							6	PHOLCODINE		false
1707	832		ADULT	5311356	398.4953	PHOLCODINE	PHOLCODINE	CN1CC[C@@]23[C@H]4OC5=C2C(C[C@@H]1[C@@H]3C=C[C@@H]4O)=CC=C5OCCN6CCOCC6	PLASMA	LPP64AWZ7L							8		t	ng × h/mL	47		ng/mL	9			UNKNOWN	mg	15		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3741728/	Homo sapiens							4	PHOLCODINE		false
1708	832		ADULT	5311356	398.4953	PHOLCODINE	PHOLCODINE	CN1CC[C@@]23[C@H]4OC5=C2C(C[C@@H]1[C@@H]3C=C[C@@H]4O)=CC=C5OCCN6CCOCC6	PLASMA	LPP64AWZ7L							8		t	ng × h/mL	91		ng/mL	14			UNKNOWN	mg	30		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3741728/	Homo sapiens							4	PHOLCODINE		false
1709	832		ADULT	5311356	398.4953	PHOLCODINE	PHOLCODINE	CN1CC[C@@]23[C@H]4OC5=C2C(C[C@@H]1[C@@H]3C=C[C@@H]4O)=CC=C5OCCN6CCOCC6	PLASMA	LPP64AWZ7L							121		t	ng × h/mL	929		ng/mL	57.1			UNKNOWN	mg	60		SINGLE	FASTED				Model-independent pharmacokinetic parameters for total (unconjugated and conjugated) pholcodine		HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3741728/	Homo sapiens							6	PHOLCODINE		false
1710	832		ADULT	5311356	398.4953	PHOLCODINE	PHOLCODINE	CN1CC[C@@]23[C@H]4OC5=C2C(C[C@@H]1[C@@H]3C=C[C@@H]4O)=CC=C5OCCN6CCOCC6	PLASMA	LPP64AWZ7L							121		∞	ng × h/mL	1004						UNKNOWN	mg	60		SINGLE	FASTED				Model-dependent pharmacokinetic parameters		HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3741728/	Homo sapiens		h	37				6	PHOLCODINE		false
1711	835		ADULT	71741	327.719	RANIMUSTINE	Ranimustine	CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O	SERUM	RYH2T97J77													μg/mL	9.1			UNKNOWN	mg	150		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/4/430920_4219402D1028_4_100_1F.pdf#page=26	Homo sapiens		h	41		Brain tumor patients		6			false
1712	835			71741	327.719	RANIMUSTINE	Ranimustine	CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O	PLASMA	RYH2T97J77																										Human plasma protein binding: 40~60% (0.1μg/mL), 20% (1μg/mL), 10% (10μg/mL)	40				EXPERIMENT	https://www.info.pmda.go.jp/go/interview/4/430920_4219402D1028_4_100_1F.pdf#page=27	Homo sapiens										false
1713	836		ADULT	5050|5282206	355.3844	REPIRINAST	REPIRINAST	CC(C)CCOC(=O)C1=CC(=O)C2=C(O1)C3=C(NC2=O)C(C)=C(C)C=C3	PLASMA	4K8KA8B61G							12		t	mg × h/L	0.307		mg/L	0.138			UNKNOWN	mg	150		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1315685/	Homo sapiens		h	5.91				12	REPIRINAST		false
1714	836		ADULT	5050|5282206	355.3844	REPIRINAST	REPIRINAST	CC(C)CCOC(=O)C1=CC(=O)C2=C(O1)C3=C(NC2=O)C(C)=C(C)C=C3	PLASMA	4K8KA8B61G							12		t	mg × h/L	0.719		mg/L	0.241			HIGHEST STUDIED	mg	450		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1315685/	Homo sapiens		h	9.79				12	REPIRINAST		false
1715	836		ADULT	5050|5282206	355.3844	REPIRINAST	REPIRINAST	CC(C)CCOC(=O)C1=CC(=O)C2=C(O1)C3=C(NC2=O)C(C)=C(C)C=C3	PLASMA	4K8KA8B61G							12		t	mg × h/L	0.502		mg/L	0.191			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1315685/	Homo sapiens		h	7.97				12	REPIRINAST		false
1716	836		ADULT	152032	285.25	MY-1250			PLASMA										∞	ng × h/mL	1720		ng/mL	363.6			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.scielo.br/j/bjps/a/73GTSDjmy8PCtSrgBjhmQVk/?lang=en	Homo sapiens		h	17.27				10	REPIRINAST		false
1717	836		ADULT	152032	285.25	MY-1250			PLASMA										∞	ng × h/mL	2272		ng/mL	441.7			HIGHEST STUDIED	mg	450		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.scielo.br/j/bjps/a/73GTSDjmy8PCtSrgBjhmQVk/?lang=en	Homo sapiens		h	17.54				10	REPIRINAST		false
1718	836		ADULT	152032	285.25	MY-1250			PLASMA										∞	ng × h/mL	1032		ng/mL	308.9			UNKNOWN	mg	150		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.scielo.br/j/bjps/a/73GTSDjmy8PCtSrgBjhmQVk/?lang=en	Homo sapiens		h	13.83				10	REPIRINAST		false
1719	836		ADULT	152032	285.25	MY-1250			PLASMA										∞	ng × h/mL	1021		ng/mL	216			UNKNOWN	mg	150		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.scielo.br/j/bjps/a/73GTSDjmy8PCtSrgBjhmQVk/?lang=en	Homo sapiens		h	13.83				10	REPIRINAST		false
1720	838		ADULT	66577020	587.7043	RETASPIMYCIN	RETASPIMYCIN	CO[C@H]1C[C@H](C)CC2=C(O)C(NC(=O)\\C(C)=C\\C=C[C@H](OC)[C@@H](OC(N)=O)\\C(C)=C\\[C@H](C)[C@H]1O)=CC(O)=C2NCC=C	PLASMA	BZF2ZM0I5Z									∞	ng × h/mL	11712		ng/mL	7800			MAX TOLERATED	mg/m²	400		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21762967	Homo sapiens		h	2.27				14	RETASPIMYCIN		false
1721	838		ADULT	66577020	587.7043	RETASPIMYCIN	RETASPIMYCIN	CO[C@H]1C[C@H](C)CC2=C(O)C(NC(=O)\\C(C)=C\\C=C[C@H](OC)[C@@H](OC(N)=O)\\C(C)=C\\[C@H](C)[C@H]1O)=CC(O)=C2NCC=C	PLASMA	BZF2ZM0I5Z									∞	ng × h/mL	5030		ng/mL	4637			MAX TOLERATED	mg/m²	400		SINGLE	UNKNOWN		week	2			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21851215	Homo sapiens		h	1.7				3	RETASPIMYCIN		false
1722	839		ADULT	65633	288.277	RITIPENEM	ritipenem	C[C@@H](O)[C@@H]1[C@H]2SC(COC(N)=O)=C(N2C1=O)C(O)=O	SERUM	D4SL77931L									∞	mg × h/L	41.5		mg/L	167			UNKNOWN	g	1		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3378958/	Homo sapiens		h	0.8				6	FCE 22101		false
1723	839		ADULT	65633	288.277	RITIPENEM	ritipenem	C[C@@H](O)[C@@H]1[C@H]2SC(COC(N)=O)=C(N2C1=O)C(O)=O	PLASMA	D4SL77931L							8		t	mg × h/L	11.24		mg/L	7.28			UNKNOWN	mg	500		STEADY-STATE			day	3			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9301999/	Homo sapiens		h	0.79				6	ritipenem acoxil		false
1724	841		ADULT	5205	261.3609	SETIPTILINE	SETIPTILINE	CN1CCC2=C(C1)C3=C(CC4=CC=CC=C24)C=CC=C3	PLASMA	7L38105Z6E																	RECOMMENDED	mg/kg	0.08		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7824756/	Homo sapiens		h	10.97	mean daily dose			45	SETIPTILINE MALEATE		false
1725	842			71622	498.6111	SIMETRIDE	Simetride	CCCC1=CC(OC)=C(OCC(=O)N2CCN(CC2)C(=O)COC3=C(OC)C=C(CCC)C=C3)C=C1	SERUM	QU6P2P8XLW																										Human serum protein binding: 98.7%	1.3				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/230109_1149108D1039_1_010_1F.pdf#page=18	Homo sapiens										false
1726	846		ADULT	159271	338.397	TILMACOXIB	TILMACOXIB	CC1=NC(C2CCCCC2)=C(O1)C3=CC(F)=C(C=C3)S(N)(=O)=O	BLOOD	G6VI5P84SX									∞	μg × h/mL	925.3		ng/mL	20445			UNKNOWN	mg	150		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12445023/	Homo sapiens		h	40.2				6	JTE-522		false
1727	846		ADULT	159271	338.397	TILMACOXIB	TILMACOXIB	CC1=NC(C2CCCCC2)=C(O1)C3=CC(F)=C(C=C3)S(N)(=O)=O	PLASMA	G6VI5P84SX									∞	μg × h/mL	7.83		ng/mL	325			UNKNOWN	mg	150		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12445023/	Homo sapiens							6	JTE-522		false
1728	846		ADULT	159271	338.397	TILMACOXIB	TILMACOXIB	CC1=NC(C2CCCCC2)=C(O1)C3=CC(F)=C(C=C3)S(N)(=O)=O	PLASMA	G6VI5P84SX							24		t	μg × h/mL	8.5		ng/mL	60.9			UNKNOWN	mg	150		STEADY-STATE	FED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12445023/	Homo sapiens		h	5				6	JTE-522		false
1729	846		ADULT	159271	338.397	TILMACOXIB	TILMACOXIB	CC1=NC(C2CCCCC2)=C(O1)C3=CC(F)=C(C=C3)S(N)(=O)=O	BLOOD	G6VI5P84SX							24		t	μg × h/mL	130.6		μg/mL	2.9			UNKNOWN	mg	150		STEADY-STATE	FED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12445023/	Homo sapiens		h	12.62				6	JTE-522		false
1730	852			5663	395.4516	VESNARINONE	Vesnarinone	COC1=C(OC)C=C(C=C1)C(=O)N2CCN(CC2)C3=CC4=C(NC(=O)CC4)C=C3	PLASMA	5COW40EV8M																										80% of the drug (OPC-8212) binds to plasma proteins.	20				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2767119/	Homo sapiens										false
1731	852		ADULT	5663	395.4516	VESNARINONE	Vesnarinone	COC1=C(OC)C=C(C=C1)C(=O)N2CCN(CC2)C3=CC4=C(NC(=O)CC4)C=C3	PLASMA	5COW40EV8M									∞	μg × h/mL	59.1		μg/mL	0.93			UNKNOWN	mg	15		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3216039/	Homo sapiens		h	50.5				3			false
1732	852		ADULT	5663	395.4516	VESNARINONE	Vesnarinone	COC1=C(OC)C=C(C=C1)C(=O)N2CCN(CC2)C3=CC4=C(NC(=O)CC4)C=C3	PLASMA	5COW40EV8M									∞	μg × h/mL	554.5		μg/mL	7.57			UNKNOWN	mg	120		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3216039/	Homo sapiens		h	45.9				3			false
1733	852		ADULT	5663	395.4516	VESNARINONE	Vesnarinone	COC1=C(OC)C=C(C=C1)C(=O)N2CCN(CC2)C3=CC4=C(NC(=O)CC4)C=C3	PLASMA	5COW40EV8M							24		t	μg × h/mL	114.46		μg/mL	6.87			UNKNOWN	mg	30		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3216039/	Homo sapiens		h	43	Day 15 (15th dose)			3			false
1734	852		ADULT	5663	395.4516	VESNARINONE	Vesnarinone	COC1=C(OC)C=C(C=C1)C(=O)N2CCN(CC2)C3=CC4=C(NC(=O)CC4)C=C3	PLASMA	5COW40EV8M									∞	μg × h/mL	119.5		μg/mL	2.21			UNKNOWN	mg	30		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3216039/	Homo sapiens		h	43				3			false
1735	852		ADULT	5663	395.4516	VESNARINONE	Vesnarinone	COC1=C(OC)C=C(C=C1)C(=O)N2CCN(CC2)C3=CC4=C(NC(=O)CC4)C=C3	PLASMA	5COW40EV8M									∞	μg × h/mL	22.3		μg/mL	0.43			UNKNOWN	mg	7.5		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3216039/	Homo sapiens		h	42.1				3			false
1736	852		ADULT	5663	395.4516	VESNARINONE	Vesnarinone	COC1=C(OC)C=C(C=C1)C(=O)N2CCN(CC2)C3=CC4=C(NC(=O)CC4)C=C3	PLASMA	5COW40EV8M									∞	μg × h/mL	228.4		μg/mL	3.8			UNKNOWN	mg	60		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3216039/	Homo sapiens		h	43.4				3			false
1737	852		ADULT	5663	395.4516	VESNARINONE	Vesnarinone	COC1=C(OC)C=C(C=C1)C(=O)N2CCN(CC2)C3=CC4=C(NC(=O)CC4)C=C3	PLASMA	5COW40EV8M									∞	μg × h/mL	957.5		μg/mL	11.18			HIGHEST STUDIED	mg	240		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3216039/	Homo sapiens		h	43.9				6			false
1738	852		ADULT	5663	395.4516	VESNARINONE	Vesnarinone	COC1=C(OC)C=C(C=C1)C(=O)N2CCN(CC2)C3=CC4=C(NC(=O)CC4)C=C3	PLASMA	5COW40EV8M									∞	μg × h/mL	133		μg/mL	2.8			UNKNOWN	mg	60		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9630823/	Homo sapiens		h	36.5				12			false
1739	852		ADULT	5663	395.4516	VESNARINONE	Vesnarinone	COC1=C(OC)C=C(C=C1)C(=O)N2CCN(CC2)C3=CC4=C(NC(=O)CC4)C=C3	PLASMA	5COW40EV8M	12560	733.9268	ERYTHROMYCIN	Erythromycin	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O	63937KV33D			∞	μg × h/mL	202		μg/mL	3.1			UNKNOWN	mg	60		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9630823/	Homo sapiens		h	46.2			500 mg three times a day for 7 days\nbefore and another 5 days after vesnarinone administration	12			true
1740	862		ADULT	108223	164.1565	2-DEOXYGLUCOSE	2-DEOXYGLUCOSE	OC[C@@H](O)[C@@H](O)[C@H](O)CC=O	PLASMA	9G2MP84A8W									?	μM × h	1107.7		μM	449.2			RECOMMENDED	mg/kg	45		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20687211	Homo sapiens		h	7.3							false
1741	865		ADULT	3398	376.809	FLUTAZOLAM	flutazolam	OCCN1C2=CC=C(Cl)C=C2C3(OCCN3CC1=O)C4=CC=CC=C4F	PLASMA	5G2K7O5D8S																						UNKNOWN				Plasma protein binding was 14.9% (total, stripped human plasma, [3H]-androstenone)	85.1	HEALTHY		FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18511263/	Homo sapiens							2			false
1742	870		ADULT	92888	151.16	4-CYCLOHEXENE-1,2-DICARBOXIMIDE, CIS-	1,2,3,6-tetrahydrophthalimide	O=C1NC(=O)C2CC=CCC12	PLASMA	ES57D28O1U							72		t	nM × h/kg	1652						UNKNOWN	mg/kg bw	1		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21381057/	Homo sapiens		h	15.7							false
1743	878		ADULT		376.3639	RIBOFLAVIN	riboflavin	CC1=C(C)C=C2N(C[C@H](O)[C@H](O)[C@H](O)CO)C3=NC(=O)NC(=O)C3=NC2=C1	PLASMA	TLM2976OFR							48		t	nM × h	883.9		nM	217.7			UNKNOWN	mg	20		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8604671/	Homo sapiens										false
1744	878		ADULT	493570	376.3639	RIBOFLAVIN	Riboflavin	CC1=C(C)C=C2N(C[C@H](O)[C@H](O)[C@H](O)CO)C3=NC(=O)NC(=O)C3=NC2=C1	PLASMA	TLM2976OFR							48		t	nM × h	886.4		nM	206.7			UNKNOWN	mg	40		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8604671/	Homo sapiens										false
1745	878		ADULT	493570	376.3639	RIBOFLAVIN	riboflavin	CC1=C(C)C=C2N(C[C@H](O)[C@H](O)[C@H](O)CO)C3=NC(=O)NC(=O)C3=NC2=C1	PLASMA	TLM2976OFR							48		t	nM × h	981.6		nM	308.2			UNKNOWN	mg	60		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8604671/	Homo sapiens										false
1746	878		ADULT	493570	376.3639	RIBOFLAVIN	Riboflavin	CC1=C(C)C=C2N(C[C@H](O)[C@H](O)[C@H](O)CO)C3=NC(=O)NC(=O)C3=NC2=C1	PLASMA	TLM2976OFR							48		t	nM × h	532.1		nM	1209.4			UNKNOWN	mg	11.6		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8604671/	Homo sapiens										false
1747	885		UNKNOWN	8522	314.1223	IODOANTIPYRINE	IODOANTIPYRINE	CN1N(C(=O)C(I)=C1C)C2=CC=CC=C2	PLASMA	V30V6H1QX4																	RECOMMENDED	MBq	18		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6531160/	Homo sapiens		h	27							false
1748	885		UNKNOWN	8522	314.1223	IODOANTIPYRINE	IODOANTIPYRINE	CN1N(C(=O)C(I)=C1C)C2=CC=CC=C2	PLASMA	V30V6H1QX4																	RECOMMENDED	MBq	18		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6531160/	Homo sapiens		h	9							false
1749	891		ADULT	38852	476.4749	METHYLDOPA	methyldopa	O.O.O.C[C@](N)(CC1=CC(O)=C(O)C=C1)C(O)=O.C[C@](N)(CC2=CC(O)=C(O)C=C2)C(O)=O	PLASMA	56LH93261Y									∞	ng × h/mL	5352.9		ng/mL	771.3			RECOMMENDED	mg	250		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21125810	Homo sapiens		h	12.6							false
1750	891		ADULT	38852	476.4749	METHYLDOPA	methyldopa	O.O.O.C[C@](N)(CC1=CC(O)=C(O)C=C1)C(O)=O.C[C@](N)(CC2=CC(O)=C(O)C=C2)C(O)=O	PLASMA	56LH93261Y									?	μg × h/mL	4.54						UNKNOWN	mg	100		SINGLE	UNKNOWN				Methyldopa is less than 15% protein bound	85	HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7047042	Homo sapiens		h	1.28							false
1751	893		ADULT	65150	221.2078	N-ACETYLMANNOSAMINE	N-ACETYLMANNOSAMINE	CC(=O)N[C@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO	PLASMA	X80PR7P73R									∞	ng × h/mL	14161		ng/mL	2585			UNKNOWN	g	10		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28641925	Homo sapiens		h	2.4				6	N-ACETYLMANNOSAMINE		false
1752	894		ADULT	68310	223.2252	N-ACETYLTYROSINE	N-acetyl-L-tyrosine	CC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O	PLASMA	DA8G610ZO5													μM	278			UNKNOWN	g	5		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2507878/	Homo sapiens				4h-infusion			5			false
1753	905		ADULT	5143	183.185	SACCHARIN	SACCHARIN	O=C1NS(=O)(=O)C2=C1C=CC=C2	PLASMA	FST467XS7D									?	μg × min/mL	3700						RECOMMENDED	mg/kg	10		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7303723/	Homo sapiens										false
1754	905		ADULT	5143	183.185	SACCHARIN	SACCHARIN	O=C1NS(=O)(=O)C2=C1C=CC=C2	PLASMA	FST467XS7D	4911		PROBENECID	probenecid	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	PO572Z7917			?	μg × min/mL	5800						RECOMMENDED	mg/kg	10		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7303723/	Homo sapiens										true
1755	905		ADULT	5143	183.185	SACCHARIN	SACCHARIN	O=C1NS(=O)(=O)C2=C1C=CC=C2	PLASMA	FST467XS7D									?	μg × min/mL	6800		μg/mL	27			RECOMMENDED	g	2		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7303723/	Homo sapiens										false
1756	905		ADULT	5143	183.185	SACCHARIN	SACCHARIN	O=C1NS(=O)(=O)C2=C1C=CC=C2	PLASMA	FST467XS7D									?	μg × min/mL	6500		μg/mL	14			RECOMMENDED	g	2		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7303723/	Homo sapiens										false
1757	936		ADULT	160883	360.4672	BUTYLSCOPOLAMINE	Butylscopolamine	CCCC[N@ ]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]3O[C@@H]23)OC(=O)[C@H](CO)C4=CC=CC=C4	PLASMA	2Z3E1OF81V									∞	ng × h/mL	3.91		ng/mL	0.29			RECOMMENDED	mg	10		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22467253/	Homo sapiens		h	22.72				24	Buscopan (Butylscopolamine bromide)		false
1758	936		ADULT	160883	360.4672	BUTYLSCOPOLAMINE	Butylscopolamine	CCCC[N@ ]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]3O[C@@H]23)OC(=O)[C@H](CO)C4=CC=CC=C4	PLASMA	2Z3E1OF81V									∞	pg × h/mL	373.1		pg/mL	61.6			RECOMMENDED	mg	10		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27557455/	Homo sapiens		h	6.3				60	Buscopan (butylscopolamine bromide)		false
1759	952		ADULT	785|152743433	110.1106	HYDROQUINONE	hydroquinone	OC1=CC=C(O)C=C1	URINE	XV74C1N1AE													nmol/mL	1125			UNKNOWN	mg	210		SINGLE	FASTED				Cmax is for total hydroquinone equivalents, accounting for both free and conjugated forms.		HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12162475/	Homo sapiens				Ingredient of bearberry leaves dry extract, in film-coated tablets			15			false
1760	952		ADULT	785|152743433	110.1106	HYDROQUINONE	hydroquinone	OC1=CC=C(O)C=C1	URINE	XV74C1N1AE													nmol/mL	1689.3			UNKNOWN	mg	210		SINGLE	FASTED				Cmax is for total hydroquinone equivalents, accounting for both free and conjugated forms.		HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12162475/	Homo sapiens				Ingredient of bearberry leaves dry extract, in aqueous solution			15			false
1761	960		ADULT	10206	606.7074	CEPHARANTHINE	Cepharanthine	COC1=CC2=C3C=C1OC4=C5[C@H](CC6=CC=C(OC7=C(OC)C=CC(C[C@H]3N(C)CC2)=C7)C=C6)N(C)CCC5=CC8=C4OCO8	PLASMA	7592YJ0J6T									∞	ng × h/mL	131.3		ng/mL	6.78			UNKNOWN	mg	120		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	http://www.info.pmda.go.jp/go/interview/2/780075_2900001A2036_2_001_1F.pdf#page=18 | https://www.jstage.jst.go.jp/article/jscpt1970/20/4/20_4_735/_article/-char/en	Homo sapiens		h	17.1				5			false
1762	960		ADULT	10206	606.7074	CEPHARANTHINE	Cepharanthine	COC1=CC2=C3C=C1OC4=C5[C@H](CC6=CC=C(OC7=C(OC)C=CC(C[C@H]3N(C)CC2)=C7)C=C6)N(C)CCC5=CC8=C4OCO8	PLASMA	7592YJ0J6T									∞	ng × h/mL	3.49		ng/mL	0.53			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	http://www.info.pmda.go.jp/go/interview/2/780075_2900001A2036_2_001_1F.pdf#page=18 | https://www.jstage.jst.go.jp/article/jscpt1970/20/4/20_4_735/_article/-char/en	Homo sapiens		h	4.1				2			false
1763	960		ADULT	10206	606.7074	CEPHARANTHINE	Cepharanthine	COC1=CC2=C3C=C1OC4=C5[C@H](CC6=CC=C(OC7=C(OC)C=CC(C[C@H]3N(C)CC2)=C7)C=C6)N(C)CCC5=CC8=C4OCO8	PLASMA	7592YJ0J6T									∞	ng × h/mL	23.8		ng/mL	2.35			UNKNOWN	mg	30		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	http://www.info.pmda.go.jp/go/interview/2/780075_2900001A2036_2_001_1F.pdf#page=18 | https://www.jstage.jst.go.jp/article/jscpt1970/20/4/20_4_735/_article/-char/en	Homo sapiens		h	9.2				5			false
1764	960		ADULT	10206	606.7074	CEPHARANTHINE	Cepharanthine	COC1=CC2=C3C=C1OC4=C5[C@H](CC6=CC=C(OC7=C(OC)C=CC(C[C@H]3N(C)CC2)=C7)C=C6)N(C)CCC5=CC8=C4OCO8	PLASMA	7592YJ0J6T									∞	ng × h/mL	26.4		ng/mL	3.46			UNKNOWN	mg	60		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	http://www.info.pmda.go.jp/go/interview/2/780075_2900001A2036_2_001_1F.pdf#page=18 | https://www.jstage.jst.go.jp/article/jscpt1970/20/4/20_4_735/_article/-char/en	Homo sapiens		h	6.8				5			false
1765	960		ADULT	10206	606.7074	CEPHARANTHINE	Cepharanthine	COC1=CC2=C3C=C1OC4=C5[C@H](CC6=CC=C(OC7=C(OC)C=CC(C[C@H]3N(C)CC2)=C7)C=C6)N(C)CCC5=CC8=C4OCO8	PLASMA	7592YJ0J6T									∞	ng × h/mL	158.8		ng/mL	187			UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Intravenous	MALE	OTHER GOV'T	http://www.info.pmda.go.jp/go/interview/2/780075_2900400A2034_2_001_1F.pdf#page=17 | https://www.jstage.jst.go.jp/article/jscpt1970/20/4/20_4_741/_article/-char/en	Homo sapiens		h	35.8				5			false
1766	960		ADULT	10206	606.7074	CEPHARANTHINE	Cepharanthine	COC1=CC2=C3C=C1OC4=C5[C@H](CC6=CC=C(OC7=C(OC)C=CC(C[C@H]3N(C)CC2)=C7)C=C6)N(C)CCC5=CC8=C4OCO8	PLASMA	7592YJ0J6T									∞	ng × h/mL	377.8		ng/mL	433			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Intravenous	MALE	OTHER GOV'T	http://www.info.pmda.go.jp/go/interview/2/780075_2900400A2034_2_001_1F.pdf#page=17 | https://www.jstage.jst.go.jp/article/jscpt1970/20/4/20_4_741/_article/-char/en	Homo sapiens		h	36.9				5			false
1767	960		ADULT	10206	606.7074	CEPHARANTHINE	Cepharanthine	COC1=CC2=C3C=C1OC4=C5[C@H](CC6=CC=C(OC7=C(OC)C=CC(C[C@H]3N(C)CC2)=C7)C=C6)N(C)CCC5=CC8=C4OCO8	PLASMA	7592YJ0J6T									∞	ng × h/mL	962.5		ng/mL	1464			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Intravenous	MALE	OTHER GOV'T	http://www.info.pmda.go.jp/go/interview/2/780075_2900400A2034_2_001_1F.pdf#page=17 | https://www.jstage.jst.go.jp/article/jscpt1970/20/4/20_4_741/_article/-char/en	Homo sapiens		h	31.8				5			false
1768	960		ADULT	10206	606.7074	CEPHARANTHINE	Cepharanthine	COC1=CC2=C3C=C1OC4=C5[C@H](CC6=CC=C(OC7=C(OC)C=CC(C[C@H]3N(C)CC2)=C7)C=C6)N(C)CCC5=CC8=C4OCO8	PLASMA	7592YJ0J6T													ng/mL	196.3			UNKNOWN	mg	100		MULTIPLE	FED		day	1			HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.jstage.jst.go.jp/article/jscpt1970/20/4/20_4_741/_article/-char/en	Homo sapiens		h	62	7 repeated doses			5			false
1769	981		ADULT	1061	94.9714	PHOSPHATE ION	Phosphate	[O-]P([O-])([O-])=O	SERUM	NK08V8K8HR							24		t	mM × h	38.7		mM	2.87			UNKNOWN	mmol	80		SINGLE	UNKNOWN				n=24 for 1/2		HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21986180/	Homo sapiens		h	2.06	4-h infusion			25	Sodium glycerophosphate (Glycophos)		false
1770	988		ADULT	440917	136.234	LIMONENE, ( )-	Limonene	CC(=C)[C@@H]1CCC(C)=CC1	PLASMA	GFD7C86Q1W									∞	ng × h/mL	311.9		ng/mL	93.6			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17540528/	Homo sapiens		h	3.42				24			false
1771	988		ADULT	440917	136.234	LIMONENE, ( )-	Limonene	CC(=C)[C@@H]1CCC(C)=CC1	PLASMA	GFD7C86Q1W									∞	ng × h/mL	449.855		ng/mL	159.573			UNKNOWN	mL	0.3		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18972832/	Homo sapiens		h	2.859				24			false
1772	988		ADULT	440917	136.234	LIMONENE, ( )-	Limonene	CC(=C)[C@@H]1CCC(C)=CC1	PLASMA	GFD7C86Q1W													μM	13.8			UNKNOWN	g/m²	3.33		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9654110/	Homo sapiens				Day 1, (10 g/m2/day)	patients with advanced cancer		3			false
1773	988		ADULT	440917	136.234	LIMONENE, ( )-	Limonene	CC(=C)[C@@H]1CCC(C)=CC1	PLASMA	GFD7C86Q1W													μM	10.9			UNKNOWN	g/m²	3.33		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9654110/	Homo sapiens				Day 21, (10 g/m2/day)	patients with advanced cancer		1			false
1774	988		ADULT	440917	136.234	LIMONENE, ( )-	Limonene	CC(=C)[C@@H]1CCC(C)=CC1	PLASMA	GFD7C86Q1W													μM	10.8			UNKNOWN	g/m²	2.67		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9654110/	Homo sapiens				Day 1, (8 g/m2/day)	patients with advanced cancer		4			false
1775	988		ADULT	440917	136.234	LIMONENE, ( )-	Limonene	CC(=C)[C@@H]1CCC(C)=CC1	PLASMA	GFD7C86Q1W													μM	20.5			UNKNOWN	g/m²	4		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9654110/	Homo sapiens				Day 1, (12 g/m2/day)	patients with advanced cancer		2			false
1776	988		ADULT	440917	136.234	LIMONENE, ( )-	Limonene	CC(=C)[C@@H]1CCC(C)=CC1	PLASMA	GFD7C86Q1W							24		t	μM × h	165						UNKNOWN	g/m²	10		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9654110/	Homo sapiens					patients with advanced cancer		3			false
1777	988		ADULT	440917	136.234	LIMONENE, ( )-	Limonene	CC(=C)[C@@H]1CCC(C)=CC1	PLASMA	GFD7C86Q1W													μM	4.9			UNKNOWN	g/m²	4		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9654110/	Homo sapiens				Day 21, (12 g/m2/day)	patients with advanced cancer		2			false
1778	988		ADULT	440917	136.234	LIMONENE, ( )-	Limonene	CC(=C)[C@@H]1CCC(C)=CC1	PLASMA	GFD7C86Q1W							24		t	μM × h	151						UNKNOWN	g/m²	8		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9654110/	Homo sapiens					patients with advanced cancer		4			false
1779	988		ADULT	440917	136.234	LIMONENE, ( )-	Limonene	CC(=C)[C@@H]1CCC(C)=CC1	PLASMA	GFD7C86Q1W													μM	12			UNKNOWN	g/m²	2.67		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9654110/	Homo sapiens				Day 21, (8 g/m2/day)	patients with advanced cancer		3			false
1780	988		ADULT	440917	136.234	LIMONENE, ( )-	Limonene	CC(=C)[C@@H]1CCC(C)=CC1	PLASMA	GFD7C86Q1W							24		t	μM × h	154.5						UNKNOWN	g/m²	12		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9654110/	Homo sapiens					patients with advanced cancer		2			false
1781	990		ADULT	170607	117.1033	N-METHYLMALONAMIC ACID	N-methylmalonamic acid	CNC(=O)CC(O)=O	URINE	P1GQ250D2I													μg/g	282			UNKNOWN	mg	2		SINGLE	UNKNOWN				Cmax measured as """"μg/g creatine""""		HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28929222/	Homo sapiens		h	7.6				4			false
1782	1009		ADULT		560.6423	PROTOPORPHYRIN	PROTOPORPHYRIN	CC1=C(CCC(O)=O)C2=Cc3nC(=CC4=C(C)C(C=C)=C(N4)C=C5nc(-c-c1-[n]2)C(C=C)=C5C)C(C)=C3CCC(O)=O	PLASMA	C2K325S808							24		t	μg × h/mL	9.6		ng/mL	742			UNKNOWN	mg	40		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9372622/	Homo sapiens		h	4							false
1783	1016		ADULT	115817	413.274	THIAMPHENICOL AMINOACETATE	Thiamphenicol glycinate	CS(=O)(=O)C1=CC=C(C=C1)[C@@H](O)[C@@H](COC(=O)CN)NC(=O)C(Cl)Cl	PLASMA	W5H94CY6V6									∞	μg × h/mL	849.1		μg/mL	26.6			UNKNOWN	mg	500		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24597465/	Homo sapiens		min	17.6				8			false
1784	1016		ADULT	115817	413.274	THIAMPHENICOL AMINOACETATE	Thiamphenicol glycinate	CS(=O)(=O)C1=CC=C(C=C1)[C@@H](O)[C@@H](COC(=O)CN)NC(=O)C(Cl)Cl	PLASMA	W5H94CY6V6									∞	μg × h/mL	1305.2		μg/mL	38.1			UNKNOWN	mg	1000		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24597465/	Homo sapiens		min	16.8				8			false
1785	1016		ADULT	115817	413.274	THIAMPHENICOL AMINOACETATE	Thiamphenicol glycinate	CS(=O)(=O)C1=CC=C(C=C1)[C@@H](O)[C@@H](COC(=O)CN)NC(=O)C(Cl)Cl	PLASMA	W5H94CY6V6									∞	μg × h/mL	2315.9		μg/mL	66.1			HIGHEST STUDIED	mg	1500		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24597465/	Homo sapiens		min	16.8				8			false
1786	1016		ADULT	27200	356.222	THIAMPHENICOL	Thiamphenicol	CS(=O)(=O)C1=CC=C(C=C1)[C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl	PLASMA	FLQ7571NPM									∞	μg × h/mL	12613.3		μg/mL	78.5			HIGHEST STUDIED	mg	1500		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24597465/	Homo sapiens							8			false
1787	1016		ADULT	27200	356.222	THIAMPHENICOL	Thiamphenicol	CS(=O)(=O)C1=CC=C(C=C1)[C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl	PLASMA	FLQ7571NPM									∞	μg × h/mL	7506.5		μg/mL	53.2			UNKNOWN	mg	1000		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24597465/	Homo sapiens							8			false
1788	1016		ADULT	115817	413.274	THIAMPHENICOL AMINOACETATE	Thiamphenicol glycinate	CS(=O)(=O)C1=CC=C(C=C1)[C@@H](O)[C@@H](COC(=O)CN)NC(=O)C(Cl)Cl	PLASMA	W5H94CY6V6									∞	μg × h/mL	234.1		μg/mL	18.58			UNKNOWN	mg	500		MULTIPLE	UNKNOWN		day	2			HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24597465/	Homo sapiens		min	20.7	Day 5 PK			8			false
1789	1016		ADULT	27200	356.222	THIAMPHENICOL	Thiamphenicol	CS(=O)(=O)C1=CC=C(C=C1)[C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl	PLASMA	FLQ7571NPM									∞	μg × h/mL	4509		μg/mL	30.4			UNKNOWN	mg	500		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24597465/	Homo sapiens							8			false
1790	1016		ADULT	27200	356.222	THIAMPHENICOL	Thiamphenicol	CS(=O)(=O)C1=CC=C(C=C1)[C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl	PLASMA	FLQ7571NPM									∞	μg × h/mL	4114.2		μg/mL	29.56			UNKNOWN	mg	500		MULTIPLE	UNKNOWN		day	2			HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24597465/	Homo sapiens							8			false
1791	1016			27200	356.222	THIAMPHENICOL	Thiamphenicol	CS(=O)(=O)C1=CC=C(C=C1)[C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl	UNKNOWN	FLQ7571NPM																										Low percentage of protein binding (Thiamphenicol): 10-20%	80				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7394975/	Homo sapiens										false
1792	1017		ADULT	864	206.326	THIOCTIC ACID	alpha-lipoic acid	OC(=O)CCCCC1CCSS1	PLASMA	73Y7P0K73Y							24		t	ng × h/mL	2621		ng/mL	1793			UNKNOWN	mg	600		SINGLE	FASTED				Controlled-release alpha-lipoic acid		HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11951812/	Homo sapiens		h	0.4				12			false
1793	1017		ADULT	864	206.326	THIOCTIC ACID	alpha-lipoic acid	OC(=O)CCCCC1CCSS1	PLASMA	73Y7P0K73Y							24		t	ng × h/mL	4466		ng/mL	6675			UNKNOWN	mg	600		SINGLE	FASTED				Quick-release alpha-lipoic acid		HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11951812/	Homo sapiens		h	0.5				12			false
1794	1017		ADULT	6112	206.326	THIOCTIC ACID, ( )-	R-alpha-lipoic acid	OC(=O)CCCC[C@@H]1CCSS1	PLASMA	VLL71EBS9Z									?	μg × h/mL	6.68		μg/mL	14.2			UNKNOWN	mg	600		SINGLE	FED				R-alpha-lipoic acid		HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18069903/	Homo sapiens		h	13.5				12			false
1795	1037		ADULT	9904	274.3978	NANDROLONE	Nandrolone	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@H]2O	SERUM	6PG9VR430D									∞	ng × h/mL	400		ng/mL	2.14			UNKNOWN	mg	50		SINGLE	UNKNOWN						HEALTHY	Intramuscular	FEMALE	EXPERIMENT	https://academic.oup.com/jcem/article/90/5/2624/2836761?login=true	Homo sapiens		day	7.1				19	Nandrolone decanoate		false
1796	1037		ADULT	9904	274.3978	NANDROLONE	Nandrolone	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@H]2O	SERUM	6PG9VR430D									∞	ng × h/mL	1261		ng/mL	5.16			HIGHEST STUDIED	mg	150		SINGLE	UNKNOWN						HEALTHY	Intramuscular	MALE	EXPERIMENT	https://academic.oup.com/jcem/article/90/5/2624/2836761?login=true	Homo sapiens		day	11.8				16	Nandrolone decanoate		false
1797	1037		ADULT	9904	274.3978	NANDROLONE	Nandrolone	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@H]2O	SERUM	6PG9VR430D									∞	ng × h/mL	862		ng/mL	4.26			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Intramuscular	MALE	EXPERIMENT	https://academic.oup.com/jcem/article/90/5/2624/2836761?login=true	Homo sapiens		day	11.7				17	Nandrolone decanoate		false
1798	1037		ADULT	9904	274.3978	NANDROLONE	Nandrolone	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@H]2O	PLASMA	6PG9VR430D									?	nM × day	155		nM	30.9			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Intramuscular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9103484/	Homo sapiens		day	0.25				7	Nandrolone phenylpropionate		false
1799	1042		ADULT	21146529	305.2276	TENOFOVIR	TENOFOVIR	O.C[C@H](CN1C=NC2=C1N=CN=C2N)OCP(O)(O)=O	PLASMA	99YXE507IL									∞	ng × h/mL	2079.1		ng/mL	209.6			UNKNOWN	mg	150		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23278367	Homo sapiens		h	18.54							false
1800	1042		ADULT	21146529	305.2276	TENOFOVIR	TENOFOVIR	O.C[C@H](CN1C=NC2=C1N=CN=C2N)OCP(O)(O)=O	PLASMA	99YXE507IL									∞	ng × h/mL	3006.1		ng/mL	456.7			RECOMMENDED	mg	300		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23278367	Homo sapiens		h	17.56							false
1801	1042		ADULT	21146529	305.2276	TENOFOVIR	TENOFOVIR	O.C[C@H](CN1C=NC2=C1N=CN=C2N)OCP(O)(O)=O	PLASMA	99YXE507IL									∞	ng × h/mL	3408.2		ng/mL	448.5			RECOMMENDED	mg	300		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23278367	Homo sapiens		h	16.86							false
1802	1042		ADULT	21146529	305.2276	TENOFOVIR	TENOFOVIR	O.C[C@H](CN1C=NC2=C1N=CN=C2N)OCP(O)(O)=O	PLASMA	99YXE507IL									∞	ng × h/mL	6373.9		ng/mL	989.8			UNKNOWN	mg	600		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23278367	Homo sapiens		h	18.92							false
1803	1042		ADULT	21146529	305.2276	TENOFOVIR	TENOFOVIR	O.C[C@H](CN1C=NC2=C1N=CN=C2N)OCP(O)(O)=O	PLASMA	99YXE507IL									∞	ng × h/mL	4476.7		ng/mL	523.4			RECOMMENDED	mg	300		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23278367	Homo sapiens		h	17.12							false
1804	1042		UNKNOWN	21146529	305.2276	TENOFOVIR	TENOFOVIR	O.C[C@H](CN1C=NC2=C1N=CN=C2N)OCP(O)(O)=O	PLASMA	99YXE507IL																						UNKNOWN				In vitro binding of tenofovir to human plasma or serum proteins is less than 0.7 and 7.2%, respectively, over the tenofovir concentration range 0.01 to 25 ug/mL.	99.3	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021356s042,022577s002lbl.pdf	Homo sapiens										false
1805	1042		ADULT	21146529	305.2276	TENOFOVIR	TENOFOVIR	O.C[C@H](CN1C=NC2=C1N=CN=C2N)OCP(O)(O)=O	PLASMA	99YXE507IL									?	μg × h/mL	0.4		μg/mL	0.03			RECOMMENDED	mg	25		MULTIPLE	FED		day	1			UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208464s000lbl.pdf	Homo sapiens										false
1806	1043		UNKNOWN		853.9061	PACLITAXEL	PACLITAXEL	CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C3=CC=CC=C3)[C@@H]4[C@@]5(CO[C@@H]5C[C@H](O)[C@@]4(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C6=CC=CC=C6)C7=CC=CC=C7	PLASMA	P88XT4IS4D																						UNKNOWN				In vitro studies of binding to human serum proteins, using paclitaxel concentrations ranging from 0.1 to 50 μg/mL, indicate that between 89 to 98% of drug is bound	6.5	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020262s049lbl.pdf	Homo sapiens										false
1807	1043		ADULT	36314	853.33093	PACLITAXEL	PACLITAXEL	CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C3=CC=CC=C3)C4[C@@]5(CO[C@@H]5C[C@H](O)[C@@]4(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C6=CC=CC=C6)C7=CC=CC=C7	PLASMA	5DFG1UEB63|P88XT4IS4D													μM	0.5			UNKNOWN	mg/m²	175		STEADY-STATE	UNKNOWN						UNKNOWN	Intravenous	FEMALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/7799018	Homo sapiens		h	14.8							false
1808	1043		ADULT	36314	853.33093	PACLITAXEL	PACLITAXEL	CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C3=CC=CC=C3)C4[C@@]5(CO[C@@H]5C[C@H](O)[C@@]4(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C6=CC=CC=C6)C7=CC=CC=C7	PLASMA	5DFG1UEB63|P88XT4IS4D									∞	μM × h	27.07		μM	6.92			UNKNOWN	mg/m²	250		STEADY-STATE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/8664192	Homo sapiens										false
1809	1044		UNKNOWN	5754	362.4599	HYDROCORTISONE	HYDROCORTISONE	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO	PLASMA	WI4X0X7BPJ																						UNKNOWN				Hydrocortisone is 90.1% bound to proteins in plasma, with 56.2% bound to albumin	9.9	UNKNOWN		UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/13700365	Homo sapiens										false
1810	1044		ADULT	5754	362.5	HYDROCORTISONE	HYDROCORTISONE	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO	PLASMA	WI4X0X7BPJ									∞	ng × h/mL	1162		ng/mL	258			RECOMMENDED	mg	20		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/2050835	Homo sapiens		h	1.82							false
1811	1045		ADULT	5757	272.382	ESTRADIOL	ESTRADIOL	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@H]2O	SERUM	4TI98Z838E													pg/mL	92			RECOMMENDED	mg	0.05		MULTIPLE	UNKNOWN		day	1			UNKNOWN	Topical	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020655s020lbl.pdf	Homo sapiens		h	1.75							false
1812	1045		ADULT	5757	272.382	ESTRADIOL	ESTRADIOL	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@H]2O	SERUM	4TI98Z838E							24		t	pg × h/mL	236		pg/mL	14.7			RECOMMENDED	mg	0.25		STEADY-STATE	UNKNOWN		day	1			UNKNOWN	Topical	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022038s005s006lbl.pdf	Homo sapiens		h	10							false
1813	1047			6013	288.4244	TESTOSTERONE	TESTOSTERONE	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O	PLASMA	3XMK78S47O													ng/dL	930.1				g	5		MULTIPLE			day	1				Topical		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01386606	Homo sapiens										false
1814	1047			6013	288.4244	TESTOSTERONE	TESTOSTERONE	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O	SERUM	3XMK78S47O							72		t	ng × h/dL	2120		ng/dL	214				mg	30		SINGLE							HEALTHY	Topical		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01725451	Homo sapiens										false
1815	1047			6013	288.4244	TESTOSTERONE	TESTOSTERONE	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O	SERUM	3XMK78S47O							72		t	ng × h/dL	3110		ng/dL	231				mg	30		SINGLE							HEALTHY	Topical		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01725451	Homo sapiens										false
1816	1047		ADULT	6013	288.4244	TESTOSTERONE	TESTOSTERONE	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O	PLASMA	3XMK78S47O							96		t	pg × h/mL	948		pg/mL	13.1			UNKNOWN	mg	8.2		SINGLE	UNKNOWN					13	UNHEALTHY	Topical	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10902784/	Homo sapiens		h	7							false
1817	1048		ADULT	441140	352.766	GRISEOFULVIN	griseofulvin	COC1=CC(OC)=C(Cl)C2=C1C(=O)[C@]3(O2)[C@H](C)CC(=O)C=C3OC	PLASMA	32HRV3E3D5									∞	μg × h/mL	21.1		μg/mL	1.25			INVESTIGATIONAL	mg	330		SINGLE	FED				Plasma, equilibrium dialysis (0.2 to 2 mcg/mL)	16	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://link.springer.com/article/10.1007/BF00547378	Homo sapiens		h	10.3							false
1818	1048		ADULT	441140	352.766	GRISEOFULVIN	griseofulvin	COC1=CC(OC)=C(Cl)C2=C1C(=O)[C@]3(O2)[C@H](C)CC(=O)C=C3OC	PLASMA	32HRV3E3D5									∞	ng × h/mL	25.9		μg/mL	1.39			INVESTIGATIONAL	mg	500		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://link.springer.com/article/10.1007/BF00547378	Homo sapiens		h	10.7							false
1819	1048		UNKNOWN	441140	352.766	GRISEOFULVIN	griseofulvin	COC1=CC(OC)=C(Cl)C2=C1C(=O)[C@]3(O2)[C@H](C)CC(=O)C=C3OC	UNKNOWN	32HRV3E3D5									?	ng × h/mL	8618.89		ng/mL	600.61			INVESTIGATIONAL	mg	250		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050475s057lbl.pdf	Homo sapiens										false
1820	1048		ADULT	441140	352.766	GRISEOFULVIN	griseofulvin	COC1=CC(OC)=C(Cl)C2=C1C(=O)[C@]3(O2)[C@H](C)CC(=O)C=C3OC	PLASMA	32HRV3E3D5									∞	ng × h/mL	18827.7		ng/mL	629.77			RECOMMENDED	mg	250		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	REVIEW	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/065200_ORIGINAL%20APPROVAL_PACKAGE.pdf	Homo sapiens		h	10.716							false
1821	1048		ADULT	441140	352.766	GRISEOFULVIN	griseofulvin	COC1=CC(OC)=C(Cl)C2=C1C(=O)[C@]3(O2)[C@H](C)CC(=O)C=C3OC	PLASMA	32HRV3E3D5									∞	ng × h/mL	20735.2		ng/mL	1310.28			RECOMMENDED	mg	250		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	REVIEW	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/065200_ORIGINAL%20APPROVAL_PACKAGE.pdf	Homo sapiens		h	9.043							false
1822	1049		UNKNOWN	3372	437.522	FLUPHENAZINE	FLUPHENAZINE	OCCN1CCN(CCCN2C3=C(SC4=C2C=C(C=C4)C(F)(F)F)C=CC=C3)CC1	PLASMA	S79426A41Z																						UNKNOWN				LC-triple quadrupole, % bound, 99.4	0.6	UNKNOWN		UNKNOWN	EXPERIMENT	https://www.agilent.com/cs/library/applications/5991-2497EN.pdf	Homo sapiens										false
1823	1049		UNKNOWN	3372	437.522	FLUPHENAZINE	FLUPHENAZINE	OCCN1CCN(CCCN2C3=C(SC4=C2C=C(C=C4)C(F)(F)F)C=CC=C3)CC1	PLASMA	S79426A41Z									∞	ng × h/mL	6.92		ng/mL	0.52			DEFINED DAILY	mg	10		SINGLE	FASTED						UNHEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/2313572	Homo sapiens		h	13							false
1824	1049		ADULT	3372	437.522	FLUPHENAZINE	FLUPHENAZINE	OCCN1CCN(CCCN2C3=C(SC4=C2C=C(C=C4)C(F)(F)F)C=CC=C3)CC1	PLASMA	S79426A41Z													ng/mL	2.3			UNKNOWN	mg	12		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/8911886	Homo sapiens		h	14.4							false
1825	1049		ADULT	3372	437.522	FLUPHENAZINE	FLUPHENAZINE	OCCN1CCN(CCCN2C3=C(SC4=C2C=C(C=C4)C(F)(F)F)C=CC=C3)CC1	PLASMA	S79426A41Z													ng/mL	261			UNKNOWN	mg	2.5		MULTIPLE	FASTED		3 days	3			HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/8911886	Homo sapiens		h	12.3							false
1826	1050		ADULT	6741	374.4706	METHYLPREDNISOLONE	METHYLPREDNISOLONE	C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]4(C)C=CC(=O)C=C14	PLASMA	X4W7ZR7023																						UNKNOWN				Methylprednisolone exhibits linear plasma protein binding averaging 77%	23	HEALTHY		UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/?term=3732369	Homo sapiens										false
1827	1050		ADULT	6741	374.5	METHYLPREDNISOLONE	METHYLPREDNISOLONE	C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]4(C)C=CC(=O)C=C14	PLASMA	X4W7ZR7023									?	ng × h/mL	931		ng/mL	213			UNKNOWN	mg	32		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/12174030	Homo sapiens		h	2.3							false
1828	1052		ADULT	43815	329.3654	PAROXETINE	PAROXETINE	FC1=CC=C(C=C1)[C@@H]2CCNC[C@H]2COC3=CC4=C(OCO4)C=C3	PLASMA	41VRH5220H							24		t	μg × h/mL	145		μg/mL	13.7			DEFINED DAILY	mg	30		SINGLE	UNKNOWN				Paroxetine is 93-95% plasma protein bound.	6	HEALTHY	Oral	MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/15992089/	Homo sapiens		h	9.8							false
1829	1052		ADULT	43815	329.3654	PAROXETINE	PAROXETINE	FC1=CC=C(C=C1)[C@@H]2CCNC[C@H]2COC3=CC4=C(OCO4)C=C3	PLASMA	41VRH5220H							24		t	μg × h/mL	1020		μg/mL	61.7			RECOMMENDED	mg	30		STEADY-STATE	UNKNOWN		day	1	Paroxetine is 93-95% plasma protein bound.		HEALTHY	Oral	MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/15992089/	Homo sapiens		h	21							false
1830	1053		ADULT	5360696	271.3972	DEXTROMETHORPHAN	DEXTROMETHORPHAN	COC1=CC=C2C[C@H]3[C@H]4CCCC[C@@]4(CCN3C)C2=C1	PLASMA	7355X3ROTS									?	nM × h	68							mg	30		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01361217	Homo sapiens										false
1831	1053		ADULT	5360696	271.3972	DEXTROMETHORPHAN	Dextromethorphan	COC1=CC=C2C[C@H]3[C@H]4CCCC[C@@]4(CCN3C)C2=C1	PLASMA	7355X3ROTS							8		t	ng × h/mL	17.8		ng/mL	2.9			UNKNOWN	mg	30		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15342614/	Homo sapiens										false
1832	1053		ADULT	5360696	271.3972	DEXTROMETHORPHAN	DEXTROMETHORPHAN	COC1=CC=C2C[C@H]3[C@H]4CCCC[C@@]4(CCN3C)C2=C1	PLASMA	7355X3ROTS							12		t	ng × h/mL	32		ng/mL	4.2			UNKNOWN	mg	45		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15342614/	Homo sapiens										false
1833	1053		ADULT	5360697	257.3706	DEXTRORPHAN	Dextrorphan	CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=CC=C(O)C=C34	PLASMA	04B7QNO9WS							12		t	ng × h/mL	2898		ng/mL	599			UNKNOWN	mg	45		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15342614/	Homo sapiens										false
1834	1053		ADULT	5360696	271.3972	DEXTROMETHORPHAN	DEXTROMETHORPHAN	COC1=CC=C2C[C@H]3[C@H]4CCCC[C@@]4(CCN3C)C2=C1	PLASMA	7355X3ROTS							12		t	ng × h/mL	52		ng/mL	7.7			UNKNOWN	mg	60		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15342614/	Homo sapiens										false
1835	1053		ADULT	5360697	257.3706	DEXTRORPHAN	Dextrorphan	CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=CC=C(O)C=C34	PLASMA	04B7QNO9WS							12		t	ng × h/mL	3608		ng/mL	709			UNKNOWN	mg	60		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15342614/	Homo sapiens										false
1836	1053		ADULT	5360696	271.3972	DEXTROMETHORPHAN	Dextromethorphan	COC1=CC=C2C[C@H]3[C@H]4CCCC[C@@]4(CCN3C)C2=C1	PLASMA	7355X3ROTS	441074		QUINIDINE	quinidine	COC1=CC2=C(C=C1)N=CC=C2[C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C	ITX08688JL	12		t	ng × h/mL	133.3		ng/mL	15.9			UNKNOWN	mg	30		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15342614/	Homo sapiens										true
1837	1053		ADULT	5360696	271.3972	DEXTROMETHORPHAN	Dextromethorphan	COC1=CC=C2C[C@H]3[C@H]4CCCC[C@@]4(CCN3C)C2=C1	PLASMA	7355X3ROTS	441074		QUINIDINE	quinidine	COC1=CC2=C(C=C1)N=CC=C2[C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C	ITX08688JL	12		t	ng × h/mL	1049		ng/mL	95.5			UNKNOWN	mg	30		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15342614/	Homo sapiens		h	13.1							true
1838	1053		ADULT	5360697	257.3706	DEXTRORPHAN	Dextrorphan	CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=CC=C(O)C=C34	PLASMA	04B7QNO9WS	441074		QUINIDINE	quinidine	COC1=CC2=C(C=C1)N=CC=C2[C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C	ITX08688JL	12		t	ng × h/mL	933.8		ng/mL	124.9			UNKNOWN	mg	30		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15342614/	Homo sapiens										true
1839	1053		ADULT	5360697	257.3706	DEXTRORPHAN	Dextrorphan	CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=CC=C(O)C=C34	PLASMA	04B7QNO9WS	441074		QUINIDINE	quinidine	COC1=CC2=C(C=C1)N=CC=C2[C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C	ITX08688JL	12		t	ng × h/mL	1000.5		ng/mL	123.5			UNKNOWN	mg	30		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15342614/	Homo sapiens										true
1840	1055		ADULT	1775|146015336	252.268	PHENYTOIN	PHENYTOIN	O=C1NC(=O)C(N1)(C2=CC=CC=C2)C3=CC=CC=C3	PLASMA	6158TKW0C5									∞	μg × h/mL	32.172		μg/mL	1.176			RECOMMENDED	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/anda/98/40-298_Phenytoin%20Sodium_Bioeqr.pdf	Homo sapiens		h	15.49							false
1841	1056		ADULT	3964	327.808	LOXAPINE	LOXAPINE	CN1CCN(CC1)C2=NC3=C(OC4=CC=C(Cl)C=C24)C=CC=C3	PLASMA	LER583670J									∞	ng × h/mL	188		ng/mL	257			RECOMMENDED	mg	10		SINGLE	UNKNOWN				Loxapine is 96.6% bound to human plasma proteins.	3.4	HEALTHY	Respiratory	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022549s000lbl.pdf	Homo sapiens		h	7.61							false
1842	1057		UNKNOWN	6230	298.4192	NORETHINDRONE	norethindrone	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C	PLASMA	T18F433X4S									∞	ng × h/mL	166.9		ng/mL	26.19			RECOMMENDED	mg	5		SINGLE	UNKNOWN				Norethindrone is 36% bound to sex hormone-binding globulin (SHBG) and 61% bound to albumin.	3	HEALTHY	Oral	FEMALE	DRUG LABEL	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=64cb920c-36e8-4d62-9d08-3ddf3989d313	Homo sapiens		h	8.51							false
1843	1058		ADULT	6918140	390.5	Treprostinil	Treprostinil	CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O	PLASMA	RUM6K67ESG									∞	ng × h/mL	2.46		ng/mL	0.54			UNKNOWN	mg	0.5		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24603117	Homo sapiens		h	1.06							false
1844	1058		ADULT	6918140	390.5	Treprostinil	Treprostinil	CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O	PLASMA	RUM6K67ESG							24		t	ng × h/mL	6.53		ng/mL	0.71			UNKNOWN	mg	0.5		MULTIPLE	FED		day	3			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24603117	Homo sapiens		h	1.34							false
1845	1058		UNKNOWN	6918140	390.5	Treprostinil	Treprostinil	CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O	PLASMA	RUM6K67ESG																						UNKNOWN				91% bound to human plasma protein.	9	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021272s020lbledt.pdf	Homo sapiens										false
1846	1060		ADULT	2083	239.3107	ALBUTEROL	Albuterol	CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1	SERUM	QF8SVZ843E									?	μg × min/L	3239						UNKNOWN	mg	1.5		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3653233/	Homo sapiens		min	237				16			false
1847	1060		ADULT	2083	239.3107	ALBUTEROL	Albuterol	CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1	SERUM	QF8SVZ843E									?	μg × min/L	3677		ng/mL	13			UNKNOWN	mg	4		SINGLE	FASTED				n=10 for AUC		HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3653233/	Homo sapiens				Liquid formulation			16			false
1848	1060		ADULT	2083	239.3107	ALBUTEROL	Albuterol	CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1	PLASMA	QF8SVZ843E																										The plasma protein binding of salbutamol was negligible. At 50 ng/ml, the binding in pooled blood bank plasma was 8% and at 200 ng/ml in three healthy volunteers the binding was 7 /- 1%.	92	HEALTHY		FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3790406/	Homo sapiens										false
1849	1060		ADULT	2083	239.3107	ALBUTEROL	Albuterol	CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1	PLASMA	QF8SVZ843E									∞	pg × h/mL	4268		pg/mL	1469			UNKNOWN	μg	180		SINGLE	UNKNOWN						HEALTHY	Respiratory	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9649352/	Homo sapiens		h	4.4				10			false
1850	1060		ADULT	2083	239.3107	ALBUTEROL	Albuterol	CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1	PLASMA	QF8SVZ843E																	UNKNOWN	μg	400		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-949_AccuNeb_BioPharmr.pdf#page=7	Homo sapiens		h	3.9	Loading dose (400 mcg iv) with a maintenance dose (20 mcg/min up to 2 h)			10			false
1851	1060		ADULT	2083	239.3107	ALBUTEROL	Albuterol	CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1	PLASMA	QF8SVZ843E							6		t	ng × h/mL	31.1		ng/mL	8.2			UNKNOWN	mg	4		UNKNOWN	FASTED		day	4			HEALTHY	Oral	MALE	EXPERIMENT	https://www.info.pmda.go.jp/go/interview/1/340278_2254001F1099_1_007_1F.pdf#page=28 | https://pubmed.ncbi.nlm.nih.gov/3793958/	Homo sapiens							12			false
1852	1060		ADULT	2083	239.3107	ALBUTEROL	Albuterol	CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1	PLASMA	QF8SVZ843E							12		t	ng × h/mL	72.6		ng/mL	14.7			UNKNOWN	mg	4		STEADY-STATE	FASTED		day	4			HEALTHY	Oral	MALE	EXPERIMENT	https://www.info.pmda.go.jp/go/interview/1/340278_2254001F1099_1_007_1F.pdf#page=28 | https://pubmed.ncbi.nlm.nih.gov/3793958/	Homo sapiens							12			false
1853	1060		ADULT	2083	239.3107	ALBUTEROL	Albuterol	CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1	PLASMA	QF8SVZ843E							12		t	ng × h/mL	77.4		ng/mL	15.1			UNKNOWN	mg	4		MULTIPLE	FASTED		day	4			HEALTHY	Oral	MALE	EXPERIMENT	https://www.info.pmda.go.jp/go/interview/1/340278_2254001F1099_1_007_1F.pdf#page=28 | https://pubmed.ncbi.nlm.nih.gov/3793958/	Homo sapiens		h	6.5	Final dose (22nd dose)			12			false
1854	1061		UNKNOWN	36462	588.5566	ETOPOSIDE	ETOPOSIDE	COC1=CC(=CC(OC)=C1O)[C@H]2[C@@H]3[C@H](COC3=O)[C@H](O[C@@H]4O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]4O)C6=C2C=C7OCOC7=C6	PLASMA	6PLQ3CP4P3																						UNKNOWN				In vitro, etoposide is highly protein bound (97%) to human plasma proteins.	3	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/019557s028lbl.pdf	Homo sapiens										false
1855	1061		ADULT	36462	588.5566	ETOPOSIDE	ETOPOSIDE	COC1=CC(=CC(OC)=C1O)[C@H]2[C@@H]3[C@H](COC3=O)[C@H](O[C@@H]4O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]4O)C6=C2C=C7OCOC7=C6	PLASMA	6PLQ3CP4P3									?	μg × min/mL	2707		μg/mL	14.7			UNKNOWN	mg/m²	80	infusion, 75 min	OTHER	UNKNOWN						UNHEALTHY	Intravenous	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/8431968	Homo sapiens		h	0.37							false
1856	1061		ADULT	36462	588.5566	ETOPOSIDE	ETOPOSIDE	COC1=CC(=CC(OC)=C1O)[C@H]2[C@@H]3[C@H](COC3=O)[C@H](O[C@@H]4O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]4O)C6=C2C=C7OCOC7=C6	PLASMA	6PLQ3CP4P3									?	μg × min/mL	5806		μg/mL	18.66			UNKNOWN	mg/m²	95	infusion, 75 min	OTHER	UNKNOWN						UNHEALTHY	Intravenous	FEMALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/8431968	Homo sapiens		h	0.32							false
1857	1062		ADULT	3001055	314.404	RANITIDINE	RANITIDINE	CNC(NCCSCC1=CC=C(CN(C)C)O1)=C[N+]([O-])=O	PLASMA	884KT10YB7									?	ng × h/mL	948.6						UNKNOWN	mg	80		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6094785/	Homo sapiens		h	1.69							false
1858	1062		ADULT	3001055	314.404	RANITIDINE	RANITIDINE	CNC(NCCSCC1=CC=C(CN(C)C)O1)=C[N+]([O-])=O	PLASMA	884KT10YB7													ng/mL	440			RECOMMENDED	mg	150		SINGLE	UNKNOWN				Serum protein binding averages 15%.	85	UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018703s068,019675s035,020251s019lbl.pdf	Homo sapiens		h	2.5							false
1859	1063		UNKNOWN	6436	434.4977	TRIAMCINOLONE ACETONIDE	TRIAMCINOLONE ACETONIDE	CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO	PLASMA	F446C597KA																						UNKNOWN					29	UNKNOWN	Respiratory	UNKNOWN	EXPERIMENT	https://www.jacionline.org/article/S0091-6749(98)70156-3/pdf	Homo sapiens		h	2							false
1860	1063		ADULT	6436	434.4977	TRIAMCINOLONE ACETONIDE	TRIAMCINOLONE ACETONIDE	CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO	PLASMA	F446C597KA									?	ng × h/mL	30.4		ng/mL	10.5			UNKNOWN	mg	5		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/7608322	Homo sapiens		h	2.6							false
1861	1064		ADULT	64929	318.752	FENOFIBRIC ACID	FENOFIBRIC ACID	CC(C)(OC1=CC=C(C=C1)C(=O)C2=CC=C(Cl)C=C2)C(O)=O	PLASMA	BGF9MN2HU1									∞	μg × h/mL	51.9		μg/mL	1.96			UNKNOWN	mg	67		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27648957	Homo sapiens		h	22.1							false
1862	1064		UNKNOWN	64929	318.752	FENOFIBRIC ACID	FENOFIBRIC ACID	CC(C)(OC1=CC=C(C=C1)C(=O)C2=CC=C(Cl)C=C2)C(O)=O	SERUM	BGF9MN2HU1																	RECOMMENDED	mg	160		MULTIPLE	UNKNOWN		day	1	Serum protein binding was approximately 99% in normal and hyperlipidemic subjects.	1	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021350s013lbl.pdf	Homo sapiens		h	16							false
1863	1066		ADULT	115237	426.5	Paliperidone		CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F	PLASMA	838F01T721									∞	ng × h/mL	257.3		ng/mL	7.5			RECOMMENDED	mg	3		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20589922/	Homo sapiens		h	22.8							false
1864	1066		ADULT	115237	426.4839	PALIPERIDONE	CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F	CC1=C(CCN2CCC(CC2)C3=NOC4=C3C=CC(F)=C4)C(=O)N5CCCC(O)C5=N1	PLASMA	838F01T721									∞	ng × h/mL	22.214		ng/mL	10.1			INVESTIGATIONAL	mg × eq	75		SINGLE	UNKNOWN						UNHEALTHY	Intramuscular	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26189570/	Homo sapiens		day	44.9							false
1865	1066		ADULT	115237	426.5	Paliperidone		CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F	PLASMA	838F01T721																	UNKNOWN				SINGLE	UNKNOWN					26	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021999s018lbl.pdf	Homo sapiens		h	23							false
1866	1066		ADULT	115237	426.4839	PALIPERIDONE	CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F	CC1=C(CCN2CCC(CC2)C3=NOC4=C3C=CC(F)=C4)C(=O)N5CCCC(O)C5=N1	PLASMA	838F01T721									∞	ng × h/mL	410						RECOMMENDED	mg	6		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.researchgate.net/profile/An_Vermeulen/publication/267692020_Population_Pharmacokinetics_of_Paliperidone_ER_in_Healthy_Subjects_and_Patients_With_Schizophrenia/links/5493e2b40cf22d7925da3fa6/Population-Pharmacokinetics-of-Paliperidone-ER-in-Healthy-Subjects-and-Patients-With-Schizophrenia.pdf	Homo sapiens										false
1867	1067		ADULT	4943	178.2707	PROPOFOL	PROPOFOL	CC(C)C1=CC=CC(C(C)C)=C1O	PLASMA	YI7VU623SF									∞	ng × h/mL	1.183		ng/mL	3.854			UNKNOWN	mg/kg	2		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/11753007	Homo sapiens		h	3.43							false
1868	1068		ADULT	2474	288.4277	BUPIVACAINE	BUPIVACAINE	CCCCN1CCCCC1C(=O)NC2=C(C)C=CC=C2C	PLASMA	Y8335394RO									∞	ng × h/mL	3868		ng/mL	952			RECOMMENDED	mg	75		SINGLE	UNKNOWN						UNHEALTHY	Epidural	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25776489/	Homo sapiens		h	3.9							false
1869	1068		ADULT	2474	288.4277	BUPIVACAINE	BUPIVACAINE	CCCCN1CCCCC1C(=O)NC2=C(C)C=CC=C2C	PLASMA	Y8335394RO									∞	ng × h/mL	4096		ng/mL	810			RECOMMENDED	mg	75		SINGLE	UNKNOWN						UNHEALTHY	Epidural	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25776489/	Homo sapiens		h	2.7							false
1870	1068		NEWBORN	2474	288.4277	BUPIVACAINE	BUPIVACAINE	CCCCN1CCCCC1C(=O)NC2=C(C)C=CC=C2C	BLOOD	Y8335394RO																	RECOMMENDED	mg/kg	2.5		SINGLE	UNKNOWN				This suggests caution in the use of bupivacaine in infants until we understand the clinical significance of this increased free fraction.	16	UNHEALTHY	Caudal	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3344993/	Homo sapiens		h	7.7							false
1871	1069		ADULT	5388962|40466924	376.4467	ENALAPRIL	Enalapril	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CCC[C@H]2C(O)=O	PLASMA	69PN84IO1A							168		t	ng × h/mL	84.9		ng/mL	44.27			UNKNOWN	mg	5		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29050316	Homo sapiens		h	10.75							false
1872	1069		ADULT	6917719	384.4241	ENALAPRILAT	enalaprilat	O.O.C[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N2CCC[C@H]2C(O)=O	PLASMA	GV0O7ES0R3							168		t	ng × h/mL	372.6		ng/mL	37.61			UNKNOWN	mg	5		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29050316	Homo sapiens		h	24.73							false
1873	1070		CHILD	4173	171.154	METRONIDAZOLE	METRONIDAZOLE	CC1=NC=C(N1CCO)[N+]([O-])=O	PLASMA	140QMO216E													mg/L	16.54			UNKNOWN	mg/kg	15		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01222585	Homo sapiens							19			false
1874	1070		ADULT	4173	171.154	METRONIDAZOLE	metronidazole	CC1=NC=C(N1CCO)[N+]([O-])=O	PLASMA	140QMO216E									∞	μg × h/mL	75.23		μg/mL	6.77			RECOMMENDED	mg	250		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22918856	Homo sapiens		h	7.76							false
1875	1070		ADULT	4173	171.154	METRONIDAZOLE	METRONIDAZOLE	CC1=NC=C(N1CCO)[N+]([O-])=O	PLASMA	140QMO216E													μg/mL	6			RECOMMENDED	mg	250		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/12623slr059_flagyl_lbl.pdf	Homo sapiens		h	8							false
1876	1070		ADULT	4173	171.154	METRONIDAZOLE	METRONIDAZOLE	CC1=NC=C(N1CCO)[N+]([O-])=O	PLASMA	140QMO216E													μg/mL	12			RECOMMENDED	mg	500		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/12623slr059_flagyl_lbl.pdf	Homo sapiens		h	8							false
1877	1070		ADULT	4173	171.154	METRONIDAZOLE	METRONIDAZOLE	CC1=NC=C(N1CCO)[N+]([O-])=O	PLASMA	140QMO216E													μg/mL	40			MAX DAILY	mg	2000		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/12623slr059_flagyl_lbl.pdf	Homo sapiens		h	8							false
1878	1070		ADULT	4173	171.154	METRONIDAZOLE	METRONIDAZOLE	CC1=NC=C(N1CCO)[N+]([O-])=O	PLASMA	140QMO216E													μg/mL	25			RECOMMENDED	mg/kg	7.5		STEADY-STATE	UNKNOWN		day	4			UNHEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/018890s052lbl.pdf	Homo sapiens										false
1879	1070		ADULT	4173	171.154	METRONIDAZOLE	METRONIDAZOLE	CC1=NC=C(N1CCO)[N+]([O-])=O	PLASMA	140QMO216E																	UNKNOWN				UNKNOWN	UNKNOWN				Less than 20% of the circulating metronidazole is bound to plasma proteins.	80	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/018890s052lbl.pdf	Homo sapiens		h	8							false
1880	1071		UNKNOWN	493570	376.4	RIBOFLAVIN	RIBOFLAVIN	CC1=CC2=C(C=C1C)N(C[C@@H](O)[C@@H](O)[C@@H](O)CO)C3=NC(=O)NC(=O)C3=N2	UNKNOWN	TLM2976OFR																	UNKNOWN	mg	10		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.glowm.com/resources/glowm/cd/pages/drugs/qr016.html	Homo sapiens		min	66							false
1881	1071		ADULT	493570	376.4	RIBOFLAVIN	RIBOFLAVIN	CC1=CC2=C(C=C1C)N(C[C@@H](O)[C@@H](O)[C@@H](O)CO)C3=NC(=O)NC(=O)C3=N2	PLASMA	TLM2976OFR							24		t	nM × h	674.2		nM	217.72			UNKNOWN	mg	20		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/8604671	Homo sapiens										false
1882	1072		ADULT	5344	267.304	SULFISOXAZOLE	SULFISOXAZOLE	CC1=NOC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1C	PLASMA	740T4C525W									?	μg × h/mL	874.15		μg/mL	111.85			UNKNOWN	g	2		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3907496	Homo sapiens		h	4.15							false
1883	1074		ADULT	5870	270.3661	ESTRONE	ESTRONE	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CCC2=O	PLASMA	2DI9HA706A							6		t	pg × h/mL	550		pg/mL	733			RECOMMENDED	mg	0.5		SINGLE	UNKNOWN						UNHEALTHY	Vaginal	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/908445/	Homo sapiens		h	3							false
1884	1075		ADULT	31307	394.4339	TRIAMCINOLONE	TRIAMCINOLONE	C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO	AQUEOUS HUMOR	1ZK20VI6TY							24		t	ng × h/mL	1911		ng/mL	7202			RECOMMENDED	mg	4		SINGLE	UNKNOWN						UNHEALTHY	Ocular	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022223,022048lbl.pdf	Homo sapiens		day	18.7							false
1885	1076		ADULT	441207	764.9391	DIGITOXIN	DIGITOXIN	C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5CC[C@]7(C)[C@H](CC[C@]67O)C8=CC(=O)OC8)C4)O[C@@H]3C)O[C@@H]2C	PLASMA	E90NZP2L9U	123619		ETORICOXIB	Etoricoxib	CC1=NC=C(C=C1)C2=NC=C(Cl)C=C2C3=CC=C(C=C3)S(C)(=O)=O	WRX4NFY03R	24		t	ng × h/mL	13.3		ng/mL	1.76			RECOMMENDED	mg	0.25		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18823299/	Homo sapiens										true
1886	1076		ADULT	441207	764.9391	DIGITOXIN	DIGITOXIN	C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5CC[C@]7(C)[C@H](CC[C@]67O)C8=CC(=O)OC8)C4)O[C@@H]3C)O[C@@H]2C	PLASMA	E90NZP2L9U							24		t	ng × h/mL	12.5		ng/mL	1.32			RECOMMENDED	mg	0.25		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18823299/	Homo sapiens										false
1887	1076		ADULT	441207	764.9391	DIGITOXIN	DIGITOXIN	C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5CC[C@]7(C)[C@H](CC[C@]67O)C8=CC(=O)OC8)C4)O[C@@H]3C)O[C@@H]2C	UNKNOWN	E90NZP2L9U																	RECOMMENDED	mg	0.5		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/914188/	Homo sapiens		day	9.5							false
1888	1076		ADULT	441207	764.9391	DIGITOXIN	DIGITOXIN	C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5CC[C@]7(C)[C@H](CC[C@]67O)C8=CC(=O)OC8)C4)O[C@@H]3C)O[C@@H]2C	UNKNOWN	E90NZP2L9U																	RECOMMENDED	mg	0.5		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/914188/	Homo sapiens		day	7.4							false
1889	1076		ADULT	441207	764.9391	DIGITOXIN	DIGITOXIN	C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5CC[C@]7(C)[C@H](CC[C@]67O)C8=CC(=O)OC8)C4)O[C@@H]3C)O[C@@H]2C	UNKNOWN	E90NZP2L9U																	RECOMMENDED	mg	0.5		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/914188/	Homo sapiens		day	9.7							false
1890	1077		ADULT	938|117629482	123.1094	NIACIN	NIACIN	OC(=O)C1=CC=CN=C1	PLASMA	2679MF687A							12		t	μg × min/mL	1150		μg/mL	5.39			UNKNOWN	mg	2000		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17463214/	Homo sapiens		min	30							false
1891	1080		ADULT	45357193	1347.4	HYDROXOCOBALAMIN	HYDROXOCOBALAMIN	CC1=CC2=C(C=C1C)N(C=N2)C3C(C(C(O3)CO)OP(=O)([O-])OC(C)CNC(=O)CCC4(C(C5C6(C(C(C(=N6)C(=C7C(C(C(=N7)C=C8C(C(C(=N8)C(=C4[N-]5)C)CCC(=O)N)(C)C)CCC(=O)N)(C)CC(=O)N)C)CCC(=O)N)(C)CC(=O)N)C)CC(=O)N)C)O.O.[Co+2]	PLASMA	Q40X8H422O									?	μM × h	4511.6						RECOMMENDED	g	5		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/8699553	Homo sapiens		h	26.2							false
1892	1081		ADULT		400.637	CALCIDIOL	CALCIDIOL		SERUM								672		t	nM × day	968.6		ng/mL	42			RECOMMENDED	mg	2.5		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18326608/	Homo sapiens		day	15.5							false
1893	1083		ADULT	3083544	344.4049	ARFORMOTEROL	ARFORMOTEROL	COC1=CC=C(C[C@@H](C)NC[C@H](O)C2=CC(NC=O)=C(O)C=C2)C=C1	PLASMA	F91H02EBWT							12		t	pg × h/mL	34.5		pg/mL	4.3			RECOMMENDED	μg	15		STEADY-STATE	UNKNOWN		day	2	The binding of arformoterol to human plasma proteins in vitro was 52-65% at concentrations of 0.25, 0.5 and 1.0 ng/mL of radiolabeled arformoterol.	48	UNKNOWN	Respiratory	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021912lbl.pdf	Homo sapiens		h	26							false
1894	1085		ADULT	3062316	488	DASATINIB	CC1=NC(=CC(NC2=NC=C(S2)C(=O)NC3=C(Cl)C=CC=C3C)=N1)N4CCN(CCO)CC4	CC1=NC(=CC(NC2=NC=C(S2)C(=O)NC3=C(Cl)C=CC=C3C)=N1)N4CCN(CCO)CC4	PLASMA	X78UG0A0RN									∞	ng × h/mL	397		ng/mL	82.2			UNKNOWN	mg	100		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://packageinserts.bms.com/pi/pi_sprycel.pdf	Homo sapiens		h	3							false
1895	1085		UNKNOWN	3062316	488	DASATINIB	CC1=NC(=CC(NC2=NC=C(S2)C(=O)NC3=C(Cl)C=CC=C3C)=N1)N4CCN(CCO)CC4	CC1=NC(=CC(NC2=NC=C(S2)C(=O)NC3=C(Cl)C=CC=C3C)=N1)N4CCN(CCO)CC4	PLASMA	X78UG0A0RN																						UNKNOWN				The serum protein binding of dasatinib was determined by equilibrium dialysis at 10 uM and was found to be 92, 97, 96, 97, and 94% in mouse, rat, dog, monkey and human, respectively.	6	UNKNOWN		UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/17429625	Homo sapiens										false
1896	1086		UNKNOWN	148123	807.3466	DOCETAXEL	DOCETAXEL	O.O.O.CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]3(C)[C@@H]2[C@H](OC(=O)C4=CC=CC=C4)[C@]5(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C6=CC=CC=C6)C(C)=C([C@@H](O)C3=O)C5(C)C	PLASMA	15H5577CQD																	UNKNOWN	mg/m²	100		MULTIPLE	UNKNOWN		hour	1	In vitro studies showed that docetaxel is about 94% protein bound, mainly to α1-acid glycoprotein, albumin, and lipoproteins. In three cancer patients, the in vitro binding to plasma proteins was found to be approximately 97%.	3	UNHEALTHY	Intravenous	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022234s000lbl.pdf	Homo sapiens		h	11.1							false
1897	1086		ADULT	148123	807.3466	DOCETAXEL	DOCETAXEL	O.O.O.CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]3(C)[C@@H]2[C@H](OC(=O)C4=CC=CC=C4)[C@]5(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C6=CC=CC=C6)C(C)=C([C@@H](O)C3=O)C5(C)C	PLASMA	15H5577CQD							25		t	nM × h	5562		nM	3737			UNKNOWN	mg/m²	100		MULTIPLE	UNKNOWN		3 weeks	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/17956601	Homo sapiens		h	0.74							false
1898	1086		ADULT	148123	807.3466	DOCETAXEL	DOCETAXEL	O.O.O.CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]3(C)[C@@H]2[C@H](OC(=O)C4=CC=CC=C4)[C@]5(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C6=CC=CC=C6)C(C)=C([C@@H](O)C3=O)C5(C)C	PLASMA	15H5577CQD							25		t	nM × h	1284		nM	742			UNKNOWN	mg/m²	20		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/17956601	Homo sapiens		h	0.99							false
1899	1087		ADULT	6918178	484.96	HALOBETASOL PROPIONATE	HALOBETASOL PROPIONATE	CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl	PLASMA	91A0K1TY3Z							12		t	pg × h/mL	1632		pg/mL	201.1			UNKNOWN	mg	1.75		STEADY-STATE	UNKNOWN		day	2			UNKNOWN	Topical	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208183s000lbl.pdf	Homo sapiens										false
1900	1087		ADULT	6918178	484.96	HALOBETASOL PROPIONATE	halobetasol propionate	CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl	PLASMA	91A0K1TY3Z							12		t	pg × h/mL	1434.9		pg/mL	199.7			RECOMMENDED	mg	1.85		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Topical	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210566s001lbl.pdf	Homo sapiens										false
1901	1088		ADULT		459.5	L-5-methyltetrahydrofolate	L-5-methyltetrahydrofolate		PLASMA		5991		ETHINYL ESTRADIOL	ethinylestradiol	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@]2(O)C#C	423D2T571U	12		t	nM × h	370		nM	57.7			RECOMMENDED	mg	0.451		SINGLE	FASTED				https://go.drugbank.com/drugs/DB11256	44	HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22909145/	Homo sapiens		h	5.5							true
1902	1089		ADULT	4369359	407.3136	SITAGLIPTIN	SITAGLIPTIN	N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC3=C(F)C=C(F)C(F)=C3	PLASMA	QFP0P1DV7Z									?	μM × h	8.52		nM	950			UNKNOWN	mg	100		SINGLE	UNKNOWN				The fraction of sitagliptin reversibly bound to plasma proteins is low (38%).	62	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022044s046lbl.pdf	Homo sapiens		h	12.4							false
1903	1090		ADULT	15541	332.3496	SPECTINOMYCIN	SPECTINOMYCIN	CN[C@@H]1[C@H](O)[C@H](NC)[C@H]2O[C@]3(O)[C@@H](O[C@H](C)CC3=O)O[C@@H]2[C@H]1O	PLASMA	93AKI1U6QF							8		t	μg × h/mL	460		μg/mL	100			RECOMMENDED	g	2		SINGLE	UNKNOWN				The antibiotic is not significantly bound to plasma protein	100	UNKNOWN	Intramuscular	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050347s060lbl.pdf	Homo sapiens		h	1.7							false
1904	1091		ADULT	5401	387.4329	TERAZOSIN	TERAZOSIN	COC1=CC2=NC(=NC(N)=C2C=C1OC)N3CCN(CC3)C(=O)C4CCCO4	PLASMA	8L5014XET7									∞	ng × h/mL	408		ng/mL	48			RECOMMENDED	mg	2		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1685091	Homo sapiens		h	8.4							false
1905	1091		ADULT	5401	387.4329	TERAZOSIN	TERAZOSIN	COC1=CC2=NC(=NC(N)=C2C=C1OC)N3CCN(CC3)C(=O)C4CCCO4	PLASMA	8L5014XET7									∞	ng × h/mL	418		ng/mL	37			RECOMMENDED	mg	2		SINGLE	FED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1685091	Homo sapiens		h	9.5							false
1906	1091		UNKNOWN	5401	387.4329	TERAZOSIN	TERAZOSIN	COC1=CC2=NC(=NC(N)=C2C=C1OC)N3CCN(CC3)C(=O)C4CCCO4	PLASMA	8L5014XET7																						UNKNOWN				The protein binding of terazosin was assessed in human plasma by ultrafiltration. Terazosin was approximately 90 to 94 percent bound to plasma proteins	8	UNKNOWN		UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2872802	Homo sapiens										false
1907	1092		ADULT	6834	319.239	BROMPHENIRAMINE	BROMPHENIRAMINE	CN(C)CCC(C1=CC=C(Br)C=C1)C2=NC=CC=C2	PLASMA	H57G17P2FN									∞	ng × h/mL	284		ng/mL	11.6			UNKNOWN	mg/kg	0.13		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6128358/	Homo sapiens		h	24.9							false
1908	1094		UNKNOWN	3672	206.2808	IBUPROFEN	Ibuprofen	CC(C)CC1=CC=C(C=C1)C(C)C(O)=O	PLASMA	WK2XYI10QM																						UNKNOWN				Ibuprofen displays extensive (99%) binding to plasma proteins.	1	UNKNOWN		UNKNOWN	REVIEW	https://onlinelibrary.wiley.com/doi/10.1002/9781118743614.ch4	Homo sapiens										false
1909	1094		ADULT	3672	206.1307	IBUPROFEN	IBUPROFEN	CC(C)CC1=CC=C(C=C1)C(C)C(O)=O	PLASMA	WK2XYI10QM									∞	μg × h/mL	103		μg/mL	27.9			UNKNOWN	mg	400		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	REVIEW	https://www.ncbi.nlm.nih.gov/pubmed/6465162	Homo sapiens		h	2.2							false
1910	1095		ADULT	3007	135.2062	AMPHETAMINE	AMPHETAMINE	CC(N)CC1=CC=CC=C1	PLASMA	CK833KGX7E									∞	ng × h/mL	1727		ng/mL	120			UNKNOWN	mg	40.3		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28936175/	Homo sapiens		h	7.9							false
1911	1096		ADULT	5826	135.2062	DEXTROAMPHETAMINE	DEXTROAMPHETAMINE	C[C@H](N)CC1=CC=CC=C1	PLASMA	TZ47U051FI									∞	ng × h/mL	431		ng/mL	24.7			RECOMMENDED	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9807980/	Homo sapiens		h	12.1							false
1912	1096		ADULT	5826	135.2062	DEXTROAMPHETAMINE	dextroamphetamine	C[C@H](N)CC1=CC=CC=C1	PLASMA	TZ47U051FI													ng/mL	36.6			RECOMMENDED	mg	15		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/040361Orig1s017lbl.pdf	Homo sapiens		h	12							false
1913	1097		ADULT	6604200	238.157	NITROFURANTOIN	NITROFURANTOIN	[O-][N+](=O)C1=CC=C(O1)\\C=N\\N2CC(=O)NC2=O	PLASMA	927AH8112L							24		t	mg × h/L	4.43		mg/L	0.326			UNKNOWN	mg	50		STEADY-STATE	UNKNOWN		day	4			HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30859184	Homo sapiens		h	2.3							false
1914	1097		ADULT	6604200	238.157	NITROFURANTOIN	NITROFURANTOIN	[O-][N+](=O)C1=CC=C(O1)\\C=N\\N2CC(=O)NC2=O	PLASMA	927AH8112L							24		t	mg × h/L	6.49		mg/L	0.69			UNKNOWN	mg	100		STEADY-STATE	UNKNOWN		day	3			HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30859184	Homo sapiens		h	1.7							false
1915	1097		UNKNOWN	6604200	238.157	NITROFURANTOIN	NITROFURANTOIN	[O-][N+](=O)C1=CC=C(O1)\\C=N\\N2CC(=O)NC2=O	PLASMA	927AH8112L																	UNKNOWN				UNKNOWN	UNKNOWN				During nitrofurantoin treatment about 90% of the drug is bound to plasma proteins.	10	UNKNOWN	UNKNOWN	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7085535	Homo sapiens										false
1916	1098		ADULT	5578	290.3177	TRIMETHOPRIM	TRIMETHOPRIM	COC1=CC(CC2=C(N)N=C(N)N=C2)=CC(OC)=C1OC	PLASMA	AN164J8Y0X							24		t	μg × h/mL	30.7		μg/mL	2.1			UNKNOWN	g	2		SINGLE	UNKNOWN						UNKNOWN	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/5416179/	Homo sapiens										false
1917	1098		ADULT	5578	290.3177	TRIMETHOPRIM	TRIMETHOPRIM	COC1=CC(CC2=C(N)N=C(N)N=C2)=CC(OC)=C1OC	PLASMA	AN164J8Y0X													μg/mL	1			RECOMMENDED	g	1		SINGLE	UNKNOWN				Approximately 44% of trimethoprim is bound to plasma proteins.	56	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018679s044lbl.pdf	Homo sapiens		h	10							false
1918	1099		ADULT	5360515	341.4009	NALTREXONE	naltrexone	OC1=CC=C2C[C@H]3N(CC4CC4)CC[C@@]56[C@@H](OC1=C25)C(=O)CC[C@@]36O	PLASMA	5S6W795CQM																	RECOMMENDED	mg	380		SINGLE	UNKNOWN				In vitro data demonstrate that naltrexone plasma protein binding is low (21%).	79	UNKNOWN	Intramuscular	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021897s015lbl.pdf	Homo sapiens		h	180							false
1919	1099		ADULT	5360515	341.4009	NALTREXONE	naltrexone	OC1=CC=C2C[C@H]3N(CC4CC4)CC[C@@]56[C@@H](OC1=C25)C(=O)CC[C@@]36O	PLASMA	5S6W795CQM									∞	ng × h/mL	3.4		ng/mL	9.7			INVESTIGATIONAL	mg	190		SINGLE	UNKNOWN						HEALTHY	Intramuscular	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/16239359	Homo sapiens		day	5.6							false
1920	1100		ADULT	5587	255.358	TRIPELENNAMINE	TRIPELENNAMINE	CN(C)CCN(CC1=CC=CC=C1)C2=NC=CC=C2	PLASMA	3C5ORO99TY									∞	ng × h/mL	398		ng/mL	82			UNKNOWN	mg	50		SINGLE	UNKNOWN						HEALTHY	Intramuscular	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3709032	Homo sapiens		h	2.9							false
1921	1100		ADULT	5587	255.358	TRIPELENNAMINE	TRIPELENNAMINE	CN(C)CCN(CC1=CC=CC=C1)C2=NC=CC=C2	PLASMA	3C5ORO99TY									∞	ng × h/mL	804		ng/mL	199			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Intramuscular	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3709032	Homo sapiens		h	4.4							false
1922	1101		ADULT	135398745	312.432	OLANZAPINE	OLANZAPINE	CN1CCN(CC1)C2=NC3=C(NC4=C2C=C(C)S4)C=CC=C3	PLASMA	N7U69T4SZR									?	ng × h/mL	712		ng/mL	17.3			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/12895191	Homo sapiens		h	28.7							false
1923	1102		ADULT	5258|15585	186.1829	SODIUM PHENYLBUTYRATE	SODIUM PHENYLBUTYRATE	[Na+].[O-]C(=O)CCCC1=CC=CC=C1	PLASMA	NT6K61736T									?	μM × h	925.5		μM	457.9			UNKNOWN	g	9		MULTIPLE	FED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11489804	Homo sapiens		h	0.76							false
1924	1102		ADULT	5258|15585	186.1829	SODIUM PHENYLBUTYRATE	SODIUM PHENYLBUTYRATE	[Na+].[O-]C(=O)CCCC1=CC=CC=C1	PLASMA	NT6K61736T									?	μM × h	2170.6		μM	949.9			UNKNOWN	g	18		MULTIPLE	FED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11489804	Homo sapiens		h	0.61							false
1925	1102		ADULT	5258|15585	186.1829	SODIUM PHENYLBUTYRATE	SODIUM PHENYLBUTYRATE	[Na+].[O-]C(=O)CCCC1=CC=CC=C1	PLASMA	NT6K61736T									?	μM × h	3778.6		μM	1679.8			RECOMMENDED	g	27		MULTIPLE	FED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11489804	Homo sapiens		h	0.58							false
1926	1102		ADULT	5258|15585	186.1829	SODIUM PHENYLBUTYRATE	SODIUM PHENYLBUTYRATE	[Na+].[O-]C(=O)CCCC1=CC=CC=C1	PLASMA	NT6K61736T									?	μM × h	4687.4		μM	1878.3			UNKNOWN	g	36		MULTIPLE	FED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11489804	Homo sapiens		h	0.94							false
1927	1102		ADULT	5258|15585	186.1829	SODIUM PHENYLBUTYRATE	SODIUM PHENYLBUTYRATE	[Na+].[O-]C(=O)CCCC1=CC=CC=C1	PLASMA	NT6K61736T									?	μM × h	4941.4		μM	1669.4			UNKNOWN	g	45		MULTIPLE	FED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11489804	Homo sapiens		h	1.16							false
1928	1102		UNKNOWN	5258|15585	186.1829	SODIUM PHENYLBUTYRATE	SODIUM PHENYLBUTYRATE	[Na+].[O-]C(=O)CCCC1=CC=CC=C1	PLASMA	NT6K61736T																	UNKNOWN				UNKNOWN	UNKNOWN				Albumin is the major binding protein for phenylbutyrate in human plasma (99.7%).	0.3	UNKNOWN	UNKNOWN	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8946671	Homo sapiens										false
1929	1102		ADULT	5258|15585	186.1829	SODIUM PHENYLBUTYRATE	SODIUM PHENYLBUTYRATE	[Na+].[O-]C(=O)CCCC1=CC=CC=C1	PLASMA	NT6K61736T													μg/mL	218			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020572s016,020573s015lbl.pdf	Homo sapiens		h	0.77							false
1930	1103		UNKNOWN	1986	222.245	ACETAZOLAMIDE	ACETAZOLAMIDE	CC(=O)NC1=NN=C(S1)S(N)(=O)=O	PLASMA	O3FX965V0I																	UNKNOWN				UNKNOWN	UNKNOWN				After oral ingestion, acetazolamide is rapidly absorbed (Tmax = 2-4 h) with a bioavailability of >90 %. Its volume of distribution is 0.3 L/kg, and plasma protein binding is 90–95 %.	5	UNKNOWN	Oral	UNKNOWN	REVIEW	https://link.springer.com/chapter/10.1007/978-1-4471-2434-4_1	Homo sapiens										false
1931	1103		ADULT	1986	222.245	ACETAZOLAMIDE	ACETAZOLAMIDE	CC(=O)NC1=NN=C(S1)S(N)(=O)=O	PLASMA	O3FX965V0I							24		t	ng × h/mL	6735		ng/mL	1313			UNKNOWN	mg	15		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27300254	Homo sapiens		h	13.1							false
1932	1103		ADULT	1986	222.245	ACETAZOLAMIDE	ACETAZOLAMIDE	CC(=O)NC1=NN=C(S1)S(N)(=O)=O	BLOOD	O3FX965V0I							96		t	ng × h/mL	52130		ng/mL	776			UNKNOWN	mg	15		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27300254	Homo sapiens		h	42.4							false
1933	1104		ADULT	4071|667490	152.177	MERCAPTOPURINE ANHYDROUS	6-Mercaptopurine	S=C1NC=NC2=C1N=CN2	PLASMA	PKK6MUZ20G									∞	ng × h/mL	135.8		ng/mL	69.5			UNKNOWN	mg	600		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/9048271	Homo sapiens										false
1934	1105		ADULT	20469	408.916	BECLOMETHASONE	BECLOMETHASONE	C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO	PLASMA	KGZ1SLC28Z									∞	pg × h/mL	283.5		pg/mL	3103.4			RECOMMENDED	μg	160		SINGLE	FASTED						HEALTHY	Respiratory	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28937845	Homo sapiens		h	0.57							false
1935	1105		ADULT	20469	408.916	BECLOMETHASONE	BECLOMETHASONE	C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO	PLASMA	KGZ1SLC28Z									∞	pg × h/mL	623.6		pg/mL	6635.1			RECOMMENDED	μg	320		SINGLE	FASTED						HEALTHY	Respiratory	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28937845	Homo sapiens		h	0.92							false
1936	1105		UNKNOWN	20469	408.916	BECLOMETHASONE	BECLOMETHASONE	C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO	PLASMA	KGZ1SLC28Z													pg/mL	88			RECOMMENDED	μg	320		SINGLE	UNKNOWN						UNKNOWN	Respiratory	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020911s029s030lbl.pdf	Homo sapiens										false
1937	1105		ADULT	62965	464.979	BECLOMETHASONE 17-MONOPROPIONATE	BECLOMETHASONE 17-MONOPROPIONATE	CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C)C(=O)CO	PLASMA	5BGA9FD55H									∞	pg × h/mL	1661.53		pg/mL	262.65			RECOMMENDED	μg	320		SINGLE	UNKNOWN						HEALTHY	Nasal	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf	Homo sapiens		h	4.457							false
1938	1105		ADULT	20469	408.916	BECLOMETHASONE	BECLOMETHASONE	C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO	PLASMA	KGZ1SLC28Z									∞	pg × h/mL	88.23		pg/mL	181.95			RECOMMENDED	μg	320		SINGLE	UNKNOWN						HEALTHY	Nasal	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf	Homo sapiens		h	0.278							false
1939	1105		UNKNOWN	20469	408.916	BECLOMETHASONE	BECLOMETHASONE	C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO	PLASMA	KGZ1SLC28Z																						UNKNOWN				Plasma protein binding is moderately high (87%)	13	UNKNOWN		UNKNOWN	OTHER GOV'T	https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Beconase_AQ/pdf/BECONASE-PI-PIL.PDF	Homo sapiens										false
1940	1106		ADULT	2381	311.4611	BIPERIDEN	BIPERIDEN	OC(CCN1CCCCC1)(C2CC3CC2C=C3)C4=CC=CC=C4	PLASMA								24		t	ng × h/mL	62.8		ng/mL	13.5			RECOMMENDED	mg	4		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3709619/	Homo sapiens		h	24.3							false
1941	1107		ADULT	441199	427.452	CEFOXITIN	CEFOXITIN	CO[C@]2(NC(=O)CC1=CC=CS1)[C@H]3SCC(COC(N)=O)=C(N3C2=O)C(O)=O	PLASMA	6OEV9DX57Y							4		t	μg × h/mL	33.5		μg/mL	24			RECOMMENDED	g	1		SINGLE	UNKNOWN					27	UNKNOWN	Intramuscular	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/318227/	Homo sapiens		h	0.67							false
1942	1109		ADULT	2756	252.339	CIMETIDINE	CIMETIDINE	CNC(NCCSCC1=C(C)NC=N1)=NC#N	PLASMA	80061L1WGD									∞	μg × h/mL	4.22		μg/mL	1.056			RECOMMENDED	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/anda/98/75285_Cimetidine.pdf	Homo sapiens		h	2.4							false
1943	1111		ADULT	62956	435.4935	FOSINOPRILAT	fosinoprilat	OC(=O)[C@@H]1C[C@H](CN1C(=O)CP(O)(=O)CCCCC2=CC=CC=C2)C3CCCCC3	SERUM	S312EY6ZT8							24		t	μg × h/mL	1.1		ng/mL	131			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1646240/	Homo sapiens										false
1944	1111		ADULT	62956	435.4935	FOSINOPRILAT	fosinoprilat	OC(=O)[C@@H]1C[C@H](CN1C(=O)CP(O)(=O)CCCCC2=CC=CC=C2)C3CCCCC3	SERUM	S312EY6ZT8							24		t	μg × h/mL	58.3		ng/mL	5598			UNKNOWN	mg	640		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1646240/	Homo sapiens										false
1945	1111		ADULT	62956	435.4935	FOSINOPRILAT	fosinoprilat	OC(=O)[C@@H]1C[C@H](CN1C(=O)CP(O)(=O)CCCCC2=CC=CC=C2)C3CCCCC3	SERUM	S312EY6ZT8							12		t	μg × h/mL	3.3		ng/mL	533			UNKNOWN	mg	40		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1646240/	Homo sapiens										false
1946	1111		ADULT	62956	435.4935	FOSINOPRILAT	fosinoprilat	OC(=O)[C@@H]1C[C@H](CN1C(=O)CP(O)(=O)CCCCC2=CC=CC=C2)C3CCCCC3	SERUM	S312EY6ZT8							12		t	μg × h/mL	4.9		ng/mL	711			UNKNOWN	mg	40		STEADY-STATE	FASTED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1646240/	Homo sapiens										false
1947	1111		ADULT	62956	435.4935	FOSINOPRILAT	fosinoprilat	OC(=O)[C@@H]1C[C@H](CN1C(=O)CP(O)(=O)CCCCC2=CC=CC=C2)C3CCCCC3	SERUM	S312EY6ZT8							12		t	μg × h/mL	5.6		ng/mL	1018			UNKNOWN	mg	80		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1646240/	Homo sapiens										false
1948	1111		ADULT	62956	435.4935	FOSINOPRILAT	fosinoprilat	OC(=O)[C@@H]1C[C@H](CN1C(=O)CP(O)(=O)CCCCC2=CC=CC=C2)C3CCCCC3	SERUM	S312EY6ZT8							12		t	μg × h/mL	7.5		ng/mL	1217			UNKNOWN	mg	80		STEADY-STATE	FASTED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1646240/	Homo sapiens										false
1949	1111		ADULT	62956	435.4935	FOSINOPRILAT	FOSINOPRILAT	OC(=O)[C@@H]1C[C@H](CN1C(=O)CP(O)(=O)CCCCC2=CC=CC=C2)C3CCCCC3	PLASMA	S312EY6ZT8									∞	ng × h/mL	3302		ng/mL	1556			UNKNOWN	mg	7.5		SINGLE	UNKNOWN					5	HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2967089/	Homo sapiens		h	3.7							false
1950	1111		ADULT	62956	435.4935	FOSINOPRILAT	FOSINOPRILAT	OC(=O)[C@@H]1C[C@H](CN1C(=O)CP(O)(=O)CCCCC2=CC=CC=C2)C3CCCCC3	PLASMA	S312EY6ZT8									∞	ng × h/mL	920		ng/mL	112			DEFINED DAILY	mg	10		SINGLE	UNKNOWN				After either oral dose of [14C]-fosinopril sodium the binding of radioactivity to plasma proteins averaged 89% at 1h and 92% at 3h.	8	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2967089/	Homo sapiens		h	4.3							false
1951	1113		ADULT		312.4094	GRANISETRON	GRANISETRON	CN1N=C(C(=O)N[C@@H]2C[C@@H]3CCC[C@H](C2)N3C)C4=C1C=CC=C4	PLASMA	WZG3J2MCOL									∞	ng × h/mL	36.87		ng/mL	4.948			UNKNOWN	μg/kg bw	10		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/22452942	Homo sapiens		h	5							false
1952	1114		ADULT	3658	374.904	HYDROXYZINE	Hydroxyzine	OCCOCCN1CCN(CC1)C(C2=CC=CC=C2)C3=CC=C(Cl)C=C3	PLASMA	30S50YM8OG							72		t	ng × h/mL	479.174		ng/mL	31.371			DEFINED DAILY	mg	25		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	http://mri.cts-mrp.eu/download/DK_H_2313_001_PAR.pdf	Homo sapiens		h	18.4							false
1953	1114		ADULT	3658	374.904	HYDROXYZINE	hydroxyzine	OCCOCCN1CCN(CC1)C(C2=CC=CC=C2)C3=CC=C(Cl)C=C3	SERUM	30S50YM8OG													ng/mL	72.5			DEFINED DAILY	mg/kg bw	0.7		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6141198/	Homo sapiens		h	20							false
1954	1114		ADULT	3658	374.904	HYDROXYZINE	Hydroxyzine	OCCOCCN1CCN(CC1)C(C2=CC=CC=C2)C3=CC=C(Cl)C=C3	PLASMA	30S50YM8OG													ng/mL	72.5			DEFINED DAILY	mg/kg bw	0.7		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://www.jacionline.org/article/0091-6749(84)90486-X/pdf	Homo sapiens		h	20							false
1955	1115		ADULT	3696	280.4	Imipramine	Imipramine	CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31	PLASMA	OGG85SX4E4									∞	ng × h/mL	427		ng/mL	24.5			INVESTIGATIONAL	mg	50		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER	https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1016/S0009-9236%2897%2990062-X	Homo sapiens		h	21.1							false
1956	1115		ADULT	3696	280.4	Imipramine	Imipramine	CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31	PLASMA	OGG85SX4E4	2995		Desipramine	Desipramine	CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31	TG537D343B							μg/L	107			DEFINED DAILY	mg	130		STEADY-STATE	UNKNOWN		day	1	It is known to bind albumin, α1-acid glycoprotein, and lipoproteins	22	HEALTHY	Oral	MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/2185906/	Homo sapiens		h	12							true
1957	1116		ADULT	441335	427.361	MOMETASONE	MOMETASONE	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl	PLASMA	8HR4QJ6DW8							24		t	pg × h/mL	1560		pg/mL	183			UNKNOWN	μg	320		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Respiratory	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26845343	Homo sapiens										false
1958	1116		ADULT	441335	427.361	MOMETASONE	MOMETASONE	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl	PLASMA	8HR4QJ6DW8									∞	pg × h/mL	92		pg/mL	7.56			RECOMMENDED	μg	100		SINGLE	FASTED						HEALTHY	Nasal	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29669668	Homo sapiens		h	19.24							false
1959	1116		UNKNOWN	441335	427.361	MOMETASONE	MOMETASONE	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl	PLASMA	8HR4QJ6DW8																						UNKNOWN				The in vitro protein binding for mometasone furoate was reported to be 98% to 99% in concentration range of 5 to 500 ng/mL	1.5	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020762s053lbl.pdf	Homo sapiens										false
1960	1117		ADULT	4634	357.4864	OXYBUTYNIN	OXYBUTYNIN	CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)C2=CC=CC=C2	PLASMA	K9P6MC7092							5		t	ng × h/mL	9.24		ng/mL	6.73			RECOMMENDED	mg	5		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3234461/	Homo sapiens		h	2.44							false
1961	1118		ADULT	6041	167.205	PHENYLEPHRINE	phenylephrine	CNC[C@H](O)C1=CC(O)=CC=C1	PLASMA	1WS297W6MV									∞	pg × h/mL	955.8		pg/mL	1354			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26267590	Homo sapiens		h	1.89							false
1962	1118		ADULT	6041	167.205	PHENYLEPHRINE	PHENYLEPHRINE	CNC[C@H](O)C1=CC(O)=CC=C1	PLASMA	1WS297W6MV									∞	pg × h/mL	2346		pg/mL	2959			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26267590	Homo sapiens		h	1.93							false
1963	1118		ADULT	6041	167.205	PHENYLEPHRINE	PHENYLEPHRINE	CNC[C@H](O)C1=CC(O)=CC=C1	PLASMA	1WS297W6MV									∞	pg × h/mL	3900		pg/mL	4492			UNKNOWN	mg	30		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26267590	Homo sapiens		h	1.64							false
1964	1119		ADULT	4906	220.3107	PRILOCAINE	prilocaine	CCCNC(C)C(=O)NC1=C(C)C=CC=C1	PLASMA	046O35D44R	3676		LIDOCAINE	Lidocaine	CCN(CC)CC(=O)NC1=C(C)C=CC=C1C	98PI200987			∞	ng × min/mL	26000		ng/mL	106			RECOMMENDED	mg	42.5		MULTIPLE	UNKNOWN		3 hours	5			UNKNOWN	Buccal	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021451s008lbl.pdf	Homo sapiens		h	2.8							true
1965	1119		UNKNOWN	4906	220.3107	PRILOCAINE	PRILOCAINE	CCCNC(C)C(=O)NC1=C(C)C=CC=C1	PLASMA	046O35D44R	3676		LIDOCAINE	lidocaine	CCN(CC)CC(=O)NC1=C(C)C=CC=C1C	98PI200987							μg/mL	0.07			UNKNOWN	g	1.5		SINGLE	UNKNOWN				Prilocaine is 55% bound to plasma proteins.	45	UNKNOWN	Topical	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019941s021lbl.pdf	Homo sapiens										true
1966	1119		UNKNOWN	4906	220.3107	PRILOCAINE	PRILOCAINE	CCCNC(C)C(=O)NC1=C(C)C=CC=C1	PLASMA	046O35D44R																	UNKNOWN				SINGLE	UNKNOWN						UNKNOWN	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019941s021lbl.pdf	Homo sapiens		min	70							false
1967	1120		ADULT	5505	270.348	TOLBUTAMIDE	TOLBUTAMIDE	CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1	PLASMA	982XCM1FOI																	UNKNOWN	mg/kg bw	20		SINGLE	FED				Approximately 95% was bound as determined by the ultracentrifugation method.	5	HEALTHY	Intravenous	MALE	EXPERIMENT	https://link.springer.com/article/10.1007%2FBF00614021	Homo sapiens		min	418							false
1968	1120		ADULT	5505	270.348	TOLBUTAMIDE	TOLBUTAMIDE	CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1	PLASMA	982XCM1FOI							48		t	μg × h/mL	998.42		μg/mL	51.1			DEFINED DAILY	g	1		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9021442/	Homo sapiens										false
1969	1121		ADULT	4771	149.2328	PHENTERMINE	PHENTERMINE	CC(C)(N)CC1=CC=CC=C1	PLASMA	C045TQL4WP	5284627		TOPIRAMATE	topiramate	CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1	0H73WJJ391			∞	ng × h/mL	2057.33		ng/mL	44.78			UNKNOWN	mg	7.5		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25668796	Homo sapiens		h	20.63							true
1970	1121		UNKNOWN	4771	149.2328	PHENTERMINE	PHENTERMINE	CC(C)(N)CC1=CC=CC=C1	PLASMA	C045TQL4WP	5284627		TOPIRAMATE	Topiramate	CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1	0H73WJJ391			∞	ng × h/mL	2000		ng/mL	49.1			RECOMMENDED	mg	15		SINGLE	UNKNOWN				Phentermine is 17.5% plasma protein bound	82.5	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000ClinPharmR.pdf	Homo sapiens		h	20							true
1971	1123		ADULT	4614|52326892	293.3166	OXAPROZIN	OXAPROZIN	OC(=O)CCC1=NC(=C(O1)C2=CC=CC=C2)C3=CC=CC=C3	PLASMA	MHJ80W9LRB									?	μg × h/mL	7042		μg/mL	103			DEFINED DAILY	g	1.2		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6480879/	Homo sapiens		h	50							false
1972	1123		ADULT	4614|52326892	293.3166	OXAPROZIN	OXAPROZIN	OC(=O)CCC1=NC(=C(O1)C2=CC=CC=C2)C3=CC=CC=C3	PLASMA	MHJ80W9LRB									?	μg × h/mL	7066		μg/mL	109			DEFINED DAILY	g	1.2		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6480879/	Homo sapiens		h	48							false
1973	1123		ADULT	4614|52326892	293.3166	OXAPROZIN	OXAPROZIN	OC(=O)CCC1=NC(=C(O1)C2=CC=CC=C2)C3=CC=CC=C3	PLASMA	MHJ80W9LRB							24		t	mg × h/L	4210		mg/L	239			RECOMMENDED	g	1.2		STEADY-STATE	FASTED		day	1		0.457	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8973987/	Homo sapiens		h	41.4	Total drug, Day 8						false
1974	1123		ADULT	4614|52326892	293.3166	OXAPROZIN	OXAPROZIN	OC(=O)CCC1=NC(=C(O1)C2=CC=CC=C2)C3=CC=CC=C3	PLASMA	MHJ80W9LRB							24		t	mg × h/L	4770		mg/L	280			UNKNOWN	g	1.8		STEADY-STATE	FASTED		day	1		0.823	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8973987/	Homo sapiens				Total drug, Day 8						false
1975	1123		ADULT	4614|52326892	293.3166	OXAPROZIN	OXAPROZIN	OC(=O)CCC1=NC(=C(O1)C2=CC=CC=C2)C3=CC=CC=C3	PLASMA	MHJ80W9LRB							24		t	mg × h/L	2970		mg/L	174			UNKNOWN	g	1.8		SINGLE	FASTED					0.305	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8973987/	Homo sapiens		h	47	Total drug						false
1976	1123		ADULT	4614|52326892	293.3166	OXAPROZIN	OXAPROZIN	OC(=O)CCC1=NC(=C(O1)C2=CC=CC=C2)C3=CC=CC=C3	PLASMA	MHJ80W9LRB							24		t	mg × h/L	1290		mg/L	78.4			UNKNOWN	g	0.6		SINGLE	FASTED					0.13	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8973987/	Homo sapiens		h	58.3	Total drug						false
1977	1123		ADULT	4614|52326892	293.3166	OXAPROZIN	OXAPROZIN	OC(=O)CCC1=NC(=C(O1)C2=CC=CC=C2)C3=CC=CC=C3	PLASMA	MHJ80W9LRB							24		t	mg × h/L	2240		mg/L	129			DEFINED DAILY	g	1.2		SINGLE	FASTED					0.208	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8973987/	Homo sapiens		h	54.9	Total drug						false
1978	1124		ADULT	8605|23676814|101633783	388.48	PENICILLIN V POTASSIUM	PENICILLIN V POTASSIUM	[K+].CC1(C)S[C@@H]2[C@H](NC(=O)COC3=CC=CC=C3)C(=O)N2[C@H]1C([O-])=O	SERUM	146T0TU1JB									∞	mg × h/L	6.89		mg/L	6.1			UNKNOWN	g	0.4		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6811219	Homo sapiens		h	0.52							false
1979	1124		ADULT	8605|23676814|101633783	388.48	PENICILLIN V POTASSIUM	PENICILLIN V POTASSIUM	[K+].CC1(C)S[C@@H]2[C@H](NC(=O)COC3=CC=CC=C3)C(=O)N2[C@H]1C([O-])=O	SERUM	146T0TU1JB									∞	mg × h/L	19.01		mg/L	15			UNKNOWN	g	1		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6811219	Homo sapiens		h	0.78							false
1980	1124		ADULT	8605|23676814|101633783	388.48	PENICILLIN V POTASSIUM	PENICILLIN V POTASSIUM	[K+].CC1(C)S[C@@H]2[C@H](NC(=O)COC3=CC=CC=C3)C(=O)N2[C@H]1C([O-])=O	SERUM	146T0TU1JB									∞	mg × h/L	33.36		mg/L	26.3			UNKNOWN	g	2		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6811219	Homo sapiens		h	0.91							false
1981	1124		ADULT	8605|23676814|101633783	388.48	PENICILLIN V POTASSIUM	PENICILLIN V POTASSIUM	[K+].CC1(C)S[C@@H]2[C@H](NC(=O)COC3=CC=CC=C3)C(=O)N2[C@H]1C([O-])=O	SERUM	146T0TU1JB									∞	mg × h/L	43.94		mg/L	35.5			UNKNOWN	g	3		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6811219	Homo sapiens		h	1.05							false
1982	1124		UNKNOWN	8605|23676814|101633783	388.48	PENICILLIN V POTASSIUM	PENICILLIN V POTASSIUM	[K+].CC1(C)S[C@@H]2[C@H](NC(=O)COC3=CC=CC=C3)C(=O)N2[C@H]1C([O-])=O	SERUM	146T0TU1JB																	UNKNOWN				UNKNOWN	UNKNOWN				Once absorbed, penicillin V is about 80% bound to serum protein.	20	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/064071s006lbl.pdf	Homo sapiens										false
1983	1125		ADULT	1054	169.1778	PYRIDOXINE	PYRIDOXINE	CC1=NC=C(CO)C(CO)=C1O	PLASMA	KV2JZ1BI6Z									?	nM × h	2008.9		nM	372.7			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7988052/	Homo sapiens										false
1984	1125		ADULT	1050	167.162	PYRIDOXAL	PYRIDOXAL	CC1=NC=C(CO)C(C=O)=C1O	PLASMA	3THM379K8A									?	nM × h	18603.4		nM	2183.2			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7988052/	Homo sapiens										false
1985	1125		ADULT	38882	265.1571	PYRIDOXAL PHOSPHATE	PYRIDOXAL PHOSPHATE	O.CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O	PLASMA	5V5IOJ8338									?	nM × h	19420.2		nM	892.9			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7988052/	Homo sapiens										false
1986	1125		ADULT	6723	183.1614	4-PYRIDOXIC ACID	4-pyridoxic acid	CC1=NC=C(CO)C(C(O)=O)=C1O	PLASMA	5K18793O8D									?	nM × h	18543.1		nM	1750.3			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7988052/	Homo sapiens										false
1987	1125		ADULT	1054	169.1778	PYRIDOXINE	PYRIDOXINE	CC1=NC=C(CO)C(CO)=C1O	PLASMA	KV2JZ1BI6Z	11224|43833352		DOXYLAMINE SUCCINATE	DOXYLAMINE SUCCINATE	OC(=O)CCC(O)=O.CN(C)CCOC(C)(C1=CC=CC=C1)C2=CC=CC=N2	V9BI9B5YI2			∞	ng × h/mL	42.5		ng/mL	47.1			RECOMMENDED	mg	20		SINGLE	FASTED						HEALTHY	Oral	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf	Homo sapiens		h	0.4							true
1988	1125		ADULT	1050	167.162	PYRIDOXAL	PYRIDOXAL	CC1=NC=C(CO)C(C=O)=C1O	BLOOD	3THM379K8A	11224|43833352		DOXYLAMINE SUCCINATE	DOXYLAMINE SUCCINATE	OC(=O)CCC(O)=O.CN(C)CCOC(C)(C1=CC=CC=C1)C2=CC=CC=N2	V9BI9B5YI2			∞	ng × h/mL	233.6		ng/mL	58.9			RECOMMENDED	mg	20		SINGLE	FASTED						HEALTHY	Oral	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf	Homo sapiens		h	8							true
1989	1125		ADULT	38882	265.1571	PYRIDOXAL PHOSPHATE	PYRIDOXAL PHOSPHATE	O.CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O	PLASMA	5V5IOJ8338	11224|43833352		DOXYLAMINE SUCCINATE	DOXYLAMINE SUCCINATE	OC(=O)CCC(O)=O.CN(C)CCOC(C)(C1=CC=CC=C1)C2=CC=CC=N2	V9BI9B5YI2	72		t	ng × h/mL	1076.2		ng/mL	30.1			RECOMMENDED	mg	20		SINGLE	FASTED						HEALTHY	Oral	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf	Homo sapiens										true
1990	1125		ADULT	1054	169.1778	PYRIDOXINE	PYRIDOXINE	CC1=NC=C(CO)C(CO)=C1O	PLASMA	KV2JZ1BI6Z	11224|43833352		DOXYLAMINE SUCCINATE	DOXYLAMINE SUCCINATE	OC(=O)CCC(O)=O.CN(C)CCOC(C)(C1=CC=CC=C1)C2=CC=CC=N2	V9BI9B5YI2	24		t	ng × h/mL	80		ng/mL	48.2			MAX DAILY	mg	20		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf	Homo sapiens										true
1991	1125		ADULT	1050	167.162	PYRIDOXAL	PYRIDOXAL	CC1=NC=C(CO)C(C=O)=C1O	BLOOD	3THM379K8A	11224|43833352		DOXYLAMINE SUCCINATE	DOXYLAMINE SUCCINATE	OC(=O)CCC(O)=O.CN(C)CCOC(C)(C1=CC=CC=C1)C2=CC=CC=N2	V9BI9B5YI2	24		t	ng × h/mL	1511.3		ng/mL	189.6			MAX DAILY	mg	20		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf	Homo sapiens										true
1992	1125		ADULT	38882	265.1571	PYRIDOXAL PHOSPHATE	PYRIDOXAL PHOSPHATE	O.CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O	PLASMA	5V5IOJ8338	11224|43833352		DOXYLAMINE SUCCINATE	DOXYLAMINE SUCCINATE	OC(=O)CCC(O)=O.CN(C)CCOC(C)(C1=CC=CC=C1)C2=CC=CC=N2	V9BI9B5YI2	24		t	ng × h/mL	1742.3		ng/mL	85.9			MAX DAILY	mg	20		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf	Homo sapiens										true
1993	1125		ADULT	1054	169.1778	PYRIDOXINE	PYRIDOXINE	CC1=NC=C(CO)C(CO)=C1O	PLASMA	KV2JZ1BI6Z	11224|43833352		DOXYLAMINE SUCCINATE	DOXYLAMINE SUCCINATE	OC(=O)CCC(O)=O.CN(C)CCOC(C)(C1=CC=CC=C1)C2=CC=CC=N2	V9BI9B5YI2			∞	ng × h/mL	35.1		ng/mL	38.9			RECOMMENDED	mg	20		SINGLE	FASTED						HEALTHY	Oral	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf	Homo sapiens		h	0.4							true
1994	1125		ADULT	1054	169.1778	PYRIDOXINE	PYRIDOXINE	CC1=NC=C(CO)C(CO)=C1O	PLASMA	KV2JZ1BI6Z	11224|43833352		DOXYLAMINE SUCCINATE	DOXYLAMINE SUCCINATE	OC(=O)CCC(O)=O.CN(C)CCOC(C)(C1=CC=CC=C1)C2=CC=CC=N2	V9BI9B5YI2			∞	ng × h/mL	27		ng/mL	12.7			RECOMMENDED	mg	20		SINGLE	HIGH-FAT						HEALTHY	Oral	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf	Homo sapiens		h	1.2							true
1995	1125		ADULT	1050	167.162	PYRIDOXAL	PYRIDOXAL	CC1=NC=C(CO)C(C=O)=C1O	BLOOD	3THM379K8A	11224|43833352		DOXYLAMINE SUCCINATE	DOXYLAMINE SUCCINATE	OC(=O)CCC(O)=O.CN(C)CCOC(C)(C1=CC=CC=C1)C2=CC=CC=N2	V9BI9B5YI2			∞	ng × h/mL	244		ng/mL	62			RECOMMENDED	mg	20		SINGLE	FASTED						HEALTHY	Oral	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf	Homo sapiens		h	8							true
1996	1125		ADULT	1050	167.162	PYRIDOXAL	PYRIDOXAL	CC1=NC=C(CO)C(C=O)=C1O	BLOOD	3THM379K8A	11224|43833352		DOXYLAMINE SUCCINATE	DOXYLAMINE SUCCINATE	OC(=O)CCC(O)=O.CN(C)CCOC(C)(C1=CC=CC=C1)C2=CC=CC=N2	V9BI9B5YI2			∞	ng × h/mL	249.2		ng/mL	33.1			RECOMMENDED	mg	20		SINGLE	HIGH-FAT						HEALTHY	Oral	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf	Homo sapiens		h	12.5							true
1997	1125		ADULT	38882	265.1571	PYRIDOXAL PHOSPHATE	PYRIDOXAL PHOSPHATE	O.CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O	PLASMA	5V5IOJ8338	11224|43833352		DOXYLAMINE SUCCINATE	DOXYLAMINE SUCCINATE	OC(=O)CCC(O)=O.CN(C)CCOC(C)(C1=CC=CC=C1)C2=CC=CC=N2	V9BI9B5YI2			?	ng × h/mL	1021.7		ng/mL	27.4			RECOMMENDED	mg	20		SINGLE	FASTED						HEALTHY	Oral	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf	Homo sapiens										true
1998	1125		ADULT	38882	265.1571	PYRIDOXAL PHOSPHATE	PYRIDOXAL PHOSPHATE	O.CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O	PLASMA	5V5IOJ8338	11224|43833352		DOXYLAMINE SUCCINATE	DOXYLAMINE SUCCINATE	OC(=O)CCC(O)=O.CN(C)CCOC(C)(C1=CC=CC=C1)C2=CC=CC=N2	V9BI9B5YI2			?	ng × h/mL	1064.6		ng/mL	30.2			RECOMMENDED	mg	20		SINGLE	HIGH-FAT						HEALTHY	Oral	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf	Homo sapiens										true
1999	1126		ADULT	5215	250.277	SULFADIAZINE	SULFADIAZINE	NC1=CC=C(C=C1)S(=O)(=O)NC2=NC=CC=N2	PLASMA								12		t	μg × h/mL	1.247		μg/mL	84.9			UNKNOWN	g	2		STEADY-STATE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/14742225/	Homo sapiens		h	11.9							false
2000	1127		UNKNOWN	16231|137319713	229.627	AMILORIDE	AMILORIDE	NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N	PLASMA	7DZO8EB0Z3																						UNKNOWN				Protein Bound: 23%	77	UNKNOWN		UNKNOWN	DRUG LABEL	https://reference.medscape.com/drug/midamor-amiloride-342406#10	Homo sapiens										false
2001	1127		ADULT	16231|137319713	229.627	AMILORIDE	AMILORIDE	NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N	PLASMA	7DZO8EB0Z3									∞	ng × h/mL	275		ng/mL	20.6			RECOMMENDED	mg	10		SINGLE	FASTED						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/9085317	Homo sapiens		h	16							false
2002	1127		ADULT	16231|137319713	229.627	AMILORIDE	AMILORIDE	NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N	PLASMA	7DZO8EB0Z3													ng/mL	1.57			UNKNOWN	mmol	17		SINGLE	UNKNOWN						UNHEALTHY	Respiratory	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/9085317	Homo sapiens										false
2003	1128			3365	306.2708	FLUCONAZOLE	FLUCONAZOLE	OC(CN1C=NC=N1)(CN2C=NC=N2)C3=CC=C(F)C=C3F	PLASMA	8VZV102JFY							168		t	μg × h/mL	156.1							mg	150		SINGLE							UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01806623	Homo sapiens										false
2004	1128			3365	306.2708	FLUCONAZOLE	FLUCONAZOLE	OC(CN1C=NC=N1)(CN2C=NC=N2)C3=CC=C(F)C=C3F	VAGINAL FLUID	8VZV102JFY							168		t	μg × h/g	79.5							mg	150		SINGLE							UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01806623	Homo sapiens										false
2005	1128			3365	306.2708	FLUCONAZOLE	FLUCONAZOLE	OC(CN1C=NC=N1)(CN2C=NC=N2)C3=CC=C(F)C=C3F	VAGINAL FLUID	8VZV102JFY							168		t	μg × h/mL	85.3							mg	150		SINGLE							UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01806623	Homo sapiens										false
2006	1128		ADULT	3365	306.2708	FLUCONAZOLE	FLUCONAZOLE	OC(CN1C=NC=N1)(CN2C=NC=N2)C3=CC=C(F)C=C3F	PLASMA	8VZV102JFY													μg/mL	6.72			MAX DAILY	mg	400		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019949s051lbl.pdf	Homo sapiens		h	30							false
2007	1128		ADULT	3365	306.2708	FLUCONAZOLE	FLUCONAZOLE	OC(CN1C=NC=N1)(CN2C=NC=N2)C3=CC=C(F)C=C3F	PLASMA	8VZV102JFY													μg/mL	2.61			RECOMMENDED	mg	150		SINGLE	UNKNOWN						UNKNOWN	Oral	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019949s051lbl.pdf	Homo sapiens										false
2008	1128		UNKNOWN	3365	306.2708	FLUCONAZOLE	FLUCONAZOLE	OC(CN1C=NC=N1)(CN2C=NC=N2)C3=CC=C(F)C=C3F	PLASMA	8VZV102JFY																						UNKNOWN				Plasma protein binding is low (11-12%)	88.5	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019949s051lbl.pdf	Homo sapiens										false
2009	1128		CHILD	3365	306.2708	FLUCONAZOLE	FLUCONAZOLE	OC(CN1C=NC=N1)(CN2C=NC=N2)C3=CC=C(F)C=C3F	PLASMA	8VZV102JFY													μg/mL	2.9			UNKNOWN	mg/kg	2		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019949s051lbl.pdf	Homo sapiens		h	25							false
2010	1128		CHILD	3365	306.2708	FLUCONAZOLE	FLUCONAZOLE	OC(CN1C=NC=N1)(CN2C=NC=N2)C3=CC=C(F)C=C3F	PLASMA	8VZV102JFY													μg/mL	9.8			UNKNOWN	mg/kg	8		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019949s051lbl.pdf	Homo sapiens		h	19.5							false
2011	1128		CHILD	3365	306.2708	FLUCONAZOLE	FLUCONAZOLE	OC(CN1C=NC=N1)(CN2C=NC=N2)C3=CC=C(F)C=C3F	PLASMA	8VZV102JFY													μg/mL	5.5			UNKNOWN	mg/kg	2		MULTIPLE	UNKNOWN		day	1			UNKNOWN	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019949s051lbl.pdf	Homo sapiens		h	17.4							false
2012	1128		CHILD	3365	306.2708	FLUCONAZOLE	FLUCONAZOLE	OC(CN1C=NC=N1)(CN2C=NC=N2)C3=CC=C(F)C=C3F	PLASMA	8VZV102JFY													μg/mL	11.4			UNKNOWN	mg/kg	4		MULTIPLE	UNKNOWN		day	1			UNKNOWN	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019949s051lbl.pdf	Homo sapiens		h	15.2							false
2013	1128		CHILD	3365	306.2708	FLUCONAZOLE	FLUCONAZOLE	OC(CN1C=NC=N1)(CN2C=NC=N2)C3=CC=C(F)C=C3F	PLASMA	8VZV102JFY													μg/mL	14.1			UNKNOWN	mg/kg	8		MULTIPLE	UNKNOWN		day	1			UNKNOWN	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019949s051lbl.pdf	Homo sapiens		h	17.6							false
2014	1128		ADULT	3365	306.2708	FLUCONAZOLE	FLUCONAZOLE	OC(CN1C=NC=N1)(CN2C=NC=N2)C3=CC=C(F)C=C3F	PLASMA	8VZV102JFY									?	μg × h/mL	76.4		μg/mL	1.54			MIN EFFICACIOUS	mg	50		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019949s051lbl.pdf	Homo sapiens		h	46.2							false
2015	1130		ADULT	43708	525.628	CEFOTIAM	CEFOTIAM	CN(C)CCN1N=NN=C1SCC2=C(N3[C@H](SC2)[C@H](NC(=O)CC4=CSC(N)=N4)C3=O)C(O)=O	SERUM	91W6Z2N718									?	mg × h/L	171.7		mg/L	124.6			UNKNOWN	g	2		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9266270	Homo sapiens		h	1.5							false
2016	1130		ADULT	43708	525.628	CEFOTIAM	CEFOTIAM	CN(C)CCN1N=NN=C1SCC2=C(N3[C@H](SC2)[C@H](NC(=O)CC4=CSC(N)=N4)C3=O)C(O)=O	MUSCLE	91W6Z2N718													mg/kg	18.8			UNKNOWN	g	2		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9266270	Homo sapiens		h	2.2							false
2017	1131		ADULT	446284	302.5	Icosapent		CCC=CCC=CCC=CCC=CCC=CCCCC(=O)O	PLASMA	AAN7QOV9EA							24		t	μg × h/mL	6.519		μg/mL	347			RECOMMENDED	g	4		STEADY-STATE	FED		day	2		1	HEALTHY	Oral	FEMALE / MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/25428605/	Homo sapiens		h	89							false
2018	1131		UNKNOWN	446284	302.5	Icosapent		CCC=CCC=CCC=CCC=CCC=CCCCC(=O)O	PLASMA	AAN7QOV9EA																	UNKNOWN				STEADY-STATE	UNKNOWN		UNKNOWN			1	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202057s035lbl.pdf	Homo sapiens		h	89							false
2019	1132		ADULT		325.426	AMDINOCILLIN	AMDINOCILLIN	CC1(C)S[C@@H]2[C@H](N=CN3CCCCCC3)C(=O)N2[C@H]1C(O)=O	PLASMA	V10579P3QZ									∞	μg × h/mL	8.1		μg/mL	3.6			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3377469/	Homo sapiens		h	1							false
2020	1132		ADULT		325.426	AMDINOCILLIN	AMDINOCILLIN	CC1(C)S[C@@H]2[C@H](N=CN3CCCCCC3)C(=O)N2[C@H]1C(O)=O	PLASMA	V10579P3QZ									∞	μg × h/mL	7.7		μg/mL	3.2			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3377469/	Homo sapiens		h	1							false
2021	1132		ADULT		325.426	AMDINOCILLIN	AMDINOCILLIN	CC1(C)S[C@@H]2[C@H](N=CN3CCCCCC3)C(=O)N2[C@H]1C(O)=O	PLASMA	V10579P3QZ									∞	μg × h/mL	10		μg/mL	4.3			UNKNOWN	mg	400		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3377469/	Homo sapiens		h	0.9							false
2022	1132		ADULT		325.426	AMDINOCILLIN	AMDINOCILLIN	CC1(C)S[C@@H]2[C@H](N=CN3CCCCCC3)C(=O)N2[C@H]1C(O)=O	PLASMA	V10579P3QZ									∞	μg × h/mL	9.7		μg/mL	4.1			UNKNOWN	mg	400		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3377469/	Homo sapiens		h	0.9							false
2023	1132		ADULT		325.426	AMDINOCILLIN	AMDINOCILLIN	CC1(C)S[C@@H]2[C@H](N=CN3CCCCCC3)C(=O)N2[C@H]1C(O)=O	PLASMA	V10579P3QZ																	UNKNOWN	mg/kg bw	10		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6282208/	Homo sapiens		min	54.38							false
2024	1132		ADULT		325.426	AMDINOCILLIN	AMDINOCILLIN	CC1(C)S[C@@H]2[C@H](N=CN3CCCCCC3)C(=O)N2[C@H]1C(O)=O	PLASMA	V10579P3QZ													μg/mL	49.5			UNKNOWN	mg/kg bw	10		STEADY-STATE	UNKNOWN		day	6			HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6282208/	Homo sapiens		min	52.39							false
2025	1132		ADULT		325.426	AMDINOCILLIN	amdinocillin	CC1(C)S[C@@H]2[C@H](N=CN3CCCCCC3)C(=O)N2[C@H]1C(O)=O	PLASMA	V10579P3QZ									?	μg × h/mL	58.81		μg/mL	49.4			UNKNOWN	mg/kg bw	10		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6311087/	Homo sapiens		h	0.888							false
2026	1132		ADULT		325.426	AMDINOCILLIN	AMDINOCILLIN	CC1(C)S[C@@H]2[C@H](N=CN3CCCCCC3)C(=O)N2[C@H]1C(O)=O	PLASMA	V10579P3QZ									?	μg × h/mL	112.97		μg/mL	87.3			UNKNOWN	mg/kg bw	15		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6311087/	Homo sapiens		h	0.886							false
2027	1132		ADULT		325.426	AMDINOCILLIN	AMDINOCILLIN	CC1(C)S[C@@H]2[C@H](N=CN3CCCCCC3)C(=O)N2[C@H]1C(O)=O	SERUM	V10579P3QZ									?	μg × h/mL	47.94		μg/mL	26.2			UNKNOWN	mg/kg bw	10		SINGLE	FASTED						HEALTHY	Intramuscular	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6311087/	Homo sapiens		h	0.96							false
2028	1132		ADULT		325.426	AMDINOCILLIN	AMDINOCILLIN	CC1(C)S[C@@H]2[C@H](N=CN3CCCCCC3)C(=O)N2[C@H]1C(O)=O	SERUM	V10579P3QZ									?	μg × h/mL	72.15		μg/mL	29.6			UNKNOWN	mg/kg bw	15		SINGLE	FASTED						HEALTHY	Intramuscular	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6311087/	Homo sapiens		h	0.859							false
2029	1133		ADULT	259331	440.403	ESTRAMUSTINE	estramustine	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OC(=O)N(CCCl)CCCl)=C4)[C@@H]1CC[C@@H]2O	BLOOD	35LT29625A							24		t	ng × h/mL	972						RECOMMENDED	mg	280		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/16568471	Homo sapiens										false
2030	1133		ADULT	259331	440.403	ESTRAMUSTINE	ESTRAMUSTINE	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OC(=O)N(CCCl)CCCl)=C4)[C@@H]1CC[C@@H]2O	PLASMA	35LT29625A							32		t	μg × h/mL	2.88		ng/mL	362			RECOMMENDED	mg	140		SINGLE	FED						UNHEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/6714283	Homo sapiens		h	13.6							false
2031	1133		UNKNOWN	259331	440.403	ESTRAMUSTINE	ESTRAMUSTINE	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OC(=O)N(CCCl)CCCl)=C4)[C@@H]1CC[C@@H]2O	PLASMA	35LT29625A																						UNKNOWN				Approximately 50% of the [3H]estramustine bound to plasma protein	50	HEALTHY		UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/7736407	Homo sapiens										false
2032	1134		UNKNOWN		307.4293	BENZTROPINE	BENZTROPINE	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(C3=CC=CC=C3)C4=CC=CC=C4	UNKNOWN	1NHL2J4X8K													ng/mL	2.5			UNKNOWN	mg	1.5		SINGLE	UNKNOWN				Benztropine is highly protein bounded (95%).	5	UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://pdf.hres.ca/dpd_pm/00029138.PDF	Homo sapiens		h	7							false
2033	1135		ADULT	26987	343.89	CLEMASTINE	CLEMASTINE	CN1CCC[C@@H]1CCO[C@](C)(C2=CC=CC=C2)C3=CC=C(Cl)C=C3	PLASMA	95QN29S1ID							24		t	ng × h/mL	4.2		ng/mL	0.7			UNKNOWN	mg	3		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15664345/	Homo sapiens		h	8							false
2034	1135		ADULT	26987	343.89	CLEMASTINE	CLEMASTINE	CN1CCC[C@@H]1CCO[C@](C)(C2=CC=CC=C2)C3=CC=C(Cl)C=C3	PLASMA	95QN29S1ID									∞	pg × h/mL	15529		pg/mL	650			UNKNOWN	mg	0.5		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-082_Tavist_biopharmr.pdf	Homo sapiens		h	17.28							false
2035	1135		ADULT	26987	343.89	CLEMASTINE	CLEMASTINE	CN1CCC[C@@H]1CCO[C@](C)(C2=CC=CC=C2)C3=CC=C(Cl)C=C3	PLASMA	95QN29S1ID									∞	pg × h/mL	26230		pg/mL	1010			UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-082_Tavist_biopharmr.pdf	Homo sapiens		h	23.94							false
2036	1136		ADULT	5284543	301.3801	DIHYDROCODEINE	DIHYDROCODEINE	COC1=CC=C2C[C@@H]3[C@@H]4CC[C@H](O)[C@@H]5OC1=C2[C@]45CCN3C	SERUM	N9I9HDB855									∞	nM × h	3367		pmol/g	487			DEFINED DAILY	mg	60		MULTIPLE	FED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://bpspubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1046/j.1365-2125.1999.00042.x	Homo sapiens										false
2037	1136		ADULT	5359421	287.3535	DIHYDROMORPHINE	dihydromorphine	CN1CC[C@@]23[C@H]4OC5=C2C(C[C@@H]1[C@@H]3CC[C@@H]4O)=CC=C5O	SERUM	C3S5FRP6JW									∞	nM × h	70		pmol/g	4.7			DEFINED DAILY	mg	60		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://bpspubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1046/j.1365-2125.1999.00042.x	Homo sapiens										false
2038	1136		ADULT	5284543	301.3801	DIHYDROCODEINE	DIHYDROCODEINE	COC1=CC=C2C[C@@H]3[C@@H]4CC[C@H](O)[C@@H]5OC1=C2[C@]45CCN3C	SERUM	N9I9HDB855									∞	nM × h	3415		nM	341			DEFINED DAILY	mg	60		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://bpspubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1046/j.1365-2125.1999.00042.x	Homo sapiens										false
2039	1136		ADULT	5359421	287.3535	DIHYDROMORPHINE	dihydromorphine	CN1CC[C@@]23[C@H]4OC5=C2C(C[C@@H]1[C@@H]3CC[C@@H]4O)=CC=C5O	SERUM	C3S5FRP6JW									∞	nM × h	65		nM	8.7			DEFINED DAILY	mg	60		MULTIPLE	FED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://bpspubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1046/j.1365-2125.1999.00042.x	Homo sapiens										false
2040	1136		ADULT	5284543	301.3801	DIHYDROCODEINE	DIHYDROCODEINE	COC1=CC=C2C[C@@H]3[C@@H]4CC[C@H](O)[C@@H]5OC1=C2[C@]45CCN3C	SERUM	N9I9HDB855									∞	nM × h	5118		nM	739			DEFINED DAILY	mg	90		MULTIPLE	FED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://bpspubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1046/j.1365-2125.1999.00042.x	Homo sapiens										false
2041	1136		ADULT	5284543	301.3801	DIHYDROCODEINE	DIHYDROCODEINE	COC1=CC=C2C[C@@H]3[C@@H]4CC[C@H](O)[C@@H]5OC1=C2[C@]45CCN3C	SERUM	N9I9HDB855									∞	nM × h	6566		nM	918			DEFINED DAILY	mg	120		MULTIPLE	FED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://bpspubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1046/j.1365-2125.1999.00042.x	Homo sapiens										false
2042	1136		ADULT	5359421	287.3535	DIHYDROMORPHINE	dihydromorphine	CN1CC[C@@]23[C@H]4OC5=C2C(C[C@@H]1[C@@H]3CC[C@@H]4O)=CC=C5O	SERUM	C3S5FRP6JW									∞	nM × h	132		nM	18			DEFINED DAILY	mg	120		MULTIPLE	FED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://bpspubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1046/j.1365-2125.1999.00042.x	Homo sapiens										false
2043	1136		ADULT	5359421	287.3535	DIHYDROMORPHINE	dihydromorphine	CN1CC[C@@]23[C@H]4OC5=C2C(C[C@@H]1[C@@H]3CC[C@@H]4O)=CC=C5O	SERUM	C3S5FRP6JW									∞	nM × h	99		nM	13			DEFINED DAILY	mg	90		MULTIPLE	FED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://bpspubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1046/j.1365-2125.1999.00042.x	Homo sapiens										false
2044	1136		ADULT	5284543	301.3801	DIHYDROCODEINE	Dihydrocodeine	COC1=CC=C2C[C@@H]3[C@@H]4CC[C@H](O)[C@@H]5OC1=C2[C@]45CCN3C	PLASMA	N9I9HDB855									∞	ng × h/mL	301.643		ng/mL	60.089			DEFINED DAILY	mg	20		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4885392/	Homo sapiens		h	3.146							false
2045	1138		UNKNOWN	31703	543.5193	DOXORUBICIN	DOXORUBICIN	COC1=CC=CC2=C1C(=O)C3=C(C2=O)C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O)C(=O)CO	PLASMA	80168379AG																						UNKNOWN				Binding of doxorubicin and its major metabolite, doxorubicinol, to plasma proteins is about 75% and is independent of plasma concentration of doxorubicin up to 1.1 ug/mL.	25	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050467s073lbl.pdf	Homo sapiens										false
2046	1138		CHILD	31703	543.5	DOXORUBICIN	DOXORUBICIN	COC1=CC=CC2=C1C(=O)C3=C(O)C4=C(C[C@](O)(C[C@@H]4O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C(=O)CO)C(O)=C3C2=O	PLASMA	80168379AG									∞	μM × h	7.4		μM	2			RECOMMENDED	mg/m²	60		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26115930	Homo sapiens		h	34.8							false
2047	1139		ADULT	5281037	424.513	EPROSARTAN	EPROSARTAN	CCCCC1=NC=C(\\C=C(/CC2=CC=CS2)C(O)=O)N1CC3=CC=C(C=C3)C(O)=O	PLASMA	2KH13Z0S0Y									?	ng × h/mL	1400		ng/mL	439			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9597557/	Homo sapiens										false
2048	1139		ADULT	5281037	424.513	EPROSARTAN	EPROSARTAN	CCCCC1=NC=C(\\C=C(/CC2=CC=CS2)C(O)=O)N1CC3=CC=C(C=C3)C(O)=O	PLASMA	2KH13Z0S0Y									?	ng × h/mL	2620		ng/mL	702			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9597557/	Homo sapiens										false
2049	1139		ADULT	5281037	424.513	EPROSARTAN	EPROSARTAN	CCCCC1=NC=C(\\C=C(/CC2=CC=CS2)C(O)=O)N1CC3=CC=C(C=C3)C(O)=O	PLASMA	2KH13Z0S0Y									?	ng × h/L	4887		ng/mL	1273			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9597557/	Homo sapiens										false
2050	1139		ADULT	5281037	424.513	EPROSARTAN	EPROSARTAN	CCCCC1=NC=C(\\C=C(/CC2=CC=CS2)C(O)=O)N1CC3=CC=C(C=C3)C(O)=O	PLASMA	2KH13Z0S0Y									?	ng × h/mL	7855		ng/mL	1857			UNKNOWN	mg	800		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9597557/	Homo sapiens										false
2051	1139		ADULT	5281037	424.513	EPROSARTAN	EPROSARTAN	CCCCC1=NC=C(\\C=C(/CC2=CC=CS2)C(O)=O)N1CC3=CC=C(C=C3)C(O)=O	PLASMA	2KH13Z0S0Y									∞	ng × h/mL	5750		ng/mL	1612			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9737815/	Homo sapiens		h	4.52							false
2052	1139		ADULT	5281037	424.513	EPROSARTAN	EPROSARTAN	CCCCC1=NC=C(\\C=C(/CC2=CC=CS2)C(O)=O)N1CC3=CC=C(C=C3)C(O)=O	PLASMA	2KH13Z0S0Y									∞	ng × h/mL	4950		ng/mL	1205			UNKNOWN	mg	300		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9737815/	Homo sapiens		h	7.25							false
2053	1139		ADULT	5281037	424.513	EPROSARTAN	EPROSARTAN	CCCCC1=NC=C(\\C=C(/CC2=CC=CS2)C(O)=O)N1CC3=CC=C(C=C3)C(O)=O	PLASMA	2KH13Z0S0Y									∞	ng × h/mL	2671		ng/mL	2246			UNKNOWN	mg	20		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9737815/	Homo sapiens		h	2.07							false
2054	1139		ADULT	5281037	424.513	EPROSARTAN	EPROSARTAN	CCCCC1=NC=C(\\C=C(/CC2=CC=CS2)C(O)=O)N1CC3=CC=C(C=C3)C(O)=O	PLASMA	2KH13Z0S0Y																	RECOMMENDED	mg	600		MULTIPLE	UNKNOWN		day	1		2	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020738s029lbl.pdf	Homo sapiens		h	20							false
2055	1140		ADULT	59768	295.374	ESMOLOL	ESMOLOL	COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1	PLASMA	MDY902UXSR									∞	μg × h/mL	0.02		μg/mL	0.22			UNKNOWN	mg/kg	0.5		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28091703	Homo sapiens		min	3.65							false
2056	1140		ADULT	59768	295.374	ESMOLOL	ESMOLOL	COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1	PLASMA	MDY902UXSR									∞	μg × h/mL	0.03		μg/mL	0.56			UNKNOWN	mg/kg	1		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28091703	Homo sapiens		min	4.77							false
2057	1140		ADULT	59768	295.374	ESMOLOL	ESMOLOL	COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1	PLASMA	MDY902UXSR									∞	μg × h/mL	0.06		μg/mL	0.96			UNKNOWN	mg	1.5		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28091703	Homo sapiens		min	4.76							false
2058	1140		UNKNOWN	59768	295.374	ESMOLOL	ESMOLOL	COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1	PLASMA	MDY902UXSR																						UNKNOWN				Esmolol hydrochloride has been shown to be 55% bound to human plasma protein, while the acid metabolite is only 10% bound.	45	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/205703s000lbl.pdf	Homo sapiens										false
2059	1141		UNKNOWN	3385|5281053	130.0772	FLUOROURACIL	FLUOROURACIL	FC1=CNC(=O)NC1=O	PLASMA	U3P01618RT																						UNKNOWN				Plasma-protein binding is 8-12%.	90	UNKNOWN		UNKNOWN	EXPERIMENT	http://www.acutetox.eu/pdf_human_short/17-5-fluorouracil%20revised.pdf	Homo sapiens										false
2060	1141		ADULT	3385	130.08	FLUOROURACIL	FLUOROURACIL	FC1=CNC(=O)NC1=O	PLASMA	U3P01618RT							24		t	ng × h/mL	22.39		ng/mL	11.49			RECOMMENDED	g	1		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Topical	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/20985lbl.pdf	Homo sapiens										false
2061	1141		ADULT	3385	130.08	FLUOROURACIL	FLUOROURACIL	FC1=CNC(=O)NC1=O	PLASMA	U3P01618RT									∞	ng × h/mL	205		ng/mL	278			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/12907286	Homo sapiens		h	0.24							false
2062	1142		ADULT	12947	433.95	HYDROXYCHLOROQUINE SULFATE	HYDROXYCHLOROQUINE SULFATE	OS(O)(=O)=O.CCN(CCO)CCCC(C)NC1=CC=NC2=C1C=CC(Cl)=C2	PLASMA	8Q2869CNVH									∞	μM × h	102.3		μM	1.22			RECOMMENDED	mg	400		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19188392	Homo sapiens		h	172.3							false
2063	1142		UNKNOWN	12947	433.95	HYDROXYCHLOROQUINE SULFATE	HYDROXYCHLOROQUINE SULFATE	OS(O)(=O)=O.CCN(CCO)CCCC(C)NC1=CC=NC2=C1C=CC(Cl)=C2	PLASMA	8Q2869CNVH																	UNKNOWN				UNKNOWN	UNKNOWN				The plasma protein binding of hydroxychloroquine was found to be stereoselective. The (S)-enantiomer of hydroxychloroquine was 64% bound in plasma, while (R)-hydroxychloroquine was 37% bound. 50% of (S)-hydroxychloroquine was bound to serum albumin, while only 29% of the (R)-enantiomer was bound. The enantioselectivity of hydroxychloroquine binding was reversed in a case of alpha1-acid glycoprotein with (R)-hydroxychloroquine being bound to a greater extent than its optical antipode (41% versus 29%). Racemic hydroxychloroquine was 52% bound in plasma.	48	UNKNOWN	UNKNOWN	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8359187	Homo sapiens										false
2064	1142		ADULT	12947	433.95	HYDROXYCHLOROQUINE SULFATE	HYDROXYCHLOROQUINE SULFATE	OS(O)(=O)=O.CCN(CCO)CCCC(C)NC1=CC=NC2=C1C=CC(Cl)=C2	PLASMA	8Q2869CNVH													ng/mL	50.3			UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/009768Orig1s051lbl.pdf	Homo sapiens		h	2963							false
2065	1142		ADULT	12947	433.95	HYDROXYCHLOROQUINE SULFATE	HYDROXYCHLOROQUINE SULFATE	OS(O)(=O)=O.CCN(CCO)CCCC(C)NC1=CC=NC2=C1C=CC(Cl)=C2	BLOOD	8Q2869CNVH													ng/mL	129.6			UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/009768Orig1s051lbl.pdf	Homo sapiens		h	537							false
2066	1143		ADULT	5311181	360.4871	ILOPROST	ILOPROST	CC#CCC(C)[C@H](O)\\C=C\\[C@H]1[C@H](O)C[C@@H]2C\\C(C[C@H]12)=C/CCCC(O)=O	SERUM	JED5K35YGL									?	pg × h/mL	47.8		pg/mL	157			RECOMMENDED	μg	5		SINGLE	UNKNOWN						UNHEALTHY	Respiratory	FEMALE / MALE	REVIEW	https://www.ema.europa.eu/en/documents/scientific-discussion/ventavis-epar-scientific-discussion_en.pdf	Homo sapiens		min	7.91							false
2067	1143		ADULT	5311181	360.4871	ILOPROST	ILOPROST	CC#CCC(C)[C@H](O)\\C=C\\[C@H]1[C@H](O)C[C@@H]2C\\C(C[C@H]12)=C/CCCC(O)=O	SERUM	JED5K35YGL									?	pg × h/mL	119		pg/mL	135			UNKNOWN	ng/kg/min	3	infusion, 45 min	OTHER	UNKNOWN				Total plasma protein binding of iloprost is concentration-independent in the range of 30 to 3000 picograms/ml and amounts to approximately 60%, of which 75% is due to albumin binding.	40	HEALTHY	Intravenous	UNKNOWN	REVIEW	https://www.ema.europa.eu/en/documents/scientific-discussion/ventavis-epar-scientific-discussion_en.pdf	Homo sapiens										false
2068	1143		UNKNOWN	5311181	360.4871	ILOPROST	ILOPROST	CC#CCC(C)[C@H](O)\\C=C\\[C@H]1[C@H](O)C[C@@H]2C\\C(C[C@H]12)=C/CCCC(O)=O	SERUM	JED5K35YGL									?	pg × h/mL	144		pg/mL	251			UNKNOWN	μg/kg bw	1		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	REVIEW	https://www.ema.europa.eu/en/documents/scientific-discussion/ventavis-epar-scientific-discussion_en.pdf	Homo sapiens										false
2069	1144		ADULT	3702	365.835	INDAPAMIDE	INDAPAMIDE	CC1CC2=C(C=CC=C2)N1NC(=O)C3=CC=C(Cl)C(=C3)S(N)(=O)=O	BLOOD	F089I0511L													ng/mL	260			MAX DAILY	g	5		SINGLE	UNKNOWN				From 71 to 79% of the Lozol (indapamide) in plasma is reversibly bound to plasma proteins.	25	HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018538s028lbl.pdf	Homo sapiens		h	14							false
2070	1144		ADULT	3702	365.835	INDAPAMIDE	INDAPAMIDE	CC1CC2=C(C=CC=C2)N1NC(=O)C3=CC=C(Cl)C(=C3)S(N)(=O)=O	PLASMA	F089I0511L									∞	ng × h/mL	919.52		ng/mL	47.79			MAX DAILY	mg	5		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/23447043	Homo sapiens		h	23.23							false
2071	1145		ADULT	5484730	631.8048	INDINAVIR	Indinavir	O.CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H]4[C@H](O)CC5=C4C=CC=C5	PLASMA	5W6YA9PKKH									?	nM × h	30691		nM	12617			RECOMMENDED	mg	800		STEADY-STATE	UNKNOWN		day	3		40	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020685s078lbl.pdf	Homo sapiens										false
2072	1145		CHILD	5484730	631.8048	INDINAVIR	INDINAVIR	O.CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H]4[C@H](O)CC5=C4C=CC=C5	PLASMA	5W6YA9PKKH							8		t	nM × h	38742		nM	17181			UNKNOWN	mg/m²	500		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020685s078lbl.pdf	Homo sapiens										false
2073	1145		ADULT	5484730	631.8048	INDINAVIR	INDINAVIr	O.CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H]4[C@H](O)CC5=C4C=CC=C5	UNKNOWN	5W6YA9PKKH							8		t	nM × h	9231						RECOMMENDED	mg	800		MULTIPLE	UNKNOWN		day	3			PREGNANT	Oral	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020685s078lbl.pdf	Homo sapiens										false
2074	1146		ADULT	5819|25201348	776.87	LEVOTHYROXINE	LEVOTHYROXINE	N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O	PLASMA	Q51BO43MG4							48		t	ng × h/mL	1764.14		ng/mL	76.64			UNKNOWN	μg	600		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30153382	Homo sapiens										false
2075	1146		UNKNOWN	5819|25201348	776.87	LEVOTHYROXINE	LEVOTHYROXINE	N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O	SERUM	Q51BO43MG4																	UNKNOWN				UNKNOWN	UNKNOWN						HEALTHY	UNKNOWN	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/30349610	Homo sapiens		day	6.2							false
2076	1146		UNKNOWN	5819|25201348	776.87	LEVOTHYROXINE	LEVOTHYROXINE	N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O	SERUM	Q51BO43MG4																	UNKNOWN				UNKNOWN	UNKNOWN						UNHEALTHY	UNKNOWN	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/30349610	Homo sapiens		h	7.5							false
2077	1146		UNKNOWN	5819|25201348	776.87	LEVOTHYROXINE	LEVOTHYROXINE	N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O	PLASMA	Q51BO43MG4																	UNKNOWN				UNKNOWN	UNKNOWN				Levothyroxine is highly bound (99.96%) to plasma proteins, including thyroxine-binding globulin, thyroxine-binding prealbumin, and thyroxine-binding albumin.	0.04	HEALTHY	UNKNOWN	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021292s004,021292s005,021292s006lbl.pdf	Homo sapiens										false
2078	1147		ADULT	4034	390.948	MECLIZINE	Meclizine	CC1=CC=CC(CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(Cl)C=C4)=C1	PLASMA	3L5TQ84570									∞	ng × h/mL	564.03		ng/mL	99.43			UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21903894/	Homo sapiens		h	5.24				19			false
2079	1147		CHILD	4034	390.948	MECLIZINE	Meclizine	CC1=CC=CC(CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(Cl)C=C4)=C1	PLASMA	3L5TQ84570							24		t	ng × h/mL	671		ng/mL	130			UNKNOWN	mg	25		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32282831/	Homo sapiens		h	8.5		Achondroplasia patients		6			false
2080	1147		CHILD	4034	390.948	MECLIZINE	Meclizine	CC1=CC=CC(CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(Cl)C=C4)=C1	PLASMA	3L5TQ84570													ng/mL	223			UNKNOWN	mg	25		MULTIPLE	FED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32282831/	Homo sapiens				Day 1 1st dose	Achondroplasia patients		5			false
2081	1147		CHILD	4034	390.948	MECLIZINE	Meclizine	CC1=CC=CC(CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(Cl)C=C4)=C1	PLASMA	3L5TQ84570							24		t	ng × h/mL	2030		ng/mL	149			UNKNOWN	mg	25		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32282831/	Homo sapiens		h	3.6	Day 1 2nd dose	Achondroplasia patients		5			false
2082	1147		CHILD	4034	390.948	MECLIZINE	Meclizine	CC1=CC=CC(CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(Cl)C=C4)=C1	PLASMA	3L5TQ84570							24		t	ng × h/mL	656		ng/mL	131.3			UNKNOWN	mg	25		STEADY-STATE	FASTED		day	1	AUC(312-336h)		UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32282831/	Homo sapiens					Achondroplasia patients		6			false
2083	1147		CHILD	4034	390.948	MECLIZINE	Meclizine	CC1=CC=CC(CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(Cl)C=C4)=C1	PLASMA	3L5TQ84570							24		t	ng × h/mL	1891		ng/mL	210.8			UNKNOWN	mg	25		STEADY-STATE	FED		day	2	AUC(312-336h)		UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32282831/	Homo sapiens					Achondroplasia patients		5			false
2084	1148		ADULT	4456	223.2915	NEOSTIGMINE	NEOSTIGMINE	CN(C)C(=O)OC1=CC(=CC=C1)[N+](C)(C)C	PLASMA	3982TWQ96G									∞	ng × h/mL	69.9		ng/mL	300			RECOMMENDED	mg/kg	0.07		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/382915/	Homo sapiens		min	79.8							false
2085	1148		ADULT	4456	223.2915	NEOSTIGMINE	NEOSTIGMINE	CN(C)C(=O)OC1=CC(=CC=C1)[N+](C)(C)C	PLASMA	3982TWQ96G																	RECOMMENDED	mg/kg	0.03		SINGLE	UNKNOWN				Protein binding of neostigmine to human serum albumin ranges from 15 to 25%	75	UNKNOWN	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204078s007lbl.pdf	Homo sapiens		h	1.5							false
2086	1149		ADULT	4463	266.2979	NEVIRAPINE	NEVIRAPINE	CC1=C2NC(=O)C3=C(N=CC=C3)N(C4CC4)C2=NC=C1	PLASMA	99DK7FVK1H							24		t	ng × h/mL	82000						MAX DAILY	mg	400		MULTIPLE	FASTED		day	1			HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/201152s013lbl.pdf	Homo sapiens										false
2087	1149		ADULT	4463	266.2979	NEVIRAPINE	NEVIRAPINE	CC1=C2NC(=O)C3=C(N=CC=C3)N(C4CC4)C2=NC=C1	PLASMA	99DK7FVK1H							24		t	ng × h/mL	96700						MAX DAILY	mg	400		MULTIPLE	FED		day	1			UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/201152s013lbl.pdf	Homo sapiens										false
2088	1149		ADULT	4463	266.2979	NEVIRAPINE	NEVIRAPINE	CC1=C2NC(=O)C3=C(N=CC=C3)N(C4CC4)C2=NC=C1	PLASMA	99DK7FVK1H									∞	ng × h/mL	161000		ng/mL	2060			MAX DAILY	mg	400		SINGLE	UNKNOWN				Nevirapine is about 60% bound to plasma proteins in the plasma concentration range of 1-10 mcg per mL.	40	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/201152s013lbl.pdf	Homo sapiens		h	45							false
2089	1150		ADULT	3675	136.1943	PHENELZINE	NNCCC1=CC=CC=C1	NNCCC1=CC=CC=C1	PLASMA	O408N561GF													ng/mL	19.8			UNKNOWN	mg	30		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/011909s038lbl.pdf	Homo sapiens		h	11.6							false
2090	1150		ADULT	3675	136.1943	PHENELZINE	NNCCC1=CC=CC=C1	NNCCC1=CC=CC=C1	PLASMA	O408N561GF									∞	ng × h/mL	384.2		ng/mL	10.14			UNKNOWN	mg	15		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/27085800	Homo sapiens		h	9.75							false
2091	1151		ADULT	54676228	331.3	PIROXICAM	PIROXICAM	CN1C(C(=O)NC2=CC=CC=N2)=C(O)C3=C(C=CC=C3)[S+]1([O-])=O	PLASMA	13T4O6VMAM									∞	μg × h/mL	135.8		μg/mL	2.3			RECOMMENDED	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/27129120	Homo sapiens		h	40.5							false
2092	1152		ADULT	119570	211.327	PRAMIPEXOLE	PRAMIPEXOLE	CCCN[C@H]1CCC2=C(C1)SC(N)=N2	PLASMA	83619PEU5T							30		t	ng × h/mL	5.29		ng/mL	0.268			UNKNOWN	mg	0.375		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/20110012	Homo sapiens		h	31.2							false
2093	1153		ADULT	5403	225.2842	TERBUTALINE	TERBUTALINE	CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1	PLASMA	N8ONU3L3PG							24		t	nM × h	148.6		nM	24			RECOMMENDED	mg	5		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2706188/	Homo sapiens		h	13.7							false
2094	1155		ADULT		416.3533	TROVAFLOXACIN	TROVAFLOXACIN	N[C@H]1[C@@H]2CN(C[C@H]12)C3=NC4=C(C=C3F)C(=O)C(=CN4C5=CC=C(F)C=C5F)C(O)=O	SERUM	9F388J00UK							24		t	mg × h/L	9.4		mg/L	1			UNKNOWN	mg	100		SINGLE	UNKNOWN					20.3	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8737145	Homo sapiens		h	9.2							false
2095	1155		ADULT		416.3533	TROVAFLOXACIN	TROVAFLOXACIN	N[C@H]1[C@@H]2CN(C[C@H]12)C3=NC4=C(C=C3F)C(=O)C(=CN4C5=CC=C(F)C=C5F)C(O)=O	SERUM	9F388J00UK							24		t	mg × h/L	26.2		mg/L	2.9			UNKNOWN	mg	300		SINGLE	UNKNOWN					25.6	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8737145	Homo sapiens		h	10.5							false
2096	1155		ADULT		416.3533	TROVAFLOXACIN	TROVAFLOXACIN	N[C@H]1[C@@H]2CN(C[C@H]12)C3=NC4=C(C=C3F)C(=O)C(=CN4C5=CC=C(F)C=C5F)C(O)=O	SERUM	9F388J00UK							24		t	mg × h/L	11.8		mg/L	1.1			UNKNOWN	mg	100		STEADY-STATE	UNKNOWN		day	1		22	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8737145	Homo sapiens		h	10.5							false
2097	1155		ADULT		416.3533	TROVAFLOXACIN	TROVAFLOXACIN	N[C@H]1[C@@H]2CN(C[C@H]12)C3=NC4=C(C=C3F)C(=O)C(=CN4C5=CC=C(F)C=C5F)C(O)=O	SERUM	9F388J00UK							24		t	mg × h/L	34.6		mg/L	3.3			UNKNOWN	mg	300		STEADY-STATE	UNKNOWN		day	1		28.3	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8737145	Homo sapiens		h	12.2							false
2098	1155		ADULT		416.3533	TROVAFLOXACIN	TROVAFLOXACIN	N[C@H]1[C@@H]2CN(C[C@H]12)C3=NC4=C(C=C3F)C(=O)C(=CN4C5=CC=C(F)C=C5F)C(O)=O	SERUM	9F388J00UK									∞	μg × h/mL	32.2		μg/mL	2.9			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9935250	Homo sapiens		h	13.6							false
2099	1156		ADULT	110634|135400189	488.603	VARDENAFIL	VARDENAFIL	CCCC1=NC(C)=C2N1NC(=NC2=O)C3=C(OCC)C=CC(=C3)S(=O)(=O)N4CCN(CC)CC4	PLASMA	UCE6F4125H									∞	ng × h/mL	22.83		ng/mL	30.1			RECOMMENDED	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27318021	Homo sapiens		h	2.21							false
2100	1157		ADULT	5978	824.3996	VINCRISTINE	VINCRISTINE	CC[C@]1(O)C[C@H]2CN(C1)CCC3=C(NC4=C3C=CC=C4)[C@@](C2)(C(=O)OC)C5=CC6=C(C=C5OC)N(C=O)[C@@H]7[C@]68CCN9CC=C[C@](CC)([C@@H]89)[C@@H](OC(C)=O)[C@]7(O)C(=O)OC	PLASMA	5J49Q6B70F									∞	ng × h/mL	14566		ng/mL	1220			UNKNOWN	mg/m²	2.25		STEADY-STATE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202497Orig1s000PharmR.pdf	Homo sapiens										false
2101	1157		UNKNOWN		824.9576	VINCRISTINE	VINCRISTINE	CC[C@]1(O)C[C@@H]2C[N@](C1)CCC3=C(NC4=C3C=CC=C4)[C@@](C2)(C(=O)OC)C5=C(OC)C=C6N(C=O)[C@@H]7[C@]8(CCN9CC=C[C@](CC)([C@@H]89)[C@@H](OC(C)=O)[C@]7(O)C(=O)OC)C6=C5	PLASMA	5J49Q6B70F																						UNKNOWN				Vincristine sulfate is extensively protein bound (75%) and is reported to be concentrated in blood platelets. Within 15 to 30 minutes after injection, over 90% of the drug is distributed from the blood into tissue, where it remains tightly, but not irreversibly, bound.	25	UNKNOWN		UNKNOWN	OTHER GOV'T	https://www.medsafe.govt.nz/profs/Datasheet/v/Vincristinesulfatempinj.pdf	Homo sapiens										false
2102	1158			5311	264.3202	VORINOSTAT	VORINOSTAT	ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1	PLASMA	58IFB293JI							24		t	μM × h	4.59		μM	0.83				mg	400		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00771472	Homo sapiens		h	1.94							false
2103	1158			5311	264.3202	VORINOSTAT	VORINOSTAT	ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1	PLASMA	58IFB293JI							24		t	μM × h	5.59		μM	1.17				mg	400		STEADY-STATE			day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00771472	Homo sapiens		h	2.3							false
2104	1158		ADULT	5311	264.3202	VORINOSTAT	VORINOSTAT	ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1	PLASMA	58IFB293JI									?	μM × h	5.5		μM	1.2			RECOMMENDED	mg	400		SINGLE	HIGH-FAT				Vorinostat is approximately 71% bound to human plasma proteins over the range of concentrations of 0.5 to 50 µg/mL.	29	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021991s002lbl.pdf	Homo sapiens		h	2							false
2105	1161		ADULT	171548	244.311	BIOTIN	biotin	OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12	PLASMA	6SO6U10H04									?	ng × h/mL	2315		ng/mL	494.9			UNKNOWN	mg	100		SINGLE	FASTED					81	HEALTHY	Oral	FEMALE / MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/26699811/	Homo sapiens										false
2106	1161		ADULT	171548	244.311	BIOTIN	biotin	OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12	PLASMA	6SO6U10H04									?	ng × h/mL	4010		ng/mL	823.8			UNKNOWN	mg	300		SINGLE	FASTED					81	HEALTHY	Oral	FEMALE / MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/26699811/	Homo sapiens										false
2107	1161		ADULT	171548	244.311	BIOTIN	biotin	OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12	SERUM	6SO6U10H04													ng/mL	41			UNKNOWN	mg	5		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.future-science.com/doi/pdf/10.4155/ipk-2017-0013	Homo sapiens		h	15							false
2108	1161		ADULT	171548	244.311	BIOTIN	biotin	OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12	SERUM	6SO6U10H04													ng/mL	91			UNKNOWN	mg	10		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.future-science.com/doi/pdf/10.4155/ipk-2017-0013	Homo sapiens		h	15							false
2109	1161		ADULT	171548	244.311	BIOTIN	biotin	OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12	SERUM	6SO6U10H04													ng/mL	184			UNKNOWN	mg	20		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	REVIEW	https://www.future-science.com/doi/pdf/10.4155/ipk-2017-0013	Homo sapiens		h	15							false
2110	1161		ADULT	171548	244.311	BIOTIN	biotin	OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12	PLASMA	6SO6U10H04									?	ng × h/mL	210		ng/mL	84.8			UNKNOWN	mg	10		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6574044/	Homo sapiens										false
2111	1161		ADULT	171548	244.311	BIOTIN	biotin	OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12	PLASMA	6SO6U10H04									?	ng × h/mL	605.1		ng/mL	214.6			UNKNOWN	mg	40		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6574044/	Homo sapiens										false
2112	1161		ADULT	171548	244.311	BIOTIN	biotin	OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12	PLASMA	6SO6U10H04									?	ng × h/mL	1652.4		ng/mL	508.5			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6574044/	Homo sapiens										false
2113	1162		UNKNOWN	13505	452.5873	DIPHENOXYLATE	DIPHENOXYLATE	CCOC(=O)C1(CCN(CCC(C#N)(C2=CC=CC=C2)C3=CC=CC=C3)CC1)C4=CC=CC=C4	UNKNOWN	73312P173G																						UNKNOWN					15.5	UNKNOWN		UNKNOWN	OTHER	https://go.drugbank.com/drugs/DB01081	Homo sapiens										false
2114	1162		ADULT	13505	452.5873	DIPHENOXYLATE	DIPHENOXYLATE	CCOC(=O)C1(CCN(CCC(C#N)(C2=CC=CC=C2)C3=CC=CC=C3)CC1)C4=CC=CC=C4	PLASMA	73312P173G													ng/mL	9.5			RECOMMENDED	mg	5		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/5026379	Homo sapiens		h	2.5							false
2115	1164		ADULT	10199199	265.821	DESMETHYLSIBUTRAMINE	DESMETHYLSIBUTRAMINE	CNC(CC(C)C)C1(CCC1)C2=CC=C(Cl)C=C2	PLASMA	889I657R9P									∞	ng × h/mL	133.03		ng/mL	7.12			DEFINED DAILY	mg	15		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15823773/	Homo sapiens		h	22.31							false
2116	1164		ADULT	134772	251.795	DIDESMETHYLSIBUTRAMINE	DIDESMETHYLSIBUTRAMINE	CC(C)CC(N)C1(CCC1)C2=CC=C(Cl)C=C2	PLASMA	987R943R3P									∞	ng × h/mL	205.86		ng/mL	8.09			DEFINED DAILY	mg	15		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15823773/	Homo sapiens		h	23.07							false
2117	1164		ADULT	5210	279.848	SIBUTRAMINE	sibutramine	CC(C)CC(N(C)C)C1(CCC1)C2=CC=C(Cl)C=C2	PLASMA	WV5EC51866									∞	pg × h/mL	23296.9		pg/mL	4368.5			DEFINED DAILY	mg	15		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29403750/	Homo sapiens		h	3.6							false
2118	1164		ADULT	10199199	265.821	DESMETHYLSIBUTRAMINE	DESMETHYLSIBUTRAMINE	CNC(CC(C)C)C1(CCC1)C2=CC=C(Cl)C=C2	PLASMA	889I657R9P									∞	pg × h/mL	100736.1		pg/mL	4067.7			DEFINED DAILY	mg	15		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29403750/	Homo sapiens		h	25.5							false
2119	1164		ADULT	134772	251.795	DIDESMETHYLSIBUTRAMINE	DIDESMETHYLSIBUTRAMINE	CC(C)CC(N)C1(CCC1)C2=CC=C(Cl)C=C2	PLASMA	987R943R3P									∞	pg × h/mL	194500.9		pg/mL	6579.8			DEFINED DAILY	mg	15		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29403750/	Homo sapiens		h	23.6							false
2120	1164		ADULT	10199199	265.821	DESMETHYLSIBUTRAMINE	DESMETHYLSIBUTRAMINE	CNC(CC(C)C)C1(CCC1)C2=CC=C(Cl)C=C2	PLASMA	889I657R9P							24		t	ng × h/mL	25.5		ng/mL	4			DEFINED DAILY	mg	15		SINGLE	UNKNOWN				sibutramine and its active metabolites desmethylsibutramine (M1) and didesmethylsibutramine (M2) are extensively bound to plasma proteins (≥94%)	6	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020632s034s035lbl.pdf	Homo sapiens										false
2121	1164		ADULT	134772	251.795	DIDESMETHYLSIBUTRAMINE	DIDESMETHYLSIBUTRAMINE	CC(C)CC(N)C1(CCC1)C2=CC=C(Cl)C=C2	PLASMA	987R943R3P									?	ng × h/mL	92.1		ng/mL	6.4			DEFINED DAILY	mg	15		SINGLE	UNKNOWN				sibutramine and its active metabolites desmethylsibutramine (M1) and didesmethylsibutramine (M2) are extensively bound to plasma proteins (≥94%)	6	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020632s034s035lbl.pdf	Homo sapiens		h	17.2							false
2122	1165		ADULT	6323289	690.847	DALFOPRISTIN	DALFOPRISTIN	CCN(CC)CCS(=O)(=O)[C@@H]1CCN2[C@H]1C(=O)O[C@H](C(C)C)[C@H](C)\\C=C\\C(=O)NC\\C=C\\C(C)=C\\[C@@H](O)CC(=O)CC3=NC(=CO3)C2=O	PLASMA	R9M4FJE48E			QUINUPRISTIN	QUINUPRISTIN		23OW28RS7P			?	μg × h/mL	10.57		μg/mL	7.96			UNKNOWN	mg/kg bw	5.25		STEADY-STATE	UNKNOWN		day	3			HEALTHY	Intravenous	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050747s015,050748s014lbl.pdf	Homo sapiens		h	1.04							true
2123	1167		ADULT	31378	380.4504	FLUDROCORTISONE	FLUDROCORTISONE	C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO	PLASMA	U0476M545B									∞	pg × h/mL	3275.8		pg/mL	1241.1			UNKNOWN	mg	0.1		SINGLE	FASTED				Fludrocortisone is 70–80% bound to human serum proteins, mainly to the globulin fractions.	30	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25611194	Homo sapiens		h	2.57							false
2124	1167		ADULT	31378	380.4504	FLUDROCORTISONE	FLUDROCORTISONE	C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO	PLASMA	U0476M545B									∞	μg × h/L	1.25		μg/L	0.19			UNKNOWN	μg	50		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27416887	Homo sapiens		h	1.35							false
2125	1168		ADULT	3825	254.0943	KETOPROFEN	KETOPROFEN	CC(C(O)=O)C1=CC=CC(=C1)C(=O)C2=CC=CC=C2	PLASMA	90Y4QC304K									∞	μg × h/mL	21.91		μg/mL	10.1			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/7439263	Homo sapiens		h	1.13							false
2126	1169			6047|6971033	197.1879	LEVODOPA	N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O	N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O	PLASMA	46627O600J																										Plasma Protein Binding: 10–30%	80				DRUG LABEL	https://www.drugs.com/monograph/levodopa-carbidopa.html	Homo sapiens										false
2127	1169		ADULT	6047|6971033	197.1879	LEVODOPA	N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O	N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O	PLASMA	46627O600J	2563|74545363|75679734		CARBIDOPA, DL-	CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN	CC(CC1=CC(O)=C(O)C=C1)(NN)C(O)=O	555UP07D5N			∞	μg × min/mL	84.8		μg/mL	0.946			RECOMMENDED	mg	100		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/22549097	Homo sapiens		min	78.7							true
2128	1170		ADULT	60795	448.385	ARIPIPRAZOLE	ARIPIPRAZOLE	ClC1=C(Cl)C(=CC=C1)N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2	PLASMA	82VFR53I78							24		t	ng × h/mL	2947		ng/mL	163			UNKNOWN	mg	10		MULTIPLE	UNKNOWN		day	1	more than 99% of aripiprazole and its otype or phenotype major active metabolite is bound to plasma protein	1	HEALTHY	Oral	MALE	REVIEW	https://www.ncbi.nlm.nih.gov/pubmed/15257633	Homo sapiens		h	52.9							false
2129	1171		ADULT	5742832|9568617|135398736	435.433	AZTREONAM	AZTREONAM	C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O	PLASMA	G2B4VE5GH8									∞	mg × h/L	208						RECOMMENDED	g	1		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3710959	Homo sapiens		h	2.67							false
2130	1171		ADULT	5742832|9568617|135398736	435.433	AZTREONAM	AZTREONAM	C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O	SERUM	G2B4VE5GH8													μg/mL	54			RECOMMENDED	mg	500		SINGLE	UNKNOWN				serum protein binding averaged 56% and was independent of dose	44	HEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050580s040,050632s013lbl.pdf	Homo sapiens										false
2131	1171		ADULT	5742832|9568617|135398736	435.433	AZTREONAM	AZTREONAM	C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O	SERUM	G2B4VE5GH8													μg/mL	90			RECOMMENDED	g	1		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050580s040,050632s013lbl.pdf	Homo sapiens										false
2132	1171		ADULT	5742832|9568617|135398736	435.433	AZTREONAM	AZTREONAM	C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O	SERUM	G2B4VE5GH8													μg/mL	204			RECOMMENDED	g	2		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050580s040,050632s013lbl.pdf	Homo sapiens										false
2133	1172		ADULT	2477	385.5031	BUSPIRONE	BUSPIRONE	O=C1CC2(CCCC2)CC(=O)N1CCCCN3CCN(CC3)C4=NC=CC=N4	PLASMA	TK65WKS8HL									∞	ng × h/mL	9.402		ng/mL	1.711			RECOMMENDED	mg	15		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11504277	Homo sapiens		h	3.062							false
2134	1172		ADULT	2477	385.5031	BUSPIRONE	BUSPIRONE	O=C1CC2(CCCC2)CC(=O)N1CCCCN3CCN(CC3)C4=NC=CC=N4	PLASMA	TK65WKS8HL									?	ng × h/mL	6.837		ng/mL	1.613			RECOMMENDED	mg	15		STEADY-STATE	FASTED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11504277	Homo sapiens										false
2135	1172		UNKNOWN	2477	385.5031	BUSPIRONE	BUSPIRONE	O=C1CC2(CCCC2)CC(=O)N1CCCCN3CCN(CC3)C4=NC=CC=N4	PLASMA	TK65WKS8HL																						UNKNOWN				An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.	14	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/18731s39s45lbl.pdf	Homo sapiens										false
2136	1173		ADULT	60846	435.5188	VALSARTAN	VALSARTAN	CCCCC(=O)N(CC1=CC=C(C=C1)C2=C(C=CC=C2)C3=NN=NN3)[C@@H](C(C)C)C(O)=O	PLASMA	80M03YXJ7I									∞	μg × h/mL	22.56		μg/mL	2.141			UNKNOWN	mg	160		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21617777	Homo sapiens		h	9.55							false
2137	1173		ADULT	60846	435.5188	VALSARTAN	VALSARTAN	CCCCC(=O)N(CC1=CC=C(C=C1)C2=C(C=CC=C2)C3=NN=NN3)[C@@H](C(C)C)C(O)=O	PLASMA	80M03YXJ7I									∞	ng × h/mL	34310		ng/mL	5756			UNKNOWN	mg	80		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27128457	Homo sapiens		h	8				30	Oral solution		false
2138	1173		ADULT	60846	435.5188	VALSARTAN	VALSARTAN	CCCCC(=O)N(CC1=CC=C(C=C1)C2=C(C=CC=C2)C3=NN=NN3)[C@@H](C(C)C)C(O)=O	PLASMA	80M03YXJ7I									∞	ng × h/mL	20650		ng/mL	2808			UNKNOWN	mg	80		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27128457	Homo sapiens		h	8.45				29	Valsartan tablet		false
2139	1174		ADULT	60877	247.25	EMTRICITABINE	EMTRICITABINE	C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F	PLASMA	G70B4ETF4S							24		t	μg × h/mL	10		μg/mL	1.8			RECOMMENDED	mg	200		MULTIPLE	UNKNOWN		day	1	In vitro binding of emtricitabine to human plasma proteins was <4% and independent of concentration over the range of 0.02–200 ug/mL	96	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021500s010,021896s004lbl.pdf	Homo sapiens		h	10							false
2140	1174		CHILD	60877	247.25	EMTRICITABINE	EMTRICITABINE	C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F	PLASMA	G70B4ETF4S									?	μg × h/mL	12.6		μg/mL	2.7			RECOMMENDED	mg/kg	5.6		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021500s010,021896s004lbl.pdf	Homo sapiens		h	8.2							false
2141	1175		ADULT	4205	265.3529	MIRTAZAPINE	CN1CCN2C(C1)C3=C(CC4=C2N=CC=C4)C=CC=C3	CN1CCN2C(C1)C3=C(CC4=C2N=CC=C4)C=CC=C3	PLASMA	A051Q2099Q																	RECOMMENDED	mg	15		SINGLE	UNKNOWN				Mirtazapine is approximately 85% bound to plasma proteins over a concentration range of 0.01 to 10 mcg/mL.	15	UNKNOWN	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020415s023s024.pdf	Homo sapiens		h	30							false
2142	1175		ADULT	4205	265.3529	MIRTAZAPINE	CN1CCN2C(C1)C3=C(CC4=C2N=CC=C4)C=CC=C3	CN1CCN2C(C1)C3=C(CC4=C2N=CC=C4)C=CC=C3	PLASMA	A051Q2099Q									∞	μg × h/L	345		μg/L	32.3			RECOMMENDED	mg	15		SINGLE	FED				Mirtazapine binds to plasma proteins (85%) in a nonspecific and reversible way.	15	HEALTHY	Oral	MALE	REVIEW	https://www.ncbi.nlm.nih.gov/pubmed/10885584	Homo sapiens		h	21.2							false
2143	1176		ADULT	448601	1019.239	OCTREOTIDE	OCTREOTIDE	C[C@@H](O)[C@@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@H](N)CC2=CC=CC=C2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@H](CC4=CNC5=C4C=CC=C5)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1	PLASMA	RWM8CCW8GP									∞	ng × h/mL	19						UNKNOWN	mg	20		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://pubmed.ncbi.nlm.nih.gov/22539587	Homo sapiens										false
2144	1176		UNKNOWN	448601	1019.239	OCTREOTIDE	OCTREOTIDE	C[C@@H](O)[C@@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@H](N)CC2=CC=CC=C2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@H](CC4=CNC5=C4C=CC=C5)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1	PLASMA	RWM8CCW8GP													ng/mL	5.2			UNKNOWN	μg	100		SINGLE	UNKNOWN				In blood, the distribution into the erythrocytes was found to be negligible and about 65% was bound in the plasma in a concentration-independent manner.	35	UNKNOWN	Subcutaneous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213224s000lbl.pdf	Homo sapiens		h	0.2							false
2145	1177		ADULT	4828	248.3208	PINDOLOL	PINDOLOL	CC(C)NCC(O)COC1=CC=CC2=C1C=CN2	PLASMA	BJ4HF6IU1D							24		t	nM × h	1200		nM	250			RECOMMENDED	mg	10		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2880722/	Homo sapiens		h	3.1							false
2146	1178		ADULT	60172	273.19	ADEFOVIR	ADEFOVIR	C1=NC(=C2C(=N1)N(C=N2)CCOCP(=O)(O)O)N	PLASMA	6GQP90I798									∞	ng × h/mL	220		ng/mL	18.4			DEFINED DAILY	mg	10		SINGLE	UNKNOWN				In vitro binding of adefovir to human plasma or human serum proteins is ≤4% over the adefovir concentration range of 0.1 to 25 ug/mL.	96	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021449s009lbl.pdf	Homo sapiens		h	7.48							false
2147	1179		ADULT	2540	610.6597	CANDESARTAN CILEXETIL	CANDESARTAN CILEXETIL	CCOC1=NC2=C(N1CC3=CC=C(C=C3)C4=C(C=CC=C4)C5=NN=NN5)C(=CC=C2)C(=O)OC(C)OC(=O)OC6CCCCC6	SERUM	R85M2X0D68									∞	ng × h/mL	485		ng/mL	55			UNKNOWN	mg	8		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10192757	Homo sapiens		h	6.7							false
2148	1179		ADULT	2540	610.6597	CANDESARTAN CILEXETIL	CANDESARTAN CILEXETIL	CCOC1=NC2=C(N1CC3=CC=C(C=C3)C4=C(C=CC=C4)C5=NN=NN5)C(=CC=C2)C(=O)OC(C)OC(=O)OC6CCCCC6	SERUM	R85M2X0D68									∞	ng × h/mL	1359		ng/mL	79			UNKNOWN	mg	8		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10192757	Homo sapiens		h	12							false
2149	1179		ADULT	2540	610.6597	CANDESARTAN CILEXETIL	CANDESARTAN CILEXETIL	CCOC1=NC2=C(N1CC3=CC=C(C=C3)C4=C(C=CC=C4)C5=NN=NN5)C(=CC=C2)C(=O)OC(C)OC(=O)OC6CCCCC6	SERUM	R85M2X0D68							24		t	ng × h/mL	509		ng/mL	61			UNKNOWN	mg	8		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10192757	Homo sapiens		h	7.1							false
2150	1179		ADULT	2540	610.6597	CANDESARTAN CILEXETIL	CANDESARTAN CILEXETIL	CCOC1=NC2=C(N1CC3=CC=C(C=C3)C4=C(C=CC=C4)C5=NN=NN5)C(=CC=C2)C(=O)OC(C)OC(=O)OC6CCCCC6	SERUM	R85M2X0D68							24		t	ng × h/mL	1152		ng/mL	92			UNKNOWN	mg	8		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10192757	Homo sapiens		h	15.7							false
2151	1179		UNKNOWN	2540	610.6597	CANDESARTAN CILEXETIL	CANDESARTAN CILEXETIL	CCOC1=NC2=C(N1CC3=CC=C(C=C3)C4=C(C=CC=C4)C5=NN=NN5)C(=CC=C2)C(=O)OC(C)OC(=O)OC6CCCCC6	PLASMA	R85M2X0D68																	UNKNOWN				UNKNOWN	UNKNOWN				Candesartan is highly bound to plasma proteins (>99%) and does not penetrate red blood cells. The protein binding is constant at candesartan plasma concentrations well above the range achieved with recommended doses.	1	UNKNOWN	UNKNOWN	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020838s041lbl.pdf	Homo sapiens										false
2152	1180		ADULT	5311051	410.907	CLOBETASOL	CLOBETASOL	C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl	PLASMA	ADN79D536H							12		t	pg × h/mL	562		pg/mL	59			UNKNOWN	g	3.57		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Topical	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18539358	Homo sapiens										false
2153	1180		UNKNOWN	5311051	410.907	CLOBETASOL	CLOBETASOL	C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl	PLASMA	ADN79D536H																						UNKNOWN					2.5	UNKNOWN		UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21965623	Homo sapiens										false
2154	1180		UNKNOWN	5311051	410.907	CLOBETASOL	CLOBETASOL	C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl	PLASMA	ADN79D536H																	RECOMMENDED	mg	12.5		SINGLE	UNKNOWN				T1/2 estimated from fig. 1 and 2		UNHEALTHY	Topical	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6851236/	Homo sapiens		h	18							false
2155	1181		ADULT	71415	410.4515	DIFLORASONE	DIFLORASONE	C[C@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO	PLASMA	T2DHJ9645W													pg/mL	0			UNKNOWN	mg	170		SINGLE	UNKNOWN						HEALTHY	Transdermal	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/102707/	Homo sapiens										false
2156	1182		UNKNOWN	657237	285.2318	FLUDARABINE	FLUDARABINE	NC1=NC(F)=NC2=C1N=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3O	PLASMA	P2K93U8740																	UNKNOWN	mg/m²	25		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020038s033lbl.pdf	Homo sapiens		h	20							false
2157	1182		ADULT	657237	285.2318	FLUDARABINE	FLUDARABINE	NC1=NC(F)=NC2=C1N=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3O	PLASMA	P2K93U8740									?	μM × h	21.55		μM	4.28			UNKNOWN	mg/m²	30		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/17211431	Homo sapiens		h	8.9							false
2158	1183		ADULT	169870	428.6041	HYDROXYPROGESTERONE CAPROATE	HYDROXYPROGESTERONE CAPROATE	CCCCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O	PLASMA	276F2O42F5							168		t	ng × h/mL	571.4		ng/mL	5			RECOMMENDED	mg	250		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intramuscular	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021945s012lbl.pdf	Homo sapiens		day	16.4							false
2159	1183		ADULT	169870	428.6041	HYDROXYPROGESTERONE CAPROATE	HYDROXYPROGESTERONE CAPROATE	CCCCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O	PLASMA	276F2O42F5							168		t	ng × h/mL	1269.6		ng/mL	12.5			RECOMMENDED	mg	250		STEADY-STATE	UNKNOWN		week	1			UNHEALTHY	Intramuscular	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021945s012lbl.pdf	Homo sapiens										false
2160	1184		UNKNOWN	9811704	645.6048	ACARBOSE	ACARBOSE	C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]3C=C(CO)[C@@H](O)[C@H](O)[C@H]3O	PLASMA	T58MSI464G									?				ng/mL	49			UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	REVIEW	https://books.google.ru/books?id=QpjsCAAAQBAJ&pg=PA543&lpg=PA543&dq=Acarbose+AUC+human&source=bl&ots=z43vS8W_1j&sig=ACfU3U1iPoHWm_dZPMGsYSpyidnw6GVLYw&hl=ru&sa=X&ved=2ahUKEwiTm4zGzYbnAhVriYsKHcGpAO8Q6AEwAnoECAYQAQ#v=onepage&q=Acarbose%20AUC%20human&f=false	Homo sapiens										false
2161	1184		UNKNOWN	9811704	645.6048	ACARBOSE	ACARBOSE	C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]3C=C(CO)[C@@H](O)[C@H](O)[C@H]3O	PLASMA	T58MSI464G									?	μg × h/mL	3.13						UNKNOWN	mg/kg	0.4		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	REVIEW	https://link.springer.com/chapter/10.1007/978-3-642-73583-7_4	Homo sapiens		h	0.55							false
2162	1184		UNKNOWN	9811704	645.6048	ACARBOSE	ACARBOSE	C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]3C=C(CO)[C@@H](O)[C@H](O)[C@H]3O	PLASMA	T58MSI464G							24		t	μg × h/mL	0.51						DEFINED DAILY	mg	300		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	REVIEW	https://link.springer.com/chapter/10.1007/978-3-642-73583-7_4	Homo sapiens										false
2163	1185		ADULT	1983	151.16	ACETAMINOPHEN	ACETAMINOPHEN	CC(=O)NC1=CC=C(O)C=C1	PLASMA	362O9ITL9D									?	μg × h/mL	43		μg/mL	28			RECOMMENDED	mg	1000		SINGLE	UNKNOWN						UNKNOWN	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204767s000lbl.pdf	Homo sapiens		h	2.4							false
2164	1187		UNKNOWN	5284513	326.4293	ACITRETIN	acitretin	COC1=CC(C)=C(\\C=C\\C(C)=C\\C=C\\C(C)=C\\C(O)=O)C(C)=C1C	PLASMA	LCH760E9T7													ng/mL	416			DEFINED DAILY	mg	50		SINGLE	FED						HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019821s024lbl.pdf	Homo sapiens										false
2165	1187		UNKNOWN	5284513	326.4293	ACITRETIN	acitretin	COC1=CC(C)=C(\\C=C\\C(C)=C\\C=C\\C(C)=C\\C(O)=O)C(C)=C1C	PLASMA	LCH760E9T7							15		t	ng × h/mL	2249		ng/mL	416			DEFINED DAILY	mg	50		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/2977392	Homo sapiens		h	2.8							false
2166	1188		ADULT	5284514|40466858	348.4382	ACRIVASTINE	ACRIVASTINE	CC1=CC=C(C=C1)C(=C/CN2CCCC2)\\C3=NC(\\C=C\\C(O)=O)=CC=C3	PLASMA	A20F9XAI7W									?	μg × h/L	650		μg/L	220			INVESTIGATIONAL	mg	16		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	http://en.cnki.com.cn/Article_en/CJFDTOTAL-XYYL200704004.htm	Homo sapiens										false
2167	1188		ADULT	5284514|40466858	348.4382	ACRIVASTINE	ACRIVASTINE	CC1=CC=C(C=C1)C(=C/CN2CCCC2)\\C3=NC(\\C=C\\C(O)=O)=CC=C3	PLASMA	A20F9XAI7W	9581|11041807|25137849		PSEUDOEPHEDRINE HYDROCHLORIDE	Pseudoephedrine hydrochloride	Cl.CN[C@@H](C)[C@@H](O)C1=CC=CC=C1	6V9V2RYJ8N							ng/mL	227			RECOMMENDED	mg	8		STEADY-STATE	UNKNOWN		day	4		50	UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019806s013lbl.pdf	Homo sapiens		h	3.5							true
2168	1189		ADULT	60164	412.5201	ADAPALENE	ADAPALENE	COC1=C(C=C(C=C1)C2=CC3=C(C=C2)C=C(C=C3)C(O)=O)C45CC6CC(CC(C6)C4)C5	PLASMA	1L4806J2QF													ng/mL	0.04			UNKNOWN	mg	6.8		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Topical	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/10898827	Homo sapiens										false
2169	1191		ADULT	83969	281.331	ALBENDAZOLE OXIDE	albendazole sulfoxide	CCC[S+]([O-])C1=CC=C2NC(NC(=O)OC)=NC2=C1	SERUM	J39B52TV34							24		t	ng × h/mL	3713.96		ng/mL	707.37			MAX DAILY	mg	800		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12784319	Homo sapiens		h	11.43							false
2170	1191		ADULT	53174	297.33	ALBENDAZOLE SULFONE	albendazole sulphone	CCCS(=O)(=O)C1=CC2=C(NC(NC(=O)OC)=N2)C=C1	SERUM	1UIC88380G							24		t	ng × h/mL	284.55		ng/mL	39.61			MAX DAILY	mg	800		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12784319	Homo sapiens		h	11.91							false
2171	1191		ADULT	83969	281.331	ALBENDAZOLE OXIDE	ALBENDAZOLE sulfoxide	CCC[S+]([O-])C1=CC=C2NC(NC(=O)OC)=NC2=C1	PLASMA	J39B52TV34													ng/mL	1310			UNKNOWN	mg	400		MULTIPLE	FED		day	2	Albendazole sulfoxide is 70% bound to plasma protein and is widely distributed throughout the body; it has been detected in urine, bile, liver, cyst wall, cyst fluid, and cerebrospinal fluid (CSF).	30	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020666s012lbl.pdf	Homo sapiens		h	8							false
2172	1192		ADULT		408.916	ALCLOMETASONE	ALCLOMETASONE	C[C@@H]1C[C@H]2[C@@H]3[C@H](Cl)CC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO	UNKNOWN	136H45TB7B							24		t	ng × h/mL/m²	7708						RECOMMENDED	mg/m²	4		SINGLE	UNKNOWN						UNKNOWN	Topical	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26063051/	Homo sapiens										false
2173	1193		ADULT	2118	308.765	ALPRAZOLAM	ALPRAZOLAM	CC1=NN=C2CN=C(C3=CC=CC=C3)C4=C(C=CC(Cl)=C4)N12	PLASMA	YU55MQ3IZY									?	ng × h/mL	261		ng/mL	17.4			RECOMMENDED	g	1		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6152055/	Homo sapiens		h	11.8							false
2174	1193		UNKNOWN	2118	308.765	ALPRAZOLAM	ALPRAZOLAM	CC1=NN=C2CN=C(C3=CC=CC=C3)C4=C(C=CC(Cl)=C4)N12	PLASMA	YU55MQ3IZY																	UNKNOWN				UNKNOWN	UNKNOWN				In vitro, alprazolam is bound (80 percent) to human serum protein. Serum albumin accounts for the majority of the binding.	20	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021726s008lbl.pdf	Homo sapiens		h	2.2							false
2175	1194		ADULT	2130	151.2487	AMANTADINE	AMANTADINE	NC12CC3CC(CC(C3)C1)C2	PLASMA	BF4C9Z1J53													μg/mL	0.24			RECOMMENDED	mg	100		SINGLE	UNKNOWN				Amantadine is approximately 67% bound to plasma proteins over a concentration range of 0.1 to 2.0 ug/mL.	33	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/016023s041,018101s016lbl.pdf	Homo sapiens										false
2176	1194		ADULT	2130	151.2487	AMANTADINE	AMANTADINE	NC12CC3CC(CC(C3)C1)C2	PLASMA	BF4C9Z1J53									?	ng × h/mL	6413.6		ng/mL	636.2			RECOMMENDED	mg	100		MULTIPLE	FASTED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/18074029	Homo sapiens		h	14.7							false
2177	1195		ADULT	6918493	378.4211	AMBRISENTAN	COC([C@H](OC1=NC(C)=CC(C)=N1)C(O)=O)(C2=CC=CC=C2)C3=CC=CC=C3	COC([C@H](OC1=NC(C)=CC(C)=N1)C(O)=O)(C2=CC=CC=C2)C3=CC=CC=C3	PLASMA	HW6NV07QEC																					STEADY-STATE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022081s033lbl.pdf	Homo sapiens		h	9							false
2178	1195		ADULT	6918493	378.4211	AMBRISENTAN	COC([C@H](OC1=NC(C)=CC(C)=N1)C(O)=O)(C2=CC=CC=C2)C3=CC=CC=C3	COC([C@H](OC1=NC(C)=CC(C)=N1)C(O)=O)(C2=CC=CC=C2)C3=CC=CC=C3	PLASMA	HW6NV07QEC									∞	ng × h/mL	6976.5		ng/mL	838.3			RECOMMENDED	mg	10		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/19455620	Homo sapiens		h	18.9							false
2179	1197		ADULT	148139	268.269	AMIFOSTINE	AMIFOSTINE	O.O.O.NCCCNCCSP(O)(O)=O	PLASMA	M487QF2F4V																	UNKNOWN	mg/m²	910	infusion, 30 min	OTHER	UNKNOWN		day	1			UNHEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020221s036lbl.pdf	Homo sapiens		min	8							false
2180	1198		UNKNOWN		131.1729	AMINOCAPROIC ACID	AMINOCAPROIC ACID	NCCCCCC(O)=O	PLASMA	U6F3787206													μg/mL	164			RECOMMENDED	g	5		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/15197scm036,scf037,scp038,scm039_amicar_lbl.pdf	Homo sapiens		h	1.2							false
2181	1199		ADULT		232.2783	AMINOGLUTETHIMIDE	AMINOGLUTETHIMIDE	CCC1(CCC(=O)NC1=O)C2=CC=C(N)C=C2	PLASMA														μg/mL	5.9			UNKNOWN	mg	250		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/018202s021lbl.pdf	Homo sapiens		h	12.5							false
2182	1199		ADULT	2145	232.2783	AMINOGLUTETHIMIDE	AMINOGLUTETHIMIDE	CCC1(CCC(=O)NC1=O)C2=CC=C(N)C=C2	PLASMA										∞	μg × h/mL	97		μg/mL	5.9			UNKNOWN	mg	500		SINGLE	FASTED				The binding ranged from 21.3 to 25.0% without concentration dependence	75	HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/6101151	Homo sapiens		h	12.5							false
2183	1200		ADULT	2161	298.29	AMLEXANOX	AMLEXANOX	CC(C)C1=CC=C2OC3=NC(N)=C(C=C3C(=O)C2=C1)C(O)=O	PLASMA	BRL1C2459K							24		t	ng × h/mL	357		ng/mL	116.7			RECOMMENDED	mg	5		SINGLE	UNKNOWN						UNHEALTHY	Topical	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020511ap.pdf	Homo sapiens		h	3.5							false
2184	1201		ADULT	2170	313.781	AMOXAPINE	AMOXAPINE	ClC1=CC2=C(OC3=C(C=CC=C3)N=C2N4CCNCC4)C=C1	PLASMA	R63VQ857OT									?	ng × h/mL	319		ng/mL	33.55			RECOMMENDED	mg	50		SINGLE	FED				In vitro tests show that amoxapine binding to human serum is approximately 90% [https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf]	10	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3997304/	Homo sapiens		h	6.02							false
2185	1202		ADOLESCENT	2187	293.3663	ANASTROZOLE	ANASTROZOLE	CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N	PLASMA	2Z07MYW1AZ									?	ng × h/mL	648		ng/mL	39.3			DEFINED DAILY	mg	1		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/19470631	Homo sapiens										false
2186	1203		ADULT	6005	267.3224	APOMORPHINE	APOMORPHINE	CN1CCC2=C3[C@H]1CC4=CC=C(O)C(O)=C4C3=CC=C2	PLASMA	N21FAR7B4S									?	pmol × h/mL	41.7		pmol/mL	47.5			RECOMMENDED	μg/kg bw	30		SINGLE	UNKNOWN						HEALTHY	Subcutaneous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2774511/	Homo sapiens		min	33.6							false
2187	1204		UNKNOWN	6918365|135413536	534.4267	APREPITANT	Aprepitant	C[C@@H](O[C@H]1OCCN(CC2=NC(=O)NN2)[C@H]1C3=CC=C(F)C=C3)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F	PLASMA	1NF15YR6UY							72		t	μg × h/mL	27.8		μg/mL	4.3			RECOMMENDED	mg	100		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209296s000lbl.pdf	Homo sapiens										false
2188	1204		UNKNOWN	6918365|135413536	534.4267	APREPITANT	Aprepitant	C[C@@H](O[C@H]1OCCN(CC2=NC(=O)NN2)[C@H]1C3=CC=C(F)C=C3)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F	PLASMA	1NF15YR6UY							72		t	μg × h/mL	43.9		μg/mL	6.1			RECOMMENDED	mg	130		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209296s000lbl.pdf	Homo sapiens										false
2189	1204		UNKNOWN	6918365|135413536	534.4267	APREPITANT	APREPITANT	C[C@@H](O[C@H]1OCCN(CC2=NC(=O)NN2)[C@H]1C3=CC=C(F)C=C3)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F	PLASMA	1NF15YR6UY									∞	ng × h/mL	27759		ng/mL	1354			UNKNOWN	mg	125		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	REVIEW	https://www.ncbi.nlm.nih.gov/pubmed/21042544	Homo sapiens		h	14							false
2190	1205		ADULT	2249	266.3361	ATENOLOL	ATENOLOL	CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1	PLASMA	50VV3VW0TI									∞	μg × h/mL	8.47		μg/mL	0.75			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/658112/	Homo sapiens		h	5.9							false
2191	1205		ADULT	2249	266.3361	ATENOLOL	ATENOLOL	CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1	PLASMA	50VV3VW0TI									∞	μg × h/mL	13.45		μg/mL	1.75			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/658112/	Homo sapiens		h	5.4							false
2192	1205		ADULT	2249	266.3361	ATENOLOL	ATENOLOL	CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1	PLASMA	50VV3VW0TI									∞	μg × h/mL	0.3						UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/658112/	Homo sapiens										false
2193	1205		UNKNOWN	2249	266.3361	ATENOLOL	ATENOLOL	CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1	PLASMA	50VV3VW0TI																	UNKNOWN				UNKNOWN	UNKNOWN				small amount (6%-16%) is bound to proteins in the plasma.	94	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/018240s032lbl.pdf	Homo sapiens		h	7							false
2194	1206		UNKNOWN		366.837	ATOVAQUONE	ATOVAQUONE	OC1=C([C@H]2CC[C@@H](CC2)C3=CC=C(Cl)C=C3)C(=O)C4=CC=CC=C4C1=O	PLASMA	Y883P1Z2LT									?	μg × h/mL	324						UNKNOWN	mg	750		SINGLE	FASTED					0.1	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020500s010lbl.pdf	Homo sapiens										false
2195	1206		UNKNOWN		366.837	ATOVAQUONE	ATOVAQUONE	OC1=C([C@H]2CC[C@@H](CC2)C3=CC=C(Cl)C=C3)C(=O)C4=CC=CC=C4C1=O	PLASMA	Y883P1Z2LT									?	μg × h/mL	801						UNKNOWN	mg	750		SINGLE	FED					0.1	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020500s010lbl.pdf	Homo sapiens										false
2196	1206		UNKNOWN		366.837	ATOVAQUONE	ATOVAQUONE	OC1=C([C@H]2CC[C@@H](CC2)C3=CC=C(Cl)C=C3)C(=O)C4=CC=CC=C4C1=O	PLASMA	Y883P1Z2LT									?	μg × h/mL	280		μg/mL	15.1			UNKNOWN	mg	500		MULTIPLE	FED		day	1		0.1	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020500s010lbl.pdf	Homo sapiens										false
2197	1206		UNKNOWN		366.837	ATOVAQUONE	ATOVAQUONE	OC1=C([C@H]2CC[C@@H](CC2)C3=CC=C(Cl)C=C3)C(=O)C4=CC=CC=C4C1=O	PLASMA	Y883P1Z2LT									?	μg × h/mL	169		μg/mL	8.8			UNKNOWN	mg	500		MULTIPLE	FASTED		day	1		0.1	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020500s010lbl.pdf	Homo sapiens										false
2198	1206		UNKNOWN		366.837	ATOVAQUONE	ATOVAQUONE	OC1=C([C@H]2CC[C@@H](CC2)C3=CC=C(Cl)C=C3)C(=O)C4=CC=CC=C4C1=O	PLASMA	Y883P1Z2LT													μg/mL	15.1			UNKNOWN	mg	500		STEADY-STATE	FED		day	1		0.1	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020500s010lbl.pdf	Homo sapiens										false
2199	1206		UNKNOWN		366.837	ATOVAQUONE	ATOVAQUONE	OC1=C([C@H]2CC[C@@H](CC2)C3=CC=C(Cl)C=C3)C(=O)C4=CC=CC=C4C1=O	PLASMA	Y883P1Z2LT													μg/mL	15.3			UNKNOWN	mg	750		STEADY-STATE	FED		day	1		0.1	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020500s010lbl.pdf	Homo sapiens										false
2200	1206		UNKNOWN		366.837	ATOVAQUONE	ATOVAQUONE	OC1=C([C@H]2CC[C@@H](CC2)C3=CC=C(Cl)C=C3)C(=O)C4=CC=CC=C4C1=O	PLASMA	Y883P1Z2LT													μg/mL	16.8			UNKNOWN	mg	1000		STEADY-STATE	FED		day	1		0.1	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020500s010lbl.pdf	Homo sapiens										false
2201	1206		UNKNOWN		366.837	ATOVAQUONE	ATOVAQUONE	OC1=C([C@H]2CC[C@@H](CC2)C3=CC=C(Cl)C=C3)C(=O)C4=CC=CC=C4C1=O	PLASMA	Y883P1Z2LT													μg/mL	24			RECOMMENDED	mg	750		STEADY-STATE	UNKNOWN		day	2		0.1	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020500s010lbl.pdf	Homo sapiens										false
2202	1207		ADULT	70788951|87793872|138402869	678.484	AURANOFIN	AURANOFIN	CC[P](CC)(CC)[Au+][S-][C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O	PLASMA	3H04W2810V							24		t	μg × h/mL	5.05		μg/mL	0.312			RECOMMENDED	mg	6		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/27821451	Homo sapiens		h	844							false
2203	1208			9444	244.2047	AZACITIDINE	AZACITIDINE	NC1=NC(=O)N(C=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O	PLASMA	M801H13NRU							8		t	ng × h/mL	1502.86							mg/m²	100		SINGLE							UNHEALTHY	Subcutaneous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00652626	Homo sapiens										false
2204	1208			9444	244.2047	AZACITIDINE	AZACITIDINE	NC1=NC(=O)N(C=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O	PLASMA	M801H13NRU							8		t	ng × h/mL	1505.16							mg/m²	100		SINGLE							UNHEALTHY	Subcutaneous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00652626	Homo sapiens										false
2205	1208			9444	244.2047	AZACITIDINE	AZACITIDINE	NC1=NC(=O)N(C=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O	PLASMA	M801H13NRU									∞	ng × h/mL	1533.37							mg/m²	100		SINGLE							UNHEALTHY	Subcutaneous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00652626	Homo sapiens										false
2206	1208			9444	244.2047	AZACITIDINE	AZACITIDINE	NC1=NC(=O)N(C=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O	PLASMA	M801H13NRU													ng/mL	1261.96				mg/m²	100		SINGLE							UNHEALTHY	Subcutaneous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00652626	Homo sapiens										false
2207	1208			9444	244.2047	AZACITIDINE	AZACITIDINE	NC1=NC(=O)N(C=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O	PLASMA	M801H13NRU							8		t	ng × h/mL	455.86							mg/m²	25		SINGLE							UNHEALTHY	Subcutaneous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00652626	Homo sapiens										false
2208	1208			9444	244.2047	AZACITIDINE	AZACITIDINE	NC1=NC(=O)N(C=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O	PLASMA	M801H13NRU							8		t	ng × h/mL	454.8							mg/m²	25		SINGLE							UNHEALTHY	Subcutaneous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00652626	Homo sapiens										false
2209	1208			9444	244.2047	AZACITIDINE	AZACITIDINE	NC1=NC(=O)N(C=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O	PLASMA	M801H13NRU									∞	ng × h/mL	460.47							mg/m²	25		SINGLE							UNHEALTHY	Subcutaneous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00652626	Homo sapiens										false
2210	1208			9444	244.2047	AZACITIDINE	AZACITIDINE	NC1=NC(=O)N(C=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O	PLASMA	M801H13NRU													ng/mL	293.38				mg/m²	25		SINGLE							UNHEALTHY	Subcutaneous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00652626	Homo sapiens										false
2211	1208			9444	244.2047	AZACITIDINE	AZACITIDINE	NC1=NC(=O)N(C=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O	PLASMA	M801H13NRU							8		t	ng × h/mL	897.43							mg/m²	50		SINGLE							UNHEALTHY	Subcutaneous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00652626	Homo sapiens										false
2212	1208			9444	244.2047	AZACITIDINE	AZACITIDINE	NC1=NC(=O)N(C=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O	PLASMA	M801H13NRU							8		t	ng × h/mL	895.38							mg/m²	50		SINGLE							UNHEALTHY	Subcutaneous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00652626	Homo sapiens										false
2213	1208			9444	244.2047	AZACITIDINE	AZACITIDINE	NC1=NC(=O)N(C=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O	PLASMA	M801H13NRU									∞	ng × h/mL	897.42							mg/m²	50		SINGLE							UNHEALTHY	Subcutaneous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00652626	Homo sapiens										false
2214	1208			9444	244.2047	AZACITIDINE	AZACITIDINE	NC1=NC(=O)N(C=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O	PLASMA	M801H13NRU													ng/mL	749.04				mg/m²	50		SINGLE							UNHEALTHY	Subcutaneous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00652626	Homo sapiens										false
2215	1208			9444	244.2047	AZACITIDINE	AZACITIDINE	NC1=NC(=O)N(C=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O	PLASMA	M801H13NRU							8		t	ng × h/mL	921.87							mg/m²	75		SINGLE							UNHEALTHY	Subcutaneous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00652626	Homo sapiens										false
2216	1208			9444	244.2047	AZACITIDINE	AZACITIDINE	NC1=NC(=O)N(C=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O	PLASMA	M801H13NRU							8		t	ng × h/mL	920.76							mg/m²	75		SINGLE							UNHEALTHY	Subcutaneous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00652626	Homo sapiens										false
2217	1208			9444	244.2047	AZACITIDINE	AZACITIDINE	NC1=NC(=O)N(C=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O	PLASMA	M801H13NRU									∞	ng × h/mL	945.5							mg/m²	75		SINGLE							UNHEALTHY	Subcutaneous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00652626	Homo sapiens										false
2218	1208			9444	244.2047	AZACITIDINE	AZACITIDINE	NC1=NC(=O)N(C=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O	PLASMA	M801H13NRU													ng/mL	745.5				mg/m²	75		SINGLE							UNHEALTHY	Subcutaneous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00652626	Homo sapiens										false
2219	1208			9444	244.2047	AZACITIDINE	AZACITIDINE	NC1=NC(=O)N(C=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O	PLASMA	M801H13NRU													ng/mL	1264.6				mg/m²	75		MULTIPLE			day	1			UNHEALTHY	Subcutaneous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01599325	Homo sapiens										false
2220	1208		ADULT	9444	244.2047	AZACITIDINE	NC1=NC(=O)N(C=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O	NC1=NC(=O)N(C=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O	PLASMA	M801H13NRU																	RECOMMENDED	mg/m²	75		SINGLE	UNKNOWN						UNHEALTHY	Subcutaneous	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050794s011lbl.pdf	Homo sapiens		min	41							false
2221	1208		ADULT	9444	244.2047	AZACITIDINE	NC1=NC(=O)N(C=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O	NC1=NC(=O)N(C=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O	PLASMA	M801H13NRU									∞	ng × h/mL	184		ng/mL	121			INVESTIGATIONAL	mg	200		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26296092	Homo sapiens		h	0.56							false
2222	1209		ADULT	19861	290.4021	AZATADINE	AZATADINE	CN1CCC(CC1)=C2C3=NC=CC=C3CCC4=C2C=CC=C4	PLASMA	94Z39NID6C									∞	ng × h/mL	20.5		ng/mL	1.4			RECOMMENDED	mg	2		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21737359/	Homo sapiens		h	10.9							false
2223	1211		ADULT	2284|78422631	213.661	BACLOFEN	BACLOFEN	NCC(CC(O)=O)C1=CC=C(Cl)C=C1	PLASMA	H789N3FKE8							6		t	μg × h/mL	1.1		μg/mL	0.2			RECOMMENDED	mg	10		STEADY-STATE	UNKNOWN		day	4			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2336342/	Homo sapiens										false
2224	1211		ADULT	2284|78422631	213.661	BACLOFEN	BACLOFEN	NCC(CC(O)=O)C1=CC=C(Cl)C=C1	PLASMA	H789N3FKE8													ng/mL	178			RECOMMENDED	mg	10		SINGLE	UNKNOWN				Plasma protein binding is approximately 30%.	70	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/21589_kemstro_lbl.pdf	Homo sapiens		h	3.75							false
2225	1212		UNKNOWN	2315	421.415	BENDROFLUMETHIAZIDE	BENDROFLUMETHIAZIDE	NS(=O)(=O)C1=CC2=C(NC(CC3=CC=CC=C3)NS2(=O)=O)C=C1C(F)(F)F	PLASMA	5Q52X6ICJI																						UNKNOWN					6	UNKNOWN		UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6369882	Homo sapiens										false
2226	1212		ADULT	2315	421.415	BENDROFLUMETHIAZIDE	BENDROFLUMETHIAZIDE	NS(=O)(=O)C1=CC2=C(NC(CC3=CC=CC=C3)NS2(=O)=O)C=C1C(F)(F)F	PLASMA	5Q52X6ICJI							12		t	μg × h/L	75		μg/L	15.4			DEFINED DAILY	mg	2.5		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7056277	Homo sapiens		h	8.6							false
2227	1212		ADULT	2315	421.415	BENDROFLUMETHIAZIDE	BENDROFLUMETHIAZIDE	NS(=O)(=O)C1=CC2=C(NC(CC3=CC=CC=C3)NS2(=O)=O)C=C1C(F)(F)F	PLASMA	5Q52X6ICJI							12		t	μg × h/L	147		μg/L	27.2			RECOMMENDED	mg	5		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7056277	Homo sapiens		h	8.4							false
2228	1212		ADULT	2315	421.415	BENDROFLUMETHIAZIDE	BENDROFLUMETHIAZIDE	NS(=O)(=O)C1=CC2=C(NC(CC3=CC=CC=C3)NS2(=O)=O)C=C1C(F)(F)F	PLASMA	5Q52X6ICJI							12		t	μg × h/L	250		μg/L	44.6			RECOMMENDED	mg	10		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7056277	Homo sapiens		h	8.4							false
2229	1213		UNKNOWN	82146	348.4779	BEXAROTENE	BEXAROTENE	CC1=C(C=C2C(=C1)C(C)(C)CCC2(C)C)C(=C)C3=CC=C(C=C3)C(O)=O	PLASMA	A61RXM4375									?	ng × h/mL	2133.34		ng/mL	652.44			UNKNOWN	mg/m²	300		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://www.researchgate.net/publication/286658511_Pharmacokinetics_of_bexarotene_soft_capsules_in_patients_with_relapsed_or_refractory_cutaneous_T-cell_lymphoma	Homo sapiens		h	3.18							false
2230	1214		ADULT	2375	430.373	BICALUTAMIDE	BICALUTAMIDE	CC(O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC2=CC=C(C#N)C(=C2)C(F)(F)F	PLASMA	A0Z3NAU9DP			GONADORELIN	LHRH		9O7312W37G											DEFINED DAILY	mg	50		SINGLE	UNKNOWN				Bicalutamide is highly protein-bound (96%)	4	HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf	Homo sapiens		day	5.8							true
2231	1214		ADULT	2375	430.4	BICALUTAMIDE	BICALUTAMIDE	C[C@](O)(C[S+]([O-])(=O)C1=CC=C(F)C=C1)C(=O)NC2=CC=C(C#N)C(=C2)C(F)(F)F	PLASMA	A0Z3NAU9DP									∞	μg × h/mL	202.5		μg/L	810.7			DEFINED DAILY	mg	50		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/22331758	Homo sapiens		h	146.4							false
2232	1215		ADULT	5311027	415.5656	BIMATOPROST	BIMATOPROST	CCNC(=O)CCC\\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\\C=C\\[C@@H](O)CCC2=CC=CC=C2	PLASMA	QXS94885MZ							24		t	ng × h/mL	0.09		ng/mL	0.08			RECOMMENDED	drop	1		STEADY-STATE	UNKNOWN		day	1	Approximately 12% of bimatoprost remains unbound in human plasma.	12	HEALTHY	Topical	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021275s022lbl.pdf	Homo sapiens										false
2233	1215		ADULT	5311027	415.5656	BIMATOPROST	BIMATOPROST	CCNC(=O)CCC\\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\\C=C\\[C@@H](O)CCC2=CC=CC=C2	PLASMA	QXS94885MZ													ng/mL	12.2			UNKNOWN	μg/kg bw	3.12		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021275s022lbl.pdf	Homo sapiens		min	45							false
2234	1217			387447	384.237	BORTEZOMIB	BORTEZOMIB	CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)B(O)O	PLASMA	69G8BD63PP													ng/mL	76.43				mg/m²	1.3		SINGLE							UNHEALTHY	Intravenous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01801436	Homo sapiens										false
2235	1217			387447	384.237	BORTEZOMIB	BORTEZOMIB	CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)B(O)O	PLASMA	69G8BD63PP																		mg/m²	1.3		SINGLE							UNHEALTHY	Intravenous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01801436	Homo sapiens		h	0.08							false
2236	1217			387447	384.237	BORTEZOMIB	BORTEZOMIB	CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)B(O)O	PLASMA	69G8BD63PP							72		t	ng × h/mL	51.86							mg/m²	1.3		SINGLE							UNHEALTHY	Intravenous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01801436	Homo sapiens										false
2237	1217			387447	384.237	BORTEZOMIB	BORTEZOMIB	CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)B(O)O	PLASMA	69G8BD63PP									∞	ng × h/mL	106.99							mg/m²	1.3		SINGLE							UNHEALTHY	Intravenous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01801436	Homo sapiens										false
2238	1217			387447	384.237	BORTEZOMIB	BORTEZOMIB	CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)B(O)O	PLASMA	69G8BD63PP													ng/mL	127.02				mg/m²	1.3		STEADY-STATE			4 days	1			UNHEALTHY	Intravenous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01801436	Homo sapiens										false
2239	1217			387447	384.237	BORTEZOMIB	BORTEZOMIB	CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)B(O)O	PLASMA	69G8BD63PP																		mg/m²	1.3		STEADY-STATE			4 days	1			UNHEALTHY	Intravenous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01801436	Homo sapiens		h	51.55							false
2240	1217			387447	384.237	BORTEZOMIB	BORTEZOMIB	CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)B(O)O	PLASMA	69G8BD63PP							72		t	ng × h/mL	190.39							mg/m²	1.3		STEADY-STATE			4 days	1			UNHEALTHY	Intravenous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01801436	Homo sapiens										false
2241	1217			387447	384.237	BORTEZOMIB	BORTEZOMIB	CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)B(O)O	PLASMA	69G8BD63PP									∞	ng × h/mL	349.62							mg/m²	1.3		STEADY-STATE			4 days	1			UNHEALTHY	Intravenous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01801436	Homo sapiens										false
2242	1217		ADULT	387447	384.237	BORTEZOMIB	bortezomib	CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)B(O)O	PLASMA	69G8BD63PP							48		t	ng × h/mL	82.8		ng/mL	106.2			UNKNOWN	mg/m²	1		MULTIPLE	UNKNOWN		4 days	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20306195	Homo sapiens		h	78.9							false
2243	1217		UNKNOWN	387447	384.237	BORTEZOMIB	BORTEZOMIB	CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)B(O)O	PLASMA	69G8BD63PP																						UNKNOWN				The binding of bortezomib to human plasma proteins averaged 83% over the concentration range of 100 to 1000 ng/mL.	17	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021602s040lbl.pdf	Homo sapiens										false
2244	1218		ADULT	72376318	442.221	BRIMONIDINE TARTRATE	BRIMONIDINE TARTRATE	O[C@@H]([C@@H](O)C(O)=O)C(O)=O.BrC1=C2N=CC=NC2=CC=C1NC3=NCCN3	PLASMA	4S9CL2DY2H									∞	pg × h/mL	375		pg/mL	73			UNKNOWN	drop	1		SINGLE	UNKNOWN						HEALTHY	Ocular	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021764s005lbl.pdf	Homo sapiens		h	2.1							false
2245	1219		ADULT	68844	383.507	BRINZOLAMIDE	BRINZOLAMIDE	CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O	BLOOD	9451Z89515													μg/mL	2.17			UNKNOWN	%	3		MULTIPLE	UNKNOWN		day	3			HEALTHY	Ocular	MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/10665514	Homo sapiens		day	111							false
2246	1219		UNKNOWN	68844	383.507	BRINZOLAMIDE	BRINZOLAMIDE	CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O	PLASMA	9451Z89515																	UNKNOWN				UNKNOWN	UNKNOWN				Binding of brinzolamide to plasma proteins is approximately 60%.	40	UNKNOWN	UNKNOWN	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020816s019lbl.pdf	Homo sapiens										false
2247	1221		NEWBORN	2471	364.416	BUMETANIDE	BUMETANIDE	CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O	SERUM	0Y2S3XUQ5H																						UNKNOWN				The degree of protein binding of bumetanide in cord sera from healthy neonates was approximately 97%, suggesting the potential for bilirubin displacement.	3	HEALTHY		UNKNOWN	DRUG LABEL	https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/9bd7a71e-0e78-dae7-e053-2995a90ad110/spl-doc?hl=bumetanide	Homo sapiens										false
2248	1221		ADULT	2471	364.416	BUMETANIDE	BUMETANIDE	CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O	PLASMA	0Y2S3XUQ5H									∞	ng × h/mL	258		ng/mL	111.38			RECOMMENDED	mg	2		SINGLE	FASTED				The plasma protein-binding is in the range of 94–96%	5	HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/22475517	Homo sapiens		h	1.88							false
2249	1221		ADULT	2471	364.416	BUMETANIDE	BUMETANIDE	CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O	PLASMA	0Y2S3XUQ5H									∞	ng × h/mL	167.34		ng/mL	42			UNKNOWN	mg	2		SINGLE	FASTED						UNKNOWN	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/8312869	Homo sapiens										false
2250	1222		UNKNOWN	54746	451.6043	CABERGOLINE	CABERGOLINE	CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(CC=C)C1	PLASMA	LL60K9J05T																	UNKNOWN				UNKNOWN	UNKNOWN				Cabergoline shows moderately low plasma protein binding (approximately 40%).	60	UNKNOWN	UNKNOWN	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/12844325	Homo sapiens										false
2251	1222		ADULT	54746	451.6043	CABERGOLINE	CABERGOLINE	CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(CC=C)C1	PLASMA	LL60K9J05T							168		t	ng × h/L	1884		ng/L	40.3			UNKNOWN	mg	1		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7883840	Homo sapiens										false
2252	1222		ADULT	54746	451.6043	CABERGOLINE	CABERGOLINE	CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(CC=C)C1	PLASMA	LL60K9J05T							168		t	ng × h/L	1295		ng/L	33.3			UNKNOWN	mg	0.5		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7883840	Homo sapiens										false
2253	1222		ADULT	54746	451.6043	CABERGOLINE	CABERGOLINE	CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(CC=C)C1	PLASMA	LL60K9J05T							168		t	ng × h/L	2546		ng/L	67			UNKNOWN	mg	1.5		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7883840	Homo sapiens										false
2254	1222		ADULT	54746	451.6043	CABERGOLINE	CABERGOLINE	CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(CC=C)C1	PLASMA	LL60K9J05T																	UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7884663	Homo sapiens		h	68.54							false
2255	1223		ADULT	5280453	416.6365	CALCITRIOL	CALCITRIOL	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\\C(CCC[C@]12C)=C\\C=C3\\C[C@@H](O)C[C@H](O)C3=C	PLASMA	FXC9231JVH			PACLITAXEL	paclitaxel	CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C3=CC=CC=C3)[C@@H]4[C@@]5(CO[C@@H]5C[C@H](O)[C@@]4(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C6=CC=CC=C6)C7=CC=CC=C7	P88XT4IS4D	24		t	pg × h/mL	8100		pg/mL	1100			UNKNOWN	μg	38		MULTIPLE	UNKNOWN		week	3			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/12496746	Homo sapiens		h	25							true
2256	1224		UNKNOWN	60953	359.3501	CAPECITABINE	CAPECITABINE	CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@@H]2O[C@H](C)[C@@H](O)[C@H]2O	PLASMA	6804DJ8Z9U																						UNKNOWN				Plasma protein binding of capecitabine and its metabolites is less than 60% and is not concentration-dependent. Capecitabine was primarily bound to human albumin (approximately 35%)	65	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf	Homo sapiens										false
2257	1224		ADULT	60953	359.3501	CAPECITABINE	CAPECITABINE	CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@@H]2O[C@H](C)[C@@H](O)[C@H]2O	BLOOD	6804DJ8Z9U									?	ng × h/mL	10238		ng/mL	9105			UNKNOWN	mg/m²	1000		MULTIPLE	FED		day	2			UNHEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/24022189	Homo sapiens		h	0.78							false
2258	1224		ADULT	13351|78436418	107.0836	.ALPHA.-FLUORO-.BETA.-ALANINE	alpha-Fluoro-beta-alanine	NCC(F)C(O)=O	BLOOD	1461S5575Q									?	ng × h/mL	45027		ng/mL	3515			UNKNOWN	mg/m²	1250		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/29948022	Homo sapiens										false
2259	1225		ADULT	3639	297.739	HYDROCHLOROTHIAZIDE	Hydrochlorothiazide	NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1Cl	PLASMA	0J48LPH2TH	44093|12851888	217.285	CAPTOPRIL	Captopril	C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O	9G64RSX1XD			∞	ng × h/mL	3615.08		ng/mL	1032.22			UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://japsonline.com/abstract.php?article_id=2146&sts=2	Homo sapiens						50 mg	24	50 mg Captopril and 25 mg Hydrochlorothiazide		true
2260	1225		ADULT	3639	297.739	HYDROCHLOROTHIAZIDE	Hydrochlorothiazide	NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1Cl	PLASMA	0J48LPH2TH	44093|12851888	217.285	CAPTOPRIL	Captopril	C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O	9G64RSX1XD			∞	ng × h/mL	954.44		ng/mL	142.5			UNKNOWN	mg	25		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11112088/	Homo sapiens		h	8.57			50 mg	4	50 mg Captopril and 25 mg Hydrochlorothiazide		true
2261	1225			44093|12851888	217.285	CAPTOPRIL	Captopril	C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O	SERUM	9G64RSX1XD																										Human serum albumin binding - Captopril (capillary electrophoresis-frontal analysis): 67% (in the presence of Hydrochlorothiazide), 66% (Captopril alone)	33				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26142561/	Homo sapiens										false
2262	1225			3639	297.739	HYDROCHLOROTHIAZIDE	Hydrochlorothiazide	NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1Cl	SERUM	0J48LPH2TH																										Human serum albumin binding - Hydrochlorothiazide (capillary electrophoresis-frontal analysis): 44% (in the presence of Captopril), 45% (Hydrochlorothiazide alone)	56				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26142561/	Homo sapiens										false
2263	1225		ADULT	3639	297.739	HYDROCHLOROTHIAZIDE	Hydrochlorothiazide	NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1Cl	PLASMA	0J48LPH2TH	44093|12851888	217.285	CAPTOPRIL	Captopril	C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O	9G64RSX1XD			∞	ng × h/mL	1760		ng/mL	210			UNKNOWN	mg	25		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3034318/	Homo sapiens		h	7.5	Day 45, Hydrochlorothiazide PK	patients with moderate essential hypertension and normal renal function	50 mg	8	50 mg Captopril and 25 mg Hydrochlorothiazide		true
2264	1225		ADULT	44093|12851888	217.285	CAPTOPRIL	Captopril	C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O	PLASMA	9G64RSX1XD	3639	297.739	HYDROCHLOROTHIAZIDE	Hydrochlorothiazide	NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1Cl	0J48LPH2TH			∞	ng × h/mL	870		ng/mL	385			UNKNOWN	mg	50		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3034318/	Homo sapiens		h	0.83	Day 1, Captopril PK	patients with moderate essential hypertension and normal renal function	25 mg	8	50 mg Captopril and 25 mg Hydrochlorothiazide		true
2265	1225		ADULT	44093|12851888	217.285	CAPTOPRIL	Captopril	C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O	PLASMA	9G64RSX1XD	3639	297.739	HYDROCHLOROTHIAZIDE	Hydrochlorothiazide	NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1Cl	0J48LPH2TH	24		t	ng × h/mL	1067		ng/mL	499			UNKNOWN	mg	50		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3034318/	Homo sapiens		h	0.83	Day 45, Captopril PK	patients with moderate essential hypertension and normal renal function	25 mg	8	50 mg Captopril and 25 mg Hydrochlorothiazide		true
2266	1225		ADULT	44093|12851888	217.285	CAPTOPRIL	Hydrochlorothiazide	C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O	PLASMA	9G64RSX1XD	44093|12851888	217.285	CAPTOPRIL	Captopril	C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O	9G64RSX1XD			∞	ng × h/mL	1629		ng/mL	164			UNKNOWN	mg	25		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3034318/	Homo sapiens		h	7.1	Day 1, Hydrochlorothiazide PK	patients with moderate essential hypertension and normal renal function	50 mg	8	50 mg Captopril and 25 mg Hydrochlorothiazide		true
2267	1225		ADULT	3639	297.739	HYDROCHLOROTHIAZIDE	Hydrochlorothiazide	NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1Cl	PLASMA	0J48LPH2TH	44093|12851888	217.285	CAPTOPRIL	Captopril	C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O	9G64RSX1XD			∞	ng × h/mL	1629		ng/mL	164			UNKNOWN	mg	25		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3034318/	Homo sapiens		h	7.1	Day 1, Hydrochlorothiazide PK	patients with moderate essential hypertension and normal renal function	50 mg	8	50 mg Captopril and 25 mg Hydrochlorothiazide		true
2268	1226		ADULT		305.4	CAPSAICIN			PLASMA										?	ng × h/mL	4.36		ng/mL	1.38			RECOMMENDED	μg/cm²	640		SINGLE	UNKNOWN						UNHEALTHY	Topical	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19494795/	Homo sapiens		h	1.64							false
2269	1227		UNKNOWN	2554	236.27	Carbamazepine	Carbamazepine	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	PLASMA	33CM23913M													μg/mL	1.9			UNKNOWN	mg	200		SINGLE	UNKNOWN					24	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021710s11s012lbl.pdf	Homo sapiens		h	37.5							false
2270	1227		UNKNOWN	2555	252.27	Carbamazepine-10,11-epoxide	Carbamazepine-10,11-epoxide	C1=CC=C2C(=C1)C3C(O3)C4=CC=CC=C4N2C(=O)N	PLASMA	QC9505F279													μg/mL	0.11			UNKNOWN	mg	200		SINGLE	UNKNOWN					50	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021710s11s012lbl.pdf	Homo sapiens		h	34							false
2271	1227		UNKNOWN	2555	252.27	Carbamazepine-10,11-epoxide	Carbamazepine-10,11-epoxide	C1=CC=C2C(=C1)C3C(O3)C4=CC=CC=C4N2C(=O)N	PLASMA	QC9505F279									?	μg × h/mL	15.7		μg/mL	1.5			UNKNOWN	mg	800		MULTIPLE	UNKNOWN		day	1			UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021710s11s012lbl.pdf	Homo sapiens										false
2272	1227		UNKNOWN	2554	236.27	Carbamazepine	Carbamazepine	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	PLASMA	33CM23913M													μg/mL	11			UNKNOWN	mg	800		MULTIPLE	UNKNOWN		day	2			UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021710s11s012lbl.pdf	Homo sapiens		h	14.5							false
2273	1227		UNKNOWN	2554	236.27	Carbamazepine	Carbamazepine	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	PLASMA	33CM23913M													μg/mL	4.3			DEFINED DAILY	mg	400		SINGLE	HIGH-FAT						UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021710s11s012lbl.pdf	Homo sapiens										false
2274	1227		UNKNOWN	2555	252.27	Carbamazepine-10,11-epoxide	Carbamazepine-10,11-epoxide	C1=CC=C2C(=C1)C3C(O3)C4=CC=CC=C4N2C(=O)N	PLASMA	QC9505F279													μg/mL	2.2			UNKNOWN	mg	800		MULTIPLE	UNKNOWN		day	2			UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021710s11s012lbl.pdf	Homo sapiens										false
2275	1227		UNKNOWN	2555	252.268	CARBAMAZEPINE-10,11-EPOXIDE	carbamazepine-10,11-epoxide	NC(=O)N1C2=C(C=CC=C2)C3OC3C4=C1C=CC=C4	PLASMA	QC9505F279									?	μg × h/mL	32.6		μg/mL	3.2			UNKNOWN	mg	1600		MULTIPLE	UNKNOWN		day	1			UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021710s11s012lbl.pdf	Homo sapiens										false
2276	1227		UNKNOWN	2554	236.2686	CARBAMAZEPINE	carbamazepine	NC(=O)N1C2=C(C=CC=C2)C=CC3=C1C=CC=C3	PLASMA	33CM23913M													μg/mL	3.2			DEFINED DAILY	mg	400		SINGLE	FASTED						UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021710s11s012lbl.pdf	Homo sapiens										false
2277	1228		ADULT	2578	214.05	CARMUSTINE	CARMUSTINE	ClCCNC(=O)N(CCCl)N=O	PLASMA	U68WG3173Y	2907 | 5702198		Cyclophosphamide | Cisplatin	Cyclophosphamide | Cisplatin	C1CNP(=O)(OC1)N(CCCl)CCCl | N.N.Cl[Pt]Cl	6UXW23996M | Q20Q21Q62J			?	μg × min/mL	456		μg/mL	3.7			UNKNOWN	mg/m²	600		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/15077226	Homo sapiens		min	18							true
2278	1228		ADULT	2578	214.05	CARMUSTINE	CARMUSTINE	ClCCNC(=O)N(CCCl)N=O	PLASMA	U68WG3173Y									?	μM × min	538		μM	7.8			UNKNOWN	mg/m²	1000		SINGLE	UNKNOWN				Plasma BCNU was largely (77%) protein bound.	23	UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/3719578	Homo sapiens										false
2279	1229		ADULT	9870843	506.578	CEFDITOREN	CEFDITOREN	CO\\N=C(/C(=O)N[C@H]1[C@H]2SCC(\\C=C/C3=C(C)N=CS3)=C(N2C1=O)C(O)=O)C4=CSC(N)=N4	PLASMA	81QS09V3YW													μg/mL	1.8			RECOMMENDED	mg	200		SINGLE	UNKNOWN				Binding of cefditoren to plasma proteins averages 88%	12	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021222s013s016lbl.pdf	Homo sapiens		h	1.6							false
2280	1230		UNKNOWN	9571075|9959752|76974613|122177179	571.498	CEFEPIME HYDROCHLORIDE	CEFEPIME HYDROCHLORIDE	O.Cl.Cl.CO\\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[N+]3(C)CCCC3)=C(N2C1=O)C([O-])=O)C4=CSC(N)=N4	SERUM	I8X1O0607P																	UNKNOWN				UNKNOWN	UNKNOWN				The serum protein binding of cefepime is approximately 20% and is independent of its concentration in serum.	80	UNKNOWN	UNKNOWN	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050679s042lbl.pdf	Homo sapiens		h	2							false
2281	1230		ADULT	9571075|9959752|76974613|122177179	571.498	CEFEPIME HYDROCHLORIDE	CEFEPIME HYDROCHLORIDE	O.Cl.Cl.CO\\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[N+]3(C)CCCC3)=C(N2C1=O)C([O-])=O)C4=CSC(N)=N4	PLASMA	I8X1O0607P									?	μg × h/mL	70.8		μg/mL	39.1			UNKNOWN	mg	500		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050679s042lbl.pdf	Homo sapiens										false
2282	1230		ADULT	9571075|9959752|76974613|122177179	571.498	CEFEPIME HYDROCHLORIDE	CEFEPIME HYDROCHLORIDE	O.Cl.Cl.CO\\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[N+]3(C)CCCC3)=C(N2C1=O)C([O-])=O)C4=CSC(N)=N4	PLASMA	I8X1O0607P									?	μg × h/mL	148.5		μg/mL	81.7			UNKNOWN	g	1		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050679s042lbl.pdf	Homo sapiens										false
2283	1230		ADULT	9571075|9959752|76974613|122177179	571.498	CEFEPIME HYDROCHLORIDE	CEFEPIME HYDROCHLORIDE	O.Cl.Cl.CO\\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[N+]3(C)CCCC3)=C(N2C1=O)C([O-])=O)C4=CSC(N)=N4	PLASMA	I8X1O0607P									?	μg × h/mL	284.8		μg/mL	163.9			UNKNOWN	g	2		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050679s042lbl.pdf	Homo sapiens										false
2284	1230		ADULT	9571075|9959752|76974613|122177179	571.498	CEFEPIME HYDROCHLORIDE	CEFEPIME HYDROCHLORIDE	O.Cl.Cl.CO\\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[N+]3(C)CCCC3)=C(N2C1=O)C([O-])=O)C4=CSC(N)=N4	PLASMA	I8X1O0607P									?	μg × h/mL	60		μg/mL	13.9			UNKNOWN	mg	500		SINGLE	UNKNOWN						HEALTHY	Intramuscular	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050679s042lbl.pdf	Homo sapiens										false
2285	1230		ADULT	9571075|9959752|76974613|122177179	571.498	CEFEPIME HYDROCHLORIDE	CEFEPIME HYDROCHLORIDE	O.Cl.Cl.CO\\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[N+]3(C)CCCC3)=C(N2C1=O)C([O-])=O)C4=CSC(N)=N4	PLASMA	I8X1O0607P									?	μg × h/mL	137		μg/mL	29.6			UNKNOWN	g	1		SINGLE	UNKNOWN						HEALTHY	Intramuscular	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050679s042lbl.pdf	Homo sapiens										false
2286	1230		ADULT	9571075|9959752|76974613|122177179	571.498	CEFEPIME HYDROCHLORIDE	CEFEPIME HYDROCHLORIDE	O.Cl.Cl.CO\\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[N+]3(C)CCCC3)=C(N2C1=O)C([O-])=O)C4=CSC(N)=N4	PLASMA	I8X1O0607P									?	μg × h/mL	262		μg/mL	57.5			UNKNOWN	g	2		SINGLE	UNKNOWN						HEALTHY	Intramuscular	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050679s042lbl.pdf	Homo sapiens										false
2287	1231		ADULT	44187	645.667	CEFOPERAZONE	CEFOPERAZONE	CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SCC(CSC4=NN=NN4C)=C(N3C2=O)C(O)=O)C5=CC=C(O)C=C5)C(=O)C1=O	SERUM	7U75I1278D									?	mg × h/L per 1.73 m²	211.62		mg/mL	154.9			UNKNOWN	g	1		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3619425	Homo sapiens		h	1.649							false
2288	1231		ADULT	44187	645.667	CEFOPERAZONE	CEFOPERAZONE	CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SCC(CSC4=NN=NN4C)=C(N3C2=O)C(O)=O)C5=CC=C(O)C=C5)C(=O)C1=O	SERUM	7U75I1278D									?	mg × h/L per 1.73 m²	421.63		mg/mL	221.8			UNKNOWN	g	2		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3619425	Homo sapiens		h	2.044							false
2289	1231		NEWBORN	44187	645.667	CEFOPERAZONE	CEFOPERAZONE	CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SCC(CSC4=NN=NN4C)=C(N3C2=O)C(O)=O)C5=CC=C(O)C=C5)C(=O)C1=O	SERUM	7U75I1278D									?	mg × h/L	541.2						UNKNOWN	mg/kg	50		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6644441	Homo sapiens		h	0.185							false
2290	1231		NEWBORN	44187	645.667	CEFOPERAZONE	CEFOPERAZONE	CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SCC(CSC4=NN=NN4C)=C(N3C2=O)C(O)=O)C5=CC=C(O)C=C5)C(=O)C1=O	SERUM	7U75I1278D									?	mg × h/L	1147.5						UNKNOWN	mg/kg	100		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6644441	Homo sapiens		h	0.063							false
2291	1231		NEWBORN	44187	645.667	CEFOPERAZONE	CEFOPERAZONE	CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SCC(CSC4=NN=NN4C)=C(N3C2=O)C(O)=O)C5=CC=C(O)C=C5)C(=O)C1=O	SERUM	7U75I1278D									?	mg × h/L	761.7						UNKNOWN	mg/kg	100		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6644441	Homo sapiens		h	0.063							false
2292	1233		ADULT		575.619	CEFOTETAN	CEFOTETAN	CO[C@]2(NC(=O)C1SC(S1)=C(C(N)=O)C(O)=O)[C@H]3SCC(CSC4=NN=NN4C)=C(N3C2=O)C(O)=O	PLASMA	48SPP0PA9Q									∞	μg × h/mL	284.42		μg/mL	69.49			UNKNOWN	g	0.5		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32103903	Homo sapiens		h	4.21							false
2293	1233		ADULT		575.619	CEFOTETAN	CEFOTETAN	CO[C@]2(NC(=O)C1SC(S1)=C(C(N)=O)C(O)=O)[C@H]3SCC(CSC4=NN=NN4C)=C(N3C2=O)C(O)=O	PLASMA	48SPP0PA9Q									∞	μg × h/mL	551.38		μg/mL	132.03			UNKNOWN	g	1		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32103903	Homo sapiens		h	4.39							false
2294	1233		ADULT		575.619	CEFOTETAN	CEFOTETAN	CO[C@]2(NC(=O)C1SC(S1)=C(C(N)=O)C(O)=O)[C@H]3SCC(CSC4=NN=NN4C)=C(N3C2=O)C(O)=O	PLASMA	48SPP0PA9Q									∞	μg × h/mL	1020.18		μg/mL	237.75			UNKNOWN	g	2		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32103903	Homo sapiens		h	4.27							false
2295	1233		ADULT		575.619	CEFOTETAN	CEFOTETAN	CO[C@]2(NC(=O)C1SC(S1)=C(C(N)=O)C(O)=O)[C@H]3SCC(CSC4=NN=NN4C)=C(N3C2=O)C(O)=O	PLASMA	48SPP0PA9Q									∞	μg × h/mL	612.06		μg/mL	147.58			UNKNOWN	g	1		MULTIPLE	UNKNOWN		day	2			HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32103903	Homo sapiens		h	4.3							false
2296	1234		ADULT	5282242	410.425	CEFTIBUTEN	CEFTIBUTEN	NC1=NC(=CS1)C(=C\\CC(O)=O)\\C(=O)N[C@H]2[C@H]3SCC=C(N3C2=O)C(O)=O	PLASMA	IW71N46B4Y							24		t	μg × h/mL	73.74		μg/mL	14.98			DEFINED DAILY	mg	400		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7726497/	Homo sapiens		h	2.45							false
2297	1234		ADULT	5282242	410.425	CEFTIBUTEN	CEFTIBUTEN	NC1=NC(=CS1)C(=C\\CC(O)=O)\\C(=O)N[C@H]2[C@H]3SCC=C(N3C2=O)C(O)=O	PLASMA	IW71N46B4Y							24		t	μg × h/mL	82.53		μg/mL	18.7			RECOMMENDED	mg	400		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7726497/	Homo sapiens		h	2.37							false
2298	1234		ADULT	5282242	410.425	CEFTIBUTEN	CEFTIBUTEN	NC1=NC(=CS1)C(=C\\CC(O)=O)\\C(=O)N[C@H]2[C@H]3SCC=C(N3C2=O)C(O)=O	PLASMA	IW71N46B4Y							24		t	μg × h/mL	80.22		μg/mL	17.85			RECOMMENDED	mg	400		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7726497/	Homo sapiens		h	2.35							false
2299	1234		ADULT	5282242	410.425	CEFTIBUTEN	CEFTIBUTEN	NC1=NC(=CS1)C(=C\\CC(O)=O)\\C(=O)N[C@H]2[C@H]3SCC=C(N3C2=O)C(O)=O	PLASMA	IW71N46B4Y									∞	μg × h/mL	42.1		μg/mL	9.85			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7726498/	Homo sapiens		h	2.01							false
2300	1234		ADULT	5282242	410.425	CEFTIBUTEN	CEFTIBUTEN	NC1=NC(=CS1)C(=C\\CC(O)=O)\\C(=O)N[C@H]2[C@H]3SCC=C(N3C2=O)C(O)=O	PLASMA	IW71N46B4Y									∞	μg × h/mL	79.2		μg/mL	17			DEFINED DAILY	mg	400		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7726498/	Homo sapiens		h	2.29							false
2301	1234		ADULT	5282242	410.425	CEFTIBUTEN	CEFTIBUTEN	NC1=NC(=CS1)C(=C\\CC(O)=O)\\C(=O)N[C@H]2[C@H]3SCC=C(N3C2=O)C(O)=O	PLASMA	IW71N46B4Y									∞	μg × h/mL	118		μg/mL	23.3			UNKNOWN	mg	800		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7726498/	Homo sapiens		h	2.25							false
2302	1234		ADULT	5282242	410.425	CEFTIBUTEN	CEFTIBUTEN	NC1=NC(=CS1)C(=C\\CC(O)=O)\\C(=O)N[C@H]2[C@H]3SCC=C(N3C2=O)C(O)=O	PLASMA	IW71N46B4Y									?	μg × h/mL	73.7		μg/mL	15			DEFINED DAILY	mg	400		SINGLE	UNKNOWN					35	HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050685s011,050686s014lbl.pdf	Homo sapiens		h	2.4							false
2303	1234		CHILD	5282242	410.425	CEFTIBUTEN	CEFTIBUTEN	NC1=NC(=CS1)C(=C\\CC(O)=O)\\C(=O)N[C@H]2[C@H]3SCC=C(N3C2=O)C(O)=O	PLASMA	IW71N46B4Y									?	μg × h/mL	56		μg/mL	13.4			DEFINED DAILY	mg/kg bw	9		SINGLE	FASTED					35	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050685s011,050686s014lbl.pdf	Homo sapiens		h	2							false
2304	1235			2662	381.372	CELECOXIB	CELECOXIB	CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(N)(=O)=O)C(F)(F)F	PLASMA	JCX84Q7J1L													ng/mL	352.6				mg	200		SINGLE								Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02413203	Homo sapiens										false
2305	1235		ADULT	2662	381.372	CELECOXIB	CELECOXIB	CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(N)(=O)=O)C(F)(F)F	PLASMA	JCX84Q7J1L													ng/mL	705			RECOMMENDED	mg	200		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020998s017lbl.pdf	Homo sapiens		h	11.2							false
2306	1235		CHILD	2662	381.4	CELECOXIB	CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)[S+](N)([O-])=O)C(F)(F)F	CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)[S+](N)([O-])=O)C(F)(F)F	PLASMA	JCX84Q7J1L									∞	μg × h/L	7709		μg/L	1234			UNKNOWN	mg/m²	250		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/12426512	Homo sapiens		h	3.7							false
2307	1236		ADULT	667467	315.86	CHLORPROTHIXENE	CHLORPROTHIXENE	CN(C)CC\\C=C1/C2=CC(Cl)=CC=C2SC3=C1C=CC=C3	PLASMA	9S7OD60EWP							24		t	ng × h/mL	187		ng/mL	11			RECOMMENDED	mg	15		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1140253/	Homo sapiens		h	8.4							false
2308	1237		ADULT	2732	338.766	CHLORTHALIDONE	CHLORTHALIDONE	NS(=O)(=O)C1=C(Cl)C=CC(=C1)C2(O)NC(=O)C3=C2C=CC=C3	PLASMA	Q0MQD1073Q							96		t	μg × h/mL	93.3		μg/mL	1.529			RECOMMENDED	mg	25		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4067856	Homo sapiens		h	54							false
2309	1237		UNKNOWN	2732	338.766	CHLORTHALIDONE	CHLORTHALIDONE	NS(=O)(=O)C1=C(Cl)C=CC(=C1)C2(O)NC(=O)C3=C2C=CC=C3	PLASMA	Q0MQD1073Q																						UNKNOWN				In the blood, approximately 75% of the drug is bound to plasma proteins	25	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019574s016lbl.pdf	Homo sapiens		h	50							false
2310	1238		ADULT		540.6876	CICLESONIDE	CICLESONIDE	CC(C)C(=O)OCC(=O)[C@@]12O[C@@H](O[C@@H]1C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]23C)C6CCCCC6	SERUM	S59502J185													nM	59.2			UNKNOWN	mg	0.64		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15139796	Homo sapiens		h	0.38							false
2311	1238		UNKNOWN		540.6876	CICLESONIDE	CICLESONIDE	CC(C)C(=O)OCC(=O)[C@@]12O[C@@H](O[C@@H]1C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]23C)C6CCCCC6	PLASMA	S59502J185																	UNKNOWN	μg	800		SINGLE	UNKNOWN				The percentage of ciclesonide and des-ciclesonide bound to human plasma proteins averaged >99% each, with <1% of unbound drug detected in the systemic circulation.	1	UNKNOWN	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021658s006lbl.pdf	Homo sapiens										false
2312	1239		UNKNOWN	2749	207.2689	CICLOPIROX	CICLOPIROX	CC1=CC(=O)N(O)C(=C1)C2CCCCC2	BLOOD	19W019ZDRJ													ng/mL	25.02			UNKNOWN	g	5		SINGLE	UNKNOWN						HEALTHY	Topical	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/20519slr005_loprox_lbl.pdf	Homo sapiens										false
2313	1239		UNKNOWN	2749	207.2689	CICLOPIROX	CICLOPIROX	CC1=CC(=O)N(O)C(=C1)C2CCCCC2	UNKNOWN	19W019ZDRJ																	UNKNOWN	mg	9		SINGLE	UNKNOWN						UNKNOWN	Topical	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/018748s024,019824s023,020519s016lbl.pdf	Homo sapiens		h	1.7							false
2314	1240		UNKNOWN	2754	369.4607	CILOSTAZOL	CILOSTAZOL	O=C1CCC2=CC(OCCCCC3=NN=NN3C4CCCCC4)=CC=C2N1	PLASMA	N7Z035406B																						UNKNOWN				Cilostazol is 95 - 98% protein bound, predominantly to albumin.	3.5	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020863s011lbl.pdf	Homo sapiens										false
2315	1240		ADULT	2754	369.4607	CILOSTAZOL	CILOSTAZOL	O=C1CCC2=CC(OCCCCC3=NN=NN3C4CCCCC4)=CC=C2N1	PLASMA	N7Z035406B									∞	ng × h/mL	13724		ng/mL	701			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/31372190	Homo sapiens		h	13.5							false
2316	1241		ADULT	156419	357.412	CINACALCET	CINACALCET	C[C@@H](NCCCC1=CC(=CC=C1)C(F)(F)F)C2=C3C=CC=CC3=CC=C2	PLASMA	UAZ6V7728S									∞	ng × h/mL	296		ng/mL	26.6			UNKNOWN	mg	75		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/15871636	Homo sapiens		h	30.4							false
2317	1241		ADULT	156419	357.412	CINACALCET	CINACALCET	C[C@@H](NCCCC1=CC(=CC=C1)C(F)(F)F)C2=C3C=CC=CC3=CC=C2	PLASMA	UAZ6V7728S									∞	ng × h/mL	346		ng/mL	20.6			UNKNOWN	mg	75		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/15871636	Homo sapiens		h	33.6							false
2318	1241		ADULT	156419	357.412	CINACALCET	CINACALCET	C[C@@H](NCCCC1=CC(=CC=C1)C(F)(F)F)C2=C3C=CC=CC3=CC=C2	BLOOD	UAZ6V7728S									∞	ng × h/mL	323		ng/mL	29.9			UNKNOWN	mg	90		SINGLE	HIGH-FAT						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/17515696	Homo sapiens		h	12.4							false
2319	1242		ADULT	62887	929.145	CISATRACURIUM	CISATRACURIUM	COC1=CC2=C(C=C1OC)[C@@H](CC3=CC(OC)=C(OC)C=C3)[N@@+](C)(CCC(=O)OCCCCCOC(=O)CC[N@@+]4(C)CCC5=C(C=C(OC)C(OC)=C5)[C@H]4CC6=CC(OC)=C(OC)C=C6)CC2	PLASMA	QX62KLI41N																	UNKNOWN	mg/kg	0.1		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/20551Orig1s026lbl.pdf	Homo sapiens		min	22							false
2320	1243		ADULT	84029	747.9534	CLARITHROMYCIN	CLARITHROMYCIN	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC	PLASMA	H1250JIK0A							24		t	mg × h/L	4.45		mg/L	1.09			RECOMMENDED	mg	250		SINGLE	FASTED					28.7	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17606673/	Homo sapiens		h	1.9							false
2321	1243		ADULT	84029	747.9534	CLARITHROMYCIN	CLARITHROMYCIN	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC	PLASMA	H1250JIK0A							24		t	mg × h/L	26.81		mg/L	2.21			RECOMMENDED	mg	500		STEADY-STATE	FASTED		day	2		23.1	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17606673/	Homo sapiens		h	3.7							false
2322	1245		ADULT	119182	303.677	CLOFARABINE	CLOFARABINE	NC1=NC(Cl)=NC2=C1N=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3F	PLASMA	762RDY0Y2H	6253		CYTARABINE	cytarabine	NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O	04079A1RDZ	24		t	ng × h/mL	1793		ng/mL	308			UNKNOWN	mg/m²	40		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/28509593	Homo sapiens		h	4.9							true
2323	1245		CHILD	119182	303.677	CLOFARABINE	CLOFARABINE	NC1=NC(Cl)=NC2=C1N=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3F	BLOOD	762RDY0Y2H									?	ng × h/mL	28						UNKNOWN	mg/m²	40		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/29773602	Homo sapiens		h	1.5							false
2324	1246		ADULT	2801	314.9	CLOMIPRAMINE	CLOMIPRAMINE	CN(C)CCCN1C2=C(CCC3=C1C=C(Cl)C=C3)C=CC=C2	PLASMA	NUV44L116D													ng/mL	92			UNKNOWN	mg	50		SINGLE	UNKNOWN						UNKNOWN	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019906s043lbl.pdf	Homo sapiens										false
2325	1246		ADULT	2801	314.9	CLOMIPRAMINE	CLOMIPRAMINE	CN(C)CCCN1C2=C(CCC3=C1C=C(Cl)C=C3)C=CC=C2	PLASMA	NUV44L116D									∞	ng × h/mL	736		ng/mL	31.3			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/8991493	Homo sapiens		h	23.5							false
2326	1247		ADULT	2812	344.837	CLOTRIMAZOLE	CLOTRIMAZOLE	ClC1=C(C=CC=C1)C(N2C=CN=C2)(C3=CC=CC=C3)C4=CC=CC=C4	PLASMA	G07GZ97H65									∞	μM × h	12.59		μM	3.3			UNKNOWN	g	1		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/7882513	Homo sapiens		h	2.99							false
2327	1248		ADULT	6098	435.881	CLOXACILLIN	CLOXACILLIN	CC1=C(C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)C(=NO1)C4=C(Cl)C=CC=C4	SERUM	O6X5QGC2VB									∞	μg × h/mL	310		μg/mL	60			RECOMMENDED	g	2		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1277730/	Homo sapiens		min	43							false
2328	1250		ADULT	6234	102.09	D-CYCLOSERINE	D-CYCLOSERINE	N[C@@H]1CONC1=O	PLASMA	95IK5KI84Z									∞	mg × h/L	643.29		mg/L	42.92			RECOMMENDED	mg	500		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/25869627	Homo sapiens		h	13.27							false
2329	1252		CHILD	457193	1255.417	DACTINOMYCIN	DACTINOMYCIN	CC(C)[C@H]1NC(=O)[C@@H](NC(=O)C2=C3N=C4C(OC3=C(C)C=C2)=C(C)C(=O)C(N)=C4C(=O)N[C@H]5[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]6CCCN6C(=O)[C@H](NC5=O)C(C)C)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]7CCCN7C1=O	PLASMA	1CC1JFE158							6		t	μg × min/L	2.67		ng/mL	25.1			UNKNOWN	mg/m²	1.1		UNKNOWN	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16115931	Homo sapiens		h	28.5							false
2330	1252		ADULT	457193	1255.417	DACTINOMYCIN	DACTINOMYCIN	CC(C)[C@H]1NC(=O)[C@@H](NC(=O)C2=C3N=C4C(OC3=C(C)C=C2)=C(C)C(=O)C(N)=C4C(=O)N[C@H]5[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]6CCCN6C(=O)[C@H](NC5=O)C(C)C)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]7CCCN7C1=O	PLASMA	1CC1JFE158									∞	mg × h/L	142.4		μg/mL	30.3			UNKNOWN	mg/kg	3		SINGLE	UNKNOWN				Binding of daptomycin was not concentration dependent (2.5 to 80 micrograms/ml). In human serum samples spiked with daptomycin, average binding was 94% +/- 2.4%. In 6 subjects given an intravenous infusion of daptomycin (3 mg/kg), average binding was 90% +/- 2.1%.	10	HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1667253	Homo sapiens		h	7.8							false
2331	1253		ADULT	28417	337.4553	DANAZOL	DANAZOL	C[C@]12CC[C@H]3[C@@H](CCC4=CC5=C(C[C@]34C)C=NO5)[C@@H]1CC[C@@]2(O)C#C	PLASMA	N29QWW3BUO									∞	ng × h/mL	601		ng/mL	69.6			RECOMMENDED	mg	400		SINGLE	FASTED						HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/017557s033s039s040s041s042lbl.pdf	Homo sapiens		h	9.7							false
2332	1254		ADULT	6914273	314.253	DANTROLENE	DANTROLENE	[O-][N+](=O)C1=CC=C(C=C1)C2=CC=C(O2)\\C=N\\N3CC(=O)NC3=O	BLOOD	F64QU97QCR																	MAX DAILY	mg	100		MULTIPLE	UNKNOWN		day	1			UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/017443s043s046s048s049lbl.pdf	Homo sapiens		h	8.7							false
2333	1254		ADULT	6914273	314.253	DANTROLENE	DANTROLENE	[O-][N+](=O)C1=CC=C(C=C1)C2=CC=C(O2)\\C=N\\N3CC(=O)NC3=O	PLASMA	F64QU97QCR									?	μg × h/mL	77.7		μg/mL	9			RECOMMENDED	mg/kg	2.5		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205579s000lbl.pdf	Homo sapiens		h	10.8							false
2334	1256		ADULT	2955	248.301	DAPSONE	DAPSONE	NC1=CC=C(C=C1)S(=O)(=O)C2=CC=C(N)C=C2	PLASMA	8W5C518302							24		t	ng × h/mL	415		ng/mL	19.7			UNKNOWN	mg	110		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Topical	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17655376	Homo sapiens		h	42							false
2335	1256		ADULT	2955	248.301	DAPSONE	DAPSONE	NC1=CC=C(C=C1)S(=O)(=O)C2=CC=C(N)C=C2	PLASMA	8W5C518302							24		t	ng × h/mL	22783		ng/mL	1375			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17655376	Homo sapiens		h	20.6							false
2336	1256		ADULT	2955	248.301	DAPSONE	DAPSONE	NC1=CC=C(C=C1)S(=O)(=O)C2=CC=C(N)C=C2	PLASMA	8W5C518302									∞	ng × h/mL	52641						UNKNOWN	mg	100		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17655376	Homo sapiens										false
2337	1256		ADULT	2955	248.301	DAPSONE	DAPSONE	NC1=CC=C(C=C1)S(=O)(=O)C2=CC=C(N)C=C2	PLASMA	8W5C518302							12		t	ng × h/mL	221.52						UNKNOWN	mg	110		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Topical	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17655376	Homo sapiens										false
2338	1256		UNKNOWN	2955	248.301	DAPSONE	DAPSONE	NC1=CC=C(C=C1)S(=O)(=O)C2=CC=C(N)C=C2	PLASMA	8W5C518302																	UNKNOWN				UNKNOWN	UNKNOWN				About 70 to 90% of dapsone is bound to plasma protein.	10	UNKNOWN	UNKNOWN	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/3530584	Homo sapiens										false
2339	1257		ADULT	444031	426.55	DARIFENACIN	DARIFENACIN	NC(=O)C([C@@H]1CCN(CCC2=CC3=C(OCC3)C=C2)C1)(C4=CC=CC=C4)C5=CC=CC=C5	PLASMA	APG9819VLM							24		t	ng × h/mL	29.24		ng/mL	2.01			DEFINED DAILY	mg	7.5		STEADY-STATE	UNKNOWN		day	1	Darifenacin is approximately 98 percent bound to plasma proteins (primarily to alpha-1-acid-glycoprotein).	2	HEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021513s010lbl.pdf	Homo sapiens		h	12.43							false
2340	1257		ADULT	444031	426.55	DARIFENACIN	DARIFENACIN	NC(=O)C([C@@H]1CCN(CCC2=CC3=C(OCC3)C=C2)C1)(C4=CC=CC=C4)C5=CC=CC=C5	PLASMA	APG9819VLM							24		t	ng × h/mL	88.9		ng/mL	5.76			RECOMMENDED	mg	15		STEADY-STATE	UNKNOWN		day	1	Darifenacin is approximately 98 percent bound to plasma proteins (primarily to alpha-1-acid-glycoprotein).	2	HEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021513s010lbl.pdf	Homo sapiens		h	12.05							false
2341	1258		UNKNOWN	451668	228.2053	DECITABINE	DECITABINE	NC1=NC(=O)N(C=N1)[C@H]2C[C@H](O)[C@@H](CO)O2	PLASMA	776B62CQ27																						UNKNOWN				As plasma protein binding of decitabine is negligible (<1%), interactions due to displacement of more highly protein bound drugs from plasma proteins are not expected.	99	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021790s021lbl.pdf	Homo sapiens										false
2342	1258		ADULT	451668	228.21	DECITABINE	DECITABINE	NC1=NC(=O)N(C=N1)[C@H]2C[C@H](O)[C@@H](CO)O2	PLASMA	776B62CQ27									∞	ng × h/mL	163		ng/mL	73.8			RECOMMENDED	mg/m²	15		STEADY-STATE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/17564707	Homo sapiens		h	0.62							false
2343	1259		ADULT	124087	310.821	DESLORATADINE	DESLORATADINE	ClC1=CC2=C(C=C1)C(=C3CCNCC3)C4=NC=CC=C4CC2	PLASMA	FVF865388R									?	ng × h/mL	56.9		ng/mL	4			DEFINED DAILY	mg	5		STEADY-STATE	UNKNOWN		day	1	Desloratadine and 3-hydroxydesloratadine are approximately 82% to 87% and 85% to 89% bound to plasma proteins, respectively.	84.5	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf	Homo sapiens		h	27							false
2344	1260		ADULT	6917715	324.4565	ETONOGESTREL	ETONOGESTREL	CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C	SERUM	304GTH6RNH									?	ng × h/mL	35.9		ng/mL	3.69			RECOMMENDED	mg	0.15		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2147817/	Homo sapiens		h	23.8							false
2345	1260		UNKNOWN	6917715	324.4565	ETONOGESTREL	etonogestrel	CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C	PLASMA	304GTH6RNH	5991		ETHINYL ESTRADIOL	Ethinyl estradiol	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@]2(O)C#C	423D2T571U			∞	pg × h/mL	33858		pg/mL	2805			DEFINED DAILY	mg	0.15		SINGLE	UNKNOWN					2	UNKNOWN	Oral	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020071s025lbl.pdf	Homo sapiens										true
2346	1260		UNKNOWN	6917715	324.4565	ETONOGESTREL	etonogestrel	CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C	PLASMA	304GTH6RNH	5991		ETHINYL ESTRADIOL	Ethinyl estradiol	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@]2(O)C#C	423D2T571U	24		t	pg × h/mL	52299		pg/mL	5840			RECOMMENDED	mg	0.15		STEADY-STATE	UNKNOWN		day	1		2	UNKNOWN	Oral	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020071s025lbl.pdf	Homo sapiens										true
2347	1262		ADULT	5311068	200.2795	DEXMEDETOMIDINE	DEXMEDETOMIDINE	C[C@H](C1=CNC=N1)C2=CC=CC(C)=C2C	PLASMA	67VB76HONO									∞	ng × h/mL	107.58		ng/mL	2.6			UNKNOWN	μg/kg bw	1		SINGLE	FASTED						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30427948/	Homo sapiens		min	138							false
2348	1263		ADULT	71384	268.2691	DEXRAZOXANE	DEXRAZOXANE	C[C@@H](CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2	PLASMA	048L81261F	31703		DOXORUBICIN	doxorubicin	COC1=CC=CC2=C1C(=O)C3=C(C2=O)C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O)C(=O)CO	80168379AG											RECOMMENDED	mg/m²	500		SINGLE	UNKNOWN				In vitro studies have shown that dexrazoxane is not bound to plasma proteins.	100	UNHEALTHY	Intravenous	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf	Homo sapiens		h	2.5							true
2349	1264			3016	284.74	DIAZEPAM	DIAZEPAM	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C3=CC=CC=C3	PLASMA	Q3JTX2Q7TU							12		t	ng × h/mL	1227		ng/mL	208				mg	20		SINGLE							UNHEALTHY	Nasal		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01417078	Homo sapiens										false
2350	1264		ADULT	3016	284.74	DIAZEPAM	DIAZEPAM	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C3=CC=CC=C3	PLASMA	Q3JTX2Q7TU							12		t	ng × h/mL	330		ng/mL	75			RECOMMENDED	mg	2		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1505149	Homo sapiens										false
2351	1264		ADULT	3016	284.74	DIAZEPAM	DIAZEPAM	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C3=CC=CC=C3	PLASMA	Q3JTX2Q7TU							12		t	ng × h/mL	779		ng/mL	172			RECOMMENDED	mg	5		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1505149	Homo sapiens										false
2352	1264		ADULT	3016	284.74	DIAZEPAM	DIAZEPAM	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C3=CC=CC=C3	PLASMA	Q3JTX2Q7TU							12		t	ng × h/mL	1530		ng/mL	317			DEFINED DAILY	mg	10		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1505149	Homo sapiens										false
2353	1264		UNKNOWN	3016	284.74	DIAZEPAM	DIAZEPAM	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C3=CC=CC=C3	PLASMA	Q3JTX2Q7TU																	UNKNOWN				UNKNOWN	UNKNOWN				Diazepam and its metabolites are highly bound to plasma proteins (diazepam 98%).	2	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/013263s094lbl.pdf	Homo sapiens		h	48							false
2354	1265		CHILD	3019	230.671	DIAZOXIDE	DIAZOXIDE	CC1=NC2=C(C=C(Cl)C=C2)S(=O)(=O)N1	PLASMA	O5CB12L4FN							8		t	μg × h/mL	345		μg/mL	45			RECOMMENDED	mg	2.5		STEADY-STATE	UNKNOWN		day	3			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28715810/	Homo sapiens		h	14.3							false
2355	1265		ADULT	3019	230.671	DIAZOXIDE	DIAZOXIDE	CC1=NC2=C(C=C(Cl)C=C2)S(=O)(=O)N1	PLASMA	O5CB12L4FN																	RECOMMENDED	mg/kg	2.5		MULTIPLE	UNKNOWN		day	3	extensively bound (more than 90%) to serum proteins, and is excreted in the kidneys.	10	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017453s020lbl.pdf	Homo sapiens		h	30							false
2356	1266			3038	305.159	DICHLORPHENAMIDE	dichlorphenamide	NS(=O)(=O)C1=CC(Cl)=C(Cl)C(=C1)S(N)(=O)=O	PLASMA	VVJ6673MHY																										The plasma protein binding of dichlorphenamide is approximately 88%.	12				DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf	Homo sapiens										false
2357	1266		ADULT	3038	305.159	DICHLORPHENAMIDE	DICHLORPHENAMIDE	NS(=O)(=O)C1=CC(Cl)=C(Cl)C(=C1)S(N)(=O)=O	PLASMA	VVJ6673MHY									∞	ng × h/mL	66456		ng/mL	3030			MAX DAILY	mg	200		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/29762909	Homo sapiens		h	41							false
2358	1267		ADULT	50599|5273537|135398739	236.2273	DIDANOSINE	DIDANOSINE	OC[C@@H]1CC[C@@H](O1)N2C=NC3=C2N=CNC3=O	PLASMA	K3GDH6OH08									∞	ng × h/mL	413		ng/mL	305			UNKNOWN	mg/kg bw	0.4		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1903100/	Homo sapiens		h	0.88							false
2359	1267		ADULT	50599|5273537|135398739	236.2273	DIDANOSINE	DIDANOSINE	OC[C@@H]1CC[C@@H](O1)N2C=NC3=C2N=CNC3=O	PLASMA	K3GDH6OH08							12		t	ng × h/mL	418		ng/mL	291			UNKNOWN	mg/kg bw	0.4		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1903100/	Homo sapiens		h	0.93							false
2360	1267		ADULT	50599|5273537|135398739	236.2273	DIDANOSINE	DIDANOSINE	OC[C@@H]1CC[C@@H](O1)N2C=NC3=C2N=CNC3=O	PLASMA	K3GDH6OH08									∞	ng × h/mL	3726		ng/mL	2818			UNKNOWN	mg/kg bw	3		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1903100/	Homo sapiens		h	1.17							false
2361	1267		ADULT	50599|5273537|135398739	236.2273	DIDANOSINE	DIDANOSINE	OC[C@@H]1CC[C@@H](O1)N2C=NC3=C2N=CNC3=O	PLASMA	K3GDH6OH08							12		t	ng × h/mL	4118		ng/mL	3041			UNKNOWN	mg/kg bw	3		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1903100/	Homo sapiens		h	1.19							false
2362	1267		ADULT	50599|5273537|135398739	236.2273	DIDANOSINE	DIDANOSINE	OC[C@@H]1CC[C@@H](O1)N2C=NC3=C2N=CNC3=O	PLASMA	K3GDH6OH08									∞	ng × h/mL	28257		ng/mL	17974			UNKNOWN	mg/kg bw	16.5		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1903100/	Homo sapiens		h	1.48							false
2363	1267		ADULT	50599|5273537|135398739	236.2273	DIDANOSINE	DIDANOSINE	OC[C@@H]1CC[C@@H](O1)N2C=NC3=C2N=CNC3=O	PLASMA	K3GDH6OH08							12		t	ng × h/mL	32264		ng/mL	18019			UNKNOWN	mg/kg bw	16.5		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1903100/	Homo sapiens		h	1.49							false
2364	1267		ADULT	50599|5273537|135398739	236.2273	DIDANOSINE	DIDANOSINE	OC[C@@H]1CC[C@@H](O1)N2C=NC3=C2N=CNC3=O	PLASMA	K3GDH6OH08									∞	ng × h/mL	351		ng/mL	244			UNKNOWN	mg/kg bw	0.8		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1903100/	Homo sapiens		h	0.76							false
2365	1267		ADULT	50599|5273537|135398739	236.2273	DIDANOSINE	DIDANOSINE	OC[C@@H]1CC[C@@H](O1)N2C=NC3=C2N=CNC3=O	PLASMA	K3GDH6OH08							12		t	ng × h/mL	421		ng/mL	343			UNKNOWN	mg/kg bw	0.8		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1903100/	Homo sapiens		h	1.1							false
2366	1267		ADULT	50599|5273537|135398739	236.2273	DIDANOSINE	DIDANOSINE	OC[C@@H]1CC[C@@H](O1)N2C=NC3=C2N=CNC3=O	PLASMA	K3GDH6OH08									∞	ng × h/mL	2374		ng/mL	1494			UNKNOWN	mg/kg bw	6		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1903100/	Homo sapiens		h	1.12							false
2367	1267		ADULT	50599|5273537|135398739	236.2273	DIDANOSINE	DIDANOSINE	OC[C@@H]1CC[C@@H](O1)N2C=NC3=C2N=CNC3=O	PLASMA	K3GDH6OH08							12		t	ng × h/mL	3377		ng/mL	2257			UNKNOWN	mg/kg bw	6		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1903100/	Homo sapiens		h	1.24							false
2368	1267		ADULT	50599|5273537|135398739	236.2273	DIDANOSINE	DIDANOSINE	OC[C@@H]1CC[C@@H](O1)N2C=NC3=C2N=CNC3=O	PLASMA	K3GDH6OH08									∞	ng × h/mL	12730		ng/mL	5787			UNKNOWN	mg/kg bw	33		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1903100/	Homo sapiens		h	1.64							false
2369	1267		ADULT	50599|5273537|135398739	236.2273	DIDANOSINE	DIDANOSINE	OC[C@@H]1CC[C@@H](O1)N2C=NC3=C2N=CNC3=O	PLASMA	K3GDH6OH08							12		t	ng × h/mL	14179		ng/mL	6041			UNKNOWN	mg/kg bw	33		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1903100/	Homo sapiens		h	1.9							false
2370	1268		ADULT	3052	199.2932	DIETHYLCARBAMAZINE	DIETHYLCARBAMAZINE	CCN(CC)C(=O)N1CCN(C)CC1	SERUM	V867Q8X3ZD									∞	ng × h/mL	5840		ng/mL	500			RECOMMENDED	mg	150		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11865970/	Homo sapiens		h	14.6							false
2371	1268		ADULT	3052	199.2932	DIETHYLCARBAMAZINE	DIETHYLCARBAMAZINE	CCN(CC)C(=O)N1CCN(C)CC1	SERUM	V867Q8X3ZD									∞	ng × h/mL	7220		ng/mL	637			RECOMMENDED	mg	150		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11865970/	Homo sapiens		h	11.4							false
2372	1269		ADULT	7029	205.2961	DIETHYLPROPION	DIETHYLPROPION	CCN(CC)C(C)C(=O)C1=CC=CC=C1	PLASMA	Q94YYU22B8									∞	ng × h/mL	36.59		ng/mL	7.04			RECOMMENDED	mg	75		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31780765	Homo sapiens		h	3.95							false
2373	1271		ADULT	2724385	780.9385	DIGOXIN	C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]7(C)[C@H](CC[C@]67O)C8=CC(=O)OC8)C4)O[C@@H]3C)O[C@@H]2C	C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]7(C)[C@H](CC[C@]67O)C8=CC(=O)OC8)C4)O[C@@H]3C)O[C@@H]2C	SERUM	73K4184T59																	UNKNOWN				UNKNOWN	UNKNOWN				Approximately 25% of digoxin in the plasma is bound to protein.	75	HEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020405s013lbl.pdf	Homo sapiens		h	42							false
2374	1271		ADULT	2724385	780.9385	DIGOXIN	C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]7(C)[C@H](CC[C@]67O)C8=CC(=O)OC8)C4)O[C@@H]3C)O[C@@H]2C	C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]7(C)[C@H](CC[C@]67O)C8=CC(=O)OC8)C4)O[C@@H]3C)O[C@@H]2C	PLASMA	73K4184T59							24		t	ng × h/mL	12.5		ng/mL	1.32			RECOMMENDED	mg	0.25		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/18823299	Homo sapiens										false
2375	1272		UNKNOWN	5280360	352.4651	DINOPROSTONE	PROSTAGLANDIN E2	CCCCC[C@H](O)\\C=C\\[C@H]1[C@H](O)CC(=O)[C@@H]1C\\C=C/CCCC(O)=O	PLASMA	K7Q1JQR04M																	UNKNOWN				UNKNOWN	UNKNOWN						UNKNOWN	UNKNOWN	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020411s023lbl.pdf	Homo sapiens		min	3.75							false
2376	1272		ADULT	5280360	352.4651	DINOPROSTONE	PROSTAGLANDIN E2	CCCCC[C@H](O)\\C=C\\[C@H]1[C@H](O)CC(=O)[C@@H]1C\\C=C/CCCC(O)=O	PLASMA	K7Q1JQR04M													pg/mL	433			RECOMMENDED	mg	0.5		SINGLE	UNKNOWN						HEALTHY	Topical	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019617s010lbl.pdf	Homo sapiens										false
2377	1273		ADULT	3108	504.6256	DIPYRIDAMOLE	DIPYRIDAMOLE	OCCN(CCO)C1=NC2=C(N=C(N=C2C(=N1)N3CCCCC3)N(CCO)CCO)N4CCCCC4	PLASMA	64ALC7F90C									∞	ng × h/mL	2492		ng/mL	475			UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	http://ijpr.sbmu.ac.ir/article_58_c020ec0b8fe53db0e9efad50d3ee292f.pdf	Homo sapiens		h	10.3							false
2378	1273		ADULT	3108	504.6256	DIPYRIDAMOLE	DIPYRIDAMOLE	OCCN(CCO)C1=NC2=C(N=C(N=C2C(=N1)N3CCCCC3)N(CCO)CCO)N4CCCCC4	PLASMA	64ALC7F90C									∞	ng × h/mL	15030		ng/mL	1881			UNKNOWN	mg	200		MULTIPLE	FASTED		2 weeks	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	http://mri.cts-mrp.eu/download/DK_H_2173_001_PAR.pdf	Homo sapiens		h	10.74							false
2379	1273		UNKNOWN	3108	504.6256	DIPYRIDAMOLE	DIPYRIDAMOLE	OCCN(CCO)C1=NC2=C(N=C(N=C2C(=N1)N3CCCCC3)N(CCO)CCO)N4CCCCC4	PLASMA	64ALC7F90C																						UNKNOWN				99% of dipyridamole is bound to plasma proteins, predominantly to alpha l-acid glycoprotein and albumin.	1	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/20884s1lbl.pdf	Homo sapiens										false
2380	1273		UNKNOWN	3108	504.6256	DIPYRIDAMOLE	DIPYRIDAMOLE	OCCN(CCO)C1=NC2=C(N=C(N=C2C(=N1)N3CCCCC3)N(CCO)CCO)N4CCCCC4	PLASMA	64ALC7F90C									∞	ng × h/mL	15779		ng/mL	2781			UNKNOWN	mg	200		SINGLE	UNKNOWN						UNKNOWN	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/2825745	Homo sapiens										false
2381	1274		ADULT	3114	339.4745	DISOPYRAMIDE	DISOPYRAMIDE	CC(C)N(CCC(C(N)=O)(C1=CC=CC=C1)C2=CC=CC=N2)C(C)C	PLASMA	GFO928U8MQ													mg/L	3.08			RECOMMENDED	mg	200		SINGLE	UNKNOWN					35	HEALTHY	Oral	FEMALE / MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/3524956/	Homo sapiens		h	8							false
2382	1274		ADULT	3114	339.4745	DISOPYRAMIDE	DISOPYRAMIDE	CC(C)N(CCC(C(N)=O)(C1=CC=CC=C1)C2=CC=CC=N2)C(C)C	PLASMA	GFO928U8MQ							24		t	μg × h/mL	27.1						RECOMMENDED	mg/kg	2		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7059444/	Homo sapiens		h	6.8							false
2383	1275		ADULT	3117	296.5	DISULFIRAM	DISULFIRAM	CCN(CC)C(=S)SSC(=S)N(CC)CC	PLASMA	TR3MLJ1UAI													nM	1.3			MAX DAILY	mg	500		SINGLE	UNKNOWN						UNHEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/1471547	Homo sapiens		h	7.3							false
2384	1276		UNKNOWN	12620	326.6	DOCOSANOL	docosanol	CCCCCCCCCCCCCCCCCCCCCCO	PLASMA	9G1OE216XY													ng/mL	318			UNKNOWN	g	5		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	REVIEW	https://mri.cts-mrp.eu/human/downloads/AT_H_0985_001_PAR.pdf	Homo sapiens										false
2385	1277		ADULT	71329	441.565	DOFETILIDE	DOFETILIDE	CN(CCOC1=CC=C(NS(C)(=O)=O)C=C1)CCC2=CC=C(NS(C)(=O)=O)C=C2	BLOOD	R4Z9X1N2ND									∞	pg × h/mL	24568		pg/mL	2054			UNKNOWN	mg	0.5		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/28800211	Homo sapiens		h	9.54							false
2386	1277		ADULT	71329	441.565	DOFETILIDE	DOFETILIDE	CN(CCOC1=CC=C(NS(C)(=O)=O)C=C1)CCC2=CC=C(NS(C)(=O)=O)C=C2	BLOOD	R4Z9X1N2ND									∞	pg × h/mL	23383		pg/mL	1807			UNKNOWN	mg	0.5		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/28800211	Homo sapiens		h	9.58							false
2387	1278		ADULT	3156	378.5072	DOXAPRAM	DOXAPRAM	CCN1CC(CCN2CCOCC2)C(C1=O)(C3=CC=CC=C3)C4=CC=CC=C4	PLASMA	94F3830Q73									∞	μg × min/mL	272						RECOMMENDED	mg/kg	1.5		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32901	Homo sapiens		h	3.4							false
2388	1278		ADULT	3156	378.5072	DOXAPRAM	DOXAPRAM	CCN1CC(CCN2CCOCC2)C(C1=O)(C3=CC=CC=C3)C4=CC=CC=C4	PLASMA	94F3830Q73									∞	μg × min/mL	596		μg/mL	0.96			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32901	Homo sapiens		h	7.5							false
2389	1279		ADULT	5281107	412.6478	DOXERCALCIFEROL	DOXERCALCIFEROL	CC(C)[C@@H](C)\\C=C\\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\\C2=C/C=C3/C[C@@H](O)C[C@H](O)C3=C	SERUM	3DIZ9LF5Y9									?	pg × h/mL	957		pg/mL	29.9			UNKNOWN	μg	5		MULTIPLE	UNKNOWN		2 days	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/12637645	Homo sapiens		h	34							false
2390	1280		ADULT	3162	270.3694	DOXYLAMINE	DOXYLAMINE	CN(C)CCOC(C)(C1=CC=CC=C1)C2=CC=CC=N2	PLASMA	95QB77JKPL									∞	ng × h/mL	859.74		ng/mL	61.94			UNKNOWN	mg	12.5		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23633146/	Homo sapiens		h	12.23							false
2391	1280		ADULT	3162	270.3694	DOXYLAMINE	DOXYLAMINE	CN(C)CCOC(C)(C1=CC=CC=C1)C2=CC=CC=N2	PLASMA	95QB77JKPL									∞	ng × h/mL	1697.58		ng/mL	124.91			UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23633146/	Homo sapiens		h	12.45							false
2392	1280		ADULT	3162	270.3694	DOXYLAMINE	DOXYLAMINE	CN(C)CCOC(C)(C1=CC=CC=C1)C2=CC=CC=N2	PLASMA	95QB77JKPL							8		t	ng × h/mL	81.1		ng/mL	12.9			UNKNOWN	mg	3.2		SINGLE	FASTED						UNHEALTHY	Nasal	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29671128/	Homo sapiens		h	10.2							false
2393	1280		ADULT	3162	270.3694	DOXYLAMINE	DOXYLAMINE	CN(C)CCOC(C)(C1=CC=CC=C1)C2=CC=CC=N2	PLASMA	95QB77JKPL							8		t	ng × h/mL	117.7		ng/mL	18.9			UNKNOWN	mg	6.3		SINGLE	FASTED						UNHEALTHY	Nasal	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29671128/	Homo sapiens		h	11.8							false
2394	1280		ADULT	3162	270.3694	DOXYLAMINE	DOXYLAMINE	CN(C)CCOC(C)(C1=CC=CC=C1)C2=CC=CC=N2	PLASMA	95QB77JKPL							8		t	ng × h/mL	161.8		ng/mL	27.1			UNKNOWN	mg	12.7		SINGLE	FASTED						UNHEALTHY	Nasal	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29671128/	Homo sapiens		h	10.1							false
2395	1280		ADULT	3162	270.3694	DOXYLAMINE	DOXYLAMINE	CN(C)CCOC(C)(C1=CC=CC=C1)C2=CC=CC=N2	PLASMA	95QB77JKPL							8		t	ng × h/mL	751.8		ng/mL	142			UNKNOWN	mg	25		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29671128/	Homo sapiens		h	10.4							false
2396	1280		ADULT	3162	270.3694	DOXYLAMINE	DOXYLAMINE	CN(C)CCOC(C)(C1=CC=CC=C1)C2=CC=CC=N2	PLASMA	95QB77JKPL													ng/mL	99			UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4056080/	Homo sapiens		h	10.1							false
2397	1280		ADULT	3162	270.3694	DOXYLAMINE	DOXYLAMINE	CN(C)CCOC(C)(C1=CC=CC=C1)C2=CC=CC=N2	PLASMA	95QB77JKPL	6019|517312|51064122|88396073|145754945		PYRIDOXINE HYDROCHLORIDE	pyridoxine hydrochloride	Cl.CC1=NC=C(CO)C(CO)=C1O	68Y4CF58BV			∞	ng × h/mL	1280.9		ng/mL	83.3			DEFINED DAILY	mg	20		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021876s000lbl.pdf	Homo sapiens		h	10.1							true
2398	1280		ADULT	3162	270.3694	DOXYLAMINE	DOXYLAMINE	CN(C)CCOC(C)(C1=CC=CC=C1)C2=CC=CC=N2	PLASMA	95QB77JKPL	6019|517312|51064122|88396073|145754945		PYRIDOXINE HYDROCHLORIDE	pyridoxine hydrochloride	Cl.CC1=NC=C(CO)C(CO)=C1O	68Y4CF58BV			∞	ng × h/mL	3721.5		ng/mL	168.6			RECOMMENDED	mg	40		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021876s000lbl.pdf	Homo sapiens		h	11.9							true
2399	1281		ADULT	3168	379.4274	DROPERIDOL	DROPERIDOL	FC1=CC=C(C=C1)C(=O)CCCN2CCC(=CC2)N3C(=O)NC4=C3C=CC=C4	PLASMA	O9U0F09D5X							10		t	μg × h/L	40		μg/L	26.6			RECOMMENDED	mg/kg	0.02		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30574300/	Homo sapiens		h	2.1							false
2400	1281		ADULT	3168	379.4274	DROPERIDOL	DROPERIDOL	FC1=CC=C(C=C1)C(=O)CCCN2CCC(=CC2)N3C(=O)NC4=C3C=CC=C4	PLASMA	O9U0F09D5X							10		t	μg × h/L	18.7		μg/L	6.5			RECOMMENDED	mg/kg	0.02		SINGLE	UNKNOWN						HEALTHY	Nasal	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30574300/	Homo sapiens		h	2.4							false
2401	1282		ADULT	60835	297.415	DULOXETINE	DULOXETINE	CNCC[C@H](OC1=C2C=CC=CC2=CC=C1)C3=CC=CS3	PLASMA	O5TNM5N07U									∞	μg × h/L	489.35		μg/L	31.82			RECOMMENDED	mg	30		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23678352	Homo sapiens		h	10.19							false
2402	1282		ADULT	60835	297.415	DULOXETINE	DULOXETINE	CNCC[C@H](OC1=C2C=CC=CC2=CC=C1)C3=CC=CS3	PLASMA	O5TNM5N07U									∞	μg × h/L	1073.99		μg/L	55.88			MAX DAILY	mg	60		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23678352	Homo sapiens		h	11.89							false
2403	1282		ADULT	60835	297.415	DULOXETINE	DULOXETINE	CNCC[C@H](OC1=C2C=CC=CC2=CC=C1)C3=CC=CS3	PLASMA	O5TNM5N07U									∞	μg × h/L	840.26		μg/L	43.09			RECOMMENDED	mg	30		MULTIPLE	FASTED		day	1			HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23678352	Homo sapiens		h	11.39							false
2404	1282		ADULT	60835	297.415	DULOXETINE	DULOXETINE	CNCC[C@H](OC1=C2C=CC=CC2=CC=C1)C3=CC=CS3	PLASMA	O5TNM5N07U									∞	μg × h/L	175.39		μg/L	10.44			UNKNOWN	mg	15		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23678352	Homo sapiens		h	9.52							false
2405	1282		UNKNOWN	60835	297.415	DULOXETINE	DULOXETINE	CNCC[C@H](OC1=C2C=CC=CC2=CC=C1)C3=CC=CS3	PLASMA	O5TNM5N07U																						UNKNOWN				Duloxetine is highly bound (>90%) to proteins in human plasma, binding primarily to albumin and α1-acid glycoprotein	10	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021427s032s038lbl.pdf	Homo sapiens										false
2406	1283		ADULT	6918296	528.5297	DUTASTERIDE	DUTASTERIDE	C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)NC5=C(C=CC(=C5)C(F)(F)F)C(F)(F)F	PLASMA	O0J6XJN02I	129211		TAMSULOSIN	tamsulosin	CCOC1=C(OCCN[C@H](C)CC2=CC(=C(OC)C=C2)S(N)(=O)=O)C=CC=C1	G3P28OML5I	24		t	ng × h/mL	56.85		ng/mL	8.91			RECOMMENDED	mg	0.5		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://link.springer.com/article/10.1365/s10337-008-0613-7	Homo sapiens		h	5.71							true
2407	1283		ADULT	6918296	528.5297	DUTASTERIDE	DUTASTERIDE	C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)NC5=C(C=CC(=C5)C(F)(F)F)C(F)(F)F	PLASMA	O0J6XJN02I																	RECOMMENDED	mg	0.5		STEADY-STATE	UNKNOWN		day	1	Protein binding >99.5%	0.5	UNKNOWN	Oral	FEMALE / MALE	REVIEW	https://www.ncbi.nlm.nih.gov/pubmed/14565784	Homo sapiens		day	35							false
2408	1284		ADULT	9051	312.4458	DYDROGESTERONE	DYDROGESTERONE	CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C	PLASMA	90I02KLE8K									∞	ng × h/mL	7.7		ng/mL	2.1			RECOMMENDED	mg	10		SINGLE	UNKNOWN				More than 90% of dydrogesterone and DHD are bound to plasma-proteins.	10	HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://data.health.gov.il/drugs/alonim/Duphaston_dr_1410193172635.pdf	Homo sapiens		h	7							false
2409	1285		ADULT	64139	315.675	EFAVIRENZ	EFAVIRENZ	FC(F)(F)[C@]1(OC(=O)NC2=CC=C(Cl)C=C12)C#CC3CC3	PLASMA	JE6H2O27P8							24		t	μM × h	184		μM	12.9			RECOMMENDED	mg	600		STEADY-STATE	UNKNOWN		day	1	Efavirenz is highly bound (approximately 99.5-99.75%) to human plasma proteins, predominantly albumin.	0.5	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020972s057,021360s045lbl.pdf	Homo sapiens		h	40				35			false
2410	1285		ADULT	64139	315.675	EFAVIRENZ	EFAVIRENZ	FC(F)(F)[C@]1(OC(=O)NC2=CC=C(Cl)C=C12)C#CC3CC3	PLASMA	JE6H2O27P8							24						μM	1.6			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020972s057,021360s045lbl.pdf	Homo sapiens										false
2411	1285		ADULT	64139	315.675	EFAVIRENZ	EFAVIRENZ	FC(F)(F)[C@]1(OC(=O)NC2=CC=C(Cl)C=C12)C#CC3CC3	PLASMA	JE6H2O27P8							24						μM	9.1			UNKNOWN	mg	1600		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020972s057,021360s045lbl.pdf	Homo sapiens										false
2412	1287		ADULT	5281081	305.286	ENTACAPONE	ENTACAPONE	CCN(CC)C(=O)C(\\C#N)=C\\C1=CC(O)=C(O)C(=C1)[N+]([O-])=O	PLASMA	4975G9NM6T	6047|38101		LEVODOPA|CARBIDOPA	levodopa|carbidopa	N[C@@H](CC1=CC=C(O)C(O)=C1)C(O)=O | O.C[C@@](CC1=CC(O)=C(O)C=C1)	46627O600J|MNX7R8C5VO			?	ng × h/mL	2084		ng/mL	1325			RECOMMENDED	mg	200		MULTIPLE	FED		day	8			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10492060	Homo sapiens		h	1.3							true
2413	1287		ADULT	5281081	305.286	ENTACAPONE	ENTACAPONE	CCN(CC)C(=O)C(\\C#N)=C\\C1=CC(O)=C(O)C(=C1)[N+]([O-])=O	PLASMA	4975G9NM6T	6047|38101		LEVODOPA|CARBIDOPA	levodopa|carbidopa	N[C@@H](CC1=CC=C(O)C(O)=C1)C(O)=O | O.C[C@@](CC1=CC(O)=C(O)C=C1)	46627O600J|MNX7R8C5VO			?	ng × h/mL	1989		ng/mL	1095			RECOMMENDED	mg	200		STEADY-STATE	FED		day	10			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10492060	Homo sapiens		h	1.8							true
2414	1287		UNKNOWN	5281081	305.286	ENTACAPONE	ENTACAPONE	CCN(CC)C(=O)C(\\C#N)=C\\C1=CC(O)=C(O)C(=C1)[N+]([O-])=O	PLASMA	4975G9NM6T	6047|38101		LEVODOPA|CARBIDOPA	levodopa|carbidopa	N[C@@H](CC1=CC=C(O)C(O)=C1)C(O)=O | O.C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O	46627O600J|MNX7R8C5VO							μg/mL	1.2			RECOMMENDED	mg	200		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020796s15lbl.pdf	Homo sapiens										true
2415	1287		UNKNOWN	5281081	305.286	ENTACAPONE	ENTACAPONE	CCN(CC)C(=O)C(\\C#N)=C\\C1=CC(O)=C(O)C(=C1)[N+]([O-])=O	PLASMA	4975G9NM6T																						UNKNOWN				Based on in vitro studies, the plasma protein binding of entacapone is 98% over the concentration range of 0.4 - ­50 ug/mL. Entacapone binds mainly to serum albumin.	2	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020796s15lbl.pdf	Homo sapiens										false
2416	1288		ADULT	58048834	414.4914	EPLERENONE	EPLERENONE	COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]34O[C@@H]3C[C@@]5(C)[C@@H](CC[C@@]56CCC(=O)O6)[C@H]14	PLASMA	6995V82D0B									∞	μg × h/mL	18.4		μg/mL	2.49			UNKNOWN	mg	100		SINGLE	FASTED				The percentage of protein binding in the concentration range at the therapeutic dose (0.02–5.0 g/ml) was approximately 60 to 33%	38.2	HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/14570778	Homo sapiens		h	3.01							false
2417	1289		ADULT	6441383	418.6523	CALCIFEDIOL	Calcifediol	O.C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\\C(CCC[C@]12C)=C\\C=C3\\C[C@@H](O)CCC3=C	PLASMA	P6YZ13C99Q									?	ng × day/mL	2324.1		ng/mL	46.92			RECOMMENDED	μg	125		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25782422/	Homo sapiens		day	33							false
2418	1290		CHILD	176870	393.4357	ERLOTINIB	ERLOTINIB	COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1	PLASMA	J4T82NDH7E							24		t	ng × h/mL	26716.7		ng/mL	1969.5				mg/m²	85		STEADY-STATE			day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01032070	Homo sapiens										false
2419	1290		UNKNOWN	176870	393.4357	ERLOTINIB	ERLOTINIB	COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1	PLASMA	J4T82NDH7E																						UNKNOWN				Following absorption, erlotinib is approximately 93% protein bound to plasma albumin and alpha-1 acid glycoprotein (AAG).	7	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021743s14s16lbl.pdf	Homo sapiens										false
2420	1290		ADULT	176870	393.4357	ERLOTINIB	ERLOTINIB	COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1	PLASMA	J4T82NDH7E									∞	μg × h/mL	32		μg/mL	4.07			UNKNOWN	mg	100		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/19956953	Homo sapiens		h	12.4							false
2421	1290		ADULT	176870	393.4357	ERLOTINIB	ERLOTINIB	COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1	PLASMA	J4T82NDH7E									∞	μg × h/mL	29.9		μg/mL	1.25			UNKNOWN	mg	100		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/19956953	Homo sapiens		h	14.4							false
2422	1291		ADULT	3261	294.738	ESTAZOLAM	ESTAZOLAM	ClC1=CC=C2N3C=NN=C3CN=C(C4=CC=CC=C4)C2=C1	PLASMA	36S3EQV54C							72		t	ng × h/mL	1050		ng/mL	54.7			UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1968715/	Homo sapiens		h	14.9							false
2423	1291		ADULT	3261	294.738	ESTAZOLAM	ESTAZOLAM	ClC1=CC=C2N3C=NN=C3CN=C(C4=CC=CC=C4)C2=C1	PLASMA	36S3EQV54C							72		t	ng × h/mL	2060		ng/mL	98.6			UNKNOWN	mg	2		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1968715/	Homo sapiens		h	14.3							false
2424	1291		ADULT	3261	294.738	ESTAZOLAM	ESTAZOLAM	ClC1=CC=C2N3C=NN=C3CN=C(C4=CC=CC=C4)C2=C1	PLASMA	36S3EQV54C									?	ng × h/mL	4343		ng/mL	194			UNKNOWN	mg	4		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2862746/	Homo sapiens		h	19							false
2425	1291		ADULT	3261	294.738	ESTAZOLAM	ESTAZOLAM	ClC1=CC=C2N3C=NN=C3CN=C(C4=CC=CC=C4)C2=C1	PLASMA	36S3EQV54C									∞	ng × h/mL	5517		ng/mL	180			UNKNOWN	mg	2		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2862746/	Homo sapiens		h	17							false
2426	1292		ADULT	969472	388.808	ESZOPICLONE	ESZOPICLONE	CN1CCN(CC1)C(=O)O[C@@H]2N(C(=O)C3=NC=CN=C23)C4=NC=C(Cl)C=C4	PLASMA	UZX80K71OE							24		t	ng × h/mL	54.76		ng/mL	6.15			RECOMMENDED	mg	1		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	REVIEW	https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-lunivia_en.pdf	Homo sapiens										false
2427	1292		ADULT	969472	388.808	ESZOPICLONE	ESZOPICLONE	CN1CCN(CC1)C(=O)O[C@@H]2N(C(=O)C3=NC=CN=C23)C4=NC=C(Cl)C=C4	PLASMA	UZX80K71OE							24		t	ng × h/mL	166.21		ng/mL	19.88			MAX DAILY	mg	3		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	REVIEW	https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-lunivia_en.pdf	Homo sapiens										false
2428	1292		ADULT	969472	388.808	ESZOPICLONE	ESZOPICLONE	CN1CCN(CC1)C(=O)O[C@@H]2N(C(=O)C3=NC=CN=C23)C4=NC=C(Cl)C=C4	PLASMA	UZX80K71OE							24		t	ng × h/mL	338.26		ng/mL	40.28			UNKNOWN	mg	6		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	REVIEW	https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-lunivia_en.pdf	Homo sapiens										false
2429	1292		ADULT	969472	388.808	ESZOPICLONE	eszopiclone	CN1CCN(CC1)C(=O)O[C@@H]2N(C(=O)C3=NC=CN=C23)C4=NC=C(Cl)C=C4	PLASMA	UZX80K71OE							24		t	ng × h/mL	62.96		ng/mL	10.29			RECOMMENDED	mg	1		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	REVIEW	https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-lunivia_en.pdf	Homo sapiens										false
2430	1292		ADULT	969472	388.808	ESZOPICLONE	eszopiclone	CN1CCN(CC1)C(=O)O[C@@H]2N(C(=O)C3=NC=CN=C23)C4=NC=C(Cl)C=C4	PLASMA	UZX80K71OE							24		t	ng × h/mL	187.76		ng/mL	25.48			MAX DAILY	mg	3		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	REVIEW	https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-lunivia_en.pdf	Homo sapiens										false
2431	1292		ADULT	969472	388.808	ESZOPICLONE	eszopiclone	CN1CCN(CC1)C(=O)O[C@@H]2N(C(=O)C3=NC=CN=C23)C4=NC=C(Cl)C=C4	PLASMA	UZX80K71OE							24		t	ng × h/mL	379.04		ng/mL	54.68			UNKNOWN	mg	6		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	REVIEW	https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-lunivia_en.pdf	Homo sapiens										false
2432	1292		ADULT	969472	388.808	ESZOPICLONE	eszopiclone	CN1CCN(CC1)C(=O)O[C@@H]2N(C(=O)C3=NC=CN=C23)C4=NC=C(Cl)C=C4	PLASMA	UZX80K71OE							24		t	ng × h/mL	66.05		ng/mL	9.58			RECOMMENDED	mg	1		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	REVIEW	https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-lunivia_en.pdf	Homo sapiens										false
2433	1292		ADULT	969472	388.808	ESZOPICLONE	eszopiclone	CN1CCN(CC1)C(=O)O[C@@H]2N(C(=O)C3=NC=CN=C23)C4=NC=C(Cl)C=C4	PLASMA	UZX80K71OE							24		t	ng × h/mL	191.07		ng/mL	26.18			MAX DAILY	mg	3		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	REVIEW	https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-lunivia_en.pdf	Homo sapiens										false
2434	1292		ADULT	969472	388.808	ESZOPICLONE	eszopiclone	CN1CCN(CC1)C(=O)O[C@@H]2N(C(=O)C3=NC=CN=C23)C4=NC=C(Cl)C=C4	PLASMA	UZX80K71OE							24		t	ng × h/mL	409.31		ng/mL	59.63			UNKNOWN	mg	6		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	REVIEW	https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-lunivia_en.pdf	Homo sapiens										false
2435	1292		ADULT	969472	388.808	ESZOPICLONE	eszopiclone	CN1CCN(CC1)C(=O)O[C@@H]2N(C(=O)C3=NC=CN=C23)C4=NC=C(Cl)C=C4	PLASMA	UZX80K71OE																	RECOMMENDED	mg	2		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	REVIEW	https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-lunivia_en.pdf	Homo sapiens		h	6.7							false
2436	1292		UNKNOWN	969472	388.808	ESZOPICLONE	eszopiclone	CN1CCN(CC1)C(=O)O[C@@H]2N(C(=O)C3=NC=CN=C23)C4=NC=C(Cl)C=C4	PLASMA	UZX80K71OE																						UNKNOWN				In vitro protein binding of eszopiclone in human plasma was 52.2-58.9% over the concentration range of 5-500 ng/mL of [14C]-eszopiclone.	44.45	UNKNOWN		UNKNOWN	REVIEW	https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-lunivia_en.pdf	Homo sapiens										false
2437	1293		ADULT	5991	296.4034	ETHINYL ESTRADIOL	C[C@]12CC[C@H]3[C@@H](CCC4=CC(O)=CC=C34)[C@@H]1CC[C@@]2(O)C#C	C[C@]12CC[C@H]3[C@@H](CCC4=CC(O)=CC=C34)[C@@H]1CC[C@@]2(O)C#C	PLASMA	423D2T571U									∞	pg × h/mL	1335.8		pg/mL	122.8			UNKNOWN	mg	0.06		SINGLE	FASTED						HEALTHY	Oral	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf	Homo sapiens		h	17.5							false
2438	1294		UNKNOWN	3291	141.1677	ETHOSUXIMIDE	ETHOSUXIMIDE	CCC1(C)CC(=O)NC1=O	SERUM	5SEH9X1D1D																						UNKNOWN				Mean % free concentration (±SEM) 78.2 ± 1.4	78.2	UNKNOWN		UNKNOWN	EXPERIMENT	https://onlinelibrary.wiley.com/doi/full/10.1111/epi.13802	Homo sapiens										false
2439	1294		ADULT	3291	141.1677	ETHOSUXIMIDE	ETHOSUXIMIDE	CCC1(C)CC(=O)NC1=O	PLASMA	5SEH9X1D1D													μg/mL	18			UNKNOWN	g	1		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	REVIEW	https://www.medicines.org.uk/emc/product/9762/smpc	Homo sapiens										false
2440	1294		ADULT	3291	141.1677	ETHOSUXIMIDE	ETHOSUXIMIDE	CCC1(C)CC(=O)NC1=O	PLASMA	5SEH9X1D1D									∞	μg × h/mL	915		μg/mL	12.4			UNKNOWN	mg	500		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/8799524	Homo sapiens		h	53.7							false
2441	1295		ADULT	3292	204.2252	ETHOTOIN	ethotoin	CCN1C(=O)NC(C1=O)C2=CC=CC=C2	SERUM	46QG38NC4U																	DEFINED DAILY	mg/kg	25		SINGLE	UNKNOWN				n=5	58.8	UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://onlinelibrary.wiley.com/doi/abs/10.1002/ana.410060506	Homo sapiens		h	5.11							false
2442	1295		ADULT	12309784	204.2252	ETHOTOIN, (R)-	CCN1C(=O)[C@H](NC1=O)C2=CC=CC=C2	CCN1C(=O)[C@H](NC1=O)C2=CC=CC=C2	PLASMA	6026V958QL									∞	μg × h/mL	510		μg/mL	26.6			DEFINED DAILY	mg	1000		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://onlinelibrary.wiley.com/doi/abs/10.1002/chir.530040303	Homo sapiens		h	12.35							false
2443	1295		ADULT	6604216	204.2252	ETHOTOIN, (S)-	O=C([C@@](C1=CC=CC=C1)([H])N2)N(CC)C2=O	CCN1C(=O)N[C@H](C1=O)C2=CC=CC=C2	PLASMA	9H44Z50DS7									∞	pg × h/mL	580		μg/mL	30.4			DEFINED DAILY	mg	1000		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://onlinelibrary.wiley.com/doi/abs/10.1002/chir.530040303	Homo sapiens		h	12.28							false
2444	1296		ADULT	3308	287.3535	ETODOLAC	ETODOLAC	CCC1=CC=CC2=C1NC3=C2CCOC3(CC)CC(O)=O	SERUM	2M36281008							24		t	μg × h/mL	65.8		μg/mL	15.9			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2525981/	Homo sapiens		h	6							false
2445	1296		ADULT	3308	287.3535	ETODOLAC	ETODOLAC	CCC1=CC=CC2=C1NC3=C2CCOC3(CC)CC(O)=O	SERUM	2M36281008							24		t	μg × h/mL	81		μg/mL	17.8			UNKNOWN	mg	200		MULTIPLE	FASTED		day	2			HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2525981/	Homo sapiens		h	6.5							false
2446	1296		ADULT	3308	287.3535	ETODOLAC	ETODOLAC	CCC1=CC=CC2=C1NC3=C2CCOC3(CC)CC(O)=O	SERUM	2M36281008							24		t	μg × h/mL	84		μg/mL	14.5			UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2938343/	Homo sapiens		h	6.1							false
2447	1297		ADULT	6917715	324.4565	ETONOGESTREL	ETONOGESTREL	CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C	SERUM	304GTH6RNH							24		t	ng × h/mL	6.097		ng/mL	0.59			UNKNOWN	μg	75		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30347490	Homo sapiens		h	29.2							false
2448	1297		UNKNOWN	6917715	324.4565	ETONOGESTREL	ETONOGESTREL	CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C	BLOOD	304GTH6RNH																						UNKNOWN				Etonogestrel is approximately 32% bound to sex hormone binding globulin (SHBG) and 66% bound to albumin in blood.	2	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021529s018lbl.pdf	Homo sapiens										false
2449	1298		ADULT	6442177	958.2	EVEROLIMUS	EVEROLIMUS	CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)C=C(C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)C=CC=CC=C(C)[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO	PLASMA	9HW64Q8G6G													ng/mL	18.84			UNKNOWN	mg	2		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://ascopubs.org/doi/abs/10.1200/jco.2010.28.15_suppl.e13157	Homo sapiens		h	45.74							false
2450	1298		UNKNOWN	6442177	958.2	EVEROLIMUS	EVEROLIMUS	CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)C=C(C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)C=CC=CC=C(C)[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO	PLASMA	9HW64Q8G6G																						UNKNOWN					27	UNKNOWN		UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/27299325	Homo sapiens										false
2451	1298		ADULT	6442177	958.2	EVEROLIMUS	EVEROLIMUS	CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)C=C(C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)C=CC=CC=C(C)[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO	BLOOD	9HW64Q8G6G							24		t	ng × h/mL	435		ng/mL	61.5			UNKNOWN	mg	10		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/28762135	Homo sapiens										false
2452	1299		ADULT	60198	296.4034	EXEMESTANE	EXEMESTANE	C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O	PLASMA	NY22HMQ4BX									?	ng × h/mL	36.4		ng/mL	16.1			MIN EFFICACIOUS	mg	25		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/14671195	Homo sapiens		h	8.9							false
2453	1300		ADULT	150311	409.4252	EZETIMIBE	EZETIMIBE	O[C@@H](CC[C@@H]1[C@H](N(C1=O)C2=CC=C(F)C=C2)C3=CC=C(O)C=C3)C4=CC=C(F)C=C4	PLASMA	EOR26LQQ24													ng/mL	3.4			DEFINED DAILY	mg	10		SINGLE	FASTED				Ezetimibe and ezetimibe-glucuronide are highly bound (>90%) to human plasma proteins.	10	UNKNOWN	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21445lbl.pdf	Homo sapiens										false
2454	1300		ADULT	150311	409.4252	EZETIMIBE	EZETIMIBE	O[C@@H](CC[C@@H]1[C@H](N(C1=O)C2=CC=C(F)C=C2)C3=CC=C(O)C=C3)C4=CC=C(F)C=C4	PLASMA	EOR26LQQ24							24		t	ng × h/mL	92		ng/mL	8.4			DEFINED DAILY	mg	10		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	REVIEW	https://www.ncbi.nlm.nih.gov/pubmed/15871634	Homo sapiens										false
2455	1300		ADULT	150311	409.4252	EZETIMIBE	EZETIMIBE	O[C@@H](CC[C@@H]1[C@H](N(C1=O)C2=CC=C(F)C=C2)C3=CC=C(O)C=C3)C4=CC=C(F)C=C4	PLASMA	EOR26LQQ24							39		t	ng × h/mL	86		ng/mL	5.2			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	REVIEW	https://www.ncbi.nlm.nih.gov/pubmed/15871634	Homo sapiens										false
2456	1302		ADULT	134018	316.375	FEBUXOSTAT	FEBUXOSTAT	CC(C)COC1=C(C=C(C=C1)C2=NC(C)=C(S2)C(O)=O)C#N	PLASMA	101V0R1N2E									∞	μg × h/mL	3.98		μg/mL	1.53			RECOMMENDED	mg	40		MULTIPLE	UNKNOWN		day	1	The drug is highly bound to albumin in blood (~99%)	1	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/16884320	Homo sapiens		h	4.2							false
2457	1303		CHILD	3331	238.24	FELBAMATE	FELBAMATE	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	PLASMA	X72RBB02N8													μg/mL	49			RECOMMENDED	mg/kg	45		STEADY-STATE	UNKNOWN		day	1			UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf027lbl.pdf	Homo sapiens		h	20							false
2458	1303		ADULT	3331	238.24	FELBAMATE	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	PLASMA	X72RBB02N8									∞	μg × h/mL	526		μg/mL	14.2			RECOMMENDED	mg	1200		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/9241102	Homo sapiens		h	19.2							false
2459	1304		ADULT	3333	384.254	FELODIPINE	FELODIPINE	CCOC(=O)C1=C(C)NC(C)=C(C1C2=C(Cl)C(Cl)=CC=C2)C(=O)OC	PLASMA	OL961R6O2C							12		t	nM × h	100.9		nM	23.1			UNKNOWN	mg	10		STEADY-STATE	FASTED		day	2			UNKNOWN	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2015166/	Homo sapiens		h	23.1							false
2460	1304		ADULT	62970	382.238	DEHYDROFELODIPINE	Dehydrofelodipine	CCOC(=O)C1=C(C2=C(Cl)C(Cl)=CC=C2)C(C(=O)OC)=C(C)N=C1C	PLASMA	1L4A1EP86I							12		t	nM × h	142		nM	35.6			UNKNOWN	mg	10		STEADY-STATE	FASTED		day	2			UNKNOWN	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2015166/	Homo sapiens										false
2461	1304		ADULT	3333	384.254	FELODIPINE	FELODIPINE	CCOC(=O)C1=C(C)NC(C)=C(C1C2=C(Cl)C(Cl)=CC=C2)C(=O)OC	PLASMA	OL961R6O2C									?	nM × h	33.7		nM	6.2			UNKNOWN	mg	5		STEADY-STATE	FASTED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3396260/	Homo sapiens		h	14.1							false
2462	1304		ADULT	3333	384.254	FELODIPINE	FELODIPINE	CCOC(=O)C1=C(C)NC(C)=C(C1C2=C(Cl)C(Cl)=CC=C2)C(=O)OC	PLASMA	OL961R6O2C									?	nM × h	87.5		nM	17.1			UNKNOWN	mg	5		STEADY-STATE	FASTED		day	2			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3396260/	Homo sapiens		h	27.5							false
2463	1305		ADULT	3342	242.2699	FENOPROFEN	FENOPROFEN	CC(C(O)=O)C1=CC(OC2=CC=CC=C2)=CC=C1	PLASMA	RA33EAC7KY							12		t	μg × h/mL	105.2		μg/mL	28.3			RECOMMENDED	mg	300		SINGLE	FASTED				http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.897.7569&rep=rep1&type=pdf	1	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/501526/	Homo sapiens		h	3							false
2464	1306		ADULT	57363	372.5441	FINASTERIDE	FINASTERIDE	CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C	PLASMA	57GNO57U7G							24		t	ng × h/mL	53		ng/mL	9.2			DEFINED DAILY	mg	1		STEADY-STATE	UNKNOWN		day	1	Approximately 90% of circulating finasteride is bound to plasma proteins.	10	HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020788s020s021s023lbl.pdf	Homo sapiens		h	4.5							false
2465	1307		ADULT	3356	414.3427	FLECAINIDE	FLECAINIDE	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1	PLASMA	K94FTS1806									∞	μg × h/mL	5.9						DEFINED DAILY	mg	200		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/1782978	Homo sapiens		h	11.5							false
2466	1307		ADULT	3356	414.3427	FLECAINIDE	FLECAINIDE	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1	PLASMA	K94FTS1806									∞	ng × h/mL	6238		ng/mL	1710			UNKNOWN	mg/kg	2		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/3094570	Homo sapiens										false
2467	1307		ADULT	3356	414.3427	FLECAINIDE	FLECAINIDE	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1	PLASMA	K94FTS1806									∞	ng × h/mL	5979		ng/mL	355			DEFINED DAILY	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/3094570	Homo sapiens										false
2468	1307		ADULT	3356	414.3427	FLECAINIDE	FLECAINIDE	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1	PLASMA	K94FTS1806																						UNKNOWN				Flecainide is not extensively bound (mean 40%) to human plasma proteins in vitro and binding is independent of total drug level.	60	HEALTHY		UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/6364769	Homo sapiens										false
2469	1308		ADULT	5790	246.19	FLOXURIDINE	OC[C@H]1O[C@H](C[C@@H]1O)N2C=C(F)C(=O)NC2=O	OC[C@H]1O[C@H](C[C@@H]1O)N2C=C(F)C(=O)NC2=O	PLASMA	039LU44I5M	60838 | 104842 | 3385		Irinotecan | 7-Ethyl-10-hydroxycamptothecin | 5-Fluorouracil	Irinotecan | 7-Ethyl-10-hydroxycamptothecin | 5-Fluorouracil	CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7 | CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)O | C1=C(C(=O)NC(=O)N1)F	7673326042 | 0H43101T0J | U3P01618RT			∞	ng × h/mL	79304		ng/mL	5547			UNKNOWN	mg/m²	10.8		MULTIPLE	UNKNOWN		2 weeks	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/19147776	Homo sapiens		h	7.5							true
2470	1309		ADULT	3373	303.29	FLUMAZENIL	FLUMAZENIL	CCOC(=O)C1=C2CN(C)C(=O)C3=C(C=CC(F)=C3)N2C=N1	PLASMA	40P7XK9392									∞	ng × h/mL	12		ng/mL	6.98			UNKNOWN	mg	2.2		SINGLE	FASTED						HEALTHY	Sublingual	FEMALE / MALE	EXPERIMENT	https://pdfs.semanticscholar.org/7fec/02a99fcca4c9565aa786b9ade3853eb74058.pdf	Homo sapiens		h	1.05							false
2471	1309		ADULT	3373	303.29	FLUMAZENIL	FLUMAZENIL	CCOC(=O)C1=C2CN(C)C(=O)C3=C(C=CC(F)=C3)N2C=N1	PLASMA	40P7XK9392									∞	ng × h/mL	9.1		ng/mL	5.28			UNKNOWN	mg	2.2		SINGLE	HIGH-FAT						HEALTHY	Sublingual	FEMALE / MALE	EXPERIMENT	https://pdfs.semanticscholar.org/7fec/02a99fcca4c9565aa786b9ade3853eb74058.pdf	Homo sapiens		h	1.12							false
2472	1309		ADULT	3373	303.29	FLUMAZENIL	FLUMAZENIL	CCOC(=O)C1=C2CN(C)C(=O)C3=C(C=CC(F)=C3)N2C=N1	PLASMA	40P7XK9392									∞	ng × h/mL	12.9		ng/mL	45.9			RECOMMENDED	mg	0.2		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pdfs.semanticscholar.org/7fec/02a99fcca4c9565aa786b9ade3853eb74058.pdf	Homo sapiens		h	1.18							false
2473	1310		ADULT		887.0108	FLUNISOLIDE	FLUNISOLIDE	O.CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO.CC6(C)O[C@@H]7C[C@H]8[C@@H]9C[C@H](F)C%10=CC(=O)C=C[C@]%10(C)[C@H]9[C@@H](O)C[C@]8(C)[C@@]7(O6)C(=O)CO	PLASMA	QK4DYS664X							12		t	ng × h/mL	1.2		ng/mL	1			UNKNOWN	μg	160		MULTIPLE	UNKNOWN		day	2			UNKNOWN	Respiratory	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021247s008lbl.pdf	Homo sapiens										false
2474	1310		ADULT		887.0108	FLUNISOLIDE	FLUNISOLIDE	O.CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO.CC6(C)O[C@@H]7C[C@H]8[C@@H]9C[C@H](F)C%10=CC(=O)C=C[C@]%10(C)[C@H]9[C@@H](O)C[C@]8(C)[C@@]7(O6)C(=O)CO	PLASMA	QK4DYS664X																	UNKNOWN	mg	0.5		SINGLE	FASTED				Plasma binding of 80%	20	HEALTHY	Respiratory	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/9505980	Homo sapiens		h	1.7							false
2475	1312		ADULT	6215	452.4882	FLUOCINOLONE ACETONIDE	fluocinolone acetonide	CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO	PLASMA										?	ng × h/mL	363.7		ng/mL	43.4			RECOMMENDED	mg	0.8		SINGLE	UNKNOWN						HEALTHY	Transdermal	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1874579/	Homo sapiens		h	18.2							false
2476	1312		ADULT	6215	452.4882	FLUOCINOLONE ACETONIDE	fluocinolone acetonide	CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO	PLASMA										?	ng × h/mL	354.8		ng/mL	54			RECOMMENDED	mg	0.8		SINGLE	UNKNOWN						HEALTHY	Topical	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1874579/	Homo sapiens		h	14.8							false
2477	1313		ADULT	3397	276.21	FLUTAMIDE	FLUTAMIDE	CC(C)C(=O)NC1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F	PLASMA	76W6J0943E							24		t	ng × h/mL	96.4		ng/mL	53.4			RECOMMENDED	mg	250		SINGLE	FASTED				Both flutamide and hydroxyflutamide are highly protein bound (>94%)	6	HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/10073738	Homo sapiens										false
2478	1313		ADULT	3397	276.21	FLUTAMIDE	FLUTAMIDE	CC(C)C(=O)NC1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F	PLASMA	76W6J0943E									?	ng × h/mL	63		ng/mL	25.2			RECOMMENDED	mg	250		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/2754024	Homo sapiens										false
2479	1313		ADULT	3397	276.21	FLUTAMIDE	FLUTAMIDE	CC(C)C(=O)NC1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F	PLASMA	76W6J0943E									?	ng × h/mL	212.1		ng/mL	112.7			DEFINED DAILY	mg	250		STEADY-STATE	FASTED		day	3			HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/2754024	Homo sapiens										false
2480	1314		ADULT	444036	500.571	FLUTICASONE PROPIONATE	FLUTICASONE PROPIONATE	CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF	PLASMA	O2GMZ0LF5W									?	pg × h/mL	14148		pg/mL	23364			UNKNOWN	μg	1000		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12680886	Homo sapiens		h	4.1							false
2481	1314		ADULT	444036	500.571	FLUTICASONE PROPIONATE	FLUTICASONE PROPIONATE	CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF	PLASMA	O2GMZ0LF5W																	UNKNOWN	mg	1		SINGLE	UNKNOWN				The percentage of fluticasone propionate bound to human plasma proteins averaged 91%.	9	HEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/076633_ORIGINAL%20APPROVAL_PACKAGE.pdf	Homo sapiens										false
2482	1315		ADULT	5324346	318.3346	FLUVOXAMINE	Fluvoxamine	COCCCC\\C(C1=CC=C(C=C1)C(F)(F)F)=N/OCCN	PLASMA	O4L1XPO44W									∞	μg × h/L	201		μg/L	16			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	MALE	REVIEW	https://link.springer.com/article/10.2165/00003088-199427030-00002	Homo sapiens				oral solution			12	Fluvoxamine		false
2483	1315		ADULT	5324346	318.3346	FLUVOXAMINE	Fluvoxamine	COCCCC\\C(C1=CC=C(C=C1)C(F)(F)F)=N/OCCN	PLASMA	O4L1XPO44W									∞	μg × h/L	845		μg/L	51			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	REVIEW	https://link.springer.com/article/10.2165/00003088-199427030-00002	Homo sapiens		h	15	capsule			10	Fluvoxamine		false
2484	1315		ADULT	5324346	318.3346	FLUVOXAMINE	Fluvoxamine	COCCCC\\C(C1=CC=C(C=C1)C(F)(F)F)=N/OCCN	PLASMA	O4L1XPO44W									∞	μg × h/L	264		μg/L	18			UNKNOWN	mg	50		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	REVIEW	https://link.springer.com/article/10.2165/00003088-199427030-00002	Homo sapiens				instant-release tablet			12	Fluvoxamine		false
2485	1315		ADULT	5324346	318.3346	FLUVOXAMINE	Fluvoxamine	COCCCC\\C(C1=CC=C(C=C1)C(F)(F)F)=N/OCCN	PLASMA	O4L1XPO44W									∞	μg × min/L	652		μg/L	30			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	REVIEW	https://link.springer.com/article/10.2165/00003088-199427030-00002	Homo sapiens		h	19	enteric-coated			6	Fluvoxamine		false
2486	1315		ADULT	5324346	318.3346	FLUVOXAMINE	Fluvoxamine	COCCCC\\C(C1=CC=C(C=C1)C(F)(F)F)=N/OCCN	PLASMA	O4L1XPO44W									∞	μg × h/L	279		μg/L	17			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	REVIEW	https://link.springer.com/article/10.2165/00003088-199427030-00002	Homo sapiens				instant-release tablet			12	Fluvoxamine		false
2487	1315		ADULT	5324346	318.3346	FLUVOXAMINE	Fluvoxamine	COCCCC\\C(C1=CC=C(C=C1)C(F)(F)F)=N/OCCN	PLASMA	O4L1XPO44W									∞	μg × h/L	860		μg/L	36			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	REVIEW	https://link.springer.com/article/10.2165/00003088-199427030-00002	Homo sapiens		h	16	oral solution			11	Fluvoxamine		false
2488	1315		ADULT	5324346	318.3346	FLUVOXAMINE	Fluvoxamine	COCCCC\\C(C1=CC=C(C=C1)C(F)(F)F)=N/OCCN	PLASMA	O4L1XPO44W									∞	μg × h/L	495		μg/L	25			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	REVIEW	https://link.springer.com/article/10.2165/00003088-199427030-00002	Homo sapiens		h	15	enteric-coated			8	Fluvoxamine		false
2489	1315		ADULT	5324346	318.3346	FLUVOXAMINE	Fluvoxamine	COCCCC\\C(C1=CC=C(C=C1)C(F)(F)F)=N/OCCN	PLASMA	O4L1XPO44W									∞	μg × h/L	315		μg/L	18			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	MALE	REVIEW	https://link.springer.com/article/10.2165/00003088-199427030-00002	Homo sapiens		h	13	capsules			12	Fluvoxamine		false
2490	1315		ADULT	5324346	318.3346	FLUVOXAMINE	Fluvoxamine	COCCCC\\C(C1=CC=C(C=C1)C(F)(F)F)=N/OCCN	PLASMA	O4L1XPO44W									∞	μg × h/L	195		μg/L	15			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	MALE	REVIEW	https://link.springer.com/article/10.2165/00003088-199427030-00002	Homo sapiens				film-coated tablet			12	Fluvoxamine		false
2491	1315		ADULT	5324346	318.3346	FLUVOXAMINE	Fluvoxamine	COCCCC\\C(C1=CC=C(C=C1)C(F)(F)F)=N/OCCN	PLASMA	O4L1XPO44W									∞	μg × h/L	1338		μg/L	39			UNKNOWN	mg	100		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	REVIEW	https://link.springer.com/article/10.2165/00003088-199427030-00002	Homo sapiens		h	25	enteric-coated	patients with hepatic cirrhosis		13	Fluvoxamine		false
2492	1316		ADULT	104741	606.8	FULVESTRANT	FULVESTRANT	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S+]([O-])CCCC(F)(F)C(F)(F)F)CC4=CC(O)=CC=C34	PLASMA	22X328QOC4|L8HA5DT6RS									?	ng × h/mL	11400		ng/mL	25.1			RECOMMENDED	mg	500		SINGLE	UNKNOWN						UNHEALTHY	Intramuscular	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021344Orig1s039lbl.pdf	Homo sapiens										false
2493	1316		ADULT	104741	606.8	FULVESTRANT	FULVESTRANT	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S+]([O-])CCCC(F)(F)C(F)(F)F)CC4=CC(O)=CC=C34	PLASMA	22X328QOC4|L8HA5DT6RS																	UNKNOWN	mg	250		SINGLE	UNKNOWN						UNHEALTHY	Intramuscular	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021344Orig1s039lbl.pdf	Homo sapiens		day	40							false
2494	1317		ADULT	3440|118985385	330.744	FUROSEMIDE	FUROSEMIDE	NS(=O)(=O)C1=CC(C(O)=O)=C(NCC2=CC=CO2)C=C1Cl	PLASMA	7LXU5N7ZO5									∞	ng × h/mL	3014.77		ng/mL	1315.34			RECOMMENDED	mg	40		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12854359	Homo sapiens		h	3.1							false
2495	1317		ADULT	3440|118985385	330.744	FUROSEMIDE	FUROSEMIDE	NS(=O)(=O)C1=CC(C(O)=O)=C(NCC2=CC=CO2)C=C1Cl	PLASMA	7LXU5N7ZO5																						UNKNOWN				Furosemide is extensively bound to plasma proteins, mainly to albumin. Plasma concentrations ranging from 1 to 400 ug/mL are 91 to 99% bound in healthy individuals. The unbound fraction averages 2.3 to 4.1% at therapeutic concentrations.	3.2	HEALTHY		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/016273s061lbl.pdf	Homo sapiens										false
2496	1318		ADULT	123631	446.902	GEFITINIB	GEFITINIB	COC1=C(OCCCN2CCOCC2)C=C3C(NC4=CC(Cl)=C(F)C=C4)=NC=NC3=C1	PLASMA	S65743JHBS									∞	ng × h/mL	1415		ng/mL	57.5			RECOMMENDED	mg	250		SINGLE	UNKNOWN		day	1	gefitinib is approximately 91% bound to plasma proteins in human plasma	9	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21487718	Homo sapiens		h	21.2				10			false
2497	1318		ADULT	123631	446.902	GEFITINIB	gefitinib	COC1=C(OCCCN2CCOCC2)C=C3C(NC4=CC(Cl)=C(F)C=C4)=NC=NC3=C1	PLASMA	S65743JHBS							24		t	ng × h/mL	8896		ng/mL	466			RECOMMENDED	mg	250		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21487718	Homo sapiens							14			false
2498	1318		ADULT	123631	446.902	GEFITINIB	GEFITINIB	COC1=C(OCCCN2CCOCC2)C=C3C(NC4=CC(Cl)=C(F)C=C4)=NC=NC3=C1	PLASMA	S65743JHBS							24		t	ng × h/mL	13103		ng/mL	724			RECOMMENDED	mg	250		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28579188	Homo sapiens		h	25				24			false
2499	1318		UNKNOWN	123631	446.902	GEFITINIB	GEFITINIB	COC1=C(OCCCN2CCOCC2)C=C3C(NC4=CC(Cl)=C(F)C=C4)=NC=NC3=C1	PLASMA	S65743JHBS																						UNKNOWN				In vitro binding of gefitinib to human plasma proteins (serum albumin and α1-acid glycoprotein) is 90% and is independent of drug concentrations.	10	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021399lbl.pdf	Homo sapiens										false
2500	1318		ADULT	123631	446.902	GEFITINIB	GEFITINIB	COC1=C(OCCCN2CCOCC2)C=C3C(NC4=CC(Cl)=C(F)C=C4)=NC=NC3=C1	PLASMA	S65743JHBS							24		t	ng × h/mL	10026		ng/mL	579			UNKNOWN	mg	400		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-399_IRESSA_Clinr.pdf	Homo sapiens		h	38.1							false
2501	1318		ADULT	123631	446.902	GEFITINIB	GEFITINIB	COC1=C(OCCCN2CCOCC2)C=C3C(NC4=CC(Cl)=C(F)C=C4)=NC=NC3=C1	PLASMA	S65743JHBS							24		t	ng × h/mL	42314		ng/mL	2160			UNKNOWN	mg	700		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-399_IRESSA_Clinr.pdf	Homo sapiens		h	72.9							false
2502	1318		ADULT	123631	446.902	GEFITINIB	GEFITINIB	COC1=C(OCCCN2CCOCC2)C=C3C(NC4=CC(Cl)=C(F)C=C4)=NC=NC3=C1	PLASMA	S65743JHBS							24		t	ng × h/mL	2985		ng/mL	178			UNKNOWN	mg	100		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-399_IRESSA_Clinr.pdf	Homo sapiens		h	55.2							false
2503	1318		ADULT	123631	446.902	GEFITINIB	GEFITINIB	COC1=C(OCCCN2CCOCC2)C=C3C(NC4=CC(Cl)=C(F)C=C4)=NC=NC3=C1	PLASMA	S65743JHBS									?	ng × h/mL	6181		ng/mL	213			UNKNOWN	mg	500		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-399_IRESSA_Clinr.pdf	Homo sapiens		h	28.2							false
2504	1318		ADULT	123631	446.1521	GEFITINIB	GEFITINIB	COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN4CCOCC4	PLASMA	S65743JHBS									∞	ng × h/mL	1415		ng/mL	57.45			UNKNOWN	mg	250		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206995orig1s000clinpharmr.pdf	Homo sapiens		h	23.83							false
2505	1318		CHILD	123631	446.1521	GEFITINIB	GEFITINIB	COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1OCCCN4CCOCC4	PLASMA	S65743JHBS							24		t	μg × h/mL	29.3		ng/mL	2210			MAX TOLERATED	mg/m²	400		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206995orig1s000clinpharmr.pdf	Homo sapiens		h	11.9							false
2506	1319		ADULT	60750	263.1981	GEMCITABINE	GEMCITABINE	NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	BLOOD	B76N6SBZ8R							24		t	nM × h	3526.4		nM	229			UNKNOWN	mg/m²	75		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/19556122	Homo sapiens										false
2507	1319		ADULT	60750	263.1981	GEMCITABINE	GEMCITABINE	NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	BLOOD	B76N6SBZ8R							24		t	nM × h	4818.5		nM	263.6			UNKNOWN	mg/m²	135		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/19556122	Homo sapiens										false
2508	1319		ADULT	60750	263.1981	GEMCITABINE	GEMCITABINE	NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	BLOOD	B76N6SBZ8R							24		t	nM × h	4863.4		nM	292.5			UNKNOWN	mg/m²	180		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/19556122	Homo sapiens										false
2509	1320			3463	250.3334	GEMFIBROZIL	GEMFIBROZIL	CC1=CC(OCCCC(C)(C)C(O)=O)=C(C)C=C1	PLASMA	Q8X02027X3													ng/mL	17400				mg	600		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01736254	Homo sapiens										false
2510	1320		ADULT	3463	250.3334	GEMFIBROZIL	Gemfibrozil	CC1=CC(OCCCC(C)(C)C(O)=O)=C(C)C=C1	PLASMA	Q8X02027X3									∞	μg × h/mL	104		μg/mL	28			UNKNOWN	mg	600		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/19648824	Homo sapiens		h	4.4							false
2511	1321		ADULT	3476	490.616	GLIMEPIRIDE	GLIMEPIRIDE	CCC1=C(C)CN(C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)C1=O	PLASMA	6KY687524K													ng/mL	551			MAX DAILY	mg	8		SINGLE	UNKNOWN				Protein binding was greater than 99.5%.	0.5	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020496s015lbl.pdf	Homo sapiens		h	5.3							false
2512	1321		ADULT	3476	490.616	GLIMEPIRIDE	GLIMEPIRIDE	CCC1=C(C)CN(C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)C1=O	PLASMA	6KY687524K									∞	μg × h/L	646.98		μg/L	74.05			RECOMMENDED	mg	2		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/20685507	Homo sapiens		h	4.08							false
2513	1322		UNKNOWN	3478	445.535	GLIPIZIDE	GLIPIZIDE	CC1=NC=C(N=C1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3	PLASMA	X7WDT95N5C																						UNKNOWN				Glipizide is 98 to 99% bound to serum proteins, primarily to albumin.	1.5	UNKNOWN		UNKNOWN	DRUG LABEL	https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/1af56e54-3db7-4b15-bf65-dfaf0eacb515/spl-doc?hl=glipizide	Homo sapiens										false
2514	1322		ADULT	3478	445.535	GLIPIZIDE	GLIPIZIDE	CC1=NC=C(N=C1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3	PLASMA	X7WDT95N5C									∞	ng × h/mL	1878		ng/mL	465			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ajol.info/index.php/tjpr/article/viewFile/66555/54281	Homo sapiens		h	3							false
2515	1322		ADULT	3478	445.535	GLIPIZIDE	GLIPIZIDE	CC1=NC=C(N=C1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3	PLASMA	X7WDT95N5C							24		t	ng × h/mL	1897		ng/mL	523			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/16509763	Homo sapiens		h	1.65							false
2516	1323		ADULT	5961|6992086	146.1445	GLUTAMINE	GLUTAMINE	N[C@@H](CCC(N)=O)C(O)=O	PLASMA	0RH81L854J									∞	μg × h/mL	31.83		μg/mL	22.67			UNKNOWN	g	2		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24771050	Homo sapiens		h	1.5							false
2517	1323		ADULT	5961|6992086	146.1445	GLUTAMINE	GLUTAMINE	N[C@@H](CCC(N)=O)C(O)=O	PLASMA	0RH81L854J									∞	μg × h/mL	57.13		μg/mL	35.34			UNKNOWN	g	4		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24771050	Homo sapiens		h	1.77							false
2518	1324		ADULT	3488	494.004	GLYBURIDE	GLYBURIDE	COC1=C(C=C(Cl)C=C1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3	PLASMA	SX6K58TVWC									∞	ng × h/mL	323.9		ng/mL	91.1			RECOMMENDED	mg	1.75		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11406737/	Homo sapiens		h	2							false
2519	1325		ADULT	5311128	1269.4105	GOSERELIN	GOSERELIN	CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC4=CN=CN4)NC(=O)[C@@H]5CCC(=O)N5)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N6CCC[C@H]6C(=O)NNC(N)=O	PLASMA	0F65R8P09N									?	μg × h/L	44.5		μg/L	7.5			UNKNOWN	μg	250		SINGLE	UNKNOWN						UNHEALTHY	Subcutaneous	MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/10926349	Homo sapiens		h	4.6							false
2520	1325		ADULT	5311128	1269.4105	GOSERELIN	GOSERELIN	CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC4=CN=CN4)NC(=O)[C@@H]5CCC(=O)N5)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N6CCC[C@H]6C(=O)NNC(N)=O	PLASMA	0F65R8P09N									?	μg × h/L	44		μg/L	9.5			UNKNOWN	μg	250		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Subcutaneous	MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/10926349	Homo sapiens		h	5							false
2521	1325		ADULT	5311128	1269.4105	GOSERELIN	GOSERELIN	CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC4=CN=CN4)NC(=O)[C@@H]5CCC(=O)N5)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N6CCC[C@H]6C(=O)NNC(N)=O	SERUM	0F65R8P09N									?	μg × h/L	41.3		μg/L	13.9			UNKNOWN	μg	250		SINGLE	UNKNOWN						HEALTHY	Subcutaneous	FEMALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/10926349	Homo sapiens		h	2.3							false
2522	1325		ADULT	5311128	1269.4105	GOSERELIN	GOSERELIN	CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC4=CN=CN4)NC(=O)[C@@H]5CCC(=O)N5)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N6CCC[C@H]6C(=O)NNC(N)=O	SERUM	0F65R8P09N									?	μg × h/L	36.9		μg/L	7.79			UNKNOWN	μg	250		SINGLE	UNKNOWN						HEALTHY	Subcutaneous	MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/10926349	Homo sapiens		h	4.2							false
2523	1325		ADULT	5311128	1269.4105	GOSERELIN	GOSERELIN	CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC4=CN=CN4)NC(=O)[C@@H]5CCC(=O)N5)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N6CCC[C@H]6C(=O)NNC(N)=O	PLASMA	0F65R8P09N							672		t	ng × day/mL	27.8		ng/mL	2.84			RECOMMENDED	mg	3.6		SINGLE	UNKNOWN						UNHEALTHY	Subcutaneous	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019726s050s051s052lbl.pdf	Homo sapiens										false
2524	1325		ADULT	5311128	1269.4105	GOSERELIN	GOSERELIN	CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC4=CN=CN4)NC(=O)[C@@H]5CCC(=O)N5)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N6CCC[C@H]6C(=O)NNC(N)=O	PLASMA	0F65R8P09N							672		t	ng × day/mL	18.5		ng/mL	1.46			RECOMMENDED	mg	3.6		SINGLE	UNKNOWN						UNHEALTHY	Subcutaneous	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019726s050s051s052lbl.pdf	Homo sapiens										false
2525	1325		ADULT	5311128	1269.4105	GOSERELIN	GOSERELIN	CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC4=CN=CN4)NC(=O)[C@@H]5CCC(=O)N5)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N6CCC[C@H]6C(=O)NNC(N)=O	PLASMA	0F65R8P09N													ng/mL	8.85			RECOMMENDED	mg	10.8		SINGLE	UNKNOWN				The plasma protein binding of goserelin was found to be 27%	73	UNHEALTHY	Subcutaneous	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/019726s059,020578s037lbl.pdf	Homo sapiens										false
2526	1325		ADULT	5311128	1269.4105	GOSERELIN	GOSERELIN	CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC4=CN=CN4)NC(=O)[C@@H]5CCC(=O)N5)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N6CCC[C@H]6C(=O)NNC(N)=O	PLASMA	0F65R8P09N													ng/mL	3			RECOMMENDED	mg	3.6		SINGLE	UNKNOWN						UNHEALTHY	Subcutaneous	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/019726s059,020578s037lbl.pdf	Homo sapiens										false
2527	1326		ADULT	38521	213.2768	GUANADREL	GUANADREL	NC(=N)NCC1COC2(CCCCC2)O1	PLASMA	765C9332T4									∞	ng × h/mL	234		ng/mL	42			UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2715368	Homo sapiens		h	3.69							false
2528	1326		ADULT	38521	213.2768	GUANADREL	GUANADREL	NC(=N)NCC1COC2(CCCCC2)O1	PLASMA	765C9332T4									∞	ng × h/mL	627		ng/mL	73			UNKNOWN	mg	25		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2715368	Homo sapiens		h	6.8							false
2529	1326		ADULT	38521	213.2768	GUANADREL	GUANADREL	NC(=N)NCC1COC2(CCCCC2)O1	PLASMA	765C9332T4							8		t	μg × h/mL	404.9		ng/mL	89.6			UNKNOWN	mg	50		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3243808	Homo sapiens							6			false
2530	1327		ADULT	16130971|16133818|25077993	1323.5024	HISTRELIN	histrelin	CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CN(CC3=CC=CC=C3)C=N2)NC(=O)[C@H](CC4=CC=C(O)C=C4)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CNC6=C5C=CC=C6)NC(=O)[C@H](CC7=CNC=N7)NC(=O)[C@@H]8CCC(=O)N8	SERUM	H50H3S3W74							96		t	ng × week/mL	0.398		ng/mL	1.1			RECOMMENDED	μg	50		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Subcutaneous implant	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16239357/	Homo sapiens		h	4							false
2531	1327		ADULT	16130971|16133818|25077993	1323.5024	HISTRELIN	histrelin	CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CN(CC3=CC=CC=C3)C=N2)NC(=O)[C@H](CC4=CC=C(O)C=C4)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CNC6=C5C=CC=C6)NC(=O)[C@H](CC7=CNC=N7)NC(=O)[C@@H]8CCC(=O)N8	SERUM	H50H3S3W74																	UNKNOWN	μg	500		SINGLE	UNKNOWN				The fraction of drug unbound in plasma measured in vitro was 29.5% ± 8.9% (mean ± SD).	29.5	HEALTHY	Subcutaneous	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021732s022lbl.pdf	Homo sapiens		h	3.92							false
2532	1328		UNKNOWN	3637|5538708|5538709	160.1759	HYDRALAZINE	HYDRALAZINE	NNC1=NN=CC2=C1C=CC=C2	PLASMA	26NAK24LS8																						UNKNOWN				Binding to human plasma protein is 87%	13	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/1996/008303s068lbl.pdf	Homo sapiens										false
2533	1328		ADULT	3637|5538708|5538709	160.0749	HYDRALAZINE	HYDRALAZINE	NNC1=NN=CC2=C1C=CC=C2	PLASMA	26NAK24LS8	3637|5538708|5538709		HYDRALAZINE	HYDRALAZINE	NNC1=NN=CC2=C1C=CC=C2	26NAK24LS8	4		t	μM × h	407		μM	3			UNKNOWN	mg	50		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/6653641	Homo sapiens		h	2							true
2534	1329		ADULT	3647	331.292	HYDROFLUMETHIAZIDE	hydroflumethiazide	NS(=O)(=O)C1=C(C=C2NCNS(=O)(=O)C2=C1)C(F)(F)F	PLASMA	501CFL162R									∞	μM × h	9.83						INVESTIGATIONAL	mg	25		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/729604/	Homo sapiens		h	16.6							false
2535	1329		ADULT	3647	331.292	HYDROFLUMETHIAZIDE	hydroflumethiazide	NS(=O)(=O)C1=C(C=C2NCNS(=O)(=O)C2=C1)C(F)(F)F	PLASMA	501CFL162R									∞	μM × h	13.12						INVESTIGATIONAL	mg	25		SINGLE	FASTED						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/729604/	Homo sapiens		h	9.6							false
2536	1329		ADULT	3647	331.292	HYDROFLUMETHIAZIDE	hydroflumethiazide	NS(=O)(=O)C1=C(C=C2NCNS(=O)(=O)C2=C1)C(F)(F)F	PLASMA	501CFL162R									?	μg × h/mL	1.717		μg/mL	0.389			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/833338/	Homo sapiens		h	2							false
2537	1330		ADULT	60753	384.576	IBUTILIDE	IBUTILIDE	CCCCCCCN(CC)CCCC(O)C1=CC=C(NS(C)(=O)=O)C=C1	PLASMA	2436VX1U9B							24		t	μg × min/L	177						DEFINED DAILY	mg	1		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/18035195	Homo sapiens		h	9.1							false
2538	1330		ADULT	60753	384.576	IBUTILIDE	IBUTILIDE	CCCCCCCN(CC)CCCC(O)C1=CC=C(NS(C)(=O)=O)C=C1	SERUM	2436VX1U9B									∞	μg × h/L	13.2		μg/L	5.8			DEFINED DAILY	mg	1		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/19025427	Homo sapiens		h	12.4							false
2539	1331		ADULT		426.5	Iloperidone			PLASMA										∞	ng × h/mL	29.4		ng/mL	2.79			UNKNOWN	mg	3		SINGLE	UNKNOWN				At therapeutic concentrations, iloperidone and its metabolites are approximately 95% bound to serum proteins	5	UNKNOWN	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21034370/	Homo sapiens		h	17.6							false
2540	1331		ADULT		426.5	Iloperidone			PLASMA																		UNKNOWN	mg	3		SINGLE	UNKNOWN				At therapeutic concentrations, the unbound fraction of iloperidone in plasma is ~3%	3	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022192s018s021lbl.pdf	Homo sapiens		h	18							false
2541	1332		ADULT	57469	240.3036	IMIQUIMOD	CC(C)CN1C=NC2=C(N)N=C3C=CC=CC3=C12	CC(C)CN1C=NC2=C(N)N=C3C=CC=CC3=C12	PLASMA	P1QW714R7M													ng/mL	0.1			RECOMMENDED	mg	12.5		STEADY-STATE	UNKNOWN		week	3			UNHEALTHY	Topical	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020723s022lbl.pdf	Homo sapiens										false
2542	1332		ADULT	57469	240.3036	IMIQUIMOD	CC(C)CN1C=NC2=C(N)N=C3C=CC=CC3=C12	CC(C)CN1C=NC2=C(N)N=C3C=CC=CC3=C12	PLASMA	P1QW714R7M									?	ng × h/mL	573		ng/mL	120			INVESTIGATIONAL	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	REVIEW	https://www.ema.europa.eu/en/documents/scientific-discussion/aldara-epar-scientific-discussion_en.pdf	Homo sapiens		h	2.7							false
2543	1333		NEWBORN	3698|5281003	187.198	INAMRINONE	INAMRINONE	NC1=CC(=CNC1=O)C2=CC=NC=C2	PLASMA	JUT23379TN							24		t	μg × h/mL	245		μg/mL	5.2			UNKNOWN	mg/kg	0.75		STEADY-STATE	UNKNOWN		day	3			UNKNOWN	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8513658/	Homo sapiens		h	5.4							false
2544	1335		ADULT	6883	236.1363	ISOSORBIDE DINITRATE	ISOSORBIDE DINITRATE	[O-][N+](=O)O[C@@H]1CO[C@@H]2[C@H](CO[C@H]12)O[N+]([O-])=O	PLASMA	IA7306519N									∞	ng × h/mL	1458		ng/mL	187			RECOMMENDED	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24851040	Homo sapiens		min	303							false
2545	1335		UNKNOWN	6883	236.1363	ISOSORBIDE DINITRATE	ISOSORBIDE DINITRATE	[O-][N+](=O)O[C@@H]1CO[C@@H]2[C@H](CO[C@H]12)O[N+]([O-])=O	PLASMA	IA7306519N																						UNKNOWN				Plasma protein binding - 0%	100	UNKNOWN		UNKNOWN	EXPERIMENT	https://www.sciencedirect.com/science/article/pii/B9780128012383967114	Homo sapiens										false
2546	1336		ADULT	27661	191.1388	ISOSORBIDE MONONITRATE	ISOSORBIDE MONONITRATE	O[C@H]1CO[C@@H]2[C@@H](CO[C@H]12)O[N+]([O-])=O	PLASMA	LX1OH63030									∞	ng × h/mL	2647		ng/mL	356			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6713775/	Homo sapiens		h	4							false
2547	1336		ADULT	27661	191.1388	ISOSORBIDE MONONITRATE	ISOSORBIDE MONONITRATE	O[C@H]1CO[C@@H]2[C@@H](CO[C@H]12)O[N+]([O-])=O	PLASMA	LX1OH63030									∞	ng × h/mL	2524		ng/mL	388			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6713775/	Homo sapiens		h	4							false
2548	1336		ADULT	27661	191.1388	ISOSORBIDE MONONITRATE	ISOSORBIDE MONONITRATE	O[C@H]1CO[C@@H]2[C@@H](CO[C@H]12)O[N+]([O-])=O	PLASMA	LX1OH63030							24		t	ng × h/mL	6979		ng/mL	557			UNKNOWN	mg	60		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7614524/	Homo sapiens		h	6.2							false
2549	1336		ADULT	27661	191.1388	ISOSORBIDE MONONITRATE	ISOSORBIDE MONONITRATE	O[C@H]1CO[C@@H]2[C@@H](CO[C@H]12)O[N+]([O-])=O	PLASMA	LX1OH63030							24		t	ng × h/mL	14241		ng/mL	1151			UNKNOWN	mg	120		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7614524/	Homo sapiens		h	6.2							false
2550	1337		ADULT	3784	371.3871	ISRADIPINE	ISRADIPINE	COC(=O)C1=C(C)NC(C)=C(C1C2=CC=CC3=NON=C23)C(=O)OC(C)C	PLASMA	YO1UK1S598									?	ng × h/mL	7.31		ng/mL	5.89			UNKNOWN	mg	2.5		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2965165/	Homo sapiens		h	2.93							false
2551	1337		ADULT	3784	371.3871	ISRADIPINE	ISRADIPINE	COC(=O)C1=C(C)NC(C)=C(C1C2=CC=CC3=NON=C23)C(=O)OC(C)C	PLASMA	YO1UK1S598									?	ng × h/mL	14.52		ng/mL	11.44			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2965165/	Homo sapiens		h	2.85							false
2552	1337		ADULT	3784	371.3871	ISRADIPINE	ISRADIPINE	COC(=O)C1=C(C)NC(C)=C(C1C2=CC=CC3=NON=C23)C(=O)OC(C)C	PLASMA	YO1UK1S598									?	ng × h/mL	31.01		ng/mL	29.84			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2965165/	Homo sapiens		h	2.68							false
2553	1338		ADULT	6917738	705.633	ITRACONAZOLE	ITRACONAZOLE	CCC(C)N1N=CN(C1=O)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(OC[C@@H]5CO[C@](CN6C=NC=N6)(O5)C7=C(Cl)C=C(Cl)C=C7)C=C4	PLASMA	304NUG5GF4									∞	μg × h/mL	2.27		ng/mL	162			DEFINED DAILY	mg	200		SINGLE	FASTED					0.2	HEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022484s000lbl.pdf	Homo sapiens										false
2554	1338		ADULT	91668165	721.633	HYDROXYITRACONAZOLE	HYDROXYITRACONAZOLE	CC(O)C(C)N1N=CN(C1=O)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(OC[C@@H]5CO[C@](CN6C=NC=N6)(O5)C7=C(Cl)C=C(Cl)C=C7)C=C4	PLASMA										∞	μg × h/mL	7.05		ng/mL	332			DEFINED DAILY	mg	200		SINGLE	HIGH-FAT					0.5	HEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022484s000lbl.pdf	Homo sapiens										false
2555	1338		ADULT	91668165	721.633	HYDROXYITRACONAZOLE	hydroxyITRACONAZOLE	CC(O)C(C)N1N=CN(C1=O)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(OC[C@@H]5CO[C@](CN6C=NC=N6)(O5)C7=C(Cl)C=C(Cl)C=C7)C=C4	PLASMA										∞	μg × h/mL	4.58		ng/mL	264			DEFINED DAILY	mg	200		SINGLE	FASTED					0.5	HEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022484s000lbl.pdf	Homo sapiens										false
2556	1338		ADULT	91668165	721.633	HYDROXYITRACONAZOLE	hydroxyITRACONAZOLE	CC(O)C(C)N1N=CN(C1=O)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(OC[C@@H]5CO[C@](CN6C=NC=N6)(O5)C7=C(Cl)C=C(Cl)C=C7)C=C4	PLASMA								24		t	ng × h/mL	2538.33		ng/mL	221.7			DEFINED DAILY	mg	200		SINGLE	FED					0.5	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022484s000lbl.pdf	Homo sapiens					moderate fat breakfast					false
2557	1338		ADULT	91668165	721.633	HYDROXYITRACONAZOLE	hydroxyITRACONAZOLE	CC(O)C(C)N1N=CN(C1=O)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(OC[C@@H]5CO[C@](CN6C=NC=N6)(O5)C7=C(Cl)C=C(Cl)C=C7)C=C4	PLASMA								24		t	ng × h/mL	19054.95		ng/mL	974.2			RECOMMENDED	mg	200		STEADY-STATE	FED		day	1		0.5	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022484s000lbl.pdf	Homo sapiens		h	20.06		moderate fat breakfast					false
2558	1338		ADULT	6917738	705.633	ITRACONAZOLE	ITRACONAZOLE	CCC(C)N1N=CN(C1=O)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(OC[C@@H]5CO[C@](CN6C=NC=N6)(O5)C7=C(Cl)C=C(Cl)C=C7)C=C4	PLASMA	304NUG5GF4							24		t	ng × h/mL	905.09		ng/mL	116.8			DEFINED DAILY	mg	200		SINGLE	FED					0.2	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022484s000lbl.pdf	Homo sapiens					moderate fat breakfast					false
2559	1338		ADULT	6917738	705.633	ITRACONAZOLE	ITRACONAZOLE	CCC(C)N1N=CN(C1=O)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(OC[C@@H]5CO[C@](CN6C=NC=N6)(O5)C7=C(Cl)C=C(Cl)C=C7)C=C4	PLASMA	304NUG5GF4							24		t	ng × h/mL	9046.81		ng/mL	658.1			RECOMMENDED	mg	200		STEADY-STATE	FED		day	1		0.2	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022484s000lbl.pdf	Homo sapiens		h	36.84		moderate fat breakfast					false
2560	1338		ADULT	6917738	705.633	ITRACONAZOLE	ITRACONAZOLE	CCC(C)N1N=CN(C1=O)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(OC[C@@H]5CO[C@](CN6C=NC=N6)(O5)C7=C(Cl)C=C(Cl)C=C7)C=C4	PLASMA	304NUG5GF4									∞	ng × h/mL	3.34		ng/mL	213			DEFINED DAILY	mg	200		SINGLE	HIGH-FAT					0.2	HEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022484s000lbl.pdf	Homo sapiens										false
2561	1339		CHILD	3821	237.725	KETAMINE	KETAMINE	CNC1(CCCCC1=O)C2=C(Cl)C=CC=C2	PLASMA	690G0D6V8H									∞	ng × min/mL	111.2		ng/mL	632			RECOMMENDED	mg	9		SINGLE	UNKNOWN						HEALTHY	Rectal	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8881626/	Homo sapiens		min	100							false
2562	1339		CHILD	3821	237.725	KETAMINE	KETAMINE	CNC1(CCCCC1=O)C2=C(Cl)C=CC=C2	PLASMA	690G0D6V8H									∞	mg × min/L	76.4		ng/mL	496			RECOMMENDED	mg/kg	3		SINGLE	UNKNOWN						HEALTHY	Nasal	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8881626/	Homo sapiens		min	123							false
2563	1339		CHILD	3821	237.725	KETAMINE	KETAMINE	CNC1(CCCCC1=O)C2=C(Cl)C=CC=C2	PLASMA	690G0D6V8H									∞	mg × min/L	163.6		ng/mL	2104			RECOMMENDED	mg/kg	9		SINGLE	UNKNOWN						HEALTHY	Nasal	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8881626/	Homo sapiens		min	120							false
2564	1339		CHILD	3821	237.725	KETAMINE	KETAMINE	CNC1(CCCCC1=O)C2=C(Cl)C=CC=C2	PLASMA	690G0D6V8H									∞	mg × min/L	148.3						RECOMMENDED	mg/kg	3		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8881626/	Homo sapiens		min	125							false
2565	1340		UNKNOWN	3827	309.425	KETOTIFEN	KETOTIFEN	CN1CCC(CC1)=C2C3=C(SC=C3)C(=O)CC4=C2C=CC=C4	PLASMA	X49220T18G																						UNKNOWN				Protein binding: High (75%)	25	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.drugs.com/mmx/ketotifen-fumarate.html	Homo sapiens										false
2566	1340		ADULT	3827	309.1187	KETOTIFEN	KETOTIFEN	CN1CCC(CC1)=C2C3=C(SC=C3)C(=O)CC4=C2C=CC=C4	PLASMA	X49220T18G									∞	pg × h/mL	4703		pg/mL	281			UNKNOWN	mg	2		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/1600111	Homo sapiens		h	13.1							false
2567	1341		ADULT	3869	328.4055	LABETALOL	LABETALOL	CC(CCC1=CC=CC=C1)NCC(O)C2=CC=C(O)C(=C2)C(N)=O	PLASMA	R5H8897N95							12		t	ng × h/mL	571		ng/mL	72.4			RECOMMENDED	mg	100		STEADY-STATE	UNKNOWN		2 days	2			HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16225568/	Homo sapiens										false
2568	1341		UNKNOWN	3869	328.4055	LABETALOL	LABETALOL	CC(CCC1=CC=CC=C1)NCC(O)C2=CC=C(O)C(=C2)C(N)=O	PLASMA	R5H8897N95																	UNKNOWN				UNKNOWN	UNKNOWN			2	Labetalol is approximately 50% protein bound.	50	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018716s026lbl.pdf	Homo sapiens		h	8							false
2569	1342			3878	256.091	LAMOTRIGINE	LAMOTRIGINE	NC1=NN=C(C(N)=N1)C2=CC=CC(Cl)=C2Cl	PLASMA	U3H27498KS													ng/mL	2912.04				mg	200		SINGLE	FASTED							Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00834561	Homo sapiens										false
2570	1342			3878	256.091	LAMOTRIGINE	LAMOTRIGINE	NC1=NN=C(C(N)=N1)C2=CC=CC(Cl)=C2Cl	PLASMA	U3H27498KS									∞	ng × h/mL	139995.13							mg	200		SINGLE	FASTED							Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00834561	Homo sapiens										false
2571	1342			3878	256.091	LAMOTRIGINE	LAMOTRIGINE	NC1=NN=C(C(N)=N1)C2=CC=CC(Cl)=C2Cl	PLASMA	U3H27498KS							120		t	ng × h/mL	120080.26							mg	200		SINGLE	FASTED							Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00834561	Homo sapiens										false
2572	1342			3878	256.091	LAMOTRIGINE	LAMOTRIGINE	NC1=NN=C(C(N)=N1)C2=CC=CC(Cl)=C2Cl	PLASMA	U3H27498KS													ng/mL	2518				mg	200		SINGLE	FED							Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00835263	Homo sapiens										false
2573	1342			3878	256.091	LAMOTRIGINE	LAMOTRIGINE	NC1=NN=C(C(N)=N1)C2=CC=CC(Cl)=C2Cl	PLASMA	U3H27498KS									∞	ng × h/mL	131594.33							mg	200		SINGLE	FED							Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00835263	Homo sapiens										false
2574	1342			3878	256.091	LAMOTRIGINE	LAMOTRIGINE	NC1=NN=C(C(N)=N1)C2=CC=CC(Cl)=C2Cl	PLASMA	U3H27498KS							120		t	ng × h/mL	113029.41							mg	200		SINGLE	FED							Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00835263	Homo sapiens										false
2575	1342		UNKNOWN	3878	256.091	LAMOTRIGINE	LAMOTRIGINE	NC1=NN=C(C(N)=N1)C2=CC=CC(Cl)=C2Cl	PLASMA	U3H27498KS																						UNKNOWN				Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mcg/mL	45	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022251,020764s029,020241s036lbl.pdf	Homo sapiens										false
2576	1342		ADULT	3878	256.091	LAMOTRIGINE	LAMOTRIGINE	NC1=NN=C(C(N)=N1)C2=CC=CC(Cl)=C2Cl	PLASMA	U3H27498KS									∞	ng × h/mL	73723		ng/mL	4900			UNKNOWN	mg	150		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/20047572	Homo sapiens		h	22.6							false
2577	1344		ADULT	3883	369.4	LANSOPRAZOLE	LANSOPRAZOLE	CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C2=NC3=C(N2)C=CC=C3	PLASMA	0K5C5T2QPG									∞	ng × h/mL	3192		ng/mL	1705			MAX DAILY	mg	30		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021566s005lbl.pdf	Homo sapiens		h	1.3							false
2578	1345		ADULT	5311221	432.5928	LATANOPROST	Latanoprost	CC(C)OC(=O)CCC\\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC2=CC=CC=C2	PLASMA	6Z5B6HVF6O									∞	ng × eq × h/mL	0.165		ng × eq/mL	0.0636			UNKNOWN	μg	2.3		SINGLE	UNKNOWN						HEALTHY	Ocular	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/4/671450_1319817Q1020_4_1F.pdf#page=40	Homo sapiens		h	1.842		Mean age 65 y		4			false
2579	1345		ADULT	6441636	390.5131	LATANOPROST ACID	Latanoprost acid	O[C@H](CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\\C=C/CCCC(O)=O)CCC2=CC=CC=C2	PLASMA	EJ85341990									∞	ng × eq × h/mL	0.0337		ng × eq/mL	0.053			UNKNOWN	μg	2.3		SINGLE	UNKNOWN						HEALTHY	Ocular	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/4/671450_1319817Q1020_4_1F.pdf#page=40	Homo sapiens		min	17		Mean age 65 y		3			false
2580	1345		ADULT	5311221	432.5928	LATANOPROST	Latanoprost	CC(C)OC(=O)CCC\\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC2=CC=CC=C2	PLASMA	6Z5B6HVF6O									∞	ng × eq × h/mL	20.2		ng × eq/mL	12.43			UNKNOWN	μg	216.1		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/4/671450_1319817Q1020_4_1F.pdf#page=40	Homo sapiens		h	1.471		Mean age 65 y		4			false
2581	1345		ADULT	6441636	390.5131	LATANOPROST ACID	Latanoprost acid	O[C@H](CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\\C=C/CCCC(O)=O)CCC2=CC=CC=C2	PLASMA	EJ85341990									∞	ng × eq × h/mL	7.15		ng × eq/mL	11.6			UNKNOWN	μg	216.1		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/4/671450_1319817Q1020_4_1F.pdf#page=40	Homo sapiens		min	16.6		Mean age 65 y		4			false
2582	1345			5311221	432.5928	LATANOPROST	Latanoprost	CC(C)OC(=O)CCC\\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC2=CC=CC=C2	PLASMA	6Z5B6HVF6O																										Human plasma protein binding: 53~87% (0.001~1μg/mL), ultrafiltration	47				EXPERIMENT	https://www.info.pmda.go.jp/go/interview/4/671450_1319817Q1020_4_1F.pdf#page=42	Homo sapiens										false
2583	1345		ADULT	6441636	390.5131	LATANOPROST ACID	Latanoprost acid	O[C@H](CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\\C=C/CCCC(O)=O)CCC2=CC=CC=C2	AQUEOUS HUMOR	EJ85341990	5281056|139196155	432.492	TIMOLOL MALEATE	Timolol maleate	OC(=O)\\C=C/C(O)=O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N2CCOCC2	P8Y54F701R			∞	ng × h/mL	206		ng/mL	30.4			UNKNOWN	μg	1.5		SINGLE	UNKNOWN						UNHEALTHY	Ocular	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2010/P201000002/40007900_22200AMX00232_A100_1.pdf#page=12 | https://www.pmda.go.jp/drugs/2010/P201000002/40007900_22200AMX00232000_K102_1.pdf#page=29	Homo sapiens		h	2.3	0.005% Latanoprost x 30 μL	Cataract patients undergoing surgery					true
2584	1345		ADULT	6441636	390.5131	LATANOPROST ACID	Latanoprost acid	O[C@H](CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\\C=C/CCCC(O)=O)CCC2=CC=CC=C2	PLASMA	EJ85341990							0.5		t	pg × h/mL	6.15		pg/mL	19.77			DEFINED DAILY	drop	2		MULTIPLE	UNKNOWN		day	1	n=9 for AUC, n=4 for t1/2		HEALTHY	Ocular	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2016/P20160921002/180078000_22800AMX00683_A100_1.pdf#page=11 | https://www.pmda.go.jp/drugs/2016/P20160921002/180078000_22800AMX00683_K100_1.pdf#page=130	Homo sapiens		h	0.3	Day 1, 1 drop/eye			10	Mikeluna combination ophthalmic solution (0.005% Latanoiprost, 2% Carteolol hydrochloride)		false
2585	1345		ADULT	6441636	390.5131	LATANOPROST ACID	Latanoprost acid	O[C@H](CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\\C=C/CCCC(O)=O)CCC2=CC=CC=C2	PLASMA	EJ85341990							0.5		t	pg × h/mL	4.97		pg/mL	18.47			DEFINED DAILY	drop	2		MULTIPLE	UNKNOWN		day	1	n=9 for AUC, n=2 for t1/2		HEALTHY	Ocular	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2016/P20160921002/180078000_22800AMX00683_A100_1.pdf#page=11 | https://www.pmda.go.jp/drugs/2016/P20160921002/180078000_22800AMX00683_K100_1.pdf#page=130	Homo sapiens		h	0.2	Day 7, 1 drop/eye			10	Mikeluna combination ophthalmic solution (0.005% Latanoiprost, 2% Carteolol hydrochloride)		false
2586	1347		CHILD	216326	259.2606	LENALIDOMIDE	LENALIDOMIDE	NC1=CC=CC2=C1CN(C3CCC(=O)NC3=O)C2=O	PLASMA	F0P408N6V4							24		t	ng × h/mL	5378.83		ng/mL	1252.08				mg/kg	2		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02538965	Homo sapiens										false
2587	1347		UNKNOWN	216326	259.2606	LENALIDOMIDE	LENALIDOMIDE	NC1=CC=CC2=C1CN(C3CCC(=O)NC3=O)C2=O	PLASMA	F0P408N6V4																						UNKNOWN				In vitro (14C)-lenalidomide binding to plasma proteins is approximately 30%.	70	UNKNOWN		UNKNOWN	DRUG LABEL	https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/5fa97bf5-28a2-48f1-8955-f56012d296be/spl-doc?hl=lenalidomide	Homo sapiens										false
2588	1347		ADULT	216326	259.2606	LENALIDOMIDE	LENALIDOMIDE	NC1=CC=CC2=C1CN(C3CCC(=O)NC3=O)C2=O	PLASMA	F0P408N6V4									∞	ng × h/mL	1472.4		ng/mL	433.1			RECOMMENDED	mg	25		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/29411269	Homo sapiens		h	3							false
2589	1348		ADULT	3902	285.3027	LETROZOLE	LETROZOLE	N#CC1=CC=C(C=C1)C(N2C=NC=N2)C3=CC=C(C=C3)C#N	PLASMA	7LKK855W8I									?	μM × h	4.26		nM	128			RECOMMENDED	mg	2.5		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE	REVIEW	https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/20726_FEMARA%202.5MG_BIOPHARMR.PDF	Homo sapiens		h	41.9							false
2590	1349			5284583	170.209	LEVETIRACETAM	LEVETIRACETAM	CC[C@H](N1CCCC1=O)C(N)=O	PLASMA	44YRR34555													μg/mL	19.635				mg	750		SINGLE	FED							Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00849485	Homo sapiens										false
2591	1349			5284583	170.209	LEVETIRACETAM	LEVETIRACETAM	CC[C@H](N1CCCC1=O)C(N)=O	PLASMA	44YRR34555									∞	μg × h/mL	186.758							mg	750		SINGLE	FED							Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00849485	Homo sapiens										false
2592	1349			5284583	170.209	LEVETIRACETAM	LEVETIRACETAM	CC[C@H](N1CCCC1=O)C(N)=O	PLASMA	44YRR34555							36		t	μg × h/mL	176.267							mg	750		SINGLE	FED							Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00849485	Homo sapiens										false
2593	1349			5284583	170.209	LEVETIRACETAM	LEVETIRACETAM	CC[C@H](N1CCCC1=O)C(N)=O	PLASMA	44YRR34555													μg/mL	21.625				mg	750		SINGLE	FASTED							Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00849862	Homo sapiens										false
2594	1349			5284583	170.209	LEVETIRACETAM	LEVETIRACETAM	CC[C@H](N1CCCC1=O)C(N)=O	PLASMA	44YRR34555									∞	μg × h/mL	186.097							mg	750		SINGLE	FASTED							Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00849862	Homo sapiens										false
2595	1349			5284583	170.209	LEVETIRACETAM	LEVETIRACETAM	CC[C@H](N1CCCC1=O)C(N)=O	PLASMA	44YRR34555							36		t	μg × h/mL	173.932							mg	750		SINGLE	FASTED							Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00849862	Homo sapiens										false
2596	1349			5284583	170.209	LEVETIRACETAM	LEVETIRACETAM	CC[C@H](N1CCCC1=O)C(N)=O	PLASMA	44YRR34555							36		t	μg × h/mL	249.26							mg	1000		SINGLE	FED							Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00859430	Homo sapiens										false
2597	1349			5284583	170.209	LEVETIRACETAM	LEVETIRACETAM	CC[C@H](N1CCCC1=O)C(N)=O	PLASMA	44YRR34555													μg/mL	26.32				mg	1000		SINGLE	FED							Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00859430	Homo sapiens										false
2598	1349			5284583	170.209	LEVETIRACETAM	LEVETIRACETAM	CC[C@H](N1CCCC1=O)C(N)=O	PLASMA	44YRR34555									∞	μg × h/mL	261.018							mg	1000		SINGLE	FED							Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00859430	Homo sapiens										false
2599	1349			5284583	170.209	LEVETIRACETAM	LEVETIRACETAM	CC[C@H](N1CCCC1=O)C(N)=O	PLASMA	44YRR34555													μg/mL	30.281				mg	1000		SINGLE	FASTED							Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00859521	Homo sapiens										false
2600	1349			5284583	170.209	LEVETIRACETAM	LEVETIRACETAM	CC[C@H](N1CCCC1=O)C(N)=O	PLASMA	44YRR34555									∞	μg × h/mL	281.155							mg	1000		SINGLE	FASTED							Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00859521	Homo sapiens										false
2601	1349			5284583	170.209	LEVETIRACETAM	LEVETIRACETAM	CC[C@H](N1CCCC1=O)C(N)=O	PLASMA	44YRR34555							36		t	μg × h/mL	269.172							mg	1000		SINGLE	FASTED							Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00859521	Homo sapiens										false
2602	1349		CHILD	5284583	170.209	LEVETIRACETAM	LEVETIRACETAM	CC[C@H](N1CCCC1=O)C(N)=O	PLASMA	44YRR34555									∞	μg × h/mL	241		μg/mL	25.8			UNKNOWN	mg/kg	20		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	REVIEW	https://doi.org/10.1111/j.1528-1167.2001.00005.x	Homo sapiens		h	6		6-12 yr					false
2603	1349		ADULT	5284583	170.209	LEVETIRACETAM	LEVETIRACETAM	CC[C@H](N1CCCC1=O)C(N)=O	PLASMA	44YRR34555							12		t	μg × h/mL	16		μg/mL	2.38			UNKNOWN	mg/kg	1		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	REVIEW	https://doi.org/10.1111/j.1528-1167.2001.00005.x	Homo sapiens		h	6.8		epileptic patients					false
2604	1349		ADULT	5284583	170.209	LEVETIRACETAM	LEVETIRACETAM	CC[C@H](N1CCCC1=O)C(N)=O	PLASMA	44YRR34555							12		t	μg × h/mL	17.7		μg/mL	2.45			UNKNOWN	mg/kg	1		SINGLE	UNKNOWN				the drug is less 10% protein bound	90	HEALTHY	Oral	FEMALE / MALE	REVIEW	https://doi.org/10.1111/j.1528-1167.2001.00005.x	Homo sapiens		h	7.2							false
2605	1351		ADULT	1549000|28145931	388.888	LEVOCETIRIZINE	LEVOCETIRIZINE	OC(=O)COCCN1CCN(CC1)[C@H](C2=CC=CC=C2)C3=CC=C(Cl)C=C3	PLASMA	6U5EA9RT2O									?	ng × h/mL	4136.4		ng/mL	512.25			UNKNOWN	mg	10		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11564134	Homo sapiens		h	7.76							false
2606	1351		ADULT	1549000|28145931	388.888	LEVOCETIRIZINE	LEVOCETIRIZINE	OC(=O)COCCN1CCN(CC1)[C@H](C2=CC=CC=C2)C3=CC=C(Cl)C=C3	PLASMA	6U5EA9RT2O							24		t	μg × h/mL	2.31		μg/mL	0.27			UNKNOWN	mg	5		SINGLE	FASTED					4.5	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11758635	Homo sapiens		h	7.05							false
2607	1351		ADULT	1549000|28145931	388.888	LEVOCETIRIZINE	LEVOCETIRIZINE	OC(=O)COCCN1CCN(CC1)[C@H](C2=CC=CC=C2)C3=CC=C(Cl)C=C3	BLOOD	6U5EA9RT2O							12		t	μg × h/mL	0.97		μg/mL	0.17			UNKNOWN	mg	5		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11758635	Homo sapiens		h	6.83							false
2608	1352		ADULT	72287	328.472	LEVOMEPROMAZINE	LEVOMEPROMAZINE	COC1=CC=C2SC3=C(C=CC=C3)N(C[C@H](C)CN(C)C)C2=C1	PLASMA	9G0LAW7ATQ							24		t	ng × h/mL	676		ng/mL	125			UNKNOWN	mg	350		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/862652/	Homo sapiens		h	24							false
2609	1353		ADULT	13109	312.4458	LEVONORGESTREL	LEVONORGESTREL	CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C	PLASMA	5W7SIA7YZW									∞	ng × h/mL	123.1		ng/mL	14.11			UNKNOWN	mg	0.75		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/12169384	Homo sapiens		h	24.4							false
2610	1353		ADULT	13109	312.4458	LEVONORGESTREL	LEVONORGESTREL	CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C	BLOOD	5W7SIA7YZW									?	ng × h/mL	360.1		ng/mL	16.2			DEFINED DAILY	mg	1.5		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/30703352	Homo sapiens		h	29.7							false
2611	1354		ADULT	3957	382.883	LORATADINE	LORATADINE	CCOC(=O)N1CCC(CC1)=C2C3=NC=CC=C3CCC4=C2C=CC(Cl)=C4	PLASMA	7AJO3BO7QN									∞	ng × h/mL	34.4		ng/mL	10.8			INVESTIGATIONAL	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22806583/	Homo sapiens		h	11							false
2612	1354		ADULT	3957	382.883	LORATADINE	LORATADINE	CCOC(=O)N1CCC(CC1)=C2C3=NC=CC=C3CCC4=C2C=CC(Cl)=C4	PLASMA	7AJO3BO7QN							24		t	ng × h/mL	96		ng/mL	27.1			INVESTIGATIONAL	mg	40		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2958516/	Homo sapiens		h	14.4							false
2613	1354		ADULT	124087	310.821	DESLORATADINE	Desloratadine	ClC1=CC2=C(C=C1)C(=C3CCNCC3)C4=NC=CC=C4CC2	PLASMA	FVF865388R									?	ng × h/mL	56.9		ng/mL	4			RECOMMENDED	mg	5		STEADY-STATE	UNKNOWN		day	1	82% to 87% bound to plasma proteins	84.5	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021165s014lbl.pdf	Homo sapiens		h	27							false
2614	1355		ADULT	3958	321.158	LORAZEPAM	LORAZEPAM	OC1N=C(C2=C(Cl)C=CC=C2)C3=C(NC1=O)C=CC(Cl)=C3	PLASMA	O26FZP769L									∞	ng × h/mL	563.1						RECOMMENDED	mg	2		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31453/	Homo sapiens		h	14.3							false
2615	1355		ADULT	3958	321.158	LORAZEPAM	LORAZEPAM	OC1N=C(C2=C(Cl)C=CC=C2)C3=C(NC1=O)C=CC(Cl)=C3	PLASMA	O26FZP769L													ng/mL	20			RECOMMENDED	mg	2		SINGLE	UNKNOWN				At clinically relevant concentrations, lorazepam is approximately 85% bound to plasma proteins.	15	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/017794s044lbl.pdf	Homo sapiens		h	12							false
2616	1358			4011	277.18304	MAPROTILINE	MAPROTILINE	CNCCCC12CCC(C3=CC=CC=C13)C4=C2C=CC=C4	PLASMA	2U1W68TROF													ng/mL	17.6			UNKNOWN	mg	75		SINGLE								Oral		DRUG LABEL	https://pdf.hres.ca/dpd_pm/00014410.PDF	Homo sapiens		h	44.3							false
2617	1358		ADULT	4011	277.18304	MAPROTILINE	MAPROTILINE	CNCCCC12CCC(C3=CC=CC=C13)C4=C2C=CC=C4	PLASMA	2U1W68TROF									∞	ng × h/mL	3244		ng/mL	139			UNKNOWN	mg	125		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/6775331	Homo sapiens										false
2618	1359				513.6655	MARAVIROC	MARAVIROC	CC(C)C1=NN=C(C)N1[C@H]2C[C@@H]3CC[C@H](C2)N3CC[C@H](NC(=O)C4CCC(F)(F)CC4)C5=CC=CC=C5	PLASMA	MD6P741W8A							72		t	ng × h/mL	1320.7							mg	300		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00717067	Homo sapiens										false
2619	1359				513.6655	MARAVIROC	MARAVIROC	CC(C)C1=NN=C(C)N1[C@H]2C[C@@H]3CC[C@H](C2)N3CC[C@H](NC(=O)C4CCC(F)(F)CC4)C5=CC=CC=C5	PLASMA	MD6P741W8A													ng/mL	335.6				mg	300		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00717067	Homo sapiens										false
2620	1359				513.6655	MARAVIROC	MARAVIROC	CC(C)C1=NN=C(C)N1[C@H]2C[C@@H]3CC[C@H](C2)N3CC[C@H](NC(=O)C4CCC(F)(F)CC4)C5=CC=CC=C5	PLASMA	MD6P741W8A									∞	ng × h/mL	1348.4							mg	300		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00717067	Homo sapiens										false
2621	1359				513.6655	MARAVIROC	MARAVIROC	CC(C)C1=NN=C(C)N1[C@H]2C[C@@H]3CC[C@H](C2)N3CC[C@H](NC(=O)C4CCC(F)(F)CC4)C5=CC=CC=C5	PLASMA	MD6P741W8A																		mg	300		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00717067	Homo sapiens		h	14.36							false
2622	1359				513.6655	MARAVIROC	MARAVIROC	CC(C)C1=NN=C(C)N1[C@H]2C[C@@H]3CC[C@H](C2)N3CC[C@H](NC(=O)C4CCC(F)(F)CC4)C5=CC=CC=C5	PLASMA	MD6P741W8A							72		t	ng × h/mL	4255.5							mg	300		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00717067	Homo sapiens										false
2623	1359				513.6655	MARAVIROC	MARAVIROC	CC(C)C1=NN=C(C)N1[C@H]2C[C@@H]3CC[C@H](C2)N3CC[C@H](NC(=O)C4CCC(F)(F)CC4)C5=CC=CC=C5	PLASMA	MD6P741W8A													ng/mL	801.16				mg	300		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00717067	Homo sapiens										false
2624	1359				513.6655	MARAVIROC	MARAVIROC	CC(C)C1=NN=C(C)N1[C@H]2C[C@@H]3CC[C@H](C2)N3CC[C@H](NC(=O)C4CCC(F)(F)CC4)C5=CC=CC=C5	PLASMA	MD6P741W8A									∞	ng × h/mL	4367.7							mg	300		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00717067	Homo sapiens										false
2625	1359				513.6655	MARAVIROC	MARAVIROC	CC(C)C1=NN=C(C)N1[C@H]2C[C@@H]3CC[C@H](C2)N3CC[C@H](NC(=O)C4CCC(F)(F)CC4)C5=CC=CC=C5	PLASMA	MD6P741W8A																		mg	300		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00717067	Homo sapiens		h	17.29							false
2626	1359		UNKNOWN		513.6655	MARAVIROC	MARAVIROC	CC(C)C1=NN=C(C)N1[C@H]2C[C@@H]3CC[C@H](C2)N3CC[C@H](NC(=O)C4CCC(F)(F)CC4)C5=CC=CC=C5	PLASMA	MD6P741W8A							12		t	ng × h/mL	2908		ng/mL	888			RECOMMENDED	mg	300		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022128s018,208984s001lbl.pdf	Homo sapiens										false
2627	1359		ADULT		513.6655	MARAVIROC	MARAVIROC	CC(C)C1=NN=C(C)N1[C@H]2C[C@@H]3CC[C@H](C2)N3CC[C@H](NC(=O)C4CCC(F)(F)CC4)C5=CC=CC=C5	PLASMA	MD6P741W8A									∞	ng × h/mL	2422		ng/mL	538			UNKNOWN	mg	300		STEADY-STATE	FASTED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/18333861	Homo sapiens		h	8.63							false
2628	1361		ADULT	4030	295.0957	MEBENDAZOLE	MEBENDAZOLE	COC(=O)NC1=NC2=C(N1)C=CC(=C2)C(=O)C3=CC=CC=C3	PLASMA	81G6I5V05I									∞	ng × h/mL	175		ng/mL	14			UNKNOWN	mg	500		SINGLE	FASTED				The plasma protein binding of mebendazole is 90 to 95%	7.5	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208398s000lbl.pdf	Homo sapiens										false
2629	1361		ADULT	4030	295.0957	MEBENDAZOLE	MEBENDAZOLE	COC(=O)NC1=NC2=C(N1)C=CC(=C2)C(=O)C3=CC=CC=C3	PLASMA	81G6I5V05I									∞	ng × h/mL	280.2		ng/mL	69.5			UNKNOWN	mg/kg	10		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/7094986	Homo sapiens		h	3.6							false
2630	1362		ADULT	4037	296.149	MECLOFENAMIC ACID	MECLOFENAMIC ACID	CC1=C(Cl)C(NC2=C(C=CC=C2)C(O)=O)=C(Cl)C=C1	PLASMA	48I5LU4ZWD									∞	μg × h/mL	30.2		μg/mL	15.1			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2322633/	Homo sapiens		h	1.4							false
2631	1363		ADULT	4044	241.2851	MEFENAMIC ACID	MEFENAMIC ACID	CC1=C(C)C(NC2=C(C=CC=C2)C(O)=O)=CC=C1	PLASMA	367589PJ2C									∞	μg × h/mL	38.03		μg/mL	5.91			RECOMMENDED	mg	250		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22116543/	Homo sapiens		h	3.46							false
2632	1363		NEWBORN	4044	241.2851	MEFENAMIC ACID	MEFENAMIC ACID	CC1=C(C)C(NC2=C(C=CC=C2)C(O)=O)=CC=C1	PLASMA	367589PJ2C													μg/mL	3.8			RECOMMENDED	mg/kg	2		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7942001/	Homo sapiens		h	18.7							false
2633	1363		ADULT	4044	241.2851	MEFENAMIC ACID	MEFENAMIC ACID	CC1=C(C)C(NC2=C(C=CC=C2)C(O)=O)=CC=C1	PLASMA	367589PJ2C																	INVESTIGATIONAL	mg	500		STEADY-STATE	UNKNOWN		day	1	Mefenamic acid has been reported as being greater than 90% bound to albumin.	10	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/015034s044lbl.pdf	Homo sapiens										false
2634	1364		ADULT	11683	384.5085	MEGESTROL ACETATE	megestrol acetate	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O	PLASMA	TJ2M0FR8ES									∞	ng × h/mL	16268		ng/mL	1618			RECOMMENDED	mg	625		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19774117/	Homo sapiens		h	39.75							false
2635	1364		ADULT	11683	384.5085	MEGESTROL ACETATE	megestrol acetate	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O	PLASMA	TJ2M0FR8ES									∞	ng × h/mL	12095		ng/mL	1133			RECOMMENDED	mg	625		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19774117/	Homo sapiens		h	33.68							false
2636	1364		ADULT	11683	384.5085	MEGESTROL ACETATE	megestrol acetate	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O	PLASMA	TJ2M0FR8ES									∞	ng × h/mL	18625		ng/mL	1364			RECOMMENDED	mg	800		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19774117/	Homo sapiens		h	32.84							false
2637	1364		ADULT	11683	384.5085	MEGESTROL ACETATE	megestrol acetate	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O	PLASMA	TJ2M0FR8ES									∞	ng × h/mL	8942		ng/mL	187			RECOMMENDED	mg	800		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19774117/	Homo sapiens		h	31.38							false
2638	1364		ADULT	11683	384.5085	MEGESTROL ACETATE	megestrol acetate	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O	PLASMA	TJ2M0FR8ES									?	ng × h/mL	10476		ng/mL	753			RECOMMENDED	mg	800		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021778s002s003lbl.pdf	Homo sapiens										false
2639	1364		ADULT	11683	384.5085	MEGESTROL ACETATE	megestrol acetate	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O	PLASMA	TJ2M0FR8ES									?	ng × h/mL	6779		ng/mL	490			RECOMMENDED	mg	750		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021778s002s003lbl.pdf	Homo sapiens										false
2640	1365		ADULT	54677470	351.4	MELOXICAM	MELOXICAM	CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C3=CC=CC=C3[S+]1([O-])=O	PLASMA	VG2QF83CGL													μg/mL	1.05			RECOMMENDED	mg	7.5		STEADY-STATE	FED		day	1			HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020938s024s025,021530s014s015lbl.pdf	Homo sapiens		h	20.1							false
2641	1365		ADULT	54677470	351.4	MELOXICAM	CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C3=CC=CC=C3[S+]1([O-])=O	CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C3=CC=CC=C3[S+]1([O-])=O	PLASMA	VG2QF83CGL									∞	ng × h/mL	40875.6		ng/mL	1288.8			RECOMMENDED	mg	15		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26638161	Homo sapiens		h	23.6							false
2642	1366		ADULT	4054	179.3	MEMANTINE	MEMANTINE	CC12CC3CC(C)(C1)CC(N)(C3)C2	PLASMA	W8O17SJF3T									∞	ng × h/mL	540		ng/mL	6.2			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/18498913	Homo sapiens		h	66.86							false
2643	1366		ADULT	4054	179.3	MEMANTINE	MEMANTINE	CC12CC3CC(C)(C1)CC(N)(C3)C2	PLASMA	W8O17SJF3T									∞	ng × h/mL	1853		ng/mL	25.34			DEFINED DAILY	mg	20		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/18498913	Homo sapiens		h	62							false
2644	1366		ADULT	4054	179.3	MEMANTINE	MEMANTINE	CC12CC3CC(C)(C1)CC(N)(C3)C2	PLASMA	W8O17SJF3T									∞	ng × h/mL	386.37		ng/mL	19.69			UNKNOWN	mg	5		MULTIPLE	FASTED		2 weeks	14			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/18498913	Homo sapiens		h	64.57							false
2645	1368		ADULT	4062	246.348	MEPIVACAINE	MEPIVACAINE	CN1CCCCC1C(=O)NC2=C(C)C=CC=C2C	PLASMA	B6E06QE59J									∞	ng × h/mL	1982.3		ng/mL	435.3			UNKNOWN	mg	20		SINGLE	UNKNOWN						HEALTHY	Intraoral Submucosal Injection	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27976931	Homo sapiens		h	1.63							false
2646	1368		ADULT	4062	246.348	MEPIVACAINE	MEPIVACAINE	CN1CCCCC1C(=O)NC2=C(C)C=CC=C2C	PLASMA	B6E06QE59J									?	μg × min/mL	440						UNKNOWN	mg	250		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/380609	Homo sapiens		min	125							false
2647	1368		UNKNOWN	4062	246.348	MEPIVACAINE	MEPIVACAINE	CN1CCCCC1C(=O)NC2=C(C)C=CC=C2C	SERUM	B6E06QE59J																						UNKNOWN				Mepivacaine concentration 1 ug/ml	25	UNKNOWN		UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6478740	Homo sapiens										false
2648	1369		ADULT	4075|122508122	153.1354	MESALAMINE	MESALAMINE	NC1=CC=C(O)C(=C1)C(O)=O	PLASMA	4Q81I59GXC									∞	ng × h/mL	9578		ng/mL	857			RECOMMENDED	g	1.2		SINGLE	FASTED				Mesalamine is approximately 43% bound to plasma proteins at the concentration of 2.5 ug/mL.	57	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022000lbl.pdf	Homo sapiens		h	8.56							false
2649	1369		ADULT	4075|122508122	153.1354	MESALAMINE	MESALAMINE	NC1=CC=C(O)C(=C1)C(O)=O	PLASMA	4Q81I59GXC									∞	ng × h/mL	21084		ng/mL	1595			RECOMMENDED	g	2.4		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022000lbl.pdf	Homo sapiens		h	7.05							false
2650	1369		ADULT	4075|122508122	153.1354	MESALAMINE	MESALAMINE	NC1=CC=C(O)C(=C1)C(O)=O	PLASMA	4Q81I59GXC									∞	ng × h/mL	44775		ng/mL	2154			RECOMMENDED	g	4.8		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022000lbl.pdf	Homo sapiens		h	7.25							false
2651	1369		ADULT	4075|122508122	153.1354	MESALAMINE	MESALAMINE	NC1=CC=C(O)C(=C1)C(O)=O	PLASMA	4Q81I59GXC									?	ng × h/mL	909		ng/mL	150			RECOMMENDED	mg	800		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204412s006lbl.pdf	Homo sapiens		h	25							false
2652	1370		UNKNOWN	5376308	236.272	METHAZOLAMIDE	METHAZOLAMIDE	CN1N=C(S\\C1=N\\C(C)=O)S(N)(=O)=O	PLASMA	W733B0S9SD									?	μg × min/mL	1130		μg/mL	2.5			RECOMMENDED	mg	25		MULTIPLE	UNKNOWN		day	2	Approximately 55% is bound to plasma proteins	45	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4c9fc6f5-acd4-4fc0-bf4b-c493a08aa3d6&type=display	Homo sapiens										false
2653	1370		UNKNOWN	5376308	236.272	METHAZOLAMIDE	METHAZOLAMIDE	CN1N=C(S\\C1=N\\C(C)=O)S(N)(=O)=O	PLASMA	W733B0S9SD									?	μg × min/mL	2571		μg/mL	5.1			RECOMMENDED	mg	50		MULTIPLE	UNKNOWN		day	2			UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4c9fc6f5-acd4-4fc0-bf4b-c493a08aa3d6&type=display	Homo sapiens										false
2654	1370		UNKNOWN	5376308	236.272	METHAZOLAMIDE	METHAZOLAMIDE	CN1N=C(S\\C1=N\\C(C)=O)S(N)(=O)=O	PLASMA	W733B0S9SD									?	μg × min/mL	5418		μg/mL	10.7			RECOMMENDED	mg	100		MULTIPLE	UNKNOWN		day	2			UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4c9fc6f5-acd4-4fc0-bf4b-c493a08aa3d6&type=display	Homo sapiens										false
2655	1370		UNKNOWN	5376308	236.272	METHAZOLAMIDE	METHAZOLAMIDE	CN1N=C(S\\C1=N\\C(C)=O)S(N)(=O)=O	PLASMA	W733B0S9SD																	UNKNOWN				STEADY-STATE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4c9fc6f5-acd4-4fc0-bf4b-c493a08aa3d6&type=display	Homo sapiens		h	14							false
2656	1371		ADULT	4104|1349907	114.169	METHIMAZOLE	methimazole	CN1C=CNC1=S	PLASMA	554Z48XN5E									∞	μg × h/L	1833						UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4042519/	Homo sapiens		h	5.3							false
2657	1371		ADULT	4104|1349907	114.169	METHIMAZOLE	METHIMAZOLE	CN1C=CNC1=S	PLASMA	554Z48XN5E									∞	μg × h/L	1661		ng/mL	248			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4042519/	Homo sapiens		h	5.3							false
2658	1371		ADULT	4104|1349907	114.169	METHIMAZOLE	methimazole	CN1C=CNC1=S	SERUM	554Z48XN5E									∞	ng × h/mL	2450						UNKNOWN	mg/kg bw	0.16		SINGLE	FED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://www.jstage.jst.go.jp/article/endocrj1954/33/5/33_5_605/_pdf	Homo sapiens		h	20.7							false
2659	1371		ADULT	4104|1349907	114.169	METHIMAZOLE	methimazole	CN1C=CNC1=S	SERUM	554Z48XN5E									∞	ng × h/mL	2922						UNKNOWN	mg/kg bw	0.21		SINGLE	FED						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.jstage.jst.go.jp/article/endocrj1954/33/5/33_5_605/_pdf	Homo sapiens		h	18.5							false
2660	1371		ADULT	4104|1349907	114.169	METHIMAZOLE	METHIMAZOLE	CN1C=CNC1=S	SERUM	554Z48XN5E									∞	ng × h/mL	2657		ng/mL	213			UNKNOWN	mg/kg bw	0.17		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.jstage.jst.go.jp/article/endocrj1954/33/5/33_5_605/_pdf	Homo sapiens		h	14							false
2661	1371		ADULT	4104|1349907	114.169	METHIMAZOLE	METHIMAZOLE	CN1C=CNC1=S	SERUM	554Z48XN5E									∞	ng × h/mL	3228		ng/mL	299			UNKNOWN	mg/kg bw	0.21		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.jstage.jst.go.jp/article/endocrj1954/33/5/33_5_605/_pdf	Homo sapiens		h	14							false
2662	1371		ADULT	4104|1349907	114.169	METHIMAZOLE	METHIMAZOLE	CN1C=CNC1=S	SERUM	554Z48XN5E									∞	ng × h/mL	4773		ng/mL	380			UNKNOWN	mg/kg bw	0.3		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.jstage.jst.go.jp/article/endocrj1954/33/5/33_5_605/_pdf	Homo sapiens		h	20.1							false
2663	1371		ADULT	4104|1349907	114.169	METHIMAZOLE	METHIMAZOLE	CN1C=CNC1=S	SERUM	554Z48XN5E									∞	ng × h/mL	7136		ng/mL	803			UNKNOWN	mg/kg bw	0.57		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.jstage.jst.go.jp/article/endocrj1954/33/5/33_5_605/_pdf	Homo sapiens		h	15							false
2664	1372		ADULT	4107	241.2405	METHOCARBAMOL	methocarbamol	COC1=C(OCC(O)COC(N)=O)C=CC=C1	PLASMA	125OD7737X									∞	mg × h/L	52.5		mg/L	21.3			RECOMMENDED	g	1.5		SINGLE	UNKNOWN				Plasma protein binding (ultrafiltration) was between 46 and 50% for healthy population (at 1, 8, 12 hr).	52	HEALTHY	Oral	MALE	EXPERIMENT	https://link.springer.com/article/10.1007%2FBF00280060	Homo sapiens		h	1.14							false
2665	1372		ADULT	4107	241.2405	METHOCARBAMOL	methocarbamol	COC1=C(OCC(O)COC(N)=O)C=CC=C1	PLASMA	125OD7737X									∞	mg × h/L	87.1		mg/L	28.7			RECOMMENDED	g	1.5		SINGLE	UNKNOWN				Plasma protein binding (ultrafiltration) was 47.3 and 48.9 % at 1 and 8 hr for patients with renal failure undergoing maintenance hemodialysis.	51.9	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://link.springer.com/article/10.1007%2FBF00280060	Homo sapiens		h	1.24							false
2666	1373		CHILD	126941	454.4393	METHOTREXATE	CN(CC1=NC2=C(N)N=C(N)N=C2N=C1)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O	CN(CC1=NC2=C(N)N=C(N)N=C2N=C1)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O	PLASMA	YL5FZ2Y5U1													μM	1.205			UNKNOWN	mg/m²	20		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205776s000lbl.pdf	Homo sapiens		h	3.25							false
2667	1373		UNKNOWN	126941	454.4393	METHOTREXATE	METHOTREXATE	CN(CC1=NC2=C(N=C1)N=C(N)N=C2N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O	SERUM	YL5FZ2Y5U1																						UNKNOWN				Methotrexate in serum is approximately 50% protein bound.	50	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205776s000lbl.pdf	Homo sapiens										false
2668	1373		ADULT	126941	454.4393	METHOTREXATE	CN(CC1=NC2=C(N)N=C(N)N=C2N=C1)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O	CN(CC1=NC2=C(N)N=C(N)N=C2N=C1)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O	PLASMA	YL5FZ2Y5U1							170		t	nM × h	3533						RECOMMENDED	mg	15		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/8485020	Homo sapiens		h	55							false
2669	1374		UNKNOWN	92154	189.2105	N-DESMETHYLMETHSUXIMIDE	N-desmethylmethsuximide	CC1(CC(=O)NC1=O)C2=CC=CC=C2	SERUM	1X877DO1N9																	UNKNOWN				STEADY-STATE	UNKNOWN				In human serum, N -desmethylmethsuximide is 45% to 60% protein bound.	55	UNHEALTHY	UNKNOWN	UNKNOWN	EXPERIMENT	http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=ovftd&NEWS=N&AN=00002826-199907000-00011	Homo sapiens										false
2670	1374		CHILD	92154	189.2105	N-DESMETHYLMETHSUXIMIDE	N-desmethylmethsuximide	CC1(CC(=O)NC1=O)C2=CC=CC=C2	SERUM	1X877DO1N9													mg/L	39.5			DEFINED DAILY	mg/kg	11.1		STEADY-STATE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://doi.org/10.1016/S0022-3476(89)80714-0	Homo sapiens		h	25.6							false
2671	1377		ADULT	8226	339.4314	METHYLERGONOVINE	METHYLERGONOVINE	CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=C3C(=CC=C4)C2=C1	PLASMA	W53L6FE61V									∞	pg × h/mL	13889		pg/mL	5918			RECOMMENDED	mg	0.2		SINGLE	FASTED						HEALTHY	Intramuscular	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/090193s000lbl.pdf	Homo sapiens		h	3.39							false
2672	1378		ADULT	6010	302.451	METHYLTESTOSTERONE	METHYLTESTOSTERONE	C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C	SERUM	V9EFU16ZIF							24		t	ng × h/mL	275.2		ng/mL	95.9			RECOMMENDED	mg	50		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://www.koreascience.or.kr/article/CFKO200311922689640.page	Homo sapiens		h	4.39							false
2673	1379		ADULT	4168	299.796	METOCLOPRAMIDE	Metoclopramide	CCN(CC)CCNC(=O)C1=C(OC)C=C(N)C(Cl)=C1	PLASMA	L4YEB44I46									∞	ng × h/mL	367		ng/mL	41			RECOMMENDED	mg	15		SINGLE	UNKNOWN				Metoclopramide is not extensively bound to plasma proteins (about 30%).	70	HEALTHY	Nasal	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209388s000lbl.pdf	Homo sapiens		h	8.1							false
2674	1380		ADULT	441350|6918925	195.2151	METIROSINE	METYROSINE	C[C@](N)(CC1=CC=C(O)C=C1)C(O)=O	PLASMA	DOQ0J0TPF7							6		t	ng × h/mL	15538		ng/mL	3313			RECOMMENDED	mg	230		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	http://q4live.s22.clientfiles.s3.amazonaws.com/265040820/files/doc_downloads/scientific-presentations/2019/Phase-II-pharmacokinetics-of-oral-SM-88-in-heavily-pretreated-advanced-pancreatic-ductal-adenocarcinoma-(PC).pdf	Homo sapiens		h	9.1							false
2675	1380		ADULT	441350|6918925	195.2151	METIROSINE	METYROSINE	C[C@](N)(CC1=CC=C(O)C=C1)C(O)=O	PLASMA	DOQ0J0TPF7							6		t	ng × h/mL	28005		ng/mL	6550			MAX DAILY	mg	920		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	http://q4live.s22.clientfiles.s3.amazonaws.com/265040820/files/doc_downloads/scientific-presentations/2019/Phase-II-pharmacokinetics-of-oral-SM-88-in-heavily-pretreated-advanced-pancreatic-ductal-adenocarcinoma-(PC).pdf	Homo sapiens		h	4.1							false
2676	1381		ADULT	18340|11426313|25137866	290.743	MIDODRINE HYDROCHLORIDE	MIDODRINE HYDROCHLORIDE	Cl.COC1=CC(C(O)CNC(=O)CN)=C(OC)C=C1	PLASMA	59JV96YTXV									?	ng × h/mL	2.5		ng/mL	2.2			UNKNOWN	mg	5		SINGLE	FASTED				Neither midodrine nor desglymidodrine are bound to plasma proteins to a significant extent.	100	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26597181	Homo sapiens		h	0.6							false
2677	1381		ADULT	18340|11426313|25137866	290.743	MIDODRINE HYDROCHLORIDE	MIDODRINE HYDROCHLORIDE	Cl.COC1=CC(C(O)CNC(=O)CN)=C(OC)C=C1	PLASMA	59JV96YTXV									?	ng × h/mL	18.5		ng/mL	21			UNKNOWN	mg	5		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26597181	Homo sapiens		h	0.54							false
2678	1382		ADULT	55245	429.6	MIFEPRISTONE	MIFEPRISTONE	CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)C5=CC=C(C=C5)N(C)C	PLASMA	320T6RNW1F									∞	mg × h/L	25.8		mg/L	1.77			DEFINED DAILY	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020687s020lbl.pdf	Homo sapiens		h	18							false
2679	1383		UNKNOWN	441314	207.2243	MIGLITOL	MIGLITOL	OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO	PLASMA	0V5436JAQW																	RECOMMENDED	mg	100		MULTIPLE	UNKNOWN		day	3			UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020682s010lbl.pdf	Homo sapiens		h	2							false
2680	1384		ADULT	51634	219.278	MIGLUSTAT	MIGLUSTAT	CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO	PLASMA	ADN3S497AZ									∞	ng × h/mL	10868		ng/mL	1328			RECOMMENDED	mg	100		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17720777	Homo sapiens		h	7.8							false
2681	1384		ADULT	51634	219.278	MIGLUSTAT	MIGLUSTAT	CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO	PLASMA	ADN3S497AZ									∞	ng × h/mL	9320		ng/mL	843			RECOMMENDED	mg	100		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17720777	Homo sapiens		h	8							false
2682	1384		UNKNOWN	51634	219.278	MIGLUSTAT	MIGLUSTAT	CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO	PLASMA	ADN3S497AZ																						UNKNOWN				Miglustat does not bind to plasma proteins.	100	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021348s010lbl.pdf	Homo sapiens										false
2683	1385		UNKNOWN	4197|5281020	211.2194	MILRINONE	MILRINONE	CC1=C(C=C(C#N)C(=O)N1)C2=CC=NC=C2	PLASMA	JU9YAX04C7													μg/L	162			UNKNOWN	mg	5		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/3053125	Homo sapiens		h	0.94							false
2684	1385		UNKNOWN	4197|5281020	211.2194	MILRINONE	MILRINONE	CC1=C(C=C(C#N)C(=O)N1)C2=CC=NC=C2	PLASMA	JU9YAX04C7													μg/L	454			UNKNOWN	μg/kg bw	75		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/3053125	Homo sapiens		h	1.7							false
2685	1385		ADULT	4197|5281020	211.2194	MILRINONE	MILRINONE	CC1=C(C=C(C#N)C(=O)N1)C2=CC=NC=C2	PLASMA	JU9YAX04C7									∞	ng × h/mL	439						UNKNOWN	mg	10		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/7728786	Homo sapiens		h	0.758							false
2686	1385		ADULT	4197|5281020	211.2194	MILRINONE	MILRINONE	CC1=C(C=C(C#N)C(=O)N1)C2=CC=NC=C2	PLASMA	JU9YAX04C7									∞	ng × h/mL	1.749						UNKNOWN	mg	10		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/7728786	Homo sapiens		h	1.92							false
2687	1386		UNKNOWN		209.2483	MINOXIDIL	MINOXIDIL	NC1=NC(=CC(N)=[N+]1[O-])N2CCCCC2	PLASMA	5965120SH1																						UNKNOWN				Minoxidil does not bind to plasma proteins, and its renal clearance corresponds to the glomerular filtration rate.	100	UNKNOWN		UNKNOWN	DRUG LABEL	https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/032835ab-1c8b-418a-9009-b6ebe58676dc/spl-doc?hl=MINOXIDIL	Homo sapiens										false
2688	1386		ADULT		209.2483	MINOXIDIL	MINOXIDIL	NC1=NC(=CC(N)=[N+]1[O-])N2CCCCC2	PLASMA	5965120SH1							12		t	ng × h/mL	18.71		ng/mL	2.13			UNKNOWN	mg	50		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Topical	MALE	DRUG LABEL	https://www.medicines.org.uk/emc/product/103/smpc	Homo sapiens										false
2689	1386		ADULT		209.2483	MINOXIDIL	MINOXIDIL	NC1=NC(=CC(N)=[N+]1[O-])N2CCCCC2	PLASMA	5965120SH1									∞	ng × h/mL	55.1		ng/mL	37.2			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/2715373	Homo sapiens		h	1.27							false
2690	1387		ADULT	5282381	382.5341	MISOPROSTOL	MISOPROSTOL	CCCCC(C)(O)C\\C=C\\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC	PLASMA	0E43V0BB57									∞	ng × h/mL	2.019		ng/mL	2.683			UNKNOWN	μg	800		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27102981	Homo sapiens		h	1.04							false
2691	1387		ADULT	5282381	382.5341	MISOPROSTOL	MISOPROSTOL	CCCCC(C)(O)C\\C=C\\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC	PLASMA	0E43V0BB57									∞	ng × h/mL	3.209		ng/mL	2.439			UNKNOWN	μg	800		SINGLE	FASTED						HEALTHY	Sublingual	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27102981	Homo sapiens		h	0.854							false
2692	1387		ADULT	5282381	382.5341	MISOPROSTOL	MISOPROSTOL	CCCCC(C)(O)C\\C=C\\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC	PLASMA	0E43V0BB57									∞	ng × h/mL	2.073		ng/mL	1.361			UNKNOWN	μg	800		SINGLE	FASTED						HEALTHY	Buccal	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27102981	Homo sapiens		h	0.837							false
2693	1387		ADULT	5282381	382.5341	MISOPROSTOL	MISOPROSTOL	CCCCC(C)(O)C\\C=C\\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC	PLASMA								4		t	pg × h/mL	417		pg/mL	811			UNKNOWN	μg	300		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019268s041lbl.pdf	Homo sapiens		h	0.5							false
2694	1387		UNKNOWN	5282381	382.5341	MISOPROSTOL	MISOPROSTOL	CCCCC(C)(O)C\\C=C\\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC	SERUM	0E43V0BB57																						UNKNOWN				The serum protein binding of misoprostol acid is less than 90% and is concentration-independent in the therapeutic range.	10	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019268s041lbl.pdf	Homo sapiens										false
2695	1388		ADULT	4211	320.041	MITOTANE	MITOTANE	ClC(Cl)C(C1=CC=C(Cl)C=C1)C2=C(Cl)C=CC=C2	PLASMA	78E4J5IB5J							2016		t	mg × day/L	790		mg/L	14.3			UNKNOWN	g	2		MULTIPLE	FED		day	3			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24057287/	Homo sapiens										false
2696	1388		ADULT	4211	320	MITOTANE	MITOTANE	ClC(Cl)C(C1=CC=C(Cl)C=C1)C2=C(Cl)C=CC=C2	PLASMA	78E4J5IB5J							2016		t	mg × day/L	543		mg/L	11.3			UNKNOWN	g	1		MULTIPLE	FED		day	3			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/24057287	Homo sapiens										false
2697	1390		UNKNOWN	4409	228.2863	NABUMETONE	NABUMETONE	COC1=CC2=C(C=C1)C=C(CCC(C)=O)C=C2	PLASMA	LW0TIW155Z									∞	ng × h/mL	204.98		ng/mL	13.48			RECOMMENDED	mg	1000		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12763542/	Homo sapiens		h	16.82							false
2698	1390		ADULT	32176	216.2326	6-METHOXY-2-NAPHTHYLACETIC ACID	6-methoxy-2-naphthylacetic acid	COC1=CC2=C(C=C1)C=C(CC(O)=O)C=C2	PLASMA	9H7K3YOD7Q									∞	μg × h/mL	1120		μg/mL	21.9			RECOMMENDED	mg	1000		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2744071/	Homo sapiens		h	26.3							false
2699	1390		ADULT	32176	216.2326	6-METHOXY-2-NAPHTHYLACETIC ACID	6-methoxy-2-naphthylacetic acid	COC1=CC2=C(C=C1)C=C(CC(O)=O)C=C2	PLASMA	9H7K3YOD7Q									∞	μg × h/mL	2150		μg/mL	33.7			RECOMMENDED	mg	1000		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2744071/	Homo sapiens		h	38.8							false
2700	1390		ADULT	32176	216.2326	6-METHOXY-2-NAPHTHYLACETIC ACID	6-methoxy-2-naphthylacetic acid	COC1=CC2=C(C=C1)C=C(CC(O)=O)C=C2	PLASMA	9H7K3YOD7Q							24		t	μg × h/mL	1022		μg/mL	52.3			RECOMMENDED	mg	1000		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2744071/	Homo sapiens		h	27.5							false
2701	1390		ADULT	32176	216.2326	6-METHOXY-2-NAPHTHYLACETIC ACID	6-methoxy-2-naphthylacetic acid	COC1=CC2=C(C=C1)C=C(CC(O)=O)C=C2	PLASMA	9H7K3YOD7Q							24		t	μg × h/mL	1270		μg/mL	66.7			RECOMMENDED	mg	1000		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2744071/	Homo sapiens		h	34.2							false
2702	1392		ADULT	47641	287.3981	NAFTIFINE	NAFTIFINE	CN(C\\C=C\\C1=CC=CC=C1)CC2=C3C=CC=CC3=CC=C2	PLASMA	4FB1TON47A							24		t	ng × h/mL	117		ng/mL	7			UNKNOWN	g	6.4		SINGLE	UNKNOWN						UNHEALTHY	Topical	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019356s008,019599s014,204286s003lbl.pdf	Homo sapiens		day	2.5							false
2703	1392		ADULT	47641	287.3981	NAFTIFINE	NAFTIFINE	CN(C\\C=C\\C1=CC=CC=C1)CC2=C3C=CC=CC3=CC=C2	PLASMA	4FB1TON47A							24		t	ng × h/mL	204		ng/mL	11			UNKNOWN	g	6.4		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Topical	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019356s008,019599s014,204286s003lbl.pdf	Homo sapiens										false
2704	1392		ADOLESCENT	47641	287.3981	NAFTIFINE	NAFTIFINE	CN(C\\C=C\\C1=CC=CC=C1)CC2=C3C=CC=CC3=CC=C2	PLASMA	4FB1TON47A							24		t	ng × h/mL	138		ng/mL	9.21			UNKNOWN	g	8.1		SINGLE	UNKNOWN						UNHEALTHY	Topical	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019356s008,019599s014,204286s003lbl.pdf	Homo sapiens										false
2705	1392		ADOLESCENT	47641	287.3981	NAFTIFINE	NAFTIFINE	CN(C\\C=C\\C1=CC=CC=C1)CC2=C3C=CC=CC3=CC=C2	PLASMA	4FB1TON47A							24		t	ng × h/mL	192		ng/mL	12.7			UNKNOWN	g	8.1		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Topical	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019356s008,019599s014,204286s003lbl.pdf	Homo sapiens										false
2706	1392		CHILD	47641	287.3981	NAFTIFINE	NAFTIFINE	CN(C\\C=C\\C1=CC=CC=C1)CC2=C3C=CC=CC3=CC=C2	PLASMA	4FB1TON47A							24		t	ng × h/mL	49.8		ng/mL	3.6			UNKNOWN	g	2.3		SINGLE	UNKNOWN						UNHEALTHY	Topical	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019356s008,019599s014,204286s003lbl.pdf	Homo sapiens										false
2707	1392		CHILD	47641	287.3981	NAFTIFINE	NAFTIFINE	CN(C\\C=C\\C1=CC=CC=C1)CC2=C3C=CC=CC3=CC=C2	PLASMA	4FB1TON47A							24		t	ng × h/mL	52.4		ng/mL	3.31			UNKNOWN	g	2.3		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Topical	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019356s008,019599s014,204286s003lbl.pdf	Homo sapiens										false
2708	1394		ADULT	5311309	317.4226	NATEGLINIDE	nateglinide	CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](CC2=CC=CC=C2)C(O)=O	PLASMA	41X3PWK4O2									∞	μg × h/mL	13.33		μg/mL	5.21			UNKNOWN	mg	120		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	REVIEW	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-204_Stsrlix_biopharmr.pdf	Homo sapiens		h	1.58				20			false
2709	1394		ADULT	5311309	317.4226	NATEGLINIDE	nateglinide	CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](CC2=CC=CC=C2)C(O)=O	PLASMA	41X3PWK4O2									∞	μg × h/mL	17.72		μg/mL	16.19			UNKNOWN	mg	120		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	REVIEW	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-204_Stsrlix_biopharmr.pdf	Homo sapiens		h	1.88				20			false
2710	1394		ADULT		317.4226	NATEGLINIDE	NATEGLINIDE	CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](CC2=CC=CC=C2)C(O)=O	BLOOD	41X3PWK4O2													ng/mL	5690			UNKNOWN	mg	120		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/11259325	Homo sapiens										false
2711	1394		ADULT		317.4226	NATEGLINIDE	NATEGLINIDE	CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](CC2=CC=CC=C2)C(O)=O	PLASMA	41X3PWK4O2							6		t	mg × h/L	10.45						UNKNOWN	mg	90		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/12940610	Homo sapiens		h	1.89							false
2712	1395		ADULT	4449	470.007	NEFAZODONE	Nefazodone	CCC1=NN(CCCN2CCN(CC2)C3=CC(Cl)=CC=C3)C(=O)N1CCOC4=CC=CC=C4	PLASMA	59H4FCV1TF							12		t	μg × h/L	3213		μg/L	880			RECOMMENDED	mg	100		STEADY-STATE	FASTED		day	2			HEALTHY	Oral	FEMALE / MALE	REVIEW	https://link.springer.com/article/10.2165/00003088-199733040-00002	Homo sapiens		h	7							false
2713	1395		ADULT	4449	470.007	NEFAZODONE	Nefazodone	CCC1=NN(CCCN2CCN(CC2)C3=CC(Cl)=CC=C3)C(=O)N1CCOC4=CC=CC=C4	PLASMA	59H4FCV1TF									∞	μg × h/L	787		μg/L	276			RECOMMENDED	mg	100		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	REVIEW	https://link.springer.com/article/10.2165/00003088-199733040-00002	Homo sapiens		h	5.7							false
2714	1395		ADULT	4449	470.007	NEFAZODONE	Nefazodone	CCC1=NN(CCCN2CCN(CC2)C3=CC(Cl)=CC=C3)C(=O)N1CCOC4=CC=CC=C4	PLASMA	59H4FCV1TF									∞	ng × h/mL	1220		ng/mL	415			RECOMMENDED	mg	200		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8951188/	Homo sapiens		h	5.2							false
2715	1395		ADULT	4449	470.007	NEFAZODONE	Nefazodone	CCC1=NN(CCCN2CCN(CC2)C3=CC(Cl)=CC=C3)C(=O)N1CCOC4=CC=CC=C4	PLASMA	59H4FCV1TF							12		t	ng × h/mL	6378		ng/mL	1588			RECOMMENDED	mg	200		STEADY-STATE	FASTED		day	2			HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8951188/	Homo sapiens										false
2716	1396		ADULT	64142|10699576	663.888	NELFINAVIR MESYLATE	NELFINAVIR MESYLATE	CS(O)(=O)=O.CC1=C(O)C=CC=C1C(=O)N[C@@H](CSC2=CC=CC=C2)[C@H](O)CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C	PLASMA	98D603VP8V																	UNKNOWN	mg	100		SINGLE	FED						HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/10200859	Homo sapiens		h	1.8							false
2717	1396		ADULT	64142|10699576	663.888	NELFINAVIR MESYLATE	NELFINAVIR MESYLATE	CS(O)(=O)=O.CC1=C(O)C=CC=C1C(=O)N[C@@H](CSC2=CC=CC=C2)[C@H](O)CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C	PLASMA	98D603VP8V																	UNKNOWN	mg	800		SINGLE	FED						HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/10200859	Homo sapiens		h	3.4							false
2718	1396		ADULT	64142|10699576	663.888	NELFINAVIR MESYLATE	NELFINAVIR MESYLATE	CS(O)(=O)=O.CC1=C(O)C=CC=C1C(=O)N[C@@H](CSC2=CC=CC=C2)[C@H](O)CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C	PLASMA	98D603VP8V							24		t	mg × h/L	52.8		mg/L	4			RECOMMENDED	mg	1250		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020778s041,020779s062,021503s024lbl.pdf	Homo sapiens										false
2719	1396		ADULT	64142|10699576	663.888	NELFINAVIR MESYLATE	NELFINAVIR MESYLATE	CS(O)(=O)=O.CC1=C(O)C=CC=C1C(=O)N[C@@H](CSC2=CC=CC=C2)[C@H](O)CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C	PLASMA	98D603VP8V							24		t	mg × h/L	43.6		mg/L	3			RECOMMENDED	mg	750		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020778s041,020779s062,021503s024lbl.pdf	Homo sapiens										false
2720	1396		ADULT	64142|10699576	663.888	NELFINAVIR MESYLATE	NELFINAVIR MESYLATE	CS(O)(=O)=O.CC1=C(O)C=CC=C1C(=O)N[C@@H](CSC2=CC=CC=C2)[C@H](O)CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C	PLASMA	98D603VP8V							12		t	mg × h/L	35.3		mg/L	4.7			RECOMMENDED	mg	1250		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020778s041,020779s062,021503s024lbl.pdf	Homo sapiens										false
2721	1396		UNKNOWN	64142|10699576	663.888	NELFINAVIR MESYLATE	NELFINAVIR MESYLATE	CS(O)(=O)=O.CC1=C(O)C=CC=C1C(=O)N[C@@H](CSC2=CC=CC=C2)[C@H](O)CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C	SERUM	98D603VP8V																	UNKNOWN				UNKNOWN	UNKNOWN				Nelfinavir in serum is extensively protein-bound (>98%).	2	UNKNOWN	UNKNOWN	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020778s041,020779s062,021503s024lbl.pdf	Homo sapiens										false
2722	1397		ADULT	151075	254.28	Nepafenac		C1=CC=C(C=C1)C(=O)C2=CC=CC(=C2N)CC(=O)N	AQUEOUS HUMOR	0J9L7J6V8C							4		t	ng × h/mL	331.1		ng/mL	205.3			RECOMMENDED	drop	1		SINGLE	UNKNOWN						UNHEALTHY	Ocular	FEMALE / MALE	DRUG LABEL	https://iovs.arvojournals.org/article.aspx?articleid=2383342	Homo sapiens										false
2723	1397		ADULT	151075	254.28	Nepafenac		C1=CC=C(C=C1)C(=O)C2=CC=CC(=C2N)CC(=O)N	PLASMA	0J9L7J6V8C													ng/mL	0.847			RECOMMENDED	drop	1		STEADY-STATE	UNKNOWN		day	1			UNKNOWN	Ocular	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203491s001lbl.pdf	Homo sapiens										false
2724	1397		ADULT	151075	254.2839	NEPAFENAC	nepafenac	NC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N	PLASMA	0J9L7J6V8C									∞	ng × h/mL	1.57		ng/mL	0.921			DEFINED DAILY	drop	1		SINGLE	UNKNOWN						HEALTHY	Ocular	FEMALE / MALE	REVIEW	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203491Orig1s000ClinPharmR.pdf#page=12	Homo sapiens		h	0.85				12			false
2725	1397		ADULT	151075	254.2839	NEPAFENAC	nepafenac	NC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N	PLASMA	0J9L7J6V8C									∞	ng × h/mL	1.43		ng/mL	0.847			DEFINED DAILY	drop	1		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Ocular	FEMALE / MALE	REVIEW	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203491Orig1s000ClinPharmR.pdf#page=12	Homo sapiens		h	0.74				12			false
2726	1397		ADULT	2136	255.2686	AMFENAC	amfenac	NC1=C(C=CC=C1CC(O)=O)C(=O)C2=CC=CC=C2	PLASMA	28O5C1J38A									∞	ng × h/mL	3.7		ng/mL	1.13			DEFINED DAILY	drop	1		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Ocular	FEMALE / MALE	REVIEW	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203491Orig1s000ClinPharmR.pdf#page=13	Homo sapiens		h	6.26				12			false
2727	1397		ADULT	2136	255.2686	AMFENAC	amfenac	NC1=C(C=CC=C1CC(O)=O)C(=O)C2=CC=CC=C2	PLASMA	28O5C1J38A									∞	ng × h/mL	3.6		ng/mL	1.15			DEFINED DAILY	drop	1		SINGLE	UNKNOWN						HEALTHY	Ocular	FEMALE / MALE	REVIEW	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203491Orig1s000ClinPharmR.pdf#page=13	Homo sapiens		h	5.49				12			false
2728	1398		ADULT	936	122.1246	NIACINAMIDE	NIACINAMIDE	NC(=O)C1=CC=CN=C1	PLASMA	25X51I8RD4	53232		LOVASTATIN	lovastatin	CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12	9LHU78OQFD	24		t	ng × h/mL	2669		ng/mL	213.2			INVESTIGATIONAL	mg	500		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://link.springer.com/article/10.1365/s10337-010-1645-3	Homo sapiens		h	15.9							true
2729	1399		ADULT	4477	327.12	NICLOSAMIDE	NICLOSAMIDE	OC1=C(C=C(Cl)C=C1)C(=O)NC2=C(Cl)C=C(C=C2)[N+]([O-])=O	PLASMA	8KK8CQ2K8G													μg/mL	0.665			DEFINED DAILY	g	2		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e14536	Homo sapiens										false
2730	1400		ADULT	4485	346.3346	NIFEDIPINE	NIFEDIPINE	COC(=O)C1=C(C)NC(C)=C(C1C2=C(C=CC=C2)[N+]([O-])=O)C(=O)OC	PLASMA	I9ZF7L6G2L									?	ng × h/mL	148		ng/mL	78.5			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3609112/	Homo sapiens		h	2.2							false
2731	1400		UNKNOWN	4485	346.3346	NIFEDIPINE	NIFEDIPINE	COC(=O)C1=C(C)NC(C)=C(C1C2=C(C=CC=C2)[N+]([O-])=O)C(=O)OC	PLASMA	I9ZF7L6G2L																	UNKNOWN				UNKNOWN	UNKNOWN				The degree of protein binding of nifedipine is high (92%-98%). Protein binding may be greatly reduced in patients with renal or hepatic impairment.	8	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020198s023lbl.pdf	Homo sapiens										false
2732	1401		ADULT	4493	317.22	NILUTAMIDE	NILUTAMIDE	CC1(C)NC(=O)N(C1=O)C2=CC(=C(C=C2)[N+]([O-])=O)C(F)(F)F	PLASMA	51G6I8B902													mg/L	2.3			DEFINED DAILY	g	0.3		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://gp2u.com.au/static/pdf/A/ANANDRON-PI.pdf	Homo sapiens		h	56							false
2733	1401		ADULT	4493	317.22	NILUTAMIDE	NILUTAMIDE	CC1(C)NC(=O)N(C1=O)C2=CC(=C(C=C2)[N+]([O-])=O)C(F)(F)F	PLASMA	51G6I8B902									∞	mg × h/L	84		mg/L	2.3			DEFINED DAILY	g	0.3		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/8453188	Homo sapiens		h	49							false
2734	1402		ADULT	4497	418.4403	NIMODIPINE	nimodipine	COCCOC(=O)C1=C(C)NC(C)=C(C1C2=CC(=CC=C2)[N+]([O-])=O)C(=O)OC(C)C	PLASMA	57WA9QZ5WH									∞	ng × h/mL	47.6		ng/mL	29			RECOMMENDED	mg	60		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7962672	Homo sapiens		h	2.27				12			false
2735	1402		ADULT	4497	418.4403	NIMODIPINE	nimodipine	COCCOC(=O)C1=C(C)NC(C)=C(C1C2=CC(=CC=C2)[N+]([O-])=O)C(=O)OC(C)C	PLASMA	57WA9QZ5WH									∞	nM × h	100		nM	20			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8249618	Homo sapiens		h	2.2				8			false
2736	1402		UNKNOWN	4497	418.4403	NIMODIPINE	nimodipine	COCCOC(=O)C1=C(C)NC(C)=C(C1C2=CC(=CC=C2)[N+]([O-])=O)C(=O)OC(C)C	PLASMA	57WA9QZ5WH																						UNKNOWN				Nimodipine is over 95% bound to plasma proteins. The binding was concentration independent over the range of 10 ng/mL to 10 ug/mL.	5	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/018869s014lbl.pdf	Homo sapiens										false
2737	1403		ADULT	4499	388.4144	NISOLDIPINE	NISOLDIPINE	COC(=O)C1=C(C)NC(C)=C(C1C2=C(C=CC=C2)[N+]([O-])=O)C(=O)OCC(C)C	PLASMA	4I8HAB65SZ									?	mg × h/mL/(mg dose/kg)	54		ng/mL	3.4			INVESTIGATIONAL	mg	20		SINGLE	UNKNOWN					0.27	HEALTHY	Oral	MALE	EXPERIMENT	https://link.springer.com/chapter/10.1007/978-3-642-73010-8_6	Homo sapiens		h	9.7							false
2738	1403		ADULT	4499	388.4144	NISOLDIPINE	NISOLDIPINE	COC(=O)C1=C(C)NC(C)=C(C1C2=C(C=CC=C2)[N+]([O-])=O)C(=O)OCC(C)C	PLASMA	4I8HAB65SZ							24		t	ng × h/mL	19.06		ng/mL	1.44			INVESTIGATIONAL	mg	20		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1634646/	Homo sapiens										false
2739	1403		ADULT	4499	388.4144	NISOLDIPINE	NISOLDIPINE	COC(=O)C1=C(C)NC(C)=C(C1C2=C(C=CC=C2)[N+]([O-])=O)C(=O)OCC(C)C	PLASMA	4I8HAB65SZ							24		t	ng × h/mL	29.42		ng/mL	2.26			INVESTIGATIONAL	mg	20		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1634646/	Homo sapiens		h	12.61							false
2740	1403		UNKNOWN	4499	388.4144	NISOLDIPINE	NISOLDIPINE	COC(=O)C1=C(C)NC(C)=C(C1C2=C(C=CC=C2)[N+]([O-])=O)C(=O)OCC(C)C	PLASMA	4I8HAB65SZ																	UNKNOWN				UNKNOWN	UNKNOWN		UNKNOWN			1	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020356s027lbl.pdf	Homo sapiens		h	13.7							false
2741	1404		ADULT	394397	265.25	TIZOXANIDE	TIZOXANIDE	C1=CC=C(C(=C1)C(=O)NC2=NC=C(S2)[N+](=O)[O-])O	PLASMA	15KFG88UOJ									∞	μg × h/mL	27.23		μg/mL	6.795			RECOMMENDED	mg	500		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22533565	Homo sapiens		h	1.38							false
2742	1404		ADOLESCENT	394397	265.25	TIZOXANIDE	TIZOXANIDE	C1=CC=C(C(=C1)C(=O)NC2=NC=C(S2)[N+](=O)[O-])O	PLASMA	15KFG88UOJ									?	μg × h/mL	39.5		μg/mL	9.1			RECOMMENDED	mg	500		SINGLE	FED				In plasma, more than 99% of tizoxanide is bound to proteins	1	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021497s001,021498s004lbl.pdf	Homo sapiens										false
2743	1405		UNKNOWN	115355	329.2281	NITISINONE	NITISINONE	[O-][N+](=O)C1=CC(=CC=C1C(=O)C2C(=O)CCCC2=O)C(F)(F)F	PLASMA	K5BN214699							120		t	ng × h/mL	77874		ng/mL	1278			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209449s000lbl.pdf	Homo sapiens										false
2744	1406		ADOLESCENT	3033637	331.457	NIZATIDINE	NIZATIDINE	CNC(NCCSCC1=CSC(CN(C)C)=N1)=C[N+]([O-])=O	PLASMA	P41PML4GHR							8		t	ng × h/mL	3764.2		ng/mL	1422.9			RECOMMENDED	mg	150		SINGLE	UNKNOWN				Approximately 35% of nizatidine is bound to plasma protein, mainly to a1-acid glycoprotein.	65	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/21494s001lbl.pdf	Homo sapiens		h	1.2							false
2745	1406		ADOLESCENT	3033637	331.457	NIZATIDINE	NIZATIDINE	CNC(NCCSCC1=CSC(CN(C)C)=N1)=C[N+]([O-])=O	PLASMA	P41PML4GHR							8		t	ng × h/mL	3776.1		ng/mL	1480.2			RECOMMENDED	mg	150		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/21494s001lbl.pdf	Homo sapiens		h	1.3							false
2746	1406		ADULT	3033637	331.457	NIZATIDINE	NIZATIDINE	CNC(NCCSCC1=CSC(CN(C)C)=N1)=C[N+]([O-])=O	PLASMA	P41PML4GHR							8		t	ng × h/mL	3703.1		ng/mL	1367.6			RECOMMENDED	mg	150		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/21494s001lbl.pdf	Homo sapiens		h	1.4							false
2747	1407		ADULT	4583|3288597	361.3675	OFLOXACIN	OFLOXACIN	CC1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N4CCN(C)CC4	PLASMA	A4P49JAZ9H									∞	μg × h/mL	14.1		μg/mL	1.5			RECOMMENDED	mg	200		SINGLE	UNKNOWN				In vitro, approximately 32% of the drug in plasma is protein bound.	68	HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019735s059lbl.pdf	Homo sapiens										false
2748	1407		ADULT	4583|3288597	361.3675	OFLOXACIN	OFLOXACIN	CC1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N4CCN(C)CC4	PLASMA	A4P49JAZ9H									∞	μg × h/mL	21.2		μg/mL	2.4			RECOMMENDED	mg	300		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019735s059lbl.pdf	Homo sapiens										false
2749	1407		ADULT	4583|3288597	361.3675	OFLOXACIN	OFLOXACIN	CC1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N4CCN(C)CC4	PLASMA	A4P49JAZ9H									∞	μg × h/mL	31.4		μg/mL	2.9			DEFINED DAILY	mg	400		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019735s059lbl.pdf	Homo sapiens										false
2750	1407		ADULT	4583|3288597	361.3675	OFLOXACIN	OFLOXACIN	CC1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N4CCN(C)CC4	PLASMA	A4P49JAZ9H									∞	μg × h/mL	61		μg/mL	4.6			DEFINED DAILY	mg	400		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019735s059lbl.pdf	Homo sapiens		h	22.5							false
2751	1407		ADULT	4583|3288597	361.3675	OFLOXACIN	OFLOXACIN	CC1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N4CCN(C)CC4	PLASMA	A4P49JAZ9H							12		t	μg × h/mL	43.5						DEFINED DAILY	mg	400		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Intravenous	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019735s059lbl.pdf	Homo sapiens										false
2752	1407		ADULT	4583|3288597	361.3675	OFLOXACIN	OFLOXACIN	CC1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N4CCN(C)CC4	PLASMA	A4P49JAZ9H							12		t	μg × h/mL	41.2						DEFINED DAILY	mg	400		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019735s059lbl.pdf	Homo sapiens										false
2753	1408		ADULT	158781	446.5016	OLMESARTAN	olmesartan	CCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=C(C=CC=C3)C4=NN=NN4)C(O)=O)C(C)(C)O	PLASMA	8W1IQP3U10									?	ng × h/mL	5975		ng/mL	2204			UNKNOWN	mg	8		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11451211	Homo sapiens		h	14.5							false
2754	1409		ADULT	3034010	495.7348	ORLISTAT	ORLISTAT	CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O	PLASMA	95M8R751W8							10		t	ng × eq × h/mL	907		ng × eq/mL	150			DEFINED DAILY	mg	360		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8973989	Homo sapiens										false
2755	1409		UNKNOWN	3034010	495.7348	ORLISTAT	ORLISTAT	CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O	PLASMA	95M8R751W8																						UNKNOWN				In vitro orlistat was 99% bound to plasma proteins (lipoproteins and albumin were major binding proteins).	1	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020766s029lbl.pdf	Homo sapiens		h	1.5							false
2756	1410		ADULT	449381|44310478	284.3514	OSELTAMIVIR ACID	OSELTAMIVIR ACID	CCC(CC)O[C@@H]1C=C(C[C@H](N)[C@H]1NC(C)=O)C(O)=O	PLASMA	K6106LV5Q8									∞	μg × h/L	6069		μg/L	441			DEFINED DAILY	mg	150		SINGLE	FED						HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/10628898/	Homo sapiens		h	8.2							false
2757	1410		ADULT	449381|44310478	284.3514	OSELTAMIVIR ACID	OSELTAMIVIR ACID	CCC(CC)O[C@@H]1C=C(C[C@H](N)[C@H]1NC(C)=O)C(O)=O	PLASMA	K6106LV5Q8									∞	μg × h/L	6218		μg/L	551			DEFINED DAILY	mg	150		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/10628898/	Homo sapiens		h	6.87							false
2758	1410		ADULT	449381|44310478	284.3514	OSELTAMIVIR ACID	OSELTAMIVIR ACID	CCC(CC)O[C@@H]1C=C(C[C@H](N)[C@H]1NC(C)=O)C(O)=O	PLASMA	K6106LV5Q8							12		t	μg × h/L	2107		μg/L	230			UNKNOWN	mg	50		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/10628898/	Homo sapiens										false
2759	1410		ADULT	449381|44310478	284.3514	OSELTAMIVIR ACID	OSELTAMIVIR ACID	CCC(CC)O[C@@H]1C=C(C[C@H](N)[C@H]1NC(C)=O)C(O)=O	PLASMA	K6106LV5Q8							12		t	μg × h/L	3845		μg/L	439			UNKNOWN	mg	100		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/10628898/	Homo sapiens										false
2760	1410		ADULT	449381|44310478	284.3514	OSELTAMIVIR ACID	OSELTAMIVIR ACID	CCC(CC)O[C@@H]1C=C(C[C@H](N)[C@H]1NC(C)=O)C(O)=O	PLASMA	K6106LV5Q8							12		t	μg × h/L	8612		μg/L	1132			UNKNOWN	mg	200		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/10628898/	Homo sapiens										false
2761	1410		ADULT	449381|44310478	284.3514	OSELTAMIVIR ACID	OSELTAMIVIR ACID	CCC(CC)O[C@@H]1C=C(C[C@H](N)[C@H]1NC(C)=O)C(O)=O	PLASMA	K6106LV5Q8							12		t	μg × h/L	20317		μg/L	2458			UNKNOWN	mg	500		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/10628898/	Homo sapiens										false
2762	1410		UNKNOWN	449381|44310478	284.3514	OSELTAMIVIR ACID	OSELTAMIVIR ACID	CCC(CC)O[C@@H]1C=C(C[C@H](N)[C@H]1NC(C)=O)C(O)=O	PLASMA	K6106LV5Q8							12		t	ng × h/mL	2719		ng/mL	348			RECOMMENDED	mg	75		MULTIPLE	UNKNOWN		day	2	The binding of oseltamivir carboxylate to human plasma protein is low (3%).	97	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021087s062lbl.pdf	Homo sapiens		h	8							false
2763	1411		ADULT	4616	286.713	OXAZEPAM	OXAZEPAM	OC1N=C(C2=CC=CC=C2)C3=C(NC1=O)C=CC(Cl)=C3	PLASMA	6GOW6DWN2A													ng/mL	268			RECOMMENDED	mg	15		SINGLE	FASTED					5.1	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1867967	Homo sapiens		h	5.7							false
2764	1411		ADULT	4616	286.713	OXAZEPAM	OXAZEPAM	OC1N=C(C2=CC=CC=C2)C3=C(NC1=O)C=CC(Cl)=C3	PLASMA	6GOW6DWN2A							24		t	ng × h/mL	4737		ng/mL	288			RECOMMENDED	mg	10		MULTIPLE	FASTED		day	3		2	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7981015	Homo sapiens										false
2765	1412			114709	254.28	LICARBAZEPINE	10-hydroxy-carbazepine	C1C(C2=CC=CC=C2N(C3=CC=CC=C31)C(=O)N)O	PLASMA	XFX1A5KJ3V													ng/mL	9349.83				mg	600		SINGLE	FED							Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00849797	Homo sapiens										false
2766	1412			114709	254.28	LICARBAZEPINE	10-hydroxy-carbazepine	C1C(C2=CC=CC=C2N(C3=CC=CC=C31)C(=O)N)O	PLASMA	XFX1A5KJ3V									∞	ng × h/mL	197864.34							mg	600		SINGLE	FED							Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00849797	Homo sapiens										false
2767	1412			114709	254.28	LICARBAZEPINE	10-hydroxy-carbazepine	C1C(C2=CC=CC=C2N(C3=CC=CC=C31)C(=O)N)O	PLASMA	XFX1A5KJ3V							48		t	ng × h/mL	179002.4							mg	600		SINGLE	FED							Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00849797	Homo sapiens										false
2768	1412			34312	252.268	OXCARBAZEPINE	OXCARBAZEPINE	NC(=O)N1C2=C(CC(=O)C3=C1C=CC=C3)C=CC=C2	PLASMA	VZI5B1W380													ng/mL	3537.63				mg	600		SINGLE	FED							Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00849797	Homo sapiens										false
2769	1412			34312	252.268	OXCARBAZEPINE	OXCARBAZEPINE	NC(=O)N1C2=C(CC(=O)C3=C1C=CC=C3)C=CC=C2	PLASMA	VZI5B1W380									∞	ng × h/mL	9679.79							mg	600		SINGLE	FED							Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00849797	Homo sapiens										false
2770	1412			34312	252.268	OXCARBAZEPINE	OXCARBAZEPINE	NC(=O)N1C2=C(CC(=O)C3=C1C=CC=C3)C=CC=C2	PLASMA	VZI5B1W380							48		t	ng × h/mL	9445.55							mg	600		SINGLE	FED							Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00849797	Homo sapiens										false
2771	1412			34312	252.268	OXCARBAZEPINE	OXCARBAZEPINE	NC(=O)N1C2=C(CC(=O)C3=C1C=CC=C3)C=CC=C2	PLASMA	VZI5B1W380													ng/mL	1630.3				mg	600		SINGLE	FASTED							Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00850174	Homo sapiens										false
2772	1412			114709	254.28	LICARBAZEPINE	10-hydroxy-carbazepine	C1C(C2=CC=CC=C2N(C3=CC=CC=C31)C(=O)N)O	PLASMA	XFX1A5KJ3V													ng/mL	7119				mg	600		SINGLE	FASTED							Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00850174	Homo sapiens										false
2773	1412			114709	254.28	LICARBAZEPINE	10-hydroxy-carbazepine	C1C(C2=CC=CC=C2N(C3=CC=CC=C31)C(=O)N)O	PLASMA	XFX1A5KJ3V									∞	ng × h/mL	173770							mg	600		SINGLE	FASTED							Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00850174	Homo sapiens										false
2774	1412			114709	254.28	LICARBAZEPINE	10-hydroxy-carbazepine	C1C(C2=CC=CC=C2N(C3=CC=CC=C31)C(=O)N)O	PLASMA	XFX1A5KJ3V							48		t	ng × h/mL	157372							mg	600		SINGLE	FASTED							Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00850174	Homo sapiens										false
2775	1412			34312	252.268	OXCARBAZEPINE	OXCARBAZEPINE	NC(=O)N1C2=C(CC(=O)C3=C1C=CC=C3)C=CC=C2	PLASMA	VZI5B1W380									∞	ng × h/mL	5873.1							mg	600		SINGLE	FASTED							Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00850174	Homo sapiens										false
2776	1412			34312	252.268	OXCARBAZEPINE	OXCARBAZEPINE	NC(=O)N1C2=C(CC(=O)C3=C1C=CC=C3)C=CC=C2	PLASMA	VZI5B1W380							48		t	ng × h/mL	5309.5							mg	600		SINGLE	FASTED							Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00850174	Homo sapiens										false
2777	1412		ADULT	34312	252.268	OXCARBAZEPINE	oxcarbazepine	NC(=O)N1C2=C(CC(=O)C3=C1C=CC=C3)C=CC=C2	PLASMA	VZI5B1W380							12		t	μg × h/mL	3.76		μg/mL	1.55			UNKNOWN	mg	300		MULTIPLE	FASTED		day	2		27	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26514967	Homo sapiens		h	2.38							false
2778	1413		ADULT	5353853	429.127	OXICONAZOLE	OXICONAZOLE	ClC1=CC=C(CO\\N=C(/CN2C=CN=C2)C3=C(Cl)C=C(Cl)C=C3)C(Cl)=C1	NAIL	C668Q9I33J							1344		t	ng × week/mg	1160		ng/mL	635			RECOMMENDED	%	1		MULTIPLE	UNKNOWN		day	2			HEALTHY	Topical	UNKNOWN	REVIEW	https://books.google.ru/books?id=Bw7MBQAAQBAJ&pg=PA201&lpg=PA201&dq=OXICONAZOLE+auc&source=bl&ots=8jqe8Z_yRv&sig=ACfU3U17TASx7dLz-CCSZUXreFaVrPmdDg&hl=en&sa=X&ved=2ahUKEwil3s2u5I3sAhXxk4sKHRGjDmYQ6AEwEnoECAEQAQ#v=onepage&q=OXICONAZOLE%20auc&f=false	Homo sapiens										false
2779	1413		UNKNOWN	5353853	429.127	OXICONAZOLE	OXICONAZOLE	ClC1=CC=C(CO\\N=C(/CN2C=CN=C2)C3=C(Cl)C=C(Cl)C=C3)C(Cl)=C1	UNKNOWN	C668Q9I33J																						UNKNOWN						UNKNOWN		UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30210010	Homo sapiens		h	4							false
2780	1414		ADULT	198082	265.35	(S)-(-)-Oxprenolol	(S)-(-)-Oxprenolol	CC(C)NC[C@@H](COC1=CC=CC=C1OCC=C)O	BLOOD										∞	μg × min/mL	60.7						UNKNOWN	mg	80		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7712670	Homo sapiens		min	108.4							false
2781	1414		ADULT	94423	265.35	(R)-(+)-Oxprenolol	(R)-(+)-Oxprenolol	CC(C)NC[C@H](COC1=CC=CC=C1OCC=C)O	PLASMA										∞	μg × min/mL	73.1						UNKNOWN	mg	80		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7712670	Homo sapiens		min	111.6							false
2782	1417		ADULT	5281104	416.6365	PARICALCITOL	PARICALCITOL	C[C@H](\\C=C\\[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\\C2=C/C=C3C[C@@H](O)C[C@H](O)C3	PLASMA	6702D36OG5									∞	ng × h/mL	2.42		ng/mL	0.11			RECOMMENDED	μg	1		MULTIPLE	UNKNOWN		day	1	Paricalcitol is extensively bound to plasma proteins (≥99.8%).	0.2	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021606s016s017lbl.pdf	Homo sapiens		h	16.8							false
2783	1417		ADOLESCENT	5281104	416.6365	PARICALCITOL	PARICALCITOL	C[C@H](\\C=C\\[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\\C2=C/C=C3C[C@@H](O)C[C@H](O)C3	PLASMA	6702D36OG5									∞	ng × h/mL	2.63		ng/mL	0.12			RECOMMENDED	μg	1		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021606s016s017lbl.pdf	Homo sapiens		h	15							false
2784	1418		UNKNOWN	446556|5288715|135410875	427.4106	PEMETREXED	PEMETREXED	NC1=NC2=C(C(CCC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CN2)C(=O)N1	PLASMA	04Q9AIZ7NO																						UNKNOWN				In vitro studies indicate that pemetrexed is approximately 81% bound to plasma proteins.	19	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021462s021lbl.pdf	Homo sapiens										false
2785	1418		ADULT	446556|5288715|135410875	427.4106	PEMETREXED	PEMETREXED	NC1=NC2=C(C(CCC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CN2)C(=O)N1	BLOOD	04Q9AIZ7NO									∞	μg × h/mL	164		μg/mL	137			UNKNOWN	mg/m²	500	infusion, 10 min	OTHER	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/16391300	Homo sapiens		h	3.71							false
2786	1419		UNKNOWN	439693	268.2691	PENTOSTATIN	PENTOSTATIN	OC[C@H]1O[C@H](C[C@@H]1O)N2C=NC3=C2N=CNC[C@H]3O	PLASMA	395575MZO7																	RECOMMENDED	mg/m²	4		SINGLE	UNKNOWN						UNKNOWN	Intravenous	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020122s015lbl.pdf	Homo sapiens		h	5.7							false
2787	1419		ADULT	439693	268.2691	PENTOSTATIN	PENTOSTATIN	OC[C@H]1O[C@H](C[C@@H]1O)N2C=NC3=C2N=CNC[C@H]3O	PLASMA	395575MZO7							14		t	μg × h/L	363.3		μg/L	102.2			RECOMMENDED	mg/m²	1.5		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/23588536	Homo sapiens										false
2788	1420		ADULT	4740	278.307	PENTOXIFYLLINE	PENTOXIFYLLINE	CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C	PLASMA	SD6QCT3TSU							24		t	ng × h/mL	4842		ng/mL	719			RECOMMENDED	mg	600		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23400743	Homo sapiens										false
2789	1420		ADULT	4740	278.307	PENTOXIFYLLINE	PENTOXIFYLLINE	CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C	PLASMA	SD6QCT3TSU							10		t	ng × h/mL	193		ng/mL	272			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3958905	Homo sapiens		h	0.48							false
2790	1420		ADULT	4740	278.307	PENTOXIFYLLINE	PENTOXIFYLLINE	CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C	PLASMA	SD6QCT3TSU							10		t	ng × h/mL	380		ng/mL	683			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3958905	Homo sapiens		h	0.39							false
2791	1420		ADULT	4740	278.307	PENTOXIFYLLINE	PENTOXIFYLLINE	CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C	PLASMA	SD6QCT3TSU							10		t	ng × h/mL	1228		ng/mL	1607			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3958905	Homo sapiens		h	0.84							false
2792	1422		ADULT	4768	303.8	PHENOXYBENZAMINE	PHENOXYBENZAMINE	CC(COC1=CC=CC=C1)N(CCCl)CC2=CC=CC=C2	PLASMA	0TTZ664R7Z									?	pg × h/mL	3746.5		pg/mL	3332.3			RECOMMENDED	mg	10		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.scientiaricerca.com/srcops/SRCOPS-02-00048.php	Homo sapiens		h	1.54							false
2793	1424		ADULT	57633863	810.453	PIMECROLIMUS	pimecrolimus	CC[C@@H]1\\C=C(C)\\C[C@H](C)C[C@H](OC)[C@H]2O[C@](O)([C@H](C)C[C@@H]2OC)C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@H](C)[C@@H](O)CC1=O)C(\\C)=C\\[C@@H]4CC[C@H](Cl)[C@@H](C4)OC	PLASMA	7KYV510875									∞	μg × h/L	24.4		μg/L	10.5			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/14606933	Homo sapiens		h	11.5							false
2794	1424		ADULT	57633863	810.453	PIMECROLIMUS	pimecrolimus	CC[C@@H]1\\C=C(C)\\C[C@H](C)C[C@H](OC)[C@H]2O[C@](O)([C@H](C)C[C@@H]2OC)C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@H](C)[C@@H](O)CC1=O)C(\\C)=C\\[C@@H]4CC[C@H](Cl)[C@@H](C4)OC	PLASMA	7KYV510875									∞	μg × h/L	159		μg/L	43.3			UNKNOWN	mg	15		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/14606933	Homo sapiens		h	10.5							false
2795	1424		ADULT	57633863	810.453	PIMECROLIMUS	pimecrolimus	CC[C@@H]1\\C=C(C)\\C[C@H](C)C[C@H](OC)[C@H]2O[C@](O)([C@H](C)C[C@@H]2OC)C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@H](C)[C@@H](O)CC1=O)C(\\C)=C\\[C@@H]4CC[C@H](Cl)[C@@H](C4)OC	PLASMA	7KYV510875									∞	μg × h/L	377		μg/L	79			UNKNOWN	mg	30		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/14606933	Homo sapiens		h	42.6							false
2796	1424		ADULT	57633863	810.453	PIMECROLIMUS	pimecrolimus	CC[C@@H]1\\C=C(C)\\C[C@H](C)C[C@H](OC)[C@H]2O[C@](O)([C@H](C)C[C@@H]2OC)C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@H](C)[C@@H](O)CC1=O)C(\\C)=C\\[C@@H]4CC[C@H](Cl)[C@@H](C4)OC	PLASMA	7KYV510875									∞	μg × h/L	966.1		μg/L	147.5			UNKNOWN	mg	60		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/14606933	Homo sapiens		h	35							false
2797	1424		ADULT	57633863	810.453	PIMECROLIMUS	pimecrolimus	CC[C@@H]1\\C=C(C)\\C[C@H](C)C[C@H](OC)[C@H]2O[C@](O)([C@H](C)C[C@@H]2OC)C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@H](C)[C@@H](O)CC1=O)C(\\C)=C\\[C@@H]4CC[C@H](Cl)[C@@H](C4)OC	BLOOD	7KYV510875							24		t	ng × h/mL	18.57		ng/mL	0.89			RECOMMENDED	%	1		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Topical	FEMALE / MALE	DRUG LABEL	https://pubmed.ncbi.nlm.nih.gov/21099191	Homo sapiens										false
2798	1424		UNKNOWN	57633863	810.453	PIMECROLIMUS	pimecrolimus	CC[C@@H]1\\C=C(C)\\C[C@H](C)C[C@H](OC)[C@H]2O[C@](O)([C@H](C)C[C@@H]2OC)C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@H](C)[C@@H](O)CC1=O)C(\\C)=C\\[C@@H]4CC[C@H](Cl)[C@@H](C4)OC	PLASMA	7KYV510875																						UNKNOWN				Laboratory in vitro plasma protein binding studies using equilibrium gel filtration have shown that 99.5% of pimecrolimus in plasma is bound to proteins over the pimecrolimus concentration range of 2-100 ng/mL tested.	0.5	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021302s018lbl.pdf	Homo sapiens										false
2799	1425		ADULT	16362	461.5462	PIMOZIDE	PIMOZIDE	FC1=CC=C(C=C1)C(CCCN2CCC(CC2)N3C(=O)NC4=C3C=CC=C4)C5=CC=C(F)C=C5	PLASMA	1HIZ4DL86F									?	mg × h/L	0.261						RECOMMENDED	mg	2		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3480904	Homo sapiens		h	109							false
2800	1425		CHILD	16362	461.5462	PIMOZIDE	PIMOZIDE	FC1=CC=C(C=C1)C(CCCN2CCC(CC2)N3C(=O)NC4=C3C=CC=C4)C5=CC=C(F)C=C5	PLASMA	1HIZ4DL86F									?	mg × h/L	0.347						RECOMMENDED	mg	2		SINGLE	FASTED						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3480904	Homo sapiens		h	57							false
2801	1426		ADULT	5282452	421.4608	PITAVASTATIN	PITAVASTATIN	O[C@H](C[C@H](O)\\C=C\\C1=C(C2=CC=C(F)C=C2)C3=C(C=CC=C3)N=C1C4CC4)CC(O)=O	BLOOD	M5681Q5F9P									?	ng × h/mL	329.96		ng/mL	113			DEFINED DAILY	mg	2		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26082816	Homo sapiens		h	9.95							false
2802	1426		ADULT	5282452	421.4608	PITAVASTATIN	PITAVASTATIN	O[C@H](C[C@H](O)\\C=C\\C1=C(C2=CC=C(F)C=C2)C3=C(C=CC=C3)N=C1C4CC4)CC(O)=O	BLOOD	M5681Q5F9P									?	ng × h/mL	285.77		ng/mL	98.4			DEFINED DAILY	mg	2		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26082816	Homo sapiens		h	9.08							false
2803	1427		ADULT	10607	414.4053	PODOFILOX	PODOFILOX	COC1=CC(=CC(OC)=C1OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@@H](O)C4=C2C=C5OCOC5=C4	PLASMA	L36H50F353													ng/mL	17			RECOMMENDED	mL	1.5		SINGLE	UNKNOWN						UNHEALTHY	Topical	UNKNOWN	DRUG LABEL	https://www.drugs.com/pro/podofilox.html	Homo sapiens		h	4.5							false
2804	1428		ADULT	4870	439.882	POLYTHIAZIDE	POLYTHIAZIDE	CN1C(CSCC(F)(F)F)NC2=C(C=C(C(Cl)=C2)S(N)(=O)=O)S1(=O)=O	PLASMA	36780APV5N							18		t	ng × h/mL	55.7		ng/mL	3.33			RECOMMENDED	mg	1		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/620486/	Homo sapiens		h	25.7							false
2805	1429		ADULT	468595	700.8	Posaconazole		CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F	PLASMA	6TK1G07BHZ							24		t	ng × h/mL	36100		ng/mL	3280			RECOMMENDED	mg	300		MULTIPLE	UNKNOWN		day	1		2	UNHEALTHY	Intravenous	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022003s018s020,0205053s002s004,0205596s001s003lbl.pdf	Homo sapiens										false
2806	1429		ADULT	21910730	700.7774	[NO STEREO] POSACONAZOLE	CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F	CCC(C(C)O)N1N=CN(C1=O)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(OCC5COC(CN6C=NC=N6)(C5)C7=C(F)C=C(F)C=C7)C=C4	PLASMA	[NO STEREO] 6TK1G07BHZ									∞	ng × h/mL	46400		ng/mL	2840			RECOMMENDED	mg	300		SINGLE	UNKNOWN					2	HEALTHY	Intravenous	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022003s018s020,0205053s002s004,0205596s001s003lbl.pdf	Homo sapiens		h	24.6							false
2807	1429		ADULT	21910730	700.7774	[NO STEREO] POSACONAZOLE	CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F	CCC(C(C)O)N1N=CN(C1=O)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(OCC5COC(CN6C=NC=N6)(C5)C7=C(F)C=C(F)C=C7)C=C4	PLASMA	[NO STEREO] 6TK1G07BHZ							24		t	ng × h/mL	51618		ng/mL	2764			RECOMMENDED	mg	300		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022003s018s020,0205053s002s004,0205596s001s003lbl.pdf	Homo sapiens		h	31							false
2808	1429		ADULT	21910730	700.7774	[NO STEREO] POSACONAZOLE	CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F	CCC(C(C)O)N1N=CN(C1=O)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(OCC5COC(CN6C=NC=N6)(C5)C7=C(F)C=C(F)C=C7)C=C4	PLASMA	[NO STEREO] 6TK1G07BHZ							12		t	ng × h/mL	9093						RECOMMENDED	mg	400		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022003s018s020,0205053s002s004,0205596s001s003lbl.pdf	Homo sapiens		h	31.7							false
2809	1429		ADULT	21910730	700.7774	[NO STEREO] POSACONAZOLE	CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F	CCC(C(C)O)N1N=CN(C1=O)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(OCC5COC(CN6C=NC=N6)(C5)C7=C(F)C=C(F)C=C7)C=C4	PLASMA	[NO STEREO] 6TK1G07BHZ							72		t	ng × h/mL	26200		ng/mL	935			RECOMMENDED	mg	300		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022003s018s020,0205053s002s004,0205596s001s003lbl.pdf	Homo sapiens										false
2810	1429		ADULT	21910730	700.7774	[NO STEREO] POSACONAZOLE	CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F	CCC(C(C)O)N1N=CN(C1=O)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(OCC5COC(CN6C=NC=N6)(C5)C7=C(F)C=C(F)C=C7)C=C4	PLASMA	[NO STEREO] 6TK1G07BHZ							72		t	ng × h/mL	38400		ng/mL	1060			RECOMMENDED	mg	300		SINGLE	FED						HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022003s018s020,0205053s002s004,0205596s001s003lbl.pdf	Homo sapiens										false
2811	1430		ADULT	4890	324.804	PRAZEPAM	PRAZEPAM	ClC1=CC=C2N(CC3CC3)C(=O)CN=C(C4=CC=CC=C4)C2=C1	PLASMA	Q30VCC064M							6		t	ng × h/mL	36		ng/mL	20			UNKNOWN	mg	30		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/387419/	Homo sapiens		h	1.31							false
2812	1431		ADULT		432.5067	PREDNISOLONE 17-ETHYL CARBONATE	PREDNISOLONE 17-ETHYL CARBONATE	CCOC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)CO	SERUM	4Z4G5V1592									?	ng × h/mL	402		ng/mL	158.4			UNKNOWN	mg	40		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8274287/	Homo sapiens										false
2813	1431		ADULT	5755	360.444	PREDNISOLONE	prednisolone	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO	SERUM	9PHQ9Y1OLM									?	ng × h/mL	251		ng/mL	43.1			UNKNOWN	mg	40		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8274287/	Homo sapiens										false
2814	1432		ADULT	5865	358.4	PREDNISONE	PREDNISONE	C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO	PLASMA	VB0R961HZT							12		t	μg × h/L	97		μg/L	15.4			RECOMMENDED	mg	20		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/17925494	Homo sapiens		h	3.85							false
2815	1432		UNKNOWN	5865	358.4281	PREDNISONE	PREDNISONE	C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO	PLASMA	VB0R961HZT																						UNKNOWN				Prednisone is <50% bound to protein in plasma	50	UNKNOWN		UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/2199128	Homo sapiens										false
2816	1433		ADULT	5486971|25271887	159.2261	PREGABALIN	CC(C)C[C@H](CN)CC(O)=O	CC(C)C[C@H](CN)CC(O)=O	PLASMA	55JG375S6M																					UNKNOWN	UNKNOWN						UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021446s035,022488s013lbl.pdf	Homo sapiens		h	6.3							false
2817	1433		ADULT	5486971|25271887	159.2261	PREGABALIN	CC(C)C[C@H](CN)CC(O)=O	CC(C)C[C@H](CN)CC(O)=O	PLASMA	55JG375S6M									∞	ng × h/mL	29831.454		ng/mL	4568.68			RECOMMENDED	mg	150		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/28513426	Homo sapiens										false
2818	1434		ADULT	4909	218.25	PRIMIDONE	PRIMIDONE	CCC1(C(=O)NCNC1=O)C2=CC=CC=C2	PLASMA	13AFD7670Q									∞	μg × h/mL	140.5		μg/mL	4.45			UNKNOWN	mg	250		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/9688064	Homo sapiens		h	21.9							false
2819	1435		ADULT	4911	285.359	PROBENECID	PROBENECID	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	PLASMA	PO572Z7917							48		t	μg × h/mL	292		μg/mL	35.3			DEFINED DAILY	mg	500		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7175716/	Homo sapiens		h	4.2							false
2820	1435		ADULT	4911	285.359	PROBENECID	probenecid	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	PLASMA	PO572Z7917							48		t	μg × h/mL	772		μg/mL	69.6			DEFINED DAILY	mg	1000		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7175716/	Homo sapiens		h	4.9							false
2821	1435		ADULT	4911	285.359	PROBENECID	PROBENECID	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	PLASMA	PO572Z7917							48		t	μg × h/mL	2109		μg/mL	148.6			UNKNOWN	mg	2000		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7175716/	Homo sapiens		h	8.5							false
2822	1436		ADULT	4912	516.842	PROBUCOL	CC(C)(SC1=CC(=C(O)C(=C1)C(C)(C)C)C(C)(C)C)SC2=CC(=C(O)C(=C2)C(C)(C)C)C(C)(C)C	CC(C)(SC1=CC(=C(O)C(=C1)C(C)(C)C)C(C)(C)C)SC2=CC(=C(O)C(=C2)C(C)(C)C)C(C)(C)C	PLASMA	P3CTH044XJ							648		t	ng × h/mL	139400		ng/mL	1706			UNKNOWN	mg	250		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/19922880	Homo sapiens		h	177.5							false
2823	1437		ADULT	4913	235.3253	PROCAINAMIDE	PROCAINAMIDE	CCN(CC)CCNC(=O)C1=CC=C(N)C=C1	PLASMA	L39WTC366D									∞	μg × h/mL	18.22		μg/mL	1.211			UNKNOWN	mg	1000		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20545s007_Procanbid_biopharmr.pdf	Homo sapiens										false
2824	1437		ADULT	4913	235.3253	PROCAINAMIDE	PROCAINAMIDE	CCN(CC)CCNC(=O)C1=CC=C(N)C=C1	PLASMA	L39WTC366D									∞	μg × h/mL	18.34		μg/mL	1.303			UNKNOWN	mg	1000		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20545s007_Procanbid_biopharmr.pdf	Homo sapiens										false
2825	1437		ADULT	4342	277.362	ACECAINIDE	ACECAINIDE	CCN(CC)CCNC(=O)C1=CC=C(NC(C)=O)C=C1	PLASMA	910Q707V6F									∞	μg × h/mL	15.165		μg/mL	0.514			UNKNOWN	mg	1000		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20545s007_Procanbid_biopharmr.pdf	Homo sapiens										false
2826	1437		ADULT	4342	277.362	ACECAINIDE	ACECAINIDE	CCN(CC)CCNC(=O)C1=CC=C(NC(C)=O)C=C1	PLASMA	910Q707V6F									∞	μg × h/mL	15.897		μg/mL	0.581			UNKNOWN	mg	1000		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20545s007_Procanbid_biopharmr.pdf	Homo sapiens										false
2827	1438		ADULT	207841|657394	323.901	PROCYCLIDINE HYDROCHLORIDE	PROCYCLIDINE HYDROCHLORIDE	Cl.OC(CCN1CCCC1)(C2CCCCC2)C3=CC=CC=C3	PLASMA	CQC932Z7YW									?	ng × h/mL	2705						UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3987788	Homo sapiens		h	11.5							false
2828	1438		ADULT	207841|657394	323.901	PROCYCLIDINE HYDROCHLORIDE	PROCYCLIDINE HYDROCHLORIDE	Cl.OC(CCN1CCCC1)(C2CCCCC2)C3=CC=CC=C3	PLASMA	CQC932Z7YW									?	ng × h/mL	2007		ng/mL	116			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3987788	Homo sapiens		h	12.6							false
2829	1439		ADULT	5994	314.5	PROGESTERONE	CC(=O)C1CCC2C3CCC4=CC(=O)CCC4(C)C3CCC12C	CC(=O)C1CCC2C3CCC4=CC(=O)CCC4(C)C3CCC12C	PLASMA	4G7DS2Q64Y|R94ZS616JR							10		t	ng × h/mL	175.7		ng/mL	60.6			DEFINED DAILY	mg	300		MULTIPLE	UNKNOWN		day	1			UNKNOWN	Oral	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019781s017,020843s011lbl.pdf	Homo sapiens										false
2830	1439		ADULT	5994	314.5	PROGESTERONE	CC(=O)C1CCC2C3CCC4=CC(=O)CCC4(C)C3CCC12C	CC(=O)C1CCC2C3CCC4=CC(=O)CCC4(C)C3CCC12C	PLASMA	4G7DS2Q64Y|R94ZS616JR							96		t	ng × h/mL	296.78		ng/mL	14.87			DEFINED DAILY	mg	90		SINGLE	UNKNOWN						HEALTHY	Vaginal	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020701s020s021s023lbl.pdf	Homo sapiens		h	34.8							false
2831	1439		ADULT	5994	314.5	PROGESTERONE	CC(=O)C1CCC2C3CCC4=CC(=O)CCC4(C)C3CCC12C	CC(=O)C1CCC2C3CCC4=CC(=O)CCC4(C)C3CCC12C	PLASMA	4G7DS2Q64Y|R94ZS616JR									?	ng × h/mL	391.98		ng/mL	15.97			DEFINED DAILY	mg	90		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Vaginal	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020701s020s021s023lbl.pdf	Homo sapiens		h	45							false
2832	1440		ADULT	4946	259.3434	PROPRANOLOL	PROPRANOLOL	CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1	PLASMA	9Y8NXQ24VQ									?	ng × h/mL	79		ng/mL	41			RECOMMENDED	mg	40		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9698776/	Homo sapiens		h	2.41							false
2833	1440		ADULT	4946	259.3434	PROPRANOLOL	PROPRANOLOL	CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1	PLASMA	9Y8NXQ24VQ									?	ng × h/mL	245		ng/mL	147			RECOMMENDED	mg	40		SINGLE	UNKNOWN						UNHEALTHY	Sublingual	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9698776/	Homo sapiens		h	0.91							false
2834	1440		ADULT	4946	259.3434	PROPRANOLOL	PROPRANOLOL	CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1	PLASMA	9Y8NXQ24VQ													ng/mL	161			RECOMMENDED	mg	40		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/016418s080,016762s017,017683s008lbl.pdf	Homo sapiens										false
2835	1440		ADULT	4946	259.3434	PROPRANOLOL	PROPRANOLOL	CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1	PLASMA	9Y8NXQ24VQ													ng/mL	47			RECOMMENDED	mg	40		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/016418s080,016762s017,017683s008lbl.pdf	Homo sapiens										false
2836	1440		ADULT	4946	259.3434	PROPRANOLOL	PROPRANOLOL	CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1	PLASMA	9Y8NXQ24VQ													ng/mL	26			RECOMMENDED	mg	40		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/016418s080,016762s017,017683s008lbl.pdf	Homo sapiens										false
2837	1441		ADULT	638678	362.3837	PROTIRELIN	Protirelin	NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC2=CNC=N2)NC(=O)[C@@H]3CCC(=O)N3	PLASMA	5Y5F15120W							5		t	ng × h/mL	347.6		ng/mL	9.5			RECOMMENDED	mg	0.5		SINGLE	FASTED						HEALTHY	Intramuscular	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/530100_7223401A1120_1_02B_1F.pdf#page=15	Homo sapiens		min	35.5				12	Protirelin tartrate monohydrate		false
2838	1442		UNKNOWN	7550|91696191	261.116	PYRIDOSTIGMINE BROMIDE	PYRIDOSTIGMINE BROMIDE	[Br-].CN(C)C(=O)OC1=CC=C[N+](C)=C1	UNKNOWN	KVI301NA53																	UNKNOWN				SINGLE	UNKNOWN				In vitro pyridostigmine bromide is significantly bound to human serum albumin (81.2+/-4.2% of the initial concentration).	18.8	UNKNOWN	UNKNOWN	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12029383	Homo sapiens										false
2839	1442		ADULT	7550|91696191	261.116	PYRIDOSTIGMINE BROMIDE	PYRIDOSTIGMINE BROMIDE	[Br-].CN(C)C(=O)OC1=CC=C[N+](C)=C1	PLASMA	KVI301NA53							24		t	ng × h/mL	819.999		ng/mL	176.03			UNKNOWN	mg	60		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://www.tandfonline.com/doi/abs/10.1080/10826070701540605	Homo sapiens		h	3.787							false
2840	1442		ADULT	7550|91696191	261.116	PYRIDOSTIGMINE BROMIDE	PYRIDOSTIGMINE BROMIDE	[Br-].CN(C)C(=O)OC1=CC=C[N+](C)=C1	PLASMA	KVI301NA53									∞	ng × h/mL	909.86						UNKNOWN	mg	60		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://www.tandfonline.com/doi/abs/10.1080/10826070701540605	Homo sapiens										false
2841	1443		UNKNOWN	4993	248.711	PYRIMETHAMINE	PYRIMETHAMINE	CCC1=NC(N)=NC(N)=C1C2=CC=C(Cl)C=C2	PLASMA	Z3614QOX8W																						UNKNOWN				Pyrimethamine is 87% bound to human plasma proteins.	13	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/8578s15lbl.pdf	Homo sapiens										false
2842	1443		ADULT	4993	248.71	PYRIMETHAMINE	PYRIMETHAMINE	CCC1=C(C(N)=NC(N)=N1)C2=CC=C(Cl)C=C2	PLASMA	Z3614QOX8W	35370		Zidovudine	Zidovudine	CC1=CN(C(=O)NC1=O)C2CC(C(O2)CO)N=[N+]=[N-]	4B9XT59T7S			∞	μg × h/mL	502.9		μg/mL	2.059			RECOMMENDED	mg	50		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/8726001	Homo sapiens		h	190.56							true
2843	1444		ADULT	5281025|25058200|139068372	883.086	QUETIAPINE FUMARATE	QUETIAPINE FUMARATE	OC(=O)\\C=C\\C(O)=O.OCCOCCN1CCN(CC1)C2=NC3=C(SC4=C2C=CC=C4)C=CC=C3.OCCOCCN5CCN(CC5)C6=NC7=C(SC8=C6C=CC=C8)C=CC=C7	PLASMA	2S3PL1B6UJ									?	ng × h/mL	187.44		ng/mL	58.23			UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25025989	Homo sapiens		h	3.86							false
2844	1444		ADULT	5281025|25058200|139068372	883.086	QUETIAPINE FUMARATE	QUETIAPINE FUMARATE	OC(=O)\\C=C\\C(O)=O.OCCOCCN1CCN(CC1)C2=NC3=C(SC4=C2C=CC=C4)C=CC=C3.OCCOCCN5CCN(CC5)C6=NC7=C(SC8=C6C=CC=C8)C=CC=C7	PLASMA	2S3PL1B6UJ									?	ng × h/mL	197.55		ng/mL	58.42			UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25025989	Homo sapiens		h	3.85							false
2845	1444		ADULT	5281025|25058200|139068372	883.086	QUETIAPINE FUMARATE	QUETIAPINE FUMARATE	OC(=O)\\C=C\\C(O)=O.OCCOCCN1CCN(CC1)C2=NC3=C(SC4=C2C=CC=C4)C=CC=C3.OCCOCCN5CCN(CC5)C6=NC7=C(SC8=C6C=CC=C8)C=CC=C7	PLASMA	2S3PL1B6UJ									?	ng × h/mL	190.39		ng/mL	60.11			UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25025989	Homo sapiens		h	3.98							false
2846	1444		UNKNOWN	5281025|25058200|139068372	883.086	QUETIAPINE FUMARATE	QUETIAPINE FUMARATE	OC(=O)\\C=C\\C(O)=O.OCCOCCN1CCN(CC1)C2=NC3=C(SC4=C2C=CC=C4)C=CC=C3.OCCOCCN5CCN(CC5)C6=NC7=C(SC8=C6C=CC=C8)C=CC=C7	PLASMA	2S3PL1B6UJ																	UNKNOWN				UNKNOWN	UNKNOWN				Quetiapine is widely distributed throughout the body with an apparent volume of distribution of 10+/-4 L/kg. It is 83% bound to plasma proteins at therapeutic concentrations.	17	UNKNOWN	UNKNOWN	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020639s070lbl.pdf	Homo sapiens										false
2847	1446		UNKNOWN	5029	359.443	RABEPRAZOLE	RABEPRAZOLE	COCCCOC1=CC=NC(C[S+]([O-])C2=NC3=C(N2)C=CC=C3)=C1C	PLASMA	32828355LL									?	μg × h/mL	0.809		μg/mL	0.406			DEFINED DAILY	mg	20		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	REVIEW	https://www.ncbi.nlm.nih.gov/pubmed/28294690	Homo sapiens		h	1.02				18			false
2848	1446		UNKNOWN	5029	359.443	RABEPRAZOLE	RABEPRAZOLE	COCCCOC1=CC=NC(C[S+]([O-])C2=NC3=C(N2)C=CC=C3)=C1C	PLASMA	32828355LL									?	μg × h/mL	5.212		μg/mL	2.5			UNKNOWN	mg	80		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	REVIEW	https://www.ncbi.nlm.nih.gov/pubmed/28294690	Homo sapiens		h	1.21				18			false
2849	1446		ADULT	5029	359.443	RABEPRAZOLE	RABEPRAZOLE	COCCCOC1=CC=NC(C[S+]([O-])C2=NC3=C(N2)C=CC=C3)=C1C	BLOOD	32828355LL									∞	ng × h/mL	2.15		ng/mL	1.54			UNKNOWN	mg	10		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/30321480	Homo sapiens		h	3.46							false
2850	1447		ADULT	208902	259.3434	RAMELTEON	RAMELTEON	CCC(=O)NCC[C@@H]1CCC2=CC=C3OCCC3=C12	SERUM	901AS54I69									∞	ng × h/mL	36.1		ng/mL	25.9			MAX DAILY	mg	64		SINGLE	FASTED				Seventy percent of the drug is bound in human serum albumin, accounting for most of the binding.	30	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16432265	Homo sapiens		h	1.9							false
2851	1448		ADULT	5362129|6992028	416.5106	RAMIPRIL	RAMIPRIL	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@H]3CCC[C@H]3C[C@H]2C(O)=O	PLASMA	L35JN3I7SJ							24		t	ng × h/mL	197		ng/mL	43.8			UNKNOWN	mg	5		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/2533075	Homo sapiens										false
2852	1448		ADULT	5464096	388.4574	RAMIPRILAT	RAMIPRILAT	C[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N2[C@H]3CCC[C@H]3C[C@H]2C(O)=O	SERUM	6N5U4QFC3G							336		t	μg × h/mL	414		ng/mL	24			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/6097458	Homo sapiens		h	113				10			false
2853	1449		UNKNOWN	56959	427.5365	RANOLAZINE	COC1=C(OCC(O)CN2CCN(CC(=O)NC3=C(C)C=CC=C3C)CC2)C=CC=C1	COC1=C(OCC(O)CN2CCN(CC(=O)NC3=C(C)C=CC=C3C)CC2)C=CC=C1	PLASMA	A6IEZ5M406													ng/mL	2600			RECOMMENDED	mg	1000		STEADY-STATE	UNKNOWN		day	2	Over the concentration range of 0.25 to 10 ug/mL, ranolazine is approximately 62% bound to human plasma proteins.	38	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021526s028lbl.pdf	Homo sapiens		h	7							false
2854	1449		ADULT	56959	427.5365	RANOLAZINE	COC1=C(OCC(O)CN2CCN(CC(=O)NC3=C(C)C=CC=C3C)CC2)C=CC=C1	COC1=C(OCC(O)CN2CCN(CC(=O)NC3=C(C)C=CC=C3C)CC2)C=CC=C1	PLASMA	A6IEZ5M406									∞	ng × h/mL	9862.7		ng/mL	741.5			RECOMMENDED	mg	500		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/23355361	Homo sapiens		h	6.4							false
2855	1450		ADULT	65981	452.5857	REPAGLINIDE	REPAGLINIDE	CCOC1=C(C=CC(CC(=O)N[C@@H](CC(C)C)C2=C(C=CC=C2)N3CCCCC3)=C1)C(O)=O	PLASMA	668Z8C33LU							24		t	ng × h/mL	447.4		ng/mL	65.8			DEFINED DAILY	mg	4		MULTIPLE	UNKNOWN		day	1	Protein binding and binding to human serum albumin was greater than 98%	2	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020741s040lbl.pdf	Homo sapiens		h	1.4							false
2856	1451		ADULT	37542	244.2047	RIBAVIRIN	NC(=O)C1=NN(C=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O	NC(=O)C1=NN(C=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O	PLASMA	49717AWG6K							12		t	ng × h/mL	228000		ng/mL	3680			RECOMMENDED	mg	600		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020903s052,021546s008lbl.pdf	Homo sapiens		h	298							false
2857	1452		ADULT		847.0047	RIFABUTIN	RIFABUTIN	CO[C@H]1\\C=C\\O[C@@]2(C)OC3=C(C)C(O)=C4C(=O)C(NC(=O)C(C)=C\\C=C\\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C5NC6(CCN(CC(C)C)CC6)N=C5C4=C3C2=O	PLASMA	1W306TDA6S									∞	ng × h/mL	9287		ng/mL	691			UNKNOWN	mg	450		SINGLE	UNKNOWN				In vitro studies show that 72%-85% of rifabutin in plasma is bound to plasma proteins.	21.5	HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/8785251/	Homo sapiens		h	45							false
2858	1452		ADULT		847.0047	RIFABUTIN	RIFABUTIN	CO[C@H]1\\C=C\\O[C@@]2(C)OC3=C(C)C(O)=C4C(=O)C(NC(=O)C(C)=C\\C=C\\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C5NC6(CCN(CC(C)C)CC6)N=C5C4=C3C2=O	PLASMA	1W306TDA6S							24		t	ng × h/mL	5803		ng/mL	613			UNKNOWN	mg	450		MULTIPLE	UNKNOWN		day	1	In vitro studies show that 72%-85% of rifabutin in plasma is bound to plasma proteins.		HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/8785251/	Homo sapiens		h	58							false
2859	1453		ADULT		822.9402	RIFAMPIN	RIFAMPIN	CO[C@H]1\\C=C\\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)C(C)=C\\C=C\\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(\\C=N\\N5CCN(C)CC5)=C(O)C4=C3C2=O	SERUM	VJT6J7R4TR													mg/L	6.3			RECOMMENDED	mg/kg	10		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22330931/	Homo sapiens										false
2860	1453		ADULT		822.9402	RIFAMPIN	RIFAMPIN	CO[C@H]1\\C=C\\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)C(C)=C\\C=C\\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(\\C=N\\N5CCN(C)CC5)=C(O)C4=C3C2=O	SERUM	VJT6J7R4TR													mg/L	3.3			RECOMMENDED	mg/kg	10		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22330931/	Homo sapiens										false
2861	1453		ADULT		822.9402	RIFAMPIN	RIFAMPIN	CO[C@H]1\\C=C\\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)C(C)=C\\C=C\\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(\\C=N\\N5CCN(C)CC5)=C(O)C4=C3C2=O	SERUM	VJT6J7R4TR	3767|6064144|6064145		ISONIAZID	isoniazid	NNC(=O)C1=CC=NC=C1	V83O1VOZ8L	24		t	mg × h/L	26.3		mg/L	7.4			RECOMMENDED	mg/kg	10		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25654354/	Homo sapiens										true
2862	1453		ADULT		822.9402	RIFAMPIN	RIFAMPIN	CO[C@H]1\\C=C\\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)C(C)=C\\C=C\\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(\\C=N\\N5CCN(C)CC5)=C(O)C4=C3C2=O	SERUM	VJT6J7R4TR	3767|6064144|6064145		ISONIAZID	isoniazid	NNC(=O)C1=CC=NC=C1	V83O1VOZ8L	24		t	mg × h/L	113		mg/L	21.6			RECOMMENDED	mg/kg	20		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25654354/	Homo sapiens										true
2863	1453		ADULT		822.9402	RIFAMPIN	RIFAMPIN	CO[C@H]1\\C=C\\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)C(C)=C\\C=C\\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(\\C=N\\N5CCN(C)CC5)=C(O)C4=C3C2=O	SERUM	VJT6J7R4TR	3767|6064144|6064145		ISONIAZID	isoniazid	NNC(=O)C1=CC=NC=C1	V83O1VOZ8L	24		t	mg × h/L	135		mg/L	25.1			RECOMMENDED	mg/kg	25		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25654354/	Homo sapiens										true
2864	1453		ADULT		822.9402	RIFAMPIN	RIFAMPIN	CO[C@H]1\\C=C\\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)C(C)=C\\C=C\\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(\\C=N\\N5CCN(C)CC5)=C(O)C4=C3C2=O	SERUM	VJT6J7R4TR	3767|6064144|6064145		ISONIAZID	isoniazid	NNC(=O)C1=CC=NC=C1	V83O1VOZ8L	24		t	mg × h/L	190		mg/L	33.1			RECOMMENDED	mg/kg	30		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25654354/	Homo sapiens										true
2865	1453		ADULT		822.9402	RIFAMPIN	RIFAMPIN	CO[C@H]1\\C=C\\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)C(C)=C\\C=C\\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(\\C=N\\N5CCN(C)CC5)=C(O)C4=C3C2=O	SERUM	VJT6J7R4TR	3767|6064144|6064145		ISONIAZID	isoniazid	NNC(=O)C1=CC=NC=C1	V83O1VOZ8L	24		t	mg × h/L	235		mg/L	35.2			RECOMMENDED	mg/kg	35		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25654354/	Homo sapiens										true
2866	1453		ADULT		822.9402	RIFAMPIN	RIFAMPIN	CO[C@H]1\\C=C\\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)C(C)=C\\C=C\\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(\\C=N\\N5CCN(C)CC5)=C(O)C4=C3C2=O	PLASMA	VJT6J7R4TR									∞	μg × h/mL	325						RECOMMENDED	mg	600		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9773393/	Homo sapiens		h	16.3							false
2867	1453		ADULT	135542225	780.9035	25-DESACETYLRIFAMPIN	25-Desacetyl Rifampicin	CO[C@H]1\\C=C\\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)C(C)=C\\C=C\\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](O)[C@@H]1C)C(\\C=N\\N5CCN(C)CC5)=C(O)C4=C3C2=O	PLASMA	MV5B51Z0LN																	RECOMMENDED	mg	600		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9773393/	Homo sapiens		h	17.3							false
2868	1454		ADULT	16667733	785.8785	RIFAXIMIN	RIFAXIMIN	CO[C@H]1\\C=C\\O[C@@]2(C)OC3=C(C2=O)C4=C(C(O)=C3C)C(O)=C(NC(=O)C(C)=C\\C=C\\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C5=C4N=C6C=C(C)C=CN56	PLASMA	L36O5T016N									?	ng × h/mL	12.3		ng/mL	3.4			RECOMMENDED	mg	550		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021361s013lbl.pdf	Homo sapiens										false
2869	1454		ADULT	16667733	785.8785	RIFAXIMIN	RIFAXIMIN	CO[C@H]1\\C=C\\O[C@@]2(C)OC3=C(C2=O)C4=C(C(O)=C3C)C(O)=C(NC(=O)C(C)=C\\C=C\\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C5=C4N=C6C=C(C)C=CN56	PLASMA	L36O5T016N									?	ng × h/mL	11.1		ng/mL	4.1			RECOMMENDED	mg	550		SINGLE	FASTED				In vivo, the mean protein binding ratio was 67.5% in healthy subjects	32.5	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021361s013lbl.pdf	Homo sapiens		h	1.8							false
2870	1454		ADULT	16667733	785.8785	RIFAXIMIN	RIFAXIMIN	CO[C@H]1\\C=C\\O[C@@]2(C)OC3=C(C2=O)C4=C(C(O)=C3C)C(O)=C(NC(=O)C(C)=C\\C=C\\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C5=C4N=C6C=C(C)C=CN56	PLASMA	L36O5T016N									?	ng × h/mL	22.5		ng/mL	4.8			RECOMMENDED	mg	550		SINGLE	FED						HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021361s013lbl.pdf	Homo sapiens		h	4.8							false
2871	1455		UNKNOWN	5070	234.198	RILUZOLE	NC1=NC2=C(S1)C=C(OC(F)(F)F)C=C2	NC1=NC2=C(S1)C=C(OC(F)(F)F)C=C2	PLASMA	7LJ087RS6F																						UNKNOWN				Plasma Protein Binding - 96% (Mainly to albumin and lipoproteins)	4	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020599s017lbl.pdf	Homo sapiens										false
2872	1455		ADOLESCENT	5070	234.198	RILUZOLE	NC1=NC2=C(S1)C=C(OC(F)(F)F)C=C2	NC1=NC2=C(S1)C=C(OC(F)(F)F)C=C2	PLASMA	7LJ087RS6F							24		t	ng × h/mL	2257		ng/mL	359			UNKNOWN	mg	50		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/21284699	Homo sapiens		h	7.8							false
2873	1456		ADULT		370.525	RIMEXOLONE	RIMEXOLONE	CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C	PLASMA	O7M2E4264D									?	ng × h/mL	564						UNKNOWN	mg	40		SINGLE	UNKNOWN						UNHEALTHY	Intraarticular	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2347958	Homo sapiens										false
2874	1456		ADULT		370.525	RIMEXOLONE	RIMEXOLONE	CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C	PLASMA	O7M2E4264D									?	ng × h/mL	1091						UNKNOWN	mg	80		SINGLE	UNKNOWN						UNHEALTHY	Intraarticular	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2347958	Homo sapiens										false
2875	1456		ADULT		370.525	RIMEXOLONE	RIMEXOLONE	CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C	PLASMA	O7M2E4264D									?	ng × h/mL	1331						UNKNOWN	mg	120		SINGLE	UNKNOWN						UNHEALTHY	Intraarticular	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2347958	Homo sapiens										false
2876	1456		ADULT		370.525	RIMEXOLONE	RIMEXOLONE	CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C	PLASMA	O7M2E4264D									?	ng × h/mL	1786						UNKNOWN	mg	160		SINGLE	UNKNOWN						UNHEALTHY	Intraarticular	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2347958	Homo sapiens										false
2877	1457		ADULT	5245	283.11	RISEDRONATE	RISEDRONATE	OC(CC1=CC=CN=C1)(P(O)(O)=O)P(O)(=O)O[Na]	PLASMA	OFG5EXG60L							24		t	ng × h/mL	6.49		ng/mL	2.05			RECOMMENDED	mg	5		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/14999521	Homo sapiens		h	1.61							false
2878	1458		ADULT	5073	410.4845	RISPERIDONE	Risperidone	CC1=C(CCN2CCC(CC2)C3=NOC4=C3C=CC(F)=C4)C(=O)N5CCCCC5=N1	PLASMA	L6UH7ZF8HC							12		t	ng × h/mL	83.1		ng/mL	17			RECOMMENDED	mg	2		STEADY-STATE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11985287/	Homo sapiens										false
2879	1458		ADULT	5073	410.4845	RISPERIDONE	Risperidone	CC1=C(CCN2CCC(CC2)C3=NOC4=C3C=CC(F)=C4)C(=O)N5CCCCC5=N1	PLASMA	L6UH7ZF8HC							24		t	ng × h/mL	53.86		ng/mL	7.77			RECOMMENDED	mg	1		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25042870/	Homo sapiens		h	4.88							false
2880	1458		ADULT	5073	410.4845	RISPERIDONE	RISPERIDONE	CC1=C(CCN2CCC(CC2)C3=NOC4=C3C=CC(F)=C4)C(=O)N5CCCCC5=N1	PLASMA	L6UH7ZF8HC																	RECOMMENDED	mg	1		SINGLE	UNKNOWN					10	HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020588s046lbl.pdf	Homo sapiens		h	20							false
2881	1459		ADULT	392622	720.944	RITONAVIR	RITONAVIR	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4	PLASMA	O3J8G9O825									?	μg × h/mL	129						RECOMMENDED	mg	600		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020659Orig1s000rev.pdf	Homo sapiens										false
2882	1459		ADULT	392622	720.944	RITONAVIR	RITONAVIR	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4	PLASMA	O3J8G9O825							12		t	μg × h/mL	77.5		μg/mL	11.2			RECOMMENDED	mg	600		STEADY-STATE	UNKNOWN		day	2		2	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020659Orig1s000rev.pdf	Homo sapiens		h	4		HIV  patients (baseline CD4  >=50 cell counts/mm3)		10			false
2883	1460		ADULT	77999	357.427	ROSIGLITAZONE	ROSIGLITAZONE	CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C3=CC=CC=N3	PLASMA	05V02F2KDG									∞	ng × h/mL	2971		ng/mL	598			UNKNOWN	mg	8		SINGLE	FASTED						UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.fda.gov/media/75754/download	Homo sapiens		h	3.37							false
2884	1460		ADULT	77999	357.427	ROSIGLITAZONE	ROSIGLITAZONE	CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C3=CC=CC=N3	PLASMA	05V02F2KDG									∞	ng × h/mL	2890		ng/mL	432			UNKNOWN	mg	8		SINGLE	FED						UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.fda.gov/media/75754/download	Homo sapiens		h	3.59							false
2885	1461		ADULT	59227	315.473	ROTIGOTINE	ROTIGOTINE	CCCN(CCC1=CC=CS1)[C@H]2CCC3=C(O)C=CC=C3C2	PLASMA	87T4T8BO2E							24		t	ng × h/mL	4.63		ng/mL	0.34			RECOMMENDED	mg	3		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Transdermal	MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/25795100/	Homo sapiens		h	6.5							false
2886	1461		UNKNOWN	59227	315.473	ROTIGOTINE	ROTIGOTINE	CCCN(CCC1=CC=CS1)[C@H]2CCC3=C(O)C=CC=C3C2	PLASMA	87T4T8BO2E																	UNKNOWN				UNKNOWN	UNKNOWN				The binding of rotigotine to human plasma proteins is approximately 92% in vitro and 89.5% in vivo.	10	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021829s019lbl.pdf	Homo sapiens										false
2887	1462		ADULT	129228	238.1935	RUFINAMIDE	RUFINAMIDE	NC(=O)C1=CN(CC2=C(F)C=CC=C2F)N=N1	PLASMA	WFW942PR79									∞	μg × h/mL	70.3		μg/mL	3.8			RECOMMENDED	mg	800		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18503564/	Homo sapiens		h	7.2							false
2888	1462		ADULT	129228	238.1935	RUFINAMIDE	RUFINAMIDE	NC(=O)C1=CN(CC2=C(F)C=CC=C2F)N=N1	PLASMA	WFW942PR79																	RECOMMENDED	mg	200		UNKNOWN	UNKNOWN		day	2	Only a small fraction of rufinamide (34%) is bound to human serum proteins, predominantly to albumin (27%), giving little risk of displacement drug-drug interactions.	66	UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204988Orig1s000lbl.pdf	Homo sapiens		h	10							false
2889	1463		ADULT	5152	415.5656	SALMETEROL	SALMETEROL	OCC1=CC(=CC=C1O)C(O)CNCCCCCCOCCCCC2=CC=CC=C2	PLASMA	2I4BC502BT	444036		FLUTICASONE PROPIONATE	Fluticasone Propionate	CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF	O2GMZ0LF5W			∞	pg × h/mL	464		pg/mL	319			RECOMMENDED	μg	50		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29493402/	Homo sapiens		h	10.72							true
2890	1463		ADULT	5152	415.5656	SALMETEROL	SALMETEROL	OCC1=CC(=CC=C1O)C(O)CNCCCCCCOCCCCC2=CC=CC=C2	PLASMA	2I4BC502BT													pg/mL	167			RECOMMENDED	μg	50		MULTIPLE	UNKNOWN		day	2		4	UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020692s028lbl.pdf	Homo sapiens		h	5.5							false
2891	1464		CHILD	5193	238.2829	SECOBARBITAL	SECOBARBITAL	CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O	PLASMA	1P7H87IN75							24		t	μg × h/mL	20.2		μg/mL	2			UNKNOWN	mg/kg	5		SINGLE	UNKNOWN						UNHEALTHY	Rectal	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7175723/	Homo sapiens		h	4.9							false
2892	1465		UNKNOWN	65863	437.77	SERTACONAZOLE	SERTACONAZOLE	ClC1=CC(Cl)=C(C=C1)C(CN2C=CN=C2)OCC3=CSC4=C3C=CC=C4Cl	PLASMA	72W71I16EG																						UNKNOWN				Protein binding >99% to plasma	1	UNKNOWN		UNKNOWN	OTHER	https://go.drugbank.com/drugs/DB01153	Homo sapiens										false
2893	1465		ADULT	65863	437.77	SERTACONAZOLE	SERTACONAZOLE	ClC1=CC(Cl)=C(C=C1)C(CN2C=CN=C2)OCC3=CSC4=C3C=CC=C4Cl	PLASMA	72W71I16EG									∞	ng × h/mL	43.31		ng/mL	1.79			UNKNOWN	mg	300		SINGLE	UNKNOWN						HEALTHY	Vaginal	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19889586	Homo sapiens		h	20.25							false
2894	1466		UNKNOWN	28179	18.998404	FLUORIDE ION	fluoride ion	[F-]	PLASMA	Q80VPU408O													μM	26.1			UNKNOWN	%	2.1		SINGLE	UNKNOWN						UNHEALTHY	Respiratory	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020478s030lbl.pdf	Homo sapiens		h	33							false
2895	1466		ADULT	28179	18.998404	FLUORIDE ION	fluoride ion	[F-]	PLASMA	Q80VPU408O													μM	25.6			UNKNOWN	%	1.7		SINGLE	UNKNOWN						HEALTHY	Respiratory	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020478s030lbl.pdf	Homo sapiens		h	24							false
2896	1467			54454	418.5662	SIMVASTATIN	SIMVASTATIN	CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12	PLASMA	AGG2FN16EV													ng/mL	6.85				mg	40		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01960140	Homo sapiens										false
2897	1467			64718	436.6	TENIVASTATIN	SIMVASTATIN ACID	CCC(C)(C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)C	PLASMA	9L6M5TH46B													ng/mL	1.93				mg	40		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01960140	Homo sapiens										false
2898	1467		ADULT	54454	418.5662	SIMVASTATIN	SIMVASTATIN	CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12	PLASMA	AGG2FN16EV									∞	ng × h/mL	38.142							mg	20		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01979185	Homo sapiens										false
2899	1467		ADULT	54454	418.5662	SIMVASTATIN	SIMVASTATIN	CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12	PLASMA	AGG2FN16EV							72		t	ng × h/mL	34.351							mg	20		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01979185	Homo sapiens										false
2900	1467		ADULT	54454	418.5662	SIMVASTATIN	SIMVASTATIN	CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12	PLASMA	AGG2FN16EV													ng/mL	5.006				mg	20		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01979185	Homo sapiens										false
2901	1467		ADULT	54454	418.5662	SIMVASTATIN	SIMVASTATIN	CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12	PLASMA	AGG2FN16EV									∞	ng × h/mL	235.795		ng/mL	54.711			UNKNOWN	mg	80		SINGLE	FASTED						HEALTHY	Oral	MALE	REVIEW	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/206679Orig1s000ClinPharmR.pdf	Homo sapiens		h	6.87							false
2902	1468		ADULT	5284616	914.2	SIROLIMUS	SIROLIMUS	CO[C@@H]1C[C@H](C[C@H](C)[C@@H]2CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1O	PLASMA	W36ZG6FT64									∞	ng × h/mL	970		ng/mL	78.2			UNKNOWN	mg	15		SINGLE	UNKNOWN					6	HEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021083s034,021110s045lbl.pdf	Homo sapiens		h	79							false
2903	1469		ADULT	154059	362.4647	SOLIFENACIN	SOLIFENACIN	O=C(O[C@H]1CN2CCC1CC2)N3CCC4=C(C=CC=C4)[C@@H]3C5=CC=CC=C5	PLASMA	A8910SQJ1U									∞	ng × h/mL	820		ng/mL	14.1			MAX DAILY	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15206986	Homo sapiens		h	50.8							false
2904	1469		UNKNOWN	154059	362.4647	SOLIFENACIN	SOLIFENACIN	O=C(O[C@H]1CN2CCC1CC2)N3CCC4=C(C=CC=C4)[C@@H]3C5=CC=CC=C5	PLASMA	A8910SQJ1U																						UNKNOWN				Solifenacin is approximately 98% (in vivo) bound to human plasma proteins, principally to ∝1-acid glycoprotein.	2	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021518s012lbl.pdf	Homo sapiens										false
2905	1470		ADULT	216239	464.825	SORAFENIB	SORAFENIB	CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1	PLASMA	9ZOQ3TZI87							8		t	μg × h/mL	17.9		μg/mL	3.8			RECOMMENDED	mg	400		MULTIPLE	UNKNOWN		day	2		0.29	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22089297/	Homo sapiens										false
2906	1470		ADULT	216239	464.825	SORAFENIB	SORAFENIB	CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1	PLASMA	9ZOQ3TZI87							8		t	μg × h/mL	12.6		μg/mL	3.1			RECOMMENDED	mg	600		MULTIPLE	UNKNOWN		day	2		0.31	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22089297/	Homo sapiens										false
2907	1470		ADULT	216239	464.0863	SORAFENIB	SORAFENIB	CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1	PLASMA	9ZOQ3TZI87									∞	mg × h/L	9.4		mg/L	0.43			UNKNOWN	mg	100		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/18477034	Homo sapiens		h	27.1							false
2908	1471		ADULT	5253	272.37	SOTALOL	SOTALOL	CC(C)NCC(O)C1=CC=C(N[S+](C)([O-])=O)C=C1	PLASMA	A6D97U294I																	UNKNOWN	mg	160		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019865s020lbl.pdf	Homo sapiens		h	12							false
2909	1471		ADULT	5253	272.37	SOTALOL	SOTALOL	CC(C)NCC(O)C1=CC=C(N[S+](C)([O-])=O)C=C1	PLASMA	A6D97U294I									∞	ng × h/mL	10402		ng/mL	781			UNKNOWN	mg	80		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.geneesmiddeleninformatiebank.nl/Pars/h33884.pdf	Homo sapiens										false
2910	1472		UNKNOWN	60464|6956367	392.3998	SPARFLOXACIN	SPARFLOXACIN	C[C@H]1CN(C[C@@H](C)N1)C2=C(F)C3=C(C(=O)C(=CN3C4CC4)C(O)=O)C(N)=C2F	PLASMA	Q90AGA787L							24		t	μg × h/mL	20.6		μg/mL	1.3			UNKNOWN	mg	400		SINGLE	UNKNOWN				Sparfloxacin exhibits low plasma protein binding in serum at about 45%	55	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/020677s006lbl.pdf	Homo sapiens		h	20							false
2911	1472		UNKNOWN	60464|6956367	392.3998	SPARFLOXACIN	SPARFLOXACIN	C[C@H]1CN(C[C@@H](C)N1)C2=C(F)C3=C(C(=O)C(=CN3C4CC4)C(O)=O)C(N)=C2F	PLASMA	Q90AGA787L							24		t	μg × h/mL	18.7		μg/mL	1.1			RECOMMENDED	mg	200		STEADY-STATE	UNKNOWN		day	1	Sparfloxacin exhibits low plasma protein binding in serum at about 45%	55	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/020677s006lbl.pdf	Homo sapiens		h	20							false
2912	1473		ADULT	76974557	416.573	SPIRONOLACTONE	SPIRONOLACTONE	CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]45CCC(=O)O5)[C@H]13	PLASMA	27O7W4T232									∞	ng × h/mL	150.41		ng/mL	47.4			RECOMMENDED	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18488807	Homo sapiens		h	2.37							false
2913	1473		UNKNOWN	76974557	416.573	SPIRONOLACTONE	SPIRONOLACTONE	CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]45CCC(=O)O5)[C@H]13	PLASMA	27O7W4T232																	UNKNOWN				UNKNOWN	UNKNOWN				Spironolactone and its metabolites are more than 90% bound to plasma proteins.	10	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/012151s075lbl.pdf	Homo sapiens		h	1.4							false
2914	1474		ADULT	18283	224.2133	STAVUDINE	STAVUDINE	CC1=CN([C@@H]2O[C@H](CO)C=C2)C(=O)NC1=O	PLASMA	BO9LE4QFZF							24		t	ng × h/mL	1966		ng/mL	228			RECOMMENDED	mg	100		STEADY-STATE	UNKNOWN		day	1	Binding of stavudine to serum proteins was negligible over the concentration range of 0.01 to 11.4 µg/mL	100	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21453_Zerit_lbl.pdf	Homo sapiens										false
2915	1474		ADULT	18283	224.2133	STAVUDINE	STAVUDINE	CC1=CN([C@@H]2O[C@H](CO)C=C2)C(=O)NC1=O	PLASMA	BO9LE4QFZF							24		t	ng × h/mL	2568		ng/mL	536			RECOMMENDED	mg	40		STEADY-STATE	UNKNOWN		day	2	Binding of stavudine to serum proteins was negligible over the concentration range of 0.01 to 11.4 µg/mL	100	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020412s041,020413s033lbl.pdf	Homo sapiens										false
2916	1475		ADULT	41693	386.551	SUFENTANIL	SUFENTANIL	CCC(=O)N(C1=CC=CC=C1)C2(COC)CCN(CCC3=CC=CS3)CC2	PLASMA	AFE2YW0IIZ									∞	pg × h/mL	278		pg/mL	63.1			RECOMMENDED	μg	30		SINGLE	UNKNOWN				Plasma protein binding of sufentanil, related to the alpha acid glycoprotein concentration, was approximately 93% in healthy males, 91% in mothers and 79% in neonates.	7	UNKNOWN	Sublingual	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209128s000lbl.pdf	Homo sapiens		h	13.4							false
2917	1476		ADULT	5339	398.393	SULFASALAZINE	OC(=O)C1=CC(=CC=C1O)\\N=N\\C2=CC=C(C=C2)S(=O)(=O)NC3=NC=CC=C3	OC(=O)C1=CC(=CC=C1O)\\N=N\\C2=CC=C(C=C2)S(=O)(=O)NC3=NC=CC=C3	PLASMA	3XC8GUZ6CB									?	μM × h	27.4						UNKNOWN	mmol	6.5		SINGLE	UNKNOWN						HEALTHY	Rectal	MALE	REVIEW	http://publications.iarc.fr/_publications/media/download/3250/cfef4a8f2e15aac3bf202aebfdc5ca409612ab71.pdf	Homo sapiens										false
2918	1476		UNKNOWN	5339	398.393	SULFASALAZINE	OC(=O)C1=CC(=CC=C1O)\\N=N\\C2=CC=C(C=C2)S(=O)(=O)NC3=NC=CC=C3	OC(=O)C1=CC(=CC=C1O)\\N=N\\C2=CC=C(C=C2)S(=O)(=O)NC3=NC=CC=C3	PLASMA	3XC8GUZ6CB																					UNKNOWN	UNKNOWN						UNKNOWN	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/007073s124lbl.pdf	Homo sapiens		h	7.6							false
2919	1476		ADULT	5339	398.393	SULFASALAZINE	OC(=O)C1=CC(=CC=C1O)\\N=N\\C2=CC=C(C=C2)S(=O)(=O)NC3=NC=CC=C3	OC(=O)C1=CC(=CC=C1O)\\N=N\\C2=CC=C(C=C2)S(=O)(=O)NC3=NC=CC=C3	PLASMA	3XC8GUZ6CB							48		t	μg × h/mL	98		μg/mL	12.9			DEFINED DAILY	g	2		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/1975737	Homo sapiens		h	3.6							false
2920	1477		ADULT		404.482	SULFINPYRAZONE	SULFINPYRAZONE	[O-][S+](CCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3)C4=CC=CC=C4	PLASMA	V6OFU47K3W									∞	mg × h/L	116		mg/L	26			UNKNOWN	mg	400		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3987792/	Homo sapiens		h	3.8							false
2921	1477		ADULT	5342	404.482	SULFINPYRAZONE	SULFINPYRAZONE	[O-][S+](CCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3)C4=CC=CC=C4	PLASMA	V6OFU47K3W									∞	mg × h/L	53		mg/L	13.4			UNKNOWN	mg	400		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3987792/	Homo sapiens		h	9.96							false
2922	1477		ADULT		420.5	SULFINPYRAZONE SULFONE	SULFINPYRAZONE SULFONE		PLASMA	5M9FOG2KDI									∞	mg × h/L	13.4		mg/L	2.2			UNKNOWN	mg	400		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3987792/	Homo sapiens		h	3.6							false
2923	1477		ADULT		420.5	SULFINPYRAZONE SULFONE			PLASMA	5M9FOG2KDI							12		t	mg × h/L	9.2		mg/L	2			UNKNOWN	mg	400		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3987792/	Homo sapiens		h	3.3							false
2924	1477		ADULT		404.482	SULFINPYRAZONE	SULFINPYRAZONE	[O-][S+](CCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3)C4=CC=CC=C4	PLASMA	V6OFU47K3W									∞	μg × h/mL	79.6						UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7059415/	Homo sapiens		h	3.79							false
2925	1477		ADULT	5342	404.482	SULFINPYRAZONE	SULFINPYRAZONE	[O-][S+](CCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3)C4=CC=CC=C4	PLASMA	V6OFU47K3W									∞	μg × h/mL	191.9						UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7059415/	Homo sapiens		h	4.17							false
2926	1477		ADULT		420.5	SULFINPYRAZONE SULFONE			PLASMA	5M9FOG2KDI									∞	μg × h/mL	5.7						UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7059415/	Homo sapiens										false
2927	1477		ADULT		420.5	SULFINPYRAZONE SULFONE			PLASMA	5M9FOG2KDI									∞	μg × h/mL	16.5						UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7059415/	Homo sapiens		h	3.8							false
2928	1478		ADULT	1548887	356.411	SULINDAC	SULINDAC	C[S+]([O-])C1=CC=C(\\C=C2\\C(C)=C(CC(O)=O)C3=C2C=CC(F)=C3)C=C1	PLASMA	184SNS8VUH							24		t	μg × h/mL	40.8		μg/mL	9.21			DEFINED DAILY	mg	400		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1038/clpt.1982.178	Homo sapiens				single 400 mg dose administered at 21:00			12			false
2929	1478		ADULT	1548887	356.411	SULINDAC	SULINDAC	C[S ]([O-])C1=CC=C(\\C=C2\\C(C)=C(CC(O)=O)C3=C2C=CC(F)=C3)C=C1	PLASMA	184SNS8VUH							12		t	μg × h/mL	15.4		μg/mL	4.69			DEFINED DAILY	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1038/clpt.1982.178	Homo sapiens				single 200 mg dose administered at 09:00			12			false
2930	1478		ADULT	1548887	356.411	SULINDAC	SULINDAC	C[S ]([O-])C1=CC=C(\\C=C2\\C(C)=C(CC(O)=O)C3=C2C=CC(F)=C3)C=C1	PLASMA	184SNS8VUH							24		t	μg × h/mL	44.8		μg/mL	8.7			DEFINED DAILY	mg	400		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1038/clpt.1982.178	Homo sapiens							12			false
2931	1478		ADULT		356.411	SULINDAC	SULINDAC	C[S ]([O-])C1=CC=C(\\C=C2\\C(C)=C(CC(O)=O)C3=C2C=CC(F)=C3)C=C1	PLASMA	184SNS8VUH							12		t	μg × h/mL	19		μg/mL	5.02			DEFINED DAILY	mg	200		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1038/clpt.1982.178	Homo sapiens							12			false
2932	1478		UNKNOWN	1548887	356.411	SULINDAC	SULINDAC	C[S+]([O-])C1=CC=C(\\C=C2\\C(C)=C(CC(O)=O)C3=C2C=CC(F)=C3)C=C1	PLASMA	184SNS8VUH																	UNKNOWN	mg	200		SINGLE	UNKNOWN				Sulindac, and its sulfone and sulfide metabolites, are 93.1, 95.4, and 97.9% bound to plasma proteins, predominantly to albumin.	6.9	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/017911s074lbl.pdf	Homo sapiens		h	7.8							false
2933	1478		ADULT	1548887	356.4	SULINDAC	SULINDAC	C[S+]([O-])C1=CC=C(\\C=C2\\C(C)=C(CC(O)=O)C3=C2C=CC(F)=C3)C=C1	PLASMA	184SNS8VUH													μg/mL	11.4			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/8366178	Homo sapiens		h	2.95							false
2934	1479		ADULT	1935	198.2637	TACRINE	TACRINE	NC1=C2CCCCC2=NC3=C1C=CC=C3	PLASMA	4VX7YNB537									∞	ng × h/mL	91.8		ng/mL	15.8			UNKNOWN	mg	40		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/7836549	Homo sapiens		h	2.8							false
2935	1480		ADULT	110635	389.404	TADALAFIL	TADALAFIL	CN1CC(=O)N2[C@H](CC3=C(NC4=C3C=CC=C4)[C@H]2C5=CC6=C(OCO6)C=C5)C1=O	PLASMA	742SXX0ICT																	RECOMMENDED	mg	40		SINGLE	UNKNOWN				At therapeutic concentrations, 94% of tadalafil in plasma is bound to proteins.	6	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022332lbl.pdf	Homo sapiens										false
2936	1480		ADULT	110635	389.404	TADALAFIL	TADALAFIL	CN1CC(=O)N2[C@H](CC3=C(NC4=C3C=CC=C4)[C@H]2C5=CC6=C(OCO6)C=C5)C1=O	BLOOD	742SXX0ICT									∞	μg × h/L	7225		μg/L	308.1			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/29719379	Homo sapiens		h	17.4							false
2937	1481		ADULT	5381	351.5	TAZAROTENE	TAZAROTENE	CCOC(=O)C1=CC=C(N=C1)C#CC2=CC=C3SCCC(C)(C)C3=C2	PLASMA	81BDR9Y8PS							24		t	pg × h/mL	105.72		pg/mL	5.44			RECOMMENDED	mg	5		SINGLE	UNKNOWN						HEALTHY	Topical	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/31641413	Homo sapiens										false
2938	1482		ADULT	65999	514.6169	TELMISARTAN	TELMISARTAN	CCCC1=NC2=C(C=C(C=C2C)C3=NC4=C(C=CC=C4)N3C)N1CC5=CC=C(C=C5)C6=C(C=CC=C6)C(O)=O	PLASMA	U5SYW473RQ									∞	ng × h/mL	3320		ng/mL	3200			UNKNOWN	mg	160		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/11014323	Homo sapiens		h	17.7							false
2939	1483		ADULT	5391	300.74	TEMAZEPAM	TEMAZEPAM	CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C3=CC=CC=C3	PLASMA	CHB1QD2QSS													ng/mL	1560			UNKNOWN	mg	40		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2574013	Homo sapiens		h	1.24							false
2940	1483		ADULT	5391	300.74	TEMAZEPAM	TEMAZEPAM	CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C3=CC=CC=C3	PLASMA	CHB1QD2QSS									∞	μg × h/mL	6.4		ng/mL	964			UNKNOWN	mg	26		SINGLE	UNKNOWN				The corresponding free fractions of temazepam increased from 2.0% at 7 minutes to 3.3% at 21 minutes. Thereafter free fractions decreased, reaching a value of 1.7% + 0.2% at 120 minutes.	2	HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8181199	Homo sapiens		h	10.7							false
2941	1483		ADULT	5391	300.74	TEMAZEPAM	TEMAZEPAM	CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C3=CC=CC=C3	PLASMA	CHB1QD2QSS							24		t	ng × h/mL	1800		ng/mL	865			RECOMMENDED	mg	30		STEADY-STATE	UNKNOWN		day	1	The unchanged drug was 96% bound to plasma proteins	4	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/018163s065lbl.pdf	Homo sapiens		h	8.8							false
2942	1484		UNKNOWN	5426	258.2295	THALIDOMIDE	THALIDOMIDE	O=C1N(C2CCC(=O)NC2=O)C(=O)C3=CC=CC=C13	PLASMA	4Z8R6ORS6L																						UNKNOWN				In human blood plasma, the geometric mean plasma protein binding was 55% and 66%, respectively, for (+)-(R)- and (-)-(S)-thalidomide	45	UNKNOWN		UNKNOWN	DRUG LABEL	https://s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB01041.pdf?1265922802	Homo sapiens										false
2943	1484		ADULT	5426	258.23	THALIDOMIDE	THALIDOMIDE	O=C1N(C2CCC(=O)NC2=O)C(=O)C3=C1C=CC=C3	PLASMA	4Z8R6ORS6L									∞	mg × h/L	19.8		mg/L	2			RECOMMENDED	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	REVIEW	https://www.ncbi.nlm.nih.gov/pubmed/15080764	Homo sapiens		h	6.17							false
2944	1485		CHILD	91669166	352.399	THIOGUANINE	THIOGUANINE	O.NC1=NC2=C(N=CN2)C(=S)N1.NC3=NC4=C(N=CN4)C(=S)N3	PLASMA	FTK8U1GZNX									∞	pmol × h/mL	586		nM	313			UNKNOWN	mg/m²	40		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/11422012	Homo sapiens										false
2945	1485		ADULT	91669166	352.399	THIOGUANINE	THIOGUANINE	O.NC1=NC2=C(N=CN2)C(=S)N1.NC3=NC4=C(N=CN4)C(=S)N3	PLASMA	FTK8U1GZNX																	UNKNOWN	mg	40		MULTIPLE	FED		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/27463047	Homo sapiens		h	4.4							false
2946	1486		ADULT	5487427	392.512	TIOTROPIUM	TIOTROPIUM	C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]3O[C@@H]23)OC(=O)C(O)(C4=CC=CS4)C5=CC=CS5	PLASMA	0EB439235F							6		t	pg × h/mL	22.1		pg/mL	10.5			DEFINED DAILY	μg	5		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Respiratory	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24165906	Homo sapiens										false
2947	1486		ADULT	5487427	392.512	TIOTROPIUM	TIOTROPIUM	C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]3O[C@@H]23)OC(=O)C(O)(C4=CC=CS4)C5=CC=CS5	PLASMA	0EB439235F																	DEFINED DAILY	μg	5		SINGLE	UNKNOWN				Tiotropium is 72% bound to plasma protein	28	UNHEALTHY	Respiratory	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021395s048lbl.pdf	Homo sapiens		h	25							false
2948	1487		ADULT	5503	311.4	TOLAZAMIDE	TOLAZAMIDE	CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CCCCCC2	SERUM	9LT1BRO48Q							24		t	μg × h/mL	260		μg/mL	21.8			RECOMMENDED	mg	500		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7175719/	Homo sapiens		h	4.6							false
2949	1488		ADULT	4659569	273.2408	TOLCAPONE	TOLCAPONE	CC1=CC=C(C=C1)C(=O)C2=CC(O)=C(O)C(=C2)[N+]([O-])=O	PLASMA	CIF6334OLY									∞	mg × h/L	0.5		mg/L	0.3			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7768073	Homo sapiens		h	1.7							false
2950	1488		ADULT	4659569	273.2408	TOLCAPONE	TOLCAPONE	CC1=CC=C(C=C1)C(=O)C2=CC(O)=C(O)C(=C2)[N+]([O-])=O	PLASMA	CIF6334OLY									∞	mg × h/L	1.1		mg/L	0.7			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/7768073	Homo sapiens		h	1.7							false
2951	1488		ADULT	4659569	273.2408	TOLCAPONE	TOLCAPONE	CC1=CC=C(C=C1)C(=O)C2=CC(O)=C(O)C(=C2)[N+]([O-])=O	PLASMA	CIF6334OLY									∞	mg × h/L	2.8		mg/L	1.3			UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7768073	Homo sapiens		h	1.6							false
2952	1488		ADULT	4659569	273.2408	TOLCAPONE	TOLCAPONE	CC1=CC=C(C=C1)C(=O)C2=CC(O)=C(O)C(=C2)[N+]([O-])=O	PLASMA	CIF6334OLY									∞	mg × h/L	5.7		mg/L	2.4			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7768073	Homo sapiens		h	1.7							false
2953	1488		ADULT	4659569	273.2408	TOLCAPONE	TOLCAPONE	CC1=CC=C(C=C1)C(=O)C2=CC(O)=C(O)C(=C2)[N+]([O-])=O	PLASMA	CIF6334OLY									∞	mg × h/L	12.2		mg/L	4.6			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7768073	Homo sapiens		h	2							false
2954	1488		ADULT	4659569	273.2408	TOLCAPONE	TOLCAPONE	CC1=CC=C(C=C1)C(=O)C2=CC(O)=C(O)C(=C2)[N+]([O-])=O	PLASMA	CIF6334OLY									∞	mg × h/L	18.5		mg/L	6.3			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7768073	Homo sapiens		h	2.1							false
2955	1488		ADULT	4659569	273.2408	TOLCAPONE	TOLCAPONE	CC1=CC=C(C=C1)C(=O)C2=CC(O)=C(O)C(=C2)[N+]([O-])=O	PLASMA	CIF6334OLY									∞	mg × h/L	43.8		mg/L	13.4			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7768073	Homo sapiens		h	2.2							false
2956	1488		ADULT	4659569	273.2408	TOLCAPONE	TOLCAPONE	CC1=CC=C(C=C1)C(=O)C2=CC(O)=C(O)C(=C2)[N+]([O-])=O	PLASMA	CIF6334OLY									∞	mg × h/L	67.7		mg/L	20.3			UNKNOWN	mg	800		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7768073	Homo sapiens		h	3.4							false
2957	1488		UNKNOWN	4659569	273.2408	TOLCAPONE	TOLCAPONE	CC1=CC=C(C=C1)C(=O)C2=CC(O)=C(O)C(=C2)[N+]([O-])=O	PLASMA	CIF6334OLY																	UNKNOWN				UNKNOWN	UNKNOWN				The plasma protein binding of tolcapone is >99.9% over the concentration range of 0.32 to 210 ug/mL. In vitro experiments have shown that tolcapone binds mainly to serum albumin.	0.1	UNKNOWN	UNKNOWN	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020697s004lbl.pdf	Homo sapiens										false
2958	1489		ADULT	216237	448.941	TOLVAPTAN	TOLVAPTAN	CC1=CC=CC=C1C(=O)NC2=CC(C)=C(C=C2)C(=O)N3CCCC(O)C4=C3C=CC(Cl)=C4	BLOOD	21G72T1950									?	ng × h/mL	683		ng/mL	125			UNKNOWN	mg	15		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/22120090	Homo sapiens		h	3.5							false
2959	1489		ADULT	216237	448.941	TOLVAPTAN	TOLVAPTAN	CC1=CC=CC=C1C(=O)NC2=CC(C)=C(C=C2)C(=O)N3CCCC(O)C4=C3C=CC(Cl)=C4	BLOOD	21G72T1950									?	ng × h/mL	719		ng/mL	154			UNKNOWN	mg	15		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/22120090	Homo sapiens		h	3.2							false
2960	1489		ADULT	216237	448.941	TOLVAPTAN	TOLVAPTAN	CC1=CC=CC=C1C(=O)NC2=CC(C)=C(C=C2)C(=O)N3CCCC(O)C4=C3C=CC(Cl)=C4	BLOOD	21G72T1950							24		t	ng × h/mL	1193		ng/mL	198			DEFINED DAILY	mg	30		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/22120090	Homo sapiens		h	3.3							false
2961	1490		ADULT	5284627	339.362	TOPIRAMATE	TOPIRAMATE	CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1	PLASMA										∞	μg × h/mL	59.8		μg/mL	1.63			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8930774	Homo sapiens		h	18.7							false
2962	1490		ADULT	5284627	339.362	TOPIRAMATE	TOPIRAMATE	CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1	PLASMA										∞	μg × h/mL	57.3		μg/mL	1.46			UNKNOWN	mg	100		SINGLE	HIGH-FAT						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8930774	Homo sapiens										false
2963	1490		ADULT	5284627	339.362	TOPIRAMATE	TOPIRAMATE	CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1	PLASMA										∞	μg × h/mL	311.2		μg/mL	8			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8930774	Homo sapiens		h	23							false
2964	1490		ADULT	5284627	339.362	TOPIRAMATE	TOPIRAMATE	CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1	PLASMA										∞	mg × h/mL	350.3		μg/mL	6.98			UNKNOWN	mg	400		SINGLE	HIGH-FAT						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8930774	Homo sapiens										false
2965	1490		ADULT	5284627	339.362	TOPIRAMATE	TOPIRAMATE	CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1	PLASMA														μg/mL	3.68			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8930774	Homo sapiens		h	23							false
2966	1490		ADULT	5284627	339.362	TOPIRAMATE	TOPIRAMATE	CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1	PLASMA														μg/mL	18.38			UNKNOWN	mg	800		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8930774	Homo sapiens		h	22							false
2967	1490		ADULT	5284627	339.362	TOPIRAMATE	TOPIRAMATE	CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1	PLASMA														μg/mL	28.73			UNKNOWN	mg	1200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8930774	Homo sapiens		h	20							false
2968	1490		UNKNOWN	5284627	339.362	TOPIRAMATE	TOPIRAMATE	CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1	PLASMA																		UNKNOWN				UNKNOWN	UNKNOWN				Topiramate is 15% to 41% bound to human plasma proteins over the blood concentration range of 0.5 to 250 ug/mL. The fraction bound decreased as blood concentration increased.	59	UNKNOWN	UNKNOWN	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020505s061,020844s052lbl.pdf	Homo sapiens										false
2969	1491			60700	421.4458	TOPOTECAN	TOPOTECAN	CC[C@@]1(O)C(=O)OCC2=C1C=C3N(CC4=CC5=C(C=CC(O)=C5CN(C)C)N=C34)C2=O	PLASMA	7M7YKX2N15																										Binding of topotecan to plasma proteins is about 35%.	65				DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/200199s003lbl.pdf	Homo sapiens										false
2970	1491		ADULT	60700	421.4458	TOPOTECAN	TOPOTECAN	CC[C@@]1(O)C(=O)OCC2=C1C=C3N(CC4=CC5=C(C=CC(O)=C5CN(C)C)N=C34)C2=O	PLASMA	7M7YKX2N15									∞	ng × h/mL	61		ng/mL	9.29			UNKNOWN	mg	4		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26291057	Homo sapiens		h	5.23							false
2971	1492		ADULT	3005573	405.96	TOREMIFENE	TOREMIFENE	CN(C)CCOC1=CC=C(C=C1)C(=C(\\CCCl)C2=CC=CC=C2)\\C3=CC=CC=C3	BLOOD	7NFE54O27T									?	μg × h/mL	28.4		ng/mL	414			UNKNOWN	mg	120		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/7781262	Homo sapiens		day	6.2							false
2972	1492		ADULT	3005573	405.96	TOREMIFENE	TOREMIFENE	CN(C)CCOC1=CC=C(C=C1)C(=C(\\CCCl)C2=CC=CC=C2)\\C3=CC=CC=C3	BLOOD	7NFE54O27T									?	μg × h/mL	34.1		ng/mL	722			UNKNOWN	mg	120		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/9871429	Homo sapiens		h	99							false
2973	1493		ADULT	41781|51371498	348.42	TORSEMIDE	TORSEMIDE	CC(C)NC(=O)NS(=O)(=O)C1=C(NC2=CC=CC(C)=C2)C=CN=C1	PLASMA	W31X2H97FB									∞	ng × h/mL	1561		ng/mL	968.7			UNKNOWN	mg	5		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19673928	Homo sapiens		h	4.4							false
2974	1493		ADULT	41781|51371498	348.42	TORSEMIDE	TORSEMIDE	CC(C)NC(=O)NS(=O)(=O)C1=C(NC2=CC=CC(C)=C2)C=CN=C1	PLASMA	W31X2H97FB									∞	ng × h/mL	3516		ng/mL	1549.9			UNKNOWN	mg	10		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19673928	Homo sapiens		h	4.5							false
2975	1493		ADULT	41781|51371498	348.42	TORSEMIDE	TORSEMIDE	CC(C)NC(=O)NS(=O)(=O)C1=C(NC2=CC=CC(C)=C2)C=CN=C1	PLASMA	W31X2H97FB																	RECOMMENDED	mg	10		MULTIPLE	UNKNOWN		day	1	Torsemide is extensively bound to plasma protein (>99%)	1	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020136s027lbl.pdf	Homo sapiens										false
2976	1494		ADULT	5464097	402.484	TRANDOLAPRILAT	TRANDOLAPRILAT	C[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N2[C@H]3CCCC[C@@H]3C[C@H]2C(O)=O	PLASMA	RR6866VL0O							24		t	ng × h/mL	19.1		ng/mL	0.99			UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020528Orig1s000rev.pdf	Homo sapiens										false
2977	1494		ADULT	5484727|37888437	430.5372	TRANDOLAPRIL	TRANDOLAPRIL	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@H]3CCCC[C@@H]3C[C@H]2C(O)=O	PLASMA	1T0N3G9CRC							6		t	ng × h/mL	1.8		ng/mL	1.3			UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020528Orig1s000rev.pdf	Homo sapiens										false
2978	1494		ADULT	5464097	402.484	TRANDOLAPRILAT	TRANDOLAPRILAT	C[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N2[C@H]3CCCC[C@@H]3C[C@H]2C(O)=O	PLASMA	RR6866VL0O							192		t	ng × h/mL	101		ng/mL	9			UNKNOWN	mg	4		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020528Orig1s000rev.pdf	Homo sapiens		h	115							false
2979	1494		ADULT	5484727|37888437	430.5372	TRANDOLAPRIL	TRANDOLAPRIL	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@H]3CCCC[C@@H]3C[C@H]2C(O)=O	PLASMA	1T0N3G9CRC									?	ng × h/mL	8.2		ng/mL	6.2			UNKNOWN	mg	4		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020528Orig1s000rev.pdf	Homo sapiens		h	8.4							false
2980	1495		ADULT	5526	157.2102	TRANEXAMIC ACID	tranexamic acid	NC[C@H]1CC[C@@H](CC1)C(O)=O	PLASMA	6T84R30KC1									∞	μg × h/mL	80.19		μg/mL	13.83			RECOMMENDED	mg	1300		SINGLE	UNKNOWN				Tranexamic acid is 3% bound to plasma proteins with no apparent binding to albumin.	97	HEALTHY	Oral	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf	Homo sapiens		h	11.08							false
2981	1495		ADULT	5526	157.2102	TRANEXAMIC ACID	tranexamic acid	NC[C@H]1CC[C@@H](CC1)C(O)=O	PLASMA	6T84R30KC1									?	μg × h/mL	77.67		μg/mL	16.41			RECOMMENDED	mg	1300		MULTIPLE	UNKNOWN		day	3			HEALTHY	Oral	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf	Homo sapiens										false
2982	1496		CHILD	5311100	458.468	FLUPROSTENOL	Fluprostenol	O[C@@H](COC1=CC(=CC=C1)C(F)(F)F)\\C=C\\[C@H]2[C@H](O)C[C@H](O)[C@@H]2C\\C=C/CCCC(O)=O	PLASMA	358S7VUE5N									∞	ng × h/mL	0.039		ng/mL	0.049			RECOMMENDED	drop	1		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Ocular	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28437175	Homo sapiens		min	31.8							false
2983	1496		ADULT	5311100	458.468	FLUPROSTENOL	fluprostenol	O[C@@H](COC1=CC(=CC=C1)C(F)(F)F)\\C=C\\[C@H]2[C@H](O)C[C@H](O)[C@@H]2C\\C=C/CCCC(O)=O	PLASMA	358S7VUE5N													ng/mL	0.018			RECOMMENDED	drop	1		MULTIPLE	UNKNOWN		day	1			UNKNOWN	Ocular	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021994lbl.pdf	Homo sapiens		min	45							false
2984	1496		UNKNOWN	5311100	458.468	FLUPROSTENOL	Fluprostenol	O[C@@H](COC1=CC(=CC=C1)C(F)(F)F)\\C=C\\[C@H]2[C@H](O)C[C@H](O)[C@@H]2C\\C=C/CCCC(O)=O	PLASMA	358S7VUE5N																						UNKNOWN				Travoprost free acid to be moderately bound (about 80%) to plasma proteins in humans	20	UNKNOWN		UNKNOWN	REVIEW	https://www.ema.europa.eu/en/documents/scientific-discussion/travatan-epar-scientific-discussion_en.pdf	Homo sapiens										false
2985	1497		ADULT	5282379	300.4351	ISOTRETINOIN	ISOTRETINOIN	CC(\\C=C\\C1=C(C)CCCC1(C)C)=C/C=C/C(C)=C\\C(O)=O	PLASMA	EH28UP18IF									?	ng × h/mL	4055		ng/mL	314			RECOMMENDED	mg	40		SINGLE	FASTED				Isotretinoin is more than 99.9% bound to plasma proteins, primarily albumin.	0.1	HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021951s000lbl.pdf	Homo sapiens		h	24							false
2986	1498		ADULT	5546	253.2626	TRIAMTERENE	TRIAMTERENE	NC1=NC2=C(N=C(C3=CC=CC=C3)C(N)=N2)C(N)=N1	PLASMA	WS821Z52LQ									∞	ng × h/mL	190.69		ng/mL	44.77			RECOMMENDED	mg	50		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21193005	Homo sapiens		h	1.75							false
2987	1498		ADULT	5546	253.2626	TRIAMTERENE	TRIAMTERENE	NC1=NC2=C(N=C(C3=CC=CC=C3)C(N)=N2)C(N)=N1	PLASMA	WS821Z52LQ							24		t	ng × h/mL	488.4		ng/mL	125.1			RECOMMENDED	mg	100		SINGLE	FASTED					38.7	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7166735	Homo sapiens										false
2988	1498		ADULT	5546	253.2626	TRIAMTERENE	TRIAMTERENE	NC1=NC2=C(N=C(C3=CC=CC=C3)C(N)=N2)C(N)=N1	PLASMA	WS821Z52LQ	3639		HYDROCHLOROTHIAZIDE	hydrochlorothiazide	NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1Cl	0J48LPH2TH	48		t	ng × h/mL	148.7		ng/mL	46.4			RECOMMENDED	mg	37.5		MULTIPLE	FASTED		day	1	triamterene is largely protein-bound (approximately 67%)	33	HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/016042s077lbl.pdf	Homo sapiens										true
2989	1498		UNKNOWN	5546	253.2626	TRIAMTERENE	TRIAMTERENE	NC1=NC2=C(N=C(C3=CC=CC=C3)C(N)=N2)C(N)=N1	PLASMA	WS821Z52LQ																	UNKNOWN				UNKNOWN	UNKNOWN						UNKNOWN		UNKNOWN	OTHER GOV'T	https://www.medicines.org.uk/emc/medicine/28009#PHARMACOKINETIC_PROPS	Homo sapiens		h	2							false
2990	1499		ADULT	1963	359.2148	.ALPHA.-HYDROXYTRIAZOLAM		OCc1nnc2CN=C(c3ccccc3Cl)c4cc(Cl)ccc4n12	PLASMA	J53Y2M2SAH									∞	ng × h/mL	5.88		ng/mL	0.91			UNKNOWN	mg	0.25		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11503006/	Homo sapiens		h	5.54		Young subjects (19~60 y)		18	Triazolam		false
2991	1499		ADULT	1963	359.2148	.ALPHA.-HYDROXYTRIAZOLAM		OCc1nnc2CN=C(c3ccccc3Cl)c4cc(Cl)ccc4n12	PLASMA	J53Y2M2SAH									∞	ng × h/mL	7.99		ng/mL	1.05			UNKNOWN	mg	0.25		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11503006/	Homo sapiens		h	5.49		Elderly subjects (61~78 y)		12	Triazolam		false
2992	1499		ADULT	5556	343.21	TRIAZOLAM	Triazolam	CC1=NN=C2CN=C(C3=C(Cl)C=CC=C3)C4=C(C=CC(Cl)=C4)N12	PLASMA	1HM943223R									∞	ng × h/mL	11.8		ng/mL	1.69			UNKNOWN	mg	0.25		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11503006/	Homo sapiens		h	3.48		Elderly subjects (61~78 y)		12	Triazolam		false
2993	1499		ADULT	5556	343.21	TRIAZOLAM	Triazolam	CC1=NN=C2CN=C(C3=C(Cl)C=CC=C3)C4=C(C=CC(Cl)=C4)N12	PLASMA	1HM943223R									∞	ng × h/mL	9.93		ng/mL	1.69			UNKNOWN	mg	0.25		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11503006/	Homo sapiens		h	3.18		Young subjects (19~60 y)		18	Triazolam		false
2994	1499		ADULT	5556	343.21	TRIAZOLAM	TRIAZOLAM	CC1=NN=C2CN=C(C3=C(Cl)C=CC=C3)C4=C(C=CC(Cl)=C4)N12	PLASMA	1HM943223R							8		t	ng × h/mL	13.05		ng/mL	3.75			RECOMMENDED	mg	0.25		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8275618/	Homo sapiens		h	4.07							false
2995	1499		ADULT	5556	343.21	TRIAZOLAM	TRIAZOLAM	CC1=NN=C2CN=C(C3=C(Cl)C=CC=C3)C4=C(C=CC(Cl)=C4)N12	PLASMA	1HM943223R							8		t	ng × h/mL	13.78		ng/mL	4.39			RECOMMENDED	mg	0.25		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8275618/	Homo sapiens		h	2.27							false
2996	1500		ADULT	5560	380.656	TRICHLORMETHIAZIDE	TRICHLORMETHIAZIDE	NS(=O)(=O)C1=CC2=C(NC(NS2(=O)=O)C(Cl)Cl)C=C1Cl	PLASMA	Q58C92TUN0									∞	ng × h/mL	210.2		ng/mL	42.2			DEFINED DAILY	mg	4		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/7286056	Homo sapiens		h	2.3							false
2997	1501		ADULT	5572	301.4662	TRIHEXYPHENIDYL	trihexyphenidyl	OC(CCN1CCCCC1)(C2CCCCC2)C3=CC=CC=C3	SERUM	6RC5V8B7PO									∞	ng × h/mL	334		ng/mL	24.4			UNKNOWN	mg	5		MULTIPLE	FASTED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3225767/	Homo sapiens		h	8.67							false
2998	1501		ADULT	5572	301.4662	TRIHEXYPHENIDYL	TRIHEXYPHENIDYL	OC(CCN1CCCCC1)(C2CCCCC2)C3=CC=CC=C3	SERUM	6RC5V8B7PO									∞	ng × h/mL	294		ng/mL	14.9			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3225767/	Homo sapiens		h	10.1							false
2999	1503		ADULT	5593	284.3529	TROPICAMIDE	TROPICAMIDE	CCN(CC1=CC=NC=C1)C(=O)C(CO)C2=CC=CC=C2	PLASMA	N0A3Z5XTC6													ng/mL	2.8			UNKNOWN	μg	400		SINGLE	UNKNOWN						UNHEALTHY	Ocular	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8083562	Homo sapiens										false
3000	1503		UNKNOWN	5593	284.3529	TROPICAMIDE	TROPICAMIDE	CCN(CC1=CC=NC=C1)C(=O)C(CO)C2=CC=CC=C2	PLASMA	N0A3Z5XTC6																	UNKNOWN				UNKNOWN	UNKNOWN						UNKNOWN		UNKNOWN	EXPERIMENT	https://www.tandfonline.com/doi/full/10.1080/24750573.2017.1347601	Homo sapiens		min	30							false
3001	1504		UNKNOWN	454216	723.6437	VALRUBICIN	VALRUBICIN	CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)C3=C(O)C4=C(C(=O)C5=C(C4=O)C(OC)=CC=C5)C(O)=C3C1	PLASMA	2C6NUM6878																						UNKNOWN				Protein binding >99%	1	UNKNOWN		UNKNOWN	REVIEW	https://clincancerres.aacrjournals.org/content/clincanres/early/2017/06/26/1078-0432.CCR-16-3083.full.pdf	Homo sapiens										false
3002	1504		UNKNOWN	454216	723.6437	VALRUBICIN	CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)C3=C(C1)C(O)=C4C(=O)C5=C(C(=O)C4=C3O)C(OC)=CC=C5	CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)C3=C(C1)C(O)=C4C(=O)C5=C(C(=O)C4=C3O)C(OC)=CC=C5	PLASMA	2C6NUM6878							6		t	nM × h	78						INVESTIGATIONAL	mg	900		SINGLE	UNKNOWN						UNHEALTHY	Intravesical	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020892s019lbl.pdf	Homo sapiens										false
3003	1505		NEWBORN	14969	1449.254	VANCOMYCIN	vancomycin	CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]5C[C@](C)(N)[C@H](O)[C@H](C)O5)C6=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]7C8=CC(=C(O)C=C8)C9=C(C=C(O)C=C9O)[C@H](NC(=O)[C@@H](NC7=O)[C@H](O)C%10=CC(Cl)=C(O6)C=C%10)C(O)=O)C(Cl)=C2	SERUM	6Q205EH1VU													mg/L	29.4			RECOMMENDED	mg/kg bw	10		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://ejhp.bmj.com/content/ejhpharm/27/e1/e25.full.pdf	Homo sapiens		h	13.7							false
3004	1505		NEWBORN	14969	1449.254	VANCOMYCIN	vancomycin	CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]5C[C@](C)(N)[C@H](O)[C@H](C)O5)C6=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]7C8=CC(=C(O)C=C8)C9=C(C=C(O)C=C9O)[C@H](NC(=O)[C@@H](NC7=O)[C@H](O)C%10=CC(Cl)=C(O6)C=C%10)C(O)=O)C(Cl)=C2	SERUM	6Q205EH1VU													mg/L	21.1			RECOMMENDED	mg/kg bw	10		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://ejhp.bmj.com/content/ejhpharm/27/e1/e25.full.pdf	Homo sapiens		h	5.5							false
3005	1505		ADULT	14969	1449.254	VANCOMYCIN	vancomycin	CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]5C[C@](C)(N)[C@H](O)[C@H](C)O5)C6=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]7C8=CC(=C(O)C=C8)C9=C(C=C(O)C=C9O)[C@H](NC(=O)[C@@H](NC7=O)[C@H](O)C%10=CC(Cl)=C(O6)C=C%10)C(O)=O)C(Cl)=C2	SERUM	6Q205EH1VU																	UNKNOWN	mg/kg bw	10		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10442692/	Homo sapiens		min	224							false
3006	1505		ADULT	14969	1449.254	VANCOMYCIN	vancomycin	CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]5C[C@](C)(N)[C@H](O)[C@H](C)O5)C6=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]7C8=CC(=C(O)C=C8)C9=C(C=C(O)C=C9O)[C@H](NC(=O)[C@@H](NC7=O)[C@H](O)C%10=CC(Cl)=C(O6)C=C%10)C(O)=O)C(Cl)=C2	SERUM	6Q205EH1VU													mg/L	35.4			UNKNOWN	mg/kg bw	10		STEADY-STATE	UNKNOWN		day	3			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10442692/	Homo sapiens		min	409							false
3007	1505		ADULT	14969	1449.254	VANCOMYCIN	vancomycin	CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]5C[C@](C)(N)[C@H](O)[C@H](C)O5)C6=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]7C8=CC(=C(O)C=C8)C9=C(C=C(O)C=C9O)[C@H](NC(=O)[C@@H](NC7=O)[C@H](O)C%10=CC(Cl)=C(O6)C=C%10)C(O)=O)C(Cl)=C2	SERUM	6Q205EH1VU													mg/L	27.2			DEFINED DAILY	mg	1000		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20015925/	Homo sapiens		h	5.4							false
3008	1505		ADULT	14969	1449.254	VANCOMYCIN	vancomycin	CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]5C[C@](C)(N)[C@H](O)[C@H](C)O5)C6=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]7C8=CC(=C(O)C=C8)C9=C(C=C(O)C=C9O)[C@H](NC(=O)[C@@H](NC7=O)[C@H](O)C%10=CC(Cl)=C(O6)C=C%10)C(O)=O)C(Cl)=C2	SERUM	6Q205EH1VU													mg/L	19.1			DEFINED DAILY	mg	986.1		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20015925/	Homo sapiens		h	8.6							false
3009	1505		ADULT	14969	1449.254	VANCOMYCIN	vancomycin	CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]5C[C@](C)(N)[C@H](O)[C@H](C)O5)C6=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]7C8=CC(=C(O)C=C8)C9=C(C=C(O)C=C9O)[C@H](NC(=O)[C@@H](NC7=O)[C@H](O)C%10=CC(Cl)=C(O6)C=C%10)C(O)=O)C(Cl)=C2	SERUM	6Q205EH1VU									∞	mg × h/L	135						UNKNOWN	mg/kg bw	10.5		MULTIPLE	UNKNOWN		day	2	Serum protein binding: 30.2% (ultrafiltration of a blood sample obtained within the first 3 h after vancomycin administration)	69.8	UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3415206/	Homo sapiens		h	5.2							false
3010	1505		ADULT	14969	1449.254	VANCOMYCIN	vancomycin	CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]5C[C@](C)(N)[C@H](O)[C@H](C)O5)C6=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]7C8=CC(=C(O)C=C8)C9=C(C=C(O)C=C9O)[C@H](NC(=O)[C@@H](NC7=O)[C@H](O)C%10=CC(Cl)=C(O6)C=C%10)C(O)=O)C(Cl)=C2	SERUM	6Q205EH1VU									∞	mg × h/L	264						UNKNOWN	mg/kg bw	11.6		MULTIPLE	UNKNOWN		day	2	Serum protein binding: 29.8% (ultrafiltration of a blood sample obtained within the first 3 h after vancomycin administration)	70.2	UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3415206/	Homo sapiens		h	10.5							false
3011	1505		ADULT	14969	1449.254	VANCOMYCIN	vancomycin	CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]5C[C@](C)(N)[C@H](O)[C@H](C)O5)C6=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]7C8=CC(=C(O)C=C8)C9=C(C=C(O)C=C9O)[C@H](NC(=O)[C@@H](NC7=O)[C@H](O)C%10=CC(Cl)=C(O6)C=C%10)C(O)=O)C(Cl)=C2	SERUM	6Q205EH1VU									∞	mg × h/L	451						UNKNOWN	mg/kg bw	11		MULTIPLE	UNKNOWN		day	2	Serum protein binding: 30.9% (ultrafiltration of a blood sample obtained within the first 3 h after vancomycin administration)	69.1	UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3415206/	Homo sapiens		h	19.9							false
3012	1505		ADULT	14969	1449.254	VANCOMYCIN	vancomycin	CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]5C[C@](C)(N)[C@H](O)[C@H](C)O5)C6=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]7C8=CC(=C(O)C=C8)C9=C(C=C(O)C=C9O)[C@H](NC(=O)[C@@H](NC7=O)[C@H](O)C%10=CC(Cl)=C(O6)C=C%10)C(O)=O)C(Cl)=C2	SERUM	6Q205EH1VU							6		t	μg × h/mL	116		μg/mL	40.3			DEFINED DAILY	mg	500		STEADY-STATE	UNKNOWN		day	4			HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3579256/	Homo sapiens		h	8.1							false
3013	1505		ADULT	14969	1449.254	VANCOMYCIN	vancomycin	CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]5C[C@](C)(N)[C@H](O)[C@H](C)O5)C6=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]7C8=CC(=C(O)C=C8)C9=C(C=C(O)C=C9O)[C@H](NC(=O)[C@@H](NC7=O)[C@H](O)C%10=CC(Cl)=C(O6)C=C%10)C(O)=O)C(Cl)=C2	SERUM	6Q205EH1VU							12		t	μg × h/mL	227		μg/mL	65.7			DEFINED DAILY	mg	1000		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3579256/	Homo sapiens		h	7.7							false
3014	1505		UNKNOWN	14969	1449.254	VANCOMYCIN	vancomycin	CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]5C[C@](C)(N)[C@H](O)[C@H](C)O5)C6=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]7C8=CC(=C(O)C=C8)C9=C(C=C(O)C=C9O)[C@H](NC(=O)[C@@H](NC7=O)[C@H](O)C%10=CC(Cl)=C(O6)C=C%10)C(O)=O)C(Cl)=C2	PLASMA	6Q205EH1VU													μg/mL	63			DEFINED DAILY	g	1		MULTIPLE	UNKNOWN		day	1	Serum protein binding (55 %), ultrafiltration (10 to 100 mcg/mL)	45	UNKNOWN	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/062911s035lbl.pdf	Homo sapiens										false
3015	1505		UNKNOWN	14969	1449.254	VANCOMYCIN	vancomycin	CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]5C[C@](C)(N)[C@H](O)[C@H](C)O5)C6=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]7C8=CC(=C(O)C=C8)C9=C(C=C(O)C=C9O)[C@H](NC(=O)[C@@H](NC7=O)[C@H](O)C%10=CC(Cl)=C(O6)C=C%10)C(O)=O)C(Cl)=C2	PLASMA	6Q205EH1VU													μg/mL	49			DEFINED DAILY	mg	500		MULTIPLE	UNKNOWN		day	4			UNKNOWN	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/062911s035lbl.pdf	Homo sapiens										false
3016	1505		CHILD	14969	1449.254	VANCOMYCIN	vancomycin	CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]5C[C@](C)(N)[C@H](O)[C@H](C)O5)C6=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]7C8=CC(=C(O)C=C8)C9=C(C=C(O)C=C9O)[C@H](NC(=O)[C@@H](NC7=O)[C@H](O)C%10=CC(Cl)=C(O6)C=C%10)C(O)=O)C(Cl)=C2	PLASMA	6Q205EH1VU							8		t	μg × h/mL	124.15		μg/mL	40.94			RECOMMENDED	mg/kg	20		STEADY-STATE	UNKNOWN		day	3			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ijccm.org/doi/IJCCM/pdf/10.5005/jp-journals-10071-23275	Homo sapiens		h	4.82							false
3017	1506		ADULT	170361	211.26	Varenicline		C1C2CNCC1C3=CC4=NC=CN=C4C=C23	PLASMA	W6HS99O8ZO									∞	ng × h/mL	97.7		ng/mL	5.7			RECOMMENDED	mg	1		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16920893/	Homo sapiens		h	11.1							false
3018	1506		ADULT	5310966	211.2624	VARENICLINE	Varenicline	C1[C@H]2CNC[C@@H]1C3=CC4=C(C=C23)N=CC=N4	PLASMA	W6HS99O8ZO							24		t	ng × h/mL	186						RECOMMENDED	mg	1		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19916991/	Homo sapiens		h	24							false
3019	1506		ADULT	5310966	211.2624	VARENICLINE	Varenicline	C1[C@H]2CNC[C@@H]1C3=CC4=C(C=C23)N=CC=N4	PLASMA	W6HS99O8ZO							24		t	ng × h/mL	194		ng/mL	9.22			RECOMMENDED	mg	1		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE / MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/21053991/	Homo sapiens		h	33							false
3020	1506		ADOLESCENT	5310966	211.2624	VARENICLINE	Varenicline	C1[C@H]2CNC[C@@H]1C3=CC4=C(C=C23)N=CC=N4	PLASMA	W6HS99O8ZO									∞	ng × h/mL	106		ng/mL	6.38			RECOMMENDED	mg	1		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21053991/	Homo sapiens		h	10.9							false
3021	1506		ADULT	170361	211.26	Varenicline	Varenicline	C1C2CNCC1C3=CC4=NC=CN=C4C=C23	PLASMA	W6HS99O8ZO																	UNKNOWN				UNKNOWN	UNKNOWN		UNKNOWN			80	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021928s032s036s038lbl.pdf032s036s038lbl.pdf	Homo sapiens		h	24							false
3022	1507		ADULT	39765	557.8274	VECURONIUM	VECURONIUM	CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N5CCCCC5)[N+]6(C)CCCCC6	PLASMA	5438723848									?	μg × min/mL	29.5		ng/mL	1200			RECOMMENDED	μg/kg bw	100		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2875724/	Homo sapiens		h	49.8							false
3023	1507		UNKNOWN	39765	557.8274	VECURONIUM	VECURONIUM	CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N5CCCCC5)[N+]6(C)CCCCC6	PLASMA	5438723848																	UNKNOWN				UNKNOWN	UNKNOWN				At clinical doses of 0.04 to 0.1 mg/kg, 60 to 80% of vecuronium bromide is usually bound to plasma protein.	20	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/075549s013lbl.pdf	Homo sapiens		min	75							false
3024	1508		ADULT	2520	454.6016	VERAPAMIL	COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1	COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1	PLASMA	CJ0O37KU29									∞	ng × h/mL	367.05		ng/mL	139.28			UNKNOWN	mg	80		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/16892180	Homo sapiens		h	7.15							false
3025	1508		ADULT	2520	454.6016	VERAPAMIL	COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1	COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1	PLASMA	CJ0O37KU29																						UNKNOWN				The mean +/- SD fraction unbound was 0.099 +/- 0.015	9.9	HEALTHY		FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/6209501	Homo sapiens										false
3026	1509		ADULT		129.16	Vigabatrin			PLASMA										∞	μg × h/mL	73		μg/mL	18.4			RECOMMENDED	g	2		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8331204/	Homo sapiens		h	7							false
3027	1509		ADULT		129.16	VIGABATRIN			PLASMA																		UNKNOWN	g	2		SINGLE	UNKNOWN				Vigabatrin does not bind to plasma proteins.	100	HEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020427s021,022006s023lbl.pdf	Homo sapiens										false
3028	1510		ADULT	5717	575.675	ZAFIRLUKAST	ZAFIRLUKAST	COC1=C(CC2=CN(C)C3=C2C=C(NC(=O)OC4CCCC4)C=C3)C=CC(=C1)C(=O)NS(=O)(=O)C5=C(C)C=CC=C5	PLASMA	XZ629S5L50									∞	ng × h/mL	1090.41		ng/mL	352.7			UNKNOWN	mg	20		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/11888331	Homo sapiens		h	2.3							false
3029	1511		ADULT	5719	305.3339	ZALEPLON	ZALEPLON	CCN(C(C)=O)C1=CC(=CC=C1)C2=CC=NC3=C(C=NN23)C#N	PLASMA	S62U433RMH									?	ng × h/mL	86.1		ng/mL	62			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10211871	Homo sapiens		h	1.05							false
3030	1511		ADULT	5719	305.3339	ZALEPLON	ZALEPLON	CCN(C(C)=O)C1=CC(=CC=C1)C2=CC=NC3=C(C=NN23)C#N	PLASMA	S62U433RMH									?	ng × h/mL	26.9		ng/mL	14.5			RECOMMENDED	mg	5		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10211871	Homo sapiens		h	1.08							false
3031	1511		UNKNOWN	5719	305.3339	ZALEPLON	ZALEPLON	CCN(C(C)=O)C1=CC(=CC=C1)C2=CC=NC3=C(C=NN23)C#N	PLASMA	S62U433RMH																						UNKNOWN				The in vitro plasma protein binding is approximately 60%±15% and is independent of zaleplon concentration over the range of 10 ng/mL to 1000 ng/mL.	40	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020859s013lbl.pdf	Homo sapiens										false
3032	1512		ADULT	60855|40469135	332.3098	ZANAMIVIR	ZANAMIVIR	CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O	SERUM	L6O3XI777I									∞	μg × h/L	266		μg/L	42			UNKNOWN	mg	16		SINGLE	UNKNOWN						HEALTHY	Nasal	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10429835/	Homo sapiens		h	3.43							false
3033	1512		ADULT	60855|40469135	332.3098	ZANAMIVIR	ZANAMIVIR	CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O	SERUM	L6O3XI777I									∞	μg × h/L	2400		μg/L	12.75			UNKNOWN	mg	16		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10429835/	Homo sapiens		h	1.67							false
3034	1512		ADULT	60855|40469135	332.3098	ZANAMIVIR	ZANAMIVIR	CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O	SERUM	L6O3XI777I									?	μg × h/L	212		μg/L	86			UNKNOWN	mg	16		MULTIPLE	UNKNOWN		day	6			HEALTHY	Nasal	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10429835/	Homo sapiens										false
3035	1512		ADULT	60855|40469135	332.3098	ZANAMIVIR	ZANAMIVIR	CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O	SERUM	L6O3XI777I									∞	μg × h/L	294		μg/L	63			UNKNOWN	mg	16		SINGLE	UNKNOWN						HEALTHY	Respiratory	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10429835/	Homo sapiens		h	2.21							false
3036	1512		ADULT	60855|40469135	332.3098	ZANAMIVIR		CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O	SERUM	L6O3XI777I									?	μg × h/L	425		μg/L	139			UNKNOWN	mg	16		MULTIPLE	UNKNOWN		day	4			HEALTHY	Respiratory	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10429835/	Homo sapiens										false
3037	1512		ADULT	60855|40469135	332.3098	ZANAMIVIR	ZANAMIVIR	CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O	SERUM	L6O3XI777I									∞	μg × h/L	247		μg/L	39			UNKNOWN	mg	10		SINGLE	UNKNOWN						HEALTHY	Respiratory	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10429835/	Homo sapiens		h	3.56							false
3038	1512		ADULT	60855|40469135	332.3098	ZANAMIVIR	ZANAMIVIR	CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O	SERUM	L6O3XI777I									?	μg × h/L	160		μg/L	54			UNKNOWN	mg	10		MULTIPLE	UNKNOWN		day	4			HEALTHY	Respiratory	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10429835/	Homo sapiens										false
3039	1513		ADULT	35370	267.2413	ZIDOVUDINE	ZIDOVUDINE	CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O	SERUM	4B9XT59T7S									∞	mg × h/L	0.26		μg/mL	0.16			UNKNOWN	mg	50		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1803995	Homo sapiens		h	1.5							false
3040	1513		ADULT	35370	267.2413	ZIDOVUDINE	ZIDOVUDINE	CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O	SERUM	4B9XT59T7S									?	mg × h/L	0.32		μg/mL	0.2			UNKNOWN	mg	50		STEADY-STATE	FASTED		day	6			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1803995	Homo sapiens		h	1.4							false
3041	1513		ADULT	35370	267.2413	ZIDOVUDINE	ZIDOVUDINE	CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O	SERUM	4B9XT59T7S									∞	mg × h/L	0.39						UNKNOWN	mg	60		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1803995	Homo sapiens		h	1.3							false
3042	1513		ADULT	35370	267.2413	ZIDOVUDINE	ZIDOVUDINE	CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O	SERUM	4B9XT59T7S									∞	mg × h/L	0.74		μg/mL	0.74			UNKNOWN	mg	100		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1803995	Homo sapiens		h	1.6							false
3043	1513		ADULT	35370	267.2413	ZIDOVUDINE	ZIDOVUDINE	CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O	SERUM	4B9XT59T7S									?	mg × h/L	0.65		μg/mL	0.55			UNKNOWN	mg	100		STEADY-STATE	FASTED		day	6			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1803995	Homo sapiens		h	1.1							false
3044	1513		ADULT	35370	267.2413	ZIDOVUDINE	ZIDOVUDINE	CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O	SERUM	4B9XT59T7S									∞	mg × h/L	1.22		μg/mL	1.72			UNKNOWN	mg	150		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1803995	Homo sapiens		h	1.7							false
3045	1513		ADULT	35370	267.2413	ZIDOVUDINE	ZIDOVUDINE	CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O	SERUM	4B9XT59T7S									∞	mg × h/L	1.33		μg/mL	1			UNKNOWN	mg	250		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1803995	Homo sapiens		h	1.5							false
3046	1513		ADULT	35370	267.2413	ZIDOVUDINE	ZIDOVUDINE	CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O	SERUM	4B9XT59T7S									?	mg × h/L	1.28		μg/mL	1			UNKNOWN	mg	250		STEADY-STATE	FASTED		day	6			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1803995	Homo sapiens		h	1.1							false
3047	1513		ADULT	35370	267.2413	ZIDOVUDINE	ZIDOVUDINE	CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O	SERUM	4B9XT59T7S									?	mg × h/L	1.31		μg/mL	1.8			UNKNOWN	mg	150		STEADY-STATE	UNKNOWN		day	6			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1803995	Homo sapiens		h	1.4							false
3048	1513		ADULT	35370	267.2413	ZIDOVUDINE	ZIDOVUDINE	CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O	PLASMA	4B9XT59T7S													μg/mL	1.1			UNKNOWN	mg/kg	2.5		STEADY-STATE	UNKNOWN		day	6	binding to plasma protein is low (less than 38%).	62	UNHEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019910s041lbl.pdf	Homo sapiens										false
3049	1513		ADULT	35370	267.2413	ZIDOVUDINE	ZIDOVUDINE	CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O	PLASMA	4B9XT59T7S									?	ng × h/mL	1400						RECOMMENDED	mg	200		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019910s041lbl.pdf	Homo sapiens		h	1							false
3050	1514		UNKNOWN	60490	236.29	ZILEUTON	Zileuton	CC(N(O)C(N)=O)C1=CC2=C(S1)C=CC=C2	PLASMA	V1L22WVE2S									?	μg × h/mL	19.2		μg/mL	4.98			RECOMMENDED	mg	600		MULTIPLE	UNKNOWN		day	4	Zileuton is 93% bound to plasma proteins, primarily to albumin, with minor binding to αl-acid glycoprotein.	7	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020471s017lbl.pdf	Homo sapiens										false
3051	1515		ADULT	60857	287.3568	ZOLMITRIPTAN	ZOLMITRIPTAN	CN(C)CCC1=CNC2=C1C=C(C[C@H]3COC(=O)N3)C=C2	PLASMA	2FS66TH3YW									∞	ng × h/mL	17.7		ng/mL	3.3			RECOMMENDED	mg	2.5		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9833595	Homo sapiens		h	2.29							false
3052	1515		ADULT	60857	287.3568	ZOLMITRIPTAN	ZOLMITRIPTAN	CN(C)CCC1=CNC2=C1C=C(C[C@H]3COC(=O)N3)C=C2	PLASMA	2FS66TH3YW									∞	ng × h/mL	21.3		ng/mL	3.8			RECOMMENDED	mg	2.5		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9833595	Homo sapiens		h	2.56							false
3053	1515		ADULT	60857	287.3568	ZOLMITRIPTAN	ZOLMITRIPTAN	CN(C)CCC1=CNC2=C1C=C(C[C@H]3COC(=O)N3)C=C2	PLASMA	2FS66TH3YW									∞	ng × h/mL	30.9		ng/mL	5.6			MAX DAILY	mg	5		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9833595	Homo sapiens		h	2.6							false
3054	1515		ADULT	60857	287.3568	ZOLMITRIPTAN	ZOLMITRIPTAN	CN(C)CCC1=CNC2=C1C=C(C[C@H]3COC(=O)N3)C=C2	PLASMA	2FS66TH3YW									∞	ng × h/mL	54.8		ng/mL	9			MAX DAILY	mg	5		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9833595	Homo sapiens		h	2.82							false
3055	1515		ADULT	60857	287.3568	ZOLMITRIPTAN	ZOLMITRIPTAN	CN(C)CCC1=CNC2=C1C=C(C[C@H]3COC(=O)N3)C=C2	PLASMA	2FS66TH3YW									∞	ng × h/mL	16.8		ng/mL	5.8			UNKNOWN	mg	0.925		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9833595	Homo sapiens		h	2.1							false
3056	1515		ADULT	60857	287.3568	ZOLMITRIPTAN	ZOLMITRIPTAN	CN(C)CCC1=CNC2=C1C=C(C[C@H]3COC(=O)N3)C=C2	PLASMA	2FS66TH3YW									∞	ng × h/mL	32.4		ng/mL	10			UNKNOWN	mg	1.475		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9833595	Homo sapiens		h	2.5							false
3057	1515		ADULT	60857	287.3568	ZOLMITRIPTAN	ZOLMITRIPTAN	CN(C)CCC1=CNC2=C1C=C(C[C@H]3COC(=O)N3)C=C2	PLASMA	2FS66TH3YW									∞	ng × h/mL	32.5		ng/mL	10.6			UNKNOWN	mg	1.85		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9833595	Homo sapiens		h	2.32							false
3058	1515		ADULT	60857	287.3568	ZOLMITRIPTAN	ZOLMITRIPTAN	CN(C)CCC1=CNC2=C1C=C(C[C@H]3COC(=O)N3)C=C2	PLASMA	2FS66TH3YW									∞	ng × h/mL	71.2		ng/mL	22.2			UNKNOWN	mg	2.95		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9833595	Homo sapiens		h	2.66							false
3059	1515		ADULT	60857	287.3568	ZOLMITRIPTAN	ZOLMITRIPTAN	CN(C)CCC1=CNC2=C1C=C(C[C@H]3COC(=O)N3)C=C2	PLASMA	2FS66TH3YW									∞	ng × h/mL	23.9		ng/mL	4.4			MAX DAILY	mg	5		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9833595	Homo sapiens										false
3060	1515		ADULT	60857	287.3568	ZOLMITRIPTAN	ZOLMITRIPTAN	CN(C)CCC1=CNC2=C1C=C(C[C@H]3COC(=O)N3)C=C2	PLASMA	2FS66TH3YW									∞	ng × h/mL	55.7		ng/mL	9.9			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9833595	Homo sapiens										false
3061	1515		UNKNOWN	60857	287.3568	ZOLMITRIPTAN	ZOLMITRIPTAN	CN(C)CCC1=CNC2=C1C=C(C[C@H]3COC(=O)N3)C=C2	PLASMA	2FS66TH3YW																	UNKNOWN				UNKNOWN	UNKNOWN				Plasma protein binding of zolmitriptan is 25% over the concentration range of 10-1000 ng/mL.	75	UNKNOWN	UNKNOWN	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020768s023,021231s014,021450s010lbl.pdf	Homo sapiens										false
3062	1516		ADULT	5734|11967800	212.226	ZONISAMIDE	ZONISAMIDE	NS(=O)(=O)CC1=NOC2=C1C=CC=C2	PLASMA	459384H98V							12		t	μg × h/mL	197.4		μg/mL	18.4			UNKNOWN	mg	100		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15496640	Homo sapiens										false
3063	1516		UNKNOWN	5734|11967800	212.226	ZONISAMIDE	ZONISAMIDE	NS(=O)(=O)CC1=NOC2=C1C=CC=C2	PLASMA	459384H98V																	UNKNOWN				UNKNOWN	UNKNOWN				Zonisamide, at concentrations of 1.0–7.0 ug/mL, is approximately 40% bound to human plasma proteins.	60	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020789s012lbl.pdf	Homo sapiens		h	63							false
3064	1517		ADULT	16131215	1416.063	ABARELIX	ABARELIX	CC(C)C[C@H](NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC2=CN=CC=C2)NC(=O)[C@@H](CC3=CC=C(Cl)C=C3)NC(=O)[C@@H](CC4=CC5=C(C=CC=C5)C=C4)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N6CCC[C@H]6C(=O)N[C@H](C)C(N)=O	PLASMA	W486SJ5824									∞	ng × h/mL	500		ng/mL	43.4			RECOMMENDED	mg	100		SINGLE	UNKNOWN				Plenaxis™ is highly bound to plasma proteins (96 to 99%)	1	HEALTHY	Intramuscular	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/21320_plenaxis_lbl.pdf	Homo sapiens		h	13.2							false
3065	1518		ADULT	5488547	460.5631	ALVIMOPAN	ALVIMOPAN	O.O.C[C@H]1CN(C[C@H](CC2=CC=CC=C2)C(=O)NCC(O)=O)CC[C@@]1(C)C3=CC(O)=CC=C3	PLASMA	677C126AET							12		t	ng × h/mL	40.2		ng/mL	10.98			RECOMMENDED	mg	12		MULTIPLE	UNKNOWN		day	2	Plasma protein binding of alvimopan and its ‘metabolite’ was independent of concentration over ranges observed clinically and averaged 80% and 94%, respectively.	20	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021775lbl.pdf	Homo sapiens		h	13.5							false
3066	1519		ADULT	166548	1140.2	Anidulafungin		CCCCCOC1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)NC4CC(C(NC(=O)C5C(C(CN5C(=O)C(NC(=O)C(NC(=O)C6CC(CN6C(=O)C(NC4=O)C(C)O)O)C(C(C7=CC=C(C=C7)O)O)O)C(C)O)C)O)O)O	PLASMA	9HLM53094I							24		t	mg × h/L	55.2		mg/L	4.2			RECOMMENDED	mg	100		STEADY-STATE	UNKNOWN		day	1		1	UNHEALTHY	Intravenous	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf	Homo sapiens		h	26.5							false
3067	1519		ADULT	166548	1140.2	Anidulafungin		CCCCCOC1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)NC4CC(C(NC(=O)C5C(C(CN5C(=O)C(NC(=O)C(NC(=O)C6CC(CN6C(=O)C(NC4=O)C(C)O)O)C(C(C7=CC=C(C=C7)O)O)O)C(C)O)C)O)O)O	PLASMA	9HLM53094I							24		t	mg × h/L	110.3		mg/L	7.2			RECOMMENDED	mg	200		STEADY-STATE	UNKNOWN		day	1		1	UNHEALTHY	Intravenous	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf	Homo sapiens		h	26.5							false
3068	1520		ADULT		388.9	BEPOTASTINE			PLASMA										∞	ng × h/mL	392.4		ng/mL	99.9			UNKNOWN	mg	19		SINGLE	FASTED				https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022288s008lbl.pdf	45	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24105252/	Homo sapiens		h	3.9							false
3069	1520		ADULT		388.9	BEPOTASTINE			PLASMA														ng/mL	7.3			RECOMMENDED	μg	0.75		MULTIPLE	UNKNOWN		day	1	The extent of protein binding of bepotastine is approximately 55% and independent of bepotastine concentration.	45	HEALTHY	Ocular	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022288s008lbl.pdf	Homo sapiens										false
3070	1521		ADULT	5361092	327.4605	BUTORPHANOL	BUTORPHANOL	OC1=CC=C2C[C@H]3N(CC4CCC4)CC[C@@]5(CCCC[C@@]35O)C2=C1	PLASMA	QV897JC36D																	MAX DAILY	mg	4		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intramuscular	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/8031438	Homo sapiens		h	2.7							false
3071	1521		ADULT	5361092	327.4605	BUTORPHANOL	BUTORPHANOL	OC1=CC=C2C[C@H]3N(CC4CCC4)CC[C@@]5(CCCC[C@@]35O)C2=C1	PLASMA	QV897JC36D									∞	pg × h/mL	4612		pg/mL	1542			RECOMMENDED	mg	1		SINGLE	UNKNOWN						HEALTHY	Nasal	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9113342/	Homo sapiens		h	4.23							false
3072	1521		ADULT	5361092	327.4605	BUTORPHANOL	BUTORPHANOL	OC1=CC=C2C[C@H]3N(CC4CCC4)CC[C@@]5(CCCC[C@@]35O)C2=C1	PLASMA	QV897JC36D							6		t	pg × h/mL	4130		pg/mL	1376			RECOMMENDED	mg	1		STEADY-STATE	UNKNOWN		day	4			HEALTHY	Nasal	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9113342/	Homo sapiens		h	7.6							false
3073	1522		ADULT	16130924|25074887	1431.038	CETRORELIX	CETRORELIX	CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC2=CN=CC=C2)NC(=O)[C@@H](CC3=CC=C(Cl)C=C3)NC(=O)[C@@H](CC4=CC5=C(C=CC=C5)C=C4)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N6CCC[C@H]6C(=O)N[C@H](C)C(N)=O	PLASMA	OON1HFZ4BA									∞	ng × h/mL	536		ng/mL	28.5			RECOMMENDED	mg	3		SINGLE	UNKNOWN				Invitro protein binding to human plasma is 86%.	14	HEALTHY	Subcutaneous	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21197lbl.pdf	Homo sapiens		h	62.8							false
3074	1522		ADULT	16130924|25074887	1431.038	CETRORELIX	CETRORELIX	CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC2=CN=CC=C2)NC(=O)[C@@H](CC3=CC=C(Cl)C=C3)NC(=O)[C@@H](CC4=CC5=C(C=CC=C5)C=C4)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N6CCC[C@H]6C(=O)N[C@H](C)C(N)=O	PLASMA	OON1HFZ4BA									∞	ng × h/mL	31.4		ng/mL	4.97			DEFINED DAILY	mg	0.25		SINGLE	UNKNOWN						HEALTHY	Subcutaneous	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21197lbl.pdf	Homo sapiens		h	5							false
3075	1522		ADULT	16130924|25074887	1431.038	CETRORELIX	CETRORELIX	CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC2=CN=CC=C2)NC(=O)[C@@H](CC3=CC=C(Cl)C=C3)NC(=O)[C@@H](CC4=CC5=C(C=CC=C5)C=C4)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N6CCC[C@H]6C(=O)N[C@H](C)C(N)=O	PLASMA	OON1HFZ4BA									?	ng × h/mL	44.5		ng/mL	6.42			RECOMMENDED	mg	0.25		MULTIPLE	UNKNOWN		day	1			HEALTHY	Subcutaneous	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21197lbl.pdf	Homo sapiens		h	20.6							false
3076	1523		ADULT	153994	456.316	CLEVIDIPINE	CLEVIDIPINE	CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C1C2=C(Cl)C(Cl)=CC=C2)C(=O)OC	PLASMA	19O2GP3B7Q							73		t	ng × h/mL	122		ng/mL	3.36			RECOMMENDED	mg/h	2	infusion, 72 hour	OTHER	FASTED						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22457015/	Homo sapiens		min	4.18							false
3077	1523		ADULT	153994	456.316	CLEVIDIPINE	CLEVIDIPINE	CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C1C2=C(Cl)C(Cl)=CC=C2)C(=O)OC	PLASMA	19O2GP3B7Q																	RECOMMENDED	mg/h	2	infusion, 24 hour	OTHER	FASTED				Clevidipine is >99.5% bound to proteins in plasma at 37°C	0.5	UNHEALTHY	Intravenous	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022156s003lbl.pdf	Homo sapiens		min	15							false
3078	1524		ADULT	2802	315.711	CLONAZEPAM	CLONAZEPAM	[O-][N+](=O)C1=CC=C2NC(=O)CN=C(C2=C1)C3=C(Cl)C=CC=C3	PLASMA	5PE9FDE8GB							24		t	ng × h/mL	102		ng/mL	2.3			RECOMMENDED	mg	0.5		SINGLE	UNKNOWN				Clonazepam is approximately 85% bound to plasma proteins. [https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017533s059lbl.pdf]	15	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://accp1.onlinelibrary.wiley.com/doi/epdf/10.1177/0091270005280861	Homo sapiens										false
3079	1524		ADULT	2802	315.711	CLONAZEPAM	CLONAZEPAM	[O-][N+](=O)C1=CC=C2NC(=O)CN=C(C2=C1)C3=C(Cl)C=CC=C3	PLASMA	5PE9FDE8GB							24		t	ng × h/mL	339		ng/mL	3			RECOMMENDED	mg	0.5		STEADY-STATE	UNKNOWN		day	3			UNHEALTHY	Oral	FEMALE / MALE	REVIEW	https://accp1.onlinelibrary.wiley.com/doi/epdf/10.1177/0091270005280861	Homo sapiens		h	40							false
3080	1525		ADULT		1355.4	CYANOCOBALAMIN	CYANOCOBALAMIN		SERUM	P6YC3EG204	158788|23669833|100958031		SALCAPROZATE SODIUM	SALCAPROZATE SODIUM	[Na+].OC1=C(C=CC=C1)C(=O)NCCCCCCCC([O-])=O	1YTW0422YU			?	pg × h/mL	127494		pg/mL	28175			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21722960/	Homo sapiens		h	25.31							true
3081	1525		ADULT		1355.4	CYANOCOBALAMIN	CYANOCOBALAMIN		SERUM	P6YC3EG204	158788|23669833|100958031		SALCAPROZATE SODIUM	SALCAPROZATE SODIUM	[Na+].OC1=C(C=CC=C1)C(=O)NCCCCCCCC([O-])=O	1YTW0422YU			?	pg × h/mL	54609		pg/mL	12847			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21722960/	Homo sapiens		h	30.06							true
3082	1525		ADULT		1355.4	CYANOCOBALAMIN	CYANOCOBALAMIN		SERUM	P6YC3EG204									∞	pg × h/mL	235165		pg/mL	221287			UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21722960/	Homo sapiens		h	15.53							false
3083	1525		ADULT		1355.4	CYANOCOBALAMIN	CYANOCOBALAMIN		SERUM	P6YC3EG204									?	pg × h/mL	23165		pg/mL	1239			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21722960/	Homo sapiens		h	25.95							false
3084	1525		UNKNOWN		1355.4	CYANOCOBALAMIN	CYANOCOBALAMIN		PLASMA	P6YC3EG204													pg/mL	757.96			UNKNOWN	μg	500		SINGLE	FASTED						HEALTHY	Nasal	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021642s002lbl.pdf	Homo sapiens										false
3085	1526		ADULT	5284373	1202.6112	CYCLOSPORINE	CYCLOSPORINE A	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\\C=C\\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	PLASMA	83HN0GTJ6D							4		t	ng × h/mL	3301		ng/mL	1220			RECOMMENDED	mg/kg	5.26		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/12118899	Homo sapiens										false
3086	1526		ADULT	5284373	1202.6112	CYCLOSPORINE	CYCLOSPORINE A	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\\C=C\\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	PLASMA	83HN0GTJ6D																	UNKNOWN	mg	300		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	REVIEW	https://www.ncbi.nlm.nih.gov/pubmed/3322675	Homo sapiens		h	6							false
3087	1527		ADULT	34328|25273607	424.5341	DIFENOXIN	DIFENOXIN	OC(=O)C1(CCN(CCC(C#N)(C2=CC=CC=C2)C3=CC=CC=C3)CC1)C4=CC=CC=C4	PLASMA	3ZZ5BJ9F2Q													ng/mL	160			RECOMMENDED	mg	1		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017744s026lbl.pdf	Homo sapiens										false
3088	1528		ADULT	16078	314.4617	DRONABINOL	DRONABINOL	CCCCCC1=CC2=C([C@@H]3C=C(C)CC[C@H]3C(C)(C)O2)C(O)=C1	PLASMA	7J8897W37S							12		t	ng × h/mL	6.16		ng/mL	2.96			UNKNOWN	mg	5		MULTIPLE	FASTED		day	2		3	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018651s029lbl.pdf	Homo sapiens										false
3089	1528		ADULT	16078	314.4617	DRONABINOL	DRONABINOL	CCCCCC1=CC2=C([C@@H]3C=C(C)CC[C@H]3C(C)(C)O2)C(O)=C1	PLASMA	7J8897W37S							12		t	ng × h/mL	15.2		ng/mL	7.88			MAX DAILY	mg	10		MULTIPLE	FASTED		day	2		3	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018651s029lbl.pdf	Homo sapiens										false
3090	1528		ADULT	16078	314.4617	DRONABINOL	DRONABINOL	CCCCCC1=CC2=C([C@@H]3C=C(C)CC[C@H]3C(C)(C)O2)C(O)=C1	PLASMA	7J8897W37S							12		t	ng × h/mL	2.88		ng/mL	1.32			RECOMMENDED	mg	2.5		MULTIPLE	FASTED		day	2		3	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018651s029lbl.pdf	Homo sapiens										false
3091	1529			150610	475.515	ERTAPENEM	ERTAPENEM	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)NC4=CC(=CC=C4)C(O)=O)=C(N2C1=O)C(O)=O	PLASMA	G32F6EID2H							12		t	μg × h/mL	6225		μg/mL	663.1				g	1		MULTIPLE			week	3			UNHEALTHY	Intravenous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02159859	Homo sapiens		h	19.3							false
3092	1529		ADULT	150610	475.515	ERTAPENEM	ERTAPENEM	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)NC4=CC(=CC=C4)C(O)=O)=C(N2C1=O)C(O)=O	PLASMA	G32F6EID2H									∞	μg × h/mL	541.8		μg/mL	70.6			RECOMMENDED	g	1		SINGLE	UNKNOWN						HEALTHY	Intramuscular	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12709348	Homo sapiens		h	3.8							false
3093	1529		ADULT	150610	475.515	ERTAPENEM	ERTAPENEM	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)NC4=CC(=CC=C4)C(O)=O)=C(N2C1=O)C(O)=O	PLASMA	G32F6EID2H							24		t	μg × h/mL	506.4		μg/mL	75.7			RECOMMENDED	g	1		MULTIPLE	UNKNOWN		day	1			HEALTHY	Intramuscular	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12709348	Homo sapiens		h	3.5							false
3094	1529		ADULT	150610	475.515	ERTAPENEM	ERTAPENEM	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)NC4=CC(=CC=C4)C(O)=O)=C(N2C1=O)C(O)=O	PLASMA	G32F6EID2H													μg/mL	155			RECOMMENDED	g	1		SINGLE	UNKNOWN				In healthy young adults, the protein binding of ertapenem decreases as plasma concentrations increase, from approximately 95% bound at an approximate plasma concentration of <100 micrograms (mcg)/mL to approximately 85% bound at an approximate plasma concentration of 300 mcg/mL.	10	HEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021337Orig1s021.pdf	Homo sapiens		h	4							false
3095	1530		ADULT	5281077	144.599	ETHCHLORVYNOL	ETHCHLORVYNOL	CCC(O)(\\C=C\\Cl)C#C	SERUM	6EIM3851UZ																	UNKNOWN				UNKNOWN	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3822854	Homo sapiens		h	25							false
3096	1531		ADULT	193962	435.277	ETRAVIRINE	ETRAVIRINE	CC1=CC(=CC(C)=C1OC2=NC(NC3=CC=C(C=C3)C#N)=NC(N)=C2Br)C#N	PLASMA		213039		DARUNAVIR	darunavir	CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CO[C@H]3OCC[C@@H]23)S(=O)(=O)C4=CC=C(N)C=C4	YO603Y8113	12		t	ng × h/mL	4531.53		ng/mL	296.74			RECOMMENDED	mg	200		STEADY-STATE	FED		day	2	Etravirine is about 99.9% bound to plasma proteins, primarily to albumin (99.6%) and alpha 1-acid glycoprotein (97.66%-99.02%) in vitro	0.1	UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022187lbl.pdf	Homo sapiens		h	41							true
3097	1532		UNKNOWN	9854489	538.576	FLUTICASONE FUROATE	FLUTICASONE FUROATE	C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)C5=CC=CO5)C(=O)SCF	PLASMA	JS86977WNV																						UNKNOWN				In vitro, fluticasone furoate was 99.4% bound to plasma protein	0.6	UNKNOWN		UNKNOWN	EXPERIMENT	https://link.springer.com/article/10.2165/00003495-200767130-00010	Homo sapiens										false
3098	1532		ADULT	9854489	538.576	FLUTICASONE FUROATE	FLUTICASONE FUROATE	C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)C5=CC=CO5)C(=O)SCF	PLASMA	JS86977WNV									∞	pg × h/mL	3505		pg/mL	4224			UNKNOWN	μg	250		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/27163502	Homo sapiens		h	13.7							false
3099	1533		ADULT	31640	352.738	HALAZEPAM	HALAZEPAM	FC(F)(F)CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C3=CC=CC=C3	PLASMA	320YC168LF									?	ng × h/mL	347		ng/mL	93			UNKNOWN	mg	40		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6145534	Homo sapiens										false
3100	1533		ADULT	2997	270.714	NORDAZEPAM	Nordazepam	ClC1=CC=C2NC(=O)CN=C(C3=CC=CC=C3)C2=C1	PLASMA	67220MCM01									?	ng × h/mL	796		ng/mL	147			UNKNOWN	mg	40		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6145534	Homo sapiens										false
3101	1533		ADULT	31640	352.738	HALAZEPAM	HALAZEPAM	FC(F)(F)CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C3=CC=CC=C3	PLASMA	320YC168LF									?	ng × h/mL	640		ng/mL	137			UNKNOWN	mg	40		STEADY-STATE	UNKNOWN		day	3			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6145534	Homo sapiens		h	1.9							false
3102	1533		ADULT	2997	270.714	NORDAZEPAM	Nordazepam	ClC1=CC=C2NC(=O)CN=C(C3=CC=CC=C3)C2=C1	PLASMA	67220MCM01									?	ng × h/mL	5863		ng/mL	916			UNKNOWN	mg	40		STEADY-STATE	UNKNOWN		day	3			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6145534	Homo sapiens										false
3103	1534		ADULT	6445540	506.698	IXABEPILONE	C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\\C)=C\\C3=CSC(C)=N3	C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\\C)=C\\C3=CSC(C)=N3	PLASMA	K27005NP0A									?	ng × h/mL	2143		ng/mL	252			RECOMMENDED	mg/m²	40		SINGLE	UNKNOWN				In vitro, the binding of ixabepilone to human serum proteins ranged from 67 to 77%, and the blood-to-plasma concentration ratios in human blood ranged from 0.65 to 0.85 over a concentration range of 50 to 5000 ng/mL.	28	UNHEALTHY	Intravenous	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022065s002lbl.pdf	Homo sapiens		h	52							false
3104	1535		ADULT	219078	250.2936	LACOSAMIDE	LACOSAMIDE	COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1	PLASMA	563KS2PQY5									∞	ng × h/mL	59120		ng/mL	2935.3			RECOMMENDED	mg	100		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	REVIEW	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ClinPharmR_P2.pdf	Homo sapiens		h	14.47							false
3105	1536		ADULT	4020	284.74	MAZINDOL	MAZINDOL	OC1(N2CCN=C2C3=CC=CC=C13)C4=CC=C(Cl)C=C4	PLASMA	C56709M5NH							24		t	ng × h/mL	35.63		ng/mL	4.09			UNKNOWN	mg	2		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27066959/	Homo sapiens		h	7.66							false
3106	1537		ADULT	4058	247.3327	MEPERIDINE	meperidine	CCOC(=O)C1(CCN(C)CC1)C2=CC=CC=C2	PLASMA	9E338QE28F							6		t	μg × min/mL	19.6		ng/mL	196			UNKNOWN	mg	30		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2891328/	Homo sapiens		min	124							false
3107	1538		ADULT	4095	309.4452	METHADONE	METHADONE	CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2	PLASMA	UC6VBE7V1Z							24		t	μg × h/mL	8.27		ng/mL	494			DEFINED DAILY	mg	76		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15151520/	Homo sapiens		h	39	average dose for full population			59			false
3108	1538		ADULT	4095	309.4452	METHADONE	METHADONE	CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2	PLASMA	UC6VBE7V1Z							72		t	ng × h/mL	1073		ng/mL	40.2			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22621465/	Homo sapiens		h	39.3							false
3109	1538		ADULT	5352621	277.4033	2-ETHYLIDENE-1,5-DIMETHYL-3,3-DIPHENYLPYRROLIDINE	2-ETHYLIDENE-1,5-DIMETHYL-3,3-DIPHENYLPYRROLIDINE	C\\C=C1\\N(C)C(C)CC1(C2=CC=CC=C2)C3=CC=CC=C3	PLASMA	Z3LC48U94I							24		t	mg × h/L	0.61		ng/mL	54			DEFINED DAILY	mg/kg	0.89		STEADY-STATE	FED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8641323/	Homo sapiens				Average dose provided			20			false
3110	1538		ADULT	4095	309.4452	METHADONE	METHADONE	CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2	PLASMA	UC6VBE7V1Z							24		t	mg × h/L	8.54		ng/mL	548			DEFINED DAILY	mg/kg	0.89		STEADY-STATE	FED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8641323/	Homo sapiens		h	31.2	average dose provided			23			false
3111	1539		ADULT	477468	1270.3	Micafungin		CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)NC4CC(C(NC(=O)C5C(C(CN5C(=O)C(NC(=O)C(NC(=O)C6CC(CN6C(=O)C(NC4=O)C(C)O)O)C(C(C7=CC(=C(C=C7)O)OS(=O)(=O)O)O)O)C(CC(=O)N)O)C)O)O)O	PLASMA	R10H71BSWG							24		t	μg × h/mL	97		μg/mL	10.1			RECOMMENDED	mg	100		STEADY-STATE	UNKNOWN		day	1		1	UNHEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021506s011s012lbl.pdf	Homo sapiens		h	13.4							false
3112	1539		ADULT	477468	1270.3	Micafungin		CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)NC4CC(C(NC(=O)C5C(C(CN5C(=O)C(NC(=O)C(NC(=O)C6CC(CN6C(=O)C(NC4=O)C(C)O)O)C(C(C7=CC(=C(C=C7)O)OS(=O)(=O)O)O)O)C(CC(=O)N)O)C)O)O)O	PLASMA	R10H71BSWG							24		t	μg × h/mL	167		μg/mL	16.4			RECOMMENDED	mg	150		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021506s011s012lbl.pdf	Homo sapiens		h	15.2							false
3113	1539		ADULT	477468	1270.3	Micafungin		CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)NC4CC(C(NC(=O)C5C(C(CN5C(=O)C(NC(=O)C(NC(=O)C6CC(CN6C(=O)C(NC4=O)C(C)O)O)C(C(C7=CC(=C(C=C7)O)OS(=O)(=O)O)O)O)C(CC(=O)N)O)C)O)O)O	PLASMA	R10H71BSWG							24		t	μg × h/mL	663		μg/mL	60.8			MAX DAILY	mg/kg bw	8		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021506s011s012lbl.pdf	Homo sapiens		h	17.2							false
3114	1540		ADULT	5878	306.4397	OXANDROLONE	OXANDROLONE	C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4CC(=O)OC[C@]4(C)[C@H]3CC[C@]12C	PLASMA	7H6TM3CT4L									∞	ng × h/mL	3380		ng/mL	417			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4729902	Homo sapiens		h	9.4							false
3115	1541		ADULT	5284604	301.34	Oxymorphone	Oxymorphone	CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O	PLASMA	9VXA968E0C							12		t	ng × h/mL	4.54		ng/mL	0.27			INVESTIGATIONAL	mg	5		SINGLE	UNKNOWN						UNKNOWN	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/201655s016lbl.pdf	Homo sapiens		h	11.3							false
3116	1541		ADULT	5284604	301.34	Oxymorphone	Oxymorphone	CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O	PLASMA	9VXA968E0C							12		t	ng × h/mL	17.81		ng/mL	1.21			INVESTIGATIONAL	mg	20		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/201655s016lbl.pdf	Homo sapiens		h	9.89							false
3117	1541		ADULT	5284604	301.34	Oxymorphone	Oxymorphone	CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O	PLASMA	9VXA968E0C							12		t	ng × h/mL	37.9		ng/mL	2.59			INVESTIGATIONAL	mg	40		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/201655s016lbl.pdf	Homo sapiens		h	9.35							false
3118	1541		ADULT	5284604	301.34	Oxymorphone	Oxymorphone	CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O	PLASMA	9VXA968E0C							12		t	ng × h/mL	5.6		ng/mL	0.7			INVESTIGATIONAL	mg	5		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/201655s016lbl.pdf	Homo sapiens										false
3119	1541		ADULT	5284604	301.34	Oxymorphone	Oxymorphone	CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O	PLASMA	9VXA968E0C							12		t	ng × h/mL	19.28		ng/mL	2.54			INVESTIGATIONAL	mg	20		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/201655s016lbl.pdf	Homo sapiens										false
3120	1541		ADULT	5284604	301.34	Oxymorphone	Oxymorphone	CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O	PLASMA	9VXA968E0C							12		t	ng × h/mL	36.98		ng/mL	4.47			INVESTIGATIONAL	mg	40		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/201655s016lbl.pdf	Homo sapiens										false
3121	1542		ADULT	30487	191.2695	PHENDIMETRAZINE	PHENDIMETRAZINE	C[C@H]1[C@@H](OCCN1C)C2=CC=CC=C2	PLASMA	AB2794W8KV													ng/mL	70			UNKNOWN	mg	35		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6688092	Homo sapiens		h	2							false
3122	1542		UNKNOWN	30487	191.2695	PHENDIMETRAZINE	PHENDIMETRAZINE	C[C@H]1[C@@H](OCCN1C)C2=CC=CC=C2	UNKNOWN	AB2794W8KV																						UNKNOWN						UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/018074s034lbl.pdf	Homo sapiens		h	3.7							false
3123	1543		ADULT	54681545	280.3178	PHENPROCOUMON, (R)-	(R)-Phenprocoumon	CC[C@H](C1=CC=CC=C1)C2=C(O)C3=C(OC2=O)C=CC=C3	PLASMA	Y513Q74WCG									∞	μg × h/mL	89.7		μM	2			RECOMMENDED	mg	12		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15128047/	Homo sapiens		h	123							false
3124	1543		ADULT	54681533	280.3178	PHENPROCOUMON, (S)-	(S)-Phenprocoumon	CC[C@@H](C1=CC=CC=C1)C2=C(O)C3=C(OC2=O)C=CC=C3	PLASMA	3DM685514V									∞	μg × h/mL	105.1		μM	2.1			RECOMMENDED	mg	12		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15128047/	Homo sapiens		h	149							false
3125	1544		ADULT	4999	386.794	QUAZEPAM	QUAZEPAM	FC1=C(C=CC=C1)C2=NCC(=S)N(CC(F)(F)F)C3=CC=C(Cl)C=C23	PLASMA	JF8V0828ZI							48		t	ng × h/mL	291		ng/mL	28			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12680887	Homo sapiens		h	14.3							false
3126	1544		ADULT	4999	386.794	QUAZEPAM	QUAZEPAM	FC1=C(C=CC=C1)C2=NCC(=S)N(CC(F)(F)F)C3=CC=C(Cl)C=C23	PLASMA	JF8V0828ZI							48		t	ng × h/mL	468		ng/mL	81.2			UNKNOWN	mg	20		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12680887	Homo sapiens		h	15.5							false
3127	1544		UNKNOWN	4999	386.794	QUAZEPAM	QUAZEPAM	FC1=C(C=CC=C1)C2=NCC(=S)N(CC(F)(F)F)C3=CC=C(Cl)C=C23	PLASMA	JF8V0828ZI																						UNKNOWN				The degree of plasma protein binding for quazepam and its two major metabolites is greater than 95%.	5	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018708s018lbl.pdf	Homo sapiens										false
3128	1545		ADULT	44154280	408.3693	REGADENOSON	REGADENOSON	O.CNC(=O)C1=CN(N=C1)C2=NC3=C(N=CN3[C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O)C(N)=N2	PLASMA	2XLN4Y044H									∞	ng × h/mL	11.7		ng/mL	13.6			RECOMMENDED	μg	400		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/20063904/	Homo sapiens		h	2							false
3129	1546		ADULT		517.763	RETAPAMULIN	RETAPAMULIN	C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@]1(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]3C)OC(=O)CS[C@H]4C[C@@H]5CC[C@H](C4)N5C	PLASMA	4MG6O8991R							24		t	ng × h/mL	49.6		ng/mL	3.5			RECOMMENDED	%	1		MULTIPLE	UNKNOWN		day	1	Retapamulin is ≈94% bound to plasma proteins and binding is independent of retapamulin concentration	6	HEALTHY	Topical	FEMALE / MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/18416589/	Homo sapiens										false
3130	1547		ADULT		495.5	SILODOSIN			PLASMA										?	ng × h/mL	373.4		ng/mL	61.6			RECOMMENDED	mg	8		STEADY-STATE	UNKNOWN		day	1	Dialysis is unlikely to be of significant benefit since silodosin is highly (97%) protein bound.	3	HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022206s012lbl.pdf	Homo sapiens		h	13.3							false
3131	1551		UNKNOWN	222786	360.444	CORTISONE	CORTISONE	C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO	PLASMA	V27W9254FZ																						UNKNOWN					16.2	UNKNOWN		MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7195404/	Homo sapiens										false
3132	1551		ADULT	222786	360.4	CORTISONE	CORTISONE	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C	PLASMA	883WKN7W8X									∞	nM × h	4109						UNKNOWN	mg	44.8		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/6691888	Homo sapiens										false
3133	1552		ADULT	448537	268.3502	DIETHYLSTILBESTROL	Diethylstilbestrol	CC\\C(C1=CC=C(O)C=C1)=C(\\CC)C2=CC=C(O)C=C2	PLASMA	731DCA35BT									?	pg × h/mL	9741.84		pg/mL	3672.44			UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://mhraproducts4853.blob.core.windows.net/docs/2759709c34db666297f0c936bbe3b0acfc88fed4#page=9	Homo sapiens				tablets						false
3134	1552		ADULT	448537	268.3502	DIETHYLSTILBESTROL	Diethylstilbestrol	CC\\C(C1=CC=C(O)C=C1)=C(\\CC)C2=CC=C(O)C=C2	UNKNOWN	731DCA35BT													ng/mL	5.64			UNKNOWN	mg	2		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24618069/	Homo sapiens				Orally disolving film			12			false
3135	1553		UNKNOWN	2197	252.2647	ANISINDIONE	ANISINDIONE	COC1=CC=C(C=C1)C2C(=O)C3=C(C=CC=C3)C2=O	PLASMA	S747T1ERAJ																	UNKNOWN				UNKNOWN	UNKNOWN						UNKNOWN	Oral	UNKNOWN	OTHER	https://www.pharmacompass.com/chemistry-chemical-name/anisindione	Homo sapiens		day	4							false
3136	1555		ADULT	51040	310.3869	AVOBENZONE	AVOBENZONE	COC1=CC=C(C=C1)C(=O)CC(=O)C2=CC=C(C=C2)C(C)(C)C	PLASMA	G63QQF2NOX													ng/mL	3.1			UNKNOWN	g	0.81		STEADY-STATE	UNKNOWN		day	4			HEALTHY	Topical	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/31058986	Homo sapiens		h	45.2							false
3137	1555		ADULT	51040	310.3869	AVOBENZONE	AVOBENZONE	COC1=CC=C(C=C1)C(=O)CC(=O)C2=CC=C(C=C2)C(C)(C)C	PLASMA	G63QQF2NOX													ng/mL	1.5			UNKNOWN	g	0.81		MULTIPLE	UNKNOWN		day	4			HEALTHY	Topical	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/31058986	Homo sapiens										false
3138	1556		ADULT	441397	465.52	BACAMPICILLIN	BACAMPICILLIN	CCOC(=O)OC(C)OC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](NC(=O)[C@H](N)C3=CC=CC=C3)C2=O	PLASMA	8GM2J22278									∞	μg × min/mL	3.09		μg/mL	13.5			UNKNOWN	mg	808		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/529016	Homo sapiens										false
3139	1558		ADULT	243|20144841	122.1213	BENZOIC ACID	BENZOIC ACID	OC(=O)C1=CC=CC=C1	PLASMA	8SKN0B0MIM									?	μg × h/mL	104.4		μg/mL	99.7			RECOMMENDED	mg	40		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1804654/	Homo sapiens		h	0.5							false
3140	1559		ADULT	7699	603.7447	BENZONATATE	Benzonatate	CCCCNc1ccc(cc1)C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC	PLASMA	5P4DHS6ENR									∞	ng × h/mL	1111		ng/mL	1063			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31129533/	Homo sapiens		h	1.01				4			false
3141	1560		UNKNOWN	2343	431.937	BENZTHIAZIDE	BENZTHIAZIDE	NS(=O)(=O)C1=CC2=C(C=C1Cl)N=C(CSCC3=CC=CC=C3)NS2(=O)=O	PLASMA	1TD8J48L61																	UNKNOWN				UNKNOWN	UNKNOWN					90	UNKNOWN	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/3828483/	Homo sapiens		h	10							false
3142	1561		ADULT	6729	433.028	BUCLIZINE	BUCLIZINE	CC(C)(C)C1=CC=C(CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(Cl)C=C4)C=C1	PLASMA										∞	μg × h/mL	5.22		μg/mL	0.45			UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubs.rsc.org/en/content/articlehtml/2014/ay/c3ay41698d	Homo sapiens		h	5.3							false
3143	1563		ADULT	2581	273.714	CARPROFEN	CARPROFEN	CC(C(O)=O)C1=CC2=C(C=C1)C3=C(N2)C=CC(Cl)=C3	PLASMA	FFL0D546HO									∞	μg × h/mL	57.8		μg/mL	10.4			UNKNOWN	mg	100		SINGLE	FASTED				The protein binding of carprofen was greater than 99% bound in both normal subjects and cirrhotic patients, indicating that liver dysfunction had no effect on the protein binding of carprofen.	1	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3886707	Homo sapiens		h	10.5							false
3144	1563		ADULT	2581	273.714	CARPROFEN	CARPROFEN	CC(C(O)=O)C1=CC2=C(C=C1)C3=C(N2)C=CC(Cl)=C3	PLASMA	FFL0D546HO									∞	μg × h/mL	52.4		μg/mL	10.2			UNKNOWN	mg	100		SINGLE	FASTED				The protein binding of carprofen was greater than 99% bound in both normal subjects and cirrhotic patients, indicating that liver dysfunction had no effect on the protein binding of carprofen.	1	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3886707	Homo sapiens		h	9.4							false
3145	1564		ADULT	5281006	389.4	CEFPROZIL	CEFPROZIL	[H][C@]12SCC(C=CC)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C3=CC=C(O)C=C3)C(O)=O	PLASMA	4W0459ZA4V									∞	ng × h/mL	9547.96		ng/mL	2429.8			UNKNOWN	mg	125		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	10.1007/s12325-020-01593-7	Homo sapiens				granule			30	Cefprozil		false
3146	1564		ADULT	5281006	389.4	CEFPROZIL	CEFPROZIL	[H][C@]12SCC(C=CC)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C3=CC=C(O)C=C3)C(O)=O	PLASMA	4W0459ZA4V									∞	ng × h/mL	10177.93		ng/mL	3873			UNKNOWN	mg	125		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	10.1007/s12325-020-01593-7	Homo sapiens				granule			30	Cefprozil		false
3147	1564		ADULT	5281006	389.4	CEFPROZIL	CEFPROZIL	[H][C@]12SCC(C=CC)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C3=CC=C(O)C=C3)C(O)=O	PLASMA	4W0459ZA4V									∞	ng × h/mL	9470.52		ng/mL	2438.8			UNKNOWN	mg	125		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	10.1007/s12325-020-01593-7	Homo sapiens		h	1.36	suspension			29	Cefprozil		false
3148	1564		ADULT	5281006	389.4	CEFPROZIL	CEFPROZIL	[H][C@]12SCC(C=CC)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C3=CC=C(O)C=C3)C(O)=O	PLASMA	4W0459ZA4V									∞	ng × h/mL	9379.22		ng/mL	3534.7			UNKNOWN	mg	125		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	10.1007/s12325-020-01593-7	Homo sapiens		h	1.37	suspension			30	Cefprozil		false
3149	1564		ADULT	5281006	389.4	CEFPROZIL	CEFPROZIL	[H][C@]12SCC(C=CC)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C3=CC=C(O)C=C3)C(O)=O	PLASMA	4W0459ZA4V									∞	mg × h/L	71		mg/L	15.8			UNKNOWN	mg	1000		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	REVIEW	https://doi.org/10.1093/clinids/14.Supplement_2.S184	Homo sapiens		h	2.2		Hepatic disease			cefprozil		false
3150	1564		ADULT	5281006	389.4	CEFPROZIL	CEFPROZIL	[H][C@]12SCC(C=CC)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C3=CC=C(O)C=C3)C(O)=O	PLASMA	4W0459ZA4V									∞	mg × h/L	260		mg/L	30.4			UNKNOWN	mg	1000		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	REVIEW	https://doi.org/10.1093/clinids/14.Supplement_2.S184	Homo sapiens		h	5.2		Renal disease (creatinine clearance of <30 mL/min)			cefprozil		false
3151	1564		ADULT	5281006	389.4	CEFPROZIL	CEFPROZIL	[H][C@]12SCC(C=CC)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C3=CC=C(O)C=C3)C(O)=O	PLASMA	4W0459ZA4V									∞	mg × h/L	63		mg/L	12.3			UNKNOWN	mg	1000		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	REVIEW	https://doi.org/10.1093/clinids/14.Supplement_2.S184	Homo sapiens		h	1.63					cefprozil		false
3152	1564		CHILD	5281006	389.4	CEFPROZIL	CEFPROZIL	[H][C@]12SCC(C=CC)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C3=CC=C(O)C=C3)C(O)=O	PLASMA	4W0459ZA4V							4		t	μg × h/mL	44.13		μg/mL	15.93			UNKNOWN	mg/kg	30		SINGLE	FED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://doi.org/10.1128/AAC.34.11.2152	Homo sapiens		h	2.14	suspension [250 mg/5 ml]			10	cefprozil		false
3153	1564		CHILD	5281006	389.4	CEFPROZIL	CEFPROZIL	[H][C@]12SCC(C=CC)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C3=CC=C(O)C=C3)C(O)=O	PLASMA	4W0459ZA4V							4		t	μg × h/mL	28.05		μg/mL	11.16			MIN EFFICACIOUS	mg/kg	15		SINGLE	FED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://doi.org/10.1128/AAC.34.11.2152	Homo sapiens		h	1.77	suspension [250 mg/5 ml]			10	cefprozil		false
3154	1564		ADULT	5281006	389.4	CEFPROZIL	CEFPROZIL	[H][C@]12SCC(C=CC)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C3=CC=C(O)C=C3)C(O)=O	PLASMA	4W0459ZA4V													mg/L	5.7				mg	250		SINGLE	UNKNOWN					55	HEALTHY	Oral	UNKNOWN	REVIEW	https://link.springer.com/article/10.2165/00003495-199345020-00008	Homo sapiens										false
3155	1565		ADULT	5281100|23663992	481.5321	CERIVASTATIN SODIUM	CERIVASTATIN SODIUM	[Na+].COCC1=C(C2=CC=C(F)C=C2)C(\\C=C\\[C@@H](O)C[C@@H](O)CC([O-])=O)=C(N=C1C(C)C)C(C)C	BLOOD	6Q18G1060S																	UNKNOWN	μg	200		STEADY-STATE	UNKNOWN		day	1	More than 99% of the circulating drug is bound to plasma proteins	1	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/20740S19lbl.pdf	Homo sapiens										false
3156	1565		ADULT	5281100|23663992	481.5321	CERIVASTATIN SODIUM	CERIVASTATIN SODIUM	[Na+].COCC1=C(C2=CC=C(F)C=C2)C(\\C=C\\[C@@H](O)C[C@@H](O)CC([O-])=O)=C(N=C1C(C)C)C(C)C	PLASMA	6Q18G1060S									?	μg × h/L	6.25		μg/L	1.01			UNKNOWN	μg	100		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020740ap_baycol_clinphrmrp1.pdf	Homo sapiens		h	3.37							false
3157	1565		ADULT	5281100|23663992	481.5321	CERIVASTATIN SODIUM	CERIVASTATIN SODIUM	[Na+].COCC1=C(C2=CC=C(F)C=C2)C(\\C=C\\[C@@H](O)C[C@@H](O)CC([O-])=O)=C(N=C1C(C)C)C(C)C	PLASMA	6Q18G1060S									?	μg × h/L	11.71		μg/L	2.15			UNKNOWN	μg	200		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020740ap_baycol_clinphrmrp1.pdf	Homo sapiens		h	3.08							false
3158	1565		ADULT	5281100|23663992	481.5321	CERIVASTATIN SODIUM	CERIVASTATIN SODIUM	[Na+].COCC1=C(C2=CC=C(F)C=C2)C(\\C=C\\[C@@H](O)C[C@@H](O)CC([O-])=O)=C(N=C1C(C)C)C(C)C	PLASMA	6Q18G1060S									?	μg × h/L	20.52		μg/L	3.55			UNKNOWN	μg	300		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020740ap_baycol_clinphrmrp1.pdf	Homo sapiens		h	4.89							false
3159	1565		ADULT	5281100|23663992	481.5321	CERIVASTATIN SODIUM	CERIVASTATIN SODIUM	[Na+].COCC1=C(C2=CC=C(F)C=C2)C(\\C=C\\[C@@H](O)C[C@@H](O)CC([O-])=O)=C(N=C1C(C)C)C(C)C	PLASMA	6Q18G1060S									?	μg × h/L	22.45		μg/L	4.04			UNKNOWN	μg	400		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020740ap_baycol_clinphrmrp1.pdf	Homo sapiens		h	4.23							false
3160	1565		ADULT	5281100|23663992	481.5321	CERIVASTATIN SODIUM	CERIVASTATIN SODIUM	[Na+].COCC1=C(C2=CC=C(F)C=C2)C(\\C=C\\[C@@H](O)C[C@@H](O)CC([O-])=O)=C(N=C1C(C)C)C(C)C	PLASMA	6Q18G1060S							168		t	μg × h/L	6.33		μg/L	1.14			UNKNOWN	μg	100		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020740ap_baycol_clinphrmrp1.pdf	Homo sapiens		h	3.19							false
3161	1565		ADULT	5281100|23663992	481.5321	CERIVASTATIN SODIUM	CERIVASTATIN SODIUM	[Na+].COCC1=C(C2=CC=C(F)C=C2)C(\\C=C\\[C@@H](O)C[C@@H](O)CC([O-])=O)=C(N=C1C(C)C)C(C)C	PLASMA	6Q18G1060S							168		t	μg × h/L	12.4		μg/L	2.31			UNKNOWN	μg	200		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020740ap_baycol_clinphrmrp1.pdf	Homo sapiens		h	2.74							false
3162	1565		ADULT	5281100|23663992	481.5321	CERIVASTATIN SODIUM	CERIVASTATIN SODIUM	[Na+].COCC1=C(C2=CC=C(F)C=C2)C(\\C=C\\[C@@H](O)C[C@@H](O)CC([O-])=O)=C(N=C1C(C)C)C(C)C	PLASMA	6Q18G1060S							168		t	μg × h/L	21.73		μg/L	3.96			UNKNOWN	μg	300		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020740ap_baycol_clinphrmrp1.pdf	Homo sapiens		h	3.79							false
3163	1565		ADULT	5281100|23663992	481.5321	CERIVASTATIN SODIUM	CERIVASTATIN SODIUM	[Na+].COCC1=C(C2=CC=C(F)C=C2)C(\\C=C\\[C@@H](O)C[C@@H](O)CC([O-])=O)=C(N=C1C(C)C)C(C)C	PLASMA	6Q18G1060S							168		t	μg × h/L	24.67		μg/L	4.41			UNKNOWN	μg	400		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020740ap_baycol_clinphrmrp1.pdf	Homo sapiens		h	5.16							false
3164	1567		ADULT		273.736	CHLORMEZANONE	chlormezanone	CN1C(C2=CC=C(Cl)C=C2)S(=O)(=O)CCC1=O	PLASMA	GP568V9G19									∞	mg × h/L	224.93		mg/L	4.62			UNKNOWN	mg	400		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/2399514	Homo sapiens		h	40.5							false
3165	1567		ADULT	2717	273.736	CHLORMEZANONE	chlormezanone	CN1C(C2=CC=C(Cl)C=C2)S(=O)(=O)CCC1=O	PLASMA	GP568V9G19							24		t	mg × h/L	164.19						UNKNOWN	mg	400		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/2399514	Homo sapiens		h	37.14							false
3166	1568		ADULT	19727|441348	307.216	CHLOROPROCAINE HYDROCHLORIDE	CHLOROPROCAINE HYDROCHLORIDE	Cl.CCN(CC)CCOC(=O)C1=C(Cl)C=C(N)C=C1	PLASMA	LT7Z1YW11H																	UNKNOWN				SINGLE	UNKNOWN						PREGNANT	Epidural	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208791s000lbl.pdf	Homo sapiens		min	3.1							false
3167	1570		ADULT	2727	276.74	CHLORPROPAMIDE	CHLORPROPAMIDE	CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1	PLASMA	WTM2C3IL2X							24		t	μg × h/mL	545		μg/mL	28.5			UNKNOWN	mg	250		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/5053812/	Homo sapiens		h	33.1							false
3168	1571		ADULT	2733	169.565	CHLORZOXAZONE	chlorzoxazone	ClC1=CC=C2OC(=O)NC2=C1	SERUM	H0DE420U8G									∞	mg × h/L	43.5		μg/mL	15			RECOMMENDED	mg	500		SINGLE	FED					3.9	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12534643/	Homo sapiens		h	1.1							false
3169	1571		ADULT	2733	169.565	CHLORZOXAZONE	chlorzoxazone	ClC1=CC=C2OC(=O)NC2=C1	SERUM	H0DE420U8G									∞	μg × h/mL	32.8		μg/mL	12.2			RECOMMENDED	mg	500		SINGLE	FED					4	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12534643/	Homo sapiens		h	1.2							false
3170	1571		ADULT	2733	169.565	CHLORZOXAZONE	chlorzoxazone	ClC1=CC=C2OC(=O)NC2=C1	SERUM	H0DE420U8G									∞	μg × h/mL	15.7		μg/mL	5.2			RECOMMENDED	mg	500		SINGLE	FED					3.2	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12534643/	Homo sapiens		h	1.4							false
3171	1571		ADULT	2733	169.565	CHLORZOXAZONE	chlorzoxazone	ClC1=CC=C2OC(=O)NC2=C1	PLASMA	H0DE420U8G							8		t	μg × h/mL	9.86		μg/mL	3.45			RECOMMENDED	mg	250		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28983678/	Homo sapiens		h	1.21							false
3172	1571		ADULT	2734	185.565	6-Hydroxychlorzoxazone	C1=C2C(=CC(=C1Cl)O)OC(=O)N2	OC1=C(Cl)C=C2NC(=O)OC2=C1	PLASMA	M5YLT4Y73F							8		t	μg × h/mL	0.95		μg/mL	0.2			RECOMMENDED	mg	250		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28983678/	Homo sapiens										false
3173	1571		ADULT	2733	169.565	CHLORZOXAZONE	chlorzoxazone	ClC1=CC=C2OC(=O)NC2=C1	PLASMA	H0DE420U8G	5280343		QUERCETIN	quercetin	OC1=CC2=C(C(O)=C1)C(=O)C(O)=C(O2)C3=CC=C(O)C(O)=C3	9IKM0I5T1E	8		t	μg × h/mL	16.69		μg/mL	5.1			RECOMMENDED	mg	250		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28983678/	Homo sapiens		h	1.65							true
3174	1571		ADULT	2734	185.565	6-Hydroxychlorzoxazone	C1=C2C(=CC(=C1Cl)O)OC(=O)N2	OC1=C(Cl)C=C2NC(=O)OC2=C1	PLASMA	M5YLT4Y73F	5280343		QUERCETIN	quercetin	OC1=CC2=C(C(O)=C1)C(=O)C(O)=C(O2)C3=CC=C(O)C(O)=C3	9IKM0I5T1E	8		t	μg × h/mL	0.64		μg/mL	0.14			RECOMMENDED	mg	250		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28983678/	Homo sapiens										true
3175	1571		ADULT	2733	169.565	CHLORZOXAZONE	chlorzoxazone	ClC1=CC=C2OC(=O)NC2=C1	PLASMA	H0DE420U8G	1983		ACETAMINOPHEN	acetaminophen	CC(=O)NC1=CC=C(O)C=C1	362O9ITL9D	10		t	μg × h/mL	4084		μg/mL	36.3			INVESTIGATIONAL	mg	750		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6631711/	Homo sapiens		h	1.12							true
3176	1572		ADULT	6435415	358.453	CILASTATIN	CILASTATIN	CC1(C)C[C@@H]1C(=O)N\\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O	PLASMA	141A6AMN38	5282372		IMIPENEM	Imipenem	O.C[C@@H](O)[C@@H]1[C@H]2CC(SCCNC=N)=C(N2C1=O)C(O)=O	71OTZ9ZE0A			∞	mg × h/L	82.19						UNKNOWN	mg	500		MULTIPLE	UNKNOWN		day	4			UNHEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3469182	Homo sapiens		h	2.1							true
3177	1573		UNKNOWN	2784	352.4467	CLIDINIUM	CLIDINIUM	C[N+]12CCC(CC1)C(C2)OC(=O)C(O)(C3=CC=CC=C3)C4=CC=CC=C4	UNKNOWN	BO76JF850N																						UNKNOWN						UNKNOWN		UNKNOWN	DRUG LABEL	https://www.pdr.net/drug-summary/Librax-chlordiazepoxide-hydrochloride-clidinium-bromide-1626	Homo sapiens		h	20							false
3178	1574		UNKNOWN		473.396	CLOFAZIMINE	clofazimine	CC(C)\\N=c1/C=C2N(C3=CC=C(Cl)C=C3)C4=C(C=CC=C4)N=C2C=C1NC5=CC=C(Cl)C=C5	PLASMA	D959AE5USF													mg/L	0.5			UNKNOWN	mg	300		MULTIPLE	UNKNOWN		week	3			UNKNOWN	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/2656045/	Homo sapiens										false
3179	1574		UNKNOWN		473.396	CLOFAZIMINE	clofazimine	CC(C)\\N=c1/C=C2N(C3=CC=C(Cl)C=C3)C4=C(C=CC=C4)N=C2C=C1NC5=CC=C(Cl)C=C5	PLASMA	D959AE5USF													mg/L	0.7			UNKNOWN	mg	100		MULTIPLE	UNKNOWN		day	1			UNKNOWN	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/2656045/	Homo sapiens										false
3180	1574		UNKNOWN		473.396	CLOFAZIMINE	clofazimine	CC(C)\\N=c1/C=C2N(C3=CC=C(Cl)C=C3)C4=C(C=CC=C4)N=C2C=C1NC5=CC=C(Cl)C=C5	PLASMA	D959AE5USF													mg/L	1			UNKNOWN	mg	300		MULTIPLE	UNKNOWN		day	1			UNKNOWN	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/2656045/	Homo sapiens										false
3181	1574		UNKNOWN		473.396	CLOFAZIMINE	clofazimine	CC(C)\\N=c1/C=C2N(C3=CC=C(Cl)C=C3)C4=C(C=CC=C4)N=C2C=C1NC5=CC=C(Cl)C=C5	PLASMA	D959AE5USF													mg/L	1.4			UNKNOWN	mg	400		MULTIPLE	UNKNOWN		day	1			UNKNOWN	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/2656045/	Homo sapiens										false
3182	1574		ADULT		473.396	CLOFAZIMINE	clofazimine	CC(C)\\N=c1/C=C2N(C3=CC=C(Cl)C=C3)C4=C(C=CC=C4)N=C2C=C1NC5=CC=C(Cl)C=C5	PLASMA	D959AE5USF							264		t	pmol × h/g	33900		pmol/g	861			UNKNOWN	mg	200		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3559339/	Homo sapiens		day	10.6							false
3183	1574		ADULT		473.396	CLOFAZIMINE	clofazimine	CC(C)\\N=c1/C=C2N(C3=CC=C(Cl)C=C3)C4=C(C=CC=C4)N=C2C=C1NC5=CC=C(Cl)C=C5	PLASMA	D959AE5USF							264		t	pmol × h/g	29100		pmol/g	604			UNKNOWN	mg	200		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3559339/	Homo sapiens										false
3184	1574		ADULT		473.396	CLOFAZIMINE	clofazimine	CC(C)\\N=c1/C=C2N(C3=CC=C(Cl)C=C3)C4=C(C=CC=C4)N=C2C=C1NC5=CC=C(Cl)C=C5	PLASMA	D959AE5USF							264		t	pmol × h/g	18000		pmol/g	469			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3559339/	Homo sapiens										false
3185	1576		ADULT	19003	341.426	CYCLACILLIN	CYCLACILLIN	CC1(C)S[C@@H]2[C@H](NC(=O)C3(N)CCCCC3)C(=O)N2[C@H]1C(O)=O	PLASMA	72ZJ154X86									?	mg × h/L	62.6		mg/L	60.1			UNKNOWN	mg	1500		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3912193	Homo sapiens		h	0.9							false
3186	1576		CHILD	19003	341.426	CYCLACILLIN	CYCLACILLIN	CC1(C)S[C@@H]2[C@H](NC(=O)C3(N)CCCCC3)C(=O)N2[C@H]1C(O)=O	SERUM	72ZJ154X86									?	μg × h/mL	42		μg/mL	25.6			UNKNOWN	mg/kg	25		STEADY-STATE	FASTED		day	3			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6576831	Homo sapiens		h	0.7							false
3187	1576		CHILD	19003	341.426	CYCLACILLIN	CYCLACILLIN	CC1(C)S[C@@H]2[C@H](NC(=O)C3(N)CCCCC3)C(=O)N2[C@H]1C(O)=O	SERUM	72ZJ154X86									?	μg × h/mL	44		μg/mL	27			UNKNOWN	mg/kg	25		STEADY-STATE	FED		day	3			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6576831	Homo sapiens		h	0.79							false
3188	1577		ADULT	22162|657209|43833353	327.846	CYCLOPENTOLATE HYDROCHLORIDE	CYCLOPENTOLATE HYDROCHLORIDE	Cl.CN(C)CCOC(=O)C(C1=CC=CC=C1)C2(O)CCCC2	PLASMA	736I6971TE							6		t	ng × min/mL	324		ng/mL	2.8			UNKNOWN	drop	2		SINGLE	UNKNOWN						HEALTHY	Ocular	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8512760	Homo sapiens		min	112							false
3189	1580		UNKNOWN	8550	578.6527	DESERPIDINE	deserpidine	CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)C6=CC(OC)=C(OC)C(OC)=C6	PLASMA	9016E3VB47									∞	pg × h/mL	4193		pg/mL	172			UNKNOWN	mg	0.25		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://www.sciencedirect.com/science/article/pii/S1570023209004073	Homo sapiens		h	42.9							false
3190	1581		UNKNOWN	28620	943.0791	DESLANOSIDE	DESLANOSIDE	C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@@H](C)O3)[C@@H](C)O2)O[C@H]5CC[C@@]6(C)[C@H](CC[C@@H]7[C@@H]6C[C@@H](O)[C@]8(C)[C@H](CC[C@]78O)C9=CC(=O)OC9)C5	SERUM	YGY317RK75																	UNKNOWN	mg	1.6		UNKNOWN	UNKNOWN						UNKNOWN	Intravenous	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/356122	Homo sapiens		h	36							false
3191	1582		ADULT	5311067	376.4617	DESOXIMETASONE	DESOXIMETASONE	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO	PLASMA	4E07GXB7AU							24		t	pg × h/mL	16272						RECOMMENDED	%	0.25		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Topical	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204141s004lbl.pdf	Homo sapiens										false
3192	1583		ADULT	5819|25201348	776.87	LEVOTHYROXINE	Thyroxine	N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O	PLASMA	Q51BO43MG4																	UNKNOWN	mg	6		UNKNOWN	UNKNOWN		day	1		1	UNHEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/363332/	Homo sapiens		day	6							false
3193	1586		ADULT	3103	281.392	DIPHENYLPYRALINE	DIPHENYLPYRALINE	CN1CCC(CC1)OC(C2=CC=CC=C2)C3=CC=CC=C3	URINE	33361OE3AV																	UNKNOWN	mg	5		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4156058/	Homo sapiens		h	32				5			false
3194	1588		ADULT	68873	366.4932	DROSPIRENONE	DROSPIRENONE	C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C5=CC(=O)CC[C@]35C)[C@@H]1[C@@H]6C[C@@H]6[C@@]27CCC(=O)O7	PLASMA	N295J34A25									?	ng × h/mL	140		ng/mL	9.85			UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22680989	Homo sapiens		h	25.5							false
3195	1588		ADULT	68873	366.4932	DROSPIRENONE	DROSPIRENONE	C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C5=CC(=O)CC[C@]35C)[C@@H]1[C@@H]6C[C@@H]6[C@@]27CCC(=O)O7	PLASMA	N295J34A25									?	ng × h/mL	506		ng/mL	33.9			UNKNOWN	mg	3		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22680989	Homo sapiens		h	28.5							false
3196	1588		ADULT	68873	366.4932	DROSPIRENONE	DROSPIRENONE	C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C5=CC(=O)CC[C@]35C)[C@@H]1[C@@H]6C[C@@H]6[C@@]27CCC(=O)O7	PLASMA	N295J34A25									?	ng × h/mL	1007		ng/mL	62.5			UNKNOWN	mg	6		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22680989	Homo sapiens		h	26.3							false
3197	1588		ADULT	68873	366.4932	DROSPIRENONE	DROSPIRENONE	C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C5=CC(=O)CC[C@]35C)[C@@H]1[C@@H]6C[C@@H]6[C@@]27CCC(=O)O7	PLASMA	N295J34A25													ng/mL	27			RECOMMENDED	mg	4		SINGLE	UNKNOWN				Drospirenone is 95% to 97% bound to serum albumin	4	HEALTHY	Oral	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211367s000lbl.pdf	Homo sapiens		h	30							false
3198	1588		ADULT	68873	366.4932	DROSPIRENONE	DROSPIRENONE	C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C5=CC(=O)CC[C@]35C)[C@@H]1[C@@H]6C[C@@H]6[C@@]27CCC(=O)O7	PLASMA	N295J34A25													ng/mL	41			RECOMMENDED	mg	4		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211367s000lbl.pdf	Homo sapiens		h	30							false
3199	1589		ADULT	3182	254.2426	DYPHYLLINE	DYPHYLLINE	CN1C2=C(N(CC(O)CO)C=N2)C(=O)N(C)C1=O	PLASMA	263T0E9RR9									∞	μg × h/mL	20.16		μg/mL	8.21			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/4009445	Homo sapiens		h	2.13							false
3200	1590		ADULT	3226	184.492	ENFLURANE	ENFLURANE	FC(F)OC(F)(F)C(F)Cl	PLASMA	91I69L5AY5													μg/mL	15			RECOMMENDED	%	2		SINGLE	UNKNOWN						UNKNOWN	Respiratory	UNKNOWN	REVIEW	https://www.springer.com/gp/book/9783540117193	Homo sapiens		min	60							false
3201	1591		ADULT	3229|28230148	320.3189	ENOXACIN	ENOXACIN	CCN1C=C(C(O)=O)C(=O)C2=C1N=C(N3CCNCC3)C(F)=C2	PLASMA	325OGW249P									∞	mg × h/L	5.35		mg/L	1.83			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3162901	Homo sapiens		h	3.2							false
3202	1591		ADULT	3229|28230148	320.3189	ENOXACIN	ENOXACIN	CCN1C=C(C(O)=O)C(=O)C2=C1N=C(N3CCNCC3)C(F)=C2	PLASMA	325OGW249P									∞	mg × h/L	29.08		mg/L	6.58			UNKNOWN	mg	800		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3162901	Homo sapiens		h	4.9							false
3203	1591		ADULT	3229|28230148	320.3189	ENOXACIN	ENOXACIN	CCN1C=C(C(O)=O)C(=O)C2=C1N=C(N3CCNCC3)C(F)=C2	PLASMA	325OGW249P									∞	mg × h/L	4.67		mg/L	1.02			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3162901	Homo sapiens		h	3.2							false
3204	1591		ADULT	3229|28230148	320.3189	ENOXACIN	ENOXACIN	CCN1C=C(C(O)=O)C(=O)C2=C1N=C(N3CCNCC3)C(F)=C2	PLASMA	325OGW249P									∞	mg × h/L	25.75		mg/L	3.8			UNKNOWN	mg	800		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3162901	Homo sapiens		h	4.9							false
3205	1591		ADULT	3229|28230148	320.3189	ENOXACIN	ENOXACIN	CCN1C=C(C(O)=O)C(=O)C2=C1N=C(N3CCNCC3)C(F)=C2	SERUM	325OGW249P													mg/L	4.8			UNKNOWN	mg	400		STEADY-STATE	FED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3162904	Homo sapiens		h	4.5							false
3206	1591		ADULT	124070	334.3	4-Oxo-enoxacin	4-oxo-enoxacin		SERUM														mg/L	0.7			UNKNOWN	mg	400		STEADY-STATE	FED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3162904	Homo sapiens										false
3207	1591		ADULT	3229|28230148	320.3189	ENOXACIN	ENOXACIN	CCN1C=C(C(O)=O)C(=O)C2=C1N=C(N3CCNCC3)C(F)=C2	SERUM	325OGW249P													mg/L	7.4			UNKNOWN	mg	600		STEADY-STATE	FED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3162904	Homo sapiens		h	6							false
3208	1591		ADULT	124070	334.3	4-Oxo-enoxacin	4-Oxo-enoxacin		SERUM														mg/L	7.4			UNKNOWN	mg	600		STEADY-STATE	FED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3162904	Homo sapiens		h	6							false
3209	1592		ADULT		0	ERGOLOIDS	Ergoloids		PLASMA	34HPE9Z8IP									∞	pg × h/mL	1051		pg/mL	239			UNKNOWN	mg	3		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3207855/	Homo sapiens		h	2.2	1mg Tablets			19	Ergoloid mesilate		false
3210	1592		ADULT		0	ERGOLOIDS	Ergoloids		PLASMA	34HPE9Z8IP									∞	pg × h/mL	2813		pg/mL	490			UNKNOWN	mg	6		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3207855/	Homo sapiens		h	3.6	1mg Tablets			19	Ergoloid mesilate		false
3211	1592		ADULT		0	ERGOLOIDS	Ergoloids		PLASMA	34HPE9Z8IP									∞	pg × h/mL	2054		pg/mL	384			UNKNOWN	mg	6		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3207855/	Homo sapiens		h	3.2	1mg Tablets			19	Ergoloid mesilate		false
3212	1592		ADULT		0	ERGOLOIDS	Ergoloids		PLASMA	34HPE9Z8IP									∞	pg × h/mL	2080		pg/mL	426			UNKNOWN	mg	6		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3207855/	Homo sapiens		h	3.7	1mg Tablets			24	Ergoloid mesilate		false
3213	1592		ADULT		0	ERGOLOIDS	Ergoloids		PLASMA	34HPE9Z8IP									∞	pg × h/mL	2089		pg/mL	343			UNKNOWN	mg	6		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3207855/	Homo sapiens		h	3.9	6mg Tablets			32	Ergoloid mesilate		false
3214	1592		ADULT		0	ERGOLOIDS	Ergoloids		PLASMA	34HPE9Z8IP									∞	pg × h/mL	2322		pg/mL	317			UNKNOWN	mg	6		SINGLE	FASTED						HEALTHY	Sublingual	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3207855/	Homo sapiens		h	4.9	1mg Tablets			24	Ergoloid mesilate		false
3215	1592		ADULT		0	ERGOLOIDS	Ergoloids		PLASMA	34HPE9Z8IP									∞	pg × h/mL	2134		pg/mL	385			UNKNOWN	mg	9		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3207855/	Homo sapiens		h	3.4	4.5mg Tablets			20	Ergoloid mesilate		false
3216	1592		ADULT		0	ERGOLOIDS	Ergoloids		PLASMA	34HPE9Z8IP									∞	pg × h/mL	2085		pg/mL	288			UNKNOWN	mg	9		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3207855/	Homo sapiens		h	4	4.5mg Tablets			20	Ergoloid mesilate		false
3217	1592		ADULT		0	ERGOLOIDS	Ergoloids		PLASMA	34HPE9Z8IP									∞	pg × h/mL	2028		pg/mL	308			UNKNOWN	mg	6		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3207855/	Homo sapiens		h	4.3	6mg Liquid			32	Ergoloid mesilate		false
3218	1594		ADULT	37497	276.417	ETIDOCAINE	ETIDOCAINE	CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C	PLASMA	I6CQM0F31V	5816|139148732		EPINEPHRINE	Adrenaline	CNC[C@H](O)C1=CC(O)=C(O)C=C1	YKH834O4BH	10		t	μg × h/mL	1.8		μg/mL	12.5			UNKNOWN	mL	20		SINGLE	UNKNOWN					6	HEALTHY	Peridural	FEMALE / MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/385208/	Homo sapiens		h	2.7							true
3219	1595		ADULT	5282375	354.4825	ETRETINATE	ETRETINATE	CCOC(=O)\\C=C(C)\\C=C\\C=C(C)\\C=C\\C1=C(C)C(C)=C(OC)C=C1C	PLASMA	65M2UDR9AG													ng/mL	100			UNKNOWN	mg	50		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9703120	Homo sapiens										false
3220	1596		ADULT	6446	336.4409	FLUOXYMESTERONE	FLUOXYMESTERONE	C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C	SERUM	9JU12S4YFY									∞	ng × h/mL	306		ng/mL	80			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4009439	Homo sapiens		h	2							false
3221	1596		ADULT	6446	336.4409	FLUOXYMESTERONE	FLUOXYMESTERONE	C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C	SERUM	9JU12S4YFY									∞	ng × h/mL	391		ng/mL	100			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Buccal	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4009439	Homo sapiens										false
3222	1599		ADULT	6037|5280354|135398658	441.3975	FOLIC ACID	FOLIC ACID	NC1=NC(=O)C2=C(N1)N=CC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=N2	PLASMA	935E97BOY8									∞	ng × h/mL	76		ng/mL	25.4			RECOMMENDED	mg	5		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18551467/	Homo sapiens		h	1.93							false
3223	1600		ADULT	3487	217.2637	GLUTETHIMIDE	Glutethimide	CCC1(CCC(=O)NC1=O)C2=CC=CC=C2	PLASMA	C8I4BVN78E													μg/mL	4.34			UNKNOWN	mg	500		SINGLE	FED				Plasma protein binding, in vitro, varied from 47.3 to 59.3 per cent of the plasma content of drug	45.8	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/5568259/	Homo sapiens										false
3224	1600		ADULT	3487	217.2637	GLUTETHIMIDE	Glutethimide	CCC1(CCC(=O)NC1=O)C2=CC=CC=C2	PLASMA	C8I4BVN78E							8		t	μg × h/mL	33.51						UNKNOWN	mg	500		MULTIPLE	UNKNOWN		day	3			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/902458/	Homo sapiens										false
3225	1600		UNKNOWN	3487	217.2637	GLUTETHIMIDE	Glutethimide	CCC1(CCC(=O)NC1=O)C2=CC=CC=C2	PLASMA	C8I4BVN78E													μg/mL	5			UNKNOWN	mg	500		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	OTHER	https://www.pharmacompass.com/chemistry-chemical-name/glutethimide	Homo sapiens										false
3226	1600		UNKNOWN	3487	217.2637	GLUTETHIMIDE	Glutethimide	CCC1(CCC(=O)NC1=O)C2=CC=CC=C2	PLASMA	C8I4BVN78E													μg/mL	6.5			UNKNOWN	mg	1000		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	OTHER	https://www.pharmacompass.com/chemistry-chemical-name/glutethimide	Homo sapiens										false
3227	1600		UNKNOWN	3487	217.2637	GLUTETHIMIDE	GLUTETHIMIDE	CCC1(CCC(=O)NC1=O)C2=CC=CC=C2	SERUM	C8I4BVN78E																	UNKNOWN					UNKNOWN						UNKNOWN		UNKNOWN	OTHER	https://www.pharmacompass.com/chemistry-chemical-name/glutethimide	Homo sapiens		h	11.6							false
3228	1602		ADULT	72474|74441479	359.3947	GREPAFLOXACIN	GREPAFLOXACIN	CC1CN(CCN1)C2=C(F)C(C)=C3C(=O)C(=CN(C4CC4)C3=C2)C(O)=O	PLASMA	L1M1U2HC31									∞	mg × h/L	5.08		mg/L	0.47			UNKNOWN	mg	200		SINGLE	UNKNOWN					50	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9433650	Homo sapiens		h	10.14							false
3229	1602		ADULT	72474|74441479	359.3947	GREPAFLOXACIN	GREPAFLOXACIN	CC1CN(CCN1)C2=C(F)C(C)=C3C(=O)C(=CN(C4CC4)C3=C2)C(O)=O	PLASMA	L1M1U2HC31									∞	mg × h/L	11.35		mg/L	0.93			UNKNOWN	mg	400		SINGLE	UNKNOWN					50	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9433650	Homo sapiens		h	11.68							false
3230	1602		ADULT	72474|74441479	359.3947	GREPAFLOXACIN	GREPAFLOXACIN	CC1CN(CCN1)C2=C(F)C(C)=C3C(=O)C(=CN(C4CC4)C3=C2)C(O)=O	PLASMA	L1M1U2HC31									∞	mg × h/L	19.73		mg/L	1.41			UNKNOWN	mg	600		SINGLE	UNKNOWN					50	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9433650	Homo sapiens		h	12.67							false
3231	1602		ADULT	72474|74441479	359.3947	GREPAFLOXACIN	GREPAFLOXACIN	CC1CN(CCN1)C2=C(F)C(C)=C3C(=O)C(=CN(C4CC4)C3=C2)C(O)=O	PLASMA	L1M1U2HC31									∞	mg × h/L	27.69		mg/L	2.26			UNKNOWN	mg	800		SINGLE	UNKNOWN					50	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9433650	Homo sapiens		h	12.25							false
3232	1602		ADULT	72474|74441479	359.3947	GREPAFLOXACIN	GREPAFLOXACIN	CC1CN(CCN1)C2=C(F)C(C)=C3C(=O)C(=CN(C4CC4)C3=C2)C(O)=O	PLASMA	L1M1U2HC31									∞	mg × h/L	45.04		mg/L	3.17			UNKNOWN	mg	1200		SINGLE	UNKNOWN					50	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9433650	Homo sapiens		h	11.68							false
3233	1602		ADULT	72474|74441479	359.3947	GREPAFLOXACIN	GREPAFLOXACIN	CC1CN(CCN1)C2=C(F)C(C)=C3C(=O)C(=CN(C4CC4)C3=C2)C(O)=O	PLASMA	L1M1U2HC31							24		t	mg × h/L	14.6		mg/L	1.43			UNKNOWN	mg	400		STEADY-STATE	UNKNOWN		day	1		50	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9433650	Homo sapiens										false
3234	1602		ADULT	72474|74441479	359.3947	GREPAFLOXACIN	GREPAFLOXACIN	CC1CN(CCN1)C2=C(F)C(C)=C3C(=O)C(=CN(C4CC4)C3=C2)C(O)=O	PLASMA	L1M1U2HC31							24		t	mg × h/L	32.2		mg/L	2.63			UNKNOWN	mg	800		STEADY-STATE	UNKNOWN		day	1		50	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9433650	Homo sapiens										false
3235	1603		ADULT	5702063	231.082	GUANABENZ	GUANABENZ	NC(=N)N\\N=C\\C1=C(Cl)C=CC=C1Cl	PLASMA	GGD30112WC									?	ng × h/mL	19		ng/mL	2.4			UNKNOWN	mg	16		SINGLE	FASTED					11	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6084122/	Homo sapiens		h	4.3							false
3236	1603		ADULT	5702063	231.082	GUANABENZ	GUANABENZ	NC(=N)N\\N=C\\C1=C(Cl)C=CC=C1Cl	PLASMA	GGD30112WC									?	ng × h/mL	97		ng/mL	7.8			UNKNOWN	mg	16		SINGLE	FASTED					13	UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6084122/	Homo sapiens		h	6.4							false
3237	1604		ADULT	443943	454.959	HALCINONIDE	HALCINONIDE	CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCl	SKIN	SI86V6QNEG							6		t	ng × h/mL	7440		ng/mL	1350			RECOMMENDED	%	0.1		SINGLE	UNKNOWN						HEALTHY	Topical	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26367752/	Homo sapiens										false
3238	1606		NEWBORN	3598	406.904	HEXACHLOROPHENE	HEXACHLOROPHENE	OC1=C(Cl)C=C(Cl)C(Cl)=C1CC2=C(Cl)C(Cl)=CC(Cl)=C2O	BLOOD	IWW5FV6NK2																	UNKNOWN	%	3		UNKNOWN	UNKNOWN						UNKNOWN	Topical	UNKNOWN	DRUG LABEL	https://pubmed.ncbi.nlm.nih.gov/894425/	Homo sapiens		h	21.15							false
3239	1609		ADULT	39468	291.3853	LEVOBUNOLOL	levobunolol	CC(C)(C)NC[C@H](O)COC1=C2CCCC(=O)C2=CC=C1	PLASMA	G6317AOI7K													ng/mL	3.72			UNKNOWN	mg	3		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/336256	Homo sapiens		h	6.1							false
3240	1609		ADULT	162349	293.4012	Dihydrobunolol	Dihydrobunolol	CC(C)(C)NCC(O)COC1=CC=CC2=C1CCCC2O	PLASMA														ng/mL	2.65			UNKNOWN	mg	3		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/336256	Homo sapiens		h	7.1							false
3241	1611		CHILD		290.83	LINDANE	LINDANE	Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl	BLOOD	59NEE7PCAB													ng/mL	28			UNKNOWN	%	1		SINGLE	UNKNOWN						UNKNOWN	Topical	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/006309shampoolbl.pdf	Homo sapiens		h	18							false
3242	1612		ADULT	92727	628.8008	LOPINAVIR	LOPINAVIR	CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC2=CC=CC=C2)NC(=O)COC3=C(C)C=CC=C3C)CC4=CC=CC=C4	PLASMA	2494G1JF75	392622		RITONAVIR	Ritonavir	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4	O3J8G9O825			?	ng × h/mL	60328		ng/mL	6539			DEFINED DAILY	mg	400		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24632753	Homo sapiens		h	8.4							true
3243	1612		ADULT	92727	628.8008	LOPINAVIR	LOPINAVIR	CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC2=CC=CC=C2)NC(=O)COC3=C(C)C=CC=C3C)CC4=CC=CC=C4	PLASMA	2494G1JF75	392622		RITONAVIR	ritonavir	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4	O3J8G9O825	24		t	μg × h/mL	154.1		μg/mL	11.8			DEFINED DAILY	mg	800		STEADY-STATE	FED		day	1			UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021251s052_021906s046lbl.pdf	Homo sapiens										true
3244	1612		ADULT	92727	628.8008	LOPINAVIR	LOPINAVIR	CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC2=CC=CC=C2)NC(=O)COC3=C(C)C=CC=C3C)CC4=CC=CC=C4	PLASMA	2494G1JF75	392622		RITONAVIR	ritonavir	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4	O3J8G9O825	12		t	μg × h/mL	92.6		μg/mL	9.8			DEFINED DAILY	mg	400		STEADY-STATE	FED		day	2	At steady state, lopinavir is approximately 98-99% bound to plasma proteins.	1.5	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021251s052_021906s046lbl.pdf	Homo sapiens										true
3245	1616		ADULT	4064	218.2502	MEPROBAMATE	MEPROBAMATE	CCCC(C)(COC(N)=O)COC(N)=O	SERUM	9I7LNY769Q													μM	18.4			UNKNOWN	mg	700		SINGLE	FASTED				The protein binding of meprobamate in human spiked serum at concentrations of 10, 20, 40 and 80 uM were 24, 23, 16, and 14%, respectively.	76	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7974621	Homo sapiens										false
3246	1616		ADULT	4064	218.2502	MEPROBAMATE	MEPROBAMATE	CCCC(C)(COC(N)=O)COC(N)=O	PLASMA	9I7LNY769Q									∞	μg × h/mL	32		μg/mL	1.8			RECOMMENDED	mg	250		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/011792s048lbl.pdf	Homo sapiens		h	9.7							false
3247	1616		ADULT	4064	218.2502	MEPROBAMATE	MEPROBAMATE	CCCC(C)(COC(N)=O)COC(N)=O	PLASMA	9I7LNY769Q									∞	μg × h/mL	46		μg/mL	2.5			RECOMMENDED	mg	350		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/011792s048lbl.pdf	Homo sapiens		h	9.6							false
3248	1617		ADULT	9015	124.1372	MEQUINOL	MEQUINOL	COC1=CC=C(O)C=C1	PLASMA	6HT8U7K3AM							12		t	ng × h/mL	33.43		ng/mL	9.92			UNKNOWN	μL	16		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Topical	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10701701/	Homo sapiens		h	5							false
3249	1618		ADULT	5991	296.4034	ETHINYL ESTRADIOL	ethinyl estradiol	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@]2(O)C#C	PLASMA	423D2T571U							24		t	pg × min/mL	963		pg/mL	175			RECOMMENDED	μg	50		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE	EXPERIMENT	https://www.sciencedirect.com/science/article/abs/pii/000293789090550Q	Homo sapiens		h	6							false
3250	1619		ADULT	5526	157.2102	TRANEXAMIC ACID	TRANEXAMIC ACID	NC[C@H]1CC[C@@H](CC1)C(O)=O	PLASMA	6T84R30KC1									∞	μg × h/mL	80.19		μg/mL	13.83			RECOMMENDED	mg	650		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf	Homo sapiens		h	11.08							false
3251	1623		CHILD	8982	414.475	NAFCILLIN	NAFCILLIN	CCOC1=C(C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)C4=C(C=CC=C4)C=C1	SERUM	4CNZ27M7RV													μg/mL	58			UNKNOWN	mg/kg	50		MULTIPLE	UNKNOWN		day	4			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2311446	Homo sapiens		min	31							false
3252	1623		ADULT	8982	414.475	NAFCILLIN	NAFCILLIN	CCOC1=C(C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)C4=C(C=CC=C4)C=C1	SERUM	4CNZ27M7RV									?	μg × h/mL	18.06						RECOMMENDED	mg	500		SINGLE	UNKNOWN				Nafcillin binds to serum proteins, mainly albumin. The degree of protein binding reported for nafcillin is 89.9 ± 1.5%	10.1	HEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050655s017lbl.pdf	Homo sapiens		min	47							false
3253	1624		ADULT	6537152	327.4605	NORELGESTROMIN	NORELGESTROMIN	CC[C@]12CC[C@H]3[C@@H](CCC4=CC(CC[C@H]34)=NO)[C@@H]1CC[C@@]2(O)C#C	PLASMA	R0TAY3X631	5991		ETHINYL ESTRADIOL	ethinyl estradiol	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@]2(O)C#C	423D2T571U			∞	pg × h/mL	156702		pg/mL	987			RECOMMENDED	mg	6		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Transdermal	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31935382	Homo sapiens		h	27.6							true
3254	1624		UNKNOWN	6537152	327.4605	NORELGESTROMIN	NORELGESTROMIN	CC[C@]12CC[C@H]3[C@@H](CCC4=CC(CC[C@H]34)=NO)[C@@H]1CC[C@@]2(O)C#C	SERUM	R0TAY3X631																						UNKNOWN				Norelgestromin and norgestrel (a serum metabolite of NGMN) are highly bound (>97%) to serum proteins.	3	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021180s043lbl.pdf	Homo sapiens										false
3255	1625		UNKNOWN	6231	298.4192	NORETHYNODREL	norethynodrel	C[C@]12CC[C@H]3[C@@H](CCC4=C3CCC(=O)C4)[C@@H]1CC[C@@]2(O)C#C	PLASMA	88181ACA0M																					SINGLE	UNKNOWN						UNKNOWN	Intravenous	FEMALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/6342899/	Homo sapiens		min	76							false
3256	1625		UNKNOWN	6231	298.4192	NORETHYNODREL	norethynodrel	C[C@]12CC[C@H]3[C@@H](CCC4=C3CCC(=O)C4)[C@@H]1CC[C@@]2(O)C#C	PLASMA	88181ACA0M																						UNKNOWN				No plasma dilution (1 mg/mL), equilibrium dialysis, plasma protein biding of men was 95%	5	UNKNOWN		MALE	EXPERIMENT	https://www.sciencedirect.com/science/article/pii/0022473175902034	Homo sapiens										false
3257	1625		UNKNOWN	6231	298.4192	NORETHYNODREL	norethynodrel	C[C@]12CC[C@H]3[C@@H](CCC4=C3CCC(=O)C4)[C@@H]1CC[C@@]2(O)C#C	PLASMA	88181ACA0M																						UNKNOWN				No plasma dilution (1 mg/mL), equilibrium dialysis, plasma protein biding of men was 95%	5	UNKNOWN		MALE	EXPERIMENT	https://www.sciencedirect.com/science/article/pii/0022473175902034	Homo sapiens										false
3258	1626		ADULT	6540478	369.4971	NORGESTIMATE	NORGESTIMATE	CC[C@]12CC[C@H]3[C@@H](CCC4=C\\C(CC[C@H]34)=N\\O)[C@@H]1CC[C@@]2(OC(C)=O)C#C	PLASMA	C291HFX4DY	5757		ESTRADIOL	estradiol	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@H]2O	4TI98Z838E			∞	pg × h/mL	9522.7		pg/mL	779.2			UNKNOWN	μg	180		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10883418	Homo sapiens		h	30.4							true
3259	1626		ADULT	6540478	369.4971	NORGESTIMATE	NORGESTIMATE	CC[C@]12CC[C@H]3[C@@H](CCC4=C\\C(CC[C@H]34)=N\\O)[C@@H]1CC[C@@]2(OC(C)=O)C#C	PLASMA	C291HFX4DY	5757		ESTRADIOL	Estradiol	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@H]2O	4TI98Z838E	24		t	pg × h/mL	2146		pg/mL	515			RECOMMENDED	mg	0.09		SINGLE	UNKNOWN				The percent protein binding of 17-deacetylnorgestimate is approximately 99%	1	HEALTHY	Oral	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021040s013lbl.pdf	Homo sapiens		h	37							true
3260	1626		ADULT	6540478	369.4971	NORGESTIMATE	NORGESTIMATE	CC[C@]12CC[C@H]3[C@@H](CCC4=C\\C(CC[C@H]34)=N\\O)[C@@H]1CC[C@@]2(OC(C)=O)C#C	PLASMA	C291HFX4DY							24		t	pg × h/mL	5322		pg/mL	643			RECOMMENDED	mg	0.09		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021040s013lbl.pdf	Homo sapiens										false
3261	1627		ADULT	6196	401.436	OXACILLIN	OXACILLIN	CC1=C(C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)C(=NO1)C4=CC=CC=C4	PLASMA	UH95VD7V76									∞	mg × h/L	125.9						UNKNOWN	mg/kg bw	30		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6619039	Homo sapiens		h	0.42							false
3262	1627		UNKNOWN	6196	401.436	OXACILLIN	OXACILLIN	CC1=C(C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)C(=NO1)C4=CC=CC=C4	SERUM	UH95VD7V76													μg/mL	43			RECOMMENDED	mg	500		SINGLE	UNKNOWN				The degree of protein binding reported for oxacillin is 94.2% ± 2.1%.	6	UNKNOWN	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050640s010lbl.pdf	Homo sapiens		min	25							false
3263	1630		ADULT	8280	157.1671	PARAMETHADIONE	PARAMETHADIONE	CCC1(C)OC(=O)N(C)C1=O	SERUM	Z615FRW64N													μg/mL	6			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1185541	Homo sapiens		h	16							false
3264	1630		ADULT	232592	143.14	5-Ethyl-5-methyl-1,3-oxazolidine-2,4-dione	5-Ethyl-5-methyl-1,3-oxazolidine-2,4-dione	CCC1(C(=O)NC(=O)O1)C	SERUM														μg/mL	8.4			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1185541	Homo sapiens		day	13							false
3265	1634		UNKNOWN	4760	222.2387	PHENINDIONE	PHENINDIONE	O=C1C(C(=O)C2=C1C=CC=C2)C3=CC=CC=C3	PLASMA	5M7Y6274ZE																	UNKNOWN	mg	125		SINGLE	UNKNOWN					12	UNKNOWN	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/1233224/	Homo sapiens		h	5							false
3266	1635		ADULT	4950|657298|5281043	170.232	PROPYLTHIOURACIL	CCCC1=CC(=O)NC(=S)N1	CCCC1=CC(=O)NC(=S)N1	PLASMA	721M9407IY									?	mg × h/L	4.19		mg/L	1.62			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/30522550	Homo sapiens		h	1.22							false
3267	1638		ADULT	5090	314.356	ROFECOXIB	ROFECOXIB	CS(=O)(=O)C1=CC=C(C=C1)C2=C(C(=O)OC2)C3=CC=CC=C3	PLASMA								24		t	ng × h/mL	4018		ng/mL	321			RECOMMENDED	mg	25		MULTIPLE	UNKNOWN		day	1	Rofecoxib is approximately 87% bound to human plasma protein over the range of concentrations of 0.05 to 25 mcg/mL.	13	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021042s033,021052s024lbl.pdf	Homo sapiens		h	17							false
3268	1640		ADULT	9833444	1143.269	SINCALIDE	SINCALIDE	CSCC[C@H](NC(=O)[C@H](CC1=CC=C(OS(O)(=O)=O)C=C1)NC(=O)[C@@H](N)CC(O)=O)C(=O)NCC(=O)N[C@@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC4=CC=CC=C4)C(N)=O	SERUM	M03GIQ7Z6P																	RECOMMENDED	μg/kg bw	0.04		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	REVIEW	https://www.wellrx.com/kinevac/monographs/	Homo sapiens		min	1.3							false
3269	1641		ADULT	17134	310.329	SULFADOXINE	SULFADOXINE	COC1=C(OC)C(NS(=O)(=O)C2=CC=C(N)C=C2)=NC=N1	PLASMA	88463U4SM5	4993		PYRIMETHAMINE	pyrimethamine	CCC1=NC(N)=NC(N)=C1C2=CC=C(Cl)C=C2	Z3614QOX8W			?	μg × h/mL	12394		μg/mL	71.7			UNKNOWN	mg	500		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11419747/	Homo sapiens		h	155.8							true
3270	1641		ADULT	17134	310.329	SULFADOXINE	SULFADOXINE	COC1=C(OC)C(NS(=O)(=O)C2=CC=C(N)C=C2)=NC=N1	PLASMA	88463U4SM5	4993		PYRIMETHAMINE	pyrimethamine	CCC1=NC(N)=NC(N)=C1C2=CC=C(Cl)C=C2	Z3614QOX8W	168		t	mg × h/L	21761.02		mg/L	165.15			UNKNOWN	mg	1500		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23084093/	Homo sapiens										true
3271	1641		UNKNOWN	17134	310.329	SULFADOXINE	SULFADOXINE	COC1=C(OC)C(NS(=O)(=O)C2=CC=C(N)C=C2)=NC=N1	PLASMA	88463U4SM5	4993		PYRIMETHAMINE	pyrimethamine	CCC1=NC(N)=NC(N)=C1C2=CC=C(Cl)C=C2	Z3614QOX8W							mg/L	60			UNKNOWN	mg	500		SINGLE	UNKNOWN					10	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/18557slr015_fansidar_lbl.pdf	Homo sapiens		h	200							true
3272	1643		ADULT	5328	270.331	SULFAMETHIZOLE	SULFAMETHIZOLE	CC1=NN=C(NS(=O)(=O)C2=CC=C(N)C=C2)S1	PLASMA	25W8454H16							24		t	μg × h/mL	144		μg/mL	62.88			UNKNOWN	g	1		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/702289/	Homo sapiens		h	1.4							false
3273	1644		ADULT	5329	253.278	SULFAMETHOXAZOLE	SULFAMETHOXAZOLE	CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1	PLASMA	JE42381TNV							48		t	μg × h/mL	1202.5		μg/mL	94.42			UNKNOWN	mg	1200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20110016	Homo sapiens										false
3274	1644		UNKNOWN	5329	253.278	SULFAMETHOXAZOLE	SULFAMETHOXAZOLE	CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1	PLASMA	JE42381TNV	5578		TRIMETHOPRIM	trimethoprim	COC1=CC(CC2=C(N)N=C(N)N=C2)=CC(OC)=C1OC	AN164J8Y0X							μg/mL	46.3			UNKNOWN	mg	800		SINGLE	UNKNOWN				70% of sulfamethoxazole is bound to plasma proteins	30	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018374s025lbl.pdf	Homo sapiens		h	12.8							true
3275	1646		ADULT	5335	314.362	SULFAPHENAZOLE	SULFAPHENAZOLE	NC1=CC=C(C=C1)S(=O)(=O)NC2=CC=NN2C3=CC=CC=C3	PLASMA								48		t	μg × h/mL	731		μg/mL	50			RECOMMENDED	mg	439		SINGLE	UNKNOWN					0.6	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2091020/	Homo sapiens		h	7							false
3276	1647		ADULT	5359	260.308	SUPROFEN	SUPROFEN	CC(C(O)=O)C1=CC=C(C=C1)C(=O)C2=CC=CS2	PLASMA	988GU2F9PE							12		t	μg × h/mL	26.1		μg/mL	18.95			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3243932	Homo sapiens										false
3277	1647		ADULT	5359	260.308	SUPROFEN	SUPROFEN	CC(C(O)=O)C1=CC=C(C=C1)C(=O)C2=CC=CS2	PLASMA	988GU2F9PE							12		t	μg × h/mL	21.2		μg/mL	8.43			UNKNOWN	mg	200		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3243932	Homo sapiens										false
3278	1648		ADULT	123630	300.291	TAZOBACTAM	TAZOBACTAM	C[C@]2(CN1C=CN=N1)[C@@H](N3[C@@H](CC3=O)S2(=O)=O)C(O)=O	PLASMA	SE10G96M8W									∞	μg × h/mL	42.4						UNKNOWN	mg	500		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1656853/	Homo sapiens		h	1.13				6			false
3279	1648		ADULT	123630	300.291	TAZOBACTAM	TAZOBACTAM	C[C@]2(CN1C=CN=N1)[C@@H](N3[C@@H](CC3=O)S2(=O)=O)C(O)=O	INFLAMMATORY EXUDATE	SE10G96M8W									∞	μg × h/mL	18		μg/mL	6.4			UNKNOWN	mg	500		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1656853/	Homo sapiens		h	0.94				6			false
3280	1648		ADULT	123630	300.291	TAZOBACTAM	TAZOBACTAM	C[C@]2(CN1C=CN=N1)[C@@H](N3[C@@H](CC3=O)S2(=O)=O)C(O)=O	PLASMA	SE10G96M8W	53234134|71457955		CEFTOLOZANE	Ceftolozane	CN1C(N)=C(NC(=O)NCCN)C=[N+]1CC2=C(N3[C@H](SC2)[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\\C4=NSC(N)=N4)C3=O)C([O-])=O	37A4IES95Q			?	μg × h/mL	24.4		μg/mL	18.4			RECOMMENDED	mg	500		SINGLE	UNKNOWN					70	HEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206829lbl.pdf	Homo sapiens		h	0.91							true
3281	1648		ADULT	123630	300.291	TAZOBACTAM	TAZOBACTAM	C[C@]2(CN1C=CN=N1)[C@@H](N3[C@@H](CC3=O)S2(=O)=O)C(O)=O	PLASMA	SE10G96M8W	53234134|71457955		CEFTOLOZANE	Ceftolozane	CN1C(N)=C(NC(=O)NCCN)C=[N+]1CC2=C(N3[C@H](SC2)[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\\C4=NSC(N)=N4)C3=O)C([O-])=O	37A4IES95Q			?	μg × h/mL	25		μg/mL	18			RECOMMENDED	mg	500		STEADY-STATE	UNKNOWN		day	3		70	HEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206829lbl.pdf	Homo sapiens		h	1.03							true
3282	1648		UNKNOWN	123630	300.291	TAZOBACTAM	TAZOBACTAM	C[C@]2(CN1C=CN=N1)[C@@H](N3[C@@H](CC3=O)S2(=O)=O)C(O)=O	PLASMA	SE10G96M8W	73246		PIPERACILLIN	Piperacillin	O.CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)C4=CC=CC=C4)C(=O)C1=O	X00B0D5O0E			?	μg × h/mL	16		μg/mL	15			RECOMMENDED	mg	250		MULTIPLE	UNKNOWN		day	4		70	UNKNOWN	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050684s88s89s90_050750s37s38s39lbl.pdf	Homo sapiens		h	0.77							true
3283	1648		UNKNOWN	123630	300.291	TAZOBACTAM	TAZOBACTAM	C[C@]2(CN1C=CN=N1)[C@@H](N3[C@@H](CC3=O)S2(=O)=O)C(O)=O	PLASMA	SE10G96M8W	73246		PIPERACILLIN	Piperacillin	O.CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)C4=CC=CC=C4)C(=O)C1=O	X00B0D5O0E			?	μg × h/mL	25		μg/mL	24			RECOMMENDED	mg	375		MULTIPLE	UNKNOWN		day	4		70	UNKNOWN	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050684s88s89s90_050750s37s38s39lbl.pdf	Homo sapiens		h	0.68							true
3284	1648		UNKNOWN	123630	300.291	TAZOBACTAM	TAZOBACTAM	C[C@]2(CN1C=CN=N1)[C@@H](N3[C@@H](CC3=O)S2(=O)=O)C(O)=O	PLASMA	SE10G96M8W	73246		PIPERACILLIN	Piperacillin	O.CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)C4=CC=CC=C4)C(=O)C1=O	X00B0D5O0E			?	μg × h/mL	39.8		μg/mL	34			RECOMMENDED	mg	500		MULTIPLE	UNKNOWN		day	4		70	UNKNOWN	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050684s88s89s90_050750s37s38s39lbl.pdf	Homo sapiens		h	0.82							true
3285	1649		UNKNOWN	452548	656.654	TENIPOSIDE	TENIPOSIDE	COC1=CC(=CC(OC)=C1O)[C@H]2[C@@H]3[C@H](COC3=O)[C@H](O[C@@H]4O[C@@H]5CO[C@H](O[C@H]5[C@H](O)[C@H]4O)C6=CC=CS6)C7=C2C=C8OCOC8=C7	PLASMA	957E6438QA																						UNKNOWN				Teniposide is highly protein bound. In vitro plasma protein binding of teniposide is >99%.	1	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020119s010s011lbl.pdf	Homo sapiens										false
3286	1649		ADULT	452548	656.654	TENIPOSIDE	COC1=CC(=CC(OC)=C1O)[C@H]2[C@@H]3[C@H](COC3=O)[C@H](O[C@@H]4O[C@@H]5CO[C@H](O[C@H]5[C@H](O)[C@H]4O)C6=CC=CS6)C7=CC8=C(OCO8)C=C27	COC1=CC(=CC(OC)=C1O)[C@H]2[C@@H]3[C@H](COC3=O)[C@H](O[C@@H]4O[C@@H]5CO[C@H](O[C@H]5[C@H](O)[C@H]4O)C6=CC=CS6)C7=CC8=C(OCO8)C=C27	PLASMA	957E6438QA									∞	μg × min/mL	1937.3		ng/mL	7083.9			UNKNOWN	mg/m²	30		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/4017164	Homo sapiens		h	20.3							false
3287	1650		ADULT	13769	300.3921	TESTOLACTONE	TESTOLACTONE	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CCC(=O)O2	PLASMA	6J9BLA949Q							6		t	μg × h/mL	3.5		μg/mL	1			UNKNOWN	mg	500		STEADY-STATE	UNKNOWN		day	4			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6643639/	Homo sapiens		h	1.7							false
3288	1651		ADULT	5419	200.2795	TETRAHYDROZOLINE	TETRAHYDROZOLINE	C1CN=C(N1)C2CCCC3=C2C=CC=C3	SERUM	S9U025Y077							24		t	ng × h/mL	3.46		ng/mL	0.218			UNKNOWN	drop	2		MULTIPLE	UNKNOWN		day	4			HEALTHY	Ocular	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21972870/	Homo sapiens		h	6							false
3289	1652		ADULT	5430	201.248	THIABENDAZOLE	THIABENDAZOLE	N1C(=NC2=C1C=CC=C2)C3=CSC=N3	SERUM	N1Q45E87DT									∞	μg × min/mL	0.9		μg/mL	5			UNKNOWN	mg/kg	25		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7050189/	Homo sapiens		h	1.17							false
3290	1654		ADULT	36921	384.427	TICARCILLIN	ticarcillin	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](C(O)=O)C3=CSC=C3)C(=O)N2[C@H]1C(O)=O	SERUM	F93UJX4SWT									∞	mg × h/L	747		mg/L	576.2			UNKNOWN	g	5		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3722046/	Homo sapiens		min	74.8							false
3291	1654		ADULT	36921	384.427	TICARCILLIN	ticarcillin	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](C(O)=O)C3=CSC=C3)C(=O)N2[C@H]1C(O)=O	SERUM	F93UJX4SWT	5280980		CLAVULANIC ACID	clavulanic acid	OC\\C=C1/O[C@@H]2CC(=O)N2[C@H]1C(O)=O	23521W1S24			∞	mg × h/L	890		mg/L	621.8			UNKNOWN	g	5		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3722046/	Homo sapiens		min	84.7							true
3292	1654		ADULT	36921	384.427	TICARCILLIN	ticarcillin	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](C(O)=O)C3=CSC=C3)C(=O)N2[C@H]1C(O)=O	SERUM	F93UJX4SWT	5280980		CLAVULANIC ACID	clavulanic acid	OC\\C=C1/O[C@@H]2CC(=O)N2[C@H]1C(O)=O	23521W1S24			∞	mg × h/L	538		mg/L	431.5			UNKNOWN	g	3		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3722046/	Homo sapiens		min	80.7							true
3293	1654		ADULT	36921	384.427	TICARCILLIN	TICARCILLIN	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](C(O)=O)C3=CSC=C3)C(=O)N2[C@H]1C(O)=O	PLASMA	F93UJX4SWT																	UNKNOWN	g	5		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7140806/	Homo sapiens		min	76							false
3294	1654		ADULT	36921	384.427	TICARCILLIN	TICARCILLIN	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](C(O)=O)C3=CSC=C3)C(=O)N2[C@H]1C(O)=O	SERUM	F93UJX4SWT	6434607|23665591		CLAVULANATE POTASSIUM	clavulanate potassium	[K+].OC\\C=C1/O[C@@H]2CC(=O)N2[C@H]1C([O-])=O	Q42OMW3AT8			?	μg × h/mL	485		μg/mL	324			UNKNOWN	g	3		SINGLE	UNKNOWN					55	UNKNOWN	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf	Homo sapiens		h	1.1							true
3295	1654		CHILD	36921	384.427	TICARCILLIN	TICARCILLIN	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](C(O)=O)C3=CSC=C3)C(=O)N2[C@H]1C(O)=O	SERUM	F93UJX4SWT	6434607|23665591		CLAVULANATE POTASSIUM	clavulanate potassium	[K+].OC\\C=C1/O[C@@H]2CC(=O)N2[C@H]1C([O-])=O	Q42OMW3AT8			?	μg × h/mL	339						UNKNOWN	mg/kg bw	50		SINGLE	UNKNOWN						UNKNOWN	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf	Homo sapiens		h	1							true
3296	1655		NEWBORN	5504	160.2157	TOLAZOLINE	TOLAZOLINE	C(C1=NCCN1)C2=CC=CC=C2	BLOOD	CHH9H12AQ3													mg/L	3.8			UNKNOWN	mg	3.2		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3576663	Homo sapiens		h	0.15							false
3297	1656		ADULT	5576	143.1406	TRIMETHADIONE	TRIMETHADIONE	CN1C(=O)OC(C)(C)C1=O	SERUM	R7GV3H6FQ4									∞	μg × h/mL	148		μg/mL	6			RECOMMENDED	mg/kg	4		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8441739/	Homo sapiens		h	14.2							false
3298	1657		ADULT	5591	441.545	TROGLITAZONE		Cc1c(C)c2OC(C)(COc3ccc(CC4SC(=O)NC4=O)cc3)CCc2c(C)c1O	PLASMA	I66ZZ0ZN0E									?	μg × h/mL	10.7		μg/mL	1.01			UNKNOWN	mg	400		SINGLE	FED					2.1	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9832300/	Homo sapiens		h	12.8		Moderate hepatic impairment		8			false
3299	1657		ADULT	5591	441.545	TROGLITAZONE		Cc1c(C)c2OC(C)(COc3ccc(CC4SC(=O)NC4=O)cc3)CCc2c(C)c1O	PLASMA	I66ZZ0ZN0E									?	μg × h/mL	7.3		μg/mL	1.2			UNKNOWN	mg	400		SINGLE	FED					2.6	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9832300/	Homo sapiens		h	7.6		Normal hepatic function		8			false
3300	1657		ADULT	5591	441.545	TROGLITAZONE		Cc1c(C)c2OC(C)(COc3ccc(CC4SC(=O)NC4=O)cc3)CCc2c(C)c1O	PLASMA	I66ZZ0ZN0E									?	μg × h/mL	8.6		μg/mL	0.74			UNKNOWN	mg	400		SINGLE	FED					1.5	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9832300/	Homo sapiens		h	13.5		Severe hepatic impairment		8			false
3301	1657		ADULT	5591	441.545	TROGLITAZONE		Cc1c(C)c2OC(C)(COc3ccc(CC4SC(=O)NC4=O)cc3)CCc2c(C)c1O	PLASMA	I66ZZ0ZN0E																						UNKNOWN				Mean plasma elimination half-life of troglitazone ranges from 16 to 34 hours.		HEALTHY		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20720s12lbl.pdf#page=3	Homo sapiens		h	34							false
3302	1657			5591	441.545	TROGLITAZONE		Cc1c(C)c2OC(C)(COc3ccc(CC4SC(=O)NC4=O)cc3)CCc2c(C)c1O	SERUM	I66ZZ0ZN0E																										Troglitazone is extensively bound (>99%) to serum albumin.	1				DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20719S12_Prelay_prntlbl.pdf#page=3	Homo sapiens										false
3303	1657		ADULT	5591	441.545	TROGLITAZONE	TROGLITAZONE	Cc1c(C)c2OC(C)(COc3ccc(CC4SC(=O)NC4=O)cc3)CCc2c(C)c1O	PLASMA	I66ZZ0ZN0E							24		t	μg × h/mL	7.4		μg/mL	0.9			UNKNOWN	mg	200		STEADY-STATE	FED		day	1			HEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20719S12_Prelay_prntlbl.pdf#page=3 | https://pubmed.ncbi.nlm.nih.gov/10471982/	Homo sapiens				Day 7			21			false
3304	1657		ADULT	5591	441.545	TROGLITAZONE	TROGLITAZONE	Cc1c(C)c2OC(C)(COc3ccc(CC4SC(=O)NC4=O)cc3)CCc2c(C)c1O	PLASMA	I66ZZ0ZN0E							24		t	μg × h/mL	13.4		μg/mL	1.61			UNKNOWN	mg	400		STEADY-STATE	FED		day	1			HEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20719S12_Prelay_prntlbl.pdf#page=3 | https://pubmed.ncbi.nlm.nih.gov/10471982/	Homo sapiens							21			false
3305	1657		ADULT	5591	441.545	TROGLITAZONE	TROGLITAZONE	Cc1c(C)c2OC(C)(COc3ccc(CC4SC(=O)NC4=O)cc3)CCc2c(C)c1O	PLASMA	I66ZZ0ZN0E							24		t	μg × h/mL	22.1		μg/mL	2.82			UNKNOWN	mg	600		STEADY-STATE	FED		day	1			HEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20719S12_Prelay_prntlbl.pdf#page=3 | https://pubmed.ncbi.nlm.nih.gov/10471982/	Homo sapiens							21			false
3306	1659		ADULT	119607	314.359	VALDECOXIB	Valdecoxib	CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(N)(=O)=O	SERUM	2919279Q3W									∞	ng × h/mL	9062		ng/mL	1385			UNKNOWN	mg	20		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16599270/	Homo sapiens		h	3.7							false
3307	1659		ADULT	119607	314.359	VALDECOXIB	Valdecoxib	CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(N)(=O)=O	PLASMA	2919279Q3W							24		t	ng × h/mL	1479		ng/mL	161.1			RECOMMENDED	mg	10		STEADY-STATE	UNKNOWN		day	1		2	HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21341se8-003_bextra_lbl.pdf	Homo sapiens		h	8.11							false
3308	1659		ADULT	119607	314.359	VALDECOXIB	Valdecoxib	CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(N)(=O)=O	PLASMA	2919279Q3W									∞	ng × h/mL	341		ng/mL	24			UNKNOWN	mg	10		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-341_Bextra_biopharmr_P1.pdf	Homo sapiens										false
3309	1659		ADULT	119607	314.359	VALDECOXIB	Valdecoxib	CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(N)(=O)=O	PLASMA	2919279Q3W									∞	ng × h/mL	371		ng/mL	26			UNKNOWN	mg	20		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-341_Bextra_biopharmr_P1.pdf	Homo sapiens										false
3310	1659		ADULT	9818888	330.358	1-HYDROXYVALDECOXIB	1-HYDROXYVALDECOXIB	NS(=O)(=O)C1=CC=C(C=C1)C2=C(CO)ON=C2C3=CC=CC=C3	PLASMA	T5Q8Y8772I									∞	ng × h/mL	31		ng/mL	2			UNKNOWN	mg	5		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-341_Bextra_biopharmr_P1.pdf	Homo sapiens										false
3311	1659		ADULT	9818888	330.358	1-HYDROXYVALDECOXIB	1-HYDROXYVALDECOXIB	NS(=O)(=O)C1=CC=C(C=C1)C2=C(CO)ON=C2C3=CC=CC=C3	PLASMA	T5Q8Y8772I									∞	ng × h/mL	33		ng/mL	2			UNKNOWN	mg	10		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-341_Bextra_biopharmr_P1.pdf	Homo sapiens										false
3312	1659		ADULT	9818888	330.358	1-HYDROXYVALDECOXIB	1-HYDROXYVALDECOXIB	NS(=O)(=O)C1=CC=C(C=C1)C2=C(CO)ON=C2C3=CC=CC=C3	PLASMA	T5Q8Y8772I									∞	ng × h/mL	36		ng/mL	2			UNKNOWN	mg	20		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-341_Bextra_biopharmr_P1.pdf	Homo sapiens										false
3313	1659		ADULT	9818888	330.358	1-HYDROXYVALDECOXIB	1-HYDROXYVALDECOXIB	NS(=O)(=O)C1=CC=C(C=C1)C2=C(CO)ON=C2C3=CC=CC=C3	PLASMA	T5Q8Y8772I									∞	ng × h/mL	19		ng/mL	1			UNKNOWN	mg	20		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-341_Bextra_biopharmr_P1.pdf	Homo sapiens										false
3314	1659		ADULT	119607	314.359	VALDECOXIB	Valdecoxib	CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(N)(=O)=O	PLASMA	2919279Q3W									∞	ng × h/mL	332		ng/mL	26			UNKNOWN	mg	5		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-341_Bextra_biopharmr_P1.pdf	Homo sapiens										false
3315	1659		ADULT	119607	314.359	VALDECOXIB	Valdecoxib	CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(N)(=O)=O	PLASMA	2919279Q3W									∞	ng × h/mL	198		ng/mL	16			UNKNOWN	mg	5		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-341_Bextra_biopharmr_P1.pdf	Homo sapiens										false
3316	1659		ADULT	119607	314.359	VALDECOXIB	Valdecoxib	CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(N)(=O)=O	PLASMA	2919279Q3W									∞	ng × h/mL	167		ng/mL	12			UNKNOWN	mg	10		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-341_Bextra_biopharmr_P1.pdf	Homo sapiens										false
3317	1659		ADULT	9818888	330.358	1-HYDROXYVALDECOXIB	1-HYDROXYVALDECOXIB	NS(=O)(=O)C1=CC=C(C=C1)C2=C(CO)ON=C2C3=CC=CC=C3	PLASMA	T5Q8Y8772I									∞	ng × h/mL	15		ng/mL	0.8			UNKNOWN	mg	10		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-341_Bextra_biopharmr_P1.pdf	Homo sapiens										false
3318	1659		ADULT	119607	314.359	VALDECOXIB	Valdecoxib	CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(N)(=O)=O	PLASMA	2919279Q3W									∞	ng × h/mL	1787		ng/mL	146			UNKNOWN	mg	10		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-341_Bextra_biopharmr_P1.pdf	Homo sapiens		h	8.31	Tablet			27			false
3319	1659		ADULT	119607	314.359	VALDECOXIB	Valdecoxib	CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(N)(=O)=O	PLASMA	2919279Q3W									∞	ng × h/mL	175		ng/mL	14			UNKNOWN	mg	20		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-341_Bextra_biopharmr_P1.pdf	Homo sapiens										false
3320	1659		ADULT	9818888	330.358	1-HYDROXYVALDECOXIB	1-HYDROXYVALDECOXIB	NS(=O)(=O)C1=CC=C(C=C1)C2=C(CO)ON=C2C3=CC=CC=C3	PLASMA	T5Q8Y8772I									∞	ng × h/mL	18		ng/mL	1			UNKNOWN	mg	5		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-341_Bextra_biopharmr_P1.pdf	Homo sapiens										false
3321	1659		ADULT	119607	314.359	VALDECOXIB	Valdecoxib	CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(N)(=O)=O	PLASMA	2919279Q3W									∞	ng × h/mL	3450		ng/mL	284			UNKNOWN	mg	20		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-341_Bextra_biopharmr_P1.pdf	Homo sapiens		h	8.53	Tablet			28			false
3322	1659		ADULT	119607	314.359	VALDECOXIB	Valdecoxib	CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(N)(=O)=O	PLASMA	2919279Q3W									∞	ng × h/mL	6957		ng/mL	568			UNKNOWN	mg	40		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-341_Bextra_biopharmr_P1.pdf	Homo sapiens		h	8.84	Tablet			28			false
3323	1660		ADULT	24066	211.2178	ZALCITABINE	ZALCITABINE	NC1=NC(=O)N(C=C1)[C@H]2CC[C@@H](CO)O2	PLASMA	6L3XT8CB3I									?	mg × h/L	0.018		μg/L	7.6			UNKNOWN	mg	0.5		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/9179531/	Homo sapiens		h	1.5							false
3324	1660		ADULT	24066	211.2178	ZALCITABINE	ZALCITABINE	NC1=NC(=O)N(C=C1)[C@H]2CC[C@@H](CO)O2	PLASMA	6L3XT8CB3I									?	mg × h/L	0.208		μg/L	79			UNKNOWN	mg	5		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/9179531/	Homo sapiens		h	1.8							false
3325	1660		CHILD	24066	211.2178	ZALCITABINE	ZALCITABINE	NC1=NC(=O)N(C=C1)[C@H]2CC[C@@H](CO)O2	PLASMA	6L3XT8CB3I									?	mg × h/L	0.025		μg/L	9.3			UNKNOWN	mg/kg bw	0.02		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/9179531/	Homo sapiens		h	1.4							false
3326	1660		UNKNOWN	24066	211.2178	ZALCITABINE	ZALCITABINE	NC1=NC(=O)N(C=C1)[C@H]2CC[C@@H](CO)O2	PLASMA	6L3XT8CB3I									?	ng × h/mL	72		ng/mL	25.2			UNKNOWN	mg	1.5		SINGLE	FASTED					96	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20199s014lbl.pdf	Homo sapiens		h	2							false
3327	1660		UNKNOWN	24066	211.2178	ZALCITABINE	ZALCITABINE	NC1=NC(=O)N(C=C1)[C@H]2CC[C@@H](CO)O2	PLASMA	6L3XT8CB3I									?	ng × h/mL	62		ng/mL	15.5			UNKNOWN	mg	1.5		SINGLE	FED					96	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20199s014lbl.pdf	Homo sapiens		h	2							false
3328	1660		ADULT	24066	211.2178	ZALCITABINE	ZALCITABINE	NC1=NC(=O)N(C=C1)[C@H]2CC[C@@H](CO)O2	PLASMA	6L3XT8CB3I									?	mg × h/L	0.022		μg/L	10.5			UNKNOWN	mg	0.5		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	REVIEW	https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20199s014lbl.pdf	Homo sapiens		h	1.3							false
3329	1661		ADULT	2342	404.4999	BENZQUINAMIDE	BENZQUINAMIDE	CCN(CC)C(=O)C1CN2CCC3=CC(OC)=C(OC)C=C3C2CC1OC(C)=O	PLASMA	0475EA27Q3							12		t	ng × h/mL	1330		ng/mL	609			RECOMMENDED	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/581593/	Homo sapiens		h	1.6							false
3330	1662		ADULT	2481	224.2563	BUTALBITAL	BUTALBITAL	CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O	PLASMA	KHS0AZ4JVK													μg/mL	26.9			UNKNOWN	g	2		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29124988/	Homo sapiens										false
3331	1662		ADULT	2481	224.2563	BUTALBITAL	BUTALBITAL	CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O	PLASMA	KHS0AZ4JVK	1983		ACETAMINOPHEN	Acetaminophen	CC(=O)NC1=CC=C(O)C=C1	362O9ITL9D							μg/mL	1			RECOMMENDED	mg	50		SINGLE	UNKNOWN				The in vitro plasma protein binding of butalbital is 45%	55	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020232s041lbl.pdf	Homo sapiens		h	35							true
3332	1663		ADULT	3033053	245.3599	DEZOCINE	DEZOCINE	C[C@@]12CCCCC[C@@H](CC3=CC=C(O)C=C13)[C@@H]2N	SERUM	VHX8K5SV4X									?	ng × h/mL	23.7						UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3709625	Homo sapiens		h	2.6							false
3333	1663		ADULT	3033053	245.3599	DEZOCINE	DEZOCINE	C[C@@]12CCCCC[C@@H](CC3=CC=C(O)C=C13)[C@@H]2N	SERUM	VHX8K5SV4X									?	ng × h/mL	49.1						UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3709625	Homo sapiens		h	2.6							false
3334	1663		ADULT	3033053	245.3599	DEZOCINE	DEZOCINE	C[C@@]12CCCCC[C@@H](CC3=CC=C(O)C=C13)[C@@H]2N	SERUM	VHX8K5SV4X									?	ng × h/mL	117.1						UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3709625	Homo sapiens		h	2.8							false
3335	1664		ADULT	6011	304.4669	DROMOSTANOLONE	DROMOSTANOLONE	C[C@@H]1C[C@@]2(C)[C@@H](CC[C@H]3[C@@H]4CC[C@H](O)[C@@]4(C)CC[C@H]23)CC1=O	PLASMA	7DR7H00HDT																	UNKNOWN				SINGLE	UNKNOWN						UNKNOWN	Intramuscular	UNKNOWN	REVIEW	https://books.google.ru/books?id=afKLA-6wW0oC&pg=PT517&redir_esc=y#v=onepage&q&f=false	Homo sapiens		day	2							false
3336	1665		ADULT	3284	167.205	ETHINAMATE	ETHINAMATE	NC(=O)OC1(CCCCC1)C#C	PLASMA	IAN371PP48													μg/mL	5.9			UNKNOWN	g	1		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4604053	Homo sapiens		h	2.3							false
3337	1666		ADULT	4162	183.2475	METHYPRYLON	METHYPRYLON	CCC1(CC)C(=O)NCC(C)C1=O	PLASMA	CUT48I42ON									?	mg × h/L	74.75		mg/L	5.62			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2866242	Homo sapiens		h	9.2							false
3338	1667		ADULT	16132147|16133834|25077405	1322.4713	NAFARELIN	NAFARELIN	CC(C)C[C@H](NC(=O)[C@@H](CC1=CC2=C(C=CC=C2)C=C1)NC(=O)[C@H](CC3=CC=C(O)C=C3)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CNC5=C4C=CC=C5)NC(=O)[C@H](CC6=CNC=N6)NC(=O)[C@@H]7CCC(=O)N7)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N8CCC[C@H]8C(=O)NCC(N)=O	SERUM	1X0094V6JV			SODIUM GLYCOCHOLATE	SODIUM GLYCOCHOLATE	[Na+].C[C@H](CCC(=O)NCC([O-])=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C	V06CXA1W3K			∞	ng × h/mL	7		ng/mL	4.02			UNKNOWN	μg	304		SINGLE	UNKNOWN						UNKNOWN	Nasal	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2970910/	Homo sapiens		h	2.4							true
3339	1667		ADULT	16132147|16133834|25077405	1322.4713	NAFARELIN	NAFARELIN	CC(C)C[C@H](NC(=O)[C@@H](CC1=CC2=C(C=CC=C2)C=C1)NC(=O)[C@H](CC3=CC=C(O)C=C3)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CNC5=C4C=CC=C5)NC(=O)[C@H](CC6=CNC=N6)NC(=O)[C@@H]7CCC(=O)N7)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N8CCC[C@H]8C(=O)NCC(N)=O	SERUM	1X0094V6JV							4		t	ng × h/mL	2.15		ng/mL	1.59			UNKNOWN	μg	391		SINGLE	UNKNOWN						UNKNOWN	Nasal	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2970910/	Homo sapiens							6			false
3340	1667		ADULT	16132147|16133834|25077405	1322.4713	NAFARELIN	NAFARELIN	CC(C)C[C@H](NC(=O)[C@@H](CC1=CC2=C(C=CC=C2)C=C1)NC(=O)[C@H](CC3=CC=C(O)C=C3)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CNC5=C4C=CC=C5)NC(=O)[C@H](CC6=CNC=N6)NC(=O)[C@@H]7CCC(=O)N7)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N8CCC[C@H]8C(=O)NCC(N)=O	SERUM	1X0094V6JV							4		t	ng × h/mL	0.58		ng/mL	0.35			UNKNOWN	μg	206		SINGLE	UNKNOWN						UNKNOWN	Nasal	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2970910/	Homo sapiens							4			false
3341	1667		ADULT	16132147|16133834|25077405	1322.4713	NAFARELIN	NAFARELIN	CC(C)C[C@H](NC(=O)[C@@H](CC1=CC2=C(C=CC=C2)C=C1)NC(=O)[C@H](CC3=CC=C(O)C=C3)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CNC5=C4C=CC=C5)NC(=O)[C@H](CC6=CNC=N6)NC(=O)[C@@H]7CCC(=O)N7)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N8CCC[C@H]8C(=O)NCC(N)=O	SERUM	1X0094V6JV									∞	ng × h/mL	49.2		ng/mL	13.66			UNKNOWN	μg	400		SINGLE	UNKNOWN						UNKNOWN	Subcutaneous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2970910/	Homo sapiens		h	2.7							false
3342	1667		ADULT	16132147|16133834|25077405	1322.4713	NAFARELIN	NAFARELIN	CC(C)C[C@H](NC(=O)[C@@H](CC1=CC2=C(C=CC=C2)C=C1)NC(=O)[C@H](CC3=CC=C(O)C=C3)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CNC5=C4C=CC=C5)NC(=O)[C@H](CC6=CNC=N6)NC(=O)[C@@H]7CCC(=O)N7)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N8CCC[C@H]8C(=O)NCC(N)=O	SERUM	1X0094V6JV							4		t	ng × h/mL	0.07		ng/mL	0.1			UNKNOWN	μg	84		SINGLE	UNKNOWN						UNKNOWN	Nasal	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2970910/	Homo sapiens							4			false
3343	1670		ADULT	37720	0	PENTOSAN POLYSULFATE	Pentosan polysulfate		PLASMA	F59P8B75R4							120		t	ng × eq × h/mL	33.8		ng × eq/mL	358			UNKNOWN	mg	450		SINGLE	FASTED				n=4 for t1/2		HEALTHY	Oral	FEMALE	OTHER GOV'T	https://www.ema.europa.eu/en/documents/assessment-report/elmiron-epar-public-assessment-report_en.pdf#page=47 | https://pubmed.ncbi.nlm.nih.gov/16278190/	Homo sapiens		h	19.5				8			false
3344	1670		ADULT	37720	0	PENTOSAN POLYSULFATE	Pentosan polysulfate		PLASMA	F59P8B75R4							120		t	ng × eq × h/mL	21		ng × eq/mL	250			UNKNOWN	mg	300		SINGLE	FASTED				n=6 for t1/2		HEALTHY	Oral	FEMALE	OTHER GOV'T	https://www.ema.europa.eu/en/documents/assessment-report/elmiron-epar-public-assessment-report_en.pdf#page=47 | https://pubmed.ncbi.nlm.nih.gov/16278190/	Homo sapiens		h	26.5				7			false
3345	1670		ADULT	37720	0	PENTOSAN POLYSULFATE	Pentosan polysulfate		PLASMA	F59P8B75R4									?	ng × h/mL	6660		ng/mL	462			MAX TOLERATED	mg/m²	400		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.ema.europa.eu/en/documents/assessment-report/elmiron-epar-public-assessment-report_en.pdf#page=47 | https://pubmed.ncbi.nlm.nih.gov/9815633/	Homo sapiens				Day 15	Patients with advanced cancer		4			false
3346	1670		ADULT	37720	0	PENTOSAN POLYSULFATE	Pentosan polysulfate		PLASMA	F59P8B75R4									?	ng × h/mL	987.5		ng/mL	68.7			MAX TOLERATED	mg/m²	400		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.ema.europa.eu/en/documents/assessment-report/elmiron-epar-public-assessment-report_en.pdf#page=47 | https://pubmed.ncbi.nlm.nih.gov/9815633/	Homo sapiens				Day 1	Patients with advanced cancer		4			false
3347	1671		ADULT		0	PORFIMER	Porfimer		SERUM	M15H03K69B									∞	ng × h/mL	2937444.7		ng/mL	43105.6			UNKNOWN	mg/kg	2		MULTIPLE	UNKNOWN		5 weeks	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20629974/	Homo sapiens		h	409.9	1st administration; administered once every 30-44 days (median 35 days)	patients undergoing photodynamic therapy		18			false
3348	1671		ADULT		0	PORFIMER	Porfimer		SERUM	M15H03K69B									∞	ng × h/mL	3937582.7		ng/mL	41307.1			UNKNOWN	mg/kg	2		MULTIPLE	UNKNOWN		5 weeks	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20629974/	Homo sapiens		h	725	1st administration; administered once every 30-44 days (median 35 days)	patients undergoing photodynamic therapy		14			false
3349	1671		ADULT		0	PORFIMER	Porfimer		PLASMA	M15H03K69B									∞	μg × h/mL	2937		μg/mL	43.1			UNKNOWN	mg/kg	2		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020451s029,021525s005lbl.pdf#page=17	Homo sapiens		h	410		Patients with cancer		18			false
3350	1671				0	PORFIMER	Porfimer		SERUM	M15H03K69B																										Porfimer sodium was approximately 90% protein bound in human serum in vitro.	10				OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020451s029,021525s005lbl.pdf#page=17	Homo sapiens										false
3351	1671		ADULT		0	PORFIMER	Porfimer		PLASMA	M15H03K69B									?	μg × h/mL	974		μg/mL	15.3			UNKNOWN	mg/kg	2		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020451Orig1s000rev.pdf#page=468	Homo sapiens		h	250		cancer patients		4			false
3352	1672		ADULT	5322	294.33	SULFACYTINE	SULFACYTINE	CCN1C=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NC1=O	PLASMA	T795873AJP																	UNKNOWN	g	1		SINGLE	UNKNOWN					14	UNKNOWN	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3606051/	Homo sapiens		h	4							false
3353	1673		UNKNOWN	8275	224.2563	TALBUTAL	TALBUTAL	CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O	PLASMA	4YIR8202AX																	UNKNOWN				UNKNOWN	UNKNOWN						UNKNOWN	UNKNOWN	UNKNOWN	REVIEW	https://link.springer.com/chapter/10.1007%2F978-94-011-3804-8_20	Homo sapiens		h	15							false
3354	1675		ADULT		190.15	CARGLUMIC ACID			PLASMA								72		t	μg × h/mL	23.2		ng/mL	2892			RECOMMENDED	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25677217/	Homo sapiens		h	5.2							false
3355	1675		ADULT		190.15	CARGLUMIC ACID			PLASMA														μg/mL	2.6			RECOMMENDED	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/30780843/	Homo sapiens		h	5.6							false
3356	1677		ADULT	3025	343.4632	DIBUCAINE	DIBUCAINE	CCCCOC1=NC2=C(C=CC=C2)C(=C1)C(=O)NCCN(CC)CC	PLASMA	L6JW2TJG99							24		t	ng × h/mL	208		ng/mL	23			UNKNOWN	mg	5		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://www.tandfonline.com/doi/pdf/10.1080/00032718108059837	Homo sapiens		h	11							false
3357	1680		ADULT	2519	194.1906	CAFFEINE	CAFFEINE	CN1C=NC2=C1C(=O)N(C)C(=O)N2C	PLASMA	3G6A5W338E									?	nM × h	43000							mg	100		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01361217	Homo sapiens										false
3358	1680		ADULT	2519	194.1906	CAFFEINE	CAFFEINE	CN1C=NC2=C1C(=O)N(C)C(=O)N2C	UNKNOWN	3G6A5W338E									∞	μg × h/mL	65.64		μg/mL	3.35			UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/28561231	Homo sapiens		h	10.19				32			false
3359	1681			6167	399.437	COLCHICINE	COLCHICINE	COC1=CC2=C(C(OC)=C1OC)C3=CC=C(OC)C(=O)C=C3[C@H](CC2)NC(C)=O	PLASMA	SML2Y3J35T													pg/mL	2023.29				mg	0.6		SINGLE								Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00960323	Homo sapiens										false
3360	1681			6167	399.437	COLCHICINE	COLCHICINE	COC1=CC2=C(C(OC)=C1OC)C3=CC=C(OC)C(=O)C=C3[C@H](CC2)NC(C)=O	PLASMA	SML2Y3J35T									?	pg × h/mL	8717.33							mg	0.6		SINGLE								Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00960323	Homo sapiens										false
3361	1681		ADULT	6167	399.437	COLCHICINE	COLCHICINE	COC1=CC2=C(C(OC)=C1OC)C3=CC=C(OC)C(=O)C=C3[C@H](CC2)NC(C)=O	PLASMA	SML2Y3J35T									∞	ng × h/mL	19.9		ng/mL	2.16			RECOMMENDED	mg	0.6		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210942s000lbl.pdf	Homo sapiens		h	31.04							false
3362	1681		ADULT	6167	399.437	COLCHICINE	COLCHICINE	COC1=CC2=C(C(OC)=C1OC)C3=CC=C(OC)C(=O)C=C3[C@H](CC2)NC(C)=O	PLASMA	SML2Y3J35T									∞	ng × h/mL	18.47		ng/mL	1.68			RECOMMENDED	mg	0.6		SINGLE	FED						HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210942s000lbl.pdf	Homo sapiens		h	30.54							false
3363	1681		UNKNOWN	6167	399.437	COLCHICINE	COLCHICINE	COC1=CC2=C(C(OC)=C1OC)C3=CC=C(OC)C(=O)C=C3[C@H](CC2)NC(C)=O	SERUM	SML2Y3J35T																						UNKNOWN				Colchicine binding to serum protein is reported to be low (39%) primarily due to albumin regardless of concentration.	61	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210942s000lbl.pdf	Homo sapiens										false
3364	1682		UNKNOWN	23535193|57828125|71587099|121232744|135564886|135673376|137157436|145948239	752.981	INDOCYANINE GREEN ACID FORM	INDOCYANINE GREEN ACID FORM	CC1(C)C(=CC=CC=CC=CC2=[N+](CCCCS([O-])(=O)=O)C3=C(C4=CC=CC=C4C=C3)C2(C)C)N(CCCCS(O)(=O)=O)C5=C1C6=CC=CC=C6C=C5	SERUM	C4V974V932																						UNKNOWN				After incubation of a micelle formulation in human serum and measurement of the free portion of ICG after an incubation period of 4 h and removal of the unbound ICG by means of ultra centrifugation, a free portion of <5% is determined.	5	UNKNOWN		UNKNOWN	PATENT	https://patents.google.com/patent/US20100303732	Homo sapiens										false
3365	1682		ADULT	23535193|57828125|71587099|121232744|135564886|135673376|137157436|145948239	752.981	INDOCYANINE GREEN ACID FORM	INDOCYANINE GREEN ACID FORM	CC1(C)C(=CC=CC=CC=CC2=[N+](CCCCS([O-])(=O)=O)C3=C(C4=CC=CC=C4C=C3)C2(C)C)N(CCCCS(O)(=O)=O)C5=C1C6=CC=CC=C6C=C5	PLASMA	C4V974V932	5556		TRIAZOLAM	Triazolam	CC1=NN=C2CN=C(C3=C(Cl)C=CC=C3)C4=C(C=CC(Cl)=C4)N12	1HM943223R			?	μg × min/mL	121.6						UNKNOWN	mg/kg	0.5		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10883415	Homo sapiens		min	2.06							true
3366	1682		ADULT	23535193|57828125|71587099|121232744|135564886|135673376|137157436|145948239	752.981	INDOCYANINE GREEN ACID FORM	INDOCYANINE GREEN ACID FORM	CC1(C)C(=CC=CC=CC=CC2=[N+](CCCCS([O-])(=O)=O)C3=C(C4=CC=CC=C4C=C3)C2(C)C)N(CCCCS(O)(=O)=O)C5=C1C6=CC=CC=C6C=C5	PLASMA	C4V974V932									∞	mg × min/L	85						UNKNOWN	mg/kg	0.5		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8822042	Homo sapiens		h	3.9							false
3367	1683		ADULT	4004	330.358	MALATHION	MALATHION	CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC	SERUM	U5N7SU872W																	UNKNOWN	g	1.8		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3612901	Homo sapiens		h	2.89							false
3368	1685		ADULT	79076	182.0889	GLYCERYL 1,2-DINITRATE	1,2-Dinitroglycerin	OCC(CO[N+]([O-])=O)O[N+]([O-])=O	PLASMA	8542I4GE54									∞	ng × min/mL	3380		ng/mL	84			UNKNOWN	mg	13		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2111749/	Homo sapiens		min	50							false
3369	1685		ADULT	4510	227.0865	NITROGLYCERIN	NITROGLYCERIN	[O-][N+](=O)OCC(CO[N+]([O-])=O)O[N+]([O-])=O	PLASMA	G59M7S0WS3									∞	pg × min/mL	12.3		pg/mL	1.7			RECOMMENDED	μg	800		SINGLE	UNKNOWN						HEALTHY	Sublingual	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208424s000lbl.pdf	Homo sapiens		min	40							false
3370	1686		UNKNOWN	3295	258.317	ETHOXZOLAMIDE	ETHOXZOLAMIDE	CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O	SERUM	Z52H4811WX																	UNKNOWN				UNKNOWN	UNKNOWN				Protein binding: ~89 %	11	UNKNOWN	UNKNOWN	UNKNOWN	OTHER	https://go.drugbank.com/drugs/DB00311	Homo sapiens										false
3371	1686		UNKNOWN	3295	258.317	ETHOXZOLAMIDE	ethoxzolamide	CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O	PLASMA	Z52H4811WX																						UNKNOWN				plasma protein binding: 96% (10 mcg/mL ethoxzolamide in human plasma)	4	UNKNOWN	Oral	UNKNOWN	REVIEW	https://journals.physiology.org/doi/abs/10.1152/physrev.1967.47.4.595	Homo sapiens		min	300							false
3372	1689		ADULT	71307	199.638	LAZABEMIDE	Lazabemide	NCCNC(=O)C1=CC=C(Cl)C=N1	PLASMA	420HD787N9							24		t	mg × h/L	4.7		mg/L	0.56			UNKNOWN	mg	150		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9056051/	Homo sapiens							6			false
3373	1689		ADULT	71307	199.638	LAZABEMIDE	Lazabemide	NCCNC(=O)C1=CC=C(Cl)C=N1	PLASMA	420HD787N9							24		t	mg × h/L	8.3		mg/L	0.95			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9056051/	Homo sapiens							6			false
3374	1689		ADULT	71307	199.638	LAZABEMIDE	Lazabemide	NCCNC(=O)C1=CC=C(Cl)C=N1	PLASMA	420HD787N9							24		t	mg × h/L	29.1		mg/L	2.08			UNKNOWN	mg	350		MULTIPLE	FASTED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9056051/	Homo sapiens							6			false
3375	1689		ADULT	71307	199.638	LAZABEMIDE	Lazabemide	NCCNC(=O)C1=CC=C(Cl)C=N1	PLASMA	420HD787N9							24		t	mg × h/L	11.7		mg/L	0.94			UNKNOWN	mg	250		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9056051/	Homo sapiens							6			false
3376	1689		ADULT	71307	199.638	LAZABEMIDE	Lazabemide	NCCNC(=O)C1=CC=C(Cl)C=N1	PLASMA	420HD787N9							24		t	mg × h/L	16.8		mg/L	1.46			UNKNOWN	mg	350		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9056051/	Homo sapiens							6			false
3377	1689		ADULT	71307	199.638	LAZABEMIDE	Lazabemide	NCCNC(=O)C1=CC=C(Cl)C=N1	PLASMA	420HD787N9							24		t	mg × h/L	4		mg/L	0.53			UNKNOWN	mg	100		MULTIPLE	FASTED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9056051/	Homo sapiens				Day 10			6			false
3378	1689		ADULT	71307	199.638	LAZABEMIDE	Lazabemide	NCCNC(=O)C1=CC=C(Cl)C=N1	PLASMA	420HD787N9							24		t	mg × h/L	7.3		mg/L	0.58			UNKNOWN	mg	150		MULTIPLE	FASTED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9056051/	Homo sapiens				Day 10			6			false
3379	1689		ADULT	71307	199.638	LAZABEMIDE	Lazabemide	NCCNC(=O)C1=CC=C(Cl)C=N1	PLASMA	420HD787N9							24		t	mg × h/L	10.9		mg/L	1.07			UNKNOWN	mg	200		MULTIPLE	FASTED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9056051/	Homo sapiens							6			false
3380	1689		ADULT	71307	199.638	LAZABEMIDE	Lazabemide	NCCNC(=O)C1=CC=C(Cl)C=N1	PLASMA	420HD787N9							24		t	mg × h/L	3.3		mg/L	0.44			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9056051/	Homo sapiens							6			false
3381	1689		ADULT	71307	199.638	LAZABEMIDE	Lazabemide	NCCNC(=O)C1=CC=C(Cl)C=N1	PLASMA	420HD787N9							24		t	mg × h/L	18.6		mg/L	1.39			UNKNOWN	mg	250		MULTIPLE	FASTED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9056051/	Homo sapiens							6			false
3382	1692			656629	408.535	OMAPATRILAT	Omapatrilat	OC(=O)[C@@H]1CCC[C@@H]2SCC[C@H](NC(=O)[C@@H](S)CC3=CC=CC=C3)C(=O)N12	PLASMA	36NLI90E7T																										Human plasma protein binding: 80%	20				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10968433/	Homo sapiens										false
3383	1692		ADULT	656629	408.535	OMAPATRILAT	Omapatrilat	OC(=O)[C@@H]1CCC[C@@H]2SCC[C@H](NC(=O)[C@@H](S)CC3=CC=CC=C3)C(=O)N12	PLASMA	36NLI90E7T									?	ng × h/mL	16.5		ng/mL	11.3			UNKNOWN	mg	10		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11014407/	Homo sapiens				First dose	mild to moderate renal impairment (30=< CLcr <80 mL/min/1.73m2)		8			false
3384	1692		ADULT	656629	408.535	OMAPATRILAT	Omapatrilat	OC(=O)[C@@H]1CCC[C@@H]2SCC[C@H](NC(=O)[C@@H](S)CC3=CC=CC=C3)C(=O)N12	PLASMA	36NLI90E7T									?	ng × h/mL	7.9		ng/mL	5.8			UNKNOWN	mg	10		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11014407/	Homo sapiens				First dose	renal impairment (hemodialysis)		6			false
3385	1692		ADULT	656629	408.535	OMAPATRILAT	Omapatrilat	OC(=O)[C@@H]1CCC[C@@H]2SCC[C@H](NC(=O)[C@@H](S)CC3=CC=CC=C3)C(=O)N12	PLASMA	36NLI90E7T									?	ng × h/mL	11.3		ng/mL	9			UNKNOWN	mg	10		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11014407/	Homo sapiens				First dose	normal renal function (CLcr >=80 mL/min/1.73m2)		8			false
3386	1692		ADULT	656629	408.535	OMAPATRILAT	Omapatrilat	OC(=O)[C@@H]1CCC[C@@H]2SCC[C@H](NC(=O)[C@@H](S)CC3=CC=CC=C3)C(=O)N12	PLASMA	36NLI90E7T									?	ng × h/mL	29.5		ng/mL	16.4			UNKNOWN	mg	10		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11014407/	Homo sapiens				First dose	severe renal impairment (CLcr <30 mL/min/1.73m2)		8			false
3387	1692		ADULT	656629	408.535	OMAPATRILAT	Omapatrilat	OC(=O)[C@@H]1CCC[C@@H]2SCC[C@H](NC(=O)[C@@H](S)CC3=CC=CC=C3)C(=O)N12	PLASMA	36NLI90E7T									?	ng × h/mL	19.5		ng/mL	13.5			UNKNOWN	mg	10		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11014407/	Homo sapiens				Last dose	normal renal function (CLcr >=80 mL/min/1.73m2)		8			false
3388	1692		ADULT	656629	408.535	OMAPATRILAT	Omapatrilat	OC(=O)[C@@H]1CCC[C@@H]2SCC[C@H](NC(=O)[C@@H](S)CC3=CC=CC=C3)C(=O)N12	PLASMA	36NLI90E7T									?	ng × h/mL	25.3		ng/mL	14.9			UNKNOWN	mg	10		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11014407/	Homo sapiens				Last dose	mild to moderate renal impairment (30=< CLcr <80 mL/min/1.73m2)		8			false
3389	1692		ADULT	656629	408.535	OMAPATRILAT	Omapatrilat	OC(=O)[C@@H]1CCC[C@@H]2SCC[C@H](NC(=O)[C@@H](S)CC3=CC=CC=C3)C(=O)N12	PLASMA	36NLI90E7T									?	ng × h/mL	25.7		ng/mL	9.9			UNKNOWN	mg	10		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11014407/	Homo sapiens				Last dose	severe renal impairment (CLcr <30 mL/min/1.73m2)		8			false
3390	1692		ADULT	656629	408.535	OMAPATRILAT	Omapatrilat	OC(=O)[C@@H]1CCC[C@@H]2SCC[C@H](NC(=O)[C@@H](S)CC3=CC=CC=C3)C(=O)N12	PLASMA	36NLI90E7T									?	ng × h/mL	17.5		ng/mL	11.9			UNKNOWN	mg	10		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11014407/	Homo sapiens				Last dose	renal impairment (hemodialysis)		6			false
3391	1692		ADULT	656629	408.535	OMAPATRILAT	Omapatrilat	OC(=O)[C@@H]1CCC[C@@H]2SCC[C@H](NC(=O)[C@@H](S)CC3=CC=CC=C3)C(=O)N12	PLASMA	36NLI90E7T									?	ng × h/mL	1890.76		ng/mL	1008.92			UNKNOWN	mg	500		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12968984/	Homo sapiens							6			false
3392	1692		ADULT	656629	408.535	OMAPATRILAT	Omapatrilat	OC(=O)[C@@H]1CCC[C@@H]2SCC[C@H](NC(=O)[C@@H](S)CC3=CC=CC=C3)C(=O)N12	PLASMA	36NLI90E7T									?	ng × h/mL	19.5		ng/mL	9.6			UNKNOWN	mg	10		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12968984/	Homo sapiens				Day 1 (fasted)			6			false
3393	1692		ADULT	656629	408.535	OMAPATRILAT	Omapatrilat	OC(=O)[C@@H]1CCC[C@@H]2SCC[C@H](NC(=O)[C@@H](S)CC3=CC=CC=C3)C(=O)N12	PLASMA	36NLI90E7T									?	ng × h/mL	63.8		ng/mL	26.4			UNKNOWN	mg	25		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12968984/	Homo sapiens				Day 1 (fasted)			6			false
3394	1692		ADULT	656629	408.535	OMAPATRILAT	Omapatrilat	OC(=O)[C@@H]1CCC[C@@H]2SCC[C@H](NC(=O)[C@@H](S)CC3=CC=CC=C3)C(=O)N12	PLASMA	36NLI90E7T									?	ng × h/mL	147.9		ng/mL	93.5			UNKNOWN	mg	50		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12968984/	Homo sapiens				Day 1 (fasted)			6			false
3395	1692		ADULT	656629	408.535	OMAPATRILAT	Omapatrilat	OC(=O)[C@@H]1CCC[C@@H]2SCC[C@H](NC(=O)[C@@H](S)CC3=CC=CC=C3)C(=O)N12	PLASMA	36NLI90E7T									?	ng × h/mL	341.6		ng/mL	181.7			UNKNOWN	mg	75		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12968984/	Homo sapiens				Day 1 (fasted)			6			false
3396	1692		ADULT	656629	408.535	OMAPATRILAT	Omapatrilat	OC(=O)[C@@H]1CCC[C@@H]2SCC[C@H](NC(=O)[C@@H](S)CC3=CC=CC=C3)C(=O)N12	PLASMA	36NLI90E7T									?	ng × h/mL	369.4		ng/mL	203.3			UNKNOWN	mg	125		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12968984/	Homo sapiens				Day 1 (fasted)			6			false
3397	1692		ADULT	656629	408.535	OMAPATRILAT	Omapatrilat	OC(=O)[C@@H]1CCC[C@@H]2SCC[C@H](NC(=O)[C@@H](S)CC3=CC=CC=C3)C(=O)N12	PLASMA	36NLI90E7T									?	ng × h/mL	92.4		ng/mL	80.7			UNKNOWN	mg	25		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12968984/	Homo sapiens		h	17.4	Day 10 (fasted)			6			false
3398	1692		ADULT	656629	408.535	OMAPATRILAT	Omapatrilat	OC(=O)[C@@H]1CCC[C@@H]2SCC[C@H](NC(=O)[C@@H](S)CC3=CC=CC=C3)C(=O)N12	PLASMA	36NLI90E7T									?	ng × h/mL	420.9		ng/mL	297.1			UNKNOWN	mg	75		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12968984/	Homo sapiens		h	14.3	Day 10 (fasted)			6			false
3399	1692		ADULT	656629	408.535	OMAPATRILAT	Omapatrilat	OC(=O)[C@@H]1CCC[C@@H]2SCC[C@H](NC(=O)[C@@H](S)CC3=CC=CC=C3)C(=O)N12	PLASMA	36NLI90E7T									?	ng × h/mL	30.1		ng/mL	14.4			UNKNOWN	mg	10		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12968984/	Homo sapiens		h	19.3	Day 10 (fasted)			6			false
3400	1692		ADULT	656629	408.535	OMAPATRILAT	Omapatrilat	OC(=O)[C@@H]1CCC[C@@H]2SCC[C@H](NC(=O)[C@@H](S)CC3=CC=CC=C3)C(=O)N12	PLASMA	36NLI90E7T									?	ng × h/mL	226.9		ng/mL	175.9			UNKNOWN	mg	50		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12968984/	Homo sapiens		h	17.1	Day 10 (fasted)			6			false
3401	1692		ADULT	656629	408.535	OMAPATRILAT	Omapatrilat	OC(=O)[C@@H]1CCC[C@@H]2SCC[C@H](NC(=O)[C@@H](S)CC3=CC=CC=C3)C(=O)N12	PLASMA	36NLI90E7T									?	ng × h/mL	745.2		ng/mL	895.3			UNKNOWN	mg	125		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12968984/	Homo sapiens				Day 10 (fasted)			2			false
3402	1692		ADULT	656629	408.535	OMAPATRILAT	Omapatrilat	OC(=O)[C@@H]1CCC[C@@H]2SCC[C@H](NC(=O)[C@@H](S)CC3=CC=CC=C3)C(=O)N12	PLASMA	36NLI90E7T									?	ng × h/mL	0.43		ng/mL	1.28			UNKNOWN	mg	2.5		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12968984/	Homo sapiens							6			false
3403	1692		ADULT	656629	408.535	OMAPATRILAT	Omapatrilat	OC(=O)[C@@H]1CCC[C@@H]2SCC[C@H](NC(=O)[C@@H](S)CC3=CC=CC=C3)C(=O)N12	PLASMA	36NLI90E7T									?	ng × h/mL	12.52		ng/mL	9.6			UNKNOWN	mg	7.5		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12968984/	Homo sapiens							6			false
3404	1692		ADULT	656629	408.535	OMAPATRILAT	Omapatrilat	OC(=O)[C@@H]1CCC[C@@H]2SCC[C@H](NC(=O)[C@@H](S)CC3=CC=CC=C3)C(=O)N12	PLASMA	36NLI90E7T									?	ng × h/mL	69.19		ng/mL	51.09			UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12968984/	Homo sapiens							6			false
3405	1692		ADULT	656629	408.535	OMAPATRILAT	Omapatrilat	OC(=O)[C@@H]1CCC[C@@H]2SCC[C@H](NC(=O)[C@@H](S)CC3=CC=CC=C3)C(=O)N12	PLASMA	36NLI90E7T									?	ng × h/mL	149.6		ng/mL	89.29			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12968984/	Homo sapiens							6			false
3406	1692		ADULT	656629	408.535	OMAPATRILAT	Omapatrilat	OC(=O)[C@@H]1CCC[C@@H]2SCC[C@H](NC(=O)[C@@H](S)CC3=CC=CC=C3)C(=O)N12	PLASMA	36NLI90E7T									?	ng × h/mL	406.52		ng/mL	286.35			UNKNOWN	mg	125		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12968984/	Homo sapiens							6			false
3407	1692		ADULT	656629	408.535	OMAPATRILAT	Omapatrilat	OC(=O)[C@@H]1CCC[C@@H]2SCC[C@H](NC(=O)[C@@H](S)CC3=CC=CC=C3)C(=O)N12	PLASMA	36NLI90E7T									?	ng × h/mL	741.39		ng/mL	491.61			UNKNOWN	mg	250		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12968984/	Homo sapiens							6			false
3408	1694		ADULT	159324	489.396	TIPIFARNIB	TIPIFARNIB	CN1C=NC=C1[C@@](N)(C2=CC=C(Cl)C=C2)C3=CC4=C(C=C3)N(C)C(=O)C=C4C5=CC(Cl)=CC=C5	PLASMA	MAT637500A									∞	μg × h/mL	3.8		ng/mL	634			MAX TOLERATED	mg	300		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/16170172	Homo sapiens		h	3.66							false
3409	1694		UNKNOWN	159324	489.396	TIPIFARNIB	TIPIFARNIB	CN1C=NC=C1[C@@](N)(C2=CC=C(Cl)C=C2)C3=CC4=C(C=C3)N(C)C(=O)C=C4C5=CC(Cl)=CC=C5	PLASMA	MAT637500A																						UNKNOWN				Although preclinical data indicate that the plasma protein binding of tipifarnib is 99.3%, in vivo pharmacokinetic data suggest that these concentrations inhibit FT activity and result in antitumor effects.	0.7	UNKNOWN		UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/17268526	Homo sapiens										false
3410	1700		ADULT	60606	321.822	CLOPIDOGREL	CLOPIDOGREL	COC(=O)[C@@H](N1CCC2=C(C1)C=CS2)C3=C(Cl)C=CC=C3	PLASMA	A74586SNO7									∞	ng × h/mL	125.5		ng/mL	38			UNKNOWN	mg	600		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/15269827	Homo sapiens		h	1							false
3411	1707		ADULT	2247	458.5703	ASTEMIZOLE	ASTEMIZOLE	COC1=CC=C(CCN2CCC(CC2)NC3=NC4=C(C=CC=C4)N3CC5=CC=C(F)C=C5)C=C1	BLOOD	7HU6337315									∞	mg × h/L	28.4		mg/L	1.9			UNKNOWN	mg	30		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10423595	Homo sapiens		h	25							false
3412	1707		ADULT	155805	444.5438	DESMETHYLASTEMIZOLE	Desmethylastemizole	OC1=CC=C(CCN2CCC(CC2)NC3=NC4=C(C=CC=C4)N3CC5=CC=C(F)C=C5)C=C1	BLOOD	L460QHM1YN									∞	mg × h/L	260		mg/L	2.1			UNKNOWN	mg	30		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10423595	Homo sapiens		h	223							false
3413	1711		UNKNOWN	3000518	284.3481	ARTENIMOL	Dihydroartemisinin	C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4	PLASMA	6A9O50735X										μg × h/mL	3.5		μg/mL	3.1			RECOMMENDED	mg/kg	2.4		MULTIPLE	UNKNOWN				Protein Binding Approximately 93%	7	UNHEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213036s000lbl.pdf	Homo sapiens		h	1.3							false
3414	1711		UNKNOWN	6917864	384.4208	ARTESUNATE	Artesunate	C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4	PLASMA	60W3249T9M										μg × h/mL	0.7		μg/mL	3.3			RECOMMENDED	mg/kg	2.4		MULTIPLE	UNKNOWN				Protein Binding Approximately 93%	7	UNHEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213036s000lbl.pdf	Homo sapiens		h	0.3							false
3415	1716			16666	156.2652	LEVOMENTHOL	Levomenthol	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	PLASMA	BZ1R15MTK7																										Human plasma protein binding (ultracentrifugation): 84.4% (0.1μg/mL), 84.7% (1μg/mL), 81.5% (10μg/mL)	15.3				OTHER GOV'T	https://www.pmda.go.jp/drugs/2010/P201000059/530277000_22200AMX00965_A100_1.pdf#page=13 | https://www.pmda.go.jp/drugs/2010/P201000059/530277000_22200AMX00965_I100_1.pdf#page=20	Homo sapiens										false
3416	1716		ADULT	71749954	332.3902	Menthol glucuronide		CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O[C@@H]2O[C@@H]([C@@H](O)[C@H](O)[C@H]2O)C(=O)O	PLASMA										∞	ng × h/mL	32115.5		ng/mL	17601.81			UNKNOWN	mg	320		SINGLE	UNKNOWN						HEALTHY	Intragastric	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2010/P201000059/530277000_22200AMX00965_A100_1.pdf#page=20 | https://www.pmda.go.jp/drugs/2010/P201000059/530277000_22200AMX00965_K101_1.pdf#page=20 | https://pubmed.ncbi.nlm.nih.gov/21544078/	Homo sapiens		h	5.8693				6			false
3417	1716		ADULT	16666	156.2652	LEVOMENTHOL	Levomenthol	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	PLASMA	BZ1R15MTK7									∞	ng × h/mL	52.64		ng/mL	31.6			DEFINED DAILY	mg	160		SINGLE	UNKNOWN						HEALTHY	Intragastric	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2010/P201000059/530277000_22200AMX00965_A100_1.pdf#page=20 | https://www.pmda.go.jp/drugs/2010/P201000059/530277000_22200AMX00965_K101_1.pdf#page=20 | https://pubmed.ncbi.nlm.nih.gov/21544078/	Homo sapiens		h	1.7739				6			false
3418	1716		ADULT	71749954	332.3902	Menthol glucuronide		CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O[C@@H]2O[C@@H]([C@@H](O)[C@H](O)[C@H]2O)C(=O)O	PLASMA										∞	ng × h/mL	15639.85		ng/mL	9882.69			DEFINED DAILY	mg	160		SINGLE	UNKNOWN						HEALTHY	Intragastric	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2010/P201000059/530277000_22200AMX00965_A100_1.pdf#page=20 | https://www.pmda.go.jp/drugs/2010/P201000059/530277000_22200AMX00965_K101_1.pdf#page=20 | https://pubmed.ncbi.nlm.nih.gov/21544078/	Homo sapiens		h	5.5689				6			false
3419	1716		ADULT	16666	156.2652	LEVOMENTHOL	Levomenthol	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	PLASMA	BZ1R15MTK7									∞	ng × h/mL	45.46		ng/mL	32.89			UNKNOWN	mg	80		SINGLE	UNKNOWN						HEALTHY	Intragastric	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2010/P201000059/530277000_22200AMX00965_A100_1.pdf#page=20 | https://www.pmda.go.jp/drugs/2010/P201000059/530277000_22200AMX00965_K101_1.pdf#page=20 | https://pubmed.ncbi.nlm.nih.gov/21544078/	Homo sapiens		h	1.0306				6			false
3420	1716		ADULT	71749954	332.3902	Menthol glucuronide		CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O[C@@H]2O[C@@H]([C@@H](O)[C@H](O)[C@H]2O)C(=O)O	PLASMA										∞	ng × h/mL	9676.67		ng/mL	5617.46			UNKNOWN	mg	80		SINGLE	UNKNOWN						HEALTHY	Intragastric	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2010/P201000059/530277000_22200AMX00965_A100_1.pdf#page=20 | https://www.pmda.go.jp/drugs/2010/P201000059/530277000_22200AMX00965_K101_1.pdf#page=20 | https://pubmed.ncbi.nlm.nih.gov/21544078/	Homo sapiens		h	7.8072				6			false
3421	1716		ADULT	16666	156.2652	LEVOMENTHOL	Levomenthol	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	PLASMA	BZ1R15MTK7									∞	ng × h/mL	109.34		ng/mL	48			UNKNOWN	mg	320		SINGLE	UNKNOWN						HEALTHY	Intragastric	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2010/P201000059/530277000_22200AMX00965_A100_1.pdf#page=20 | https://www.pmda.go.jp/drugs/2010/P201000059/530277000_22200AMX00965_K101_1.pdf#page=20 | https://pubmed.ncbi.nlm.nih.gov/21544078/	Homo sapiens		h	1.222				6			false
3422	1717		ADULT	8271	246.2619	MEPHOBARBITAL	MEPHOBARBITAL	CCC1(C(=O)NC(=O)N(C)C1=O)C2=CC=CC=C2	PLASMA	5NC67NU76B																	UNKNOWN	mg	400		SINGLE	UNKNOWN				The R-enantiomer of mephobarbital was bound to plasma proteins in a higher extent (67%) than the S-enantiomer (59%).	32.6	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2083148	Homo sapiens										false
3423	1717		ADULT	8271	246.2619	MEPHOBARBITAL	MEPHOBARBITAL	CCC1(C(=O)NC(=O)N(C)C1=O)C2=CC=CC=C2	PLASMA	5NC67NU76B									∞	μg × h/mL	7.95		μg/mL	0.73			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2249375	Homo sapiens		h	6.94							false
3424	1717		ADULT	8271	246.2619	MEPHOBARBITAL	MEPHOBARBITAL	CCC1(C(=O)NC(=O)N(C)C1=O)C2=CC=CC=C2	PLASMA	5NC67NU76B									∞	μg × h/mL	1.29		μg/mL	0.24			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2249375	Homo sapiens		h	3.05							false
3425	1720		ADULT	5161	258.2262	SALSALATE	Salsalate	OC(=O)C1=C(OC(=O)C2=C(O)C=CC=C2)C=CC=C1	PLASMA	V9MO595C9I									?	μg × h/mL	101		μg/mL	45			UNKNOWN	mg	1500		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3956057/	Homo sapiens		h	1.2		Normal renal function		24			false
3426	1720		ADULT	338|118212070	138.1207	SALICYLIC ACID	Salicylic acid	OC(=O)C1=C(O)C=CC=C1	PLASMA	O414PZ4LPZ									?	μg × h/mL	847		μg/mL	88			UNKNOWN	mg	1500		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3956057/	Homo sapiens		h	3.8				24			false
3427	1720		ADULT	5161	258.2262	SALSALATE	Salsalate	OC(=O)C1=C(OC(=O)C2=C(O)C=CC=C2)C=CC=C1	PLASMA	V9MO595C9I									?	μg × h/mL	50		μg/mL	17			UNKNOWN	mg	1500		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3956057/	Homo sapiens		h	2.1		Patients with renal failure undergoing hemodialysis		5			false
3428	1720		ADULT	338|118212070	138.1207	SALICYLIC ACID	Salicylic acid	OC(=O)C1=C(O)C=CC=C1	PLASMA	O414PZ4LPZ									?	μg × h/mL	1301		μg/mL	97			UNKNOWN	mg	1500		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3956057/	Homo sapiens		h	8.1		Patients with renal failure undergoing hemodialysis		5			false
3429	1720		ADULT	5161	258.2262	SALSALATE	Salsalate	OC(=O)C1=C(OC(=O)C2=C(O)C=CC=C2)C=CC=C1	PLASMA	V9MO595C9I									?	μg × h/mL	50		μg/mL	21.1			UNKNOWN	mg	1000		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7309902/	Homo sapiens		h	1.1				12			false
3430	1720		ADULT	338|118212070	138.1207	SALICYLIC ACID	salicylic acid	OC(=O)C1=C(O)C=CC=C1	PLASMA	O414PZ4LPZ									?	μg × h/mL	498		μg/mL	54.4			UNKNOWN	mg	1000		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7309902/	Homo sapiens		h	3.5				12			false
3431	1720			338|118212070	138.1207	SALICYLIC ACID	Salicylic acid	OC(=O)C1=C(O)C=CC=C1	SERUM	O414PZ4LPZ																										Human albumin binding: 90~95% (<=100μg/mL)	5				OTHER	https://www.pdr.net/drug-summary/Salsalate-salsalate-1649#16	Homo sapiens										false
3432	1722		ADULT	6305|6923516	204.2252	TRYPTOPHAN	TRYPTOPHAN	N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O	PLASMA	8DUH1N11BX							10		t	μM × h	2538		μM	717			UNKNOWN	mg/kg	100		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6210561/	Homo sapiens		h	2							false
3433	1726		ADULT	5735	388.808	ZOPICLONE	Zopiclone	CN1CCN(CC1)C(=O)OC2N(C(=O)C3=C2N=CC=N3)C4=CC=C(Cl)C=N4	PLASMA	03A5ORL08Q									?	ng × h/mL	865.1		ng/mL	131.3			UNKNOWN	mg	15		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7905394/	Homo sapiens		min	334.7				12			false
3434	1726		ADULT	5735	388.808	ZOPICLONE	Zopiclone	CN1CCN(CC1)C(=O)OC2N(C(=O)C3=C2N=CC=N3)C4=CC=C(Cl)C=N4	PLASMA	03A5ORL08Q													ng/mL	67.76			RECOMMENDED	mg	7.5		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/780069_1129007F1026_1_011_1F.pdf#page=18	Homo sapiens		h	3.66				6			false
3435	1726		ADULT	5735	388.808	ZOPICLONE	Zopiclone	CN1CCN(CC1)C(=O)OC2N(C(=O)C3=C2N=CC=N3)C4=CC=C(Cl)C=N4	PLASMA	03A5ORL08Q													ng/mL	80.87			MAX DAILY	mg	10		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/780069_1129007F1026_1_011_1F.pdf#page=18	Homo sapiens		h	3.94				6			false
3436	1726		ADULT	5735	388.808	ZOPICLONE	Zopiclone	CN1CCN(CC1)C(=O)OC2N(C(=O)C3=C2N=CC=N3)C4=CC=C(Cl)C=N4	PLASMA	03A5ORL08Q													ng/mL	69.78			RECOMMENDED	mg	7.5		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/780069_1129007F1026_1_011_1F.pdf#page=18	Homo sapiens		h	3.88		Elderly subjects (>=60 y)		5			false
3437	1726			5735	388.808	ZOPICLONE	Zopiclone	CN1CCN(CC1)C(=O)OC2N(C(=O)C3=C2N=CC=N3)C4=CC=C(Cl)C=N4	PLASMA	03A5ORL08Q																										Human plasma protein binding: 43.5, 46.0%; Human albumin binding: 69.0% (healthy adult), 68.4% (elderly subjects)	54				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/780069_1129007F1026_1_011_1F.pdf#page=19	Homo sapiens										false
3438	1727		ADULT	2164	226.2722	AMOBARBITAL	Amobarbital	CCC1(CCC(C)C)C(=O)NC(=O)NC1=O	SERUM	GWH6IJ239E									?	μg × h/mL	56.07						UNKNOWN	mg	120		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/975717/	Homo sapiens							4	Amobarbital sodium		false
3439	1727			2164	226.2722	AMOBARBITAL	Amobarbital	CCC1(CCC(C)C)C(=O)NC(=O)NC1=O	SERUM	GWH6IJ239E									?	μg × h/mL	56.2						UNKNOWN	mg	120		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/975717/	Homo sapiens							4	Amobarbital sodium		false
3440	1727		ADULT	2164	226.2722	AMOBARBITAL	Amobarbital	CCC1(CCC(C)C)C(=O)NC(=O)NC1=O	SERUM	GWH6IJ239E																	UNKNOWN	mg	120		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/975717/	Homo sapiens		h	23.8				36	Amobarbital sodium		false
3441	1727			2164	226.2722	AMOBARBITAL	Amobarbital	CCC1(CCC(C)C)C(=O)NC(=O)NC1=O	PLASMA	GWH6IJ239E																										Protein binding of amobarbital in plasma is in the vicinity of 55% to 60%, as established in vitro with the help of dialysis and ultracentrifugation.	40				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/975717/	Homo sapiens										false
3442	1728		ADULT	2441	316.153	BROMAZEPAM	Bromazepam	BrC1=CC=C2NC(=O)CN=C(C3=NC=CC=C3)C2=C1	PLASMA	X015L14V0O									∞	ng × h/mL	1328		ng/mL	43.1			RECOMMENDED	mg	3		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/14517708/	Homo sapiens		h	32.1				8			false
3443	1728		ADULT	2441	316.153	BROMAZEPAM	Bromazepam	BrC1=CC=C2NC(=O)CN=C(C3=NC=CC=C3)C2=C1	SERUM	X015L14V0O													ng/mL	72			RECOMMENDED	mg	6		SINGLE	FASTED					29.4	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2882883/	Homo sapiens		h	28.5		Young female subjects (23.9 y)		7			false
3444	1728		ADULT	2441	316.153	BROMAZEPAM	Bromazepam	BrC1=CC=C2NC(=O)CN=C(C3=NC=CC=C3)C2=C1	SERUM	X015L14V0O													ng/mL	126			RECOMMENDED	mg	6		SINGLE	FASTED					34.2	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2882883/	Homo sapiens		h	32.2		Elderly male subjects (70.0 y)		8			false
3445	1728		ADULT	2441	316.153	BROMAZEPAM	Bromazepam	BrC1=CC=C2NC(=O)CN=C(C3=NC=CC=C3)C2=C1	SERUM	X015L14V0O													ng/mL	139			RECOMMENDED	mg	6		SINGLE	FASTED					35.5	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2882883/	Homo sapiens		h	28.2		Elderly female subjects (66.1 y)		7			false
3446	1728		ADULT	2441	316.153	BROMAZEPAM	Bromazepam	BrC1=CC=C2NC(=O)CN=C(C3=NC=CC=C3)C2=C1	PLASMA	X015L14V0O							10		t	ng × h/mL	1844		ng/mL	259			RECOMMENDED	mg	10		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/112268_1124020C1045_2_16A_1F.pdf#page=18 | https://pubmed.ncbi.nlm.nih.gov/2273442/	Homo sapiens							7			false
3447	1728		ADULT	2441	316.153	BROMAZEPAM	Bromazepam	BrC1=CC=C2NC(=O)CN=C(C3=NC=CC=C3)C2=C1	PLASMA	X015L14V0O							10		t	ng × h/mL	1233		ng/mL	169			RECOMMENDED	mg	10		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/112268_1124020C1045_2_16A_1F.pdf#page=18 | https://pubmed.ncbi.nlm.nih.gov/2273442/	Homo sapiens							7			false
3448	1728		ADULT	2441	316.153	BROMAZEPAM	Bromazepam	BrC1=CC=C2NC(=O)CN=C(C3=NC=CC=C3)C2=C1	SERUM	X015L14V0O													ng/mL	88			RECOMMENDED	mg	6		SINGLE	FASTED					28.4	HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/112268_1124020C1045_2_16A_1F.pdf#page=18 | https://pubmed.ncbi.nlm.nih.gov/2882883/	Homo sapiens		h	20.4		Young male subjects (24.3 y)		10			false
3449	1728		ADULT	2441	316.153	BROMAZEPAM	Bromazepam	BrC1=CC=C2NC(=O)CN=C(C3=NC=CC=C3)C2=C1	PLASMA	X015L14V0O									∞	μg × h/mL	2.99		μg/mL	0.131			RECOMMENDED	mg	12		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/112268_1124020C1045_2_16A_1F.pdf#page=18 | https://pubmed.ncbi.nlm.nih.gov/5586/	Homo sapiens							10			false
3450	1728			2441	316.153	BROMAZEPAM	Bromazepam	BrC1=CC=C2NC(=O)CN=C(C3=NC=CC=C3)C2=C1	PLASMA	X015L14V0O																										Human plasma protein binding: 70.1%	29.9				EXPERIMENT	https://www.info.pmda.go.jp/go/interview/2/112268_1124020C1045_2_16A_1F.pdf#page=19	Homo sapiens										false
3451	1729		ADULT	5280961	270.2369	GENISTEIN	Genistein	OC1=CC=C(C=C1)C2=COC3=C(C(O)=CC(O)=C3)C2=O	PLASMA	DH2M523P0H									?	μg × h/mL	4.54		ng/mL	341			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11285356/	Homo sapiens		h	6.78		Premenopausal women		6			false
3452	1729		ADULT	5280961	270.2369	GENISTEIN	Genistein	OC1=CC=C(C=C1)C2=COC3=C(C(O)=CC(O)=C3)C2=O	SERUM	DH2M523P0H									∞	μM × h	6.33		μM	0.48			UNKNOWN	mg/kg bw	0.4		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12540402/	Homo sapiens		h	7.68		Premenopausal women		8			false
3453	1729		ADULT	5280961	270.2369	GENISTEIN	Genistein	OC1=CC=C(C=C1)C2=COC3=C(C(O)=CC(O)=C3)C2=O	SERUM	DH2M523P0H									∞	μM × h	5.35		μM	0.43			UNKNOWN	mg/kg bw	0.4		SINGLE	FED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12540402/	Homo sapiens		h	8.31		Premenopausal women consumed soy milk (500mL, 50mg natural isoflavones) daily for 7 days prior to the genistein administration		8			false
3454	1729		ADULT	5280961	270.2369	GENISTEIN	Genistein	OC1=CC=C(C=C1)C2=COC3=C(C(O)=CC(O)=C3)C2=O	SERUM	DH2M523P0H									∞	μM × h	9.77		μM	0.87			UNKNOWN	mg/kg bw	0.8		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12540402/	Homo sapiens		h	7.41		Premenopausal women		8			false
3455	1729		ADULT	5280961	270.2369	GENISTEIN	Genistein	OC1=CC=C(C=C1)C2=COC3=C(C(O)=CC(O)=C3)C2=O	PLASMA	DH2M523P0H									∞	ng × h/mL	2637.1		ng/mL	241.2			UNKNOWN	mg	30		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15943224/	Homo sapiens		h	7.6				10			false
3456	1729		ADULT	5280961	270.2369	GENISTEIN	Genistein	OC1=CC=C(C=C1)C2=COC3=C(C(O)=CC(O)=C3)C2=O	PLASMA	DH2M523P0H									∞	mg × h/mL	6562.2		ng/mL	550.4			UNKNOWN	mg	60		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15943224/	Homo sapiens		h	7.5				10			false
3457	1729		ADULT	5280961	270.2369	GENISTEIN	Genistein	OC1=CC=C(C=C1)C2=COC3=C(C(O)=CC(O)=C3)C2=O	PLASMA	DH2M523P0H									∞	ng × h/mL	19782.7		ng/mL	1484.1			UNKNOWN	mg	150		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15943224/	Homo sapiens		h	8				10			false
3458	1729		ADULT	5280961	270.2369	GENISTEIN	Genistein	OC1=CC=C(C=C1)C2=COC3=C(C(O)=CC(O)=C3)C2=O	PLASMA	DH2M523P0H									∞	ng × h/mL	26132.2		ng/mL	1773.1			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15943224/	Homo sapiens		h	9.5				10			false
3459	1730			32893	135.2062	LEVAMFETAMINE	LEVAMFETAMINE	C[C@@H](N)CC1=CC=CC=C1	PLASMA	R87US8P740																										d- and l-amphetamine isomers are estimated to be 16% to 20% bound to plasma proteins	82				OTHER	https://pubmed.ncbi.nlm.nih.gov/28910145/	Homo sapiens										false
3460	1730		ADULT	32893	135.2062	LEVAMFETAMINE	R87US8P740	C[C@@H](N)CC1=CC=CC=C1	PLASMA	R87US8P740	5826		DEXTROAMPHETAMINE	TZ47U051FI	C[C@H](N)CC1=CC=CC=C1	TZ47U051FI			∞	ng × h/mL	370.9		ng/mL	16.4			DEFINED DAILY	mg	7.5		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29174216/	Homo sapiens		h	14.47							true
3461	1730		ADULT	32893	135.2062	LEVAMFETAMINE	R87US8P740	C[C@@H](N)CC1=CC=CC=C1	PLASMA	R87US8P740	5826		DEXTROAMPHETAMINE	TZ47U051FI	C[C@H](N)CC1=CC=CC=C1	TZ47U051FI			∞	ng × h/mL	357.4		ng/mL	14.6			DEFINED DAILY	mg	7.5		SINGLE	HIGH-FAT						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29174216/	Homo sapiens		h	14.84							true
3462	1732		ADULT	1051	247.142	PYRIDOXAL PHOSPHATE		Cc1ncc(COP(=O)(O)O)c(C=O)c1O	SERUM	5V5IOJ8338	3002119	398.549	FURSULTIAMINE		C\\C(=C(\\CCO)/SSCC1CCCO1)\\N(Cc2cnc(C)nc2N)C=O	05J61265PX	24		t	ng × h/mL	653.7		ng/mL	220.7			UNKNOWN	mg	30		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/780075_3179107F1041_1_031_1F.pdf#page=20	Homo sapiens		h	17.2				12	Pyridoxal phosphate monohydrate		true
3463	1734		ADULT	190	135.1267	ADENINE	Adenine	NC1=NC=NC2=C1N=CN2	PLASMA	JAC85A2161													μM	6.8			UNKNOWN	μmol/kg	27		SINGLE	UNKNOWN				Cmax value was directly read from the figure.		HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/3/180095_4191001F1037_3_001_1F.pdf	Homo sapiens							1			false
3464	1738		ADULT	446220	303.3529	COCAINE	COCAINE	COC(=O)[C@@H]1[C@H]2CC[C@@H](C[C@@H]1OC(=O)C3=CC=CC=C3)N2C	PLASMA	I5Y540LHVR							6		t	ng × h/mL	840		ng/mL	550			UNKNOWN	mg	100		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7242115/	Homo sapiens		min	78.9							false
3465	1740		ADULT	5311071	398.6642	DIHYDROTACHYSTEROL	DIHYDROTACHYSTEROL	CC(C)[C@@H](C)\\C=C\\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\\C2=C/C=C3\\C[C@@H](O)CC[C@@H]3C	SERUM	R5LM3H112R									∞	ng × h/mL	111.5		ng/mL	6.3			RECOMMENDED	mg	1		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7988630/	Homo sapiens		h	7.7							false
3466	1740		ADULT	5311071	398.6642	DIHYDROTACHYSTEROL	DIHYDROTACHYSTEROL	CC(C)[C@@H](C)\\C=C\\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\\C2=C/C=C3\\C[C@@H](O)CC[C@@H]3C	SERUM	R5LM3H112R									∞	ng × h/mL	195.5		ng/mL	21.8			RECOMMENDED	mg	1		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7988630/	Homo sapiens		h	6.6							false
3467	1740		ADULT	5311071	398.6642	DIHYDROTACHYSTEROL	DIHYDROTACHYSTEROL	CC(C)[C@@H](C)\\C=C\\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\\C2=C/C=C3\\C[C@@H](O)CC[C@@H]3C	SERUM	R5LM3H112R									∞	ng × h/mL	223		ng/mL	21.3			RECOMMENDED	mg	1		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7988630/	Homo sapiens		h	7.9							false
3468	1740		ADULT	5311071	398.6642	DIHYDROTACHYSTEROL	DIHYDROTACHYSTEROL	CC(C)[C@@H](C)\\C=C\\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\\C2=C/C=C3\\C[C@@H](O)CC[C@@H]3C	SERUM	R5LM3H112R									∞	ng × h/mL	212.5		ng/mL	22.3			RECOMMENDED	mg	1		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7988630/	Homo sapiens		h	8.2							false
3469	1741		ADULT	5281855	302.1926	ELLAGIC ACID	ELLAGIC ACID	OC1=CC2=C3C(OC(=O)C4=CC(O)=C(O)C(OC2=O)=C34)=C1O	PLASMA	19YRN3ZS9P									∞	ng × h/mL	17.61		ng/mL	3.25			UNKNOWN	mg	13.5		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16172180	Homo sapiens		h	8.57							false
3470	1741		ADULT	5281855	302.1926	ELLAGIC ACID	ELLAGIC ACID	OC1=CC2=C3C(OC(=O)C4=CC(O)=C(O)C(OC2=O)=C34)=C1O	SERUM	19YRN3ZS9P									?	ng × h/mL	1041.8		ng/mL	200.2			UNKNOWN	mg	40		SINGLE	UNKNOWN				Ellagic acid is about 50% bound to human plasma proteins.	50	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://scialert.net/abstract/?doi=pjn.2009.1661.1664	Homo sapiens		h	8.4							false
3471	1742		ADULT	48041	352.4699	ENCAINIDE	ENCAINIDE	COC1=CC=C(C=C1)C(=O)NC2=C(CCC3CCCCN3C)C=CC=C2	PLASMA	SY3J0147NB									∞	ng × h/mL	747						UNKNOWN	mg	25		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1909559	Homo sapiens		h	3.3							false
3472	1742		ADULT	48041	352.4699	ENCAINIDE	ENCAINIDe	COC1=CC=C(C=C1)C(=O)NC2=C(CCC3CCCCN3C)C=CC=C2	PLASMA	SY3J0147NB									∞	ng × h/mL	641						UNKNOWN	mg	25		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1909559	Homo sapiens		h	3.3							false
3473	1742		ADULT	48041	352.4699	ENCAINIDE	ENCAINIDE	COC1=CC=C(C=C1)C(=O)NC2=C(CCC3CCCCN3C)C=CC=C2	PLASMA	SY3J0147NB									∞	ng × h/mL	124		ng/mL	60.8			UNKNOWN	mg	25		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1909559	Homo sapiens		h	1.2							false
3474	1742		ADULT	48041	352.4699	ENCAINIDE	ENCAINIDE	COC1=CC=C(C=C1)C(=O)NC2=C(CCC3CCCCN3C)C=CC=C2	PLASMA	SY3J0147NB									∞	μg × h/mL	335		ng/mL	100.7			UNKNOWN	mg	25		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1909559	Homo sapiens		h	2.6							false
3475	1742		ADULT	48041	352.4699	ENCAINIDE	ENCAINIDE	COC1=CC=C(C=C1)C(=O)NC2=C(CCC3CCCCN3C)C=CC=C2	PLASMA	SY3J0147NB							8		t	ng × h/mL	147		ng/mL	75.2			UNKNOWN	mg	25		MULTIPLE	UNKNOWN		day	3			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1909559	Homo sapiens		h	2.8							false
3476	1742		ADULT	48041	352.4699	ENCAINIDE	ENCAINIDE	COC1=CC=C(C=C1)C(=O)NC2=C(CCC3CCCCN3C)C=CC=C2	PLASMA	SY3J0147NB							8		t	ng × h/mL	416		ng/mL	151			UNKNOWN	mg	25		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1909559	Homo sapiens		h	3.1							false
3477	1743		ADULT	2758	154.2493	EUCALYPTOL	Eucalyptol	CC12CCC(CC1)C(C)(C)O2	PLASMA	RV6J6604TK													nM	19			UNKNOWN	mg	1.02		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20425757/	Homo sapiens							1			false
3478	1743			2758	154.2493	EUCALYPTOL	Eucalyptol	CC12CCC(CC1)C(C)(C)O2	PLASMA	RV6J6604TK																										Human plasma protein binding: 100% (prediction)	0				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33848890/	Homo sapiens										false
3479	1743		ADULT	2758	154.2493	EUCALYPTOL	Eucalyptol	CC12CCC(CC1)C(C)(C)O2	SERUM	RV6J6604TK							1		t	ng × min/mL	23076		ng/mL	790.75			UNKNOWN	mL	4		SINGLE	UNKNOWN						HEALTHY	Respiratory	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8866111/	Homo sapiens		min	104.6				4			false
3480	1743		ADULT	2758	154.2493	EUCALYPTOL	Eucalyptol	CC12CCC(CC1)C(C)(C)O2	SERUM	RV6J6604TK													ng/mL	275			UNKNOWN	mL	2		SINGLE	UNKNOWN						HEALTHY	Respiratory	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8866111/ | https://pubmed.ncbi.nlm.nih.gov/7552045/	Homo sapiens		min	19.9				1			false
3481	1745		ADULT	6021|5274258|135398641	268.2261	INOSINE	Inosine	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N2C=NC3=C2N=CNC3=O	PLASMA	5A614L51CT																	UNKNOWN				SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/2431857/	Homo sapiens		min	50					Inosine pranobex		false
3482	1745			6021|5274258|135398641	268.2261	INOSINE	Inosine	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N2C=NC3=C2N=CNC3=O	PLASMA	5A614L51CT																										Human plasma protein binding: 0%	100				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/790005_3999007F1031_1_M01_1F.pdf#page=21	Homo sapiens										false
3483	1754		ADULT	51|156274072	146.0981	OXOGLURIC ACID	Oxogluric acid	OC(=O)CCC(=O)C(O)=O	PLASMA	8ID597Z82X									?	μg × h/mL	376		μg/mL	39			UNKNOWN	mg	11.7		SINGLE	UNKNOWN						HEALTHY	Respiratory	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21787714/	Homo sapiens		h	7				6			false
3484	1754		ADULT	51|156274072	146.0981	OXOGLURIC ACID	Oxogluric acid	OC(=O)CCC(=O)C(O)=O	PLASMA	8ID597Z82X																						UNKNOWN				In plasma from three separate donors, binding of aKG to human plasma protein was negligible (∼100% was unbound; data not shown). (equilibrium dialysis)	100	HEALTHY		MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24770989/	Homo sapiens							3			false
3485	1756		ADULT	4754	179.2157	PHENACETIN	phenacetin	CCOC1=CC=C(NC(C)=O)C=C1	PLASMA	ER0CTH01H9							8		t	μg × h/mL	20.72		μg/mL	13.5			UNKNOWN	g	1.5		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://accp1.onlinelibrary.wiley.com/doi/abs/10.1002/j.1552-4604.1974.tb02323.x	Homo sapiens		h	0.6							false
3486	1756		ADULT	4754	179.2157	PHENACETIN	phenacetin	CCOC1=CC=C(NC(C)=O)C=C1	PLASMA	ER0CTH01H9									∞	μg × h/mL	5.3		μg/mL	2.5			UNKNOWN	mg	900		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://journals.lww.com/drug-monitoring/Abstract/1998/08000/Effect_of_Active_and_Passive_Cigarette_Smoking_on.2.aspx	Homo sapiens		h	0.9							false
3487	1756		ADULT	1983	151.1626	ACETAMINOPHEN	acetaminophen	CC(=O)NC1=CC=C(O)C=C1	PLASMA	362O9ITL9D									∞	μg × h/mL	40.4		μg/mL	6.9			UNKNOWN	mg	900		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://journals.lww.com/drug-monitoring/Abstract/1998/08000/Effect_of_Active_and_Passive_Cigarette_Smoking_on.2.aspx	Homo sapiens		h	2.6							false
3488	1756		UNKNOWN	4754	179.2157	PHENACETIN	phenacetin	CCOC1=CC=C(NC(C)=O)C=C1	PLASMA	ER0CTH01H9																						UNKNOWN				Plasma protein binding: 30.0% (method unknown)	70	UNKNOWN		UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23607050/	Homo sapiens										false
3489	1756		ADULT	4754	179.2157	PHENACETIN	phenacetin	CCOC1=CC=C(NC(C)=O)C=C1	PLASMA	ER0CTH01H9									∞	μg × h/mL	1.84		μg/mL	1.84			UNKNOWN	mg	900		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.jstage.jst.go.jp/article/jscpt1970/19/4/19_4_767/_pdf	Homo sapiens		h	1.1							false
3490	1756		ADULT	4754	179.2157	PHENACETIN	phenacetin	CCOC1=CC=C(NC(C)=O)C=C1	PLASMA	ER0CTH01H9									∞	μg × h/mL	1.58		μg/mL	1.48			UNKNOWN	mg	900		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.jstage.jst.go.jp/article/jscpt1970/19/4/19_4_767/_pdf	Homo sapiens		h	0.98							false
3491	1760		ADULT	3348|74685737	501.6564	FEXOFENADINE	Fexofenadine	CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN2CCC(CC2)C(O)(C3=CC=CC=C3)C4=CC=CC=C4	PLASMA	E6582LOH6V							24		t	ng × h/mL	2720.1		ng/mL	406.9			UNKNOWN	mg	120		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1576325/	Homo sapiens		h	12.6							false
3492	1760		ADULT	3348|74685737	501.6564	FEXOFENADINE	FEXOFENADINE	CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN2CCC(CC2)C(O)(C3=CC=CC=C3)C4=CC=CC=C4	PLASMA	E6582LOH6V							24		t	ng × h/mL	2712.1		ng/mL	458.1			UNKNOWN	mg	120		SINGLE	HIGH-FAT						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1576325/	Homo sapiens		h	11.6							false
3493	1760		ADULT	5405	471.6734	TERFENADINE	TERFENADINE	CC(C)(C)C1=CC=C(C=C1)C(O)CCCN2CCC(CC2)C(O)(C3=CC=CC=C3)C4=CC=CC=C4	PLASMA	7BA5G9Y06Q									?	ng × h/mL	11.864		ng/mL	1.544			UNKNOWN	mg	60		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6113858/	Homo sapiens										false
3494	1760		ADULT	5405	471.6734	TERFENADINE	TERFENADINE	CC(C)(C)C1=CC=C(C=C1)C(O)CCCN2CCC(CC2)C(O)(C3=CC=CC=C3)C4=CC=CC=C4	PLASMA	7BA5G9Y06Q									?	ng × h/mL	44.341		ng/mL	4.519			UNKNOWN	mg	180		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6113858/	Homo sapiens										false
3495	1761		ADULT	6288|6971019	119.1192	THREONINE	THREONINE	C[C@@H](O)[C@H](N)C(O)=O	PLASMA	2ZD004190S							2.5		t	μg × h/mL	300		μM	200			RECOMMENDED	mg/kg	15		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/685879/	Homo sapiens		h	1							false
3496	1769			5311507	400.965	ZUCLOPENTHIXOL	Zuclopenthixol	OCCN1CCN(CC\\C=C2\\C3=C(SC4=C2C=C(Cl)C=C4)C=CC=C3)CC1	UNKNOWN	47ISU063SG																										Protein binding: 98%	2				OTHER	https://www.medicines.org.uk/emc/product/993/smpc#PHARMACOKINETIC_PROPS	Homo sapiens										false
3497	1769		UNKNOWN	5311507	400.965	ZUCLOPENTHIXOL	Zuclopenthixol	OCCN1CCN(CC\\C=C2\\C3=C(SC4=C2C=C(Cl)C=C4)C=CC=C3)CC1	SERUM	47ISU063SG																						UNKNOWN						UNKNOWN		UNKNOWN	OTHER	https://www.medicines.org.uk/emc/product/994/smpc#PHARMACOKINETIC_PROPS	Homo sapiens		day	1							false
3498	1773		ADULT	5283734	416.6365	TACALCITOL	Tacalcitol	CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\\C2=C/C=C3/C[C@@H](O)C[C@H](O)C3=C	SERUM	C2W72OJ5ZU													pg/mL	25			MAX DAILY	μg	200		MULTIPLE	UNKNOWN		day	1	Cmax was below LOQ (25pg/mL).		HEALTHY	Topical	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/470310_2691700M2025_2_002_1F.pdf#page=40	Homo sapiens				5-day treatment			6			false
3499	1773		ADULT	5283734	416.6365	TACALCITOL	Tacalcitol	CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\\C2=C/C=C3/C[C@@H](O)C[C@H](O)C3=C	SERUM	C2W72OJ5ZU													pg/mL	25			MAX DAILY	μg	200		MULTIPLE	UNKNOWN		day	1	Cmax>25pg/mL (LOQ), Catalcitol was detected in serum after 4 hours in 4 out of 7 psoriasis vulgaris patients.		UNHEALTHY	Topical	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/470310_2691700M2025_2_002_1F.pdf#page=40	Homo sapiens				28-day treatment	psoriasis vulgaris patients		7			false
3500	1773		ADULT	5283734	416.6365	TACALCITOL	Tacalcitol	CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\\C2=C/C=C3/C[C@@H](O)C[C@H](O)C3=C	SERUM	C2W72OJ5ZU													pg/mL	25			RECOMMENDED	μg	140		MULTIPLE	UNKNOWN		day	1	Cmax>25pg/mL (LOQ), Catalcitol was detected in serum after 4 hours in 5 out of 7 psoriasis vulgaris patients.		UNHEALTHY	Topical	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/470310_2691700M2025_2_002_1F.pdf#page=40	Homo sapiens				28-day treatment	psoriasis vulgaris patients		7			false
3501	1773			5283734	416.6365	TACALCITOL	Tacalcitol	CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\\C2=C/C=C3/C[C@@H](O)C[C@H](O)C3=C	PLASMA	C2W72OJ5ZU																										Human plasma protein binding: 100%, ultrafiltration	0				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/470310_2691700M2025_2_002_1F.pdf#page=41	Homo sapiens										false
3502	1776		UNKNOWN	91276	306.3999	ROXATIDINE	Roxatidine	OCC(=O)NCCCOC1=CC(CN2CCCCC2)=CC=C1	UNKNOWN	IV9VHT3YUM																						UNKNOWN				Roxatidine acetate protein binding is approximately 15%	85	UNKNOWN		UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2905248/	Homo sapiens								Roxatidine acetate		false
3503	1776		ADULT	91276	306.3999	ROXATIDINE	Roxatidine	OCC(=O)NCCCOC1=CC(CN2CCCCC2)=CC=C1	PLASMA	IV9VHT3YUM									∞	ng × h/mL	1353.2		ng/mL	157.5			UNKNOWN	mg	37.5		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_A100_2.pdf#page=7 | https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_K100_2.pdf#page=70	Homo sapiens		h	5.57				8	Roxatidine acetate hydrochloride		false
3504	1776		ADULT	91276	306.3999	ROXATIDINE	Roxatidine	OCC(=O)NCCCOC1=CC(CN2CCCCC2)=CC=C1	PLASMA	IV9VHT3YUM									∞	ng × h/mL	2424.5		ng/mL	329			RECOMMENDED	mg	75		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_A100_2.pdf#page=7 | https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_K100_2.pdf#page=70	Homo sapiens		h	5.03				8	Roxatidine acetate hydrochloride		false
3505	1776		ADULT	91276	306.3999	ROXATIDINE	Roxatidine	OCC(=O)NCCCOC1=CC(CN2CCCCC2)=CC=C1	PLASMA	IV9VHT3YUM									∞	ng × h/mL	5275.2		ng/mL	628.5			RECOMMENDED	mg	150		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_A100_2.pdf#page=7 | https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_K100_2.pdf#page=70	Homo sapiens		h	5.01				8	Roxatidine acetate hydrochloride		false
3506	1776		CHILD	91276	306.3999	ROXATIDINE	Roxatidine	OCC(=O)NCCCOC1=CC(CN2CCCCC2)=CC=C1	PLASMA	IV9VHT3YUM									∞	ng × h/mL	2053.6		ng/mL	353.6			UNKNOWN	mg	37.5		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_A100_2.pdf#page=8 | https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_K100_2.pdf#page=82	Homo sapiens		h	4.62		Stomach ulcer, acute gastritis, reflux esophagitis patients		12	Roxatidine acetate hydrochloride		false
3507	1776		CHILD	91276	306.3999	ROXATIDINE	Roxatidine	OCC(=O)NCCCOC1=CC(CN2CCCCC2)=CC=C1	PLASMA	IV9VHT3YUM									∞	ng × h/mL	3587.5		ng/mL	530.2			RECOMMENDED	mg	75		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_A100_2.pdf#page=8 | https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_K100_2.pdf#page=83	Homo sapiens		h	4.17		Stomach ulcer, acute gastritis, reflux esophagitis patients		14	Roxatidine acetate hydrochloride		false
3508	1777		ADULT	54683745	353.3255	ACENOCOUMAROL, (S)-	(S)-acenocoumarol	CC(=O)C[C@@H](C1=CC=C(C=C1)[N+]([O-])=O)C2=C(O)C3=C(OC2=O)C=CC=C3	PLASMA	4O90VF03HV									∞	ng × h/mL	205.9		ng/mL	60			RECOMMENDED	mg	8		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12844136/	Homo sapiens		h	1							false
3509	1777		ADULT	54699177	353.3255	ACENOCOUMAROL, (R)-	ACENOCOUMAROL, (R)-	CC(=O)C[C@H](C1=CC=C(C=C1)[N+]([O-])=O)C2=C(O)C3=C(OC2=O)C=CC=C3	PLASMA	JRD7912W79									∞	ng × h/mL	2602		ng/mL	360			RECOMMENDED	mg	8		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12844136/	Homo sapiens		h	8.8							false
3510	1778		ADULT	5280453	416.6365	CALCITRIOL	Calcitriol	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\\C(CCC[C@]12C)=C\\C=C3\\C[C@@H](O)C[C@H](O)C3=C	PLASMA	FXC9231JVH									?	pg × h/mL	3296.928		pg/mL	67.492			UNKNOWN	μg	1		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://mhraproducts4853.blob.core.windows.net/docs/5b74a841dd7fdbfa216d1071546233c80df37bd3#page=9	Homo sapiens										false
3511	1778		ADULT	5280453	416.6365	CALCITRIOL	Calcitriol	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\\C(CCC[C@]12C)=C\\C=C3\\C[C@@H](O)C[C@H](O)C3=C	PLASMA	FXC9231JVH							72		t	pg × h/mL	1365.6		pg/mL	63.4			UNKNOWN	μg	4		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11981071/	Homo sapiens		h	48.63				6			false
3512	1778		ADULT	5280453	416.6365	CALCITRIOL	Calcitriol	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\\C(CCC[C@]12C)=C\\C=C3\\C[C@@H](O)C[C@H](O)C3=C	PLASMA	FXC9231JVH							72		t	pg × h/mL	1074.1		pg/mL	70.9			UNKNOWN	μg	4		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11981071/	Homo sapiens		h	47.13				6			false
3513	1778		ADULT	5280453	416.6365	CALCITRIOL	Calcitriol	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\\C(CCC[C@]12C)=C\\C=C3\\C[C@@H](O)C[C@H](O)C3=C	PLASMA	FXC9231JVH							72		t	pg × h/mL	2957.9		pg/mL	147			UNKNOWN	μg	4		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11981071/	Homo sapiens		h	36.66		Uraemic patients		6			false
3514	1778		ADULT	5280453	416.6365	CALCITRIOL	Calcitriol	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\\C(CCC[C@]12C)=C\\C=C3\\C[C@@H](O)C[C@H](O)C3=C	PLASMA	FXC9231JVH							72		t	pg × h/mL	2092.1		pg/mL	73			UNKNOWN	μg	4		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11981071/	Homo sapiens		h	29.19		Uraemic patients		6			false
3515	1778		ADULT	5280453	416.6365	CALCITRIOL	Calcitriol	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\\C(CCC[C@]12C)=C\\C=C3\\C[C@@H](O)C[C@H](O)C3=C	PLASMA	FXC9231JVH							81		t	pg × h/mL	2305		pg/mL	57.49			MAX DAILY	μg	4		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400061_3112001M1259_1_902_1F.pdf#page=20	Homo sapiens		h	20.92	1μg x 4 tablets			18			false
3516	1778		ADULT	5280453	416.6365	CALCITRIOL	Calcitriol	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\\C(CCC[C@]12C)=C\\C=C3\\C[C@@H](O)C[C@H](O)C3=C	PLASMA	FXC9231JVH							72		t	pg × h/mL	3837.179		pg/mL	76.96			RECOMMENDED	μg	3		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400061_3112001M1259_1_902_1F.pdf#page=21	Homo sapiens		h	14.275	3μg tablets			12			false
3517	1778			5282181	400.6371	ALFACALCIDOL	Alfacalcidol	CC(C)CCC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\\C2=C/C=C3/C[C@@H](O)C[C@H](O)C3=C	PLASMA	URQ2517572																										Human plasma protein binding: 13% (alpha-globulin), 58% (lipoprotein)	19				EXPERIMENT	https://www.jstage.jst.go.jp/article/vso/52/9-10/52_KJ00001705074/_article/-char/en	Homo sapiens										false
3518	1779		ADULT	2159	369.479	AMISULPRIDE	AMISULPRIDE	CCN1CCCC1CNC(=O)C2=C(OC)C=C(N)C(=C2)S(=O)(=O)CC	PLASMA	8110R61I4U																	INVESTIGATIONAL	mg	50		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	REVIEW	https://www.ncbi.nlm.nih.gov/pubmed/12404702	Homo sapiens		h	11.7							false
3519	1779		ADULT	2159	369.479	AMISULPRIDE	AMISULPRIDE	CCN1CCCC1CNC(=O)C2=C(OC)C=C(N)C(=C2)S(=O)(=O)CC	PLASMA	8110R61I4U									∞	ng × h/mL	5043.2		ng/mL	586.3			INVESTIGATIONAL	mg	200		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/28793958	Homo sapiens										false
3520	1780		ADULT	2196	219.2365	ANIRACETAM	Aniracetam	COC1=CC=C(C=C1)C(=O)N2CCCC2=O	PLASMA	5L16LKN964													μg/L	2.3			UNKNOWN	mg	300		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://link.springer.com/article/10.2165/00002512-199404030-00007	Homo sapiens		min	35							false
3521	1780		ADULT	2196	219.2365	ANIRACETAM	Aniracetam	COC1=CC=C(C=C1)C(=O)N2CCCC2=O	PLASMA	5L16LKN964													μg/L	14.1			UNKNOWN	mg	1200		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://link.springer.com/article/10.2165/00002512-199404030-00007	Homo sapiens		min	35							false
3522	1780			2196	219.2365	ANIRACETAM	Aniracetam	COC1=CC=C(C=C1)C(=O)N2CCCC2=O	PLASMA	5L16LKN964																										Plasma protein binding was 66%.	34				EXPERIMENT	https://link.springer.com/article/10.2165/00002512-199404030-00007	Homo sapiens										false
3523	1780		ADULT	2196	219.2365	ANIRACETAM	Aniracetam	COC1=CC=C(C=C1)C(=O)N2CCCC2=O	PLASMA	5L16LKN964									∞	ng × h/mL	4.62		ng/mL	8.75			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19025058/	Homo sapiens		h	0.47				20			false
3524	1780		ADULT	12025	85.1045	PYRROLIDONE	2-Pyrrolidinone	O=C1CCCN1	SERUM	KKL5D39EOL									?	μg × h/mL	2.5		μg/mL	0.332			UNKNOWN	mg	200		SINGLE							UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9062694/	Homo sapiens		h	11.5		Elderly patients with cerebrovascular disease (CVD) (mean age 84.5 y)					false
3525	1782		ADULT	54766	367.44	BAMBUTEROL	Bambuterol	CN(C)C(=O)OC1=CC(=CC(OC(=O)N(C)C)=C1)C(O)CNC(C)(C)C	PLASMA	Y1850G1OVC							24		t	nM × h	55.3		nM	10.3			UNKNOWN	mg	20		STEADY-STATE	FED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10718774/	Homo sapiens		h	16.52		n=24 (Cmax), 24 (AUC), 18 (t1/2); Dose 15		26			false
3526	1782		ADULT	54766	367.44	BAMBUTEROL	Bambuterol	CN(C)C(=O)OC1=CC(=CC(OC(=O)N(C)C)=C1)C(O)CNC(C)(C)C	PLASMA	Y1850G1OVC							24		∞	nM × h	108.6		nM	14.23			UNKNOWN	mg	30		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10718774/	Homo sapiens		h	16.85		n=22 (Cmax), 20 (AUC), 16 (t1/2)		26			false
3527	1782		ADULT	5403	225.2842	TERBUTALINE	Terbutaline	CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1	PLASMA	N8ONU3L3PG									∞	nM × h	208.1		nM	7.1			UNKNOWN	mg	10		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10718774/	Homo sapiens		h	26.5		n=21 (Cmax), 21 (AUC), 17 (T1/2)		26			false
3528	1782		ADULT	5403	225.2842	TERBUTALINE	Terbutaline	CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1	PLASMA	N8ONU3L3PG							24		t	nM × h	196		nM	12.2			UNKNOWN	mg	10		STEADY-STATE	FED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10718774/	Homo sapiens		h	22.25		n=24 (Cmax), 24 (AUC), 22 (T1/2); Dose 15		26			false
3529	1782		ADULT	5403	225.2842	TERBUTALINE	Terbutaline	CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1	PLASMA	N8ONU3L3PG							24		∞	nM × h	387.6		nM	12.17			UNKNOWN	mg	20		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10718774/	Homo sapiens		h	22.46		n=23 (Cmax), 24 (AUC), 22 (T1/2)		26			false
3530	1782		ADULT	5403	225.2842	TERBUTALINE	Terbutaline	CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1	PLASMA	N8ONU3L3PG							24		t	nM × h	350.9		nM	20.4			UNKNOWN	mg	20		STEADY-STATE	FED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10718774/	Homo sapiens		h	22.81		n=24 (Cmax), 24 (AUC), 23 (T1/2); Dose 15		26			false
3531	1782		ADULT	5403	225.2842	TERBUTALINE	Terbutaline	CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1	PLASMA	N8ONU3L3PG							24		∞	nM × h	556.9		nM	16.32			HIGHEST STUDIED	mg	30		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10718774/	Homo sapiens		h	22.1		n=23 (Cmax), 23 (AUC), 23 (T1/2)		26			false
3532	1782		ADULT	54766	367.44	BAMBUTEROL	Bambuterol	CN(C)C(=O)OC1=CC(=CC(OC(=O)N(C)C)=C1)C(O)CNC(C)(C)C	PLASMA	Y1850G1OVC							24		t	nM × h	20.1		nM	4.35			UNKNOWN	mg	10		STEADY-STATE	FED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10718774/	Homo sapiens		h	20.9		n=23 (Cmax), 19 (AUC), 10 (t1/2); Dose 15		26			false
3533	1782		ADULT	54766	367.44	BAMBUTEROL	Bambuterol	CN(C)C(=O)OC1=CC(=CC(OC(=O)N(C)C)=C1)C(O)CNC(C)(C)C	PLASMA	Y1850G1OVC							24		∞	nM × h	66.8		nM	8.56			UNKNOWN	mg	20		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10718774/	Homo sapiens		h	18.47		n=23 (Cmax), 22 (AUC), 12 (t1/2)		26			false
3534	1782		ADULT	54766	367.44	BAMBUTEROL	Bambuterol	CN(C)C(=O)OC1=CC(=CC(OC(=O)N(C)C)=C1)C(O)CNC(C)(C)C	PLASMA	Y1850G1OVC									∞	nM × h	37.3		nM	3.69			UNKNOWN	mg	10		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10718774/	Homo sapiens		h	20.14		n=20 (Cmax), 15 (AUC), 15 (t1/2)		26			false
3535	1782		ADULT	5403	225.2842	TERBUTALINE	Terbutaline	CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1	PLASMA	N8ONU3L3PG							24		t	nM × h	550		nM	31.36			HIGHEST STUDIED	mg	30		STEADY-STATE	FED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10718774/	Homo sapiens		h	22.64		n=23 (Cmax), 23 (AUC), 23 (T1/2)		26			false
3536	1782		ADULT	54766	367.44	BAMBUTEROL	Bambuterol	CN(C)C(=O)OC1=CC(=CC(OC(=O)N(C)C)=C1)C(O)CNC(C)(C)C	PLASMA	Y1850G1OVC							24		t	nM × h	123.7		nM	16.75			UNKNOWN	mg	30		STEADY-STATE	FED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10718774/	Homo sapiens		h	15.04		n=23 (Cmax), 23 (AUC), 20 (t1/2); Dose 15		26			false
3537	1782		UNKNOWN	54766	367.44	BAMBUTEROL	Bambuterol	CN(C)C(=O)OC1=CC(=CC(OC(=O)N(C)C)=C1)C(O)CNC(C)(C)C	PLASMA	Y1850G1OVC																						UNKNOWN				Protein binding of bambuterol is low, 40-50 % at therapeutic concentrations.	50	UNKNOWN		UNKNOWN	EXPERIMENT	https://www.ijpsonline.com/articles/formulation-and-evaluation-of-solid-selfemulsifying-drug-delivery-system-of-bambuterol-hydrochloride.pdf	Homo sapiens										false
3538	1783		ADULT	6917951	398.492	BERAPROST	Beraprost	CC#CCC(C)[C@H](O)\\C=C\\[C@H]1[C@H](O)C[C@@H]2OC3=C(C=CC=C3CCCC(O)=O)[C@H]12	PLASMA	35E3NJJ4O6							48		t	pg × h/mL	978		pg/mL	84.9			UNKNOWN	μg	120		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27681484/	Homo sapiens		h	14.7		Normal kidney function (stage 1 CKD)		6			false
3539	1783		ADULT	6917951	398.492	BERAPROST	Beraprost	CC#CCC(C)[C@H](O)\\C=C\\[C@H]1[C@H](O)C[C@@H]2OC3=C(C=CC=C3CCCC(O)=O)[C@H]12	PLASMA	35E3NJJ4O6							48		t	pg × h/mL	1252		pg/mL	119.8			UNKNOWN	μg	120		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27681484/	Homo sapiens		h	8		Stage 2 CKD		6			false
3540	1783		ADULT		398.492	BERAPROST	Beraprost	CC#CCC(C)[C@H](O)\\C=C\\[C@H]1[C@H](O)C[C@@H]2OC3=C(C=CC=C3CCCC(O)=O)[C@H]12	PLASMA	35E3NJJ4O6							48		t	pg × h/mL	1862		pg/mL	190.6			UNKNOWN	μg	120		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27681484/	Homo sapiens		h	13.8		Stage 3 CKD		6			false
3541	1783		ADULT		398.492	BERAPROST	Beraprost	CC#CCC(C)[C@H](O)\\C=C\\[C@H]1[C@H](O)C[C@@H]2OC3=C(C=CC=C3CCCC(O)=O)[C@H]12	PLASMA	35E3NJJ4O6							48		t	pg × h/mL	1766		pg/mL	240.2			UNKNOWN	μg	120		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27681484/	Homo sapiens		h	18.8		Stage 4 CKD		6			false
3542	1783		ADULT	10501053	398.492	ESUBERAPROST	Esuberaprost	CC#CC[C@H](C)[C@H](O)\\C=C\\[C@H]1[C@H](O)C[C@@H]2OC3=C(C=CC=C3CCCC(O)=O)[C@H]12	PLASMA	1JSN1I7582							48		t	pg × h/mL	155		pg/mL	22.4			UNKNOWN	μg	120		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27681484/	Homo sapiens		h	19.8		Normal kidney function (stage 1 CKD)		6			false
3543	1783		ADULT	10501053	398.492	ESUBERAPROST	Esuberaprost	CC#CC[C@H](C)[C@H](O)\\C=C\\[C@H]1[C@H](O)C[C@@H]2OC3=C(C=CC=C3CCCC(O)=O)[C@H]12	PLASMA	1JSN1I7582							48		t	pg × h/mL	226		pg/mL	30.8			UNKNOWN	μg	120		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27681484/	Homo sapiens		h	8.6		Stage 2 CKD		6			false
3544	1783		ADULT	10501053	398.492	ESUBERAPROST	Esuberaprost	CC#CC[C@H](C)[C@H](O)\\C=C\\[C@H]1[C@H](O)C[C@@H]2OC3=C(C=CC=C3CCCC(O)=O)[C@H]12	PLASMA	1JSN1I7582							48		t	pg × h/mL	341		pg/mL	46.68			UNKNOWN	μg	120		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27681484/	Homo sapiens		h	15.48		Stage 3 CKD		6			false
3545	1783		ADULT	10501053	398.492	ESUBERAPROST	Esuberaprost	CC#CC[C@H](C)[C@H](O)\\C=C\\[C@H]1[C@H](O)C[C@@H]2OC3=C(C=CC=C3CCCC(O)=O)[C@H]12	PLASMA	1JSN1I7582							48		t	pg × h/mL	328.98		pg/mL	54.4			UNKNOWN	μg	120		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27681484/	Homo sapiens		h	8.6		Stage 4 CKD		6			false
3546	1783		ADULT	6917951	398.492	BERAPROST	Beraprost	CC#CCC(C)[C@H](O)\\C=C\\[C@H]1[C@H](O)C[C@@H]2OC3=C(C=CC=C3CCCC(O)=O)[C@H]12	PLASMA	35E3NJJ4O6																						FASTED				Human plasma protein binding: 90.8% (0.05ng/mL), 91.0% (0.5ng/mL), 91.6% (5ng/mL); HSA (40ng/mL) binding: 85.8% (0.5ng/mL); ultrafiltration	8.4	HEALTHY		MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27681484/	Homo sapiens										false
3547	1783		ADULT	10501053	398.492	ESUBERAPROST	Esuberaprost	CC#CC[C@H](C)[C@H](O)\\C=C\\[C@H]1[C@H](O)C[C@@H]2OC3=C(C=CC=C3CCCC(O)=O)[C@H]12	PLASMA	1JSN1I7582							8		t	pg × h/mL	44.5		pg/mL	57.7			UNKNOWN	μg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7506323/	Homo sapiens		h	0.5				12			false
3548	1783		ADULT	10501053	398.492	ESUBERAPROST	Esuberaprost	CC#CC[C@H](C)[C@H](O)\\C=C\\[C@H]1[C@H](O)C[C@@H]2OC3=C(C=CC=C3CCCC(O)=O)[C@H]12	PLASMA	1JSN1I7582							8		t	pg × h/mL	105.6		pg/mL	122.4			UNKNOWN	μg	40		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7506323/	Homo sapiens		h	0.53				12			false
3549	1783		ADULT	10501053	398.492	ESUBERAPROST	Esuberaprost	CC#CC[C@H](C)[C@H](O)\\C=C\\[C@H]1[C@H](O)C[C@@H]2OC3=C(C=CC=C3CCCC(O)=O)[C@H]12	PLASMA	1JSN1I7582							8		t	pg × h/mL	168.7		pg/mL	185			UNKNOWN	μg	60		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7506323/	Homo sapiens		h	0.62				12			false
3550	1783		ADULT	10501053	398.492	ESUBERAPROST	Esuberaprost	CC#CC[C@H](C)[C@H](O)\\C=C\\[C@H]1[C@H](O)C[C@@H]2OC3=C(C=CC=C3CCCC(O)=O)[C@H]12	PLASMA	1JSN1I7582							8		t	pg × h/mL	43.4		pg/mL	40.4			UNKNOWN	μg	20		MULTIPLE	UNKNOWN		day	3			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7506323/	Homo sapiens		h	0.62	Day 4 (fasted)			12			false
3551	1783		ADULT	10501053	398.492	ESUBERAPROST	Esuberaprost	CC#CC[C@H](C)[C@H](O)\\C=C\\[C@H]1[C@H](O)C[C@@H]2OC3=C(C=CC=C3CCCC(O)=O)[C@H]12	PLASMA	1JSN1I7582							8		t	pg × h/mL	108.6		pg/mL	122			UNKNOWN	μg	40		MULTIPLE	UNKNOWN		day	3			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7506323/	Homo sapiens		h	0.64	Day 4 (fasted)			12			false
3552	1783		ADULT	10501053	398.492	ESUBERAPROST	Esuberaprost	CC#CC[C@H](C)[C@H](O)\\C=C\\[C@H]1[C@H](O)C[C@@H]2OC3=C(C=CC=C3CCCC(O)=O)[C@H]12	PLASMA	1JSN1I7582							8		t	pg × h/mL	184.9		pg/mL	150.6			UNKNOWN	μg	60		MULTIPLE	UNKNOWN		day	3			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7506323/	Homo sapiens		h	0.91	Day 4 (fasted)			12			false
3553	1783		ADULT	6917951	398.492	BERAPROST	Beraprost	CC#CCC(C)[C@H](O)\\C=C\\[C@H]1[C@H](O)C[C@@H]2OC3=C(C=CC=C3CCCC(O)=O)[C@H]12	PLASMA	35E3NJJ4O6							24		t	ng × h/mL	1.66		ng/mL	0.44			UNKNOWN	μg	50		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/480220_3399005F1021_1_A07_1F.pdf#page=21	Homo sapiens		h	1.11				8			false
3554	1783		ADULT	10501053	398.492	ESUBERAPROST	Esuberaprost	CC#CC[C@H](C)[C@H](O)\\C=C\\[C@H]1[C@H](O)C[C@@H]2OC3=C(C=CC=C3CCCC(O)=O)[C@H]12	PLASMA	1JSN1I7582							24		t	pg × h/mL	159		pg/mL	184.3			UNKNOWN	μg	40		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700047/48022000_21900AMX01753_K100_1.pdf#page=11	Homo sapiens					Immediate release tablets		12			false
3555	1783		ADULT	6917951	398.492	BERAPROST	Beraprost	CC#CCC(C)[C@H](O)\\C=C\\[C@H]1[C@H](O)C[C@@H]2OC3=C(C=CC=C3CCCC(O)=O)[C@H]12	PLASMA	35E3NJJ4O6							24		t	pg × h/mL	1119		pg/mL	97.1			UNKNOWN	μg	120		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700047/48022000_21900AMX01753_K100_1.pdf#page=11	Homo sapiens					Sustained release tablets		12			false
3556	1783		ADULT	10501053	398.492	ESUBERAPROST	Esuberaprost	CC#CC[C@H](C)[C@H](O)\\C=C\\[C@H]1[C@H](O)C[C@@H]2OC3=C(C=CC=C3CCCC(O)=O)[C@H]12	PLASMA	1JSN1I7582							24		t	pg × h/mL	234		pg/mL	27.7			UNKNOWN	μg	120		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700047/48022000_21900AMX01753_K100_1.pdf#page=11	Homo sapiens					Sustained release tablets		12			false
3557	1783		ADULT	6917951	398.492	BERAPROST	Beraprost	CC#CCC(C)[C@H](O)\\C=C\\[C@H]1[C@H](O)C[C@@H]2OC3=C(C=CC=C3CCCC(O)=O)[C@H]12	PLASMA	35E3NJJ4O6							24		t	pg × h/mL	717		pg/mL	485.6			UNKNOWN	μg	40		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700047/48022000_21900AMX01753_K100_1.pdf#page=11	Homo sapiens					Immediate release tablets		12			false
3558	1783		ADULT	6917951	398.492	BERAPROST	Beraprost	CC#CCC(C)[C@H](O)\\C=C\\[C@H]1[C@H](O)C[C@@H]2OC3=C(C=CC=C3CCCC(O)=O)[C@H]12	PLASMA	35E3NJJ4O6							12		t	pg × h/mL	810		pg/mL	170.4			UNKNOWN	μg	120		MULTIPLE	FED		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700047/48022000_21900AMX01753_K100_1.pdf#page=12	Homo sapiens				Day 1	Sustained-release tablets		12			false
3559	1783		ADULT	6917951	398.492	BERAPROST	Beraprost	CC#CCC(C)[C@H](O)\\C=C\\[C@H]1[C@H](O)C[C@@H]2OC3=C(C=CC=C3CCCC(O)=O)[C@H]12	PLASMA	35E3NJJ4O6							12		t	pg × h/mL	1225		pg/mL	214.7			UNKNOWN	μg	120		STEADY-STATE	FED		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700047/48022000_21900AMX01753_K100_1.pdf#page=12	Homo sapiens				Day 7	Sustained-release tablets		12			false
3560	1783		ADULT	10501053	398.492	ESUBERAPROST	Esuberaprost	CC#CC[C@H](C)[C@H](O)\\C=C\\[C@H]1[C@H](O)C[C@@H]2OC3=C(C=CC=C3CCCC(O)=O)[C@H]12	PLASMA	1JSN1I7582							12		t	pg × h/mL	190		pg/mL	46.7			UNKNOWN	μg	120		MULTIPLE	FED		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700047/48022000_21900AMX01753_K100_1.pdf#page=12	Homo sapiens				Day 1	Sustained-release tablets		12			false
3561	1783		ADULT	10501053	398.492	ESUBERAPROST	Esuberaprost	CC#CC[C@H](C)[C@H](O)\\C=C\\[C@H]1[C@H](O)C[C@@H]2OC3=C(C=CC=C3CCCC(O)=O)[C@H]12	PLASMA	1JSN1I7582							12		t	pg × h/mL	221		pg/mL	45.3			UNKNOWN	μg	120		STEADY-STATE	FED		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700047/48022000_21900AMX01753_K100_1.pdf#page=12	Homo sapiens				Day 7	Sustained-release tablets		12			false
3562	1783		ADULT	6917951	398.492	BERAPROST	Beraprost	CC#CCC(C)[C@H](O)\\C=C\\[C@H]1[C@H](O)C[C@@H]2OC3=C(C=CC=C3CCCC(O)=O)[C@H]12	PLASMA	35E3NJJ4O6							6		t	pg × h/mL	462		pg/mL	228.4			UNKNOWN	μg	40		MULTIPLE	FED		day	3			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700047/48022000_21900AMX01753_K100_1.pdf#page=12	Homo sapiens				Day 1	Immediate-release tablets		12			false
3563	1783		ADULT	6917951	398.492	BERAPROST	Beraprost	CC#CCC(C)[C@H](O)\\C=C\\[C@H]1[C@H](O)C[C@@H]2OC3=C(C=CC=C3CCCC(O)=O)[C@H]12	PLASMA	35E3NJJ4O6							6		t	pg × h/mL	550		pg/mL	242.2			UNKNOWN	μg	40		STEADY-STATE	FED		day	3			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700047/48022000_21900AMX01753_K100_1.pdf#page=12	Homo sapiens				Day 7	Immediate-release tablets		12			false
3564	1783		ADULT	10501053	398.492	ESUBERAPROST	Esuberaprost	CC#CC[C@H](C)[C@H](O)\\C=C\\[C@H]1[C@H](O)C[C@@H]2OC3=C(C=CC=C3CCCC(O)=O)[C@H]12	PLASMA	1JSN1I7582							6		t	pg × h/mL	105		pg/mL	67.6			UNKNOWN	μg	40		MULTIPLE	FED		day	3			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700047/48022000_21900AMX01753_K100_1.pdf#page=12	Homo sapiens				Day 1	Immediate-release tablets		12			false
3565	1783		ADULT	10501053	398.492	ESUBERAPROST	Esuberaprost	CC#CC[C@H](C)[C@H](O)\\C=C\\[C@H]1[C@H](O)C[C@@H]2OC3=C(C=CC=C3CCCC(O)=O)[C@H]12	PLASMA	1JSN1I7582							6		t	pg × h/mL	115		pg/mL	66.7			UNKNOWN	μg	40		STEADY-STATE	FED		day	3			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700047/48022000_21900AMX01753_K100_1.pdf#page=12	Homo sapiens				Day 7	Immediate-release tablets		12			false
3566	1783		ADULT	10501053	398.492	ESUBERAPROST	Esuberaprost	CC#CC[C@H](C)[C@H](O)\\C=C\\[C@H]1[C@H](O)C[C@@H]2OC3=C(C=CC=C3CCCC(O)=O)[C@H]12	PLASMA	1JSN1I7582							48		t	pg × h/mL	360		pg/mL	77			UNKNOWN	μg	180		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700047/48022000_21900AMX01753_K101_1.pdf#page=4	Homo sapiens							6			false
3567	1783		ADULT	10501053	398.492	ESUBERAPROST	Esuberaprost	CC#CC[C@H](C)[C@H](O)\\C=C\\[C@H]1[C@H](O)C[C@@H]2OC3=C(C=CC=C3CCCC(O)=O)[C@H]12	PLASMA	1JSN1I7582							48		t	pg × h/mL	355		pg/mL	42.3			UNKNOWN	μg	180		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700047/48022000_21900AMX01753_K101_1.pdf#page=4	Homo sapiens							6			false
3568	1783		ADULT	6917951	398.492	BERAPROST	Beraprost	CC#CCC(C)[C@H](O)\\C=C\\[C@H]1[C@H](O)C[C@@H]2OC3=C(C=CC=C3CCCC(O)=O)[C@H]12	PLASMA	35E3NJJ4O6							48		t	pg × h/mL	1076		pg/mL	178.5			UNKNOWN	μg	120		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700047/48022000_21900AMX01753_K101_1.pdf#page=4	Homo sapiens							6			false
3569	1783		ADULT	6917951	398.492	BERAPROST	Beraprost	CC#CCC(C)[C@H](O)\\C=C\\[C@H]1[C@H](O)C[C@@H]2OC3=C(C=CC=C3CCCC(O)=O)[C@H]12	PLASMA	35E3NJJ4O6							48		t	pg × h/mL	1073		pg/mL	113.2			UNKNOWN	μg	120		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700047/48022000_21900AMX01753_K101_1.pdf#page=4	Homo sapiens							6			false
3570	1783		ADULT	10501053	398.492	ESUBERAPROST	Esuberaprost	CC#CC[C@H](C)[C@H](O)\\C=C\\[C@H]1[C@H](O)C[C@@H]2OC3=C(C=CC=C3CCCC(O)=O)[C@H]12	PLASMA	1JSN1I7582							48		t	pg × h/mL	233		pg/mL	56			UNKNOWN	μg	120		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700047/48022000_21900AMX01753_K101_1.pdf#page=4	Homo sapiens							6			false
3571	1783		ADULT	10501053	398.492	ESUBERAPROST	Esuberaprost	CC#CC[C@H](C)[C@H](O)\\C=C\\[C@H]1[C@H](O)C[C@@H]2OC3=C(C=CC=C3CCCC(O)=O)[C@H]12	PLASMA	1JSN1I7582							48		t	pg × h/mL	214		pg/mL	35.1			UNKNOWN	μg	120		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700047/48022000_21900AMX01753_K101_1.pdf#page=4	Homo sapiens							6			false
3572	1783		ADULT	6917951	398.492	BERAPROST	Beraprost	CC#CCC(C)[C@H](O)\\C=C\\[C@H]1[C@H](O)C[C@@H]2OC3=C(C=CC=C3CCCC(O)=O)[C@H]12	PLASMA	35E3NJJ4O6							48		t	pg × h/mL	1989		pg/mL	264.5			UNKNOWN	μg	180		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700047/48022000_21900AMX01753_K101_1.pdf#page=4	Homo sapiens							6			false
3573	1783		ADULT	6917951	398.492	BERAPROST	Beraprost	CC#CCC(C)[C@H](O)\\C=C\\[C@H]1[C@H](O)C[C@@H]2OC3=C(C=CC=C3CCCC(O)=O)[C@H]12	PLASMA	35E3NJJ4O6							48		t	pg × h/mL	2242		pg/mL	177.4			UNKNOWN	μg	180		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700047/48022000_21900AMX01753_K101_1.pdf#page=4	Homo sapiens							6			false
3574	1784		ADULT	85318	137.136	2-PYRIDINEACETIC ACID	2-pyridylacetic acid	OC(=O)CC1=NC=CC=C1	PLASMA	13Z7401TV3									∞	ng × h/mL	1196		ng/mL	339.4			UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/14765546/	Homo sapiens		h	5.17							false
3575	1785		ADULT	39042	361.819	BEZAFIBRATE	Bezafibrate	CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O	PLASMA	Y9449Q51XH									∞	μg × h/mL	256.5						UNKNOWN	mg	300		SINGLE	FASTED						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7318880/	Homo sapiens		h	20.1		CLcr=13 mL/min, patients with impaired renal function and hyperlipoproteinaemia		1			false
3576	1785		ADULT	39042	361.819	BEZAFIBRATE	Bezafibrate	CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O	PLASMA	Y9449Q51XH									∞	μg × h/mL	154.4		μg/mL	16.3			UNKNOWN	mg	300		SINGLE	FASTED				n=12 for Cmax		UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7318880/	Homo sapiens		h	7.8		CLcr: 20~40 (mean 27.4) mL/min, patients with impaired renal function and hyperlipoproteinaemia		8			false
3577	1785		ADULT	39042	361.819	BEZAFIBRATE	Bezafibrate	CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O	PLASMA	Y9449Q51XH									∞	μg × h/mL	69.4						UNKNOWN	mg	300		SINGLE	FASTED						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7318880/	Homo sapiens		h	4.6		CLcr: >40 (mean 60) mL/min, patients with impaired renal function and hyperlipoproteinaemia		3			false
3578	1785			39042	361.819	BEZAFIBRATE	Bezafibrate	CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O	SERUM	Y9449Q51XH																										Human serum albumin binding: 93.6% (10μg/mL, ultrafiltration), 94.6% (10μg/mL, equilibrium dialysis)	5.4				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/230034_2183005G1234_1_005_1F.pdf#page=20	Homo sapiens										false
3579	1785		ADULT	39042	361.819	BEZAFIBRATE	Bezafibrate	CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O	PLASMA	Y9449Q51XH							24		t	μg × h/mL	8.02		μg/mL	2.06			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/340409_2183005G1099_1_003_1F.pdf#page=12	Homo sapiens		h	1.9				14			false
3580	1785		ADULT	39042	361.819	BEZAFIBRATE	Bezafibrate	CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O	PLASMA	Y9449Q51XH							24		t	μg × h/mL	7.41		μg/mL	1.8			UNKNOWN	mg	100		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/340409_2183005G1099_1_003_1F.pdf#page=13	Homo sapiens		h	2				14			false
3581	1785		ADULT	39042	361.819	BEZAFIBRATE	Bezafibrate	CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O	PLASMA	Y9449Q51XH							24		t	μg × h/mL	13.27		μg/mL	3.46			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/340409_2183005G1099_1_003_1F.pdf#page=13	Homo sapiens		h	2.3				14			false
3582	1785		ADULT	39042	361.819	BEZAFIBRATE	Bezafibrate	CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O	PLASMA	Y9449Q51XH							24		t	μg × h/mL	15.37		μg/mL	3.75			UNKNOWN	mg	200		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/340409_2183005G1099_1_003_1F.pdf#page=14	Homo sapiens		h	2.3				14			false
3583	1785			39042	361.819	BEZAFIBRATE	Bezafibrate	CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O	SERUM	Y9449Q51XH																										The protein-binding of bezafibrate in serum is approximately 95%.	5				OTHER	https://www.medicines.org.uk/emc/product/6547#PHARMACOKINETIC_PROPS	Homo sapiens										false
3584	1786		ADULT	2378	310.3917	BIFONAZOLE	Bifonazole	C1=CN(C=N1)C(C2=CC=CC=C2)C3=CC=C(C=C3)C4=CC=CC=C4	SERUM	QYJ305Z91O													ng/mL	1			UNKNOWN	mg	15.2		SINGLE	UNKNOWN						HEALTHY	Transdermal	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/630004_2655708N1261_1_003_1F.pdf#page=22	Homo sapiens				Skin with no inflammation, cream			5			false
3585	1786		ADULT	2378	310.3917	BIFONAZOLE	Bifonazole	C1=CN(C=N1)C(C2=CC=CC=C2)C3=CC=C(C=C3)C4=CC=CC=C4	SERUM	QYJ305Z91O													ng/mL	3.4			UNKNOWN	mg	15.2		SINGLE	UNKNOWN						HEALTHY	Transdermal	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/630004_2655708N1261_1_003_1F.pdf#page=22	Homo sapiens				Skin with inflammation, cream			5			false
3586	1787			125564	367.5028	BLONANSERIN	Blonanserin	CCN1CCN(CC1)C2=NC3=C(CCCCCC3)C(=C2)C4=CC=C(F)C=C4	SERUM	AQ316B4F8C																										Human serum protein binding (equilibrium dialysis): >=99.68% (10ng/mL), 99.83% (100ng/mL), 99.88% (2μg/mL)	0.12				OTHER GOV'T	https://www.pmda.go.jp/drugs/2008/P200800002/40009300_22000AMX00011_A100_4.pdf#page=30 | https://www.pmda.go.jp/drugs/2008/P200800002/40009300_22000AMX00011_I103_2.pdf#page=2	Homo sapiens										false
3587	1787		ADULT	125564	367.5028	BLONANSERIN	Blonanserin	CCN1CCN(CC1)C2=NC3=C(CCCCCC3)C(=C2)C4=CC=C(F)C=C4	PLASMA	AQ316B4F8C							12		t	ng × h/mL	0.39		ng/mL	0.1			UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2008/P200800002/40009300_22000AMX00011_A100_4.pdf#page=31 | https://www.pmda.go.jp/drugs/2008/P200800002/40009300_22000AMX00011_K149_2.pdf#page=10	Homo sapiens				powder			6			false
3588	1787		ADULT	125564	367.5028	BLONANSERIN	Blonanserin	CCN1CCN(CC1)C2=NC3=C(CCCCCC3)C(=C2)C4=CC=C(F)C=C4	PLASMA	AQ316B4F8C							12		t	ng × h/mL	1.23		ng/mL	0.26			UNKNOWN	mg	2		SINGLE	FASTED				AUCinf=1.60ng x h/mL		HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2008/P200800002/40009300_22000AMX00011_A100_4.pdf#page=31 | https://www.pmda.go.jp/drugs/2008/P200800002/40009300_22000AMX00011_K149_2.pdf#page=10	Homo sapiens				powder			6			false
3589	1787		ADULT	125564	367.5028	BLONANSERIN	Blonanserin	CCN1CCN(CC1)C2=NC3=C(CCCCCC3)C(=C2)C4=CC=C(F)C=C4	PLASMA	AQ316B4F8C							12		t	ng × h/mL	2.52		ng/mL	0.33			UNKNOWN	mg	4		SINGLE	FASTED				AUCinf=4.97ng x h/mL		HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2008/P200800002/40009300_22000AMX00011_A100_4.pdf#page=31 | https://www.pmda.go.jp/drugs/2008/P200800002/40009300_22000AMX00011_K149_2.pdf#page=10	Homo sapiens		h	13	powder			6			false
3590	1787		ADULT	125564	367.5028	BLONANSERIN	Blonanserin	CCN1CCN(CC1)C2=NC3=C(CCCCCC3)C(=C2)C4=CC=C(F)C=C4	PLASMA	AQ316B4F8C									?	ng × h/mL	1.91		ng/mL	0.3			UNKNOWN	mg	6		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2008/P200800002/40009300_22000AMX00011_A100_4.pdf#page=32 | https://www.pmda.go.jp/drugs/2008/P200800002/40009300_22000AMX00011_K149_2.pdf#page=38	Homo sapiens		h	12.4	tablets			8			false
3591	1787		ADULT	125564	367.5028	BLONANSERIN	Blonanserin	CCN1CCN(CC1)C2=NC3=C(CCCCCC3)C(=C2)C4=CC=C(F)C=C4	PLASMA	AQ316B4F8C									?	ng × h/mL	0.84		ng/mL	0.131			UNKNOWN	mg	4		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2008/P200800002/40009300_22000AMX00011_A100_4.pdf#page=32 | https://www.pmda.go.jp/drugs/2008/P200800002/40009300_22000AMX00011_K149_2.pdf#page=38	Homo sapiens		h	8.26	tablets			8			false
3592	1787		ADULT	125564	367.5028	BLONANSERIN	Blonanserin	CCN1CCN(CC1)C2=NC3=C(CCCCCC3)C(=C2)C4=CC=C(F)C=C4	PLASMA	AQ316B4F8C									?	ng × h/mL	6.13		ng/mL	0.946			RECOMMENDED	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2008/P200800002/40009300_22000AMX00011_A100_4.pdf#page=32 | https://www.pmda.go.jp/drugs/2008/P200800002/40009300_22000AMX00011_K149_2.pdf#page=38	Homo sapiens		h	19	tablets			7			false
3593	1787		ADULT	125564	367.5028	BLONANSERIN	Blonanserin	CCN1CCN(CC1)C2=NC3=C(CCCCCC3)C(=C2)C4=CC=C(F)C=C4	PLASMA	AQ316B4F8C									?	ng × h/mL	2.6		ng/mL	0.417			RECOMMENDED	mg	8		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2008/P200800002/40009300_22000AMX00011_A100_4.pdf#page=32 | https://www.pmda.go.jp/drugs/2008/P200800002/40009300_22000AMX00011_K149_2.pdf#page=38	Homo sapiens		h	11.1	tablets			8			false
3594	1787		ADULT	125564	367.5028	BLONANSERIN	Blonanserin	CCN1CCN(CC1)C2=NC3=C(CCCCCC3)C(=C2)C4=CC=C(F)C=C4	PLASMA	AQ316B4F8C									?	ng × h/mL	4.71		ng/mL	0.679			RECOMMENDED	mg	12		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2008/P200800002/40009300_22000AMX00011_A100_4.pdf#page=32 | https://www.pmda.go.jp/drugs/2008/P200800002/40009300_22000AMX00011_K149_2.pdf#page=38	Homo sapiens		h	15.5	tablets			8			false
3595	1787		ADULT	125564	367.5028	BLONANSERIN	Blonanserin	CCN1CCN(CC1)C2=NC3=C(CCCCCC3)C(=C2)C4=CC=C(F)C=C4	PLASMA	AQ316B4F8C									∞	ng × h/mL	22.3		ng/mL	5.46			UNKNOWN	mg	40		SINGLE	FASTED				n=2 for t1/2 and AUC		HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2008/P200800002/40009300_22000AMX00011_A100_4.pdf#page=33 | https://www.pmda.go.jp/drugs/2008/P200800002/40009300_22000AMX00011_K150_2.pdf#page=17	Homo sapiens		h	8.7	suspension	Caucasian		6			false
3596	1787		ADULT	125564	367.5028	BLONANSERIN	Blonanserin	CCN1CCN(CC1)C2=NC3=C(CCCCCC3)C(=C2)C4=CC=C(F)C=C4	PLASMA	AQ316B4F8C									∞	ng × h/mL	52.2		ng/mL	8.21			UNKNOWN	mg	50		SINGLE	FASTED				n=3 for t1/2 and AUC		HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2008/P200800002/40009300_22000AMX00011_A100_4.pdf#page=33 | https://www.pmda.go.jp/drugs/2008/P200800002/40009300_22000AMX00011_K150_2.pdf#page=17	Homo sapiens		h	14.1	suspension	Caucasian		6			false
3597	1787		ADULT	125564	367.5028	BLONANSERIN	Blonanserin	CCN1CCN(CC1)C2=NC3=C(CCCCCC3)C(=C2)C4=CC=C(F)C=C4	PLASMA	AQ316B4F8C									∞	ng × h/mL	15.5		ng/mL	3.38			UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2008/P200800002/40009300_22000AMX00011_A100_4.pdf#page=33 | https://www.pmda.go.jp/drugs/2008/P200800002/40009300_22000AMX00011_K150_2.pdf#page=17	Homo sapiens		h	7.7	suspension	Caucasian		6			false
3598	1787		ADULT	125564	367.5028	BLONANSERIN	Blonanserin	CCN1CCN(CC1)C2=NC3=C(CCCCCC3)C(=C2)C4=CC=C(F)C=C4	PLASMA	AQ316B4F8C													ng/mL	0.195			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2008/P200800002/40009300_22000AMX00011_A100_4.pdf#page=33 | https://www.pmda.go.jp/drugs/2008/P200800002/40009300_22000AMX00011_K150_2.pdf#page=17	Homo sapiens				suspension	Caucasian		6			false
3599	1787		ADULT	125564	367.5028	BLONANSERIN	Blonanserin	CCN1CCN(CC1)C2=NC3=C(CCCCCC3)C(=C2)C4=CC=C(F)C=C4	PLASMA	AQ316B4F8C									∞	ng × h/mL	4.6		ng/mL	0.51			UNKNOWN	mg	10		SINGLE	FASTED				n=4 for t1/2 and AUC		HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2008/P200800002/40009300_22000AMX00011_A100_4.pdf#page=33 | https://www.pmda.go.jp/drugs/2008/P200800002/40009300_22000AMX00011_K150_2.pdf#page=17	Homo sapiens		h	4.5	suspension	Caucasian		6			false
3600	1787		ADULT	125564	367.5028	BLONANSERIN	Blonanserin	CCN1CCN(CC1)C2=NC3=C(CCCCCC3)C(=C2)C4=CC=C(F)C=C4	PLASMA	AQ316B4F8C													ng/mL	0.88			UNKNOWN	mg	2		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2008/P200800002/40009300_22000AMX00011_A100_4.pdf#page=33 | https://www.pmda.go.jp/drugs/2008/P200800002/40009300_22000AMX00011_K150_2.pdf#page=17	Homo sapiens				suspension	Caucasian		6			false
3601	1787		ADULT	125564	367.5028	BLONANSERIN	Blonanserin	CCN1CCN(CC1)C2=NC3=C(CCCCCC3)C(=C2)C4=CC=C(F)C=C4	PLASMA	AQ316B4F8C							12		t	ng × h/mL	3.06		ng/mL	0.538			UNKNOWN	mg	2		STEADY-STATE	FED		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2008/P200800002/40009300_22000AMX00011_A100_4.pdf#page=33 | https://www.pmda.go.jp/drugs/2008/P200800002/40009300_22000AMX00011_K150_2.pdf#page=5	Homo sapiens		h	63.3	tablets, 19th dose (single dose on Day 10)			10			false
3602	1787		ADULT	125564	367.5028	BLONANSERIN	Blonanserin	CCN1CCN(CC1)C2=NC3=C(CCCCCC3)C(=C2)C4=CC=C(F)C=C4	PLASMA	AQ316B4F8C									∞	ng × h/mL	2.14		ng/mL	0.317			UNKNOWN	mg	2		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2008/P200800002/40009300_22000AMX00011_A100_4.pdf#page=33 | https://www.pmda.go.jp/drugs/2008/P200800002/40009300_22000AMX00011_K150_2.pdf#page=5	Homo sapiens		h	12.5	tablets			10			false
3603	1787		ADULT	125564	367.5028	BLONANSERIN	Blonanserin	CCN1CCN(CC1)C2=NC3=C(CCCCCC3)C(=C2)C4=CC=C(F)C=C4	PLASMA	AQ316B4F8C							24		t	ng × h/mL	2.6219		ng/mL	0.4399			UNKNOWN	mg	10		MULTIPLE	FASTED		day	1	n=7 for t1/2		HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2008/P200800002/40009300_22000AMX00011_A100_4.pdf#page=34 | https://www.pmda.go.jp/drugs/2008/P200800002/40009300_22000AMX00011_K150_2.pdf#page=27	Homo sapiens		h	4.8	suspension, Day 1	Caucasian		8			false
3604	1787		ADULT	125564	367.5028	BLONANSERIN	Blonanserin	CCN1CCN(CC1)C2=NC3=C(CCCCCC3)C(=C2)C4=CC=C(F)C=C4	PLASMA	AQ316B4F8C							24		t	ng × h/mL	0.8984		ng/mL	0.1457			UNKNOWN	mg	5		MULTIPLE	FASTED		day	1	n=6 for t1/2 and AUC		HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2008/P200800002/40009300_22000AMX00011_A100_4.pdf#page=34 | https://www.pmda.go.jp/drugs/2008/P200800002/40009300_22000AMX00011_K150_2.pdf#page=27	Homo sapiens		h	5.6	suspension, Day 1	Caucasian		8			false
3605	1787		ADULT	125564	367.5028	BLONANSERIN	Blonanserin	CCN1CCN(CC1)C2=NC3=C(CCCCCC3)C(=C2)C4=CC=C(F)C=C4	PLASMA	AQ316B4F8C							24		t	ng × h/mL	13.6851		ng/mL	2.4153			UNKNOWN	mg	25		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2008/P200800002/40009300_22000AMX00011_A100_4.pdf#page=34 | https://www.pmda.go.jp/drugs/2008/P200800002/40009300_22000AMX00011_K150_2.pdf#page=27	Homo sapiens		h	7	suspension, Day 1	Caucasian		8			false
3606	1787		ADULT	125564	367.5028	BLONANSERIN	Blonanserin	CCN1CCN(CC1)C2=NC3=C(CCCCCC3)C(=C2)C4=CC=C(F)C=C4	PLASMA	AQ316B4F8C							24		t	ng × h/mL	1.4432		ng/mL	0.1293			UNKNOWN	mg	5		MULTIPLE	FASTED		day	1	n=5 for t1/2 and AUC		HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2008/P200800002/40009300_22000AMX00011_A100_4.pdf#page=34 | https://www.pmda.go.jp/drugs/2008/P200800002/40009300_22000AMX00011_K150_2.pdf#page=27	Homo sapiens		h	12.6	suspension, Day 5	Caucasian		8			false
3607	1787		ADULT	125564	367.5028	BLONANSERIN	Blonanserin	CCN1CCN(CC1)C2=NC3=C(CCCCCC3)C(=C2)C4=CC=C(F)C=C4	PLASMA	AQ316B4F8C							24		t	ng × h/mL	2.766		ng/mL	0.338			UNKNOWN	mg	10		MULTIPLE	FASTED		day	1	n=7 for t1/2		HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2008/P200800002/40009300_22000AMX00011_A100_4.pdf#page=34 | https://www.pmda.go.jp/drugs/2008/P200800002/40009300_22000AMX00011_K150_2.pdf#page=27	Homo sapiens		h	8	suspension, Day 5	Caucasian		8			false
3608	1787		ADULT	125564	367.5028	BLONANSERIN	Blonanserin	CCN1CCN(CC1)C2=NC3=C(CCCCCC3)C(=C2)C4=CC=C(F)C=C4	PLASMA	AQ316B4F8C							12		t	pg × h/mL	833.9		pg/mL	136.9			UNKNOWN	mg	2		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2008/P200800002/40009300_22000AMX00011_A100_4.pdf#page=35 | https://www.pmda.go.jp/drugs/2008/P200800002/40009300_22000AMX00011_K150_2.pdf#page=40	Homo sapiens				tablets			12			false
3609	1787		ADULT	125564	367.5028	BLONANSERIN	Blonanserin	CCN1CCN(CC1)C2=NC3=C(CCCCCC3)C(=C2)C4=CC=C(F)C=C4	PLASMA	AQ316B4F8C							12		t	pg × h/mL	355.9		pg/mL	62.9			UNKNOWN	mg	2		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2008/P200800002/40009300_22000AMX00011_A100_4.pdf#page=35 | https://www.pmda.go.jp/drugs/2008/P200800002/40009300_22000AMX00011_K150_2.pdf#page=40	Homo sapiens				tablets			12			false
3610	1788		ADULT	4828	248.3208	PINDOLOL	PINDOLOL	CC(C)NCC(O)COC1=CC=CC2=C1C=CN2	PLASMA	BJ4HF6IU1D							58		t	ng × h/mL	75		ng/mL	7.9			UNKNOWN	mg	1		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1678271/	Homo sapiens							12	BOPINDOLOL		false
3611	1788		ADULT	4828	248.3208	PINDOLOL	PINDOLOL	CC(C)NCC(O)COC1=CC=CC2=C1C=CN2	PLASMA	BJ4HF6IU1D							216		t	ng × h/mL	234		ng/mL	2.2			UNKNOWN	mg	14		SINGLE	UNKNOWN						HEALTHY	Transdermal	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1678271/	Homo sapiens				7 days application			12	BOPINDOLOL		false
3612	1788		ADULT	4828	248.3208	PINDOLOL	PINDOLOL	CC(C)NCC(O)COC1=CC=CC2=C1C=CN2	PLASMA	BJ4HF6IU1D							132		t	ng × h/mL	153		ng/mL	2.4			UNKNOWN	mg	14		SINGLE	UNKNOWN						HEALTHY	Transdermal	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1678271/	Homo sapiens				3.5 days application			12	BOPINDOLOL		false
3613	1788		ADULT	4828	248.3208	PINDOLOL	PINDOLOL	CC(C)NCC(O)COC1=CC=CC2=C1C=CN2	PLASMA	BJ4HF6IU1D							216		t	ng × h/mL	232		ng/mL	2.1			UNKNOWN	mg	7		SINGLE	UNKNOWN						HEALTHY	Transdermal	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1678271/	Homo sapiens				7 days application			12	BOPINDOLOL		false
3614	1788		ADULT	4828	248.3208	PINDOLOL	PINDOLOL	CC(C)NCC(O)COC1=CC=CC2=C1C=CN2	PLASMA	BJ4HF6IU1D							36		t	ng × h/mL	64		ng/mL	7.1			UNKNOWN	mg	1		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1678271/	Homo sapiens							12	BOPINDOLOL		false
3615	1788		ADULT	4828	248.3208	PINDOLOL	PINDOLOL	CC(C)NCC(O)COC1=CC=CC2=C1C=CN2	PLASMA	BJ4HF6IU1D							216		t	ng × h/mL	353		ng/mL	3.2			UNKNOWN	mg	14		SINGLE	UNKNOWN						HEALTHY	Transdermal	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1678271/	Homo sapiens				7 days application			12	BOPINDOLOL		false
3616	1788		ADULT	4828	248.3208	PINDOLOL	PINDOLOL	CC(C)NCC(O)COC1=CC=CC2=C1C=CN2	PLASMA	BJ4HF6IU1D							216		t	ng × h/mL	547		ng/mL	5.1			HIGHEST STUDIED	mg	21		SINGLE	UNKNOWN						HEALTHY	Transdermal	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1678271/	Homo sapiens				7 days application			12	BOPINDOLOL		false
3617	1788		ADULT	4828	248.3208	PINDOLOL	PINDOLOL	CC(C)NCC(O)COC1=CC=CC2=C1C=CN2	PLASMA	BJ4HF6IU1D							72		t	ng × h/mL	40		ng/mL	1.5			UNKNOWN	mg	14		SINGLE	UNKNOWN						HEALTHY	Transdermal	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1678271/	Homo sapiens				1 day application			12	BOPINDOLOL		false
3618	1788		ADULT	4828	248.3208	PINDOLOL	PINDOLOL	CC(C)NCC(O)COC1=CC=CC2=C1C=CN2	PLASMA	BJ4HF6IU1D									∞	ng × h/mL	32.7		ng/mL	3.5			UNKNOWN	mg	0.5		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1678272/	Homo sapiens		h	6.6		hypertensive patients. moderate renal clearance.		6	BOPINDOLOL		false
3619	1788		ADULT	4828	248.3208	PINDOLOL	PINDOLOL	CC(C)NCC(O)COC1=CC=CC2=C1C=CN2	PLASMA	BJ4HF6IU1D									∞	ng × h/mL	19.9		ng/mL	2.4			UNKNOWN	mg	0.5		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1678272/	Homo sapiens		h	7.6		hypertensive patients. severe renal impairment.		6	BOPINDOLOL		false
3620	1788		ADULT	4828	248.3208	PINDOLOL	PINDOLOL	CC(C)NCC(O)COC1=CC=CC2=C1C=CN2	PLASMA	BJ4HF6IU1D									∞	ng × h/mL	22.4		ng/mL	2.8			UNKNOWN	mg	0.5		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1678272/	Homo sapiens		h	7.3	4 weeks dosing	hypertensive patients. normal renal function.		6	BOPINDOLOL		false
3621	1788		ADULT	4828	248.3208	PINDOLOL	PINDOLOL	CC(C)NCC(O)COC1=CC=CC2=C1C=CN2	PLASMA	BJ4HF6IU1D									∞	ng × h/mL	42.2		ng/mL	4.3			UNKNOWN	mg	0.5		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1678272/	Homo sapiens		h	9.9	4 weeks dosing	hypertensive patients. moderate renal clearance.		6	BOPINDOLOL		false
3622	1788		ADULT	4828	248.3208	PINDOLOL	PINDOLOL	CC(C)NCC(O)COC1=CC=CC2=C1C=CN2	PLASMA	BJ4HF6IU1D									∞	ng × h/mL	17.8		ng/mL	2.3			UNKNOWN	mg	0.5		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1678272/	Homo sapiens		h	6.2		hypertensive patients. normal renal function.		6	BOPINDOLOL		false
3623	1788		ADULT	4828	248.3208	PINDOLOL	PINDOLOL	CC(C)NCC(O)COC1=CC=CC2=C1C=CN2	PLASMA	BJ4HF6IU1D									?	μg × h/L	51.38						UNKNOWN	mg	1		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2868747/	Homo sapiens		h	4.75				9	BOPINDOLOL		false
3624	1788		ADULT	4828	248.3208	PINDOLOL	PINDOLOL	CC(C)NCC(O)COC1=CC=CC2=C1C=CN2	PLASMA	BJ4HF6IU1D									?	μg × h/L	129.38						UNKNOWN	mg	4		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2868747/	Homo sapiens		h	4.49				9	BOPINDOLOL		false
3625	1790		ADULT	130395	313.31	4-(4-Guanidinobenzoyloxy)phenylacetic acid		C1=CC(=CC=C1CC(=O)O)OC(=O)C2=CC=C(C=C2)N=C(N)N	PLASMA								4		t	ng × h/mL	683		ng/mL	371			UNKNOWN	mg	600		MULTIPLE	FASTED		day	4			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33982445/	Homo sapiens		h	1.58	Day 1	Day 1: 1st and 4t doses-fasted, 2nd and 3rd doses-fed		7	Camostat mesylate		false
3626	1790		ADULT	130395	313.31	4-(4-Guanidinobenzoyloxy)phenylacetic acid		C1=CC(=CC=C1CC(=O)O)OC(=O)C2=CC=C(C=C2)N=C(N)N	PLASMA								4		t	ng × h/mL	206		ng/mL	95.8			UNKNOWN	mg	600		MULTIPLE	FED		day	4			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33982445/	Homo sapiens		h	1.33	Day 3	Day 2: no dose, Days 3~9: 1st~3rd doses-fed, 4th dose-fasted		7	Camostat mesylate		false
3627	1790		ADULT	130395	313.31	4-(4-Guanidinobenzoyloxy)phenylacetic acid		C1=CC(=CC=C1CC(=O)O)OC(=O)C2=CC=C(C=C2)N=C(N)N	PLASMA								4		t	ng × h/mL	194		ng/mL	93.5			UNKNOWN	mg	600		MULTIPLE	FED		day	4			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33982445/	Homo sapiens		h	1.16	Day 9	Day 2: no dose, Days 3~9: 1st~3rd doses-fed, 4th dose-fasted		7	Camostat mesylate		false
3628	1790		ADULT	130395	313.31	4-(4-Guanidinobenzoyloxy)phenylacetic acid		C1=CC(=CC=C1CC(=O)O)OC(=O)C2=CC=C(C=C2)N=C(N)N	PLASMA								4		t	ng × h/mL	366		ng/mL	218			UNKNOWN	mg	600		MULTIPLE	UNKNOWN		day	4			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33982445/	Homo sapiens		h	1.05	Day 3	Day 2: no dose, Days 3~9: 1st~3rd doses-1 h before a meal, 4th dose-fasted		7	Camostat mesylate		false
3629	1790		ADULT	130395	313.31	4-(4-Guanidinobenzoyloxy)phenylacetic acid		C1=CC(=CC=C1CC(=O)O)OC(=O)C2=CC=C(C=C2)N=C(N)N	PLASMA								4		t	ng × h/mL	556		ng/mL	367			UNKNOWN	mg	600		MULTIPLE	UNKNOWN		day	4			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33982445/	Homo sapiens		h	0.962	Day 9	Day 2: no dose, Days 3~9: 1st~3rd doses-1 h before a meal, 4th dose-fasted		7	Camostat mesylate		false
3630	1790		ADULT	130395	313.31	4-(4-Guanidinobenzoyloxy)phenylacetic acid		C1=CC(=CC=C1CC(=O)O)OC(=O)C2=CC=C(C=C2)N=C(N)N	PLASMA								4		t	ng × h/mL	227		ng/mL	177			UNKNOWN	mg	600		MULTIPLE	UNKNOWN		day	4			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33982445/	Homo sapiens		h	1.35	Day 1	Day 1: 1st~3rd doses-30 min before a meal, 4th dose-fasted		7	Camostat mesylate		false
3631	1790		ADULT	130395	313.31	4-(4-Guanidinobenzoyloxy)phenylacetic acid		C1=CC(=CC=C1CC(=O)O)OC(=O)C2=CC=C(C=C2)N=C(N)N	PLASMA										?	ng × h/mL	10400		ng/mL	87.1			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/180188_3999003F1297_1_007_3F.pdf#page=31	Homo sapiens		min	100				5			false
3632	1790			2536	398.4125	CAMOSTAT	Camostat	CN(C)C(=O)COC(=O)CC1=CC=C(OC(=O)C2=CC=C(NC(N)=N)C=C2)C=C1	SERUM	0FD207WKDU																										Human serum protein binding: 25.8~28.2%	71.8				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/180188_3999003F1297_1_007_3F.pdf#page=33	Homo sapiens										false
3633	1794		ADULT	193653	179.194	CARBOCYSTEINE	Carbocysteine	N[C@@H](CSCC(O)=O)C(O)=O	PLASMA	740J2QX53R									∞	μg × h/mL	14.88		μg/mL	8.02			UNKNOWN	mg	750		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16724543/	Homo sapiens		h	2.02				18			false
3634	1794		ADULT	193653	179.194	CARBOCYSTEINE	Carbocysteine	N[C@@H](CSCC(O)=O)C(O)=O	PLASMA	740J2QX53R									∞	mg × h/L	63.15		mg/L	13.38			UNKNOWN	g	1.5		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7139067/	Homo sapiens		h	2.05	Syrup			12			false
3635	1794		ADULT	193653	179.194	CARBOCYSTEINE	Carbocysteine	N[C@@H](CSCC(O)=O)C(O)=O	PLASMA	740J2QX53R									∞	μg × h/mL	22.8		μg/mL	5.6			UNKNOWN	mg	1000		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://scholar.google.com/scholar?cluster=7613016307870987923&hl=ja&as_sdt=0,33	Homo sapiens		h	1.5				20			false
3636	1796		ADULT	5282138	492.5204	CILNIDIPINE	Cilnidipine	COCCOC(=O)C1=C(C)NC(C)=C(C1C2=CC(=CC=C2)[N ]([O-])=O)C(=O)OC\\C=C\\C3=CC=CC=C3	PLASMA	97T5AZ1JIP							24		t	ng × h/mL	11.6		ng/mL	2.4			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/340409_2149037F1105_1_003_1F.pdf#page=17	Homo sapiens		h	2.8				29			false
3637	1796		ADULT	5282138	492.5204	CILNIDIPINE	Cilnidipine	COCCOC(=O)C1=C(C)NC(C)=C(C1C2=CC(=CC=C2)[N ]([O-])=O)C(=O)OC\\C=C\\C3=CC=CC=C3	PLASMA	97T5AZ1JIP							24		t	ng × h/mL	46.1		ng/mL	8.6			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/340409_2149037F1105_1_003_1F.pdf#page=18	Homo sapiens		h	4.9				28			false
3638	1796		ADULT	5282138	492.5204	CILNIDIPINE	Cilnidipine	COCCOC(=O)C1=C(C)NC(C)=C(C1C2=CC(=CC=C2)[N ]([O-])=O)C(=O)OC\\C=C\\C3=CC=CC=C3	PLASMA	97T5AZ1JIP							24		t	ng × h/mL	23.7		ng/mL	4.7			UNKNOWN	mg	5		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/111890_2149037F1032_2_008_2F.pdf#page=38	Homo sapiens							6			false
3639	1796		ADULT	5282138	492.5204	CILNIDIPINE	Cilnidipine	COCCOC(=O)C1=C(C)NC(C)=C(C1C2=CC(=CC=C2)[N ]([O-])=O)C(=O)OC\\C=C\\C3=CC=CC=C3	PLASMA	97T5AZ1JIP							24		t	ng × h/mL	60.1		ng/mL	15.7			UNKNOWN	mg	20		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/111890_2149037F1032_2_008_2F.pdf#page=38	Homo sapiens							6			false
3640	1796		ADULT	5282138	492.5204	CILNIDIPINE	Cilnidipine	COCCOC(=O)C1=C(C)NC(C)=C(C1C2=CC(=CC=C2)[N ]([O-])=O)C(=O)OC\\C=C\\C3=CC=CC=C3	PLASMA	97T5AZ1JIP							24		t	ng × h/mL	27.5		ng/mL	5.4			UNKNOWN	mg	10		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/111890_2149037F1032_2_008_2F.pdf#page=38	Homo sapiens							6			false
3641	1796		ADULT	5282138	492.5204	CILNIDIPINE	Cilnidipine	COCCOC(=O)C1=C(C)NC(C)=C(C1C2=CC(=CC=C2)[N ]([O-])=O)C(=O)OC\\C=C\\C3=CC=CC=C3	PLASMA	97T5AZ1JIP							24		∞	ng × h/mL	51.4		ng/mL	9.5			UNKNOWN	mg	10		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/111890_2149037F1032_2_008_2F.pdf#page=38	Homo sapiens		h	5.2	Day 1			6			false
3642	1796		ADULT	5282138	492.5204	CILNIDIPINE	Cilnidipine	COCCOC(=O)C1=C(C)NC(C)=C(C1C2=CC(=CC=C2)[N ]([O-])=O)C(=O)OC\\C=C\\C3=CC=CC=C3	PLASMA	97T5AZ1JIP							24		∞	ng × h/mL	101.8		ng/mL	13.5			UNKNOWN	mg	10		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/111890_2149037F1032_2_008_2F.pdf#page=38	Homo sapiens				Day 4			6			false
3643	1796		ADULT	5282138	492.5204	CILNIDIPINE	Cilnidipine	COCCOC(=O)C1=C(C)NC(C)=C(C1C2=CC(=CC=C2)[N ]([O-])=O)C(=O)OC\\C=C\\C3=CC=CC=C3	PLASMA	97T5AZ1JIP							24		∞	ng × h/mL	95.5		ng/mL	16.5			UNKNOWN	mg	10		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/111890_2149037F1032_2_008_2F.pdf#page=38	Homo sapiens		h	8.1	Day 7			6			false
3644	1796			5282138	492.5204	CILNIDIPINE	Cilnidipine	COCCOC(=O)C1=C(C)NC(C)=C(C1C2=CC(=CC=C2)[N ]([O-])=O)C(=O)OC\\C=C\\C3=CC=CC=C3	SERUM	97T5AZ1JIP																										Human serum protein binding: 99.3% (0.5 mcg/mL)	0.7				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/111890_2149037F1032_2_008_2F.pdf#page=41	Homo sapiens										false
3645	1797		ADULT	1547484	368.5139	CINNARIZINE	Cinnarizine	C(\\C=C\\C1=CC=CC=C1)N2CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4	PLASMA	3DI2E1X18L									?	ng × h/mL	473		ng/mL	53.1			UNKNOWN	mg	25		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26775868/	Homo sapiens		h	6.3				10			false
3646	1797		ADULT	1547484	368.5139	CINNARIZINE	Cinnarizine	C(\\C=C\\C1=CC=CC=C1)N2CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4	PLASMA	3DI2E1X18L									?	ng × h/mL	301		ng/mL	41.4			UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26775868/	Homo sapiens		h	8.5				10			false
3647	1797		ADULT	1547484	368.5139	CINNARIZINE	Cinnarizine	C(\\C=C\\C1=CC=CC=C1)N2CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4	PLASMA	3DI2E1X18L									∞	ng × h/mL	4437		ng/mL	275			UNKNOWN	mg	75		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8328998/	Homo sapiens		h	23.6				6			false
3648	1797		ADULT	1547484	368.5139	CINNARIZINE	Cinnarizine	C(\\C=C\\C1=CC=CC=C1)N2CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4	PLASMA	3DI2E1X18L							12		t	ng × h/mL	5074						UNKNOWN	mg	75		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8328998/	Homo sapiens				Day 15 (29th dose)			5			false
3649	1797			1547484	368.5139	CINNARIZINE	Cinnarizine	C(\\C=C\\C1=CC=CC=C1)N2CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4	PLASMA	3DI2E1X18L																										The plasma protein binding of cinnarizine is 91%.	9				OTHER GOV'T	https://www.medicines.org.uk/emc/search?q=CINNARIZINE | https://mhraproducts4853.blob.core.windows.net/docs/c2da91b40d9fa5e87f4e8c0fa45abf0c622ee820#page=5	Homo sapiens										false
3650	1797		ADULT	1547484	368.5139	CINNARIZINE	Cinnarizine	C(\\C=C\\C1=CC=CC=C1)N2CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4	PLASMA	3DI2E1X18L							24		t	ng × h/mL	583		ng/mL	73.7			UNKNOWN	mg	50		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	EXPERIMENT	https://www.sciencedirect.com/science/article/pii/S0378434700817211	Homo sapiens		h	4.4	Tablets			6			false
3651	1797		ADULT	1547484	368.5139	CINNARIZINE	Cinnarizine	C(\\C=C\\C1=CC=CC=C1)N2CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4	PLASMA	3DI2E1X18L									?	ng × h/mL	855		ng/mL	122			UNKNOWN	mg	75		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://www.tandfonline.com/doi/abs/10.1080/01483918408068873	Homo sapiens		h	2.7	Capsule			6			false
3652	1798		ADULT	2763	289.154	CIPROFIBRATE	Ciprofibrate	CC(C)(OC1=CC=C(C=C1)C2CC2(Cl)Cl)C(O)=O	PLASMA	F8252JGO9S							168		t	μg × h/mL	818.58		μg/mL	20.93			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21763220/	Homo sapiens							22			false
3653	1798		ADULT	2763	289.154	CIPROFIBRATE	Ciprofibrate	CC(C)(OC1=CC=C(C=C1)C2CC2(Cl)Cl)C(O)=O	PLASMA	F8252JGO9S							168		t	μg × h/mL	1370		μg/mL	24			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2611089/	Homo sapiens		h	81				6			false
3654	1798		ADULT	2763	289.154	CIPROFIBRATE	Ciprofibrate	CC(C)(OC1=CC=C(C=C1)C2CC2(Cl)Cl)C(O)=O	PLASMA	F8252JGO9S							168		t	μg × h/mL	1759		μg/mL	22			UNKNOWN	mg	100		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2611089/	Homo sapiens		h	117		Mild renal impairment		6			false
3655	1798		ADULT	2763	289.154	CIPROFIBRATE	Ciprofibrate	CC(C)(OC1=CC=C(C=C1)C2CC2(Cl)Cl)C(O)=O	PLASMA	F8252JGO9S							168		t	μg × h/mL	2445		μg/mL	17			UNKNOWN	mg	100		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2611089/	Homo sapiens		h	172		Severe renal impairment		6			false
3656	1798		ADULT	2763	289.154	CIPROFIBRATE	Ciprofibrate	CC(C)(OC1=CC=C(C=C1)C2CC2(Cl)Cl)C(O)=O	PLASMA	F8252JGO9S							78		t	μg × h/mL	2431						UNKNOWN	mg	100		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2611089/	Homo sapiens		h	154	Ciprofibrate was administered 24h before starting a period of haemodialysis which had a mean duration of 5h.	Severe chronic renal impairment requiring routine haemodialysis		5			false
3657	1798		ADULT	2763	289.154	CIPROFIBRATE	Ciprofibrate	CC(C)(OC1=CC=C(C=C1)C2CC2(Cl)Cl)C(O)=O	PLASMA	F8252JGO9S							24		t	μg × h/mL	1666		μg/mL	66			UNKNOWN	mg	100		STEADY-STATE	FED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8831918/	Homo sapiens		h	104				7			false
3658	1798		ADULT	2763	289.154	CIPROFIBRATE	Ciprofibrate	CC(C)(OC1=CC=C(C=C1)C2CC2(Cl)Cl)C(O)=O	PLASMA	F8252JGO9S							24		t	μg × h/mL	2832		μg/mL	111			UNKNOWN	mg	200		STEADY-STATE	FED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8831918/	Homo sapiens		h	96				6			false
3659	1798			2763	289.154	CIPROFIBRATE	Ciprofibrate	CC(C)(OC1=CC=C(C=C1)C2CC2(Cl)Cl)C(O)=O	PLASMA	F8252JGO9S																										The plasma protein binding of ciprofibrate is about 98% in the therapeutic range.	2				REVIEW	https://www.medicines.org.uk/emc/product/4997/smpc#PHARMACOKINETIC_PROPS	Homo sapiens										false
3660	1799		ADULT	9880	416.938	CYPROTERONE ACETATE	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O	PLASMA	4KM2BN5JHF													ng/mL	406			RECOMMENDED	mg	300		STEADY-STATE	UNKNOWN		week	1			UNKNOWN	Intramuscular	MALE	DRUG LABEL	https://www.bayer.ca/omr/online/androcur-pm-en.pdf	Homo sapiens		day	3.9							false
3661	1799		ADULT	9880	416.938	CYPROTERONE ACETATE	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O	PLASMA	4KM2BN5JHF									∞	ng × h/mL	70						RECOMMENDED	mg	300		STEADY-STATE	UNKNOWN		week	1			UNHEALTHY	Intramuscular	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/6458025	Homo sapiens										false
3662	1800		ADULT	5311064	317.3795	DENOPAMINE	Denopamine	COC1=C(OC)C=C(CCNC[C@H](O)C2=CC=C(O)C=C2)C=C1	BLOOD	V5F60UPD8P									?	ng × h/mL	65.3		ng/mL	10.7			UNKNOWN	mg	10		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.jstage.jst.go.jp/article/jsdt1985/24/3/24_3_322/_article/-char/en	Homo sapiens		h	4.5		Renal impairment patients with hemodialysis		5			false
3663	1800		ADULT	5311064	317.3795	DENOPAMINE	Denopamine	COC1=C(OC)C=C(CCNC[C@H](O)C2=CC=C(O)C=C2)C=C1	BLOOD	V5F60UPD8P									?	ng × h/mL	137		ng/mL	22.4			UNKNOWN	mg	10		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.jstage.jst.go.jp/article/jsdt1985/24/3/24_3_322/_article/-char/en	Homo sapiens		h	4.8		Renal impairment patients with hemodialysis (HD day)		5			false
3664	1800		ADULT	5311064	317.3795	DENOPAMINE	Denopamine	COC1=C(OC)C=C(CCNC[C@H](O)C2=CC=C(O)C=C2)C=C1	BLOOD	V5F60UPD8P									?	ng × h/mL	72.2		ng/mL	11.6			UNKNOWN	mg	10		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.jstage.jst.go.jp/article/jsdt1985/24/3/24_3_322/_article/-char/en	Homo sapiens		h	5.4		Renal impairment patients, 20=< Clcr <50 mL/min		5			false
3665	1800		ADULT	5311064	317.3795	DENOPAMINE	Denopamine	COC1=C(OC)C=C(CCNC[C@H](O)C2=CC=C(O)C=C2)C=C1	BLOOD	V5F60UPD8P									?	ng × h/mL	55.6		ng/mL	7.8			UNKNOWN	mg	10		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.jstage.jst.go.jp/article/jsdt1985/24/3/24_3_322/_article/-char/en	Homo sapiens		h	4		Renal impairment patients, Clcr <20 mL/min		5			false
3666	1800		ADULT	5311064	317.3795	DENOPAMINE	Denopamine	COC1=C(OC)C=C(CCNC[C@H](O)C2=CC=C(O)C=C2)C=C1	BLOOD	V5F60UPD8P									?	ng × h/mL	80.8		ng/mL	14.2			UNKNOWN	mg	10		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.jstage.jst.go.jp/article/jsdt1985/24/3/24_3_322/_article/-char/en	Homo sapiens		h	5		Renal impairment patients, 50=< Clcr <80 mL/min		5			false
3667	1800		ADULT	5311064	317.3795	DENOPAMINE	Denopamine	COC1=C(OC)C=C(CCNC[C@H](O)C2=CC=C(O)C=C2)C=C1	BLOOD	V5F60UPD8P									?	ng × h/mL	65.3		ng/mL	10.7			UNKNOWN	mg	10		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.jstage.jst.go.jp/article/jsdt1985/24/3/24_3_322/_article/-char/en	Homo sapiens		h	4.5		Renal impairment patients with hemodialysis (non-HD day)		5			false
3668	1800		ADULT	5311064	317.3795	DENOPAMINE	Denopamine	COC1=C(OC)C=C(CCNC[C@H](O)C2=CC=C(O)C=C2)C=C1	BLOOD	V5F60UPD8P									?	ng × h/mL	43.6		ng/mL	12.3			UNKNOWN	mg	10		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.jstage.jst.go.jp/article/jsdt1985/24/3/24_3_322/_article/-char/en	Homo sapiens		h	3.6		Renal impairment patients, Clcr >=80 mL/min		6			false
3669	1800			5311064	317.3795	DENOPAMINE	Denopamine	COC1=C(OC)C=C(CCNC[C@H](O)C2=CC=C(O)C=C2)C=C1	PLASMA	V5F60UPD8P																										Human plasma protein binding: 43%	57				DRUG LABEL	https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/400315_2119004C1032_1_06#page=2	Homo sapiens										false
3670	1800		ADULT	5311064	317.3795	DENOPAMINE	Denopamine	COC1=C(OC)C=C(CCNC[C@H](O)C2=CC=C(O)C=C2)C=C1	PLASMA	V5F60UPD8P									∞	ng × h/mL	68.3		ng/mL	19.2			UNKNOWN	mg	10		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	DRUG LABEL	https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/400315_2119004C1032_1_06#page=2 | https://pubmed.ncbi.nlm.nih.gov/2229268/	Homo sapiens		h	4.02	5mg x 2 tablets			9			false
3671	1800		ADULT	5311064	317.3795	DENOPAMINE	Denopamine	COC1=C(OC)C=C(CCNC[C@H](O)C2=CC=C(O)C=C2)C=C1	PLASMA	V5F60UPD8P									∞	ng × h/mL	57.2		ng/mL	15.5			UNKNOWN	mg	10		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	DRUG LABEL	https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/400315_2119004C1032_1_06#page=2 | https://pubmed.ncbi.nlm.nih.gov/2229268/	Homo sapiens		h	4	10mg x 1 tablets			9			false
3672	1800		ADULT	5311064	317.3795	DENOPAMINE	Denopamine	COC1=C(OC)C=C(CCNC[C@H](O)C2=CC=C(O)C=C2)C=C1	PLASMA	V5F60UPD8P									∞	ng × h/mL	59.3		ng/mL	16.9			UNKNOWN	mg	10		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	DRUG LABEL	https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/400315_2119004C1032_1_06#page=2 | https://pubmed.ncbi.nlm.nih.gov/2229268/	Homo sapiens		h	3.67	200mg fine granules			9			false
3673	1801		NEWBORN	53708	248.301	ENOXIMONE	Enoximone	CSC1=CC=C(C=C1)C(=O)C2=C(C)NC(=O)N2	SERUM	C7Z4ITI7L7													ng/mL	1536			UNKNOWN	μg/kg/min	10		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10992825/	Homo sapiens		h	6.4	Approximately 10 min before the anticipated discontinuation of CPB, a loading dose of enoximone 1 mg kg- 1 was given over 2 min into a central vein. An infusion of enoximone 10 ug kg- 1 min-1 was then started.	Infants (median 6.0 weeks) who required inotropic support following cardiac surgery		20			false
3674	1801		NEWBORN	158474	264.3	Enoximone sulfoxide		CC1=C(NC(=O)N1)C(=O)C2=CC=C(C=C2)S(=O)C	SERUM																		UNKNOWN	μg/kg/min	10		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10992825/	Homo sapiens		h	7.4	Approximately 10 min before the anticipated discontinuation of CPB, a loading dose of enoximone 1 mg kg- 1 was given over 2 min into a central vein. An infusion of enoximone 10 ug kg- 1 min-1 was then started.	Infants (median 6.0 weeks) who required inotropic support following cardiac surgery		20			false
3675	1801		NEWBORN	53708	248.301	ENOXIMONE	Enoximone	CSC1=CC=C(C=C1)C(=O)C2=C(C)NC(=O)N2	SERUM	C7Z4ITI7L7													ng/mL	1483			UNKNOWN	μg/kg/min	10		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10992825/	Homo sapiens		h	5.2	Approximately 10 min before the anticipated discontinuation of CPB, a loading dose of enoximone 1 mg kg- 1 was given over 2 min into a central vein. An infusion of enoximone 10 ug kg- 1 min-1 was then started.	Patients with normal hepatic function (Infants (median 6.0 weeks) who required inotropic support following cardiac surgery)		14			false
3676	1801		NEWBORN	158474	264.3	Enoximone sulfoxide		CC1=C(NC(=O)N1)C(=O)C2=CC=C(C=C2)S(=O)C	SERUM																		UNKNOWN	μg/kg/min	10		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10992825/	Homo sapiens		h	6.9	Approximately 10 min before the anticipated discontinuation of CPB, a loading dose of enoximone 1 mg kg- 1 was given over 2 min into a central vein. An infusion of enoximone 10 ug kg- 1 min-1 was then started.	Patients with normal renal function (Infants (median 6.0 weeks) who required inotropic support following cardiac surgery)		16			false
3677	1801		NEWBORN	53708	248.301	ENOXIMONE	Enoximone	CSC1=CC=C(C=C1)C(=O)C2=C(C)NC(=O)N2	SERUM	C7Z4ITI7L7													ng/mL	2974			UNKNOWN	μg/kg/min	10		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10992825/	Homo sapiens		h	7.6	Approximately 10 min before the anticipated discontinuation of CPB, a loading dose of enoximone 1 mg kg- 1 was given over 2 min into a central vein. An infusion of enoximone 10 ug kg- 1 min-1 was then started.	Patients with hepatic dysfunction (Infants (median 6.0 weeks) who required inotropic support following cardiac surgery)		6			false
3678	1801		NEWBORN	158474	264.3	Enoximone sulfoxide		CC1=C(NC(=O)N1)C(=O)C2=CC=C(C=C2)S(=O)C	SERUM																		UNKNOWN	μg/kg/min	10		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10992825/	Homo sapiens		h	16.2	Approximately 10 min before the anticipated discontinuation of CPB, a loading dose of enoximone 1 mg kg- 1 was given over 2 min into a central vein. An infusion of enoximone 10 ug kg- 1 min-1 was then started.	Patients with renal dysfunction (Infants (median 6.0 weeks) who required inotropic support following cardiac surgery)		3			false
3679	1801		ADULT	158474	264.3	Enoximone sulfoxide	Enoximone sulfoxide	CC1=C(NC(=O)N1)C(=O)C2=CC=C(C=C2)S(=O)C	PLASMA														ng/mL	1021			UNKNOWN	mg	50		STEADY-STATE	FED		day	3			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1831816/	Homo sapiens					moderate-to-severe heart failure patients		10			false
3680	1801		ADULT	53708	248.301	ENOXIMONE	Enoximone	CSC1=CC=C(C=C1)C(=O)C2=C(C)NC(=O)N2	PLASMA	C7Z4ITI7L7													ng/mL	190			UNKNOWN	mg	100		STEADY-STATE	FED		day	3			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1831816/	Homo sapiens					moderate-to-severe heart failure patients		10			false
3681	1801		ADULT	158474	264.3	Enoximone sulfoxide		CC1=C(NC(=O)N1)C(=O)C2=CC=C(C=C2)S(=O)C	PLASMA														ng/mL	1074			UNKNOWN	mg	100		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1831816/	Homo sapiens		h	5.88		moderate-to-severe heart failure patients		10			false
3682	1801		ADULT	158474	264.3	Enoximone sulfoxide	Enoximone sulfoxide	CC1=C(NC(=O)N1)C(=O)C2=CC=C(C=C2)S(=O)C	PLASMA														ng/mL	1653			UNKNOWN	mg	100		STEADY-STATE	FED		day	3			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1831816/	Homo sapiens					moderate-to-severe heart failure patients		10			false
3683	1801		ADULT	53708	248.301	ENOXIMONE	Enoximone	CSC1=CC=C(C=C1)C(=O)C2=C(C)NC(=O)N2	PLASMA	C7Z4ITI7L7													ng/mL	182			UNKNOWN	mg	100		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1831816/	Homo sapiens		h	6.12		moderate-to-severe heart failure patients		10			false
3684	1801		ADULT	53708	248.301	ENOXIMONE	Enoximone	CSC1=CC=C(C=C1)C(=O)C2=C(C)NC(=O)N2	PLASMA	C7Z4ITI7L7													ng/mL	115			UNKNOWN	mg	50		STEADY-STATE	FED		day	3			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1831816/	Homo sapiens					moderate-to-severe heart failure patients		10			false
3685	1801		ADULT	53708	248.301	ENOXIMONE	Enoximone	CSC1=CC=C(C=C1)C(=O)C2=C(C)NC(=O)N2	PLASMA	C7Z4ITI7L7																	UNKNOWN	mg/kg	1		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2960700/	Homo sapiens		h	2.9	Dose: 1 or 2 mg/kg	Patients with congestive heart failure		7			false
3686	1801		ADULT	53708	248.301	ENOXIMONE	Enoximone	CSC1=CC=C(C=C1)C(=O)C2=C(C)NC(=O)N2	PLASMA	C7Z4ITI7L7																	UNKNOWN	mg	75		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2960700/	Homo sapiens		h	2.3				2			false
3687	1801		ADULT	53708	248.301	ENOXIMONE	Enoximone	CSC1=CC=C(C=C1)C(=O)C2=C(C)NC(=O)N2	PLASMA	C7Z4ITI7L7																						UNKNOWN				Enoximone is 65% bound to albumin, which accounts for most of the drug bound to human plasma protein.	35	UNKNOWN		UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2960700/	Homo sapiens										false
3688	1801		ADULT	53708	248.301	ENOXIMONE	Enoximone	CSC1=CC=C(C=C1)C(=O)C2=C(C)NC(=O)N2	PLASMA	C7Z4ITI7L7																						UNKNOWN				ultrafiltration, average from three volunteers	27.8	HEALTHY		UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3244103/	Homo sapiens							3			false
3689	1801		ADULT	53708	248.301	ENOXIMONE	Enoximone	CSC1=CC=C(C=C1)C(=O)C2=C(C)NC(=O)N2	PLASMA	C7Z4ITI7L7									?	μg × h/mL	0.22		μg/mL	0.31			UNKNOWN	mg/kg	0.25		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7738792/	Homo sapiens		h	2.07				6			false
3690	1801		ADULT	53708	248.301	ENOXIMONE	Enoximone	CSC1=CC=C(C=C1)C(=O)C2=C(C)NC(=O)N2	PLASMA	C7Z4ITI7L7									?	μg × h/mL	2.74		μg/mL	5.38			UNKNOWN	mg/kg	2		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7738792/	Homo sapiens		h	2.72				6			false
3691	1801		ADULT	53708	248.301	ENOXIMONE	Enoximone	CSC1=CC=C(C=C1)C(=O)C2=C(C)NC(=O)N2	PLASMA	C7Z4ITI7L7									?	μg × h/mL	1.04		μg/mL	3.4			UNKNOWN	mg/kg	1		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7738792/	Homo sapiens		h	1.96				6			false
3692	1801		ADULT	158474	264.3	Enoximone sulfoxide		CC1=C(NC(=O)N1)C(=O)C2=CC=C(C=C2)S(=O)C	PLASMA										?	μg × h/mL	1.08		μg/mL	0.53			UNKNOWN	mg/kg	0.5		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7738792/	Homo sapiens		h	2.1				6			false
3693	1801		ADULT	158474	264.3	Enoximone sulfoxide		CC1=C(NC(=O)N1)C(=O)C2=CC=C(C=C2)S(=O)C	PLASMA										?	μg × h/mL	2.18		μg/mL	1.08			UNKNOWN	mg/kg	1		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7738792/	Homo sapiens		h	1.99				6			false
3694	1801		ADULT	53708	248.301	ENOXIMONE	Enoximone	CSC1=CC=C(C=C1)C(=O)C2=C(C)NC(=O)N2	PLASMA	C7Z4ITI7L7									?	μg × h/mL	0.96		μg/mL	2.35			UNKNOWN	mg/kg	1		MULTIPLE	UNKNOWN		3 hours	1			HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7738792/	Homo sapiens		h	2.1	4 cosecutive doses			6			false
3695	1801		ADULT	53708	248.301	ENOXIMONE	Enoximone	CSC1=CC=C(C=C1)C(=O)C2=C(C)NC(=O)N2	PLASMA	C7Z4ITI7L7									?	μg × h/mL	2.21		μg/mL	0.51			UNKNOWN	μg/kg/min	10		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7738792/	Homo sapiens		h	2.66	4-h infusion			5			false
3696	1801		ADULT	158474	264.3	Enoximone sulfoxide		CC1=C(NC(=O)N1)C(=O)C2=CC=C(C=C2)S(=O)C	PLASMA										?	μg × h/mL	4.2		μg/mL	0.8			UNKNOWN	μg/kg/min	10		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7738792/	Homo sapiens		h	2.49	4-h infusion			5			false
3697	1801		ADULT	158474	264.3	Enoximone sulfoxide		CC1=C(NC(=O)N1)C(=O)C2=CC=C(C=C2)S(=O)C	PLASMA										?	μg × h/mL	1.97		μg/mL	1.05			UNKNOWN	mg/kg	1		MULTIPLE	UNKNOWN		3 hours	1			HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7738792/	Homo sapiens		h	2.03	4 cosecutive doses			6			false
3698	1801		ADULT	53708	248.301	ENOXIMONE	Enoximone	CSC1=CC=C(C=C1)C(=O)C2=C(C)NC(=O)N2	PLASMA	C7Z4ITI7L7									?	μg × h/mL	0.48		μg/mL	1.82			UNKNOWN	mg/kg	0.5		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7738792/	Homo sapiens		h	1.94				6			false
3699	1801		ADULT	158474	264.3	Enoximone sulfoxide		CC1=C(NC(=O)N1)C(=O)C2=CC=C(C=C2)S(=O)C	PLASMA										?	μg × h/mL	0.43		μg/mL	0.23			UNKNOWN	mg/kg	0.25		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7738792/	Homo sapiens		h	2.02				6			false
3700	1801		ADULT	158474	264.3	Enoximone sulfoxide		CC1=C(NC(=O)N1)C(=O)C2=CC=C(C=C2)S(=O)C	PLASMA										?	μg × h/mL	4.87		μg/mL	1.82			UNKNOWN	mg/kg	2		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7738792/	Homo sapiens		h	2.16				6			false
3701	1802		ADULT	123619	358.842	ETORICOXIB	Etoricoxib	CC1=NC=C(C=C1)C2=NC=C(Cl)C=C2C3=CC=C(C=C3)S(C)(=O)=O	PLASMA	WRX4NFY03R									∞	μg × h/mL	3.47		ng/mL	201			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11583479/	Homo sapiens		h	22.5				12			false
3702	1802		ADULT	123619	358.842	ETORICOXIB	Etoricoxib	CC1=NC=C(C=C1)C2=NC=C(Cl)C=C2C3=CC=C(C=C3)S(C)(=O)=O	PLASMA	WRX4NFY03R									∞	μg × h/mL	6.7		ng/mL	411			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11583479/	Homo sapiens		h	21.9				12			false
3703	1802		ADULT	123619	358.842	ETORICOXIB	Etoricoxib	CC1=NC=C(C=C1)C2=NC=C(Cl)C=C2C3=CC=C(C=C3)S(C)(=O)=O	PLASMA	WRX4NFY03R									∞	μg × h/mL	13.29		ng/mL	788			UNKNOWN	mg	40		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11583479/	Homo sapiens		h	22.3				12			false
3704	1802		ADULT	123619	358.842	ETORICOXIB	Etoricoxib	CC1=NC=C(C=C1)C2=NC=C(Cl)C=C2C3=CC=C(C=C3)S(C)(=O)=O	PLASMA	WRX4NFY03R									∞	μg × h/mL	40.56		ng/mL	2186			HIGHEST STUDIED	mg	120		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11583479/	Homo sapiens		h	21.7				12			false
3705	1802		ADULT	123619	358.842	ETORICOXIB	Etoricoxib	CC1=NC=C(C=C1)C2=NC=C(Cl)C=C2C3=CC=C(C=C3)S(C)(=O)=O	PLASMA	WRX4NFY03R									∞	μg × h/mL	1.55		ng/mL	95			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11583479/	Homo sapiens		h	22.2				12			false
3706	1802		ADULT	123619	358.842	ETORICOXIB	Etoricoxib	CC1=NC=C(C=C1)C2=NC=C(Cl)C=C2C3=CC=C(C=C3)S(C)(=O)=O	PLASMA	WRX4NFY03R							24		t	μg × h/mL	37.83		μg/mL	3.59			UNKNOWN	mg	120		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12638395/	Homo sapiens		h	25.2				24			false
3707	1802		ADULT	123619	358.842	ETORICOXIB	Etoricoxib	CC1=NC=C(C=C1)C2=NC=C(Cl)C=C2C3=CC=C(C=C3)S(C)(=O)=O	PLASMA	WRX4NFY03R									∞	μg × h/mL	18.57		μg/mL	1.27			UNKNOWN	mg	60		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12638395/	Homo sapiens		h	29.9				12			false
3708	1802		ADULT	123619	358.842	ETORICOXIB	Etoricoxib	CC1=NC=C(C=C1)C2=NC=C(Cl)C=C2C3=CC=C(C=C3)S(C)(=O)=O	PLASMA	WRX4NFY03R									∞	μg × h/mL	76.1		μg/mL	4.37			HIGHEST STUDIED	mg	240		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12638395/	Homo sapiens		h	27.6				12			false
3709	1802		ADULT	123619	358.842	ETORICOXIB	Etoricoxib	CC1=NC=C(C=C1)C2=NC=C(Cl)C=C2C3=CC=C(C=C3)S(C)(=O)=O	PLASMA	WRX4NFY03R							24		t	μg × h/mL	18.43		μg/mL	2.05			UNKNOWN	mg	120		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12638395/	Homo sapiens		h	23.8				24			false
3710	1802		ADULT	123619	358.842	ETORICOXIB	Etoricoxib	CC1=NC=C(C=C1)C2=NC=C(Cl)C=C2C3=CC=C(C=C3)S(C)(=O)=O	PLASMA	WRX4NFY03R									∞	μg × h/mL	40.16		μg/mL	1.56			UNKNOWN	mg	120		SINGLE	HIGH-FAT						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12638395/	Homo sapiens		h	27.6				12			false
3711	1802		ADULT	123619	358.842	ETORICOXIB	Etoricoxib	CC1=NC=C(C=C1)C2=NC=C(Cl)C=C2C3=CC=C(C=C3)S(C)(=O)=O	PLASMA	WRX4NFY03R									∞	μg × h/mL	41.35		μg/mL	2.43			UNKNOWN	mg	120		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12638395/	Homo sapiens		h	28.7				12			false
3712	1802		ADULT	123619	358.842	ETORICOXIB	Etoricoxib	CC1=NC=C(C=C1)C2=NC=C(Cl)C=C2C3=CC=C(C=C3)S(C)(=O)=O	PLASMA	WRX4NFY03R									∞	μg × h/mL	9.08		μg/mL	0.53			UNKNOWN	mg	30		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12638395/	Homo sapiens		h	28.5				12			false
3713	1802		ADULT	123619	358.842	ETORICOXIB	Etoricoxib	CC1=NC=C(C=C1)C2=NC=C(Cl)C=C2C3=CC=C(C=C3)S(C)(=O)=O	PLASMA	WRX4NFY03R									∞	μg × h/mL	35.84		μg/mL	2.14			UNKNOWN	mg	120		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12638395/	Homo sapiens		h	28.4				12			false
3714	1802		ADULT	123619	358.842	ETORICOXIB	Etoricoxib	CC1=NC=C(C=C1)C2=NC=C(Cl)C=C2C3=CC=C(C=C3)S(C)(=O)=O	PLASMA	WRX4NFY03R							24		t	μg × h/mL	17.77		ng/mL	1694			UNKNOWN	mg	60		STEADY-STATE	FASTED		day	1	The average in vitro protein binding was 91.9%.	18.1	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/14517196/	Homo sapiens		h	21.2				58			false
3715	1802		ADULT	123619	358.842	ETORICOXIB	Etoricoxib	CC1=NC=C(C=C1)C2=NC=C(Cl)C=C2C3=CC=C(C=C3)S(C)(=O)=O	PLASMA	WRX4NFY03R							24		t	μg × h/mL	20.66		ng/mL	1654			UNKNOWN	mg	60		STEADY-STATE	FASTED		day	1	The average in vitro protein binding was 89.6% in patients with mild hepatic insufficiency.	10.4	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/14517196/	Homo sapiens		h	24.7		Mild hepatic impairment		9			false
3716	1802		ADULT	123619	358.842	ETORICOXIB	Etoricoxib	CC1=NC=C(C=C1)C2=NC=C(Cl)C=C2C3=CC=C(C=C3)S(C)(=O)=O	PLASMA	WRX4NFY03R							24		t	μg × h/mL	15.92		ng/mL	1680			UNKNOWN	mg	60		STEADY-STATE	FASTED		2 days	1	The average in vitro protein binding was 89.9% in patients with moderate hepatic insufficiency.	10.1	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/14517196/	Homo sapiens		h	30.9		Moderate hepatic impairment		10			false
3717	1802		ADULT	123619	358.842	ETORICOXIB	Etoricoxib	CC1=NC=C(C=C1)C2=NC=C(Cl)C=C2C3=CC=C(C=C3)S(C)(=O)=O	PLASMA	WRX4NFY03R									∞	μg × h/mL	31.36		ng/mL	1698			UNKNOWN	mg	120		SINGLE	FASTED				The average in vitro protein binding was 87.4% for patients with moderate to severe renal insufficiency.	12.6	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/14681341/	Homo sapiens		h	24.8		Severe renal impairment		5			false
3718	1802		ADULT	123619	358.842	ETORICOXIB	Etoricoxib	CC1=NC=C(C=C1)C2=NC=C(Cl)C=C2C3=CC=C(C=C3)S(C)(=O)=O	PLASMA	WRX4NFY03R									∞	μg × h/mL	33.49		ng/mL	2209			UNKNOWN	mg	120		SINGLE	FASTED				The average in vitro protein binding was 91.9%.	8.1	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/14681341/	Homo sapiens		h	20.9				152			false
3719	1802		ADULT	123619	358.842	ETORICOXIB	Etoricoxib	CC1=NC=C(C=C1)C2=NC=C(Cl)C=C2C3=CC=C(C=C3)S(C)(=O)=O	PLASMA	WRX4NFY03R									∞	μg × h/mL	34.71		ng/mL	1917			UNKNOWN	mg	120		SINGLE	FASTED				The average in vitro protein binding was 87.4% for patients with moderate to severe renal insufficiency.	12.6	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/14681341/	Homo sapiens		h	21.9		Moderate renal impairment		12			false
3720	1802		ADULT	123619	358.842	ETORICOXIB	Etoricoxib	CC1=NC=C(C=C1)C2=NC=C(Cl)C=C2C3=CC=C(C=C3)S(C)(=O)=O	PLASMA	WRX4NFY03R									∞	μg × h/mL	22.87		ng/mL	1752			UNKNOWN	mg	120		SINGLE	FASTED				The average in vitro protein binding was 86.5% for patients with end-stage renal disease with hemodialysis initiated 4 hours postdose, and 87.6% for patients with end-stage renal disease with hemodialysis initiated 48 hours postdose.	12.4	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/14681341/	Homo sapiens		h	19.3		End-stage renal impairment		5			false
3721	1803		ADULT	3547	291.369	FASUDIL	Fasudil	O=S(=O)(N1CCCNCC1)C2=C3C=CN=CC3=CC=C2	PLASMA	Q0CH43PGXS									∞	ng × h/mL	94.8		ng/mL	215.7			UNKNOWN	mg/kg bw	0.4		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/100898_2190414A1033_1_1F.pdf#page=21	Homo sapiens		min	15.6				4			false
3722	1803		ADULT	3547	291.369	FASUDIL	Fasudil	O=S(=O)(N1CCCNCC1)C2=C3C=CN=CC3=CC=C2	PLASMA	Q0CH43PGXS									∞	ng × h/mL	46.1		ng/mL	100.4			UNKNOWN	mg/kg bw	0.2		SINGLE	UNKNOWN				Plasma protein binding: 36.2% (49% (in vitro, 100ng/mL, n=3)	63.8	HEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/100898_2190414A1033_1_1F.pdf#page=21 | https://www.info.pmda.go.jp/go/interview/1/100898_2190414A1033_1_1F.pdf#page=23	Homo sapiens		min	14.2				4			false
3723	1803		ADULT	3547	291.369	FASUDIL	Fasudil	O=S(=O)(N1CCCNCC1)C2=C3C=CN=CC3=CC=C2	PLASMA	Q0CH43PGXS							2		t	ng × h/mL	120		ng/mL	166.9			RECOMMENDED	mg	30		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/100898_2190414A1033_1_1F.pdf#page=22	Homo sapiens		min	21.6	Day 7	Subarachnoid hemorrhage		5			false
3724	1803		ADULT	3547	291.369	FASUDIL	Fasudil	O=S(=O)(N1CCCNCC1)C2=C3C=CN=CC3=CC=C2	PLASMA	Q0CH43PGXS							2		t	ng × h/mL	89		ng/mL	126.9			RECOMMENDED	mg	30		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/100898_2190414A1033_1_1F.pdf#page=22	Homo sapiens		min	28.6		Subarachnoid hemorrhage		6			false
3725	1803		ADULT	3547	291.369	FASUDIL	Fasudil	O=S(=O)(N1CCCNCC1)C2=C3C=CN=CC3=CC=C2	PLASMA	Q0CH43PGXS							2		t	ng × h/mL	86.9		ng/mL	125			RECOMMENDED	mg	30		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/100898_2190414A1033_1_1F.pdf#page=22	Homo sapiens		min	24.4	Day 1	Subarachnoid hemorrhage		6			false
3726	1803		ADULT	3547	291.369	FASUDIL	Fasudil	O=S(=O)(N1CCCNCC1)C2=C3C=CN=CC3=CC=C2	PLASMA	Q0CH43PGXS							2		t	ng × h/mL	31.4		ng/mL	74.8			UNKNOWN	mg/kg bw	0.2		MULTIPLE	UNKNOWN		day	2			HEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/100898_2190414A1033_1_1F.pdf#page=22	Homo sapiens		min	10.6	5th dose (Day 3)			4			false
3727	1803		ADULT	3547	291.369	FASUDIL	Fasudil	O=S(=O)(N1CCCNCC1)C2=C3C=CN=CC3=CC=C2	PLASMA	Q0CH43PGXS							2		t	ng × h/mL	27.2		ng/mL	71.7			UNKNOWN	mg/kg bw	0.2		MULTIPLE	UNKNOWN		day	2			HEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/100898_2190414A1033_1_1F.pdf#page=22	Homo sapiens		min	10.3	1st dose			4			false
3728	1805			667431	323.411	GLICLAZIDE	Gliclazide	CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2C[C@@H]3CCC[C@@H]3C2	PLASMA	G4PX8C4HKV																										About 95% (85-97%) of gliclazide is bound to protein\nin plasma, mostly to albumin.	5				OTHER GOV'T	https://mhraproducts4853.blob.core.windows.net/docs/7357945bb5a0c49133c4ea64d51e2fb31ffe976d#page=15	Homo sapiens										false
3729	1805		ADULT	667431	323.411	GLICLAZIDE	Gliclazide	CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2C[C@@H]3CCC[C@@H]3C2	PLASMA	G4PX8C4HKV													μg/mL	2.6			RECOMMENDED	mg	40		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=16	Homo sapiens		h	8.6				5			false
3730	1805		ADULT	667431	323.411	GLICLAZIDE	Gliclazide	CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2C[C@@H]3CCC[C@@H]3C2	PLASMA	G4PX8C4HKV													μg/mL	2.2			RECOMMENDED	mg	40		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=16	Homo sapiens		h	12.3		Diabetes patients		8			false
3731	1805		ADULT	667431	323.411	GLICLAZIDE	Gliclazide	CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2C[C@@H]3CCC[C@@H]3C2	UNKNOWN	G4PX8C4HKV									?	μg × h/mL	23.6		μg/mL	1.6			RECOMMENDED	mg	40		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=19	Homo sapiens		h	9.6							false
3732	1805		ADULT	667431	323.411	GLICLAZIDE	Gliclazide	CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2C[C@@H]3CCC[C@@H]3C2	UNKNOWN	G4PX8C4HKV									?	μg × h/mL	55.65		μg/mL	4.3			RECOMMENDED	mg	80		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=19	Homo sapiens		h	9.1							false
3733	1805		ADULT	667431	323.411	GLICLAZIDE	Gliclazide	CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2C[C@@H]3CCC[C@@H]3C2	UNKNOWN	G4PX8C4HKV													μg/mL	4			RECOMMENDED	mg	40		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=19	Homo sapiens		h	11.8		Elderly subjects (ave. 77 y)					false
3734	1805		ADULT	667431	323.411	GLICLAZIDE	Gliclazide	CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2C[C@@H]3CCC[C@@H]3C2	UNKNOWN	G4PX8C4HKV													μg/mL	6.3			RECOMMENDED	mg	80		SINGLE	UNKNOWN				Absorption was 20% better than elderly subjects.		HEALTHY	Oral	FEMALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=19	Homo sapiens		h	20.5		Young subjects (ave. 26 y)					false
3735	1805		ADULT	667431	323.411	GLICLAZIDE	Gliclazide	CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2C[C@@H]3CCC[C@@H]3C2	SERUM	G4PX8C4HKV							24		t	μg × h/mL	71.8		μg/mL	4.5			RECOMMENDED	mg	80		SINGLE	UNKNOWN				Fu=~8-9%, ultrafiltration	9	UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=19 | https://pubmed.ncbi.nlm.nih.gov/6396398/	Homo sapiens		h	11.6		Diabetes patients		12			false
3736	1805		ADULT	667431	323.411	GLICLAZIDE	Gliclazide	CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2C[C@@H]3CCC[C@@H]3C2	SERUM	G4PX8C4HKV							24		t	μg × h/mL	92.5		μg/mL	7.7			RECOMMENDED	mg	80		MULTIPLE	UNKNOWN		day	1	Fu=~7%, ultrafiltration	7	UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=19 | https://pubmed.ncbi.nlm.nih.gov/6396398/	Homo sapiens		h	11.4	7-day administration	Diabetes patients		8			false
3737	1805		ADULT	667431	323.411	GLICLAZIDE	Gliclazide	CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2C[C@@H]3CCC[C@@H]3C2	SERUM	G4PX8C4HKV							24		t	μg × h/mL	37.2		μg/mL	2.8			RECOMMENDED	mg	40		SINGLE	FASTED				Fu=~8%, AUC24,free/AUC24,total=2.8/37.2=7.5%, ultrafiltration	8	HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=19 | https://pubmed.ncbi.nlm.nih.gov/6396398/	Homo sapiens		h	12.3				12			false
3738	1805		ADULT	667431	323.411	GLICLAZIDE	Gliclazide	CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2C[C@@H]3CCC[C@@H]3C2	PLASMA	G4PX8C4HKV																						UNKNOWN				Human plasma protein binding: 93.7% (diabetes patients, 60~120mg/day administration, ultrafiltration)	6.3	UNHEALTHY		UNKNOWN	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=20	Homo sapiens					Diabetes patients					false
3739	1805			667431	323.411	GLICLAZIDE	Gliclazide	CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2C[C@@H]3CCC[C@@H]3C2	PLASMA	G4PX8C4HKV																										Plasma protein binding is approximately 95%.	5				OTHER	https://www.medicines.org.uk/emc/product/11631/smpc#PHARMACOKINETIC_PROPS	Homo sapiens										false
3740	1806		ADULT	91610	527.632	GLIQUIDONE	Gliquidone	COC1=CC2=C(C=C1)C(C)(C)C(=O)N(CCC3=CC=C(C=C3)S(=O)(=O)NC(=O)NC4CCCCC4)C2=O	PLASMA	C7C2QDD75P									∞	μg × h/mL	5.1		μg/mL	0.65			UNKNOWN	mg	30		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9105542/	Homo sapiens		h	8		non-insulin-dependent (type 2) diabetes mellitus, n=8 for AUC and t1/2		20			false
3741	1806		ADULT	91610	527.632	GLIQUIDONE	Gliquidone	COC1=CC2=C(C=C1)C(C)(C)C(=O)N(CCC3=CC=C(C=C3)S(=O)(=O)NC(=O)NC4CCCCC4)C2=O	SERUM	C7C2QDD75P									∞	μg × h/mL	4.98		μg/mL	0.87			UNKNOWN	mg	60		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://www.jstage.jst.go.jp/article/amjsphcs/20/0/20_504/_article/-char/en	Homo sapiens		h	3.06				18			false
3742	1807		ADULT	3671	230.3055	IBUDILAST	IBUDILAST	CC(C)C(=O)C1=C2C=CC=CN2N=C1C(C)C	BLOOD	M0TTH61XC5							30		t	ng × h/mL	334		ng/mL	25			RECOMMENDED	mg	10		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	http://www.info.pmda.go.jp/go/interview/1/230109_4490010N1021_1_013_1F.pdf#PAGE=19	Homo sapiens		h	12				20			false
3743	1807		ADULT	3671	230.3055	IBUDILAST	Ibudilast	CC(C)C(=O)C1=C2C=CC=CN2N=C1C(C)C	BLOOD	M0TTH61XC5													ng/mL	30			RECOMMENDED	mg	10		STEADY-STATE	UNKNOWN		day	3			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	http://www.info.pmda.go.jp/go/interview/1/230109_4490010N1021_1_013_1F.pdf#PAGE=19	Homo sapiens							6			false
3744	1807			3671	230.3055	IBUDILAST	Ibudilast	CC(C)C(=O)C1=C2C=CC=CN2N=C1C(C)C	SERUM	M0TTH61XC5																										Human serum albumin binding: 97%	3				OTHER GOV'T	http://www.info.pmda.go.jp/go/interview/1/230109_4490010N1021_1_013_1F.pdf#PAGE=20	Homo sapiens										false
3745	1807		ADULT	3671	230.3055	IBUDILAST	Ibudilast	CC(C)C(=O)C1=C2C=CC=CN2N=C1C(C)C	PLASMA	M0TTH61XC5							12		t	ng × h/mL	507		ng/mL	59.9			UNKNOWN	mg	30		STEADY-STATE	FED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19032723/	Homo sapiens				Day 14 PK			10			false
3746	1807		ADULT	3671	230.3055	IBUDILAST	Ibudilast	CC(C)C(=O)C1=C2C=CC=CN2N=C1C(C)C	PLASMA	M0TTH61XC5							24		t	ng × h/mL	373		ng/mL	32			RECOMMENDED	mg	30		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19032723/	Homo sapiens		h	19.2				14			false
3747	1807		ADULT	3671	230.3055	IBUDILAST	Ibudilast	CC(C)C(=O)C1=C2C=CC=CN2N=C1C(C)C	PLASMA	M0TTH61XC5							12		t	ng × h/mL	517		ng/mL	59.9			UNKNOWN	mg	30		STEADY-STATE	FED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19032723/	Homo sapiens				Day 4 PK			10			false
3748	1807		ADULT	3671	230.3055	IBUDILAST	Ibudilast	CC(C)C(=O)C1=C2C=CC=CN2N=C1C(C)C	SERUM	M0TTH61XC5									∞	ng × h/mL	118.44		ng/mL	12.9			RECOMMENDED	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19629961/	Homo sapiens		h	7.76				26			false
3749	1807			3671	230.3055	IBUDILAST	Ibudilast	CC(C)C(=O)C1=C2C=CC=CN2N=C1C(C)C	PLASMA	M0TTH61XC5																										Human plasma protein binding (1 mcM): 98.6% (ultrafiltration), 99.5% (equilibrium dialysis)	0.5			MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19925385/	Homo sapiens										false
3750	1808		ADULT	3689	325.4446	IFENPRODIL	Ifenprodil	CC(C(O)C1=CC=C(O)C=C1)N2CCC(CC3=CC=CC=C3)CC2	PLASMA	R8OE3P6O5S									∞	ng × h/mL	41.3		ng/mL	19.1			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.sciencedirect.com/science/article/pii/S2211383513000336	Homo sapiens		h	3.61				10			false
3751	1808		ADULT	3689	325.4446	IFENPRODIL	Ifenprodil	CC(C(O)C1=CC=C(O)C=C1)N2CCC(CC3=CC=CC=C3)CC2	PLASMA	R8OE3P6O5S									∞	ng × h/mL	63.1		ng/mL	28.9			UNKNOWN	mg	15		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.sciencedirect.com/science/article/pii/S2211383513000336	Homo sapiens		h	4.07				10			false
3752	1808		ADULT	3689	325.4446	IFENPRODIL	Ifenprodil	CC(C(O)C1=CC=C(O)C=C1)N2CCC(CC3=CC=CC=C3)CC2	PLASMA	R8OE3P6O5S									∞	ng × h/mL	21.7		ng/mL	10.13			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.sciencedirect.com/science/article/pii/S2211383513000336	Homo sapiens		h	3.87				10			false
3753	1808		ADULT	3689	325.4446	IFENPRODIL	Ifenprodil	CC(C(O)C1=CC=C(O)C=C1)N2CCC(CC3=CC=CC=C3)CC2	PLASMA	R8OE3P6O5S									∞	ng × h/mL	47		ng/mL	20.4			UNKNOWN	mg	10		STEADY-STATE	FASTED		day	1			HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.sciencedirect.com/science/article/pii/S2211383513000336	Homo sapiens		h	4.25	Day 7 PK			10			false
3754	1809		ADULT	5464343|40466903	405.4449	IMIDAPRIL	Imidapril	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@@H](CN(C)C2=O)C(O)=O	PLASMA	BW7H1TJS22							24		t	ng × h/mL	168.4		ng/mL	36.1			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400315_2144008F1021_1_090_1F.pdf#page=25	Homo sapiens		h	1.94				8			false
3755	1809		ADULT	5464344	377.3917	IMIDAPRILAT	Imidaprilat	C[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N2[C@@H](CN(C)C2=O)C(O)=O	PLASMA	WUU07Y30IA							24		t	ng × h/mL	197.1		ng/mL	18.6			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400315_2144008F1021_1_090_1F.pdf#page=25	Homo sapiens		h	5.83				8			false
3756	1809		ADULT	5464343|40466903	405.4449	IMIDAPRIL	Imidapril	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@@H](CN(C)C2=O)C(O)=O	PLASMA	BW7H1TJS22							24		t	ng × h/mL	124.3		ng/mL	34.3			UNKNOWN	mg	10		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400315_2144008F1021_1_090_1F.pdf#page=25	Homo sapiens		h	1.78				8			false
3757	1809		ADULT	5464344	377.3917	IMIDAPRILAT	Imidaprilat	C[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N2[C@@H](CN(C)C2=O)C(O)=O	PLASMA	WUU07Y30IA							24		t	ng × h/mL	137		ng/mL	12			UNKNOWN	mg	10		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400315_2144008F1021_1_090_1F.pdf#page=25	Homo sapiens		h	6.85				8			false
3758	1809			5464344	377.3917	IMIDAPRILAT	Imidaprilat	C[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N2[C@@H](CN(C)C2=O)C(O)=O	PLASMA	WUU07Y30IA																										Human plasma protein binding (ultrafiltration): 85% (imidapril), 51% (imidaprilat)	49				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400315_2144008F1021_1_090_1F.pdf#page=26	Homo sapiens										false
3759	1809			5464343|40466903	405.4449	IMIDAPRIL	Imidapril	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@@H](CN(C)C2=O)C(O)=O	PLASMA	BW7H1TJS22																										Human plasma protein binding (ultrafiltration): 85% (imidapril), 51% (imidaprilat)	15				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400315_2144008F1021_1_090_1F.pdf#page=26	Homo sapiens										false
3760	1809		ADULT	5464343|40466903	405.4449	IMIDAPRIL	Imidapril	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@@H](CN(C)C2=O)C(O)=O	PLASMA	BW7H1TJS22							24		t	ng × h/mL	113.3		ng/mL	28.9			UNKNOWN	mg	10		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2002/P200200004/40031500_20500AMZ00544_260_2.pdf#page=4	Homo sapiens		h	1.7	1st dose			6			false
3761	1809		ADULT	5464343|40466903	405.4449	IMIDAPRIL	Imidapril	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@@H](CN(C)C2=O)C(O)=O	PLASMA	BW7H1TJS22							24		t	ng × h/mL	112		ng/mL	21.6			UNKNOWN	mg	5		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2002/P200200004/40031500_20500AMZ00544_260_2.pdf#page=4	Homo sapiens		h	1.8	1st dose	Renal impairment with hypertension		3			false
3762	1809		ADULT	5464344	377.3917	IMIDAPRILAT	Imidaprilat	C[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N2[C@@H](CN(C)C2=O)C(O)=O	PLASMA	WUU07Y30IA							24		t	ng × h/mL	107.8		ng/mL	7.8			UNKNOWN	mg	10		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2002/P200200004/40031500_20500AMZ00544_260_2.pdf#page=4	Homo sapiens		h	14.8	1st dose			6			false
3763	1809		ADULT	5464343|40466903	405.4449	IMIDAPRIL	Imidapril	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@@H](CN(C)C2=O)C(O)=O	PLASMA	BW7H1TJS22							24		t	ng × h/mL	113.6		ng/mL	27.1			UNKNOWN	mg	10		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2002/P200200004/40031500_20500AMZ00544_260_2.pdf#page=4	Homo sapiens		h	1.6	Day 7			6			false
3764	1809		ADULT	5464344	377.3917	IMIDAPRILAT	Imidaprilat	C[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N2[C@@H](CN(C)C2=O)C(O)=O	PLASMA	WUU07Y30IA							24		t	ng × h/mL	246.6		ng/mL	20.3			UNKNOWN	mg	10		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2002/P200200004/40031500_20500AMZ00544_260_2.pdf#page=4	Homo sapiens		h	7.6	Day 7			6			false
3765	1809		ADULT	5464343|40466903	405.4449	IMIDAPRIL	Imidapril	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@@H](CN(C)C2=O)C(O)=O	PLASMA	BW7H1TJS22							24		t	ng × h/mL	107.2		ng/mL	18.6			UNKNOWN	mg	5		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2002/P200200004/40031500_20500AMZ00544_260_2.pdf#page=4	Homo sapiens		h	2.4	Day 8	Renal impairment with hypertension		3			false
3766	1809		ADULT	5464344	377.3917	IMIDAPRILAT	Imidaprilat	C[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N2[C@@H](CN(C)C2=O)C(O)=O	PLASMA	WUU07Y30IA							24		t	ng × h/mL	103.9		ng/mL	7.2			UNKNOWN	mg	5		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2002/P200200004/40031500_20500AMZ00544_260_2.pdf#page=4	Homo sapiens				1st dose	Renal impairment with hypertension		3			false
3767	1809		ADULT	5464344	377.3917	IMIDAPRILAT	Imidaprilat	C[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N2[C@@H](CN(C)C2=O)C(O)=O	PLASMA	WUU07Y30IA							24		t	ng × h/mL	337.4		ng/mL	18.1			UNKNOWN	mg	5		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2002/P200200004/40031500_20500AMZ00544_260_2.pdf#page=4	Homo sapiens		h	17.7	Day 8	Renal impairment with hypertension		3			false
3768	1809		ADULT	5464343|40466903	405.4449	IMIDAPRIL	Imidapril	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@@H](CN(C)C2=O)C(O)=O	PLASMA	BW7H1TJS22							24		t	ng × h/mL	183.3		ng/mL	31.5			UNKNOWN	mg	10		MULTIPLE	UNKNOWN		hour	1			UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2002/P200200004/40031500_20500AMZ00544_260_2.pdf#page=4	Homo sapiens		h	2.5	1st dase	Renal impairment with hypertension		5			false
3769	1809		ADULT	5464343|40466903	405.4449	IMIDAPRIL	Imidapril	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@@H](CN(C)C2=O)C(O)=O	PLASMA	BW7H1TJS22							24		t	ng × h/mL	188.7		ng/mL	31.8			UNKNOWN	mg	10		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2002/P200200004/40031500_20500AMZ00544_260_2.pdf#page=4	Homo sapiens		h	2.5	Day 8	Renal impairment with hypertension		5			false
3770	1809		ADULT	5464344	377.3917	IMIDAPRILAT	Imidaprilat	C[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N2[C@@H](CN(C)C2=O)C(O)=O	PLASMA	WUU07Y30IA							24		t	ng × h/mL	361		ng/mL	23.7			UNKNOWN	mg	10		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2002/P200200004/40031500_20500AMZ00544_260_2.pdf#page=4	Homo sapiens		h	20.6	1st dose	Renal impairment with hypertension		5			false
3771	1809		ADULT	5464344	377.3917	IMIDAPRILAT	Imidaprilat	C[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N2[C@@H](CN(C)C2=O)C(O)=O	PLASMA	WUU07Y30IA							24		t	ng × h/mL	818.7		ng/mL	47.8			UNKNOWN	mg	10		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2002/P200200004/40031500_20500AMZ00544_260_2.pdf#page=4	Homo sapiens		h	12.4	Day 8	Renal impairment with hypertension		5			false
3772	1810		UNKNOWN	132999	468.5851	IVABRADINE	IVABRADINE	COC1=CC2=C(CC(=O)N(CCCN(C)C[C@H]3CC4=CC(OC)=C(OC)C=C34)CC2)C=C1OC	BLOOD	3H48L0LPZQ									∞	μg × h/mL	171.19		ng/mL	35.98			UNKNOWN	mg	5		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://doi.org/10.1016/j.apsb.2012.01.004	Homo sapiens		h	5.03							false
3773	1812		ADULT	28864	338.4466	LISURIDE	Lisuride	CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2CC3=CNC4=C3C(=CC=C4)C2=C1	PLASMA	E0QN3D755O									?	pg × h/mL	363		pg/mL	307			UNKNOWN	μg	25		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2050175/	Homo sapiens		h	14				12			false
3774	1812		ADULT	28864	338.4466	LISURIDE	Lisuride	CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2CC3=CNC4=C3C(=CC=C4)C2=C1	PLASMA	E0QN3D755O									?	pg × h/mL	321		pg/mL	184			UNKNOWN	μg	25		SINGLE	UNKNOWN						HEALTHY	Intramuscular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2050175/	Homo sapiens		h	19				12			false
3775	1812		ADULT	28864	338.4466	LISURIDE	Lisuride	CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2CC3=CNC4=C3C(=CC=C4)C2=C1	PLASMA	E0QN3D755O									?	pg × h/mL	326		pg/mL	180			UNKNOWN	μg	25		SINGLE	UNKNOWN						HEALTHY	Subcutaneous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2050175/	Homo sapiens		h	25				12			false
3776	1812		ADULT	28864	338.4466	LISURIDE	Lisuride	CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2CC3=CNC4=C3C(=CC=C4)C2=C1	PLASMA	E0QN3D755O									?	pg × h/mL	450		pg/mL	450			UNKNOWN	μg	25		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6532807/	Homo sapiens		min	170		Elderly subjects		6			false
3777	1812			28864	338.4466	LISURIDE	Lisuride	CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2CC3=CNC4=C3C(=CC=C4)C2=C1	PLASMA	E0QN3D755O																										Lisuride was bound to plasma proteins to 60-70%, independently of the concentration investigated. On an average of four concentrations (0.01, 0.1, 1,5 ng/ml) lisuride binding was 66 ± 3%.	34				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6532807/	Homo sapiens										false
3778	1812		ADULT	28864	338.4466	LISURIDE	Lisuride	CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2CC3=CNC4=C3C(=CC=C4)C2=C1	PLASMA	E0QN3D755O									?	pg × h/mL	730		pg/mL	280			UNKNOWN	μg	200		SINGLE	FED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6532807/	Homo sapiens					Elderly subjects		6			false
3779	1813			54690031	371.819	LORNOXICAM	Lornoxicam	CN1C(C(=O)NC2=NC=CC=C2)=C(O)C3=C(C=C(Cl)S3)S1(=O)=O	SERUM	ER09126G7A																										Human serum protein binding: 99.30~99.35% (0.1~10μg/mL)	0.65				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400059_1149036F1025_1_023_1F.pdf#page=23	Homo sapiens										false
3780	1813		ADULT	54690031	371.819	LORNOXICAM	Lornoxicam	CN1C(C(=O)NC2=NC=CC=C2)=C(O)C3=C(C=C(Cl)S3)S1(=O)=O	PLASMA	ER09126G7A									∞	ng × h/mL	546		ng/mL	136			UNKNOWN	mg	2		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2000/g001210/83repo01.pdf#page=14 | https://www.pmda.go.jp/drugs/2000/g001210/83ctdp_1-355.pdf#page=239	Homo sapiens		h	2.16				6			false
3781	1813		ADULT	54690031	371.819	LORNOXICAM	Lornoxicam	CN1C(C(=O)NC2=NC=CC=C2)=C(O)C3=C(C=C(Cl)S3)S1(=O)=O	PLASMA	ER09126G7A									∞	ng × h/mL	2645		ng/mL	931			RECOMMENDED	mg	8		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2000/g001210/83repo01.pdf#page=14 | https://www.pmda.go.jp/drugs/2000/g001210/83ctdp_1-355.pdf#page=239	Homo sapiens		h	2.83				6			false
3782	1813		ADULT	54690031	371.819	LORNOXICAM	Lornoxicam	CN1C(C(=O)NC2=NC=CC=C2)=C(O)C3=C(C=C(Cl)S3)S1(=O)=O	PLASMA	ER09126G7A									∞	ng × h/mL	601		ng/mL	210			UNKNOWN	mg	2		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2000/g001210/83repo01.pdf#page=14 | https://www.pmda.go.jp/drugs/2000/g001210/83ctdp_1-355.pdf#page=239	Homo sapiens		h	2.41				6			false
3783	1813		ADULT	54690031	371.819	LORNOXICAM	Lornoxicam	CN1C(C(=O)NC2=NC=CC=C2)=C(O)C3=C(C=C(Cl)S3)S1(=O)=O	PLASMA	ER09126G7A									∞	ng × h/mL	1248		ng/mL	414			RECOMMENDED	mg	4		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2000/g001210/83repo01.pdf#page=14 | https://www.pmda.go.jp/drugs/2000/g001210/83ctdp_1-355.pdf#page=239	Homo sapiens		h	2.3				6			false
3784	1813		ADULT	54690031	371.819	LORNOXICAM	Lornoxicam	CN1C(C(=O)NC2=NC=CC=C2)=C(O)C3=C(C=C(Cl)S3)S1(=O)=O	PLASMA	ER09126G7A									∞	ng × h/mL	600.99		ng/mL	210			UNKNOWN	mg	2		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2000/g001210/83repo01.pdf#page=14 | https://www.pmda.go.jp/drugs/2000/g001210/83ctdp_1-355.pdf#page=239	Homo sapiens		h	2.41				6			false
3785	1813		ADULT	54690031	371.819	LORNOXICAM	Lornoxicam	CN1C(C(=O)NC2=NC=CC=C2)=C(O)C3=C(C=C(Cl)S3)S1(=O)=O	PLASMA	ER09126G7A									∞	ng × h/mL	3349		ng/mL	591			RECOMMENDED	mg	8		MULTIPLE	FED		day	3			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2000/g001210/83repo01.pdf#page=14 | https://www.pmda.go.jp/drugs/2000/g001210/83ctdp_1-355.pdf#page=242	Homo sapiens		h	3.27	Day 1			6			false
3786	1813		ADULT	54690031	371.819	LORNOXICAM	Lornoxicam	CN1C(C(=O)NC2=NC=CC=C2)=C(O)C3=C(C=C(Cl)S3)S1(=O)=O	PLASMA	ER09126G7A									∞	ng × h/mL	6312		ng/mL	687			RECOMMENDED	mg	8		STEADY-STATE	FED		day	3			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2000/g001210/83repo01.pdf#page=14 | https://www.pmda.go.jp/drugs/2000/g001210/83ctdp_1-355.pdf#page=242	Homo sapiens		h	5.27	Day 8			6			false
3787	1813		ADULT	54690031	371.819	LORNOXICAM	Lornoxicam	CN1C(C(=O)NC2=NC=CC=C2)=C(O)C3=C(C=C(Cl)S3)S1(=O)=O	PLASMA	ER09126G7A									?	ng × h/mL	1606		ng/mL	301			RECOMMENDED	mg	4		STEADY-STATE	FASTED		day	2	Patients' plasma protein binding: 99.62% (99.55~99.66%, 4 patients, equilibrium dialysis)	0.38	UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2000/g001210/83repo01.pdf#page=14 | https://www.pmda.go.jp/drugs/2000/g001210/83ctdp_1-355.pdf#page=248	Homo sapiens				Day 6 (single dose)	Chronic rheumatism or osteoarthrosis patients, non-Japanese		12			false
3788	1813		ADULT	54690031	371.819	LORNOXICAM	Lornoxicam	CN1C(C(=O)NC2=NC=CC=C2)=C(O)C3=C(C=C(Cl)S3)S1(=O)=O	PLASMA	ER09126G7A									∞	ng × h/mL	1338		ng/mL	276			RECOMMENDED	mg	4		MULTIPLE	FED		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2000/g001210/83repo01.pdf#page=14 | https://www.pmda.go.jp/drugs/2000/g001210/83ctdp_1-355.pdf#page=248	Homo sapiens		min	154	Day 9	Elderly subjects (66~79 y), non-Japanese		12			false
3789	1813		ADULT	54690031	371.819	LORNOXICAM	Lornoxicam	CN1C(C(=O)NC2=NC=CC=C2)=C(O)C3=C(C=C(Cl)S3)S1(=O)=O	PLASMA	ER09126G7A									∞	ng × h/mL	1552		ng/mL	353			RECOMMENDED	mg	4		MULTIPLE	FED		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2000/g001210/83repo01.pdf#page=14 | https://www.pmda.go.jp/drugs/2000/g001210/83ctdp_1-355.pdf#page=248	Homo sapiens		min	154	Day 1	Elderly subjects (66~79 y), non-Japanese		12			false
3790	1813		ADULT	54690031	371.819	LORNOXICAM	Lornoxicam	CN1C(C(=O)NC2=NC=CC=C2)=C(O)C3=C(C=C(Cl)S3)S1(=O)=O	PLASMA	ER09126G7A									∞	ng × h/mL	3805.2		ng/mL	867.33			RECOMMENDED	mg	8		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2000/g001210/83repo01.pdf#page=15 | https://www.pmda.go.jp/drugs/2000/g001210/83ctdp_1-355.pdf#page=249	Homo sapiens		h	3.86	Day 1	Hepatic impairment patients, non-Japanese		12			false
3791	1813		ADULT	54690031	371.819	LORNOXICAM	Lornoxicam	CN1C(C(=O)NC2=NC=CC=C2)=C(O)C3=C(C=C(Cl)S3)S1(=O)=O	PLASMA	ER09126G7A									∞	ng × h/mL	3719.1		ng/mL	787.42			RECOMMENDED	mg	8		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2000/g001210/83repo01.pdf#page=15 | https://www.pmda.go.jp/drugs/2000/g001210/83ctdp_1-355.pdf#page=249	Homo sapiens		h	4.37	Day 3	Hepatic impairment patients, non-Japanese		12			false
3792	1813		ADULT	54690031	371.819	LORNOXICAM	Lornoxicam	CN1C(C(=O)NC2=NC=CC=C2)=C(O)C3=C(C=C(Cl)S3)S1(=O)=O	PLASMA	ER09126G7A									∞	ng × h/mL	3442.6		ng/mL	756.17			RECOMMENDED	mg	8		MULTIPLE	FASTED		day	2			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2000/g001210/83repo01.pdf#page=15 | https://www.pmda.go.jp/drugs/2000/g001210/83ctdp_1-355.pdf#page=249	Homo sapiens		h	3.36	Day 1	Normal hepatic function, non-Japanes		12			false
3793	1813		ADULT	54690031	371.819	LORNOXICAM	Lornoxicam	CN1C(C(=O)NC2=NC=CC=C2)=C(O)C3=C(C=C(Cl)S3)S1(=O)=O	PLASMA	ER09126G7A									∞	ng × h/mL	3733.7		ng/mL	742.33			RECOMMENDED	mg	8		MULTIPLE	FASTED		day	2			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2000/g001210/83repo01.pdf#page=15 | https://www.pmda.go.jp/drugs/2000/g001210/83ctdp_1-355.pdf#page=249	Homo sapiens		h	3.85	Day 3	Normal hepatic function, non-Japanese		12			false
3794	1813		ADULT	54690031	371.819	LORNOXICAM	Lornoxicam	CN1C(C(=O)NC2=NC=CC=C2)=C(O)C3=C(C=C(Cl)S3)S1(=O)=O	PLASMA	ER09126G7A									∞	ng × h/mL	4724		ng/mL	587			RECOMMENDED	mg	8		SINGLE	FASTED						UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.pmda.go.jp/drugs/2000/g001210/83repo01.pdf#page=15 | https://www.pmda.go.jp/drugs/2000/g001210/83ctdp_1-355.pdf#page=250	Homo sapiens		h	4.3		Renal impairment patients (CLcr: 30-60 mL/min), non-Japanese		9			false
3795	1813		ADULT	54690031	371.819	LORNOXICAM	Lornoxicam	CN1C(C(=O)NC2=NC=CC=C2)=C(O)C3=C(C=C(Cl)S3)S1(=O)=O	PLASMA	ER09126G7A									∞	ng × h/mL	3882		ng/mL	696			RECOMMENDED	mg	8		SINGLE	FASTED				n=8 for Cmax		UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.pmda.go.jp/drugs/2000/g001210/83repo01.pdf#page=15 | https://www.pmda.go.jp/drugs/2000/g001210/83ctdp_1-355.pdf#page=250	Homo sapiens		h	3.4		Renal impairment patients (CLcr: 0-10 mL/min), non-Japanese		9			false
3796	1813		ADULT	54690031	371.819	LORNOXICAM	Lornoxicam	CN1C(C(=O)NC2=NC=CC=C2)=C(O)C3=C(C=C(Cl)S3)S1(=O)=O	PLASMA	ER09126G7A									∞	ng × h/mL	3148		ng/mL	554			RECOMMENDED	mg	8		SINGLE	FASTED						UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.pmda.go.jp/drugs/2000/g001210/83repo01.pdf#page=15 | https://www.pmda.go.jp/drugs/2000/g001210/83ctdp_1-355.pdf#page=250	Homo sapiens		h	5.1		Renal impairment patients (CLcr: 10-30 mL/min), non-Japanese		9			false
3797	1814			151166	293.721	LUMIRACOXIB	Lumiracoxib	CC1=CC(CC(O)=O)=C(NC2=C(Cl)C=CC=C2F)C=C1	PLASMA	V91T9204HU																										In vitro protein binding of lumiracoxib was high (>99%) at 1 and 10 mcg/mL.	1				OTHER GOV'T	https://mhraproducts4853.blob.core.windows.net/docs/57920ad7838765ea88ca7e6139bfb364771a77d2#page=43 | https://mhraproducts4853.blob.core.windows.net/docs/57920ad7838765ea88ca7e6139bfb364771a77d2#page=95	Homo sapiens										false
3798	1814		ADULT	151166	293.721	LUMIRACOXIB	Lumiracoxib	CC1=CC(CC(O)=O)=C(NC2=C(Cl)C=CC=C2F)C=C1	PLASMA	V91T9204HU									?	ng × h/mL	29036		ng/mL	6689			UNKNOWN	mg	400		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://mhraproducts4853.blob.core.windows.net/docs/57920ad7838765ea88ca7e6139bfb364771a77d2#page=91	Homo sapiens					patients with moderate hepatic impairment		8			false
3799	1814		ADULT	151166	293.721	LUMIRACOXIB	Lumiracoxib	CC1=CC(CC(O)=O)=C(NC2=C(Cl)C=CC=C2F)C=C1	PLASMA	V91T9204HU									?	ng × h/mL	28654		ng/mL	7486			UNKNOWN	mg	400		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://mhraproducts4853.blob.core.windows.net/docs/57920ad7838765ea88ca7e6139bfb364771a77d2#page=91	Homo sapiens							8			false
3800	1814		ADULT	151166	293.721	LUMIRACOXIB	Lumiracoxib	CC1=CC(CC(O)=O)=C(NC2=C(Cl)C=CC=C2F)C=C1	PLASMA	V91T9204HU									?	ng × h/mL	11074		ng/mL	3165			UNKNOWN	mg	200		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://mhraproducts4853.blob.core.windows.net/docs/57920ad7838765ea88ca7e6139bfb364771a77d2#page=91	Homo sapiens					Patients with end-stage renal disease post-dialysis		8			false
3801	1814		ADULT	151166	293.721	LUMIRACOXIB	Lumiracoxib	CC1=CC(CC(O)=O)=C(NC2=C(Cl)C=CC=C2F)C=C1	PLASMA	V91T9204HU									?	ng × h/mL	10644		ng/mL	3039			UNKNOWN	mg	200		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://mhraproducts4853.blob.core.windows.net/docs/57920ad7838765ea88ca7e6139bfb364771a77d2#page=91	Homo sapiens					Patients with end-stage renal disease with dislysis		8			false
3802	1814		ADULT	151166	293.721	LUMIRACOXIB	Lumiracoxib	CC1=CC(CC(O)=O)=C(NC2=C(Cl)C=CC=C2F)C=C1	PLASMA	V91T9204HU									?	ng × h/mL	14231		ng/mL	4719			UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://mhraproducts4853.blob.core.windows.net/docs/57920ad7838765ea88ca7e6139bfb364771a77d2#page=91	Homo sapiens							8			false
3803	1814		ADULT	151166	293.721	LUMIRACOXIB	Lumiracoxib	CC1=CC(CC(O)=O)=C(NC2=C(Cl)C=CC=C2F)C=C1	PLASMA	V91T9204HU							12		t	ng × h/mL	12502		ng/mL	2550.4			UNKNOWN	mg	200		STEADY-STATE			day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://onlinelibrary.wiley.com/doi/10.1046/j.1365-2036.2003.01691.x	Homo sapiens				Day 6 PK	Administered before or after food (with the exception of day 6, when fasting for 10 h was required before blood sampling for the pharmacokinetic analyses		21			false
3804	1814		ADULT	151166	293.721	LUMIRACOXIB	Lumiracoxib	CC1=CC(CC(O)=O)=C(NC2=C(Cl)C=CC=C2F)C=C1	PLASMA	V91T9204HU							24		t	μg × h/L	31942		μg/L	6635			UNKNOWN	mg	400		STEADY-STATE	FASTED		day	1	Median protein binding of lumiracoxib in plasma was 98.3%, 98.2% and 98.3% on day-1 and 2 and 10 hours post-dose on day 7, respectively.	1.7	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15139795/	Homo sapiens		h	5.8	Day 7 PK	Patients with rheumatoid arthritis		22			false
3805	1815		ADULT	6398761	418.6093	MAXACALCITOL	maxacalcitol	C[C@H](OCCC(C)(C)O)[C@H]1CC[C@H]2\\C(CCC[C@]12C)=C\\C=C3\\C[C@@H](O)C[C@H](O)C3=C	SERUM	N2UJM5NBF6									∞	pg × h/mL	473		pg/mL	74.7			UNKNOWN	μg	1.25		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32181403/	Homo sapiens		min	431		Taiwan		8			false
3806	1815		ADULT	6398761	418.6093	MAXACALCITOL	maxacalcitol	C[C@H](OCCC(C)(C)O)[C@H]1CC[C@H]2\\C(CCC[C@]12C)=C\\C=C3\\C[C@@H](O)C[C@H](O)C3=C	SERUM	N2UJM5NBF6									∞	pg × h/mL	763		pg/mL	159			UNKNOWN	μg	2.5		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32181403/	Homo sapiens		min	828		Taiwan		8			false
3807	1815		ADULT	6398761	418.6093	MAXACALCITOL	maxacalcitol	C[C@H](OCCC(C)(C)O)[C@H]1CC[C@H]2\\C(CCC[C@]12C)=C\\C=C3\\C[C@@H](O)C[C@H](O)C3=C	SERUM	N2UJM5NBF6									∞	pg × h/mL	1460		pg/mL	321			UNKNOWN	μg	5		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32181403/	Homo sapiens		min	316		Taiwan		8			false
3808	1817		ADULT	130956	322.1483	MINODRONIC ACID	Minodronic acid	OC(CC1=CN=C2C=CC=CN12)(P(O)(O)=O)P(O)(O)=O	PLASMA	40SGR63TGL									∞	ng × h/mL	1.074		ng/mL	0.2564			UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Oral	FEMALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/800126_3999026F1026_1_017_1F.pdf#page=44	Homo sapiens		h	11.5		Young subjects (20~31 y)		10	Minodronic acid monoydrate		false
3809	1817		ADULT	130956	322.1483	MINODRONIC ACID	Minodronic acid	OC(CC1=CN=C2C=CC=CN12)(P(O)(O)=O)P(O)(O)=O	PLASMA	40SGR63TGL									∞	ng × h/mL	3.051		ng/mL	0.6512			UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Oral	FEMALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/800126_3999026F1026_1_017_1F.pdf#page=44	Homo sapiens		h	9.9		Elderly subjects (65~79 y)		10	Minodronic acid monoydrate		false
3810	1817		ADULT	130956	322.1483	MINODRONIC ACID	Minodronic acid	OC(CC1=CN=C2C=CC=CN12)(P(O)(O)=O)P(O)(O)=O	PLASMA	40SGR63TGL									∞	ng × h/mL	1.325		ng/mL	0.3134			UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/800126_3999026F1026_1_017_1F.pdf#page=44	Homo sapiens		h	8.2		Young subjects (20~31 y)		10	Minodronic acid monoydrate		false
3811	1817		ADULT	130956	322.1483	MINODRONIC ACID	Minodronic acid	OC(CC1=CN=C2C=CC=CN12)(P(O)(O)=O)P(O)(O)=O	PLASMA	40SGR63TGL									∞	ng × h/mL	2.814		ng/mL	0.5555			UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/800126_3999026F1026_1_017_1F.pdf#page=44	Homo sapiens		h	9.7		Elderly subjects (65~79 y)		10	Minodronic acid monoydrate		false
3812	1817		ADULT	130956	322.1483	MINODRONIC ACID	Minodronic acid	OC(CC1=CN=C2C=CC=CN12)(P(O)(O)=O)P(O)(O)=O	PLASMA	40SGR63TGL							6		t	ng × h/mL	1.92		ng/mL	0.676			UNKNOWN	mg	2		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/800126_3999026F1026_1_017_1F.pdf#page=45	Homo sapiens				Day 1			6	Minodronic acid monoydrate		false
3813	1817		ADULT	130956	322.1483	MINODRONIC ACID	Minodronic acid	OC(CC1=CN=C2C=CC=CN12)(P(O)(O)=O)P(O)(O)=O	PLASMA	40SGR63TGL							6		t	ng × h/mL	3.24		ng/mL	0.93			UNKNOWN	mg	2		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/800126_3999026F1026_1_017_1F.pdf#page=45	Homo sapiens				Day 7			6	Minodronic acid monoydrate		false
3814	1817		ADULT	130956	322.1483	MINODRONIC ACID	Minodronic acid	OC(CC1=CN=C2C=CC=CN12)(P(O)(O)=O)P(O)(O)=O	PLASMA	40SGR63TGL									?	ng × h/mL	4.12		ng/mL	1.405			UNKNOWN	mg	4		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/800126_3999026F1026_1_017_1F.pdf#page=46	Homo sapiens		h	1.3				8	Minodronic acid monoydrate		false
3815	1817		ADULT	130956	322.1483	MINODRONIC ACID	Minodronic acid	OC(CC1=CN=C2C=CC=CN12)(P(O)(O)=O)P(O)(O)=O	PLASMA	40SGR63TGL									?	ng × h/mL	1.41		ng/mL	0.638			UNKNOWN	mg	4		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/800126_3999026F1026_1_017_1F.pdf#page=46	Homo sapiens		h	1.4		Administered 1h before a meal, n=7 for t1/2		8	Minodronic acid monoydrate		false
3816	1817		ADULT	130956	322.1483	MINODRONIC ACID	Minodronic acid	OC(CC1=CN=C2C=CC=CN12)(P(O)(O)=O)P(O)(O)=O	PLASMA	40SGR63TGL									∞	ng × h/mL	1.549		ng/mL	0.3895			UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/800126_3999026F1026_1_017_1F.pdf#page=46	Homo sapiens		h	9.7				29	Minodronic acid monoydrate		false
3817	1817		ADULT	130956	322.1483	MINODRONIC ACID	Minodronic acid	OC(CC1=CN=C2C=CC=CN12)(P(O)(O)=O)P(O)(O)=O	PLASMA	40SGR63TGL									?	ng × h/mL	0.7		ng/mL	0.216			UNKNOWN	mg	4		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/800126_3999026F1026_1_017_1F.pdf#page=46	Homo sapiens		h	1.7		Administered 3h after a meal, n=3 for t1/2		8	Minodronic acid monoydrate		false
3818	1817		ADULT	130956	322.1483	MINODRONIC ACID	Minodronic acid	OC(CC1=CN=C2C=CC=CN12)(P(O)(O)=O)P(O)(O)=O	PLASMA	40SGR63TGL									∞	ng × h/mL	0.445		ng/mL	0.1913			UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/800126_3999026F1026_1_017_1F.pdf#page=46	Homo sapiens		h	6.6		Administered 30 min before a meal		29	Minodronic acid monoydrate		false
3819	1817			130956	322.1483	MINODRONIC ACID	Minodronic acid	OC(CC1=CN=C2C=CC=CN12)(P(O)(O)=O)P(O)(O)=O	PLASMA	40SGR63TGL																										Human plasma protein binding: 61.2%~61.9% (ultrafiltration)	38.1				OTHER GOV'T	https://www.pmda.go.jp/drugs/2009/P200900002/80012600_22100AMX00391_A101_1.pdf#page=19	Homo sapiens										false
3820	1817		ADULT	130956	322.1483	MINODRONIC ACID	Minodronic acid	OC(CC1=CN=C2C=CC=CN12)(P(O)(O)=O)P(O)(O)=O	PLASMA	40SGR63TGL									?	ng × h/mL	0.19		ng/mL	0.119			UNKNOWN	mg	0.5		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2009/P200900002/80012600_22100AMX00391_K100_1.pdf#page=26	Homo sapiens							3	Minodronic acid monoydrate		false
3821	1817		ADULT	130956	322.1483	MINODRONIC ACID	Minodronic acid	OC(CC1=CN=C2C=CC=CN12)(P(O)(O)=O)P(O)(O)=O	PLASMA	40SGR63TGL									?	ng × h/mL	0.37		ng/mL	0.189			UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2009/P200900002/80012600_22100AMX00391_K100_1.pdf#page=26	Homo sapiens							3	Minodronic acid monoydrate		false
3822	1817		ADULT	130956	322.1483	MINODRONIC ACID	Minodronic acid	OC(CC1=CN=C2C=CC=CN12)(P(O)(O)=O)P(O)(O)=O	PLASMA	40SGR63TGL									?	ng × h/mL	2.15		ng/mL	0.726			UNKNOWN	mg	2		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2009/P200900002/80012600_22100AMX00391_K100_1.pdf#page=26	Homo sapiens							3	Minodronic acid monoydrate		false
3823	1817		ADULT	130956	322.1483	MINODRONIC ACID	Minodronic acid	OC(CC1=CN=C2C=CC=CN12)(P(O)(O)=O)P(O)(O)=O	PLASMA	40SGR63TGL									?	ng × h/mL	2.26		ng/mL	0.665			UNKNOWN	mg	4		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2009/P200900002/80012600_22100AMX00391_K100_1.pdf#page=26	Homo sapiens							3	Minodronic acid monoydrate		false
3824	1817		ADULT	130956	322.1483	MINODRONIC ACID	Minodronic acid	OC(CC1=CN=C2C=CC=CN12)(P(O)(O)=O)P(O)(O)=O	PLASMA	40SGR63TGL									?	ng × h/mL	9.28		ng/mL	2.431			UNKNOWN	mg	8		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2009/P200900002/80012600_22100AMX00391_K100_1.pdf#page=26	Homo sapiens							3	Minodronic acid monoydrate		false
3825	1817		ADULT	130956	322.1483	MINODRONIC ACID	Minodronic acid	OC(CC1=CN=C2C=CC=CN12)(P(O)(O)=O)P(O)(O)=O	PLASMA	40SGR63TGL									?	ng × h/mL	0.01		ng/mL	0.017			UNKNOWN	mg	0.2		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2009/P200900002/80012600_22100AMX00391_K100_1.pdf#page=26	Homo sapiens							3	Minodronic acid monoydrate		false
3826	1817		ADULT	130956	322.1483	MINODRONIC ACID	Minodronic acid	OC(CC1=CN=C2C=CC=CN12)(P(O)(O)=O)P(O)(O)=O	PLASMA	40SGR63TGL									?	ng × h/mL	0.04		ng/mL	0.072			UNKNOWN	mg	0.1		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2009/P200900002/80012600_22100AMX00391_K100_1.pdf#page=26	Homo sapiens							3	Minodronic acid monoydrate		false
3827	1817		ADULT	130956	322.1483	MINODRONIC ACID	Minodronic acid	OC(CC1=CN=C2C=CC=CN12)(P(O)(O)=O)P(O)(O)=O	PLASMA	40SGR63TGL									∞	ng × h/mL	3.52		ng/mL	0.874			UNKNOWN	mg	4		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2009/P200900002/80012600_22100AMX00391_K100_1.pdf#page=28	Homo sapiens		h	2.3				6	Minodronic acid monoydrate		false
3828	1817		ADULT	130956	322.1483	MINODRONIC ACID	Minodronic acid	OC(CC1=CN=C2C=CC=CN12)(P(O)(O)=O)P(O)(O)=O	PLASMA	40SGR63TGL									∞	ng × h/mL	10.98		ng/mL	2.85			UNKNOWN	mg	8		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2009/P200900002/80012600_22100AMX00391_K100_1.pdf#page=28	Homo sapiens		h	4.7				6	Minodronic acid monoydrate		false
3829	1817		ADULT		322.1483	MINODRONIC ACID	Minodronic acid	OC(CC1=CN=C2C=CC=CN12)(P(O)(O)=O)P(O)(O)=O	PLASMA	40SGR63TGL									∞	ng × h/mL	10.16		ng/mL	2.333			UNKNOWN	mg	12		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2009/P200900002/80012600_22100AMX00391_K100_1.pdf#page=28	Homo sapiens		h	4.4				6	Minodronic acid monoydrate		false
3830	1819		ADULT	4235	268.739	MOCLOBEMIDE	MOCLOBEMIDE	ClC1=CC=C(C=C1)C(=O)NCCN2CCOCC2	PLASMA	PJ0Y7AZB63									∞	mg × h/L	2.36		mg/L	0.94			DEFINED DAILY	mg	150		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ingentaconnect.com/contentone/govi/pharmaz/2019/00000074/00000002/art00006?crawler=true&mimetype=application/pdf	Homo sapiens		h	1.16	Hoffmann la Roche 150mg tablet			10	Auroris		false
3831	1819		ADULT	4235	268.739	MOCLOBEMIDE	MOCLOBEMIDE	ClC1=CC=C(C=C1)C(=O)NCCN2CCOCC2	PLASMA	PJ0Y7AZB63									∞	mg × h/L	2.66		mg/L	1.05			DEFINED DAILY	mg	150		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ingentaconnect.com/contentone/govi/pharmaz/2019/00000074/00000002/art00006?crawler=true&mimetype=application/pdf	Homo sapiens		h	1.2	Jelfa 150mg tablet			10	Moclobemide		false
3832	1820		ADULT	34040	484.386	NICERGOLINE	NICERGOLINE	CO[C@]12C[C@@H](COC(=O)C3=CN=CC(Br)=C3)CN(C)[C@@H]1CC4=CN(C)C5=C4C2=CC=C5	PLASMA	JCV8365FWN									∞	ng × h/mL	388.38		ng/mL	34.504			DEFINED DAILY	mg	30		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5760819/pdf/main.pdf	Homo sapiens		h	8.427	capsules from SN pharmaceutical company (Harbin, China) or Ethypharm pharmaceutical Co. Ltd. (EPC, France)			20	nicergoline		false
3833	1821		ADULT	47528	211.1748	NICORANDIL	Nicorandil	[O-][N ](=O)OCCNC(=O)C1=CC=CN=C1	PLASMA	260456HAM0									∞	ng × h/mL	242.77		ng/mL	173.59			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://mhraproducts4853.blob.core.windows.net/docs/0333728229ac707af08e4320dadca85f6555c479#page=9	Homo sapiens		h	1.51				32			false
3834	1821			47528	211.1748	NICORANDIL	Nicorandil	[O-][N ](=O)OCCNC(=O)C1=CC=CN=C1	PLASMA	260456HAM0																										Nicorandil is only slightly bound to human plasma proteins (bound fraction estimated at about 25%).	75				OTHER	https://www.medicines.org.uk/emc/product/9071/smpc#PHARMACOKINETIC_PROPS	Homo sapiens										false
3835	1821		ADULT	47528	211.1748	NICORANDIL	Nicorandil	[O-][N ](=O)OCCNC(=O)C1=CC=CN=C1	PLASMA	260456HAM0									?	ng × h/mL	2274.8						UNKNOWN	mg	47.25		MULTIPLE	UNKNOWN		hour	1			HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700050/45004500_20500AMZ00348000_Q100_1.pdf#page=10 |  https://www.pmda.go.jp/drugs/2007/P200700050/45004500_20500AMZ00348000_W104_1.pdf#page=17	Homo sapiens		h	1.72	12mg single dose and 9mg/h infusion for 235min			6			false
3836	1821		ADULT	47528	211.1748	NICORANDIL	Nicorandil	[O-][N ](=O)OCCNC(=O)C1=CC=CN=C1	PLASMA	260456HAM0									?	ng × h/mL	1994.4						UNKNOWN	mg	35.5		MULTIPLE	UNKNOWN		hour	1			HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700050/45004500_20500AMZ00348000_Q100_1.pdf#page=10 |  https://www.pmda.go.jp/drugs/2007/P200700050/45004500_20500AMZ00348000_W104_1.pdf#page=17	Homo sapiens		h	1.99	12mg single dose and 6mg/h infusion for 235min			6			false
3837	1821		ADULT	47528	211.1748	NICORANDIL	Nicorandil	[O-][N ](=O)OCCNC(=O)C1=CC=CN=C1	PLASMA	260456HAM0									?	ng × h/mL	3549.9						UNKNOWN	mg	59		MULTIPLE	UNKNOWN		hour	1			HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700050/45004500_20500AMZ00348000_Q100_1.pdf#page=10 |  https://www.pmda.go.jp/drugs/2007/P200700050/45004500_20500AMZ00348000_W104_1.pdf#page=17	Homo sapiens		h	2.01	12mg single dose and 12mg/h infusion for 235min			4			false
3838	1821		ADULT	47528	211.1748	NICORANDIL	Nicorandil	[O-][N ](=O)OCCNC(=O)C1=CC=CN=C1	PLASMA	260456HAM0									∞	ng × h/mL	301.8		ng/mL	978.3			UNKNOWN	mg	18		SINGLE	UNKNOWN				Cmax=C5min		UNHEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700050/45004500_20500AMZ00348000_Q100_1.pdf#page=10 | https://www.pmda.go.jp/drugs/2007/P200700050/45004500_20500AMZ00348000_W104_1.pdf#page=19	Homo sapiens		h	0.25		Accute heart failure patients		7			false
3839	1821		ADULT	47528	211.1748	NICORANDIL	Nicorandil	[O-][N ](=O)OCCNC(=O)C1=CC=CN=C1	PLASMA	260456HAM0									∞	ng × h/mL	52.6		ng/mL	134.7			UNKNOWN	mg	4		SINGLE	UNKNOWN				Cmax=C5min		UNHEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700050/45004500_20500AMZ00348000_Q100_1.pdf#page=10 | https://www.pmda.go.jp/drugs/2007/P200700050/45004500_20500AMZ00348000_W104_1.pdf#page=19	Homo sapiens		h	2.1		Accute heart failure patients		6			false
3840	1821		ADULT	47528	211.1748	NICORANDIL	Nicorandil	[O-][N ](=O)OCCNC(=O)C1=CC=CN=C1	PLASMA	260456HAM0									∞	ng × h/mL	104		ng/mL	271.9			UNKNOWN	mg	8		SINGLE	UNKNOWN				Cmax=C5min		UNHEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700050/45004500_20500AMZ00348000_Q100_1.pdf#page=10 | https://www.pmda.go.jp/drugs/2007/P200700050/45004500_20500AMZ00348000_W104_1.pdf#page=19	Homo sapiens		h	1.48		Accute heart failure patients		7			false
3841	1821		ADULT	47528	211.1748	NICORANDIL	Nicorandil	[O-][N ](=O)OCCNC(=O)C1=CC=CN=C1	PLASMA	260456HAM0									∞	ng × h/mL	207.8		ng/mL	503.7			UNKNOWN	mg	12		SINGLE	UNKNOWN				Cmax=C5min		UNHEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700050/45004500_20500AMZ00348000_Q100_1.pdf#page=10 | https://www.pmda.go.jp/drugs/2007/P200700050/45004500_20500AMZ00348000_W104_1.pdf#page=19	Homo sapiens		h	2.18		Accute heart failure patients		7			false
3842	1821		ADULT	47528	211.1748	NICORANDIL	Nicorandil	[O-][N ](=O)OCCNC(=O)C1=CC=CN=C1	PLASMA	260456HAM0									?	ng × h/mL	187.7		ng/mL	199.6			UNKNOWN	mg	6		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700050/45004500_20500AMZ00348000_Q100_1.pdf#page=9 | https://www.pmda.go.jp/drugs/2007/P200700050/45004500_20500AMZ00348000_W104_1.pdf#page=15	Homo sapiens		h	1.14				6			false
3843	1821		ADULT	47528	211.1748	NICORANDIL	Nicorandil	[O-][N ](=O)OCCNC(=O)C1=CC=CN=C1	PLASMA	260456HAM0									?	ng × h/mL	422		ng/mL	502.5			UNKNOWN	mg	12		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700050/45004500_20500AMZ00348000_Q100_1.pdf#page=9 | https://www.pmda.go.jp/drugs/2007/P200700050/45004500_20500AMZ00348000_W104_1.pdf#page=15	Homo sapiens		h	2.52				5			false
3844	1821		ADULT	47528	211.1748	NICORANDIL	Nicorandil	[O-][N ](=O)OCCNC(=O)C1=CC=CN=C1	PLASMA	260456HAM0									?	ng × h/mL	766.2		ng/mL	761			UNKNOWN	mg	18		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700050/45004500_20500AMZ00348000_Q100_1.pdf#page=9 | https://www.pmda.go.jp/drugs/2007/P200700050/45004500_20500AMZ00348000_W104_1.pdf#page=15	Homo sapiens		h	1.1				5			false
3845	1821		ADULT	47528	211.1748	NICORANDIL	Nicorandil	[O-][N ](=O)OCCNC(=O)C1=CC=CN=C1	PLASMA	260456HAM0									?	ng × h/mL	993		ng/mL	888.2			UNKNOWN	mg	24		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700050/45004500_20500AMZ00348000_Q100_1.pdf#page=9 | https://www.pmda.go.jp/drugs/2007/P200700050/45004500_20500AMZ00348000_W104_1.pdf#page=15	Homo sapiens		h	1.17				5			false
3846	1821		ADULT	47528	211.1748	NICORANDIL	Nicorandil	[O-][N ](=O)OCCNC(=O)C1=CC=CN=C1	PLASMA	260456HAM0									∞	ng × h/mL	72.4		ng/mL	150			UNKNOWN	μg/kg bw	54		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700050/45004500_20500AMZ00348000_W104_1.pdf#page=16	Homo sapiens		h	0.77				7			false
3847	1821		ADULT	47528	211.1748	NICORANDIL	Nicorandil	[O-][N ](=O)OCCNC(=O)C1=CC=CN=C1	PLASMA	260456HAM0									∞	ng × h/mL	213		ng/mL	394			UNKNOWN	μg/kg bw	103		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700050/45004500_20500AMZ00348000_W104_1.pdf#page=16	Homo sapiens		h	1.2				8			false
3848	1821		ADULT	47528	211.1748	NICORANDIL	Nicorandil	[O-][N ](=O)OCCNC(=O)C1=CC=CN=C1	PLASMA	260456HAM0									∞	ng × h/mL	114		ng/mL	245			UNKNOWN	μg/kg bw	74		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700050/45004500_20500AMZ00348000_W104_1.pdf#page=16	Homo sapiens		h	1				8			false
3849	1821		ADULT	47528	211.1748	NICORANDIL	Nicorandil	[O-][N ](=O)OCCNC(=O)C1=CC=CN=C1	PLASMA	260456HAM0									∞	ng × h/mL	30.7		ng/mL	63.8			UNKNOWN	μg/kg bw	20		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700050/45004500_20500AMZ00348000_W104_1.pdf#page=16	Homo sapiens		h	1.2				8			false
3850	1821		ADULT	47528	211.1748	NICORANDIL	Nicorandil	[O-][N ](=O)OCCNC(=O)C1=CC=CN=C1	PLASMA	260456HAM0									∞	ng × h/mL	35.7		ng/mL	68.5			UNKNOWN	μg/kg bw	28		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700050/45004500_20500AMZ00348000_W104_1.pdf#page=16	Homo sapiens		h	0.74				8			false
3851	1821		ADULT	47528	211.1748	NICORANDIL	Nicorandil	[O-][N ](=O)OCCNC(=O)C1=CC=CN=C1	PLASMA	260456HAM0									∞	ng × h/mL	69.1		ng/mL	143			UNKNOWN	μg/kg bw	39		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700050/45004500_20500AMZ00348000_W104_1.pdf#page=16	Homo sapiens		h	1.1				8			false
3852	1821		ADULT	47528	211.1748	NICORANDIL	Nicorandil	[O-][N ](=O)OCCNC(=O)C1=CC=CN=C1	PLASMA	260456HAM0									∞	ng × h/mL	464		ng/mL	889			UNKNOWN	μg/kg bw	200		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700050/45004500_20500AMZ00348000_W104_1.pdf#page=16	Homo sapiens		h	0.73				8			false
3853	1821		ADULT	47528	211.1748	NICORANDIL	Nicorandil	[O-][N ](=O)OCCNC(=O)C1=CC=CN=C1	PLASMA	260456HAM0									∞	ng × h/mL	333		ng/mL	619			UNKNOWN	μg/kg bw	144		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700050/45004500_20500AMZ00348000_W104_1.pdf#page=16	Homo sapiens		h	0.76				8			false
3854	1821		ADULT	47528	211.1748	NICORANDIL	Nicorandil	[O-][N ](=O)OCCNC(=O)C1=CC=CN=C1	PLASMA	260456HAM0									?	ng × h/mL	264		ng/mL	738			UNKNOWN	mg/kg	158		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700050/45004500_20500AMZ00348000_W104_1.pdf#page=20	Homo sapiens		h	8.6		Congestive heart failure patients		6			false
3855	1821		ADULT	47528	211.1748	NICORANDIL	Nicorandil	[O-][N ](=O)OCCNC(=O)C1=CC=CN=C1	PLASMA	260456HAM0									?	ng × h/mL	424		ng/mL	1195			UNKNOWN	mg/kg	251		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700050/45004500_20500AMZ00348000_W104_1.pdf#page=20	Homo sapiens		h	5.8		Congestive heart failure patients		5			false
3856	1821		ADULT	47528	211.1748	NICORANDIL	Nicorandil	[O-][N ](=O)OCCNC(=O)C1=CC=CN=C1	PLASMA	260456HAM0									?	ng × h/mL	981		ng/mL	2209			UNKNOWN	mg/kg	398		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700050/45004500_20500AMZ00348000_W104_1.pdf#page=20	Homo sapiens		h	9		Congestive heart failure patients		5			false
3857	1821		ADULT	47528	211.1748	NICORANDIL	Nicorandil	[O-][N ](=O)OCCNC(=O)C1=CC=CN=C1	PLASMA	260456HAM0									?	ng × h/mL	1268		ng/mL	2303			UNKNOWN	mg/kg	630		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700050/45004500_20500AMZ00348000_W104_1.pdf#page=20	Homo sapiens		h	8.3		Congestive heart failure patients		6			false
3858	1821			47528	211.1748	NICORANDIL	Nicorandil	[O-][N ](=O)OCCNC(=O)C1=CC=CN=C1	SERUM	260456HAM0																										Human serum protein binding (ultrafiltration): 41.5% (1μg/mL), 36.7% (10μg/mL), 34.2% (100μg/mL)	58.5				OTHER GOV'T	https://www.pmda.go.jp/drugs/2007/P200700050/45004500_20500AMZ00348000_W104_1.pdf#page=4	Homo sapiens										false
3859	1822		ADULT	4494	385.3707	NILVADIPINE	NILVADIPINE	COC(=O)C1=C(NC(C)=C(C1C2=CC(=CC=C2)[N ]([O-])=O)C(=O)OC(C)C)C#N	PLASMA	0214FUT37J									∞	ng × h/mL	10.7		ng/mL	2.51			UNKNOWN	mg	4		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3392233/	Homo sapiens		h	10.8				6	NILVADIPINE		false
3860	1822		ADULT	4494	385.3707	NILVADIPINE	NILVADIPINE	COC(=O)C1=C(NC(C)=C(C1C2=CC(=CC=C2)[N ]([O-])=O)C(=O)OC(C)C)C#N	PLASMA	0214FUT37J							12		t	ng × h/mL	11.8		ng/mL	3.22			UNKNOWN	mg	4		STEADY-STATE	FED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3392233/	Homo sapiens				4 days dosing			6	NILVADIPINE		false
3861	1822		ADULT	4494	385.3707	NILVADIPINE	NILVADIPINE	COC(=O)C1=C(NC(C)=C(C1C2=CC(=CC=C2)[N ]([O-])=O)C(=O)OC(C)C)C#N	PLASMA	0214FUT37J							12		t	ng × h/mL	12.7		ng/mL	3.21			UNKNOWN	mg	4		STEADY-STATE	FED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3392233/	Homo sapiens		h	14.8	6 days dosing			6	NILVADIPINE		false
3862	1822		ADULT	4494	385.3707	NILVADIPINE	NILVADIPINE	COC(=O)C1=C(NC(C)=C(C1C2=CC(=CC=C2)[N ]([O-])=O)C(=O)OC(C)C)C#N	PLASMA	0214FUT37J									∞	ng × h/mL	5.28		ng/mL	1.48			UNKNOWN	mg	2		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3680562/	Homo sapiens		h	10.7				6	NILVADIPINE		false
3863	1822		ADULT	4494	385.3707	NILVADIPINE	NILVADIPINE	COC(=O)C1=C(NC(C)=C(C1C2=CC(=CC=C2)[N ]([O-])=O)C(=O)OC(C)C)C#N	PLASMA	0214FUT37J									∞	ng × h/mL	11.6		ng/mL	3.48			UNKNOWN	mg	4		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3680562/	Homo sapiens		h	10.9				6	NILVADIPINE		false
3864	1822		ADULT	4494	385.3707	NILVADIPINE	NILVADIPINE	COC(=O)C1=C(NC(C)=C(C1C2=CC(=CC=C2)[N ]([O-])=O)C(=O)OC(C)C)C#N	PLASMA	0214FUT37J									∞	ng × h/mL	18.9		ng/mL	6.69			HIGHEST STUDIED	mg	6		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3680562/	Homo sapiens		h	11.4				6	NILVADIPINE		false
3865	1822		ADULT	4494	385.3707	NILVADIPINE	NILVADIPINE	COC(=O)C1=C(NC(C)=C(C1C2=CC(=CC=C2)[N ]([O-])=O)C(=O)OC(C)C)C#N	PLASMA	0214FUT37J							12		t	ng × h/mL	16.3		ng/mL	5.67			UNKNOWN	mg	6		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3680587/	Homo sapiens					study 1		8	NILVADIPINE		false
3866	1822		ADULT	4494	385.3707	NILVADIPINE	NILVADIPINE	COC(=O)C1=C(NC(C)=C(C1C2=CC(=CC=C2)[N ]([O-])=O)C(=O)OC(C)C)C#N	PLASMA	0214FUT37J							12		t	ng × h/mL	13.8		ng/mL	5.3			UNKNOWN	mg	6		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3680587/	Homo sapiens					study 2		8	NILVADIPINE		false
3867	1822		ADULT	4494	385.3707	NILVADIPINE	NILVADIPINE	COC(=O)C1=C(NC(C)=C(C1C2=CC(=CC=C2)[N ]([O-])=O)C(=O)OC(C)C)C#N	PLASMA	0214FUT37J							12		t	ng × h/mL	17.1		ng/mL	6.33			UNKNOWN	mg	6		SINGLE	LOW-FAT						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3680587/	Homo sapiens					464-kcal meal		8	NILVADIPINE		false
3868	1822		ADULT	4494	385.3707	NILVADIPINE	NILVADIPINE	COC(=O)C1=C(NC(C)=C(C1C2=CC(=CC=C2)[N ]([O-])=O)C(=O)OC(C)C)C#N	PLASMA	0214FUT37J							12		t	ng × h/mL	15.8		ng/mL	4.61			UNKNOWN	mg	6		SINGLE	HIGH-FAT						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3680587/	Homo sapiens					748-kcal meal		8	NILVADIPINE		false
3869	1823		ADULT	4495	308.31	NIMESULIDE	Nimesulide	CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C(C=C1)[N ]([O-])=O	PLASMA	V4TKW1454M									?	mg × h/L	12.3		mg/L	1.36			UNKNOWN	mg	25		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	REVIEW	https://link.springer.com/chapter/10.1007/3-7643-7410-1_2	Homo sapiens		h	4.44	granulles			6			false
3870	1823		ADULT	4495	308.31	NIMESULIDE	Nimesulide	CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C(C=C1)[N ]([O-])=O	PLASMA	V4TKW1454M									?	mg × h/L	22.57		mg/L	2.3			UNKNOWN	mg	50		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	REVIEW	https://link.springer.com/chapter/10.1007/3-7643-7410-1_2	Homo sapiens		h	4.63	granulles			6			false
3871	1823		ADULT	4495	308.31	NIMESULIDE	Nimesulide	CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C(C=C1)[N ]([O-])=O	PLASMA	V4TKW1454M									?	mg × h/L	54.09		mg/L	4.8			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	REVIEW	https://link.springer.com/chapter/10.1007/3-7643-7410-1_2	Homo sapiens		h	4.73	granulles			6			false
3872	1823		ADULT	4495	308.31	NIMESULIDE	Nimesulide	CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C(C=C1)[N ]([O-])=O	PLASMA	V4TKW1454M									?	mg × h/L	81.97		mg/L	9.85			UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	REVIEW	https://link.springer.com/chapter/10.1007/3-7643-7410-1_2	Homo sapiens		h	4.95	Tablets			12			false
3873	1823		ADULT	4495	308.31	NIMESULIDE	Nimesulide	CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C(C=C1)[N ]([O-])=O	PLASMA	V4TKW1454M							12		t	mg × h/L	43		mg/L	6.17			UNKNOWN	mg	100		MULTIPLE	UNKNOWN		day	2	AUC?=57,82 mg x h/L		HEALTHY	Oral	FEMALE / MALE	REVIEW	https://link.springer.com/chapter/10.1007/3-7643-7410-1_2	Homo sapiens		h	4.75	Tablets, Day 1 (7-day administration)			12			false
3874	1823		ADULT	4495	308.31	NIMESULIDE	Nimesulide	CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C(C=C1)[N ]([O-])=O	PLASMA	V4TKW1454M							12		t	mg × h/L	66.13		mg/L	8.37			UNKNOWN	mg	100		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE / MALE	REVIEW	https://link.springer.com/chapter/10.1007/3-7643-7410-1_2	Homo sapiens		h	4.81	Tablets, Day 7 (7-day administration)			12			false
3875	1823		ADULT	4495	308.31	NIMESULIDE	Nimesulide	CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C(C=C1)[N ]([O-])=O	PLASMA	V4TKW1454M							12		t	mg × h/L	24.36		mg/L	2.94			UNKNOWN	mg	200		MULTIPLE	UNKNOWN		day	2			HEALTHY	Rectal	FEMALE / MALE	REVIEW	https://link.springer.com/chapter/10.1007/3-7643-7410-1_2	Homo sapiens		h	4.76	Suppository, Day 7 (7-day administration)			12			false
3876	1823			4495	308.31	NIMESULIDE	Nimesulide	CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C(C=C1)[N ]([O-])=O	PLASMA	V4TKW1454M																										Fu=0.7-4% (0.5-10mg/L), equlibrium dialysis	4				REVIEW	https://link.springer.com/chapter/10.1007/3-7643-7410-1_2	Homo sapiens										false
3877	1823			4495	308.31	NIMESULIDE	Nimesulide	CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C(C=C1)[N ]([O-])=O	SERUM	V4TKW1454M																										0.77-30mg/L, equilibrium dialysis	1				REVIEW	https://link.springer.com/chapter/10.1007/3-7643-7410-1_2 | https://pubmed.ncbi.nlm.nih.gov/7506199/	Homo sapiens										false
3878	1823		CHILD	4495	308.31	NIMESULIDE	Nimesulide	CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C(C=C1)[N ]([O-])=O	PLASMA	V4TKW1454M													mg/L	75			UNKNOWN	mg	100		SINGLE	UNKNOWN						UNHEALTHY	Rectal	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2227079/	Homo sapiens		h	3.15		Children prior to undergoing minor surgery		45			false
3879	1823		ADULT	4495	308.31	NIMESULIDE	Nimesulide	CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C(C=C1)[N ]([O-])=O	PLASMA	V4TKW1454M									∞	ng × h/mL	113		ng/mL	12.06			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22451531/	Homo sapiens		h	4.51				28			false
3880	1823		ADULT	4495	308.31	NIMESULIDE	Nimesulide	CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C(C=C1)[N ]([O-])=O	PLASMA	V4TKW1454M									∞	μg × h/L	49000		ng/mL	5099			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27284972/	Homo sapiens		h	4.8				12			false
3881	1823		ADULT	4495	308.31	NIMESULIDE	Nimesulide	CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C(C=C1)[N ]([O-])=O	PLASMA	V4TKW1454M													mg/L	4.58			UNKNOWN	mg	100		SINGLE	UNKNOWN				Cmax=2.86~4.58mg/L, t1/2=1.96~4.73h		HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7506196/	Homo sapiens		h	4.73							false
3882	1823		ADULT	4495	308.31	NIMESULIDE	Nimesulide	CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C(C=C1)[N ]([O-])=O	PLASMA	V4TKW1454M							8		t	ng × h/mL	5.6		ng/mL	65.3			UNKNOWN	mg	10		SINGLE	UNKNOWN						HEALTHY	Topical	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9832296/	Homo sapiens		h	10.1				12			false
3883	1824		ADULT	4507	360.3612	NITRENDIPINE	NITRENDIPINE	CCOC(=O)C1=C(C)NC(C)=C(C1C2=CC(=CC=C2)[N ]([O-])=O)C(=O)OC	SERUM	9B627AW319									?	ng × h/mL	29.6		ng/mL	18.1			UNKNOWN	mg	2		SINGLE	FASTED				in vitro	1.7	UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2054271/	Homo sapiens		h	10.4		chronic renal failure and moderate to severe hypertension		12	[13C4]NITRENDIPINE		false
3884	1824		ADULT	4507	360.3612	NITRENDIPINE	NITRENDIPINE	CCOC(=O)C1=C(C)NC(C)=C(C1C2=CC(=CC=C2)[N ]([O-])=O)C(=O)OC	SERUM	9B627AW319									?	ng × h/mL	65.2		ng/mL	12.5			UNKNOWN	mg	20		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2054271/	Homo sapiens		h	10.5		chronic renal failure and moderate to severe hypertension		12	NITRENDIPINE		false
3885	1824		ADULT	146012	358.3	Dehydronitrendipine	Dehydronitrendipine		PLASMA										∞	ng × h/mL	45.8						UNKNOWN	mg	20		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2713213/	Homo sapiens		h	11.5				9	NITRENDIPINE		false
3886	1824		ADULT	4507	360.3612	NITRENDIPINE	NITRENDIPINE	CCOC(=O)C1=C(C)NC(C)=C(C1C2=CC(=CC=C2)[N ]([O-])=O)C(=O)OC	PLASMA	9B627AW319									∞	ng × h/mL	26.3		ng/mL	8			UNKNOWN	mg	20		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2713213/	Homo sapiens		h	12.7				9	NITRENDIPINE		false
3887	1824		ADULT	4507	360.3612	NITRENDIPINE	NITRENDIPINE	CCOC(=O)C1=C(C)NC(C)=C(C1C2=CC(=CC=C2)[N ]([O-])=O)C(=O)OC	PLASMA	9B627AW319									∞	ng × h/mL	38.1		ng/mL	3.31			UNKNOWN	mg	40		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2713213/	Homo sapiens		h	13.6	via oral osmotic pumping device (Osmet)			9	NITRENDIPINE		false
3888	1824		ADULT	4507	360.3612	NITRENDIPINE	NITRENDIPINE	CCOC(=O)C1=C(C)NC(C)=C(C1C2=CC(=CC=C2)[N ]([O-])=O)C(=O)OC	PLASMA	9B627AW319									∞	ng × h/mL	33.7						UNKNOWN	μg/kg bw	40		SINGLE	FED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2713213/	Homo sapiens		h	11.7				9	NITRENDIPINE		false
3889	1824		ADULT	146012	358.3	Dehydronitrendipine	Dehydronitrendipine		PLASMA										∞	ng × h/mL	5.56						UNKNOWN	μg/kg bw	40		SINGLE	FED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2713213/	Homo sapiens		h	13.4				9	NITRENDIPINE		false
3890	1824		ADULT	146012	358.3	Dehydronitrendipine			PLASMA										∞	ng × h/mL	71.8						UNKNOWN	mg	40		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2713213/	Homo sapiens		h	14	via oral osmotic pumping device (Osmet)			9	NITRENDIPINE		false
3891	1824		ADULT	4507	360.3612	NITRENDIPINE	NITRENDIPINE	CCOC(=O)C1=C(C)NC(C)=C(C1C2=CC(=CC=C2)[N ]([O-])=O)C(=O)OC	PLASMA	9B627AW319									?	ng × h/mL	48.9						UNKNOWN	mg	10		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3179170/	Homo sapiens		h	3.6		elderly hypertensive patients 66 to 91 years (mean 76.5±7 s.d.)		23	NITRENDIPINE		false
3892	1824		ADULT	4507	360.3612	NITRENDIPINE	NITRENDIPINE	CCOC(=O)C1=C(C)NC(C)=C(C1C2=CC(=CC=C2)[N ]([O-])=O)C(=O)OC	PLASMA	9B627AW319									?	ng × h/mL	54.3						UNKNOWN	mg	10		MULTIPLE	FED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3179170/	Homo sapiens		h	3.43		elderly hypertensive patients 66 to 91 years (mean 76.5±7 s.d.)		23	NITRENDIPINE		false
3893	1824		ADULT	4507	360.3612	NITRENDIPINE	NITRENDIPINE	CCOC(=O)C1=C(C)NC(C)=C(C1C2=CC(=CC=C2)[N ]([O-])=O)C(=O)OC	PLASMA	9B627AW319									?	ng × h/mL	61.23						UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3435690/	Homo sapiens		h	7.85	solution			6	NITRENDIPINE		false
3894	1824		ADULT	4507	360.3612	NITRENDIPINE	NITRENDIPINE	CCOC(=O)C1=C(C)NC(C)=C(C1C2=CC(=CC=C2)[N ]([O-])=O)C(=O)OC	PLASMA	9B627AW319									?	ng × h/mL	27.7						UNKNOWN	mg	2		SINGLE	FASTED					2	HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3435690/	Homo sapiens		h	8.56				6	[13C4]NITRENDIPINE		false
3895	1826			115368	426.575	PEROSPIRONE	Perospirone	O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN3CCN(CC3)C4=NSC5=C4C=CC=C5	SERUM	N303OK87DT																										Human serum protein binding (equilibrium dialysis): 97.3% (0.1μg/mL), 96.8% (1μg/mL), 95.9% (10μg/mL)	2.7				OTHER GOV'T	https://www.pmda.go.jp/drugs/2000/g001211/82ctdp_1-336.pdf#page=175 | https://www.info.pmda.go.jp/go/interview/2/400093_1179043F1032_2_022_1F.pdf#page=23	Homo sapiens										false
3896	1826		ADULT	115368	426.575	PEROSPIRONE	Perospirone	O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN3CCN(CC3)C4=NSC5=C4C=CC=C5	SERUM	N303OK87DT									?	ng × h/mL	13.6		ng/mL	5.7			UNKNOWN	mg	8		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2000/g001211/82ctdp_1-336.pdf#page=203 | https://www.info.pmda.go.jp/go/interview/2/400093_1179043F1032_2_022_1F.pdf#page=19	Homo sapiens		h	2.3				6			false
3897	1826		ADULT	10252810	442.6	2-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-7a-hydroxy-4,5,6,7-tetrahydro-3aH-isoindole-1,3-dione		C1CCC2(C(C1)C(=O)N(C2=O)CCCCN3CCN(CC3)C4=NSC5=CC=CC=C54)O	SERUM										?	ng × h/mL	51.3		ng/mL	13.3			UNKNOWN	mg	8		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2000/g001211/82ctdp_1-336.pdf#page=203 | https://www.info.pmda.go.jp/go/interview/2/400093_1179043F1032_2_022_1F.pdf#page=19	Homo sapiens							6			false
3898	1826		ADULT	115368	426.575	PEROSPIRONE	Perospirone	O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN3CCN(CC3)C4=NSC5=C4C=CC=C5	SERUM	N303OK87DT									?	ng × h/mL	4		ng/mL	1.9			UNKNOWN	mg	4		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2000/g001211/82ctdp_1-336.pdf#page=203 | https://www.info.pmda.go.jp/go/interview/2/400093_1179043F1032_2_022_1F.pdf#page=19	Homo sapiens							6			false
3899	1826		ADULT	10252810	442.6	2-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-7a-hydroxy-4,5,6,7-tetrahydro-3aH-isoindole-1,3-dione		C1CCC2(C(C1)C(=O)N(C2=O)CCCCN3CCN(CC3)C4=NSC5=CC=CC=C54)O	SERUM										?	ng × h/mL	26.5		ng/mL	7.9			UNKNOWN	mg	4		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2000/g001211/82ctdp_1-336.pdf#page=203 | https://www.info.pmda.go.jp/go/interview/2/400093_1179043F1032_2_022_1F.pdf#page=19	Homo sapiens							6			false
3900	1826		ADULT	10252810	442.6	2-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-7a-hydroxy-4,5,6,7-tetrahydro-3aH-isoindole-1,3-dione		C1CCC2(C(C1)C(=O)N(C2=O)CCCCN3CCN(CC3)C4=NSC5=CC=CC=C54)O	SERUM										?	ng × h/mL	18.6		ng/mL	6.7			UNKNOWN	mg	4		MULTIPLE	FED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2000/g001211/82ctdp_1-336.pdf#page=204 | https://www.info.pmda.go.jp/go/interview/2/400093_1179043F1032_2_022_1F.pdf#page=20	Homo sapiens				Day 1			6			false
3901	1826		ADULT	115368	426.575	PEROSPIRONE	Perospirone	O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN3CCN(CC3)C4=NSC5=C4C=CC=C5	SERUM	N303OK87DT									?	ng × h/mL	3		ng/mL	2.1			UNKNOWN	mg	4		MULTIPLE	FED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2000/g001211/82ctdp_1-336.pdf#page=204 | https://www.info.pmda.go.jp/go/interview/2/400093_1179043F1032_2_022_1F.pdf#page=20	Homo sapiens				Day 1			6			false
3902	1826		ADULT	115368	426.575	PEROSPIRONE	Perospirone	O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN3CCN(CC3)C4=NSC5=C4C=CC=C5	SERUM	N303OK87DT									?	ng × h/mL	2.93		ng/mL	1.7			UNKNOWN	mg	4		MULTIPLE	FED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2000/g001211/82ctdp_1-336.pdf#page=204 | https://www.info.pmda.go.jp/go/interview/2/400093_1179043F1032_2_022_1F.pdf#page=20	Homo sapiens				Day 3			6			false
3903	1826		ADULT	10252810	442.6	2-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-7a-hydroxy-4,5,6,7-tetrahydro-3aH-isoindole-1,3-dione		C1CCC2(C(C1)C(=O)N(C2=O)CCCCN3CCN(CC3)C4=NSC5=CC=CC=C54)O	SERUM										?	ng × h/mL	20.4		ng/mL	6.9			UNKNOWN	mg	4		MULTIPLE	FED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2000/g001211/82ctdp_1-336.pdf#page=204 | https://www.info.pmda.go.jp/go/interview/2/400093_1179043F1032_2_022_1F.pdf#page=20	Homo sapiens				Day 3			6			false
3904	1826		ADULT	115368	426.575	PEROSPIRONE	Perospirone	O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN3CCN(CC3)C4=NSC5=C4C=CC=C5	SERUM	N303OK87DT									?	ng × h/mL	1.685		ng/mL	0.882			UNKNOWN	mg	2		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2000/g001211/82ctdp_1-336.pdf#page=209 | https://www.info.pmda.go.jp/go/interview/2/400093_1179043F1032_2_022_1F.pdf#page=21	Homo sapiens							12			false
3905	1826		ADULT	115368	426.575	PEROSPIRONE	Perospirone	O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN3CCN(CC3)C4=NSC5=C4C=CC=C5	SERUM	N303OK87DT									?	ng × h/mL	0.704		ng/mL	0.546			UNKNOWN	mg	2		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2000/g001211/82ctdp_1-336.pdf#page=209 | https://www.info.pmda.go.jp/go/interview/2/400093_1179043F1032_2_022_1F.pdf#page=21	Homo sapiens							12			false
3906	1826		ADULT	10252810	442.6	2-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-7a-hydroxy-4,5,6,7-tetrahydro-3aH-isoindole-1,3-dione		C1CCC2(C(C1)C(=O)N(C2=O)CCCCN3CCN(CC3)C4=NSC5=CC=CC=C54)O	SERUM										?	ng × h/mL	15.16		ng/mL	4.75			UNKNOWN	mg	2		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2000/g001211/82ctdp_1-336.pdf#page=209 | https://www.info.pmda.go.jp/go/interview/2/400093_1179043F1032_2_022_1F.pdf#page=21	Homo sapiens							12			false
3907	1826		ADULT	10252810	442.6	2-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-7a-hydroxy-4,5,6,7-tetrahydro-3aH-isoindole-1,3-dione		C1CCC2(C(C1)C(=O)N(C2=O)CCCCN3CCN(CC3)C4=NSC5=CC=CC=C54)O	SERUM										?	ng × h/mL	9.637		ng/mL	3.781			UNKNOWN	mg	2		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2000/g001211/82ctdp_1-336.pdf#page=209 | https://www.info.pmda.go.jp/go/interview/2/400093_1179043F1032_2_022_1F.pdf#page=21	Homo sapiens							12			false
3908	1827		ADULT	4830	375.4802	PIPAMPERONE	Pipamperone	NC(=O)C1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)N3CCCCC3	PLASMA	5402501F0W									∞	ng × h/mL	3107		ng/mL	266			UNKNOWN	mg	120		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12109042/	Homo sapiens							24	Pipamperone hydrochloride 144mg (120mg as free base)		false
3909	1829		ADULT	4843	142.1558	PIRACETAM	Piracetam	NC(=O)CN1CCCC1=O	PLASMA	ZH516LNZ10									∞	μg × h/mL	521.7		μg/mL	85.3			UNKNOWN	mg	3200		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/820110_1190013S1037_1_09D_1F.pdf#page=31 | https://www.info.pmda.go.jp/go/interview/1/820110_1190013S1037_1_09D_1F.pdf#page=112	Homo sapiens		h	4.6				6			false
3910	1829		ADULT	4843	142.1558	PIRACETAM	Piracetam	NC(=O)CN1CCCC1=O	PLASMA	ZH516LNZ10									∞	μg × h/mL	1192.5		μg/mL	173.7			UNKNOWN	mg	6400		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/820110_1190013S1037_1_09D_1F.pdf#page=31 | https://www.info.pmda.go.jp/go/interview/1/820110_1190013S1037_1_09D_1F.pdf#page=112	Homo sapiens		h	5.6				6			false
3911	1829		ADULT	4843	142.1558	PIRACETAM	Piracetam	NC(=O)CN1CCCC1=O	PLASMA	ZH516LNZ10									∞	μg × h/mL	1199.3		μg/mL	136.5			UNKNOWN	mg	6400		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/820110_1190013S1037_1_09D_1F.pdf#page=32	Homo sapiens		h	5.2				6			false
3912	1829		ADULT	4843	142.1558	PIRACETAM	Piracetam	NC(=O)CN1CCCC1=O	PLASMA	ZH516LNZ10									∞	μg × h/mL	1192.5		μg/mL	173.7			UNKNOWN	mg	6400		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/820110_1190013S1037_1_09D_1F.pdf#page=32	Homo sapiens		h	5.6				6			false
3913	1829		ADULT	4843	142.1558	PIRACETAM	Piracetam	NC(=O)CN1CCCC1=O	PLASMA	ZH516LNZ10									∞	μg × h/mL	1661.7		μg/mL	211.2			UNKNOWN	mg	6400		STEADY-STATE	UNKNOWN		day	3			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/820110_1190013S1037_1_09D_1F.pdf#page=32 | https://www.info.pmda.go.jp/go/interview/1/820110_1190013S1037_1_09D_1F.pdf#page=114	Homo sapiens		h	5	Day 7			6			false
3914	1829		ADULT	4843	142.1558	PIRACETAM	Piracetam	NC(=O)CN1CCCC1=O	PLASMA	ZH516LNZ10									∞	μg × h/mL	1590.1		μg/mL	177			UNKNOWN	mg	6400		STEADY-STATE	UNKNOWN		day	3			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/820110_1190013S1037_1_09D_1F.pdf#page=32 | https://www.info.pmda.go.jp/go/interview/1/820110_1190013S1037_1_09D_1F.pdf#page=114	Homo sapiens		h	5	Day 4			6			false
3915	1829			4843	142.1558	PIRACETAM	Piracetam	NC(=O)CN1CCCC1=O	SERUM	ZH516LNZ10																										Human serum protein binding: 4.8% (20μg/mL), 1.0% (200μg/mL), 0.8% (1000μg/mL)	99				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/820110_1190013S1037_1_09D_1F.pdf#page=37	Homo sapiens										false
3916	1830		ADULT	4849	362.4	PIRETANIDE	PIRETANIDE	NS(=O)(=O)C1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)N3CCCC3	PLASMA	DQ6KK6GV93									∞	μg × min/mL	51095						UNKNOWN	mg	6		SINGLE	FASTED						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2506054/	Homo sapiens		min	97		congestive heart failure		6	PIRETANIDE		false
3917	1830		ADULT	4849	362.4	PIRETANIDE	PIRETANIDE	NS(=O)(=O)C1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)N3CCCC3	PLASMA	DQ6KK6GV93																	UNKNOWN	mg	6		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3449067/	Homo sapiens		h	1.29				10	PIRETANIDE		false
3918	1830		ADULT	4849	362.4	PIRETANIDE	PIRETANIDE	NS(=O)(=O)C1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)N3CCCC3	PLASMA	DQ6KK6GV93													mg/mL	366			UNKNOWN	mg	6		SINGLE	UNKNOWN						HEALTHY	Intramuscular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3449067/	Homo sapiens							10	PIRETANIDE		false
3919	1830		ADULT	4849	362.4	PIRETANIDE	PIRETANIDE	NS(=O)(=O)C1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)N3CCCC3	SERUM	DQ6KK6GV93							24		t	μg × h/mL	2.05						UNKNOWN	mg	18		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6342640/	Homo sapiens		h	2.2		chronic renal insufficiency		4	PIRETANIDE		false
3920	1830		ADULT	4849	362.4	PIRETANIDE	PIRETANIDE	NS(=O)(=O)C1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)N3CCCC3	PLASMA	DQ6KK6GV93							24		t	μg × h/mL	2.08						UNKNOWN	mg	24		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6519164/	Homo sapiens					chronic renal failure		5	PIRETANIDE		false
3921	1830		ADULT	4849	362.4	PIRETANIDE	PIRETANIDE	NS(=O)(=O)C1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)N3CCCC3	PLASMA	DQ6KK6GV93							24		t	μg × h/mL	4.68						UNKNOWN	mg	48		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6519164/	Homo sapiens					chronic renal failure		10	PIRETANIDE		false
3922	1830		ADULT	4849	362.4	PIRETANIDE	PIRETANIDE	NS(=O)(=O)C1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)N3CCCC3	PLASMA	DQ6KK6GV93							24		t	μg × h/mL	8.23						UNKNOWN	mg	96		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6519164/	Homo sapiens					chronic renal failure		9	PIRETANIDE		false
3923	1831		ADULT	27400	295.442	PIZOTYLINE	PIZOTYLINE	CN1CCC(CC1)=C2C3=C(CCC4=C2C=CC=C4)SC=C3	PLASMA	0BY8440V3N													ng/mL	5			UNKNOWN	mg	1		SINGLE	UNKNOWN					9	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.medicines.org.uk/emc/product/5917/smpc#gref	Homo sapiens		h	23					PIZOTYLINE MALATE		false
3924	1831		ADULT	27400	295.442	PIZOTYLINE	PIZOTYLINE	CN1CCC(CC1)=C2C3=C(CCC4=C2C=CC=C4)SC=C3	PLASMA	0BY8440V3N													ng/mL	14			RECOMMENDED	mg	1		STEADY-STATE	UNKNOWN		day	3			UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.medicines.org.uk/emc/product/5917/smpc#gref	Homo sapiens								PIZOTYLINE MALATE		false
3925	1832		ADULT	4922	334.41	PROGLUMIDE	Proglumide	CCCN(CCC)C(=O)C(CCC(O)=O)NC(=O)C1=CC=CC=C1	SERUM	EPL8W5565D													ng/mL	7847			UNKNOWN	mg	400		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/35336003/	Homo sapiens		h	3				4			false
3926	1832		ADULT	4922	334.41	PROGLUMIDE	Proglumide	CCCN(CCC)C(=O)C(CCC(O)=O)NC(=O)C1=CC=CC=C1	SERUM	EPL8W5565D													ng/mL	10635			UNKNOWN	mg	400		SINGLE	FED						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/35336003/	Homo sapiens		h	3		Hepatic impairment (Child-Pugh B cirrhosis)		3			false
3927	1832		ADULT	4922	334.41	PROGLUMIDE	Proglumide	CCCN(CCC)C(=O)C(CCC(O)=O)NC(=O)C1=CC=CC=C1	SERUM	EPL8W5565D													ng/mL	9721			UNKNOWN	mg	400		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/35336003/	Homo sapiens		h	3		Hepatic impairment (Child-Pugh A cirrhosis)		4			false
3928	1833		ADULT	104758|5281913|135400182	458.488	RALTITREXED	RALTITREXED	CN(CC1=CC2=C(C=C1)N=C(C)NC2=O)C3=CC=C(S3)C(=O)N[C@@H](CCC(O)=O)C(O)=O	PLASMA	FCB9EGG971									∞	ng × h/mL	2341.7		ng/mL	736.8			UNKNOWN	mg/m²	3		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/9619761	Homo sapiens		min	12							false
3929	1833		ADULT	104758|5281913|135400182	458.488	RALTITREXED	RALTITREXED	CN(CC1=CC2=C(C=C1)N=C(C)NC2=O)C3=CC=C(S3)C(=O)N[C@@H](CCC(O)=O)C(O)=O	BLOOD	FCB9EGG971									∞	ng × h/mL	1547.9		ng/mL	567.1			UNKNOWN	mg/m²	3	infusion, 15 min	OTHER	UNKNOWN		day	1			HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/9820178	Homo sapiens		h	1.82							false
3930	1833		UNKNOWN	104758|5281913|135400182	458.488	RALTITREXED	RALTITREXED	CN(CC1=CC2=C(C=C1)N=C(C)NC2=O)C3=CC=C(S3)C(=O)N[C@@H](CCC(O)=O)C(O)=O	PLASMA	FCB9EGG971																						UNKNOWN				Raltitrexed is 93% protein bound in humans.	7	UNKNOWN		UNKNOWN	OTHER GOV'T	https://www.pfizer.ca/sites/default/files/201710/TOMUDEX_PM.pdf	Homo sapiens										false
3931	1834		ADULT	123879	416.466	RAMATROBAN	Ramatroban	OC(=O)CCN1C2=C(C[C@@H](CC2)NS(=O)(=O)C3=CC=C(F)C=C3)C4=C1C=CC=C4	PLASMA	P1ALI72U6C									?	ng × h/mL	996.6		ng/mL	209			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/3/630004_4490021F1025_3_001_1F.pdf#page=30 | https://www.pmda.go.jp/drugs/2000/g000302/index.html#page=149	Homo sapiens		h	2.17	Tablet			6			false
3932	1834		ADULT	123879	416.466	RAMATROBAN	Ramatroban	OC(=O)CCN1C2=C(C[C@@H](CC2)NS(=O)(=O)C3=CC=C(F)C=C3)C4=C1C=CC=C4	PLASMA	P1ALI72U6C									?	ng × h/mL	884.8		ng/mL	265			UNKNOWN	mg	50		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/3/630004_4490021F1025_3_001_1F.pdf#page=30 | https://www.pmda.go.jp/drugs/2000/g000302/index.html#page=149	Homo sapiens		h	1.52	Tablet			6			false
3933	1834		ADULT	123879	416.466	RAMATROBAN	Ramatroban	OC(=O)CCN1C2=C(C[C@@H](CC2)NS(=O)(=O)C3=CC=C(F)C=C3)C4=C1C=CC=C4	PLASMA	P1ALI72U6C							12		t	ng × h/mL	1139.1		ng/mL	320.9			RECOMMENDED	mg	75		MULTIPLE	FED		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/3/630004_4490021F1025_3_001_1F.pdf#page=31 | https://www.pmda.go.jp/drugs/2000/g000302/index.html#page=150	Homo sapiens		h	2.63	Day 1 (single dose), tablet			6			false
3934	1834		ADULT	123879	416.466	RAMATROBAN	Ramatroban	OC(=O)CCN1C2=C(C[C@@H](CC2)NS(=O)(=O)C3=CC=C(F)C=C3)C4=C1C=CC=C4	PLASMA	P1ALI72U6C							12		t	ng × h/mL	1142.2		ng/mL	302.5			RECOMMENDED	mg	75		MULTIPLE	FED		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/3/630004_4490021F1025_3_001_1F.pdf#page=31 | https://www.pmda.go.jp/drugs/2000/g000302/index.html#page=150	Homo sapiens		h	2.13	Day 9 (single dose), tablet			6			false
3935	1834		ADULT	123879	416.466	RAMATROBAN	Ramatroban	OC(=O)CCN1C2=C(C[C@@H](CC2)NS(=O)(=O)C3=CC=C(F)C=C3)C4=C1C=CC=C4	PLASMA	P1ALI72U6C							12		t	ng × h/mL	1188		ng/mL	404.5			UNKNOWN	mg	50		MULTIPLE	FED		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/3/630004_4490021F1025_3_001_1F.pdf#page=32 | https://www.pmda.go.jp/drugs/2000/g000302/index.html#page=160	Homo sapiens		h	2.34	Day 1 (single dose), tablet	Elderly subjects		6			false
3936	1834		ADULT	123879	416.466	RAMATROBAN	Ramatroban	OC(=O)CCN1C2=C(C[C@@H](CC2)NS(=O)(=O)C3=CC=C(F)C=C3)C4=C1C=CC=C4	PLASMA	P1ALI72U6C							12		t	ng × h/mL	1220.3		ng/mL	457.9			UNKNOWN	mg	50		MULTIPLE	FED		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/3/630004_4490021F1025_3_001_1F.pdf#page=32 | https://www.pmda.go.jp/drugs/2000/g000302/index.html#page=160	Homo sapiens		h	2.93	Day 9 (single dose), tablet	Elderly subjects		6			false
3937	1834		UNKNOWN	123879	416.466	RAMATROBAN	Ramatroban	OC(=O)CCN1C2=C(C[C@@H](CC2)NS(=O)(=O)C3=CC=C(F)C=C3)C4=C1C=CC=C4	PLASMA	P1ALI72U6C																						UNKNOWN				Fu=1.95~2.74% (Human plasma, ultrafiltration)	1.95	UNKNOWN		FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/3/630004_4490021F1025_3_001_1F.pdf#page=34 | https://www.pmda.go.jp/drugs/2000/g000302/index.html#page=136	Homo sapiens										false
3938	1834		ADULT	123879	416.466	RAMATROBAN	Ramatroban	OC(=O)CCN1C2=C(C[C@@H](CC2)NS(=O)(=O)C3=CC=C(F)C=C3)C4=C1C=CC=C4	PLASMA	P1ALI72U6C									?	ng × h/mL	137.4		ng/mL	85			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2000/g000302/index.html#page=146	Homo sapiens		h	1.93	Oral solution			3			false
3939	1834		ADULT	123879	416.466	RAMATROBAN	Ramatroban	OC(=O)CCN1C2=C(C[C@@H](CC2)NS(=O)(=O)C3=CC=C(F)C=C3)C4=C1C=CC=C4	PLASMA	P1ALI72U6C									?	ng × h/mL	555.2		ng/mL	349.6			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2000/g000302/index.html#page=146	Homo sapiens		h	1.95	Oral solution			6			false
3940	1834		ADULT	123879	416.466	RAMATROBAN	Ramatroban	OC(=O)CCN1C2=C(C[C@@H](CC2)NS(=O)(=O)C3=CC=C(F)C=C3)C4=C1C=CC=C4	PLASMA	P1ALI72U6C									?	ng × h/mL	193.6		ng/mL	126.9			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2000/g000302/index.html#page=146	Homo sapiens		h	1.79	Oral solution			3			false
3941	1834		ADULT	123879	416.466	RAMATROBAN	Ramatroban	OC(=O)CCN1C2=C(C[C@@H](CC2)NS(=O)(=O)C3=CC=C(F)C=C3)C4=C1C=CC=C4	PLASMA	P1ALI72U6C									?	ng × h/mL	422.9		ng/mL	103.7			UNKNOWN	mg	25		SINGLE	FASTED				n=3 for AUC and t1/2		HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2000/g000302/index.html#page=148	Homo sapiens		h	2.21	Tablet			6			false
3942	1834		ADULT	123879	416.466	RAMATROBAN	Ramatroban	OC(=O)CCN1C2=C(C[C@@H](CC2)NS(=O)(=O)C3=CC=C(F)C=C3)C4=C1C=CC=C4	PLASMA	P1ALI72U6C									?	ng × h/mL	972.8		ng/mL	211.1			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2000/g000302/index.html#page=148	Homo sapiens		h	2.03	Tablet			6			false
3943	1834		ADULT	123879	416.466	RAMATROBAN	Ramatroban	OC(=O)CCN1C2=C(C[C@@H](CC2)NS(=O)(=O)C3=CC=C(F)C=C3)C4=C1C=CC=C4	PLASMA	P1ALI72U6C									?	ng × h/mL	1284.9		ng/mL	237.2			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2000/g000302/index.html#page=148	Homo sapiens		h	2.33	Tablet			6			false
3944	1834		ADULT	123879	416.466	RAMATROBAN	Ramatroban	OC(=O)CCN1C2=C(C[C@@H](CC2)NS(=O)(=O)C3=CC=C(F)C=C3)C4=C1C=CC=C4	PLASMA	P1ALI72U6C									?	ng × h/mL	3214.8		ng/mL	689.1			DEFINED DAILY	mg	150		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2000/g000302/index.html#page=148	Homo sapiens		h	4.45	Tablet			6			false
3945	1834		ADULT	123879	416.466	RAMATROBAN	Ramatroban	OC(=O)CCN1C2=C(C[C@@H](CC2)NS(=O)(=O)C3=CC=C(F)C=C3)C4=C1C=CC=C4	PLASMA	P1ALI72U6C							12		t	ng × h/mL	1703.1		ng/mL	518.1			UNKNOWN	mg	100		MULTIPLE	FED		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2000/g000302/index.html#page=150	Homo sapiens		h	2.54	Day 1 (single dose), tablet			6			false
3946	1834		ADULT	123879	416.466	RAMATROBAN	Ramatroban	OC(=O)CCN1C2=C(C[C@@H](CC2)NS(=O)(=O)C3=CC=C(F)C=C3)C4=C1C=CC=C4	PLASMA	P1ALI72U6C							12		t	ng × h/mL	2099.4		ng/mL	749.8			UNKNOWN	mg	100		MULTIPLE	FED		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2000/g000302/index.html#page=150	Homo sapiens		h	2.31	Day 9 (single dose), tablet			6			false
3947	1835		ADULT	108000|135418340	279.3364	RAMOSETRON	Ramosetron	CN1C=C(C(=O)[C@@H]2CCC3=C(C2)N=CN3)C4=C1C=CC=C4	PLASMA	7ZRO0SC54Y									∞	pg × h/mL	12.15		pg/mL	2.79			UNKNOWN	mg	0.6		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/800126_2399014F1026_1_016_1F.pdf#page=44	Homo sapiens		h	3.8	Day 4			6	Ramosetron hydrochloride		false
3948	1835		ADULT	108000|135418340	279.3364	RAMOSETRON	Ramosetron	CN1C=C(C(=O)[C@@H]2CCC3=C(C2)N=CN3)C4=C1C=CC=C4	PLASMA	7ZRO0SC54Y									∞	pg × h/mL	11		pg/mL	2.42			UNKNOWN	mg	0.6		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/800126_2399014F1026_1_016_1F.pdf#page=44	Homo sapiens		h	3.75	Day 7			6	Ramosetron hydrochloride		false
3949	1835		ADULT	108000|135418340	279.3364	RAMOSETRON	Ramosetron	CN1C=C(C(=O)[C@@H]2CCC3=C(C2)N=CN3)C4=C1C=CC=C4	PLASMA	7ZRO0SC54Y									∞	pg × h/mL	11.92		pg/mL	2.39			UNKNOWN	mg	0.6		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/800126_2399014F1026_1_016_1F.pdf#page=44	Homo sapiens		h	4.09	Day 1			6	Ramosetron hydrochloride		false
3950	1835			108000|135418340	279.3364	RAMOSETRON	Ramosetron	CN1C=C(C(=O)[C@@H]2CCC3=C(C2)N=CN3)C4=C1C=CC=C4	PLASMA	7ZRO0SC54Y																										Human plasma protein binding (ultrafiltration): 89.1~91.5% (0.3~10ng/mL)	8.5				OTHER GOV'T	https://www.pmda.go.jp/drugs/2008/P200800026/80012600_22000AMX01708_A100_1.pdf#page=16 | https://www.pmda.go.jp/drugs/2008/P200800026/80012600_22000AMX01708_K101_1.pdf#page=6	Homo sapiens										false
3951	1835		ADULT	108000|135418340	279.3364	RAMOSETRON	Ramosetron	CN1C=C(C(=O)[C@@H]2CCC3=C(C2)N=CN3)C4=C1C=CC=C4	PLASMA	7ZRO0SC54Y									∞	pg × h/mL	151.8		pg/mL	23.3			DEFINED DAILY	μg	5		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2008/P200800026/80012600_22000AMX01708_A100_1.pdf#page=16 | https://www.pmda.go.jp/drugs/2008/P200800026/80012600_22000AMX01708_K105_1.pdf#page=10 | https://www.info.pmda.go.jp/go/interview/1/800126_2399014F1026_1_016_1F.pdf#page=47	Homo sapiens		h	5.6				20			false
3952	1835		ADULT	108000|135418340	279.3364	RAMOSETRON	Ramosetron	CN1C=C(C(=O)[C@@H]2CCC3=C(C2)N=CN3)C4=C1C=CC=C4	PLASMA	7ZRO0SC54Y									∞	pg × h/mL	160.6		pg/mL	23.3			DEFINED DAILY	μg	5		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2008/P200800026/80012600_22000AMX01708_A100_1.pdf#page=16 | https://www.pmda.go.jp/drugs/2008/P200800026/80012600_22000AMX01708_K105_1.pdf#page=10 | https://www.info.pmda.go.jp/go/interview/1/800126_2399014F1026_1_016_1F.pdf#page=47	Homo sapiens		h	6.1				19			false
3953	1835		ADULT	108000|135418340	279.3364	RAMOSETRON	Ramosetron	CN1C=C(C(=O)[C@@H]2CCC3=C(C2)N=CN3)C4=C1C=CC=C4	PLASMA	7ZRO0SC54Y									∞	pg × h/mL	215.9		pg/mL	27.4			DEFINED DAILY	μg	5		SINGLE	FASTED						HEALTHY	Oral	FEMALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2008/P200800026/80012600_22000AMX01708_A100_1.pdf#page=17 | https://www.pmda.go.jp/drugs/2008/P200800026/80012600_22000AMX01708_K105_1.pdf#page=20 | https://www.info.pmda.go.jp/go/interview/1/800126_2399014F1026_1_016_1F.pdf#page=44	Homo sapiens		h	7.2				20			false
3954	1835		ADULT	108000|135418340	279.3364	RAMOSETRON	Ramosetron	CN1C=C(C(=O)[C@@H]2CCC3=C(C2)N=CN3)C4=C1C=CC=C4	PLASMA	7ZRO0SC54Y									∞	pg × h/mL	125.3		pg/mL	18.5			DEFINED DAILY	μg	5		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2008/P200800026/80012600_22000AMX01708_A100_1.pdf#page=17 | https://www.pmda.go.jp/drugs/2008/P200800026/80012600_22000AMX01708_K105_1.pdf#page=20 | https://www.info.pmda.go.jp/go/interview/1/800126_2399014F1026_1_016_1F.pdf#page=44	Homo sapiens		h	5.7				20			false
3955	1836		ADULT	5042|5282133	370.786	REBAMIPIDE	Rebamipide	OC(=O)C(CC1=CC(=O)NC2=C1C=CC=C2)NC(=O)C3=CC=C(Cl)C=C3	SERUM	LR583V32ZR									∞	ng × h/mL	851.68		ng/mL	218.12			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20110013/	Homo sapiens		h	1.96				30			false
3956	1836			5042|5282133	370.786	REBAMIPIDE	Rebamipide	OC(=O)C(CC1=CC(=O)NC2=C1C=CC=C2)NC(=O)C3=CC=C(Cl)C=C3	PLASMA	LR583V32ZR																										Human plasma protein binding: 98.4~98.6% (0.05~5μg/mL)	1.4				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/180078_1319760Q1029_1_006_1F.pdf#page=31	Homo sapiens										false
3957	1836		ADULT	5042|5282133	370.786	REBAMIPIDE	Rebamipide	OC(=O)C(CC1=CC(=O)NC2=C1C=CC=C2)NC(=O)C3=CC=C(Cl)C=C3	PLASMA	LR583V32ZR							24		t	ng × h/mL	5.45		ng/mL	0.96			UNKNOWN	drop	2		SINGLE	UNKNOWN						HEALTHY	Ocular	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2011/P201100164/180078000_22300AMX01213000_A100_1.pdf#page=20 | https://www.pmda.go.jp/drugs/2011/P201100164/180078000_22300AMX01213000_K100_1.pdf#page=278	Homo sapiens		h	10.26	1 drop (50μL)/eye			6	0.5% Rebamipide ophthalmic solution		false
3958	1836		ADULT	5042|5282133	370.786	REBAMIPIDE	Rebamipide	OC(=O)C(CC1=CC(=O)NC2=C1C=CC=C2)NC(=O)C3=CC=C(Cl)C=C3	PLASMA	LR583V32ZR							24		t	ng × h/mL	4.71		ng/mL	1			UNKNOWN	drop	2		SINGLE	UNKNOWN						HEALTHY	Ocular	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2011/P201100164/180078000_22300AMX01213000_A100_1.pdf#page=20 | https://www.pmda.go.jp/drugs/2011/P201100164/180078000_22300AMX01213000_K100_1.pdf#page=278	Homo sapiens		h	5.64	1 drop (50μL)/eye			6	1% Rebamipide ophthalmic solution		false
3959	1836		ADULT	5042|5282133	370.786	REBAMIPIDE	Rebamipide	OC(=O)C(CC1=CC(=O)NC2=C1C=CC=C2)NC(=O)C3=CC=C(Cl)C=C3	PLASMA	LR583V32ZR							24		t	ng × h/mL	5.55		ng/mL	0.79			UNKNOWN	drop	2		SINGLE	UNKNOWN						HEALTHY	Ocular	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2011/P201100164/180078000_22300AMX01213000_A100_1.pdf#page=20 | https://www.pmda.go.jp/drugs/2011/P201100164/180078000_22300AMX01213000_K100_1.pdf#page=278	Homo sapiens		h	11.34	1 drop (50μL)/eye			6	2% Rebamipide ophthalmic solution		false
3960	1836		ADULT	5042|5282133	370.786	REBAMIPIDE	Rebamipide	OC(=O)C(CC1=CC(=O)NC2=C1C=CC=C2)NC(=O)C3=CC=C(Cl)C=C3	PLASMA	LR583V32ZR							15		t	ng × h/mL	10.3		ng/mL	2.18			UNKNOWN	drop	2		MULTIPLE	UNKNOWN		day	4	n=4 for t1/2		HEALTHY	Ocular	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2011/P201100164/180078000_22300AMX01213000_A100_1.pdf#page=20 | https://www.pmda.go.jp/drugs/2011/P201100164/180078000_22300AMX01213000_K100_1.pdf#page=290	Homo sapiens		h	5.19	1 drop (50μL)/eye, Day 1 (after 4th dose)			6	2% Rebamipide ophthalmic solution		false
3961	1836		ADULT	5042|5282133	370.786	REBAMIPIDE	Rebamipide	OC(=O)C(CC1=CC(=O)NC2=C1C=CC=C2)NC(=O)C3=CC=C(Cl)C=C3	PLASMA	LR583V32ZR							15		t	ng × h/mL	13.48		ng/mL	1.66			UNKNOWN	drop	2		MULTIPLE	UNKNOWN		day	4	n=4 for t1/2		HEALTHY	Ocular	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2011/P201100164/180078000_22300AMX01213000_A100_1.pdf#page=20 | https://www.pmda.go.jp/drugs/2011/P201100164/180078000_22300AMX01213000_K100_1.pdf#page=290	Homo sapiens		h	10.64	1 drop (50μL)/eye, Day 14 (after 4th dose)			6	2% Rebamipide ophthalmic solution		false
3962	1836		ADULT	5042|5282133	370.786	REBAMIPIDE	Rebamipide	OC(=O)C(CC1=CC(=O)NC2=C1C=CC=C2)NC(=O)C3=CC=C(Cl)C=C3	PLASMA	LR583V32ZR													ng/mL	4.39			UNKNOWN	drop	2		MULTIPLE	UNKNOWN		day	4			UNHEALTHY	Ocular	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2011/P201100164/180078000_22300AMX01213000_A100_1.pdf#page=21	Homo sapiens				1 drop (50μL)/eye, 12 weeks	Dry eye patients			1% Rebamipide ophthalmic solution		false
3963	1836		ADULT	5042|5282133	370.786	REBAMIPIDE	Rebamipide	OC(=O)C(CC1=CC(=O)NC2=C1C=CC=C2)NC(=O)C3=CC=C(Cl)C=C3	PLASMA	LR583V32ZR													ng/mL	2.19			UNKNOWN	drop	2		MULTIPLE	UNKNOWN		day	4			UNHEALTHY	Ocular	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2011/P201100164/180078000_22300AMX01213000_A100_1.pdf#page=21	Homo sapiens				1 drop (50μL)/eye, 12 weeks	Dry eye patients			2% Rebamipide ophthalmic solution		false
3964	1836		ADULT	5042|5282133	370.786	REBAMIPIDE	Rebamipide	OC(=O)C(CC1=CC(=O)NC2=C1C=CC=C2)NC(=O)C3=CC=C(Cl)C=C3	PLASMA	LR583V32ZR													ng/mL	2.13			UNKNOWN	drop	2		MULTIPLE	UNKNOWN		day	4			UNHEALTHY	Ocular	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2011/P201100164/180078000_22300AMX01213000_A100_1.pdf#page=21	Homo sapiens				1 drop (50μL)/eye, 12 weeks	Dry eye patients			0.5% Rebamipide ophthalmic solution		false
3965	1838			5160|74685715	429.506	SARPOGRELATE	Sarpogrelate	COC1=CC(CCC2=CC=CC=C2OCC(CN(C)C)OC(=O)CCC(O)=O)=CC=C1	PLASMA	19P708E787																										Human plasma protein Fu=96.8% (0.5μM), 95.1% (10μM); equilibrium dialysis	96.8				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24167220/	Homo sapiens										false
3966	1838			3070706	329.4333	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL	COC1=CC=CC(CCC2=C(OCC(O)CN(C)C)C=CC=C2)=C1	PLASMA	5CY97N9NO2																										Human plasma protein Fu=72.0% (0.5μM), 68.1% (10μM); equilibrium dialysis	72				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24167220/	Homo sapiens										false
3967	1838		ADULT	5160|74685715	429.506	SARPOGRELATE	Sarpogrelate	COC1=CC(CCC2=CC=CC=C2OCC(CN(C)C)OC(=O)CCC(O)=O)=CC=C1	PLASMA	19P708E787									∞	μg × h/mL	1772.7		μg/L	761			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24325365/	Homo sapiens		h	0.7	Immediate release			41	Sarpogrelate hydrochloride		false
3968	1838		ADULT	5160|74685715	429.506	SARPOGRELATE	Sarpogrelate	COC1=CC(CCC2=CC=CC=C2OCC(CN(C)C)OC(=O)CCC(O)=O)=CC=C1	PLASMA	19P708E787									∞	μg × h/mL	1927.3		μg/L	467.3			UNKNOWN	mg	300		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24325365/	Homo sapiens		h	1.45	Controlled release			41	Sarpogrelate hydrochloride		false
3969	1838		ADULT	5160|74685715	429.506	SARPOGRELATE	Sarpogrelate	COC1=CC(CCC2=CC=CC=C2OCC(CN(C)C)OC(=O)CCC(O)=O)=CC=C1	PLASMA	19P708E787									∞	μg × h/mL	2352.5		μg/L	721.4			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24325365/	Homo sapiens		h	3.23	Controlled release			41	Sarpogrelate hydrochloride		false
3970	1838		ADULT	5160|74685715	429.506	SARPOGRELATE	Sarpogrelate	COC1=CC(CCC2=CC=CC=C2OCC(CN(C)C)OC(=O)CCC(O)=O)=CC=C1	PLASMA	19P708E787							12		t	μg × h/mL	1358.4		μg/mL	506.5			UNKNOWN	mg	100		STEADY-STATE	FASTED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26089136/	Homo sapiens		h	1.12	Immediate release			32			false
3971	1838		ADULT	3070706	329.4333	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL	COC1=CC=CC(CCC2=C(OCC(O)CN(C)C)C=CC=C2)=C1	PLASMA	5CY97N9NO2							12		t	μg × h/mL	291.1		μg/mL	49.3			UNKNOWN	mg	100		STEADY-STATE	FASTED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26089136/	Homo sapiens		h	4.66	Immediate release			32			false
3972	1838		ADULT	3070706	329.4333	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL	COC1=CC=CC(CCC2=C(OCC(O)CN(C)C)C=CC=C2)=C1	PLASMA	5CY97N9NO2							24		t	μg × h/mL	361		μg/mL	62.4			UNKNOWN	mg	300		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26089136/	Homo sapiens		h	5.44	Controlled release			34			false
3973	1838		ADULT	5160|74685715	429.506	SARPOGRELATE	Sarpogrelate	COC1=CC(CCC2=CC=CC=C2OCC(CN(C)C)OC(=O)CCC(O)=O)=CC=C1	PLASMA	19P708E787							24		t	μg × h/mL	1754		μg/mL	565			UNKNOWN	mg	300		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26089136/	Homo sapiens		h	3.59	Controlled release			34			false
3974	1838		ADULT	5160|74685715	429.506	SARPOGRELATE	Sarpogrelate	COC1=CC(CCC2=CC=CC=C2OCC(CN(C)C)OC(=O)CCC(O)=O)=CC=C1	PLASMA	19P708E787									∞	μg × h/mL	0.2908		μg/mL	0.3636			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/3/400315_3399006C1020_3_160_1F.pdf#page=23	Homo sapiens		h	0.753				30	Sarpogrelate hydrochloride		false
3975	1838		ADULT	5160|74685715	429.506	SARPOGRELATE	Sarpogrelate	COC1=CC(CCC2=CC=CC=C2OCC(CN(C)C)OC(=O)CCC(O)=O)=CC=C1	PLASMA	19P708E787									∞	μg × h/mL	0.5958		μg/mL	0.7218			RECOMMENDED	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/3/400315_3399006C1020_3_160_1F.pdf#page=23	Homo sapiens		h	0.753				30	Sarpogrelate hydrochloride		false
3976	1838			5160|74685715	429.506	SARPOGRELATE	Sarpogrelate	COC1=CC(CCC2=CC=CC=C2OCC(CN(C)C)OC(=O)CCC(O)=O)=CC=C1	SERUM	19P708E787																										Human serum protein binding: >=95%	5				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/3/400315_3399006C1020_3_160_1F.pdf#page=25	Homo sapiens										false
3977	1839		ADULT	60149	440.941	SERTINDOLE	Sertindole	FC1=CC=C(C=C1)N2C=C(C3CCN(CCN4CCNC4=O)CC3)C5=C2C=CC(Cl)=C5	PLASMA	GVV4Z879SP									?	ng × h/mL	346		ng/mL	3.2			UNKNOWN	mg	4		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9218930/	Homo sapiens		h	86		Normal renal function		6			false
3978	1839		ADULT	9824456	438.925	DEHYDROSERTINDOLE	Dehydrosertindole	FC1=CC=C(C=C1)N2C=C(C3CCN(CCN4C=CNC4=O)CC3)C5=C2C=CC(Cl)=C5	PLASMA	AW4678O9A2									?	ng × h/mL	494		ng/mL	2.2			UNKNOWN	mg	4		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9218930/	Homo sapiens		h	242		Normal renal function		6			false
3979	1839		ADULT	60149	440.941	SERTINDOLE	Sertindole	FC1=CC=C(C=C1)N2C=C(C3CCN(CCN4CCNC4=O)CC3)C5=C2C=CC(Cl)=C5	PLASMA	GVV4Z879SP									?	ng × h/mL	225		ng/mL	2.4			UNKNOWN	mg	4		SINGLE	FASTED						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9218930/	Homo sapiens		h	75		Mild renal impairment		7			false
3980	1839		ADULT	9824456	438.925	DEHYDROSERTINDOLE	Dehydrosertindole	FC1=CC=C(C=C1)N2C=C(C3CCN(CCN4C=CNC4=O)CC3)C5=C2C=CC(Cl)=C5	PLASMA	AW4678O9A2									?	ng × h/mL	320		ng/mL	1.7			UNKNOWN	mg	4		SINGLE	FASTED						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9218930/	Homo sapiens		h	150		Mild renal impairment		7			false
3981	1839		ADULT	60149	440.941	SERTINDOLE	Sertindole	FC1=CC=C(C=C1)N2C=C(C3CCN(CCN4CCNC4=O)CC3)C5=C2C=CC(Cl)=C5	PLASMA	GVV4Z879SP									?	ng × h/mL	323		ng/mL	3.3			UNKNOWN	mg	4		SINGLE	FASTED						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9218930/	Homo sapiens		h	93		Moderate renal impairment		4			false
3982	1839		ADULT	9824456	438.925	DEHYDROSERTINDOLE	Dehydrosertindole	FC1=CC=C(C=C1)N2C=C(C3CCN(CCN4C=CNC4=O)CC3)C5=C2C=CC(Cl)=C5	PLASMA	AW4678O9A2									?	ng × h/mL	442		ng/mL	1.8			UNKNOWN	mg	4		SINGLE	FASTED						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9218930/	Homo sapiens		h	135		Moderate renal impairment		4			false
3983	1839		ADULT	60149	440.941	SERTINDOLE	Sertindole	FC1=CC=C(C=C1)N2C=C(C3CCN(CCN4CCNC4=O)CC3)C5=C2C=CC(Cl)=C5	PLASMA	GVV4Z879SP									?	ng × h/mL	282		ng/mL	3.3			UNKNOWN	mg	4		SINGLE	FASTED						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9218930/	Homo sapiens		h	73		Severe renal impairment		7			false
3984	1839		ADULT	9824456	438.925	DEHYDROSERTINDOLE	Dehydrosertindole	FC1=CC=C(C=C1)N2C=C(C3CCN(CCN4C=CNC4=O)CC3)C5=C2C=CC(Cl)=C5	PLASMA	AW4678O9A2									?	ng × h/mL	349		ng/mL	1.5			UNKNOWN	mg	4		SINGLE	FASTED						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9218930/	Homo sapiens		h	165		Severe renal impairment		7			false
3985	1839		ADULT	60149	440.941	SERTINDOLE	Sertindole	FC1=CC=C(C=C1)N2C=C(C3CCN(CCN4CCNC4=O)CC3)C5=C2C=CC(Cl)=C5	PLASMA	GVV4Z879SP																						UNKNOWN				The mean percentage of [14C]sertindole bound to plasma proteins for the four groups of subjects ranged from 99.41±99.45%. (equilibrium dialysis)	0.55	UNKNOWN		MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9218930/	Homo sapiens					Healthy and Renal impairment subjects					false
3986	1839		ADULT	60149	440.941	SERTINDOLE	Sertindole	FC1=CC=C(C=C1)N2C=C(C3CCN(CCN4CCNC4=O)CC3)C5=C2C=CC(Cl)=C5	PLASMA	GVV4Z879SP																						UNKNOWN				The mean (SD) proportion of sertindole bound to plasma proteins in the hemodialysis subjects was 99.18 (0.15)% and 99.08 (0.17)% before and after hemodialysis, respectively. (equilibrium dialysis)	0.82	UNHEALTHY		MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9218930/	Homo sapiens					Severe renal impairment subjects on hemodialysis		6			false
3987	1839		ADULT	60149	440.941	SERTINDOLE	Sertindole	FC1=CC=C(C=C1)N2C=C(C3CCN(CCN4CCNC4=O)CC3)C5=C2C=CC(Cl)=C5	PLASMA	GVV4Z879SP							24		t	ng × h/mL	953.2		ng/mL	53.13			UNKNOWN	mg	12		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9284851/	Homo sapiens		h	84.9	10 days	Young male subjects (mean 29 y)		12			false
3988	1839		ADULT	9824456	438.925	DEHYDROSERTINDOLE	Dehydrosertindole	FC1=CC=C(C=C1)N2C=C(C3CCN(CCN4C=CNC4=O)CC3)C5=C2C=CC(Cl)=C5	PLASMA	AW4678O9A2							24		t	ng × h/mL	723.8		ng/mL	38.34			UNKNOWN	mg	12		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9284851/	Homo sapiens		h	99.7	10 days	Young male subjects (mean 29 y)		12			false
3989	1839		ADULT	60149	440.941	SERTINDOLE	Sertindole	FC1=CC=C(C=C1)N2C=C(C3CCN(CCN4CCNC4=O)CC3)C5=C2C=CC(Cl)=C5	PLASMA	GVV4Z879SP							24		t	ng × h/mL	839.4		ng/mL	43.91			UNKNOWN	mg	12		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9284851/	Homo sapiens		h	90.5	10 days	Elderly male subjects (mean 71 y)		11			false
3990	1839		ADULT	9824456	438.925	DEHYDROSERTINDOLE	Dehydrosertindole	FC1=CC=C(C=C1)N2C=C(C3CCN(CCN4C=CNC4=O)CC3)C5=C2C=CC(Cl)=C5	PLASMA	AW4678O9A2							24		t	ng × h/mL	645.4		ng/mL	34.06			UNKNOWN	mg	12		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9284851/	Homo sapiens		h	108.7	10 days	Elderly male subjects (mean 71 y)		11			false
3991	1839		ADULT	60149	440.941	SERTINDOLE	Sertindole	FC1=CC=C(C=C1)N2C=C(C3CCN(CCN4CCNC4=O)CC3)C5=C2C=CC(Cl)=C5	PLASMA	GVV4Z879SP							24		t	ng × h/mL	1231.4		ng/mL	63.74			UNKNOWN	mg	12		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9284851/	Homo sapiens		h	99	10 days	Young female subjects (mean 22 y)		11			false
3992	1839		ADULT	9824456	438.925	DEHYDROSERTINDOLE	Dehydrosertindole	FC1=CC=C(C=C1)N2C=C(C3CCN(CCN4C=CNC4=O)CC3)C5=C2C=CC(Cl)=C5	PLASMA	AW4678O9A2							24		t	ng × h/mL	846.5		ng/mL	43.29			UNKNOWN	mg	12		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9284851/	Homo sapiens		h	97.9	10 days	Young female subjects (mean 22 y)		11			false
3993	1839		ADULT	60149	440.941	SERTINDOLE	Sertindole	FC1=CC=C(C=C1)N2C=C(C3CCN(CCN4CCNC4=O)CC3)C5=C2C=CC(Cl)=C5	PLASMA	GVV4Z879SP							24		t	ng × h/mL	1084.9		ng/mL	57.6			UNKNOWN	mg	12		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9284851/	Homo sapiens		h	101.5	10 days	Elderly female subjects (mean 73 y)		12			false
3994	1839		ADULT	9824456	438.925	DEHYDROSERTINDOLE	Dehydrosertindole	FC1=CC=C(C=C1)N2C=C(C3CCN(CCN4C=CNC4=O)CC3)C5=C2C=CC(Cl)=C5	PLASMA	AW4678O9A2							24		t	ng × h/mL	925.4		ng/mL	51.58			UNKNOWN	mg	12		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9284851/	Homo sapiens		h	110.3	10 days	Elderly female subjects (mean 73 y)		12			false
3995	1839		ADULT	9824456	438.925	DEHYDROSERTINDOLE	Dehydrosertindole	FC1=CC=C(C=C1)N2C=C(C3CCN(CCN4C=CNC4=O)CC3)C5=C2C=CC(Cl)=C5	PLASMA	AW4678O9A2							24		t	ng × h/mL	14		ng/mL	0.9			UNKNOWN	mg	4		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9284851/	Homo sapiens					Elderly male subjects (mean 71 y)		11			false
3996	1839		ADULT	9824456	438.925	DEHYDROSERTINDOLE	Dehydrosertindole	FC1=CC=C(C=C1)N2C=C(C3CCN(CCN4C=CNC4=O)CC3)C5=C2C=CC(Cl)=C5	PLASMA	AW4678O9A2							24		t	ng × h/mL	14.7		ng/mL	0.97			UNKNOWN	mg	4		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9284851/	Homo sapiens					Elderly female subjects (mean 73 y)		12			false
3997	1839		ADULT	60149	440.941	SERTINDOLE	Sertindole	FC1=CC=C(C=C1)N2C=C(C3CCN(CCN4CCNC4=O)CC3)C5=C2C=CC(Cl)=C5	PLASMA	GVV4Z879SP							24		t	ng × h/mL	24.2		ng/mL	1.41			UNKNOWN	mg	4		SINGLE	FASTED					0.64	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9284851/	Homo sapiens					Young male subjects (mean 29 y)		12			false
3998	1839		ADULT	9824456	438.925	DEHYDROSERTINDOLE	Dehydrosertindole	FC1=CC=C(C=C1)N2C=C(C3CCN(CCN4C=CNC4=O)CC3)C5=C2C=CC(Cl)=C5	PLASMA	AW4678O9A2							24		t	ng × h/mL	12		ng/mL	0.78			UNKNOWN	mg	4		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9284851/	Homo sapiens					Young male subjects (mean 29 y)		12			false
3999	1839		ADULT	60149	440.941	SERTINDOLE	Sertindole	FC1=CC=C(C=C1)N2C=C(C3CCN(CCN4CCNC4=O)CC3)C5=C2C=CC(Cl)=C5	PLASMA	GVV4Z879SP							24		t	ng × h/mL	24.3		ng/mL	1.41			UNKNOWN	mg	4		SINGLE	FASTED					0.57	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9284851/	Homo sapiens					Elderly male subjects (mean 71 y)		11			false
4000	1839		ADULT	60149	440.941	SERTINDOLE	Sertindole	FC1=CC=C(C=C1)N2C=C(C3CCN(CCN4CCNC4=O)CC3)C5=C2C=CC(Cl)=C5	PLASMA	GVV4Z879SP							24		t	ng × h/mL	41.5		ng/mL	2.34			UNKNOWN	mg	4		SINGLE	FASTED					0.55	HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9284851/	Homo sapiens					Young female subjects (mean 22 y)		11			false
4001	1839		ADULT	9824456	438.925	DEHYDROSERTINDOLE	Dehydrosertindole	FC1=CC=C(C=C1)N2C=C(C3CCN(CCN4C=CNC4=O)CC3)C5=C2C=CC(Cl)=C5	PLASMA	AW4678O9A2							24		t	ng × h/mL	13.7		ng/mL	0.89			UNKNOWN	mg	4		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9284851/	Homo sapiens					Young female subjects (mean 22 y)		11			false
4002	1839		ADULT	60149	440.941	SERTINDOLE	Sertindole	FC1=CC=C(C=C1)N2C=C(C3CCN(CCN4CCNC4=O)CC3)C5=C2C=CC(Cl)=C5	PLASMA	GVV4Z879SP							24		t	ng × h/mL	31.6		ng/mL	1.83			UNKNOWN	mg	4		SINGLE	FASTED					0.56	HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9284851/	Homo sapiens					Elderly female subjects (mean 73 y)		12			false
4003	1839			60149	440.941	SERTINDOLE	Sertindole	FC1=CC=C(C=C1)N2C=C(C3CCN(CCN4CCNC4=O)CC3)C5=C2C=CC(Cl)=C5	PLASMA	GVV4Z879SP																										Sertindole is about 99.5% bound to plasma proteins, primarily to albumin and α1-acid glycoprotein.	0.5				OTHER GOV'T	https://www.ema.europa.eu/en/documents/referral/opinion-following-article-36-referral-sertindole-international-non-proprietary-name-inn-sertindole_en.pdf#page=31	Homo sapiens										false
4004	1841		ADULT	5355	341.426	SULPIRIDE	sulpiride	CCN1CCCC1CNC(=O)C2=C(OC)C=CC(=C2)S(N)(=O)=O	PLASMA	7MNE9M8287									∞	mg × h/L/(mg dose/kg)	7.81						UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Intramuscular	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1815069/	Homo sapiens		h	7.17				12			false
4005	1841		ADULT	5355	341.426	SULPIRIDE	sulpiride	CCN1CCCC1CNC(=O)C2=C(OC)C=CC(=C2)S(N)(=O)=O	PLASMA	7MNE9M8287									∞	mg × h/L/(mg dose/kg)	9.03						UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1815069/	Homo sapiens		h	6.47				15			false
4006	1841		ADULT	5355	341.426	SULPIRIDE	sulpiride	CCN1CCCC1CNC(=O)C2=C(OC)C=CC(=C2)S(N)(=O)=O	PLASMA	7MNE9M8287									∞	ng × h/mL	1402.5		ng/mL	89.8			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23585286/	Homo sapiens		h	9				16			false
4007	1842		ADULT	114750	405.4084	TALTIRELIN	taltirelin	CN1C(=O)C[C@H](NC1=O)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N3CCC[C@H]3C(N)=O	SERUM	DOZ62MV6A5																		mg	0.5		SINGLE	UNKNOWN				The t1/2 is said to be about 2 h for all tested single oral doses (0.5 to 40 mg).		HEALTHY	Oral	MALE	REVIEW	https://doi.org/10.1111/j.1527-3458.1998.tb00039.x	Homo sapiens		h	2				12			false
4008	1843		ADULT	108143	351.4388	TAMIBAROTENE	Tamibarotene	CC1(C)CCC(C)(C)C2=CC(NC(=O)C3=CC=C(C=C3)C(O)=O)=CC=C12	PLASMA	08V52GZ3H9									∞	ng × h/mL	312		ng/mL	43.2			RECOMMENDED	mg	4		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26202410/	Homo sapiens		h	3.38		Patients with advanced hepatocellular carcinoma (Chhild-Pugh A)		3			false
4009	1843		ADULT	108143	351.4388	TAMIBAROTENE	Tamibarotene	CC1(C)CCC(C)(C)C2=CC(NC(=O)C3=CC=C(C=C3)C(O)=O)=CC=C12	PLASMA	08V52GZ3H9									∞	ng × h/mL	751		ng/mL	97.1			RECOMMENDED	mg	6		SINGLE	UNKNOWN						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26202410/	Homo sapiens		h	3.38		Patients with advanced hepatocellular carcinoma (Chhild-Pugh A)		6			false
4010	1843		UNKNOWN	108143	351.4388	TAMIBAROTENE	Tamibarotene	CC1(C)CCC(C)(C)C2=CC(NC(=O)C3=CC=C(C=C3)C(O)=O)=CC=C12	PLASMA	08V52GZ3H9							10		t	ng × h/mL	311.1		ng/mL	63.1			DEFINED DAILY	mg/m²	6		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33829292/	Homo sapiens		h	11.96		Pediatric and young adult patients (4-23 y, mean 8.0 y) with recurrent/refractory solid tumors		3			false
4011	1843		UNKNOWN	108143	351.4388	TAMIBAROTENE	Tamibarotene	CC1(C)CCC(C)(C)C2=CC(NC(=O)C3=CC=C(C=C3)C(O)=O)=CC=C12	PLASMA	08V52GZ3H9							10		t	ng × h/mL	438.9		ng/mL	104.4			RECOMMENDED	mg/m²	8		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33829292/	Homo sapiens		h	2.35		Pediatric and young adult patients (4-23 y, mean 8.0 y) with recurrent/refractory solid tumors		3			false
4012	1843		UNKNOWN	108143	351.4388	TAMIBAROTENE	Tamibarotene	CC1(C)CCC(C)(C)C2=CC(NC(=O)C3=CC=C(C=C3)C(O)=O)=CC=C12	PLASMA	08V52GZ3H9							10		t	ng × h/mL	444.2		ng/mL	126.3			RECOMMENDED	mg/m²	10		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33829292/	Homo sapiens		h	2.49		Pediatric and young adult patients (4-23 y, mean 8.0 y) with recurrent/refractory solid tumors		9			false
4013	1843		UNKNOWN	108143	351.4388	TAMIBAROTENE	Tamibarotene	CC1(C)CCC(C)(C)C2=CC(NC(=O)C3=CC=C(C=C3)C(O)=O)=CC=C12	PLASMA	08V52GZ3H9							10		t	ng × h/mL	514.1		ng/mL	131.9			MAX DAILY	mg/m²	12		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33829292/	Homo sapiens		h	2.21		Pediatric and young adult patients (4-23 y, mean 8.0 y) with recurrent/refractory solid tumors		6			false
4014	1843		ADULT	108143	351.4388	TAMIBAROTENE	Tamibarotene	CC1(C)CCC(C)(C)C2=CC(NC(=O)C3=CC=C(C=C3)C(O)=O)=CC=C12	PLASMA	08V52GZ3H9									?	ng × h/mL	128.37		ng/mL	18.02			UNKNOWN	mg	2		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/480114_4291014F1021_1_A04_1F.pdf#page=13 | https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/480114_4291014F1021_1_12#page=4	Homo sapiens		h	3.4		Acute promyelocytic leukemia (APL) patients		4			false
4015	1843		ADULT	108143	351.4388	TAMIBAROTENE	Tamibarotene	CC1(C)CCC(C)(C)C2=CC(NC(=O)C3=CC=C(C=C3)C(O)=O)=CC=C12	PLASMA	08V52GZ3H9									?	ng × h/mL	320.41		ng/mL	44.87			UNKNOWN	mg	4		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/480114_4291014F1021_1_A04_1F.pdf#page=13 | https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/480114_4291014F1021_1_12#page=4	Homo sapiens		h	4.5		Acute promyelocytic leukemia (APL) patients		3			false
4016	1843		ADULT	108143	351.4388	TAMIBAROTENE	Tamibarotene	CC1(C)CCC(C)(C)C2=CC(NC(=O)C3=CC=C(C=C3)C(O)=O)=CC=C12	PLASMA	08V52GZ3H9									?	ng × h/mL	430.26		ng/mL	65.22			UNKNOWN	mg	6		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/480114_4291014F1021_1_A04_1F.pdf#page=13 | https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/480114_4291014F1021_1_12#page=4	Homo sapiens		h	4		Acute promyelocytic leukemia (APL) patients		3			false
4017	1843			108143	351.4388	TAMIBAROTENE	Tamibarotene	CC1(C)CCC(C)(C)C2=CC(NC(=O)C3=CC=C(C=C3)C(O)=O)=CC=C12	PLASMA	08V52GZ3H9																										Human plasma protein binding: >99.9% (25ng/mL), 99.7% (100ng/mL), 99.4% (400ng/mL)	0.6			MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2005/P200500012/48011400_21700AMZ00596_Q100_2.pdf#page=30 | https://www.pmda.go.jp/drugs/2005/P200500012/48011400_21700AMZ00596_W101_1.pdf#page=1 | https://pubmed.ncbi.nlm.nih.gov/9105544/	Homo sapiens										false
4018	1844		ADULT	54677971	337.374	TENOXICAM	TENOXICAM	CN1C(C(=O)NC2=NC=CC=C2)=C(O)C3=C(C=CS3)S1(=O)=O	PLASMA	Z1R9N0A399																	UNKNOWN	mg	20		STEADY-STATE	FED		day	1		1.2	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2053921/	Homo sapiens				2 weeks dosing	arthritis		10	TENOXICAM		false
4019	1844		ADULT	54677971	337.374	TENOXICAM	TENOXICAM	CN1C(C(=O)NC2=NC=CC=C2)=C(O)C3=C(C=CS3)S1(=O)=O	PLASMA	Z1R9N0A399									∞	μg × h/mL	242.5		μg/mL	2.76			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2788089/	Homo sapiens		h	66.3				8	TENOXICAM		false
4020	1844		ADULT	54677971	337.374	TENOXICAM	TENOXICAM	CN1C(C(=O)NC2=NC=CC=C2)=C(O)C3=C(C=CS3)S1(=O)=O	PLASMA	Z1R9N0A399									∞	μg × h/mL	262.2		μg/mL	13.63			UNKNOWN	mg	20		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2788089/	Homo sapiens		h	74.2				8	TENOXICAM		false
4021	1844		ADULT	54677971	337.374	TENOXICAM	TENOXICAM	CN1C(C(=O)NC2=NC=CC=C2)=C(O)C3=C(C=CS3)S1(=O)=O	PLASMA	Z1R9N0A399									∞	mg × h/L	134						UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3497039/	Homo sapiens		h	72.1				12	TENOXICAM		false
4022	1844		ADULT	54677971	337.374	TENOXICAM	TENOXICAM	CN1C(C(=O)NC2=NC=CC=C2)=C(O)C3=C(C=CS3)S1(=O)=O	PLASMA	Z1R9N0A399									∞	mg × h/L	260						UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3497039/	Homo sapiens		h	80.8				12	TENOXICAM		false
4023	1844		ADULT	54677971	337.374	TENOXICAM	TENOXICAM	CN1C(C(=O)NC2=NC=CC=C2)=C(O)C3=C(C=CS3)S1(=O)=O	PLASMA	Z1R9N0A399									∞	mg × h/L	460						HIGHEST STUDIED	mg	40		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3497039/	Homo sapiens		h	75.1				12	TENOXICAM		false
4024	1845		UNKNOWN	443951	340.4625	TERGURIDE	Terguride	CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C)C1	UNKNOWN	21OJT43Q88									?	ng × h/mL	3.78						UNKNOWN	mg	1		UNKNOWN	UNKNOWN		day	1		32	UNKNOWN	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12704865/	Homo sapiens										false
4025	1845		ADULT	443951	340.4625	TERGURIDE	Terguride	CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C)C1	PLASMA	21OJT43Q88									?	ng × h/mL	1.12		ng/mL	1.53			UNKNOWN	μg	50		SINGLE	UNKNOWN				Cmax=C5min		HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2373136/	Homo sapiens		h	1.55				20			false
4026	1845		ADULT	443951	340.4625	TERGURIDE	Terguride	CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C)C1	PLASMA	21OJT43Q88									?	ng × h/mL	0.77		ng/mL	0.38			UNKNOWN	μg	250		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2373136/	Homo sapiens		h	1.06	Day 1			5			false
4027	1845		ADULT	443951	340.4625	TERGURIDE	Terguride	CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C)C1	PLASMA	21OJT43Q88									?	ng × h/mL	1.55		ng/mL	0.4			UNKNOWN	μg	250		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2373136/	Homo sapiens		h	1.78	Day 1			5			false
4028	1845		ADULT	443951	340.4625	TERGURIDE	Terguride	CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C)C1	PLASMA	21OJT43Q88									?	ng × h/mL	1.37		ng/mL	0.42			UNKNOWN	μg	250		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2373136/	Homo sapiens		h	2.07	After one week			5			false
4029	1845		ADULT	443951	340.4625	TERGURIDE	Terguride	CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C)C1	PLASMA	21OJT43Q88									?	ng × h/mL	1.85		ng/mL	0.64			UNKNOWN	μg	250		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2373136/	Homo sapiens		h	2.27	After one week			5			false
4030	1845		ADULT	443951	340.4625	TERGURIDE	Terguride	CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C)C1	PLASMA	21OJT43Q88									?	ng × h/mL	0.64		ng/mL	0.31			UNKNOWN	μg	500		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2373136/	Homo sapiens		h	0.74	Day 1			5			false
4031	1845		ADULT	443951	340.4625	TERGURIDE	Terguride	CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C)C1	PLASMA	21OJT43Q88									?	ng × h/mL	3.09		ng/mL	0.95			UNKNOWN	μg	500		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2373136/	Homo sapiens		h	1.62	Day 1			5			false
4032	1845		ADULT	443951	340.4625	TERGURIDE	Terguride	CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C)C1	PLASMA	21OJT43Q88									?	ng × h/mL	1.49		ng/mL	0.6			UNKNOWN	μg	500		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2373136/	Homo sapiens		h	1.34	After one week			5			false
4033	1845		ADULT	443951	340.4625	TERGURIDE	Terguride	CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C)C1	PLASMA	21OJT43Q88									?	ng × h/mL	3.11		ng/mL	0.82			UNKNOWN	μg	500		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2373136/	Homo sapiens		h	2.05	After one week			5			false
4034	1845		ADULT	443951	340.4625	TERGURIDE	Terguride	CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C)C1	PLASMA	21OJT43Q88									?	ng × h/mL	3		ng/mL	1.51			UNKNOWN	μg	750		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2373136/	Homo sapiens		h	1.73	Day 1			5			false
4035	1845		ADULT	443951	340.4625	TERGURIDE	Terguride	CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C)C1	PLASMA	21OJT43Q88									?	ng × h/mL	5.56		ng/mL	1.64			UNKNOWN	μg	750		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2373136/	Homo sapiens		h	1.61	Day 1			5			false
4036	1845		ADULT	443951	340.4625	TERGURIDE	Terguride	CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C)C1	PLASMA	21OJT43Q88									?	ng × h/mL	1.87		ng/mL	0.93			UNKNOWN	μg	750		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2373136/	Homo sapiens		h	1.32	After one week			5			false
4037	1845		ADULT	443951	340.4625	TERGURIDE	Terguride	CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C)C1	PLASMA	21OJT43Q88									?	ng × h/mL	3.81		ng/mL	1.03			UNKNOWN	μg	750		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2373136/	Homo sapiens		h	1.49	After one week			5			false
4038	1845		ADULT	443951	340.4625	TERGURIDE	Terguride	CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C)C1	PLASMA	21OJT43Q88									?	ng × h/mL	9.49		ng/mL	2.28			UNKNOWN	mg	1		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3732377/	Homo sapiens		h	2.47		Eight patients with a prolactinoma and one with acromegaly		9			false
4039	1845		ADULT	443951	340.4625	TERGURIDE	Terguride	CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C)C1	PLASMA	21OJT43Q88									?	ng × h/mL	9.49		ng/mL	2.28			UNKNOWN	mg	1		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3732377/	Homo sapiens		h	2.47		Eight patients with a prolactinoma and one with acromegaly		9			false
4040	1846		ADULT	644076	1056.2	LYPRESSIN	Lypressin	C1C[C@H](N(C1)C(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N	PLASMA	7CZF3L922Y							24		t	ng × h/mL	11.2		ng/mL	1.16			RECOMMENDED	mg	1		MULTIPLE	UNKNOWN		day	4	steady-state		UNHEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/022231Orig1s000IntegratedR.pdf#page=49 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022231s000lbl.pdf#page=8	Homo sapiens		h	3	equivalent to 0.85 mg Terlipressin	derived from PPK			Terlipressin acetate		false
4041	1846		ADULT	72081	1227.4	TERLIPRESSIN	Terlipressin	C1C[C@H](N(C1)C(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N	PLASMA	7Z5X49W53P							24		t	ng × h/mL	123		ng/mL	70.5			RECOMMENDED	mg	1		MULTIPLE	UNKNOWN		day	4	steady-state		UNHEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/022231Orig1s000IntegratedR.pdf#page=49 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022231s000lbl.pdf#page=8	Homo sapiens		h	0.9	equivalent to 0.85 mg Terlipressin	derived from PPK			Terlipressin acetate		false
4042	1847			27200	356.222	THIAMPHENICOL	Thiamphenicol	CS(=O)(=O)C1=CC=C(C=C1)[C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl	PLASMA	FLQ7571NPM																										little bound to plasma proteins (0 to 10%)	100				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/624692/	Homo sapiens										false
4043	1847			27200	356.222	THIAMPHENICOL	Thiamphenicol	CS(=O)(=O)C1=CC=C(C=C1)[C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl	SERUM	FLQ7571NPM																										Human serum protein binding: <=10%	90				REVIEW	https://pubmed.ncbi.nlm.nih.gov/6523312/	Homo sapiens										false
4044	1847		ADULT	27200	356.222	THIAMPHENICOL	Thiamphenicol	CS(=O)(=O)C1=CC=C(C=C1)[C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl	PLASMA	FLQ7571NPM									∞	μg × h/mL	30.1						UNKNOWN	g	0.5		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/6523312/	Homo sapiens		h	2.1				6			false
4045	1847		ADULT	27200	356.222	THIAMPHENICOL	Thiamphenicol	CS(=O)(=O)C1=CC=C(C=C1)[C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl	PLASMA	FLQ7571NPM									∞	μg × h/mL	34		μg/mL	8.3			UNKNOWN	g	0.5		SINGLE	UNKNOWN						HEALTHY	Intramuscular	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/6523312/	Homo sapiens		h	2.8				6			false
4046	1847		ADULT	27200	356.222	THIAMPHENICOL	Thiamphenicol	CS(=O)(=O)C1=CC=C(C=C1)[C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl	PLASMA	FLQ7571NPM									∞	μg × h/mL	29.4		μg/mL	5.6			UNKNOWN	g	0.5		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/6523312/	Homo sapiens		h	2.7				6			false
4047	1847		ADULT	27200	356.222	THIAMPHENICOL	Thiamphenicol	CS(=O)(=O)C1=CC=C(C=C1)[C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl	PLASMA	FLQ7571NPM									∞	μg × h/mL	117.1		μg/mL	32.3			UNKNOWN	g	1.5		SINGLE	UNKNOWN						HEALTHY	Intramuscular	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/6523312/	Homo sapiens		h	3.2				6			false
4048	1847		ADULT	27200	356.222	THIAMPHENICOL	Thiamphenicol	CS(=O)(=O)C1=CC=C(C=C1)[C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl	PLASMA	FLQ7571NPM									∞	μg × h/mL	167.3		μg/mL	17.6			UNKNOWN	g	2.5		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/6523312/	Homo sapiens		h	6.1				6			false
4049	1847		ADULT	27200	356.222	THIAMPHENICOL	Thiamphenicol	CS(=O)(=O)C1=CC=C(C=C1)[C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl	PLASMA	FLQ7571NPM									∞	μg × h/mL	28.8		μg/mL	5.9			UNKNOWN	g	0.5		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/6523312/	Homo sapiens		h	2.6	0.5g/1 capsule			6			false
4050	1847		ADULT	27200	356.222	THIAMPHENICOL	Thiamphenicol	CS(=O)(=O)C1=CC=C(C=C1)[C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl	PLASMA	FLQ7571NPM									∞	μg × h/mL	29.4		μg/mL	5.6			UNKNOWN	g	0.5		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/6523312/	Homo sapiens		h	2.7	0.5g/2 capsules			6			false
4051	1847		ADULT	27200	356.222	THIAMPHENICOL	Thiamphenicol	CS(=O)(=O)C1=CC=C(C=C1)[C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl	PLASMA	FLQ7571NPM									∞	μg × h/mL	149.1		μg/mL	18.6			UNKNOWN	g	2.5		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/6523312/	Homo sapiens		h	5.1	2.5g/1 sachet			6			false
4052	1847		ADULT	27200	356.222	THIAMPHENICOL	Thiamphenicol	CS(=O)(=O)C1=CC=C(C=C1)[C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl	PLASMA	FLQ7571NPM									∞	μg × h/mL	167.3		μg/mL	16.7			UNKNOWN	g	2.5		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/6523312/	Homo sapiens		h	6.1	2.5g/10 capsules			6			false
4053	1847		ADULT	27200	356.222	THIAMPHENICOL	Thiamphenicol	CS(=O)(=O)C1=CC=C(C=C1)[C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl	PLASMA	FLQ7571NPM									∞	μg × h/mL	158.9		μg/mL	17.6			UNKNOWN	g	2.5		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/6523312/	Homo sapiens		h	6	2.5g/1 sachet			6			false
4054	1847		ADULT	27200	356.222	THIAMPHENICOL	Thiamphenicol	CS(=O)(=O)C1=CC=C(C=C1)[C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl	PLASMA	FLQ7571NPM									∞	μg × h/mL	178.6		μg/mL	16.1			UNKNOWN	g	2.5		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/6523312/	Homo sapiens		h	7.3	2.5g/5 capsules			6			false
4055	1847		ADULT	27200	356.222	THIAMPHENICOL	Thiamphenicol	CS(=O)(=O)C1=CC=C(C=C1)[C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl	PLASMA	FLQ7571NPM									∞	μg × h/mL	171.6		μg/mL	17.8			UNKNOWN	g	2.5		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/6523312/	Homo sapiens		h	6.9	2.5g/1 sachet			6			false
4056	1848		CHILD	5468	260.308	TIAPROFENIC ACID	Tiaprofenic acid	CC(C(O)=O)C1=CC=C(S1)C(=O)C2=CC=CC=C2	PLASMA	1LS1T6R34C	1244|3000715	242.338	THIOPENTAL	Thiopental	CCCC(C)C1(CC)C(=O)NC(=S)NC1=O	JI8Z5M7NA3			∞	mg × h/L	37.7		mg/L	7.4			UNKNOWN	mg/kg	3		SINGLE	UNKNOWN						HEALTHY	Intragastric	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1748142/	Homo sapiens		h	2.69		Age 4.2 y (3.5-4.5 y)	and alcuronium	4			true
4057	1848		CHILD	5468	260.308	TIAPROFENIC ACID	Tiaprofenic acid	CC(C(O)=O)C1=CC=C(S1)C(=O)C2=CC=CC=C2	PLASMA	1LS1T6R34C	1244|3000715	242.338	THIOPENTAL	Thiopental	CCCC(C)C1(CC)C(=O)NC(=S)NC1=O	JI8Z5M7NA3			∞	mg × h/L	35.8		mg/L	7.8			UNKNOWN	mg/kg	3		SINGLE	UNKNOWN						HEALTHY	Intragastric	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1748142/	Homo sapiens		h	2		Age 6.3 y (5.66-6.8 y)	and alcuronium	4			true
4058	1848		CHILD	5468	260.308	TIAPROFENIC ACID	Tiaprofenic acid	CC(C(O)=O)C1=CC=C(S1)C(=O)C2=CC=CC=C2	PLASMA	1LS1T6R34C	1244|3000715	242.338	THIOPENTAL	Thiopental	CCCC(C)C1(CC)C(=O)NC(=S)NC1=O	JI8Z5M7NA3			∞	mg × h/L	44.3		mg/L	11.1			UNKNOWN	mg/kg	3		SINGLE	UNKNOWN						HEALTHY	Intragastric	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1748142/	Homo sapiens		h	2.36		Age 9.3 y (7.75-10.6 y)	and alcuronium	4			true
4059	1848		CHILD	5468	260.308	TIAPROFENIC ACID	Tiaprofenic acid	CC(C(O)=O)C1=CC=C(S1)C(=O)C2=CC=CC=C2	PLASMA	1LS1T6R34C	1244|3000715	242.338	THIOPENTAL	Thiopental	CCCC(C)C1(CC)C(=O)NC(=S)NC1=O	JI8Z5M7NA3			∞	mg × h/L	39.3		mg/L	8.78			UNKNOWN	mg/kg	3		SINGLE	UNKNOWN						HEALTHY	Intragastric	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1748142/	Homo sapiens		h	2.35		Age 6.6 y (3.5-10.6 y)	and alcuronium	12			true
4060	1848			5468	260.308	TIAPROFENIC ACID	Tiaprofenic acid	CC(C(O)=O)C1=CC=C(S1)C(=O)C2=CC=CC=C2	SERUM	1LS1T6R34C																										Human albumin binding: 97.9% (ultrafiltration)	2.1				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/301929/	Homo sapiens										false
4061	1848		ADULT	5468	260.308	TIAPROFENIC ACID	Tiaprofenic acid	CC(C(O)=O)C1=CC=C(S1)C(=O)C2=CC=CC=C2	PLASMA	1LS1T6R34C							8		t	μg × h/mL	77.25		μg/mL	21.3			UNKNOWN	mg	200		MULTIPLE	FASTED		day	3			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3582474/	Homo sapiens		h	2.05	Day 1	Elderly Patients with Arthritis (69-78 y)		10			false
4062	1848		ADULT	5468	260.308	TIAPROFENIC ACID	Tiaprofenic acid	CC(C(O)=O)C1=CC=C(S1)C(=O)C2=CC=CC=C2	PLASMA	1LS1T6R34C							8		t	μg × h/mL	79.6		μg/mL	20.7			UNKNOWN	mg	200		MULTIPLE	FASTED		day	3			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3582474/	Homo sapiens		h	2.25	Day 8	Elderly Patients with Arthritis (69-78 y)		10			false
4063	1848		ADULT	5468	260.308	TIAPROFENIC ACID	Tiaprofenic acid	CC(C(O)=O)C1=CC=C(S1)C(=O)C2=CC=CC=C2	PLASMA	1LS1T6R34C									?	μg × h/mL	76.71		μg/mL	22			UNKNOWN	mg	200		STEADY-STATE	UNKNOWN		day	3	Fu<1.5%, equilibrium dialysis	1.5	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4067848/	Homo sapiens		h	2.77				6			false
4064	1848		ADULT	5468	260.308	TIAPROFENIC ACID	Tiaprofenic acid	CC(C(O)=O)C1=CC=C(S1)C(=O)C2=CC=CC=C2	PLASMA	1LS1T6R34C									?	μg × h/mL	65.53		μg/mL	21.9			UNKNOWN	mg	200		STEADY-STATE	UNKNOWN		day	3	Fu<1.5%, equilibrium dialysis	1.5	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4067848/	Homo sapiens		h	2.47		Arthritic subjects		8			false
4065	1848		NEWBORN	5468	260.308	TIAPROFENIC ACID	Tiaprofenic acid	CC(C(O)=O)C1=CC=C(S1)C(=O)C2=CC=CC=C2	PLASMA	1LS1T6R34C									∞	mg × h/L	35.33		mg/L	10.55			UNKNOWN	mg/kg	3		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8864796/	Homo sapiens		h	1.82		Healthy infants (6-35 months, mean 15.2 months)		10			false
4066	1848			5468	260.308	TIAPROFENIC ACID	Tiaprofenic acid	CC(C(O)=O)C1=CC=C(S1)C(=O)C2=CC=CC=C2	PLASMA	1LS1T6R34C																										Human protein binding: 97-98%	3				OTHER	https://www.medicines.org.uk/emc/product/2256#PHARMACOKINETIC_PROPS	Homo sapiens										false
4067	1849		ADULT	610479	261.704	TOLFENAMIC ACID	TOLFENAMIC ACID	CC1=C(Cl)C=CC=C1NC2=C(C=CC=C2)C(O)=O	PLASMA	3G943U18KM									∞	μg × h/mL	8.24						RECOMMENDED	mg	100		SINGLE	UNKNOWN					1.1	HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	doi:10.1007/bf00544587	Homo sapiens		h	1.7				6	tolfenamic acid		false
4068	1849		ADULT	610479	261.704	TOLFENAMIC ACID	TOLFENAMIC ACID	CC1=C(Cl)C=CC=C1NC2=C(C=CC=C2)C(O)=O	PLASMA	3G943U18KM									∞	μg × h/mL	11.17						RECOMMENDED	mg	100		SINGLE	FASTED					0.3	HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	doi:10.1007/bf00544587	Homo sapiens		h	1.62	sodium salt of tolfenamic acid, 100 mg as acid, was dissolved in 100 cc of physiological sodium chloride solution. The solution was infused over 30 rain via a cubital vein			6	tolfenamic acid		false
4069	1849		ADULT	610479	261.704	TOLFENAMIC ACID	TOLFENAMIC ACID	CC1=C(Cl)C=CC=C1NC2=C(C=CC=C2)C(O)=O	PLASMA	3G943U18KM									∞	μg × h/mL	7.5		μg/mL	1.9			RECOMMENDED	mg	100		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	doi:10.1007/bf00544587	Homo sapiens		h	2.5	Medica Pharmaceutical Company Ltd capsule			6	Clotam		false
4070	1850		UNKNOWN		761.837	TRABECTEDIN	TRABECTEDIN	COC1=CC2=C(CCN[C@]23CS[C@H]4[C@H]5[C@@H]6N(C)[C@@H](CC7=CC(C)=C(OC)C(O)=C67)[C@H](O)N5[C@@H](COC3=O)C8=C9OCOC9=C(C)C(OC(C)=O)=C48)C=C1O	PLASMA	ID0YZQ2TCP																						UNKNOWN				Binding of trabectedin to human plasma proteins was approximately 97%, independent of trabectedin concentrations ranging from 10 ng/mL to 100 ng/mL.	3	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207953s000lbl.pdf	Homo sapiens										false
4071	1850		ADULT		761.837	TRABECTEDIN	TRABECTEDIN	COC1=CC2=C(CCN[C@]23CS[C@H]4[C@H]5[C@@H]6N(C)[C@@H](CC7=CC(C)=C(OC)C(O)=C67)[C@H](O)N5[C@@H](COC3=O)C8=C9OCOC9=C(C)C(OC(C)=O)=C48)C=C1O	BLOOD	ID0YZQ2TCP									∞	ng × h/mL	33		μg/mL	11.3			MAX TOLERATED	mg/m²	0.61		MULTIPLE	UNKNOWN		hour	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/19417019	Homo sapiens										false
4072	1850		ADULT		761.837	TRABECTEDIN	TRABECTEDIN	COC1=CC2=C(CCN[C@]23CS[C@H]4[C@H]5[C@@H]6N(C)[C@@H](CC7=CC(C)=C(OC)C(O)=C67)[C@H](O)N5[C@@H](COC3=O)C8=C9OCOC9=C(C)C(OC(C)=O)=C48)C=C1O	BLOOD	ID0YZQ2TCP									∞	μg × h/mL	23.5		μg/mL	6.47			MAX TOLERATED	mg/m²	0.58		MULTIPLE	UNKNOWN		hour	3			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/19417019	Homo sapiens										false
4073	1851		ADULT	5282230	327.3313	TRANILAST	Tranilast	COC1=C(OC)C=C(\\C=C\\C(=O)NC2=C(C=CC=C2)C(O)=O)C=C1	PLASMA	HVF50SMY6E									?	μg × h/mL	93.02		μg/mL	10.04			UNKNOWN	mg	80		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17044126/	Homo sapiens		h	9.1				22			false
4074	1851		ADULT	5282230	327.3313	TRANILAST	Tranilast	COC1=C(OC)C=C(\\C=C\\C(=O)NC2=C(C=CC=C2)C(O)=O)C=C1	PLASMA	HVF50SMY6E							4		t	ng × h/mL	50.8		ng/mL	17.8			RECOMMENDED	drop	4		SINGLE	UNKNOWN						HEALTHY	Ocular	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/230034_1319736Q1076_1_004_1F.pdf#page=17	Homo sapiens		h	3.6	2 drops/eye x both eyes			6	Rizaben eye drops 0.5%		false
4075	1851		ADULT	5282230	327.3313	TRANILAST	Tranilast	COC1=C(OC)C=C(\\C=C\\C(=O)NC2=C(C=CC=C2)C(O)=O)C=C1	PLASMA	HVF50SMY6E							4		t	ng × h/mL	75.6		ng/mL	25			RECOMMENDED	drop	4		MULTIPLE	UNKNOWN		day	4			HEALTHY	Ocular	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/230034_1319736Q1076_1_004_1F.pdf#page=17	Homo sapiens		h	3.9	2 drops/eye x both eyes, Day 8			6	Rizaben eye drops 0.5%		false
4076	1851		ADULT	5282230	327.3313	TRANILAST	Tranilast	COC1=C(OC)C=C(\\C=C\\C(=O)NC2=C(C=CC=C2)C(O)=O)C=C1	SERUM	HVF50SMY6E													μg/mL	22.2			UNKNOWN	mg/kg	2.5		STEADY-STATE	UNKNOWN		day	3			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/230034_4490002C1123_1_002_1F.pdf#page=23	Homo sapiens				Day 2 (5-day repeated administration)			3			false
4077	1851		ADULT	5282230	327.3313	TRANILAST	Tranilast	COC1=C(OC)C=C(\\C=C\\C(=O)NC2=C(C=CC=C2)C(O)=O)C=C1	PLASMA	HVF50SMY6E									?	μg × h/mL	114.4		μg/mL	12.6			RECOMMENDED	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/230034_4490002C1123_1_002_1F.pdf#page=23	Homo sapiens		h	5.3				10			false
4078	1851		ADULT	5282230	327.3313	TRANILAST	Tranilast	COC1=C(OC)C=C(\\C=C\\C(=O)NC2=C(C=CC=C2)C(O)=O)C=C1	PLASMA	HVF50SMY6E																						UNKNOWN				Human plasma protein binding: 81.7% (2-h after 5mg/kg PO administration)	18.3	HEALTHY		UNKNOWN	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/230034_4490002C1123_1_002_1F.pdf#page=24	Homo sapiens							3			false
4079	1851		ADULT	5282230	327.3313	TRANILAST	Tranilast	COC1=C(OC)C=C(\\C=C\\C(=O)NC2=C(C=CC=C2)C(O)=O)C=C1	PLASMA	HVF50SMY6E									∞	μg × h/mL	422		μg/mL	42.2			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.jfda-online.com/journal/vol10/iss3/6/	Homo sapiens		h	7.58				24			false
4080	1853		ADULT	72172|6992132	308.3728	UBENIMEX	Ubenimex	CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1)C(O)=O	PLASMA	I0J33N5627									∞	μg × h/L	3957.04		μg/L	2416.83			UNKNOWN	mg	30		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://en.cnki.com.cn/Article_en/CJFDTotal-ZXYZ201206014.htm	Homo sapiens		h	3.49				24			false
4081	1853		ADULT	72172|6992132	308.3728	UBENIMEX	Ubenimex	CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1)C(O)=O	SERUM	I0J33N5627							24		t	μg × h/mL	5.211		μg/mL	2.213			DEFINED DAILY	mg	30		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/530191_4299002M1034_1_005_1F.pdf#page=33	Homo sapiens		h	5.74				5			false
4082	1853			72172|6992132	308.3728	UBENIMEX	Ubenimex	CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1)C(O)=O	SERUM	I0J33N5627																										Human serum protein binding: 16.76% (0.5 mcg/mL), 11.65% (2.0 mcG/mL)	88.35				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/530191_4299002M1034_1_005_1F.pdf#page=33	Homo sapiens										false
4083	1854		ADULT	444020	267.2762	VOGLIBOSE	Voglibose	OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O	BLOOD	S77P977AG8							24		t	ng × h/mL	168		ng/mL	20.7			UNKNOWN	mg	80		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/400061_3969004F1020_2_001_1F.pdf#page=40	Homo sapiens		h	5.33				6			false
4084	1854			444020	267.2762	VOGLIBOSE	Voglibose	OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O	SERUM	S77P977AG8																										Human serum protein binding: 1% (5ng/mL), 4% (50ng/mL), 7% (500ng/mL)	93				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/400061_3969004F1020_2_001_1F.pdf#page=47	Homo sapiens										false
4085	1855		ADULT	92400	429.552	ZOFENOPRIL	Zofenopril	C[C@H](CSC(=O)C1=CC=CC=C1)C(=O)N2C[C@H](C[C@H]2C(O)=O)SC3=CC=CC=C3	PLASMA	290ZY759PI																						UNKNOWN				After administration of both PO 14C-Zofenopril and iv 14C-Zofenoprilat L-arginine salt, the binding of radioactivity to plasma proteins averaged -86% at 20 min and 75% at 2 h.	14	HEALTHY		MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2292772/	Homo sapiens							6			false
4086	1855		ADULT	92400	429.552	ZOFENOPRIL	Zofenopril	C[C@H](CSC(=O)C1=CC=CC=C1)C(=O)N2C[C@H](C[C@H]2C(O)=O)SC3=CC=CC=C3	PLASMA	290ZY759PI									∞	ng × h/mL	61.04		ng/mL	51.96			UNKNOWN	mg	15		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24935917/	Homo sapiens		h	1.74				12	Zofenopril calcium		false
4087	1855		ADULT	92400	429.552	ZOFENOPRIL	Zofenopril	C[C@H](CSC(=O)C1=CC=CC=C1)C(=O)N2C[C@H](C[C@H]2C(O)=O)SC3=CC=CC=C3	PLASMA	290ZY759PI							24		t	ng × h/mL	77.8		ng/mL	71.22			UNKNOWN	mg	30		STEADY-STATE	UNKNOWN		day	1	AUCinf=78.83 ng x h/mL		HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24935917/	Homo sapiens		h	2.55	Day 6			12	Zofenopril calcium		false
4088	1855		ADULT	3034048	325.446	ZOFENOPRILAT	Zofenoprilat	C[C@H](CS)C(=O)N1C[C@H](C[C@H]1C(O)=O)SC2=CC=CC=C2	PLASMA	4G4WDK2YBS									∞	ng × h/mL	1453.86		ng/mL	689			UNKNOWN	mg	30		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24935917/	Homo sapiens		h	6.45				12	Zofenopril calcium		false
4089	1855		ADULT	3034048	325.446	ZOFENOPRILAT	Zofenoprilat	C[C@H](CS)C(=O)N1C[C@H](C[C@H]1C(O)=O)SC2=CC=CC=C2	PLASMA	4G4WDK2YBS									∞	ng × h/mL	3550.01		ng/mL	1563.89			UNKNOWN	mg	60		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24935917/	Homo sapiens		h	5.69				12	Zofenopril calcium		false
4090	1855		ADULT	3034048	325.446	ZOFENOPRILAT	Zofenoprilat	C[C@H](CS)C(=O)N1C[C@H](C[C@H]1C(O)=O)SC2=CC=CC=C2	PLASMA	4G4WDK2YBS									∞	ng × h/mL	1577.25		ng/mL	528.34			UNKNOWN	mg	30		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24935917/	Homo sapiens		h	6.22				12	Zofenopril calcium		false
4091	1855		ADULT	3034048	325.446	ZOFENOPRILAT	Zofenoprilat	C[C@H](CS)C(=O)N1C[C@H](C[C@H]1C(O)=O)SC2=CC=CC=C2	PLASMA	4G4WDK2YBS							24		t	ng × h/mL	1041.27		ng/mL	581.16			UNKNOWN	mg	30		STEADY-STATE	UNKNOWN		day	1	AUCinf=1108.28 ng x h/mL		HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24935917/	Homo sapiens		h	7	Day 6			12	Zofenopril calcium		false
4092	1855		ADULT	92400	429.552	ZOFENOPRIL	Zofenopril	C[C@H](CSC(=O)C1=CC=CC=C1)C(=O)N2C[C@H](C[C@H]2C(O)=O)SC3=CC=CC=C3	PLASMA	290ZY759PI									∞	ng × h/mL	99.02		ng/mL	95.95			UNKNOWN	mg	30		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24935917/	Homo sapiens		h	1.52				12	Zofenopril calcium		false
4093	1855		ADULT	92400	429.552	ZOFENOPRIL	Zofenopril	C[C@H](CSC(=O)C1=CC=CC=C1)C(=O)N2C[C@H](C[C@H]2C(O)=O)SC3=CC=CC=C3	PLASMA	290ZY759PI									∞	ng × h/mL	229.8		ng/mL	177.94			UNKNOWN	mg	60		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24935917/	Homo sapiens		h	1.39				12	Zofenopril calcium		false
4094	1855		ADULT	92400	429.552	ZOFENOPRIL	Zofenopril	C[C@H](CSC(=O)C1=CC=CC=C1)C(=O)N2C[C@H](C[C@H]2C(O)=O)SC3=CC=CC=C3	PLASMA	290ZY759PI									∞	ng × h/mL	60.02		ng/mL	36.2			UNKNOWN	mg	30		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24935917/	Homo sapiens		h	1.19				12	Zofenopril calcium		false
4095	1855		ADULT	3034048	325.446	ZOFENOPRILAT	Zofenoprilat	C[C@H](CS)C(=O)N1C[C@H](C[C@H]1C(O)=O)SC2=CC=CC=C2	PLASMA	4G4WDK2YBS									∞	ng × h/mL	804.96		ng/mL	339.59			UNKNOWN	mg	15		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24935917/	Homo sapiens		h	5.38				12	Zofenopril calcium		false
4096	1856			5736	331.86	ZOTEPINE	Zotepine	CN(C)CCOC1=CC2=C(SC3=CC=C(Cl)C=C13)C=CC=C2	PLASMA	U29O83JAZW																										In total 97% of zotepine is plasma protein bound.	3				REVIEW	https://pubmed.ncbi.nlm.nih.gov/20486863/	Homo sapiens										false
4097	1856		ADULT	5736	331.86	ZOTEPINE	Zotepine	CN(C)CCOC1=CC2=C(SC3=CC=C(Cl)C=C13)C=CC=C2	PLASMA	U29O83JAZW									∞	ng × h/mL	316.3		ng/mL	30.9			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/4/171911_1179024C1033_4_002_1F.pdf#page=22 | https://www.sciencedirect.com/science/article/pii/S0924977X98806068	Homo sapiens		h	13				24			false
4098	1856		ADULT	5736	331.86	ZOTEPINE	Zotepine	CN(C)CCOC1=CC2=C(SC3=CC=C(Cl)C=C13)C=CC=C2	PLASMA	U29O83JAZW									∞	ng × h/mL	159		ng/mL	13.2			UNKNOWN	mg	50		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/4/171911_1179024C1033_4_002_1F.pdf#page=22 | https://www.sciencedirect.com/science/article/pii/S0924977X98806068	Homo sapiens		h	12.8				24			false
4099	1856		ADULT	5736	331.86	ZOTEPINE	Zotepine	CN(C)CCOC1=CC2=C(SC3=CC=C(Cl)C=C13)C=CC=C2	PLASMA	U29O83JAZW									∞	ng × h/mL	123		ng/mL	7.8			UNKNOWN	mg	25		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/4/171911_1179024C1033_4_002_1F.pdf#page=22 | https://www.sciencedirect.com/science/article/pii/S0924977X98806068	Homo sapiens		h	14.1				24			false
4100	1856			5736	331.86	ZOTEPINE	Zotepine	CN(C)CCOC1=CC2=C(SC3=CC=C(Cl)C=C13)C=CC=C2	SERUM	U29O83JAZW																										Human serum albumin binding: 97%	3				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/4/171911_1179024C1033_4_002_1F.pdf#page=25	Homo sapiens										false
4101	1857		ADULT	2811	318.821	CLOTIAZEPAM	Clotiazepam	CCC1=CC2=C(S1)N(C)C(=O)CN=C2C3=C(Cl)C=CC=C3	PLASMA	ZCN055599V									?	ng × h/mL	528.2		ng/mL	178.8			UNKNOWN	mg	5		SINGLE	FASTED				tablets		HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2575522/	Homo sapiens		h	4.62				6			false
4102	1857		ADULT	2811	318.821	CLOTIAZEPAM	Clotiazepam	CCC1=CC2=C(S1)N(C)C(=O)CN=C2C3=C(Cl)C=CC=C3	PLASMA	ZCN055599V							24		t	ng × h/mL	1798		ng/mL	383			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/300119_1179012F1169_1_071_1F.pdf#page=21	Homo sapiens		h	5.3				12			false
4103	1857		ADULT	2811	318.821	CLOTIAZEPAM	Clotiazepam	CCC1=CC2=C(S1)N(C)C(=O)CN=C2C3=C(Cl)C=CC=C3	PLASMA	ZCN055599V							12		t	ng × h/mL	494		ng/mL	162			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/300119_1179012F1169_1_071_1F.pdf#page=22	Homo sapiens		h	5.4				20			false
4104	1857			2811	318.821	CLOTIAZEPAM	Clotiazepam	CCC1=CC2=C(S1)N(C)C(=O)CN=C2C3=C(Cl)C=CC=C3	PLASMA	ZCN055599V																										Plasma protein binding: >=99%	1				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/300119_1179012F1169_1_071_1F.pdf#page=24 | https://pubmed.ncbi.nlm.nih.gov/6125154/	Homo sapiens										false
4105	1858		ADULT	3332	212.2439	FELBINAC	Felbinac	OC(=O)CC1=CC=C(C=C1)C2=CC=CC=C2	PLASMA	94WNJ5U8L7									∞	mg × h/mL	182		ng/mL	44879			UNKNOWN	mg	377		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32700191/	Homo sapiens		h	5.83				6	Felbinac trometamol		false
4106	1858		ADULT	3332	212.2439	FELBINAC	Felbinac	OC(=O)CC1=CC=C(C=C1)C2=CC=CC=C2	PLASMA	94WNJ5U8L7							8		t	mg × h/mL	28		ng/mL	7530			UNKNOWN	mg	47.13		MULTIPLE	UNKNOWN		day	3			HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32700191/	Homo sapiens		h	6.59	7th dose			10	Felbinac trometamol		false
4107	1858		ADULT	3332	212.2439	FELBINAC	Felbinac	OC(=O)CC1=CC=C(C=C1)C2=CC=CC=C2	PLASMA	94WNJ5U8L7									∞	mg × h/mL	5.6		ng/mL	1442			UNKNOWN	mg	11.78		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32700191/	Homo sapiens		h	4.25				6	Felbinac trometamol		false
4108	1858		ADULT	3332	212.2439	FELBINAC	Felbinac	OC(=O)CC1=CC=C(C=C1)C2=CC=CC=C2	PLASMA	94WNJ5U8L7									∞	mg × h/mL	10.7		ng/mL	2697			UNKNOWN	mg	23.56		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32700191/	Homo sapiens		h	5.18				6	Felbinac trometamol		false
4109	1858		ADULT	3332	212.2439	FELBINAC	Felbinac	OC(=O)CC1=CC=C(C=C1)C2=CC=CC=C2	PLASMA	94WNJ5U8L7									∞	mg × h/mL	22.2		ng/mL	5772			UNKNOWN	mg	47.13		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32700191/	Homo sapiens		h	4.8				6	Felbinac trometamol		false
4110	1858		ADULT	3332	212.2439	FELBINAC	Felbinac	OC(=O)CC1=CC=C(C=C1)C2=CC=CC=C2	PLASMA	94WNJ5U8L7									∞	mg × h/mL	54		ng/mL	11947			UNKNOWN	mg	94.25		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32700191/	Homo sapiens		h	6.24				6	Felbinac trometamol		false
4111	1858		ADULT	3332	212.2439	FELBINAC	Felbinac	OC(=O)CC1=CC=C(C=C1)C2=CC=CC=C2	PLASMA	94WNJ5U8L7							8		t	mg × h/mL	18		ng/mL	5817			UNKNOWN	mg	47.13		MULTIPLE	UNKNOWN		day	1			HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32700191/	Homo sapiens		h	6.12	Day 1 single dose			10	Felbinac trometamol		false
4112	1858		ADULT	3332	212.2439	FELBINAC	Felbinac	OC(=O)CC1=CC=C(C=C1)C2=CC=CC=C2	PLASMA	94WNJ5U8L7									∞	mg × h/mL	96		ng/mL	22043			UNKNOWN	mg	164.92		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32700191/	Homo sapiens		h	5.46				6	Felbinac trometamol		false
4113	1858		ADULT	3332	212.2439	FELBINAC	Felbinac	OC(=O)CC1=CC=C(C=C1)C2=CC=CC=C2	PLASMA	94WNJ5U8L7									∞	mg × h/mL	119		ng/mL	34889			UNKNOWN	mg	259.16		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32700191/	Homo sapiens		h	5.46				6	Felbinac trometamol		false
4114	1858		ADULT	3332	212.2439	FELBINAC	Felbinac	OC(=O)CC1=CC=C(C=C1)C2=CC=CC=C2	PLASMA	94WNJ5U8L7							8		t	mg × h/mL	95		ng/mL	26473			UNKNOWN	mg	188.5		MULTIPLE	UNKNOWN		day	3			HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32700191/	Homo sapiens		h	7.38	7th dose			10	Felbinac trometamol		false
4115	1858		ADULT	3332	212.2439	FELBINAC	Felbinac	OC(=O)CC1=CC=C(C=C1)C2=CC=CC=C2	PLASMA	94WNJ5U8L7							8		t	mg × h/mL	35		ng/mL	11474			UNKNOWN	mg	94.25		MULTIPLE	UNKNOWN		day	1			HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32700191/	Homo sapiens		h	5.79	Day 1 single dose			10	Felbinac trometamol		false
4116	1858		ADULT	3332	212.2439	FELBINAC	Felbinac	OC(=O)CC1=CC=C(C=C1)C2=CC=CC=C2	PLASMA	94WNJ5U8L7							8		t	mg × h/mL	48		ng/mL	13568			UNKNOWN	mg	94.25		MULTIPLE	UNKNOWN		day	3			HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32700191/	Homo sapiens		h	7	7th dose			10	Felbinac trometamol		false
4117	1858		ADULT	3332	212.2439	FELBINAC	Felbinac	OC(=O)CC1=CC=C(C=C1)C2=CC=CC=C2	PLASMA	94WNJ5U8L7							8		t	mg × h/mL	65		ng/mL	21230			UNKNOWN	mg	188.5		MULTIPLE	UNKNOWN		day	1			HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32700191/	Homo sapiens		h	5.71	Day 1 single dose			10	Felbinac trometamol		false
4118	1859		ADULT	4810	241.677	MOXONIDINE	MOXONIDINE	COC1=NC(C)=NC(Cl)=C1NC2=NCCN2	PLASMA	CC6X0L40GW									∞	ng × h/mL	3.45		ng/mL	1.04			UNKNOWN	mg	0.2		SINGLE	FASTED						HEALTHY	Oral	MALE	REVIEW	https://journals.lww.com/cardiovascularpharm/Abstract/1992/20004/Clinical_Pharmacokinetics_of_Moxonidine.8.aspx	Homo sapiens		h	2.85				15	MOXONIDINE		false
4119	1859		ADULT	4810	241.677	MOXONIDINE	MOXONIDINE	COC1=NC(C)=NC(Cl)=C1NC2=NCCN2	PLASMA	CC6X0L40GW									∞	ng × h/mL	3.23		ng/mL	0.89			UNKNOWN	mg	0.2		SINGLE	FED						HEALTHY	Oral	MALE	REVIEW	https://journals.lww.com/cardiovascularpharm/Abstract/1992/20004/Clinical_Pharmacokinetics_of_Moxonidine.8.aspx	Homo sapiens		h	2.1				15	MOXONIDINE		false
4120	1859		ADULT	4810	241.677	MOXONIDINE	MOXONIDINE	COC1=NC(C)=NC(Cl)=C1NC2=NCCN2	PLASMA	CC6X0L40GW									∞	ng × h/mL	3.67		ng/mL	1.5			UNKNOWN	mg	0.2		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	REVIEW	https://journals.lww.com/cardiovascularpharm/Abstract/1992/20004/Clinical_Pharmacokinetics_of_Moxonidine.8.aspx	Homo sapiens		h	1.98				18	MOXONIDINE		false
4121	1859		ADULT	4810	241.677	MOXONIDINE	MOXONIDINE	COC1=NC(C)=NC(Cl)=C1NC2=NCCN2	PLASMA	CC6X0L40GW									∞	ng × h/mL	4.18		ng/mL	1.29			UNKNOWN	mg	0.2		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	REVIEW	https://journals.lww.com/cardiovascularpharm/Abstract/1992/20004/Clinical_Pharmacokinetics_of_Moxonidine.8.aspx	Homo sapiens		h	2.12				12	MOXONIDINE		false
4122	1859		ADULT	4810	241.677	MOXONIDINE	MOXONIDINE	COC1=NC(C)=NC(Cl)=C1NC2=NCCN2	PLASMA	CC6X0L40GW									∞	ng × h/mL	4.2		ng/mL	3.97			UNKNOWN	mg	0.2		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	REVIEW	https://journals.lww.com/cardiovascularpharm/Abstract/1992/20004/Clinical_Pharmacokinetics_of_Moxonidine.8.aspx	Homo sapiens		h	2.18				18	MOXONIDINE		false
4123	1859		ADULT	4810	241.677	MOXONIDINE	MOXONIDINE	COC1=NC(C)=NC(Cl)=C1NC2=NCCN2	PLASMA	CC6X0L40GW									∞	ng × h/mL	4.02		ng/mL	1.33			UNKNOWN	mg	0.2		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	REVIEW	https://journals.lww.com/cardiovascularpharm/Abstract/1992/20004/Clinical_Pharmacokinetics_of_Moxonidine.8.aspx	Homo sapiens		h	1.97				12	MOXONIDINE		false
4124	1860			119369	427.5381	MOZAVAPTAN	Mozavaptan	CN(C)C1CCCN(C(=O)C2=CC=C(NC(=O)C3=CC=CC=C3C)C=C2)C4=C1C=CC=C4	PLASMA	17OJ42922Y																										Human plasma protein binding: 95.9~98.2% (ultrafiltration)	1.8				OTHER GOV'T	https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_A102_1.pdf#page=23	Homo sapiens										false
4125	1860		ADULT	119369	427.5381	MOZAVAPTAN	Mozavaptan	CN(C)C1CCCN(C(=O)C2=CC=C(NC(=O)C3=CC=CC=C3C)C=C2)C4=C1C=CC=C4	PLASMA	17OJ42922Y							48		t	ng × h/mL	10.89		ng/mL	5.491			UNKNOWN	mg	60		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_A102_1.pdf#page=24 | https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_K115_1.pdf#page=33	Homo sapiens		h	2.23				8			false
4126	1860		ADULT	119369	427.5381	MOZAVAPTAN	Mozavaptan	CN(C)C1CCCN(C(=O)C2=CC=C(NC(=O)C3=CC=CC=C3C)C=C2)C4=C1C=CC=C4	PLASMA	17OJ42922Y							48		t	ng × h/mL	23.54		ng/mL	10.079			UNKNOWN	mg	90		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_A102_1.pdf#page=24 | https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_K115_1.pdf#page=33	Homo sapiens		h	2.38				8			false
4127	1860		ADULT	119369	427.5381	MOZAVAPTAN	Mozavaptan	CN(C)C1CCCN(C(=O)C2=CC=C(NC(=O)C3=CC=CC=C3C)C=C2)C4=C1C=CC=C4	PLASMA	17OJ42922Y							48		t	ng × h/mL	5.84		ng/mL	2.826			DEFINED DAILY	mg	30		SINGLE	FASTED				n=6 for t1/2		HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_A102_1.pdf#page=24 | https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_K115_1.pdf#page=33	Homo sapiens		h	1.75				8			false
4128	1860		ADULT	119369	427.5381	MOZAVAPTAN	Mozavaptan	CN(C)C1CCCN(C(=O)C2=CC=C(NC(=O)C3=CC=CC=C3C)C=C2)C4=C1C=CC=C4	PLASMA	17OJ42922Y							24		t	ng × h/mL	10.89		ng/mL	4.36			DEFINED DAILY	mg	30		MULTIPLE	FED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_A102_1.pdf#page=24 | https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_K115_1.pdf#page=44	Homo sapiens		h	2.51	Day 10			10			false
4129	1860		ADULT	119369	427.5381	MOZAVAPTAN	Mozavaptan	CN(C)C1CCCN(C(=O)C2=CC=C(NC(=O)C3=CC=CC=C3C)C=C2)C4=C1C=CC=C4	PLASMA	17OJ42922Y							24		t	ng × h/mL	8.87		ng/mL	4.459			DEFINED DAILY	mg	30		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_A102_1.pdf#page=24 | https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_K115_1.pdf#page=44	Homo sapiens		h	2.06				10			false
4130	1860		ADULT	119369	427.5381	MOZAVAPTAN	Mozavaptan	CN(C)C1CCCN(C(=O)C2=CC=C(NC(=O)C3=CC=CC=C3C)C=C2)C4=C1C=CC=C4	PLASMA	17OJ42922Y							48		t	ng × h/mL	7.05		ng/mL	3.747			DEFINED DAILY	mg	30		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_A102_1.pdf#page=26 | https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_K115_1.pdf#page=15	Homo sapiens							15			false
4131	1860		ADULT	119369	427.5381	MOZAVAPTAN	Mozavaptan	CN(C)C1CCCN(C(=O)C2=CC=C(NC(=O)C3=CC=CC=C3C)C=C2)C4=C1C=CC=C4	PLASMA	17OJ42922Y							48		t	ng × h/mL	9.13		ng/mL	3.306			DEFINED DAILY	mg	30		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_A102_1.pdf#page=26 | https://www.pmda.go.jp/drugs/2006/P200600027/18007800_21800AMZ10369_K115_1.pdf#page=15	Homo sapiens							15			false
4132	1861		CHILD	3337	231.2573	FENFLURAMINE	FENFLURAMINE	CCNC(C)CC1=CC(=CC=C1)C(F)(F)F	PLASMA	2DS058H2CF							24		t	ng × h/mL	1390		ng/mL	68			RECOMMENDED	mg/kg	0.35		STEADY-STATE	UNKNOWN		day	2	Fenfluramine is 50% bound to human plasma proteins in vitro and binding is independent of drug concentrations.	50	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212102s000lbl.pdf	Homo sapiens		h	20							false
4133	1862		ADULT	68791|137319722	111.102	IMEXON	IMEXON	NC1=NC(=O)N2CC12	PLASMA	8F63U28T2V	135398738		DACARBAZINE	dacarbazine	CN(C)\\N=N\\C1=C(N=CN1)C(N)=O	7GR28W0FJI			?	μg × h/mL	82.1		μg/mL	62			MAX TOLERATED	mg/m²	1000	infusion, 30 min	OTHER	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/20564083	Homo sapiens		h	1							true
4134	1862		ADULT	68791|137319722	111.102	IMEXON	IMEXON	NC1=NC(=O)N2CC12	PLASMA	8F63U28T2V	135398738		DACARBAZINE	dacarbazine	CN(C)\\N=N\\C1=C(N=CN1)C(N)=O	7GR28W0FJI			?	μg × h/mL	55.3		μg/mL	38.5			MAX TOLERATED	mg/m²	1000	infusion, 45 min	OTHER	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/20564083	Homo sapiens		h	0.99							true
4135	1863		ADULT	448013	507.683	PATUPILONE	PATUPILONE	C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\\C)=C\\C3=CSC(C)=N3	PLASMA	UEC0H0URSE									∞	ng × h/mL	1386		ng/mL	139			UNKNOWN	mg/m²	11		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19451434	Homo sapiens		h	100				6	PATUPILONE		false
4136	1864		ADULT	448055	275.3428	ROLIPRAM, (R)-	(R)-Rolipram	COC1=C(OC2CCCC2)C=C(C=C1)[C@@H]3CNC(=O)C3	PLASMA	DPX51KUP08																						UNKNOWN				High protein binding of approximately 96% was observed in arterial plasma (R-[11C]rolipram, ultrafiltration).	4	HEALTHY		FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12458404/	Homo sapiens							11			false
4137	1864		ADULT	158758	275.3428	ROLIPRAM, (S)-	Rolipram, (S)-	COC1=C(OC2CCCC2)C=C(C=C1)[C@H]3CNC(=O)C3	PLASMA	H6G4VMQ24K							24		t	ng × h/mL	18.5		ng/mL	1.21			UNKNOWN	mg	12.5		SINGLE	UNKNOWN						HEALTHY	Topical	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2095571/	Homo sapiens		h	3.7	0.1mg ( )-Rolipram iv			6			false
4138	1864		ADULT	448055	275.3428	ROLIPRAM, (R)-	Rolipram, (-)-	COC1=C(OC2CCCC2)C=C(C=C1)[C@@H]3CNC(=O)C3	PLASMA	DPX51KUP08									?	ng × h/mL	4.27		ng/mL	5.6			UNKNOWN	mg	0.1		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2328751/	Homo sapiens		h	8.4	0.1mg (-)-Rolipram iv administration			6			false
4139	1864		ADULT	158758	275.3428	ROLIPRAM, (S)-	Rolipram, (S)-	COC1=C(OC2CCCC2)C=C(C=C1)[C@H]3CNC(=O)C3	PLASMA	H6G4VMQ24K									?	ng × h/mL	4.24		ng/mL	3.9			UNKNOWN	mg	0.1		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2328751/	Homo sapiens		h	5.7	0.1mg (plus)-Rolipram iv administration			6			false
4140	1864		ADULT	158758	275.3428	ROLIPRAM, (S)-	Rolipram, (S)-	COC1=C(OC2CCCC2)C=C(C=C1)[C@H]3CNC(=O)C3	PLASMA	H6G4VMQ24K									?	ng × h/mL	29.2		ng/mL	15.7			UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2328751/	Homo sapiens		h	4.6	1.0mg (plus)-Rolipram oral administration			6			false
4141	1864		ADULT	448055	275.3428	ROLIPRAM, (R)-	Rolipram, (-)-	COC1=C(OC2CCCC2)C=C(C=C1)[C@@H]3CNC(=O)C3	PLASMA	DPX51KUP08									?	ng × h/mL	28.9		ng/mL	16.4			UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2328751/	Homo sapiens		h	9.4	1.0mg (-)-Rolipram oral administration			6			false
4142	1866		ADULT	6100671	326.4326	AJMALINE	Ajmaline	CC[C@H]1[C@@H]2C[C@H]3[C@@H]4N(C)C5=C(C=CC=C5)[C@]46C[C@@H]([C@H]2[C@H]6O)N3[C@@H]1O	PLASMA	1PON08459R									?	mg × h/L	0.32						UNKNOWN	mg	50		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2591421/	Homo sapiens		min	95		Patients with acute myocardial infarction and ventricular arrhythmia of Lown class IT - IIIB of acute onset (normal kidney and liver function)		5			false
4143	1866		ADULT	6100671	326.4326	AJMALINE	Ajmaline	CC[C@H]1[C@@H]2C[C@H]3[C@@H]4N(C)C5=C(C=CC=C5)[C@]46C[C@@H]([C@H]2[C@H]6O)N3[C@@H]1O	PLASMA	1PON08459R									?	mg × h/L	0.36						UNKNOWN	mg	50		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2591421/	Homo sapiens		min	99		Patients with acute myocardial infarction and ventricular arrhythmia of Lown class IT - IIIB of acute onset (acute renal failure and hemodialysis treatment)		4			false
4144	1866		ADULT	6100671	326.4326	AJMALINE	Ajmaline	CC[C@H]1[C@@H]2C[C@H]3[C@@H]4N(C)C5=C(C=CC=C5)[C@]46C[C@@H]([C@H]2[C@H]6O)N3[C@@H]1O	PLASMA	1PON08459R									?	mg × h/L	0.64						UNKNOWN	mg	50		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2591421/	Homo sapiens		min	80		Patients with acute myocardial infarction and ventricular arrhythmia of Lown class IT - IIIB of acute onset (impaired hepatic function)		4			false
4145	1866		ADULT	6100671	326.4326	AJMALINE	Ajmaline	CC[C@H]1[C@@H]2C[C@H]3[C@@H]4N(C)C5=C(C=CC=C5)[C@]46C[C@@H]([C@H]2[C@H]6O)N3[C@@H]1O	PLASMA	1PON08459R									?	mg × h/L	0.71						UNKNOWN	mg	50		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2591421/	Homo sapiens		min	90		Patients with acute myocardial infarction and ventricular arrhythmia of Lown class IT - IIIB of acute onset (cardiogenic shock)		3			false
4146	1866		ADULT	6100671	326.4326	AJMALINE	Ajmaline	CC[C@H]1[C@@H]2C[C@H]3[C@@H]4N(C)C5=C(C=CC=C5)[C@]46C[C@@H]([C@H]2[C@H]6O)N3[C@@H]1O	PLASMA	1PON08459R									?	mg × h/L	0.16						UNKNOWN	mg	50		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2591421/	Homo sapiens		min	58		Patients with acute myocardial infarction and ventricular arrhythmia of Lown class IT - IIIB of acute onset (pretreated with phenobarbital for seizures)		3			false
4147	1866		ADULT	6100671	326.4326	AJMALINE	Ajmaline	CC[C@H]1[C@@H]2C[C@H]3[C@@H]4N(C)C5=C(C=CC=C5)[C@]46C[C@@H]([C@H]2[C@H]6O)N3[C@@H]1O	PLASMA	1PON08459R																						UNKNOWN				Plasma protein binding determined in 4 patients was 76 ± 9% at an ajmaline plasma level of 0.10-0.25μg/mL (ultrafiltration).	24	UNHEALTHY		UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2591421/	Homo sapiens					Patients with acute myocardial infarction and ventricular arrhythmia of Lown class IT - IIIB of acute onset		4			false
4148	1872		ADULT	208925	186.2912	ARUNDIC ACID	Arundic acid	CCCCCC[C@@H](CCC)C(O)=O	PLASMA	F2628ZD0FO									∞	μg × h/mL	152		μg/mL	50.8			UNKNOWN	mg/kg/h	6		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17389553/	Homo sapiens		h	2.6				6			false
4149	1872		ADULT	208925	186.2912	ARUNDIC ACID	Arundic acid	CCCCCC[C@@H](CCC)C(O)=O	PLASMA	F2628ZD0FO									∞	μg × h/mL	157.8		μg/mL	57.8			UNKNOWN	mg/kg/h	8		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17389553/	Homo sapiens		h	2.1				6			false
4150	1872		ADULT	208925	186.2912	ARUNDIC ACID	Arundic acid	CCCCCC[C@@H](CCC)C(O)=O	PLASMA	F2628ZD0FO									∞	μg × h/mL	223.1		μg/mL	80.2			UNKNOWN	mg/kg/h	10		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17389553/	Homo sapiens		h	2.3				6			false
4151	1872		ADULT	208925	186.2912	ARUNDIC ACID	Arundic acid	CCCCCC[C@@H](CCC)C(O)=O	PLASMA	F2628ZD0FO									∞	μg × h/mL	47.2		μg/mL	17.8			UNKNOWN	mg/kg/h	2		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17389553/	Homo sapiens		h	2.2		Patients with acute ischemic stroke		9			false
4152	1872		ADULT	208925	186.2912	ARUNDIC ACID	Arundic acid	CCCCCC[C@@H](CCC)C(O)=O	PLASMA	F2628ZD0FO									∞	μg × h/mL	106.7		μg/mL	34.5			UNKNOWN	mg/kg/h	4		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17389553/	Homo sapiens		h	2.3		Patients with acute ischemic stroke		7			false
4153	1872		ADULT	208925	186.2912	ARUNDIC ACID	Arundic acid	CCCCCC[C@@H](CCC)C(O)=O	PLASMA	F2628ZD0FO									∞	μg × h/mL	143.5		μg/mL	44.7			UNKNOWN	mg/kg/h	6		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17389553/	Homo sapiens		h	1.8		patients with acute ischemic stroke		8			false
4154	1872		ADULT	208925	186.2912	ARUNDIC ACID	Arundic acid	CCCCCC[C@@H](CCC)C(O)=O	PLASMA	F2628ZD0FO									∞	μg × h/mL	178.6		μg/mL	66			UNKNOWN	mg/kg/h	8		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17389553/	Homo sapiens		h	2		Patients with acute ischemic stroke		5			false
4155	1872		ADULT	208925	186.2912	ARUNDIC ACID	Arundic acid	CCCCCC[C@@H](CCC)C(O)=O	PLASMA	F2628ZD0FO									∞	μg × h/mL	210.6		μg/mL	44.6			UNKNOWN	mg/kg/h	10		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17389553/	Homo sapiens		h	3		Patients with acute ischemic stroke		6			false
4156	1872		ADULT	208925	186.2912	ARUNDIC ACID	Arundic acid	CCCCCC[C@@H](CCC)C(O)=O	PLASMA	F2628ZD0FO									∞	μg × h/mL	225		μg/mL	70			UNKNOWN	mg/kg/h	12		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17389553/	Homo sapiens		h	2.3		Patients with acute ischemic stroke		8			false
4157	1872		ADULT	208925	186.2912	ARUNDIC ACID	Arundic acid	CCCCCC[C@@H](CCC)C(O)=O	PLASMA	F2628ZD0FO									∞	μg × h/mL	54.3		μg/mL	19			UNKNOWN	mg/kg/h	2		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17389553/	Homo sapiens		h	2.1				6			false
4158	1872		ADULT	208925	186.2912	ARUNDIC ACID	Arundic acid	CCCCCC[C@@H](CCC)C(O)=O	PLASMA	F2628ZD0FO									∞	μg × h/mL	100		μg/mL	38.1			UNKNOWN	mg/kg/h	4		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17389553/	Homo sapiens		h	1.8				6			false
4159	1872			208925	186.2912	ARUNDIC ACID	Arundic acid	CCCCCC[C@@H](CCC)C(O)=O	PLASMA	F2628ZD0FO																										Plasma protein binding, primarily to albumin, was high (~99%).	1				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17389553/	Homo sapiens										false
4160	1875		ADULT	29976|6419915|91982148	677.61	DILAZEP DIHYDROCHLORIDE	DILAZEP DIHYDROCHLORIDE	Cl.Cl.COC1=CC(=CC(OC)=C1OC)C(=O)OCCCN2CCCN(CCCOC(=O)C3=CC(OC)=C(OC)C(OC)=C3)CC2	PLASMA	LV48LW10EO													ng/mL	173			UNKNOWN	mg	600		SINGLE	UNKNOWN						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2724090/	Homo sapiens		h	3				6	DILAZEP		false
4161	1876		ADULT	21855	292.418	DIMETHINDENE	DIMETHINDENE	CC(C1=C(CCN(C)C)CC2=C1C=CC=C2)C3=CC=CC=N3	PLASMA	661FH77Z3P									∞	ng × h/mL	101.3		ng/mL	14.6			UNKNOWN	mg	4		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/2096106/	Homo sapiens		h	5.41							false
4162	1877		ADULT	5284550	295.442	DOTHIEPIN	Dothiepin	CN(C)CC\\C=C1\\C2=CC=CC=C2SCC3=C1C=CC=C3	PLASMA	W13O82Z7HL									∞	μg × h/mL	576.42		μg/mL	29.49			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3735103/	Homo sapiens		h	21.58				22			false
4163	1877		ADULT	5284550	295.442	DOTHIEPIN	Dothiepin	CN(C)CC\\C=C1\\C2=CC=CC=C2SCC3=C1C=CC=C3	PLASMA	W13O82Z7HL									∞	μg × h/mL	961.69		μg/mL	51.1			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3735103/	Homo sapiens		h	19.33				22			false
4164	1877		ADULT	5284550	295.442	DOTHIEPIN	Dothiepin	CN(C)CC\\C=C1\\C2=CC=CC=C2SCC3=C1C=CC=C3	PLASMA	W13O82Z7HL									∞	μg × h/mL	1586.14		μg/mL	84.95			UNKNOWN	mg	150		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3735103/	Homo sapiens		h	18.45				22			false
4165	1877		ADULT	5284550	295.442	DOTHIEPIN	Dothiepin	CN(C)CC\\C=C1\\C2=CC=CC=C2SCC3=C1C=CC=C3	PLASMA	W13O82Z7HL													ng/mL	27.6			RECOMMENDED	mg	75		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/200022_1179027F1025_2_090_1F.pdf#page=18	Homo sapiens							16	Dothiepin hydrochloride		false
4166	1877		ADULT	5284550	295.442	DOTHIEPIN	Dothiepin	CN(C)CC\\C=C1\\C2=CC=CC=C2SCC3=C1C=CC=C3	PLASMA	W13O82Z7HL									?	ng × h/mL	117.6		ng/mL	9			RECOMMENDED	mg	25		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/200022_1179027F1025_2_090_1F.pdf#page=19 | https://pubmed.ncbi.nlm.nih.gov/6662179/	Homo sapiens		h	14.4		Young subjects (21~25 y)		7	Dothiepin hydrochloride		false
4167	1877		ADULT	5284550	295.442	DOTHIEPIN	Dothiepin	CN(C)CC\\C=C1\\C2=CC=CC=C2SCC3=C1C=CC=C3	PLASMA	W13O82Z7HL									?	ng × h/mL	458.7		ng/mL	17.7			RECOMMENDED	mg	25		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/200022_1179027F1025_2_090_1F.pdf#page=19 | https://pubmed.ncbi.nlm.nih.gov/6662179/	Homo sapiens		h	22		Elderly subjects (65~74 y)		7	Dothiepin hydrochloride		false
4168	1877			5284550	295.442	DOTHIEPIN	Dothiepin	CN(C)CC\\C=C1\\C2=CC=CC=C2SCC3=C1C=CC=C3	PLASMA	W13O82Z7HL																										Human plasma protein binding: 93.7~94.4%	5.6				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/200022_1179027F1025_2_090_1F.pdf#page=20	Homo sapiens										false
4169	1880		ADULT	3371	281.2299	FLUFENAMIC ACID	Flufenamic acid	OC(=O)C1=C(NC2=CC(=CC=C2)C(F)(F)F)C=CC=C1	BLOOD	60GCX7Y6BH									?	μg × h/mL	47.54		μg/mL	7.85			UNKNOWN	mg	250		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400059_1141004F1086_1_009_1F.pdf#page=15	Homo sapiens							12	Flufenamate aluminum		false
4170	1880		UNKNOWN	3371	281.2299	FLUFENAMIC ACID	Flufenamic acid	OC(=O)C1=C(NC2=CC(=CC=C2)C(F)(F)F)C=CC=C1	PLASMA	60GCX7Y6BH																	UNKNOWN				SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	REVIEW	https://www.sciencedirect.com/science/article/pii/S0099542808602683	Homo sapiens		h	3							false
4171	1882		ADULT	3608	236.267	HEXOBARBITAL	HEXOBARBITAL	CN1C(=O)NC(=O)C(C)(C1=O)C2=CCCCC2	BLOOD	AL8Z8K3P6S																	RECOMMENDED	mg/kg	4.1		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1164825/	Homo sapiens		min	376							false
4172	1882		ADULT	3608	236.267	HEXOBARBITAL	HEXOBARBITAL	CN1C(=O)NC(=O)C(C)(C1=O)C2=CCCCC2	BLOOD	AL8Z8K3P6S																	RECOMMENDED	mg/kg	2.97		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1164825/	Homo sapiens		min	419							false
4173	1882		ADULT	3608	236.267	HEXOBARBITAL	HEXOBARBITAL	CN1C(=O)NC(=O)C(C)(C1=O)C2=CCCCC2	BLOOD	AL8Z8K3P6S																	RECOMMENDED	mg/kg	7.32		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1164825/	Homo sapiens		min	490							false
4174	1882		ADULT	3608	236.267	HEXOBARBITAL	HEXOBARBITAL	CN1C(=O)NC(=O)C(C)(C1=O)C2=CCCCC2	BLOOD	AL8Z8K3P6S																	RECOMMENDED	mg/kg	7.32		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1164825/	Homo sapiens		min	261							false
4175	1888		ADULT	4747	365.492	PERICIAZINE	Periciazine	OC1CCN(CCCN2C3=C(SC4=C2C=C(C=C4)C#N)C=CC=C3)CC1	PLASMA	3405M6FD73									∞	ng × h/mL	77.4		ng/mL	9.156			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28012307/	Homo sapiens		h	8.2				20			false
4176	1889			132916	438.4531	PRANAZEPIDE	Pranazepide	FC1=C(C=CC=C1)C2=N[C@H](NC(=O)C3=CC4=C(N3)C=CC=C4)C(=O)N5CCC6=CC=CC2=C56	PLASMA	10TO0RP68C																											0.005				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11560875/	Homo sapiens										false
4177	1890		ADULT	104850	463.787	RIMONABANT	RIMONABANT	CC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(Cl)C=C(Cl)C=C3)C4=CC=C(Cl)C=C4	PLASMA	RML78EN3XE							24		t	ng × h/mL	2960		ng/mL	196			UNKNOWN	mg	20		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1016/j.clpt.2005.12.177	Homo sapiens		h	216	21 days dosing			8	RIMONABANT		false
4178	1890		ADULT	104850	463.787	RIMONABANT	RIMONABANT	CC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(Cl)C=C(Cl)C=C3)C4=CC=C(Cl)C=C4	PLASMA	RML78EN3XE							24		t	ng × h/mL	4830		ng/mL	326			UNKNOWN	mg	40		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1016/j.clpt.2005.12.177	Homo sapiens		h	193	21 days dosing			8	RIMONABANT		false
4179	1890		ADULT	104850	463.787	RIMONABANT	RIMONABANT	CC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(Cl)C=C(Cl)C=C3)C4=CC=C(Cl)C=C4	PLASMA	RML78EN3XE							24		t	ng × h/mL	6760		ng/mL	416			HIGHEST STUDIED	mg	60		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1016/j.clpt.2005.12.177	Homo sapiens		h	151	21 days dosing			8	RIMONABANT		false
4180	1890		ADULT	104850	463.787	RIMONABANT	RIMONABANT	CC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(Cl)C=C(Cl)C=C3)C4=CC=C(Cl)C=C4	PLASMA	RML78EN3XE							24		t	ng × h/mL	2480		ng/mL	188			RECOMMENDED	mg	20		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1016/j.clpt.2005.12.177	Homo sapiens		h	376	21 days dosing	obesity		16	RIMONABANT		false
4181	1890		ADULT	104850	463.787	RIMONABANT	RIMONABANT	CC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(Cl)C=C(Cl)C=C3)C4=CC=C(Cl)C=C4	PLASMA	RML78EN3XE							24		t	ng × h/mL	1480		ng/mL	118			UNKNOWN	mg	10		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1016/j.clpt.2005.12.177	Homo sapiens		h	180	21 days dosing			8	RIMONABANT		false
4182	1890		ADULT	104850	463.787	RIMONABANT	RIMONABANT	CC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(Cl)C=C(Cl)C=C3)C4=CC=C(Cl)C=C4	PLASMA	RML78EN3XE							24		t	ng × h/mL	665		ng/mL	57.9			UNKNOWN	mg	3		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1016/j.clpt.2005.12.177	Homo sapiens		h	210	21 days dosing			8	RIMONABANT		false
4183	1890		ADULT	104850	463.787	RIMONABANT	RIMONABANT	CC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(Cl)C=C(Cl)C=C3)C4=CC=C(Cl)C=C4	PLASMA	RML78EN3XE							24		t	ng × h/mL	2959.98		ng/mL	28.1			RECOMMENDED	mg	20		STEADY-STATE	FASTED		day	1		0.1	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.ema.europa.eu/en/documents/product-information/acomplia-epar-product-information_en.pdf	Homo sapiens		day	9	13 days dosing				RIMONABANT		false
4184	1891		UNKNOWN	9047	280.303	SULFALENE	SULFALENE	COC1=NC=CN=C1NS(=O)(=O)C2=CC=C(N)C=C2	UNKNOWN	T6BL4ZC15G																	UNKNOWN	g	1		SINGLE	FASTED						UNKNOWN	Oral	UNKNOWN	EXPERIMENT	https://link.springer.com/content/pdf/10.1007/BF00773103.pdf	Homo sapiens		h	59.4				53	SULFALENE		false
4185	1891		UNKNOWN	9047	280.303	SULFALENE	SULFALENE	COC1=NC=CN=C1NS(=O)(=O)C2=CC=C(N)C=C2	PLASMA	T6BL4ZC15G	5578	290.3177	TRIMETHOPRIM	trimethoprim	COC1=CC(CC2=C(N)N=C(N)N=C2)=CC(OC)=C1OC	AN164J8Y0X							mg/L	65			UNKNOWN	mg	200		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7410285/	Homo sapiens		h	70	loading dose of twice the maintenance dose of sulfametopyrazine (sulfalene) 200 mg plus trimethoprim 250 mg was used; dosing was continued for 10 days, and blood and urine concentrations were monitored for 14 days.		250 mg	6	SULFALENE		true
4186	1893		ADULT	1174|5274267	112.0868	URACIL	URACIL	O=C1NC=CC(=O)N1	PLASMA	56HH86ZVCT	5386		TEGAFUR	ftorafur	FC1=CN(C2CCCO2)C(=O)NC1=O	1548R74NSZ	6		t	μM × h	20.1		μM	20.3			MAX TOLERATED	mg/m²	350		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8612313/	Homo sapiens										true
4187	1900		ADULT	3380	313.2832	FLUNITRAZEPAM	Flunitrazepam	CN1C2=C(C=C(C=C2)[N ]([O-])=O)C(=NCC1=O)C3=C(F)C=CC=C3	PLASMA	620X0222FQ													ng/mL	12.9			UNKNOWN	mg	2		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2096104/	Homo sapiens		h	22.5				6			false
4188	1900		ADULT	3380	313.2832	FLUNITRAZEPAM	Flunitrazepam	CN1C2=C(C=C(C=C2)[N ]([O-])=O)C(=NCC1=O)C3=C(F)C=CC=C3	PLASMA	620X0222FQ													ng/mL	9.2			UNKNOWN	mg	2		SINGLE	FASTED						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2096104/	Homo sapiens		h	20.2		Alcoholic cirrhosis		6			false
4189	1900		ADULT	3380	313.2832	FLUNITRAZEPAM	Flunitrazepam	CN1C2=C(C=C(C=C2)[N ]([O-])=O)C(=NCC1=O)C3=C(F)C=CC=C3	PLASMA	620X0222FQ													ng/mL	13.1			UNKNOWN	mg	2		SINGLE	FASTED						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2096104/	Homo sapiens		h	25.3		Patients with acute viral hepatitis		6			false
4190	1900		ADULT	3380	313.2832	FLUNITRAZEPAM	Flunitrazepam	CN1C2=C(C=C(C=C2)[N ]([O-])=O)C(=NCC1=O)C3=C(F)C=CC=C3	PLASMA	620X0222FQ							72		t	ng × h/mL	203		ng/mL	21.7			MAX DAILY	mg	2		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/170033_1124008F1024_1_020_1F.pdf#page=18	Homo sapiens		h	21.2				48			false
4191	1900		ADULT	3380	313.2832	FLUNITRAZEPAM	Flunitrazepam	CN1C2=C(C=C(C=C2)[N ]([O-])=O)C(=NCC1=O)C3=C(F)C=CC=C3	BLOOD	620X0222FQ													ng/mL	10.2			MAX DAILY	mg	2		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/170033_1124008F1024_1_020_1F.pdf#page=18 | https://www.jstage.jst.go.jp/article/jscpt1970/9/3/9_3_251/_article/-char/en	Homo sapiens				Day 1			5			false
4192	1900		ADULT	3380	313.2832	FLUNITRAZEPAM	Flunitrazepam	CN1C2=C(C=C(C=C2)[N ]([O-])=O)C(=NCC1=O)C3=C(F)C=CC=C3	BLOOD	620X0222FQ													ng/mL	12.2			MAX DAILY	mg	2		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/170033_1124008F1024_1_020_1F.pdf#page=18 | https://www.jstage.jst.go.jp/article/jscpt1970/9/3/9_3_251/_article/-char/en	Homo sapiens				Day 5			5			false
4193	1900		ADULT	3380	313.2832	FLUNITRAZEPAM	Flunitrazepam	CN1C2=C(C=C(C=C2)[N ]([O-])=O)C(=NCC1=O)C3=C(F)C=CC=C3	BLOOD	620X0222FQ													ng/mL	12.9			MAX DAILY	mg	2		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/170033_1124008F1024_1_020_1F.pdf#page=18 | https://www.jstage.jst.go.jp/article/jscpt1970/9/3/9_3_251/_article/-char/en	Homo sapiens				Day 7			5			false
4194	1900			3380	313.2832	FLUNITRAZEPAM	Flunitrazepam	CN1C2=C(C=C(C=C2)[N ]([O-])=O)C(=NCC1=O)C3=C(F)C=CC=C3	PLASMA	620X0222FQ																										Human plasma protein binding: 77.6~79.6% (1~20ng/mL)	20.4				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/170033_1124008F1024_1_020_1F.pdf#page=19	Homo sapiens										false
4195	1900		ADULT	3380	313.2832	FLUNITRAZEPAM	Flunitrazepam	CN1C2=C(C=C(C=C2)[N ]([O-])=O)C(=NCC1=O)C3=C(F)C=CC=C3	BLOOD	620X0222FQ							24		t	ng × h/mL	232.8		ng/mL	47.5			UNKNOWN	mg	2		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://www.jstage.jst.go.jp/article/jscpt1970/9/3/9_3_251/_article/-char/en	Homo sapiens		h	24				5			false
4196	1900		ADULT	3380	313.2832	FLUNITRAZEPAM	Flunitrazepam	CN1C2=C(C=C(C=C2)[N ]([O-])=O)C(=NCC1=O)C3=C(F)C=CC=C3	BLOOD	620X0222FQ							24		t	ng × h/mL	116.7		ng/mL	11.5			RECOMMENDED	mg	2		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.jstage.jst.go.jp/article/jscpt1970/9/3/9_3_251/_article/-char/en	Homo sapiens		h	6.8				5			false
4197	1900		ADULT	3380	313.2832	FLUNITRAZEPAM	Flunitrazepam	CN1C2=C(C=C(C=C2)[N ]([O-])=O)C(=NCC1=O)C3=C(F)C=CC=C3	BLOOD	620X0222FQ							24		t	ng × h/mL	240.2		ng/mL	25			UNKNOWN	mg	4		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.jstage.jst.go.jp/article/jscpt1970/9/3/9_3_251/_article/-char/en	Homo sapiens		h	6.2				5			false
4198	1902		ADULT	5356	290.359	SULTHIAME	SULTHIAME	NS(=O)(=O)C1=CC=C(C=C1)N2CCCCS2(=O)=O	PLASMA	I00Q766CZ2									∞	μg × h/mL	8.57		μg/mL	0.18			RECOMMENDED	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31990440/	Homo sapiens		h	90.9				4	SULTHIAME		false
4199	1902		ADULT	5356	290.359	SULTHIAME	SULTHIAME	NS(=O)(=O)C1=CC=C(C=C1)N2CCCCS2(=O)=O	PLASMA	I00Q766CZ2									∞	μg × h/mL	24.04		μg/mL	1.88			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31990440/	Homo sapiens		h	40				4	SULTHIAME		false
4200	1902		ADULT	5356	290.359	SULTHIAME	SULTHIAME	NS(=O)(=O)C1=CC=C(C=C1)N2CCCCS2(=O)=O	PLASMA	I00Q766CZ2									∞	μg × h/mL	1.24		μg/mL	0.02			RECOMMENDED	mg	50		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31990440/	Homo sapiens		h	50.8				4	SULTHIAME		false
4201	1902		UNKNOWN	5356	290.359	SULTHIAME	SULTHIAME	NS(=O)(=O)C1=CC=C(C=C1)N2CCCCS2(=O)=O	PLASMA	I00Q766CZ2																	UNKNOWN				SINGLE					About 29% of the active ingredient is bound to plasma proteins.	71		Oral	UNKNOWN	OTHER GOV'T	https://www.pharmadoor.com.br/images/medicamentos/bulas/bula_ospolot.pdf	Homo sapiens								SULTHIAME		false
4202	1903		ADULT	864	206.326	THIOCTIC ACID	THIOCTIC ACID	OC(=O)CCCCC1CCSS1	PLASMA	73Y7P0K73Y									?	μg × h/mL	5.6		μg/mL	7.6			UNKNOWN	mg	600		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30241687/	Homo sapiens		h	0.5				41	THIOCTIC ACID		false
4203	1904		ADULT	854026	242.3162	HUPERZINE A	HUPERZINE A	C\\C=C1/[C@@H]2CC3=C(C=CC(=O)N3)[C@@]1(N)CC(C)=C2	PLASMA	0111871I23									∞	μg × min/L	2450.34		μg/L	2.59			RECOMMENDED	mg	0.4		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18348466/	Homo sapiens		min	716.25				12	HUPERZINE A		false
4204	1920		ADULT	644160	150.1299	XYLOSE	XYLOSE	OC[C@@H](O)[C@H](O)[C@@H](O)C=O	SERUM	A1TA934AKO							8		t	μg × h/mL	1733		μg/mL	440			UNKNOWN	g	25		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	REVIEW	https://www.gastrojournal.org/article/0016-5085(88)90318-6/abstract	Homo sapiens		min	75							false
4205	1921		UNKNOWN	4680	339.385	PAPAVERINE	PAPAVERINE	COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1	PLASMA	DAA13NKG2Q													ng/mL	54.7			UNKNOWN	mg	3		SINGLE	UNKNOWN						UNHEALTHY	Intravascular	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24217241/	Homo sapiens				A maximum of 3 mL of a 1 mg/1 mL diluted papaverine solution was injected intravascularly (intraluminally) for spasm prophylaxis.	coronary artery bypass grafting		15	PAPAVERINE		false
4206	1921		ADULT	4680	339.385	PAPAVERINE	PAPAVERINE	COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1	PLASMA	DAA13NKG2Q									?	mg × h/mL	375						UNKNOWN	mg	80		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3413033/	Homo sapiens							9	PAPAVERINE		false
4207	1921		ADULT	4680	339.385	PAPAVERINE	PAPAVERINE	COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1	PLASMA	DAA13NKG2Q									?	mg × h/mL	1760						UNKNOWN	mg	80		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3413033/	Homo sapiens		h	1.9				9	PAPAVERINE		false
4208	1921		ADULT	4680	339.385	PAPAVERINE	PAPAVERINE	COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1	PLASMA	DAA13NKG2Q									?	mg × h/mL	855						UNKNOWN	mg	80		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3413033/	Homo sapiens					irritable bowel disease		7	PAPAVERINE		false
4209	1921		ADULT	4680	339.385	PAPAVERINE	PAPAVERINE	COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1	PLASMA	DAA13NKG2Q									?	mg × h/mL	1965						UNKNOWN	mg	80		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3413033/	Homo sapiens		h	3.4		irritable bowel disease		7	PAPAVERINE		false
4210	1921		ADULT	4680	339.385	PAPAVERINE	PAPAVERINE	COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1	PLASMA	DAA13NKG2Q							10		t	ng × h/mL	1308		ng/mL	583			UNKNOWN	mg	150		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/489763/	Homo sapiens				papaverine HCl elixir, 100 mg/15 ml, Lot L-7468, Cooper Laboratories			6	PAPAVERINE HYDROCHLORIDE		false
4211	1921		ADULT	4680	339.385	PAPAVERINE	PAPAVERINE	COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1	PLASMA	DAA13NKG2Q							10		t	ng × h/mL	1247		ng/mL	536			UNKNOWN	mg	150		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/489763/	Homo sapiens				Papaverine HCl tablets, N.F., 30 mg/ tablet (150 mg/5 tablets), Lot 5EAO4B, Eli Lilly			6	PAPAVERINE HYDROCHLORIDE		false
4212	1921		ADULT	4680	339.385	PAPAVERINE	PAPAVERINE	COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1	PLASMA	DAA13NKG2Q							10		t	ng × h/mL	409		ng/mL	117			UNKNOWN	mg	150		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/489763/	Homo sapiens				Pavabid Capsules, 150 mg papaverine HCl, Lot E5120, Marion Laboratories			6	PAPAVERINE HYDROCHLORIDE		false
4213	1921		ADULT	4680	339.385	PAPAVERINE	PAPAVERINE	COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1	PLASMA	DAA13NKG2Q							10		t	ng × h/mL	800		ng/mL	218			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/489763/	Homo sapiens				sustained-release tablets 200 mg papaverine HCl, Lot 1700, Bucker Pharmacal			6	PAPAVERINE HYDROCHLORIDE		false
4214	1924		ADULT	5280343	302.2357	QUERCETIN	QUERCETIN	OC1=CC2=C(C(O)=C1)C(=O)C(O)=C(O2)C3=CC=C(O)C(O)=C3	SERUM	9IKM0I5T1E									?	μg × min/mL	2077		μg/mL	500			UNKNOWN	mg/m²	630		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9816216/	Homo sapiens		min	47							false
4215	1931		ADULT	896	232.2783	MELATONIN	MELATONIN	COC1=CC2=C(NC=C2CCNC(C)=O)C=C1	PLASMA	JL5DK93RCL									∞	pg × min/mL	67047375.2		pg/mL	1416325			HIGHEST STUDIED	mg	100		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26184078/	Homo sapiens		min	46.2				12	MELATONIN		false
4216	1931		ADULT	896	232.2783	MELATONIN	MELATONIN	COC1=CC2=C(NC=C2CCNC(C)=O)C=C1	PLASMA	JL5DK93RCL									∞	pg × min/mL	9634812.7		pg/mL	312162.5			UNKNOWN	mg	10		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26184078/	Homo sapiens		min	42.3				12	MELATONIN		false
4217	1931		ADULT	896	232.2783	MELATONIN	MELATONIN	COC1=CC2=C(NC=C2CCNC(C)=O)C=C1	PLASMA	JL5DK93RCL									∞	pg × min/mL	14179767.6		pg/mL	389875			HIGHEST STUDIED	mg	10		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26893170/	Homo sapiens		min	39.4				12	MELATONIN		false
4218	1931		ADULT	896	232.2783	MELATONIN	MELATONIN	COC1=CC2=C(NC=C2CCNC(C)=O)C=C1	PLASMA	JL5DK93RCL									?	pg × h/mL	44441		pg/mL	26813			RECOMMENDED	mg	3		SINGLE	UNKNOWN						UNHEALTHY	Nasogastric	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31004517/	Homo sapiens		h	0.7				7	MELATONIN		false
4219	1933		ADULT	2353	336.3612	BERBERINE	BERBERINE	COC1=C(OC)C2=C(C=C1)C=C3C4=CC5=C(OCO5)C=C4CC[N ]3=C2	PLASMA	0I8Y3P32UF									∞	μg × h/L	6.28		μg/L	0.33			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30587933/	Homo sapiens		h	30.6				60	BERBERINE		false
4220	1933		ADULT	2353	336.3612	BERBERINE	BERBERINE	COC1=C(OC)C2=C(C=C1)C=C3C4=CC5=C(OCO5)C=C4CC[N ]3=C2	PLASMA	0I8Y3P32UF									∞	μg × h/L	38.74		μg/L	0.99			UNKNOWN	mg	300		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30587933/	Homo sapiens		h	33.44	7 days			60	BERBERINE		false
4221	1935		ADULT	323	146.1427	COUMARIN	COUMARIN	O=C1OC2=C(C=CC=C2)C=C1	BLOOD	A4VZ22K1WT																	UNKNOWN	mg/kg	0.125		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1036930	Homo sapiens		h	1.81							false
4222	1935		ADULT	323	146.1427	COUMARIN	COUMARIN	O=C1OC2=C(C=CC=C2)C=C1	BLOOD	A4VZ22K1WT																	UNKNOWN	mg/kg	0.2		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1036930	Homo sapiens		h	1.45							false
4223	1935		ADULT	323	146.1427	COUMARIN	COUMARIN	O=C1OC2=C(C=CC=C2)C=C1	BLOOD	A4VZ22K1WT																	UNKNOWN	mg/kg	0.25		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1036930	Homo sapiens		h	1.49							false
4224	1935		ADULT	323	146.1427	COUMARIN	COUMARIN	O=C1OC2=C(C=CC=C2)C=C1	BLOOD	A4VZ22K1WT									?	mg × h/mL	0.029						UNKNOWN	mg/kg	0.857		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/598421	Homo sapiens		h	1.018							false
4225	1935		ADULT	323	146.1427	COUMARIN	COUMARIN	O=C1OC2=C(C=CC=C2)C=C1	BLOOD	A4VZ22K1WT									?	mg × h/mL	0.191						UNKNOWN	mg/kg	0.25		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/598421	Homo sapiens		h	0.769							false
4226	1938		ADULT	119|6992099	103.1198	.GAMMA.-AMINOBUTYRIC ACID	Gamma-aminobutyric acid	NCCCC(O)=O	PLASMA	2ACZ6IPC6I							24		t	ng × h/mL	932.91		ng/mL	688.53			UNKNOWN	g	2		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26617516/	Homo sapiens		h	5.08				11			false
4227	1938		ADULT	119|6992099	103.1198	.GAMMA.-AMINOBUTYRIC ACID	Gamma-aminobutyric acid	NCCCC(O)=O	PLASMA	2ACZ6IPC6I							24		t	ng × h/mL	1078.11		ng/mL	767.77			UNKNOWN	g	2		STEADY-STATE	UNKNOWN		day	3			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26617516/	Homo sapiens		h	5.24	Day 8 (single dose)			11			false
4228	1943		ADULT	6473	212.2456	BUTETHAL	BUTETHAL	CCCCC1(CC)C(=O)NC(=O)NC1=O	PLASMA	OHZ8QAW6YC																	UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://link.springer.com/article/10.1007/BF00558339	Homo sapiens		h	37.5							false
4229	1945		ADULT	68861	311.418	DIENOGEST	DIENOGEST	C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N	PLASMA	46M3EV8HHE	5757		ESTRADIOL	Estradiol	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@H]2O	4TI98Z838E	24		t	ng × h/mL	828		ng/mL	85.2			RECOMMENDED	mg	3		STEADY-STATE	FASTED		day	1	A relatively high fraction (10%) of circulating dienogest is present in the free form	10	HEALTHY	Oral	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022252s001lbl.pdf	Homo sapiens		h	12.3							true
4230	1945		ADULT	68861	311.418	DIENOGEST	DIENOGEST	C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N	PLASMA	46M3EV8HHE									∞	ng × h/mL	1827.014		ng/mL	110.41			UNKNOWN	mg	2		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/24890474	Homo sapiens		h	14.82							false
4231	1948		ADULT		94.11	DALFAMPRIDINE			PLASMA								24		t	ng × h/mL	246.48		ng/mL	23.77			RECOMMENDED	mg	10		SINGLE	FASTED				https://link.springer.com/article/10.2165/11205910-000000000-00000	97	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22058101/	Homo sapiens		h	0.16							false
4232	1949		ADULT		471.5	DABIGATRAN			PLASMA								24		t	ng × h/mL	2232		ng/mL	348			RECOMMENDED	mg	150		STEADY-STATE	UNKNOWN		day	2	Protein binding studies with radiolabelled dabigatran showed that 35% of the dabigatran is bound to plasma proteins.	65	HEALTHY	Oral	FEMALE / MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/18399711/	Homo sapiens		h	11.3							false
4233	1950		ADULT		2086.75	SUCRALFATE	SUCRALFATE		PLASMA	XX73205DH5									?	μg × h/mL	35		μg/mL	1.27			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9257738/	Homo sapiens		h	20							false
4234	1956		ADULT	20824	378.4	CARBENICILLIN	CARBENICILLIN	CC1(C)S[C@@H]2[C@H](NC(=O)C(C(O)=O)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O	SERUM	G42ZU72N5G							6		t	μg × h/mL	16		μg/mL	6.5			RECOMMENDED	mg	382		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050435s009lbl.pdf	Homo sapiens		h	2							false
4235	1960		ADULT	5904	334.39	PENICILLIN G	PENICILLIN G	CC1(C)S[C@@H]2[C@H](NC(=O)CC3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O	SERUM	Q42T66VG0C																	UNKNOWN	unit	1200000		SINGLE	UNKNOWN						HEALTHY	Intramuscular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21991307/	Homo sapiens		day	4.1							false
4236	1960		ADULT	5904	334.39	PENICILLIN G	PENICILLIN G	CC1(C)S[C@@H]2[C@H](NC(=O)CC3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O	PLASMA	Q42T66VG0C																	UNKNOWN	unit	12000000		STEADY-STATE	UNKNOWN		day	1		65	UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8218695/	Homo sapiens										false
4237	1960		UNKNOWN	5904	334.39	PENICILLIN G	PENICILLIN G	CC1(C)S[C@@H]2[C@H](NC(=O)CC3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O	SERUM	Q42T66VG0C													μg/mL	400			UNKNOWN	unit	5000000		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050638s019lbl.pdf	Homo sapiens										false
4238	1960		UNKNOWN	5904	334.39	PENICILLIN G	PENICILLIN G	CC1(C)S[C@@H]2[C@H](NC(=O)CC3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O	SERUM	Q42T66VG0C																						UNKNOWN				Approximately 60% of penicillin G is bound to serum protein.	40	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/050141s237lbl.pdf	Homo sapiens										false
4239	1962		UNKNOWN	3737	613.9136	IOTHALAMIC ACID	IOTHALAMIC ACID	CNC(=O)C1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I	PLASMA	16CHD79MIX																						UNKNOWN				In vitro protein binding = 9.55%	90.45	UNKNOWN		UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11403171	Homo sapiens										false
4240	1962		ADULT	3737	613.9136	IOTHALAMIC ACID	IOTHALAMIC ACID	CNC(=O)C1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I	SERUM	16CHD79MIX																	UNKNOWN	mmol	63		SINGLE	UNKNOWN						UNHEALTHY	Intravascular	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3230149	Homo sapiens		h	64							false
4241	1966		UNKNOWN	135398738	182.1832	DACARBAZINE	DACARBAZINE	CN(C)\\N=N\\C1=C(N=CN1)C(N)=O	PLASMA	7GR28W0FJI																						UNKNOWN				Plasma protein binding is 5 %.	95	UNKNOWN		UNKNOWN	OTHER GOV'T	https://www.medicines.org.uk/emc/product/7747/smpc	Homo sapiens										false
4242	1966		ADULT	135398738	182.1832	DACARBAZINE	DACARBAZINE	CN(C)\\N=N\\C1=C(N=CN1)C(N)=O	PLASMA	7GR28W0FJI									∞	μM × min	14.8		μg/mL	6.2			UNKNOWN	mg/m²	750		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	REVIEW	https://www.ncbi.nlm.nih.gov/pubmed/26940170	Homo sapiens		min	41.4							false
4243	1967		ADULT	2973	560.684	DEFEROXAMINE	DEFEROXAMINE	CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN	PLASMA	J06Y7MXW4D													μM	6.1			RECOMMENDED	mg/kg	10		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/11206963/	Homo sapiens										false
4244	1967		ADULT	2973	560.684	DEFEROXAMINE	DEFEROXAMINE	CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN	PLASMA	J06Y7MXW4D													μM	2.5			RECOMMENDED	mg/kg	10		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/11206963/	Homo sapiens										false
4245	1967		ADULT	2973	560.684	DEFEROXAMINE	DEFEROXAMINE	CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN	PLASMA	J06Y7MXW4D													μM	12.9			RECOMMENDED	mg/kg	100	bolus, 1440 min	OTHER	UNKNOWN		day	1			UNHEALTHY	Intravenous	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/11206963/	Homo sapiens										false
4246	1967		ADULT	2973	560.684	DEFEROXAMINE	DEFEROXAMINE	CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN	PLASMA	J06Y7MXW4D													μM	2.7			RECOMMENDED	mg/kg	100	bolus, 1440 min	OTHER	UNKNOWN		day	1			HEALTHY	Intravenous	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/11206963/	Homo sapiens										false
4247	1967		ADULT	2973	560.684	DEFEROXAMINE	DEFEROXAMINE	CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN	PLASMA	J06Y7MXW4D									?	μM × h	354		μM	7.4			RECOMMENDED	mg/kg	10	bolus, 2880 min	OTHER	UNKNOWN		day	1			UNHEALTHY	Intravenous	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/11206963/	Homo sapiens		h	3.05							false
4248	1967		ADULT	2973	560.684	DEFEROXAMINE	DEFEROXAMINE	CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN	PLASMA	J06Y7MXW4D													μM	15.7			RECOMMENDED	mg/kg	10		SINGLE	UNKNOWN						HEALTHY	Intramuscular	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/11206963/	Homo sapiens										false
4249	1967		ADULT	2973	560.684	DEFEROXAMINE	DEFEROXAMINE	CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN	PLASMA	J06Y7MXW4D													μM	7			RECOMMENDED	mg/kg	10		SINGLE	UNKNOWN						HEALTHY	Intramuscular	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/11206963/	Homo sapiens										false
4250	1967		UNKNOWN	2973	560.684	DEFEROXAMINE	DEFEROXAMINE	CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN	PLASMA	J06Y7MXW4D													μM	10.1			RECOMMENDED	mg/kg	40		SINGLE	UNKNOWN						UNKNOWN	Subcutaneous	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/11206963/	Homo sapiens		h	7.59							false
4251	1968		ADULT	41867	543.5193	EPIRUBICIN	EPIRUBICIN	COC1=CC=CC2=C1C(=O)C3=C(C2=O)C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)C4=C3O)C(=O)CO	PLASMA	3Z8479ZZ5X									?	μg × h/mL	1.6		μg/mL	5.7			UNKNOWN	mg/m²	60		SINGLE	UNKNOWN				Binding of epirubicin to plasma proteins, predominantly albumin, is about 77% and is not affected by drug concentration.	23	UNHEALTHY	Intravenous	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/050807lbl.pdf	Homo sapiens		h	35.3							false
4252	1968		ADULT	41867	543.5193	EPIRUBICIN	EPIRUBICIN	COC1=CC=CC2=C1C(=O)C3=C(C2=O)C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)C4=C3O)C(=O)CO	PLASMA	3Z8479ZZ5X									?	μg × h/mL	4.2		μg/mL	9.3			UNKNOWN	mg/m²	150		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/050807lbl.pdf	Homo sapiens		h	31.1							false
4253	1970		ADULT	4033	156.054	MECHLORETHAMINE	MECHLORETHAMINE	CN(CCCl)CCCl	PLASMA	50D9XSG0VR									∞	μg × h/mL	3.17		μg/mL	1.72			UNKNOWN	mg/kg	0.2		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/11129502	Homo sapiens		h	0.16							false
4254	1971		ADULT	5565	146.2339	TRIENTINE	TRIENTINE	NCCNCCNCCN	PLASMA	SJ76Y07H5F									∞	mg × h/L	2.08		mg/L	0.39			UNKNOWN	mg	100		STEADY-STATE	FASTED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19602718	Homo sapiens		h	5.06							false
4255	1971		ADULT	5565	146.2339	TRIENTINE	TRIENTINE	NCCNCCNCCN	PLASMA	SJ76Y07H5F									∞	mg × h/L	3.77		mg/L	0.69			RECOMMENDED	mg	300		STEADY-STATE	FASTED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19602718	Homo sapiens		h	5.35							false
4256	1971		ADULT	5565	146.2339	TRIENTINE	TRIENTINE	NCCNCCNCCN	PLASMA	SJ76Y07H5F									∞	mg × h/L	11.14		mg/L	1.55			RECOMMENDED	mg	600		STEADY-STATE	FASTED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19602718	Homo sapiens		h	10.37							false
4257	1971		ADULT	5565	146.2339	TRIENTINE	TRIENTINE	NCCNCCNCCN	PLASMA	SJ76Y07H5F									∞	mg × h/L	31.03		mg/L	5.61			UNKNOWN	mg	1800		STEADY-STATE	FASTED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19602718	Homo sapiens		h	14.21							false
4258	1972		UNKNOWN		416.3533	TROVAFLOXACIN	trovafloxacin	N[C@H]1[C@@H]2CN(C[C@H]12)C3=NC4=C(C=C3F)C(=O)C(=CN4C5=CC=C(F)C=C5F)C(O)=O	SERUM	9F388J00UK									∞	μg × h/mL	28.1		μg/mL	2.7			UNKNOWN	mg	200		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a.pdf	Homo sapiens		h	9.4							false
4259	1972		UNKNOWN		416.3533	TROVAFLOXACIN	trovafloxacin	N[C@H]1[C@@H]2CN(C[C@H]12)C3=NC4=C(C=C3F)C(=O)C(=CN4C5=CC=C(F)C=C5F)C(O)=O	SERUM	9F388J00UK							24		t	μg × h/mL	32.2		μg/mL	3.1			UNKNOWN	mg	200		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a.pdf	Homo sapiens		h	11.7							false
4260	1972		UNKNOWN		416.3533	TROVAFLOXACIN	trovafloxacin	N[C@H]1[C@@H]2CN(C[C@H]12)C3=NC4=C(C=C3F)C(=O)C(=CN4C5=CC=C(F)C=C5F)C(O)=O	SERUM	9F388J00UK									∞	μg × h/mL	46.1		μg/mL	3.6			UNKNOWN	mg	300		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a.pdf	Homo sapiens		h	11.2							false
4261	1972		UNKNOWN		416.3533	TROVAFLOXACIN	trovafloxacin	N[C@H]1[C@@H]2CN(C[C@H]12)C3=NC4=C(C=C3F)C(=O)C(=CN4C5=CC=C(F)C=C5F)C(O)=O	SERUM	9F388J00UK							24		t	μg × h/mL	46.3		μg/mL	4.4			UNKNOWN	mg	300		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a.pdf	Homo sapiens		h	12.7							false
4262	1974		ADULT	32170	284.374	ARTICAINE	Articaine	CCCNC(C)C(=O)NC1=C(SC=C1C)C(=O)OC	PLASMA	D3SQ406G9X	5816|139148732		EPINEPHRINE	adrenaline	CNC[C@H](O)C1=CC(O)=C(O)C=C1	YKH834O4BH			∞	μM × h	26.1		mg/mL	5.3			UNKNOWN	mg	600		STEADY-STATE	UNKNOWN		day	1			UNKNOWN	Epidural	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9055188	Homo sapiens		h	2.19							true
4263	1974		UNKNOWN	32170	284.374	ARTICAINE	ARTICAINE	CCCNC(C)C(=O)NC1=C(SC=C1C)C(=O)OC	SERUM	D3SQ406G9X																						UNKNOWN				Approximately 60% to 80% of articaine HCl is bound to human serum albumin and γ -globulins at 37°C in vitro.	30	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022466lbl.pdf	Homo sapiens										false
4264	1974		UNKNOWN	32170	284.374	ARTICAINE	ARTICAINE	CCCNC(C)C(=O)NC1=C(SC=C1C)C(=O)OC	PLASMA	D3SQ406G9X	5816|139148732		EPINEPHRINE	epinephrine	CNC[C@H](O)C1=CC(O)=C(O)C=C1	YKH834O4BH							ng/mL	2037			UNKNOWN	mg	476		SINGLE	UNKNOWN						UNKNOWN	Intraoral Submucosal Injection	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022466lbl.pdf	Homo sapiens		min	43.8							true
4265	1974		UNKNOWN	32170	284.374	ARTICAINE	articaine	CCCNC(C)C(=O)NC1=C(SC=C1C)C(=O)OC	PLASMA	D3SQ406G9X	5816|139148732		EPINEPHRINE	epinephrine	CNC[C@H](O)C1=CC(O)=C(O)C=C1	YKH834O4BH							ng/mL	385			RECOMMENDED	mg	68		SINGLE	UNKNOWN						UNKNOWN	Dental	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022466lbl.pdf	Homo sapiens										true
4266	1974		UNKNOWN	32170	284.374	ARTICAINE	articaine	CCCNC(C)C(=O)NC1=C(SC=C1C)C(=O)OC	PLASMA	D3SQ406G9X	5816|139148732		EPINEPHRINE	epinephrine	CNC[C@H](O)C1=CC(O)=C(O)C=C1	YKH834O4BH							ng/mL	900			RECOMMENDED	mg	204		SINGLE	UNKNOWN						UNKNOWN	Dental	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022466lbl.pdf	Homo sapiens										true
4267	1975		UNKNOWN	65628	358.263	BENDAMUSTINE	BENDAMUSTINE	CN1C(CCCC(O)=O)=NC2=C1C=CC(=C2)N(CCCl)CCCl	PLASMA	9266D9P3PQ																						UNKNOWN				In vitro, the binding of bendamustine to human serum plasma proteins ranged from 94-96% and was concentration independent from 1-50 μg/mL.	5	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208194s000lbl.pdf	Homo sapiens										false
4268	1975		ADULT	65628	358.263	BENDAMUSTINE	BENDAMUSTINE	CN1C(CCCC(O)=O)=NC2=C1C=CC(=C2)N(CCCl)CCCl	PLASMA	9266D9P3PQ									∞	ng × min/mL	444631		ng/mL	8797			RECOMMENDED	mg/kg	160		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/17486132	Homo sapiens		min	41							false
4269	1975		ADULT	65628	358.263	BENDAMUSTINE	BENDAMUSTINE	CN1C(CCCC(O)=O)=NC2=C1C=CC(=C2)N(CCCl)CCCl	BLOOD	9266D9P3PQ									∞	ng × h/mL	6398		μg/mL	5.32			UNKNOWN	mg/m²	120		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/23322528	Homo sapiens		h	0.65							false
4270	1975		UNKNOWN	65628	358.263	BENDAMUSTINE	BENDAMUSTINE	CN1C(CCCC(O)=O)=NC2=C1C=CC(=C2)N(CCCl)CCCl	PLASMA	9266D9P3PQ									?	μg × h/mL	11.17						UNKNOWN	mg/kg	4.2		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/4095129	Homo sapiens		min	36.1							false
4271	1976		ADULT	47472	411.776	BUTOCONAZOLE	BUTOCONAZOLE	ClC1=CC=C(CCC(CN2C=CN=C2)SC3=C(Cl)C=CC=C3Cl)C=C1	PLASMA	0Q771797PH									∞	pg × h/mL	113290.135		pg/mL	4471.25			DEFINED DAILY	mg	100		SINGLE	UNKNOWN						HEALTHY	Vaginal	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24939312	Homo sapiens		h	17.834							false
4272	1976		ADULT	47472	411.776	BUTOCONAZOLE	BUTOCONAZOLE	ClC1=CC=C(CCC(CN2C=CN=C2)SC3=C(Cl)C=CC=C3Cl)C=C1	PLASMA	0Q771797PH							96		t	ng × h/mL	73.48		ng/mL	1.74			DEFINED DAILY	g	0.1		SINGLE	UNKNOWN						HEALTHY	Vaginal	FEMALE	EXPERIMENT	https://www.researchgate.net/publication/289924108_Pharmacokinetics_of_butoconazole_nitrate_suppositories_in_human	Homo sapiens										false
4273	1976		ADULT	47472	411.776	BUTOCONAZOLE	BUTOCONAZOLE	ClC1=CC=C(CCC(CN2C=CN=C2)SC3=C(Cl)C=CC=C3Cl)C=C1	PLASMA	0Q771797PH							96		t	ng × h/mL	36.38		ng/mL	0.895			UNKNOWN	g	0.05		SINGLE	UNKNOWN						HEALTHY	Vaginal	FEMALE	EXPERIMENT	https://www.researchgate.net/publication/289924108_Pharmacokinetics_of_butoconazole_nitrate_suppositories_in_human	Homo sapiens										false
4274	1977		ADULT	10339178	371.254	CARBOPLATIN	carboplatin	N.N.[Pt++].[O-]C(=O)C1(CCC1)C([O-])=O	PLASMA	BG3F62OND5									∞	μg × h/mL	197.71		μg/mL	38.99			UNKNOWN	mg/m²	375		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3283185	Homo sapiens		h	39.81							false
4275	1977		UNKNOWN	10339178	371.254	CARBOPLATIN	CARBOPLATIN	N.N.[Pt++].[O-]C(=O)C1(CCC1)C([O-])=O	PLASMA	BG3F62OND5																						UNKNOWN				Carboplatin is not bound to plasma proteins.	100	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020452s005lbl.pdf	Homo sapiens										false
4276	1978		ADULT	18381	470.326	DICLOXACILLIN	DICLOXACILLIN	CC1=C(C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)C(=NO1)C4=C(Cl)C=CC=C4Cl	PLASMA	COF19H7WBK													μg/mL	17			UNKNOWN	mg	500		SINGLE	UNKNOWN				dicloxacillin sodium is 95% to 99% bound to serum proteins, mainly albumin.	3	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=65c3e99b-ec77-416c-ad70-596d6f0a9c31&type=display	Homo sapiens		h	0.7							false
4277	1978		ADULT	18381	470.326	DICLOXACILLIN	DICLOXACILLIN	CC1=C(C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)C(=NO1)C4=C(Cl)C=CC=C4Cl	PLASMA	COF19H7WBK									∞	μg × h/mL	32.78		μg/mL	13.62			RECOMMENDED	g	0.25		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26527863	Homo sapiens		h	1.38							false
4278	1978		ADULT	18381	470.326	DICLOXACILLIN	DICLOXACILLIN	CC1=C(C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)C(=NO1)C4=C(Cl)C=CC=C4Cl	PLASMA	COF19H7WBK									∞	μg × h/mL	62.43		μg/mL	24.28			UNKNOWN	g	0.5		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26527863	Homo sapiens		h	1.44							false
4279	1978		ADULT	18381	470.326	DICLOXACILLIN	DICLOXACILLIN	CC1=C(C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)C(=NO1)C4=C(Cl)C=CC=C4Cl	PLASMA	COF19H7WBK									∞	μg × h/mL	110.93		μg/mL	45.02			UNKNOWN	g	1		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26527863	Homo sapiens		h	1.51							false
4280	1978		ADULT	18381	470.326	DICLOXACILLIN	DICLOXACILLIN	CC1=C(C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)C(=NO1)C4=C(Cl)C=CC=C4Cl	PLASMA	COF19H7WBK									∞	μg × h/mL	207.4		μg/mL	79.97			DEFINED DAILY	g	2		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26527863	Homo sapiens		h	1.71							false
4281	1979		ADULT		457.4764	MINOCYCLINE	MINOCYCLINE	CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=CC(O)=C4C(=O)C3=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O)N(C)C	PLASMA	FYY3R43WGO							24		t	μg × h/mL	33.32		μg/mL	2.63			RECOMMENDED	mg	135		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/050808s014lbl.pdf	Homo sapiens										false
4282	1980		UNKNOWN	23939	195.084	PLATINUM	platinum	[Pt]	PLASMA	49DFR088MY																						UNKNOWN				In patients, plasma protein binding of platinum is irreversible and is greater than 90%.	10	UNKNOWN		UNKNOWN	DRUG LABEL	https://s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00526.pdf?1265922796	Homo sapiens										false
4283	1980		ADULT	43805	395.3	OXALIPLATIN	OXALIPLATIN	O=C1O[Pt]2(NC3CCCCC3N2)OC1=O	PLASMA	04ZR38536J							96		t	μg × h/mL	205.75		μg/mL	4.66			UNKNOWN	mg/m²	130		STEADY-STATE	UNKNOWN		3 weeks	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/16395593	Homo sapiens		h	42.84							false
4284	1981		ADULT	57697	228.2101	PEMIROLAST	PEMIROLAST	CC1=CC=CN2C(=O)C(=CN=C12)C3=NN=NN3	PLASMA	2C09NV773M													ng/mL	4.7			RECOMMENDED	drop	2		STEADY-STATE	UNKNOWN		day	4			HEALTHY	Ocular	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21079lbl.pdf	Homo sapiens		h	4.5							false
4285	1982		ADULT	69046	277.3	DEACETYLBISACODYL		C1=CC=NC(=C1)C(C2=CC=C(C=C2)O)C3=CC=C(C=C3)O	PLASMA	R09078E41Y									∞	ng × h/mL	209		ng/mL	18.1			RECOMMENDED	mg	10		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21697613/	Homo sapiens		h	7.3							false
4286	1982		ADULT	69046	277.3172	DEACETYLBISACODYL	C1=CC=NC(=C1)C(C2=CC=C(C=C2)O)C3=CC=C(C=C3)O	OC1=CC=C(C=C1)C(C2=CC=C(O)C=C2)C3=CC=CC=N3	PLASMA	R09078E41Y							24		t	ng × h/mL	275		ng/mL	21.3			RECOMMENDED	mg	10		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21697613/	Homo sapiens		h	10							false
4287	1982		ADULT	69046	277.3	Dihydroxydiphenyl-pyridyl methane	C1=CC=NC(=C1)C(C2=CC=C(C=C2)O)C3=CC=C(C=C3)O	C1=CC=NC(=C1)C(C2=CC=C(C=C2)O)C3=CC=C(C=C3)O	PLASMA	R09078E41Y													ng/mL	2.3			RECOMMENDED	mg	10		SINGLE	UNKNOWN				Plasma levels of the free BHPM were low, with 13 out of 16 subjects studied having plasma BHPM concentrations below the lower limit of quantification (0.1 ng/mL).		HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202535s005lbl.pdf	Homo sapiens		h	7.4							false
4288	1983		ADULT	4908	259.3467	PRIMAQUINE	PRIMAQUINE	COC1=CC(NC(C)CCCN)=C2N=CC=CC2=C1	PLASMA	MVR3634GX1							24		t	μg × h/mL	0.5		ng/mL	53			UNKNOWN	mg	15		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4027117/	Homo sapiens		h	5.9							false
4289	1983		ADULT	4908	259.3467	PRIMAQUINE	PRIMAQUINE	COC1=CC(NC(C)CCCN)=C2N=CC=CC2=C1	PLASMA	MVR3634GX1							24		t	μg × h/mL	1		ng/mL	104			UNKNOWN	mg	30		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4027117/	Homo sapiens		h	7.4							false
4290	1983		ADULT	4908	259.3467	PRIMAQUINE	PRIMAQUINE	COC1=CC(NC(C)CCCN)=C2N=CC=CC2=C1	PLASMA	MVR3634GX1									∞	ng × h/mL	468		ng/mL	65			UNKNOWN	mg	15		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4027118/	Homo sapiens		h	4.4							false
4291	1983		ADULT	4908	259.3467	PRIMAQUINE	PRIMAQUINE	COC1=CC(NC(C)CCCN)=C2N=CC=CC2=C1	PLASMA	MVR3634GX1									∞	ng × h/mL	443		ng/mL	66			UNKNOWN	mg	15		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4027118/	Homo sapiens		h	4.3							false
4292	1984		ADULT	4915	221.3	PROCARBAZINE	PROCARBAZINE	CNNCC1=CC=C(C=C1)C(=O)NC(C)C	PLASMA	35S93Y190K									∞	μg × h/mL	0.217		μg/mL	0.692			MAX DAILY	mg	300		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/16317293	Homo sapiens		h	0.154							false
4293	1986		UNKNOWN		268.226	hypoxanthine arabinoside	hypoxanthine arabinoside		PLASMA																		UNKNOWN	mg/kg	7.5		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/1348236	Homo sapiens		h	3							false
4294	1988		ADULT	6806	556.8623	ACETRIZOIC ACID	ACETRIZOIC ACID	CC(=O)NC1=C(I)C(C(O)=O)=C(I)C=C1I	PLASMA	24256BQV7M							24		t	ng × h/mL	1342		ng/mL	248			RECOMMENDED	mg	50		SINGLE	FASTED						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2524207/	Homo sapiens		h	2.3							false
4295	1988		ADULT	6806	556.8623	ACETRIZOIC ACID	ACETRIZOIC ACID	CC(=O)NC1=C(I)C(C(O)=O)=C(I)C=C1I	PLASMA	24256BQV7M													ng/mL	416			RECOMMENDED	mg	50		SINGLE	UNKNOWN				Acitretin is more than 99.9% bound to plasma proteins, primarily albumin.	0.1	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019821s028lbl.pdf	Homo sapiens										false
4296	1989		ADULT	2165|3647519	355.861	AMODIAQUINE	AMODIAQUINE	CCN(CC)CC1=C(O)C=CC(NC2=C3C=CC(Cl)=CC3=NC=C2)=C1	PLASMA	220236ED28	6917864		ARTESUNATE	artesunate	C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4	60W3249T9M											RECOMMENDED	mg	270		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20368402/	Homo sapiens		h	7.9							true
4297	1989		ADULT	2165|3647519	355.861	AMODIAQUINE	AMODIAQUINE	CCN(CC)CC1=C(O)C=CC(NC2=C3C=CC(Cl)=CC3=NC=C2)=C1	BLOOD	220236ED28													mg/L	415			RECOMMENDED	mg/kg	10		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8983859/	Homo sapiens		h	2.1							false
4298	1989		ADULT	2165|3647519	355.861	AMODIAQUINE	AMODIAQUINE	CCN(CC)CC1=C(O)C=CC(NC2=C3C=CC(Cl)=CC3=NC=C2)=C1	BLOOD	220236ED28													mg/L	322			RECOMMENDED	mg/kg	10		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8983859/	Homo sapiens		h	10.1							false
4299	1989		ADULT	2165|3647519	355.861	AMODIAQUINE	AMODIAQUINE	CCN(CC)CC1=C(O)C=CC(NC2=C3C=CC(Cl)=CC3=NC=C2)=C1	BLOOD	220236ED28									∞	ng × h/mL	77		mg/L	21			RECOMMENDED	mg/kg	10		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8983859/	Homo sapiens		h	3.7							false
4300	1995		ADULT	40692	378.3122	MEFLOQUINE	MEFLOQUINE	O[C@H]([C@H]1CCCCN1)C2=C3C=CC=C(C3=NC(=C2)C(F)(F)F)C(F)(F)F	PLASMA	TML814419R									∞	μg × h/mL	432		ng/mL	1018			RECOMMENDED	mg	750		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9860148	Homo sapiens		h	396							false
4301	1995		UNKNOWN	40692	378.3122	MEFLOQUINE	MEFLOQUINE	O[C@H]([C@H]1CCCCN1)C2=C3C=CC=C(C3=NC(=C2)C(F)(F)F)C(F)(F)F	PLASMA	TML814419R																						UNKNOWN				Protein binding is about 98%	2	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019591s026s028lbl.pdf	Homo sapiens										false
4302	1996		ADULT		442.4187	METHACYCLINE	METHACYCLINE	CN(C)[C@H]1[C@@H]2[C@@H](O)[C@@H]3C(=C)C4=C(C(O)=CC=C4)C(=O)C3=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O	SERUM	IR235I7C5P							24		t	μg × h/mL	47.5		μg/mL	4			UNKNOWN	mg	200		MULTIPLE	UNKNOWN		day	1			HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4199710/	Homo sapiens		h	16							false
4303	1997		ADULT	5852|6926437	149.211	PENICILLAMINE	PENICILLAMINE	CC(C)(S)[C@@H](N)C(O)=O	PLASMA	GNN1DV99GX							24		t	μg × h/mL	83.97		μg/mL	8.04			UNKNOWN	mg	500		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	REVIEW	https://purehost.bath.ac.uk/ws/portalfiles/portal/188880438/David_Huw_Llewellyn_thesis.pdf	Homo sapiens		h	5.01							false
4304	1997		ADULT	5852|6926437	149.211	PENICILLAMINE	PENICILLAMINE	CC(C)(S)[C@@H](N)C(O)=O	PLASMA	GNN1DV99GX							24		t	μg × h/mL	73.19		μg/mL	5.36			UNKNOWN	mg	500		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	REVIEW	https://purehost.bath.ac.uk/ws/portalfiles/portal/188880438/David_Huw_Llewellyn_thesis.pdf	Homo sapiens		h	5.37							false
4305	2000		ADULT	5311399	597.8912	RAPACURONIUM	RAPACURONIUM	CCC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N5CCCCC5)[N+]6(CC=C)CCCCC6	PLASMA	GG1LBM463S							2		t	μg × min/mL	160		μg/mL	7			RECOMMENDED	mg/kg	0.6		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10500937/	Homo sapiens		min	70.3							false
4306	2000		ADULT	5311399	597.8912	RAPACURONIUM	RAPACURONIUM	CCC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N5CCCCC5)[N+]6(CC=C)CCCCC6	PLASMA	GG1LBM463S																	RECOMMENDED	mg/kg	1.5		STEADY-STATE	UNKNOWN		day	1	The protein binding was variable and ranged between 50% and 88%, which was at least partly due to hydrolysis of rapacuronium bromide to its 3-hydroxy metabolite.	12	UNHEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020984s003lbl.pdf	Homo sapiens		min	27.8							false
4307	2003		ADULT	5577	388.4574	TRIMETHOBENZAMIDE	trimethobenzamide	COC1=CC(=CC(OC)=C1OC)C(=O)NCC2=CC=C(OCCN(C)C)C=C2	PLASMA	W2X096QY97									∞	ng × h/mL	10465		ng/mL	3729			RECOMMENDED	mg	200		SINGLE	FASTED						HEALTHY	Intramuscular	FEMALE / MALE	REVIEW	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/017531_S010_TIGAN_CAPSULE_AP.pdf	Homo sapiens		h	6.8							false
4308	2003		ADULT	5577	388.4574	TRIMETHOBENZAMIDE	trimethobenzamide	COC1=CC(=CC(OC)=C1OC)C(=O)NCC2=CC=C(OCCN(C)C)C=C2	PLASMA	W2X096QY97									∞	ng × h/mL	10218		ng/mL	3817			RECOMMENDED	mg	300		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	REVIEW	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/017531_S010_TIGAN_CAPSULE_AP.pdf	Homo sapiens		h	7.8							false
4309	2003		ADULT	5577	388.4574	TRIMETHOBENZAMIDE	trimethobenzamide	COC1=CC(=CC(OC)=C1OC)C(=O)NCC2=CC=C(OCCN(C)C)C=C2	PLASMA	W2X096QY97									∞	ng × h/mL	13647		ng/mL	5211			RECOMMENDED	mg	400		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	REVIEW	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/017531_S010_TIGAN_CAPSULE_AP.pdf	Homo sapiens		h	7.4							false
4310	2003		ADULT	5577	388.4574	TRIMETHOBENZAMIDE	trimethobenzamide	COC1=CC(=CC(OC)=C1OC)C(=O)NCC2=CC=C(OCCN(C)C)C=C2	PLASMA	W2X096QY97									∞	ng × h/mL	10581		ng/mL	3537			RECOMMENDED	mg	200		SINGLE	FASTED						HEALTHY	Intramuscular	MALE	REVIEW	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/017531_S010_TIGAN_CAPSULE_AP.pdf	Homo sapiens		h	7							false
4311	2003		ADULT	5577	388.4574	TRIMETHOBENZAMIDE	trimethobenzamide	COC1=CC(=CC(OC)=C1OC)C(=O)NCC2=CC=C(OCCN(C)C)C=C2	PLASMA	W2X096QY97									∞	ng × h/mL	10621		ng/mL	4002			RECOMMENDED	mg	200		SINGLE	FASTED						HEALTHY	Intramuscular	FEMALE	REVIEW	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/017531_S010_TIGAN_CAPSULE_AP.pdf	Homo sapiens		h	6.7							false
4312	2003		ADULT	5577	388.4574	TRIMETHOBENZAMIDE	trimethobenzamide	COC1=CC(=CC(OC)=C1OC)C(=O)NCC2=CC=C(OCCN(C)C)C=C2	PLASMA	W2X096QY97									∞	ng × h/mL	10041		ng/mL	3536			RECOMMENDED	mg	300		SINGLE	FASTED						HEALTHY	Oral	MALE	REVIEW	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/017531_S010_TIGAN_CAPSULE_AP.pdf	Homo sapiens		h	7.8							false
4313	2003		ADULT	5577	388.4574	TRIMETHOBENZAMIDE	trimethobenzamide	COC1=CC(=CC(OC)=C1OC)C(=O)NCC2=CC=C(OCCN(C)C)C=C2	PLASMA	W2X096QY97									∞	ng × h/mL	10436		ng/mL	4219			RECOMMENDED	mg	300		SINGLE	FASTED						HEALTHY	Oral	FEMALE	REVIEW	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/017531_S010_TIGAN_CAPSULE_AP.pdf	Homo sapiens		h	7.8							false
4314	2003		ADULT	5577	388.4574	TRIMETHOBENZAMIDE	trimethobenzamide	COC1=CC(=CC(OC)=C1OC)C(=O)NCC2=CC=C(OCCN(C)C)C=C2	PLASMA	W2X096QY97									∞	ng × h/mL	10448		ng/mL	3712			RECOMMENDED	mg	200		SINGLE	FASTED						HEALTHY	Intramuscular	FEMALE / MALE	REVIEW	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/017531_S010_TIGAN_CAPSULE_AP.pdf	Homo sapiens		h	6.8							false
4315	2003		ADULT	5577	388.4574	TRIMETHOBENZAMIDE	trimethobenzamide	COC1=CC(=CC(OC)=C1OC)C(=O)NCC2=CC=C(OCCN(C)C)C=C2	PLASMA	W2X096QY97									∞	ng × h/mL	11544		ng/mL	3982			RECOMMENDED	mg	200		SINGLE	FASTED						HEALTHY	Intramuscular	FEMALE / MALE	REVIEW	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/017531_S010_TIGAN_CAPSULE_AP.pdf	Homo sapiens		h	6.5							false
4316	2003		ADULT	5577	388.4574	TRIMETHOBENZAMIDE	trimethobenzamide	COC1=CC(=CC(OC)=C1OC)C(=O)NCC2=CC=C(OCCN(C)C)C=C2	PLASMA	W2X096QY97									∞	ng × h/mL	10371		ng/mL	3847			RECOMMENDED	mg	300		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	REVIEW	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/017531_S010_TIGAN_CAPSULE_AP.pdf	Homo sapiens		h	8							false
4317	2003		ADULT	5577	388.4574	TRIMETHOBENZAMIDE	trimethobenzamide	COC1=CC(=CC(OC)=C1OC)C(=O)NCC2=CC=C(OCCN(C)C)C=C2	PLASMA	W2X096QY97									∞	ng × h/mL	9768		ng/mL	3863			RECOMMENDED	mg	300		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	REVIEW	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/017531_S010_TIGAN_CAPSULE_AP.pdf	Homo sapiens		h	7.6							false
4318	2005		ADULT	3037981|135398671	685.69	VIOMYCIN	VIOMYCIN	NCCC[C@H](N)CC(=O)N[C@H]1CNC(=O)[C@@H](NC(=O)\\C(NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC1=O)=C\\NC(N)=O)[C@H]2C[C@H](O)NC(N)=N2	PLASMA	YVU35998K5													μg/mL	50			UNKNOWN	g	1		SINGLE	UNKNOWN						HEALTHY	Intramuscular	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/6391781/	Homo sapiens										false
4319	2006		ADULT	166592	441.456	CEPHALOGLYCIN	CEPHALOGLYCIN	O.O.CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C3=CC=CC=C3)C2=O)C(O)=O	PLASMA	NE7R11LA95							8		t	μg × h/mL	3		μg/mL	0.8			RECOMMENDED	g	0.5		SINGLE	FED				https://pubmed.ncbi.nlm.nih.gov/3319507/	75	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4887297/	Homo sapiens		h	1							false
4320	2009		ADULT	23930	54.938046	MANGANESE	MANGANESE	[Mn]	PLASMA	42Z2K6ZL8P									∞	μM × h	8.89		μM	14.1			UNKNOWN	μmol/kg	5		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9245963/	Homo sapiens		h	8							false
4321	2009		ADULT	23930	54.938046	MANGANESE	MANGANESE	[Mn]	PLASMA	42Z2K6ZL8P									∞	μM × h	26		μM	37.9			UNKNOWN	μmol/kg	10		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9245963/	Homo sapiens		h	8							false
4322	2009		ADULT	23930	54.938046	MANGANESE	MANGANESE	[Mn]	PLASMA	42Z2K6ZL8P									∞	μM × h	11.5		μM	38.3			UNKNOWN	μmol/kg	5		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9245963/	Homo sapiens		h	8							false
4323	2009		ADULT	23930	54.938046	MANGANESE	MANGANESE	[Mn]	PLASMA	42Z2K6ZL8P									∞	μM × h	27.6		μM	78.8			UNKNOWN	μmol/kg	10		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9245963/	Homo sapiens		h	8							false
4324	2009		ADULT	60683	638.4554	FODIPIR	FODIPIR	CC1=NC=C(COP(O)(O)=O)C(CN(CCN(CC(O)=O)CC2=C(O)C(C)=NC=C2COP(O)(O)=O)CC(O)=O)=C1O	PLASMA	P28BIW0UTB									∞	μM × h	43.7		μM	26.4			UNKNOWN	μmol/kg	5		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9245963/	Homo sapiens		min	121							false
4325	2009		ADULT	60683	638.4554	FODIPIR	FODIPIR	CC1=NC=C(COP(O)(O)=O)C(CN(CCN(CC(O)=O)CC2=C(O)C(C)=NC=C2COP(O)(O)=O)CC(O)=O)=C1O	PLASMA	P28BIW0UTB									∞	μM × h	96.8		μM	61.1			UNKNOWN	μmol/kg	10		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9245963/	Homo sapiens		min	113							false
4326	2009		ADULT	60683	638.4554	FODIPIR	FODIPIR	CC1=NC=C(COP(O)(O)=O)C(CN(CCN(CC(O)=O)CC2=C(O)C(C)=NC=C2COP(O)(O)=O)CC(O)=O)=C1O	PLASMA	P28BIW0UTB									∞	μM × h	47.8		μM	38.6			UNKNOWN	μmol/kg	10		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9245963/	Homo sapiens		min	112							false
4327	2009		ADULT	60683	638.4554	FODIPIR	FODIPIR	CC1=NC=C(COP(O)(O)=O)C(CN(CCN(CC(O)=O)CC2=C(O)C(C)=NC=C2COP(O)(O)=O)CC(O)=O)=C1O	PLASMA	P28BIW0UTB									∞	μM × h	96		μM	85.2			UNKNOWN	μmol/kg	10		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9245963/	Homo sapiens		min	117							false
4328	2010		ADULT	5563	229.384	TRICLOFOS	Triclofos	OP(O)(=O)OCC(Cl)(Cl)Cl	PLASMA	J712EO9048																	RECOMMENDED	g	1		SINGLE	UNKNOWN					65	UNKNOWN	Oral	UNKNOWN	REVIEW	https://www.sciencedirect.com/science/article/pii/B9780080552323627977	Homo sapiens		h	8							false
4329	2014		ADULT	132862|46906075	188.2275	TILARGININE	l-NMMA	CNC(=N)NCCC[C@H](N)C(O)=O	PLASMA	27JT06E6GR									?	μg × min/mL	260.4		μg/mL	12.9			UNKNOWN	mg/kg	3		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10336578/	Homo sapiens		min	63.5				7	NG-monomethyl-l-arginine		false
4330	2015		ADULT	6400678	514.582	CEFMATILEN	CEFMATILEN	NC1=NC(=CS1)C(=N\\O)\\C(=O)N[C@H]2[C@H]3SCC(SCSC4=CNN=N4)=C(N3C2=O)C(O)=O	PLASMA	T750UM24H8							24		t	μg × h/mL	20.35		μg/mL	2.79			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29681381/	Homo sapiens		h	3.23				6	S-1090		false
4331	2015		ADULT	6400678	514.582	CEFMATILEN	CEFMATILEN	NC1=NC(=CS1)C(=N\\O)\\C(=O)N[C@H]2[C@H]3SCC(SCSC4=CNN=N4)=C(N3C2=O)C(O)=O	PLASMA	T750UM24H8							24		t	μg × h/mL	25.51		μg/mL	3.78			UNKNOWN	mg	100		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29681381/	Homo sapiens		h	2.77				6	S-1090		false
4332	2015		ADULT		514.582	CEFMATILEN	CEFMATILEN	NC1=NC(=CS1)C(=N\\O)\\C(=O)N[C@H]2[C@H]3SCC(SCSC4=CNN=N4)=C(N3C2=O)C(O)=O	PLASMA	T750UM24H8							12		t	μg × h/mL	11.37		μg/mL	2.01			UNKNOWN	mg	50		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29681381/	Homo sapiens		h	2.89				12	S-1090		false
4333	2015		ADULT		514.582	CEFMATILEN	CEFMATILEN	NC1=NC(=CS1)C(=N\\O)\\C(=O)N[C@H]2[C@H]3SCC(SCSC4=CNN=N4)=C(N3C2=O)C(O)=O	PLASMA	T750UM24H8							12		t	μg × h/mL	15.06		μg/mL	2.58			UNKNOWN	mg	75		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29681381/	Homo sapiens		h	2.99				12	S-1090		false
4334	2015		ADULT		514.582	CEFMATILEN	CEFMATILEN	NC1=NC(=CS1)C(=N\\O)\\C(=O)N[C@H]2[C@H]3SCC(SCSC4=CNN=N4)=C(N3C2=O)C(O)=O	PLASMA	T750UM24H8							12		t	μg × h/mL	19.25		μg/mL	3.1			UNKNOWN	mg	100		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29681381/	Homo sapiens		h	2.84				12	S-1090		false
4335	2015		ADULT		514.582	CEFMATILEN	CEFMATILEN	NC1=NC(=CS1)C(=N\\O)\\C(=O)N[C@H]2[C@H]3SCC(SCSC4=CNN=N4)=C(N3C2=O)C(O)=O	PLASMA	T750UM24H8							12		t	μg × h/mL	27.52		μg/mL	4.25			UNKNOWN	mg	200		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29681381/	Homo sapiens		h	3.08				12	S-1090		false
4336	2015		ADULT		514.582	CEFMATILEN	CEFMATILEN	NC1=NC(=CS1)C(=N\\O)\\C(=O)N[C@H]2[C@H]3SCC(SCSC4=CNN=N4)=C(N3C2=O)C(O)=O	PLASMA	T750UM24H8							12		t	μg × h/mL	39.53		μg/mL	6.1			UNKNOWN	mg	400		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29681381/	Homo sapiens		h	2.08				6	S-1090		false
4337	2015		ADULT		514.582	CEFMATILEN	CEFMATILEN	NC1=NC(=CS1)C(=N\\O)\\C(=O)N[C@H]2[C@H]3SCC(SCSC4=CNN=N4)=C(N3C2=O)C(O)=O	PLASMA	T750UM24H8							12		t	μg × h/mL	24.89		μg/mL	3.98			UNKNOWN	mg	200		MULTIPLE	FED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29681381/	Homo sapiens		h	2.53				6	S-1090		false
4338	2015			6400678	514.582	CEFMATILEN	CEFMATILEN	NC1=NC(=CS1)C(=N\\O)\\C(=O)N[C@H]2[C@H]3SCC(SCSC4=CNN=N4)=C(N3C2=O)C(O)=O	PLASMA	T750UM24H8																										The binding percentage did not depend on the serum concentrations observed in pracatice and was not affected by multiple administrations.	2.7				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29681381/	Homo sapiens								S-1090		false
4339	2021		ADULT	5977	177.457	CHLOROBUTANOL	CHLOROBUTANOL	CC(C)(O)C(Cl)(Cl)Cl	PLASMA	HM4YQM8WRC																	UNKNOWN	mg	600		SINGLE	FASTED				The binding of chlorbutol to human plasma proteins was 57%.	43	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7159691	Homo sapiens		day	10							false
4340	2023		ADULT	13804|11583971|76963096	488.324	CITICOLINE	CITICOLINE	[H ].C[N ](C)(C)CCOP([O-])(=O)OP([O-])(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N2C=CC(N)=NC2=O	PLASMA	536BQ2JVC7									∞	μg × h/mL	145.912		μg/mL	2.011			UNKNOWN	mg	1000		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22951317/	Homo sapiens		h	74.119	test preparation of citicoline (tablet containing citicoline 1000 mg control release (CR), manufactured by Cosmas Pharmacls)			12	CITICOLINE		false
4341	2023		ADULT	13804|11583971|76963096	488.324	CITICOLINE	CITICOLINE	[H ].C[N ](C)(C)CCOP([O-])(=O)OP([O-])(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N2C=CC(N)=NC2=O	PLASMA	536BQ2JVC7									∞	μg × h/mL	127.778		μg/mL	2.085			UNKNOWN	mg	1000		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22951317/	Homo sapiens		h	66.348	reference preparation Strocit CR (containing citicoline 1000 mg control release (CR), manufactured by Sun Pharmaceuticals Industry, Ltd.)			12	CITICOLINE		false
4342	2035		ADULT	7019255	254.3667	ENZACAMENE	Enzacamene	CC1=CC=C(C=C1)\\C=C2/[C@H]3CC[C@@](C)(C2=O)C3(C)C	PLASMA	8I3XWY40L9													ng/mL	18			UNKNOWN	g	3.5		MULTIPLE	UNKNOWN		day	1			HEALTHY	Transdermal	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30094825/ | https://pubmed.ncbi.nlm.nih.gov/18221342/	Homo sapiens		h	3.98	Day 1	postmenopausal females		17	Enzacamene		false
4343	2035		ADULT	7019255	254.3667	ENZACAMENE	Enzacamene	CC1=CC=C(C=C1)\\C=C2/[C@H]3CC[C@@](C)(C2=O)C3(C)C	PLASMA	8I3XWY40L9													ng/mL	21			UNKNOWN	g	4		MULTIPLE	UNKNOWN		day	1			HEALTHY	Transdermal	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30094825/ | https://pubmed.ncbi.nlm.nih.gov/18221342/	Homo sapiens		h	3.98	Day 1	postmenopausal females		15	Enzacamene		false
4344	2035		ADULT	7019255	254.3667	ENZACAMENE	Enzacamene	CC1=CC=C(C=C1)\\C=C2/[C@H]3CC[C@@](C)(C2=O)C3(C)C	PLASMA	8I3XWY40L9													ng/mL	34			UNKNOWN	g	4		MULTIPLE	UNKNOWN		day	1			HEALTHY	Transdermal	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30094825/ | https://pubmed.ncbi.nlm.nih.gov/18221342/	Homo sapiens		h	3.98	Day 5	postmenopausal females		15	Enzacamene		false
4345	2035		ADULT	7019255	254.3667	ENZACAMENE	Enzacamene	CC1=CC=C(C=C1)\\C=C2/[C@H]3CC[C@@](C)(C2=O)C3(C)C	PLASMA	8I3XWY40L9													ng/mL	29			UNKNOWN	g	3.5		MULTIPLE	UNKNOWN		day	1			HEALTHY	Transdermal	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30094825/ | https://pubmed.ncbi.nlm.nih.gov/18221342/	Homo sapiens		h	3.98	Day 5	postmenopausal females		17	Enzacamene		false
4346	2039		ADULT	4117	179.2588	METHOXYPHENAMINE	METHOXYPHENAMINE	CNC(C)CC1=C(OC)C=CC=C1	PLASMA	J3Z5SRI26Z							24		t	ng × h/mL	1315		ng/mL	157			UNKNOWN	mg	60.3		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3625484	Homo sapiens		h	2							false
4347	2058		ADULT	10783	161.652	CLOMETHIAZOLE	Clomethiazole	CC1=C(CCCl)SC=N1	SERUM	0C5DBZ19HV							10		t	μg × min/mL	110.8		μg/mL	1.55			UNKNOWN	mg	600		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10397378/	Homo sapiens							10	Clomethiazole edisylate 600mg (390mg free base)		false
4348	2058		ADULT	10783	161.652	CLOMETHIAZOLE	Clomethiazole	CC1=C(CCCl)SC=N1	SERUM	0C5DBZ19HV							10		t	μg × min/mL	73.2		μg/mL	0.4			UNKNOWN	mg	600		SINGLE	FASTED						HEALTHY	Rectal	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10397378/	Homo sapiens							10	Clomethiazole edisylate 600mg (390mg free base)		false
4349	2058		ADULT	10783	161.652	CLOMETHIAZOLE	Clomethiazole	CC1=C(CCCl)SC=N1	PLASMA	0C5DBZ19HV													μM	40			UNKNOWN	μmol/kg	265		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12734608/	Homo sapiens		h	10				8	Clomethiazole edisilate, 68mg/kg		false
4350	2058		ADULT	10783	161.652	CLOMETHIAZOLE	Clomethiazole	CC1=C(CCCl)SC=N1	PLASMA	0C5DBZ19HV													μM	33			UNKNOWN	μmol/kg	265		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12734608/	Homo sapiens		h	12		Hepatic impairment, Child-Pugh A		8	Clomethiazole edisilate, 68mg/kg		false
4351	2058		ADULT	10783	161.652	CLOMETHIAZOLE	Clomethiazole	CC1=C(CCCl)SC=N1	PLASMA	0C5DBZ19HV													μM	39			UNKNOWN	μmol/kg	265		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12734608/	Homo sapiens		h	19		Hepatic impairment, Child-Pugh B/C		8	Clomethiazole edisilate, 68mg/kg		false
4352	2058		ADULT	10783	161.652	CLOMETHIAZOLE	Clomethiazole	CC1=C(CCCl)SC=N1	PLASMA	0C5DBZ19HV									∞	mg × min/L	224						UNKNOWN	mg	162		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6995129/	Homo sapiens		h	8.7		Cirrhosis patients		8			false
4353	2058		ADULT	10783	161.652	CLOMETHIAZOLE	Clomethiazole	CC1=C(CCCl)SC=N1	PLASMA	0C5DBZ19HV									∞	mg × min/L	149						UNKNOWN	mg	162		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6995129/	Homo sapiens		h	6.6				6			false
4354	2058		ADULT	10783	161.652	CLOMETHIAZOLE	Clomethiazole	CC1=C(CCCl)SC=N1	PLASMA	0C5DBZ19HV									∞	mg × min/L	303		μg/mL	1.95			UNKNOWN	mg	192		SINGLE	UNKNOWN						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6995129/	Homo sapiens		h	8.9		Cirrhosis patients		8			false
4355	2058		ADULT	10783	161.652	CLOMETHIAZOLE	Clomethiazole	CC1=C(CCCl)SC=N1	PLASMA	0C5DBZ19HV									∞	mg × min/L	17.5		μg/mL	0.27			UNKNOWN	mg	192		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6995129/	Homo sapiens							6			false
4356	2058		ADULT	10783	161.652	CLOMETHIAZOLE	Clomethiazole	CC1=C(CCCl)SC=N1	PLASMA	0C5DBZ19HV																						UNKNOWN				Human plasma protein binding: 55.8%, equilibrium dialysis	44.2	UNHEALTHY		MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6995129/	Homo sapiens					Cirrhosis patients		8			false
4357	2058		ADULT	10783	161.652	CLOMETHIAZOLE	Clomethiazole	CC1=C(CCCl)SC=N1	PLASMA	0C5DBZ19HV																						UNKNOWN				Human plasma protein binding: 64.4%, equilibrium dialysis	35.6	HEALTHY		MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6995129/	Homo sapiens							6			false
4358	2059		ADULT	20556914	279.37	Mebeverine Acid		CCN(CCCC(=O)O)C(C)CC1=CC=C(C=C1)OC	PLASMA										∞	ng × h/mL	339.21		ng/mL	28.79			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28192719/	Homo sapiens		h	15.78				10	Mebeverine hydrochloride		false
4359	2059		ADULT	26649	265.39	1-BUTANOL, 4-(ETHYL(2-(4-METHOXYPHENYL)-1-METHYLETHYL)AMINO)-		CCN(CCCCO)C(C)CC1=CC=C(C=C1)OC	PLASMA										∞	ng × h/mL	47.57		ng/mL	6.61			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28192719/	Homo sapiens		h	2.99				10	Mebeverine hydrochloride		false
4360	2059		ADULT	45038887	265.35	O-Desmethyl Mebeverine Acid		CCN(C(CC1=CC=C(C=C1)O)C)CCCC(O)=O	PLASMA										∞	ng × h/mL	7669.41		ng/mL	685.28			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28192719/	Homo sapiens		h	7.39				10	Mebeverine hydrochloride		false
4361	2059			4031	429.5491	MEBEVERINE	Mebeverine	CCN(CCCCOC(=O)C1=CC(OC)=C(OC)C=C1)C(C)CC2=CC=C(OC)C=C2	PLASMA	7F80CC3NNV																										Plasma protein binding: 75%	25				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28435220/	Homo sapiens								Mebeverine hydrochloride		false
4362	2059		ADULT	20556914	279.37	Mebeverine Acid		CCN(CCCC(=O)O)C(C)CC1=CC=C(C=C1)OC	PLASMA										∞	ng × h/mL	365.85		ng/mL	62.52			UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.mathewsopenaccess.com/full-text/the-rapid-and-sensitive-hplc-ms-ms-method-of-determination-of-mebeverine-metabolites-in-human-plasma	Homo sapiens		h	2.87	Duspatalin (200mg prolonged-release capsules)			24	Mabeverine hydrochloride		false
4363	2059		ADULT	45038887	265.35	O-Desmethyl Mebeverine Acid		CCN(CCCC(=O)O)C(C)CC1=CC=C(C=C1)O	PLASMA										∞	ng × h/mL	2551.74		ng/mL	291.81			UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.mathewsopenaccess.com/full-text/the-rapid-and-sensitive-hplc-ms-ms-method-of-determination-of-mebeverine-metabolites-in-human-plasma	Homo sapiens		h	7.52	Duspatalin (200mg prolonged-release capsules)			24	Mabeverine hydrochloride		false
4364	2059		ADULT	4031	429.5491	MEBEVERINE	Mebeverine	CCN(CCCCOC(=O)C1=CC(OC)=C(OC)C=C1)C(C)CC2=CC=C(OC)C=C2	PLASMA	7F80CC3NNV																						UNKNOWN				Human plasma protein (healthy, 6.5%) binding: 83.51% (2 mcM), equilibrium hydrolysis	16.49	HEALTHY		FEMALE / MALE	EXPERIMENT	https://zjps.journals.ekb.eg/article_186342.html	Homo sapiens							5	Mebeverine hydrochloride		false
4365	2059		ADULT	4031	429.5491	MEBEVERINE	Mebeverine	CCN(CCCCOC(=O)C1=CC(OC)=C(OC)C=C1)C(C)CC2=CC=C(OC)C=C2	PLASMA	7F80CC3NNV																						UNKNOWN				Human plasma protein (renal failure patients, 5.6%) binding: 74.32% (2 mcM), equilibrium dialysis	25.68	HEALTHY		FEMALE / MALE	EXPERIMENT	https://zjps.journals.ekb.eg/article_186342.html	Homo sapiens							5	Mebeverine hydrochloride		false
4366	2063		ADULT	65894	285.316	FAROPENEM	Faropenem	C[C@@H](O)[C@@H]1[C@H]2SC([C@H]3CCCO3)=C(N2C1=O)C(O)=O	PLASMA	F52Y83BGH3							24		t	μg × h/mL	3.95		μg/mL	2.36			RECOMMENDED	mg	150		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/730155_6139001R1032_1_011_1F.pdf#page=33	Homo sapiens		h	0.76				6			false
4367	2063		ADULT	65894	285.316	FAROPENEM	Faropenem	C[C@@H](O)[C@@H]1[C@H]2SC([C@H]3CCCO3)=C(N2C1=O)C(O)=O	PLASMA	F52Y83BGH3							24		t	μg × h/mL	11.73		μg/mL	6.24			RECOMMENDED	mg	300		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/730155_6139001R1032_1_011_1F.pdf#page=33	Homo sapiens		h	0.85				6			false
4368	2063		ADULT	65894	285.316	FAROPENEM	Faropenem	C[C@@H](O)[C@@H]1[C@H]2SC([C@H]3CCCO3)=C(N2C1=O)C(O)=O	PLASMA	F52Y83BGH3							24		t	μg × h/mL	19.59		μg/mL	7.37			RECOMMENDED	mg	600		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/730155_6139001R1032_1_011_1F.pdf#page=33	Homo sapiens		h	1.08				6			false
4369	2063		ADULT	65894	285.316	FAROPENEM	Faropenem	C[C@@H](O)[C@@H]1[C@H]2SC([C@H]3CCCO3)=C(N2C1=O)C(O)=O	PLASMA	F52Y83BGH3							24		t	μg × h/mL	4.18		μg/mL	1.9			RECOMMENDED	mg	200		MULTIPLE	FED		day	3			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/730155_6139001R1032_1_011_1F.pdf#page=34	Homo sapiens		h	0.96	Day 1 (1st dose)			6			false
4370	2063		ADULT	65894	285.316	FAROPENEM	Faropenem	C[C@@H](O)[C@@H]1[C@H]2SC([C@H]3CCCO3)=C(N2C1=O)C(O)=O	PLASMA	F52Y83BGH3							24		t	μg × h/mL	4.14		μg/mL	1.89			RECOMMENDED	mg	200		MULTIPLE	FED		day	3			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/730155_6139001R1032_1_011_1F.pdf#page=34	Homo sapiens		h	0.93				6			false
4371	2063		ADULT	65894	285.316	FAROPENEM	Faropenem	C[C@@H](O)[C@@H]1[C@H]2SC([C@H]3CCCO3)=C(N2C1=O)C(O)=O	PLASMA	F52Y83BGH3							24		t	μg × h/mL	4.34		μg/mL	2.02			RECOMMENDED	mg	200		MULTIPLE	FED		day	3			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/730155_6139001R1032_1_011_1F.pdf#page=34	Homo sapiens		h	0.89	Day 4 (10th dose)			6			false
4372	2063		ADULT	65894	285.316	FAROPENEM	Faropenem	C[C@@H](O)[C@@H]1[C@H]2SC([C@H]3CCCO3)=C(N2C1=O)C(O)=O	PLASMA	F52Y83BGH3							24		t	μg × h/mL	11.73		μg/mL	6.24			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/730155_6139001R1032_1_011_1F.pdf#page=35	Homo sapiens		h	0.85				6			false
4373	2063		ADULT	65894	285.316	FAROPENEM	Faropenem	C[C@@H](O)[C@@H]1[C@H]2SC([C@H]3CCCO3)=C(N2C1=O)C(O)=O	PLASMA	F52Y83BGH3							24		t	μg × h/mL	9.75		μg/mL	4.25			UNKNOWN	mg	300		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/730155_6139001R1032_1_011_1F.pdf#page=35	Homo sapiens		h	1.01				6			false
4374	2063		ADULT	65894	285.316	FAROPENEM	Faropenem	C[C@@H](O)[C@@H]1[C@H]2SC([C@H]3CCCO3)=C(N2C1=O)C(O)=O	PLASMA	F52Y83BGH3							24		t	μg × h/mL	16.49		μg/mL	3.49			UNKNOWN	mg	300		SINGLE	FED						UNKNOWN	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/730155_6139001R1032_1_011_1F.pdf#page=35	Homo sapiens		h	1.61		Elderly subjects (67-85 y)		12			false
4375	2063		ADULT	65894	285.316	FAROPENEM	Faropenem	C[C@@H](O)[C@@H]1[C@H]2SC([C@H]3CCCO3)=C(N2C1=O)C(O)=O	PLASMA	F52Y83BGH3							24		t	μg × h/mL	9.75		μg/mL	4.25			UNKNOWN	mg	300		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/730155_6139001R1032_1_011_1F.pdf#page=35	Homo sapiens		h	1.01		Young subjects (29.2  - 4.9 y)		6			false
4376	2063		CHILD	65894	285.316	FAROPENEM	Faropenem	C[C@@H](O)[C@@H]1[C@H]2SC([C@H]3CCCO3)=C(N2C1=O)C(O)=O	PLASMA	F52Y83BGH3							24		t	μg × h/mL	4.1		μg/mL	1.32			UNKNOWN	mg	5		SINGLE	FED						UNKNOWN	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/730155_6139001R1032_1_011_1F.pdf#page=37	Homo sapiens		h	1.66				12			false
4377	2063		CHILD	65894	285.316	FAROPENEM	Faropenem	C[C@@H](O)[C@@H]1[C@H]2SC([C@H]3CCCO3)=C(N2C1=O)C(O)=O	PLASMA	F52Y83BGH3							24		t	μg × h/mL	5.89		μg/mL	2.08			UNKNOWN	mg	10		SINGLE	FED						UNKNOWN	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/730155_6139001R1032_1_011_1F.pdf#page=37	Homo sapiens		h	1.14				11			false
4378	2063			65894	285.316	FAROPENEM	Faropenem	C[C@@H](O)[C@@H]1[C@H]2SC([C@H]3CCCO3)=C(N2C1=O)C(O)=O	SERUM	F52Y83BGH3																										Human serum protein binding: 90.7% (5 mcg/mL, ultrafiltration); Human serum albumin binding: 86.4% (5% human serum albumin, 20 mcg/mL, ultrafiltration)	9.3				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/730155_6139001R1032_1_011_1F.pdf#page=37	Homo sapiens										false
4379	2064			2132	378.103	AMBROXOL	Ambroxol	NC1=C(CN[C@H]2CC[C@H](O)CC2)C=C(Br)C=C1Br	PLASMA	200168S0CL																										Following oral administration, ambroxol is rapidly and almost completely absorbed, with a bioavailability of 79% and plasma protein binding of 90%.	10				REVIEW	https://pubmed.ncbi.nlm.nih.gov/30372367/	Homo sapiens										false
4380	2064		ADULT	2132	378.103	AMBROXOL	Ambroxol	NC1=C(CN[C@H]2CC[C@H](O)CC2)C=C(Br)C=C1Br	PLASMA	200168S0CL							24		t	ng × h/mL	1228		ng/mL	76.1			UNKNOWN	mg	75		STEADY-STATE	FED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32372294/	Homo sapiens				Day 4 morning dose (fasted)			23	Ambroxol hydrochloride ER capsule		false
4381	2064		ADULT	2132	378.103	AMBROXOL	Ambroxol	NC1=C(CN[C@H]2CC[C@H](O)CC2)C=C(Br)C=C1Br	PLASMA	200168S0CL							24		t	ng × h/mL	1147		ng/mL	96.4			UNKNOWN	mg	30		STEADY-STATE	FED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32372294/	Homo sapiens				Day 4 morning dose (fasted)			23	Ambroxol hydrochloride IR tablets		false
4382	2064		ADULT	2132	378.103	AMBROXOL	Ambroxol	NC1=C(CN[C@H]2CC[C@H](O)CC2)C=C(Br)C=C1Br	PLASMA	200168S0CL							24		t	ng × h/mL	198.8		ng/mL	30.7			RECOMMENDED	mg	15		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/470310_2239001F1696_1_004_1F.pdf#page=62	Homo sapiens				Tablets			24	Ambroxol hydrochloride		false
4383	2064		ADULT	2132	378.103	AMBROXOL	Ambroxol	NC1=C(CN[C@H]2CC[C@H](O)CC2)C=C(Br)C=C1Br	PLASMA	200168S0CL							24		t	ng × h/mL	200		ng/mL	30.5			RECOMMENDED	mg	15		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/470310_2239001F1696_1_004_1F.pdf#page=62	Homo sapiens				Solution			24	Ambroxol hydrochloride		false
4384	2064		ADULT	2132	378.103	AMBROXOL	Ambroxol	NC1=C(CN[C@H]2CC[C@H](O)CC2)C=C(Br)C=C1Br	PLASMA	200168S0CL							30		t	ng × h/mL	216.6		ng/mL	29.9			RECOMMENDED	mg	15		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/470310_2239001F1696_1_004_1F.pdf#page=63	Homo sapiens		h	8.8	Dry syrup 3%			24	Ambroxol hydrochloride		false
4385	2064		ADULT	2132	378.103	AMBROXOL	Ambroxol	NC1=C(CN[C@H]2CC[C@H](O)CC2)C=C(Br)C=C1Br	PLASMA	200168S0CL							30		t	ng × h/mL	213.1		ng/mL	30			RECOMMENDED	mg	15		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/470310_2239001F1696_1_004_1F.pdf#page=63	Homo sapiens		h	8.9	Solution			24	Ambroxol hydrochloride		false
4386	2064		CHILD	2132	378.103	AMBROXOL	Ambroxol	NC1=C(CN[C@H]2CC[C@H](O)CC2)C=C(Br)C=C1Br	PLASMA	200168S0CL							30		t	ng × h/mL	226.4		ng/mL	28.3			DEFINED DAILY	mL/kg	0.3		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/470310_2239001F1696_1_004_1F.pdf#page=65	Homo sapiens		h	3.2	Syrup, 0.3mL/kg=0.9mg/kg			9	Ambroxol hydrochloride		false
4387	2064		CHILD	2132	378.103	AMBROXOL	Ambroxol	NC1=C(CN[C@H]2CC[C@H](O)CC2)C=C(Br)C=C1Br	PLASMA	200168S0CL							30		t	ng × h/mL	482.1		ng/mL	60.3			UNKNOWN	mg	30		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/470310_2239001F1696_1_004_1F.pdf#page=66	Homo sapiens		h	8.7	Dry Syrup 1.5%			16	Ambroxol hydrochloride		false
4388	2064		ADULT	2132	378.103	AMBROXOL	Ambroxol	NC1=C(CN[C@H]2CC[C@H](O)CC2)C=C(Br)C=C1Br	PLASMA	200168S0CL							30		?	ng × h/mL	579.462		ng/mL	28.985			DEFINED DAILY	mg	45		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/470310_2239001F1696_1_004_1F.pdf#page=69	Homo sapiens		h	12.149	Tablets			18	Ambroxol hydrochloride		false
4389	2064		ADULT	2132	378.103	AMBROXOL	Ambroxol	NC1=C(CN[C@H]2CC[C@H](O)CC2)C=C(Br)C=C1Br	PLASMA	200168S0CL							30		?	ng × h/mL	689.543		ng/mL	35.256			DEFINED DAILY	mg	45		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/470310_2239001F1696_1_004_1F.pdf#page=69	Homo sapiens		h	12.178	Tablets			20	Ambroxol hydrochloride		false
4390	2064			2132	378.103	AMBROXOL	Ambroxol	NC1=C(CN[C@H]2CC[C@H](O)CC2)C=C(Br)C=C1Br	SERUM	200168S0CL																										human serum albumin binding 8equilibrium dialysis): 70.9~78.3%	21.7				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/470310_2239001F1696_1_004_1F.pdf#page=70	Homo sapiens										false
4391	2068		ADULT	12555	309.4054	BENZYDAMINE	BENZYDAMINE	CN(C)CCCOC1=NN(CC2=CC=CC=C2)C3=C1C=CC=C3	PLASMA	4O21U048EF									∞	ng × h/mL	541		ng/mL	68			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1932611/	Homo sapiens		h	8.1				6	BENZYDAMINE HYDROCHLORIDE		false
4392	2068		ADULT	12555	309.4054	BENZYDAMINE	BENZYDAMINE	CN(C)CCCOC1=NN(CC2=CC=CC=C2)C3=C1C=CC=C3	PLASMA	4O21U048EF									∞	ng × h/mL	4907		ng/mL	459			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1932611/	Homo sapiens		h	7.8	solution			6	BENZYDAMINE HYDROCHLORIDE		false
4393	2068		ADULT	12555	309.4054	BENZYDAMINE	BENZYDAMINE	CN(C)CCCOC1=NN(CC2=CC=CC=C2)C3=C1C=CC=C3	PLASMA	4O21U048EF									∞	ng × h/mL	494		ng/mL	35			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral transmucosal	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1932611/	Homo sapiens		h	9.4	mouthwash			6	BENZYDAMINE HYDROCHLORIDE		false
4394	2068		ADULT	12555	309.4054	BENZYDAMINE	BENZYDAMINE	CN(C)CCCOC1=NN(CC2=CC=CC=C2)C3=C1C=CC=C3	PLASMA	4O21U048EF									∞	ng × h/mL	4994		ng/mL	546			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1932611/	Homo sapiens		h	7.8	solution			6	BENZYDAMINE HYDROCHLORIDE		false
4395	2068		ADULT	12555	309.4054	BENZYDAMINE	BENZYDAMINE	CN(C)CCCOC1=NN(CC2=CC=CC=C2)C3=C1C=CC=C3	PLASMA	4O21U048EF									∞	ng × h/mL	455		ng/mL	14			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Topical	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1932611/	Homo sapiens				dermal cream			6	BENZYDAMINE HYDROCHLORIDE		false
4396	2068		ADULT	12555	309.4054	BENZYDAMINE	BENZYDAMINE	CN(C)CCCOC1=NN(CC2=CC=CC=C2)C3=C1C=CC=C3	PLASMA	4O21U048EF									∞	ng × h/mL	162		ng/mL	10			UNKNOWN	mg	140		SINGLE	FASTED						HEALTHY	Vaginal	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1932611/	Homo sapiens				vaginal douche			6	BENZYDAMINE HYDROCHLORIDE		false
4397	2068		ADULT	65465	325.4	Benzydamine N-oxide	Benzydamine N-oxide		PLASMA										?	ng × h/mL	17.284						UNKNOWN	mg	6		SINGLE	UNKNOWN						HEALTHY	Vaginal	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32410819/	Homo sapiens							12	BENZYDAMINE HYDROCHLORIDE		false
4398	2068		ADULT	65465	325.4	Benzydamine N-oxide			PLASMA										?	ng × h/mL	30.477						UNKNOWN	mg	6		MULTIPLE	UNKNOWN		day	1			HEALTHY	Vaginal	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32410819/	Homo sapiens				3 days dosing			12	BENZYDAMINE HYDROCHLORIDE		false
4399	2068		ADULT	12555	309.4054	BENZYDAMINE	BENZYDAMINE	CN(C)CCCOC1=NN(CC2=CC=CC=C2)C3=C1C=CC=C3	PLASMA	4O21U048EF									?	ng × h/mL	60.996						UNKNOWN	mg	6		SINGLE	UNKNOWN						HEALTHY	Vaginal	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32410819/	Homo sapiens							12	BENZYDAMINE HYDROCHLORIDE		false
4400	2068		ADULT	12555	309.4054	BENZYDAMINE	BENZYDAMINE	CN(C)CCCOC1=NN(CC2=CC=CC=C2)C3=C1C=CC=C3	PLASMA	4O21U048EF									?	ng × h/mL	100.264						UNKNOWN	mg	6		MULTIPLE	UNKNOWN		day	1			HEALTHY	Vaginal	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32410819/	Homo sapiens				3 days dosing			12	BENZYDAMINE HYDROCHLORIDE		false
4401	2068		UNKNOWN	12555	309.4054	BENZYDAMINE	BENZYDAMINE	CN(C)CCCOC1=NN(CC2=CC=CC=C2)C3=C1C=CC=C3	PLASMA	4O21U048EF													μg/mL	0.8			UNKNOWN	mg	100		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/4044147/	Homo sapiens		h	13					BENZYDAMINE		false
4402	2069		ADULT	2442	376.13	BROMHEXINE	Bromhexine	CN(CC1=C(N)C(Br)=CC(Br)=C1)C2CCCCC2	PLASMA	Q1J152VB1P									∞	ng × h/mL	94.2		ng/mL	24.6			UNKNOWN	mg	8		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20031363/	Homo sapiens		h	3.6				5			false
4403	2069		ADULT	2132	378.103	AMBROXOL	Ambroxol	NC1=C(CN[C@H]2CC[C@H](O)CC2)C=C(Br)C=C1Br	PLASMA	200168S0CL									∞	nmol × h/mL	39.3		ng/mL	3.11			UNKNOWN	mg	8		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20031363/	Homo sapiens		h	8.4				5			false
4404	2069			2442	376.13	BROMHEXINE	Bromhexine	CN(CC1=C(N)C(Br)=CC(Br)=C1)C2CCCCC2	PLASMA	Q1J152VB1P																										Unchanged bromhexine is bound to plasma proteins by 95%.	5				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32458206/	Homo sapiens										false
4405	2069		ADULT	2442	376.13	BROMHEXINE	Bromhexine	CN(CC1=C(N)C(Br)=CC(Br)=C1)C2CCCCC2	PLASMA	Q1J152VB1P							4		t	nM × h	140		nM	89			UNKNOWN	mg	32		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6897618/	Homo sapiens							10			false
4406	2070		ADULT	2472	373.4494	BUNAZOSIN	BUNAZOSIN	CCCC(=O)N1CCCN(CC1)C2=NC(N)=C3C=C(OC)C(OC)=CC3=N2	PLASMA	9UUW4V7G2H							48		t	μg × h/L	86.6		μg/L	5.4			RECOMMENDED	mg	6		SINGLE	FASTED				Equilibrium dialysis indicated that the free fraction of bunazosin in plasma was 3%.	3	HEALTHY	Oral	FEMALE	EXPERIMENT	https://link.springer.com/article/10.1007/BF03258454	Homo sapiens		h	20.9				6	BUNAZOSIN		false
4407	2070		ADULT	2472	373.4494	BUNAZOSIN	BUNAZOSIN	CCCC(=O)N1CCCN(CC1)C2=NC(N)=C3C=C(OC)C(OC)=CC3=N2	PLASMA	9UUW4V7G2H							48		t	μg × h/L	106		μg/L	6.1			RECOMMENDED	mg	6		SINGLE	FASTED				Equilibrium dialysis indicated that the free fraction of bunazosin in plasma was 3%.	3	HEALTHY	Oral	MALE	EXPERIMENT	https://link.springer.com/article/10.1007/BF03258454	Homo sapiens		h	16				6	BUNAZOSIN		false
4408	2070		ADULT	2472	373.4494	BUNAZOSIN	BUNAZOSIN	CCCC(=O)N1CCCN(CC1)C2=NC(N)=C3C=C(OC)C(OC)=CC3=N2	PLASMA	9UUW4V7G2H							24		t	μg × h/L	147.6		μg/L	11.4			RECOMMENDED	mg	6		MULTIPLE	FASTED		day	1	Equilibrium dialysis indicated that the free fraction of bunazosin in plasma was 3%.	3	HEALTHY	Oral	MALE	EXPERIMENT	https://link.springer.com/article/10.1007/BF03258454	Homo sapiens				Day 14	elderly volunteers		12	BUNAZOSIN		false
4409	2070		ADULT	2472	373.4494	BUNAZOSIN	BUNAZOSIN	CCCC(=O)N1CCCN(CC1)C2=NC(N)=C3C=C(OC)C(OC)=CC3=N2	PLASMA	9UUW4V7G2H							24		t	μg × h/L	220.5		μg/L	17.8			RECOMMENDED	mg	6		MULTIPLE	FASTED		day	1	Equilibrium dialysis indicated that the free fraction of bunazosin in plasma was 3%.	3	HEALTHY	Oral	FEMALE	EXPERIMENT	https://link.springer.com/article/10.1007/BF03258454	Homo sapiens				Day 14	elderly volunteers		12	BUNAZOSIN		false
4410	2070		ADULT	2472	373.4494	BUNAZOSIN	BUNAZOSIN	CCCC(=O)N1CCCN(CC1)C2=NC(N)=C3C=C(OC)C(OC)=CC3=N2	PLASMA	9UUW4V7G2H							24		t	μg × h/L	184		μg/L	14.6			RECOMMENDED	mg	6		MULTIPLE	FASTED		day	1	Equilibrium dialysis indicated that the free fraction of bunazosin in plasma was 3%.	3	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://link.springer.com/article/10.1007/BF03258454	Homo sapiens				Day 14	elderly volunteers		12	BUNAZOSIN		false
4411	2070		ADULT	2472	373.4494	BUNAZOSIN	BUNAZOSIN	CCCC(=O)N1CCCN(CC1)C2=NC(N)=C3C=C(OC)C(OC)=CC3=N2	PLASMA	9UUW4V7G2H													ng/mL	15			RECOMMENDED	mg	6		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8929232/	Homo sapiens		h	12					BUNAZOSIN		false
4412	2071		ADULT	6540466|88621644|136478868	466.404	CARUMONAM	Carumonam	NC(=O)OC[C@@H]1[C@H](NC(=O)C(=N/OCC(O)=O)\\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O	SERUM	486890PI06									∞	μg × h/mL	602						UNKNOWN	g	1		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1929242/	Homo sapiens		h	5.08		CLcr: 10 to 49 mL/min/1.73m^2		6			false
4413	2071		ADULT	6540466|88621644|136478868	466.404	CARUMONAM	Carumonam	NC(=O)OC[C@@H]1[C@H](NC(=O)C(=N/OCC(O)=O)\\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O	SERUM	486890PI06									∞	μg × h/mL	117						UNKNOWN	g	1		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1929242/	Homo sapiens		h	1.53		CLcr: >=85 mL/min/1.73m^2		7			false
4414	2071		ADULT	6540466|88621644|136478868	466.404	CARUMONAM	Carumonam	NC(=O)OC[C@@H]1[C@H](NC(=O)C(=N/OCC(O)=O)\\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O	SERUM	486890PI06									∞	μg × h/mL	1112						UNKNOWN	g	1		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1929242/	Homo sapiens		h	12.8		CLcr: <10 mL/min/1.73m^2, on maintenance hemodialysis		6			false
4415	2071		ADULT	6540466|88621644|136478868	466.404	CARUMONAM	Carumonam	NC(=O)OC[C@@H]1[C@H](NC(=O)C(=N/OCC(O)=O)\\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O	SERUM	486890PI06									∞	μg × h/mL	186						UNKNOWN	g	1		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1929242/	Homo sapiens		h	2		CLcr: 50 to 84 mL/min/1.73m^2		7			false
4416	2071		ADULT	6540466|88621644|136478868	466.404	CARUMONAM	Carumonam	NC(=O)OC[C@@H]1[C@H](NC(=O)C(=N/OCC(O)=O)\\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O	PLASMA	486890PI06									?	mg × h/L	293		mg/L	208			UNKNOWN	g	2		MULTIPLE	UNKNOWN		day	4			HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2745245/	Homo sapiens		h	1.3	Last dose (15th)			12			false
4417	2071		ADULT	6540466|88621644|136478868	466.404	CARUMONAM	Carumonam	NC(=O)OC[C@@H]1[C@H](NC(=O)C(=N/OCC(O)=O)\\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O	PLASMA	486890PI06									?	mg × h/L	170		mg/L	111			UNKNOWN	g	1		MULTIPLE	UNKNOWN		day	3			HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2745245/	Homo sapiens		h	1.5	1st dose			12			false
4418	2071		ADULT	6540466|88621644|136478868	466.404	CARUMONAM	Carumonam	NC(=O)OC[C@@H]1[C@H](NC(=O)C(=N/OCC(O)=O)\\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O	PLASMA	486890PI06									?	mg × h/L	147		mg/L	105			UNKNOWN	g	1		MULTIPLE	UNKNOWN		day	3			HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2745245/	Homo sapiens		h	1.3	Last dose (10th)			12			false
4419	2071		ADULT	6540466|88621644|136478868	466.404	CARUMONAM	Carumonam	NC(=O)OC[C@@H]1[C@H](NC(=O)C(=N/OCC(O)=O)\\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O	PLASMA	486890PI06									?	mg × h/L	300		mg/L	214			UNKNOWN	g	2		MULTIPLE	UNKNOWN		day	3			HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2745245/	Homo sapiens		h	1.4	Last dose (5th)			12			false
4420	2071		ADULT	6540466|88621644|136478868	466.404	CARUMONAM	Carumonam	NC(=O)OC[C@@H]1[C@H](NC(=O)C(=N/OCC(O)=O)\\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O	PLASMA	486890PI06									∞	μg × h/mL	186.7		μg/mL	175			UNKNOWN	g	1		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3364953/	Homo sapiens		h	1.3				12			false
4421	2071		ADULT	6540466|88621644|136478868	466.404	CARUMONAM	Carumonam	NC(=O)OC[C@@H]1[C@H](NC(=O)C(=N/OCC(O)=O)\\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O	PLASMA	486890PI06							8		t	μg × h/mL	156.4		μg/mL	192.2			UNKNOWN	g	1		MULTIPLE	UNKNOWN		day	3			HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3364953/	Homo sapiens		h	1.5	Last dose			12			false
4422	2071		ADULT	6540466|88621644|136478868	466.404	CARUMONAM	Carumonam	NC(=O)OC[C@@H]1[C@H](NC(=O)C(=N/OCC(O)=O)\\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O	PLASMA	486890PI06							8		t	μg × h/mL	287.7		μg/mL	297.7			UNKNOWN	g	2		MULTIPLE	UNKNOWN		day	3			HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3364953/	Homo sapiens		h	1.5	Last dose			12			false
4423	2071		ADULT	6540466|88621644|136478868	466.404	CARUMONAM	Carumonam	NC(=O)OC[C@@H]1[C@H](NC(=O)C(=N/OCC(O)=O)\\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O	PLASMA	486890PI06									∞	μg × h/mL	330.6		μg/mL	300.7			UNKNOWN	g	2		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3364953/	Homo sapiens		h	1.4				12			false
4424	2071		ADULT	6540466|88621644|136478868	466.404	CARUMONAM	Carumonam	NC(=O)OC[C@@H]1[C@H](NC(=O)C(=N/OCC(O)=O)\\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O	PLASMA	486890PI06																										Human plasma protein binding: 28% (10~100 mcg/mL, ultrafiltration)	72	HEALTHY		MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3364953/	Homo sapiens										false
4425	2071		ADULT	6540466|88621644|136478868	466.404	CARUMONAM	Carumonam	NC(=O)OC[C@@H]1[C@H](NC(=O)C(=N/OCC(O)=O)\\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O	PLASMA	486890PI06									∞	μg × h/mL	179						UNKNOWN	mg	1020		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3729324/	Homo sapiens		h	1.7				9			false
4426	2071		ADULT	6540466|88621644|136478868	466.404	CARUMONAM	Carumonam	NC(=O)OC[C@@H]1[C@H](NC(=O)C(=N/OCC(O)=O)\\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O	PLASMA	486890PI06									∞	μg × h/mL	1302						UNKNOWN	mg	1040		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3729324/	Homo sapiens		h	11.3		Severe renal impairment		7			false
4427	2071		ADULT	6540466|88621644|136478868	466.404	CARUMONAM	Carumonam	NC(=O)OC[C@@H]1[C@H](NC(=O)C(=N/OCC(O)=O)\\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O	PLASMA	486890PI06									∞	μg × h/mL	783						UNKNOWN	mg	1040		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3729324/	Homo sapiens		h	6.6		Moderate renal impairment		5			false
4428	2071		ADULT	6540466|88621644|136478868	466.404	CARUMONAM	Carumonam	NC(=O)OC[C@@H]1[C@H](NC(=O)C(=N/OCC(O)=O)\\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O	PLASMA	486890PI06									∞	μg × h/mL	493						UNKNOWN	mg	1040		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3729324/	Homo sapiens		h	4.5		Mild renal impairment		4			false
4429	2071		ADULT	6540466|88621644|136478868	466.404	CARUMONAM	Carumonam	NC(=O)OC[C@@H]1[C@H](NC(=O)C(=N/OCC(O)=O)\\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O	PLASMA	486890PI06									∞	μg × h/mL	113.4						UNKNOWN	mg	1000		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6395801/	Homo sapiens		h	1.77				8	Carumonam disodium		false
4430	2071		ADULT	6540466|88621644|136478868	466.404	CARUMONAM	Carumonam	NC(=O)OC[C@@H]1[C@H](NC(=O)C(=N/OCC(O)=O)\\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O	PLASMA	486890PI06	4911	285.359	PROBENECID	Probenecid	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	PO572Z7917			∞	μg × h/mL	107.4						UNKNOWN	mg	1000		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6395801/	Homo sapiens		h	1.99			2000mg oral	8	Carumonam disodium		true
4431	2071		ADULT	6540466|88621644|136478868	466.404	CARUMONAM	Carumonam	NC(=O)OC[C@@H]1[C@H](NC(=O)C(=N/OCC(O)=O)\\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O	PLASMA	486890PI06									∞	μg × h/mL	56.9						UNKNOWN	mg	500		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6395801/	Homo sapiens		h	1.76				8	Carumonam disodium		false
4432	2071			6540466|88621644|136478868	466.404	CARUMONAM	Carumonam	NC(=O)OC[C@@H]1[C@H](NC(=O)C(=N/OCC(O)=O)\\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O	PLASMA	486890PI06																										Human plasma protein binding: 82% (25~400 mcg/mL), equilibrium dialysis and ultrafiltration	0.82				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6395801/	Homo sapiens										false
4433	2071		ADULT	6540466|88621644|136478868	466.404	CARUMONAM	Carumonam	NC(=O)OC[C@@H]1[C@H](NC(=O)C(=N/OCC(O)=O)\\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O	PLASMA	486890PI06									∞	μg × h/mL	230.4						UNKNOWN	mg	2000		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6395801/	Homo sapiens		h	1.93				8	Carumonam disodium		false
4434	2074		ADULT	5526	157.2102	TRANEXAMIC ACID	Tranexamic acid	NC[C@H]1CC[C@@H](CC1)C(O)=O	PLASMA	6T84R30KC1													μg/mL	1.75			UNKNOWN	mg	200		SINGLE							HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/4/530258_2329004C1129_4_002_1F.pdf#page=19	Homo sapiens		h	1.73					Cetraxate hydrochloride		false
4435	2075		ADULT	65864	496.466	FLOMOXEF	Flomoxef	CO[C@]1(NC(=O)CSC(F)F)[C@H]2OCC(CSC3=NN=NN3CCO)=C(N2C1=O)C(O)=O	PLASMA	V9E5U5XF42									∞	mg × h/L	53.1		mg/L	38.9			UNKNOWN	mg	500		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31822449/	Homo sapiens					Male patients with benign prostatic hypertrophy who underwent transurethral resection of the prostate		25			false
4436	2075		ADULT	65864	496.466	FLOMOXEF	Flomoxef	CO[C@]1(NC(=O)CSC(F)F)[C@H]2OCC(CSC3=NN=NN3CCO)=C(N2C1=O)C(O)=O	PLASMA	V9E5U5XF42									∞	mg × h/L	111.9		mg/L	76.6			UNKNOWN	mg	1000		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31822449/	Homo sapiens					Male patients with benign prostatic hypertrophy who underwent transurethral resection of the prostate		29			false
4437	2075		CHILD	65864	496.466	FLOMOXEF	Flomoxef	CO[C@]1(NC(=O)CSC(F)F)[C@H]2OCC(CSC3=NN=NN3CCO)=C(N2C1=O)C(O)=O	SERUM	V9E5U5XF42									?	μg × h/mL	15.2		μg/mL	10			UNKNOWN	mg/kg	10		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8371488/	Homo sapiens		h	0.66	On non-hemodialysis day	Normal renal function		1			false
4438	2075		CHILD	65864	496.466	FLOMOXEF	Flomoxef	CO[C@]1(NC(=O)CSC(F)F)[C@H]2OCC(CSC3=NN=NN3CCO)=C(N2C1=O)C(O)=O	SERUM	V9E5U5XF42									?	μg × h/mL	611.5		μg/mL	36			UNKNOWN	mg/kg	10		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8371488/	Homo sapiens		h	13.63	On hemodialysis day	pediatric patients with chronic renal failure on hemodialysis		5			false
4439	2075		CHILD	65864	496.466	FLOMOXEF	Flomoxef	CO[C@]1(NC(=O)CSC(F)F)[C@H]2OCC(CSC3=NN=NN3CCO)=C(N2C1=O)C(O)=O	SERUM	V9E5U5XF42									?	μg × h/mL	616.5		μg/mL	33.3			UNKNOWN	mg/kg	10		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8371488/	Homo sapiens		h	15.03	On non-hemodialysis day	pediatric patients with chronic renal failure on hemodialysis		5			false
4440	2075		CHILD	65864	496.466	FLOMOXEF	Flomoxef	CO[C@]1(NC(=O)CSC(F)F)[C@H]2OCC(CSC3=NN=NN3CCO)=C(N2C1=O)C(O)=O	SERUM	V9E5U5XF42									?	μg × h/mL	387		μg/mL	17.6			UNKNOWN	mg/kg	5		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8371488/	Homo sapiens		h	16.77	On non-hemodialysis day	pediatric patients with chronic renal failure on hemodialysis		2			false
4441	2075			65864	496.466	FLOMOXEF	Flomoxef	CO[C@]1(NC(=O)CSC(F)F)[C@H]2OCC(CSC3=NN=NN3CCO)=C(N2C1=O)C(O)=O	SERUM	V9E5U5XF42																										Human serum protein binding: 35%, ultrafiltration	65				EXPERIMENT	https://www.jstage.jst.go.jp/article/chemotherapy1953/35/Supplement1/35_Supplement1_161/_article/-char/en	Homo sapiens										false
4442	2077		ADULT	157355	344.3124	LACTITOL	LACTITOL	OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO	SERUM	L2B0WJF7ZY									∞	ng × h/mL	6.019		ng/mL	776			RECOMMENDED	g	20		SINGLE	FED				Lactitol is minimally absorbed systemically following oral administration.		HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211281s000lbl.pdf	Homo sapiens		h	2.4							false
4443	2077		ADULT	157355	344.3124	LACTITOL	Lactitol	OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO	PLASMA	L2B0WJF7ZY									∞	ng × h/mL	14941		ng/mL	2780			RECOMMENDED	g	21		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/211281Orig1s000MultidisciplineR.pdf	Homo sapiens		h	2.16							false
4444	2077		ADULT	157355	344.3124	LACTITOL	lactitol	OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO	PLASMA	L2B0WJF7ZY									∞	ng × h/mL	6019		ng/mL	776			RECOMMENDED	g	21		SINGLE	HIGH-FAT						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/211281Orig1s000MultidisciplineR.pdf	Homo sapiens		h	2.43							false
4445	2079		ADULT	15387	263.3504	MELPERONE	MELPERONE	CC1CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1	PLASMA	J8WA3K39B7									∞	nM × h	478		nM	100			RECOMMENDED	mg	50		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7140807/	Homo sapiens		h	4.3				9	MELPERONE		false
4446	2079		ADULT	15387	263.3504	MELPERONE	MELPERONE	CC1CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1	PLASMA	J8WA3K39B7									∞	nM × h	218		nM	43			RECOMMENDED	mg	25		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7140807/	Homo sapiens		h	4				9	MELPERONE		false
4447	2079		ADULT	15387	263.3504	MELPERONE	MELPERONE	CC1CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1	PLASMA	J8WA3K39B7									∞	nM × h	1490		nM	340			HIGHEST STUDIED	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7140807/	Homo sapiens		h	2.9				9	MELPERONE		false
4448	2079		ADULT	15387	263.3504	MELPERONE	MELPERONE	CC1CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1	PLASMA	J8WA3K39B7									∞	nM × h	211						UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7140807/	Homo sapiens		h	3.2				6	MELPERONE		false
4449	2079		ADULT	15387	263.3504	MELPERONE	MELPERONE	CC1CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1	PLASMA	J8WA3K39B7									∞	nM × h	523						UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7140807/	Homo sapiens		h	2.8				6	MELPERONE		false
4450	2079		ADULT	15387	263.3504	MELPERONE	MELPERONE	CC1CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1	PLASMA	J8WA3K39B7							8		t	nM × h	570		nM	206			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Intramuscular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7140807/	Homo sapiens		h	6.6				8	MELPERONE		false
4451	2080		ADULT	41049	233.3492	MEPTAZINOL	Meptazinol	CCC1(CCCCN(C)C1)C2=CC(O)=CC=C2	PLASMA	18Y7S5JKZD									∞	μg × h/L	89.56		μg/L	22.91			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19819764/	Homo sapiens		h	2.44				6			false
4452	2080		ADULT	41049	233.3492	MEPTAZINOL	Meptazinol	CCC1(CCCCN(C)C1)C2=CC(O)=CC=C2	PLASMA	18Y7S5JKZD									∞	μg × h/L	164.75		μg/L	55.11			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19819764/	Homo sapiens		h	2.19				6			false
4453	2080		ADULT	41049	233.3492	MEPTAZINOL	Meptazinol	CCC1(CCCCN(C)C1)C2=CC(O)=CC=C2	PLASMA	18Y7S5JKZD									∞	μg × h/L	418.28		μg/L	118.07			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19819764/	Homo sapiens		h	2				6			false
4454	2080		ADULT	41049	233.3492	MEPTAZINOL	Meptazinol	CCC1(CCCCN(C)C1)C2=CC(O)=CC=C2	PLASMA	18Y7S5JKZD							6		t	ng × h/mL	243		ng/mL	55.6			UNKNOWN	mg	200		MULTIPLE	UNKNOWN		day	4	n=9 for t1/2		UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6499901/	Homo sapiens		h	4.97	13th dose	Geriatric patients		10			false
4455	2080		ADULT	41049	233.3492	MEPTAZINOL	Meptazinol	CCC1(CCCCN(C)C1)C2=CC(O)=CC=C2	PLASMA	18Y7S5JKZD																	UNKNOWN	mg	200			UNKNOWN				The mean plasma protein binding of meptazinol was 33.8% (  0.74 SEM). (dialysis)	66.2	UNHEALTHY		FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6499901/	Homo sapiens					Geriatric patients		9			false
4456	2080		ADULT	41049	233.3492	MEPTAZINOL	Meptazinol	CCC1(CCCCN(C)C1)C2=CC(O)=CC=C2	PLASMA	18Y7S5JKZD									∞	ng × h/mL	202		ng/mL	41.3			UNKNOWN	mg	200		SINGLE	UNKNOWN				n=9 for t1/2		UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6499901/	Homo sapiens		h	3.39		Geriatric patients		10			false
4457	2080		ADULT	41049	233.3492	MEPTAZINOL	Meptazinol	CCC1(CCCCN(C)C1)C2=CC(O)=CC=C2	PLASMA	18Y7S5JKZD							6		t	ng × h/mL	143		ng/mL	53.5			UNKNOWN	mg	200		MULTIPLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6499901/  | https://pubmed.ncbi.nlm.nih.gov/6617729/	Homo sapiens		h	2.13		Young subjects		8			false
4458	2080		ADULT	41049	233.3492	MEPTAZINOL	Meptazinol	CCC1(CCCCN(C)C1)C2=CC(O)=CC=C2	PLASMA	18Y7S5JKZD									∞	ng × h/mL	156		ng/mL	55.6			UNKNOWN	mg	200		SINGLE	FED				n=9 for t1/2		HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6499901/ | https://pubmed.ncbi.nlm.nih.gov/6617729/	Homo sapiens		h	1.94		Young subjects		8			false
4459	2080		ADULT	41049	233.3492	MEPTAZINOL	Meptazinol	CCC1(CCCCN(C)C1)C2=CC(O)=CC=C2	PLASMA	18Y7S5JKZD									?	ng × h/mL	322.9						UNKNOWN	mg	25		SINGLE	FED						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6617729/	Homo sapiens		h	2.93		Elderly patients		7			false
4460	2080		ADULT	41049	233.3492	MEPTAZINOL	Meptazinol	CCC1(CCCCN(C)C1)C2=CC(O)=CC=C2	PLASMA	18Y7S5JKZD									?	ng × h/mL	316.7						UNKNOWN	mg	25		SINGLE	FED						UNHEALTHY	Intramuscular	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6617729/	Homo sapiens		h	3.08		Elderly patients		7			false
4461	2080		ADULT	41049	233.3492	MEPTAZINOL	Meptazinol	CCC1(CCCCN(C)C1)C2=CC(O)=CC=C2	PLASMA	18Y7S5JKZD									?	ng × h/mL	216.4						UNKNOWN	mg	25		SINGLE	FED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6617729/	Homo sapiens		h	2.06		Young subjects		14			false
4462	2081		ADULT	23939	195.084	PLATINUM	Platinum	[Pt]	PLASMA	49DFR088MY	146034004	853.9061	PACLITAXEL	Paclitaxel	CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C3=CC=CC=C3)[C@@H]4[C@@]5(CO[C@@H]5C[C@H](O)[C@@]4(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C6=CC=CC=C6)C7=CC=CC=C7	P88XT4IS4D			?	μg × h/mL	2.59		μg/mL	1.01			UNKNOWN	mg/m²	20		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16912889/	Homo sapiens		h	2.1		Patients with non-small-cell lung carcinoma		19			true
4463	2081		ADULT	23939	195.084	PLATINUM	Platinum	[Pt]	PLASMA	49DFR088MY							24		t	μg × h/mL	19.45		μg/mL	6.1			RECOMMENDED	mg/m²	80		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/530169_4291405F1025_2_011_1F.pdf#page=27	Homo sapiens		h	5.69		Cancer patients		5			false
4464	2081		ADULT	23939	195.084	PLATINUM	Platinum	[Pt]	PLASMA	49DFR088MY							24		t	μg × h/mL	30		μg/mL	6.34			RECOMMENDED	mg/m²	100		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/530169_4291405F1025_2_011_1F.pdf#page=27	Homo sapiens		h	5.3		Cancer patients		2			false
4465	2081		ADULT	23939	195.084	PLATINUM	Platinum	[Pt]	PLASMA	49DFR088MY																	RECOMMENDED	mg/m²	100		SINGLE	UNKNOWN				Human plasma protein binding: >81% (from AUC, ultrafiltration)	19	UNHEALTHY	Intravenous	FEMALE	EXPERIMENT	https://www.info.pmda.go.jp/go/interview/2/530169_4291405F1025_2_011_1F.pdf#page=28	Homo sapiens					Cancer patient		1			false
4466	2082		ADULT	4450	253.3389	NEFOPAM	Nefopam	CN1CCOC(C2=CC=CC=C2)C3=C(C1)C=CC=C3	PLASMA	4UP8060B7J									∞	nM × h	377		nM	48.5			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12787260/	Homo sapiens		h	5.1				24			false
4467	2082		ADULT	601526	239.3163	N-Desmethylnefopam	Desmethylnefopam	C1COC(c2ccccc2)c3ccccc3CN1	PLASMA										∞	nM × h	748		nM	47.4			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12787260/	Homo sapiens		h	10.6				24			false
4468	2082		ADULT	4450	253.3389	NEFOPAM	Nefopam	CN1CCOC(C2=CC=CC=C2)C3=C(C1)C=CC=C3	PLASMA	4UP8060B7J									∞	nM × h	1029		nM	183.1			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12787260/	Homo sapiens		h	5.1				24			false
4469	2082		ADULT	601526	239.3163	N-Desmethylnefopam		C1COC(c2ccccc2)c3ccccc3CN1	PLASMA										∞	nM × h	787		nM	31			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12787260/	Homo sapiens		h	15				24			false
4470	2082			4450	253.3389	NEFOPAM	Nefopam	CN1CCOC(C2=CC=CC=C2)C3=C(C1)C=CC=C3	PLASMA	4UP8060B7J																										Nefopam is not highly bound to plasma proteins (about 60%–75%).	25				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20971961/	Homo sapiens										false
4471	2082		ADULT	4450	253.3389	NEFOPAM	Nefopam	CN1CCOC(C2=CC=CC=C2)C3=C(C1)C=CC=C3	PLASMA	4UP8060B7J									∞	ng × h/mL	410.45		ng/mL	50.89			UNKNOWN	mg	75		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26796604/	Homo sapiens		h	8.08				8			false
4472	2082		ADULT	601526	239.3163	N-Desmethylnefopam		C1COC(c2ccccc2)c3ccccc3CN1	PLASMA										∞	ng × h/mL	672.93		ng/mL	41.45			UNKNOWN	mg	75		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26796604/	Homo sapiens		h	10.25				8			false
4473	2083		ADULT	39214	272.692	NIMUSTINE	Nimustine	CC1=NC(N)=C(CNC(=O)N(CCCl)N=O)C=N1	CEREBROSPINAL FLUID	0S726V972K	6253	243.2166	CYTARABINE	Ara-C	NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O	04079A1RDZ	24		t	μg × h/mL	1.08		μg/mL	1.08			UNKNOWN	mg	5		SINGLE	UNKNOWN						UNHEALTHY	Intraventricular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11305611/	Homo sapiens					Metastatic diseases in the right frontal pole, stalk, supracellebellar cistern, vermis and fourth ventricle	and Methotrexate	1			true
4474	2083		ADULT	39214	272.692	NIMUSTINE	Nimustine	CC1=NC(N)=C(CNC(=O)N(CCCl)N=O)C=N1	CEREBROSPINAL FLUID	0S726V972K													μg/mL	0.59			UNKNOWN	mg	100		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://www.info.pmda.go.jp/go/interview/2/430574_4219400D1029_2_ND7_1F.pdf#page=30	Homo sapiens		h	0.49	100~150mg/body (1.72~2.50mg/kg) IV	Brain tumor patients		14	Nimustine hydrochloride		false
4475	2083		ADULT	39214	272.692	NIMUSTINE	Nimustine	CC1=NC(N)=C(CNC(=O)N(CCCl)N=O)C=N1	BLOOD	0S726V972K									∞	μg × h/mL	2.21		μg/mL	3.86			UNKNOWN	mg	100		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://www.info.pmda.go.jp/go/interview/2/430574_4219400D1029_2_ND7_1F.pdf#page=31	Homo sapiens		h	0.58	100~150mg/body (1.72~2.50mg/kg) IV	Brain tumor patients		14	Nimustine hydrochloride		false
4476	2083			39214	272.692	NIMUSTINE	Nimustine	CC1=NC(N)=C(CNC(=O)N(CCCl)N=O)C=N1	SERUM	0S726V972K																										4 mcg/mL, ultrafiltration	35.1				EXPERIMENT	https://www.info.pmda.go.jp/go/interview/2/430574_4219400D1029_2_ND7_1F.pdf#page=33 | https://pubmed.ncbi.nlm.nih.gov/2245489/	Homo sapiens										false
4477	2085		ADULT	272833	364.416	PHENETICILLIN	PHENETICILLIN	CC(OC1=CC=CC=C1)C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O	PLASMA	EFA30X554H									∞	μg × h/mL	29.3		μg/mL	23			RECOMMENDED	mg	500		STEADY-STATE	FASTED		day	1		20	UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3924086/	Homo sapiens		min	63							false
4478	2094		ADULT	134748	373.4463	NOR-TRIMEBUTINE		CCC(COC(=O)c1cc(OC)c(OC)c(OC)c1)(NC)c2ccccc2	PLASMA	OI1BF6F0VD									∞	ng × h/mL	4533.4		ng/mL	1271.1			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16854404/	Homo sapiens		h	6.9				24	Trimebutine maleate		false
4479	2094		ADULT	5573	387.4694	TRIMEBUTINE	Trimebutine	CCC(COC(=O)C1=CC(OC)=C(OC)C(OC)=C1)(N(C)C)C2=CC=CC=C2	PLASMA	QZ1OJ92E5R							8		t	ng × h/mL	72.1		ng/mL	44.3			UNKNOWN	mg	100		SINGLE	UNKNOWN				AUCinf = 77.3 ng x h/mL		HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400315_2399006F1331_1_100_1F.pdf#page=19	Homo sapiens		h	1.83				11	Trimebutine maleate		false
4480	2094			5573	387.4694	TRIMEBUTINE	Trimebutine	CCC(COC(=O)C1=CC(OC)=C(OC)C(OC)=C1)(N(C)C)C2=CC=CC=C2	SERUM	QZ1OJ92E5R																										Human serum protein binding: 77% (equilibrium dialysis)	23				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400315_2399006F1331_1_100_1F.pdf#page=22	Homo sapiens										false
4481	2095		ADULT	5606	227.73	TULOBUTEROL	Tulobuterol	CC(C)(C)NCC(O)C1=C(Cl)C=CC=C1	SERUM	591I9SU0F7									?	ng × h/mL	27.8		ng/mL	1.4			UNKNOWN	mg	2		SINGLE	UNKNOWN						UNKNOWN	Topical	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8099880/	Homo sapiens		h	5.9	Transdermal patch			5			false
4482	2095		ADULT	5606	227.73	TULOBUTEROL	Tulobuterol	CC(C)(C)NCC(O)C1=C(Cl)C=CC=C1	SERUM	591I9SU0F7									?	ng × h/mL	53.8		ng/mL	3.3			UNKNOWN	mg	4		SINGLE	UNKNOWN						UNKNOWN	Topical	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8099880/	Homo sapiens		h	8.4	Transdermal patch			4			false
4483	2095		ADULT	5606	227.73	TULOBUTEROL	Tulobuterol	CC(C)(C)NCC(O)C1=C(Cl)C=CC=C1	SERUM	591I9SU0F7									?	ng × h/mL	82.2		ng/mL	4.3			UNKNOWN	mg	6		SINGLE	UNKNOWN						UNKNOWN	Topical	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8099880/	Homo sapiens		h	8.8	Transdermal patch			5			false
4484	2095		ADULT	5606	227.73	TULOBUTEROL	Tulobuterol	CC(C)(C)NCC(O)C1=C(Cl)C=CC=C1	SERUM	591I9SU0F7									?	ng × h/mL	27.8		ng/mL	3.1			UNKNOWN	mg	1		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8099880/	Homo sapiens		h	6.1				5			false
4485	2095		ADULT	5606	227.73	TULOBUTEROL	Tulobuterol	CC(C)(C)NCC(O)C1=C(Cl)C=CC=C1	SERUM	591I9SU0F7									?	ng × h/mL	4.9		ng/mL	0.7			UNKNOWN	μg	400		SINGLE	UNKNOWN						UNKNOWN	Respiratory	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8099880/	Homo sapiens		h	3.4	Inhalation	including 6 smokers		12			false
4486	2095		ADULT	5606	227.73	TULOBUTEROL	Tulobuterol	CC(C)(C)NCC(O)C1=C(Cl)C=CC=C1	SERUM	591I9SU0F7									?	ng × h/mL	9		ng/mL	1.4			UNKNOWN	μg	600		SINGLE	UNKNOWN						UNKNOWN	Respiratory	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8099880/	Homo sapiens		h	3.2	Inhalation	including smokers		6			false
4487	2095		ADULT	5606	227.73	TULOBUTEROL	Tulobuterol	CC(C)(C)NCC(O)C1=C(Cl)C=CC=C1	SERUM	591I9SU0F7									?	ng × h/mL	14.7		ng/mL	2			UNKNOWN	μg	800		SINGLE	UNKNOWN						UNKNOWN	Respiratory	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8099880/	Homo sapiens		h	4.1	Inhalation	including smokers		6			false
4488	2095		ADULT	5606	227.73	TULOBUTEROL	Tulobuterol	CC(C)(C)NCC(O)C1=C(Cl)C=CC=C1	PLASMA	591I9SU0F7							48		t	ng × h/mL	10.75		ng/mL	0.48			UNKNOWN	mg	0.5		SINGLE	UNKNOWN						HEALTHY	Topical	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/780075_2259707S1110_1_007_1F.pdf#page=20	Homo sapiens		h	11.1	Transdermal patch, 24h application			23			false
4489	2095		ADULT	5606	227.73	TULOBUTEROL	Tulobuterol	CC(C)(C)NCC(O)C1=C(Cl)C=CC=C1	PLASMA	591I9SU0F7							48		t	ng × h/mL	11.09		ng/mL	0.59			UNKNOWN	mg	1		SINGLE	UNKNOWN						HEALTHY	Topical	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/780075_2259707S1110_1_007_1F.pdf#page=21	Homo sapiens		h	10.4	Transdermal patch, 24h application			24			false
4490	2095		ADULT	5606	227.73	TULOBUTEROL	Tulobuterol	CC(C)(C)NCC(O)C1=C(Cl)C=CC=C1	PLASMA	591I9SU0F7							48		t	ng × h/mL	27.62		ng/mL	1.29			RECOMMENDED	mg	2		SINGLE	UNKNOWN						HEALTHY	Topical	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/780075_2259707S1110_1_007_1F.pdf#page=22	Homo sapiens		h	11	Transdermal patch, 24h application			24			false
4491	2095		ADULT	5606	227.73	TULOBUTEROL	Tulobuterol	CC(C)(C)NCC(O)C1=C(Cl)C=CC=C1	SERUM	591I9SU0F7									?	ng × h/mL	30.5		ng/mL	6			DEFINED DAILY	mg	2		SINGLE							HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/430920_2259002F1090_2_10A_1F.pdf#page=27	Homo sapiens		h	3.19				10	Tulobuterol hydrochloride		false
4492	2095		CHILD	5606	227.73	TULOBUTEROL	Tulobuterol	CC(C)(C)NCC(O)C1=C(Cl)C=CC=C1	BLOOD	591I9SU0F7													ng/mL	4.46			RECOMMENDED	μg/kg bw	20		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/430920_2259002F1090_2_10A_1F.pdf#page=28	Homo sapiens		h	3.56	Dry syrup	Asthma children		5	Tulobuterol hydrochloride		false
4493	2095			5606	227.73	TULOBUTEROL	Tulobuterol	CC(C)(C)NCC(O)C1=C(Cl)C=CC=C1	SERUM	591I9SU0F7																										Human serum protein binding: 28.14 -1.53%	71.86				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/430920_2259002F1090_2_10A_1F.pdf#page=29	Homo sapiens										false
4494	2096		ADULT	71927	202.2325	AMEZINIUM	Amezinium	COC1=[N ](N=CC(N)=C1)C2=CC=CC=C2	PLASMA	T4VA39MO9X							72		t	ng × h/mL	741.6		ng/mL	26.5			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/300119_2190022F1237_1_081_1F.pdf#page=17	Homo sapiens		h	25.5				16	Amezinium metilsulfate		false
4495	2096		ADULT	71927	202.2325	AMEZINIUM	Amezinium	COC1=[N ](N=CC(N)=C1)C2=CC=CC=C2	PLASMA	T4VA39MO9X													ng/mL	25.3			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400093_2190022F1024_1_022_1F.pdf#page=18	Homo sapiens		h	13.6							false
4496	2096		ADULT	71927	202.2325	AMEZINIUM	Amezinium	COC1=[N ](N=CC(N)=C1)C2=CC=CC=C2	PLASMA	T4VA39MO9X													ng/mL	82			UNKNOWN	mg	20		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400093_2190022F1024_1_022_1F.pdf#page=18	Homo sapiens		h	25.9	Non-dialysis day	Renal impairment					false
4497	2096		ADULT	71927	202.2325	AMEZINIUM	Amezinium	COC1=[N ](N=CC(N)=C1)C2=CC=CC=C2	PLASMA	T4VA39MO9X													ng/mL	70.7			UNKNOWN	mg	20		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400093_2190022F1024_1_022_1F.pdf#page=18	Homo sapiens		h	19.2	Dialysis day (administered right before dialysis)	Renal impairment					false
4498	2096		ADULT	71927	202.2325	AMEZINIUM	Amezinium	COC1=[N ](N=CC(N)=C1)C2=CC=CC=C2	PLASMA	T4VA39MO9X													ng/mL	15.4			UNKNOWN	mg	5		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400093_2190022F1024_1_022_1F.pdf#page=18	Homo sapiens							6	Amezinium metilsulfate		false
4499	2096		ADULT	71927	202.2325	AMEZINIUM	Amezinium	COC1=[N ](N=CC(N)=C1)C2=CC=CC=C2	PLASMA	T4VA39MO9X													ng/mL	25.3			UNKNOWN	mg	10		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400093_2190022F1024_1_022_1F.pdf#page=18	Homo sapiens							6	Amezinium metilsulfate		false
4500	2096		ADULT	71927	202.2325	AMEZINIUM	Amezinium	COC1=[N ](N=CC(N)=C1)C2=CC=CC=C2	PLASMA	T4VA39MO9X													ng/mL	65.8			UNKNOWN	mg	20		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400093_2190022F1024_1_022_1F.pdf#page=18	Homo sapiens							6	Amezinium metilsulfate		false
4501	2096		ADULT	71927	202.2325	AMEZINIUM	Amezinium	COC1=[N ](N=CC(N)=C1)C2=CC=CC=C2	PLASMA	T4VA39MO9X													ng/mL	124.3			UNKNOWN	mg	40		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400093_2190022F1024_1_022_1F.pdf#page=18	Homo sapiens							6	Amezinium metilsulfate		false
4502	2096		ADULT	71927	202.2325	AMEZINIUM	Amezinium	COC1=[N ](N=CC(N)=C1)C2=CC=CC=C2	PLASMA	T4VA39MO9X																						UNKNOWN				Human plasma protein binding: 20.7% (2h after 10mg oral administration, ultrafiltration)	79.3	HEALTHY		UNKNOWN	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400093_2190022F1024_1_022_1F.pdf#page=21	Homo sapiens								Amezinium metilsulfate		false
4503	2098		ADULT	3116	416.5139	DISTIGMINE	Distigmine	CN(CCCCCCN(C)C(=O)OC1=CC=C[N ](C)=C1)C(=O)OC2=C[N ](C)=CC=C2	PLASMA	T940307O7B									∞	μg × h/L	228.4		ng/mL	4.4			RECOMMENDED	mg	5		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/480306_1231014F1054_1_003_1F.pdf#page=19 | https://pubmed.ncbi.nlm.nih.gov/10475142/	Homo sapiens		h	69.5				5	Distigmine bromide		false
4504	2098			3116	416.5139	DISTIGMINE	Distigmine	CN(CCCCCCN(C)C(=O)OC1=CC=C[N ](C)=C1)C(=O)OC2=C[N ](C)=CC=C2	PLASMA	T940307O7B																										Human plasma protein binding: 16.8% (1ng/mL), 12.8% (5ng/mL), 15.5% (20ng/mL)	83.2				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/480306_1231014F1054_1_003_1F.pdf#page=22	Homo sapiens								Distigmine bromide		false
4505	2103		ADULT	65907	643.6351	NEMORUBICIN	NEMORUBICIN	CO[C@@H]1CN(CCO1)[C@H]2C[C@H](O[C@H]3C[C@@](O)(CC4=C(O)C5=C(C(=O)C6=C(C=CC=C6OC)C5=O)C(O)=C34)C(=O)CO)O[C@@H](C)[C@H]2O	PLASMA	7618O47BQM									?	ng × h/mL	15.1		ng/mL	2.3			MAX TOLERATED	mg/m²	1.25		MULTIPLE	UNKNOWN		3 weeks	1			UNHEALTHY	Intravenous	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/10732743	Homo sapiens		h	60.9							false
4506	2106		ADULT	2136	255.2686	AMFENAC	Amfenac	NC1=C(C=CC=C1CC(O)=O)C(=O)C2=CC=CC=C2	AQUEOUS HUMOR	28O5C1J38A							4		t	ng × h/mL	178.1		ng/mL	70.1			UNKNOWN	drop	1		SINGLE	UNKNOWN						UNHEALTHY	Ocular	UNKNOWN	EXPERIMENT	https://iovs.arvojournals.org/article.aspx?articleid=2383342	Homo sapiens					patients requiring cataract extraction with planned IOL implantation					false
4507	2106		ADULT	2136	255.2686	AMFENAC	Amfenac	NC1=C(C=CC=C1CC(O)=O)C(=O)C2=CC=CC=C2	PLASMA	28O5C1J38A									?	μg × h/mL	6.11		μg/mL	5.62			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8376494/	Homo sapiens		h	1.3				4			false
4508	2107			6009	231.2936	AMINOPHENAZONE	AMINOPHENAZONE	CN(C)C1=C(C)N(C)N(C1=O)C2=CC=CC=C2	PLASMA	01704YP3MO																											85				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15437290/	Homo sapiens										false
4509	2107		UNKNOWN	6009	231.2936	AMINOPHENAZONE	Aminophenazone	CN(C)C1=C(C)N(C)N(C1=O)C2=CC=CC=C2	PLASMA	01704YP3MO													μg/mL	17.4			UNKNOWN	mg	600		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/7002187/	Homo sapiens		h	2.6							false
4510	2107		UNKNOWN	6009	231.2936	AMINOPHENAZONE	AMINOPHENAZONE	CN(C)C1=C(C)N(C)N(C1=O)C2=CC=CC=C2	PLASMA	01704YP3MO													μg/mL	2.7			UNKNOWN	mg	250		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/7002187/	Homo sapiens		h	2.3							false
4511	2112		ADULT	2377	269.3813	BIFEMELANE	Bifemelane	CNCCCCOC1=C(CC2=CC=CC=C2)C=CC=C1	PLASMA	Z4501GN13G									?	ng × h/mL	46.29		ng/mL	7.57			UNKNOWN	mg	50		SINGLE	FED						UNHEALTHY	Oral	MALE	EXPERIMENT	https://www.jstage.jst.go.jp/article/jscpt1970/22/4/22_4_737/_article/-char/en	Homo sapiens		h	4.73		Elderly patients (mean 77.1 y)		8	Bifemelane hydrochloride		false
4512	2112		ADULT	2377	269.3813	BIFEMELANE	Bifemelane	CNCCCCOC1=C(CC2=CC=CC=C2)C=CC=C1	PLASMA	Z4501GN13G									?	ng × h/mL	99.12		ng/mL	18.61			UNKNOWN	mg	50		SINGLE	FED						UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://www.jstage.jst.go.jp/article/jscpt1970/22/4/22_4_737/_article/-char/en	Homo sapiens		h	4.69		Elderly patients (mean 80.4 y)		9	Bifemelane hydrochloride		false
4513	2112		ADULT	2377	269.3813	BIFEMELANE	Bifemelane	CNCCCCOC1=C(CC2=CC=CC=C2)C=CC=C1	PLASMA	Z4501GN13G									?	ng × h/mL	74.26		ng/mL	13.41			UNKNOWN	mg	50		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.jstage.jst.go.jp/article/jscpt1970/22/4/22_4_737/_article/-char/en	Homo sapiens		h	4.71		Elderly patients (mean 78.9 y)		17	Bifemelane hydrochloride		false
4514	2112		ADULT	2377	269.3813	BIFEMELANE	Bifemelane	CNCCCCOC1=C(CC2=CC=CC=C2)C=CC=C1	PLASMA	Z4501GN13G									?	ng × h/mL	20.24		ng/mL	3.21			UNKNOWN	mg	50		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.jstage.jst.go.jp/article/jscpt1970/22/4/22_4_737/_article/-char/en	Homo sapiens		h	3.21		Young subjects (mean 21.3 y)		8	Bifemelane hydrochloride		false
4515	2115		ADULT	42499	283.75	N-desbenzyl-clebopride	N-desbenzyl-clebopride		PLASMA																		UNKNOWN	mg	15.171		SINGLE	UNKNOWN				mean value for doses ranged from 3.2 to 30 mg.		UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://link.springer.com/article/10.1007/BF03258378	Homo sapiens		h	1.5	Mean received dose of 15.175 mg (3.2 to 30 mg). The starting dose was 0.03 mg/kg/day, increasing to a maximum of 0.48 mg/kg/day.			12	CLEBOPRIDE		false
4516	2115		ADULT	2780	373.876	CLEBOPRIDE	CLEBOPRIDE	COC1=C(C=C(Cl)C(N)=C1)C(=O)NC2CCN(CC3=CC=CC=C3)CC2	PLASMA	I0A84520Y9									?	ng × h/mL	842		μg/L	215			UNKNOWN	mg	15.171		SINGLE	UNKNOWN				mean values for doses ranged from 3.2 to 30 mg.		UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://link.springer.com/article/10.1007/BF03258378	Homo sapiens		h	9.5	Mean received dose of 15.175 mg (3.2 to 30 mg). The starting dose was 0.03 mg/kg/day, increasing to a maximum of 0.48 mg/kg/day.			12	CLEBOPRIDE		false
4517	2115		ADULT	2780	373.876	CLEBOPRIDE	CLEBOPRIDE	COC1=C(C=C(Cl)C(N)=C1)C(=O)NC2CCN(CC3=CC=CC=C3)CC2	PLASMA	I0A84520Y9									∞	pg × h/mL	8045		pg/mL	2073			UNKNOWN	mg	1.36		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20598654/	Homo sapiens		h	5.45				12	CLEBOPRIDE		false
4518	2116		UNKNOWN	2782	325.835	CLEMIZOLE	CLEMIZOLE	ClC1=CC=C(CN2C(CN3CCCC3)=NC4=C2C=CC=C4)C=C1	PLASMA	T97CB3796L																	UNKNOWN	mg	100		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/23143674	Homo sapiens		h	3.4							false
4519	2117		ADULT	735998	259.774	CLOBENZOREX	CLOBENZOREX	C[C@@H](CC1=CC=CC=C1)NCC2=C(Cl)C=CC=C2	PLASMA	4A5352XI2A									∞	ng × h/mL	17.777		ng/mL	1.777			DEFINED DAILY	mg	60		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.scirp.org/html/12-2500247_29756.htm	Homo sapiens		h	15.002	slow release formulation			30	CLOBENZOREX		false
4520	2117		ADULT	735998	259.774	CLOBENZOREX	CLOBENZOREX	C[C@@H](CC1=CC=CC=C1)NCC2=C(Cl)C=CC=C2	PLASMA	4A5352XI2A									∞	ng × h/mL	11.076		ng/mL	3.429			UNKNOWN	mg	30		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.scirp.org/html/12-2500247_29756.htm	Homo sapiens		h	3.118	immediate release formulation			30	CLOBENZOREX		false
4521	2127		ADULT	17506|129630823	263.311	ETHAMSYLATE	ETHAMSYLATE	CCNCC.OC1=CC=C(O)C(=C1)S(O)(=O)=O	PLASMA	24YL531VOH									∞	μg × h/mL	84.8		μg/mL	8.05			RECOMMENDED	mg	500		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24227961/	Homo sapiens		h	9.4				24	ETHAMSYLATE		false
4522	2127		UNKNOWN	17506|129630823	263.311	ETHAMSYLATE	ETHAMSYLATE	CCNCC.OC1=CC=C(O)C(=C1)S(O)(=O)=O	PLASMA	24YL531VOH													μg/mL	15			RECOMMENDED	mg	500		SINGLE	UNKNOWN					5	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://webcache.googleusercontent.com/search?q=cache:_8wbgGwkacYJ:https://mri.cts-mrp.eu/Human/Downloads/PL_H_0390_001_FinalSPC.pdf+&cd=11&hl=ru&ct=clnk&gl=ru&lr=lang_en%7Clang_ru	Homo sapiens		h	3.7					ETHAMSYLATE		false
4523	2129		ADULT	6042|23423984	300.808	THIAMINE	Thiamine	[Cl-].CC1=C(CCO)SC=[N ]1CC2=C(N)N=C(C)N=C2	PLASMA	X66NSO3N35	92140	656.7233	RIBOFLAVIN TETRABUTYRATE	riboflavin tetrabutyrate	CCCC(=O)OC[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)[C@H](CN1C2=NC(=O)NC(=O)C2=NC3=C1C=C(C)C(C)=C3)OC(=O)CCC	F211C9MSGY			∞	nM × h	1907.1		nM	439.8			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27707509/	Homo sapiens		h	6.2			pyridoxal-5-phosphate, hydroxocobalamin acetate, and ascorbic acid	23			true
4524	2129		ADULT	6042|23423984	300.808	THIAMINE	Thiamine	[Cl-].CC1=C(CCO)SC=[N ]1CC2=C(N)N=C(C)N=C2	PLASMA	X66NSO3N35	92140	656.7233	RIBOFLAVIN TETRABUTYRATE	riboflavin tetrabutyrate	CCCC(=O)OC[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)[C@H](CN1C2=NC(=O)NC(=O)C2=NC3=C1C=C(C)C(C)=C3)OC(=O)CCC	F211C9MSGY			∞	nM × h	1050.3		nM	237.7			UNKNOWN	mg	50		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27707509/	Homo sapiens		h	10.4			pyridoxal-5-phosphate, hydroxocobalamin acetate, and ascorbic acid	24			true
4525	2129		ADULT	6042|23423984	300.808	THIAMINE	Thiamine	[Cl-].CC1=C(CCO)SC=[N ]1CC2=C(N)N=C(C)N=C2	BLOOD	X66NSO3N35							48		t	ng × h/mL	4142.9		ng/mL	349.8			RECOMMENDED	mg	10		SINGLE	FASTED						HEALTHY	Subcutaneous	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/480235_3122401A2053_1_081_1F.pdf#page=16	Homo sapiens		h	11.8				14			false
4526	2129		ADULT	6042|23423984	300.808	THIAMINE	Thiamine	[Cl-].CC1=C(CCO)SC=[N ]1CC2=C(N)N=C(C)N=C2	BLOOD	X66NSO3N35							48		t	ng × h/mL	4004.4		ng/mL	340.6			RECOMMENDED	mg	10		SINGLE	FASTED						HEALTHY	Intramuscular	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/480235_3122401A2053_1_081_1F.pdf#page=17	Homo sapiens		h	12.1				14			false
4527	2132		UNKNOWN		300.3556	ITASETRON	Itasetron	CN1[C@H]2CC[C@@H]1C[C@@H](C2)NC(=O)N3C(=O)NC4=C3C=CC=C4	PLASMA	00S0D0OEKR																	UNKNOWN	mg	5		UNKNOWN	UNKNOWN						UNKNOWN	Oral	UNKNOWN	REVIEW	https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1527-3458.1996.tb00297.x	Homo sapiens		h	11.4							false
4528	2134		ADULT	60652	308.765	LIAROZOLE	LIAROZOLE	ClC1=CC=CC(=C1)C(N2C=CN=C2)C3=CC=C4N=CNC4=C3	PLASMA	K0Q29TGV9Y									?	mg × h/L	23.9		mg/L	3.67			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10763459	Homo sapiens							18	LIAROZOLE		false
4529	2137		ADULT	4041	270.757	MEDAZEPAM	MEDAZEPAM	CN1CCN=C(C2=CC=CC=C2)C3=CC(Cl)=CC=C13	PLASMA	P0J3387W3S													μg/mL	0.21			UNKNOWN	mg	10		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/37864/	Homo sapiens							3	MEDAZEPAM		false
4530	2137		ADULT	4041	270.757	MEDAZEPAM	MEDAZEPAM	CN1CCN=C(C2=CC=CC=C2)C3=CC(Cl)=CC=C13	BLOOD	P0J3387W3S													μg/mL	0.58			UNKNOWN	mg	50		MULTIPLE	UNKNOWN		day	1	levels ranging from 0.38 to 0.58 ug/ml		HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/5487421/	Homo sapiens				4 days dosing			1	MEDAZEPAM		false
4531	2137		ADULT	3016	284.74	DIAZEPAM	DiAZEPAM	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C3=CC=CC=C3	BLOOD	Q3JTX2Q7TU													μg/mL	0.07			UNKNOWN	mg	50		MULTIPLE	UNKNOWN		day	1	ranging from 0.05 to 0.07 ug/ml		HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/5487421/	Homo sapiens				4 days dosing			1	MEDAZEPAM		false
4532	2137		ADULT	2997	270.714	NORDAZEPAM	NORDAZEPAM	ClC1=CC=C2NC(=O)CN=C(C3=CC=CC=C3)C2=C1	BLOOD	67220MCM01													μg/mL	0.45			UNKNOWN	mg	50		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/5487421/	Homo sapiens				4 days dosing			1	MEDAZEPAM		false
4533	2137		ADULT	3016	284.74	DIAZEPAM	diazepam	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C3=CC=CC=C3	BLOOD	Q3JTX2Q7TU													μg/mL	0.08			UNKNOWN	mg	50		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/5487421/	Homo sapiens							1	MEDAZEPAM		false
4534	2137		ADULT	2997	270.714	NORDAZEPAM	NORDAZEPAM	ClC1=CC=C2NC(=O)CN=C(C3=CC=CC=C3)C2=C1	BLOOD	67220MCM01													μg/mL	0.13			UNKNOWN	mg	50		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/5487421/	Homo sapiens							1	MEDAZEPAM		false
4535	2137		ADULT	4041	270.757	MEDAZEPAM	MEDAZEPAM	CN1CCN=C(C2=CC=CC=C2)C3=CC(Cl)=CC=C13	BLOOD	P0J3387W3S													μg/mL	0.37			UNKNOWN	mg	50		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/5487421/	Homo sapiens							1	MEDAZEPAM		false
4536	2137		ADULT	4041	270.757	MEDAZEPAM	MEDAZEPAM	CN1CCN=C(C2=CC=CC=C2)C3=CC(Cl)=CC=C13	BLOOD	P0J3387W3S													μg/mL	0.98			UNKNOWN	mg	50		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/5487421/	Homo sapiens							1	MEDAZEPAM		false
4537	2138		ADULT	6292	250.2952	METHAQUALONE	METHAQUALONE	CC1=NC2=C(C=CC=C2)C(=O)N1C3=C(C)C=CC=C3	SERUM	7ZKH8MQW6T									∞	μg × h/mL	46.7		μg/mL	3.1			RECOMMENDED	mg	300		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4427217/	Homo sapiens		h	19							false
4538	2147			4904	295.4186	PRIDINOL	Pridinol	OC(CCN1CCCCC1)(C2=CC=CC=C2)C3=CC=CC=C3	SERUM	9E75Q6SUUB																										Human serum albumin binding: 31.33% (150 mcM), 28.50% (300 mcM); equilibrium dialysis	68.67				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15490448/	Homo sapiens										false
4539	2147		ADULT	4904	295.4186	PRIDINOL	Pridinol	OC(CCN1CCCCC1)(C2=CC=CC=C2)C3=CC=CC=C3	PLASMA	9E75Q6SUUB									∞	ng × h/mL	197.11		ng/mL	31.04			UNKNOWN	mg	3		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33835016/	Homo sapiens		h	18				33			false
4540	2148		ADULT	4905	306.4644	PRIFINIUM	Prifinium	CC[N ]1(CC)CCC(C1C)=C(C2=CC=CC=C2)C3=CC=CC=C3	SERUM	3C7TTK1K7K																	UNKNOWN	mg	7.5		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6134685/	Homo sapiens		h	2.13				6			false
4541	2148		ADULT	4905	306.4644	PRIFINIUM	Prifinium	CC[N ]1(CC)CCC(C1C)=C(C2=CC=CC=C2)C3=CC=CC=C3	SERUM	3C7TTK1K7K													ng/mL	6.76			UNKNOWN	mg	60		SINGLE	UNKNOWN				Cmax: 6.76~14.3ng/mL		HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6134685/	Homo sapiens		h	2.18				6			false
4542	2152		ADULT	644020	234.3803	SPARTEINE	SPARTEINE	C1CCN2C[C@@H]3C[C@@H](CN4CCCC[C@H]34)[C@@H]2C1	PLASMA	298897D62S																	UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://link.springer.com/article/10.1007/BF00404298	Homo sapiens		min	117.45							false
4543	2152		ADULT	644020	234.3803	SPARTEINE	SPARTEINE	C1CCN2C[C@@H]3C[C@@H](CN4CCCC[C@H]34)[C@@H]2C1	PLASMA	298897D62S																	UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://link.springer.com/article/10.1007/BF00404298	Homo sapiens		min	117.8							false
4544	2152		ADULT	644020	234.3803	SPARTEINE	SPARTEINE	C1CCN2C[C@@H]3C[C@@H](CN4CCCC[C@H]34)[C@@H]2C1	PLASMA	298897D62S																					SINGLE	UNKNOWN				Approximately 50% of sparteine is bound to plasma proteins.	50	HEALTHY	UNKNOWN	UNKNOWN	EXPERIMENT	https://link.springer.com/article/10.1007/BF00404298	Homo sapiens										false
4545	2154		ADULT	23480	281.4351	TERODILINE	Terodiline	CC(CC(C1=CC=CC=C1)C2=CC=CC=C2)NC(C)(C)C	SERUM	70KG06964W									?	μg × h/L	5901		μg/L	79			UNKNOWN	mg	25		SINGLE	FASTED				equilibrium dialysis	13.5	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3395665/	Homo sapiens		h	60				8			false
4546	2154		ADULT	23480	281.4351	TERODILINE	Terodiline	CC(CC(C1=CC=CC=C1)C2=CC=CC=C2)NC(C)(C)C	SERUM	70KG06964W													μg/L	41			UNKNOWN	mg	12.5		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7617541/	Homo sapiens		h	61				10			false
4547	2154		ADULT	23480	281.4351	TERODILINE	Terodiline	CC(CC(C1=CC=CC=C1)C2=CC=CC=C2)NC(C)(C)C	SERUM	70KG06964W													μg/L	76			UNKNOWN	mg	25		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7617541/	Homo sapiens		h	63				10			false
4548	2154		ADULT	23480	281.4351	TERODILINE	Terodiline	CC(CC(C1=CC=CC=C1)C2=CC=CC=C2)NC(C)(C)C	SERUM	70KG06964W													μg/L	306			UNKNOWN	mg	12.5		STEADY-STATE	UNKNOWN		day	2	equilibrium dialysis	8.9	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7617541/	Homo sapiens		h	66				10			false
4549	2154		ADULT	23480	281.4351	TERODILINE	Terodiline	CC(CC(C1=CC=CC=C1)C2=CC=CC=C2)NC(C)(C)C	SERUM	70KG06964W													μg/L	476			UNKNOWN	mg	25		STEADY-STATE	UNKNOWN		day	2	equilibrium dialysis	6.6	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7617541/	Homo sapiens		h	62				10			false
4550	2162		ADULT	2312	289.4555	BENCYCLANE	Bencyclane	CN(C)CCCOC2(CC1=CC=CC=C1)CCCCCC2	SERUM	6I97Z6S135													ng/mL	41			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4009414/	Homo sapiens							5			false
4551	2162		ADULT	2312	289.4555	BENCYCLANE	Bencyclane	CN(C)CCCOC2(CC1=CC=CC=C1)CCCCCC2	PLASMA	6I97Z6S135													μg/mL	2			UNKNOWN	mg	200		SINGLE	UNKNOWN				t1/2=360-480 min		UNKNOWN	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/965131/	Homo sapiens		min	480		Healthy subjects and patients			Bencyclane hydrogen fumarate (200mg)		false
4552	2162		ADULT	2312	289.4555	BENCYCLANE	Bencyclane	CN(C)CCCOC2(CC1=CC=CC=C1)CCCCCC2	PLASMA	6I97Z6S135													μg/mL	3			UNKNOWN	mg	200		SINGLE	UNKNOWN						UNKNOWN	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/965131/	Homo sapiens					Healthy subjects and patients					false
4553	2162			2312	289.4555	BENCYCLANE	Bencyclane	CN(C)CCCOC2(CC1=CC=CC=C1)CCCCCC2	UNKNOWN	6I97Z6S135																										A parallel """"in vitro"""" study with 14C-bencyclane (U.R. Kleeberg, 1973, unpublished) showed an approx. 40% protein binding, an approx. 30% erythrocyte binding, and an approx. 10% thrombocyte binding. About 20% bencyclane remain free.	20				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/965131/	Homo sapiens										false
4554	2164		ADULT	2793	481.073	CLOCAPRAMINE	clocapramine	NC(=O)C1(CCN(CCCN2C3=C(CCC4=C2C=C(Cl)C=C4)C=CC=C3)CC1)N5CCCCC5	PLASMA	6EEL1GB72K									∞	ng × h/mL	436		ng/mL	12.9			HIGHEST STUDIED	mg	50		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2566185/	Homo sapiens		h	46				3			false
4555	2169		ADULT	94532	193.2854	ETAFEDRINE	ETAFEDRINE	CCN(C)[C@@H](C)[C@H](O)C1=CC=CC=C1	PLASMA	2Y6VQU63E8													μg/mL	0.1			UNKNOWN	mg	24		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	REVIEW	http://www.inchem.org/documents/pims/pharm/pim209.htm	Homo sapiens		h	6							false
4556	2174		ADULT	4604	157.0843	OTERACIL	oteracil	OC(=O)C1=NC(=O)NC(=O)N1	PLASMA	5VT6420TIG	5386	200.1671	TEGAFUR	tegafur	FC1=CN(C2CCCO2)C(=O)NC1=O	1548R74NSZ	10		t	ng × h/mL	1004		ng/mL	210			RECOMMENDED	mg/m²	15.7		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17683513/	Homo sapiens		h	3.5		patients with advanced gastric cancers at least 2 weeks after total gastrectomy	As part of S-1 (tegafur, gimeracil, and oteracil)	6	potassium oxonate		true
4557	2174		ADULT	4604	157.0843	OTERACIL	oteracil	OC(=O)C1=NC(=O)NC(=O)N1	PLASMA	5VT6420TIG	5386	200.1671	TEGAFUR	tegafur	FC1=CN(C2CCCO2)C(=O)NC1=O	1548R74NSZ	10		t	ng × h/mL	276		ng/mL	55			RECOMMENDED	mg/m²	15.7		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17683513/	Homo sapiens		h	2.8		patients with advanced gastric cancers before total gastrectomy	As part of S-1 (tegafur, gimeracil, and oteracil)	6	potassium oxonate		true
4558	2174		ADULT	4604	157.0843	OTERACIL	oteracil	OC(=O)C1=NC(=O)NC(=O)N1	PLASMA	5VT6420TIG	5386	200.1671	TEGAFUR	tegafur	FC1=CN(C2CCCO2)C(=O)NC1=O	1548R74NSZ	48		t	ng × h/mL	12.8		ng/mL	1.93			UNKNOWN	mg/m²	11.8		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21143703/	Homo sapiens					Caucasian	As part of S-1 (tegafur, gimeracil, and oteracil)	10			true
4559	2174		ADULT	4604	157.0843	OTERACIL	oteracil	OC(=O)C1=NC(=O)NC(=O)N1	PLASMA	5VT6420TIG	5386	200.1671	TEGAFUR	tegafur	FC1=CN(C2CCCO2)C(=O)NC1=O	1548R74NSZ	48		t	ng × h/mL	7.81		ng/mL	1.21			UNKNOWN	mg/m²	11.8		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21143703/	Homo sapiens					Asian	As part of S-1 (tegafur, gimeracil, and oteracil)	11			true
4560	2176		ADULT	157385	410.956	PIRLIMYCIN	Pirlimycin	CC[C@@H]1CCN[C@@H](C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O	SERUM	LM19JT6G5K							8		t	ng × h/mL	2592						UNKNOWN	mg	500		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6480775/	Homo sapiens							2	Pirlimycin hydroxhloride		false
4561	2176		ADULT	157385	410.956	PIRLIMYCIN	Pirlimycin	CC[C@@H]1CCN[C@@H](C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O	SERUM	LM19JT6G5K							8		t	ng × h/mL	44.5						UNKNOWN	mg	50		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6480775/	Homo sapiens							1	Pirlimycin hydroxhloride		false
4562	2179		ADULT	5469	355.84	TIARAMIDE	Tiaramide	OCCN1CCN(CC1)C(=O)CN2C(=O)SC3=CC=C(Cl)C=C23	SERUM	BB17WGM686													μg/mL	1.7			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6125356/	Homo sapiens		h	1.34				4			false
4563	2179		ADULT	5469	355.84	TIARAMIDE	Tiaramide	OCCN1CCN(CC1)C(=O)CN2C(=O)SC3=CC=C(Cl)C=C23	SERUM	BB17WGM686									?	μg × h/mL	5.36		μg/mL	1.79			MAX DAILY	mg	300		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/3/171911_1148001F1059_3_003_1F.pdf#page=18	Homo sapiens		h	1.59				5			false
4564	2179			5469	355.84	TIARAMIDE	Tiaramide	OCCN1CCN(CC1)C(=O)CN2C(=O)SC3=CC=C(Cl)C=C23	PLASMA	BB17WGM686																										Human plasma protein binding: 47~49% (ultrafiltration)	51				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/3/171911_1148001F1059_3_003_1F.pdf#page=21	Homo sapiens										false
4565	2182		ADULT	3036703	527.6042	ZOSUQUIDAR	ZOSUQUIDAR	O[C@@H](COC1=C2C=CC=NC2=CC=C1)CN3CCN(CC3)[C@@H]4C5=C(C=CC=C5)[C@@H]6[C@H](C7=C4C=CC=C7)C6(F)F	PLASMA	AB5K82X98Y	122130370	778.9323	VINORELBINE	vinorelbine	CCC1=C[C@@H]2CN(C1)CC3=C(NC4=C3C=CC=C4)[C@@](C2)(C(=O)OC)C5=C(OC)C=C6N(C)[C@@H]7[C@]8(CCN9CC=C[C@](CC)([C@@H]89)[C@@H](OC(C)=O)[C@]7(O)C(=O)OC)C6=C5	Q6C979R91Y			?	μg × h/L	1111		μM	0.31			MAX TOLERATED	mg/m²	300		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15809877	Homo sapiens		h	16.7	300 mg/m2 orally every 12 h for 3 days weekly for 3 weeks		22.5 mg/m2 IV weekly for 3 weeks every 28 days	1	ZOSUQUIDAR		true
4566	2182		ADULT		527.6042	ZOSUQUIDAR	ZOSUQUIDAR	O[C@@H](COC1=C2C=CC=NC2=CC=C1)CN3CCN(CC3)[C@@H]4C5=C(C=CC=C5)[C@@H]6[C@H](C7=C4C=CC=C7)C6(F)F	PLASMA	AB5K82X98Y									?	μg × h/L	19400		μg/L	427			MIN EFFICACIOUS	mg/m²	480		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/15161679	Homo sapiens		h	17							false
4567	2191		ADULT	20007|2724039	210.271	UNITHIOL	Unithiol	[Na ].[O-]S(=O)(=O)CC(S)CS	PLASMA	690VN2L7TK									?	μM × h	2.5		μM	0.82			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1941628/	Homo sapiens		h	4.3				10			false
4568	2191			20007|2724039	210.271	UNITHIOL	Unithiol	[Na ].[O-]S(=O)(=O)CC(S)CS	PLASMA	690VN2L7TK																										When the binding of 14C-DMPS to plasma protein was measured by equilibrium dialysis, it was found to be about 90% for man.	10				REVIEW	https://pubmed.ncbi.nlm.nih.gov/6307120/	Homo sapiens										false
4569	2194		ADULT		579.7	Hydroxy-dihydroergocornin	OH-Dihydroergocornin		PLASMA														μg/L	0.98			RECOMMENDED	mg	27		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17941060/	Homo sapiens										false
4570	2194		ADULT		593.7	Hydroxy-dihydroergocryptine	OH-dihydroergocryptine		PLASMA														μg/L	0.53			RECOMMENDED	mg	27		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17941060/	Homo sapiens										false
4571	2194		ADULT		627.7	Hydroxy-dihydroergocristine	OH-dihydroergocristine		PLASMA														μg/L	0.3			RECOMMENDED	mg	27		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17941060/	Homo sapiens										false
4572	2194		ADULT	168871	563.6877	DIHYDROERGOCORNINE	DIHYDROERGOCORNINE	CC(C)[C@@H]1N2C(=O)[C@](NC(=O)[C@@H]3C[C@H]4[C@@H](CC5=CNC6=CC=CC4=C56)N(C)C3)(O[C@@]2(O)[C@@H]7CCCN7C1=O)C(C)C	PLASMA	IK4C1OC8NE													μg/L	0.04			RECOMMENDED	mg	27		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17941060/	Homo sapiens										false
4573	2194		ADULT	114948	577.7	Dihydroergocryptine	Dihydroergocryptine	CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@@H]4C[C@H]5[C@@H](CC6=CNC7=CC=CC5=C67)N(C4)C)O	PLASMA														μg/L	0.04			RECOMMENDED	mg	27		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17941060/	Homo sapiens										false
4574	2194		ADULT	107715	611.7305	DIHYDROERGOCRISTINE	dihydroergocristine	CC(C)[C@@]5(NC(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C)C1)O[C@@]6(O)[C@@H]7CCCN7C(=O)[C@H](CC8=CC=CC=C8)N6C5=O	PLASMA	05D48LUM4Z													μg/L	0.04			RECOMMENDED	mg	27		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17941060/	Homo sapiens										false
4575	2197		ADULT	359	126.11	PHLOROGLUCINOL	Phloroglucinol	OC1=CC(O)=CC(O)=C1	PLASMA	DHD7FFG6YS									∞	ng × h/mL	466.6		ng/mL	515.6			UNKNOWN	mg	160		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28485775/	Homo sapiens		h	1.384				24			false
4576	2198		ADULT	5748845	522.558	CEFOSELIS	Cefoselis	CO\\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[N ]3=CC=C(N)N3CCO)=C(N2C1=O)C([O-])=O)C4=CSC(N)=N4	PLASMA	0B50MLU3H1							12		t	μg × h/mL	159.7		μg/mL	83.8			UNKNOWN	g	1		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7840572/	Homo sapiens		h	2				6			false
4577	2198		ADULT	5748845	522.558	CEFOSELIS	Cefoselis	CO\\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[N ]3=CC=C(N)N3CCO)=C(N2C1=O)C([O-])=O)C4=CSC(N)=N4	PLASMA	0B50MLU3H1							12		t	μg × h/mL	303.7		μg/mL	142.6			UNKNOWN	g	2		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7840572/	Homo sapiens		h	2				6			false
4578	2205		ADULT	197835	383.3945	HYDRASTINE	HYDRASTINE	COC1=C(OC)C2=C(C=C1)[C@H](OC2=O)[C@@H]3N(C)CCC4=C3C=C5OCOC5=C4	SERUM	8890V3217X									?	ng × h/mL	495		ng/mL	208			UNKNOWN	mg/kg	1.13		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25609220	Homo sapiens		h	4.8							false
4579	2210		UNKNOWN	5648	306.5	Valethamate	Valethamate	CCC(C)C(C1=CC=CC=C1)C(=O)OCC[N+](C)(CC)CC	PLASMA	D64S64QVX7																						UNKNOWN						UNKNOWN		UNKNOWN	OTHER	https://www.ijrcog.org/index.php/ijrcog/article/view/1221	Homo sapiens		h	4							false
4580	2215		ADULT	5743	392.5	DEXAMETHASONE	DEXAMETHASONE	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO	PLASMA	7S5I7G3JQL									∞	ng × h/mL	51.2		ng/mL	9.87			RECOMMENDED	mg	2		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/22047811	Homo sapiens		h	3.93							false
4581	2215		UNKNOWN	5743	392.4611	DEXAMETHASONE	DEXAMETHASONE	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO	PLASMA	7S5I7G3JQL																						UNKNOWN				Dexamethasone was 70% protein bound over a wide concentration range	30	UNKNOWN		UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/3806166	Homo sapiens										false
4582	2216		ADULT	65016	505.627	AMPRENAVIR	AMPRENAVIR	CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CCOC2)S(=O)(=O)C3=CC=C(N)C=C3	PLASMA	5S0W860XNR							12		t	μg × h/mL	18.5		μg/mL	5.36			RECOMMENDED	mg	1200		MULTIPLE	UNKNOWN		day	2	In vitro binding is approximately 90% to plasma proteins.	10	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/21007lbl.pdf	Homo sapiens		h	8.85							false
4583	2216		ADULT	65016	505.627	AMPRENAVIR	AMPRENAVIR	CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CCOC2)S(=O)(=O)C3=CC=C(N)C=C3	PLASMA	5S0W860XNR									∞	μg × h/mL	22.06		μg/mL	6.18			UNKNOWN	mg	1200		SINGLE	HIGH-FAT						HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/21007lbl.pdf	Homo sapiens										false
4584	2216		ADULT	65016	505.627	AMPRENAVIR	AMPRENAVIR	CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CCOC2)S(=O)(=O)C3=CC=C(N)C=C3	PLASMA	5S0W860XNR									∞	μg × h/mL	28.05		μg/mL	9.72			UNKNOWN	mg	1200		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/21007lbl.pdf	Homo sapiens										false
4585	2216		CHILD	65016	505.627	AMPRENAVIR	AMPRENAVIR	CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CCOC2)S(=O)(=O)C3=CC=C(N)C=C3	PLASMA	5S0W860XNR							12		t	μg × h/mL	15.46		μg/mL	6.77			RECOMMENDED	mg/kg bw	20		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/21007lbl.pdf	Homo sapiens										false
4586	2216		CHILD	65016	505.627	AMPRENAVIR	AMPRENAVIR	CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CCOC2)S(=O)(=O)C3=CC=C(N)C=C3	PLASMA	5S0W860XNR							8		t	μg × h/mL	8.73		μg/mL	3.99			RECOMMENDED	mg/kg bw	15		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/21007lbl.pdf	Homo sapiens										false
4587	2217		ADULT	5280723	354.481	ALPROSTADIL	CCCCC[C@H](O)\\C=C\\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O	CCCCC[C@H](O)\\C=C\\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O	PLASMA	F5TD010360							150		t	pg × min/mL	174		pg/mL	7.09			RECOMMENDED	μg	20		SINGLE	UNKNOWN				Approximately 93% of PGE1 found in plasma is protein-bound.	7	HEALTHY	Intravenous	MALE	DRUG LABEL	https://www.endo.com/File%20Library/Products/Prescribing%20Information/edex_prescribing_information.html	Homo sapiens		min	9.5							false
4588	2218		ADULT	4091	129.16	METFORMIN	METFORMIN	CN(C)C(=N)NC(N)=N	PLASMA	9100L32L2N									?	ng × h/mL	7694.78		ng/mL	815.39			RECOMMENDED	mg	750		SINGLE	HIGH-FAT						HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212595s000lbl.pdf	Homo sapiens		h	4.19							false
4589	2219		ADULT	60933	315.2176	CIDOFOVIR	CIDOFOVIR	O.O.NC1=NC(=O)N(C[C@@H](CO)OCP(O)(O)=O)C=C1	SERUM	JIL713Q00N									∞	μg × h/mL	8.35		μg/mL	3.12			UNKNOWN	mg/kg	1	infusion, 1 hour	OTHER	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7574510	Homo sapiens		h	1.44							false
4590	2219		ADULT	60933	315.2176	CIDOFOVIR	CIDOFOVIR	O.O.NC1=NC(=O)N(C[C@@H](CO)OCP(O)(O)=O)C=C1	SERUM	JIL713Q00N									∞	μg × h/mL	19.96		μg/mL	7.34			UNKNOWN	mg/kg	3	infusion, 1 hour	OTHER	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7574510	Homo sapiens		h	2.72							false
4591	2219		ADULT	60933	315.2176	CIDOFOVIR	CIDOFOVIR	O.O.NC1=NC(=O)N(C[C@@H](CO)OCP(O)(O)=O)C=C1	SERUM	JIL713Q00N									∞	μg × h/mL	28.34		μg/mL	11.5			UNKNOWN	mg/kg	5	infusion, 1 hour	OTHER	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7574510	Homo sapiens		h	2.42							false
4592	2220		ADULT	9782	392.4611	BETAMETHASONE	BETAMETHASONE	C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO	PLASMA	9842X06Q6M									∞	μg × min/mL	46.3		ng/mL	101			UNKNOWN	mg	8		SINGLE	UNKNOWN				plasma protein binding: 64% (equilibrium dialysis method)	36	HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6662164/	Homo sapiens		min	335							false
4593	2220		ADULT	9782	392.4611	BETAMETHASONE	BETAMETHASONE	C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO	PLASMA	9842X06Q6M							24		t	ng × h/mL	796		ng/mL	76.8			UNKNOWN	mg	6		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/31808984	Homo sapiens		h	13.9							false
4594	2220		ADULT	9782	392.4611	BETAMETHASONE	BETAMETHASONE	C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO	PLASMA	9842X06Q6M							24		t	ng × h/mL	811		ng/mL	67.6			UNKNOWN	mg	6		SINGLE	FASTED						HEALTHY	Intramuscular	FEMALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/31808984	Homo sapiens		h	10.2							false
4595	2221		ADULT	12560	733.9268	ERYTHROMYCIN	ERYTHROMYCIN	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O	SERUM	63937KV33D									?	μg × h/mL	6.1		μg/mL	2.44			UNKNOWN	mg	500		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6628511/	Homo sapiens										false
4596	2221		ADULT	12560	733.9268	ERYTHROMYCIN	ERYTHROMYCIN	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O	SERUM	63937KV33D									?	μg × h/mL	3.1		μg/mL	1.18			UNKNOWN	mg	500		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6628511/	Homo sapiens										false
4597	2221		ADULT	12560	733.9268	ERYTHROMYCIN	ERYTHROMYCIN	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O	SERUM	63937KV33D													μg/mL	1.99			UNKNOWN	mg	250		MULTIPLE	FASTED		day	4			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6628511/	Homo sapiens										false
4598	2221		ADULT	12560	733.9268	ERYTHROMYCIN	ERYTHROMYCIN	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O	SERUM	63937KV33D													μg/mL	1.62			UNKNOWN	mg	250		MULTIPLE	FASTED		day	4			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6628511/	Homo sapiens										false
4599	2221		ADULT	12560	733.9268	ERYTHROMYCIN	ERYTHROMYCIN	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O	PLASMA	63937KV33D									∞	ng × h/mL	4096.7		ng/mL	1386.1			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/062055Orig1s034.pdf	Homo sapiens		h	5.31							false
4600	2221		ADULT	12560	733.9268	ERYTHROMYCIN	ERYTHROMYCIN	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O	PLASMA	63937KV33D									∞	ng × h/mL	3544.7		ng/mL	1161.5			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/062055Orig1s034.pdf	Homo sapiens		h	4.48							false
4601	2222		ADULT		323.129	CHLORAMPHENICOL	CHLORAMPHENICOL	OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O	BLOOD	66974FR9Q1									?	μg × h/mL	59.1		μg/mL	16.9			DEFINED DAILY	mg	500		MULTIPLE	UNKNOWN		day	4			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2713219/	Homo sapiens		h	3.5							false
4602	2222		CHILD	5959	323.129	CHLORAMPHENICOL	CHLORAMPHENICOL	OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O	SERUM	66974FR9Q1																	UNKNOWN	mg/kg	25		MULTIPLE	UNKNOWN		day	4			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7463235/	Homo sapiens		h	5.1							false
4603	2222		CHILD	656580	423.202	CHLORAMPHENICOL SUCCINATE	CHLORAMPHENICOL SUCCINATE	O[C@@H]([C@@H](COC(=O)CCC(O)=O)NC(=O)C(Cl)Cl)C1=CC=C(C=C1)[N+]([O-])=O	SERUM	ZCX619U9A1																	UNKNOWN	mg/kg	25		MULTIPLE	UNKNOWN		day	4			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7463235/	Homo sapiens		h	2.2							false
4604	2223		ADULT	5460161	89.07	LACTATE ION, L-	L-lactate	C[C@H](O)C([O-])=O	PLASMA	435SSH7H89							3.5		t	mg × h/dL	53.35		μg/mL	20.2			UNKNOWN	mmol	39.76	infusion, 190 min	OTHER	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15236001/	Homo sapiens										false
4605	2223		ADULT	61503	90.0779	LACTIC ACID, D-	C[C@H](C(=O)O)O	C[C@@H](O)C(O)=O	PLASMA	3Q6M5SET7W							3.5		t	mg × h/dL	4.44		mg/dL	2.03			UNKNOWN	mmol	39.76	infusion, 190 min	OTHER	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15236001/	Homo sapiens										false
4606	2224		ADULT	91268	198.1793	THEOPHYLLINE	THEOPHYLLINE	O.CN1C2=C(N=CN2)C(=O)N(C)C1=O	SERUM	C137DTR5RG									∞	μg × h/mL	95.5		μg/mL	7.3			RECOMMENDED	mg	200		SINGLE	FASTED				https://pubmed.ncbi.nlm.nih.gov/354635/	41	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7332727/	Homo sapiens		h	8.51							false
4607	2225		ADULT	6249|7048611	349.405	AMPICILLIN	AMPICILLIN	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O	PLASMA	7C782967RD	4911		PROBENECID	probenecid	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	PO572Z7917			∞	μg × h/mL	58.74		μg/mL	15.04			UNKNOWN	mg	1500		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20399996	Homo sapiens		h	1.82							true
4608	2225		UNKNOWN	6249|7048611	349.405	AMPICILLIN	AMPICILLIN	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O	SERUM	7C782967RD																						UNKNOWN				Ampicillin has been found to be approximately 28% reversibly bound to human serum protein	72	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050608s040lbl.pdf	Homo sapiens										false
4609	2225		ADULT	6249|7048611	349.405	AMPICILLIN	AMPICILLIN	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O	PLASMA	7C782967RD	130313		SULBACTAM	sulbactam	CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O	S4TF6I2330							μg/mL	129.5			RECOMMENDED	mg	2000		SINGLE	UNKNOWN						UNKNOWN	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050608s040lbl.pdf	Homo sapiens		h	1							true
4610	2227		ADULT	3033	296.149	DICLOFENAC	DICLOFENAC	OC(=O)CC1=C(NC2=C(Cl)C=CC=C2Cl)C=CC=C1	PLASMA	144O8QL0L1									∞	ng × h/mL	1208		ng/mL	902			RECOMMENDED	mg	50		STEADY-STATE	UNKNOWN		day	3			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19531931	Homo sapiens		h	1.64							false
4611	2227		ADULT	3033	296.149	DICLOFENAC	DICLOFENAC	OC(=O)CC1=C(NC2=C(Cl)C=CC=C2Cl)C=CC=C1	PLASMA	144O8QL0L1									∞	ng × h/mL	319		ng/mL	302			UNKNOWN	mg	12.5		STEADY-STATE	UNKNOWN		day	3			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19531931	Homo sapiens		h	1.19							false
4612	2227		ADULT	3033	296.149	DICLOFENAC	DICLOFENAC	OC(=O)CC1=C(NC2=C(Cl)C=CC=C2Cl)C=CC=C1	PLASMA	144O8QL0L1									∞	ng × h/mL	609		ng/mL	749			RECOMMENDED	mg	25		STEADY-STATE	UNKNOWN		day	3			HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19531931	Homo sapiens		h	1.87							false
4613	2227		ADULT	3033	296.149	DICLOFENAC	DICLOFENAC	OC(=O)CC1=C(NC2=C(Cl)C=CC=C2Cl)C=CC=C1	SERUM	144O8QL0L1																	UNKNOWN				UNKNOWN	UNKNOWN				Diclofenac is more than 99% bound to human serum proteins, primarily to albumin. Serum protein binding is constant over the concentration range (0.15-105 ug/mL) achieved with recommended doses.	1	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019201s038lbl.pdf	Homo sapiens		h	2.3							false
4614	2228		UNKNOWN	2022|5280999|135398513	225.2046	ACYCLOVIR	ACYCLOVIR	NC1=NC2=C(N=CN2COCCO)C(=O)N1	PLASMA	X4HES1O11F																						UNKNOWN				Plasma protein binding range 9% to 33%	79	UNKNOWN		UNKNOWN	EXPERIMENT	https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/018828s030,020089s019,019909s020lbl.pdf	Homo sapiens										false
4615	2228		ADULT	2022|5280999|135398513	225.2046	ACYCLOVIR	ACYCLOVIR	NC1=NC2=C(N=CN2COCCO)C(=O)N1	PLASMA	X4HES1O11F									∞	ng × h/mL	3015.7		ng/mL	599.2			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/17692728	Homo sapiens		h	3.9							false
4616	2229		ADULT	446541	320.3371	MYCOPHENOLIC ACID	MYCOPHENOLIC ACID	COC1=C(C)C2=C(C(=O)OC2)C(O)=C1C\\C=C(/C)CCC(O)=O	PLASMA	HU9DX48N0T	5284373		CYCLOSPORINE	Cyclosporin	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\\C=C\\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	83HN0GTJ6D	12		t	μg × h/mL	57.4		μg/mL	18.9			RECOMMENDED	mg	720		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050791s019lbl.pdf	Homo sapiens										true
4617	2229		UNKNOWN	446541	320.3371	MYCOPHENOLIC ACID	MYCOPHENOLIC ACID	COC1=C(C)C2=C(C(=O)OC2)C(O)=C1C\\C=C(/C)CCC(O)=O	PLASMA	HU9DX48N0T																	RECOMMENDED	mg	720		MULTIPLE	UNKNOWN		day	2			UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.novartis.com.sg/system/files/product-info/MYFORTIC%20PI%20Nov2013.SINv1_.pdf	Homo sapiens		h	11.7							false
4618	2230		CHILD	2725	274.788	CHLORPHENIRAMINE	chlorpheniramine	CN(C)CCC(C1=CC=C(Cl)C=C1)C2=CC=CC=N2	SERUM	3U6IO1965U									?	ng × h/mL	246.16		ng/mL	13.5			UNKNOWN	mg/kg bw	0.12		SINGLE	FASTED						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7069073/	Homo sapiens		h	13.1							false
4619	2230		ADULT	2725	274.788	CHLORPHENIRAMINE	CHLORPHENIRAMINE	CN(C)CCC(C1=CC=C(Cl)C=C1)C2=CC=CC=N2	SERUM	3U6IO1965U									∞	ng × h/mL	961		ng/mL	25.9			UNKNOWN	mg	8		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7104467/	Homo sapiens		h	25.4							false
4620	2230		ADULT	2725	274.788	CHLORPHENIRAMINE	CHLORPHENIRAMINE	CN(C)CCC(C1=CC=C(Cl)C=C1)C2=CC=CC=N2	SERUM	3U6IO1965U									∞	ng × h/mL	1075.7		ng/mL	30.6			UNKNOWN	mg	8		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7104467/	Homo sapiens		h	24.5							false
4621	2230		ADULT	2725	274.788	CHLORPHENIRAMINE	CHLORPHENIRAMINE	CN(C)CCC(C1=CC=C(Cl)C=C1)C2=CC=CC=N2	SERUM	3U6IO1965U									∞	ng × h/mL	1202.1		ng/mL	32.5			UNKNOWN	mg	4		STEADY-STATE	UNKNOWN		day	4			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7104467/	Homo sapiens		h	25.1							false
4622	2231		ADULT	447043	748.9845	AZITHROMYCIN ANHYDROUS	AZITHROMYCIN ANHYDROUS	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O	SERUM	J2KLZ20U1M							24		t	mg × h/L	10		mg/L	0.94			UNKNOWN	mg	2000		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18252692/	Homo sapiens										false
4623	2231		ADULT	447043	748.9845	AZITHROMYCIN ANHYDROUS	AZITHROMYCIN ANHYDROUS	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O	SERUM	J2KLZ20U1M							24		t	mg × h/L	3.1		mg/L	0.39			UNKNOWN	mg	500		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18252692/	Homo sapiens										false
4624	2231		ADULT	447043	748.9845	AZITHROMYCIN ANHYDROUS	AZITHROMYCIN ANHYDROUS	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O	UNKNOWN	J2KLZ20U1M							72		t	μg × h/mL	4.3		μg/mL	0.5			DEFINED DAILY	mg	500		SINGLE	FASTED				The serum protein binding of azithromycin is variable in the concentration range approximating human exposure, decreasing from 51% at 0.02 mcg/mL to 7% at 2 mcg/mL.	71	HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050710s44-050711s41-050784s28lbl.pdf	Homo sapiens										false
4625	2231		ADULT	447043	748.9845	AZITHROMYCIN ANHYDROUS	AZITHROMYCIN ANHYDROUS	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O	SERUM	J2KLZ20U1M									∞	μg × h/mL	17.4		μg/mL	0.54			RECOMMENDED	mg	500		MULTIPLE	UNKNOWN		day	1	The serum protein binding of azithromycin is variable in the concentration range approximating human exposure, decreasing from 51% at 0.02 mcg/mL to 7% at 2 mcg/mL.	71	HEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050710s44-050711s41-050784s28lbl.pdf	Homo sapiens		h	71.8							false
4626	2232		ADULT	5479529	424.385	CEFUROXIME	CEFUROXIME	CO\\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O)C3=CC=CO3	PLASMA	O1R9FJ93ED									?	μg × h/mL	88.6		μg/mL	32.8			RECOMMENDED	mg	750		SINGLE	FED						HEALTHY	Intramuscular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/949172/	Homo sapiens		h	82.3							false
4627	2232		ADULT	5479529	424.385	CEFUROXIME	CEFUROXIME	CO\\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O)C3=CC=CO3	PLASMA	O1R9FJ93ED													μg/mL	27			RECOMMENDED	mg	750		SINGLE	UNKNOWN				Cefuroxime is approximately 50% bound to serum protein.	50	HEALTHY	Intramuscular	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050558s075lbl.pdf	Homo sapiens		min	80							false
4628	2233		ADULT	4725|5281036|135398748	253.2578	PENCICLOVIR	PENCICLOVIR	NC1=NC2=C(N=CN2CCC(CO)CO)C(=O)N1	PLASMA	359HUE8FJC													ng/mL	0			UNKNOWN	mg	1.8		SINGLE	UNKNOWN						HEALTHY	Topical	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020629s016lbl.pdf	Homo sapiens										false
4629	2233		ADULT	4725|5281036|135398748	253.2578	PENCICLOVIR	PENCICLOVIR	NC1=NC2=C(N=CN2CCC(CO)CO)C(=O)N1	PLASMA	359HUE8FJC													ng/mL	0			UNKNOWN	mg	1.8		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Topical	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020629s016lbl.pdf	Homo sapiens										false
4630	2234		ADULT	62884|657316|85427946	276.202	BUPROPION HYDROCHLORIDE	bupropion hydrochloride	Cl.CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1	PLASMA	ZG7E5POY8O									∞	ng × h/mL	469		ng/mL	93			UNKNOWN	mg	75		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28685396	Homo sapiens		h	10							false
4631	2234		ADULT	444	239.741	BUPROPION	BUPROPION	CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1	PLASMA	01ZG3TPX31									∞	ng × h/mL	688		ng/mL	134			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28685396	Homo sapiens		h	10							false
4632	2234		ADULT	62884|657316|85427946	276.202	BUPROPION HYDROCHLORIDE	bupropion hydrochloride	Cl.CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1	PLASMA	ZG7E5POY8O													ng/mL	91			RECOMMENDED	mg	150		SINGLE	UNKNOWN				In vitro tests show that bupropion is 84% bound to human plasma proteins at concentrations up to 200 mcg/mL.	16	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020711s026lbl.pdf	Homo sapiens		h	21							false
4633	2234		ADULT	62884|657316|85427946	276.202	BUPROPION HYDROCHLORIDE	bupropion hydrochloride	Cl.CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1	PLASMA	ZG7E5POY8O													ng/mL	136			RECOMMENDED	mg	150		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020711s026lbl.pdf	Homo sapiens										false
4634	2235		ADULT	7028	165.2322	PSEUDOEPHEDRINE	PSEUDOEPHEDRINE	CN[C@@H](C)[C@@H](O)C1=CC=CC=C1	PLASMA	7CUC9DDI9F									∞	ng × h/mL	4346		ng/mL	292			RECOMMENDED	mg	120		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/073585Orig1s000.pdf	Homo sapiens		h	6.3							false
4635	2236		ADULT	62921	365.404	CEPHALEXIN	CEPHALEXIN	O.CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C3=CC=CC=C3)C2=O)C(O)=O	PLASMA	OBN7UDS42Y									∞	μg × h/mL	31.22		μg/mL	18.25			UNKNOWN	mg	500		SINGLE	FASTED				Only 15% of Cephalexin bind to plasma proteins	85	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23688276/	Homo sapiens		h	1.12							false
4636	2236		CHILD	62921	365.404	CEPHALEXIN	CEPHALEXIN	O.CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C3=CC=CC=C3)C2=O)C(O)=O	PLASMA	OBN7UDS42Y									?	mg × h/L	245		mg/L	126			UNKNOWN	mg/kg	40		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23811740	Homo sapiens										false
4637	2237		ADULT	54670067	176.1241	ASCORBIC ACID	ASCORBIC ACID	OC[C@H](O)[C@H]1OC(=O)C(O)=C1O	PLASMA	PQ6CK8PD0R									?	mM × h	124		mM	33			UNKNOWN	g/m²	50		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23670640/	Homo sapiens		h	1.8							false
4638	2239		ADULT	10297	151.2056	PHENYLPROPANOLAMINE	PHENYLPROPANOLAMINE	C[C@H](N)[C@H](O)C1=CC=CC=C1	PLASMA	33RU150WUN									∞	ng × h/mL	1104		ng/mL	107			RECOMMENDED	mg	25		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11361053/	Homo sapiens		h	4							false
4639	2240		ADULT	2369	307.4	BETAXOLOL	BETAXOLOL	CC(C)NCC(O)COC1=CC=C(CCOCC2CC2)C=C1	BLOOD	O0ZR1R6RZ2									∞	μg × h/L	2096		ng/mL	89.8			UNKNOWN	mg	40		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/1865331	Homo sapiens										false
4640	2240		ADULT	2369	307.4	BETAXOLOL	BETAXOLOL	CC(C)NCC(O)COC1=CC=C(CCOCC2CC2)C=C1	BLOOD	O0ZR1R6RZ2									∞	μg × h/L	610						UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/1865331	Homo sapiens										false
4641	2240		ADULT	2369	307.4	BETAXOLOL	BETAXOLOL	CC(C)NCC(O)COC1=CC=C(CCOCC2CC2)C=C1	PLASMA	O0ZR1R6RZ2									∞	ng × h/mL	971.11						DEFINED DAILY	mg	20		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/6104973	Homo sapiens		h	12.3							false
4642	2241		ADULT	4679	383.37	PANTOPRAZOLE	PANTOPRAZOLE	COC1=CC=NC(C[S+]([O-])C2=NC3=C(N2)C=C(OC(F)F)C=C3)=C1OC	PLASMA	D8TST4O562									∞	μg × h/mL	4.8		μg/mL	2.4			UNKNOWN	mg	40		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/20987lbl.pdf	Homo sapiens		h	1							false
4643	2242		ADULT		285.8	ASENAPINE			PLASMA								12		t	ng × h/mL	32.1		ng/mL	4.73			RECOMMENDED	mg	5		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Sublingual	FEMALE / MALE	EXPERIMENT	https://onlinelibrary.wiley.com/doi/epdf/10.1002/gps.2737	Homo sapiens										false
4644	2242		ADULT		285.8	ASENAPINE			PLASMA																		RECOMMENDED	mg	3.8		SINGLE	UNKNOWN				Asenapine is highly bound (95%) to plasma proteins, including albumin and α1-acid glycoprotein.	5	HEALTHY	Transdermal	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212268s000lbl.pdf	Homo sapiens		h	30							false
4645	2243		ADULT	6441383	418.6523	CALCIFEDIOL	CALCIFEDIOL	O.C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\\C(CCC[C@]12C)=C\\C=C3\\C[C@@H](O)CCC3=C	PLASMA	P6YZ13C99Q							24		t	ng × h/mL	1704.4		ng/mL	73.2			RECOMMENDED	mg	20		STEADY-STATE	FED		day	1	Calcifediol is extensively bound to plasma proteins (>98%). https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208010s005lbl.pdf	2	HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24516879/	Homo sapiens		day	11							false
4646	2244		ADULT	47964	381.404	CEFADROXIL	CEFADROXIL	O.CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C3=CC=C(O)C=C3)C2=O)C(O)=O	PLASMA	280111G160									∞	μg × h/mL	50.8		μg/mL	17.9			RECOMMENDED	mg	500		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7073267/	Homo sapiens		h	1.2							false
4647	2245		ADULT	77016	280.2748	3-METHYLFLAVONE-8-CARBOXYLIC ACID	3-Methylflavone-8-carboxylic acid	CC1=C(OC2=C(C=CC=C2C(O)=O)C1=O)C3=CC=CC=C3	PLASMA	O8RCM70C48									?	mg × h/L/(mg dose/kg)	4.49		mg/L	4.61			UNKNOWN	mg/kg	1.18		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1026965	Homo sapiens		min	40.1							false
4648	2245		ADULT	77016	280.2748	3-METHYLFLAVONE-8-CARBOXYLIC ACID	3-Methylflavone-8-carboxylic acid	CC1=C(OC2=C(C=CC=C2C(O)=O)C1=O)C3=CC=CC=C3	PLASMA	O8RCM70C48									?	mg × h/L/(mg dose/kg)	4.02						UNKNOWN	mg/kg	2.55		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1026965	Homo sapiens										false
4649	2245		ADULT	77016	280.2748	3-METHYLFLAVONE-8-CARBOXYLIC ACID	3-Methylflavone-8-carboxylic acid	CC1=C(OC2=C(C=CC=C2C(O)=O)C1=O)C3=CC=CC=C3	PLASMA	O8RCM70C48									∞	μg × h/mL	27.85		μg/mL	14.4			RECOMMENDED	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11232858/	Homo sapiens		h	4.06							false
4650	2246		ADULT	5284584	367.784	LORACARBEF	LORACARBEF	O.N[C@@H](C(=O)N[C@H]1[C@H]2CCC(Cl)=C(N2C1=O)C(O)=O)C3=CC=CC=C3	SERUM	3X11EVM5SU									?	mg × h/L	33.04		mg/L	19.21			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1468429	Homo sapiens		min	70.31							false
4651	2246		ADULT	5284584	367.784	LORACARBEF	LORACARBEF	O.N[C@@H](C(=O)N[C@H]1[C@H]2CCC(Cl)=C(N2C1=O)C(O)=O)C3=CC=CC=C3	SERUM	3X11EVM5SU									?	mg × h/L	35.38		mg/L	13.64			UNKNOWN	mg	400		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1468429	Homo sapiens		min	102.33							false
4652	2246		CHILD	5284584	367.784	LORACARBEF	LORACARBEF	O.N[C@@H](C(=O)N[C@H]1[C@H]2CCC(Cl)=C(N2C1=O)C(O)=O)C3=CC=CC=C3	PLASMA	3X11EVM5SU													μg/mL	8			UNKNOWN	mg	200		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/96/050667ap.pdf	Homo sapiens										false
4653	2246		CHILD	5284584	367.784	LORACARBEF	LORACARBEF	O.N[C@@H](C(=O)N[C@H]1[C@H]2CCC(Cl)=C(N2C1=O)C(O)=O)C3=CC=CC=C3	PLASMA	3X11EVM5SU													μg/mL	14			UNKNOWN	mg	400		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/96/050667ap.pdf	Homo sapiens										false
4654	2247		ADULT	175805	274.4011	ROPIVACAINE	ROPIVACAINE	CCCN1CCCC[C@H]1C(=O)NC2=C(C)C=CC=C2C	PLASMA	7IO5LYA57N									?	mg × h/L	135.5		mg/L	2.4			UNKNOWN	mg	1493	infusion, 72 hour	OTHER	UNKNOWN						UNHEALTHY	Epidural	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020533s035lbl.pdf	Homo sapiens		h	5							false
4655	2247		ADULT	175805	274.4011	ROPIVACAINE	ROPIVACAINE	CCCN1CCCC[C@H]1C(=O)NC2=C(C)C=CC=C2C	PLASMA	7IO5LYA57N									?	mg × h/L	145		mg/L	2.8			UNKNOWN	mg	2075	infusion, 72 hour	OTHER	UNKNOWN						UNHEALTHY	Epidural	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020533s035lbl.pdf	Homo sapiens		h	5.7							false
4656	2247		ADULT	175805	274.4011	ROPIVACAINE	ROPIVACAINE	CCCN1CCCC[C@H]1C(=O)NC2=C(C)C=CC=C2C	PLASMA	7IO5LYA57N									?	mg × h/L	7.2		mg/L	1.1			UNKNOWN	mg	150		SINGLE	UNKNOWN						UNHEALTHY	Epidural	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020533s035lbl.pdf	Homo sapiens		h	5.7							false
4657	2247		ADULT	175805	274.4011	ROPIVACAINE	ROPIVACAINE	CCCN1CCCC[C@H]1C(=O)NC2=C(C)C=CC=C2C	PLASMA	7IO5LYA57N									?	mg × h/L	11.3		mg/L	1.6			UNKNOWN	mg	187.5		SINGLE	UNKNOWN						UNHEALTHY	Epidural	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020533s035lbl.pdf	Homo sapiens		h	7.1							false
4658	2247		ADULT	175805	274.4011	ROPIVACAINE	ROPIVACAINE	CCCN1CCCC[C@H]1C(=O)NC2=C(C)C=CC=C2C	PLASMA	7IO5LYA57N									?	mg × h/L	13		mg/L	2.3			UNKNOWN	mg	300		SINGLE	UNKNOWN						UNHEALTHY	Epidural	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020533s035lbl.pdf	Homo sapiens		h	6.8							false
4659	2247		ADULT	175805	274.4011	ROPIVACAINE	ROPIVACAINE	CCCN1CCCC[C@H]1C(=O)NC2=C(C)C=CC=C2C	PLASMA	7IO5LYA57N									?	mg × h/L	1.8		mg/L	1.2			UNKNOWN	mg	40	infusion, 20 min	OTHER	UNKNOWN		day	1			HEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020533s035lbl.pdf	Homo sapiens		h	1.9							false
4660	2248		ADULT	4914	236.3101	PROCAINE	PROCAINE	CCN(CC)CCOC(=O)C1=CC=C(N)C=C1	PLASMA	4Z8Y51M438									∞	μg × min/mL	12.5		μg/mL	12			RECOMMENDED	mg/kg	60		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/573562/	Homo sapiens		min	8.3							false
4661	2249		UNKNOWN	3121	144.2114	VALPROIC ACID	valproic acid	CCCC(CCC)C(O)=O	PLASMA	614OI1Z5WI																	RECOMMENDED	mg	1000		STEADY-STATE	UNKNOWN		day	1			UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018081s065_018082s048lbl.pdf	Homo sapiens		h	16							false
4662	2249		UNKNOWN	3121	144.2114	VALPROIC ACID	valproate	CCCC(CCC)C(O)=O	PLASMA	614OI1Z5WI							24		t	mg × h/L	1951		mg/L	107.2			DEFINED DAILY	mg	500		MULTIPLE	FED		day	2			HEALTHY	Oral	FEMALE / MALE	REVIEW	https://www.ncbi.nlm.nih.gov/pubmed/17523712	Homo sapiens										false
4663	2251		ADULT	4917	373.943	PROCHLORPERAZINE	prochlorperazine	CN1CCN(CCCN2C3=CC(Cl)=CC=C3SC4=C2C=CC=C4)CC1	PLASMA	YHP6YLT61T							12		t	ng × h/mL	32.3		ng/mL	3.9			DEFINED DAILY	mg	25		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://bpspubs.onlinelibrary.wiley.com/doi/pdf/10.1111/j.1365-2125.1991.tb03973.x	Homo sapiens		h	18.1							false
4664	2251		ADULT	4917	373.943	PROCHLORPERAZINE	prochlorperazine	CN1CCN(CCCN2C3=CC(Cl)=CC=C3SC4=C2C=CC=C4)CC1	PLASMA	YHP6YLT61T																	DEFINED DAILY	mg/kg	12.5		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://bpspubs.onlinelibrary.wiley.com/doi/pdf/10.1111/j.1365-2125.1991.tb03973.x	Homo sapiens		h	9							false
4665	2251		ADULT	4917	373.943	PROCHLORPERAZINE	prochlorperazine	CN1CCN(CCCN2C3=CC(Cl)=CC=C3SC4=C2C=CC=C4)CC1	PLASMA	YHP6YLT61T													ng/mL	4			DEFINED DAILY	mg	50		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://bpspubs.onlinelibrary.wiley.com/doi/pdf/10.1111/j.1365-2125.1991.tb03973.x	Homo sapiens		h	8							false
4666	2252		UNKNOWN	2162	408.876	AMLODIPINE	AMLODIPINE	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C2=C(Cl)C=CC=C2)C(=O)OC	PLASMA	1J444QC288																						UNKNOWN				Determined by equilibrium dialysis, plasma protein binding of radiolabelled amlodipine 50 ug/L was 98%.	2	UNKNOWN		UNKNOWN	REVIEW	https://link.springer.com/article/10.2165%2F00003088-199222010-00003	Homo sapiens										false
4667	2252		ADULT	2162	408.876	AMLODIPINE	AMLODIPINE	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C2=C(Cl)C=CC=C2)C(=O)OC	PLASMA	1J444QC288									?	μg × h/L	187		μg/L	3			RECOMMENDED	mg	5		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	REVIEW	https://link.springer.com/article/10.2165%2F00003088-199222010-00003	Homo sapiens		h	48							false
4668	2252		ADULT	2162	408.876	AMLODIPINE	AMLODIPINE	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C2=C(Cl)C=CC=C2)C(=O)OC	PLASMA	1J444QC288									?	μg × h/L	238		μg/L	5.9			MAX DAILY	mg	10		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	REVIEW	https://link.springer.com/article/10.2165%2F00003088-199222010-00003	Homo sapiens		h	36							false
4669	2252		ADULT	2162	408.876	AMLODIPINE	AMLODIPINE	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C2=C(Cl)C=CC=C2)C(=O)OC	PLASMA	1J444QC288									?	μg × h/L	464		μg/L	10.4			UNKNOWN	mg	20		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	REVIEW	https://link.springer.com/article/10.2165%2F00003088-199222010-00003	Homo sapiens		h	37							false
4670	2252		ADULT	2162	408.876	AMLODIPINE	AMLODIPINE	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C2=C(Cl)C=CC=C2)C(=O)OC	PLASMA	1J444QC288							144		t	ng × h/mL	114		ng/mL	2.3			RECOMMENDED	mg	5		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7867683	Homo sapiens										false
4671	2252		ADULT	2162	408.876	AMLODIPINE	AMLODIPINE	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C2=C(Cl)C=CC=C2)C(=O)OC	PLASMA	1J444QC288									∞	ng × h/mL	169		ng/mL	3.5			RECOMMENDED	mg	5		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8112371	Homo sapiens		h	41							false
4672	2252		ADULT	2162	408.876	AMLODIPINE	AMLODIPINE	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C2=C(Cl)C=CC=C2)C(=O)OC	PLASMA	1J444QC288									∞	ng × h/mL	214		ng/mL	10.5			RECOMMENDED	mg	5		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8112371	Homo sapiens		h	47							false
4673	2253		ADULT	3345	336.4705	FENTANYL	FENTANYL	CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C3=CC=CC=C3	PLASMA	UF599785JZ									∞	ng × h/mL	4.18		ng/mL	0.61			RECOMMENDED	μg	400		SINGLE	UNKNOWN						HEALTHY	Oral transmucosal	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23497761/	Homo sapiens		h	7.9							false
4674	2253		ADULT	3345	336.4705	FENTANYL	FENTANYL	CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C3=CC=CC=C3	PLASMA	UF599785JZ									∞	ng × h/mL	1.76		ng/mL	0.93			RECOMMENDED	μg	100		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23497761/	Homo sapiens		h	4.5							false
4675	2253		ADULT	3345	336.4705	FENTANYL	FENTANYL	CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C3=CC=CC=C3	PLASMA	UF599785JZ									∞	ng × h/mL	5.76		ng/mL	0.81			RECOMMENDED	μg	400		SINGLE	UNKNOWN						HEALTHY	Sublingual	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23497761/	Homo sapiens		h	10							false
4676	2254		ADULT	4171	267.3639	METOPROLOL	METOPROLOL	COCCC1=CC=C(OCC(O)CNC(C)C)C=C1	PLASMA	GEB06NHM23									?	ng × h/mL	279		ng/mL	76			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10741632/	Homo sapiens		h	2.8							false
4677	2254		UNKNOWN	4171	267.3639	METOPROLOL	METOPROLOL	COCCC1=CC=C(OCC(O)CNC(C)C)C=C1	PLASMA	GEB06NHM23																	UNKNOWN				UNKNOWN	UNKNOWN				About 10% of metoprolol in plasma is bound to serum albumin	90	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017963s068lbl.pdf	Homo sapiens		h	9							false
4678	2255		ADULT		444.4346	TETRACYCLINE	tetracycline	CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)C4=C(C=CC=C4O)[C@@]3(C)O)=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O	PLASMA	F8VB5M810T									∞	μg × h/mL	26.91		μg/mL	2.5			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6487493/	Homo sapiens		h	7.85							false
4679	2255		ADULT		444.4346	TETRACYCLINE	TETRACYCLINE	CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)C4=C(C=CC=C4O)[C@@]3(C)O)=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O	PLASMA	F8VB5M810T									∞	μg × h/mL	27.27						UNKNOWN	mg	300		STEADY-STATE	FASTED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6487493/	Homo sapiens										false
4680	2255		ADULT		444.4346	TETRACYCLINE	TETRACYCLINE	CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)C4=C(C=CC=C4O)[C@@]3(C)O)=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O	SERUM	F8VB5M810T									∞	μg × h/mL	27		μg/mL	2.6			UNKNOWN	mg	500		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/856000/	Homo sapiens		h	5.6							false
4681	2255		ADULT		444.4346	TETRACYCLINE	TETRACYCLINE	CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)C4=C(C=CC=C4O)[C@@]3(C)O)=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O	SERUM	F8VB5M810T									∞	μg × h/mL	31.7		μg/mL	2.7			UNKNOWN	mg	500		SINGLE	HIGH-FAT						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/856000/	Homo sapiens		h	6.2							false
4682	2255		ADULT		444.4346	TETRACYCLINE	TETRACYCLINE	CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)C4=C(C=CC=C4O)[C@@]3(C)O)=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O	SERUM	F8VB5M810T									∞	μg × h/mL	25.5		μg/mL	2			UNKNOWN	mg	500		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/856000/	Homo sapiens		h	7.2							false
4683	2255		ADULT		444.4346	TETRACYCLINE	TETRACYCLINE	CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)C4=C(C=CC=C4O)[C@@]3(C)O)=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O	SERUM	F8VB5M810T									∞	μg × h/mL	74.7		μg/mL	4.1			UNKNOWN	mg	500		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/856000/	Homo sapiens		h	8.1							false
4684	2255		ADULT		444.4346	TETRACYCLINE	TETRACYCLINE	CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)C4=C(C=CC=C4O)[C@@]3(C)O)=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O	SERUM	F8VB5M810T									∞	μg × h/mL	55.7		μg/mL	4.5			UNKNOWN	mg	500		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/856000/	Homo sapiens		h	6.7							false
4685	2255		ADULT		444.4346	TETRACYCLINE	TETRACYCLINE	CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)C4=C(C=CC=C4O)[C@@]3(C)O)=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O	SERUM	F8VB5M810T									∞	μg × h/mL	56.6		μg/mL	4.5			UNKNOWN	mg	500		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/856000/	Homo sapiens		h	6.1							false
4686	2256		ADULT	5816|139148732	183.2044	EPINEPHRINE	EPINEPHRINE	CNC[C@H](O)C1=CC(O)=C(O)C=C1	PLASMA	YKH834O4BH									∞	ng × h/mL	0.724		ng/mL	0.486			UNKNOWN	mg	0.3		SINGLE	UNKNOWN						HEALTHY	Intramuscular	FEMALE / MALE	EXPERIMENT	https://www.jacionline.org/article/S0091-6749(11)02197-X/pdf	Homo sapiens										false
4687	2256		ADULT	5816|139148732	183.2044	EPINEPHRINE	EPINEPHRINE	CNC[C@H](O)C1=CC(O)=C(O)C=C1	PLASMA	YKH834O4BH							2		t	ng × min/mL	18.3		pg/mL	309			UNKNOWN	mg	0.3		SINGLE	UNKNOWN						HEALTHY	Intramuscular	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26994624	Homo sapiens										false
4688	2256		ADULT	5816|139148732	183.2044	EPINEPHRINE	EPINEPHRINE	CNC[C@H](O)C1=CC(O)=C(O)C=C1	PLASMA	YKH834O4BH							2		t	ng × min/mL	19.4		pg/mL	386			UNKNOWN	mg	5		MULTIPLE	UNKNOWN						HEALTHY	Nasal	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26994624	Homo sapiens										false
4689	2257		ADULT	3394	244.26	FLURBIPROFEN	CC(C(O)=O)C1=CC=C(C(F)=C1)C2=CC=CC=C2	CC(C(O)=O)C1=CC=C(C(F)=C1)C2=CC=CC=C2	PLASMA	5GRO578KLP									∞	μg × h/mL	83		μg/mL	14			RECOMMENDED	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018766s015lbl.pdf	Homo sapiens		h	7.5							false
4690	2257		ADULT	3394	244.26	FLURBIPROFEN		CC(C(O)=O)C1=CC=C(C(F)=C1)C2=CC=CC=C2	PLASMA	5GRO578KLP									∞	μg × h/mL	124.2		μg/mL	19.67			UNKNOWN	mg	150		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/19808137	Homo sapiens		h	4.77							false
4691	2258		ADULT	174174	289.3694	ATROPINE	ATROPINE	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C3=CC=CC=C3	PLASMA	7C0697DR9I													ng/mL	9.6			RECOMMENDED	mg	1.67		SINGLE	UNKNOWN				The protein binding of atropine is 14 to 22% in plasma	82	UNKNOWN	Intramuscular	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/212319s000lbl.pdf	Homo sapiens										false
4692	2258		ADULT	174174	289.3694	ATROPINE	ATROPINE	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C3=CC=CC=C3	PLASMA	7C0697DR9I							90		t	pg × min/mL	43245		pg/mL	860			UNKNOWN	mg	0.4		SINGLE	UNKNOWN						UNHEALTHY	Ocular	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/3046815	Homo sapiens										false
4693	2258		ADULT	174174	289.3694	ATROPINE	ATROPINE	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C3=CC=CC=C3	PLASMA	7C0697DR9I									?	ng × h/mL	47.6		ng/mL	11.7			RECOMMENDED	mg	1.67		SINGLE	UNKNOWN						HEALTHY	Intramuscular	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/3740650	Homo sapiens		h	4.1							false
4694	2259		ADULT	5288783	412.6047	CALCIPOTRIENE	CALCIPOTRIENE	C[C@H](\\C=C\\[C@@H](O)C1CC1)[C@H]2CC[C@@H]3[C@]2(C)CCC\\C3=C/C=C4/C[C@@H](O)C[C@H](O)C4=C	PLASMA	143NQ3779B	21800		BETAMETHASONE DIPROPIONATE	betamethasone dipropionate	CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C	826Y60901U			?	pg × h/mL	82.5		pg/mL	55.9			RECOMMENDED	%	0.005		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Topical	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207589s000lbl.pdf	Homo sapiens										true
4695	2259		ADULT	9547352	412.6	MC1080	MC1080		PLASMA		21800		BETAMETHASONE DIPROPIONATE	Betamethasone dipropionate	CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C	826Y60901U			?	pg × h/mL	59.3		pg/mL	24.4			UNKNOWN	%	0.005		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Topical	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207589s000lbl.pdf	Homo sapiens										true
4696	2260		UNKNOWN	2726	318.864	CHLORPROMAZINE	CHLORPROMAZINE	CN(C)CCCN1C2=CC(Cl)=CC=C2SC3=C1C=CC=C3	PLASMA	U42B7VYA4P																	UNKNOWN				UNKNOWN	UNKNOWN				More than 90% of the plasma content of chlorpromazine over a concentration range from 0.008 to 15.1 ug/ml was bound to human plasma protein.	10	UNKNOWN	UNKNOWN	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4399487	Homo sapiens										false
4697	2260		ADULT	2726	318.864	CHLORPROMAZINE	CHLORPROMAZINE	CN(C)CCCN1C2=CC(Cl)=CC=C2SC3=C1C=CC=C3	PLASMA	U42B7VYA4P									?	ng × h/mL	135						UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8157044	Homo sapiens		h	11.1							false
4698	2260		ADULT	2726	318.864	CHLORPROMAZINE	CHLORPROMAZINE	CN(C)CCCN1C2=CC(Cl)=CC=C2SC3=C1C=CC=C3	PLASMA	U42B7VYA4P									?	ng × h/mL	27.8		ng/mL	4.31			UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8157044	Homo sapiens		h	5.48							false
4699	2260		ADULT	2726	318.864	CHLORPROMAZINE	CHLORPROMAZINE	CN(C)CCCN1C2=CC(Cl)=CC=C2SC3=C1C=CC=C3	PLASMA	U42B7VYA4P									?	ng × h/mL	81.8		ng/mL	11.9			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8157044	Homo sapiens		h	9.52							false
4700	2260		ADULT	2726	318.864	CHLORPROMAZINE	CHLORPROMAZINE	CN(C)CCCN1C2=CC(Cl)=CC=C2SC3=C1C=CC=C3	PLASMA	U42B7VYA4P									?	ng × h/mL	247		ng/mL	37.9			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8157044	Homo sapiens		h	11.05							false
4701	2261		UNKNOWN	2764|4011971	331.3415	CIPROFLOXACIN	CIPROFLOXACIN	OC(=O)C1=CN(C2CC2)C3=CC(N4CCNCC4)=C(F)C=C3C1=O	SERUM	5E8K9I0O4U							12		t	μg × h/mL	13.7		μg/mL	2.97			RECOMMENDED	mg	500		STEADY-STATE	UNKNOWN		day	2	The binding of ciprofloxacin to serum proteins is 20% to 40%	30	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019537s086lbl.pdf	Homo sapiens		h	4							false
4702	2261		UNKNOWN	2764|4011971	331.3415	CIPROFLOXACIN	CIPROFLOXACIN	OC(=O)C1=CN(C2CC2)C3=CC(N4CCNCC4)=C(F)C=C3C1=O	SERUM	5E8K9I0O4U							12		t	μg × h/mL	12.7		μg/mL	4.56			UNKNOWN	mg	400		STEADY-STATE	UNKNOWN		day	2			UNKNOWN	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019537s086lbl.pdf	Homo sapiens										false
4703	2261		UNKNOWN	2764|4011971	331.3415	CIPROFLOXACIN	CIPROFLOXACIN	OC(=O)C1=CN(C2CC2)C3=CC(N4CCNCC4)=C(F)C=C3C1=O	SERUM	5E8K9I0O4U									?	μg × h/mL	31.6		μg/mL	3.59			RECOMMENDED	mg	750		STEADY-STATE	UNKNOWN		day	2			UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019537s086lbl.pdf	Homo sapiens										false
4704	2261		UNKNOWN	2764|4011971	331.3415	CIPROFLOXACIN	CIPROFLOXACIN	OC(=O)C1=CN(C2CC2)C3=CC(N4CCNCC4)=C(F)C=C3C1=O	SERUM	5E8K9I0O4U									?	μg × h/mL	32.9		μg/mL	4.07			UNKNOWN	mg	400		STEADY-STATE	UNKNOWN		day	3			UNKNOWN	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019537s086lbl.pdf	Homo sapiens										false
4705	2261		UNKNOWN	2764|4011971	331.3415	CIPROFLOXACIN	CIPROFLOXACIN	OC(=O)C1=CN(C2CC2)C3=CC(N4CCNCC4)=C(F)C=C3C1=O	SERUM	5E8K9I0O4U									?	μg × h/mL	4.8		μg/mL	1.2			RECOMMENDED	mg	250		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019537s086lbl.pdf	Homo sapiens		h	4							false
4706	2261		UNKNOWN	2764|4011971	331.3415	CIPROFLOXACIN	CIPROFLOXACIN	OC(=O)C1=CN(C2CC2)C3=CC(N4CCNCC4)=C(F)C=C3C1=O	SERUM	5E8K9I0O4U									?	μg × h/mL	11.6		μg/mL	2.4			RECOMMENDED	mg	500		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019537s086lbl.pdf	Homo sapiens		h	4							false
4707	2261		UNKNOWN	2764|4011971	331.3415	CIPROFLOXACIN	CIPROFLOXACIN	OC(=O)C1=CN(C2CC2)C3=CC(N4CCNCC4)=C(F)C=C3C1=O	SERUM	5E8K9I0O4U									?	μg × h/mL	20.2		μg/mL	4.3			RECOMMENDED	mg	750		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019537s086lbl.pdf	Homo sapiens		h	4							false
4708	2261		UNKNOWN	2764|4011971	331.3415	CIPROFLOXACIN	CIPROFLOXACIN	OC(=O)C1=CN(C2CC2)C3=CC(N4CCNCC4)=C(F)C=C3C1=O	SERUM	5E8K9I0O4U									?	μg × h/mL	30.8		μg/mL	5.4			UNKNOWN	mg	1000		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019537s086lbl.pdf	Homo sapiens		h	4							false
4709	2262		UNKNOWN	3715	357.788	INDOMETHACIN	INDOMETHACIN	COC1=CC2=C(C=C1)N(C(=O)C3=CC=C(Cl)C=C3)C(C)=C2CC(O)=O	PLASMA	XXE1CET956													μg/mL	2			DEFINED DAILY	mg	50		SINGLE	UNKNOWN				Indomethacin is highly bound to protein in plasma (about 99%) over the expected range of therapeutic plasma concentrations	1	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/ae5c0754-71eb-42ac-b3ab-e16fe61949b5/spl-doc?hl=INDOMETHACIN	Homo sapiens										false
4710	2262		ADULT	3715	357.0768	INDOMETHACIN	INDOMETHACIN	COC1=CC2=C(C=C1)N(C(=O)C3=CC=C(Cl)C=C3)C(C)=C2CC(O)=O	PLASMA	XXE1CET956									∞	ng × h/mL	7762		ng/mL	2369			DEFINED DAILY	mg	50		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204768Orig1s000ClinPharmR.pdf	Homo sapiens		h	7.22							false
4711	2264		ADULT	4594	345.416	OMEPRAZOLE	OMEPRAZOLE	COC1=CC2=C(NC(=N2)[S+]([O-])CC3=C(C)C(OC)=C(C)C=N3)C=C1	PLASMA	KG60484QX9									?	nM × h	1200							mg	20		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01361217	Homo sapiens										false
4712	2264		ADULT	4594	345.416	OMEPRAZOLE	OMEPRAZOLE	COC1=CC2=C(NC(=N2)[S+]([O-])CC3=C(C)C(OC)=C(C)C=N3)C=C1	PLASMA	KG60484QX9									?	ng × h/mL	1220		ng/mL	668			RECOMMENDED	mg/kg	1		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019810s096lbl.pdf	Homo sapiens										false
4713	2264		ADULT	4594	345.416	OMEPRAZOLE	omeprazole	COC1=CC2=C(NC(=N2)[S+]([O-])CC3=C(C)C(OC)=C(C)C=N3)C=C1	PLASMA	KG60484QX9									?	nM × h	1179						UNKNOWN	mg	20		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/2350532	Homo sapiens		h	0.58							false
4714	2266		ADULT	89594	162.2316	NICOTINE	NICOTINE	CN1CCC[C@H]1C2=CN=CC=C2	PLASMA	6M3C89ZY6R							1		t	ng × h/mL	6		ng/mL	12			RECOMMENDED	mg	1		SINGLE	UNKNOWN				Plasma protein binding of nicotine is <5%.	95	UNKNOWN	Nasal	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020385s011lbl.pdf	Homo sapiens		min	3							false
4715	2267		ADULT	62933	650.855	TIMOLOL	TIMOLOL	O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N2CCOCC2.CC(C)(C)NC[C@H](O)COC3=NSN=C3N4CCOCC4	PLASMA	817W3C6175									?	ng × h/mL	110		ng/mL	26			UNKNOWN	mg	5		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18201139/	Homo sapiens		h	2.4							false
4716	2268		UNKNOWN	54678486	308.3279	WARFARIN	WARFARIN	CC(=O)CC(C1=CC=CC=C1)C2=C(O)C3=C(OC2=O)C=CC=C3	PLASMA	5Q7ZVV76EI																	UNKNOWN				SINGLE	UNKNOWN				Approximately 99% of the drug is bound to plasma proteins.	1	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/009218s107lbl.pdf	Homo sapiens		day	7							false
4717	2268		ADULT	54678486	308.3279	WARFARIN	WARFARIN	CC(=O)CC(C1=CC=CC=C1)C2=C(O)C3=C(OC2=O)C=CC=C3	PLASMA	5Q7ZVV76EI							96		t	ng × h/mL	52278		ng/mL	2186			INVESTIGATIONAL	mg	25		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/19552747	Homo sapiens		h	32.4							false
4718	2269		ADOLESCENT	60854	412.936	ZIPRASIDONE	ZIPRASIDONE	ClC1=C(CCN2CCN(CC2)C3=NSC4=C3C=CC=C4)C=C5CC(=O)NC5=C1	SERUM	6UKA5VEJ6X									∞	ng × h/mL	457		ng/mL	51			RECOMMENDED	mg	20		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16721322	Homo sapiens		h	4.1							false
4719	2269		UNKNOWN	60854	412.936	ZIPRASIDONE	ZIPRASIDONE	ClC1=C(CCN2CCN(CC2)C3=NSC4=C3C=CC=C4)C=C5CC(=O)NC5=C1	PLASMA	6UKA5VEJ6X																						UNKNOWN				greater than 99% bound to plasma proteins	1	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020825s053,020919s040,s021483s013lbl.pdf	Homo sapiens										false
4720	2270		UNKNOWN	2094|5270529|135401907	136.1115	ALLOPURINOL	ALLOPURINOL	O=C1NC=NC2=C1C=NN2	PLASMA	63CZ7GJN5I													μg/mL	3			RECOMMENDED	mg	300		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/016084s044lbl.pdf	Homo sapiens		h	2							false
4721	2270		ADULT	2094|5270529|135401907	136.1115	ALLOPURINOL	ALLOPURINOL	O=C1NC=NC2=C1C=NN2	PLASMA	63CZ7GJN5I							24		t	μg × h/mL	4.46		μg/mL	0.64			RECOMMENDED	mg	200		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/10583019	Homo sapiens										false
4722	2271		ADULT	644073	467.6401	BUPRENORPHINE	BUPRENORPHINE	CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]4CC5=CC=C(O)C6=C5[C@@]3(CCN4CC7CC7)[C@H]2O6	PLASMA	40D3SCR4GZ									∞	ng × h/mL	0.63		ng/mL	0.17			RECOMMENDED	μg	75		SINGLE	UNKNOWN				Buprenorphine is approximately 96% protein bound, primarily to alpha and beta globulin.	4	UNKNOWN	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/207932s012lbl.pdf	Homo sapiens		h	3							false
4723	2273		ADULT	2712	299.755	CHLORDIAZEPOXIDE	CHLORDIAZEPOXIDE	CNC1=NC2=C(C=C(Cl)C=C2)C(C3=CC=CC=C3)=[N+]([O-])C1	BLOOD	6RZ6XEZ3CR													μg/mL	1.65			UNKNOWN	mg	50		SINGLE	UNKNOWN						UNKNOWN	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/359214	Homo sapiens										false
4724	2273		UNKNOWN	2712	299.755	CHLORDIAZEPOXIDE	CHLORDIAZEPOXIDE	CNC1=NC2=C(C=C(Cl)C=C2)C(C3=CC=CC=C3)=[N+]([O-])C1	PLASMA	6RZ6XEZ3CR																						UNKNOWN				about 94 to 97 % of the total amount of drug present in plasma is protein bound	95.5	UNKNOWN		UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/359214	Homo sapiens										false
4725	2273		ADULT	2712	299.755	CHLORDIAZEPOXIDE	CHLORDIAZEPOXIDE	CNC1=NC2=C(C=C(Cl)C=C2)C(C3=CC=CC=C3)=[N+]([O-])C1	BLOOD	6RZ6XEZ3CR													μg/mL	0.86			RECOMMENDED	mg	25		SINGLE	UNKNOWN						UNKNOWN	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/359214	Homo sapiens										false
4726	2273		ADULT	2712	299.755	CHLORDIAZEPOXIDE	CHLORDIAZEPOXIDE	CNC1=NC2=C(C=C(Cl)C=C2)C(C3=CC=CC=C3)=[N+]([O-])C1	PLASMA	6RZ6XEZ3CR									∞	μg × h/mL	26.7		μg/mL	0.84			UNKNOWN	mg	25		SINGLE	UNKNOWN						HEALTHY	Intramuscular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7286030	Homo sapiens		h	16.5							false
4727	2273		ADULT	2712	299.755	CHLORDIAZEPOXIDE	CHLORDIAZEPOXIDE	CNC1=NC2=C(C=C(Cl)C=C2)C(C3=CC=CC=C3)=[N+]([O-])C1	PLASMA	6RZ6XEZ3CR									∞	μg × h/mL	53.6		μg/mL	0.69			UNKNOWN	mg	25		SINGLE	UNKNOWN						UNHEALTHY	Intramuscular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7286030	Homo sapiens		h	40.1							false
4728	2273		ADULT	2712	299.755	CHLORDIAZEPOXIDE	CHLORDIAZEPOXIDE	CNC1=NC2=C(C=C(Cl)C=C2)C(C3=CC=CC=C3)=[N+]([O-])C1	BLOOD	6RZ6XEZ3CR									?	μg × h/mL	7.16						UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/770046	Homo sapiens		h	8.4							false
4729	2274		ADULT	2719	319.872	CHLOROQUINE	CHLOROQUINE	CCN(CC)CCCC(C)NC1=CC=NC2=C1C=CC(Cl)=C2	PLASMA	886U3H6UFF									∞	ng × h/mL	134087		ng/mL	700			RECOMMENDED	mg/kg	5		MULTIPLE	UNKNOWN		day	1	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/006002s045lbl.pdf	45	UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18594802/	Homo sapiens		h	209							false
4730	2275		ADULT	2803	230.094	CLONIDINE	CLONIDINE	ClC1=CC=CC(Cl)=C1NC2=NCCN2	PLASMA	MN3L5RMN02									∞	pg × h/mL	7313		pg/mL	443			RECOMMENDED	mg	0.1		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022331s021lbl.pdf	Homo sapiens		h	12.57							false
4731	2276		ADULT	39186	414.518	DILTIAZEM	diltiazem	COC1=CC=C(C=C1)[C@@H]2SC3=C(C=CC=C3)N(CCN(C)C)C(=O)[C@@H]2OC(C)=O	PLASMA	EE92BBP03H																	DEFINED DAILY	mg	360		SINGLE	FASTED				In vitro binding studies show diltiazem is 70% to 80% bound to plasma proteins.	25	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021392s019lbl.pdf	Homo sapiens		h	7.5							false
4732	2276		ADULT	39186	414.518	DILTIAZEM	DILTIAZEM	COC1=CC=C(C=C1)[C@@H]2SC3=C(C=CC=C3)N(CCN(C)C)C(=O)[C@@H]2OC(C)=O	PLASMA	EE92BBP03H							24		t	ng × h/mL	2410		ng/mL	166.4			DEFINED DAILY	mg	240		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/11329099	Homo sapiens										false
4733	2277		ADULT	3676	234.3373	LIDOCAINE	LIDOCAINE	CCN(CC)CC(=O)NC1=C(C)C=CC=C1C	PLASMA	98PI200987							24		t	ng × h/mL	4100		ng/mL	212			UNKNOWN	mg	84		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Topical	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12455305/	Homo sapiens		h	6.81							false
4734	2277		ADULT	3676	234.3373	LIDOCAINE	LIDOCAINE	CCN(CC)CC(=O)NC1=C(C)C=CC=C1C	PLASMA	98PI200987							24		t	ng × h/mL	4704		ng/mL	231			UNKNOWN	mg	84		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Topical	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12455305/	Homo sapiens		h	7.94							false
4735	2278		ADULT	446596	500.6222	MUPIROCIN	MUPIROCIN	C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]2CO[C@@H](C\\C(C)=C\\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]2O	PLASMA	D0GX863OA5																	UNKNOWN				SINGLE	UNKNOWN				Mupirocin is highly protein bound (greater than 97%)	3	HEALTHY	Intravenous	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050591s034lbl.pdf	Homo sapiens		min	30							false
4736	2279		ADULT	5284596	327.3743	NALOXONE	NALOXONE	OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O	PLASMA	36B82AMQ7N							1.5		t	ng × min/mL	37.1		ng/mL	1.09			RECOMMENDED	mg/kg	10		SINGLE	UNKNOWN						HEALTHY	Nasal	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28444856/	Homo sapiens		min	28.2							false
4737	2279		ADULT	5284596	327.3743	NALOXONE	NALOXONE	OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O	PLASMA	36B82AMQ7N									?	ng × h/mL	7.9		ng/mL	4.83			RECOMMENDED	mg	4		SINGLE	UNKNOWN						HEALTHY	Nasal	UNKNOWN	DRUG LABEL	https://www.fda.gov/media/95283/download	Homo sapiens										false
4738	2279		ADULT	5284596	327.3743	NALOXONE	NALOXONE	OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O	PLASMA	36B82AMQ7N									?	ng × h/mL	1.68		ng/mL	0.87			RECOMMENDED	mg	0.4		SINGLE	UNKNOWN						HEALTHY	Intramuscular	UNKNOWN	DRUG LABEL	https://www.fda.gov/media/95283/download	Homo sapiens		h	1.2							false
4739	2279		ADULT	5284596	327.3743	NALOXONE	NALOXONE	OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O	PLASMA	36B82AMQ7N									?	ng × h/mL	15		ng/mL	9.62			RECOMMENDED	mg	8		SINGLE	UNKNOWN						HEALTHY	Nasal	UNKNOWN	DRUG LABEL	https://www.fda.gov/media/95283/download	Homo sapiens		h	2.1							false
4740	2280		ADULT	156391	230.2592	NAPROXEN	NAPROXEN	COC1=CC2=C(C=C1)C=C(C=C2)[C@H](C)C(O)=O	PLASMA	57Y76R9ATQ							24		t	μg × h/mL	1446		μg/L	95			RECOMMENDED	mg	500		STEADY-STATE	UNKNOWN		day	2	At therapeutic levels, naproxen is greater than 99% albumin-bound.	1	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020353s034lbl.pdf	Homo sapiens		h	15							false
4741	2280		ADULT		230.2592	NAPROXEN	NAPROXEN	COC1=CC2=C(C=C1)C=C(C=C2)[C@H](C)C(O)=O	PLASMA	57Y76R9ATQ							24		t	μg × h/mL	1448		μg/mL	94			RECOMMENDED	mg	1000		STEADY-STATE	UNKNOWN		day	1			UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020353s034lbl.pdf	Homo sapiens										false
4742	2281		ADOLESCENT	4440	335.464	NARATRIPTAN	NARATRIPTAN	CNS(=O)(=O)CCC1=CC2=C(NC=C2C3CCN(C)CC3)C=C1	SERUM	QX3KXL1ZA2									∞	ng × h/mL	74.6		ng/mL	7.97			RECOMMENDED	mg	2.5		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11210397/	Homo sapiens		h	4.9							false
4743	2281		UNKNOWN	4440	335.464	NARATRIPTAN	NARATRIPTAN	CNS(=O)(=O)CCC1=CC2=C(NC=C2C3CCN(C)CC3)C=C1	PLASMA	QX3KXL1ZA2									∞	ng × h/mL	107.97		ng/mL	92			RECOMMENDED	mg	2.5		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502011000100003&lang=en	Homo sapiens										false
4744	2282			4595	293.363	ONDANSETRON	ONDANSETRON	CN1C2=C(C3=C1C=CC=C3)C(=O)C(CN4C=CN=C4C)CC2	PLASMA	4AF302ESOS													ng/mL	32.096				mg	8		SINGLE								Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00934180	Homo sapiens										false
4745	2282			4595	293.363	ONDANSETRON	ONDANSETRON	CN1C2=C(C3=C1C=CC=C3)C(=O)C(CN4C=CN=C4C)CC2	PLASMA	4AF302ESOS									∞	ng × h/mL	237.935							mg	8		SINGLE								Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00934180	Homo sapiens										false
4746	2282			4595	293.363	ONDANSETRON	ONDANSETRON	CN1C2=C(C3=C1C=CC=C3)C(=O)C(CN4C=CN=C4C)CC2	PLASMA	4AF302ESOS							24		t	ng × h/mL	224.155							mg	8		SINGLE								Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00934180	Homo sapiens										false
4747	2282			4595	293.363	ONDANSETRON	ONDANSETRON	CN1C2=C(C3=C1C=CC=C3)C(=O)C(CN4C=CN=C4C)CC2	PLASMA	4AF302ESOS													ng/mL	30.196				mg	8		SINGLE								Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00934921	Homo sapiens										false
4748	2282			4595	293.363	ONDANSETRON	ONDANSETRON	CN1C2=C(C3=C1C=CC=C3)C(=O)C(CN4C=CN=C4C)CC2	PLASMA	4AF302ESOS									∞	ng × h/mL	293.492							mg	8		SINGLE								Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00934921	Homo sapiens										false
4749	2282			4595	293.363	ONDANSETRON	ONDANSETRON	CN1C2=C(C3=C1C=CC=C3)C(=O)C(CN4C=CN=C4C)CC2	PLASMA	4AF302ESOS							24		t	ng × h/mL	270.928							mg	8		SINGLE								Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00934921	Homo sapiens										false
4750	2282		ADULT	4595	293.363	ONDANSETRON	ONDANSETRON	CN1C2=C(C3=C1C=CC=C3)C(=O)C(CN4C=CN=C4C)CC2	PLASMA	4AF302ESOS													ng/mL	26.2			RECOMMENDED	mg	8		SINGLE	UNKNOWN				Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.	27	HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020103s035_020605s019_020781s019lbl.pdf	Homo sapiens		h	3.1							false
4751	2282		ADULT	4595	293.363	ONDANSETRON	ONDANSETRON	CN1C2=C(C3=C1C=CC=C3)C(=O)C(CN4C=CN=C4C)CC2	PLASMA	4AF302ESOS													ng/mL	42.7			RECOMMENDED	mg	8		SINGLE	UNKNOWN				Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.		HEALTHY	Oral	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020103s035_020605s019_020781s019lbl.pdf	Homo sapiens		h	3.5							false
4752	2282		ADULT	4595	293.363	ONDANSETRON	ONDANSETRON	CN1C2=C(C3=C1C=CC=C3)C(=O)C(CN4C=CN=C4C)CC2	PLASMA	4AF302ESOS													ng/mL	125.8			MAX DAILY	mg	24		SINGLE	UNKNOWN				Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.		HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020103s035_020605s019_020781s019lbl.pdf	Homo sapiens		h	4.7							false
4753	2282		ADULT	4595	293.363	ONDANSETRON	ONDANSETRON	CN1C2=C(C3=C1C=CC=C3)C(=O)C(CN4C=CN=C4C)CC2	PLASMA	4AF302ESOS													ng/mL	194.4			MAX DAILY	mg	24		SINGLE	UNKNOWN				Plasma protein binding of ondansetron as measured in vitro was 70% to 76% over the concentration range of 10 to 500 ng/mL.		HEALTHY	Oral	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020103s035_020605s019_020781s019lbl.pdf	Homo sapiens		h	5.8							false
4754	2283		ADULT	4601	269.3813	ORPHENADRINE	orphenadrine	CN(C)CCOC(C1=CC=CC=C1)C2=C(C)C=CC=C2	PLASMA	AL805O9OG9									∞	ng × h/mL	1739.15		ng/mL	41.89			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	REVIEW	https://www.accessdata.fda.gov/drugsatfda_docs/anda/99/40249_Orphenadrine%20Citrate_Bioeqr.pdf	Homo sapiens		h	21.02							false
4755	2283		ADULT	4601	269.3813	ORPHENADRINE	orphenadrine	CN(C)CCOC(C1=CC=CC=C1)C2=C(C)C=CC=C2	PLASMA	AL805O9OG9									∞	ng × h/mL	1772.44		ng/mL	49.19			UNKNOWN	mg	100		SINGLE	FED						HEALTHY	Oral	MALE	REVIEW	https://www.accessdata.fda.gov/drugsatfda_docs/anda/99/40249_Orphenadrine%20Citrate_Bioeqr.pdf	Homo sapiens		h	22.29							false
4756	2283			4601	269.3813	ORPHENADRINE	orphenadrine	CN(C)CCOC(C1=CC=CC=C1)C2=C(C)C=CC=C2	PLASMA	AL805O9OG9																										Plasma protein binding (93 %), ultrafiltration (100 mcM drug, 475 mcM plasma protein)	7				EXPERIMENT	https://www.sciencedirect.com/science/article/pii/S0021967307003342?via%3Dihub	Homo sapiens										false
4757	2284		ADULT	5284603	315.3636	OXYCODONE	OXYCODONE	COC1=CC=C2C[C@H]3N(C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O	PLASMA	CD35PMG570									?	ng × h/mL	268.2		ng/mL	39.3			RECOMMENDED	mg	30		SINGLE	UNKNOWN					55	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	Homo sapiens		h	3.85							false
4758	2284		ADULT	5284603	315.3636	OXYCODONE	OXYCODONE	COC1=CC=C2C[C@H]3N(C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O	PLASMA	CD35PMG570									?	ng × h/mL	105		ng/mL	19			UNKNOWN	mg	10		SINGLE	FASTED					55	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	Homo sapiens		h	2.9							false
4759	2284		ADULT	5284603	315.3636	OXYCODONE	OXYCODONE	COC1=CC=C2C[C@H]3N(C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O	PLASMA	CD35PMG570									?	ng × h/mL	133		ng/mL	17.7			UNKNOWN	mg	10		SINGLE	FED					55	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	Homo sapiens		h	3.3							false
4760	2284		ADULT	5284603	315.3636	OXYCODONE	OXYCODONE	COC1=CC=C2C[C@H]3N(C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O	PLASMA	CD35PMG570									?	ng × h/mL	128.2		ng/mL	22.2			RECOMMENDED	mg	15		SINGLE	UNKNOWN					55	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	Homo sapiens		h	3.55							false
4761	2284		ADULT	5284603	315.3636	OXYCODONE	OXYCODONE	COC1=CC=C2C[C@H]3N(C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O	PLASMA	CD35PMG570									t	ng × h/mL	113.3		ng/mL	15.7			RECOMMENDED	mg	5		STEADY-STATE	UNKNOWN		day	4		55	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	Homo sapiens										false
4762	2284		UNKNOWN	5284603	315.3636	OXYCODONE	OXYCODONE	COC1=CC=C2C[C@H]3N(C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O	PLASMA	CD35PMG570									t	ng × h/mL	99		ng/mL	12.9			RECOMMENDED	mg	3.33		STEADY-STATE	UNKNOWN		day	6		55	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf	Homo sapiens										false
4763	2285		ADULT	441278	285.4238	PENTAZOCINE	PENTAZOCINE	C[C@H]1[C@H]2CC3=CC=C(O)C=C3[C@]1(C)CCN2CC=C(C)C	PLASMA	RP4A60D26L									?	ng × h/mL	536		ng/mL	102			UNKNOWN	mg	40		SINGLE	UNKNOWN						HEALTHY	Intramuscular	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3709032/	Homo sapiens		h	4.6							false
4764	2285		ADULT	441278	285.4238	PENTAZOCINE	PENTAZOCINE	C[C@H]1[C@H]2CC3=CC=C(O)C=C3[C@]1(C)CCN2CC=C(C)C	PLASMA	RP4A60D26L									?	ng × h/mL	1311		ng/mL	227			UNKNOWN	mg	80		SINGLE	UNKNOWN						HEALTHY	Intramuscular	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3709032/	Homo sapiens		h	5.3							false
4765	2286		ADULT	77991	250.3367	RIVASTIGMINE	RIVASTIGMINE	CCN(C)C(=O)OC1=CC(=CC=C1)[C@H](C)N(C)C	PLASMA	PKI06M3IW0									∞	ng × h/mL	129.46		ng/mL	37.23			RECOMMENDED	mg	6		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28670911	Homo sapiens		h	1.76							false
4766	2286		UNKNOWN	77991	250.3367	RIVASTIGMINE	RIVASTIGMINE	CCN(C)C(=O)OC1=CC(=CC=C1)[C@H](C)N(C)C	PLASMA	PKI06M3IW0																						UNKNOWN				Rivastigmine is weakly bound to plasma proteins (approximately 40%) over the therapeutic range.	60	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020823s032%2C021025s022lbl.pdf	Homo sapiens										false
4767	2287		UNKNOWN	441243	670.8408	SAQUINAVIR	Saquinavir	CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(N)=O)NC(=O)C4=NC5=C(C=CC=C5)C=C4	PLASMA	L3JE09KZ2F							24		t	ng × h/mL	21747						UNKNOWN	mg	1200		STEADY-STATE	UNKNOWN		day	3			UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021785s001,002,020828s019,020,020628s022,023lbl.pdf	Homo sapiens										false
4768	2288		ADULT	26757	187.2808	SELEGILINE	C[C@H](CC1=CC=CC=C1)N(C)CC#C	C[C@H](CC1=CC=CC=C1)N(C)CC#C	PLASMA	2K1V7GP655																	RECOMMENDED	mg	1.25		SINGLE	UNKNOWN				Up to 85% of plasma selegiline is reversibly bound to proteins.	15	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021479s005lbl.pdf	Homo sapiens		h	1.3							false
4769	2288		ADULT	26757	187.2808	SELEGILINE	SELEGILINE	C[C@H](CC1=CC=CC=C1)N(C)CC#C	PLASMA	2K1V7GP655							5		t	ng × h/mL	11		ng/mL	8.9			DEFINED DAILY	mg	10		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/10215747	Homo sapiens		h	1.8							false
4770	2289		ADULT	5358	295.4	SUMATRIPTAN	SUMATRIPTAN	CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1	PLASMA	8R78F6L9VO									∞	ng × h/mL	43		ng/mL	77			UNKNOWN	mg	3		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7768259/	Homo sapiens		h	1.6							false
4771	2289		ADULT	5358	295.4	SUMATRIPTAN	SUMATRIPTAN	CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1	PLASMA	8R78F6L9VO									∞	ng × h/mL	41		ng/mL	42			UNKNOWN	mg	3		SINGLE	FASTED						HEALTHY	Subcutaneous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7768259/	Homo sapiens		h	1.6							false
4772	2289		ADULT	5358	295.4	SUMATRIPTAN	sumatriptan	CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1	PLASMA	8R78F6L9VO									∞	ng × h/mL	105		ng/mL	80			UNKNOWN	mg	8		SINGLE	FASTED						HEALTHY	Subcutaneous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7768259/	Homo sapiens		h	2							false
4773	2289		ADULT	5358	295.4	SUMATRIPTAN	sumatriptan	CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1	PLASMA	8R78F6L9VO							12		t	ng × h/mL	44		ng/mL	18			RECOMMENDED	mg	25		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7768259/	Homo sapiens		h	1.5							false
4774	2289		ADULT	5358	295.4	SUMATRIPTAN	sumatriptan	CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1	PLASMA	8R78F6L9VO							12		t	ng × h/mL	83		ng/mL	29			RECOMMENDED	mg	50		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7768259/	Homo sapiens		h	1.5							false
4775	2289		ADULT	5358	295.4	SUMATRIPTAN	sumatriptan	CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1	PLASMA	8R78F6L9VO							12		t	ng × h/mL	158		ng/mL	49			RECOMMENDED	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7768259/	Homo sapiens		h	2							false
4776	2289		ADULT	5358	295.4	SUMATRIPTAN	sumatriptan	CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1	PLASMA	8R78F6L9VO							12		t	ng × h/mL	380		ng/mL	90			MAX DAILY	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7768259/	Homo sapiens		h	2.1							false
4777	2289		ADULT	5358	295.4	SUMATRIPTAN	sumatriptan	CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1	PLASMA	8R78F6L9VO							12		t	ng × h/mL	476		ng/mL	112			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7768259/	Homo sapiens		h	14.4							false
4778	2289		ADULT	5358	295.4	SUMATRIPTAN	sumatriptan	CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1	PLASMA	8R78F6L9VO							12		t	ng × h/mL	590		ng/mL	144			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7768259/	Homo sapiens		h	83							false
4779	2289		ADULT	5358	295.4	SUMATRIPTAN	sumatriptan	CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1	PLASMA	8R78F6L9VO									∞	ng × h/mL	239		ng/mL	194			UNKNOWN	mg	16		SINGLE	FASTED						HEALTHY	Subcutaneous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7768259/	Homo sapiens		h	2.1							false
4780	2289		ADULT	5358	295.4	SUMATRIPTAN	sumatriptan	CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1	PLASMA	8R78F6L9VO									∞	ng × h/mL	14		ng/mL	12			UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Subcutaneous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7768259/	Homo sapiens		h	2							false
4781	2290		ADULT	1549008	291.4299	TERBINAFINE	TERBINAFINE	CN(C\\C=C\\C#CC(C)(C)C)CC1=C2C=CC=CC2=CC=C1	PLASMA	G7RIW8S0XP									?	μg × h/mL	4.74		μg/mL	1.34			DEFINED DAILY	mg	250		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8593011/	Homo sapiens										false
4782	2290		ADULT	1549008	291.4299	TERBINAFINE	TERBINAFINE	CN(C\\C=C\\C#CC(C)(C)C)CC1=C2C=CC=CC2=CC=C1	PLASMA	G7RIW8S0XP							24		t	μg × h/mL	10.48		μg/mL	1.7			RECOMMENDED	mg	250		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8593011/	Homo sapiens		day	16.5							false
4783	2290		UNKNOWN	1549008	291.4299	TERBINAFINE	TERBINAFINE	CN(C\\C=C\\C#CC(C)(C)C)CC1=C2C=CC=CC2=CC=C1	PLASMA	G7RIW8S0XP									?	μg × h/mL	4.56		μg/mL	1			DEFINED DAILY	mg	250		SINGLE	UNKNOWN				In plasma, terbinafine is >99% bound to plasma proteins and there are no specific binding sites.	1	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020539s021lbl.pdf	Homo sapiens		h	36							false
4784	2291		ADULT	5452	370.575	THIORIDAZINE	THIORIDAZINE	CSC1=CC2=C(SC3=C(C=CC=C3)N2CCC4CCCCN4C)C=C1	PLASMA	N3D6TG58NI									?	ng × h/mL	1338		ng/mL	131			RECOMMENDED	mg	50		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10952475	Homo sapiens		h	12.2							false
4785	2291		ADULT	5452	370.575	THIORIDAZINE	THIORIDAZINE	CSC1=CC2=C(SC3=C(C=CC=C3)N2CCC4CCCCN4C)C=C1	PLASMA	N3D6TG58NI									∞	nM × h	709		nM	117			UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2007317	Homo sapiens		h	4.7							false
4786	2291		UNKNOWN	5452	370.575	THIORIDAZINE	Mellaril	CSC1=CC2=C(SC3=C(C=CC=C3)N2CCC4CCCCN4C)C=C1	PLASMA	N3D6TG58NI																						UNKNOWN				protein binding is high (more than 95%)	5	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.rxmed.com/b.main/b2.pharmaceutical/b2.1.monographs/cps-_monographs/CPS-_(General_Monographs-_M)/MELLARIL.html	Homo sapiens										false
4787	2292		ADULT	941651	443.625	THIOTHIXENE	THIOTHIXENE	CN(C)S(=O)(=O)C1=CC=C2SC3=C(C=CC=C3)\\C(=C\\CCN4CCN(C)CC4)C2=C1	SERUM	7318FJ13YJ							72		t	ng × h/mL	117		ng/mL	27.2			UNKNOWN	mg	20		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9447478	Homo sapiens		h	13.7							false
4788	2293		UNKNOWN	122130370	778.9323	VINORELBINE	VINORELBINE	CCC1=C[C@@H]2CN(C1)CC3=C(NC4=C3C=CC=C4)[C@@](C2)(C(=O)OC)C5=C(OC)C=C6N(C)[C@@H]7[C@]8(CCN9CC=C[C@](CC)([C@@H]89)[C@@H](OC(C)=O)[C@]7(O)C(=O)OC)C6=C5	PLASMA	Q6C979R91Y																						UNKNOWN				The binding to plasma constituents in cancer patients ranged from 79.6% to 91.2%	14.6	UNHEALTHY		UNKNOWN	DRUG LABEL	https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/6a16e044-7d0e-44bd-8e7e-588a5063935f/spl-doc?hl=VINORELBINE	Homo sapiens										false
4789	2293		ADULT	5311497	778.39417	VINORELBINE	VINORELBINE	CCC1=C[C@@H]2C[N@](C1)CC3=C(NC4=CC=CC=C34)[C@@](C2)(C(=O)OC)C5=C(OC)C=C6N(C)[C@@H]7[C@]8(CCN9CC=C[C@](CC)([C@@H]89)[C@@H](OC(C)=O)[C@]7(O)C(=O)OC)C6=C5	PLASMA	Q6C979R91Y									∞	ng × h/mL	1299		ng/mL	133.4			UNKNOWN	mg/m²	80		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/11822766	Homo sapiens		h	29.4							false
4790	2293		ADULT	5311497	778.39417	VINORELBINE	VINORELBINE	CCC1=C[C@@H]2C[N@](C1)CC3=C(NC4=CC=CC=C34)[C@@](C2)(C(=O)OC)C5=C(OC)C=C6N(C)[C@@H]7[C@]8(CCN9CC=C[C@](CC)([C@@H]89)[C@@H](OC(C)=O)[C@]7(O)C(=O)OC)C6=C5	PLASMA	Q6C979R91Y									∞	ng × h/mL	1042		ng/mL	761.8			UNKNOWN	mg/m²	25		SINGLE	FASTED						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/11822766	Homo sapiens		h	37.9							false
4791	2294		ADULT		263.37	DESVENLAFAXINE			PLASMA										∞	ng × h/mL	591		ng/mL	39.6			RECOMMENDED	mg	75		SINGLE	FASTED				Plasma protein binding of desvenlafaxine is 30% and is independent of drug concentration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/204150s010lbl.pdf	70	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19142106/	Homo sapiens		h	10.9							false
4792	2295		UNKNOWN	30323	527.5199	DAUNORUBICIN	DAUNORUBICIN	COC1=CC=CC2=C1C(=O)C3=C(C2=O)C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O)C(C)=O	PLASMA	ZS7284E0ZP																						UNKNOWN				Protein binding 97%	3	UNKNOWN		UNKNOWN	REVIEW	https://clincancerres.aacrjournals.org/content/clincanres/early/2017/06/26/1078-0432.CCR-16-3083.full.pdf	Homo sapiens										false
4793	2295		ADULT	30323	527.5	DAUNORUBICIN	DAUNORUBICIN	COC1=CC=CC2=C1C(=O)C3=C(O)C4=C(C[C@](O)(C[C@@H]4O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C(C)=O)C(O)=C3C2=O	PLASMA	ZS7284E0ZP	6253		Cytarabine	Cytarabine	C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O	04079A1RDZ			?	μg × h/mL	637		μg/mL	26			RECOMMENDED	mg/m²	44		MULTIPLE	UNKNOWN		2 days	1			UNHEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209401s000lbl.pdf	Homo sapiens		h	31.5							true
4794	2298		ADULT	154100|11021937|67108156	269.767	METHYLPHENIDATE HYDROCHLORIDE	METHYLPHENIDATE HYDROCHLORIDE	Cl.COC(=O)[C@@H]([C@H]1CCCCN1)C2=CC=CC=C2	PLASMA	4B3SC438HI									∞	ng × h/mL	41.8		ng/mL	3.7			UNKNOWN	mg	18		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021121s038lbl.pdf	Homo sapiens		h	3.5							false
4795	2298		UNKNOWN	154100|11021937|67108156	269.767	METHYLPHENIDATE HYDROCHLORIDE	METHYLPHENIDATE HYDROCHLORIDE	Cl.COC(=O)[C@@H]([C@H]1CCCCN1)C2=CC=CC=C2	PLASMA	4B3SC438HI																	UNKNOWN				UNKNOWN	UNKNOWN				Binding of methylphenidate to plasma proteins is low (10% to 33%).	90	UNKNOWN	UNKNOWN	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/010187s091,018029s059lbl.pdf	Homo sapiens										false
4796	2299		ADULT	5320|5969238|6456071	214.242	SULFACETAMIDE	SULFACETAMIDE	CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1	PLASMA	4965G3J0F5									∞	μg × h/mL	1803		μg/mL	99.2			UNKNOWN	mg	750		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6663474/	Homo sapiens		h	10.3							false
4797	2299		ADULT	5320|5969238|6456071	214.242	SULFACETAMIDE	SULFACETAMIDE	CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1	PLASMA	4965G3J0F5																	UNKNOWN				SINGLE	UNKNOWN				It is bound to plasma protein to the extent of15 to 18%	82	UNKNOWN	Ocular	UNKNOWN	REVIEW	https://sci-hub.st/https://www.sciencedirect.com/science/article/pii/S0099542808606103	Homo sapiens		h	13							false
4798	2300		ADULT	6042|23423984	300.808	THIAMINE	thiamine	[Cl-].CC1=C(CCO)SC=[N+]1CC2=C(N)N=C(C)N=C2	BLOOD	X66NSO3N35							10		t	nM × h	214		nM	40			UNKNOWN	mg	100		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22305197/	Homo sapiens										false
4799	2300		ADULT	6042|23423984	300.808	THIAMINE	thiamine	[Cl-].CC1=C(CCO)SC=[N+]1CC2=C(N)N=C(C)N=C2	PLASMA	X66NSO3N35							10		t	nM × h	177		nM	39			UNKNOWN	mg	100		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22305197/	Homo sapiens										false
4800	2300		ADULT	6042|23423984	300.808	THIAMINE	thiamine	[Cl-].CC1=C(CCO)SC=[N+]1CC2=C(N)N=C(C)N=C2	BLOOD	X66NSO3N35							10		t	nM × h	623		nM	95			UNKNOWN	mg	500		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22305197/	Homo sapiens										false
4801	2300		ADULT	6042|23423984	300.808	THIAMINE	thiamine	[Cl-].CC1=C(CCO)SC=[N+]1CC2=C(N)N=C(C)N=C2	PLASMA	X66NSO3N35							10		t	nM × h	612		nM	113			UNKNOWN	mg	500		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22305197/	Homo sapiens		h	3.92							false
4802	2300		ADULT	6042|23423984	300.808	THIAMINE	thiamine	[Cl-].CC1=C(CCO)SC=[N+]1CC2=C(N)N=C(C)N=C2	BLOOD	X66NSO3N35							10		t	nM × h	2046		nM	386			UNKNOWN	mg	1500		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22305197/	Homo sapiens		h	4.78							false
4803	2300		ADULT	6042|23423984	300.808	THIAMINE	thiamine	[Cl-].CC1=C(CCO)SC=[N+]1CC2=C(N)N=C(C)N=C2	PLASMA	X66NSO3N35							10		t	nM × h	2059		nM	397			UNKNOWN	mg	1500		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22305197/	Homo sapiens		h	2.97							false
4804	2303		UNKNOWN	8944	352.4699	ANILERIDINE	ANILERIDINE	CCOC(=O)C1(CCN(CCC2=CC=C(N)C=C2)CC1)C3=CC=CC=C3	PLASMA	71Q1A3O279																						UNKNOWN				Protein binding > 95%	5	UNKNOWN		UNKNOWN	OTHER	https://go.drugbank.com/drugs/DB00913	Homo sapiens										false
4805	2304		ADULT	4737	226.2722	PENTOBARBITAL	PENTOBARBITAL	CCCC(C)C1(CC)C(=O)NC(=O)NC1=O	PLASMA	I4744080IR							24		t	μg × h/mL	8.2		μg/mL	1.15			RECOMMENDED	mg	50		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7062221/	Homo sapiens		h	50							false
4806	2305		ADULT	5288826	285.3377	MORPHINE	MORPHINE	CN1CC[C@@]23[C@H]4OC5=C2C(C[C@@H]1[C@@H]3C=C[C@@H]4O)=CC=C5O	PLASMA	76I7G6D29C							24		t	nM × h	165		nM	63			RECOMMENDED	mg	2		SINGLE	FASTED				morphine is 30 to 35% reversibly bound to plasma proteins. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019516s055lbl.pdf	65	HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://link.springer.com/article/10.2165/00003088-199324040-00007	Homo sapiens		h	15.1							false
4807	2306		ADULT	2244	180.1574	ASPIRIN	ASPIRIN	CC(=O)OC1=C(C=CC=C1)C(O)=O	PLASMA	R16CO5Y76E									∞	mg × h/L	10.31		mg/L	54.25			UNKNOWN	mg	500		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/24672263	Homo sapiens		h	0.322							false
4808	2306		ADULT	2244	180.1574	ASPIRIN	ASPIRIN	CC(=O)OC1=C(C=CC=C1)C(O)=O	PLASMA	R16CO5Y76E									∞	mg × h/L	5.12		mg/L	4.84			UNKNOWN	mg	500		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/24672263	Homo sapiens		h	0.422							false
4809	2306		UNKNOWN	2244	180.1574	ASPIRIN	ASPIRIN	CC(=O)OC1=C(C=CC=C1)C(O)=O	PLASMA	R16CO5Y76E																						UNKNOWN				Acetylsalicylic Acid fu 0.68	68	UNKNOWN		UNKNOWN	REVIEW	https://www.ncbi.nlm.nih.gov/pubmed/30115648	Homo sapiens										false
4810	2307		ADULT	44257|5282445|135398654	241.2471	SAPROPTERIN	SAPROPTERIN	C[C@H](O)[C@H](O)[C@H]1CNC2=C(N1)C(=O)N=C(N)N2	PLASMA	EGX657432I									∞	ng × h/mL	559		ng/mL	84.1			RECOMMENDED	mg/kg	10		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20206791/	Homo sapiens		h	3.67							false
4811	2309			60823	558.6398	ATORVASTATIN	ATORVASTATIN	CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C3=CC=C(F)C=C3)C4=CC=CC=C4	PLASMA	A0JWA85V8F							48		t	ng × h/mL	140.79							mg	80		SINGLE								Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00844376	Homo sapiens										false
4812	2309			60823	558.6398	ATORVASTATIN	ATORVASTATIN	CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C3=CC=C(F)C=C3)C4=CC=CC=C4	PLASMA	A0JWA85V8F									∞	ng × h/mL	142.86							mg	80		SINGLE								Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00844376	Homo sapiens										false
4813	2309			60823	558.6398	ATORVASTATIN	ATORVASTATIN	CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C3=CC=C(F)C=C3)C4=CC=CC=C4	PLASMA	A0JWA85V8F									?	ng × h/mL	137.49							mg	80		SINGLE								Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00844376	Homo sapiens										false
4814	2309			60823	558.6398	ATORVASTATIN	ATORVASTATIN	CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C3=CC=C(F)C=C3)C4=CC=CC=C4	PLASMA	A0JWA85V8F													ng/mL	33.24				mg	80		SINGLE								Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00844376	Homo sapiens										false
4815	2309			60823	558.6398	ATORVASTATIN	ATORVASTATIN	CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C3=CC=C(F)C=C3)C4=CC=CC=C4	PLASMA	A0JWA85V8F																		mg	80		SINGLE								Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00844376	Homo sapiens		h	7.21							false
4816	2309		ADULT	60823	558.6398	ATORVASTATIN	ATORVASTATIN	CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C3=CC=C(F)C=C3)C4=CC=CC=C4	BLOOD	A0JWA85V8F									∞	ng × h/mL	45		ng/mL	8.8			DEFINED DAILY	mg	20		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/29683561	Homo sapiens		h	6.2							false
4817	2309		UNKNOWN	60823	558.6398	ATORVASTATIN	ATORVASTATIN	CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C3=CC=C(F)C=C3)C4=CC=CC=C4	BLOOD	A0JWA85V8F									∞	ng × h/mL	35.04		ng/mL	9.52			DEFINED DAILY	mg	20		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/31450089	Homo sapiens		h	16.57							false
4818	2310			60606	321.822	CLOPIDOGREL	CLOPIDOGREL	COC(=O)[C@@H](N1CCC2=C(C1)C=CS2)C3=C(Cl)C=CC=C3	PLASMA	A74586SNO7									∞	ng × h/mL	1.09							mg	75		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02185534	Homo sapiens										false
4819	2310			60606	321.822	CLOPIDOGREL	CLOPIDOGREL	COC(=O)[C@@H](N1CCC2=C(C1)C=CS2)C3=C(Cl)C=CC=C3	PLASMA	A74586SNO7													ng/mL	0.521				mg	75		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02185534	Homo sapiens										false
4820	2310			60606	321.822	CLOPIDOGREL	CLOPIDOGREL	COC(=O)[C@@H](N1CCC2=C(C1)C=CS2)C3=C(Cl)C=CC=C3	PLASMA	A74586SNO7							36		t	ng × h/mL	0.767							mg	75		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02185534	Homo sapiens										false
4821	2310		ADULT	115366|24883467|138753050	419.9	CLOPIDOGREL BISULFATE	CLOPIDOGREL BISULFATE	OS(O)(=O)=O.COC(=O)[C@@H](N1CCC2=C(C1)C=CS2)C3=C(Cl)C=CC=C3	PLASMA	08I79HTP27							24		t	pg × h/mL	50600		pg/mL	15800			UNKNOWN	mg	300		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22128201	Homo sapiens		h	5.4							false
4822	2310		ADULT	115366|24883467|138753050	419.9	CLOPIDOGREL BISULFATE	CLOPIDOGREL BISULFATE	OS(O)(=O)=O.COC(=O)[C@@H](N1CCC2=C(C1)C=CS2)C3=C(Cl)C=CC=C3	PLASMA	08I79HTP27							24		t	pg × h/mL	9890		pg/mL	4600			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22128201	Homo sapiens		h	7.9							false
4823	2310		ADULT	115366|24883467|138753050	419.9	CLOPIDOGREL BISULFATE	CLOPIDOGREL BISULFATE	OS(O)(=O)=O.COC(=O)[C@@H](N1CCC2=C(C1)C=CS2)C3=C(Cl)C=CC=C3	PLASMA	08I79HTP27							24		t	pg × h/mL	7440		pg/mL	2520			RECOMMENDED	mg	75		MULTIPLE	FED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22128201	Homo sapiens		h	7.4							false
4824	2310		ADULT	115366|24883467|138753050	419.9	CLOPIDOGREL BISULFATE	CLOPIDOGREL BISULFATE	OS(O)(=O)=O.COC(=O)[C@@H](N1CCC2=C(C1)C=CS2)C3=C(Cl)C=CC=C3	PLASMA	08I79HTP27							24		t	pg × h/mL	3130		pg/mL	1500			RECOMMENDED	mg	75		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22128201	Homo sapiens		h	8.5							false
4825	2310		UNKNOWN	115366|24883467|138753050	419.9	CLOPIDOGREL BISULFATE	CLOPIDOGREL BISULFATE	OS(O)(=O)=O.COC(=O)[C@@H](N1CCC2=C(C1)C=CS2)C3=C(Cl)C=CC=C3	PLASMA	08I79HTP27																	UNKNOWN				UNKNOWN	UNKNOWN				Clopidogrel and the main circulating inactive metabolite bind reversibly in vitro to human plasma proteins (98% and 94%, respectively). The binding is nonsaturable in vitro up to a concentration of 100 mcg/mL.	2	UNKNOWN	UNKNOWN	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020839s044lbl.pdf	Homo sapiens										false
4826	2311		UNKNOWN	441384	670.743	ABACAVIR SULFATE	ABACAVIR SULFATE	OS(O)(=O)=O.NC1=NC2=C(N=CN2[C@@H]3C[C@H](CO)C=C3)C(NC4CC4)=N1.NC5=NC6=C(N=CN6[C@@H]7C[C@H](CO)C=C7)C(NC8CC8)=N5	PLASMA	J220T4J9Q2							12		t	μg × h/mL	6.02		μg/mL	3			RECOMMENDED	mg	300		STEADY-STATE	UNKNOWN		day	2	Binding of abacavir to human plasma proteins is approximately 50% and was independent of concentration.	50	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020977s033s034,020978s036s037lbl.pdf	Homo sapiens										false
4827	2311		UNKNOWN	441384	670.743	ABACAVIR SULFATE	ABACAVIR SULFATE	OS(O)(=O)=O.NC1=NC2=C(N=CN2[C@@H]3C[C@H](CO)C=C3)C(NC4CC4)=N1.NC5=NC6=C(N=CN6[C@@H]7C[C@H](CO)C=C7)C(NC8CC8)=N5	PLASMA	J220T4J9Q2									∞	μg × h/mL	11.95		μg/mL	4.26			RECOMMENDED	mg	600		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020977s033s034,020978s036s037lbl.pdf	Homo sapiens		h	1.54							false
4828	2312		ADULT	456255	462.503	CEFAMANDOLE	CEFAMANDOLE	CN1N=NN=C1SCC2=C(N3[C@H](SC2)[C@H](NC(=O)[C@H](O)C4=CC=CC=C4)C3=O)C(O)=O	PLASMA	5CKP8C2LLI									?	μg × min/mL	5934		μg/mL	113			RECOMMENDED	mg	15		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/671221/	Homo sapiens		min	23.64							false
4829	2314		ADULT	148192	704.8555	ATAZANAVIR	ATAZANAVIR	COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC2=CC=C(C=C2)C3=NC=CC=C3)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C	PLASMA	QZU4H47A3S									?	ng × h/mL	28132		ng/mL	5199			RECOMMENDED	mg	400		STEADY-STATE	FED		day	1	Atazanavir is 86% bound to human serum proteins and protein binding is independent of concentration. Atazanavir binds to both alpha-1-acid glycoprotein (AAG) and albumin to a similar extent (89% and 86%, respectively).	14	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021567s026lbl.pdf	Homo sapiens		h	7.9							false
4830	2314		ADULT	148192	704.8555	ATAZANAVIR	ATAZANAVIR	COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC2=CC=C(C=C2)C3=NC=CC=C3)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C	PLASMA	QZU4H47A3S									?	ng × h/mL	14874		ng/mL	2298			RECOMMENDED	mg	400		STEADY-STATE	FED		day	1			UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021567s026lbl.pdf	Homo sapiens		h	6.5							false
4831	2314		ADULT	148192	704.8555	ATAZANAVIR	ATAZANAVIR	COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC2=CC=C(C=C2)C3=NC=CC=C3)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C	PLASMA	QZU4H47A3S	392622		RITONAVIR	ritonavir	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4	O3J8G9O825			?	ng × h/mL	57039		ng/mL	6129			RECOMMENDED	mg	300		STEADY-STATE	FED		day	1			HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021567s026lbl.pdf	Homo sapiens		h	18.1							true
4832	2314		ADULT	148192	704.8555	ATAZANAVIR	ATAZANAVIR	COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC2=CC=C(C=C2)C3=NC=CC=C3)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C	PLASMA	QZU4H47A3S	392622		RITONAVIR	ritonavir	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4	O3J8G9O825			?	ng × h/mL	46073		ng/mL	4422			RECOMMENDED	mg	300		STEADY-STATE	FED		day	1			UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021567s026lbl.pdf	Homo sapiens		h	8.6							true
4833	2315		UNKNOWN	38101	244.2444	CARBIDOPA	CARBIDOPA	O.C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O	PLASMA	MNX7R8C5VO																						UNKNOWN				Plasma Protein Binding: about 36%	64	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.drugs.com/monograph/levodopa-carbidopa.html	Homo sapiens										false
4834	2315		ADULT	38101	244.2444	CARBIDOPA	CARBIDOPA	O.C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O	PLASMA	MNX7R8C5VO	6047|6971033		LEVODOPA	LEVODOPA	N[C@@H](CC1=CC=C(O)C(O)=C1)C(O)=O	46627O600J			∞	ng × h/mL	559.92		ng/mL	108.57			RECOMMENDED	mg	25		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/30295551	Homo sapiens		h	2.09							true
4835	2316		ADULT	33255	454.507	CEFAZOLIN	CEFAZOLIN	CC1=NN=C(SCC2=C(N3[C@H](SC2)[C@H](NC(=O)CN4C=NN=N4)C3=O)C(O)=O)S1	PLASMA	IHS69L0Y4T									∞	μg × h/mL	509.9		μg/mL	280.9			MAX TOLERATED	g	2		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050779s025lbl.pdf	Homo sapiens		h	2.01							false
4836	2317		ADULT	6533629	383.403	CEFTIZOXIME	CEFTIZOXIME	CO\\N=C(/C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O)C3=CSC(N)=N3	SERUM	C43C467DPE									∞	μg × h/L	68631		μg/L	34721			UNKNOWN	g	0.5		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26896348	Homo sapiens		h	2.57							false
4837	2317		ADULT	6533629	383.403	CEFTIZOXIME	CEFTIZOXIME	CO\\N=C(/C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O)C3=CSC(N)=N3	SERUM	C43C467DPE									?	mg × h/L	51						UNKNOWN	g	0.5		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6296034	Homo sapiens		h	1.8							false
4838	2318		ADULT	2771	324.3919	CITALOPRAM	CITALOPRAM	CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C3=CC=C(F)C=C3	PLASMA										∞	ng × h/mL	533.2		ng/mL	10.6			UNKNOWN	mg	10		SINGLE	FASTED					18	HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020822a_clinpharmr.pdf	Homo sapiens		h	36.3							false
4839	2318		ADULT	2771	324.3919	CITALOPRAM	CITALOPRAM	CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C3=CC=C(F)C=C3	PLASMA										∞	ng × h/mL	1010.4		ng/mL	21.7			DEFINED DAILY	mg	20		SINGLE	FASTED					18	HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020822a_clinpharmr.pdf	Homo sapiens		h	38.5							false
4840	2318		ADULT	2771	324.3919	CITALOPRAM	CITALOPRAM	CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C3=CC=C(F)C=C3	PLASMA										∞	ng × h/mL	2070.3		ng/mL	43.7			DEFINED DAILY	mg	40		SINGLE	FASTED					18	HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020822a_clinpharmr.pdf	Homo sapiens		h	40							false
4841	2318		ADULT	2771	324.3919	CITALOPRAM	CITALOPRAM	CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C3=CC=C(F)C=C3	PLASMA										∞	ng × h/mL	2946.5		ng/mL	65.6			UNKNOWN	mg	60		SINGLE	FASTED					18	HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020822a_clinpharmr.pdf	Homo sapiens		h	39.5							false
4842	2318		ADULT	162180	310.3654	DESMETHYLCITALOPRAM	demethylcitalopram	CNCCCC1(OCC2=C1C=CC(=C2)C#N)C3=CC=C(F)C=C3	PLASMA	3KBX9104IR									?	ng × h/mL	204.5		ng/mL	3.2			DEFINED DAILY	mg	20		SINGLE	FASTED					26	HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020822a_clinpharmr.pdf	Homo sapiens										false
4843	2318		ADULT	162180	310.3654	DESMETHYLCITALOPRAM	demethylcitalopram	CNCCCC1(OCC2=C1C=CC(=C2)C#N)C3=CC=C(F)C=C3	PLASMA	3KBX9104IR									∞	ng × h/mL	843.7		ng/mL	6.1			DEFINED DAILY	mg	40		SINGLE	FASTED					26	HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020822a_clinpharmr.pdf	Homo sapiens		h	79.3							false
4844	2318		ADULT	162180	310.3654	DESMETHYLCITALOPRAM	demethylcitalopram	CNCCCC1(OCC2=C1C=CC(=C2)C#N)C3=CC=C(F)C=C3	PLASMA	3KBX9104IR									∞	ng × h/mL	1153.2		ng/mL	8.5			UNKNOWN	mg	60		SINGLE	FASTED					26	HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020822a_clinpharmr.pdf	Homo sapiens		h	77.5							false
4845	2319		ADULT	5311065	1069.217	DESMOPRESSIN	DESMOPRESSIN	NC(=O)CC[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC3=CC=C(O)C=C3)NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N4CCC[C@H]4C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O	PLASMA	ENR1LLB0FP									?	pg × h/mL	483		pg/mL	98			RECOMMENDED	μg	300		SINGLE	UNKNOWN						HEALTHY	Nasal	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3141199/	Homo sapiens		h	3.62							false
4846	2320		ADULT	3042	309.4867	DICYCLOMINE	DICYCLOMINE	CCN(CC)CCOC(=O)C1(CCCCC1)C2CCCCC2	PLASMA	4KV4X8IF6V									∞	ng × h/mL	207.88		ng/mL	47.98			RECOMMENDED	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/anda/99/40230_Dicyclomine%20Hydrochloride_Bioeqr.pdf	Homo sapiens		h	6.09							false
4847	2320		ADULT	3042	309.4867	DICYCLOMINE	DICYCLOMINE	CCN(CC)CCOC(=O)C1(CCCCC1)C2CCCCC2	PLASMA	4KV4X8IF6V									∞	ng × h/mL	202.67		ng/mL	50.47			RECOMMENDED	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/anda/99/40230_Dicyclomine%20Hydrochloride_Bioeqr.pdf	Homo sapiens		h	6.66							false
4848	2320		UNKNOWN	3042	309.4867	DICYCLOMINE	dicyclomine	CCN(CC)CCOC(=O)C1(CCCCC1)C2CCCCC2	PLASMA	4KV4X8IF6V																	RECOMMENDED	mg	20		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/007409s041lbl.pdf	Homo sapiens		h	1.8							false
4849	2321		ADULT		326.3896	HYDRODOLASETRON	HYDRODOLASETRON	OC1C[N@]2[C@H]3CC(C[C@@H]2C[C@@H]1C3)OC(=O)C4=CNC5=CC=CC=C45	PLASMA	YC09CA0VBB													ng/mL	320			UNKNOWN	mg	100		SINGLE	UNKNOWN				69 to 77% of hydrodolasetron (dolasetron active metabolite) is bound to plasma protein	27	HEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020623s010lbl.pdf%2C020624s023lbl.pdf	Homo sapiens		h	7.3							false
4850	2321		ADULT		326.3896	HYDRODOLASETRON	HYDRODOLASETRON	OC1C[N@]2[C@H]3CC(C[C@@H]2C[C@@H]1C3)OC(=O)C4=CNC5=CC=CC=C45	PLASMA	YC09CA0VBB													ng/mL	556			UNKNOWN	mg	200		SINGLE	UNKNOWN				69 to 77% of hydrodolasetron (dolasetron active metabolite) is bound to plasma protein		HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020623s010lbl.pdf%2C020624s023lbl.pdf	Homo sapiens		h	8.1							false
4851	2322		ADULT	77992	243.3043	FROVATRIPTAN	FROVATRIPTAN	CN[C@@H]1CCC2=C(C1)C3=C(N2)C=CC(=C3)C(N)=O	PLASMA	H82Q2D5WA7									∞	ng × h/mL	50.7		ng/mL	2.44			DEFINED DAILY	mg	2.5		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25092964	Homo sapiens		h	29.3							false
4852	2322		UNKNOWN	77992	243.3043	FROVATRIPTAN	FROVATRIPTAN	CN[C@@H]1CCC2=C(C1)C3=C(N2)C=CC(=C3)C(N)=O	SERUM	H82Q2D5WA7																						UNKNOWN				Binding of frovatriptan to serum proteins is low (approximately 15%).	85	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf	Homo sapiens										false
4853	2323		ADULT	5282384	804.834	GATIFLOXACIN	GATIFLOXACIN	O.O.O.COC1=C(N2CCNC(C)C2)C(F)=CC3=C1N(C=C(C(O)=O)C3=O)C4CC4.COC5=C(N6CCNC(C)C6)C(F)=CC7=C5N(C=C(C(O)=O)C7=O)C8CC8	SERUM	L4618BD7KJ									∞	μg × h/mL	33		μg/mL	3.8			DEFINED DAILY	mg	400		SINGLE	UNKNOWN				Serum protein binding of gatifloxacin is approximately 20% in volunteers and is concentration independent.	80	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21061s023,024,21062s026,037lbl.pdf	Homo sapiens		h	7.8							false
4854	2323		ADULT	5282384	804.834	GATIFLOXACIN	GATIFLOXACIN	O.O.O.COC1=C(N2CCNC(C)C2)C(F)=CC3=C1N(C=C(C(O)=O)C3=O)C4CC4.COC5=C(N6CCNC(C)C6)C(F)=CC7=C5N(C=C(C(O)=O)C7=O)C8CC8	SERUM	L4618BD7KJ							24		t	μg × h/mL	34.4		μg/mL	4.2			RECOMMENDED	mg	400		STEADY-STATE	UNKNOWN		day	1	Serum protein binding of gatifloxacin is approximately 20% in volunteers and is concentration independent.	80	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21061s023,024,21062s026,037lbl.pdf	Homo sapiens		h	7.1							false
4855	2323		ADULT	5282384	804.834	GATIFLOXACIN	GATIFLOXACIN	O.O.O.COC1=C(N2CCNC(C)C2)C(F)=CC3=C1N(C=C(C(O)=O)C3=O)C4CC4.COC5=C(N6CCNC(C)C6)C(F)=CC7=C5N(C=C(C(O)=O)C7=O)C8CC8	SERUM	L4618BD7KJ							24		t	μg × h/mL	51		μg/mL	4.2			RECOMMENDED	mg	400		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21061s023,024,21062s026,037lbl.pdf	Homo sapiens										false
4856	2323		ADULT	5282384	804.834	GATIFLOXACIN	GATIFLOXACIN	O.O.O.COC1=C(N2CCNC(C)C2)C(F)=CC3=C1N(C=C(C(O)=O)C3=O)C4CC4.COC5=C(N6CCNC(C)C6)C(F)=CC7=C5N(C=C(C(O)=O)C7=O)C8CC8	SERUM	L4618BD7KJ									∞	μg × h/mL	35.1		μg/mL	5.5			DEFINED DAILY	mg	400		SINGLE	UNKNOWN				Serum protein binding of gatifloxacin is approximately 20% in volunteers and is concentration independent.	80	HEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21061s023,024,21062s026,037lbl.pdf	Homo sapiens		h	7.4							false
4857	2323		ADULT	5282384	804.834	GATIFLOXACIN	GATIFLOXACIN	O.O.O.COC1=C(N2CCNC(C)C2)C(F)=CC3=C1N(C=C(C(O)=O)C3=O)C4CC4.COC5=C(N6CCNC(C)C6)C(F)=CC7=C5N(C=C(C(O)=O)C7=O)C8CC8	SERUM	L4618BD7KJ							24		t	μg × h/mL	35.4		μg/mL	4.6			RECOMMENDED	mg	400		STEADY-STATE	UNKNOWN		day	1	Serum protein binding of gatifloxacin is approximately 20% in volunteers and is concentration independent.	80	HEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21061s023,024,21062s026,037lbl.pdf	Homo sapiens		h	13.9							false
4858	2324		ADULT	3518	198.3085	GUANETHIDINE	guanethidine	NC(=N)NCCN1CCCCCCC1	PLASMA	ZTI6C33Q2Q																	DEFINED DAILY	mg	160		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/374089/	Homo sapiens		day	1.5							false
4859	2324		ADULT	3518	198.3085	GUANETHIDINE	guanethidine	NC(=N)NCCN1CCCCCCC1	PLASMA	ZTI6C33Q2Q							24		t	μg × h/mL	2.68						UNKNOWN	mg	160		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/374089/	Homo sapiens										false
4860	2324		ADULT	3518	198.3085	GUANETHIDINE	guanethidine	NC(=N)NCCN1CCCCCCC1	PLASMA	ZTI6C33Q2Q							24		t	μg × h/mL	2.06						UNKNOWN	mg	80		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/374089/	Homo sapiens										false
4861	2324		ADULT	3518	198.3085	GUANETHIDINE	GUANETHIDINE	NC(=N)NCCN1CCCCCCC1	PLASMA	ZTI6C33Q2Q							24		t	μg × h/mL	0.3						UNKNOWN	mg	40		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/374089/	Homo sapiens										false
4862	2325		ADULT	60852	319.2289	IBANDRONIC ACID	IBANDRONATE	CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O	PLASMA	UMD7G2653W									∞	ng × h/mL	549.24		ng/mL	90.64			UNKNOWN	mg	150		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://synapse.koreamed.org/Synapse/Data/PDFData/1179TCP/tcp-22-22.pdf	Homo sapiens		h	32.38							false
4863	2326		UNKNOWN	3826	255.2686	KETOROLAC	KETOROLAC	OC(=O)C1CCN2C1=CC=C2C(=O)C3=CC=CC=C3	PLASMA	YZI5105V0L									∞	ng × h/mL	11152.8		ng/mL	2382.2			DEFINED DAILY	mg	30		SINGLE	UNKNOWN						UNHEALTHY	Intramuscular	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022382s000lbl.pdf	Homo sapiens		h	4.8							false
4864	2326		UNKNOWN	3826	255.2686	KETOROLAC	KETOROLAC	OC(=O)C1CCN2C1=CC=C2C(=O)C3=CC=CC=C3	PLASMA	YZI5105V0L									∞	ng × h/mL	7477.3		ng/mL	1805.8			UNKNOWN	mg	31.5		SINGLE	UNKNOWN						HEALTHY	Nasal	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022382s000lbl.pdf	Homo sapiens		h	5.24							false
4865	2327		ADULT	3033924	740.7503	LEVOFLOXACIN	LEVOFLOXACIN	O.C[C@H]1COC2=C(N3CCN(C)CC3)C(F)=CC4=C2N1C=C(C(O)=O)C4=O.C[C@H]5COC6=C(N7CCN(C)CC7)C(F)=CC8=C6N5C=C(C(O)=O)C8=O	UNKNOWN	6GNT3Y5LMF									∞	mg × h/L	19.88		mg/L	2.04			UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/9068926	Homo sapiens		h	5.97							false
4866	2327		ADULT	3033924	740.7503	LEVOFLOXACIN	LEVOFLOXACIN	O.C[C@H]1COC2=C(N3CCN(C)CC3)C(F)=CC4=C2N1C=C(C(O)=O)C4=O.C[C@H]5COC6=C(N7CCN(C)CC7)C(F)=CC8=C6N5C=C(C(O)=O)C8=O	UNKNOWN	6GNT3Y5LMF									∞	mg × h/L	111		mg/L	8.85			UNKNOWN	mg	1000		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/9068926	Homo sapiens		h	7.9							false
4867	2327		ADULT	3033924	740.7503	LEVOFLOXACIN	LEVOFLOXACIN	O.C[C@H]1COC2=C(N3CCN(C)CC3)C(F)=CC4=C2N1C=C(C(O)=O)C4=O.C[C@H]5COC6=C(N7CCN(C)CC7)C(F)=CC8=C6N5C=C(C(O)=O)C8=O	UNKNOWN	6GNT3Y5LMF							24		t	mg × h/L	118		mg/L	11.8			UNKNOWN	mg	1000		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/9068926	Homo sapiens		h	8.9							false
4868	2327		ADULT	3033924	740.7503	LEVOFLOXACIN	LEVOFLOXACIN	O.C[C@H]1COC2=C(N3CCN(C)CC3)C(F)=CC4=C2N1C=C(C(O)=O)C4=O.C[C@H]5COC6=C(N7CCN(C)CC7)C(F)=CC8=C6N5C=C(C(O)=O)C8=O	UNKNOWN	6GNT3Y5LMF							12		t	mg × h/L	59		mg/L	7.8			UNKNOWN	mg	500		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/9068926	Homo sapiens		h	8.4							false
4869	2327		ADULT	3033924	740.7503	LEVOFLOXACIN	LEVOFLOXACIN	O.C[C@H]1COC2=C(N3CCN(C)CC3)C(F)=CC4=C2N1C=C(C(O)=O)C4=O.C[C@H]5COC6=C(N7CCN(C)CC7)C(F)=CC8=C6N5C=C(C(O)=O)C8=O	UNKNOWN	6GNT3Y5LMF									∞	mg × h/L	55.3		mg/L	6.3			UNKNOWN	mg	500		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/9068926	Homo sapiens		h	6.6							false
4870	2327		ADULT	3033924	740.7503	LEVOFLOXACIN	LEVOFLOXACIN	O.C[C@H]1COC2=C(N3CCN(C)CC3)C(F)=CC4=C2N1C=C(C(O)=O)C4=O.C[C@H]5COC6=C(N7CCN(C)CC7)C(F)=CC8=C6N5C=C(C(O)=O)C8=O	UNKNOWN	6GNT3Y5LMF							12		t	mg × h/L	49.6		mg/L	7.9			UNKNOWN	mg	500		MULTIPLE	UNKNOWN		day	2			HEALTHY	Intravenous	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/9068926	Homo sapiens		h	7.6							false
4871	2329		ADULT	3052776	171.2383	RASAGILINE	RASAGILINE	C#CCN[C@@H]1CCC2=CC=CC=C12	PLASMA	003N66TS6T									∞	ng × h/mL	53.53		ng/mL	56.13			MAX DAILY	mg	10		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15628826	Homo sapiens		h	3.17							false
4872	2330		ADULT	19649	581.5741	STREPTOMYCIN	STREPTOMYCIN	CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]3NC(N)=N)O[C@@H](C)[C@]2(O)C=O	PLASMA	Y45QSO73OB									?	μg × h/mL	264		μg/mL	42.6			RECOMMENDED	mg/kg	18		SINGLE	UNKNOWN						UNHEALTHY	Intramuscular	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11560193/	Homo sapiens		h	2.67							false
4873	2331		UNKNOWN		822.0334	TACROLIMUS	TACROLIMUS	O.CO[C@@H]1C[C@@H](CC[C@H]1O)\\C=C(/C)[C@H]2OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@H](C[C@@H](C)C\\C(C)=C\\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)OC	BLOOD	WM0HAQ4WNM							24		t	ng × h/mL	372		ng/mL	26			UNKNOWN	mg/kg	0.2		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204096s000lbl.pdf	Homo sapiens										false
4874	2331		UNKNOWN		822.0334	TACROLIMUS	TACROLIMUS	O.CO[C@@H]1C[C@@H](CC[C@H]1O)\\C=C(/C)[C@H]2OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@H](C[C@@H](C)C\\C(C)=C\\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)OC	BLOOD	WM0HAQ4WNM							24		t	ng × h/mL	74		ng/mL	6.2			UNKNOWN	mg	4		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204096s000lbl.pdf	Homo sapiens										false
4875	2332		ADULT	443879	325.4876	TOLTERODINE	TOLTERODINE	CC(C)N(CC[C@H](C1=CC=CC=C1)C2=C(O)C=CC(C)=C2)C(C)C	PLASMA	WHE7A56U7K													μg/L	5.2			UNKNOWN	mg	4		MULTIPLE	UNKNOWN		day	2			UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-228_Detrol%20LA_BioPharmr.pdf	Homo sapiens		h	2.2		Extensive metabolizers		8			false
4876	2332		ADULT	443879	325.4876	TOLTERODINE	TOLTERODINE	CC(C)N(CC[C@H](C1=CC=CC=C1)C2=C(O)C=CC(C)=C2)C(C)C	PLASMA	WHE7A56U7K									∞	μg × h/L	23		μg/L	1.8			UNKNOWN	mg	8		SINGLE	HIGH-FAT						UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-228_Detrol%20LA_BioPharmr.pdf	Homo sapiens		h	8.1	PR capsule	Extensive metabolizers		16			false
4877	2332		ADULT	443879	325.4876	TOLTERODINE	TOLTERODINE	CC(C)N(CC[C@H](C1=CC=CC=C1)C2=C(O)C=CC(C)=C2)C(C)C	PLASMA	WHE7A56U7K													μg/L	38			UNKNOWN	mg	4		MULTIPLE	UNKNOWN		day	2			UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-228_Detrol%20LA_BioPharmr.pdf	Homo sapiens		h	9.6		Poor metabolizers					false
4878	2332		ADULT	443879	325.4876	TOLTERODINE	TOLTERODINE	CC(C)N(CC[C@H](C1=CC=CC=C1)C2=C(O)C=CC(C)=C2)C(C)C	PLASMA	WHE7A56U7K									∞	μg × h/L	27		μg/L	2.3			UNKNOWN	mg	8		SINGLE	FASTED						UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-228_Detrol%20LA_BioPharmr.pdf	Homo sapiens		h	7.9	PR capsule	Extensive metabolizers		16			false
4879	2332		ADULT	443879	325.4876	TOLTERODINE	TOLTERODINE	CC(C)N(CC[C@H](C1=CC=CC=C1)C2=C(O)C=CC(C)=C2)C(C)C	PLASMA	WHE7A56U7K													μg/L	3.2			UNKNOWN	mg	4		SINGLE	UNKNOWN				parameter dose-normalized from 4 to 2 mg		UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-228_Detrol%20LA_BioPharmr.pdf	Homo sapiens		h	2		Extensive metabolizers		8			false
4880	2332		ADULT	443879	325.4876	TOLTERODINE	TOLTERODINE	CC(C)N(CC[C@H](C1=CC=CC=C1)C2=C(O)C=CC(C)=C2)C(C)C	PLASMA	WHE7A56U7K													μg/L	20			UNKNOWN	mg	4		SINGLE	UNKNOWN				Cmax normalized back		HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-228_Detrol%20LA_BioPharmr.pdf	Homo sapiens		h	6.5		Poor metabolizers		8			false
4881	2333		ADULT	19493	133.1903	TRANYLCYPROMINE	N[C@@H]1C[C@H]1C2=CC=CC=C2	N[C@@H]1C[C@H]1C2=CC=CC=C2	PLASMA	3E3V44J4Z9									∞	ng × h/mL	373		ng/mL	112			UNKNOWN	mg	20		STEADY-STATE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/3757407	Homo sapiens		h	2.45							false
4882	2334		ADULT		810.9741	VINBLASTINE	vinblastine	CC[C@]1(O)C[C@@H]2CN(C1)CCC3=C(NC4=C3C=CC=C4)[C@@](C2)(C(=O)OC)C5=C(OC)C=C6N(C)[C@@H]7[C@]8(CCN9CC=C[C@](CC)([C@@H]89)[C@@H](OC(C)=O)[C@]7(O)C(=O)OC)C6=C5	SERUM	5V9KLZ54CY																						UNKNOWN				Binding was linear up to drug concentrations of 80-100 uM. At concentrations attained in therapy (10 nM) serum binding was high was found to be 99.7%	0.3	HEALTHY		UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6873152/	Homo sapiens										false
4883	2334		UNKNOWN		810.9741	VINBLASTINE	vinblastine	CC[C@]1(O)C[C@@H]2CN(C1)CCC3=C(NC4=C3C=CC=C4)[C@@](C2)(C(=O)OC)C5=C(OC)C=C6N(C)[C@@H]7[C@]8(CCN9CC=C[C@](CC)([C@@H]89)[C@@H](OC(C)=O)[C@]7(O)C(=O)OC)C6=C5	SERUM	5V9KLZ54CY																						UNKNOWN				Binding was linear up to drug concentrations of 80-100 uM. At concentrations attained in therapy (10 nM) serum binding was found to be 98.9%	1.1	UNHEALTHY		UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6873152/	Homo sapiens										false
4884	2334		UNKNOWN		810.9741	VINBLASTINE	vinblastine	CC[C@]1(O)C[C@@H]2CN(C1)CCC3=C(NC4=C3C=CC=C4)[C@@](C2)(C(=O)OC)C5=C(OC)C=C6N(C)[C@@H]7[C@]8(CCN9CC=C[C@](CC)([C@@H]89)[C@@H](OC(C)=O)[C@]7(O)C(=O)OC)C6=C5	SERUM	5V9KLZ54CY																	UNKNOWN	mg	7		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7070351/	Homo sapiens		h	31.4							false
4885	2334		UNKNOWN		810.9741	VINBLASTINE	vinblastine	CC[C@]1(O)C[C@@H]2CN(C1)CCC3=C(NC4=C3C=CC=C4)[C@@](C2)(C(=O)OC)C5=C(OC)C=C6N(C)[C@@H]7[C@]8(CCN9CC=C[C@](CC)([C@@H]89)[C@@H](OC(C)=O)[C@]7(O)C(=O)OC)C6=C5	SERUM	5V9KLZ54CY																	UNKNOWN	mg	10		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7070351/	Homo sapiens		h	26.2							false
4886	2334		UNKNOWN		810.9741	VINBLASTINE	vinblastine	CC[C@]1(O)C[C@@H]2CN(C1)CCC3=C(NC4=C3C=CC=C4)[C@@](C2)(C(=O)OC)C5=C(OC)C=C6N(C)[C@@H]7[C@]8(CCN9CC=C[C@](CC)([C@@H]89)[C@@H](OC(C)=O)[C@]7(O)C(=O)OC)C6=C5	SERUM	5V9KLZ54CY																	UNKNOWN	mg	14		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7070351/	Homo sapiens		h	16.7							false
4887	2334		UNKNOWN		810.9741	VINBLASTINE	vinblastine	CC[C@]1(O)C[C@@H]2CN(C1)CCC3=C(NC4=C3C=CC=C4)[C@@](C2)(C(=O)OC)C5=C(OC)C=C6N(C)[C@@H]7[C@]8(CCN9CC=C[C@](CC)([C@@H]89)[C@@H](OC(C)=O)[C@]7(O)C(=O)OC)C6=C5	SERUM	5V9KLZ54CY																	UNKNOWN	mg/kg	0.2		SINGLE	UNKNOWN						UNKNOWN	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/889590/	Homo sapiens		min	1173							false
4888	2335		ADULT	121586	290.1049	ZOLEDRONIC ACID	ZOLEDRONIC ACID	O.OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O	PLASMA	6XC1PAD3KF							24		t	ng × h/mL	420		ng/mL	264			UNKNOWN	mg	4		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/21563999	Homo sapiens		h	39							false
4889	2337		ADULT	60815	376.4467	REMIFENTANIL	REMIFENTANIL	CCC(=O)N(C1=CC=CC=C1)C2(CCN(CCC(=O)OC)CC2)C(=O)OC	BLOOD	P10582JYYK							72		t	ng × h/mL	745		ng/mL	14			UNKNOWN	μg/kg/h	6	infusion, 72 hour	OTHER	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/14766712	Homo sapiens		min	11.4							false
4890	2337		ADULT	131560	362.4	Remifentanil acid	Remifentanil acid	CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC(=O)O)C(=O)OC	BLOOD	E1EZX4S2E1							72		t	μg × h/mL	8080		μg/mL	194			UNKNOWN	μg/kg/h	6	infusion, 72 hour	OTHER	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/14766712	Homo sapiens		h	2.48							false
4891	2337		ADULT	60815	376.4467	REMIFENTANIL	REMIFENTANIL	CCC(=O)N(C1=CC=CC=C1)C2(CCN(CCC(=O)OC)CC2)C(=O)OC	PLASMA	P10582JYYK																	UNKNOWN	μg/kg/min	0.5	infusion, 1 min	OTHER	UNKNOWN		day	1	70% bound to plasma proteins of which two-thirds is binding to alpha-1-acid-glycoprotein.	30	UNHEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020630s020lbl.pdf	Homo sapiens										false
4892	2338		ADULT	2200	265.3529	ANTAZOLINE	Antazoline	C(N(CC1=CC=CC=C1)C2=CC=CC=C2)C3=NCCN3	PLASMA	DHA8014SS1									∞	mg × h/L	0.91		mg/L	2.02			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26895496/	Homo sapiens		h	2.29				10	Antazoline mesylate		false
4893	2339		UNKNOWN	6322|28782	174.201	ARGININE	L-arginine	N[C@@H](CCCNC(N)=N)C(O)=O	PLASMA	94ZLA3W45F																						UNKNOWN				in-vitro, dialysis	100	UNKNOWN		UNKNOWN	EXPERIMENT	https://www.jci.org/articles/view/103568	Homo sapiens										false
4894	2339		ADULT	6322|28782	174.201	ARGININE	L-arginine	N[C@@H](CCCNC(N)=N)C(O)=O	PLASMA	94ZLA3W45F									∞	M × min	265435		μM	6219			UNKNOWN	g	30		SINGLE	FED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1873701/	Homo sapiens		min	41.6							false
4895	2339		ADULT	6322|28782	174.201	ARGININE	L-arginine	N[C@@H](CCCNC(N)=N)C(O)=O	PLASMA	94ZLA3W45F									∞	M × min	38223		μM	882			UNKNOWN	g	6		SINGLE	FED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1873701/	Homo sapiens		min	59.6							false
4896	2339		ADULT	6322|28782	174.201	ARGININE	L-arginine	N[C@@H](CCCNC(N)=N)C(O)=O	PLASMA	94ZLA3W45F									∞	M × min	24788		μM	310			UNKNOWN	g	6		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1873701/	Homo sapiens		min	77.5							false
4897	2340		ADULT	5282372	317.361	IMIPENEM	IMIPENEM	O.C[C@@H](O)[C@@H]1[C@H]2CC(SCCNC=N)=C(N2C1=O)C(O)=O	BLOOD	71OTZ9ZE0A	6435415		CILASTATIN	Cilastatin	CC1(C)C[C@@H]1C(=O)N\\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O	141A6AMN38	6		t	mg × h/L	28.17		mg/L	15.86			DEFINED DAILY	g	0.5		MULTIPLE	UNKNOWN		day	4			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31124013	Homo sapiens		h	0.28							true
4898	2340		ADULT	5282372	317.361	IMIPENEM	IMIPENEM	O.C[C@@H](O)[C@@H]1[C@H]2CC(SCCNC=N)=C(N2C1=O)C(O)=O	BLOOD	71OTZ9ZE0A	6435415		CILASTATIN	Cilastatin	CC1(C)C[C@@H]1C(=O)N\\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O	141A6AMN38							mg/L	48.43			DEFINED DAILY	g	0.5		MULTIPLE	UNKNOWN		day	4			HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31124013	Homo sapiens										true
4899	2340		ADULT	5282372	317.361	IMIPENEM	IMIPENEM	O.C[C@@H](O)[C@@H]1[C@H]2CC(SCCNC=N)=C(N2C1=O)C(O)=O	PLASMA	71OTZ9ZE0A									?	mg × h/L	18.7						UNKNOWN	mg	250	bolus, 5 min	OTHER	UNKNOWN		week	1			HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6583194	Homo sapiens		h	1							false
4900	2340		ADULT	5282372	317.361	IMIPENEM	IMIPENEM	O.C[C@@H](O)[C@@H]1[C@H]2CC(SCCNC=N)=C(N2C1=O)C(O)=O	PLASMA	71OTZ9ZE0A									?	mg × h/L	36.5						UNKNOWN	mg	500	bolus, 5 min	OTHER	UNKNOWN		week	1			HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6583194	Homo sapiens		h	1							false
4901	2341		UNKNOWN	4086	211.2576	METAPROTERENOL	METAPROTERENOL	CC(C)NCC(O)C1=CC(O)=CC(O)=C1	PLASMA	53QOG569E0																	UNKNOWN				SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/1969785/	Homo sapiens		h	2.1							false
4902	2344		ADULT	6000	609.7312	TUBOCURARINE	TUBOCURARINE	COC1=CC2=C3C=C1OC4=C(O)C=CC(C[C@@H]5C6=C(CC[N+]5(C)C)C=C(OC)C(O)=C6OC7=CC=C(C[C@@H]3N(C)CC2)C=C7)=C4	PLASMA	W9YXS298BM									∞	μg × min/mL	117		μg/mL	1.173			INVESTIGATIONAL	μg/kg/min	16	infusion, 22 min	OTHER	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7114542/	Homo sapiens		min	89							false
4903	2346		ADULT	154101	233.3062	DEXMETHYLPHENIDATE	DEXMETHYLPHENIDATE	COC(=O)[C@@H]([C@H]1CCCCN1)C2=CC=CC=C2	PLASMA	M32RH9MFGP									∞	ng × h/mL	131.9		ng/mL	22.13			MAX DAILY	mg	20		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/14747426	Homo sapiens		h	2.81							false
4904	2346		ADULT	154101	233.3062	DEXMETHYLPHENIDATE	DEXMETHYLPHENIDATE	COC(=O)[C@@H]([C@H]1CCCCN1)C2=CC=CC=C2	PLASMA	M32RH9MFGP									∞	ng × h/mL	120.9		ng/mL	23.72			MAX DAILY	mg	20		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/14747426	Homo sapiens		h	2.68							false
4905	2346		ADULT	154101	233.3062	DEXMETHYLPHENIDATE	DEXMETHYLPHENIDATE	COC(=O)[C@@H]([C@H]1CCCCN1)C2=CC=CC=C2	PLASMA	M32RH9MFGP									∞	ng × h/mL	79.8		ng/mL	10.7			MAX DAILY	mg	20		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28590363	Homo sapiens		h	3.3							false
4906	2347		ADULT	54331|10199068	259.1941	FOSFOMYCIN TROMETHAMINE	FOSFOMYCIN TROMETHAMINE	C[C@@H]1O[C@@H]1P(O)(O)=O.NC(CO)(CO)CO	PLASMA	7FXW6U30GY									∞	μg × h/mL	191		μg/mL	26.8			RECOMMENDED	g	3		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28630194	Homo sapiens		h	9.04							false
4907	2347		UNKNOWN	54331|10199068	259.1941	FOSFOMYCIN TROMETHAMINE	FOSFOMYCIN TROMETHAMINE	C[C@@H]1O[C@@H]1P(O)(O)=O.NC(CO)(CO)CO	PLASMA	7FXW6U30GY																	UNKNOWN				UNKNOWN	UNKNOWN				Fosfomycin is not bound to plasma proteins.	100	UNKNOWN	UNKNOWN	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/050717s009lbl.pdf	Homo sapiens										false
4908	2348		ADULT	5509	257.2845	TOLMETIN	TOLMETIN	CN1C(CC(O)=O)=CC=C1C(=O)C2=CC=C(C)C=C2	PLASMA	D8K2JPN18B									∞	μg × h/mL	50.5		μg/mL	29.3			RECOMMENDED	mg	300		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1126116/	Homo sapiens		h	0.83							false
4909	2349		ADULT	3961	422.911	LOSARTAN	LOSARTAN	CCCCC1=NC(Cl)=C(CO)N1CC2=CC=C(C=C2)C3=C(C=CC=C3)C4=NN=NN4	PLASMA	JMS50MPO89							24		t	ng × h/mL	442		ng/mL	224			DEFINED DAILY	mg	50		MULTIPLE	UNKNOWN		day	1	Both losartan and its active metabolite are highly bound to plasma proteins, primarily albumin, with plasma free fractions of 1.3% and 0.2%, respectively.	1.3	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020386s062lbl.pdf	Homo sapiens		h	2.1							false
4910	2350		UNKNOWN	2484	317.4672	BUTENAFINE	BUTENAFINE	CN(CC1=CC=C(C=C1)C(C)(C)C)CC2=C3C=CC=CC3=CC=C2	BLOOD	91Y494NL0X							24		t	ng × h/mL	23.9		ng/mL	1.4			UNKNOWN	g	6		MULTIPLE	UNKNOWN		day	1			HEALTHY	Topical	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/20524s5lbl.pdf	Homo sapiens										false
4911	2350		UNKNOWN	2484	317.4672	BUTENAFINE	BUTENAFINE	CN(CC1=CC=C(C=C1)C(C)(C)C)CC2=C3C=CC=CC3=CC=C2	BLOOD	91Y494NL0X							24		t	ng × h/mL	87.8		ng/mL	5			UNKNOWN	g	20		MULTIPLE	UNKNOWN		day	1			HEALTHY	Topical	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/20524s5lbl.pdf	Homo sapiens		h	35							false
4912	2351		ADULT	71158	181.21	ACAMPROSATE	ACAMPROSATE	CC(=O)NCCCS([O-])(=O)=O	PLASMA	N4K14YGM3J									∞	ng × h/mL	3829.56		ng/mL	244.64			UNKNOWN	mg	666		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26360834	Homo sapiens		h	10.26							false
4913	2352		ADULT	1978	336.4259	ACEBUTOLOL	ACEBUTOLOL	CCCC(=O)NC1=CC(C(C)=O)=C(OCC(O)CNC(C)C)C=C1	PLASMA	67P356D8GH									∞	ng × h/mL	4492		ng/mL	92			RECOMMENDED	mg	400		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6884417/	Homo sapiens										false
4914	2352		UNKNOWN	1978	336.4259	ACEBUTOLOL	ACEBUTOLOL	CCCC(=O)NC1=CC(C(C)=O)=C(OCC(O)CNC(C)C)C=C1	PLASMA	67P356D8GH																	UNKNOWN				UNKNOWN	UNKNOWN				Sectral has a low binding affinity for plasma proteins (about 26%).	74	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018917s025lbl.pdf	Homo sapiens		h	4							false
4915	2353		ADULT	2088	249.1	ALENDRONATE	ALENDRONATE	NCCCC(O)(P(O)(O)=O)P(O)([O-])=O	PLASMA	X1J18R4W8P									∞	ng × h/mL	155.53		ng/mL	56.62			RECOMMENDED	mg	70		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/28744102	Homo sapiens		h	1.73							false
4916	2354		ADULT	51263	416.5172	ALFENTANIL	ALFENTANIL	CCN1N=NN(CCN2CCC(COC)(CC2)N(C(=O)CC)C3=CC=CC=C3)C1=O	PLASMA	1N74HM2BS7									∞	ng × min/mL	1985.7						UNKNOWN	mg	0.54		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7598917	Homo sapiens		min	60.1							false
4917	2354		ADULT	51263	416.5172	ALFENTANIL	ALFENTANIL	CCN1N=NN(CCN2CCC(COC)(CC2)N(C(=O)CC)C3=CC=CC=C3)C1=O	PLASMA	1N74HM2BS7									∞	ng × min/mL	1241.2		ng/mL	20.1			UNKNOWN	mg	0.54		SINGLE	UNKNOWN						HEALTHY	Nasal	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7598917	Homo sapiens		min	59.4							false
4918	2354		UNKNOWN	51263	416.5172	ALFENTANIL	ALFENTANIL	CCN1N=NN(CCN2CCC(COC)(CC2)N(C(=O)CC)C3=CC=CC=C3)C1=O	PLASMA	1N74HM2BS7																						UNKNOWN				Plasma protein binding of alfentanil is approximately 92%.	8	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019353s021lbl.pdf	Homo sapiens										false
4919	2355		ADULT	2092	389.4488	ALFUZOSIN	ALFUZOSIN	COC1=CC2=NC(=NC(N)=C2C=C1OC)N(C)CCCNC(=O)C3CCCO3	PLASMA	90347YTW5F							24		t	ng × h/mL	194		ng/mL	13.6			RECOMMENDED	mg	10		MULTIPLE	FED		day	1	Results of in vitro studies indicate that alfuzosin is moderately bound to human plasma proteins (82% to 90%), with linear binding over a wide concentration range (5 to 5,000 ng/mL).	14	HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021287s013lbl.pdf	Homo sapiens		h	10							false
4920	2356			5493444	551.7583	ALISKIREN	ALISKIREN	COCCCOC1=C(OC)C=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=C1	PLASMA	502FWN4Q32													ng/mL	273				mg	300		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01570686	Homo sapiens										false
4921	2356			5493444	551.7583	ALISKIREN	ALISKIREN	COCCCOC1=C(OC)C=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=C1	PLASMA	502FWN4Q32													ng/mL	252				mg	300		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01570686	Homo sapiens										false
4922	2356			5493444	551.7583	ALISKIREN	ALISKIREN	COCCCOC1=C(OC)C=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=C1	PLASMA	502FWN4Q32							24		t	ng × h/mL	1580							mg	300		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01570686	Homo sapiens										false
4923	2356			5493444	551.7583	ALISKIREN	ALISKIREN	COCCCOC1=C(OC)C=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=C1	PLASMA	502FWN4Q32							24		t	ng × h/mL	1540							mg	300		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01570686	Homo sapiens										false
4924	2356			5493444	551.7583	ALISKIREN	ALISKIREN	COCCCOC1=C(OC)C=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=C1	PLASMA	502FWN4Q32													ng/mL	108				mg	300		STEADY-STATE	FED		day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01570686	Homo sapiens										false
4925	2356			5493444	551.7583	ALISKIREN	ALISKIREN	COCCCOC1=C(OC)C=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=C1	PLASMA	502FWN4Q32													ng/mL	102				mg	300		STEADY-STATE	FED		day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01570686	Homo sapiens										false
4926	2356			5493444	551.7583	ALISKIREN	ALISKIREN	COCCCOC1=C(OC)C=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=C1	PLASMA	502FWN4Q32							24		t	ng × h/mL	872							mg	300		STEADY-STATE	FED		day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01570686	Homo sapiens										false
4927	2356			5493444	551.7583	ALISKIREN	ALISKIREN	COCCCOC1=C(OC)C=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=C1	PLASMA	502FWN4Q32							24		t	ng × h/mL	1100							mg	300		STEADY-STATE	FED		day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01570686	Homo sapiens										false
4928	2356		ADULT	5493444	551.7583	ALISKIREN	ALISKIREN	COCCCOC1=C(OC)C=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=C1	PLASMA	502FWN4Q32									∞	ng × h/mL	1399		ng/mL	290.2			RECOMMENDED	mg	300		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/18611061/	Homo sapiens		h	41							false
4929	2357		ADULT	123606	335.464	ALMOTRIPTAN	ALMOTRIPTAN	CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N3CCCC3)C=C2	PLASMA	1O4XL5SN61																	UNKNOWN				UNKNOWN	UNKNOWN				Almotriptan is minimally protein bound (approximately 35%)	65	UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021001s015lbl.pdf	Homo sapiens		h	3.5							false
4930	2357		ADULT	123606	335.464	ALMOTRIPTAN	ALMOTRIPTAN	CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N3CCCC3)C=C2	PLASMA	1O4XL5SN61									∞	ng × h/mL	312		ng/mL	52.6			RECOMMENDED	mg	12.5		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/12723463	Homo sapiens		h	6.1							false
4931	2358		ADULT	2099	294.351	ALOSETRON	ALOSETRON	CN1C2=C(C3=C1C=CC=C3)C(=O)N(CC4=C(C)N=CN4)CC2	SERUM	13Z9HTH115									∞	ng × h/mL	66.1		ng/mL	43.1			UNKNOWN	mg	2		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11874386	Homo sapiens		h	1.65							false
4932	2358		ADULT	2099	294.351	ALOSETRON	ALOSETRON	CN1C2=C(C3=C1C=CC=C3)C(=O)N(CC4=C(C)N=CN4)CC2	SERUM	13Z9HTH115									∞	ng × h/mL	36.6		ng/mL	14.6			UNKNOWN	mg	2		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11874386	Homo sapiens		h	1.44							false
4933	2358		ADULT	2099	294.351	ALOSETRON	ALOSETRON	CN1C2=C(C3=C1C=CC=C3)C(=O)N(CC4=C(C)N=CN4)CC2	SERUM	13Z9HTH115									∞	ng × h/mL	49.3		ng/mL	40.2			UNKNOWN	mg	2		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11874386	Homo sapiens		h	1.52							false
4934	2358		ADULT	2099	294.351	ALOSETRON	ALOSETRON	CN1C2=C(C3=C1C=CC=C3)C(=O)N(CC4=C(C)N=CN4)CC2	SERUM	13Z9HTH115									∞	ng × h/mL	24.6		ng/mL	9.35			UNKNOWN	mg	2		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11874386	Homo sapiens		h	1.45							false
4935	2358		ADULT	2099	294.351	ALOSETRON	ALOSETRON	CN1C2=C(C3=C1C=CC=C3)C(=O)N(CC4=C(C)N=CN4)CC2	SERUM	13Z9HTH115													ng/mL	5			DEFINED DAILY	mg	1		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021107s013lbl.pdf	Homo sapiens										false
4936	2358		ADULT	2099	294.351	ALOSETRON	ALOSETRON	CN1C2=C(C3=C1C=CC=C3)C(=O)N(CC4=C(C)N=CN4)CC2	SERUM	13Z9HTH115													ng/mL	9			DEFINED DAILY	mg	1		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021107s013lbl.pdf	Homo sapiens										false
4937	2358		UNKNOWN	2099	294.351	ALOSETRON	ALOSETRON	CN1C2=C(C3=C1C=CC=C3)C(=O)N(CC4=C(C)N=CN4)CC2	PLASMA	13Z9HTH115																						UNKNOWN				Plasma protein binding is 82% over a concentration range of 20 to 4,000 ng/mL.	18	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021107s013lbl.pdf	Homo sapiens										false
4938	2359		ADULT	137|7048523	131.1299	AMINOLEVULINIC ACID	AMINOLEVULINIC ACID	NCC(=O)CCC(O)=O	PLASMA	88755TAZ87									∞	μg × h/mL	13.7		μg/mL	15.44			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11961050/	Homo sapiens		min	50.1							false
4939	2359		ADULT	137|7048523	131.1299	AMINOLEVULINIC ACID	AMINOLEVULINIC ACID	NCC(=O)CCC(O)=O	PLASMA	88755TAZ87									∞	μg × h/mL	7.4		μg/mL	4.65			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11961050/	Homo sapiens		min	44.4				6			false
4940	2359		ADULT	137|7048523	131.1299	AMINOLEVULINIC ACID	AMINOLEVULINIC ACID	NCC(=O)CCC(O)=O	PLASMA	88755TAZ87									∞	μg × h/L	27143.5		μg/L	8239.1			RECOMMENDED	mg/kg bw	20		SINGLE	UNKNOWN				Across the concentration range of 0.05 to 5 μg/L, the mean protein binding of 5-ALA in human plasma was 12%	88	HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208630Orig1s000ClinPharmR.pdf	Homo sapiens		h	1.94				7			false
4941	2359		ADULT	137|7048523	131.1299	AMINOLEVULINIC ACID	AMINOLEVULINIC ACID	NCC(=O)CCC(O)=O	PLASMA	88755TAZ87									∞	μg × h/L	424.2		μg/L	274.7			UNKNOWN	mg/kg bw	0.2		SINGLE	UNKNOWN				Across the concentration range of 0.05 to 5 μg/L, the mean protein binding of 5-ALA in human plasma was 12%	88	HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208630Orig1s000ClinPharmR.pdf	Homo sapiens		h	0.75				7			false
4942	2359		ADULT	137|7048523	131.1299	AMINOLEVULINIC ACID	AMINOLEVULINIC ACID	NCC(=O)CCC(O)=O	PLASMA	88755TAZ87									∞	μg × h/L	2901.3		μg/L	1862.6			UNKNOWN	mg/kg bw	2		SINGLE	UNKNOWN				Across the concentration range of 0.05 to 5 μg/L, the mean protein binding of 5-ALA in human plasma was 12%	88	HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208630Orig1s000ClinPharmR.pdf	Homo sapiens		h	0.84				7			false
4943	2360		ADULT	2157	645.3116	AMIODARONE	amiodarone	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C3=C(O1)C=CC=C3	SERUM	N3RQ532IUT							96		t	ng × h/mL	3600		ng/mL	2920			UNKNOWN	mg/kg	1.25		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21052689/	Homo sapiens										false
4944	2360		ADULT	2157	645.3116	AMIODARONE	amiodarone	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C3=C(O1)C=CC=C3	SERUM	N3RQ532IUT							96		t	ng × h/mL	8100		ng/mL	7140			UNKNOWN	mg/kg	2.5		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21052689/	Homo sapiens										false
4945	2360		ADULT	2157	645.3116	AMIODARONE	amiodarone	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C3=C(O1)C=CC=C3	SERUM	N3RQ532IUT							96		t	ng × h/mL	16600		ng/mL	13660			UNKNOWN	mg/kg	5		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21052689/	Homo sapiens		day	14.6							false
4946	2360		ADULT		617.2584	DESETHYLAMIODARONE	Desethylamiodarone	CCCCC1=C(C(=O)C2=CC(I)=C(OCCNCC)C(I)=C2)C3=C(O1)C=CC=C3	SERUM	M31FU99E3Y													ng/mL	9			UNKNOWN	mg/kg	1.25		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21052689/	Homo sapiens										false
4947	2360		ADULT	104774	617.2584	DESETHYLAMIODARONE	Desethylamiodarone	CCCCC1=C(C(=O)C2=CC(I)=C(OCCNCC)C(I)=C2)C3=C(O1)C=CC=C3	SERUM	M31FU99E3Y													ng/mL	23.8			UNKNOWN	mg/kg	2.5		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21052689/	Homo sapiens										false
4948	2360		ADULT		617.2584	DESETHYLAMIODARONE	Desethylamiodarone	CCCCC1=C(C(=O)C2=CC(I)=C(OCCNCC)C(I)=C2)C3=C(O1)C=CC=C3	SERUM	M31FU99E3Y									∞	ng × h/mL	16900		ng/mL	41.2			UNKNOWN	mg/kg	5		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21052689/	Homo sapiens		day	14.2							false
4949	2360		ADULT	2157	645.3116	AMIODARONE	amiodarone	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C3=C(O1)C=CC=C3	PLASMA	N3RQ532IUT																	RECOMMENDED	mg	200		MULTIPLE	UNKNOWN		day	1		0.023	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3242577/	Homo sapiens										false
4950	2360		UNKNOWN	2157	645.3116	AMIODARONE	AMIODARONE	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C3=C(O1)C=CC=C3	SERUM	N3RQ532IUT													mg/L	1.7			DEFINED DAILY	mg	800		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6851030/	Homo sapiens		h	4.62							false
4951	2361		ADULT	62883	419.45	AMOXICILLIN	AMOXICILLIN	O.O.O.CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)C3=CC=C(O)C=C3)C(=O)N2[C@H]1C(O)=O	PLASMA	804826J2HU							6		t	μg × h/mL	37.6		μg/mL	11.8			RECOMMENDED	mg	500		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/836010/	Homo sapiens		h	0.5							false
4952	2362		ADULT	2182|135409400	256.088	ANAGRELIDE	ANAGRELIDE	ClC1=CC=C2NC3=NC(=O)CN3CC2=C1Cl	PLASMA	K9X45X0051									∞	ng × h/mL	28.39		ng/mL	10.28			RECOMMENDED	mg	2		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/19302911	Homo sapiens		h	1.38							false
4953	2363		ADULT	92721	526.649	ARGATROBAN	ARGATROBAN	O.C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)C2=C3NCC(C)CC3=CC=C2	PLASMA	IY90U61Z3S									∞	ng × h/mL	1727.7		ng/mL	538.6			UNKNOWN	μg/kg/min	2.5	infusion, 4 hour	OTHER	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10730687	Homo sapiens		min	60.6							false
4954	2363		UNKNOWN	92721	526.649	ARGATROBAN	ARGATROBAN	O.C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)C2=C3NCC(C)CC3=CC=C2	SERUM	IY90U61Z3S																						UNKNOWN				Argatroban is 54% bound to human serum proteins, with binding to albumin and α1-acid glycoprotein being 20% and 34%, respectively.	46	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022485lbl.pdf	Homo sapiens										false
4955	2364		ADULT	54841	255.35	Atomoxetine	Atomoxetine	CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2	PLASMA	ASW034S0B8									∞	ng × h/mL	2693.29		ng/mL	414.82			RECOMMENDED	mg	40		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23812961	Homo sapiens		h	3.64							false
4956	2364		UNKNOWN	54841	255.35	Atomoxetine	Atomoxetine	CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2	PLASMA	ASW034S0B8																						UNKNOWN				At therapeutic concentrations, 98% of atomoxetine in plasma is bound to protein, primarily albumin.	2	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021411s035lbl.pdf	Homo sapiens										false
4957	2365		ADULT	54360|50986914	418.359	AZELASTINE HYDROCHLORIDE	AZELASTINE HYDROCHLORIDE	Cl.CN1CCCC(CC1)N2N=C(CC3=CC=C(Cl)C=C3)C4=CC=CC=C4C2=O	PLASMA										?	pg × h/mL	1526.8		pg/mL	61.59			UNKNOWN	mg	0.28		SINGLE	UNKNOWN						HEALTHY	Nasal	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23681835	Homo sapiens										false
4958	2365		UNKNOWN	54360|50986914	418.359	AZELASTINE HYDROCHLORIDE	AZELASTINE HYDROCHLORIDE	Cl.CN1CCCC(CC1)N2N=C(CC3=CC=C(Cl)C=C3)C4=CC=CC=C4C2=O	PLASMA																		UNKNOWN				UNKNOWN	UNKNOWN				In vitro studies with human plasma indicate that the plasma protein binding of azelastine and its metabolite, desmethylazelastine, are approximately 88% and 97%, respectively.	12	UNKNOWN	UNKNOWN	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020114s028lbl.pdf	Homo sapiens		h	22							false
4959	2366		ADOLESCENT		357.3175	BALSALAZIDE	BALSALAZIDE	OC(=O)CCNC(=O)C1=CC=C(C=C1)\\N=N\\C2=CC(C(O)=O)=C(O)C=C2	PLASMA	P80AL8J7ZP							8		t	ng × h/mL	2031		ng/mL	452			DEFINED DAILY	mg	6.75		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/19633577	Homo sapiens										false
4960	2366		ADOLESCENT	4075|122508122	153.1354	MESALAMINE	5-aminosalicylic acid	NC1=CC=C(O)C(=C1)C(O)=O	PLASMA	4Q81I59GXC							8		t	ng × h/mL	1931		ng/mL	344			DEFINED DAILY	mg	6.25		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/19633577	Homo sapiens										false
4961	2367		ADULT	5362124	424.5	BENAZEPRIL	BENAZEPRIL	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCC3=C(C=CC=C3)N(CC(O)=O)C2=O	PLASMA	UDM7Q7QWP8							8		t	pmol × h/g	334		pmol/g	437			RECOMMENDED	mg	10		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/2344861	Homo sapiens		h	0.6							false
4962	2368		UNKNOWN	2351	366.5396	BEPRIDIL	BEPRIDIL	CC(C)COCC(CN(CC1=CC=CC=C1)C2=CC=CC=C2)N3CCCC3	PLASMA	755BO701MA																						UNKNOWN				Greater than 99.7% of added bepridil-14C was bound to freshly collected human plasma.	0.3	HEALTHY		UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/3875635	Homo sapiens										false
4963	2368		ADULT	2351	366.5396	BEPRIDIL	BEPRIDIL	CC(C)COCC(CN(CC1=CC=CC=C1)C2=CC=CC=C2)N3CCCC3	PLASMA	755BO701MA									∞	ng × h/mL	4.87		ng/mL	806			RECOMMENDED	mg	200		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/7650227	Homo sapiens		h	38.2							false
4964	2370		ADULT	60726	334.165	BROMFENAC	BROMFENAC	NC1=C(C=CC=C1CC(O)=O)C(=O)C2=CC=C(Br)C=C2	AQUEOUS HUMOR	864P0921DW									?	ng × h/mL	313.8		ng/mL	58.4			UNKNOWN	drop	1		SINGLE	UNKNOWN						UNHEALTHY	Ocular	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19049295	Homo sapiens		h	1.4							false
4965	2370		UNKNOWN	60726	334.165	BROMFENAC	BROMFENAC	NC1=C(C=CC=C1CC(O)=O)C(=O)C2=CC=C(Br)C=C2	PLASMA	864P0921DW																	UNKNOWN				UNKNOWN	UNKNOWN				Bromfenac showed high binding to plasma proteins. In vitro, the 99.8% were bound to proteins in human plasma.	0.2	UNKNOWN	UNKNOWN	UNKNOWN	OTHER GOV'T	https://www.ema.europa.eu/en/documents/assessment-report/yellox-epar-public-assessment-report_en.pdf	Homo sapiens										false
4966	2371		ADULT	31101	654.594	BROMOCRIPTINE	BROMOCRIPTINE	CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5=C(Br)NC6=C5C(=CC=C6)C4=C3)(O[C@@]2(O)[C@@H]7CCCN7C1=O)C(C)C	PLASMA	3A64E3G5ZO							24		t	pg × h/mL	2377		pg/mL	628			RECOMMENDED	mg	5		STEADY-STATE	UNKNOWN		day	1	In vitro experiments showed that bromocriptine was 90% - 96% bound to serum albumin.	4	UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017962s081lbl.pdf	Homo sapiens		h	4.85							false
4967	2372		ADULT	5282409	406.86	CARBINOXAMINE MALEATE	CARBINOXAMINE MALEATE	OC(=O)\\C=C/C(O)=O.CN(C)CCOC(C1=CC=C(Cl)C=C1)C2=CC=CC=N2	PLASMA	02O55696WH	10297		PHENYLPROPANOLAMINE	phenylpropanolamine	C[C@H](N)[C@H](O)C1=CC=CC=C1	33RU150WUN							ng/mL	16.9			UNKNOWN	mg	8		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1363194	Homo sapiens		h	14.5							true
4968	2372		UNKNOWN	5282409	406.86	CARBINOXAMINE MALEATE	CARBINOXAMINE MALEATE	OC(=O)\\C=C/C(O)=O.CN(C)CCOC(C1=CC=C(Cl)C=C1)C2=CC=CC=N2	PLASMA	02O55696WH																	UNKNOWN				UNKNOWN	UNKNOWN				Carbinoxamine binds to human plasma proteins in vitro (69%). It principally binds to a1-acid glycoprotein.	31	UNKNOWN	UNKNOWN	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17339039	Homo sapiens										false
4969	2372		ADULT	5282409	406.86	CARBINOXAMINE MALEATE	CARBINOXAMINE MALEATE	OC(=O)\\C=C/C(O)=O.CN(C)CCOC(C1=CC=C(Cl)C=C1)C2=CC=CC=N2	PLASMA	02O55696WH	6041		PHENYLEPHRINE	phenylephrine	CNC[C@H](O)C1=CC(O)=CC=C1	1WS297W6MV							ng/mL	4.5			UNKNOWN	mg	4		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7488301	Homo sapiens		h	30							true
4970	2372		ADULT	5282409	406.86	CARBINOXAMINE MALEATE	CARBINOXAMINE MALEATE	OC(=O)\\C=C/C(O)=O.CN(C)CCOC(C1=CC=C(Cl)C=C1)C2=CC=CC=N2	PLASMA	02O55696WH	6041		PHENYLEPHRINE	phenylephrine	CNC[C@H](O)C1=CC(O)=CC=C1	1WS297W6MV							ng/mL	13.5			UNKNOWN	mg	4		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7488301	Homo sapiens		h	22							true
4971	2373		ADULT	5281075	368.5075	CARBOPROST	CARBOPROST	CCCCC[C@](C)(O)\\C=C\\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\\C=C/CCCC(O)=O	PLASMA	7B5032XT6O							2		t	pg × h/mL	1332		pg/mL	2060			RECOMMENDED	μg	250		MULTIPLE	UNKNOWN		2 hours	1			PREGNANT	Intramuscular	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017989s019lbl.pdf	Homo sapiens		min	20							false
4972	2374		ADULT	2583	292.3734	CARTEOLOL	CARTEOLOL	CC(C)(C)NCC(O)COC1=CC=CC2=C1CCC(=O)N2	PLASMA	8NF31401XG									?	ng × h/mL	10.27		ng/mL	3.64			UNKNOWN	%	2		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Ocular	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16003515	Homo sapiens										false
4973	2374		UNKNOWN	2583	292.3734	CARTEOLOL	carteolol	CC(C)(C)NCC(O)COC1=CC=CC2=C1CCC(=O)N2	PLASMA	8NF31401XG																						UNKNOWN					40	UNKNOWN		UNKNOWN	REVIEW	https://www.ncbi.nlm.nih.gov/books/NBK501515/	Homo sapiens										false
4974	2374		ADULT	2583	292.3734	CARTEOLOL	carteolol	CC(C)(C)NCC(O)COC1=CC=CC2=C1CCC(=O)N2	PLASMA	8NF31401XG							24		t	ng × h/mL	12.7		ng/mL	0.998			RECOMMENDED	drop	1		SINGLE	UNKNOWN						HEALTHY	Ocular	MALE	REVIEW	https://www.pmda.go.jp/files/000223317.pdf	Homo sapiens		h	12.5							false
4975	2374		ADULT	2583	292.3734	CARTEOLOL	carteolol	CC(C)(C)NCC(O)COC1=CC=CC2=C1CCC(=O)N2	PLASMA	8NF31401XG							24		t	ng × h/mL	18		ng/mL	1.627			RECOMMENDED	drop	1		MULTIPLE	UNKNOWN		day	1			HEALTHY	Ocular	MALE	EXPERIMENT	https://www.pmda.go.jp/files/000223317.pdf	Homo sapiens		h	14.1							false
4976	2375		ADULT	51038	385.823	CEFACLOR	CEFACLOR	O.N[C@@H](C(=O)N[C@H]1[C@H]2SCC(Cl)=C(N2C1=O)C(O)=O)C3=CC=CC=C3	PLASMA	69K7K19H4L									∞	μg × h/mL	17.5		μg/mL	17.3			RECOMMENDED	mg	250		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2393282/	Homo sapiens		h	0.6							false
4977	2376		ADULT	6915944	395.414	CEFDINIR	CEFDINIR	NC1=NC(=CS1)C(=N\\O)\\C(=O)N[C@H]2[C@H]3SCC(C=C)=C(N3C2=O)C(O)=O	PLASMA	CI0FAO63WC									∞	μg × h/mL	4.08		μg/mL	1			UNKNOWN	mg	200		SINGLE	FASTED				Cefdinir is not an extensively bound drug (61%).	39	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7625793	Homo sapiens		h	1.43							false
4978	2376		ADULT	6915944	395.414	CEFDINIR	CEFDINIR	NC1=NC(=CS1)C(=N\\O)\\C(=O)N[C@H]2[C@H]3SCC(C=C)=C(N3C2=O)C(O)=O	PLASMA	CI0FAO63WC									∞	μg × h/mL	6.53		μg/mL	1.55			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7625793	Homo sapiens		h	1.46							false
4979	2376		ADULT	6915944	395.414	CEFDINIR	CEFDINIR	NC1=NC(=CS1)C(=N\\O)\\C(=O)N[C@H]2[C@H]3SCC(C=C)=C(N3C2=O)C(O)=O	PLASMA	CI0FAO63WC									∞	μg × h/mL	8.83		μg/mL	2.15			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7625793	Homo sapiens		h	1.43							false
4980	2376		ADULT	6915944	395.414	CEFDINIR	CEFDINIR	NC1=NC(=CS1)C(=N\\O)\\C(=O)N[C@H]2[C@H]3SCC(C=C)=C(N3C2=O)C(O)=O	PLASMA	CI0FAO63WC									∞	μg × h/mL	9.84		μg/mL	2.35			MAX DAILY	mg	600		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7625793	Homo sapiens		h	1.5							false
4981	2377		ADULT	5362065	453.4545	CEFIXIME		Nc1nc(cs1)\\C(=N\\OCC(=O)O)\\C(=O)N[C@H]2[C@H]3SCC(=C(N3C2=O)C(=O)O)C=C	SERUM	97I1C92E55									∞	μg × h/mL	14.99		μg/mL	1.95			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3693588/	Homo sapiens		h	2.29				12			false
4982	2377		ADULT	5362065	453.4545	CEFIXIME		Nc1nc(cs1)\\C(=N\\OCC(=O)O)\\C(=O)N[C@H]2[C@H]3SCC(=C(N3C2=O)C(=O)O)C=C	SERUM	97I1C92E55									∞	μg × h/mL	5.32		μg/mL	0.69			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3693588/	Homo sapiens		h	2.54				12			false
4983	2377		ADULT	5362065	453.4545	CEFIXIME		Nc1nc(cs1)\\C(=N\\OCC(=O)O)\\C(=O)N[C@H]2[C@H]3SCC(=C(N3C2=O)C(=O)O)C=C	SERUM	97I1C92E55									∞	μg × h/mL	8.66		μg/mL	1.13			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3693588/	Homo sapiens		h	2.38				12			false
4984	2377		ADULT	5362065	453.4545	CEFIXIME		Nc1nc(cs1)\\C(=N\\OCC(=O)O)\\C(=O)N[C@H]2[C@H]3SCC(=C(N3C2=O)C(=O)O)C=C	SERUM	97I1C92E55									?	mg × h/L	49.5		mg/L	5.68			UNKNOWN	mg	400		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202091s009lbl.pdf#page=12	Homo sapiens		h	4.2		Elderly adults		12			false
4985	2377		ADULT	5362065	453.4545	CEFIXIME		Nc1nc(cs1)\\C(=N\\OCC(=O)O)\\C(=O)N[C@H]2[C@H]3SCC(=C(N3C2=O)C(=O)O)C=C	SERUM	97I1C92E55									?	mg × h/L	34.9		mg/L	4.74			UNKNOWN	mg	400		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202091s009lbl.pdf#page=12	Homo sapiens		h	3.5		Young adults		12			false
4986	2377				453.4545	CEFIXIME			SERUM	97I1C92E55																										Serum protein binding is concentration independent with a bound fraction of approximately 65%.	35				DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202091s009lbl.pdf#page=12	Homo sapiens										false
4987	2377		ADULT	5362065	453.4545	CEFIXIME	Cefixime	Nc1nc(cs1)\\C(=N\\OCC(=O)O)\\C(=O)N[C@H]2[C@H]3SCC(=C(N3C2=O)C(=O)O)C=C	PLASMA	97I1C92E55									∞	μg × h/mL	30.211		μg/mL	3.696			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/202091Orig1s000ClinPharmR.pdf#page=23	Homo sapiens		h	3.479				24			false
4988	2377		ADULT	5362065	453.4545	CEFIXIME		Nc1nc(cs1)\\C(=N\\OCC(=O)O)\\C(=O)N[C@H]2[C@H]3SCC(=C(N3C2=O)C(=O)O)C=C	PLASMA	97I1C92E55									∞	μg × h/mL	15.864		μg/mL	1.837			UNKNOWN	mg	200		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/202091Orig1s000ClinPharmR.pdf#page=23	Homo sapiens		h	3.461				24			false
4989	2378		ADULT	9570757	511.558	CEFMENOXIME	CEFMENOXIME	CO\\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC3=NN=NN3C)=C(N2C1=O)C(O)=O)C4=CSC(N)=N4	SERUM	KBZ4844CXN									?	μg × h/mL	84						UNKNOWN	mg/kg bw	15		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6095752	Homo sapiens		h	1.06							false
4990	2378		ADULT	9570757	511.558	CEFMENOXIME	CEFMENOXIME	CO\\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC3=NN=NN3C)=C(N2C1=O)C(O)=O)C4=CSC(N)=N4	PLASMA	KBZ4844CXN													μg/mL	88.3			UNKNOWN	mg/kg bw	10		SINGLE	UNKNOWN				intermediate degree of protein binding (77%)	23	HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6098220	Homo sapiens		h	1.34							false
4991	2378		ADULT	9570757	511.558	CEFMENOXIME	CEFMENOXIME	CO\\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC3=NN=NN3C)=C(N2C1=O)C(O)=O)C4=CSC(N)=N4	PLASMA	KBZ4844CXN													μg/mL	95.5			UNKNOWN	mg/kg bw	10		SINGLE	UNKNOWN				intermediate degree of protein binding (77%)	23	UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6098220	Homo sapiens		h	8.14							false
4992	2379		ADULT	42008	471.534	CEFMETAZOLE	CEFMETAZOLE	CO[C@]1(NC(=O)CSCC#N)[C@H]2SCC(CSC3=NN=NN3C)=C(N2C1=O)C(O)=O	PLASMA	3J962UJT8H									∞	μg × h/mL	83.1						UNKNOWN	g	0.5		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2291659	Homo sapiens		h	1.5							false
4993	2379		ADULT	42008	471.534	CEFMETAZOLE	CEFMETAZOLE	CO[C@]1(NC(=O)CSCC#N)[C@H]2SCC(CSC3=NN=NN3C)=C(N2C1=O)C(O)=O	PLASMA	3J962UJT8H									∞	μg × h/mL	151						UNKNOWN	g	1		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2291659	Homo sapiens		h	1.43							false
4994	2379		ADULT	42008	471.534	CEFMETAZOLE	CEFMETAZOLE	CO[C@]1(NC(=O)CSCC#N)[C@H]2SCC(CSC3=NN=NN3C)=C(N2C1=O)C(O)=O	PLASMA	3J962UJT8H									∞	μg × h/mL	301						UNKNOWN	g	2		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2291659	Homo sapiens		h	1.3							false
4995	2380		ADULT	43507	519.554	CEFORANIDE	CEFORANIDE	NCC1=C(CC(=O)N[C@H]2[C@H]3SCC(CSC4=NN=NN4CC(O)=O)=C(N3C2=O)C(O)=O)C=CC=C1	SERUM	8M1YF8951V									∞	μg × h/mL	1.28		μg/mL	39			UNKNOWN	mg	250		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7073268	Homo sapiens		h	2.69							false
4996	2380		ADULT	43507	519.554	CEFORANIDE	CEFORANIDE	NCC1=C(CC(=O)N[C@H]2[C@H]3SCC(CSC4=NN=NN4CC(O)=O)=C(N3C2=O)C(O)=O)C=CC=C1	SERUM	8M1YF8951V									∞	μg × h/mL	227		μg/mL	71			UNKNOWN	mg	500		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7073268	Homo sapiens		h	2.65							false
4997	2380		ADULT	43507	519.554	CEFORANIDE	CEFORANIDE	NCC1=C(CC(=O)N[C@H]2[C@H]3SCC(CSC4=NN=NN4CC(O)=O)=C(N3C2=O)C(O)=O)C=CC=C1	SERUM	8M1YF8951V									∞	μg × h/mL	398		μg/mL	135			UNKNOWN	mg	1000		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7073268	Homo sapiens		h	2.68							false
4998	2380		ADULT	43507	519.554	CEFORANIDE	CEFORANIDE	NCC1=C(CC(=O)N[C@H]2[C@H]3SCC(CSC4=NN=NN4CC(O)=O)=C(N3C2=O)C(O)=O)C=CC=C1	SERUM	8M1YF8951V									∞	μg × h/mL	120		μg/mL	21			UNKNOWN	mg	250		SINGLE	UNKNOWN						HEALTHY	Intramuscular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7073268	Homo sapiens		h	3							false
4999	2380		ADULT	43507	519.554	CEFORANIDE	CEFORANIDE	NCC1=C(CC(=O)N[C@H]2[C@H]3SCC(CSC4=NN=NN4CC(O)=O)=C(N3C2=O)C(O)=O)C=CC=C1	SERUM	8M1YF8951V									∞	μg × h/mL	241		μg/mL	38			UNKNOWN	mg	500		SINGLE	UNKNOWN						HEALTHY	Intramuscular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7073268	Homo sapiens		h	2.89							false
5000	2380		ADULT	43507	519.554	CEFORANIDE	CEFORANIDE	NCC1=C(CC(=O)N[C@H]2[C@H]3SCC(CSC4=NN=NN4CC(O)=O)=C(N3C2=O)C(O)=O)C=CC=C1	SERUM	8M1YF8951V									∞	μg × h/mL	393		μg/mL	69			UNKNOWN	mg	1000		SINGLE	UNKNOWN						HEALTHY	Intramuscular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7073268	Homo sapiens		h	2.78							false
5001	2381		ADULT	6335986	427.455	CEFPODOXIME	CEFPODOXIME	COCC1=C(N2[C@H](SC1)[C@H](NC(=O)C(=N/OC)\\C3=CSC(N)=N3)C2=O)C(O)=O	PLASMA	7R4F94TVGY									∞	μg × h/mL	11.8		μg/mL	2.18			UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2393268/	Homo sapiens		h	2.7							false
5002	2381		ADULT	6335986	427.455	CEFPODOXIME	CEFPODOXIME	COCC1=C(N2[C@H](SC1)[C@H](NC(=O)C(=N/OC)\\C3=CSC(N)=N3)C2=O)C(O)=O	PLASMA	7R4F94TVGY									?	μg × h/mL	11.8		μg/mL	2.33			RECOMMENDED	mg	200		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2393268/	Homo sapiens		h	2.6							false
5003	2381		ADULT	6335986	427.455	CEFPODOXIME	CEFPODOXIME	COCC1=C(N2[C@H](SC1)[C@H](NC(=O)C(=N/OC)\\C3=CSC(N)=N3)C2=O)C(O)=O	PLASMA	7R4F94TVGY									∞	μg × h/mL	25		μg/mL	4.16			UNKNOWN	mg	400		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2393268/	Homo sapiens		h	2.6							false
5004	2381		ADULT	6335986	427.455	CEFPODOXIME	CEFPODOXIME	COCC1=C(N2[C@H](SC1)[C@H](NC(=O)C(=N/OC)\\C3=CSC(N)=N3)C2=O)C(O)=O	PLASMA	7R4F94TVGY									?	μg × h/mL	24		μg/mL	4.2			RECOMMENDED	mg	400		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2393268/	Homo sapiens		h	2.7							false
5005	2383		ADULT	6024	396.438	CEPHALOTHIN	CEPHALOTHIN	CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CC3=CC=CS3)C2=O)C(O)=O	PLASMA	R72LW146E6									∞	μg × h/mL	25.2		μg/mL	20.8			UNKNOWN	g	3		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15830475/	Homo sapiens		min	28							false
5006	2384		ADULT		349.406	CEPHRADINE	Cephradine		PLASMA	F1BC02I72W							12		t	μg × h/mL	27.5		μg/mL	17.7			RECOMMENDED	mg	500		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/848940/	Homo sapiens		h	0.61							false
5007	2385		CHILD	2678|74548902	388.888	CETIRIZINE	CETIRIZINE	OC(=O)COCCN1CCN(CC1)C(C2=CC=CC=C2)C3=CC=C(Cl)C=C3	PLASMA	YO7261ME24							24		t	ng × h/mL	6375.6		ng/mL	978.4			RECOMMENDED	mg	10		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2571627/	Homo sapiens		h	6.9							false
5008	2385		ADULT	2678|74548902	388.888	CETIRIZINE	CETIRIZINE	OC(=O)COCCN1CCN(CC1)C(C2=CC=CC=C2)C3=CC=C(Cl)C=C3	PLASMA	YO7261ME24													ng/mL	311			RECOMMENDED	mg	10		MULTIPLE	UNKNOWN		day	1		7	HEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/19835slr016,21150slr005,30346slr011_zyrtec_lbl.pdf	Homo sapiens		h	8.3							false
5009	2386		ADULT	18642481	199.313	CEVIMELINE	CEVIMELINE	C[C@H]1O[C@]2(CS1)CN3CC[C@H]2CC3	PLASMA	K9V0CDQ56E									∞	mg × h/g	0.52		mg/g	0.09			RECOMMENDED	mg	30		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12642962	Homo sapiens		h	0.09							false
5010	2386		UNKNOWN	18642481	199.313	CEVIMELINE	CEVIMELINE	C[C@H]1O[C@]2(CS1)CN3CC[C@H]2CC3	PLASMA	K9V0CDQ56E																						UNKNOWN				<20% BOUND TO HUMAN PLASMA PROTEINS	80	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020989s006lbl.pdf	Homo sapiens										false
5011	2387		ADULT	6917698	465.945	CISAPRIDE	CISAPRIDE	CO[C@H]1CN(CCCOC2=CC=C(F)C=C2)CC[C@H]1NC(=O)C3=C(OC)C=C(N)C(Cl)=C3	PLASMA	UVL329170W									∞	ng × h/mL	719		ng/mL	69.5			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020210_S000_Cisapride_BIOPHARMR.pdf	Homo sapiens		h	7.7							false
5012	2387		ADULT	3019427	313.78	Norcisapride	Norcisapride		PLASMA										∞	ng × h/mL	88.1		ng/mL	7.5			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020210_S000_Cisapride_BIOPHARMR.pdf	Homo sapiens		h	8.2							false
5013	2387		ADULT	6917698	465.945	CISAPRIDE	CISAPRIDE	CO[C@H]1CN(CCCOC2=CC=C(F)C=C2)CC[C@H]1NC(=O)C3=C(OC)C=C(N)C(Cl)=C3	PLASMA	UVL329170W							24		t	ng × h/mL	1193		ng/mL	75.7			UNKNOWN	mg	10		STEADY-STATE	UNKNOWN		day	4			HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020210_S000_Cisapride_BIOPHARMR.pdf	Homo sapiens		h	7.77							false
5014	2387		ADULT	6917698	465.945	CISAPRIDE	CISAPRIDE	CO[C@H]1CN(CCCOC2=CC=C(F)C=C2)CC[C@H]1NC(=O)C3=C(OC)C=C(N)C(Cl)=C3	PLASMA	UVL329170W							24		t	ng × h/mL	1925		ng/mL	115.1			UNKNOWN	mg	20		STEADY-STATE	UNKNOWN		day	4			HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020210_S000_Cisapride_BIOPHARMR.pdf	Homo sapiens		h	8.98							false
5015	2387		ADULT	6917698	465.945	CISAPRIDE	CISAPRIDE	CO[C@H]1CN(CCCOC2=CC=C(F)C=C2)CC[C@H]1NC(=O)C3=C(OC)C=C(N)C(Cl)=C3	PLASMA	UVL329170W							24		t	ng × h/mL	2978		ng/mL	190.4			UNKNOWN	mg	40		STEADY-STATE	UNKNOWN		day	4			HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020210_S000_Cisapride_BIOPHARMR.pdf	Homo sapiens		h	9.76							false
5016	2388		ADULT	2882	468.3665	CROMOLYN	CROMOLYN	OC(COC1=C2C(=O)C=C(OC2=CC=C1)C(O)=O)COC3=C4C(=O)C=C(OC4=CC=C3)C(O)=O	PLASMA	Y0TK0FS77W	3672		IBUPROFEN	Ibuprofen	CC(C)CC1=CC=C(C=C1)C(C)C(O)=O	WK2XYI10QM							ng/mL	46.69			RECOMMENDED	mg	17.1		SINGLE	UNKNOWN						HEALTHY	Respiratory	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28856569/	Homo sapiens		h	1.8							true
5017	2388		ADULT	2882	468.3665	CROMOLYN	CROMOLYN	OC(COC1=C2C(=O)C=C(OC2=CC=C1)C(O)=O)COC3=C4C(=O)C=C(OC4=CC=C3)C(O)=O	PLASMA	Y0TK0FS77W	3672		IBUPROFEN	Ibuprofen	CC(C)CC1=CC=C(C=C1)C(C)C(O)=O	WK2XYI10QM							ng/mL	96.75			RECOMMENDED	mg	34.2		SINGLE	UNKNOWN						HEALTHY	Respiratory	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28856569/	Homo sapiens		h	1.8							true
5018	2388		ADULT	2882	468.3665	CROMOLYN	CROMOLYN	OC(COC1=C2C(=O)C=C(OC2=CC=C1)C(O)=O)COC3=C4C(=O)C=C(OC4=CC=C3)C(O)=O	CEREBROSPINAL FLUID	Y0TK0FS77W	3672		IBUPROFEN	Ibuprofen	CC(C)CC1=CC=C(C=C1)C(C)C(O)=O	WK2XYI10QM							ng/mL	0.24			RECOMMENDED	mg	17.1		SINGLE	UNKNOWN						HEALTHY	Respiratory	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28856569/	Homo sapiens										true
5019	2388		ADULT	2882	468.3665	CROMOLYN	CROMOLYN	OC(COC1=C2C(=O)C=C(OC2=CC=C1)C(O)=O)COC3=C4C(=O)C=C(OC4=CC=C3)C(O)=O	CEREBROSPINAL FLUID	Y0TK0FS77W	3672		IBUPROFEN	Ibuprofen	CC(C)CC1=CC=C(C=C1)C(C)C(O)=O	WK2XYI10QM							ng/mL	0.34			RECOMMENDED	mg	34.2		SINGLE	UNKNOWN						HEALTHY	Respiratory	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28856569/	Homo sapiens										true
5020	2388		ADULT	2882	468.3665	CROMOLYN	CROMOLYN	OC(COC1=C2C(=O)C=C(OC2=CC=C1)C(O)=O)COC3=C4C(=O)C=C(OC4=CC=C3)C(O)=O	PLASMA	Y0TK0FS77W									?	ng × h/mL	338		ng/mL	156			RECOMMENDED	mg	40		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32944204/	Homo sapiens										false
5021	2388		ADULT	2882	468.3665	CROMOLYN	CROMOLYN	OC(COC1=C2C(=O)C=C(OC2=CC=C1)C(O)=O)COC3=C4C(=O)C=C(OC4=CC=C3)C(O)=O	PLASMA	Y0TK0FS77W									?	ng × h/mL	526		ng/mL	236			RECOMMENDED	mg	80		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32944204/	Homo sapiens										false
5022	2389		ADULT	6726	266.3807	CYCLIZINE	CYCLIZINE	CN1CCN(CC1)C(C2=CC=CC=C2)C3=CC=CC=C3	PLASMA	QRW9FCR9P2									?	ng × h/mL	273.53		ng/mL	90			UNKNOWN	mg	18.682		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://www.sciencedirect.com/science/article/pii/0928098796001777	Homo sapiens		h	13.53							false
5023	2390		ADULT	2895	275.4	CYCLOBENZAPRINE	CYCLOBENZAPRINE	CN(C)CCC=C1C2=C(C=CC=C2)C=CC3=C1C=CC=C3	PLASMA	69O5WQQ5TI									∞	ng × h/mL	354.1		ng/mL	8.3			RECOMMENDED	mg	15		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/19243711	Homo sapiens		h	33.4							false
5024	2391		ADULT	213039	547.7	Darunavir		CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N	PLASMA	YO603Y8113	392622		Ritonavir		CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O	O3J8G9O825	24		t	ng × h/mL	57055		ng/mL	5272			RECOMMENDED	mg	800		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21926632/	Homo sapiens										true
5025	2391		ADULT	213039	547.7	Darunavir		CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N	PLASMA	YO603Y8113	392622		Ritonavir	Ritonavir	CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O	O3J8G9O825	24		t	ng × h/mL	93026						RECOMMENDED	mg	800		STEADY-STATE	UNKNOWN		day	1		5	UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf	Homo sapiens		h	15							true
5026	2391		ADULT	213039	547.7	Darunavir		CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N	PLASMA	YO603Y8113	392622		Ritonavir		CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O	O3J8G9O825	24		t	ng × h/mL	124698						RECOMMENDED	mg	600		STEADY-STATE	UNKNOWN		day	2		5	UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf	Homo sapiens		h	15							true
5027	2391		CHILD	213039	547.7	Darunavir		CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N	PLASMA	YO603Y8113	392622		Ritonavir		CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O	O3J8G9O825	24		t	ng × h/mL	126377						RECOMMENDED	mg	600		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf	Homo sapiens										true
5028	2392		ADULT	5625	456.561	DELAVIRDINE	DELAVIRDINE	CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(NS(C)(=O)=O)=C4	PLASMA	DOL5F9JD3E													μM	12.6			UNKNOWN	mg	200		STEADY-STATE	UNKNOWN		day	3		2.3	UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9164415/	Homo sapiens		h	2.59							false
5029	2392		ADULT	5625	456.561	DELAVIRDINE	DELAVIRDINE	CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(NS(C)(=O)=O)=C4	PLASMA	DOL5F9JD3E													μM	18.8			UNKNOWN	mg	300		STEADY-STATE	UNKNOWN		day	3		2.3	UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9164415/	Homo sapiens		h	3.33							false
5030	2392		ADULT	5625	456.561	DELAVIRDINE	DELAVIRDINE	CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(NS(C)(=O)=O)=C4	PLASMA	DOL5F9JD3E													μM	26.6			RECOMMENDED	mg	400		STEADY-STATE	UNKNOWN		day	3		2.3	UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9164415/	Homo sapiens		h	4.12							false
5031	2392		ADULT	468304	414.481	N-DESISOPROPYL DELAVIRDINE	N-DESISOPROPYL DELAVIRDINE	CS(=O)(=O)NC1=CC2=C(NC(=C2)C(=O)N3CCN(CC3)C4=NC=CC=C4N)C=C1	PLASMA	TV9X4GSK6W													μM	2.18			UNKNOWN	mg	200		STEADY-STATE	UNKNOWN		day	3			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9164415/	Homo sapiens		h	4.71							false
5032	2392		ADULT	468304	414.481	N-DESISOPROPYL DELAVIRDINE	N-DESISOPROPYL DELAVIRDINE	CS(=O)(=O)NC1=CC2=C(NC(=C2)C(=O)N3CCN(CC3)C4=NC=CC=C4N)C=C1	PLASMA	TV9X4GSK6W													μM	2.88			UNKNOWN	mg	300		STEADY-STATE	UNKNOWN		day	3			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9164415/	Homo sapiens		h	6.18							false
5033	2392		ADULT	468304	414.481	N-DESISOPROPYL DELAVIRDINE	N-DESISOPROPYL DELAVIRDINE	CS(=O)(=O)NC1=CC2=C(NC(=C2)C(=O)N3CCN(CC3)C4=NC=CC=C4N)C=C1	PLASMA	TV9X4GSK6W													μM	3.23			RECOMMENDED	mg	400		STEADY-STATE	UNKNOWN		day	3			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9164415/	Homo sapiens		h	7.5							false
5034	2392		ADULT	5625	456.561	DELAVIRDINE	DELAVIRDINE	CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(NS(C)(=O)=O)=C4	PLASMA	DOL5F9JD3E									?	μM × h	180		μM	35			RECOMMENDED	mg	400		STEADY-STATE	UNKNOWN		day	3		2	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20705s03lbl.pdf	Homo sapiens		h	5.8							false
5035	2393		ADULT	2995	266.3807	DESIPRAMINE	DESIPRAMINE	CNCCCN1C2=CC=CC=C2CCC3=C1C=CC=C3	PLASMA	TG537D343B									∞	ng × h/mL	656		ng/mL	21.8			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16680561	Homo sapiens		h	21							false
5036	2393		UNKNOWN	2995	266.3807	DESIPRAMINE	DESIPRAMINE	CNCCCN1C2=CC=CC=C2CCC3=C1C=CC=C3	PLASMA	TG537D343B																						UNKNOWN					9.78	UNKNOWN		UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4386616	Homo sapiens										false
5037	2394		ADULT	3059	250.1976	DIFLUNISAL	DIFLUNISAL	OC(=O)C1=CC(=CC=C1O)C2=C(F)C=C(F)C=C2	PLASMA	7C546U4DEN									?	μg × h/mL	678		mg/L	173.66			RECOMMENDED	mg	500		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2029803/	Homo sapiens		h	11.4							false
5038	2394		ADULT	3059	250.1976	DIFLUNISAL	DIFLUNISAL	OC(=O)C1=CC(=CC=C1O)C2=C(F)C=C(F)C=C2	PLASMA	7C546U4DEN							24		t	μg × h/mL	2782		μg/mL	150			UNKNOWN	mg	500		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3841206	Homo sapiens										false
5039	2394		ADULT	3059	250.1976	DIFLUNISAL	DIFLUNISAL	OC(=O)C1=CC(=CC=C1O)C2=C(F)C=C(F)C=C2	PLASMA	7C546U4DEN							24		t	μg × h/mL	2839		μg/mL	186			UNKNOWN	mg	100		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3841206	Homo sapiens										false
5040	2395		ADULT	10531	583.6774	DIHYDROERGOTAMINE	DIHYDROERGOTAMINE	CN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)C(=O)N[C@]5(C)O[C@@]6(O)[C@@H]7CCCN7C(=O)[C@H](CC8=CC=CC=C8)N6C5=O	PLASMA	436O5HM03C							24		t	ng × h/mL	5.05		ng/mL	1.02			RECOMMENDED	mg	1		SINGLE	UNKNOWN				https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020148Orig1s025lbl.pdf	7	HEALTHY	Nasal	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8841149/	Homo sapiens		h	7.952							false
5041	2396		ADULT	3055	309.4452	DIPHENIDOL	DIPHENIDOL	OC(CCCN1CCCCC1)(C2=CC=CC=C2)C3=CC=CC=C3	PLASMA	NQO8R319LY							12		t	ng × h/mL	445.57		ng/mL	157.4			UNKNOWN	mg	25		MULTIPLE	FED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18506741/	Homo sapiens		h	3.23							false
5042	2397		ADOLESCENT	36811	301.3801	DOBUTAMINE	DOBUTAMINE	CC(CCC1=CC=C(O)C=C1)NCCC2=CC(O)=C(O)C=C2	PLASMA	3S12J47372							0.3		t	ng × h/mL	14						UNKNOWN	μg/kg/min	2.5	infusion, 20 min	OTHER	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/699477/	Homo sapiens		min	2.37							false
5043	2398		ADULT	3152	379.492	DONEPEZIL	DONEPEZIL	COC1=CC2=C(C=C1OC)C(=O)C(CC3CCN(CC4=CC=CC=C4)CC3)C2	BLOOD	8SSC91326P									∞	ng × h/mL	2889.3		ng/mL	34.1			UNKNOWN	mg	5		STEADY-STATE	FASTED		day	1		4.4	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9839760	Homo sapiens		h	72.7							false
5044	2398		ADULT	3152	379.492	DONEPEZIL	DONEPEZIL	COC1=CC2=C(C=C1OC)C(=O)C(CC3CCN(CC4=CC=CC=C4)CC3)C2	BLOOD	8SSC91326P									∞	ng × h/mL	5051.9		ng/mL	60.5			UNKNOWN	mg	10		STEADY-STATE	FASTED		day	1		4.4	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9839760	Homo sapiens		h	73.5							false
5045	2399		ADULT	5284549	324.44	DORZOLAMIDE	DORZOLAMIDE	CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O	BLOOD	9JDX055TW1									∞	μM × h	22667						UNKNOWN	μg	7.7		MULTIPLE	FED		day	4			HEALTHY	Topical	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7720769	Homo sapiens		day	133							false
5046	2400		ADULT	3157	451.4751	DOXAZOSIN	DOXAZOSIN	COC1=CC2=NC(=NC(N)=C2C=C1OC)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4	PLASMA	NW1291F1W8									∞	ng × h/mL	162		ng/mL	9.7			RECOMMENDED	mg	1		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2139337/	Homo sapiens		h	12.9							false
5047	2400		ADULT	3157	451.4751	DOXAZOSIN	DOXAZOSIN	COC1=CC2=NC(=NC(N)=C2C=C1OC)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4	PLASMA	NW1291F1W8									∞	ng × h/mL	268		ng/mL	13.6			RECOMMENDED	mg	1		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2139337/	Homo sapiens		h	15							false
5048	2400		ADULT	3157	451.4751	DOXAZOSIN	DOXAZOSIN	COC1=CC2=NC(=NC(N)=C2C=C1OC)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4	PLASMA	NW1291F1W8													ng/mL	14.3			RECOMMENDED	mg	1		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2951261/	Homo sapiens		h	11.9							false
5049	2400		ADULT	3157	451.4751	DOXAZOSIN	DOXAZOSIN	COC1=CC2=NC(=NC(N)=C2C=C1OC)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4	PLASMA	NW1291F1W8													ng/mL	42.3			RECOMMENDED	mg	4		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2951261/	Homo sapiens		h	12.8							false
5050	2400		ADULT	3157	451.4751	DOXAZOSIN	DOXAZOSIN	COC1=CC2=NC(=NC(N)=C2C=C1OC)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4	PLASMA	NW1291F1W8													ng/mL	65.5			RECOMMENDED	mg	8		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2951261/	Homo sapiens		h	8.3							false
5051	2400		ADULT	3157	451.4751	DOXAZOSIN	DOXAZOSIN	COC1=CC2=NC(=NC(N)=C2C=C1OC)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4	PLASMA	NW1291F1W8													ng/mL	151.7			RECOMMENDED	mg	16		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2951261/	Homo sapiens		h	11.6							false
5052	2401		ADULT	208898	556.756	DRONEDARONE	DRONEDARONE	CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C2=C(CCCC)OC3=C2C=C(NS(C)(=O)=O)C=C3	PLASMA	JQZ1L091Y2	4171		METOPROLOL	metoprolol	COCCC1=CC=C(OCC(O)CNC(C)C)C=C1	GEB06NHM23	24		t	ng × h/mL	1386		ng/mL	96.2			UNKNOWN	mg	1600		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://onlinelibrary.wiley.com/doi/full/10.1046/j.1472-8206.2003.00216.x	Homo sapiens		h	12							true
5053	2402		ADULT	3198	381.684	ECONAZOLE	ECONAZOLE	ClC1=CC=C(COC(CN2C=CN=C2)C3=C(Cl)C=C(Cl)C=C3)C=C1	PLASMA	6Z1Y2V4A7M									?	ng × h/mL	53						UNKNOWN	mg	150		SINGLE	UNKNOWN						HEALTHY	Vaginal	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32410819	Homo sapiens										false
5054	2402		ADULT	3198	381.684	ECONAZOLE	ECONAZOLE	ClC1=CC=C(COC(CN2C=CN=C2)C3=C(Cl)C=C(Cl)C=C3)C=C1	PLASMA	6Z1Y2V4A7M									?	ng × h/mL	81.77						UNKNOWN	mg	150		MULTIPLE	UNKNOWN		day	1			HEALTHY	Vaginal	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32410819	Homo sapiens										false
5055	2402		ADULT	3198	381.684	ECONAZOLE	ECONAZOLE	ClC1=CC=C(COC(CN2C=CN=C2)C3=C(Cl)C=C(Cl)C=C3)C=C1	PLASMA	6Z1Y2V4A7M							12		t	pg × h/mL	3440		pg/mL	417			RECOMMENDED	mg	24		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Topical	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/205175s000lbl.pdf	Homo sapiens										false
5056	2403		ADULT	77993	382.5	Eletriptan	Eletriptan	CN1CCCC1CC2=CNC3=C2C=C(C=C3)CCS(=O)(=O)C4=CC=CC=C4	PLASMA	22QOO9B8KI									∞	ng × h/mL	291.3		ng/mL	46.5			RECOMMENDED	mg	20		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29497279	Homo sapiens		h	4.92							false
5057	2403		ADULT	77993	382.5	Eletriptan	Eletriptan	CN1CCCC1CC2=CNC3=C2C=C(C=C3)CCS(=O)(=O)C4=CC=CC=C4	PLASMA	22QOO9B8KI									∞	ng × h/mL	575.6		ng/mL	94.72			DEFINED DAILY	mg	40		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29497279	Homo sapiens		h	4.63							false
5058	2403		ADULT	77993	382.5	Eletriptan	Eletriptan	CN1CCCC1CC2=CNC3=C2C=C(C=C3)CCS(=O)(=O)C4=CC=CC=C4	PLASMA	22QOO9B8KI									∞	ng × h/mL	1282		ng/mL	200.1			MAX DAILY	mg	80		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29497279	Homo sapiens		h	4.58							false
5059	2403		ADULT	77993	382.5	Eletriptan	Eletriptan	CN1CCCC1CC2=CNC3=C2C=C(C=C3)CCS(=O)(=O)C4=CC=CC=C4	PLASMA	22QOO9B8KI									∞	ng × h/mL	1278		ng/mL	183.6			DEFINED DAILY	mg	40		MULTIPLE	FASTED		day	2			HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29497279	Homo sapiens		h	4.75							false
5060	2403		UNKNOWN	77993	382.5	Eletriptan	Eletriptan	CN1CCCC1CC2=CNC3=C2C=C(C=C3)CCS(=O)(=O)C4=CC=CC=C4	PLASMA	22QOO9B8KI																						UNKNOWN				lasma protein binding is moderate and approximately 85%.	15	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021016s021s023s024s027lbl.pdf	Homo sapiens										false
5061	2404		ADULT	3219	302.4145	EMEDASTINE	EMEDASTINE	CCOCCN1C(=NC2=C1C=CC=C2)N3CCCN(C)CC3	PLASMA	9J1H7Y9OJV							24		t	ng × h/mL	16.9		ng/mL	2			UNKNOWN	mg	2		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11317479	Homo sapiens		h	6.4							false
5062	2404		ADULT	3219	302.4145	EMEDASTINE	EMEDASTINE	CCOCCN1C(=NC2=C1C=CC=C2)N3CCCN(C)CC3	PLASMA	9J1H7Y9OJV							24		t	ng × h/mL	29.7		ng/mL	2.9			UNKNOWN	mg	2		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11317479	Homo sapiens		h	10.1							false
5063	2404		ADULT	3219	302.4145	EMEDASTINE	EMEDASTINE	CCOCCN1C(=NC2=C1C=CC=C2)N3CCCN(C)CC3	PLASMA	9J1H7Y9OJV									?	ng × h/mL	24.4		ng/mL	4			UNKNOWN	mg	2		STEADY-STATE	FASTED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11317479	Homo sapiens		h	6.6							false
5064	2404		ADULT	3219	302.4145	EMEDASTINE	EMEDASTINE	CCOCCN1C(=NC2=C1C=CC=C2)N3CCCN(C)CC3	PLASMA	9J1H7Y9OJV									?	ng × h/mL	46.4		ng/mL	6			UNKNOWN	mg	2		STEADY-STATE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11317479	Homo sapiens		h	9.1							false
5065	2405		ADULT	3241	249.3104	EPINASTINE	EPINASTINE	NC1=NCC2N1C3=C(CC4=C2C=CC=C4)C=CC=C3	PLASMA	Q13WX941EF									∞	ng × h/mL	144.88		ng/mL	14.82			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31947890	Homo sapiens		h	7.08							false
5066	2405		ADULT	3241	249.3104	EPINASTINE	EPINASTINE	NC1=NCC2N1C3=C(CC4=C2C=CC=C4)C=CC=C3	PLASMA	Q13WX941EF									∞	ng × h/mL	157.38		ng/mL	15.69			UNKNOWN	mg	20		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31947890	Homo sapiens		h	7.35							false
5067	2405		UNKNOWN	3241	249.3104	EPINASTINE	EPINASTINE	NC1=NCC2N1C3=C(CC4=C2C=CC=C4)C=CC=C3	PLASMA	Q13WX941EF																	UNKNOWN				SINGLE	UNKNOWN					35.8	UNKNOWN	Oral	UNKNOWN	REVIEW	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-565_Elestat_BioPharmr.pdf	Homo sapiens										false
5068	2405		ADULT	3241	249.3104	EPINASTINE	EPINASTINE	NC1=NCC2N1C3=C(CC4=C2C=CC=C4)C=CC=C3	PLASMA	Q13WX941EF													ng/mL	15.5			UNKNOWN	mg	20.6		SINGLE	UNKNOWN						UNKNOWN	Oral	MALE	REVIEW	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-565_Elestat_BioPharmr.pdf	Homo sapiens										false
5069	2405		ADULT	3241	249.3104	EPINASTINE	EPINASTINE	NC1=NCC2N1C3=C(CC4=C2C=CC=C4)C=CC=C3	PLASMA	Q13WX941EF									∞	ng × h/mL	0.465		ng/mL	0.025			RECOMMENDED	%	0.05		SINGLE	UNKNOWN						UNHEALTHY	Ocular	UNKNOWN	REVIEW	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-565_Elestat_BioPharmr.pdf	Homo sapiens		h	9.26							false
5070	2405		ADULT	3241	249.3104	EPINASTINE	EPINASTINE	NC1=NCC2N1C3=C(CC4=C2C=CC=C4)C=CC=C3	PLASMA	Q13WX941EF									∞	ng × h/mL	0.347		ng/mL	0.042			RECOMMENDED	%	0.05		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Ocular	UNKNOWN	REVIEW	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-565_Elestat_BioPharmr.pdf	Homo sapiens		h	11.9							false
5071	2406		ADULT	5280888	370.4804	6-Keto-prostaglandin F1alpha	5280888	CCCCC[C@H](O)\\C=C\\[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC(=O)CCCCC(O)=O	PLASMA										∞	pg × h/mL	1972		pg/mL	347			RECOMMENDED	ng/kg/min	2	infusion, 2 hour	OTHER	FED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22515646/	Homo sapiens		h	0.22							false
5072	2406		UNKNOWN	5282411	352.4651	EPOPROSTENOL	EPOPROSTENOL	CCCCC[C@H](O)\\C=C\\[C@H]1[C@H](O)C[C@@H]2O\\C(C[C@H]12)=C/CCCC(O)=O	BLOOD	DCR9Z582X0																	UNKNOWN				UNKNOWN	UNKNOWN		UNKNOWN				UNKNOWN	UNKNOWN	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020444s024lbl.pdf	Homo sapiens		min	6							false
5073	2407			667484	244.289	ETOMIDATE	Etomidate	CCOC(=O)C1=CN=CN1[C@H](C)C2=CC=CC=C2	PLASMA	Z22628B598																										Etomidate is 75% protein bound. In plasma, it binds solely to albumin.	25				REVIEW	https://pubmed.ncbi.nlm.nih.gov/34060021/	Homo sapiens										false
5074	2407		ADULT	667484	244.289	ETOMIDATE	Etomidate	CCOC(=O)C1=CN=CN1[C@H](C)C2=CC=CC=C2	BLOOD	Z22628B598													ng/mL	2000			UNKNOWN	mg/kg	0.48		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3729056/ | https://pubmed.ncbi.nlm.nih.gov/34060021/	Homo sapiens		min	324		Healthy surgical patients		20			false
5075	2408		UNKNOWN	3341|74604247	305.756	FENOLDOPAM	FENOLDOPAM	OC1=CC=C(C=C1)C2CNCCC3=C(Cl)C(O)=C(O)C=C23	PLASMA	INU8H2KAWG									∞	ng × h/mL	44.7		ng/mL	26.5			UNKNOWN	mg	100		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/1673097	Homo sapiens		h	2.9							false
5076	2408		UNKNOWN	3341|74604247	305.756	FENOLDOPAM	FENOLDOPAM	OC1=CC=C(C=C1)C2CNCCC3=C(Cl)C(O)=C(O)C=C23	PLASMA	INU8H2KAWG									∞	ng × h/mL	26.8		ng/mL	10.9			UNKNOWN	mg	100		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/1673097	Homo sapiens		h	2.6							false
5077	2409		ADULT	3348|74685737	501.6564	FEXOFENADINE	FEXOFENADINE	CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN2CCC(CC2)C(O)(C3=CC=CC=C3)C4=CC=CC=C4	PLASMA	E6582LOH6V									∞	ng × h/mL	3507.8		ng/mL	523.28			UNKNOWN	mg	120		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27151911	Homo sapiens		h	9.26							false
5078	2410		ADULT	3386	309.3261	FLUOXETINE	FLUOXETINE	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C2=CC=CC=C2	PLASMA	01K63SUP8D									∞	ng × h/mL	1101.46		ng/mL	22.56			RECOMMENDED	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15968712	Homo sapiens		h	46.39							false
5079	2410		ADULT	3386	309.3261	FLUOXETINE	FLUOXETINE	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C2=CC=CC=C2	PLASMA	01K63SUP8D									∞	pg × h/mL	788626.72		pg/mL	13576.38			RECOMMENDED	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16229112	Homo sapiens		h	49.7							false
5080	2410		UNKNOWN	3386	309.3261	FLUOXETINE	FLUOXETINE	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C2=CC=CC=C2	PLASMA	01K63SUP8D																						UNKNOWN				Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α1-glycoprotein.	5.5	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018936s091lbl.pdf	Homo sapiens										false
5081	2411		ADULT	128762	403.9	hydroxyethyl-flurazepam	Hydroxyethylflurazepam	CCN(CCN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3F)CCO	PLASMA														ng/mL	8.6			RECOMMENDED	mg	15		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	OTHER	https://pdf.hres.ca/dpd_pm/00013427.PDF	Homo sapiens		h	2.5							false
5082	2411		ADULT		401.88	Flurazepam aldehyde	flurazepam aldehyde		PLASMA														ng/mL	2.5			RECOMMENDED	mg	15		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	OTHER	https://pdf.hres.ca/dpd_pm/00013427.PDF	Homo sapiens		h	2.5							false
5083	2411		ADULT		288.71	N-Desalkylflurazepam	desalkylflurazepam	Fc1ccccc1C2=NCC(=O)Nc3ccc(Cl)cc23	PLASMA														ng/mL	14			RECOMMENDED	mg	15		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	OTHER	https://pdf.hres.ca/dpd_pm/00013427.PDF	Homo sapiens		h	75							false
5084	2412		ADULT	1548972	411.4659	FLUVASTATIN	FLUVASTATIN	CC(C)N1C(\\C=C\\[C@H](O)C[C@H](O)CC(O)=O)=C(C2=C1C=CC=C2)C3=CC=C(F)C=C3	PLASMA	4L066368AS									∞	μg × h/mL	206.2		μg/mL	205			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/29368187	Homo sapiens		h	0.54							false
5085	2413		ADULT	3415	126.0053	FOSCARNET	FOSCARNET	OC(=O)P(O)(O)=O	PLASMA	364P9RVW4X									∞	μM × h	494		μM	64.9			UNKNOWN	mg/kg bw	180		SINGLE	UNKNOWN						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9527775/	Homo sapiens		h	5.4							false
5086	2413		ADULT	3415	126.0053	FOSCARNET	FOSCARNET	OC(=O)P(O)(O)=O	PLASMA	364P9RVW4X									∞	μM × h	688		μM	78.7			UNKNOWN	mg/kg bw	90		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9527775/	Homo sapiens		h	5.7							false
5087	2413		ADULT	3415	126.0053	FOSCARNET	FOSCARNET	OC(=O)P(O)(O)=O	PLASMA	364P9RVW4X									∞	μM × h	300		μM	46.4			UNKNOWN	mg/kg bw	90		SINGLE	UNKNOWN						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9527775/	Homo sapiens		h	6.7							false
5088	2413		ADULT	3415	126.0053	FOSCARNET	FOSCARNET	OC(=O)P(O)(O)=O	PLASMA	364P9RVW4X									∞	μM × h	646		μM	86.2			UNKNOWN	mg/kg bw	90		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9527775/	Homo sapiens		h	7.6							false
5089	2413		ADULT	3415	126.0053	FOSCARNET	FOSCARNET	OC(=O)P(O)(O)=O	PLASMA	364P9RVW4X									∞	μM × h	826		μM	86.4			UNKNOWN	mg/kg bw	180		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9527775/	Homo sapiens		h	5.6							false
5090	2413		ADULT	3415	126.0053	FOSCARNET	FOSCARNET	OC(=O)P(O)(O)=O	PLASMA	364P9RVW4X									∞	μM × h	3308		μM	887.3			RECOMMENDED	mg/kg bw	90		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9527775/	Homo sapiens		h	5.7							false
5091	2413		ADULT	3415	126.0053	FOSCARNET	FOSCARNET	OC(=O)P(O)(O)=O	PLASMA	364P9RVW4X													μM	589			RECOMMENDED	mg/kg bw	60		STEADY-STATE	UNKNOWN		day	3	In vitro studies have shown that 14 – 17% of foscarnet is protein bound at plasma drug concentrations of 1 – 1000 μM.	84.5	UNHEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020068s020lbl.pdf	Homo sapiens		h	4							false
5092	2413		ADULT	3415	126.0053	FOSCARNET	FOSCARNET	OC(=O)P(O)(O)=O	PLASMA	364P9RVW4X													μM	623			RECOMMENDED	mg/kg bw	90		STEADY-STATE	UNKNOWN		day	2	In vitro studies have shown that 14 – 17% of foscarnet is protein bound at plasma drug concentrations of 1 – 1000 μM.	84.5	UNHEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020068s020lbl.pdf	Homo sapiens		h	3.3							false
5093	2414		ADULT	9651	287.3535	GALANTAMINE	GALANTAMINE	COC1=C2O[C@H]3C[C@@H](O)C=C[C@]34CCN(C)CC(C=C1)=C24	PLASMA	0D3Q044KCA							24		t	ng × h/mL	1050		ng/mL	84.3			RECOMMENDED	mg	24		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16238894	Homo sapiens		h	8.53							false
5094	2414		UNKNOWN	9651	287.3535	GALANTAMINE	GALANTAMINE	COC1=C2O[C@H]3C[C@@H](O)C=C[C@]34CCN(C)CC(C=C1)=C24	PLASMA	0D3Q044KCA																						UNKNOWN				The plasma protein binding of galantamine is 18% at therapeutically relevant concentrations.	82	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021615s021lbl.pdf	Homo sapiens										false
5095	2415		ADULT	9571107	389.4	GEMIFLOXACIN	CON=C1CN(CC1CN)C2=C(C=C3C(=O)C(=CN(C3=N2)C4CC4)C(=O)O)F	CON=C1CN(CC1CN)C2=C(C=C3C(=O)C(=CN(C3=N2)C4CC4)C(=O)O)F	PLASMA	OKR68Y0E4T							24		t	μg × h/mL	9.93		μg/mL	1.61			DEFINED DAILY	mg	320		MULTIPLE	UNKNOWN		day	1	In vitro binding of gemifloxacin to plasma proteins in healthy subjects is approximately 60 to 70% and is concentration independent.	35	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021158s013lbl.pdf	Homo sapiens		h	7							false
5096	2416		ADULT	3494	318.4305	GLYCOPYRRONIUM	GLYCOPYRRONIUM	C[N+]1(C)CCC(C1)OC(=O)C(O)(C2CCCC2)C3=CC=CC=C3	PLASMA	A14FB57V1D							24		t	ng × h/mL	0.88		ng/mL	0.08			RECOMMENDED	%	2.4		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Topical	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210361lbl.pdf	Homo sapiens										false
5097	2416		ADULT	3494	318.4305	GLYCOPYRRONIUM	Glycopyrronium	C[N+]1(C)CCC(C1)OC(=O)C(O)(C2CCCC2)C3=CC=CC=C3	PLASMA	A14FB57V1D							8		t	μg × h/L	8.64						UNKNOWN	μg/kg bw	6		SINGLE	UNKNOWN						UNKNOWN	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210997s000lbl.pdf	Homo sapiens		h	0.83							false
5098	2416		ADULT	3494	318.4305	GLYCOPYRRONIUM	Glycopyrronium	C[N+]1(C)CCC(C1)OC(=O)C(O)(C2CCCC2)C3=CC=CC=C3	PLASMA	A14FB57V1D							8		t	μg × h/L	6.64		μg/L	3.47			UNKNOWN	μg/kg bw	8		SINGLE	UNKNOWN						UNKNOWN	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210997s000lbl.pdf	Homo sapiens										false
5099	2416		UNKNOWN	3494	318.4305	GLYCOPYRRONIUM	GLYCOPYRRONIUM	C[N+]1(C)CCC(C1)OC(=O)C(O)(C2CCCC2)C3=CC=CC=C3	PLASMA	A14FB57V1D																						UNKNOWN				At concentration of 1000 ng/m (in vitro)	68.3	UNKNOWN		UNKNOWN	REVIEW	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207930Orig1s000PharmR.pdf	Homo sapiens										false
5100	2417		UNKNOWN	3519|137319710	246.093	GUANFACINE	GUANFACINE	NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl	PLASMA	30OMY4G3MK									∞	ng × h/mL	56		ng/mL	2.5			RECOMMENDED	mg	1		MULTIPLE	UNKNOWN		day	1	Guanfacine is readily absorbed and approximately 70% bound to plasma proteins independent of drug concentration.	30	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022037s009lbl.pdf	Homo sapiens		h	16							false
5101	2417		CHILD	3519|137319710	246.093	GUANFACINE	GUANFACINE	NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl	PLASMA	30OMY4G3MK									?	ng × h/mL	162		ng/mL	10			RECOMMENDED	mg	4		MULTIPLE	UNKNOWN		day	1			UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022037s009lbl.pdf	Homo sapiens										false
5102	2417		ADOLESCENT	3519|137319710	246.093	GUANFACINE	GUANFACINE	NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl	PLASMA	30OMY4G3MK									?	ng × h/mL	116		ng/mL	7			RECOMMENDED	mg	4		MULTIPLE	UNKNOWN		day	1			UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022037s009lbl.pdf	Homo sapiens										false
5103	2418		ADULT	774	111.0796	HISTAMINE	Histamine	NCCC1=CNC=N1	PLASMA	820484N8I3							24		t	nM × min	1877		nM	39			UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Subcutaneous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/12092744	Homo sapiens		min	12							false
5104	2419		UNKNOWN	42890	497.4939	IDARUBICIN	IDARUBICIN	C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]2C[C@@](O)(CC3=C(O)C4=C(C(=O)C5=C(C=CC=C5)C4=O)C(O)=C23)C(C)=O	PLASMA	ZRP63D75JW																						UNKNOWN				The percentages of idarubicin and idarubicinol bound to human plasma proteins averaged 97% and 94%, respectively, at concentrations similar to maximum plasma levels obtained in the pharmacokinetic studies.	3	UNKNOWN		UNKNOWN	DRUG LABEL	https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/7c20b574-285b-49eb-a98e-6752e4bb481d/spl-doc?hl=IDARUBICIN	Homo sapiens										false
5105	2419		ADULT	42890	497.4939	IDARUBICIN	IDARUBICIN	C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]2C[C@@](O)(CC3=C(O)C4=C(C(=O)C5=C(C=CC=C5)C4=O)C(O)=C23)C(C)=O	PLASMA	ZRP63D75JW							264		t	ng × h/mL	423.2		ng/mL	7.7			UNKNOWN	mg/m²	40		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/12621462	Homo sapiens		h	38.8							false
5106	2420		ADULT	5291	493.6027	IMATINIB	IMATINIB	CN1CCN(CC2=CC=C(C=C2)C(=O)NC3=CC(NC4=NC(=CC=N4)C5=CN=CC=C5)=C(C)C=C3)CC1	PLASMA	BKJ8M8G5HI									∞	ng × h/mL	38.8		ng/mL	1907.5			RECOMMENDED	mg	400		STEADY-STATE	UNKNOWN		day	1	imatinib is known to be 89% to 96% protein bound to protein in vitro, mostly to albumin	4	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/14990650	Homo sapiens		h	14.8							false
5107	2420		ADULT	5291	493.6027	IMATINIB	IMATINIB	CN1CCN(CC2=CC=C(C=C2)C(=O)NC3=CC(NC4=NC(=CC=N4)C5=CN=CC=C5)=C(C)C=C3)CC1	PLASMA	BKJ8M8G5HI									∞	ng × h/mL	89.9		ng/mL	3508.9			RECOMMENDED	mg	600		STEADY-STATE	UNKNOWN		day	1	imatinib is known to be 89% to 96% protein bound to protein in vitro, mostly to albumin	4	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/14990650	Homo sapiens		h	15.6							false
5108	2420		ADULT	5291	493.6027	IMATINIB	IMATINIB	CN1CCN(CC2=CC=C(C=C2)C(=O)NC3=CC(NC4=NC(=CC=N4)C5=CN=CC=C5)=C(C)C=C3)CC1	PLASMA	BKJ8M8G5HI									∞	ng × h/mL	174.1		ng/mL	4478			UNKNOWN	mg	500		STEADY-STATE	UNKNOWN		day	2	imatinib is known to be 89% to 96% protein bound to protein in vitro, mostly to albumin	4	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/14990650	Homo sapiens		h	17							false
5109	2420		ADULT	5291	493.6027	IMATINIB	IMATINIB	CN1CCN(CC2=CC=C(C=C2)C(=O)NC3=CC(NC4=NC(=CC=N4)C5=CN=CC=C5)=C(C)C=C3)CC1	PLASMA	BKJ8M8G5HI									∞	μg × h/mL	97.3		μg/mL	4.75			UNKNOWN	mg	500		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18359865	Homo sapiens		h	23.6							false
5110	2420		ADULT	5291	493.6027	IMATINIB	IMATINIB	CN1CCN(CC2=CC=C(C=C2)C(=O)NC3=CC(NC4=NC(=CC=N4)C5=CN=CC=C5)=C(C)C=C3)CC1	PLASMA	BKJ8M8G5HI									∞	μg × h/mL	63.7		μg/mL	4.82			UNKNOWN	mg	600		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18359865	Homo sapiens		h	83.3							false
5111	2420		ADULT	9869737	479.5762	CGP-74588	N-Desmethyl Imatinib	CC1=C(NC2=NC(=CC=N2)C3=CN=CC=C3)C=C(NC(=O)C4=CC=C(CN5CCNCC5)C=C4)C=C1	PLASMA	6GOH0N63QD									∞	μg × h/mL	19.7		μg/mL	1.18			UNKNOWN	mg	500		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18359865	Homo sapiens		h	10.2							false
5112	2420		ADULT	9869737	479.5762	CGP-74588	N-Desmethyl Imatinib	CC1=C(NC2=NC(=CC=N2)C3=CN=CC=C3)C=C(NC(=O)C4=CC=C(CN5CCNCC5)C=C4)C=C1	PLASMA	6GOH0N63QD									∞	μg × h/mL	10.1		μg/mL	0.71			UNKNOWN	mg	600		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18359865	Homo sapiens		h	50.8							false
5113	2420		ADULT	5291	493.6027	IMATINIB	IMATINIB	CN1CCN(CC2=CC=C(C=C2)C(=O)NC3=CC(NC4=NC(=CC=N4)C5=CN=CC=C5)=C(C)C=C3)CC1	PLASMA	BKJ8M8G5HI							24		t	mg × h/L	19.9		mg/L	1.74			RECOMMENDED	mg	400		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/15796158	Homo sapiens		h	15.8							false
5114	2420		ADULT	5291	493.6027	IMATINIB	IMATINIB	CN1CCN(CC2=CC=C(C=C2)C(=O)NC3=CC(NC4=NC(=CC=N4)C5=CN=CC=C5)=C(C)C=C3)CC1	PLASMA	BKJ8M8G5HI									∞	μg × h/mL	38.8		ng/mL	1907.5			RECOMMENDED	mg	400		SINGLE	UNKNOWN					5	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/16122278	Homo sapiens										false
5115	2421		ADULT	657309	332.4571	IPRATROPIUM	IPRATROPIUM	CC(C)[N@+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](CO)C3=CC=CC=C3	PLASMA	GR88G0I6UL	2083		ALBUTEROL	Albuterol	CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1	QF8SVZ843E			?	pg × h/mL	1.04		pg/mL	33.5			RECOMMENDED	μg	20		MULTIPLE	UNKNOWN		day	4	Ipratropium bromide is minimally bound (0% to 9% in vitro) to plasma albumin and alpha1-acid glycoprotein.	95.5	UNHEALTHY	Respiratory	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021747s010lbl.pdf	Homo sapiens		h	2							true
5116	2421		ADULT	657309	332.4571	IPRATROPIUM	IPRATROPIUM	CC(C)[N@+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](CO)C3=CC=CC=C3	PLASMA	GR88G0I6UL	2083		ALBUTEROL	albuterol	CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1	QF8SVZ843E			?	pg × h/mL	131		pg/mL	35.4			RECOMMENDED	μg	20		STEADY-STATE	UNKNOWN		day	4			UNKNOWN	Respiratory	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021747s010lbl.pdf	Homo sapiens										true
5117	2421		ADULT	657309	332.4571	IPRATROPIUM	IPRATROPIUM	CC(C)[N@+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](CO)C3=CC=CC=C3	PLASMA	GR88G0I6UL	2083		ALBUTEROL	albuterol	CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1	QF8SVZ843E			?	pg × h/mL	123		pg/mL	31.7			RECOMMENDED	μg	20		STEADY-STATE	UNKNOWN		day	4			UNKNOWN	Respiratory	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021747s010lbl.pdf	Homo sapiens										true
5118	2422		ADULT	3749	428.5294	IRBESARTAN	IRBESARTAN	CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=C(C=CC=C4)C5=NN=NN5	PLASMA	J0E2756Z7N									?	μg × h/mL	9.7		μg/mL	1.9			RECOMMENDED	mg	150		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9549663	Homo sapiens		h	16							false
5119	2422		ADULT	3749	428.5294	IRBESARTAN	IRBESARTAN	CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=C(C=CC=C4)C5=NN=NN5	PLASMA	J0E2756Z7N									?	μg × h/mL	20		μg/mL	2.9			UNKNOWN	mg	300		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9549663	Homo sapiens		h	14							false
5120	2422		ADULT	3749	428.5294	IRBESARTAN	IRBESARTAN	CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=C(C=CC=C4)C5=NN=NN5	PLASMA	J0E2756Z7N									?	μg × h/mL	32.6		μg/mL	4.9			UNKNOWN	mg	600		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9549663	Homo sapiens		h	14							false
5121	2422		ADULT	3749	428.5294	IRBESARTAN	IRBESARTAN	CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=C(C=CC=C4)C5=NN=NN5	PLASMA	J0E2756Z7N									?	μg × h/mL	44.8		μg/mL	5.3			UNKNOWN	mg	900		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9549663	Homo sapiens		h	17							false
5122	2422		ADULT	3749	428.5294	IRBESARTAN	IRBESARTAN	CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=C(C=CC=C4)C5=NN=NN5	PLASMA	J0E2756Z7N									?	μg × h/mL	9.3		μg/mL	2.04			RECOMMENDED	mg	150		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9549663	Homo sapiens		h	11							false
5123	2422		ADULT	3749	428.5294	IRBESARTAN	IRBESARTAN	CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=C(C=CC=C4)C5=NN=NN5	PLASMA	J0E2756Z7N									?	μg × h/mL	19.8		μg/mL	3.3			UNKNOWN	mg	300		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9549663	Homo sapiens		h	11							false
5124	2422		ADULT	3749	428.5294	IRBESARTAN	IRBESARTAN	CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=C(C=CC=C4)C5=NN=NN5	PLASMA	J0E2756Z7N									?	μg × h/mL	31.9		μg/mL	4.4			UNKNOWN	mg	600		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9549663	Homo sapiens		h	15							false
5125	2422		ADULT	3749	428.5294	IRBESARTAN	IRBESARTAN	CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=C(C=CC=C4)C5=NN=NN5	PLASMA	J0E2756Z7N									?	μg × h/mL	34.2		μg/mL	5.6			UNKNOWN	mg	900		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9549663	Homo sapiens		h	14							false
5126	2422		UNKNOWN	3749	428.5294	IRBESARTAN	IRBESARTAN	CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=C(C=CC=C4)C5=NN=NN5	SERUM	J0E2756Z7N																	UNKNOWN				UNKNOWN	UNKNOWN				Irbesartan is 90% bound to serum proteins (primarily albumin and α1-acid glycoprotein) with negligible binding to cellular components of blood.	10	UNKNOWN	UNKNOWN	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020758s079lbl.pdf	Homo sapiens										false
5127	2423		ADULT	60838	586.678	IRINOTECAN	Irinotecan	CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC5=CC=C(OC(=O)N6CCC(CC6)N7CCCCC7)C=C15	PLASMA	7673326042							24		t	ng × h/mL	10200		ng/mL	1660			UNKNOWN	mg/m²	125		SINGLE	UNKNOWN				Irinotecan exhibits moderate plasma protein binding (30% to 68% bound).	51	UNHEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020571s051lbl.pdf	Homo sapiens		h	5.8							false
5128	2423		ADULT	60838	586.678	IRINOTECAN	IRINOTECAN	CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC5=CC=C(OC(=O)N6CCC(CC6)N7CCCCC7)C=C15	PLASMA	7673326042							24		t	ng × h/mL	20604		ng/mL	3392			UNKNOWN	mg/m²	340		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020571s051lbl.pdf	Homo sapiens		h	11.7							false
5129	2424		UNKNOWN	208908	581.058	LAPATINIB	LAPATINIB	CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(Cl)=C(OCC5=CC(F)=CC=C5)C=C4	PLASMA																							UNKNOWN				Lapatinib is highly bound (>99%) to albumin and alpha-1 acid glycoprotein	1	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022059s007lbl.pdf	Homo sapiens										false
5130	2424		ADULT	208908	580.1347	LAPATINIB	LAPATINIB	C[S+]([O-])(=O)CCNCC1=CC=C(O1)C2=CC3=C(NC4=CC=C(OCC5=CC(F)=CC=C5)C(Cl)=C4)N=CN=C3C=C2	PLASMA	0VUA21238F									∞	μg × h/mL	36.2		μg/mL	2.43			UNKNOWN	mg	1250		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/tykerb.pdf	Homo sapiens		h	24							false
5131	2425		ADULT	47499	520.473	LATAMOXEF	LATAMOXEF	CO[C@]2(NC(=O)C(C(O)=O)C1=CC=C(O)C=C1)[C@H]3OCC(CSC4=NN=NN4C)=C(N3C2=O)C(O)=O	SERUM	VUF6C936Z3									∞	μg × h/mL	294						UNKNOWN	g	1		SINGLE	UNKNOWN				protein binding between 45 and 60%	40	HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6252833	Homo sapiens		h	2.85							false
5132	2425		ADULT	47499	520.473	LATAMOXEF	LATAMOXEF	CO[C@]2(NC(=O)C(C(O)=O)C1=CC=C(O)C=C1)[C@H]3OCC(CSC4=NN=NN4C)=C(N3C2=O)C(O)=O	PLASMA	VUF6C936Z3																	UNKNOWN	mg	500		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6643333	Homo sapiens		h	0.23							false
5133	2425		ADULT	47499	520.473	LATAMOXEF	LATAMOXEF	CO[C@]2(NC(=O)C(C(O)=O)C1=CC=C(O)C=C1)[C@H]3OCC(CSC4=NN=NN4C)=C(N3C2=O)C(O)=O	PLASMA	VUF6C936Z3													mg/L	17.8			UNKNOWN	mg	500		SINGLE	UNKNOWN						HEALTHY	Intramuscular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6643333	Homo sapiens										false
5134	2425		ADULT	47499	520.473	LATAMOXEF	LATAMOXEF	CO[C@]2(NC(=O)C(C(O)=O)C1=CC=C(O)C=C1)[C@H]3OCC(CSC4=NN=NN4C)=C(N3C2=O)C(O)=O	PLASMA	VUF6C936Z3													mg/L	21.8			UNKNOWN	mg	500		MULTIPLE	UNKNOWN		day	3			HEALTHY	Intramuscular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6643333	Homo sapiens										false
5135	2426		ADULT	657181	1209.3983	LEUPROLIDE	LEUPROLIDE	CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=C3C=CC=C4)NC(=O)[C@H](CC5=CNC=N5)NC(=O)[C@@H]6CCC(=O)N6	PLASMA	EFY6W0M8TG									∞	ng × h/mL	426.2		ng/mL	32.48			RECOMMENDED	mg	11.25		SINGLE	UNKNOWN						UNHEALTHY	Subcutaneous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27824264	Homo sapiens										false
5136	2426		ADULT	657181	1209.3983	LEUPROLIDE	LEUPROLIDE	CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=C3C=CC=C4)NC(=O)[C@H](CC5=CNC=N5)NC(=O)[C@@H]6CCC(=O)N6	PLASMA	EFY6W0M8TG																	UNKNOWN	mg	1		SINGLE	UNKNOWN				In vitro binding to human plasma proteins ranged from 43% to 49%	54	HEALTHY	Intravenous	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019943s031,020011s038,020708s031lbl.pdf	Homo sapiens		h	3							false
5137	2428		ADULT	3000540	406.537	LINCOMYCIN	LINCOMYCIN	CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@@H](C)O)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O	SERUM	BOD072YW0F									∞	μg × h/mL	72.5						RECOMMENDED	mg	600		SINGLE	UNKNOWN				Serum protein binding, as determined by ultrafiltration, ranged from 28% to 86%,	43	HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3950061	Homo sapiens		h	5.1							false
5138	2428		ADULT	3000540	406.537	LINCOMYCIN	LINCOMYCIN	CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@@H](C)O)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O	SERUM	BOD072YW0F									∞	μg × h/mL	125.8						UNKNOWN	mg	1200		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3950061	Homo sapiens		h	5.4							false
5139	2428		ADULT	3000540	406.537	LINCOMYCIN	LINCOMYCIN	CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@@H](C)O)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O	SERUM	BOD072YW0F									∞	μg × h/mL	212.8						UNKNOWN	mg	2400		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3950061	Homo sapiens		h	6.4							false
5140	2428		UNKNOWN	3000540	406.537	LINCOMYCIN	LINCOMYCIN	CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@@H](C)O)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O	SERUM	BOD072YW0F													μg/mL	11.6			RECOMMENDED	mg	600		SINGLE	UNKNOWN						UNKNOWN	Intramuscular	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/050317s183lbl.pdf	Homo sapiens		h	5.4							false
5141	2428		UNKNOWN	3000540	406.537	LINCOMYCIN	LINCOMYCIN	CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@@H](C)O)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O	SERUM	BOD072YW0F													μg/mL	15.9			RECOMMENDED	mg	600		SINGLE	UNKNOWN						UNKNOWN	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/050317s183lbl.pdf	Homo sapiens		h	5.4							false
5142	2429		ADULT	5919|23666110|24812736	672.9553	LIOTHYRONINE SODIUM	LIOTHYRONINE SODIUM	[Na+].N[C@@H](CC1=CC(I)=C(OC2=CC=C(O)C(I)=C2)C(I)=C1)C([O-])=O	PLASMA	GCA9VV7D2N							24		t	ng × h/dL	4740		ng/dL	346			UNKNOWN	μg	50		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24977379	Homo sapiens		h	22.04							false
5143	2429		ADULT	5919|23666110|24812736	672.9553	LIOTHYRONINE SODIUM	LIOTHYRONINE SODIUM	[Na+].N[C@@H](CC1=CC(I)=C(OC2=CC=C(O)C(I)=C2)C(I)=C1)C([O-])=O	PLASMA	GCA9VV7D2N							96		t	ng × h/dL	13938		ng/dL	404			UNKNOWN	μg	50		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24977379	Homo sapiens										false
5144	2429		ADULT	5919|23666110|24812736	672.9553	LIOTHYRONINE SODIUM	LIOTHYRONINE SODIUM	[Na+].N[C@@H](CC1=CC(I)=C(OC2=CC=C(O)C(I)=C2)C(I)=C1)C([O-])=O	PLASMA	GCA9VV7D2N							24		t	ng × h/dL	4926						UNKNOWN	μg	50		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24977379	Homo sapiens										false
5145	2429		ADULT	5919|23666110|24812736	672.9553	LIOTHYRONINE SODIUM	LIOTHYRONINE SODIUM	[Na+].N[C@@H](CC1=CC(I)=C(OC2=CC=C(O)C(I)=C2)C(I)=C1)C([O-])=O	PLASMA	GCA9VV7D2N							96		t	ng × h/dL	12929		ng/dL	342			UNKNOWN	μg	50		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24977379	Homo sapiens										false
5146	2429		ADULT	5919|23666110|24812736	672.9553	LIOTHYRONINE SODIUM	LIOTHYRONINE SODIUM	[Na+].N[C@@H](CC1=CC(I)=C(OC2=CC=C(O)C(I)=C2)C(I)=C1)C([O-])=O	PLASMA	GCA9VV7D2N							24		t	ng × h/dL	4370						UNKNOWN	μg	50		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24977379	Homo sapiens										false
5147	2431		ADULT	3948|74685900	351.13943	LOMEFLOXACIN	LOMEFLOXACIN	CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N3CCNC(C)C3)C(F)=C12	PLASMA	L6BR2WJD8V									∞	μg × h/mL	25.9		μg/mL	2.8			DEFINED DAILY	mg	400		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/20013s015lbl.pdf	Homo sapiens		h	7.75							false
5148	2432		ADULT	3955	476.2231	LOPERAMIDE	LOPERAMIDE	CN(C)C(=O)C(CCN1CCC(O)(CC1)C2=CC=C(Cl)C=C2)(C3=CC=CC=C3)C4=CC=CC=C4	PLASMA	6X9OC3H4II																	DEFINED DAILY	mg	4		SINGLE	UNKNOWN				the plasma protein binding of loperamide is about 95%	5	HEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/017694s052lbl.pdf052lbl.pdf	Homo sapiens		h	10.8							false
5149	2432		ADULT	3955	476.2231	LOPERAMIDE	LOPERAMIDE	CN(C)C(=O)C(CCN1CCC(O)(CC1)C2=CC=C(Cl)C=C2)(C3=CC=CC=C3)C4=CC=CC=C4	BLOOD	6X9OC3H4II									∞	ng × h/mL	26.1		ng/mL	2.24			UNKNOWN	mg	8		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/438356	Homo sapiens		h	11.2							false
5150	2433		ADULT	13221|46912050|85320918	203.752	MECAMYLAMINE HYDROCHLORIDE	MECAMYLAMINE HYDROCHLORIDE	Cl.CNC1(C)C2CCC(C2)C1(C)C	PLASMA	4956DJR58O							24		t	ng × h/mL	115.3		ng/mL	7.89			UNKNOWN	mg	2.5		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11354389	Homo sapiens		h	10.1							false
5151	2433		ADULT	13221|46912050|85320918	203.752	MECAMYLAMINE HYDROCHLORIDE	MECAMYLAMINE HYDROCHLORIDE	Cl.CNC1(C)C2CCC(C2)C1(C)C	PLASMA	4956DJR58O							72		t	ng × h/mL	149.3						UNKNOWN	mg	2.5		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11354389	Homo sapiens										false
5152	2433		ADULT	13221|46912050|85320918	203.752	MECAMYLAMINE HYDROCHLORIDE	MECAMYLAMINE HYDROCHLORIDE	Cl.CNC1(C)C2CCC(C2)C1(C)C	PLASMA	4956DJR58O									∞	ng × h/mL	150.6						UNKNOWN	mg	2.5		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11354389	Homo sapiens										false
5153	2433		ADULT	13221|46912050|85320918	203.752	MECAMYLAMINE HYDROCHLORIDE	MECAMYLAMINE HYDROCHLORIDE	Cl.CNC1(C)C2CCC(C2)C1(C)C	PLASMA	4956DJR58O							24		t	ng × h/mL	352.3		ng/mL	23.68			UNKNOWN	mg	7.5		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11354389	Homo sapiens		h	10.5							false
5154	2433		ADULT	13221|46912050|85320918	203.752	MECAMYLAMINE HYDROCHLORIDE	MECAMYLAMINE HYDROCHLORIDE	Cl.CNC1(C)C2CCC(C2)C1(C)C	PLASMA	4956DJR58O							72		t	ng × h/mL	467.3						UNKNOWN	mg	7.5		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11354389	Homo sapiens										false
5155	2433		ADULT	13221|46912050|85320918	203.752	MECAMYLAMINE HYDROCHLORIDE	MECAMYLAMINE HYDROCHLORIDE	Cl.CNC1(C)C2CCC(C2)C1(C)C	PLASMA	4956DJR58O									∞	ng × h/mL	472.6						UNKNOWN	mg	7.5		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11354389	Homo sapiens										false
5156	2435		UNKNOWN	4071|667490	152.177	MERCAPTOPURINE ANHYDROUS	6-MERCAPTOPURINE	S=C1NC=NC2=C1N=CN2	PLASMA	PKK6MUZ20G																						UNKNOWN				Plasma protein binding averages 19% over the concentration range 10 to 50 mcg/mL (a concentration only achieved by intravenous administration of mercaptopurine at doses exceeding 5 to 10 mg/kg).	81	UNKNOWN		UNKNOWN	DRUG LABEL	https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/15904472-4c32-4224-95d3-eb131a7ff9c8/spl-doc?hl=mercaptopurine	Homo sapiens										false
5157	2435		CHILD	4071|667490	152.177	MERCAPTOPURINE ANHYDROUS	6-MERCAPTOPURINE	S=C1NC=NC2=C1N=CN2	PLASMA	PKK6MUZ20G							8		t	ng × h/mL	200		ng/mL	74			UNKNOWN	mg/m²	75		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/3470165	Homo sapiens		h	2							false
5158	2435		ADULT	4071|667490	152.177	MERCAPTOPURINE ANHYDROUS	6-Mercaptopurine	S=C1NC=NC2=C1N=CN2	PLASMA	PKK6MUZ20G									∞	ng × h/mL	135.8		ng/mL	69.5			UNKNOWN	mg	600		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/9048271	Homo sapiens										false
5159	2440		ADULT	9681	353.458	METHYSERGIDE	METHYSERGIDE	CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CN(C)C4=C3C(=CC=C4)C2=C1	PLASMA	XZA9HY6Z98									∞	nM × min	2027		nM	33			UNKNOWN	mg	0.753		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3709634/	Homo sapiens		min	45							false
5160	2440		ADULT	9681	353.458	METHYSERGIDE	METHYSERGIDE	CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CN(C)C4=C3C(=CC=C4)C2=C1	PLASMA	XZA9HY6Z98									∞	nM × min	563.9		nM	5			UNKNOWN	mg	2		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3709634/	Homo sapiens		min	62							false
5161	2441		ADULT	162812	267.3639	DESACETYLMETIPRANOLOL	Desacetylmetipranolol	CC(C)NCC(O)COC1=C(C)C(C)=C(O)C(C)=C1	PLASMA	5GA6I7V01M									?	ng × h/mL	111.4		ng/mL	33.8			UNKNOWN	mg	40		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1971217	Homo sapiens										false
5162	2441		ADULT	162812	267.3639	DESACETYLMETIPRANOLOL	Desacetylmetipranolol	CC(C)NCC(O)COC1=C(C)C(C)=C(O)C(C)=C1	SERUM	5GA6I7V01M									?	μg × h/L	254.4		μg/L	77.15			UNKNOWN	mg	40		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6120080	Homo sapiens		h	3.271							false
5163	2442		UNKNOWN	4170	365.835	METOLAZONE	METOLAZONE	CC1NC2=CC(Cl)=C(C=C2C(=O)N1C3=C(C)C=CC=C3)S(N)(=O)=O	BLOOD	TZ7V40X7VX							48		t	ng × h/mL	99.74		ng/mL	3.63			RECOMMENDED	mg	2.5		UNKNOWN	UNKNOWN		day	1	Clinical studies have shown that ninety to nine-five percent of metolazone is bound to red blood cells and plasma protein	7.5	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	http://products.sanofi.ca/en/zaroxolyn.pdf	Homo sapiens										false
5164	2442		ADULT	4170	365.835	METOLAZONE	METOLAZONE	CC1NC2=CC(Cl)=C(C=C2C(=O)N1C3=C(C)C=CC=C3)S(N)(=O)=O	PLASMA	TZ7V40X7VX									∞	ng × h/mL	50.51		ng/mL	8.225			INVESTIGATIONAL	mg	0.5		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/29145890	Homo sapiens		h	7.47							false
5165	2443		ADULT	4174	226.2738	METYRAPONE	METYRAPONE	CC(C)(C(=O)C1=CN=CC=C1)C2=CN=CC=C2	PLASMA	ZS9KD92H6V													μg/mL	3.7			RECOMMENDED	mg	750		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/012911s026lbl.pdf	Homo sapiens		h	1.9							false
5166	2443		ADULT	4174	226.2738	METYRAPONE	metyrapone	CC(C)(C(=O)C1=CN=CC=C1)C2=CN=CC=C2	PLASMA	ZS9KD92H6V													μg/mL	7.3			UNKNOWN	mg	2000		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/012911s026lbl.pdf	Homo sapiens										false
5167	2444		ADULT	656511	539.582	MEZLOCILLIN	MEZLOCILLIN	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)C4=CC=CC=C4)C(=O)N2[C@H]1C(O)=O	SERUM	OH2O403D1G									?	mg × h/L	275		mg/L	216.6			UNKNOWN	g	4		SINGLE	FASTED						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3680597	Homo sapiens		h	1.32							false
5168	2444		ADULT	656511	539.582	MEZLOCILLIN	MEZLOCILLIN	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)C4=CC=CC=C4)C(=O)N2[C@H]1C(O)=O	SERUM	OH2O403D1G									?	mg × h/L	403		mg/L	317			UNKNOWN	g	5		SINGLE	FASTED						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3680597	Homo sapiens		h	1.13							false
5169	2444		ADULT	656511	539.582	MEZLOCILLIN	MEZLOCILLIN	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)C4=CC=CC=C4)C(=O)N2[C@H]1C(O)=O	SERUM	OH2O403D1G									?	mg × h/L	415.2		mg/L	138.84			UNKNOWN	g	3		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3818496	Homo sapiens		h	2.1							false
5170	2445		ADULT	4192	325.767	MIDAZOLAM	MIDAZOLAM	CC1=NC=C2CN=C(C3=C(F)C=CC=C3)C4=C(C=CC(Cl)=C4)N12	PLASMA	R60L0SM5BC									?	nM × h	30							mg	2		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01361217	Homo sapiens										false
5171	2445		ADULT	4192	325.767	MIDAZOLAM	MIDAZOLAM	CC1=NC=C2CN=C(C3=C(F)C=CC=C3)C4=C(C=CC(Cl)=C4)N12	PLASMA	R60L0SM5BC									∞	ng × h/mL	103.348							mg	6		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01989169	Homo sapiens										false
5172	2445		ADULT	4192	325.767	MIDAZOLAM	MIDAZOLAM	CC1=NC=C2CN=C(C3=C(F)C=CC=C3)C4=C(C=CC(Cl)=C4)N12	PLASMA	R60L0SM5BC							72		t	ng × h/mL	100.935							mg	6		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01989169	Homo sapiens										false
5173	2445		ADULT	4192	325.767	MIDAZOLAM	MIDAZOLAM	CC1=NC=C2CN=C(C3=C(F)C=CC=C3)C4=C(C=CC(Cl)=C4)N12	PLASMA	R60L0SM5BC													ng/mL	35.124				mg	6		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01989169	Homo sapiens										false
5174	2445		ADULT	4192	325.767	MIDAZOLAM	MIDAZOLAM	CC1=NC=C2CN=C(C3=C(F)C=CC=C3)C4=C(C=CC(Cl)=C4)N12	PLASMA	R60L0SM5BC									∞	ng × h/mL	402.7		ng/mL	113.9			RECOMMENDED	mg	10		SINGLE	UNKNOWN				is approximately 97% bound to plasma protein, principally albumin	3	HEALTHY	Intramuscular	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209566Orig1s000lbl.pdf	Homo sapiens										false
5175	2445		ADULT	4192	325.767	MIDAZOLAM	MIDAZOLAM	CC1=NC=C2CN=C(C3=C(F)C=CC=C3)C4=C(C=CC(Cl)=C4)N12	PLASMA	R60L0SM5BC									∞	ng × h/mL	126.2		ng/mL	54.7			RECOMMENDED	mg	5		SINGLE	UNKNOWN				is approximately 97% bound to plasma protein, principally albumin	3	HEALTHY	Nasal	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211321s000lbl.pdf	Homo sapiens										false
5176	2446		UNKNOWN	4212	444.4809	MITOXANTRONE	MITOXANTRONE	OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C3=C(C2=O)C(O)=CC=C3O	PLASMA	BZ114NVM5P																						UNKNOWN				Mitoxantrone is 78% bound to plasma proteins in the observed concentration range of 26 to 455 ng/mL.	22	UNKNOWN		UNKNOWN	DRUG LABEL	https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/fcb8ef8a-f770-4416-8fc5-fa01d98c8eee/spl-doc?hl=MITOXANTRONE	Homo sapiens										false
5177	2446		ADULT	4212	444.4809	MITOXANTRONE	MITOXANTRONE	OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C3=C(C2=O)C(O)=CC=C3O	PLASMA	BZ114NVM5P									∞	μg × h/mL	1.26						UNKNOWN	mg/m²	12		MULTIPLE	UNKNOWN		3 weeks	1			UNHEALTHY	Intravenous	FEMALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/1558794	Homo sapiens		h	19.83							false
5178	2446		ADULT	4212	444.4809	MITOXANTRONE	MITOXANTRONE	OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C3=C(C2=O)C(O)=CC=C3O	PLASMA	BZ114NVM5P									∞	mg × h/L	5.195		mg/L	6.429			MAX TOLERATED	mg/m²	90		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/8402672	Homo sapiens										false
5179	2446		ADULT	4212	444.4809	MITOXANTRONE	MITOXANTRONE	OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C3=C(C2=O)C(O)=CC=C3O	PLASMA	BZ114NVM5P									∞	ng × h/mL	1922						UNKNOWN	mg/m²	40		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/8410125	Homo sapiens		h	37.1							false
5180	2447		ADULT		1029.3	MIVACURIUM, TRANS-TRANS-	MIVACURIUM, TRANS-TRANS-		PLASMA	294JG9B7GL									∞	μg × min/mL	2.932		ng/mL	4486			UNKNOWN	mg/kg	0.15		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9054251/	Homo sapiens		min	2.4							false
5181	2447		ADULT		1029.3	MIVACURIUM, CIS-TRANS-	MIVACURIUM, CIS-TRANS-		PLASMA	TA6ZI937GP									∞	μg × min/mL	1.178		ng/mL	2198			UNKNOWN	mg/kg	0.15		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9054251/	Homo sapiens		min	2							false
5182	2447		ADULT		1029.3	MIVACURIUM, CIS-CIS-	MIVACURIUM, CIS-CIS-		PLASMA	45R5FKB2CT									∞	μg × min/mL	1.295		ng/mL	504			UNKNOWN	mg/kg	0.15		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9054251/	Homo sapiens		min	28.5							false
5183	2449		ADULT	23897	276.374	MOLINDONE	MOLINDONE	CCC1=C(C)NC2=C1C(=O)C(CN3CCOCC3)CC2	PLASMA	RT3Y3QMF8N									?	ng × h/mL	1897		ng/mL	482			RECOMMENDED	mg	150		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2861214/	Homo sapiens										false
5184	2449		ADULT	23897	276.374	MOLINDONE	MOLINDONE	CCC1=C(C)NC2=C1C(=O)C(CN3CCOCC3)CC2	PLASMA	RT3Y3QMF8N									?	μg × h/mL	1.76						RECOMMENDED	mg	75		SINGLE	UNKNOWN						HEALTHY	Intramuscular	FEMALE / MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/7656507/	Homo sapiens		h	2							false
5185	2450			5281040	586.183	MONTELUKAST	MONTELUKAST	CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C3=CC(\\C=C\\C4=NC5=C(C=CC(Cl)=C5)C=C4)=CC=C3)C=CC=C1	PLASMA	MHM278SD3E							24		t	ng × h/mL	214		ng/mL	23.4				mg	1		MULTIPLE			day	1			UNHEALTHY	Respiratory		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00636207	Homo sapiens		h	8.2							false
5186	2450			5281040	586.183	MONTELUKAST	MONTELUKAST	CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C3=CC(\\C=C\\C4=NC5=C(C=CC(Cl)=C5)C=C4)=CC=C3)C=CC=C1	PLASMA	MHM278SD3E							24		t	ng × h/mL	1850							mg	10		MULTIPLE			day	1			UNHEALTHY	Respiratory		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00636207	Homo sapiens										false
5187	2450			5281040	586.183	MONTELUKAST	MONTELUKAST	CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C3=CC(\\C=C\\C4=NC5=C(C=CC(Cl)=C5)C=C4)=CC=C3)C=CC=C1	PLASMA	MHM278SD3E							24		t	ng × h/mL	1880							mg	10		MULTIPLE			day	1			UNHEALTHY	Respiratory		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00636207	Homo sapiens										false
5188	2450			5281040	586.183	MONTELUKAST	MONTELUKAST	CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C3=CC(\\C=C\\C4=NC5=C(C=CC(Cl)=C5)C=C4)=CC=C3)C=CC=C1	PLASMA	MHM278SD3E													ng/mL	242				mg	10		MULTIPLE			day	1			UNHEALTHY	Respiratory		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00636207	Homo sapiens										false
5189	2450			5281040	586.183	MONTELUKAST	MONTELUKAST	CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C3=CC(\\C=C\\C4=NC5=C(C=CC(Cl)=C5)C=C4)=CC=C3)C=CC=C1	PLASMA	MHM278SD3E													ng/mL	225				mg	10		MULTIPLE			day	1			UNHEALTHY	Respiratory		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00636207	Homo sapiens										false
5190	2450			5281040	586.183	MONTELUKAST	MONTELUKAST	CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C3=CC(\\C=C\\C4=NC5=C(C=CC(Cl)=C5)C=C4)=CC=C3)C=CC=C1	PLASMA	MHM278SD3E																		mg	10		MULTIPLE			day	1			UNHEALTHY	Respiratory		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00636207	Homo sapiens		h	7.7							false
5191	2450			5281040	586.183	MONTELUKAST	MONTELUKAST	CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C3=CC(\\C=C\\C4=NC5=C(C=CC(Cl)=C5)C=C4)=CC=C3)C=CC=C1	PLASMA	MHM278SD3E																		mg	10		MULTIPLE			day	1			UNHEALTHY	Respiratory		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00636207	Homo sapiens		h	7.4							false
5192	2450			5281040	586.183	MONTELUKAST	MONTELUKAST	CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C3=CC(\\C=C\\C4=NC5=C(C=CC(Cl)=C5)C=C4)=CC=C3)C=CC=C1	PLASMA	MHM278SD3E							24		t	ng × h/mL	576							mg	3		MULTIPLE			day	1			UNHEALTHY	Respiratory		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00636207	Homo sapiens										false
5193	2450			5281040	586.183	MONTELUKAST	MONTELUKAST	CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C3=CC(\\C=C\\C4=NC5=C(C=CC(Cl)=C5)C=C4)=CC=C3)C=CC=C1	PLASMA	MHM278SD3E							24		t	ng × h/mL	526							mg	3		MULTIPLE			day	1			UNHEALTHY	Respiratory		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00636207	Homo sapiens										false
5194	2450			5281040	586.183	MONTELUKAST	MONTELUKAST	CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C3=CC(\\C=C\\C4=NC5=C(C=CC(Cl)=C5)C=C4)=CC=C3)C=CC=C1	PLASMA	MHM278SD3E													ng/mL	76				mg	3		MULTIPLE			day	1			UNHEALTHY	Respiratory		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00636207	Homo sapiens										false
5195	2450			5281040	586.183	MONTELUKAST	MONTELUKAST	CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C3=CC(\\C=C\\C4=NC5=C(C=CC(Cl)=C5)C=C4)=CC=C3)C=CC=C1	PLASMA	MHM278SD3E													ng/mL	64.8				mg	3		MULTIPLE			day	1			UNHEALTHY	Respiratory		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00636207	Homo sapiens										false
5196	2450			5281040	586.183	MONTELUKAST	MONTELUKAST	CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C3=CC(\\C=C\\C4=NC5=C(C=CC(Cl)=C5)C=C4)=CC=C3)C=CC=C1	PLASMA	MHM278SD3E																		mg	3		MULTIPLE			day	1			UNHEALTHY	Respiratory		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00636207	Homo sapiens		h	7.6							false
5197	2450			5281040	586.183	MONTELUKAST	MONTELUKAST	CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C3=CC(\\C=C\\C4=NC5=C(C=CC(Cl)=C5)C=C4)=CC=C3)C=CC=C1	PLASMA	MHM278SD3E																		mg	3		MULTIPLE			day	1			UNHEALTHY	Respiratory		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00636207	Homo sapiens		h	8.1							false
5198	2450			5281040	586.183	MONTELUKAST	MONTELUKAST	CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C3=CC(\\C=C\\C4=NC5=C(C=CC(Cl)=C5)C=C4)=CC=C3)C=CC=C1	PLASMA	MHM278SD3E													ng/mL	5.1				mg	0.3		SINGLE							UNHEALTHY	Respiratory		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00636207	Homo sapiens										false
5199	2450			5281040	586.183	MONTELUKAST	MONTELUKAST	CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C3=CC(\\C=C\\C4=NC5=C(C=CC(Cl)=C5)C=C4)=CC=C3)C=CC=C1	PLASMA	MHM278SD3E													ng/mL	5.24				mg	0.3		SINGLE							UNHEALTHY	Respiratory		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00636207	Homo sapiens										false
5200	2450			5281040	586.183	MONTELUKAST	MONTELUKAST	CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C3=CC(\\C=C\\C4=NC5=C(C=CC(Cl)=C5)C=C4)=CC=C3)C=CC=C1	PLASMA	MHM278SD3E							24		t	ng × h/mL	155		ng/mL	18.5				mg	1		SINGLE							UNHEALTHY	Respiratory		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00636207	Homo sapiens		h	5.7							false
5201	2450			5281040	586.183	MONTELUKAST	MONTELUKAST	CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C3=CC(\\C=C\\C4=NC5=C(C=CC(Cl)=C5)C=C4)=CC=C3)C=CC=C1	PLASMA	MHM278SD3E							24		t	ng × h/mL	132		ng/mL	13.8				mg	1		SINGLE							UNHEALTHY	Respiratory		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00636207	Homo sapiens										false
5202	2450			5281040	586.183	MONTELUKAST	MONTELUKAST	CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C3=CC(\\C=C\\C4=NC5=C(C=CC(Cl)=C5)C=C4)=CC=C3)C=CC=C1	PLASMA	MHM278SD3E							24		t	ng × h/mL	1600		ng/mL	224				mg	10		SINGLE							UNHEALTHY	Respiratory		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00636207	Homo sapiens		h	5.7							false
5203	2450			5281040	586.183	MONTELUKAST	MONTELUKAST	CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C3=CC(\\C=C\\C4=NC5=C(C=CC(Cl)=C5)C=C4)=CC=C3)C=CC=C1	PLASMA	MHM278SD3E							24		t	ng × h/mL	1576							mg	10		SINGLE							UNHEALTHY	Respiratory		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00636207	Homo sapiens										false
5204	2450			5281040	586.183	MONTELUKAST	MONTELUKAST	CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C3=CC(\\C=C\\C4=NC5=C(C=CC(Cl)=C5)C=C4)=CC=C3)C=CC=C1	PLASMA	MHM278SD3E							24		t	ng × h/mL	1500							mg	10		SINGLE							UNHEALTHY	Respiratory		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00636207	Homo sapiens										false
5205	2450			5281040	586.183	MONTELUKAST	MONTELUKAST	CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C3=CC(\\C=C\\C4=NC5=C(C=CC(Cl)=C5)C=C4)=CC=C3)C=CC=C1	PLASMA	MHM278SD3E													ng/mL	233				mg	10		SINGLE							UNHEALTHY	Respiratory		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00636207	Homo sapiens										false
5206	2450			5281040	586.183	MONTELUKAST	MONTELUKAST	CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C3=CC(\\C=C\\C4=NC5=C(C=CC(Cl)=C5)C=C4)=CC=C3)C=CC=C1	PLASMA	MHM278SD3E													ng/mL	184				mg	10		SINGLE							UNHEALTHY	Respiratory		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00636207	Homo sapiens										false
5207	2450			5281040	586.183	MONTELUKAST	MONTELUKAST	CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C3=CC(\\C=C\\C4=NC5=C(C=CC(Cl)=C5)C=C4)=CC=C3)C=CC=C1	PLASMA	MHM278SD3E							24		t	ng × h/mL	491		ng/mL	54.3				mg	3		SINGLE							UNHEALTHY	Respiratory		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00636207	Homo sapiens		h	6.9							false
5208	2450			5281040	586.183	MONTELUKAST	MONTELUKAST	CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C3=CC(\\C=C\\C4=NC5=C(C=CC(Cl)=C5)C=C4)=CC=C3)C=CC=C1	PLASMA	MHM278SD3E							24		t	ng × h/mL	403							mg	3		SINGLE							UNHEALTHY	Respiratory		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00636207	Homo sapiens										false
5209	2450			5281040	586.183	MONTELUKAST	MONTELUKAST	CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C3=CC(\\C=C\\C4=NC5=C(C=CC(Cl)=C5)C=C4)=CC=C3)C=CC=C1	PLASMA	MHM278SD3E							24		t	ng × h/mL	357							mg	3		SINGLE							UNHEALTHY	Respiratory		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00636207	Homo sapiens										false
5210	2450			5281040	586.183	MONTELUKAST	MONTELUKAST	CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C3=CC(\\C=C\\C4=NC5=C(C=CC(Cl)=C5)C=C4)=CC=C3)C=CC=C1	PLASMA	MHM278SD3E													ng/mL	60				mg	3		SINGLE							UNHEALTHY	Respiratory		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00636207	Homo sapiens										false
5211	2450			5281040	586.183	MONTELUKAST	MONTELUKAST	CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C3=CC(\\C=C\\C4=NC5=C(C=CC(Cl)=C5)C=C4)=CC=C3)C=CC=C1	PLASMA	MHM278SD3E													ng/mL	44.3				mg	3		SINGLE							UNHEALTHY	Respiratory		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00636207	Homo sapiens										false
5212	2450		ADULT	5281040	586.183	MONTELUKAST	MONTELUKAST	CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C3=CC(\\C=C\\C4=NC5=C(C=CC(Cl)=C5)C=C4)=CC=C3)C=CC=C1	PLASMA	MHM278SD3E							24		t	ng × h/mL	3540		ng/mL	541.5			RECOMMENDED	mg	10		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9429741/	Homo sapiens		h	5.3							false
5213	2450		ADULT	5281040	586.183	MONTELUKAST	MONTELUKAST	CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C3=CC(\\C=C\\C4=NC5=C(C=CC(Cl)=C5)C=C4)=CC=C3)C=CC=C1	PLASMA	MHM278SD3E							24		t	ng × h/mL	3978		ng/mL	602.8			RECOMMENDED	mg	10		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9429741/	Homo sapiens		h	5.6							false
5214	2451			152946|40467042	401.4314	MOXIFLOXACIN	MOXIFLOXACIN	COC1=C2N(C=C(C(O)=O)C(=O)C2=CC(F)=C1N3C[C@@H]4CCCN[C@@H]4C3)C5CC5	AQUEOUS HUMOR	U188XYD42P													ng/mL	443.07				drop	1		MULTIPLE			day	4			UNHEALTHY	Ocular		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01296191	Homo sapiens										false
5215	2451		ADULT	152946|40467042	401.4314	MOXIFLOXACIN	MOXIFLOXACIN	COC1=C2N(C=C(C(O)=O)C(=O)C2=CC(F)=C1N3C[C@@H]4CCCN[C@@H]4C3)C5CC5	PLASMA	U188XYD42P									?	mg × h/L	36.1		mg/L	3.1			DEFINED DAILY	mg	400		SINGLE	UNKNOWN				Moxifloxacin is approximately 30–50% bound to serum proteins, independent of drug concentration.	60	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf	Homo sapiens		h	13.55							false
5216	2451		ADULT	152946|40467042	401.4314	MOXIFLOXACIN	MOXIFLOXACIN	COC1=C2N(C=C(C(O)=O)C(=O)C2=CC(F)=C1N3C[C@@H]4CCCN[C@@H]4C3)C5CC5	PLASMA	U188XYD42P									?	mg × h/L	48		mg/L	4.5			RECOMMENDED	mg	400		MULTIPLE	UNKNOWN		day	1	Moxifloxacin is approximately 30–50% bound to serum proteins, independent of drug concentration.		HEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf	Homo sapiens		h	12.7							false
5217	2451		ADULT	152946|40467042	401.4314	MOXIFLOXACIN	MOXIFLOXACIN	COC1=C2N(C=C(C(O)=O)C(=O)C2=CC(F)=C1N3C[C@@H]4CCCN[C@@H]4C3)C5CC5	PLASMA	U188XYD42P									?	mg × h/L	39.3		mg/L	3.9			DEFINED DAILY	mg	400		SINGLE	UNKNOWN				Moxifloxacin is approximately 30–50% bound to serum proteins, independent of drug concentration.	60	HEALTHY	Intravenous	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf	Homo sapiens		h	11.8							false
5218	2451		ADULT	152946|40467042	401.4314	MOXIFLOXACIN	MOXIFLOXACIN	COC1=C2N(C=C(C(O)=O)C(=O)C2=CC(F)=C1N3C[C@@H]4CCCN[C@@H]4C3)C5CC5	PLASMA	U188XYD42P									?	mg × h/L	38		mg/L	4.2			RECOMMENDED	mg	400		MULTIPLE	UNKNOWN		day	1	Moxifloxacin is approximately 30–50% bound to serum proteins, independent of drug concentration.		HEALTHY	Intravenous	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf	Homo sapiens		h	14.8							false
5219	2452		ADULT	5311304	357.4434	NALBUPHINE	NALBUPHINE	O[C@H]1CC[C@@]2(O)[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC6CCC6)[C@H]1O5	PLASMA	L2T84IQI2K									∞	μg × h/L	139.9						RECOMMENDED	mg	10		SINGLE	FASTED				nalbuphine was 50% bound on plasma proteins in healthy volunteers	50	HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2758732	Homo sapiens		h	2.28							false
5220	2452		ADULT	5311304	357.4434	NALBUPHINE	NALBUPHINE	O[C@H]1CC[C@@]2(O)[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC6CCC6)[C@H]1O5	PLASMA	L2T84IQI2K									∞	μg × h/L	25.8		μg/L	7.3			UNKNOWN	mg	30		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2758732	Homo sapiens		h	10.6							false
5221	2452		CHILD	5311304	357.4434	NALBUPHINE	NALBUPHINE	O[C@H]1CC[C@@]2(O)[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC6CCC6)[C@H]1O5	PLASMA	L2T84IQI2K									∞	ng × h/mL	58.2		ng/mL	24.8			UNKNOWN	mg/kg	0.3		SINGLE	FASTED						HEALTHY	Rectal	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9107559	Homo sapiens		h	2.7							false
5222	2453		ADULT	5284594	339.4281	NALMEFENE	NALMEFENE	OC1=C2O[C@H]3C(=C)CC[C@@]4(O)[C@H]5CC(C=C1)=C2[C@@]34CCN5CC6CC6	PLASMA	TOV02TDP9I									∞	ng × h/mL	274		ng/mL	24.3			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3680580/	Homo sapiens		h	10.3							false
5223	2453		ADULT	5284594	339.4281	NALMEFENE	NALMEFENE	OC1=C2O[C@H]3C(=C)CC[C@@]4(O)[C@H]5CC(C=C1)=C2[C@@]34CCN5CC6CC6	PLASMA	TOV02TDP9I									∞	ng × h/mL	647		ng/mL	57.9			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3680580/	Homo sapiens		h	11.4							false
5224	2453		ADULT	5284594	339.4281	NALMEFENE	NALMEFENE	OC1=C2O[C@H]3C(=C)CC[C@@]4(O)[C@H]5CC(C=C1)=C2[C@@]34CCN5CC6CC6	PLASMA	TOV02TDP9I									∞	ng × h/mL	1320		ng/mL	155			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3680580/	Homo sapiens		h	9.8							false
5225	2453		ADULT	5284594	339.4281	NALMEFENE	NALMEFENE	OC1=C2O[C@H]3C(=C)CC[C@@]4(O)[C@H]5CC(C=C1)=C2[C@@]34CCN5CC6CC6	PLASMA	TOV02TDP9I									∞	ng × h/mL	1876		ng/mL	177			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3680580/	Homo sapiens		h	11.7							false
5226	2453		ADULT	5284594	339.4281	NALMEFENE	NALMEFENE	OC1=C2O[C@H]3C(=C)CC[C@@]4(O)[C@H]5CC(C=C1)=C2[C@@]34CCN5CC6CC6	PLASMA	TOV02TDP9I									∞	ng × h/mL	314						UNKNOWN	mg	20		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3680580/	Homo sapiens		h	9.1							false
5227	2453		ADULT	5284594	339.4281	NALMEFENE	NALMEFENE	OC1=C2O[C@H]3C(=C)CC[C@@]4(O)[C@H]5CC(C=C1)=C2[C@@]34CCN5CC6CC6	PLASMA	TOV02TDP9I									∞	ng × h/mL	16.9						UNKNOWN	mg	2		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3943269/	Homo sapiens										false
5228	2453		ADULT	5284594	339.4281	NALMEFENE	NALMEFENE	OC1=C2O[C@H]3C(=C)CC[C@@]4(O)[C@H]5CC(C=C1)=C2[C@@]34CCN5CC6CC6	PLASMA	TOV02TDP9I									∞	ng × h/mL	109						UNKNOWN	mg	6		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3943269/	Homo sapiens		h	8.2							false
5229	2453		ADULT	5284594	339.4281	NALMEFENE	NALMEFENE	OC1=C2O[C@H]3C(=C)CC[C@@]4(O)[C@H]5CC(C=C1)=C2[C@@]34CCN5CC6CC6	PLASMA	TOV02TDP9I									∞	ng × h/mL	191						UNKNOWN	mg	12		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3943269/	Homo sapiens		h	8.6							false
5230	2453		ADULT	5284594	339.4281	NALMEFENE	NALMEFENE	OC1=C2O[C@H]3C(=C)CC[C@@]4(O)[C@H]5CC(C=C1)=C2[C@@]34CCN5CC6CC6	PLASMA	TOV02TDP9I									∞	ng × h/mL	385						UNKNOWN	mg	24		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3943269/	Homo sapiens		h	8.9							false
5231	2453		ADULT	5284594	339.4281	NALMEFENE	NALMEFENE	OC1=C2O[C@H]3C(=C)CC[C@@]4(O)[C@H]5CC(C=C1)=C2[C@@]34CCN5CC6CC6	PLASMA	TOV02TDP9I									∞	ng × h/mL	16.6						UNKNOWN	mg	1		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8877019/	Homo sapiens		h	10.8							false
5232	2453		ADULT	5284594	339.4281	NALMEFENE	NALMEFENE	OC1=C2O[C@H]3C(=C)CC[C@@]4(O)[C@H]5CC(C=C1)=C2[C@@]34CCN5CC6CC6	PLASMA	TOV02TDP9I									∞	ng × h/mL	29.4						UNKNOWN	mg	2		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8877019/	Homo sapiens		h	9.4							false
5233	2454		ADULT	50294	371.3408	NEDOCROMIL	NEDOCROMIL	CCCC1=C2OC(=CC(=O)C2=CC3=C1N(CC)C(=CC3=O)C(O)=O)C(O)=O	PLASMA										?	ng × h/mL	10.4		ng/mL	13.7			UNKNOWN	μg/kg bw	6		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2825746/	Homo sapiens										false
5234	2454		ADULT	50294	371.3408	NEDOCROMIL	NEDOCROMIL	CCCC1=C2OC(=CC(=O)C2=CC3=C1N(CC)C(=CC3=O)C(O)=O)C(O)=O	PLASMA										?	ng × h/mL	49.1		ng/mL	5.8			UNKNOWN	mg	70.5		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2825746/	Homo sapiens		h	21.1							false
5235	2454		ADULT	50294	371.3408	NEDOCROMIL	NEDOCROMIL	CCCC1=C2OC(=CC(=O)C2=CC3=C1N(CC)C(=CC3=O)C(O)=O)C(O)=O	PLASMA										?	ng × h/mL	9.4		ng/mL	3.3			UNKNOWN	mg	4		SINGLE	FASTED						HEALTHY	Respiratory	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2825746/	Homo sapiens		h	2.3							false
5236	2454		ADULT	50294	371.3408	NEDOCROMIL	NEDOCROMIL	CCCC1=C2OC(=CC(=O)C2=CC3=C1N(CC)C(=CC3=O)C(O)=O)C(O)=O	PLASMA										?	ng × h/mL	5.6		ng/mL	2.8			UNKNOWN	mg	4		SINGLE	FASTED						UNHEALTHY	Respiratory	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2825746/	Homo sapiens		h	1.5							false
5237	2454		ADULT	50294	371.3408	NEDOCROMIL	NEDOCROMIL	CCCC1=C2OC(=CC(=O)C2=CC3=C1N(CC)C(=CC3=O)C(O)=O)C(O)=O	PLASMA										?	ng × h/mL	6.2		ng/mL	2.6			UNKNOWN	mg	20		SINGLE	UNKNOWN						HEALTHY	Respiratory	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020750ap_Tilade_clinphrmr.pdf	Homo sapiens										false
5238	2454		ADULT	50294	371.3408	NEDOCROMIL	NEDOCROMIL	CCCC1=C2OC(=CC(=O)C2=CC3=C1N(CC)C(=CC3=O)C(O)=O)C(O)=O	PLASMA										?	ng × h/mL	4.6		ng/mL	2.1			UNKNOWN	mg	4		SINGLE	UNKNOWN						HEALTHY	Respiratory	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020750ap_Tilade_clinphrmr.pdf	Homo sapiens										false
5239	2454		ADULT	50294	371.3408	NEDOCROMIL	NEDOCROMIL	CCCC1=C2OC(=CC(=O)C2=CC3=C1N(CC)C(=CC3=O)C(O)=O)C(O)=O	PLASMA										∞	ng × h/mL	8.9		ng/mL	13.4			UNKNOWN	mg	0.42		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020750ap_Tilade_clinphrmr.pdf	Homo sapiens		h	31.6							false
5240	2455		ADULT	4474	479.525	NICARDIPINE	NICARDIPINE	COC(=O)C1=C(C)NC(C)=C(C1C2=CC(=CC=C2)[N+]([O-])=O)C(=O)OCCN(C)CC3=CC=CC=C3	PLASMA	CZ5312222S									?	ng × h/mL	846.3		ng/mL	18.8			RECOMMENDED	mg/h	0.5	infusion, 48 hour	OTHER	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2357865	Homo sapiens		h	20.6							false
5241	2455		ADULT	4474	479.525	NICARDIPINE	NICARDIPINE	COC(=O)C1=C(C)NC(C)=C(C1C2=CC(=CC=C2)[N+]([O-])=O)C(=O)OCCN(C)CC3=CC=CC=C3	PLASMA	CZ5312222S									?	ng × h/mL	1426.2		ng/mL	35.1			UNKNOWN	mg/h	1		STEADY-STATE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2357865	Homo sapiens		h	11.3							false
5242	2455		ADULT	4474	479.525	NICARDIPINE	NICARDIPINE	COC(=O)C1=C(C)NC(C)=C(C1C2=CC(=CC=C2)[N+]([O-])=O)C(=O)OCCN(C)CC3=CC=CC=C3	PLASMA	CZ5312222S									?	ng × h/mL	2996.1		ng/mL	64.1			UNKNOWN	mg/h	2	infusion, 48 hour	OTHER	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2357865	Homo sapiens		h	14							false
5243	2455		ADULT	4474	479.525	NICARDIPINE	NICARDIPINE	COC(=O)C1=C(C)NC(C)=C(C1C2=CC(=CC=C2)[N+]([O-])=O)C(=O)OCCN(C)CC3=CC=CC=C3	PLASMA	CZ5312222S									?	ng × h/mL	7510.7		ng/mL	183.9			UNKNOWN	mg/h	4	infusion, 48 hour	OTHER	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2357865	Homo sapiens		h	17.9							false
5244	2455		UNKNOWN	4474	479.525	NICARDIPINE	NICARDIPINE	COC(=O)C1=C(C)NC(C)=C(C1C2=CC(=CC=C2)[N+]([O-])=O)C(=O)OCCN(C)CC3=CC=CC=C3	PLASMA	CZ5312222S																						UNKNOWN				Nicardipine is highly protein bound (>95%) in human plasma over a wide concentration range.	5	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019734s017lbl.pdf	Homo sapiens										false
5245	2457		ADULT	4539|6919051	319.3308	NORFLOXACIN	NORFLOXACIN	CCN1C=C(C(O)=O)C(=O)C2=C1C=C(N3CCNCC3)C(F)=C2	PLASMA	N0F8P22L1P									∞	μg × h/mL	9.8		μg/mL	2.02			UNKNOWN	mg	400		SINGLE	FASTED				The serum protein binding of norfloxacin is between 10 and 15%.	85	HEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019384s067lbl.pdf	Homo sapiens		h	4		elderly subjects (67-74 yr)		6			false
5246	2458		UNKNOWN	4543	263.3767	NORTRIPTYLINE	NORTRIPTYLINE	CNCCC=C1C2=CC=CC=C2CCC3=C1C=CC=C3	PLASMA	BL03SY4LXB									∞	ng × h/mL	767.28		ng/mL	16.91			RECOMMENDED	mg	25		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://pdf.hres.ca/dpd_pm/00001266.PDF	Homo sapiens		h	32.75							false
5247	2458		ADULT	4543	263.3767	NORTRIPTYLINE	NORTRIPTYLINE	CNCCC=C1C2=CC=CC=C2CCC3=C1C=CC=C3	PLASMA	BL03SY4LXB									∞	nM × h	1591		nM	36			RECOMMENDED	mg	25		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12814461	Homo sapiens		h	29.3							false
5248	2458		ADULT	4543	263.3767	NORTRIPTYLINE	NORTRIPTYLINE	CNCCC=C1C2=CC=CC=C2CCC3=C1C=CC=C3	PLASMA	BL03SY4LXB																						UNKNOWN				There was a twofold variation in percent unbound NT (range 5.4% to 11.3%)	8.35	UNHEALTHY		FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7094510	Homo sapiens										false
5249	2459		UNKNOWN	5281071|25271818	337.4122	OLOPATADINE	OLOPATADINE	CN(C)CC\\C=C1/C2=CC(CC(O)=O)=CC=C2OCC3=C1C=CC=C3	PLASMA	D27V6190PM							12		t	ng × h/mL	9.7		ng/mL	1.6			UNKNOWN	drop	1		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Ocular	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206276s000lbl.pdf	Homo sapiens		h	3.4							false
5250	2460		ADULT		302.239	OLSALAZINE	OLSALAZINE	OC(=O)C1=CC(=CC=C1O)\\N=N\\C2=CC(C(O)=O)=C(O)C=C2	SERUM	ULS5I8J03O									?	μM × h	117		μM	32			UNKNOWN	g	4		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3203708/	Homo sapiens										false
5251	2460		ADULT		302.239	OLSALAZINE	OLSALAZINE	OC(=O)C1=CC(=CC=C1O)\\N=N\\C2=CC(C(O)=O)=C(O)C=C2	SERUM	ULS5I8J03O									?	μM × h	13		μM	2.3			DEFINED DAILY	g	1		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3203708/	Homo sapiens										false
5252	2460		ADULT		302.239	OLSALAZINE	OLSALAZINE	OC(=O)C1=CC(=CC=C1O)\\N=N\\C2=CC(C(O)=O)=C(O)C=C2	SERUM	ULS5I8J03O									?	μM × h	13		μM	3.6			DEFINED DAILY	g	1		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3203708/	Homo sapiens										false
5253	2460		ADULT		302.239	OLSALAZINE	OLSALAZINE	OC(=O)C1=CC(=CC=C1O)\\N=N\\C2=CC(C(O)=O)=C(O)C=C2	SERUM	ULS5I8J03O									?	μM × h	22		μM	5.9			UNKNOWN	g	2		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3203708/	Homo sapiens										false
5254	2460		ADULT		302.239	OLSALAZINE	OLSALAZINE	OC(=O)C1=CC(=CC=C1O)\\N=N\\C2=CC(C(O)=O)=C(O)C=C2	SERUM	ULS5I8J03O									?	μM × h	6.5		μM	7.5			UNKNOWN	mg	10		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3203708/	Homo sapiens		min	56							false
5255	2461		ADULT	4636	260.37	OXYMETAZOLINE	OXYMETAZOLINE	CC1=CC(=C(O)C(C)=C1CC2=NCCN2)C(C)(C)C	PLASMA	8VLN5B44ZY							24		t	pg × h/mL	895		pg/mL	60.5			UNKNOWN	mg	3		SINGLE	UNKNOWN				Oxymetazoline is 56.7% to 57.5% bound to human plasma proteins.		UNHEALTHY	Topical	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf	Homo sapiens										false
5256	2461		ADULT	4636	264.36	OXYMETAZOLINE	OXYMETAZOLINE	CC1=CC(=C(O)C(C)=C1CC2=NCCN2)C(C)(C)C	PLASMA	8VLN5B44ZY	5411		Tetracaine	Tetracaine	CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C	0619F35CGV			∞	ng × h/mL	4.24		ng/mL	1.78			UNKNOWN	mg	0.3		SINGLE	UNKNOWN						HEALTHY	Nasal	FEMALE / MALE	DRUG LABEL	https://www.fda.gov/media/98992/download	Homo sapiens		h	5.23							true
5257	2462		ADULT	6337614	296.4	PALONOSETRON	PALONOSETRON	C1CC2CN(C(=O)C3=CC=CC(=C23)C1)C4CN5CCC4CC5	PLASMA	5D06587D6R									?	μg × h/L	35.8		ng/L	5630			UNKNOWN	μg/kg bw	3		MULTIPLE	UNKNOWN		day	1	Approximately 62% of palonosetron is bound to plasma proteins	38	UNHEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021372s018s019lbl.pdf	Homo sapiens										false
5258	2462		ADULT	6337614	296.4	PALONOSETRON	PALONOSETRON	C1CC2CN(C(=O)C3=CC=CC(=C23)C1)C4CN5CCC4CC5	PLASMA	5D06587D6R																	UNKNOWN				UNKNOWN	UNKNOWN						HEALTHY	UNKNOWN	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021372s018s019lbl.pdf	Homo sapiens		h	40							false
5259	2463		ADULT	60342|16760602|71306478|139058471	369.1095	PAMIDRONATE DISODIUM	Pamidronate disodium	O.O.O.O.O.[Na+].[Na+].NCCC(O)(P(O)([O-])=O)P(O)([O-])=O	PLASMA	8742T8ZQZA							36		t	μg × h/mL	10.2		μg/mL	1.92			UNKNOWN	mg	90		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9115053/	Homo sapiens										false
5260	2463		ADULT	60342|16760602|71306478|139058471	369.1095	PAMIDRONATE DISODIUM	pamidronate disodium	O.O.O.O.O.[Na+].[Na+].NCCC(O)(P(O)([O-])=O)P(O)([O-])=O	PLASMA	8742T8ZQZA													μg/mL	0.73			RECOMMENDED	mg	30		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021113s017lbl.pdf	Homo sapiens		h	28							false
5261	2463		ADULT	60342|16760602|71306478|139058471	369.1095	PAMIDRONATE DISODIUM	Pamidronate disodium	O.O.O.O.O.[Na+].[Na+].NCCC(O)(P(O)([O-])=O)P(O)([O-])=O	PLASMA	8742T8ZQZA													μg/mL	1.44			RECOMMENDED	mg	60		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021113s017lbl.pdf	Homo sapiens		h	28							false
5262	2463		ADULT	60342|16760602|71306478|139058471	369.1095	PAMIDRONATE DISODIUM	Pamidronate disodium	O.O.O.O.O.[Na+].[Na+].NCCC(O)(P(O)([O-])=O)P(O)([O-])=O	PLASMA	8742T8ZQZA													μg/mL	2.61			RECOMMENDED	mg	90		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021113s017lbl.pdf	Homo sapiens		h	28							false
5263	2464		ADULT	441289	572.8619	PANCURONIUM	PANCURONIUM	CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)[N+]5(C)CCCCC5)[N+]6(C)CCCCC6	PLASMA	J76UF062FS													ng/mL	600			UNKNOWN	mg	4		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1276000	Homo sapiens										false
5264	2464		ADULT	441289	572.8619	PANCURONIUM	PANCURONIUM	CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)[N+]5(C)CCCCC5)[N+]6(C)CCCCC6	PLASMA	J76UF062FS													ng/mL	460			UNKNOWN	mg	4		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1276000	Homo sapiens										false
5265	2464		ADULT	441289	572.8619	PANCURONIUM	PANCURONIUM	CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)[N+]5(C)CCCCC5)[N+]6(C)CCCCC6	PLASMA	J76UF062FS													μg/mL	0.761			UNKNOWN	mg	6		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/789085	Homo sapiens		min	12.46							false
5266	2465		ADULT	37464	291.4284	PENBUTOLOL	PENBUTOLOL	CC(C)(C)NC[C@H](O)COC1=C(C=CC=C1)C2CCCC2	BLOOD	78W62V43DY													μg/mL	285			UNKNOWN	mg	40		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2906875	Homo sapiens		h	1.21							false
5267	2465		ADULT	37464	291.4284	PENBUTOLOL	PENBUTOLOL	CC(C)(C)NC[C@H](O)COC1=C(C=CC=C1)C2CCCC2	PLASMA	78W62V43DY																	UNKNOWN	mg	40		SINGLE	UNKNOWN				Penbutolol is approximately 80% to 98% bound to plasma proteins.	2	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018976s012lbl.pdf	Homo sapiens										false
5268	2466		ADULT	47811	314.488	PERGOLIDE	PERGOLIDE	CCCN1C[C@H](CSC)C[C@H]2[C@H]1CC3=CNC4=C3C2=CC=C4	PLASMA	24MJ822NZ9							6		t	ng × h/mL	573		ng/mL	127			UNKNOWN	mg	0.25		STEADY-STATE	UNKNOWN		day	3			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15965310/	Homo sapiens										false
5269	2466		ADULT	47811	314.488	PERGOLIDE	PERGOLIDE	CCCN1C[C@H](CSC)C[C@H]2[C@H]1CC3=CNC4=C3C2=CC=C4	PLASMA	24MJ822NZ9							6		t	ng × h/mL	1094		ng/mL	209			UNKNOWN	mg	0.5		STEADY-STATE	UNKNOWN		day	3			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15965310/	Homo sapiens		h	22.8							false
5270	2466		ADULT	47811	314.488	PERGOLIDE	PERGOLIDE	CCCN1C[C@H](CSC)C[C@H]2[C@H]1CC3=CNC4=C3C2=CC=C4	PLASMA	24MJ822NZ9							6		t	ng × h/mL	2392		ng/mL	472			UNKNOWN	mg	1		STEADY-STATE	UNKNOWN		day	3			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15965310/	Homo sapiens										false
5271	2466		ADULT	47811	314.488	PERGOLIDE	PERGOLIDE	CCCN1C[C@H](CSC)C[C@H]2[C@H]1CC3=CNC4=C3C2=CC=C4	PLASMA	24MJ822NZ9																	UNKNOWN	μg	138		SINGLE	FASTED					9	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6113911/	Homo sapiens										false
5272	2468		UNKNOWN	4748	403.969	PERPHENAZINE	perphenazine	OCCN1CCN(CCCN2C3=C(SC4=C2C=C(Cl)C=C4)C=CC=C3)CC1	PLASMA	FTA7XXY4EZ									∞	ng × h/mL	6.673		ng/mL	0.546			INVESTIGATIONAL	mg	16		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	REVIEW	https://www.accessdata.fda.gov/drugsatfda_docs/anda/98/40226_Perphenazaine_Bioeqr.pdf	Homo sapiens		h	9.12							false
5273	2468		UNKNOWN	4748	403.969	PERPHENAZINE	perphenazine	OCCN1CCN(CCCN2C3=C(SC4=C2C=C(Cl)C=C4)C=CC=C3)CC1	PLASMA	FTA7XXY4EZ													pg/mL	984			RECOMMENDED	mg	4		STEADY-STATE	UNKNOWN		day	3	t1/2 was ranged between 9 and 12 hrs.		UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/089683s024lbl.pdf	Homo sapiens		h	12							false
5274	2468		UNKNOWN	10432233	419.968	7-HYDROXYPERPHENAZINE	7-hydroxyperphenazine	OCCN1CCN(CCCN2C3=CC=C(O)C=C3SC4=C2C=C(Cl)C=C4)CC1	PLASMA	72JU1448JM													pg/mL	509			RECOMMENDED	mg	4		STEADY-STATE	UNKNOWN		day	3	t1/2 was ranged between 9.9 and 18.8 hrs.		UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/089683s024lbl.pdf	Homo sapiens		h	18.8							false
5275	2468		UNKNOWN	4748	403.969	PERPHENAZINE	perphenazine	OCCN1CCN(CCCN2C3=C(SC4=C2C=C(Cl)C=C4)C=CC=C3)CC1	UNKNOWN	FTA7XXY4EZ																	UNKNOWN				UNKNOWN	UNKNOWN				Drug is 91% to 99% protein-bound.	9	UNKNOWN	UNKNOWN	UNKNOWN	DRUG LABEL	https://www.glowm.com/resources/glowm/cd/pages/drugs/p024.html	Homo sapiens										false
5276	2469		ADULT	5775	281.35	PHENTOLAMINE	PHENTOLAMINE	CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC=CC(O)=C3	PLASMA	Z468598HBV									∞	ng × h/mL	197.59		ng/mL	67.05			UNKNOWN	mg	60		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/24452521	Homo sapiens		h	3.32							false
5277	2470		ADULT	55329	263.3387	PINACIDIL	PINACIDIL	O.CC(NC(NC1=CC=NC=C1)=NC#N)C(C)(C)C	PLASMA	7B0ZZH8P2W							12		t	ng × h/mL	365.4		ng/mL	69.7			UNKNOWN	mg	12.5		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10028374	Homo sapiens		h	10.7							false
5278	2471		ADOLESCENT	4829	356.439	PIOGLITAZONE	PIOGLITAZONE	CCC1=CC=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)N=C1	PLASMA	X4OV71U42S							24		t	ng × h/mL	8662		ng/mL	890			RECOMMENDED	mg	45		STEADY-STATE	FED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/16172178	Homo sapiens		h	12.6							false
5279	2472		ADULT	73246	535.57	PIPERACILLIN	PIPERACILLIN	O.CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)C4=CC=CC=C4)C(=O)C1=O	PLASMA	X00B0D5O0E									?	μg × h/mL	344.3		μg/mL	150			RECOMMENDED	g	4.5		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23590897/	Homo sapiens		h	1.85							false
5280	2473		UNKNOWN	4845	240.2988	PIRBUTEROL	PIRBUTEROL	CC(C)(C)NCC(O)C1=NC(CO)=C(O)C=C1	PLASMA	OG645J8RVW													μg/L	6.2			UNKNOWN	mg	10		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/2863125	Homo sapiens		h	2							false
5281	2473		UNKNOWN	4845	240.2988	PIRBUTEROL	PIRBUTEROL	CC(C)(C)NCC(O)C1=NC(CO)=C(O)C=C1	PLASMA	OG645J8RVW													μg/L	9.8			UNKNOWN	mg	15		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/2863125	Homo sapiens										false
5282	2474		ADULT	4884|6738089|6765491|6789253|135398747|135484646	137.1592	PRALIDOXIME	PRALIDOXIME	C[N+]1=C(\\C=N\\O)C=CC=C1	PLASMA	P7MU9UTP52									∞	ng × h/mL	10070		ng/mL	3988			UNKNOWN	mg	700		SINGLE	UNKNOWN						HEALTHY	Intramuscular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20804498	Homo sapiens		h	2.94							false
5283	2474		ADULT	4884|6738089|6765491|6789253|135398747|135484646	137.1592	PRALIDOXIME	PRALIDOXIME	C[N+]1=C(\\C=N\\O)C=CC=C1	PLASMA	P7MU9UTP52													μg/mL	7.5			UNKNOWN	mg	1000		SINGLE	UNKNOWN				Pralidoxime chloride is not bound to plasma protein	100	HEALTHY	Intramuscular	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/014134s022lbl.pdf	Homo sapiens		h	3							false
5284	2474		ADULT	4884|6738089|6765491|6789253|135398747|135484646	137.1592	PRALIDOXIME	PRALIDOXIME	C[N+]1=C(\\C=N\\O)C=CC=C1	PLASMA	P7MU9UTP52													μg/mL	9.9			UNKNOWN	mg	1000		SINGLE	UNKNOWN						UNHEALTHY	Intramuscular	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/014134s022lbl.pdf	Homo sapiens		h	3							false
5285	2475			54687	424.5277	PRAVASTATIN	PRAVASTATIN	CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12	PLASMA	KXO2KT9N0G									∞	ng × h/mL	299.56							mg	80		SINGLE	FED						HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00829309	Homo sapiens										false
5286	2475			54687	424.5277	PRAVASTATIN	PRAVASTATIN	CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12	PLASMA	KXO2KT9N0G							16		t	ng × h/mL	251.86							mg	80		SINGLE	FED						HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00829309	Homo sapiens										false
5287	2475			54687	424.5277	PRAVASTATIN	PRAVASTATIN	CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12	PLASMA	KXO2KT9N0G									∞	ng × h/mL	273.32							mg	80		SINGLE	FED						HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00829309	Homo sapiens										false
5288	2475			54687	424.5277	PRAVASTATIN	PRAVASTATIN	CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12	PLASMA	KXO2KT9N0G							16		t	ng × h/mL	241.29							mg	80		SINGLE	FED						HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00829309	Homo sapiens										false
5289	2475		ADULT	54687	424.5277	PRAVASTATIN	PRAVASTATIN	CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12	PLASMA	KXO2KT9N0G									∞	μg × h/mL	66.2		μg/L	27.4			UNKNOWN	mg	19.2		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://link.springer.com/article/10.2165/00003088-200039060-00002	Homo sapiens		h	1.77							false
5290	2476		ADULT	4893	383.4011	PRAZOSIN	PRAZOSIN	COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N3CCN(CC3)C(=O)C4=CC=CO4	PLASMA	XM03YJ541D									?	ng × h/mL	281		ng/mL	40			RECOMMENDED	mg	20		SINGLE	UNKNOWN					7.5	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7379445/	Homo sapiens		h	5.8							false
5291	2477		ADULT	4926	284.419	PROMAZINE	PROMAZINE	CN(C)CCCN1C2=CC=CC=C2SC3=C1C=CC=C3	PLASMA	O9M39HTM5W													ng/mL	137			UNKNOWN	mg	100		SINGLE	FASTED					17	UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2265236/	Homo sapiens		min	759							false
5292	2477		ADULT	4926	284.419	PROMAZINE	PROMAZINE	CN(C)CCCN1C2=CC=CC=C2SC3=C1C=CC=C3	PLASMA	O9M39HTM5W													ng/mL	71.1			UNKNOWN	mg	100		SINGLE	FASTED					16	UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2265236/	Homo sapiens		min	613							false
5293	2477		ADULT	4926	284.419	PROMAZINE	PROMAZINE	CN(C)CCCN1C2=CC=CC=C2SC3=C1C=CC=C3	PLASMA	O9M39HTM5W									∞	μg × min/mL	45.7						UNKNOWN	mg	100		SINGLE	FASTED					10.4	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7714731/	Homo sapiens		min	558							false
5294	2477		ADULT	4926	284.419	PROMAZINE	PROMAZINE	CN(C)CCCN1C2=CC=CC=C2SC3=C1C=CC=C3	PLASMA	O9M39HTM5W									∞	μg × min/mL	132.2						UNKNOWN	mg	100		SINGLE	FASTED					35.5	UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7714731/	Homo sapiens		min	1163							false
5295	2478		ADULT	4932	341.444	PROPAFENONE	CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC2=CC=CC=C2	CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC2=CC=CC=C2	PLASMA	68IQX3T69U									?	ng × h/mL	322.43		ng/mL	189.94			RECOMMENDED	mg	150		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/19402341	Homo sapiens										false
5296	2478		ADULT	4932	341.444	PROPAFENONE	CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC2=CC=CC=C2	CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC2=CC=CC=C2	PLASMA	68IQX3T69U																						UNKNOWN				In normal serum the unbound fraction of propafenone was 0.027 at a propafenone concentration of 0.25 ug/ml, 0.041 within the therapeutic concentration range (0.5-2 ug/ml), 0.138 at a propafenone concentration of 25 ug/ml, and 0.187 when the propafenone concentration was increased to 100 ug/ml.	4.1	HEALTHY		MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/2753068	Homo sapiens										false
5297	2478		ADULT	4932	341.444	PROPAFENONE	CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC2=CC=CC=C2	CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC2=CC=CC=C2	PLASMA	68IQX3T69U									?	ng × h/mL	2900		ng/mL	314			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/3606933	Homo sapiens		h	3.61							false
5298	2479		ADULT	9279|521275	448.393	PROPANTHELINE BROMIDE	PROPANTHELINE BROMIDE	[Br-].CC(C)[N+](C)(CCOC(=O)C1C2=CC=CC=C2OC3=C1C=CC=C3)C(C)C	PLASMA	UX9Z118X9F							24		t	ng × h/mL	186.9		ng/mL	51.5			UNKNOWN	mg	45		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6689152	Homo sapiens										false
5299	2479		ADULT	9279|521275	448.393	PROPANTHELINE BROMIDE	PROPANTHELINE BROMIDE	[Br-].CC(C)[N+](C)(CCOC(=O)C1C2=CC=CC=C2OC3=C1C=CC=C3)C(C)C	PLASMA	UX9Z118X9F									∞	ng × h/mL	62.2		ng/mL	20.6			UNKNOWN	mg	30		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7389749	Homo sapiens		h	1.57							false
5300	2479		ADULT	9279|521275	448.393	PROPANTHELINE BROMIDE	PROPANTHELINE BROMIDE	[Br-].CC(C)[N+](C)(CCOC(=O)C1C2=CC=CC=C2OC3=C1C=CC=C3)C(C)C	PLASMA	UX9Z118X9F									∞	ng × h/mL	159		ng/mL	53.1			UNKNOWN	mg	60		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7389749	Homo sapiens		h	1.56							false
5301	2480		ADULT	4976	263.3767	PROTRIPTYLINE	PROTRIPTYLINE	CNCCCC1C2=CC=CC=C2C=CC3=C1C=CC=C3	PLASMA	4NDU154T12									?	ng × h/mL	1448		ng/mL	14.1			UNKNOWN	mg	30		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/639433/	Homo sapiens		h	74.3							false
5302	2481		ADULT	107994	410.4629	QUINAPRILAT	QUINAPRILAT	C[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N2CC3=C(C[C@H]2C(O)=O)C=CC=C3	PLASMA	34SSX5LDE5							12		t	μg × h/L	1706						UNKNOWN	mg	10		STEADY-STATE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8198942/	Homo sapiens		h	3.7							false
5303	2481		ADULT	107994	410.4629	QUINAPRILAT	QUINAPRILAT	C[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N2CC3=C(C[C@H]2C(O)=O)C=CC=C3	PLASMA	34SSX5LDE5									∞	ng × h/mL	580		ng/mL	345			UNKNOWN	mg	2.5		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8739020/	Homo sapiens		h	2.26							false
5304	2481		ADULT	107994	410.4629	QUINAPRILAT	QUINAPRILAT	C[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N2CC3=C(C[C@H]2C(O)=O)C=CC=C3	PLASMA	34SSX5LDE5									∞	ng × h/mL	2670		ng/mL	1526			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8739020/	Homo sapiens		h	2.29							false
5305	2482		ADULT	5035	473.6	RALOXIFENE	RALOXIFENE	OC1=CC=C(C=C1)C2=C(C(=O)C3=CC=C(OCCN4CCCCC4)C=C3)C5=C(S2)C=C(O)C=C5	PLASMA	YX9162EO3I									∞	ng × h/mL	27.2		ng/mL	0.5			DEFINED DAILY	mg	60		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022042lbl.pdf	Homo sapiens		h	27.7							false
5306	2483		ADULT	5071	179.3018	RIMANTADINE	rimantadine	CC(N)C12CC3CC(CC(C3)C1)C2	PLASMA										∞	ng × h/mL	20300		ng/mL	416			RECOMMENDED	mg	100		MULTIPLE	FASTED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3606083/	Homo sapiens		h	33							false
5307	2483		ADULT	5071	179.3018	RIMANTADINE	rimantadine	CC(N)C12CC3CC(CC(C3)C1)C2	PLASMA										∞	ng × h/mL	8170		ng/mL	181			INVESTIGATIONAL	mg	100		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3606083/	Homo sapiens		h	26							false
5308	2483		ADULT	5071	179.3018	RIMANTADINE	RIMANTADINE	CC(N)C12CC3CC(CC(C3)C1)C2	PLASMA														ng/mL	74			RECOMMENDED	mg	100		SINGLE	UNKNOWN					60	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019649s015lbl.pdf	Homo sapiens		h	25.4							false
5309	2484		ADULT	33572	287.35	RITODRINE	RITODRINE	CC(NCCC1=CC=C(O)C=C1)C(O)C2=CC=C(O)C=C2	PLASMA	I0Q6O6740J									∞	ng × h/mL	24.03		ng/mL	8.06			UNKNOWN	mg	20		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/20863008	Homo sapiens		h	4.3							false
5310	2485		ADULT	5078	269.3449	RIZATRIPTAN	RIZATRIPTAN	CN(C)CCC1=CNC2=C1C=C(CN3C=NC=N3)C=C2	PLASMA	51086HBW8G									∞	ng × h/mL	16		ng/mL	6.2			UNKNOWN	mg	2.5		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10233200/	Homo sapiens		h	2.1							false
5311	2485		ADULT	5078	269.3449	RIZATRIPTAN	RIZATRIPTAN	CN(C)CCC1=CNC2=C1C=C(CN3C=NC=N3)C=C2	PLASMA	51086HBW8G									∞	ng × h/mL	33		ng/mL	12.7			RECOMMENDED	mg	5		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10233200/	Homo sapiens		h	2.2							false
5312	2485		ADULT	5078	269.3449	RIZATRIPTAN	RIZATRIPTAN	CN(C)CCC1=CNC2=C1C=C(CN3C=NC=N3)C=C2	PLASMA	51086HBW8G									∞	ng × h/mL	72		ng/mL	28.6			RECOMMENDED	mg	10		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10233200/	Homo sapiens		h	2.4							false
5313	2485		ADULT	5078	269.3449	RIZATRIPTAN	RIZATRIPTAN	CN(C)CCC1=CNC2=C1C=C(CN3C=NC=N3)C=C2	PLASMA	51086HBW8G									∞	ng × h/mL	127		ng/mL	44.8			UNKNOWN	mg	15		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10233200/	Homo sapiens		h	2.4							false
5314	2485		ADULT	5078	269.3449	RIZATRIPTAN	RIZATRIPTAN	CN(C)CCC1=CNC2=C1C=C(CN3C=NC=N3)C=C2	PLASMA	51086HBW8G									∞	ng × h/mL	19		ng/mL	6.1			UNKNOWN	mg	2.5		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10233200/	Homo sapiens		h	2.2							false
5315	2485		ADULT	5078	269.3449	RIZATRIPTAN	RIZATRIPTAN	CN(C)CCC1=CNC2=C1C=C(CN3C=NC=N3)C=C2	PLASMA	51086HBW8G									∞	ng × h/mL	42		ng/mL	13.2			RECOMMENDED	mg	5		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10233200/	Homo sapiens		h	2.4							false
5316	2485		ADULT	5078	269.3449	RIZATRIPTAN	RIZATRIPTAN	CN(C)CCC1=CNC2=C1C=C(CN3C=NC=N3)C=C2	PLASMA	51086HBW8G									∞	ng × h/mL	97		ng/mL	32.1			RECOMMENDED	mg	10		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10233200/	Homo sapiens		h	2.6							false
5317	2485		ADULT	5078	269.3449	RIZATRIPTAN	RIZATRIPTAN	CN(C)CCC1=CNC2=C1C=C(CN3C=NC=N3)C=C2	PLASMA	51086HBW8G									∞	ng × h/mL	161		ng/mL	54			UNKNOWN	mg	15		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10233200/	Homo sapiens		h	2.4							false
5318	2485		ADULT	5078	269.3449	RIZATRIPTAN	RIZATRIPTAN	CN(C)CCC1=CNC2=C1C=C(CN3C=NC=N3)C=C2	PLASMA	51086HBW8G									∞	ng × h/mL	68						UNKNOWN	mg	4		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10233200/	Homo sapiens		h	2.9							false
5319	2485		ADULT	5078	269.3449	RIZATRIPTAN	RIZATRIPTAN	CN(C)CCC1=CNC2=C1C=C(CN3C=NC=N3)C=C2	PLASMA	51086HBW8G									∞	ng × h/mL	84						UNKNOWN	mg	4		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10233200/	Homo sapiens		h	2.4							false
5320	2485		ADULT	5078	269.3449	RIZATRIPTAN	RIZATRIPTAN	CN(C)CCC1=CNC2=C1C=C(CN3C=NC=N3)C=C2	PLASMA	51086HBW8G									∞	ng × h/mL	69.88		ng/mL	27.29			RECOMMENDED	mg	10		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16432269/	Homo sapiens										false
5321	2486		NEWBORN	441290	529.7742	ROCURONIUM	ROCURONIUM	CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N5CCOCC5)[N+]6(CC=C)CCCC6	PLASMA	WRE554RFEZ																	INVESTIGATIONAL	mg/kg	0.45		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020214Orig1s038lbl.pdf	Homo sapiens		h	0.9							false
5322	2486		ADULT	441290	529.7742	ROCURONIUM	Rocuronium	CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N5CCOCC5)[N+]6(CC=C)CCCC6	PLASMA	WRE554RFEZ																	INVESTIGATIONAL	mg/kg	0.6		SINGLE	UNKNOWN				Rocuronium is approximately 30% bound to human plasma proteins	70	UNHEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020214Orig1s038lbl.pdf	Homo sapiens		h	1.4							false
5323	2487		ADULT	68727|66766793|139059798	296.836	ROPINIROLE HYDROCHLORIDE	ROPINIROLE HYDROCHLORIDE	Cl.CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1	PLASMA	D7ZD41RZI9							8		t	ng × h/mL	29.1		ng/mL	6.53			UNKNOWN	mg	2		STEADY-STATE	FASTED		day	3			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9578193	Homo sapiens										false
5324	2487		ADULT	68727|66766793|139059798	296.836	ROPINIROLE HYDROCHLORIDE	ROPINIROLE HYDROCHLORIDE	Cl.CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1	PLASMA	D7ZD41RZI9							8		t	ng × h/mL	25.9		ng/mL	5.01			UNKNOWN	mg	2		STEADY-STATE	FED		day	3			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9578193	Homo sapiens										false
5325	2487		UNKNOWN	68727|66766793|139059798	296.836	ROPINIROLE HYDROCHLORIDE	ROPINIROLE HYDROCHLORIDE	Cl.CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1	PLASMA	D7ZD41RZI9																	UNKNOWN				UNKNOWN	UNKNOWN				Ropinirole is widely distributed throughout the body, with an apparent volume of distribution of 7.5 L/kg. It is up to 40% bound to plasma proteins and has a blood-to-plasma ratio of 1:1.	60	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020658Orig1s037lbl.pdf	Homo sapiens		h	6							false
5326	2488		ADULT	446157	481.538	ROSUVASTATIN	rosuvastatin	CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\\C=C\\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O	PLASMA	413KH5ZJ73									∞	ng × h/mL	75.93		ng/mL	10.22			RECOMMENDED	mg	5		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18042475	Homo sapiens		h	13.01							false
5327	2488		ADULT	446157	481.538	ROSUVASTATIN	rosuvastatin	CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\\C=C\\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O	PLASMA	413KH5ZJ73									∞	ng × h/mL	216.77		ng/mL	25.86			RECOMMENDED	mg	10		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18042475	Homo sapiens		h	13.33							false
5328	2488		ADULT	446157	481.538	ROSUVASTATIN	rosuvastatin	CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\\C=C\\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O	PLASMA	413KH5ZJ73									∞	ng × h/mL	311.35		ng/mL	44.99			RECOMMENDED	mg	20		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18042475	Homo sapiens		h	15.4							false
5329	2488		UNKNOWN	446157	481.538	ROSUVASTATIN	rosuvastatin	CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\\C=C\\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O	PLASMA	413KH5ZJ73																						UNKNOWN				Rosuvastatin is 88% bound to plasma proteins, mostly albumin.	12	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208647s000lbl.pdf	Homo sapiens										false
5330	2489		ADULT	68617	306.23	SERTRALINE	SERTRALINE	CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C3=CC=CC=C13	PLASMA	QUC7NX6WMB							24		t	μg × h/L	546		μg/L	20.6			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	REVIEW	https://link.springer.com/article/10.2165/00003088-200241150-00002	Homo sapiens		h	25.4							false
5331	2490		ADULT	5212|5281023|135398744	474.576	SILDENAFIL	SILDENAFIL	CCCC1=NN(C)C2=C1N=C(NC2=O)C3=C(OCC)C=CC(=C3)S(=O)(=O)N4CCN(C)CC4	PLASMA	3M7OB98Y7H																	MAX DAILY	mg	100		SINGLE	UNKNOWN				Sildenafil and its major circulating N-desmethyl metabolite are both approximately 96% bound to plasma proteins.	4	HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/20895s039s042lbl.pdf	Homo sapiens		h	4							false
5332	2490		ADULT	5212|5281023|135398744	474.576	SILDENAFIL	SILDENAFIL	CCCC1=NN(C)C2=C1N=C(NC2=O)C3=C(OCC)C=CC(=C3)S(=O)(=O)N4CCN(C)CC4	PLASMA	3M7OB98Y7H									∞	ng × h/mL	530		ng/mL	159			RECOMMENDED	mg	50		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/11879254	Homo sapiens		h	4.07							false
5333	2491		UNKNOWN	3033702	438.561	SPIRAPRILAT	spiraprilat	C[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N2CC3(C[C@H]2C(O)=O)SCCS3	PLASMA	QS56V5Y7EC									?	μg × h/L	152.5		μg/L	37.85			RECOMMENDED	mg	6		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/7601014/	Homo sapiens		h	1.85							false
5334	2491		UNKNOWN	3033702	438.561	SPIRAPRILAT	SPIRAPRILAT	C[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N2CC3(C[C@H]2C(O)=O)SCCS3	PLASMA	QS56V5Y7EC									?	μg × h/L	846.75		μg/L	81.6			RECOMMENDED	mg	6		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/7601014/	Homo sapiens										false
5335	2492		ADULT	5329102	398.4738	SUNITINIB	SUNITINIB	CCN(CC)CCNC(=O)C1=C(C)NC(\\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C	PLASMA	V99T50803M									∞	ng × h/mL	1369		ng/mL	21.9			DEFINED DAILY	mg	50		MULTIPLE	FASTED		day	1	sunitinib is 95% protein bound to albumin in vitro	5	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20049443	Homo sapiens		h	63.8							false
5336	2492		ADULT	10292573	370.4206	N-DESETHYL SUNITINIB	N-Desethyl Sunitinib	CCNCCNC(=O)C1=C(C)NC(\\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C	PLASMA	42LJ35612R									∞	ng × h/mL	559		ng/mL	4.35			DEFINED DAILY	mg	50		MULTIPLE	FASTED		day	1	SU12662 is 90% bound	10	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20049443	Homo sapiens		h	111							false
5337	2492		UNKNOWN	5329102	398.4738	SUNITINIB	SUNITINIB	CCN(CC)CCNC(=O)C1=C(C)NC(\\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C	PLASMA	V99T50803M																						UNKNOWN				Binding of sunitinib and its primary active metabolite to human plasma protein in vitro was 95% and 90%, respectively, with no concentration dependence in the range of 100 – 4000 ng/mL.	5	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021938s13s17s18lbl.pdf	Homo sapiens										false
5338	2492		CHILD	5329102	398.2118	SUNITINIB	SUNITINIB	CCN(CC)CCNC(=O)C1=C(C)NC(\\C=C2/C(=O)NC3=CC=C(F)C=C23)=C1C	PLASMA	V99T50803M									∞	ng × h/L	791		ng/mL	21.3			MAX TOLERATED	mg/m²	15		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/22179104	Homo sapiens		h	22.7							false
5339	2492		ADULT	5329102	398.2118	SUNITINIB	SUNITINIB	CCN(CC)CCNC(=O)C1=C(C)NC(\\C=C2/C(=O)NC3=CC=C(F)C=C23)=C1C	PLASMA	V99T50803M	176870		ERLOTINIB	ERLOTINIB	COCCOC1=CC2=NC=NC(NC3=CC=CC(=C3)C#C)=C2C=C1OCCOC	J4T82NDH7E	24		t	ng × h/mL	1056		ng/mL	51.1			UNKNOWN	mg	37.5		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/22743295	Homo sapiens										true
5340	2493		CHILD	2733526	371.5146	TAMOXIFEN	CC\\C(C1=CC=CC=C1)=C(/C2=CC=CC=C2)C3=CC=C(OCCN(C)C)C=C3	CC\\C(C1=CC=CC=C1)=C(/C2=CC=CC=C2)C3=CC=C(OCCN(C)C)C=C3	PLASMA	094ZI81Y45									∞	ng × h/mL	4110		ng/mL	187			DEFINED DAILY	mg	20		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021807s005lbl.pdf	Homo sapiens										false
5341	2493		ADULT	2733526	371.5146	TAMOXIFEN	CC\\C(C1=CC=CC=C1)=C(/C2=CC=CC=C2)C3=CC=C(OCCN(C)C)C=C3	CC\\C(C1=CC=CC=C1)=C(/C2=CC=CC=C2)C3=CC=C(OCCN(C)C)C=C3	BLOOD	094ZI81Y45							480		t	ng × h/mL	3370.1		ng/mL	63.6			DEFINED DAILY	mg	30		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/8740091	Homo sapiens		h	209.8							false
5342	2494			129211	408.512	TAMSULOSIN	TAMSULOSIN	CCOC1=C(OCCN[C@H](C)CC2=CC(=C(OC)C=C2)S(N)(=O)=O)C=CC=C1	PLASMA	G3P28OML5I													ng/mL	9.015				mg	0.4		SINGLE	FED						HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01149733	Homo sapiens										false
5343	2494			129211	408.512	TAMSULOSIN	TAMSULOSIN	CCOC1=C(OCCN[C@H](C)CC2=CC(=C(OC)C=C2)S(N)(=O)=O)C=CC=C1	PLASMA	G3P28OML5I							60		t	ng × h/mL	148.9023							mg	0.4		SINGLE	FED						HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01149733	Homo sapiens										false
5344	2494			129211	408.512	TAMSULOSIN	TAMSULOSIN	CCOC1=C(OCCN[C@H](C)CC2=CC(=C(OC)C=C2)S(N)(=O)=O)C=CC=C1	PLASMA	G3P28OML5I									∞	ng × h/mL	157.9455							mg	0.4		SINGLE	FED						HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01149733	Homo sapiens										false
5345	2494			129211	408.512	TAMSULOSIN	TAMSULOSIN	CCOC1=C(OCCN[C@H](C)CC2=CC(=C(OC)C=C2)S(N)(=O)=O)C=CC=C1	PLASMA	G3P28OML5I													ng/mL	8.8694				mg	0.4		SINGLE	FED						HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01149733	Homo sapiens										false
5346	2494			129211	408.512	TAMSULOSIN	TAMSULOSIN	CCOC1=C(OCCN[C@H](C)CC2=CC(=C(OC)C=C2)S(N)(=O)=O)C=CC=C1	PLASMA	G3P28OML5I							60		t	ng × h/mL	137.0248							mg	0.4		SINGLE	FED						HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01149733	Homo sapiens										false
5347	2494			129211	408.512	TAMSULOSIN	TAMSULOSIN	CCOC1=C(OCCN[C@H](C)CC2=CC(=C(OC)C=C2)S(N)(=O)=O)C=CC=C1	PLASMA	G3P28OML5I									∞	ng × h/mL	143.2749							mg	0.4		SINGLE	FED						HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01149733	Homo sapiens										false
5348	2494		ADULT	5362376|25137847	444.973	TAMSULOSIN HYDROCHLORIDE	TAMSULOSIN HYDROCHLORIDE	Cl.CCOC1=C(OCCN[C@H](C)CC2=CC(=C(OC)C=C2)S(N)(=O)=O)C=CC=C1	PLASMA	11SV1951MR									?	ng × h/mL	151		ng/mL	10.1			RECOMMENDED	mg	0.4		MULTIPLE	LOW-FAT		day	1	Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).	6	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020579s033lbl.pdf	Homo sapiens										false
5349	2494		ADULT	5362376|25137847	444.973	TAMSULOSIN HYDROCHLORIDE	TAMSULOSIN HYDROCHLORIDE	Cl.CCOC1=C(OCCN[C@H](C)CC2=CC(=C(OC)C=C2)S(N)(=O)=O)C=CC=C1	PLASMA	11SV1951MR									?	ng × h/mL	199		ng/mL	17.1			RECOMMENDED	mg	0.4		MULTIPLE	FASTED		day	1			HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020579s033lbl.pdf	Homo sapiens										false
5350	2494		ADULT	5362376|25137847	444.973	TAMSULOSIN HYDROCHLORIDE	TAMSULOSIN HYDROCHLORIDE	Cl.CCOC1=C(OCCN[C@H](C)CC2=CC(=C(OC)C=C2)S(N)(=O)=O)C=CC=C1	PLASMA	11SV1951MR									?	ng × h/mL	440		ng/mL	29.8			MAX DAILY	mg	0.8		MULTIPLE	LOW-FAT		day	1			HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020579s033lbl.pdf	Homo sapiens										false
5351	2494		ADULT	5362376|25137847	444.973	TAMSULOSIN HYDROCHLORIDE	TAMSULOSIN HYDROCHLORIDE	Cl.CCOC1=C(OCCN[C@H](C)CC2=CC(=C(OC)C=C2)S(N)(=O)=O)C=CC=C1	PLASMA	11SV1951MR									?	ng × h/mL	449		ng/mL	29.1			MAX DAILY	mg	0.8		MULTIPLE	HIGH-FAT		day	1			HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020579s033lbl.pdf	Homo sapiens										false
5352	2494		ADULT	5362376|25137847	444.973	TAMSULOSIN HYDROCHLORIDE	TAMSULOSIN HYDROCHLORIDE	Cl.CCOC1=C(OCCN[C@H](C)CC2=CC(=C(OC)C=C2)S(N)(=O)=O)C=CC=C1	PLASMA	11SV1951MR									?	ng × h/mL	557		ng/mL	41.6			MAX DAILY	mg	0.8		MULTIPLE	FASTED		day	1			HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020579s033lbl.pdf	Homo sapiens		h	14.9							false
5353	2495		UNKNOWN	480953	532.462	TERCONAZOLE	terconazole	CC(C)N1CCN(CC1)C2=CC=C(OC[C@@H]3CO[C@](CN4C=NC=N4)(O3)C5=C(Cl)C=C(Cl)C=C5)C=C2	PLASMA	0KJ2VE664U																	UNKNOWN	mg	30		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	http://rxproduct.taro.ca/media/oMedia/Taro-Terconazole%20Vag%20Cr%20PM.pdf	Homo sapiens		h	6.9							false
5354	2495		UNKNOWN	480953	532.462	TERCONAZOLE	TERCONAZOLE	CC(C)N1CCN(CC1)C2=CC=C(OC[C@@H]3CO[C@](CN4C=NC=N4)(O3)C5=C(Cl)C=C(Cl)C=C5)C=C2	PLASMA	0KJ2VE664U																						UNKNOWN				In vitro, terconazole is highly protein bound (94.9%) and the degree of binding is independent of drug concentration.	5.1	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/19579slr026,19641slr022,19964slr021_terazol_lbl.pdf	Homo sapiens										false
5355	2495		ADULT	480953	532.462	TERCONAZOLE	terconazole	CC(C)N1CCN(CC1)C2=CC=C(OC[C@@H]3CO[C@](CN4C=NC=N4)(O3)C5=C(Cl)C=C(Cl)C=C5)C=C2	PLASMA	0KJ2VE664U													ng/mL	5.9			RECOMMENDED	mg	40		MULTIPLE	UNKNOWN		day	1			HEALTHY	Vaginal	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019579s035,019641s028,019964s030lbl.pdf	Homo sapiens										false
5356	2496		ADULT	11634155	317.4226	TETRABENAZINE	TETRABENAZINE	COC1=C(OC)C=C2[C@@H]3CC(=O)[C@@H](CC(C)C)CN3CCC2=C1	PLASMA	Z9O08YRN8O									∞	ng × h/mL	3.45		ng/mL	1.66			UNKNOWN	mg	25		SINGLE	UNKNOWN				83%–88% Protein binding (https://www.ncbi.nlm.nih.gov/pubmed/19750050)	14	HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/23339053	Homo sapiens		h	2.13							false
5357	2497		ADULT	60648|40467242	375.548	TIAGABINE	TIAGABINE	CC1=C(SC=C1)C(=CCCN2CCC[C@H](C2)C(O)=O)C3=C(C)C=CS3	BLOOD	Z80I64HMNP									∞	ng × h/mL	2190		ng/mL	552			UNKNOWN	mg	24		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/7555975	Homo sapiens		h	7.3							false
5358	2497		ADULT	60648|40467242	375.548	TIAGABINE	TIAGABINE	CC1=C(SC=C1)C(=CCCN2CCC[C@H](C2)C(O)=O)C3=C(C)C=CS3	BLOOD	Z80I64HMNP									∞	ng × h/mL	826		ng/mL	265			UNKNOWN	mg	10		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/7555975	Homo sapiens		h	6.5							false
5359	2498			5472	263.786	TICLOPIDINE	TICLOPIDINE	ClC1=C(CN2CCC3=C(C2)C=CS3)C=CC=C1	PLASMA	OM90ZUW7M1																										Binds reversibly (98%) to plasma proteins, mainly to serum albumin and lipoproteins.	2				DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/anda/99/75161_Ticlopidine%20Hydrochloride_Prntlbl.pdf	Homo sapiens										false
5360	2498		ADULT	5472	263.786	TICLOPIDINE	TICLOPIDINE	ClC1=C(CN2CCC3=C(C2)C=CS3)C=CC=C1	PLASMA	OM90ZUW7M1									∞	ng × h/mL	1053.9		ng/mL	365.3			RECOMMENDED	mg	250		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/12419644	Homo sapiens		h	7.46							false
5361	2500		ADULT	5482	387.711	TIOCONAZOLE	TIOCONAZOLE	ClC1=C(COC(CN2C=CN=C2)C3=C(Cl)C=C(Cl)C=C3)C=CS1	PLASMA	S57Y5X1117							24		t	ng × h/mL	150		ng/mL	13			RECOMMENDED	%	6		SINGLE	UNKNOWN						HEALTHY	Vaginal	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6873743/	Homo sapiens										false
5362	2501		ADULT	54682461	602.7	Tipranavir		CCCC1(CC(=C(C(=O)O1)C(CC)C2=CC(=CC=C2)NS(=O)(=O)C3=NC=C(C=C3)C(F)(F)F)O)CCC4=CC=CC=C4	PLASMA	ZZT404XD09	392622		Ritonavir		CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O	O3J8G9O825	12		t	μM × h	851		μM	94.8			RECOMMENDED	mg	500		STEADY-STATE	FED		day	2		0.1	UNHEALTHY	Oral	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021814s011lbl.pdf	Homo sapiens		h	5.5							true
5363	2501		ADULT	54682461	602.7	Tipranavir		CCCC1(CC(=C(C(=O)O1)C(CC)C2=CC(=CC=C2)NS(=O)(=O)C3=NC=C(C=C3)C(F)(F)F)O)CCC4=CC=CC=C4	PLASMA	ZZT404XD09	392622		Ritonavir		CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O	O3J8G9O825	12		t	μM × h	710		μM	77.6			RECOMMENDED	mg	500		STEADY-STATE	FED		day	2			UNHEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021814s011lbl.pdf	Homo sapiens		h	6							true
5364	2501		CHILD	54682461	602.7	Tipranavir		CCCC1(CC(=C(C(=O)O1)C(CC)C2=CC(=CC=C2)NS(=O)(=O)C3=NC=C(C=C3)C(F)(F)F)O)CCC4=CC=CC=C4	PLASMA	ZZT404XD09	392622		Ritonavir		CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O	O3J8G9O825	12		t	μM × h	1190		μM	135			RECOMMENDED	mg/m²	375		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021814s011lbl.pdf	Homo sapiens		h	8.1							true
5365	2502		ADULT	60947|40466968	440.597	TIROFIBAN	TIROFIBAN	CCCCS(=O)(=O)N[C@@H](CC1=CC=C(OCCCCC2CCNCC2)C=C1)C(O)=O	PLASMA	GGX234SI5H									∞	ng × h/mL	92.5						UNKNOWN	μg/kg/min	0.1	infusion, 4 hour	OTHER	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7955799/	Homo sapiens		h	2							false
5366	2502		ADULT	60947|40466968	440.597	TIROFIBAN	TIROFIBAN	CCCCS(=O)(=O)N[C@@H](CC1=CC=C(OCCCCC2CCNCC2)C=C1)C(O)=O	PLASMA	GGX234SI5H									∞	ng × h/mL	193.4						UNKNOWN	μg/kg/min	0.15	infusion, 4 hour	OTHER	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7955799/	Homo sapiens		h	1.6							false
5367	2502		ADULT	60947|40466968	440.597	TIROFIBAN	TIROFIBAN	CCCCS(=O)(=O)N[C@@H](CC1=CC=C(OCCCCC2CCNCC2)C=C1)C(O)=O	PLASMA	GGX234SI5H									∞	ng × h/mL	209.5						UNKNOWN	μg/kg/min	0.2	infusion, 4 hour	OTHER	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7955799/	Homo sapiens		h	1.1							false
5368	2503		ADULT	5487	253.711	TIZANIDINE	TIZANIDINE	ClC1=C(NC2=NCCN2)C3=NSN=C3C=C1	BLOOD	6AI06C00GW									?	ng × h/mL	13		ng/mL	3.1			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/3447935	Homo sapiens		h	2.8							false
5369	2503		ADULT	5487	253.711	TIZANIDINE	TIZANIDINE	ClC1=C(NC2=NCCN2)C3=NSN=C3C=C1	BLOOD	6AI06C00GW									?	ng × h/mL	54		ng/mL	11			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/3447935	Homo sapiens		h	3.2							false
5370	2504		ADULT	3080827	192.26	(S)-Tocainide	(S)-Tocainide		PLASMA										?	μg × h/mL	11.7						UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2127569	Homo sapiens		h	17.1							false
5371	2504		ADULT	3080825	192.26	R(-)-Tocainide	R(-)-Tocainide		PLASMA										?	μg × h/mL	7.8						UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2127569	Homo sapiens		h	11.7							false
5372	2504		ADULT	38945	192.2575	TOCAINIDE	TOCAINIDE	CC(N)C(=O)NC1=C(C)C=CC=C1C	PLASMA	27DXO59SAN									∞	μg × h/mL	84		μg/mL	3.2			UNKNOWN	mg	400		SINGLE	UNKNOWN						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3116834	Homo sapiens		h	15							false
5373	2505		ADULT	33741	263.3752	TRAMADOL	TRAMADOL	COC1=CC=CC(=C1)[C@@]2(O)CCCC[C@@H]2CN(C)C	PLASMA	39J1LGJ30J							24		t	ng × h/mL	5678		ng/mL	332			UNKNOWN	mg	200		STEADY-STATE	FASTED		day	1	The binding of tramadol to human plasma proteins is approximately 20% and binding also appears to be independent of concentration up to 10 µg/mL.	80	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022370s000lbl.pdf	Homo sapiens										false
5374	2505		ADULT	9838803	249.35	O-Desmethyltramadol	O-Desmethyl-Tramadol		PLASMA	9W28LW2ET5							24		t	ng × h/mL	1319		ng/mL	70			UNKNOWN	mg	200		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022370s000lbl.pdf	Homo sapiens										false
5375	2506		ADULT	5533	371.864	TRAZODONE	TRAZODONE	ClC1=CC=CC(=C1)N2CCN(CCCN3N=C4C=CC=CN4C3=O)CC2	PLASMA	YBK48BXK30									∞	μg × h/mL	13.3		μg/mL	1.88			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1438031/	Homo sapiens		h	7.8							false
5376	2506		UNKNOWN	5533	371.864	TRAZODONE	TRAZODONE	ClC1=CC=CC(=C1)N2CCN(CCCN3N=C4C=CC=CN4C3=O)CC2	PLASMA	YBK48BXK30																	UNKNOWN				UNKNOWN	UNKNOWN				Trazodone is 89 to 95% protein bound in vitro at concentrations attained with therapeutic doses in humans.	5	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/018207s033lbl.pdf	Homo sapiens										false
5377	2507		ADULT	5566	407.5	TRIFLUOPERAZINE	TRIFLUOPERAZINE	CN1CCN(CCCN2C3=C(SC4=C2C=C(C=C4)C(F)(F)F)C=CC=C3)CC1	PLASMA	214IZI85K3									∞	ng × h/mL	10.144		ng/mL	1.053			RECOMMENDED	mg	5		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/3137618	Homo sapiens		h	12.9							false
5378	2508		CHILD		298.447	TRIMEPRAZINE	TRIMEPRAZINE		PLASMA								24		t	μM × h	2758		μM	0.357			RECOMMENDED	mg/kg	3		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2255680/	Homo sapiens		h	6.8							false
5379	2509		ADULT	5584	294.4338	TRIMIPRAMINE	TRIMIPRAMINE	CC(CN(C)C)CN1C2=C(CCC3=C1C=CC=C3)C=CC=C2	PLASMA	6S082C9NDT									?	μg × h/mL	2.13		ng/mL	92.1			RECOMMENDED	mg	75		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/14520122/	Homo sapiens		h	31							false
5380	2510		ADULT	5282443	278.3914	TRIPROLIDINE	TRIPROLIDINE	CC1=CC=C(C=C1)C(=C/CN2CCCC2)\\C3=NC=CC=C3	PLASMA	2L8T9S52QM							12		t	ng × h/mL	31.22		ng/mL	5.6			RECOMMENDED	mg	2.5		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2355108/	Homo sapiens		h	6							false
5381	2511		ADULT	5596	392.5106	TROSPIUM	TROSPIUM	OC(C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)[N+]23CCCC3)(C4=CC=CC=C4)C5=CC=CC=C5	PLASMA	T4Y8ORK057									∞	ng × h/mL	36.4		ng/mL	3.5			RECOMMENDED	mg	20		SINGLE	UNKNOWN				Protein binding ranged from 50 to 85% when concentration levels of trospium chloride (0.5-50 ng/mL) were incubated with human serum in vitro.	32.5	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021595s009lbl.pdf	Homo sapiens		h	18.3							false
5382	2512		ADULT	5656	277.4018	VENLAFAXINE	VENLAFAXINE	COC1=CC=C(C=C1)C(CN(C)C)C2(O)CCCCC2	PLASMA	GRZ5RCB1QG									?	ng × h/mL	1536.3		ng/mL	26.9			RECOMMENDED	mg	75		STEADY-STATE	FED		day	1		73	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022104s016lbl.pdf	Homo sapiens		h	7.5							false
5383	2512		ADULT	125017	263.3752	DESVENLAFAXINE	O-Desmethylvenlafaxine	CN(C)CC(C1=CC=C(O)C=C1)C2(O)CCCCC2	PLASMA	NG99554ANW									?	ng × h/mL	2926		ng/mL	97.9			RECOMMENDED	mg	75		STEADY-STATE	FED		day	1		70	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022104s016lbl.pdf	Homo sapiens		h	12.5							false
5384	2512		ADULT	5656	277.4018	VENLAFAXINE	VENLAFAXINE	COC1=CC=C(C=C1)C(CN(C)C)C2(O)CCCCC2	PLASMA	GRZ5RCB1QG													ng/mL	150			UNKNOWN	mg	150		STEADY-STATE	FED		day	1		73	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022104s016lbl.pdf	Homo sapiens		h	10.7							false
5385	2512		ADULT	125017	263.3752	DESVENLAFAXINE	Desvenlafaxine	CN(C)CC(C1=CC=C(O)C=C1)C2(O)CCCCC2	PLASMA	NG99554ANW													ng/mL	260			UNKNOWN	mg	150		STEADY-STATE	FED		day	1		70	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022104s016lbl.pdf	Homo sapiens		h	12.5							false
5386	2513		UNKNOWN	5732	307.3895	ZOLPIDEM	ZOLPIDEM	CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C3=CC=C(C)C=C3	PLASMA	7K383OQI23													ng/mL	59			DEFINED DAILY	mg	5		SINGLE	UNKNOWN					7.5	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019908s027lbl.pdf	Homo sapiens		h	26							false
5387	2513		UNKNOWN	5732	307.3895	ZOLPIDEM	ZOLPIDEM	CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C3=CC=C(C)C=C3	PLASMA	7K383OQI23													ng/mL	121			DEFINED DAILY	mg	10		SINGLE	UNKNOWN					7.5	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019908s027lbl.pdf	Homo sapiens		h	2.5							false
5388	2514		ADULT	2216	245.109	APRACLONIDINE	APRACLONIDINE	NC1=CC(Cl)=C(NC2=NCCN2)C(Cl)=C1	PLASMA	843CEN85DI													ng/mL	0.9			RECOMMENDED	drop	1		MULTIPLE	UNKNOWN		day	3			HEALTHY	Ocular	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020258s026lbl.pdf	Homo sapiens		h	8							false
5389	2514		UNKNOWN	2216	245.109	APRACLONIDINE	APRACLONIDINE	NC1=CC(Cl)=C(NC2=NCCN2)C(Cl)=C1	PLASMA	843CEN85DI																	UNKNOWN				UNKNOWN	UNKNOWN				Protein binding has been measured in human plasma by ultrafiltration and equilibrium dialysis. Both methods indicated the extent of binding to be low (22-29%).	74.5	UNKNOWN	Topical	UNKNOWN	DRUG LABEL	https://www.google.ru/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwiUl-C6ho7sAhWj_CoKHXPHBYkQFjAYegQIHBAB&url=http%3A%2F%2Fwww.ask.novartispharma.ca%2Fdownload.htm%3Fres%3Diopidine_scrip_e.pdf%26resTitleId%3D1430&usg=AOvVaw2NI2gLoHBJh4I8Nn1NkVE2	Homo sapiens										false
5390	2515		ADULT	60789	317.3795	ARBUTAMINE	ARBUTAMINE	O[C@@H](CNCCCCC1=CC=C(O)C=C1)C2=CC(O)=C(O)C=C2	PLASMA	B07L15YAEV																	UNKNOWN	μg/kg	10		SINGLE	UNKNOWN					42	HEALTHY	Intravenous	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020420ap-1.pdf	Homo sapiens		min	5							false
5391	2516		UNKNOWN	5311017	239.3553	BENZPHETAMINE	BENZPHETAMINE	C[C@@H](CC1=CC=CC=C1)N(C)CC2=CC=CC=C2	PLASMA	0M3S43XK27																						UNKNOWN				Protein binding: 75-99%	13	UNKNOWN		UNKNOWN	OTHER	https://go.drugbank.com/drugs/DB00865	Homo sapiens										false
5392	2518		ADULT	16119814	1093.3131	CASPOFUNGIN	CASPOFUNGIN	CC[C@H](C)C[C@H](C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C4=CC=C(O)C=C4)[C@H](O)CCN	PLASMA	F0XDI6ZL63							24		t	mg × h/L	88.7		mg/L	7.51			RECOMMENDED	mg	50		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25139840	Homo sapiens		h	15.67							false
5393	2518		ADULT	16119814	1093.3131	CASPOFUNGIN	CASPOFUNGIN	CC[C@H](C)C[C@H](C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C4=CC=C(O)C=C4)[C@H](O)CCN	PLASMA	F0XDI6ZL63							24		t	mg × h/L	107.2		mg/L	8.65			RECOMMENDED	mg	50		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25139840	Homo sapiens		h	18.49							false
5394	2518		UNKNOWN	16119814	1093.3131	CASPOFUNGIN	CASPOFUNGIN	CC[C@H](C)C[C@H](C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C4=CC=C(O)C=C4)[C@H](O)CCN	PLASMA	F0XDI6ZL63																						UNKNOWN				Caspofungin is extensively bound to albumin (~97%)	3	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021227s038lbl.pdf	Homo sapiens										false
5395	2519		ADULT	2997	270.714	NORDAZEPAM	N-desmethyldiazepam	ClC1=CC=C2NC(=O)CN=C(C3=CC=CC=C3)C2=C1	PLASMA	67220MCM01													μg/L	413			RECOMMENDED	mg	20		SINGLE	FED				non-smokers		HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6119204/	Homo sapiens		h	54.7							false
5396	2519		ADULT	2997	270.714	NORDAZEPAM	N-desmethyldiazepam	ClC1=CC=C2NC(=O)CN=C(C3=CC=CC=C3)C2=C1	PLASMA	67220MCM01													μg/L	245			RECOMMENDED	mg	20		SINGLE	FED				smokers		HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6119204/	Homo sapiens		h	29.8							false
5397	2519		ADULT	2809|74648480	314.723	CLORAZEPIC ACID	chlorazepate	OC(=O)C1N=C(C2=CC=CC=C2)C3=C(NC1=O)C=CC(Cl)=C3	PLASMA	D51WO0G0L4																	RECOMMENDED	mg	20		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6137019/	Homo sapiens		h	2.42							false
5398	2519		ADULT	2997	270.714	NORDAZEPAM	desmethyldiazepam	ClC1=CC=C2NC(=O)CN=C(C3=CC=CC=C3)C2=C1	PLASMA	67220MCM01																	RECOMMENDED	mg	20		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6137019/	Homo sapiens		h	46							false
5399	2519		ADULT	2809|74648480	314.723	CLORAZEPIC ACID	chlorazepate	OC(=O)C1N=C(C2=CC=CC=C2)C3=C(NC1=O)C=CC(Cl)=C3	PLASMA	D51WO0G0L4																	RECOMMENDED	mg	20		SINGLE	UNKNOWN						HEALTHY	Intramuscular	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6137019/	Homo sapiens		h	2.291							false
5400	2519		ADULT	2997	270.714	NORDAZEPAM	desmethyldiazepam	ClC1=CC=C2NC(=O)CN=C(C3=CC=CC=C3)C2=C1	PLASMA	67220MCM01																	RECOMMENDED	mg	20		SINGLE	UNKNOWN						HEALTHY	Intramuscular	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6137019/	Homo sapiens		h	45.1							false
5401	2520		ADULT	151171	498.5744	CONIVAPTAN	CONIVAPTAN	CC1=NC2=C(N1)C3=CC=CC=C3N(CC2)C(=O)C4=CC=C(NC(=O)C5=C(C=CC=C5)C6=CC=CC=C6)C=C4	PLASMA	0NJ98Y462X													ng/mL	619			RECOMMENDED	mg/kg	40		SINGLE	UNKNOWN				Conivaptan is extensively bound to human plasma proteins, being 99% bound over the concentration range of approximately 10 to 1000 ng/mL.	1	HEALTHY	Intravenous	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021697s003lbl.pdf	Homo sapiens		h	5							false
5402	2520		ADULT	151171	498.5744	CONIVAPTAN	CONIVAPTAN	CC1=NC2=C(N1)C3=CC=CC=C3N(CC2)C(=O)C4=CC=C(NC(=O)C5=C(C=CC=C5)C6=CC=CC=C6)C=C4	PLASMA	0NJ98Y462X									∞	ng × h/mL	4813		ng/mL	2681			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/10638391	Homo sapiens		h	3.1							false
5403	2522		ADULT		442.4666	ELTROMBOPAG	ELTROMBOPAG	CC1=NN(C(=O)\\C1=N/NC2=C(O)C(=CC=C2)C3=CC(=CC=C3)C(O)=O)C4=CC(C)=C(C)C=C4	PLASMA	S56D65XJ9G							24		t	μg × h/mL	101		μg/mL	7.03			RECOMMENDED	mg	50		STEADY-STATE	UNKNOWN		day	1	In vitro studies suggest that eltrombopag is highly bound to human plasma proteins (greater than 99%).	1	UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022291s027,207027s010lbl.pdf	Homo sapiens		h	21							false
5404	2523		ADULT	146570	324.4	Escitalopram	Escitalopram	CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F	PLASMA	4O4S742ANY									∞	nM × h	1102		nM	58.6			UNKNOWN	mg	10		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16291715	Homo sapiens		h	26.6							false
5405	2523		ADULT		324.4	Escitalopram	Escitalopram	CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F	PLASMA	4O4S742ANY									∞	nM × h	1964		nM	58			MAX DAILY	mg	20		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16291715	Homo sapiens		h	26.7							false
5406	2523		ADULT	146570	324.4	Escitalopram	Escitalopram	CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F	PLASMA	4O4S742ANY									?	nM × h	1109		nM	63.4			RECOMMENDED	mg	10		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16291715	Homo sapiens		h	29							false
5407	2523		ADULT	146570	324.4	Escitalopram	Escitalopram	CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F	PLASMA	4O4S742ANY									?	nM × h	3391		nM	198.4			UNKNOWN	mg	30		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16291715	Homo sapiens		h	32.5							false
5408	2523		UNKNOWN	146570	324.4	Escitalopram	Escitalopram	CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F	PLASMA	4O4S742ANY																						UNKNOWN				The binding of escitalopram to human plasma proteins is approximately 56%.	44	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021323s047lbl.pdf	Homo sapiens										false
5409	2524		ADULT	11597698	263.3785	LISDEXAMFETAMINE	LISDEXAMFETAMINE	C[C@@H](CC1=CC=CC=C1)NC(=O)[C@@H](N)CCCCN	PLASMA	H645GUL8KJ							24		t	ng × h/mL	60.7		ng/mL	47.9			MAX DAILY	mg	70		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18021493/	Homo sapiens		h	12							false
5410	2525		ADULT	9034	262.3043	METHOHEXITAL	METHOHEXITAL	CCC#CC(C)C1(CC=C)C(=O)NC(=O)N(C)C1=O	PLASMA	E5B8ND5IPE																	UNKNOWN	%	1		SINGLE	UNKNOWN					27.1	UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17171861	Homo sapiens										false
5411	2525		ADULT	9034	262.3043	METHOHEXITAL	METHOHEXITAL	CCC#CC(C)C1(CC=C)C(=O)NC(=O)N(C)C1=O	PLASMA	E5B8ND5IPE									∞	mg × h/L	2.39						UNKNOWN	mg/kg	2		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2024566	Homo sapiens		min	151							false
5412	2525		ADULT		262.3043	METHOHEXITAL	METHOHEXITAL		PLASMA	E5B8ND5IPE									∞	mg × h/L	2.24						UNKNOWN	mg/kg	2		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2024566/	Homo sapiens		min	136							false
5413	2525		ADULT		262.3043	METHOHEXITAL			PLASMA	E5B8ND5IPE									∞	mg × h/L	2.71						UNKNOWN	mg/kg	2		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2024566/	Homo sapiens		min	204							false
5414	2525		CHILD	9034	262.3043	METHOHEXITAL	METHOHEXITAL	CCC#CC(C)C1(CC=C)C(=O)NC(=O)N(C)C1=O	PLASMA	E5B8ND5IPE													μg/mL	2.8			UNKNOWN	mg/kg	25		SINGLE	UNKNOWN						HEALTHY	Rectal	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4005094	Homo sapiens		min	102							false
5415	2526		ADULT	5284592	372.5408	NABILONE	NABILONE	CCCCCCC(C)(C)C1=CC2=C([C@@H]3CC(=O)CC[C@H]3C(C)(C)O2)C(O)=C1	PLASMA	2N4O9L084N									?	ng × h/mL	345						UNKNOWN	mg	2		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/872500	Homo sapiens		h	2							false
5416	2526		ADULT	5284592	372.5408	NABILONE	NABILONE	CCCCCCC(C)(C)C1=CC2=C([C@@H]3CC(=O)CC[C@H]3C(C)(C)O2)C(O)=C1	PLASMA	2N4O9L084N									?	ng × h/mL	90						UNKNOWN	mg	0.5		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/872500	Homo sapiens		h	1.7							false
5417	2527		ADULT	10413	104.1	4-Hydroxybutanoic acid	4-Hydroxybutanoic acid	C(CC(=O)O)CO	PLASMA	30IW36W5B2									?	μg × min/mL	3122		μg/mL	54			UNKNOWN	mg/kg	25		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1389947	Homo sapiens		min	27							false
5418	2527		ADULT	10413	104.1	4-Hydroxybutanoic acid	4-Hydroxybutanoic acid	C(CC(=O)O)CO	PLASMA	30IW36W5B2									∞	μg × min/mL	905		μg/mL	23			UNKNOWN	mg/kg	12.5		SINGLE	FASTED					99	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8299669	Homo sapiens		min	20							false
5419	2527		ADULT	10413	104.1	4-Hydroxybutanoic acid	4-Hydroxybutanoic acid	C(CC(=O)O)CO	PLASMA	30IW36W5B2									∞	μg × min/mL	1271		μg/mL	23			UNKNOWN	mg/kg	25		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8299669	Homo sapiens		min	22							false
5420	2527		ADULT	10413	104.1	4-Hydroxybutanoic acid	4-Hydroxybutanoic acid	C(CC(=O)O)CO	PLASMA	30IW36W5B2									∞	μg × min/mL	1565		μg/mL	20			UNKNOWN	mg/kg	50		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8299669	Homo sapiens		min	23							false
5421	2528		ADULT		221.34	TAPENTADOL			PLASMA										∞	ng × h/mL	221.34		ng/mL	221.34			UNKNOWN	mg	86		SINGLE	FASTED						HEALTHY	Oral	MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/23357834/	Homo sapiens		h	1.16							false
5422	2528		UNKNOWN		221.34	TAPENTADOL			PLASMA																		RECOMMENDED	mg	100		SINGLE	UNKNOWN				The plasma protein binding is low and amounts to approximately 20%.	80	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022304s022lbl.pdf	Homo sapiens		h	4							false
5423	2529		ADULT	5280980	199.1608	CLAVULANIC ACID	CLAVULANIC ACID	OC\\C=C1/O[C@@H]2CC(=O)N2[C@H]1C(O)=O	PLASMA	23521W1S24	62883		AMOXICILLIN	amoxicillin	O.O.O.CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)C3=CC=C(O)C=C3)C(=O)N2[C@H]1C(O)=O	804826J2HU			?	μg × h/mL	5.49		μg/mL	2.63			RECOMMENDED	mg	125		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12562705/	Homo sapiens		h	1							true
5424	2530		UNKNOWN	17676	411.56	ACETOPHENAZINE	ACETOPHENAZINE	CC(=O)C1=CC2=C(SC3=C(C=CC=C3)N2CCCN4CCN(CCO)CC4)C=C1	PLASMA	8620H6K4QH																	RECOMMENDED	mg	20		SINGLE	UNKNOWN					10	UNKNOWN	Oral	UNKNOWN	REVIEW	https://jamanetwork.com/journals/jama/article-abstract/182936	Homo sapiens										false
5425	2532		ADULT	2131	537.565	AMBENONIUM	AMBENONIUM	CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=C(Cl)C=CC=C1)CC2=C(Cl)C=CC=C2	SERUM	L16PUN799N							3		t	μg × min/mL	0.5		ng/mL	5.61			UNKNOWN	mg	5		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1516600/	Homo sapiens										false
5426	2532		ADULT	2131	537.565	AMBENONIUM	AMBENONIUM	CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=C(Cl)C=CC=C1)CC2=C(Cl)C=CC=C2	SERUM	L16PUN799N							3		t	μg × min/mL	1.07		ng/mL	9.12			UNKNOWN	mg	10		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1516600/	Homo sapiens										false
5427	2532		ADULT	2131	537.565	AMBENONIUM	AMBENONIUM	CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=C(Cl)C=CC=C1)CC2=C(Cl)C=CC=C2	SERUM	L16PUN799N							3		t	μg × min/mL	0.23		ng/mL	2.5			UNKNOWN	mg	10		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1516600/	Homo sapiens										false
5428	2532		ADULT	2131	537.565	AMBENONIUM	AMBENONIUM	CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=C(Cl)C=CC=C1)CC2=C(Cl)C=CC=C2	SERUM	L16PUN799N							3		t	μg × min/mL	0.112		ng/mL	1.29			UNKNOWN	mg	5		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1516600/	Homo sapiens										false
5429	2532		ADULT	2131	537.565	AMBENONIUM	AMBENONIUM	CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=C(Cl)C=CC=C1)CC2=C(Cl)C=CC=C2	SERUM	L16PUN799N	91438	400.4648	PREDNISONE ACETATE	Prednisone acetate	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3C(=O)C[C@]12C	OU93QEL83U	24		t	μg × h/mL	1.38		μg/mL	0.129			RECOMMENDED	mg	10		MULTIPLE	UNKNOWN		day	5			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1823874/	Homo sapiens				10 mg administered 5 times	Patient 2, renal impairment		1			true
5430	2532		ADULT	2131	537.565	AMBENONIUM	AMBENONIUM	CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=C(Cl)C=CC=C1)CC2=C(Cl)C=CC=C2	SERUM	L16PUN799N	91438	400.4648	PREDNISONE ACETATE	Prednisone acetate	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3C(=O)C[C@]12C	OU93QEL83U	24		t	μg × h/mL	6.5		μg/mL	0.812			RECOMMENDED	mg	5		MULTIPLE	UNKNOWN		day	5			UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1823874/	Homo sapiens					Patient 3		1			true
5431	2532		ADULT	2131	537.565	AMBENONIUM	AMBENONIUM	CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=C(Cl)C=CC=C1)CC2=C(Cl)C=CC=C2	SERUM	L16PUN799N													ng/mL	8.4			RECOMMENDED	mg	10		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2613842/	Homo sapiens										false
5432	2533		ADULT	6479523	461.492	AZLOCILLIN	AZLOCILLIN	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCNC3=O)C4=CC=CC=C4)C(=O)N2[C@H]1C(O)=O	PLASMA	HUM6H389W0									?	μg × h/mL	592						UNKNOWN	g	4		MULTIPLE	UNKNOWN		day	4			HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2751284	Homo sapiens		h	1.29							false
5433	2533		ADULT	6479523	461.492	AZLOCILLIN	AZLOCILLIN	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCNC3=O)C4=CC=CC=C4)C(=O)N2[C@H]1C(O)=O	PLASMA	HUM6H389W0									?	μg × h/mL	772						UNKNOWN	g	5		MULTIPLE	UNKNOWN		day	3			HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2751284	Homo sapiens		h	1.46							false
5434	2533		ADULT	6479523	461.492	AZLOCILLIN	AZLOCILLIN	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCNC3=O)C4=CC=CC=C4)C(=O)N2[C@H]1C(O)=O	PLASMA	HUM6H389W0									?	μg × h/mL	374						UNKNOWN	g	4		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3729353	Homo sapiens		h	1.26							false
5435	2533		ADULT	6479523	461.492	AZLOCILLIN	AZLOCILLIN	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCNC3=O)C4=CC=CC=C4)C(=O)N2[C@H]1C(O)=O	PLASMA	HUM6H389W0													μg/mL	414			UNKNOWN	g	4		MULTIPLE	UNKNOWN		day	4			HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3780161	Homo sapiens		h	1.1							false
5436	2535		ADULT	2368	177.2462	BETHANIDINE	BETHANIDINE	CNC(NC)=NCC1=CC=CC=C1	PLASMA	W8S3YM7AUU							4		t	μg × h/mL	0.5		μg/mL	0.4			RECOMMENDED	mg	25		SINGLE	UNKNOWN				Equilibrium dialysis studies showed that less than 8% of BHS-14C at a concentration of 1 mkg/ ml is bound to crystalline human albumin	90	UNHEALTHY	Intravenous	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1120401/	Homo sapiens		h	11							false
5437	2536		ADULT	2431	243.163	BRETYLIUM	BRETYLIUM	CC[N+](C)(C)CC1=C(Br)C=CC=C1	PLASMA	RZR75EQ2KJ													ng/mL	1100			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7104462/	Homo sapiens		min	535							false
5438	2538		CHILD	43594	542.566	CEFONICID	CEFONICID	O[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSC3=NN=NN3CS(O)(=O)=O)=C(N2C1=O)C(O)=O)C4=CC=CC=C4	SERUM	6532B86WFG									?	μg × h/mL	1.11		μg/mL	213			UNKNOWN	mg/kg bw	50		SINGLE	UNKNOWN						UNHEALTHY	Intramuscular	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2917594	Homo sapiens		h	3.24							false
5439	2538		ADULT	43594	542.566	CEFONICID	CEFONICID	O[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSC3=NN=NN3CS(O)(=O)=O)=C(N2C1=O)C(O)=O)C4=CC=CC=C4	SERUM	6532B86WFG									?	μg × h/mL	1644		μg/mL	127			UNKNOWN	g	1		SINGLE	UNKNOWN						UNHEALTHY	Intramuscular	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8340557	Homo sapiens		h	11.6							false
5440	2539		ADULT	636405|5282213	612.637	CEFPIRAMIDE	CEFPIRAMIDE	CN1N=NN=C1SCC2=C(N3[C@H](SC2)[C@H](NC(=O)[C@H](NC(=O)C4=CN=C(C)C=C4O)C5=CC=C(O)C=C5)C3=O)C(O)=O	PLASMA	P936YA152N									?	mg × h/L	672						UNKNOWN	g	1		SINGLE	UNKNOWN				The average unbound fraction was 1.9% ± 0.3% in normal subjects.	1.9	HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1686912	Homo sapiens		h	5.3							false
5441	2539		ADULT	636405|5282213	612.637	CEFPIRAMIDE	CEFPIRAMIDE	CN1N=NN=C1SCC2=C(N3[C@H](SC2)[C@H](NC(=O)[C@H](NC(=O)C4=CN=C(C)C=C4O)C5=CC=C(O)C=C5)C3=O)C(O)=O	PLASMA	P936YA152N									?	mg × h/L	1598						UNKNOWN	g	1		SINGLE	UNKNOWN				The average unbound fraction was 10.4% ± 9.5% in patients with cirrhosis	10.4	UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2007321	Homo sapiens		h	13.8							false
5442	2539		ADULT	636405|5282213	612.637	CEFPIRAMIDE	CEFPIRAMIDE	CN1N=NN=C1SCC2=C(N3[C@H](SC2)[C@H](NC(=O)[C@H](NC(=O)C4=CN=C(C)C=C4O)C5=CC=C(O)C=C5)C3=O)C(O)=O	PLASMA	P936YA152N									?	mg × h/L	672						UNKNOWN	g	1		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8198940	Homo sapiens		h	5.3							false
5443	2539		ADULT	636405|5282213	612.637	CEFPIRAMIDE	CEFPIRAMIDE	CN1N=NN=C1SCC2=C(N3[C@H](SC2)[C@H](NC(=O)[C@H](NC(=O)C4=CN=C(C)C=C4O)C5=CC=C(O)C=C5)C3=O)C(O)=O	PLASMA	P936YA152N									?	mg × h/L	1300						UNKNOWN	g	1		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8198940	Homo sapiens		h	12							false
5444	2540		ADULT	30699	423.463	CEPHAPIRIN	CEPHAPIRIN	CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CSC3=CC=NC=C3)C2=O)C(O)=O	SERUM	89B59H32VN							4.5		t	μg × h/mL	72		μg/mL	92			RECOMMENDED	g	2		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/984783/	Homo sapiens		h	0.36							false
5445	2541		ADULT	10007	183.678	CHLORPHENTERMINE	CHLORPHENTERMINE	CC(C)(N)CC1=CC=C(Cl)C=C1	PLASMA	NHW07912O7							48		t	μg × h/mL	10.6		μg/mL	0.4			RECOMMENDED	mg	100		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/5416167/	Homo sapiens		h	41							false
5446	2543		UNKNOWN	54680690	464.853	DEMECLOCYCLINE	demeclocycline	CN(C)[C@H]1[C@@H]2C[C@@H]3[C@H](O)C4=C(C(O)=CC=C4Cl)C(=O)C3=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O	SERUM	5R5W9ICI6O													mg/L	1.2			RECOMMENDED	mg	150		SINGLE	UNKNOWN				Protein binding 75-91%	17	UNKNOWN	Oral	UNKNOWN	REVIEW	https://academic.oup.com/jac/article/58/2/256/718565	Homo sapiens										false
5447	2543		UNKNOWN	54680690	464.853	DEMECLOCYCLINE	demeclocycline	CN(C)[C@H]1[C@@H]2C[C@@H]3[C@H](O)C4=C(C(O)=CC=C4Cl)C(=O)C3=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O	SERUM	5R5W9ICI6O													mg/L	1.7			RECOMMENDED	mg	300		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	REVIEW	https://academic.oup.com/jac/article/58/2/256/718565	Homo sapiens		h	13.5							false
5448	2543		UNKNOWN	54680690	464.853	DEMECLOCYCLINE	demeclocycline	CN(C)[C@H]1[C@@H]2C[C@@H]3[C@H](O)C4=C(C(O)=CC=C4Cl)C(=O)C3=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O	SERUM	5R5W9ICI6O													mg/L	2.5			UNKNOWN	mg	500		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	REVIEW	https://academic.oup.com/jac/article/58/2/256/718565	Homo sapiens		h	13							false
5449	2543		UNKNOWN	54680690	464.853	DEMECLOCYCLINE	demeclocycline	CN(C)[C@H]1[C@@H]2C[C@@H]3[C@H](O)C4=C(C(O)=CC=C4Cl)C(=O)C3=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O	PLASMA	5R5W9ICI6O																	UNKNOWN	mg	150		SINGLE	UNKNOWN				plasma protein, dialysis equilibrium method	60	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050261s101lbl.pdf	Homo sapiens		h	13							false
5450	2543			54680690	464.853	DEMECLOCYCLINE	demeclocycline	CN(C)[C@H]1[C@@H]2C[C@@H]3[C@H](O)C4=C(C(O)=CC=C4Cl)C(=O)C3=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O	PLASMA	5R5W9ICI6O																										plasma protein, ultra-filtration method	10				DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050261s101lbl.pdf	Homo sapiens										false
5451	2543		UNKNOWN	54680690	464.853	DEMECLOCYCLINE	demeclocycline	CN(C)[C@H]1[C@@H]2C[C@@H]3[C@H](O)C4=C(C(O)=CC=C4Cl)C(=O)C3=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O	PLASMA	5R5W9ICI6O													mg/L	2.4			RECOMMENDED	mg	300		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	OTHER	https://www.medicines.org.uk/emc/product/499/smpc#PHARMACOKINETIC_PROPS	Homo sapiens										false
5452	2545		ADULT	6127	278.4113	DIPHEMANIL	DIPHEMANIL	C[N+]1(C)CCC(CC1)=C(C2=CC=CC=C2)C3=CC=CC=C3	PLASMA	Q26TX1UD0W									?	μg × h/L	433		μg/L	47.9			UNKNOWN	mg	250		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1623915/	Homo sapiens		h	8.35				6			false
5453	2545		NEWBORN	6127	278.4113	DIPHEMANIL	DIPHEMANIL	C[N+]1(C)CCC(CC1)=C(C2=CC=CC=C2)C3=CC=CC=C3	PLASMA	Q26TX1UD0W																	RECOMMENDED	mg/kg	3		SINGLE	FASTED						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8087216/	Homo sapiens		h	8.6							false
5454	2546		ADULT	681	153.079	DOPAMINE	DOPAMINE	NCCC1=CC=C(O)C(O)=C1	PLASMA	VTD58H1Z2X									∞	ng × h/mL	2926		ng/mL	1712			UNKNOWN	mg	250		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/2775615	Homo sapiens		h	1.6							false
5455	2548		ADULT	3202	166.2401	EDROPHONIUM	EDROPHONIUM	CC[N+](C)(C)C1=CC(O)=CC=C1	PLASMA	70FP3JLY7N			ATROPINE	atropine	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C3=CC=CC=C3	7C0697DR9I											RECOMMENDED	mg/kg	1		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2169210/	Homo sapiens		min	84.2							true
5456	2548		ADULT	3202	166.2401	EDROPHONIUM	EDROPHONIUM	CC[N+](C)(C)C1=CC(O)=CC=C1	PLASMA	70FP3JLY7N			ATROPINE	atropine	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C3=CC=CC=C3	7C0697DR9I											RECOMMENDED	mg/kg	1		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2169210/	Homo sapiens		min	56.6							true
5457	2548		ADULT	3202	166.2401	EDROPHONIUM	EDROPHONIUM	CC[N+](C)(C)C1=CC(O)=CC=C1	BLOOD	70FP3JLY7N			ATROPINE	atropine	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C3=CC=CC=C3	7C0697DR9I											RECOMMENDED	mg/kg	0.5		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7224209/	Homo sapiens		min	110							true
5458	2548		ADULT	3202	166.2401	EDROPHONIUM	EDROPHONIUM	CC[N+](C)(C)C1=CC(O)=CC=C1	BLOOD	70FP3JLY7N			ATROPINE	atropine	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C3=CC=CC=C3	7C0697DR9I											RECOMMENDED	mg/kg	1		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7224209/	Homo sapiens		min	110							true
5459	2549		ADULT	8223	581.6615	ERGOTAMINE	ERGOTAMINE	CN1C[C@@H](C=C2[C@H]1CC3=CNC4=C3C2=CC=C4)C(=O)N[C@]5(C)O[C@@]6(O)[C@@H]7CCCN7C(=O)[C@H](CC8=CC=CC=C8)N6C5=O	PLASMA	PR834Q503T									?	pg × h/mL	61		pg/mL	21.4			UNKNOWN	mg	2		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3732370/	Homo sapiens										false
5460	2549		ADULT	8223	581.6615	ERGOTAMINE	ergotamine	CN1C[C@@H](C=C2[C@H]1CC3=CNC4=C3C2=CC=C4)C(=O)N[C@]5(C)O[C@@]6(O)[C@@H]7CCCN7C(=O)[C@H](CC8=CC=CC=C8)N6C5=O	PLASMA	PR834Q503T									?	pg × h/mL	1216		pg/mL	454			UNKNOWN	mg	2		SINGLE	FASTED						HEALTHY	Rectal	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3732370/	Homo sapiens		h	3.35							false
5461	2549		ADULT	8223	581.6615	ERGOTAMINE	ERGOTAMINE	CN1C[C@@H](C=C2[C@H]1CC3=CNC4=C3C2=CC=C4)C(=O)N[C@]5(C)O[C@@]6(O)[C@@H]7CCCN7C(=O)[C@H](CC8=CC=CC=C8)N6C5=O	PLASMA	PR834Q503T									?	ng × h/mL	4.38						UNKNOWN	μg/kg bw	3.89		SINGLE	FED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3932078/	Homo sapiens		h	2.15							false
5462	2549		ADULT	8223	581.6615	ERGOTAMINE	Ergotamine	CN1C[C@@H](C=C2[C@H]1CC3=CNC4=C3C2=CC=C4)C(=O)N[C@]5(C)O[C@@]6(O)[C@@H]7CCCN7C(=O)[C@H](CC8=CC=CC=C8)N6C5=O	PLASMA	PR834Q503T									?	ng × h/mL	2.04						UNKNOWN	μg/kg bw	1.94		SINGLE	FED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3932078/	Homo sapiens		h	2.13							false
5463	2549		ADULT	8223	581.6615	ERGOTAMINE	Ergotamine	CN1C[C@@H](C=C2[C@H]1CC3=CNC4=C3C2=CC=C4)C(=O)N[C@]5(C)O[C@@]6(O)[C@@H]7CCCN7C(=O)[C@H](CC8=CC=CC=C8)N6C5=O	PLASMA	PR834Q503T									?	ng × h/mL	1.36						UNKNOWN	μg/kg bw	1.01		SINGLE	FED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3932078/	Homo sapiens		h	2.08							false
5464	2550		UNKNOWN	3290	312.472	PROFENAMINE	PROFENAMINE	CCN(CC)C(C)CN1C2=CC=CC=C2SC3=C1C=CC=C3	UNKNOWN	7WI4P02YN1																						UNKNOWN					7	UNKNOWN		UNKNOWN	OTHER	https://go.drugbank.com/drugs/DB00392	Homo sapiens										false
5465	2553		ADULT	10770	261.3593	HEXYLCAINE	HEXYLCAINE	CC(CNC1CCCCC1)OC(=O)C2=CC=CC=C2	PLASMA	511IU0826Z													μg/mL	205			UNKNOWN	mL	5		SINGLE	UNKNOWN						HEALTHY	Intrathecal	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/693515/	Homo sapiens		min	13							false
5466	2555		ADULT	47576	531.431	KETOCONAZOLE	KETOCONAZOLE	CC(=O)N1CCN(CC1)C2=CC=C(OC[C@@H]3CO[C@](CN4C=CN=C4)(O3)C5=C(Cl)C=C(Cl)C=C5)C=C2	PLASMA	R9400W927I							12		t	mg × min/L	1053		μg/mL	6			RECOMMENDED	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6271723/	Homo sapiens		min	122							false
5467	2555		ADULT	47576	531.431	KETOCONAZOLE	KETOCONAZOLE	CC(=O)N1CCN(CC1)C2=CC=C(OC[C@@H]3CO[C@](CN4C=CN=C4)(O3)C5=C(Cl)C=C(Cl)C=C5)C=C2	PLASMA	R9400W927I													μg/mL	3.5			RECOMMENDED	mg	200		SINGLE	FED				In vitro, the plasma protein binding is about 99% mainly to the albumin fraction.	1	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/018533s041lbl.pdf	Homo sapiens		h	2							false
5468	2557		UNKNOWN	3998	186.231	MAFENIDE	mafenide	NCC1=CC=C(C=C1)S(N)(=O)=O	BLOOD	58447S8P4L													μg/mL	26			UNKNOWN	g	14		SINGLE	UNKNOWN						UNKNOWN	Topical	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/19832lbl.pdf	Homo sapiens										false
5469	2557		UNKNOWN	8739	201.2	CARZENIDE	CARZENIDE	NS(=O)(=O)C1=CC=C(C=C1)C(O)=O	BLOOD	30Z5HQB5A4													μg/mL	10			UNKNOWN	g	14		SINGLE	UNKNOWN						UNKNOWN	Topical	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/19832lbl.pdf	Homo sapiens										false
5470	2557		UNKNOWN	3998	186.231	MAFENIDE	mafenide	NCC1=CC=C(C=C1)S(N)(=O)=O	BLOOD	58447S8P4L													μg/mL	197			UNKNOWN	g	77		SINGLE	UNKNOWN						UNKNOWN	Topical	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/19832lbl.pdf	Homo sapiens										false
5471	2557		UNKNOWN	8739	201.2	CARZENIDE	CARZENIDE	NS(=O)(=O)C1=CC=C(C=C1)C(O)=O	BLOOD	30Z5HQB5A4													μg/mL	340			UNKNOWN	g	77		SINGLE	UNKNOWN						UNKNOWN	Topical	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/19832lbl.pdf	Homo sapiens										false
5472	2559		ADULT	4078	386.574	MESORIDAZINE	MESORIDAZINE	CN1CCCCC1CCN2C3=CC(=CC=C3SC4=C2C=CC=C4)[S+](C)[O-]	PLASMA	5XE4NWM740							24		t	ng × h/mL	2400		ng/mL	240			RECOMMENDED	mg	50		SINGLE	FASTED				https://pubmed.ncbi.nlm.nih.gov/39211/	75	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17410120/	Homo sapiens		h	12.5							false
5473	2560		ADULT	4097	340.436	METHANTHELINE	METHANTHELINE	CC[N+](C)(CC)CCOC(=O)C1C2=CC=CC=C2OC3=C1C=CC=C3	PLASMA	36EI79TX7I													ng/mL	25			RECOMMENDED	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22527350/	Homo sapiens		h	2							false
5474	2561		ADULT	6087	380.415	METHICILLIN	METHICILLIN	COC1=CC=CC(OC)=C1C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O	PLASMA	Q91FH1328A									∞	μg × h/mL	27.5		μg/mL	25			UNKNOWN	mg/kg	15		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/404369/	Homo sapiens		h	1.05							false
5475	2562		ADULT	21233	652.8189	METOCURINE	METOCURINE	COC1=CC2=C3C=C1OC4=C(OC)C=CC(C[C@@H]5C6=C(CC[N+]5(C)C)C=C(OC)C(OC)=C6OC7=CC=C(C[C@@H]3[N+](C)(C)CC2)C=C7)=C4	SERUM	V0M92G2U26													μg/mL	1.05			RECOMMENDED	mg/kg	0.3		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7023284/	Homo sapiens		h	11.4							false
5476	2562		ADULT	21233	652.8189	METOCURINE	METOCURINE	COC1=CC2=C3C=C1OC4=C(OC)C=CC(C[C@@H]5C6=C(CC[N+]5(C)C)C=C(OC)C(OC)=C6OC7=CC=C(C[C@@H]3[N+](C)(C)CC2)C=C7)=C4	SERUM	V0M92G2U26													μg/mL	0.46			RECOMMENDED	mg/kg	0.3		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7023284/	Homo sapiens		h	6							false
5477	2563		ADULT	4178	179.2588	MEXILETINE	MEXILETINE	CC(N)COC1=C(C)C=CC=C1C	PLASMA	1U511HHV4Z									∞	μg × h/mL	2.96		μg/mL	0.21			UNKNOWN	mg	100		SINGLE	UNKNOWN				Protein binding of mexiletine is 60%	40	HEALTHY	Oral	UNKNOWN	REVIEW	https://www.ema.europa.eu/en/documents/assessment-report/namuscla-epar-public-assessment-report_en.pdf	Homo sapiens		h	9.4							false
5478	2563		ADULT	4178	179.2588	MEXILETINE	MEXILETINE	CC(N)COC1=C(C)C=CC=C1C	PLASMA	1U511HHV4Z									∞	μg × h/mL	5.8		μg/mL	0.35			UNKNOWN	mg	150		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	REVIEW	https://www.ema.europa.eu/en/documents/assessment-report/namuscla-epar-public-assessment-report_en.pdf	Homo sapiens		h	10.8							false
5479	2563		ADULT	4178	179.2588	MEXILETINE	MEXILETINE	CC(N)COC1=C(C)C=CC=C1C	PLASMA	1U511HHV4Z									∞	μg × h/mL	7.76		μg/mL	0.45			RECOMMENDED	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	REVIEW	https://www.ema.europa.eu/en/documents/assessment-report/namuscla-epar-public-assessment-report_en.pdf	Homo sapiens		h	11.1							false
5480	2563		ADULT	4178	179.2588	MEXILETINE	MEXILETINE	CC(N)COC1=C(C)C=CC=C1C	PLASMA	1U511HHV4Z									∞	μg × h/mL	6.7		μg/mL	0.46			RECOMMENDED	mg	300		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	REVIEW	https://www.ema.europa.eu/en/documents/assessment-report/namuscla-epar-public-assessment-report_en.pdf	Homo sapiens		h	10							false
5481	2563		ADULT	4178	179.2588	MEXILETINE	MEXILETINE	CC(N)COC1=C(C)C=CC=C1C	PLASMA	1U511HHV4Z									∞	μg × h/mL	8.3		μg/mL	0.81			RECOMMENDED	mg	400		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	REVIEW	https://www.ema.europa.eu/en/documents/assessment-report/namuscla-epar-public-assessment-report_en.pdf	Homo sapiens		h	7							false
5482	2563		ADULT	4178	179.2588	MEXILETINE	MEXILETINE	CC(N)COC1=C(C)C=CC=C1C	PLASMA	1U511HHV4Z									∞	μg × h/mL	22		μg/mL	1.2			RECOMMENDED	mg	200		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Oral	UNKNOWN	REVIEW	https://www.ema.europa.eu/en/documents/assessment-report/namuscla-epar-public-assessment-report_en.pdf	Homo sapiens		h	9.9							false
5483	2563		ADULT	4178	179.2588	MEXILETINE	MEXILETINE	CC(N)COC1=C(C)C=CC=C1C	PLASMA	1U511HHV4Z									∞	μg × h/mL	3.7		μg/mL	0.59			UNKNOWN	mg	100		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Oral	UNKNOWN	REVIEW	https://www.ema.europa.eu/en/documents/assessment-report/namuscla-epar-public-assessment-report_en.pdf	Homo sapiens		h	14.1							false
5484	2564		ADULT		246.35	MILNACIPRAN			PLASMA										∞	ng × h/mL	1316.9		ng/mL	132			RECOMMENDED	mg	50		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26663198/	Homo sapiens		h	7							false
5485	2564		ADULT		246.35	MILNACIPRAN			PLASMA														ng/mL	150			RECOMMENDED	mg	50		SINGLE	UNKNOWN					87	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8923123/	Homo sapiens		h	8							false
5486	2564		UNKNOWN		246.35	MILNACIPRAN			PLASMA																		RECOMMENDED	mg	50		SINGLE	UNKNOWN				Milnacipran has a low binding to plasma proteins (13%)	87	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022256s023lbl.pdf	Homo sapiens		h	6							false
5487	2565		ADULT	34633	427.517	MORICIZINE	MORICIZINE	CCOC(=O)NC1=CC2=C(SC3=C(C=CC=C3)N2C(=O)CCN4CCOCC4)C=C1	BLOOD	2GT1D0TMX1									?	mg × h/L	0.569		mg/L	0.3035			UNKNOWN	mg	150		MULTIPLE	UNKNOWN		day	3			HEALTHY	Oral	MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/2407090	Homo sapiens		h	1.5				11			false
5488	2565		ADULT	34633	427.517	MORICIZINE	MORICIZINE	CCOC(=O)NC1=CC2=C(SC3=C(C=CC=C3)N2C(=O)CCN4CCOCC4)C=C1	BLOOD	2GT1D0TMX1									?	mg × h/L	0.747		mg/L	0.444			UNKNOWN	mg	200		MULTIPLE	UNKNOWN		day	3			HEALTHY	Oral	MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/2407090	Homo sapiens		h	1.4				11			false
5489	2565		ADULT	34633	427.517	MORICIZINE	MORICIZINE	CCOC(=O)NC1=CC2=C(SC3=C(C=CC=C3)N2C(=O)CCN4CCOCC4)C=C1	BLOOD	2GT1D0TMX1									?	mg × h/L	1.008		mg/L	0.5			UNKNOWN	mg	250		MULTIPLE	UNKNOWN		day	3			HEALTHY	Oral	MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/2407090	Homo sapiens		h	1.4				11			false
5490	2565		ADULT	34633	427.517	MORICIZINE	MORICIZINE	CCOC(=O)NC1=CC2=C(SC3=C(C=CC=C3)N2C(=O)CCN4CCOCC4)C=C1	BLOOD	2GT1D0TMX1									?	mg × h/L	0.993		mg/L	0.597			UNKNOWN	mg	300		MULTIPLE	UNKNOWN		day	3			HEALTHY	Oral	MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/2407090	Homo sapiens		h	1.4				11			false
5491	2566		ADULT	189562	405.435	NEBIVOLOL	NEBIVOLOL	O[C@H](CNC[C@@H](O)[C@H]1CCC2=C(O1)C=CC(F)=C2)[C@@H]3CCC4=CC(F)=CC=C4O3	PLASMA	030Y90569U									?	ng × h/mL	7.76		ng/mL	1.48			RECOMMENDED	mg	10		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/18083889/	Homo sapiens		h	11							false
5492	2566		UNKNOWN	189562	405.435	NEBIVOLOL	NEBIVOLOL	O[C@H](CNC[C@@H](O)[C@H]1CCC2=C(O1)C=CC(F)=C2)[C@@H]3CCC4=CC(F)=CC=C4O3	PLASMA	030Y90569U																	UNKNOWN				UNKNOWN	UNKNOWN				The in vitro human plasma protein binding of nebivolol is approximately 98%, mostly to albumin, and is independent of nebivolol concentrations.	2	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf	Homo sapiens										false
5493	2568		ADULT	104811	342.389	OXYPHENBUTAZONE	OXYPHENBUTAZONE	O.CCCCC1C(=O)N(N(C1=O)C2=CC=C(O)C=C2)C3=CC=CC=C3	PLASMA	H806S4B3NS							48		t	μg × h/mL	397.401		μg/mL	21.42			UNKNOWN	mg	97.49		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10518246/	Homo sapiens										false
5494	2568		ADULT	104811	342.389	OXYPHENBUTAZONE	oxyphenbutazone	O.CCCCC1C(=O)N(N(C1=O)C2=CC=C(O)C=C2)C3=CC=CC=C3	PLASMA	H806S4B3NS							48		t	μg × h/mL	482.606		μg/mL	24.54			UNKNOWN	mg	95.38		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10518246/	Homo sapiens										false
5495	2568		ADULT	104811	342.389	OXYPHENBUTAZONE	oxyphenbutazone	O.CCCCC1C(=O)N(N(C1=O)C2=CC=C(O)C=C2)C3=CC=CC=C3	PLASMA	H806S4B3NS							48		t	μg × h/mL	463.858		μg/mL	24.05			UNKNOWN	mg	98.82		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10518246/	Homo sapiens										false
5496	2568		ADULT	104811	342.389	OXYPHENBUTAZONE	oxyphenbutazone	O.CCCCC1C(=O)N(N(C1=O)C2=CC=C(O)C=C2)C3=CC=CC=C3	PLASMA	H806S4B3NS							48		t	μg × h/mL	285.932		μg/mL	12			UNKNOWN	mg	94.99		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10518246/	Homo sapiens										false
5497	2568		ADULT	104811	342.389	OXYPHENBUTAZONE	oxyphenbutazone	O.CCCCC1C(=O)N(N(C1=O)C2=CC=C(O)C=C2)C3=CC=CC=C3	PLASMA	H806S4B3NS							48		t	μg × h/mL	381.688		μg/mL	18.24			UNKNOWN	mg	95.75		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10518246/	Homo sapiens										false
5498	2569		ADULT	5749	348.4996	OXYPHENONIUM	OXYPHENONIUM	CC[N+](C)(CC)CCOC(=O)C(O)(C1CCCCC1)C2=CC=CC=C2	PLASMA	D2G5508Y7I									?	μg × min/mL	5.9						UNKNOWN	mg	2		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	OTHER	https://core.ac.uk/download/pdf/232467634.pdf	Homo sapiens		h	2							false
5499	2569		ADULT	5749	348.4996	OXYPHENONIUM	OXYPHENONIUM	CC[N+](C)(CC)CCOC(=O)C(O)(C1CCCCC1)C2=CC=CC=C2	PLASMA	D2G5508Y7I									?				ng/mL	5			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	OTHER	https://core.ac.uk/download/pdf/232467634.pdf	Homo sapiens		min	190							false
5500	2569		ADULT	5749	348.4996	OXYPHENONIUM	OXYPHENONIUM	CC[N+](C)(CC)CCOC(=O)C(O)(C1CCCCC1)C2=CC=CC=C2	PLASMA	D2G5508Y7I									?	μg × min/mL	4.6		ng/mL	80			UNKNOWN	mg	2		SINGLE	UNKNOWN						HEALTHY	Intramuscular	UNKNOWN	OTHER	https://core.ac.uk/download/pdf/232467634.pdf	Homo sapiens		min	130							false
5501	2570		ADULT	4688	159.2276	PARGYLINE	PARGYLINE	CN(CC#C)CC1=CC=CC=C1	PLASMA	9MV14S8G3E							24		t	ng × h/mL	272		ng/mL	75			UNKNOWN	mg	50		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/490428/	Homo sapiens		h	5							false
5502	2571		ADULT	4761	240.3434	PHENIRAMINE	PHENIRAMINE	CN(C)CCC(C1=CC=CC=C1)C2=CC=CC=N2	PLASMA	134FM9ZZ6M							24		t	ng × h/mL	5768		ng/mL	274			UNKNOWN	mg	30.5		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3988394/	Homo sapiens		h	17							false
5503	2572		ADULT	4762	177.2429	PHENMETRAZINE	PHENMETRAZINE	CC1NCCOC1C2=CC=CC=C2	PLASMA	XA501VL3VR													μg/L	120			UNKNOWN	mg	75		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6026786/	Homo sapiens		h	8							false
5504	2574		NEWBORN	50192	602.8912	PIPECURONIUM	PIPECURONIUM	CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N5CC[N+](C)(C)CC5)N6CC[N+](C)(C)CC6	PLASMA	1N3O74HM92									?	μg × min/mL	106.7		μg/mL	3.5			UNKNOWN	μg/kg	100		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8751042	Homo sapiens		min	2.5							false
5505	2574		CHILD	50192	602.8912	PIPECURONIUM	PIPECURONIUM	CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N5CC[N+](C)(C)CC5)N6CC[N+](C)(C)CC6	PLASMA	1N3O74HM92									?	μg × min/mL	95.85		μg/mL	4.4			UNKNOWN	μg/kg	140		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8751042	Homo sapiens		min	2							false
5506	2574		ADULT	50192	602.8912	PIPECURONIUM	PIPECURONIUM	CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N5CC[N+](C)(C)CC5)N6CC[N+](C)(C)CC6	PLASMA	1N3O74HM92									?	μg × min/mL	50.6		μg/mL	1.6			UNKNOWN	μg/kg	120		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8751042	Homo sapiens		min	5.8							false
5507	2575		ADULT	19933	211.652	(4-CHLOROPHENYL)BIGUANIDE	4-chlorophenylbiguanide	NC(=N)NC(=N)NC1=CC=C(Cl)C=C1	PLASMA	61UQ98597T									∞	ng × h/mL	249		ng/mL	10			UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3440097/	Homo sapiens										false
5508	2575		ADULT	9049	251.715	CYCLOGUANIL	cycloguanil	CC1(C)N=C(N)N=C(N)N1C2=CC=C(Cl)C=C2	BLOOD	26RM326WVN									∞	ng × h/mL	834		ng/mL	50			UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3440097/	Homo sapiens										false
5509	2575		ADULT	9049	251.715	CYCLOGUANIL	cycloguanil	CC1(C)N=C(N)N=C(N)N1C2=CC=C(Cl)C=C2	PLASMA	26RM326WVN									∞	ng × h/mL	661		ng/mL	41			UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3440097/	Homo sapiens										false
5510	2575		ADULT	4923|5353897|5361395|6178111|6328384	253.731	PROGUANIL	PROGUANIL	CC(C)NC(=N)NC(=N)NC1=CC=C(Cl)C=C1	PLASMA	S61K3P7B2V									∞	ng × h/mL	2975		ng/mL	170			UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3440097/	Homo sapiens		h	16.1							false
5511	2575		ADULT	4923|5353897|5361395|6178111|6328384	253.731	PROGUANIL	PROGUANIL	CC(C)NC(=N)NC(=N)NC1=CC=C(Cl)C=C1	BLOOD	S61K3P7B2V									∞	ng × h/mL	14070		ng/mL	980			UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3440097/	Homo sapiens		h	15.7							false
5512	2575		ADULT	19933	211.652	(4-CHLOROPHENYL)BIGUANIDE	4-chlorophenylbiguanide	NC(=N)NC(=N)NC1=CC=C(Cl)C=C1	BLOOD	61UQ98597T									∞	ng × h/mL	883		ng/mL	39			UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3440097/	Homo sapiens										false
5513	2575		ADULT	9049	251.715	CYCLOGUANIL	cycloguanil	CC1(C)N=C(N)N=C(N)N1C2=CC=C(Cl)C=C2	PLASMA	26RM326WVN							24		t	μg × min/mL	190						RECOMMENDED	mg	200		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8329294/	Homo sapiens										false
5514	2575		ADULT	4923|5353897|5361395|6178111|6328384	253.731	PROGUANIL	PROGUANIL	CC(C)NC(=N)NC(=N)NC1=CC=C(Cl)C=C1	PLASMA	S61K3P7B2V													ng/mL	190			RECOMMENDED	mg	200		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8329294/	Homo sapiens		h	21		Extensive metabolizers					false
5515	2575		ADULT	9049	251.715	CYCLOGUANIL	cycloGUANIL	CC1(C)N=C(N)N=C(N)N1C2=CC=C(Cl)C=C2	PLASMA	26RM326WVN							72		t	μg × min/mL	141						DEFINED DAILY	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8329294/	Homo sapiens										false
5516	2575		ADULT	4923|5353897|5361395|6178111|6328384	253.731	PROGUANIL	PROGUANIL	CC(C)NC(=N)NC(=N)NC1=CC=C(Cl)C=C1	PLASMA	S61K3P7B2V													ng/mL	209			DEFINED DAILY	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8329294/	Homo sapiens		h	18		Extensive metabolizers		6			false
5517	2576		ADULT	4927	284.419	PROMETHAZINE	promethazine	CC(CN1C2=C(SC3=C1C=CC=C3)C=CC=C2)N(C)C	PLASMA	FF28EJQ494									∞	ng × h/mL	256		ng/mL	9.04			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Rectal	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10965395/	Homo sapiens		h	17.2							false
5518	2576		ADULT	4927	284.419	PROMETHAZINE	PROMETHAZINE	CC(CN1C2=C(SC3=C1C=CC=C3)C=CC=C2)N(C)C	PLASMA	FF28EJQ494									∞	ng × h/mL	361		ng/mL	19.3			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10965395/	Homo sapiens		h	18.6							false
5519	2576		ADULT	4927	284.419	PROMETHAZINE	PROMETHAZINE	CC(CN1C2=C(SC3=C1C=CC=C3)C=CC=C2)N(C)C	PLASMA	FF28EJQ494									∞	ng × h/mL	146		ng/mL	5.75			UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Rectal	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10965395/	Homo sapiens		h	17.7							false
5520	2576		ADULT	4927	284.419	PROMETHAZINE	PROMETHAZINE	CC(CN1C2=C(SC3=C1C=CC=C3)C=CC=C2)N(C)C	PLASMA	FF28EJQ494							24		t	ng × h/mL	146.62		ng/mL	11.28			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Rectal	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6743785/	Homo sapiens										false
5521	2576		ADULT	4927	284.419	PROMETHAZINE	PROMETHAZINE	CC(CN1C2=C(SC3=C1C=CC=C3)C=CC=C2)N(C)C	PLASMA	FF28EJQ494							24		t	ng × h/mL	180.14		ng/mL	21.84			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6743785/	Homo sapiens										false
5522	2576		ADULT	4927	284.419	PROMETHAZINE	PROMETHAZINE	CC(CN1C2=C(SC3=C1C=CC=C3)C=CC=C2)N(C)C	PLASMA	FF28EJQ494							24		t	ng × h/mL	627.13		ng/mL	48.26			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Intramuscular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6743785/	Homo sapiens										false
5523	2576		ADULT	4927	284.419	PROMETHAZINE	PROMETHAZINE	CC(CN1C2=C(SC3=C1C=CC=C3)C=CC=C2)N(C)C	BLOOD	FF28EJQ494									?	ng × h/mL	14466		ng/mL	10			UNKNOWN	mg	12.5		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6849764/	Homo sapiens		h	12.2							false
5524	2576		ADULT	4927	284.419	PROMETHAZINE	PROMETHAZINE	CC(CN1C2=C(SC3=C1C=CC=C3)C=CC=C2)N(C)C	BLOOD	FF28EJQ494									?	ng × h/mL	11511		ng/mL	13.2			UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6849764/	Homo sapiens										false
5525	2577		UNKNOWN	4940	340.482	PROPIOMAZINE	propiomazine	CCC(=O)C1=CC=C2SC3=C(C=CC=C3)N(CC(C)N(C)C)C2=C1	PLASMA	242Z0PM79Y																						UNKNOWN				Protein binding: 81%	19	UNKNOWN		UNKNOWN	OTHER	https://go.drugbank.com/drugs/DB00777	Homo sapiens										false
5526	2577		UNKNOWN	4940	340.482	PROPIOMAZINE	propiomazine	CCC(=O)C1=CC=C2SC3=C(C=CC=C3)N(CC(C)N(C)C)C2=C1	SERUM	242Z0PM79Y																					SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://www.scopus.com/record/display.uri?eid=2-s2.0-0019424663&origin=inward&txGid=47771f176f85945174ddee4f8734fce1	Homo sapiens		h	8.6							false
5527	2577		UNKNOWN	4940	340.482	PROPIOMAZINE	propiomazine	CCC(=O)C1=CC=C2SC3=C(C=CC=C3)N(CC(C)N(C)C)C2=C1	SERUM	242Z0PM79Y																	UNKNOWN	mg	20		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://www.scopus.com/record/display.uri?eid=2-s2.0-0019424663&origin=inward&txGid=47771f176f85945174ddee4f8734fce1	Homo sapiens		h	7.7							false
5528	2577		UNKNOWN	4940	340.482	PROPIOMAZINE	propiomazine	CCC(=O)C1=CC=C2SC3=C(C=CC=C3)N(CC(C)N(C)C)C2=C1	SERUM	242Z0PM79Y																					SINGLE	UNKNOWN						HEALTHY	Intramuscular	UNKNOWN	EXPERIMENT	https://www.scopus.com/record/display.uri?eid=2-s2.0-0019424663&origin=inward&txGid=47771f176f85945174ddee4f8734fce1	Homo sapiens		h	10.8							false
5529	2579		ADULT	5314	290.399	SUCCINYLCHOLINE	SUCCINYLCHOLINE	C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C	PLASMA	J2R869A8YF									?	μg × min/mL	18.5						UNKNOWN	mg/kg bw	1		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/14564614/	Homo sapiens		s	25.4							false
5530	2579		ADULT	5314	290.399	SUCCINYLCHOLINE	SUCCINYLCHOLINE	C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C	PLASMA	J2R869A8YF									?	μg × min/mL	58.6						UNKNOWN	mg/kg bw	2		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/14564614/	Homo sapiens		s	26.3							false
5531	2581		ADULT	2955	248.301	DAPSONE	Dapsone	NC1=CC=C(C=C1)S(=O)(=O)C2=CC=C(N)C=C2	PLASMA	8W5C518302													ng/mL	600			UNKNOWN	mg	330		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	REVIEW	https://doi.org/10.1016/S0099-5428(08)60377-9	Homo sapiens										false
5532	2584		UNKNOWN	5583	369.4176	TRIMETREXATE	trimetrexate	COC1=CC(NCC2=CC=C3N=C(N)N=C(N)C3=C2C)=CC(OC)=C1OC	PLASMA	UPN4ITI8T4	15150|443893|5282143|78759347|135403647|135883785		LEUCOVORIN CALCIUM	calcium folinate	[Ca++].NC1=NC(=O)C2=C(NCC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)N2C=O)N1	RPR1R4C0P4			?	mg × h/L	15.8		mg/L	3.1			DEFINED DAILY	mg/m²	30		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Intravenous	UNKNOWN	REVIEW	https://www.ncbi.nlm.nih.gov/pubmed/7789290	Homo sapiens		h	11							true
5533	2588		UNKNOWN	2911	287.4397	CYCRIMINE	CYCRIMINE	OC(CCN1CCCCC1)(C2CCCC2)C3=CC=CC=C3	PLASMA	543567RFQQ																	UNKNOWN	mg	2.5		UNKNOWN	UNKNOWN		day	4		79	UNKNOWN	Oral	UNKNOWN	OTHER	https://go.drugbank.com/drugs/DB00942	Homo sapiens										false
5534	2590		ADULT	52195	308.4174	INDECAINIDE	INDECAINIDE	CC(C)NCCCC1(C(N)=O)C2=CC=CC=C2C3=C1C=CC=C3	BLOOD	3AZF20DM1T													ng/mL	409			UNKNOWN	mg	248		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3351153	Homo sapiens		h	10.3							false
5535	2590		ADULT	127612	266.34	Desisopropyl indecainide	Deisopropylindecainide	C1=CC=C2C(=C1)C3=CC=CC=C3C2(CCCN)C(=O)N	BLOOD														ng/mL	37			UNKNOWN	mg	248		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3351153	Homo sapiens		h	15.7							false
5536	2592		ADULT	5436|3032285	254.349	THIAMYLAL	THIAMYLAL	CCCC(C)C1(CC=C)C(=O)NC(=S)NC1=O	SERUM	01T23W89FR																	UNKNOWN	μmol	9		SINGLE	UNKNOWN				Both enantiomers of thiamylal bind to site II of human albumin with higher affinity for S(-)-enantiomer.	6.7	HEALTHY	UNKNOWN	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10960410	Homo sapiens										false
5537	2592		ADULT	5436|3032285	254.349	THIAMYLAL	THIAMYLAL	CCCC(C)C1(CC=C)C(=O)NC(=S)NC1=O	SERUM	01T23W89FR																	UNKNOWN	μmol	18		SINGLE	UNKNOWN				Both enantiomers of thiamylal bind to site II of human albumin with higher affinity for S(-)-enantiomer.	7.2	HEALTHY	UNKNOWN	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10960410	Homo sapiens										false
5538	2592		ADULT	5436|3032285	254.349	THIAMYLAL	THIAMYLAL	CCCC(C)C1(CC=C)C(=O)NC(=S)NC1=O	SERUM	01T23W89FR																	UNKNOWN	μmol	90		SINGLE	UNKNOWN				Both enantiomers of thiamylal bind to site II of human albumin with higher affinity for S(-)-enantiomer.	8.2	HEALTHY	UNKNOWN	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10960410	Homo sapiens										false
5539	2594		ADULT	10113978	437.1634	PAZOPANIB	PAZOPANIB	CN(C1=CC2=NN(C)C(C)=C2C=C1)C3=CC=NC(NC4=CC(=C(C)C=C4)S(N)(=O)=O)=N3	PLASMA	7RN5DR86CK									∞	μg × h/mL	1037		μg/mL	58.1			UNKNOWN	mg	800		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022465lbl.pdf	Homo sapiens										false
5540	2594		UNKNOWN	10113978	437.518	PAZOPANIB	PAZOPANIB	CN(C1=CC2=NN(C)C(C)=C2C=C1)C3=CC=NC(NC4=CC(=C(C)C=C4)S(N)(=O)=O)=N3	PLASMA	7RN5DR86CK																						UNKNOWN				Binding of pazopanib to human plasma protein in vivo was greater than 99% with no concentration dependence over the range of 10 to 100 ug/mL.	1	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022465s-010S-012lbl.pdf	Homo sapiens										false
5541	2594		ADULT	10113978	437.1634	PAZOPANIB	PAZOPANIB	CN(C1=CC2=NN(C)C(C)=C2C=C1)C3=CC=NC(NC4=CC(=C(C)C=C4)S(N)(=O)=O)=N3	BLOOD	7RN5DR86CK							24		t	mg × h/L	821		mg/L	44.8			UNKNOWN	mg	800		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/31125423	Homo sapiens										false
5542	2594		ADULT	10113978	437.1634	PAZOPANIB	PAZOPANIB	CN(C1=CC2=NN(C)C(C)=C2C=C1)C3=CC=NC(NC4=CC(=C(C)C=C4)S(N)(=O)=O)=N3	BLOOD	7RN5DR86CK							24		t	mg × h/L	895		mg/L	50.2			UNKNOWN	mg	600		MULTIPLE	FED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/31125423	Homo sapiens										false
5543	2596		ADULT	5910	208.2569	PILOCARPINE	PILOCARPINE	CC[C@H]1[C@@H](CC2=CN=CN2C)COC1=O	PLASMA	01MI4Q9DI3							6		t	ng × h/mL	33		ng/mL	15			RECOMMENDED	mg	5		MULTIPLE	UNKNOWN		day	3	Pilocarpine does not bind to human or rat plasma proteins over a concentration range of 5 to 25,000 ng/mL.	100	HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/020237s012lbl.pdf	Homo sapiens		h	0.76							false
5544	2597		ADULT		303.3529	SCOPOLAMINE	SCOPOLAMINE	CN1[C@H]2C[C@@H](C[C@@H]1[C@H]3O[C@@H]23)OC(=O)[C@H](CO)C4=CC=CC=C4	PLASMA	DL48G20X8X									∞	ng × min/mL	369		ng/mL	5			RECOMMENDED	mg	0.5		SINGLE	UNKNOWN				Hithertoexisting measurements of the protein binding of scopolamineare in rats and showed a low value of 30+/- 10%	70	HEALTHY	Intravenous	FEMALE / MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/16175141/	Homo sapiens		min	68.7							false
5545	2597		ADULT		303.3529	SCOPOLAMINE	SCOPOLAMINE	CN1[C@H]2C[C@@H](C[C@@H]1[C@H]3O[C@@H]23)OC(=O)[C@H](CO)C4=CC=CC=C4	PLASMA	DL48G20X8X							24		t	ng × h/mL	2.1						RECOMMENDED	mg	1		SINGLE	UNKNOWN						HEALTHY	Topical	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017874s043s044lbl.pdf	Homo sapiens		h	9.5							false
5546	2599		ADULT	5881	288.4244	PRASTERONE	C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O	C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O	SERUM	459AG36T1B							12		t	nM × h	176.1		nM	36.7			INVESTIGATIONAL	mg	50		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/10372727	Homo sapiens		h	5.35							false
5547	2601		ADULT	176167	515.605	ENZASTAURIN	ENZASTAURIN	CN1C=C(C2=C1C=CC=C2)C3=C(C(=O)NC3=O)C4=CN(C5CCN(CC6=NC=CC=C6)CC5)C7=C4C=CC=C7	PLASMA	UC96G28EQF							24		t	ng × h/mL	17400		ng/mL	1310			UNKNOWN	mg	700		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/16943527	Homo sapiens		h	14.4							false
5548	2601		UNKNOWN	176167	515.605	ENZASTAURIN	ENZASTAURIN	CN1C=C(C2=C1C=CC=C2)C3=C(C(=O)NC3=O)C4=CN(C5CCN(CC6=NC=CC=C6)CC5)C7=C4C=CC=C7	PLASMA	UC96G28EQF																						UNKNOWN				In vitro preclinical assays show ∼95% plasma protein binding and an IC90 of 70 nmol/L for PKCβ	5	UNKNOWN		UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/17671157	Homo sapiens										false
5549	2602			25473	1049.853	ROSE BENGAL POTASSIUM	Rose Bengal	[K ].[K ].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C2=C3C=C(I)C(=O)C(I)=C3OC4=C2C=C(I)C([O-])=C4I	PLASMA	1ZPG1ELY14																										In human blood plasma, RB is almost quantitatively bound to proteins. In fact, less than 5% of the RB is present molecularly dissolved in plasma.	5				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19582268/	Homo sapiens										false
5550	2602			25473	1049.853	ROSE BENGAL POTASSIUM	Rose Bengal	[K ].[K ].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C2=C3C=C(I)C(=O)C(I)=C3OC4=C2C=C(I)C([O-])=C4I	SERUM	1ZPG1ELY14																										fu (rose bengal: 11.5 mcM): 66.3% (0.5mcM HSA), 32% (1.5mcM HSA), 9.5% (5mcM HSA), 2.2% (21mcM HSA); cell uptake assay	33.7				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2457477/	Homo sapiens										false
5551	2604		ADULT	222528	392.572	DEOXYCHOLIC ACID	DEOXYCHOLIC ACID	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C	PLASMA	005990WHZZ							24		t	ng × h/mL	7241		ng/mL	249			RECOMMENDED	mg	100		SINGLE	FASTED				Deoxycholic acid is extensively bound to proteins in plasma (98%). https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206333s002s003lbl.pdf	2	HEALTHY	Subcutaneous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25684122/	Homo sapiens		h	6.5							false
5552	2606		ADULT	216235	454.905	SITAXENTAN	sitaxentan	CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(=O)CC3=C(C)C=C4OCOC4=C3)=C1Cl	PLASMA	J9QH779MEM	5212|5281023|135398744	474.576	SILDENAFIL	Sildenafil	CCCC1=NN(C)C2=C1N=C(NC2=O)C3=C(OCC)C=CC(=C3)S(=O)(=O)N4CCN(C)CC4	3M7OB98Y7H			?	μg × h/mL	25.2		μg/mL	10.2			UNKNOWN	mg	100		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20078609/	Homo sapiens		h	8.42	Day 7		on Day 7 (100mg)	22	Sitaxentan sodium		true
5553	2606		ADULT	216235	454.905	SITAXENTAN	Sitaxentan	CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(=O)CC3=C(C)C=C4OCOC4=C3)=C1Cl	PLASMA	J9QH779MEM							24		t	μg × h/mL	40		μg/mL	13			DEFINED DAILY	mg	100		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.ema.europa.eu/en/documents/scientific-discussion/thelin-epar-scientific-discussion_en.pdf#page=10 | https://www.ema.europa.eu/en/documents/scientific-discussion/thelin-epar-scientific-discussion_en.pdf#page=11	Homo sapiens		h	7	Based on Cmax data, steady-state was reached after 5 days in healthy volunteers.				Sitaxentan sodium		false
5554	2606			216235	454.905	SITAXENTAN	Sitaxentan	CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(=O)CC3=C(C)C=C4OCOC4=C3)=C1Cl	PLASMA	J9QH779MEM																										Sitaxentan was highly bound to plasma proteins, i.e. about 99.5% in humans at the Cmax level (10 µg/ml).	0.5				OTHER GOV'T	https://www.ema.europa.eu/en/documents/scientific-discussion/thelin-epar-scientific-discussion_en.pdf#page=5 | https://www.ema.europa.eu/en/documents/product-information/thelin-epar-product-information_en.pdf#page=10 | https://pubmed.ncbi.nlm.nih.gov/17385944/	Homo sapiens										false
5555	2608		ADULT	65781	380.498	ECABET	ECABET	CC(C)C1=C(C=C2C(CC[C@H]3[C@@](C)(CCC[C@]23C)C(O)=O)=C1)S(O)(=O)=O	PLASMA	2K02669KWP									?	ng × h/mL	36943		ng/mL	4926			UNKNOWN	g	1		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18258501/	Homo sapiens		h	6.63				10	ECABET		false
5556	2609		ADULT	9874315	611.7272	LERCANIDIPINE, (S)-	Lercanidipine, (S)-	COC(=O)C1=C(C)NC(C)=C([C@H]1C2=CC(=CC=C2)[N ]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C3=CC=CC=C3)C4=CC=CC=C4	PLASMA	J8GF8BXI8S									∞	ng × h/mL	13.68		ng/mL	2.37			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15556551/	Homo sapiens		h	9.3				6			false
5557	2609		ADULT	9809926	611.7272	LERCANIDIPINE. (R)-	Lercanidipine. (R)-	COC(=O)C1=C(C)NC(C)=C([C@@H]1C2=CC(=CC=C2)[N ]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C3=CC=CC=C3)C4=CC=CC=C4	PLASMA	J3YZX94597									∞	ng × h/mL	11.24		ng/mL	1.68			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15556551/	Homo sapiens		h	7.5				6			false
5558	2609			65866	611.7272	LERCANIDIPINE	Lercanidipine	COC(=O)C1=C(C)NC(C)=C(C1C2=CC=CC(=C2)[N ]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C3=CC=CC=C3)C4=CC=CC=C4	PLASMA	V7XTJ4R0BH																										LER is highly bound to plasma protein (>98%) in humans.	2				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15556551/	Homo sapiens										false
5559	2609		ADULT	65866	611.7272	LERCANIDIPINE	Lercanidipine	COC(=O)C1=C(C)NC(C)=C(C1C2=CC=CC(=C2)[N ]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C3=CC=CC=C3)C4=CC=CC=C4	PLASMA	V7XTJ4R0BH									∞	ng × h/mL	12.04		ng/mL	3.231			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27232153/	Homo sapiens		h	9.2				59			false
5560	2609		ADULT	65866	611.7272	LERCANIDIPINE	Lercanidipine	COC(=O)C1=C(C)NC(C)=C(C1C2=CC=CC(=C2)[N ]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C3=CC=CC=C3)C4=CC=CC=C4	PLASMA	V7XTJ4R0BH	60846	435.5188	VALSARTAN	Valsartan	CCCCC(=O)N(CC1=CC=C(C=C1)C2=C(C=CC=C2)C3=NN=NN3)[C@@H](C(C)C)C(O)=O	80M03YXJ7I			∞	ng × h/mL	12.741		ng/mL	2.244			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27405507/	Homo sapiens		h	5.221	Fixed-dose combination		160 mg	18			true
5561	2610		ADULT	104827	373.898	METHYLENE BLUE	METHYLENE BLUE	O.O.O.[Cl-].CN(C)C1=CC2=[S+]C3=C(C=CC(=C3)N(C)C)N=C2C=C1	PLASMA	T42P99266K									∞	μM × min	134		μM	8			RECOMMENDED	mg	100		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10952480/	Homo sapiens		h	6.6							false
5562	2610		ADULT	104827	373.898	METHYLENE BLUE	METHYLENE BLUE	O.O.O.[Cl-].CN(C)C1=CC2=[S+]C3=C(C=CC(=C3)N(C)C)N=C2C=C1	PLASMA	T42P99266K									?	ng × h/mL	13977		ng/mL	2917			RECOMMENDED	mg/kg	2		SINGLE	UNKNOWN				Methylene blue exhibits concentration-dependent partitioning into blood cells in vitro	6	HEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204630s006lbl.pdf	Homo sapiens		h	24							false
5563	2612		ADULT	2710	300.826	CHLORCYCLIZINE	CHLORCYCLIZINE	CN1CCN(CC1)C(C2=CC=CC=C2)C3=CC=C(Cl)C=C3	PLASMA	M26C4IP44P													ng/mL	79.71			UNKNOWN	mg	75		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30711416/	Homo sapiens										false
5564	2614		ADULT	443884	325.4048	ERGONOVINE	ergonovine	C[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=C3C(=CC=C4)C2=C1	PLASMA	WH41D8433D									∞	μg × h/L	3.11		μg/L	1.07			UNKNOWN	mg	0.2		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8161717/	Homo sapiens		h	1.9							false
5565	2614		ADULT	443884	325.4048	ERGONOVINE	ergonovine	C[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=C3C(=CC=C4)C2=C1	PLASMA	WH41D8433D									∞	μg × h/L	1.69						UNKNOWN	mg	0.075		SINGLE	FED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8161717/	Homo sapiens		h	2.06							false
5566	2615		ADULT	5359271	313.3908	ETHYLMORPHINE	ETHYLMORPHINE	CCOC1=C2O[C@H]3[C@@H](O)C=C[C@H]4[C@H]5CC(C=C1)=C2[C@@]34CCN5C	SERUM	RWO67D87EU							8		t	μM × min	222		μM	1.09			UNKNOWN	mg/kg bw	1.5		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7654478	Homo sapiens		h	1.97							false
5567	2618		ADULT	54675769	612.6243	NOVOBIOCIN	NOVOBIOCIN	CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](OC2=CC=C3C(O)=C(NC(=O)C4=CC(CC=C(C)C)=C(O)C=C4)C(=O)OC3=C2C)OC1(C)C	SERUM	17EC19951N							12		t	μg × h/mL	407		μg/mL	62.5			UNKNOWN	mg	500		STEADY-STATE	FASTED		day	2			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3752982	Homo sapiens		h	5.85							false
5568	2618		UNKNOWN	54675769	612.6243	NOVOBIOCIN	NOVOBIOCIN	CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](OC2=CC=C3C(O)=C(NC(=O)C4=CC(CC=C(C)C)=C(O)C=C4)C(=O)OC3=C2C)OC1(C)C	SERUM	17EC19951N																	UNKNOWN				UNKNOWN	UNKNOWN				Novobiocin is highly serum protein bound (~99%).	1	UNKNOWN	UNKNOWN	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8243034	Homo sapiens										false
5569	2621		ADULT	5280343	302.2357	QUERCETIN	quercetin	OC1=CC2=C(C(O)=C1)C(=O)C(O)=C(O2)C3=CC=C(O)C(O)=C3	PLASMA	9IKM0I5T1E							24		t	μg × h/L	381		μg/L	23.5			RECOMMENDED	mg	16		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11151743/	Homo sapiens										false
5570	2621		ADULT	5280343	302.2357	QUERCETIN	quercetin	OC1=CC2=C(C(O)=C1)C(=O)C(O)=C(O2)C3=CC=C(O)C(O)=C3	PLASMA	9IKM0I5T1E							24		t	μg × h/L	636		μg/L	47.6			RECOMMENDED	mg	40		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11151743/	Homo sapiens										false
5571	2621		ADULT	5280343	302.2357	QUERCETIN	quercetin	OC1=CC2=C(C(O)=C1)C(=O)C(O)=C(O2)C3=CC=C(O)C(O)=C3	PLASMA	9IKM0I5T1E							24		t	μg × h/L	1017		μg/L	89.9			RECOMMENDED	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11151743/	Homo sapiens										false
5572	2625		ADULT	2783	277.19	CLENBUTEROL	Clenbuterol	CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1	PLASMA	XTZ6AXU7KN									∞	ng × h/L	14164.8		mg/L	329.7			DEFINED DAILY	μg	40		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26770490/	Homo sapiens		h	33.15	Day 9 PK, 40 mcg as Clenbuterol hydrochloride			9			false
5573	2625		ADULT	2783	277.19	CLENBUTEROL	Clenbuterol	CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1	PLASMA	XTZ6AXU7KN									∞	ng × h/L	4889.4		ng/L	133.2			DEFINED DAILY	μg	40		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26770490/	Homo sapiens		h	26.56	40 mcg as Clenbuterol hydrochloride			9			false
5574	2625		ADULT	2783	277.19	CLENBUTEROL	Clenbuterol	CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1	PLASMA	XTZ6AXU7KN																	HIGHEST STUDIED	μg	80		SINGLE	FASTED				Approximately 96-98% clenbuterol was bound to plasma protein at the period of 1 to 24 h after administration.	2	HEALTHY	Oral	MALE	EXPERIMENT	https://www.jstage.jst.go.jp/article/bpb1978/8/5/8_5_385/_article/-char/en	Homo sapiens				80 mcg as Clenbuterol hydrochloride			3			false
5575	2626		ADULT		217.27	Noramidopyrine	4-methylaminoantipyrine	CC1=C(C(=O)N(N1C)C2=CC=CC=C2)NC	PLASMA														μg/mL	12.3			UNKNOWN	g	1		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2753071/	Homo sapiens		h	2.6		21-30 yo		12			false
5576	2626		ADULT		217.27	Noramidopyrine	4-methylaminoantipyrine	CC1=C(C(=O)N(N1C)C2=CC=CC=C2)NC	PLASMA														μg/mL	13.9			UNKNOWN	g	1		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2753071/	Homo sapiens		h	4.5		73-90 yo		9			false
5577	2626		ADULT		217.27	Noramidopyrine	4-methylaminoantipyrine	CC1=C(C(=O)N(N1C)C2=CC=CC=C2)NC	PLASMA										∞	mg × h/L	51.33						UNKNOWN	g	1		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4043141/	Homo sapiens		h	2.81				6			false
5578	2626		ADULT		217.27	Noramidopyrine	4-methylaminoantipyrine	CC1=C(C(=O)N(N1C)C2=CC=CC=C2)NC	PLASMA	NER31DE951									∞	mg × h/L	69.05		μg/mL	13.85			UNKNOWN	g	1		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4043141/	Homo sapiens		h	2.62				6			false
5579	2626		ADULT		217.27	Noramidopyrine	4-methylaminoantipyrine	CC1=C(C(=O)N(N1C)C2=CC=CC=C2)NC	PLASMA	NER31DE951																	UNKNOWN	g	1		SINGLE	UNKNOWN					42.4	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4054207/	Homo sapiens							18			false
5580	2626		ADULT	65743	245.2771	4-ACETAMINOANTIPYRINE	4-acetylaminoantipyrine	CN1N(C(=O)C(NC(C)=O)=C1C)C2=CC=CC=C2	PLASMA	535H9N144Z																	UNKNOWN	g	1		SINGLE	UNKNOWN					85.8	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4054207/	Homo sapiens							14			false
5581	2626		ADULT	2151	203.2404	AMPYRONE	4-aminoantipyrine	CN1N(C(=O)C(N)=C1C)C2=CC=CC=C2	PLASMA	0M0B7474RA																	UNKNOWN	g	1		SINGLE	UNKNOWN					52.1	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4054207/	Homo sapiens							20			false
5582	2626		ADULT		231.25	4-Formylaminoantipyrine	4-formylaminoantipyrine	CC1=C(C(=O)N(N1C)C2=CC=CC=C2)NC=O	PLASMA	63DKU1M0XK																	UNKNOWN	g	1		SINGLE	UNKNOWN					82.2	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4054207/	Homo sapiens							14			false
5583	2627		ADULT	3151	425.911	DOMPERIDONE	domperidone	ClC1=CC2=C(C=C1)N(C3CCN(CCCN4C(=O)NC5=C4C=CC=C5)CC3)C(=O)N2	PLASMA	5587267Z69									∞	ng × h/mL	87.08		ng/mL	17.67			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17598698/	Homo sapiens		h	13.68				36			false
5584	2627		ADULT		425.911	DOMPERIDONE	domperidone	ClC1=CC2=C(C=C1)N(C3CCN(CCCN4C(=O)NC5=C4C=CC=C5)CC3)C(=O)N2	PLASMA	5587267Z69									∞	ng × h/mL	289						UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Intramuscular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7250152/	Homo sapiens							5			false
5585	2627		ADULT		425.911	DOMPERIDONE	domperidone	ClC1=CC2=C(C=C1)N(C3CCN(CCCN4C(=O)NC5=C4C=CC=C5)CC3)C(=O)N2	PLASMA	5587267Z69									∞	ng × h/mL	249						UNKNOWN	mg	60		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7250152/	Homo sapiens				10-mg film-coated tablets			7			false
5586	2627		ADULT		425.911	DOMPERIDONE	domperidone	ClC1=CC2=C(C=C1)N(C3CCN(CCCN4C(=O)NC5=C4C=CC=C5)CC3)C(=O)N2	PLASMA	5587267Z69									∞	ng × h/mL	463						UNKNOWN	mg	60		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7250152/	Homo sapiens							4			false
5587	2627		ADULT		425.911	DOMPERIDONE	domperidone	ClC1=CC2=C(C=C1)N(C3CCN(CCCN4C(=O)NC5=C4C=CC=C5)CC3)C(=O)N2	PLASMA	5587267Z69									∞	ng × h/mL	57.7						UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7250152/	Homo sapiens							5			false
5588	2627		ADULT	3151	425.911	DOMPERIDONE	domperidone	ClC1=CC2=C(C=C1)N(C3CCN(CCCN4C(=O)NC5=C4C=CC=C5)CC3)C(=O)N2	PLASMA	5587267Z69									∞	ng × h/mL	327						UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7250152/	Homo sapiens		h	7.45				5			false
5589	2627		ADULT	3151	425.911	DOMPERIDONE	domperidone	ClC1=CC2=C(C=C1)N(C3CCN(CCCN4C(=O)NC5=C4C=CC=C5)CC3)C(=O)N2	PLASMA	5587267Z69																						UNKNOWN					5.5	HEALTHY		MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7250152/	Homo sapiens							5			false
5590	2627		ADULT		425.911	DOMPERIDONE	domperidone	ClC1=CC2=C(C=C1)N(C3CCN(CCCN4C(=O)NC5=C4C=CC=C5)CC3)C(=O)N2	PLASMA	5587267Z69									∞	ng × h/mL	259						UNKNOWN	mg	60		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7250152/	Homo sapiens				10 mg/ml aqueous solution (oral drops)			5			false
5591	2627		ADULT		425.911	DOMPERIDONE	domperidone	ClC1=CC2=C(C=C1)N(C3CCN(CCCN4C(=O)NC5=C4C=CC=C5)CC3)C(=O)N2	PLASMA	5587267Z69									∞	ng × h/mL	243						UNKNOWN	mg	60		SINGLE	FASTED						HEALTHY	Rectal	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7250152/	Homo sapiens							3			false
5592	2629		ADULT	2119	249.3486	ALPRENOLOL	ALPRENOLOL	CC(C)NCC(O)COC1=C(CC=C)C=CC=C1	PLASMA	877K5MQ27W													ng/mL	216.9			RECOMMENDED	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/881641/	Homo sapiens		h	4				1	ALPRENOLOL		false
5593	2629		ADULT	2119	249.3486	ALPRENOLOL	ALPRENOLOL	CC(C)NCC(O)COC1=C(CC=C)C=CC=C1	PLASMA	877K5MQ27W									?	ng × h/mL	706						RECOMMENDED	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/891097/	Homo sapiens							5	ALPRENOLOL		false
5594	2629		ADULT	2119	249.3486	ALPRENOLOL	ALPRENOLOL	CC(C)NCC(O)COC1=C(CC=C)C=CC=C1	PLASMA	877K5MQ27W									?	ng × h/mL	67						UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/891097/	Homo sapiens							5	ALPRENOLOL		false
5595	2630		ADULT	2218	322.487	APRINDINE	APRINDINE	CCN(CC)CCCN(C1CC2=C(C1)C=CC=C2)C3=CC=CC=C3	PLASMA	5Y48085P9Q									∞	μg × h/mL	0.43		μg/mL	0.055			UNKNOWN	mg	25		SINGLE	FASTED				The bound fraction in plasma remained constant (94-97%) over the in vivo concentration range (0.2-2.0 ug/ml).	95.5	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6714286/	Homo sapiens		h	8				5	APRINDINE		false
5596	2630		ADULT	2218	322.487	APRINDINE	APRINDINE	CCN(CC)CCCN(C1CC2=C(C1)C=CC=C2)C3=CC=CC=C3	PLASMA	5Y48085P9Q									∞	μg × h/mL	9.16		μg/mL	0.59			UNKNOWN	mg	100		SINGLE	FASTED				The bound fraction in plasma remained constant (94-97%) over the in vivo concentration range (0.2-2.0 ug/ml).	95.5	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6714286/	Homo sapiens		h	15.8				5	APRINDINE		false
5597	2630		ADULT	2218	322.487	APRINDINE	APRINDINE	CCN(CC)CCCN(C1CC2=C(C1)C=CC=C2)C3=CC=CC=C3	PLASMA	5Y48085P9Q									∞	μg × h/mL	1.16		μg/mL	0.12			UNKNOWN	mg	50		SINGLE	FASTED				The bound fraction in plasma remained constant (94-97%) over the in vivo concentration range (0.2-2.0 ug/ml).	95.5	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6714286/	Homo sapiens		h	9.4				5	APRINDINE		false
5598	2632		ADULT	2663	379.4937	CELIPROLOL	Celiprolol	CCN(CC)C(=O)NC1=CC(C(C)=O)=C(OCC(O)CNC(C)(C)C)C=C1	PLASMA	DRB57K47QC							24		t	ng × h/mL	9729		ng/mL	1676			RECOMMENDED	mg	400		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2427859/	Homo sapiens		h	7.49	Day 7	Elderly subjects (60-71 y)		12			false
5599	2632		ADULT	2663	379.4937	CELIPROLOL	Celiprolol	CCN(CC)C(=O)NC1=CC(C(C)=O)=C(OCC(O)CNC(C)(C)C)C=C1	PLASMA	DRB57K47QC									∞	ng × h/mL	3688		ng/mL	687			RECOMMENDED	mg	200		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2427859/	Homo sapiens		h	5.61	Day 1	Elderly subjects (60-71 y)		12			false
5600	2632		ADULT	2663	379.4937	CELIPROLOL	Celiprolol	CCN(CC)C(=O)NC1=CC(C(C)=O)=C(OCC(O)CNC(C)(C)C)C=C1	PLASMA	DRB57K47QC							24		t	ng × h/mL	3317		ng/mL	597			RECOMMENDED	mg	200		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2427859/	Homo sapiens		h	7.91	Day 7	Elderly subjects (60-71 y)		12			false
5601	2632		ADULT	2663	379.4937	CELIPROLOL	Celiprolol	CCN(CC)C(=O)NC1=CC(C(C)=O)=C(OCC(O)CNC(C)(C)C)C=C1	PLASMA	DRB57K47QC									∞	ng × h/mL	15020		ng/mL	2478			RECOMMENDED	mg	600		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2427859/	Homo sapiens		h	5.44	Day 1	Elderly subjects (60-71 y)		12			false
5602	2632		ADULT	2663	379.4937	CELIPROLOL	Celiprolol	CCN(CC)C(=O)NC1=CC(C(C)=O)=C(OCC(O)CNC(C)(C)C)C=C1	PLASMA	DRB57K47QC							24		t	ng × h/mL	16550		ng/mL	2597			RECOMMENDED	mg	600		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2427859/	Homo sapiens		h	7.33	Day 7	Elderly subjects (60-71 y)		12			false
5603	2632		ADULT	2663	379.4937	CELIPROLOL	Celiprolol	CCN(CC)C(=O)NC1=CC(C(C)=O)=C(OCC(O)CNC(C)(C)C)C=C1	PLASMA	DRB57K47QC									∞	ng × h/mL	9092		ng/mL	1583			RECOMMENDED	mg	400		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2427859/	Homo sapiens		h	5	Day 1	Elderly subjects (60-71 y)		12			false
5604	2632			2663	379.4937	CELIPROLOL	Celiprolol	CCN(CC)C(=O)NC1=CC(C(C)=O)=C(OCC(O)CNC(C)(C)C)C=C1	PLASMA	DRB57K47QC																										approximately 25% plasma protein binding	75				REVIEW	https://pubmed.ncbi.nlm.nih.gov/28742547/	Homo sapiens										false
5605	2632		ADULT	3079418	379.4937	Celiprolol, R-		CCN(CC)C(=O)NC1=CC(=C(C=C1)OC[C@@H](CNC(C)(C)C)O)C(=O)C	PLASMA										∞	ng × h/mL	1619		ng/mL	317			RECOMMENDED	mg	200		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/34585840/	Homo sapiens		h	4.3				195			false
5606	2632		ADULT	11406333	379.4937	Celiprolol, S-		CCN(CC)C(=O)NC1=CC(=C(C=C1)OC[C@H](CNC(C)(C)C)O)C(=O)C	PLASMA										∞	ng × h/mL	1642		ng/mL	307			RECOMMENDED	mg	200		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/34585840/	Homo sapiens		h	4.7				195			false
5607	2632		ADULT	2663	379.4937	CELIPROLOL	Celiprolol	CCN(CC)C(=O)NC1=CC(C(C)=O)=C(OCC(O)CNC(C)(C)C)C=C1	PLASMA	DRB57K47QC									∞	ng × h/mL	3262		ng/mL	624			RECOMMENDED	mg	200		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/34585840/	Homo sapiens		h	4.5				195			false
5608	2632		ADULT	2663	379.4937	CELIPROLOL	Celiprolol	CCN(CC)C(=O)NC1=CC(C(C)=O)=C(OCC(O)CNC(C)(C)C)C=C1	PLASMA	DRB57K47QC							24		t	ng × h/mL	304		ng/mL	116			RECOMMENDED	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/530263_2149029F1020_1_14F_1F.pdf#page=19	Homo sapiens		h	1.45				5	Celiprolol hydrochloride		false
5609	2632		ADULT	2663	379.4937	CELIPROLOL	Celiprolol	CCN(CC)C(=O)NC1=CC(C(C)=O)=C(OCC(O)CNC(C)(C)C)C=C1	PLASMA	DRB57K47QC							24		t	ng × h/mL	1830		ng/mL	295			RECOMMENDED	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/530263_2149029F1020_1_14F_1F.pdf#page=19	Homo sapiens		h	4.81				5	Celiprolol hydrochloride		false
5610	2632		ADULT	2663	379.4937	CELIPROLOL	Celiprolol	CCN(CC)C(=O)NC1=CC(C(C)=O)=C(OCC(O)CNC(C)(C)C)C=C1	PLASMA	DRB57K47QC							24		t	ng × h/mL	6810		ng/mL	855			UNKNOWN	mg	400		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/530263_2149029F1020_1_14F_1F.pdf#page=19	Homo sapiens		h	5.89				5	Celiprolol hydrochloride		false
5611	2632		ADULT	2663	379.4937	CELIPROLOL	Celiprolol	CCN(CC)C(=O)NC1=CC(C(C)=O)=C(OCC(O)CNC(C)(C)C)C=C1	PLASMA	DRB57K47QC							24		t	ng × h/mL	47.6		ng/mL	13.1			UNKNOWN	mg	50		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/530263_2149029F1020_1_14F_1F.pdf#page=19	Homo sapiens		h	3.94				5	Celiprolol hydrochloride		false
5612	2632		ADULT	2663	379.4937	CELIPROLOL	Celiprolol	CCN(CC)C(=O)NC1=CC(C(C)=O)=C(OCC(O)CNC(C)(C)C)C=C1	PLASMA	DRB57K47QC							24		t	ng × h/mL	1812		ng/mL	187			RECOMMENDED	mg	200		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/530263_2149029F1020_1_14F_1F.pdf#page=20	Homo sapiens					hypertension with normal renal function		5	Celiprolol hydrochloride		false
5613	2632		ADULT	2663	379.4937	CELIPROLOL	Celiprolol	CCN(CC)C(=O)NC1=CC(C(C)=O)=C(OCC(O)CNC(C)(C)C)C=C1	PLASMA	DRB57K47QC							24		t	ng × h/mL	3063		ng/mL	477			RECOMMENDED	mg	200		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/530263_2149029F1020_1_14F_1F.pdf#page=20	Homo sapiens					hypertension with renal impairment		4	Celiprolol hydrochloride		false
5614	2632			2663	379.4937	CELIPROLOL	Celiprolol	CCN(CC)C(=O)NC1=CC(C(C)=O)=C(OCC(O)CNC(C)(C)C)C=C1	PLASMA	DRB57K47QC																										Human plasmaprotein binding: 20~27% (0.1~10μg/mL)	73				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/530263_2149029F1020_1_14F_1F.pdf#page=20	Homo sapiens										false
5615	2635		ADULT	3447	321.3715	GABEXATE	Gabexate	CCOC(=O)C1=CC=C(OC(=O)CCCCCNC(N)=N)C=C1	BLOOD	4V7M9137X9													ng/mL	109			UNKNOWN	mg/kg/h	2		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/730119_3999403D1221_1_001_1F.pdf#page=24	Homo sapiens				Continuous infusion			4	Gabexate mesilate		false
5616	2635		ADULT	3447	321.3715	GABEXATE	Gabexate	CCOC(=O)C1=CC=C(OC(=O)CCCCCNC(N)=N)C=C1	BLOOD	4V7M9137X9													ng/mL	267			UNKNOWN	mg/kg/h	2		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/730119_3999403D1221_1_001_1F.pdf#page=24	Homo sapiens				Continuous infusion	Septic patients with DIC or pre-DIC		5	Gabexate mesilate		false
5617	2636		ADULT	33625	347.4534	INDORAMIN	Indoramin	O=C(NC1CCN(CCC2=CNC3=C2C=CC=C3)CC1)C4=CC=CC=C4	PLASMA	0Z802HMY7H							24		t	ng × h/mL	81.2		ng/mL	10.4			UNKNOWN	mg	37.5		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2328193/	Homo sapiens		h	4.1		Pregnant women		13			false
5618	2636		ADULT	33625	347.4534	INDORAMIN	Indoramin	O=C(NC1CCN(CCC2=CNC3=C2C=CC=C3)CC1)C4=CC=CC=C4	PLASMA	0Z802HMY7H							24		t	ng × h/mL	73.2		ng/mL	15.3			UNKNOWN	mg	37.5		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2328193/	Homo sapiens		h	3.5		Post-partum women		13			false
5619	2636		ADULT	33625	347.4534	INDORAMIN	Indoramin	O=C(NC1CCN(CCC2=CNC3=C2C=CC=C3)CC1)C4=CC=CC=C4	PLASMA	0Z802HMY7H							12		t	ng × h/mL	343		ng/mL	52.7			UNKNOWN	mg	50		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2423791/	Homo sapiens		h	10.7		cirrhotic liver patients		9			false
5620	2636		ADULT	33625	347.4534	INDORAMIN	Indoramin	O=C(NC1CCN(CCC2=CNC3=C2C=CC=C3)CC1)C4=CC=CC=C4	PLASMA	0Z802HMY7H							12		t	ng × h/mL	349		ng/mL	51.7			UNKNOWN	mg	25		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2423791/	Homo sapiens		h	12.2		cirrhotic liver patients		6			false
5621	2636		ADULT	33625	347.4534	INDORAMIN	Indoramin	O=C(NC1CCN(CCC2=CNC3=C2C=CC=C3)CC1)C4=CC=CC=C4	PLASMA	0Z802HMY7H									∞	ng × h/mL	246						UNKNOWN	mg/kg	0.15		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2423791/	Homo sapiens		h	9.1		cirrhotic liver patients		9			false
5622	2636		ADULT	33625	347.4534	INDORAMIN	Indoramin	O=C(NC1CCN(CCC2=CNC3=C2C=CC=C3)CC1)C4=CC=CC=C4	PLASMA	0Z802HMY7H							12		t	ng × h/mL	81.9		ng/mL	18			UNKNOWN	mg	37.5		MULTIPLE	FASTED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2897212/	Homo sapiens		h	4.22	Day 1			9			false
5623	2636		ADULT	33625	347.4534	INDORAMIN	Indoramin	O=C(NC1CCN(CCC2=CNC3=C2C=CC=C3)CC1)C4=CC=CC=C4	PLASMA	0Z802HMY7H							12		t	ng × h/mL	489		ng/mL	70.3			UNKNOWN	mg	37.5		MULTIPLE	FASTED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2897212/	Homo sapiens		h	4.67	Day 8			9			false
5624	2636		ADULT	33625	347.4534	INDORAMIN	Indoramin	O=C(NC1CCN(CCC2=CNC3=C2C=CC=C3)CC1)C4=CC=CC=C4	PLASMA	0Z802HMY7H							12		t	ng × h/mL	524		ng/mL	76.6			UNKNOWN	mg	37.5		MULTIPLE	FASTED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2897212/	Homo sapiens		h	4.57	Day 15 (single administration)			9			false
5625	2636		ADULT	33625	347.4534	INDORAMIN	Indoramin	O=C(NC1CCN(CCC2=CNC3=C2C=CC=C3)CC1)C4=CC=CC=C4	PLASMA	0Z802HMY7H							24		t	ng × h/mL	296		ng/mL	35.2			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3191938/	Homo sapiens		h	5.4				5			false
5626	2636		ADULT	33625	347.4534	INDORAMIN	Indoramin	O=C(NC1CCN(CCC2=CNC3=C2C=CC=C3)CC1)C4=CC=CC=C4	PLASMA	0Z802HMY7H									?	ng × h/mL	137						UNKNOWN	mg/kg	0.15		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3653231/	Homo sapiens		h	4.1				9			false
5627	2636		ADULT	33625	347.4534	INDORAMIN	Indoramin	O=C(NC1CCN(CCC2=CNC3=C2C=CC=C3)CC1)C4=CC=CC=C4	PLASMA	0Z802HMY7H									?	ng × h/mL	127		ng/mL	22.4			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3653231/	Homo sapiens		h	3.43	Tablet			9			false
5628	2636		ADULT	33625	347.4534	INDORAMIN	Indoramin	O=C(NC1CCN(CCC2=CNC3=C2C=CC=C3)CC1)C4=CC=CC=C4	PLASMA	0Z802HMY7H									?	ng × h/mL	236		ng/mL	65.8			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3653231/	Homo sapiens		h	3.48	Oral solution			9			false
5629	2636		ADULT	33625	347.4534	INDORAMIN	Indoramin	O=C(NC1CCN(CCC2=CNC3=C2C=CC=C3)CC1)C4=CC=CC=C4	PLASMA	0Z802HMY7H									?	ng × h/mL	697		ng/mL	37.6			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6499905/	Homo sapiens		h	14.7		Elderly women (68~71 y)		5			false
5630	2636		ADULT	33625	347.4534	INDORAMIN	Indoramin	O=C(NC1CCN(CCC2=CNC3=C2C=CC=C3)CC1)C4=CC=CC=C4	PLASMA	0Z802HMY7H									?	ng × h/mL	268		ng/mL	20.8			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6499905/	Homo sapiens		h	5.1		Middle age women (46~55 y)		6			false
5631	2636			33625	347.4534	INDORAMIN	Indoramin	O=C(NC1CCN(CCC2=CNC3=C2C=CC=C3)CC1)C4=CC=CC=C4	PLASMA	0Z802HMY7H																										Human plasma protein binding (equilibrium dialysis): 85.6% (81ng/mL), 72.2% (129ng/mL)	14.3				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6628508/	Homo sapiens										false
5632	2636		ADULT	33625	347.4534	INDORAMIN	Indoramin	O=C(NC1CCN(CCC2=CNC3=C2C=CC=C3)CC1)C4=CC=CC=C4	PLASMA	0Z802HMY7H																						UNKNOWN				Human plasma protein binding (equilibrium dialysis): 91.7% (54~205ng/mL)	8.3	HEALTHY		MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/788751/	Homo sapiens							3			false
5633	2636			33625	347.4534	INDORAMIN	Indoramin	O=C(NC1CCN(CCC2=CNC3=C2C=CC=C3)CC1)C4=CC=CC=C4	PLASMA	0Z802HMY7H																										Over 90% of plasma indoramin was protein bound.	10				OTHER	https://www.medicines.org.uk/emc/product/6666/smpc#PHARMACOKINETIC_PROPS	Homo sapiens										false
5634	2637		UNKNOWN	3792	358.4314	ITOPRIDE	ITOPRIDE	COC1=C(OC)C=C(C=C1)C(=O)NCC2=CC=C(OCCN(C)C)C=C2	PLASMA	81BMQ80QRL													g/mL	0.28			RECOMMENDED	mg	50		SINGLE	UNKNOWN				Approximately 96% of itopride HCl is bound to plasma proteins. Albumin accounts for most of the binding. 1-acid glycoprotein accounts for <15% of binding.	4	UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://getzpharma.com/wp-content/uploads/2016/07/Regasta-Tab-Leaflet-Pakistan.pdf	Homo sapiens								Itopride hydrochloride		false
5635	2637		ADULT	3792	358.4314	ITOPRIDE	ITOPRIDE	COC1=C(OC)C=C(C=C1)C(=O)NCC2=CC=C(OCCN(C)C)C=C2	PLASMA	81BMQ80QRL							24		t	ng × h/mL	2895.5		ng/mL	426.2			UNKNOWN	mg	150		STEADY-STATE	FED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24470753/	Homo sapiens		h	5.9				23	Itopride hydrochloride		false
5636	2637		ADULT	3792	358.4314	ITOPRIDE	ITOPRIDE	COC1=C(OC)C=C(C=C1)C(=O)NCC2=CC=C(OCCN(C)C)C=C2	PLASMA	81BMQ80QRL							24		t	ng × h/mL	2606.5		ng/mL	244.4			UNKNOWN	mg	150		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24470753/	Homo sapiens		h	7.4				23	Itopride hydrochloride		false
5637	2637		ADULT	3792	358.4314	ITOPRIDE	ITOPRIDE	COC1=C(OC)C=C(C=C1)C(=O)NCC2=CC=C(OCCN(C)C)C=C2	PLASMA	81BMQ80QRL							24		t	ng × h/mL	2740.5		ng/mL	416.2			RECOMMENDED	mg	50		STEADY-STATE	FASTED		day	3			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24470753/	Homo sapiens		h	5.2				23	Itopride hydrochloride		false
5638	2638		ADULT	3947	418.958	LOFEPRAMINE	Lofepramine	CN(CCCN1C2=CC=CC=C2CCC3=C1C=CC=C3)CC(=O)C4=CC=C(Cl)C=C4	PLASMA	OCA4JT7PAW									∞	μg × h/L	46		μg/L	30			UNKNOWN	mg	70		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2677125/	Homo sapiens		h	1.4		Elderly subjects		6			false
5639	2638		ADULT	3947	418.958	LOFEPRAMINE	Lofepramine	CN(CCCN1C2=CC=CC=C2CCC3=C1C=CC=C3)CC(=O)C4=CC=C(Cl)C=C4	PLASMA	OCA4JT7PAW									∞	μg × h/L	113		μg/L	50			UNKNOWN	mg	105		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2677125/	Homo sapiens		h	2.5		Elderly subjects		6			false
5640	2638		ADULT	3947	418.958	LOFEPRAMINE	Lofepramine	CN(CCCN1C2=CC=CC=C2CCC3=C1C=CC=C3)CC(=O)C4=CC=C(Cl)C=C4	PLASMA	OCA4JT7PAW									∞	μg × h/L	128		μg/L	50			UNKNOWN	mg	140		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2677125/	Homo sapiens		h	2.5		Elderly subjects		6			false
5641	2638			3947	418.958	LOFEPRAMINE	Lofepramine	CN(CCCN1C2=CC=CC=C2CCC3=C1C=CC=C3)CC(=O)C4=CC=C(Cl)C=C4	PLASMA	OCA4JT7PAW																										By the ultrafiltration technique, lofepramine was found to be bound to plasma proteins of the rat, dog and man to an extent of 99%.	1				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/848046/	Homo sapiens										false
5642	2638		ADULT	3947	418.958	LOFEPRAMINE	Lofepramine	CN(CCCN1C2=CC=CC=C2CCC3=C1C=CC=C3)CC(=O)C4=CC=C(Cl)C=C4	PLASMA	OCA4JT7PAW													ng/mL	22.9			UNKNOWN	mg	50		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/430574_1174004F1028_2_A12_1F.pdf#page=17 | https://www.jstage.jst.go.jp/article/jscpt1970/7/2/7_2_161/_article/-char/en	Homo sapiens		h	2.7				5			false
5643	2638		ADULT	2995	266.3807	DESIPRAMINE	Desipramine	CNCCCN1C2=CC=CC=C2CCC3=C1C=CC=C3	PLASMA	TG537D343B													ng/mL	9.8			UNKNOWN	mg	50		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/430574_1174004F1028_2_A12_1F.pdf#page=17 | https://www.jstage.jst.go.jp/article/jscpt1970/7/2/7_2_161/_article/-char/en	Homo sapiens		h	3.4				5			false
5644	2638			3947	418.958	LOFEPRAMINE	Lofepramine	CN(CCCN1C2=CC=CC=C2CCC3=C1C=CC=C3)CC(=O)C4=CC=C(Cl)C=C4	PLASMA	OCA4JT7PAW																										Human plasma protein binding: 99.3%	0.7				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/430574_1174004F1028_2_A12_1F.pdf#page=18	Homo sapiens										false
5645	2639		ADULT	4184	264.3648	MIANSERIN	Mianserin	CN1CCN2C(C1)C3=C(CC4=C2C=CC=C4)C=CC=C3	PLASMA	250PJI13LM							24		∞	ng × h/mL	541.8		ng/mL	14.6			UNKNOWN	mg	30		SINGLE	FASTED						HEALTHY	Rectal	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27190632/	Homo sapiens							3	Mianserin hydrochloride		false
5646	2639		ADULT	4184	264.3648	MIANSERIN	Mianserin	CN1CCN2C(C1)C3=C(CC4=C2C=CC=C4)C=CC=C3	PLASMA	250PJI13LM									∞	ng × h/mL	435.4		ng/mL	40.7			UNKNOWN	mg	30		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27190632/ | https://www.info.pmda.go.jp/go/interview/4/181615_1179033F1020_4_014_1F.pdf#page=17	Homo sapiens		h	18.3	30mg tablet x 1			24	Mianserin hydrochloride		false
5647	2639		ADULT	4184	264.3648	MIANSERIN	Mianserin	CN1CCN2C(C1)C3=C(CC4=C2C=CC=C4)C=CC=C3	PLASMA	250PJI13LM									∞	ng × h/mL	157.6						UNKNOWN	mg/kg	0.15		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6824562/	Homo sapiens		h	9.6		Young subjects		8	Mianserin hydrochloride		false
5648	2639		ADULT	4184	264.3648	MIANSERIN	Mianserin	CN1CCN2C(C1)C3=C(CC4=C2C=CC=C4)C=CC=C3	PLASMA	250PJI13LM																	UNKNOWN				SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6824562/	Homo sapiens		h	27	60mg to four patients, 40mg to ten payients	Elderly subjects		14	Mianserin hydrochloride		false
5649	2639		ADULT	4184	264.3648	MIANSERIN	Mianserin	CN1CCN2C(C1)C3=C(CC4=C2C=CC=C4)C=CC=C3	PLASMA	250PJI13LM									∞	ng × h/mL	275						UNKNOWN	mg	30		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6824562/	Homo sapiens		h	7.3		Young subjects		5	Mianserin hydrochloride		false
5650	2639		ADULT	4184	264.3648	MIANSERIN	Mianserin	CN1CCN2C(C1)C3=C(CC4=C2C=CC=C4)C=CC=C3	PLASMA	250PJI13LM									?	μg × h/L	1356		μg/L	102			UNKNOWN	mg	60		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7075657/	Homo sapiens		h	21				8			false
5651	2639			4184	264.3648	MIANSERIN	Mianserin	CN1CCN2C(C1)C3=C(CC4=C2C=CC=C4)C=CC=C3	PLASMA	250PJI13LM																										Human plasma protein binding: 90%	10			FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/4/181615_1179033F1020_4_014_1F.pdf#page=18	Homo sapiens										false
5652	2640		ADULT	119584	421.893	MOSAPRIDE	Mosapride	CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC2CN(CC3=CC=C(F)C=C3)CCO2	PLASMA	I8MFJ1C0BY									∞	ng × h/mL	67		ng/mL	30.7			UNKNOWN	mg	5		SINGLE	FASTED				t1/2=1.4-2.0 h		HEALTHY	Oral	MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/18457463/	Homo sapiens		h	1.4				5			false
5653	2640		ADULT	119584	421.893	MOSAPRIDE	Mosapride	CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC2CN(CC3=CC=C(F)C=C3)CCO2	PLASMA	I8MFJ1C0BY									∞	ng × h/mL	170		ng/mL	63.6			UNKNOWN	mg	10		SINGLE	FASTED				t1/2=1.4-2.0 h		HEALTHY	Oral	MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/18457463/	Homo sapiens		h	1.4				5			false
5654	2640		ADULT	119584	421.893	MOSAPRIDE	Mosapride	CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC2CN(CC3=CC=C(F)C=C3)CCO2	PLASMA	I8MFJ1C0BY									∞	ng × h/mL	380		ng/mL	182.2			UNKNOWN	mg	20		SINGLE	FASTED				t1/2=1.4-2.0 h		HEALTHY	Oral	MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/18457463/	Homo sapiens		h	1.4				5			false
5655	2640		ADULT	119584	421.893	MOSAPRIDE	Mosapride	CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC2CN(CC3=CC=C(F)C=C3)CCO2	PLASMA	I8MFJ1C0BY									∞	ng × h/mL	699		ng/mL	312.3			UNKNOWN	mg	40		SINGLE	FASTED				t1/2=1.4-2.0 h		HEALTHY	Oral	MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/18457463/	Homo sapiens		h	1.4				5			false
5656	2640			119584	421.893	MOSAPRIDE	Mosapride	CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC2CN(CC3=CC=C(F)C=C3)CCO2	PLASMA	I8MFJ1C0BY																										The protein binding rate in human plasma was 97% after a single dose of mosapride 20 or 40 mg.	3				REVIEW	https://pubmed.ncbi.nlm.nih.gov/18457463/	Homo sapiens								Mosapride citrate		false
5657	2640		ADULT	119584	421.893	MOSAPRIDE	Mosapride	CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC2CN(CC3=CC=C(F)C=C3)CCO2	PLASMA	I8MFJ1C0BY		0	PANCRELIPASE	Pancreatin		FQ3DRG0N5K			∞	ng × h/mL	56.53		ng/mL	23.41			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/34837418/	Homo sapiens		h	3.1			and simethicone	61			true
5658	2640		ADULT	119584	421.893	MOSAPRIDE	Mosapride	CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC2CN(CC3=CC=C(F)C=C3)CCO2	PLASMA	I8MFJ1C0BY							2		t	ng × h/mL	29.1		ng/mL	26.4			UNKNOWN	mg	5		MULTIPLE	FASTED		2 hours	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2009/P200900025/10011900_22000AMX00570_A100_1.pdf#page=12	Homo sapiens				1st dose			6			false
5659	2640		ADULT	119584	421.893	MOSAPRIDE	Mosapride	CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC2CN(CC3=CC=C(F)C=C3)CCO2	PLASMA	I8MFJ1C0BY							24		t	ng × h/mL	130.9		ng/mL	40.4			UNKNOWN	mg	5		MULTIPLE	FASTED		2 hours	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2009/P200900025/10011900_22000AMX00570_A100_1.pdf#page=12	Homo sapiens				2nd dose			6			false
5660	2640		ADULT	119584	421.893	MOSAPRIDE	Mosapride	CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC2CN(CC3=CC=C(F)C=C3)CCO2	PLASMA	I8MFJ1C0BY							3		t	ng × h/mL	46.7		ng/mL	30.7			UNKNOWN	mg	5		MULTIPLE	FASTED		3 hours	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2009/P200900025/10011900_22000AMX00570_A100_1.pdf#page=13	Homo sapiens				1st dose			11			false
5661	2640		ADULT	119584	421.893	MOSAPRIDE	Mosapride	CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC2CN(CC3=CC=C(F)C=C3)CCO2	PLASMA	I8MFJ1C0BY							24		t	ng × h/mL	152.1		ng/mL	39.3			UNKNOWN	mg	5		MULTIPLE	FASTED		3 hours	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2009/P200900025/10011900_22000AMX00570_A100_1.pdf#page=13	Homo sapiens				2nd dose			11			false
5662	2640		ADULT	119584	421.893	MOSAPRIDE	Mosapride	CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC2CN(CC3=CC=C(F)C=C3)CCO2	PLASMA	I8MFJ1C0BY							3		t	ng × h/mL	96.5		ng/mL	62.9			UNKNOWN	mg	10		MULTIPLE	FASTED		3 hours	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2009/P200900025/10011900_22000AMX00570_A100_1.pdf#page=13	Homo sapiens				1st dose			11			false
5663	2640		ADULT	119584	421.893	MOSAPRIDE	Mosapride	CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC2CN(CC3=CC=C(F)C=C3)CCO2	PLASMA	I8MFJ1C0BY							24		t	ng × h/mL	346.8		ng/mL	95.8			UNKNOWN	mg	10		MULTIPLE	FASTED		3 hours	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2009/P200900025/10011900_22000AMX00570_A100_1.pdf#page=13	Homo sapiens				2nd dose			11			false
5664	2640		ADULT	119584	421.893	MOSAPRIDE	Mosapride	CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC2CN(CC3=CC=C(F)C=C3)CCO2	PLASMA	I8MFJ1C0BY							3		t	ng × h/mL	161.2		ng/mL	113.6			UNKNOWN	mg	20		MULTIPLE	FASTED		3 hours	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2009/P200900025/10011900_22000AMX00570_A100_1.pdf#page=13	Homo sapiens				1st dose			11			false
5665	2640		ADULT	119584	421.893	MOSAPRIDE	Mosapride	CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC2CN(CC3=CC=C(F)C=C3)CCO2	PLASMA	I8MFJ1C0BY							24		t	ng × h/mL	554		ng/mL	154.6			UNKNOWN	mg	20		MULTIPLE	FASTED		3 hours	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2009/P200900025/10011900_22000AMX00570_A100_1.pdf#page=13	Homo sapiens				2nd dose			11			false
5666	2640		ADULT	119584	421.893	MOSAPRIDE	Mosapride	CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC2CN(CC3=CC=C(F)C=C3)CCO2	PLASMA	I8MFJ1C0BY	24436|516914|139036570|139036601|139064522	142.042	SODIUM SULFATE ANHYDROUS	Sodium sulfate anhydrous	[Na ].[Na ].[O-]S([O-])(=O)=O	36KCS0R750	2		t	ng × h/mL	32.5		ng/mL	26.5			UNKNOWN	mg	5		MULTIPLE	FASTED		2 hours	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2009/P200900025/10011900_22000AMX00570_A100_1.pdf#page=14	Homo sapiens				1st dose		and sodium bicarbonate, sodium chloride, potassium chloride	24			true
5667	2640		ADULT	119584	421.893	MOSAPRIDE	Mosapride	CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC2CN(CC3=CC=C(F)C=C3)CCO2	PLASMA	I8MFJ1C0BY	24436|516914|139036570|139036601|139064522	142.042	SODIUM SULFATE ANHYDROUS	Sodium sulfate anhydrous	[Na ].[Na ].[O-]S([O-])(=O)=O	36KCS0R750	2		t	ng × h/mL	58		ng/mL	47.8			UNKNOWN	mg	10		MULTIPLE	FASTED		2 hours	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2009/P200900025/10011900_22000AMX00570_A100_1.pdf#page=14	Homo sapiens				1st dose		and sodium bicarbonate, sodium chloride, potassium chloride	24			true
5668	2640		ADULT	119584	421.893	MOSAPRIDE	Mosapride	CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC2CN(CC3=CC=C(F)C=C3)CCO2	PLASMA	I8MFJ1C0BY	24436|516914|139036570|139036601|139064522	142.042	SODIUM SULFATE ANHYDROUS	Sodium sulfate anhydrous	[Na ].[Na ].[O-]S([O-])(=O)=O	36KCS0R750	24		t	ng × h/mL	305.7		ng/mL	104.7			UNKNOWN	mg	10		MULTIPLE	FASTED		2 hours	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2009/P200900025/10011900_22000AMX00570_A100_1.pdf#page=14	Homo sapiens				2nd dose		and sodium bicarbonate, sodium chloride, potassium chloride	24			true
5669	2640		ADULT	119584	421.893	MOSAPRIDE	Mosapride	CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC2CN(CC3=CC=C(F)C=C3)CCO2	PLASMA	I8MFJ1C0BY	24436|516914|139036570|139036601|139064522	142.042	SODIUM SULFATE ANHYDROUS	Sodium sulfate anhydrous	[Na ].[Na ].[O-]S([O-])(=O)=O	36KCS0R750	2		t	ng × h/mL	150.3		ng/mL	116.1			UNKNOWN	mg	20		MULTIPLE	FASTED		2 hours	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2009/P200900025/10011900_22000AMX00570_A100_1.pdf#page=14	Homo sapiens				1st dose		and sodium bicarbonate, sodium chloride, potassium chloride	24			true
5670	2640		ADULT	119584	421.893	MOSAPRIDE	Mosapride	CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC2CN(CC3=CC=C(F)C=C3)CCO2	PLASMA	I8MFJ1C0BY	24436|516914|139036570|139036601|139064522	142.042	SODIUM SULFATE ANHYDROUS	Sodium sulfate anhydrous	[Na ].[Na ].[O-]S([O-])(=O)=O	36KCS0R750	24		t	ng × h/mL	848.8		ng/mL	272.6			UNKNOWN	mg	20		MULTIPLE	FASTED		2 hours	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2009/P200900025/10011900_22000AMX00570_A100_1.pdf#page=14	Homo sapiens				2nd dose		and sodium bicarbonate, sodium chloride, potassium chloride	23			true
5671	2640		ADULT	119584	421.893	MOSAPRIDE	Mosapride	CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC2CN(CC3=CC=C(F)C=C3)CCO2	PLASMA	I8MFJ1C0BY	24436|516914|139036570|139036601|139064522	142.042	SODIUM SULFATE ANHYDROUS	Sodium sulfate anhydrous	[Na ].[Na ].[O-]S([O-])(=O)=O	36KCS0R750	2		t	ng × h/mL	154.6		ng/mL	154.2			UNKNOWN	mg	20		MULTIPLE	FASTED		2 hours	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2009/P200900025/10011900_22000AMX00570_A100_1.pdf#page=14	Homo sapiens				1st dose		and sodium bicarbonate, sodium chloride, potassium chloride	24			true
5672	2640		ADULT	119584	421.893	MOSAPRIDE	Mosapride	CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC2CN(CC3=CC=C(F)C=C3)CCO2	PLASMA	I8MFJ1C0BY	24436|516914|139036570|139036601|139064522	142.042	SODIUM SULFATE ANHYDROUS	Sodium sulfate anhydrous	[Na ].[Na ].[O-]S([O-])(=O)=O	36KCS0R750	24		t	ng × h/mL	913		ng/mL	265.3			UNKNOWN	mg	20		MULTIPLE	FASTED		2 hours	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2009/P200900025/10011900_22000AMX00570_A100_1.pdf#page=14	Homo sapiens				2nd dose		and sodium bicarbonate, sodium chloride, potassium chloride	24			true
5673	2640		ADULT	119584	421.893	MOSAPRIDE	Mosapride	CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC2CN(CC3=CC=C(F)C=C3)CCO2	PLASMA	I8MFJ1C0BY	24436|516914|139036570|139036601|139064522	142.042	SODIUM SULFATE ANHYDROUS	Sodium sulfate anhydrous	[Na ].[Na ].[O-]S([O-])(=O)=O	36KCS0R750	24		t	ng × h/mL	131.1		ng/mL	41.7			UNKNOWN	mg	5		MULTIPLE	FASTED		2 hours	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2009/P200900025/10011900_22000AMX00570_A100_1.pdf#page=14	Homo sapiens				2nd dose		and sodium bicarbonate, sodium chloride, potassium chloride	24			true
5674	2641		ADULT	4413	347.3706	NAFAMOSTAT	Nafamostat	NC(=N)NC1=CC=C(C=C1)C(=O)OC2=CC3=C(C=C2)C=C(C=C3)C(N)=N	PLASMA	Y25LQ0H97D									∞	ng × min/mL	3571.14		ng/mL	40.4			UNKNOWN	mg	20		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18392693/	Homo sapiens		min	128.19				10	Nafamostat mesilate		false
5675	2641		ADULT	4413	347.3706	NAFAMOSTAT	Nafamostat	NC(=N)NC1=CC=C(C=C1)C(=O)OC2=CC3=C(C=C2)C=C(C=C3)C(N)=N	PLASMA	Y25LQ0H97D									∞	ng × min/mL	6880.46		ng/mL	60.43			UNKNOWN	mg	40		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18392693/	Homo sapiens		min	122.91				10	Nafamostat mesilate		false
5676	2641		ADULT	4413	347.3706	NAFAMOSTAT	Nafamostat	NC(=N)NC1=CC=C(C=C1)C(=O)OC2=CC3=C(C=C2)C=C(C=C3)C(N)=N	PLASMA	Y25LQ0H97D									∞	ng × min/mL	1655.84		ng/mL	14.49			UNKNOWN	mg	10		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18392693/	Homo sapiens		min	112.42				10	Nafamostat mesilate		false
5677	2641		ADULT	4413	347.3706	NAFAMOSTAT	Nafamostat	NC(=N)NC1=CC=C(C=C1)C(=O)OC2=CC3=C(C=C2)C=C(C=C3)C(N)=N	BLOOD	Y25LQ0H97D													ng/mL	16.4			RECOMMENDED	mg	10		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/530169_3999407D1181_2_008_1F.pdf#page=23	Homo sapiens				90-min infusion				Nafamostat mesilate		false
5678	2641		ADULT	4413	347.3706	NAFAMOSTAT	Nafamostat	NC(=N)NC1=CC=C(C=C1)C(=O)OC2=CC3=C(C=C2)C=C(C=C3)C(N)=N	BLOOD	Y25LQ0H97D													ng/mL	93.2			UNKNOWN	mg	40		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/530169_3999407D1181_2_008_1F.pdf#page=23	Homo sapiens		min	23.1	90-min infusion				Nafamostat mesilate		false
5679	2641		ADULT	4413	347.3706	NAFAMOSTAT	Nafamostat	NC(=N)NC1=CC=C(C=C1)C(=O)OC2=CC3=C(C=C2)C=C(C=C3)C(N)=N	BLOOD	Y25LQ0H97D													ng/mL	61.5			RECOMMENDED	mg	20		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/530169_3999407D1181_2_008_1F.pdf#page=23	Homo sapiens				90-min infusion				Nafamostat mesilate		false
5680	2641			4413	347.3706	NAFAMOSTAT	Nafamostat	NC(=N)NC1=CC=C(C=C1)C(=O)OC2=CC3=C(C=C2)C=C(C=C3)C(N)=N	SERUM	Y25LQ0H97D																										Human serum protein binding: 66.64% (equilibrium dialysis)	33.36				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/530169_3999407D1181_2_008_1F.pdf#page=24	Homo sapiens										false
5681	2643		ADULT	119607	314.359	VALDECOXIB	Valdecoxib	CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(N)(=O)=O	PLASMA	2919279Q3W									∞	ng × h/mL	1133		ng/mL	130			UNKNOWN	mg	10		SINGLE	UNKNOWN						HEALTHY	Intramuscular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11583480/	Homo sapiens		h	5.44				4	Parecoxib sodium		false
5682	2643		ADULT	119828|6335917	370.422	PARECOXIB	Parecoxib	CCC(=O)NS(=O)(=O)C1=CC=C(C=C1)C2=C(C)ON=C2C3=CC=CC=C3	PLASMA	9TUW81Y3CE									∞	ng × h/mL	1167		ng/mL	1681			UNKNOWN	mg	40		SINGLE	UNKNOWN						HEALTHY	Intramuscular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11583480/	Homo sapiens		h	0.87				12	Parecoxib sodium		false
5683	2643		ADULT	119828|6335917	370.422	PARECOXIB	Parecoxib	CCC(=O)NS(=O)(=O)C1=CC=C(C=C1)C2=C(C)ON=C2C3=CC=CC=C3	PLASMA	9TUW81Y3CE									∞	ng × h/mL	579		ng/mL	1013			UNKNOWN	mg	20		SINGLE	UNKNOWN						HEALTHY	Intramuscular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11583480/	Homo sapiens		h	0.48				8	Parecoxib sodium		false
5684	2643		ADULT	119607	314.359	VALDECOXIB	Valdecoxib	CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(N)(=O)=O	PLASMA	2919279Q3W									∞	ng × h/mL	5215		ng/mL	498			UNKNOWN	mg	40		SINGLE	UNKNOWN						HEALTHY	Intramuscular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11583480/	Homo sapiens		h	7.35				12	Parecoxib sodium		false
5685	2643		ADULT	119607	314.359	VALDECOXIB	Valdecoxib	CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(N)(=O)=O	PLASMA	2919279Q3W									∞	ng × h/mL	2782		ng/mL	263			UNKNOWN	mg	20		SINGLE	UNKNOWN						HEALTHY	Intramuscular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11583480/	Homo sapiens		h	9.94				8	Parecoxib sodium		false
5686	2643		ADULT	119828|6335917	370.422	PARECOXIB	Parecoxib	CCC(=O)NS(=O)(=O)C1=CC=C(C=C1)C2=C(C)ON=C2C3=CC=CC=C3	PLASMA	9TUW81Y3CE									∞	ng × h/mL	37.3		ng/mL	39.3			UNKNOWN	mg	1		SINGLE	UNKNOWN				n=1 for AUC and t1/2		HEALTHY	Intramuscular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11583480/	Homo sapiens		h	0.36				4	Parecoxib sodium		false
5687	2643		ADULT	119607	314.359	VALDECOXIB	Valdecoxib	CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(N)(=O)=O	PLASMA	2919279Q3W									∞	ng × h/mL	127		ng/mL	16.8			UNKNOWN	mg	1		SINGLE	UNKNOWN						HEALTHY	Intramuscular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11583480/	Homo sapiens		h	6.83				4	Parecoxib sodium		false
5688	2643		ADULT	119828|6335917	370.422	PARECOXIB	Parecoxib	CCC(=O)NS(=O)(=O)C1=CC=C(C=C1)C2=C(C)ON=C2C3=CC=CC=C3	PLASMA	9TUW81Y3CE									∞	ng × h/mL	41.9		ng/mL	57.9			UNKNOWN	mg	2		SINGLE	UNKNOWN						HEALTHY	Intramuscular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11583480/	Homo sapiens		h	0.43				4	Parecoxib sodium		false
5689	2643		ADULT	119607	314.359	VALDECOXIB	Valdecoxib	CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(N)(=O)=O	PLASMA	2919279Q3W									∞	ng × h/mL	258		ng/mL	26.4			UNKNOWN	mg	2		SINGLE	UNKNOWN						HEALTHY	Intramuscular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11583480/	Homo sapiens		h	6.28				4	Parecoxib sodium		false
5690	2643		ADULT	119828|6335917	370.422	PARECOXIB	Parecoxib	CCC(=O)NS(=O)(=O)C1=CC=C(C=C1)C2=C(C)ON=C2C3=CC=CC=C3	PLASMA	9TUW81Y3CE									∞	ng × h/mL	130		ng/mL	276			UNKNOWN	mg	5		SINGLE	UNKNOWN						HEALTHY	Intramuscular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11583480/	Homo sapiens		h	0.25				4	Parecoxib sodium		false
5691	2643		ADULT	119607	314.359	VALDECOXIB	Valdecoxib	CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(N)(=O)=O	PLASMA	2919279Q3W									∞	ng × h/mL	563		ng/mL	66.6			UNKNOWN	mg	5		SINGLE	UNKNOWN						HEALTHY	Intramuscular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11583480/	Homo sapiens		h	5.67				4	Parecoxib sodium		false
5692	2643		ADULT	119828|6335917	370.422	PARECOXIB	Parecoxib	CCC(=O)NS(=O)(=O)C1=CC=C(C=C1)C2=C(C)ON=C2C3=CC=CC=C3	PLASMA	9TUW81Y3CE									∞	ng × h/mL	275		ng/mL	437			UNKNOWN	mg	10		SINGLE	UNKNOWN						HEALTHY	Intramuscular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11583480/	Homo sapiens		h	0.41				4	Parecoxib sodium		false
5693	2643			119828|6335917	370.422	PARECOXIB	Parecoxib	CCC(=O)NS(=O)(=O)C1=CC=C(C=C1)C2=C(C)ON=C2C3=CC=CC=C3	PLASMA	9TUW81Y3CE																										Plasma protein binding is approximately 98% over the concentration range achieved with the highest recommended dose, 80 mg/day.	2				OTHER	https://www.medicines.org.uk/emc/product/8118/smpc#PHARMACOKINETIC_PROPS	Homo sapiens										false
5694	2644		ADULT	4848	351.4023	PIRENZEPINE	PIRENZEPINE	CN1CCN(CC(=O)N2C3=NC=CC=C3NC(=O)C4=C2C=CC=C4)CC1	PLASMA	3G0285N20N									?	ng × h/mL	1213						UNKNOWN	mg	50		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2344866/	Homo sapiens		h	17.3		end state renal disease/maintenance haemodialysis		7	PIRENZEPINE		false
5695	2644		ADULT	4848	351.4023	PIRENZEPINE	PIRENZEPINE	CN1CCN(CC(=O)N2C3=NC=CC=C3NC(=O)C4=C2C=CC=C4)CC1	PLASMA	3G0285N20N									?	ng × h/mL	1462						UNKNOWN	mg	50		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2344866/	Homo sapiens		h	18		moderate renal insufficiency		6	PIRENZEPINE		false
5696	2644		ADULT	4848	351.4023	PIRENZEPINE	PIRENZEPINE	CN1CCN(CC(=O)N2C3=NC=CC=C3NC(=O)C4=C2C=CC=C4)CC1	PLASMA	3G0285N20N									?	ng × h/mL	1013						UNKNOWN	mg	50		SINGLE	FASTED						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2344866/	Homo sapiens		h	14.7		mild renal dysfunction		6	PIRENZEPINE		false
5697	2644		UNKNOWN	4848	351.4023	PIRENZEPINE	PIRENZEPINE	CN1CCN(CC(=O)N2C3=NC=CC=C3NC(=O)C4=C2C=CC=C4)CC1	PLASMA	3G0285N20N									?	ng × h/mL	844		ng/mL	57.2			UNKNOWN	mg	50		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3675700/	Homo sapiens		h	13.9		gastric ulcer patients			PIRENZEPINE		false
5698	2644		UNKNOWN	4848	351.4023	PIRENZEPINE	PIRENZEPINE	CN1CCN(CC(=O)N2C3=NC=CC=C3NC(=O)C4=C2C=CC=C4)CC1	PLASMA	3G0285N20N									?	ng × h/mL	663		ng/mL	48			UNKNOWN	mg	50		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3675700/	Homo sapiens		h	17.9		duodenal ulcer patients			PIRENZEPINE		false
5699	2646		ADULT	688563|51599618	290.3575	PROCATEROL	procaterol	CC[C@@H](NC(C)C)[C@@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2	PLASMA	X7I3EMM5K0									∞	pg × h/mL	518		pg/mL	113				μg	25		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1467453/	Homo sapiens		h	3.1				14			false
5700	2646		ADULT	688563|51599618	290.3575	PROCATEROL	procaterol	CC[C@@H](NC(C)C)[C@@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2	PLASMA	X7I3EMM5K0									∞	pg × h/mL	1100		pg/mL	205				μg	50		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1467453/	Homo sapiens		h	3.2				14			false
5701	2646		ADULT	688563|51599618	290.3575	PROCATEROL	procaterol	CC[C@@H](NC(C)C)[C@@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2	PLASMA	X7I3EMM5K0									∞	pg × h/mL	1380		pg/mL	233				μg	75		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1467453/	Homo sapiens		h	3.7				14			false
5702	2646		ADULT	688563|51599618	290.3575	PROCATEROL	procaterol	CC[C@@H](NC(C)C)[C@@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2	PLASMA	X7I3EMM5K0									∞	pg × h/mL	1590		pg/mL	276			HIGHEST STUDIED	μg	100		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1467453/	Homo sapiens		h	3.5				14			false
5703	2647		ADULT	107706	434.463	SIVELESTAT	Sivelestat	CC(C)(C)C(=O)OC1=CC=C(C=C1)S(=O)(=O)NC2=C(C=CC=C2)C(=O)NCC(O)=O	PLASMA	DWI62G0P59									∞	μg × h/mL	61.113		μg/mL	11.678			UNKNOWN	mg/kg/h	0.5		SINGLE	FASTED				Cmax = C2h, t1/2=t1/2(10->30h)		HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/730119_3999422D1020_2_001_1F.pdf#page=41 | https://www.pmda.go.jp/drugs/2002/P200200016/18018800_21400AMZ00459_X100_1.pdf#page=27	Homo sapiens		min	390.9	2h infusion			5	Sivelestat sodium		false
5704	2647		ADULT	107706	434.463	SIVELESTAT	Sivelestat	CC(C)(C)C(=O)OC1=CC=C(C=C1)S(=O)(=O)NC2=C(C=CC=C2)C(=O)NCC(O)=O	PLASMA	DWI62G0P59									∞	μg × h/mL	136.864		μg/mL	28.883			UNKNOWN	mg/kg/h	1		SINGLE	FASTED				Cmax = C2h, t1/2=t1/2(10->30h)		HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/730119_3999422D1020_2_001_1F.pdf#page=41 | https://www.pmda.go.jp/drugs/2002/P200200016/18018800_21400AMZ00459_X100_1.pdf#page=27	Homo sapiens		min	350.7	2h infusion			6	Sivelestat sodium		false
5705	2647			107706	434.463	SIVELESTAT	Sivelestat	CC(C)(C)C(=O)OC1=CC=C(C=C1)S(=O)(=O)NC2=C(C=CC=C2)C(=O)NCC(O)=O	SERUM	DWI62G0P59																										Human serum protein binding: 99.6% (10~20 mcg/mL), 96.7% (200 mcg/mL, saturated)	0.4				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/2/730119_3999422D1020_2_001_1F.pdf#page=42	Homo sapiens										false
5706	2647		ADULT	107706	434.463	SIVELESTAT	Sivelestat	CC(C)(C)C(=O)OC1=CC=C(C=C1)S(=O)(=O)NC2=C(C=CC=C2)C(=O)NCC(O)=O	PLASMA	DWI62G0P59							14		t	μg × h/mL	59.06		μg/mL	13.08			UNKNOWN	mg/kg/h	0.5		MULTIPLE	FASTED		day	2	Cmax = C2h, t1/2=t1/2(10->30h)		HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2002/P200200016/18018800_21400AMZ00459_X100_1.pdf#page=31	Homo sapiens		min	374.3	2h infusion, Day 3 (last dose (5th))			6	Sivelestat sodium		false
5707	2647		ADULT	107706	434.463	SIVELESTAT	Sivelestat	CC(C)(C)C(=O)OC1=CC=C(C=C1)S(=O)(=O)NC2=C(C=CC=C2)C(=O)NCC(O)=O	PLASMA	DWI62G0P59													μg/mL	11.365			UNKNOWN	mg/kg/h	0.5		MULTIPLE	FASTED		day	2	Cmax = C2h		HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2002/P200200016/18018800_21400AMZ00459_X100_1.pdf#page=31	Homo sapiens				2h infusion, Day 1 (1st dose)			6	Sivelestat sodium		false
5708	2647		ADULT	107706	434.463	SIVELESTAT	Sivelestat	CC(C)(C)C(=O)OC1=CC=C(C=C1)S(=O)(=O)NC2=C(C=CC=C2)C(=O)NCC(O)=O	PLASMA	DWI62G0P59							14		∞	μg × h/mL	31.0376		μg/mL	10.588			UNKNOWN	mg/kg	0.5		SINGLE	FASTED				t1/2=t1/2(6.0833->12.0833h)		HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2002/P200200016/18018800_21400AMZ00459_X100_1.pdf#page=45	Homo sapiens		min	220.9	5min administration			5	Sivelestat sodium		false
5709	2647		ADULT	107706	434.463	SIVELESTAT	Sivelestat	CC(C)(C)C(=O)OC1=CC=C(C=C1)S(=O)(=O)NC2=C(C=CC=C2)C(=O)NCC(O)=O	PLASMA	DWI62G0P59							14		∞	μg × h/mL	59.5		μg/mL	18.308			UNKNOWN	mg/kg	1		SINGLE	FASTED				t1/2=t1/2(6.0833->12.0833h)		HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2002/P200200016/18018800_21400AMZ00459_X100_1.pdf#page=45	Homo sapiens		min	238.9	5min administration			5	Sivelestat sodium		false
5710	2647		ADULT	107706	434.463	SIVELESTAT	Sivelestat	CC(C)(C)C(=O)OC1=CC=C(C=C1)S(=O)(=O)NC2=C(C=CC=C2)C(=O)NCC(O)=O	PLASMA	DWI62G0P59							12.0833		t	μg × h/mL	55.364		μg/mL	19.68			UNKNOWN	mg/kg	1		MULTIPLE	FASTED		day	2	t1/2=t1/2(6.0833->12.0833h)		HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2002/P200200016/18018800_21400AMZ00459_X100_1.pdf#page=49	Homo sapiens		min	265.9	5min administration, Day 3 (last dose (5th))			5	Sivelestat sodium		false
5711	2647		ADULT	107706	434.463	SIVELESTAT	Sivelestat	CC(C)(C)C(=O)OC1=CC=C(C=C1)S(=O)(=O)NC2=C(C=CC=C2)C(=O)NCC(O)=O	PLASMA	DWI62G0P59							14						μg/mL	17.575			UNKNOWN	mg/kg	1		MULTIPLE	FASTED		day	2			HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2002/P200200016/18018800_21400AMZ00459_X100_1.pdf#page=49	Homo sapiens				5min administration, Day 1 (1st dose)			5	Sivelestat sodium		false
5712	2651		ADULT	656665	284.3529	TROPISETRON	Tropisetron	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C3=CNC4=C3C=CC=C4	PLASMA	6I819NIK1W									∞	ng × h/mL	20.7		ng/mL	15.1			RECOMMENDED	mg	2		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11736884/	Homo sapiens		h	5.6		CYP2D6 extensive metabolizers		18			false
5713	2651		ADULT	656665	284.3529	TROPISETRON	Tropisetron	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C3=CNC4=C3C=CC=C4	PLASMA	6I819NIK1W									∞	ng × h/mL	32.9		ng/mL	3.46			RECOMMENDED	mg	5		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11736884/	Homo sapiens		h	5.7		CYP2D6 extensive metabolizers		18			false
5714	2651		UNKNOWN	656665	284.3529	TROPISETRON	Tropisetron	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C3=CNC4=C3C=CC=C4	PLASMA	6I819NIK1W																						UNKNOWN				Tropisetron exhibits a more moderate protein binding behavior of between 59–71%.	41	UNKNOWN		UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/30672837/	Homo sapiens										false
5715	2651		ADULT	656665	284.3529	TROPISETRON	Tropisetron	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C3=CNC4=C3C=CC=C4	PLASMA	6I819NIK1W									?	mg × h/mL	195		mg/mL	76			UNKNOWN	mg	10		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/8363993/ | https://www.sciencedirect.com/science/article/pii/S0923753419650428/pdf?md5=053694846466cf9e1daea50a7812ae48&pid=1-s2.0-S0923753419650428-main.pdf	Homo sapiens		h	6.7		Elderly patients					false
5716	2651		ADULT	656665	284.3529	TROPISETRON	Tropisetron	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C3=CNC4=C3C=CC=C4	PLASMA	6I819NIK1W									?	mg × h/mL	410		mg/mL	150			UNKNOWN	mg	10		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/8363993/ | https://www.sciencedirect.com/science/article/pii/S0923753419650428/pdf?md5=053694846466cf9e1daea50a7812ae48&pid=1-s2.0-S0923753419650428-main.pdf	Homo sapiens		h	13.5		Cirrhotic patients					false
5717	2651		ADULT	656665	284.3529	TROPISETRON	Tropisetron	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C3=CNC4=C3C=CC=C4	PLASMA	6I819NIK1W									?	mg × h/mL	450		mg/mL	211			UNKNOWN	mg	10		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/8363993/ | https://www.sciencedirect.com/science/article/pii/S0923753419650428/pdf?md5=053694846466cf9e1daea50a7812ae48&pid=1-s2.0-S0923753419650428-main.pdf	Homo sapiens		h	12.1		Renal patients					false
5718	2651		ADULT	656665	284.3529	TROPISETRON	Tropisetron	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C3=CNC4=C3C=CC=C4	PLASMA	6I819NIK1W									?	mg × h/mL	1192		mg/mL	82			UNKNOWN	mg	10		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/8363993/ | https://www.sciencedirect.com/science/article/pii/S0923753419650428/pdf?md5=053694846466cf9e1daea50a7812ae48&pid=1-s2.0-S0923753419650428-main.pdf	Homo sapiens		h	30.3		CYP2D6 poor metabolizers					false
5719	2651		UNKNOWN	656665	284.3529	TROPISETRON	Tropisetron	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C3=CNC4=C3C=CC=C4	PLASMA	6I819NIK1W									?	mg × h/mL	239		mg/mL	84			UNKNOWN	mg	10		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/8363993/ | https://www.sciencedirect.com/science/article/pii/S0923753419650428/pdf?md5=053694846466cf9e1daea50a7812ae48&pid=1-s2.0-S0923753419650428-main.pdf	Homo sapiens		h	7.3		CYP2D6 extensive metabolizers					false
5720	2652		ADULT	59693	223.2731	FADROZOLE	Fadrozole	N#CC1=CC=C(C=C1)C2CCCC3=CN=CN23	PLASMA	H3988M64PU									∞	ng × h/mL	336		ng/mL	32.3			UNKNOWN	mg	12		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8298071/	Homo sapiens		h	1.8				9			false
5721	2652		ADULT	59693	223.2731	FADROZOLE	Fadrozole	N#CC1=CC=C(C=C1)C2CCCC3=CN=CN23	PLASMA	H3988M64PU									∞	ng × h/mL	306		ng/mL	27.4			UNKNOWN	mg	12		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8298071/	Homo sapiens		h	2.5		Immediate after dosing		9			false
5722	2652		ADULT	59693	223.2731	FADROZOLE	Fadrozole	N#CC1=CC=C(C=C1)C2CCCC3=CN=CN23	PLASMA	H3988M64PU							12		t	ng × h/mL	10.7		ng/mL	1.5			UNKNOWN	mg	0.3		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8302763/	Homo sapiens				day 5	Postmenopausal women, fasted on Day 5 dose		18			false
5723	2652		ADULT	59693	223.2731	FADROZOLE	Fadrozole	N#CC1=CC=C(C=C1)C2CCCC3=CN=CN23	PLASMA	H3988M64PU							12		t	ng × h/mL	10.5		ng/mL	1.5			UNKNOWN	mg	1		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8302763/	Homo sapiens				day 5	Postmenopausal women, fasted on Day 5 dose		18			false
5724	2652		ADULT	59693	223.2731	FADROZOLE	Fadrozole	N#CC1=CC=C(C=C1)C2CCCC3=CN=CN23	PLASMA	H3988M64PU							12		t	ng × h/mL	10.7		ng/mL	1.5			UNKNOWN	mg	2		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8302763/	Homo sapiens				day 5	Postmenopausal women, fasted on Day 5 dose		18			false
5725	2653		ADULT	30668	259.132	LOFEXIDINE	LOFEXIDINE	CC(OC1=C(Cl)C=CC=C1Cl)C2=NCCN2	PLASMA	UI82K0T627									∞	ng × h/mL	31652		ng/mL	1755			UNKNOWN	mg	1.2		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18393298/	Homo sapiens		h	11.16							false
5726	2653		ADULT	30668	259.132	LOFEXIDINE	LOFEXIDINE	CC(OC1=C(Cl)C=CC=C1Cl)C2=NCCN2	PLASMA	UI82K0T627									∞	ng × h/mL	54321		ng/mL	2795			UNKNOWN	mg	2		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18393298/	Homo sapiens		h	11.44							false
5727	2653		ADULT	30668	259.132	LOFEXIDINE	lofexidine	CC(OC1=C(Cl)C=CC=C1Cl)C2=NCCN2	PLASMA	UI82K0T627							5		t	ng × h/mL	25.8		ng/mL	6.29			RECOMMENDED	mg	0.6		STEADY-STATE	UNKNOWN		day	4	Plasma Protein Binding: 55%	45	UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209229Orig1s000MultidisciplineR.pdf	Homo sapiens		h	12							false
5728	2656		ADULT	3678	281.4351	ALVERINE	ALVERINE	CCN(CCCC1=CC=CC=C1)CCCC2=CC=CC=C2	PLASMA	46TIR1560O									∞	pg × h/mL	15562.3		pg/mL	2574			UNKNOWN	mg	120		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29404023	Homo sapiens		h	11.37							false
5729	2656		ADULT	9926231	297.4	Para hydroxy alverine	4-Hydroxy Alverine		PLASMA										∞	pg × h/mL	19755.5		pg/mL	2841.78			UNKNOWN	mg	250		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29404023	Homo sapiens		h	9.84							false
5730	2658		ADULT	6047|6971033	197.1879	LEVODOPA	LEVODOPA	N[C@@H](CC1=CC=C(O)C(O)=C1)C(O)=O	PLASMA	46627O600J	6047|6971033	197.1879	LEVODOPA	levodopa	N[C@@H](CC1=CC=C(O)C(O)=C1)C(O)=O	46627O600J	3		t	μM × h	511		μM	8.37			UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://onlinelibrary.wiley.com/doi/epdf/10.1111/ncn3.152	Homo sapiens		min	72			100 mg	10	BENSERAZIDE		true
5731	2658		ADULT	2327	257.2432	BENSERAZIDE	benserazide	NC(CO)C(=O)NNCC1=CC=C(O)C(O)=C1O	PLASMA	762OS3ZEJU	6047|6971033	197.1879	LEVODOPA	levodopa	N[C@@H](CC1=CC=C(O)C(O)=C1)C(O)=O	46627O600J							μM	0.287			UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://onlinelibrary.wiley.com/doi/epdf/10.1111/ncn3.152	Homo sapiens		min	48.6			100 mg	10	BENSERAZIDE		true
5732	2658		ADULT	2327	257.2432	BENSERAZIDE	BENSERAZIDE	NC(CO)C(=O)NNCC1=CC=C(O)C(O)=C1O	PLASMA	762OS3ZEJU	6047|6971033	197.1879	LEVODOPA	levodopa	N[C@@H](CC1=CC=C(O)C(O)=C1)C(O)=O	46627O600J			?	ng × h/mL	1.8		ng/mL	1.5			RECOMMENDED	mg	25		STEADY-STATE	UNKNOWN		day	3			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10053234/	Homo sapiens				standard-release formulation	Parkinson's disease	100 mg	5	BENSERAZIDE		true
5733	2658		ADULT	2327	257.2432	BENSERAZIDE	BENSERAZIDE	NC(CO)C(=O)NNCC1=CC=C(O)C(O)=C1O	PLASMA	762OS3ZEJU	6047|6971033	197.1879	LEVODOPA	levodopa	N[C@@H](CC1=CC=C(O)C(O)=C1)C(O)=O	46627O600J			?	ng × h/mL	3.7		ng/mL	2.2			RECOMMENDED	mg	50		STEADY-STATE	UNKNOWN		day	3			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10053234/	Homo sapiens				standard-release formulation	Parkinson's disease	200 mg	5	BENSERAZIDE		true
5734	2658		ADULT	2327	257.2432	BENSERAZIDE	BENSERAZIDE	NC(CO)C(=O)NNCC1=CC=C(O)C(O)=C1O	PLASMA	762OS3ZEJU	6047|6971033	197.1879	LEVODOPA	levodopa	N[C@@H](CC1=CC=C(O)C(O)=C1)C(O)=O	46627O600J			?	ng × h/mL	3.7		ng/mL	1.9			RECOMMENDED	mg	50		STEADY-STATE	UNKNOWN		day	3			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10053234/	Homo sapiens				controlled-release formulation	Parkinson's disease	200 mg	5	BENSERAZIDE		true
5735	2658		ADULT	6047|6971033	197.1879	LEVODOPA	LEVODOPA	N[C@@H](CC1=CC=C(O)C(O)=C1)C(O)=O	PLASMA	46627O600J	6047|6971033	197.1879	LEVODOPA	levodopa	N[C@@H](CC1=CC=C(O)C(O)=C1)C(O)=O	46627O600J			∞	ng × h/mL	2753.7		ng/mL	627.5			UNKNOWN	mg	25		SINGLE	FASTED						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31378952/	Homo sapiens		h	1.79	generic preparation of levodopa/benserazide, Teva Italia	Parkinson's disease	100 mg	14	BENSERAZIDE		true
5736	2658		ADULT	6047|6971033	197.1879	LEVODOPA	LEVODOPA	N[C@@H](CC1=CC=C(O)C(O)=C1)C(O)=O	PLASMA	46627O600J	6047|6971033	197.1879	LEVODOPA	levodopa	N[C@@H](CC1=CC=C(O)C(O)=C1)C(O)=O	46627O600J			∞	ng × h/mL	2784.7		ng/mL	620.2			UNKNOWN	mg	25		SINGLE	FASTED						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31378952/	Homo sapiens		h	2.28	originator (Madopar)	Parkinson's disease	100 mg	14	BENSERAZIDE		true
5737	2662		ADULT	456390	414.681	HALOFUGINONE	halofuginone	O[C@H]1CCCN[C@@H]1CC(=O)CN2C=NC3=CC(Br)=C(Cl)C=C3C2=O	PLASMA	L31MM1385E									∞	ng × h/mL	12.58		ng/mL	0.54			UNKNOWN	mg	0.5		MULTIPLE	FED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16815702	Homo sapiens		h	17.2				5	halofuginone		false
5738	2662		ADULT	456390	414.681	HALOFUGINONE	halofuginone	O[C@H]1CCCN[C@@H]1CC(=O)CN2C=NC3=CC(Br)=C(Cl)C=C3C2=O	PLASMA	L31MM1385E									∞	ng × h/mL	85.66		ng/mL	3.09			MAX TOLERATED	mg	3.5		MULTIPLE	FED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16815702	Homo sapiens		h	30.8				3	halofuginone		false
5739	2662		ADULT	456390	414.681	HALOFUGINONE	halofuginone	O[C@H]1CCCN[C@@H]1CC(=O)CN2C=NC3=CC(Br)=C(Cl)C=C3C2=O	PLASMA	L31MM1385E									∞	ng × h/mL	67.97		ng/mL	1.7			UNKNOWN	mg	2		MULTIPLE	FED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16815702	Homo sapiens		h	37				6	halofuginone		false
5740	2662		ADULT	456390	414.681	HALOFUGINONE	halofuginone	O[C@H]1CCCN[C@@H]1CC(=O)CN2C=NC3=CC(Br)=C(Cl)C=C3C2=O	PLASMA	L31MM1385E									∞	ng × h/mL	15.2		ng/mL	0.42			UNKNOWN	mg	0.5		MULTIPLE	FED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16815702	Homo sapiens		h	25				6	halofuginone		false
5741	2663			4581	153.1784	OCTOPAMINE	Octopamine	NCC(O)C1=CC=C(O)C=C1	SERUM	14O50WS8JD																										Human albumine binding: 33% (50ng/mL)	67				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4277715/	Homo sapiens										false
5742	2663		ADULT	4581	153.1784	OCTOPAMINE	Octopamine	NCC(O)C1=CC=C(O)C=C1	SERUM	14O50WS8JD													ng/mL	39.1			UNKNOWN	mg	2		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4277715/	Homo sapiens		min	243		Elderly patients (>=50 y)		4			false
5743	2663		ADULT	4581	153.1784	OCTOPAMINE	Octopamine	NCC(O)C1=CC=C(O)C=C1	SERUM	14O50WS8JD													ng/mL	213			UNKNOWN	mg	8		SINGLE	FASTED				n=2 for Cmax		UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4277715/	Homo sapiens		min	175		Elderly patients (>=50 y)		4			false
5744	2665		ADULT	6918030	477.635	VAPIPROST	Vapiprost	O[C@H]1C[C@H](OCC2=CC=C(C=C2)C3=CC=CC=C3)[C@H](CC\\C=C/CCC(O)=O)[C@H]1N4CCCCC4	PLASMA	H84XT1COAU									?	ng × min/mL	1944		ng/mL	38			UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1834144/	Homo sapiens		min	84				4			false
5745	2665		ADULT	6918030	477.635	VAPIPROST	Vapiprost	O[C@H]1C[C@H](OCC2=CC=C(C=C2)C3=CC=CC=C3)[C@H](CC\\C=C/CCC(O)=O)[C@H]1N4CCCCC4	PLASMA	H84XT1COAU									?	ng × min/mL	6478		ng/mL	160			UNKNOWN	mg	4		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1834144/	Homo sapiens		min	70				3			false
5746	2665		ADULT	6918030	477.635	VAPIPROST	Vapiprost	O[C@H]1C[C@H](OCC2=CC=C(C=C2)C3=CC=CC=C3)[C@H](CC\\C=C/CCC(O)=O)[C@H]1N4CCCCC4	PLASMA	H84XT1COAU									?	ng × min/mL	2781		ng/mL	69			UNKNOWN	mg	2		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1834144/	Homo sapiens		min	69				4			false
5747	2665		ADULT	6918030	477.635	VAPIPROST	Vapiprost	O[C@H]1C[C@H](OCC2=CC=C(C=C2)C3=CC=CC=C3)[C@H](CC\\C=C/CCC(O)=O)[C@H]1N4CCCCC4	PLASMA	H84XT1COAU									?	ng × min/mL	1295		ng/mL	237			UNKNOWN	mg	8		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1834144/	Homo sapiens		min	68				6			false
5748	2665		ADULT	6918030	477.635	VAPIPROST	Vapiprost	O[C@H]1C[C@H](OCC2=CC=C(C=C2)C3=CC=CC=C3)[C@H](CC\\C=C/CCC(O)=O)[C@H]1N4CCCCC4	PLASMA	H84XT1COAU									?	ng × min/mL	22198		ng/mL	431			UNKNOWN	mg	16		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1834144/	Homo sapiens		min	86				6			false
5749	2665		ADULT	6918030	477.635	VAPIPROST	Vapiprost	O[C@H]1C[C@H](OCC2=CC=C(C=C2)C3=CC=CC=C3)[C@H](CC\\C=C/CCC(O)=O)[C@H]1N4CCCCC4	PLASMA	H84XT1COAU									∞	ng × h/mL	284.39		ng/mL	100.36			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1839540/	Homo sapiens		h	1.07				6			false
5750	2665		ADULT	6918030	477.635	VAPIPROST	Vapiprost	O[C@H]1C[C@H](OCC2=CC=C(C=C2)C3=CC=CC=C3)[C@H](CC\\C=C/CCC(O)=O)[C@H]1N4CCCCC4	PLASMA	H84XT1COAU									∞	ng × h/mL	299.74		ng/mL	118.89			UNKNOWN	mg	20		MULTIPLE	FED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1839540/	Homo sapiens		h	1.12	Day 1 (over-night fast on the 1st, 3rd, and 5th (final) days)			6			false
5751	2665		ADULT	6918030	477.635	VAPIPROST	Vapiprost	O[C@H]1C[C@H](OCC2=CC=C(C=C2)C3=CC=CC=C3)[C@H](CC\\C=C/CCC(O)=O)[C@H]1N4CCCCC4	PLASMA	H84XT1COAU									∞	ng × h/mL	386.71		ng/mL	125.14			UNKNOWN	mg	20		MULTIPLE	FED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1839540/	Homo sapiens		h	1.18	Day 5 (9th (last) dose, over-night fast on the 1st, 3rd, and 5th (final) days)			6			false
5752	2665		ADULT	6918030	477.635	VAPIPROST	Vapiprost	O[C@H]1C[C@H](OCC2=CC=C(C=C2)C3=CC=CC=C3)[C@H](CC\\C=C/CCC(O)=O)[C@H]1N4CCCCC4	PLASMA	H84XT1COAU									∞	ng × h/mL	63.73		ng/mL	23.98			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1839540/	Homo sapiens		h	0.99				6			false
5753	2665		ADULT	6918030	477.635	VAPIPROST	Vapiprost	O[C@H]1C[C@H](OCC2=CC=C(C=C2)C3=CC=CC=C3)[C@H](CC\\C=C/CCC(O)=O)[C@H]1N4CCCCC4	PLASMA	H84XT1COAU									∞	ng × h/mL	124.27		ng/mL	43			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1839540/	Homo sapiens		h	1.1				6			false
5754	2665		ADULT	6918030	477.635	VAPIPROST	Vapiprost	O[C@H]1C[C@H](OCC2=CC=C(C=C2)C3=CC=CC=C3)[C@H](CC\\C=C/CCC(O)=O)[C@H]1N4CCCCC4	PLASMA	H84XT1COAU									∞	ng × h/mL	341.64		ng/mL	81.4			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.jstage.jst.go.jp/article/jscpt1970/26/1/26_1_305/_article/-char/en	Homo sapiens		h	14.19		Elderly subjects (65~72 y)		6			false
5755	2665		ADULT	6918030	477.635	VAPIPROST	Vapiprost	O[C@H]1C[C@H](OCC2=CC=C(C=C2)C3=CC=CC=C3)[C@H](CC\\C=C/CCC(O)=O)[C@H]1N4CCCCC4	PLASMA	H84XT1COAU									∞	ng × h/mL	124.27		ng/mL	43			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.jstage.jst.go.jp/article/jscpt1970/26/1/26_1_305/_article/-char/en	Homo sapiens		h	1.1		Young subjects		6			false
5756	2667		ADULT	91562	339.324	CEPHACETRILE	CEPHACETRILE	CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CC#N)C2=O)C(O)=O	PLASMA	FDM21QQ344							6		t	μg × h/mL	71		μg/mL	122.2			UNKNOWN	mg/kg	15		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4479808/	Homo sapiens		h	2							false
5757	2672		ADULT	8969	354.4427	YOHIMBINE	Yohimbine	COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12	PLASMA	2Y49VWD90Q									∞	ng × h/mL	55.7		ng/mL	37.3			UNKNOWN	mg	8		SINGLE	FASTED						HEALTHY	Oral	MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/11744068/	Homo sapiens		h	1.3		Young adults		11			false
5758	2672			8969	354.4427	YOHIMBINE	Yohimbine	COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12	PLASMA	2Y49VWD90Q																										Human plasma protein binding: 82% (ultrafiltration)	18				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8097957/	Homo sapiens										false
5759	2672		ADULT	8969	354.4427	YOHIMBINE	Yohimbine	COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12	PLASMA	2Y49VWD90Q									∞	ng × h/mL	41.8		ng/mL	78.7			UNKNOWN	mg	5.4		MULTIPLE	UNKNOWN		day	3			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9234649/	Homo sapiens		h	0.09	Day 7	Subjects fasted overnight before all blood collections (Days 1 and 7).		4	Yohimbine HCl		false
5760	2672		ADULT	8969	354.4427	YOHIMBINE	Yohimbine	COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12	PLASMA	2Y49VWD90Q									∞	ng × h/mL	319		ng/mL	366			UNKNOWN	mg	16.2		MULTIPLE	UNKNOWN		day	3			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9234649/	Homo sapiens		h	0.39	Day 7	Subjects fasted overnight before all blood collections (Days 1 and 7).		4	Yohimbine HCl		false
5761	2672		ADULT	8969	354.4427	YOHIMBINE	Yohimbine	COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12	PLASMA	2Y49VWD90Q									∞	ng × h/mL	30.8		ng/mL	50.9			UNKNOWN	mg	5.4		MULTIPLE	UNKNOWN		day	3			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9234649/	Homo sapiens		h	0.29	Day 1	Subjects fasted overnight before all blood collections (Days 1 and 7).		4	Yohimbine HCl		false
5762	2672		ADULT	8969	354.4427	YOHIMBINE	Yohimbine	COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12	PLASMA	2Y49VWD90Q									∞	ng × h/mL	80.2		ng/mL	131			UNKNOWN	mg	10.8		MULTIPLE	UNKNOWN		day	3			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9234649/	Homo sapiens		h	0.32	Day 7	Subjects fasted overnight before all blood collections (Days 1 and 7).		4	Yohimbine HCl		false
5763	2672		ADULT	8969	354.4427	YOHIMBINE	Yohimbine	COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12	PLASMA	2Y49VWD90Q									∞	ng × h/mL	119		ng/mL	154			UNKNOWN	mg	10.8		MULTIPLE	UNKNOWN		day	3			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9234649/	Homo sapiens		h	0.21	Day 1	Subjects fasted overnight before all blood collections (Days 1 and 7).		4	Yohimbine HCl		false
5764	2672		ADULT	8969	354.4427	YOHIMBINE	Yohimbine	COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12	PLASMA	2Y49VWD90Q									∞	ng × h/mL	476		ng/mL	400			UNKNOWN	mg	16.2		MULTIPLE	UNKNOWN		day	3			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9234649/	Homo sapiens		h	0.34	Day 1	Subjects fasted overnight before all blood collections (Days 1 and 7).		4	Yohimbine HCl		false
5765	2672		ADULT	8969	354.4427	YOHIMBINE	Yohimbine	COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12	PLASMA	2Y49VWD90Q									∞	ng × h/mL	72.4		ng/mL	49.5			UNKNOWN	mg	21.6		MULTIPLE	UNKNOWN		day	3			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9234649/	Homo sapiens		h	0.16	Day 1	Subjects fasted overnight before all blood collections (Days 1 and 7).		4	Yohimbine HCl		false
5766	2672		ADULT	8969	354.4427	YOHIMBINE	Yohimbine	COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C(NC5=C4C=CC=C5)[C@@H]3C[C@H]12	PLASMA	2Y49VWD90Q									∞	ng × h/mL	75.1		ng/mL	51.7			UNKNOWN	mg	21.6		MULTIPLE	UNKNOWN		day	3			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9234649/	Homo sapiens		h	0.24	Day 7	Subjects fasted overnight before all blood collections (Days 1 and 7).		4	Yohimbine HCl		false
5767	2677		ADULT	107715	611.7305	DIHYDROERGOCRISTINE	DIHYDROERGOCRISTINE	CC(C)[C@@]5(NC(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C)C1)O[C@@]6(O)[C@@H]7CCCN7C(=O)[C@H](CC8=CC=CC=C8)N6C5=O	PLASMA	05D48LUM4Z									∞	μg × h/L	0.46		μg/L	0.28			RECOMMENDED	mg	18		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16379666/	Homo sapiens		h	3.5							false
5768	2677		ADULT	91800137	627.7299	8'-HYDROXY-DIHYDROERGOCRISTINE	8\'-hydroxy-dihydroergocristine	CC(C)[C@@]5(NC(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=C3C2=CC=C4)N(C)C1)O[C@@]6(O)[C@@H]7CCC(O)N7C(=O)[C@H](CC8=CC=CC=C8)N6C5=O	PLASMA	P4G0O1T30U									∞	μg × h/L	13.36		μg/L	5.63			RECOMMENDED	mg	18		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16379666/	Homo sapiens		h	3.9							false
5769	2681		ADULT	370	170.1195	GALLIC ACID	GALLIC ACID	OC(=O)C1=CC(O)=C(O)C(O)=C1	PLASMA	632XD903SP							12		t	μM × h	4.29		μM	1.83			RECOMMENDED	mmol	0.3		SINGLE	UNKNOWN				tablets		HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11285327/	Homo sapiens		h	1.19							false
5770	2681		ADULT	370	170.1195	GALLIC ACID	GALLIC ACID	OC(=O)C1=CC(O)=C(O)C(O)=C1	PLASMA	632XD903SP							12		t	μM × h	4.55		μM	2.09			RECOMMENDED	mmol	0.3		SINGLE	UNKNOWN				tea		HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11285327/	Homo sapiens		h	1.06							false
5771	2684		ADOLESCENT		492.7	LURASIDONE			PLASMA										∞	ng × h/mL	153		ng/mL	38.4			RECOMMENDED	mg	40		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26631428/	Homo sapiens		h	21.3							false
5772	2684		ADULT		492.7	LURASIDONE	LURASIDONE		PLASMA																		RECOMMENDED	mg	40		SINGLE	UNKNOWN				LATUDA is highly bound (~99%) to serum proteins	1	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/200603s035lbl.pdf	Homo sapiens										false
5773	2718		ADULT	40854	315.347	OXFENDAZOLE	OXFENDAZOLE	COC(=O)NC1=NC2=CC=C(C=C2N1)[S ]([O-])C3=CC=CC=C3	PLASMA	OMP2H17F9E									∞	ng × h/mL	13100		ng/mL	1160			UNKNOWN	mg/kg	1		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30745383/	Homo sapiens		h	8.5				10	OXFENDAZOLE		false
5774	2718		ADULT	40854	315.347	OXFENDAZOLE	OXFENDAZOLE	COC(=O)NC1=NC2=CC=C(C=C2N1)[S ]([O-])C3=CC=CC=C3	PLASMA	OMP2H17F9E									∞	ng × h/mL	11700		ng/mL	944			UNKNOWN	mg/kg	0.5		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30745383/	Homo sapiens		h	9.07				10	OXFENDAZOLE		false
5775	2718		ADULT	40854	315.347	OXFENDAZOLE	OXFENDAZOLE	COC(=O)NC1=NC2=CC=C(C=C2N1)[S ]([O-])C3=CC=CC=C3	PLASMA	OMP2H17F9E									∞	ng × h/mL	30800		ng/mL	2440			UNKNOWN	mg/kg	3		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30745383/	Homo sapiens		h	10.3				10	OXFENDAZOLE		false
5776	2718		ADULT	40854	315.347	OXFENDAZOLE	OXFENDAZOLE	COC(=O)NC1=NC2=CC=C(C=C2N1)[S ]([O-])C3=CC=CC=C3	PLASMA	OMP2H17F9E									∞	ng × h/mL	73700		ng/mL	4780			UNKNOWN	mg/kg	7.5		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30745383/	Homo sapiens		h	9.59				10	OXFENDAZOLE		false
5777	2718		ADULT	40854	315.347	OXFENDAZOLE	OXFENDAZOLE	COC(=O)NC1=NC2=CC=C(C=C2N1)[S ]([O-])C3=CC=CC=C3	PLASMA	OMP2H17F9E									∞	ng × h/mL	99500		ng/mL	6250			UNKNOWN	mg/kg	15		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30745383/	Homo sapiens		h	9.97				10	OXFENDAZOLE		false
5778	2718		ADULT	40854	315.347	OXFENDAZOLE	OXFENDAZOLE	COC(=O)NC1=NC2=CC=C(C=C2N1)[S ]([O-])C3=CC=CC=C3	PLASMA	OMP2H17F9E									∞	ng × h/mL	78300		ng/mL	5300			UNKNOWN	mg/kg	30		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30745383/	Homo sapiens		h	9.82				10	OXFENDAZOLE		false
5779	2718		ADULT	40854	315.347	OXFENDAZOLE	OXFENDAZOLE	COC(=O)NC1=NC2=CC=C(C=C2N1)[S ]([O-])C3=CC=CC=C3	PLASMA	OMP2H17F9E									∞	ng × h/mL	109000		ng/mL	6770			HIGHEST STUDIED	mg/kg	60		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30745383/	Homo sapiens		h	11				10	OXFENDAZOLE		false
5780	2718		ADULT	40854	315.347	OXFENDAZOLE	OXFENDAZOLE	COC(=O)NC1=NC2=CC=C(C=C2N1)[S ]([O-])C3=CC=CC=C3	PLASMA	OMP2H17F9E							24		t	ng × h/mL	30200		ng/mL	2960			UNKNOWN	mg/kg	3		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32816721/	Homo sapiens							8	OXFENDAZOLE		false
5781	2718		ADULT	40854	315.347	OXFENDAZOLE	OXFENDAZOLE	COC(=O)NC1=NC2=CC=C(C=C2N1)[S ]([O-])C3=CC=CC=C3	PLASMA	OMP2H17F9E							24		t	ng × h/mL	52500		ng/mL	4160			UNKNOWN	mg/kg	7.5		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32816721/	Homo sapiens							8	OXFENDAZOLE		false
5782	2718		ADULT	40854	315.347	OXFENDAZOLE	OXFENDAZOLE	COC(=O)NC1=NC2=CC=C(C=C2N1)[S ]([O-])C3=CC=CC=C3	PLASMA	OMP2H17F9E							24		∞	ng × h/mL	65400		ng/mL	4500			UNKNOWN	mg/kg	3		SINGLE	HIGH-FAT						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32816721/	Homo sapiens		h	8.05				12	OXFENDAZOLE		false
5783	2718		ADULT	40854	315.347	OXFENDAZOLE	OXFENDAZOLE	COC(=O)NC1=NC2=CC=C(C=C2N1)[S ]([O-])C3=CC=CC=C3	PLASMA	OMP2H17F9E							24		∞	ng × h/mL	34800		ng/mL	3010			UNKNOWN	mg/kg	3		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32816721/	Homo sapiens		h	7.65				12	OXFENDAZOLE		false
5784	2718		ADULT	40854	315.347	OXFENDAZOLE	OXFENDAZOLE	COC(=O)NC1=NC2=CC=C(C=C2N1)[S ]([O-])C3=CC=CC=C3	PLASMA	OMP2H17F9E							24		t	ng × h/mL	79200		ng/mL	5990			HIGHEST STUDIED	mg/kg	15		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32816721/	Homo sapiens							8	OXFENDAZOLE		false
5785	2718		ADULT	40854	315.347	OXFENDAZOLE	OXFENDAZOLE	COC(=O)NC1=NC2=CC=C(C=C2N1)[S ]([O-])C3=CC=CC=C3	PLASMA	OMP2H17F9E							24		t	ng × h/mL	38200		ng/mL	3500			UNKNOWN	mg/kg	3		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32816721/	Homo sapiens		h	9.21	5 days dosing			8	OXFENDAZOLE		false
5786	2718		ADULT	40854	315.347	OXFENDAZOLE	OXFENDAZOLE	COC(=O)NC1=NC2=CC=C(C=C2N1)[S ]([O-])C3=CC=CC=C3	PLASMA	OMP2H17F9E							24		t	ng × h/mL	65700		ng/mL	5980			UNKNOWN	mg/kg	7.5		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32816721/	Homo sapiens		h	10.5	5 days dosing			8	OXFENDAZOLE		false
5787	2718		ADULT	40854	315.347	OXFENDAZOLE	OXFENDAZOLE	COC(=O)NC1=NC2=CC=C(C=C2N1)[S ]([O-])C3=CC=CC=C3	PLASMA	OMP2H17F9E							24		t	ng × h/mL	69600		ng/mL	6000			HIGHEST STUDIED	mg/kg	15		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32816721/	Homo sapiens		h	11.8	5 days dosing			8	OXFENDAZOLE		false
5788	2744		ADULT	59757	385.844	TEPOXALIN	Tepoxalin	COC1=CC=C(C=C1)N2N=C(CCC(=O)N(C)O)C=C2C3=CC=C(Cl)C=C3	PLASMA	TZ4OX61974									?	ng × h/mL	667		ng/mL	219			UNKNOWN	mg	35		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8739025/	Homo sapiens		h	1.7				10			false
5789	2744		ADULT	59757	385.844	TEPOXALIN	Tepoxalin	COC1=CC=C(C=C1)N2N=C(CCC(=O)N(C)O)C=C2C3=CC=C(Cl)C=C3	PLASMA	TZ4OX61974									?	ng × h/mL	2113		ng/mL	450			UNKNOWN	mg	75		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8739025/	Homo sapiens		h	3.2				10			false
5790	2744		ADULT	59757	385.844	TEPOXALIN	Tepoxalin	COC1=CC=C(C=C1)N2N=C(CCC(=O)N(C)O)C=C2C3=CC=C(Cl)C=C3	PLASMA	TZ4OX61974									?	ng × h/mL	2916		ng/mL	466			UNKNOWN	mg	150		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8739025/	Homo sapiens		h	3.4				10			false
5791	2744		ADULT	59757	385.844	TEPOXALIN	Tepoxalin	COC1=CC=C(C=C1)N2N=C(CCC(=O)N(C)O)C=C2C3=CC=C(Cl)C=C3	PLASMA	TZ4OX61974									?	ng × h/mL	4923		ng/mL	516			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8739025/	Homo sapiens		h	6.2				10			false
5792	2744		ADULT	188850	356.8	3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)pyrazol-3-yl]propanoic Acid		COC1=CC=C(C=C1)N2C(=CC(=N2)CCC(=O)O)C3=CC=C(C=C3)Cl	PLASMA										?	ng × h/mL	14737		ng/mL	909			UNKNOWN	mg	75		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8739025/	Homo sapiens		h	12.5				10			false
5793	2744		ADULT	188850	356.8	3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)pyrazol-3-yl]propanoic Acid		COC1=CC=C(C=C1)N2C(=CC(=N2)CCC(=O)O)C3=CC=C(C=C3)Cl	PLASMA										?	ng × h/mL	6851		ng/mL	427			UNKNOWN	mg	35		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8739025/	Homo sapiens		h	14.5				10			false
5794	2744		ADULT	188850	356.8	3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)pyrazol-3-yl]propanoic Acid		COC1=CC=C(C=C1)N2C(=CC(=N2)CCC(=O)O)C3=CC=C(C=C3)Cl	PLASMA										?	ng × h/mL	21857		ng/mL	1406			UNKNOWN	mg	150		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8739025/	Homo sapiens		h	14				10			false
5795	2744		ADULT	188850	356.8	3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)pyrazol-3-yl]propanoic Acid		COC1=CC=C(C=C1)N2C(=CC(=N2)CCC(=O)O)C3=CC=C(C=C3)Cl	PLASMA										?	ng × h/mL	24896		ng/mL	1344			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8739025/	Homo sapiens							10			false
5796	2770		UNKNOWN	155815	380.3939	VARESPLADIB	CCC1=C(C(=O)C(N)=O)C2=C(C=CC=C2OCC(O)=O)N1CC3=CC=CC=C3	CCC1=C(C(=O)C(N)=O)C2=C(C=CC=C2OCC(O)=O)N1CC3=CC=CC=C3	PLASMA	2Q3P98DATH									∞	ng × h/mL	755.3		ng/mL	163.6			UNKNOWN	mg	50		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/11145235	Homo sapiens										false
5797	2770		UNKNOWN	155815	380.3939	VARESPLADIB	CCC1=C(C(=O)C(N)=O)C2=C(C=CC=C2OCC(O)=O)N1CC3=CC=CC=C3	CCC1=C(C(=O)C(N)=O)C2=C(C=CC=C2OCC(O)=O)N1CC3=CC=CC=C3	UNKNOWN	2Q3P98DATH																	UNKNOWN				SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	REVIEW	https://www.ncbi.nlm.nih.gov/pubmed/11311112	Homo sapiens		h	5							false
5798	2772		ADULT	3276	214.1787	ETANIDAZOLE	ETANIDAZOLE	OCCNC(=O)CN1C=CN=C1[N ]([O-])=O	SERUM	30DKA3Q1HL									?	mM × h	2.55						UNKNOWN	g/m²	4		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1826961	Homo sapiens							110	ETANIDAZOLE		false
5799	2772		ADULT	3276	214.1787	ETANIDAZOLE	ETANIDAZOLE	OCCNC(=O)CN1C=CN=C1[N ]([O-])=O	PLASMA	30DKA3Q1HL													μg/mL	287			UNKNOWN	g/m²	2		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2522918	Homo sapiens		h	5.8				6	ETANIDAZOLE		false
5800	2773		ADULT	177358	376.1	PICOPLATIN	PICOPLATIN	CC1=CC=CC=[N]1[Pt](N)(Cl)Cl	PLASMA	B5TAN0L720									∞	μg × h/L	12000		μg/mL	7530			RECOMMENDED	mg/m²	120		STEADY-STATE	UNKNOWN		3 weeks	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/12645906	Homo sapiens		h	0.83							false
5801	2773		ADULT	177358	376.1	PICOPLATIN	PICOPLATIN	CC1=CC=CC=[N]1[Pt](N)(Cl)Cl	PLASMA	B5TAN0L720									∞	μg × h/L	13078		μg/L	3250			RECOMMENDED	mg/m²	120		STEADY-STATE	UNKNOWN		3 weeks	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/12671715	Homo sapiens		h	85.7							false
5802	2775		ADULT	60511	268.3535	REMACEMIDE	Remacemide	CC(CC1=CC=CC=C1)(NC(=O)CN)C2=CC=CC=C2	PLASMA	EH6763C1IC									?	ng × h/mL	1288		ng/mL	458			UNKNOWN	mg	600		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12160664	Homo sapiens				On day 1 they received a total of 450 mg calculated as remacemide free base. On subsequent days they received four doses of 150 mg following the same dosing schedule, to provide a total daily dose of 600 mg remacemide hydrochloride			29	Remacemide		false
5803	2775		ADULT	164087	211.3	AR-R12495	AR-R12495	CC(CC1=CC=CC=C1)(C2=CC=CC=C2)N	PLASMA										?	ng × h/mL	439.5		ng/mL	86.8			UNKNOWN	mg	600		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12160664	Homo sapiens				On day 1 they received a total of 450 mg calculated as remacemide free base. On subsequent days they received four doses of 150 mg following the same dosing schedule, to provide a total daily dose of 600 mg remacemide hydrochloride			29	Remacemide		false
5804	2776		ADULT	3455	450.6	VANOXERINE	VANOXERINE	FC1=CC=C(C=C1)C(OCCN2CCN(CCCC3=CC=CC=C3)CC2)C4=CC=C(F)C=C4	PLASMA	90X28IKH43									?	nM × h	365		nM	81.1			UNKNOWN	mg	75		STEADY-STATE	FED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/8289134	Homo sapiens		h	53.5							false
5805	2779		ADULT	65970	333.3075	ANDOLAST	ANDOLAST	O=C(NC1=CC=C(C=C1)C2=NN=NN2)C3=CC=C(C=C3)C4=NN=NN4	PLASMA	6513M33209									?	ng × min/mL	9626		ng/mL	30.5			UNKNOWN	mg	8		SINGLE	FASTED						UNHEALTHY	Respiratory	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11745909	Homo sapiens		h	4.6				12	ANDOLAST		false
5806	2780		ADULT	5813717	288.3	APAZIQUONE	APAZIQUONE	CN1C(\\C=C\\CO)=C(CO)C2=C1C(=O)C=C(N3CC3)C2=O	PLASMA	H464ZO600O									∞	μg × min/mL	8.1		ng/mL	1418			MAX TOLERATED	mg/m²	27		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/8196081	Homo sapiens		min	7.8							false
5807	2782		ADULT	57030	375.3675	BREQUINAR	BREQUINAR	CC1=C(N=C2C=CC(F)=CC2=C1C(O)=O)C3=CC=C(C=C3)C4=C(F)C=CC=C4	PLASMA	5XL19F49H6									?	mg × h/mL	9653.7		ng/mL	4046			UNKNOWN	mg/m²	330		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15831236	Homo sapiens		h	0.6				7	BREQUINAR		false
5808	2785		ADULT	213040	481.6	DOFEQUIDAR	DOFEQUIDAR	OC(COC1=C2C=CC=NC2=CC=C1)CN3CCN(CC3)C(=O)C(C4=CC=CC=C4)C5=CC=CC=C5	PLASMA	0BJK6B565B									?	μg × h/mL	11		μg/mL	3.04			UNKNOWN	mg	600		MULTIPLE	UNKNOWN		3 weeks	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/16144929	Homo sapiens		h	3.4							false
5809	2787		ADULT	6917908	467.4778	EDATREXATE	EDATREXATE	CCC(CC1=NC2=C(N=C1)N=C(N)N=C2N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O	PLASMA	JT4X6Z1HRR	6006|5282144|135403648	473.4393	LEUCOVORIN	leucovorin	NC1=NC(=O)C2=C(NCC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1	Q573I9DVLP			?	ng × h/mL	39702		ng/mL	13272			UNKNOWN	mg/m²	1080		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9816135	Homo sapiens		h	4.1	2-h infusion, once a week for 3 weeks, recycled every 28 days, day 8		10 mg/m2, every 6 h for 10 doses	1	EDATREXATE		true
5810	2791		ADULT	54677946|152743265	356.803	LAQUINIMOD	Laquinimod	CCN(C(=O)C1=C(O)C2=C(C=CC=C2Cl)N(C)C1=O)C3=CC=CC=C3	PLASMA	908SY76S4G									?	ng × h/mL	6996		ng/mL	376			UNKNOWN	mg	0.5		MULTIPLE			day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://academic.oup.com/ecco-jcc/article/8/Supplement_1/S226/369200?login=true	Homo sapiens				Week 4,  A loading dose regimen of twice the intended daily dose was given during the first two days of study drug treatment.	active moderate-to-severe Crohn's disease patients					false
5811	2791		ADULT	54677946|152743265	356.803	LAQUINIMOD	Laquinimod	CCN(C(=O)C1=C(O)C2=C(C=CC=C2Cl)N(C)C1=O)C3=CC=CC=C3	PLASMA	908SY76S4G									?	ng × h/mL	17552		ng/mL	885			UNKNOWN	mg	1.5		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://academic.oup.com/ecco-jcc/article/8/Supplement_1/S226/369200?login=true	Homo sapiens				Week 4,  A loading dose regimen of twice the intended daily dose was given during the first two days of study drug treatment.	active moderate-to-severe Crohn's disease patients		7			false
5812	2791		ADULT	54677946|152743265	356.803	LAQUINIMOD	Laquinimod	CCN(C(=O)C1=C(O)C2=C(C=CC=C2Cl)N(C)C1=O)C3=CC=CC=C3	PLASMA	908SY76S4G									?	ng × h/mL	28883		ng/mL	1447			UNKNOWN	mg	2		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://academic.oup.com/ecco-jcc/article/8/Supplement_1/S226/369200?login=true	Homo sapiens				Week 4,  A loading dose regimen of twice the intended daily dose was given during the first two days of study drug treatment.	active moderate-to-severe Crohn's disease patients		4			false
5813	2791		ADULT	54677946|152743265	356.803	LAQUINIMOD	Laquinimod	CCN(C(=O)C1=C(O)C2=C(C=CC=C2Cl)N(C)C1=O)C3=CC=CC=C3	PLASMA	908SY76S4G							24		t	ng × h/mL	7559		ng/mL	380.4			UNKNOWN	mg	0.6		SINGLE	FASTED				t1/2=80~90h		HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29786964/	Homo sapiens		h	90				47			false
5814	2791		ADULT	54677946|152743265	356.803	LAQUINIMOD	Laquinimod	CCN(C(=O)C1=C(O)C2=C(C=CC=C2Cl)N(C)C1=O)C3=CC=CC=C3	PLASMA	908SY76S4G							24		t	ng × h/mL	14872		ng/mL	749.1			UNKNOWN	mg	1.2		SINGLE	FASTED				t1/2=80~90h		HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29786964/	Homo sapiens		h	90				49			false
5815	2791			54677946|152743265	356.803	LAQUINIMOD	Laquinimod	CCN(C(=O)C1=C(O)C2=C(C=CC=C2Cl)N(C)C1=O)C3=CC=CC=C3	PLASMA	908SY76S4G																										Human plasma protein binding: >98%	2				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29786964/	Homo sapiens										false
5816	2791		ADULT	54677946|152743265	356.803	LAQUINIMOD	Laquinimod	CCN(C(=O)C1=C(O)C2=C(C=CC=C2Cl)N(C)C1=O)C3=CC=CC=C3	PLASMA	908SY76S4G	135398735	822.9402	RIFAMPIN	Rifampicin	CO[C@H]1\\C=C\\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)C(C)=C\\C=C\\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(\\C=N\\N5CCN(C)CC5)=C(O)C4=C3C2=O	VJT6J7R4TR			∞	ng × h/mL	1497.9		ng/mL	123.1			UNKNOWN	mg	0.6		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32237115/	Homo sapiens		h	11.2			600mg qd, Days -9 to 12	14			true
5817	2791		ADULT	54677946|152743265	356.803	LAQUINIMOD	Laquinimod	CCN(C(=O)C1=C(O)C2=C(C=CC=C2Cl)N(C)C1=O)C3=CC=CC=C3	PLASMA	908SY76S4G									∞	ng × h/mL	7140.6		ng/mL	107			UNKNOWN	mg	0.6		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32237115/	Homo sapiens		h	75.3				14			false
5818	2791		ADULT	54677946|152743265	356.803	LAQUINIMOD	Laquinimod	CCN(C(=O)C1=C(O)C2=C(C=CC=C2Cl)N(C)C1=O)C3=CC=CC=C3	PLASMA	908SY76S4G	47576	531.431	KETOCONAZOLE	Ketoconazole	CC(=O)N1CCN(CC1)C2=CC=C(OC[C@@H]3CO[C@](CN4C=CN=C4)(O3)C5=C(Cl)C=C(Cl)C=C5)C=C2	R9400W927I			∞	ng × h/mL	21694		ng/mL	99.5			UNKNOWN	mg	0.6		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32237115/	Homo sapiens		h	209			400mg qd, Days -1 to 21	14			true
5819	2791		ADULT	54677946|152743265	356.803	LAQUINIMOD	Laquinimod	CCN(C(=O)C1=C(O)C2=C(C=CC=C2Cl)N(C)C1=O)C3=CC=CC=C3	PLASMA	908SY76S4G									∞	ng × h/mL	7368.1		ng/mL	115			UNKNOWN	mg	0.6		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32237115/	Homo sapiens		h	71.8				14			false
5820	2794		ADULT	114709	254.2839	LICARBAZEPINE	LICARBAZEPINE	NC(=O)N1C2=CC=CC=C2CC(O)C3=C1C=CC=C3	PLASMA	XFX1A5KJ3V									∞	μM × h	503		μM	30.7			UNKNOWN	mg	500		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18258749/	Homo sapiens		h	9.3				24	LICARBAZEPINE		false
5821	2794		ADULT	114709	254.2839	LICARBAZEPINE	LICARBAZEPINE	NC(=O)N1C2=CC=CC=C2CC(O)C3=C1C=CC=C3	PLASMA	XFX1A5KJ3V									?	μM × h	747		μM	77.6			UNKNOWN	mg	500		STEADY-STATE	FASTED		day	3			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18258749/	Homo sapiens		h	11.3				24	LICARBAZEPINE		false
5822	2794		UNKNOWN	114709	254.2839	LICARBAZEPINE	LICARBAZEPINE	NC(=O)N1C2=CC=CC=C2CC(O)C3=C1C=CC=C3	PLASMA	XFX1A5KJ3V																						UNKNOWN				extent of binding of licarbazepine enantiomers to total plasma proteins was 30% and independent of the drug concentration (10, 25 and 50 ug/mL) and species considered (mouse or human)	70	HEALTHY		UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20578208/	Homo sapiens								LICARBAZEPINE		false
5823	2796		ADULT	80274	428.5246	LOTRAFIBAN	LOTRAFIBAN	CN1CC2=C(N[C@@H](CC(O)=O)C1=O)C=CC(=C2)C(=O)N3CCC(CC3)C4CCNCC4	PLASMA	KLQ306I83X							24		t	ng × h/mL	835						MAX DAILY	mg	100		MULTIPLE	UNKNOWN		day	2	Lotrafiban has an estimated bioavailability of approximately 2%, which may account for its high pharmacokinetic variability.	2	UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11309549	Homo sapiens							28	LOTRAFIBAN		false
5824	2801		ADULT	5745207	302.3434	PRIRALFINAMIDE	priralfinamide	C[C@H](NCC1=CC=C(OCC2=C(F)C=CC=C2)C=C1)C(N)=O	PLASMA	3LPF0S0GVV									∞	mg × h/L	41.3		μg/mL	3.28			MAX TOLERATED	mg	320		SINGLE	FASTED				Saliva/plasma ratio: 0.10 at 8 h, 0.03 at 48 h	10	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21071997/	Homo sapiens		h	14.7				6	PRIRALFINAMIDE METHANESULFONATE, [14C]-		false
5825	2804		ADULT	183092	329.3968	SUNEPITRON	CP-93393	O=C1CCC(=O)N1C[C@H]2CC[C@H]3CN(CCN3C2)C4=NC=CC=N4	PLASMA	2GT50C8U60									∞	ng × h/mL	87.33		ng/mL	10.92			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9571226/	Homo sapiens		h	4.1		Poor metabolizers		2	CP-93393, [14C]-		false
5826	2804		ADULT	183092	329.3968	SUNEPITRON	CP-93393	O=C1CCC(=O)N1C[C@H]2CC[C@H]3CN(CCN3C2)C4=NC=CC=N4	PLASMA	2GT50C8U60									∞	ng × h/mL	2.36		ng/mL	1.02			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9571226/	Homo sapiens		h	0.9		Extensive metabolizers		4	CP-93,393, [14C]-		false
5827	2806		ADULT	457954	260.267	TIAZOFURIN	Tiazofurin	NC(=O)C1=CSC(=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O	PLASMA	ULJ82834RE									?	μM × h	6214		μM	1330			UNKNOWN	mg/m²	5500		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1568787/	Homo sapiens		h	6.07	1-h infusion	Patients with solid tumors		1			false
5828	2806		ADULT	457954	260.267	TIAZOFURIN	Tiazofurin	NC(=O)C1=CSC(=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O	PLASMA	ULJ82834RE									?	μM × h	7013		μM	1586			UNKNOWN	mg/m²	6600		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1568787/	Homo sapiens		h	5.78	1-h infusion	Patients with solid tumors		1			false
5829	2806		ADULT	457954	260.267	TIAZOFURIN	Tiazofurin	NC(=O)C1=CSC(=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O	PLASMA	ULJ82834RE									?	μM × h	1002		μM	244.6			UNKNOWN	mg/m²	1100		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1568787/	Homo sapiens		h	5.23	1-h infusion	Patients with solid tumors		1			false
5830	2806		ADULT	457954	260.267	TIAZOFURIN	Tiazofurin	NC(=O)C1=CSC(=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O	PLASMA	ULJ82834RE									?	μM × h	2671		μM	441.4			UNKNOWN	mg/m²	2200		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1568787/	Homo sapiens		h	6.23	1-h infusion	Patients with solid tumors		11			false
5831	2806		ADULT	457954	260.267	TIAZOFURIN	Tiazofurin	NC(=O)C1=CSC(=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O	PLASMA	ULJ82834RE									?	μM × h	4267		μM	735.5			UNKNOWN	mg/m²	3300		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1568787/	Homo sapiens		h	6.57	1-h infusion	Patients with solid tumors		7			false
5832	2806		ADULT	457954	260.267	TIAZOFURIN	Tiazofurin	NC(=O)C1=CSC(=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O	PLASMA	ULJ82834RE									?	μM × h	4451		μM	903.6			UNKNOWN	mg/m²	4400		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1568787/	Homo sapiens		h	5.98	1-h infusion	Patients with solid tumors		2			false
5833	2806		ADULT	457954	260.267	TIAZOFURIN	Tiazofurin	NC(=O)C1=CSC(=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O	PLASMA	ULJ82834RE							24		t	mg × h/L	1044		μg/mL	8.49			UNKNOWN	mg/m²	720		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3986812/	Homo sapiens		h	7.7		Patients with advanced cancer		5			false
5834	2806		ADULT	457954	260.267	TIAZOFURIN	Tiazofurin	NC(=O)C1=CSC(=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O	PLASMA	ULJ82834RE							24		t	mg × h/L	1366		μg/mL	11.4			UNKNOWN	mg/m²	900		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3986812/	Homo sapiens		h	11.7		Patients with advanced cancer		2			false
5835	2806		ADULT	457954	260.267	TIAZOFURIN	Tiazofurin	NC(=O)C1=CSC(=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O	PLASMA	ULJ82834RE							24		t	mg × h/L	1915		μg/mL	16			UNKNOWN	mg/m²	1800		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3986812/	Homo sapiens		h	7		Patients with advanced cancer		2			false
5836	2807		ADULT	135413511	178.15	TIRAPAZAMINE	TIRAPAZAMINE	NC1=[N+]([O-])C2=CC=CC=C2[N+]([O-])=N1	PLASMA	1UD32YR59G									?	μg × min/mL	1409.8		μg/mL	7.118			MAX TOLERATED	mg/m²	390		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/9137522	Homo sapiens		min	56.3							false
5837	2808		ADULT	5281884	1214.6	VALSPODAR	VALSPODAR	C\\C=C\\C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@@H](NC1=O)C(C)C)C(C)C	BLOOD	Q7ZP55KF3X	31703		Doxorubicin	Doxorubicin	CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O	80168379AG	48		t	μg × h/mL	58.2		ng/mL	2495			UNKNOWN	mg/kg	8		STEADY-STATE	UNKNOWN		3 weeks	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/11223552	Homo sapiens										true
5838	2808		ADULT	5281884	1214.6	VALSPODAR	VALSPODAR	C\\C=C\\C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@@H](NC1=O)C(C)C)C(C)C	PLASMA	Q7ZP55KF3X									∞	μg × h/mL	19.8		μg/mL	2.3			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/9855321	Homo sapiens		h	24.7							false
5839	2815		ADULT	6918305	332.52	GANAXOLONE	ganaxolone	CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@](C)(O)CC[C@]4(C)[C@H]3CC[C@]12C	PLASMA	98WI44OHIQ									∞	ng × h/mL	668		ng/mL	130			UNKNOWN	mg	500		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11232855	Homo sapiens		h	6.1					ganaxolone		false
5840	2815		ADULT	6918305	332.52	GANAXOLONE	ganaxolone	CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@](C)(O)CC[C@]4(C)[C@H]3CC[C@]12C	PLASMA	98WI44OHIQ									∞	ng × h/mL	235.53		ng/mL	32.34			UNKNOWN	mg	50		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9579942	Homo sapiens							5	ganaxolone		false
5841	2815		ADULT	6918305	332.52	GANAXOLONE	ganaxolone	CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@](C)(O)CC[C@]4(C)[C@H]3CC[C@]12C	PLASMA	98WI44OHIQ									∞	ng × h/mL	1093.13		ng/mL	106.23			UNKNOWN	mg	200		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9579942	Homo sapiens		h	65.1				4	ganaxolone		false
5842	2815		ADULT	6918305	332.52	GANAXOLONE	ganaxolone	CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@](C)(O)CC[C@]4(C)[C@H]3CC[C@]12C	PLASMA	98WI44OHIQ									∞	ng × h/mL	3103.04		ng/mL	376.03			MAX DAILY	mg	500		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9579942	Homo sapiens		h	37.7				4	ganaxolone		false
5843	2818		ADULT	159594	510.6218	ATRASENTAN	atrasentan	CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1C2=CC=C(OC)C=C2)C(O)=O)C3=CC4=C(OCO4)C=C3	PLASMA	V6D7VK2215							24		t	ng × h/mL	5354		ng/mL	544			UNKNOWN	mg	45		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15240529	Homo sapiens		h	30				5	atrasentan		false
5844	2818		ADULT	159594	510.6218	ATRASENTAN	atrasentan	CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1C2=CC=C(OC)C=C2)C(O)=O)C3=CC4=C(OCO4)C=C3	PLASMA	V6D7VK2215							24		t	ng × h/mL	1591		ng/mL	358			UNKNOWN	mg	20		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15240529	Homo sapiens		h	40.9				4	atrasentan		false
5845	2818		ADULT	159594	510.6218	ATRASENTAN	atrasentan	CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1C2=CC=C(OC)C=C2)C(O)=O)C3=CC4=C(OCO4)C=C3	PLASMA	V6D7VK2215									∞	ng × h/mL	536		ng/mL	62			UNKNOWN	mg	10		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15240529	Homo sapiens		h	23.2				3	atrasentan		false
5846	2818		ADULT	159594	510.6218	ATRASENTAN	atrasentan	CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1C2=CC=C(OC)C=C2)C(O)=O)C3=CC4=C(OCO4)C=C3	PLASMA	V6D7VK2215							24		t	ng × h/mL	2338		ng/mL	489			UNKNOWN	mg	75		MULTIPLE	UNKNOWN		day	1	atrasentan is 98.8% bound to plasma proteins	1.2	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15240529	Homo sapiens		h	36.1				9	atrasentan		false
5847	2818		ADULT	159594	510.6218	ATRASENTAN	atrasentan	CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1C2=CC=C(OC)C=C2)C(O)=O)C3=CC4=C(OCO4)C=C3	PLASMA	V6D7VK2215							24		t	ng × h/mL	1492		ng/mL	242			UNKNOWN	mg	30		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15240529	Homo sapiens		h	32				3	atrasentan		false
5848	2818		ADULT	159594	510.6218	ATRASENTAN	atrasentan	CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1C2=CC=C(OC)C=C2)C(O)=O)C3=CC4=C(OCO4)C=C3	PLASMA	V6D7VK2215							24		t	ng × h/mL	3162		ng/mL	819			UNKNOWN	mg	60		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15240529	Homo sapiens		h	32.6				8	atrasentan		false
5849	2818		ADULT	159594	510.6218	ATRASENTAN	Atrasentan	CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1C2=CC=C(OC)C=C2)C(O)=O)C3=CC4=C(OCO4)C=C3	PLASMA	V6D7VK2215							24		t	ng × h/mL	580		ng/mL	89			UNKNOWN	mg	5		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15240529	Homo sapiens		h	34.1				3	atrasentan		false
5850	2818		ADULT	159594	510.6218	ATRASENTAN	Atrasentan	CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1C2=CC=C(OC)C=C2)C(O)=O)C3=CC4=C(OCO4)C=C3	PLASMA	V6D7VK2215							6		t	ng × h/mL	0.71		ng/mL	0.28			UNKNOWN	mg	0.25		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21372210	Homo sapiens							20	Atrasentan		false
5851	2818		ADULT	159594	510.6218	ATRASENTAN	Atrasentan	CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1C2=CC=C(OC)C=C2)C(O)=O)C3=CC4=C(OCO4)C=C3	PLASMA	V6D7VK2215							6		t	ng × h/mL	5.31		ng/mL	1.72			UNKNOWN	mg	0.75		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21372210	Homo sapiens							23	Atrasentan		false
5852	2818		ADULT	159594	510.6218	ATRASENTAN	Atrasentan	CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1C2=CC=C(OC)C=C2)C(O)=O)C3=CC4=C(OCO4)C=C3	PLASMA	V6D7VK2215							6		t	ng × h/mL	13.07		ng/mL	4.12			UNKNOWN	mg	1.75		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21372210	Homo sapiens							21	Atrasentan		false
5853	2819			24768032	173.2542	BICIFADINE	bicifadine	CC1=CC=C(C=C1)[C@@]23C[C@@H]2CNC3	PLASMA	B0SV3N7J3H																										human plasma: 100 ng/mL, ultrafiltration method	2.2				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17991767/	Homo sapiens								BICIFADINE HIDROCHLORIDE, [14C]-		false
5854	2819		ADULT	24768032	173.2542	BICIFADINE	BICIFADINE	CC1=CC=C(C=C1)[C@@]23C[C@@H]2CNC3	PLASMA	B0SV3N7J3H									∞	ng × h/mL	34271		ng/mL	1780			UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17991768/	Homo sapiens		h	1.63				8	BICIFADINE HIDROCHLORIDE		false
5855	2820		ADULT	208951	385.4583	BIFEPRUNOX	bifeprunox	O=C1NC2=CC=CC(N3CCN(CC4=CC=CC(=C4)C5=CC=CC=C5)CC3)=C2O1	PLASMA	AP69E83Z79							24		t	ng × h/mL	381.5						UNKNOWN	mg	20		MULTIPLE	UNKNOWN		day	1	Bifeprunox was demonstrated to be highly bound to circulating plasma proteins (>99%) in both healthy adults and in patients with hepatic or renal impairment	1	HEALTHY	Oral	UNKNOWN	REVIEW	https://www.formularywatch.com/view/bifeprunox-partial-dopamine-receptor-agonist-treatment-schizophrenia	Homo sapiens								bifeprunox		false
5856	2820		ADULT	208951	385.4583	BIFEPRUNOX	bifeprunox	O=C1NC2=CC=CC(N3CCN(CC4=CC=CC(=C4)C5=CC=CC=C5)CC3)=C2O1	PLASMA	AP69E83Z79							24		t	ng × h/mL	825.1						UNKNOWN	mg	40		MULTIPLE	UNKNOWN		day	1	Bifeprunox was demonstrated to be highly bound to circulating plasma proteins (>99%) in both healthy adults and in patients with hepatic or renal impairment	1	HEALTHY	Oral	UNKNOWN	REVIEW	https://www.formularywatch.com/view/bifeprunox-partial-dopamine-receptor-agonist-treatment-schizophrenia	Homo sapiens								bifeprunox		false
5857	2822		ADULT	9939609	666.771	DARAPLADIB	DARAPLADIB	CCN(CC)CCN(CC1=CC=C(C=C1)C2=CC=C(C=C2)C(F)(F)F)C(=O)CN3C4=C(CCC4)C(=O)N=C3SCC5=CC=C(F)C=C5	PLASMA	UI1U1MYH09									∞	ng × h/mL	645		ng/mL	17.9			UNKNOWN	mg	160		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26465780	Homo sapiens		h	39.2				24	DARAPLADIB		false
5858	2822		ADULT	9939609	666.771	DARAPLADIB	DARAPLADIB	CCN(CC)CCN(CC1=CC=C(C=C1)C2=CC=C(C=C2)C(F)(F)F)C(=O)CN3C4=C(CCC4)C(=O)N=C3SCC5=CC=C(F)C=C5	PLASMA	UI1U1MYH09									?	ng × h/mL	519		ng/mL	34.4			UNKNOWN	mg	160		MULTIPLE	FED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26465780	Homo sapiens		h	116	day 28			24	DARAPLADIB		false
5859	2826		ADULT	66000	367.3984	FRADAFIBAN	fradafiban	NC(=N)C1=CC=C(C=C1)C2=CC=C(OC[C@@H]3C[C@@H](CC(O)=O)C(=O)N3)C=C2	PLASMA	DQ0H2B8YKN													ng/mL	394			UNKNOWN	mg	60		STEADY-STATE	UNKNOWN		day	3			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11250974	Homo sapiens							21	LEFRADAFIBAN		false
5860	2826		ADULT	66000	367.3984	FRADAFIBAN	fradafiban	NC(=N)C1=CC=C(C=C1)C2=CC=C(OC[C@@H]3C[C@@H](CC(O)=O)C(=O)N3)C=C2	PLASMA	DQ0H2B8YKN													ng/mL	158			UNKNOWN	mg	30		STEADY-STATE	UNKNOWN		day	3			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11250974	Homo sapiens							16	LEFRADAFIBAN		false
5861	2826		ADULT	66000	367.3984	FRADAFIBAN	fradafiban	NC(=N)C1=CC=C(C=C1)C2=CC=C(OC[C@@H]3C[C@@H](CC(O)=O)C(=O)N3)C=C2	PLASMA	DQ0H2B8YKN													ng/mL	314			UNKNOWN	mg	45		STEADY-STATE	UNKNOWN		day	3			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11250974	Homo sapiens							16	LEFRADAFIBAN		false
5862	2827		UNKNOWN	9829523	570.6371	MIDOSTAURIN	MIDOSTAURIN	CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N3C4=C(C=CC=C4)C5=C3C6=C(C7=C(C=CC=C7)N26)C8=C5CNC8=O)N(C)C(=O)C9=CC=CC=C9	PLASMA	ID912S5VON																						UNKNOWN				Midostaurin, CGP62221, and CGP52421 are greater than 99.8% bound to plasma protein in vitro.	0.2	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997s000lbl.pdf	Homo sapiens										false
5863	2827		UNKNOWN	9829523	570.2267	MIDOSTAURIN	MIDOSTAURIN	CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N3C4=C(C=CC=C4)C5=C3C6=C(C7=C(C=CC=C7)N26)C8=C5CNC8=O)N(C)C(=O)C9=CC=CC=C9	PLASMA	ID912S5VON									∞	ng × h/mL	15700		ng/mL	1210			UNKNOWN	mg	50		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.ema.europa.eu/en/documents/assessment-report/rydapt-epar-public-assessment-report_en.pdf	Homo sapiens		h	20							false
5864	2828		CHILD	54369	325.3651	PIRITREXIM	Piritrexim	COC1=CC(CC2=CN=C3N=C(N)N=C(N)C3=C2C)=C(OC)C=C1	PLASMA	MK2A783ZUT									?	μM × h	9.3		μM	2.3			UNKNOWN	mg/m²	10		MULTIPLE	FED		day	3			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1732038	Homo sapiens		h	2.2				4	Piritrexim		false
5865	2828		CHILD	54369	325.3651	PIRITREXIM	Piritrexim	COC1=CC(CC2=CN=C3N=C(N)N=C(N)C3=C2C)=C(OC)C=C1	PLASMA	MK2A783ZUT									?	μM × h	12.4		μM	3.3			UNKNOWN	mg/m²	20		MULTIPLE	FED		day	3			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1732038	Homo sapiens		h	2.1				3	Piritrexim		false
5866	2828		CHILD	54369	325.3651	PIRITREXIM	Piritrexim	COC1=CC(CC2=CN=C3N=C(N)N=C(N)C3=C2C)=C(OC)C=C1	PLASMA	MK2A783ZUT									?	μM × h	8		μM	2.3			UNKNOWN	mg/m²	15		MULTIPLE	FED		day	3			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1732038	Homo sapiens		h	2.3				4	Piritrexim		false
5867	2828		ADULT	54369	325.3651	PIRITREXIM	PIRITREXIM	COC1=CC(CC2=CN=C3N=C(N)N=C(N)C3=C2C)=C(OC)C=C1	PLASMA	MK2A783ZUT									?	μM × h	13.3		μM	3.3			UNKNOWN	mg/m²	25		MULTIPLE	FED		day	3			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1732038	Homo sapiens		h	2.11				4	PIRITREXIM		false
5868	2829		ADULT	128814	419.4697	RAGAGLITAZAR	RAGAGLITAZAR	CCO[C@H](CC1=CC=C(OCCN2C3=CC=CC=C3OC4=C2C=CC=C4)C=C1)C(O)=O	PLASMA	Q5ELR5A7Y5							24		t	mg × h/L	374		mg/L	25.1			UNKNOWN	mg	120		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/14551179	Homo sapiens		h	75				6	RAGAGLITAZAR		false
5869	2829		ADULT	128814	419.4697	RAGAGLITAZAR	RAGAGLITAZAR	CCO[C@H](CC1=CC=C(OCCN2C3=CC=CC=C3OC4=C2C=CC=C4)C=C1)C(O)=O	PLASMA	Q5ELR5A7Y5							24		t	mg × h/L	211		mg/L	10.9			UNKNOWN	mg	16		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/14551179	Homo sapiens		h	91	7 days			6	RAGAGLITAZAR		false
5870	2830		ADULT	5362391	366.3344	RIDOGREL	RIDOGREL	OC(=O)CCCCO\\N=C(\\C1=CN=CC=C1)C2=CC=CC(=C2)C(F)(F)F	PLASMA	QTS5QOO42O									?	μg × h/mL	57.2		μg/mL	11.1			UNKNOWN	mg	300		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.gastrojournal.org/article/0016-5085(95)28039-1/fulltext	Homo sapiens		h	5.1				12	RIDOGREL		false
5871	2831		ADULT	60919	411.4591	TASOSARTAN	Tasosartan	CC1=NC2=C(CCC(=O)N2CC3=CC=C(C=C3)C4=C(C=CC=C4)C5=NN=NN5)C(C)=N1	PLASMA	48G92V856H							24		t	ng × h/mL	1190.4		ng/mL	874.1			UNKNOWN	mg	50		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10709151/	Homo sapiens				Day 10	Patients with stage 1 and 2 essential hypertension		16			false
5872	2831		ADULT	60919	411.4591	TASOSARTAN	Tasosartan	CC1=NC2=C(CCC(=O)N2CC3=CC=C(C=C3)C4=C(C=CC=C4)C5=NN=NN5)C(C)=N1	PLASMA	48G92V856H													ng/mL	1596			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11046101/	Homo sapiens		h	5.3				12			false
5873	2831		ADULT	60919	411.4591	TASOSARTAN	Tasosartan	CC1=NC2=C(CCC(=O)N2CC3=CC=C(C=C3)C4=C(C=CC=C4)C5=NN=NN5)C(C)=N1	PLASMA	48G92V856H																	UNKNOWN	mg	50		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11046101/	Homo sapiens		h	5.2				12			false
5874	2831		UNKNOWN	60919	411.4591	TASOSARTAN	Tasosartan	CC1=NC2=C(CCC(=O)N2CC3=CC=C(C=C3)C4=C(C=CC=C4)C5=NN=NN5)C(C)=N1	UNKNOWN	48G92V856H																						UNKNOWN				t1/2=3~7 h		UNKNOWN		UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/9438775/	Homo sapiens		h	7							false
5875	2835		ADULT	135412795	296.387	BENTAZEPAM	BENTAZEPAM	O=C1CN=C(C2=C(N1)SC3=C2CCCC3)C4=CC=CC=C4	PLASMA	66JKK43S1Z													ng/mL	386			UNKNOWN	mg	25		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2877954/	Homo sapiens		h	3.34				10	BENTAZEPAM		false
5876	2835		ADULT	135412795	296.387	BENTAZEPAM	BENTAZEPAM	O=C1CN=C(C2=C(N1)SC3=C2CCCC3)C4=CC=CC=C4	PLASMA	66JKK43S1Z													ng/mL	313.2			UNKNOWN	mg	25		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2893777/	Homo sapiens							10	BENTAZEPAM		false
5877	2836		ADULT	31593	260.25	Benznidazole		C1=CC=C(C=C1)CNC(=O)CN2C=CN=C2[N+](=O)[O-]	PLASMA	YC42NRJ1ZD									∞	μg × h/mL	48.4		μg/mL	2.2			INVESTIGATIONAL	mg	100		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28167552/	Homo sapiens		h	12.1							false
5878	2836		ADULT	31593	260.25	Benznidazole		C1=CC=C(C=C1)CNC(=O)CN2C=CN=C2[N+](=O)[O-]	PLASMA	YC42NRJ1ZD													μg/mL	12.54			INVESTIGATIONAL	mg/kg	3.5		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6783051/	Homo sapiens		h	13.75							false
5879	2836		ADULT	31593	260.25	Benznidazole		C1=CC=C(C=C1)CNC(=O)CN2C=CN=C2[N+](=O)[O-]	SERUM	YC42NRJ1ZD							12		t	mg × h/L	43.5		mg/L	2.4			INVESTIGATIONAL	mg	100		SINGLE	FASTED					48	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209570lbl.pdf	Homo sapiens		h	13							false
5880	2837		UNKNOWN	446727	333.135	BRIVUDINE	BRIVUDINE	OC[C@H]1O[C@H](C[C@@H]1O)N2C=C(\\C=C\\Br)C(=O)NC2=O	PLASMA	2M3055079H																	UNKNOWN	mg	250		SINGLE	FASTED						UNKNOWN	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10348194/	Homo sapiens		h	20				1			false
5881	2837			446727	333.135	BRIVUDINE	BRIVUDINE	OC[C@H]1O[C@H](C[C@@H]1O)N2C=C(\\C=C\\Br)C(=O)NC2=O	PLASMA	2M3055079H																											5				REVIEW	https://pubmed.ncbi.nlm.nih.gov/12861349/	Homo sapiens										false
5882	2837		ADULT	446727	333.135	BRIVUDINE	BRIVUDINE	OC[C@H]1O[C@H](C[C@@H]1O)N2C=C(\\C=C\\Br)C(=O)NC2=O	SERUM	2M3055079H													μg/mL	1.8			UNKNOWN	mg	250		SINGLE							HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3035076/	Homo sapiens							3			false
5883	2838		ADULT	2467	307.3847	BUFLOMEDIL	BUFLOMEDIL	COC1=CC(OC)=C(C(=O)CCCN2CCCC2)C(OC)=C1	SERUM	V7I71DQ432									∞	mg × h/L	2.32						UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7286057/	Homo sapiens		h	3.29				8	BUFLOMEDIL HYDROCHLORIDE		false
5884	2838		ADULT	2467	307.3847	BUFLOMEDIL	BUFLOMEDIL	COC1=CC(OC)=C(C(=O)CCCN2CCCC2)C(OC)=C1	SERUM	V7I71DQ432									∞	mg × h/L	9.26						HIGHEST STUDIED	mg	200		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7286057/	Homo sapiens		h	3.39				8	BUFLOMEDIL HYDROCHLORIDE		false
5885	2838		ADULT	2467	307.3847	BUFLOMEDIL	BUFLOMEDIL	COC1=CC(OC)=C(C(=O)CCCN2CCCC2)C(OC)=C1	SERUM	V7I71DQ432									∞	mg × h/L	4.52						UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7286057/	Homo sapiens		h	3.07				8	BUFLOMEDIL HYDROCHLORIDE		false
5886	2839		ADULT	7012	164.2011	2-PHENYLBUTYRIC ACID	2-phenylbutyric acid	CCC(C(O)=O)C1=CC=CC=C1	PLASMA	S7S079H2C2							24		t	ng × h/mL	14728.949		ng/mL	932.421			UNKNOWN	mg	22.5		SINGLE	UNKNOWN		UNKNOWN	0			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24995954/	Homo sapiens										false
5887	2839		ADULT	7012	164.2011	2-PHENYLBUTYRIC ACID	2-phenylbutyric acid	CCC(C(O)=O)C1=CC=CC=C1	PLASMA	S7S079H2C2							24		t	ng × h/mL	52592.188		ng/mL	3357.437			UNKNOWN	mg	90		SINGLE	UNKNOWN		UNKNOWN				HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24995954/	Homo sapiens										false
5888	2839		ADULT	7012	164.2011	2-PHENYLBUTYRIC ACID	2-phenylbutyric acid	CCC(C(O)=O)C1=CC=CC=C1	PLASMA	S7S079H2C2							24		t	ng × h/mL	39843.405		ng/mL	2624.067			UNKNOWN	mg	67.5		SINGLE	UNKNOWN		UNKNOWN	4			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24995954/	Homo sapiens										false
5889	2839		ADULT	7012	164.2011	2-PHENYLBUTYRIC ACID	2-phenylbutyric acid	CCC(C(O)=O)C1=CC=CC=C1	PLASMA	S7S079H2C2							24		t	ng × h/mL	24864.77		ng/mL	1680.594			UNKNOWN	mg	45		SINGLE	UNKNOWN		UNKNOWN				HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24995954/	Homo sapiens										false
5890	2839		UNKNOWN	7012	164.2011	2-PHENYLBUTYRIC ACID	2-phenylbutyric acid	CCC(C(O)=O)C1=CC=CC=C1	PLASMA	S7S079H2C2									∞	μg × h/mL	49.6		μg/mL	1.77			UNKNOWN	mg	45		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9089001/	Homo sapiens		h	28							false
5891	2843			50942	266.2533	DOXOFYLLINE	Doxofylline	CN1C2=C(N(CC3OCCO3)C=N2)C(=O)N(C)C1=O	PLASMA	MPM23GMO7Z																										Human plasma protein binding: 92.60% (50mcg/mL), 92.13% (200mcg/mL), 91.43% (400mcg/mL); equilibrium dialysis	7.4				EXPERIMENT	http://wprim.whocc.org.cn/admin/article/articleDetail?WPRIMID=557546&articleId=557546	Homo sapiens										false
5892	2843		ADULT	50942	266.2533	DOXOFYLLINE	Doxofylline	CN1C2=C(N(CC3OCCO3)C=N2)C(=O)N(C)C1=O	SERUM	MPM23GMO7Z									∞	ng × h/mL	4814		ng/mL	1687			UNKNOWN	mg	400		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18254143/	Homo sapiens		h	3.32				12			false
5893	2843		ADULT	50942	266.2533	DOXOFYLLINE	Doxofylline	CN1C2=C(N(CC3OCCO3)C=N2)C(=O)N(C)C1=O	PLASMA	MPM23GMO7Z									∞	μg × h/mL	1.76		μg/mL	1.7			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31181483/	Homo sapiens		h	1				12			false
5894	2844		UNKNOWN	35802	313.2832	FLUBENDAZOLE	FLUBENDAZOLE	COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=C(F)C=C3	UNKNOWN	R8M46911LR													ng/mL	0.35			UNKNOWN	mg	100		SINGLE	FASTED						UNKNOWN	Oral	UNKNOWN	OTHER	https://www.ema.europa.eu/en/documents/mrl-report/flubendazole-summary-report-2-committee-veterinary-medicinal-products_en.pdf	Homo sapiens					Population size is unknown			FLUBENDAZOLE		false
5895	2844		UNKNOWN	35802	313.2832	FLUBENDAZOLE	FLUBENDAZOLE	COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=C(F)C=C3	UNKNOWN	R8M46911LR													ng/mL	0.74			UNKNOWN	mg	2000		SINGLE	FASTED						UNKNOWN	Oral	UNKNOWN	OTHER	https://www.ema.europa.eu/en/documents/mrl-report/flubendazole-summary-report-2-committee-veterinary-medicinal-products_en.pdf	Homo sapiens					Population size is unknown			FLUBENDAZOLE		false
5896	2844		UNKNOWN	35802	313.2832	FLUBENDAZOLE	FLUBENDAZOLE	COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=C(F)C=C3	UNKNOWN	R8M46911LR													ng/mL	4.06			UNKNOWN	mg	2000		SINGLE	FED						UNKNOWN	Oral	UNKNOWN	OTHER	https://www.ema.europa.eu/en/documents/mrl-report/flubendazole-summary-report-2-committee-veterinary-medicinal-products_en.pdf	Homo sapiens					Population size is unknown			FLUBENDAZOLE		false
5897	2846		ADULT	11273	302.4079	FORMESTANE	formestane	C[C@]12CC[C@H]3[C@@H](CCC4=C(O)C(=O)CC[C@]34C)[C@@H]1CCC2=O	PLASMA	PUB9T8T355									∞	nM × h	5055		nM	48			UNKNOWN	mg	250		SINGLE	UNKNOWN						UNHEALTHY	Intramuscular	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11358673/	Homo sapiens					62 - 78 yo; breast cancer diagnosed between 1.5 and 17.5 yr before entry in the trial.		7			false
5898	2846			11273	302.4079	FORMESTANE	formestane	C[C@]12CC[C@H]3[C@@H](CCC4=C(O)C(=O)CC[C@]34C)[C@@H]1CCC2=O	PLASMA	PUB9T8T355																										At therapeutically effective concentrations, 82 to 86% of a dose of formestane is bound to plasma proteins.	16				REVIEW	https://pubmed.ncbi.nlm.nih.gov/7680986/	Homo sapiens										false
5899	2846		ADULT	11273	302.4079	FORMESTANE	formestane	C[C@]12CC[C@H]3[C@@H](CCC4=C(O)C(=O)CC[C@]34C)[C@@H]1CCC2=O	PLASMA	PUB9T8T355							336		t	ng × h/mL	978.3		ng/mL	13.5			UNKNOWN	mg	250		SINGLE	UNKNOWN				t1/2 refers to half-life at gamma phase.		HEALTHY	Intramuscular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9831486/	Homo sapiens		h	85.66	Particle size 8.0 μm formulation			6			false
5900	2846		ADULT	11273	302.4079	FORMESTANE	formestane	C[C@]12CC[C@H]3[C@@H](CCC4=C(O)C(=O)CC[C@]34C)[C@@H]1CCC2=O	PLASMA	PUB9T8T355							336		t	ng × h/mL	1135.2		ng/mL	22			UNKNOWN	mg	250		SINGLE	UNKNOWN				t1/2 refers to half-life at gamma phase.		HEALTHY	Intramuscular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9831486/	Homo sapiens		h	57.33	Particle size 4.2 μm formulation			6			false
5901	2847		ADULT	3418	218.1006	FOSFOSAL	fosfosal	OC(=O)C1=C(OP(O)(O)=O)C=CC=C1	PLASMA	124X2V25W4													μg/mL	276			UNKNOWN	mg	2400		STEADY-STATE	UNKNOWN		day	3			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3264273	Homo sapiens							6	fosfosal		false
5902	2848		ADULT	1550874	191.2264	IDROCILAMIDE	IDROCILAMIDE	OCCNC(=O)C=CC1=CC=CC=C1	SERUM	6C816LUB1O																	UNKNOWN	mg	400		SINGLE	UNKNOWN						UNKNOWN	Topical	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7192119/	Homo sapiens		h	1					IDROCILAMIDE		false
5903	2848		ADULT	1550874	191.2264	IDROCILAMIDE	IDROCILAMIDE	OCCNC(=O)C=CC1=CC=CC=C1	SERUM	6C816LUB1O																	UNKNOWN	mg	60		SINGLE	UNKNOWN						UNKNOWN	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7192119/	Homo sapiens		h	1					IDROCILAMIDE		false
5904	2848		ADULT	1550874	191.2264	IDROCILAMIDE	IDROCILAMIDE	OCCNC(=O)C=CC1=CC=CC=C1	SERUM	6C816LUB1O																	UNKNOWN	mg	400		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7192119/	Homo sapiens		h	1					IDROCILAMIDE		false
5905	2849		ADULT	65859	236.3101	LEVODROPROPIZINE	Levodropropizine	OC[C@@H](O)CN1CCN(CC1)C2=CC=CC=C2	PLASMA	3O31P6T4G3							12		t	μg × h/L	1229.2		μg/L	247.99			UNKNOWN	mg	90		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29872264/	Homo sapiens		h	3.1		Controlled-release tablets		47			false
5906	2849		ADULT	65859	236.3101	LEVODROPROPIZINE	Levodropropizine	OC[C@@H](O)CN1CCN(CC1)C2=CC=CC=C2	PLASMA	3O31P6T4G3							6		t	μg × h/L	774.32		μg/L	278.14			UNKNOWN	mg	60		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29872264/	Homo sapiens		h	2.3		Immediate-release tablets		46			false
5907	2849		ADULT	65859	236.3101	LEVODROPROPIZINE	Levodropropizine	OC[C@@H](O)CN1CCN(CC1)C2=CC=CC=C2	PLASMA	3O31P6T4G3							12		t	μg × h/L	1292.76		μg/L	225.46			UNKNOWN	mg	90		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29872264/	Homo sapiens		h	2.85		Controlled-release tablets		46			false
5908	2851		ADULT	5219	170.1692	LINSIDOMINE	Linsidomine	[NH-]C1=C[N ](=NO1)N2CCOCC2	PLASMA	5O5U71P6VQ																	UNKNOWN	mg	1		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	OTHER	https://doi-org.ezproxy.cul.columbia.edu/10.1007/BF02411402#page=302 | https://pubmed.ncbi.nlm.nih.gov/7509893/	Homo sapiens		h	29.5		Coronary patients		6			false
5909	2851		ADULT	5219	170.1692	LINSIDOMINE	Linsidomine	[NH-]C1=C[N ](=NO1)N2CCOCC2	PLASMA	5O5U71P6VQ													ng/mL	5.08			UNKNOWN	mg/h	0.8		SINGLE	UNKNOWN				Cmax=mean concentration after infusion		UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7509893/	Homo sapiens		h	21.8		Myocardial infarction patients		10			false
5910	2852		ADULT	39562	321.158	LONIDAMINE	LONIDAMINE	OC(=O)C1=NN(CC2=C(Cl)C=C(Cl)C=C2)C3=C1C=CC=C3	PLASMA	U78804BIDR													μg/mL	15.5			UNKNOWN	mg	150		MULTIPLE	UNKNOWN		day	3	Pharmacokinetic studies were performed after 1 month of treatment in 17 patients. Heparinised blood was taken after the 1st 150 mg dose.		UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1911204/	Homo sapiens		h	3.9	Lonidamine tablets were initially given by increments over 1 week to a final dose of 600 mg (150 mg in the morning, 150 mg in the afternoon and 300 mg at night).	advanced breast cancer		32	LONIDAMINE		false
5911	2852		ADULT	39562	321.158	LONIDAMINE	LONIDAMINE	OC(=O)C1=NN(CC2=C(Cl)C=C(Cl)C=C2)C3=C1C=CC=C3	PLASMA	U78804BIDR									?	μg × h/mL	136.1		μg/mL	21.8			UNKNOWN	mg	300		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6717895/	Homo sapiens		h	14.8		cancer		14	LONIDAMINE		false
5912	2852		ADULT	39562	321.158	LONIDAMINE	LONIDAMINE	OC(=O)C1=NN(CC2=C(Cl)C=C(Cl)C=C2)C3=C1C=CC=C3	PLASMA	U78804BIDR									?	μg × h/mL	186.2		μg/mL	22.4			UNKNOWN	mg	600		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6717895/	Homo sapiens		h	12.1		cancer		14	LONIDAMINE		false
5913	2853		ADULT	6842999	287.292	NIFURTIMOX	Nifurtimox	CC1CS(=O)(=O)CCN1\\N=C\\C2=CC=C(O2)[N ]([O-])=O	PLASMA	M84I3K7C2O							24		t	μg × h/L	2670		μg/L	568			UNKNOWN	mg	120		SINGLE	FED				The plasma proteins binding of nifurtimox is 42%.	58	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213464s000lbl.pdf#page=9 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213464Orig1s000MultidisciplineR.pdf#page=218 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213464Orig1s000MultidisciplineR.pdf#page=216	Homo sapiens		h	3.3		Chronic Chagas disease patients		12	Nifurtimox		false
5914	2853		UNKNOWN	6842999	287.292	NIFURTIMOX	Nifurtimox	CC1CS(=O)(=O)CCN1\\N=C\\C2=CC=C(O2)[N ]([O-])=O	PLASMA	M84I3K7C2O									?	μg × h/L	2670		μg/L	568			UNKNOWN	mg	120		UNKNOWN	HIGH-FAT		day	1		57.6	UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213464Orig1s000MultidisciplineR.pdf#page=38	Homo sapiens		h	3.3				13	Nifurtimox		false
5915	2856		ADULT	4626	158.1552	OXIRACETAM	OXIracetam	NC(=O)CN1CC(O)CC1=O	PLASMA	P7U817352G							12		t	μM × h	1360		μM	196			UNKNOWN	mg	800		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2253653/	Homo sapiens		h	16.6		Aged between 73 and 98 years; \npresenting a cerebral impairment which justified a nootropic treatment.		18			false
5916	2856		ADULT	4626	158.1552	OXIRACETAM	OXIRACETAM	NC(=O)CN1CC(O)CC1=O	PLASMA	P7U817352G							12		∞	μM × h	511		μM	107			UNKNOWN	mg	800		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2253653/	Homo sapiens		h	7.7		41-55 yo.		6			false
5917	2860		ADULT	68712	180.2468	RILMENIDINE	rilmenidine	C1CC1C(NC2=NCCO2)C3CC3	PLASMA	P67IM25ID8									∞	ng × h/mL	38.61						RECOMMENDED	mg	1		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2782323/	Homo sapiens		h	8.31				12			false
5918	2860		ADULT	68712	180.2468	RILMENIDINE	rilmenidine	C1CC1C(NC2=NCCO2)C3CC3	PLASMA	P67IM25ID8									∞	ng × h/mL	38.33		ng/mL	3.49			RECOMMENDED	mg	1		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2782323/	Homo sapiens		h	8.51				12			false
5919	2860		ADULT	68712	180.2468	RILMENIDINE	rilmenidine	C1CC1C(NC2=NCCO2)C3CC3	PLASMA	P67IM25ID8													ng/mL	7.85			UNKNOWN	mg	2		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2894159/	Homo sapiens		h	6.9		mild to moderate hypertensive patients; 19 -63 yo.		11			false
5920	2860		ADULT	68712	180.2468	RILMENIDINE	rilmenidine	C1CC1C(NC2=NCCO2)C3CC3	PLASMA	P67IM25ID8													ng/mL	3.6			UNKNOWN	mg	1		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2894159/	Homo sapiens		h	18		Mild to moderate hypertension presenting renal failure (glomerular filtration rate 75-45 ml/min).		5			false
5921	2860		ADULT	68712	180.2468	RILMENIDINE	rilmenidine	C1CC1C(NC2=NCCO2)C3CC3	PLASMA	P67IM25ID8													ng/mL	5.05			UNKNOWN	mg	1		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2894159/	Homo sapiens		h	23		Mild to moderate hypertension presenting renal failure (glomerular filtration rate 45-15 ml/min).		4			false
5922	2860		ADULT	68712	180.2468	RILMENIDINE	rilmenidine	C1CC1C(NC2=NCCO2)C3CC3	PLASMA	P67IM25ID8													ng/mL	3.28			UNKNOWN	mg	1		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2894159/	Homo sapiens		h	7.3		mild to moderate hypertensive patients; 19 -63 yo.		11			false
5923	2860		ADULT	68712	180.2468	RILMENIDINE	rilmenidine	C1CC1C(NC2=NCCO2)C3CC3	PLASMA	P67IM25ID8									∞	ng × h/mL	78		ng/mL	4.64			UNKNOWN	mg	1		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2894159/	Homo sapiens		h	13		Elderly hypertensive patients; 70 -95 yo.		16			false
5924	2860		ADULT		180.2468	RILMENIDINE	rilmenidine	C1CC1C(NC2=NCCO2)C3CC3	PLASMA	P67IM25ID8													ng/mL	5.33			UNKNOWN	mg	1		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2894159/	Homo sapiens		h	34		Mild to moderate hypertension presenting renal failure (glomerular filtration rate 15-5 ml/min).		6			false
5925	2860		ADULT		180.2468	RILMENIDINE	rilmenidine	C1CC1C(NC2=NCCO2)C3CC3	PLASMA														ng/mL	3.15			UNKNOWN	mg	1		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2894159/	Homo sapiens		h	12		Patients with severe hepatic insufficiency		8			false
5926	2861		ADULT	71815	185.1805	SECNIDAZOLE	SECNIDAZOLE	CC(O)CN1C(C)=NC=C1[N+]([O-])=O	PLASMA	R3459K699K									∞	μg × h/mL	1410		μg/mL	45.4			RECOMMENDED	g	2		SINGLE	FED				Plasma Protein Binding <5%	95	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209363Orig1s000ClinPharmR.pdf	Homo sapiens		h	17.6							false
5927	2862		ADULT	68770	363.4943	TALINOLOL	talinolol	CC(C)(C)NCC(O)COC1=CC=C(NC(=O)NC2CCCCC2)C=C1	PLASMA	3S82268BKG									∞	ng × h/mL	1860		ng/mL	147.8			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17466606/	Homo sapiens		h	12				12			false
5928	2862			68770	363.4943	TALINOLOL	talinolol	CC(C)(C)NCC(O)COC1=CC=C(NC(=O)NC2CCCCC2)C=C1	PLASMA	3S82268BKG																											39		Intravenous		REVIEW	https://pubmed.ncbi.nlm.nih.gov/30115648/	Homo sapiens										false
5929	2863		ADULT	4488	282.218	NIFLUMIC ACID	niflumic acid	OC(=O)C1=CC=CN=C1NC2=CC(=CC=C2)C(F)(F)F	PLASMA	4U5MP5IUD8									?	μg × min/mL	2212		μg/mL	5.7			UNKNOWN	mg	504		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://link.springer.com/article/10.1007/BF02976244	Homo sapiens		min	229.4				5	TALNIFLUMATE		false
5930	2863		ADULT	48229	414.3341	TALNIFLUMATE	TALNIFLUMATE	FC(F)(F)C1=CC(NC2=C(C=CC=N2)C(=O)OC3OC(=O)C4=C3C=CC=C4)=CC=C1	PLASMA	JFK78S0U9S									?	ng × min/mL	1752		ng/mL	423			UNKNOWN	mg	740		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15470687/	Homo sapiens		min	121				8	TALNIFLUMATE		false
5931	2863		ADULT	4488	282.218	NIFLUMIC ACID	Niflumic acid	OC(=O)C1=CC=CN=C1NC2=CC(=CC=C2)C(F)(F)F	PLASMA	4U5MP5IUD8									?	ng × min/mL	16296		ng/mL	4121			UNKNOWN	mg	740		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15470687/	Homo sapiens		min	111				8	TALNIFLUMATE		false
5932	2863		ADULT	4488	282.218	NIFLUMIC ACID	niflumic acid	OC(=O)C1=CC=CN=C1NC2=CC(=CC=C2)C(F)(F)F	PLASMA	4U5MP5IUD8									?	ng × h/mL	795.5		ng/mL	187.9			UNKNOWN	mg	740		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19359802/	Homo sapiens		h	3				24	TALNIFLUMATE		false
5933	2865		ADULT	50248	359.658	TRICLABENDAZOLE	triclabendazole	CSC1=NC2=C(N1)C=C(OC3=C(Cl)C(Cl)=CC=C3)C(Cl)=C2	PLASMA	4784C8E03O							48		t	μM × h	1.55		μM	0.34			RECOMMENDED	mg/kg	10		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9663817/	Homo sapiens										false
5934	2865		ADULT	50248	359.658	TRICLABENDAZOLE	triclabendazole	CSC1=NC2=C(N1)C=C(OC3=C(Cl)C(Cl)=CC=C3)C(Cl)=C2	PLASMA	4784C8E03O							48		t	μM × h	5.72		μM	1.16			RECOMMENDED	mg/kg	10		MULTIPLE	FED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9663817/	Homo sapiens										false
5935	2865		UNKNOWN	50248	359.658	TRICLABENDAZOLE	triclabendazole	CSC1=NC2=C(N1)C=C(OC3=C(Cl)C(Cl)=CC=C3)C(Cl)=C2	PLASMA	4784C8E03O									?	μM × h	5.72		μM	1.16			RECOMMENDED	mg/kg	10		SINGLE	UNKNOWN				Protein-binding of triclabendazole in human plasma 96.7%	3.3	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf	Homo sapiens		h	8							false
5936	2866		ADULT	68705051	262.22	2‐Hydroxy‐4‐trifluoromethylbenzoic acid	2\u2010Hydroxy\u20104\u2010trifluoromethylbenzoic acid	CC(C)(C)OC(=O)C1=C(C=C(C=C1)C(F)(F)F)O	PLASMA										∞	μg × h/mL	4471.33		μg/mL	88.61			RECOMMENDED	mg	600		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20184225/	Homo sapiens		h	48.67				24	TRIFLUSAL		false
5937	2867		ADULT	47979	383.463	VERALIPRIDE	VERALIPRIDE	COC1=C(OC)C(=CC(=C1)S(N)(=O)=O)C(=O)NCC2CCCN2CC=C	PLASMA	S7064109UD									?	mg × h/L	1.927		mg/L	0.3381			RECOMMENDED	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3981429/	Homo sapiens		h	4.14				5	VERALIPRIDE		false
5938	2867		ADULT	47979	383.463	VERALIPRIDE	VERALIPRIDE	COC1=C(OC)C(=CC(=C1)S(N)(=O)=O)C(=O)NCC2CCCN2CC=C	PLASMA	S7064109UD									?	mg × h/L	3.097		mg/L	0.539			UNKNOWN	mg	150		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3981429/	Homo sapiens		h	3.51				5	VERALIPRIDE		false
5939	2867		ADULT	47979	383.463	VERALIPRIDE	VERALIPRIDE	COC1=C(OC)C(=CC(=C1)S(N)(=O)=O)C(=O)NCC2CCCN2CC=C	PLASMA	S7064109UD									?	mg × h/L	6.25		mg/L	0.994			UNKNOWN	mg	250		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3981429/	Homo sapiens		h	4.21				5	VERALIPRIDE		false
5940	2867		ADULT	47979	383.463	VERALIPRIDE	VERALIPRIDE	COC1=C(OC)C(=CC(=C1)S(N)(=O)=O)C(=O)NCC2CCCN2CC=C	PLASMA	S7064109UD									?	mg × h/L	4.53		mg/L	0.876			UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3981429/	Homo sapiens		h	4.25				5	VERALIPRIDE		false
5941	2868		ADULT	11755113	485.5	AMRUBICINOL			PLASMA										?	ng × h/mL	2476		ng/mL	170			UNKNOWN	mg/m²	35		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16028099/	Homo sapiens		h	18	days 1-3 every 3 weeks			6	AMRUBICIN		false
5942	2868		ADULT	3035016	483.4673	AMRUBICIN	AMRUBICIN	CC(=O)[C@@]1(N)C[C@H](O[C@H]2C[C@H](O)[C@H](O)CO2)C3=C(O)C4=C(C(=O)C5=C(C=CC=C5)C4=O)C(O)=C3C1	PLASMA	93N13LB4Z2									?	ng × h/mL	8601		ng/mL	1693			UNKNOWN	mg/m²	30		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16028099/	Homo sapiens		h	4.7	days 1-3 every 3 weeks			6	AMRUBICIN		false
5943	2868		ADULT	3035016	483.4673	AMRUBICIN	AMRUBICIN	CC(=O)[C@@]1(N)C[C@H](O[C@H]2C[C@H](O)[C@H](O)CO2)C3=C(O)C4=C(C(=O)C5=C(C=CC=C5)C4=O)C(O)=C3C1	PLASMA	93N13LB4Z2									?	ng × h/mL	13071		ng/mL	3414			UNKNOWN	mg/m²	35		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16028099/	Homo sapiens		h	7.1	days 1-3 every 3 weeks			6	AMRUBICIN		false
5944	2868		ADULT	3035016	483.4673	AMRUBICIN	AMRUBICIN	CC(=O)[C@@]1(N)C[C@H](O[C@H]2C[C@H](O)[C@H](O)CO2)C3=C(O)C4=C(C(=O)C5=C(C=CC=C5)C4=O)C(O)=C3C1	PLASMA	93N13LB4Z2									?	ng × h/mL	16706		ng/mL	4869			MAX TOLERATED	mg/m²	40		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16028099/	Homo sapiens		h	7.4	days 1-3 every 3 weeks			3	AMRUBICIN		false
5945	2868		ADULT	11755113	485.5	AMRUBICINOL			PLASMA										?	ng × h/mL	1361		ng/mL	77			UNKNOWN	mg/m²	30		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16028099/	Homo sapiens		h	13.8	days 1-3 every 3 weeks			6	AMRUBICIN		false
5946	2868		ADULT	11755113	485.5	AMRUBICINOL			PLASMA										?	ng × h/mL	4097		ng/mL	333			MAX TOLERATED	mg/m²	40		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16028099/	Homo sapiens		h	17.9	days 1-3 every 3 weeks			3	AMRUBICIN		false
5947	2868		ADULT	11755113	485.5	AMRUBICINOL	AMRUBICINOL		PLASMA										?	ng × h/mL	1514		ng/mL	87			RECOMMENDED	mg/m²	30		MULTIPLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16418698/	Homo sapiens							4	AMRUBICIN		false
5948	2868		ADULT	3035016	483.4673	AMRUBICIN	AMRUBICIN	CC(=O)[C@@]1(N)C[C@H](O[C@H]2C[C@H](O)[C@H](O)CO2)C3=C(O)C4=C(C(=O)C5=C(C=CC=C5)C4=O)C(O)=C3C1	PLASMA	93N13LB4Z2									?	ng × h/mL	16706		ng/mL	4869			RECOMMENDED	mg/m²	40		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16418698/	Homo sapiens							2	AMRUBICIN		false
5949	2868		ADULT	3035016	483.4673	AMRUBICIN	AMRUBICIN	CC(=O)[C@@]1(N)C[C@H](O[C@H]2C[C@H](O)[C@H](O)CO2)C3=C(O)C4=C(C(=O)C5=C(C=CC=C5)C4=O)C(O)=C3C1	PLASMA	93N13LB4Z2									?	ng × h/mL	13447		ng/mL	3349			RECOMMENDED	mg/m²	35		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16418698/	Homo sapiens							3	AMRUBICIN		false
5950	2868		ADULT	3035016	483.4673	AMRUBICIN	AMRUBICIN	CC(=O)[C@@]1(N)C[C@H](O[C@H]2C[C@H](O)[C@H](O)CO2)C3=C(O)C4=C(C(=O)C5=C(C=CC=C5)C4=O)C(O)=C3C1	PLASMA	93N13LB4Z2									?	ng × h/mL	10262		ng/mL	1867			RECOMMENDED	mg/m²	30		MULTIPLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16418698/	Homo sapiens							4	AMRUBICIN		false
5951	2868		ADULT	11755113	485.5	AMRUBICINOL	AMRUBICINOL		PLASMA										?	ng × h/mL	2585		ng/mL	94			HIGHEST STUDIED	mg/m²	45		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16418698/	Homo sapiens							6	AMRUBICIN		false
5952	2868		ADULT	11755113	485.5	AMRUBICINOL	AMRUBICINOL		PLASMA										?	ng × h/mL	4097		ng/mL	333			RECOMMENDED	mg/m²	40		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16418698/	Homo sapiens							2	AMRUBICIN		false
5953	2868		ADULT	3035016	483.4673	AMRUBICIN	AMRUBICIN	CC(=O)[C@@]1(N)C[C@H](O[C@H]2C[C@H](O)[C@H](O)CO2)C3=C(O)C4=C(C(=O)C5=C(C=CC=C5)C4=O)C(O)=C3C1	PLASMA	93N13LB4Z2							24		?	ng × h/mL	13490		ng/mL	3407			HIGHEST STUDIED	mg/m²	45		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16418698/	Homo sapiens							6	AMRUBICIN		false
5954	2868		ADULT	11755113	485.5	AMRUBICINOL	AMRUBICINOL		PLASMA										?	ng × h/mL	2325		ng/mL	162			RECOMMENDED	mg/m²	35		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16418698/	Homo sapiens							3	AMRUBICIN		false
5955	2868		ADULT	11755113	485.5	amrubicinol	amrubicinol		PLASMA								24		t	ng × h/mL	265		ng/mL	64.9			MAX TOLERATED	mg/m²	65		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22237957/	Homo sapiens		h	13.3	weekly (repetition of dose on 1st and 8th day with a rest on day 15)			4	amrubicin		false
5956	2868		ADULT	11755113	485.5	amrubicinol			PLASMA								24		t	ng × h/mL	378		ng/mL	44.8			RP2D	mg/m²	60		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22237957/	Homo sapiens		h	13.39	weekly (repetition of dose on 1st and 8th day with a rest on day 15)			2	amrubicin		false
5957	2868		ADULT	3035016	483.4673	AMRUBICIN	amrubicin	CC(=O)[C@@]1(N)C[C@H](O[C@H]2C[C@H](O)[C@H](O)CO2)C3=C(O)C4=C(C(=O)C5=C(C=CC=C5)C4=O)C(O)=C3C1	PLASMA	93N13LB4Z2							24		t	ng × h/mL	5279		ng/mL	7290			MAX TOLERATED	mg/m²	65		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22237957/	Homo sapiens		h	4.66	weekly (repetition of dose on 1st and 8th day with a rest on day 15)			4	amrubicin		false
5958	2868		ADULT	3035016	483.4673	AMRUBICIN	amrubicin	CC(=O)[C@@]1(N)C[C@H](O[C@H]2C[C@H](O)[C@H](O)CO2)C3=C(O)C4=C(C(=O)C5=C(C=CC=C5)C4=O)C(O)=C3C1	PLASMA	93N13LB4Z2							24		t	ng × h/mL	5737		ng/mL	7919			RP2D	mg/m²	60		MULTIPLE	UNKNOWN		week	1			UNKNOWN	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22237957/	Homo sapiens		h	3.63	weekly (repetition of dose on 1st and 8th day with a rest on day 15)			2	amrubicin		false
5959	2868		ADULT	11755113	485.5	amrubicinol			PLASMA								24		t	ng × h/mL	624		ng/mL	42.5			UNKNOWN	mg/m²	40		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23400695/	Homo sapiens				day 3			24	amrubicin		false
5960	2868		ADULT	3035016	483.4673	AMRUBICIN	amrubicin	CC(=O)[C@@]1(N)C[C@H](O[C@H]2C[C@H](O)[C@H](O)CO2)C3=C(O)C4=C(C(=O)C5=C(C=CC=C5)C4=O)C(O)=C3C1	PLASMA	93N13LB4Z2							24		t	ng × h/mL	2152		ng/mL	4024			UNKNOWN	mg/m²	40		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23400695/	Homo sapiens				day 3			24	amrubicin		false
5961	2868		ADULT	3035016	483.4673	AMRUBICIN	amrubicin	CC(=O)[C@@]1(N)C[C@H](O[C@H]2C[C@H](O)[C@H](O)CO2)C3=C(O)C4=C(C(=O)C5=C(C=CC=C5)C4=O)C(O)=C3C1	PLASMA	93N13LB4Z2							24		t	ng × h/mL	1968		ng/mL	3329			UNKNOWN	mg/m²	40		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23400695/	Homo sapiens							24	amrubicin		false
5962	2868		ADULT	11755113	485.5	amrubicinol			PLASMA								24		t	ng × h/mL	378		ng/mL	26.8			UNKNOWN	mg/m²	40		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23400695/	Homo sapiens							24	amrubicin		false
5963	2870		ADULT	6456014	433.4996	BELOTECAN	BELOTECAN	CC[C@@]1(O)C(=O)OCC2=C1C=C3N(CC4=C(CCNC(C)C)C5=C(C=CC=C5)N=C34)C2=O	PLASMA	27Z82M2G1N	84691|5460033|5702198	300.051	CISPLATIN	Cisplatin	N.N.[Cl-].[Cl-].[Pt  ]	Q20Q21Q62J			∞	μg × h/L	117.32		μg/L	58.23			UNKNOWN	mg/m²	0.4		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17947485/	Homo sapiens		h	8.63			Cisplatin (60 mg/m2) was given on day 1	3	BELOTECAN		true
5964	2870		ADULT	6456014	433.4996	BELOTECAN	BELOTECAN	CC[C@@]1(O)C(=O)OCC2=C1C=C3N(CC4=C(CCNC(C)C)C5=C(C=CC=C5)N=C34)C2=O	PLASMA	27Z82M2G1N	84691|5460033|5702198	300.051	CISPLATIN	Cisplatin	N.N.[Cl-].[Cl-].[Pt  ]	Q20Q21Q62J			∞	μg × h/L	155.64		μg/L	91.81			MAX TOLERATED	mg/m²	0.5		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17947485/	Homo sapiens		h	8.55			Cisplatin (60 mg/m2) was given on day 1	6	BELOTECAN		true
5965	2870		ADULT	6456014	433.4996	BELOTECAN	BELOTECAN	CC[C@@]1(O)C(=O)OCC2=C1C=C3N(CC4=C(CCNC(C)C)C5=C(C=CC=C5)N=C34)C2=O	PLASMA	27Z82M2G1N	84691|5460033|5702198	300.051	CISPLATIN	Cisplatin	N.N.[Cl-].[Cl-].[Pt  ]	Q20Q21Q62J			∞	μg × h/L	182.16		μg/L	86.5			HIGHEST STUDIED	mg/m²	0.55		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17947485/	Homo sapiens		h	11.57	Day 4		Cisplatin (60 mg/m2) was given on day 1	5	BELOTECAN		true
5966	2870		ADULT	6456014	433.4996	BELOTECAN	BELOTECAN	CC[C@@]1(O)C(=O)OCC2=C1C=C3N(CC4=C(CCNC(C)C)C5=C(C=CC=C5)N=C34)C2=O	PLASMA	27Z82M2G1N	84691|5460033|5702198	300.051	CISPLATIN	Cisplatin	N.N.[Cl-].[Cl-].[Pt  ]	Q20Q21Q62J			∞	μg × h/L	102.74		μg/L	47.37			UNKNOWN	mg/m²	0.4		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17947485/	Homo sapiens		h	9.03	Day 4		Cisplatin (60 mg/m2) was given on day 1	3	BELOTECAN		true
5967	2870		ADULT	6456014	433.4996	BELOTECAN	BELOTECAN	CC[C@@]1(O)C(=O)OCC2=C1C=C3N(CC4=C(CCNC(C)C)C5=C(C=CC=C5)N=C34)C2=O	PLASMA	27Z82M2G1N	84691|5460033|5702198	300.051	CISPLATIN	Cisplatin	N.N.[Cl-].[Cl-].[Pt  ]	Q20Q21Q62J			∞	μg × h/L	111.72		μg/L	66.47			UNKNOWN	mg/m²	0.45		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17947485/	Homo sapiens		h	5.16			Cisplatin (60 mg/m2) was given on day 1	3	BELOTECAN		true
5968	2870		ADULT	6456014	433.4996	BELOTECAN	BELOTECAN	CC[C@@]1(O)C(=O)OCC2=C1C=C3N(CC4=C(CCNC(C)C)C5=C(C=CC=C5)N=C34)C2=O	PLASMA	27Z82M2G1N	84691|5460033|5702198	300.051	CISPLATIN	Cisplatin	N.N.[Cl-].[Cl-].[Pt  ]	Q20Q21Q62J			∞	μg × h/L	148.06		μg/L	75.69			MAX TOLERATED	mg/m²	0.5		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17947485/	Homo sapiens		h	8.74	Day 4		Cisplatin (60 mg/m2) was given on day 1	6	BELOTECAN		true
5969	2870		ADULT	6456014	433.4996	BELOTECAN	BELOTECAN	CC[C@@]1(O)C(=O)OCC2=C1C=C3N(CC4=C(CCNC(C)C)C5=C(C=CC=C5)N=C34)C2=O	PLASMA	27Z82M2G1N	84691|5460033|5702198	300.051	CISPLATIN	Cisplatin	N.N.[Cl-].[Cl-].[Pt  ]	Q20Q21Q62J			∞	μg × h/L	115.85		μg/L	70.78			UNKNOWN	mg/m²	0.45		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17947485/	Homo sapiens		h	6.35	Day 4		Cisplatin (60 mg/m2) was given on day 1	3	BELOTECAN		true
5970	2870		ADULT	6456014	433.4996	BELOTECAN	BELOTECAN	CC[C@@]1(O)C(=O)OCC2=C1C=C3N(CC4=C(CCNC(C)C)C5=C(C=CC=C5)N=C34)C2=O	PLASMA	27Z82M2G1N	84691|5460033|5702198	300.051	CISPLATIN	Cisplatin	N.N.[Cl-].[Cl-].[Pt  ]	Q20Q21Q62J			∞	μg × h/L	179.25		μg/L	91.78			HIGHEST STUDIED	mg/m²	0.55		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17947485/	Homo sapiens		h	8.75			Cisplatin (60 mg/m2) was given on day 1	5	BELOTECAN		true
5971	2871			185460|40467029	463.6117	BILASTINE	Bilastine	CCOCCN1C(=NC2=C1C=CC=C2)C3CCN(CCC4=CC=C(C=C4)C(C)(C)C(O)=O)CC3	PLASMA	PA1123N395																										Human plasma protein binding: 84.2~90.0% (0.2~1μg/mL), ultrafiltration	10				OTHER GOV'T	https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=13	Homo sapiens										false
5972	2871		ADULT	185460|40467029	463.6117	BILASTINE	Bilastine	CCOCCN1C(=NC2=C1C=CC=C2)C3CCN(CCC4=CC=C(C=C4)C(C)(C)C(O)=O)CC3	PLASMA	PA1123N395									∞	ng × h/mL	3435		ng/mL	756			UNKNOWN	mg	50		SINGLE	FASTED				n=8 for t1/2 and AUC		HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=23 | https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=86	Homo sapiens		h	12.9				9			false
5973	2871		ADULT	185460|40467029	463.6117	BILASTINE	Bilastine	CCOCCN1C(=NC2=C1C=CC=C2)C3CCN(CCC4=CC=C(C=C4)C(C)(C)C(O)=O)CC3	PLASMA	PA1123N395									∞	ng × h/mL	1373		ng/mL	275			DEFINED DAILY	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=23 | https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=86	Homo sapiens		h	12				9			false
5974	2871		ADULT	185460|40467029	463.6117	BILASTINE	Bilastine	CCOCCN1C(=NC2=C1C=CC=C2)C3CCN(CCC4=CC=C(C=C4)C(C)(C)C(O)=O)CC3	PLASMA	PA1123N395									∞	ng × h/mL	681		ng/mL	153			UNKNOWN	mg	10		SINGLE	FASTED				n=6 for t1/2 and AUC		HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=23 | https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=86	Homo sapiens		h	13.9				9			false
5975	2871		ADULT	185460|40467029	463.6117	BILASTINE	Bilastine	CCOCCN1C(=NC2=C1C=CC=C2)C3CCN(CCC4=CC=C(C=C4)C(C)(C)C(O)=O)CC3	PLASMA	PA1123N395									?	ng × h/mL	1284		ng/mL	277.9			DEFINED DAILY	mg	20		SINGLE	FASTED				n=19 for t1/2		HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=23 | https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_K101_1.pdf.pdf#page=48	Homo sapiens		h	10.54				20			false
5976	2871		ADULT	185460|40467029	463.6117	BILASTINE	Bilastine	CCOCCN1C(=NC2=C1C=CC=C2)C3CCN(CCC4=CC=C(C=C4)C(C)(C)C(O)=O)CC3	PLASMA	PA1123N395									?	ng × h/mL	770.6		ng/mL	120.2			DEFINED DAILY	mg	20		SINGLE	HIGH-FAT				n=18 for t1/2		HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=23 | https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_K101_1.pdf.pdf#page=48	Homo sapiens		h	11.58				20			false
5977	2871		ADULT	185460|40467029	463.6117	BILASTINE	Bilastine	CCOCCN1C(=NC2=C1C=CC=C2)C3CCN(CCC4=CC=C(C=C4)C(C)(C)C(O)=O)CC3	PLASMA	PA1123N395							24		t	ng × h/mL	4474		ng/mL	1006			DEFINED DAILY	mg	50		MULTIPLE	FED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=24 | https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=93	Homo sapiens				Day 14 (fasted)			9			false
5978	2871		ADULT	185460|40467029	463.6117	BILASTINE	Bilastine	CCOCCN1C(=NC2=C1C=CC=C2)C3CCN(CCC4=CC=C(C=C4)C(C)(C)C(O)=O)CC3	PLASMA	PA1123N395							24		t	ng × h/mL	1439		ng/mL	345			DEFINED DAILY	mg	20		MULTIPLE	FED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=24 | https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=93	Homo sapiens				Day 1 (fasted)			9			false
5979	2871		ADULT	185460|40467029	463.6117	BILASTINE	Bilastine	CCOCCN1C(=NC2=C1C=CC=C2)C3CCN(CCC4=CC=C(C=C4)C(C)(C)C(O)=O)CC3	PLASMA	PA1123N395							24		t	ng × h/mL	1551		ng/mL	341			DEFINED DAILY	mg	20		MULTIPLE	FED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=24 | https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=93	Homo sapiens				Day 14 (fasted)			9			false
5980	2871		ADULT	185460|40467029	463.6117	BILASTINE	Bilastine	CCOCCN1C(=NC2=C1C=CC=C2)C3CCN(CCC4=CC=C(C=C4)C(C)(C)C(O)=O)CC3	PLASMA	PA1123N395							24		t	ng × h/mL	3992		ng/mL	949			DEFINED DAILY	mg	50		MULTIPLE	FED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=24 | https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=93	Homo sapiens				Day 1 (fasted)			9			false
5981	2871		ADULT	185460|40467029	463.6117	BILASTINE	Bilastine	CCOCCN1C(=NC2=C1C=CC=C2)C3CCN(CCC4=CC=C(C=C4)C(C)(C)C(O)=O)CC3	PLASMA	PA1123N395									∞	ng × h/mL	326		ng/mL	59.6			UNKNOWN	mg	5		SINGLE	FASTED				n=2 for t1/2 and AUC		HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=25 | https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=118	Homo sapiens		h	30.1		non-Japanese		9			false
5982	2871		ADULT	185460|40467029	463.6117	BILASTINE	Bilastine	CCOCCN1C(=NC2=C1C=CC=C2)C3CCN(CCC4=CC=C(C=C4)C(C)(C)C(O)=O)CC3	PLASMA	PA1123N395									∞	ng × h/mL	693		ng/mL	135			UNKNOWN	mg	10		SINGLE	FASTED				n=3 for t1/2 and AUC		HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=25 | https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=118	Homo sapiens		h	14.4		non-Japanese		9			false
5983	2871		ADULT	185460|40467029	463.6117	BILASTINE	Bilastine	CCOCCN1C(=NC2=C1C=CC=C2)C3CCN(CCC4=CC=C(C=C4)C(C)(C)C(O)=O)CC3	PLASMA	PA1123N395									∞	ng × h/mL	3348		ng/mL	761			UNKNOWN	mg	50		SINGLE	FASTED				n=3 for t1/2 and AUC		HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=25 | https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=118	Homo sapiens		h	14.8		non-Japanese		9			false
5984	2871		ADULT	185460|40467029	463.6117	BILASTINE	Bilastine	CCOCCN1C(=NC2=C1C=CC=C2)C3CCN(CCC4=CC=C(C=C4)C(C)(C)C(O)=O)CC3	PLASMA	PA1123N395									∞	ng × h/mL	5153		ng/mL	1419			UNKNOWN	mg	100		SINGLE	FASTED				n=3 for t1/2 and AUC		HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=25 | https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=118	Homo sapiens		h	17.9		non-Japanese		9			false
5985	2871		ADULT	185460|40467029	463.6117	BILASTINE	Bilastine	CCOCCN1C(=NC2=C1C=CC=C2)C3CCN(CCC4=CC=C(C=C4)C(C)(C)C(O)=O)CC3	PLASMA	PA1123N395							24		t	ng × h/mL	876		ng/mL	182			DEFINED DAILY	mg	20		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=25 | https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=121	Homo sapiens		h	9.63	Day 14	non-Japanese		9			false
5986	2871		ADULT	185460|40467029	463.6117	BILASTINE	Bilastine	CCOCCN1C(=NC2=C1C=CC=C2)C3CCN(CCC4=CC=C(C=C4)C(C)(C)C(O)=O)CC3	PLASMA	PA1123N395							24		t	ng × h/mL	2982		ng/mL	821			UNKNOWN	mg	50		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=25 | https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=121	Homo sapiens		h	4.57	Day 1	non-Japanese		9			false
5987	2871		ADULT	185460|40467029	463.6117	BILASTINE	Bilastine	CCOCCN1C(=NC2=C1C=CC=C2)C3CCN(CCC4=CC=C(C=C4)C(C)(C)C(O)=O)CC3	PLASMA	PA1123N395							24		t	ng × h/mL	3087		ng/mL	740			UNKNOWN	mg	50		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=25 | https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=121	Homo sapiens		h	9.66	Day 14	non-Japanese		9			false
5988	2871		ADULT	185460|40467029	463.6117	BILASTINE	Bilastine	CCOCCN1C(=NC2=C1C=CC=C2)C3CCN(CCC4=CC=C(C=C4)C(C)(C)C(O)=O)CC3	PLASMA	PA1123N395							24		t	ng × h/mL	5675		ng/mL	1580			UNKNOWN	mg	100		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=25 | https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=121	Homo sapiens		h	4.03	Day 1	non-Japanese		9			false
5989	2871		ADULT	185460|40467029	463.6117	BILASTINE	Bilastine	CCOCCN1C(=NC2=C1C=CC=C2)C3CCN(CCC4=CC=C(C=C4)C(C)(C)C(O)=O)CC3	PLASMA	PA1123N395							24		t	ng × h/mL	5109		ng/mL	1278			UNKNOWN	mg	100		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=25 | https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=121	Homo sapiens		h	10.2	Day 14	non-Japanese		9			false
5990	2871		ADULT	185460|40467029	463.6117	BILASTINE	Bilastine	CCOCCN1C(=NC2=C1C=CC=C2)C3CCN(CCC4=CC=C(C=C4)C(C)(C)C(O)=O)CC3	PLASMA	PA1123N395							24		t	ng × h/mL	506		ng/mL	106			UNKNOWN	mg	10		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=25 | https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=121	Homo sapiens		h	4.33	Day 1	non-Japanese		9			false
5991	2871		ADULT	185460|40467029	463.6117	BILASTINE	Bilastine	CCOCCN1C(=NC2=C1C=CC=C2)C3CCN(CCC4=CC=C(C=C4)C(C)(C)C(O)=O)CC3	PLASMA	PA1123N395							24		t	ng × h/mL	454		ng/mL	99.1			UNKNOWN	mg	10		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=25 | https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=121	Homo sapiens		h	7.76	Day 14	non-Japanese		9			false
5992	2871		ADULT	185460|40467029	463.6117	BILASTINE	Bilastine	CCOCCN1C(=NC2=C1C=CC=C2)C3CCN(CCC4=CC=C(C=C4)C(C)(C)C(O)=O)CC3	PLASMA	PA1123N395							24		t	ng × h/mL	990		ng/mL	232			DEFINED DAILY	mg	20		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=25 | https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=121	Homo sapiens		h	4.57	Day 1	non-Japanese		9			false
5993	2871		ADULT	185460|40467029	463.6117	BILASTINE	Bilastine	CCOCCN1C(=NC2=C1C=CC=C2)C3CCN(CCC4=CC=C(C=C4)C(C)(C)C(O)=O)CC3	PLASMA	PA1123N395									∞	ng × h/mL	1205		ng/mL	273			DEFINED DAILY	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=26 | https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=125	Homo sapiens		h	13.11		Young male subjects (18-35 y), non-Japanese		8			false
5994	2871		ADULT	185460|40467029	463.6117	BILASTINE	Bilastine	CCOCCN1C(=NC2=C1C=CC=C2)C3CCN(CCC4=CC=C(C=C4)C(C)(C)C(O)=O)CC3	PLASMA	PA1123N395									∞	ng × h/mL	1483		ng/mL	410			DEFINED DAILY	mg	20		SINGLE	FASTED						HEALTHY	Oral	FEMALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=26 | https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=125	Homo sapiens		h	10.35		Young female subjects (18-35 y), non-Japanese		8			false
5995	2871		ADULT	185460|40467029	463.6117	BILASTINE	Bilastine	CCOCCN1C(=NC2=C1C=CC=C2)C3CCN(CCC4=CC=C(C=C4)C(C)(C)C(O)=O)CC3	PLASMA	PA1123N395									∞	ng × h/mL	1213		ng/mL	195			DEFINED DAILY	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=26 | https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=126	Homo sapiens		h	11.8		Elderly male subjects (>=65 y), non-Japanese		8			false
5996	2871		ADULT	185460|40467029	463.6117	BILASTINE	Bilastine	CCOCCN1C(=NC2=C1C=CC=C2)C3CCN(CCC4=CC=C(C=C4)C(C)(C)C(O)=O)CC3	PLASMA	PA1123N395									∞	ng × h/mL	1195		ng/mL	226			DEFINED DAILY	mg	20		SINGLE	FASTED						HEALTHY	Oral	FEMALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=26 | https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=126	Homo sapiens		h	11.22		Elderly female subjects (>=65 y), non-Japanese		8			false
5997	2871		ADULT	185460|40467029	463.6117	BILASTINE	Bilastine	CCOCCN1C(=NC2=C1C=CC=C2)C3CCN(CCC4=CC=C(C=C4)C(C)(C)C(O)=O)CC3	PLASMA	PA1123N395									?	ng × h/mL	1654.6		ng/mL	228.8			DEFINED DAILY	mg	20		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=26 | https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=130	Homo sapiens		h	18.4		Severe renal impairment (ave 65 y), non-Japanese		6			false
5998	2871		ADULT	185460|40467029	463.6117	BILASTINE	Bilastine	CCOCCN1C(=NC2=C1C=CC=C2)C3CCN(CCC4=CC=C(C=C4)C(C)(C)C(O)=O)CC3	PLASMA	PA1123N395									?	ng × h/mL	732.8		ng/mL	144			DEFINED DAILY	mg	20		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=26 | https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=130	Homo sapiens		h	9.26		Nomal renal function (ave 65.7 y), non-Japanese		6			false
5999	2871		ADULT	185460|40467029	463.6117	BILASTINE	Bilastine	CCOCCN1C(=NC2=C1C=CC=C2)C3CCN(CCC4=CC=C(C=C4)C(C)(C)C(O)=O)CC3	PLASMA	PA1123N395									?	ng × h/mL	946.9		ng/mL	172.1			DEFINED DAILY	mg	20		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=26 | https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=130	Homo sapiens		h	15.1		Mild renal impairment (ave 71.2 y), non-Japanese		6			false
6000	2871		ADULT	185460|40467029	463.6117	BILASTINE	Bilastine	CCOCCN1C(=NC2=C1C=CC=C2)C3CCN(CCC4=CC=C(C=C4)C(C)(C)C(O)=O)CC3	PLASMA	PA1123N395									?	ng × h/mL	1378.6		ng/mL	271.1			DEFINED DAILY	mg	20		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=26 | https://www.pmda.go.jp/drugs/2016/P20161025003/400107000_22800AMX00690000_A100_2.pdf#page=130	Homo sapiens		h	10.5		Moderate renal impairment (ave 71.3 y), non-Japanese		6			false
6001	2873			68778	293.4458	BUDIPINE	Budipine	CC(C)(C)N1CCC(CC1)(C2=CC=CC=C2)C3=CC=CC=C3	PLASMA	L9026OPI2Z																										Plasma protein binding is 96%.	4				REVIEW	https://pubmed.ncbi.nlm.nih.gov/16784759/	Homo sapiens										false
6002	2875		ADULT	21772	293.4458	BUTRIPTYLINE	Butriptyline	CC(CC1C2=CC=CC=C2CCC3=CC=CC=C13)CN(C)C	PLASMA	Z22441975X									∞	ng × h/mL	638.7		ng/mL	46.5			UNKNOWN	mg	75		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6894708/	Homo sapiens		h	19.8				14	Butriptyline hydrochloride 25mg tablet (24.2mg free base)		false
6003	2875		ADULT	21772	293.4458	BUTRIPTYLINE	Butriptyline	CC(CC1C2=CC=CC=C2CCC3=CC=CC=C13)CN(C)C	PLASMA	Z22441975X									∞	ng × h/mL	536.6		ng/mL	20.3			UNKNOWN	mg	75		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6894708/	Homo sapiens		h	19.3				14	Butriptyline hydrochloride SR formulation 75mg tablet (72.6mg free base)		false
6004	2876			54910	261.704	CICLETANINE	Cicletanine	CC1=C(O)C2=C(C=N1)C(OC2)C3=CC=C(Cl)C=C3	PLASMA	CHG7QC509W																										Human protein binding: 93%	7				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3358898/	Homo sapiens										false
6005	2876		ADULT	54910	261.704	CICLETANINE	Cicletanine	CC1=C(O)C2=C(C=N1)C(OC2)C3=CC=C(Cl)C=C3	PLASMA	CHG7QC509W							72		t	μg × h/mL	115		μg/mL	20			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3358898/ | https://link.springer.com/chapter/10.1007/978-1-4613-2067-8_27	Homo sapiens		h	7.4		Normal renal function (CLcr: 101 to 145 mL/min)		6			false
6006	2876		ADULT	54910	261.704	CICLETANINE	Cicletanine	CC1=C(O)C2=C(C=N1)C(OC2)C3=CC=C(Cl)C=C3	PLASMA	CHG7QC509W							72		t	μg × h/mL	81		μg/mL	14			UNKNOWN	mg	300		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3358898/ | https://link.springer.com/chapter/10.1007/978-1-4613-2067-8_27	Homo sapiens		h	12.4		Patients with mild renal impairment (CLcr: 39 to 112 mL/min)		9			false
6007	2876		ADULT	54910	261.704	CICLETANINE	Cicletanine	CC1=C(O)C2=C(C=N1)C(OC2)C3=CC=C(Cl)C=C3	PLASMA	CHG7QC509W							72		t	μg × h/mL	109		μg/mL	13			UNKNOWN	mg	300		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3358898/ | https://link.springer.com/chapter/10.1007/978-1-4613-2067-8_27	Homo sapiens		h	31		Patients with severe renal impairment (CLcr: 7 to 30 mL/min)		10			false
6008	2877		ADULT	71587527	358.4513	CIMETROPIUM	CIMETROPIUM	C[N ]2(CC1CC1)[C@H]3CC(C[C@H]2[C@@H]4O[C@H]34)OC(=O)[C@H](CO)C5=CC=CC=C5	PLASMA	1N3H74AYTK									?	ng × h/mL	22.68		ng/mL	6.39			UNKNOWN	mg	150		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16810649/	Homo sapiens		h	2.7				8	CIMETROPIUM BROMIDE		false
6009	2877		ADULT	71587527	358.4513	CIMETROPIUM	CIMETROPIUM	C[N ]2(CC1CC1)[C@H]3CC(C[C@H]2[C@@H]4O[C@H]34)OC(=O)[C@H](CO)C5=CC=CC=C5	PLASMA	1N3H74AYTK																	UNKNOWN	mg	10		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3761170/	Homo sapiens		min	50				8	CIMETROPIUM BROMIDE		false
6010	2877		ADULT	71587527	358.4513	CIMETROPIUM	CIMETROPIUM	C[N ]2(CC1CC1)[C@H]3CC(C[C@H]2[C@@H]4O[C@H]34)OC(=O)[C@H](CO)C5=CC=CC=C5	PLASMA	1N3H74AYTK													ng/mL	23.8			UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3761170/	Homo sapiens		min	119				8	CIMETROPIUM BROMIDE		false
6011	2878		ADULT	73115	260.219	CLEVUDINE	Clevudine	CC1=CN([C@H]2O[C@@H](CO)[C@H](O)[C@H]2F)C(=O)NC1=O	PLASMA	IN51MVP5F1							24		t	μg × h/mL	3		μg/mL	0.4			UNKNOWN	mg	50		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15239097/	Homo sapiens		h	61		Patients With Chronic Hepatitis B		10			false
6012	2878		ADULT	73115	260.219	CLEVUDINE	Clevudine	CC1=CN([C@H]2O[C@@H](CO)[C@H](O)[C@H]2F)C(=O)NC1=O	PLASMA	IN51MVP5F1							24		t	μg × h/mL	5.7		μg/mL	0.8			UNKNOWN	mg	100		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15239097/	Homo sapiens		h	43.6		Patients With Chronic Hepatitis B		10			false
6013	2878		ADULT	73115	260.219	CLEVUDINE	Clevudine	CC1=CN([C@H]2O[C@@H](CO)[C@H](O)[C@H]2F)C(=O)NC1=O	PLASMA	IN51MVP5F1							24		t	μg × h/mL	12.3		μg/mL	1.6			UNKNOWN	mg	200		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15239097/	Homo sapiens		h	50.8		Patients With Chronic Hepatitis B		6			false
6014	2878		ADULT	73115	260.219	CLEVUDINE	Clevudine	CC1=CN([C@H]2O[C@@H](CO)[C@H](O)[C@H]2F)C(=O)NC1=O	PLASMA	IN51MVP5F1							24		t	μg × h/mL	0.54		μg/mL	0.017			UNKNOWN	mg	10		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18363895/	Homo sapiens				Week 12	patients with chronic hepatitis B		10			false
6015	2878		ADULT	73115	260.219	CLEVUDINE	Clevudine	CC1=CN([C@H]2O[C@@H](CO)[C@H](O)[C@H]2F)C(=O)NC1=O	PLASMA	IN51MVP5F1							24		t	μg × h/mL	2.01		μg/mL	0.056			UNKNOWN	mg	30		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18363895/	Homo sapiens		h	71.2	Week 12	patients with chronic hepatitis B		10			false
6016	2878		ADULT	73115	260.219	CLEVUDINE	Clevudine	CC1=CN([C@H]2O[C@@H](CO)[C@H](O)[C@H]2F)C(=O)NC1=O	PLASMA	IN51MVP5F1							24		t	μg × h/mL	2.95		μg/mL	0.068			UNKNOWN	mg	50		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18363895/	Homo sapiens		h	72.9	Week 12	patients with chronic hepatitis B		10			false
6017	2879		ADULT	5284535	392.873	CLOPREDNOL	CLOPREDNOL	C[C@]12C[C@H](O)[C@H]3[C@@H](C=C(Cl)C4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO	PLASMA	SYP56O3GJG													ng/mL	426			UNKNOWN	mg	20		SINGLE	UNKNOWN				Plasma protein binding was 74 to 94%.	16	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3403094/	Homo sapiens							8	CLOPREDNOL		false
6018	2879		ADULT	5284535	392.873	CLOPREDNOL	CLOPREDNOL	C[C@]12C[C@H](O)[C@H]3[C@@H](C=C(Cl)C4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO	PLASMA	SYP56O3GJG									∞	ng × h/mL	126		ng/mL	41.3			UNKNOWN	mg	2.5		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/660508/	Homo sapiens		h	1.87				12	CLOPREDNOL		false
6019	2880		ADULT	57337	271.4387	DELMOPINOL	Delmopinol	CCCC(CCC)CCCC1COCCN1CCO	PLASMA	DT67WL708F							4		t	nM × h	15		nM	8			UNKNOWN	mL	10		SINGLE	FASTED				n=2 for t1/2, AUC4=AUC(2-6h)		HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9879639/	Homo sapiens				2 mg/mL			6	Delmopinol hydrochloride, 14C-		false
6020	2880		ADULT	57337	271.4387	DELMOPINOL	Delmopinol	CCCC(CCC)CCCC1COCCN1CCO	PLASMA	DT67WL708F							6		t	nM × h	160		nM	49			UNKNOWN	mL	10		SINGLE	FASTED				n=2 for t1/2, AUC6=AUC(4-10h)		HEALTHY	Oral transmucosal	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9879639/	Homo sapiens		h	2.4	Mouth wash, 2 mg/mL, 60s			6	Delmopinol hydrochloride, 14C-		false
6021	2883		ADULT	42723	277.3404	ELLIPTINIUM	ELLIPTINIUM	CC1=C2NC3=C(C=C(O)C=C3)C2=C(C)C4=C[N ](C)=CC=C14	PLASMA	1F1959S062									?	μg × h/mL	2.5		ng/mL	1633			UNKNOWN	mg/m²	98.2		SINGLE	UNKNOWN				In vitro plasma protein binding (78%) was found to be independent of the concentration (0.1-5.0 micrograms/ml).	22	UNHEALTHY	Intravenous	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6891926/	Homo sapiens		h	14.3	100 min infusion			1	Elliptinium acetate		false
6022	2883		ADULT	42723	277.3404	ELLIPTINIUM	ELLIPTINIUM	CC1=C2NC3=C(C=C(O)C=C3)C2=C(C)C4=C[N ](C)=CC=C14	PLASMA	1F1959S062									?	μg × h/mL	3.33		ng/mL	936			UNKNOWN	mg/m²	94.9		SINGLE	UNKNOWN				In vitro plasma protein binding (78%) was found to be independent of the concentration (0.1-5.0 micrograms/ml).	22	UNHEALTHY	Intravenous	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6891926/	Homo sapiens		h	23.9	100 min infusion			1	Elliptinium acetate		false
6023	2887			5743585	284.374	ETOZOLIN	Etozolin	CCOC(=O)\\C=C1/SC(N2CCCCC2)C(=O)N1C	UNKNOWN	UEO8UW9V1Z																										Protein binding: 35% (species unknown)	65				REVIEW	https://link.springer.com/chapter/10.1007/978-3-642-79565-7_5 | https://pubmed.ncbi.nlm.nih.gov/7173295/	Homo sapiens										false
6024	2888		ADULT	5487713	444.5304	FAZADINIUM	Fazadinium	CC1=C(N(\\N=N\\N2C3=[N ](C=CC=C3)C(C)=C2C4=CC=CC=C4)C5=[N ]1C=CC=C5)C6=CC=CC=C6	PLASMA	0R97XIX3OA	6283|3000714|12832575|23665410|23675349	264.32	THIOPENTAL SODIUM	Thiopentone	[Na ].CCCC(C)C1(CC)C(=O)NC(=S)[N-]C1=O	49Y44QZL70											UNKNOWN	mg/kg	1		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/42420/	Homo sapiens		min	85	iv single dose of 1, 1.5,or 2mg/kg according to the duration of the surgical procedure	Patients with normal renal function		11			true
6025	2888		ADULT	5487713	444.5304	FAZADINIUM	Fazadinium	CC1=C(N(\\N=N\\N2C3=[N ](C=CC=C3)C(C)=C2C4=CC=CC=C4)C5=[N ]1C=CC=C5)C6=CC=CC=C6	PLASMA	0R97XIX3OA	6283|3000714|12832575|23665410|23675349	264.32	THIOPENTAL SODIUM	Thiopentone	[Na ].CCCC(C)C1(CC)C(=O)NC(=S)[N-]C1=O	49Y44QZL70											UNKNOWN	mg/kg	1		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/42420/	Homo sapiens		min	140	iv single dose of 1, 1.5,or 2mg/kg according to the duration of the surgical procedure	Patients with renal failure undergoing surgery		14			true
6026	2888		ADULT	5487713	444.5304	FAZADINIUM	Fazadinium	CC1=C(N(\\N=N\\N2C3=[N ](C=CC=C3)C(C)=C2C4=CC=CC=C4)C5=[N ]1C=CC=C5)C6=CC=CC=C6	PLASMA	0R97XIX3OA	6283|3000714|12832575|23665410|23675349	264.32	THIOPENTAL SODIUM	Thiopentone	[Na ].CCCC(C)C1(CC)C(=O)NC(=S)[N-]C1=O	49Y44QZL70											UNKNOWN	mg/kg	1		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6107098/	Homo sapiens		min	82	iv single dose of 1, 1.5, or 2mg/kg according to the duration of operation	Patients with normal hepatic function	and suxamethonium, phenoperidine, fentanyl	11			true
6027	2888		ADULT	5487713	444.5304	FAZADINIUM	Fazadinium	CC1=C(N(\\N=N\\N2C3=[N ](C=CC=C3)C(C)=C2C4=CC=CC=C4)C5=[N ]1C=CC=C5)C6=CC=CC=C6	PLASMA	0R97XIX3OA	6283|3000714|12832575|23665410|23675349	264.32	THIOPENTAL SODIUM	Thiopentone	[Na ].CCCC(C)C1(CC)C(=O)NC(=S)[N-]C1=O	49Y44QZL70											UNKNOWN	mg/kg	1		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6107098/	Homo sapiens		min	153	iv single dose of 1, 1.5, or 2mg/kg according to the duration of operation	Patients with cirrhosis	and suxamethonium, phenoperidine, fentanyl	8			true
6028	2888		ADULT	5487713	444.5304	FAZADINIUM	Fazadinium	CC1=C(N(\\N=N\\N2C3=[N ](C=CC=C3)C(C)=C2C4=CC=CC=C4)C5=[N ]1C=CC=C5)C6=CC=CC=C6	PLASMA	0R97XIX3OA	6283|3000714|12832575|23665410|23675349	264.32	THIOPENTAL SODIUM	Thiopentone	[Na ].CCCC(C)C1(CC)C(=O)NC(=S)[N-]C1=O	49Y44QZL70											UNKNOWN	mg/kg	1		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6107098/	Homo sapiens		min	103	iv single dose of 1, 1.5, or 2mg/kg according to the duration of operation	Patients with cholestasis	and suxamethonium, phenoperidine, fentanyl	8			true
6029	2888		ADULT	5487713	444.5304	FAZADINIUM	Fazadinium	CC1=C(N(\\N=N\\N2C3=[N ](C=CC=C3)C(C)=C2C4=CC=CC=C4)C5=[N ]1C=CC=C5)C6=CC=CC=C6	PLASMA	0R97XIX3OA																	UNKNOWN	mg/kg	0.5		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6108730/	Homo sapiens		min	30.2		Patients during neuroleptanaesthesia		4			false
6030	2888		ADULT	5487713	444.5304	FAZADINIUM	Fazadinium	CC1=C(N(\\N=N\\N2C3=[N ](C=CC=C3)C(C)=C2C4=CC=CC=C4)C5=[N ]1C=CC=C5)C6=CC=CC=C6	PLASMA	0R97XIX3OA																	UNKNOWN	mg/kg	1		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6108730/	Homo sapiens		min	50.1		Patients during neuroleptanaesthesia		5			false
6031	2888		ADULT	5487713	444.5304	FAZADINIUM	Fazadinium	CC1=C(N(\\N=N\\N2C3=[N ](C=CC=C3)C(C)=C2C4=CC=CC=C4)C5=[N ]1C=CC=C5)C6=CC=CC=C6	PLASMA	0R97XIX3OA																	UNKNOWN	mg/kg	1.5		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6108730/ | https://pubmed.ncbi.nlm.nih.gov/28133/	Homo sapiens		min	76.4		Patients undergoing abdominal surgery		10			false
6032	2888		ADULT	5487713	444.5304	FAZADINIUM	Fazadinium	CC1=C(N(\\N=N\\N2C3=[N ](C=CC=C3)C(C)=C2C4=CC=CC=C4)C5=[N ]1C=CC=C5)C6=CC=CC=C6	SERUM	0R97XIX3OA																						UNKNOWN				Human serum protein binding: 51% (1.5μg/mL), ultracentrifugation	49	HEALTHY		UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6122460/	Homo sapiens							6			false
6033	2888		ADULT	5487713	444.5304	FAZADINIUM	Fazadinium	CC1=C(N(\\N=N\\N2C3=[N ](C=CC=C3)C(C)=C2C4=CC=CC=C4)C5=[N ]1C=CC=C5)C6=CC=CC=C6	SERUM	0R97XIX3OA																						UNKNOWN				Human serum protein binding: 57% (1.5μg/mL), ultracentrifugation	43	UNHEALTHY		UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6122460/	Homo sapiens					Patient with cirrhosis		5			false
6034	2889		ADULT	51755	455.399	FENTICONAZOLE	Fenticonazole	ClC1=CC(Cl)=C(C=C1)C(CN2C=CN=C2)OCC3=CC=C(SC4=CC=CC=C4)C=C3	PLASMA	QG05NRB077									∞	ng × h/mL	12.914		ng/mL	0.499			UNKNOWN	g	0.1		SINGLE	FASTED						HEALTHY	Topical	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29404019/	Homo sapiens		h	27.883				12			false
6035	2889		ADULT	51755	455.399	FENTICONAZOLE	Fenticonazole	ClC1=CC(Cl)=C(C=C1)C(CN2C=CN=C2)OCC3=CC=C(SC4=CC=CC=C4)C=C3	PLASMA	QG05NRB077									∞	ng × h/mL	159.22		ng/mL	5.957			UNKNOWN	g	0.1		SINGLE	FASTED						HEALTHY	Vaginal	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29404019/	Homo sapiens		h	26.51				10			false
6036	2890		ADULT	12818200	366.475	GLIBORNURIDE	Glibornuride	CC1=CC=C(C=C1)S(=O)(=O)NC(=O)N[C@@H]2[C@H](O)[C@]3(C)CC[C@H]2C3(C)C	PLASMA	VP83E7434R									?	μg × h/mL	18.5						UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3157397/	Homo sapiens		h	9.2				8			false
6037	2901		ADULT	23009	226.2325	NIMORAZOLE	NIMORAZOLE	[O-][N ](=O)C1=CN=CN1CCN2CCOCC2	PLASMA	469ULX0H4G									∞	μg × h/mL	26		μg/mL	5.9			UNKNOWN	g	0.5		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6871077/	Homo sapiens		h	2.6				1	NIMORAZOLE		false
6038	2901		ADULT	23009	226.2325	NIMORAZOLE	NIMORAZOLE	[O-][N ](=O)C1=CN=CN1CCN2CCOCC2	PLASMA	469ULX0H4G									∞	μg × h/mL	91		μg/mL	14.7			UNKNOWN	g	1		SINGLE	FED						UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6871077/	Homo sapiens		h	3.7				1	NIMORAZOLE		false
6039	2901		ADULT	23009	226.2325	NIMORAZOLE	NIMORAZOLE	[O-][N ](=O)C1=CN=CN1CCN2CCOCC2	PLASMA	469ULX0H4G									∞	μg × h/mL	376		μg/mL	79.3			HIGHEST STUDIED	g	3.5		SINGLE	FED						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6871077/	Homo sapiens		h	2.9				1	NIMORAZOLE		false
6040	2901		ADULT	23009	226.2325	NIMORAZOLE	NIMORAZOLE	[O-][N ](=O)C1=CN=CN1CCN2CCOCC2	PLASMA	469ULX0H4G									∞	μg × h/mL	469		μg/mL	69.5			UNKNOWN	g	3		SINGLE	FED						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6871077/	Homo sapiens		h	4.2				1	NIMORAZOLE		false
6041	2901		ADULT	23009	226.2325	NIMORAZOLE	NIMORAZOLE	[O-][N ](=O)C1=CN=CN1CCN2CCOCC2	PLASMA	469ULX0H4G									∞	μg × h/mL	122		μg/mL	22.4			UNKNOWN	g	2		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6871077/	Homo sapiens		h	3.1				1	NIMORAZOLE		false
6042	2901		ADULT	23009	226.2325	NIMORAZOLE	NIMORAZOLE	[O-][N ](=O)C1=CN=CN1CCN2CCOCC2	PLASMA	469ULX0H4G									∞	μg × h/mL	293		μg/mL	49.8			UNKNOWN	g	2		SINGLE	FED						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6871077/	Homo sapiens		h	3.5				1	NIMORAZOLE		false
6043	2901		ADULT	23009	226.2325	NIMORAZOLE	NIMORAZOLE	[O-][N ](=O)C1=CN=CN1CCN2CCOCC2	PLASMA	469ULX0H4G									∞	μg × h/mL	40		μg/mL	10			UNKNOWN	g	1		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6871077/	Homo sapiens		h	2.4				1	NIMORAZOLE		false
6044	2901		ADULT	23009	226.2325	NIMORAZOLE	NIMORAZOLE	[O-][N ](=O)C1=CN=CN1CCN2CCOCC2	PLASMA	469ULX0H4G									∞	μg × h/mL	262		μg/mL	41			UNKNOWN	g	3		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6871077/	Homo sapiens		h	3.7				1	NIMORAZOLE		false
6045	2907		ADULT	134019	325.3651	PIXANTRONE	PIXANTRONe	NCCNC1=CC=C(NCCN)C2=C1C(=O)C3=C(C=NC=C3)C2=O	PLASMA	F5SXN2KNMR							24		t	ng × h/mL	982						UNKNOWN	mg/m²	33		MULTIPLE	UNKNOWN		week	1		50	UNKNOWN	Intravenous	UNKNOWN	DRUG LABEL	https://ec.europa.eu/health/documents/community-register/2017/20170322137183/anx_137183_en.pdf	Homo sapiens		h	23.3				3	PIXANTRONE DIMALEATE		false
6046	2907		ADULT	134019	325.3651	PIXANTRONE	PIXANTRONe	NCCNC1=CC=C(NCCN)C2=C1C(=O)C3=C(C=NC=C3)C2=O	PLASMA	F5SXN2KNMR							24		t	ng × h/mL	1727						UNKNOWN	mg/m²	49		MULTIPLE	UNKNOWN		week	1		50	UNKNOWN	Intravenous	UNKNOWN	DRUG LABEL	https://ec.europa.eu/health/documents/community-register/2017/20170322137183/anx_137183_en.pdf	Homo sapiens		h	23.3				6	PIXANTRONE DIMALEATE		false
6047	2907		ADULT	134019	325.3651	PIXANTRONE	PIXANTRONe	NCCNC1=CC=C(NCCN)C2=C1C(=O)C3=C(C=NC=C3)C2=O	PLASMA	F5SXN2KNMR							24		t	ng × h/mL	3811						UNKNOWN	mg/m²	88		MULTIPLE	UNKNOWN		week	1		50	UNKNOWN	Intravenous	UNKNOWN	DRUG LABEL	https://ec.europa.eu/health/documents/community-register/2017/20170322137183/anx_137183_en.pdf	Homo sapiens		h	23.3				2	PIXANTRONE DIMALEATE		false
6048	2907		UNKNOWN	134019	325.3651	PIXANTRONE	PIXANTRONE	NCCNC1=CC=C(NCCN)C2=C1C(=O)C3=C(C=NC=C3)C2=O	PLASMA	F5SXN2KNMR									∞	nM × h	502.6		nM	318.1			UNKNOWN	mg/m²	16.5		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11205916/	Homo sapiens		h	11.23		advanced solid malignancies		3	PIXANTRONE		false
6049	2907		UNKNOWN	134019	325.3651	PIXANTRONE	PIXANTRONE	NCCNC1=CC=C(NCCN)C2=C1C(=O)C3=C(C=NC=C3)C2=O	PLASMA	F5SXN2KNMR									∞	nM × h	1074.8		nM	701.4			UNKNOWN	mg/m²	25		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11205916/	Homo sapiens		h	16.46		advanced solid malignancies		6	PIXANTRONE		false
6050	2907		UNKNOWN	134019	325.3651	PIXANTRONE	PIXANTRONE	NCCNC1=CC=C(NCCN)C2=C1C(=O)C3=C(C=NC=C3)C2=O	PLASMA	F5SXN2KNMR									∞	nM × h	1773.4		nM	1193			UNKNOWN	mg/m²	37.5		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11205916/	Homo sapiens		h	13.77		advanced solid malignancies		1	PIXANTRONE		false
6051	2907		UNKNOWN	134019	325.3651	PIXANTRONE	PIXANTRONE	NCCNC1=CC=C(NCCN)C2=C1C(=O)C3=C(C=NC=C3)C2=O	PLASMA	F5SXN2KNMR									∞	nM × h	5027.1		nM	4297.6			UNKNOWN	mg/m²	75		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11205916/	Homo sapiens		h	8.89		advanced solid malignancies		1	PIXANTRONE		false
6052	2907		UNKNOWN	134019	325.3651	PIXANTRONE	PIXANTRONE	NCCNC1=CC=C(NCCN)C2=C1C(=O)C3=C(C=NC=C3)C2=O	PLASMA	F5SXN2KNMR									∞	nM × h	7882.3		nM	7120.8			UNKNOWN	mg/m²	112.5		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11205916/	Homo sapiens		h	9.5		advanced solid malignancies		3	PIXANTRONE		false
6053	2907		UNKNOWN	134019	325.3651	PIXANTRONE	PIXANTRONE	NCCNC1=CC=C(NCCN)C2=C1C(=O)C3=C(C=NC=C3)C2=O	PLASMA	F5SXN2KNMR									∞	nM × h	8058.5		nM	3852.1			MAX TOLERATED	mg/m²	150		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11205916/	Homo sapiens		h	11.91		advanced solid malignancies		2	PIXANTRONE		false
6054	2907		ADULT	134019	325.3651	PIXANTRONE	PIXANTRONE	NCCNC1=CC=C(NCCN)C2=C1C(=O)C3=C(C=NC=C3)C2=O	PLASMA	F5SXN2KNMR									?	nM × h	438.1		nM	52.4			UNKNOWN	mg/m²	5		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11432625/	Homo sapiens		h	36.3		non-Hodgkin's lymphoma		1	PIXANTRONE DIMALEATE		false
6055	2907		ADULT	134019	325.3651	PIXANTRONE	PIXANTRONE	NCCNC1=CC=C(NCCN)C2=C1C(=O)C3=C(C=NC=C3)C2=O	PLASMA	F5SXN2KNMR									?	nM × h	451.1		nM	213.2			UNKNOWN	mg/m²	10		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11432625/	Homo sapiens		h	21.4		non-Hodgkin's lymphoma		3	PIXANTRONE DIMALEATE		false
6056	2907		ADULT	134019	325.3651	PIXANTRONE	PIXANTRONE	NCCNC1=CC=C(NCCN)C2=C1C(=O)C3=C(C=NC=C3)C2=O	PLASMA	F5SXN2KNMR									?	nM × h	781.9		nM	483.2			UNKNOWN	mg/m²	16.5		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11432625/	Homo sapiens		h	20.8		non-Hodgkin's lymphoma		4	PIXANTRONE DIMALEATE		false
6057	2907		ADULT	134019	325.3651	PIXANTRONE	PIXANTRONE	NCCNC1=CC=C(NCCN)C2=C1C(=O)C3=C(C=NC=C3)C2=O	PLASMA	F5SXN2KNMR									?	nM × h	1321.2		nM	762.4			UNKNOWN	mg/m²	25		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11432625/	Homo sapiens		h	19.7		non-Hodgkin's lymphoma		4	PIXANTRONE DIMALEATE		false
6058	2907		ADULT	134019	325.3651	PIXANTRONE	PIXANTRONE	NCCNC1=CC=C(NCCN)C2=C1C(=O)C3=C(C=NC=C3)C2=O	PLASMA	F5SXN2KNMR									?	nM × h	2530.5		nM	1189.6			UNKNOWN	mg/m²	35		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11432625/	Homo sapiens		h	31.9		non-Hodgkin's lymphoma		3	PIXANTRONE DIMALEATE		false
6059	2907		ADULT	134019	325.3651	PIXANTRONE	PIXANTRONE	NCCNC1=CC=C(NCCN)C2=C1C(=O)C3=C(C=NC=C3)C2=O	PLASMA	F5SXN2KNMR									?	nM × h	2266.8		nM	1447.5			MAX TOLERATED	mg/m²	56		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11432625/	Homo sapiens		h	22.3		non-Hodgkin's lymphoma		3	PIXANTRONE DIMALEATE		false
6060	2907		ADULT	134019	325.3651	PIXANTRONE	PIXANTRONE	NCCNC1=CC=C(NCCN)C2=C1C(=O)C3=C(C=NC=C3)C2=O	PLASMA	F5SXN2KNMR									?	nM × h	3679.9		nM	2241.9			RP2D	mg/m²	84		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11432625/	Homo sapiens		h	17.5		non-Hodgkin's lymphoma		6	PIXANTRONE DIMALEATE		false
6061	2909		ADULT	51712	269.3831	PRAMIRACETAM	Pramiracetam	CC(C)N(CCNC(=O)CN1CCCC1=O)C(C)C	PLASMA	4449F8I3LE									?	μg × h/mL	87.56		μg/mL	8.98			UNKNOWN	mg	1600		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4008675/	Homo sapiens		h	4.5				6			false
6062	2909		ADULT	51712	269.3831	PRAMIRACETAM	Pramiracetam	CC(C)N(CCNC(=O)CN1CCCC1=O)C(C)C	PLASMA	4449F8I3LE									?	μg × h/mL	20.99		μg/mL	2.71			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4008675/	Homo sapiens		h	5				6			false
6063	2909		ADULT	51712	269.3831	PRAMIRACETAM	Pramiracetam	CC(C)N(CCNC(=O)CN1CCCC1=O)C(C)C	PLASMA	4449F8I3LE									?	μg × h/mL	40.09		μg/mL	5.4			UNKNOWN	mg	800		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4008675/	Homo sapiens		h	4.7				6			false
6064	2909		ADULT	51712	269.3831	PRAMIRACETAM	Pramiracetam	CC(C)N(CCNC(=O)CN1CCCC1=O)C(C)C	PLASMA	4449F8I3LE									?	μg × h/mL	63.18		μg/mL	6.13			UNKNOWN	mg	1200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4008675/	Homo sapiens		h	6.5				6			false
6065	2916		ADULT	42262	467.6434	TIROPRAMIDE	Tiropramide	CCCN(CCC)C(=O)C(CC1=CC=C(OCCN(CC)CC)C=C1)NC(=O)C2=CC=CC=C2	PLASMA	R7S0904CN2									∞	ng × h/mL	352.81		ng/mL	106.76			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17127027/	Homo sapiens		h	3.07				12	Tiropramide		false
6066	2922		UNKNOWN	5666	237.2949	VILOXAZINE	Viloxazine	CCOC1=C(OCC2CNCCO2)C=CC=C1	PLASMA	5I5Y2789ZF																						UNKNOWN				Human plasma protein binding: 75.7% (10mcg/mL), 79.5% (3mcg/mL), 81.4% (1mcg/mL), 82.2% (0.5mcg/mL)	24.3	UNKNOWN		UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/211964Orig1s000IntegratedR.pdf#page=140	Homo sapiens										false
6067	2922		ADULT	5666	237.2949	VILOXAZINE	Viloxazine	CCOC1=C(OCC2CNCCO2)C=CC=C1	PLASMA	5I5Y2789ZF									∞	μg × h/mL	27.3		μg/mL	1.33			UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/211964Orig1s000IntegratedR.pdf#page=214	Homo sapiens		h	7.02				28			false
6068	2922		ADULT	5666	237.2949	VILOXAZINE	Viloxazine	CCOC1=C(OCC2CNCCO2)C=CC=C1	PLASMA	5I5Y2789ZF							24		t	μg × h/mL	24.7		μg/mL	1.66			UNKNOWN	mg	200		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/211964Orig1s000IntegratedR.pdf#page=215	Homo sapiens				Day 6 (multiply dosed from days 3 to 6)			27			false
6069	2922		ADULT	5666	237.2949	VILOXAZINE	Viloxazine	CCOC1=C(OCC2CNCCO2)C=CC=C1	PLASMA	5I5Y2789ZF									∞	μg × h/mL	24.45		μg/mL	1.21			UNKNOWN	mg	200		SINGLE	FED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/211964Orig1s000IntegratedR.pdf#page=216	Homo sapiens					with Applesauce (no meal)		27			false
6070	2922		ADULT	5666	237.2949	VILOXAZINE	Viloxazine	CCOC1=C(OCC2CNCCO2)C=CC=C1	PLASMA	5I5Y2789ZF									∞	μg × h/mL	23.68		μg/mL	1.22			UNKNOWN	mg	200		SINGLE	HIGH-FAT						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/211964Orig1s000IntegratedR.pdf#page=216	Homo sapiens							27			false
6071	2922		ADULT	5666	237.2949	VILOXAZINE	Viloxazine	CCOC1=C(OCC2CNCCO2)C=CC=C1	PLASMA	5I5Y2789ZF									∞	μg × h/mL	25.64		μg/mL	1.34			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/211964Orig1s000IntegratedR.pdf#page=216	Homo sapiens							27			false
6072	2922		ADULT	5666	237.2949	VILOXAZINE	Viloxazine	CCOC1=C(OCC2CNCCO2)C=CC=C1	PLASMA	5I5Y2789ZF									∞	μg × h/mL	61.84		μg/mL	2.83			DEFINED DAILY	mg	400		SINGLE	FED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/211964Orig1s000IntegratedR.pdf#page=222	Homo sapiens					Normal Renal Function					false
6073	2922		ADULT	5666	237.2949	VILOXAZINE	Viloxazine	CCOC1=C(OCC2CNCCO2)C=CC=C1	PLASMA	5I5Y2789ZF									∞	μg × h/mL	67.59		μg/mL	3.06			DEFINED DAILY	mg	400		SINGLE	FED						UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/211964Orig1s000IntegratedR.pdf#page=222	Homo sapiens					Mild Renal Impairment					false
6074	2922		ADULT	5666	237.2949	VILOXAZINE	Viloxazine	CCOC1=C(OCC2CNCCO2)C=CC=C1	PLASMA	5I5Y2789ZF									∞	μg × h/mL	80.38		μg/mL	3.25			DEFINED DAILY	mg	400		SINGLE	FED						UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/211964Orig1s000IntegratedR.pdf#page=222	Homo sapiens					Moderate Renal Impairment					false
6075	2922		ADULT	5666	237.2949	VILOXAZINE	Viloxazine	CCOC1=C(OCC2CNCCO2)C=CC=C1	PLASMA	5I5Y2789ZF									∞	μg × h/mL	117.5		μg/mL	4.65			DEFINED DAILY	mg	400		SINGLE	FED						UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/211964Orig1s000IntegratedR.pdf#page=222	Homo sapiens					Severe Renal Impairment without dialysis					false
6076	2922		ADULT	5666	237.2949	VILOXAZINE	Viloxazine	CCOC1=C(OCC2CNCCO2)C=CC=C1	PLASMA	5I5Y2789ZF							24		t	μg × h/mL	134.32		μg/mL	8			UNKNOWN	mg	900		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/211964Orig1s000IntegratedR.pdf#page=223	Homo sapiens					CYP2D6 poor metabolizer (PM)		7			false
6077	2922		ADULT	5666	237.2949	VILOXAZINE	Viloxazine	CCOC1=C(OCC2CNCCO2)C=CC=C1	PLASMA	5I5Y2789ZF							24		t	μg × h/mL	106.89		μg/mL	6.59			UNKNOWN	mg	900		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/211964Orig1s000IntegratedR.pdf#page=223	Homo sapiens					CYP2D6 extensive metabolizer (EM)		29			false
6078	2925		ADULT	219101	327.4174	TRAXOPRODIL	TRAXOPRODIL	C[C@@H]([C@@H](O)C1=CC=C(O)C=C1)N2CCC(O)(CC2)C3=CC=CC=C3	PLASMA	UTC046R5HM									∞	ng × h/mL	1370		ng/mL	674			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16984212	Homo sapiens		h	3.5	Pharmacokinetic parameters of traxoprodil in cytochrome P450 2D6 extensive metabolisers are provided			5	TRAXOPRODIL		false
6079	2925		ADULT	219101	327.4174	TRAXOPRODIL	TRAXOPRODIL	C[C@@H]([C@@H](O)C1=CC=C(O)C=C1)N2CCC(O)(CC2)C3=CC=CC=C3	PLASMA	UTC046R5HM									∞	ng × h/mL	856		ng/mL	246			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16984212	Homo sapiens		h	3.68	2-hour intravenous infusion; Pharmacokinetic parameters of traxoprodil in cytochrome P450 2D6 extensive metabolisers are provided			11	TRAXOPRODIL		false
6080	2927		ADULT	169371	440.4	AMINOPTERIN	AMINOPTERIN	NC1=NC2=NC=C(CNC3=CC=C(C=C3)C(=O)NC(CCC(O)=O)C(O)=O)N=C2C(N)=N1	PLASMA	JYB41CTM2Q									?	μM × h	0.51		μM	0.166			UNKNOWN	mg/m²	2		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/16299240	Homo sapiens										false
6081	2927		ADULT	169371	440.4	AMINOPTERIN	AMINOPTERIN	NC1=NC2=NC=C(CNC3=CC=C(C=C3)C(=O)NC(CCC(O)=O)C(O)=O)N=C2C(N)=N1	PLASMA	JYB41CTM2Q									?	μM × h	1.2						UNKNOWN	mg/m²	2		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/9552052	Homo sapiens		h	3.64							false
6082	2928		UNKNOWN	3194	274.18	EBSELEN	ebselen	O=C1N([Se]C2=C1C=CC=C2)C3=CC=CC=C3	PLASMA	40X2P7DPGH									∞	ng × h/mL	546.31		ng/mL	30.3			MAX TOLERATED	mg	200		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.sto.nato.int/publications/STO Meeting Proceedings/RTO-MP-AVT-158/MP-AVT-158-23.pdf	Homo sapiens		h	6.42				6	EBSELEN		false
6083	2928		UNKNOWN	3194	274.18	EBSELEN	ebselen	O=C1N([Se]C2=C1C=CC=C2)C3=CC=CC=C3	PLASMA	40X2P7DPGH									∞	ng × h/mL	883.15		ng/mL	67.5			MAX TOLERATED	mg	400		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.sto.nato.int/publications/STO Meeting Proceedings/RTO-MP-AVT-158/MP-AVT-158-23.pdf	Homo sapiens		h	12.1				6	EBSELEN		false
6084	2928		UNKNOWN	3194	274.18	EBSELEN	ebselen	O=C1N([Se]C2=C1C=CC=C2)C3=CC=CC=C3	PLASMA	40X2P7DPGH									∞	ng × h/mL	710.1		ng/mL	70.3			MAX TOLERATED	mg	800		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.sto.nato.int/publications/STO Meeting Proceedings/RTO-MP-AVT-158/MP-AVT-158-23.pdf	Homo sapiens		h	14.4				6	EBSELEN		false
6085	2928		UNKNOWN	3194	274.18	EBSELEN	ebselen	O=C1N([Se]C2=C1C=CC=C2)C3=CC=CC=C3	PLASMA	40X2P7DPGH									∞	ng × h/mL	992.64		ng/mL	83.4			MAX TOLERATED	mg	1600		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.sto.nato.int/publications/STO Meeting Proceedings/RTO-MP-AVT-158/MP-AVT-158-23.pdf	Homo sapiens		h	16.7				6	EBSELEN		false
6086	2929		ADULT	5288209	391.5457	FENRETINIDE	CC(\\C=C\\C1=C(C)CCCC1(C)C)=C/C=C/C(C)=C/C(=O)NC2=CC=C(O)C=C2	CC(\\C=C\\C1=C(C)CCCC1(C)C)=C/C=C/C(C)=C/C(=O)NC2=CC=C(O)C=C2	PLASMA	187EJ7QEXL	4666		[NO STEREO] NSC-LSC-1|[NO STEREO] PACLITAXEL	CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C	CC(=O)OC1C2=C(C)C(CC(O)(C(OC(=O)C3=CC=CC=C3)C4C5(COC5CC(O)C4(C)C1=O)OC(C)=O)C2(C)C)OC(=O)C(O)C(NC(=O)C6=CC=CC=C6)C7=CC=CC=C7	[NO STEREO] 5DFG1UEB63|[NO STEREO] P88XT4IS4D	12		t	μM × h	60.3		μM	7.3			RECOMMENDED	mg/m²	1800		MULTIPLE	HIGH-FAT		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/16034523	Homo sapiens		h	14.5							true
6087	2933		ADULT	71157	246.3049	NEFIRACETAM	Nefiracetam	CC1=CC=CC(C)=C1NC(=O)CN2CCCC2=O	SERUM	1JK12GX30N									∞	μg × h/mL	78.9		μg/mL	10.6			UNKNOWN	mg	600		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1360528	Homo sapiens		h	3.85				5	Nefiracetam		false
6088	2933		ADULT	71157	246.3049	NEFIRACETAM	Nefiracetam	CC1=CC=CC(C)=C1NC(=O)CN2CCCC2=O	SERUM	1JK12GX30N									∞	μg × h/mL	167		μg/mL	22.6			UNKNOWN	mg	1200		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1360528	Homo sapiens		h	3.77				5	Nefiracetam		false
6089	2933		ADULT	71157	246.3049	NEFIRACETAM	Nefiracetam	CC1=CC=CC(C)=C1NC(=O)CN2CCCC2=O	SERUM	1JK12GX30N									∞	μg × h/mL	16.1		μg/mL	2.08			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1360528	Homo sapiens		h	4.78				5	Nefiracetam		false
6090	2933		ADULT	71157	246.3049	NEFIRACETAM	Nefiracetam	CC1=CC=CC(C)=C1NC(=O)CN2CCCC2=O	SERUM	1JK12GX30N									∞	μg × h/mL	27.1		μg/mL	4.02			UNKNOWN	mg	200		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1360528	Homo sapiens		h	3.33				5	Nefiracetam		false
6091	2933		ADULT	71157	246.3049	NEFIRACETAM	Nefiracetam	CC1=CC=CC(C)=C1NC(=O)CN2CCCC2=O	SERUM	1JK12GX30N									∞	pg × h/mL	19.59		μg/mL	1.97			UNKNOWN	mg	100		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1360528	Homo sapiens		h	5.86				5	Nefiracetam		false
6092	2933		ADULT	71157	246.3049	NEFIRACETAM	Nefiracetam	CC1=CC=CC(C)=C1NC(=O)CN2CCCC2=O	SERUM	1JK12GX30N									∞	μg × h/mL	5.67		μg/mL	0.68			UNKNOWN	mg	30		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1360528	Homo sapiens		h	4.43				3	Nefiracetam		false
6093	2933		ADULT	71157	246.3049	NEFIRACETAM	Nefiracetam	CC1=CC=CC(C)=C1NC(=O)CN2CCCC2=O	SERUM	1JK12GX30N													μg/mL	4.1			UNKNOWN	mg	200		STEADY-STATE	FED		day	3			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1360528	Homo sapiens							6	NEFIRACETAM		false
6094	2933		UNKNOWN	71157	246.3049	NEFIRACETAM	NEFIRACETAM	CC1=CC=CC(C)=C1NC(=O)CN2CCCC2=O	SERUM	1JK12GX30N													μM	16.3			UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	REVIEW	https://www.ncbi.nlm.nih.gov/pubmed/10820661	Homo sapiens		h	3.9				5			false
6095	2934		ADULT	148177	461.6584	PERIFOSINE	PERIFOSINE	CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1	BLOOD	2GWV496552									∞	ng × h/mL	98016		ng/mL	763			UNKNOWN	mg	100		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/20079628	Homo sapiens		h	100.3							false
6096	2934		ADULT	148177	461.6584	PERIFOSINE	PERIFOSINE	CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1	BLOOD	2GWV496552									∞	ng × h/mL	398084		ng/mL	3691			UNKNOWN	mg	800		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/20079628	Homo sapiens		h	81							false
6097	2935		ADULT	31553	482.4362	SILIBININ A	SILIBININ A	COC1=C(O)C=CC(=C1)[C@H]2OC3=C(O[C@@H]2CO)C=CC(=C3)[C@H]4OC5=C(C(=O)[C@@H]4O)C(O)=CC(O)=C5	PLASMA	33X338MNE4									?	ng × h/mL	37.17		ng/mL	15.69			UNKNOWN	mg	48.7		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29273470/	Homo sapiens		h	1.98	Formulation also contains: 250 mg Milk Thistle (Silybum marianum PE 80% silymarin); 29 mg Pomegrantate (punica granatum PE); 20 mg Grape Seed (80% oligomeric proanthocyanidins); 20 mg Turmeric (95% curcuminoids); 50 mg Ashwagandha (Withania somnifera 4:1 PE); 9 mg Bacopa (Bacopa monnieri PE 50%); 35 mg Green Tea (98% polyphenols); 30 mg Horny Goat Weed; 4 mg Black Tea (PE 50% polyphenols); 4 mg White Tea (PE 90% polyphenols); 7 mg Blueberry; 7 mg Red Raspberry; 11 mg Bilberry; 12 mg Panax Ginseng (Root PE 80% ginsenosides); 8 mg Harada (Terminalia chebula fruit); 7 mg Boswellia (PE 65% boswellic acid); 7 mg Maca; 5 mg Shilajit (20% fulvic acid); 28 mg Resveratrol; 7.5 mg Ascorbic Acid			12	SILIBININ A		false
6098	2938		ADULT	9841398	315.4	A-86929	A-86929		PLASMA	S3ZIH99X6E									∞	ng × h/mL	42.7		ng/mL	19.4			UNKNOWN	mg	5		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10564839/	Homo sapiens		h	4.3				7	ABT-431		false
6099	2938		ADULT	9841398	315.4	A-86929	A-86929		PLASMA	S3ZIH99X6E									∞	ng × h/mL	16.1		ng/mL	19.1			UNKNOWN	mg	6.6		SINGLE	UNKNOWN						HEALTHY	Respiratory	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10564839/	Homo sapiens		h	3.2				6	ABT-431		false
6100	2938		ADULT	9841398	315.4	A-86929	A-86929		PLASMA	S3ZIH99X6E									∞	ng × h/mL	22.5		ng/mL	13.6			HIGHEST STUDIED	mg	19.8		SINGLE	UNKNOWN						HEALTHY	Respiratory	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10564839/	Homo sapiens		h	5.5				2	ABT-431		false
6101	2938		ADULT	9841398	315.4	A-86929	A-86929		PLASMA	S3ZIH99X6E									∞	ng × h/L	10.6		ng/mL	15.2			UNKNOWN	mg	3.3		SINGLE	UNKNOWN		day	1			HEALTHY	Respiratory	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10564839/	Homo sapiens		h	3.2				6	ABT-431		false
6102	2938		ADULT	9841398	315.4	A-86929	A-86929		PLASMA	S3ZIH99X6E									∞	ng × h/mL	26		ng/mL	24.2			UNKNOWN	mg	13.2		SINGLE	UNKNOWN						HEALTHY	Respiratory	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10564839/	Homo sapiens		h	3.2				4	ABT-431		false
6103	2939		ADULT		447.82	6-hydroxyalbaconazole	6-hydroxyalbaconazole		PLASMA										∞	ng × h/mL	53474.6		ng/mL	235			UNKNOWN	mg	400		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23390369	Homo sapiens		h	72.3	tablet			39	albaconazole		false
6104	2939		ADULT	208952	431.823	ALBACONAZOLE	albaconazole	C[C@@H](N1C=NC2=C(C=CC(Cl)=C2)C1=O)[C@](O)(CN3C=NC=N3)C4=C(F)C=C(F)C=C4	PLASMA	YDW24Y8IAB									∞	ng × h/mL	107796.1		ng/mL	1670			UNKNOWN	mg	400		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23390369	Homo sapiens		h	64.2	tablet			39	albaconazole		false
6105	2939		ADULT		447.82	6-hydroxyalbaconazole	6-hydroxyalbaconazole		PLASMA										∞	ng × h/mL	51216.1		ng/mL	226			UNKNOWN	mg	400		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23390369	Homo sapiens		h	67.1	capsule			39	albaconazole		false
6106	2939		ADULT	208952	431.823	ALBACONAZOLE	albaconazole	C[C@@H](N1C=NC2=C(C=CC(Cl)=C2)C1=O)[C@](O)(CN3C=NC=N3)C4=C(F)C=C(F)C=C4	PLASMA	YDW24Y8IAB									∞	ng × h/mL	114472.3		ng/mL	2350			UNKNOWN	mg	400		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23390369	Homo sapiens		h	57.7	capsule			39	albaconazole		false
6107	2940		ADULT	178030	193.2489	ALVAMELINE	ALVAMELINE	CCN1N=NC(=N1)C2=CCCN(C)C2	SERUM	4XFD7B36M6																	UNKNOWN	mg	150		MULTIPLE	FASTED		day	3			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9488097/	Homo sapiens		h	3.7		Alzheimer's disease patients		6	ALVAMELINE		false
6108	2940		ADULT	178030	193.2489	ALVAMELINE	ALVAMELINE	CCN1N=NC(=N1)C2=CCCN(C)C2	SERUM	4XFD7B36M6																	UNKNOWN	mg	125		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9488097/	Homo sapiens		h	3.1		Alzheimer's disease patients		6	ALVAMELINE		false
6109	2941		ADULT	9859827	253.22	1,3-dioxolane guanosine		C1[C@@H](O[C@@H](O1)CO)N2C=NC3C2=NC(=NC3=O)N	PLASMA										?	ng × h/mL	6834		ng/mL	1545			UNKNOWN	mg	500		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/20038617	Homo sapiens		h	17.6				6	Amdoxovir		false
6110	2941		ADULT	124088	252.23	AMDOXOVIR	Amdoxovir	NC1=NC2=C(N=CN2[C@H]3CO[C@@H](CO)O3)C(N)=N1	PLASMA	54I81H0M9C									?	ng × h/mL	1326		ng/mL	499			UNKNOWN	mg	500		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20038617	Homo sapiens		h	1.4				6	Amdoxovir		false
6111	2944		UNKNOWN	129869	336.5982	ATIPRIMOD	ATIPRIMOD	CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1	PLASMA	MG7D3QD743																	UNKNOWN	mg	90		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	PATENT	https://patents.google.com/patent/US20100203146A1/en	Homo sapiens		day	63							false
6112	2946		ADULT	3086671	318.366	ATRELEUTON	ATRELEUTON	C[C@H](C#CC1=CC=C(CC2=CC=C(F)C=C2)S1)N(O)C(N)=O	PLASMA	U301T88E1M									∞	μg × h/mL	3.4		μg/mL	0.17			UNKNOWN	mg	10		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9569998/	Homo sapiens		h	15				8	ATRELEUTON		false
6113	2946		ADULT	3086671	318.366	ATRELEUTON	ATRELEUTON	C[C@H](C#CC1=CC=C(CC2=CC=C(F)C=C2)S1)N(O)C(N)=O	PLASMA	U301T88E1M									∞	μg × h/mL	6.5		μg/mL	0.31			UNKNOWN	mg	20		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9569998/	Homo sapiens		h	15.2				8	ATRELEUTON		false
6114	2946		ADULT	3086671	318.366	ATRELEUTON	ATRELEUTON	C[C@H](C#CC1=CC=C(CC2=CC=C(F)C=C2)S1)N(O)C(N)=O	PLASMA	U301T88E1M									∞	μg × h/mL	12.5		μg/mL	0.6			UNKNOWN	mg	40		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9569998/	Homo sapiens		h	15				8	ATRELEUTON		false
6115	2946		ADULT	3086671	318.366	ATRELEUTON	ATRELEUTON	C[C@H](C#CC1=CC=C(CC2=CC=C(F)C=C2)S1)N(O)C(N)=O	PLASMA	U301T88E1M									∞	μg × h/mL	26.3		μg/mL	1.17			UNKNOWN	mg	80		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9569998/	Homo sapiens		h	15.4				8	ATRELEUTON		false
6116	2946		ADULT	3086671	318.366	ATRELEUTON	ATRELEUTON	C[C@H](C#CC1=CC=C(CC2=CC=C(F)C=C2)S1)N(O)C(N)=O	PLASMA	U301T88E1M									∞	μg × h/mL	37.6		μg/mL	1.82			UNKNOWN	mg	120		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9569998/	Homo sapiens		h	13.7				8	ATRELEUTON		false
6117	2946		ADULT	3086671	318.366	ATRELEUTON	ATRELEUTON	C[C@H](C#CC1=CC=C(CC2=CC=C(F)C=C2)S1)N(O)C(N)=O	PLASMA	U301T88E1M									∞	μg × h/mL	53.3		μg/mL	2.35			HIGHEST STUDIED	mg	160		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9569998/	Homo sapiens		h	15.6				8	ATRELEUTON		false
6118	2949		UNKNOWN	184841	379.4274	BELAPERIDONE	BELAPERIDONE	FC1=CC=C(C=C1)[C@H]2C[C@@H]3CN(CCN4C(=O)NC5=C(C=CC=C5)C4=O)C[C@H]23	PLASMA	4DN0TK4892																	UNKNOWN				UNKNOWN	UNKNOWN				Plasma protein binding: 98.6%	1.4	UNKNOWN	Oral	UNKNOWN	REVIEW	http://wxjs.chinayyhg.com/upload/Files/Drugs_of_the_Future/1998-(Vol-23)/df23-0191.pdf	Homo sapiens		h	12							false
6119	2950		ADULT	60691	251.3263	BESIPIRDINE	BESIPIRDINE	CCCN(N1C=CC2=C1C=CC=C2)C3=CC=NC=C3	PLASMA	95PY16J933													ng/mL	72.2			MAX TOLERATED	mg	50		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7674813/	Homo sapiens							1	BESIPIRDINE		false
6120	2950		ADULT	60691	251.3263	BESIPIRDINE	BESIPIRDINE	CCCN(N1C=CC2=C1C=CC=C2)C3=CC=NC=C3	PLASMA	95PY16J933													ng/mL	165			HIGHEST STUDIED	mg	60		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7674813/	Homo sapiens							1	BESIPIRDINE		false
6121	2951		ADULT	9576891	297.781	BIMOCLOMOL	bimoclomol	OC(CO\\N=C(/Cl)C1=CN=CC=C1)CN2CCCCC2	PLASMA	9IYF14814M									∞	ng × h/g	360		ng/g	400			UNKNOWN	mg/kg	0.53		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/11484067	Homo sapiens		min	22.2					bimoclomol		false
6122	2951		ADULT	9576891	297.781	BIMOCLOMOL	bimoclomol	OC(CO\\N=C(/Cl)C1=CN=CC=C1)CN2CCCCC2	PLASMA	9IYF14814M									∞	ng × h/g	840		ng/g	710			UNKNOWN	mg/kg	1.07		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/11484067	Homo sapiens		min	36					bimoclomol		false
6123	2953		ADULT	216208	505.6086	CAPROMORELIN	Capromorelin	CN1N=C2CCN(C[C@@]2(CC3=CC=CC=C3)C1=O)C(=O)[C@@H](COCC4=CC=CC=C4)NC(=O)C(C)(C)N	PLASMA	0MQ44VUN84									∞	ng × h/mL	254.6		ng/mL	90.5			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25448190/	Homo sapiens		h	2.54		Able-bodied participants		10	Capromorelin tartrate		false
6124	2953		ADULT	216208	505.6086	CAPROMORELIN	Capromorelin	CN1N=C2CCN(C[C@@]2(CC3=CC=CC=C3)C1=O)C(=O)[C@@H](COCC4=CC=CC=C4)NC(=O)C(C)(C)N	PLASMA	0MQ44VUN84									∞	ng × h/mL	97.9		ng/mL	28.1			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25448190/	Homo sapiens		h	2.75		Able-bodied participants		10	Capromorelin tartrate		false
6125	2953		ADULT	216208	505.6086	CAPROMORELIN	Capromorelin	CN1N=C2CCN(C[C@@]2(CC3=CC=CC=C3)C1=O)C(=O)[C@@H](COCC4=CC=CC=C4)NC(=O)C(C)(C)N	PLASMA	0MQ44VUN84									∞	ng × h/mL	527.8		ng/mL	187.1			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25448190/	Homo sapiens		h	2.56		Able-bodied participants		10	Capromorelin tartrate		false
6126	2953		ADULT	216208	505.6086	CAPROMORELIN	Capromorelin	CN1N=C2CCN(C[C@@]2(CC3=CC=CC=C3)C1=O)C(=O)[C@@H](COCC4=CC=CC=C4)NC(=O)C(C)(C)N	PLASMA	0MQ44VUN84									∞	ng × h/mL	135.3		ng/mL	33.9			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25448190/	Homo sapiens		h	3.02		Spinal cord injury participants		6	Capromorelin tartrate		false
6127	2953		ADULT	216208	505.6086	CAPROMORELIN	Capromorelin	CN1N=C2CCN(C[C@@]2(CC3=CC=CC=C3)C1=O)C(=O)[C@@H](COCC4=CC=CC=C4)NC(=O)C(C)(C)N	PLASMA	0MQ44VUN84									∞	ng × h/mL	346		ng/mL	71.2			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25448190/	Homo sapiens		h	3.1		Spinal cord injury participants		5	Capromorelin tartrate		false
6128	2953		ADULT	216208	505.6086	CAPROMORELIN	Capromorelin	CN1N=C2CCN(C[C@@]2(CC3=CC=CC=C3)C1=O)C(=O)[C@@H](COCC4=CC=CC=C4)NC(=O)C(C)(C)N	PLASMA	0MQ44VUN84									∞	ng × h/mL	798.9		ng/mL	206.5			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25448190/	Homo sapiens		h	2.91		Spinal cord injury participants		5	Capromorelin tartrate		false
6129	2955		ADULT	9812632	640.8563	CEMADOTIN	CEMADOTIN	CC(C)[C@H](NC(=O)[C@H](C(C)C)N(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)NCC3=CC=CC=C3	PLASMA	6SQ8M7ZSFV							24		t	μM × h	6.3		μM	1.2			UNKNOWN	mg/m²	3		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9704730	Homo sapiens		h	11	day 5			5	CEMADOTIN		false
6130	2955		ADULT	9812632	640.8563	CEMADOTIN	CEMADOTIN	CC(C)[C@H](NC(=O)[C@H](C(C)C)N(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)NCC3=CC=CC=C3	PLASMA	6SQ8M7ZSFV							24		t	μM × h	10.1		μM	0.75			MAX TOLERATED	mg/m²	2.5		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9704730	Homo sapiens		h	13	day 1			9	CEMADOTIN		false
6131	2955		ADULT	9812632	640.8563	CEMADOTIN	CEMADOTIN	CC(C)[C@H](NC(=O)[C@H](C(C)C)N(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)NCC3=CC=CC=C3	PLASMA	6SQ8M7ZSFV							24		t	μM × h	8.9		μM	1.3			UNKNOWN	mg/m²	3		SINGLE	UNKNOWN			1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9704730	Homo sapiens		h	10	day 1			5	CEMADOTIN		false
6132	2955		ADULT	9812632	640.8563	CEMADOTIN	CEMADOTIN	CC(C)[C@H](NC(=O)[C@H](C(C)C)N(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)NCC3=CC=CC=C3	PLASMA	6SQ8M7ZSFV							24		t	μM × h	10.5		μM	0.97			MAX TOLERATED	mg/m²	2.5		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9704730	Homo sapiens		h	10	day 5			9	CEMADOTIN		false
6133	2960		ADULT	219023	398.3595	DIFLOMOTECAN	diflomotecan	CC[C@@]1(O)CC(=O)OCC2=C1C=C3N(CC4=CC5=C(C=C(F)C(F)=C5)N=C34)C2=O	PLASMA	QKT1LC4J1P									?	ng × h/mL	114.5		ng/mL	31.04			UNKNOWN	mg	2		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18654747	Homo sapiens		h	4.32				8	diflomotecan		false
6134	2960		ADULT	219023	398.3595	DIFLOMOTECAN	diflomotecan	CC[C@@]1(O)CC(=O)OCC2=C1C=C3N(CC4=CC5=C(C=C(F)C(F)=C5)N=C34)C2=O	PLASMA	QKT1LC4J1P									?	ng × h/mL	156.83		ng/mL	45.25			UNKNOWN	mg	4		MULTIPLE	UNKNOWN		3 weeks	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18654747	Homo sapiens		h	3.26				6	diflomotecan		false
6135	2960		ADULT	219023	398.3595	DIFLOMOTECAN	diflomotecan	CC[C@@]1(O)CC(=O)OCC2=C1C=C3N(CC4=CC5=C(C=C(F)C(F)=C5)N=C34)C2=O	PLASMA	QKT1LC4J1P									?	ng × h/mL	120		ng/mL	37.7			UNKNOWN	mg	3		MULTIPLE	UNKNOWN		3 weeks	1			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18654747	Homo sapiens		h	4.56				1	diflomotecan		false
6136	2965		ADULT	444912	520.5784	ELINAFIDE	ELINAFIDE	O=C1N(CCNCCCNCCN2C(=O)C3=CC=CC4=CC=CC(C2=O)=C34)C(=O)C5=C6C(C=CC=C16)=CC=C5	PLASMA	HL580335SI							24		t	ng × h/mL	238		ng/mL	47.8			UNKNOWN	mg/m²	4		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11157040	Homo sapiens		h	37.2				3	LU79553		false
6137	2965		ADULT	444912	520.5784	ELINAFIDE	ELINAFIDE	O=C1N(CCNCCCNCCN2C(=O)C3=CC=CC4=CC=CC(C2=O)=C34)C(=O)C5=C6C(C=CC=C16)=CC=C5	PLASMA	HL580335SI							24		t	ng × h/mL	620.6		ng/mL	177.1			UNKNOWN	mg/m²	10		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11157040	Homo sapiens		h	44.1				2	LU79553		false
6138	2965		ADULT	444912	520.5784	ELINAFIDE	ELINAFIDE	O=C1N(CCNCCCNCCN2C(=O)C3=CC=CC4=CC=CC(C2=O)=C34)C(=O)C5=C6C(C=CC=C16)=CC=C5	PLASMA	HL580335SI							24		t	ng × h/mL	384.4		ng/mL	105.5			UNKNOWN	mg/m²	6.6		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11157040	Homo sapiens		h	42.7				2	LU79553		false
6139	2965		ADULT	444912	520.5784	ELINAFIDE	ELINAFIDE	O=C1N(CCNCCCNCCN2C(=O)C3=CC=CC4=CC=CC(C2=O)=C34)C(=O)C5=C6C(C=CC=C16)=CC=C5	PLASMA	HL580335SI							24		t	ng × h/mL	123		ng/mL	22.3			UNKNOWN	mg/m²	2		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11157040	Homo sapiens		h	39.8				2	LU79553		false
6140	2965		ADULT	444912	520.5784	ELINAFIDE	ELINAFIDE	O=C1N(CCNCCCNCCN2C(=O)C3=CC=CC4=CC=CC(C2=O)=C34)C(=O)C5=C6C(C=CC=C16)=CC=C5	PLASMA	HL580335SI							24		t	ng × h/mL	658.9		ng/mL	74			UNKNOWN	mg/m²	14		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11157040	Homo sapiens		h	36				1	LU79553		false
6141	2965		ADULT	444912	520.5784	ELINAFIDE	ELINAFIDE	O=C1N(CCNCCCNCCN2C(=O)C3=CC=CC4=CC=CC(C2=O)=C34)C(=O)C5=C6C(C=CC=C16)=CC=C5	PLASMA	HL580335SI							24		t	ng × h/mL	978.7		ng/mL	177.8			MAX TOLERATED	mg/m²	18		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11157040	Homo sapiens		h	37.3				4	LU79553		false
6142	2969		ADULT	208923	452.5427	ENSACULIN	ENSACULIN	COC1=CC2=C(C=C1OCCCN3CCN(CC3)C4=C(OC)C=CC=C4)C(C)=C(C)C(=O)O2	PLASMA	869PGR00AT									?	ng × h/mL	99.5		ng/mL	16.8			UNKNOWN	mg	20		MULTIPLE	FED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9590466	Homo sapiens		h	11.1				9	KA 672		false
6143	2969		ADULT	208923	452.5427	ENSACULIN	ENSACULIN	COC1=CC2=C(C=C1OCCCN3CCN(CC3)C4=C(OC)C=CC=C4)C(C)=C(C)C(=O)O2	PLASMA	869PGR00AT									?	ng × h/mL	43.8		ng/mL	9.6			UNKNOWN	mg	10		MULTIPLE	FED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9590466	Homo sapiens		h	8.3				9	KA 672		false
6144	2969		ADULT	208923	452.5427	ENSACULIN	ENSACULIN	COC1=CC2=C(C=C1OCCCN3CCN(CC3)C4=C(OC)C=CC=C4)C(C)=C(C)C(=O)O2	PLASMA	869PGR00AT									∞	ng × h/mL	255		ng/mL	25.4			UNKNOWN	mg	60		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9590466	Homo sapiens		h	16.1				5	KA 672		false
6145	2969		ADULT	208923	452.5427	ENSACULIN	ENSACULIN	COC1=CC2=C(C=C1OCCCN3CCN(CC3)C4=C(OC)C=CC=C4)C(C)=C(C)C(=O)O2	PLASMA	869PGR00AT									∞	ng × h/mL	202.9		ng/mL	35.6			UNKNOWN	mg	20		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9590466	Homo sapiens		h	13.7				9	KA 672		false
6146	2969		ADULT	208923	452.5427	ENSACULIN	ENSACULIN	COC1=CC2=C(C=C1OCCCN3CCN(CC3)C4=C(OC)C=CC=C4)C(C)=C(C)C(=O)O2	PLASMA	869PGR00AT									∞	ng × h/mL	61.8		ng/mL	7.6			UNKNOWN	mg	10		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9590466	Homo sapiens		h	17.5				9	KA 672		false
6147	2970		ADULT	208928	345.3995	EPTAPIRONE	Eptapirone	CN1C(=O)C=NN(CCCCN2CCN(CC2)C3=NC=CC=N3)C1=O	PLASMA	3M824XRO8N																	UNKNOWN	mg	1.5		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/16272182	Homo sapiens		h	2					Eptapirone		false
6148	2971		ADULT	178087	400.3787	FANDOFLOXACIN	FANDOFLOXACIN	CN1CCN(CC1)C2=C(F)C=C3C(=O)C(=CN(C4=NC=C(F)C=C4)C3=C2)C(O)=O	PLASMA	I6406OC637									?	mg × h/L	87.7		mg/L	5.65			UNKNOWN	mg	300		STEADY-STATE	FASTED		day	1	somewhat more than 50% is protein-bound	50	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9786475	Homo sapiens		h	17.54				9	DW-116		false
6149	2971		ADULT	178087	400.3787	FANDOFLOXACIN	FANDOFLOXACIN	CN1CCN(CC1)C2=C(F)C=C3C(=O)C(=CN(C4=NC=C(F)C=C4)C3=C2)C(O)=O	PLASMA	I6406OC637									?	mg × h/L	82.2		mg/L	5.47			UNKNOWN	mg	300		STEADY-STATE	FED		day	1	somewhat more than 50% is protein-bound	50	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9786475	Homo sapiens		h	18.34				9	DW-116		false
6150	2971		ADULT	178087	400.3787	FANDOFLOXACIN	FANDOFLOXACIN	CN1CCN(CC1)C2=C(F)C=C3C(=O)C(=CN(C4=NC=C(F)C=C4)C3=C2)C(O)=O	PLASMA	I6406OC637									?	mg × h/L	114.8		mg/L	8			UNKNOWN	mg	400		STEADY-STATE	FASTED		day	1	somewhat more than 50% is protein-bound	50	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9786475	Homo sapiens		h	16.74				9	DW-116		false
6151	2971		ADULT	178087	400.3787	FANDOFLOXACIN	FANDOFLOXACIN	CN1CCN(CC1)C2=C(F)C=C3C(=O)C(=CN(C4=NC=C(F)C=C4)C3=C2)C(O)=O	PLASMA	I6406OC637									?	mg × h/L	107.4		mg/L	7.36			UNKNOWN	mg	400		STEADY-STATE	FED		day	1	somewhat more than 50% is protein-bound	50	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9786475	Homo sapiens		h	17.15				9	DW-116		false
6152	2972		ADULT	6918277	322.3363	FINROZOLE	FINROZOLE	O[C@@H](CC1=CC=C(F)C=C1)[C@H](N2C=NC=N2)C3=CC=C(C=C3)C#N	SERUM	40028KHQ6B									∞	ng × h/mL	57.68		ng/mL	8.88			UNKNOWN	mg	9		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11736883	Homo sapiens		h	7.85				8	FINROZOLE		false
6153	2972		ADULT	6918277	322.3363	FINROZOLE	FINROZOLE	O[C@@H](CC1=CC=C(F)C=C1)[C@H](N2C=NC=N2)C3=CC=C(C=C3)C#N	SERUM	40028KHQ6B									∞	ng × h/mL	118.23		ng/mL	18.2			UNKNOWN	mg	30		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11736883	Homo sapiens		h	7.71				8	FINROZOLE		false
6154	2972		ADULT	6918277	322.3363	FINROZOLE	finrozole	O[C@@H](CC1=CC=C(F)C=C1)[C@H](N2C=NC=N2)C3=CC=C(C=C3)C#N	SERUM	40028KHQ6B									∞	ng × h/mL	13.25		ng/mL	2.11			UNKNOWN	mg	3		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11736883	Homo sapiens		h	8.36				8	finrozole		false
6155	2975		ADULT	53421	361.395	FOSTEDIL	FOSTEDIL	CCOP(=O)(CC1=CC=C(C=C1)C2=NC3=C(S2)C=CC=C3)OCC	PLASMA	D41WS786UL									?	μg × h/mL	17.33		μg/mL	2.33			UNKNOWN	mg/kg	12		SINGLE	FASTED				The in vitro protein binding of [14C]fostedil at concentrations of 0.1-100 ug/mL ranged from 95-97% in dog plasma. The binding was not concentration dependent, and saturation of the binding sites was not apparent at concentrations up to 100 ug/mL.	4	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6542139	Homo sapiens		h	8.45				12	FOSTEDIL		false
6156	2976		ADULT	35370	267.2413	ZIDOVUDINE	Zidovudine		PLASMA	4B9XT59T7S													ng/mL	69.4			UNKNOWN	mg	800		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10839658	Homo sapiens		h	7.1				10	FOZIVUDINE TIDOXIL		false
6157	2976		ADULT	64140	745.95	FOZIVUDINE TIDOXIL	FOZIVUDINE TIDOXIL		PLASMA	687805287F													mg/L	8.39			UNKNOWN	mg	800		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10839658	Homo sapiens		h	4.4				10	FOZIVUDINE TIDOXIL		false
6158	2976		ADULT	35370	267.2413	ZIDOVUDINE	Zidovudine		PLASMA	4B9XT59T7S													ng/mL	30.03			UNKNOWN	mg	200		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10839658	Homo sapiens		h	7.1				10	FOZIVUDINE TIDOXIL		false
6159	2976		ADULT	35370	267.2413	ZIDOVUDINE	Zidovudine		PLASMA	4B9XT59T7S													ng/mL	70.54			UNKNOWN	mg	400		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10839658	Homo sapiens		h	6.1				10	FOZIVUDINE TIDOXIL		false
6160	2976		ADULT	64140	745.95	FOZIVUDINE TIDOXIL	FOZIVUDINE TIDOXIL		PLASMA	687805287F													mg/L	4.14			UNKNOWN	mg	400		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10839658	Homo sapiens		h	4				10	FOZIVUDINE TIDOXIL		false
6161	2976		ADULT	64140	745.95	FOZIVUDINE TIDOXIL	FOZIVUDINE TIDOXIL		PLASMA	687805287F													mg/L	1.92			UNKNOWN	mg	200		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10839658	Homo sapiens		h	3.5				10	FOZIVUDINE TIDOXIL		false
6162	2993		ADULT	10180	340.482	LUCANTHONE	LUCANTHONE	CCN(CC)CCNC1=C2C(=O)C3=C(SC2=C(C)C=C1)C=CC=C3	SERUM	FC6D57000M							25		t	μg × h/mL	96						RECOMMENDED	mg/kg	10		STEADY-STATE	UNKNOWN		2 days	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9989518/	Homo sapiens										false
6163	2998		ADULT	471161	376.235	MARIBAVIR	Maribavir	CC(C)NC1=NC2=C(C=C(Cl)C(Cl)=C2)N1[C@H]3O[C@@H](CO)[C@H](O)[C@@H]3O	PLASMA	PTB4X93HE1							12		t	μg × h/mL	128		μg/mL	17.2			UNKNOWN	mg	400		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215596lbl.pdf3page=10	Homo sapiens		h	4.32		Transplant patients, Fasted/Fed					false
6164	2998			471161	376.235	MARIBAVIR	Maribavir	CC(C)NC1=NC2=C(C=C(Cl)C(Cl)=C2)N1[C@H]3O[C@@H](CO)[C@H](O)[C@@H]3O	PLASMA	PTB4X93HE1																										Huma plasma protein binding: 98% (0.05~200μg/mL)	2				DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215596lbl.pdf3page=10	Homo sapiens										false
6165	2998		ADULT	471161	376.235	MARIBAVIR	Maribavir	CC(C)NC1=NC2=C(C=C(Cl)C(Cl)=C2)N1[C@H]3O[C@@H](CO)[C@H](O)[C@@H]3O	PLASMA	PTB4X93HE1									∞	μg × h/mL	10.77		μg/mL	2.66			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215596Orig1s000IntegratedR.pdf#page=161	Homo sapiens		h	3.28				10			false
6166	2998		ADULT	471161	376.235	MARIBAVIR	Maribavir	CC(C)NC1=NC2=C(C=C(Cl)C(Cl)=C2)N1[C@H]3O[C@@H](CO)[C@H](O)[C@@H]3O	PLASMA	PTB4X93HE1									∞	μg × h/mL	16.31		μg/mL	3.32			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215596Orig1s000IntegratedR.pdf#page=161	Homo sapiens		h	3.01				10			false
6167	2998		ADULT	471161	376.235	MARIBAVIR	Maribavir	CC(C)NC1=NC2=C(C=C(Cl)C(Cl)=C2)N1[C@H]3O[C@@H](CO)[C@H](O)[C@@H]3O	PLASMA	PTB4X93HE1									∞	μg × h/mL	34.16		μg/mL	7.45			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215596Orig1s000IntegratedR.pdf#page=161	Homo sapiens		h	3.64				10			false
6168	2998		ADULT	471161	376.235	MARIBAVIR	Maribavir	CC(C)NC1=NC2=C(C=C(Cl)C(Cl)=C2)N1[C@H]3O[C@@H](CO)[C@H](O)[C@@H]3O	PLASMA	PTB4X93HE1									∞	μg × h/mL	183.05		μg/mL	26.39			UNKNOWN	mg	800		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215596Orig1s000IntegratedR.pdf#page=161	Homo sapiens		h	4.04				10			false
6169	2998		ADULT	471161	376.235	MARIBAVIR	Maribavir	CC(C)NC1=NC2=C(C=C(Cl)C(Cl)=C2)N1[C@H]3O[C@@H](CO)[C@H](O)[C@@H]3O	PLASMA	PTB4X93HE1									∞	μg × h/mL	97.8		μg/mL	16.68			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215596Orig1s000IntegratedR.pdf#page=161	Homo sapiens		h	3.91				10			false
6170	2998		ADULT	471161	376.235	MARIBAVIR	Maribavir	CC(C)NC1=NC2=C(C=C(Cl)C(Cl)=C2)N1[C@H]3O[C@@H](CO)[C@H](O)[C@@H]3O	PLASMA	PTB4X93HE1									∞	μg × h/mL	436.75		μg/mL	48.81			UNKNOWN	mg	1600		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215596Orig1s000IntegratedR.pdf#page=161	Homo sapiens		h	4.8				10			false
6171	2998		ADULT	471161	376.235	MARIBAVIR	Maribavir	CC(C)NC1=NC2=C(C=C(Cl)C(Cl)=C2)N1[C@H]3O[C@@H](CO)[C@H](O)[C@@H]3O	PLASMA	PTB4X93HE1							8		t	μg × h/mL	26.73		μg/mL	6.999			UNKNOWN	mg	200		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215596Orig1s000IntegratedR.pdf#page=163	Homo sapiens		h	3.78	Day 28	HIV infected men		6			false
6172	2998		ADULT	471161	376.235	MARIBAVIR	Maribavir	CC(C)NC1=NC2=C(C=C(Cl)C(Cl)=C2)N1[C@H]3O[C@@H](CO)[C@H](O)[C@@H]3O	PLASMA	PTB4X93HE1							8		t	μg × h/mL	55.49		μg/mL	18.102			UNKNOWN	mg	400		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215596Orig1s000IntegratedR.pdf#page=163	Homo sapiens		h	5.86	Day 1	HIV infected men		10			false
6173	2998		ADULT	471161	376.235	MARIBAVIR	Maribavir	CC(C)NC1=NC2=C(C=C(Cl)C(Cl)=C2)N1[C@H]3O[C@@H](CO)[C@H](O)[C@@H]3O	PLASMA	PTB4X93HE1							12		t	μg × h/mL	126.76		μg/mL	33.499			UNKNOWN	mg	600		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215596Orig1s000IntegratedR.pdf#page=163	Homo sapiens		h	6.1	Day 28	HIV infected men		5			false
6174	2998		ADULT	471161	376.235	MARIBAVIR	Maribavir	CC(C)NC1=NC2=C(C=C(Cl)C(Cl)=C2)N1[C@H]3O[C@@H](CO)[C@H](O)[C@@H]3O	PLASMA	PTB4X93HE1							8		t	μg × h/mL	77.42		μg/mL	19.189			UNKNOWN	mg	400		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215596Orig1s000IntegratedR.pdf#page=163	Homo sapiens		h	5.37	Day 28	HIV infected men		9			false
6175	2998		ADULT	471161	376.235	MARIBAVIR	Maribavir	CC(C)NC1=NC2=C(C=C(Cl)C(Cl)=C2)N1[C@H]3O[C@@H](CO)[C@H](O)[C@@H]3O	PLASMA	PTB4X93HE1							12		t	μg × h/mL	122.01		μg/mL	30.551			UNKNOWN	mg	600		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215596Orig1s000IntegratedR.pdf#page=163	Homo sapiens		h	5.23	Day 1	HIV infected men		7			false
6176	2998		ADULT	471161	376.235	MARIBAVIR	Maribavir	CC(C)NC1=NC2=C(C=C(Cl)C(Cl)=C2)N1[C@H]3O[C@@H](CO)[C@H](O)[C@@H]3O	PLASMA	PTB4X93HE1							12		t	μg × h/mL	154.82		μg/mL	35.366			UNKNOWN	mg	900		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215596Orig1s000IntegratedR.pdf#page=163	Homo sapiens		h	5.04	Day 1	HIV infected men		12			false
6177	2998		ADULT	471161	376.235	MARIBAVIR	Maribavir	CC(C)NC1=NC2=C(C=C(Cl)C(Cl)=C2)N1[C@H]3O[C@@H](CO)[C@H](O)[C@@H]3O	PLASMA	PTB4X93HE1							12		t	μg × h/mL	229.92		μg/mL	43.532			UNKNOWN	mg	900		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215596Orig1s000IntegratedR.pdf#page=163	Homo sapiens		h	4.73	Day 28	HIV infected men		8			false
6178	2998		ADULT	471161	376.235	MARIBAVIR	Maribavir	CC(C)NC1=NC2=C(C=C(Cl)C(Cl)=C2)N1[C@H]3O[C@@H](CO)[C@H](O)[C@@H]3O	PLASMA	PTB4X93HE1							12		t	μg × h/mL	206.05		μg/mL	34.005			UNKNOWN	mg	1200		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215596Orig1s000IntegratedR.pdf#page=163	Homo sapiens		h	6.39	Day 1	HIV infected men		10			false
6179	2998		ADULT	471161	376.235	MARIBAVIR	Maribavir	CC(C)NC1=NC2=C(C=C(Cl)C(Cl)=C2)N1[C@H]3O[C@@H](CO)[C@H](O)[C@@H]3O	PLASMA	PTB4X93HE1							12		t	μg × h/mL	249		μg/mL	43.905			UNKNOWN	mg	1200		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215596Orig1s000IntegratedR.pdf#page=163	Homo sapiens		h	5.83	Day 28	HIV infected men		9			false
6180	2998		ADULT	471161	376.235	MARIBAVIR	Maribavir	CC(C)NC1=NC2=C(C=C(Cl)C(Cl)=C2)N1[C@H]3O[C@@H](CO)[C@H](O)[C@@H]3O	PLASMA	PTB4X93HE1							8		t	μg × h/mL	12.79		μg/mL	3.783			UNKNOWN	mg	100		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215596Orig1s000IntegratedR.pdf#page=163	Homo sapiens		h	5.07	Day 1	HIV infected men		11			false
6181	2998		ADULT	471161	376.235	MARIBAVIR	Maribavir	CC(C)NC1=NC2=C(C=C(Cl)C(Cl)=C2)N1[C@H]3O[C@@H](CO)[C@H](O)[C@@H]3O	PLASMA	PTB4X93HE1							8		t	μg × h/mL	17.2		μg/mL	4.371			UNKNOWN	mg	100		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215596Orig1s000IntegratedR.pdf#page=163	Homo sapiens		h	5.67	Day 28	HIV infected men		11			false
6182	2998		ADULT	471161	376.235	MARIBAVIR	Maribavir	CC(C)NC1=NC2=C(C=C(Cl)C(Cl)=C2)N1[C@H]3O[C@@H](CO)[C@H](O)[C@@H]3O	PLASMA	PTB4X93HE1							8		t	μg × h/mL	28.79		μg/mL	8.154			UNKNOWN	mg	200		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215596Orig1s000IntegratedR.pdf#page=163	Homo sapiens		h	4.55	Day 1	HIV infected men		12			false
6183	2998		ADULT	471161	376.235	MARIBAVIR	Maribavir	CC(C)NC1=NC2=C(C=C(Cl)C(Cl)=C2)N1[C@H]3O[C@@H](CO)[C@H](O)[C@@H]3O	PLASMA	PTB4X93HE1									∞	μg × h/mL	85.6		μg/mL	11.4			UNKNOWN	mg	400		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215596Orig1s000IntegratedR.pdf#page=167	Homo sapiens							29			false
6184	2998		ADULT	471161	376.235	MARIBAVIR	Maribavir	CC(C)NC1=NC2=C(C=C(Cl)C(Cl)=C2)N1[C@H]3O[C@@H](CO)[C@H](O)[C@@H]3O	PLASMA	PTB4X93HE1									∞	μg × h/mL	99		μg/mL	15.9			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215596Orig1s000IntegratedR.pdf#page=167	Homo sapiens							29			false
6185	2998		ADULT	471161	376.235	MARIBAVIR	Maribavir	CC(C)NC1=NC2=C(C=C(Cl)C(Cl)=C2)N1[C@H]3O[C@@H](CO)[C@H](O)[C@@H]3O	PLASMA	PTB4X93HE1																						UNKNOWN				The mean protein binding was >98% in all renal function categories.	2	UNKNOWN		FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215596Orig1s000IntegratedR.pdf#page=170	Homo sapiens					All renal functions					false
6186	2998		ADULT	471161	376.235	MARIBAVIR	Maribavir	CC(C)NC1=NC2=C(C=C(Cl)C(Cl)=C2)N1[C@H]3O[C@@H](CO)[C@H](O)[C@@H]3O	PLASMA	PTB4X93HE1									∞	μg × h/mL	138.3		μg/mL	20.98			UNKNOWN	mg	400		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215596Orig1s000IntegratedR.pdf#page=172	Homo sapiens					Mild/Moderate renal impairment		10			false
6187	2998		ADULT	471161	376.235	MARIBAVIR	Maribavir	CC(C)NC1=NC2=C(C=C(Cl)C(Cl)=C2)N1[C@H]3O[C@@H](CO)[C@H](O)[C@@H]3O	PLASMA	PTB4X93HE1									∞	μg × h/mL	127.6		μg/mL	21.88			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215596Orig1s000IntegratedR.pdf#page=172	Homo sapiens					Healthy control		12			false
6188	2998		ADULT	471161	376.235	MARIBAVIR	Maribavir	CC(C)NC1=NC2=C(C=C(Cl)C(Cl)=C2)N1[C@H]3O[C@@H](CO)[C@H](O)[C@@H]3O	PLASMA	PTB4X93HE1									∞	μg × h/mL	122.6		μg/mL	20.34			UNKNOWN	mg	400		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215596Orig1s000IntegratedR.pdf#page=172	Homo sapiens					Severe renal impairment		8			false
6189	2998		ADULT	471161	376.235	MARIBAVIR	Maribavir	CC(C)NC1=NC2=C(C=C(Cl)C(Cl)=C2)N1[C@H]3O[C@@H](CO)[C@H](O)[C@@H]3O	PLASMA	PTB4X93HE1									∞	μg × h/mL	78.6		μg/mL	12.72			UNKNOWN	mg	200		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215596Orig1s000IntegratedR.pdf#page=175	Homo sapiens					Moderate hepatic impairment (Child-Pugh B (score 7 to 9))		10			false
6190	2998		ADULT	471161	376.235	MARIBAVIR	Maribavir	CC(C)NC1=NC2=C(C=C(Cl)C(Cl)=C2)N1[C@H]3O[C@@H](CO)[C@H](O)[C@@H]3O	PLASMA	PTB4X93HE1									∞	μg × h/mL	62.3		μg/mL	9.45			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215596Orig1s000IntegratedR.pdf#page=175	Homo sapiens					Healthy control		10			false
6191	3001		ADULT	65935	339.407	MOGUISTEINE	MOGUISTEINE	CCOC(=O)CC(=O)N1CCSC1COC2=C(OC)C=CC=C2	PLASMA	6Y556547YY									∞	ng × h/mL	11637.72		ng/mL	3570.47			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30703444	Homo sapiens		h	1.54				4	MOGUISTEINE		false
6192	3001		ADULT	65935	339.407	MOGUISTEINE	MOGUISTEINE	CCOC(=O)CC(=O)N1CCSC1COC2=C(OC)C=CC=C2	PLASMA	6Y556547YY									∞	ng × h/mL	5547.88		ng/mL	1397.87			UNKNOWN	mg	200		MULTIPLE	FASTED		day	3			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30703444	Homo sapiens		h	1.57	200 mg moguisteine three times per day for five days.			4	MOGUISTEINE		false
6193	3003		ADULT	216385	324.349	ODIPARCIL	ODIPARCIL	CC1=CC(=O)OC2=C1C=CC(O[C@@H]3SC[C@@H](O)[C@H](O)[C@H]3O)=C2	PLASMA	FIK1414ZI8									∞	ng × h/mL	18260		ng/mL	1710			UNKNOWN	mg	500		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18757783	Homo sapiens				odiparcil 500 mg orally every 12 hours on days 1-5			24	ODIPARCIL		false
6194	3004		ADULT	47318	226.342	OLTIPRAZ	oltipraz	CC1=C(SSC1=S)C2=NC=CN=C2	PLASMA	6N510JUL1Y													ng/mL	27.7			UNKNOWN	mg	90		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20664537/	Homo sapiens							17	oltipraz		false
6195	3004		ADULT	47318	226.342	OLTIPRAZ	oltipraz	CC1=C(SSC1=S)C2=NC=CN=C2	PLASMA	6N510JUL1Y													ng/mL	45			UNKNOWN	mg	60		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20664537/	Homo sapiens							28	oltipraz		false
6196	3004		ADULT	128585	224.4	7-Methyl-6,8-bis(methylthio)pyrrolo(1,2-a)pyrazine	7-Methyl-6,8-bis(methylthio)pyrrolo(1,2-a)pyrazine	CC1=C(N2C=CN=CC2=C1SC)SC	PLASMA														ng/mL	50.6			UNKNOWN	mg	60		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20664537/	Homo sapiens							28	Oltipraz		false
6197	3004		ADULT	128585	224.4	7-Methyl-6,8-bis(methylthio)pyrrolo(1,2-a)pyrazine		CC1=C(N2C=CN=CC2=C1SC)SC	PLASMA														ng/mL	37.1			UNKNOWN	mg	90		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20664537/	Homo sapiens							17	Oltipraz		false
6198	3008		ADULT	60923	587.171	QUIFLAPON	QUIFLAPON	CC(C)(C)SC1=C(CC(C)(C)C(O)=O)N(CC2=CC=C(Cl)C=C2)C3=C1C=C(OCC4=NC5=C(C=CC=C5)C=C4)C=C3	PLASMA	9295C885I4									?	μg × h/mL	39.93		μg/mL	6.9			UNKNOWN	mg	250		MULTIPLE	FED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8033491	Homo sapiens		h	5.74				6	QUIFLAPON		false
6199	3008		ADULT	60923	587.171	QUIFLAPON	QUIFLAPON	CC(C)(C)SC1=C(CC(C)(C)C(O)=O)N(CC2=CC=C(Cl)C=C2)C3=C1C=C(OCC4=NC5=C(C=CC=C5)C=C4)C=C3	PLASMA	9295C885I4									?	μg × h/mL	86.3		μg/mL	8.1			UNKNOWN	mg	250		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8527269	Homo sapiens		h	9.2	day10			6	QUIFLAPON		false
6200	3008		ADULT	60923	587.171	QUIFLAPON	QUIFLAPON	CC(C)(C)SC1=C(CC(C)(C)C(O)=O)N(CC2=CC=C(Cl)C=C2)C3=C1C=C(OCC4=NC5=C(C=CC=C5)C=C4)C=C3	PLASMA	9295C885I4									?	μg × h/mL	170		μg/mL	15.81			UNKNOWN	mg	500		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8527269	Homo sapiens		h	12.2				6	QUIFLAPON		false
6201	3008		ADULT	60923	587.171	QUIFLAPON	QUIFLAPON	CC(C)(C)SC1=C(CC(C)(C)C(O)=O)N(CC2=CC=C(Cl)C=C2)C3=C1C=C(OCC4=NC5=C(C=CC=C5)C=C4)C=C3	PLASMA	9295C885I4									?	μg × h/mL	65.9		μg/mL	5.93			UNKNOWN	mg	125		MULTIPLE	FASTED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8527269	Homo sapiens		h	8.3	day 10			5	QUIFLAPON		false
6202	3018		ADULT	60803	372.68	SIPATRIGINE	sipatrigine	CN1CCN(CC1)C2=NC(N)=C(C=N2)C3=C(Cl)C(Cl)=CC(Cl)=C3	PLASMA	OON9AVW1T3									?	ng × h/mL	321		ng/mL	95			UNKNOWN	mg/kg	0.25		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8799514	Homo sapiens		h	21.7	Loading infusions of 0.5, 1, 1.5, 2 and 2.5 mg kg−1 over 1 h were followed by respective maintenance infusions of 0.25, 0.5, 0.75, 1 and 1.25 mg kg−1 over 30 min at 8 hourly intervals for 3 days.			4	619C89		false
6203	3018		ADULT	10316381	358.6	78C90	78C90	C1CN(CCN1)C2=NC=C(C(=N2)N)C3=C(C(=CC(=C3)Cl)Cl)Cl	PLASMA										?	ng × h/mL	741		mg/mL	120			UNKNOWN	mg/kg	1		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8799514	Homo sapiens		h	45	Loading infusions of 0.5, 1, 1.5, 2 and 2.5 mg kg−1 over 1 h were followed by respective maintenance infusions of 0.25, 0.5, 0.75, 1 and 1.25 mg kg−1 over 30 min at 8 hourly intervals for 3 days.			7	619C89		false
6204	3018		ADULT	10316381	358.6	78C90	78C90	C1CN(CCN1)C2=NC=C(C(=N2)N)C3=C(C(=CC(=C3)Cl)Cl)Cl	PLASMA										?	ng × h/mL	840		ng/mL	117			HIGHEST STUDIED	mg/kg	1.25		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8799514	Homo sapiens		h	33	Loading infusions of 0.5, 1, 1.5, 2 and 2.5 mg kg−1 over 1 h were followed by respective maintenance infusions of 0.25, 0.5, 0.75, 1 and 1.25 mg kg−1 over 30 min at 8 hourly intervals for 3 days.			3	619C89		false
6205	3018		ADULT	60803	372.68	SIPATRIGINE	sipatrigine	CN1CCN(CC1)C2=NC(N)=C(C=N2)C3=C(Cl)C(Cl)=CC(Cl)=C3	PLASMA	OON9AVW1T3									?	ng × h/mL	545		ng/mL	157			UNKNOWN	mg/kg	0.5		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8799514	Homo sapiens		h	25	Loading infusions of 0.5, 1, 1.5, 2 and 2.5 mg kg−1 over 1 h were followed by respective maintenance infusions of 0.25, 0.5, 0.75, 1 and 1.25 mg kg−1 over 30 min at 8 hourly intervals for 3 days.			5	619C89		false
6206	3018		ADULT	60803	372.68	SIPATRIGINE	Sipatrigine	CN1CCN(CC1)C2=NC(N)=C(C=N2)C3=C(Cl)C(Cl)=CC(Cl)=C3	PLASMA	OON9AVW1T3									?	ng × h/mL	1363		ng/mL	266			UNKNOWN	mg/kg	1		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8799514	Homo sapiens		h	19.7	Loading infusions of 0.5, 1, 1.5, 2 and 2.5 mg kg−1 over 1 h were followed by respective maintenance infusions of 0.25, 0.5, 0.75, 1 and 1.25 mg kg−1 over 30 min at 8 hourly intervals for 3 days.			7	619C89		false
6207	3018		ADULT	10316381	358.6	78C90	78C90	C1CN(CCN1)C2=NC=C(C(=N2)N)C3=C(C(=CC(=C3)Cl)Cl)Cl	PLASMA										?	ng × h/mL	304		ng/mL	51			UNKNOWN	mg/kg	0.5		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8799514	Homo sapiens		h	58	Loading infusions of 0.5, 1, 1.5, 2 and 2.5 mg kg−1 over 1 h were followed by respective maintenance infusions of 0.25, 0.5, 0.75, 1 and 1.25 mg kg−1 over 30 min at 8 hourly intervals for 3 days.			5	619C89		false
6208	3018		ADULT	60803	372.68	SIPATRIGINE	sipatrigine	CN1CCN(CC1)C2=NC(N)=C(C=N2)C3=C(Cl)C(Cl)=CC(Cl)=C3	PLASMA	OON9AVW1T3									?	ng × h/mL	2406		ng/mL	370			UNKNOWN	mg/kg	0.75		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8799514	Homo sapiens		h	28.5				4	619C89		false
6209	3018		ADULT	60803	372.68	SIPATRIGINE	SIPATRIGINE	CN1CCN(CC1)C2=NC(N)=C(C=N2)C3=C(Cl)C(Cl)=CC(Cl)=C3	PLASMA	OON9AVW1T3									?	ng × h/mL	1370		ng/mL	269			HIGHEST STUDIED	mg/kg	1.25		MULTIPLE	UNKNOWN		3 days	3			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8799514	Homo sapiens		h	18.5	Loading infusions of 0.5, 1, 1.5, 2 and 2.5 mg kg−1 over 1 h were followed by respective maintenance infusions of 0.25, 0.5, 0.75, 1 and 1.25 mg kg−1 over 30 min at 8 hourly intervals for 3 days.			3	619C89		false
6210	3018		ADULT	10316381	358.6	78C90	78C90	C1CN(CCN1)C2=NC=C(C(=N2)N)C3=C(C(=CC(=C3)Cl)Cl)Cl	PLASMA										?	ng × h/mL	441		ng/mL	89			UNKNOWN	mg/kg	0.75		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8799514	Homo sapiens		h	74	Loading infusions of 0.5, 1, 1.5, 2 and 2.5 mg kg−1 over 1 h were followed by respective maintenance infusions of 0.25, 0.5, 0.75, 1 and 1.25 mg kg−1 over 30 min at 8 hourly intervals for 3 days.			4	619C89		false
6211	3018		ADULT	10316381	358.6	78C90	78C90	C1CN(CCN1)C2=NC=C(C(=N2)N)C3=C(C(=CC(=C3)Cl)Cl)Cl	PLASMA										?	ng × h/mL	215		ng/mL	33			UNKNOWN	mg/kg	0.25		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8799514	Homo sapiens		h	61	Loading infusions of 0.5, 1, 1.5, 2 and 2.5 mg kg−1 over 1 h were followed by respective maintenance infusions of 0.25, 0.5, 0.75, 1 and 1.25 mg kg−1 over 30 min at 8 hourly intervals for 3 days.			4	619C89		false
6212	3040		ADULT	14017587	309.2699	ACENEURAMIC ACID	ACENEURAMIC ACID	CC(=O)N[C@H]([C@@H](O)CC(=O)C(O)=O)[C@@H](O)[C@H](O)[C@H](O)CO	PLASMA	GZP2782OP0									?	μg × h/mL	1.731		μg/mL	0.285			UNKNOWN	mg	2000		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://transmedcomms.biomedcentral.com/articles/10.1186/s41231-018-0025-0	Homo sapiens				Day 7			1	ACENEURAMIC ACID		false
6213	3040		ADULT	14017587	309.2699	ACENEURAMIC ACID	ACENEURAMIC ACID	CC(=O)N[C@H]([C@@H](O)CC(=O)C(O)=O)[C@@H](O)[C@H](O)[C@H](O)CO	PLASMA	GZP2782OP0									∞	μg × h/mL	2.279		μg/mL	0.624			UNKNOWN	mg	2000		SINGLE	FASTED						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://transmedcomms.biomedcentral.com/articles/10.1186/s41231-018-0025-0	Homo sapiens		h	7.089				1	ACENEURAMIC ACID		false
6214	3041		ADULT	36573	163.152	ACESULFAME	Acesulfame	CC1=CC(=O)NS(=O)(=O)O1	UNKNOWN	MA3UYZ6K1H							6		t	ng × h/mL	36480.85		ng/mL	945.3			UNKNOWN	mg	41		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29077645/	Homo sapiens				Breast Milk PK			34	Acesulfame potassium		false
6215	3059		ADULT	104845	332.477	ALFAXALONE	Alfaxalone	CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C	PLASMA	BD07M97B2A													μg/mL	5.57			UNKNOWN	mg/kg	0.5		SINGLE	UNKNOWN				t1/2=t1/2Keo		HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31124836/	Homo sapiens		min	8	Bolus injection (15 sec)			12			false
6216	3060		ADULT	71916	251.2784	ALIBENDOL	Alibendol	COC1=C(O)C(=CC(CC=C)=C1)C(=O)NCCO	PLASMA	A8CO1VZK2Z									?	μg × h/mL	10.62		μg/mL	5.82			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ingentaconnect.com/content/ben/cpa/2016/00000012/00000003/art00013	Homo sapiens		h	1.47							false
6217	3063		ADULT	120738	261.3593	ALPHAPRODINE	ALPHAPRODINE	CCC(=O)O[C@@]1(CCN(C)C[C@@H]1C)C2=CC=CC=C2	PLASMA	001O2254AC									?	μg × min/mL	50.08						UNKNOWN	mg/kg bw	35		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7358866	Homo sapiens		min	4.6							false
6218	3075		ADULT	121928	305.3673	AMIPRILOSE	amiprilose	CN(C)CCCO[C@H]1[C@H](O[C@@H]2OC(C)(C)O[C@H]12)[C@H](O)CO	PLASMA	S0FG5X68QT									?	ng × min/L	361		mg/mL	6806			UNKNOWN	mg	100		SINGLE	FED				513 ng/mL plasma, equilibrium dialysis	95	HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7175698/	Homo sapiens		min	244				10	AMIPRILOSE HYDROCHLORIDE		false
6219	3088			68827	282.334	ARTEMISININ	Artemisinin	C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4	SERUM	9RMU91N5K2																										Human serum protein binding: 100% (gel filtration)	0				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8347159/	Homo sapiens										false
6220	3088		ADULT	68827	282.334	ARTEMISININ	Artemisinin	C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4	PLASMA	9RMU91N5K2									∞	ng × h/mL	2601		ng/mL	588			UNKNOWN	mg	500		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8730315/	Homo sapiens		h	2.3		falciparum malaria patients		19			false
6221	3088		ADULT	68827	282.334	ARTEMISININ	Artemisinin	C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4	PLASMA	9RMU91N5K2									∞	ng × h/mL	432		ng/mL	116			UNKNOWN	mg	500		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8730315/	Homo sapiens		h	2.2		falciparum malaria patients		19			false
6222	3088		ADULT	68827	282.3322	ARTEMISININ	Artemisinin	C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4	PLASMA	9RMU91N5K2									∞	ng × h/mL	1560		ng/mL	450			UNKNOWN	mg	500		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9604124/	Homo sapiens		h	2				8			false
6223	3088		ADULT	68827	282.3322	ARTEMISININ	Artemisinin	C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4	PLASMA	9RMU91N5K2									∞	ng × h/mL	3758		ng/mL	792			UNKNOWN	mg	1000		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9604124/	Homo sapiens		h	2.84				8			false
6224	3088		ADULT	68827	282.3322	ARTEMISININ	Artemisinin	C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4	PLASMA	9RMU91N5K2									∞	ng × h/mL	674		ng/mL	205			UNKNOWN	mg	250		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9604124/	Homo sapiens		h	1.38				8			false
6225	3130		ADULT	51045	363.4528	BUCINDOLOL	BUCINDOLOL	CC(C)(CC1=CNC2=C1C=CC=C2)NCC(O)COC3=C(C=CC=C3)C#N	PLASMA	E9UO06K7CE									?	ng × h/mL	528		ng/mL	88			UNKNOWN	mg	150		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2859199/	Homo sapiens		h	3.58				6	BUCINDOLOL		false
6226	3131		ADULT	65770	288.4322	BUMECAINE		CCCCN1CCCC1C(=O)Nc2c(C)cc(C)cc2C	SERUM	B77K612SPZ									?	μg × min/mL	34.2		μg/mL	0.61			UNKNOWN	mg	50		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	MALE	EXPERIMENT	https://link.springer.com/article/10.1007/BF00765964	Homo sapiens		h	2.3				3			false
6227	3131		ADULT	65770	288.4322	BUMECAINE		CCCCN1CCCC1C(=O)Nc2c(C)cc(C)cc2C	SERUM	B77K612SPZ									?	μg × min/mL	68.7		μg/mL	1.22			UNKNOWN	mg	100		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	MALE	EXPERIMENT	https://link.springer.com/article/10.1007/BF00765964	Homo sapiens		h	1.75				3			false
6228	3173		ADULT	2799	365.337	CLOFOCTOL	clofoctol	CC(C)(C)CC(C)(C)C1=CC(CC2=C(Cl)C=C(Cl)C=C2)=C(O)C=C1	PLASMA	704083NI0R									∞	mg × h/L	80.91		mg/L	38.07			UNKNOWN	g	1.5		SINGLE	UNKNOWN						UNHEALTHY	Rectal	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3610901/	Homo sapiens		h	1.18		patients undergoing pulmonary resection for lung cancer		4			false
6229	3175			33176	357.788	CLOMETACIN	Clometacin	COC1=CC2=C(C=C1)C(C(=O)C3=CC=C(Cl)C=C3)=C(C)N2CC(O)=O	SERUM	L9M34YK25C																										Human serum albumin (600 mcM) binding: 99.3~99.5% (2.8~140 mcM), equilibrium dialysis	0.6				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6626262/	Homo sapiens										false
6230	3177			3080836|9822751	408.879	CLONIXIN LYSINE	Lysine clonixinate	NCCCC[C@H](N)C(O)=O.CC1=C(Cl)C=CC=C1NC2=NC=CC=C2C(O)=O	PLASMA	06PW4M190R																	UNKNOWN				UNKNOWN					Lysine clonixinate is 96% to 98% protein-bound	3				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16614691/	Homo sapiens								Lysine clonixinate		false
6231	3177		ADULT	28718	262.692	CLONIXIN	Clonixin	CC1=C(Cl)C=CC=C1NC2=NC=CC=C2C(O)=O	PLASMA	V7DXN0M42R									∞	μg × h/mL	49.88		μg/mL	29.4			RECOMMENDED	mg	250		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20420792/	Homo sapiens		h	1.3	250 mg - equivalent to 160.617 mg of clonixin			25	Lysine clonixinate		false
6232	3195		ADULT	7965	99.1741	CYCLOHEXYLAMINE	cyclohexylamine	NC1CCCCC1	PLASMA	I6GH4W7AEG							8		t	ng × h/mL	1912		ng/mL	400			UNKNOWN	g	2.2		STEADY-STATE	UNKNOWN		day	3			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1379387/	Homo sapiens		h	4							false
6233	3202		ADULT	53555|51705606	283.3251	DAZMEGREL	DAZMEGREL	CC1=C(CN2C=CN=C2)C3=C(C=CC=C3)N1CCC(O)=O	PLASMA	31340R8PVU													μg/mL	3			UNKNOWN	mg	200		MULTIPLE	FASTED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3513767	Homo sapiens		h	0.88				9	DAZMEGREL		false
6234	3246		ADULT	65853	220.2676	ELTOPRAZINE	ELTOPRAZINE	C1CN(CCN1)C2=CC=CC3=C2OCCO3	PLASMA	510M006KO6									∞	ng × h/mL	746		ng/mL	62.9			UNKNOWN	mg	30		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1761079	Homo sapiens		h	5.9				18	ELTOPRAZINE		false
6235	3246		ADULT	65853	220.2676	ELTOPRAZINE	ELTOPRAZINE	C1CN(CCN1)C2=CC=CC3=C2OCCO3	PLASMA	510M006KO6																	UNKNOWN	mg	8		SINGLE	FED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2288834	Homo sapiens		h	9.3				12	ELTOPRAZINE		false
6236	3260		ADULT	3371	281.2299	FLUFENAMIC ACID	Flufenamic acid	OC(=O)C1=C(NC2=CC(=CC=C2)C(F)(F)F)C=CC=C1	PLASMA	60GCX7Y6BH							12		t	ng × h/mL	484						UNKNOWN	mg	230		MULTIPLE	UNKNOWN		day	2	AUC12 = AUC(144-156 h), C144h (end of 8th dose) = 48.7 ng/mL		HEALTHY	Topical	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28561421/	Homo sapiens							12			false
6237	3260		ADULT	3371	281.2299	FLUFENAMIC ACID	Flufenamic acid	OC(=O)C1=C(NC2=CC(=CC=C2)C(F)(F)F)C=CC=C1	PLASMA	60GCX7Y6BH							48		t	ng × h/mL	449		ng/mL	31.3			UNKNOWN	mg	230		SINGLE	UNKNOWN						HEALTHY	Topical	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28561421/	Homo sapiens							12			false
6238	3260		ADULT	3371	281.2299	FLUFENAMIC ACID	Flufenamic acid	OC(=O)C1=C(NC2=CC(=CC=C2)C(F)(F)F)C=CC=C1	PLASMA	60GCX7Y6BH							36		t	ng × h/mL	168100		ng/mL	5810			UNKNOWN	g	1		SINGLE	UNKNOWN						HEALTHY	Intramuscular	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28561421/	Homo sapiens		h	9.18				12			false
6239	3262		UNKNOWN	1892	224.2166	ETOFYLLINE	ETOFYLLINE	CN1C2=C(N(CCO)C=N2)C(=O)N(C)C1=O	PLASMA	L164909TBI																	UNKNOWN	mg	200		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7263108/	Homo sapiens		h	4.1					ETOFYLLINE		false
6240	3262		UNKNOWN	1892	224.2166	ETOFYLLINE	ETOFYLLINE	CN1C2=C(N(CCO)C=N2)C(=O)N(C)C1=O	PLASMA	L164909TBI																	UNKNOWN	mg	200		SINGLE	UNKNOWN						UNKNOWN	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7263108/	Homo sapiens		h	4.1					ETOFYLLINE		false
6241	3263		ADULT	94158	88.0621	Oxirane-2-carboxylic acid	C1C(O1)C(=O)O	OC(=O)C1CO1	PLASMA														μg/mL	1.6			UNKNOWN	mg	150		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	REVIEW	https://books.google.ru/books?id=QpjsCAAAQBAJ&pg=PA671&lpg=PA671&dq=ETOMOXIR+pharmacokinetic&source=bl&ots=z44oXbX-Yp&sig=ACfU3U15Zu0lCHZdkI0D-L38ubwkNFuXCg&hl=en&sa=X&ved=2ahUKEwid59_gr-3nAhUiyaYKHW7KAa4Q6AEwBXoECAoQAQ#v=onepage&q=ETOMOXIR%20pharmacokinetic&f=false	Homo sapiens		h	1.4							false
6242	3264		UNKNOWN	8367	188.2688	ETRYPTAMINE	ETRYPTAMINE	CCC(N)CC1=CNC2=C1C=CC=C2	PLASMA	GR181O3R32																					SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8099943/	Homo sapiens		h	8.2							false
6243	3266		ADULT	5472495	372.41	EXISULIND	EXISULIND	CC1=C(CC(O)=O)C2=C(C=CC(F)=C2)\\C1=C/C3=CC=C(C=C3)S(C)(=O)=O	PLASMA	K619IIG2R9									?	μM × h	127		μM	18.2			MAX TOLERATED	mg	400		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10656435	Homo sapiens		h	6.03	First dose	two-compartment model analysis		6	EXISULIND		false
6244	3266		ADULT	5472495	372.41	EXISULIND	EXISULIND	CC1=C(CC(O)=O)C2=C(C=CC(F)=C2)\\C1=C/C3=CC=C(C=C3)S(C)(=O)=O	PLASMA	K619IIG2R9									?	mg × h/L	48.7		mg/L	9.85			MAX TOLERATED	mg	400		SINGLE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10656435	Homo sapiens		h	4.88	first dose	noncompartmental analysis		6	EXISULIND		false
6245	3266		ADULT	5472495	372.41	EXISULIND	EXISULIND	CC1=C(CC(O)=O)C2=C(C=CC(F)=C2)\\C1=C/C3=CC=C(C=C3)S(C)(=O)=O	PLASMA	K619IIG2R9									?	μM × h	174		μM	48.1			MAX TOLERATED	mg	400		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10656435	Homo sapiens		h	10.9	6-month dose	two-compartment model analysis		2	EXISULIND		false
6246	3272			65394	297.133	FENCLOFENAC	Fenclofenac	OC(=O)CC1=C(OC2=C(Cl)C=C(Cl)C=C2)C=CC=C1	PLASMA	Y01JW64D01																										Fenclofenac in plasma is highly bound to plasma proteins, the degree of protein binding being 99.5%.	0.5				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6628527/	Homo sapiens										false
6247	3272		ADULT	65394	297.133	FENCLOFENAC	Fenclofenac	OC(=O)CC1=C(OC2=C(Cl)C=C(Cl)C=C2)C=CC=C1	PLASMA	Y01JW64D01									∞	μg × h/mL	457		μg/mL	18.2			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7250145/	Homo sapiens		h	24.2				4			false
6248	3272		ADULT	65394	297.133	FENCLOFENAC	Fenclofenac	OC(=O)CC1=C(OC2=C(Cl)C=C(Cl)C=C2)C=CC=C1	PLASMA	Y01JW64D01									∞	μg × h/mL	1323		μg/mL	45.3			UNKNOWN	mg	500		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7250145/	Homo sapiens		h	32.4				4			false
6249	3272		ADULT	65394	297.133	FENCLOFENAC	Fenclofenac	OC(=O)CC1=C(OC2=C(Cl)C=C(Cl)C=C2)C=CC=C1	PLASMA	Y01JW64D01									∞	μg × h/mL	1716		μg/mL	63.5			HIGHEST STUDIED	mg	600		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7250145/	Homo sapiens		h	27.2				9			false
6250	3272		ADULT	65394	297.133	FENCLOFENAC	Fenclofenac	OC(=O)CC1=C(OC2=C(Cl)C=C(Cl)C=C2)C=CC=C1	PLASMA	Y01JW64D01							12		t	μg × h/mL	884		μg/mL	86.9			UNKNOWN	mg	600		STEADY-STATE	FED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7250145/	Homo sapiens		h	25.9	Day 5 PK			5			false
6251	3273		ADULT	28858	253.705	FENCLOZIC ACID	fenclozic acid	OC(=O)CC1=CSC(=N1)C2=CC=C(Cl)C=C2	SERUM	58SRQ4DV53													μg/mL	13.6			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4903318/	Homo sapiens		h	25				7			false
6252	3273		ADULT		253.705	FENCLOZIC ACID	fenclozic acid	OC(=O)CC1=CSC(=N1)C2=CC=C(Cl)C=C2	SERUM	58SRQ4DV53													μg/mL	84.2			UNKNOWN	mg	150		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4903318/	Homo sapiens		h	45.8	15 doses	Patients with rheumatoid arthritis		5			false
6253	3273		ADULT	28858	253.705	FENCLOZIC ACID	fenclozic acid	OC(=O)CC1=CSC(=N1)C2=CC=C(Cl)C=C2	SERUM	58SRQ4DV53													μg/mL	55.2			UNKNOWN	mg	400		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4903318/	Homo sapiens		h	23				3			false
6254	3274		UNKNOWN	3336	315.4513	FENDILINE	Fendiline	CC(NCCC(C1=CC=CC=C1)C2=CC=CC=C2)C3=CC=CC=C3	PLASMA	S253D559A8																	HIGHEST STUDIED	mg	1200		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3566858/	Homo sapiens		h	20				6	Fendiline		false
6255	3274		ADULT	3336	315.4513	FENDILINE	Fendiline	CC(NCCC(C1=CC=CC=C1)C2=CC=CC=C2)C3=CC=CC=C3	PLASMA	S253D559A8									?	ng × h/mL	111.2		ng/mL	7.2			UNKNOWN	mg	50		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7117293/	Homo sapiens		h	22				6	Fendiline		false
6256	3274		ADULT	3336	315.4513	FENDILINE	Fendiline	CC(NCCC(C1=CC=CC=C1)C2=CC=CC=C2)C3=CC=CC=C3	PLASMA	S253D559A8									?	ng × h/mL	219.6		ng/mL	8.8			UNKNOWN	mg	75		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7117293/	Homo sapiens		h	35.6				6	Fendiline		false
6257	3274		ADULT	3336	315.4513	FENDILINE	Fendiline	CC(NCCC(C1=CC=CC=C1)C2=CC=CC=C2)C3=CC=CC=C3	PLASMA	S253D559A8									?	ng × h/mL	39.8		ng/mL	4.2			UNKNOWN	mg	3		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7117293/	Homo sapiens		h	19.4				6	Fendiline		false
6258	3277		ADULT	3344	260.3315	FENSPIRIDE	Fenspiride	O=C1NCC2(CCN(CCC3=CC=CC=C3)CC2)O1	PLASMA	S983QC7HKM									?	ng × h/mL	9576.89		ng/mL	381.58			UNKNOWN	mg	80		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21899503/	Homo sapiens							15			false
6259	3277		ADULT	3344	260.3315	FENSPIRIDE	Fenspiride	O=C1NCC2(CCN(CCC3=CC=CC=C3)CC2)O1	PLASMA	S983QC7HKM									?	ng × h/mL	11208.73		ng/mL	1034.09			UNKNOWN	mg	80		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21899503/	Homo sapiens				Day 7 PK			26			false
6260	3277		ADULT	3344	260.3315	FENSPIRIDE	fenspiride	O=C1NCC2(CCN(CCC3=CC=CC=C3)CC2)O1	PLASMA	S983QC7HKM									?	ng × h/mL	10259.9		ng/mL	329.35			UNKNOWN	mg	80		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21899503/	Homo sapiens							15			false
6261	3277		ADULT	3344	260.3315	FENSPIRIDE	Fenspiride	O=C1NCC2(CCN(CCC3=CC=CC=C3)CC2)O1	PLASMA	S983QC7HKM									?	μg × h/mL	6.03		ng/mL	206			UNKNOWN	mg	80		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7901024/	Homo sapiens		h	16				12			false
6262	3277		ADULT	3344	260.3315	FENSPIRIDE	Fenspiride	O=C1NCC2(CCN(CCC3=CC=CC=C3)CC2)O1	PLASMA	S983QC7HKM									?	μg × h/mL	6.73						UNKNOWN	mg	80		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7901024/	Homo sapiens		h	14				12			false
6263	3291			71693	311.418	FOMOCAINE	Fomocaine	C(CN1CCOCC1)CC2=CC=C(COC3=CC=CC=C3)C=C2	PLASMA	4XO7A09HQM																										Human plasma protein binding: 95%	5				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/581056/	Homo sapiens										false
6264	3314		ADULT	3590	145.2426	HEPTAMINOL	Heptaminol	CC(N)CCCC(C)(C)O	PLASMA	3DQS188SY5													mg/L	1.6			UNKNOWN	mg	300		SINGLE	UNKNOWN				t1/2=2.2-2.7 h		HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3435592/	Homo sapiens		h	2.7	Tablets			10			false
6265	3314		ADULT	3590	145.2426	HEPTAMINOL	Heptaminol	CC(N)CCCC(C)(C)O	PLASMA	3DQS188SY5													μg/mL	2.19			UNKNOWN	g	0.47		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6874820/	Homo sapiens		h	2.1	Syrup formulation			5			false
6266	3321		ADULT	54459	204.2252	IDAZOXAN	Idazoxan	C1CN=C(N1)C2COC3=CC=CC=C3O2	PLASMA	Y310PA316B									?	ng × h/mL	179.5						UNKNOWN	mg/kg	0.3		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2872058/	Homo sapiens		h	5.59				5	Idazoxan		false
6267	3321		ADULT	54459	204.2252	IDAZOXAN	Idazoxan	C1CN=C(N1)C2COC3=CC=CC=C3O2	PLASMA	Y310PA316B									?	ng × h/mL	560.5						UNKNOWN	mg/kg	0.3		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2872058/	Homo sapiens		h	4.2				5	Idazoxan		false
6268	3324		ADULT	55008	525.765	ILMOFOSINE	ILMOFOSINE	CCCCCCCCCCCCCCCCSCC(COC)COP([O-])(=O)OCC[N ](C)(C)C	PLASMA	5ZZK34MC3V									?	μg × h/mL	109.2		μg/mL	30.2			RP2D	mg/m²	450		SINGLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/14977826	Homo sapiens		h	37.15	weekly 2-h infusion			5	ILMOFOSINE		false
6269	3324		ADULT	55008	525.765	ILMOFOSINE	ILMOFOSINE	CCCCCCCCCCCCCCCCSCC(COC)COP([O-])(=O)OCC[N ](C)(C)C	PLASMA	5ZZK34MC3V									?	μg × h/mL	148.26		μg/mL	33.91			UNKNOWN	mg/m²	650		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/14977826	Homo sapiens		h	41.65	weekly 2-h infusion			3	ILMOFOSINE		false
6270	3353		ADULT	68706	312.75	LONAZOLAC	LONAZOLAC	OC(=O)CC1=CN(N=C1C2=CC=C(Cl)C=C2)C3=CC=CC=C3	PLASMA	13097143QI													mg/L	1.8			RECOMMENDED	mg	300		MULTIPLE	UNKNOWN		day	2	The mean unbound fraction of lonazolac was higher in synovial fluid (1.9%) compared to plasma (0.7%).	0.7	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9726694/	Homo sapiens							10	LONAZOLAC		false
6271	3370		ADULT	6257	223.2252	MEPHENOXALONE	MEPHENOXALONE	COC1=C(OCC2CNC(=O)O2)C=CC=C1	PLASMA	CZ87T54W8W									∞	ng × h/mL	16274		ng/mL	2849			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11499633/	Homo sapiens		h	2.77							false
6272	3387		ADULT	6435801	250.1889	MIDAFOTEL	SDZ-EAA-494	OC(=O)[C@H]1CN(C\\C=C\\P(O)(O)=O)CCN1	PLASMA	7LYU6ZF84G													ng/mL	199			UNKNOWN	mg	1000		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/8269915	Homo sapiens		h	20				8	D-CPP-ENE		false
6273	3389		ADULT	26105	201.1799	MISONIDAZOLE	MISONIDAZOLE	COCC(O)CN1C=CN=C1[N ]([O-])=O	PLASMA	8FE7LTN8XE									?	mg × h/L	348.5		mg/L	31.3			UNKNOWN	mg/m²	600		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6698564	Homo sapiens							6	MISONIDAZOLE		false
6274	3389		ADULT	26105	201.1799	MISONIDAZOLE	MISONIDAZOLE	COCC(O)CN1C=CN=C1[N ]([O-])=O	PLASMA	8FE7LTN8XE									?	mg × h/L	2150		mg/L	125			MAX DAILY	g/m²	3		SINGLE	FASTED						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6698564	Homo sapiens		min	18				1	MISONIDAZOLE		false
6275	3414			5497	178.231	NIKETHAMIDE	Nikethamide	CCN(CC)C(=O)C1=CN=CC=C1	PLASMA	368IVD6M32																										Human plasma protein binding: 55.35%	44.65				EXPERIMENT	https://www.sciencedirect.com/science/article/pii/S0022286021021529	Homo sapiens										false
6276	3418		ADULT	19910	190.1555	NITROXOLINE	NITROXOLINE	OC1=CC=C(C2=CC=CN=C12)[N ]([O-])=O	PLASMA	A8M33244M6									∞	μg × h/mL	5.97		μg/mL	5.425			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20833114/	Homo sapiens		h	1.7				2	NITROXOLINE		false
6277	3418		ADULT	19910	190.1555	NITROXOLINE	NITROXOLINE	OC1=CC=C(C2=CC=CN=C12)[N ]([O-])=O	PLASMA	A8M33244M6													mg/L	9.5			UNKNOWN	mg/kg	3		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/7030714/|https://pubmed.ncbi.nlm.nih.gov/30184207/	Homo sapiens				200 to 250 mg (mean 3 mg/kg of body weight)			8	NITROXOLINE		false
6278	3430		ADULT	28061	219.626	ORNIDAZOLE	ORNIDAZOLE	CC1=NC=C(N1CC(O)CCl)[N ]([O-])=O	PLASMA	62XCK0G93T									∞	ng × h/mL	332948		ng/mL	16185			RECOMMENDED	mg	1000		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25384588/	Homo sapiens		h	14.7				6	ORNIDAZOLE		false
6279	3430		UNKNOWN	28061	219.626	ORNIDAZOLE	ORNIDAZOLE	CC1=NC=C(N1CC(O)CCl)[N ]([O-])=O	PLASMA	62XCK0G93T																	UNKNOWN				UNKNOWN	UNKNOWN				Plasma protein binding of ornidazole is about 13%	87	UNKNOWN		UNKNOWN	OTHER GOV'T	https://www.medsafe.govt.nz/profs/datasheet/a/arrowornidazoletab.pdf	Homo sapiens		h	13					ORNIDAZOLE		false
6280	3466			65944	244.268	PIDOTIMOD	Pidotimod	OC(=O)[C@@H]1CSCN1C(=O)[C@@H]2CCC(=O)N2	PLASMA	785363R681																										Human plasma protein binding: 4%	96				REVIEW	https://mansapublishers.com/index.php/IJCH/article/view/2111	Homo sapiens										false
6281	3466		ADULT	65944	244.268	PIDOTIMOD	Pidotimod	OC(=O)[C@@H]1CSCN1C(=O)[C@@H]2CCC(=O)N2	PLASMA	785363R681									∞	μg × h/mL	25.1		μg/mL	5.57			UNKNOWN	mg	800		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19604731/	Homo sapiens		h	1.82				20			false
6282	3471		ADULT	50981	254.2856	PIMONIDAZOLE	Ro 03-8799	OC(CN1C=CN=C1[N ]([O-])=O)CN2CCCCC2	PLASMA	46JO4D76R2									∞	mg × h/L	4.01						UNKNOWN	mg	87		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6519157	Homo sapiens							2	Ro 03-8799		false
6283	3471		ADULT	50981	254.2856	PIMONIDAZOLE	Ro 03-8799	OC(CN1C=CN=C1[N ]([O-])=O)CN2CCCCC2	PLASMA	46JO4D76R2										mg × h/L	27.925						UNKNOWN	mg	460		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6519157	Homo sapiens							4	Ro 03-8799		false
6284	3476		UNKNOWN	159977	297.355	PIPOFEZINE	PIPOFEZINE	CN1CCN(CC1)C2=NN=C3OC4=C(C=CC=C4)N(C)C3=C2	PLASMA	P8T739L1FA													ng/mL	24.5			UNKNOWN	mg	25		SINGLE	UNKNOWN					10	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.stada.ru/upload/iblock/d24/Azafen_tabletki_25mg_instrukciya_010221.pdf	Homo sapiens								PIPOFEZINE		false
6285	3491		ADULT	4994	167.205	PYRITHYLDIONE	PYRITHYLDIONE	CCC1(CC)C(=O)NC=CC1=O	PLASMA	8AB20823CK																					SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/10663456/	Homo sapiens		h	14.5							false
6286	3504		ADULT	68909	367.344	RIODIPINE	RIODIPINE	COC(=O)C1=C(C)NC(C)=C(C1C2=C(OC(F)F)C=CC=C2)C(=O)OC	PLASMA	W12VDB26LB													ng/mL	10.7			UNKNOWN	mg	20		SINGLE	FASTED				When [14C]ryosidine was added to pre-dose human plasma at a concentration of 0.25 or 0.5 ug/ml, equilibrium dialysis showed that 94% and 96%, respectively, of the 14C was protein-bound.	5	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4082636/	Homo sapiens		min	80				3	RIODIPINE		false
6287	3508		ADULT	71321	309.745	ROMAZARIT	ROMAZARIT	CC1=C(COC(C)(C)C(O)=O)OC(=N1)C2=CC=C(Cl)C=C2	PLASMA	CN68E94R2X									?	mg × h/L	958		mg/L	144			UNKNOWN	mg	1500		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2088768	Homo sapiens							6	ROMAZARIT		false
6288	3510		ADULT	54676478	308.3312	ROQUINIMEX	ROQUINIMEX	CN(C(=O)C1=C(O)C2=C(C=CC=C2)N(C)C1=O)C3=CC=CC=C3	PLASMA	372T2944C0													μM	1.2			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10760843/	Homo sapiens		h	31				7	ROQUINIMEX		false
6289	3510		ADULT	54676478	308.3312	ROQUINIMEX	ROQUINIMEX	CN(C(=O)C1=C(O)C2=C(C=CC=C2)N(C)C1=O)C3=CC=CC=C3	PLASMA	372T2944C0													μM	1.6			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10760843/	Homo sapiens		h	32				7	ROQUINIMEX		false
6290	3510		ADULT	54676478	308.3312	ROQUINIMEX	ROQUINIMEX	CN(C(=O)C1=C(O)C2=C(C=CC=C2)N(C)C1=O)C3=CC=CC=C3	PLASMA	372T2944C0													μM	1.4			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10760843/	Homo sapiens		h	31				14	ROQUINIMEX		false
6291	3510		ADULT	54676478	308.3312	ROQUINIMEX	ROQUINIMEX	CN(C(=O)C1=C(O)C2=C(C=CC=C2)N(C)C1=O)C3=CC=CC=C3	PLASMA	372T2944C0													μM	4			UNKNOWN	mg/kg	0.2		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9171853/	Homo sapiens		h	42				4	ROQUINIMEX		false
6292	3513		ADULT	3058739	301.5078	SAFINGOL	SAFINGOL	CCCCCCCCCCCCCCC[C@H](O)[C@@H](N)CO	PLASMA	OWA98U788S	84691|5460033|5702198	300.051	CISPLATIN	cisplatin	N.N.[Cl-].[Cl-].[Pt  ]	Q20Q21Q62J			?	μM × h	104.9		μM	25.6			UNKNOWN	mg/m²	930		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21257722	Homo sapiens							6	SAFINGOL		true
6293	3513		ADULT	3058739	301.5078	SAFINGOL	SAFINGOL	CCCCCCCCCCCCCCC[C@H](O)[C@@H](N)CO	PLASMA	OWA98U788S	84691|5460033|5702198	300.051	CISPLATIN	cisplatin	N.N.[Cl-].[Cl-].[Pt  ]	Q20Q21Q62J			?	μM × h	109.9		μM	23.5			MAX TOLERATED	mg/m²	840		SINGLE	UNKNOWN		3 weeks	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21257722	Homo sapiens							3	SAFINGOL		true
6294	3513		ADULT	3058739	301.5078	SAFINGOL	SAFINGOL	CCCCCCCCCCCCCCC[C@H](O)[C@@H](N)CO	PLASMA	OWA98U788S									?	ng × h/mL	1251		ng/mL	1040			UNKNOWN	mg/m²	120		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9815717	Homo sapiens		h	3.97				3	SAFINGOL		false
6295	3532		ADULT	11033	215.23	SULFACARBAMIDE	Sulfacarbamide	NC(=O)NS(=O)(=O)C1=CC=C(N)C=C1	SERUM	W6CD25Z4QR									?	mg × h/L	97.1						UNKNOWN	g	1		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://www.karger.com/Article/Abstract/238430	Homo sapiens		h	3.1	Dose unknown						false
6296	3534		ADULT	7181	284.358	SULFAETHIDOLE	sulfaethidole	CCC1=NN=C(NS(=O)(=O)C2=CC=C(N)C=C2)S1	SERUM	R77Q4O5ZMD	18381		DICLOXACILLIN	dicloxacillin	CC1=C(C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)C(=NO1)C4=C(Cl)C=CC=C4Cl	COF19H7WBK							μg/mL	125			DEFINED DAILY	g	1		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://doi.org/10.1002/j.1552-4604.1980.tb02547.x	Homo sapiens										true
6297	3534		UNKNOWN	7181	284.358	SULFAETHIDOLE	Sulfaethidole	CCC1=NN=C(NS(=O)(=O)C2=CC=C(N)C=C2)S1	PLASMA	R77Q4O5ZMD																						UNKNOWN				Sulfaethidole demonstrates high protein binding (96-99%) and the corresponding low free plasma concentration.	2.5	UNKNOWN		UNKNOWN	OTHER	https://www.karger.com/Article/Abstract/414185	Homo sapiens										false
6298	3555		ADULT	9915886	563.617	THIOCOLCHICOSIDE	Thiocolchicoside	COC1=C(OC)C2=C(CC[C@H](NC(C)=O)C3=CC(=O)C(SC)=CC=C23)C=C1O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O	PLASMA	T1X8S697GT									∞	ng × h/mL	417		ng/mL	174.8				mg	8		SINGLE	UNKNOWN						HEALTHY	Intramuscular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15312157/	Homo sapiens		h	1.5		Nonsmoking		6			false
6299	3561		ADULT	38409	331.171	TICRYNAFEN	TICRYNAFEN	OC(=O)COC1=C(Cl)C(Cl)=C(C=C1)C(=O)C2=CC=CS2	PLASMA	HC95205SY4													mg/dL	2.48			UNKNOWN	mg	250		SINGLE	UNKNOWN				Tienilic acid was found to be extentively (more than 98%) bound to plasma proteins.	2	HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7398677	Homo sapiens		h	1.56							false
6300	3561		ADULT	38409	331.171	TICRYNAFEN	TICRYNAFEN	OC(=O)COC1=C(Cl)C(Cl)=C(C=C1)C(=O)C2=CC=CS2	PLASMA	HC95205SY4													mg/dL	4.48			UNKNOWN	mg	500		SINGLE	UNKNOWN				Tienilic acid was found to be extentively (more than 98%) bound to plasma proteins.	2	HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7398677	Homo sapiens		h	2.43							false
6301	3561		ADULT	38409	331.171	TICRYNAFEN	TICRYNAFEN	OC(=O)COC1=C(Cl)C(Cl)=C(C=C1)C(=O)C2=CC=CS2	PLASMA	HC95205SY4													mg/dL	10.1			UNKNOWN	mg	1000		SINGLE	UNKNOWN				Tienilic acid was found to be extentively (more than 98%) bound to plasma proteins.	2	HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7398677	Homo sapiens										false
6302	3588		ADULT	3655	214.2631	VELNACRINE	velnacrine	NC1=C2C=CC=CC2=NC3=C1C(O)CCC3	PLASMA	Y2P6NV151K									∞	ng × h/mL	294		ng/mL	91.8			UNKNOWN	mg	50		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2229455/	Homo sapiens		h	2		Participants were elderly (60-72 yo).		10	HP 029		false
6303	3588		ADULT		214.2631	VELNACRINE	velnacrine	NC1=C2C=CC=CC2=NC3=C1C(O)CCC3	PLASMA	Y2P6NV151K									∞	ng × h/mL	809.5		ng/mL	226.3			UNKNOWN	mg	100		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2229455/	Homo sapiens		h	2.4		Participants were elderly (60-74 yo).		10	HP 029		false
6304	3588		ADULT		214.2631	VELNACRINE	velnacrine	NC1=C2C=CC=CC2=NC3=C1C(O)CCC3	PLASMA	Y2P6NV151K									∞	ng × h/mL	1110.3		ng/mL	284			UNKNOWN	mg	100		MULTIPLE	UNKNOWN		day	3			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2229455/	Homo sapiens		h	3		Participants were elderly (61-70 yo).		10	HP 029		false
6305	3588		ADULT	3655	214.2631	VELNACRINE	velnacrine	NC1=C2C=CC=CC2=NC3=C1C(O)CCC3	PLASMA	Y2P6NV151K									∞	ng × h/mL	163.3		ng/mL	49.9			UNKNOWN	mg	25		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2229455/	Homo sapiens		h	2		Participants were elderly (60-73 yo).		10	HP 029		false
6306	3588		ADULT	3655	214.2631	VELNACRINE	velnacrine	NC1=C2C=CC=CC2=NC3=C1C(O)CCC3	PLASMA	Y2P6NV151K									∞	ng × h/mL	886		ng/mL	213			MAX TOLERATED	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2592587/	Homo sapiens		h	2.7		Participants were elderly (60-76 yo).		24			false
6307	3588		ADULT	3655	214.2631	VELNACRINE	velnacrine	NC1=C2C=CC=CC2=NC3=C1C(O)CCC3	PLASMA	Y2P6NV151K									∞	ng × h/mL	946		ng/mL	175			MAX TOLERATED	mg	100		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2592587/	Homo sapiens		h	2.7		Participants were elderly (60-76 yo).		24			false
6308	3588		ADULT		214.2631	VELNACRINE	velnacrine	NC1=C2C=CC=CC2=NC3=C1C(O)CCC3	PLASMA	Y2P6NV151K																						FED				measured at 40 ng/mL of velnacrine	47	UNHEALTHY		FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8739821/	Homo sapiens					65-85 yo; hospitalized for a variety of acute illnesses		10	1-hydroxy tacrine hydrochloride		false
6309	3588		ADULT	3655	214.2631	VELNACRINE	velnacrine	NC1=C2C=CC=CC2=NC3=C1C(O)CCC3	PLASMA	Y2P6NV151K																						FED				measured at 40 ng/mL of velnacrine	45.2	HEALTHY		FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8739821/	Homo sapiens					18-30 yo		11	1-hydroxy tacrine hydrochloride		false
6310	3588		ADULT	3655	214.2631	VELNACRINE	velnacrine	NC1=C2C=CC=CC2=NC3=C1C(O)CCC3	PLASMA	Y2P6NV151K																						FED				measured at 40 ng/mL of velnacrine	48.1	HEALTHY		FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8739821/	Homo sapiens					73-87 yo		10	1-hydroxy tacrine hydrochloride		false
6311	3591		ADULT	9913	311.3369	XANTHINOL	Xanthinol	CN(CCO)CC(O)CN1C=NC2=C1C(=O)N(C)C(=O)N2C	PLASMA	TN1B5910V2									∞	ng × h/mL	4457		ng/mL	615			RECOMMENDED	mg	150		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18718822/	Homo sapiens		h	4.89				20	Xanthinol nicotinate		false
6312	3800		UNKNOWN	213037	576.493	ATACIGUAT	ATACIGUAT	ClC1=CC=C(S1)S(=O)(=O)NC2=C(C=C(Cl)C=C2)C(=O)NC3=CC=C(C=C3)S(=O)(=O)N4CCOCC4	PLASMA	QP166M390Q							24		t	μg × h/mL	31.08		μg/mL	1.89			UNKNOWN	mg	25		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/clinical-study-results/DFI6174_summary.pdf	Homo sapiens										false
6313	3800		UNKNOWN	213037	576.493	ATACIGUAT	ATACIGUAT	ClC1=CC=C(S1)S(=O)(=O)NC2=C(C=C(Cl)C=C2)C(=O)NC3=CC=C(C=C3)S(=O)(=O)N4CCOCC4	PLASMA	QP166M390Q							24		t	μg × h/mL	173.54		μg/mL	12.66			UNKNOWN	mg	100		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/clinical-study-results/DFI6174_summary.pdf	Homo sapiens										false
6314	3800		UNKNOWN	213037	576.493	ATACIGUAT	ATACIGUAT	ClC1=CC=C(S1)S(=O)(=O)NC2=C(C=C(Cl)C=C2)C(=O)NC3=CC=C(C=C3)S(=O)(=O)N4CCOCC4	PLASMA	QP166M390Q							24		t	μg × h/mL	245.68		μg/mL	22.07			UNKNOWN	mg	200		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pharma/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/clinical-study-results/DFI6174_summary.pdf	Homo sapiens										false
6315	3860		ADULT	10391	197.661	BECLAMIDE	BECLAMIDE	ClCCC(=O)NCC1=CC=CC=C1	PLASMA	F5N0ALI65V							8		t	μg × h/mL	59		μg/mL	11			RECOMMENDED	g	1		SINGLE	UNKNOWN				http://www.druginfosys.com/drug.aspx?drugCode=75&type=1	50	HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1233999/	Homo sapiens		h	3							false
6316	3885		ADULT	39941	301.724	BENOXAPROFEN	BENOXAPROFEN	CC(C(O)=O)C1=CC2=C(OC(=N2)C3=CC=C(Cl)C=C3)C=C1	PLASMA	17SZX404IM									?	μg × h/mL	503						UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/303114	Homo sapiens		h	4.84							false
6317	3885		ADULT	39941	301.724	BENOXAPROFEN	BENOXAPROFEN	CC(C(O)=O)C1=CC2=C(OC(=N2)C3=CC=C(Cl)C=C3)C=C1	PLASMA	17SZX404IM													μg/mL	43			UNKNOWN	mg	100		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/303114	Homo sapiens										false
6318	3885		ADULT	39941	301.724	BENOXAPROFEN	BENOXAPROFEN	CC(C(O)=O)C1=CC2=C(OC(=N2)C3=CC=C(Cl)C=C3)C=C1	PLASMA	17SZX404IM													μg/mL	94			UNKNOWN	mg	300		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Rectal	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6930484	Homo sapiens		h	38							false
6319	4012		ADULT	3442	179.2157	FUSARIC ACID	Fusaric acid	CCCCC1=CN=C(C=C1)C(O)=O	PLASMA	JWJ963070N							15		t	μg × h/mL	784.8		μg/mL	60			UNKNOWN	mg/kg	15		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4214231/	Homo sapiens		h	8.7				5			false
6320	4026		ADULT	12598	409.587	BUTAPERAZINE	BUTAPERAZINE	CCCC(=O)C1=CC2=C(SC3=C(C=CC=C3)N2CCCN4CCN(C)CC4)C=C1	PLASMA	TXP4T9106S							48		t	ng × h/mL	1990		ng/mL	211			UNKNOWN	mg	30		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2860932/	Homo sapiens		h	17							false
6321	4068		UNKNOWN	6488	237.094	CARBROMAL	CARBROMAL	CCC(Br)(CC)C(=O)NC(N)=O	SERUM														μM	30			RECOMMENDED	g	1		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28110/ | https://link.springer.com/article/10.1007%2FBF00277561	Homo sapiens										false
6322	4068		UNKNOWN	21691267	194.07	Bromoethylbutyramide	bromoethylbutyramide	CCC(CCBr)C(=O)N	SERUM														μM	20			RECOMMENDED	g	1		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28110/ | https://link.springer.com/article/10.1007%2FBF00277561	Homo sapiens										false
6323	4275		ADULT	25223	183.678	CLORTERMINE	CLORTERMINE	CC(C)(N)CC1=C(Cl)C=CC=C1	PLASMA	4FA88HM3IX																	UNKNOWN				SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	REVIEW	http://www.inchem.org/documents/pims/pharm/pim936.htm#PartTitle:6.%20%20KINETICS	Homo sapiens		h	31							false
6324	4321		UNKNOWN	5281769	516.4509	CYNARINE	cynarine	O[C@@H]1C[C@](C[C@@H](OC(=O)\\C=C\\C2=CC=C(O)C(O)=C2)[C@H]1O)(OC(=O)\\C=C\\C3=CC(O)=C(O)C=C3)C(O)=O	PLASMA	85D81U9JAV							12		t	ng × h/mL	151		ng/mL	27.9			UNKNOWN	mg	300		SINGLE	UNKNOWN						UNKNOWN	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20058327/	Homo sapiens		h	3.6				10	1,5-dicaffeoylquinic acid		false
6325	4675		ADULT	54685524	408.3576	ETHYL BISCOUMACETATE	ETHYL BISCOUMACETATE	CCOC(=O)C(C1=C(O)C2=C(OC1=O)C=CC=C2)C3=C(O)C4=C(OC3=O)C=CC=C4	SERUM	08KL644731																	RECOMMENDED	mg	300		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7874379/	Homo sapiens		h	0.66							false
6326	4675		ADULT	54692989	424.4	7-Hydroxy ethyl biscoumacetate	7-hydroxy ethyl biscoumacetate	CCOC(=O)C(C1=C(C2=C(C=C(C=C2)O)OC1=O)O)C3=C(C4=CC=CC=C4OC3=O)O	SERUM																		RECOMMENDED	mg	300		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7874379/	Homo sapiens		h	2.03							false
6327	4675		ADULT	54685524	408.3576	ETHYL BISCOUMACETATE	ETHYL BISCOUMACETATE	CCOC(=O)C(C1=C(O)C2=C(OC1=O)C=CC=C2)C3=C(O)C4=C(OC3=O)C=CC=C4	PLASMA	08KL644731	24705		TRISILOXANE	Octamethyltrisiloxane	C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C	9G1ZW13R0G							mg/L	40.3			RECOMMENDED	mg	300		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8351679/	Homo sapiens										true
6328	4675		ADULT	54685524	408.3576	ETHYL BISCOUMACETATE	ETHYL BISCOUMACETATE	CCOC(=O)C(C1=C(O)C2=C(OC1=O)C=CC=C2)C3=C(O)C4=C(OC3=O)C=CC=C4	PLASMA	08KL644731													mg/L	31			RECOMMENDED	mg	300		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8351679/	Homo sapiens										false
6329	4684		UNKNOWN	30768|135413553	300.783	ETIFOXINE	Etifoxine	CCNC1=NC2=CC=C(Cl)C=C2C(C)(O1)C3=CC=CC=C3	PLASMA	X24X82MX4X																	RECOMMENDED	mg	50		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/25589941/	Homo sapiens		h	6							false
6330	4684		ADULT	30768|135413553	300.783	ETIFOXINE	Etifoxine	CCNC1=NC2=CC=C(Cl)C=C2C(C)(O1)C3=CC=CC=C3	PLASMA	X24X82MX4X							4		t	ng × h/mL	68		ng/mL	32			UNKNOWN	mg	50		SINGLE	UNKNOWN				Equilibrium dialysis, 1 mcM	0.29	HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/35524344/	Homo sapiens							4			false
6331	4780		ADULT	68792	279.315	FEXINIDAZOLE	FEXINIDAZOLE	CSC1=CC=C(OCC2=NC=C(N2C)[N ]([O-])=O)C=C1	PLASMA	306ERL82IR							24		t	ng × h/mL	3718		ng/mL	303			UNKNOWN	mg	1200		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24535888/	Homo sapiens				Day 7			6	FEXINIDAZOLE		false
6332	4780		ADULT	68792	279.315	FEXINIDAZOLE	FEXINIDAZOLE	CSC1=CC=C(OCC2=NC=C(N2C)[N ]([O-])=O)C=C1	PLASMA	306ERL82IR									∞	ng × h/mL	1287		ng/mL	130			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24535888/	Homo sapiens		h	9				6	FEXINIDAZOLE		false
6333	4780		ADULT	68792	279.315	FEXINIDAZOLE	FEXINIDAZOLE	CSC1=CC=C(OCC2=NC=C(N2C)[N ]([O-])=O)C=C1	PLASMA	306ERL82IR									∞	ng × h/mL	1384		ng/mL	139			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24535888/	Homo sapiens		h	12				6	FEXINIDAZOLE		false
6334	4780		ADULT	68792	279.315	FEXINIDAZOLE	FEXINIDAZOLE	CSC1=CC=C(OCC2=NC=C(N2C)[N ]([O-])=O)C=C1	PLASMA	306ERL82IR									∞	ng × h/mL	2075		ng/mL	171			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24535888/	Homo sapiens		h	15				6	FEXINIDAZOLE		false
6335	4780		ADULT	68792	279.315	FEXINIDAZOLE	FEXINIDAZOLE	CSC1=CC=C(OCC2=NC=C(N2C)[N ]([O-])=O)C=C1	PLASMA	306ERL82IR							24		t	ng × h/mL	7085		ng/mL	516			UNKNOWN	mg	2400		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24535888/	Homo sapiens				Day 7			6	FEXINIDAZOLE		false
6336	4780		ADULT	68792	279.315	FEXINIDAZOLE	FEXINIDAZOLE	CSC1=CC=C(OCC2=NC=C(N2C)[N ]([O-])=O)C=C1	PLASMA	306ERL82IR							24		t	ng × h/mL	9625		ng/mL	653			HIGHEST STUDIED	mg	3600		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24535888/	Homo sapiens				Day 7			6	FEXINIDAZOLE		false
6337	4780		ADULT	68792	279.315	FEXINIDAZOLE	FEXINIDAZOLE	CSC1=CC=C(OCC2=NC=C(N2C)[N ]([O-])=O)C=C1	PLASMA	306ERL82IR									∞	ng × h/mL	5492		ng/mL	479			UNKNOWN	mg	1200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24535888/	Homo sapiens		h	9				6	FEXINIDAZOLE		false
6338	4780		ADULT	68792	279.315	FEXINIDAZOLE	FEXINIDAZOLE	CSC1=CC=C(OCC2=NC=C(N2C)[N ]([O-])=O)C=C1	PLASMA	306ERL82IR									∞	ng × h/mL	7387		ng/mL	532			UNKNOWN	mg	800		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24535888/	Homo sapiens		h	13				6	FEXINIDAZOLE		false
6339	4780		ADULT		279.315	FEXINIDAZOLE	FEXINIDAZOLE	CSC1=CC=C(OCC2=NC=C(N2C)[N ]([O-])=O)C=C1	PLASMA	306ERL82IR									∞	ng × h/mL	12627		ng/mL	749			UNKNOWN	mg	3000		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24535888/	Homo sapiens		h	13				6	FEXINIDAZOLE		false
6340	4780		ADULT	68792	279.315	FEXINIDAZOLE	FEXINIDAZOLE	CSC1=CC=C(OCC2=NC=C(N2C)[N ]([O-])=O)C=C1	PLASMA	306ERL82IR									∞	ng × h/mL	21636		ng/mL	1790			UNKNOWN	mg	1200		SINGLE	HIGH-FAT						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24535888/	Homo sapiens		h	11				12	FEXINIDAZOLE		false
6341	4780		ADULT	68792	279.315	FEXINIDAZOLE	FEXINIDAZOLE	CSC1=CC=C(OCC2=NC=C(N2C)[N ]([O-])=O)C=C1	PLASMA	306ERL82IR									∞	ng × h/mL	6094		ng/mL	483			UNKNOWN	mg	1800		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24535888/	Homo sapiens		h	10				6	FEXINIDAZOLE		false
6342	4780		ADULT	68792	279.315	FEXINIDAZOLE	FEXINIDAZOLE	CSC1=CC=C(OCC2=NC=C(N2C)[N ]([O-])=O)C=C1	PLASMA	306ERL82IR							24		t	ng × h/mL	9300.62		ng/mL	636.05			HIGHEST STUDIED	mg	3600		MULTIPLE	FASTED		day	1	The plasma protein binding of fexinidazole has shown to be high in all species (87.7 to 95.4%)	8.45	HEALTHY	Oral	MALE	OTHER GOV'T	https://www.ema.europa.eu/en/documents/outside-eu-assessment-report/fexinidazole-winthrop-assessment-report_en.pdf	Homo sapiens		h	10	Day 14			5	FEXINIDAZOLE		false
6343	4798		ADULT	4474062	239.266	FLOSEQUINAN	FLOSEQUINAN	CN1C=C([S+](C)[O-])C(=O)C2=CC=C(F)C=C12	PLASMA	6NB119DLU7							72		t	μg × h/mL	11.44		μg/mL	3.19			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3905414	Homo sapiens		h	1.6							false
6344	4798		ADULT	131270	255.27	Flosequinoxan	Flosequinoxan		PLASMA								72		t	μg × h/mL	160.9		μg/mL	3.63			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3905414	Homo sapiens		h	37.8							false
6345	4876		ADULT	6913994	430.386	FOSTRIECIN	FOSTRIECIN	C[C@@](O)(\\C=C\\[C@H]1CC=CC(=O)O1)[C@@H](C[C@@H](O)\\C=C/C=C\\C=C\\CO)OP(O)(O)=O	PLASMA	ZO1648L551									?	mg × h/L	9.965		mg/L	6.354			UNKNOWN	mg/m²	20		SINGLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10070885	Homo sapiens		h	0.76	Fostriecin was administered intravenously over 60 min on days 1-5 at 4-week intervals. Day 1 of the first course.			1	FOSTRIECIN		false
6346	4904		ADULT		660.0353	FYTIC ACID	FYTIC ACID	OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H]1OP(O)(O)=O	PLASMA	7IGF0S7R8I							8		t	μg × h/mL	0.52		μg/mL	0.12			UNKNOWN	mg	1400		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11673644/	Homo sapiens		h	4							false
6347	4923		ADULT	55191	359.4659	GEPIRONE	GEPIRONE	CC1(C)CC(=O)N(CCCCN2CCN(CC2)C3=NC=CC=N3)C(=O)C1	PLASMA	JW5Y7B8Z18							30		t	ng × h/mL	54.9		ng/mL	6.1			UNKNOWN	mg	10		MULTIPLE	FASTED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12949996/	Homo sapiens				immediate-release formulation			11	GEPIRONE		false
6348	4923		ADULT	88747	164.2077	1-(2-PYRIMIDINYL)PIPERAZINE	1-(2-pyrimidinyl)-piperazine	C1CN(CCN1)C2=NC=CC=N2	PLASMA	H3B5B38F56							30		t	ng × h/mL	92.8		ng/mL	6.3			UNKNOWN	mg	10		MULTIPLE	FASTED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12949996/	Homo sapiens				immediate-release formulation			11	GEPIRONE		false
6349	4923		ADULT	55191	359.4659	GEPIRONE	GEPIRONE	CC1(C)CC(=O)N(CCCCN2CCN(CC2)C3=NC=CC=N3)C(=O)C1	PLASMA	JW5Y7B8Z18							30		t	ng × h/mL	55.3		ng/mL	4.3			UNKNOWN	mg	20		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12949996/	Homo sapiens				extended-release formulation			11	GEPIRONE		false
6350	4923		ADULT	88747	164.2077	1-(2-PYRIMIDINYL)PIPERAZINE	1-(2-pyrimidinyl)-piperazine	C1CN(CCN1)C2=NC=CC=N2	PLASMA	H3B5B38F56							30		t	ng × h/mL	74		ng/mL	4.2			UNKNOWN	mg	20		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12949996/	Homo sapiens				extended-release formulation			11	GEPIRONE		false
6351	4923		ADULT	55191	359.4659	GEPIRONE	GEPIRONE	CC1(C)CC(=O)N(CCCCN2CCN(CC2)C3=NC=CC=N3)C(=O)C1	PLASMA	JW5Y7B8Z18							30		t	ng × h/mL	51.8		ng/mL	3.6			UNKNOWN	mg	25		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12949996/	Homo sapiens				extended-release formulation			11	GEPIRONE		false
6352	4923		ADULT	88747	164.2077	1-(2-PYRIMIDINYL)PIPERAZINE	1-(2-pyrimidinyl)-piperazine	C1CN(CCN1)C2=NC=CC=N2	PLASMA	H3B5B38F56							30		t	ng × h/mL	67.6		ng/mL	3.6			UNKNOWN	mg	25		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12949996/	Homo sapiens				extended-release formulation			11	GEPIRONE		false
6353	4923		ADULT	55191	359.4659	GEPIRONE	GEPIRONE	CC1(C)CC(=O)N(CCCCN2CCN(CC2)C3=NC=CC=N3)C(=O)C1	PLASMA	JW5Y7B8Z18							30		∞	ng × h/mL	38.71		ng/mL	4.13			UNKNOWN	mg	20		SINGLE	HIGH-FAT						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24944406/	Homo sapiens							27	GEPIRONE		false
6354	4923		ADULT	88747	164.2077	1-(2-PYRIMIDINYL)PIPERAZINE	1-(2-PYRIMIDINYL)PIPERAZINE	C1CN(CCN1)C2=NC=CC=N2	PLASMA	H3B5B38F56							30		∞	ng × h/mL	52.77		ng/mL	3.21			UNKNOWN	mg	20		SINGLE	HIGH-FAT						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24944406/	Homo sapiens							27	GEPIRONE		false
6355	4923		ADULT	88747	164.2077	1-(2-PYRIMIDINYL)PIPERAZINE	1-(2-PYRIMIDINYL)PIPERAZINE	C1CN(CCN1)C2=NC=CC=N2	PLASMA	H3B5B38F56							30		∞	ng × h/mL	55.39		ng/mL	2.8			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24944406/	Homo sapiens							27	GEPIRONE		false
6356	4923		ADULT	9842584	375.5	3-Hydroxygepirone			PLASMA								30		∞	ng × h/mL	138		ng/mL	6.54			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24944406/	Homo sapiens							27	GEPIRONE		false
6357	4923		ADULT	9842584	375.5	3-Hydroxygepirone			PLASMA								30		∞	ng × h/mL	157		ng/mL	7.69			UNKNOWN	mg	20		SINGLE	HIGH-FAT						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24944406/	Homo sapiens							27	GEPIRONE		false
6358	4923		ADULT	55191	359.4659	GEPIRONE	GEPIRONE	CC1(C)CC(=O)N(CCCCN2CCN(CC2)C3=NC=CC=N3)C(=O)C1	PLASMA	JW5Y7B8Z18							30		∞	ng × h/mL	31.14		ng/mL	2.55			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24944406/	Homo sapiens							27	GEPIRONE		false
6359	4923		ADULT	55191	359.4659	GEPIRONE	GEPIRONE	CC1(C)CC(=O)N(CCCCN2CCN(CC2)C3=NC=CC=N3)C(=O)C1	PLASMA	JW5Y7B8Z18									∞	ng × h/mL	55.26		ng/mL	18.73			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8103528/	Homo sapiens		h	2.94				12	GEPIRONE		false
6360	4923		ADULT	88747	164.2077	1-(2-PYRIMIDINYL)PIPERAZINE	1-(2-pyrimidinyl)-piperazine	C1CN(CCN1)C2=NC=CC=N2	PLASMA	H3B5B38F56									∞	ng × h/mL	93		ng/mL	12.03			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8103528/	Homo sapiens		h	5.76				12	GEPIRONE		false
6361	4923		ADULT	55191	359.4659	GEPIRONE	GEPIRONE	CC1(C)CC(=O)N(CCCCN2CCN(CC2)C3=NC=CC=N3)C(=O)C1	PLASMA	JW5Y7B8Z18									∞	ng × h/mL	75.69		ng/mL	16.98			UNKNOWN	mg	20		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8103528/	Homo sapiens		h	3.32				12	GEPIRONE		false
6362	4923		ADULT	88747	164.2077	1-(2-PYRIMIDINYL)PIPERAZINE	1-(2-pyrimidinyl)-piperazine	C1CN(CCN1)C2=NC=CC=N2	PLASMA	H3B5B38F56									∞	ng × h/mL	99.2		ng/mL	12.55			UNKNOWN	mg	20		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8103528/	Homo sapiens		h	6.06				12	GEPIRONE		false
6363	4932		ADULT	65631	297.3484	GLAZIOVINE	glaziovine	COC1=CC2=C3C(CC4(C=CC(=O)C=C4)C3=C1O)N(C)CC2	PLASMA	KE7J8A65P6													ng/mL	441			HIGHEST STUDIED	mg	20		SINGLE							HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/668777/	Homo sapiens							4			false
6364	4932		ADULT	65631	297.3484	GLAZIOVINE	glaziovine	COC1=CC2=C3C(CC4(C=CC(=O)C=C4)C3=C1O)N(C)CC2	PLASMA	KE7J8A65P6													ng/mL	1211			HIGHEST STUDIED	mg	20		SINGLE							HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/668777/	Homo sapiens							4			false
6365	4958		ADULT	65938	487.5041	GORALATIDE	GORALATIDE	CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(O)=O	PLASMA	H041538E9P													nM	156			UNKNOWN	nmol/kg	128		SINGLE	UNKNOWN						HEALTHY	Subcutaneous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7895600	Homo sapiens							6	GORALATIDE		false
6366	4958		ADULT	65938	487.5041	GORALATIDE	GORALATIDE	CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(O)=O	PLASMA	H041538E9P													nM	110			UNKNOWN	nmol/kg	128		SINGLE	UNKNOWN						HEALTHY	Intramuscular	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7895600	Homo sapiens							6	GORALATIDE		false
6367	4958		ADULT	65938	487.5041	GORALATIDE	GORALATIDE	CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(O)=O	PLASMA	H041538E9P									?	nM × h	117						UNKNOWN	nmol/kg	128		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7895600	Homo sapiens		min	4.5	12-hr intravenous infusion			6	GORALATIDE		false
6368	5053		ADULT		295.3325	Indobufen, (R)-		CC[C@H](C1=CC=C(N2CC3=C(C2=O)C=CC=C3)C=C1)C(O)=O	SERUM										∞	mg × h/L	2262		mg/L	23			UNKNOWN	mg	200		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11370020/	Homo sapiens		h	7.4		Patients with Obliterative Atherosclerosis		11			false
6369	5053		ADULT	44562	295.3325	INDOBUFEN, (S)-	Indobufen, (S)-	CC[C@H](C(O)=O)C1=CC=C(C=C1)N2CC3=C(C=CC=C3)C2=O	SERUM	58LEO57GJB									∞	mg × h/L	1309		mg/L	17.8			UNKNOWN	mg	200		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11370020/	Homo sapiens		h	4.5		Patients with Obliterative Atherosclerosis		11			false
6370	5053			107641	295.3325	INDOBUFEN	Indobufen	CCC(C(O)=O)C1=CC=C(C=C1)N2CC3=CC=CC=C3C2=O	SERUM	6T9949G4LZ																										Human serum protein binding: >99% (2.5~100mg/L)	1				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12237835/	Homo sapiens										false
6371	5053		ADULT		295.3325	Indobufen, (R)-		CC[C@H](C1=CC=C(N2CC3=C(C2=O)C=CC=C3)C=C1)C(O)=O	PLASMA														μg/mL	9.73			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1596290/	Homo sapiens		h	8.68		Young subjects (23-39 y)		12			false
6372	5053		ADULT	44562	295.3325	INDOBUFEN, (S)-	Indobufen, (S)-	CC[C@H](C(O)=O)C1=CC=C(C=C1)N2CC3=C(C=CC=C3)C2=O	PLASMA	58LEO57GJB													μg/mL	7.93			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1596290/	Homo sapiens		h	6.21		Young subjects (23-39 y)		12			false
6373	5053		ADULT	107641	295.3325	INDOBUFEN	Indobufen	CCC(C(O)=O)C1=CC=C(C=C1)N2CC3=CC=CC=C3C2=O	PLASMA	6T9949G4LZ													μg/mL	32.6			UNKNOWN	mg	200		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3733275/	Homo sapiens		h	12.8		Elderly subjects (54-81 y)					false
6374	5053		ADULT	107641	295.3325	INDOBUFEN	Indobufen	CCC(C(O)=O)C1=CC=C(C=C1)N2CC3=CC=CC=C3C2=O	PLASMA	6T9949G4LZ									∞	μg × h/mL	74.78		μg/mL	14.61			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/456404/	Homo sapiens		h	7.63				6			false
6375	5053		ADULT	107641	295.3325	INDOBUFEN	Indobufen	CCC(C(O)=O)C1=CC=C(C=C1)N2CC3=CC=CC=C3C2=O	PLASMA	6T9949G4LZ									∞	μg × h/mL	64.67		μg/mL	10.24			UNKNOWN	mg	100		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/456404/	Homo sapiens		h	6.77				6			false
6376	5160		ADULT	9794203	198.2637	LANICEMINE	lanicemine	N[C@@H](CC1=NC=CC=C1)C2=CC=CC=C2	PLASMA	9TMU325RK3									?	μg × h/mL	17.9		μg/mL	1.3			UNKNOWN	mg	150		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25259653/	Homo sapiens		h	16.1				6	lanicemine		false
6377	5225		ADULT	3025944	326.172	LOMEGUATRIB	LOMEGUATRIB	NC1=NC(OCC2=CC(Br)=CS2)=C3NC=NC3=N1	BLOOD	S79265T71M	5394		TEMOZOLOMIDE	Temozolomide	CN1N=NC2=C(N=CN2C1=O)C(N)=O	YF1K15M17Y	8		t	ng × h/mL	104.4		ng/mL	35.2			UNKNOWN	mg	40		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/18475294	Homo sapiens		h	1.4							true
6378	5250		ADULT	65998	433.515	LUBELUZOLE	LUBELUZOLE	CN(C1CCN(C[C@H](O)COC2=CC(F)=C(F)C=C2)CC1)C3=NC4=C(S3)C=CC=C4	PLASMA	V2SIB71583									∞	ng × h/mL	2191						UNKNOWN	mg	15		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9444444	Homo sapiens		min	101				5	LUBELUZOLE		false
6379	5250		ADULT	65998	433.515	LUBELUZOLE	LUBELUZOLE	CN(C1CCN(C[C@H](O)COC2=CC(F)=C(F)C=C2)CC1)C3=NC4=C(S3)C=CC=C4	PLASMA	V2SIB71583									∞	ng × h/mL	1422						UNKNOWN	mg	10		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9444444	Homo sapiens		min	58.8				6	LUBELUZOLE		false
6380	5250		ADULT	65998	433.515	LUBELUZOLE	LUBELUZOLE	CN(C1CCN(C[C@H](O)COC2=CC(F)=C(F)C=C2)CC1)C3=NC4=C(S3)C=CC=C4	PLASMA	V2SIB71583									∞	ng × h/mL	904						UNKNOWN	mg	5		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9444444	Homo sapiens		min	46.3				6	LUBELUZOLE		false
6381	5289		ADULT	9949848	340.499	MEDROGESTONE	Medrogestone	CC(=O)[C@@]1(C)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C	PLASMA	077DN93G5B									∞	ng × h/mL	98.05		ng/mL	8.21			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9766865/	Homo sapiens		h	34.95				12			false
6382	5356		UNKNOWN	10082|3032307	288.429	METHITURAL	METHITURAL	CCCC(C)C1(CCSC)C(=O)NC(=S)NC1=O	PLASMA	DZQ457UJ3Y													mg/L	35			UNKNOWN	mg/kg bw	50		SINGLE	UNKNOWN						UNKNOWN	Intravenous	UNKNOWN	EXPERIMENT	https://www.karger.com/Article/PDF/134815	Homo sapiens										false
6383	5442		ADULT	6437850	197.2244	MOFEGILINE	MOFEGILINE	NC\\C(CCC1=CC=C(F)C=C1)=C\\F	PLASMA	1FMJ6D8Y1B									∞	pg × h/mL	105170		pg/mL	27202			UNKNOWN	mg	48		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7554709	Homo sapiens		h	3.02				3	MOFEGILINE		false
6384	5442		ADULT	6437850	197.2244	MOFEGILINE	MOFEGILINE	NC\\C(CCC1=CC=C(F)C=C1)=C\\F	PLASMA	1FMJ6D8Y1B									∞	pg × h/mL	54359		pg/mL	14018			UNKNOWN	mg	24		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7554709	Homo sapiens		h	2.79				3	MOFEGILINE		false
6385	5475		ADULT	206044	516.5418	MURAGLITAZAR	MURAGLITAZAR	COC1=CC=C(OC(=O)N(CC(O)=O)CC2=CC=C(OCCC3=C(C)OC(=N3)C4=CC=CC=C4)C=C2)C=C1	PLASMA	W1MKM70WQI									?	μg × h/mL	12		μg/mL	1.8			UNKNOWN	mg	10		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17062777	Homo sapiens		h	35.1				6	MURAGLITAZAR		false
6386	5545		ADULT	71147	369.4574	NICAINOPROL	nicainoprol	CC(C)NCC(O)COC1=CC=CC2=C1N(CCC2)C(=O)C3=CC=CN=C3	PLASMA	1UA960P80H									?	ng × h/mL	10205		ng/mL	1672			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3677541	Homo sapiens		min	104.2				8	nicainoprol		false
6387	5545		ADULT	71147	369.4574	NICAINOPROL	nicainoprol	CC(C)NCC(O)COC1=CC=CC2=C1N(CCC2)C(=O)C3=CC=CN=C3	PLASMA	1UA960P80H									?	ng × h/mL	7388		ng/mL	2450			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3677541	Homo sapiens		min	106.6				8	nicainoprol		false
6388	5563		ADULT	6433427	285.276	NIFURATEL	NIFURATEL	CSCC1CN(\\N=C\\C2=CC=C(O2)[N ]([O-])=O)C(=O)O1	PLASMA	U60U6P08SP									∞	ng × h/mL	155.02		ng/mL	44.89				mg	400		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17702193/	Homo sapiens		h	3.58				24	NIFURATEL		false
6389	5608		ADULT	91668	370.4819	NOMEGESTROL ACETATE	Nomegestrol acetate	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O	SERUM	83J78V5W05	5757	272.382	ESTRADIOL	17beta-estradiol	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@H]2O	4TI98Z838E	24		t	ng × h/mL	50.4		ng/mL	7.19			RECOMMENDED	mg	2.5		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22898360/	Homo sapiens		h	41.9			1.5mg	19			true
6390	5608		ADULT	91668	370.4819	NOMEGESTROL ACETATE	Nomegestrol acetate	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O	SERUM	83J78V5W05	5757	272.382	ESTRADIOL	17beta-estradiol	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@H]2O	4TI98Z838E	24		t	ng × h/mL	106		ng/mL	12.3			RECOMMENDED	mg	2.5		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22898360/	Homo sapiens		h	45.9			1.5mg	23			true
6391	5608		ADOLESCENT	91668	370.4819	NOMEGESTROL ACETATE	Nomegestrol acetate	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O	PLASMA	83J78V5W05	5757	272.382	ESTRADIOL	17beta-estradiol	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@H]2O	4TI98Z838E			∞	ng × h/mL	96		ng/mL	6.9			RECOMMENDED	mg	2.5		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26365792/	Homo sapiens		h	39.3			1.5mg	15	Nomegestrol acetate		true
6392	5608		ADULT	91668	370.4819	NOMEGESTROL ACETATE	Nomegestrol acetate	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O	PLASMA	83J78V5W05	5757	272.382	ESTRADIOL	17beta-estradiol	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@H]2O	4TI98Z838E			∞	ng × h/mL	106		ng/mL	6.6			RECOMMENDED	mg	2.5		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26365792/	Homo sapiens		h	48.1			1.5mg	15	Nomegestrol acetate		true
6393	5608			91668	370.4819	NOMEGESTROL ACETATE	Nomegestrol acetate	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O	SERUM	83J78V5W05																										Nomegestrol acetate is extensively bound to albumin (97-98 %), but does not bind to sex hormone binding globulin (SHBG) or corticoid binding globulin (CBG).	2				OTHER GOV'T	https://www.medicines.org.uk/emc/product/3038#PHARMACOKINETIC_PROPS	Homo sapiens										false
6394	5669		ADULT	105160	195.08	Platinum (IV) ion	Platinum (IV) ion	[Pt 4]	PLASMA										?	mg × h/L	6.62		mg/L	0.576			UNKNOWN	mg/m²	78		SINGLE	UNKNOWN				more than 70% of platinum protein bound by the end of the infusion	30	UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8306332	Homo sapiens		min	16.2				2	ORMAPLATIN		false
6395	5669		ADULT	105160	195.08	Platinum (IV) ion	Platinum (IV) ion	[Pt 4]	PLASMA										?	mg × h/L	4.37		mg/L	0.78			MAX TOLERATED	mg/m²	98		SINGLE	UNKNOWN				more than 70% of platinum protein bound by the end of the infusion.	30	UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8306332	Homo sapiens		min	11.9				7	ORMAPLATIN		false
6396	5669		ADULT	105160	195.08	Platinum (IV) ion	Platinum (IV) ion	[Pt 4]	PLASMA										?	mg × h/L	8.05		mg/L	0.995			UNKNOWN	mg/m²	123		SINGLE	UNKNOWN				more than 70% of platinum protein bound by the end of the infusion.	30	UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8306332	Homo sapiens		min	10.5				5	ORMAPLATIN		false
6397	5824		UNKNOWN	11226	367.4813	PHENOPERIDINE	PHENOPERIDINE	CCOC(=O)C1(CCN(CCC(O)C2=CC=CC=C2)CC1)C3=CC=CC=C3	PLASMA	G9BH09J4JW																	UNKNOWN	μg/kg bw	15		SINGLE	UNKNOWN					21.17	UNKNOWN	Intravenous	UNKNOWN	EXPERIMENT	https://academic.oup.com/jpp/article-abstract/34/Supplement_12/95P/6198346?redirectedFrom=PDF	Homo sapiens							13	PHENOPERIDINE		false
6398	5824		ADULT	11226	367.4813	PHENOPERIDINE	PHENOPERIDINE	CCOC(=O)C1(CCN(CCC(O)C2=CC=CC=C2)CC1)C3=CC=CC=C3	PLASMA	G9BH09J4JW									∞	ng × min/mL	1330						UNKNOWN	mg	2		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4027103/	Homo sapiens		min	193	Phenoperidine 2 mg was administered 10 min following induction and before the surgical incision.	anaesthetized patients undergoing general surgery		5	PHENOPERIDINE		false
6399	5828		UNKNOWN	4655	165.2322	PHOLEDRINE	pholedrine	CNC(C)CC1=CC=C(O)C=C1	PLASMA	AY28O44JGD													ng/mL	60.7			UNKNOWN	mg	40		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10348201/	Homo sapiens										false
6400	5995		UNKNOWN	14670	285.407	PROTHIPENDYL	prothipendyl	CN(C)CCCN1C2=NC=CC=C2SC3=C1C=CC=C3	UNKNOWN	5O6VWA87VA																	UNKNOWN				UNKNOWN	UNKNOWN						UNKNOWN	Oral	UNKNOWN	OTHER	https://link.springer.com/chapter/10.1007%2F978-3-642-25761-2_10	Homo sapiens		h	2.5							false
6401	5995		ADULT	14670	285.407	PROTHIPENDYL	prothipendyl	CN(C)CCCN1C2=NC=CC=C2SC3=C1C=CC=C3	SERUM	5O6VWA87VA													ng/mL	18			RECOMMENDED	mg	40		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://onlinelibrary.wiley.com/doi/abs/10.1002/dta.2319	Homo sapiens										false
6402	5995		ADULT	14670	285.407	PROTHIPENDYL	prothipendyl	CN(C)CCCN1C2=NC=CC=C2SC3=C1C=CC=C3	SERUM	5O6VWA87VA													ng/mL	42.6			RECOMMENDED	mg	80		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://onlinelibrary.wiley.com/doi/abs/10.1002/dta.2319	Homo sapiens										false
6403	6001		ADULT	4980	204.2682	PSILOCIN	psilocin	CN(C)CCC1=CNC2=C1C(O)=CC=C2	PLASMA	CMS88KUW0G									?	μg × h/L	140		μg/L	16			UNKNOWN	mg/kg	0.3		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28353056	Homo sapiens		h	3				12	psilocybin		false
6404	6001		ADULT	4980	204.2682	PSILOCIN	psilocin	CN(C)CCC1=CNC2=C1C(O)=CC=C2	PLASMA	CMS88KUW0G									?	μg × h/L	213		μg/L	26			UNKNOWN	mg/kg	0.45		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28353056	Homo sapiens		h	3				11	PSILOCYBINE		false
6405	6001		ADULT	4980	204.2682	PSILOCIN	psilocin	CN(C)CCC1=CNC2=C1C(O)=CC=C2	PLASMA	CMS88KUW0G									?	μg × h/L	267		μg/L	37.6			UNKNOWN	mg/kg	0.6		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28353056	Homo sapiens		h	3				10	psilocybin		false
6406	6112			133017	415.958	RUPATADINE	Rupatadine	CC1=CN=CC(CN2CCC(CC2)=C3C4=NC=CC=C4CCC5=C3C=CC(Cl)=C5)=C1	PLASMA	2AE8M83G3E																										Human plasma protein binding: 98.3~99.1% (1~25ng/mL), equlibrium dialysis	0.9				OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170830003/470006000_22900AMX00962_A100_1.pdf#page=13	Homo sapiens								Rupatadine fumarate		false
6407	6112		ADULT	124087	310.821	DESLORATADINE	Desloratadine	ClC1=CC2=C(C=C1)C(=C3CCNCC3)C4=NC=CC=C4CC2	PLASMA	FVF865388R									?	ng × h/mL	50.5		ng/mL	3.6			MAX DAILY	mg	20		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170830003/470006000_22900AMX00962_A100_1.pdf#page=25	Homo sapiens		h	1.8				24	Rupatadine fumarate		false
6408	6112		ADULT	133017	415.958	RUPATADINE	Rupatadine	CC1=CN=CC(CN2CCC(CC2)=C3C4=NC=CC=C4CCC5=C3C=CC(Cl)=C5)=C1	PLASMA	2AE8M83G3E									∞	ng × h/mL	15.4		ng/mL	4.6			DEFINED DAILY	mg	10		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170830003/470006000_22900AMX00962_A100_1.pdf#page=25	Homo sapiens		h	4.8	Day 1			7	Rupatadine fumarate		false
6409	6112		ADULT	133017	415.958	RUPATADINE	Rupatadine	CC1=CN=CC(CN2CCC(CC2)=C3C4=NC=CC=C4CCC5=C3C=CC(Cl)=C5)=C1	PLASMA	2AE8M83G3E							24		t	ng × h/mL	18.6		ng/mL	5			DEFINED DAILY	mg	10		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170830003/470006000_22900AMX00962_A100_1.pdf#page=25	Homo sapiens		h	6.6	Day 5			7	Rupatadine fumarate		false
6410	6112		ADULT	133017	415.958	RUPATADINE	Rupatadine	CC1=CN=CC(CN2CCC(CC2)=C3C4=NC=CC=C4CCC5=C3C=CC(Cl)=C5)=C1	PLASMA	2AE8M83G3E							24		t	ng × h/mL	35.6		ng/mL	10.6			MAX DAILY	mg	20		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170830003/470006000_22900AMX00962_A100_1.pdf#page=25	Homo sapiens		h	10.6	Day 5			7	Rupatadine fumarate		false
6411	6112		ADULT	133017	415.958	RUPATADINE	Rupatadine	CC1=CN=CC(CN2CCC(CC2)=C3C4=NC=CC=C4CCC5=C3C=CC(Cl)=C5)=C1	PLASMA	2AE8M83G3E									∞	ng × h/mL	27.8		ng/mL	6.9			MAX DAILY	mg	20		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170830003/470006000_22900AMX00962_A100_1.pdf#page=25	Homo sapiens		h	7.1	Day 1			7	Rupatadine fumarate		false
6412	6112		ADULT	133017	415.958	RUPATADINE	Rupatadine	CC1=CN=CC(CN2CCC(CC2)=C3C4=NC=CC=C4CCC5=C3C=CC(Cl)=C5)=C1	PLASMA	2AE8M83G3E									∞	ng × h/mL	60.3		ng/mL	18.1			UNKNOWN	mg	40		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170830003/470006000_22900AMX00962_A100_1.pdf#page=25	Homo sapiens		h	7.9	Day 1			7	Rupatadine fumarate		false
6413	6112		ADULT	133017	415.958	RUPATADINE	Rupatadine	CC1=CN=CC(CN2CCC(CC2)=C3C4=NC=CC=C4CCC5=C3C=CC(Cl)=C5)=C1	PLASMA	2AE8M83G3E							24		t	ng × h/mL	75.5		ng/mL	18.2			UNKNOWN	mg	40		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170830003/470006000_22900AMX00962_A100_1.pdf#page=25	Homo sapiens		h	12.8	Day 5			7	Rupatadine fumarate		false
6414	6112		ADULT	124087	310.821	DESLORATADINE	Desloratadine	ClC1=CC2=C(C=C1)C(=C3CCNCC3)C4=NC=CC=C4CC2	PLASMA	FVF865388R									∞	ng × h/mL	29.6		ng/mL	2			DEFINED DAILY	mg	10		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170830003/470006000_22900AMX00962_A100_1.pdf#page=25	Homo sapiens				Day 1			7	Rupatadine fumarate		false
6415	6112		ADULT	124087	310.821	DESLORATADINE	Desloratadine	ClC1=CC2=C(C=C1)C(=C3CCNCC3)C4=NC=CC=C4CC2	PLASMA	FVF865388R									?	ng × h/mL	47.7		ng/mL	3.2			MAX DAILY	mg	20		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170830003/470006000_22900AMX00962_A100_1.pdf#page=25	Homo sapiens		h	3				24	Rupatadine fumarate		false
6416	6112		ADULT	124087	310.821	DESLORATADINE	Desloratadine	ClC1=CC2=C(C=C1)C(=C3CCNCC3)C4=NC=CC=C4CC2	PLASMA	FVF865388R							24		t	ng × h/mL	32.7		ng/mL	2.6			DEFINED DAILY	mg	10		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170830003/470006000_22900AMX00962_A100_1.pdf#page=25	Homo sapiens		h	20.7	Day 5			7	Rupatadine fumarate		false
6417	6112		ADULT	124087	310.821	DESLORATADINE	Desloratadine	ClC1=CC2=C(C=C1)C(=C3CCNCC3)C4=NC=CC=C4CC2	PLASMA	FVF865388R									∞	ng × h/mL	49.5		ng/mL	3			MAX DAILY	mg	20		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170830003/470006000_22900AMX00962_A100_1.pdf#page=25	Homo sapiens				Day 1			7	Rupatadine fumarate		false
6418	6112		ADULT	124087	310.821	DESLORATADINE	Desloratadine	ClC1=CC2=C(C=C1)C(=C3CCNCC3)C4=NC=CC=C4CC2	PLASMA	FVF865388R									∞	ng × h/mL	57.8		ng/mL	5			MAX DAILY	mg	20		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170830003/470006000_22900AMX00962_A100_1.pdf#page=25	Homo sapiens		h	24.8	Day 5			7	Rupatadine fumarate		false
6419	6112		ADULT	124087	310.821	DESLORATADINE	Desloratadine	ClC1=CC2=C(C=C1)C(=C3CCNCC3)C4=NC=CC=C4CC2	PLASMA	FVF865388R									∞	ng × h/mL	132.3		ng/mL	11.7			UNKNOWN	mg	40		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170830003/470006000_22900AMX00962_A100_1.pdf#page=25	Homo sapiens		h	24.5	Day 5			7	Rupatadine fumarate		false
6420	6112		ADULT	124087	310.821	DESLORATADINE	Desloratadine	ClC1=CC2=C(C=C1)C(=C3CCNCC3)C4=NC=CC=C4CC2	PLASMA	FVF865388R									∞	ng × h/mL	117.1		ng/mL	9.9			UNKNOWN	mg	40		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170830003/470006000_22900AMX00962_A100_1.pdf#page=25	Homo sapiens				Day 1			7	Rupatadine fumarate		false
6421	6112		ADULT	133017	415.958	RUPATADINE	Rupatadine	CC1=CN=CC(CN2CCC(CC2)=C3C4=NC=CC=C4CCC5=C3C=CC(Cl)=C5)=C1	PLASMA	2AE8M83G3E									?	ng × h/mL	16.6		ng/mL	4.6			MAX DAILY	mg	20		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170830003/470006000_22900AMX00962_A100_1.pdf#page=25	Homo sapiens		h	0.9				24	Rupatadine fumarate		false
6422	6112		ADULT	133017	415.958	RUPATADINE	Rupatadine	CC1=CN=CC(CN2CCC(CC2)=C3C4=NC=CC=C4CCC5=C3C=CC(Cl)=C5)=C1	PLASMA	2AE8M83G3E									?	ng × h/mL	20.4		ng/mL	4.3			MAX DAILY	mg	20		SINGLE	HIGH-FAT						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170830003/470006000_22900AMX00962_A100_1.pdf#page=25	Homo sapiens		h	1.8				24	Rupatadine fumarate		false
6423	6112		ADULT	133017	415.958	RUPATADINE	Rupatadine	CC1=CN=CC(CN2CCC(CC2)=C3C4=NC=CC=C4CCC5=C3C=CC(Cl)=C5)=C1	PLASMA	2AE8M83G3E							24		t	ng × h/mL	9.8		ng/mL	2.5			DEFINED DAILY	mg	10		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170830003/470006000_22900AMX00962_A100_1.pdf#page=26	Homo sapiens		h	6.2	Day 1	Elderly subjects (64~72 y)		12	Rupatadine fumarate		false
6424	6112		ADULT	133017	415.958	RUPATADINE	Rupatadine	CC1=CN=CC(CN2CCC(CC2)=C3C4=NC=CC=C4CCC5=C3C=CC(Cl)=C5)=C1	PLASMA	2AE8M83G3E							24		t	ng × h/mL	14.2		ng/mL	3.2			DEFINED DAILY	mg	10		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170830003/470006000_22900AMX00962_A100_1.pdf#page=26	Homo sapiens		h	8.7	Day 7	Elderly subjects (64~72 y)		12	Rupatadine fumarate		false
6425	6112		ADULT	133017	415.958	RUPATADINE	Rupatadine	CC1=CN=CC(CN2CCC(CC2)=C3C4=NC=CC=C4CCC5=C3C=CC(Cl)=C5)=C1	PLASMA	2AE8M83G3E							24		t	ng × h/mL	6.4		ng/mL	1.5			DEFINED DAILY	mg	10		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170830003/470006000_22900AMX00962_A100_1.pdf#page=26	Homo sapiens		h	4	Day 1	Young subjects (18~35 y)		12	Rupatadine fumarate		false
6426	6112		ADULT	133017	415.958	RUPATADINE	Rupatadine	CC1=CN=CC(CN2CCC(CC2)=C3C4=NC=CC=C4CCC5=C3C=CC(Cl)=C5)=C1	PLASMA	2AE8M83G3E							24		t	ng × h/mL	8.4		ng/mL	2			DEFINED DAILY	mg	10		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170830003/470006000_22900AMX00962_A100_1.pdf#page=26	Homo sapiens		h	5.9	Day 7	Young subjects (18~35 y)		12	Rupatadine fumarate		false
6427	6112		ADULT	133017	415.958	RUPATADINE	Rupatadine	CC1=CN=CC(CN2CCC(CC2)=C3C4=NC=CC=C4CCC5=C3C=CC(Cl)=C5)=C1	PLASMA	2AE8M83G3E							24		t	ng × h/mL	11.3		ng/mL	4			DEFINED DAILY	mg	10		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170830003/470006000_22900AMX00962_A100_1.pdf#page=26	Homo sapiens		h	6.1	Day 1			45	Rupatadine fumarate		false
6428	6112		ADULT	133017	415.958	RUPATADINE	Rupatadine	CC1=CN=CC(CN2CCC(CC2)=C3C4=NC=CC=C4CCC5=C3C=CC(Cl)=C5)=C1	PLASMA	2AE8M83G3E							24		t	ng × h/mL	14.6		ng/mL	4.5			DEFINED DAILY	mg	10		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170830003/470006000_22900AMX00962_A100_1.pdf#page=26	Homo sapiens		h	9.2	Day 5			45	Rupatadine fumarate		false
6429	6112		ADULT	133017	415.958	RUPATADINE	Rupatadine	CC1=CN=CC(CN2CCC(CC2)=C3C4=NC=CC=C4CCC5=C3C=CC(Cl)=C5)=C1	PLASMA	2AE8M83G3E							24		t	ng × h/mL	214.5		ng/mL	68.4			UNKNOWN	mg	100		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170830003/470006000_22900AMX00962_A100_1.pdf#page=26	Homo sapiens		h	9.9	Day 1			41	Rupatadine fumarate		false
6430	6112		ADULT	133017	415.958	RUPATADINE	Rupatadine	CC1=CN=CC(CN2CCC(CC2)=C3C4=NC=CC=C4CCC5=C3C=CC(Cl)=C5)=C1	PLASMA	2AE8M83G3E							24		t	ng × h/mL	296.4		ng/mL	81.1			UNKNOWN	mg	100		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170830003/470006000_22900AMX00962_A100_1.pdf#page=26	Homo sapiens		h	13.8	Day 5			41	Rupatadine fumarate		false
6431	6112		ADULT	124087	310.821	DESLORATADINE	Desloratadine	ClC1=CC2=C(C=C1)C(=C3CCNCC3)C4=NC=CC=C4CC2	PLASMA	FVF865388R							24		t	ng × h/mL	17		ng/mL	1.8			DEFINED DAILY	mg	10		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170830003/470006000_22900AMX00962_A100_1.pdf#page=26	Homo sapiens		h	9.3	Day 1			45	Rupatadine fumarate		false
6432	6112		ADULT	124087	310.821	DESLORATADINE	Desloratadine	ClC1=CC2=C(C=C1)C(=C3CCNCC3)C4=NC=CC=C4CC2	PLASMA	FVF865388R							24		t	ng × h/mL	28.2		ng/mL	2.5			DEFINED DAILY	mg	10		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170830003/470006000_22900AMX00962_A100_1.pdf#page=26	Homo sapiens		h	21.5	Day 5			45	Rupatadine fumarate		false
6433	6112		ADULT	124087	310.821	DESLORATADINE	Desloratadine	ClC1=CC2=C(C=C1)C(=C3CCNCC3)C4=NC=CC=C4CC2	PLASMA	FVF865388R							24		t	ng × h/mL	198.9		ng/mL	23.1			UNKNOWN	mg	100		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170830003/470006000_22900AMX00962_A100_1.pdf#page=26	Homo sapiens		h	11	Day 1			41	Rupatadine fumarate		false
6434	6112		ADULT	124087	310.821	DESLORATADINE	Desloratadine	ClC1=CC2=C(C=C1)C(=C3CCNCC3)C4=NC=CC=C4CC2	PLASMA	FVF865388R							24		t	ng × h/mL	399.7		ng/mL	35.5			UNKNOWN	mg	100		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170830003/470006000_22900AMX00962_A100_1.pdf#page=26	Homo sapiens		h	21.4	Day 5			41	Rupatadine fumarate		false
6435	6112		ADULT	124087	310.821	DESLORATADINE	Desloratadine	ClC1=CC2=C(C=C1)C(=C3CCNCC3)C4=NC=CC=C4CC2	PLASMA	FVF865388R							24		t	ng × h/mL	16.47		ng/mL	1.5			DEFINED DAILY	mg	10		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170830003/470006000_22900AMX00962_A100_1.pdf#page=26 | https://www.pmda.go.jp/drugs/2017/P20170830003/470006000_22900AMX00962_K101_1.pdf#page=95	Homo sapiens		h	2	Day 1	Elderly subjects (64~72 y)		12	Rupatadine fumarate		false
6436	6112		ADULT	124087	310.821	DESLORATADINE	Desloratadine	ClC1=CC2=C(C=C1)C(=C3CCNCC3)C4=NC=CC=C4CC2	PLASMA	FVF865388R							24		t	ng × h/mL	30.66		ng/mL	2.34			DEFINED DAILY	mg	10		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170830003/470006000_22900AMX00962_A100_1.pdf#page=26 | https://www.pmda.go.jp/drugs/2017/P20170830003/470006000_22900AMX00962_K101_1.pdf#page=95	Homo sapiens		h	2	Day 7	Elderly subjects (64~72 y)		12	Rupatadine fumarate		false
6437	6112		ADULT	124087	310.821	DESLORATADINE	Desloratadine	ClC1=CC2=C(C=C1)C(=C3CCNCC3)C4=NC=CC=C4CC2	PLASMA	FVF865388R							24		t	ng × h/mL	15.86		ng/mL	1.43			DEFINED DAILY	mg	10		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170830003/470006000_22900AMX00962_A100_1.pdf#page=26 | https://www.pmda.go.jp/drugs/2017/P20170830003/470006000_22900AMX00962_K101_1.pdf#page=95	Homo sapiens		h	2	Day 1	Young subjects (18~35 y)		12	Rupatadine fumarate		false
6438	6112		ADULT	124087	310.821	DESLORATADINE	Desloratadine	ClC1=CC2=C(C=C1)C(=C3CCNCC3)C4=NC=CC=C4CC2	PLASMA	FVF865388R							24		t	ng × h/mL	24.66		ng/mL	1.91			DEFINED DAILY	mg	10		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170830003/470006000_22900AMX00962_A100_1.pdf#page=26 | https://www.pmda.go.jp/drugs/2017/P20170830003/470006000_22900AMX00962_K101_1.pdf#page=95	Homo sapiens		h	3	Day 7	Young subjects (18~35 y)		12	Rupatadine fumarate		false
6439	6177		ADULT	42548	343.5062	SITAMAQUINE	SITAMAQUINE	CCN(CC)CCCCCCNC1=C2N=CC=C(C)C2=CC(OC)=C1	PLASMA	5AIJ4TGC6B							24		t	ng × h/mL	6916		ng/mL	484.3			MAX TOLERATED	mg	150		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10235511	Homo sapiens							2	SITAMAQUINE		false
6440	6177		ADULT	42548	343.5062	SITAMAQUINE	SITAMAQUINE	CCN(CC)CCCCCCNC1=C2N=CC=C(C)C2=CC(OC)=C1	PLASMA	5AIJ4TGC6B									∞	ng × h/mL	7147		ng/mL	577			UNKNOWN	mg/kg	2		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21633025	Homo sapiens							10	SITAMAQUINE		false
6441	6177		ADULT	42548	343.5062	SITAMAQUINE	SITAMAQUINE	CCN(CC)CCCCCCNC1=C2N=CC=C(C)C2=CC(OC)=C1	PLASMA	5AIJ4TGC6B									∞	ng × h/mL	8350		ng/mL	503			UNKNOWN	mg/kg	2		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21633025	Homo sapiens		h	18.3	day 21			10	SITAMAQUINE		false
6442	6177		ADULT	42548	343.5062	SITAMAQUINE	SITAMAQUINE	CCN(CC)CCCCCCNC1=C2N=CC=C(C)C2=CC(OC)=C1	PLASMA	5AIJ4TGC6B									∞	ng × h/mL	8574		ng/mL	639			UNKNOWN	mg/kg	2		SINGLE	FED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21633025	Homo sapiens							10	SITAMAQUINE		false
6443	6177		ADULT	42548	343.5062	SITAMAQUINE	SITAMAQUINE	CCN(CC)CCCCCCNC1=C2N=CC=C(C)C2=CC(OC)=C1	PLASMA	5AIJ4TGC6B									∞	ng × h/mL	7723		ng/mL	451			UNKNOWN	mg/kg	2		MULTIPLE	FED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21633025	Homo sapiens		h	19.3	day 21			10	SITAMAQUINE		false
6444	6292		ADULT	115358	463.4926	TAFENOQUINE	TAFENOQUINE	COC1=NC2=C(C(C)=C1)C(OC3=CC=CC(=C3)C(F)(F)F)=C(OC)C=C2NC(C)CCCN	PLASMA	262P8GS9L9									∞	μg × h/mL	70		ng/mL	147			RECOMMENDED	mg	200		SINGLE	HIGH-FAT				Tafenoquine is greater than 99.5% bound to protein in humans.	0.5	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210607lbl.pdf	Homo sapiens		day	16.5							false
6445	6302		ADULT	71792	165.2322	TALSACLIDINE	TALSACLIDINE	C#CCO[C@H]1CN2CCC1CC2	PLASMA	1O8VSL798T									?	ng × h/mL	12		ng/mL	2.7			UNKNOWN	mg	0.5		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10188789	Homo sapiens							6	WAL 2014		false
6446	6302		ADULT	71792	165.2322	TALSACLIDINE	TALSACLIDINE	C#CCO[C@H]1CN2CCC1CC2	PLASMA	1O8VSL798T									?	ng × h/mL	4500		ng/mL	730			UNKNOWN	mg	160		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10188789	Homo sapiens							6	WAL 2014		false
6447	6302		ADULT	71792	165.2322	TALSACLIDINE	talsaclidine	C#CCO[C@H]1CN2CCC1CC2	PLASMA	1O8VSL798T																						UNKNOWN				The plasma protein binding in human plasma was low (< 1 %) and independent of the concentration used (0,1, 0,6 and 12 ug/mL (talsaclidine)	99	UNHEALTHY		UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11037112	Homo sapiens								talsaclidine		false
6448	6348		ADULT	65649	182.243	TENILSETAM	TENILSETAM	O=C1NCCNC1C2=CC=CS2	PLASMA	O4Q7XM74N6							24		t	μg × h/mL	31.97		μg/mL	2.03			UNKNOWN	mg	75		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://doi.org/10.1002/ddr.430090203	Homo sapiens		h	18.31				10	TENILSETAM		false
6449	6348		ADULT	65649	182.243	TENILSETAM	TENILSETAM	O=C1NCCNC1C2=CC=CS2	PLASMA	O4Q7XM74N6							24		t	μg × h/mL	65.98		μg/mL	4.33			UNKNOWN	mg	150		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://doi.org/10.1002/ddr.430090203	Homo sapiens		h	18.39				10	TENILSETAM		false
6450	6348		ADULT	65649	182.243	TENILSETAM	TENILSETAM	O=C1NCCNC1C2=CC=CS2	PLASMA	O4Q7XM74N6							24		t	μg × h/mL	146.99		μg/mL	9.03			UNKNOWN	mg	300		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://doi.org/10.1002/ddr.430090203	Homo sapiens		h	21.84				10	TENILSETAM		false
6451	6511		ADULT	159325	600.4733	TORCETRAPIB	torcetrapib	CCOC(=O)N1[C@H](CC)C[C@H](N(CC2=CC(=CC(=C2)C(F)(F)F)C(F)(F)F)C(=O)OC)C3=C1C=CC(=C3)C(F)(F)F	PLASMA	4N4457MV2U									∞	ng × h/mL	7570		ng/mL	576			UNKNOWN	mg	120		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18694908	Homo sapiens		h	211				6	torcetrapib		false
6452	6511		ADULT	12889	258.12	bistrifluoromethylbenzoic acid	bistrifluoromethylbenzoic acid		PLASMA	NN52L84T3A									∞	ng × h/mL	452000		ng/mL	2920			UNKNOWN	mg	120		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18694908	Homo sapiens		h	117				6	torcetrapib		false
6453	6604		ADULT	20140	143.2267	VALNOCTAMIDE	Valnoctamide	CCC(C)C(CC)C(N)=O	PLASMA	3O25NRX9YG									?	mg × h/L	71		mg/L	5.8			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2111246/	Homo sapiens		h	9.3				7			false
6454	6697		CHILD	43008|135413504	315.3702	ALIZAPRIDE	Alizapride	COC1=C(C=C2N=NNC2=C1)C(=O)NCC3CCCN3CC=C	PLASMA	P55703ZRZY							8		t	ng × h/mL	5574						UNKNOWN	mg/kg	4		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11468033/	Homo sapiens		h	2.27		Preschooler (2-5 yr), receiving chemotherapy for solid tumours		6			false
6455	6697		CHILD	43008|135413504	315.3702	ALIZAPRIDE	Alizapride	COC1=C(C=C2N=NNC2=C1)C(=O)NCC3CCCN3CC=C	PLASMA	P55703ZRZY							8		t	ng × h/mL	4260.5						UNKNOWN	mg/kg	3.97		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11468033/	Homo sapiens		h	4.68		Infant (4w-1yr) and Toddler (1-2 yr), receiving chemotehrapy for solid tumours		5			false
6456	6697		ADOLESCENT	43008|135413504	315.3702	ALIZAPRIDE	Alizapride	COC1=C(C=C2N=NNC2=C1)C(=O)NCC3CCCN3CC=C	PLASMA	P55703ZRZY							8		t	ng × h/mL	7595						UNKNOWN	mg/kg	3.78		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11468033/	Homo sapiens		h	2.28		Receiving chemotherapy for solid tumours, 10-15 yr		6			false
6457	6697		ADULT	43008|135413504	315.3702	ALIZAPRIDE	Alizapride	COC1=C(C=C2N=NNC2=C1)C(=O)NCC3CCCN3CC=C	PLASMA	P55703ZRZY									?	mg × h/L	1.706						UNKNOWN	mg	50		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6827466/	Homo sapiens		h	2.17				3			false
6458	6697		ADULT	43008|135413504	315.3702	ALIZAPRIDE	Alizapride	COC1=C(C=C2N=NNC2=C1)C(=O)NCC3CCCN3CC=C	PLASMA	P55703ZRZY									?	mg × h/L	4.66						UNKNOWN	mg	150		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6827466/	Homo sapiens		h	2.51				3			false
6459	6697		ADULT	43008|135413504	315.3702	ALIZAPRIDE	Alizapride	COC1=C(C=C2N=NNC2=C1)C(=O)NCC3CCCN3CC=C	PLASMA	P55703ZRZY									?	mg × h/L	6.573						UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6827466/	Homo sapiens		h	3.22				3			false
6460	6697		ADULT	43008|135413504	315.3702	ALIZAPRIDE	Alizapride	COC1=C(C=C2N=NNC2=C1)C(=O)NCC3CCCN3CC=C	PLASMA	P55703ZRZY									?	mg × h/L	3.76						UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6827466/	Homo sapiens		h	3.14				3			false
6461	6697		ADULT	43008|135413504	315.3702	ALIZAPRIDE	Alizapride	COC1=C(C=C2N=NNC2=C1)C(=O)NCC3CCCN3CC=C	PLASMA	P55703ZRZY									?	mg × h/L	3.533						UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6827466/	Homo sapiens		h	3.2				3			false
6462	6697		ADULT	43008|135413504	315.3702	ALIZAPRIDE	Alizapride	COC1=C(C=C2N=NNC2=C1)C(=O)NCC3CCCN3CC=C	PLASMA	P55703ZRZY									?	mg × h/L	1.977						UNKNOWN	mg	50		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6827466/	Homo sapiens		h	1.98				3			false
6463	6697		ADULT	43008|135413504	315.3702	ALIZAPRIDE	Alizapride	COC1=C(C=C2N=NNC2=C1)C(=O)NCC3CCCN3CC=C	PLASMA	P55703ZRZY									?	mg × h/L	7.587						UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6827466/	Homo sapiens		h	2.52				3			false
6464	6697		ADULT	43008|135413504	315.3702	ALIZAPRIDE	Alizapride	COC1=C(C=C2N=NNC2=C1)C(=O)NCC3CCCN3CC=C	PLASMA	P55703ZRZY									?	mg × h/L	3.17						UNKNOWN	mg	150		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6827466/	Homo sapiens		h	2.26				3			false
6465	6699		ADULT	2446	344.247	BROMOPRIDE	BROMOPRIDE	CCN(CC)CCNC(=O)C1=C(OC)C=C(N)C(Br)=C1	PLASMA	75473V2YZK									t	ng × h/mL	194		ng/mL	58			UNKNOWN	mg	10		SINGLE	UNKNOWN				Over a wide drug concentration range of up to 650 ng/ml, bromopride was only 40 per cent bound to plasma proteins.	60	HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3730521/	Homo sapiens		h	2.9				6	BROMOPRIDE		false
6466	6699		ADULT	2446	344.247	BROMOPRIDE	BROMOPRIDE	CCN(CC)CCNC(=O)C1=C(OC)C=C(N)C(Br)=C1	PLASMA	75473V2YZK									t	ng × h/mL	191		ng/mL	25			UNKNOWN	mg	20		SINGLE	UNKNOWN				Over a wide drug concentration range of up to 650 ng/ml, bromopride was only 40 per cent bound to plasma proteins.	60	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3730521/	Homo sapiens		h	4.2				6	BROMOPRIDE		false
6467	6699		ADULT	2446	344.247	BROMOPRIDE	BROMOPRIDE	CCN(CC)CCNC(=O)C1=C(OC)C=C(N)C(Br)=C1	PLASMA	75473V2YZK									t	ng × h/mL	680		ng/mL	127			RECOMMENDED	mg	20		SINGLE	UNKNOWN				Over a wide drug concentration range of up to 650 ng/ml, bromopride was only 40 per cent bound to plasma proteins.	60	HEALTHY	Intramuscular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3730521/	Homo sapiens		h	4.8				6	BROMOPRIDE		false
6468	6700		ADULT	305	104.1708	CHOLINE	CHOLINE	C[N ](C)(C)CCO	PLASMA	N91BDP6H0X									∞	μg × h/mL	3.31		μg/mL	0.38			RECOMMENDED	mg	1200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31040642/	Homo sapiens		h	5.25				48	CHOLINE ALFOSCERATE		false
6469	6702		ADULT	53276	304.3195	FLUPIRTINE	flupirtine	CCOC(=O)NC1=C(N)N=C(NCC2=CC=C(F)C=C2)C=C1	SERUM	MOH3ET196H									∞	μg × h/L	6070		μg/L	773			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral		EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3200777/	Homo sapiens		h	6.5		18-35 year old		91	flupirtine maleate		false
6470	6702		ADULT	53276	304.3195	FLUPIRTINE	flupirtine	CCOC(=O)NC1=C(N)N=C(NCC2=CC=C(F)C=C2)C=C1	SERUM	MOH3ET196H									∞	μg × h/L	6656		μg/L	722			UNKNOWN	mg	100		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3200777/	Homo sapiens		h	9.8		mild renal impairment, 50-70 yo		12	flupirtine maleate		false
6471	6702		ADULT	53276	304.3195	FLUPIRTINE	flupirtine	CCOC(=O)NC1=C(N)N=C(NCC2=CC=C(F)C=C2)C=C1	SERUM	MOH3ET196H									∞	μg × h/L	10346		μg/L	1116			UNKNOWN	mg	100		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3200777/	Homo sapiens		h	14		66-83 yo		7	flupirtine maleate		false
6472	6702		ADULT	53276	304.3195	FLUPIRTINE	flupirtine	CCOC(=O)NC1=C(N)N=C(NCC2=CC=C(F)C=C2)C=C1	SERUM	MOH3ET196H							8		t	μg × h/L	9991		μg/L	1977			UNKNOWN	mg	100		MULTIPLE	FED		day	3	sample collected on day 12		HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3200777/	Homo sapiens		h	18.6		66-83 yo		11	flupirtine maleate		false
6473	6704		ADULT	3822	395.4268	KETANSERIN	Ketanserin	FC1=CC=C(C=C1)C(=O)C2CCN(CCN3C(=O)NC4=C(C=CC=C4)C3=O)CC2	PLASMA	97F9DE4CT4									?	ng × h/mL	632		ng/mL	127			UNKNOWN	mg	40		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2378791/	Homo sapiens		h	29		Non-dialysis patients		6			false
6474	6704		ADULT	3822	395.4268	KETANSERIN	Ketanserin	FC1=CC=C(C=C1)C(=O)C2CCN(CCN3C(=O)NC4=C(C=CC=C4)C3=O)CC2	PLASMA	97F9DE4CT4									?	ng × h/mL	637		ng/mL	60.7			UNKNOWN	mg	40		SINGLE	FASTED						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2378791/	Homo sapiens		h	28		Dialysis patients		6			false
6475	6704		ADULT	3822	395.4268	KETANSERIN	Ketanserin	FC1=CC=C(C=C1)C(=O)C2CCN(CCN3C(=O)NC4=C(C=CC=C4)C3=O)CC2	PLASMA	97F9DE4CT4							12		t	ng × h/mL	855		ng/mL	46.1			UNKNOWN	mg	40		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2378791/	Homo sapiens		h	40		Chronic renal insufficiency w/o dialysis		2			false
6476	6704		ADULT	3822	395.4268	KETANSERIN	Ketanserin	FC1=CC=C(C=C1)C(=O)C2CCN(CCN3C(=O)NC4=C(C=CC=C4)C3=O)CC2	PLASMA	97F9DE4CT4							12		t	ng × h/mL	265		ng/mL	14.2			UNKNOWN	mg	20		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2378791/	Homo sapiens		h	39		Chronic renal insufficiency (3 w/dialysis, one w/o dialysis)		4			false
6477	6704			3822	395.4268	KETANSERIN	Ketanserin	FC1=CC=C(C=C1)C(=O)C2CCN(CCN3C(=O)NC4=C(C=CC=C4)C3=O)CC2	PLASMA	97F9DE4CT4																										The extent of plasma protein binding of ketanserin ranged from 91.8 to 94.8% (93.7% ± 1.0) in patients with renal insufficiency, and from 94.5 to 95.4% (95.0 ± 0.2, means ± s.d.) in eight healthy volunteers (equilibrium dialysis).	6.3				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2378791/	Homo sapiens										false
6478	6704		ADULT	3822	395.4268	KETANSERIN	Ketanserin	FC1=CC=C(C=C1)C(=O)C2CCN(CCN3C(=O)NC4=C(C=CC=C4)C3=O)CC2	PLASMA	97F9DE4CT4									?	ng × h/mL	279		ng/mL	71.4			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3792432/	Homo sapiens		h	16.5				10			false
6479	6704		ADULT	3822	395.4268	KETANSERIN	Ketanserin	FC1=CC=C(C=C1)C(=O)C2CCN(CCN3C(=O)NC4=C(C=CC=C4)C3=O)CC2	PLASMA	97F9DE4CT4									?	ng × h/mL	625		ng/mL	198			UNKNOWN	mg	40		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3792432/	Homo sapiens		h	17.8				10			false
6480	6704		ADULT	3822	395.4268	KETANSERIN	Ketanserin	FC1=CC=C(C=C1)C(=O)C2CCN(CCN3C(=O)NC4=C(C=CC=C4)C3=O)CC2	PLASMA	97F9DE4CT4									?	ng × h/mL	992		ng/mL	287			UNKNOWN	mg	60		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3792432/	Homo sapiens		h	16.9				10			false
6481	6704		ADULT	3822	395.4268	KETANSERIN	Ketanserin	FC1=CC=C(C=C1)C(=O)C2CCN(CCN3C(=O)NC4=C(C=CC=C4)C3=O)CC2	PLASMA	97F9DE4CT4									∞	ng × h/mL	385.3						UNKNOWN	mg	10		SINGLE	FASTED				Equilibrium dialysis	9.36	HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6196551/	Homo sapiens		h	15.6				8			false
6482	6704		ADULT	3822	395.4268	KETANSERIN	Ketanserin	FC1=CC=C(C=C1)C(=O)C2CCN(CCN3C(=O)NC4=C(C=CC=C4)C3=O)CC2	PLASMA	97F9DE4CT4									∞	ng × h/mL	392.7		ng/mL	110.2			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6196551/	Homo sapiens		h	18.5				8			false
6483	6704		ADULT	3822	395.4268	KETANSERIN	Ketanserin	FC1=CC=C(C=C1)C(=O)C2CCN(CCN3C(=O)NC4=C(C=CC=C4)C3=O)CC2	PLASMA	97F9DE4CT4																	UNKNOWN	mg/kg bw	0.15		SINGLE	FASTED				Ultrafiltration	6.1	HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6617728/	Homo sapiens		h	12.4				6			false
6484	6704		ADULT	3822	395.4268	KETANSERIN	Ketanserin	FC1=CC=C(C=C1)C(=O)C2CCN(CCN3C(=O)NC4=C(C=CC=C4)C3=O)CC2	PLASMA	97F9DE4CT4													μg/L	193			UNKNOWN	mg	40		SINGLE	FASTED				Ultrafiltration	6.1	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6617728/	Homo sapiens		h	12.8				6			false
6485	6708			4746	277.4879	PERHEXILINE	Perhexiline	C(C(C1CCCCC1)C2CCCCC2)C3CCCCN3	PLASMA	KU65374X44																										equilibrium dialysis	2.4				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27518281/	Homo sapiens										false
6486	6708		ADULT	4746	277.4879	PERHEXILINE	Perhexiline	C(C(C1CCCCC1)C2CCCCC2)C3CCCCN3	PLASMA	KU65374X44									?	ng × h/mL	1010		ng/mL	66.8			UNKNOWN	mg	150		SINGLE	FASTED						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7264901/	Homo sapiens		h	11.2				5	Perhexiline maleate		false
6487	6708		ADULT	4746	277.4879	PERHEXILINE	Perhexiline	C(C(C1CCCCC1)C2CCCCC2)C3CCCCN3	PLASMA	KU65374X44									?	ng × h/mL	5110		ng/mL	274			UNKNOWN	mg	300		SINGLE	FASTED						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7264901/	Homo sapiens		h	19.1				5	Perhexiline maleate		false
6488	6709		ADULT	4850	298.3397	PIRIBEDIL	PIRIBEDIL	C(N1CCN(CC1)C2=NC=CC=N2)C3=CC4=C(OCO4)C=C3	PLASMA	DO22K1PRDJ									∞	μg × h/L	47.1		μg/L	46.5			UNKNOWN	mg	4		SINGLE	FASTED						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15726579/	Homo sapiens		h	11.8				10	PIRIBEDIL		false
6489	6709		ADULT		298.3397	PIRIBEDIL	PIRIBEDIL		PLASMA										∞	μg × h/L	96.7		μg/L	86			UNKNOWN	mg	8		SINGLE	FASTED						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15726579/	Homo sapiens		h	11.8				10	PIRIBEDIL		false
6490	6709		ADULT	4850	298.3397	PIRIBEDIL	PIRIBEDIL	C(N1CCN(CC1)C2=NC=CC=N2)C3=CC4=C(OCO4)C=C3	PLASMA	DO22K1PRDJ									∞	μg × h/L	253.4		μg/L	222.3			UNKNOWN	mg	16		SINGLE	FASTED						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15726579/	Homo sapiens		h	12.9				10	PIRIBEDIL		false
6491	6709		ADULT	4850	298.3397	PIRIBEDIL	PIRIBEDIL	C(N1CCN(CC1)C2=NC=CC=N2)C3=CC4=C(OCO4)C=C3	PLASMA	DO22K1PRDJ									∞	μg × h/L	23.9		μg/L	23.2			UNKNOWN	mg	2		SINGLE	FASTED						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15726579/	Homo sapiens		h	11.9				10	PIRIBEDIL		false
6492	6709		ADULT	4850	298.3397	PIRIBEDIL	PIRIBEDIL	C(N1CCN(CC1)C2=NC=CC=N2)C3=CC4=C(OCO4)C=C3	PLASMA	DO22K1PRDJ									∞	pg × h/mL	4080		ng/mL	350.91			RECOMMENDED	mg	50		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.researchgate.net/publication/361801101_Simple_and_rapid_LC-MSMS_method_for_determination_of_Piribedil_in_human_plasma	Homo sapiens							15	PIRIBEDIL		false
6493	6711		ADULT	6324616	697.7686	RIFAMYCIN	RIFAMYCIN	CO[C@H]1\\C=C\\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)C(C)=C\\C=C\\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C=C(O)C4=C3C2=O	PLASMA	DU69T8ZZPA													ng/mL	8.72			RECOMMENDED	mg	388		MULTIPLE	UNKNOWN		day	2	Plasma protein binding was approximately 80% in vitro.	20	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210910s000lbl.pdf	Homo sapiens										false
6494	6711		ADULT	6324616	697.7686	RIFAMYCIN	RIFAMYCIN	CO[C@H]1\\C=C\\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)C(C)=C\\C=C\\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C=C(O)C4=C3C2=O	PLASMA	DU69T8ZZPA									∞	ng × h/mL	11865.21		ng/mL	36025			UNKNOWN	mg	250		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210910Orig1s000MultidisciplineR.pdf	Homo sapiens		h	3.04							false
6495	6712		ADULT	10635	290.4403	STANOLONE	STANOLONE	C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O	PLASMA	08J2K08A3Y																					UNKNOWN	UNKNOWN				in vitro	2	HEALTHY	UNKNOWN	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1778174/	Homo sapiens										false
6496	6712		ADULT	10635	290.4403	STANOLONE	STANOLONE	C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O	SERUM	08J2K08A3Y							24		t	nM × h	44.8		nM	7.8			UNKNOWN	mg	16		SINGLE	UNKNOWN						HEALTHY	Topical	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9709942/	Homo sapiens		day	12							false
6497	6715		ADULT	3121	144.2114	VALPROIC ACID	valproic acid	CCCC(CCC)C(O)=O	SERUM	614OI1Z5WI													mg/L	75			UNKNOWN	mg	900		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6440792/	Homo sapiens				enteric-coated tablet			6	VALPROMIDE		false
6498	6715		ADULT	3121	144.2114	VALPROIC ACID	valproic acid	CCCC(CCC)C(O)=O	SERUM	614OI1Z5WI													mg/L	82			UNKNOWN	mg	900		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6440792/	Homo sapiens				aqueous solution (4 mg/ml)			6	VALPROMIDE		false
6499	6715		UNKNOWN	71113	143.2267	VALPROMIDE	VALPROMIDE	CCCC(CCC)C(N)=O	UNKNOWN	RUA6CWU76G																	UNKNOWN	mg	300		SINGLE	UNKNOWN						UNKNOWN	Intravenous	UNKNOWN	REVIEW	https://www.sciencedirect.com/science/article/abs/pii/0378517385902194|https://pubmed.ncbi.nlm.nih.gov/2029804/	Homo sapiens		h	0.84				6	VALPROMIDE		false
6500	6716		ADULT	155774	339.3868	XAMOTEROL	XAMOTEROL	OC(CNCCNC(=O)N1CCOCC1)COC2=CC=C(O)C=C2	PLASMA	7HE0JQL703									?	ng × h/mL	1054						UNKNOWN	mg	14		SINGLE	FED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2904884/	Homo sapiens		h	7.7				12	XAMOTEROL		false
6501	6716		ADULT	155774	339.3868	XAMOTEROL	XAMOTEROL	OC(CNCCNC(=O)N1CCOCC1)COC2=CC=C(O)C=C2	PLASMA	7HE0JQL703									?	ng × h/mL	168		ng/mL	27.6			UNKNOWN	mg	50		SINGLE	FED				There was no significant binding of xamoterol to plasma proteins with the mean percentage binding being 3.0  /- 0.4% (range of 0.1 to 5.9% in the 12 subjects). The extent of binding was similar across the concentration range examined.	97	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2904884/	Homo sapiens		h	15.7				12	XAMOTEROL		false
6502	6716		ADULT	155774	339.3868	XAMOTEROL	XAMOTEROL	OC(CNCCNC(=O)N1CCOCC1)COC2=CC=C(O)C=C2	PLASMA	7HE0JQL703									?	ng × h/mL	711		ng/mL	146			UNKNOWN	mg	200		SINGLE	FED				There was no significant binding of xamoterol to plasma proteins with the mean percentage binding being 3.0  /- 0.4% (range of 0.1 to 5.9% in the 12 subjects). The extent of binding was similar across the concentration range examined.	97	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2904884/	Homo sapiens		h	16.1				12	XAMOTEROL		false
6503	6717			82148	243.301	AGOMELATINE	Agomelatine	COC1=CC2=C(CCNC(C)=O)C=CC=C2C=C1	PLASMA	137R1N49AD																										Human plasma protein binding: 95%	5				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28392509/	Homo sapiens										false
6504	6717		ADULT	82148	243.301	AGOMELATINE	Agomelatine	COC1=CC2=C(CCNC(C)=O)C=CC=C2C=C1	PLASMA	137R1N49AD									∞	ng × h/mL	12.795		ng/mL	12.032			UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28392509/	Homo sapiens		h	0.813		Chinese		56			false
6505	6717		ADULT	82148	243.301	AGOMELATINE	Agomelatine	COC1=CC2=C(CCNC(C)=O)C=CC=C2C=C1	PLASMA	137R1N49AD									?	ng × h/mL	261.2		ng/mL	211.3			UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30789308/	Homo sapiens		h	0.9				36			false
6506	6717		ADULT	82148	243.301	AGOMELATINE	Agomelatine	COC1=CC2=C(CCNC(C)=O)C=CC=C2C=C1	PLASMA	137R1N49AD									?	ng × h/mL	236.9		ng/mL	176.5			UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30789308/	Homo sapiens		h	0.9				19			false
6507	6717		ADULT	82148	243.301	AGOMELATINE	Agomelatine	COC1=CC2=C(CCNC(C)=O)C=CC=C2C=C1	PLASMA	137R1N49AD									?	ng × h/mL	288.4		ng/mL	250.2			UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30789308/	Homo sapiens		h	0.9				17			false
6508	6717		ADULT	82148	243.301	AGOMELATINE	Agomelatine	COC1=CC2=C(CCNC(C)=O)C=CC=C2C=C1	PLASMA	137R1N49AD									?	ng × h/mL	223.48		ng/mL	182.6			UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30789308/	Homo sapiens		h	0.9		Caucasian		30			false
6509	6717		ADULT	82148	243.301	AGOMELATINE	Agomelatine	COC1=CC2=C(CCNC(C)=O)C=CC=C2C=C1	PLASMA	137R1N49AD									?	ng × h/mL	459.2		ng/mL	385.1			UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30789308/	Homo sapiens		h	0.9		Latin		5			false
6510	6717		ADULT	82148	243.301	AGOMELATINE	Agomelatine	COC1=CC2=C(CCNC(C)=O)C=CC=C2C=C1	PLASMA	137R1N49AD									?	ng × h/mL	403.9		ng/mL	203.8			UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30789308/	Homo sapiens		h	1		Black		1			false
6511	6717		ADULT	82148	243.301	AGOMELATINE	Agomelatine	COC1=CC2=C(CCNC(C)=O)C=CC=C2C=C1	PLASMA	137R1N49AD									?	ng × h/mL	4.9		ng/mL	3			UNKNOWN	mg	25		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.ema.europa.eu/en/documents/assessment-report/valdoxan-epar-public-assessment-report_en.pdf#page=15	Homo sapiens		h	0.9				8			false
6512	6717		ADULT	82148	243.301	AGOMELATINE	Agomelatine	COC1=CC2=C(CCNC(C)=O)C=CC=C2C=C1	PLASMA	137R1N49AD									?	ng × h/mL	405		ng/mL	191			UNKNOWN	mg	25		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.ema.europa.eu/en/documents/assessment-report/valdoxan-epar-public-assessment-report_en.pdf#page=15	Homo sapiens		h	3.3		Mild hepatic impairment		8			false
6513	6717		ADULT	82148	243.301	AGOMELATINE	Agomelatine	COC1=CC2=C(CCNC(C)=O)C=CC=C2C=C1	PLASMA	137R1N49AD									?	ng × h/mL	539		ng/mL	283			UNKNOWN	mg	25		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.ema.europa.eu/en/documents/assessment-report/valdoxan-epar-public-assessment-report_en.pdf#page=15	Homo sapiens		h	2.4		Moderate hepatic impairment		8			false
6514	6719		ADULT	9854012	776.359	CANGRELOR	CANGRELOR	CSCCNC1=C2N=CN([C@@H]3O[C@H](COP(O)(=O)OP(O)(=O)C(Cl)(Cl)P(O)(O)=O)[C@@H](O)[C@H]3O)C2=NC(SCCC(F)(F)F)=N1	PLASMA	6AQ1Y404U7									∞	ng × h/mL	249		ng/mL	299			UNKNOWN	μg/kg	135	bolus, 1 hour	OTHER	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19779037	Homo sapiens		min	3.61							false
6515	6719		ADULT	9854012	776.359	CANGRELOR	CANGRELOR	CSCCNC1=C2N=CN([C@@H]3O[C@H](COP(O)(=O)OP(O)(=O)C(Cl)(Cl)P(O)(O)=O)[C@@H](O)[C@H]3O)C2=NC(SCCC(F)(F)F)=N1	PLASMA	6AQ1Y404U7									∞	ng × h/mL	478		ng/mL	635			UNKNOWN	μg/kg	270	bolus, 1 hour	OTHER	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19779037	Homo sapiens		min	3.71							false
6516	6719		UNKNOWN	9854012	776.359	CANGRELOR	CANGRELOR	CSCCNC1=C2N=CN([C@@H]3O[C@H](COP(O)(=O)OP(O)(=O)C(Cl)(Cl)P(O)(O)=O)[C@@H](O)[C@H]3O)C2=NC(SCCC(F)(F)F)=N1	PLASMA	6AQ1Y404U7																	UNKNOWN				UNKNOWN	UNKNOWN				Plasma protein binding of KENGREAL is about 97-98%.	2	UNKNOWN	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/204958s002lbl.pdf	Homo sapiens										false
6517	6721		UNKNOWN	62865	323.455	CYAMEMAZINE	CYAMEMAZINE	CC(CN(C)C)CN1C2=CC=CC=C2SC3=C1C=C(C=C3)C#N	UNKNOWN	A2JGV5CNU4													ng/mL	3.1			UNKNOWN	mg	25		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/15492772/	Homo sapiens		h	10.99				12	CYAMEMAZINE		false
6518	6725		ADULT	5756	288.3814	ESTRIOL	Estriol	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1C[C@@H](O)[C@@H]2O	PLASMA	FB33469R8E									?	pg × h/mL	36.33		pg/mL	13.77			UNKNOWN	μg	20		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Vaginal	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26786399/	Homo sapiens				Day 21	Postmenopausal women		12			false
6519	6725		ADULT	5756	288.3814	ESTRIOL	Estriol	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1C[C@@H](O)[C@@H]2O	PLASMA	FB33469R8E									?	pg × h/mL	73.71		pg/mL	22.8			UNKNOWN	μg	50		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Vaginal	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26786399/	Homo sapiens				Day 21	Postmenopausal women		12			false
6520	6725		ADULT	5756	288.3814	ESTRIOL	Estriol	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1C[C@@H](O)[C@@H]2O	PLASMA	FB33469R8E									?	pg × h/mL	171.65		pg/mL	60.57			UNKNOWN	μg	20		SINGLE	UNKNOWN						HEALTHY	Vaginal	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26786399/	Homo sapiens		h	1.59		Postmenopausal women		12			false
6521	6725		ADULT	5756	288.3814	ESTRIOL	Estriol	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1C[C@@H](O)[C@@H]2O	PLASMA	FB33469R8E									?	pg × h/mL	406.75		pg/mL	106.4			UNKNOWN	μg	50		SINGLE	UNKNOWN						HEALTHY	Vaginal	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26786399/	Homo sapiens		h	1.65		Postmenopausal women		12			false
6522	6725		ADULT	5756	288.3814	ESTRIOL	Estriol	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1C[C@@H](O)[C@@H]2O	PLASMA	FB33469R8E									∞	pg × h/mL	18323		pg/mL	155			UNKNOWN	mg	0.5		MULTIPLE	UNKNOWN		day	1			HEALTHY	Vaginal	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30480330/	Homo sapiens				Vaginal ring, 600mg, 0.500mg/day, 21 days	Postmenopausal women		11			false
6523	6725		ADULT	5756	288.3814	ESTRIOL	Estriol	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1C[C@@H](O)[C@@H]2O	PLASMA	FB33469R8E									∞	pg × h/mL	5643		pg/mL	68			UNKNOWN	mg	0.125		MULTIPLE	UNKNOWN		day	1			HEALTHY	Vaginal	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30480330/	Homo sapiens				Vaginal ring, 100mg, 0.125mg/day, 21 days	Postmenopausal women		10			false
6524	6725		ADULT	5756	288.3814	ESTRIOL	Estriol	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1C[C@@H](O)[C@@H]2O	SERUM	FB33469R8E									?	nM × h	2.145		nM	0.546			UNKNOWN	mg	0.5		SINGLE	UNKNOWN						UNHEALTHY	Vaginal	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33129232/	Homo sapiens		h	2.72		postmenopausal women who had been applying E3 cream		10			false
6525	6725			5756	288.3814	ESTRIOL	Estriol	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1C[C@@H](O)[C@@H]2O	SERUM	FB33469R8E																										Nearly all (90%) estriol is bound to albumin in the plasma and estriol is hardly bound to sex hormone-binding globulin (SHBG).	10				OTHER	https://www.medicines.org.uk/emc/product/10400/smpc#PHARMACOKINETIC_PROPS	Homo sapiens										false
6526	6726		ADULT	6918248	390.4021	FLIBANSERIN	FLIBANSERIN	FC(F)(F)C1=CC=CC(=C1)N2CCN(CCN3C(=O)NC4=C3C=CC=C4)CC2	PLASMA	37JK4STR6Z									∞	ng × h/mL	1543		ng/mL	419			RECOMMENDED	mg	100		SINGLE	UNKNOWN				Approximately 98% of flibanserin is bound to human serum proteins, mainly to albumin.	2	HEALTHY	Oral	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022526s009lbl.pdf	Homo sapiens		h	11							false
6527	6727		ADULT	104799	315.691	FOTEMUSTINE	Fotemustine	CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O	PLASMA	GQ7JL9P5I2									?	μg × h/mL	3.6		μg/mL	3.26			UNKNOWN	mg/m²	100		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1451232/	Homo sapiens		h	0.34		patients with metastatic colorectal adenocarcinoma		17			false
6528	6727		ADULT	104799	315.691	FOTEMUSTINE	Fotemustine	CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O	PLASMA	GQ7JL9P5I2									?	μg × h/mL	1.98		μg/mL	0.65			UNKNOWN	mg/m²	100		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intra-arterial	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1451232/	Homo sapiens		h	0.34	hepatic intra-arterial route	patients with evolutive liver metastases arising from a primary colorectal carcinoma		9			false
6529	6727		ADULT	104799	315.691	FOTEMUSTINE	Fotemustine	CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O	PLASMA	GQ7JL9P5I2									?	mg × h/L	5.96		mg/L	5.35			UNKNOWN	mg/m²	300		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8462123/	Homo sapiens		min	34.99	Mean values from day 1 and 2 PK parameters	patients with high-grade gliomas		4			false
6530	6727		ADULT	104799	315.691	FOTEMUSTINE	Fotemustine	CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O	PLASMA	GQ7JL9P5I2									?	mg × h/L	7.38		mg/L	6.94			UNKNOWN	mg/m²	350		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8462123/	Homo sapiens		min	29.11	Mean values from day 1 and 2 PK parameters	patients with high-grade gliomas		5			false
6531	6727		ADULT	104799	315.691	FOTEMUSTINE	Fotemustine	CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O	PLASMA	GQ7JL9P5I2									?	mg × h/L	7.17		mg/L	7.06			UNKNOWN	mg/m²	400		MULTIPLE	UNKNOWN		day	1	n=2 on Day 1, N=3 on Day 2		UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8462123/	Homo sapiens		min	25.58	Mean values from day 1 and 2 PK parameters	patients with high-grade gliomas		3			false
6532	6727		ADULT	104799	315.691	FOTEMUSTINE	Fotemustine	CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O	PLASMA	GQ7JL9P5I2									?	mg × h/L	9.29		mg/L	8.19			UNKNOWN	mg/m²	450		MULTIPLE	UNKNOWN		day	1	n=6 on Day 1, N=3 on Day 2		UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8462123/	Homo sapiens		min	32.26	Mean values from day 1 and 2 PK parameters	patients with high-grade gliomas		6			false
6533	6727		ADULT	104799	315.691	FOTEMUSTINE	Fotemustine	CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O	PLASMA	GQ7JL9P5I2									?	mg × h/L	12.22		mg/L	18.08			UNKNOWN	mg/m²	500		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8462123/	Homo sapiens		min	20.25	Mean values from day 1 and 2 PK parameters	patients with high-grade gliomas		4			false
6534	6728		ADULT	5311037	384.429	ISTRADEFYLLINE	ISTRADEFYLLINE	CCN1C2=C(N(C)C(\\C=C\\C3=CC(OC)=C(OC)C=C3)=N2)C(=O)N(CC)C1=O	PLASMA	2GZ0LIK7T4							24		t	ng × h/mL	3249		ng/mL	230.9			RECOMMENDED	mg	20		STEADY-STATE	UNKNOWN		day	1	Istradefylline is extensively plasma protein bound (97-98%).	2	HEALTHY	Oral	MALE	REVIEW	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/022075Orig1s000ClinPharmR.pdf	Homo sapiens		h	72.1							false
6535	6730		ADULT	3033825	280.2847	LEVOSIMENDAN	LEVOSIMENDAN	C[C@@H]1CC(=O)NN=C1C2=CC=C(NN=C(C#N)C#N)C=C2	PLASMA	C6T4514L4E									∞	ng × h/mL	5970						UNKNOWN	μg/kg/min	0.1		STEADY-STATE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15025738/	Homo sapiens		h	1.4	continuous  intravenous  infusion  for  7  days	heart failure		12	LEVOSIMENDAN		false
6536	6730		ADULT	10465484	203.24	OR-1855	OR-1855	C[C@@H]1CC(=O)NN=C1C2=CC=C(NN=C(C#N)C#N)C=C2	PLASMA	C6T4514L4E									∞	ng × h/mL	1650		ng/mL	7.8			UNKNOWN	μg/kg/min	0.05		STEADY-STATE	UNKNOWN		week	1		58	UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15025738/	Homo sapiens		h	72.6	continuous  intravenous  infusion  for  7  days	heart failure		12	LEVOSIMENDAN		false
6537	6730		ADULT	10465484	203.24	OR-1855	OR-1855		PLASMA										∞	ng × h/mL	3950		ng/mL	18.1			UNKNOWN	μg/kg/min	0.1		STEADY-STATE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15025738/	Homo sapiens		h	78.4	continuous  intravenous  infusion  for  7  days	heart failure		12	LEVOSIMENDAN		false
6538	6730		ADULT	9816296	245.28	OR-1896	OR-1896		PLASMA	IKC90B19NV									∞	ng × h/mL	2370		ng/mL	9.9			UNKNOWN	μg/kg/min	0.05		STEADY-STATE	UNKNOWN		week	1		61	UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15025738/	Homo sapiens		h	81.3	continuous  intravenous  infusion  for  7  days	heart failure		12	LEVOSIMENDAN		false
6539	6730		ADULT	9816296	245.28	OR-1896	OR-1896		PLASMA	IKC90B19NV									∞	ng × h/mL	3890		ng/mL	17.1			UNKNOWN	μg/kg/min	0.1		STEADY-STATE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15025738/	Homo sapiens		h	81.2	continuous  intravenous  infusion  for  7  days	heart failure		12	LEVOSIMENDAN		false
6540	6730		ADULT	3033825	280.2847	LEVOSIMENDAN	LEVOSIMENDAN	C[C@@H]1CC(=O)NN=C1C2=CC=C(NN=C(C#N)C#N)C=C2	PLASMA	C6T4514L4E									∞	ng × h/mL	2510						UNKNOWN	μg/kg/min	0.05		STEADY-STATE	UNKNOWN		week	1		3	UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15025738/	Homo sapiens		h	1.1	continuous  intravenous  infusion  for  7  days	heart failure		12	LEVOSIMENDAN		false
6541	6730		ADULT	10465484	203.24	OR-1855	OR-1855		PLASMA								8		t	ng × h/mL	120		ng/mL	17.1			UNKNOWN	mg	2		MULTIPLE	UNKNOWN		day	4			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15342615/	Homo sapiens				14 days dosing	severe congestive heart failure		7	LEVOSIMENDAN		false
6542	6730		ADULT	9816296	245.28	OR-1896	OR-1896		PLASMA	IKC90B19NV							8		t	ng × h/mL	47		ng/mL	6.1			UNKNOWN	mg	2		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15342615/	Homo sapiens				14 days dosing	severe congestive heart failure		9	LEVOSIMENDAN		false
6543	6730		ADULT	9816296	245.28	OR-1896	OR-1896		PLASMA	IKC90B19NV							8		t	ng × h/mL	65		ng/mL	8.9			UNKNOWN	mg	2		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15342615/	Homo sapiens				14 days dosing	severe congestive heart failure		7	LEVOSIMENDAN		false
6544	6730		ADULT	3033825	280.2847	LEVOSIMENDAN	LEVOSIMENDAN	C[C@@H]1CC(=O)NN=C1C2=CC=C(NN=C(C#N)C#N)C=C2	PLASMA	C6T4514L4E									?	ng × h/mL	56		ng/mL	25			UNKNOWN	mg	2		MULTIPLE	UNKNOWN		day	4			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15342615/	Homo sapiens				14 days dosing	severe congestive heart failure		8	LEVOSIMENDAN		false
6545	6730		ADULT	10465484	203.24	OR-1855	OR-1855	C[C@@H]1CC(=O)NN=C1C2=CC=C(NN=C(C#N)C#N)C=C2	PLASMA	C6T4514L4E							8		t	ng × h/mL	40		ng/mL	5.2			UNKNOWN	mg	2		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15342615/	Homo sapiens				14 days dosing	severe congestive heart failure		9	LEVOSIMENDAN		false
6546	6730		ADULT	9816296	245.28	OR-1896	OR-1896		PLASMA	IKC90B19NV							8		t	ng × h/mL	126		ng/mL	16.9			UNKNOWN	mg	2		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15342615/	Homo sapiens				14 days dosing	severe congestive heart failure		9	LEVOSIMENDAN		false
6547	6730		ADULT	3033825	280.2847	LEVOSIMENDAN	LEVOSIMENDAN	C[C@@H]1CC(=O)NN=C1C2=CC=C(NN=C(C#N)C#N)C=C2	PLASMA	C6T4514L4E									?	ng × h/mL	91		ng/mL	38			UNKNOWN	mg	2		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15342615/	Homo sapiens				14 days dosing	severe congestive heart failure		8	LEVOSIMENDAN		false
6548	6730		ADULT	10465484	203.24	OR-1855	OR-1855		PLASMA								8		t	ng × h/mL	113		ng/mL	15.3			UNKNOWN	mg	2		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15342615/	Homo sapiens				14 days dosing	severe congestive heart failure		9	LEVOSIMENDAN		false
6549	6730		ADULT	3033825	280.2847	LEVOSIMENDAN	LEVOSIMENDAN	C[C@@H]1CC(=O)NN=C1C2=CC=C(NN=C(C#N)C#N)C=C2	PLASMA	C6T4514L4E									?	ng × h/mL	57		ng/mL	25			UNKNOWN	mg	2		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15342615/	Homo sapiens				14 days dosing	severe congestive heart failure		8	LEVOSIMENDAN		false
6550	6730		ADULT	3033825	280.2847	LEVOSIMENDAN	LEVOSIMENDAN	C[C@@H]1CC(=O)NN=C1C2=CC=C(NN=C(C#N)C#N)C=C2	PLASMA	C6T4514L4E									?	ng × h/mL	56		ng/mL	25			UNKNOWN	mg	2		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15342615/	Homo sapiens				14 days dosing	severe congestive heart failure		8	LEVOSIMENDAN		false
6551	6730		ADULT	9816296	245.28	OR-1896	OR-1896		PLASMA	IKC90B19NV							8		t	ng × h/mL	128		ng/mL	17.4			UNKNOWN	mg	2		MULTIPLE	UNKNOWN		day	4			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15342615/	Homo sapiens				14 days dosing	severe congestive heart failure		7	LEVOSIMENDAN		false
6552	6730		ADULT	10465484	203.24	OR-1855	OR-1855		PLASMA								8		t	ng × h/mL	59		ng/mL	7.7			UNKNOWN	mg	2		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15342615/	Homo sapiens				14 days dosing	severe congestive heart failure		7	LEVOSIMENDAN		false
6553	6730		ADULT	3033825	280.2847	LEVOSIMENDAN	LEVOSIMENDAN	C[C@@H]1CC(=O)NN=C1C2=CC=C(NN=C(C#N)C#N)C=C2	PLASMA	C6T4514L4E									∞	ng × h/mL	207.5		ng/mL	256.1			UNKNOWN	mg	2		SINGLE	FASTED					0.85	HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27122803/	Homo sapiens		h	1.18				14	LEVOSIMENDAN		false
6554	6731		ADULT	6445230	476.5641	NALFURAFINE	Nalfurafine	CN([C@@H]1CC[C@@]2(O)[C@H]3CC4=C5C(O[C@@H]1[C@@]25CCN3CC6CC6)=C(O)C=C4)C(=O)\\C=C\\C7=COC=C7	PLASMA	XC41AVD567							48		t	pg × h/mL	114.46		pg/mL	12.67			UNKNOWN	μg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/480220_1190015M1029_1_A13_1F.pdf#page=40 | https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=376	Homo sapiens		h	5.99				12			false
6555	6731		ADULT	6445230	476.5641	NALFURAFINE	Nalfurafine	CN([C@@H]1CC[C@@]2(O)[C@H]3CC4=C5C(O[C@@H]1[C@@]25CCN3CC6CC6)=C(O)C=C4)C(=O)\\C=C\\C7=COC=C7	PLASMA	XC41AVD567							48		t	pg × h/mL	126.03		pg/mL	13.68			UNKNOWN	μg	10		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/480220_1190015M1029_1_A13_1F.pdf#page=40 | https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=376	Homo sapiens		h	5.9				12			false
6556	6731		UNKNOWN	6445230	476.5641	NALFURAFINE	Nalfurafine	CN([C@@H]1CC[C@@]2(O)[C@H]3CC4=C5C(O[C@@H]1[C@@]25CCN3CC6CC6)=C(O)C=C4)C(=O)\\C=C\\C7=COC=C7	PLASMA	XC41AVD567																						UNKNOWN				Human plasma protein binding: 73.3~76.3% (1, 10, 100ng/mL)	23.7	UNKNOWN		UNKNOWN	OTHER GOV'T	https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=30 | https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_I100_1.pdf#page=105	Homo sapiens										false
6557	6731		ADULT	6445230	476.5641	NALFURAFINE	Nalfurafine	CN([C@@H]1CC[C@@]2(O)[C@H]3CC4=C5C(O[C@@H]1[C@@]25CCN3CC6CC6)=C(O)C=C4)C(=O)\\C=C\\C7=COC=C7	PLASMA	XC41AVD567									∞	pg × h/mL	666.03		pg/mL	209.37			UNKNOWN	μg	30		SINGLE	FASTED						HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=30 | https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=361	Homo sapiens		h	7.93				20			false
6558	6731		ADULT	6445230	476.5641	NALFURAFINE	Nalfurafine	CN([C@@H]1CC[C@@]2(O)[C@H]3CC4=C5C(O[C@@H]1[C@@]25CCN3CC6CC6)=C(O)C=C4)C(=O)\\C=C\\C7=COC=C7	PLASMA	XC41AVD567									∞	pg × h/mL	387.45		pg/mL	27.85			UNKNOWN	μg	30		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=30 | https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=361	Homo sapiens		h	8.27				20			false
6559	6731		ADULT	6445230	476.5641	NALFURAFINE	Nalfurafine	CN([C@@H]1CC[C@@]2(O)[C@H]3CC4=C5C(O[C@@H]1[C@@]25CCN3CC6CC6)=C(O)C=C4)C(=O)\\C=C\\C7=COC=C7	PLASMA	XC41AVD567									∞	pg × h/mL	297		pg/mL	19.1			UNKNOWN	μg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=31 | https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=396	Homo sapiens		h	9.75				6			false
6560	6731		ADULT	6445230	476.5641	NALFURAFINE	Nalfurafine	CN([C@@H]1CC[C@@]2(O)[C@H]3CC4=C5C(O[C@@H]1[C@@]25CCN3CC6CC6)=C(O)C=C4)C(=O)\\C=C\\C7=COC=C7	PLASMA	XC41AVD567									∞	pg × h/mL	604		pg/mL	40.1			UNKNOWN	μg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=31 | https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=396	Homo sapiens		h	10.1				6			false
6561	6731		ADULT	6445230	476.5641	NALFURAFINE	Nalfurafine	CN([C@@H]1CC[C@@]2(O)[C@H]3CC4=C5C(O[C@@H]1[C@@]25CCN3CC6CC6)=C(O)C=C4)C(=O)\\C=C\\C7=COC=C7	PLASMA	XC41AVD567									∞	pg × h/mL	967		pg/mL	90.3			UNKNOWN	μg	40		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=31 | https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=396	Homo sapiens		h	10.5				6			false
6562	6731		ADULT	6445230	476.5641	NALFURAFINE	Nalfurafine	CN([C@@H]1CC[C@@]2(O)[C@H]3CC4=C5C(O[C@@H]1[C@@]25CCN3CC6CC6)=C(O)C=C4)C(=O)\\C=C\\C7=COC=C7	PLASMA	XC41AVD567							12		t	pg × h/mL	73.9		pg/mL	9.52			UNKNOWN	μg	10		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=32 | https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=409	Homo sapiens		h	5.78	Day 1			5			false
6563	6731		ADULT	6445230	476.5641	NALFURAFINE	Nalfurafine	CN([C@@H]1CC[C@@]2(O)[C@H]3CC4=C5C(O[C@@H]1[C@@]25CCN3CC6CC6)=C(O)C=C4)C(=O)\\C=C\\C7=COC=C7	PLASMA	XC41AVD567							24		t	pg × h/mL	66.1		pg/mL	9.68			UNKNOWN	μg	10		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=32 | https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=409	Homo sapiens		h	5.77	Day 7			5			false
6564	6731		ADULT	6445230	476.5641	NALFURAFINE	Nalfurafine	CN([C@@H]1CC[C@@]2(O)[C@H]3CC4=C5C(O[C@@H]1[C@@]25CCN3CC6CC6)=C(O)C=C4)C(=O)\\C=C\\C7=COC=C7	PLASMA	XC41AVD567							12		t	pg × h/mL	324		pg/mL	28.8			UNKNOWN	μg	20		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=32 | https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=409	Homo sapiens		h	9.08	Day 1			6			false
6565	6731		ADULT	6445230	476.5641	NALFURAFINE	Nalfurafine	CN([C@@H]1CC[C@@]2(O)[C@H]3CC4=C5C(O[C@@H]1[C@@]25CCN3CC6CC6)=C(O)C=C4)C(=O)\\C=C\\C7=COC=C7	PLASMA	XC41AVD567							24		t	pg × h/mL	436		pg/mL	33.8			UNKNOWN	μg	20		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=32 | https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=409	Homo sapiens		h	9.6	Day 7			6			false
6566	6731		ADULT	6445230	476.5641	NALFURAFINE	Nalfurafine	CN([C@@H]1CC[C@@]2(O)[C@H]3CC4=C5C(O[C@@H]1[C@@]25CCN3CC6CC6)=C(O)C=C4)C(=O)\\C=C\\C7=COC=C7	PLASMA	XC41AVD567									∞	pg × h/mL	66.26		pg/mL	3.15			DEFINED DAILY	μg	2.5		MULTIPLE	FED		day	1	n=2 for AUC and t1/2		UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=32 | https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=455	Homo sapiens		h	14.21	Day 1	Patients with hemodialysis		8			false
6567	6731		ADULT	6445230	476.5641	NALFURAFINE	Nalfurafine	CN([C@@H]1CC[C@@]2(O)[C@H]3CC4=C5C(O[C@@H]1[C@@]25CCN3CC6CC6)=C(O)C=C4)C(=O)\\C=C\\C7=COC=C7	PLASMA	XC41AVD567									∞	pg × h/mL	210.25		pg/mL	5.7			DEFINED DAILY	μg	2.5		MULTIPLE	FED		day	1	n=6 for AUC and t1/2		UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=32 | https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=455	Homo sapiens		h	25.33	Day 12	Patients with hemodialysis		7			false
6568	6731		ADULT	6445230	476.5641	NALFURAFINE	Nalfurafine	CN([C@@H]1CC[C@@]2(O)[C@H]3CC4=C5C(O[C@@H]1[C@@]25CCN3CC6CC6)=C(O)C=C4)C(=O)\\C=C\\C7=COC=C7	PLASMA	XC41AVD567									∞	pg × h/mL	120.59		pg/mL	6.51			MAX DAILY	μg	5		MULTIPLE	FED		day	1			UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=32 | https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=455	Homo sapiens		h	14.03	Day 1	Patients with hemodialysis		8			false
6569	6731		ADULT	6445230	476.5641	NALFURAFINE	Nalfurafine	CN([C@@H]1CC[C@@]2(O)[C@H]3CC4=C5C(O[C@@H]1[C@@]25CCN3CC6CC6)=C(O)C=C4)C(=O)\\C=C\\C7=COC=C7	PLASMA	XC41AVD567									∞	pg × h/mL	358.86		pg/mL	10.25			MAX DAILY	μg	5		MULTIPLE	FED		day	1			UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=32 | https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=455	Homo sapiens		h	28.34	Day 12	Patients with hemodialysis		7			false
6570	6731		ADULT	6445230	476.5641	NALFURAFINE	Nalfurafine	CN([C@@H]1CC[C@@]2(O)[C@H]3CC4=C5C(O[C@@H]1[C@@]25CCN3CC6CC6)=C(O)C=C4)C(=O)\\C=C\\C7=COC=C7	PLASMA	XC41AVD567									∞	pg × h/mL	34.58		pg/mL	3.63			DEFINED DAILY	μg	2.5		SINGLE	FASTED				n=4 for AUC and t1/2		UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=33 | https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=469	Homo sapiens		h	5.37		Patients with cirrhosis		6			false
6571	6731		ADULT	6445230	476.5641	NALFURAFINE	Nalfurafine	CN([C@@H]1CC[C@@]2(O)[C@H]3CC4=C5C(O[C@@H]1[C@@]25CCN3CC6CC6)=C(O)C=C4)C(=O)\\C=C\\C7=COC=C7	PLASMA	XC41AVD567									∞	pg × h/mL	58.06		pg/mL	6.76			MAX DAILY	μg	5		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_A100_2.pdf#page=33 | https://www.pmda.go.jp/drugs/2009/P200900003/48022000_22100AMX00392_K100_1.pdf#page=469	Homo sapiens		h	6.61		Patients with cirrhosis		6			false
6572	6733		ADULT	3052762	367.87	PRUCALOPRIDE	Prucalopride	COCCCN1CCC(CC1)NC(=O)C2=C3OCCC3=C(N)C(Cl)=C2	PLASMA								24		t	ng × h/mL	109		ng/mL	7			RECOMMENDED	mg	2		STEADY-STATE	UNKNOWN		day	1	The plasma protein binding of prucalopride is approximately 30%.	70	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210166s000lbl.pdf	Homo sapiens		day	1							false
6573	6735		ADULT	131682	302.3434	SAFINAMIDE	safinamide	C[C@H](NCC1=CC=C(OCC2=CC(F)=CC=C2)C=C1)C(N)=O	PLASMA	90ENL74SIG									∞	ng × h/mL	19000		ng/mL	650			RECOMMENDED	mg	100		SINGLE	UNKNOWN				The extent of protein binding in human plasma was concentration independent, the unbound fraction was 11-12% for safinamide	11.5	HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.ema.europa.eu/en/documents/assessment-report/xadago-epar-public-assessment-report_en.pdf	Homo sapiens										false
6574	6735		UNKNOWN	131682	302.3434	SAFINAMIDE	safinamide	C[C@H](NCC1=CC=C(OCC2=CC(F)=CC=C2)C=C1)C(N)=O	PLASMA	90ENL74SIG																	UNKNOWN				SINGLE	UNKNOWN						UNKNOWN	Intravenous	UNKNOWN	OTHER GOV'T	https://www.ema.europa.eu/en/documents/assessment-report/xadago-epar-public-assessment-report_en.pdf	Homo sapiens		h	26							false
6575	6736		ADULT	5287969	401.84	ALVOCIDIB	flavopiridol	CN1CC[C@@H]([C@H](O)C1)C2=C3OC(=CC(=O)C3=C(O)C=C2O)C4=C(Cl)C=CC=C4	PLASMA	45AD6X575G									?	μM × h	11.2		μM	1.78			MAX TOLERATED	mg	100		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/20460644	Homo sapiens		h	3.84							false
6576	6737		ADULT	156414	485.938	CANERTINIB	CANERTINIB	FC1=C(Cl)C=C(NC2=NC=NC3=CC(OCCCN4CCOCC4)=C(NC(=O)C=C)C=C23)C=C1	PLASMA	C78W1K5ASF													ng/mL	175.2			MAX TOLERATED	mg	250		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/15534081	Homo sapiens		h	1.8							false
6577	6737		ADULT	156414	485.938	CANERTINIB	CANERTINIB	FC1=C(Cl)C=C(NC2=NC=NC3=CC(OCCCN4CCOCC4)=C(NC(=O)C=C)C=C23)C=C1	PLASMA	C78W1K5ASF									?	ng × h/mL	2385		ng/mL	265			MAX TOLERATED	mg	500		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/16899614	Homo sapiens		h	4.4							false
6578	6737		ADULT	156414	485.938	CANERTINIB	CANERTINIB	FC1=C(Cl)C=C(NC2=NC=NC3=CC(OCCCN4CCOCC4)=C(NC(=O)C=C)C=C23)C=C1	PLASMA	C78W1K5ASF									?	ng × h/mL	3518		ng/mL	2233			MAX TOLERATED	mg	225		MULTIPLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/16899614	Homo sapiens		h	3.2							false
6579	6739		ADULT	156422	527.6572	DORAMAPIMOD	DORAMAPIMOD	CC1=CC=C(C=C1)N2N=C(C=C2NC(=O)NC3=C4C=CC=CC4=C(OCCN5CCOCC5)C=C3)C(C)(C)C	PLASMA	HO1A8B3YVV							24		t	ng × h/mL	5924		ng/mL	1108			UNKNOWN	mg	150		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://www.jacionline.org/article/S0091-6749(02)82128-5/pdf	Homo sapiens		h	9.1							false
6580	6741		ADULT	216215|135416855|135803998|136242243	284.699	FENOBAM	Fenobam	O.CN1CC(=O)N=C1NC(=O)NC2=CC(Cl)=CC=C2	PLASMA	07O6708M02									?	ng × h/mL	67.8		ng/mL	1.4			UNKNOWN	mg	50		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31568235/	Homo sapiens							8	Fenobam		false
6581	6741		ADULT	216215|135416855|135803998|136242243	284.699	FENOBAM	Fenobam	O.CN1CC(=O)N=C1NC(=O)NC2=CC(Cl)=CC=C2	PLASMA	07O6708M02									?	ng × h/mL	183.6		ng/mL	3.6			UNKNOWN	mg	150		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31568235/	Homo sapiens							8	Fenobam		false
6582	6741		ADULT	216215|135416855|135803998|136242243	284.699	FENOBAM	Fenobam	O.CN1CC(=O)N=C1NC(=O)NC2=CC(Cl)=CC=C2	PLASMA	07O6708M02									?	ng × h/mL	167.4		ng/mL	2.9			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31568235/	Homo sapiens							8	Fenobam		false
6583	6742		ADULT	91649	292.2112	HYDROXYFLUTAMIDE	HYDROXYFLUTAMIDE	CC(C)(O)C(=O)NC1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F	PLASMA	31D90UKP5Y													ng/mL	1629			RECOMMENDED	mg	250		STEADY-STATE	UNKNOWN		day	3			UNKNOWN	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/18554s23lbl.pdf	Homo sapiens		h	9.6							false
6584	6742		ADULT	91649	292.2112	HYDROXYFLUTAMIDE	HYDROXYFLUTAMIDE	CC(C)(O)C(=O)NC1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F	PLASMA	31D90UKP5Y									∞	ng × h/mL	4993		ng/mL	967			RECOMMENDED	mg	250		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/10073738	Homo sapiens		h	7.1							false
6585	6745		ADULT	5329098	238.2845	SEMAXANIB	SEMAXANIB	CC1=CC(C)=C(N1)\\C=C2/C(=O)NC3=C2C=CC=C3	PLASMA	71IA9S35AJ							24		t	μg × h/L	3589		μg/L	2979			MAX TOLERATED	mg/m²	145		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/16222321	Homo sapiens		h	0.82							false
6586	6747		ADULT	6029	244.2	URIDINE	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N2C=CC(=O)NC2=O	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N2C=CC(=O)NC2=O	PLASMA	WHI7HQ7H85									∞	μM × h	164.1		μM	36.1			UNKNOWN	g	4.15		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/21379380	Homo sapiens		h	4.6							false
6587	6748		ADULT	151194	346.813	VATALANIB	VATALANIB	ClC1=CC=C(NC2=NN=C(CC3=CC=NC=C3)C4=C2C=CC=C4)C=C1	PLASMA	5DX9U76296																						UNKNOWN				The parent drug is ∼98% bound to plasma proteins, presumably primarily bound to alpha-1-acid glycoprotein.	2	UNHEALTHY		UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4243874/	Homo sapiens										false
6588	6748		ADULT	151194	346.813	VATALANIB	VATALANIB	ClC1=CC=C(NC2=NN=C(CC3=CC=NC=C3)C4=C2C=CC=C4)C=C1	BLOOD	5DX9U76296									?	mg × h/L	23.3						UNKNOWN	mg	1250		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/24838014	Homo sapiens										false
6589	6749		ADULT	50515	283.3251	AMONAFIDE	AMONAFIDE	CN(C)CCN1C(=O)C2=CC(N)=CC3=CC=CC(C1=O)=C23	PLASMA	1Q8D39N37L									?	μg × h/mL	40						UNKNOWN	mg/m²	1800		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1988134	Homo sapiens		h	5.6	Amonafide was given i.v. over 2-4 h daily for 5 days.			1	AMONAFIDE		false
6590	6749		ADULT	50515	283.3251	AMONAFIDE	AMONAFIDE	CN(C)CCN1C(=O)C2=CC(N)=CC3=CC=CC(C1=O)=C23	PLASMA	1Q8D39N37L									?	μg × h/mL	16.64		μg/mL	3.25			UNKNOWN	mg/m²	1104		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2549205	Homo sapiens		h	6.7	2-hour infusion every 28 days			1	AMONAFIDE		false
6591	6751		ADULT	11452716	414.5	APRATASTAT	APRATASTAT	CC1(C)SCCN([C@H]1C(=O)NO)[S+]([O-])(=O)C2=CC=C(OCC#CCO)C=C2	PLASMA	C6BZ5263BJ									∞	ng × h/mL	1155		ng/mL	624			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/21059888	Homo sapiens		h	2.5							false
6592	6752		ADULT	179340	414.5393	ASIMADOLINE	ASIMADOLINE	CN([C@H](CN1CC[C@H](O)C1)C2=CC=CC=C2)C(=O)C(C3=CC=CC=C3)C4=CC=CC=C4	PLASMA	D0VK52NV5M									∞	ng × h/mL	1205.2		ng/mL	213.6			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10971307/	Homo sapiens		h	10.57				8	ASIMADOLINE		false
6593	6752		ADULT	179340	414.5393	ASIMADOLINE	ASIMADOLINE	CN([C@H](CN1CC[C@H](O)C1)C2=CC=CC=C2)C(=O)C(C3=CC=CC=C3)C4=CC=CC=C4	PLASMA	D0VK52NV5M									∞	ng × h/mL	58.5		ng/mL	18			UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10971307/	Homo sapiens		h	2.55				8	ASIMADOLINE		false
6594	6752		ADULT	179340	414.5393	ASIMADOLINE	ASIMADOLINE	CN([C@H](CN1CC[C@H](O)C1)C2=CC=CC=C2)C(=O)C(C3=CC=CC=C3)C4=CC=CC=C4	PLASMA	D0VK52NV5M									∞	ng × h/mL	375.9		ng/mL	90.7			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10971307/	Homo sapiens		h	15.1				8	ASIMADOLINE		false
6595	6752			179340	414.5393	ASIMADOLINE	ASIMADOLINE	CN([C@H](CN1CC[C@H](O)C1)C2=CC=CC=C2)C(=O)C(C3=CC=CC=C3)C4=CC=CC=C4	SERUM	D0VK52NV5M																										<1% (serum protein binding was >99%)	1				REVIEW	https://pubmed.ncbi.nlm.nih.gov/20809870/	Homo sapiens								ASIMADOLINE		false
6596	6753		ADULT	5362422	477.64	BATIMASTAT	Batimastat	CNC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(C)C)[C@H](CSC2=CC=CS2)C(=O)NO	SERUM	BK349F52C9																						UNKNOWN				Serum levels of batimastat were measured in ultrafiltered supernatants and estimated protein binding was above 97%.	3	UNHEALTHY		UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8913840/	Homo sapiens					patients with advanced cancer		5			false
6597	6753		ADULT	5362422	477.64	BATIMASTAT	Batimastat	CNC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(C)C)[C@H](CSC2=CC=CS2)C(=O)NO	SERUM	BK349F52C9									?	ng × h/mL	160877		ng/mL	805			UNKNOWN	mg/m²	600		SINGLE	UNKNOWN						UNHEALTHY	Intraperitoneal	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8913840/	Homo sapiens		h	522		patients with advanced cancer		3			false
6598	6753		ADULT	5362422	477.64	BATIMASTAT	Batimastat	CNC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(C)C)[C@H](CSC2=CC=CS2)C(=O)NO	SERUM	BK349F52C9									?	ng × h/mL	371783		ng/mL	1225			UNKNOWN	mg/m²	1200		SINGLE	UNKNOWN						UNHEALTHY	Intraperitoneal	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8913840/	Homo sapiens		h	577		patients with advanced cancer		3			false
6599	6753		ADULT	5362422	477.64	BATIMASTAT	Batimastat	CNC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(C)C)[C@H](CSC2=CC=CS2)C(=O)NO	SERUM	BK349F52C9									?	ng × h/mL	362140		ng/mL	1570			UNKNOWN	mg/m²	1800		SINGLE	UNKNOWN						UNHEALTHY	Intraperitoneal	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8913840/	Homo sapiens		h	449		patients with advanced cancer		3			false
6600	6770		ADULT	572	183.0997	FOSMIDOMYCIN	Fosmidomycin	ON(CCCP(O)(O)=O)C=O	PLASMA	5829E3D9I9									∞	μg × h/mL	27.67		μg/mL	4.58			UNKNOWN	mg	1200		MULTIPLE	UNKNOWN		day	3	Plasma protein binding of fosmidomycin in human is about 1%	99	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17531088	Homo sapiens		h	0.5				15	Fosmidomycin		false
6601	6770		ADULT	572	183.0997	FOSMIDOMYCIN	fosmidomycin	ON(CCCP(O)(O)=O)C=O	SERUM	5829E3D9I9									?	ng × h/mL	210						UNKNOWN	mg/kg	30		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7073262	Homo sapiens		h	1.65				10	fosmidomycin		false
6602	6770		ADULT	572	183.0997	FOSMIDOMYCIN	fosmidomycin	ON(CCCP(O)(O)=O)C=O	SERUM	5829E3D9I9									?	μg × h/mL	42.2		μg/mL	11.1			UNKNOWN	mg/kg	7.5		SINGLE	UNKNOWN						HEALTHY	Intramuscular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7073262	Homo sapiens		h	1.58				10	fosmidomycin		false
6603	6770		ADULT	572	183.0997	FOSMIDOMYCIN	fosmidomycin	ON(CCCP(O)(O)=O)C=O	SERUM	5829E3D9I9									?	μg × h/mL	14		μg/mL	2.33			UNKNOWN	mg	500		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7073262	Homo sapiens		h	1.87				10	fosmidomycin		false
6604	6777		ADULT	148138|5288038|135413518	443.4531	LOMETREXOL	lometrexol	NC1=NC2=C(C[C@@H](CCC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CN2)C(=O)N1	PLASMA	6P3AVY8A7Q									?	mg × min/mL	0.46						UNKNOWN	mg/m²	12		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7735480	Homo sapiens		min	10					lometrexol		false
6605	6778		ADULT	148195	638.822	LONAFARNIB	Lonafarnib	NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]3C4=C(CCC5=CC(Cl)=CC(Br)=C35)C=C(Br)C=N4)CC1	PLASMA	IOW153004F							12		t	ng × h/mL	12365		ng/mL	1777			UNKNOWN	mg/m²	115		STEADY-STATE	FED		day	2	n=15 for AUC		UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213969s000lbl.pdf#page=14	Homo sapiens					Patients with HGPS		23			false
6606	6778		ADULT	148195	638.822	LONAFARNIB	Lonafarnib	NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]3C4=C(CCC5=CC(Cl)=CC(Br)=C35)C=C(Br)C=N4)CC1	PLASMA	IOW153004F							12		t	ng × h/mL	19539		ng/mL	2695			UNKNOWN	mg/m²	150		STEADY-STATE	FED		day	2	n=8 for AUC		UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213969s000lbl.pdf#page=14	Homo sapiens					Patients with HGPS		18			false
6607	6778			148195	638.822	LONAFARNIB	Lonafarnib	NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]3C4=C(CCC5=CC(Cl)=CC(Br)=C35)C=C(Br)C=N4)CC1	PLASMA	IOW153004F																										Human plasma protein binding: >=99.2% to 99.7% (0.5~40μg/mL)	0.3				OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213969Orig1s000IntegratedR.pdf#page=153	Homo sapiens										false
6608	6778		ADULT	148195	638.822	LONAFARNIB	Lonafarnib	NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]3C4=C(CCC5=CC(Cl)=CC(Br)=C35)C=C(Br)C=N4)CC1	PLASMA	IOW153004F									∞	ng × h/mL	2505		ng/mL	229			UNKNOWN	mg	100		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213969Orig1s000IntegratedR.pdf#page=156	Homo sapiens		h	3.93		Young subjects (18~45 y)		24			false
6609	6778		ADULT	148195	638.822	LONAFARNIB	Lonafarnib	NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]3C4=C(CCC5=CC(Cl)=CC(Br)=C35)C=C(Br)C=N4)CC1	PLASMA	IOW153004F									∞	ng × h/mL	3870		ng/mL	291			UNKNOWN	mg	100		SINGLE	FED				n=23 for AUC and t1/2		HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213969Orig1s000IntegratedR.pdf#page=156	Homo sapiens		h	4.77		Elderly subjects (>=65 y)		24			false
6610	6778		ADULT	148195	638.822	LONAFARNIB	Lonafarnib	NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]3C4=C(CCC5=CC(Cl)=CC(Br)=C35)C=C(Br)C=N4)CC1	PLASMA	IOW153004F									∞	ng × h/mL	2638		ng/mL	237			UNKNOWN	mg	100		SINGLE	FED				n=23 for AUC and t1/2		HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213969Orig1s000IntegratedR.pdf#page=156	Homo sapiens		h	4.01				24			false
6611	6778		ADULT	148195	638.822	LONAFARNIB	Lonafarnib	NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]3C4=C(CCC5=CC(Cl)=CC(Br)=C35)C=C(Br)C=N4)CC1	PLASMA	IOW153004F									∞	ng × h/mL	3685		ng/mL	283			UNKNOWN	mg	100		SINGLE	FED						HEALTHY	Oral	FEMALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213969Orig1s000IntegratedR.pdf#page=156	Homo sapiens		h	4.66				24			false
6612	6778		ADULT	148195	638.822	LONAFARNIB	Lonafarnib	NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]3C4=C(CCC5=CC(Cl)=CC(Br)=C35)C=C(Br)C=N4)CC1	PLASMA	IOW153004F	392622	720.944	RITONAVIR	Ritonavir	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4	O3J8G9O825			∞	ng × h/mL	13186.3		ng/mL	422.88			UNKNOWN	mg	50		SINGLE	FASTED						UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213969Orig1s000IntegratedR.pdf#page=157	Homo sapiens		h	13.37		Mild hepatic impairment (Child-Pugh 5 to 6)	100 mg	9			true
6613	6778		ADULT	148195	638.822	LONAFARNIB	Lonafarnib	NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]3C4=C(CCC5=CC(Cl)=CC(Br)=C35)C=C(Br)C=N4)CC1	PLASMA	IOW153004F	392622	720.944	RITONAVIR	Ritonavir	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4	O3J8G9O825			∞	ng × h/mL	15762.97		ng/mL	491.1			UNKNOWN	mg	50		SINGLE	FASTED						UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213969Orig1s000IntegratedR.pdf#page=157	Homo sapiens		h	10.27		Moderate hepatic impairment (Child-Pugh 7 to 9)	100 mg	7			true
6614	6778		ADULT	148195	638.822	LONAFARNIB	Lonafarnib	NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]3C4=C(CCC5=CC(Cl)=CC(Br)=C35)C=C(Br)C=N4)CC1	PLASMA	IOW153004F	392622	720.944	RITONAVIR	Ritonavir	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4	O3J8G9O825			∞	ng × h/mL	13048.67		ng/mL	456.67			UNKNOWN	mg	50		SINGLE	FASTED						UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213969Orig1s000IntegratedR.pdf#page=157	Homo sapiens		h	12.28		Moderate hepatic impairment (Child-Pugh >9)	100 mg	11			true
6615	6778		ADULT	148195	638.822	LONAFARNIB	Lonafarnib	NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]3C4=C(CCC5=CC(Cl)=CC(Br)=C35)C=C(Br)C=N4)CC1	PLASMA	IOW153004F	392622	720.944	RITONAVIR	Ritonavir	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4	O3J8G9O825			∞	ng × h/mL	13400		ng/mL	392			UNKNOWN	mg	50		SINGLE	FASTED						UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213969Orig1s000IntegratedR.pdf#page=158	Homo sapiens		h	13.8		Severe renal impairment	100 mg	4			true
6616	6778		ADULT	148195	638.822	LONAFARNIB	Lonafarnib	NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]3C4=C(CCC5=CC(Cl)=CC(Br)=C35)C=C(Br)C=N4)CC1	PLASMA	IOW153004F	392622	720.944	RITONAVIR	Ritonavir	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4	O3J8G9O825			∞	ng × h/mL	7390		ng/mL	312			UNKNOWN	mg	50		SINGLE	FASTED						UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213969Orig1s000IntegratedR.pdf#page=158	Homo sapiens		h	9.32		Severe matched controls with normal renal function	100 mg	4			true
6617	6778		ADULT	148195	638.822	LONAFARNIB	Lonafarnib	NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]3C4=C(CCC5=CC(Cl)=CC(Br)=C35)C=C(Br)C=N4)CC1	PLASMA	IOW153004F	392622	720.944	RITONAVIR	Ritonavir	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4	O3J8G9O825			∞	ng × h/mL	17600		ng/mL	445			UNKNOWN	mg	50		SINGLE	FASTED				n=4 for AUC		UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213969Orig1s000IntegratedR.pdf#page=158	Homo sapiens		h	16.3		Moderate renal impairment	100 mg	5			true
6618	6778		ADULT	148195	638.822	LONAFARNIB	Lonafarnib	NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]3C4=C(CCC5=CC(Cl)=CC(Br)=C35)C=C(Br)C=N4)CC1	PLASMA	IOW153004F	392622	720.944	RITONAVIR	Ritonavir	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4	O3J8G9O825			∞	ng × h/mL	13700		ng/mL	510			UNKNOWN	mg	50		SINGLE	FASTED						UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213969Orig1s000IntegratedR.pdf#page=158	Homo sapiens		h	10.5		Moderate marched controls with normal renal function	100 mg	5			true
6619	6778		ADULT	148195	638.822	LONAFARNIB	Lonafarnib	NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]3C4=C(CCC5=CC(Cl)=CC(Br)=C35)C=C(Br)C=N4)CC1	PLASMA	IOW153004F									∞	ng × h/mL	1150		ng/mL	117			UNKNOWN	mg	75		SINGLE	HIGH-FAT				n=13 for AUC		HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213969Orig1s000IntegratedR.pdf#page=159	Homo sapiens							14			false
6620	6778		ADULT	148195	638.822	LONAFARNIB	Lonafarnib	NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]3C4=C(CCC5=CC(Cl)=CC(Br)=C35)C=C(Br)C=N4)CC1	PLASMA	IOW153004F									∞	ng × h/mL	1560		ng/mL	248			UNKNOWN	mg	75		SINGLE	FASTED				n=13 for AUC		HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213969Orig1s000IntegratedR.pdf#page=159	Homo sapiens							14			false
6621	6778		ADULT	148195	638.822	LONAFARNIB	Lonafarnib	NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]3C4=C(CCC5=CC(Cl)=CC(Br)=C35)C=C(Br)C=N4)CC1	PLASMA	IOW153004F									∞	ng × h/mL	1240		ng/mL	194			UNKNOWN	mg	75		SINGLE	LOW-FAT				n=12 for AUC		HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213969Orig1s000IntegratedR.pdf#page=159	Homo sapiens							14			false
6622	6778		ADULT	148195	638.822	LONAFARNIB	Lonafarnib	NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]3C4=C(CCC5=CC(Cl)=CC(Br)=C35)C=C(Br)C=N4)CC1	PLASMA	IOW153004F									∞	ng × h/mL	1560		ng/mL	248			UNKNOWN	mg	75		SINGLE	FASTED				n=12 for AUC		HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213969Orig1s000IntegratedR.pdf#page=159	Homo sapiens							14			false
6623	6778		ADULT	148195	638.822	LONAFARNIB	Lonafarnib	NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]3C4=C(CCC5=CC(Cl)=CC(Br)=C35)C=C(Br)C=N4)CC1	PLASMA	IOW153004F							18.2		t	ng × h/mL	2077		ng/mL	323			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213969Orig1s000IntegratedR.pdf#page=160	Homo sapiens							12			false
6624	6778		ADULT	148195	638.822	LONAFARNIB	Lonafarnib	NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]3C4=C(CCC5=CC(Cl)=CC(Br)=C35)C=C(Br)C=N4)CC1	PLASMA	IOW153004F							24		t	ng × h/mL	1556		ng/mL	154			UNKNOWN	mg	100		SINGLE	HIGH-FAT						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213969Orig1s000IntegratedR.pdf#page=160	Homo sapiens							12			false
6625	6780		ADULT	153241	452.4599	MERIMEPODIB	VX-497	COC1=C(C=CC(NC(=O)NC2=CC(CNC(=O)O[C@H]3CCOC3)=CC=C2)=C1)C4=CN=CO4	PLASMA	2ZL2BA06FU							24		t	ng × h/mL	3543		ng/mL	1748			UNKNOWN	mg	100		STEADY-STATE	UNKNOWN		day	3			UNHEALTHY	Oral	UNKNOWN	OTHER	https://www.natap.org/1999/aasld/rpt10.htm	Homo sapiens							7	VX-497		false
6626	6780		ADULT	153241	452.4599	MERIMEPODIB	VX-497	COC1=C(C=CC(NC(=O)NC2=CC(CNC(=O)O[C@H]3CCOC3)=CC=C2)=C1)C4=CN=CO4	PLASMA	2ZL2BA06FU							24		t	ng × h/mL	8210		ng/mL	3195			UNKNOWN	mg	200		STEADY-STATE	UNKNOWN		day	3			UNHEALTHY	Oral	UNKNOWN	OTHER	https://www.natap.org/1999/aasld/rpt10.htm	Homo sapiens							7	VX-497		false
6627	6790		ADULT	213049	465.4041	POSIZOLID	AZD-5847	OC[C@H](O)C(=O)N1CCC(=CC1)C2=C(F)C=C(C=C2F)N3C[C@H](COC4=NOC=C4)OC3=O	PLASMA	82V2M8K24R							24		t	μg × h/mL	64.75		μg/mL	7.69			UNKNOWN	mg	500		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29269434/	Homo sapiens		h	4.8				15	AZD-5847		false
6628	6790		ADULT	213049	465.4041	POSIZOLID	AZD-5847	OC[C@H](O)C(=O)N1CCC(=CC1)C2=C(F)C=C(C=C2F)N3C[C@H](COC4=NOC=C4)OC3=O	PLASMA	82V2M8K24R							12		t	μg × h/mL	43.97		μg/mL	5.56			UNKNOWN	mg	500		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29269434/	Homo sapiens		h	5.3				15	AZD-5847		false
6629	6790		ADULT	213049	465.4041	POSIZOLID	AZD-5847	OC[C@H](O)C(=O)N1CCC(=CC1)C2=C(F)C=C(C=C2F)N3C[C@H](COC4=NOC=C4)OC3=O	PLASMA	82V2M8K24R							12		t	μg × h/mL	73.89		μg/mL	8.4			UNKNOWN	mg	1200		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29269434/	Homo sapiens		h	6.1				14	AZD-5847		false
6630	6790		ADULT	213049	465.4041	POSIZOLID	AZD-5847	OC[C@H](O)C(=O)N1CCC(=CC1)C2=C(F)C=C(C=C2F)N3C[C@H](COC4=NOC=C4)OC3=O	PLASMA	82V2M8K24R							12		t	μg × h/mL	93.19		μg/mL	11.54			HIGHEST STUDIED	mg	800		STEADY-STATE	UNKNOWN		day	2	is 80% protein-bound	20	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29269434/	Homo sapiens		h	6.2				15	AZD-5847		false
6631	6791		UNKNOWN	153270	523.5378	PRALNACASAN	PRALNACASAN	CCO[C@@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]2CCCN3N2C(=O)[C@H](CCC3=O)NC(=O)C4=NC=CC5=CC=CC=C45	PLASMA	N986NI319S																						UNKNOWN				Protein Binding fraction unbound 0.006	0.6	UNKNOWN		UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3062473/	Homo sapiens										false
6632	6792		ADULT	466151	423.506	PRINOMASTAT	Prinomastat	CC1(C)SCCN([C@H]1C(=O)NO)S(=O)(=O)C2=CC=C(OC3=CC=NC=C3)C=C2	PLASMA	10T6626FRK							12		t	ng × h/mL	413		ng/mL	291			UNKNOWN	mg	10		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/14871966	Homo sapiens		h	2.7				6	Prinomastat		false
6633	6792		ADULT	466151	423.506	PRINOMASTAT	Prinomastat	CC1(C)SCCN([C@H]1C(=O)NO)S(=O)(=O)C2=CC=C(OC3=CC=NC=C3)C=C2	PLASMA	10T6626FRK							12		t	ng × h/mL	3107		ng/mL	1861			UNKNOWN	mg	50		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/14871966	Homo sapiens		h	2.08				6	Prinomastat		false
6634	6792		ADULT	466151	423.506	PRINOMASTAT	Prinomastat	CC1(C)SCCN([C@H]1C(=O)NO)S(=O)(=O)C2=CC=C(OC3=CC=NC=C3)C=C2	PLASMA	10T6626FRK							12		t	ng × h/mL	5156		ng/mL	2083			HIGHEST STUDIED	mg	100		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/14871966	Homo sapiens		h	2.46				6	Prinomastat		false
6635	6792		ADULT	466151	423.506	PRINOMASTAT	Prinomastat	CC1(C)SCCN([C@H]1C(=O)NO)S(=O)(=O)C2=CC=C(OC3=CC=NC=C3)C=C2	PLASMA	10T6626FRK							12		t	ng × h/mL	314		ng/mL	199			UNKNOWN	mg	5		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/14871966	Homo sapiens		h	5.01				6	Prinomastat		false
6636	6797		ADULT	2746	269.2985	TACEDINALINE	TACEDINALINE	CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(N)C=CC=C2	PLASMA	UMF554N5FG									∞	ng × h/mL	4810		ng/mL	325			MAX TOLERATED	mg/m²	8		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11291827	Homo sapiens		h	14.1							false
6637	6798		ADULT	164509	337.3725	TALAMPANEL	TALAMPANEL	C[C@@H]1CC2=C(C=C3OCOC3=C2)C(=NN1C(C)=O)C4=CC=C(N)C=C4	PLASMA	CVS43XG1L5									∞	μg × h/L	489		μg/L	95.5			UNKNOWN	mg	35		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12581229	Homo sapiens		h	3.3				13	TALAMPANEL		false
6638	6799		ADULT	5311424	382.4544	TALNETANT	talnetant	CC[C@H](NC(=O)C1=C(O)C(=NC2=CC=CC=C12)C3=CC=CC=C3)C4=CC=CC=C4	PLASMA	CZ3T9T146K																	UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18755817/	Homo sapiens		h	2.56				12	talnetant		false
6639	6800		ADULT	4369524	297.375	TANAPROGET	tanaproget	CN1C(=CC=C1C2=CC3=C(NC(=S)OC3(C)C)C=C2)C#N	PLASMA	W9F9H8GXWR									?	ng × h/mL	134.9		ng/mL	10.04			UNKNOWN	mg	7		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17046384	Homo sapiens		h	30.2				6	tanaproget		false
6640	6800		ADULT	4369524	297.375	TANAPROGET	tanaproget	CN1C(=CC=C1C2=CC3=C(NC(=S)OC3(C)C)C=C2)C#N	PLASMA	W9F9H8GXWR									?	ng × h/mL	1.58		ng/mL	0.3			UNKNOWN	mg	0.1		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17046384	Homo sapiens		h	4.6				4	tanaproget		false
6641	6800		ADULT	4369524	297.375	TANAPROGET	tanaproget	CN1C(=CC=C1C2=CC3=C(NC(=S)OC3(C)C)C=C2)C#N	PLASMA	W9F9H8GXWR									?	ng × h/mL	45.5		ng/mL	3.93			UNKNOWN	mg	3		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17046384	Homo sapiens		h	18				6	tanaproget		false
6642	6800		ADULT	4369524	297.375	TANAPROGET	tanaproget	CN1C(=CC=C1C2=CC3=C(NC(=S)OC3(C)C)C=C2)C#N	PLASMA	W9F9H8GXWR									?	ng × h/mL	3.48		ng/mL	0.64			UNKNOWN	mg	0.3		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17046384	Homo sapiens		h	4.3				6	tanaproget		false
6643	6800		ADULT	4369524	297.375	TANAPROGET	tanaproget	CN1C(=CC=C1C2=CC3=C(NC(=S)OC3(C)C)C=C2)C#N	PLASMA	W9F9H8GXWR									?	ng × h/mL	152.9		ng/mL	16.21			MAX DAILY	mg	15		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17046384	Homo sapiens		h	16.5				6	tanaproget		false
6644	6800		ADULT	4369524	297.375	TANAPROGET	tanaproget	CN1C(=CC=C1C2=CC3=C(NC(=S)OC3(C)C)C=C2)C#N	PLASMA	W9F9H8GXWR									?	ng × h/mL	15.9		ng/mL	1.99			UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17046384	Homo sapiens		h	11.7				6	tanaproget		false
6645	6800		ADULT	4369524	297.375	TANAPROGET	tanaproget	CN1C(=CC=C1C2=CC3=C(NC(=S)OC3(C)C)C=C2)C#N	PLASMA	W9F9H8GXWR									?	ng × h/mL	112.2		ng/mL	12.63			UNKNOWN	mg	7		SINGLE	HIGH-FAT						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17046384	Homo sapiens		h	20.4				5	tanaproget		false
6646	6803		UNKNOWN	60809	281.417	XANOMELINE	xanomeline	CCCCCCOC1=NSN=C1C2=CCCN(C)C2	PLASMA	9ORI6L73CJ									t	ng × h/mL	42.8		ng/mL	8.95			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://link.springer.com/chapter/10.1007/978-1-4615-8149-9_40	Homo sapiens		h	2.96	Dose is based on a free base.			9	Xanomeline tartrate		false
6647	6803		UNKNOWN	60809	281.417	XANOMELINE	xanomeline	CCCCCCOC1=NSN=C1C2=CCCN(C)C2	PLASMA	9ORI6L73CJ									t	ng × h/mL	65.8		ng/mL	13.81			UNKNOWN	mg	150		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://link.springer.com/chapter/10.1007/978-1-4615-8149-9_40	Homo sapiens		h	4.56	Dose is based on a free base.			9	Xanomeline tartrate		false
6648	6803		UNKNOWN	60809	281.417	XANOMELINE	Xanomeline	CCCCCCOC1=NSN=C1C2=CCCN(C)C2	PLASMA	9ORI6L73CJ													ng/mL	4.13			UNKNOWN	mg	75		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://link.springer.com/chapter/10.1007/978-1-4615-8149-9_40	Homo sapiens				Day 7 PK, Doses are based on a free base.			6	Xanomeline tartrate		false
6649	6804		ADULT	1613	419.377	ZOPOLRESTAT	Zopolrestat	OC(=O)CC1=NN(CC2=NC3=C(S2)C=CC(=C3)C(F)(F)F)C(=O)C4=C1C=CC=C4	PLASMA	1PV3S9WP3D							24		t	μg × h/mL	3646		μg/mL	208			UNKNOWN	mg	1000		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11847537/	Homo sapiens		h	27.5	Day 10	Non-insulin-dependent diabetic patients		8			false
6650	6804		ADULT	1613	419.377	ZOPOLRESTAT	Zopolrestat	OC(=O)CC1=NN(CC2=NC3=C(S2)C=CC(=C3)C(F)(F)F)C(=O)C4=C1C=CC=C4	PLASMA	1PV3S9WP3D							24		t	μg × h/mL	1412		μg/mL	100			UNKNOWN	mg	1000		SINGLE	FASTED						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11847537/	Homo sapiens		h	26.3		Non-insulin-dependent diabetic patients		8			false
6651	6804		ADULT	1613	419.377	ZOPOLRESTAT	Zopolrestat	OC(=O)CC1=NN(CC2=NC3=C(S2)C=CC(=C3)C(F)(F)F)C(=O)C4=C1C=CC=C4	PLASMA	1PV3S9WP3D							24		t	μg × h/mL	3720		μg/mL	239			UNKNOWN	mg	1000		STEADY-STATE	FASTED		day	1	800mg QD X 8 healthy and 1200mg QD x 8 healthy subjects		HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11847537/	Homo sapiens		h	30.3				16			false
6652	6804		ADULT	1613	419.377	ZOPOLRESTAT	Zopolrestat	OC(=O)CC1=NN(CC2=NC3=C(S2)C=CC(=C3)C(F)(F)F)C(=O)C4=C1C=CC=C4	PLASMA	1PV3S9WP3D							24		t	μg × h/mL	3646		μg/mL	208			UNKNOWN	mg	1000		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11847537/	Homo sapiens		h	27.5		Non-insulin-dependent diabetic patients		8			false
6653	6804		ADULT	1613	419.377	ZOPOLRESTAT	Zopolrestat	OC(=O)CC1=NN(CC2=NC3=C(S2)C=CC(=C3)C(F)(F)F)C(=O)C4=C1C=CC=C4	PLASMA	1PV3S9WP3D							24		t	μg × h/mL	3040		μg/mL	196			UNKNOWN	mg	800		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7929871/	Homo sapiens		h	32.8	Day 15			8			false
6654	6804		ADULT	1613	419.377	ZOPOLRESTAT	Zopolrestat	OC(=O)CC1=NN(CC2=NC3=C(S2)C=CC(=C3)C(F)(F)F)C(=O)C4=C1C=CC=C4	PLASMA	1PV3S9WP3D							24		t	μg × h/mL	2850		μg/mL	167			UNKNOWN	mg	800		STEADY-STATE	FED		day	1			HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7929871/	Homo sapiens		h	32.8	Day 7 or 11			8			false
6655	6804		ADULT	1613	419.377	ZOPOLRESTAT	Zopolrestat	OC(=O)CC1=NN(CC2=NC3=C(S2)C=CC(=C3)C(F)(F)F)C(=O)C4=C1C=CC=C4	PLASMA	1PV3S9WP3D							24		t	μg × h/mL	2790		μg/mL	168			UNKNOWN	mg	800		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7929871/	Homo sapiens		h	32.8	Day 7 or 11			8			false
6656	6804		ADULT	1613	419.377	ZOPOLRESTAT	Zopolrestat	OC(=O)CC1=NN(CC2=NC3=C(S2)C=CC(=C3)C(F)(F)F)C(=O)C4=C1C=CC=C4	PLASMA	1PV3S9WP3D							24		t	μg × h/mL	2000		μg/mL	154			UNKNOWN	mg	1200		MULTIPLE	FASTED		day	1			HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7929871/	Homo sapiens				Day 1			8			false
6657	6804		ADULT	1613	419.377	ZOPOLRESTAT	Zopolrestat	OC(=O)CC1=NN(CC2=NC3=C(S2)C=CC(=C3)C(F)(F)F)C(=O)C4=C1C=CC=C4	PLASMA	1PV3S9WP3D							24		t	μg × h/mL	4370		μg/mL	256			UNKNOWN	mg	1200		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7929871/	Homo sapiens		h	28.1	Day 7	4 Fasted, 4 Fed		8			false
6658	6804		ADULT	1613	419.377	ZOPOLRESTAT	Zopolrestat	OC(=O)CC1=NN(CC2=NC3=C(S2)C=CC(=C3)C(F)(F)F)C(=O)C4=C1C=CC=C4	PLASMA	1PV3S9WP3D							24		t	μg × h/mL	4380		μg/mL	267			UNKNOWN	mg	1200		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7929871/	Homo sapiens		h	28.1	Day 11	4 Fasted, 4 Fed		8			false
6659	6804		ADULT	1613	419.377	ZOPOLRESTAT	Zopolrestat	OC(=O)CC1=NN(CC2=NC3=C(S2)C=CC(=C3)C(F)(F)F)C(=O)C4=C1C=CC=C4	PLASMA	1PV3S9WP3D							24		t	μg × h/mL	4360		μg/mL	281			UNKNOWN	mg	1200		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7929871/	Homo sapiens		h	28.1	Day 15			8			false
6660	6804		ADULT	1613	419.377	ZOPOLRESTAT	Zopolrestat	OC(=O)CC1=NN(CC2=NC3=C(S2)C=CC(=C3)C(F)(F)F)C(=O)C4=C1C=CC=C4	PLASMA	1PV3S9WP3D							24		t	μg × h/mL	4280		μg/mL	256			UNKNOWN	mg	1200		STEADY-STATE	FED		day	1			HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7929871/	Homo sapiens		h	28.1	Day 7 or 11			8			false
6661	6804		ADULT	1613	419.377	ZOPOLRESTAT	Zopolrestat	OC(=O)CC1=NN(CC2=NC3=C(S2)C=CC(=C3)C(F)(F)F)C(=O)C4=C1C=CC=C4	PLASMA	1PV3S9WP3D							24		t	μg × h/mL	4460		μg/mL	267			UNKNOWN	mg	1200		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7929871/	Homo sapiens		h	28.1	Day 7 or 11			8			false
6662	6804		ADULT	1613	419.377	ZOPOLRESTAT	Zopolrestat	OC(=O)CC1=NN(CC2=NC3=C(S2)C=CC(=C3)C(F)(F)F)C(=O)C4=C1C=CC=C4	PLASMA	1PV3S9WP3D							24		t	μg × h/mL	2900		μg/mL	167			UNKNOWN	mg	800		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7929871/	Homo sapiens		h	32.8	Day 11	4 Fasted, 4 Fed		8			false
6663	6804		ADULT	1613	419.377	ZOPOLRESTAT	Zopolrestat	OC(=O)CC1=NN(CC2=NC3=C(S2)C=CC(=C3)C(F)(F)F)C(=O)C4=C1C=CC=C4	PLASMA	1PV3S9WP3D																						UNKNOWN				Human plasma protein binding (ultrafiltration): >99% (Fu=0.22% (39μg/mL), 0.27% (77μg/mL), 0.32% (120μg/mL), 0.40% (190μg/mL), 0.59% (290μg/mL), 0.81% (370μg/mL)	0.22	HEALTHY		MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7929871/	Homo sapiens							3			false
6664	6804		ADULT	1613	419.377	ZOPOLRESTAT	Zopolrestat	OC(=O)CC1=NN(CC2=NC3=C(S2)C=CC(=C3)C(F)(F)F)C(=O)C4=C1C=CC=C4	PLASMA	1PV3S9WP3D							48		t	μg × h/mL	71		μg/mL	7.7			UNKNOWN	mg	50		SINGLE	FASTED				n=3 for AUC		HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7929871/	Homo sapiens		h	18.6				4			false
6665	6804		ADULT	1613	419.377	ZOPOLRESTAT	Zopolrestat	OC(=O)CC1=NN(CC2=NC3=C(S2)C=CC(=C3)C(F)(F)F)C(=O)C4=C1C=CC=C4	PLASMA	1PV3S9WP3D							48		t	μg × h/mL	165		μg/mL	14			UNKNOWN	mg	100		SINGLE	FASTED				n=3 for AUC		HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7929871/	Homo sapiens		h	18.6				4			false
6666	6804		ADULT	1613	419.377	ZOPOLRESTAT	Zopolrestat	OC(=O)CC1=NN(CC2=NC3=C(S2)C=CC(=C3)C(F)(F)F)C(=O)C4=C1C=CC=C4	PLASMA	1PV3S9WP3D							48		t	μg × h/mL	328		μg/mL	23.9			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7929871/	Homo sapiens		h	18.6				4			false
6667	6804		ADULT	1613	419.377	ZOPOLRESTAT	Zopolrestat	OC(=O)CC1=NN(CC2=NC3=C(S2)C=CC(=C3)C(F)(F)F)C(=O)C4=C1C=CC=C4	PLASMA	1PV3S9WP3D							48		t	μg × h/mL	636		μg/mL	44.7			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7929871/	Homo sapiens		h	18.6				4			false
6668	6804		ADULT	1613	419.377	ZOPOLRESTAT	Zopolrestat	OC(=O)CC1=NN(CC2=NC3=C(S2)C=CC(=C3)C(F)(F)F)C(=O)C4=C1C=CC=C4	PLASMA	1PV3S9WP3D							48		t	μg × h/mL	1010		μg/mL	74.6			UNKNOWN	mg	600		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7929871/	Homo sapiens		h	18.6				4			false
6669	6804		ADULT	1613	419.377	ZOPOLRESTAT	Zopolrestat	OC(=O)CC1=NN(CC2=NC3=C(S2)C=CC(=C3)C(F)(F)F)C(=O)C4=C1C=CC=C4	PLASMA	1PV3S9WP3D							48		t	μg × h/mL	2130		μg/mL	84			UNKNOWN	mg	800		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7929871/	Homo sapiens		h	18.6				4			false
6670	6804		ADULT	1613	419.377	ZOPOLRESTAT	Zopolrestat	OC(=O)CC1=NN(CC2=NC3=C(S2)C=CC(=C3)C(F)(F)F)C(=O)C4=C1C=CC=C4	PLASMA	1PV3S9WP3D							48		t	μg × h/mL	2140		μg/mL	122			UNKNOWN	mg	1000		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7929871/	Homo sapiens		h	18.6				4			false
6671	6804		ADULT	1613	419.377	ZOPOLRESTAT	Zopolrestat	OC(=O)CC1=NN(CC2=NC3=C(S2)C=CC(=C3)C(F)(F)F)C(=O)C4=C1C=CC=C4	PLASMA	1PV3S9WP3D							48		t	μg × h/mL	2760		μg/mL	136			UNKNOWN	mg	1200		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7929871/	Homo sapiens		h	18.6				4			false
6672	6804		ADULT	1613	419.377	ZOPOLRESTAT	Zopolrestat	OC(=O)CC1=NN(CC2=NC3=C(S2)C=CC(=C3)C(F)(F)F)C(=O)C4=C1C=CC=C4	PLASMA	1PV3S9WP3D							24		t	μg × h/mL	1430		μg/mL	108			UNKNOWN	mg	800		MULTIPLE	FASTED		day	1			HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7929871/	Homo sapiens				Day 1			8			false
6673	6804		ADULT	1613	419.377	ZOPOLRESTAT	Zopolrestat	OC(=O)CC1=NN(CC2=NC3=C(S2)C=CC(=C3)C(F)(F)F)C(=O)C4=C1C=CC=C4	PLASMA	1PV3S9WP3D							24		t	μg × h/mL	2740		μg/mL	168			UNKNOWN	mg	800		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7929871/	Homo sapiens		h	32.8	Day 7	4 Fasted, 4 Fed		8			false
6674	6807		ADULT	51576	218.2054	ACIFRAN	ACIFRAN	CC1(OC(=CC1=O)C(O)=O)C2=CC=CC=C2	PLASMA	B1X701S0MV									∞	μg × h/mL	15.6		μg/mL	4.26			UNKNOWN	mg	200		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2295219	Homo sapiens		h	1.4				3	ACIFRAN		false
6675	6807		ADULT	51576	218.2054	ACIFRAN	ACIFRAN	CC1(OC(=CC1=O)C(O)=O)C2=CC=CC=C2	PLASMA	B1X701S0MV									?	μg × h/mL	16.4		μg/mL	5.22			UNKNOWN	mg	200		MULTIPLE	FED		day	2		12.2	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2295219	Homo sapiens		h	1.7	day 4			3	ACIFRAN		false
6676	6809		ADULT	5839	360.444	ALDOSTERONE	Aldosterone	C[C@]12CCC(=O)C=C1CC[C@H]3[C@@H]4CC[C@H](C(=O)CO)[C@]4(C[C@H](O)[C@H]23)C=O	PLASMA	4964P6T9RB																						UNKNOWN				Human plasma protein binding: 16.4% (micro-dialysis)	83.6	HEALTHY		FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/13769961/	Homo sapiens										false
6677	6809		ADULT	5839	360.444	ALDOSTERONE	Aldosterone	C[C@]12CCC(=O)C=C1CC[C@H]3[C@@H]4CC[C@H](C(=O)CO)[C@]4(C[C@H](O)[C@H]23)C=O	PLASMA	4964P6T9RB																						UNKNOWN				Human plasma protein binding: 40% (micro-dialysis)	60	UNHEALTHY		FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/13769961/	Homo sapiens					Enovid-treated women					false
6678	6809		ADULT	5839	360.444	ALDOSTERONE	Aldosterone	C[C@]12CCC(=O)C=C1CC[C@H]3[C@@H]4CC[C@H](C(=O)CO)[C@]4(C[C@H](O)[C@H]23)C=O	PLASMA	4964P6T9RB																						UNKNOWN				Human plasma protein binding: 17% (micro-dialysis)	83	HEALTHY		FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/13769961/	Homo sapiens					Late pregnancy women					false
6679	6816		ADULT	107926	418.284	BRETAZENIL	Bretazenil	CC(C)(C)OC(=O)C1=C2[C@@H]3CCCN3C(=O)C4=C(C=CC=C4Br)N2C=N1	PLASMA	OSZ0E9DGOJ							6		t	ng × h/mL	17.6		ng/mL	5			UNKNOWN	mg	0.5		SINGLE	FED						HEALTHY	Sublingual	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8799523/	Homo sapiens		h	2.2				12			false
6680	6816		ADULT	107926	418.284	BRETAZENIL	Bretazenil	CC(C)(C)OC(=O)C1=C2[C@@H]3CCCN3C(=O)C4=C(C=CC=C4Br)N2C=N1	PLASMA	OSZ0E9DGOJ	702	46.0684	ALCOHOL	Alcohol	CCO	3K9958V90M	6		t	ng × h/mL	19.2		ng/mL	5.4			UNKNOWN	mg	0.5		SINGLE	FED						HEALTHY	Sublingual	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8799523/	Homo sapiens		h	2.3				12			true
6681	6831			2966	175.2303	DEBRISOQUIN	Debrisoquine	NC(=N)N1CCC2=C(C1)C=CC=C2	PLASMA	X31CDK040E																										Human plasma protein binding: 25%	75				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7378259/	Homo sapiens										false
6682	6842		ADULT	3448|28360827	140.1399	GABOXADOL	gaboxadol	OC1=NOC2=C1CCNC2	PLASMA	K1M5RVL18S									∞	ng × h/mL	408		ng/mL	123			UNKNOWN	mg	10		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19094161	Homo sapiens		h	2.1				7	gaboxadol		false
6683	6842		ADULT	3448|28360827	140.1399	GABOXADOL	gaboxadol	OC1=NOC2=C1CCNC2	PLASMA	K1M5RVL18S									∞	ng × h/mL	440		ng/mL	147			UNKNOWN	mg	10		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19094161	Homo sapiens		h	1.5				15	gaboxadol		false
6684	6853		ADULT	5761	323.432	LYSERGIDE	Lysergic Acid Diethylamide	CCN(CC)C(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=C3C(=CC=C4)C2=C1	PLASMA	8NA5SWF92O									∞	ng × h/mL	20.3		ng/mL	3.1			UNKNOWN	μg	200		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28197931/	Homo sapiens		h	1.5				16	Lysergic Acid Diethylamide		false
6685	6853		ADULT	5761	323.432	LYSERGIDE	Lysergic Acid Diethylamide	CCN(CC)C(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=C3C(=CC=C4)C2=C1	PLASMA	8NA5SWF92O									∞	ng × h/mL	8.1		ng/mL	1.3			UNKNOWN	μg	100		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28197931/	Homo sapiens		h	2.6				24	Lysergic Acid Diethylamide		false
6686	6859		ADULT	60663	495.6287	MIBEFRADIL	mibefradil	COCC(=O)O[C@]3(CCN(C)CCCC1=NC2=C(N1)C=CC=C2)CCC4=C(C=CC(F)=C4)[C@@H]3C(C)C	PLASMA	27B90X776A													ng/mL	115			UNKNOWN	mg	40		SINGLE	FASTED				The extent of plasma protein binding, predominantly to alpha1-acid glycoprotein, is approximately 99.5%	0.5	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9811158	Homo sapiens		h	9.8							false
6687	6859		ADULT	60663	495.6287	MIBEFRADIL	MIBEFRADIL	COCC(=O)O[C@]3(CCN(C)CCCC1=NC2=C(N1)C=CC=C2)CCC4=C(C=CC(F)=C4)[C@@H]3C(C)C	PLASMA	27B90X776A													ng/mL	61			UNKNOWN	mg	80		SINGLE	FASTED				The extent of plasma protein binding, predominantly to alpha1-acid glycoprotein, is approximately 99.5%	0.5	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9811158	Homo sapiens		h	14.9							false
6688	6859		ADULT	60663	495.6287	MIBEFRADIL	MIBEFRADIL	COCC(=O)O[C@]3(CCN(C)CCCC1=NC2=C(N1)C=CC=C2)CCC4=C(C=CC(F)=C4)[C@@H]3C(C)C	PLASMA	27B90X776A													ng/mL	495			UNKNOWN	mg	120		SINGLE	FASTED				The extent of plasma protein binding, predominantly to alpha1-acid glycoprotein, is approximately 99.5%	0.5	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9811158	Homo sapiens		h	13.2							false
6689	6859		ADULT	60663	495.6287	MIBEFRADIL	MIBEFRADIL	COCC(=O)O[C@]3(CCN(C)CCCC1=NC2=C(N1)C=CC=C2)CCC4=C(C=CC(F)=C4)[C@@H]3C(C)C	PLASMA	27B90X776A													ng/mL	777			UNKNOWN	mg	160		SINGLE	FASTED				The extent of plasma protein binding, predominantly to alpha1-acid glycoprotein, is approximately 99.5%	0.5	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9811158	Homo sapiens		h	17.1							false
6690	6859		ADULT	60663	495.6287	MIBEFRADIL	MIBEFRADIL	COCC(=O)O[C@]3(CCN(C)CCCC1=NC2=C(N1)C=CC=C2)CCC4=C(C=CC(F)=C4)[C@@H]3C(C)C	PLASMA	27B90X776A							24		t	ng × h/mL	12574		ng/mL	718			RECOMMENDED	mg	100		STEADY-STATE	FASTED		day	1	The extent of plasma protein binding, predominantly to alpha1-acid glycoprotein, is approximately 99.5%	0.5	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9811158	Homo sapiens		h	35.4							false
6691	6866		ADULT	4528	238.3275	NOMIFENSINE	NOMIFENSINE	CN1CC(C2=CC=CC=C2)C3=C(C1)C(N)=CC=C3	PLASMA	1LGS5JRP31													ng/mL	53			UNKNOWN	mg	100		SINGLE	UNKNOWN				Nomifensine is 60-75% bound to serum proteins.	25	HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/7049645	Homo sapiens		h	2.2							false
6692	6866		ADULT	4528	238.3275	NOMIFENSINE	NOMIFENSINE	CN1CC(C2=CC=CC=C2)C3=C(C1)C(N)=CC=C3	PLASMA	1LGS5JRP31									?	μg × h/L	196.8		μg/L	84			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7082545	Homo sapiens		h	1.9							false
6693	6869		ADULT	107867	421.5352	OTENZEPAD	OTENZEPAD	CCN(CC)CC1CCCCN1CC(=O)N2C3=CC=CC=C3C(=O)NC4=CC=CN=C24	PLASMA	OM7J0XAL0S																	UNKNOWN	mg	40		SINGLE	FED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1914372	Homo sapiens		min	208				8			false
6694	6870		ADULT	439280|6971044	220.2246	OXITRIPTAN	Oxitriptan	N[C@@H](CC1=CNC2=CC=C(O)C=C12)C(O)=O	SERUM	C1LJO185Q9																						FASTED				19% of circulating 5HTP was bound to serum proteins (clinically relevant concentration range of 10 to 100μM; ultrafiltration).	81	HEALTHY		UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6182005/	Homo sapiens							20			false
6695	6870		ADULT	439280|6971044	220.2246	OXITRIPTAN	Oxitriptan	N[C@@H](CC1=CNC2=CC=C(O)C=C12)C(O)=O	PLASMA	C1LJO185Q9	38101	244.2444	CARBIDOPA	Carbidopa	O.C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O	MNX7R8C5VO											UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6187038/	Homo sapiens		h	4.34			50 mg po	5			true
6696	6870		ADULT	439280|6971044	220.2246	OXITRIPTAN	Oxitriptan	N[C@@H](CC1=CNC2=CC=C(O)C=C12)C(O)=O	PLASMA	C1LJO185Q9	38101	244.2444	CARBIDOPA	Carbidopa	O.C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O	MNX7R8C5VO			?	mg × h/L	9.2		mg/L	1.47			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6187038/	Homo sapiens		h	4.4	Enteric-coated tablets		50 mg po	5			true
6697	6872		ADULT	8249	205.2596	PHENFORMIN	phenformin	NC(=N)NC(=N)NCCC1=CC=CC=C1	PLASMA	DD5K7529CE																	RECOMMENDED	mg	100		SINGLE	UNKNOWN					81	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1133221/	Homo sapiens		h	11							false
6698	6880		ADULT	3033769	347.237	RACLOPRIDE	raclopride	CCN1CCC[C@H]1CNC(=O)C2=C(OC)C(Cl)=CC(Cl)=C2O	PLASMA	430K3SOZ7G									∞	nM × h	1949		nM	92.5			UNKNOWN	mg	8		SINGLE	UNKNOWN						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7647082/	Homo sapiens		h	7.38	raclopride extended release (ER) capsules	psychiatric patients		4			false
6699	6880		ADULT	3033769	347.237	RACLOPRIDE	raclopride	CCN1CCC[C@H]1CNC(=O)C2=C(OC)C(Cl)=CC(Cl)=C2O	PLASMA	430K3SOZ7G							12		t	nM × h	2648		nM	288.25			UNKNOWN	mg	12		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7647082/	Homo sapiens		h	9.3	raclopride extended release (ER) capsules	psychiatric patients		4			false
6700	6880		ADULT	3033769	347.237	RACLOPRIDE	raclopride	CCN1CCC[C@H]1CNC(=O)C2=C(OC)C(Cl)=CC(Cl)=C2O	PLASMA	430K3SOZ7G							12		t	nM × h	4025		nM	448.75			UNKNOWN	mg	16		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7647082/	Homo sapiens		h	13.29	raclopride extended release (ER) capsules	psychiatric patients		4			false
6701	6880		ADULT	3033769	347.237	RACLOPRIDE	raclopride	CCN1CCC[C@H]1CNC(=O)C2=C(OC)C(Cl)=CC(Cl)=C2O	PLASMA	430K3SOZ7G							12		t	nM × h	1597		nM	158.8			UNKNOWN	mg	8		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7647082/	Homo sapiens		h	27.56	raclopride extended release (ER) capsules	psychiatric patients		4			false
6702	6881		ADULT	5074	477.569	RITANSERIN	ritanserin	CC1=C(CCN2CCC(CC2)=C(C3=CC=C(F)C=C3)C4=CC=C(F)C=C4)C(=O)N5C=CSC5=N1	PLASMA	145TFV465S									∞	ng × h/mL	2031		ng/mL	73.6			UNKNOWN	mg	10		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1910052	Homo sapiens		h	39.2				5	ritanserin		false
6703	6881		ADULT	5074	477.569	RITANSERIN	Ritanserin	CC1=C(CCN2CCC(CC2)=C(C3=CC=C(F)C=C3)C4=CC=C(F)C=C4)C(=O)N5C=CSC5=N1	PLASMA	145TFV465S									∞	ng × h/mL	3867		ng/mL	121			UNKNOWN	mg	10		SINGLE	FED						HEALTHY	Oral	MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/1910052	Homo sapiens		h	41				6	Ritanserin		false
6704	6885		ADULT	337359	236.1992	SORBINIL	Sorbinil	FC1=CC=C2OCC[C@]3(NC(=O)NC3=O)C2=C1	PLASMA	G4186B906P									?	μg × h/mL	547		μg/mL	5.36			UNKNOWN	mg	250		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3107606	Homo sapiens		h	76.5				8	Sorbinil		false
6705	6885		ADULT	337359	236.1992	SORBINIL	Sorbinil	FC1=CC=C2OCC[C@]3(NC(=O)NC3=O)C2=C1	PLASMA	G4186B906P									?	μg × h/mL	528		μg/mL	6.25			UNKNOWN	mg	250		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3107606	Homo sapiens		h	58.9				8	Sorbinil		false
6706	6892		ADULT	60021	417.3811	TEMAFLOXACIN	TEMAFLOXACIN	CC1CN(CCN1)C2=CC3=C(C=C2F)C(=O)C(=CN3C4=C(F)C=C(F)C=C4)C(O)=O	PLASMA	1WZ12GTT67									∞	mg × h/L	50.3		mg/L	5.33			UNKNOWN	mg	600		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1319868	Homo sapiens		h	8.1							false
6707	6892		ADULT	60021	417.3811	TEMAFLOXACIN	TEMAFLOXACIN	CC1CN(CCN1)C2=CC3=C(C=C2F)C(=O)C(=CN3C4=C(F)C=C(F)C=C4)C(O)=O	PLASMA	1WZ12GTT67									∞	mg × h/L	92.7		mg/L	5.7			UNKNOWN	mg	600		SINGLE	FASTED				Protein binding of temafloxacin is low (~26%)	74	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1319868	Homo sapiens		h	11.7							false
6708	6892		ADULT	60021	417.3811	TEMAFLOXACIN	TEMAFLOXACIN	CC1CN(CCN1)C2=CC3=C(C=C2F)C(=O)C(=CN3C4=C(F)C=C(F)C=C4)C(O)=O	PLASMA	1WZ12GTT67									∞	μg × h/mL	15.02		μg/mL	1.61			UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2039194	Homo sapiens		h	7.9							false
6709	6892		ADULT	60021	417.3811	TEMAFLOXACIN	TEMAFLOXACIN	CC1CN(CCN1)C2=CC3=C(C=C2F)C(=O)C(=CN3C4=C(F)C=C(F)C=C4)C(O)=O	PLASMA	1WZ12GTT67									∞	μg × h/mL	29.69		μg/mL	2.43			UNKNOWN	mg	400		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2039194	Homo sapiens		h	7.9							false
6710	6892		ADULT	60021	417.3811	TEMAFLOXACIN	TEMAFLOXACIN	CC1CN(CCN1)C2=CC3=C(C=C2F)C(=O)C(=CN3C4=C(F)C=C(F)C=C4)C(O)=O	PLASMA	1WZ12GTT67									∞	μg × h/mL	49.54		μg/mL	3.87			UNKNOWN	mg	600		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2039194	Homo sapiens		h	7.8							false
6711	6897		ADULT	53359	357.347	TOLRESTAT	Tolrestat	COC1=C(C2=CC=CC(C(=S)N(C)CC(O)=O)=C2C=C1)C(F)(F)F	PLASMA	0T93LG5NMK									?	μg × h/mL	86		μg/mL	18.2			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1544287/	Homo sapiens		h	10.6				8			false
6712	6897		ADULT	53359	357.347	TOLRESTAT	Tolrestat	COC1=C(C2=CC=CC(C(=S)N(C)CC(O)=O)=C2C=C1)C(F)(F)F	PLASMA	0T93LG5NMK									?	μg × h/mL	104		μg/mL	18.5			UNKNOWN	mg	200		SINGLE	FASTED						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1544287/	Homo sapiens		h	11.7		Mild/moderate renal impairment		11			false
6713	6897		ADULT	53359	357.347	TOLRESTAT	Tolrestat	COC1=C(C2=CC=CC(C(=S)N(C)CC(O)=O)=C2C=C1)C(F)(F)F	PLASMA	0T93LG5NMK									?	μg × h/mL	193		μg/mL	19			UNKNOWN	mg	200		SINGLE	FASTED						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1544287/	Homo sapiens		h	16.4		Renal impairment with dialysis		7			false
6714	6897		ADULT	53359	357.347	TOLRESTAT	Tolrestat	COC1=C(C2=CC=CC(C(=S)N(C)CC(O)=O)=C2C=C1)C(F)(F)F	PLASMA	0T93LG5NMK													μg/mL	11.3			UNKNOWN	mg	200		SINGLE	FASTED					0.64	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8529328/	Homo sapiens		h	13				12			false
6715	6897		ADULT	53359	357.347	TOLRESTAT	Tolrestat	COC1=C(C2=CC=CC(C(=S)N(C)CC(O)=O)=C2C=C1)C(F)(F)F	PLASMA	0T93LG5NMK									?	μg × h/mL	55.1		μg/mL	11.1			UNKNOWN	mg	200		SINGLE	FASTED					0.64	UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8529328/	Homo sapiens		h	13.9		Patients with insulin-independent diabetes		12			false
6716	6897		ADULT	53359	357.347	TOLRESTAT	Tolrestat	COC1=C(C2=CC=CC(C(=S)N(C)CC(O)=O)=C2C=C1)C(F)(F)F	PLASMA	0T93LG5NMK									?	μg × h/mL	57.1		μg/mL	14.8			UNKNOWN	mg	200		STEADY-STATE	FASTED		day	2	Cmax: average on Days 10, 12, and 14		UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8529328/	Homo sapiens		h	13.9		Patients with insulin-independent diabetes		12			false
6717	6897		ADULT	53359	357.347	TOLRESTAT	Tolrestat	COC1=C(C2=CC=CC(C(=S)N(C)CC(O)=O)=C2C=C1)C(F)(F)F	PLASMA	0T93LG5NMK													μg/mL	27			UNKNOWN	mg	200		STEADY-STATE	UNKNOWN		day	2		0.76	HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8681485/	Homo sapiens		h	11.4		Young subjects		10			false
6718	6897		ADULT	53359	357.347	TOLRESTAT	Tolrestat	COC1=C(C2=CC=CC(C(=S)N(C)CC(O)=O)=C2C=C1)C(F)(F)F	PLASMA	0T93LG5NMK													μg/mL	21			UNKNOWN	mg	200		STEADY-STATE	UNKNOWN		day	2		0.73	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8681485/	Homo sapiens		h	17.2		Young subjects		10			false
6719	6897		ADULT	53359	357.347	TOLRESTAT	Tolrestat	COC1=C(C2=CC=CC(C(=S)N(C)CC(O)=O)=C2C=C1)C(F)(F)F	PLASMA	0T93LG5NMK													μg/mL	30			UNKNOWN	mg	200		STEADY-STATE	UNKNOWN		day	2		0.77	HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8681485/	Homo sapiens		h	15.2		Elderly subjects		12			false
6720	6897		ADULT	53359	357.347	TOLRESTAT	Tolrestat	COC1=C(C2=CC=CC(C(=S)N(C)CC(O)=O)=C2C=C1)C(F)(F)F	PLASMA	0T93LG5NMK													μg/mL	23			UNKNOWN	mg	200		STEADY-STATE	UNKNOWN		day	2		0.8	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8681485/	Homo sapiens		h	15.2		Elderly subjects		13			false
6721	6897		ADULT	53359	357.347	TOLRESTAT	Tolrestat	COC1=C(C2=CC=CC(C(=S)N(C)CC(O)=O)=C2C=C1)C(F)(F)F	PLASMA	0T93LG5NMK													μg/mL	15.9			UNKNOWN	mg	200		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8681485/	Homo sapiens		h	10.9		Young subjects with diabetes		9			false
6722	6897		ADULT	53359	357.347	TOLRESTAT	Tolrestat	COC1=C(C2=CC=CC(C(=S)N(C)CC(O)=O)=C2C=C1)C(F)(F)F	PLASMA	0T93LG5NMK													μg/mL	18.1			UNKNOWN	mg	200		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8681485/	Homo sapiens		h	10.8		Elderly subjects with diabetes		8			false
6723	6899		ADULT	6509849	515.087	VERLUKAST	VERLUKAST	CN(C)C(=O)CCS[C@H](SCCC(O)=O)C1=CC(\\C=C\\C2=NC3=C(C=CC(Cl)=C3)C=C2)=CC=C1	PLASMA	5Q9O54P0H7									?	μg × h/mL	159.4		μg/mL	41.3			UNKNOWN	mg	500		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12959296/	Homo sapiens							12	VERLUKAST		false
6724	6899		ADULT	6509849	515.087	VERLUKAST	VERLUKAST	CN(C)C(=O)CCS[C@H](SCCC(O)=O)C1=CC(\\C=C\\C2=NC3=C(C=CC(Cl)=C3)C=C2)=CC=C1	PLASMA	5Q9O54P0H7									?	μg × h/mL	19.7		μg/mL	6.7			UNKNOWN	mg	75		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12959296/	Homo sapiens							12	VERLUKAST		false
6725	6899		ADULT	6509849	515.087	VERLUKAST	VERLUKAST	CN(C)C(=O)CCS[C@H](SCCC(O)=O)C1=CC(\\C=C\\C2=NC3=C(C=CC(Cl)=C3)C=C2)=CC=C1	PLASMA	5Q9O54P0H7									?	μg × h/mL	138.8		μg/mL	32.1			UNKNOWN	mg	500		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12959296/	Homo sapiens							12	VERLUKAST		false
6726	6901		ADULT	15376	354.4427	VINCAMINE	VINCAMINE	CC[C@@]12CCCN3CCC4=C([C@H]13)N(C5=C4C=CC=C5)[C@](O)(C2)C(=O)OC	PLASMA	996XVD0JHT									∞	ng × h/mL	514.65		ng/mL	91.67			UNKNOWN	mg	60		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10738641/	Homo sapiens		h	4.18				16	VINCAMINE		false
6727	6901		UNKNOWN	15376	354.4427	VINCAMINE	VINCAMINE	CC[C@@]12CCCN3CCC4=C([C@H]13)N(C5=C4C=CC=C5)[C@](O)(C2)C(=O)OC	PLASMA	996XVD0JHT																	UNKNOWN					UNKNOWN				64% bound to plasma proteins	36	UNKNOWN		UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4010386/	Homo sapiens								VINCAMINE		false
6728	6901		ADULT	15376	354.4427	VINCAMINE	VINCAMINE	CC[C@@]12CCCN3CCC4=C([C@H]13)N(C5=C4C=CC=C5)[C@](O)(C2)C(=O)OC	PLASMA	996XVD0JHT									?	μg × h/L	443		μg/L	155			UNKNOWN	mg	60		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6654533/	Homo sapiens		h	1.43				6	VINCAMINE		false
6729	6907		ADULT	5733	291.73	ZOMEPIRAC	ZOMEPIRAC	CN1C(CC(O)=O)=CC(C)=C1C(=O)C2=CC=C(Cl)C=C2	PLASMA	822G987U9J							14		t	μg × h/mL	232.7		μg/mL	2.47			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7357796	Homo sapiens										false
6730	6907		ADULT	5733	291.73	ZOMEPIRAC	ZOMEPIRAC	CN1C(CC(O)=O)=CC(C)=C1C(=O)C2=CC=C(Cl)C=C2	PLASMA	822G987U9J							12		t	μg × h/mL	494.4		μg/mL	4.42			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7357796	Homo sapiens										false
6731	6907		ADULT	5733	291.73	ZOMEPIRAC	ZOMEPIRAC	CN1C(CC(O)=O)=CC(C)=C1C(=O)C2=CC=C(Cl)C=C2	PLASMA	822G987U9J							12		t	μg × h/mL	1102.7		μg/mL	7.94			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7357796	Homo sapiens										false
6732	6908		ADULT	6103	168.58	ZOXAZOLAMINE	ZOXAZOLAMINE	NC1=NC2=CC(Cl)=CC=C2O1	PLASMA	9DOW362Q29													mg/L	7.5			UNKNOWN	g	1		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/13571254/	Homo sapiens										false
6733	6927		ADULT	57030	375.3675	BREQUINAR	BREQUINAR	CC1=C(N=C2C=CC(F)=CC2=C1C(O)=O)C3=CC=C(C=C3)C4=C(F)C=CC=C4	PLASMA	5XL19F49H6																						UNKNOWN				Brequinar is a weakly acidic, low-clearance, and highly protein-bound (> 98% bound) antitumor agent.	2	HEALTHY		UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/7987984	Homo sapiens										false
6734	6927		ADULT	57030	375.3675	BREQUINAR	CC1=C(N=C2C=CC(F)=CC2=C1C(O)=O)C3=CC=C(C=C3)C4=CC=CC=C4F	CC1=C(N=C2C=CC(F)=CC2=C1C(O)=O)C3=CC=C(C=C3)C4=CC=CC=C4F	PLASMA	5XL19F49H6							24		t	μg × h/mL	54		μg/mL	30.6			RECOMMENDED	mg/m²	170		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/8499153	Homo sapiens		h	2.1							false
6735	6929		ADULT	73951997	316.4776	CALUSTERONE	CALUSTERONE	C[C@H]1CC2=CC(=O)CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC[C@]4(C)O)[C@H]13	PLASMA	0678G6Q58A																	UNKNOWN	mg	100		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/161435/	Homo sapiens		h	24							false
6736	6936		ADULT	9853710	774.925	CILUPREVIR	CILUPREVIR	COC1=CC2=C(C=C1)C(O[C@@H]3C[C@@H]4N(C3)C(=O)[C@H](CCCCCC=C[C@@H]5C[C@]5(NC4=O)C(O)=O)NC(=O)OC6CCCC6)=CC(=N2)C7=CSC(NC(C)C)=N7	PLASMA	75C8DU40T0							8		t	ng × h/mL	5323.08		ng/mL	1189.16			UNKNOWN	mg	10		SINGLE	UNKNOWN						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15732092	Homo sapiens							8	BILN-2061		false
6737	6936		ADULT	9853710	774.925	CILUPREVIR	CILUPREVIR	COC1=CC2=C(C=C1)C(O[C@@H]3C[C@@H]4N(C3)C(=O)[C@H](CCCCCC=C[C@@H]5C[C@]5(NC4=O)C(O)=O)NC(=O)OC6CCCC6)=CC(=N2)C7=CSC(NC(C)C)=N7	PLASMA	75C8DU40T0							8		t	ng × h/mL	13318.27		ng/mL	2799.99			UNKNOWN	mg	10		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15732092	Homo sapiens							8	BILN-2061		false
6738	6938		ADULT	9824350	436.545	CIPEMASTAT	CIPEMASTAT	CN1C(=O)N(C[C@@H]([C@@H](CC2CCCC2)C(=O)N3CCCCC3)C(=O)NO)C(=O)C1(C)C	PLASMA	02HQ4TYQ60									∞	mg × h/L	19.71		ng/mL	3323			UNKNOWN	mg	150		MULTIPLE	FED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11371662	Homo sapiens		h	23.9	Study day 28			9	CIPEMASTAT		false
6739	6938		ADULT	9824350	436.545	CIPEMASTAT	CIPEMASTAT	CN1C(=O)N(C[C@@H]([C@@H](CC2CCCC2)C(=O)N3CCCCC3)C(=O)NO)C(=O)C1(C)C	PLASMA	02HQ4TYQ60									∞	mg × h/L	20.66		ng/mL	3566			UNKNOWN	mg	150		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11371662	Homo sapiens				Study day 1			9	CIPEMASTAT		false
6740	6939		ADULT	6445533	379.4522	DACINOSTAT	DACINOSTAT	OCCN(CCC1=CNC2=C1C=CC=C2)CC3=CC=C(\\C=C\\C(=O)NO)C=C3	BLOOD	V10P524501							24		t	ng × h/mL	2314		ng/mL	824.8			RECOMMENDED	mg/m²	72		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/18927309	Homo sapiens		h	8.29							false
6741	6949		ADULT	119373	563.6429	ELACRIDAR	ELACRIDAR	COC1=CC2=C(CN(CCC3=CC=C(NC(=O)C4=CC=CC5=C4NC6=C(OC)C=CC=C6C5=O)C=C3)CC2)C=C1OC	PLASMA	N488540F94	60700	421.4458	TOPOTECAN	topotecan	CC[C@@]1(O)C(=O)OCC2=C1C=C3N(CC4=CC5=C(C=CC(O)=C5CN(C)C)N=C34)C2=O	7M7YKX2N15			?	μg × h/L	2629		μg/L	185			UNKNOWN	mg	1000		MULTIPLE	FED		week	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17545533	Homo sapiens				1000 mg of elacridar on days 1 and 8 1 h before or simultaneously with 2.0 mg oral topotecan			4	ELACRIDAR		true
6742	6962		ADULT	10518	250.2936	HEPTABARBITAL	HEPTABARBITAL	CCC1(C(=O)NC(=O)NC1=O)C2=CCCCCC2	PLASMA	V10R70ML23							12		t	mg × h/L	14.6		mg/L	1.94			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9299	Homo sapiens		h	7.7							false
6743	6962		ADULT	10518	250.2936	HEPTABARBITAL	HEPTABARBITAL	CCC1(C(=O)NC(=O)NC1=O)C2=CCCCCC2	PLASMA	V10R70ML23									∞	mg × h/L	23.6						UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9299	Homo sapiens										false
6744	6972		ADULT	216416	413.5512	LASOFOXIFENE	Lasofoxifene	OC1=CC2=C(C=C1)[C@H]([C@H](CC2)C3=CC=CC=C3)C4=CC=C(OCCN5CCCC5)C=C4	PLASMA	337G83N988									∞	ng × h/mL	37.1		ng/mL	0.173			UNKNOWN	mg	0.25		SINGLE	FASTED				equilibrium dialysis	0.717	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16397281/	Homo sapiens		h	195		Mild hepatic impairment (Child-Pugh A)		6			false
6745	6972		ADULT	216416	413.5512	LASOFOXIFENE	Lasofoxifene	OC1=CC2=C(C=C1)[C@H]([C@H](CC2)C3=CC=CC=C3)C4=CC=C(OCCN5CCCC5)C=C4	PLASMA	337G83N988									∞	ng × h/mL	52.6		ng/mL	0.214			UNKNOWN	mg	0.25		SINGLE	FASTED				equilibrium dialysis	0.433	UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16397281/	Homo sapiens		h	252		Moderate hepatic impairment (Child-Pugh B)		6			false
6746	6972		ADULT	216416	413.5512	LASOFOXIFENE	Lasofoxifene	OC1=CC2=C(C=C1)[C@H]([C@H](CC2)C3=CC=CC=C3)C4=CC=C(OCCN5CCCC5)C=C4	PLASMA	337G83N988									∞	ng × h/mL	38.1		ng/mL	0.169			UNKNOWN	mg	0.25		SINGLE	FASTED				equilibrium dialysis	0.508	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16397281/	Homo sapiens		h	193				6			false
6747	6972		ADULT	216416	413.5512	LASOFOXIFENE	Lasofoxifene	OC1=CC2=C(C=C1)[C@H]([C@H](CC2)C3=CC=CC=C3)C4=CC=C(OCCN5CCCC5)C=C4	PLASMA	337G83N988							24		t	ng × h/mL	1.67		ng/mL	0.09			UNKNOWN	mg	0.01		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16397284/	Homo sapiens				Day 14 (a loading dose equivalent to 5 times the maintenance dose was administered on day 1)	Postmenopausal women		8			false
6748	6972		ADULT	216416	413.5512	LASOFOXIFENE	Lasofoxifene	OC1=CC2=C(C=C1)[C@H]([C@H](CC2)C3=CC=CC=C3)C4=CC=C(OCCN5CCCC5)C=C4	PLASMA	337G83N988							24		t	ng × h/mL	5.14		ng/mL	0.25			UNKNOWN	mg	0.03		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16397284/	Homo sapiens		h	182	Day 14 (a loading dose equivalent to 5 times the maintenance dose was administered on day 1)	Postmenopausal women		8			false
6749	6972		ADULT	216416	413.5512	LASOFOXIFENE	Lasofoxifene	OC1=CC2=C(C=C1)[C@H]([C@H](CC2)C3=CC=CC=C3)C4=CC=C(OCCN5CCCC5)C=C4	PLASMA	337G83N988							24		t	ng × h/mL	15.7		ng/mL	0.74			UNKNOWN	mg	0.1		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16397284/	Homo sapiens		h	171	Day 14 (a loading dose equivalent to 5 times the maintenance dose was administered on day 1)	Postmenopausal women		16			false
6750	6972		ADULT	216416	413.5512	LASOFOXIFENE	Lasofoxifene	OC1=CC2=C(C=C1)[C@H]([C@H](CC2)C3=CC=CC=C3)C4=CC=C(OCCN5CCCC5)C=C4	PLASMA	337G83N988							24		t	ng × h/mL	43.2		ng/mL	2.08			UNKNOWN	mg	0.3		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16397284/	Homo sapiens		h	147	Day 14 (a loading dose equivalent to 5 times the maintenance dose was administered on day 1)	Postmenopausal women		8			false
6751	6972		ADULT	216416	413.5512	LASOFOXIFENE	Lasofoxifene	OC1=CC2=C(C=C1)[C@H]([C@H](CC2)C3=CC=CC=C3)C4=CC=C(OCCN5CCCC5)C=C4	PLASMA	337G83N988							24		t	ng × h/mL	137		ng/mL	6.43			UNKNOWN	mg	1		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16397284/	Homo sapiens		h	134	Day 14 (a loading dose equivalent to 5 times the maintenance dose was administered on day 1)	Postmenopausal women		8			false
6752	6972		ADULT	216416	413.5512	LASOFOXIFENE	Lasofoxifene	OC1=CC2=C(C=C1)[C@H]([C@H](CC2)C3=CC=CC=C3)C4=CC=C(OCCN5CCCC5)C=C4	PLASMA	337G83N988									∞	ng × h/mL	45.8		ng/mL	0.25			UNKNOWN	mg	0.25		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16707415/	Homo sapiens		h	151.1		Postmenopausal Japanese women					false
6753	6972		ADULT	216416	413.5512	LASOFOXIFENE	Lasofoxifene	OC1=CC2=C(C=C1)[C@H]([C@H](CC2)C3=CC=CC=C3)C4=CC=C(OCCN5CCCC5)C=C4	PLASMA	337G83N988									∞	ng × h/mL	85.5		ng/mL	0.5			UNKNOWN	mg	0.5		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16707415/	Homo sapiens		h	134.8		Postmenopausal Japanese women					false
6754	6972		ADULT	216416	413.5512	LASOFOXIFENE	Lasofoxifene	OC1=CC2=C(C=C1)[C@H]([C@H](CC2)C3=CC=CC=C3)C4=CC=C(OCCN5CCCC5)C=C4	PLASMA	337G83N988									?	ng × h/mL	14.5		ng/mL	0.1			UNKNOWN	mg	0.1		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16707415/	Homo sapiens					Postmenopausal Japanese women					false
6755	6972		ADULT	216416	413.5512	LASOFOXIFENE	Lasofoxifene	OC1=CC2=C(C=C1)[C@H]([C@H](CC2)C3=CC=CC=C3)C4=CC=C(OCCN5CCCC5)C=C4	PLASMA	337G83N988									∞	ng × h/mL	45.6		ng/mL	0.24			UNKNOWN	mg	0.25		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16707415/	Homo sapiens		h	164.3		Postmenopausal White women					false
6756	6972		ADULT	216416	413.5512	LASOFOXIFENE	Lasofoxifene	OC1=CC2=C(C=C1)[C@H]([C@H](CC2)C3=CC=CC=C3)C4=CC=C(OCCN5CCCC5)C=C4	PLASMA	337G83N988									∞	ng × h/mL	77.5		ng/mL	0.44			UNKNOWN	mg	0.5		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16707415/	Homo sapiens		h	146.3		Postmenopausal White women					false
6757	6972		ADULT	216416	413.5512	LASOFOXIFENE	Lasofoxifene	OC1=CC2=C(C=C1)[C@H]([C@H](CC2)C3=CC=CC=C3)C4=CC=C(OCCN5CCCC5)C=C4	PLASMA	337G83N988									?	ng × h/mL	14.5		ng/mL	0.09			UNKNOWN	mg	0.1		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16707415/	Homo sapiens					Postmenopausal White women					false
6758	6972		ADULT	216416	413.5512	LASOFOXIFENE	Lasofoxifene	OC1=CC2=C(C=C1)[C@H]([C@H](CC2)C3=CC=CC=C3)C4=CC=C(OCCN5CCCC5)C=C4	PLASMA	337G83N988									∞	ng × h/mL	52.7		μg/mL	0.218			UNKNOWN	mg	0.25		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16822276/	Homo sapiens		h	196		Post menopausal women		15			false
6759	6976		ADULT	172997	473.926	LIXIVAPTAN	LIXIVAPTAN	CC1=C(C=C(F)C=C1)C(=O)NC2=CC(Cl)=C(C=C2)C(=O)N3CC4=CC=CN4CC5=CC=CC=C35	PLASMA	8F5X4B082E									?	ng × h/mL	14884		ng/mL	1877			UNKNOWN	mg	300		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12395330	Homo sapiens		h	21.62				5	VPA-985		false
6760	6976		ADULT	172997	473.926	LIXIVAPTAN	LIXIVAPTAN	CC1=C(C=C(F)C=C1)C(=O)NC2=CC(Cl)=C(C=C2)C(=O)N3CC4=CC=CN4CC5=CC=CC=C35	PLASMA	8F5X4B082E									?	ng × h/mL	8775		ng/mL	1208			UNKNOWN	mg	200		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12395330	Homo sapiens		h	22.56				4	VPA-985		false
6761	6976		ADULT	172997	473.926	LIXIVAPTAN	LIXIVAPTAN	CC1=C(C=C(F)C=C1)C(=O)NC2=CC(Cl)=C(C=C2)C(=O)N3CC4=CC=CN4CC5=CC=CC=C35	PLASMA	8F5X4B082E									?	ng × h/mL	4391		ng/mL	719			UNKNOWN	mg	100		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12395330	Homo sapiens		h	9.05				4	VPA-985		false
6762	6976		ADULT	172997	473.926	LIXIVAPTAN	LIXIVAPTAN	CC1=C(C=C(F)C=C1)C(=O)NC2=CC(Cl)=C(C=C2)C(=O)N3CC4=CC=CN4CC5=CC=CC=C35	PLASMA	8F5X4B082E									?	ng × h/mL	953		ng/mL	210			UNKNOWN	mg	50		SINGLE	FASTED						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12395330	Homo sapiens		h	12.49				5	VPA 985		false
6763	6976		ADULT	172997	473.926	LIXIVAPTAN	LIXIVAPTAN	CC1=C(C=C(F)C=C1)C(=O)NC2=CC(Cl)=C(C=C2)C(=O)N3CC4=CC=CN4CC5=CC=CC=C35	PLASMA	8F5X4B082E									?	ng × h/mL	499		ng/mL	183			UNKNOWN	mg	25		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12395330	Homo sapiens		h	14.61				4	VPA-985		false
6764	6978		ADULT	119031	331.4079	MARIMASTAT	MARIMASTAT	CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C	PLASMA	D5EQV23TDS									?	ng × h/mL	2623		ng/mL	540			UNKNOWN	mg	100		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/9626215	Homo sapiens		h	4.9							false
6765	6982		ADULT	24466	269.13	METOPRINE	Metoprine	CC1=NC(N)=NC(N)=C1C2=CC(Cl)=C(Cl)C=C2	PLASMA	2L9RKX796Q							120		t	μg × h/mL	52		μg/mL	0.6			UNKNOWN	mg/m²	65		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7332733	Homo sapiens							1	Metoprine		false
6766	6998		CHILD	1684	381.349	PLECONARIL	Pleconaril	CC1=NOC(CCCOC2=C(C)C=C(C=C2C)C3=NOC(=N3)C(F)(F)F)=C1	PLASMA	9H4570Q89D							24		t	ng × h/mL	8131.2		ng/mL	1272.5			UNKNOWN	mg/kg	5		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10049279/	Homo sapiens		h	5.7	Oral solution	patients with viral infection		13			false
6767	6998		ADULT	1684	381.349	PLECONARIL	Pleconaril	CC1=NOC(CCCOC2=C(C)C=C(C=C2C)C3=NOC(=N3)C(F)(F)F)=C1	PLASMA	9H4570Q89D									∞	mg × h/mL	3.2		mg/L	0.3			UNKNOWN	mg	50		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10354965/	Homo sapiens		h	34				5			false
6768	6998		ADULT	1684	381.349	PLECONARIL	Pleconaril	CC1=NOC(CCCOC2=C(C)C=C(C=C2C)C3=NOC(=N3)C(F)(F)F)=C1	PLASMA	9H4570Q89D									∞	mg × h/mL	3.67		mg/L	0.44			UNKNOWN	mg	100		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10354965/	Homo sapiens		h	18				5			false
6769	6998		ADULT	1684	381.349	PLECONARIL	Pleconaril	CC1=NOC(CCCOC2=C(C)C=C(C=C2C)C3=NOC(=N3)C(F)(F)F)=C1	PLASMA	9H4570Q89D									∞	mg × h/mL	8.76		mg/L	1.66			UNKNOWN	mg	200		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10354965/	Homo sapiens		h	19.9				5			false
6770	6998		ADULT	1684	381.349	PLECONARIL	Pleconaril	CC1=NOC(CCCOC2=C(C)C=C(C=C2C)C3=NOC(=N3)C(F)(F)F)=C1	PLASMA	9H4570Q89D									∞	mg × h/mL	16.21		mg/L	2.03			UNKNOWN	mg	400		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10354965/	Homo sapiens		h	35.2				5			false
6771	6998		ADULT	1684	381.349	PLECONARIL	Pleconaril	CC1=NOC(CCCOC2=C(C)C=C(C=C2C)C3=NOC(=N3)C(F)(F)F)=C1	PLASMA	9H4570Q89D									∞	mg × h/mL	19.11		mg/L	3.39			UNKNOWN	mg	600		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10354965/	Homo sapiens		h	22.3				5			false
6772	6998		ADULT	1684	381.349	PLECONARIL	Pleconaril	CC1=NOC(CCCOC2=C(C)C=C(C=C2C)C3=NOC(=N3)C(F)(F)F)=C1	PLASMA	9H4570Q89D									∞	mg × h/mL	31.14		mg/L	4.3			UNKNOWN	mg	800		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10354965/	Homo sapiens		h	28.2				5			false
6773	6998		ADULT	1684	381.349	PLECONARIL	Pleconaril	CC1=NOC(CCCOC2=C(C)C=C(C=C2C)C3=NOC(=N3)C(F)(F)F)=C1	PLASMA	9H4570Q89D									∞	mg × h/mL	49.3		mg/L	5.25			UNKNOWN	mg	1000		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10354965/	Homo sapiens		h	27				5			false
6774	6998			1684	381.349	PLECONARIL	Pleconaril	CC1=NOC(CCCOC2=C(C)C=C(C=C2C)C3=NOC(=N3)C(F)(F)F)=C1	UNKNOWN	9H4570Q89D																										Human protein binding*>99%	1				REVIEW	https://pubmed.ncbi.nlm.nih.gov/12627933/	Homo sapiens										false
6775	6998		NEWBORN	1684	381.349	PLECONARIL	Pleconaril	CC1=NOC(CCCOC2=C(C)C=C(C=C2C)C3=NOC(=N3)C(F)(F)F)=C1	PLASMA	9H4570Q89D									?	ng × h/mL	6824		ng/mL	836			UNKNOWN	mg/kg	8.5		STEADY-STATE	UNKNOWN		day	3			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26407253/	Homo sapiens		h	22.8	9 liquid formulation (5 mg/kg dose) and 23 suspension (8.5 mg/kg dose), 7-day administration	Neonates with suspected enterovirus sepsis		32			false
6776	6998		ADULT	1684	381.349	PLECONARIL	Pleconaril	CC1=NOC(CCCOC2=C(C)C=C(C=C2C)C3=NOC(=N3)C(F)(F)F)=C1	PLASMA	9H4570Q89D									?	mg × h/L	9.08		mg/L	1.14			UNKNOWN	mg	200		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9756781/	Homo sapiens		h	6.74				12			false
6777	6998		ADULT	1684	381.349	PLECONARIL	Pleconaril	CC1=NOC(CCCOC2=C(C)C=C(C=C2C)C3=NOC(=N3)C(F)(F)F)=C1	PLASMA	9H4570Q89D									?	mg × h/L	4.08		mg/L	0.46			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9756781/	Homo sapiens		h	4.38				12			false
6778	7005		ADULT	159603	314.3822	RESIQUIMOD	RESIQUIMOD	CCOCC1=NC2=C(N1CC(C)(C)O)C3=C(C=CC=C3)N=C2N	PLASMA	V3DMU7PVXF									∞	ng × h/mL	45.66		ng/mL	7.55			UNKNOWN	mg/kg	0.02		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17532523	Homo sapiens		h	6.82				11	RESIQUIMOD		false
6779	7008		ADULT	153999	468.5	RUBOXISTAURIN	RUBOXISTAURIN	CN(C)C[C@@H]1CCN2C=C(C3=C2C=CC=C3)C4=C(C(=O)NC4=O)C5=CN(CCO1)C6=C5C=CC=C6	PLASMA	721809WQCP									∞	nM × h	1364		nM	200			UNKNOWN	mg	64		SINGLE	HIGH-FAT						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/16433874	Homo sapiens		h	13.8							false
6780	7019		ADULT	158797	303.826	TECALCET	TECALCET	COC1=CC=CC(=C1)[C@@H](C)NCCCC2=C(Cl)C=CC=C2	PLASMA	8I16YLE4US									?	ng × h/mL	44		ng/mL	7.4			UNKNOWN	mg	400		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11200930	Homo sapiens							5	KRN568		false
6781	7019		ADULT	158797	303.826	TECALCET	TECALCET	COC1=CC=CC(=C1)[C@@H](C)NCCCC2=C(Cl)C=CC=C2	PLASMA	8I16YLE4US									?	ng × h/mL	40.5		ng/mL	6.4			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11200930	Homo sapiens							5	KRN568		false
6782	7026			5724	441.636	ZENARESTAT	Zenarestat	OC(=O)CN1C(=O)N(CC2=C(F)C=C(Br)C=C2)C(=O)C3=CC=C(Cl)C=C13	PLASMA	180C9PJ8JT																										Human plasma protein binding: 99.3~99.4%	0.6				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8079505/	Homo sapiens										false
6783	7026		ADULT	5724	441.636	ZENARESTAT	Zenarestat	OC(=O)CN1C(=O)N(CC2=C(F)C=C(Br)C=C2)C(=O)C3=CC=C(Cl)C=C13	PLASMA	180C9PJ8JT									∞	μg × h/mL	218		μg/mL	41.6			UNKNOWN	mg	600		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8300896/	Homo sapiens		h	7.7				6			false
6784	7026		ADULT	5724	441.636	ZENARESTAT	Zenarestat	OC(=O)CN1C(=O)N(CC2=C(F)C=C(Br)C=C2)C(=O)C3=CC=C(Cl)C=C13	PLASMA	180C9PJ8JT									∞	μg × h/mL	66.8		μg/mL	22.6			UNKNOWN	mg	150		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8300896/	Homo sapiens		h	7.7				6			false
6785	7026		ADULT	5724	441.636	ZENARESTAT	Zenarestat	OC(=O)CN1C(=O)N(CC2=C(F)C=C(Br)C=C2)C(=O)C3=CC=C(Cl)C=C13	PLASMA	180C9PJ8JT							12		t	μg × h/mL	68.7		μg/mL	15.1			UNKNOWN	mg	300		MULTIPLE	FED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8300896/	Homo sapiens				Day 1			6			false
6786	7026		ADULT	5724	441.636	ZENARESTAT	Zenarestat	OC(=O)CN1C(=O)N(CC2=C(F)C=C(Br)C=C2)C(=O)C3=CC=C(Cl)C=C13	PLASMA	180C9PJ8JT							12		t	μg × h/mL	74.1		μg/mL	17.6			UNKNOWN	mg	300		MULTIPLE	FED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8300896/	Homo sapiens		h	10.2	Day 8 (single dose)			6			false
6787	7026		ADULT	5724	441.636	ZENARESTAT	Zenarestat	OC(=O)CN1C(=O)N(CC2=C(F)C=C(Br)C=C2)C(=O)C3=CC=C(Cl)C=C13	PLASMA	180C9PJ8JT									∞	μg × h/mL	135		μg/mL	39			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8300896/	Homo sapiens		h	8.8				6			false
6788	7026		ADULT	5724	441.636	ZENARESTAT	Zenarestat	OC(=O)CN1C(=O)N(CC2=C(F)C=C(Br)C=C2)C(=O)C3=CC=C(Cl)C=C13	PLASMA	180C9PJ8JT									∞	μg × h/mL	309		μg/mL	75.7			UNKNOWN	mg	600		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8300896/	Homo sapiens		h	8.2				6			false
6789	7064		ADULT	31404	220.3505	BUTYLATED HYDROXYTOLUENE	butylated hydroxytoluene	CC1=CC(=C(O)C(=C1)C(C)(C)C)C(C)(C)C	PLASMA	1P9D0Z171K									?	μg × h/L	76		μg/mL	0.09			UNKNOWN	mg/kg bw	0.5		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2606406/	Homo sapiens					non-smoking		7	butylated hydroxytoluene		false
6790	7098		ADULT	7172	167.205	OXEDRINE	OXEDRINE	CNCC(O)C1=CC=C(O)C=C1	PLASMA	PEG5DP7434	2519		CAFFEINE	caffeine	CN1C=NC2=C1C(=O)N(C)C(=O)N2C	3G6A5W338E			∞	ng × min/mL	427.9		ng/mL	1.75			RECOMMENDED	mg	21		SINGLE	UNKNOWN				Rest		HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18341680/	Homo sapiens		h	2.56							true
6791	7098		ADULT	7172	167.205	OXEDRINE	OXEDRINE	CNCC(O)C1=CC=C(O)C=C1	PLASMA	PEG5DP7434	2519		CAFFEINE	caffeine	CN1C=NC2=C1C(=O)N(C)C(=O)N2C	3G6A5W338E			∞	ng × min/mL	466.4		ng/mL	1.86			RECOMMENDED	mg	21		SINGLE	UNKNOWN				Exercise		HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18341680/	Homo sapiens		h	2.64							true
6792	7426		CHILD	6058|118985556	77.149	CYSTEAMINE	CYSTEAMINE	NCCS	PLASMA	5UX2SD1KE2							6		t	μM × h	96		μM	37.72			RECOMMENDED	mg	450		SINGLE	UNKNOWN					48	UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203389s000lbl.pdf	Homo sapiens										false
6793	7426		CHILD	6058|118985556	77.149	CYSTEAMINE	CYSTEAMINE	NCCS	PLASMA	5UX2SD1KE2							6		t	mg × min/L	351		mg/L	2.7			RECOMMENDED	mg/m²	404		STEADY-STATE	UNKNOWN		day	4		48	UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213491s000lbl.pdf	Homo sapiens		min	90							false
6794	7433		ADULT	3724	1550.1819	IODIXANOL	IODIXANOL	CC(=O)N(CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I)C2=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C2I	PLASMA	HW8W27HTXX																	UNKNOWN	mg/kg bw	300		SINGLE	UNKNOWN				In an in vitro human plasma study, iodixanol did not bind to protein.	100	HEALTHY	Intravenous	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020351s050lbl.pdf	Homo sapiens		h	2.1							false
6795	7433		ADULT	3724	1550.1819	IODIXANOL	IODIXANOL	CC(=O)N(CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I)C2=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C2I	PLASMA	HW8W27HTXX																	UNKNOWN				UNKNOWN	UNKNOWN						UNHEALTHY	UNKNOWN	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020351s050lbl.pdf	Homo sapiens		h	23							false
6796	7434		ADULT	21585658|101589918	1620.6707	DAPTOMYCIN	DAPTOMYCIN	CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]3[C@@H](C)OC(=O)[C@H](CC(=O)C4=CC=CC=C4N)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC3=O)[C@H](C)CC(O)=O	PLASMA	NWQ5N31VKK							24		t	μg × h/mL	499		μg/mL	59.1				mg/kg	6		STEADY-STATE			day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00428844	Homo sapiens										false
6797	7434		ADULT	21585658|101589918	1620.6707	DAPTOMYCIN	DAPTOMYCIN	CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]3[C@@H](C)OC(=O)[C@H](CC(=O)C4=CC=CC=C4N)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC3=O)[C@H](C)CC(O)=O	PLASMA	NWQ5N31VKK							24		t	μg × h/mL	821		μg/mL	92.3				mg/kg	8		STEADY-STATE			day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00428844	Homo sapiens										false
6798	7434		ADULT	21585658|101589918	1620.6707	DAPTOMYCIN	DAPTOMYCIN	CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]3[C@@H](C)OC(=O)[C@H](CC(=O)C4=CC=CC=C4N)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC3=O)[C@H](C)CC(O)=O	PLASMA	NWQ5N31VKK							24		t	μg × h/mL	494		μg/mL	57.8			RECOMMENDED	mg/kg	4		STEADY-STATE	UNKNOWN		day	1	Daptomycin is reversibly bound to human plasma proteins, primarily to serum albumin, in a concentration-independent manner. The overall mean binding ranges from 90 to 93%.	8.5	HEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	Homo sapiens		h	8.1							false
6799	7434		ADULT	21585658|101589918	1620.6707	DAPTOMYCIN	DAPTOMYCIN	CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]3[C@@H](C)OC(=O)[C@H](CC(=O)C4=CC=CC=C4N)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC3=O)[C@H](C)CC(O)=O	PLASMA	NWQ5N31VKK							24		t	μg × h/mL	632		μg/mL	93.9			RECOMMENDED	mg/kg	6		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	Homo sapiens		h	7.9							false
6800	7434		ADULT	21585658|101589918	1620.6707	DAPTOMYCIN	DAPTOMYCIN	CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]3[C@@H](C)OC(=O)[C@H](CC(=O)C4=CC=CC=C4N)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC3=O)[C@H](C)CC(O)=O	PLASMA	NWQ5N31VKK							24		t	μg × h/mL	858		μg/mL	123.3			UNKNOWN	mg/kg	8		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	Homo sapiens		h	8.3							false
6801	7434		ADULT	21585658|101589918	1620.6707	DAPTOMYCIN	DAPTOMYCIN	CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]3[C@@H](C)OC(=O)[C@H](CC(=O)C4=CC=CC=C4N)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC3=O)[C@H](C)CC(O)=O	PLASMA	NWQ5N31VKK							24		t	μg × h/mL	1039		μg/mL	141.1			UNKNOWN	mg/kg	10		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	Homo sapiens		h	7.9							false
6802	7434		ADULT	21585658|101589918	1620.6707	DAPTOMYCIN	DAPTOMYCIN	CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]3[C@@H](C)OC(=O)[C@H](CC(=O)C4=CC=CC=C4N)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC3=O)[C@H](C)CC(O)=O	PLASMA	NWQ5N31VKK							24		t	μg × h/mL	1277		μg/mL	183.7			UNKNOWN	mg/kg	12		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	Homo sapiens		h	7.7							false
6803	7435		ADOLESCENT	3883	369.361	DEXLANSOPRAZOLE	DEXLANSOPRAZOLE	CC1=C(C[S+]([O-])C2=NC3=C(N2)C=CC=C3)N=CC=C1OCC(F)(F)F	PLASMA	UYE4T5I70X													ng/mL	691				mg	30		MULTIPLE			day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00847210	Homo sapiens		h	1.66							false
6804	7435		ADOLESCENT	3883	369.361	DEXLANSOPRAZOLE	DEXLANSOPRAZOLE	CC1=C(C[S+]([O-])C2=NC3=C(N2)C=CC=C3)N=CC=C1OCC(F)(F)F	PLASMA	UYE4T5I70X													ng/mL	1136				mg	60		MULTIPLE			day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00847210	Homo sapiens		h	2.59							false
6805	7435		CHILD	3883	369.361	DEXLANSOPRAZOLE	DEXLANSOPRAZOLE	CC1=C(C[S+]([O-])C2=NC3=C(N2)C=CC=C3)N=CC=C1OCC(F)(F)F	PLASMA	UYE4T5I70X							24		t	ng × h/mL	2149							mg	15		MULTIPLE			day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01045096	Homo sapiens										false
6806	7435		CHILD	3883	369.361	DEXLANSOPRAZOLE	DEXLANSOPRAZOLE	CC1=C(C[S+]([O-])C2=NC3=C(N2)C=CC=C3)N=CC=C1OCC(F)(F)F	PLASMA	UYE4T5I70X													ng/mL	1005				mg	30		MULTIPLE			day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01045096	Homo sapiens										false
6807	7435		CHILD	3883	369.361	DEXLANSOPRAZOLE	DEXLANSOPRAZOLE	CC1=C(C[S+]([O-])C2=NC3=C(N2)C=CC=C3)N=CC=C1OCC(F)(F)F	PLASMA	UYE4T5I70X									?	ng × h/mL	2892							mg	30		MULTIPLE			day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01045096	Homo sapiens										false
6808	7435		CHILD	3883	369.361	DEXLANSOPRAZOLE	DEXLANSOPRAZOLE	CC1=C(C[S+]([O-])C2=NC3=C(N2)C=CC=C3)N=CC=C1OCC(F)(F)F	PLASMA	UYE4T5I70X							24		t	ng × h/mL	2628							mg	30		MULTIPLE			day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01045096	Homo sapiens										false
6809	7435		CHILD	3883	369.361	DEXLANSOPRAZOLE	DEXLANSOPRAZOLE	CC1=C(C[S+]([O-])C2=NC3=C(N2)C=CC=C3)N=CC=C1OCC(F)(F)F	PLASMA	UYE4T5I70X													ng/mL	964				mg	60		MULTIPLE			day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01045096	Homo sapiens										false
6810	7435		CHILD	3883	369.361	DEXLANSOPRAZOLE	DEXLANSOPRAZOLE	CC1=C(C[S+]([O-])C2=NC3=C(N2)C=CC=C3)N=CC=C1OCC(F)(F)F	PLASMA	UYE4T5I70X									?	ng × h/mL	3747							mg	60		MULTIPLE			day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01045096	Homo sapiens										false
6811	7435		CHILD	3883	369.361	DEXLANSOPRAZOLE	DEXLANSOPRAZOLE	CC1=C(C[S+]([O-])C2=NC3=C(N2)C=CC=C3)N=CC=C1OCC(F)(F)F	PLASMA	UYE4T5I70X							24		t	ng × h/mL	3330							mg	60		MULTIPLE			day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01045096	Homo sapiens										false
6812	7435		CHILD	3883	369.361	DEXLANSOPRAZOLE	DEXLANSOPRAZOLE	CC1=C(C[S+]([O-])C2=NC3=C(N2)C=CC=C3)N=CC=C1OCC(F)(F)F	PLASMA	UYE4T5I70X									?	ng × h/mL	1914							mg	15		MULTIPLE			day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01045096	Homo sapiens										false
6813	7435		CHILD	3883	369.361	DEXLANSOPRAZOLE	DEXLANSOPRAZOLE	CC1=C(C[S+]([O-])C2=NC3=C(N2)C=CC=C3)N=CC=C1OCC(F)(F)F	PLASMA	UYE4T5I70X													ng/mL	559				mg	15		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01045096	Homo sapiens										false
6814	7435		UNKNOWN	3883	369.361	DEXLANSOPRAZOLE	DEXLANSOPRAZOLE	CC1=C(C[S+]([O-])C2=NC3=C(N2)C=CC=C3)N=CC=C1OCC(F)(F)F	PLASMA	UYE4T5I70X							24		t	ng × h/mL	3275		ng/mL	658			RECOMMENDED	mg	30		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022287s031lbl.pdf	Homo sapiens										false
6815	7435		UNKNOWN	3883	369.361	DEXLANSOPRAZOLE	DEXLANSOPRAZOLE	CC1=C(C[S+]([O-])C2=NC3=C(N2)C=CC=C3)N=CC=C1OCC(F)(F)F	PLASMA	UYE4T5I70X							24		t	ng × h/mL	6529		ng/mL	1397			RECOMMENDED	mg	60		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022287s031lbl.pdf	Homo sapiens										false
6816	7443		ADULT		1755.6	telavancin			PLASMA										∞	μg × h/mL	747		μg/mL	93.6			RECOMMENDED	mg/kg	10		SINGLE	UNKNOWN				Telavancin binds to human plasma proteins, primarily to serum albumin, in a concentration-independent manner. The mean binding is approximately 90% and is not affected by renal or hepatic impairment.	10	HEALTHY	Intravenous	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022110s016lbl.pdf	Homo sapiens		h	8							false
6817	7452		ADULT	3738	1626.2332	IOTROLAN	IOTROLAN	CN(C(=O)CC(=O)N(C)C1=C(I)C(C(=O)NC(CO)C(O)CO)=C(I)C(C(=O)NC(CO)C(O)CO)=C1I)C2=C(I)C(C(=O)NC(CO)C(O)CO)=C(I)C(C(=O)NC(CO)C(O)CO)=C2I	PLASMA	16FL47B687																	UNKNOWN	mg	5112		SINGLE	UNKNOWN						UNHEALTHY	Lumbar injection	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2568801	Homo sapiens		h	4							false
6818	7453		ADULT	180	58.0791	ACETONE	acetone	CC(C)=O	SERUM	1364PS73AF													mg/L	335			INVESTIGATIONAL	mL	21		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2914047/	Homo sapiens										false
6819	7453		ADULT	3776	60.095	ISOPROPYL ALCOHOL	ISOPROPYL ALCOHOL	CC(C)O	SERUM	ND2M416302													mg/L	258			INVESTIGATIONAL	mL	21		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2914047/	Homo sapiens										false
6820	7465		ADULT	441074	324.4168	QUINIDINE	QUINIDINE	COC1=CC2=C(C=C1)N=CC=C2[C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C	PLASMA	ITX08688JL							3		t	μg × h/mL	12.8		μg/mL	3.4			UNKNOWN	mg/kg	3.74		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/512840/	Homo sapiens		h	5.8							false
6821	7465		ADULT	441074	324.4168	QUINIDINE	QUINIDINE	COC1=CC2=C(C=C1)N=CC=C2[C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C	PLASMA	ITX08688JL																	RECOMMENDED	mg	202		SINGLE	UNKNOWN				At concentrations of 2 to 5 mg/L (6.5 to 16.2 µmol/L), the fraction of quinidine bound to plasma proteins (mainly to α1-acid glycoprotein and to albumin) is 80 to 88% in adults and older childre	12	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/089338s036lbl.pdf	Homo sapiens		h	8							false
6822	7490		ADULT	5918	109.1292	AMIFAMPRIDINE	amifampridine	NC1=CC=NC=C1N	PLASMA	RU4S6E2G0J									∞	ng × h/mL	109		ng/mL	40.6			RECOMMENDED	mg	20		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26101174/	Homo sapiens		h	2.28							false
6823	7490		ADULT	5918	109.1292	AMIFAMPRIDINE	AMIFAMPRIDINE	NC1=CC=NC=C1N	PLASMA	RU4S6E2G0J									∞	ng × h/mL	117		ng/mL	59.1			RECOMMENDED	mg	20		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26101174/	Homo sapiens		h	2.5							false
6824	7490		ADULT		151.17	3-N-ACETYL-AMIFAMPRIDINE	3-N-ACETYL-AMIFAMPRIDINE		PLASMA	21G4M49F34									∞	ng × h/mL	1220		ng/mL	189			RECOMMENDED	mg	20		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26101174/	Homo sapiens		h	4.03							false
6825	7490		ADULT		151.17	3-N-ACETYL-AMIFAMPRIDINE			PLASMA	21G4M49F34									∞	ng × h/mL	1444		ng/mL	268			RECOMMENDED	mg	20		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26101174/	Homo sapiens		h	4.1							false
6826	7503		ADULT	17358	146.055	SULFUR HEXAFLUORIDE	SULFUR HEXAFLUORIDE	FS(F)(F)(F)(F)F	BLOOD	WS7LR3I1D6																	UNKNOWN	mL/kg	0.3		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/203684s005lbl.pdf	Homo sapiens		min	10							false
6827	7504		ADULT	8259	149.404	2,2,2-TRICHLOROETHANOL	trichloroethanol	OCC(Cl)(Cl)Cl	PLASMA	AW835AJ62N							48		t	μM × h	1056		μM	106			UNKNOWN	mg	1500		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18243465/	Homo sapiens		h	12.8							false
6828	7505		UNKNOWN	25513|3032574|4453619|14157395|129627853	497.354	PENTETATE CALCIUM TRISODIUM	PENTETATE CALCIUM TRISODIUM	[Na+].[Na+].[Na+].[Ca++].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O	PLASMA	G79YN26H5B																	UNKNOWN				SINGLE	UNKNOWN						UNKNOWN	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021749s008lbl.pdf	Homo sapiens		min	1.4							false
6829	7509		ADULT	180	58.0791	ACETONE	ACETONE	CC(C)=O	BLOOD	1364PS73AF									?	mM × h	2.02		mM	1.01			INVESTIGATIONAL	mmol/h	5.5	inhalation, 2 hour	OTHER	UNKNOWN						HEALTHY	Respiratory	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10353310/	Homo sapiens		h	4.3							false
6830	7523		UNKNOWN	667550	254.2806	DEXKETOPROFEN	DEXKETOPROFEN	C[C@H](C(O)=O)C1=CC(=CC=C1)C(=O)C2=CC=CC=C2	PLASMA	6KD9E78X68																	UNKNOWN					UNKNOWN					0.8	UNKNOWN		UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11368291/	Homo sapiens								DEXKETOPROFEN		false
6831	7523		ADULT	667550	254.2806	DEXKETOPROFEN	DEXKETOPROFEN	C[C@H](C(O)=O)C1=CC(=CC=C1)C(=O)C2=CC=CC=C2	PLASMA	6KD9E78X68							10		t	mg × h/L	4.03		mg/L	3.1			RECOMMENDED	mg	25		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8922555/	Homo sapiens							18	DEXKETOPROFEN		false
6832	7523		ADULT	667550	254.2806	DEXKETOPROFEN	DEXKETOPROFEN	C[C@H](C(O)=O)C1=CC(=CC=C1)C(=O)C2=CC=CC=C2	PLASMA	6KD9E78X68							4772.94		∞	ng × h/mL	4772.94		ng/mL	3519.96			RECOMMENDED	mg	25		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.oatext.com/pdf/TiM-19-176.pdf	Homo sapiens		h	1.31				27	DEXKETOPROFEN		false
6833	7524		ADULT	3034366	179.1711	GLUCOSAMINE	Glucosamine	N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO	PLASMA	N08U5BOQ1K							24		t	ng × h/mL	9697		ng/mL	1069.2			UNKNOWN	mg	750		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16168682/	Homo sapiens				3-day administration			12			false
6834	7524		ADULT	3034366	179.1711	GLUCOSAMINE	Glucosamine	N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO	PLASMA	N08U5BOQ1K							24		t	ng × h/mL	14564		ng/mL	1601.9			UNKNOWN	mg	1500		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16168682/	Homo sapiens				3-day administration			12			false
6835	7524		ADULT	3034366	179.1711	GLUCOSAMINE	Glucosamine	N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO	PLASMA	N08U5BOQ1K							24		t	ng × h/mL	22095		ng/mL	2503.1			UNKNOWN	mg	3000		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16168682/	Homo sapiens				3-day administration			12			false
6836	7524			3034366	179.1711	GLUCOSAMINE	Glucosamine	N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO	PLASMA	N08U5BOQ1K																										At each tested concentration (400, 1000, and 4000 ng/mL) no significant binding of radioactivity to human plasma or synovial fluid proteins occurred. (equilibrium dialysis)	100				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22112180/	Homo sapiens										false
6837	7524		ADULT	3034366	179.1711	GLUCOSAMINE	Glucosamine	N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO	PLASMA	N08U5BOQ1K									∞	ng × h/mL	16874		ng/mL	2224			UNKNOWN	mg	1500		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32901283/	Homo sapiens		h	5.6	Tablets			14	Blackmores brand		false
6838	7524		ADULT	3034366	179.1711	GLUCOSAMINE	Glucosamine	N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO	PLASMA	N08U5BOQ1K									∞	ng × h/mL	16718		ng/mL	2125			UNKNOWN	mg	1500		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32901283/	Homo sapiens		h	5.8	Powder (oral solution)			14	DONA brand		false
6839	7524		UNKNOWN	3034366	179.1711	GLUCOSAMINE	Glucosamine	N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO	PLASMA	N08U5BOQ1K																	UNKNOWN				UNKNOWN	UNKNOWN				Unbound glucosamine did not bind to plasma proteins of humans, dogs, or rats.	100	UNKNOWN		UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/9606479/	Homo sapiens								GLUCOSAMINE		false
6840	7527		ADULT	9800194	383.486	TEBIPENEM	Tebipenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN(C3)C4=NCCS4)=C(N2C1=O)C(O)=O	PLASMA	Q2TWQ1I31U							8		t	μg × h/mL	5.22		μg/mL	5.08			UNKNOWN	mg	150		MULTIPLE	FED		day	3	n=55 for t1/2		HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19673356/	Homo sapiens		h	0.4	Day 7	Patients with otolaryngological infections		66	TBPM-PI		false
6841	7527		ADULT	9800194	383.486	TEBIPENEM	Tebipenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN(C3)C4=NCCS4)=C(N2C1=O)C(O)=O	PLASMA	Q2TWQ1I31U							12		t	μg × h/mL	7.93		μg/mL	7.92			UNKNOWN	mg	250		MULTIPLE	FED		day	2	n=46 for t1/2		HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19673356/	Homo sapiens		h	0.34	Day 7	Patients with otolaryngological infections		61	TBPM-PI		false
6842	7527		ADULT	9800194	383.486	TEBIPENEM	Tebipenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN(C3)C4=NCCS4)=C(N2C1=O)C(O)=O	PLASMA	Q2TWQ1I31U							8		t	μg × h/mL	13.62		μg/mL	8.69			UNKNOWN	mg	300		MULTIPLE	FED		day	3	n=60 for t1/2		HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19673356/	Homo sapiens		h	0.54	Day 7	Patients with otolaryngological infections		64	TBPM-PI		false
6843	7527		ADULT	9800194	383.486	TEBIPENEM	Tebipenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN(C3)C4=NCCS4)=C(N2C1=O)C(O)=O	PLASMA	Q2TWQ1I31U							8		t	μg × h/mL	6.68		μg/mL	6.08			UNKNOWN	mg	200		MULTIPLE	FED		day	3			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19673356/ | http://journal.chemotherapy.or.jp/detail_e.php?-DB=jsc&-recid=4826&-action=browse	Homo sapiens		h	0.36	Day 7			8	TBPM-PI		false
6844	7527		ADULT	9800194	383.486	TEBIPENEM	Tebipenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN(C3)C4=NCCS4)=C(N2C1=O)C(O)=O	PLASMA	Q2TWQ1I31U							8		t	μg × h/mL	3.2		μg/mL	2.71			UNKNOWN	mg	100		MULTIPLE	FED		day	3			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19673356/ | http://journal.chemotherapy.or.jp/detail_e.php?-DB=jsc&-recid=4826&-action=browse	Homo sapiens		h	0.44	Day 7			8	TBPM-PI		false
6845	7527		ADULT	9800194	383.486	TEBIPENEM	Tebipenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN(C3)C4=NCCS4)=C(N2C1=O)C(O)=O	PLASMA	Q2TWQ1I31U							8		t	μg × h/mL	11.35		μg/mL	4.74			UNKNOWN	mg	300		MULTIPLE	FED		day	3			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19673356/ | http://journal.chemotherapy.or.jp/detail_e.php?-DB=jsc&-recid=4826&-action=browse	Homo sapiens		h	0.67	Day 7			8	TBPM-PI		false
6846	7527			9800194	383.486	TEBIPENEM	Tebipenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN(C3)C4=NCCS4)=C(N2C1=O)C(O)=O	SERUM	Q2TWQ1I31U																										Human serum protein binding (ultrafiltration): 73.9% (0.1μg/mL), 67.0% (1, 10μg/mL), 59.7% (100μg/mL)	26.1				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19882982/	Homo sapiens										false
6847	7527		ADULT	9800194	383.486	TEBIPENEM	Tebipenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN(C3)C4=NCCS4)=C(N2C1=O)C(O)=O	PLASMA	Q2TWQ1I31U									∞	μg × h/mL	10.46		μg/mL	11.81			UNKNOWN	mg	250		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30903927/	Homo sapiens		h	0.77	Granules			4	Tebipenem pivoxil		false
6848	7527		ADULT	9800194	383.486	TEBIPENEM	Tebipenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN(C3)C4=NCCS4)=C(N2C1=O)C(O)=O	PLASMA	Q2TWQ1I31U									∞	μg × h/mL	9.52		μg/mL	3.9			UNKNOWN	mg	250		SINGLE	HIGH-FAT						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30903927/	Homo sapiens		h	0.91	Granules			4	Tebipenem pivoxil		false
6849	7527		ADULT	9800194	383.486	TEBIPENEM	Tebipenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN(C3)C4=NCCS4)=C(N2C1=O)C(O)=O	PLASMA	Q2TWQ1I31U									∞	ng × h/mL	6215		ng/mL	1852			UNKNOWN	mg	300		SINGLE	FED				n=3 for AUC and t1/2		HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31262768/	Homo sapiens		h	1.1	2-h release tablets			6	TBPM-HBr		false
6850	7527		ADULT	9800194	383.486	TEBIPENEM	Tebipenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN(C3)C4=NCCS4)=C(N2C1=O)C(O)=O	PLASMA	Q2TWQ1I31U									∞	ng × h/mL	6549		ng/mL	1677			UNKNOWN	mg	300		SINGLE	FED				n=3 for AUC and t1/2		HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31262768/	Homo sapiens		h	0.9	4-h release tablets			6	TBPM-HBr		false
6851	7527		ADULT	9800194	383.486	TEBIPENEM	Tebipenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN(C3)C4=NCCS4)=C(N2C1=O)C(O)=O	PLASMA	Q2TWQ1I31U									∞	ng × h/mL	16547		ng/mL	5830			UNKNOWN	mg	600		SINGLE	FED				n=4 for AUC and t1/2		HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31262768/	Homo sapiens		h	1.1	4-h release tablets			6	TBPM-HBr		false
6852	7527		ADULT	9800194	383.486	TEBIPENEM	Tebipenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN(C3)C4=NCCS4)=C(N2C1=O)C(O)=O	PLASMA	Q2TWQ1I31U									?	ng × h/mL	6579		ng/mL	2288			UNKNOWN	mg	300		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31262768/	Homo sapiens				6-h release tablets			6	TBPM-HBr		false
6853	7527		ADULT	9800194	383.486	TEBIPENEM	Tebipenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN(C3)C4=NCCS4)=C(N2C1=O)C(O)=O	PLASMA	Q2TWQ1I31U									∞	ng × h/mL	6137		ng/mL	2058			UNKNOWN	mg	300		SINGLE	FED				n=5 for AUC and t1/2		HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31262768/	Homo sapiens		h	0.9	Immediate-release tablets			6	TBPM-HBr		false
6854	7527		ADULT	9800194	383.486	TEBIPENEM	Tebipenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN(C3)C4=NCCS4)=C(N2C1=O)C(O)=O	PLASMA	Q2TWQ1I31U									∞	ng × h/mL	14200		ng/mL	6451			UNKNOWN	mg	600		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31262768/	Homo sapiens		h	0.9	Immediate-release tablets			6	TBPM-HBr		false
6855	7527		ADULT	9800194	383.486	TEBIPENEM	Tebipenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN(C3)C4=NCCS4)=C(N2C1=O)C(O)=O	PLASMA	Q2TWQ1I31U							8		t	ng × h/mL	7726		ng/mL	7759			UNKNOWN	mg	300		MULTIPLE	FASTED		day	3			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31262768/	Homo sapiens		h	0.82	Day 1, Immediate-release tablets			6	TBPM-HBr		false
6856	7527		ADULT	9800194	383.486	TEBIPENEM	Tebipenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN(C3)C4=NCCS4)=C(N2C1=O)C(O)=O	PLASMA	Q2TWQ1I31U									∞	ng × h/mL	872		ng/mL	256			UNKNOWN	mg	100		SINGLE	FASTED				n=3 for AUC and t1/2		HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31262768/	Homo sapiens		h	2	12-h release tablets			6	TBPM-HBr		false
6857	7527		ADULT	9800194	383.486	TEBIPENEM	Tebipenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN(C3)C4=NCCS4)=C(N2C1=O)C(O)=O	PLASMA	Q2TWQ1I31U							8		t	ng × h/mL	20592		ng/mL	13428			UNKNOWN	mg	600		MULTIPLE	FASTED		day	3			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31262768/	Homo sapiens		h	0.79	Day 1, Immediate-release tablets			6	TBPM-HBr		false
6858	7527		ADULT	9800194	383.486	TEBIPENEM	Tebipenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN(C3)C4=NCCS4)=C(N2C1=O)C(O)=O	PLASMA	Q2TWQ1I31U									?	ng × h/mL	3738		ng/mL	1209			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31262768/	Homo sapiens				12-h release tablets			6	TBPM-HBr		false
6859	7527		ADULT	9800194	383.486	TEBIPENEM	Tebipenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN(C3)C4=NCCS4)=C(N2C1=O)C(O)=O	PLASMA	Q2TWQ1I31U									∞	ng × h/mL	5192		ng/mL	1944			UNKNOWN	mg	600		SINGLE	FASTED				n=8 for AUC and t1/2		HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31262768/	Homo sapiens		h	3.8	12-h release tablets			9	TBPM-HBr		false
6860	7527		ADULT	9800194	383.486	TEBIPENEM	Tebipenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN(C3)C4=NCCS4)=C(N2C1=O)C(O)=O	PLASMA	Q2TWQ1I31U									∞	ng × h/mL	10571		ng/mL	2943			UNKNOWN	mg	900		SINGLE	FASTED				n=5 for AUC and t1/2		HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31262768/	Homo sapiens		h	2.5	12-h release tablets			6	TBPM-HBr		false
6861	7527		ADULT	9800194	383.486	TEBIPENEM	Tebipenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN(C3)C4=NCCS4)=C(N2C1=O)C(O)=O	PLASMA	Q2TWQ1I31U							8		t	ng × h/mL	7484		ng/mL	6493			UNKNOWN	mg	300		MULTIPLE	FASTED		day	3			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31262768/	Homo sapiens		h	0.72	Day 14, Immediate-release tablets			6	TBPM-HBr		false
6862	7527		ADULT	9800194	383.486	TEBIPENEM	Tebipenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN(C3)C4=NCCS4)=C(N2C1=O)C(O)=O	PLASMA	Q2TWQ1I31U									∞	ng × h/mL	7268		ng/mL	4062			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31262768/	Homo sapiens		h	0.8	2-h release tablets			6	TBPM-HBr		false
6863	7527		ADULT	9800194	383.486	TEBIPENEM	Tebipenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN(C3)C4=NCCS4)=C(N2C1=O)C(O)=O	PLASMA	Q2TWQ1I31U							8		t	ng × h/mL	17924		ng/mL	15090			UNKNOWN	mg	600		MULTIPLE	FASTED		day	3			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31262768/	Homo sapiens		h	0.83	Day 14, Immediate-release tablets			6	TBPM-HBr		false
6864	7527		ADULT	9800194	383.486	TEBIPENEM	Tebipenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN(C3)C4=NCCS4)=C(N2C1=O)C(O)=O	PLASMA	Q2TWQ1I31U									∞	ng × h/mL	6267		ng/mL	3064			UNKNOWN	mg	300		SINGLE	FASTED				n=5 for AUC and t1/2		HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31262768/	Homo sapiens		h	0.8	4-h release tablets			6	TBPM-HBr		false
6865	7527		ADULT	9800194	383.486	TEBIPENEM	Tebipenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN(C3)C4=NCCS4)=C(N2C1=O)C(O)=O	PLASMA	Q2TWQ1I31U									∞	ng × h/mL	13602		ng/mL	6216			UNKNOWN	mg	600		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31262768/	Homo sapiens		h	1	4-h release tablets			6	TBPM-HBr		false
6866	7527		ADULT	9800194	383.486	TEBIPENEM	Tebipenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN(C3)C4=NCCS4)=C(N2C1=O)C(O)=O	PLASMA	Q2TWQ1I31U									∞	ng × h/mL	2875		ng/mL	2893			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31262768/	Homo sapiens		h	0.9	Immediate-release tablets			6	TBPM-HBr		false
6867	7527		ADULT	9800194	383.486	TEBIPENEM	Tebipenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN(C3)C4=NCCS4)=C(N2C1=O)C(O)=O	PLASMA	Q2TWQ1I31U									∞	ng × h/mL	4456		ng/mL	1810			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31262768/	Homo sapiens		h	1.2	6-h release tablets			6	TBPM-HBr		false
6868	7527		ADULT	9800194	383.486	TEBIPENEM	Tebipenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN(C3)C4=NCCS4)=C(N2C1=O)C(O)=O	PLASMA	Q2TWQ1I31U									∞	ng × h/mL	6488		ng/mL	4006			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31262768/	Homo sapiens		h	0.8	Immediate-release tablets			6	TBPM-HBr		false
6869	7527		ADULT	9800194	383.486	TEBIPENEM	Tebipenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN(C3)C4=NCCS4)=C(N2C1=O)C(O)=O	PLASMA	Q2TWQ1I31U									∞	ng × h/mL	12715		ng/mL	6203			UNKNOWN	mg	600		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31262768/	Homo sapiens		h	1.1	Immediate-release tablets			6	TBPM-HBr		false
6870	7527		ADULT	9800194	383.486	TEBIPENEM	Tebipenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN(C3)C4=NCCS4)=C(N2C1=O)C(O)=O	PLASMA	Q2TWQ1I31U									∞	ng × h/mL	21913		ng/mL	12652			UNKNOWN	mg	900		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31262768/	Homo sapiens		h	1	Immediate-release tablets			6	TBPM-HBr		false
6871	7527		ADULT	9800194	383.486	TEBIPENEM	Tebipenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN(C3)C4=NCCS4)=C(N2C1=O)C(O)=O	PLASMA	Q2TWQ1I31U									?	ng × h/mL	7175		ng/mL	1892			UNKNOWN	mg	300		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31262768/	Homo sapiens				12-h release tablets			6	TBPM-HBr		false
6872	7527		ADULT	9800194	383.486	TEBIPENEM	Tebipenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN(C3)C4=NCCS4)=C(N2C1=O)C(O)=O	PLASMA	Q2TWQ1I31U									∞	ng × h/mL	14727		ng/mL	3014			UNKNOWN	mg	600		SINGLE	FED				n=3 for AUC and t1/2		HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31262768/	Homo sapiens		h	1.3	12-h release tablets			6	TBPM-HBr		false
6873	7527		ADULT	9800194	383.486	TEBIPENEM	Tebipenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN(C3)C4=NCCS4)=C(N2C1=O)C(O)=O	PLASMA	Q2TWQ1I31U									∞	ng × h/mL	6407.34		ng/mL	6087.5			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/34326771/	Homo sapiens		h	0.84	Granules			12	Tebipenem pivoxil		false
6874	7527		ADULT	9800194	383.486	TEBIPENEM	Tebipenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN(C3)C4=NCCS4)=C(N2C1=O)C(O)=O	PLASMA	Q2TWQ1I31U									∞	ng × h/mL	12517.7		ng/mL	11099.17			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/34326771/	Homo sapiens		h	0.76	Granules			12	Tebipenem pivoxil		false
6875	7527		ADULT	9800194	383.486	TEBIPENEM	Tebipenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN(C3)C4=NCCS4)=C(N2C1=O)C(O)=O	PLASMA	Q2TWQ1I31U									∞	ng × h/mL	23126.57		ng/mL	17825			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/34326771/	Homo sapiens		h	0.92	Granules			12	Tebipenem pivoxil		false
6876	7527		ADULT	9800194	383.486	TEBIPENEM	Tebipenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN(C3)C4=NCCS4)=C(N2C1=O)C(O)=O	PLASMA	Q2TWQ1I31U									∞	μg × h/mL	12.29		μg/mL	9.85			UNKNOWN	mg	250		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2009/P200900019/78000900_22100AMX00643_A100_1.pdf#page=45 | https://www.pmda.go.jp/drugs/2009/P200900019/78000900_22100AMX00643_K101_1.pdf#page=24	Homo sapiens		h	0.88		Normal renal function, CLcr >=80 mL/min		6	TBPM-PI tablets		false
6877	7527		ADULT	9800194	383.486	TEBIPENEM	Tebipenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN(C3)C4=NCCS4)=C(N2C1=O)C(O)=O	PLASMA	Q2TWQ1I31U									∞	μg × h/mL	16.45		μg/mL	7.17			UNKNOWN	mg	250		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2009/P200900019/78000900_22100AMX00643_A100_1.pdf#page=45 | https://www.pmda.go.jp/drugs/2009/P200900019/78000900_22100AMX00643_K101_1.pdf#page=24	Homo sapiens		h	1.49		Mild renal impairment, 80> CLcr >=50 mL/min		6	TBPM-PI tablets		false
6878	7527		ADULT	9800194	383.486	TEBIPENEM	Tebipenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN(C3)C4=NCCS4)=C(N2C1=O)C(O)=O	PLASMA	Q2TWQ1I31U									∞	μg × h/mL	29.22		μg/mL	13.26			UNKNOWN	mg	250		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2009/P200900019/78000900_22100AMX00643_A100_1.pdf#page=45 | https://www.pmda.go.jp/drugs/2009/P200900019/78000900_22100AMX00643_K101_1.pdf#page=24	Homo sapiens		h	1.44		Moderate renal impairment, 50> CLcr >=30 mL/min		2	TBPM-PI tablets		false
6879	7527		ADULT	9800194	383.486	TEBIPENEM	Tebipenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN(C3)C4=NCCS4)=C(N2C1=O)C(O)=O	PLASMA	Q2TWQ1I31U									∞	μg × h/mL	92.59		μg/mL	13.88			UNKNOWN	mg	250		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2009/P200900019/78000900_22100AMX00643_A100_1.pdf#page=45 | https://www.pmda.go.jp/drugs/2009/P200900019/78000900_22100AMX00643_K101_1.pdf#page=24	Homo sapiens		h	4.11		Severe renal impairment, CLcr <30 mL/min		3	TBPM-PI tablets		false
6880	7555			176077	163.1717	MIGALASTAT	MIGALASTAT	OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O	PLASMA	C4XNY919FW							10		t	ng × h/mL	8941.6							mg	150		SINGLE							UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00304512	Homo sapiens										false
6881	7555			176077	163.1717	MIGALASTAT	MIGALASTAT	OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O	PLASMA	C4XNY919FW							10		t	ng × h/mL	13217.2							mg	250		SINGLE							UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00304512	Homo sapiens										false
6882	7555			176077	163.1717	MIGALASTAT	MIGALASTAT	OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O	PLASMA	C4XNY919FW							10		t	ng × h/mL	2628.9							mg	50		SINGLE							UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00304512	Homo sapiens										false
6883	7555			176077	163.1717	MIGALASTAT	MIGALASTAT	OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O	PLASMA	C4XNY919FW							10		t	ng × h/mL	10637.9							mg	150		STEADY-STATE			2 days	1			UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00304512	Homo sapiens										false
6884	7555			176077	163.1717	MIGALASTAT	MIGALASTAT	OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O	PLASMA	C4XNY919FW							10		t	ng × h/mL	8581.9							mg	150		STEADY-STATE			2 days	1			UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00304512	Homo sapiens										false
6885	7555			176077	163.1717	MIGALASTAT	MIGALASTAT	OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O	PLASMA	C4XNY919FW							10		t	ng × h/mL	14850.6							mg	250		STEADY-STATE			2 days	1			UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00304512	Homo sapiens										false
6886	7555			176077	163.1717	MIGALASTAT	MIGALASTAT	OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O	PLASMA	C4XNY919FW							10		t	ng × h/mL	9970.3							mg	250		STEADY-STATE			2 days	1			UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00304512	Homo sapiens										false
6887	7555			176077	163.1717	MIGALASTAT	MIGALASTAT	OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O	PLASMA	C4XNY919FW							10		t	ng × h/mL	3191.6							mg	50		STEADY-STATE			2 days	1			UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00304512	Homo sapiens										false
6888	7555			176077	163.1717	MIGALASTAT	MIGALASTAT	OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O	PLASMA	C4XNY919FW							10		t	ng × h/mL	2300.3							mg	50		STEADY-STATE			2 days	1			UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00304512	Homo sapiens										false
6889	7555		ADULT	176077	163.1717	MIGALASTAT	MIGALASTAT	OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O	PLASMA	C4XNY919FW							12		t	ng × h/mL	10638		ng/mL	2029			RECOMMENDED	mg	150		STEADY-STATE	FASTED		2 days	1	Migalastat, in concentration range of 1 to uM, does not bind to human plasma protein.	100	UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208623Orig1s000MultidisciplineR.pdf	Homo sapiens										false
6890	7555		ADULT	176077	163.1717	MIGALASTAT	migalastat	OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O	PLASMA	C4XNY919FW									∞	ng × h/mL	9805		ng/mL	1561			RECOMMENDED	mg	150		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208623Orig1s000MultidisciplineR.pdf	Homo sapiens		h	3.9							false
6891	7555		ADULT	176077	163.1717	MIGALASTAT	migalastat	OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O	PLASMA	C4XNY919FW									∞	ng × h/mL	6132		ng/mL	1323			RECOMMENDED	mg	150		SINGLE	HIGH-FAT						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208623Orig1s000MultidisciplineR.pdf	Homo sapiens		h	4.9							false
6892	7625		UNKNOWN	6212	119.378	CHLOROFORM	chloroform	ClC(Cl)Cl	BLOOD	7V31YC746X									∞	μg × min/mL	293						UNKNOWN	mg	500		SINGLE	UNKNOWN						UNKNOWN	Oral	MALE	OTHER	https://link.springer.com/article/10.1007/BF01067908	Homo sapiens		min	96							false
6893	7625		UNKNOWN	6212	119.378	CHLOROFORM	chloroform	ClC(Cl)Cl	BLOOD	7V31YC746X									∞	μg × min/mL	176						UNKNOWN	mg	500		SINGLE	UNKNOWN						UNKNOWN	Oral	FEMALE	OTHER	https://link.springer.com/article/10.1007/BF01067908	Homo sapiens		min	86							false
6894	7666		ADULT	91536	259.3434	LEVOPROPRANOLOL	LEVOPROPRANOLOL	CC(C)NC[C@H](O)COC1=C2C=CC=CC2=CC=C1	PLASMA	74MLR03FLC							12		t	ng × h/mL	273.6		ng/mL	74.6			UNKNOWN	mg	40		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2642031/	Homo sapiens		h	4.39	(S)-propranolol HCl			8	PROPRANOLOL HYDROCHLORIDE, (-)-		false
6895	7666		ADULT	91536	259.3434	LEVOPROPRANOLOL	LEVOPROPRANOLOL	CC(C)NC[C@H](O)COC1=C2C=CC=CC2=CC=C1	PLASMA	74MLR03FLC									∞	ng × h/mL	66		ng/mL	134			UNKNOWN	mg	20		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7696378/	Homo sapiens		h	2.9	(S)-propranolol HCl			10	PROPRANOLOL HYDROCHLORIDE, (-)-		false
6896	7666		ADULT	91536	259.3434	LEVOPROPRANOLOL	LEVOPROPRANOLOL	CC(C)NC[C@H](O)COC1=C2C=CC=CC2=CC=C1	PLASMA	74MLR03FLC									∞	ng × h/mL	98		ng/mL	25			UNKNOWN	mg	20		STEADY-STATE	UNKNOWN		day	3			HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7696378/	Homo sapiens		h	3.8	(S)-propranolol HCl			10	PROPRANOLOL HYDROCHLORIDE, (-)-		false
6897	7817		ADULT		126.97	SELENITE ION			PLASMA										∞	μM × h	200		μM	9.5			UNKNOWN	mg/m²	4.5		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26102212/	Homo sapiens		h	18.25							false
6898	7850			10178705	393.84	BESIFLOXACIN	BESIFLOXACIN	N[C@@H]1CCCCN(C1)C2=C(F)C=C3C(=O)C(=CN(C4CC4)C3=C2Cl)C(O)=O	AQUEOUS HUMOR	BFE2NBZ7NX													ng/mL	56.4525				drop	1		MULTIPLE			day	4			UNHEALTHY	Ocular		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01296191	Homo sapiens										false
6899	7850		ADULT		393.84	Besifloxacin			CORNEA								24		t	μg × h/mL	1.232		μg/g	610			RECOMMENDED	drop	1		MULTIPLE	UNKNOWN		day	4			UNKNOWN	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19492955/	Homo sapiens		h	3.4							false
6900	7850		ADULT		393.84	Besifloxacin			PLASMA														ng/mL	0.37			RECOMMENDED	drop	1		SINGLE	UNKNOWN						UNHEALTHY	Ocular	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022308s013lbl.pdf	Homo sapiens		h	7							false
6901	7852		CHILD	644241	529.5158	NILOTINIB	NILOTINIB	CC1=CN(C=N1)C2=CC(=CC(NC(=O)C3=CC(NC4=NC(=CC=N4)C5=CN=CC=C5)=C(C)C=C3)=C2)C(F)(F)F	PLASMA	F41401512X													ng/mL	405.111				mg/m²	230		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01077544	Homo sapiens										false
6902	7852		CHILD	644241	529.5158	NILOTINIB	NILOTINIB	CC1=CN(C=N1)C2=CC(=CC(NC(=O)C3=CC(NC4=NC(=CC=N4)C5=CN=CC=C5)=C(C)C=C3)=C2)C(F)(F)F	PLASMA	F41401512X							24		t	ng × h/mL	4160.969							mg/m²	230		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01077544	Homo sapiens										false
6903	7852		CHILD	644241	529.5158	NILOTINIB	NILOTINIB	CC1=CN(C=N1)C2=CC(=CC(NC(=O)C3=CC(NC4=NC(=CC=N4)C5=CN=CC=C5)=C(C)C=C3)=C2)C(F)(F)F	PLASMA	F41401512X							12		t	ng × h/mL	2795.782							mg/m²	230		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01077544	Homo sapiens										false
6904	7852		CHILD	644241	529.5158	NILOTINIB	NILOTINIB	CC1=CN(C=N1)C2=CC(=CC(NC(=O)C3=CC(NC4=NC(=CC=N4)C5=CN=CC=C5)=C(C)C=C3)=C2)C(F)(F)F	PLASMA	F41401512X													ng/mL	402.715				mg/m²	230		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01077544	Homo sapiens										false
6905	7852		CHILD	644241	529.5158	NILOTINIB	NILOTINIB	CC1=CN(C=N1)C2=CC(=CC(NC(=O)C3=CC(NC4=NC(=CC=N4)C5=CN=CC=C5)=C(C)C=C3)=C2)C(F)(F)F	PLASMA	F41401512X							24		t	ng × h/mL	5707.368							mg/m²	230		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01077544	Homo sapiens										false
6906	7852		CHILD	644241	529.5158	NILOTINIB	NILOTINIB	CC1=CN(C=N1)C2=CC(=CC(NC(=O)C3=CC(NC4=NC(=CC=N4)C5=CN=CC=C5)=C(C)C=C3)=C2)C(F)(F)F	PLASMA	F41401512X							12		t	ng × h/mL	3393.296							mg/m²	230		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01077544	Homo sapiens										false
6907	7852		CHILD	644241	529.5158	NILOTINIB	NILOTINIB	CC1=CN(C=N1)C2=CC(=CC(NC(=O)C3=CC(NC4=NC(=CC=N4)C5=CN=CC=C5)=C(C)C=C3)=C2)C(F)(F)F	PLASMA	F41401512X							12		t	ng × h/mL	15129.182							mg/m²	230		STEADY-STATE			day	2			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01077544	Homo sapiens										false
6908	7852		CHILD	644241	529.5158	NILOTINIB	NILOTINIB	CC1=CN(C=N1)C2=CC(=CC(NC(=O)C3=CC(NC4=NC(=CC=N4)C5=CN=CC=C5)=C(C)C=C3)=C2)C(F)(F)F	PLASMA	F41401512X							12		t	ng × h/mL	14383.076							mg/m²	230		STEADY-STATE			day	2			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01077544	Homo sapiens										false
6909	7852		ADULT	644241	529.5158	NILOTINIB	NILOTINIB	CC1=CN(C=N1)C2=CC(=CC(NC(=O)C3=CC(NC4=NC(=CC=N4)C5=CN=CC=C5)=C(C)C=C3)=C2)C(F)(F)F	SERUM	F41401512X							12		t	ng × h/mL	12700		ng/mL	1550			RECOMMENDED	mg	400		STEADY-STATE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19924121	Homo sapiens										false
6910	7852		ADULT	644241	529.5158	NILOTINIB	NILOTINIB	CC1=CN(C=N1)C2=CC(=CC(NC(=O)C3=CC(NC4=NC(=CC=N4)C5=CN=CC=C5)=C(C)C=C3)=C2)C(F)(F)F	SERUM	F41401512X							12		t	ng × h/mL	18200		ng/mL	2300			RECOMMENDED	mg	400		STEADY-STATE	HIGH-FAT		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19924121	Homo sapiens										false
6911	7852		ADULT	644241	529.5158	NILOTINIB	NILOTINIB	CC1=CN(C=N1)C2=CC(=CC(NC(=O)C3=CC(NC4=NC(=CC=N4)C5=CN=CC=C5)=C(C)C=C3)=C2)C(F)(F)F	SERUM	F41401512X							12		t	ng × h/mL	24500		ng/mL	3320			UNKNOWN	mg	600		STEADY-STATE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19924121	Homo sapiens										false
6912	7852		ADULT	644241	529.5158	NILOTINIB	NILOTINIB	CC1=CN(C=N1)C2=CC(=CC(NC(=O)C3=CC(NC4=NC(=CC=N4)C5=CN=CC=C5)=C(C)C=C3)=C2)C(F)(F)F	SERUM	F41401512X							12		t	ng × h/mL	43100		ng/mL	6010			UNKNOWN	mg	600		STEADY-STATE	HIGH-FAT		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19924121	Homo sapiens										false
6913	7852		ADULT	644241	529.5158	NILOTINIB	NILOTINIB	CC1=CN(C=N1)C2=CC(=CC(NC(=O)C3=CC(NC4=NC(=CC=N4)C5=CN=CC=C5)=C(C)C=C3)=C2)C(F)(F)F	SERUM	F41401512X							24		t	ng × h/mL	4480		ng/mL	403			UNKNOWN	mg	50		STEADY-STATE	UNKNOWN		day	1	The extent of nilotinib binding to human plasma is high (98% on average).	2	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022068s000_ClinPharmR.pdf	Homo sapiens										false
6914	7852		ADULT	644241	529.5158	NILOTINIB	NILOTINIB	CC1=CN(C=N1)C2=CC(=CC(NC(=O)C3=CC(NC4=NC(=CC=N4)C5=CN=CC=C5)=C(C)C=C3)=C2)C(F)(F)F	SERUM	F41401512X							24		t	ng × h/mL	26600		ng/mL	2190			UNKNOWN	mg	800		STEADY-STATE	UNKNOWN		day	1	The extent of nilotinib binding to human plasma is high (98% on average).	2	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022068s000_ClinPharmR.pdf	Homo sapiens										false
6915	7852		ADULT	644241	529.5158	NILOTINIB	NILOTINIB	CC1=CN(C=N1)C2=CC(=CC(NC(=O)C3=CC(NC4=NC(=CC=N4)C5=CN=CC=C5)=C(C)C=C3)=C2)C(F)(F)F	SERUM	F41401512X							24		t	ng × h/mL	28000		ng/mL	2490			UNKNOWN	mg	1200		STEADY-STATE	UNKNOWN		day	1	The extent of nilotinib binding to human plasma is high (98% on average).	2	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022068s000_ClinPharmR.pdf	Homo sapiens										false
6916	7852		UNKNOWN	644241	529.5158	NILOTINIB	NILOTINIB	CC1=CN(C=N1)C2=CC(=CC(NC(=O)C3=CC(NC4=NC(=CC=N4)C5=CN=CC=C5)=C(C)C=C3)=C2)C(F)(F)F	PLASMA	F41401512X																						UNKNOWN				The average nilotinib plasma protein binding was 97.4%, 99.1%, 98.2%, 99.0% and 98.4% in the mouse, rat, dog, monkey and human, respectively.	1.6	UNKNOWN		UNKNOWN	OTHER GOV'T	https://www.ema.europa.eu/en/documents/scientific-discussion/tasigna-epar-scientific-discussion_en.pdf	Homo sapiens										false
6917	7852		UNKNOWN	644241	529.5158	NILOTINIB	NILOTINIB	CC1=CN(C=N1)C2=CC(=CC(NC(=O)C3=CC(NC4=NC(=CC=N4)C5=CN=CC=C5)=C(C)C=C3)=C2)C(F)(F)F	PLASMA	F41401512X							12		t	ng × h/mL	11865		ng/mL	1360			UNKNOWN	mg	300		STEADY-STATE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/30179260	Homo sapiens										false
6918	7852		UNKNOWN	644241	529.5158	NILOTINIB	NILOTINIB	CC1=CN(C=N1)C2=CC(=CC(NC(=O)C3=CC(NC4=NC(=CC=N4)C5=CN=CC=C5)=C(C)C=C3)=C2)C(F)(F)F	PLASMA	F41401512X							12		t	ng × h/mL	13656		ng/mL	1595			UNKNOWN	mg	400		STEADY-STATE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/30179260	Homo sapiens										false
6919	7853			54671008	444.4163	RALTEGRAVIR	RALTEGRAVIR	CN1C(=O)C(O)=C(N=C1C(C)(C)NC(=O)C2=NN=C(C)O2)C(=O)NCC3=CC=C(F)C=C3	PLASMA	22VKV8053U							84		t	ng × h/mL	4070		ng/mL	1300				mg	400		STEADY-STATE			day	2				Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01785160	Homo sapiens										false
6920	7853		ADULT	54671008	444.4163	RALTEGRAVIR	RALTEGRAVIR	CN1C(=O)C(O)=C(N=C1C(C)(C)NC(=O)C2=NN=C(C)O2)C(=O)NCC3=CC=C(F)C=C3	PLASMA	22VKV8053U													ng/mL	830.204			UNKNOWN	mg	400		MULTIPLE	FED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT03537404	Homo sapiens										false
6921	7853			54671008	444.4163	RALTEGRAVIR	RALTEGRAVIR	CN1C(=O)C(O)=C(N=C1C(C)(C)NC(=O)C2=NN=C(C)O2)C(=O)NCC3=CC=C(F)C=C3	PLASMA	22VKV8053U													nM	20163				mg	1200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT03667547	Homo sapiens		h	7.5							false
6922	7853		ADULT	54671008	444.4163	RALTEGRAVIR	RALTEGRAVIR	CN1C(=O)C(O)=C(N=C1C(C)(C)NC(=O)C2=NN=C(C)O2)C(=O)NCC3=CC=C(F)C=C3	PLASMA	22VKV8053U							12		t	μM × h	14.3		nM	142			RECOMMENDED	mg	400		MULTIPLE	UNKNOWN		day	2	Raltegravir is approximately 83% bound to human plasma protein over the concentration range of 2 to 10 µM.	17	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022145lbl.pdf	Homo sapiens		h	9							false
6923	7855		UNKNOWN	2585	406.4742	CARVEDILOL	CARVEDILOL	COC1=C(OCCNCC(O)COC2=CC=CC3=C2C4=C(N3)C=CC=C4)C=CC=C1	PLASMA								12		t	ng × h/mL	139		ng/mL	26.5			INVESTIGATIONAL	mg	6.25		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10934668	Homo sapiens										false
6924	7855		ADULT	185394	406.4742	CARVEDILOL, (+)-	(R)-Carvedilol	COC1=C(OCCNC[C@@H](O)COC2=C3C(NC4=C3C=CC=C4)=CC=C2)C=CC=C1	PLASMA	N6E193E020							12		t	ng × h/mL	94.3		ng/mL	18.4			INVESTIGATIONAL	mg	6.25		STEADY-STATE	FASTED		day	2			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10934668	Homo sapiens										false
6925	7855		ADULT	185395	406.4742	CARVEDILOL, (-)-	(S)-Carvedilol	COC1=C(OCCNC[C@H](O)COC2=C3C(NC4=C3C=CC=C4)=CC=C2)C=CC=C1	PLASMA	GW13D96IND							12		t	ng × h/mL	42.2		ng/mL	8.46			INVESTIGATIONAL	mg	6.25		STEADY-STATE	FASTED		day	2			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10934668	Homo sapiens										false
6926	7856		ADULT	123600	239.3107	LEVALBUTEROL	LEVALBUTEROL	CC(C)(C)NC[C@H](O)C1=CC(CO)=C(O)C=C1	PLASMA	EDN2NBH5SS									?	ng × h/mL	3.3		ng/mL	1.1			RECOMMENDED	mg	1.25		SINGLE	UNKNOWN						HEALTHY	Respiratory	UNKNOWN	DRUG LABEL	https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f3ce78d9-e923-400e-b3cd-3e6124ac7f6d&type=display	Homo sapiens		h	3.3							false
6927	7856		ADULT	123600	239.3107	LEVALBUTEROL	LEVALBUTEROL	CC(C)(C)NC[C@H](O)C1=CC(CO)=C(O)C=C1	PLASMA	EDN2NBH5SS									?	ng × h/mL	17.4		ng/mL	4.5			UNKNOWN	mg	1.25		MULTIPLE	UNKNOWN		2 hours	4			HEALTHY	Respiratory	UNKNOWN	DRUG LABEL	https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f3ce78d9-e923-400e-b3cd-3e6124ac7f6d&type=display	Homo sapiens		h	4							false
6928	7856		CHILD	123600	239.3107	LEVALBUTEROL	LEVALBUTEROL	CC(C)(C)NC[C@H](O)C1=CC(CO)=C(O)C=C1	PLASMA	EDN2NBH5SS									∞	ng × h/mL	1.36		ng/mL	0.303			RECOMMENDED	mg	0.31		SINGLE	UNKNOWN						UNHEALTHY	Respiratory	UNKNOWN	DRUG LABEL	https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f3ce78d9-e923-400e-b3cd-3e6124ac7f6d&type=display	Homo sapiens										false
6929	7856		CHILD	123600	239.3107	LEVALBUTEROL	LEVALBUTEROL	CC(C)(C)NC[C@H](O)C1=CC(CO)=C(O)C=C1	PLASMA	EDN2NBH5SS									∞	ng × h/mL	2.55		ng/mL	0.521			RECOMMENDED	mg	0.63		SINGLE	UNKNOWN						UNHEALTHY	Respiratory	UNKNOWN	DRUG LABEL	https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f3ce78d9-e923-400e-b3cd-3e6124ac7f6d&type=display	Homo sapiens										false
6930	7856		ADULT	123600	239.3107	LEVALBUTEROL	LEVALBUTEROL	CC(C)(C)NC[C@H](O)C1=CC(CO)=C(O)C=C1	PLASMA	EDN2NBH5SS							6		t	pg × h/mL	695		pg/mL	199			RECOMMENDED	μg	90		SINGLE	UNKNOWN						UNHEALTHY	Respiratory	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021730s039lbl.pdf	Homo sapiens										false
6931	7856		ADULT	123600	239.3107	LEVALBUTEROL	LEVALBUTEROL	CC(C)(C)NC[C@H](O)C1=CC(CO)=C(O)C=C1	PLASMA	EDN2NBH5SS							6		t	pg × h/mL	798		pg/mL	238			UNKNOWN	μg	180		SINGLE	UNKNOWN						UNHEALTHY	Respiratory	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021730s039lbl.pdf	Homo sapiens										false
6932	7856		CHILD	123600	239.3107	LEVALBUTEROL	LEVALBUTEROL	CC(C)(C)NC[C@H](O)C1=CC(CO)=C(O)C=C1	PLASMA	EDN2NBH5SS							6		t	pg × h/mL	579		pg/mL	163			RECOMMENDED	μg	90		SINGLE	UNKNOWN						UNHEALTHY	Respiratory	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021730s039lbl.pdf	Homo sapiens										false
6933	7856		CHILD	123600	239.3107	LEVALBUTEROL	LEVALBUTEROL	CC(C)(C)NC[C@H](O)C1=CC(CO)=C(O)C=C1	PLASMA	EDN2NBH5SS							6		t	pg × h/mL	828		pg/mL	238			UNKNOWN	μg	180		SINGLE	UNKNOWN						UNHEALTHY	Respiratory	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021730s039lbl.pdf	Homo sapiens										false
6934	7856		UNKNOWN	123600	239.3107	LEVALBUTEROL	LEVALBUTEROL	CC(C)(C)NC[C@H](O)C1=CC(CO)=C(O)C=C1	PLASMA	EDN2NBH5SS																						UNKNOWN				in vitro the binding of R-Albuterol to plasma proteins was low (5.4-13.55%) (fresh human plasma)	90.55	UNKNOWN		UNKNOWN	REVIEW	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021730s000_PharmR.pdf	Homo sapiens										false
6935	7857		ADULT	247	117.1463	BETAINE	BETAINE	C[N+](C)(C)CC([O-])=O	PLASMA	3SCV180C9W									∞	mM × h	5.518		mM	0.939			UNKNOWN	mg/kg bw	50		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/12534635	Homo sapiens		h	14.38							false
6936	7857		ADULT	247	117.1463	BETAINE	BETAINE	C[N+](C)(C)CC([O-])=O	PLASMA	3SCV180C9W							24		t	mM × h	12.528		mM	1.456			UNKNOWN	mg/kg bw	50		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/12534635	Homo sapiens		h	41.17							false
6937	7860		ADULT	135409453	301.3867	TEGASEROD	TEGASEROD	CCCCCNC(=N)N\\N=C\\C1=CNC2=C1C=C(OC)C=C2	PLASMA	458VC51857									?	ng × h/mL	10.5		ng/mL	2.9			RECOMMENDED	mg	6		SINGLE	FASTED				Protein binding of tegaserod is approximately 98%.	2	UNHEALTHY	Oral	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021200Orig1s015lbl.pdf	Homo sapiens		h	6.35							false
6938	7863		ADULT	688523	211.2576	METHOXAMINE	METHOXAMINE	COC1=CC=C(OC)C(=C1)[C@@H](O)[C@H](C)N	PLASMA	HUQ1KC1YLI									∞	ng × h/mL	178.95		ng/mL	15.69			RECOMMENDED	mg	10		SINGLE	UNKNOWN						HEALTHY	Rectal	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24499494/	Homo sapiens		h	6.15							false
6939	7866		ADULT		1632.3	DEGARELIX			PLASMA								28		t	ng × day/mL	635		ng/mL	66			RECOMMENDED	mg	240		SINGLE	UNKNOWN				Estimated plasma protein binding is ~ 90%.	10	UNKNOWN	Subcutaneous	FEMALE / MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/26513436/	Homo sapiens		day	43							false
6940	7866		ADULT		1632.3	DEGARELIX			PLASMA										?	ng × day/mL	1054		ng/mL	26.2			RECOMMENDED	mg	240		SINGLE	UNKNOWN				In vitro plasma protein binding of degarelix isestimated to be approximately 90%.	10	UNHEALTHY	Subcutaneous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022201s016lbl.pdf	Homo sapiens		day	53							false
6941	7868		ADULT		341.49	5-hydroxymethyl tolterodine			PLASMA														ng/mL	1.89			RECOMMENDED	mg	4		SINGLE	UNKNOWN				Plasma protein binding of the active metabolite is low (approximately 50%) and is primarily bound to albumin and alpha-1-acid glycoprotein.	50	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022030s014lbl.pdf	Homo sapiens		h	7.31							false
6942	7869		ADULT	3406	82.1	FOMEPIZOLE	FOMEPIZOLE	CC1=CNN=C1	PLASMA	83LCM6L2BY													μg/mL	18.5			UNKNOWN	mg/kg	10		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/15167624	Homo sapiens		h	14.5							false
6943	7870		ADULT	5282448	1508.263	FONDAPARINUX	FONDAPARINUX	CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]5NS(O)(=O)=O)[C@H](O)[C@H]4O)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3NS(O)(=O)=O)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O	PLASMA	J177FOW5JL							24		t	mg × h/L	19.6		mg/L	1.46			RECOMMENDED	mg	10		SINGLE	UNKNOWN						HEALTHY	Subcutaneous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12383043	Homo sapiens										false
6944	7870		ADULT	5282448	1508.263	FONDAPARINUX	FONDAPARINUX	CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]5NS(O)(=O)=O)[C@H](O)[C@H]4O)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3NS(O)(=O)=O)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O	PLASMA	J177FOW5JL							24		t	mg × h/L	20.66		mg/L	1.52			RECOMMENDED	mg	10		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Subcutaneous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12383043	Homo sapiens										false
6945	7870		ADULT	5282448	1508.263	FONDAPARINUX	FONDAPARINUX	CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]5NS(O)(=O)=O)[C@H](O)[C@H]4O)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3NS(O)(=O)=O)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O	PLASMA	J177FOW5JL													mg/L	0.34			DEFINED DAILY	mg	2.5		SINGLE	UNKNOWN				In vitro, fondaparinux sodium is highly (at least 94%) and specifically bound to antithrombin III (ATIII) and does not bind significantly to other plasma proteins (including platelet Factor 4 [PF4]) or red blood cells.	6	UNKNOWN	Subcutaneous	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021345s019lbl.pdf	Homo sapiens		h	19							false
6946	7870		ADULT	5282448	1508.263	FONDAPARINUX	FONDAPARINUX	CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]5NS(O)(=O)=O)[C@H](O)[C@H]4O)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3NS(O)(=O)=O)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O	PLASMA	J177FOW5JL													mg/L	0.445			DEFINED DAILY	mg	2.5		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Subcutaneous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021345s019lbl.pdf	Homo sapiens										false
6947	7871		ADULT	3083544	344.4049	FORMOTEROL	FORMOTEROL	COC1=CC=C(C[C@@H](C)NC[C@H](O)C2=CC=C(O)C(NC=O)=C2)C=C1	PLASMA	5ZZ84GCW8B	62965		BECLOMETHASONE 17-MONOPROPIONATE	Beclomethasone 17-monopropionate	CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C)C(=O)CO	5BGA9FD55H			∞	pg × h/mL	104.52		pg/mL	26.65			UNKNOWN	μg	24		SINGLE	FASTED						UNHEALTHY	Respiratory	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24746942	Homo sapiens		h	4.71							true
6948	7871		UNKNOWN	3083544	344.4049	FORMOTEROL	FORMOTEROL	COC1=CC=C(C[C@@H](C)NC[C@H](O)C2=CC=C(O)C(NC=O)=C2)C=C1	PLASMA	5ZZ84GCW8B																						UNKNOWN				The binding of formoterol to human plasma proteins in vitro was 61% to 64% at concentrations from 0.1 to 100 ng/mL.	37.5	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022007s004lbl.pdf	Homo sapiens										false
6949	7872		ADULT		614.4	FOSAPREPITANT			PLASMA										∞	ng × h/mL	44578						UNKNOWN	mg	100		SINGLE	FASTED				Aprepitant is greater than 95% bound to plasma proteins. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022023s019lbl.pdf	5	HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17525168/	Homo sapiens		min	2.2							false
6950	7873		ADULT	16130957|16134406	1570.319	GANIRELIX	GANIRELIX	CCNC(NCC)=NCCCC[C@@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC2=CN=CC=C2)NC(=O)[C@@H](CC3=CC=C(Cl)C=C3)NC(=O)[C@@H](CC4=CC5=C(C=CC=C5)C=C4)NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N6CCC[C@H]6C(=O)N[C@H](C)C(N)=O	SERUM	IX503L9WN0									∞	ng × h/mL	96		ng/mL	14.8			DEFINED DAILY	μg	250		SINGLE	UNKNOWN				In vitro protein binding to human plasma is 81.9%	18.1	HEALTHY	Subcutaneous	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/21057lbl.pdf	Homo sapiens		h	12.8							false
6951	7873		ADULT	16130957|16134406	1570.319	GANIRELIX	GANIRELIX	CCNC(NCC)=NCCCC[C@@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC2=CN=CC=C2)NC(=O)[C@@H](CC3=CC=C(Cl)C=C3)NC(=O)[C@@H](CC4=CC5=C(C=CC=C5)C=C4)NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N6CCC[C@H]6C(=O)N[C@H](C)C(N)=O	SERUM	IX503L9WN0							24		t	ng × h/mL	77.1		ng/mL	11.2			DEFINED DAILY	μg	250		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Subcutaneous	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/21057lbl.pdf	Homo sapiens		h	16.2							false
6952	7874		ADULT	3657	76.055	HYDROXYUREA	HYDROXYUREA	NC(=O)NO	PLASMA	X6Q56QN5QC									∞	μM × h	3934		μM	793.75			UNKNOWN	mg	2000		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/9473217	Homo sapiens		h	3.32							false
6953	7875		ADULT	10271828	392.5	15-Hydroxy Lubiprostone		CCCCC(C(CCC1C(CC(=O)C1CCCCCCC(=O)O)O)O)(F)F	PLASMA										?	pg × h/mL	57.1		pg/mL	41.5			RECOMMENDED	μg	24		SINGLE	UNKNOWN					6	UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021908s010lbl.pdf	Homo sapiens		h	1.15							false
6954	7875		ADULT	53394016	392.4778	15-Hydroxy Lubiprostone	CCCCC(C(CCC1C(CC(=O)C1CCCCCCC(=O)O)O)O)(F)F	CCCCC(F)(F)C(O)CCC1C(O)CC(=O)C1CCCCCCC(O)=O	PLASMA										?	pg × h/mL	39.6		pg/mL	37.5			RECOMMENDED	μg	24		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021908s010lbl.pdf	Homo sapiens										false
6955	7876		ADULT		356.4	METHYLNALTREXONE			PLASMA								6		t	ng × h/mL	224		ng/mL	538			UNKNOWN	mg/kg	0.3		SINGLE	FED				The fraction of methylnaltrexone bound to human plasma proteins is 11% to 15%, as determined by equilibrium dialysis.[https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021964s019,208271s003lbl.pdf]	85	HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15831777/	Homo sapiens		h	2.5							false
6956	7878		ADULT	65015	502.8	PLERIXAFOR	PLERIXAFOR	C(N1CCCNCCNCCCNCC1)C2=CC=C(CN3CCCNCCNCCCNCC3)C=C2	PLASMA	S915P5499N									∞	ng × h/mL	5260		ng/mL	1029			RECOMMENDED	μg/kg bw	240		SINGLE	UNKNOWN						UNHEALTHY	Subcutaneous	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/19135941	Homo sapiens		h	5.6							false
6957	7879		UNKNOWN	148121	477.4726	PRALATREXATE	PRALATREXATE	NC1=NC(N)=C2N=C(CC(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=NC2=N1	PLASMA	A8Q8I19Q20																						UNKNOWN				In vitro studies indicate that pralatrexate is approximately 67% bound to plasma proteins.	33	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022468s009lbl.pdf	Homo sapiens										false
6958	7879		ADULT	148121	477.4726	PRALATREXATE	PRALATREXATE	NC1=NC(N)=C2N=C(CC(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=NC2=N1	PLASMA	A8Q8I19Q20	4911		PROBENECID	Probenecid	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	PO572Z7917			∞	μg × h/mL	4.9		μg/mL	4.9			UNKNOWN	mg/m²	40		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/16136310	Homo sapiens		h	1.8							true
6959	7880		ADULT	10405534	349.4	R-138727	Prasugrel metabolite		PLASMA										∞	ng × h/mL	163		ng/mL	163.2			DEFINED DAILY	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/27474356	Homo sapiens		h	4.2							false
6960	7880		ADULT	10405534	349.4	R-138727	Prasugrel metabolite		BLOOD										∞	ng × h/mL	178.8		ng/mL	153.3			UNKNOWN	mg	20		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/28417436	Homo sapiens		h	3.5							false
6961	7881		ADULT		315.4	SAXAGLIPTIN			PLASMA										?	ng × h/mL	78		ng/mL	24			RECOMMENDED	mg	5		SINGLE	UNKNOWN				The in vitro protein binding of saxagliptin and its active metabolite in human serum is negligible.	100	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022350lbl.pdf	Homo sapiens		h	2.5							false
6962	7882		ADULT	6918289	1030.3	TEMSIROLIMUS	TEMSIROLIMUS	CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OC(=O)C(C)(CO)CO	BLOOD	624KN6GM2T									∞	ng × h/mL	1627		ng/mL	585			RECOMMENDED	mg	25		SINGLE	UNKNOWN				Plasma protein binding is approximately 89%	11	UNHEALTHY	Intravenous	UNKNOWN	DRUG LABEL	http://secure.healthlinks.net.au/content/pf/retriever.cfm?product=pfptorii10613	Homo sapiens		h	17.3							false
6963	7883		ADULT	1990	75.0666	ACETOHYDROXAMIC ACID	ACETOHYDROXAMIC ACID	CC(=O)NO	PLASMA	4RZ82L2GY5													μg/mL	9			RECOMMENDED	mg	250		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3928387/	Homo sapiens		h	21.9							false
6964	7886		ADULT	16960	319.239	DEXBROMPHENIRAMINE	DEXBROMPHENIRAMINE	CN(C)CC[C@@H](C1=CC=C(Br)C=C1)C2=NC=CC=C2	PLASMA	75T64B71RP									?	ng × h/mL	234.2		ng/mL	27.98			UNKNOWN	mg	6		STEADY-STATE	FASTED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3981411/	Homo sapiens		h	22							false
6965	7888		ADULT	753	92.0938	GLYCERIN	GLYCErol	OCC(O)CO	SERUM	PDC6A3C0OX																	UNKNOWN	mmol/m²	120		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4300572/	Homo sapiens		min	39.3							false
6966	7888		ADULT	753	92.0938	GLYCERIN	GLYCErin	OCC(O)CO	SERUM	PDC6A3C0OX													mg/L	1770			UNKNOWN	g/kg	1.2		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8369006/	Homo sapiens		h	0.895							false
6967	7902		ADULT	444412|5287865|135398561	459.4558	LEVOMEFOLIC ACID	LEVOMEFOLIC ACID	CN1[C@@H](CNC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNC3=C1C(=O)N=C(N)N3	SERUM	8S95DH25XC							24		t	ng × h/mL	1563		ng/mL	340			UNKNOWN	mg	12.5		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8405015/	Homo sapiens										false
6968	7902		ADULT	444412|5287865|135398561	459.4558	LEVOMEFOLIC ACID	LEVOMEFOLIC ACID	CN1[C@@H](CNC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNC3=C1C(=O)N=C(N)N3	SERUM	8S95DH25XC													ng/mL	275			UNKNOWN	mg	15		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020140s002lbl.pdf	Homo sapiens		h	6.8							false
6969	7902		ADULT	149436|135398559	473.4393	LEVOLEUCOVORIN	LEVOLEUCOVORIN	NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1	SERUM	990S25980Y									∞	ng × h/mL	30719		ng/mL	10895			UNKNOWN	mg/m²	200		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020140s002lbl.pdf	Homo sapiens										false
6970	7902		ADULT	444412|5287865|135398561	459.4558	LEVOMEFOLIC ACID	LEVOMEFOLIC ACID	CN1[C@@H](CNC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNC3=C1C(=O)N=C(N)N3	SERUM	8S95DH25XC									∞	ng × h/mL	52105		ng/mL	4930			UNKNOWN	mg/m²	200		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020140s002lbl.pdf	Homo sapiens										false
6971	7904		ADULT	5310993	154.1234	ACIPIMOX	acipimox	CC1=[N ]([O-])C=C(N=C1)C(O)=O	PLASMA	K9AY9IR2SD							24		t	μg × h/mL	12.84		μg/mL	3.51			RECOMMENDED	mg	250		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19798634/	Homo sapiens		h	1.406	gelatin capsule			5	Free acid powder		false
6972	7904		ADULT	5310993	154.1234	ACIPIMOX	acipimox	CC1=[N ]([O-])C=C(N=C1)C(O)=O	PLASMA	K9AY9IR2SD							24		t	μg × h/mL	3.8		μg/mL	1.03			RECOMMENDED	mg	250		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19798634/	Homo sapiens		h	1.467	Enterion capsule			5	Free acid powder		false
6973	7904		ADULT	5310993	154.1234	ACIPIMOX	acipimox	CC1=[N ]([O-])C=C(N=C1)C(O)=O	PLASMA	K9AY9IR2SD							24		t	μg × h/mL	1.66		μg/mL	0.5			RECOMMENDED	mg	250		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19798634/	Homo sapiens		h	2.236	Enterion capsule			6	Free acid powder		false
6974	7904		ADULT	5310993	154.1234	ACIPIMOX	acipimox	CC1=[N ]([O-])C=C(N=C1)C(O)=O	PLASMA	K9AY9IR2SD							24		t	μg × h/mL	14.07		μg/mL	4.68			RECOMMENDED	mg	250		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19798634/	Homo sapiens		h	1.487	Immediate release capsule			6	Sodium salt		false
6975	7904		ADULT	5310993	154.1234	ACIPIMOX	acipimox	CC1=[N ]([O-])C=C(N=C1)C(O)=O	PLASMA	K9AY9IR2SD							24		t	μg × h/mL	1.77		μg/mL	0.43			RECOMMENDED	mg	250		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19798634/	Homo sapiens		h	1.348	Enterion capsule delivery to colon			6	Sodium salt		false
6976	7904		ADULT	5310993	154.1234	ACIPIMOX	acipimox	CC1=[N ]([O-])C=C(N=C1)C(O)=O	PLASMA	K9AY9IR2SD							24		t	μg × h/mL	7.32		μg/mL	2.31			RECOMMENDED	mg	250		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19798634/	Homo sapiens		h	1.468	Enterion capsule			5	Sodium salt		false
6977	7904		UNKNOWN	5310993	154.1234	ACIPIMOX	acipimox	CC1=[N ]([O-])C=C(N=C1)C(O)=O	PLASMA	K9AY9IR2SD							12		t	μg × h/mL	13.345		μg/mL	3.858			HIGHEST STUDIED	mg	250		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23447078/	Homo sapiens		h	1.39				20			false
6978	7909		ADULT	9932888	439.4626	LESTAURTINIB	LESTAURTINIB	C[C@]12O[C@H](C[C@]1(O)CO)N3C4=C(C=CC=C4)C5=C3C6=C(C7=C5C(=O)NC7)C8=C(C=CC=C8)N26	PLASMA	DO989GC5D1							12		t	ng × h/mL	3530		ng/mL	618			UNKNOWN	mg	20		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15528978	Homo sapiens		h	9.2							false
6979	7912		ADULT	9294	165.2322	EPHEDRINE	EPHEDRINE	CN[C@@H](C)[C@H](O)C1=CC=CC=C1	PLASMA	GN83C131XS													ng/mL	79.4			UNKNOWN	mg	22		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/973934/	Homo sapiens		h	6.75							false
6980	7912		ADULT	9294	165.2322	EPHEDRINE	EPHEDRINE	CN[C@@H](C)[C@H](O)C1=CC=CC=C1	PLASMA	GN83C131XS													ng/mL	87.4			UNKNOWN	mg	11		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/973934/	Homo sapiens		h	6.69							false
6981	7923		ADULT	1030	76.0944	PROPYLENE GLYCOL	PROPYLENE GLYCOL	CC(O)CO	PLASMA	6DC9Q167V3							8		t	mg × h/mL	3.23		mg/mL	0.8			UNKNOWN	mg	20.7		STEADY-STATE	UNKNOWN		day	3			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4032274/	Homo sapiens		h	3.79							false
6982	7936		ADULT	25151504	776	Cobicistat		CC(C)C1=NC(=CS1)CN(C)C(=O)NC(CCN2CCOCC2)C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5	PLASMA	LW2E03M5PG	148192		Atazanavir		CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC	QZU4H47A3S	24		t	mg × h/mL	7.6		μg/mL	0.99			RECOMMENDED	mg	150		STEADY-STATE	UNKNOWN		day	1	Cobicistat is 97–98% bound to human plasma proteins. The terminal plasma half-life of cobicistat following administration of TYBOST is approximately 3 to 4 hours.	2.5	UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203094s008lbl.pdf	Homo sapiens		h	3.5							true
6983	7938		ADULT		215.29	HEXAMINOLEVULINATE			PLASMA														ng/mL	343			RECOMMENDED	mg	100		SINGLE	UNKNOWN						HEALTHY	Intravesical	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16554454/	Homo sapiens										false
6984	7938		ADULT		215.29	HEXAMINOLEVULINATE	HEXAMINOLEVULINATE		PLASMA																		UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Intravesical	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022555s005lbl.pdf	Homo sapiens		h	76							false
6985	7957		ADULT	3100	255.3547	DIPHENHYDRAMINE	DIPHENHYDRAMINE	CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2	PLASMA	8GTS82S83M																						UNKNOWN				By contrast, the percentages of unbound diphenhydramine (26.40% +/- 6.46% versus 18.30% +/- 4.31, mean +/- SD) and propranolol (13.81% +/- 1.33% versus 11.68% +/- 2.37) were significantly (p less than 0.05) higher in Chinese subjects compared to Caucasians.	18.3	HEALTHY		UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/2369804	Homo sapiens										false
6986	7957		ADOLESCENT	3100	255.3547	DIPHENHYDRAMINE	DIPHENHYDRAMINE	CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2	PLASMA	8GTS82S83M													ng/mL	93			UNKNOWN	mg	50		SINGLE	UNKNOWN						UNKNOWN	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/28967696	Homo sapiens										false
6987	7957		ADULT	3100	255.3547	DIPHENHYDRAMINE	DIPHENHYDRAMINE	CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2	PLASMA	8GTS82S83M									∞	ng × h/mL	887						UNKNOWN	mg	50		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/3760245	Homo sapiens		h	8.5							false
6988	7957		ADULT	3100	255.3547	DIPHENHYDRAMINE	DIPHENHYDRAMINE	CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2	PLASMA	8GTS82S83M									∞	ng × h/mL	667						UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/3760245	Homo sapiens		h	9.2							false
6989	7958		ADULT		461.4618	MORPHINE-3-GLUCURONIDE	Morphine-3-glucuronide	CN1CC[C@@]23[C@H]4OC5=C2C(C[C@@H]1[C@@H]3C=C[C@@H]4O)=CC=C5O[C@@H]6O[C@@H]([C@@H](O)[C@H](O)[C@H]6O)C(O)=O	PLASMA	O27Z9CH39A													ng/mL	53.5			UNKNOWN	mg	30		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1391681/	Homo sapiens		h	1.71				8	Codeine phosphate		false
6990	7958		ADULT	5489029	475.4884	CODEINE-6-GLUCURONIDE	Codeine-6-glucuronide	COC1=CC=C2C[C@@H]3[C@@H]4C=C[C@H](O[C@@H]5O[C@@H]([C@@H](O)[C@H](O)[C@H]5O)C(O)=O)[C@@H]6OC1=C2[C@]46CCN3C	PLASMA	E2M937KY47													ng/mL	968			UNKNOWN	mg	30		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1391681/	Homo sapiens		h	2.75				8	Codeine phosphate		false
6991	7958		ADULT		317.3795	CODEINE	Codeine	O.COC1=CC=C2C[C@@H]3[C@@H]4C=C[C@H](O)[C@@H]5OC1=C2[C@]45CCN3C	PLASMA	Q830PW7520													ng/mL	66.9			UNKNOWN	mg	30		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1391681/	Homo sapiens		h	1.47				8	Codeine phosphate		false
6992	7958		ADULT	5362471	317.3795	CODEINE	codeine	O.COC1=CC=C2C[C@@H]3[C@@H]4C=C[C@H](O)[C@@H]5OC1=C2[C@]45CCN3C	PLASMA	Q830PW7520									?	ng × h/mL	849		ng/mL	229			UNKNOWN	mg	60		SINGLE	UNKNOWN						HEALTHY	Intramuscular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7094509/	Homo sapiens		h	2.8		smoking subjects		12	codeine		false
6993	7958		ADULT	5362471	317.3795	CODEINE	codeine	O.COC1=CC=C2C[C@@H]3[C@@H]4C=C[C@H](O)[C@@H]5OC1=C2[C@]45CCN3C	PLASMA	Q830PW7520									?	ng × h/mL	467		ng/mL	93			UNKNOWN	mg	60		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7094509/	Homo sapiens		h	2.7		nonsmoking subjects		11	codeine sulfate		false
6994	7958		ADULT	5362471	317.3795	CODEINE	codeine	O.COC1=CC=C2C[C@@H]3[C@@H]4C=C[C@H](O)[C@@H]5OC1=C2[C@]45CCN3C	PLASMA	Q830PW7520									?	ng × h/mL	466		ng/mL	145			UNKNOWN	mg	60		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7094509/	Homo sapiens		h	2.8		smoking subjects		12	codeine sulfate		false
6995	7958		ADULT	5362471	317.3795	CODEINE	codeine	O.COC1=CC=C2C[C@@H]3[C@@H]4C=C[C@H](O)[C@@H]5OC1=C2[C@]45CCN3C	PLASMA	Q830PW7520									?	ng × h/mL	937		ng/mL	242			UNKNOWN	mg	60		SINGLE	UNKNOWN						HEALTHY	Intramuscular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7094509/	Homo sapiens		h	2.9		nonsmoking subjects		11	codeine		false
6996	7959		ADULT	4189	416.129	MICONAZOLE	MICONAZOLE	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C3=C(Cl)C=C(Cl)C=C3)C=C1	PLASMA	7NNO0D7S5M							24		t	μg × h/mL	136.1		μg/mL	39.1			RECOMMENDED	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15373926/	Homo sapiens		h	6.5							false
6997	7960		ADULT		246.348	LEVOMILNACIPRAN			PLASMA								24		t	ng × h/mL	5196		ng/mL	341			MAX DAILY	mg	120		STEADY-STATE	UNKNOWN		day	1	plasma protein binding is 22% over concentration range of 10 to 1000 ng/mL.	78	UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204168s000lbl.pdf	Homo sapiens		h	12							false
6998	7961		ADULT		307.4	ALCAFTADINE			PLASMA								6		t	ng × h/mL	0.04		ng/mL	0.05			RECOMMENDED	drop	1		SINGLE	UNKNOWN					60.8	HEALTHY	Intraocular	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21314437/	Homo sapiens		h	1.1							false
6999	7963		ADULT	4236	273.35	ARMODAFINIL	ARMODAFINIL	NC(=O)C[S+]([O-])C(C1=CC=CC=C1)C2=CC=CC=C2	PLASMA	V63XWA605I									∞	μg × h/mL	15.9		μg/mL	1.1			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19133704	Homo sapiens		h	13.8							false
7000	7963		ADULT	4236	273.35	ARMODAFINIL	ARMODAFINIL	NC(=O)C[S+]([O-])C(C1=CC=CC=C1)C2=CC=CC=C2	PLASMA	V63XWA605I									∞	μg × h/mL	40.6		μg/mL	2.4			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19133704	Homo sapiens										false
7001	7963		ADULT	4236	273.35	ARMODAFINIL	ARMODAFINIL	NC(=O)C[S+]([O-])C(C1=CC=CC=C1)C2=CC=CC=C2	PLASMA	V63XWA605I									∞	μg × h/mL	75.9		μg/mL	4.1			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19133704	Homo sapiens										false
7002	7963		ADULT	4236	273.35	ARMODAFINIL	ARMODAFINIL	NC(=O)C[S+]([O-])C(C1=CC=CC=C1)C2=CC=CC=C2	PLASMA	V63XWA605I									∞	μg × h/mL	146		μg/mL	7			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19133704	Homo sapiens										false
7003	7963		ADULT	4236	273.35	ARMODAFINIL	ARMODAFINIL	NC(=O)C[S+]([O-])C(C1=CC=CC=C1)C2=CC=CC=C2	PLASMA	V63XWA605I									∞	μg × h/mL	142.9		μg/mL	6.9			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19133704	Homo sapiens										false
7004	7963		ADULT	4236	273.35	ARMODAFINIL	ARMODAFINIL	NC(=O)C[S+]([O-])C(C1=CC=CC=C1)C2=CC=CC=C2	PLASMA	V63XWA605I									?	μg × h/mL	23.4		μg/mL	1.8			UNKNOWN	mg	50		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19133704	Homo sapiens										false
7005	7963		ADULT	4236	273.35	ARMODAFINIL	ARMODAFINIL	NC(=O)C[S+]([O-])C(C1=CC=CC=C1)C2=CC=CC=C2	PLASMA	V63XWA605I									?	μg × h/mL	56.2		μg/mL	4			UNKNOWN	mg	100		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19133704	Homo sapiens										false
7006	7963		ADULT	4236	273.35	ARMODAFINIL	ARMODAFINIL	NC(=O)C[S+]([O-])C(C1=CC=CC=C1)C2=CC=CC=C2	PLASMA	V63XWA605I									?	μg × h/mL	105.9		μg/mL	7.4			UNKNOWN	mg	200		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19133704	Homo sapiens										false
7007	7963		ADULT	4236	273.35	ARMODAFINIL	ARMODAFINIL	NC(=O)C[S+]([O-])C(C1=CC=CC=C1)C2=CC=CC=C2	PLASMA	V63XWA605I									?	μg × h/mL	136.1		μg/mL	10.5			UNKNOWN	mg	250		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19133704	Homo sapiens										false
7008	7963		ADULT	4236	273.35	ARMODAFINIL	ARMODAFINIL	NC(=O)C[S+]([O-])C(C1=CC=CC=C1)C2=CC=CC=C2	PLASMA	V63XWA605I									?	μg × h/mL	150.4		μg/mL	10			UNKNOWN	mg	300		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19133704	Homo sapiens										false
7009	7963		ADULT	4236	273.35	ARMODAFINIL	ARMODAFINIL	NC(=O)C[S+]([O-])C(C1=CC=CC=C1)C2=CC=CC=C2	PLASMA	V63XWA605I									?	μg × h/mL	189.5		μg/mL	13.4			UNKNOWN	mg	400		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19133704	Homo sapiens										false
7010	7963		ADULT	4236	273.35	ARMODAFINIL	ARMODAFINIL	NC(=O)C[S+]([O-])C(C1=CC=CC=C1)C2=CC=CC=C2	PLASMA	V63XWA605I									∞	μg × h/mL	43.8		μg/mL	2.2			UNKNOWN	mg	100		SINGLE	HIGH-FAT						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19133704	Homo sapiens										false
7011	7964		CHILD	9854073	835.9324	CABAZITAXEL	CABAZITAXEL	CO[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)C4=CC=CC=C4)[C@]5(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C6=CC=CC=C6)C(C)=C([C@@H](OC)C(=O)[C@]13C)C5(C)C	PLASMA	51F690397J							71		t	ng × h/mL	669.5		ng/mL	204.864				mg/m²	20		SINGLE							UNHEALTHY	Intravenous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01751308	Homo sapiens										false
7012	7964		CHILD	9854073	835.9324	CABAZITAXEL	CABAZITAXEL	CO[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)C4=CC=CC=C4)[C@]5(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C6=CC=CC=C6)C(C)=C([C@@H](OC)C(=O)[C@]13C)C5(C)C	PLASMA	51F690397J							71		t	ng × h/mL	879		ng/mL	283.657				mg/m²	25		SINGLE							UNHEALTHY	Intravenous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01751308	Homo sapiens										false
7013	7964		CHILD	9854073	835.9324	CABAZITAXEL	CABAZITAXEL	CO[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)C4=CC=CC=C4)[C@]5(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C6=CC=CC=C6)C(C)=C([C@@H](OC)C(=O)[C@]13C)C5(C)C	PLASMA	51F690397J							71		t	ng × h/mL	1002.5		ng/mL	233.29				mg/m²	35		SINGLE							UNHEALTHY	Intravenous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01751308	Homo sapiens										false
7014	7964		ADULT	9854073	835.9324	CABAZITAXEL	CO[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)C4=CC=CC=C4)[C@]5(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C6=CC=CC=C6)C(C)=C([C@@H](OC)C(=O)[C@]13C)C5(C)C	CO[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)C4=CC=CC=C4)[C@]5(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C6=CC=CC=C6)C(C)=C([C@@H](OC)C(=O)[C@]13C)C5(C)C	PLASMA	51F690397J									?	ng × h/mL	991		ng/mL	226			RECOMMENDED	mg/m²	25		MULTIPLE	UNKNOWN		3 weeks	1			UNHEALTHY	Intravenous	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/201023lbl.pdf	Homo sapiens		h	96							false
7015	7964		UNKNOWN	9854073	835.9324	CABAZITAXEL	CABAZITAXEL	CO[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)C4=CC=CC=C4)[C@]5(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C6=CC=CC=C6)C(C)=C([C@@H](OC)C(=O)[C@]13C)C5(C)C	SERUM	51F690397J																						UNKNOWN				In vitro, the binding of cabazitaxel to human serum proteins was 89 to 92% and was not saturable up to 50,000 ng/mL, which covers the maximum concentration observed in clinical trials	9.5	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/201023lbl.pdf	Homo sapiens										false
7016	7965		UNKNOWN	25102847	501.5057	CABOZANTINIB	CABOZANTINIB	COC1=C(OC)C=C2C(OC3=CC=C(NC(=O)C4(CC4)C(=O)NC5=CC=C(F)C=C5)C=C3)=CC=NC2=C1	PLASMA	1C39JW444G																						UNKNOWN				Cabozantinib is highly protein bound in human plasma (≥ 99.7%).	0.3	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208692s000lbl.pdf	Homo sapiens										false
7017	7965		ADULT	25102847	501.17	CABOZANTINIB	CABOZANTINIB	COC1=C(OC)C=C2C(OC3=CC=C(NC(=O)C4(CC4)C(=O)NC5=CC=C(F)C=C5)C=C3)=CC=NC2=C1	PLASMA	1C39JW444G									∞	ng × h/mL	58300		ng/mL	554			UNKNOWN	mg	140		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/27139820	Homo sapiens		h	112							false
7018	7966		ADULT	33036	274.788	DEXCHLORPHENIRAMINE	DEXCHLORPHENIRAMINE	CN(C)CC[C@@H](C1=CC=C(Cl)C=C1)C2=NC=CC=C2	PLASMA	3Q9Q0B929N	1983		ACETAMINOPHEN	paracetamol	CC(=O)NC1=CC=C(O)C=C1	362O9ITL9D	24		t	ng × h/mL	67.58		ng/mL	2.5			RECOMMENDED	mg	1.5		SINGLE	FASTED				Protein binding is approximately 72%. https://gp2u.com.au/static/pdf/P/POLARAMINE-PI.pdf	28	HEALTHY	Oral	UNKNOWN	EXPERIMENT	http://en.cnki.com.cn/Article_en/CJFDTotal-BSDZ200803014.htm	Homo sapiens		h	19.66							true
7019	7967		ADULT	5277135	447.884	ELVITEGRAVIR	ELVITEGRAVIR	COC1=CC2=C(C=C1CC3=C(F)C(Cl)=CC=C3)C(=O)C(=CN2[C@H](CO)C(C)C)C(O)=O	PLASMA	4GDQ854U53	392622		RITONAVIR	ritonavir	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4	O3J8G9O825	24		t	μg × h/mL	18		μg/mL	1.2			RECOMMENDED	mg	85		STEADY-STATE	FED		day	1	Elvitegravir is 98-99% bound to human plasma proteins and the binding is independent of drug concentration over the range of 1 ng/mL to 1.6 µg/mL	1	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203093s000lbl.pdf	Homo sapiens		h	8.7							true
7020	7968		UNKNOWN	11354606	729.8966	ERIBULIN	ERIBULIN	CO[C@H]1[C@@H](C[C@H](O)CN)O[C@H]2C[C@H]3O[C@H](C[C@@H](C)C3=C)CC[C@@H]4O[C@H](CC4=C)CC[C@@]56C[C@H]7O[C@@H]8[C@@H](O[C@H]9CC[C@H](CC(=O)C[C@H]12)O[C@@H]9[C@@H]8O5)[C@H]7O6	PLASMA	LR24G6354G																						UNKNOWN				The human plasma protein binding of eribulin at concentrations of 100 ng/mL to 1,000 ng/mL ranges from 49% to 65%	43	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/201532s010lbl.pdf	Homo sapiens										false
7021	7968		ADULT	11354606	729.8966	ERIBULIN	ERIBULIN	CO[C@H]1[C@@H](C[C@H](O)CN)O[C@H]2C[C@H]3O[C@H](C[C@@H](C)C3=C)CC[C@@H]4O[C@H](CC4=C)CC[C@@]56C[C@H]7O[C@@H]8[C@@H](O[C@H]9CC[C@H](CC(=O)C[C@H]12)O[C@@H]9[C@@H]8O5)[C@H]7O6	PLASMA	LR24G6354G									∞	ng × h/mL	32364.4		ng/mL	1213.3			MAX TOLERATED	mg/m²	1.5		MULTIPLE	UNKNOWN		4 weeks	2			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/30679780	Homo sapiens		h	28.07							false
7022	7969		ADULT	107970	307.4708	FINGOLIMOD	FINGOLIMOD	CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1	PLASMA	3QN8BYN5QF									∞	ng × h/mL	149		ng/mL	0.65			UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/22149256	Homo sapiens		h	7							false
7023	7970		ADULT	6918554|86314533	392.4907	INDACATEROL	INDACATEROL	CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C3=C4C=CC(=O)NC4=C(O)C=C3	SERUM	8OR09251MQ							24		t	ng × h/mL	0.974		ng/mL	0.206			UNKNOWN	μg	150		SINGLE	UNKNOWN						HEALTHY	Respiratory	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24705947/	Homo sapiens										false
7024	7970		ADULT	6918554|86314533	392.4907	INDACATEROL	INDACATEROL	CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C3=C4C=CC(=O)NC4=C(O)C=C3	SERUM	8OR09251MQ							24		t	ng × h/mL	2.43		ng/mL	0.518			UNKNOWN	μg	300		SINGLE	UNKNOWN						HEALTHY	Respiratory	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24705947/	Homo sapiens										false
7025	7970		ADULT	6918554|86314533	392.4907	INDACATEROL	INDACATEROL	CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C3=C4C=CC(=O)NC4=C(O)C=C3	SERUM	8OR09251MQ							24		t	ng × h/mL	2.51		ng/mL	0.299			UNKNOWN	μg	150		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Respiratory	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24705947/	Homo sapiens		h	116							false
7026	7970		ADULT	6918554|86314533	392.4907	INDACATEROL	INDACATEROL	CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C3=C4C=CC(=O)NC4=C(O)C=C3	SERUM	8OR09251MQ							24		t	ng × h/mL	6.52		ng/mL	0.697			UNKNOWN	μg	300		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Respiratory	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24705947/	Homo sapiens		h	118							false
7027	7970		ADULT	6918554|86314533	392.4907	INDACATEROL	INDACATEROL	CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C3=C4C=CC(=O)NC4=C(O)C=C3	PLASMA	8OR09251MQ	67204829		GLYCOPYRROLATE	glycopyrrolate	[Br-].C[N+]1(C)CC[C@@H](C1)OC(=O)[C@@](O)(C2CCCC2)C3=CC=CC=C3	V92SO9WP2I	24		t	pg × h/mL	907		pg/mL	339			UNKNOWN	μg	110		SINGLE	UNKNOWN						HEALTHY	Respiratory	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207930Orig1s000ClinPharmR.pdf	Homo sapiens										true
7028	7970		ADULT	6918554|86314533	392.4907	INDACATEROL	INDACATEROL	CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C3=C4C=CC(=O)NC4=C(O)C=C3	PLASMA	8OR09251MQ	67204829		GLYCOPYRROLATE	glycopyrrolate	[Br-].C[N+]1(C)CC[C@@H](C1)OC(=O)[C@@](O)(C2CCCC2)C3=CC=CC=C3	V92SO9WP2I	24		t	pg × h/mL	2750		pg/mL	528			UNKNOWN	μg	110		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Respiratory	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207930Orig1s000ClinPharmR.pdf	Homo sapiens										true
7029	7972		ADULT	26879	204.291	LEVAMISOLE	LEVAMISOLE	C1CN2C[C@@H](N=C2S1)C3=CC=CC=C3	PLASMA	2880D3468G									∞	mg × h/L	7.44		mg/L	0.69			UNKNOWN	mg/kg bw	2.5		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7166176/	Homo sapiens		h	6.04							false
7030	7972		ADULT	26879	204.291	LEVAMISOLE	LEVAMISOLE	C1CN2C[C@@H](N=C2S1)C3=CC=CC=C3	PLASMA	2880D3468G									∞	mg × h/L	6.1		mg/L	0.74			UNKNOWN	mg/kg bw	2.5		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7166176/	Homo sapiens		h	3.88							false
7031	7972		ADULT	26879	204.291	LEVAMISOLE	LEVAMISOLE	C1CN2C[C@@H](N=C2S1)C3=CC=CC=C3	PLASMA	2880D3468G									∞	mg × h/L	6.88		mg/L	1.28			UNKNOWN	mg/kg bw	5		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7166176/	Homo sapiens		h	2.71							false
7032	7972		ADULT	26879	204.291	LEVAMISOLE	LEVAMISOLE	C1CN2C[C@@H](N=C2S1)C3=CC=CC=C3	PLASMA	2880D3468G									∞	mg × h/L	19.69		mg/L	1.84			UNKNOWN	mg/kg bw	5		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7166176/	Homo sapiens		h	5.58							false
7033	7972		ADULT	26879	204.291	LEVAMISOLE	LEVAMISOLE	C1CN2C[C@@H](N=C2S1)C3=CC=CC=C3	PLASMA	2880D3468G									∞	mg × h/L	4.48		mg/L	0.75			UNKNOWN	mg/kg bw	2.5		SINGLE	FASTED						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7166176/	Homo sapiens		h	2.85							false
7034	7972		ADULT	26879	204.291	LEVAMISOLE	LEVAMISOLE	C1CN2C[C@@H](N=C2S1)C3=CC=CC=C3	PLASMA	2880D3468G									∞	mg × h/L	7.16		mg/L	0.97			UNKNOWN	mg/kg bw	2.5		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7166176/	Homo sapiens		h	3.72							false
7035	7972		ADULT	26879	204.291	LEVAMISOLE	LEVAMISOLE	C1CN2C[C@@H](N=C2S1)C3=CC=CC=C3	PLASMA	2880D3468G									∞	mg × h/L	18.96		mg/L	1.53			UNKNOWN	mg/kg bw	5		SINGLE	FASTED						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7166176/	Homo sapiens		h	5.75							false
7036	7972		ADULT	26879	204.291	LEVAMISOLE	LEVAMISOLE	C1CN2C[C@@H](N=C2S1)C3=CC=CC=C3	PLASMA	2880D3468G									∞	mg × h/L	13.78		mg/L	1.93			UNKNOWN	mg/kg bw	5		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7166176/	Homo sapiens		h	3.65							false
7037	7972		ADULT	26879	204.291	LEVAMISOLE	LEVAMISOLE	C1CN2C[C@@H](N=C2S1)C3=CC=CC=C3	PLASMA	2880D3468G							24		t	mg × h/L	4.15		mg/L	0.76			UNKNOWN	mg	150		UNKNOWN	UNKNOWN					49	HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-elmisol_en.pdf	Homo sapiens		h	4.4							false
7038	7972		ADULT	26879	204.291	LEVAMISOLE	LEVAMISOLE	C1CN2C[C@@H](N=C2S1)C3=CC=CC=C3	PLASMA	2880D3468G									∞	mg × h/L	3.07		mg/L	0.72			UNKNOWN	mg	150		UNKNOWN	UNKNOWN					49	HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-elmisol_en.pdf	Homo sapiens		h	5.56							false
7039	7972		CHILD	26879	204.291	LEVAMISOLE	LEVAMISOLE	C1CN2C[C@@H](N=C2S1)C3=CC=CC=C3	PLASMA	2880D3468G									∞	mg × h/L	3.54		mg/L	0.53			UNKNOWN	mg/kg bw	2.5		MULTIPLE	UNKNOWN		2 days	1			UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-elmisol_en.pdf	Homo sapiens		h	3.07							false
7040	7973		ADULT	60657	307.4278	LEVOBETAXOLOL	LEVOBETAXOLOL	CC(C)NC[C@H](O)COC1=CC=C(CCOCC2CC2)C=C1	PLASMA	75O9XHA4TU													ng/mL	0.5			RECOMMENDED	drop	1		STEADY-STATE	FASTED		day	2			HEALTHY	Ocular	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021114s003lbl.pdf	Homo sapiens		h	20							false
7041	7974		UNKNOWN	92253	288.4277	LEVOBUPIVACAINE	LEVOBUPIVACAINE	CCCCN1CCCC[C@H]1C(=O)NC2=C(C)C=CC=C2C	PLASMA	A5H73K9U3W							24		t	μg × h/mL	3.561		μg/mL	0.582			UNKNOWN	mg	75		SINGLE	UNKNOWN					3	UNKNOWN	Epidural	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20997lbl.pdf	Homo sapiens										false
7042	7974		UNKNOWN	92253	288.4277	LEVOBUPIVACAINE	LEVOBUPIVACAINE	CCCCN1CCCC[C@H]1C(=O)NC2=C(C)C=CC=C2C	PLASMA	A5H73K9U3W							24		t	μg × h/mL	4.93		μg/mL	0.811			UNKNOWN	mg	112.5		SINGLE	UNKNOWN					3	UNKNOWN	Epidural	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20997lbl.pdf	Homo sapiens										false
7043	7974		UNKNOWN	92253	288.4277	LEVOBUPIVACAINE	LEVOBUPIVACAINE	CCCCN1CCCC[C@H]1C(=O)NC2=C(C)C=CC=C2C	PLASMA	A5H73K9U3W							24		t	μg × h/mL	2.999		μg/mL	0.474			UNKNOWN	mg/kg bw	1		SINGLE	UNKNOWN					3	UNKNOWN	Brachial plexus block	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20997lbl.pdf	Homo sapiens										false
7044	7974		UNKNOWN	92253	288.4277	LEVOBUPIVACAINE	LEVOBUPIVACAINE	CCCCN1CCCC[C@H]1C(=O)NC2=C(C)C=CC=C2C	PLASMA	A5H73K9U3W							24		t	μg × h/mL	5.311		μg/mL	0.961			UNKNOWN	mg/kg bw	2		SINGLE	UNKNOWN					3	UNKNOWN	Brachial plexus block	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20997lbl.pdf	Homo sapiens										false
7045	7976		ADULT	9941444	1047.2062	PASIREOTIDE	PASIREOTIDE	NCCCC[C@@H]1NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@@H](NC(=O)[C@@H]4C[C@H](CN4C(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CC6=CC=C(OCC7=CC=CC=C7)C=C6)NC1=O)OC(=O)NCCN)C8=CC=CC=C8	PLASMA	98H1T17066													ng/mL	7.19			UNKNOWN	mg	20		SINGLE	UNKNOWN						UNHEALTHY	Intramuscular	FEMALE / MALE	EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01673646	Homo sapiens										false
7046	7976		ADULT	9941444	1047.2062	PASIREOTIDE	PASIREOTIDE	NCCCC[C@@H]1NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@@H](NC(=O)[C@@H]4C[C@H](CN4C(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CC6=CC=C(OCC7=CC=CC=C7)C=C6)NC1=O)OC(=O)NCCN)C8=CC=CC=C8	PLASMA	98H1T17066													ng/mL	10.3			UNKNOWN	mg	40		SINGLE	UNKNOWN						UNHEALTHY	Intramuscular	FEMALE / MALE	EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01673646	Homo sapiens										false
7047	7976		ADULT	9941444	1047.2062	PASIREOTIDE	PASIREOTIDE	NCCCC[C@@H]1NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@@H](NC(=O)[C@@H]4C[C@H](CN4C(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CC6=CC=C(OCC7=CC=CC=C7)C=C6)NC1=O)OC(=O)NCCN)C8=CC=CC=C8	PLASMA	98H1T17066													ng/mL	17			UNKNOWN	mg	60		SINGLE	UNKNOWN						UNHEALTHY	Intramuscular	FEMALE / MALE	EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01673646	Homo sapiens										false
7048	7976		ADULT	9941444	1047.2062	PASIREOTIDE	PASIREOTIDE	NCCCC[C@@H]1NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@@H](NC(=O)[C@@H]4C[C@H](CN4C(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CC6=CC=C(OCC7=CC=CC=C7)C=C6)NC1=O)OC(=O)NCCN)C8=CC=CC=C8	PLASMA	98H1T17066							28		t	ng × h/mL	4090		ng/mL	5.9			UNKNOWN	mg	60		SINGLE	FASTED						UNHEALTHY	Subcutaneous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24800725/	Homo sapiens		h	12							false
7049	7976		ADULT	9941444	1047.2062	PASIREOTIDE	PASIREOTIDE	NCCCC[C@@H]1NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@@H](NC(=O)[C@@H]4C[C@H](CN4C(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CC6=CC=C(OCC7=CC=CC=C7)C=C6)NC1=O)OC(=O)NCCN)C8=CC=CC=C8	PLASMA	98H1T17066							12		t	ng × h/mL	161.1		ng/mL	38.7			RECOMMENDED	mg	0.6		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Subcutaneous	FEMALE / MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/29032486/	Homo sapiens		h	4.4							false
7050	7977		UNKNOWN	3425	540.696	ROMIDEPSIN	ROMIDEPSIN	C\\C=C1/NC(=O)[C@H]2CSSCC\\C=C\\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C	PLASMA	CX3T89XQBK																						UNKNOWN				Romidepsin is highly protein bound in plasma (92% to 94%) over the concentration range of 50 ng/mL to 1000 ng/mL	7	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022393lbl.pdf	Homo sapiens										false
7051	7977		ADULT	3425	540.696	ROMIDEPSIN	ROMIDEPSIN	C\\C=C1/NC(=O)[C@H]2CSSCC\\C=C\\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C	PLASMA	CX3T89XQBK									∞	ng × h/mL	915.3		ng/mL	229			UNKNOWN	mg/m²	8		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26053962	Homo sapiens		h	9.7							false
7052	7979		ADULT		475.6	ULIPRISTAL			PLASMA										∞	ng × h/mL	556		ng/mL	176			RECOMMENDED	mg	30		SINGLE	FASTED				Ulipristal acetate is highly bound (> 94%) to plasma proteins, including high density lipoprotein, alpha-l-acid glycoprotein, and albumin.	6	HEALTHY	Oral	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022474s010lbl.pdf	Homo sapiens		h	32							false
7053	7983		ADULT	6057|6942100	181.1885	TYROSINE	TYROSINE	N[C@@H](CC1=CC=C(O)C=C1)C(O)=O	PLASMA	42HK56048U													nmol/mL	154			UNKNOWN	mg/kg	100		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	REVIEW	https://chiro.org/Graphics_Box_NUTRITION/L-Tyrosine_Monograph.pdf	Homo sapiens							12	TYROSINE		false
7054	7983		ADULT	6057|6942100	181.1885	TYROSINE	TYROSINE	N[C@@H](CC1=CC=C(O)C=C1)C(O)=O	PLASMA	42HK56048U													nmol/mL	203			UNKNOWN	mg/kg	150		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	REVIEW	https://chiro.org/Graphics_Box_NUTRITION/L-Tyrosine_Monograph.pdf	Homo sapiens							12	TYROSINE		false
7055	7985		UNKNOWN	64929	318.752	FENOFIBRIC ACID	FENOFIBRIC ACID	CC(C)(OC1=CC=C(C=C1)C(=O)C2=CC=C(Cl)C=C2)C(O)=O	SERUM	BGF9MN2HU1																	UNKNOWN	mg	105		STEADY-STATE	UNKNOWN		day	1	Serum protein binding was approximately 99% in normal and hyperlipidemic subjects.	1	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022418lbl.pdf	Homo sapiens										false
7056	7985		UNKNOWN	64929	318.752	FENOFIBRIC ACID	FENOFIBRIC ACID	CC(C)(OC1=CC=C(C=C1)C(=O)C2=CC=C(Cl)C=C2)C(O)=O	PLASMA	BGF9MN2HU1									∞	μg × h/mL	162.96		μg/mL	12			UNKNOWN	mg	105		SINGLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022418s000_ClinPharmR.pdf	Homo sapiens										false
7057	7985		UNKNOWN	64929	318.752	FENOFIBRIC ACID	FENOFIBRIC ACID	CC(C)(OC1=CC=C(C=C1)C(=O)C2=CC=C(Cl)C=C2)C(O)=O	PLASMA	BGF9MN2HU1									∞	μg × h/mL	124.89		μg/mL	8.37			UNKNOWN	mg	105		SINGLE	FED		day	1			HEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022418s000_ClinPharmR.pdf	Homo sapiens										false
7058	7996		ADULT	455041	229.256	APRICITABINE	apricitabine	NC1=NC(=O)N(C=C1)[C@H]2CO[C@@H](CO)S2	PLASMA	K1YX059ML1									?	ng × h/mL	38100		ng/mL	9720			UNKNOWN	mg	800		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18211121	Homo sapiens		h	2.69				13	apricitabine		false
7059	7996		ADULT	455041	229.256	APRICITABINE	apricitabine	NC1=NC(=O)N(C=C1)[C@H]2CO[C@@H](CO)S2	PLASMA	K1YX059ML1									?	ng × h/mL	53200		ng/mL	11500			UNKNOWN	mg	1200		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18211121	Homo sapiens		h	1.91				5	apricitabine		false
7060	7996		ADULT	455041	229.256	APRICITABINE	apricitabine	NC1=NC(=O)N(C=C1)[C@H]2CO[C@@H](CO)S2	PLASMA	K1YX059ML1									?	ng × h/mL	24100		ng/mL	4920			UNKNOWN	mg	400		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18211121	Homo sapiens		h	2.45				6	apricitabine		false
7061	7998		ADULT	100427	221.022	PALIFOSFAMIDE	C(CCl)NP(=O)(NCCCl)O	OP(=O)(NCCCl)NCCCl	PLASMA	6A4U6NN813									?	mM × h	6.96		μM	185.4			UNKNOWN	g	11.54		MULTIPLE	UNKNOWN		3 weeks	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/9528844	Homo sapiens										false
7062	8002		ADULT	11556427	637.5084	ANACETRAPIB	ANACETRAPIB	COC1=C(C=C(C(C)C)C(F)=C1)C2=C(CN3[C@@H](C)[C@H](OC3=O)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C(C=C2)C(F)(F)F	PLASMA	P7T269PR6S									∞	μM × h	14		nM	860			UNKNOWN	mg	250		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19843057	Homo sapiens		h	44.2				6	ANACETRAPIB		false
7063	8002		ADULT	11556427	637.5084	ANACETRAPIB	ANACETRAPIB	COC1=C(C=C(C(C)C)C(F)=C1)C2=C(CN3[C@@H](C)[C@H](OC3=O)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C(C=C2)C(F)(F)F	PLASMA	P7T269PR6S									∞	μM × h	4		nM	168			UNKNOWN	mg	125		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19843057	Homo sapiens		h	55.7	1x125 mg			6	ANACETRAPIB		false
7064	8002		ADULT	11556427	637.5084	ANACETRAPIB	ANACETRAPIB	COC1=C(C=C(C(C)C)C(F)=C1)C2=C(CN3[C@@H](C)[C@H](OC3=O)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C(C=C2)C(F)(F)F	PLASMA	P7T269PR6S									∞	μM × h	9.9		nM	731			UNKNOWN	mg	125		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19843057	Homo sapiens		h	46.1	2x50mg   2x10mg   5x1mg			6	ANACETRAPIB		false
7065	8002		ADULT	11556427	637.5084	ANACETRAPIB	ANACETRAPIB	COC1=C(C=C(C(C)C)C(F)=C1)C2=C(CN3[C@@H](C)[C@H](OC3=O)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C(C=C2)C(F)(F)F	PLASMA	P7T269PR6S									∞	μM × h	5.3		nM	414			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19843057	Homo sapiens		h	34.5				6	ANACETRAPIB		false
7066	8002		ADULT	11556427	637.5084	ANACETRAPIB	ANACETRAPIB	COC1=C(C=C(C(C)C)C(F)=C1)C2=C(CN3[C@@H](C)[C@H](OC3=O)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C(C=C2)C(F)(F)F	PLASMA	P7T269PR6S									∞	μM × h	2.9		nM	246			UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19843057	Homo sapiens		h	28.7				6	ANACETRAPIB		false
7067	8002		ADULT	11556427	637.5084	ANACETRAPIB	ANACETRAPIB	COC1=C(C=C(C(C)C)C(F)=C1)C2=C(CN3[C@@H](C)[C@H](OC3=O)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C(C=C2)C(F)(F)F	PLASMA	P7T269PR6S									∞	μM × h	2		nM	145			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19843057	Homo sapiens		h	28.88				6	ANACETRAPIB		false
7068	8002		ADULT	11556427	637.5084	ANACETRAPIB	ANACETRAPIB	COC1=C(C=C(C(C)C)C(F)=C1)C2=C(CN3[C@@H](C)[C@H](OC3=O)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C(C=C2)C(F)(F)F	PLASMA	P7T269PR6S									∞	μM × h	0.68		nM	56			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19843057	Homo sapiens		h	21				6	ANACETRAPIB		false
7069	8002		ADULT	11556427	637.5084	ANACETRAPIB	ANACETRAPIB	COC1=C(C=C(C(C)C)C(F)=C1)C2=C(CN3[C@@H](C)[C@H](OC3=O)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C(C=C2)C(F)(F)F	PLASMA	P7T269PR6S									∞	μM × h	0.26		nM	24			UNKNOWN	mg	2		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19843057	Homo sapiens		h	9.3				6	ANACETRAPIB		false
7070	8002		ADULT	11556427	637.5084	ANACETRAPIB	ANACETRAPIB	COC1=C(C=C(C(C)C)C(F)=C1)C2=C(CN3[C@@H](C)[C@H](OC3=O)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C(C=C2)C(F)(F)F	PLASMA	P7T269PR6S									∞	μM × h	13.6		nM	889			UNKNOWN	mg	1000		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19843057	Homo sapiens		h	61.9				6	ANACETRAPIB		false
7071	8002		ADULT	11556427	637.5084	ANACETRAPIB	ANACETRAPIB	COC1=C(C=C(C(C)C)C(F)=C1)C2=C(CN3[C@@H](C)[C@H](OC3=O)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C(C=C2)C(F)(F)F	PLASMA	P7T269PR6S									∞	μM × h	117.4		nM	9140			UNKNOWN	mg	800		SINGLE	HIGH-FAT						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19843057	Homo sapiens		h	82.6				6	ANACETRAPIB		false
7072	8002		ADULT	11556427	637.5084	ANACETRAPIB	ANACETRAPIB	COC1=C(C=C(C(C)C)C(F)=C1)C2=C(CN3[C@@H](C)[C@H](OC3=O)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C(C=C2)C(F)(F)F	PLASMA	P7T269PR6S									∞	μM × h	82		nM	5064			UNKNOWN	mg	400		SINGLE	HIGH-FAT						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19843057	Homo sapiens		h	61.5				6	ANACETRAPIB		false
7073	8002		ADULT	11556427	637.5084	ANACETRAPIB	ANACETRAPIB	COC1=C(C=C(C(C)C)C(F)=C1)C2=C(CN3[C@@H](C)[C@H](OC3=O)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C(C=C2)C(F)(F)F	PLASMA	P7T269PR6S									∞	μM × h	44		nM	3959			UNKNOWN	mg	200		SINGLE	HIGH-FAT						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19843057	Homo sapiens		h	50.9				6	ANACETRAPIB		false
7074	8002		ADULT	11556427	637.5084	ANACETRAPIB	ANACETRAPIB	COC1=C(C=C(C(C)C)C(F)=C1)C2=C(CN3[C@@H](C)[C@H](OC3=O)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C(C=C2)C(F)(F)F	PLASMA	P7T269PR6S									∞	μM × h	23.9		nM	1498			UNKNOWN	mg	125		SINGLE	HIGH-FAT						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19843057	Homo sapiens		h	54.4				6	ANACETRAPIB		false
7075	8002		ADULT	11556427	637.5084	ANACETRAPIB	ANACETRAPIB	COC1=C(C=C(C(C)C)C(F)=C1)C2=C(CN3[C@@H](C)[C@H](OC3=O)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C(C=C2)C(F)(F)F	PLASMA	P7T269PR6S									∞	μM × h	34.2		nM	2421			UNKNOWN	mg	100		SINGLE	HIGH-FAT						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19843057	Homo sapiens		h	62				6	ANACETRAPIB		false
7076	8002		ADULT	11556427	637.5084	ANACETRAPIB	ANACETRAPIB	COC1=C(C=C(C(C)C)C(F)=C1)C2=C(CN3[C@@H](C)[C@H](OC3=O)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C(C=C2)C(F)(F)F	PLASMA	P7T269PR6S									∞	μM × h	10.7		nM	972			UNKNOWN	mg	25		SINGLE	HIGH-FAT						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19843057	Homo sapiens		h	42.2				6	ANACETRAPIB		false
7077	8002		ADULT	11556427	637.5084	ANACETRAPIB	ANACETRAPIB	COC1=C(C=C(C(C)C)C(F)=C1)C2=C(CN3[C@@H](C)[C@H](OC3=O)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C(C=C2)C(F)(F)F	PLASMA	P7T269PR6S									∞	μM × h	9		nM	561			UNKNOWN	mg	125		SINGLE	LOW-FAT						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19843057	Homo sapiens		h	50.2				6	ANACETRAPIB		false
7078	8002		ADULT	11556427	637.5084	ANACETRAPIB	ANACETRAPIB	COC1=C(C=C(C(C)C)C(F)=C1)C2=C(CN3[C@@H](C)[C@H](OC3=O)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C(C=C2)C(F)(F)F	PLASMA	P7T269PR6S									∞	μM × h	15.7		nM	788			UNKNOWN	mg	500		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19843057	Homo sapiens		h	60				6	ANACETRAPIB		false
7079	8002		ADULT	11556427	637.5084	ANACETRAPIB	ANACETRAPIB	COC1=C(C=C(C(C)C)C(F)=C1)C2=C(CN3[C@@H](C)[C@H](OC3=O)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C=C(C=C2)C(F)(F)F	PLASMA	P7T269PR6S							24		t	μM × h	34.95		μM	3.45			UNKNOWN	mg	300		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23958252	Homo sapiens							12	ANACETRAPIB		false
7080	8003		ADULT	9828911	546.7036	ANAMORELIN	Anamorelin	CN(C)N(C)C(=O)[C@@]2(CC1=CC=CC=C1)CCCN(C2)C(=O)[C@@H](CC3=CNC4=C3C=CC=C4)NC(=O)C(C)(C)N	PLASMA	DD5RBA1NKF									∞	ng × h/mL	366		ng/mL	184			UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26640742/	Homo sapiens		h	6.08				8	Anamorelin		false
7081	8003		ADULT	9828911	546.7036	ANAMORELIN	Anamorelin	CN(C)N(C)C(=O)[C@@]2(CC1=CC=CC=C1)CCCN(C2)C(=O)[C@@H](CC3=CNC4=C3C=CC=C4)NC(=O)C(C)(C)N	PLASMA	DD5RBA1NKF									∞	ng × h/mL	197		ng/mL	80.6			UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26640742/	Homo sapiens		h	7.03				6	Anamorelin		false
7082	8004		ADULT	24872560	477.435	APALUTAMIDE	CNC(=O)C1=CC=C(C=C1F)N2C(=S)N(C(=O)C23CCC3)C4=CN=C(C#N)C(=C4)C(F)(F)F	CNC(=O)C1=CC=C(C=C1F)N2C(=S)N(C(=O)C23CCC3)C4=CN=C(C#N)C(=C4)C(F)(F)F	PLASMA	4T36H88UA7							24		t	μg × h/mL	100		μg/mL	6			RECOMMENDED	mg	240		STEADY-STATE	UNKNOWN		day	1	Apalutamide was 96% and N-desmethyl apalutamide was 95% bound to plasma proteins with no concentration dependency.	4	UNHEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210951s000lbl.pdf	Homo sapiens		h	72							false
7083	8006		ADULT	9852519	649.655	AVATROMBOPAG	AVATROMBOPAG	OC(=O)C1CCN(CC1)C2=NC=C(C=C2Cl)C(=O)NC3=NC(C4=CC(Cl)=CS4)=C(S3)N5CCN(CC5)C6CCCCC6	PLASMA	3H8GSZ4SQL									∞	ng × h/mL	3160		ng/mL	95.4			RECOMMENDED	mg	20		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28339166/	Homo sapiens		h	18.6							false
7084	8006		ADULT	9852519	649.655	AVATROMBOPAG	AVATROMBOPAG	OC(=O)C1CCN(CC1)C2=NC=C(C=C2Cl)C(=O)NC3=NC(C4=CC(Cl)=CS4)=C(S3)N5CCN(CC5)C6CCCCC6	PLASMA	3H8GSZ4SQL									∞	ng × h/mL	5900		ng/mL	164			RECOMMENDED	mg	40		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28339166/	Homo sapiens		h	18							false
7085	8006		ADULT	9852519	649.655	AVATROMBOPAG	AVATROMBOPAG	OC(=O)C1CCN(CC1)C2=NC=C(C=C2Cl)C(=O)NC3=NC(C4=CC(Cl)=CS4)=C(S3)N5CCN(CC5)C6CCCCC6	PLASMA	3H8GSZ4SQL									∞	ng × h/mL	10000		ng/mL	284			MAX DAILY	mg	60		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28339166/	Homo sapiens		h	18.2							false
7086	8006		ADULT	9852519	649.655	AVATROMBOPAG	AVATROMBOPAG	OC(=O)C1CCN(CC1)C2=NC=C(C=C2Cl)C(=O)NC3=NC(C4=CC(Cl)=CS4)=C(S3)N5CCN(CC5)C6CCCCC6	PLASMA	3H8GSZ4SQL									∞	ng × h/mL	3340		ng/mL	117			RECOMMENDED	mg	40		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28339166/	Homo sapiens										false
7087	8006		ADULT	9852519	649.655	AVATROMBOPAG	AVATROMBOPAG	OC(=O)C1CCN(CC1)C2=NC=C(C=C2Cl)C(=O)NC3=NC(C4=CC(Cl)=CS4)=C(S3)N5CCN(CC5)C6CCCCC6	PLASMA	3H8GSZ4SQL									∞	ng × h/mL	4840		ng/mL	183			MAX DAILY	mg	60		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28339166/	Homo sapiens										false
7088	8006		ADULT	9852519	649.655	AVATROMBOPAG	AVATROMBOPAG	OC(=O)C1CCN(CC1)C2=NC=C(C=C2Cl)C(=O)NC3=NC(C4=CC(Cl)=CS4)=C(S3)N5CCN(CC5)C6CCCCC6	PLASMA	3H8GSZ4SQL									∞	ng × h/mL	10863.5		ng/mL	388			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30203841	Homo sapiens		h	18							false
7089	8009		ADULT	10275777	451.905	BETRIXABAN	BETRIXABAN	COC1=CC(C(=O)NC2=NC=C(Cl)C=C2)=C(NC(=O)C3=CC=C(C=C3)C(=N)N(C)C)C=C1	PLASMA	74RWP7W0J9									∞	ng × h/mL	83.1		ng/mL	9.37			UNKNOWN	mg	40		SINGLE	FASTED				plasma protein binding - 60%	40	HEALTHY	Oral	UNKNOWN	REVIEW	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208383Orig1s000ClinPharmR.pdf	Homo sapiens										false
7090	8009		ADULT	10275777	451.905	BETRIXABAN	BETRIXABAN	COC1=CC(C(=O)NC2=NC=C(Cl)C=C2)=C(NC(=O)C3=CC=C(C=C3)C(=N)N(C)C)C=C1	PLASMA	74RWP7W0J9									∞	ng × h/mL	393		ng/mL	38			RECOMMENDED	mg	80		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	REVIEW	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208383Orig1s000ClinPharmR.pdf	Homo sapiens										false
7091	8009		ADULT	10275777	451.905	BETRIXABAN	BETRIXABAN	COC1=CC(C(=O)NC2=NC=C(Cl)C=C2)=C(NC(=O)C3=CC=C(C=C3)C(=N)N(C)C)C=C1	PLASMA	74RWP7W0J9									∞	ng × h/mL	600		ng/mL	58.2			UNKNOWN	mg	120		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	REVIEW	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208383Orig1s000ClinPharmR.pdf	Homo sapiens										false
7092	8009		ADULT	10275777	451.905	BETRIXABAN	BETRIXABAN	COC1=CC(C(=O)NC2=NC=C(Cl)C=C2)=C(NC(=O)C3=CC=C(C=C3)C(=N)N(C)C)C=C1	PLASMA	74RWP7W0J9							12		t	ng × h/mL	179		ng/mL	23.2			UNKNOWN	mg	40		MULTIPLE	FASTED		day	2			HEALTHY	Oral	UNKNOWN	REVIEW	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208383Orig1s000ClinPharmR.pdf	Homo sapiens		h	39.7							false
7093	8009		ADULT	10275777	451.905	BETRIXABAN	BETRIXABAN	COC1=CC(C(=O)NC2=NC=C(Cl)C=C2)=C(NC(=O)C3=CC=C(C=C3)C(=N)N(C)C)C=C1	PLASMA	74RWP7W0J9							12		t	ng × h/mL	488		ng/mL	73.1			RECOMMENDED	mg	80		MULTIPLE	FASTED		day	2			HEALTHY	Oral	UNKNOWN	REVIEW	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208383Orig1s000ClinPharmR.pdf	Homo sapiens		h	37.3							false
7094	8009		ADULT	10275777	451.905	BETRIXABAN	BETRIXABAN	COC1=CC(C(=O)NC2=NC=C(Cl)C=C2)=C(NC(=O)C3=CC=C(C=C3)C(=N)N(C)C)C=C1	PLASMA	74RWP7W0J9							12		t	ng × h/mL	821		ng/mL	122			UNKNOWN	mg	120		MULTIPLE	FASTED		day	2			HEALTHY	Oral	UNKNOWN	REVIEW	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208383Orig1s000ClinPharmR.pdf	Homo sapiens		h	35.9							false
7095	8011		ADULT	25195624	464.936	BEXAGLIFLOZIN	BEXAGLIFLOZIN	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C2=CC(CC3=CC=C(OCCOC4CC4)C=C3)=C(Cl)C=C2	PLASMA	EY00JF42FV									∞	ng × eq × h/g	2604		ng × eq/g	692			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31432741	Homo sapiens		h	5.6				6	BEXAGLIFLOZIN		false
7096	8012		ADULT	9941379	1025.1627	BREMELANOTIDE	BREMELANOTIDE	CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CN=CN5)NC1=O)C(O)=O	PLASMA	6Y24O4F92S									∞	ng × h/mL	276		ng/mL	72.8			RECOMMENDED	mg	1.75		SINGLE	UNKNOWN					79	HEALTHY	Subcutaneous	FEMALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210557Orig1s000MultidisciplineR.pdf	Homo sapiens		h	2.7							false
7097	8013		ADULT	44242317	585.5527	CADAZOLID	Cadazolid	OC[C@H]1CN(C(=O)O1)C2=CC=C(OCC3(O)CCN(CC3)C4=C(F)C=C5C(=O)C(=CN(C6CC6)C5=C4)C(O)=O)C(F)=C2	PLASMA	2OEA2UN10Y							12		t	ng × h/mL	25.03		ng/mL	3.28			UNKNOWN	mg	3000		MULTIPLE	FASTED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24106141	Homo sapiens		h	13.02				6	Cadazolid		false
7098	8013		ADULT	44242317	585.5527	CADAZOLID	Cadazolid	OC[C@H]1CN(C(=O)O1)C2=CC=C(OCC3(O)CCN(CC3)C4=C(F)C=C5C(=O)C(=CN(C6CC6)C5=C4)C(O)=O)C(F)=C2	PLASMA	2OEA2UN10Y							12		t	ng × h/mL	17.68		ng/mL	2.24			UNKNOWN	mg	1000		MULTIPLE	FASTED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24106141	Homo sapiens		h	14.17				6	Cadazolid		false
7099	8013		ADULT	44242317	585.5527	CADAZOLID	Cadazolid	OC[C@H]1CN(C(=O)O1)C2=CC=C(OCC3(O)CCN(CC3)C4=C(F)C=C5C(=O)C(=CN(C6CC6)C5=C4)C(O)=O)C(F)=C2	PLASMA	2OEA2UN10Y							24		t	ng × h/mL	13.36		ng/mL	1.82			UNKNOWN	mg	300		MULTIPLE	FASTED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24106141	Homo sapiens		h	14.08				6	Cadazolid		false
7100	8013		ADULT	44242317	585.5527	CADAZOLID	Cadazolid	OC[C@H]1CN(C(=O)O1)C2=CC=C(OCC3(O)CCN(CC3)C4=C(F)C=C5C(=O)C(=CN(C6CC6)C5=C4)C(O)=O)C(F)=C2	PLASMA	2OEA2UN10Y							144		t	ng × h/mL	125		ng/mL	2.64			UNKNOWN	mg	3000		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26419191	Homo sapiens							6	cadazolid		false
7101	8015		ADULT	24989044	480.22333	COPANLISIB	COC1=C(OCCCN2CCOCC2)C=CC3=C1N=C(NC(=O)C4=CN=C(N)N=C4)N5CCN=C35	COC1=C(OCCCN2CCOCC2)C=CC3=C1N=C(NC(=O)C4=CN=C(N)N=C4)N5CCN=C35	PLASMA	WI6V529FZ9							25		t	ng × h/mL	1570		ng/mL	463			RECOMMENDED	mg	60		STEADY-STATE	UNKNOWN		week	1			UNKNOWN	Intravenous	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209936s000lbl.pdf	Homo sapiens		h	39.1							false
7102	8015		ADULT	24989044	480.22333	COPANLISIB	COC1=C(OCCCN2CCOCC2)C=CC3=C1N=C(NC(=O)C4=CN=C(N)N=C4)N5CCN=C35	COC1=C(OCCCN2CCOCC2)C=CC3=C1N=C(NC(=O)C4=CN=C(N)N=C4)N5CCN=C35	PLASMA	WI6V529FZ9							25		t	μg × h/L	1280		μg/L	447			INVESTIGATIONAL	mg/kg	0.8		MULTIPLE	FED		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/27915408	Homo sapiens		h	35.6							false
7103	8018		UNKNOWN	11578213	635.974	DELAFLOXACIN MEGLUMINE	DELAFLOXACIN MEGLUMINE	CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.NC1=C(F)C=C(F)C(=N1)N2C=C(C(O)=O)C(=O)C3=CC(F)=C(N4CC(O)C4)C(Cl)=C23	PLASMA	N7V53U4U4T							12		t	μg × h/mL	21.8		μg/mL	8.94			RECOMMENDED	mg	300		SINGLE	UNKNOWN				The plasma protein binding of delafloxacin is approximately 84%; delafloxacin primarily binds to albumin.	16	UNKNOWN	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208610s007,208611s006lbl.pdf	Homo sapiens		h	3.7							false
7104	8018		UNKNOWN	11578213	635.974	DELAFLOXACIN MEGLUMINE	DELAFLOXACIN MEGLUMINE	CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.NC1=C(F)C=C(F)C(=N1)N2C=C(C(O)=O)C(=O)C3=CC(F)=C(N4CC(O)C4)C(Cl)=C23	PLASMA	N7V53U4U4T							12		t	μg × h/mL	23.4		μg/mL	9.29			RECOMMENDED	mg	300		STEADY-STATE	UNKNOWN		day	2			UNKNOWN	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208610s007,208611s006lbl.pdf	Homo sapiens										false
7105	8018		UNKNOWN	11578213	635.974	DELAFLOXACIN MEGLUMINE	DELAFLOXACIN MEGLUMINE	CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.NC1=C(F)C=C(F)C(=N1)N2C=C(C(O)=O)C(=O)C3=CC(F)=C(N4CC(O)C4)C(Cl)=C23	PLASMA	N7V53U4U4T							12		t	μg × h/mL	22.7		μg/mL	7.17			RECOMMENDED	mg	450		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208610s007,208611s006lbl.pdf	Homo sapiens										false
7106	8018		UNKNOWN	11578213	635.974	DELAFLOXACIN MEGLUMINE	DELAFLOXACIN MEGLUMINE	CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.NC1=C(F)C=C(F)C(=N1)N2C=C(C(O)=O)C(=O)C3=CC(F)=C(N4CC(O)C4)C(Cl)=C23	PLASMA	N7V53U4U4T							12		t	μg × h/mL	30.8		μg/mL	7.45			RECOMMENDED	mg	450		STEADY-STATE	UNKNOWN		day	2			UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208610s007,208611s006lbl.pdf	Homo sapiens										false
7107	8019		ADULT	65808	454.6016	DEXVERAPAMIL	DEXVERAPAMIL	COC1=C(OC)C=C(CCN(C)CCC[C@@](C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1	PLASMA	QR5PYD126V									?	ng × h/mL	1707		ng/mL	308			UNKNOWN	mg	250		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8398588/	Homo sapiens		h	5.6				6	R-verapamil		false
7108	8019		ADULT	65808	454.6016	DEXVERAPAMIL	DEXVERAPAMIL	COC1=C(OC)C=C(CCN(C)CCC[C@@](C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1	PLASMA	QR5PYD126V									?	ng × h/mL	11818		ng/mL	2103			UNKNOWN	mg	1000		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8398588/	Homo sapiens		h	5.5				4	R-verapamil		false
7109	8019		ADULT	65808	454.6016	DEXVERAPAMIL	DEXVERAPAMIL	COC1=C(OC)C=C(CCN(C)CCC[C@@](C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1	PLASMA	QR5PYD126V									?	ng × h/mL	3974		ng/mL	892			UNKNOWN	mg	500		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8398588/	Homo sapiens		h	4				8	R-verapamil		false
7110	8022		ADULT	58460047	425.749	DORAVIRINE	DORAVIRINE	CN1C(=O)NN=C1CN2C=CC(=C(OC3=CC(Cl)=CC(=C3)C#N)C2=O)C(F)(F)F	PLASMA	913P6LK81M							24		t	μg × h/mL	16.1		μg/mL	0.962			RECOMMENDED	mg	100		STEADY-STATE	UNKNOWN		day	1	Plasma protein binding 76%	24	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf	Homo sapiens		h	15							false
7111	8023		ADULT	11250647	631.6	ELAGOLIX	ELAGOLIX	COC1=C(F)C(=CC=C1)C2=C(C)N(CC3=C(F)C=CC=C3C(F)(F)F)C(=O)N(C[C@H](NCCCC(O)=O)C4=CC=CC=C4)C2=O	PLASMA	5B2546MB5Z									∞	ng × h/mL	3231		ng/mL	1314			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/30570832	Homo sapiens		h	5.48							false
7112	8024		ADULT	9939892	695.888	ELOBIXIBAT	ELOBIXIBAT	CCCCC1(CCCC)CN(C2=CC=CC=C2)C3=C(C=C(OCC(=O)N[C@@H](C(=O)NCC(O)=O)C4=CC=CC=C4)C(SC)=C3)S(=O)(=O)C1	PLASMA	865UEK4EJC									?	pg × h/mL	1355.22		pg/mL	236.11			RECOMMENDED	mg	10		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29959787/	Homo sapiens		h	6.19	Day 14			8	ELOBIXIBAT		false
7113	8024		ADULT	9939892	695.888	ELOBIXIBAT	ELOBIXIBAT	CCCCC1(CCCC)CN(C2=CC=CC=C2)C3=C(C=C(OCC(=O)N[C@@H](C(=O)NCC(O)=O)C4=CC=CC=C4)C(SC)=C3)S(=O)(=O)C1	PLASMA	865UEK4EJC									?	pg × h/mL	1662.6		pg/mL	413.05			UNKNOWN	mg	2.5		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29959787/	Homo sapiens		h	2.17				10	ELOBIXIBAT		false
7114	8024		ADULT	9939892	695.888	ELOBIXIBAT	ELOBIXIBAT	CCCCC1(CCCC)CN(C2=CC=CC=C2)C3=C(C=C(OCC(=O)N[C@@H](C(=O)NCC(O)=O)C4=CC=CC=C4)C(SC)=C3)S(=O)(=O)C1	PLASMA	865UEK4EJC									?	pg × h/mL	3445.62		pg/mL	953.18			UNKNOWN	mg	20		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29959787/	Homo sapiens		h	7.23	Day 14			10	ELOBIXIBAT		false
7115	8024		ADULT	9939892	695.888	ELOBIXIBAT	ELOBIXIBAT	CCCCC1(CCCC)CN(C2=CC=CC=C2)C3=C(C=C(OCC(=O)N[C@@H](C(=O)NCC(O)=O)C4=CC=CC=C4)C(SC)=C3)S(=O)(=O)C1	PLASMA	865UEK4EJC									?	pg × h/mL	248.66		pg/mL	82.66			UNKNOWN	mg	2.5		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29959787/	Homo sapiens		h	2.34	Day 14			10	ELOBIXIBAT		false
7116	8024		ADULT	9939892	695.888	ELOBIXIBAT	ELOBIXIBAT	CCCCC1(CCCC)CN(C2=CC=CC=C2)C3=C(C=C(OCC(=O)N[C@@H](C(=O)NCC(O)=O)C4=CC=CC=C4)C(SC)=C3)S(=O)(=O)C1	PLASMA	865UEK4EJC									?	pg × h/mL	12839.38		pg/mL	3165.49			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29959787/	Homo sapiens		h	11.53				9	ELOBIXIBAT		false
7117	8024		ADULT	9939892	695.888	ELOBIXIBAT	ELOBIXIBAT	CCCCC1(CCCC)CN(C2=CC=CC=C2)C3=C(C=C(OCC(=O)N[C@@H](C(=O)NCC(O)=O)C4=CC=CC=C4)C(SC)=C3)S(=O)(=O)C1	PLASMA	865UEK4EJC									?	pg × h/mL	5462.58		pg/mL	1357.49			RECOMMENDED	mg	10		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29959787/	Homo sapiens		h	5.69				10	ELOBIXIBAT		false
7118	8024		ADULT	9939892	695.888	ELOBIXIBAT	ELOBIXIBAT	CCCCC1(CCCC)CN(C2=CC=CC=C2)C3=C(C=C(OCC(=O)N[C@@H](C(=O)NCC(O)=O)C4=CC=CC=C4)C(SC)=C3)S(=O)(=O)C1	PLASMA	865UEK4EJC									?	pg × h/mL	6265		pg/mL	1611			RECOMMENDED	mg	10		SINGLE	FASTED				The percent plasma protein binding of 14C-elobixibat 400 nmol/L in human plasma was 99.5% ± 0.0%.	0.5	HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.pmda.go.jp/files/000232054.pdf	Homo sapiens		h	6.6				10	ELOBIXIBAT		false
7119	8025		ADULT	89683805	473.375	ENASIDENIB	CC(C)(O)CNC1=NC(=NC(NC2=CC(=NC=C2)C(F)(F)F)=N1)C3=CC=CC(=N3)C(F)(F)F	CC(C)(O)CNC1=NC(=NC(NC2=CC(=NC=C2)C(F)(F)F)=N1)C3=CC=CC(=N3)C(F)(F)F	PLASMA	3T1SS4E7AG													μg/mL	13			RECOMMENDED	mg	100		STEADY-STATE	FASTED		day	1	Human plasma protein binding of enasidenib is 98.5% and of its metabolite AGI-16903 is 96.6% in vitro.	1.5	UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf	Homo sapiens		h	137							false
7120	8025		ADULT	89683805	473.375	ENASIDENIB	CC(C)(O)CNC1=NC(=NC(NC2=CC(=NC=C2)C(F)(F)F)=N1)C3=CC=CC(=N3)C(F)(F)F	CC(C)(O)CNC1=NC(=NC(NC2=CC(=NC=C2)C(F)(F)F)=N1)C3=CC=CC(=N3)C(F)(F)F	PLASMA	3T1SS4E7AG									∞	ng × h/mL	49500		ng/mL	822			RECOMMENDED	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/30386625	Homo sapiens		h	25.5							false
7121	8026		ADULT	50922675	539.1518	ENCORAFENIB	ENCORAFENIB	COC(=O)N[C@@H](C)CNC1=NC(=CC=N1)C2=CN(N=C2C3=C(F)C(NS(C)(=O)=O)=CC(Cl)=C3)C(C)C	PLASMA	8L7891MRB6									∞	ng × h/mL	3940		ng/mL	1050			UNKNOWN	mg	100		SINGLE	UNKNOWN					6.77	HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.ema.europa.eu/en/documents/assessment-report/braftovi-epar-public-assessment-report_en.pdf	Homo sapiens		h	6.11							false
7122	8026		ADULT	50922675	539.1518	ENCORAFENIB	ENCORAFENIB	COC(=O)N[C@@H](C)CNC1=NC(=CC=N1)C2=CN(N=C2C3=C(F)C(NS(C)(=O)=O)=CC(Cl)=C3)C(C)C	PLASMA	8L7891MRB6			CETUXIMAB	cetuximab		PQX0D8J21J			∞	ng × h/mL	16946		ng/mL	5153			DEFINED DAILY	mg	450		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/28363909	Homo sapiens		h	3							true
7123	8027		ADULT		558.5554	ERAVACYCLINE	ERAVACYCLINE	CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C(=O)C3=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O)C(O)=C(NC(=O)CN5CCCC5)C=C4F	PLASMA	07896928ZC							12		t	ng × h/mL	4305		ng/mL	2125			RECOMMENDED	mg/kg	1		SINGLE	UNKNOWN				Protein binding of eravacycline to human plasma proteins increases with increasing plasma concentrations, with 79% to 90% (bound) at plasma concentrations ranging from 100 to 10,000 ng/mL.	15.5	HEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211109lbl.pdf	Homo sapiens		h	20							false
7124	8027		ADULT		558.5554	ERAVACYCLINE	ERAVACYCLINE	CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C(=O)C3=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O)C(O)=C(NC(=O)CN5CCCC5)C=C4F	PLASMA	07896928ZC							12		t	ng × h/mL	6309		ng/mL	1825			RECOMMENDED	mg/kg	1		STEADY-STATE	UNKNOWN		day	2	Protein binding of eravacycline to human plasma proteins increases with increasing plasma concentrations, with 79% to 90% (bound) at plasma concentrations ranging from 100 to 10,000 ng/mL.	15.5	HEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211109lbl.pdf	Homo sapiens		h	20							false
7125	8029		UNKNOWN	206530	357.4864	ESOXYBUTYNIN	ESOXYBUTYNIN	CCN(CC)CC#CCOC(=O)[C@](O)(C1CCCCC1)C2=CC=CC=C2	PLASMA	39EY4NVB8T																						UNKNOWN					24.3	UNKNOWN		UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11939551	Homo sapiens										false
7126	8030		ADULT	49836058	638.647	EVACETRAPIB	EVACETRAPIB	CN1N=NC(=N1)N(CC2=CC(=CC(=C2)C(F)(F)F)C(F)(F)F)[C@H]3CCCN(C[C@H]4CC[C@@H](CC4)C(O)=O)C5=C(C)C=C(C)C=C35	PLASMA	51XWV9K850									?	ng × h/mL	13700		ng/mL	1330			UNKNOWN	mg	600		STEADY-STATE	LOW-FAT		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24961753	Homo sapiens		h	37.4	Study drug was administered for 14 days			25	EVACETRAPIB		false
7127	8031		ADULT	11984561	449.036	EVOFOSFAMIDE	Evofosfamide	CN1C(COP(=O)(NCCBr)NCCBr)=CN=C1[N ]([O-])=O	PLASMA	8A9RZ3HN8W									?	μg × h/mL	14.1		μg/mL	14.7			UNKNOWN	mg/m²	575		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21415214/	Homo sapiens		h	0.83	Averages of cycle 1, day 1 and cycle 1, day 15 values	Patients with Advanced Solid Malignancies		12			false
7128	8031		ADULT	11984561	449.036	EVOFOSFAMIDE	Evofosfamide	CN1C(COP(=O)(NCCBr)NCCBr)=CN=C1[N ]([O-])=O	PLASMA	8A9RZ3HN8W									?	μg × h/mL	23		μg/mL	19.7			UNKNOWN	mg/m²	670		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21415214/	Homo sapiens		h	0.84	Averages of cycle 1, day 1 and cycle 1, day 15 values	Patients with Advanced Solid Malignancies		17			false
7129	8031		ADULT	11984561	449.036	EVOFOSFAMIDE	Evofosfamide	CN1C(COP(=O)(NCCBr)NCCBr)=CN=C1[N ]([O-])=O	PLASMA	8A9RZ3HN8W									?	μg × h/mL	25.8		μg/mL	21.2			UNKNOWN	mg/m²	940		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21415214/	Homo sapiens		h	0.8	Averages of cycle 1, day 1 and cycle 1, day 15 values	Patients with Advanced Solid Malignancies		5			false
7130	8031		ADULT	132324	309.924	N,N'-BIS(2-BROMOETHYL)PHOSPHORODIAMIDIC ACID	DIBROMO ISOPHORAMIDE MUSTARD	OP(=O)(NCCBr)NCCBr	PLASMA	GS36DA0M3T									?	μg × h/mL	0.08		μg/mL	0.06			UNKNOWN	mg/m²	120		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21415214/	Homo sapiens		h	0.81	Averages of cycle 1, day 1 and cycle 1, day 15 values	Patients with Advanced Solid Malignancies		3			false
7131	8031		ADULT	132324	309.924	N,N'-BIS(2-BROMOETHYL)PHOSPHORODIAMIDIC ACID	DIBROMO ISOPHORAMIDE MUSTARD	OP(=O)(NCCBr)NCCBr	PLASMA	GS36DA0M3T									?	μg × h/mL	0.11		μg/mL	0.11			UNKNOWN	mg/m²	240		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21415214/	Homo sapiens		h	0.46	Averages of cycle 1, day 1 and cycle 1, day 15 values	Patients with Advanced Solid Malignancies		2			false
7132	8031		ADULT	132324	309.924	N,N'-BIS(2-BROMOETHYL)PHOSPHORODIAMIDIC ACID	DIBROMO ISOPHORAMIDE MUSTARD	OP(=O)(NCCBr)NCCBr	PLASMA	GS36DA0M3T									?	μg × h/mL	0.16		μg/mL	0.15			UNKNOWN	mg/m²	480		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21415214/	Homo sapiens		h	0.54	Averages of cycle 1, day 1 and cycle 1, day 15 values	Patients with Advanced Solid Malignancies		6			false
7133	8031		ADULT	132324	309.924	N,N'-BIS(2-BROMOETHYL)PHOSPHORODIAMIDIC ACID	DIBROMO ISOPHORAMIDE MUSTARD	OP(=O)(NCCBr)NCCBr	PLASMA	GS36DA0M3T									?	μg × h/mL	0.26		μg/mL	0.19			UNKNOWN	mg/m²	575		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21415214/	Homo sapiens		h	0.67	Averages of cycle 1, day 1 and cycle 1, day 15 values	Patients with Advanced Solid Malignancies		12			false
7134	8031		ADULT	132324	309.924	N,N'-BIS(2-BROMOETHYL)PHOSPHORODIAMIDIC ACID	DIBROMO ISOPHORAMIDE MUSTARD	OP(=O)(NCCBr)NCCBr	PLASMA	GS36DA0M3T									?	μg × h/mL	0.37		μg/mL	0.22			UNKNOWN	mg/m²	670		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21415214/	Homo sapiens		h	0.87	Averages of cycle 1, day 1 and cycle 1, day 15 values	Patients with Advanced Solid Malignancies		17			false
7135	8031		ADULT	132324	309.924	N,N'-BIS(2-BROMOETHYL)PHOSPHORODIAMIDIC ACID	DIBROMO ISOPHORAMIDE MUSTARD	OP(=O)(NCCBr)NCCBr	PLASMA	GS36DA0M3T									?	μg × h/mL	0.54		μg/mL	0.37			UNKNOWN	mg/m²	940		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21415214/	Homo sapiens		h	0.61	Averages of cycle 1, day 1 and cycle 1, day 15 values	Patients with Advanced Solid Malignancies		5			false
7136	8031		ADULT	11984561	449.036	EVOFOSFAMIDE	Evofosfamide	CN1C(COP(=O)(NCCBr)NCCBr)=CN=C1[N ]([O-])=O	PLASMA	8A9RZ3HN8W									?	μg × h/mL	3.9		μg/mL	4.2			UNKNOWN	mg/m²	120		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21415214/	Homo sapiens		h	0.83	Averages of cycle 1, day 1 and cycle 1, day 15 values	Patients with Advanced Solid Malignancies		3			false
7137	8031		ADULT	11984561	449.036	EVOFOSFAMIDE	Evofosfamide	CN1C(COP(=O)(NCCBr)NCCBr)=CN=C1[N ]([O-])=O	PLASMA	8A9RZ3HN8W									?	μg × h/mL	8.4		μg/mL	14.7			UNKNOWN	mg/m²	240		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21415214/	Homo sapiens		h	0.98	Averages of cycle 1, day 1 and cycle 1, day 15 values	Patients with Advanced Solid Malignancies		2			false
7138	8031		ADULT	11984561	449.036	EVOFOSFAMIDE	Evofosfamide	CN1C(COP(=O)(NCCBr)NCCBr)=CN=C1[N ]([O-])=O	PLASMA	8A9RZ3HN8W									?	μg × h/mL	14.5		μg/mL	22.5			UNKNOWN	mg/m²	480		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21415214/	Homo sapiens		h	0.98	Averages of cycle 1, day 1 and cycle 1, day 15 values	Patients with Advanced Solid Malignancies		6			false
7139	8040		ADULT	11984591	628.629	R406	R406	OS(=O)(=O)C1=CC=CC=C1.COC2=CC(NC3=NC(NC4=NC5=C(OC(C)(C)C(=O)N5)C=C4)=C(F)C=N3)=CC(OC)=C2OC	PLASMA										∞	ng × h/mL	6490		ng/mL	605			UNKNOWN	mg	75		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23190017	Homo sapiens		h	17.9							false
7140	8041			11317439	473.4839	TEMSAVIR	BMS-626529	COC1=C2C(=CNC2=C(N=C1)N3C=NC(C)=N3)C(=O)C(=O)N4CCN(CC4)C(=O)C5=CC=CC=C5	PLASMA	4B6J53W8N3							12		t	μg × h/mL	13.8		μg/mL	2.55			UNKNOWN	mg	1200		SINGLE								Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01009814	Homo sapiens										false
7141	8041		ADULT	11317439	473.4839	TEMSAVIR	temsavir	COC1=C2C(=CNC2=C(N=C1)N3C=NC(C)=N3)C(=O)C(=O)N4CCN(CC4)C(=O)C5=CC=CC=C5	PLASMA	4B6J53W8N3							24		t	μg × h/mL	42.6		μg/mL	3.39			UNKNOWN	mg	1200		MULTIPLE	FED		day	2			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22896665/	Homo sapiens										false
7142	8041		ADULT	11317439	473.4839	TEMSAVIR	Temsavir	COC1=C2C(=CNC2=C(N=C1)N3C=NC(C)=N3)C(=O)C(=O)N4CCN(CC4)C(=O)C5=CC=CC=C5	PLASMA	4B6J53W8N3			other antiretroviral drugs						?	ng × h/mL	12900		ng/mL	1770			RECOMMENDED	mg	600		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf	Homo sapiens										true
7143	8041		UNKNOWN	11317439	473.4839	TEMSAVIR	temsavir	COC1=C2C(=CNC2=C(N=C1)N3C=NC(C)=N3)C(=O)C(=O)N4CCN(CC4)C(=O)C5=CC=CC=C5	PLASMA	4B6J53W8N3																	RECOMMENDED	mg	600		SINGLE	UNKNOWN				Dosing in absolute bioavailability study: single-dose administration of fostemsavir extendedrelease tablet 600 mg followed by single IV infusion of [13C] temsavir 100 mcg.	26.9	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf	Homo sapiens		h	11							false
7144	8043		ADULT	135564985	364.4	GANETESPIB	GANETESPIB	CC(C)C1=C(O)C=C(O)C(=C1)C2=NNC(=O)N2C3=CC4=C(C=C3)N(C)C=C4	PLASMA	2E8412Y946									?	ng × h/mL	8430		ng/mL	4410			RECOMMENDED	mg/m²	200		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/25248753	Homo sapiens		h	4.69							false
7145	8045			49803313	552.7115	GILTERITINIB	GILTERITINIB	CCC1=NC(C(N)=O)=C(NC2=CC(OC)=C(C=C2)N3CCC(CC3)N4CCN(C)CC4)N=C1NC5CCOCC5	PLASMA	66D92MGC8M													ng/mL	136.7				mg	120		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02014558	Homo sapiens										false
7146	8045			49803313	552.7115	GILTERITINIB	GILTERITINIB	CCC1=NC(C(N)=O)=C(NC2=CC(OC)=C(C=C2)N3CCC(CC3)N4CCN(C)CC4)N=C1NC5CCOCC5	PLASMA	66D92MGC8M							24		t	ng × h/mL	2480							mg	120		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02014558	Homo sapiens										false
7147	8045			49803313	552.7115	GILTERITINIB	GILTERITINIB	CCC1=NC(C(N)=O)=C(NC2=CC(OC)=C(C=C2)N3CCC(CC3)N4CCN(C)CC4)N=C1NC5CCOCC5	PLASMA	66D92MGC8M									?	ng × h/mL	2480							mg	120		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02014558	Homo sapiens										false
7148	8045			49803313	552.7115	GILTERITINIB	GILTERITINIB	CCC1=NC(C(N)=O)=C(NC2=CC(OC)=C(C=C2)N3CCC(CC3)N4CCN(C)CC4)N=C1NC5CCOCC5	PLASMA	66D92MGC8M							24		t	ng × h/mL	3022							mg	200		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02014558	Homo sapiens										false
7149	8045			49803313	552.7115	GILTERITINIB	GILTERITINIB	CCC1=NC(C(N)=O)=C(NC2=CC(OC)=C(C=C2)N3CCC(CC3)N4CCN(C)CC4)N=C1NC5CCOCC5	PLASMA	66D92MGC8M													ng/mL	168.2				mg	200		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02014558	Homo sapiens										false
7150	8045			49803313	552.7115	GILTERITINIB	GILTERITINIB	CCC1=NC(C(N)=O)=C(NC2=CC(OC)=C(C=C2)N3CCC(CC3)N4CCN(C)CC4)N=C1NC5CCOCC5	PLASMA	66D92MGC8M									?	ng × h/mL	3024							mg	200		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02014558	Homo sapiens										false
7151	8045			49803313	552.7115	GILTERITINIB	GILTERITINIB	CCC1=NC(C(N)=O)=C(NC2=CC(OC)=C(C=C2)N3CCC(CC3)N4CCN(C)CC4)N=C1NC5CCOCC5	PLASMA	66D92MGC8M							24		t	ng × h/mL	4163							mg	300		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02014558	Homo sapiens										false
7152	8045			49803313	552.7115	GILTERITINIB	GILTERITINIB	CCC1=NC(C(N)=O)=C(NC2=CC(OC)=C(C=C2)N3CCC(CC3)N4CCN(C)CC4)N=C1NC5CCOCC5	PLASMA	66D92MGC8M													ng/mL	204.3				mg	300		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02014558	Homo sapiens										false
7153	8045			49803313	552.7115	GILTERITINIB	GILTERITINIB	CCC1=NC(C(N)=O)=C(NC2=CC(OC)=C(C=C2)N3CCC(CC3)N4CCN(C)CC4)N=C1NC5CCOCC5	PLASMA	66D92MGC8M									?	ng × h/mL	4181							mg	300		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02014558	Homo sapiens										false
7154	8045			49803313	552.7115	GILTERITINIB	GILTERITINIB	CCC1=NC(C(N)=O)=C(NC2=CC(OC)=C(C=C2)N3CCC(CC3)N4CCN(C)CC4)N=C1NC5CCOCC5	PLASMA	66D92MGC8M							24		t	ng × h/mL	360							mg	40		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02014558	Homo sapiens										false
7155	8045			49803313	552.7115	GILTERITINIB	GILTERITINIB	CCC1=NC(C(N)=O)=C(NC2=CC(OC)=C(C=C2)N3CCC(CC3)N4CCN(C)CC4)N=C1NC5CCOCC5	PLASMA	66D92MGC8M									?	ng × h/mL	360.4							mg	40		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02014558	Homo sapiens										false
7156	8045			49803313	552.7115	GILTERITINIB	GILTERITINIB	CCC1=NC(C(N)=O)=C(NC2=CC(OC)=C(C=C2)N3CCC(CC3)N4CCN(C)CC4)N=C1NC5CCOCC5	PLASMA	66D92MGC8M													ng/mL	24.98				mg	40		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02014558	Homo sapiens										false
7157	8045			49803313	552.7115	GILTERITINIB	GILTERITINIB	CCC1=NC(C(N)=O)=C(NC2=CC(OC)=C(C=C2)N3CCC(CC3)N4CCN(C)CC4)N=C1NC5CCOCC5	PLASMA	66D92MGC8M							24		t	ng × h/mL	3324							mg	450		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02014558	Homo sapiens										false
7158	8045			49803313	552.7115	GILTERITINIB	GILTERITINIB	CCC1=NC(C(N)=O)=C(NC2=CC(OC)=C(C=C2)N3CCC(CC3)N4CCN(C)CC4)N=C1NC5CCOCC5	PLASMA	66D92MGC8M													ng/mL	207.6				mg	450		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02014558	Homo sapiens										false
7159	8045			49803313	552.7115	GILTERITINIB	GILTERITINIB	CCC1=NC(C(N)=O)=C(NC2=CC(OC)=C(C=C2)N3CCC(CC3)N4CCN(C)CC4)N=C1NC5CCOCC5	PLASMA	66D92MGC8M									?	ng × h/mL	2544							mg	450		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02014558	Homo sapiens										false
7160	8045			49803313	552.7115	GILTERITINIB	GILTERITINIB	CCC1=NC(C(N)=O)=C(NC2=CC(OC)=C(C=C2)N3CCC(CC3)N4CCN(C)CC4)N=C1NC5CCOCC5	PLASMA	66D92MGC8M							24		t	ng × h/mL	1216							mg	80		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02014558	Homo sapiens										false
7161	8045			49803313	552.7115	GILTERITINIB	GILTERITINIB	CCC1=NC(C(N)=O)=C(NC2=CC(OC)=C(C=C2)N3CCC(CC3)N4CCN(C)CC4)N=C1NC5CCOCC5	PLASMA	66D92MGC8M													ng/mL	75.29				mg	80		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02014558	Homo sapiens										false
7162	8045			49803313	552.7115	GILTERITINIB	GILTERITINIB	CCC1=NC(C(N)=O)=C(NC2=CC(OC)=C(C=C2)N3CCC(CC3)N4CCN(C)CC4)N=C1NC5CCOCC5	PLASMA	66D92MGC8M									?	ng × h/mL	1216							mg	80		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02014558	Homo sapiens										false
7163	8045			49803313	552.7115	GILTERITINIB	GILTERITINIB	CCC1=NC(C(N)=O)=C(NC2=CC(OC)=C(C=C2)N3CCC(CC3)N4CCN(C)CC4)N=C1NC5CCOCC5	PLASMA	66D92MGC8M							24		t	ng × h/mL	6943							mg	120		STEADY-STATE			day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02014558	Homo sapiens										false
7164	8045			49803313	552.7115	GILTERITINIB	GILTERITINIB	CCC1=NC(C(N)=O)=C(NC2=CC(OC)=C(C=C2)N3CCC(CC3)N4CCN(C)CC4)N=C1NC5CCOCC5	PLASMA	66D92MGC8M													ng/mL	374.2				mg	120		STEADY-STATE			day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02014558	Homo sapiens										false
7165	8045			49803313	552.7115	GILTERITINIB	GILTERITINIB	CCC1=NC(C(N)=O)=C(NC2=CC(OC)=C(C=C2)N3CCC(CC3)N4CCN(C)CC4)N=C1NC5CCOCC5	PLASMA	66D92MGC8M									?	ng × h/mL	6943							mg	120		STEADY-STATE			day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02014558	Homo sapiens										false
7166	8045			49803313	552.7115	GILTERITINIB	GILTERITINIB	CCC1=NC(C(N)=O)=C(NC2=CC(OC)=C(C=C2)N3CCC(CC3)N4CCN(C)CC4)N=C1NC5CCOCC5	PLASMA	66D92MGC8M							24		t	ng × h/mL	31428							mg	200		STEADY-STATE			day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02014558	Homo sapiens										false
7167	8045			49803313	552.7115	GILTERITINIB	GILTERITINIB	CCC1=NC(C(N)=O)=C(NC2=CC(OC)=C(C=C2)N3CCC(CC3)N4CCN(C)CC4)N=C1NC5CCOCC5	PLASMA	66D92MGC8M													ng/mL	1462				mg	200		STEADY-STATE			day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02014558	Homo sapiens										false
7168	8045			49803313	552.7115	GILTERITINIB	GILTERITINIB	CCC1=NC(C(N)=O)=C(NC2=CC(OC)=C(C=C2)N3CCC(CC3)N4CCN(C)CC4)N=C1NC5CCOCC5	PLASMA	66D92MGC8M									?	ng × h/mL	32248							mg	200		STEADY-STATE			day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02014558	Homo sapiens										false
7169	8045			49803313	552.7115	GILTERITINIB	GILTERITINIB	CCC1=NC(C(N)=O)=C(NC2=CC(OC)=C(C=C2)N3CCC(CC3)N4CCN(C)CC4)N=C1NC5CCOCC5	PLASMA	66D92MGC8M																		mg	200		STEADY-STATE			day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02014558	Homo sapiens		h	141.9							false
7170	8045			49803313	552.7115	GILTERITINIB	GILTERITINIB	CCC1=NC(C(N)=O)=C(NC2=CC(OC)=C(C=C2)N3CCC(CC3)N4CCN(C)CC4)N=C1NC5CCOCC5	PLASMA	66D92MGC8M							24		t	ng × h/mL	31005							mg	300		STEADY-STATE			day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02014558	Homo sapiens										false
7171	8045			49803313	552.7115	GILTERITINIB	GILTERITINIB	CCC1=NC(C(N)=O)=C(NC2=CC(OC)=C(C=C2)N3CCC(CC3)N4CCN(C)CC4)N=C1NC5CCOCC5	PLASMA	66D92MGC8M													ng/mL	1525				mg	300		STEADY-STATE			day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02014558	Homo sapiens										false
7172	8045			49803313	552.7115	GILTERITINIB	GILTERITINIB	CCC1=NC(C(N)=O)=C(NC2=CC(OC)=C(C=C2)N3CCC(CC3)N4CCN(C)CC4)N=C1NC5CCOCC5	PLASMA	66D92MGC8M									?	ng × h/mL	31749							mg	300		STEADY-STATE			day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02014558	Homo sapiens										false
7173	8045			49803313	552.7115	GILTERITINIB	GILTERITINIB	CCC1=NC(C(N)=O)=C(NC2=CC(OC)=C(C=C2)N3CCC(CC3)N4CCN(C)CC4)N=C1NC5CCOCC5	PLASMA	66D92MGC8M																		mg	300		STEADY-STATE			day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02014558	Homo sapiens		h	142.2							false
7174	8045			49803313	552.7115	GILTERITINIB	GILTERITINIB	CCC1=NC(C(N)=O)=C(NC2=CC(OC)=C(C=C2)N3CCC(CC3)N4CCN(C)CC4)N=C1NC5CCOCC5	PLASMA	66D92MGC8M							24		t	ng × h/mL	2482							mg	40		STEADY-STATE			day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02014558	Homo sapiens										false
7175	8045			49803313	552.7115	GILTERITINIB	GILTERITINIB	CCC1=NC(C(N)=O)=C(NC2=CC(OC)=C(C=C2)N3CCC(CC3)N4CCN(C)CC4)N=C1NC5CCOCC5	PLASMA	66D92MGC8M									?	ng × h/mL	1990							mg	40		STEADY-STATE			day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02014558	Homo sapiens										false
7176	8045			49803313	552.7115	GILTERITINIB	GILTERITINIB	CCC1=NC(C(N)=O)=C(NC2=CC(OC)=C(C=C2)N3CCC(CC3)N4CCN(C)CC4)N=C1NC5CCOCC5	PLASMA	66D92MGC8M													ng/mL	107.6				mg	40		STEADY-STATE			day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02014558	Homo sapiens										false
7177	8045			49803313	552.7115	GILTERITINIB	GILTERITINIB	CCC1=NC(C(N)=O)=C(NC2=CC(OC)=C(C=C2)N3CCC(CC3)N4CCN(C)CC4)N=C1NC5CCOCC5	PLASMA	66D92MGC8M							24		t	ng × h/mL	34768							mg	450		STEADY-STATE			day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02014558	Homo sapiens										false
7178	8045			49803313	552.7115	GILTERITINIB	GILTERITINIB	CCC1=NC(C(N)=O)=C(NC2=CC(OC)=C(C=C2)N3CCC(CC3)N4CCN(C)CC4)N=C1NC5CCOCC5	PLASMA	66D92MGC8M													ng/mL	1528				mg	450		STEADY-STATE			day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02014558	Homo sapiens										false
7179	8045			49803313	552.7115	GILTERITINIB	GILTERITINIB	CCC1=NC(C(N)=O)=C(NC2=CC(OC)=C(C=C2)N3CCC(CC3)N4CCN(C)CC4)N=C1NC5CCOCC5	PLASMA	66D92MGC8M									?	ng × h/mL	35506							mg	450		STEADY-STATE			day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02014558	Homo sapiens										false
7180	8045			49803313	552.7115	GILTERITINIB	GILTERITINIB	CCC1=NC(C(N)=O)=C(NC2=CC(OC)=C(C=C2)N3CCC(CC3)N4CCN(C)CC4)N=C1NC5CCOCC5	PLASMA	66D92MGC8M							24		t	ng × h/mL	6958							mg	80		STEADY-STATE			day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02014558	Homo sapiens										false
7181	8045			49803313	552.7115	GILTERITINIB	GILTERITINIB	CCC1=NC(C(N)=O)=C(NC2=CC(OC)=C(C=C2)N3CCC(CC3)N4CCN(C)CC4)N=C1NC5CCOCC5	PLASMA	66D92MGC8M													ng/mL	376.4				mg	80		STEADY-STATE			day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02014558	Homo sapiens										false
7182	8045			49803313	552.7115	GILTERITINIB	GILTERITINIB	CCC1=NC(C(N)=O)=C(NC2=CC(OC)=C(C=C2)N3CCC(CC3)N4CCN(C)CC4)N=C1NC5CCOCC5	PLASMA	66D92MGC8M									?	ng × h/mL	7111							mg	80		STEADY-STATE			day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02014558	Homo sapiens										false
7183	8045			49803313	552.7115	GILTERITINIB	GILTERITINIB	CCC1=NC(C(N)=O)=C(NC2=CC(OC)=C(C=C2)N3CCC(CC3)N4CCN(C)CC4)N=C1NC5CCOCC5	PLASMA	66D92MGC8M																		mg	80		STEADY-STATE			day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02014558	Homo sapiens		h	86.11							false
7184	8045			49803313	552.7115	GILTERITINIB	GILTERITINIB	CCC1=NC(C(N)=O)=C(NC2=CC(OC)=C(C=C2)N3CCC(CC3)N4CCN(C)CC4)N=C1NC5CCOCC5	PLASMA	66D92MGC8M																		mg	40		STEADY-STATE			day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02014558	Homo sapiens		h	151.8							false
7185	8045			49803313	552.7115	GILTERITINIB	GILTERITINIB	CCC1=NC(C(N)=O)=C(NC2=CC(OC)=C(C=C2)N3CCC(CC3)N4CCN(C)CC4)N=C1NC5CCOCC5	PLASMA	66D92MGC8M																		mg	120		STEADY-STATE			day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02014558	Homo sapiens		h	45.85							false
7186	8045		ADULT	49803313	552.7115	GILTERITINIB	GILTERITINIB	CCC1=NC(C(N)=O)=C(NC2=CC(OC)=C(C=C2)N3CCC(CC3)N4CCN(C)CC4)N=C1NC5CCOCC5	PLASMA	66D92MGC8M							24		t	ng × h/mL	3324		ng/mL	216			UNKNOWN	mg	450		SINGLE	UNKNOWN				In vivo plasma protein binding in humans is approximately 94%, and gilteritinib is primarily bound to albumin	6	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32304015	Homo sapiens										false
7187	8045		ADULT	49803313	552.7115	GILTERITINIB	GILTERITINIB	CCC1=NC(C(N)=O)=C(NC2=CC(OC)=C(C=C2)N3CCC(CC3)N4CCN(C)CC4)N=C1NC5CCOCC5	PLASMA	66D92MGC8M							24		t	ng × h/mL	37468		ng/mL	1528			UNKNOWN	mg	450		MULTIPLE	UNKNOWN		day	1	In vivo plasma protein binding in humans is approximately 94%, and gilteritinib is primarily bound to albumin	6	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32304015	Homo sapiens										false
7188	8045		ADULT	49803313	552.7115	GILTERITINIB	GILTERITINIB	CCC1=NC(C(N)=O)=C(NC2=CC(OC)=C(C=C2)N3CCC(CC3)N4CCN(C)CC4)N=C1NC5CCOCC5	PLASMA	66D92MGC8M							24		t	ng × h/mL	28711		ng/mL	1257			MAX TOLERATED	mg	300		MULTIPLE	UNKNOWN		day	1	In vivo plasma protein binding in humans is approximately 94%, and gilteritinib is primarily bound to albumin	6	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32304015	Homo sapiens		h	159							false
7189	8045		ADULT	49803313	552.7115	GILTERITINIB	GILTERITINIB	CCC1=NC(C(N)=O)=C(NC2=CC(OC)=C(C=C2)N3CCC(CC3)N4CCN(C)CC4)N=C1NC5CCOCC5	PLASMA	66D92MGC8M							24		t	ng × h/mL	2446		ng/mL	137			MAX TOLERATED	mg	300		SINGLE	UNKNOWN				In vivo plasma protein binding in humans is approximately 94%, and gilteritinib is primarily bound to albumin	6	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32304015	Homo sapiens										false
7190	8045		ADULT	49803313	552.7115	GILTERITINIB	GILTERITINIB	CCC1=NC(C(N)=O)=C(NC2=CC(OC)=C(C=C2)N3CCC(CC3)N4CCN(C)CC4)N=C1NC5CCOCC5	PLASMA	66D92MGC8M							24		t	ng × h/mL	6943		ng/mL	374			RECOMMENDED	mg	120		STEADY-STATE	UNKNOWN		day	1	In vivo, gilteritinib is approximately 94% bound to human plasma proteins.	6	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211349s000lbl.pdf	Homo sapiens		h	113				3			false
7191	8045		UNKNOWN	49803313	552.7115	GILTERITINIB	GILTERITINIB	CCC1=NC(C(N)=O)=C(NC2=CC(OC)=C(C=C2)N3CCC(CC3)N4CCN(C)CC4)N=C1NC5CCOCC5	PLASMA	66D92MGC8M																						UNKNOWN				In vivo, gilteritinib is approximately 94% bound to human plasma proteins.	6	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211349s001lbl.pdf	Homo sapiens										false
7192	8045		ADULT	49803313	552.7115	GILTERITINIB	GILTERITINIB	CCC1=NC(C(N)=O)=C(NC2=CC(OC)=C(C=C2)N3CCC(CC3)N4CCN(C)CC4)N=C1NC5CCOCC5	PLASMA	66D92MGC8M							24		t	ng × h/mL	3340.23		ng/mL	216.38			DEFINED DAILY	mg	120		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/30039554	Homo sapiens		h	84							false
7193	8048		ADULT	9867642	435.896	LAROPIPRANT	Laropiprant	CS(=O)(=O)C1=C2N(CC3=CC=C(Cl)C=C3)C4=C(CC[C@@H]4CC(O)=O)C2=CC(F)=C1	PLASMA	G7N11T8O78									∞	μM × h	10.8		μM	2.34			UNKNOWN	mg	40		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17431030/	Homo sapiens							6			false
7194	8048		ADULT	9867642	435.896	LAROPIPRANT	Laropiprant	CS(=O)(=O)C1=C2N(CC3=CC=C(Cl)C=C3)C4=C(CC[C@@H]4CC(O)=O)C2=CC(F)=C1	PLASMA	G7N11T8O78									∞	μM × h	19.69		μM	2.4			UNKNOWN	mg	40		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19433974/	Homo sapiens		h	26		Severe renal impairment		8			false
7195	8048		ADULT	9867642	435.896	LAROPIPRANT	Laropiprant	CS(=O)(=O)C1=C2N(CC3=CC=C(Cl)C=C3)C4=C(CC[C@@H]4CC(O)=O)C2=CC(F)=C1	PLASMA	G7N11T8O78									∞	μM × h	12.46		μM	2.35			UNKNOWN	mg	40		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19433974/	Homo sapiens		h	14.8		Normal renal function		8			false
7196	8048		ADULT	9867642	435.896	LAROPIPRANT	Laropiprant	CS(=O)(=O)C1=C2N(CC3=CC=C(Cl)C=C3)C4=C(CC[C@@H]4CC(O)=O)C2=CC(F)=C1	PLASMA	G7N11T8O78	84029	747.9534	CLARITHROMYCIN	Clarithromycin	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC	H1250JIK0A			∞	μM × h	19.4		μM	3			UNKNOWN	mg	40		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20337634/	Homo sapiens		h	15.8				8			true
7197	8048		ADULT	9867642	435.896	LAROPIPRANT	Laropiprant	CS(=O)(=O)C1=C2N(CC3=CC=C(Cl)C=C3)C4=C(CC[C@@H]4CC(O)=O)C2=CC(F)=C1	PLASMA	G7N11T8O78									∞	μM × h	14		μM	2.06			UNKNOWN	mg	40		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20337634/	Homo sapiens		h	18				8			false
7198	8048		ADULT	9867642	435.896	LAROPIPRANT	Laropiprant	CS(=O)(=O)C1=C2N(CC3=CC=C(Cl)C=C3)C4=C(CC[C@@H]4CC(O)=O)C2=CC(F)=C1	PLASMA	G7N11T8O78									∞	μM × h	33.3		μM	4.73			UNKNOWN	mg	40		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20484612/	Homo sapiens		h	14.5		Moderate hepatic impairment		8			false
7199	8048		ADULT	9867642	435.896	LAROPIPRANT	Laropiprant	CS(=O)(=O)C1=C2N(CC3=CC=C(Cl)C=C3)C4=C(CC[C@@H]4CC(O)=O)C2=CC(F)=C1	PLASMA	G7N11T8O78									∞	μM × h	12		μM	2.18			UNKNOWN	mg	40		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20484612/	Homo sapiens		h	16.7		Normal hepatic function		8			false
7200	8048			9867642	435.896	LAROPIPRANT	Laropiprant	CS(=O)(=O)C1=C2N(CC3=CC=C(Cl)C=C3)C4=C(CC[C@@H]4CC(O)=O)C2=CC(F)=C1	PLASMA	G7N11T8O78																										LRPT is highly bound (> 99%) to plasma proteins.	1				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22607011/	Homo sapiens										false
7201	8050		ADULT	45138674	572.5	Letermovir		COC1=C(C=C(C=C1)C(F)(F)F)N2C(C3=C(C(=CC=C3)F)N=C2N4CCN(CC4)C5=CC(=CC=C5)OC)CC(=O)O	PLASMA	1H09Y5WO1F									∞	μg × h/mL	33.61		μg/mL	15.88			INVESTIGATIONAL	mg	240		STEADY-STATE	FASTED		day	1			HEALTHY	Intravenous	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28675594/	Homo sapiens		h	28.31							false
7202	8050		ADULT	45138674	572.5	Letermovir		COC1=C(C=C(C=C1)C(F)(F)F)N2C(C3=C(C(=CC=C3)F)N=C2N4CCN(CC4)C5=CC(=CC=C5)OC)CC(=O)O	PLASMA	1H09Y5WO1F									∞	μg × h/mL	105.66		μg/mL	27.33			RECOMMENDED	mg	480		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28675594/	Homo sapiens		h	13.05							false
7203	8050		ADULT	9916099	572.5506	[NO STEREO] LETERMOVIR	COC1=C(C=C(C=C1)C(F)(F)F)N2C(C3=C(C(=CC=C3)F)N=C2N4CCN(CC4)C5=CC(=CC=C5)OC)CC(=O)O	COC1=CC=CC(=C1)N2CCN(CC2)C3=NC4=C(C=CC=C4F)C(CC(O)=O)N3C5=C(OC)C=CC(=C5)C(F)(F)F	PLASMA	[NO STEREO] 1H09Y5WO1F							24		t	ng × h/mL	7121		ng/mL	1361			INVESTIGATIONAL	mg	60		STEADY-STATE	UNKNOWN		day	1		0.95	HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28722153/	Homo sapiens		h	14.71							false
7204	8052		ADULT	16678941	452.4069	LUMACAFTOR	LUMACAFTOR	CC1=C(N=C(NC(=O)C2(CC2)C3=CC4=C(OC(F)(F)O4)C=C3)C=C1)C5=CC(=CC=C5)C(O)=O	PLASMA	EGP8L81APK							12		t	μg × h/mL	198		μg/mL	25			RECOMMENDED	mg	400		STEADY-STATE	UNKNOWN		day	2	Lumacaftor is approximately 99% bound to plasma proteins, primarily to albumin.	1	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206038s010lbl.pdf	Homo sapiens										false
7205	8052		ADULT	16678941	452.4069	LUMACAFTOR	LUMACAFTOR	CC1=C(N=C(NC(=O)C2(CC2)C3=CC4=C(OC(F)(F)O4)C=C3)C=C1)C5=CC(=CC=C5)C(O)=O	PLASMA	EGP8L81APK																	UNKNOWN	mg	200		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206038s010lbl.pdf	Homo sapiens		h	25.2							false
7206	8053		ADULT		784.874	LURBINECTEDIN	LURBINECTEDIN	COC1=CC2=C(NC3=C2CCN[C@]34CS[C@H]5[C@H]6[C@@H]7N(C)[C@@H](CC8=CC(C)=C(OC)C(O)=C78)[C@H](O)N6[C@@H](COC4=O)C9=C%10OCOC%10=C(C)C(OC(C)=O)=C59)C=C1	PLASMA	2CN60TN6ZS									∞	ng × h/mL	532.6		ng/mL	153.8			RECOMMENDED	mg	7		MULTIPLE	UNKNOWN		3 weeks	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/24563480	Homo sapiens		h	51.4							false
7207	8054		ADULT	20761479	474.5548	[NO STEREO] MACIMORELIN	CC(C)(C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC3=CNC4=CC=CC=C43)NC=O)N	CC(C)(N)C(=O)NC(CC1=CNC2=CC=CC=C12)C(=O)NC(CC3=CNC4=CC=CC=C34)NC=O	PLASMA	[NO STEREO] 8680B21W73									∞	ng × h/mL	38		ng/mL	9.24			RECOMMENDED	mg	0.5		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	REVIEW	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/205598Orig1s000ClinPharmR.pdf	Homo sapiens		h	3.51							false
7208	8054		ADULT	9804938	474.6	Macimorelin		CC(C)(C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC3=CNC4=CC=CC=C43)NC=O)N	PLASMA	8680B21W73									∞	ng × h/mL	75.7		ng/mL	21.9			INVESTIGATIONAL	mg/kg	2		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	REVIEW	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/205598Orig1s000ClinPharmR.pdf	Homo sapiens		h	7.23							false
7209	8054		ADULT	9804938	474.6	Macimorelin		CC(C)(C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC3=CNC4=CC=CC=C43)NC=O)N	PLASMA	8680B21W73									∞	ng × h/mL	59.45		ng/mL	9.17			RECOMMENDED	mg/kg	0.5		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	REVIEW	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/205598Orig1s000ClinPharmR.pdf	Homo sapiens		h	3.76							false
7210	8054		ADULT	20761479	474.5548	[NO STEREO] MACIMORELIN	CC(C)(C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC3=CNC4=CC=CC=C43)NC=O)N	CC(C)(N)C(=O)NC(CC1=CNC2=CC=CC=C12)C(=O)NC(CC3=CNC4=CC=CC=C34)NC=O	PLASMA	[NO STEREO] 8680B21W73									∞	μg × h/L	32		μg/L	10.6			RECOMMENDED	mg/kg	0.5		MULTIPLE	FASTED		day	1		22	HEALTHY	Oral	FEMALE / MALE	REVIEW	https://www.ema.europa.eu/en/documents/assessment-report/macimorelin-aeterna-zentaris-epar-public-assessment-report_en.pdf	Homo sapiens		h	3.9							false
7211	8058		ADULT	54732242	570.6356	NALDEMEDINE	NALDEMEDINE	CC(C)(NC(=O)C1=C(O)[C@@H]2OC3=C4C(C[C@H]5N(CC6CC6)CC[C@@]24[C@@]5(O)C1)=CC=C3O)C7=NC(=NO7)C8=CC=CC=C8	PLASMA	03KSI6WLXH									∞	ng × h/mL	11.6		ng/mL	1.98			UNKNOWN	mg	0.1		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/28960888	Homo sapiens		h	8.3							false
7212	8059		ADULT	10331844	240.21	NAPABUCASIN	NAPABUCASIN	CC(=O)C1=CC2=C(O1)C(=O)C3=C(C=CC=C3)C2=O	PLASMA	Z1HHM49K7O									∞	ng × h/mL	10666		ng/mL	1083			UNKNOWN	mg	480		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/31028219	Homo sapiens		h	5.96							false
7213	8060		ADULT	11404337	317.3844	OBATOCLAX	OBATOCLAX	COC1=CC(=N\\C1=C/C2=C(C)C=C(C)N2)C3=CC4=C(N3)C=CC=C4	PLASMA	QN4128B52A							24		t	ng × h/mL	277		ng/mL	92.6			UNKNOWN	mg/m²	40		MULTIPLE	UNKNOWN		3 weeks	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18931344	Homo sapiens		h	59.6	3-hour infusion every 3 weeks			4	Obatoclax mesylate		false
7214	8060		ADULT	11404337	317.3844	OBATOCLAX	OBATOCLAX	COC1=CC(=N\\C1=C/C2=C(C)C=C(C)N2)C3=CC4=C(N3)C=CC=C4	PLASMA	QN4128B52A									∞	ng × h/mL	599		ng/mL	155			UNKNOWN	mg/m²	28		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20538761	Homo sapiens		h	39	weekly 3-hour infusions			6	OBATOCLAX		false
7215	8060		ADULT	11404337	317.3844	OBATOCLAX	OBATOCLAX	COC1=CC(=N\\C1=C/C2=C(C)C=C(C)N2)C3=CC4=C(N3)C=CC=C4	PLASMA	QN4128B52A									∞	ng × h/mL	34.37		ng/mL	27.1			MAX TOLERATED	mg/m²	1.25		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20538761	Homo sapiens		h	11.66	weekly 1-hour infusion			1	OBATOCLAX		false
7216	8060		ADULT	11404337	317.3844	OBATOCLAX	OBATOCLAX	COC1=CC(=N\\C1=C/C2=C(C)C=C(C)N2)C3=CC4=C(N3)C=CC=C4	PLASMA	QN4128B52A									∞	ng × h/mL	55.01		ng/mL	33.46			UNKNOWN	mg/m²	7		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20538761	Homo sapiens		h	45.46	weekly 1-hour infusion			3	OBATOCLAX		false
7217	8060		ADULT	11404337	317.3844	OBATOCLAX	OBATOCLAX	COC1=CC(=N\\C1=C/C2=C(C)C=C(C)N2)C3=CC4=C(N3)C=CC=C4	PLASMA	QN4128B52A									∞	ng × h/mL	401		ng/mL	114.7			MAX TOLERATED	mg/m²	20		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20538761	Homo sapiens		h	28.8	weekly 3-hour infusions			6	OBATOCLAX		false
7218	8061		ADULT		556.6505	OMADACYCLINE	OMADACYCLINE	CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C(=O)C3=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O)C(O)=C(CNCC(C)(C)C)C=C4N(C)C	PLASMA	090IP5RV8F									?	ng × h/mL	12140		ng/mL	2120			RECOMMENDED	mg	100		STEADY-STATE	UNKNOWN		day	1	Plasma protein binding 20%	80	HEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209816_209817lbl.pdf	Homo sapiens		h	16							false
7219	8061		ADULT		556.6505	OMADACYCLINE	OMADACYCLINE	CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C(=O)C3=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O)C(O)=C(CNCC(C)(C)C)C=C4N(C)C	PLASMA	090IP5RV8F									?	ng × h/mL	9399		ng/mL	548			DEFINED DAILY	mg	300		SINGLE	UNKNOWN				Plasma protein binding 20%.	80	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209816_209817lbl.pdf	Homo sapiens		h	14.96							false
7220	8061		ADULT		556.6505	OMADACYCLINE	OMADACYCLINE	CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C(=O)C3=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O)C(O)=C(CNCC(C)(C)C)C=C4N(C)C	PLASMA	090IP5RV8F									?	ng × h/mL	11156		ng/mL	952			RECOMMENDED	mg	300		STEADY-STATE	UNKNOWN		day	1	Plasma protein binding 20%.	80	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209816_209817lbl.pdf	Homo sapiens		h	15.5							false
7221	8061		ADULT		556.6505	OMADACYCLINE	OMADACYCLINE	CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C(=O)C3=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O)C(O)=C(CNCC(C)(C)C)C=C4N(C)C	PLASMA	090IP5RV8F									?	ng × h/mL	8977		ng/mL	874			DEFINED DAILY	mg	450		SINGLE	UNKNOWN				Plasma protein binding 20%.	80	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209816_209817lbl.pdf	Homo sapiens		h	13.45							false
7222	8061		ADULT		556.6505	OMADACYCLINE	OMADACYCLINE	CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C(=O)C3=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O)C(O)=C(CNCC(C)(C)C)C=C4N(C)C	PLASMA	090IP5RV8F									?	ng × h/mL	13367		ng/mL	1077			RECOMMENDED	mg	450		STEADY-STATE	UNKNOWN		day	1	Plasma protein binding 20%.	80	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209816_209817lbl.pdf	Homo sapiens		h	19.83							false
7223	8061		ADULT		556.6505	OMADACYCLINE	OMADACYCLINE	CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C(=O)C3=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O)C(O)=C(CNCC(C)(C)C)C=C4N(C)C	PLASMA	090IP5RV8F									?	ng × h/mL	93.58		ng/mL	1507			DEFINED DAILY	mg	100		SINGLE	UNKNOWN				Plasma protein binding 20%	80	HEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209816_209817lbl.pdf	Homo sapiens		h	16.2							false
7224	8061		ADULT		556.6505	OMADACYCLINE	OMADACYCLINE	CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C(=O)C3=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O)C(O)=C(CNCC(C)(C)C)C=C4N(C)C	PLASMA	090IP5RV8F									∞	ng × h/mL	10158.6		ng/mL	640.84			DEFINED DAILY	mg	300		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209816Orig1s000,209817Orig1s000MultidisciplineR.pdf	Homo sapiens		h	13.81							false
7225	8061		ADULT		556.6505	OMADACYCLINE	OMADACYCLINE	CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C(=O)C3=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O)C(O)=C(CNCC(C)(C)C)C=C4N(C)C	PLASMA	090IP5RV8F									∞	ng × h/mL	4028.85		ng/mL	271.1			DEFINED DAILY	mg	300		SINGLE	HIGH-FAT						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209816Orig1s000,209817Orig1s000MultidisciplineR.pdf	Homo sapiens		h	13.5							false
7226	8065		ADULT	75093025	765.877	[NO STEREO] PARITAPREVIR	CC1=CN=C(C=N1)C(=O)NC2CCCCCC=CC3CC3(NC(=O)C4CC(CN4C2=O)OC5=NC6=CC=CC=C6C7=CC=CC=C75)C(=O)NS(=O)(=O)C8CC8	CC1=CN=C(C=N1)C(=O)NC2CCCCCC=CC3CC3(NC(=O)C4CC(CN4C2=O)OC5=NC6=CC=CC=C6C7=CC=CC=C57)C(=O)NS(=O)(=O)C8CC8	PLASMA	[NO STEREO] OU2YM37K86	76192587		[NO STEREO] OMBITASVIR	CC(C)C(C(=O)N1CCCC1C(=O)NC2=CC=C(C=C2)C3CCC(N3C4=CC=C(C=C4)C(C)(C)C)C5=CC=C(C=C5)NC(=O)C6CCCN6C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC	COC(=O)NC(C(C)C)C(=O)N1CCCC1C(=O)NC2=CC=C(C=C2)C3CCC(N3C4=CC=C(C=C4)C(C)(C)C)C5=CC=C(NC(=O)C6CCCN6C(=O)C(NC(=O)OC)C(C)C)C=C5	[NO STEREO] 2302768XJ8	24		t	ng × h/mL	2220		ng/mL	262			RECOMMENDED	mg	150		STEADY-STATE	FED		day	1		2.2	UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206619lbl.pdf	Homo sapiens		h	5.5							true
7227	8069		ADULT	42613186	592.6828	PLAZOMICIN	PLAZOMICIN	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@@H](C[C@H](N)[C@@H](O[C@H]3OC(CNCCO)=CC[C@H]3N)[C@@H]2O)NC(=O)[C@@H](O)CCN)OC[C@]1(C)O	PLASMA	LYO9XZ250J									∞	μg × h/mL	257		μg/mL	73.7			DEFINED DAILY	mg/kg	15		SINGLE	UNKNOWN				The average binding of plazomicin to human plasma proteins is approximately 20%.	80	HEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210303orig1s000lbl.pdf	Homo sapiens		h	3.5							false
7228	8071		ADULT	9949641	334.3718	PLINABULIN	PLINABULIN	CC(C)(C)C1=C(C=[c]2-n[c](=O)\\c(-nc2=O)=C\\C3=CC=CC=C3)N=CN1	BLOOD	986FY7F8XR									∞	ng × h/mL	3319		ng/mL	527			RECOMMENDED	mg/m²	30		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/21138873	Homo sapiens		h	6.35							false
7229	8072		ADULT	11363176	460.974	PONESIMOD	Ponesimod	CCC\\N=C1/S\\C(=C/C2=CC(Cl)=C(OC[C@H](O)CO)C=C2)C(=O)N1C3=C(C)C=CC=C3	PLASMA	5G7AKV2MKP									∞	ng × h/mL	6719		ng/mL	194			UNKNOWN	mg	40		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213498Orig1s000ClinPharmR.pdf#page=102	Homo sapiens		h	28.9		Caucasian		10			false
7230	8072		ADULT	11363176	460.974	PONESIMOD	Ponesimod	CCC\\N=C1/S\\C(=C/C2=CC(Cl)=C(OC[C@H](O)CO)C=C2)C(=O)N1C3=C(C)C=CC=C3	PLASMA	5G7AKV2MKP									∞	ng × h/mL	7627		ng/mL	196			UNKNOWN	mg	40		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213498Orig1s000ClinPharmR.pdf#page=102	Homo sapiens		h	33.1		Japanese		10			false
7231	8072		UNKNOWN	11363176	460.974	PONESIMOD	Ponesimod	CCC\\N=C1/S\\C(=C/C2=CC(Cl)=C(OC[C@H](O)CO)C=C2)C(=O)N1C3=C(C)C=CC=C3	PLASMA	5G7AKV2MKP									?	ng × h/mL	1246		ng/mL	48.55			UNKNOWN	mg	5		SINGLE	UNKNOWN						UNKNOWN	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213498Orig1s000ClinPharmR.pdf#page=38	Homo sapiens										false
7232	8072		UNKNOWN	11363176	460.974	PONESIMOD	Ponesimod	CCC\\N=C1/S\\C(=C/C2=CC(Cl)=C(OC[C@H](O)CO)C=C2)C(=O)N1C3=C(C)C=CC=C3	PLASMA	5G7AKV2MKP									?	ng × h/mL	2124		ng/mL	61.4			UNKNOWN	mg	10		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213498Orig1s000ClinPharmR.pdf#page=38	Homo sapiens										false
7233	8072		ADULT	11363176	460.974	PONESIMOD	Ponesimod	CCC\\N=C1/S\\C(=C/C2=CC(Cl)=C(OC[C@H](O)CO)C=C2)C(=O)N1C3=C(C)C=CC=C3	PLASMA	5G7AKV2MKP									∞	ng × h/mL	1028		ng/mL	37.1			UNKNOWN	mg	5		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213498Orig1s000ClinPharmR.pdf#page=43	Homo sapiens		h	27.6				3			false
7234	8072		ADULT	11363176	460.974	PONESIMOD	Ponesimod	CCC\\N=C1/S\\C(=C/C2=CC(Cl)=C(OC[C@H](O)CO)C=C2)C(=O)N1C3=C(C)C=CC=C3	PLASMA	5G7AKV2MKP									∞	ng × h/mL	1335		ng/mL	48.5			UNKNOWN	mg	5		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213498Orig1s000ClinPharmR.pdf#page=43	Homo sapiens		h	32.9				14			false
7235	8072		ADULT	11363176	460.974	PONESIMOD	Ponesimod	CCC\\N=C1/S\\C(=C/C2=CC(Cl)=C(OC[C@H](O)CO)C=C2)C(=O)N1C3=C(C)C=CC=C3	PLASMA	5G7AKV2MKP									∞	ng × h/mL	2236		ng/mL	61.4			UNKNOWN	mg	10		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213498Orig1s000ClinPharmR.pdf#page=43	Homo sapiens		h	31.7				14			false
7236	8072		ADULT	11363176	460.974	PONESIMOD	Ponesimod	CCC\\N=C1/S\\C(=C/C2=CC(Cl)=C(OC[C@H](O)CO)C=C2)C(=O)N1C3=C(C)C=CC=C3	PLASMA	5G7AKV2MKP									∞	ng × h/mL	913		ng/mL	27.2			UNKNOWN	mg	8		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213498Orig1s000ClinPharmR.pdf#page=77	Homo sapiens		h	33.4				6			false
7237	8072		ADULT	11363176	460.974	PONESIMOD	Ponesimod	CCC\\N=C1/S\\C(=C/C2=CC(Cl)=C(OC[C@H](O)CO)C=C2)C(=O)N1C3=C(C)C=CC=C3	PLASMA	5G7AKV2MKP									∞	ng × h/mL	2344		ng/mL	71			RECOMMENDED	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213498Orig1s000ClinPharmR.pdf#page=77	Homo sapiens		h	27.7				6			false
7238	8072		ADULT	11363176	460.974	PONESIMOD	Ponesimod	CCC\\N=C1/S\\C(=C/C2=CC(Cl)=C(OC[C@H](O)CO)C=C2)C(=O)N1C3=C(C)C=CC=C3	PLASMA	5G7AKV2MKP									∞	ng × h/mL	5266		ng/mL	163			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213498Orig1s000ClinPharmR.pdf#page=77	Homo sapiens		h	28.8				6			false
7239	8072		ADULT	11363176	460.974	PONESIMOD	Ponesimod	CCC\\N=C1/S\\C(=C/C2=CC(Cl)=C(OC[C@H](O)CO)C=C2)C(=O)N1C3=C(C)C=CC=C3	PLASMA	5G7AKV2MKP									∞	ng × h/mL	9153		ng/mL	274			UNKNOWN	mg	75		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213498Orig1s000ClinPharmR.pdf#page=77	Homo sapiens		h	31.4				6			false
7240	8072		ADULT	11363176	460.974	PONESIMOD	Ponesimod	CCC\\N=C1/S\\C(=C/C2=CC(Cl)=C(OC[C@H](O)CO)C=C2)C(=O)N1C3=C(C)C=CC=C3	PLASMA	5G7AKV2MKP									∞	ng × h/mL	96		ng/mL	3.4			UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213498Orig1s000ClinPharmR.pdf#page=77	Homo sapiens		h	21.7				6			false
7241	8072		ADULT	11363176	460.974	PONESIMOD	Ponesimod	CCC\\N=C1/S\\C(=C/C2=CC(Cl)=C(OC[C@H](O)CO)C=C2)C(=O)N1C3=C(C)C=CC=C3	PLASMA	5G7AKV2MKP									∞	ng × h/mL	405		ng/mL	13.7			UNKNOWN	mg	3		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213498Orig1s000ClinPharmR.pdf#page=77	Homo sapiens		h	30.1				6			false
7242	8072		ADULT	11363176	460.974	PONESIMOD	Ponesimod	CCC\\N=C1/S\\C(=C/C2=CC(Cl)=C(OC[C@H](O)CO)C=C2)C(=O)N1C3=C(C)C=CC=C3	PLASMA	5G7AKV2MKP							24		t	ng × h/mL	643		ng/mL	40.3			UNKNOWN	mg	5		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213498Orig1s000ClinPharmR.pdf#page=82	Homo sapiens		h	30.9	Day 7 PK			8			false
7243	8072		ADULT	11363176	460.974	PONESIMOD	Ponesimod	CCC\\N=C1/S\\C(=C/C2=CC(Cl)=C(OC[C@H](O)CO)C=C2)C(=O)N1C3=C(C)C=CC=C3	PLASMA	5G7AKV2MKP							24		t	ng × h/mL	1400		ng/mL	88.3			UNKNOWN	mg	10		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213498Orig1s000ClinPharmR.pdf#page=82	Homo sapiens		h	32.1	Day 7 PK			8			false
7244	8072		ADULT	11363176	460.974	PONESIMOD	Ponesimod	CCC\\N=C1/S\\C(=C/C2=CC(Cl)=C(OC[C@H](O)CO)C=C2)C(=O)N1C3=C(C)C=CC=C3	PLASMA	5G7AKV2MKP							24		t	ng × h/mL	3473		ng/mL	207			RECOMMENDED	mg	20		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213498Orig1s000ClinPharmR.pdf#page=82	Homo sapiens		h	32.7	Day 7 PK			8			false
7245	8072		ADULT	11363176	460.974	PONESIMOD	Ponesimod	CCC\\N=C1/S\\C(=C/C2=CC(Cl)=C(OC[C@H](O)CO)C=C2)C(=O)N1C3=C(C)C=CC=C3	PLASMA	5G7AKV2MKP							24		t	ng × h/mL	292		ng/mL	20.3			UNKNOWN	mg	5		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213498Orig1s000ClinPharmR.pdf#page=82	Homo sapiens				Day 1 PK			8			false
7246	8072		ADULT	11363176	460.974	PONESIMOD	Ponesimod	CCC\\N=C1/S\\C(=C/C2=CC(Cl)=C(OC[C@H](O)CO)C=C2)C(=O)N1C3=C(C)C=CC=C3	PLASMA	5G7AKV2MKP							24		t	ng × h/mL	684		ng/mL	48.5			UNKNOWN	mg	10		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213498Orig1s000ClinPharmR.pdf#page=82	Homo sapiens				Day 1 PK			8			false
7247	8072		ADULT	11363176	460.974	PONESIMOD	Ponesimod	CCC\\N=C1/S\\C(=C/C2=CC(Cl)=C(OC[C@H](O)CO)C=C2)C(=O)N1C3=C(C)C=CC=C3	PLASMA	5G7AKV2MKP							24		t	ng × h/mL	1318		ng/mL	91.7			RECOMMENDED	mg	20		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213498Orig1s000ClinPharmR.pdf#page=82	Homo sapiens				Day 1 PK			8			false
7248	8072		ADULT	11363176	460.974	PONESIMOD	Ponesimod	CCC\\N=C1/S\\C(=C/C2=CC(Cl)=C(OC[C@H](O)CO)C=C2)C(=O)N1C3=C(C)C=CC=C3	PLASMA	5G7AKV2MKP							24		t	ng × h/mL	667		ng/mL	46.8			UNKNOWN	mg	10		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213498Orig1s000ClinPharmR.pdf#page=83	Homo sapiens				Day 1			11			false
7249	8072		ADULT	11363176	460.974	PONESIMOD	Ponesimod	CCC\\N=C1/S\\C(=C/C2=CC(Cl)=C(OC[C@H](O)CO)C=C2)C(=O)N1C3=C(C)C=CC=C3	PLASMA	5G7AKV2MKP							24		t	ng × h/mL	2085		ng/mL	138			RECOMMENDED	mg	20		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213498Orig1s000ClinPharmR.pdf#page=83	Homo sapiens				Day 5			11			false
7250	8072		ADULT	11363176	460.974	PONESIMOD	Ponesimod	CCC\\N=C1/S\\C(=C/C2=CC(Cl)=C(OC[C@H](O)CO)C=C2)C(=O)N1C3=C(C)C=CC=C3	PLASMA	5G7AKV2MKP							24		t	ng × h/mL	4277		ng/mL	292			UNKNOWN	mg	40		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213498Orig1s000ClinPharmR.pdf#page=83	Homo sapiens				Day 9			11			false
7251	8072		ADULT	11363176	460.974	PONESIMOD	Ponesimod	CCC\\N=C1/S\\C(=C/C2=CC(Cl)=C(OC[C@H](O)CO)C=C2)C(=O)N1C3=C(C)C=CC=C3	PLASMA	5G7AKV2MKP							24		t	ng × h/mL	6325		ng/mL	411			UNKNOWN	mg	40		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213498Orig1s000ClinPharmR.pdf#page=83	Homo sapiens		h	33.5	Day 15			11			false
7252	8072		UNKNOWN	11363176	460.974	PONESIMOD	Ponesimod	CCC\\N=C1/S\\C(=C/C2=CC(Cl)=C(OC[C@H](O)CO)C=C2)C(=O)N1C3=C(C)C=CC=C3	PLASMA	5G7AKV2MKP																						UNKNOWN				Human plasma protein binding (equilibrium dialysis): 99.58% (99.69% (100ng/mL), 99.52% (500ng/mL), 99.47% (3000ng/mL), 99.65% (20000ng/mL), 99.53% (100000ng/mL), 99.61% (200000ng/mL))	0.42	UNKNOWN		UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213498Orig1s000ClinPharmR.pdf#page=9 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213498Orig1s000ClinPharmR.pdf#page=67	Homo sapiens										false
7253	8072		ADULT	11363176	460.974	PONESIMOD	Ponesimod	CCC\\N=C1/S\\C(=C/C2=CC(Cl)=C(OC[C@H](O)CO)C=C2)C(=O)N1C3=C(C)C=CC=C3	PLASMA	5G7AKV2MKP									∞	ng × h/mL	5070		ng/mL	49.2			UNKNOWN	mg	10		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213498Orig1s000ClinPharmR.pdf#page=93	Homo sapiens		h	80.5		Severe hepatic impairment		8			false
7254	8072		ADULT	11363176	460.974	PONESIMOD	Ponesimod	CCC\\N=C1/S\\C(=C/C2=CC(Cl)=C(OC[C@H](O)CO)C=C2)C(=O)N1C3=C(C)C=CC=C3	PLASMA	5G7AKV2MKP									∞	ng × h/mL	2190		ng/mL	54.7			UNKNOWN	mg	10		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213498Orig1s000ClinPharmR.pdf#page=93	Homo sapiens		h	45.7		Mild hepatic impairment		8			false
7255	8072		ADULT	11363176	460.974	PONESIMOD	Ponesimod	CCC\\N=C1/S\\C(=C/C2=CC(Cl)=C(OC[C@H](O)CO)C=C2)C(=O)N1C3=C(C)C=CC=C3	PLASMA	5G7AKV2MKP									∞	ng × h/mL	3320		ng/mL	51.4			UNKNOWN	mg	10		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213498Orig1s000ClinPharmR.pdf#page=93	Homo sapiens		h	55.6		Moderate hepatic impairment		8			false
7256	8072		ADULT	11363176	460.974	PONESIMOD	Ponesimod	CCC\\N=C1/S\\C(=C/C2=CC(Cl)=C(OC[C@H](O)CO)C=C2)C(=O)N1C3=C(C)C=CC=C3	PLASMA	5G7AKV2MKP									∞	ng × h/mL	1650		ng/mL	48.2			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213498Orig1s000ClinPharmR.pdf#page=93	Homo sapiens		h	31.6		Normal hepatic function		8			false
7257	8072		ADULT	11363176	460.974	PONESIMOD	Ponesimod	CCC\\N=C1/S\\C(=C/C2=CC(Cl)=C(OC[C@H](O)CO)C=C2)C(=O)N1C3=C(C)C=CC=C3	PLASMA	5G7AKV2MKP									∞	ng × h/mL	1587		ng/mL	46.8			UNKNOWN	mg	10		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213498Orig1s000ClinPharmR.pdf#page=97	Homo sapiens		h	34.4		Moderate renal impairment		8			false
7258	8072		ADULT	11363176	460.974	PONESIMOD	Ponesimod	CCC\\N=C1/S\\C(=C/C2=CC(Cl)=C(OC[C@H](O)CO)C=C2)C(=O)N1C3=C(C)C=CC=C3	PLASMA	5G7AKV2MKP									∞	ng × h/mL	1554		ng/mL	50			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213498Orig1s000ClinPharmR.pdf#page=97	Homo sapiens		h	26.4		Normal renal function		8			false
7259	8072		ADULT	11363176	460.974	PONESIMOD	Ponesimod	CCC\\N=C1/S\\C(=C/C2=CC(Cl)=C(OC[C@H](O)CO)C=C2)C(=O)N1C3=C(C)C=CC=C3	PLASMA	5G7AKV2MKP									∞	ng × h/mL	1773		ng/mL	54.5			UNKNOWN	mg	10		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213498Orig1s000ClinPharmR.pdf#page=97	Homo sapiens		h	27.9		Severe renal impairment		8			false
7260	8073		ADULT	53387035	455.4722	PRADIGASTAT	PRADIGASTAT	OC(=O)C[C@H]1CC[C@@H](CC1)C2=CC=C(C=C2)C3=CC=C(NC4=CC=C(N=C4)C(F)(F)F)C=N3	PLASMA	2U23G6VNUZ									∞	ng × h/mL	37200		ng/mL	184			UNKNOWN	mg	40		SINGLE	FASTED				Protein binding % = 99.4	0.6	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25627776	Homo sapiens		h	145				9	PRADIGASTAT		false
7261	8073		ADULT	53387035	455.4722	PRADIGASTAT	PRADIGASTAT	OC(=O)C[C@H]1CC[C@@H](CC1)C2=CC=C(C=C2)C3=CC=C(NC4=CC=C(N=C4)C(F)(F)F)C=N3	PLASMA	2U23G6VNUZ							24		t	ng × h/mL	18561		ng/mL	1065			UNKNOWN	mg	300		SINGLE	FASTED						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25854859	Homo sapiens		h	80.2				8	PRADIGASTAT		false
7262	8073		ADULT	53387035	455.4722	PRADIGASTAT	PRADIGASTAT	OC(=O)C[C@H]1CC[C@@H](CC1)C2=CC=C(C=C2)C3=CC=C(NC4=CC=C(N=C4)C(F)(F)F)C=N3	PLASMA	2U23G6VNUZ									∞	ng × h/mL	428000		ng/mL	10500			UNKNOWN	mg	115		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27274009	Homo sapiens		h	109				8	PRADIGASTAT		false
7263	8074		ADULT	456199	359.26	PRETOMANID	PRETOMANID	[O-][N+](=O)C1=CN2C[C@@H](COC2=N1)OCC3=CC=C(OC(F)(F)F)C=C3	PLASMA	2XOI31YC4N									∞	μg × h/mL	53		μg/mL	2			RECOMMENDED	mg	200		SINGLE	FED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212862Orig1s000Lbl.pdf	Homo sapiens		h	17.4							false
7264	8075		ADULT	12988957	239.34	TV-45065	TV-45065	CS(=O)(=O)C1=CC=CC(=C1)C2CCNCC2	PLASMA										∞	ng × h/mL	54.5		μg/mL	804			UNKNOWN	mg	45		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26407011	Homo sapiens		h	8.5				12	pridopidine		false
7265	8075		ADULT	9795739	281.414	PRIDOPIDINE	pridopidine	CCCN1CCC(CC1)C2=CC(=CC=C2)S(C)(=O)=O	PLASMA	HD4TW8S2VK									∞	ng × h/mL	2365		ng/mL	263			UNKNOWN	mg	45		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26407011	Homo sapiens		h	7.6				12	pridopidine		false
7266	8075		ADULT	12988957	239.34	TV-45065	TV-45065	CS(=O)(=O)C1=CC=CC(=C1)C2CCNCC2	PLASMA										?	ng × h/mL	5141		ng/mL	37.5			UNKNOWN	mg	45		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26407011	Homo sapiens		h	13.6				12	pridopidine		false
7267	8075		ADULT	9795739	281.414	PRIDOPIDINE	pridopidine	CCCN1CCC(CC1)C2=CC(=CC=C2)S(C)(=O)=O	PLASMA	HD4TW8S2VK									?	ng × h/mL	3851		ng/mL	426			UNKNOWN	mg	45		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26407011	Homo sapiens		h	9.6				12	pridopidine		false
7268	8078		ADULT	44129647|121301826	348.375	RELEBACTAM ANHYDROUS	RELEBACTAM ANHYDROUS	OS(=O)(=O)ON1[C@H]2C[N@]([C@@H](CC2)C(=O)NC3CCNCC3)C1=O	PLASMA	1OQF7TT3PF									∞	μM × h	7.97						UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29914955/	Homo sapiens		h	1.39							false
7269	8078		ADULT	44129647|121301826	348.375	RELEBACTAM ANHYDROUS	RELEBACTAM ANHYDROUS	OS(=O)(=O)ON1[C@H]2C[N@]([C@@H](CC2)C(=O)NC3CCNCC3)C1=O	PLASMA	1OQF7TT3PF									∞	μM × h	81.8						UNKNOWN	mg	250		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29914955/	Homo sapiens		h	1.63							false
7270	8078		ADULT	44129647|121301826	348.375	RELEBACTAM ANHYDROUS	RELEBACTAM ANHYDROUS	OS(=O)(=O)ON1[C@H]2C[N@]([C@@H](CC2)C(=O)NC3CCNCC3)C1=O	PLASMA	1OQF7TT3PF									∞	μM × h	396						UNKNOWN	mg	1150		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29914955/	Homo sapiens		h	1.78							false
7271	8078		ADULT	44129647|121301826	348.375	RELEBACTAM ANHYDROUS	RELEBACTAM ANHYDROUS	OS(=O)(=O)ON1[C@H]2C[N@]([C@@H](CC2)C(=O)NC3CCNCC3)C1=O	PLASMA	1OQF7TT3PF	5282372		IMIPENEM	Imipenem	O.C[C@@H](O)[C@@H]1[C@H]2CC(SCCNC=N)=C(N2C1=O)C(O)=O	71OTZ9ZE0A	24		t	μM × h	427.3		μM	64			RECOMMENDED	mg	250		MULTIPLE	UNKNOWN		day	4	The binding of relebactam to human plasma proteins is approximately 22 % and is independent of concentration at a range of 5 to 50 µM.	78	UNHEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212819s000lbl.pdf	Homo sapiens		h	1.2							true
7272	8079		ADULT	9867812	439.305	REMIMAZOLAM	remimazolam	COC(=O)CC[C@@H]1N=C(C2=NC=CC=C2)C3=C(C=CC(Br)=C3)N4C(C)=CN=C14	PLASMA	7V4A8U16MB									∞	ng × h/mL	11.49		ng/mL	189.2			UNKNOWN	mg/kg	0.01		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22190555/	Homo sapiens		h	0.597							false
7273	8079		ADULT	9867812	439.305	REMIMAZOLAM	Remimazolam	COC(=O)CC[C@@H]1N=C(C2=NC=CC=C2)C3=C(C=CC(Br)=C3)N4C(C)=CN=C14	PLASMA	7V4A8U16MB									∞	ng × h/mL	105.3		ng/mL	1882			UNKNOWN	mg/kg	0.1		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22190555/	Homo sapiens		h	0.794							false
7274	8079		ADULT	9867812	439.305	REMIMAZOLAM	Remimazolam	COC(=O)CC[C@@H]1N=C(C2=NC=CC=C2)C3=C(C=CC(Br)=C3)N4C(C)=CN=C14	PLASMA	7V4A8U16MB									∞	ng × h/mL	339.3		ng/mL	6095			UNKNOWN	mg/kg	0.3		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22190555/	Homo sapiens		h	0.72							false
7275	8080			44631912	434.5373	RIBOCICLIB	RIBOCICLIB	CN(C)C(=O)C1=CC2=C(N=C(NC3=NC=C(C=C3)N4CCNCC4)N=C2)N1C5CCCC5	PLASMA	TK8ERE8P56																										Binding of ribociclib to human plasma proteins in vitro was approximately 70% and independent of concentration (10 to 10,000 ng/mL).	30				DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209092s004lbl.pdf	Homo sapiens										false
7276	8080		ADULT	44631912	434.25427	RIBOCICLIB	RIBOCICLIB	CN(C)C(=O)C1=CC2=C(N=C(NC3=NC=C(C=C3)N4CCNCC4)N=C2)N1C5CCCC5	PLASMA	TK8ERE8P56	3902		LETROZOLE	letrozole	N#CC1=CC=C(C=C1)C(N2C=NC=N2)C3=CC=C(C=C3)C#N	7LKK855W8I	6		t	ng × h/mL	4714		ng/mL	1168			DEFINED DAILY	mg	600		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/27336726	Homo sapiens		h	30							true
7277	8081		UNKNOWN	6918735|23696523	473.472	RIGOSERTIB SODIUM	RIGOSERTIB SODIUM	[Na ].COC1=CC(OC)=C(\\C=C\\S(=O)(=O)CC2=CC(NCC([O-])=O)=C(OC)C=C2)C(OC)=C1	PLASMA	406FL5G00V																	UNKNOWN				UNKNOWN	UNKNOWN				% Bound=97.7; ON 01910.Na plasma\nconcentration = 100 ug/mL	2.3	UNKNOWN	UNKNOWN	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19466411	Homo sapiens								RIGOSERTIB SODIUM		false
7278	8081		ADULT	6918735|23696523	473.472	RIGOSERTIB SODIUM	RIGOSERTIB SODIUM	[Na ].COC1=CC(OC)=C(\\C=C\\S(=O)(=O)CC2=CC(NCC([O-])=O)=C(OC)C=C2)C(OC)=C1	PLASMA	406FL5G00V									∞	μg × h/mL	4.96		μg/mL	2.34			UNKNOWN	mg	700		STEADY-STATE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24493827	Homo sapiens		h	1.99	Day 21			2	RIGOSERTIB SODIUM		false
7279	8081		ADULT	6918735|23696523	473.472	RIGOSERTIB SODIUM	RIGOSERTIB SODIUM	[Na ].COC1=CC(OC)=C(\\C=C\\S(=O)(=O)CC2=CC(NCC([O-])=O)=C(OC)C=C2)C(OC)=C1	PLASMA	406FL5G00V									∞	μg × h/mL	6.99		μg/mL	2.54			MAX TOLERATED	mg	560		STEADY-STATE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24493827	Homo sapiens		h	4.03	Day 21			24	RIGOSERTIB SODIUM		false
7280	8081		ADULT	6918735|23696523	473.472	RIGOSERTIB SODIUM	RIGOSERTIB SODIUM	[Na ].COC1=CC(OC)=C(\\C=C\\S(=O)(=O)CC2=CC(NCC([O-])=O)=C(OC)C=C2)C(OC)=C1	PLASMA	406FL5G00V									∞	μg × h/mL	19.58		μg/mL	5.93			UNKNOWN	mg	700		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24493827	Homo sapiens		h	3.09	Day 1			7	RIGOSERTIB SODIUM		false
7281	8081		ADULT	6918735|23696523	473.472	RIGOSERTIB SODIUM	RIGOSERTIB SODIUM	[Na ].COC1=CC(OC)=C(\\C=C\\S(=O)(=O)CC2=CC(NCC([O-])=O)=C(OC)C=C2)C(OC)=C1	PLASMA	406FL5G00V									∞	μg × h/mL	2.61		μg/mL	0.73			UNKNOWN	mg	280		STEADY-STATE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24493827	Homo sapiens		h	5.28	Day 21			3	RIGOSERTIB SODIUM		false
7282	8081		ADULT	6918735|23696523	473.472	RIGOSERTIB SODIUM	RIGOSERTIB SODIUM	[Na ].COC1=CC(OC)=C(\\C=C\\S(=O)(=O)CC2=CC(NCC([O-])=O)=C(OC)C=C2)C(OC)=C1	PLASMA	406FL5G00V									∞	μg × h/mL	9.32		μg/mL	4.04			MAX TOLERATED	mg	560		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24493827	Homo sapiens		h	2.42	Day 1			32	RIGOSERTIB SODIUM		false
7283	8081		ADULT	6918735|23696523	473.472	RIGOSERTIB SODIUM	RIGOSERTIB SODIUM	[Na ].COC1=CC(OC)=C(\\C=C\\S(=O)(=O)CC2=CC(NCC([O-])=O)=C(OC)C=C2)C(OC)=C1	PLASMA	406FL5G00V									∞	μg × h/mL	4.93		μg/mL	1.84			UNKNOWN	mg	280		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24493827	Homo sapiens		h	2.81	Day 1			5	RIGOSERTIB SODIUM		false
7284	8081		ADULT	6918735|23696523	473.472	RIGOSERTIB SODIUM	RIGOSERTIB SODIUM	[Na ].COC1=CC(OC)=C(\\C=C\\S(=O)(=O)CC2=CC(NCC([O-])=O)=C(OC)C=C2)C(OC)=C1	PLASMA	406FL5G00V									∞	μg × h/mL	3.49		μg/mL	0.2			UNKNOWN	mg	140		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24493827	Homo sapiens		h	21.56	Day 1			5	RIGOSERTIB SODIUM		false
7285	8081		ADULT	6918735|23696523	473.472	RIGOSERTIB SODIUM	RIGOSERTIB SODIUM	[Na ].COC1=CC(OC)=C(\\C=C\\S(=O)(=O)CC2=CC(NCC([O-])=O)=C(OC)C=C2)C(OC)=C1	PLASMA	406FL5G00V									∞	μg × h/mL	4.59		μg/mL	0.43			UNKNOWN	mg	280		STEADY-STATE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24493827	Homo sapiens		h	25.69	Day 21			4	RIGOSERTIB SODIUM		false
7286	8081		ADULT	6918735|23696523	473.472	RIGOSERTIB SODIUM	RIGOSERTIB SODIUM	[Na ].COC1=CC(OC)=C(\\C=C\\S(=O)(=O)CC2=CC(NCC([O-])=O)=C(OC)C=C2)C(OC)=C1	PLASMA	406FL5G00V									∞	μg × h/mL	1.52		μg/mL	0.4			UNKNOWN	mg	70		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24493827	Homo sapiens		h	3.34	Day 1			3	RIGOSERTIB SODIUM		false
7287	8081		ADULT	6918735|23696523	473.472	RIGOSERTIB SODIUM	RIGOSERTIB SODIUM	[Na ].COC1=CC(OC)=C(\\C=C\\S(=O)(=O)CC2=CC(NCC([O-])=O)=C(OC)C=C2)C(OC)=C1	PLASMA	406FL5G00V									?	μg × h/mL	976		μg/mL	248			MAX TOLERATED	mg	3200		STEADY-STATE	UNKNOWN		week	2			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24947095	Homo sapiens		h	2.3	4-hour  infusion			8	RIGOSERTIB SODIUM		false
7288	8081		ADULT	6918735|23696523	473.472	RIGOSERTIB SODIUM	RIGOSERTIB SODIUM	[Na ].COC1=CC(OC)=C(\\C=C\\S(=O)(=O)CC2=CC(NCC([O-])=O)=C(OC)C=C2)C(OC)=C1	PLASMA	406FL5G00V										μg × h/mL	997		μg/mL	210			UNKNOWN	mg	4000		MULTIPLE	UNKNOWN		week	2			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24947095	Homo sapiens		h	1.5	4-hour  infusion			5	RIGOSERTIB SODIUM		false
7289	8084		ADULT	11256664	352.3407	ROXADUSTAT	Roxadustat	CC1=NC(C(=O)NCC(O)=O)=C(O)C2=CC=C(OC3=CC=CC=C3)C=C12	PLASMA	X3O30D9YMX									∞	ng × h/mL	39800		ng/mL	6780			RECOMMENDED	mg	100		SINGLE	UNKNOWN					0.871	HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://pubmed.ncbi.nlm.nih.gov/26947173/ | https://www.pmda.go.jp/drugs/2019/P20191007001/800126000_30100AMX00239_K103_1.pdf#page=36	Homo sapiens		h	16		Normal renal function		12			false
7290	8084		ADULT	11256664	352.3407	ROXADUSTAT	Roxadustat	CC1=NC(C(=O)NCC(O)=O)=C(O)C2=CC=C(OC3=CC=CC=C3)C=C12	PLASMA	X3O30D9YMX									∞	ng × h/mL	76600		ng/mL	6910			RECOMMENDED	mg	100		SINGLE	UNKNOWN					1.16	UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://pubmed.ncbi.nlm.nih.gov/26947173/ | https://www.pmda.go.jp/drugs/2019/P20191007001/800126000_30100AMX00239_K103_1.pdf#page=36	Homo sapiens		h	16.8		ESRD on HD/HDF (hemodiafiltration), treatment period 2 (drug was administered 2h prior to the start of a second 4-h dialysis session)		12			false
7291	8084		ADULT	11256664	352.3407	ROXADUSTAT	Roxadustat	CC1=NC(C(=O)NCC(O)=O)=C(O)C2=CC=C(OC3=CC=CC=C3)C=C12	PLASMA	X3O30D9YMX									∞	ng × h/mL	82500		ng/mL	6730			RECOMMENDED	mg	100		SINGLE	UNKNOWN					1.06	UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://pubmed.ncbi.nlm.nih.gov/26947173/ | https://www.pmda.go.jp/drugs/2019/P20191007001/800126000_30100AMX00239_K103_1.pdf#page=36	Homo sapiens		h	18.5		Severe renal impairment		9			false
7292	8084		ADULT	11256664	352.3407	ROXADUSTAT	Roxadustat	CC1=NC(C(=O)NCC(O)=O)=C(O)C2=CC=C(OC3=CC=CC=C3)C=C12	PLASMA	X3O30D9YMX									∞	ng × h/mL	77400		ng/mL	6950			RECOMMENDED	mg	100		SINGLE	UNKNOWN					1.1	UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://pubmed.ncbi.nlm.nih.gov/26947173/ | https://www.pmda.go.jp/drugs/2019/P20191007001/800126000_30100AMX00239_K103_1.pdf#page=36	Homo sapiens		h	17.2		ESRD on HD/HDF (hemodiafiltration), treatment period 1 (drug was administered 2h after a 4-h dialysis session on day 1)		12			false
7293	8084		ADULT	11256664	352.3407	ROXADUSTAT	Roxadustat	CC1=NC(C(=O)NCC(O)=O)=C(O)C2=CC=C(OC3=CC=CC=C3)C=C12	PLASMA	X3O30D9YMX									∞	ng × h/mL	49807		ng/mL	8498			RECOMMENDED	mg	100		SINGLE	FASTED				equilibrium dialysis	0.81	HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://pubmed.ncbi.nlm.nih.gov/27352308/ | https://www.pmda.go.jp/drugs/2019/P20191007001/800126000_30100AMX00239_K103_1.pdf#page=71	Homo sapiens		h	12.6		Normal hepatic function		8			false
7294	8084		ADULT	11256664	352.3407	ROXADUSTAT	Roxadustat	CC1=NC(C(=O)NCC(O)=O)=C(O)C2=CC=C(OC3=CC=CC=C3)C=C12	PLASMA	X3O30D9YMX									∞	ng × h/mL	63693		ng/mL	6975			RECOMMENDED	mg	100		SINGLE	FASTED				equilibrium dialysis	1.1	UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://pubmed.ncbi.nlm.nih.gov/27352308/ | https://www.pmda.go.jp/drugs/2019/P20191007001/800126000_30100AMX00239_K103_1.pdf#page=71	Homo sapiens		h	14.7		Moderate hepatic impairment (cirrhosis)		8			false
7295	8084		ADULT	11256664	352.3407	ROXADUSTAT	Roxadustat	CC1=NC(C(=O)NCC(O)=O)=C(O)C2=CC=C(OC3=CC=CC=C3)C=C12	PLASMA	X3O30D9YMX									∞	μg × h/mL	88.1		μg/mL	7.82			RECOMMENDED	mg	100		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://pubmed.ncbi.nlm.nih.gov/29966038/ | https://www.pmda.go.jp/drugs/2019/P20191007001/800126000_30100AMX00239_K102_1.pdf#page=11	Homo sapiens		h	11.5		Young subjects (22~39 y)		15			false
7296	8084		ADULT	11256664	352.3407	ROXADUSTAT	Roxadustat	CC1=NC(C(=O)NCC(O)=O)=C(O)C2=CC=C(OC3=CC=CC=C3)C=C12	PLASMA	X3O30D9YMX									∞	μg × h/mL	87.5		μg/mL	10.4			RECOMMENDED	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://pubmed.ncbi.nlm.nih.gov/29966038/ | https://www.pmda.go.jp/drugs/2019/P20191007001/800126000_30100AMX00239_K102_1.pdf#page=11	Homo sapiens		h	12.3		Young subjects (22~39 y)		15			false
7297	8084		ADULT	11256664	352.3407	ROXADUSTAT	Roxadustat	CC1=NC(C(=O)NCC(O)=O)=C(O)C2=CC=C(OC3=CC=CC=C3)C=C12	PLASMA	X3O30D9YMX									∞	μg × h/mL	74.9		μg/mL	8.41			RECOMMENDED	mg	100		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29981285/	Homo sapiens		h	11.4		Young subjects (24~43 y), n=17 for Cmax		16			false
7298	8084			11256664	352.3407	ROXADUSTAT	Roxadustat	CC1=NC(C(=O)NCC(O)=O)=C(O)C2=CC=C(OC3=CC=CC=C3)C=C12	PLASMA	X3O30D9YMX																										Human plasma protein binding: 99%　(2~40 mcg/mL, equilibrium dialysis)	1				OTHER GOV'T	https://www.pmda.go.jp/drugs/2019/P20191007001/800126000_30100AMX00239_A100_1.pdf#page=25 | https://www.pmda.go.jp/drugs/2019/P20191007001/800126000_30100AMX00239_K100_1.pdf#page=156	Homo sapiens										false
7299	8084		ADULT	11256664	352.3407	ROXADUSTAT	Roxadustat	CC1=NC(C(=O)NCC(O)=O)=C(O)C2=CC=C(OC3=CC=CC=C3)C=C12	PLASMA	X3O30D9YMX									∞	μg × h/mL	13.8		μg/mL	1.9			UNKNOWN	mg/kg bw	0.3		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2019/P20191007001/800126000_30100AMX00239_A100_1.pdf#page=28	Homo sapiens		h	8.3				6			false
7300	8084		ADULT	11256664	352.3407	ROXADUSTAT	Roxadustat	CC1=NC(C(=O)NCC(O)=O)=C(O)C2=CC=C(OC3=CC=CC=C3)C=C12	PLASMA	X3O30D9YMX									∞	μg × h/mL	99.7		μg/mL	12.9			UNKNOWN	mg/kg bw	2		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2019/P20191007001/800126000_30100AMX00239_A100_1.pdf#page=28	Homo sapiens		h	9.3				6			false
7301	8084		ADULT	11256664	352.3407	ROXADUSTAT	Roxadustat	CC1=NC(C(=O)NCC(O)=O)=C(O)C2=CC=C(OC3=CC=CC=C3)C=C12	PLASMA	X3O30D9YMX									∞	μg × h/mL	139.3		μg/mL	18.9			UNKNOWN	mg/kg bw	3		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2019/P20191007001/800126000_30100AMX00239_A100_1.pdf#page=28	Homo sapiens		h	9				6			false
7302	8084		ADULT	11256664	352.3407	ROXADUSTAT	Roxadustat	CC1=NC(C(=O)NCC(O)=O)=C(O)C2=CC=C(OC3=CC=CC=C3)C=C12	PLASMA	X3O30D9YMX									∞	μg × h/mL	168.8		μg/mL	20.8			UNKNOWN	mg/kg bw	4		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2019/P20191007001/800126000_30100AMX00239_A100_1.pdf#page=28	Homo sapiens		h	8				6			false
7303	8084		ADULT	11256664	352.3407	ROXADUSTAT	Roxadustat	CC1=NC(C(=O)NCC(O)=O)=C(O)C2=CC=C(OC3=CC=CC=C3)C=C12	PLASMA	X3O30D9YMX							24		t	μg × h/mL	12		μg/mL	1.8			UNKNOWN	mg/kg bw	0.3		MULTIPLE	FASTED		week	3			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2019/P20191007001/800126000_30100AMX00239_A100_1.pdf#page=28	Homo sapiens		h	10.4	Day 12			7			false
7304	8084		ADULT	11256664	352.3407	ROXADUSTAT	Roxadustat	CC1=NC(C(=O)NCC(O)=O)=C(O)C2=CC=C(OC3=CC=CC=C3)C=C12	PLASMA	X3O30D9YMX							24		t	μg × h/mL	153.1		μg/mL	18.1			UNKNOWN	mg/kg bw	3		MULTIPLE	FASTED		week	3			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2019/P20191007001/800126000_30100AMX00239_A100_1.pdf#page=28	Homo sapiens		h	9.7	Day 12			7			false
7305	8084		ADULT	11256664	352.3407	ROXADUSTAT	Roxadustat	CC1=NC(C(=O)NCC(O)=O)=C(O)C2=CC=C(OC3=CC=CC=C3)C=C12	PLASMA	X3O30D9YMX							24		t	μg × h/mL	39.7		μg/mL	5.2			UNKNOWN	mg/kg bw	1		MULTIPLE	FASTED		week	3			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2019/P20191007001/800126000_30100AMX00239_A100_1.pdf#page=28	Homo sapiens		h	9	Day 12			7			false
7306	8084		ADULT	11256664	352.3407	ROXADUSTAT	Roxadustat	CC1=NC(C(=O)NCC(O)=O)=C(O)C2=CC=C(OC3=CC=CC=C3)C=C12	PLASMA	X3O30D9YMX									∞	μg × h/mL	43.6		μg/mL	5.4			UNKNOWN	mg/kg bw	1		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2019/P20191007001/800126000_30100AMX00239_A100_1.pdf#page=28	Homo sapiens		h	8.4				6			false
7307	8084		ADULT	11256664	352.3407	ROXADUSTAT	Roxadustat	CC1=NC(C(=O)NCC(O)=O)=C(O)C2=CC=C(OC3=CC=CC=C3)C=C12	PLASMA	X3O30D9YMX							24		t	μg × h/mL	10.7		μg/mL	1.6			UNKNOWN	mg/kg bw	0.3		MULTIPLE	FASTED		week	3			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2019/P20191007001/800126000_30100AMX00239_A100_1.pdf#page=28	Homo sapiens		h	9.9	Day 1			7			false
7308	8084		ADULT	11256664	352.3407	ROXADUSTAT	Roxadustat	CC1=NC(C(=O)NCC(O)=O)=C(O)C2=CC=C(OC3=CC=CC=C3)C=C12	PLASMA	X3O30D9YMX							24		t	μg × h/mL	37.4		μg/mL	5.4			UNKNOWN	mg/kg bw	1		MULTIPLE	FASTED		week	3			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2019/P20191007001/800126000_30100AMX00239_A100_1.pdf#page=28	Homo sapiens		h	9.6	Day 1			7			false
7309	8084		ADULT	11256664	352.3407	ROXADUSTAT	Roxadustat	CC1=NC(C(=O)NCC(O)=O)=C(O)C2=CC=C(OC3=CC=CC=C3)C=C12	PLASMA	X3O30D9YMX							24		t	μg × h/mL	138.5		μg/mL	18.8			UNKNOWN	mg/kg bw	3		MULTIPLE	FASTED		week	3			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2019/P20191007001/800126000_30100AMX00239_A100_1.pdf#page=28	Homo sapiens		h	9.9	Day 1			7			false
7310	8084		ADULT	11256664	352.3407	ROXADUSTAT	Roxadustat	CC1=NC(C(=O)NCC(O)=O)=C(O)C2=CC=C(OC3=CC=CC=C3)C=C12	PLASMA	X3O30D9YMX									∞	μg × h/mL	65.6		μg/mL	5.6			UNKNOWN	mg/kg bw	1		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2019/P20191007001/800126000_30100AMX00239_A100_1.pdf#page=29	Homo sapiens		h	15.5	Day 1	Dosed within 1h after hemodialysis		6			false
7311	8084		ADULT	11256664	352.3407	ROXADUSTAT	Roxadustat	CC1=NC(C(=O)NCC(O)=O)=C(O)C2=CC=C(OC3=CC=CC=C3)C=C12	PLASMA	X3O30D9YMX									∞	μg × h/mL	149.9		μg/mL	13			UNKNOWN	mg/kg bw	2		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2019/P20191007001/800126000_30100AMX00239_A100_1.pdf#page=29	Homo sapiens		h	20.9	Day 1	Dosed within 1h after hemodialysis		6			false
7312	8084		ADULT	11256664	352.3407	ROXADUSTAT	Roxadustat	CC1=NC(C(=O)NCC(O)=O)=C(O)C2=CC=C(OC3=CC=CC=C3)C=C12	PLASMA	X3O30D9YMX									∞	μg × h/mL	56.6		μg/mL	4.4			UNKNOWN	mg/kg bw	1		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2019/P20191007001/800126000_30100AMX00239_A100_1.pdf#page=29	Homo sapiens		h	15.8	Day 8	Dosed 2.5h before hemodialysis		6			false
7313	8084		ADULT	11256664	352.3407	ROXADUSTAT	Roxadustat	CC1=NC(C(=O)NCC(O)=O)=C(O)C2=CC=C(OC3=CC=CC=C3)C=C12	PLASMA	X3O30D9YMX									∞	μg × h/mL	135.3		μg/mL	9.4			UNKNOWN	mg/kg bw	2		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2019/P20191007001/800126000_30100AMX00239_A100_1.pdf#page=29	Homo sapiens		h	16.2	Day 8	Dosed 2.5h before hemodialysis		6			false
7314	8084		ADULT	11256664	352.3407	ROXADUSTAT	Roxadustat	CC1=NC(C(=O)NCC(O)=O)=C(O)C2=CC=C(OC3=CC=CC=C3)C=C12	PLASMA	X3O30D9YMX									∞	μg × h/mL	108.7		μg/mL	16			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2019/P20191007001/800126000_30100AMX00239_A100_1.pdf#page=29 | https://www.pmda.go.jp/drugs/2019/P20191007001/800126000_30100AMX00239_K102_1.pdf#page=115	Homo sapiens		h	17.8				6			false
7315	8086		UNKNOWN		487.5024	SARECYCLINE	SARECYCLINE	CON(C)CC1=CC=C(O)C2=C1C[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C2=O	PLASMA	94O110CX2E									?	ng × h/mL	14000		ng/mL	1210			RECOMMENDED	mg	60		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209521Orig1s000MultidisciplineR.pdf	Homo sapiens										false
7316	8086		UNKNOWN		487.5024	SARECYCLINE	SARECYCLINE	CON(C)CC1=CC=C(O)C2=C1C[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C2=O	PLASMA	94O110CX2E									?	ng × h/mL	21800		ng/mL	1790			RECOMMENDED	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209521Orig1s000MultidisciplineR.pdf	Homo sapiens										false
7317	8086		UNKNOWN		487.5024	SARECYCLINE	SARECYCLINE	CON(C)CC1=CC=C(O)C2=C1C[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C2=O	PLASMA	94O110CX2E									?	ng × h/mL	32200		ng/mL	2570			RECOMMENDED	mg	150		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209521Orig1s000MultidisciplineR.pdf	Homo sapiens										false
7318	8086		UNKNOWN		487.5024	SARECYCLINE	SARECYCLINE	CON(C)CC1=CC=C(O)C2=C1C[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C2=O	PLASMA	94O110CX2E									?	ng × h/mL	20700		ng/mL	1590			RECOMMENDED	mg	60		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209521Orig1s000MultidisciplineR.pdf	Homo sapiens		h	21.9							false
7319	8086		UNKNOWN		487.5024	SARECYCLINE	SARECYCLINE	CON(C)CC1=CC=C(O)C2=C1C[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C2=O	PLASMA	94O110CX2E									?	ng × h/mL	33800		ng/mL	2620			RECOMMENDED	mg	100		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209521Orig1s000MultidisciplineR.pdf	Homo sapiens		h	20.7							false
7320	8086		UNKNOWN		487.5024	SARECYCLINE	SARECYCLINE	CON(C)CC1=CC=C(O)C2=C1C[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C2=O	PLASMA	94O110CX2E									∞	ng × h/mL	48200		ng/mL	3820			RECOMMENDED	mg	150		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209521Orig1s000MultidisciplineR.pdf	Homo sapiens		h	20.9							false
7321	8086		UNKNOWN		487.5024	SARECYCLINE	SARECYCLINE	CON(C)CC1=CC=C(O)C2=C1C[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C2=O	PLASMA	94O110CX2E									∞	ng × h/mL	31800		ng/mL	1700			RECOMMENDED	mg	150		SINGLE	FED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209521Orig1s000MultidisciplineR.pdf	Homo sapiens										false
7322	8086		UNKNOWN		487.5024	SARECYCLINE	SARECYCLINE	CON(C)CC1=CC=C(O)C2=C1C[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C2=O	PLASMA	94O110CX2E									∞	ng × h/mL	43200		ng/mL	2480			RECOMMENDED	mg	150		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209521Orig1s000MultidisciplineR.pdf	Homo sapiens										false
7323	8087		ADULT		4114	SEMAGLUTIDE	SEMAGLUTIDE		PLASMA	53AXN4NNHX									∞	nM × h	3026		nM	9.5			UNKNOWN	mg	0.5		SINGLE	UNKNOWN						HEALTHY	Subcutaneous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29205786	Homo sapiens		h	150							false
7324	8087		ADULT		4114	SEMAGLUTIDE	SEMAGLUTIDE		PLASMA	53AXN4NNHX									∞	nM × h	3080		nM	9.7			UNKNOWN	mg	0.5		SINGLE	UNKNOWN						UNHEALTHY	Subcutaneous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29205786	Homo sapiens		h	151							false
7325	8087		UNKNOWN		4114	SEMAGLUTIDE	SEMAGLUTIDE		PLASMA	53AXN4NNHX																	UNKNOWN				UNKNOWN	UNKNOWN				Semaglutide is extensively bound to plasma albumin (>99%).	1	UNKNOWN	UNKNOWN	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213182s000,213051s001lbl.pdf	Homo sapiens										false
7326	8089		ADULT	44599207	516.6	SIPONIMOD	SIPONIMOD	CCC1=CC(=CC=C1CN2CC(C2)C(O)=O)C(\\C)=N\\OCC3=CC=C(C4CCCCC4)C(=C3)C(F)(F)F	PLASMA	RR6P8L282I									?	ng × h/mL	558		ng/mL	30.4			RECOMMENDED	mg	2		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209884s000lbl.pdf	Homo sapiens		h	30							false
7327	8096		ADULT	148201	646.7315	TARIQUIDAR	TARIQUIDAR	COC1=CC(NC(=O)C2=CN=C3C=CC=CC3=C2)=C(C=C1OC)C(=O)NC4=CC=C(CCN5CCC6=CC(OC)=C(OC)C=C6C5)C=C4	BLOOD	J58862DTVD									?	mg × h/L	14.48		mg/L	1.31			UNKNOWN	mg/kg bw	4	infusion, 1.72 hour	OTHER	UNKNOWN		day	1			HEALTHY	Intravenous	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/23146816	Homo sapiens		h	43							false
7328	8096		ADULT	148201	646.7315	TARIQUIDAR	TARIQUIDAR	COC1=CC(NC(=O)C2=CN=C3C=CC=CC3=C2)=C(C=C1OC)C(=O)NC4=CC=C(CCN5CCC6=CC(OC)=C(OC)C=C6C5)C=C4	BLOOD	J58862DTVD									?	mg × h/L	19.96		mg/L	2.03			UNKNOWN	mg/kg bw	6	infusion, 1.83 hour	OTHER	UNKNOWN		day	1			HEALTHY	Intravenous	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/23146816	Homo sapiens		h	16							false
7329	8096		ADULT	148201	646.7315	TARIQUIDAR	TARIQUIDAR	COC1=CC(NC(=O)C2=CN=C3C=CC=CC3=C2)=C(C=C1OC)C(=O)NC4=CC=C(CCN5CCC6=CC(OC)=C(OC)C=C6C5)C=C4	BLOOD	J58862DTVD									?	mg × h/L	18.83		mg/L	1.92			UNKNOWN	mg/kg bw	8	infusion, 2.42 hour	OTHER	UNKNOWN		day	1			HEALTHY	Intravenous	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/23146816	Homo sapiens		h	25							false
7330	8097		ADULT	10160238	415.11	TASISULAM	tasisulam	ClC1=CC=C(C(=O)NS(=O)(=O)C2=CC=C(Br)S2)C(Cl)=C1	PLASMA	1YC4W9MSLJ									∞	μg × h/mL	91900		μg/mL	185			UNKNOWN	mg	2000		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23228983	Homo sapiens		h	399				6	tasisulam		false
7331	8097		ADULT	10160238	415.11	TASISULAM	tasisulam	ClC1=CC=C(C(=O)NS(=O)(=O)C2=CC=C(Br)S2)C(Cl)=C1	PLASMA	1YC4W9MSLJ									?	μg × h/mL	9070		μg/mL	68.1			UNKNOWN	mg	600		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23228983	Homo sapiens							4	tasisulam		false
7332	8097		ADULT	10160238	415.11	TASISULAM	tasisulam	ClC1=CC=C(C(=O)NS(=O)(=O)C2=CC=C(Br)S2)C(Cl)=C1	PLASMA	1YC4W9MSLJ									∞	pmol × h/mL	94700		μg/mL	256			MAX TOLERATED	mg	2500		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23228983	Homo sapiens		h	273				13	tasisulam		false
7333	8101		ADULT	25025298	546.929	TELOTRISTAT	TELOTRISTAT	CC1=NN(C=C1)C2=C(C=CC(Cl)=C2)[C@@H](OC3=NC(N)=NC(=C3)C4=CC=C(C[C@H](N)C(O)=O)C=C4)C(F)(F)F	PLASMA	381V4FCV2Z									∞	ng × h/mL	2320		ng/mL	610			UNKNOWN	mg	500		SINGLE	FASTED				telotristat is greater than 99% bound to human plasma proteins	1	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208794s000lbl.pdf	Homo sapiens		h	5							false
7334	8102			46199646	520.4976	TEZACAFTOR	TEZACAFTOR	CC(C)(CO)C1=CC2=C(C=C(F)C(NC(=O)C3(CC3)C4=CC5=C(OC(F)(F)O5)C=C4)=C2)N1C[C@@H](O)CO	PLASMA	8RW88Y506K									?	ng × h/mL	6260							mg	10		STEADY-STATE			day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01531673	Homo sapiens										false
7335	8102			46199646	520.4976	TEZACAFTOR	TEZACAFTOR	CC(C)(CO)C1=CC2=C(C=C(F)C(NC(=O)C3(CC3)C4=CC5=C(OC(F)(F)O5)C=C4)=C2)N1C[C@@H](O)CO	PLASMA	8RW88Y506K									?	ng × h/mL	98900							mg	150		STEADY-STATE			day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01531673	Homo sapiens										false
7336	8102		ADULT	46199646	520.4976	TEZACAFTOR	TEZACAFTOR	CC(C)(CO)C1=CC2=C(C=C(F)C(NC(=O)C3(CC3)C4=CC5=C(OC(F)(F)O5)C=C4)=C2)N1C[C@@H](O)CO	PLASMA	8RW88Y506K	16220172		IVACAFTOR	ivacaftor	CC(C)(C)C1=CC(=C(NC(=O)C2=CNC3=C(C=CC=C3)C2=O)C=C1O)C(C)(C)C	1Y740ILL1Z	24		t	μg × h/mL	84.5		μg/mL	5.95			RECOMMENDED	mg	100		STEADY-STATE	UNKNOWN		day	1	Tezacaftor is approximately 99% bound to plasma proteins, primarily to albumin.	1	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210491lbl.pdf	Homo sapiens		h	15							true
7337	8102		ADULT	46199646	520.4976	TEZACAFTOR	TEZACAFTOR	CC(C)(CO)C1=CC2=C(C=C(F)C(NC(=O)C3(CC3)C4=CC5=C(OC(F)(F)O5)C=C4)=C2)N1C[C@@H](O)CO	PLASMA	8RW88Y506K							24		t	ng × h/mL	225000		ng/mL	15000			UNKNOWN	mg	300		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210491Orig1s000ClinPharmR.pdf	Homo sapiens		h	83.23							false
7338	8103		ADULT	23729157	230.2658	TIRASEMTIV	TIRASEMTIV	CCC(CC)N1C(=O)NC2=C1N=C(C=N2)C#C	PLASMA	G8WSM7R635							24		t	μg × h/mL	182.63		μg/mL	11.815			UNKNOWN	mg	500		SINGLE	UNKNOWN			500			UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22591195	Homo sapiens							19	TIRASEMTIV		false
7339	8103		ADULT	23729157	230.2658	TIRASEMTIV	TIRASEMTIV	CCC(CC)N1C(=O)NC2=C1N=C(C=N2)C#C	PLASMA	G8WSM7R635							24		t	μg × h/mL	175.881		μg/mL	11.271			UNKNOWN	mg	500		SINGLE	UNKNOWN						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22591195	Homo sapiens							46	TIRASEMTIV		false
7340	8103		ADULT	23729157	230.2658	TIRASEMTIV	TIRASEMTIV	CCC(CC)N1C(=O)NC2=C1N=C(C=N2)C#C	PLASMA	G8WSM7R635							12		t	μg × h/mL	238.2		μg/mL	18.3			UNKNOWN	mg	750		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24872402	Homo sapiens							33	TIRASEMTIV		false
7341	8104		ADULT	11618368	406.499	TOZADENANT	TOZADENANT	COC1=CC=C(N2CCOCC2)C3=C1N=C(NC(=O)N4CCC(C)(O)CC4)S3	PLASMA	D9K857J81I									∞	μg × h/mL	35.1		μg/mL	1.74			UNKNOWN	mg	240		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27489076	Homo sapiens		h	15				6	TOZADENANT		false
7342	8106		UNKNOWN	123723	361.4336	VELIFLAPON	VELIFLAPON	OC(=O)[C@H](C1CCCC1)C2=CC=C(OCC3=NC4=C(C=CC=C4)C=C3)C=C2	PLASMA	JXH6X663L0													μg/mL	11			UNKNOWN	mg	250		STEADY-STATE	UNKNOWN		day	3			UNKNOWN	Oral	UNKNOWN	EXPERIMENT	https://patents.google.com/patent/US20060257481A1	Homo sapiens		h	2.5							false
7343	8107		ADULT	10343454	444.931	VERCIRNON	Vercirnon	CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C=C(Cl)C=C2)C(=O)C3=CC=[N ]([O-])C=C3	PLASMA	MWI54OUA12									∞	ng × h/mL	14929		ng/mL	993.4			UNKNOWN	mg	500		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27121943/	Homo sapiens		h	16.3	Formulation B, intended for use in Phase III clinical program			24	Vercirnon		false
7344	8108		ADULT	44472635	444.5255	VIBEGRON	Vibegron	O[C@@H]([C@H]1CC[C@@H](CC2=CC=C(NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)C=C2)N1)C5=CC=CC=C5	PLASMA	M5TSE03W5U									∞	μM × h	3.51		ng/mL	177			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213006Orig1s000ClinPharmR.pdf#page=33	Homo sapiens		h	133		Mass balance study		6			false
7345	8108		ADULT	44472635	444.5255	VIBEGRON	Vibegron	O[C@@H]([C@H]1CC[C@@H](CC2=CC=C(NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)C=C2)N1)C5=CC=CC=C5	PLASMA	M5TSE03W5U									∞	ng × h/mL	1890		ng/mL	142			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213006Orig1s000ClinPharmR.pdf#page=35	Homo sapiens		h	73.5				6			false
7346	8108		ADULT	44472635	444.5255	VIBEGRON	Vibegron	O[C@@H]([C@H]1CC[C@@H](CC2=CC=C(NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)C=C2)N1)C5=CC=CC=C5	PLASMA	M5TSE03W5U									∞	ng × h/mL	2280		ng/mL	195			UNKNOWN	mg	150		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213006Orig1s000ClinPharmR.pdf#page=35	Homo sapiens		h	68.4				6			false
7347	8108		ADULT	44472635	444.5255	VIBEGRON	Vibegron	O[C@@H]([C@H]1CC[C@@H](CC2=CC=C(NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)C=C2)N1)C5=CC=CC=C5	PLASMA	M5TSE03W5U									∞	ng × h/mL	3620		ng/mL	274			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213006Orig1s000ClinPharmR.pdf#page=35	Homo sapiens		h	75.8				18			false
7348	8108		ADULT	44472635	444.5255	VIBEGRON	Vibegron	O[C@@H]([C@H]1CC[C@@H](CC2=CC=C(NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)C=C2)N1)C5=CC=CC=C5	PLASMA	M5TSE03W5U									∞	ng × h/mL	7380		ng/mL	618			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213006Orig1s000ClinPharmR.pdf#page=35	Homo sapiens		h	63.8				6			false
7349	8108		ADULT	44472635	444.5255	VIBEGRON	Vibegron	O[C@@H]([C@H]1CC[C@@H](CC2=CC=C(NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)C=C2)N1)C5=CC=CC=C5	PLASMA	M5TSE03W5U									∞	ng × h/mL	9160		ng/mL	645			UNKNOWN	mg	450		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213006Orig1s000ClinPharmR.pdf#page=35	Homo sapiens		h	60.5				6			false
7350	8108		ADULT	44472635	444.5255	VIBEGRON	Vibegron	O[C@@H]([C@H]1CC[C@@H](CC2=CC=C(NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)C=C2)N1)C5=CC=CC=C5	PLASMA	M5TSE03W5U									∞	ng × h/mL	15500		ng/mL	1330			UNKNOWN	mg	600		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213006Orig1s000ClinPharmR.pdf#page=35	Homo sapiens		h	60.7				5			false
7351	8108		ADULT	44472635	444.5255	VIBEGRON	Vibegron	O[C@@H]([C@H]1CC[C@@H](CC2=CC=C(NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)C=C2)N1)C5=CC=CC=C5	PLASMA	M5TSE03W5U													ng/mL	0.14			UNKNOWN	mg	2		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213006Orig1s000ClinPharmR.pdf#page=35	Homo sapiens							3			false
7352	8108		ADULT	44472635	444.5255	VIBEGRON	Vibegron	O[C@@H]([C@H]1CC[C@@H](CC2=CC=C(NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)C=C2)N1)C5=CC=CC=C5	PLASMA	M5TSE03W5U							24		t	ng × h/mL	14.3		ng/mL	0.79			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213006Orig1s000ClinPharmR.pdf#page=35	Homo sapiens							6			false
7353	8108		ADULT	44472635	444.5255	VIBEGRON	Vibegron	O[C@@H]([C@H]1CC[C@@H](CC2=CC=C(NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)C=C2)N1)C5=CC=CC=C5	PLASMA	M5TSE03W5U									∞	ng × h/mL	71.6		ng/mL	4.76			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213006Orig1s000ClinPharmR.pdf#page=35	Homo sapiens		h	45.5				6			false
7354	8108		ADULT	44472635	444.5255	VIBEGRON	Vibegron	O[C@@H]([C@H]1CC[C@@H](CC2=CC=C(NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)C=C2)N1)C5=CC=CC=C5	PLASMA	M5TSE03W5U									∞	ng × h/mL	119		ng/mL	5.25			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213006Orig1s000ClinPharmR.pdf#page=35	Homo sapiens		h	64.1				6			false
7355	8108		ADULT	44472635	444.5255	VIBEGRON	Vibegron	O[C@@H]([C@H]1CC[C@@H](CC2=CC=C(NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)C=C2)N1)C5=CC=CC=C5	PLASMA	M5TSE03W5U									∞	ng × h/mL	542		ng/mL	31.7			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213006Orig1s000ClinPharmR.pdf#page=35	Homo sapiens		h	50.4				6			false
7356	8108		ADULT	44472635	444.5255	VIBEGRON	Vibegron	O[C@@H]([C@H]1CC[C@@H](CC2=CC=C(NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)C=C2)N1)C5=CC=CC=C5	PLASMA	M5TSE03W5U									∞	ng × h/mL	948		ng/mL	50.2			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213006Orig1s000ClinPharmR.pdf#page=35	Homo sapiens		h	95.1		Elderly subjects		12			false
7357	8108		ADULT	44472635	444.5255	VIBEGRON	Vibegron	O[C@@H]([C@H]1CC[C@@H](CC2=CC=C(NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)C=C2)N1)C5=CC=CC=C5	PLASMA	M5TSE03W5U									∞	μM × h	2.35		ng/mL	106			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	FEMALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213006Orig1s000ClinPharmR.pdf#page=36	Homo sapiens					Elderly females		6			false
7358	8108		ADULT	44472635	444.5255	VIBEGRON	Vibegron	O[C@@H]([C@H]1CC[C@@H](CC2=CC=C(NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)C=C2)N1)C5=CC=CC=C5	PLASMA	M5TSE03W5U									∞	μM × h	1.77		ng/mL	96.4			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213006Orig1s000ClinPharmR.pdf#page=36	Homo sapiens					Elderly males		6			false
7359	8108		ADULT	44472635	444.5255	VIBEGRON	Vibegron	O[C@@H]([C@H]1CC[C@@H](CC2=CC=C(NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)C=C2)N1)C5=CC=CC=C5	PLASMA	M5TSE03W5U							24		t	ng × h/mL	164		ng/mL	15.6			UNKNOWN	mg	25		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213006Orig1s000ClinPharmR.pdf#page=40	Homo sapiens		h	94.9	Day 14 PK	Young males		5			false
7360	8108		ADULT	44472635	444.5255	VIBEGRON	Vibegron	O[C@@H]([C@H]1CC[C@@H](CC2=CC=C(NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)C=C2)N1)C5=CC=CC=C5	PLASMA	M5TSE03W5U							24		t	ng × h/mL	507		ng/mL	41.6			UNKNOWN	mg	50		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213006Orig1s000ClinPharmR.pdf#page=40	Homo sapiens		h	78	Day 14 PK	Young males		6			false
7361	8108		ADULT	44472635	444.5255	VIBEGRON	Vibegron	O[C@@H]([C@H]1CC[C@@H](CC2=CC=C(NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)C=C2)N1)C5=CC=CC=C5	PLASMA	M5TSE03W5U							24		t	ng × h/mL	1280		ng/mL	169			UNKNOWN	mg	100		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213006Orig1s000ClinPharmR.pdf#page=40	Homo sapiens		h	80.8	Day 14 PK	Young males		6			false
7362	8108		ADULT	44472635	444.5255	VIBEGRON	Vibegron	O[C@@H]([C@H]1CC[C@@H](CC2=CC=C(NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)C=C2)N1)C5=CC=CC=C5	PLASMA	M5TSE03W5U							24		t	ng × h/mL	2230		ng/mL	224			UNKNOWN	mg	100		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213006Orig1s000ClinPharmR.pdf#page=40	Homo sapiens		h	89.4	Day 14 PK	Elderly males and females		12			false
7363	8108		ADULT	44472635	444.5255	VIBEGRON	Vibegron	O[C@@H]([C@H]1CC[C@@H](CC2=CC=C(NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)C=C2)N1)C5=CC=CC=C5	PLASMA	M5TSE03W5U							24		t	ng × h/mL	2410		ng/mL	305			UNKNOWN	mg	150		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213006Orig1s000ClinPharmR.pdf#page=40	Homo sapiens		h	80	Day 14 PK	Young males		6			false
7364	8108		ADULT	44472635	444.5255	VIBEGRON	Vibegron	O[C@@H]([C@H]1CC[C@@H](CC2=CC=C(NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)C=C2)N1)C5=CC=CC=C5	PLASMA	M5TSE03W5U							24		t	ng × h/mL	2370		ng/mL	276			UNKNOWN	mg	150		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213006Orig1s000ClinPharmR.pdf#page=40	Homo sapiens		h	78.6	Day 28 PK	Middle-aged males and females		18			false
7365	8108		ADULT	44472635	444.5255	VIBEGRON	Vibegron	O[C@@H]([C@H]1CC[C@@H](CC2=CC=C(NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)C=C2)N1)C5=CC=CC=C5	PLASMA	M5TSE03W5U							24		t	ng × h/mL	2560		ng/mL	216			UNKNOWN	mg	150		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213006Orig1s000ClinPharmR.pdf#page=40	Homo sapiens		h	80.4	Day 14 PK	Middle-aged males and females		11			false
7366	8108		ADULT	44472635	444.5255	VIBEGRON	Vibegron	O[C@@H]([C@H]1CC[C@@H](CC2=CC=C(NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)C=C2)N1)C5=CC=CC=C5	PLASMA	M5TSE03W5U							24		t	ng × h/mL	3200		ng/mL	313			UNKNOWN	mg	200		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213006Orig1s000ClinPharmR.pdf#page=40	Homo sapiens		h	65.1	Day 14 PK	Young males		5			false
7367	8108		ADULT	44472635	444.5255	VIBEGRON	Vibegron	O[C@@H]([C@H]1CC[C@@H](CC2=CC=C(NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)C=C2)N1)C5=CC=CC=C5	PLASMA	M5TSE03W5U							24		t	ng × h/mL	6980		ng/mL	733			UNKNOWN	mg	300		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213006Orig1s000ClinPharmR.pdf#page=40	Homo sapiens		h	58.8	Day 14 PK	Young males		6			false
7368	8108		ADULT	44472635	444.5255	VIBEGRON	Vibegron	O[C@@H]([C@H]1CC[C@@H](CC2=CC=C(NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)C=C2)N1)C5=CC=CC=C5	PLASMA	M5TSE03W5U							24		t	ng × h/mL	10400		ng/mL	1400			UNKNOWN	mg	400		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213006Orig1s000ClinPharmR.pdf#page=40	Homo sapiens		h	59.4	Day 14 PK	Young males		6			false
7369	8108		ADULT	44472635	444.5255	VIBEGRON	Vibegron	O[C@@H]([C@H]1CC[C@@H](CC2=CC=C(NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)C=C2)N1)C5=CC=CC=C5	PLASMA	M5TSE03W5U									∞	ng × h/mL	1820		ng/mL	168			UNKNOWN	mg	100		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213006Orig1s000ClinPharmR.pdf#page=42	Homo sapiens		h	94.5		Patients with Moderate hepatic impairment		8			false
7370	8108		ADULT	44472635	444.5255	VIBEGRON	Vibegron	O[C@@H]([C@H]1CC[C@@H](CC2=CC=C(NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)C=C2)N1)C5=CC=CC=C5	PLASMA	M5TSE03W5U									∞	ng × h/mL	1440		ng/mL	125			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213006Orig1s000ClinPharmR.pdf#page=42	Homo sapiens		h	92.5		Normal hepatic function		8			false
7371	8108		ADULT	44472635	444.5255	VIBEGRON	Vibegron	O[C@@H]([C@H]1CC[C@@H](CC2=CC=C(NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)C=C2)N1)C5=CC=CC=C5	PLASMA	M5TSE03W5U									∞	ng × h/mL	6337.17		ng/mL	342.83			UNKNOWN	mg	100		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213006Orig1s000ClinPharmR.pdf#page=45	Homo sapiens		h	130.6		Patients with Severe renal insufficiency		8			false
7372	8108		ADULT	44472635	444.5255	VIBEGRON	Vibegron	O[C@@H]([C@H]1CC[C@@H](CC2=CC=C(NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)C=C2)N1)C5=CC=CC=C5	PLASMA	M5TSE03W5U									∞	ng × h/mL	7137.53		ng/mL	404.5			UNKNOWN	mg	100		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213006Orig1s000ClinPharmR.pdf#page=45	Homo sapiens		h	108.2		Patients with Moderate renal insufficiency		8			false
7373	8108		ADULT	44472635	444.5255	VIBEGRON	Vibegron	O[C@@H]([C@H]1CC[C@@H](CC2=CC=C(NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)C=C2)N1)C5=CC=CC=C5	PLASMA	M5TSE03W5U									∞	ng × h/mL	5156.07		ng/mL	473.01			UNKNOWN	mg	100		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213006Orig1s000ClinPharmR.pdf#page=45	Homo sapiens		h	96.2		Patients with Mild renal insufficiency		8			false
7374	8108		ADULT	44472635	444.5255	VIBEGRON	Vibegron	O[C@@H]([C@H]1CC[C@@H](CC2=CC=C(NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)C=C2)N1)C5=CC=CC=C5	PLASMA	M5TSE03W5U									∞	ng × h/mL	3466.04		ng/mL	240.8			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213006Orig1s000ClinPharmR.pdf#page=45	Homo sapiens		h	98.8		Normal renal function		8			false
7375	8108		UNKNOWN	44472635	444.5255	VIBEGRON	Vibegron	O[C@@H]([C@H]1CC[C@@H](CC2=CC=C(NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)C=C2)N1)C5=CC=CC=C5	PLASMA	M5TSE03W5U																						UNKNOWN				Human plasma protein binding: ca.50% (0.1 to 100 mcM)	50	UNKNOWN		UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213006Orig1s000ClinPharmR.pdf#page=5 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213006Orig1s000ClinPharmR.pdf#page=10	Homo sapiens										false
7376	8108		ADULT	44472635	444.5255	VIBEGRON	Vibegron	O[C@@H]([C@H]1CC[C@@H](CC2=CC=C(NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)C=C2)N1)C5=CC=CC=C5	PLASMA	M5TSE03W5U									∞	ng × h/mL	721.9		ng/mL	23.65			RECOMMENDED	mg	75		SINGLE	HIGH-FAT						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213006Orig1s000ClinPharmR.pdf#page=50	Homo sapiens		h	79.42		n=14 for AUC and t1/2		15			false
7377	8108		ADULT	44472635	444.5255	VIBEGRON	Vibegron	O[C@@H]([C@H]1CC[C@@H](CC2=CC=C(NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)C=C2)N1)C5=CC=CC=C5	PLASMA	M5TSE03W5U									∞	ng × h/mL	1146		ng/mL	63.96			RECOMMENDED	mg	75		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213006Orig1s000ClinPharmR.pdf#page=50	Homo sapiens		h	87.2		n=14 for AUC and t1/2		15			false
7378	8108		ADULT	44472635	444.5255	VIBEGRON	Vibegron	O[C@@H]([C@H]1CC[C@@H](CC2=CC=C(NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)C=C2)N1)C5=CC=CC=C5	PLASMA	M5TSE03W5U									∞	ng × h/mL	1370		ng/mL	81.11			RECOMMENDED	mg	75		SINGLE	FED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213006Orig1s000ClinPharmR.pdf#page=50	Homo sapiens		h	87.86		Crushed tablet in applesauce; n=28 for AUC and t1/2		29			false
7379	8108		ADULT	44472635	444.5255	VIBEGRON	Vibegron	O[C@@H]([C@H]1CC[C@@H](CC2=CC=C(NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)C=C2)N1)C5=CC=CC=C5	PLASMA	M5TSE03W5U									∞	ng × h/mL	1524		ng/mL	114.4			RECOMMENDED	mg	75		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213006Orig1s000ClinPharmR.pdf#page=50	Homo sapiens		h	82.35		Intact tablet; n=28 for AUC and t1/2		29			false
7380	8109		ADULT	9952884	401.44	VOSAROXIN	Vosaroxin	CN[C@H]1CN(C[C@@H]1OC)C2=NC3=C(C=C2)C(=O)C(=CN3C4=NC=CS4)C(O)=O	PLASMA	K6A90IIZ19									∞	ng × h/mL	31245						UNKNOWN	mg/m²	18		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21760592/	Homo sapiens		h	25.13	18-90 mg/m2/dose, Day 1	Patients with advanced relapsed or refractory leukemia not expected to respond to standard therapy		41			false
7381	8109		ADULT	9952884	401.44	VOSAROXIN	Vosaroxin	CN[C@H]1CN(C[C@@H]1OC)C2=NC3=C(C=C2)C(=O)C(=CN3C4=NC=CS4)C(O)=O	PLASMA	K6A90IIZ19									∞	ng × h/mL	39450		ng/mL	1916			UNKNOWN	mg/m²	72		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21760592/	Homo sapiens		h	26.6	Day 1	Patients with advanced relapsed or refractory leukemia not expected to respond to standard therapy		11			false
7382	8109		ADULT	9952884	401.44	VOSAROXIN	Vosaroxin	CN[C@H]1CN(C[C@@H]1OC)C2=NC3=C(C=C2)C(=O)C(=CN3C4=NC=CS4)C(O)=O	PLASMA	K6A90IIZ19									∞	ng × h/mL	14212						UNKNOWN	mg/m²	9		MULTIPLE	UNKNOWN		week	2			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21760592/	Homo sapiens		h	26.58	Day 1, 9-50mg/m2/dose	Patients with advanced relapsed or refractory leukemia not expected to respond to standard therapy		31			false
7383	8109		ADULT	9952884	401.44	VOSAROXIN	Vosaroxin	CN[C@H]1CN(C[C@@H]1OC)C2=NC3=C(C=C2)C(=O)C(=CN3C4=NC=CS4)C(O)=O	PLASMA	K6A90IIZ19									∞	ng × h/mL	17067						UNKNOWN	mg/m²	9		MULTIPLE	UNKNOWN		week	2			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21760592/	Homo sapiens		h	28.21	Day 4, 9-50mg/m2/dose	Patients with advanced relapsed or refractory leukemia not expected to respond to standard therapy		30			false
7384	8109		ADULT	9952884	401.44	VOSAROXIN	Vosaroxin	CN[C@H]1CN(C[C@@H]1OC)C2=NC3=C(C=C2)C(=O)C(=CN3C4=NC=CS4)C(O)=O	PLASMA	K6A90IIZ19									∞	ng × h/mL	15983						UNKNOWN	mg/m²	9		MULTIPLE	UNKNOWN		week	2			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21760592/	Homo sapiens		h	23.74	Day 11, 9-50mg/m2/dose	Patients with advanced relapsed or refractory leukemia not expected to respond to standard therapy		28			false
7385	8109		ADULT	9952884	401.44	VOSAROXIN	Vosaroxin	CN[C@H]1CN(C[C@@H]1OC)C2=NC3=C(C=C2)C(=O)C(=CN3C4=NC=CS4)C(O)=O	PLASMA	K6A90IIZ19									∞	ng × h/mL	15637						UNKNOWN	mg/m²	9		MULTIPLE	UNKNOWN		week	2			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21760592/	Homo sapiens		h	22.3	Day 8, 9-50mg/m2/dose	Patients with advanced relapsed or refractory leukemia not expected to respond to standard therapy		29			false
7386	8109		ADULT	9952884	401.44	VOSAROXIN	Vosaroxin	CN[C@H]1CN(C[C@@H]1OC)C2=NC3=C(C=C2)C(=O)C(=CN3C4=NC=CS4)C(O)=O	PLASMA	K6A90IIZ19							72		∞	ng × h/mL	462		ng/mL	4148			UNKNOWN	mg/m²	90		MULTIPLE	UNKNOWN		3 days	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25403830/	Homo sapiens		h	20.41	Day 4			7			false
7387	8109		ADULT	9952884	401.44	VOSAROXIN	Vosaroxin	CN[C@H]1CN(C[C@@H]1OC)C2=NC3=C(C=C2)C(=O)C(=CN3C4=NC=CS4)C(O)=O	PLASMA	K6A90IIZ19							72		∞	ng × h/mL	848		ng/mL	2865			UNKNOWN	mg/m²	72		MULTIPLE	UNKNOWN		3 days	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25403830/	Homo sapiens		h	28.27	Day 1			6			false
7388	8109		ADULT	9952884	401.44	VOSAROXIN	Vosaroxin	CN[C@H]1CN(C[C@@H]1OC)C2=NC3=C(C=C2)C(=O)C(=CN3C4=NC=CS4)C(O)=O	PLASMA	K6A90IIZ19							72		∞	ng × h/mL	903		ng/mL	3028			UNKNOWN	mg/m²	72		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25403830/	Homo sapiens		h	22.51	Day 1			10			false
7389	8109		ADULT	9952884	401.44	VOSAROXIN	Vosaroxin	CN[C@H]1CN(C[C@@H]1OC)C2=NC3=C(C=C2)C(=O)C(=CN3C4=NC=CS4)C(O)=O	PLASMA	K6A90IIZ19							72		∞	ng × h/mL	838		ng/mL	3328			UNKNOWN	mg/m²	90		MULTIPLE	UNKNOWN		3 days	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25403830/	Homo sapiens		h	23.57	Day 1			8			false
7390	8109		ADULT	9952884	401.44	VOSAROXIN	Vosaroxin	CN[C@H]1CN(C[C@@H]1OC)C2=NC3=C(C=C2)C(=O)C(=CN3C4=NC=CS4)C(O)=O	PLASMA	K6A90IIZ19							72		∞	ng × h/mL	228		ng/mL	2450			UNKNOWN	mg/m²	72		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25403830/	Homo sapiens		h	27.29	Day 1			8			false
7391	8109		ADULT	9952884	401.44	VOSAROXIN	Vosaroxin	CN[C@H]1CN(C[C@@H]1OC)C2=NC3=C(C=C2)C(=O)C(=CN3C4=NC=CS4)C(O)=O	PLASMA	K6A90IIZ19							72		∞	ng × h/mL	539		ng/mL	5792			UNKNOWN	mg/m²	72		MULTIPLE	UNKNOWN		3 days	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25403830/	Homo sapiens		h	23.52	Day 4			5			false
7392	8109			9952884	401.44	VOSAROXIN	Vosaroxin	CN[C@H]1CN(C[C@@H]1OC)C2=NC3=C(C=C2)C(=O)C(=CN3C4=NC=CS4)C(O)=O	SERUM	K6A90IIZ19																										In human serum, vosaroxin protein binding was approximately 72%.	28				REVIEW	https://pubmed.ncbi.nlm.nih.gov/28504025/	Homo sapiens										false
7393	8116		ADULT	72402	363.3667	9-AMINOCAMPTOTHECIN	9-AMINOCAMPTOTHECIN	CC[C@@]1(O)C(=O)OCC2=C1C=C3N(CC4=CC5=C(C=CC=C5N)N=C34)C2=O	PLASMA	5MB77ICE2Q									∞	ng × h/mL	1385.39		ng/mL	147.57			UNKNOWN	mg/m²	1.75		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21191594	Homo sapiens		h	8.65				8	9-AMINOCAMPTOTHECIN		false
7394	8116		ADULT	72402	363.3667	9-AMINOCAMPTOTHECIN	9-AMINOCAMPTOTHECIN	CC[C@@]1(O)C(=O)OCC2=C1C=C3N(CC4=CC5=C(C=CC=C5N)N=C34)C2=O	PLASMA	5MB77ICE2Q									∞	ng × h/mL	2214.92		ng/mL	85.98			UNKNOWN	mg/m²	1.5		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21191594	Homo sapiens		h	21.25	Patients were continuously given  a  dose of 1.5 mg/m2 daily for 5 days			8	9-AMINOCAMPTOTHECIN		false
7395	8124		ADULT	108144	424.668	CARBOXYAMIDOTRIAZOLE	CARBOXYAMIDOTRIAZOLE	NC(=O)C1=C(N)N(CC2=CC(Cl)=C(C(=O)C3=CC=C(Cl)C=C3)C(Cl)=C2)N=N1	PLASMA	6ST3ZF52WB									∞	μg × h/mL	138.89		μg/mL	1.822			UNKNOWN	mg/m²	250		MULTIPLE	FED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10485080	Homo sapiens							12	CARBOXYAMIDOTRIAZOLE		false
7396	8124		ADULT	108144	424.668	CARBOXYAMIDOTRIAZOLE	Carboxyamidotriazole	NC(=O)C1=C(N)N(CC2=CC(Cl)=C(C(=O)C3=CC=C(Cl)C=C3)C(Cl)=C2)N=N1	PLASMA	6ST3ZF52WB									∞	μg × h/mL	52.5		μg/mL	0.583			UNKNOWN	mg/m²	250		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10485080	Homo sapiens							12	Carboxyamidotriazole		false
7397	8124		ADULT	108144	424.668	CARBOXYAMIDOTRIAZOLE	Carboxyamidotriazole	NC(=O)C1=C(N)N(CC2=CC(Cl)=C(C(=O)C3=CC=C(Cl)C=C3)C(Cl)=C2)N=N1	PLASMA	6ST3ZF52WB							24		t	mg × h/L	5.9		mg/L	0.32			UNKNOWN	mg/m²	250		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11801543	Homo sapiens		h	76				6	Carboxyamidotriazole		false
7398	8124		ADULT	108144	424.668	CARBOXYAMIDOTRIAZOLE	Carboxyamidotriazole	NC(=O)C1=C(N)N(CC2=CC(Cl)=C(C(=O)C3=CC=C(Cl)C=C3)C(Cl)=C2)N=N1	PLASMA	6ST3ZF52WB							24		t	mg × h/L	11		mg/L	0.6			UNKNOWN	mg/m²	200		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11801543	Homo sapiens		h	66				8	Carboxyamidotriazole		false
7399	8124		ADULT	108144	424.668	CARBOXYAMIDOTRIAZOLE	Carboxyamidotriazole	NC(=O)C1=C(N)N(CC2=CC(Cl)=C(C(=O)C3=CC=C(Cl)C=C3)C(Cl)=C2)N=N1	PLASMA	6ST3ZF52WB							24		t	mg × h/L	2.7		mg/L	0.17			UNKNOWN	mg/m²	75		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11801543	Homo sapiens		h	89				6	Carboxyamidotriazole		false
7400	8124		ADULT	108144	424.668	CARBOXYAMIDOTRIAZOLE	Carboxyamidotriazole	NC(=O)C1=C(N)N(CC2=CC(Cl)=C(C(=O)C3=CC=C(Cl)C=C3)C(Cl)=C2)N=N1	PLASMA	6ST3ZF52WB							24		t	mg × h/L	10.6		mg/L	0.57			UNKNOWN	mg/m²	300		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11801543	Homo sapiens		h	71				8	Carboxyamidotriazole		false
7401	8125		ADULT		684.7	CEFTAROLINE			PLASMA								12		t	mg × h/L	51.9		mg/L	22.3			RECOMMENDED	mg	600		SINGLE	UNKNOWN					20	HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27044549/	Homo sapiens		h	2.1							false
7402	8127		ADULT	11750009	402.5276	CLASCOTERONE		CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)CO	PLASMA	XN7MM8XG2M							12		t	ng × h/mL	19.96		ng/mL	4.81			UNKNOWN	mg	225		MULTIPLE	FED		day	2			HEALTHY	Topical	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33942574/	Homo sapiens				Day 1			24			false
7403	8127		ADULT	11750009	402.5276	CLASCOTERONE		CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)CO	PLASMA	XN7MM8XG2M							12		t	ng × h/mL	59.86		ng/mL	7.65			UNKNOWN	mg	225		MULTIPLE	FED		day	2	n=21 for AUC, n=20 for t1/2		HEALTHY	Topical	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33942574/	Homo sapiens		h	26.8	Day 4 (single dose)			22			false
7404	8127		ADULT	440707	346.4605	CORTODOXONE	Cortexolone	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO	PLASMA	WDT5SLP0HQ							24		t	ng × h/mL	15.52		ng/mL	1.16			UNKNOWN	mg	225		MULTIPLE	FED		day	2	n=2 for AUC		HEALTHY	Topical	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33942574/	Homo sapiens				Day 1			5			false
7405	8127		ADULT	440707	346.4605	CORTODOXONE	Cortexolone	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO	PLASMA	WDT5SLP0HQ							12		t	ng × h/mL	11.24		ng/mL	1.27			UNKNOWN	mg	225		MULTIPLE	FED		day	2	n=8 for AUC, n=7 for t1/2		HEALTHY	Topical	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33942574/	Homo sapiens		h	90.1	Day 4 (single dose)			21			false
7406	8127		ADULT	11750009	402.5276	CLASCOTERONE		CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)CO	PLASMA	XN7MM8XG2M							12		t	ng × h/mL	37.1		ng/mL	4.5			UNKNOWN	g	6		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Topical	UNKNOWN	DRUG LABEL	https://www.winlevi-hcp.com/pdf/winlevi-prescribing-information.pdf#page=2	Homo sapiens				Day 14	Patients with moderate to severe acne vulgaris		20			false
7407	8127			11750009	402.5276	CLASCOTERONE		CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)CO	PLASMA	XN7MM8XG2M																										Human plasma protein binding: 84~89%	11				DRUG LABEL	https://www.winlevi-hcp.com/pdf/winlevi-prescribing-information.pdf#page=2	Homo sapiens					Patients with moderate to severe acne vulgaris					false
7408	8135		UNKNOWN	44480399	393.3927	FRUQUINTINIB	FRUQUINTINIB	CNC(=O)C1=C(C)OC2=C1C=CC(OC3=NC=NC4=CC(OC)=C(OC)C=C34)=C2	PLASMA	49DXG3M5ZW																						UNKNOWN				The plasma protein binding fraction is 88–95 % in mouse, rat, dog and human, invariable up to 10 µM.	8.5	UNKNOWN		UNKNOWN	EXPERIMENT	https://link.springer.com/article/10.1007%2Fs00280-014-2471-3	Homo sapiens										false
7409	8135		ADULT	44480399	393.3927	FRUQUINTINIB	CNC(=O)C1=C(C)OC2=CC(OC3=C4C=C(OC)C(OC)=CC4=NC=N3)=CC=C12	CNC(=O)C1=C(C)OC2=CC(OC3=C4C=C(OC)C(OC)=CC4=NC=N3)=CC=C12	PLASMA	49DXG3M5ZW							24		t	ng × h/mL	5212		ng/mL	290			RECOMMENDED	mg	4		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	REVIEW	https://www.ncbi.nlm.nih.gov/pubmed/31496821	Homo sapiens		h	42							false
7410	8139		ADULT	11753673	597.747	REVEFENACIN	REVEFENACIN	CN(CCN1CCC(CC1)OC(=O)NC2=C(C=CC=C2)C3=CC=CC=C3)C(=O)C4=CC=C(CN5CCC(CC5)C(N)=O)C=C4	PLASMA	G2AE2VE07O							6		t	ng × h/mL	0.092		ng/mL	0.114			RECOMMENDED	μg	175		STEADY-STATE	UNKNOWN		day	1	In vitro protein binding of revefenacin to human plasma proteins was 71%.	29	UNHEALTHY	Respiratory	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210598Orig1s000ClinPharmR.pdf	Homo sapiens										false
7411	8139		ADULT	11753673	597.747	REVEFENACIN	REVEFENACIN	CN(CCN1CCC(CC1)OC(=O)NC2=C(C=CC=C2)C3=CC=CC=C3)C(=O)C4=CC=C(CN5CCC(CC5)C(N)=O)C=C4	PLASMA	G2AE2VE07O							6		t	ng × h/mL	0.443		ng/mL	0.577			MAX DAILY	μg	700		STEADY-STATE	UNKNOWN		day	1	In vitro protein binding of revefenacin to human plasma proteins was 71%.	29	UNHEALTHY	Respiratory	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210598Orig1s000ClinPharmR.pdf	Homo sapiens		h	23							false
7412	8139		ADULT		598.7	THRX-195518	THRX-195518		PLASMA	A6X64T4LZ4							6		t	ng × h/mL	0.299		ng/mL	0.178			RECOMMENDED	μg	175		STEADY-STATE	UNKNOWN		day	1	In vitro protein binding of THRX-195518 to human plasma proteins was 58%.	42	UNHEALTHY	Respiratory	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210598Orig1s000ClinPharmR.pdf	Homo sapiens		h	23.5							false
7413	8139		ADULT		598.7	THRX-195518			PLASMA	A6X64T4LZ4							6		t	ng × h/mL	1.48		ng/mL	0.948			MAX DAILY	μg	700		STEADY-STATE	UNKNOWN		day	1	In vitro protein binding of THRX-195518 to human plasma proteins was 58%.	42	UNHEALTHY	Respiratory	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210598Orig1s000ClinPharmR.pdf	Homo sapiens		h	22.3							false
7414	8139		ADULT	11753673	597.747	REVEFENACIN	REVEFENACIN	CN(CCN1CCC(CC1)OC(=O)NC2=C(C=CC=C2)C3=CC=CC=C3)C(=O)C4=CC=C(CN5CCC(CC5)C(N)=O)C=C4	PLASMA	G2AE2VE07O							6		t	ng × h/mL	0.161		ng/mL	0.309			RECOMMENDED	μg	175		SINGLE	UNKNOWN						HEALTHY	Respiratory	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210598Orig1s000ClinPharmR.pdf	Homo sapiens										false
7415	8139		ADULT		598.7	THRX-195518	THRX-195518		PLASMA	A6X64T4LZ4							6		t	ng × h/mL	0.117		ng/mL	0.0742			RECOMMENDED	μg	175		SINGLE	UNKNOWN						HEALTHY	Respiratory	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210598Orig1s000ClinPharmR.pdf	Homo sapiens										false
7416	8139		ADULT	11753673	597.747	REVEFENACIN	REVEFENACIN	CN(CCN1CCC(CC1)OC(=O)NC2=C(C=CC=C2)C3=CC=CC=C3)C(=O)C4=CC=C(CN5CCC(CC5)C(N)=O)C=C4	PLASMA	G2AE2VE07O							6		t	ng × h/mL	0.0702		ng/mL	0.105			RECOMMENDED	μg	175		SINGLE	UNKNOWN						UNHEALTHY	Respiratory	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210598Orig1s000ClinPharmR.pdf	Homo sapiens										false
7417	8139		ADULT		598.7	THRX-195518			PLASMA	A6X64T4LZ4							6		t	ng × h/mL	0.259		ng/mL	0.178			RECOMMENDED	μg	175		SINGLE	UNKNOWN						UNHEALTHY	Respiratory	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210598Orig1s000ClinPharmR.pdf	Homo sapiens										false
7418	8141		ADULT	6918256|16759177|136797998	397.187	GV 150526A	GV 150526A	[Na ].[O-]C(=O)C1=C(\\C=C\\C(=O)NC2=CC=CC=C2)C3=C(N1)C=C(Cl)C=C3Cl	PLASMA	80W7787JVB													μg/mL	135			UNKNOWN	mg	400		STEADY-STATE	UNKNOWN		day	2	1 h	3.6	UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10805066	Homo sapiens		h	55.9	GV 150526A 800 mg LD followed by 400 mg every 12 h for\n5 doses			7	GV 150526A		false
7419	8142		ADULT	9832687	393.459	GW-406381	GW-406381	CCOC1=CC=C(C=C1)C2=NN3N=CC=CC3=C2C4=CC=C(C=C4)S(C)(=O)=O	PLASMA	5Y869C2THE									∞	ng × h/mL	700						UNKNOWN	mg	35		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26331692	Homo sapiens							12	GW-406381		false
7420	8150		ADULT	6918263	487.5024	PHENSERINE TARTRATE	PHENSERINE TARTRATE	O[C@@H]([C@@H](O)C(O)=O)C(O)=O.CN1CC[C@]2(C)[C@H]1N(C)C3=CC=C(OC(=O)NC4=CC=CC=C4)C=C23	PLASMA	A2TJL9CO2K							24		t	ng × h/mL	35.72		ng/mL	9.87			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16248851	Homo sapiens		h	6.53				6	PHENSERINE TARTRATE		false
7421	8165		ADULT	46220502	506.2718	ABEMACICLIB	CCN1CCN(CC2=CN=C(NC3=NC=C(F)C(=N3)C4=CC(F)=C5N=C(C)N(C(C)C)C5=C4)C=C2)CC1	CCN1CCN(CC2=CN=C(NC3=NC=C(F)C(=N3)C4=CC(F)=C5N=C(C)N(C(C)C)C5=C4)C=C2)CC1	PLASMA	60UAB198HK							24		t	ng × h/mL	5520		ng/mL	298			MAX TOLERATED	mg	200		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://cancerdiscovery.aacrjournals.org/content/candisc/6/7/740.full.pdf	Homo sapiens		h	17.4							false
7422	8165			46220502	506.5934	ABEMACICLIB	ABEMACICLIB	CCN1CCN(CC2=CN=C(NC3=NC(C4=CC(F)=C5N=C(C)N(C(C)C)C5=C4)=C(F)C=N3)C=C2)CC1	PLASMA	60UAB198HK									?	ng × h/mL	3350							mg	200		STEADY-STATE			day	2			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02152631	Homo sapiens										false
7423	8165		UNKNOWN	46220502	506.5934	ABEMACICLIB	ABEMACICLIB	CCN1CCN(CC2=CN=C(NC3=NC(C4=CC(F)=C5N=C(C)N(C(C)C)C5=C4)=C(F)C=N3)C=C2)CC1	PLASMA	60UAB198HK																						UNKNOWN				In vitro, abemaciclib was bound to human plasma proteins, serum albumin, and alpha-1-acid glycoprotein in a concentration independent manner from 152 ng/mL to 5066 ng/mL. In a clinical study, the mean (standard deviation, SD) bound fraction was 96.3% (1.1) for abemaciclib, 93.4% (1.3) for M2, 96.8% (0.8) for M18, and 97.8% (0.6) for M20.	3.7	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208716s000lbl.pdf	Homo sapiens										false
7424	8166		ADULT	56649450	441.47	ALPELISIB	CC1=C(SC(NC(=O)N2CCC[C@H]2C(N)=O)=N1)C3=CC(=NC=C3)C(C)(C)C(F)(F)F	CC1=C(SC(NC(=O)N2CCC[C@H]2C(N)=O)=N1)C3=CC(=NC=C3)C(C)(C)C(F)(F)F	PLASMA	08W5N2C97Q							24		t	ng × h/mL	33224		ng/mL	2480			RECOMMENDED	mg	300		STEADY-STATE	FED		day	1	Protein binding of alpelisib is 89% and is independent of concentration.	11	UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212526s000lbl.pdf	Homo sapiens		h	8.5							false
7425	8167		ADULT	135564749	370.4	APABETALONE	APABETALONE	COC1=CC(OC)=C2C(=O)NC(=NC2=C1)C3=CC(C)=C(OCCO)C(C)=C3	PLASMA	8R4A7GDZ1D							48		t	ng × h/mL	2306		ng/mL	360			UNKNOWN	mg	100		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/29854980	Homo sapiens		h	5.97							false
7426	8168		ADULT	9912992	479.508	AVOSENTAN	avosentan	COC1=C(OC2=C(OC)N=C(N=C2NS(=O)(=O)C3=NC=C(C)C=C3)C4=CC=NC=C4)C=CC=C1	PLASMA	L94KSX715K										ng × h/mL	641		ng/mL	54.3			UNKNOWN	mg	1.5		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19279566	Homo sapiens							8	avosentan		false
7427	8168		ADULT	9912992	479.508	AVOSENTAN	avosentan	COC1=C(OC2=C(OC)N=C(N=C2NS(=O)(=O)C3=NC=C(C)C=C3)C4=CC=NC=C4)C=CC=C1	PLASMA	L94KSX715K										ng × h/mL	15646		ng/mL	1883.7			UNKNOWN	mg	50		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19279566	Homo sapiens							8	avosentan		false
7428	8168		ADULT	9912992	479.508	AVOSENTAN	avosentan	COC1=C(OC2=C(OC)N=C(N=C2NS(=O)(=O)C3=NC=C(C)C=C3)C4=CC=NC=C4)C=CC=C1	PLASMA	L94KSX715K									?	ng × h/mL	247		ng/mL	19.6			UNKNOWN	mg	0.5		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19279566	Homo sapiens							9	avosentan		false
7429	8168		ADULT	9912992	479.508	AVOSENTAN	avosentan	COC1=C(OC2=C(OC)N=C(N=C2NS(=O)(=O)C3=NC=C(C)C=C3)C4=CC=NC=C4)C=CC=C1	PLASMA	L94KSX715K										ng × h/mL	2106		ng/mL	228.9			UNKNOWN	mg	5		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19279566	Homo sapiens							9	avosentan		false
7430	8170			44205240	371.417	BARICITINIB	BARICITINIB	CCS(=O)(=O)N1CC(CC#N)(C1)N2C=C(C=N2)C3=NC=NC4=C3C=CN4	PLASMA	ISP4442I3Y													ng/mL	29				mg	2		STEADY-STATE			day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02708095	Homo sapiens										false
7431	8170			44205240	371.417	BARICITINIB	BARICITINIB	CCS(=O)(=O)N1CC(CC#N)(C1)N2C=C(C=N2)C3=NC=NC4=C3C=CN4	PLASMA	ISP4442I3Y													ng/mL	59.2				mg	4		STEADY-STATE			day	1			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02708095	Homo sapiens										false
7432	8170			44205240	371.417	BARICITINIB	BARICITINIB	CCS(=O)(=O)N1CC(CC#N)(C1)N2C=C(C=N2)C3=NC=NC4=C3C=CN4	PLASMA	ISP4442I3Y													ng/mL	136				mg	10		MULTIPLE			day	1			HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02758613	Homo sapiens										false
7433	8170			44205240	371.417	BARICITINIB	BARICITINIB	CCS(=O)(=O)N1CC(CC#N)(C1)N2C=C(C=N2)C3=NC=NC4=C3C=CN4	PLASMA	ISP4442I3Y													ng/mL	48				mg	4		MULTIPLE			day	1			HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02758613	Homo sapiens										false
7434	8170			44205240	371.417	BARICITINIB	BARICITINIB	CCS(=O)(=O)N1CC(CC#N)(C1)N2C=C(C=N2)C3=NC=NC4=C3C=CN4	PLASMA	ISP4442I3Y									∞	ng × h/mL	777							mg	10		SINGLE			day	1			HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02758613	Homo sapiens										false
7435	8170			44205240	371.417	BARICITINIB	BARICITINIB	CCS(=O)(=O)N1CC(CC#N)(C1)N2C=C(C=N2)C3=NC=NC4=C3C=CN4	PLASMA	ISP4442I3Y													ng/mL	147				mg	10		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02758613	Homo sapiens										false
7436	8170			44205240	371.417	BARICITINIB	BARICITINIB	CCS(=O)(=O)N1CC(CC#N)(C1)N2C=C(C=N2)C3=NC=NC4=C3C=CN4	PLASMA	ISP4442I3Y									∞	ng × h/mL	270							mg	4		SINGLE			day	1			HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02758613	Homo sapiens										false
7437	8170			44205240	371.417	BARICITINIB	BARICITINIB	CCS(=O)(=O)N1CC(CC#N)(C1)N2C=C(C=N2)C3=NC=NC4=C3C=CN4	PLASMA	ISP4442I3Y													ng/mL	47.8				mg	4		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02758613	Homo sapiens										false
7438	8170			44205240	371.417	BARICITINIB	BARICITINIB	CCS(=O)(=O)N1CC(CC#N)(C1)N2C=C(C=N2)C3=NC=NC4=C3C=CN4	PLASMA	ISP4442I3Y							24		t	ng × h/mL	771							mg	10		STEADY-STATE			day	1			HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02758613	Homo sapiens										false
7439	8170			44205240	371.417	BARICITINIB	BARICITINIB	CCS(=O)(=O)N1CC(CC#N)(C1)N2C=C(C=N2)C3=NC=NC4=C3C=CN4	PLASMA	ISP4442I3Y							24		t	ng × h/mL	265							mg	4		STEADY-STATE			day	1			HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02758613	Homo sapiens										false
7440	8170			44205240	371.417	BARICITINIB	BARICITINIB	CCS(=O)(=O)N1CC(CC#N)(C1)N2C=C(C=N2)C3=NC=NC4=C3C=CN4	PLASMA	ISP4442I3Y							48		t	ng × h/mL	216		ng/mL	47.8				mg	4		SINGLE	FASTED						HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT03212638	Homo sapiens										false
7441	8170			44205240	371.417	BARICITINIB	BARICITINIB	CCS(=O)(=O)N1CC(CC#N)(C1)N2C=C(C=N2)C3=NC=NC4=C3C=CN4	PLASMA	ISP4442I3Y							48		t	ng × h/mL	273		ng/mL	32.5				mg	4		SINGLE	HIGH-FAT						HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT03212638	Homo sapiens										false
7442	8170		ADULT	44205240	371.417	BARICITINIB	BARICITINIB	CCS(=O)(=O)N1CC(CC#N)(C1)N2C=C(C=N2)C3=NC=NC4=C3C=CN4	PLASMA	ISP4442I3Y									∞	ng × h/mL	236		ng/mL	36.2			UNKNOWN	mg	4		SINGLE	FASTED					50	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/28749581	Homo sapiens		h	7.28							false
7443	8172		ADULT	10288191	441.227	BINIMETINIB	BINIMETINIB	CN1C=NC2=C1C=C(C(=O)NOCCO)C(NC3=C(F)C=C(Br)C=C3)=C2F	PLASMA	181R97MR71							8		t	ng × h/mL	1710		ng/mL	545			MAX TOLERATED	mg	60		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/28152546	Homo sapiens										false
7444	8172		ADULT	10288191	441.227	BINIMETINIB	BINIMETINIB	CN1C=NC2=C1C=C(C(=O)NOCCO)C(NC3=C(F)C=C(Br)C=C3)=C2F	PLASMA	181R97MR71							8		t	ng × h/mL	964		ng/mL	241			RECOMMENDED	mg	45		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/28152546	Homo sapiens										false
7445	8173		ADULT	11234052	370.3776	BRIVANIB	BRIVANIB	C[C@@H](O)COC1=CN2N=CN=C(OC3=C(F)C4=C(NC(C)=C4)C=C3)C2=C1C	PLASMA	DDU33B674I									?	ng × h/mL	62813		ng/mL	6610			MAX TOLERATED	mg	800		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21131369	Homo sapiens		h	12.3	day 26			20	Brivanib alaninate		false
7446	8173		ADULT	11234052	370.3776	BRIVANIB	BRIVANIB	C[C@@H](O)COC1=CN2N=CN=C(OC3=C(F)C4=C(NC(C)=C4)C=C3)C2=C1C	PLASMA	DDU33B674I									∞	ng × h/mL	53685		ng/mL	2847			MAX TOLERATED	mg	800		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21461891	Homo sapiens		h	18.3				19	Brivanib alaninate		false
7447	8173		ADULT	11234052	370.3776	BRIVANIB	BRIVANIB	C[C@@H](O)COC1=CN2N=CN=C(OC3=C(F)C4=C(NC(C)=C4)C=C3)C2=C1C	PLASMA	DDU33B674I									∞	ng × h/mL	45892		ng/mL	6146			UNKNOWN	mg	800		SINGLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/20671097	Homo sapiens		h	13.8							false
7448	8173		UNKNOWN	11234052	370.3776	BRIVANIB	BRIVANIB	C[C@@H](O)COC1=CN2N=CN=C(OC3=C(F)C4=C(NC(C)=C4)C=C3)C2=C1C	PLASMA	DDU33B674I																						UNKNOWN				The serum protein binding of brivanib is 98.7% in humans.	1.3	UNKNOWN		UNKNOWN	REVIEW	https://www.tandfonline.com/doi/full/10.1517/13543784.2011.565329	Homo sapiens										false
7449	8174		ADULT	16654980	410.4	BUPARLISIB	BUPARLISIB	NC1=CC(=C(C=N1)C2=CC(=NC(=N2)N3CCOCC3)N4CCOCC4)C(F)(F)F	PLASMA	0ZM2Z182GD							24		t	ng × h/mL	22400		ng/mL	1880			MAX TOLERATED	mg	100		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/27793950	Homo sapiens		h	38.3							false
7450	8174		ADULT	16654980	410.3935	BUPARLISIB	BUPARLISIB	NC1=CC(=C(C=N1)C2=NC(=NC(=C2)N3CCOCC3)N4CCOCC4)C(F)(F)F	PLASMA																							UNKNOWN				Plasma protein binding was similar across normal (as assessed by the geometric mean of the unbound fraction [GMfu] 0.17; percentage coefficient of variation [CV%] 17.2), mild (GMfu 0.17; CV% 14.1), and moderate groups (GMfu 0.17; CV% 15.6), whereas it was reduced in the severe hepatic impairment group (GMfu 0.21; CV% 14.35). Plasma protein binding of buparlisib is moderate (79–85% across species) and independent of drug concentration.	17	HEALTHY		UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/32031037	Homo sapiens										false
7451	8176		ADULT		378.4824	CEBRANOPADOL	cebranopadol	CN(C)[C@]1(CC[C@@]2(CC1)OCCC3=C2NC4=C3C=C(F)C=C4)C5=CC=CC=C5	PLASMA	7GDW9S3GN3									?	pg × h/mL	14474		pg/mL	891			UNKNOWN	μg	1200		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28623508	Homo sapiens							7	cebranopadol		false
7452	8176		ADULT		378.4824	CEBRANOPADOL	cebranopadol	CN(C)[C@]1(CC[C@@]2(CC1)OCCC3=C2NC4=C3C=C(F)C=C4)C5=CC=CC=C5	PLASMA	7GDW9S3GN3									?	pg × h/mL	4260		pg/mL	255			UNKNOWN	μg	400		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28623508	Homo sapiens							12	cebranopadol		false
7453	8176		ADULT		378.4824	CEBRANOPADOL	cebranopadol	CN(C)[C@]1(CC[C@@]2(CC1)OCCC3=C2NC4=C3C=C(F)C=C4)C5=CC=CC=C5	PLASMA	7GDW9S3GN3									?	pg × h/mL	18785		pg/mL	1119			UNKNOWN	μg	1600		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28623508	Homo sapiens							8	cebranopadol		false
7454	8176		ADULT		378.4824	CEBRANOPADOL	cebranopadol	CN(C)[C@]1(CC[C@@]2(CC1)OCCC3=C2NC4=C3C=C(F)C=C4)C5=CC=CC=C5	PLASMA	7GDW9S3GN3									?	pg × h/mL	1953		pg/mL	145			UNKNOWN	μg	400		SINGLE	UNKNOWN			1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28623508	Homo sapiens							12	cebranopadol		false
7455	8178		UNKNOWN	44591583	251.045	CRISABOROLE	AN-2728	OB1OCC2=C1C=CC(OC3=CC=C(C=C3)C#N)=C2	PLASMA	Q2R47HGR7P																						UNKNOWN				Based on an in vitro study, crisaborole is 97% bound to human plasma proteins.	3	UNKNOWN		UNKNOWN	DRUG LABEL	https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/609b77de-1ca3-4783-b8f5-01a9c0f1d77d/spl-doc?hl=crisaborole	Homo sapiens										false
7456	8178		ADOLESCENT	44591583	251.045	CRISABOROLE	AN-2728	OB1OCC2=C1C=CC(OC3=CC=C(C=C3)C#N)=C2	PLASMA	Q2R47HGR7P							12		t	ng × h/mL	448		ng/mL	105			UNKNOWN	mg/cm²	3		SINGLE	UNKNOWN						UNHEALTHY	Topical	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26777394	Homo sapiens		h	7.17							false
7457	8178		ADULT	44591583	251.045	CRISABOROLE	AN-2728	OB1OCC2=C1C=CC(OC3=CC=C(C=C3)C#N)=C2	PLASMA	Q2R47HGR7P							24		t	ng × h/mL	1171		ng/mL	163.7			UNKNOWN	mg	435		SINGLE	UNKNOWN						HEALTHY	Topical	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/31657024	Homo sapiens										false
7458	8180		ADULT	214347	329.3984	DAPIVIRINE	DAPIVIRINE	CC1=CC(C)=C(NC2=NC(NC3=CC=C(C=C3)C#N)=NC=C2)C(C)=C1	PLASMA	TCN4MG2VXS							168		t	pg × h/mL	7952		pg/mL	91			UNKNOWN	mg	1.25		SINGLE	UNKNOWN						HEALTHY	Vaginal	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27809557/	Homo sapiens		h	59	fast-dissolving dapivirine film			10	DAPIVIRINE		false
7459	8180		ADULT	214347	329.3984	DAPIVIRINE	DAPIVIRINE	CC1=CC(C)=C(NC2=NC(NC3=CC=C(C=C3)C#N)=NC=C2)C(C)=C1	PLASMA	TCN4MG2VXS							168		t	pg × h/mL	7832		pg/mL	132			UNKNOWN	mg	1.25		SINGLE	UNKNOWN						HEALTHY	Vaginal	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27809557/	Homo sapiens		h	52	semisolid dapivirine gel			10	DAPIVIRINE		false
7460	8180		ADULT	214347	329.3984	DAPIVIRINE	DAPIVIRINE	CC1=CC(C)=C(NC2=NC(NC3=CC=C(C=C3)C#N)=NC=C2)C(C)=C1	PLASMA	TCN4MG2VXS													pg/mL	280			UNKNOWN	mg	25		SINGLE	UNKNOWN						HEALTHY	Vaginal	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/34118115/	Homo sapiens				vaginal ring for 91 days			16	DAPIVIRINE		false
7461	8180		ADULT	214347	329.3984	DAPIVIRINE	DAPIVIRINE	CC1=CC(C)=C(NC2=NC(NC3=CC=C(C=C3)C#N)=NC=C2)C(C)=C1	PLASMA	TCN4MG2VXS							2184		t	ng × day/mL	33.249		pg/mL	487			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Vaginal	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/34118115/	Homo sapiens				vaginal ring for 91 days			16	DAPIVIRINE		false
7462	8180		ADULT	214347	329.3984	DAPIVIRINE	DAPIVIRINE	CC1=CC(C)=C(NC2=NC(NC3=CC=C(C=C3)C#N)=NC=C2)C(C)=C1	PLASMA	TCN4MG2VXS							2184		t	ng × day/mL	34.78		pg/mL	505			UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Vaginal	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/34118115/	Homo sapiens				vaginal ring for 91 days			16	DAPIVIRINE		false
7463	8180		ADULT	214347	329.3984	DAPIVIRINE	DAPIVIRINE	CC1=CC(C)=C(NC2=NC(NC3=CC=C(C=C3)C#N)=NC=C2)C(C)=C1	PLASMA	TCN4MG2VXS							672		t	pg × h/mL	229408		pg/mL	462			RECOMMENDED	mg	25		SINGLE	UNKNOWN					0.4	HEALTHY	Vaginal	FEMALE	DRUG LABEL	https://www.ema.europa.eu/en/documents/outside-eu-product-information/dapivirine-vaginal-ring-25-mg-product-information_en-0.pdf	Homo sapiens		h	81.5	vaginal ring for 28 days				DAPIVIRINE		false
7464	8181			46926350	396.486	DINACICLIB	DINACICLIB	CCC1=C2N=C(C=C(NCC3=C[N+]([O-])=CC=C3)N2N=C1)N4CCCC[C@H]4CCO	PLASMA	4V8ECV0NBQ																										Fraction unbound Fu = 20.5	20.5				EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/27496135	Homo sapiens										false
7465	8181		ADULT	46926350	396.5	DINACICLIB	DINACICLIB	CCC1=C2N=C(C=C(NCC3=CC=C[N+]([O-])=C3)N2N=C1)N4CCCC[C@H]4CCO	PLASMA	4V8ECV0NBQ									∞	ng × h/mL	3940		ng/mL	1810			RECOMMENDED	mg/m²	50		STEADY-STATE	UNKNOWN		3 weeks	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/28859059	Homo sapiens		h	3.1							false
7466	8182		ADULT	135398510	392.4294	DOVITINIB	DOVITINIB	CN1CCN(CC1)C2=CC3=C(C=C2)N=C(N3)C4=C(N)C5=C(NC4=O)C=CC=C5F	PLASMA	I35H55G906							24		t	ng × h/mL	3033.87		ng/mL	213.35			MAX TOLERATED	mg	400		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/21976540	Homo sapiens		h	13.51							false
7467	8182		ADULT	135398510	392.4294	DOVITINIB	DOVITINIB	CN1CCN(CC1)C2=CC3=C(C=C2)N=C(N3)C4=C(N)C5=C(NC4=O)C=CC=C5F	PLASMA	I35H55G906									?	ng × h/mL	5576.4		ng/mL	326.3			UNKNOWN	mg	500		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/24691021	Homo sapiens										false
7468	8182		UNKNOWN	135398510	392.4294	DOVITINIB	DOVITINIB	CN1CCN(CC1)C2=CC3=C(C=C2)N=C(N3)C4=C(N)C5=C(NC4=O)C=CC=C5F	PLASMA	I35H55G906																						UNKNOWN				Table 1. Pharmacokinetic values of the inhibitors used in drug–drug interaction predictions. fu,p, unbound fraction in plasma. 0.04	4	UNKNOWN		UNKNOWN	REVIEW	https://www.ncbi.nlm.nih.gov/pubmed/29956478	Homo sapiens										false
7469	8183		ADULT	50905713	416.11523	DUVELISIB	DUVELISIB	C[C@H](NC1=C2N=CNC2=NC=N1)C3=CC4=C(C(Cl)=CC=C4)C(=O)N3C5=CC=CC=C5	PLASMA	610V23S0JI							12		t	μg × h/mL	7.9		μg/mL	1.5			DEFINED DAILY	mg	50		STEADY-STATE	UNKNOWN		day	2	Protein binding of duvelisib is greater than 98% with no concentration dependence.	2	UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211155s000lbl.pdf	Homo sapiens		h	4.7							false
7470	8183		ADULT	50905713	416.11523	DUVELISIB	DUVELISIB	C[C@H](NC1=C2N=CNC2=NC=N1)C3=CC4=C(C(Cl)=CC=C4)C(=O)N3C5=CC=CC=C5	PLASMA	610V23S0JI									∞	ng × h/mL	7098.4		ng/mL	1062			DEFINED DAILY	mg	50		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033052/	Homo sapiens		h	6.8							false
7471	8185		ADULT	46196517	320.837	ENCENICLINE	ENCENICLINE	ClC1=CC=CC2=C1SC(=C2)C(=O)N[C@H]3CN4CCC3CC4	PLASMA	5FI5376A0X									∞	ng × h/mL	2800		ng/mL	35.6			UNKNOWN	mg	60		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25438724	Homo sapiens		h	63				6	ENCENICLINE		false
7472	8185		ADULT	46196517	320.837	ENCENICLINE	encenicline	ClC1=CC=CC2=C1SC(=C2)C(=O)N[C@H]3CN4CCC3CC4	PLASMA	5FI5376A0X									∞	ng × h/mL	8890		ng/mL	100			MAX DAILY	mg	180		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25438724	Homo sapiens		h	60.6				6	ENCENICLINE		false
7473	8185		ADULT	46196517	320.837	ENCENICLINE	ENCENICLINE	ClC1=CC=CC2=C1SC(=C2)C(=O)N[C@H]3CN4CCC3CC4	PLASMA	5FI5376A0X									∞	ng × h/mL	358		ng/mL	4.66			UNKNOWN	mg	7		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25438724	Homo sapiens		h	60.3				6	ENCENICLINE		false
7474	8185		ADULT	46196517	320.837	ENCENICLINE	encenicline	ClC1=CC=CC2=C1SC(=C2)C(=O)N[C@H]3CN4CCC3CC4	PLASMA	5FI5376A0X									∞	ng × h/mL	45.6		ng/mL	0.588			UNKNOWN	mg	1		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25438724	Homo sapiens		h	52.6				6	encenicline		false
7475	8186		ADULT	4261	376.4085	ENTINOSTAT	ENTINOSTAT	NC1=C(NC(=O)C2=CC=C(CNC(=O)OCC3=CN=CC=C3)C=C2)C=CC=C1	PLASMA	1ZNY4FKK9H																						UNKNOWN				The time to equilibrium was established to be within 5 h, and the mean unbound fraction of MS-275 (f (u)) over a presumed therapeutic concentration range in healthy volunteer human plasma was 0.188 +/- 0.0075 as compared to 0.168 +/- 0.0144 in cancer patients.	0.188	HEALTHY		UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/16028097/	Homo sapiens										false
7476	8186		ADULT	4261	376.4	ENTINOSTAT	ENTINOSTAT	NC1=C(NC(=O)C2=CC=C(CNC(=O)OCC3=CC=CN=C3)C=C2)C=CC=C1	PLASMA	1ZNY4FKK9H	5282379		Isotretinoin	Isotretinoin	CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C	EH28UP18IF			∞	ng × h/mL	586.6		ng/mL	114.3			RECOMMENDED	mg/m²	4		MULTIPLE	FASTED		week	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/22134508	Homo sapiens		h	129.7							true
7477	8187		ADULT	44814423	436.883	ERTUGLIFLOZIN	ERTUGLIFLOZIN	CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]34OC[C@](CO)(O3)[C@@H](O)[C@H](O)[C@H]4O)C=C1	PLASMA	6C282481IP									?	ng × h/mL	398		ng/mL	81.3			RECOMMENDED	mg	5		STEADY-STATE	UNKNOWN		day	1	Plasma protein binding of ertugliflozin is 93.6%	6.4	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209803s000lbl.pdf	Homo sapiens		h	16.6							false
7478	8190		ADULT	60150535	378.4244	FINERENONE	Finerenone	CCOC1=NC=C(C)C2=C1[C@H](C3=C(OC)C=C(C=C3)C#N)C(C(N)=O)=C(C)N2	PLASMA	DE2O63YV8R									?	μg × h/L	12.99		μg/L	5.431			UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215341Orig1s000IntegratedR.pdf#page=146	Homo sapiens		h	1.702				5			false
7479	8190		ADULT	60150535	378.4244	FINERENONE	Finerenone	CCOC1=NC=C(C)C2=C1[C@H](C3=C(OC)C=C(C=C3)C#N)C(C(N)=O)=C(C)N2	PLASMA	DE2O63YV8R									?	μg × h/L	25.23		μg/L	12.54			UNKNOWN	mg	2.5		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215341Orig1s000IntegratedR.pdf#page=146	Homo sapiens		h	1.741				5			false
7480	8190		ADULT	60150535	378.4244	FINERENONE	Finerenone	CCOC1=NC=C(C)C2=C1[C@H](C3=C(OC)C=C(C=C3)C#N)C(C(N)=O)=C(C)N2	PLASMA	DE2O63YV8R									?	μg × h/L	51.13		μg/L	25.45			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215341Orig1s000IntegratedR.pdf#page=146	Homo sapiens		h	1.874				6			false
7481	8190		ADULT	60150535	378.4244	FINERENONE	Finerenone	CCOC1=NC=C(C)C2=C1[C@H](C3=C(OC)C=C(C=C3)C#N)C(C(N)=O)=C(C)N2	PLASMA	DE2O63YV8R									?	μg × h/L	132.1		μg/L	42.49			RECOMMENDED	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215341Orig1s000IntegratedR.pdf#page=147	Homo sapiens		h	2.066				6			false
7482	8190		ADULT	60150535	378.4244	FINERENONE	Finerenone	CCOC1=NC=C(C)C2=C1[C@H](C3=C(OC)C=C(C=C3)C#N)C(C(N)=O)=C(C)N2	PLASMA	DE2O63YV8R									?	μg × h/L	470.3		μg/L	154.4			UNKNOWN	mg	40		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215341Orig1s000IntegratedR.pdf#page=147	Homo sapiens		h	2.834				6			false
7483	8190		ADULT	60150535	378.4244	FINERENONE	Finerenone	CCOC1=NC=C(C)C2=C1[C@H](C3=C(OC)C=C(C=C3)C#N)C(C(N)=O)=C(C)N2	PLASMA	DE2O63YV8R									?	μg × h/L	161.4		μg/L	63.58			RECOMMENDED	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215341Orig1s000IntegratedR.pdf#page=147	Homo sapiens		h	1.776				6			false
7484	8190		ADULT	60150535	378.4244	FINERENONE	Finerenone	CCOC1=NC=C(C)C2=C1[C@H](C3=C(OC)C=C(C=C3)C#N)C(C(N)=O)=C(C)N2	PLASMA	DE2O63YV8R									?	μg × h/L	208.3		μg/L	90.54			UNKNOWN	mg	10		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215341Orig1s000IntegratedR.pdf#page=149	Homo sapiens		h	1.779	Day 1			11			false
7485	8190		ADULT	60150535	378.4244	FINERENONE	Finerenone	CCOC1=NC=C(C)C2=C1[C@H](C3=C(OC)C=C(C=C3)C#N)C(C(N)=O)=C(C)N2	PLASMA	DE2O63YV8R									?	μg × h/L	318.5		μg/L	177.3			UNKNOWN	mg	20		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215341Orig1s000IntegratedR.pdf#page=149	Homo sapiens		h	1.685	Day 1			9			false
7486	8190		ADULT	60150535	378.4244	FINERENONE	Finerenone	CCOC1=NC=C(C)C2=C1[C@H](C3=C(OC)C=C(C=C3)C#N)C(C(N)=O)=C(C)N2	PLASMA	DE2O63YV8R									?	μg × h/L	928.7		μg/L	287.2			UNKNOWN	mg	40		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215341Orig1s000IntegratedR.pdf#page=149	Homo sapiens		h	3.044	Day 1			9			false
7487	8190		ADULT	60150535	378.4244	FINERENONE	Finerenone	CCOC1=NC=C(C)C2=C1[C@H](C3=C(OC)C=C(C=C3)C#N)C(C(N)=O)=C(C)N2	PLASMA	DE2O63YV8R	4192	325.767	MIDAZOLAM	Midazolam	CC1=NC=C2CN=C(C3=C(F)C=CC=C3)C4=C(C=CC(Cl)=C4)N12	R60L0SM5BC	24		t	μg × h/L	661		μg/L	167.2			UNKNOWN	mg	20		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215341Orig1s000IntegratedR.pdf#page=150	Homo sapiens		h	4.295	Day 10		7.5 mg on Days 1, 2, and 10	6			true
7488	8190		ADULT	60150535	378.4244	FINERENONE	Finerenone	CCOC1=NC=C(C)C2=C1[C@H](C3=C(OC)C=C(C=C3)C#N)C(C(N)=O)=C(C)N2	PLASMA	DE2O63YV8R							12		t	μg × h/L	232.5		μg/L	94.54			UNKNOWN	mg	10		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215341Orig1s000IntegratedR.pdf#page=150	Homo sapiens		h	2.564	Day 10			9			false
7489	8190		ADULT	60150535	378.4244	FINERENONE	Finerenone	CCOC1=NC=C(C)C2=C1[C@H](C3=C(OC)C=C(C=C3)C#N)C(C(N)=O)=C(C)N2	PLASMA	DE2O63YV8R							12		t	μg × h/L	420.7		μg/L	170.6			UNKNOWN	mg	20		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215341Orig1s000IntegratedR.pdf#page=150	Homo sapiens		h	2.832	Day 10			9			false
7490	8190		ADULT	60150535	378.4244	FINERENONE	Finerenone	CCOC1=NC=C(C)C2=C1[C@H](C3=C(OC)C=C(C=C3)C#N)C(C(N)=O)=C(C)N2	PLASMA	DE2O63YV8R							24		t	μg × h/L	1022		μg/L	258.6			UNKNOWN	mg	40		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215341Orig1s000IntegratedR.pdf#page=150	Homo sapiens		h	3.112	Day 10			9			false
7491	8190		ADULT	60150535	378.4244	FINERENONE	Finerenone	CCOC1=NC=C(C)C2=C1[C@H](C3=C(OC)C=C(C=C3)C#N)C(C(N)=O)=C(C)N2	PLASMA	DE2O63YV8R	4192	325.767	MIDAZOLAM	Midazolam	CC1=NC=C2CN=C(C3=C(F)C=CC=C3)C4=C(C=CC(Cl)=C4)N12	R60L0SM5BC			?	μg × h/L	221		μg/L	105			UNKNOWN	mg	10		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215341Orig1s000IntegratedR.pdf#page=159	Homo sapiens		h	2.26	IR tablet	Mild renal impairment	7.5 mg on Days 1, 2, and 10	8			true
7492	8190		ADULT	60150535	378.4244	FINERENONE	Finerenone	CCOC1=NC=C(C)C2=C1[C@H](C3=C(OC)C=C(C=C3)C#N)C(C(N)=O)=C(C)N2	PLASMA	DE2O63YV8R	4192	325.767	MIDAZOLAM	Midazolam	CC1=NC=C2CN=C(C3=C(F)C=CC=C3)C4=C(C=CC(Cl)=C4)N12	R60L0SM5BC			?	μg × h/L	352		μg/L	110			UNKNOWN	mg	10		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215341Orig1s000IntegratedR.pdf#page=159	Homo sapiens		h	2.8	IR tablet	Moderate renal impairment	7.5 mg on Days 1, 2, and 10	7			true
7493	8190		ADULT	60150535	378.4244	FINERENONE	Finerenone	CCOC1=NC=C(C)C2=C1[C@H](C3=C(OC)C=C(C=C3)C#N)C(C(N)=O)=C(C)N2	PLASMA	DE2O63YV8R	4192	325.767	MIDAZOLAM	Midazolam	CC1=NC=C2CN=C(C3=C(F)C=CC=C3)C4=C(C=CC(Cl)=C4)N12	R60L0SM5BC			?	μg × h/L	317		μg/L	88.4			UNKNOWN	mg	10		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215341Orig1s000IntegratedR.pdf#page=159	Homo sapiens		h	2.78	IR tablet	Severe renal impairment	7.5 mg on Days 1, 2, and 10	9			true
7494	8190		ADULT	60150535	378.4244	FINERENONE	Finerenone	CCOC1=NC=C(C)C2=C1[C@H](C3=C(OC)C=C(C=C3)C#N)C(C(N)=O)=C(C)N2	PLASMA	DE2O63YV8R	4192	325.767	MIDAZOLAM	Midazolam	CC1=NC=C2CN=C(C3=C(F)C=CC=C3)C4=C(C=CC(Cl)=C4)N12	R60L0SM5BC			?	μg × h/L	218		μg/L	95.5			UNKNOWN	mg	10		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215341Orig1s000IntegratedR.pdf#page=159	Homo sapiens		h	2.21	IR tablet	Normal renal function	7.5 mg on Days 1, 2, and 10	8			true
7495	8190		ADULT	60150535	378.4244	FINERENONE	Finerenone	CCOC1=NC=C(C)C2=C1[C@H](C3=C(OC)C=C(C=C3)C#N)C(C(N)=O)=C(C)N2	PLASMA	DE2O63YV8R	4192	325.767	MIDAZOLAM	Midazolam	CC1=NC=C2CN=C(C3=C(F)C=CC=C3)C4=C(C=CC(Cl)=C4)N12	R60L0SM5BC			?	μg × h/L	118		μg/L	45.9			UNKNOWN	mg	5		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215341Orig1s000IntegratedR.pdf#page=164	Homo sapiens		h	2.71		Mild hepatic impairment (Child Pugh A)	7.5 mg on Days 1, 2, and 10	9			true
7496	8190		ADULT	60150535	378.4244	FINERENONE	Finerenone	CCOC1=NC=C(C)C2=C1[C@H](C3=C(OC)C=C(C=C3)C#N)C(C(N)=O)=C(C)N2	PLASMA	DE2O63YV8R	4192	325.767	MIDAZOLAM	Midazolam	CC1=NC=C2CN=C(C3=C(F)C=CC=C3)C4=C(C=CC(Cl)=C4)N12	R60L0SM5BC			?	μg × h/L	150		μg/L	47.2			UNKNOWN	mg	5		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215341Orig1s000IntegratedR.pdf#page=164	Homo sapiens		h	3.18		Moderate hepatic impairment (Child Pugh B)	7.5 mg on Days 1, 2, and 10	9			true
7497	8190		ADULT	60150535	378.4244	FINERENONE	Finerenone	CCOC1=NC=C(C)C2=C1[C@H](C3=C(OC)C=C(C=C3)C#N)C(C(N)=O)=C(C)N2	PLASMA	DE2O63YV8R	4192	325.767	MIDAZOLAM	Midazolam	CC1=NC=C2CN=C(C3=C(F)C=CC=C3)C4=C(C=CC(Cl)=C4)N12	R60L0SM5BC			?	μg × h/L	108		μg/L	47.6			UNKNOWN	mg	5		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215341Orig1s000IntegratedR.pdf#page=164	Homo sapiens		h	2.29		Normal hepatic function	7.5 mg on Days 1, 2, and 10	9			true
7498	8190		ADULT	60150535	378.4244	FINERENONE	Finerenone	CCOC1=NC=C(C)C2=C1[C@H](C3=C(OC)C=C(C=C3)C#N)C(C(N)=O)=C(C)N2	PLASMA	DE2O63YV8R							24		t	μg × h/L	686		μg/L	160			UNKNOWN	mg	20		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215341Orig1s000IntegratedR.pdf#page=30 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215341Orig1s000IntegratedR.pdf#page=32	Homo sapiens		h	2.6							false
7499	8190		ADULT	60150535	378.4244	FINERENONE	Finerenone	CCOC1=NC=C(C)C2=C1[C@H](C3=C(OC)C=C(C=C3)C#N)C(C(N)=O)=C(C)N2	PLASMA	DE2O63YV8R							24		t	ng × h/L	343		μg/L	80			UNKNOWN	mg	10		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215341Orig1s000IntegratedR.pdf#page=30 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215341Orig1s000IntegratedR.pdf#page=32	Homo sapiens		h	2.6							false
7500	8190		UNKNOWN	60150535	378.4244	FINERENONE	Finerenone	CCOC1=NC=C(C)C2=C1[C@H](C3=C(OC)C=C(C=C3)C#N)C(C(N)=O)=C(C)N2	PLASMA	DE2O63YV8R																						UNKNOWN				Human plasma protein binding: 91.7% (94.5 to 4288 mcg/L)	8.3	UNKNOWN		UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215341Orig1s000IntegratedR.pdf#page=31 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215341Orig1s000IntegratedR.pdf#page=89 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215341Orig1s000IntegratedR.pdf#page=128	Homo sapiens										false
7501	8192		UNKNOWN	214350	359.703	FLINDOKALNER	FLINDOKALNER	COC1=C(C=C(Cl)C=C1)[C@]2(F)C(=O)NC3=C2C=CC(=C3)C(F)(F)F	PLASMA	J57O328W4W																						UNKNOWN				protein binding of 14C-BMS-204352 in human serum at 250 ng/ml = 99.6%	0.38	UNKNOWN		UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11745906	Homo sapiens								FLINDOKALNER		false
7502	8192		ADULT	214350	359.703	FLINDOKALNER	FLINDOKALNER	COC1=C(C=C(Cl)C=C1)[C@]2(F)C(=O)NC3=C2C=CC(=C3)C(F)(F)F	PLASMA	J57O328W4W									∞	ng × h/mL	184		ng/mL	121			UNKNOWN	mg	10		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15502007	Homo sapiens		h	37				8	FLINDOKALNER		false
7503	8193		ADULT	5351387	396.3283	FOSBRETABULIN	FOSBRETABULIN	COC1=CC(\\C=C/C2=CC(OP(O)(O)=O)=C(OC)C=C2)=CC(OC)=C1OC	PLASMA	I5590ES2QZ									?	μM × h	1.19		μM	1.8			UNKNOWN	mg/m²	10		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21276042	Homo sapiens		h	0.15				3	combretastatin A4 phosphate		false
7504	8193		ADULT	5351344	316.3484	COMBRESTATIN A4	combretastatin A4	COC1=CC(\\C=C/C2=CC(O)=C(OC)C=C2)=CC(OC)=C1OC	PLASMA	16U6OP69RQ									?	μM × h	1.11		μM	0.57			UNKNOWN	mg/m²	33		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21276042	Homo sapiens		h	2.59				3	combretastatin A4 phosphate		false
7505	8193		ADULT	5351344	316.3484	COMBRESTATIN A4	combretastatin A4	COC1=CC(\\C=C/C2=CC(O)=C(OC)C=C2)=CC(OC)=C1OC	PLASMA	16U6OP69RQ									?	μM × h	0.25		μM	0.18			UNKNOWN	mg/m²	10		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21276042	Homo sapiens		h	2.18				3	combretastatin A4 phosphate		false
7506	8193		ADULT	5351387	396.3283	FOSBRETABULIN	FOSBRETABULIN	COC1=CC(\\C=C/C2=CC(OP(O)(O)=O)=C(OC)C=C2)=CC(OC)=C1OC	PLASMA	I5590ES2QZ									?	μM × h	6.07		μM	13.21			UNKNOWN	mg/m²	33		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21276042	Homo sapiens		h	0.22				3	combretastatin A4 phosphate		false
7507	8193		ADULT	5351387	396.3283	FOSBRETABULIN	FOSBRETABULIN	COC1=CC(\\C=C/C2=CC(OP(O)(O)=O)=C(OC)C=C2)=CC(OC)=C1OC	PLASMA	I5590ES2QZ									?	μM × h	10.54		μM	19.5			MAX TOLERATED	mg/m²	65		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21276042	Homo sapiens		h	0.37				6	combretastatin A4 phosphate		false
7508	8193		ADULT	5351344	316.3484	COMBRESTATIN A4	combretastatin A4	COC1=CC(\\C=C/C2=CC(O)=C(OC)C=C2)=CC(OC)=C1OC	PLASMA	16U6OP69RQ									?	μM × h	3.16		μM	1.58			HIGHEST STUDIED	mg/m²	85		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21276042	Homo sapiens		h	2.34				2	combretastatin A4 phosphate		false
7509	8193		ADULT	5351344	316.3484	COMBRESTATIN A4	combretastatin A4	COC1=CC(\\C=C/C2=CC(O)=C(OC)C=C2)=CC(OC)=C1OC	PLASMA	16U6OP69RQ									?	μM × h	3.19		μM	1.73			MAX TOLERATED	mg/m²	65		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21276042	Homo sapiens		h	1.9				6	combretastatin A4 phosphate		false
7510	8193		ADULT	5351387	396.3283	FOSBRETABULIN	FOSBRETABULIN	COC1=CC(\\C=C/C2=CC(OP(O)(O)=O)=C(OC)C=C2)=CC(OC)=C1OC	PLASMA	I5590ES2QZ									?	μM × h	19.69		μM	24.42			HIGHEST STUDIED	mg/m²	85		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21276042	Homo sapiens		h	0.46				2	combretastatin A4 phosphate		false
7511	8194		ADULT	11188409	388.5451	GALETERONE	Galeterone	C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2N5C=NC6=C5C=CC=C6	PLASMA	WA33E149SW							6		t	ng × h/mL	2684						UNKNOWN	mg	2550		SINGLE	UNKNOWN						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26527750	Homo sapiens							28	Galeterone		false
7512	8194		ADULT	11188409	388.5451	GALETERONE	Galeterone	C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2N5C=NC6=C5C=CC=C6	PLASMA	WA33E149SW							6		t	ng × h/mL	2646						UNKNOWN	mg	1700		SINGLE	UNKNOWN						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26527750	Homo sapiens							28	Galeterone		false
7513	8194		ADULT	11188409	388.5451	GALETERONE	Galeterone	C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2N5C=NC6=C5C=CC=C6	PLASMA	WA33E149SW							6		t	ng × h/mL	2528						UNKNOWN	mg	3400		SINGLE	UNKNOWN						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26527750	Homo sapiens							28	Galeterone		false
7514	8198			11610526	377.3603	LASMIDITAN	LASMIDITAN	CN1CCC(CC1)C(=O)C2=NC(NC(=O)C3=C(F)C=C(F)C=C3F)=CC=C2	PLASMA	760I9WM792							24		t	ng × h/mL	3189.08		ng/mL	526.15			UNKNOWN	mg	400		SINGLE							HEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT03465436	Homo sapiens										false
7515	8198		ADULT	11610526	377.3603	LASMIDITAN	LASMIDITAN	CN1CCC(CC1)C(=O)C2=NC(NC(=O)C3=C(F)C=C(F)C=C3F)=CC=C2	SERUM	760I9WM792									∞	ng × h/mL	1892		ng/mL	322.8			MAX DAILY	mg	200		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/29563831/	Homo sapiens										false
7516	8198		ADULT	11610526	377.3603	LASMIDITAN	LASMIDITAN	CN1CCC(CC1)C(=O)C2=NC(NC(=O)C3=C(F)C=C(F)C=C3F)=CC=C2	SERUM	760I9WM792									∞	ng × h/mL	2244		ng/mL	394.7			MAX DAILY	mg	200		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/29563831/	Homo sapiens										false
7517	8199		ADULT	133021	379.879	LICOFELONE	LICOFELONE	CC1(C)CN2C(CC(O)=O)=C(C(=C2C1)C3=CC=CC=C3)C4=CC=C(Cl)C=C4	PLASMA	P5T6BYS22Y							12		t	ng × h/mL	4582		ng/mL	1665			UNKNOWN	mg	200		SINGLE	UNKNOWN						UNKNOWN	Oral	FEMALE / MALE	REVIEW	http://ijpt.iums.ac.ir/article-1-226-en.html	Homo sapiens		h	11.1							false
7518	8199		ADULT	133021	379.879	LICOFELONE	LICOFELONE	CC1(C)CN2C(CC(O)=O)=C(C(=C2C1)C3=CC=CC=C3)C4=CC=C(Cl)C=C4	PLASMA	P5T6BYS22Y													ng/mL	1727			UNKNOWN	mg	200		STEADY-STATE	UNKNOWN		day	2			UNKNOWN	Oral	FEMALE / MALE	REVIEW	http://ijpt.iums.ac.ir/article-1-226-en.html	Homo sapiens										false
7519	8200		ADULT	11485656	375.3989	LINIFANIB	LINIFANIB	CC1=CC(NC(=O)NC2=CC=C(C=C2)C3=C4C(N)=NNC4=CC=C3)=C(F)C=C1	PLASMA	CO93X137CW									∞	μg × h/mL	5.8		μg/mL	0.25			MAX TOLERATED	mg/kg bw	0.25		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/19720910	Homo sapiens		h	18.9							false
7520	8200		ADULT	11485656	375.3989	LINIFANIB	LINIFANIB	CC1=CC(NC(=O)NC2=CC=C(C=C2)C3=C4C(N)=NNC4=CC=C3)=C(F)C=C1	PLASMA	CO93X137CW							24		t	μg × h/mL	4.3		μg/mL	0.31			MAX TOLERATED	mg/kg bw	0.25		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/19720910	Homo sapiens										false
7521	8200			11485656	375.3989	LINIFANIB	LINIFANIB	CC1=CC(NC(=O)NC2=CC=C(C=C2)C3=C4C(N)=NNC4=CC=C3)=C(F)C=C1	PLASMA	CO93X137CW																										A paper detailing the properties of the multikinase inhibitor ABT-869 did not indicate whether plasma protein binding data were used in the optimization leading to this highly protein-bound (mouse: 98.2%, human 99.0%) compound.	1				EXPERIMENT	https://www.sciencedirect.com/science/article/pii/S0065774307420310	Homo sapiens										false
7522	8201		ADULT	11552706	383.4591	LOSMAPIMOD	LOSMAPIMOD	CC1=C(F)C=C(C=C1C2=NC=C(C=C2)C(=O)NCC(C)(C)C)C(=O)NC3CC3	PLASMA	F2DQF16BXE									∞	μg × h/L	528		μg/L	45.9			UNKNOWN	mg	15		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/23215699	Homo sapiens		h	9.439							false
7523	8202		ADULT	25062766	414.4598	MOMELOTINIB	MOMELOTINIB	O=C(NCC#N)C1=CC=C(C=C1)C2=NC(NC3=CC=C(C=C3)N4CCOCC4)=NC=C2	PLASMA	6O01GMS00P									∞	ng × h/mL	16327		ng/mL	1860			UNKNOWN	mg	200		SINGLE	UNKNOWN				FU,% 19.2 ± 0.5	19.2	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29311136	Homo sapiens		h	6							false
7524	8203		ADULT	11667893	373.4509	MOTESANIB	MOTESANIB	CC1(C)CNC2=CC(NC(=O)C3=C(NCC4=CC=NC=C4)N=CC=C3)=CC=C12	PLASMA	U1JK633AYI							24		t	μg × h/mL	1.06		ng/mL	238			UNKNOWN	mg	50		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/18574557	Homo sapiens		h	5.67							false
7525	8204		UNKNOWN	9915743	557.043	NERATINIB	NERATINIB	CCOC1=C(NC(=O)\\C=C\\CN(C)C)C=C2C(=C1)N=CC(C#N)=C2NC3=CC(Cl)=C(OCC4=NC=CC=C4)C=C3	PLASMA	JJH94R3PWB																						UNKNOWN				In vitro protein binding of neratinib in human plasma was greater than 99% and independent of concentration.	1	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208051s000lbl.pdf	Homo sapiens										false
7526	8204		ADULT	9915743	556.1989	NERATINIB	NERATINIB	CCOC1=C(NC(=O)\\C=C\\CN(C)C)C=C2C(=C1)N=CC(C#N)=C2NC3=CC(Cl)=C(OCC4=NC=CC=C4)C=C3	BLOOD	JJH94R3PWB							24		t	ng × h/mL	891		ng/mL	71.8			UNKNOWN	mg	240		SINGLE	FED						HEALTHY	Oral	UNKNOWN	REVIEW	https://www.ncbi.nlm.nih.gov/pubmed/27284682	Homo sapiens		h	12.6							false
7527	8204		ADULT	9915743	556.1989	NERATINIB	NERATINIB	CCOC1=C(NC(=O)\\C=C\\CN(C)C)C=C2C(=C1)N=CC(C#N)=C2NC3=CC(Cl)=C(OCC4=NC=CC=C4)C=C3	BLOOD	JJH94R3PWB							24		t	ng × h/mL	1060		ng/mL	73.1			UNKNOWN	mg	240		STEADY-STATE	FED		day	1			HEALTHY	Oral	UNKNOWN	REVIEW	https://www.ncbi.nlm.nih.gov/pubmed/27284682	Homo sapiens		h	14.6							false
7528	8204		ADULT	9915743	556.1989	NERATINIB	NERATINIB	CCOC1=C(NC(=O)\\C=C\\CN(C)C)C=C2C(=C1)N=CC(C#N)=C2NC3=CC(Cl)=C(OCC4=NC=CC=C4)C=C3	BLOOD	JJH94R3PWB							24		t	ng × h/mL	1640		ng/mL	76.3			UNKNOWN	mg	240		SINGLE	FED						UNHEALTHY	Oral	UNKNOWN	REVIEW	https://www.ncbi.nlm.nih.gov/pubmed/27284682	Homo sapiens		h	14.3							false
7529	8204		ADULT	9915743	556.1989	NERATINIB	NERATINIB	CCOC1=C(NC(=O)\\C=C\\CN(C)C)C=C2C(=C1)N=CC(C#N)=C2NC3=CC(Cl)=C(OCC4=NC=CC=C4)C=C3	BLOOD	JJH94R3PWB							24		t	ng × h/mL	1110		ng/mL	81.5			UNKNOWN	mg	240		STEADY-STATE	FED		day	1			UNHEALTHY	Oral	UNKNOWN	REVIEW	https://www.ncbi.nlm.nih.gov/pubmed/27284682	Homo sapiens		h	22.7							false
7530	8205		ADULT	24958200	320.16373	NIRAPARIB	NIRAPARIB	NC(=O)C1=CC=CC2=CN(N=C12)C3=CC=C(C=C3)[C@@H]4CCCNC4	PLASMA	HMC2H89N35													ng/mL	804			UNKNOWN	mg	300		SINGLE	FASTED				Niraparib is 83.0% bound to human plasma proteins	17	HEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208447s014lbl.pdf	Homo sapiens										false
7531	8205		ADULT	24958200	320.16373	NIRAPARIB	NIRAPARIB	NC(=O)C1=CC=CC2=CN(N=C12)C3=CC=C(C=C3)[C@@H]4CCCNC4	PLASMA	HMC2H89N35									∞	ng × h/mL	29016.1		ng/mL	803.7			UNKNOWN	mg	300		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/29322231	Homo sapiens		h	50.5							false
7532	8206		ADULT	10152654	525.559	ODANACATIB	ODANACATIB	CC(C)(F)C[C@H](N[C@@H](C1=CC=C(C=C1)C2=CC=C(C=C2)S(C)(=O)=O)C(F)(F)F)C(=O)NC3(CC3)C#N	PLASMA	N673F6W2VH							24		t	μM × h	16.1		nM	839.2			UNKNOWN	mg	300		SINGLE	HIGH-FAT						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23013236	Homo sapiens		h	62.6				12	ODANACATIB		false
7533	8206		ADULT	10152654	525.559	ODANACATIB	Odanacatib	CC(C)(F)C[C@H](N[C@@H](C1=CC=C(C=C1)C2=CC=C(C=C2)S(C)(=O)=O)C(F)(F)F)C(=O)NC3(CC3)C#N	PLASMA	N673F6W2VH							24		t	μM × h	11.3		nM	630.4			UNKNOWN	mg	100		SINGLE	HIGH-FAT						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23013236	Homo sapiens		h	48.2				12	Odanacatib		false
7534	8206		ADULT	10152654	525.559	ODANACATIB	odanacatib	CC(C)(F)C[C@H](N[C@@H](C1=CC=C(C=C1)C2=CC=C(C=C2)S(C)(=O)=O)C(F)(F)F)C(=O)NC3(CC3)C#N	PLASMA	N673F6W2VH							24		t	μM × h	13.6		nM	738.5			UNKNOWN	mg	200		SINGLE	HIGH-FAT						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23013236	Homo sapiens		h	50.5				12	odanacatib		false
7535	8206		ADULT	10152654	525.559	ODANACATIB	ODANACATIB	CC(C)(F)C[C@H](N[C@@H](C1=CC=C(C=C1)C2=CC=C(C=C2)S(C)(=O)=O)C(F)(F)F)C(=O)NC3(CC3)C#N	PLASMA	N673F6W2VH							24		t	μM × h	9.4		nM	477.3			MAX DAILY	mg	600		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23013236	Homo sapiens		h	59.2				8	ODANACATIB		false
7536	8206		ADULT	10152654	525.559	ODANACATIB	ODANACATIB	CC(C)(F)C[C@H](N[C@@H](C1=CC=C(C=C1)C2=CC=C(C=C2)S(C)(=O)=O)C(F)(F)F)C(=O)NC3(CC3)C#N	PLASMA	N673F6W2VH							24		t	μM × h	3.2		nM	154.7			UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23013236	Homo sapiens							8	ODANACATIB		false
7537	8206		ADULT	10152654	525.559	ODANACATIB	Odanacatib	CC(C)(F)C[C@H](N[C@@H](C1=CC=C(C=C1)C2=CC=C(C=C2)S(C)(=O)=O)C(F)(F)F)C(=O)NC3(CC3)C#N	PLASMA	N673F6W2VH							24		t	μM × h	6.7		nM	344.7			UNKNOWN	mg	25		SINGLE	HIGH-FAT						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23013236	Homo sapiens							12	Odanacatib		false
7538	8206		ADULT	10152654	525.559	ODANACATIB	Odanacatib	CC(C)(F)C[C@H](N[C@@H](C1=CC=C(C=C1)C2=CC=C(C=C2)S(C)(=O)=O)C(F)(F)F)C(=O)NC3(CC3)C#N	PLASMA	N673F6W2VH							24		t	μM × h	6.4		nM	353.5			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23013236	Homo sapiens							8	ODANACATIB		false
7539	8206		ADULT	10152654	525.559	ODANACATIB	odanacatib	CC(C)(F)C[C@H](N[C@@H](C1=CC=C(C=C1)C2=CC=C(C=C2)S(C)(=O)=O)C(F)(F)F)C(=O)NC3(CC3)C#N	PLASMA	N673F6W2VH	10152654	525.559	ODANACATIB	odanacatib	CC(C)(F)C[C@H](N[C@@H](C1=CC=C(C=C1)C2=CC=C(C=C2)S(C)(=O)=O)C(F)(F)F)C(=O)NC3(CC3)C#N	N673F6W2VH			∞	μM × h	2.7		nM	56.2			UNKNOWN	mg	1		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27402726	Homo sapiens		h	104.4				21	13C-odanacatib		true
7540	8207		UNKNOWN	44139752	227.237	OSILODROSTAT	OSILODROSTAT	FC1=CC(=CC=C1[C@H]2CCC3=CN=CN23)C#N	PLASMA	5YL4IQ1078									?	ng × h/mL	38.6		ng/mL	7.91			RECOMMENDED	mg	2		SINGLE	UNKNOWN					63.6	UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212801Orig1s000ClinPharmR.pdf	Homo sapiens										false
7541	8207		UNKNOWN	44139752	227.237	OSILODROSTAT	OSILODROSTAT	FC1=CC(=CC=C1[C@H]2CCC3=CN=CN23)C#N	PLASMA	5YL4IQ1078									?	ng × h/mL	1680		ng/mL	306			MAX DAILY	mg	30		MULTIPLE	UNKNOWN		day	2		63.6	UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212801Orig1s000ClinPharmR.pdf	Homo sapiens										false
7542	8208		ADULT	52938427	404.4617	OZANIMOD	CC(C)OC1=CC=C(C=C1C#N)C2=NC(=NO2)C3=CC=CC4=C3CC[C@@H]4NCCO	CC(C)OC1=CC=C(C=C1C#N)C2=NC(=NO2)C3=CC=CC4=C3CC[C@@H]4NCCO	PLASMA	Z80293URPV							16		t	ng × h/mL	7.66		ng/mL	0.409			UNKNOWN	mg	1.5		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/28398597	Homo sapiens		h	21.4							false
7543	8209		ADULT	89553848	326.3929	[NO STEREO] PEFICITINIB	NC(=O)C1=CN=C2NC=CC2=C1NC3C4CC5C[C@H]3CC(O)(C5)C4	NC(=O)C1=CN=C2NC=CC2=C1NC3C4CC5C[C@H]3CC(O)(C5)C4	PLASMA	[NO STEREO] HPH1166CKX							12		t	ng × h/mL	1380		ng/mL	373			INVESTIGATIONAL	mg	100		STEADY-STATE	FED		day	2			HEALTHY	Oral	MALE	REVIEW	https://www.ncbi.nlm.nih.gov/pubmed/31093950	Homo sapiens		h	14.2							false
7544	8210		ADULT	25151352	417.815	PEXIDARTINIB	FC(F)(F)C1=NC=C(CNC2=NC=C(CC3=CNC4=C3C=C(Cl)C=N4)C=C2)C=C1	FC(F)(F)C1=NC=C(CNC2=NC=C(CC3=CNC4=C3C=C(Cl)C=N4)C=C2)C=C1	PLASMA	6783M2LV5X							12		t	ng × h/mL	77465		ng/mL	8625			RECOMMENDED	mg	400		STEADY-STATE	UNKNOWN		day	2	In vitro plasma protein binding: Greater than 99%; Human serum albumin: 99.9%; α-1 acid glycoprotein: 89.9%	1	UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211810s000lbl.pdf	Homo sapiens		h	26.6							false
7545	8212		ADULT	24889392	560.667	QUIZARTINIB	QUIZARTINIB	CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C3=CN4C(SC5=C4C=CC(OCCN6CCOCC6)=C5)=N3)=NO1	PLASMA	7LA4O6Q0D3							24		t	ng × h/mL	10000						UNKNOWN	mg	300		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/24002496	Homo sapiens		day	1.5							false
7546	8212		ADULT	24889392	560.667	QUIZARTINIB	QUIZARTINIB	CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C3=CN4C(SC5=C4C=CC(OCCN6CCOCC6)=C5)=N3)=NO1	PLASMA	7LA4O6Q0D3													ng × eq/g	400			UNKNOWN	mg	60		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/27460866	Homo sapiens										false
7547	8213		ADULT	153948	420.189	RANIRESTAT	Ranirestat	FC1=C(CN2C(=O)C3=CC=CN3[C@@]4(CC(=O)NC4=O)C2=O)C=CC(Br)=C1	PLASMA	Z26P56GFTV									∞	μg × h/mL	60.4		ng/mL	3213			UNKNOWN	mg	40		SINGLE	FASTED				Plasma Protein-Binding Ratio (%) of Ranirestat, Median=99.335	0.665	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32437025	Homo sapiens		h	105.6	Mild Hepatic Impairment			10	Ranirestat		false
7548	8213		ADULT	153948	420.189	RANIRESTAT	Ranirestat	FC1=C(CN2C(=O)C3=CC=CN3[C@@]4(CC(=O)NC4=O)C2=O)C=CC(Br)=C1	PLASMA	Z26P56GFTV									∞	μg × h/mL	67		ng/mL	3016			UNKNOWN	mg	40		SINGLE	FASTED				Plasma Protein-Binding Ratio (%) of Ranirestat, Median=98.970	1.03	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32437025	Homo sapiens		h	131.6	Moderate Hepatic Impairment			5	Ranirestat		false
7549	8213		ADULT	153948	420.189	RANIRESTAT	Ranirestat	FC1=C(CN2C(=O)C3=CC=CN3[C@@]4(CC(=O)NC4=O)C2=O)C=CC(Br)=C1	PLASMA	Z26P56GFTV									∞	μg × h/mL	71.1		ng/mL	3644			UNKNOWN	mg	40		SINGLE	FASTED				Plasma Protein-Binding Ratio (%) of Ranirestat, Median=99.230	0.77	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32437025	Homo sapiens		h	133.7	Normal Hepatic Function			5	Ranirestat		false
7550	8216		ADULT	64627	356.5	ROLOFYLLINE	ROLOFYLLINE	CCCN1C2=C(NC(=N2)C34CC5CC3C[C@H](C4)C5)C(=O)N(CCC)C1=O	PLASMA	7805S5HIHX	4192		Midazolam	Midazolam	CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F	R60L0SM5BC	24		t	nM × h	3588		nM	637			UNKNOWN	mg	30		STEADY-STATE	FASTED		day	1			HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/20027108	Homo sapiens										true
7551	8217		ADULT	9931954	323.3641	RUCAPARIB	RUCAPARIB	CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=CC(F)=CC(N2)=C34	PLASMA	8237F3U7EH							24		t	ng × h/mL	5740		ng/mL	629			UNKNOWN	mg	300		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/29799676	Homo sapiens		h	15.2							false
7552	8218		ADULT	10127622	457.681	SELUMETINIB	SELUMETINIB	CN1C=NC2=C1C=C(C(=O)NOCCO)C(NC3=C(Cl)C=C(Br)C=C3)=C2F	PLASMA	6UH91I579U																						UNKNOWN				fu,av (%), median (min‐max): 0.400 (0.330‐0.456)	0.4	HEALTHY		UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412920/	Homo sapiens										false
7553	8218		ADULT	10127622	457.681	SELUMETINIB	SELUMETINIB	CN1C=NC2=C1C=C(C(=O)NOCCO)C(NC3=C(Cl)C=C(Br)C=C3)=C2F	PLASMA	6UH91I579U							12		t	ng × h/mL	3299		ng/mL	647			UNKNOWN	mg	100		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/21519015	Homo sapiens		h	10							false
7554	8219		ADULT	24831714	424.938	SOTAGLIFLOZIN	sotagliflozin	CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@@H]3O[C@H](SC)[C@@H](O)[C@H](O)[C@H]3O)C=C1	PLASMA	6B4ZBS263Y									?	ng × h/mL	1752		ng/mL	291			UNKNOWN	mg	300		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22739142/	Homo sapiens							12	LX4211		false
7555	8219		ADULT	24831714	424.938	SOTAGLIFLOZIN	sotagliflozin	CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@@H]3O[C@H](SC)[C@@H](O)[C@H](O)[C@H]3O)C=C1	PLASMA	6B4ZBS263Y									?	ng × h/mL	732		ng/mL	113			UNKNOWN	mg	150		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22739142/	Homo sapiens							12	LX4211		false
7556	8219		ADULT	24831714	424.938	SOTAGLIFLOZIN	sotagliflozin	CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@@H]3O[C@H](SC)[C@@H](O)[C@H](O)[C@H]3O)C=C1	PLASMA	6B4ZBS263Y							24		t	ng × h/mL	2213		ng/mL	180			UNKNOWN	mg	400		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25529979/	Homo sapiens		h	16.6	severe renal impairment			15	LX4211		false
7557	8219		ADULT	24831714	424.938	SOTAGLIFLOZIN	SOTAGLIFLOZIN	CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@@H]3O[C@H](SC)[C@@H](O)[C@H](O)[C@H]3O)C=C1	PLASMA	6B4ZBS263Y							24		t	ng × h/mL	2879		ng/mL	274			UNKNOWN	mg	400		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25529979/	Homo sapiens		h	18.1	moderate renal impairment			16	LX4211		false
7558	8221		ADULT	135565082	380.3509	TALAZOPARIB	TALAZOPARIB	CN1N=CN=C1[C@@H]2[C@H](NC3=CC(F)=CC4=C3C2=NNC4=O)C5=CC=C(F)C=C5	PLASMA	9QHX048FRV									∞	ng × h/mL	193		ng/mL	9.97			RECOMMENDED	mg	1		SINGLE	FASTED						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31489639/	Homo sapiens										false
7559	8221		ADULT	135565082	380.3509	TALAZOPARIB	TALAZOPARIB	CN1N=CN=C1[C@@H]2[C@H](NC3=CC(F)=CC4=C3C2=NNC4=O)C5=CC=C(F)C=C5	PLASMA	9QHX048FRV							24		t	ng × h/mL	196		ng/mL	19.8			RECOMMENDED	mg	1		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31489639/	Homo sapiens										false
7560	8221		ADULT	135565082	380.3509	TALAZOPARIB	TALAZOPARIB	CN1N=CN=C1[C@@H]2[C@H](NC3=CC(F)=CC4=C3C2=NNC4=O)C5=CC=C(F)C=C5	PLASMA	9QHX048FRV									?	ng × h/mL	208		ng/mL	16.4			RECOMMENDED	mg	1		STEADY-STATE	UNKNOWN		day	1	In vitro, protein binding of talazoparib is 74% and is independent of talazoparib concentration.	26	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211651s000lbl.pdf	Homo sapiens		h	90							false
7561	8222		ADULT	51001932	460.5315	TASELISIB	Taselisib	CC(C)N1N=C(C)N=C1C2=CN3CCOC4=C(C=CC(=C4)C5=CN(N=C5)C(C)(C)C(N)=O)C3=N2	PLASMA	L08J2O299M							24		t	μM × h	8.1		μM	0.441			HIGHEST STUDIED	mg	16		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28331003/	Homo sapiens							11	Taselisib		false
7562	8222		ADULT	51001932	460.5315	TASELISIB	Taselisib	CC(C)N1N=C(C)N=C1C2=CN3CCOC4=C(C=CC(=C4)C5=CN(N=C5)C(C)(C)C(N)=O)C3=N2	PLASMA	L08J2O299M							24		t	μM × h	1.79		μM	0.111			UNKNOWN	mg	3		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28331003/	Homo sapiens							6	Taselisib		false
7563	8222		ADULT	51001932	460.5315	TASELISIB	Taselisib	CC(C)N1N=C(C)N=C1C2=CN3CCOC4=C(C=CC(=C4)C5=CN(N=C5)C(C)(C)C(N)=O)C3=N2	PLASMA	L08J2O299M							24		t	μM × h	5.1		μM	0.302			UNKNOWN	mg	12		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28331003/	Homo sapiens							10	Taselisib		false
7564	8222		ADULT	51001932	460.5315	TASELISIB	Taselisib	CC(C)N1N=C(C)N=C1C2=CN3CCOC4=C(C=CC(=C4)C5=CN(N=C5)C(C)(C)C(N)=O)C3=N2	PLASMA	L08J2O299M							24		t	μM × h	3.21		μM	0.188			UNKNOWN	mg	8		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28331003/	Homo sapiens							4	Taselisib		false
7565	8222		ADULT	51001932	460.5315	TASELISIB	Taselisib	CC(C)N1N=C(C)N=C1C2=CN3CCOC4=C(C=CC(=C4)C5=CN(N=C5)C(C)(C)C(N)=O)C3=N2	PLASMA	L08J2O299M							24		t	μM × h	1.49		μM	0.091			UNKNOWN	mg	5		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28331003/	Homo sapiens							3	Taselisib		false
7566	8223		ADULT	9938840	407.911	TERUTROBAN	TERUTROBAN	CC1=C(CCC(O)=O)C2=C(C[C@@H](CC2)NS(=O)(=O)C3=CC=C(Cl)C=C3)C=C1	PLASMA	A6WX9391D8									?	ng × h/mL	3029		ng/mL	496			UNKNOWN	mg	10		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15978101	Homo sapiens		h	8				6	S18886		false
7567	8223		ADULT	9938840	407.911	TERUTROBAN	TERUTROBAN	CC1=C(CCC(O)=O)C2=C(C[C@@H](CC2)NS(=O)(=O)C3=CC=C(Cl)C=C3)C=C1	PLASMA	A6WX9391D8									?	ng × h/mL	5852		ng/mL	1480			UNKNOWN	mg	30		SINGLE	UNKNOWN						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15978101	Homo sapiens		h	6.7				6	S18886		false
7568	8223		ADULT	9938840	407.911	TERUTROBAN	TERUTROBAN	CC1=C(CCC(O)=O)C2=C(C[C@@H](CC2)NS(=O)(=O)C3=CC=C(Cl)C=C3)C=C1	PLASMA	A6WX9391D8									?	ng × h/mL	283		ng/mL	42			UNKNOWN	mg	1		SINGLE	UNKNOWN						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15978101	Homo sapiens		h	7.4				7	S18886		false
7569	8223		ADULT	9938840	407.911	TERUTROBAN	TERUTROBAN	CC1=C(CCC(O)=O)C2=C(C[C@@H](CC2)NS(=O)(=O)C3=CC=C(Cl)C=C3)C=C1	PLASMA	A6WX9391D8									?	ng × h/mL	1023		ng/mL	236			UNKNOWN	mg	5		SINGLE	UNKNOWN						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15978101	Homo sapiens		h	6.8				5	S18886		false
7570	8223		ADULT	9938840	407.911	TERUTROBAN	TERUTROBAN	CC1=C(CCC(O)=O)C2=C(C[C@@H](CC2)NS(=O)(=O)C3=CC=C(Cl)C=C3)C=C1	PLASMA	A6WX9391D8									?	ng × h/mL	495		ng/mL	124			UNKNOWN	mg	2.5		SINGLE	UNKNOWN						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15978101	Homo sapiens		h	7.2				6	S18886		false
7571	8224		UNKNOWN		491.385	TESEVATINIB	TESEVATINIB	COC1=C(OC[C@H]2C[C@H]3CN(C)C[C@H]3C2)C=C4N=CN=C(NC5=C(F)C(Cl)=C(Cl)C=C5)C4=C1	PLASMA	F6XM2TN5A1																						UNKNOWN				Equilibrium dialysis shows that the protein binding rate of XL-647 in human plasma is 93-97.5%	5	UNKNOWN		UNKNOWN	EXPERIMENT	https://patents.google.com/patent/CN103313713B/en	Homo sapiens										false
7572	8224		ADULT	10458325	491.4	TESEVATINIB	TESEVATINIB	COC1=CC2=C(C=C1OC[C@H]3C[C@H]4CN(C)C[C@H]4C3)N=CN=C2NC5=C(F)C(Cl)=C(Cl)C=C5	PLASMA	F6XM2TN5A1							24		t	ng × h/mL	748		ng/mL	233.1			MAX TOLERATED	mg	350		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/30030583	Homo sapiens		h	55.5							false
7573	8226			9911830	454.863	TIVOZANIB	Tivozanib	COC1=CC2=NC=CC(OC3=CC(Cl)=C(NC(=O)NC4=NOC(C)=C4)C=C3)=C2C=C1OC	PLASMA	172030934T																										Human plasma protein binding: 99.7% (500, 500, 5000ng/mL; primarily to albumin in vitro and is independent of concentration)	0.3				OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=177 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212904s000lbl.pdf#page=15	Homo sapiens										false
7574	8226		ADULT	9911830	454.863	TIVOZANIB	Tivozanib	COC1=CC2=NC=CC(OC3=CC(Cl)=C(NC(=O)NC4=NOC(C)=C4)C=C3)=C2C=C1OC	SERUM	172030934T									∞	ng × h/mL	1084		ng/mL	12.1			UNKNOWN	mg	1.5		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=265	Homo sapiens		h	89.3				7	Tivozanib hydrochloride		false
7575	8226		ADULT	9911830	454.863	TIVOZANIB	Tivozanib	COC1=CC2=NC=CC(OC3=CC(Cl)=C(NC(=O)NC4=NOC(C)=C4)C=C3)=C2C=C1OC	SERUM	172030934T									∞	ng × h/mL	2491		ng/mL	14.4			UNKNOWN	mg	1.5		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=265	Homo sapiens		h	122				30	Tivozanib hydrochloride		false
7576	8226		ADULT	9911830	454.863	TIVOZANIB	Tivozanib	COC1=CC2=NC=CC(OC3=CC(Cl)=C(NC(=O)NC4=NOC(C)=C4)C=C3)=C2C=C1OC	SERUM	172030934T									∞	ng × h/mL	2309		ng/mL	18.8			UNKNOWN	mg	1.5		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=265	Homo sapiens		h	121				30	Tivozanib hydrochloride		false
7577	8226		ADULT	9911830	454.863	TIVOZANIB	Tivozanib	COC1=CC2=NC=CC(OC3=CC(Cl)=C(NC(=O)NC4=NOC(C)=C4)C=C3)=C2C=C1OC	SERUM	172030934T									∞	ng × h/mL	1680		ng/mL	15.9			UNKNOWN	mg	1.5		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=265	Homo sapiens		h	103		Normal hepatic function			Tivozanib hydrochloride		false
7578	8226		ADULT	9911830	454.863	TIVOZANIB	Tivozanib	COC1=CC2=NC=CC(OC3=CC(Cl)=C(NC(=O)NC4=NOC(C)=C4)C=C3)=C2C=C1OC	SERUM	172030934T									∞	ng × h/mL	4449		ng/mL	21.66			UNKNOWN	mg	1.5		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=265	Homo sapiens		h	316.2		Moderate hepatic impairment			Tivozanib hydrochloride		false
7579	8226		ADULT	9911830	454.863	TIVOZANIB	Tivozanib	COC1=CC2=NC=CC(OC3=CC(Cl)=C(NC(=O)NC4=NOC(C)=C4)C=C3)=C2C=C1OC	SERUM	172030934T									∞	ng × h/mL	1960		ng/mL	16.21			UNKNOWN	mg	1.5		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=265	Homo sapiens		h	118.7		Mild hepatic impairment			Tivozanib hydrochloride		false
7580	8226		ADULT	9911830	454.863	TIVOZANIB	Tivozanib	COC1=CC2=NC=CC(OC3=CC(Cl)=C(NC(=O)NC4=NOC(C)=C4)C=C3)=C2C=C1OC	SERUM	172030934T									∞	ng × h/mL	6715		ng/mL	17.33			UNKNOWN	mg	1.5		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=265	Homo sapiens		h	577.8		Severe hepatic impairment			Tivozanib hydrochloride		false
7581	8226		ADULT	9911830	454.863	TIVOZANIB	Tivozanib	COC1=CC2=NC=CC(OC3=CC(Cl)=C(NC(=O)NC4=NOC(C)=C4)C=C3)=C2C=C1OC	SERUM	172030934T							24		t	ng × h/mL	1997.2		ng/mL	110			UNKNOWN	mg	2		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=266	Homo sapiens				Day 28	Patients with solid tumors		7	Tivozanib hydrochloride		false
7582	8226		ADULT	9911830	454.863	TIVOZANIB	Tivozanib	COC1=CC2=NC=CC(OC3=CC(Cl)=C(NC(=O)NC4=NOC(C)=C4)C=C3)=C2C=C1OC	SERUM	172030934T							24		t	ng × h/mL	258.2		ng/mL	15.51			UNKNOWN	mg	1.5		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=266	Homo sapiens				Day 1	Subjects with recurrent or RCC, or primary RCC not amenable to surgery		21	Tivozanib hydrochloride		false
7583	8226		ADULT	9911830	454.863	TIVOZANIB	Tivozanib	COC1=CC2=NC=CC(OC3=CC(Cl)=C(NC(=O)NC4=NOC(C)=C4)C=C3)=C2C=C1OC	SERUM	172030934T							24		t	ng × h/mL	131.2		ng/mL	9.293			UNKNOWN	mg	1		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=266	Homo sapiens				Day 1	Patients with solid tumors		18	Tivozanib hydrochloride		false
7584	8226		ADULT	9911830	454.863	TIVOZANIB	Tivozanib	COC1=CC2=NC=CC(OC3=CC(Cl)=C(NC(=O)NC4=NOC(C)=C4)C=C3)=C2C=C1OC	SERUM	172030934T							24		t	ng × h/mL	1640.6		ng/mL	94.29			UNKNOWN	mg	1.5		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=266	Homo sapiens				Day 21	Subjects with recurrent or RCC, or primary RCC not amenable to surgery		21	Tivozanib hydrochloride		false
7585	8226		ADULT	9911830	454.863	TIVOZANIB	Tivozanib	COC1=CC2=NC=CC(OC3=CC(Cl)=C(NC(=O)NC4=NOC(C)=C4)C=C3)=C2C=C1OC	SERUM	172030934T							24		t	ng × h/mL	159.2		ng/mL	10.19			UNKNOWN	mg	1.5		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=266	Homo sapiens				Day 1	Patients with solid tumors		16	Tivozanib hydrochloride		false
7586	8226		ADULT	9911830	454.863	TIVOZANIB	Tivozanib	COC1=CC2=NC=CC(OC3=CC(Cl)=C(NC(=O)NC4=NOC(C)=C4)C=C3)=C2C=C1OC	SERUM	172030934T							24		t	ng × h/mL	274.3		ng/mL	17.65			UNKNOWN	mg	2		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=266	Homo sapiens				Day 1	Patients with solid tumors		7	Tivozanib hydrochloride		false
7587	8226		ADULT	9911830	454.863	TIVOZANIB	Tivozanib	COC1=CC2=NC=CC(OC3=CC(Cl)=C(NC(=O)NC4=NOC(C)=C4)C=C3)=C2C=C1OC	SERUM	172030934T							24		t	ng × h/mL	856		ng/mL	50.03			UNKNOWN	mg	1		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=266	Homo sapiens				Day 28	Patients with solid tumors		18	Tivozanib hydrochloride		false
7588	8226		ADULT	9911830	454.863	TIVOZANIB	Tivozanib	COC1=CC2=NC=CC(OC3=CC(Cl)=C(NC(=O)NC4=NOC(C)=C4)C=C3)=C2C=C1OC	SERUM	172030934T							24		t	ng × h/mL	1180.2		ng/mL	67.46			UNKNOWN	mg	1.5		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=266	Homo sapiens				Day 28	Patients with solid tumors		16	Tivozanib hydrochloride		false
7589	8229		UNKNOWN	11960529	244.2923	VELIPARIB	VELIPARIB	C[C@@]1(CCCN1)C2=NC3=C(N2)C=CC=C3C(N)=O	PLASMA	01O4K0631N																						UNKNOWN				Protein binding values in plasma (assessed in vitro as % bound at 5 μM) for ABT-888 were moderate in all species, averaging 42% in dog, 41% in monkey, 43% in mouse, 49% in rat and 51% in human.	49	UNKNOWN		UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2953793/	Homo sapiens										false
7590	8229		ADULT	11960529	244.2923	VELIPARIB	VELIPARIB	C[C@@]1(CCCN1)C2=NC3=C(N2)C=CC=C3C(N)=O	PLASMA	01O4K0631N																						UNKNOWN				It is noteworthy that the trough concentration of veliparib in ascites was higher than that in plasma. The unbound fraction of veliparib was 0.67–0.73 in plasma, and 0.76–0.86 in ascites	70	UNHEALTHY		UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5734661/	Homo sapiens										false
7591	8229		ADULT	11960529	244.2923	VELIPARIB	Veliparib	C[C@@]1(CCCN1)C2=NC3=C(N2)C=CC=C3C(N)=O	PLASMA	01O4K0631N									∞	μg × h/mL	11.4		μg/mL	1.46			UNKNOWN	mg	200		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/29733524	Homo sapiens		h	4.9							false
7592	8231		ADULT	10461508	618.8	VOLASERTIB	VOLASERTIB	CC[C@H]1N(C(C)C)C2=NC(NC3=CC=C(C=C3OC)C(=O)NC4CCC(CC4)N5CCN(CC6CC6)CC5)=NC=C2N(C)C1=O	PLASMA	6EM57086EA									∞	ng × h/mL	5300		ng/mL	501			MAX TOLERATED	mg	300		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26627079	Homo sapiens		h	112							false
7593	8233		ADULT	644019	314.4617	CANNABIDIOL	CANNABIDIOL	CCCCCC1=CC(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(O)=C1	PLASMA	19GBJ60SN5									∞	ng × h/mL	3900		ng/mL	782			UNKNOWN	mg	6000		SINGLE	FASTED				High plasma protein binding (i.e., >94 %) was observed for cannabidiol.	6	HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf	Homo sapiens		h	15.42							false
7594	8233		ADULT	644019	314.4617	CANNABIDIOL	CANNABIDIOL	CCCCCC1=CC(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(O)=C1	PLASMA	19GBJ60SN5									∞	ng × h/mL	8670		ng/mL	1588			UNKNOWN	mg	1500		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf	Homo sapiens										false
7595	8233		ADULT	644019	314.4617	CANNABIDIOL	CANNABIDIOL	CCCCCC1=CC(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(O)=C1	PLASMA	19GBJ60SN5									∞	ng × h/mL	2198		ng/mL	327			UNKNOWN	mg	1500		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf	Homo sapiens										false
7596	8233		ADULT	644019	314.4617	CANNABIDIOL	CANNABIDIOL	CCCCCC1=CC(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(O)=C1	PLASMA	19GBJ60SN5									?	ng × h/mL	1745		ng/mL	330.3			UNKNOWN	mg	750		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf	Homo sapiens		h	56.41							false
7597	8233		ADULT	644019	314.4617	CANNABIDIOL	CANNABIDIOL	CCCCCC1=CC(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(O)=C1	PLASMA	19GBJ60SN5									?	ng × h/mL	3236		ng/mL	541.2			UNKNOWN	mg	1500		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf	Homo sapiens		h	60.54							false
7598	8233		ADULT	644019	314.4617	CANNABIDIOL	CANNABIDIOL	CCCCCC1=CC(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(O)=C1	PLASMA	19GBJ60SN5									∞	ng × h/mL	1618		ng/mL	292.4			UNKNOWN	mg	1500		SINGLE	FASTED				High plasma protein binding (i.e., >94 %) was observed for cannabidiol.	6	HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf	Homo sapiens		h	14.43							false
7599	8237		ADULT	11174599	319.268	TETRODOTOXIN	TETRODOTOXIN	NC1=N[C@H](O)[C@H]2[C@H]3O[C@]4(O)O[C@@H]([C@@H](O)[C@@]2(N1)[C@@H]4O)[C@]3(O)CO	PLASMA	3KUM2721U9									∞	ng × h/mL	6.4983		ng/mL	0.9914			UNKNOWN	μL	45		SINGLE	FASTED						HEALTHY	Subcutaneous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32784930	Homo sapiens		h	4.28				9	TETRODOTOXIN		false
7600	8241		ADULT	5282338	450.552	ACOTIAMIDE	ACOTIAMIDE	COC1=CC(O)=C(C=C1OC)C(=O)NC2=NC(=CS2)C(=O)NCCN(C(C)C)C(C)C	PLASMA	D42OWK5383									∞	ng × h/mL	511.75		ng/mL	25.71			RECOMMENDED	mg	100		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://journals.innovareacademics.in/index.php/ijpps/article/view/38410	Homo sapiens		h	23.49				24	ACOTIAMIDE		false
7601	8241		ADULT	5282338	450.552	ACOTIAMIDE	ACOTIAMIDE	COC1=CC(O)=C(C=C1OC)C(=O)NC2=NC(=CS2)C(=O)NCCN(C(C)C)C(C)C	PLASMA	D42OWK5383									?	ng × h/mL	1659.57		ng/mL	451.59			HIGHEST STUDIED	mg	900		MULTIPLE	FASTED		day	3	protein binding rate (84.21%-85.95%) in human plasma in the in vitro	14.92	HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/files/000153467.pdf	Homo sapiens							76	ACOTIAMIDE		false
7602	8241		ADULT	5282338	450.552	ACOTIAMIDE	ACOTIAMIDE	COC1=CC(O)=C(C=C1OC)C(=O)NC2=NC(=CS2)C(=O)NCCN(C(C)C)C(C)C	PLASMA	D42OWK5383									?	ng × h/mL	1215		ng/mL	168.2			UNKNOWN	mg	300		MULTIPLE	FASTED		day	3	protein binding rate (84.21%-85.95%) in human plasma in the in vitro	14.92	HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/files/000153467.pdf	Homo sapiens		h	11.25				18	ACOTIAMIDE		false
7603	8241		ADULT	5282338	450.552	ACOTIAMIDE	ACOTIAMIDE	COC1=CC(O)=C(C=C1OC)C(=O)NC2=NC(=CS2)C(=O)NCCN(C(C)C)C(C)C	PLASMA	D42OWK5383									?	ng × h/mL	537.2		ng/mL	200			UNKNOWN	mg	300		SINGLE	FASTED				protein binding rate (84.21%-85.95%) in human plasma in the in vitro	14.92	HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/files/000153467.pdf	Homo sapiens		h	8.99				18	ACOTIAMIDE		false
7604	8243		ADULT	44513473	383.4475	ANAGLIPTIN	Anagliptin	CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N	PLASMA	K726J96838									∞	ng × h/mL	1960		ng/mL	422			UNKNOWN	mg	100		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2012/P201200123/300297000_22400AMX01387000_A100_1.pdf#page=35	Homo sapiens		h	4.05				11			false
7605	8243		ADULT	44513473	383.4475	ANAGLIPTIN	Anagliptin	CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N	PLASMA	K726J96838									∞	ng × h/mL	2200		ng/mL	499			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2012/P201200123/300297000_22400AMX01387000_A100_1.pdf#page=35	Homo sapiens		h	3.02				11			false
7606	8243			44513473	383.4475	ANAGLIPTIN	Anagliptin	CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N	SERUM	K726J96838																										Human serum protein binding: 37.1% (100000ng/mL)~48.2% (10ng/mL), ultrafiltration	51.8				OTHER GOV'T	https://www.pmda.go.jp/drugs/2012/P201200123/300297000_22400AMX01387000_A100_1.pdf#page=36	Homo sapiens										false
7607	8243		ADULT	44513473	383.4475	ANAGLIPTIN	Anagliptin	CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N	PLASMA	K726J96838									∞	ng × h/mL	2460		ng/mL	544			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2012/P201200123/300297000_22400AMX01387000_A100_1.pdf#page=39	Homo sapiens		h	9.9		Dosed right before a meal		6			false
7608	8243		ADULT	44513473	383.4475	ANAGLIPTIN	Anagliptin	CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N	PLASMA	K726J96838									∞	ng × h/mL	2650		ng/mL	624			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2012/P201200123/300297000_22400AMX01387000_A100_1.pdf#page=39	Homo sapiens		h	6.2				6			false
7609	8243		ADULT	44513473	383.4475	ANAGLIPTIN	Anagliptin	CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N	PLASMA	K726J96838									∞	ng × h/mL	202		ng/mL	57.7			UNKNOWN	mg	10		SINGLE	FASTED				n=2 for t1/2		HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2012/P201200123/300297000_22400AMX01387000_A100_1.pdf#page=39	Homo sapiens		h	5.06				6			false
7610	8243		ADULT	44513473	383.4475	ANAGLIPTIN	Anagliptin	CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N	PLASMA	K726J96838									∞	ng × h/mL	1050		ng/mL	266			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2012/P201200123/300297000_22400AMX01387000_A100_1.pdf#page=39	Homo sapiens		h	7.61		Dosed right before a meal		6			false
7611	8243		ADULT	44513473	383.4475	ANAGLIPTIN	Anagliptin	CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N	PLASMA	K726J96838									∞	ng × h/mL	1040		ng/mL	253			UNKNOWN	mg	50		SINGLE	FASTED				n=5 for t1/2		HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2012/P201200123/300297000_22400AMX01387000_A100_1.pdf#page=39	Homo sapiens		h	6.51				6			false
7612	8243		ADULT	44513473	383.4475	ANAGLIPTIN	Anagliptin	CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N	PLASMA	K726J96838									∞	ng × h/mL	641		ng/mL	186			UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2012/P201200123/300297000_22400AMX01387000_A100_1.pdf#page=39	Homo sapiens		h	4.82				6			false
7613	8243		ADULT	44513473	383.4475	ANAGLIPTIN	Anagliptin	CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N	PLASMA	K726J96838									∞	ng × h/mL	5360		ng/mL	1040			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2012/P201200123/300297000_22400AMX01387000_A100_1.pdf#page=39	Homo sapiens		h	5.75				6			false
7614	8243		ADULT	44513473	383.4475	ANAGLIPTIN	Anagliptin	CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N	PLASMA	K726J96838									∞	ng × h/mL	12600		ng/mL	3330			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2012/P201200123/300297000_22400AMX01387000_A100_1.pdf#page=39	Homo sapiens		h	6				6			false
7615	8243		ADULT	44513473	383.4475	ANAGLIPTIN	Anagliptin	CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N	PLASMA	K726J96838									∞	ng × h/mL	4900		ng/mL	1250			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2012/P201200123/300297000_22400AMX01387000_A100_1.pdf#page=39	Homo sapiens		h	6.59		Dosed right before a meal		6			false
7616	8243		ADULT	44513473	383.4475	ANAGLIPTIN	Anagliptin	CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N	PLASMA	K726J96838									∞	ng × h/mL	4740		ng/mL	1280			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2012/P201200123/300297000_22400AMX01387000_A100_1.pdf#page=40	Homo sapiens		h	7.93	Day 0	Dosed 5 min before a meal		6			false
7617	8243		ADULT	44513473	383.4475	ANAGLIPTIN	Anagliptin	CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N	PLASMA	K726J96838									∞	ng × h/mL	4890		ng/mL	1200			UNKNOWN	mg	200		MULTIPLE	FASTED		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2012/P201200123/300297000_22400AMX01387000_A100_1.pdf#page=40	Homo sapiens		h	7.03	Day 7 (last dose (13th))	Dosed 5 min before a meal		6			false
7618	8243		ADULT	44513473	383.4475	ANAGLIPTIN	Anagliptin	CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N	PLASMA	K726J96838									∞	ng × h/mL	12533		ng/mL	3349			UNKNOWN	mg	400		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2012/P201200123/300297000_22400AMX01387000_A100_1.pdf#page=43	Homo sapiens		h	7.17		Mild renal impairment		6			false
7619	8243		ADULT	44513473	383.4475	ANAGLIPTIN	Anagliptin	CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N	PLASMA	K726J96838									∞	ng × h/mL	7582		ng/mL	2401			UNKNOWN	mg	400		SINGLE	FASTED				n=5 for AUC and t1/2		HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2012/P201200123/300297000_22400AMX01387000_A100_1.pdf#page=43	Homo sapiens		h	9.58				6			false
7620	8243		ADULT	44513473	383.4475	ANAGLIPTIN	Anagliptin	CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N	PLASMA	K726J96838									∞	ng × h/mL	20446		ng/mL	2991			UNKNOWN	mg	400		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2012/P201200123/300297000_22400AMX01387000_A100_1.pdf#page=43	Homo sapiens		h	7.25		Severe renal impairment		6			false
7621	8243		ADULT	44513473	383.4475	ANAGLIPTIN	Anagliptin	CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N	PLASMA	K726J96838									∞	ng × h/mL	24437		ng/mL	3396			UNKNOWN	mg	400		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2012/P201200123/300297000_22400AMX01387000_A100_1.pdf#page=43	Homo sapiens		h	8.54		ESRD w/hemodialysis, no dialysis during PK study		6			false
7622	8243		ADULT	44513473	383.4475	ANAGLIPTIN	Anagliptin	CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N	PLASMA	K726J96838									∞	ng × h/mL	13370		ng/mL	2769			UNKNOWN	mg	400		SINGLE	FASTED				n=5 for t1/2		UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2012/P201200123/300297000_22400AMX01387000_A100_1.pdf#page=43	Homo sapiens		h	6.84		Moderate renal impairment		6			false
7623	8243		ADULT	44513473	383.4475	ANAGLIPTIN	Anagliptin	CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N	PLASMA	K726J96838									∞	ng × h/mL	21263		ng/mL	3381			UNKNOWN	mg	400		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2012/P201200123/300297000_22400AMX01387000_A100_1.pdf#page=43 | https://www.pmda.go.jp/drugs/2012/P201200123/300297000_22400AMX01387000_K105_1.pdf#page=120	Homo sapiens		h	8.55		ESRD w/hemodialysis, started dialysis 4 h after drug administration		6			false
7624	8243		ADULT	44513473	383.4475	ANAGLIPTIN	Anagliptin	CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N	PLASMA	K726J96838									∞	ng × h/mL	11294		ng/mL	2704.5			UNKNOWN	mg	400		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2012/P201200123/300297000_22400AMX01387000_A100_1.pdf#page=44	Homo sapiens		h	5.99		Moderate hepatic impairment (Child-Pugh Class B)		8			false
7625	8243		ADULT	44513473	383.4475	ANAGLIPTIN	Anagliptin	CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N	PLASMA	K726J96838									∞	ng × h/mL	9650		ng/mL	2522.9			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2012/P201200123/300297000_22400AMX01387000_A100_1.pdf#page=44	Homo sapiens		h	8.45				8			false
7626	8245		ADULT	11219835	284.242	ATALUREN	Ataluren	OC(=O)C1=CC=CC(=C1)C2=NOC(=N2)C3=C(F)C=CC=C3	PLASMA	K16AME9I3V							72		t	μg × h/mL	482		μg/mL	90			UNKNOWN	mg/kg bw	30		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17389552/	Homo sapiens		h	4.7				6			false
7627	8245		ADULT	11219835	284.242	ATALUREN	Ataluren	OC(=O)C1=CC=CC(=C1)C2=NOC(=N2)C3=C(F)C=CC=C3	PLASMA	K16AME9I3V							72		t	μg × h/mL	2200		μg/mL	210			UNKNOWN	mg/kg bw	100		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17389552/	Homo sapiens		h	5.4				6			false
7628	8245		ADULT	11219835	284.242	ATALUREN	Ataluren	OC(=O)C1=CC=CC(=C1)C2=NOC(=N2)C3=C(F)C=CC=C3	PLASMA	K16AME9I3V							72		t	μg × h/mL	2937		μg/mL	314			UNKNOWN	mg/kg bw	200		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17389552/	Homo sapiens		h	6.3				6			false
7629	8245		ADULT	11219835	284.242	ATALUREN	Ataluren	OC(=O)C1=CC=CC(=C1)C2=NOC(=N2)C3=C(F)C=CC=C3	PLASMA	K16AME9I3V							72		t	μg × h/mL	3001		μg/mL	260			UNKNOWN	mg/kg bw	150		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17389552/	Homo sapiens		h	5.1				6			false
7630	8245		ADULT	11219835	284.242	ATALUREN	Ataluren	OC(=O)C1=CC=CC(=C1)C2=NOC(=N2)C3=C(F)C=CC=C3	PLASMA	K16AME9I3V							72		t	μg × h/mL	684		μg/mL	109			UNKNOWN	mg/kg bw	50		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17389552/	Homo sapiens		h	5.3				12			false
7631	8245		ADULT	11219835	284.242	ATALUREN	Ataluren	OC(=O)C1=CC=CC(=C1)C2=NOC(=N2)C3=C(F)C=CC=C3	PLASMA	K16AME9I3V							12		t	μg × h/mL	314		μg/mL	41			UNKNOWN	mg/kg bw	30		MULTIPLE	FED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17389552/	Homo sapiens		h	8.6	Day 1 AM dose (1st)			6			false
7632	8245		ADULT	11219835	284.242	ATALUREN	Ataluren	OC(=O)C1=CC=CC(=C1)C2=NOC(=N2)C3=C(F)C=CC=C3	PLASMA	K16AME9I3V							12		t	μg × h/mL	330		μg/mL	50			UNKNOWN	mg/kg bw	30		MULTIPLE	FED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17389552/	Homo sapiens		h	4.7	Day 7 AM dose (13th)			6			false
7633	8245		ADULT	11219835	284.242	ATALUREN	Ataluren	OC(=O)C1=CC=CC(=C1)C2=NOC(=N2)C3=C(F)C=CC=C3	PLASMA	K16AME9I3V							12		t	μg × h/mL	415		μg/mL	59			UNKNOWN	mg/kg bw	50		MULTIPLE	FED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17389552/	Homo sapiens		h	3.4	Day 1 AM dose (1st)			6			false
7634	8245		ADULT	11219835	284.242	ATALUREN	Ataluren	OC(=O)C1=CC=CC(=C1)C2=NOC(=N2)C3=C(F)C=CC=C3	PLASMA	K16AME9I3V							12		t	μg × h/mL	574		μg/mL	80			UNKNOWN	mg/kg bw	50		MULTIPLE	FED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17389552/	Homo sapiens		h	5.3	Day 7 AM dose (13th)			6			false
7635	8245		ADULT	11219835	284.242	ATALUREN	Ataluren	OC(=O)C1=CC=CC(=C1)C2=NOC(=N2)C3=C(F)C=CC=C3	PLASMA	K16AME9I3V							12		t	μg × h/mL	551		μg/mL	81			UNKNOWN	mg/kg bw	50		MULTIPLE	FED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17389552/	Homo sapiens		h	3.3	Day 1 AM dose (1st)			6			false
7636	8245		ADULT	11219835	284.242	ATALUREN	Ataluren	OC(=O)C1=CC=CC(=C1)C2=NOC(=N2)C3=C(F)C=CC=C3	PLASMA	K16AME9I3V							12		t	μg × h/mL	81		μg/mL	13			UNKNOWN	mg/kg bw	10		MULTIPLE	FED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17389552/	Homo sapiens		h	2.5	Day 7 AM dose (13th)			6			false
7637	8245		ADULT	11219835	284.242	ATALUREN	Ataluren	OC(=O)C1=CC=CC(=C1)C2=NOC(=N2)C3=C(F)C=CC=C3	PLASMA	K16AME9I3V							12		t	μg × h/mL	91		μg/mL	16			UNKNOWN	mg/kg bw	10		MULTIPLE	FED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17389552/	Homo sapiens		h	2.4	Day 1 AM dose (1st)			6			false
7638	8245		ADULT	11219835	284.242	ATALUREN	Ataluren	OC(=O)C1=CC=CC(=C1)C2=NOC(=N2)C3=C(F)C=CC=C3	PLASMA	K16AME9I3V							12		t	μg × h/mL	164		μg/mL	26			UNKNOWN	mg/kg bw	20		MULTIPLE	FED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17389552/	Homo sapiens		h	3.3	Day 1 AM dose (1st)			6			false
7639	8245		ADULT	11219835	284.242	ATALUREN	Ataluren	OC(=O)C1=CC=CC(=C1)C2=NOC(=N2)C3=C(F)C=CC=C3	PLASMA	K16AME9I3V							12		t	μg × h/mL	179		μg/mL	32			UNKNOWN	mg/kg bw	20		MULTIPLE	FED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17389552/	Homo sapiens		h	3.5	Day 7 AM dose (13th)			6			false
7640	8245		ADULT	11219835	284.242	ATALUREN	Ataluren	OC(=O)C1=CC=CC(=C1)C2=NOC(=N2)C3=C(F)C=CC=C3	PLASMA	K16AME9I3V							12		t	μg × h/mL	463		μg/mL	65			UNKNOWN	mg/kg bw	50		MULTIPLE	FED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17389552/	Homo sapiens		h	6.3	Day 7 AM dose (13th)			6			false
7641	8245		ADULT	11219835	284.242	ATALUREN	Ataluren	OC(=O)C1=CC=CC(=C1)C2=NOC(=N2)C3=C(F)C=CC=C3	PLASMA	K16AME9I3V							72		t	μg × h/mL	900		μg/mL	99			UNKNOWN	mg/kg bw	50		SINGLE	HIGH-FAT						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17389552/	Homo sapiens		h	4.8				12			false
7642	8245		ADULT	11219835	284.242	ATALUREN	Ataluren	OC(=O)C1=CC=CC(=C1)C2=NOC(=N2)C3=C(F)C=CC=C3	PLASMA	K16AME9I3V							12		t	μg × h/mL	359		μg/mL	53			UNKNOWN	mg/kg bw	50		MULTIPLE	FED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17389552/	Homo sapiens		h	3.9	Day 14 AM dose (27th)			6			false
7643	8245		ADULT	11219835	284.242	ATALUREN	Ataluren	OC(=O)C1=CC=CC(=C1)C2=NOC(=N2)C3=C(F)C=CC=C3	PLASMA	K16AME9I3V							12		t	μg × h/mL	688		μg/mL	85			UNKNOWN	mg/kg bw	50		MULTIPLE	FED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17389552/	Homo sapiens		h	6.8	Day 1 PM dose (2nd)			6			false
7644	8245		ADULT	11219835	284.242	ATALUREN	Ataluren	OC(=O)C1=CC=CC(=C1)C2=NOC(=N2)C3=C(F)C=CC=C3	PLASMA	K16AME9I3V							12		t	μg × h/mL	644		μg/mL	76			UNKNOWN	mg/kg bw	50		MULTIPLE	FED		day	2	n=5 for t1/2		HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17389552/	Homo sapiens		h	7.9	Day 7 PM dose (14th)			6			false
7645	8245		ADULT	11219835	284.242	ATALUREN	Ataluren	OC(=O)C1=CC=CC(=C1)C2=NOC(=N2)C3=C(F)C=CC=C3	PLASMA	K16AME9I3V							12		t	μg × h/mL	540		μg/mL	76			UNKNOWN	mg/kg bw	50		MULTIPLE	FED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17389552/	Homo sapiens		h	9	Day 14 PM dose (28th)			6			false
7646	8245		ADULT	11219835	284.242	ATALUREN	Ataluren	OC(=O)C1=CC=CC(=C1)C2=NOC(=N2)C3=C(F)C=CC=C3	PLASMA	K16AME9I3V							72		t	μg × h/mL	27		μg/mL	6			UNKNOWN	mg/kg bw	3		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17389552/	Homo sapiens		h	3.1				6			false
7647	8245		ADULT	11219835	284.242	ATALUREN	Ataluren	OC(=O)C1=CC=CC(=C1)C2=NOC(=N2)C3=C(F)C=CC=C3	PLASMA	K16AME9I3V							72		t	μg × h/mL	110		μg/mL	27			UNKNOWN	mg/kg bw	10		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17389552/	Homo sapiens		h	3.6				6			false
7648	8245		ADULT	11219835	284.242	ATALUREN	Ataluren	OC(=O)C1=CC=CC(=C1)C2=NOC(=N2)C3=C(F)C=CC=C3	PLASMA	K16AME9I3V									∞	μg × h/mL	228.5		μg/mL	47.1			UNKNOWN	mg/kg bw	20		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30629861/	Homo sapiens		h	3.4		Japanese		8			false
7649	8245		ADULT	11219835	284.242	ATALUREN	Ataluren	OC(=O)C1=CC=CC(=C1)C2=NOC(=N2)C3=C(F)C=CC=C3	PLASMA	K16AME9I3V									∞	μg × h/mL	345.2		μg/mL	48.8			UNKNOWN	mg/kg bw	20		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30629861/	Homo sapiens		h	3.4		Caucasian		8			false
7650	8245		ADULT	11219835	284.242	ATALUREN	Ataluren	OC(=O)C1=CC=CC(=C1)C2=NOC(=N2)C3=C(F)C=CC=C3	PLASMA	K16AME9I3V									∞	μg × h/mL	57.2		μg/mL	13.5			UNKNOWN	mg/kg bw	5		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30629861/	Homo sapiens		h	3.2		Caucasian		8			false
7651	8245		ADULT	11219835	284.242	ATALUREN	Ataluren	OC(=O)C1=CC=CC(=C1)C2=NOC(=N2)C3=C(F)C=CC=C3	PLASMA	K16AME9I3V									∞	μg × h/mL	49.3		μg/mL	15.9			UNKNOWN	mg/kg bw	5		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30629861/	Homo sapiens		h	3.2		Japanese		8			false
7652	8245		ADULT	11219835	284.242	ATALUREN	Ataluren	OC(=O)C1=CC=CC(=C1)C2=NOC(=N2)C3=C(F)C=CC=C3	PLASMA	K16AME9I3V									∞	μg × h/mL	131.1		μg/mL	29.9			UNKNOWN	mg/kg bw	10		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30629861/	Homo sapiens		h	3.4		Caucasian		8			false
7653	8245		ADULT	11219835	284.242	ATALUREN	Ataluren	OC(=O)C1=CC=CC(=C1)C2=NOC(=N2)C3=C(F)C=CC=C3	PLASMA	K16AME9I3V									∞	μg × h/mL	104.5		μg/mL	25.2			UNKNOWN	mg/kg bw	10		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30629861/	Homo sapiens		h	3.3		Japanese		8			false
7654	8245			11219835	284.242	ATALUREN	Ataluren	OC(=O)C1=CC=CC(=C1)C2=NOC(=N2)C3=C(F)C=CC=C3	PLASMA	K16AME9I3V																										Human plasma protein binding: 99.6% (50~50000ng/mL, ultrafiltration)	0.4				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32196986/	Homo sapiens										false
7655	8247		ADULT	61361	190.2384	BUTYLPHTHALIDE	BUTYLPHTHALIDE	CCCCC1OC(=O)C2=C1C=CC=C2	PLASMA	822Q956KGM									∞	ng × h/mL	864		ng/mL	514			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23169608/	Homo sapiens		h	5.33				4	BUTYLPHTHALIDE		false
7656	8248		ADULT	25154714	738.875	DACLATASVIR	DACLATASVIR	COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)[C@@H]6CCCN6C(=O)[C@@H](NC(=O)OC)C(C)C	PLASMA	LI2427F9CI									∞	ng × h/mL	162		ng/mL	16.4			UNKNOWN	mg	1		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/29353349/	Homo sapiens		h	9.83							false
7657	8248		ADULT	25154714	738.875	DACLATASVIR	DACLATASVIR	COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)[C@@H]6CCCN6C(=O)[C@@H](NC(=O)OC)C(C)C	PLASMA	LI2427F9CI									∞	ng × h/mL	13471		ng/mL	1226			UNKNOWN	mg	50		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/29353349/	Homo sapiens		h	13.5							false
7658	8248		ADULT	25154714	738.875	DACLATASVIR	DACLATASVIR	COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)[C@@H]6CCCN6C(=O)[C@@H](NC(=O)OC)C(C)C	PLASMA	LI2427F9CI									∞	ng × h/mL	31793		ng/mL	2816			UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/29353349/	Homo sapiens		h	11							false
7659	8248		ADULT	25154714	738.875	DACLATASVIR	DACLATASVIR	COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)[C@@H]6CCCN6C(=O)[C@@H](NC(=O)OC)C(C)C	PLASMA	LI2427F9CI							24		t	ng × h/mL	2371		ng/mL	291			UNKNOWN	mg	10		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/29353349/	Homo sapiens										false
7660	8248		ADULT	25154714	738.875	DACLATASVIR	DACLATASVIR	COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)[C@@H]6CCCN6C(=O)[C@@H](NC(=O)OC)C(C)C	PLASMA	LI2427F9CI							24		t	ng × h/mL	2453		ng/mL	257			UNKNOWN	mg	10		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/29353349/	Homo sapiens										false
7661	8248		ADULT	25154714	738.875	DACLATASVIR	DACLATASVIR	COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)[C@@H]6CCCN6C(=O)[C@@H](NC(=O)OC)C(C)C	PLASMA	LI2427F9CI							24		t	ng × h/mL	4548		ng/mL	610			UNKNOWN	mg	30		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/29353349/	Homo sapiens										false
7662	8248		ADULT	25154714	738.875	DACLATASVIR	DACLATASVIR	COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)[C@@H]6CCCN6C(=O)[C@@H](NC(=O)OC)C(C)C	PLASMA	LI2427F9CI							24		t	ng × h/mL	6275		ng/mL	734			UNKNOWN	mg	30		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/29353349/	Homo sapiens										false
7663	8248		ADULT	25154714	738.875	DACLATASVIR	DACLATASVIR	COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)[C@@H]6CCCN6C(=O)[C@@H](NC(=O)OC)C(C)C	PLASMA	LI2427F9CI							24		t	ng × h/mL	11475		ng/mL	1295			DEFINED DAILY	mg	60		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/29353349/	Homo sapiens										false
7664	8248		ADULT	25154714	738.875	DACLATASVIR	DACLATASVIR	COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)[C@@H]6CCCN6C(=O)[C@@H](NC(=O)OC)C(C)C	PLASMA	LI2427F9CI							24		t	ng × h/mL	15666		ng/mL	1582			RECOMMENDED	mg	60		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/29353349/	Homo sapiens										false
7665	8248		ADULT	25154714	738.875	DACLATASVIR	DACLATASVIR	COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)[C@@H]6CCCN6C(=O)[C@@H](NC(=O)OC)C(C)C	PLASMA	LI2427F9CI							24		t	ng × h/mL	9680						RECOMMENDED	mg	60		STEADY-STATE	UNKNOWN		day	1		1	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/206843s006lbl.pdf	Homo sapiens		h	13.5							false
7666	8250		ADULT	6480466	534.4844	DELAMANID	DELAMANID	C[C@]4(COC1=CC=C(C=C1)N2CCC(CC2)OC3=CC=C(OC(F)(F)F)C=C3)CN5C=C(N=C5O4)[N ]([O-])=O	PLASMA	8OOT6M1PC7							12		t	mg × h/L	2.9		mg/L	0.31			RECOMMENDED	mg	100		MULTIPLE	FED		day	2	Delamanid highly binds to all plasma proteins with a binding to total proteins of ≥ 99.5%. https://www.ema.europa.eu/en/documents/product-information/deltyba-epar-product-information_en.pdf	0.5	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33378452/	Homo sapiens		h	10.3				31	DELAMANID		false
7667	8253		ADULT	92943	392.5338	DEXTROMORAMIDE	Dextromoramide	C[C@H](CN1CCOCC1)C(C(=O)N2CCCC2)(C3=CC=CC=C3)C4=CC=CC=C4	PLASMA	9S4S6CIY83									∞	mg × h/L	0.81		μg/L	106			UNKNOWN	mg	7.5		SINGLE	FASTED				n=5 for t1/2		UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2714730/	Homo sapiens		h	12.3		SURGICAL PATIENTS		9			false
7668	8253		ADULT	92943	392.5338	DEXTROMORAMIDE	Dextromoramide	C[C@H](CN1CCOCC1)C(C(=O)N2CCCC2)(C3=CC=CC=C3)C4=CC=CC=C4	PLASMA	9S4S6CIY83							24		t	μg × h/L	1775.4		μg/L	2000			UNKNOWN	mg	5		SINGLE	UNKNOWN				Cmax value was read directly from Figure 1.		UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8931067/	Homo sapiens		h	9.02		Patients receiving chronic opioid analgesia		5			false
7669	8253		ADULT	92943	392.5338	DEXTROMORAMIDE	Dextromoramide	C[C@H](CN1CCOCC1)C(C(=O)N2CCCC2)(C3=CC=CC=C3)C4=CC=CC=C4	PLASMA	9S4S6CIY83							24		t	μg × h/L	526		μg/L	40			UNKNOWN	mg	5		SINGLE	UNKNOWN				Cmax value was read directly from Figure 1.		UNHEALTHY	Sublingual	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8931067/	Homo sapiens		h	12.37		Patients receiving chronic opioid analgesia		3			false
7670	8254		ADULT	15942827	146.1412	DIANHYDROGALACTITOL	Dianhydrogalactitol	O[C@@H]([C@@H](O)[C@H]1CO1)[C@@H]2CO2	PLASMA	4S465RYF7M																	UNKNOWN	mg/kg	0.7		SINGLE	UNKNOWN				Human plasma protein binding: 8~25%	75	UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3699079/	Homo sapiens					Cancer patients		3			false
7671	8257		ADULT	182137	237.725	ESKETAMINE	esketamine	CN[C@@]1(CCCCC1=O)C2=C(Cl)C=CC=C2	PLASMA	50LFG02TXD													ng/mL	128			UNKNOWN	mg/kg	0.35		SINGLE	UNKNOWN						HEALTHY	Respiratory	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28100533/	Homo sapiens										false
7672	8257		ADULT	182137	237.725	ESKETAMINE	esketamine	CN[C@@]1(CCCCC1=O)C2=C(Cl)C=CC=C2	PLASMA	50LFG02TXD													ng/mL	180			UNKNOWN	mg/kg	0.5		SINGLE	UNKNOWN						HEALTHY	Respiratory	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28100533/	Homo sapiens										false
7673	8257		ADULT	182137	237.725	ESKETAMINE	esketamine	CN[C@@]1(CCCCC1=O)C2=C(Cl)C=CC=C2	PLASMA	50LFG02TXD													ng/mL	227			UNKNOWN	mg/kg	0.7		SINGLE	UNKNOWN						HEALTHY	Respiratory	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28100533/	Homo sapiens										false
7674	8257		ADULT	11775775	223.699	NORKETAMINE, (S)-	NORKETAMINE, (S)-	N[C@@]1(CCCCC1=O)C2=C(Cl)C=CC=C2	PLASMA	205K4OI46B													ng/mL	52			UNKNOWN	mg/kg	0.35		SINGLE	UNKNOWN						HEALTHY	Respiratory	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28100533/	Homo sapiens										false
7675	8257		ADULT	11775775	223.699	NORKETAMINE, (S)-	NORKETAMINE, (S)-	N[C@@]1(CCCCC1=O)C2=C(Cl)C=CC=C2	PLASMA	205K4OI46B													ng/mL	97			UNKNOWN	mg/kg	0.5		SINGLE	UNKNOWN						HEALTHY	Respiratory	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28100533/	Homo sapiens										false
7676	8257		ADULT	11775775	223.699	NORKETAMINE, (S)-	NORKETAMINE, (S)-	N[C@@]1(CCCCC1=O)C2=C(Cl)C=CC=C2	PLASMA	205K4OI46B													ng/mL	153			UNKNOWN	mg/kg	0.7		SINGLE	UNKNOWN						HEALTHY	Respiratory	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28100533/	Homo sapiens										false
7677	8257		ADULT	182137	237.725	ESKETAMINE	ESKETAMINE	CN[C@@]1(CCCCC1=O)C2=C(Cl)C=CC=C2	PLASMA	50LFG02TXD									∞	ng × h/mL	475.2		ng/mL	2277.6			RECOMMENDED	mg/kg	0.5		SINGLE	UNKNOWN						UNHEALTHY	Intramuscular	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31827320/	Homo sapiens		min	287.5							false
7678	8257		UNKNOWN	182137	237.725	ESKETAMINE	esketamine	CN[C@@]1(CCCCC1=O)C2=C(Cl)C=CC=C2	PLASMA	50LFG02TXD																						UNKNOWN				The unbound plasma fraction is 57-55%	56	UNKNOWN		UNKNOWN	REVIEW	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211243Orig1s000ClinPharmR.pdf	Homo sapiens										false
7679	8257		ADULT	182137	237.725	ESKETAMINE	esketamine	CN[C@@]1(CCCCC1=O)C2=C(Cl)C=CC=C2	PLASMA	50LFG02TXD																	UNKNOWN				SINGLE	UNKNOWN						UNKNOWN	Respiratory	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211243Orig1s000ClinPharmR.pdf	Homo sapiens		h	11.1							false
7680	8257		ADULT	11775775	223.699	NORKETAMINE, (S)-	NORKETAMINE, (S)-	N[C@@]1(CCCCC1=O)C2=C(Cl)C=CC=C2	PLASMA	205K4OI46B																	UNKNOWN				SINGLE	UNKNOWN						UNKNOWN	Respiratory	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211243Orig1s000ClinPharmR.pdf	Homo sapiens		h	7.5							false
7681	8259		ADULT	9870652	501.646	FIMASARTAN	Fimasartan	CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC2=CC=C(C=C2)C3=C(C=CC=C3)C4=NN=NN4	PLASMA	P58222188P									∞	ng × h/mL	1116		ng/mL	227			UNKNOWN	mg	240		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21910510/	Homo sapiens		h	10.1				6			false
7682	8259		ADULT	9870652	501.646	FIMASARTAN	Fimasartan	CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC2=CC=C(C=C2)C3=C(C=CC=C3)C4=NN=NN4	PLASMA	P58222188P									∞	ng × h/mL	1033		ng/mL	183			UNKNOWN	mg	240		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21910510/	Homo sapiens		h	13.1				5			false
7683	8259		ADULT	9870652	501.646	FIMASARTAN	Fimasartan	CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC2=CC=C(C=C2)C3=C(C=CC=C3)C4=NN=NN4	PLASMA	P58222188P									∞	ng × h/mL	98.8		ng/mL	11.6			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21910510/	Homo sapiens		h	5.53				6			false
7684	8259		ADULT	9870652	501.646	FIMASARTAN	Fimasartan	CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC2=CC=C(C=C2)C3=C(C=CC=C3)C4=NN=NN4	PLASMA	P58222188P									∞	ng × h/mL	413		ng/mL	66.2			UNKNOWN	mg	60		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21910510/	Homo sapiens		h	5.37				6			false
7685	8259		ADULT	9870652	501.646	FIMASARTAN	Fimasartan	CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC2=CC=C(C=C2)C3=C(C=CC=C3)C4=NN=NN4	PLASMA	P58222188P									∞	ng × h/mL	783		ng/mL	136			UNKNOWN	mg	120		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21910510/	Homo sapiens		h	9.33				6			false
7686	8259		ADULT	9870652	501.646	FIMASARTAN	Fimasartan	CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC2=CC=C(C=C2)C3=C(C=CC=C3)C4=NN=NN4	PLASMA	P58222188P									∞	ng × h/mL	1116		ng/mL	227			UNKNOWN	mg	240		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21910510/	Homo sapiens		h	10.1				6			false
7687	8259		ADULT	9870652	501.646	FIMASARTAN	Fimasartan	CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC2=CC=C(C=C2)C3=C(C=CC=C3)C4=NN=NN4	PLASMA	P58222188P									∞	ng × h/mL	2448		ng/mL	601			UNKNOWN	mg	480		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21910510/	Homo sapiens		h	16.2				6			false
7688	8259		ADULT	9870652	501.646	FIMASARTAN	Fimasartan	CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC2=CC=C(C=C2)C3=C(C=CC=C3)C4=NN=NN4	PLASMA	P58222188P							24		t	ng × h/mL	636		ng/mL	123			UNKNOWN	mg	120		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21910510/	Homo sapiens		h	4.73	Day 1			6			false
7689	8259		ADULT	9870652	501.646	FIMASARTAN	Fimasartan	CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC2=CC=C(C=C2)C3=C(C=CC=C3)C4=NN=NN4	PLASMA	P58222188P							24		t	ng × h/mL	801		ng/mL	224			UNKNOWN	mg	120		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21910510/	Homo sapiens		h	14	Day 7			6			false
7690	8259		ADULT	9870652	501.646	FIMASARTAN	Fimasartan	CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC2=CC=C(C=C2)C3=C(C=CC=C3)C4=NN=NN4	PLASMA	P58222188P							24		t	ng × h/mL	1157		ng/mL	309			UNKNOWN	mg	360		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21910510/	Homo sapiens		h	5.71	Day 1			6			false
7691	8259		ADULT	9870652	501.646	FIMASARTAN	Fimasartan	CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC2=CC=C(C=C2)C3=C(C=CC=C3)C4=NN=NN4	PLASMA	P58222188P							24		t	ng × h/mL	1441		ng/mL	403			UNKNOWN	mg	360		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21910510/	Homo sapiens		h	17.9	Day 7			5			false
7692	8259		ADULT	9870652	501.646	FIMASARTAN	Fimasartan	CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC2=CC=C(C=C2)C3=C(C=CC=C3)C4=NN=NN4	PLASMA	P58222188P									∞	ng × h/mL	932		ng/mL	289.3			UNKNOWN	mg	120		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24084213/	Homo sapiens		h	7.4				6			false
7693	8259		ADULT	9870652	501.646	FIMASARTAN	Fimasartan	CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC2=CC=C(C=C2)C3=C(C=CC=C3)C4=NN=NN4	PLASMA	P58222188P									∞	ng × h/mL	1509.7		ng/mL	422			UNKNOWN	mg	120		SINGLE	FASTED						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24084213/	Homo sapiens		h	8.2		Mild hepatic impairment		6			false
7694	8259		ADULT	9870652	501.646	FIMASARTAN	Fimasartan	CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC2=CC=C(C=C2)C3=C(C=CC=C3)C4=NN=NN4	PLASMA	P58222188P									∞	ng × h/mL	4768.1		ng/mL	1864.4			UNKNOWN	mg	120		SINGLE	FASTED						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24084213/	Homo sapiens		h	8.5		Moderate hepatic impairment		6			false
7695	8259		ADULT	9870652	501.646	FIMASARTAN	Fimasartan	CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC2=CC=C(C=C2)C3=C(C=CC=C3)C4=NN=NN4	PLASMA	P58222188P									?	μg × h/mL	913.6		μg/mL	281.9			UNKNOWN	mg	120		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25336916/	Homo sapiens		h	9.8				8			false
7696	8259		ADULT	9870652	501.646	FIMASARTAN	Fimasartan	CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC2=CC=C(C=C2)C3=C(C=CC=C3)C4=NN=NN4	PLASMA	P58222188P									?	μg × h/mL	1580.8		μg/mL	457.7			UNKNOWN	mg	120		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25336916/	Homo sapiens		h	11.35		Severe renal impairment (eGFR <30 mL/min/1.73 m2)		8			false
7697	8259			9870652	501.646	FIMASARTAN	Fimasartan	CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC2=CC=C(C=C2)C3=C(C=CC=C3)C4=NN=NN4	PLASMA	P58222188P																										Plasma protein binding: 95%	5				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29676941/	Homo sapiens										false
7698	8262		ADULT	214351	366.437	ILAPRAZOLE	Ilaprazole	COC1=C(C)C(C[S ]([O-])C2=NC3=C(N2)C=CC(=C3)N4C=CC=C4)=NC=C1	PLASMA	776Q6XX45J									∞	ng × h/mL	2051		ng/mL	305			UNKNOWN	mg	10		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25041486/	Homo sapiens		h	4.7	Day 1			34			false
7699	8262		ADULT	214351	366.437	ILAPRAZOLE	Ilaprazole	COC1=C(C)C(C[S ]([O-])C2=NC3=C(N2)C=CC(=C3)N4C=CC=C4)=NC=C1	PLASMA	776Q6XX45J							24		t	ng × h/mL	2092		ng/mL	293			UNKNOWN	mg	10		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25041486/	Homo sapiens		h	5.1	Day 5			34			false
7700	8262		ADULT	214351	366.437	ILAPRAZOLE	Ilaprazole	COC1=C(C)C(C[S ]([O-])C2=NC3=C(N2)C=CC(=C3)N4C=CC=C4)=NC=C1	PLASMA	776Q6XX45J									∞	ng × h/mL	3948		ng/mL	565			UNKNOWN	mg	20		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25041486/	Homo sapiens		h	5.2	Day 1			34			false
7701	8262		ADULT	214351	366.437	ILAPRAZOLE	Ilaprazole	COC1=C(C)C(C[S ]([O-])C2=NC3=C(N2)C=CC(=C3)N4C=CC=C4)=NC=C1	PLASMA	776Q6XX45J							24		t	ng × h/mL	4463		ng/mL	638			UNKNOWN	mg	20		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25041486/	Homo sapiens		h	5.2	Day 5			34			false
7702	8262		ADULT	214351	366.437	ILAPRAZOLE	Ilaprazole	COC1=C(C)C(C[S ]([O-])C2=NC3=C(N2)C=CC(=C3)N4C=CC=C4)=NC=C1	PLASMA	776Q6XX45J									∞	ng × h/mL	7630		ng/mL	1103			UNKNOWN	mg	40		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25041486/	Homo sapiens		h	5	Day 1			34			false
7703	8262		ADULT	214351	366.437	ILAPRAZOLE	Ilaprazole	COC1=C(C)C(C[S ]([O-])C2=NC3=C(N2)C=CC(=C3)N4C=CC=C4)=NC=C1	PLASMA	776Q6XX45J							24		t	ng × h/mL	7918		ng/mL	1114			UNKNOWN	mg	40		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25041486/	Homo sapiens		h	5.3	Day 5			34			false
7704	8262		ADULT	214351	366.437	ILAPRAZOLE	Ilaprazole	COC1=C(C)C(C[S ]([O-])C2=NC3=C(N2)C=CC(=C3)N4C=CC=C4)=NC=C1	PLASMA	776Q6XX45J									∞	ng × h/mL	1754.8		ng/mL	482.2			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26998954/	Homo sapiens		h	3.3				15			false
7705	8262		ADULT	214351	366.437	ILAPRAZOLE	Ilaprazole	COC1=C(C)C(C[S ]([O-])C2=NC3=C(N2)C=CC(=C3)N4C=CC=C4)=NC=C1	PLASMA	776Q6XX45J									∞	ng × h/mL	3562.6		ng/mL	834.3			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26998954/	Homo sapiens		h	3.4				15			false
7706	8262		ADULT	214351	366.437	ILAPRAZOLE	Ilaprazole	COC1=C(C)C(C[S ]([O-])C2=NC3=C(N2)C=CC(=C3)N4C=CC=C4)=NC=C1	PLASMA	776Q6XX45J									∞	ng × h/mL	7056.6		ng/mL	1718.9			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26998954/	Homo sapiens		h	3.3				15			false
7707	8262		ADULT	214351	366.437	ILAPRAZOLE	Ilaprazole	COC1=C(C)C(C[S ]([O-])C2=NC3=C(N2)C=CC(=C3)N4C=CC=C4)=NC=C1	PLASMA	776Q6XX45J									∞	ng × h/mL	1984.2		ng/mL	347.9			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26998954/	Homo sapiens		h	3.5				15			false
7708	8262		ADULT	214351	366.437	ILAPRAZOLE	Ilaprazole	COC1=C(C)C(C[S ]([O-])C2=NC3=C(N2)C=CC(=C3)N4C=CC=C4)=NC=C1	PLASMA	776Q6XX45J									∞	ng × h/mL	2010.6		ng/mL	497.9			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26998954/	Homo sapiens		h	3.56				8			false
7709	8262		ADULT	214351	366.437	ILAPRAZOLE	Ilaprazole	COC1=C(C)C(C[S ]([O-])C2=NC3=C(N2)C=CC(=C3)N4C=CC=C4)=NC=C1	PLASMA	776Q6XX45J									∞	ng × h/mL	1462.49		ng/mL	464.25			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26998954/	Homo sapiens		h	2.93				7			false
7710	8262		ADULT	214351	366.437	ILAPRAZOLE	Ilaprazole	COC1=C(C)C(C[S ]([O-])C2=NC3=C(N2)C=CC(=C3)N4C=CC=C4)=NC=C1	PLASMA	776Q6XX45J									∞	ng × h/mL	3940.26		ng/mL	844.01			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26998954/	Homo sapiens		h	3.63				8			false
7711	8262		ADULT	214351	366.437	ILAPRAZOLE	Ilaprazole	COC1=C(C)C(C[S ]([O-])C2=NC3=C(N2)C=CC(=C3)N4C=CC=C4)=NC=C1	PLASMA	776Q6XX45J									∞	ng × h/mL	3184.85		ng/mL	824.62			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26998954/	Homo sapiens		h	3.22				7			false
7712	8262		ADULT	214351	366.437	ILAPRAZOLE	Ilaprazole	COC1=C(C)C(C[S ]([O-])C2=NC3=C(N2)C=CC(=C3)N4C=CC=C4)=NC=C1	PLASMA	776Q6XX45J									∞	ng × h/mL	8042.04		ng/mL	1848.9			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26998954/	Homo sapiens		h	3.36				8			false
7713	8262		ADULT	214351	366.437	ILAPRAZOLE	Ilaprazole	COC1=C(C)C(C[S ]([O-])C2=NC3=C(N2)C=CC(=C3)N4C=CC=C4)=NC=C1	PLASMA	776Q6XX45J									∞	ng × h/mL	5930.34		ng/mL	1570.48			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26998954/	Homo sapiens		h	2.89				7			false
7714	8262		ADULT	214351	366.437	ILAPRAZOLE	Ilaprazole	COC1=C(C)C(C[S ]([O-])C2=NC3=C(N2)C=CC(=C3)N4C=CC=C4)=NC=C1	PLASMA	776Q6XX45J									∞	ng × h/mL	2774.9		ng/mL	834.6			UNKNOWN	mg	10		STEADY-STATE	FASTED		day	1			HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27067231/	Homo sapiens		h	2.5	Day 1			10			false
7715	8262		ADULT	214351	366.437	ILAPRAZOLE	Ilaprazole	COC1=C(C)C(C[S ]([O-])C2=NC3=C(N2)C=CC(=C3)N4C=CC=C4)=NC=C1	PLASMA	776Q6XX45J									∞	ng × h/mL	2654.8		ng/mL	836.6			UNKNOWN	mg	10		STEADY-STATE	FASTED		day	1			HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27067231/	Homo sapiens		h	2.8	Day 5			15			false
7716	8264		ADULT	6918485	437.465	ISAVUCONAZOLE	ISAVUCONAZOLE	C[C@@H](C1=NC(=CS1)C2=CC=C(C=C2)C#N)[C@](O)(CN3C=NC=N3)C4=C(F)C=CC(F)=C4	PLASMA	60UTO373KE									?	ng × h/mL	121402		ng/mL	7499			INVESTIGATIONAL	mg	200		STEADY-STATE	UNKNOWN		day	1	Isavuconazole is highly protein bound (greater than 99%), predominantly to albumin.	1	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/207500s005,207501s004lbl.pdf	Homo sapiens		h	130							false
7717	8264		ADULT	6918485	437.465	ISAVUCONAZOLE	ISAVUCONAZOLE	C[C@@H](C1=NC(=CS1)C2=CC=C(C=C2)C#N)[C@](O)(CN3C=NC=N3)C4=C(F)C=CC(F)=C4	PLASMA	60UTO373KE									?	ng × h/mL	352805		ng/mL	20028			MAX DAILY	mg	600		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/207500s005,207501s004lbl.pdf	Homo sapiens										false
7718	8266		ADULT	197033	319.4433	LATREPIRDINE	Latrepirdine	CN1CCC2=C(C1)C3=C(C=CC(C)=C3)N2CCC4=CN=C(C)C=C4	PLASMA	OD9237K1Z6									∞	ng × h/mL	10.4		ng/mL	1.3			UNKNOWN	mg	8.14		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27072954/	Homo sapiens		h	6.8	Immediate-release formulation	Elderly subjects (50-79 y), CYP2D6 EM		12			false
7719	8266		ADULT	197033	319.4433	LATREPIRDINE	Latrepirdine	CN1CCC2=C(C1)C3=C(C=CC(C)=C3)N2CCC4=CN=C(C)C=C4	UNKNOWN	OD9237K1Z6							8		t	μg × h/mL	0.149		μg/mL	0.03			UNKNOWN	mg	40		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33898159/	Homo sapiens										false
7720	8266		ADULT	197033	319.4433	LATREPIRDINE	Latrepirdine	CN1CCC2=C(C1)C3=C(C=CC(C)=C3)N2CCC4=CN=C(C)C=C4	UNKNOWN	OD9237K1Z6							8		t	μg × h/mL	0.0645		μg/mL	0.0122			UNKNOWN	mg	20		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33898159/	Homo sapiens										false
7721	8268		ADULT	9822750	408.876	LEVAMLODIPINE	LEVAMLODIPINE	CCOC(=O)C1=C(COCCN)NC(C)=C([C@@H]1C2=C(Cl)C=CC=C2)C(=O)OC	PLASMA	0P6NLP6806									∞	ng × h/mL	161.7		ng/mL	3.1			DEFINED DAILY	mg	5		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17213004/	Homo sapiens		h	55							false
7722	8268		ADULT	9822750	408.876	LEVAMLODIPINE	LEVAMLODIPINE	CCOC(=O)C1=C(COCCN)NC(C)=C([C@@H]1C2=C(Cl)C=CC=C2)C(=O)OC	PLASMA	0P6NLP6806	65999		TELMISARTAN	telmisartan	CCCC1=NC2=C(C=C(C=C2C)C3=NC4=C(C=CC=C4)N3C)N1CC5=CC=C(C=C5)C6=C(C=CC=C6)C(O)=O	U5SYW473RQ			∞	ng × h/mL	147.43		ng/mL	2.71			DEFINED DAILY	mg	5		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29559771/	Homo sapiens		h	45.1							true
7723	8271		ADULT	11988953	434.546	LUSEOGLIFLOZIN	luseogliflozin	CCOC1=CC=C(CC2=C(C)C=C(OC)C(=C2)[C@@H]3S[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C=C1	PLASMA	C596HWF74Z									∞	ng × h/mL	8510		ng/mL	721			HIGHEST STUDIED	mg	25		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24535625/	Homo sapiens		h	12.6		Japanese		8			false
7724	8271		ADULT	11988953	434.546	LUSEOGLIFLOZIN	luseogliflozin	CCOC1=CC=C(CC2=C(C)C=C(OC)C(=C2)[C@@H]3S[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C=C1	PLASMA	C596HWF74Z									∞	ng × h/mL	1930		ng/mL	205			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24535625/	Homo sapiens		h	10.3	Preprandial	Japanese		8			false
7725	8271		ADULT	11988953	434.546	LUSEOGLIFLOZIN	luseogliflozin	CCOC1=CC=C(CC2=C(C)C=C(OC)C(=C2)[C@@H]3S[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C=C1	PLASMA	C596HWF74Z							24		t	ng × h/mL	1980		ng/mL	248			UNKNOWN	mg	5		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24535625/	Homo sapiens		h	10.7	Multiple ascending dose: Subjects received a daily dose of luseogliflozin for 7 days orally just before food intake (breakfast). Administration of luseogliflozin was initiated with 5 mg, only increasing to 10 mg after safety\ndata had been reviewed by the investigator and 5 mg had been evaluated to be tolerable and\nsafe.	Japanese		8			false
7726	8271		ADULT	11988953	434.546	LUSEOGLIFLOZIN	luseogliflozin	CCOC1=CC=C(CC2=C(C)C=C(OC)C(=C2)[C@@H]3S[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C=C1	PLASMA	C596HWF74Z									∞	ng × h/mL	337		ng/mL	38.2			UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24535625/	Homo sapiens		h	10.4		Japanese		3			false
7727	8271		ADULT	11988953	434.546	LUSEOGLIFLOZIN	luseogliflozin	CCOC1=CC=C(CC2=C(C)C=C(OC)C(=C2)[C@@H]3S[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C=C1	PLASMA	C596HWF74Z									∞	ng × h/mL	1830		ng/mL	187			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24535625/	Homo sapiens		h	9.72		Japanese		8			false
7728	8274		ADULT	12001014|135497803	531.667	MIRODENAFIL	MIRODENAFIL	CCCOC1=C(C=C(C=C1)S(=O)(=O)N2CCN(CCO)CC2)C3=NC4=C(N(CC)C=C4CCC)C(=O)N3	PLASMA	504G362H0H									∞	ng × h/mL	931.4		ng/mL	373.4			RECOMMENDED	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20110038/	Homo sapiens		h	1.96				19	MIRODENAFIL		false
7729	8274		ADULT	12001014|135497803	531.667	MIRODENAFIL	MIRODENAFIL	CCCOC1=C(C=C(C=C1)S(=O)(=O)N2CCN(CCO)CC2)C3=NC4=C(N(CC)C=C4CCC)C(=O)N3	PLASMA	504G362H0H									∞	ng × h/mL	0.272		ng/mL	0.135			UNKNOWN	μg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23390072/	Homo sapiens		h	1.8				4	MIRODENAFIL		false
7730	8274		ADULT	136808002	488.6	SK-3541	SK-3541		PLASMA										∞	ng × h/mL	0.184		ng/mL	0.079			UNKNOWN	μg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23390072/	Homo sapiens		h	2.44				4	MIRODENAFIL		false
7731	8274		ADULT	136808002	488.6	SK-3541	SK-3541		PLASMA										∞	ng × h/mL	514		ng/mL	122			RECOMMENDED	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23390072/	Homo sapiens		h	3.39				6	MIRODENAFIL		false
7732	8274		ADULT	12001014|135497803	531.667	MIRODENAFIL	MIRODENAFIL	CCCOC1=C(C=C(C=C1)S(=O)(=O)N2CCN(CCO)CC2)C3=NC4=C(N(CC)C=C4CCC)C(=O)N3	PLASMA	504G362H0H									∞	ng × h/mL	888		ng/mL	404			RECOMMENDED	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23390072/	Homo sapiens		h	1.32				6	MIRODENAFIL		false
7733	8274		ADULT	12001014|135497803	531.667	MIRODENAFIL	MIRODENAFIL	CCCOC1=C(C=C(C=C1)S(=O)(=O)N2CCN(CCO)CC2)C3=NC4=C(N(CC)C=C4CCC)C(=O)N3	PLASMA	504G362H0H									∞	ng × h/mL	976.5		ng/mL	331.1			RECOMMENDED	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.scirp.org/pdf/PP_2014012316183810.pdf	Homo sapiens		h	1.81				17	MIRODENAFIL		false
7734	8276		ADULT	74089869|76550146	1793.101	[NO STEREO] ORITAVANCIN	CC1C(C(CC(O1)OC2C3C(=O)NC(C4=C(C(=CC(=C4)O)O)C5=C(C=CC(=C5)C(C(=O)N3)NC(=O)C6C7=CC(=C(C(=C7)OC8=C(C=C2C=C8)Cl)OC9C(C(C(C(O9)CO)O)O)OC1CC(C(C(O1)C)O)(C)NCC1=CC=C(C=C1)C1=CC=C(C=C1)Cl)OC1=C(C=C(C=C1)C(C(C(=O)NC(C(=O)N6)CC(=O)N)NC(=O)C(CC(C)C)NC)O)Cl)O)C(=O)O)(C)N)O	CNC(CC(C)C)C(=O)NC1C(O)C2=CC(Cl)=C(OC3=C(OC4OC(CO)C(O)C(O)C4OC5CC(C)(NCC6=CC=C(C=C6)C7=CC=C(Cl)C=C7)C(O)C(C)O5)C8=CC(=C3)C(NC(=O)C(CC(N)=O)NC1=O)C(=O)NC9C%10=CC(=C(O)C=C%10)C%11=C(C=C(O)C=C%11O)C(NC(=O)C(NC9=O)C(OC%12CC(C)(N)C(O)C(C)O%12)C%13=CC(Cl)=C(O8)C=C%13)C(O)=O)C=C2	PLASMA	[NO STEREO] PUG62FRZ2E									∞	μg × h/mL	2800		μg/mL	138			RECOMMENDED	mg	1200		SINGLE	UNKNOWN					15	UNHEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206334s000lbl.pdf	Homo sapiens		h	13.4							false
7735	8278		UNKNOWN	16063245	530.5038	RADOTINIB	Radotinib	CC1=CN(C=N1)C2=CC(=CC(NC(=O)C3=CC(NC4=NC(=CC=N4)C5=NC=CN=C5)=C(C)C=C3)=C2)C(F)(F)F	PLASMA	I284LJY110													ng/mL	250			UNKNOWN	mg	400		MULTIPLE	UNKNOWN		day	2			UNKNOWN	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32095473/	Homo sapiens										false
7736	8279		ADULT	204104	362.4432	REVAPRAZAN	REVAPRAZAN	CC1N(CCC2=C1C=CC=C2)C3=NC(NC4=CC=C(F)C=C4)=NC(C)=C3C	SERUM	5P184180P5							24		t	pg × h/mL	1315.4		pg/mL	93.7			RECOMMENDED	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://doi.org/10.1111/apt.16121	Homo sapiens				tablet			7	Revaprazan		false
7737	8279		ADULT	204104	362.4432	REVAPRAZAN	REVAPRAZAN	CC1N(CCC2=C1C=CC=C2)C3=NC(NC4=CC=C(F)C=C4)=NC(C)=C3C	SERUM	5P184180P5							24		t	pg × h/mL	2126.8		pg/mL	162.2			RECOMMENDED	mg	200		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://doi.org/10.1111/apt.16121	Homo sapiens				tablet for 7 days			7	Revaprazan		false
7738	8279		ADULT	204104	362.4432	REVAPRAZAN	REVAPRAZAN	CC1N(CCC2=C1C=CC=C2)C3=NC(NC4=CC=C(F)C=C4)=NC(C)=C3C	PLASMA	5P184180P5									∞	μg × h/L	3239.5		μg/L	450.8			RECOMMENDED	mg	400		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://link.springer.com/article/10.1007%2Fs10337-011-1951-4	Homo sapiens		h	12.6	tablet			6	Revaprazan		false
7739	8279		ADULT	204104	362.4432	REVAPRAZAN	REVAPRAZAN	CC1N(CCC2=C1C=CC=C2)C3=NC(NC4=CC=C(F)C=C4)=NC(C)=C3C	PLASMA	5P184180P5									∞	μg × h/L	1851.8		μg/L	271.2			RECOMMENDED	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://link.springer.com/article/10.1007%2Fs10337-011-1951-4	Homo sapiens		h	10.3	tablet			6	Revaprazan		false
7740	8279		ADULT	204104	362.4432	REVAPRAZAN	REVAPRAZAN	CC1N(CCC2=C1C=CC=C2)C3=NC(NC4=CC=C(F)C=C4)=NC(C)=C3C	PLASMA	5P184180P5									∞	ng × h/mL	2573.95		ng/mL	364.58			RECOMMENDED	mg	200		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.sciencedirect.com/science/article/abs/pii/S0149291812004316	Homo sapiens		h	2	7 days treatment			28	Revaprazan		false
7741	8279		ADULT	204104	362.4432	REVAPRAZAN	REVAPRAZAN	CC1N(CCC2=C1C=CC=C2)C3=NC(NC4=CC=C(F)C=C4)=NC(C)=C3C	PLASMA	5P184180P5									∞	ng × h/mL	2370.49		ng/mL	328.23			RECOMMENDED	mg	200		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.sciencedirect.com/science/article/abs/pii/S0149291812004316	Homo sapiens		h	2	Combination with itopride 150 mg (administered TID 50mg)			28	Revaprazan		false
7742	8283		UNKNOWN	6918584	2178.006	SUGAMMADEX SODIUM	SUGAMMADEX SODIUM	[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].O[C@@H]1[C@@H](O)[C@@H]2O[C@H]3O[C@H](CSCCC([O-])=O)[C@@H](O[C@H]4O[C@H](CSCCC([O-])=O)[C@@H](O[C@H]5O[C@H](CSCCC([O-])=O)[C@@H](O[C@H]6O[C@H](CSCCC([O-])=O)[C@@H](O[C@H]7O[C@H](CSCCC([O-])=O)[C@@H](O[C@H]8O[C@H](CSCCC([O-])=O)[C@@H](O[C@H]9O[C@H](CSCCC([O-])=O)[C@@H](O[C@H]1O[C@@H]2CSCCC([O-])=O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O	PLASMA	ERJ6X2MXV7																	UNKNOWN				UNKNOWN	UNKNOWN		UNKNOWN		Neither sugammadex nor the complex of sugammadex and rocuronium binds to plasma proteins or erythrocytes.	100	UNKNOWN	UNKNOWN	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022225s006lbl.pdf	Homo sapiens										false
7743	8285			11949652	426.578	TENELIGLIPTIN	Teneligliptin	CC1=NN(C(=C1)N2CCN(CC2)[C@@H]3CN[C@@H](C3)C(=O)N4CCSC4)C5=CC=CC=C5	PLASMA	28ZHI4CF9C																										Human plasma protein binding: 82.2% (20ng/mL), 77.6% (100ng/mL), 78.1% (500ng/mL); ultrafiltration	17.8				OTHER GOV'T	https://www.pmda.go.jp/drugs/2012/P201200070/400315000_22400AMX00728_A100_2.pdf#page=30 | https://www.pmda.go.jp/drugs/2012/P201200070/400315000_22400AMX00728_I100_2.pdf#page=35	Homo sapiens										false
7744	8285		ADULT	11949652	426.578	TENELIGLIPTIN	Teneligliptin	CC1=NN(C(=C1)N2CCN(CC2)[C@@H]3CN[C@@H](C3)C(=O)N4CCSC4)C5=CC=CC=C5	PLASMA	28ZHI4CF9C							72		t	ng × h/mL	1861.1		ng/mL	236.2			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2012/P201200070/400315000_22400AMX00728_A100_2.pdf#page=30 | https://www.pmda.go.jp/drugs/2012/P201200070/400315000_22400AMX00728_K102_2.pdf#page=18	Homo sapiens		h	27.8				14			false
7745	8285		ADULT	11949652	426.578	TENELIGLIPTIN	Teneligliptin	CC1=NN(C(=C1)N2CCN(CC2)[C@@H]3CN[C@@H](C3)C(=O)N4CCSC4)C5=CC=CC=C5	PLASMA	28ZHI4CF9C							72		t	ng × h/mL	1814.6		ng/mL	187.5			UNKNOWN	mg	20		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2012/P201200070/400315000_22400AMX00728_A100_2.pdf#page=30 | https://www.pmda.go.jp/drugs/2012/P201200070/400315000_22400AMX00728_K102_2.pdf#page=18	Homo sapiens		h	28.3				14			false
7746	8285		ADULT	11949652	426.578	TENELIGLIPTIN	Teneligliptin	CC1=NN(C(=C1)N2CCN(CC2)[C@@H]3CN[C@@H](C3)C(=O)N4CCSC4)C5=CC=CC=C5	PLASMA	28ZHI4CF9C									∞	ng × h/mL	298		ng/mL	13.9			UNKNOWN	mg	2.5		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2012/P201200070/400315000_22400AMX00728_A100_2.pdf#page=32	Homo sapiens		h	31.4				6			false
7747	8285		ADULT	11949652	426.578	TENELIGLIPTIN	Teneligliptin	CC1=NN(C(=C1)N2CCN(CC2)[C@@H]3CN[C@@H](C3)C(=O)N4CCSC4)C5=CC=CC=C5	PLASMA	28ZHI4CF9C									∞	ng × h/mL	876.9		ng/mL	77.22			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2012/P201200070/400315000_22400AMX00728_A100_2.pdf#page=32	Homo sapiens		h	25.7				6			false
7748	8285		ADULT	11949652	426.578	TENELIGLIPTIN	Teneligliptin	CC1=NN(C(=C1)N2CCN(CC2)[C@@H]3CN[C@@H](C3)C(=O)N4CCSC4)C5=CC=CC=C5	PLASMA	28ZHI4CF9C									∞	ng × h/mL	2028.9		ng/mL	187.2			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2012/P201200070/400315000_22400AMX00728_A100_2.pdf#page=32	Homo sapiens		h	24.2				6			false
7749	8285		ADULT	11949652	426.578	TENELIGLIPTIN	Teneligliptin	CC1=NN(C(=C1)N2CCN(CC2)[C@@H]3CN[C@@H](C3)C(=O)N4CCSC4)C5=CC=CC=C5	PLASMA	28ZHI4CF9C									∞	ng × h/mL	3705.1		ng/mL	382.4			UNKNOWN	mg	40		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2012/P201200070/400315000_22400AMX00728_A100_2.pdf#page=32	Homo sapiens		h	20.8				6			false
7750	8285		ADULT	11949652	426.578	TENELIGLIPTIN	Teneligliptin	CC1=NN(C(=C1)N2CCN(CC2)[C@@H]3CN[C@@H](C3)C(=O)N4CCSC4)C5=CC=CC=C5	PLASMA	28ZHI4CF9C									∞	ng × h/mL	7649.7		ng/mL	955.77			UNKNOWN	mg	80		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2012/P201200070/400315000_22400AMX00728_A100_2.pdf#page=32	Homo sapiens		h	24.8				6			false
7751	8285		ADULT	11949652	426.578	TENELIGLIPTIN	Teneligliptin	CC1=NN(C(=C1)N2CCN(CC2)[C@@H]3CN[C@@H](C3)C(=O)N4CCSC4)C5=CC=CC=C5	PLASMA	28ZHI4CF9C									∞	ng × h/mL	18180.6		ng/mL	2107.83			UNKNOWN	mg	160		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2012/P201200070/400315000_22400AMX00728_A100_2.pdf#page=32	Homo sapiens		h	23.5				6			false
7752	8285		ADULT	11949652	426.578	TENELIGLIPTIN	Teneligliptin	CC1=NN(C(=C1)N2CCN(CC2)[C@@H]3CN[C@@H](C3)C(=O)N4CCSC4)C5=CC=CC=C5	PLASMA	28ZHI4CF9C									∞	ng × h/mL	3613.5		ng/mL	420.67			UNKNOWN	mg	40		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2012/P201200070/400315000_22400AMX00728_A100_2.pdf#page=32	Homo sapiens		h	27.5		1 min before breakfast		6			false
7753	8285		ADULT	11949652	426.578	TENELIGLIPTIN	Teneligliptin	CC1=NN(C(=C1)N2CCN(CC2)[C@@H]3CN[C@@H](C3)C(=O)N4CCSC4)C5=CC=CC=C5	PLASMA	28ZHI4CF9C							24		t	ng × h/mL	1057.2		ng/mL	160.6			UNKNOWN	mg	20		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2012/P201200070/400315000_22400AMX00728_A100_2.pdf#page=33	Homo sapiens		h	25.8	Day 1	30 min before breakfast		7			false
7754	8285		ADULT	11949652	426.578	TENELIGLIPTIN	Teneligliptin	CC1=NN(C(=C1)N2CCN(CC2)[C@@H]3CN[C@@H](C3)C(=O)N4CCSC4)C5=CC=CC=C5	PLASMA	28ZHI4CF9C							24		t	ng × h/mL	1514.6		ng/mL	220.14			UNKNOWN	mg	20		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2012/P201200070/400315000_22400AMX00728_A100_2.pdf#page=33	Homo sapiens		h	30.2	Day 10 (no doses on days 2 and 3)	30 min before breakfast		7			false
7755	8285		ADULT	11949652	426.578	TENELIGLIPTIN	Teneligliptin	CC1=NN(C(=C1)N2CCN(CC2)[C@@H]3CN[C@@H](C3)C(=O)N4CCSC4)C5=CC=CC=C5	PLASMA	28ZHI4CF9C							24		t	ng × h/mL	5257.7		ng/mL	926.73			UNKNOWN	mg	80		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2012/P201200070/400315000_22400AMX00728_A100_2.pdf#page=33	Homo sapiens		h	17.6	Day 1	30 min before breakfast		7			false
7756	8285		ADULT	11949652	426.578	TENELIGLIPTIN	Teneligliptin	CC1=NN(C(=C1)N2CCN(CC2)[C@@H]3CN[C@@H](C3)C(=O)N4CCSC4)C5=CC=CC=C5	PLASMA	28ZHI4CF9C							24		t	ng × h/mL	7292.2		ng/mL	1180.9			UNKNOWN	mg	80		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2012/P201200070/400315000_22400AMX00728_A100_2.pdf#page=33	Homo sapiens		h	23.7	Day 10 (no doses on days 2 and 3)	30 min before breakfast		7			false
7757	8285		ADULT	11949652	426.578	TENELIGLIPTIN	Teneligliptin	CC1=NN(C(=C1)N2CCN(CC2)[C@@H]3CN[C@@H](C3)C(=O)N4CCSC4)C5=CC=CC=C5	PLASMA	28ZHI4CF9C							24		∞	ng × h/mL	1772.7		ng/mL	176.5			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2012/P201200070/400315000_22400AMX00728_A100_2.pdf#page=38	Homo sapiens		h	26.1		Normal renal function, 30 min before breakfast		8			false
7758	8285		ADULT	11949652	426.578	TENELIGLIPTIN	Teneligliptin	CC1=NN(C(=C1)N2CCN(CC2)[C@@H]3CN[C@@H](C3)C(=O)N4CCSC4)C5=CC=CC=C5	PLASMA	28ZHI4CF9C							24		∞	ng × h/mL	2234.2		ng/mL	208			UNKNOWN	mg	20		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2012/P201200070/400315000_22400AMX00728_A100_2.pdf#page=38	Homo sapiens		h	27.7		Mild renal impairment, 30 min before breakfast		8			false
7759	8285		ADULT	11949652	426.578	TENELIGLIPTIN	Teneligliptin	CC1=NN(C(=C1)N2CCN(CC2)[C@@H]3CN[C@@H](C3)C(=O)N4CCSC4)C5=CC=CC=C5	PLASMA	28ZHI4CF9C							24		∞	ng × h/mL	3090.3		ng/mL	203.6			UNKNOWN	mg	20		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2012/P201200070/400315000_22400AMX00728_A100_2.pdf#page=38	Homo sapiens		h	36		Moderate renal impairment, 30 min before breakfast		8			false
7760	8285		ADULT	11949652	426.578	TENELIGLIPTIN	Teneligliptin	CC1=NN(C(=C1)N2CCN(CC2)[C@@H]3CN[C@@H](C3)C(=O)N4CCSC4)C5=CC=CC=C5	PLASMA	28ZHI4CF9C							24		∞	ng × h/mL	2833.3		ng/mL	191.6			UNKNOWN	mg	20		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2012/P201200070/400315000_22400AMX00728_A100_2.pdf#page=38	Homo sapiens		h	29.8		Severe renal impairment, 30 min before breakfast		8			false
7761	8285		ADULT	11949652	426.578	TENELIGLIPTIN	Teneligliptin	CC1=NN(C(=C1)N2CCN(CC2)[C@@H]3CN[C@@H](C3)C(=O)N4CCSC4)C5=CC=CC=C5	PLASMA	28ZHI4CF9C							24		∞	ng × h/mL	2472.9		ng/mL	219			UNKNOWN	mg	20		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2012/P201200070/400315000_22400AMX00728_A100_2.pdf#page=39	Homo sapiens		h	23.6		ESRD w/hemodialysis, post-dialysis dosing		8			false
7762	8285		ADULT	11949652	426.578	TENELIGLIPTIN	Teneligliptin	CC1=NN(C(=C1)N2CCN(CC2)[C@@H]3CN[C@@H](C3)C(=O)N4CCSC4)C5=CC=CC=C5	PLASMA	28ZHI4CF9C							24		∞	ng × h/mL	2162.5		ng/mL	164.5			UNKNOWN	mg	20		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2012/P201200070/400315000_22400AMX00728_A100_2.pdf#page=39	Homo sapiens		h	22.7		ESRD w/hemodialysis, pre-dialysis dosing		8			false
7763	8285		ADULT	11949652	426.578	TENELIGLIPTIN	Teneligliptin	CC1=NN(C(=C1)N2CCN(CC2)[C@@H]3CN[C@@H](C3)C(=O)N4CCSC4)C5=CC=CC=C5	PLASMA	28ZHI4CF9C							24		∞	ng × h/mL	1843.1		ng/mL	195.8			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2012/P201200070/400315000_22400AMX00728_A100_2.pdf#page=39	Homo sapiens		h	18.3		Normal renal function 2, 30 min before breakfast		8			false
7764	8285		ADULT	11949652	426.578	TENELIGLIPTIN	Teneligliptin	CC1=NN(C(=C1)N2CCN(CC2)[C@@H]3CN[C@@H](C3)C(=O)N4CCSC4)C5=CC=CC=C5	PLASMA	28ZHI4CF9C							24		∞	ng × h/mL	1548.8		ng/mL	185.9			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2012/P201200070/400315000_22400AMX00728_A100_2.pdf#page=40	Homo sapiens		h	24.8		Normal hepatic function, 30 min before breakfast		8			false
7765	8285		ADULT	11949652	426.578	TENELIGLIPTIN	Teneligliptin	CC1=NN(C(=C1)N2CCN(CC2)[C@@H]3CN[C@@H](C3)C(=O)N4CCSC4)C5=CC=CC=C5	PLASMA	28ZHI4CF9C							24		∞	ng × h/mL	2207.9		ng/mL	229.3			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2012/P201200070/400315000_22400AMX00728_A100_2.pdf#page=40	Homo sapiens		h	27.9		Mild hepatic impairment, 30 min before breakfast		8			false
7766	8285		ADULT	11949652	426.578	TENELIGLIPTIN	Teneligliptin	CC1=NN(C(=C1)N2CCN(CC2)[C@@H]3CN[C@@H](C3)C(=O)N4CCSC4)C5=CC=CC=C5	PLASMA	28ZHI4CF9C							24		∞	ng × h/mL	2418.9		ng/mL	247.6			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2012/P201200070/400315000_22400AMX00728_A100_2.pdf#page=40	Homo sapiens		h	30.9		Moderate hepatic impairment, 30 min before breakfast		8			false
7767	8287			46908928	404.4535	TOFOGLIFLOZIN	Tofogliflozin	O.CCC1=CC=C(CC2=CC3=C(CO[C@]34O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C=C2)C=C1	PLASMA	P8DD8KX4O4																										Human plasm protein binding (equilibrium dialysis): 82.3% (0.1μg/mL), 82.6% (1μg/mL), 82.5% (10μg/mL)	17.4				OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_A100_1.pdf#page=30 | https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_I100_1.pdf#page=64	Homo sapiens										false
7768	8287		ADULT	46908928	404.4535	TOFOGLIFLOZIN	Tofogliflozin	O.CCC1=CC=C(CC2=CC3=C(CO[C@]34O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C=C2)C=C1	PLASMA	P8DD8KX4O4									∞	ng × h/mL	1820		ng/mL	394			DEFINED DAILY	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_A100_1.pdf#page=33 | https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_K101_1.pdf#page=44	Homo sapiens		h	5.7		Caucasian		6			false
7769	8287		ADULT	46908928	404.4535	TOFOGLIFLOZIN	Tofogliflozin	O.CCC1=CC=C(CC2=CC3=C(CO[C@]34O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C=C2)C=C1	PLASMA	P8DD8KX4O4									∞	ng × h/mL	7090		ng/mL	1570			UNKNOWN	mg	80		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_A100_1.pdf#page=33 | https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_K101_1.pdf#page=44	Homo sapiens		h	5.36		Caucasian		6			false
7770	8287		ADULT	46908928	404.4535	TOFOGLIFLOZIN	Tofogliflozin	O.CCC1=CC=C(CC2=CC3=C(CO[C@]34O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C=C2)C=C1	PLASMA	P8DD8KX4O4									∞	ng × h/mL	1330		ng/mL	310			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_A100_1.pdf#page=33 | https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_K101_1.pdf#page=44	Homo sapiens		h	5.71		Japanese		6			false
7771	8287		ADULT	46908928	404.4535	TOFOGLIFLOZIN	Tofogliflozin	O.CCC1=CC=C(CC2=CC3=C(CO[C@]34O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C=C2)C=C1	PLASMA	P8DD8KX4O4									∞	ng × h/mL	38100		ng/mL	6740			UNKNOWN	mg	320		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_A100_1.pdf#page=33 | https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_K101_1.pdf#page=44	Homo sapiens		h	5.53		Japanese		6			false
7772	8287		ADULT	46908928	404.4535	TOFOGLIFLOZIN	Tofogliflozin	O.CCC1=CC=C(CC2=CC3=C(CO[C@]34O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C=C2)C=C1	PLASMA	P8DD8KX4O4									∞	ng × h/mL	1040		ng/mL	220			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_A100_1.pdf#page=33 | https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_K101_1.pdf#page=44	Homo sapiens		h	6.09		Caucasian		6			false
7773	8287		ADULT	46908928	404.4535	TOFOGLIFLOZIN	Tofogliflozin	O.CCC1=CC=C(CC2=CC3=C(CO[C@]34O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C=C2)C=C1	PLASMA	P8DD8KX4O4									∞	ng × h/mL	5640		ng/mL	1210			UNKNOWN	mg	40		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_A100_1.pdf#page=33 | https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_K101_1.pdf#page=44	Homo sapiens		h	5.77		Japanese		6			false
7774	8287		ADULT	46908928	404.4535	TOFOGLIFLOZIN	Tofogliflozin	O.CCC1=CC=C(CC2=CC3=C(CO[C@]34O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C=C2)C=C1	PLASMA	P8DD8KX4O4									∞	ng × h/mL	99100		ng/mL	11900			UNKNOWN	mg	640		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_A100_1.pdf#page=33 | https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_K101_1.pdf#page=44	Homo sapiens		h	6.06		Japanese		6			false
7775	8287		ADULT	46908928	404.4535	TOFOGLIFLOZIN	Tofogliflozin	O.CCC1=CC=C(CC2=CC3=C(CO[C@]34O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C=C2)C=C1	PLASMA	P8DD8KX4O4									∞	ng × h/mL	21800		ng/mL	3710			UNKNOWN	mg	160		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_A100_1.pdf#page=33 | https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_K101_1.pdf#page=44	Homo sapiens		h	5.63		Japanese		6			false
7776	8287		ADULT	46908928	404.4535	TOFOGLIFLOZIN	Tofogliflozin	O.CCC1=CC=C(CC2=CC3=C(CO[C@]34O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C=C2)C=C1	PLASMA	P8DD8KX4O4									∞	ng × h/mL	8830		ng/mL	1930			UNKNOWN	mg	80		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_A100_1.pdf#page=33 | https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_K101_1.pdf#page=44	Homo sapiens		h	5.73		Japanese		6			false
7777	8287		ADULT	46908928	404.4535	TOFOGLIFLOZIN	Tofogliflozin	O.CCC1=CC=C(CC2=CC3=C(CO[C@]34O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C=C2)C=C1	PLASMA	P8DD8KX4O4									∞	ng × h/mL	1900		ng/mL	506			DEFINED DAILY	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_A100_1.pdf#page=33 | https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_K101_1.pdf#page=44	Homo sapiens		h	5.29		Japanese		6			false
7778	8287		ADULT	46908928	404.4535	TOFOGLIFLOZIN	Tofogliflozin	O.CCC1=CC=C(CC2=CC3=C(CO[C@]34O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C=C2)C=C1	PLASMA	P8DD8KX4O4							24		t	ng × h/mL	192		ng/mL	59.9			UNKNOWN	mg	2.5		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_A100_1.pdf#page=35 | https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_K101_1.pdf#page=72	Homo sapiens		h	4.35	Day 7	Administered 15 min before meal		6			false
7779	8287		ADULT	46908928	404.4535	TOFOGLIFLOZIN	Tofogliflozin	O.CCC1=CC=C(CC2=CC3=C(CO[C@]34O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C=C2)C=C1	PLASMA	P8DD8KX4O4							24		t	ng × h/mL	6740		ng/mL	1660			UNKNOWN	mg	80		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_A100_1.pdf#page=35 | https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_K101_1.pdf#page=72	Homo sapiens		h	17	Day 7	Administered 15 min before meal		6			false
7780	8287		ADULT	46908928	404.4535	TOFOGLIFLOZIN	Tofogliflozin	O.CCC1=CC=C(CC2=CC3=C(CO[C@]34O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C=C2)C=C1	PLASMA	P8DD8KX4O4							24		t	ng × h/mL	1550		ng/mL	391			UNKNOWN	mg	20		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_A100_1.pdf#page=35 | https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_K101_1.pdf#page=72	Homo sapiens		h	7.64	Day 7	Administered 15 min before meal		6			false
7781	8287		ADULT	46908928	404.4535	TOFOGLIFLOZIN	Tofogliflozin	O.CCC1=CC=C(CC2=CC3=C(CO[C@]34O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C=C2)C=C1	PLASMA	P8DD8KX4O4							24		t	ng × h/mL	1680		ng/mL	484			UNKNOWN	mg	20		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_A100_1.pdf#page=35 | https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_K101_1.pdf#page=72	Homo sapiens		h	4.14	Day 1	Administered 15 min before meal		6			false
7782	8287		ADULT	46908928	404.4535	TOFOGLIFLOZIN	Tofogliflozin	O.CCC1=CC=C(CC2=CC3=C(CO[C@]34O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C=C2)C=C1	PLASMA	P8DD8KX4O4							24		t	ng × h/mL	204		ng/mL	69.3			UNKNOWN	mg	2.5		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_A100_1.pdf#page=35 | https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_K101_1.pdf#page=72	Homo sapiens		h	4.37	Day 1	Administered 15 min before meal		6			false
7783	8287		ADULT	46908928	404.4535	TOFOGLIFLOZIN	Tofogliflozin	O.CCC1=CC=C(CC2=CC3=C(CO[C@]34O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C=C2)C=C1	PLASMA	P8DD8KX4O4							24		t	ng × h/mL	7240		ng/mL	1810			UNKNOWN	mg	80		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_A100_1.pdf#page=35 | https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_K101_1.pdf#page=72	Homo sapiens		h	4.07	Day 1	Administered 15 min before meal		6			false
7784	8287		ADULT	46908928	404.4535	TOFOGLIFLOZIN	Tofogliflozin	O.CCC1=CC=C(CC2=CC3=C(CO[C@]34O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C=C2)C=C1	PLASMA	P8DD8KX4O4							24		t	ng × h/mL	184		ng/mL	35.6			UNKNOWN	mg	2.5		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_A100_1.pdf#page=37 | https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_K101_1.pdf#page=415	Homo sapiens		h	4.71	Day 1	Administrated 15 min before meal		8			false
7785	8287		ADULT	46908928	404.4535	TOFOGLIFLOZIN	Tofogliflozin	O.CCC1=CC=C(CC2=CC3=C(CO[C@]34O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C=C2)C=C1	PLASMA	P8DD8KX4O4							24		t	ng × h/mL	179		ng/mL	36.7			UNKNOWN	mg	2.5		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_A100_1.pdf#page=37 | https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_K101_1.pdf#page=415	Homo sapiens		h	5.08	Day 14	Administrated 15 min before meal		8			false
7786	8287		ADULT	46908928	404.4535	TOFOGLIFLOZIN	Tofogliflozin	O.CCC1=CC=C(CC2=CC3=C(CO[C@]34O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C=C2)C=C1	PLASMA	P8DD8KX4O4							24		t	ng × h/mL	380		ng/mL	89.4			UNKNOWN	mg	5		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_A100_1.pdf#page=37 | https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_K101_1.pdf#page=415	Homo sapiens		h	5.19	Day 1	Administrated 15 min before meal		8			false
7787	8287		ADULT	46908928	404.4535	TOFOGLIFLOZIN	Tofogliflozin	O.CCC1=CC=C(CC2=CC3=C(CO[C@]34O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C=C2)C=C1	PLASMA	P8DD8KX4O4							24		t	ng × h/mL	387		ng/mL	77			UNKNOWN	mg	5		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_A100_1.pdf#page=37 | https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_K101_1.pdf#page=415	Homo sapiens		h	4.8	Day 14	Administrated 15 min before meal		7			false
7788	8287		ADULT	46908928	404.4535	TOFOGLIFLOZIN	Tofogliflozin	O.CCC1=CC=C(CC2=CC3=C(CO[C@]34O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C=C2)C=C1	PLASMA	P8DD8KX4O4							24		t	ng × h/mL	4740		ng/mL	1000			DEFINED DAILY	mg	60		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_A100_1.pdf#page=38 | https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_K101_1.pdf#page=415	Homo sapiens		h	4.44	Day 14	Administrated 15 min before meal		7			false
7789	8287		ADULT	46908928	404.4535	TOFOGLIFLOZIN	Tofogliflozin	O.CCC1=CC=C(CC2=CC3=C(CO[C@]34O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C=C2)C=C1	PLASMA	P8DD8KX4O4							24		t	ng × h/mL	1380		ng/mL	340			DEFINED DAILY	mg	20		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_A100_1.pdf#page=38 | https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_K101_1.pdf#page=415	Homo sapiens		h	4.34	Day 14	Administrated 15 min before meal		8			false
7790	8287		ADULT	46908928	404.4535	TOFOGLIFLOZIN	Tofogliflozin	O.CCC1=CC=C(CC2=CC3=C(CO[C@]34O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C=C2)C=C1	PLASMA	P8DD8KX4O4							24		t	ng × h/mL	1500		ng/mL	355			DEFINED DAILY	mg	20		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_A100_1.pdf#page=38 | https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_K101_1.pdf#page=415	Homo sapiens		h	4.75	Day 1	Administrated 15 min before meal		8			false
7791	8287		ADULT	46908928	404.4535	TOFOGLIFLOZIN	Tofogliflozin	O.CCC1=CC=C(CC2=CC3=C(CO[C@]34O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C=C2)C=C1	PLASMA	P8DD8KX4O4							24		t	ng × h/mL	4620		ng/mL	939			DEFINED DAILY	mg	60		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_A100_1.pdf#page=38 | https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_K101_1.pdf#page=415	Homo sapiens		h	4.74	Day 1	Administrated 15 min before meal		8			false
7792	8287		ADULT	46908928	404.4535	TOFOGLIFLOZIN	Tofogliflozin	O.CCC1=CC=C(CC2=CC3=C(CO[C@]34O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C=C2)C=C1	PLASMA	P8DD8KX4O4							24		t	ng × h/mL	10900		ng/mL	2030			DEFINED DAILY	mg	120		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_A100_1.pdf#page=38 | https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_K101_1.pdf#page=415	Homo sapiens		h	4.98	Day 1	Administrated 15 min before meal		8			false
7793	8287		ADULT	46908928	404.4535	TOFOGLIFLOZIN	Tofogliflozin	O.CCC1=CC=C(CC2=CC3=C(CO[C@]34O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C=C2)C=C1	PLASMA	P8DD8KX4O4							24		t	ng × h/mL	9690		ng/mL	1610			DEFINED DAILY	mg	120		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_A100_1.pdf#page=38 | https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_K101_1.pdf#page=415	Homo sapiens		h	4.75	Day 14	Administrated 15 min before meal		8			false
7794	8287		ADULT	46908928	404.4535	TOFOGLIFLOZIN	Tofogliflozin	O.CCC1=CC=C(CC2=CC3=C(CO[C@]34O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C=C2)C=C1	PLASMA	P8DD8KX4O4									∞	ng × h/mL	1970		ng/mL	360			DEFINED DAILY	mg	20		SINGLE	UNKNOWN				equilibrium dialysis	19.7	UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_A100_1.pdf#page=40 | https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_A100_1.pdf#page=41 | https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_K101_1.pdf#page=420	Homo sapiens		h	6.52		Type-2 diabetes parients with severe renal impairment		8			false
7795	8287		ADULT	46908928	404.4535	TOFOGLIFLOZIN	Tofogliflozin	O.CCC1=CC=C(CC2=CC3=C(CO[C@]34O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C=C2)C=C1	PLASMA	P8DD8KX4O4									∞	ng × h/mL	2040		ng/mL	399			DEFINED DAILY	mg	20		SINGLE	UNKNOWN				equilibrium dialysis	15.6	UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_A100_1.pdf#page=40 | https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_A100_1.pdf#page=41 | https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_K101_1.pdf#page=420	Homo sapiens		h	6.06		Type-2 diabetes parients with moderate renal impairment		9			false
7796	8287		ADULT	46908928	404.4535	TOFOGLIFLOZIN	Tofogliflozin	O.CCC1=CC=C(CC2=CC3=C(CO[C@]34O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C=C2)C=C1	PLASMA	P8DD8KX4O4									∞	ng × h/mL	2070		ng/mL	391			DEFINED DAILY	mg	20		SINGLE	UNKNOWN				equilibrium dialysis	15.1	UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_A100_1.pdf#page=40 | https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_A100_1.pdf#page=41 | https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_K101_1.pdf#page=420	Homo sapiens		h	5.65		Type-2 diabetes parients with mild renal impairment		8			false
7797	8287		ADULT	46908928	404.4535	TOFOGLIFLOZIN	Tofogliflozin	O.CCC1=CC=C(CC2=CC3=C(CO[C@]34O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C=C2)C=C1	PLASMA	P8DD8KX4O4									∞	ng × h/mL	1740		ng/mL	410			DEFINED DAILY	mg	20		SINGLE	UNKNOWN				equilibrium dialysis	16.9	UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_A100_1.pdf#page=40 | https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_A100_1.pdf#page=41 | https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_K101_1.pdf#page=420	Homo sapiens		h	6.21		Type-2 diabetes parients with normal renal function		11			false
7798	8287		ADULT	46908928	404.4535	TOFOGLIFLOZIN	Tofogliflozin	O.CCC1=CC=C(CC2=CC3=C(CO[C@]34O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C=C2)C=C1	PLASMA	P8DD8KX4O4									∞	ng × h/mL	6720		ng/mL	1230			UNKNOWN	mg	40		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_A100_1.pdf#page=42 | https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_K101_1.pdf#page=89	Homo sapiens		h	9.01		Administered 15 min before meal		9			false
7799	8287		ADULT	46908928	404.4535	TOFOGLIFLOZIN	Tofogliflozin	O.CCC1=CC=C(CC2=CC3=C(CO[C@]34O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C=C2)C=C1	PLASMA	P8DD8KX4O4									∞	ng × h/mL	3830		ng/mL	846			UNKNOWN	mg	40		SINGLE	UNKNOWN						UNHEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_A100_1.pdf#page=42 | https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_K101_1.pdf#page=89	Homo sapiens		h	11.5		Administered 15 min before meal		8			false
7800	8287		ADULT	46908928	404.4535	TOFOGLIFLOZIN	Tofogliflozin	O.CCC1=CC=C(CC2=CC3=C(CO[C@]34O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C=C2)C=C1	PLASMA	P8DD8KX4O4									∞	ng × h/mL	3730		ng/mL	1050			DEFINED DAILY	mg	40		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_K101_1.pdf#page=20 | https://www.info.pmda.go.jp/go/interview/2/270072_3969021F1024_2_002_1F.pdf#page=49	Homo sapiens		h	5.65		Administered 15 min before meal		14			false
7801	8287		ADULT	46908928	404.4535	TOFOGLIFLOZIN	Tofogliflozin	O.CCC1=CC=C(CC2=CC3=C(CO[C@]34O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C=C2)C=C1	PLASMA	P8DD8KX4O4									∞	ng × h/mL	1890		ng/mL	444			DEFINED DAILY	mg	20		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_K101_1.pdf#page=20 | https://www.info.pmda.go.jp/go/interview/2/270072_3969021F1024_2_002_1F.pdf#page=49	Homo sapiens		h	5.65		Administered 15 min before meal		15			false
7802	8287		ADULT	46908928	404.4535	TOFOGLIFLOZIN	Tofogliflozin	O.CCC1=CC=C(CC2=CC3=C(CO[C@]34O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C=C2)C=C1	PLASMA	P8DD8KX4O4									∞	ng × h/mL	4190		ng/mL	1020			DEFINED DAILY	mg	40		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_K101_1.pdf#page=20 | https://www.info.pmda.go.jp/go/interview/2/270072_3969021F1024_2_002_1F.pdf#page=49	Homo sapiens		h	5.39				15			false
7803	8287		ADULT	46908928	404.4535	TOFOGLIFLOZIN	Tofogliflozin	O.CCC1=CC=C(CC2=CC3=C(CO[C@]34O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C=C2)C=C1	PLASMA	P8DD8KX4O4									∞	ng × h/mL	2140		ng/mL	509			DEFINED DAILY	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_K101_1.pdf#page=20 | https://www.info.pmda.go.jp/go/interview/2/270072_3969021F1024_2_002_1F.pdf#page=49	Homo sapiens		h	5.4				15			false
7804	8287		ADULT	46908928	404.4535	TOFOGLIFLOZIN	Tofogliflozin	O.CCC1=CC=C(CC2=CC3=C(CO[C@]34O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C=C2)C=C1	PLASMA	P8DD8KX4O4									∞	ng × h/mL	1990		ng/mL	344			DEFINED DAILY	mg	20		SINGLE	HIGH-FAT						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_K101_1.pdf#page=20 | https://www.info.pmda.go.jp/go/interview/2/270072_3969021F1024_2_002_1F.pdf#page=49	Homo sapiens		h	5.82				15			false
7805	8287		ADULT	46908928	404.4535	TOFOGLIFLOZIN	Tofogliflozin	O.CCC1=CC=C(CC2=CC3=C(CO[C@]34O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C=C2)C=C1	PLASMA	P8DD8KX4O4									∞	ng × h/mL	3690		ng/mL	742			DEFINED DAILY	mg	40		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400036/780069000_22600AMX00549_K101_1.pdf#page=20 | https://www.info.pmda.go.jp/go/interview/2/270072_3969021F1024_2_002_1F.pdf#page=49	Homo sapiens		h	5.48				14			false
7806	8291			9930049	349.4644	VERNAKALANT	Vernakalant	COC1=C(OC)C=C(CCO[C@@H]2CCCC[C@H]2N3CC[C@@H](O)C3)C=C1	PLASMA	9G468C8B13																										Human plasma protein binding: 53~63%	37				REVIEW	https://journals.sagepub.com/doi/full/10.4137/CMT.S1079	Homo sapiens										false
7807	8291		ADULT	9930049	349.4644	VERNAKALANT	Vernakalant	COC1=C(OC)C=C(CCO[C@@H]2CCCC[C@H]2N3CC[C@@H](O)C3)C=C1	PLASMA	9G468C8B13									∞	μg × h/mL	10.24		μg/mL	5.84			UNKNOWN	mg/kg	2		MULTIPLE	UNKNOWN		hour	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18927241/	Homo sapiens		h	2.9	2 mg/kg (10min infusion) and subsequent 3 mg/kg (after 30min observation)	CYP2D6 EMs, Atrial fibrillation patients		8			false
7808	8291		ADULT	9930049	349.4644	VERNAKALANT	Vernakalant	COC1=C(OC)C=C(CCO[C@@H]2CCCC[C@H]2N3CC[C@@H](O)C3)C=C1	PLASMA	9G468C8B13									∞	μg × h/mL	0.171		μg/mL	0.083			UNKNOWN	mg/kg	0.1		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18927241/	Homo sapiens		h	2.6		CYP2D6 EM		1			false
7809	8291		ADULT	9930049	349.4644	VERNAKALANT	Vernakalant	COC1=C(OC)C=C(CCO[C@@H]2CCCC[C@H]2N3CC[C@@H](O)C3)C=C1	PLASMA	9G468C8B13									∞	μg × h/mL	0.686		μg/mL	0.316			UNKNOWN	mg/kg	0.5		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18927241/	Homo sapiens		h	1.7		CYP2D6 EMs		4			false
7810	8291		ADULT	9930049	349.4644	VERNAKALANT	Vernakalant	COC1=C(OC)C=C(CCO[C@@H]2CCCC[C@H]2N3CC[C@@H](O)C3)C=C1	PLASMA	9G468C8B13									∞	μg × h/mL	1.48		μg/mL	0.715			UNKNOWN	mg/kg	1		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18927241/	Homo sapiens		h	1.6		CYP2D6 EMs		4			false
7811	8291		ADULT	9930049	349.4644	VERNAKALANT	Vernakalant	COC1=C(OC)C=C(CCO[C@@H]2CCCC[C@H]2N3CC[C@@H](O)C3)C=C1	PLASMA	9G468C8B13									∞	μg × h/mL	2.7		μg/mL	1.14			UNKNOWN	mg/kg	2		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18927241/	Homo sapiens		h	1.7		CYP2D6 EMs		4			false
7812	8291		ADULT	9930049	349.4644	VERNAKALANT	Vernakalant	COC1=C(OC)C=C(CCO[C@@H]2CCCC[C@H]2N3CC[C@@H](O)C3)C=C1	PLASMA	9G468C8B13									∞	μg × h/mL	8.05		μg/mL	2.04			UNKNOWN	mg/kg	4		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18927241/	Homo sapiens		h	2.2		2 extensive metabolizers (CYP2D6)		3			false
7813	8291		ADULT	9930049	349.4644	VERNAKALANT	Vernakalant	COC1=C(OC)C=C(CCO[C@@H]2CCCC[C@H]2N3CC[C@@H](O)C3)C=C1	PLASMA	9G468C8B13									∞	μg × h/mL	8.1		μg/mL	2.85			UNKNOWN	mg/kg	5		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18927241/	Homo sapiens		h	2.2		CYP2D6 EMs		4			false
7814	8291		ADULT	9930049	349.4644	VERNAKALANT	Vernakalant	COC1=C(OC)C=C(CCO[C@@H]2CCCC[C@H]2N3CC[C@@H](O)C3)C=C1	PLASMA	9G468C8B13									∞	μg × h/mL	9.98		μg/mL	2.19			UNKNOWN	mg/kg	4		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18927241/	Homo sapiens		h	2.6		3 extensive metabolizers and one poor metabolizer (CYP2D6)		4			false
7815	8291		ADULT	9930049	349.4644	VERNAKALANT	Vernakalant	COC1=C(OC)C=C(CCO[C@@H]2CCCC[C@H]2N3CC[C@@H](O)C3)C=C1	PLASMA	9G468C8B13									∞	μg × h/mL	0.351		μg/mL	0.145			UNKNOWN	mg/kg	0.25		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18927241/	Homo sapiens		h	1.8		CYP2D6 EM		1			false
7816	8291		ADULT	9930049	349.4644	VERNAKALANT	Vernakalant	COC1=C(OC)C=C(CCO[C@@H]2CCCC[C@H]2N3CC[C@@H](O)C3)C=C1	PLASMA	9G468C8B13									∞	μg × h/mL	15.44		μg/mL	1.86			UNKNOWN	mg/kg	0.5		MULTIPLE	UNKNOWN		hour	1			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18927241/	Homo sapiens		h	8.5	0.5 mg/kg (10min infusion) and subsequent 1 mg/kg (after 30min observation)	CYP2D6 (*4/*4) PMs, Atrial fibrillation patients		2			false
7817	8291		ADULT	9930049	349.4644	VERNAKALANT	Vernakalant	COC1=C(OC)C=C(CCO[C@@H]2CCCC[C@H]2N3CC[C@@H](O)C3)C=C1	PLASMA	9G468C8B13									∞	μg × h/mL	5.37		μg/mL	1.87			UNKNOWN	mg/kg	0.5		MULTIPLE	UNKNOWN		hour	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18927241/	Homo sapiens		h	3.9	0.5 mg/kg (10min infusion) and subsequent 1 mg/kg (after 30min observation)	All patients, Atrial fibrillation patients		17			false
7818	8291		ADULT	9930049	349.4644	VERNAKALANT	Vernakalant	COC1=C(OC)C=C(CCO[C@@H]2CCCC[C@H]2N3CC[C@@H](O)C3)C=C1	PLASMA	9G468C8B13									∞	μg × h/mL	9.69		μg/mL	5.5			UNKNOWN	mg/kg	2		MULTIPLE	UNKNOWN		hour	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18927241/	Homo sapiens		h	2.7	2 mg/kg (10min infusion) and subsequent 3 mg/kg (after 30min observation)	All patients, Atrial fibrillation patients		10			false
7819	8291		ADULT	9930049	349.4644	VERNAKALANT	Vernakalant	COC1=C(OC)C=C(CCO[C@@H]2CCCC[C@H]2N3CC[C@@H](O)C3)C=C1	PLASMA	9G468C8B13							1.5		t	μg × h/mL	4.58		μg/mL	4.96			UNKNOWN	mg/kg	3		MULTIPLE	UNKNOWN		hour	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18927241/	Homo sapiens				3 mg/kg (10min infusion) and subsequent 2 mg/kg (after 15min observation)	Patients with typical AFL and dysrhythmic symptoms lasting more than 3 hours but no more than 45 days		32			false
7820	8291		ADULT	9930049	349.4644	VERNAKALANT	Vernakalant	COC1=C(OC)C=C(CCO[C@@H]2CCCC[C@H]2N3CC[C@@H](O)C3)C=C1	PLASMA	9G468C8B13									∞	μg × h/mL	4.29		μg/mL	2.6			UNKNOWN	mg/kg	2		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18927241/	Homo sapiens		h	2.6	2 mg/kg (10min infusion)	All patients, Atrial fibrillation patients		7			false
7821	8291		ADULT	9930049	349.4644	VERNAKALANT	Vernakalant	COC1=C(OC)C=C(CCO[C@@H]2CCCC[C@H]2N3CC[C@@H](O)C3)C=C1	PLASMA	9G468C8B13							1.5		t	μg × h/mL	2.09		μg/mL	2.98			UNKNOWN	mg/kg	3		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18927241/	Homo sapiens				3 mg/kg (10min infusion)	Patients with typical AFL and dysrhythmic symptoms lasting more than 3 hours but no more than 45 days		4			false
7822	8291		ADULT	9930049	349.4644	VERNAKALANT	Vernakalant	COC1=C(OC)C=C(CCO[C@@H]2CCCC[C@H]2N3CC[C@@H](O)C3)C=C1	PLASMA	9G468C8B13									∞	μg × h/mL	0.2		μg/mL	0.307			UNKNOWN	mg/kg	0.5		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18927241/	Homo sapiens		h	4.4		CYP2D6 EM, Atrial fibrillation patients		1			false
7823	8291		ADULT	9930049	349.4644	VERNAKALANT	Vernakalant	COC1=C(OC)C=C(CCO[C@@H]2CCCC[C@H]2N3CC[C@@H](O)C3)C=C1	PLASMA	9G468C8B13									∞	μg × h/mL	3.53		μg/mL	2.71			UNKNOWN	mg/kg	2		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18927241/	Homo sapiens		h	2.4	2 mg/kg (10min infusion)	CYP2D6 EMs, Atrial fibrillation patients		5			false
7824	8291		ADULT	9930049	349.4644	VERNAKALANT	Vernakalant	COC1=C(OC)C=C(CCO[C@@H]2CCCC[C@H]2N3CC[C@@H](O)C3)C=C1	PLASMA	9G468C8B13									∞	μg × h/mL	2.88		μg/mL	1.81			UNKNOWN	mg/kg	0.5		MULTIPLE	UNKNOWN		hour	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18927241/	Homo sapiens		h	2.7	0.5 mg/kg (10min infusion) and subsequent 1 mg/kg (after 30min observation)	CYP2D6 EMs, Atrial fibrillation patients		10			false
7825	8291		ADULT	9930049	349.4644	VERNAKALANT	Vernakalant	COC1=C(OC)C=C(CCO[C@@H]2CCCC[C@H]2N3CC[C@@H](O)C3)C=C1	PLASMA	9G468C8B13							1.5		t	μg × h/mL	2.52		μg/mL	4.25			UNKNOWN	mg/kg	3		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18927241/	Homo sapiens				3 mg/kg (10min infusion)	Patients with AF or nontypical forms of AFL and dysrhythmic symptoms were stratified by AF duration (>3 hours but ≤7 days or 8 days to ≤45 days)		60			false
7826	8291		ADULT	9930049	349.4644	VERNAKALANT	Vernakalant	COC1=C(OC)C=C(CCO[C@@H]2CCCC[C@H]2N3CC[C@@H](O)C3)C=C1	PLASMA	9G468C8B13							1.5		t	μg × h/mL	2.52		μg/mL	4.25			UNKNOWN	mg/kg	3		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18927241/	Homo sapiens				3 mg/kg (10min infusion)	Patients with AF or nontypical forms of AFL and dysrhythmic symptoms were stratified by AF duration (>3 hours but ≤7 days or 8 days to ≤45 days)		60			false
7827	8291		ADULT	9930049	349.4644	VERNAKALANT	Vernakalant	COC1=C(OC)C=C(CCO[C@@H]2CCCC[C@H]2N3CC[C@@H](O)C3)C=C1	PLASMA	9G468C8B13							1.5		t	μg × h/mL	4.08		μg/mL	4.81			UNKNOWN	mg/kg	3		MULTIPLE	UNKNOWN		hour	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18927241/	Homo sapiens				3 mg/kg (10min infusion) and subsequent 2 mg/kg (after 15min observation)	Patients with AF or nontypical forms of AFL and dysrhythmic symptoms were stratified by AF duration (>3 hours but ≤7 days or 8 days to ≤45 days)		140			false
7828	8292		ADULT	15981397	345.391	VONOPRAZAN	Vonoprazan	CNCC1=CN(C(=C1)C2=C(F)C=CC=C2)S(=O)(=O)C3=CN=CC=C3	PLASMA	1R5L3J156G							24		t	ng × h/mL	112.4		ng/mL	18.1			UNKNOWN	mg	15		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25707624/	Homo sapiens		h	6	Day 7	Japanese		9			false
7829	8292		ADULT	15981397	345.391	VONOPRAZAN	Vonoprazan	CNCC1=CN(C(=C1)C2=C(F)C=CC=C2)S(=O)(=O)C3=CN=CC=C3	PLASMA	1R5L3J156G							24		t	ng × h/mL	121.6		ng/mL	19.5			UNKNOWN	mg	20		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25707624/	Homo sapiens		h	5.8	Day 1	Japanese		9			false
7830	8292		ADULT	15981397	345.391	VONOPRAZAN	Vonoprazan	CNCC1=CN(C(=C1)C2=C(F)C=CC=C2)S(=O)(=O)C3=CN=CC=C3	PLASMA	1R5L3J156G							24		t	ng × h/mL	177.1		ng/mL	26.2			UNKNOWN	mg	20		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25707624/	Homo sapiens		h	6.9	Day 1	non-Japanese		9			false
7831	8292		ADULT	15981397	345.391	VONOPRAZAN	Vonoprazan	CNCC1=CN(C(=C1)C2=C(F)C=CC=C2)S(=O)(=O)C3=CN=CC=C3	PLASMA	1R5L3J156G							24		t	ng × h/mL	195.7		ng/mL	26.2			UNKNOWN	mg	20		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25707624/	Homo sapiens		h	8.6	Day 7	non-Japanese		9			false
7832	8292		ADULT	15981397	345.391	VONOPRAZAN	Vonoprazan	CNCC1=CN(C(=C1)C2=C(F)C=CC=C2)S(=O)(=O)C3=CN=CC=C3	PLASMA	1R5L3J156G							24		t	ng × h/mL	151.6		ng/mL	23.3			UNKNOWN	mg	20		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25707624/	Homo sapiens		h	6.1	Day 7	Japanese		9			false
7833	8292		ADULT	15981397	345.391	VONOPRAZAN	Vonoprazan	CNCC1=CN(C(=C1)C2=C(F)C=CC=C2)S(=O)(=O)C3=CN=CC=C3	PLASMA	1R5L3J156G							24		t	ng × h/mL	255.5		ng/mL	37.2			UNKNOWN	mg	30		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25707624/	Homo sapiens		h	6.1	Day 1	non-Japanese		9			false
7834	8292		ADULT	15981397	345.391	VONOPRAZAN	Vonoprazan	CNCC1=CN(C(=C1)C2=C(F)C=CC=C2)S(=O)(=O)C3=CN=CC=C3	PLASMA	1R5L3J156G							24		t	ng × h/mL	231.3		ng/mL	38.8			UNKNOWN	mg	30		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25707624/	Homo sapiens		h	5.7	Day 1	Japanese		9			false
7835	8292		ADULT	15981397	345.391	VONOPRAZAN	Vonoprazan	CNCC1=CN(C(=C1)C2=C(F)C=CC=C2)S(=O)(=O)C3=CN=CC=C3	PLASMA	1R5L3J156G							24		t	ng × h/mL	338.5		ng/mL	41.6			UNKNOWN	mg	30		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25707624/	Homo sapiens		h	8.8	Day 7	non-Japanese		9			false
7836	8292		ADULT	15981397	345.391	VONOPRAZAN	Vonoprazan	CNCC1=CN(C(=C1)C2=C(F)C=CC=C2)S(=O)(=O)C3=CN=CC=C3	PLASMA	1R5L3J156G							24		t	ng × h/mL	291.2		ng/mL	48.6			UNKNOWN	mg	30		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25707624/	Homo sapiens		h	5.8	Day 7	Japanese		9			false
7837	8292		ADULT	15981397	345.391	VONOPRAZAN	Vonoprazan	CNCC1=CN(C(=C1)C2=C(F)C=CC=C2)S(=O)(=O)C3=CN=CC=C3	PLASMA	1R5L3J156G							24		t	ng × h/mL	420.8		ng/mL	58.5			UNKNOWN	mg	40		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25707624/	Homo sapiens		h	6.3	Day 1	non-Japanese		9			false
7838	8292		ADULT	15981397	345.391	VONOPRAZAN	Vonoprazan	CNCC1=CN(C(=C1)C2=C(F)C=CC=C2)S(=O)(=O)C3=CN=CC=C3	PLASMA	1R5L3J156G							24		t	ng × h/mL	61.6		ng/mL	10.1			UNKNOWN	mg	10		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25707624/	Homo sapiens		h	7	Day 1	Japanese		9			false
7839	8292		ADULT	15981397	345.391	VONOPRAZAN	Vonoprazan	CNCC1=CN(C(=C1)C2=C(F)C=CC=C2)S(=O)(=O)C3=CN=CC=C3	PLASMA	1R5L3J156G							24		t	ng × h/mL	488.4		ng/mL	59.9			UNKNOWN	mg	40		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25707624/	Homo sapiens		h	8.2	Day 7	non-Japanese		9			false
7840	8292		ADULT	15981397	345.391	VONOPRAZAN	Vonoprazan	CNCC1=CN(C(=C1)C2=C(F)C=CC=C2)S(=O)(=O)C3=CN=CC=C3	PLASMA	1R5L3J156G							24		t	ng × h/mL	391.6		ng/mL	62			UNKNOWN	mg	40		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25707624/	Homo sapiens		h	6.7	Day 1	Japanese		9			false
7841	8292		ADULT	15981397	345.391	VONOPRAZAN	Vonoprazan	CNCC1=CN(C(=C1)C2=C(F)C=CC=C2)S(=O)(=O)C3=CN=CC=C3	PLASMA	1R5L3J156G							24		t	ng × h/mL	79.5		ng/mL	12			UNKNOWN	mg	10		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25707624/	Homo sapiens		h	7	Day 7	Japanese		9			false
7842	8292		ADULT	15981397	345.391	VONOPRAZAN	Vonoprazan	CNCC1=CN(C(=C1)C2=C(F)C=CC=C2)S(=O)(=O)C3=CN=CC=C3	PLASMA	1R5L3J156G							24		t	ng × h/mL	458.5		ng/mL	75.2			UNKNOWN	mg	40		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25707624/	Homo sapiens		h	6.1	Day 7	Japanese		9			false
7843	8292		ADULT	15981397	345.391	VONOPRAZAN	Vonoprazan	CNCC1=CN(C(=C1)C2=C(F)C=CC=C2)S(=O)(=O)C3=CN=CC=C3	PLASMA	1R5L3J156G							24		t	ng × h/mL	97.5		ng/mL	16.1			UNKNOWN	mg	15		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25707624/	Homo sapiens		h	5.8	Day 1	Japanese		9			false
7844	8292		ADULT	15981397	345.391	VONOPRAZAN	Vonoprazan	CNCC1=CN(C(=C1)C2=C(F)C=CC=C2)S(=O)(=O)C3=CN=CC=C3	PLASMA	1R5L3J156G							24		t	ng × h/mL	81.4		ng/mL	10.9			UNKNOWN	mg	10		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25707624/	Homo sapiens		h	7.5	Day 1	non-Japanese		9			false
7845	8292		ADULT	15981397	345.391	VONOPRAZAN	Vonoprazan	CNCC1=CN(C(=C1)C2=C(F)C=CC=C2)S(=O)(=O)C3=CN=CC=C3	PLASMA	1R5L3J156G							24		t	ng × h/mL	104.9		ng/mL	12.2			UNKNOWN	mg	10		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25707624/	Homo sapiens		h	8.8	Day 7	no-Japanese		9			false
7846	8292		ADULT	15981397	345.391	VONOPRAZAN	Vonoprazan	CNCC1=CN(C(=C1)C2=C(F)C=CC=C2)S(=O)(=O)C3=CN=CC=C3	PLASMA	1R5L3J156G									∞	ng × h/mL	4.6		ng/mL	0.4			UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26111126/	Homo sapiens		h	7.8		non-Japanese		6			false
7847	8292		ADULT	15981397	345.391	VONOPRAZAN	Vonoprazan	CNCC1=CN(C(=C1)C2=C(F)C=CC=C2)S(=O)(=O)C3=CN=CC=C3	PLASMA	1R5L3J156G									∞	ng × h/mL	33.4		ng/mL	3.9			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26111126/	Homo sapiens		h	9		non-Japanese		6			false
7848	8292		ADULT	15981397	345.391	VONOPRAZAN	Vonoprazan	CNCC1=CN(C(=C1)C2=C(F)C=CC=C2)S(=O)(=O)C3=CN=CC=C3	PLASMA	1R5L3J156G									∞	ng × h/mL	59.2		ng/mL	7.9			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26111126/	Homo sapiens		h	8.1		non-Japanese		6			false
7849	8292		ADULT	15981397	345.391	VONOPRAZAN	Vonoprazan	CNCC1=CN(C(=C1)C2=C(F)C=CC=C2)S(=O)(=O)C3=CN=CC=C3	PLASMA	1R5L3J156G									∞	ng × h/mL	4.3		ng/mL	0.7			UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26111126/	Homo sapiens		h	5.1		Japanese		5			false
7850	8292		ADULT	15981397	345.391	VONOPRAZAN	Vonoprazan	CNCC1=CN(C(=C1)C2=C(F)C=CC=C2)S(=O)(=O)C3=CN=CC=C3	PLASMA	1R5L3J156G									∞	ng × h/mL	109.6		ng/mL	14			UNKNOWN	mg	15		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26111126/	Homo sapiens		h	7.3		non-Japanese		6			false
7851	8292		ADULT	15981397	345.391	VONOPRAZAN	Vonoprazan	CNCC1=CN(C(=C1)C2=C(F)C=CC=C2)S(=O)(=O)C3=CN=CC=C3	PLASMA	1R5L3J156G									∞	ng × h/mL	31.6		ng/mL	4.2			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26111126/	Homo sapiens		h	7.6		Japanese		9			false
7852	8292		ADULT	15981397	345.391	VONOPRAZAN	Vonoprazan	CNCC1=CN(C(=C1)C2=C(F)C=CC=C2)S(=O)(=O)C3=CN=CC=C3	PLASMA	1R5L3J156G									∞	ng × h/mL	169.9		ng/mL	23			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26111126/	Homo sapiens		h	7.8		non-Japanese		6			false
7853	8292		ADULT	15981397	345.391	VONOPRAZAN	Vonoprazan	CNCC1=CN(C(=C1)C2=C(F)C=CC=C2)S(=O)(=O)C3=CN=CC=C3	PLASMA	1R5L3J156G									∞	ng × h/mL	60.8		ng/mL	9.7			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26111126/	Homo sapiens		h	6.9		Japanese		8			false
7854	8292		ADULT	15981397	345.391	VONOPRAZAN	Vonoprazan	CNCC1=CN(C(=C1)C2=C(F)C=CC=C2)S(=O)(=O)C3=CN=CC=C3	PLASMA	1R5L3J156G									∞	ng × h/mL	289.9		ng/mL	38.6			UNKNOWN	mg	30		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26111126/	Homo sapiens		h	8.1		non-Japanese		6			false
7855	8292		ADULT	15981397	345.391	VONOPRAZAN	Vonoprazan	CNCC1=CN(C(=C1)C2=C(F)C=CC=C2)S(=O)(=O)C3=CN=CC=C3	PLASMA	1R5L3J156G									∞	ng × h/mL	475.2		ng/mL	51.8			UNKNOWN	mg	40		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26111126/	Homo sapiens		h	8.4		non-Japanese		6			false
7856	8292		ADULT	15981397	345.391	VONOPRAZAN	Vonoprazan	CNCC1=CN(C(=C1)C2=C(F)C=CC=C2)S(=O)(=O)C3=CN=CC=C3	PLASMA	1R5L3J156G									∞	ng × h/mL	161.6		ng/mL	25			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26111126/	Homo sapiens		h	6.9		Japanese		7			false
7857	8292		ADULT	15981397	345.391	VONOPRAZAN	Vonoprazan	CNCC1=CN(C(=C1)C2=C(F)C=CC=C2)S(=O)(=O)C3=CN=CC=C3	PLASMA	1R5L3J156G									∞	ng × h/mL	474.6		ng/mL	71.9			UNKNOWN	mg	40		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26111126/	Homo sapiens		h	7.1		Japanese		9			false
7858	8292		ADULT	15981397	345.391	VONOPRAZAN	Vonoprazan	CNCC1=CN(C(=C1)C2=C(F)C=CC=C2)S(=O)(=O)C3=CN=CC=C3	PLASMA	1R5L3J156G									∞	ng × h/mL	911.3		ng/mL	129.8			UNKNOWN	mg	80		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26111126/	Homo sapiens		h	8.7		Japanese		7			false
7859	8292		ADULT	15981397	345.391	VONOPRAZAN	Vonoprazan	CNCC1=CN(C(=C1)C2=C(F)C=CC=C2)S(=O)(=O)C3=CN=CC=C3	PLASMA	1R5L3J156G									∞	ng × h/mL	1985		ng/mL	303.8			UNKNOWN	mg	120		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26111126/	Homo sapiens		h	6.6		Japanese		8			false
7860	8292			15981397	345.391	VONOPRAZAN	Vonoprazan	CNCC1=CN(C(=C1)C2=C(F)C=CC=C2)S(=O)(=O)C3=CN=CC=C3	PLASMA	1R5L3J156G																										The plasma protein binding of vonoprazan is 80 % in healthy subjects.	20	HEALTHY			EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26369775/	Homo sapiens										false
7861	8292			15981397	345.391	VONOPRAZAN	Vonoprazan	CNCC1=CN(C(=C1)C2=C(F)C=CC=C2)S(=O)(=O)C3=CN=CC=C3	PLASMA	1R5L3J156G																										Human plasma protein binding: 86.5% (100ng/mL), 85.1% (1000ng/mL), 88% (10000ng/mL)	12				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400256_3399103F1020_1_006_1F.pdf#page=46 | https://pubmed.ncbi.nlm.nih.gov/26369775/	Homo sapiens										false
7862	8295		ADULT	10173277	418.5	APILIMOD	APILIMOD	CC1=CC=CC(\\C=N\\NC2=NC(OCCC3=CC=CC=N3)=NC(=C2)N4CCOCC4)=C1	PLASMA	GFW2K84S4L							8		t	ng × h/mL	511		ng/mL	274			UNKNOWN	mg	100		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://assets.website-files.com/5bd270b2e599946e65c2ff05/5bd3e30af2904427b3a4e03b_LAM-Therapeutics_ASH_2017.pdf	Homo sapiens		h	3.9							false
7863	8317		ADULT	11249342	337.4	Posiphen	( )-PHENSERINE	C[C@]12CCN([C@H]1N(C3=C2C=C(C=C3)OC(=O)NC4=CC=CC=C4)C)C	PLASMA	Z0O4TJ588O									?	ng × h/mL	570		ng/mL	118.5			UNKNOWN	mg	240		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22791904	Homo sapiens							5	( )-PHENSERINE		false
7864	8317		ADULT	101714372	323.4	N8-Norposiphen		C[C@@]12CCN([C@@H]1NC3=C2C=C(C=C3)OC(=O)NC4=CC=CC=C4)C	CEREBROSPINAL FLUID														ng/mL	3.2			UNKNOWN	mg	240		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22791904	Homo sapiens							5	( )-PHENSERINE		false
7865	8317		ADULT	89286503	323.4	N1-Norposiphen		C[C@@]12CCN[C@@H]1N(C3=C2C=C(C=C3)OC(=O)NC4=CC=CC=C4)C	CEREBROSPINAL FLUID														ng/mL	1.7			UNKNOWN	mg	240		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22791904	Homo sapiens							5	( )-PHENSERINE		false
7866	8317		ADULT	89286503	323.4	N1-Norposiphen	N1-Norposiphen	C[C@@]12CCN[C@@H]1N(C3=C2C=C(C=C3)OC(=O)NC4=CC=CC=C4)C	PLASMA										?	ng × h/mL	214.4		ng/mL	25.6			UNKNOWN	mg	240		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22791904	Homo sapiens							5	( )-PHENSERINE		false
7867	8317		ADULT	11249342	337.4	Posiphen	Posiphen	C[C@]12CCN([C@H]1N(C3=C2C=C(C=C3)OC(=O)NC4=CC=CC=C4)C)C	CEREBROSPINAL FLUID	Z0O4TJ588O													ng/mL	1.6			UNKNOWN	mg	240		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22791904	Homo sapiens							5	( )-PHENSERINE		false
7868	8317		ADULT	101714372	323.4	N8-Norposiphen		C[C@@]12CCN([C@@H]1NC3=C2C=C(C=C3)OC(=O)NC4=CC=CC=C4)C	PLASMA										?	ng × h/mL	261.3		ng/mL	31			UNKNOWN	mg	240		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22791904	Homo sapiens							5	( )-PHENSERINE		false
7869	8335		ADULT	3071	246.3065	3,3'-DIINDOLYLMETHANE	3,3\'-DIINDOLYLMETHANE	C(C1=CNC2=C1C=CC=C2)C3=CNC4=C3C=CC=C4	PLASMA	SSZ9HQT61Z									?	ng × h/mL	314		ng/mL	79			UNKNOWN	mg	150		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18843002	Homo sapiens		h	3				3	BioResponse 3,3′-diindolylmethane		false
7870	8335		ADULT	3071	246.3065	3,3'-DIINDOLYLMETHANE	3,3\'-DIINDOLYLMETHANE	C(C1=CNC2=C1C=CC=C2)C3=CNC4=C3C=CC=C4	PLASMA	SSZ9HQT61Z									?	ng × h/mL	532		ng/mL	108			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18843002	Homo sapiens		h	4.5				6	BioResponse 3,3′-diindolylmethane		false
7871	8335		ADULT	3071	246.3065	3,3'-DIINDOLYLMETHANE	3,3\'-DIINDOLYLMETHANE	C(C1=CNC2=C1C=CC=C2)C3=CNC4=C3C=CC=C4	PLASMA	SSZ9HQT61Z									?	ng × h/mL	450		ng/mL	104			UNKNOWN	mg	150		SINGLE	UNKNOWN						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20733950	Homo sapiens							3	BioResponse 3,3’-Diindolylmethane		false
7872	8335		ADULT	3071	246.3065	3,3'-DIINDOLYLMETHANE	3,3\'-DIINDOLYLMETHANE	C(C1=CNC2=C1C=CC=C2)C3=CNC4=C3C=CC=C4	PLASMA	SSZ9HQT61Z									?	ng × h/mL	599		ng/mL	134			UNKNOWN	mg	225		SINGLE	UNKNOWN						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20733950	Homo sapiens							4	BioResponse 3,3’-Diindolylmethane		false
7873	8335		ADULT	3071	246.3065	3,3'-DIINDOLYLMETHANE	3,3\'-DIINDOLYLMETHANE	C(C1=CNC2=C1C=CC=C2)C3=CNC4=C3C=CC=C4	PLASMA	SSZ9HQT61Z									?	ng × h/mL	192		ng/mL	42			UNKNOWN	mg	75		SINGLE	UNKNOWN						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20733950	Homo sapiens							3	BioResponse 3,3’- Diindolylmethane		false
7874	8335		ADULT	3071	246.3065	3,3'-DIINDOLYLMETHANE	3,3\'-DIINDOLYLMETHANE	C(C1=CNC2=C1C=CC=C2)C3=CNC4=C3C=CC=C4	PLASMA	SSZ9HQT61Z									?	ng × h/mL	899		ng/mL	236			UNKNOWN	mg	300		SINGLE	UNKNOWN						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20733950	Homo sapiens							4	BioResponse 3,3’-Diindolylmethane		false
7875	8343		ADULT	515328	245.2077	5-FLUORO-2'-DEOXYCYTIDINE	NC1=NC(=O)N(C=C1F)[C@H]2C[C@H](O)[C@@H](CO)O2	NC1=NC(=O)N(C=C1F)[C@H]2C[C@H](O)[C@@H](CO)O2	PLASMA	KUA4693H5W	29243		TETRAHYDROURIDINE	tetrahydrouridine	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N2CCC(O)NC2=O	0NIZ8H6OL8			∞	μg × min/mL	912		ng/mL	4107			MAX TOLERATED	mg/m²	100		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26321472	Homo sapiens										true
7876	8345		ADULT	46239015	376.254	MK-8776	MK-8776	CN1C=C(C=N1)C2=C3N=C([C@@H]4CCCNC4)C(Br)=C(N)N3N=C2	PLASMA	K2ZSF0992C									∞	ng × h/mL	1420		ng/mL	1010			UNKNOWN	mg/m²	20		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25605849/	Homo sapiens		h	7.28	was administered intravenously (IV) using an infusion pump over at least 15 minutes (for all dose levels up to part B 112 mg/m2)			3	MK-8776		false
7877	8345		ADULT	46239015	376.254	MK-8776	MK-8776	CN1C=C(C=N1)C2=C3N=C([C@@H]4CCCNC4)C(Br)=C(N)N3N=C2	PLASMA	K2ZSF0992C									∞	ng × h/mL	5060		ng/mL	4970			UNKNOWN	mg/m²	80		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25605849/	Homo sapiens		h	7.38	was administered intravenously (IV) using an infusion pump over at least 15 minutes (for all dose levels up to part B 112 mg/m2)			6	MK-8776		false
7878	8345		ADULT	46239015	376.254	MK-8776	MK-8776	CN1C=C(C=N1)C2=C3N=C([C@@H]4CCCNC4)C(Br)=C(N)N3N=C2	PLASMA	K2ZSF0992C									∞	ng × h/mL	8410		ng/mL	4680			UNKNOWN	mg	200		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25605849/	Homo sapiens		h	6.28	200 mg as a flat dose (ie, 112 mg/m2 at a BSA of 1.8 m2)			2	MK-8776		false
7879	8345		ADULT	46239015	376.254	MK-8776	MK-8776	CN1C=C(C=N1)C2=C3N=C([C@@H]4CCCNC4)C(Br)=C(N)N3N=C2	PLASMA	K2ZSF0992C									∞	ng × h/mL	19000		ng/mL	6220			HIGHEST STUDIED	mg/m²	150		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25605849/	Homo sapiens		h	9.18	was administered intravenously (IV) using an infusion\npump over at least 30 minutes			3	MK-8776		false
7880	8345		ADULT	46239015	376.254	MK-8776	MK-8776	CN1C=C(C=N1)C2=C3N=C([C@@H]4CCCNC4)C(Br)=C(N)N3N=C2	PLASMA	K2ZSF0992C									∞	ng × h/mL	2250		ng/mL	1220			UNKNOWN	mg/m²	40		SINGLE	UNKNOWN				MK-8776 is not highly protein bound (49% in human plasma) and when administered as a 15- to 30-minute IV infusion, plasma concentration declined in a multiphasic manner, exhibiting a rapid distribution phase.	51	UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25605849/	Homo sapiens		h	7.67	was administered intravenously (IV) using an infusion pump over at least 15 minutes (for all dose levels up to part B 112 mg/m2)			7	MK-8776		false
7881	8350		ADULT	76470875	838.865	GLECAPREVIR	CC1(CC1)S(=O)(=O)NC(=O)C2(CC2C(F)F)NC(=O)C3CC4CN3C(=O)C(NC(=O)OC5CCCC5OCC=CC(C6=NC7=CC=CC=C7N=C6O4)(F)F)C(C)(C)C	CC(C)(C)C1NC(=O)OC2CCCC2OCC=CC(F)(F)C3=NC4=CC=CC=C4N=C3OC5CC(N(C5)C1=O)C(=O)NC6(CC6C(F)F)C(=O)NS(=O)(=O)C7(C)CC7	PLASMA				PIBRENTASVIR	Pibrentasvir		2WU922TK3L	24		t	ng × h/mL	4500		ng/mL	1270			UNKNOWN	mg	300		MULTIPLE	FED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/28800195	Homo sapiens		h	8.69							true
7882	8351		ADULT		1113.2	PIBRENTASVIR	PIBRENTASVIR		PLASMA	2WU922TK3L									∞	ng × h/mL	118		ng/mL	18.3			UNKNOWN	mg	60		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28464496	Homo sapiens		h	14.8							false
7883	8351		ADULT		1113.2	PIBRENTASVIR	PIBRENTASVIR		PLASMA	2WU922TK3L									∞	ng × h/mL	594		ng/mL	87.1			RECOMMENDED	mg	120		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28464496	Homo sapiens		h	14.5							false
7884	8351		ADULT		1113.2	PIBRENTASVIR	PIBRENTASVIR		PLASMA	2WU922TK3L									∞	ng × h/mL	474		ng/mL	64.4			RECOMMENDED	mg	120		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28464496	Homo sapiens		h	17.7							false
7885	8351		ADULT		1113.2	PIBRENTASVIR	PIBRENTASVIR		PLASMA	2WU922TK3L									∞	ng × h/mL	408		ng/mL	71.7			RECOMMENDED	mg	120		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28464496	Homo sapiens		h	16.9							false
7886	8351		ADULT		1113.2	PIBRENTASVIR	PIBRENTASVIR		PLASMA	2WU922TK3L									∞	ng × h/mL	1040		ng/mL	167			UNKNOWN	mg	240		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28464496	Homo sapiens		h	16.4							false
7887	8351		ADULT		1113.2	PIBRENTASVIR	PIBRENTASVIR		PLASMA	2WU922TK3L									∞	ng × h/mL	1630		ng/mL	223			UNKNOWN	mg	405		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28464496	Homo sapiens		h	17.7							false
7888	8351		ADULT		1113.2	PIBRENTASVIR	PIBRENTASVIR		PLASMA	2WU922TK3L									∞	ng × h/mL	2560		ng/mL	343			UNKNOWN	mg	600		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28464496	Homo sapiens		h	14.4							false
7889	8351		ADULT		1113.2	PIBRENTASVIR	PIBRENTASVIR		PLASMA	2WU922TK3L							24		t	ng × h/mL	54.5		ng/mL	9.68			UNKNOWN	mg	30		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28464496	Homo sapiens		h	21.9							false
7890	8351		ADULT		1113.2	PIBRENTASVIR	PIBRENTASVIR		PLASMA	2WU922TK3L							24		t	ng × h/mL	180		ng/mL	31			UNKNOWN	mg	60		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28464496	Homo sapiens		h	20.8							false
7891	8351		ADULT		1113.2	PIBRENTASVIR	PIBRENTASVIR		PLASMA	2WU922TK3L							24		t	ng × h/mL	881		ng/mL	123			UNKNOWN	mg	180		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28464496	Homo sapiens		h	22.5							false
7892	8351		ADULT		1113.2	PIBRENTASVIR	PIBRENTASVIR		PLASMA	2WU922TK3L							24		t	ng × h/mL	2170		ng/mL	324			UNKNOWN	mg	600		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28464496	Homo sapiens		h	21.1							false
7893	8351		ADULT		1113.2	PIBRENTASVIR	PIBRENTASVIR		PLASMA	2WU922TK3L									∞	ng × h/mL	0.56		ng/mL	0.1			UNKNOWN	mg	1.5		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28464496	Homo sapiens		h	3.8							false
7894	8351		ADULT		1113.2	PIBRENTASVIR	PIBRENTASVIR		PLASMA	2WU922TK3L									∞	ng × h/mL	16.6		ng/mL	2.63			UNKNOWN	mg	15		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28464496	Homo sapiens		h	12.6							false
7895	8351		UNKNOWN		1113.2	PIBRENTASVIR	PIBRENTASVIR		PLASMA	2WU922TK3L																	UNKNOWN				UNKNOWN	UNKNOWN				% bound to human plasma proteins is >99.9.	0.1	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209394s010lbl.pdf	Homo sapiens										false
7896	8361		ADULT	3035714	371.41	ABT-751	ABT-751	COC1=CC=C(C=C1)S(=O)(=O)NC2=C(NC3=CC=C(O)C=C3)N=CC=C2	PLASMA	WDT5V5OB9F							24		t	μg × h/mL	50.2		μg/mL	13			UNKNOWN	mg	300		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16675578	Homo sapiens							4	ABT-751		false
7897	8361		ADULT	3035714	371.41	ABT-751	ABT-751	COC1=CC=C(C=C1)S(=O)(=O)NC2=C(NC3=CC=C(O)C=C3)N=CC=C2	PLASMA	WDT5V5OB9F							12		t	μg × h/mL	43.5		μg/mL	9			UNKNOWN	mg	175		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16675578	Homo sapiens							8	ABT-751		false
7898	8361		ADULT	3035714	371.41	ABT-751	ABT-751	COC1=CC=C(C=C1)S(=O)(=O)NC2=C(NC3=CC=C(O)C=C3)N=CC=C2	PLASMA	WDT5V5OB9F							12		t	μg × h/mL	31.4		μg/mL	5.8			MAX TOLERATED	mg	150		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16675578	Homo sapiens							9	ABT-751		false
7899	8361		ADULT	3035714	371.41	ABT-751	ABT-751	COC1=CC=C(C=C1)S(=O)(=O)NC2=C(NC3=CC=C(O)C=C3)N=CC=C2	PLASMA	WDT5V5OB9F							24		t	μg × h/mL	60.5		μg/mL	12.7			MAX TOLERATED	mg	250		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16675578	Homo sapiens							6	ABT-751		false
7900	8361		ADULT	3035714	371.41	ABT-751	ABT-751	COC1=CC=C(C=C1)S(=O)(=O)NC2=C(NC3=CC=C(O)C=C3)N=CC=C2	PLASMA	WDT5V5OB9F							24		t	μg × h/mL	42.8		μg/mL	6.6			UNKNOWN	mg	200		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16675578	Homo sapiens							3	ABT-751		false
7901	8372		ADULT	91933867	555.6	ADOMEGLIVANT	ADOMEGLIVANT	CC1=CC(O[C@@H](CCC(F)(F)F)C2=CC=C(C=C2)C(=O)NCCC(O)=O)=CC(C)=C1C3=CC=C(C=C3)C(C)(C)C	PLASMA	74Z5ZL2KVG									∞	ng × h/mL	1410000		ng/mL	15200			UNKNOWN	mg	500		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/25656305	Homo sapiens		h	57.9							false
7902	8373		ADULT	25195461	344.878	JNJ-40411813	JNJ-40411813	CCCCN1C=CC(N2CCC(CC2)C3=CC=CC=C3)=C(Cl)C1=O	PLASMA	612BYT76F3									?	ng × h/mL	6404		ng/mL	789			UNKNOWN	mg	100		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25735992	Homo sapiens		h	24.2				6	JNJ-40411813		false
7903	8373		ADULT	25195461	344.878	JNJ-40411813	JNJ-40411813	CCCCN1C=CC(N2CCC(CC2)C3=CC=CC=C3)=C(Cl)C1=O	PLASMA	612BYT76F3									?	ng × h/mL	10150		ng/mL	1246			UNKNOWN	mg	100		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25735992	Homo sapiens		h	29.6				6	JNJ-40411813		false
7904	8373		ADULT	25195461	344.878	JNJ-40411813	JNJ-40411813	CCCCN1C=CC(N2CCC(CC2)C3=CC=CC=C3)=C(Cl)C1=O	PLASMA	612BYT76F3									?	ng × h/mL	16191		ng/mL	1750			UNKNOWN	mg	225		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25735992	Homo sapiens		h	34.2				6	JNJ-40411813		false
7905	8375		ADULT	10407120	375.4204	AFN-1252	AFN-1252	CN(CC1=C(C)C2=C(O1)C=CC=C2)C(=O)\\C=C\\C3=CN=C4NC(=O)CCC4=C3	PLASMA	T3O718IKKM									∞	ng × h/mL	53887		ng/mL	2842			UNKNOWN	mg	400		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26357940/	Homo sapiens		h	7.74				6	AFN-1252		false
7906	8375		ADULT	10407120	375.4204	AFN-1252	AFN-1252	CN(CC1=C(C)C2=C(O1)C=CC=C2)C(=O)\\C=C\\C3=CN=C4NC(=O)CCC4=C3	PLASMA	T3O718IKKM									∞	ng × h/mL	23931		ng/mL	1413			UNKNOWN	mg	100		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26357940/	Homo sapiens		h	8.57				6	AFN–1252		false
7907	8375		ADULT	10407120	375.4204	AFN-1252	AFN-1252	CN(CC1=C(C)C2=C(O1)C=CC=C2)C(=O)\\C=C\\C3=CN=C4NC(=O)CCC4=C3	PLASMA	T3O718IKKM									∞	ng × h/mL	30755		ng/mL	1753			UNKNOWN	mg	200		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26357940/	Homo sapiens		h	9.72				6	AFN-1252		false
7908	8375		ADULT	10407120	375.4204	AFN-1252	AFN-1252	CN(CC1=C(C)C2=C(O1)C=CC=C2)C(=O)\\C=C\\C3=CN=C4NC(=O)CCC4=C3	PLASMA	T3O718IKKM									∞	ng × h/mL	53322		ng/mL	2707			UNKNOWN	mg	300		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26357940/	Homo sapiens		h	9.42				6	AFN-1252		false
7909	8375		ADULT	10407120	375.4204	AFN-1252	AFN-1252	CN(CC1=C(C)C2=C(O1)C=CC=C2)C(=O)\\C=C\\C3=CN=C4NC(=O)CCC4=C3	PLASMA	T3O718IKKM									∞	ng × h/mL	41918		ng/mL	2008			UNKNOWN	mg	200		MULTIPLE	FASTED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26357940/	Homo sapiens		h	8.81				6	AFN-1252		false
7910	8375		ADULT	10407120	375.4204	AFN-1252	AFN-1252	CN(CC1=C(C)C2=C(O1)C=CC=C2)C(=O)\\C=C\\C3=CN=C4NC(=O)CCC4=C3	PLASMA	T3O718IKKM									∞	ng × h/mL	65276		ng/mL	2900			HIGHEST STUDIED	mg	400		MULTIPLE	FASTED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26357940/	Homo sapiens		h	8.95				6	AFN-1252		false
7911	8375		ADULT	10407120	375.4204	AFN-1252	AFN-1252	CN(CC1=C(C)C2=C(O1)C=CC=C2)C(=O)\\C=C\\C3=CN=C4NC(=O)CCC4=C3	PLASMA	T3O718IKKM									∞	ng × h/mL	61215		ng/mL	2807			UNKNOWN	mg	300		MULTIPLE	FASTED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26357940/	Homo sapiens		h	10.31				6	AFN-1252		false
7912	8375		ADULT	10407120	375.4204	AFN-1252	AFN-1252	CN(CC1=C(C)C2=C(O1)C=CC=C2)C(=O)\\C=C\\C3=CN=C4NC(=O)CCC4=C3	PLASMA	T3O718IKKM									∞	ng × h/mL	27025		ng/mL	1323			UNKNOWN	mg	100		MULTIPLE	FASTED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26357940/	Homo sapiens		h	9.12				6	AFN-1252		false
7913	8393		ADULT	68947304	385.397	AMG-319	AMG-319	C[C@H](NC1=C2N=CNC2=NC=N1)C3=C(N=C4C=C(F)C=CC4=C3)C5=NC=CC=C5	BLOOD	19DG7G1U5Q																	UNKNOWN	mg	400		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://doi.org/10.1182/blood.V122.21.678.678	Homo sapiens		h	6.6				10	AMG-319		false
7914	8395		ADULT	16129483	377.4416	AMISELIMOD	AMISELIMOD	CCCCCCCOC1=C(C=C(CCC(N)(CO)CO)C=C1)C(F)(F)F	PLASMA	358M5150LY									∞	ng × h/g	120		ng/g	0.211			UNKNOWN	mg	0.4		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/30231665	Homo sapiens		h	451							false
7915	8421		ADULT	12082259	415.791	ARHALOFENATE	ARHALOFENATE	CC(=O)NCCOC(=O)[C@H](OC1=CC(=CC=C1)C(F)(F)F)C2=CC=C(Cl)C=C2	PLASMA	1P01UJR9X1									?	μg × h/mL	2960		μg/mL	140			UNKNOWN	mg	800		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27980008	Homo sapiens		h	50	day 14			16	ARHALOFENATE		false
7916	8422		ADULT	56941241	446.901	GDC-0810	ARN-810	CC\\C(=C(\\C1=CC=C(\\C=C\\C(O)=O)C=C1)C2=CC3=C(NN=C3)C=C2)C4=C(Cl)C=C(F)C=C4	PLASMA	9MM2R1A06R									∞	μg × h/mL	114		μg/mL	22.2			RECOMMENDED	mg	600		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31266752	Homo sapiens		h	7.91				6	ARN-810		false
7917	8422		ADULT	56941241	446.901	GDC-0810	ARN-810	CC\\C(=C(\\C1=CC=C(\\C=C\\C(O)=O)C=C1)C2=CC3=C(NN=C3)C=C2)C4=C(Cl)C=C(F)C=C4	PLASMA	9MM2R1A06R							24		t	μg × h/mL	102		μg/mL	25			RECOMMENDED	mg	600		STEADY-STATE	FED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31266752	Homo sapiens							5	ARN-810		false
7918	8422		ADULT	56941241	446.901	GDC-0810	ARN-810	CC\\C(=C(\\C1=CC=C(\\C=C\\C(O)=O)C=C1)C2=CC3=C(NN=C3)C=C2)C4=C(Cl)C=C(F)C=C4	PLASMA	9MM2R1A06R									∞	μg × h/mL	65.7		μg/mL	15.9			UNKNOWN	mg	800		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31266752	Homo sapiens		h	10.1				4	ARN-810		false
7919	8422		ADULT	56941241	446.901	GDC-0810	ARN-810	CC\\C(=C(\\C1=CC=C(\\C=C\\C(O)=O)C=C1)C2=CC3=C(NN=C3)C=C2)C4=C(Cl)C=C(F)C=C4	PLASMA	9MM2R1A06R							24		t	μg × h/mL	80.4		μg/mL	18.4			UNKNOWN	mg	800		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31266752	Homo sapiens							4	ARN-810		false
7920	8423		ADULT	46188928	428.4352	Larotrectinib	O[C@H]1CCN(C1)C(=O)NC2=C3N=C(C=CN3N=C2)N4CCC[C@@H]4C5=CC(F)=CC=C5F	O[C@H]1CCN(C1)C(=O)NC2=C3N=C(C=CN3N=C2)N4CCC[C@@H]4C5=CC(F)=CC=C5F	PLASMA	PF9462I9HX							24		t	ng × h/mL	4351		ng/mL	788			RECOMMENDED	mg	100		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211710s000lbl.pdf	Homo sapiens										false
7921	8423		ADULT	67330092	428.4352	Larotrectinib	C1CC(N(C1)C2=NC3=C(C=NN3C=C2)NC(=O)N4CCC(C4)O)C5=C(C=CC(=C5)F)F	OC1CCN(C1)C(=O)NC2=C3N=C(C=CN3N=C2)N4CCCC4C5=C(F)C=CC(F)=C5	PLASMA	PF9462I9HX																	RECOMMENDED	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211710s000lbl.pdf	Homo sapiens		h	2.9							false
7922	8424		ADULT		469.613	ARTEFENOMEL	artefenomel	C(CN1CCOCC1)OC2=CC=C(C=C2)[C@H]3CC[C@]4(CC3)OOC5(O4)C6CC7CC(C6)CC5C7	PLASMA	RIK029813G									∞	ng × h/mL	3180		ng/mL	339			UNKNOWN	mg	200		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26448141	Homo sapiens		h	46.3				20	artefenomel		false
7923	8424		ADULT		469.613	ARTEFENOMEL	artefenomel	C(CN1CCOCC1)OC2=CC=C(C=C2)[C@H]3CC[C@]4(CC3)OOC5(O4)C6CC7CC(C6)CC5C7	PLASMA	RIK029813G									∞	ng × h/mL	6450		ng/mL	732			UNKNOWN	mg	400		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26448141	Homo sapiens		h	62.3				20	artefenomel		false
7924	8424		ADULT		469.613	ARTEFENOMEL	artefenomel	C(CN1CCOCC1)OC2=CC=C(C=C2)[C@H]3CC[C@]4(CC3)OOC5(O4)C6CC7CC(C6)CC5C7	PLASMA	RIK029813G									∞	ng × h/mL	25100		ng/mL	1500			HIGHEST STUDIED	mg	1200		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26448141	Homo sapiens		h	57				21	artefenomel		false
7925	8424		ADULT		469.613	ARTEFENOMEL	artefenomel	C(CN1CCOCC1)OC2=CC=C(C=C2)[C@H]3CC[C@]4(CC3)OOC5(O4)C6CC7CC(C6)CC5C7	PLASMA	RIK029813G									∞	ng × h/mL	19700		ng/mL	1710			UNKNOWN	mg	800		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26448141	Homo sapiens		h	58				20	artefenomel		false
7926	8430		ADULT	9918559	477.5124	AVN-944	AVN-944	CC[C@H](CC#N)OC(=O)N[C@@H](C)C1=CC(NC(=O)NC2=CC(OC)=C(C=C2)C3=CN=CO3)=CC=C1	PLASMA	I3NPL1V48Q									∞	ng × h/mL	14540		ng/mL	5418			UNKNOWN	mg	250		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18971325	Homo sapiens		h	1.56				4	AVN-944		false
7927	8439		ADULT	11438771	325.767	BASIMGLURANT	BASIMGLURANT	CC1=NC(C#CC2=CC(Cl)=NC=C2)=C(C)N1C3=CC=C(F)C=C3	PLASMA	3110E3AO8S									∞	ng × eq × h/mL	296		ng × eq/mL	16.3			UNKNOWN	mg	1		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27123695	Homo sapiens		h	178	Healthy volunteers received a single 1 mg [12C/14C]-basimglurant (2.22 MBq) oral dose and a concomitant i.v. tracer dose of 100 μg of [13C6]-basimglurant. Single oral dose of 1 mg [12C/14C]-basimglurant  (consisting  of  0.76 mg 12C  and  0.24 mg 14C) followed  30 min later by a 30 min i.v. infusion  of  100 μg [13C6]-labeled basimglurant. Statistics  of [14C]-radioactivity plasma PK parameters.			6	BASIMGLURANT		false
7928	8440		ADULT	57336276	445.464	BASMISANIL	BASMISANIL	CC1=C(COC2=NC=C(C=C2)C(=O)N3CCS(=O)(=O)CC3)C(=NO1)C4=CC=C(F)C=C4	PLASMA	788PET5SUA									∞	μg × h/mL	17.5		μg/mL	1.2			INVESTIGATIONAL	mg	120		SINGLE	FED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/28236228	Homo sapiens		h	7							false
7929	8453		UNKNOWN	10472693	344.4861	BEMPEDOIC ACID	Bempedoic Acid	CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O	PLASMA	1EJ6Z6Q368									?	μg × h/mL	289		μg/mL	20.6			RECOMMENDED	mg	180		STEADY-STATE	UNKNOWN		day	1			UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211616s000lbl.pdf	Homo sapiens		h	21							false
7930	8455		UNKNOWN	6439522	254.3236	BENVITIMOD	Benvitimod	CC(C)C1=C(O)C=C(\\C=C\\C2=CC=CC=C2)C=C1O	PLASMA	84HW7D0V04																						UNKNOWN				Human plasma protein binding: 99.1-99.4% (20-1000 ng/mL)	0.6	UNKNOWN		UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215272Orig1s000MultidisciplineR.pdf#page=35	Homo sapiens										false
7931	8455		ADULT	6439522	254.3236	BENVITIMOD	Benvitimod	CC(C)C1=C(O)C=C(\\C=C\\C2=CC=CC=C2)C=C1O	PLASMA	84HW7D0V04									?	pg × h/mL	608.6		pg/mL	116			UNKNOWN	g	5.23		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Topical	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215272Orig1s000MultidisciplineR.pdf#page=61 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215272s000lbl.pdf#page=5	Homo sapiens				Day 29; 5.23g applied to 27.2%BSA (21-46%)	Subjects with extensive plaque psoriasis; n=11 for AUClast		19			false
7932	8455		ADULT	6439522	254.3236	BENVITIMOD	Benvitimod	CC(C)C1=C(O)C=C(\\C=C\\C2=CC=CC=C2)C=C1O	PLASMA	84HW7D0V04									?	pg × h/mL	4067		pg/mL	898			UNKNOWN	g	5.23		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Topical	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215272Orig1s000MultidisciplineR.pdf#page=61 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215272s000lbl.pdf#page=5	Homo sapiens		h	6.41	Day 1; 5.23g applied to 27.2%BSA (21-46%)	Subjects with extensive plaque psoriasis; n=17 for AUClast, n=2 for t1/2		21			false
7933	8459		ADULT	16736529	318.761	BIIB021	BIIB021	COC1=C(C)C=NC(CN2C=NC3=C2N=C(N)N=C3Cl)=C1C	PLASMA	851B9FQ7Q0							6		t	ng × h/mL	2942		ng/mL	1439			UNKNOWN	mg	600		SINGLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22898035	Homo sapiens							12	BIIB021		false
7934	8465		ADULT	119058036	0	VOSORITIDE	Vosoritide		PLASMA	7SE5582Q2P									?	ng × min/mL	129		pg/mL	749			UNKNOWN	μg/kg	2.5		MULTIPLE	UNKNOWN		day	1			HEALTHY	Subcutaneous	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214938Orig1s000IntegratedR.pdf#page=195	Homo sapiens				Day 1	n=1 for AUC		4			false
7935	8465		ADULT	119058036	0	VOSORITIDE	Vosoritide		PLASMA	7SE5582Q2P									?	ng × min/mL	110		pg/mL	736			UNKNOWN	μg/kg	2.5		MULTIPLE	UNKNOWN		day	1			HEALTHY	Subcutaneous	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214938Orig1s000IntegratedR.pdf#page=195	Homo sapiens				Day 10	n=1 for AUC		6			false
7936	8465		ADULT	119058036	0	VOSORITIDE	Vosoritide		PLASMA	7SE5582Q2P									?	ng × min/mL	129		pg/mL	749			UNKNOWN	μg/kg	2.5		SINGLE	UNKNOWN						HEALTHY	Subcutaneous	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214938Orig1s000IntegratedR.pdf#page=195	Homo sapiens					n=1 for AUC		4			false
7937	8465		ADULT	119058036	0	VOSORITIDE	Vosoritide		PLASMA	7SE5582Q2P									?	ng × min/mL	83.2		pg/mL	1820			UNKNOWN	μg/kg	5		SINGLE	UNKNOWN						HEALTHY	Subcutaneous	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214938Orig1s000IntegratedR.pdf#page=195	Homo sapiens					n=7 for AUC		11			false
7938	8465		ADULT	119058036	0	VOSORITIDE	Vosoritide		PLASMA	7SE5582Q2P									?	ng × min/mL	74.2		pg/mL	1410			UNKNOWN	μg/kg	5		MULTIPLE	UNKNOWN		day	1			HEALTHY	Subcutaneous	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214938Orig1s000IntegratedR.pdf#page=195	Homo sapiens				Day 1	n=3 for AUC		6			false
7939	8465		ADULT	119058036	0	VOSORITIDE	Vosoritide		PLASMA	7SE5582Q2P									?	ng × min/mL	607		pg/mL	6750			UNKNOWN	μg/kg	10		SINGLE	UNKNOWN						HEALTHY	Subcutaneous	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214938Orig1s000IntegratedR.pdf#page=195	Homo sapiens		min	53.8		n=2 for t1/2		5			false
7940	8465		ADULT	119058036	0	VOSORITIDE	Vosoritide		PLASMA	7SE5582Q2P									?	ng × min/mL	69.5		pg/mL	1400			UNKNOWN	μg/kg	5		MULTIPLE	UNKNOWN		day	1			HEALTHY	Subcutaneous	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214938Orig1s000IntegratedR.pdf#page=195	Homo sapiens				Day 10	n=4 for AUC		5			false
7941	8465		ADULT	119058036	0	VOSORITIDE	Vosoritide		PLASMA	7SE5582Q2P									?	ng × min/mL	83		pg/mL	1420			UNKNOWN	μg/kg	5		MULTIPLE	UNKNOWN		day	1			HEALTHY	Subcutaneous	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214938Orig1s000IntegratedR.pdf#page=195	Homo sapiens				Day 6	n=4 for AUC		6			false
7942	8465		ADULT	119058036	0	VOSORITIDE	Vosoritide		PLASMA	7SE5582Q2P									?	ng × min/mL	687		pg/mL	8830			UNKNOWN	μg/kg	15		SINGLE	UNKNOWN						HEALTHY	Subcutaneous	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214938Orig1s000IntegratedR.pdf#page=195	Homo sapiens		min	69.5		n=3 for t1/2		4			false
7943	8465		ADULT	119058036	0	VOSORITIDE	Vosoritide		PLASMA	7SE5582Q2P									?	ng × min/mL	63.8		pg/mL	804			UNKNOWN	μg/kg	2.5		MULTIPLE	UNKNOWN		day	1			HEALTHY	Subcutaneous	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214938Orig1s000IntegratedR.pdf#page=195	Homo sapiens				Day 6	n=1 for AUC		5			false
7944	8465		CHILD	119058036	0	VOSORITIDE	Vosoritide		PLASMA	7SE5582Q2P									?	ng × min/mL	32.2		pg/mL	1360			UNKNOWN	μg/kg	7.5		SINGLE	UNKNOWN						UNHEALTHY	Subcutaneous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214938Orig1s000IntegratedR.pdf#page=197	Homo sapiens					Children with Achondroplasia		7			false
7945	8465		CHILD	119058036	0	VOSORITIDE	Vosoritide		PLASMA	7SE5582Q2P									?	ng × min/mL	689		pg/mL	16800			UNKNOWN	μg/kg	30		SINGLE	UNKNOWN						UNHEALTHY	Subcutaneous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214938Orig1s000IntegratedR.pdf#page=197	Homo sapiens		min	27		Children with Achondroplasia; n=8 for t1/2		9			false
7946	8465		CHILD	119058036	0	VOSORITIDE	Vosoritide		PLASMA	7SE5582Q2P									?	ng × min/mL	175		pg/mL	4750			UNKNOWN	μg/kg	15		SINGLE	UNKNOWN						UNHEALTHY	Subcutaneous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214938Orig1s000IntegratedR.pdf#page=197	Homo sapiens		min	24.4		Children with Achondroplasia; n=2 for t1/2		10			false
7947	8465		CHILD	119058036	0	VOSORITIDE	Vosoritide		PLASMA	7SE5582Q2P									?	ng × min/mL	1.37		pg/mL	549			UNKNOWN	μg/kg	2.5		SINGLE	UNKNOWN						UNHEALTHY	Subcutaneous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214938Orig1s000IntegratedR.pdf#page=197	Homo sapiens					Children with Achondroplasia		1			false
7948	8465		CHILD	119058036	0	VOSORITIDE	Vosoritide		PLASMA	7SE5582Q2P									?	ng × min/mL	161		mg/mL	4.71			UNKNOWN	μg/kg	15		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Subcutaneous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214938Orig1s000IntegratedR.pdf#page=208	Homo sapiens				Week 13	Children with Achondroplasia		56			false
7949	8465		CHILD	119058036	0	VOSORITIDE	Vosoritide		PLASMA	7SE5582Q2P									?	ng × min/mL	205		mg/mL	5.72			UNKNOWN	μg/kg	15		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Subcutaneous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214938Orig1s000IntegratedR.pdf#page=208	Homo sapiens				Week 39	Children with Achondroplasia		54			false
7950	8465		CHILD	119058036	0	VOSORITIDE	Vosoritide		PLASMA	7SE5582Q2P									?	ng × min/mL	290		mg/mL	5.8			UNKNOWN	μg/kg	15		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Subcutaneous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214938Orig1s000IntegratedR.pdf#page=208	Homo sapiens		min	27.9	Week 52	Children with Achondroplasia; n=48 for t1/2		56			false
7951	8465		CHILD	119058036	0	VOSORITIDE	Vosoritide		PLASMA	7SE5582Q2P									?	ng × min/mL	242		mg/mL	7.18			UNKNOWN	μg/kg	15		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Subcutaneous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214938Orig1s000IntegratedR.pdf#page=208	Homo sapiens		min	21	Day 1	Children with Achondroplasia; n=55 for t1/2		58			false
7952	8465		CHILD	119058036	0	VOSORITIDE	Vosoritide		PLASMA	7SE5582Q2P									?	ng × min/mL	256		mg/mL	6.52			UNKNOWN	μg/kg	15		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Subcutaneous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214938Orig1s000IntegratedR.pdf#page=208	Homo sapiens		min	26.6	Week 26	Children with Achondroplasia; n=53 for t1/2		55			false
7953	8479		ADULT	68165256	584.092	BRIGATINIB	BRIGATINIB	COC1=C(NC2=NC(NC3=C(C=CC=C3)P(C)(C)=O)=C(Cl)C=N2)C=CC(=C1)N4CCC(CC4)N5CCN(C)CC5	PLASMA	HYW8DB273J							24		t	ng × h/mL	8165		ng/mL	552			DEFINED DAILY	mg	180		STEADY-STATE	UNKNOWN		day	1	Brigatinib is 66% bound to human plasma proteins	34	UNKNOWN	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208772lbl.pdf	Homo sapiens		h	25							false
7954	8479		ADULT	68165256	584.092	BRIGATINIB	BRIGATINIB	COC1=C(NC2=NC(NC3=C(C=CC=C3)P(C)(C)=O)=C(Cl)C=N2)C=CC(=C1)N4CCC(CC4)N5CCN(C)CC5	PLASMA	HYW8DB273J									∞	ng × h/mL	13261		ng/mL	701.3			DEFINED DAILY	mg	180		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/30570839	Homo sapiens		h	31							false
7955	8490		ADULT	54713659	405.3522	CABOTEGRAVIR	cabotegravir	C[C@H]1CO[C@@H]2CN3C=C(C(=O)NCC4=C(F)C=C(F)C=C4)C(=O)C(O)=C3C(=O)N12	PLASMA	HMH0132Z1Q									∞	μg × h/mL	146		μg/mL	3.61			UNKNOWN	mg	30		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28739783/	Homo sapiens		h	38.5				15			false
7956	8490		ADULT	54713659	405.3522	CABOTEGRAVIR	cabotegravir	C[C@H]1CO[C@@H]2CN3C=C(C(=O)NCC4=C(F)C=C(F)C=C4)C(=O)C(O)=C3C(=O)N12	PLASMA	HMH0132Z1Q		822.9402	RIFAMPIN	rifampin	CO[C@H]1\\C=C\\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)C(C)=C\\C=C\\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(\\C=N\\N5CCN(C)CC5)=C(O)C4=C3C2=O	VJT6J7R4TR			∞	μg × h/mL	59.7		μg/mL	3.39			UNKNOWN	mg	30		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28739783/	Homo sapiens		h	16.4				15			true
7957	8490		ADULT	54713659	405.3522	CABOTEGRAVIR	cabotegravir	C[C@H]1CO[C@@H]2CN3C=C(C(=O)NCC4=C(F)C=C(F)C=C4)C(=O)C(O)=C3C(=O)N12	PLASMA	HMH0132Z1Q									∞	μg × h/mL	144		μg/mL	3.4				mg	30		SINGLE	FASTED				unbound fraction at 24 hours	0.12	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30809978/	Homo sapiens		h	40.8				8			false
7958	8490		ADULT	54713659	405.3522	CABOTEGRAVIR	cabotegravir	C[C@H]1CO[C@@H]2CN3C=C(C(=O)NCC4=C(F)C=C(F)C=C4)C(=O)C(O)=C3C(=O)N12	PLASMA	HMH0132Z1Q									∞	μg × h/mL	146		μg/mL	3.44				mg	30		SINGLE	FASTED				unbound fraction at 24 hours	0.17	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30809978/	Homo sapiens		h	39.6		Patients with severe renal impairment		8			false
7959	8506		ADULT	11502996	435.5552	CERALIFIMOD	Ceralifimod	CCCC1=CC(OC)=C(COC2=CC3=C(C=C2)C(C)=C(CN4CC(C4)C(O)=O)CC3)C=C1	PLASMA	BZ2O8A84A4							24		t	pg × h/mL	18620		pg/mL	985			UNKNOWN	mg	0.1		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25855155	Homo sapiens							24	Ceralifimod		false
7960	8506		ADULT	11502996	435.5552	CERALIFIMOD	Ceralifimod	CCCC1=CC(OC)=C(COC2=CC3=C(C=C2)C(C)=C(CN4CC(C4)C(O)=O)CC3)C=C1	PLASMA	BZ2O8A84A4							24		t	pg × h/mL	9219		pg/mL	434			UNKNOWN	mg	0.01		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25855155	Homo sapiens		h	81.9				22	Ceralifimod		false
7961	8506		ADULT	11502996	435.5552	CERALIFIMOD	Ceralifimod	CCCC1=CC(OC)=C(COC2=CC3=C(C=C2)C(C)=C(CN4CC(C4)C(O)=O)CC3)C=C1	PLASMA	BZ2O8A84A4							24		t	pg × h/mL	9530		pg/mL	507			UNKNOWN	mg	0.05		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25855155	Homo sapiens							24	Ceralifimod		false
7962	8506		ADULT	11502996	435.5552	CERALIFIMOD	Ceralifimod	CCCC1=CC(OC)=C(COC2=CC3=C(C=C2)C(C)=C(CN4CC(C4)C(O)=O)CC3)C=C1	PLASMA	BZ2O8A84A4							24		t	pg × h/mL	24527		pg/mL	1166			UNKNOWN	mg	0.025		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25855155	Homo sapiens		h	81.8				21	Ceralifimod		false
7963	8506		ADULT	11502996	435.5552	CERALIFIMOD	Ceralifimod	CCCC1=CC(OC)=C(COC2=CC3=C(C=C2)C(C)=C(CN4CC(C4)C(O)=O)CC3)C=C1	PLASMA	BZ2O8A84A4							24		t	pg × h/mL	4908		pg/mL	262			UNKNOWN	mg	0.025		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25855155	Homo sapiens							24	Ceralifimod		false
7964	8506		ADULT	11502996	435.5552	CERALIFIMOD	Ceralifimod	CCCC1=CC(OC)=C(COC2=CC3=C(C=C2)C(C)=C(CN4CC(C4)C(O)=O)CC3)C=C1	PLASMA	BZ2O8A84A4							24		t	pg × h/mL	48497		pg/mL	2260			UNKNOWN	mg	0.05		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25855155	Homo sapiens		h	89				20	Ceralifimod		false
7965	8506		ADULT	11502996	435.5552	CERALIFIMOD	Ceralifimod	CCCC1=CC(OC)=C(COC2=CC3=C(C=C2)C(C)=C(CN4CC(C4)C(O)=O)CC3)C=C1	PLASMA	BZ2O8A84A4							24		t	pg × h/mL	93517		pg/mL	4428			UNKNOWN	mg	0.1		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25855155	Homo sapiens		h	84.8				22	Ceralifimod		false
7966	8506		ADULT	11502996	435.5552	CERALIFIMOD	Ceralifimod	CCCC1=CC(OC)=C(COC2=CC3=C(C=C2)C(C)=C(CN4CC(C4)C(O)=O)CC3)C=C1	PLASMA	BZ2O8A84A4							24		t	pg × h/mL	1967		pg/mL	111			UNKNOWN	mg	0.01		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25855155	Homo sapiens							24	Ceralifimod		false
7967	8508		ADULT	130021	179.1971	SGS-742	CGP-36742	CCCCP(O)(=O)CCCN	PLASMA	GBZ5UC0RME									∞	μM × h	208		μM	27.6			UNKNOWN	mg	600		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8739022	Homo sapiens		h	2.9				12			false
7968	8508		ADULT	130021	179.1971	SGS-742	CGP-36742	CCCCP(O)(=O)CCCN	PLASMA	GBZ5UC0RME									∞	μM × h	385		μM	262			UNKNOWN	mg	600		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8739022	Homo sapiens		h	2.1				12			false
7969	8508		ADULT	130021	179.1971	SGS-742	CGP-36742	CCCCP(O)(=O)CCCN	PLASMA	GBZ5UC0RME									∞	μM × h	136		μM	15.9			UNKNOWN	mg	600		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8739022	Homo sapiens		h	2.9				12			false
7970	8508		ADULT	130021	179.1971	SGS-742	CGP-36742	CCCCP(O)(=O)CCCN	PLASMA	GBZ5UC0RME							8		t	μM × h	252		μM	48			UNKNOWN	mg	600		MULTIPLE	UNKNOWN		day	3			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8739022	Homo sapiens		h	3.9				12	CGP-36742		false
7971	8512		ADULT	9808022	565.6986	CINACIGUAT	CINACIGUAT	OC(=O)CCCCN(CCC1=C(OCC2=CC=C(CCC3=CC=CC=C3)C=C2)C=CC=C1)CC4=CC=C(C=C4)C(O)=O	PLASMA	59K0Y58UAD									?	μg × h/L	11.07		μg/L	3.32			UNKNOWN	μg	400		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://onlinelibrary.wiley.com/doi/10.1093/eurjhf/hsq013	Homo sapiens		h	1.56							false
7972	8512		UNKNOWN	9808022	565.6986	CINACIGUAT	CINACIGUAT	OC(=O)CCCCN(CCC1=C(OCC2=CC=C(CCC3=CC=CC=C3)C=C2)C=CC=C1)CC4=CC=C(C=C4)C(O)=O	PLASMA	59K0Y58UAD																	UNKNOWN	μg	400		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3363258/	Homo sapiens		h	1.56							false
7973	8513		ADULT	44469321	390.238	CIPARGAMIN	KAE609	C[C@H]1CC2=C(NC3=C2C=C(F)C(Cl)=C3)[C@@]4(N1)C(=O)NC5=C4C=C(Cl)C=C5	PLASMA	Z7Q4FWA04P							24		t	μg × h/mL	1.91		ng/mL	161			UNKNOWN	mg	10		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25114127	Homo sapiens		h	21.4				8	KAE609		false
7974	8513		ADULT	44469321	390.238	CIPARGAMIN	KAE609	C[C@H]1CC2=C(NC3=C2C=C(F)C(Cl)=C3)[C@@]4(N1)C(=O)NC5=C4C=C(Cl)C=C5	PLASMA	Z7Q4FWA04P							24		t	μg × h/mL	19.8		ng/mL	1170			UNKNOWN	mg	100		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25114127	Homo sapiens		h	23.1				8	KAE609		false
7975	8513		ADULT	44469321	390.238	CIPARGAMIN	KAE609	C[C@H]1CC2=C(NC3=C2C=C(F)C(Cl)=C3)[C@@]4(N1)C(=O)NC5=C4C=C(Cl)C=C5	PLASMA	Z7Q4FWA04P							24		t	μg × h/mL	14.1		ng/mL	991			UNKNOWN	mg	60		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25114127	Homo sapiens		h	28				8	KAE609		false
7976	8513		ADULT	44469321	390.238	CIPARGAMIN	KAE609	C[C@H]1CC2=C(NC3=C2C=C(F)C(Cl)=C3)[C@@]4(N1)C(=O)NC5=C4C=C(Cl)C=C5	PLASMA	Z7Q4FWA04P							24		t	μg × h/mL	6.42		ng/mL	468			UNKNOWN	mg	30		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25114127	Homo sapiens		h	22.4				8	KAE609		false
7977	8513		ADULT	44469321	390.238	CIPARGAMIN	KAE609	C[C@H]1CC2=C(NC3=C2C=C(F)C(Cl)=C3)[C@@]4(N1)C(=O)NC5=C4C=C(Cl)C=C5	PLASMA	Z7Q4FWA04P							24		t	μg × h/mL	29.4		ng/mL	1770			HIGHEST STUDIED	mg	150		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25114127	Homo sapiens		h	26.9				8	KAE609		false
7978	8514		ADULT	71576543	512.6957	CIRAPARANTAG	ciraparantag	N[C@@H](CCCNC(N)=N)C(=O)NCCCN1CCN(CCCNC(=O)[C@@H](N)CCCNC(N)=N)CC1	SERUM	U2R67KV65Q													ng/mL	861			UNKNOWN	mg	50		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33205809/	Homo sapiens		h	0.24				8	ciraparantag		false
7979	8514		ADULT	71576543	512.6957	CIRAPARANTAG	ciraparantag	N[C@@H](CCCNC(N)=N)C(=O)NCCCN1CCN(CCCNC(=O)[C@@H](N)CCCNC(N)=N)CC1	SERUM	U2R67KV65Q							24		t	ng × h/mL	3800		ng/mL	10570			HIGHEST STUDIED	mg	300		SINGLE	UNKNOWN				ciraparantag did not bind to plasma proteins in human plasma	100	HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33205809/	Homo sapiens		h	0.32				8	ciraparantag		false
7980	8514		ADULT	71576543	512.6957	CIRAPARANTAG	ciraparantag	N[C@@H](CCCNC(N)=N)C(=O)NCCCN1CCN(CCCNC(=O)[C@@H](N)CCCNC(N)=N)CC1	SERUM	U2R67KV65Q													ng/mL	7755			UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33205809/	Homo sapiens		h	0.33				8	ciraparantag		false
7981	8514		ADULT	71576543	512.6957	CIRAPARANTAG	ciraparantag	N[C@@H](CCCNC(N)=N)C(=O)NCCCN1CCN(CCCNC(=O)[C@@H](N)CCCNC(N)=N)CC1	SERUM	U2R67KV65Q													ng/mL	861			UNKNOWN	mg	25		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33205809/	Homo sapiens		h	0.19				8	ciraparantag		false
7982	8514		ADULT	71576543	512.6957	CIRAPARANTAG	ciraparantag	N[C@@H](CCCNC(N)=N)C(=O)NCCCN1CCN(CCCNC(=O)[C@@H](N)CCCNC(N)=N)CC1	SERUM	U2R67KV65Q													ng/mL	3860			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33205809/	Homo sapiens		h	0.24				8	ciraparantag		false
7983	8514		ADULT	71576543	512.6957	CIRAPARANTAG	ciraparantag	N[C@@H](CCCNC(N)=N)C(=O)NCCCN1CCN(CCCNC(=O)[C@@H](N)CCCNC(N)=N)CC1	SERUM	U2R67KV65Q									?				ng/mL	173			UNKNOWN	mg	5		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33205809/	Homo sapiens							8	ciraparantag		false
7984	8514		ADULT	71576543	512.6957	CIRAPARANTAG	ciraparantag	N[C@@H](CCCNC(N)=N)C(=O)NCCCN1CCN(CCCNC(=O)[C@@H](N)CCCNC(N)=N)CC1	SERUM	U2R67KV65Q							24		t	ng × h/mL	151		ng/mL	634			UNKNOWN	mg	15		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33205809/	Homo sapiens		h	0.2				8	ciraparantag		false
7985	8528		ADULT	24770514	388.587	CPI-613	CPI-613	OC(=O)CCCCC(CCSCC1=CC=CC=C1)SCC2=CC=CC=C2	PLASMA	E76113IR49									?	ng × h/mL	70.9		ng/mL	82.66			MAX TOLERATED	mg/m²	500		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28495639	Homo sapiens		h	0.52							false
7986	8535		UNKNOWN	16061579|135463437	363.2206	CYCLIC PYRANOPTERIN MONOPHOSPHATE	Cyclic pyranopterin monophosphate	NC1=NC(=O)C2=C(N[C@@H]3O[C@@H]4COP(O)(=O)O[C@@H]4C(O)(O)[C@@H]3N2)N1	PLASMA	4X7K2681Y7																						UNKNOWN				Human plasma protein binding: 6-12.4% (0.1-10mcM)	87.6	UNKNOWN		UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214018Orig1s000IntegratedR.pdf#page=29 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214018Orig1s000IntegratedR.pdf#page=186	Homo sapiens										false
7987	8535		ADULT	16061579|135463437	363.2206	CYCLIC PYRANOPTERIN MONOPHOSPHATE	Cyclic pyranopterin monophosphate	NC1=NC(=O)C2=C(N[C@@H]3O[C@@H]4COP(O)(=O)O[C@@H]4C(O)(O)[C@@H]3N2)N1	PLASMA	4X7K2681Y7									∞	ng × h/mL	5960		ng/mL	2800			UNKNOWN	mg/kg	0.68		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214018Orig1s000IntegratedR.pdf#page=93	Homo sapiens		h	1.64				6			false
7988	8535		ADULT	16061579|135463437	363.2206	CYCLIC PYRANOPTERIN MONOPHOSPHATE	Cyclic pyranopterin monophosphate	NC1=NC(=O)C2=C(N[C@@H]3O[C@@H]4COP(O)(=O)O[C@@H]4C(O)(O)[C@@H]3N2)N1	PLASMA	4X7K2681Y7									∞	ng × h/mL	523		ng/mL	285			UNKNOWN	mg/kg	0.075		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214018Orig1s000IntegratedR.pdf#page=93	Homo sapiens		h	1.22				6			false
7989	8535		ADULT	16061579|135463437	363.2206	CYCLIC PYRANOPTERIN MONOPHOSPHATE	Cyclic pyranopterin monophosphate	NC1=NC(=O)C2=C(N[C@@H]3O[C@@H]4COP(O)(=O)O[C@@H]4C(O)(O)[C@@H]3N2)N1	PLASMA	4X7K2681Y7									∞	ng × h/mL	1790		ng/mL	873			UNKNOWN	mg/kg	0.25		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214018Orig1s000IntegratedR.pdf#page=93	Homo sapiens		h	1.67				6			false
7990	8542		ADULT	91617630	393.4342	DAPRODUSTAT	OC(=O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C3CCCCC3)C1=O	OC(=O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C3CCCCC3)C1=O	PLASMA	JVR38ZM64B									∞	ng × h/mL	348		ng/mL	140			INVESTIGATIONAL	mg	10		STEADY-STATE	UNKNOWN		week	3			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/31619187	Homo sapiens		h	2.1							false
7991	8553		ADULT	25117126	510.493	DEFACTINIB	DEFACTINIB	CNC(=O)C1=CC=C(NC2=NC(NCC3=NC=CN=C3N(C)S(C)(=O)=O)=C(C=N2)C(F)(F)F)C=C1	SERUM	53O87HA2QU							12		t	ng × h/mL	3519		ng/mL	603.2			UNKNOWN	mg	425		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26334219	Homo sapiens		h	6.5							false
7992	8553		ADULT		510.493	DEFACTINIB	DEFACTINIB	CNC(=O)C1=CC=C(NC2=NC(NCC3=NC=CN=C3N(C)S(C)(=O)=O)=C(C=N2)C(F)(F)F)C=C1	SERUM	53O87HA2QU							12		t	ng × h/mL	1261		ng/mL	436.9			UNKNOWN	mg	500		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26334219	Homo sapiens		h	7.8							false
7993	8553		ADULT		510.493	DEFACTINIB	DEFACTINIB	CNC(=O)C1=CC=C(NC2=NC(NCC3=NC=CN=C3N(C)S(C)(=O)=O)=C(C=N2)C(F)(F)F)C=C1	SERUM	53O87HA2QU							12		t	ng × h/mL	1400		ng/mL	295			UNKNOWN	mg	300		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26334219	Homo sapiens		h	9.2							false
7994	8553		ADULT		510.493	DEFACTINIB	DEFACTINIB	CNC(=O)C1=CC=C(NC2=NC(NCC3=NC=CN=C3N(C)S(C)(=O)=O)=C(C=N2)C(F)(F)F)C=C1	SERUM	53O87HA2QU							12		t	ng × h/mL	632		ng/mL	184.4			UNKNOWN	mg	200		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26334219	Homo sapiens		h	2.1							false
7995	8553		ADULT		510.493	DEFACTINIB	DEFACTINIB	CNC(=O)C1=CC=C(NC2=NC(NCC3=NC=CN=C3N(C)S(C)(=O)=O)=C(C=N2)C(F)(F)F)C=C1	SERUM	53O87HA2QU							12		t	ng × h/mL	340		ng/mL	75.4			UNKNOWN	mg	100		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26334219	Homo sapiens		h	11.7							false
7996	8553		ADULT		510.493	DEFACTINIB	DEFACTINIB	CNC(=O)C1=CC=C(NC2=NC(NCC3=NC=CN=C3N(C)S(C)(=O)=O)=C(C=N2)C(F)(F)F)C=C1	SERUM	53O87HA2QU							12		t	ng × h/mL	357		ng/mL	93.1			UNKNOWN	mg	50		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26334219	Homo sapiens		h	5.6							false
7997	8553		ADULT		510.493	DEFACTINIB	DEFACTINIB	CNC(=O)C1=CC=C(NC2=NC(NCC3=NC=CN=C3N(C)S(C)(=O)=O)=C(C=N2)C(F)(F)F)C=C1	SERUM								12		t	ng × h/mL	47		ng/mL	7.8			UNKNOWN	mg	25		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26334219	Homo sapiens										false
7998	8553		ADULT		510.493	DEFACTINIB	DEFACTINIB	CNC(=O)C1=CC=C(NC2=NC(NCC3=NC=CN=C3N(C)S(C)(=O)=O)=C(C=N2)C(F)(F)F)C=C1	SERUM								12		t	ng × h/mL	32		ng/mL	7.7			UNKNOWN	mg	12.5		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26334219	Homo sapiens		h	3.8							false
7999	8553		ADULT	25117126	510.493	DEFACTINIB	DEFACTINIB	CNC(=O)C1=CC=C(NC2=NC(NCC3=NC=CN=C3N(C)S(C)(=O)=O)=C(C=N2)C(F)(F)F)C=C1	SERUM	53O87HA2QU							12		t	ng × h/mL	6334.2						UNKNOWN	mg	425		MULTIPLE	FED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26334219	Homo sapiens										false
8000	8553		ADULT	25117126	510.493	DEFACTINIB	DEFACTINIB	CNC(=O)C1=CC=C(NC2=NC(NCC3=NC=CN=C3N(C)S(C)(=O)=O)=C(C=N2)C(F)(F)F)C=C1	SERUM	53O87HA2QU							12		t	ng × h/mL	8372.7						UNKNOWN	mg	300		MULTIPLE	FED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26334219	Homo sapiens										false
8001	8553		ADULT	25117126	510.493	DEFACTINIB	DEFACTINIB	CNC(=O)C1=CC=C(NC2=NC(NCC3=NC=CN=C3N(C)S(C)(=O)=O)=C(C=N2)C(F)(F)F)C=C1	SERUM	53O87HA2QU							12		t	ng × h/mL	2952.9						UNKNOWN	mg	750		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26334219	Homo sapiens										false
8002	8553		ADULT	25117126	510.493	DEFACTINIB	DEFACTINIB	CNC(=O)C1=CC=C(NC2=NC(NCC3=NC=CN=C3N(C)S(C)(=O)=O)=C(C=N2)C(F)(F)F)C=C1	SERUM	53O87HA2QU							12		t	ng × h/mL	1639.3						UNKNOWN	mg	500		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26334219	Homo sapiens										false
8003	8553		ADULT	25117126	510.493	DEFACTINIB	DEFACTINIB	CNC(=O)C1=CC=C(NC2=NC(NCC3=NC=CN=C3N(C)S(C)(=O)=O)=C(C=N2)C(F)(F)F)C=C1	SERUM	53O87HA2QU							12		t	ng × h/mL	25782.6						UNKNOWN	mg	425		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26334219	Homo sapiens										false
8004	8553		ADULT		510.493	DEFACTINIB	DEFACTINIB	CNC(=O)C1=CC=C(NC2=NC(NCC3=NC=CN=C3N(C)S(C)(=O)=O)=C(C=N2)C(F)(F)F)C=C1	SERUM	53O87HA2QU							12		t	ng × h/mL	714						UNKNOWN	mg	50		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26334219	Homo sapiens										false
8005	8553		ADULT	25117126	510.493	DEFACTINIB	DEFACTINIB	CNC(=O)C1=CC=C(NC2=NC(NCC3=NC=CN=C3N(C)S(C)(=O)=O)=C(C=N2)C(F)(F)F)C=C1	SERUM	53O87HA2QU							12		t	ng × h/mL	884						UNKNOWN	mg	100		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26334219	Homo sapiens										false
8006	8553		ADULT	25117126	510.493	DEFACTINIB	DEFACTINIB	CNC(=O)C1=CC=C(NC2=NC(NCC3=NC=CN=C3N(C)S(C)(=O)=O)=C(C=N2)C(F)(F)F)C=C1	SERUM	53O87HA2QU							12		t	ng × h/mL	5180						UNKNOWN	mg	300		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26334219	Homo sapiens										false
8007	8553		ADULT	25117126	510.493	DEFACTINIB	DEFACTINIB	CNC(=O)C1=CC=C(NC2=NC(NCC3=NC=CN=C3N(C)S(C)(=O)=O)=C(C=N2)C(F)(F)F)C=C1	SERUM	53O87HA2QU							12		t	ng × h/mL	2148.8						UNKNOWN	mg	200		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26334219	Homo sapiens										false
8008	8553		ADULT		510.493	DEFACTINIB	DEFACTINIB	CNC(=O)C1=CC=C(NC2=NC(NCC3=NC=CN=C3N(C)S(C)(=O)=O)=C(C=N2)C(F)(F)F)C=C1	SERUM	53O87HA2QU							12		t	ng × h/mL	258.5						UNKNOWN	mg	25		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26334219	Homo sapiens										false
8009	8553		ADULT		510.493	DEFACTINIB	DEFACTINIB	CNC(=O)C1=CC=C(NC2=NC(NCC3=NC=CN=C3N(C)S(C)(=O)=O)=C(C=N2)C(F)(F)F)C=C1	SERUM	53O87HA2QU							12		t	ng × h/mL	201.6						UNKNOWN	mg	12.5		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26334219	Homo sapiens										false
8010	8553		ADULT	25117126	510.493	DEFACTINIB	DEFACTINIB	CNC(=O)C1=CC=C(NC2=NC(NCC3=NC=CN=C3N(C)S(C)(=O)=O)=C(C=N2)C(F)(F)F)C=C1	SERUM	53O87HA2QU							12		t	ng × h/mL	3101		ng/mL	596.5			UNKNOWN	mg	300		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26334219	Homo sapiens		h	8.6							false
8011	8553		ADULT	25117126	510.493	DEFACTINIB	DEFACTINIB	CNC(=O)C1=CC=C(NC2=NC(NCC3=NC=CN=C3N(C)S(C)(=O)=O)=C(C=N2)C(F)(F)F)C=C1	SERUM	53O87HA2QU							12		t	ng × h/mL	2658		ng/mL	552.6			UNKNOWN	mg	425		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26334219	Homo sapiens		h	8.9							false
8012	8553		ADULT	25117126	510.493	DEFACTINIB	DEFACTINIB	CNC(=O)C1=CC=C(NC2=NC(NCC3=NC=CN=C3N(C)S(C)(=O)=O)=C(C=N2)C(F)(F)F)C=C1	SERUM	53O87HA2QU							12		t	ng × h/mL	1737		ng/mL	356.8			UNKNOWN	mg	750		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26334219	Homo sapiens		h	11.1							false
8013	8553		ADULT	25117126	510.493	DEFACTINIB	DEFACTINIB	CNC(=O)C1=CC=C(NC2=NC(NCC3=NC=CN=C3N(C)S(C)(=O)=O)=C(C=N2)C(F)(F)F)C=C1	SERUM	53O87HA2QU									∞	μg × h/mL	2.68		μg/mL	0.61			UNKNOWN	mg	600		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/27025608	Homo sapiens		h	2.79				3			false
8014	8553		ADULT	25117126	510.493	DEFACTINIB	DEFACTINIB	CNC(=O)C1=CC=C(NC2=NC(NCC3=NC=CN=C3N(C)S(C)(=O)=O)=C(C=N2)C(F)(F)F)C=C1	SERUM	53O87HA2QU									∞	μg × h/mL	3.78		μg/mL	0.63			UNKNOWN	mg	200		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/27025608	Homo sapiens		h	4.29				3			false
8015	8553		ADULT	25117126	510.493	DEFACTINIB	DEFACTINIB	CNC(=O)C1=CC=C(NC2=NC(NCC3=NC=CN=C3N(C)S(C)(=O)=O)=C(C=N2)C(F)(F)F)C=C1	SERUM	53O87HA2QU									∞	μg × h/mL	3.84		μg/mL	0.67			RECOMMENDED	mg	400		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/27025608	Homo sapiens		h	2.45				3			false
8016	8553		ADULT	25117126	510.493	DEFACTINIB	DEFACTINIB	CNC(=O)C1=CC=C(NC2=NC(NCC3=NC=CN=C3N(C)S(C)(=O)=O)=C(C=N2)C(F)(F)F)C=C1	SERUM	53O87HA2QU							12		t	μg × h/mL	6.24		μg/mL	0.93			UNKNOWN	mg	200		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/27025608	Homo sapiens		h	2.95				3			false
8017	8553		ADULT	25117126	510.493	DEFACTINIB	DEFACTINIB	CNC(=O)C1=CC=C(NC2=NC(NCC3=NC=CN=C3N(C)S(C)(=O)=O)=C(C=N2)C(F)(F)F)C=C1	SERUM	53O87HA2QU							12		t	μg × h/mL	5.71		μg/mL	0.96			RECOMMENDED	mg	400		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/27025608	Homo sapiens		h	2.95				3			false
8018	8553		ADULT	25117126	510.493	DEFACTINIB	DEFACTINIB	CNC(=O)C1=CC=C(NC2=NC(NCC3=NC=CN=C3N(C)S(C)(=O)=O)=C(C=N2)C(F)(F)F)C=C1	SERUM	53O87HA2QU							12		t	μg × h/mL	4.88		μg/mL	0.98			UNKNOWN	mg	600		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/27025608	Homo sapiens		h	2.27				3			false
8019	8556		ADULT	24800541	413.275	DELANZOMIB	DELANZOMIB	CC(C)C[C@H](NC(=O)[C@@H](NC(=O)C1=NC(=CC=C1)C2=CC=CC=C2)[C@@H](C)O)B(O)O	BLOOD	6IF28942WO									?	ng × h/mL	1454.6		ng/mL	470.7			MAX TOLERATED	mg/m²	1.5		MULTIPLE	UNKNOWN		week	2			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/23058787	Homo sapiens										false
8020	8563		ADULT	59868	211.327	DEXPRAMIPEXOLE	DEXPRAMIPEXOLE	CCCN[C@@H]1CCC2=C(C1)SC(N)=N2	PLASMA	WI638GUS96							12		t	ng × h/mL	3749		ng/mL	479			UNKNOWN	mg	150		MULTIPLE	FASTED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20959524	Homo sapiens		h	8.1				6	DEXPRAMIPEXOLE		false
8021	8563		ADULT	59868	211.327	DEXPRAMIPEXOLE	DEXPRAMIPEXOLE	CCCN[C@@H]1CCC2=C(C1)SC(N)=N2	PLASMA	WI638GUS96									∞	ng × h/mL	8624		ng/mL	781			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20959524	Homo sapiens		h	6.4				6	DEXPRAMIPEXOLE		false
8022	8564		ADULT	204105	382.4528	DEXTOFISOPAM	DEXTOFISOPAM	CC[C@@H]1C2=C(C=C(OC)C(OC)=C2)C(=NN=C1C)C3=CC(OC)=C(OC)C=C3	PLASMA	EZ15I5D6C1									∞	ng × h/mL	1729		ng/mL	756			UNKNOWN	mg	400		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	OTHER	https://www.researchgate.net/publication/228774168_The_potential_of_dextofisopam_for_treatment_of_irritable_bowel_syndrome_and_inflammatory_bowel_disease	Homo sapiens		h	10.15				6	DEXTOFISOPAM		false
8023	8564		ADULT	204105	382.4528	DEXTOFISOPAM	DEXTOFISOPAM	CC[C@@H]1C2=C(C=C(OC)C(OC)=C2)C(=NN=C1C)C3=CC(OC)=C(OC)C=C3	PLASMA	EZ15I5D6C1									∞	ng × h/mL	844		ng/mL	402			UNKNOWN	mg	200		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE / MALE	OTHER	https://www.researchgate.net/publication/228774168_The_potential_of_dextofisopam_for_treatment_of_irritable_bowel_syndrome_and_inflammatory_bowel_disease	Homo sapiens		h	11.2	day 7			18	DEXTOFISOPAM		false
8024	8564		ADULT	204105	382.4528	DEXTOFISOPAM	DEXTOFISOPAM	CC[C@@H]1C2=C(C=C(OC)C(OC)=C2)C(=NN=C1C)C3=CC(OC)=C(OC)C=C3	PLASMA	EZ15I5D6C1							12		t	ng × h/mL	3338		ng/mL	1508			UNKNOWN	mg	600		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE / MALE	OTHER	https://www.researchgate.net/publication/228774168_The_potential_of_dextofisopam_for_treatment_of_irritable_bowel_syndrome_and_inflammatory_bowel_disease	Homo sapiens				day 1			6	DEXTOFISOPAM		false
8025	8564		ADULT	204105	382.4528	DEXTOFISOPAM	DEXTOFISOPAM	CC[C@@H]1C2=C(C=C(OC)C(OC)=C2)C(=NN=C1C)C3=CC(OC)=C(OC)C=C3	PLASMA	EZ15I5D6C1							12		t	ng × h/mL	3490		ng/mL	1251			UNKNOWN	mg	600		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE / MALE	OTHER	https://www.researchgate.net/publication/228774168_The_potential_of_dextofisopam_for_treatment_of_irritable_bowel_syndrome_and_inflammatory_bowel_disease	Homo sapiens		h	10.1	day 7			6	DEXTOFISOPAM		false
8026	8573		ADULT	9810929	785.091	DOLASTATIN 10	DOLASTATIN 10	CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](CC2=CC=CC=C2)C3=NC=CS3)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C	PLASMA	EI946JT51X									?	ng × h/L	14.96		ng/mL	57.3			UNKNOWN	μg/m²	65		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10778954	Homo sapiens		h	0.09				4	DOLASTATIN 10		false
8027	8573		ADULT	9810929	785.091	DOLASTATIN 10	DOLASTATIN 10	CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](CC2=CC=CC=C2)C3=NC=CS3)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C	PLASMA	EI946JT51X									?	ng × h/L	19.7		ng/mL	55			UNKNOWN	μg/m²	100		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10778954	Homo sapiens		h	0.13				4	DOLASTATIN 10		false
8028	8573		ADULT	9810929	785.091	DOLASTATIN 10	DOLASTATIN 10	CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](CC2=CC=CC=C2)C3=NC=CS3)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C	PLASMA	EI946JT51X									?	ng × h/L	52.49		ng/mL	143.9			UNKNOWN	μg/m²	200		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10778954	Homo sapiens		h	0.12				5	DOLASTATIN 10		false
8029	8573		ADULT	9810929	785.091	DOLASTATIN 10	DOLASTATIN 10	CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](CC2=CC=CC=C2)C3=NC=CS3)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C	PLASMA	EI946JT51X									?	ng × h/L	89.9		ng/mL	96			UNKNOWN	μg/m²	300		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10778954	Homo sapiens		h	0.06				5	DOLASTATIN 10		false
8030	8597		ADULT	300471	400.518	ELESCLOMOL	ELESCLOMOL	CN(NC(=O)CC(=O)NN(C)C(=S)C1=CC=CC=C1)C(=S)C2=CC=CC=C2	PLASMA	6UK191M53P			PACLITAXEL	Paclitaxel	CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C3=CC=CC=C3)[C@@H]4[C@@]5(CO[C@@H]5C[C@H](O)[C@@]4(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C6=CC=CC=C6)C7=CC=CC=C7	P88XT4IS4D			∞	μM × h	38.2		μM	12.84			MAX TOLERATED	mg/m²	438		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/17255281	Homo sapiens		h	1.06							true
8031	8607		ADULT	25141092	560.6375	ENTRECTINIB	CN1CCN(CC1)C2=CC(NC3CCOCC3)=C(C=C2)C(=O)NC4=NNC5=C4C=C(CC6=CC(F)=CC(F)=C6)C=C5	CN1CCN(CC1)C2=CC(NC3CCOCC3)=C(C=C2)C(=O)NC4=NNC5=C4C=C(CC6=CC(F)=CC(F)=C6)C=C5	PLASMA	L5ORF0AN1I							24		t	nM × h	31800		nM	2250			RECOMMENDED	mg	600		SINGLE	UNKNOWN				Entrectinib and its active major metabolite M5 are both > 99% bound to human plasma proteins in vitro.	1	UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf	Homo sapiens		h	20							false
8032	8613		ADULT	91469	242.2699	EQUOL, (-)-	EQUOL, (-)-	OC1=CC=C(C=C1)[C@H]2COC3=C(C2)C=CC(O)=C3	PLASMA	2T6D2HPX7Q									∞	ng × h/mL	25299		nM	4953			UNKNOWN	mg	30		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19776178	Homo sapiens		h	8.2				12	EQUOL, (-)-		false
8033	8613		ADULT	91469	242.2699	EQUOL, (-)-	EQUOL, (-)-	OC1=CC=C(C=C1)[C@H]2COC3=C(C2)C=CC(O)=C3	PLASMA	2T6D2HPX7Q									∞	ng × h/mL	8584		nM	1907			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19776178	Homo sapiens		h	7.4				12	S-(-)Equol		false
8034	8615		ADULT	23642301	1194.273	ELACESTRANT	ELACESTRANT	CC(C)CC(NC(=O)C(N)CCC(O)=O)C(=O)NC(C)C(=O)NC(CS)C(=O)NC(CCC(O)=O)C(=O)NC(CO)C(=O)NC(C(C)O)C(=O)NC(CCCNC(N)=N)C(=O)NC(C)C(=O)NC(CC(N)=O)C(=O)NC(C(C)O)C(O)=O	PLASMA	FM6A2627A8							24		∞	ng × h/mL	774		ng/mL	31.5			UNKNOWN	mg	200		SINGLE	FASTED				Plasma protein binding of elacestrant is >99% and independent of concentration.	1	HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32661909/	Homo sapiens		h	27.4				6	ELACESTRANT		false
8035	8615		ADULT	23642301	1194.273	ELACESTRANT	ELACESTRANT	CC(C)CC(NC(=O)C(N)CCC(O)=O)C(=O)NC(C)C(=O)NC(CS)C(=O)NC(CCC(O)=O)C(=O)NC(CO)C(=O)NC(C(C)O)C(=O)NC(CCCNC(N)=N)C(=O)NC(C)C(=O)NC(CC(N)=O)C(=O)NC(C(C)O)C(O)=O	PLASMA	FM6A2627A8							24		?	ng × h/mL	627		ng/mL	43.5			UNKNOWN	mg	200		MULTIPLE	FASTED		day	1	Plasma protein binding of elacestrant is >99% and independent of concentration.	1	HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32661909/	Homo sapiens		h	47.3				8	ELACESTRANT		false
8036	8615		ADULT	23642301	1194.273	ELACESTRANT	ELACESTRANT	CC(C)CC(NC(=O)C(N)CCC(O)=O)C(=O)NC(C)C(=O)NC(CS)C(=O)NC(CCC(O)=O)C(=O)NC(CO)C(=O)NC(C(C)O)C(=O)NC(CCCNC(N)=N)C(=O)NC(C)C(=O)NC(CC(N)=O)C(=O)NC(C(C)O)C(O)=O	PLASMA	FM6A2627A8							24		?	ng × h/mL	8327		ng/mL	543			HIGHEST STUDIED	mg	1000		MULTIPLE	FED		day	1	Plasma protein binding of elacestrant is >99% and independent of concentration.	1	HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32661909/	Homo sapiens		h	41.6				3	ELACESTRANT		false
8037	8615		ADULT	23642301	1194.273	ELACESTRANT	ELACESTRANT	CC(C)CC(NC(=O)C(N)CCC(O)=O)C(=O)NC(C)C(=O)NC(CS)C(=O)NC(CCC(O)=O)C(=O)NC(CO)C(=O)NC(C(C)O)C(=O)NC(CCCNC(N)=N)C(=O)NC(C)C(=O)NC(CC(N)=O)C(=O)NC(C(C)O)C(O)=O	PLASMA	FM6A2627A8							24		t	ng × h/mL	2440		ng/mL	119			RECOMMENDED	mg	345		SINGLE	UNKNOWN				Plasma protein binding of elacestrant is >99% and independent of concentration.	1	UNKNOWN	Oral	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217639s000lbl.pdf	Homo sapiens		h	40					ELACESTRANT		false
8038	8616		ADULT	67462786	446.5	ERDAFITINIB	ERDAFITINIB	COC1=CC(=CC(OC)=C1)N(CCNC(C)C)C2=CC=C3N=CC(=NC3=C2)C4=CN(C)N=C4	PLASMA	890E37NHMV									?	ng × h/mL	29268		ng/mL	1399			RECOMMENDED	mg	8		STEADY-STATE	UNKNOWN		day	1	Erdafitinib protein binding was 99.8% in patients, primarily to alpha-1-acid glycoprotein.	0.2	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf	Homo sapiens		h	59							false
8039	8617		ADULT	71777283	304.3808	ESTETROL	ESTETROL	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1[C@@H](O)[C@@H](O)[C@@H]2O	PLASMA	ENB39R14VF							24		t	ng × h/mL	194.2		ng/mL	87.3			UNKNOWN	mg	40		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/28267365	Homo sapiens										false
8040	8617		ADULT	71777283	304.3808	ESTETROL	ESTETROL	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1[C@@H](O)[C@@H](O)[C@@H]2O	PLASMA	ENB39R14VF													ng/mL	8.01			RECOMMENDED	mg	10		SINGLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/28267365	Homo sapiens										false
8041	8637		ADULT	44224257	420.476	FILANESIB	filanesib	CON(C)C(=O)N1N=C(S[C@@]1(CCCN)C2=CC=CC=C2)C3=C(F)C=CC(F)=C3	PLASMA	8A49OSO368									∞	ng × h/mL	1570		ng/mL	72			MAX TOLERATED	mg/m²	2.5		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/25684345	Homo sapiens		h	66							false
8042	8663		ADULT	25101874	448.5175	GEPOTIDACIN	gepotidacin	O=C1C=CC2=C3N1C[C@@H](CN4CCC(CC4)NCC5=NC=C6OCCCC6=C5)N3C(=O)C=N2	PLASMA	DVF0PR037D									∞	μg × h/mL	22.37		μg/mL	5.306			UNKNOWN	mg	750		SINGLE	UNKNOWN				Protein binding was determined in human plasma samples using equilibrium dialysis and was found to be low (33%).	67	UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32429000/	Homo sapiens		h	10.88	Moderate Renal Impairment			8	gepotidacin		false
8043	8663		ADULT	25101874	448.5175	GEPOTIDACIN	gepotidacin	O=C1C=CC2=C3N1C[C@@H](CN4CCC(CC4)NCC5=NC=C6OCCCC6=C5)N3C(=O)C=N2	PLASMA	DVF0PR037D									∞	μg × h/mL	14.84		μg/mL	4.498			UNKNOWN	mg	750		SINGLE	UNKNOWN				Protein binding was determined in human plasma samples using equilibrium dialysis and was found to be low (33%).	67	HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32429000/	Homo sapiens		h	11.5	Normal Renal Function			8	gepotidacin		false
8044	8663		ADULT	25101874	448.5175	GEPOTIDACIN	Gepotidacin	O=C1C=CC2=C3N1C[C@@H](CN4CCC(CC4)NCC5=NC=C6OCCCC6=C5)N3C(=O)C=N2	SALIVA	DVF0PR037D									∞	μg × h/mL	14.33		μg/mL	2.58			UNKNOWN	mg	750		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32429000/	Homo sapiens		h	9.71	Moderate Renal Impairment			8	Gepotidacin		false
8045	8663		ADULT	25101874	448.5175	GEPOTIDACIN	Gepotidacin	O=C1C=CC2=C3N1C[C@@H](CN4CCC(CC4)NCC5=NC=C6OCCCC6=C5)N3C(=O)C=N2	PLASMA	DVF0PR037D									∞	μg × h/mL	28.55		μg/mL	7.084			UNKNOWN	mg	750		SINGLE	UNKNOWN				Protein binding was determined in human plasma samples using equilibrium dialysis and was found to be low (33%).	67	UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32429000/	Homo sapiens		h	11.06	Severe Renal Impairment			8	Gepotidacin		false
8046	8663		ADULT	25101874	448.5175	GEPOTIDACIN	Gepotidacin	O=C1C=CC2=C3N1C[C@@H](CN4CCC(CC4)NCC5=NC=C6OCCCC6=C5)N3C(=O)C=N2	SALIVA	DVF0PR037D									∞	μg × h/mL	16.33		μg/mL	3.26			UNKNOWN	mg	750		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32429000/	Homo sapiens		h	8.73	severe Renal Impairment			8	Gepotidacin		false
8047	8663		ADULT	25101874	448.5175	GEPOTIDACIN	Gepotidacin	O=C1C=CC2=C3N1C[C@@H](CN4CCC(CC4)NCC5=NC=C6OCCCC6=C5)N3C(=O)C=N2	SALIVA	DVF0PR037D									∞	μg × h/mL	9.78		μg/mL	2.76			UNKNOWN	mg	750		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32429000/	Homo sapiens		h	9.6	Normal Renal Function			8	Gepotidacin		false
8048	8663		ADULT	25101874	448.5175	GEPOTIDACIN	Gepotidacin	O=C1C=CC2=C3N1C[C@@H](CN4CCC(CC4)NCC5=NC=C6OCCCC6=C5)N3C(=O)C=N2	PLASMA	DVF0PR037D									∞	μg × h/mL	15.9		μg/mL	3.2			UNKNOWN	mg	1500		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33450142/	Homo sapiens		h	9.07	normal hepatic function			9	Gepotidacin		false
8049	8663		ADULT	25101874	448.5175	GEPOTIDACIN	Gepotidacin	O=C1C=CC2=C3N1C[C@@H](CN4CCC(CC4)NCC5=NC=C6OCCCC6=C5)N3C(=O)C=N2	PLASMA	DVF0PR037D									∞	μg × h/mL	19.5		μg/mL	3.91			UNKNOWN	mg	1500		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33450142/	Homo sapiens		h	8.52	Moderate Hepatic Impairment			8	Gepotidacin		false
8050	8663		ADULT	25101874	448.5175	GEPOTIDACIN	Gepotidacin	O=C1C=CC2=C3N1C[C@@H](CN4CCC(CC4)NCC5=NC=C6OCCCC6=C5)N3C(=O)C=N2	SALIVA	DVF0PR037D									∞	μg × h/mL	9.82		μg/mL	1.65			UNKNOWN	mg	1500		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33450142/	Homo sapiens		h	6.75	Moderate Hepatic Impairment			8	Gepotidacin		false
8051	8663		ADULT	25101874	448.5175	GEPOTIDACIN	gepotidacin	O=C1C=CC2=C3N1C[C@@H](CN4CCC(CC4)NCC5=NC=C6OCCCC6=C5)N3C(=O)C=N2	SALIVA	DVF0PR037D									∞	μg × h/mL	8.04		μg/mL	1.29			UNKNOWN	mg	1500		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33450142/	Homo sapiens		h	9.24	Normal Hepatic Function			9	Gepotidacin		false
8052	8663		ADULT	25101874	448.5175	GEPOTIDACIN	Gepotidacin	O=C1C=CC2=C3N1C[C@@H](CN4CCC(CC4)NCC5=NC=C6OCCCC6=C5)N3C(=O)C=N2	SALIVA	DVF0PR037D									∞	μg × h/mL	14.1		μg/mL	2.7			UNKNOWN	mg	1500		SINGLE	FED						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33450142/	Homo sapiens		h	7.18	Severe Hepatic Impairment			8	Gepotidacin		false
8053	8663		ADULT	25101874	448.5175	GEPOTIDACIN	Gepotidacin	O=C1C=CC2=C3N1C[C@@H](CN4CCC(CC4)NCC5=NC=C6OCCCC6=C5)N3C(=O)C=N2	PLASMA	DVF0PR037D									∞	μg × h/mL	25.4		μg/mL	5.54			UNKNOWN	mg	1500		SINGLE	FED						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33450142/	Homo sapiens		h	8.21	Severe Hepatic Impairment			8	Gepotidacin		false
8054	8675		ADULT	24996872	456.558	GSK-1292263	GSK-1292263	CC(C)C1=NOC(=N1)N2CCC(COC3=CN=C(C=C3)C4=CC=C(C=C4)S(C)(=O)=O)CC2	PLASMA	R1J57STA6O	446157	481.538	ROSUVASTATIN	Rosuvastatin	CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\\C=C\\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O	413KH5ZJ73	24		t	ng × h/mL	13956		ng/mL	870			UNKNOWN	mg	300		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23256625	Homo sapiens		h	12			single 10 mg dose	27	GSK-1292263		true
8055	8679		ADULT	9827968	518.584	GSK-256066	GSK-256066	COC1=CC=CC(NC2=C(C=NC3=C(C)C=C(C=C23)S(=O)(=O)C4=CC(=CC=C4)C(=O)N(C)C)C(N)=O)=C1	PLASMA	2D6GK059SR									?	pg × h/mL	36.8		pg/mL	18.3			UNKNOWN	μg	87.5		SINGLE	UNKNOWN						UNHEALTHY	Respiratory	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20193079	Homo sapiens							19	GSK-256066		false
8056	8679		ADULT	9827968	518.584	GSK-256066	GSK256066	COC1=CC=CC(NC2=C(C=NC3=C(C)C=C(C=C23)S(=O)(=O)C4=CC(=CC=C4)C(=O)N(C)C)C(N)=O)=C1	PLASMA	2D6GK059SR									?	pg × h/mL	64.8		pg/mL	17.3			UNKNOWN	μg	8.75		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Respiratory	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20193079	Homo sapiens							19	GSK256066		false
8057	8685		ADULT	10253143	449.254	GW842166	GW842166	FC(F)(F)C1=C(C=NC(NC2=CC=C(Cl)C=C2Cl)=N1)C(=O)NCC3CCOCC3	PLASMA	VL1I6P2DZ8							24		t	μg × h/mL	3.57		μg/mL	0.285			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21540741	Homo sapiens							28			false
8058	8685		ADULT	10253143	449.254	GW842166	GW842166	FC(F)(F)C1=C(C=NC(NC2=CC=C(Cl)C=C2Cl)=N1)C(=O)NCC3CCOCC3	PLASMA	VL1I6P2DZ8							24		t	μg × h/mL	9.01		μg/mL	0.714			UNKNOWN	mg	800		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21540741	Homo sapiens							28			false
8059	8696		ADULT	5281051	504.4432	HYPERICIN	Hypericin	CC1=CC(O)=C2C(=O)C3=C(O)C=C(O)C4=C3C5=C6C7=C(C(O)=CC(C)=C7C1=C25)C(=O)C8=C(O)C=C(O)C4=C68	PLASMA	7V2F1075HD									?	ng × h/mL	1920		ng/mL	1.5			UNKNOWN	μg	250		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7857509/	Homo sapiens		h	24.8				4	Hypericum extract LI 160, 300mg (250μg hypericin)		false
8060	8696		ADULT	5281051	504.4432	HYPERICIN	Hypericin	CC1=CC(O)=C2C(=O)C3=C(O)C=C(O)C4=C3C5=C6C7=C(C(O)=CC(C)=C7C1=C25)C(=O)C8=C(O)C=C(O)C4=C68	PLASMA	7V2F1075HD									?	ng × h/mL	23090		ng/mL	14.2			UNKNOWN	μg	1500		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7857509/	Homo sapiens		h	26.5				4	Hypericum extract LI 160, 900mg (750μg hypericin)		false
8061	8696		ADULT	5281051	504.4432	HYPERICIN	Hypericin	CC1=CC(O)=C2C(=O)C3=C(O)C=C(O)C4=C3C5=C6C7=C(C(O)=CC(C)=C7C1=C25)C(=O)C8=C(O)C=C(O)C4=C68	PLASMA	7V2F1075HD									?	ng × h/mL	8820		ng/mL	7.5			UNKNOWN	μg	750		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7857509/	Homo sapiens		h	26				3	Hypericum extract LI 160, 900mg (750μg hypericin)		false
8062	8696		ADULT	5281051	504.4432	HYPERICIN	Hypericin	CC1=CC(O)=C2C(=O)C3=C(O)C=C(O)C4=C3C5=C6C7=C(C(O)=CC(C)=C7C1=C25)C(=O)C8=C(O)C=C(O)C4=C68	PLASMA	7V2F1075HD									∞	μg × h/L	41.4		μg/L	1.3			UNKNOWN	μg	250		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8878586/	Homo sapiens		h	24.5				12	St. John’s Wort extract LI 16, 300mg		false
8063	8696		ADULT	5281051	504.4432	HYPERICIN	Hypericin	CC1=CC(O)=C2C(=O)C3=C(O)C=C(O)C4=C3C5=C6C7=C(C(O)=CC(C)=C7C1=C25)C(=O)C8=C(O)C=C(O)C4=C68	PLASMA	7V2F1075HD									∞	μg × h/L	198		μg/L	7.2			UNKNOWN	μg	750		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8878586/	Homo sapiens		h	43.1				12	St. John’s Wort extract LI 16, 900mg		false
8064	8696		ADULT	5281051	504.4432	HYPERICIN	Hypericin	CC1=CC(O)=C2C(=O)C3=C(O)C=C(O)C4=C3C5=C6C7=C(C(O)=CC(C)=C7C1=C25)C(=O)C8=C(O)C=C(O)C4=C68	PLASMA	7V2F1075HD									∞	μg × h/L	494		μg/L	16.6			UNKNOWN	μg	1500		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8878586/	Homo sapiens		h	48.2				12	St. John’s Wort extract LI 16, 1800mg		false
8065	8697		ADULT	5488822	514.5	Icariside II	Icariside II	C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC2=C(OC3=C(C(=CC(=C3C2=O)O)O)CC=C(C)C)C4=CC=C(C=C4)OC)O)O)O	PLASMA										∞	mg × h/mL	255		ng/mL	10.08			UNKNOWN	mg	80		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://link.springer.com/content/pdf/10.1365/s10337-008-0685-4.pdf	Homo sapiens		h	2.21				6	Icariin		false
8066	8697		ADULT	5318997	676.6617	ICARIIN	Icariin	COC1=CC=C(C=C1)C2=C(O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)C(=O)C4=C(O2)C(CC=C(C)C)=C(O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C=C4O	PLASMA	VNM47R2QSQ									∞	ng × h/mL	279		ng/mL	7.89			UNKNOWN	mg	80		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://link.springer.com/content/pdf/10.1365/s10337-008-0685-4.pdf	Homo sapiens		h	3.16				6	Icariin		false
8067	8703		ADULT		520.5439	INCB-3284	INCB-3284	COC1=CC=C(C=N1)[C@]2(O)CC[C@@H](CC2)N3CC[C@H](C3)NC(=O)CNC(=O)C4=CC=CC(=C4)C(F)(F)F	SERUM	0W6K09GAQB																					MULTIPLE	UNKNOWN		day	1	In protein binding, INCB3284 had a high free fraction (58%) in human serum at concentrations of 1 and 10 μM	58	HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/24900329/	Homo sapiens		h	15					INCB3284		false
8068	8707		ADULT	3071	246.3065	3,3'-DIINDOLYLMETHANE	3,3\'-Diindolylmethane	C(C1=CNC2=C1C=CC=C2)C3=CNC4=C3C=CC=C4	PLASMA	SSZ9HQT61Z							24		t	ng × h/mL	1608		ng/mL	262			UNKNOWN	mg	800		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17164373	Homo sapiens		h	4.2				4	INDOLE-3-CARBINOL		false
8069	8707		ADULT	3071	246.3065	3,3'-DIINDOLYLMETHANE	3,3\'-Diindolylmethane	C(C1=CNC2=C1C=CC=C2)C3=CNC4=C3C=CC=C4	PLASMA	SSZ9HQT61Z							24		t	ng × h/mL	3212		ng/mL	510			UNKNOWN	mg	1200		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17164373	Homo sapiens		h	5				8	Indole-3-carbinol		false
8070	8707		ADULT	3071	246.3065	3,3'-DIINDOLYLMETHANE	3,3\'-Diindolylmethane	C(C1=CNC2=C1C=CC=C2)C3=CNC4=C3C=CC=C4	PLASMA	SSZ9HQT61Z							24		t	ng × h/mL	329		ng/mL	61			MAX TOLERATED	mg	400		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17164373/	Homo sapiens		h	3.8				4	INDOLE-3-CARBINOL		false
8071	8707		ADULT	3071	246.3065	3,3'-DIINDOLYLMETHANE	3,3\'-DIINDOLYLMETHANE	C(C1=CNC2=C1C=CC=C2)C3=CNC4=C3C=CC=C4	PLASMA	SSZ9HQT61Z							24		t	ng × h/mL	372		ng/mL	69			UNKNOWN	mg	400		MULTIPLE	FASTED		day	2			HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17164373/	Homo sapiens		h	6				14	Indole-3-carbinol		false
8072	8707		ADULT	3071	246.3065	3,3'-DIINDOLYLMETHANE	3,3\'-DIINDOLYLMETHANE	C(C1=CNC2=C1C=CC=C2)C3=CNC4=C3C=CC=C4	PLASMA	SSZ9HQT61Z							24		t	ng × h/mL	3376		ng/mL	607			UNKNOWN	mg	1000		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17164373/	Homo sapiens		h	5.7				3	Indole-3-carbinol		false
8073	8707		ADULT	3071	246.3065	3,3'-DIINDOLYLMETHANE	3,3\'-DIINDOLYLMETHANE	C(C1=CNC2=C1C=CC=C2)C3=CNC4=C3C=CC=C4	PLASMA	SSZ9HQT61Z							24		t	ng × h/mL	364		ng/mL	93			UNKNOWN	mg	600		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17164373/	Homo sapiens		h	2				4	INDOLE-3-CARBINOL		false
8074	8708		ADULT	405012|6920151	218.2518	INDOXIMOD	CN1C=C(C[C@@H](N)C(O)=O)C2=C1C=CC=C2	CN1C=C(C[C@@H](N)C(O)=O)C2=C1C=CC=C2	PLASMA	TX5CYN1KMZ							48		t	ng × h/mL	30000						RECOMMENDED	mg	1200		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/25327557	Homo sapiens		h	11.3							false
8075	8708		ADULT	405012|6920151	218.2518	INDOXIMOD	CN1C=C(C[C@@H](N)C(O)=O)C2=C1C=CC=C2	CN1C=C(C[C@@H](N)C(O)=O)C2=C1C=CC=C2	PLASMA	TX5CYN1KMZ													μM	12			INVESTIGATIONAL	mg	2000		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/27008709	Homo sapiens		h	10.5							false
8076	8712		ADULT	24951021	360.4904	ISTAROXIME	istaroxime	C[C@]12CC[C@H]3[C@@H](CC(=O)[C@H]4CC(CC[C@]34C)=NOCCN)[C@@H]1CCC2=O	PLASMA	W8I9H2TPPL																	UNKNOWN	μg/kg/min	3.33		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17239705/	Homo sapiens		min	16.6				6	istaroxime		false
8077	8712		ADULT	24951021	360.4904	ISTAROXIME	istaroxime	C[C@]12CC[C@H]3[C@@H](CC(=O)[C@H]4CC(CC[C@]34C)=NOCCN)[C@@H]1CCC2=O	PLASMA	W8I9H2TPPL													ng/mL	90.9			UNKNOWN	μg/kg/min	5		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17239705/	Homo sapiens		min	18.3				3	istaroxime		false
8078	8712		ADULT	24951021	360.4904	ISTAROXIME	istaroxime	C[C@]12CC[C@H]3[C@@H](CC(=O)[C@H]4CC(CC[C@]34C)=NOCCN)[C@@H]1CCC2=O	PLASMA	W8I9H2TPPL													ng/mL	14.46			UNKNOWN	μg/kg/min	0.5		SINGLE	UNKNOWN		hour	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17239705/	Homo sapiens							6	istaroxime		false
8079	8716		ADULT	16058752	372.3357	JNJ-37822681	JNJ-37822681	FC1=CC=C(CN2CCC(CC2)NC3=NN=C(C=C3)C(F)(F)F)C=C1F	PLASMA	GJB2URS7NJ							12		t	ng × h/mL	127		ng/mL	28.6			UNKNOWN	mg	10		SINGLE	UNKNOWN				plasma protein binding of JNJ037822681 is not high (82.1%).	7.9	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22773165	Homo sapiens							12			false
8080	8716		ADULT	16058752	372.3357	JNJ-37822681	JNJ-37822681	FC1=CC=C(CN2CCC(CC2)NC3=NN=C(C=C3)C(F)(F)F)C=C1F	PLASMA	GJB2URS7NJ							12		t	ng × h/mL	341		ng/mL	47.3			UNKNOWN	mg	10		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22773165	Homo sapiens		h	30.5				12			false
8081	8734			23635314	431.5268	KX-01	KX-01	O=C(CC1=NC=C(C=C1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4	SERUM	4V9848RS5G																										KX2-391 is 83 % protein-bound in the serum.	17				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23314737/	Homo sapiens										false
8082	8734		ADULT	23635314	431.5268	KX-01	KX-01	O=C(CC1=NC=C(C=C1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4	PLASMA	4V9848RS5G									∞	ng × h/mL	16.28		ng/mL	3.73			UNKNOWN	mg	2		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23361621/	Homo sapiens		h	3.45	Day 22	patients with advanced solid cancers or lymphoma		3			false
8083	8734		ADULT	23635314	431.5268	KX-01	KX-01	O=C(CC1=NC=C(C=C1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4	PLASMA	4V9848RS5G									∞	ng × h/mL	31		ng/mL	9.55			UNKNOWN	mg	5		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23361621/	Homo sapiens		h	3.01	Day 1	patients with advanced solid cancers or lymphoma		4			false
8084	8734		ADULT	23635314	431.5268	KX-01	KX-01	O=C(CC1=NC=C(C=C1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4	PLASMA	4V9848RS5G									∞	ng × h/mL	85.95		ng/mL	16.6			UNKNOWN	mg	5		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23361621/	Homo sapiens		h	4.95	Day 22	patients with advanced solid cancers or lymphoma		3			false
8085	8734		ADULT	23635314	431.5268	KX-01	KX-01	O=C(CC1=NC=C(C=C1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4	PLASMA	4V9848RS5G									∞	ng × h/mL	68.65		ng/mL	26.45			UNKNOWN	mg	10		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23361621/	Homo sapiens		h	2.98	Day 1	patients with advanced solid cancers or lymphoma		4			false
8086	8734		ADULT	23635314	431.5268	KX-01	KX-01	O=C(CC1=NC=C(C=C1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4	PLASMA	4V9848RS5G									∞	ng × h/mL	58.48		ng/mL	14.9			UNKNOWN	mg	10		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23361621/	Homo sapiens		h	2.96	Day 22	patients with advanced solid cancers or lymphoma		3			false
8087	8734		ADULT	23635314	431.5268	KX-01	KX-01	O=C(CC1=NC=C(C=C1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4	PLASMA	4V9848RS5G									∞	ng × h/mL	143.79		ng/mL	37.85			UNKNOWN	mg	20		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23361621/	Homo sapiens		h	5.6	Day 1	patients with advanced solid cancers or lymphoma		4			false
8088	8734		ADULT	23635314	431.5268	KX-01	KX-01	O=C(CC1=NC=C(C=C1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4	PLASMA	4V9848RS5G									∞	ng × h/mL	104.49		ng/mL	33.85			UNKNOWN	mg	20		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23361621/	Homo sapiens		h	3.52	Day 22	patients with advanced solid cancers or lymphoma		4			false
8089	8734		ADULT	23635314	431.5268	KX-01	KX-01	O=C(CC1=NC=C(C=C1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4	PLASMA	4V9848RS5G									∞	ng × h/mL	332.97		ng/mL	79.75			UNKNOWN	mg	40		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23361621/	Homo sapiens		h	3.47	Day 1	patients with advanced solid cancers or lymphoma		14			false
8090	8734		ADULT	23635314	431.5268	KX-01	KX-01	O=C(CC1=NC=C(C=C1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4	PLASMA	4V9848RS5G									∞	ng × h/mL	336.09		ng/mL	73.1			UNKNOWN	mg	40		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23361621/	Homo sapiens		h	4.53	Day 22 (Subjects received 40 mg KX2-391 in a 3 week on, 1-week off schedule)	patients with advanced solid cancers or lymphoma		6			false
8091	8734		ADULT	23635314	431.5268	KX-01	KX-01	O=C(CC1=NC=C(C=C1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4	PLASMA	4V9848RS5G									∞	ng × h/mL	196.78		ng/mL	58.7			UNKNOWN	mg	40		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23361621/	Homo sapiens		h	3.4	Day 29	patients with advanced solid cancers or lymphoma		5			false
8092	8734		ADULT	23635314	431.5268	KX-01	KX-01	O=C(CC1=NC=C(C=C1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4	PLASMA	4V9848RS5G									∞	ng × h/mL	166.75		ng/mL	60.5			UNKNOWN	mg	40		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23361621/	Homo sapiens		h	4.63	Day 57	patients with advanced solid cancers or lymphoma		5			false
8093	8734		ADULT	23635314	431.5268	KX-01	KX-01	O=C(CC1=NC=C(C=C1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4	PLASMA	4V9848RS5G									∞	ng × h/mL	1898.74		ng/mL	188			UNKNOWN	mg	50		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23361621/	Homo sapiens		h	9.34	Day 1	patients with advanced solid cancers or lymphoma		4			false
8094	8734		ADULT	23635314	431.5268	KX-01	KX-01	O=C(CC1=NC=C(C=C1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4	PLASMA	4V9848RS5G									∞	ng × h/mL	94.2		ng/mL	21.7			UNKNOWN	mg	50		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23361621/	Homo sapiens		h	3.22	Day 22	patients with advanced solid cancers or lymphoma		1			false
8095	8734		ADULT	23635314	431.5268	KX-01	KX-01	O=C(CC1=NC=C(C=C1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4	PLASMA	4V9848RS5G									∞	ng × h/mL	360.42		ng/mL	117			UNKNOWN	mg	60		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23361621/	Homo sapiens		h	3.77	Day 1	patients with advanced solid cancers or lymphoma		6			false
8096	8734		ADULT	23635314	431.5268	KX-01	KX-01	O=C(CC1=NC=C(C=C1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4	PLASMA	4V9848RS5G									∞	ng × h/mL	984.8		ng/mL	273			UNKNOWN	mg	80		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23361621/	Homo sapiens		h	2.89	Day 1	patients with advanced solid cancers or lymphoma		5			false
8097	8734		ADULT	23635314	431.5268	KX-01	KX-01	O=C(CC1=NC=C(C=C1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4	PLASMA	4V9848RS5G									∞	ng × h/mL	298.27		ng/mL	98.6			UNKNOWN	mg	60		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23361621/	Homo sapiens		h	4.67	Day 22	patients with advanced solid cancers or lymphoma		4			false
8098	8734		ADULT	23635314	431.5268	KX-01	KX-01	O=C(CC1=NC=C(C=C1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4	PLASMA	4V9848RS5G									∞	ng × h/mL	560.25		ng/mL	143.3			UNKNOWN	mg	80		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23361621/	Homo sapiens		h	5.7	Day 22	patients with advanced solid cancers or lymphoma		2			false
8099	8734		ADULT	23635314	431.5268	KX-01	KX-01	O=C(CC1=NC=C(C=C1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4	PLASMA	4V9848RS5G									∞	ng × h/mL	15.39		ng/mL	3.61			UNKNOWN	mg	2		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23361621/	Homo sapiens		h	3.95	Day 1	patients with advanced solid cancers or lymphoma		3			false
8100	8734		ADULT	23635314	431.5268	KX-01	KX-01	O=C(CC1=NC=C(C=C1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4	PLASMA	4V9848RS5G							24		t	ng × h/mL	5		ng/mL	0.34			UNKNOWN	mg	250		MULTIPLE	UNKNOWN		day	1			HEALTHY	Topical	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/34783452/	Homo sapiens				Treatment group: Face	Subjects With Actinic Keratosis		9			false
8101	8734		ADULT	23635314	431.5268	KX-01	KX-01	O=C(CC1=NC=C(C=C1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4	PLASMA	4V9848RS5G							24		t	ng × h/mL	3.18		ng/mL	0.18			UNKNOWN	mg	250		MULTIPLE	UNKNOWN		day	1			HEALTHY	Topical	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/34783452/	Homo sapiens				Treatment group: Scalp	Subjects With Actinic Keratosis		9			false
8102	8734		ADULT	23635314	431.5268	KX-01	KX-01	O=C(CC1=NC=C(C=C1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4	PLASMA	4V9848RS5G							24		t	ng × h/mL	4.09		ng/mL	0.26			UNKNOWN	mg	250		MULTIPLE	UNKNOWN		day	1	n=12 for t1/2 (estimated)		HEALTHY	Topical	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/34783452/	Homo sapiens		day	1	Treatment group: Combined (Face plus Scalp)	Subjects With Actinic Keratosis		18			false
8103	8741		ADULT	3885	242.2699	LAPACHONE	LAPACHONE	CC1(C)CCC2=C(O1)C3=C(C=CC=C3)C(=O)C2=O	PLASMA	6N4FA2QQ6A									∞	ng × h/mL	22.71		ng/mL	3.56			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29066863	Homo sapiens		h	5.89				8	LAPACHONE		false
8104	8741		ADULT	3885	242.2699	LAPACHONE	LAPACHONE	CC1(C)CCC2=C(O1)C3=C(C=CC=C3)C(=O)C2=O	PLASMA	6N4FA2QQ6A									∞	ng × h/mL	93.69		ng/mL	14.96			UNKNOWN	mg	100		MULTIPLE	FASTED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29066863	Homo sapiens		h	18.16				8	LAPACHONE		false
8105	8746		ADULT	25185057	507.726	LEFAMULIN	LEFAMULIN	C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@]1(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]3C)OC(=O)CS[C@@H]4CC[C@@H](N)C[C@H]4O	PLASMA	21904A5386							24		t	μg × h/mL	27		μg/mL	3.5			RECOMMENDED	mg	150		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211672s000,211673s000lbl.pdf	Homo sapiens		h	8							false
8106	8746		ADULT	25185057	507.726	LEFAMULIN	LEFAMULIN	C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@]1(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]3C)OC(=O)CS[C@@H]4CC[C@@H](N)C[C@H]4O	PLASMA	21904A5386							24		t	μg × h/mL	30.7		μg/mL	2.24			RECOMMENDED	mg	600		SINGLE	FASTED						UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211672s000,211673s000lbl.pdf	Homo sapiens		h	8							false
8107	8746		ADULT	25185057	507.726	LEFAMULIN	LEFAMULIN	C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@]1(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]3C)OC(=O)CS[C@@H]4CC[C@@H](N)C[C@H]4O	PLASMA	21904A5386							24		t	μg × h/mL	32.7		μg/mL	2.24			RECOMMENDED	mg	600		STEADY-STATE	FASTED		day	2			UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211672s000,211673s000lbl.pdf	Homo sapiens		h	8							false
8108	8746		ADULT	25185057	507.726	LEFAMULIN	LEFAMULIN	C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@]1(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]3C)OC(=O)CS[C@@H]4CC[C@@H](N)C[C@H]4O	PLASMA	21904A5386							24		t	μg × h/mL	28.6		μg/mL	3.6			RECOMMENDED	mg	150		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211672s000,211673s000lbl.pdf	Homo sapiens		h	8							false
8109	8747		ADULT	56944144	410.4166	LEMBOREXANT	CC1=NC(C)=C(OC[C@]2(C[C@H]2C(=O)NC3=NC=C(F)C=C3)C4=CC=CC(F)=C4)C=N1	CC1=NC(C)=C(OC[C@]2(C[C@H]2C(=O)NC3=NC=C(F)C=C3)C4=CC=CC(F)=C4)C=N1	PLASMA	0K5743G68X																	RECOMMENDED	mg	5		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212028s000lbl.pdf	Homo sapiens		h	17							false
8110	8747		ADULT	56944144	410.4166	LEMBOREXANT	CC1=NC(C)=C(OC[C@]2(C[C@H]2C(=O)NC3=NC=C(F)C=C3)C4=CC=CC(F)=C4)C=N1	CC1=NC(C)=C(OC[C@]2(C[C@H]2C(=O)NC3=NC=C(F)C=C3)C4=CC=CC(F)=C4)C=N1	PLASMA	0K5743G68X													ng/mL	203			INVESTIGATIONAL	mg	25		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/27338807	Homo sapiens										false
8111	8748		ADULT	16739244	310.3504	LERSIVIRINE	LERSIVIRINE	CCC1=NN(CCO)C(CC)=C1OC2=CC(=CC(=C2)C#N)C#N	PLASMA	R3ZGC15A9A							12		t	ng × h/mL	4719.4		ng/mL	979.1			UNKNOWN	mg	500		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19779321	Homo sapiens				day 8			6	LERSIVIRINE		false
8112	8748		ADULT	16739244	310.3504	LERSIVIRINE	LERSIVIRINE	CCC1=NN(CCO)C(CC)=C1OC2=CC(=CC(=C2)C#N)C#N	PLASMA	R3ZGC15A9A							24		t	ng × h/mL	6530.1		ng/mL	1245.3			UNKNOWN	mg	750		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19779321	Homo sapiens				day 8			6	LERSIVIRINE		false
8113	8748		ADULT	16739244	310.3504	LERSIVIRINE	LERSIVIRINE	CCC1=NN(CCO)C(CC)=C1OC2=CC(=CC(=C2)C#N)C#N	PLASMA	R3ZGC15A9A									∞	ng × h/mL	4100		ng/mL	1010			UNKNOWN	mg	500		SINGLE	FASTED				plasma protein binding of lersivirine is low to moderate (fraction unbound = 0.424)	57.6	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20124396	Homo sapiens		h	5.83				4	LERSIVIRINE		false
8114	8748		ADULT	16739244	310.3504	LERSIVIRINE	LERSIVIRINE	CCC1=NN(CCO)C(CC)=C1OC2=CC(=CC(=C2)C#N)C#N	PLASMA	R3ZGC15A9A									?	ng × h/mL	17750		ng/mL	1727			UNKNOWN	mg	2400		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22371898	Homo sapiens							48	LERSIVIRINE		false
8115	8752		ADULT	11351021	434.534	LEXIBULIN	LEXIBULIN	CCC[C@H](NC1=NC(=NC=C1C)C2=CC(OC)=C(NC(=O)NCC)C=C2)C3=CN=CC=C3	PLASMA	2GTU230HA1									?	ng × h/mL	5640						MAX TOLERATED	mg/m²	358		MULTIPLE	UNKNOWN		3 weeks	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20733579	Homo sapiens		h	4.6				2	LEXIBULIN		false
8116	8752		ADULT	11351021	434.534	LEXIBULIN	LEXIBULIN	CCC[C@H](NC1=NC(=NC=C1C)C2=CC(OC)=C(NC(=O)NCC)C=C2)C3=CN=CC=C3	PLASMA	2GTU230HA1									∞	ng × h/mL	1315		ng/mL	376.2			MAX TOLERATED	mg/m²	164		MULTIPLE	FASTED		2 weeks	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22451157	Homo sapiens		h	2.44	Cycle 2			5	LEXIBULIN		false
8117	8752		ADULT	11351021	434.534	LEXIBULIN	LEXIBULIN	CCC[C@H](NC1=NC(=NC=C1C)C2=CC(OC)=C(NC(=O)NCC)C=C2)C3=CN=CC=C3	PLASMA	2GTU230HA1									∞	ng × h/mL	941.5		ng/mL	320			MAX TOLERATED	mg/m²	164		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22451157	Homo sapiens		h	4.28	Cycle 1			6	LEXIBULIN		false
8118	8754		ADULT	501254	280.3229	LISOFYLLINE	LISOFYLLINE	C[C@@H](O)CCCCN1C(=O)N(C)C2=C(N(C)C=N2)C1=O	PLASMA	L1F2Q2X956													μM	10.88			UNKNOWN	mg/kg	3		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10673700	Homo sapiens							19	LISOFYLLINE		false
8119	8754		ADULT	501254	280.3229	LISOFYLLINE	LISOFYLLINE	C[C@@H](O)CCCCN1C(=O)N(C)C2=C(N(C)C=N2)C1=O	PLASMA	L1F2Q2X956									∞	ng × h/mL	343		ng/mL	226			UNKNOWN	mg/kg	226		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9435196	Homo sapiens		h	0.9				12	LISOFYLLINE		false
8120	8754		ADULT	501254	280.3229	LISOFYLLINE	LISOFYLLINE	C[C@@H](O)CCCCN1C(=O)N(C)C2=C(N(C)C=N2)C1=O	PLASMA	L1F2Q2X956									∞	ng × h/mL	2756		ng/mL	5698			UNKNOWN	mg/kg	3		SINGLE	FED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9435196	Homo sapiens		h	0.77				12	LISOFYLLINE		false
8121	8765		ADULT	23633604	538.5177	LX-1031	LX-1031	COC1=CC(=CC=C1)C2=CC=C(C=C2)[C@@H](OC3=NC(N)=NC(=C3)C4=CC=C(C[C@H](N)C(O)=O)C=C4)C(F)(F)F	PLASMA	J08E1J78GK													ng/mL	384			UNKNOWN	mg	1000		SINGLE	FED						UNHEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/21159063	Homo sapiens		h	20							false
8122	8776		ADULT	9831643	674.955	MARALIXIBAT	Maralixibat	CCCCC1(CCCC)CS(=O)(=O)C2=C(C=C(C=C2)N(C)C)[C@H]([C@H]1O)C3=CC=C(OCC4=CC=C(C[N ]56CCN(CC5)CC6)C=C4)C=C3	PLASMA	UYB6UOF69L							24		t	ng × h/mL	1.668		ng/mL	0.727			UNKNOWN	mg	100		SINGLE	FED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214662Orig1s000IntegratedR.pdf#page=191	Homo sapiens					Administrated immediately prior to consuming a morning meal		6			false
8123	8776		ADULT	9831643	674.955	MARALIXIBAT	Maralixibat	CCCCC1(CCCC)CS(=O)(=O)C2=C(C=C(C=C2)N(C)C)[C@H]([C@H]1O)C3=CC=C(OCC4=CC=C(C[N ]56CCN(CC5)CC6)C=C4)C=C3	PLASMA	UYB6UOF69L							24		t	ng × h/mL	7.51		ng/mL	2.078			UNKNOWN	mg	300		SINGLE	FED				n=2 for t1/2		HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214662Orig1s000IntegratedR.pdf#page=191	Homo sapiens		h	2.023		Administrated immediately prior to consuming a morning meal		6			false
8124	8776		ADULT	9831643	674.955	MARALIXIBAT	Maralixibat	CCCCC1(CCCC)CS(=O)(=O)C2=C(C=C(C=C2)N(C)C)[C@H]([C@H]1O)C3=CC=C(OCC4=CC=C(C[N ]56CCN(CC5)CC6)C=C4)C=C3	PLASMA	UYB6UOF69L							24		t	ng × h/mL	14.191		ng/mL	2.401			UNKNOWN	mg	500		SINGLE	FED				n=5 for t1/2		HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214662Orig1s000IntegratedR.pdf#page=191	Homo sapiens		h	3.791		Administrated immediately prior to consuming a morning meal		6			false
8125	8776		ADULT	9831643	674.955	MARALIXIBAT	Maralixibat	CCCCC1(CCCC)CS(=O)(=O)C2=C(C=C(C=C2)N(C)C)[C@H]([C@H]1O)C3=CC=C(OCC4=CC=C(C[N ]56CCN(CC5)CC6)C=C4)C=C3	PLASMA	UYB6UOF69L							24		t	ng × h/mL	0.946		ng/mL	0.454			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214662Orig1s000IntegratedR.pdf#page=191	Homo sapiens							6			false
8126	8776		ADULT	9831643	674.955	MARALIXIBAT	Maralixibat	CCCCC1(CCCC)CS(=O)(=O)C2=C(C=C(C=C2)N(C)C)[C@H]([C@H]1O)C3=CC=C(OCC4=CC=C(C[N ]56CCN(CC5)CC6)C=C4)C=C3	PLASMA	UYB6UOF69L							24		t	ng × h/mL	0.161		ng/mL	0.081			UNKNOWN	mg	20		SINGLE	FED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214662Orig1s000IntegratedR.pdf#page=191	Homo sapiens					Administrated immediately prior to consuming a morning meal		6			false
8127	8776		ADULT	9831643	674.955	MARALIXIBAT	Maralixibat	CCCCC1(CCCC)CS(=O)(=O)C2=C(C=C(C=C2)N(C)C)[C@H]([C@H]1O)C3=CC=C(OCC4=CC=C(C[N ]56CCN(CC5)CC6)C=C4)C=C3	PLASMA	UYB6UOF69L							24		t	ng × h/mL	0.6		ng/mL	0.31			UNKNOWN	mg	50		SINGLE	FED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214662Orig1s000IntegratedR.pdf#page=191	Homo sapiens					Administrated immediately prior to consuming a morning meal		6			false
8128	8776		ADULT	9831643	674.955	MARALIXIBAT	Maralixibat	CCCCC1(CCCC)CS(=O)(=O)C2=C(C=C(C=C2)N(C)C)[C@H]([C@H]1O)C3=CC=C(OCC4=CC=C(C[N ]56CCN(CC5)CC6)C=C4)C=C3	PLASMA	UYB6UOF69L							24		t	ng × h/mL	0.032		ng/mL	0.032			UNKNOWN	mg	5		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214662Orig1s000IntegratedR.pdf#page=195	Homo sapiens				Day 14 PK			8			false
8129	8776		ADULT	9831643	674.955	MARALIXIBAT	Maralixibat	CCCCC1(CCCC)CS(=O)(=O)C2=C(C=C(C=C2)N(C)C)[C@H]([C@H]1O)C3=CC=C(OCC4=CC=C(C[N ]56CCN(CC5)CC6)C=C4)C=C3	PLASMA	UYB6UOF69L							24		t	ng × h/mL	0.248		ng/mL	0.129			UNKNOWN	mg	10		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214662Orig1s000IntegratedR.pdf#page=195	Homo sapiens				Day 14 PK			8			false
8130	8776		ADULT	9831643	674.955	MARALIXIBAT	Maralixibat	CCCCC1(CCCC)CS(=O)(=O)C2=C(C=C(C=C2)N(C)C)[C@H]([C@H]1O)C3=CC=C(OCC4=CC=C(C[N ]56CCN(CC5)CC6)C=C4)C=C3	PLASMA	UYB6UOF69L							24		t	ng × h/mL	1.152		ng/mL	0.376			UNKNOWN	mg	20		MULTIPLE	UNKNOWN		day	1	n=1 for t1/2		HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214662Orig1s000IntegratedR.pdf#page=195	Homo sapiens		h	1.275	Day 14 PK	Administered every morning		8			false
8131	8776		ADULT	9831643	674.955	MARALIXIBAT	Maralixibat	CCCCC1(CCCC)CS(=O)(=O)C2=C(C=C(C=C2)N(C)C)[C@H]([C@H]1O)C3=CC=C(OCC4=CC=C(C[N ]56CCN(CC5)CC6)C=C4)C=C3	PLASMA	UYB6UOF69L							24		t	ng × h/mL	0.424		ng/mL	0.31			UNKNOWN	mg	20		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214662Orig1s000IntegratedR.pdf#page=195	Homo sapiens				Day 14 PK	Administered every morning repeat		8			false
8132	8776		ADULT	9831643	674.955	MARALIXIBAT	Maralixibat	CCCCC1(CCCC)CS(=O)(=O)C2=C(C=C(C=C2)N(C)C)[C@H]([C@H]1O)C3=CC=C(OCC4=CC=C(C[N ]56CCN(CC5)CC6)C=C4)C=C3	PLASMA	UYB6UOF69L							24		t	ng × h/mL	5		ng/mL	0.781			UNKNOWN	mg	60		MULTIPLE	UNKNOWN		day	1	n=2 for t1/2		HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214662Orig1s000IntegratedR.pdf#page=195	Homo sapiens		h	4.367	Day 14 PK			8			false
8133	8776		ADULT	9831643	674.955	MARALIXIBAT	Maralixibat	CCCCC1(CCCC)CS(=O)(=O)C2=C(C=C(C=C2)N(C)C)[C@H]([C@H]1O)C3=CC=C(OCC4=CC=C(C[N ]56CCN(CC5)CC6)C=C4)C=C3	PLASMA	UYB6UOF69L							24		t	ng × h/mL	4.614		ng/mL	1.146			UNKNOWN	mg	100		MULTIPLE	UNKNOWN		day	1	n=2 for t1/2		HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214662Orig1s000IntegratedR.pdf#page=195	Homo sapiens		h	4.282	Day 14 PK			8			false
8134	8776		ADULT	9831643	674.955	MARALIXIBAT	Maralixibat	CCCCC1(CCCC)CS(=O)(=O)C2=C(C=C(C=C2)N(C)C)[C@H]([C@H]1O)C3=CC=C(OCC4=CC=C(C[N ]56CCN(CC5)CC6)C=C4)C=C3	PLASMA	UYB6UOF69L									?	ng × h/mL	2.24		ng/mL	1.27			UNKNOWN	mg	30		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214662Orig1s000IntegratedR.pdf#page=198	Homo sapiens		h	1.61				12			false
8135	8776		ADULT	9831643	674.955	MARALIXIBAT	Maralixibat	CCCCC1(CCCC)CS(=O)(=O)C2=C(C=C(C=C2)N(C)C)[C@H]([C@H]1O)C3=CC=C(OCC4=CC=C(C[N ]56CCN(CC5)CC6)C=C4)C=C3	PLASMA	UYB6UOF69L									?	ng × h/mL	0.514		ng/mL	0.437			UNKNOWN	mg	30		SINGLE	FED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214662Orig1s000IntegratedR.pdf#page=198	Homo sapiens							8			false
8136	8776		ADULT	9831643	674.955	MARALIXIBAT	Maralixibat	CCCCC1(CCCC)CS(=O)(=O)C2=C(C=C(C=C2)N(C)C)[C@H]([C@H]1O)C3=CC=C(OCC4=CC=C(C[N ]56CCN(CC5)CC6)C=C4)C=C3	PLASMA	UYB6UOF69L									?	ng × h/mL	3.07		ng/mL	1.5			UNKNOWN	mg	45		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214662Orig1s000IntegratedR.pdf#page=198	Homo sapiens		h	1.44				12			false
8137	8776		ADULT	9831643	674.955	MARALIXIBAT	Maralixibat	CCCCC1(CCCC)CS(=O)(=O)C2=C(C=C(C=C2)N(C)C)[C@H]([C@H]1O)C3=CC=C(OCC4=CC=C(C[N ]56CCN(CC5)CC6)C=C4)C=C3	PLASMA	UYB6UOF69L									?	ng × h/mL	1.4		ng/mL	0.564			UNKNOWN	mg	45		SINGLE	FED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214662Orig1s000IntegratedR.pdf#page=198	Homo sapiens							9			false
8138	8776		ADULT	9831643	674.955	MARALIXIBAT	Maralixibat	CCCCC1(CCCC)CS(=O)(=O)C2=C(C=C(C=C2)N(C)C)[C@H]([C@H]1O)C3=CC=C(OCC4=CC=C(C[N ]56CCN(CC5)CC6)C=C4)C=C3	PLASMA	UYB6UOF69L									?	ng × h/mL	10.2		ng/mL	3.05			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214662Orig1s000IntegratedR.pdf#page=198	Homo sapiens		h	1.97				12			false
8139	8776		UNKNOWN	9831643	674.955	MARALIXIBAT	Maralixibat	CCCCC1(CCCC)CS(=O)(=O)C2=C(C=C(C=C2)N(C)C)[C@H]([C@H]1O)C3=CC=C(OCC4=CC=C(C[N ]56CCN(CC5)CC6)C=C4)C=C3	PLASMA	UYB6UOF69L																						UNKNOWN				Human plasma protein binding: 95.9% (0.25mcg/mL), 97.3% (2.5mcg/mL), 96% (25mcg/mL)	2.7	UNKNOWN		UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214662Orig1s000IntegratedR.pdf3page=34 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214662Orig1s000IntegratedR.pdf#page=186	Homo sapiens										false
8140	8782		UNKNOWN	9935639	498.418	MELPHALAN FLUFENAMIDE	Melphalan flufenamide	CCOC(=O)[C@H](CC1=CC=C(F)C=C1)NC(=O)[C@@H](N)CC2=CC=C(C=C2)N(CCCl)CCCl	PLASMA	F70C5K4786																	UNKNOWN				SINGLE	UNKNOWN						UNKNOWN	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214383Orig1s000MultidisciplineR.pdf3page=47	Homo sapiens		min	2.1							false
8141	8782		UNKNOWN	460612|6918992	305.2	MELPHALAN	Melphalan	N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O	PLASMA	Q41OR9510P																	UNKNOWN				SINGLE	UNKNOWN						UNKNOWN	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214383Orig1s000MultidisciplineR.pdf3page=47	Homo sapiens		min	70							false
8142	8782		UNKNOWN	460612|6918992	305.2	MELPHALAN	Melphalan	N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O	PLASMA	Q41OR9510P									∞	ng × h/mL	3143		ng/mL	432			DEFINED DAILY	mg	40		SINGLE	UNKNOWN						UNKNOWN	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214383Orig1s000MultidisciplineR.pdf3page=48	Homo sapiens										false
8143	8782		UNKNOWN	460612|6918992	305.2	MELPHALAN	Melphalan	N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O	PLASMA	Q41OR9510P									∞	ng × h/mL	2933		ng/mL	419			DEFINED DAILY	mg	40		STEADY-STATE	UNKNOWN		4 weeks	1			UNKNOWN	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214383Orig1s000MultidisciplineR.pdf3page=48	Homo sapiens										false
8144	8782		UNKNOWN	460612|6918992	305.2	MELPHALAN	Melphalan	N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O	PLASMA	Q41OR9510P									∞	ng × h/mL	8233		ng/mL	580			DEFINED DAILY	mg	40		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214383Orig1s000MultidisciplineR.pdf3page=53	Homo sapiens		min	80		Patients with Moderate Renal Impairment		7			false
8145	8782		UNKNOWN	460612|6918992	305.2	MELPHALAN	Melphalan	N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O	PLASMA	Q41OR9510P									∞	ng × h/mL	8233		ng/mL	580			DEFINED DAILY	mg	40		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214383Orig1s000MultidisciplineR.pdf3page=53	Homo sapiens		min	80		Patients with Moderate Renal Impairment		7			false
8146	8782		UNKNOWN	460612|6918992	305.2	MELPHALAN	Melphalan	N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O	PLASMA	Q41OR9510P									∞	ng × h/mL	62222		ng/mL	516			DEFINED DAILY	mg	40		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214383Orig1s000MultidisciplineR.pdf3page=56	Homo sapiens					Patients with Normal Hepatic Function		7			false
8147	8782		UNKNOWN	460612|6918992	305.2	MELPHALAN	Melphalan	N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O	PLASMA	Q41OR9510P									∞	ng × h/mL	72466		ng/mL	503			DEFINED DAILY	mg	40		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214383Orig1s000MultidisciplineR.pdf3page=56	Homo sapiens					Patients with Mild Hepatic Impairment		1			false
8148	8782		UNKNOWN	9935639	498.418	MELPHALAN FLUFENAMIDE	Melphalan flufenamide	CCOC(=O)[C@H](CC1=CC=C(F)C=C1)NC(=O)[C@@H](N)CC2=CC=C(C=C2)N(CCCl)CCCl	PLASMA	F70C5K4786									∞	ng × h/mL	3839		ng/mL	161			DEFINED DAILY	mg	40		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214383Orig1s000MultidisciplineR.pdf3page=56	Homo sapiens					Patients with Normal Hepatic Function		6			false
8149	8782		UNKNOWN	9935639	498.418	MELPHALAN FLUFENAMIDE	Melphalan flufenamide	CCOC(=O)[C@H](CC1=CC=C(F)C=C1)NC(=O)[C@@H](N)CC2=CC=C(C=C2)N(CCCl)CCCl	PLASMA	F70C5K4786									∞	ng × h/mL	1872		ng/mL	87			DEFINED DAILY	mg	40		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214383Orig1s000MultidisciplineR.pdf3page=56	Homo sapiens					Patients with Mild Hepatic Impairment		1			false
8150	8782		UNKNOWN	460612|6918992	305.2	MELPHALAN	Melphalan	N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O	PLASMA	Q41OR9510P									∞	ng × h/mL	52192		ng/mL	433			DEFINED DAILY	mg	40		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214383Orig1s000MultidisciplineR.pdf3page=56	Homo sapiens					Patients with Normal Hepatic Function		80			false
8151	8782		UNKNOWN	460612|6918992	305.2	MELPHALAN	Melphalan	N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O	PLASMA	Q41OR9510P									∞	ng × h/mL	53938		ng/mL	429			DEFINED DAILY	mg	40		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214383Orig1s000MultidisciplineR.pdf3page=56	Homo sapiens					Patients with Mild Hepatic Impairment		80			false
8152	8783		ADULT	44603533	552.5309	MERESTINIB	MERESTINIB	CN1N=CC2=C1C=C(C3=CNN=C3)C(OC4=C(F)C=C(NC(=O)C5=CC=C(C)N(C5=O)C6=CC=C(F)C=C6)C=C4)=C2	PLASMA	5OGS5K699E									∞	ng × h/mL	6190		ng/mL	401			RECOMMENDED	mg	120		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/30833489	Homo sapiens		h	9.9							false
8153	8784		ADULT	11311503	260.22	RO5012433	RO5012433	C[C@]1([C@@H]([C@H](O[C@H]1N2C=CC(=O)NC2=O)CO)O)F	PLASMA	44V7045CXS									∞	μg × h/mL	20.5		μg/mL	0.854			UNKNOWN	mg	2000		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24025983	Homo sapiens		h	21.8				8			false
8154	8784		ADULT	11311503	260.22	RO5012433	RO5012433	C[C@]1([C@@H]([C@H](O[C@H]1N2C=CC(=O)NC2=O)CO)O)F	PLASMA	44V7045CXS									∞	μg × h/mL	6.35		μg/mL	0.361			UNKNOWN	mg	500		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24025983	Homo sapiens		h	19				8			false
8155	8784		ADOLESCENT	11311503	260.22	RO5012433	RO5012433	C[C@]1([C@@H]([C@H](O[C@H]1N2C=CC(=O)NC2=O)CO)O)F	PLASMA	44V7045CXS									∞	μg × h/mL	11.2		μg/mL	0.557			UNKNOWN	mg	1000		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24025983	Homo sapiens		h	22.7				10			false
8156	8784		ADULT	6481236	259.23	RO4995855	RO4995855	C[C@]1([C@@H]([C@H](O[C@H]1N2C=CC(=NC2=O)N)CO)O)F	PLASMA	05J68784G1									∞	μg × h/mL	113		μg/mL	10.2			UNKNOWN	mg	2000		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24025983	Homo sapiens		h	5.54				8			false
8157	8784		ADULT	6481236	259.23	RO4995855	RO4995855	C[C@]1([C@@H]([C@H](O[C@H]1N2C=CC(=NC2=O)N)CO)O)F	PLASMA	05J68784G1									∞	μg × h/mL	28.8		μg/mL	4.23			UNKNOWN	mg	500		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24025983	Homo sapiens		h	4.96				8			false
8158	8787		ADULT	9889366	438.604	MIBAMPATOR	LY451395	CC(C)S(=O)(=O)NC[C@H](C)C1=CC=C(C=C1)C2=CC=C(CCNS(C)(=O)=O)C=C2	PLASMA	A9V5BW73UU													ng/mL	219			MAX DAILY	mg	20		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://www.infona.pl/resource/bwmeta1.element.elsevier-5cd0537d-6221-32c8-84c4-5a0d08804218	Homo sapiens		h	11.8				6	LY451395		false
8159	8787		ADULT	9889366	438.604	MIBAMPATOR	LY451395	CC(C)S(=O)(=O)NC[C@H](C)C1=CC=C(C=C1)C2=CC=C(CCNS(C)(=O)=O)C=C2	PLASMA	A9V5BW73UU													ng/mL	0.082			UNKNOWN	μg	5		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://www.infona.pl/resource/bwmeta1.element.elsevier-5cd0537d-6221-32c8-84c4-5a0d08804218	Homo sapiens		h	8.39				6	LY451395		false
8160	8793		ADULT	9853498	587.709	MK-0359	MK-0359	CC1=NOC(=N1)C(=C\\C2=CC(=CC=C2)C3=C4N=CC=CC4=CC(=C3)C(C)(C)S(C)(=O)=O)\\C5=CC=C(C=C5)S(C)(=O)=O	BLOOD	G6GSO9SDNJ									?	nM × h	3367						UNKNOWN	mg	15		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19135348	Homo sapiens							8	MK-0359		false
8161	8794		ADULT	11394238	358.4099	CERC-301	MK-0657, (-)-	CC1=CC=C(COC(=O)N2CC[C@H](CNC3=NC=CC=N3)[C@H](F)C2)C=C1	PLASMA	5HAM167S5T	6047|6971033	197.1879	LEVODOPA	levodopa	N[C@@H](CC1=CC=C(O)C(O)=C1)C(O)=O	46627O600J							nM	408			UNKNOWN	mg	7		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29059133	Homo sapiens						2-hour intravenous infusion at greater than or equal to 1 mg/kg per hour	22	MK-0657, (-)-		true
8162	8805		ADULT	9801985	416.4	Ro 27-4006	Ro 27-4006	CN1C=C(C2=C1C=C(C=C2)[N ](=O)[O-])C3=C(C(=O)NC3=O)C4=CN(C5=CC=CC=C54)CO	PLASMA										?	μg × h/mL	17.5		μg/mL	1.4			UNKNOWN	mg/m²	560		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15310782	Homo sapiens		h	8.8				6	Ro 31-7453		false
8163	8805		ADULT	9801985	416.4	Ro 27-4006	Ro 27-4006	CN1C=C(C2=C1C=C(C=C2)[N ](=O)[O-])C3=C(C(=O)NC3=O)C4=CN(C5=CC=CC=C54)CO	PLASMA										?	μg × h/mL	16.6		μg/mL	1.2			UNKNOWN	mg/m²	800		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15310782	Homo sapiens		h	13.1				7	Ro 31-7453		false
8164	8805		ADULT	9886463	386.4	Ro 27-0431	Ro 27-0431	CN1C=C(C2=C1C=C(C=C2)[N ](=O)[O-])C3=C(C(=O)NC3=O)C4=CNC5=CC=CC=C54	PLASMA										?	μg × h/mL	7.9		μg/mL	0.9			UNKNOWN	mg/m²	400		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15310782	Homo sapiens		h	12				7	Ro 31-7453		false
8165	8805		ADULT	9801985	386.4	Ro 27-0431	Ro 27-0431		PLASMA										?	μg × h/mL	5.2		μg/mL	0.6			UNKNOWN	mg/m²	280		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15310782	Homo sapiens		h	24.5				9	Ro 31-7453		false
8166	8805		ADULT	5327686	400.3868	MKC-1	Ro 31-7453	CN1C=C(C2=C1C=CC=C2)C3=C(C(=O)NC3=O)C4=CN(C)C5=C4C=CC(=C5)[N ]([O-])=O	PLASMA	DNZ11VPY7Q									?	μg × h/mL	19.3		μg/mL	2.6			UNKNOWN	mg/m²	400		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15310782	Homo sapiens		h	23.1				7	Ro 31-7453		false
8167	8805		ADULT	9801985	416.4	Ro 27-4006	Ro 27-4006	CN1C=C(C2=C1C=C(C=C2)[N ](=O)[O-])C3=C(C(=O)NC3=O)C4=CN(C5=CC=CC=C54)CO	PLASMA										?	μg × h/mL	11.9		μg/mL	1.5			UNKNOWN	mg/m²	400		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15310782	Homo sapiens		h	13.8				7	Ro 31-7453		false
8168	8805		ADULT	5327686	400.3868	MKC-1	Ro 31-7453	CN1C=C(C2=C1C=CC=C2)C3=C(C(=O)NC3=O)C4=CN(C)C5=C4C=CC(=C5)[N ]([O-])=O	PLASMA	DNZ11VPY7Q									?	μg × h/mL	11.8		μg/mL	1.5			UNKNOWN	mg/m²	280		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15310782	Homo sapiens		h	17.6				9	Ro 31-7453		false
8169	8805		ADULT	9886463	386.4	Ro 27-0431	Ro 27-0431	CN1C=C(C2=C1C=C(C=C2)[N ](=O)[O-])C3=C(C(=O)NC3=O)C4=CNC5=CC=CC=C54	PLASMA										?	μg × h/mL	8.5		μg/mL	0.7			UNKNOWN	mg/m²	800		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15310782	Homo sapiens		h	13.4				8	Ro 31-7453		false
8170	8805		ADULT	9886463	386.4	Ro 27-0431		CN1C=C(C2=C1C=C(C=C2)[N ](=O)[O-])C3=C(C(=O)NC3=O)C4=CNC5=CC=CC=C54	PLASMA										?	μg × h/mL	8.7		μg/mL	0.4			UNKNOWN	mg/m²	560		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15310782	Homo sapiens		h	15.5				6	Ro 31-7453		false
8171	8805		ADULT	5327686	400.3868	MKC-1	MKC-1	CN1C=C(C2=C1C=CC=C2)C3=C(C(=O)NC3=O)C4=CN(C)C5=C4C=CC(=C5)[N ]([O-])=O	PLASMA	DNZ11VPY7Q									?	μg × h/mL	21.1		μg/mL	1.8			UNKNOWN	mg/m²	560		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15310782	Homo sapiens		h	9.2				6	MKC-1		false
8172	8805		ADULT	5327686	400.3868	MKC-1	Ro 31-7453	CN1C=C(C2=C1C=CC=C2)C3=C(C(=O)NC3=O)C4=CN(C)C5=C4C=CC(=C5)[N ]([O-])=O	PLASMA	DNZ11VPY7Q									?	μg × h/mL	16.1		μg/mL	1.3			UNKNOWN	mg/m²	800		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15310782	Homo sapiens		h	12.5				7	Ro 31-7453		false
8173	8805		ADULT	9801985	416.4	Ro 27-4006	Ro 27-4006	CN1C=C(C2=C1C=C(C=C2)[N ](=O)[O-])C3=C(C(=O)NC3=O)C4=CN(C5=CC=CC=C54)CO	PLASMA										?	μg × h/mL	10.7		μg/mL	1.2			UNKNOWN	mg/m²	280		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15310782	Homo sapiens		h	15.8				9	Ro 31-7453		false
8174	8810		ADULT	16049404	458.6	MOTOLIMOD	MOTOLIMOD	CCCN(CCC)C(=O)C1=CC2=CC=C(C=C2N=C(N)C1)C3=CC=C(C=C3)C(=O)N4CCCC4	PLASMA	WP6PY72ZH3									?	ng × h/mL	77.83		ng/mL	23.03			MAX TOLERATED	mg/m²	3.9		SINGLE	UNKNOWN						UNHEALTHY	Subcutaneous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/24807889	Homo sapiens		h	5.55							false
8175	8841		ADULT	11462174	348.3703	OC-459	OC000459	CC1=C(CC2=NC3=C(C=CC=C3)C=C2)C4=C(C=CC(F)=C4)N1CC(O)=O	PLASMA	04XB9TB8OL																	UNKNOWN	mg	200		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/23025511/	Homo sapiens		h	15				35	OC000459		false
8176	8845		ADULT	66553195	386.557	OLICERIDINE		COc1ccsc1CNCC[C@]2(CCOC3(CCCC3)C2)c4ccccn4	PLASMA	MCN858TCP0									∞	ng × h/mL	374.18						MAX DAILY	mg	27		MULTIPLE	UNKNOWN		day	12			HEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210730Orig1s000MultidisciplineR.pdf#page=141	Homo sapiens		h	1.567	2mg x 9 (T0h, T4h, T8h, T12h, T14h, T16h, T18h, T20h, T22h), 3mg x 3 (T2h, T6h, T10h)			62			false
8177	8845			66553195	386.557	OLICERIDINE	Oliceridine	COc1ccsc1CNCC[C@]2(CCOC3(CCCC3)C2)c4ccccn4	PLASMA	MCN858TCP0																										Human plasma protein binding of oliceridine is 77% (23% free or unbound), as assessed by equilibrium dialysis.	23				OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210730Orig1s000MultidisciplineR.pdf#page=22	Homo sapiens										false
8178	8845		ADULT	66553195	386.557	OLICERIDINE		COc1ccsc1CNCC[C@]2(CCOC3(CCCC3)C2)c4ccccn4	PLASMA	MCN858TCP0									∞	μg × h/L	11.14		μg/L	3.09			UNKNOWN	mg	0.25		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210730Orig1s000MultidisciplineR.pdf#page=337 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210730Orig1s000MultidisciplineR.pdf#page=351	Homo sapiens		h	2.82		CYP2D6 poor metabolizer		4			false
8179	8845		ADULT	66553195	386.557	OLICERIDINE		COc1ccsc1CNCC[C@]2(CCOC3(CCCC3)C2)c4ccccn4	PLASMA	MCN858TCP0									∞	μg × h/L	5.29		μg/L	2.29			UNKNOWN	mg	0.25		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210730Orig1s000MultidisciplineR.pdf#page=337 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210730Orig1s000MultidisciplineR.pdf#page=351	Homo sapiens		h	1.56		CYP2D6 extensive metabolizers		5			false
8180	8845		ADULT	66553195	386.557	OLICERIDINE		COc1ccsc1CNCC[C@]2(CCOC3(CCCC3)C2)c4ccccn4	PLASMA	MCN858TCP0									∞	μg × h/L	108.2		μg/L	117.3			UNKNOWN	mg	4.5		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210730Orig1s000MultidisciplineR.pdf#page=337 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210730Orig1s000MultidisciplineR.pdf#page=356	Homo sapiens		h	1.7		CYP2D6 EM		25			false
8181	8845		ADULT	66553195	386.557	OLICERIDINE		COc1ccsc1CNCC[C@]2(CCOC3(CCCC3)C2)c4ccccn4	PLASMA	MCN858TCP0									∞	μg × h/L	39.1		μg/L	45.2			UNKNOWN	mg	1.5		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210730Orig1s000MultidisciplineR.pdf#page=337 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210730Orig1s000MultidisciplineR.pdf#page=356	Homo sapiens		h	1.7		CYP2D6 EM		24			false
8182	8845		ADULT	66553195	386.557	OLICERIDINE		COc1ccsc1CNCC[C@]2(CCOC3(CCCC3)C2)c4ccccn4	PLASMA	MCN858TCP0									∞	μg × h/L	75.6		μg/L	54.7			UNKNOWN	mg	1.5		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210730Orig1s000MultidisciplineR.pdf#page=337 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210730Orig1s000MultidisciplineR.pdf#page=356	Homo sapiens		h	3.49		CYP2D6 PM		5			false
8183	8845		ADULT	66553195	386.557	OLICERIDINE		COc1ccsc1CNCC[C@]2(CCOC3(CCCC3)C2)c4ccccn4	PLASMA	MCN858TCP0									∞	μg × h/L	73.8		μg/L	81.3			UNKNOWN	mg	3		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210730Orig1s000MultidisciplineR.pdf#page=337 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210730Orig1s000MultidisciplineR.pdf#page=356	Homo sapiens		h	1.67		CYP2D6 EM		25			false
8184	8845		ADULT	66553195	386.557	OLICERIDINE		COc1ccsc1CNCC[C@]2(CCOC3(CCCC3)C2)c4ccccn4	PLASMA	MCN858TCP0									∞	μg × h/L	136.6		μg/L	54			UNKNOWN	mg	3		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210730Orig1s000MultidisciplineR.pdf#page=337 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210730Orig1s000MultidisciplineR.pdf#page=356	Homo sapiens		h	3.6		CYP2D6 PM		5			false
8185	8845		ADULT	66553195	386.557	OLICERIDINE		COc1ccsc1CNCC[C@]2(CCOC3(CCCC3)C2)c4ccccn4	PLASMA	MCN858TCP0									∞	μg × h/L	229.3		μg/L	127.8			UNKNOWN	mg	4.5		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210730Orig1s000MultidisciplineR.pdf#page=337 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210730Orig1s000MultidisciplineR.pdf#page=356	Homo sapiens		h	3.64		CYP2D6 PM		5			false
8186	8845		ADULT	66553195	386.557	OLICERIDINE		COc1ccsc1CNCC[C@]2(CCOC3(CCCC3)C2)c4ccccn4	PLASMA	MCN858TCP0									∞	μg × h/L	171.59		μg/L	239.7			UNKNOWN	mg	6		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210730Orig1s000MultidisciplineR.pdf#page=337 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210730Orig1s000MultidisciplineR.pdf#page=367	Homo sapiens		h	3.63		CYP2D6 EM		44			false
8187	8845		ADULT	66553195	386.557	OLICERIDINE		COc1ccsc1CNCC[C@]2(CCOC3(CCCC3)C2)c4ccccn4	PLASMA	MCN858TCP0									∞	μg × h/L	243		μg/L	183.8			UNKNOWN	mg	6		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210730Orig1s000MultidisciplineR.pdf#page=337 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210730Orig1s000MultidisciplineR.pdf#page=367	Homo sapiens		h	4.07		CYP2D6 PM		5			false
8188	8845		ADULT	66553195	386.557	OLICERIDINE		COc1ccsc1CNCC[C@]2(CCOC3(CCCC3)C2)c4ccccn4	PLASMA	MCN858TCP0									∞	pg × h/mL	134		pg/mL	19.5			UNKNOWN	μg	100		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210730Orig1s000MultidisciplineR.pdf#page=358	Homo sapiens		h	1.62				8			false
8189	8845		ADULT	66553195	386.557	OLICERIDINE		COc1ccsc1CNCC[C@]2(CCOC3(CCCC3)C2)c4ccccn4	PLASMA	MCN858TCP0									∞	ng × h/mL	23.7		ng/mL	34.8			UNKNOWN	mg	1		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210730Orig1s000MultidisciplineR.pdf#page=372	Homo sapiens		h	2.07		Normal hepatic function		8			false
8190	8845		ADULT	66553195	386.557	OLICERIDINE		COc1ccsc1CNCC[C@]2(CCOC3(CCCC3)C2)c4ccccn4	PLASMA	MCN858TCP0									∞	ng × h/mL	22.5		ng/mL	41.4			UNKNOWN	mg	0.5		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210730Orig1s000MultidisciplineR.pdf#page=372	Homo sapiens		h	2.61		Mild hepatic impairment		8			false
8191	8845		ADULT	66553195	386.557	OLICERIDINE		COc1ccsc1CNCC[C@]2(CCOC3(CCCC3)C2)c4ccccn4	PLASMA	MCN858TCP0									∞	ng × h/mL	23.9		ng/mL	8.4			UNKNOWN	mg	0.5		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210730Orig1s000MultidisciplineR.pdf#page=372	Homo sapiens		h	5.77		Severe hepatic impairment		8			false
8192	8845		ADULT	66553195	386.557	OLICERIDINE		COc1ccsc1CNCC[C@]2(CCOC3(CCCC3)C2)c4ccccn4	PLASMA	MCN858TCP0									∞	ng × h/mL	29.5		ng/mL	41.9			UNKNOWN	mg	0.5		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210730Orig1s000MultidisciplineR.pdf#page=372	Homo sapiens		h	4.33		Moderate hepatic impairment		8			false
8193	8845		ADULT	66553195	386.557	OLICERIDINE		COc1ccsc1CNCC[C@]2(CCOC3(CCCC3)C2)c4ccccn4	PLASMA	MCN858TCP0									∞	ng × h/mL	10.2		ng/mL	4.94			UNKNOWN	mg	0.5		SINGLE	UNKNOWN				n=7 for AUC and T1/2		UNHEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210730Orig1s000MultidisciplineR.pdf#page=377 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210730Orig1s000MultidisciplineR.pdf#page=336	Homo sapiens		h	2.99		End-stage renal disease		8			false
8194	8845		ADULT	66553195	386.557	OLICERIDINE		COc1ccsc1CNCC[C@]2(CCOC3(CCCC3)C2)c4ccccn4	PLASMA	MCN858TCP0									∞	ng × h/mL	18.1		ng/mL	8.79			UNKNOWN	mg	1		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210730Orig1s000MultidisciplineR.pdf#page=377 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210730Orig1s000MultidisciplineR.pdf#page=336	Homo sapiens		h	2.34				8			false
8195	8846		ADULT	76192587	894.1091	[NO STEREO] OMBITASVIR	CC(C)C(C(=O)N1CCCC1C(=O)NC2=CC=C(C=C2)C3CCC(N3C4=CC=C(C=C4)C(C)(C)C)C5=CC=C(C=C5)NC(=O)C6CCCN6C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC	COC(=O)NC(C(C)C)C(=O)N1CCCC1C(=O)NC2=CC=C(C=C2)C3CCC(N3C4=CC=C(C=C4)C(C)(C)C)C5=CC=C(NC(=O)C6CCCN6C(=O)C(NC(=O)OC)C(C)C)C=C5	PLASMA	[NO STEREO] 2302768XJ8	75093025		[NO STEREO] PARITAPREVIR	CC1=CN=C(C=N1)C(=O)NC2CCCCCC=CC3CC3(NC(=O)C4CC(CN4C2=O)OC5=NC6=CC=CC=C6C7=CC=CC=C75)C(=O)NS(=O)(=O)C8CC8	CC1=CN=C(C=N1)C(=O)NC2CCCCCC=CC3CC3(NC(=O)C4CC(CN4C2=O)OC5=NC6=CC=CC=C6C7=CC=CC=C57)C(=O)NS(=O)(=O)C8CC8	[NO STEREO] OU2YM37K86	24		t	ng × h/mL	1000		ng/mL	68			RECOMMENDED	mg	25		STEADY-STATE	FED		day	1		0.1	UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206619lbl.pdf	Homo sapiens		h	23							true
8196	8847		ADULT	11689883	401.4347	OMECAMTIV MECARBIL	omecamtiv mecarbil	COC(=O)N1CCN(CC2=CC=CC(NC(=O)NC3=CN=C(C)C=C3)=C2F)CC1	PLASMA	2M19539ERK													ng/mL	905			MAX TOLERATED	mg/kg/h	0.5		MULTIPLE	UNKNOWN		week	1			HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21856480	Homo sapiens							16	omecamtiv mecarbil		false
8197	8849		ADULT	11955716	409.5	ONALESPIB	ONALESPIB	CC(C)C1=C(O)C=C(O)C(=C1)C(=O)N2CC3=C(C2)C=C(CN4CCN(C)CC4)C=C3	PLASMA	Q7Y33N57ZZ							24		t	ng × h/mL	4905		ng/mL	1790			RECOMMENDED	mg/m²	260		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/25336693	Homo sapiens		h	6.6							false
8198	8854		ADULT	11717074	339.4281	ORG-25935	ORG-25935	COC1=CC2=C(C=C1)[C@H]([C@@H](CN(C)CC(O)=O)CC2)C3=CC=CC=C3	PLASMA	55L20667O4													ng/mL	72			UNKNOWN	mg	4		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17098748	Homo sapiens							28	ORG-25935		false
8199	8854		ADULT	11717074	339.4281	ORG-25935	ORG-25935	COC1=CC2=C(C=C1)[C@H]([C@@H](CN(C)CC(O)=O)CC2)C3=CC=CC=C3	PLASMA	55L20667O4													ng/mL	243			UNKNOWN	mg	16		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17098748	Homo sapiens							46	ORG-25935		false
8200	8854		ADULT	11717074	339.4281	ORG-25935	ORG-25935	COC1=CC2=C(C=C1)[C@H]([C@@H](CN(C)CC(O)=O)CC2)C3=CC=CC=C3	PLASMA	55L20667O4													ng/mL	159			UNKNOWN	mg	8		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17098748	Homo sapiens							43	ORG-25935		false
8201	8854		ADULT	11717074	339.4281	ORG-25935	ORG-25935	COC1=CC2=C(C=C1)[C@H]([C@@H](CN(C)CC(O)=O)CC2)C3=CC=CC=C3	PLASMA	55L20667O4													ng/mL	165			UNKNOWN	mg	12		MULTIPLE	UNKNOWN		day	2			UNKNOWN	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17098748	Homo sapiens							27	ORG-25935		false
8202	8858		ADULT	9796590	307.3465	ORTERONEL	Orteronel	CNC(=O)C1=CC2=C(C=C1)C=C(C=C2)[C@@]3(O)CCN4C=NC=C34	PLASMA	UE5K2FNS92							8		t	μg × h/mL	7.64		μg/mL	1.58			UNKNOWN	mg	200		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25537627	Homo sapiens							3	Orteronel		false
8203	8858		ADULT	9796590	307.3465	ORTERONEL	Orteronel	CNC(=O)C1=CC2=C(C=C1)C=C(C=C2)[C@@]3(O)CCN4C=NC=C34	PLASMA	UE5K2FNS92							8		t	μg × h/mL	14.5		μg/mL	3.1			UNKNOWN	mg	300		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25537627	Homo sapiens							3	Orteronel		false
8204	8858		ADULT	9796590	307.3465	ORTERONEL	Orteronel	CNC(=O)C1=CC2=C(C=C1)C=C(C=C2)[C@@]3(O)CCN4C=NC=C34	PLASMA	UE5K2FNS92							8		t	μg × h/mL	28.6		μg/mL	4.7			UNKNOWN	mg	400		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25537627	Homo sapiens							3	Orteronel		false
8205	8858		ADULT	9796590	307.3465	ORTERONEL	Orteronel	CNC(=O)C1=CC2=C(C=C1)C=C(C=C2)[C@@]3(O)CCN4C=NC=C34	PLASMA	UE5K2FNS92									?	ng × h/mL	17456		ng/mL	1765			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27163497	Homo sapiens		h	10.5				39	Orteronel		false
8206	8858		ADULT	9796590	307.3465	ORTERONEL	Orteronel	CNC(=O)C1=CC2=C(C=C1)C=C(C=C2)[C@@]3(O)CCN4C=NC=C34	PLASMA	UE5K2FNS92									?	ng × h/mL	24128		ng/mL	2832			UNKNOWN	mg	400		SINGLE	HIGH-FAT						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27163497	Homo sapiens		h	7.6				42	Orteronel		false
8207	8858		ADULT	9796590	307.3465	ORTERONEL	Orteronel	CNC(=O)C1=CC2=C(C=C1)C=C(C=C2)[C@@]3(O)CCN4C=NC=C34	PLASMA	UE5K2FNS92									?	ng × h/mL	23019		ng/mL	2994			UNKNOWN	mg	400		SINGLE	LOW-FAT						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27163497	Homo sapiens		h	8.2				39	Orteronel		false
8208	8861		ADULT	90479076|135565623|137171658|139033031|163321054	1326.495	OTL-38	OTL-0038	CC1(C)\\C(=C/C=C2\\CCCC(\\C=C\\C3=[N ](CCCCS(O)(=O)=O)C4=C(C=C(C=C4)S([O-])(=O)=O)C3(C)C)=C2OC5=CC=C(C[C@H](NC(=O)C6=CC=C(NCC7=NC8=C(N=C7)N=C(N)NC8=O)C=C6)C(O)=O)C=C5)N(CCCCS(O)(=O)=O)C9=C1C=C(C=C9)S(O)(=O)=O	PLASMA	F7BD3Z4X8L									?	ng × h/mL	250		ng/mL	173			UNKNOWN	mg/kg	0.05		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27306792/	Homo sapiens										false
8209	8861		ADULT	90479076|135565623|137171658|139033031|163321054	1326.495	OTL-38	OTL-0038	CC1(C)\\C(=C/C=C2\\CCCC(\\C=C\\C3=[N ](CCCCS(O)(=O)=O)C4=C(C=C(C=C4)S([O-])(=O)=O)C3(C)C)=C2OC5=CC=C(C[C@H](NC(=O)C6=CC=C(NCC7=NC8=C(N=C7)N=C(N)NC8=O)C=C6)C(O)=O)C=C5)N(CCCCS(O)(=O)=O)C9=C1C=C(C=C9)S(O)(=O)=O	PLASMA	F7BD3Z4X8L									?	ng × h/mL	59.2		ng/mL	61.7			UNKNOWN	mg/kg	0.025		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27306792/	Homo sapiens										false
8210	8861		ADULT	90479076|135565623|137171658|139033031|163321054	1326.495	OTL-38	OTL-0038	CC1(C)\\C(=C/C=C2\\CCCC(\\C=C\\C3=[N ](CCCCS(O)(=O)=O)C4=C(C=C(C=C4)S([O-])(=O)=O)C3(C)C)=C2OC5=CC=C(C[C@H](NC(=O)C6=CC=C(NCC7=NC8=C(N=C7)N=C(N)NC8=O)C=C6)C(O)=O)C=C5)N(CCCCS(O)(=O)=O)C9=C1C=C(C=C9)S(O)(=O)=O	PLASMA	F7BD3Z4X8L									?	ng × h/mL	830		ng/mL	458			UNKNOWN	mg/kg	0.1		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27306792/	Homo sapiens										false
8211	8861		ADULT	90479076|135565623|137171658|139033031|163321054	1326.495	OTL-38	OTL-0038	CC1(C)\\C(=C/C=C2\\CCCC(\\C=C\\C3=[N ](CCCCS(O)(=O)=O)C4=C(C=C(C=C4)S([O-])(=O)=O)C3(C)C)=C2OC5=CC=C(C[C@H](NC(=O)C6=CC=C(NCC7=NC8=C(N=C7)N=C(N)NC8=O)C=C6)C(O)=O)C=C5)N(CCCCS(O)(=O)=O)C9=C1C=C(C=C9)S(O)(=O)=O	PLASMA	F7BD3Z4X8L									?	ng × h/mL	1250		ng/mL	606			UNKNOWN	mg/kg	0.2		SINGLE	UNKNOWN				AUCinf=1280 ng*h/mL		HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27306792/	Homo sapiens		h	2.6							false
8212	8861		UNKNOWN	90479076|135565623|137171658|139033031|163321054	1326.495	OTL-38	OTL-0038	CC1(C)\\C(=C/C=C2\\CCCC(\\C=C\\C3=[N ](CCCCS(O)(=O)=O)C4=C(C=C(C=C4)S([O-])(=O)=O)C3(C)C)=C2OC5=CC=C(C[C@H](NC(=O)C6=CC=C(NCC7=NC8=C(N=C7)N=C(N)NC8=O)C=C6)C(O)=O)C=C5)N(CCCCS(O)(=O)=O)C9=C1C=C(C=C9)S(O)(=O)=O	PLASMA	F7BD3Z4X8L									∞	ng × h/mL	63.6		ng/mL	59.1			RECOMMENDED	mg	3.2		SINGLE	UNKNOWN						UNKNOWN	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214907s000lbl.pdf#page=7	Homo sapiens		h	0.44							false
8213	8870		ADULT		596.569	PCI-27483	PCI-27483	NC(=N)C1=CC=C2N=C(NC2=C1)C3=C(O)C(=CC(CC(=O)N[C@@H](CC(O)=O)C(O)=O)=C3)C4=C(O)C=CC(=C4)S(N)(=O)=O	PLASMA	6073LCU8U9													μg/mL	5.14			UNKNOWN	mg/kg	0.8		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Subcutaneous	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/30844808	Homo sapiens								PCI-27483		false
8214	8870		ADULT		596.569	PCI-27483	PCI-27483	NC(=N)C1=CC=C2N=C(NC2=C1)C3=C(O)C(=CC(CC(=O)N[C@@H](CC(O)=O)C(O)=O)=C3)C4=C(O)C=CC(=C4)S(N)(=O)=O	PLASMA	6073LCU8U9													μg/mL	6.26			UNKNOWN	mg/kg	1.2		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Subcutaneous	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/30844808	Homo sapiens								PCI-27483		false
8215	8880		ADULT	44187362	431.2008	PIMASERTIB	Pimasertib	OC[C@@H](O)CNC(=O)C1=C(NC2=CC=C(I)C=C2F)C=NC=C1	PLASMA	6ON9RK82AL									∞	ng × h/mL	1160.8		ng/mL	283.8			MAX TOLERATED	mg	60		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26657199/	Homo sapiens		h	3.019	Day 1			12			false
8216	8880		ADULT	44187362	431.2008	PIMASERTIB	Pimasertib	OC[C@@H](O)CNC(=O)C1=C(NC2=CC=C(I)C=C2F)C=NC=C1	PLASMA	6ON9RK82AL									∞	ng × h/mL	952.1		ng/mL	261.83			MAX TOLERATED	mg	60		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26657199/	Homo sapiens		h	3.53	Day 21			12			false
8217	8880		ADULT	44187362	431.2008	PIMASERTIB	Pimasertib	OC[C@@H](O)CNC(=O)C1=C(NC2=CC=C(I)C=C2F)C=NC=C1	PLASMA	6ON9RK82AL									?	ng × eq × h/mL	5318		ng × eq/mL	774			UNKNOWN	mg	60		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27483391/	Homo sapiens		h	17	Day 8			6			false
8218	8880		ADULT	44187362	431.2008	PIMASERTIB	Pimasertib	OC[C@@H](O)CNC(=O)C1=C(NC2=CC=C(I)C=C2F)C=NC=C1	PLASMA	6ON9RK82AL																						UNKNOWN				5.4~7.1%	6.7	UNHEALTHY		MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27483391/	Homo sapiens							6			false
8219	8880		ADULT	44187362	431.2008	PIMASERTIB	Pimasertib	OC[C@@H](O)CNC(=O)C1=C(NC2=CC=C(I)C=C2F)C=NC=C1	PLASMA	6ON9RK82AL									?	ng × h/mL	937		ng/mL	265			UNKNOWN	mg	60		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27483391/	Homo sapiens		h	6.3	Day 1			6			false
8220	8891		ADULT	46700756	365.4	PREXASERTIB	PREXASERTIB	COC1=CC=CC(OCCCN)=C1C2=CC(NC3=NC=C(N=C3)C#N)=NN2	PLASMA	820NH671E6									∞	ng × h/mL	1340		ng/mL	460			MAX TOLERATED	mg/m²	105		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/27044938	Homo sapiens		h	11.9							false
8221	8898		ADULT	5281807	416.3781	PUERARIN	PUERARIN	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C2=C(O)C=CC3=C2OC=C(C3=O)C4=CC=C(O)C=C4	BLOOD	Z9W8997416									∞	ng × h/mL	85.9		ng/mL	11.07			UNKNOWN	mg	9.984		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25264914	Homo sapiens		h	4.48				10	PUERARIN		false
8222	8912		ADULT	10200813	397.3996	RADIPRODIL	RADIPRODIL	FC1=CC=C(CC2CCN(CC2)C(=O)C(=O)NC3=CC4=C(NC(=O)O4)C=C3)C=C1	PLASMA	5XGC17ZKUF									∞	ng × h/mL	2042		ng/mL	89.4			UNKNOWN	mg	30		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30705758	Homo sapiens		h	15.8				10	RADIPRODIL		false
8223	8914		ADULT	14539800	413.4686	RAPASTINEL	GLYX-13	C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@@H]([C@@H](C)O)C(N)=O	PLASMA	6A1X56B95E									∞	μg × min/mL	32		μg/mL	5.2			UNKNOWN	mg/kg	1		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/24251380/	Homo sapiens		min	4.7				25	GLYX-13		false
8224	8914		ADULT	14539800	413.4686	RAPASTINEL	GLYX-13	C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@@H]([C@@H](C)O)C(N)=O	PLASMA	6A1X56B95E									∞	μg × min/mL	4030		μg/mL	182			HIGHEST STUDIED	mg/kg	20		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/24251380/	Homo sapiens		min	14				21	GLYX-13		false
8225	8914		ADULT	14539800	413.4686	RAPASTINEL	GLYX-13	C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@@H]([C@@H](C)O)C(N)=O	PLASMA	6A1X56B95E									∞	μg × min/mL	288		μg/mL	26			UNKNOWN	mg/kg	5		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/24251380/	Homo sapiens		min	7.4				20	GLYX-13		false
8226	8914		ADULT	14539800	413.4686	RAPASTINEL	GLYX-13	C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@@H]([C@@H](C)O)C(N)=O	PLASMA	6A1X56B95E									∞	μg × min/mL	1162		μg/mL	100				mg/kg	10		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/24251380/	Homo sapiens		min	9				17	GLYX-13		false
8227	8916		ADULT	16046068	314.3541	RAXATRIGINE	RAXATRIGINE	NC(=O)[C@@H]1CC[C@@H](N1)C2=CC=C(OCC3=C(F)C=CC=C3)C=C2	PLASMA	QQS4J85K6Y							24		t	ng × h/mL	60100		ng/mL	4410			UNKNOWN	mg	400		STEADY-STATE	FASTED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30144099	Homo sapiens				Day 35			33	RAXATRIGINE		false
8228	8916		ADULT	16046068	314.3541	RAXATRIGINE	RAXATRIGINE	NC(=O)[C@@H]1CC[C@@H](N1)C2=CC=C(OCC3=C(F)C=CC=C3)C=C2	PLASMA	QQS4J85K6Y									∞	ng × h/mL	38700		ng/mL	3780			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30144099	Homo sapiens		h	8.91				22	RAXATRIGINE		false
8229	8925		ADULT	51049968	534.5571	RIMEGEPANT	RIMEGEPANT	N[C@H]1[C@@H](CC[C@@H](OC(=O)N2CCC(CC2)N3C(=O)NC4=C3C=CC=N4)C5=NC=CC=C15)C6=CC=CC(F)=C6F	PLASMA	997WVV895X									∞	ng × h/mL	4718.71		ng/mL	1045.53			RECOMMENDED	mg	75		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	OTHER	https://www.biohavenpharma.com/sites/default/files/documents/rimegepant-ph1-elderly-pk-2019-ahs.pdf	Homo sapiens		h	10.398							false
8230	8930		ADULT	15950826	268.022	RRX-001	RRX-001	[O-][N ](=O)C1(CN(C1)C(=O)CBr)[N ]([O-])=O	PLASMA	7RPW6SU9SC									∞	ng × h/mL	457.4		ng/mL	161.3			UNKNOWN	mg/m²	83		SINGLE	UNKNOWN			1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26296952	Homo sapiens		h	0.6				6	RRX-001		false
8231	8930		ADULT	15950826	268.022	RRX-001	RRX-001	[O-][N ](=O)C1(CN(C1)C(=O)CBr)[N ]([O-])=O	PLASMA	7RPW6SU9SC									∞	ng × h/mL	1217.5		ng/mL	251.1			UNKNOWN	mg/m²	83		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26296952	Homo sapiens		h	0.45	day 22			6	RRX-001		false
8232	8935		UNKNOWN	11667832	370.4421	SAMIDORPHAN	Samidorphan	NC(=O)C1=CC=C2C[C@H]3N(CC4CC4)CC[C@@]5(CC(=O)CC[C@@]35O)C2=C1O	PLASMA	7W2581Z5L8	135398745	312.432	OLANZAPINE	Olanzapine	CN1CCN(CC1)C2=NC3=C(NC4=C2C=C(C)S4)C=CC=C3	N7U69T4SZR	24		t	ng × h/mL	364		ng/mL	45.1			RECOMMENDED	mg	10		STEADY-STATE	UNKNOWN		day	11	Human plasma protein binding: 23%-33%; t1/2=7-11 h (please see the above)	67	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213378s000lbl.pdf#page=25	Homo sapiens		h	11			20 mg				true
8233	8935		UNKNOWN	11667832	370.4421	SAMIDORPHAN	Samidorphan	NC(=O)C1=CC=C2C[C@H]3N(CC4CC4)CC[C@@]5(CC(=O)CC[C@@]35O)C2=C1O	PLASMA	7W2581Z5L8	135398745	312.432	OLANZAPINE	Olanzapine	CN1CCN(CC1)C2=NC3=C(NC4=C2C=C(C)S4)C=CC=C3	N7U69T4SZR			∞	ng × h/mL	627.907		ng/mL	16.291			RECOMMENDED	mg	10		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213378Orig1Orig2s000MultidisciplineR.pdf#page=275	Homo sapiens					n=44 for AUCinf	10 mg	45			true
8234	8935		ADULT	11667832	370.4421	SAMIDORPHAN	Samidorphan	NC(=O)C1=CC=C2C[C@H]3N(CC4CC4)CC[C@@]5(CC(=O)CC[C@@]35O)C2=C1O	PLASMA	7W2581Z5L8							24		t	ng × h/mL	113.1		ng/mL	13.3			UNKNOWN	mg	5		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213378Orig1Orig2s000MultidisciplineR.pdf#page=306	Homo sapiens							19			false
8235	8935		ADULT	11667832	370.4421	SAMIDORPHAN	Samidorphan	NC(=O)C1=CC=C2C[C@H]3N(CC4CC4)CC[C@@]5(CC(=O)CC[C@@]35O)C2=C1O	PLASMA	7W2581Z5L8									?	ng × h/mL	27.7		ng/mL	11.2			UNKNOWN	mg	1		SINGLE	UNKNOWN						UNKNOWN	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213378Orig1Orig2s000MultidisciplineR.pdf#page=307	Homo sapiens										false
8236	8935		ADULT	11667832	370.4421	SAMIDORPHAN	Samidorphan	NC(=O)C1=CC=C2C[C@H]3N(CC4CC4)CC[C@@]5(CC(=O)CC[C@@]35O)C2=C1O	PLASMA	7W2581Z5L8									?	ng × h/mL	41.3		ng/mL	4.1			UNKNOWN	mg	2		SINGLE	UNKNOWN						UNKNOWN	Sublingual	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213378Orig1Orig2s000MultidisciplineR.pdf#page=307	Homo sapiens										false
8237	8935		ADULT	11667832	370.4421	SAMIDORPHAN	Samidorphan	NC(=O)C1=CC=C2C[C@H]3N(CC4CC4)CC[C@@]5(CC(=O)CC[C@@]35O)C2=C1O	PLASMA	7W2581Z5L8									?	ng × h/mL	39.9		ng/mL	4.1			UNKNOWN	mg	2		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213378Orig1Orig2s000MultidisciplineR.pdf#page=307	Homo sapiens										false
8238	8935		ADULT	11667832	370.4421	SAMIDORPHAN	Samidorphan	NC(=O)C1=CC=C2C[C@H]3N(CC4CC4)CC[C@@]5(CC(=O)CC[C@@]35O)C2=C1O	PLASMA	7W2581Z5L8									?	ng × h/mL	246		ng/mL	27.8			UNKNOWN	mg	10		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213378Orig1Orig2s000MultidisciplineR.pdf#page=307	Homo sapiens										false
8239	8937		UNKNOWN	68289010	345.3613	SAVOLITINIB	SAVOLITINIB	C[C@H](N1N=NC2=C1N=C(C=N2)C3=CN(C)N=C3)C4=CN5C=CN=C5C=C4	PLASMA	2A2DA6857R																						UNKNOWN				Volitinib had moderate plasma protein binding rate (60%∼70% in rat, dog, and human; 40% in mouse; 80% in monkey) and exhibited wide distribution to different organs in rat, with high exposures in liver and kidney, very low in brain, spinal cord and testis comparing to the plasma level.	35	UNKNOWN		UNKNOWN	EXPERIMENT	https://cancerres.aacrjournals.org/content/73/8_Supplement/3371	Homo sapiens										false
8240	8937		ADULT	68289010	345.4	SAVOLITINIB	SAVOLITINIB	C[C@H](N1N=NC2=C1N=C(C=N2)C3=CN(C)N=C3)C4=CN5C=CN=C5C=C4	PLASMA	2A2DA6857R									?	ng × h/mL	17053.9		ng/mL	2414.8			RECOMMENDED	mg	600		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/30952639	Homo sapiens		h	3.711							false
8241	8943		ADULT	71481097	443.306	SELINEXOR	FC(F)(F)C1=CC(=CC(=C1)C2=NN(C=N2)\\C=C/C(=O)NNC3=CN=CC=N3)C(F)(F)F	FC(F)(F)C1=CC(=CC(=C1)C2=NN(C=N2)\\C=C/C(=O)NNC3=CN=CC=N3)C(F)(F)F	PLASMA	31TZ62FO8F									?	ng × h/mL	5386		ng/mL	680			RECOMMENDED	mg	80		SINGLE	UNKNOWN				The protein binding of selinexor is 95%.	5	UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212306s000lbl.pdf	Homo sapiens		h	7							false
8242	8946		ADULT	5745214	744.8961	SEMAPIMOD	SEMAPIMOD	C\\C(=N/NC(N)=N)C1=CC(=CC(NC(=O)CCCCCCCCC(=O)NC2=CC(=CC(=C2)C(\\C)=N\\NC(N)=N)C(\\C)=N\\NC(N)=N)=C1)C(\\C)=N\\NC(N)=N	PLASMA	9SGW2H1K8P									?	μg × min/mL	246		μg/mL	3.8			UNKNOWN	mg/m²	32		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11297238	Homo sapiens		h	1.02				6	SEMAPIMOD		false
8243	8946		ADULT	5745214	744.8961	SEMAPIMOD	SEMAPIMOD	C\\C(=N/NC(N)=N)C1=CC(=CC(NC(=O)CCCCCCCCC(=O)NC2=CC(=CC(=C2)C(\\C)=N\\NC(N)=N)C(\\C)=N\\NC(N)=N)=C1)C(\\C)=N\\NC(N)=N	PLASMA	9SGW2H1K8P									?	μg × min/L	432		μg/mL	6.2			UNKNOWN	mg/m²	32		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11297238	Homo sapiens		h	1.42				6	SEMAPIMOD		false
8244	8948		ADULT	92787	318.4935	SEPRANOLONE	isoallopregnanolone	CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	SERUM	3P8Z6V53MU									∞	nM × min	21009		nM	143			UNKNOWN	mg/kg	0.2		SINGLE	UNKNOWN		day	1			HEALTHY	Intravenous	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18949461	Homo sapiens		min	847	doses 0.04, 0.06 and 0.1 mg/kg were administered at 30 min interval			6	isoallopregnanolone		false
8245	8952		UNKNOWN	11993702	1117.309	SETMELANOTIDE	Setmelanotide	C[C@H]1NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CN=CN5)NC1=O)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O	PLASMA	N7T15V1FUY									?	ng × h/mL	35.8		ng/mL	6.65			UNKNOWN	mg	0.5		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Subcutaneous	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213793Orig1s000ClinPharmR.pdf#page=17 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213793Orig1s000ClinPharmR.pdf#page=46	Homo sapiens				Steady-state plasma concentrations were achieved within 2 days (QD)	Phase 2, Patients with Rare Genetic Disorders of Obesity		13			false
8246	8952		UNKNOWN	11993702	1117.309	SETMELANOTIDE	Setmelanotide	C[C@H]1NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CN=CN5)NC1=O)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O	PLASMA	N7T15V1FUY									?	ng × h/mL	59.3		ng/mL	10.4			UNKNOWN	mg	1		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Subcutaneous	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213793Orig1s000ClinPharmR.pdf#page=17 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213793Orig1s000ClinPharmR.pdf#page=46	Homo sapiens				Steady-state plasma concentrations were achieved within 2 days (QD)	Phase 2, Patients with Rare Genetic Disorders of Obesity		25			false
8247	8952		UNKNOWN	11993702	1117.309	SETMELANOTIDE	Setmelanotide	C[C@H]1NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CN=CN5)NC1=O)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O	PLASMA	N7T15V1FUY									?	ng × h/mL	106		ng/mL	17.5			UNKNOWN	mg	1.5		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Subcutaneous	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213793Orig1s000ClinPharmR.pdf#page=17 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213793Orig1s000ClinPharmR.pdf#page=46	Homo sapiens				Steady-state plasma concentrations were achieved within 2 days (QD)	Phase 2, Patients with Rare Genetic Disorders of Obesity		22			false
8248	8952		UNKNOWN	11993702	1117.309	SETMELANOTIDE	Setmelanotide	C[C@H]1NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CN=CN5)NC1=O)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O	PLASMA	N7T15V1FUY									?	ng × h/mL	146		ng/mL	25.1			UNKNOWN	mg	2		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Subcutaneous	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213793Orig1s000ClinPharmR.pdf#page=17 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213793Orig1s000ClinPharmR.pdf#page=46	Homo sapiens				Steady-state plasma concentrations were achieved within 2 days (QD)	Phase 2, Patients with Rare Genetic Disorders of Obesity		29			false
8249	8952		UNKNOWN	11993702	1117.309	SETMELANOTIDE	Setmelanotide	C[C@H]1NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CN=CN5)NC1=O)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O	PLASMA	N7T15V1FUY									?	ng × h/mL	188		ng/mL	32.8			UNKNOWN	mg	2.5		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Subcutaneous	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213793Orig1s000ClinPharmR.pdf#page=17 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213793Orig1s000ClinPharmR.pdf#page=46	Homo sapiens				Steady-state plasma concentrations were achieved within 2 days (QD)	Phase 2, Patients with Rare Genetic Disorders of Obesity		19			false
8250	8952		UNKNOWN	11993702	1117.309	SETMELANOTIDE	Setmelanotide	C[C@H]1NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CN=CN5)NC1=O)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O	PLASMA	N7T15V1FUY									?	ng × h/mL	207		ng/mL	38			UNKNOWN	mg	2.5		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Subcutaneous	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213793Orig1s000ClinPharmR.pdf#page=17 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213793Orig1s000ClinPharmR.pdf#page=46	Homo sapiens				Steady-state plasma concentrations were achieved within 2 days (QD)	Phase 2, Patients with Rare Genetic Disorders of Obesity		10			false
8251	8952		ADULT	11993702	1117.309	SETMELANOTIDE	setmelanotide	C[C@H]1NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CN=CN5)NC1=O)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O	PLASMA	N7T15V1FUY													ng/mL	25.4			UNKNOWN	mg/kg	0.0215		SINGLE	UNKNOWN						HEALTHY	Subcutaneous	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213793Orig1s000ClinPharmR.pdf#page=34	Homo sapiens		h	8.98	Average PK parameters (Doses: 0.0025, 0.01, 0.02, 0.025, and 0.05 mg/kg)	Adult healthy obese subjects		36			false
8252	8952		ADULT	11993702	1117.309	SETMELANOTIDE	setmelanotide	C[C@H]1NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CN=CN5)NC1=O)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O	PLASMA	N7T15V1FUY							24		t	ng × h/mL	243		ng/mL	14.2			UNKNOWN	mg	0.75		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Subcutaneous	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213793Orig1s000ClinPharmR.pdf#page=38	Homo sapiens		h	5.91	Day 8 PK	Phase 1B/2A Healthy Obese Subjects		9			false
8253	8952		ADULT	11993702	1117.309	SETMELANOTIDE	setmelanotide	C[C@H]1NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CN=CN5)NC1=O)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O	PLASMA	N7T15V1FUY							24		t	ng × h/mL	271		ng/mL	23			UNKNOWN	mg	1.5		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Subcutaneous	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213793Orig1s000ClinPharmR.pdf#page=38	Homo sapiens		h	7.55	Day 8 PK	Phase 1B/2A Healthy Obese Subjects		9			false
8254	8952		ADULT	11993702	1117.309	SETMELANOTIDE	setmelanotide	C[C@H]1NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CN=CN5)NC1=O)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O	PLASMA	N7T15V1FUY							24		t	ng × h/mL	347		ng/mL	27.5			UNKNOWN	mg	2		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Subcutaneous	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213793Orig1s000ClinPharmR.pdf#page=38	Homo sapiens		h	7.73	Day 8 PK	Phase 1B/2A Healthy Obese Subjects		12			false
8255	8952		ADULT	11993702	1117.309	SETMELANOTIDE	Setmelanotide	C[C@H]1NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CN=CN5)NC1=O)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O	PLASMA	N7T15V1FUY							24		t	ng × h/mL	253		ng/mL	19.7			UNKNOWN	mg	2		SINGLE	UNKNOWN						HEALTHY	Subcutaneous	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213793Orig1s000ClinPharmR.pdf#page=40	Homo sapiens		h	6.18		Healthy Obese Subjects		6			false
8256	8952		UNKNOWN	11993702	1117.309	SETMELANOTIDE	Setmelanotide	C[C@H]1NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CN=CN5)NC1=O)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O	PLASMA	N7T15V1FUY									?	ng × h/mL	111		ng/mL	24.8			UNKNOWN	mg	1.5		SINGLE	UNKNOWN						UNHEALTHY	Subcutaneous	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213793Orig1s000ClinPharmR.pdf#page=43	Homo sapiens					Phase 2, Patients with Rare Genetic Disorders of Obesity, 15-26 years		6			false
8257	8952		UNKNOWN	11993702	1117.309	SETMELANOTIDE	Setmelanotide	C[C@H]1NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CN=CN5)NC1=O)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O	PLASMA	N7T15V1FUY									?	ng × h/mL	36.2		ng/mL	17.5			UNKNOWN	mg	2		SINGLE	UNKNOWN						UNHEALTHY	Subcutaneous	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213793Orig1s000ClinPharmR.pdf#page=43	Homo sapiens					Phase 2, Patients with Rare Genetic Disorders of Obesity, 15-26 years		3			false
8258	8952		UNKNOWN	11993702	1117.309	SETMELANOTIDE	Setmelanotide	C[C@H]1NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CN=CN5)NC1=O)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O	PLASMA	N7T15V1FUY									?	ng × h/mL	180		ng/mL	24.4			UNKNOWN	mg	2.5		UNKNOWN	UNKNOWN		day	1			UNHEALTHY	Subcutaneous	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213793Orig1s000ClinPharmR.pdf#page=52	Homo sapiens					Phase 3, POMC Deficient Obesity; pediatrics, adolescents and adults		3			false
8259	8952		UNKNOWN	11993702	1117.309	SETMELANOTIDE	Setmelanotide	C[C@H]1NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CN=CN5)NC1=O)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O	PLASMA	N7T15V1FUY									?	ng × h/mL	38.3		ng/mL	6.47			UNKNOWN	mg	0.5		UNKNOWN	UNKNOWN		day	1			UNHEALTHY	Subcutaneous	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213793Orig1s000ClinPharmR.pdf#page=52	Homo sapiens					Phase 3, POMC Deficient Obesity; pediatrics, adolescents and adults		4			false
8260	8952		UNKNOWN	11993702	1117.309	SETMELANOTIDE	Setmelanotide	C[C@H]1NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CN=CN5)NC1=O)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O	PLASMA	N7T15V1FUY									?	ng × h/mL	74.2		ng/mL	11.5			UNKNOWN	mg	1		UNKNOWN	UNKNOWN		day	1			UNHEALTHY	Subcutaneous	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213793Orig1s000ClinPharmR.pdf#page=52	Homo sapiens					Phase 3, POMC Deficient Obesity; pediatrics, adolescents and adults		10			false
8261	8952		UNKNOWN	11993702	1117.309	SETMELANOTIDE	Setmelanotide	C[C@H]1NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CN=CN5)NC1=O)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O	PLASMA	N7T15V1FUY									?	ng × h/mL	147		ng/mL	22.4			UNKNOWN	mg	1.5		UNKNOWN	UNKNOWN		day	1			UNHEALTHY	Subcutaneous	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213793Orig1s000ClinPharmR.pdf#page=52	Homo sapiens					Phase 3, POMC Deficient Obesity; pediatrics, adolescents and adults		20			false
8262	8952		UNKNOWN	11993702	1117.309	SETMELANOTIDE	Setmelanotide	C[C@H]1NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CN=CN5)NC1=O)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O	PLASMA	N7T15V1FUY									?	ng × h/mL	159		ng/mL	24.5			UNKNOWN	mg	2		UNKNOWN	UNKNOWN		day	1			UNHEALTHY	Subcutaneous	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213793Orig1s000ClinPharmR.pdf#page=52	Homo sapiens					Phase 3, POMC Deficient Obesity; pediatrics, adolescents and adults		6			false
8263	8952		UNKNOWN	11993702	1117.309	SETMELANOTIDE	Setmelanotide	C[C@H]1NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CN=CN5)NC1=O)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O	PLASMA	N7T15V1FUY									?	ng × h/mL	56.2		ng/mL	7.21			UNKNOWN	mg	0.5		UNKNOWN	UNKNOWN		day	1			UNHEALTHY	Subcutaneous	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213793Orig1s000ClinPharmR.pdf#page=61	Homo sapiens					Phase 3, LEPR Deficient Obesity; adolescents and adults		4			false
8264	8952		UNKNOWN	11993702	1117.309	SETMELANOTIDE	Setmelanotide	C[C@H]1NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CN=CN5)NC1=O)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O	PLASMA	N7T15V1FUY									?	ng × h/mL	79.1		ng/mL	10.4			UNKNOWN	mg	1		UNKNOWN	UNKNOWN		day	1			UNHEALTHY	Subcutaneous	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213793Orig1s000ClinPharmR.pdf#page=61	Homo sapiens					Phase 3, LEPR Deficient Obesity; adolescents and adults		13			false
8265	8952		UNKNOWN	11993702	1117.309	SETMELANOTIDE	Setmelanotide	C[C@H]1NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CN=CN5)NC1=O)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O	PLASMA	N7T15V1FUY									?	ng × h/mL	130		ng/mL	17			UNKNOWN	mg	1.5		UNKNOWN	UNKNOWN		day	1			UNHEALTHY	Subcutaneous	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213793Orig1s000ClinPharmR.pdf#page=61	Homo sapiens					Phase 3, LEPR Deficient Obesity; adolescents and adults		12			false
8266	8952		UNKNOWN	11993702	1117.309	SETMELANOTIDE	Setmelanotide	C[C@H]1NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CN=CN5)NC1=O)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O	PLASMA	N7T15V1FUY									?	ng × h/mL	178		ng/mL	23.9			UNKNOWN	mg	2		UNKNOWN	UNKNOWN		day	1			UNHEALTHY	Subcutaneous	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213793Orig1s000ClinPharmR.pdf#page=61	Homo sapiens					Phase 3, LEPR Deficient Obesity; adolescents and adults		15			false
8267	8952		UNKNOWN	11993702	1117.309	SETMELANOTIDE	Setmelanotide	C[C@H]1NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CN=CN5)NC1=O)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O	PLASMA	N7T15V1FUY									?	ng × h/mL	260		ng/mL	31.1			UNKNOWN	mg	2.5		UNKNOWN	UNKNOWN		day	1			UNHEALTHY	Subcutaneous	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213793Orig1s000ClinPharmR.pdf#page=61	Homo sapiens					Phase 3, LEPR Deficient Obesity; adolescents and adults		10			false
8268	8952		UNKNOWN	11993702	1117.309	SETMELANOTIDE	Setmelanotide	C[C@H]1NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CN=CN5)NC1=O)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O	PLASMA	N7T15V1FUY									?	ng × h/mL	383		ng/mL	38.9			UNKNOWN	mg	3		UNKNOWN	UNKNOWN		day	1			UNHEALTHY	Subcutaneous	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213793Orig1s000ClinPharmR.pdf#page=61	Homo sapiens					Phase 3, LEPR Deficient Obesity; adolescents and adults		3			false
8269	8952		UNKNOWN	11993702	1117.309	SETMELANOTIDE	Setmelanotide	C[C@H]1NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CN=CN5)NC1=O)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O	PLASMA	N7T15V1FUY																						UNKNOWN				Human plasma protein binding: 79.1%	20.9	UNKNOWN		UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213793Orig1s000PharmR.pdf#page=27	Homo sapiens										false
8270	8956		ADULT	9908378	389.4	SL651498	SL-65.1498	CN1C2=C(C=C(C=C2)F)C3=C1C(=O)N(C=C3C(=O)N4CCCC4)C5=CC=CC=C5	PLASMA	082VH54RF1													ng/mL	375			UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18635696	Homo sapiens		h	11				20	SL-65.1498		false
8271	8957		ADULT	91439	416.6365	SMILAGENIN	SMILAGENIN	C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC[C@@H]5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@]23C)O[C@]16CC[C@@H](C)CO6	PLASMA	GQE3Q7YMVZ													ng/mL	480			UNKNOWN	mg	150		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	OTHER	https://www.kinetassist.com/images/Kinetic_modelling_poster_WPC_final.pdf	Homo sapiens				In patients with PD, a single dose of 150 mg/day produced a plasma Cmax of approximately 480 ng/ml after 28 days of dosing.				SMILAGENIN		false
8272	8964		ADULT	44603362	389.4503	SOLCITINIB	CC1(C)CN(C1)C(=O)C2=CC=C(C=C2)C3=CC=CC4=NC(NC(=O)C5CC5)=NN34	CC1(C)CN(C1)C(=O)C2=CC=C(C=C2)C3=CC=CC4=NC(NC(=O)C5CC5)=NN34	PLASMA	3V7GQ1260K									∞	mg × h/L	7546.1		ng/mL	1871.7			INVESTIGATIONAL	mg	400		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://s3.amazonaws.com/ctr-gsk-7381/117171/efaf9f51-b67c-4381-a287-1d4fd566eb6e/df2d37af-3eb3-4e7b-9c87-e5b9e2b74657/117171-Clinical-Study-Result-Summary-v1.pdf	Homo sapiens		h	1.8							false
8273	8964		ADULT	44603362	389.4503	SOLCITINIB	CC1(C)CN(C1)C(=O)C2=CC=C(C=C2)C3=CC=CC4=NC(NC(=O)C5CC5)=NN34	CC1(C)CN(C1)C(=O)C2=CC=C(C=C2)C3=CC=CC4=NC(NC(=O)C5CC5)=NN34	PLASMA	3V7GQ1260K									?	ng × h/mL	7656.32						INVESTIGATIONAL	mg	400		STEADY-STATE	FED		day	2			UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/27055521	Homo sapiens										false
8274	8968		ADULT	73309142	527.6	17-OH-PX-866	17-OH-PX-866	CC(=O)OC1CC2(C(CCC2O)C3=C1C4(C(OC(=O)C(=CN(CC=C)CC=C)C4=C(C3=O)O)COC)C)C	PLASMA										∞	ng × h/mL	4.88		ng/mL	1.21			MAX TOLERATED	mg	8		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22693357	Homo sapiens		h	3.88				17	SONOLISIB		false
8275	8968		ADULT	73309142	527.6	17-OH-PX-866	PX-866-17OH	CC(=O)OC1CC2(C(CCC2O)C3=C1C4(C(OC(=O)C(=CN(CC=C)CC=C)C4=C(C3=O)O)COC)C)C	PLASMA										∞	ng × h/mL	8.77		ng/mL	4.02			UNKNOWN	mg	8		MULTIPLE	UNKNOWN		2 weeks	10			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22693357	Homo sapiens							4	SONOLISIB		false
8276	8968		ADULT	73309142	527.6	17-OH-PX-866		CC(=O)OC1CC2(C(CCC2O)C3=C1C4(C(OC(=O)C(=CN(CC=C)CC=C)C4=C(C3=O)O)COC)C)C	PLASMA										∞	ng × h/mL	7.91		ng/mL	2.44			UNKNOWN	mg	16		MULTIPLE	UNKNOWN		2 weeks	10			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22693357	Homo sapiens							5	SONOLISIB		false
8277	8968		ADULT	73309142	527.6	17-OH-PX-866	17-OH-PX-866	CC(=O)OC1CC2(C(CCC2O)C3=C1C4(C(OC(=O)C(=CN(CC=C)CC=C)C4=C(C3=O)O)COC)C)C	PLASMA										∞	ng × h/mL	5.53		ng/mL	2.86			UNKNOWN	mg	10		MULTIPLE	UNKNOWN		2 weeks	10			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22693357	Homo sapiens							4	SONOLISIB		false
8278	8968		ADULT	73309142	527.6	17-OH-PX-866	17-OH-PX-866	CC(=O)OC1CC2(C(CCC2O)C3=C1C4(C(OC(=O)C(=CN(CC=C)CC=C)C4=C(C3=O)O)COC)C)C	PLASMA										∞	ng × h/mL	6.82		ng/mL	2.86			MAX TOLERATED	mg	12		MULTIPLE	UNKNOWN		2 weeks	10			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22693357	Homo sapiens							16	SONOLISIB		false
8279	8968		ADULT	73309142	527.6	17-OH-PX-866	17-OH-PX-866	CC(=O)OC1CC2(C(CCC2O)C3=C1C4(C(OC(=O)C(=CN(CC=C)CC=C)C4=C(C3=O)O)COC)C)C	PLASMA										∞	ng × h/mL	2.7		ng/mL	0.76			UNKNOWN	mg	10		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22693357	Homo sapiens		h	2.22				3	SONOLISIB		false
8280	8968		ADULT	73309142	527.6	17-OH-PX-866		CC(=O)OC1CC2(C(CCC2O)C3=C1C4(C(OC(=O)C(=CN(CC=C)CC=C)C4=C(C3=O)O)COC)C)C	PLASMA										∞	ng × h/mL	6.47		ng/mL	2.39			UNKNOWN	mg	8		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22693357	Homo sapiens							6	SONOLISIB		false
8281	8968		ADULT	73309142	527.6	17-OH-PX-866		CC(=O)OC1CC2(C(CCC2O)C3=C1C4(C(OC(=O)C(=CN(CC=C)CC=C)C4=C(C3=O)O)COC)C)C	PLASMA										∞	ng × h/mL	3.21		ng/mL	0.73			UNKNOWN	mg	8		MULTIPLE	FED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22693357	Homo sapiens							6	SONOLISIB		false
8282	8968		ADULT	16717829	527.6	17-OH PX-866	17-OH PX-866		PLASMA										∞	ng × h/mL	3.21		ng/mL	0.73			RECOMMENDED	mg	8		MULTIPLE	FED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/22693357	Homo sapiens										false
8283	8968		ADULT	16717829	527.6	17-OH PX-866	17-OH PX-866		PLASMA										∞	ng × h/mL	6.47		ng/mL	2.39			RECOMMENDED	mg	8		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/22693357	Homo sapiens										false
8284	8975		ADULT	465951	353.416	SUTEZOLID		CC(=O)NC[C@H]1CN(C(=O)O1)c2ccc(N3CCSCC3)c(F)c2	PLASMA	3A71182L8P							12		t	ng × h/mL	845.8		ng/mL	252.4			UNKNOWN	mg	100		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21078950/	Homo sapiens		h	2.725	Day 14			8			false
8285	8975		ADULT	465951	353.416	SUTEZOLID		CC(=O)NC[C@H]1CN(C(=O)O1)c2ccc(N3CCSCC3)c(F)c2	PLASMA	3A71182L8P							12		t	ng × h/mL	2133		ng/mL	458.7			UNKNOWN	mg	300		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21078950/	Homo sapiens		h	2.55	Day 14			8			false
8286	8975		ADULT	465951	353.416	SUTEZOLID		CC(=O)NC[C@H]1CN(C(=O)O1)c2ccc(N3CCSCC3)c(F)c2	PLASMA	3A71182L8P							12		t	ng × h/mL	4294		ng/mL	942.7			UNKNOWN	mg	600		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21078950/	Homo sapiens		h	2.925	Day 14			7			false
8287	8975		ADULT	465951	353.416	SUTEZOLID		CC(=O)NC[C@H]1CN(C(=O)O1)c2ccc(N3CCSCC3)c(F)c2	PLASMA	3A71182L8P							24		t	ng × h/mL	10100		ng/mL	2016			UNKNOWN	mg	1200		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21078950/	Homo sapiens		h	3.38	Day 14			8			false
8288	8975		ADULT	465951	353.416	SUTEZOLID		CC(=O)NC[C@H]1CN(C(=O)O1)c2ccc(N3CCSCC3)c(F)c2	PLASMA	3A71182L8P							24		t	ng × h/mL	6494		ng/mL	986			UNKNOWN	mg	600		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24732289/	Homo sapiens				Day 14			25			false
8289	8975		ADULT	465951	353.416	SUTEZOLID		CC(=O)NC[C@H]1CN(C(=O)O1)c2ccc(N3CCSCC3)c(F)c2	PLASMA	3A71182L8P							24		t	ng × h/mL	7127		ng/mL	1972			UNKNOWN	mg	1200		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24732289/	Homo sapiens				Day 14			25			false
8290	8982		ADULT	9810101	528.685	TABIMORELIN	TABIMORELIN	CNC(=O)[C@@H](CC1=CC=CC=C1)N(C)C(=O)[C@@H](CC2=CC3=C(C=CC=C3)C=C2)N(C)C(=O)\\C=C\\CC(C)(C)N	SERUM	L51CBE03KF									?	ng × h/mL	276		ng/mL	76.7			UNKNOWN	mg/kg bw	1.5		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11032702	Homo sapiens		h	6.9				6	NN703		false
8291	8982		ADULT	9810101	528.685	TABIMORELIN	TABIMORELIN	CNC(=O)[C@@H](CC1=CC=CC=C1)N(C)C(=O)[C@@H](CC2=CC3=C(C=CC=C3)C=C2)N(C)C(=O)\\C=C\\CC(C)(C)N	SERUM	L51CBE03KF									?	ng × h/mL	840		ng/mL	178.8			UNKNOWN	mg/kg bw	3		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11032702	Homo sapiens		h	16.1				6	NN703		false
8292	8982		ADULT	9810101	528.685	TABIMORELIN	TABIMORELIN	CNC(=O)[C@@H](CC1=CC=CC=C1)N(C)C(=O)[C@@H](CC2=CC3=C(C=CC=C3)C=C2)N(C)C(=O)\\C=C\\CC(C)(C)N	SERUM	L51CBE03KF									?	ng × h/mL	2747		ng/mL	668.1			UNKNOWN	mg/kg bw	6		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11032702	Homo sapiens		h	15				6	NN703		false
8293	8982		ADULT	9810101	528.685	TABIMORELIN	TABIMORELIN	CNC(=O)[C@@H](CC1=CC=CC=C1)N(C)C(=O)[C@@H](CC2=CC3=C(C=CC=C3)C=C2)N(C)C(=O)\\C=C\\CC(C)(C)N	SERUM	L51CBE03KF									?	ng × h/mL	6798		ng/mL	1686.7			HIGHEST STUDIED	mg/kg bw	12		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11032702	Homo sapiens		h	13.2				6	NN703		false
8294	8986		ADULT	6440175	585.6884	TANESPIMYCIN	TANESPIMYCIN	CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\\C(C)=C\\C=C[C@H](OC)[C@@H](OC(N)=O)\\C(C)=C\\[C@H](C)[C@H]1O)C2=O	PLASMA	4GY0AVT3L4																						UNKNOWN				17AAG and 17AG in plasma were >90% protein bound.	10	UNHEALTHY		UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/15867239	Homo sapiens										false
8295	8986		ADULT	6440175	585.6884	TANESPIMYCIN	TANESPIMYCIN	CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\\C(C)=C\\C=C[C@H](OC)[C@@H](OC(N)=O)\\C(C)=C\\[C@H](C)[C@H]1O)C2=O	PLASMA	4GY0AVT3L4									∞	ng × h/mL	20768		ng/mL	8532.2			UNKNOWN	mg/m²	340		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/20652703	Homo sapiens		h	3.4							false
8296	8995		ADULT	9808844	409.826	TELATINIB	TELATINIB	CNC(=O)C1=NC=CC(COC2=C3OC=CC3=C(NC4=CC=C(Cl)C=C4)N=N2)=C1	PLASMA	18P7197Q7J							12		t	mg × h/L	6.29		mg/L	0.964			MAX TOLERATED	mg	1500		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/19002179	Homo sapiens		h	6.6							false
8297	8996		ADULT	476861	358.4712	TERAMEPROCOL	terameprocol	COC1=C(OC)C=C(C[C@H](C)[C@H](C)CC2=CC(OC)=C(OC)C=C2)C=C1	SERUM	53YET703F2																	UNKNOWN	mg	750		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18418294	Homo sapiens		h	17.1	starting dose of terameprocol was 750 mg/day for 5 consecutive days each month by intravenous infusion.			16	terameprocol		false
8298	9001		ADULT	29243	248.2331	TETRAHYDROURIDINE	TETRAHYDROURIDINE	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N2CCC(O)NC2=O	PLASMA	0NIZ8H6OL8	515328	245.2077	5-FLUORO-2'-DEOXYCYTIDINE	5-FLUORO-2'-DEOXYCYTIDINE	NC1=NC(=O)N(C=C1F)[C@H]2C[C@H](O)[C@@H](CO)O2	KUA4693H5W			∞	μg × min/mL	7969		ng/mL	16452			UNKNOWN	mg/m²	350		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26321472	Homo sapiens				3 h IV infusion		3-h infusion of FdCyd, 100 mg/m2	7	TETRAHYDROURIDINE		true
8299	9001		ADULT	29243	248.2331	TETRAHYDROURIDINE	TETRAHYDROURIDINE	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N2CCC(O)NC2=O	PLASMA	0NIZ8H6OL8	515328	245.2077	5-FLUORO-2'-DEOXYCYTIDINE	5-FLUORO-2'-DEOXYCYTIDINE	NC1=NC(=O)N(C=C1F)[C@H]2C[C@H](O)[C@@H](CO)O2	KUA4693H5W			∞	μg × min/mL	1606		ng/mL	1428			UNKNOWN	mg/m²	1750		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26321472	Homo sapiens						100 mg/m2, p.o	7	TETRAHYDROURIDINE		true
8300	9015		ADULT	15547703	406.4727	TOSEDOSTAT	TOSEDOSTAT	CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)C2=CC=CC=C2	PLASMA	KZK563J2UW									?	ng × h/mL	2520		ng/mL	1400			UNKNOWN	mg	180		MULTIPLE	FED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20877350	Homo sapiens		h	1.1				3	TOSEDOSTAT		false
8301	9021		ADULT	9571836	195.245	TRIAPINE	TRIAPINE	NC(=S)N\\N=C\\C1=NC=CC=C1N	PLASMA	U4XIL4091C							8		t	mg × min/L	254.5		μg/mL	1.56			UNKNOWN	mg/m²	96		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/14519631	Homo sapiens		min	63							false
8302	9023		ADULT	69286	428.6026	TRIHEPTANOIN	TRIHEPTANOIN	CCCCCCC(=O)OCC(COC(=O)CCCCCC)OC(=O)CCCCCC	PLASMA	2P6O7CFW5K							8		t	μM × h	336.5		μM	178.9			UNKNOWN	mg/kg	300		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213687s000lbl.pdf	Homo sapiens										false
8303	9023		ADULT	69286	428.6026	TRIHEPTANOIN	TRIHEPTANOIN	CCCCCCC(=O)OCC(COC(=O)CCCCCC)OC(=O)CCCCCC	PLASMA	2P6O7CFW5K										μM × h	789.8		μM	319.9			UNKNOWN	mg/kg	300		MULTIPLE	UNKNOWN		2 days	8			HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213687s000lbl.pdf	Homo sapiens										false
8304	9023		ADULT	69286	428.6026	TRIHEPTANOIN	TRIHEPTANOIN	CCCCCCC(=O)OCC(COC(=O)CCCCCC)OC(=O)CCCCCC	PLASMA	2P6O7CFW5K							8		t	μM × h	569.1		μM	259.1			UNKNOWN	mg/kg	400		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213687s000lbl.pdf	Homo sapiens										false
8305	9027		ADULT	68748835	549.5436	UBROGEPANT	UBROGEPANT	C[C@@H]1[C@@H](C[C@H](NC(=O)C2=CN=C3C[C@]4(CC3=C2)C(=O)NC5=C4C=CC=N5)C(=O)N1CC(F)(F)F)C6=CC=CC=C6	PLASMA	AD0O8X2QJR							24		t	nM × h	1306.54		nM	281.97			RECOMMENDED	mg	50		SINGLE							HEALTHY	Oral	FEMALE	EXPERIMENT	https://journals.sagepub.com/doi/pdf/10.1177/2515816320905082	Homo sapiens		h	3.54							false
8306	9027		ADULT	68748835	549.5436	UBROGEPANT	UBROGEPANT	C[C@@H]1[C@@H](C[C@H](NC(=O)C2=CN=C3C[C@]4(CC3=C2)C(=O)NC5=C4C=CC=N5)C(=O)N1CC(F)(F)F)C6=CC=CC=C6	PLASMA	AD0O8X2QJR									∞	ng × h/mL	1249.39		ng/mL	274.25			RECOMMENDED	mg	100		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31628854/	Homo sapiens		h	4.41							false
8307	9027		ADULT	68748835	549.5436	UBROGEPANT	UBROGEPANT	C[C@@H]1[C@@H](C[C@H](NC(=O)C2=CN=C3C[C@]4(CC3=C2)C(=O)NC5=C4C=CC=N5)C(=O)N1CC(F)(F)F)C6=CC=CC=C6	PLASMA	AD0O8X2QJR									∞	ng × h/mL	5127.06		ng/mL	1029.75			INVESTIGATIONAL	mg	400		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31628854/	Homo sapiens		h	5.06							false
8308	9032		ADULT	23634441	306.701	VADADUSTAT	C1=CC(=CC(=C1)Cl)C2=CC(=C(N=C2)C(=O)NCC(=O)O)O	OC(=O)CNC(=O)C1=C(O)C=C(C=N1)C2=CC(Cl)=CC=C2	PLASMA	I60W9520VV									∞	μg × h/mL	395		μg/mL	53.7			UNKNOWN	mg	600		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.postersessiononline.eu/173580348_eu/congresos/54ERA/aula/-MP_418_54ERA.pdf	Homo sapiens		h	4.95							false
8309	9037		ADULT	42642648	466.943	VARLITINIB	C[C@@H]1COC(NC2=CC3=C(C=C2)N=CN=C3NC4=CC(Cl)=C(OCC5=NC=CS5)C=C4)=N1	C[C@@H]1COC(NC2=CC3=C(C=C2)N=CN=C3NC4=CC(Cl)=C(OCC5=NC=CS5)C=C4)=N1	UNKNOWN	846Y8197W1	4666		PACLITAXEL	paclitaxel	CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C3=CC=CC=C3)[C@@H]4[C@@]5(CO[C@@H]5C[C@H](O)[C@@]4(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C6=CC=CC=C6)C7=CC=CC=C7	P88XT4IS4D	24		t	ng × h/mL	5314.6		ng/mL	3137.5			RECOMMENDED	mg	300		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	http://aslanpharma.com/app/uploads/2018/06/2018-ASCO-ASLAN001-004.pdf	Homo sapiens										true
8310	9039		UNKNOWN	67683363	883.0019	VELPATASVIR	VELPATASVIR	COC[C@H]1C[C@H](N(C1)C(=O)[C@H](NC(=O)OC)C2=CC=CC=C2)C3=NC=C(N3)C4=CC5=C(C=C4)C6=CC7=C(C=C6OC5)C8=C(C=C7)N=C(N8)[C@@H]9CC[C@H](C)N9C(=O)[C@@H](NC(=O)OC)C(C)C	PLASMA	KCU0C7RS7Z																	UNKNOWN				UNKNOWN	UNKNOWN				Velpatasvir was highly bound to plasma proteins across species (fraction unbound range, ∼0.2% to 0.4%) by equilibrium dialysis.	0.3	UNKNOWN	UNKNOWN	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28193657	Homo sapiens										false
8311	9039		ADULT	67683363	883.0019	VELPATASVIR	VELPATASVIR	COC[C@H]1C[C@H](N(C1)C(=O)[C@H](NC(=O)OC)C2=CC=CC=C2)C3=NC=C(N3)C4=CC5=C(C=C4)C6=CC7=C(C=C6OC5)C8=C(C=C7)N=C(N8)[C@@H]9CC[C@H](C)N9C(=O)[C@@H](NC(=O)OC)C(C)C	PLASMA	KCU0C7RS7Z									∞	ng × h/mL	159		ng/mL	22.4			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28193657	Homo sapiens		h	11.2							false
8312	9039		ADULT	67683363	883.0019	VELPATASVIR	VELPATASVIR	COC[C@H]1C[C@H](N(C1)C(=O)[C@H](NC(=O)OC)C2=CC=CC=C2)C3=NC=C(N3)C4=CC5=C(C=C4)C6=CC7=C(C=C6OC5)C8=C(C=C7)N=C(N8)[C@@H]9CC[C@H](C)N9C(=O)[C@@H](NC(=O)OC)C(C)C	PLASMA	KCU0C7RS7Z									∞	ng × h/mL	3020		ng/mL	371			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28193657	Homo sapiens		h	13.6							false
8313	9039		ADULT	67683363	883.0019	VELPATASVIR	VELPATASVIR	COC[C@H]1C[C@H](N(C1)C(=O)[C@H](NC(=O)OC)C2=CC=CC=C2)C3=NC=C(N3)C4=CC5=C(C=C4)C6=CC7=C(C=C6OC5)C8=C(C=C7)N=C(N8)[C@@H]9CC[C@H](C)N9C(=O)[C@@H](NC(=O)OC)C(C)C	PLASMA	KCU0C7RS7Z									∞	ng × h/mL	5060		ng/mL	575			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28193657	Homo sapiens		h	15.7							false
8314	9039		ADULT	67683363	883.0019	VELPATASVIR	VELPATASVIR	COC[C@H]1C[C@H](N(C1)C(=O)[C@H](NC(=O)OC)C2=CC=CC=C2)C3=NC=C(N3)C4=CC5=C(C=C4)C6=CC7=C(C=C6OC5)C8=C(C=C7)N=C(N8)[C@@H]9CC[C@H](C)N9C(=O)[C@@H](NC(=O)OC)C(C)C	PLASMA	KCU0C7RS7Z									∞	ng × h/mL	4980		ng/mL	608			UNKNOWN	mg	150		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28193657	Homo sapiens		h	16.2							false
8315	9039		ADULT	67683363	883.0019	VELPATASVIR	VELPATASVIR	COC[C@H]1C[C@H](N(C1)C(=O)[C@H](NC(=O)OC)C2=CC=CC=C2)C3=NC=C(N3)C4=CC5=C(C=C4)C6=CC7=C(C=C6OC5)C8=C(C=C7)N=C(N8)[C@@H]9CC[C@H](C)N9C(=O)[C@@H](NC(=O)OC)C(C)C	PLASMA	KCU0C7RS7Z									∞	ng × h/mL	9580		ng/mL	1120			UNKNOWN	mg	450		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28193657	Homo sapiens		h	15							false
8316	9039		ADULT	67683363	883.0019	VELPATASVIR	VELPATASVIR	COC[C@H]1C[C@H](N(C1)C(=O)[C@H](NC(=O)OC)C2=CC=CC=C2)C3=NC=C(N3)C4=CC5=C(C=C4)C6=CC7=C(C=C6OC5)C8=C(C=C7)N=C(N8)[C@@H]9CC[C@H](C)N9C(=O)[C@@H](NC(=O)OC)C(C)C	PLASMA	KCU0C7RS7Z									?	ng × h/mL	172		ng/mL	28.3			UNKNOWN	mg	5		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28193657	Homo sapiens		h	13.7							false
8317	9039		ADULT	67683363	883.0019	VELPATASVIR	VELPATASVIR	COC[C@H]1C[C@H](N(C1)C(=O)[C@H](NC(=O)OC)C2=CC=CC=C2)C3=NC=C(N3)C4=CC5=C(C=C4)C6=CC7=C(C=C6OC5)C8=C(C=C7)N=C(N8)[C@@H]9CC[C@H](C)N9C(=O)[C@@H](NC(=O)OC)C(C)C	PLASMA	KCU0C7RS7Z									?	ng × h/mL	3030		ng/mL	411			UNKNOWN	mg	50		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28193657	Homo sapiens		h	13							false
8318	9039		ADULT	67683363	883.0019	VELPATASVIR	VELPATASVIR	COC[C@H]1C[C@H](N(C1)C(=O)[C@H](NC(=O)OC)C2=CC=CC=C2)C3=NC=C(N3)C4=CC5=C(C=C4)C6=CC7=C(C=C6OC5)C8=C(C=C7)N=C(N8)[C@@H]9CC[C@H](C)N9C(=O)[C@@H](NC(=O)OC)C(C)C	PLASMA	KCU0C7RS7Z									?	ng × h/mL	4890		ng/mL	669			UNKNOWN	mg	150		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28193657	Homo sapiens		h	15.2							false
8319	9039		ADULT	67683363	883.0019	VELPATASVIR	VELPATASVIR	COC[C@H]1C[C@H](N(C1)C(=O)[C@H](NC(=O)OC)C2=CC=CC=C2)C3=NC=C(N3)C4=CC5=C(C=C4)C6=CC7=C(C=C6OC5)C8=C(C=C7)N=C(N8)[C@@H]9CC[C@H](C)N9C(=O)[C@@H](NC(=O)OC)C(C)C	PLASMA	KCU0C7RS7Z									?	ng × h/mL	9510		ng/mL	1200			UNKNOWN	mg	450		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28193657	Homo sapiens		h	11.7							false
8320	9039		ADULT	67683363	883.0019	VELPATASVIR	VELPATASVIR	COC[C@H]1C[C@H](N(C1)C(=O)[C@H](NC(=O)OC)C2=CC=CC=C2)C3=NC=C(N3)C4=CC5=C(C=C4)C6=CC7=C(C=C6OC5)C8=C(C=C7)N=C(N8)[C@@H]9CC[C@H](C)N9C(=O)[C@@H](NC(=O)OC)C(C)C	PLASMA	KCU0C7RS7Z									∞	ng × h/mL	7120		ng/mL	800			UNKNOWN	mg	100		SINGLE	LOW-FAT						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28193657	Homo sapiens		h	16.7							false
8321	9039		ADULT	67683363	883.0019	VELPATASVIR	VELPATASVIR	COC[C@H]1C[C@H](N(C1)C(=O)[C@H](NC(=O)OC)C2=CC=CC=C2)C3=NC=C(N3)C4=CC5=C(C=C4)C6=CC7=C(C=C6OC5)C8=C(C=C7)N=C(N8)[C@@H]9CC[C@H](C)N9C(=O)[C@@H](NC(=O)OC)C(C)C	PLASMA	KCU0C7RS7Z									∞	ng × h/mL	3620		ng/mL	398			UNKNOWN	mg	100		SINGLE	HIGH-FAT						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28193657	Homo sapiens		h	14.2							false
8322	9040		ADULT	54674461	426.3795	VERICIGUAT	Vericiguat	COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=C2C=C(F)C=N4	PLASMA	LV66ADM269									?	μg × h/mL	6680		μg/L	350			RECOMMENDED	mg	10		STEADY-STATE	FED		day	1			UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214377Orig1s000IntegratedR.pdf#page=223	Homo sapiens		h	20		patients with heart failure					false
8323	9040			54674461	426.3795	VERICIGUAT	Vericiguat	COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=C2C=C(F)C=N4	PLASMA	LV66ADM269																										Protein binding of vericiguat is about 98%, primarily to serum albumin.	2				OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214377Orig1s000IntegratedR.pdf#page=223	Homo sapiens										false
8324	9040		ADULT	54674461	426.3795	VERICIGUAT	Vericiguat	COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=C2C=C(F)C=N4	PLASMA	LV66ADM269									∞	μg × h/L	2730		μg/L	115			UNKNOWN	mg	5		SINGLE	HIGH-FAT						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_A100_1.pdf#page=30 | https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_K108_1.pdf#page=17	Homo sapiens		h	18.9	tablet			15			false
8325	9040		ADULT	54674461	426.3795	VERICIGUAT	Vericiguat	COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=C2C=C(F)C=N4	PLASMA	LV66ADM269									∞	μg × h/L	754		μg/L	41			UNKNOWN	mg	1.25		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_A100_1.pdf#page=30 | https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_K108_1.pdf#page=17	Homo sapiens		h	18.8	tablet			15			false
8326	9040		ADULT	54674461	426.3795	VERICIGUAT	Vericiguat	COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=C2C=C(F)C=N4	PLASMA	LV66ADM269									∞	μg × h/L	2300		μg/L	106			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_A100_1.pdf#page=30 | https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_K108_1.pdf#page=17	Homo sapiens		h	20.4	tablet			15			false
8327	9040		ADULT	54674461	426.3795	VERICIGUAT	Vericiguat	COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=C2C=C(F)C=N4	PLASMA	LV66ADM269									∞	μg × h/L	3260		μg/L	176			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_A100_1.pdf#page=30 | https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_K108_1.pdf#page=17	Homo sapiens		h	21.4	oral solution			15			false
8328	9040		ADULT	54674461	426.3795	VERICIGUAT	Vericiguat	COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=C2C=C(F)C=N4	PLASMA	LV66ADM269									∞	μg × h/L	1360		μg/L	72			UNKNOWN	mg	2.5		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_A100_1.pdf#page=31 | https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_K108_1.pdf#page=40	Homo sapiens		h	18.5				27			false
8329	9040		ADULT	54674461	426.3795	VERICIGUAT	Vericiguat	COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=C2C=C(F)C=N4	PLASMA	LV66ADM269									∞	μg × h/L	2520		μg/L	129			UNKNOWN	mg	5		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_A100_1.pdf#page=31 | https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_K108_1.pdf#page=40	Homo sapiens		h	18.1				27			false
8330	9040		ADULT	54674461	426.3795	VERICIGUAT	Vericiguat	COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=C2C=C(F)C=N4	PLASMA	LV66ADM269									∞	μg × h/L	5480		μg/L	279			UNKNOWN	mg	10		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_A100_1.pdf#page=31 | https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_K108_1.pdf#page=40	Homo sapiens		h	17.6				27			false
8331	9040		ADULT	54674461	426.3795	VERICIGUAT	Vericiguat	COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=C2C=C(F)C=N4	PLASMA	LV66ADM269									∞	μg × h/L	3890		μg/L	202			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_A100_1.pdf#page=31 | https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_K108_1.pdf#page=40	Homo sapiens		h	18.2				27			false
8332	9040		ADULT	54674461	426.3795	VERICIGUAT	Vericiguat	COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=C2C=C(F)C=N4	PLASMA	LV66ADM269									∞	μg × h/L	3890		μg/L	195			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_A100_1.pdf#page=31 | https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_K108_1.pdf#page=41	Homo sapiens		h	18.9				29			false
8333	9040		ADULT	54674461	426.3795	VERICIGUAT	Vericiguat	COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=C2C=C(F)C=N4	PLASMA	LV66ADM269									∞	μg × h/L	5600		μg/L	274			UNKNOWN	mg	10		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_A100_1.pdf#page=31 | https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_K108_1.pdf#page=41	Homo sapiens		h	18				29			false
8334	9040		ADULT	54674461	426.3795	VERICIGUAT	Vericiguat	COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=C2C=C(F)C=N4	PLASMA	LV66ADM269							24		t	μg × h/L	703		μg/L	61.8			UNKNOWN	mg	1.25		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_A100_1.pdf#page=34 | https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_K108_1.pdf#page=119	Homo sapiens		h	22.3	Day 1			9			false
8335	9040		ADULT	54674461	426.3795	VERICIGUAT	Vericiguat	COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=C2C=C(F)C=N4	PLASMA	LV66ADM269							24		t	μg × h/L	2540		μg/L	236			UNKNOWN	mg	5		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_A100_1.pdf#page=34 | https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_K108_1.pdf#page=119	Homo sapiens		h	21.1	Day 1			9			false
8336	9040		ADULT	54674461	426.3795	VERICIGUAT	Vericiguat	COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=C2C=C(F)C=N4	PLASMA	LV66ADM269							24		t	μg × h/L	3230		μg/L	324			UNKNOWN	mg	7.5		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_A100_1.pdf#page=34 | https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_K108_1.pdf#page=119	Homo sapiens		h	17.9	Day 1			9			false
8337	9040		ADULT	54674461	426.3795	VERICIGUAT	Vericiguat	COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=C2C=C(F)C=N4	PLASMA	LV66ADM269							24		t	μg × h/L	4410		μg/L	365			UNKNOWN	mg	10		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_A100_1.pdf#page=34 | https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_K108_1.pdf#page=119	Homo sapiens		h	18.3	Day 1			9			false
8338	9040		ADULT	54674461	426.3795	VERICIGUAT	Vericiguat	COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=C2C=C(F)C=N4	PLASMA	LV66ADM269							24		t	μg × h/L	666		μg/L	46.4			UNKNOWN	mg	1.25		MULTIPLE	HIGH-FAT		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_A100_1.pdf#page=34 | https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_K108_1.pdf#page=120	Homo sapiens				Day 5 (fed)			9			false
8339	9040		ADULT	54674461	426.3795	VERICIGUAT	Vericiguat	COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=C2C=C(F)C=N4	PLASMA	LV66ADM269							24		t	μg × h/L	2370		μg/L	161			UNKNOWN	mg	5		MULTIPLE	HIGH-FAT		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_A100_1.pdf#page=34 | https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_K108_1.pdf#page=120	Homo sapiens				Day 5 (fed)			9			false
8340	9040		ADULT	54674461	426.3795	VERICIGUAT	Vericiguat	COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=C2C=C(F)C=N4	PLASMA	LV66ADM269							24		t	μg × h/L	3300		μg/L	242			UNKNOWN	mg	7.5		MULTIPLE	HIGH-FAT		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_A100_1.pdf#page=34 | https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_K108_1.pdf#page=120	Homo sapiens				Day 5 (fed)			9			false
8341	9040		ADULT	54674461	426.3795	VERICIGUAT	Vericiguat	COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=C2C=C(F)C=N4	PLASMA	LV66ADM269							24		t	μg × h/L	4340		μg/L	285			UNKNOWN	mg	10		MULTIPLE	HIGH-FAT		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_A100_1.pdf#page=34 | https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_K108_1.pdf#page=120	Homo sapiens				Day 5 (fed)			9			false
8342	9040		ADULT	54674461	426.3795	VERICIGUAT	Vericiguat	COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=C2C=C(F)C=N4	PLASMA	LV66ADM269							24		t	μg × h/L	1170		μg/L	89.2			UNKNOWN	mg	1.25		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_A100_1.pdf#page=34 | https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_K108_1.pdf#page=121	Homo sapiens		h	27	Day 11			9			false
8343	9040		ADULT	54674461	426.3795	VERICIGUAT	Vericiguat	COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=C2C=C(F)C=N4	PLASMA	LV66ADM269							24		t	μg × h/L	3670		μg/L	289			UNKNOWN	mg	5		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_A100_1.pdf#page=34 | https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_K108_1.pdf#page=121	Homo sapiens		h	23.5	Day 11			9			false
8344	9040		ADULT	54674461	426.3795	VERICIGUAT	Vericiguat	COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=C2C=C(F)C=N4	PLASMA	LV66ADM269							24		t	μg × h/L	4810		μg/L	407			UNKNOWN	mg	7.5		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_A100_1.pdf#page=34 | https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_K108_1.pdf#page=121	Homo sapiens		h	22.1	Day 11			9			false
8345	9040		ADULT	54674461	426.3795	VERICIGUAT	Vericiguat	COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=C2C=C(F)C=N4	PLASMA	LV66ADM269							24		t	μg × h/L	6170		μg/L	472			UNKNOWN	mg	10		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_A100_1.pdf#page=34 | https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_K108_1.pdf#page=121	Homo sapiens		h	20.7	Day 11			9			false
8346	9040		ADULT	54674461	426.3795	VERICIGUAT	Vericiguat	COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=C2C=C(F)C=N4	PLASMA	LV66ADM269									∞	μg × h/L	273		μg/L	17.2			UNKNOWN	mg	0.5		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_A100_1.pdf#page=35 | https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_K108_1.pdf#page=67	Homo sapiens		h	17.2		non-smokers		7			false
8347	9040		ADULT	54674461	426.3795	VERICIGUAT	Vericiguat	COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=C2C=C(F)C=N4	PLASMA	LV66ADM269									∞	μg × h/L	618		μg/L	39.3			UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_A100_1.pdf#page=35 | https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_K108_1.pdf#page=67	Homo sapiens		h	19.4		non-smokers		8			false
8348	9040		ADULT	54674461	426.3795	VERICIGUAT	Vericiguat	COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=C2C=C(F)C=N4	PLASMA	LV66ADM269									∞	μg × h/L	1450		μg/L	82.7			UNKNOWN	mg	2.5		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_A100_1.pdf#page=35 | https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_K108_1.pdf#page=67	Homo sapiens		h	19.4		non-smokers		8			false
8349	9040		ADULT	54674461	426.3795	VERICIGUAT	Vericiguat	COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=C2C=C(F)C=N4	PLASMA	LV66ADM269									∞	μg × h/L	2900		μg/L	158			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_A100_1.pdf#page=35 | https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_K108_1.pdf#page=67	Homo sapiens		h	19.8		non-smokers		7			false
8350	9040		ADULT	54674461	426.3795	VERICIGUAT	Vericiguat	COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=C2C=C(F)C=N4	PLASMA	LV66ADM269									∞	μg × h/L	2500		μg/L	194			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_A100_1.pdf#page=35 | https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_K108_1.pdf#page=67	Homo sapiens		h	14.5		smokers		6			false
8351	9040		ADULT	54674461	426.3795	VERICIGUAT	Vericiguat	COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=C2C=C(F)C=N4	PLASMA	LV66ADM269									∞	μg × h/L	4460		μg/L	259			UNKNOWN	mg	7.5		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_A100_1.pdf#page=35 | https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_K108_1.pdf#page=67	Homo sapiens		h	19.8		non-smokers		8			false
8352	9040		ADULT	54674461	426.3795	VERICIGUAT	Vericiguat	COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=C2C=C(F)C=N4	PLASMA	LV66ADM269									∞	μg × h/L	4940		μg/L	285			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_A100_1.pdf#page=35 | https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_K108_1.pdf#page=67	Homo sapiens		h	20.7		non-smokers		8			false
8353	9040		ADULT	54674461	426.3795	VERICIGUAT	Vericiguat	COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=C2C=C(F)C=N4	PLASMA	LV66ADM269									∞	μg × h/L	7900		μg/L	430			UNKNOWN	mg	15		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_A100_1.pdf#page=35 | https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_K108_1.pdf#page=67	Homo sapiens		h	17.2		non-smokers		4			false
8354	9040		ADULT	54674461	426.3795	VERICIGUAT	Vericiguat	COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=C2C=C(F)C=N4	PLASMA	LV66ADM269							24		t	μg × h/L	2230		μg/L	185			UNKNOWN	mg	5		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_A100_1.pdf#page=35 | https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_K108_1.pdf#page=89	Homo sapiens		h	24.7	Day 7			8			false
8355	9040		ADULT	54674461	426.3795	VERICIGUAT	Vericiguat	COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=C2C=C(F)C=N4	PLASMA	LV66ADM269							24		t	μg × h/L	3840		μg/L	310			UNKNOWN	mg	10		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_A100_1.pdf#page=35 | https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_K108_1.pdf#page=89	Homo sapiens		h	19.9	Day 7			8			false
8356	9040		ADULT	54674461	426.3795	VERICIGUAT	Vericiguat	COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=C2C=C(F)C=N4	PLASMA	LV66ADM269							12		t	μg × h/L	2600		μg/L	312			UNKNOWN	mg	5		MULTIPLE	FASTED		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_A100_1.pdf#page=35 | https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_K108_1.pdf#page=89	Homo sapiens		h	20.7	Day 7 (single dose)			7			false
8357	9040		ADULT	54674461	426.3795	VERICIGUAT	Vericiguat	COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=C2C=C(F)C=N4	PLASMA	LV66ADM269							24		t	μg × h/L	423		μg/L	38.5			UNKNOWN	mg	1.25		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_A100_1.pdf#page=35 | https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_K108_1.pdf#page=89	Homo sapiens				Day 1			9			false
8358	9040		ADULT	54674461	426.3795	VERICIGUAT	Vericiguat	COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=C2C=C(F)C=N4	PLASMA	LV66ADM269							24		t	μg × h/L	2240		μg/L	200			UNKNOWN	mg	10		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_A100_1.pdf#page=35 | https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_K108_1.pdf#page=89	Homo sapiens				Day 1			8			false
8359	9040		ADULT	54674461	426.3795	VERICIGUAT	Vericiguat	COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=C2C=C(F)C=N4	PLASMA	LV66ADM269							24		t	μg × h/L	1370		μg/L	114			UNKNOWN	mg	5		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_A100_1.pdf#page=35 | https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_K108_1.pdf#page=89	Homo sapiens				Day 1			8			false
8360	9040		ADULT	54674461	426.3795	VERICIGUAT	Vericiguat	COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=C2C=C(F)C=N4	PLASMA	LV66ADM269							12		t	μg × h/L	951		μg/L	136			UNKNOWN	mg	5		MULTIPLE	FASTED		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_A100_1.pdf#page=35 | https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_K108_1.pdf#page=89	Homo sapiens				Day 1			7			false
8361	9040		ADULT	54674461	426.3795	VERICIGUAT	Vericiguat	COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=C2C=C(F)C=N4	PLASMA	LV66ADM269							24		t	μg × h/L	656		μg/L	51.4			UNKNOWN	mg	1.25		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_A100_1.pdf#page=35 | https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_K108_1.pdf#page=89	Homo sapiens		h	25.7	Day 7			9			false
8362	9040		ADULT	54674461	426.3795	VERICIGUAT	Vericiguat	COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=C2C=C(F)C=N4	PLASMA	LV66ADM269									∞	μg × h/L	1330		μg/L	83.1			UNKNOWN	mg	2.5		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_A100_1.pdf#page=36	Homo sapiens		h	20.7		Normal renal function		8			false
8363	9040		ADULT	54674461	426.3795	VERICIGUAT	Vericiguat	COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=C2C=C(F)C=N4	PLASMA	LV66ADM269									∞	μg × h/L	1390		μg/L	76.2			UNKNOWN	mg	2.5		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_A100_1.pdf#page=36	Homo sapiens		h	17.1		Mild renal impairment		9			false
8364	9040		ADULT	54674461	426.3795	VERICIGUAT	Vericiguat	COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=C2C=C(F)C=N4	PLASMA	LV66ADM269									∞	μg × h/L	2200		μg/L	92.7			UNKNOWN	mg	2.5		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_A100_1.pdf#page=36	Homo sapiens		h	32.1		Moderate renal impairment		14			false
8365	9040		ADULT	54674461	426.3795	VERICIGUAT	Vericiguat	COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=C2C=C(F)C=N4	PLASMA	LV66ADM269									∞	μg × h/L	2940		μg/L	91.4			UNKNOWN	mg	2.5		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_A100_1.pdf#page=36	Homo sapiens		h	36.9		Severe renal impairment		9			false
8366	9040		ADULT	54674461	426.3795	VERICIGUAT	Vericiguat	COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=C2C=C(F)C=N4	PLASMA	LV66ADM269									∞	μg × h/L	1550		μg/L	66.6			UNKNOWN	mg	2.5		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_A100_1.pdf#page=37 | https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_K109_1.pdf#page=72	Homo sapiens		h	19.8		Mild hepatic impairment (Child-Pugh A)		9			false
8367	9040		ADULT	54674461	426.3795	VERICIGUAT	Vericiguat	COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=C2C=C(F)C=N4	PLASMA	LV66ADM269									∞	μg × h/L	1780		μg/L	69.5			UNKNOWN	mg	2.5		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_A100_1.pdf#page=37 | https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_K109_1.pdf#page=72	Homo sapiens		h	23.7		Moderate hepatic impairment (Child-Pugh B)		9			false
8368	9040		ADULT	54674461	426.3795	VERICIGUAT	Vericiguat	COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=C2C=C(F)C=N4	PLASMA	LV66ADM269									∞	μg × h/L	1250		μg/L	68.7			UNKNOWN	mg	2.5		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_A100_1.pdf#page=37 | https://www.pmda.go.jp/drugs/2021/P20210602001/630004000_30300AMX00275_K109_1.pdf#page=72	Homo sapiens		h	20.2		Normal hepatic function		9			false
8369	9041		ADULT	11414799	279.3364	VERUBULIN	VERUBULIN	COC1=CC=C(C=C1)N(C)C2=C3C=CC=CC3=NC(C)=N2	PLASMA	X97O9FTB92									∞	ng × h/mL	116.8		ng/mL	21.3			MAX TOLERATED	mg/m²	3.3		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21159616	Homo sapiens		h	6.4				13	VERUBULIN		false
8370	9041		ADULT	11414799	279.3364	VERUBULIN	VERUBULIN	COC1=CC=C(C=C1)N(C)C2=C3C=CC=CC3=NC(C)=N2	PLASMA	X97O9FTB92									∞	ng × h/mL	183.6		ng/mL	62			UNKNOWN	mg/m²	4.5		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21159616	Homo sapiens		h	5.7				7	VERUBULIN		false
8371	9041		ADULT	11414799	279.3364	VERUBULIN	VERUBULIN	COC1=CC=C(C=C1)N(C)C2=C3C=CC=CC3=NC(C)=N2	PLASMA	X97O9FTB92									∞	ng × h/mL	139.3		ng/mL	30.7			UNKNOWN	mg/m²	3.9		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21159616	Homo sapiens		h	7.5				6	VERUBULIN		false
8372	9043		ADULT	46241268	410.5	VESATOLIMOD	VESATOLIMOD	CCCCOC1=NC2=C(NC(=O)CN2CC3=CC(CN4CCCC4)=CC=C3)C(N)=N1	PLASMA	O8M467C50G									∞	pg × h/mL	10703.3		pg/mL	810.1			UNKNOWN	mg	2		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/25105516	Homo sapiens		h	17.7							false
8373	9044		ADULT	9820008	355.3596	VIDOFLUDIMUS	Vidofludimus	COC1=CC(=CC=C1)C2=CC(F)=C(NC(=O)C3=C(CCC3)C(O)=O)C=C2	PLASMA	8Y1PJ3VG81							24		t	μg × h/mL	100.294		μg/mL	6.543			UNKNOWN	mg	30		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32361977	Homo sapiens		h	30.414				12	Vidofludimus calcium		false
8374	9044		ADULT	9820008	355.3596	VIDOFLUDIMUS	vidofludimus	COC1=CC(=CC=C1)C2=CC(F)=C(NC(=O)C3=C(CCC3)C(O)=O)C=C2	PLASMA	8Y1PJ3VG81							24		t	μg × h/mL	158.686		μg/mL	10.911			UNKNOWN	mg	40		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32361977	Homo sapiens		h	28.566				12	vidofludimus calcium		false
8375	9044		ADULT	9820008	355.3596	VIDOFLUDIMUS	vidofludimus	COC1=CC(=CC=C1)C2=CC(F)=C(NC(=O)C3=C(CCC3)C(O)=O)C=C2	PLASMA	8Y1PJ3VG81							24		t	μg × h/mL	166.401		μg/mL	10.783			UNKNOWN	mg	50		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32361977	Homo sapiens		h	29.805				16	vidofludimus calcium		false
8376	9048		ADULT	6918486	1214.622	VOCLOSPORIN	Voclosporin	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\\C=C\\C=C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	PLASMA	2PN063X6B1									∞	ng × h/mL	195.8		ng/mL	48.6			UNKNOWN	mg/kg	0.25		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213716Orig1s000MultidisciplineR.pdf#page=281	Homo sapiens		h	6.9							false
8377	9048		ADULT	6918486	1214.622	VOCLOSPORIN	Voclosporin	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\\C=C\\C=C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	PLASMA	2PN063X6B1									∞	ng × h/mL	468.3		ng/mL	117.9			UNKNOWN	mg/kg	0.5		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213716Orig1s000MultidisciplineR.pdf#page=281	Homo sapiens		h	8.5							false
8378	9048		ADULT	6918486	1214.622	VOCLOSPORIN	Voclosporin	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\\C=C\\C=C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	PLASMA	2PN063X6B1									∞	ng × h/mL	2191.6		ng/mL	496.2			UNKNOWN	mg/kg	1		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213716Orig1s000MultidisciplineR.pdf#page=281	Homo sapiens		h	11.9							false
8379	9048		ADULT	6918486	1214.622	VOCLOSPORIN	Voclosporin	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\\C=C\\C=C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	PLASMA	2PN063X6B1									∞	ng × h/mL	3098.5		ng/mL	705.2			UNKNOWN	mg/kg	1.5		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213716Orig1s000MultidisciplineR.pdf#page=281	Homo sapiens		h	12.5							false
8380	9048		ADULT	6918486	1214.622	VOCLOSPORIN	Voclosporin	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\\C=C\\C=C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	PLASMA	2PN063X6B1									?	ng × h/mL	207.8		ng/mL	43.4			UNKNOWN	mg/kg	0.25		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213716Orig1s000MultidisciplineR.pdf#page=281 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213716Orig1s000MultidisciplineR.pdf#page=293	Homo sapiens		h	30.2	Day 13 PK (Days 3 to 13)						false
8381	9048		ADULT	6918486	1214.622	VOCLOSPORIN	Voclosporin	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\\C=C\\C=C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	PLASMA	2PN063X6B1									?	ng × h/mL	804.6		ng/mL	190.8			UNKNOWN	mg/kg	0.5		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213716Orig1s000MultidisciplineR.pdf#page=281 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213716Orig1s000MultidisciplineR.pdf#page=293	Homo sapiens		h	33.2	Day 13 PK (Days 3 to 13)						false
8382	9048		ADULT	6918486	1214.622	VOCLOSPORIN	Voclosporin	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\\C=C\\C=C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	PLASMA	2PN063X6B1									?	ng × h/mL	4567.7		ng/mL	843.9			UNKNOWN	mg/kg	1.5		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213716Orig1s000MultidisciplineR.pdf#page=281 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213716Orig1s000MultidisciplineR.pdf#page=293	Homo sapiens		h	36.8	Day 13 PK (Days 3 to 13)						false
8383	9048		ADULT	6918486	1214.622	VOCLOSPORIN	Voclosporin	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\\C=C\\C=C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	PLASMA	2PN063X6B1									?	ng × h/mL	2880.2		ng/mL	607.2			UNKNOWN	mg/kg	1		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213716Orig1s000MultidisciplineR.pdf#page=281 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213716Orig1s000MultidisciplineR.pdf#page=293	Homo sapiens		h	31.4	Day 13 PK (Days 3 to 13)						false
8384	9048		ADULT	6918486	1214.622	VOCLOSPORIN	Voclosporin	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\\C=C\\C=C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	PLASMA	2PN063X6B1									∞	ng × h/mL	5079.6		ng/mL	874.9			UNKNOWN	mg/kg	3		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213716Orig1s000MultidisciplineR.pdf#page=282	Homo sapiens		h	17.4							false
8385	9048		ADULT	6918486	1214.622	VOCLOSPORIN	Voclosporin	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\\C=C\\C=C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	PLASMA	2PN063X6B1									∞	ng × h/mL	7693.6		ng/mL	955.5			UNKNOWN	mg/kg	4.5		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213716Orig1s000MultidisciplineR.pdf#page=282	Homo sapiens		h	42.3							false
8386	9048		ADULT	6918486	1214.622	VOCLOSPORIN	Voclosporin	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\\C=C\\C=C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	PLASMA	2PN063X6B1									∞	ng × h/mL	142.9		ng/mL	32			UNKNOWN	mg/kg	0.25		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213716Orig1s000MultidisciplineR.pdf#page=282	Homo sapiens		h	5.7							false
8387	9048		ADULT	6918486	1214.622	VOCLOSPORIN	Voclosporin	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\\C=C\\C=C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	PLASMA	2PN063X6B1									∞	ng × h/mL	354.4		ng/mL	77			UNKNOWN	mg/kg	0.5		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213716Orig1s000MultidisciplineR.pdf#page=282	Homo sapiens		h	7.9							false
8388	9048		ADULT	6918486	1214.622	VOCLOSPORIN	Voclosporin	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\\C=C\\C=C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	PLASMA	2PN063X6B1									∞	ng × h/mL	2166.5		ng/mL	459			UNKNOWN	mg/kg	1.5		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213716Orig1s000MultidisciplineR.pdf#page=282	Homo sapiens		h	14.3							false
8389	9048		ADULT	6918486	1214.622	VOCLOSPORIN	Voclosporin	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\\C=C\\C=C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	PLASMA	2PN063X6B1									∞	ng × h/mL	591		ng/mL	70.3			UNKNOWN	mg/kg	0.25		MULTIPLE	UNKNOWN		day	2	AUC24=372 ng*h/mL		HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213716Orig1s000MultidisciplineR.pdf#page=293	Homo sapiens		h	27.1	Day 13 PK (Days 3 to 13)	Healthy Japanese subjects		8			false
8390	9048		ADULT	6918486	1214.622	VOCLOSPORIN	Voclosporin	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\\C=C\\C=C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	PLASMA	2PN063X6B1							24		t	ng × h/mL	492		ng/mL	130			UNKNOWN	mg/kg	0.5		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213716Orig1s000MultidisciplineR.pdf#page=293	Homo sapiens					Healthy Japanese subjects		8			false
8391	9048		ADULT	6918486	1214.622	VOCLOSPORIN	Voclosporin	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\\C=C\\C=C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	PLASMA	2PN063X6B1									∞	ng × h/mL	1480		ng/mL	160			UNKNOWN	mg/kg	0.5		MULTIPLE	UNKNOWN		day	2	AUC24=921 ng*h/mL		HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213716Orig1s000MultidisciplineR.pdf#page=293	Homo sapiens		h	29.6	Day 13 PK (Days 3 to 13)	Healthy Japanese subjects		8			false
8392	9048		ADULT	6918486	1214.622	VOCLOSPORIN	Voclosporin	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\\C=C\\C=C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	PLASMA	2PN063X6B1							24		t	ng × h/mL	199		ng/mL	46.6			UNKNOWN	mg/kg	0.25		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213716Orig1s000MultidisciplineR.pdf#page=293	Homo sapiens					Healthy Japanese subjects		8			false
8393	9048		ADULT	6918486	1214.622	VOCLOSPORIN	Voclosporin	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\\C=C\\C=C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	PLASMA	2PN063X6B1									∞	ng × h/mL	8080		ng/mL	619			UNKNOWN	mg/kg	1.5		MULTIPLE	UNKNOWN		day	2	AUC24=4390 ng*h/mL		HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213716Orig1s000MultidisciplineR.pdf#page=293	Homo sapiens		h	30.6	Day 13 PK (Days 3 to 13)	Healthy Japanese subjects		8			false
8394	9048		ADULT	6918486	1214.622	VOCLOSPORIN	Voclosporin	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\\C=C\\C=C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	PLASMA	2PN063X6B1							24		t	ng × h/mL	1260		ng/mL	314			UNKNOWN	mg/kg	1		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213716Orig1s000MultidisciplineR.pdf#page=293	Homo sapiens					Healthy Japanese subjects		8			false
8395	9048		ADULT	6918486	1214.622	VOCLOSPORIN	Voclosporin	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\\C=C\\C=C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	PLASMA	2PN063X6B1									∞	ng × h/mL	4180		ng/mL	416			UNKNOWN	mg/kg	1		MULTIPLE	UNKNOWN		day	2	AUC24=2510 ng*h/mL		HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213716Orig1s000MultidisciplineR.pdf#page=293	Homo sapiens		h	29.9	Day 13 PK (Days 3 to 13)	Healthy Japanese subjects		8			false
8396	9048		ADULT	6918486	1214.622	VOCLOSPORIN	Voclosporin	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\\C=C\\C=C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	PLASMA	2PN063X6B1							24		t	ng × h/mL	1780		ng/mL	441			UNKNOWN	mg/kg	1.5		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213716Orig1s000MultidisciplineR.pdf#page=293	Homo sapiens					Healthy Japanese subjects		8			false
8397	9048		UNKNOWN	6918486	1214.622	VOCLOSPORIN	Voclosporin	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\\C=C\\C=C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	PLASMA	2PN063X6B1																						UNKNOWN				Human plasma protein binding: 96.97% (97-98%, 50-800 ng/mL)	3.03	UNKNOWN		UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213716Orig1s000MultidisciplineR.pdf#page=48 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213716Orig1s000MultidisciplineR.pdf#page=50	Homo sapiens										false
8398	9048		UNKNOWN	6918486	1214.622	VOCLOSPORIN	Voclosporin	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\\C=C\\C=C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	PLASMA	2PN063X6B1																	UNKNOWN				STEADY-STATE	UNKNOWN				t1/2=24.9-36.5 h (steady-state)		UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213716Orig1s000MultidisciplineR.pdf#page=94	Homo sapiens		h	30							false
8399	9051		ADULT	77050711	527.3943	OTESECONAZOLE	Oteseconazole	O[C@@](CN1C=NN=N1)(C2=C(F)C=C(F)C=C2)C(F)(F)C3=NC=C(C=C3)C4=CC=C(OCC(F)(F)F)C=C4	PLASMA	VHH774W97N									∞	ng × h/mL	84635		ng/mL	165			UNKNOWN	mg	80		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215888Orig1s000IntegratedR.pdf#page=174	Homo sapiens		h	536				6			false
8400	9051		ADULT	77050711	527.3943	OTESECONAZOLE	Oteseconazole	O[C@@](CN1C=NN=N1)(C2=C(F)C=C(F)C=C2)C(F)(F)C3=NC=C(C=C3)C4=CC=C(OCC(F)(F)F)C=C4	PLASMA	VHH774W97N									∞	ng × h/mL	108869		ng/mL	180			UNKNOWN	mg	160		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215888Orig1s000IntegratedR.pdf#page=174	Homo sapiens		h	618				6			false
8401	9051		ADULT	77050711	527.3943	OTESECONAZOLE	Oteseconazole	O[C@@](CN1C=NN=N1)(C2=C(F)C=C(F)C=C2)C(F)(F)C3=NC=C(C=C3)C4=CC=C(OCC(F)(F)F)C=C4	PLASMA	VHH774W97N									∞	ng × h/mL	35037		ng/mL	79.7			UNKNOWN	mg	40		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215888Orig1s000IntegratedR.pdf#page=174	Homo sapiens		h	548				6			false
8402	9051		ADULT	77050711	527.3943	OTESECONAZOLE	Oteseconazole	O[C@@](CN1C=NN=N1)(C2=C(F)C=C(F)C=C2)C(F)(F)C3=NC=C(C=C3)C4=CC=C(OCC(F)(F)F)C=C4	PLASMA	VHH774W97N									∞	ng × h/mL	241971		ng/mL	338			UNKNOWN	mg	320		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215888Orig1s000IntegratedR.pdf#page=174	Homo sapiens		h	873				6			false
8403	9051		ADULT	77050711	527.3943	OTESECONAZOLE	Oteseconazole	O[C@@](CN1C=NN=N1)(C2=C(F)C=C(F)C=C2)C(F)(F)C3=NC=C(C=C3)C4=CC=C(OCC(F)(F)F)C=C4	PLASMA	VHH774W97N									∞	ng × h/mL	16145		ng/mL	44.7			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215888Orig1s000IntegratedR.pdf#page=174	Homo sapiens		h	393		n=5 for AUC and t1/2		6			false
8404	9051		ADULT	77050711	527.3943	OTESECONAZOLE	Oteseconazole	O[C@@](CN1C=NN=N1)(C2=C(F)C=C(F)C=C2)C(F)(F)C3=NC=C(C=C3)C4=CC=C(OCC(F)(F)F)C=C4	PLASMA	VHH774W97N									∞	ng × h/mL	953119		ng/mL	988			UNKNOWN	mg	320		SINGLE	HIGH-FAT						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215888Orig1s000IntegratedR.pdf#page=174	Homo sapiens		h	1467				6			false
8405	9051		ADULT	77050711	527.3943	OTESECONAZOLE	Oteseconazole	O[C@@](CN1C=NN=N1)(C2=C(F)C=C(F)C=C2)C(F)(F)C3=NC=C(C=C3)C4=CC=C(OCC(F)(F)F)C=C4	PLASMA	VHH774W97N									∞	ng × h/mL	10202		ng/mL	531			UNKNOWN	mg	40		MULTIPLE	HIGH-FAT		day	1			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215888Orig1s000IntegratedR.pdf#page=175	Homo sapiens		h	2103	Day 7 PK			6			false
8406	9051		ADULT	77050711	527.3943	OTESECONAZOLE	Oteseconazole	O[C@@](CN1C=NN=N1)(C2=C(F)C=C(F)C=C2)C(F)(F)C3=NC=C(C=C3)C4=CC=C(OCC(F)(F)F)C=C4	PLASMA	VHH774W97N									∞	ng × h/mL	23143		ng/mL	1130			UNKNOWN	mg	80		MULTIPLE	HIGH-FAT		day	1			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215888Orig1s000IntegratedR.pdf#page=175	Homo sapiens		h	2445	Day 7 PK			6			false
8407	9051		ADULT	77050711	527.3943	OTESECONAZOLE	Oteseconazole	O[C@@](CN1C=NN=N1)(C2=C(F)C=C(F)C=C2)C(F)(F)C3=NC=C(C=C3)C4=CC=C(OCC(F)(F)F)C=C4	PLASMA	VHH774W97N									∞	ng × h/mL	38661		ng/mL	1920			UNKNOWN	mg	160		MULTIPLE	HIGH-FAT		day	1			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215888Orig1s000IntegratedR.pdf#page=175	Homo sapiens		h	3227	Day 7 PK			6			false
8408	9051		ADULT	77050711	527.3943	OTESECONAZOLE	Oteseconazole	O[C@@](CN1C=NN=N1)(C2=C(F)C=C(F)C=C2)C(F)(F)C3=NC=C(C=C3)C4=CC=C(OCC(F)(F)F)C=C4	PLASMA	VHH774W97N									∞	ng × h/mL	67164		ng/mL	3300			UNKNOWN	mg	320		MULTIPLE	HIGH-FAT		day	1			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215888Orig1s000IntegratedR.pdf#page=175	Homo sapiens		h	5207	Day 7 PK			6			false
8409	9051		ADULT	77050711	527.3943	OTESECONAZOLE	Oteseconazole	O[C@@](CN1C=NN=N1)(C2=C(F)C=C(F)C=C2)C(F)(F)C3=NC=C(C=C3)C4=CC=C(OCC(F)(F)F)C=C4	PLASMA	VHH774W97N							72		t	ng × h/mL	422455.21		ng/mL	6575			UNKNOWN	mg	300		MULTIPLE	FED		day	1			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215888Orig1s000IntegratedR.pdf#page=177	Homo sapiens		h	2378.14	Day 14 PK	Western subjects		12			false
8410	9051		ADULT	77050711	527.3943	OTESECONAZOLE	Oteseconazole	O[C@@](CN1C=NN=N1)(C2=C(F)C=C(F)C=C2)C(F)(F)C3=NC=C(C=C3)C4=CC=C(OCC(F)(F)F)C=C4	PLASMA	VHH774W97N							72		t	ng × h/mL	538229.5		ng/mL	8680			UNKNOWN	mg	300		MULTIPLE	FED		day	1			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215888Orig1s000IntegratedR.pdf#page=177	Homo sapiens		h	1514.47	Day 14 PK	Japanese subjects		11			false
8411	9051		ADULT	77050711	527.3943	OTESECONAZOLE	Oteseconazole	O[C@@](CN1C=NN=N1)(C2=C(F)C=C(F)C=C2)C(F)(F)C3=NC=C(C=C3)C4=CC=C(OCC(F)(F)F)C=C4	PLASMA	VHH774W97N							72		t	ng × h/mL	900275		ng/mL	15000			UNKNOWN	mg	600		MULTIPLE	FED		day	1			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215888Orig1s000IntegratedR.pdf#page=177	Homo sapiens		h	4390.84	Day 14 PK	Japanese subjects		11			false
8412	9051		ADULT	77050711	527.3943	OTESECONAZOLE	Oteseconazole	O[C@@](CN1C=NN=N1)(C2=C(F)C=C(F)C=C2)C(F)(F)C3=NC=C(C=C3)C4=CC=C(OCC(F)(F)F)C=C4	PLASMA	VHH774W97N							72		t	ng × h/mL	852537.5		ng/mL	12850			UNKNOWN	mg	600		MULTIPLE	FED		day	1			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215888Orig1s000IntegratedR.pdf#page=177	Homo sapiens		h	2753.12	Day 14 PK	Western subjects; n=8 for t1/2		12			false
8413	9051		ADULT	77050711	527.3943	OTESECONAZOLE	Oteseconazole	O[C@@](CN1C=NN=N1)(C2=C(F)C=C(F)C=C2)C(F)(F)C3=NC=C(C=C3)C4=CC=C(OCC(F)(F)F)C=C4	PLASMA	VHH774W97N							72		t	ng × h/mL	17110		ng/mL	538			UNKNOWN	mg	150		SINGLE	FASTED						HEALTHY	Oral	FEMALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215888Orig1s000IntegratedR.pdf#page=179	Homo sapiens				Capsule			12			false
8414	9051		ADULT	77050711	527.3943	OTESECONAZOLE	Oteseconazole	O[C@@](CN1C=NN=N1)(C2=C(F)C=C(F)C=C2)C(F)(F)C3=NC=C(C=C3)C4=CC=C(OCC(F)(F)F)C=C4	PLASMA	VHH774W97N							72		t	ng × h/mL	23200		ng/mL	781.2			UNKNOWN	mg	150		SINGLE	HIGH-FAT						HEALTHY	Oral	FEMALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215888Orig1s000IntegratedR.pdf#page=179	Homo sapiens				Capsule			12			false
8415	9051		ADULT	77050711	527.3943	OTESECONAZOLE	Oteseconazole	O[C@@](CN1C=NN=N1)(C2=C(F)C=C(F)C=C2)C(F)(F)C3=NC=C(C=C3)C4=CC=C(OCC(F)(F)F)C=C4	PLASMA	VHH774W97N							72		t	ng × h/mL	17430		ng/mL	629.3			UNKNOWN	mg	150		SINGLE	LOW-FAT						HEALTHY	Oral	FEMALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215888Orig1s000IntegratedR.pdf#page=179	Homo sapiens				Capsule			11			false
8416	9051		ADULT	77050711	527.3943	OTESECONAZOLE	Oteseconazole	O[C@@](CN1C=NN=N1)(C2=C(F)C=C(F)C=C2)C(F)(F)C3=NC=C(C=C3)C4=CC=C(OCC(F)(F)F)C=C4	PLASMA	VHH774W97N							72		t	ng × h/mL	20600		ng/mL	793.7			UNKNOWN	mg	150		SINGLE	HIGH-FAT						HEALTHY	Oral	FEMALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215888Orig1s000IntegratedR.pdf#page=179	Homo sapiens				Tablet			8			false
8417	9051		ADULT	77050711	527.3943	OTESECONAZOLE	Oteseconazole	O[C@@](CN1C=NN=N1)(C2=C(F)C=C(F)C=C2)C(F)(F)C3=NC=C(C=C3)C4=CC=C(OCC(F)(F)F)C=C4	PLASMA	VHH774W97N									∞	ng × h/mL	4301156.522		ng/mL	3507			RECOMMENDED	mg	600		SINGLE	HIGH-FAT				Radioactivity: Cmax=3609ngEq/mL, AUCinf=4196317.888 ngEq*h/mL, t1/2=2233.69 h		HEALTHY	Oral	FEMALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215888Orig1s000IntegratedR.pdf#page=183	Homo sapiens		h	2114.012		n=9 for AUC and t1/2		10			false
8418	9051		ADULT	77050711	527.3943	OTESECONAZOLE	Oteseconazole	O[C@@](CN1C=NN=N1)(C2=C(F)C=C(F)C=C2)C(F)(F)C3=NC=C(C=C3)C4=CC=C(OCC(F)(F)F)C=C4	PLASMA	VHH774W97N							8		t	μg × h/mL	4.23		μg/mL	0.97			RECOMMENDED	mg	600		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215888Orig1s000IntegratedR.pdf#page=192	Homo sapiens					Subjects with moderate to severe acute vulvovaginal candidiasis					false
8419	9051		ADULT	77050711	527.3943	OTESECONAZOLE	Oteseconazole	O[C@@](CN1C=NN=N1)(C2=C(F)C=C(F)C=C2)C(F)(F)C3=NC=C(C=C3)C4=CC=C(OCC(F)(F)F)C=C4	PLASMA	VHH774W97N							8		t	μg × h/mL	1.87		μg/mL	0.41			UNKNOWN	mg	300		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215888Orig1s000IntegratedR.pdf#page=192	Homo sapiens					Subjects with moderate to severe acute vulvovaginal candidiasis					false
8420	9051		ADULT	77050711	527.3943	OTESECONAZOLE	Oteseconazole	O[C@@](CN1C=NN=N1)(C2=C(F)C=C(F)C=C2)C(F)(F)C3=NC=C(C=C3)C4=CC=C(OCC(F)(F)F)C=C4	PLASMA	VHH774W97N							8		t	μg × h/mL	12.3		μg/mL	1.8			RECOMMENDED	mg	150		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215888Orig1s000IntegratedR.pdf#page=193	Homo sapiens				Day 7 (24-week treatment: 7 QD and 23 QW)	Subjects with RVVC					false
8421	9051		ADULT	77050711	527.3943	OTESECONAZOLE	Oteseconazole	O[C@@](CN1C=NN=N1)(C2=C(F)C=C(F)C=C2)C(F)(F)C3=NC=C(C=C3)C4=CC=C(OCC(F)(F)F)C=C4	PLASMA	VHH774W97N							8		t	μg × h/mL	21.6		μg/mL	3.12			RECOMMENDED	mg	300		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215888Orig1s000IntegratedR.pdf#page=193	Homo sapiens				Day 7 (24-week treatment: 7 QD and 23 QW)	Subjects with RVVC					false
8422	9051		ADULT	77050711	527.3943	OTESECONAZOLE	Oteseconazole	O[C@@](CN1C=NN=N1)(C2=C(F)C=C(F)C=C2)C(F)(F)C3=NC=C(C=C3)C4=CC=C(OCC(F)(F)F)C=C4	PLASMA	VHH774W97N							8		t	μg × h/mL	9.12		μg/mL	1.34			RECOMMENDED	mg	150		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215888Orig1s000IntegratedR.pdf#page=193	Homo sapiens				Day 7 (12-week treatment: 7 QD, 11 QW, and placebo for 12 weeks)	Subjects with RVVC					false
8423	9051		ADULT	77050711	527.3943	OTESECONAZOLE	Oteseconazole	O[C@@](CN1C=NN=N1)(C2=C(F)C=C(F)C=C2)C(F)(F)C3=NC=C(C=C3)C4=CC=C(OCC(F)(F)F)C=C4	PLASMA	VHH774W97N							8		t	μg × h/mL	20.5		μg/mL	2.75			RECOMMENDED	mg	150		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215888Orig1s000IntegratedR.pdf#page=193	Homo sapiens				Day 7 (12-week treatment: 7 QD, 11 QW, and placebo for 12 weeks)	Subjects with RVVC					false
8424	9051		UNKNOWN	77050711	527.3943	OTESECONAZOLE	Oteseconazole	O[C@@](CN1C=NN=N1)(C2=C(F)C=C(F)C=C2)C(F)(F)C3=NC=C(C=C3)C4=CC=C(OCC(F)(F)F)C=C4	PLASMA	VHH774W97N																						UNKNOWN				Human plasma protein binding (equilibrium dialysis): 99.7-98.2% (99.5% (0.26mcg/mL), 99.7% (2.6mcg/mL), 98.2% (26mcg/mL), 98.5% (105mcg/mL))	0.3	UNKNOWN		UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215888Orig1s000IntegratedR.pdf#page=35 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215888Orig1s000IntegratedR.pdf#page=165	Homo sapiens										false
8425	9060		ADULT	68071	256.2534	PINOCEMBRIN	pinocembrin	OC1=CC2=C(C(=O)C[C@H](O2)C3=CC=CC=C3)C(O)=C1	PLASMA	8T7C8CH791									∞	ng × min/mL	10338.1		ng/mL	277			UNKNOWN	mg	20		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24733513	Homo sapiens		min	47.4				8			false
8426	9060		ADULT	68071	256.2534	PINOCEMBRIN	pinocembrin	OC1=CC2=C(C(=O)C[C@H](O2)C3=CC=CC=C3)C(O)=C1	PLASMA	8T7C8CH791									∞	μg × min/mL	89.34		μg/mL	2.46			UNKNOWN	mg	150		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25814318	Homo sapiens		min	54.5				6			false
8427	9060		ADULT	68071	256.2534	PINOCEMBRIN	pinocembrin	OC1=CC2=C(C(=O)C[C@H](O2)C3=CC=CC=C3)C(O)=C1	PLASMA	8T7C8CH791									∞	μg × min/mL	30.82		μg/mL	0.82			UNKNOWN	mg	60		MULTIPLE	UNKNOWN		day	2			HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25814318	Homo sapiens		min	50.3				10	pinocembrin		false
8428	9060		ADULT	68071	256.2534	PINOCEMBRIN	pinocembrin	OC1=CC2=C(C(=O)C[C@H](O2)C3=CC=CC=C3)C(O)=C1	PLASMA	8T7C8CH791									∞	μg × min/mL	44		μg/mL	1.22			UNKNOWN	mg	80		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25814318	Homo sapiens		min	55.7				8			false
8429	9060		ADULT	68071	256.2534	PINOCEMBRIN	pinocembrin	OC1=CC2=C(C(=O)C[C@H](O2)C3=CC=CC=C3)C(O)=C1	PLASMA	8T7C8CH791									∞	μg × min/mL	10.34		μg/mL	0.28			UNKNOWN	mg	20		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25814318	Homo sapiens		min	47.4				8			false
8430	9152		ADULT	49841217	581.6435	AVACOPAN	CCX-168	CC1=C(C=C(NC(=O)[C@H]2CCCN([C@H]2C3=CC=C(NC4CCCC4)C=C3)C(=O)C5=C(C)C=CC=C5F)C=C1)C(F)(F)F	PLASMA	O880NM097T									∞	ng × h/mL	2030		ng/mL	197			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27768695	Homo sapiens		h	64				6	CCX-168		false
8431	9152		ADULT	49841217	581.6	Avacopan	CCX-168	CC1=C(C(=CC=C1)F)C(=O)N2CCCC(C2C3=CC=C(C=C3)NC4CCCC4)C(=O)NC5=CC(=C(C=C5)C)C(F)(F)F	PLASMA	O880NM097T									∞	ng × h/mL	13000		ng/mL	359			UNKNOWN	mg	50		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27768695	Homo sapiens		h	120	7 days			6	CCX-168		false
8432	9162		ADULT	44181686	463.4643	AMG-337	COCCOC1=CN=C2C=CN([C@H](C)C3=NN=C4N3C=C(C=C4F)C5=CN(C)N=C5)C(=O)C2=C1	COCCOC1=CN=C2C=CN([C@H](C)C3=NN=C4N3C=C(C=C4F)C5=CN(C)N=C5)C(=O)C2=C1	PLASMA	08WG8S0L8D							24		t	μg × h/mL	47.8		μg/mL	4.01			MAX TOLERATED	mg	300		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/30425090	Homo sapiens		h	7							false
8433	9169		ADULT	46190695	447.5	MK-3697	MK-3697		PLASMA	M8238285OA																										Additional profiling established that compound 24 was moderately bound to plasma proteins with 84% (rat), 83% (dog), and 96% (human) binding across species and a logD of 1.9.	4				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25248679/	Homo sapiens										false
8434	9171		UNKNOWN	77843966|139033164	752.215	CEFIDEROCOL	Cefiderocol	CC(C)(O\\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[N+]4(CCNC(=O)C3=C(Cl)C(O)=C(O)C=C3)CCCC4)=C(N2C1=O)C([O-])=O)C5=CSC(N)=N5)C(O)=O	UNKNOWN	SZ34OMG6E8							24		t	mg × h/L	1184		mg/L	138			RECOMMENDED	g	2		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209445s000lbl.pdf	Homo sapiens										false
8435	9171		UNKNOWN	77843966|139033164	752.215	CEFIDEROCOL	Cefiderocol	CC(C)(O\\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[N+]4(CCNC(=O)C3=C(Cl)C(O)=C(O)C=C3)CCCC4)=C(N2C1=O)C([O-])=O)C5=CSC(N)=N5)C(O)=O	UNKNOWN	SZ34OMG6E8									?	mg × h/mL	386		mg/L	89.7			RECOMMENDED	g	2		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209445s000lbl.pdf	Homo sapiens										false
8436	9177		UNKNOWN	76829165	380.3676	UPADACITINIB	CCC1CN(CC1C2=CN=C3N2C4=C(NC=C4)N=C3)C(=O)NCC(F)(F)F	CCC1CN(CC1C2=CN=C3C=NC4=C(C=CN4)N23)C(=O)NCC(F)(F)F	PLASMA	4RA0KN46E0																						UNKNOWN				Upadacitinib is 52% bound to plasma proteins.	48	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211675s000lbl.pdf	Homo sapiens										false
8437	9177		ADULT	58557659	380.3676	UPADACITINIB	UPADACITINIB	CC[C@@H]1CN(C[C@@H]1C2=CN=C3C=NC4=C(C=CN4)N23)C(=O)NCC(F)(F)F	PLASMA	4RA0KN46E0									∞	ng × h/mL	491		ng/mL	63.7			MAX DAILY	mg	30		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/29688617	Homo sapiens		h	18.1							false
8438	9178		ADULT	46848915	428.4	TAK-063	TAK-063	COC1=CN(N=C(C1=O)C2=CC=NN2C3=CC=CC=C3)C4=C(C=C(C=C4)N5C=CC=N5)F	PLASMA	6650W303H0									∞	ng × h/mL	5788.1		ng/mL	245.8			UNKNOWN	mg	1000		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27572830	Homo sapiens		h	14.6				11	TAK-063		false
8439	9178		UNKNOWN	46848915	428.4	TAK-063	TAK-063	COC1=CN(N=C(C1=O)C2=CC=NN2C3=CC=CC=C3)C4=C(C=C(C=C4)N5C=CC=N5)F	PLASMA	6650W303H0																						UNKNOWN				% Protein binding = 96.4 (concentration = 0.05 ug/ml)	3.6	UNKNOWN		UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29345044	Homo sapiens								TAK-063		false
8440	9193		UNKNOWN	15664	184.2371	ABAMETAPIR	Abametapir	CC1=CN=C(C=C1)C2=NC=C(C)C=C2	PLASMA	6UO390AMFB																						UNKNOWN				Human plasma protein binding: 91.3-92.3%	7.7	UNKNOWN		UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000PharmR.pdf#page=26	Homo sapiens										false
8441	9193		UNKNOWN	23248833	214.22	ABAMETAPIR CARBOXYL	ABAMETAPIR CARBOXYL	Cc1ccc(nc1)c2ccc(cn2)C(=O)O	PLASMA	53DTP6U9Q2																						UNKNOWN				Human plasma protein binding: 96-97.5%	2.5	UNKNOWN		UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/206966Orig1s000PharmR.pdf#page=26	Homo sapiens										false
8442	9195		ADULT	71226662	465.1913	ACALABRUTINIB	ACALABRUTINIB	CC#CC(=O)N1CCC[C@H]1C2=NC(=C3N2C=CN=C3N)C4=CC=C(C=C4)C(=O)NC5=NC=CC=C5	PLASMA	I42748ELQW									∞	ng × h/mL	1111		ng/mL	323			UNKNOWN	mg	100		MULTIPLE	UNKNOWN		day	2	Reversible binding of acalabrutinib to human plasma protein was 97.5%	2.5	UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/210259s000lbl.pdf	Homo sapiens		h	0.9							false
8443	9195		ADULT	71226662	465.1913	ACALABRUTINIB	ACALABRUTINIB	CC#CC(=O)N1CCC[C@H]1C2=NC(=C3N2C=CN=C3N)C4=CC=C(C=C4)C(=O)NC5=NC=CC=C5	PLASMA	I42748ELQW							24		t	ng × h/mL	1850		ng/mL	827			DEFINED DAILY	mg	200		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/29737219	Homo sapiens		h	0.6							false
8444	9196		ADULT	11618268	401.3964	ACALISIB	ACALISIB	C[C@H](NC1=C2NC=NC2=NC=N1)C3=NC4=C(C=C(F)C=C4)C(=O)N3C5=CC=CC=C5	PLASMA	OVW60IDW1D							6		t	ng × h/mL	8440		ng/mL	2760			MAX TOLERATED	mg	400		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.lymmcare.nl/cmsje/upload/publicaties/KaterASH2013Po2881_QR.pdf	Homo sapiens										false
8445	9215		CHILD	31703	543.5	DOXORUBICIN	DOXORUBICIN	COC1=CC=CC2=C1C(=O)C3=C(O)C4=C(C[C@](O)(C[C@@H]4O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C(=O)CO)C(O)=C3C2=O	PLASMA	80168379AG									∞	μM × h	7.4		μM	2			RECOMMENDED	mg/m²	60		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26115930	Homo sapiens		h	34.8							false
8446	9226		ADULT	11526038	490.5476	PEMAFIBRATE	PEMAFIBRATE	CC[C@@H](OC1=CC(CN(CCCOC2=CC=C(OC)C=C2)C3=NC4=C(O3)C=CC=C4)=CC=C1)C(O)=O	PLASMA	17VGG92R23									∞	ng × h/mL	20		ng/mL	5.7			UNKNOWN	mg	0.4		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/31900032	Homo sapiens										false
8447	9234		ADULT	50515	283.3251	AMONAFIDE	AMONAFIDE	CN(C)CCN1C(=O)C2=CC(N)=CC3=CC=CC(C1=O)=C23	PLASMA	1Q8D39N37L									∞	ng × h/mL	674		ng/mL	61.5			UNKNOWN	mg	700		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22349808	Homo sapiens		h	11.6				15	AMONAFIDE		false
8448	9234		ADULT	50515	283.3251	AMONAFIDE	AMONAFIDE	CN(C)CCN1C(=O)C2=CC(N)=CC3=CC=CC(C1=O)=C23	PLASMA	1Q8D39N37L									∞	ng × h/mL	1472		ng/mL	174			UNKNOWN	mg	700		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22349808	Homo sapiens		h	8.31				15	AMONAFIDE		false
8449	9234		ADULT	50515	283.3251	AMONAFIDE	AMONAFIDE	CN(C)CCN1C(=O)C2=CC(N)=CC3=CC=CC(C1=O)=C23	PLASMA	1Q8D39N37L							2321		?	ng × h/mL	2321		ng/mL	644			UNKNOWN	mg	360		MULTIPLE	UNKNOWN		day	3			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22349808	Homo sapiens		h	11.7	day 6			6	AMONAFIDE		false
8450	9234		ADULT	50515	283.3251	AMONAFIDE	AMONAFIDE	CN(C)CCN1C(=O)C2=CC(N)=CC3=CC=CC(C1=O)=C23	PLASMA	1Q8D39N37L							8		t	ng × h/mL	129		ng/mL	29.5			UNKNOWN	mg	500		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23178951	Homo sapiens							3	AMONAFIDE		false
8451	9234		ADULT	50515	283.3251	AMONAFIDE	AMONAFIDE	CN(C)CCN1C(=O)C2=CC(N)=CC3=CC=CC(C1=O)=C23	PLASMA	1Q8D39N37L							8		t	ng × h/mL	534		ng/mL	81.7			UNKNOWN	mg	500		MULTIPLE	FASTED		day	3			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23178951	Homo sapiens							3	AMONAFIDE		false
8452	9234		UNKNOWN	11282283	447.51	AMUVATINIB	AMUVATINIB	S=C(NCC1=CC2=C(OCO2)C=C1)N3CCN(CC3)C4=NC=NC5=C4OC6=C5C=CC=C6	SERUM	SO9S6QZB4R																	UNKNOWN				UNKNOWN	UNKNOWN				95% of amuvatinib binds serum proteins	5	UNKNOWN	UNKNOWN	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24326130	Homo sapiens								AMUVATINIB		false
8453	9240		ADULT	29769|23662354|139072523	164.179	MESNA	mesna	[Na ].[O-]S(=O)(=O)CCS	PLASMA	NR7O1405Q9							8		t	mg × h/L	217.72						UNKNOWN	mg	920		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1508821/	Homo sapiens							5	ARGIMESNA		false
8454	9241		ADULT	11531457	401.518	ARTEMISONE	artemisone	C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4)N5CCS(=O)(=O)CC5	PLASMA	796LMW5BUZ									?	ng × h/mL	337.3		ng/mL	130.3			UNKNOWN	mg	80		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18559649	Homo sapiens		h	3.07				7	artemisone		false
8455	9241		ADULT	11531457	401.518	ARTEMISONE	artemisone	C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4)N5CCS(=O)(=O)CC5	PLASMA	796LMW5BUZ									?	ng × h/mL	190.7		ng/mL	95			UNKNOWN	mg	40		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18559649	Homo sapiens		h	4.37				7	artemisone		false
8456	9252		ADULT	9838180	265.244	[NO STEREO] AVE-1330A FREE ACID|[NO STEREO] AVIBACTAM	C1CC(N2CC1N(C2=O)OS(=O)(=O)O)C(=O)N	NC(=O)C1CCC2CN1C(=O)N2OS(O)(=O)=O	PLASMA	[NO STEREO] 06MFO7817I|[NO STEREO] 7352665165	2650		Ceftazidime	CC(C)(C(=O)O)ON=C(C1=CSC(=N1)N)C(=O)NC2C3N(C2=O)C(=C(CS3)C[N+]4=CC=CC=C4)C(=O)[O-]	CC(C)(C(=O)O)ON=C(C1=CSC(=N1)N)C(=O)NC2C3N(C2=O)C(=C(CS3)C[N+]4=CC=CC=C4)C(=O)[O-]	9M416Z9QNR			∞	mg × h/L	42.1		mg/L	15.2			RECOMMENDED	g	0.5		SINGLE	UNKNOWN					93	HEALTHY	Intravenous	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/206494s005,s006lbl.pdf	Homo sapiens		h	2.22							true
8457	9252		ADULT	9835049|90333665	265.244	AVIBACTAM	Avibactam	NC(=O)[C@@H]1CC[C@@H]2C[N@]1C(=O)N2OS(O)(=O)=O	PLASMA	7352665165	6536864|73415797|131673973		CEFTAZIDIME	Ceftazidime	[H+].O.O.O.O.O.CC(C)(O\\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[N+]3=CC=CC=C3)=C(N2C1=O)C([O-])=O)C4=CSC(N)=N4)C([O-])=O	9M416Z9QNR	8		t	mg × h/L	38.2		mg/L	14.6			RECOMMENDED	g	0.5		MULTIPLE	UNKNOWN		day	3			HEALTHY	Intravenous	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/206494s005,s006lbl.pdf	Homo sapiens		h	2.71							true
8458	9255		ADULT	457388|132283238	284.2288	R-1479	R-1479		PLASMA	M71RA9DMGJ							12		t	mg × h/L	63.3		mg/L	9.9			UNKNOWN	mg	1500		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18570306/	Homo sapiens				14 days dosing	hepatitis C virus		15	BALAPIRAVIR		false
8459	9255		ADULT	457388|132283238	284.2288	R-1479	R-1479		SERUM	M71RA9DMGJ									?	μM × h	110.56		μM	16.54			UNKNOWN	mg	1500		SINGLE	UNKNOWN						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22807519/	Homo sapiens				Dengue virus			10	BALAPIRAVIR		false
8460	9255		ADULT	457388|132283238	284.2288	R-1479	R-1479		SERUM	M71RA9DMGJ									?	μM × h	167.04		μM	23.86			UNKNOWN	mg	3000		SINGLE	UNKNOWN						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22807519/	Homo sapiens				Dengue virus			22	BALAPIRAVIR		false
8461	9261		ADULT	57345941	576.7246	BELIZATINIB	BELIZATINIB	CC(C)NC(=O)[C@@H]1CC[C@@H](CC1)[n]2\\c(-nc3ccc(CN4CCC(CC4)C(C)(C)O)cc23)=N\\C(=O)C5=CC=C(F)C=C5	PLASMA	Z8A6022P3J													nM	3327.36			UNKNOWN	mg	480		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31217479	Homo sapiens							4	BELIZATINIB		false
8462	9267		ADULT	5284569	299.3642	HYDROCODONE	Hydrocodone	COC1=CC=C2C[C@@H]3[C@@H]4CCC(=O)[C@@H]5OC1=C2[C@]45CCN3C	PLASMA	6YKS4Y3WQ7	1983	151.1626	ACETAMINOPHEN	Acetaminophen	CC(=O)NC1=CC=C(O)C=C1	362O9ITL9D			∞	ng × h/mL	252.7		ng/mL	40.4			UNKNOWN	mg	12.24		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29025138/	Homo sapiens					Nondependent, Recreational Drug Users	650 mg	42			true
8463	9267		ADULT	5284569	299.3642	HYDROCODONE	Hydrocodone	COC1=CC=C2C[C@@H]3[C@@H]4CCC(=O)[C@@H]5OC1=C2[C@]45CCN3C	PLASMA	6YKS4Y3WQ7	1983	151.1626	ACETAMINOPHEN	Acetaminophen	CC(=O)NC1=CC=C(O)C=C1	362O9ITL9D			∞	ng × h/mL	278.3		ng/mL	34.7			UNKNOWN	mg	12.24		SINGLE	UNKNOWN						HEALTHY	Nasal	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29025138/	Homo sapiens					Nondependent, Recreational Drug Users	650 mg	43			true
8464	9267		ADULT	5284569	299.3642	HYDROCODONE	Hydrocodone	COC1=CC=C2C[C@@H]3[C@@H]4CCC(=O)[C@@H]5OC1=C2[C@]45CCN3C	PLASMA	6YKS4Y3WQ7	1983	151.1626	ACETAMINOPHEN	Acetaminophen	CC(=O)NC1=CC=C(O)C=C1	362O9ITL9D			∞	ng × h/mL	130.91		ng/mL	16.04			UNKNOWN	mg	6.12		SINGLE	HIGH-FAT						HEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208653s007lbl.pdf#page=30	Homo sapiens		h	4.51			325 mg	38			true
8465	9267		ADULT	5284569	299.3642	HYDROCODONE	Hydrocodone	COC1=CC=C2C[C@@H]3[C@@H]4CCC(=O)[C@@H]5OC1=C2[C@]45CCN3C	PLASMA	6YKS4Y3WQ7	1983	151.1626	ACETAMINOPHEN	Acetaminophen	CC(=O)NC1=CC=C(O)C=C1	362O9ITL9D			∞	ng × h/mL	125.73		ng/mL	19.18			UNKNOWN	mg	6.12		SINGLE	HIGH-FAT						HEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208653s007lbl.pdf#page=30	Homo sapiens		h	4.33			325 mg	38			true
8466	9267		ADULT	5284569	299.3642	HYDROCODONE	Hydrocodone	COC1=CC=C2C[C@@H]3[C@@H]4CCC(=O)[C@@H]5OC1=C2[C@]45CCN3C	PLASMA	6YKS4Y3WQ7	1983	151.1626	ACETAMINOPHEN	Acetaminophen	CC(=O)NC1=CC=C(O)C=C1	362O9ITL9D	4		t	ng × h/mL	92.94		ng/mL	33.95			UNKNOWN	mg	12.24		MULTIPLE	FASTED		day	6	AUCinf = 219.36 ng x h/mL		HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208653Orig1s000ClinPharmR.pdf#page=25	Homo sapiens		h	4.45	Day 1 (single dose)		650 mg	24			true
8467	9267		ADULT	5284569	299.3642	HYDROCODONE	Hydrocodone	COC1=CC=C2C[C@@H]3[C@@H]4CCC(=O)[C@@H]5OC1=C2[C@]45CCN3C	PLASMA	6YKS4Y3WQ7	1983	151.1626	ACETAMINOPHEN	Acetaminophen	CC(=O)NC1=CC=C(O)C=C1	362O9ITL9D	4		t	ng × h/mL	195.07		ng/mL	62.79			UNKNOWN	mg	12.24		MULTIPLE	FASTED		day	6			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208653Orig1s000ClinPharmR.pdf#page=25	Homo sapiens		h	4.87	Day 4 (14th dose, q4h x 13 doses (Days 2 to 4))		650 mg	24			true
8468	9267		ADULT	5284569	299.3642	HYDROCODONE	Hydrocodone	COC1=CC=C2C[C@@H]3[C@@H]4CCC(=O)[C@@H]5OC1=C2[C@]45CCN3C	PLASMA	6YKS4Y3WQ7	1983	151.1626	ACETAMINOPHEN	Acetaminophen	CC(=O)NC1=CC=C(O)C=C1	362O9ITL9D			∞	ng × h/mL	1272		ng/mL	208			UNKNOWN	mg	73.44		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208653Orig1s000ClinPharmR.pdf#page=27	Homo sapiens		h	5		opioid-experienced, nondependent subjects	3900 mg	61			true
8469	9267		ADULT	5284569	299.3642	HYDROCODONE	Hydrocodone	COC1=CC=C2C[C@@H]3[C@@H]4CCC(=O)[C@@H]5OC1=C2[C@]45CCN3C	PLASMA	6YKS4Y3WQ7	1983	151.1626	ACETAMINOPHEN	Acetaminophen	CC(=O)NC1=CC=C(O)C=C1	362O9ITL9D							ng/mL	27			UNKNOWN	mg	24.48		SINGLE	UNKNOWN						HEALTHY	Nasal	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208653Orig1s000ClinPharmR.pdf#page=29	Homo sapiens					opioid-experienced, non-dependent subjects	1300 mg				true
8470	9267		ADULT	5284569	299.3642	HYDROCODONE	Hydrocodone	COC1=CC=C2C[C@@H]3[C@@H]4CCC(=O)[C@@H]5OC1=C2[C@]45CCN3C	PLASMA	6YKS4Y3WQ7	1983	151.1626	ACETAMINOPHEN	Acetaminophen	CC(=O)NC1=CC=C(O)C=C1	362O9ITL9D							ng/mL	9.4			UNKNOWN	mg	6.12		SINGLE	UNKNOWN						HEALTHY	Nasal	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208653Orig1s000ClinPharmR.pdf#page=29	Homo sapiens					opioid-experienced, non-dependent subjects	325 mg				true
8471	9267		ADULT	5284569	299.3642	HYDROCODONE	Hydrocodone	COC1=CC=C2C[C@@H]3[C@@H]4CCC(=O)[C@@H]5OC1=C2[C@]45CCN3C	PLASMA	6YKS4Y3WQ7									∞	ng × h/mL	194.7		ng/mL	25.6			UNKNOWN	mg	12.24		SINGLE	FASTED						HEALTHY	Nasal	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208653Orig1s000ClinPharmR.pdf#page=31 | https://pubmed.ncbi.nlm.nih.gov/29092079/	Homo sapiens		h	5.29		Nondependent, Recreational Drug Users		24			false
8472	9275		ADULT	118596030	449.3799	BICTEGRAVIR	BICTEGRAVIR	OC1=C2N(C[C@H]3O[C@@H]4CC[C@@H](C4)N3C2=O)C=C(C(=O)NCC5=C(F)C=C(F)C=C5F)C1=O	PLASMA	8GB79LOJ07									?	ng × h/mL	9983		ng/mL	741.5			UNKNOWN	mg	5		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28196003/	Homo sapiens		h	20.8							false
8473	9275		ADULT	118596030	449.3799	BICTEGRAVIR	BICTEGRAVIR	OC1=C2N(C[C@H]3O[C@@H]4CC[C@@H](C4)N3C2=O)C=C(C(=O)NCC5=C(F)C=C(F)C=C5F)C1=O	PLASMA	8GB79LOJ07									?	ng × h/mL	48950.3		ng/mL	3475			UNKNOWN	mg	25		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28196003/	Homo sapiens		h	15.9							false
8474	9275		ADULT	118596030	449.3799	BICTEGRAVIR	BICTEGRAVIR	OC1=C2N(C[C@H]3O[C@@H]4CC[C@@H](C4)N3C2=O)C=C(C(=O)NCC5=C(F)C=C(F)C=C5F)C1=O	PLASMA	8GB79LOJ07									?	ng × h/mL	87538.4		ng/mL	6080			UNKNOWN	mg	50		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28196003/	Homo sapiens		h	17.8							false
8475	9275		ADULT	118596030	449.3799	BICTEGRAVIR	BICTEGRAVIR	OC1=C2N(C[C@H]3O[C@@H]4CC[C@@H](C4)N3C2=O)C=C(C(=O)NCC5=C(F)C=C(F)C=C5F)C1=O	PLASMA	8GB79LOJ07									?	ng × h/mL	178901.7		ng/mL	12235			UNKNOWN	mg	100		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28196003/	Homo sapiens		h	20.9							false
8476	9275		ADULT		471.3618	BICTEGRAVIR SODIUM	Bictegravir Sodium	[Na+].[O-]C1=C2N(C[C@H]3O[C@@H]4CC[C@@H](C4)N3C2=O)C=C(C(=O)NCC5=C(F)C=C(F)C=C5F)C1=O	PLASMA	4L5MP1Y7W7	60877		EMTRICITABINE	Emtricitabine	NC1=NC(=O)N(C=C1F)[C@@H]2CS[C@H](CO)O2	G70B4ETF4S			?	μg × h/mL	102		μg/mL	6.15			RECOMMENDED	mg	50		MULTIPLE	UNKNOWN		day	1	Bictegravir >99 % bound to human plasma proteins.	1	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210251s000lbl.pdf	Homo sapiens		h	17.3							true
8477	9280		ADULT	25212181	409.053	BIXALOMER	Bixalomer	ClCC1CO1.NCCCN(CCCN)CCCCN(CCCN)CCCN	PLASMA	3160WY51LV									?	ng × h/mL	0		ng/mL	0			UNKNOWN	mg	2500		SINGLE	FED				Radioactivity in blood was below the limit of quantitation (0.08 μCi; 80μCi (total radioactivity) x 0.1% (detection limit in blood)).		HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/800126_2190032M1027_1_018_1F.pdf#page=36	Homo sapiens							10			false
8478	9286		ADULT	9837243	212.2887	BRIVARACETAM	BRIVARACETAM	CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1	PLASMA	U863JGG2IA									∞	μg × h/mL	27.5		μg/mL	2.2			UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18341673	Homo sapiens		h	7.7							false
8479	9286		ADULT	9837243	212.2887	BRIVARACETAM	BRIVARACETAM	CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1	PLASMA	U863JGG2IA									∞	μg × h/mL	56		μg/mL	4.7			UNKNOWN	mg	400		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18341673	Homo sapiens		h	7.3							false
8480	9286		ADULT	9837243	212.2887	BRIVARACETAM	BRIVARACETAM	CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1	PLASMA	U863JGG2IA									∞	μg × h/mL	104.1		μg/mL	9			UNKNOWN	mg	800		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18341673	Homo sapiens		h	7.8							false
8481	9286		ADULT	9837243	212.2887	BRIVARACETAM	BRIVARACETAM	CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1	PLASMA	U863JGG2IA									?	μg × h/mL	28		μg/mL	3.5			UNKNOWN	mg	200		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18341673	Homo sapiens		h	7.3							false
8482	9286		ADULT	9837243	212.2887	BRIVARACETAM	BRIVARACETAM	CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1	PLASMA	U863JGG2IA									?	μg × h/mL	55.4		μg/mL	7.7			UNKNOWN	mg	400		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18341673	Homo sapiens		h	6.8							false
8483	9286		ADULT	9837243	212.2887	BRIVARACETAM	BRIVARACETAM	CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1	PLASMA	U863JGG2IA									?	μg × h/mL	90.8		μg/mL	13.3			UNKNOWN	mg	800		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18341673	Homo sapiens		h	6.3							false
8484	9286		UNKNOWN	9837243	212.2887	BRIVARACETAM	BRIVARACETAM	CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1	PLASMA	U863JGG2IA																	UNKNOWN				UNKNOWN	UNKNOWN				Brivaracetam is weakly bound to plasma proteins (≤20%).	80	UNKNOWN	UNKNOWN	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/205836s005,205837s004,205838s003lbl.pdf	Homo sapiens										false
8485	9293		ADULT		420.5191	LEVOCABASTINE	LEVOCABASTINE	C[C@@H]1CN(CC[C@]1(C(O)=O)C2=CC=CC=C2)[C@H]3CC[C@](CC3)(C#N)C4=CC=C(F)C=C4	PLASMA	H68BP06S81									∞	ng × h/mL	319		ng/mL	7.4			UNKNOWN	mg	0.5		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7907347/	Homo sapiens		h	35.7							false
8486	9293		UNKNOWN		420.5191	LEVOCABASTINE	LEVOCABASTINE	C[C@@H]1CN(CC[C@]1(C(O)=O)C2=CC=CC=C2)[C@H]3CC[C@](CC3)(C#N)C4=CC=C(F)C=C4	PLASMA	H68BP06S81									?	μg × h/L	337		μg/L	7.3			UNKNOWN	mg	0.5		SINGLE	UNKNOWN					45	HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/8549024/	Homo sapiens		h	37.5							false
8487	9293		UNKNOWN		420.5191	LEVOCABASTINE	LEVOCABASTINE	C[C@@H]1CN(CC[C@]1(C(O)=O)C2=CC=CC=C2)[C@H]3CC[C@](CC3)(C#N)C4=CC=C(F)C=C4	PLASMA	H68BP06S81									?	μg × h/L	580		μg/L	12.1			UNKNOWN	mg	1		SINGLE	UNKNOWN					45	HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/8549024/	Homo sapiens		h	37.5							false
8488	9293		UNKNOWN		420.5191	LEVOCABASTINE	LEVOCABASTINE	C[C@@H]1CN(CC[C@]1(C(O)=O)C2=CC=CC=C2)[C@H]3CC[C@](CC3)(C#N)C4=CC=C(F)C=C4	PLASMA	H68BP06S81									?	μg × h/L	1142		μg/L	22.2			UNKNOWN	mg	2		SINGLE	UNKNOWN					45	HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/8549024/	Homo sapiens										false
8489	9314		ADULT	441457	151.2056	CATHINE	Cathine	C[C@H](N)[C@@H](O)C1=CC=CC=C1	PLASMA	E1L4ZW2F8O									?	μg × min/L	713		μg/L	71.2			UNKNOWN	g/kg	0.498		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12848785/	Homo sapiens		h	5.22	0.6 g authentic khat leaves per kg BW for 1h			4			false
8490	9318		ADULT	11962412	267.672	CENOBAMATE	CENOBAMATE	NC(=O)O[C@@H](CN1N=CN=N1)C2=C(Cl)C=CC=C2	PLASMA	P85X70RZWS									∞	μg × h/mL	322		μg/mL	4.42			RECOMMENDED	mg	200		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32087001/	Homo sapiens		h	54.7							false
8491	9318		ADULT	11962412	267.672	CENOBAMATE	CENOBAMATE	NC(=O)O[C@@H](CN1N=CN=N1)C2=C(Cl)C=CC=C2	PLASMA	P85X70RZWS									∞	μg × h/mL	1960		μg/mL	17.2			UNKNOWN	mg	750		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32087001/	Homo sapiens		h	75.6							false
8492	9318		ADULT	11962412	267.672	CENOBAMATE	CENOBAMATE	NC(=O)O[C@@H](CN1N=CN=N1)C2=C(Cl)C=CC=C2	PLASMA	P85X70RZWS									∞	μg × h/mL	4.53		μg/mL	0.1			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32087001/	Homo sapiens		h	35.9							false
8493	9318		ADULT	11962412	267.672	CENOBAMATE	CENOBAMATE	NC(=O)O[C@@H](CN1N=CN=N1)C2=C(Cl)C=CC=C2	PLASMA	P85X70RZWS									?	μg × h/mL	484		μg/mL	24.1			RECOMMENDED	mg	200		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32087001/	Homo sapiens										false
8494	9318		ADULT	11962412	267.672	CENOBAMATE	CENOBAMATE	NC(=O)O[C@@H](CN1N=CN=N1)C2=C(Cl)C=CC=C2	PLASMA	P85X70RZWS									?	μg × h/mL	873		μg/mL	46.1			MAX DAILY	mg	400		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32087001/	Homo sapiens										false
8495	9318		ADULT	11962412	267.672	CENOBAMATE	CENOBAMATE	NC(=O)O[C@@H](CN1N=CN=N1)C2=C(Cl)C=CC=C2	PLASMA	P85X70RZWS									?	μg × h/mL	861						MAX DAILY	mg	400		STEADY-STATE	UNKNOWN		day	1	Plasma protein binding of cenobamate is moderate (60%) and independent of concentration.	40	HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212839Orig1s000ClinPharmR.pdf	Homo sapiens										false
8496	9318		ADULT	11962412	267.672	CENOBAMATE	CENOBAMATE	NC(=O)O[C@@H](CN1N=CN=N1)C2=C(Cl)C=CC=C2	PLASMA	P85X70RZWS									?	μg × h/mL	482						RECOMMENDED	mg	200		STEADY-STATE	UNKNOWN		day	1	Plasma protein binding of cenobamate is moderate (60%) and independent of concentration.	40	HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212839Orig1s000ClinPharmR.pdf	Homo sapiens										false
8497	9319		UNKNOWN	44595079	445.538	CERDULATINIB	CERDULATINIB	CCS(=O)(=O)N1CCN(CC1)C2=CC=C(NC3=NC(NC4CC4)=C(C=N3)C(N)=O)C=C2	PLASMA	D1LXQ45S1O																						UNKNOWN				In whole blood assays we observed a reduced inhibition of anti-IgM and IL-4 signalling, this is because plasma protein binding for cerdulatinib is ~78%.	22	UNKNOWN		UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5417366/	Homo sapiens										false
8498	9319		ADULT	44595079	445.538	CERDULATINIB	CERDULATINIB	CCS(=O)(=O)N1CCN(CC1)C2=CC=C(NC3=NC(NC4CC4)=C(C=N3)C(N)=O)C=C2	PLASMA	D1LXQ45S1O							8		t	μg × h/mL	7.1		μM	1.06			UNKNOWN	mg	100		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/30592080	Homo sapiens		h	11.5							false
8499	9323		ADULT	11488110	464.82	CEVIPABULIN	CEVIPABULIN	CNCCCOC1=CC(F)=C(C(F)=C1)C2=C(N[C@@H](C)C(F)(F)F)N3N=CN=C3N=C2Cl	PLASMA	P14M0DWS2J									∞	ng × h/mL	2768		ng/mL	582			UNKNOWN	mg/m²	31.5		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20697774	Homo sapiens		h	27.2					CEVIPABULIN		false
8500	9332		ADULT	56330|40466888	417.4986	CILAZAPRIL ANHYDROUS	Cilazapril	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCCN3CCC[C@H](N3C2=O)C(O)=O	PLASMA	8Q9454114Q							24		t	ng × h/mL	52.6		ng/mL	17			UNKNOWN	mg	0.5		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2527533/	Homo sapiens		h	18.4				24			false
8501	9332		ADULT	56330|40466888	417.4986	CILAZAPRIL ANHYDROUS	Cilazapril	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCCN3CCC[C@H](N3C2=O)C(O)=O	PLASMA	8Q9454114Q							24		t	ng × h/mL	99.8		ng/mL	33.9			UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2527533/	Homo sapiens		h	18.5				24			false
8502	9332		ADULT	56330|40466888	417.4986	CILAZAPRIL ANHYDROUS	Cilazapril	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCCN3CCC[C@H](N3C2=O)C(O)=O	PLASMA	8Q9454114Q							24		t	ng × h/mL	256		ng/mL	82.7			UNKNOWN	mg	2.5		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2527533/	Homo sapiens		h	13.4				24			false
8503	9332		ADULT	56330|40466888	417.4986	CILAZAPRIL ANHYDROUS	Cilazapril	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCCN3CCC[C@H](N3C2=O)C(O)=O	PLASMA	8Q9454114Q							24		t	ng × h/mL	496		ng/mL	182			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2527533/	Homo sapiens		h	13.8				24			false
8504	9332		ADULT	64766	389.4455	CILAZAPRILAT	Cilazaprilat	OC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCCN3CCC[C@H](N3C2=O)C(O)=O	PLASMA	WBL76FH528							24		t	ng × h/mL	42.1		ng/mL	5.4			UNKNOWN	mg	0.5		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2527533/	Homo sapiens		h	48.9				24			false
8505	9332		ADULT	64766	389.4455	CILAZAPRILAT	Cilazaprilat	OC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCCN3CCC[C@H](N3C2=O)C(O)=O	PLASMA	WBL76FH528							24		t	ng × h/mL	79.1		ng/mL	12.4			UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2527533/	Homo sapiens		h	39.8				24			false
8506	9332		ADULT	64766	389.4455	CILAZAPRILAT	Cilazaprilat	OC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCCN3CCC[C@H](N3C2=O)C(O)=O	PLASMA	WBL76FH528							24		t	ng × h/mL	175		ng/mL	37.7			UNKNOWN	mg	2.5		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2527533/	Homo sapiens		h	38.5				24			false
8507	9332		ADULT	64766	389.4455	CILAZAPRILAT	Cilazaprilat	OC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCCN3CCC[C@H](N3C2=O)C(O)=O	PLASMA	WBL76FH528							24		t	ng × h/mL	342		ng/mL	94.2			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2527533/	Homo sapiens		h	35.8				24			false
8508	9332		ADULT	64766	389.4455	CILAZAPRILAT	Cilazaprilat	OC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCCN3CCC[C@H](N3C2=O)C(O)=O	PLASMA	WBL76FH528							24		t	ng × h/mL	89		ng/mL	10.81			UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2527539/	Homo sapiens					Normal renal function, CrCL  >70 ml/min/1.73 m2		6			false
8509	9332		ADULT	64766	389.4455	CILAZAPRILAT	Cilazaprilat	OC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCCN3CCC[C@H](N3C2=O)C(O)=O	PLASMA	WBL76FH528							24		t	ng × h/mL	507		ng/mL	26.26			UNKNOWN	mg	1		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2527539/	Homo sapiens					CrCL  < 5 ml/min/1.73 m2, requiring periodic haemodialysis		4			false
8510	9332		ADULT	64766	389.4455	CILAZAPRILAT	Cilazaprilat	OC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCCN3CCC[C@H](N3C2=O)C(O)=O	PLASMA	WBL76FH528							24		t	ng × h/mL	313		ng/mL	20.03			UNKNOWN	mg	1		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2527539/	Homo sapiens					CrCL  5-15 ml/min/1.73 m2, not requiring periodic haemodialysis		6			false
8511	9332		ADULT	64766	389.4455	CILAZAPRILAT	Cilazaprilat	OC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCCN3CCC[C@H](N3C2=O)C(O)=O	PLASMA	WBL76FH528							24		t	ng × h/mL	255		ng/mL	22.47			UNKNOWN	mg	1		SINGLE	FASTED						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2527539/	Homo sapiens					CrCL  20-40 ml/min/1.73 m2		4			false
8512	9332		ADULT	64766	389.4455	CILAZAPRILAT	Cilazaprilat	OC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCCN3CCC[C@H](N3C2=O)C(O)=O	PLASMA	WBL76FH528							24		t	ng × h/mL	102		ng/mL	11.83			UNKNOWN	mg	1		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2527539/	Homo sapiens					CrCL  40-70 ml/min/1.73 m2		5			false
8513	9332		ADULT	56330|40466888	417.4986	CILAZAPRIL ANHYDROUS	Cilazapril	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCCN3CCC[C@H](N3C2=O)C(O)=O	PLASMA	8Q9454114Q							24		t	ng × h/mL	210		ng/mL	51.18			UNKNOWN	mg	1		SINGLE	FASTED						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2527539/	Homo sapiens					CrCL 20-40 ml/min/1.73 m2		4			false
8514	9332		ADULT	56330|40466888	417.4986	CILAZAPRIL ANHYDROUS	Cilazapril	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCCN3CCC[C@H](N3C2=O)C(O)=O	PLASMA	8Q9454114Q							24		t	ng × h/mL	131		ng/mL	38.71			UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2527539/	Homo sapiens					Normal renal function, CrCL > 70/mL/min/1.73m2		6			false
8515	9332		ADULT	56330|40466888	417.4986	CILAZAPRIL ANHYDROUS	Cilazapril	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCCN3CCC[C@H](N3C2=O)C(O)=O	PLASMA	8Q9454114Q							24		t	ng × h/mL	239		ng/mL	47.52			UNKNOWN	mg	1		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2527539/	Homo sapiens					CrCL 5-15 ml/min/1.73 m2, not requiring periodic haemodialysis		6			false
8516	9332		ADULT	56330|40466888	417.4986	CILAZAPRIL ANHYDROUS	Cilazapril	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCCN3CCC[C@H](N3C2=O)C(O)=O	PLASMA	8Q9454114Q							24		t	ng × h/mL	319		ng/mL	52.76			UNKNOWN	mg	1		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2527539/	Homo sapiens					CrCL < 5 ml/min/1.73 m2, requiring periodic haemodialysis		4			false
8517	9332		ADULT	56330|40466888	417.4986	CILAZAPRIL ANHYDROUS	Cilazapril	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCCN3CCC[C@H](N3C2=O)C(O)=O	PLASMA	8Q9454114Q							24		t	ng × h/mL	99		ng/mL	38.57			UNKNOWN	mg	1		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2527539/	Homo sapiens					CrCL 40-70 ml/min/1.73 m2		5			false
8518	9332		ADULT	56330|40466888	417.4986	CILAZAPRIL ANHYDROUS	Cilazapril	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCCN3CCC[C@H](N3C2=O)C(O)=O	PLASMA	8Q9454114Q							8		t	ng × h/mL	40.09		ng/mL	19.08			RECOMMENDED	mg	1		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/300119_2144005F1060_1_091_1F.pdf#page=22	Homo sapiens		h	1.1				20			false
8519	9356		ADULT	6918540	389.595	DALCETRAPIB	DALCETRAPIB	CCC(CC)CC1(CCCCC1)C(=O)NC2=C(SC(=O)C(C)C)C=CC=C2	PLASMA	3D050LIQ3H							24		t	μg × h/mL	88.4		μg/mL	8.26			UNKNOWN	mg	4500		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/21366361	Homo sapiens		h	19.2							false
8520	9359		ADULT	9947999	292.203	DASOTRALINE	DASOTRALINE	N[C@@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C3=C1C=CC=C3	PLASMA	4D28EY0L5T									?	ng × h/mL	740		ng/mL	14			UNKNOWN	mg	36		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26794682	Homo sapiens							39	DASOTRALINE		false
8521	9384		ADULT	12358972	167.2911	DEXMECAMYLAMINE	TC-5214	CN[C@@]1(C)[C@@H]2CC[C@@H](C2)C1(C)C	PLASMA	5Y1141YI4U							72		t	ng × h/mL	248.2		ng/mL	7.606			UNKNOWN	mg	2		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24760402	Homo sapiens		h	26.4	moderate renal impairment			8	TC-5214		false
8522	9384		ADULT	12358972	167.2911	DEXMECAMYLAMINE	Dexmecamylamine	CN[C@@]1(C)[C@@H]2CC[C@@H](C2)C1(C)C	PLASMA	5Y1141YI4U							72		t	ng × h/mL	537.68		ng/mL	33.16			UNKNOWN	mg	8		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24760402	Homo sapiens		h	10.4				8	Dexmecamylamine		false
8523	9384		ADULT	12358972	167.2911	DEXMECAMYLAMINE	Dexmecamylamine	CN[C@@]1(C)[C@@H]2CC[C@@H](C2)C1(C)C	PLASMA	5Y1141YI4U							72		t	ng × h/mL	767.28		ng/mL	31.544			UNKNOWN	mg	8		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24760402	Homo sapiens		h	14	mild renal impairment			8	Dexmecamylamine		false
8524	9395		ADULT	24794466	679.8493	DIFELIKEFALIN	Difelikefalin	CC(C)C[C@@H](NC(=O)[C@@H](CC1=CC=CC=C1)NC(=O)[C@H](N)CC2=CC=CC=C2)C(=O)N[C@H](CCCCN)C(=O)N3CCC(N)(CC3)C(O)=O	PLASMA	NA1U919MRO									?	ng × h/mL	94		ng/mL	61.9			UNKNOWN	μg/kg	5		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.13173	Homo sapiens		h	2				41			false
8525	9395		ADULT	24794466	679.8493	DIFELIKEFALIN	Difelikefalin	CC(C)C[C@@H](NC(=O)[C@@H](CC1=CC=CC=C1)NC(=O)[C@H](N)CC2=CC=CC=C2)C(=O)N[C@H](CCCCN)C(=O)N3CCC(N)(CC3)C(O)=O	PLASMA	NA1U919MRO									?	ng × h/mL	246		ng/mL	168.8			UNKNOWN	μg/kg	15		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.13173	Homo sapiens		h	2				40			false
8526	9395		UNKNOWN	24794466	679.8493	DIFELIKEFALIN	Difelikefalin	CC(C)C[C@@H](NC(=O)[C@@H](CC1=CC=CC=C1)NC(=O)[C@H](N)CC2=CC=CC=C2)C(=O)N[C@H](CCCCN)C(=O)N3CCC(N)(CC3)C(O)=O	PLASMA	NA1U919MRO																						UNKNOWN				Human plasma protein binding: 27%	73	UNKNOWN		UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/33190563/	Homo sapiens										false
8527	9395		UNKNOWN	24794466	679.8493	DIFELIKEFALIN	Difelikefalin	CC(C)C[C@@H](NC(=O)[C@@H](CC1=CC=CC=C1)NC(=O)[C@H](N)CC2=CC=CC=C2)C(=O)N[C@H](CCCCN)C(=O)N3CCC(N)(CC3)C(O)=O	PLASMA	NA1U919MRO																	UNKNOWN				UNKNOWN	UNKNOWN				t1/2=23-31 h		UNHEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf#page=52	Homo sapiens		h	31		Hemodialysis patients prior to dialysis					false
8528	9419		ADULT	71661251	882.0171	ELBASVIR	ELBASVIR	COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC4=C(C=C3)N5[C@@H](OC6=CC(=CC=C6C5=C4)C7=CN=C(N7)[C@@H]8CCCN8C(=O)[C@@H](NC(=O)OC)C(C)C)C9=CC=CC=C9	PLASMA	632L571YDK	71576667		GRAZOPREVIR	GRAZOPREVIR	O.COC1=CC2=C(C=C1)N=C3CCCCC[C@@H]4C[C@H]4OC(=O)N[C@H](C(=O)N5C[C@@H](C[C@H]5C(=O)N[C@@]6(C[C@H]6C=C)C(=O)NS(=O)(=O)C7CC7)OC3=N2)C(C)(C)C	4O2AB118LA											DEFINED DAILY	mg	50		SINGLE	UNKNOWN				Elbasvir and grazoprevir are extensively bound (greater than 99.9% and 98.8%, respectively) to human plasma proteins.	0.1	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208261s002lbl.pdf	Homo sapiens		h	24							true
8529	9419		ADULT	71661251	882.0171	ELBASVIR	ELBASVIR	COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC4=C(C=C3)N5[C@@H](OC6=CC(=CC=C6C5=C4)C7=CN=C(N7)[C@@H]8CCCN8C(=O)[C@@H](NC(=O)OC)C(C)C)C9=CC=CC=C9	PLASMA	632L571YDK	71576667		GRAZOPREVIR	GRAZOPREVIR	O.COC1=CC2=C(C=C1)N=C3CCCCC[C@@H]4C[C@H]4OC(=O)N[C@H](C(=O)N5C[C@@H](C[C@H]5C(=O)N[C@@]6(C[C@H]6C=C)C(=O)NS(=O)(=O)C7CC7)OC3=N2)C(C)(C)C	4O2AB118LA			∞	nM × h	2710.5		nM	198			DEFINED DAILY	mg	50		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/29724498	Homo sapiens		h	16.5							true
8530	9424		ADULT	31402	318.4935	ELTANOLONE	ELTANOLONE	CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	PLASMA	BXO86P3XXW									∞	μg × h/L	163						UNKNOWN	mg/kg	0.5		MULTIPLE	UNKNOWN		4 weeks	2			HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2334030	Homo sapiens		h	1.26	The volunteers received two bolus doses of PE (Pregnanolone  emulsion  (PE) formulated as pregnanolone 4 mg, soya bean oil 200 mg, acetyl triglycerides 70 mg, egg yolk phosphatides 18 mg, glycerol 17 mg) with an interval \nof at least 2 weeks between the first and the second doses.			1	ELTANOLONE		false
8531	9442		ADULT	10299876	487.139	EPROTIROME	EPROTIROME	CC(C)C1=C(O)C=CC(OC2=C(Br)C=C(NC(=O)CC(O)=O)C=C2Br)=C1	PLASMA	958AQ7B6R1																	MAX DAILY	μg	2000		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18160532	Homo sapiens		h	2				6	KB-2115		false
8532	9460		ADULT	71242808	374.4754	EVOCALCET	evocalcet	C[C@@H](N[C@H]1CCN(C1)C2=CC=C(CC(O)=O)C=C2)C3=C4C=CC=CC4=CC=C3	PLASMA	E58MLH082P										ng × h/mL	601.6		ng/mL	59			UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30168004/	Homo sapiens		h	19.77				6			false
8533	9460		ADULT	71242808	374.4754	EVOCALCET	evocalcet	C[C@@H](N[C@H]1CCN(C1)C2=CC=C(CC(O)=O)C=C2)C3=C4C=CC=CC4=CC=C3	PLASMA	E58MLH082P										ng × h/mL	4038.5		ng/mL	376			UNKNOWN	mg	6		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30168004/	Homo sapiens		h	14.76				6			false
8534	9460		ADULT	71242808	374.4754	EVOCALCET	evocalcet	C[C@@H](N[C@H]1CCN(C1)C2=CC=C(CC(O)=O)C=C2)C3=C4C=CC=CC4=CC=C3	PLASMA	E58MLH082P										ng × h/mL	8855.8		ng/mL	867			UNKNOWN	mg	12		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30168004/	Homo sapiens		h	12.98				6			false
8535	9460		ADULT	71242808	374.4754	EVOCALCET	evocalcet	C[C@@H](N[C@H]1CCN(C1)C2=CC=C(CC(O)=O)C=C2)C3=C4C=CC=CC4=CC=C3	PLASMA	E58MLH082P										ng × h/mL	15307.4		ng/mL	1400			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30168004/	Homo sapiens		h	18.89				6			false
8536	9460		ADULT	71242808	374.4754	EVOCALCET	evocalcet	C[C@@H](N[C@H]1CCN(C1)C2=CC=C(CC(O)=O)C=C2)C3=C4C=CC=CC4=CC=C3	PLASMA	E58MLH082P							24		t	ng × h/mL	3860.6		ng/mL	394			UNKNOWN	mg	6		MULTIPLE	FED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30168004/	Homo sapiens		h	18.5				6			false
8537	9460		ADULT	71242808	374.4754	EVOCALCET	evocalcet	C[C@@H](N[C@H]1CCN(C1)C2=CC=C(CC(O)=O)C=C2)C3=C4C=CC=CC4=CC=C3	PLASMA	E58MLH082P							24		t	ng × h/mL	10836.3		ng/mL	1050			UNKNOWN	mg	12		MULTIPLE	FED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30168004/	Homo sapiens		h	16.3				6			false
8538	9460		ADULT	71242808	374.4754	EVOCALCET	evocalcet	C[C@@H](N[C@H]1CCN(C1)C2=CC=C(CC(O)=O)C=C2)C3=C4C=CC=CC4=CC=C3	PLASMA	E58MLH082P									∞	ng × h/mL	1288.5		ng/mL	61.9			UNKNOWN	mg	1		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30254496/	Homo sapiens		h	20.9		Secondary hyperparathyroidism patients receiving hemodialysis		29			false
8539	9460		ADULT	71242808	374.4754	EVOCALCET	evocalcet	C[C@@H](N[C@H]1CCN(C1)C2=CC=C(CC(O)=O)C=C2)C3=C4C=CC=CC4=CC=C3	PLASMA	E58MLH082P									∞	ng × h/mL	5267.8		ng/mL	210			UNKNOWN	mg	4		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30254496/	Homo sapiens		h	22.4		Secondary hyperparathyroidism patients receiving hemodialysis		28			false
8540	9460		ADULT	71242808	374.4754	EVOCALCET	evocalcet	C[C@@H](N[C@H]1CCN(C1)C2=CC=C(CC(O)=O)C=C2)C3=C4C=CC=CC4=CC=C3	PLASMA	E58MLH082P									∞	ng × h/mL	14680.4		ng/mL	706			UNKNOWN	mg	12		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30254496/	Homo sapiens		h	22.5		Secondary hyperparathyroidism patients receiving hemodialysis		26			false
8541	9463		ADULT	25109292	337.392	EZUTROMID	EZUTROMID	CCS(=O)(=O)C1=CC2=C(OC(=N2)C3=CC4=C(C=CC=C4)C=C3)C=C1	PLASMA	645R07LF0D									?	ng × h/mL	830		ng/mL	122			UNKNOWN	mg/kg	200		MULTIPLE	HIGH-FAT		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25651188	Homo sapiens		h	29	day 10			6	EZUTROMID		false
8542	9463		ADULT	25109292	337.392	EZUTROMID	EZUTROMID	CCS(=O)(=O)C1=CC2=C(OC(=N2)C3=CC4=C(C=CC=C4)C=C3)C=C1	PLASMA	645R07LF0D									∞	ng × h/mL	4215		ng/mL	531			UNKNOWN	mg/kg	400		SINGLE	HIGH-FAT						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25651188	Homo sapiens		h	9.8				6	EZUTROMID		false
8543	9463		CHILD	25109292	337.392	EZUTROMID	EZUTROMID	CCS(=O)(=O)C1=CC2=C(OC(=N2)C3=CC4=C(C=CC=C4)C=C3)C=C1	PLASMA	645R07LF0D									∞	ng × h/mL	672		ng/mL	80.6			UNKNOWN	mg	2500		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30650257	Homo sapiens		h	6.53	day 1			12	EZUTROMID		false
8544	9463		ADULT	25109292	337.392	EZUTROMID	EZUTROMID	CCS(=O)(=O)C1=CC2=C(OC(=N2)C3=CC4=C(C=CC=C4)C=C3)C=C1	PLASMA	645R07LF0D									?	ng × h/mL	551		ng/mL	65.7			UNKNOWN	mg	2500		MULTIPLE	FED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30650257	Homo sapiens				day 14 AM			11	EZUTROMID		false
8545	9466			492405|5274251	157.1026	FAVIPIRAVIR	Favipiravir	NC(=O)C1=C(O)N=CC(F)=N1	SERUM	EW5GL2X7E0																										Human serum protein binding (ultrafiltration): 53.4% (0.3μg/mL), 54.4% (3μg/mL), 53.6% (30μg/mL)	45.6				OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_A100_2.pdf#page=36 | https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_I100_1.pdf#page=34	Homo sapiens										false
8546	9466		ADULT	492405|5274251	157.1026	FAVIPIRAVIR	Favipiravir	NC(=O)C1=C(O)N=CC(F)=N1	PLASMA	EW5GL2X7E0									∞	μg × h/mL	42.11		μg/mL	15.58			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_A100_2.pdf#page=70 | https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_K100_1.pdf#page=19	Homo sapiens		h	1.8				12			false
8547	9466		ADULT	492405|5274251	157.1026	FAVIPIRAVIR	Favipiravir	NC(=O)C1=C(O)N=CC(F)=N1	PLASMA	EW5GL2X7E0									∞	μg × h/mL	36.64		μg/mL	7.18			UNKNOWN	mg	400		SINGLE	HIGH-FAT						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_A100_2.pdf#page=70 | https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_K100_1.pdf#page=19	Homo sapiens		h	1.7				12			false
8548	9466		ADULT	492405|5274251	157.1026	FAVIPIRAVIR	Favipiravir	NC(=O)C1=C(O)N=CC(F)=N1	PLASMA	EW5GL2X7E0									∞	μg × h/mL	280.95		μg/mL	44.24			RECOMMENDED	mg	1200		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_A100_2.pdf#page=70 | https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_K100_1.pdf#page=21	Homo sapiens		h	3.4				16			false
8549	9466		ADULT	492405|5274251	157.1026	FAVIPIRAVIR	Favipiravir	NC(=O)C1=C(O)N=CC(F)=N1	PLASMA	EW5GL2X7E0									∞	μg × h/mL	271.58		μg/mL	40.29			RECOMMENDED	mg	1200		SINGLE	HIGH-FAT						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_A100_2.pdf#page=70 | https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_K100_1.pdf#page=21	Homo sapiens		h	3.2				16			false
8550	9466		ADULT	492405|5274251	157.1026	FAVIPIRAVIR	Favipiravir	NC(=O)C1=C(O)N=CC(F)=N1	PLASMA	EW5GL2X7E0									∞	μg × h/mL	9.23		μg/mL	4.06			UNKNOWN	mg	90		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_A100_2.pdf#page=76 | https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_K100_1.pdf#page=50	Homo sapiens		h	1.5				6			false
8551	9466		ADULT	492405|5274251	157.1026	FAVIPIRAVIR	Favipiravir	NC(=O)C1=C(O)N=CC(F)=N1	PLASMA	EW5GL2X7E0									∞	μg × h/mL	1093.62		μg/mL	83.62			UNKNOWN	mg	2000		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_A100_2.pdf#page=76 | https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_K100_1.pdf#page=50	Homo sapiens		h	4.3				6			false
8552	9466		ADULT	492405|5274251	157.1026	FAVIPIRAVIR	Favipiravir	NC(=O)C1=C(O)N=CC(F)=N1	PLASMA	EW5GL2X7E0									∞	μg × h/mL	2.58		μg/mL	1.39			UNKNOWN	mg	30		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_A100_2.pdf#page=76 | https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_K100_1.pdf#page=50	Homo sapiens		h	1.3				6			false
8553	9466		ADULT	492405|5274251	157.1026	FAVIPIRAVIR	Favipiravir	NC(=O)C1=C(O)N=CC(F)=N1	PLASMA	EW5GL2X7E0									∞	μg × h/mL	19.67		μg/mL	8.39			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_A100_2.pdf#page=76 | https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_K100_1.pdf#page=50	Homo sapiens		h	1.5				6			false
8554	9466		ADULT	492405|5274251	157.1026	FAVIPIRAVIR	Favipiravir	NC(=O)C1=C(O)N=CC(F)=N1	PLASMA	EW5GL2X7E0									∞	μg × h/mL	39.41		μg/mL	16.59			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_A100_2.pdf#page=76 | https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_K100_1.pdf#page=50	Homo sapiens		h	1.6				6			false
8555	9466		ADULT	492405|5274251	157.1026	FAVIPIRAVIR	Favipiravir	NC(=O)C1=C(O)N=CC(F)=N1	PLASMA	EW5GL2X7E0									∞	μg × h/mL	113.15		μg/mL	33.35			UNKNOWN	mg	800		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_A100_2.pdf#page=76 | https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_K100_1.pdf#page=50	Homo sapiens		h	2.2				6			false
8556	9466		ADULT	492405|5274251	157.1026	FAVIPIRAVIR	Favipiravir	NC(=O)C1=C(O)N=CC(F)=N1	PLASMA	EW5GL2X7E0									∞	μg × h/mL	538.42		μg/mL	78.61			RECOMMENDED	mg	1600		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_A100_2.pdf#page=76 | https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_K100_1.pdf#page=50	Homo sapiens		h	3.9				6			false
8557	9466		ADULT	492405|5274251	157.1026	FAVIPIRAVIR	Favipiravir	NC(=O)C1=C(O)N=CC(F)=N1	PLASMA	EW5GL2X7E0									∞	μg × h/mL	1297.56		μg/mL	92.17			UNKNOWN	mg	2400		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_A100_2.pdf#page=76 | https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_K100_1.pdf#page=50	Homo sapiens		h	4.5				6			false
8558	9466		ADULT	492405|5274251	157.1026	FAVIPIRAVIR	Favipiravir	NC(=O)C1=C(O)N=CC(F)=N1	PLASMA	EW5GL2X7E0									∞	μg × h/mL	43.66		μg/mL	18.52			UNKNOWN	mg	400		MULTIPLE	FASTED		day	3			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_A100_2.pdf#page=78 | https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_K100_1.pdf#page=52	Homo sapiens		h	1.8	Day 1 (TID on Days 1and 2, QD from Days 3 to 7)			6			false
8559	9466		ADULT	492405|5274251	157.1026	FAVIPIRAVIR	Favipiravir	NC(=O)C1=C(O)N=CC(F)=N1	PLASMA	EW5GL2X7E0									∞	μg × h/mL	381.57		μg/mL	36.15			UNKNOWN	mg	400		MULTIPLE	FASTED		day	3			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_A100_2.pdf#page=78 | https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_K100_1.pdf#page=52	Homo sapiens		h	8.7	Day 4			6			false
8560	9466		ADULT	492405|5274251	157.1026	FAVIPIRAVIR	Favipiravir	NC(=O)C1=C(O)N=CC(F)=N1	PLASMA	EW5GL2X7E0									∞	μg × h/mL	50.02		μg/mL	17.24			UNKNOWN	mg	400		MULTIPLE	FASTED		day	3			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_A100_2.pdf#page=78 | https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_K100_1.pdf#page=52	Homo sapiens		h	2.1	Day 1			6			false
8561	9466		ADULT	492405|5274251	157.1026	FAVIPIRAVIR	Favipiravir	NC(=O)C1=C(O)N=CC(F)=N1	PLASMA	EW5GL2X7E0									∞	μg × h/mL	460.49		μg/mL	43.83			UNKNOWN	mg	400		MULTIPLE	FASTED		day	3			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_A100_2.pdf#page=78 | https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_K100_1.pdf#page=52	Homo sapiens		h	5.2	Day 8			6			false
8562	9466		ADULT	492405|5274251	157.1026	FAVIPIRAVIR	Favipiravir	NC(=O)C1=C(O)N=CC(F)=N1	PLASMA	EW5GL2X7E0									∞	μg × h/mL	81.87		μg/mL	21.88			UNKNOWN	mg	400		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_A100_2.pdf#page=78 | https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_K100_1.pdf#page=52	Homo sapiens		h	2.7	Day 7 (TID on Days 1and 2, QD from Days 3 to 7)			6			false
8563	9466		ADULT	492405|5274251	157.1026	FAVIPIRAVIR	Favipiravir	NC(=O)C1=C(O)N=CC(F)=N1	PLASMA	EW5GL2X7E0									∞	μg × h/mL	91.4		μg/mL	36.24			RECOMMENDED	mg	600		MULTIPLE	FASTED		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_A100_2.pdf#page=78 | https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_K100_1.pdf#page=53	Homo sapiens		h	2.2	Day 1 (BID on Days 1and 2, QD from Days 3 to 7)			6			false
8564	9466		ADULT	492405|5274251	157.1026	FAVIPIRAVIR	Favipiravir	NC(=O)C1=C(O)N=CC(F)=N1	PLASMA	EW5GL2X7E0									∞	μg × h/mL	215.05		μg/mL	36.23			RECOMMENDED	mg	600		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_A100_2.pdf#page=78 | https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_K100_1.pdf#page=53	Homo sapiens		h	3.7	Day 7 (BID on Days 1and 2, QD from Days 3 to 7)			5			false
8565	9466		ADULT	492405|5274251	157.1026	FAVIPIRAVIR	Favipiravir	NC(=O)C1=C(O)N=CC(F)=N1	PLASMA	EW5GL2X7E0									∞	μg × h/mL	151.46		μg/mL	25.56			UNKNOWN	mg	400		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_A100_2.pdf#page=79 | https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_K100_1.pdf#page=56	Homo sapiens		h	3.3	Day 5 (BID from Days 1 to 4, QD on Day 5)	Administered between meals		6			false
8566	9466		ADULT	492405|5274251	157.1026	FAVIPIRAVIR	Favipiravir	NC(=O)C1=C(O)N=CC(F)=N1	PLASMA	EW5GL2X7E0									∞	μg × h/mL	45.55		μg/mL	16.97			UNKNOWN	mg	400		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_A100_2.pdf#page=79 | https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_K100_1.pdf#page=56	Homo sapiens		h	1.8	Day 1 (BID from Days 1 to 4, QD on Day 5)	Administered between meals		6			false
8567	9466		ADULT	492405|5274251	157.1026	FAVIPIRAVIR	Favipiravir	NC(=O)C1=C(O)N=CC(F)=N1	PLASMA	EW5GL2X7E0									∞	μg × h/mL	153.07		μg/mL	31.88			RECOMMENDED	mg	600		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_A100_2.pdf#page=79 | https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_K100_1.pdf#page=56	Homo sapiens		h	3.1	Day 5 (BID on Day 1, QD from Days 2 to 5)	Administered between meals		6			false
8568	9466		ADULT	492405|5274251	157.1026	FAVIPIRAVIR	Favipiravir	NC(=O)C1=C(O)N=CC(F)=N1	PLASMA	EW5GL2X7E0									∞	μg × h/mL	74.57		μg/mL	23			RECOMMENDED	mg	600		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_A100_2.pdf#page=79 | https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_K100_1.pdf#page=56	Homo sapiens		h	2.1	Day 1 (BID on Day 1, QD from Days 2 to 5)	Administered between meals		6			false
8569	9466		ADULT	492405|5274251	157.1026	FAVIPIRAVIR	Favipiravir	NC(=O)C1=C(O)N=CC(F)=N1	PLASMA	EW5GL2X7E0									∞	μg × h/mL	475.22		μg/mL	51.6			RECOMMENDED	mg	1200		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_A100_2.pdf#page=80 | https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_K100_1.pdf#page=60	Homo sapiens		h	7	Day 1 (1200mg on Day 1 (dose 1), 400mg on Day1 (dose 2), 400mg BID from Days 2 to 6, 400mg QD on Day 7)	Administered between meals		6			false
8570	9466		ADULT	492405|5274251	157.1026	FAVIPIRAVIR	Favipiravir	NC(=O)C1=C(O)N=CC(F)=N1	PLASMA	EW5GL2X7E0									∞	μg × h/mL	203.87		μg/mL	43.04			RECOMMENDED	mg	1200		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_A100_2.pdf#page=80 | https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_K100_1.pdf#page=60	Homo sapiens		h	3	Day 1 (1200mg on Day 1 (dose 1), 600mg on Day1 (dose 2), 600mg BID from Days 2 to 6, 600mg QD on Day 7)	Administered between meals		6			false
8571	9466		ADULT	492405|5274251	157.1026	FAVIPIRAVIR	Favipiravir	NC(=O)C1=C(O)N=CC(F)=N1	PLASMA	EW5GL2X7E0									∞	μg × h/mL	504.87		μg/mL	40.55			UNKNOWN	mg	400		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_A100_2.pdf#page=80 | https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_K100_1.pdf#page=60	Homo sapiens		h	6.7	Day 7 (1200mg on Day 1 (dose 1), 400mg on Day1 (dose 2), 400mg BID from Days 2 to 6, 400mg QD on Day 7)	Administered between meals		6			false
8572	9466		ADULT	492405|5274251	157.1026	FAVIPIRAVIR	Favipiravir	NC(=O)C1=C(O)N=CC(F)=N1	PLASMA	EW5GL2X7E0									∞	μg × h/mL	805.28		μg/mL	61.49			RECOMMENDED	mg	600		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_A100_2.pdf#page=80 | https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_K100_1.pdf#page=60	Homo sapiens		h	4.8	Day 7 (1200mg on Day 1 (dose 1), 600mg on Day1 (dose 2), 600mg BID from Days 2 to 6, 600mg QD on Day 7)	Administered between meals		5			false
8573	9466		ADULT	492405|5274251	157.1026	FAVIPIRAVIR	Favipiravir	NC(=O)C1=C(O)N=CC(F)=N1	PLASMA	EW5GL2X7E0							24		t	μg × h/mL	957		μg/mL	57.6			UNKNOWN	mg	800		MULTIPLE	FASTED		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_A100_2.pdf#page=88 | https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_K100_1.pdf#page=94	Homo sapiens				Day 5 (1200mg BID on Day 1, 800mg BID from Days 2 to 5)	US subjects		58			false
8574	9466		ADULT	492405|5274251	157.1026	FAVIPIRAVIR	Favipiravir	NC(=O)C1=C(O)N=CC(F)=N1	PLASMA	EW5GL2X7E0							24		t	μg × h/mL	346		μg/mL	35.9			RECOMMENDED	mg	1200		MULTIPLE	FASTED		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_A100_2.pdf#page=88 | https://www.pmda.go.jp/drugs/2014/P201400047/480297000_22600AMX00533_K100_1.pdf#page=94	Homo sapiens				Day 1 (1200mg BID on Day 1, 800mg BID from Days 2 to 5)	US subjects		58			false
8575	9482		ADULT	54708673	503.6358	FILIBUVIR	FILIBUVIR	CCC1=CC(CC[C@@]2(CC(O)=C(CC3=NN4C(=N3)N=C(C)C=C4C)C(=O)O2)C5CCCC5)=CC(CC)=N1	PLASMA	198J479Y2L							12		t	ng × h/mL	291172		ng/mL	50274			UNKNOWN	mg	700		MULTIPLE	FED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21488067	Homo sapiens		h	7.47	day 3			10	FILIBUVIR		false
8576	9482		ADULT	54708673	503.6358	FILIBUVIR	FILIBUVIR	CCC1=CC(CC[C@@]2(CC(O)=C(CC3=NN4C(=N3)N=C(C)C=C4C)C(=O)O2)C5CCCC5)=CC(CC)=N1	PLASMA	198J479Y2L							12		t	ng × h/mL	198507		ng/mL	38735			UNKNOWN	mg	700		SINGLE	FED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21488067	Homo sapiens				day 1			10	FILIBUVIR		false
8577	9482		UNKNOWN	54708673	503.6358	FILIBUVIR	FILIBUVIR	CCC1=CC(CC[C@@]2(CC(O)=C(CC3=NN4C(=N3)N=C(C)C=C4C)C(=O)O2)C5CCCC5)=CC(CC)=N1	PLASMA	198J479Y2L																	UNKNOWN				UNKNOWN	UNKNOWN					2.12	UNKNOWN	UNKNOWN	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23183437	Homo sapiens								FILIBUVIR		false
8578	9499		ADULT	6451149	578.5917	NETUPITANT	NETUPITANT	CN(C(=O)C(C)(C)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C2=C(C=C(N=C2)N3CCN(C)CC3)C4=C(C)C=CC=C4	PLASMA	7732P08TIR									?	ng × h/mL	14401		ng/mL	434			RECOMMENDED	mg	300		SINGLE	UNKNOWN				Human plasma protein binding of netupitant is greater than 99.5% at drug concentrations ranging from 10-1300 ng/mL and protein binding of its major metabolites (M1, M2 and M3) is greater than 97% at drug concentrations ranging from 100 to 2000 ng/mL.	0.5	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205718s000lbl.pdf	Homo sapiens		h	96							false
8579	9524		ADULT	71576667	784.919	GRAZOPREVIR	GRAZOPREVIR	O.COC1=CC2=C(C=C1)N=C3CCCCC[C@@H]4C[C@H]4OC(=O)N[C@H](C(=O)N5C[C@@H](C[C@H]5C(=O)N[C@@]6(C[C@H]6C=C)C(=O)NS(=O)(=O)C7CC7)OC3=N2)C(C)(C)C	PLASMA	4O2AB118LA				ELBASVIR			24		t	ng × h/mL	1420		ng/mL	165			RECOMMENDED	mg	100		STEADY-STATE	UNKNOWN		day	1	Elbasvir and grazoprevir are extensively bound (greater than 99.9% and 98.8%, respectively) to human plasma proteins.	1.2	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208261s006lbl.pdf	Homo sapiens		h	31							true
8580	9537		ADULT	60199242	389.487	VENGLUSTAT	IBIGLUSTAT	CC(C)(NC(=O)O[C@@H]1CN2CCC1CC2)C3=CSC(=N3)C4=CC=C(F)C=C4	PLASMA	BLP1XA3FZA							24		t	ng × h/mL	2420		ng/mL	142			UNKNOWN	mg	20		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32851809	Homo sapiens		h	35	Day 14; venglustat L-malate 20 mg (provided as 5-mg capsules; free venglustat dose - 14.9 mg)			9	IBIGLUSTAT		false
8581	9537		ADULT	60199242	389.487	VENGLUSTAT	IBIGLUSTAT	CC(C)(NC(=O)O[C@@H]1CN2CCC1CC2)C3=CSC(=N3)C4=CC=C(F)C=C4	PLASMA	BLP1XA3FZA									∞	ng × h/mL	20600		ng/mL	529			UNKNOWN	mg	150		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32851809	Homo sapiens		h	26.9	150 mg of venglustatL-malate (providing 112 mg of free venglustat)			5	IBIGLUSTAT		false
8582	9537		ADULT	60199242	389.487	VENGLUSTAT	IBIGLUSTAT	CC(C)(NC(=O)O[C@@H]1CN2CCC1CC2)C3=CSC(=N3)C4=CC=C(F)C=C4	PLASMA	BLP1XA3FZA							24		t	ng × h/mL	1100		ng/mL	68			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32851809	Homo sapiens				Day 1; venglustat L-malate 20 mg (provided as 5-mg capsules; free venglustat dose - 14.9 mg)			9	IBIGLUSTAT		false
8583	9541		UNKNOWN	53358942	616.482	IDASANUTLIN	IDASANUTLIN	COC1=C(NC(=O)[C@@H]2N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]2C3=C(F)C(Cl)=CC=C3)C4=C(F)C=C(Cl)C=C4)C=CC(=C1)C(O)=O	PLASMA	QSQ883V35U																						UNKNOWN				Later, the more precise plasma protein binding data were measured and confirmed that 99.99% of protein was bound in human plasma.	0.01	UNKNOWN		UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26586447	Homo sapiens										false
8584	9547		ADULT	3083511	279.722	IMEPITOIN	IMEPITOIN	ClC1=CC=C(C=C1)N2CC(=NC2=O)N3CCOCC3	UNKNOWN	19V39682LI																	UNKNOWN	mg	200		MULTIPLE	UNKNOWN		day	3			HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/24357084/	Homo sapiens		h	8.18	1 week dosing				IMEPITOIN		false
8585	9547		ADULT	3083511	279.722	IMEPITOIN	IMEPITOIN	ClC1=CC=C(C=C1)N2CC(=NC2=O)N3CCOCC3	UNKNOWN	19V39682LI																	UNKNOWN	mg	300		MULTIPLE	UNKNOWN		day	3			HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/24357084/	Homo sapiens		h	19.6	1 week dosing				IMEPITOIN		false
8586	9547		ADULT	3083511	279.722	IMEPITOIN	IMEPITOIN	ClC1=CC=C(C=C1)N2CC(=NC2=O)N3CCOCC3	UNKNOWN	19V39682LI																	UNKNOWN	mg	500		MULTIPLE	UNKNOWN		day	3			HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/24357084/	Homo sapiens		h	14.3	1 week dosing				IMEPITOIN		false
8587	9550		ADULT	2929	389.834	INDIBULIN	INDIBULIN	ClC1=CC=C(CN2C=C(C(=O)C(=O)NC3=CC=NC=C3)C4=C2C=CC=C4)C=C1	PLASMA	80K4H2RB8P							24		t	ng × h/mL	597		ng/mL	95			UNKNOWN	mg	600		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/19404582	Homo sapiens		h	24							false
8588	9556		ADULT	9796068	292.0307	INIPARIB	INIPARIB	NC(=O)C1=CC=C(I)C(=C1)[N ]([O-])=O	PLASMA	2ZWI7KHK8F													ng/mL	1517			MAX TOLERATED	mg/kg	8.6		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26285766	Homo sapiens				Iniparib was administered intravenously (IV) on two consecutive days weekly (weeks 1-4)			5	INIPARIB		false
8589	9556		ADULT	9796068	292.0307	INIPARIB	INIPARIB	NC(=O)C1=CC=C(I)C(=C1)[N ]([O-])=O	PLASMA	2ZWI7KHK8F													ng/mL	2139			UNKNOWN	mg/kg	9.5		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26285766	Homo sapiens				Iniparib was administered intravenously (IV) on two consecutive days weekly (weeks 1-4)			4	INIPARIB		false
8590	9556		ADULT	9796068	292.0307	INIPARIB	INIPARIB	NC(=O)C1=CC=C(I)C(=C1)[N ]([O-])=O	PLASMA	2ZWI7KHK8F	60750|426756	263.1981|371.25	Gemcitabine|Carboplatin	Gemcitabine|Carboplatin	NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F|C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt 2]	B76N6SBZ8R|BG3F62OND5			?	ng × h/mL	2420		ng/mL	2410			UNKNOWN	mg/kg	5.6		MULTIPLE	UNKNOWN		week	2			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31172407	Homo sapiens		h	1.4	day 11			32	INIPARIB		true
8591	9556		ADULT	9796068	292.0307	INIPARIB	INIPARIB	NC(=O)C1=CC=C(I)C(=C1)[N ]([O-])=O	PLASMA	2ZWI7KHK8F	60750|426756	263.1981|371.25	Gemcitabine|Carboplatin	Gemcitabine|Carboplatin	NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F|C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt 2]	B76N6SBZ8R|BG3F62OND5			?	ng × h/mL	2060		ng/mL	2190			UNKNOWN	mg/kg	5.6		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31172407	Homo sapiens		h	0.65	day 1			34	INIPARIB		true
8592	9556		ADULT	9796068	292.0307	INIPARIB	INIPARIB	NC(=O)C1=CC=C(I)C(=C1)[N ]([O-])=O	PLASMA	2ZWI7KHK8F	60750|426756	263.1981|371.25	Gemcitabine|Carboplatin	Gemcitabine|Carboplatin	NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F|C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt 2]	B76N6SBZ8R|BG3F62OND5			?	ng × h/mL	4160		ng/mL	3820			UNKNOWN	mg/kg	11.2		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31172407	Homo sapiens		h	0.92				34	INIPARIB		true
8593	9556		ADULT	9796068	292.0307	INIPARIB	INIPARIB	NC(=O)C1=CC=C(I)C(=C1)[N ]([O-])=O	PLASMA	2ZWI7KHK8F	60750|426756	263.1981|371.25	GEMCITABINE|Carboplatin	Gemcitabine|Carboplatin	NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F|C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt 2]	B76N6SBZ8R|BG3F62OND5			?	ng × h/mL	3610		ng/mL	3790			UNKNOWN	mg/kg	11.2		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31172407	Homo sapiens		h	1.32	day 8			33	INIPARIB		true
8594	9595		UNKNOWN	25183872	361.029	IXAZOMIB	IXAZOMIB	CC(C)C[C@H](NC(=O)CNC(=O)C1=C(Cl)C=CC(Cl)=C1)B(O)O	PLASMA	71050168A2																						UNKNOWN				Ixazomib is 99% bound to plasma proteins and distributes into red blood cells with a blood-to-plasma ratio of 10.	1	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208462lbl.pdf	Homo sapiens										false
8595	9595		ADULT	25183872	361.029	IXAZOMIB	IXAZOMIB	CC(C)C[C@H](NC(=O)CNC(=O)C1=C(Cl)C=CC(Cl)=C1)B(O)O	BLOOD	71050168A2							216		t	ng × h/mL	1470		ng/mL	77			UNKNOWN	mg	4		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26872892	Homo sapiens										false
8596	9595		ADULT	25183872	361.029	IXAZOMIB	IXAZOMIB	CC(C)C[C@H](NC(=O)CNC(=O)C1=C(Cl)C=CC(Cl)=C1)B(O)O	BLOOD	71050168A2							216		t	ng × h/mL	999		ng/mL	22.8			UNKNOWN	mg	4		SINGLE	HIGH-FAT						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26872892	Homo sapiens										false
8597	9601		ADULT	6441636	390.5131	LATANOPROST ACID	Latanoprost acid	O[C@H](CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\\C=C/CCCC(O)=O)CCC2=CC=CC=C2	PLASMA	EJ85341990													pg/mL	56.95			UNKNOWN	drop	2		MULTIPLE	UNKNOWN		day	1			HEALTHY	Ocular	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207795Orig1s000ClinPharmR.pdf#page=21	Homo sapiens				Day 1, 0.024% eye drops, 1 drop/eye x both eyes			16			false
8598	9601		ADULT	6441636	390.5131	LATANOPROST ACID	Latanoprost acid	O[C@H](CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\\C=C/CCCC(O)=O)CCC2=CC=CC=C2	PLASMA	EJ85341990													pg/mL	42.3			UNKNOWN	drop	2		MULTIPLE	UNKNOWN		day	1			HEALTHY	Ocular	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207795Orig1s000ClinPharmR.pdf#page=21	Homo sapiens				Day 28, 0.024% eye drops, 1 drop/eye x both eyes			13			false
8599	9610		ADULT	53465279	404.281	LESINURAD	LESINURAD	OC(=O)CSC1=NN=C(Br)N1C2=CC=C(C3CC3)C4=C2C=CC=C4	PLASMA	09ERP08I3W							24		t	μg × h/mL	0.787		μg/mL	0.303			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26170627/	Homo sapiens		h	2.73							false
8600	9610		ADULT	53465279	404.281	LESINURAD	LESINURAD	OC(=O)CSC1=NN=C(Br)N1C2=CC=C(C3CC3)C4=C2C=CC=C4	PLASMA	09ERP08I3W							24		t	μg × h/mL	3.12		μg/mL	1.54			UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26170627/	Homo sapiens		h	3.99							false
8601	9610		ADULT	53465279	404.281	LESINURAD	LESINURAD	OC(=O)CSC1=NN=C(Br)N1C2=CC=C(C3CC3)C4=C2C=CC=C4	PLASMA	09ERP08I3W							24		t	μg × h/mL	17.5		μg/mL	7.68			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26170627/	Homo sapiens		h	12.7							false
8602	9610		ADULT	53465279	404.281	LESINURAD	LESINURAD	OC(=O)CSC1=NN=C(Br)N1C2=CC=C(C3CC3)C4=C2C=CC=C4	PLASMA	09ERP08I3W							24		t	μg × h/mL	31.9		μg/mL	11.8			DEFINED DAILY	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26170627/	Homo sapiens		h	5.97							false
8603	9610		ADULT	53465279	404.281	LESINURAD	LESINURAD	OC(=O)CSC1=NN=C(Br)N1C2=CC=C(C3CC3)C4=C2C=CC=C4	PLASMA	09ERP08I3W							24		t	μg × h/mL	10.9		μg/mL	3.21			UNKNOWN	mg	100		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26170627/	Homo sapiens		h	34.6							false
8604	9610		ADULT	53465279	404.281	LESINURAD	LESINURAD	OC(=O)CSC1=NN=C(Br)N1C2=CC=C(C3CC3)C4=C2C=CC=C4	PLASMA	09ERP08I3W							24		t	μg × h/mL	56.4		μg/mL	17.7			UNKNOWN	mg	400		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26170627/	Homo sapiens		h	5.19							false
8605	9610		ADULT	53465279	404.281	LESINURAD	LESINURAD	OC(=O)CSC1=NN=C(Br)N1C2=CC=C(C3CC3)C4=C2C=CC=C4	PLASMA	09ERP08I3W							24		t	μg × h/mL	106		μg/mL	22			UNKNOWN	mg	600		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26170627/	Homo sapiens		h	8.04							false
8606	9610		ADULT	53465279	404.281	LESINURAD	LESINURAD	OC(=O)CSC1=NN=C(Br)N1C2=CC=C(C3CC3)C4=C2C=CC=C4	PLASMA	09ERP08I3W							24		t	μg × h/mL	14.2		μg/mL	4.74			UNKNOWN	mg	100		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26170627/	Homo sapiens		h	4.23							false
8607	9610		ADULT	53465279	404.281	LESINURAD	LESINURAD	OC(=O)CSC1=NN=C(Br)N1C2=CC=C(C3CC3)C4=C2C=CC=C4	PLASMA	09ERP08I3W							24		t	μg × h/mL	12.1		μg/mL	4.02			UNKNOWN	mg	100		MULTIPLE	FED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26170627/	Homo sapiens		h	10.6							false
8608	9610		ADULT	53465279	404.281	LESINURAD	lesinurad	OC(=O)CSC1=NN=C(Br)N1C2=CC=C(C3CC3)C4=C2C=CC=C4	PLASMA	09ERP08I3W							24		t	μg × h/mL	29.8		μg/mL	5.54			DEFINED DAILY	mg	200		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26170627/	Homo sapiens		h	3.77							false
8609	9610		ADULT	53465279	404.281	LESINURAD	LESINURAD	OC(=O)CSC1=NN=C(Br)N1C2=CC=C(C3CC3)C4=C2C=CC=C4	PLASMA	09ERP08I3W							24		t	μg × h/mL	30.3		μg/mL	6.51			RECOMMENDED	mg	200		MULTIPLE	FED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26170627/	Homo sapiens		h	8.2							false
8610	9610		ADULT	53465279	404.281	LESINURAD	LESINURAD	OC(=O)CSC1=NN=C(Br)N1C2=CC=C(C3CC3)C4=C2C=CC=C4	PLASMA	09ERP08I3W							24		t	μg × h/mL	28.7		μg/mL	10.8			DEFINED DAILY	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26170627/	Homo sapiens		h	4.72							false
8611	9610		ADULT	53465279	404.281	LESINURAD	LESINURAD	OC(=O)CSC1=NN=C(Br)N1C2=CC=C(C3CC3)C4=C2C=CC=C4	PLASMA	09ERP08I3W							24		t	μg × h/mL	33.1		μg/mL	11.7			RECOMMENDED	mg	200		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26170627/	Homo sapiens		h	8.91							false
8612	9610		ADULT	53465279	404.281	LESINURAD	LESINURAD	OC(=O)CSC1=NN=C(Br)N1C2=CC=C(C3CC3)C4=C2C=CC=C4	PLASMA	09ERP08I3W							24		t	μg × h/mL	70.5		μg/mL	23.1			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26170627/	Homo sapiens		h	8.91							false
8613	9610		ADULT	53465279	404.281	LESINURAD	LESINURAD	OC(=O)CSC1=NN=C(Br)N1C2=CC=C(C3CC3)C4=C2C=CC=C4	PLASMA	09ERP08I3W							24		t	μg × h/mL	89.8		μg/mL	21.9			UNKNOWN	mg	400		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26170627/	Homo sapiens		h	7.48							false
8614	9617		ADULT	36604	149.2328	LEVMETAMFETAMINE	LEVMETAMFETAMINE	CN[C@H](C)CC1=CC=CC=C1	PLASMA	Y24T9BT2Q2									∞	ng × h/mL	1190.7		ng/mL	65.4			UNKNOWN	mg/kg	0.25		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17015058/	Homo sapiens		h	13.6				12	LEVMETAMFETAMINE		false
8615	9618		ADULT	10917	161.1989	LEVOCARNITINE	LEVOCARNITINE	C[N+](C)(C)C[C@H](O)CC([O-])=O	PLASMA										?	nmol × h/mL	779.9		nmol/mL	80.3			UNKNOWN	g	2		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7658356	Homo sapiens										false
8616	9618		ADULT	10917	161.1989	LEVOCARNITINE	LEVOCARNITINE	C[N+](C)(C)C[C@H](O)CC([O-])=O	PLASMA										?	nmol × h/mL	771.4		nmol/mL	79.2			UNKNOWN	mg	1980		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7658356	Homo sapiens										false
8617	9621		ADULT	3883	369.361	LEVOLANSOPRAZOLE	Levolansoprazole	CC1=C(C[S ]([O-])C2=NC3=C(N2)C=CC=C3)N=CC=C1OCC(F)(F)F	PLASMA	FB55O16184									?	ng × h/mL	524		ng/mL	337			UNKNOWN	mg	60		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16755125/	Homo sapiens		h	0.6		Homozygous extensive metabolizers (CYP2C19)		8	Racemic lansoprazole		false
8618	9621		ADULT	3883	369.361	LEVOLANSOPRAZOLE	Levolansoprazole	CC1=C(C[S ]([O-])C2=NC3=C(N2)C=CC=C3)N=CC=C1OCC(F)(F)F	PLASMA	FB55O16184									?	ng × h/mL	967		ng/mL	528			UNKNOWN	mg	60		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16755125/	Homo sapiens		h	0.7		Heterozygous extensive metabolizers (CYP2C19)		8	Racemic lansoprazole		false
8619	9621		ADULT	3883	369.361	LEVOLANSOPRAZOLE	Levolansoprazole	CC1=C(C[S ]([O-])C2=NC3=C(N2)C=CC=C3)N=CC=C1OCC(F)(F)F	PLASMA	FB55O16184									?	ng × h/mL	3892		ng/mL	1156			UNKNOWN	mg	60		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16755125/	Homo sapiens		h	1.6		Poor metabolizers (CYP2C19)		8	Racemic lansoprazole		false
8620	9621		ADULT	3883	369.361	LEVOLANSOPRAZOLE	Levolansoprazole	CC1=C(C[S ]([O-])C2=NC3=C(N2)C=CC=C3)N=CC=C1OCC(F)(F)F	PLASMA	FB55O16184									?	ng × h/mL	451		ng/mL	167			UNKNOWN	mg	30		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16755125/	Homo sapiens		h	1.2	28 days	Extensive metabolizers (CYP2C19) with renal transplantation		8	Racemic lansoprazole		false
8621	9621		ADULT	3883	369.361	LEVOLANSOPRAZOLE	Levolansoprazole	CC1=C(C[S ]([O-])C2=NC3=C(N2)C=CC=C3)N=CC=C1OCC(F)(F)F	PLASMA	FB55O16184									∞	ng × h/mL	1161.07		ng/mL	848.13			UNKNOWN	mg	30		MULTIPLE	FASTED		day	2			HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31338800/	Homo sapiens		h	1.02	Day 1 (single dose)			14	Racemic lansoprazole		false
8622	9621		ADULT	3883	369.361	LEVOLANSOPRAZOLE	Levolansoprazole	CC1=C(C[S ]([O-])C2=NC3=C(N2)C=CC=C3)N=CC=C1OCC(F)(F)F	PLASMA	FB55O16184									∞	ng × h/mL	1180.29		ng/mL	811.63			UNKNOWN	mg	30		MULTIPLE	FASTED		day	2			HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31338800/	Homo sapiens		h	0.87	Day 5			14	Racemic lansoprazole		false
8623	9621		ADULT	3883	369.361	LEVOLANSOPRAZOLE	Levolansoprazole	CC1=C(C[S ]([O-])C2=NC3=C(N2)C=CC=C3)N=CC=C1OCC(F)(F)F	SERUM	FB55O16184									∞	μg × h/mL	1.56		μg/mL	0.36			UNKNOWN	mg	30		SINGLE	FASTED				ultrafiltration	5.8	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8710755/	Homo sapiens							6	Racemic Lansoprazole		false
8624	9625		ADULT	9844194	405.435	LEVONEBIVOLOL	Levonebivolol	O[C@@H](CNC[C@H](O)[C@@H]1CCC2=C(O1)C=CC(F)=C2)[C@H]3CCC4=CC(F)=CC=C4O3	PLASMA	GMK2E335DQ									∞	ng × h/mL	9.4		ng/mL	2.5			UNKNOWN	mg	10		SINGLE	FASTED						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24141040/	Homo sapiens		h	14.5		patient with systemic arterial hypertension		1	Racemic nebivolol		false
8625	9625		ADULT	9844194	405.435	LEVONEBIVOLOL	Levonebivolol	O[C@@H](CNC[C@H](O)[C@@H]1CCC2=C(O1)C=CC(F)=C2)[C@H]3CCC4=CC(F)=CC=C4O3	PLASMA	GMK2E335DQ									∞	ng × h/mL	6.83		ng/mL	1.31			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26914703/	Homo sapiens		h	13.79		Normal renal function		22	Racemic nebivolol		false
8626	9625		ADULT	9844194	405.435	LEVONEBIVOLOL	Levonebivolol	O[C@@H](CNC[C@H](O)[C@@H]1CCC2=C(O1)C=CC(F)=C2)[C@H]3CCC4=CC(F)=CC=C4O3	PLASMA	GMK2E335DQ									∞	ng × h/mL	9.94		ng/mL	1.98			UNKNOWN	mg	10		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26914703/	Homo sapiens		h	12.43		Chronic kidney disease patients		12	Racemic nebivolol		false
8627	9625		ADULT	9844194	405.435	LEVONEBIVOLOL	Levonebivolol	O[C@@H](CNC[C@H](O)[C@@H]1CCC2=C(O1)C=CC(F)=C2)[C@H]3CCC4=CC(F)=CC=C4O3	PLASMA	GMK2E335DQ									∞	ng × h/mL	6.41		ng/mL	1.38			UNKNOWN	mg	10		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26914703/	Homo sapiens		h	12.87		Hemodialysis patients		12	Racemic nebivolol		false
8628	9625		ADULT	9844194	405.435	LEVONEBIVOLOL	Levonebivolol	O[C@@H](CNC[C@H](O)[C@@H]1CCC2=C(O1)C=CC(F)=C2)[C@H]3CCC4=CC(F)=CC=C4O3	PLASMA	GMK2E335DQ									?	μg × h/mL	48						UNKNOWN	mg/kg	0.073		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9112066/	Homo sapiens		h	12.1				8	Racemic nebivolol		false
8629	9625		ADULT	9844194	405.435	LEVONEBIVOLOL	Levonebivolol	O[C@@H](CNC[C@H](O)[C@@H]1CCC2=C(O1)C=CC(F)=C2)[C@H]3CCC4=CC(F)=CC=C4O3	PLASMA	GMK2E335DQ									?	μg × h/mL	36.7						UNKNOWN	mg/kg	0.073		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9112066/	Homo sapiens		h	11.3		Obese subjects		8	Racemic nebivolol		false
8630	9625			9844194	405.435	LEVONEBIVOLOL	Levonebivolol	O[C@@H](CNC[C@H](O)[C@@H]1CCC2=C(O1)C=CC(F)=C2)[C@H]3CCC4=CC(F)=CC=C4O3	PLASMA	GMK2E335DQ																										Binding to plasma protein (mainly albumins) is hardly stereospecific (98.1  -0.2% for D-nebivolol; 98.0 -0.3% for Lnebivolol).	2				REVIEW	https://pubmed.ncbi.nlm.nih.gov/9990650/	Homo sapiens										false
8631	9627		ADULT	35805	457.6038	LEVORMELOXIFENE	Levormeloxifene	COC1=CC2=C(C=C1)[C@H]([C@H](C3=CC=CC=C3)C(C)(C)O2)C4=CC=C(OCCN5CCCC5)C=C4	PLASMA	9512UKZ352									∞	ng × h/mL	9771		ng/mL	147			UNKNOWN	mg	40		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11219480/	Homo sapiens		h	126		Postmenopausal white women (50~58 y)		15			false
8632	9627		ADULT	35805	457.6038	LEVORMELOXIFENE	Levormeloxifene	COC1=CC2=C(C=C1)[C@H]([C@H](C3=CC=CC=C3)C(C)(C)O2)C4=CC=C(OCCN5CCCC5)C=C4	PLASMA	9512UKZ352									∞	ng × h/mL	12181		ng/mL	141			UNKNOWN	mg	40		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11219480/	Homo sapiens		h	151		Postmenopausal white women (66~79 y)		13			false
8633	9627		ADULT	35805	457.6038	LEVORMELOXIFENE	Levormeloxifene	COC1=CC2=C(C=C1)[C@H]([C@H](C3=CC=CC=C3)C(C)(C)O2)C4=CC=C(OCCN5CCCC5)C=C4	PLASMA	9512UKZ352									?	μg × h/mL	3.2		ng/mL	27			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11874392/	Homo sapiens		h	8.4		Postmenopausal women		6			false
8634	9627		ADULT	35805	457.6038	LEVORMELOXIFENE	Levormeloxifene	COC1=CC2=C(C=C1)[C@H]([C@H](C3=CC=CC=C3)C(C)(C)O2)C4=CC=C(OCCN5CCCC5)C=C4	PLASMA	9512UKZ352									?	μg × h/mL	26		ng/mL	443			UNKNOWN	mg	80		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11874392/	Homo sapiens		h	5.8		Postmenopausal women		6			false
8635	9627		ADULT	35805	457.6038	LEVORMELOXIFENE	Levormeloxifene	COC1=CC2=C(C=C1)[C@H]([C@H](C3=CC=CC=C3)C(C)(C)O2)C4=CC=C(OCCN5CCCC5)C=C4	PLASMA	9512UKZ352													ng/mL	5.6			UNKNOWN	mg	2.5		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11874392/	Homo sapiens					Postmenopausal women		6			false
8636	9627		ADULT	35805	457.6038	LEVORMELOXIFENE	Levormeloxifene	COC1=CC2=C(C=C1)[C@H]([C@H](C3=CC=CC=C3)C(C)(C)O2)C4=CC=C(OCCN5CCCC5)C=C4	PLASMA	9512UKZ352									?	μg × h/mL	10		ng/mL	128			UNKNOWN	mg	30		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11874392/	Homo sapiens		h	6.9		Postmenopausal women		6			false
8637	9627		ADULT	35805	457.6038	LEVORMELOXIFENE	Levormeloxifene	COC1=CC2=C(C=C1)[C@H]([C@H](C3=CC=CC=C3)C(C)(C)O2)C4=CC=C(OCCN5CCCC5)C=C4	PLASMA	9512UKZ352									?	μg × h/mL	64		ng/mL	1115			UNKNOWN	mg	160		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11874392/	Homo sapiens		h	5.4		Postmenopausal women		6			false
8638	9627		ADULT	35805	457.6038	LEVORMELOXIFENE	Levormeloxifene	COC1=CC2=C(C=C1)[C@H]([C@H](C3=CC=CC=C3)C(C)(C)O2)C4=CC=C(OCCN5CCCC5)C=C4	PLASMA	9512UKZ352									?	μg × h/mL	129		ng/mL	2737			UNKNOWN	mg	320		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11874392/	Homo sapiens		h	6		Postmenopausal women		6			false
8639	9627		ADULT	35805	457.6038	LEVORMELOXIFENE	Levormeloxifene	COC1=CC2=C(C=C1)[C@H]([C@H](C3=CC=CC=C3)C(C)(C)O2)C4=CC=C(OCCN5CCCC5)C=C4	PLASMA	9512UKZ352							24		t	μg × h/mL	1		ng/mL	71			UNKNOWN	mg	20		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11874392/	Homo sapiens				1st dose (35-day administration)	Postmenopausal women		6			false
8640	9627		ADULT	35805	457.6038	LEVORMELOXIFENE	Levormeloxifene	COC1=CC2=C(C=C1)[C@H]([C@H](C3=CC=CC=C3)C(C)(C)O2)C4=CC=C(OCCN5CCCC5)C=C4	PLASMA	9512UKZ352							24		t	μg × h/mL	4.7		ng/mL	254			UNKNOWN	mg	20		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11874392/	Homo sapiens		h	5.9	Last dose (35-day administration)	Postmenopausal women		6			false
8641	9627		ADULT	35805	457.6038	LEVORMELOXIFENE	Levormeloxifene	COC1=CC2=C(C=C1)[C@H]([C@H](C3=CC=CC=C3)C(C)(C)O2)C4=CC=C(OCCN5CCCC5)C=C4	PLASMA	9512UKZ352							24		t	μg × h/mL	19.8		ng/mL	1081			UNKNOWN	mg	80		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11874392/	Homo sapiens		h	5.4	Last dose (35-day administration)	Postmenopausal women		6			false
8642	9627		ADULT	35805	457.6038	LEVORMELOXIFENE	Levormeloxifene	COC1=CC2=C(C=C1)[C@H]([C@H](C3=CC=CC=C3)C(C)(C)O2)C4=CC=C(OCCN5CCCC5)C=C4	PLASMA	9512UKZ352							24		t	μg × h/mL	9		ng/mL	769			UNKNOWN	mg	160		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11874392/	Homo sapiens				1st dose (35-day administration)	Postmenopausal women		6			false
8643	9627		ADULT	35805	457.6038	LEVORMELOXIFENE	Levormeloxifene	COC1=CC2=C(C=C1)[C@H]([C@H](C3=CC=CC=C3)C(C)(C)O2)C4=CC=C(OCCN5CCCC5)C=C4	PLASMA	9512UKZ352							24		t	μg × h/mL	33.4		ng/mL	2031			UNKNOWN	mg	160		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11874392/	Homo sapiens		h	5.5	Last dose (35-day administration)	Postmenopausal women		12			false
8644	9627		ADULT	35805	457.6038	LEVORMELOXIFENE	Levormeloxifene	COC1=CC2=C(C=C1)[C@H]([C@H](C3=CC=CC=C3)C(C)(C)O2)C4=CC=C(OCCN5CCCC5)C=C4	PLASMA	9512UKZ352							24		t	μg × h/mL	2.4		ng/mL	182			UNKNOWN	mg	40		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11874392/	Homo sapiens				1st dose (56-day administration)	Postmenopausal women		12			false
8645	9627		ADULT	35805	457.6038	LEVORMELOXIFENE	Levormeloxifene	COC1=CC2=C(C=C1)[C@H]([C@H](C3=CC=CC=C3)C(C)(C)O2)C4=CC=C(OCCN5CCCC5)C=C4	PLASMA	9512UKZ352							24		t	μg × h/mL	8.5		ng/mL	477			UNKNOWN	mg	40		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11874392/	Homo sapiens		h	5.1	Last day (56-day administration)	Postmenopausal women		12			false
8646	9627		ADULT	35805	457.6038	LEVORMELOXIFENE	Levormeloxifene	COC1=CC2=C(C=C1)[C@H]([C@H](C3=CC=CC=C3)C(C)(C)O2)C4=CC=C(OCCN5CCCC5)C=C4	PLASMA	9512UKZ352							24		t	μg × h/mL	4.8		ng/mL	387			UNKNOWN	mg	80		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11874392/	Homo sapiens				1st dose (35-day administration)	Postmenopausal women		6			false
8647	9627		ADULT	35805	457.6038	LEVORMELOXIFENE	Levormeloxifene	COC1=CC2=C(C=C1)[C@H]([C@H](C3=CC=CC=C3)C(C)(C)O2)C4=CC=C(OCCN5CCCC5)C=C4	PLASMA	9512UKZ352							24		t	μg × h/mL	4.9		ng/mL	377			UNKNOWN	mg	80		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11874392/	Homo sapiens				1st day (56-day administration)	Postmenopausal women		12			false
8648	9627		ADULT	35805	457.6038	LEVORMELOXIFENE	Levormeloxifene	COC1=CC2=C(C=C1)[C@H]([C@H](C3=CC=CC=C3)C(C)(C)O2)C4=CC=C(OCCN5CCCC5)C=C4	PLASMA	9512UKZ352							24		t	μg × h/mL	15.2		ng/mL	879			UNKNOWN	mg	80		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11874392/	Homo sapiens		h	4.8	Last day (56-day administration)	Postmenopausal women		12			false
8649	9627		ADULT	35805	457.6038	LEVORMELOXIFENE	Levormeloxifene	COC1=CC2=C(C=C1)[C@H]([C@H](C3=CC=CC=C3)C(C)(C)O2)C4=CC=C(OCCN5CCCC5)C=C4	PLASMA	9512UKZ352																						UNKNOWN				Human plasma protein binding: 97.3~99.9% (equilibrium dialysis)	0.1	HEALTHY		UNKNOWN	EXPERIMENT	https://www.sciencedirect.com/science/article/pii/S0940299398800018#page=114	Homo sapiens							12			false
8650	9633		ADULT	11965427	615.481	LIFITEGRAST	LIFITEGRAST	CS(=O)(=O)C1=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(CN(CC3)C(=O)C4=CC5=C(C=CO5)C=C4)C=C2Cl)C(O)=O)=CC=C1	AQUEOUS HUMOR	038E5L962W									?	ng × h/mL	311.929		ng/mL	74.792			RECOMMENDED	%	5		SINGLE	UNKNOWN						HEALTHY	Ocular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20334535	Homo sapiens										false
8651	9633		ADULT	11965427	615.481	LIFITEGRAST	LIFITEGRAST	CS(=O)(=O)C1=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(CN(CC3)C(=O)C4=CC5=C(C=CO5)C=C4)C=C2Cl)C(O)=O)=CC=C1	AQUEOUS HUMOR	038E5L962W									?	ng × h/mL	127.594		ng/mL	91.413			RECOMMENDED	%	5		MULTIPLE	UNKNOWN		day	2			HEALTHY	Ocular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20334535	Homo sapiens										false
8652	9633		ADULT	11965427	615.481	LIFITEGRAST	LIFITEGRAST	CS(=O)(=O)C1=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(CN(CC3)C(=O)C4=CC5=C(C=CO5)C=C4)C=C2Cl)C(O)=O)=CC=C1	AQUEOUS HUMOR	038E5L962W									?	ng × h/mL	101.009		ng/mL	126.383			RECOMMENDED	%	5		MULTIPLE	UNKNOWN		day	3			HEALTHY	Ocular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20334535	Homo sapiens										false
8653	9633		ADULT	11965427	615.481	LIFITEGRAST	LIFITEGRAST	CS(=O)(=O)C1=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(CN(CC3)C(=O)C4=CC5=C(C=CO5)C=C4)C=C2Cl)C(O)=O)=CC=C1	AQUEOUS HUMOR	038E5L962W									?	ng × h/mL	52.238		ng/mL	16.222			UNKNOWN	%	1		SINGLE	UNKNOWN						HEALTHY	Ocular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20334535	Homo sapiens										false
8654	9633		ADULT	11965427	615.481	LIFITEGRAST	LIFITEGRAST	CS(=O)(=O)C1=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(CN(CC3)C(=O)C4=CC5=C(C=CO5)C=C4)C=C2Cl)C(O)=O)=CC=C1	AQUEOUS HUMOR	038E5L962W									?	ng × h/mL	62.443		ng/mL	34.763			UNKNOWN	%	1		MULTIPLE	UNKNOWN		day	2			HEALTHY	Ocular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20334535	Homo sapiens										false
8655	9633		ADULT	11965427	615.481	LIFITEGRAST	LIFITEGRAST	CS(=O)(=O)C1=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(CN(CC3)C(=O)C4=CC5=C(C=CO5)C=C4)C=C2Cl)C(O)=O)=CC=C1	AQUEOUS HUMOR	038E5L962W									?	ng × h/mL	29.537		ng/mL	27.457			UNKNOWN	%	1		MULTIPLE	UNKNOWN		day	3			HEALTHY	Ocular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20334535	Homo sapiens										false
8656	9633		ADULT	11965427	615.481	LIFITEGRAST	LIFITEGRAST	CS(=O)(=O)C1=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(CN(CC3)C(=O)C4=CC5=C(C=CO5)C=C4)C=C2Cl)C(O)=O)=CC=C1	AQUEOUS HUMOR	038E5L962W									?	ng × h/mL	2.457		ng/mL	10.756			UNKNOWN	%	0.3		SINGLE	UNKNOWN						HEALTHY	Ocular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20334535	Homo sapiens										false
8657	9633		ADULT	11965427	615.481	LIFITEGRAST	LIFITEGRAST	CS(=O)(=O)C1=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(CN(CC3)C(=O)C4=CC5=C(C=CO5)C=C4)C=C2Cl)C(O)=O)=CC=C1	AQUEOUS HUMOR	038E5L962W									?	ng × h/mL	24.793		ng/mL	24.395			UNKNOWN	%	0.3		MULTIPLE	UNKNOWN		day	2			HEALTHY	Ocular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20334535	Homo sapiens										false
8658	9633		ADULT	11965427	615.481	LIFITEGRAST	LIFITEGRAST	CS(=O)(=O)C1=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(CN(CC3)C(=O)C4=CC5=C(C=CO5)C=C4)C=C2Cl)C(O)=O)=CC=C1	AQUEOUS HUMOR	038E5L962W									?	ng × h/mL	7.432		ng/mL	7.49			UNKNOWN	%	0.3		MULTIPLE	UNKNOWN		day	3			HEALTHY	Ocular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20334535	Homo sapiens										false
8659	9633		UNKNOWN	11965427	615.481	LIFITEGRAST	LIFITEGRAST	CS(=O)(=O)C1=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(CN(CC3)C(=O)C4=CC5=C(C=CO5)C=C4)C=C2Cl)C(O)=O)=CC=C1	PLASMA	038E5L962W																					UNKNOWN	UNKNOWN				Human plasma protein binding of lifitegrast was approximately 99%, independent of concentration (50 to 1000 ng/mL). Binding to isolated human serum albumin was 95% to 98%, and 31.6% to 51.1% to human α1-acid glycoprotein.	1	UNKNOWN	Ocular	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208073Orig1s000ClinPharmR.pdf	Homo sapiens										false
8660	9647		ADULT	49843517	591.546	LUSUTROMBOPAG	LUSUTROMBOPAG	CCCCCCO[C@@H](C)C1=C(OC)C(=CC=C1)C2=CSC(NC(=O)C3=CC(Cl)=C(\\C=C(/C)C(O)=O)C(Cl)=C3)=N2	PLASMA	6LL5JFU42F									?	ng × h/mL	3381		ng/mL	181			RECOMMENDED	mg	3		STEADY-STATE	UNKNOWN		day	1	Lusutrombopag was shown to be highly bound to human plasma proteins, with a high binding ratio of 99.996% or more at concentrations ranging from 5 to 50 µg/mL.		HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.ema.europa.eu/en/documents/assessment-report/lusutrombopag-shionogi-epar-public-assessment-report_en.pdf	Homo sapiens										false
8661	9647		ADULT	49843517	591.546	LUSUTROMBOPAG	LUSUTROMBOPAG	CCCCCCO[C@@H](C)C1=C(OC)C(=CC=C1)C2=CSC(NC(=O)C3=CC(Cl)=C(\\C=C(/C)C(O)=O)C(Cl)=C3)=N2	PLASMA	6LL5JFU42F									?	ng × h/mL	4187		ng/mL	191			RECOMMENDED	mg	3		STEADY-STATE	UNKNOWN		day	1	Lusutrombopag was shown to be highly bound to human plasma proteins, with a high binding ratio of 99.996% or more at concentrations ranging from 5 to 50 µg/mL.		UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.ema.europa.eu/en/documents/assessment-report/lusutrombopag-shionogi-epar-public-assessment-report_en.pdf	Homo sapiens										false
8662	9647		ADULT	49843517	591.546	LUSUTROMBOPAG	LUSUTROMBOPAG	CCCCCCO[C@@H](C)C1=C(OC)C(=CC=C1)C2=CSC(NC(=O)C3=CC(Cl)=C(\\C=C(/C)C(O)=O)C(Cl)=C3)=N2	PLASMA	6LL5JFU42F									?	ng × h/mL	3678		ng/mL	170			RECOMMENDED	mg	3		STEADY-STATE	UNKNOWN		day	1	Lusutrombopag was shown to be highly bound to human plasma proteins, with a high binding ratio of 99.996% or more at concentrations ranging from 5 to 50 µg/mL.		UNHEALTHY	Oral	MALE	OTHER GOV'T	https://www.ema.europa.eu/en/documents/assessment-report/lusutrombopag-shionogi-epar-public-assessment-report_en.pdf	Homo sapiens										false
8663	9647		ADULT	49843517	591.546	LUSUTROMBOPAG	LUSUTROMBOPAG	CCCCCCO[C@@H](C)C1=C(OC)C(=CC=C1)C2=CSC(NC(=O)C3=CC(Cl)=C(\\C=C(/C)C(O)=O)C(Cl)=C3)=N2	PLASMA	6LL5JFU42F									?	ng × h/mL	4808		ng/mL	217			RECOMMENDED	mg	3		STEADY-STATE	UNKNOWN		day	1	Lusutrombopag was shown to be highly bound to human plasma proteins, with a high binding ratio of 99.996% or more at concentrations ranging from 5 to 50 µg/mL.		UNHEALTHY	Oral	FEMALE	OTHER GOV'T	https://www.ema.europa.eu/en/documents/assessment-report/lusutrombopag-shionogi-epar-public-assessment-report_en.pdf	Homo sapiens										false
8664	9654		ADULT	11347535	313.777	MARIZOMIB	MARIZOMIB	C[C@@]12OC(=O)[C@@]1(NC(=O)[C@@H]2CCCl)[C@@H](O)[C@H]3CCCC=C3	BLOOD	703P9YDP7F													ng/mL	34.53			MAX DAILY	mg/m²	0.9		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27117181	Homo sapiens		min	30							false
8665	9657		ADULT	9926832	313.3908	MAVOGLURANT	MAVOGLURANT	COC(=O)N1CC[C@@H]2[C@H]1CCC[C@@]2(O)C#CC3=CC=CC(C)=C3	PLASMA	GT0I9SV4F6							24		∞	nM × h	6292		nM	447			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23775850	Homo sapiens		h	12				4	MAVOGLURANT		false
8666	9657		ADULT	9926832	313.3908	MAVOGLURANT	MAVOGLURANT	COC(=O)N1CC[C@@H]2[C@H]1CCC[C@@]2(O)C#CC3=CC=CC(C)=C3	PLASMA	GT0I9SV4F6									∞	ng × h/mL	1760		ng/mL	832			UNKNOWN	mg	50		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27823869	Homo sapiens		h	9.11				12	MAVOGLURANT		false
8667	9660		ADULT	123868	146.1876	MELDONIUM	MELDONIUM	C[N ](C)(C)NCCC([O-])=O	PLASMA	73H7UDN6EC									∞	mg × h/L	22.25		μg/mL	11			UNKNOWN	mg	250		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20116348/	Homo sapiens		h	5.56				10	MELDONIUM		false
8668	9660		ADULT	123868	146.1876	MELDONIUM	MELDONIUM	C[N ](C)(C)NCCC([O-])=O	PLASMA	73H7UDN6EC									∞	mg × h/L	47.85		μg/mL	22.71			UNKNOWN	mg	500		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20116348/	Homo sapiens		h	6.46				10	MELDONIUM		false
8669	9660		ADULT	123868	146.1876	MELDONIUM	MELDONIUM	C[N ](C)(C)NCCC([O-])=O	PLASMA	73H7UDN6EC									∞	mg × h/L	85.4		μg/mL	39.3			HIGHEST STUDIED	mg	1000		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20116348/	Homo sapiens		h	6.55				10	MELDONIUM		false
8670	9660		ADULT	123868	146.1876	MELDONIUM	MELDONIUM	C[N ](C)(C)NCCC([O-])=O	PLASMA	73H7UDN6EC									∞	mg × h/L	76.26		μg/mL	25.5			RECOMMENDED	mg	500		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20116348/	Homo sapiens		h	15.34	6 days dosing			10	MELDONIUM		false
8671	9660		ADULT	123868	146.1876	MELDONIUM	MELDONIUM	C[N ](C)(C)NCCC([O-])=O	PLASMA	73H7UDN6EC									∞	mg × h/L	33.57		mg/L	5.89			UNKNOWN	mg	250		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21679246/	Homo sapiens		h	3.61				10	MELDONIUM		false
8672	9660		ADULT	123868	146.1876	MELDONIUM	MELDONIUM	C[N ](C)(C)NCCC([O-])=O	PLASMA	73H7UDN6EC									∞	mg × h/L	70.79		mg/L	13.75			UNKNOWN	mg	500		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21679246/	Homo sapiens		h	5.28				10	MELDONIUM		false
8673	9660		ADULT	123868	146.1876	MELDONIUM	MELDONIUM	C[N ](C)(C)NCCC([O-])=O	PLASMA	73H7UDN6EC									∞	mg × h/L	135.4		mg/L	30.38			UNKNOWN	mg	1000		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21679246/	Homo sapiens		h	6.09				10	MELDONIUM		false
8674	9660		ADULT	123868	146.1876	MELDONIUM	MELDONIUM	C[N ](C)(C)NCCC([O-])=O	PLASMA	73H7UDN6EC									∞	mg × h/L	163.76		mg/L	35.5			UNKNOWN	mg	1250		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21679246/	Homo sapiens		h	6.07				10	MELDONIUM		false
8675	9660		ADULT	123868	146.1876	MELDONIUM	MELDONIUM	C[N ](C)(C)NCCC([O-])=O	PLASMA	73H7UDN6EC									∞	mg × h/L	281.12		mg/L	23.97			UNKNOWN	mg	500		STEADY-STATE	UNKNOWN		day	3			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21679246/	Homo sapiens		h	14.6	13 days dosing			10	MELDONIUM		false
8676	9660		ADULT	123868	146.1876	MELDONIUM	MELDONIUM	C[N ](C)(C)NCCC([O-])=O	PLASMA	73H7UDN6EC									∞	mg × h/L	206.45		mg/L	46.27			HIGHEST STUDIED	mg	1500		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21679246/	Homo sapiens		h	6.58				10	MELDONIUM		false
8677	9678		ADULT	7456	152.1473	METHYLPARABEN	methylparaben	COC(=O)C1=CC=C(O)C=C1	SERUM	A2I8C7HI9T	7175	180.2005	PROPYLPARABEN	propylparaben	CCCOC(=O)C1=CC=C(O)C=C1	Z8IX2SC1OH			∞	μM × h	1.4		nM	57			UNKNOWN	mg	62.4		SINGLE	UNKNOWN						HEALTHY	Transdermal	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/36220432/	Homo sapiens		h	12.2	An ingredient of a paraben mixture cream containing 0.26% methylparaben, 0.26% ethylparaben, and 0.28% propylparaben.			5	methylparaben		true
8678	9688		ADULT	5284380	307.965	MITOLACTOL	MITOLACTOL	O[C@@H](CBr)[C@@H](O)[C@@H](O)[C@H](O)CBr	PLASMA	LJ2P1SIK8Y									?	nM × min	24.7		μM	81.9			UNKNOWN	mg/m²	1800		SINGLE	FASTED						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3517245	Homo sapiens		min	92.4				1	MITOLACTOL		false
8679	9691		ADULT	44449087	473.392	MONEPANTEL	MONEPANTEL	C[C@](COC1=C(C=CC(=C1)C#N)C(F)(F)F)(NC(=O)C2=CC=C(SC(F)(F)F)C=C2)C#N	PLASMA	82MA79VJ33									∞	ng × h/mL	1590		ng/mL	194			UNKNOWN	mg/kg bw	5		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32960289/	Homo sapiens		h	15				4	MONEPANTEL		false
8680	9735		ADULT	71811910	554.7	OMAVELOXOLONE	OMAVELOXOLONE	CC(F)(F)C(=O)N[C@]12CCC(C)(C)C[C@H]1[C@H]3C(=O)C=C4[C@@]5(C)C=C(C#N)C(=O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)CC2	PLASMA	G69Z98951Q							24		t	ng × h/mL	114.4		ng/mL	15.7			UNKNOWN	mg	20		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/28919776	Homo sapiens		h	9.2							false
8681	9736		ADULT	6918405	402.4409	OMBRABULIN	OMBRABULIN	COC1=CC(\\C=C/C2=CC(NC(=O)[C@@H](N)CO)=C(OC)C=C2)=CC(OC)=C1OC	PLASMA	82JB1524Q6									∞	ng × h/mL	750		ng/mL	1800			RECOMMENDED	mg/m²	50		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24477603	Homo sapiens		min	17.6				6	OMBRABULIN		false
8682	9738		ADULT	25167777	505.496	OMIPALISIB	OMIPALISIB	COC1=NC=C(C=C1NS(=O)(=O)C2=C(F)C=C(F)C=C2)C3=CC4=C(C=C3)N=CC=C4C5=CN=NC=C5	PLASMA	1X8F5A3NA0							24		t	ng × h/mL	474		ng/mL	42.1			MAX TOLERATED	mg	2.5		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26603258	Homo sapiens										false
8683	9742		ADULT	135565903	413.169	OPICAPONE	OPICAPONE	CC1=C(Cl)C(C)=[N+]([O-])C(Cl)=C1C2=NOC(=N2)C3=CC(O)=C(O)C(=C3)[N+]([O-])=O	PLASMA	Y5929UIJ5N							24		t	ng × h/mL	238		ng/mL	95			UNKNOWN	mg	5		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23336248/	Homo sapiens		h	1.1							false
8684	9742		ADULT	135565903	413.169	OPICAPONE	OPICAPONE	CC1=C(Cl)C(C)=[N+]([O-])C(Cl)=C1C2=NOC(=N2)C3=CC(O)=C(O)C(=C3)[N+]([O-])=O	PLASMA	Y5929UIJ5N							24		t	ng × h/mL	1441		ng/mL	301			UNKNOWN	mg	30		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23336248/	Homo sapiens		h	1.4							false
8685	9742		ADULT	135565903	413.169	OPICAPONE	OPICAPONE	CC1=C(Cl)C(C)=[N+]([O-])C(Cl)=C1C2=NOC(=N2)C3=CC(O)=C(O)C(=C3)[N+]([O-])=O	PLASMA	Y5929UIJ5N							24		t	ng × h/mL	124		ng/mL	58			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23336248/	Homo sapiens										false
8686	9742		ADULT	135565903	413.169	OPICAPONE	OPICAPONE	CC1=C(Cl)C(C)=[N+]([O-])C(Cl)=C1C2=NOC(=N2)C3=CC(O)=C(O)C(=C3)[N+]([O-])=O	PLASMA	Y5929UIJ5N							24		t	ng × h/mL	1432		ng/mL	343			UNKNOWN	mg	30		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23336248/	Homo sapiens		h	1.4							false
8687	9742		ADULT	135565903	413.169	OPICAPONE	OPICAPONE	CC1=C(Cl)C(C)=[N+]([O-])C(Cl)=C1C2=NOC(=N2)C3=CC(O)=C(O)C(=C3)[N+]([O-])=O	PLASMA	Y5929UIJ5N									∞	ng × h/mL	1321		ng/mL	424.5			RECOMMENDED	mg	25		SINGLE	FASTED				Opicapone is highly bound to plasma proteins (99.9%).	0.1	HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212489Orig1s000SumR.pdf	Homo sapiens		h	0.97							false
8688	9742		ADULT	135565903	413.169	OPICAPONE	OPICAPONE	CC1=C(Cl)C(C)=[N+]([O-])C(Cl)=C1C2=NOC(=N2)C3=CC(O)=C(O)C(=C3)[N+]([O-])=O	PLASMA	Y5929UIJ5N									∞	ng × h/mL	2244		ng/mL	756.2			RECOMMENDED	mg	50		SINGLE	FASTED				Opicapone is highly bound to plasma proteins (99.9%).	0.1	HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212489Orig1s000SumR.pdf	Homo sapiens		h	0.92							false
8689	9747		ADULT	5496659	446.4983	OTAMIXABAN	otamixaban	COC(=O)[C@H](CC1=CC(=CC=C1)C(N)=N)[C@@H](C)NC(=O)C2=CC=C(C=C2)C3=CC=[N ]([O-])C=C3	PLASMA	S173RED00L							24		t	ng × h/mL	6476		ng/mL	252			UNKNOWN	μg/kg/h	100	infusion, 24 hour	OTHER	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17178269	Homo sapiens							20	otamixaban		false
8690	9747		ADULT	5496659	446.4983	OTAMIXABAN	otamixaban	COC(=O)[C@H](CC1=CC(=CC=C1)C(N)=N)[C@@H](C)NC(=O)C2=CC=C(C=C2)C3=CC=[N ]([O-])C=C3	PLASMA	S173RED00L							24		t	ng × h/mL	12007		ng/mL	458			UNKNOWN	μg/kg/h	125	infusion, 24 hour	OTHER	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17178269	Homo sapiens							20	otamixaban		false
8691	9747		ADULT	5496659	446.4983	OTAMIXABAN	otamixaban	COC(=O)[C@H](CC1=CC(=CC=C1)C(N)=N)[C@@H](C)NC(=O)C2=CC=C(C=C2)C3=CC=[N ]([O-])C=C3	PLASMA	S173RED00L							24		t	ng × h/mL	15674		ng/mL	635			UNKNOWN	μg/kg/h	150	infusion, 24 hour	OTHER	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17178269	Homo sapiens							20	otamixaban		false
8692	9747		ADULT	5496659	446.4983	OTAMIXABAN	otamixaban	COC(=O)[C@H](CC1=CC(=CC=C1)C(N)=N)[C@@H](C)NC(=O)C2=CC=C(C=C2)C3=CC=[N ]([O-])C=C3	PLASMA	S173RED00L							24		t	ng × h/mL	2437		ng/mL	85			UNKNOWN	μg/kg/h	50	infusion, 24 hour	OTHER	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17178269	Homo sapiens							20	otamixaban		false
8693	9748		ADULT	10480380	482.4	N-Desethyl otenabant	CE-156,706		SERUM	SRU4YD01MF									∞	ng × h/mL	3966		ng/mL	42			UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22187487	Homo sapiens		h	139				5	CP-945,598		false
8694	9748		ADULT	10052040	510.418	OTENABANT	CP-945,598	CCNC1(CCN(CC1)C2=C3N=C(N(C3=NC=N2)C4=CC=C(Cl)C=C4)C5=C(Cl)C=CC=C5)C(N)=O	SERUM	J8211Y53EF									∞	ng × h/mL	0.01		ng/mL	14			UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22187487	Homo sapiens		h	159				5	CP-945,598		false
8695	9753		UNKNOWN	9863827	363.4097	OZENOXACIN	CC1=CC(=CN=C1NC)C2=C(C3=C(C=C2)C(=O)C(=CN3C4CC4)C(=O)O)C	CNC1=NC=C(C=C1C)C2=C(C)C3=C(C=C2)C(=O)C(=CN3C4CC4)C(O)=O	PLASMA	V0LH498RFO																	UNKNOWN				UNKNOWN	UNKNOWN		UNKNOWN			22.5	UNKNOWN	Topical	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208945lbl.pdf	Homo sapiens										false
8696	9756		ADULT	459963|5480200|6529858|44332876|58665287	364.3978	PAFURAMIDINE	pafuramidine	CONC(=N)C1=CC=C(C=C1)C2=CC=C(O2)C3=CC=C(C=C3)C(=N)NOC	PLASMA	H1VG379J2X							144		t	ng × h/mL	292		ng/mL	15.9			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19346370	Homo sapiens		h	17.2				15	pafuramidine		false
8697	9756		ADULT	126437	304.3	Furamidine	Furamidine	C1=CC(=CC=C1C2=CC=C(O2)C3=CC=C(C=C3)C(=N)N)C(=N)N	PLASMA	08GH1YF0RA							144		t	ng × h/mL	112		ng/mL	3.6			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	PATENT	https://pubmed.ncbi.nlm.nih.gov/19346370	Homo sapiens		h	30.9				14	pafuramidine		false
8698	9760		ADULT	16220188	406.3833	PAMAPIMOD	Pamapimod	CN1C(=O)C(OC2=C(F)C=C(F)C=C2)=CC3=C1N=C(NC(CCO)CCO)N=C3	PLASMA	8S2C9V11K4							24		t	μg × h/mL	21.9		μg/mL	6.7			UNKNOWN	mg	300		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20100913	Homo sapiens		h	4.2				15	Pamapimod		false
8699	9770		ADULT	11526038	490.5476	PEMAFIBRATE	Pemafibrate	CC[C@@H](OC1=CC(CN(CCCOC2=CC=C(OC)C=C2)C3=NC4=C(O3)C=CC=C4)=CC=C1)C(O)=O	PLASMA	17VGG92R23																						UNKNOWN				Human plasma protein Fu=0.15% (500ng/mL), 0.17% (2500ng/mL), 0.17% (10000ng/mL), equilibrium dialysis	0.15	HEALTHY		MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_A100_1.pdf#page=33 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_I100_1.pdf#page=112	Homo sapiens							3			false
8700	9770		ADULT	11526038	490.5476	PEMAFIBRATE	Pemafibrate	CC[C@@H](OC1=CC(CN(CCCOC2=CC=C(OC)C=C2)C3=NC4=C(O3)C=CC=C4)=CC=C1)C(O)=O	PLASMA	17VGG92R23									∞	ng × h/mL	5.75		ng/mL	1.82			RECOMMENDED	mg	0.1		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_A100_1.pdf#page=33 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=270	Homo sapiens		h	1.88				16			false
8701	9770		ADULT	11526038	490.5476	PEMAFIBRATE	Pemafibrate	CC[C@@H](OC1=CC(CN(CCCOC2=CC=C(OC)C=C2)C3=NC4=C(O3)C=CC=C4)=CC=C1)C(O)=O	PLASMA	17VGG92R23									∞	ng × h/mL	5.18		ng/mL	1.54			RECOMMENDED	mg	0.1		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_A100_1.pdf#page=33 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=270	Homo sapiens		h	1.73				16			false
8702	9770		ADULT	11526038	490.5476	PEMAFIBRATE	Pemafibrate	CC[C@@H](OC1=CC(CN(CCCOC2=CC=C(OC)C=C2)C3=NC4=C(O3)C=CC=C4)=CC=C1)C(O)=O	PLASMA	17VGG92R23									∞	ng × h/mL	15.936		ng/mL	4.504			UNKNOWN	mg	0.3		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_A100_1.pdf#page=36 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=55	Homo sapiens		h	2.061				8			false
8703	9770		ADULT	11526038	490.5476	PEMAFIBRATE	Pemafibrate	CC[C@@H](OC1=CC(CN(CCCOC2=CC=C(OC)C=C2)C3=NC4=C(O3)C=CC=C4)=CC=C1)C(O)=O	PLASMA	17VGG92R23									∞	ng × h/mL	24.031		ng/mL	6.007			UNKNOWN	mg	0.5		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_A100_1.pdf#page=36 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=55	Homo sapiens		h	2.06				8			false
8704	9770		ADULT	11526038	490.5476	PEMAFIBRATE	Pemafibrate	CC[C@@H](OC1=CC(CN(CCCOC2=CC=C(OC)C=C2)C3=NC4=C(O3)C=CC=C4)=CC=C1)C(O)=O	PLASMA	17VGG92R23									∞	ng × h/mL	54.538		ng/mL	14.325			UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_A100_1.pdf#page=36 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=55	Homo sapiens		h	2.435				8			false
8705	9770		ADULT	11526038	490.5476	PEMAFIBRATE	Pemafibrate	CC[C@@H](OC1=CC(CN(CCCOC2=CC=C(OC)C=C2)C3=NC4=C(O3)C=CC=C4)=CC=C1)C(O)=O	PLASMA	17VGG92R23							24		t	ng × h/mL	4.468		ng/mL	1.175			UNKNOWN	mg	0.1		MULTIPLE	FED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_A100_1.pdf#page=36 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=86	Homo sapiens				Day 1			8			false
8706	9770		ADULT	11526038	490.5476	PEMAFIBRATE	Pemafibrate	CC[C@@H](OC1=CC(CN(CCCOC2=CC=C(OC)C=C2)C3=NC4=C(O3)C=CC=C4)=CC=C1)C(O)=O	PLASMA	17VGG92R23							24		t	ng × h/mL	4.04		ng/mL	1.172			UNKNOWN	mg	0.1		MULTIPLE	FED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_A100_1.pdf#page=36 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=86	Homo sapiens		h	1.494	Day 7			8			false
8707	9770		ADULT	11526038	490.5476	PEMAFIBRATE	Pemafibrate	CC[C@@H](OC1=CC(CN(CCCOC2=CC=C(OC)C=C2)C3=NC4=C(O3)C=CC=C4)=CC=C1)C(O)=O	PLASMA	17VGG92R23							24		t	ng × h/mL	9.239		ng/mL	2.328			UNKNOWN	mg	0.2		MULTIPLE	FED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_A100_1.pdf#page=36 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=86	Homo sapiens				Day 1			8			false
8708	9770		ADULT	11526038	490.5476	PEMAFIBRATE	Pemafibrate	CC[C@@H](OC1=CC(CN(CCCOC2=CC=C(OC)C=C2)C3=NC4=C(O3)C=CC=C4)=CC=C1)C(O)=O	PLASMA	17VGG92R23							24		t	ng × h/mL	9.024		ng/mL	2.524			UNKNOWN	mg	0.2		MULTIPLE	FED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_A100_1.pdf#page=36 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=86	Homo sapiens		h	1.562	Day 7			8			false
8709	9770		ADULT	11526038	490.5476	PEMAFIBRATE	Pemafibrate	CC[C@@H](OC1=CC(CN(CCCOC2=CC=C(OC)C=C2)C3=NC4=C(O3)C=CC=C4)=CC=C1)C(O)=O	PLASMA	17VGG92R23							24		t	ng × h/mL	25.608		ng/mL	6.374			UNKNOWN	mg	0.4		MULTIPLE	FED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_A100_1.pdf#page=36 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=86	Homo sapiens				Day 1			8			false
8710	9770		ADULT	11526038	490.5476	PEMAFIBRATE	Pemafibrate	CC[C@@H](OC1=CC(CN(CCCOC2=CC=C(OC)C=C2)C3=NC4=C(O3)C=CC=C4)=CC=C1)C(O)=O	PLASMA	17VGG92R23							24		t	ng × h/mL	23.305		ng/mL	6.775			UNKNOWN	mg	0.4		MULTIPLE	FED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_A100_1.pdf#page=36 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=86	Homo sapiens		h	1.806	Day 7			8			false
8711	9770		ADULT	11526038	490.5476	PEMAFIBRATE	Pemafibrate	CC[C@@H](OC1=CC(CN(CCCOC2=CC=C(OC)C=C2)C3=NC4=C(O3)C=CC=C4)=CC=C1)C(O)=O	PLASMA	17VGG92R23							12		t	ng × h/mL	4.884		ng/mL	1.401			UNKNOWN	mg	0.2		MULTIPLE	FED		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_A100_1.pdf#page=36 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=86	Homo sapiens				Day 1			8			false
8712	9770		ADULT	11526038	490.5476	PEMAFIBRATE	Pemafibrate	CC[C@@H](OC1=CC(CN(CCCOC2=CC=C(OC)C=C2)C3=NC4=C(O3)C=CC=C4)=CC=C1)C(O)=O	PLASMA	17VGG92R23							12		t	ng × h/mL	5.404		ng/mL	1.593			UNKNOWN	mg	0.2		MULTIPLE	FED		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_A100_1.pdf#page=36 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=86	Homo sapiens		h	1.528	Day 7			8			false
8713	9770		ADULT	11526038	490.5476	PEMAFIBRATE	Pemafibrate	CC[C@@H](OC1=CC(CN(CCCOC2=CC=C(OC)C=C2)C3=NC4=C(O3)C=CC=C4)=CC=C1)C(O)=O	PLASMA	17VGG92R23							12		t	ng × h/mL	10.975		ng/mL	2.968			UNKNOWN	mg	0.4		MULTIPLE	FED		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_A100_1.pdf#page=36 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=86	Homo sapiens				Day 1			8			false
8714	9770		ADULT	11526038	490.5476	PEMAFIBRATE	Pemafibrate	CC[C@@H](OC1=CC(CN(CCCOC2=CC=C(OC)C=C2)C3=NC4=C(O3)C=CC=C4)=CC=C1)C(O)=O	PLASMA	17VGG92R23							12		t	ng × h/mL	25.858		ng/mL	6.334			UNKNOWN	mg	0.8		MULTIPLE	FED		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_A100_1.pdf#page=36 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=86	Homo sapiens				Day 1			8			false
8715	9770		ADULT	11526038	490.5476	PEMAFIBRATE	Pemafibrate	CC[C@@H](OC1=CC(CN(CCCOC2=CC=C(OC)C=C2)C3=NC4=C(O3)C=CC=C4)=CC=C1)C(O)=O	PLASMA	17VGG92R23							12		t	ng × h/mL	12.207		ng/mL	3.572			UNKNOWN	mg	0.4		MULTIPLE	FED		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_A100_1.pdf#page=36 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=86	Homo sapiens		h	1.708	Day 7			8			false
8716	9770		ADULT	11526038	490.5476	PEMAFIBRATE	Pemafibrate	CC[C@@H](OC1=CC(CN(CCCOC2=CC=C(OC)C=C2)C3=NC4=C(O3)C=CC=C4)=CC=C1)C(O)=O	PLASMA	17VGG92R23							12		t	ng × h/mL	29.768		ng/mL	7.229			UNKNOWN	mg	0.8		MULTIPLE	FED		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_A100_1.pdf#page=36 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=86	Homo sapiens		h	2.088	Day 7			8			false
8717	9770		ADULT	11526038	490.5476	PEMAFIBRATE	Pemafibrate	CC[C@@H](OC1=CC(CN(CCCOC2=CC=C(OC)C=C2)C3=NC4=C(O3)C=CC=C4)=CC=C1)C(O)=O	PLASMA	17VGG92R23							12		t	ng × h/mL	9.17		ng/mL	2.38			UNKNOWN	mg	0.4		MULTIPLE	FED		day	2			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_A100_1.pdf#page=37 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=110	Homo sapiens		h	2.09	Day 7	non-Japanese		10			false
8718	9770		ADULT	11526038	490.5476	PEMAFIBRATE	Pemafibrate	CC[C@@H](OC1=CC(CN(CCCOC2=CC=C(OC)C=C2)C3=NC4=C(O3)C=CC=C4)=CC=C1)C(O)=O	PLASMA	17VGG92R23							12		t	ng × h/mL	17.07		ng/mL	5.57			UNKNOWN	mg	0.8		MULTIPLE	FED		day	2			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_A100_1.pdf#page=37 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=110	Homo sapiens		h	2.05	Day 1	non-Japanese		10			false
8719	9770		ADULT	11526038	490.5476	PEMAFIBRATE	Pemafibrate	CC[C@@H](OC1=CC(CN(CCCOC2=CC=C(OC)C=C2)C3=NC4=C(O3)C=CC=C4)=CC=C1)C(O)=O	PLASMA	17VGG92R23							12		t	ng × h/mL	22.67		ng/mL	5.96			UNKNOWN	mg	0.8		MULTIPLE	FED		day	2			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_A100_1.pdf#page=37 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=110	Homo sapiens		h	2.44	Day 7	non-Japanese		10			false
8720	9770		ADULT	11526038	490.5476	PEMAFIBRATE	Pemafibrate	CC[C@@H](OC1=CC(CN(CCCOC2=CC=C(OC)C=C2)C3=NC4=C(O3)C=CC=C4)=CC=C1)C(O)=O	PLASMA	17VGG92R23							24		t	ng × h/mL	12.69		ng/mL	4.59			UNKNOWN	mg	0.4		MULTIPLE	FED		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_A100_1.pdf#page=37 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=110	Homo sapiens		h	1.42	Day 1	non-Japanese		10			false
8721	9770		ADULT	11526038	490.5476	PEMAFIBRATE	Pemafibrate	CC[C@@H](OC1=CC(CN(CCCOC2=CC=C(OC)C=C2)C3=NC4=C(O3)C=CC=C4)=CC=C1)C(O)=O	PLASMA	17VGG92R23							24		t	ng × h/mL	13.85		ng/mL	4.27			UNKNOWN	mg	0.4		MULTIPLE	FED		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_A100_1.pdf#page=37 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=110	Homo sapiens		h	1.68	Day 7	non-Japanese		10			false
8722	9770		ADULT	11526038	490.5476	PEMAFIBRATE	Pemafibrate	CC[C@@H](OC1=CC(CN(CCCOC2=CC=C(OC)C=C2)C3=NC4=C(O3)C=CC=C4)=CC=C1)C(O)=O	PLASMA	17VGG92R23							24		t	ng × h/mL	30.71		ng/mL	8.86			UNKNOWN	mg	0.8		MULTIPLE	FED		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_A100_1.pdf#page=37 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=110	Homo sapiens		h	2.2	Day 1	non-Japanese		10			false
8723	9770		ADULT	11526038	490.5476	PEMAFIBRATE	Pemafibrate	CC[C@@H](OC1=CC(CN(CCCOC2=CC=C(OC)C=C2)C3=NC4=C(O3)C=CC=C4)=CC=C1)C(O)=O	PLASMA	17VGG92R23							24		t	ng × h/mL	35.16		ng/mL	9.25			UNKNOWN	mg	0.8		MULTIPLE	FED		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_A100_1.pdf#page=37 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=110	Homo sapiens		h	2.29	Day 7	non-Japanese		10			false
8724	9770		ADULT	11526038	490.5476	PEMAFIBRATE	Pemafibrate	CC[C@@H](OC1=CC(CN(CCCOC2=CC=C(OC)C=C2)C3=NC4=C(O3)C=CC=C4)=CC=C1)C(O)=O	PLASMA	17VGG92R23							24		t	ng × h/mL	53.52		ng/mL	17.11			UNKNOWN	mg	1.6		MULTIPLE	FED		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_A100_1.pdf#page=37 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=110	Homo sapiens		h	3.99	Day 1	non-Japanese		10			false
8725	9770		ADULT	11526038	490.5476	PEMAFIBRATE	Pemafibrate	CC[C@@H](OC1=CC(CN(CCCOC2=CC=C(OC)C=C2)C3=NC4=C(O3)C=CC=C4)=CC=C1)C(O)=O	PLASMA	17VGG92R23							24		t	ng × h/mL	59.98		ng/mL	17.94			UNKNOWN	mg	1.6		MULTIPLE	FED		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_A100_1.pdf#page=37 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=110	Homo sapiens		h	3.04	Day 7	non-Japanese		10			false
8726	9770		ADULT	11526038	490.5476	PEMAFIBRATE	Pemafibrate	CC[C@@H](OC1=CC(CN(CCCOC2=CC=C(OC)C=C2)C3=NC4=C(O3)C=CC=C4)=CC=C1)C(O)=O	PLASMA	17VGG92R23							12		t	ng × h/mL	1.36		ng/mL	0.5			UNKNOWN	mg	0.1		MULTIPLE	FED		day	2			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_A100_1.pdf#page=37 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=110	Homo sapiens		h	1.26	Day 1	non-Japanese		10			false
8727	9770		ADULT	11526038	490.5476	PEMAFIBRATE	Pemafibrate	CC[C@@H](OC1=CC(CN(CCCOC2=CC=C(OC)C=C2)C3=NC4=C(O3)C=CC=C4)=CC=C1)C(O)=O	PLASMA	17VGG92R23							12		t	ng × h/mL	1.63		ng/mL	0.52			UNKNOWN	mg	0.1		MULTIPLE	FED		day	2			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_A100_1.pdf#page=37 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=110	Homo sapiens		h	1.51	Day 7	non-Japanese		10			false
8728	9770		ADULT	11526038	490.5476	PEMAFIBRATE	Pemafibrate	CC[C@@H](OC1=CC(CN(CCCOC2=CC=C(OC)C=C2)C3=NC4=C(O3)C=CC=C4)=CC=C1)C(O)=O	PLASMA	17VGG92R23							12		t	ng × h/mL	2.74		ng/mL	0.87			UNKNOWN	mg	0.2		MULTIPLE	FED		day	2			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_A100_1.pdf#page=37 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=110	Homo sapiens		h	1.43	Day 1	non-Japanese		10			false
8729	9770		ADULT	11526038	490.5476	PEMAFIBRATE	Pemafibrate	CC[C@@H](OC1=CC(CN(CCCOC2=CC=C(OC)C=C2)C3=NC4=C(O3)C=CC=C4)=CC=C1)C(O)=O	PLASMA	17VGG92R23							12		t	ng × h/mL	3.46		ng/mL	0.86			UNKNOWN	mg	0.2		MULTIPLE	FED		day	2			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_A100_1.pdf#page=37 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=110	Homo sapiens		h	1.78	Day 7	non-Japanese		10			false
8730	9770		ADULT	11526038	490.5476	PEMAFIBRATE	Pemafibrate	CC[C@@H](OC1=CC(CN(CCCOC2=CC=C(OC)C=C2)C3=NC4=C(O3)C=CC=C4)=CC=C1)C(O)=O	PLASMA	17VGG92R23							12		t	ng × h/mL	7.27		ng/mL	2.36			UNKNOWN	mg	0.4		MULTIPLE	FED		day	2			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_A100_1.pdf#page=37 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=110	Homo sapiens		h	1.91	Day 1	non-Japanese		10			false
8731	9770		ADULT	11526038	490.5476	PEMAFIBRATE	Pemafibrate	CC[C@@H](OC1=CC(CN(CCCOC2=CC=C(OC)C=C2)C3=NC4=C(O3)C=CC=C4)=CC=C1)C(O)=O	PLASMA	17VGG92R23							24		t	ng × h/mL	10.232		ng/mL	2.42			DEFINED DAILY	mg	0.2		MULTIPLE	FED		day	1			UNHEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_A100_1.pdf#page=37 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=86	Homo sapiens				Day 1	Hypertriglyceridemia patients		9			false
8732	9770		ADULT	11526038	490.5476	PEMAFIBRATE	Pemafibrate	CC[C@@H](OC1=CC(CN(CCCOC2=CC=C(OC)C=C2)C3=NC4=C(O3)C=CC=C4)=CC=C1)C(O)=O	PLASMA	17VGG92R23							24		t	ng × h/mL	10.499		ng/mL	2.264			DEFINED DAILY	mg	0.2		MULTIPLE	FED		day	1			UNHEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_A100_1.pdf#page=37 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=86	Homo sapiens		h	2.295	Day 15	Hypertriglyceridemia patients		9			false
8733	9770		ADULT	11526038	490.5476	PEMAFIBRATE	Pemafibrate	CC[C@@H](OC1=CC(CN(CCCOC2=CC=C(OC)C=C2)C3=NC4=C(O3)C=CC=C4)=CC=C1)C(O)=O	PLASMA	17VGG92R23							12		t	ng × h/mL	5.59		ng/mL	1.517			DEFINED DAILY	mg	0.2		MULTIPLE	FED		day	2			UNHEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_A100_1.pdf#page=37 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=86	Homo sapiens				Day 1	Hypertriglyceridemia patients		10			false
8734	9770		ADULT	11526038	490.5476	PEMAFIBRATE	Pemafibrate	CC[C@@H](OC1=CC(CN(CCCOC2=CC=C(OC)C=C2)C3=NC4=C(O3)C=CC=C4)=CC=C1)C(O)=O	PLASMA	17VGG92R23							12		t	ng × h/mL	6.301		ng/mL	1.478			DEFINED DAILY	mg	0.2		MULTIPLE	FED		day	2			UNHEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_A100_1.pdf#page=37 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=86	Homo sapiens		h	2.043	Day 15 (single dose)	Hypertriglyceridemia patients		10			false
8735	9770		ADULT	11526038	490.5476	PEMAFIBRATE	Pemafibrate	CC[C@@H](OC1=CC(CN(CCCOC2=CC=C(OC)C=C2)C3=NC4=C(O3)C=CC=C4)=CC=C1)C(O)=O	PLASMA	17VGG92R23									∞	ng × h/mL	9.311		ng/mL	3.015			DEFINED DAILY	mg	0.2		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_A100_1.pdf#page=39 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=134 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=135	Homo sapiens		h	1.637		Normal hepatic function		8			false
8736	9770		ADULT	11526038	490.5476	PEMAFIBRATE	Pemafibrate	CC[C@@H](OC1=CC(CN(CCCOC2=CC=C(OC)C=C2)C3=NC4=C(O3)C=CC=C4)=CC=C1)C(O)=O	PLASMA	17VGG92R23									∞	ng × h/mL	20.32		ng/mL	6.78			DEFINED DAILY	mg	0.2		SINGLE	FASTED				n=7 for AUC and t1/2		UNHEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_A100_1.pdf#page=39 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=134 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=135	Homo sapiens		h	2.035		Mild hepatic impairment (Child-Pugh A)		8			false
8737	9770		ADULT	11526038	490.5476	PEMAFIBRATE	Pemafibrate	CC[C@@H](OC1=CC(CN(CCCOC2=CC=C(OC)C=C2)C3=NC4=C(O3)C=CC=C4)=CC=C1)C(O)=O	PLASMA	17VGG92R23									∞	ng × h/mL	40.445		ng/mL	11.564			DEFINED DAILY	mg	0.2		SINGLE	FASTED						UNHEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_A100_1.pdf#page=39 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=134 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=135	Homo sapiens		h	3.515		Moderate hepatic impairment (Child-Pugh B)		6			false
8738	9770		ADULT	11526038	490.5476	PEMAFIBRATE	Pemafibrate	CC[C@@H](OC1=CC(CN(CCCOC2=CC=C(OC)C=C2)C3=NC4=C(O3)C=CC=C4)=CC=C1)C(O)=O	PLASMA	17VGG92R23									∞	ng × h/mL	12.112		ng/mL	4.01			DEFINED DAILY	mg	0.2		SINGLE	FASTED						UNHEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_A100_1.pdf#page=39 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=134 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=135	Homo sapiens		h	2.031		Fatty liver patients		10			false
8739	9770		ADULT	11526038	490.5476	PEMAFIBRATE	Pemafibrate	CC[C@@H](OC1=CC(CN(CCCOC2=CC=C(OC)C=C2)C3=NC4=C(O3)C=CC=C4)=CC=C1)C(O)=O	PLASMA	17VGG92R23									∞	ng × h/mL	12.041		ng/mL	3.504			DEFINED DAILY	mg	0.2		SINGLE	FASTED						UNHEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_A100_1.pdf#page=39 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=155 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=156	Homo sapiens		h	2.498		Moderate renal impairment		8			false
8740	9770		ADULT	11526038	490.5476	PEMAFIBRATE	Pemafibrate	CC[C@@H](OC1=CC(CN(CCCOC2=CC=C(OC)C=C2)C3=NC4=C(O3)C=CC=C4)=CC=C1)C(O)=O	PLASMA	17VGG92R23									∞	ng × h/mL	16.788		ng/mL	3.928			DEFINED DAILY	mg	0.2		SINGLE	FASTED						UNHEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_A100_1.pdf#page=39 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=155 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=156	Homo sapiens		h	2.978		ESRD		7			false
8741	9770		ADULT	11526038	490.5476	PEMAFIBRATE	Pemafibrate	CC[C@@H](OC1=CC(CN(CCCOC2=CC=C(OC)C=C2)C3=NC4=C(O3)C=CC=C4)=CC=C1)C(O)=O	PLASMA	17VGG92R23									∞	ng × h/mL	9.953		ng/mL	2.983			DEFINED DAILY	mg	0.2		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_A100_1.pdf#page=39 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=155 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=156	Homo sapiens		h	2.371		Normal renal function		8			false
8742	9770		ADULT	11526038	490.5476	PEMAFIBRATE	Pemafibrate	CC[C@@H](OC1=CC(CN(CCCOC2=CC=C(OC)C=C2)C3=NC4=C(O3)C=CC=C4)=CC=C1)C(O)=O	PLASMA	17VGG92R23									∞	ng × h/mL	16.5		ng/mL	4.986			DEFINED DAILY	mg	0.2		SINGLE	FASTED				n=7 for AUC and t1/2		UNHEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_A100_1.pdf#page=39 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=155 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=156	Homo sapiens		h	2.873		Mild renal impairment		8			false
8743	9770		ADULT	11526038	490.5476	PEMAFIBRATE	Pemafibrate	CC[C@@H](OC1=CC(CN(CCCOC2=CC=C(OC)C=C2)C3=NC4=C(O3)C=CC=C4)=CC=C1)C(O)=O	PLASMA	17VGG92R23									∞	ng × h/mL	11.032		ng/mL	5.229			DEFINED DAILY	mg	0.2		SINGLE	FASTED				n=6 for AUC and t1/2		UNHEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_A100_1.pdf#page=39 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=155 | https://www.pmda.go.jp/drugs/2017/P20170718001/270072000_22900AMX00581_K101_1.pdf#page=156	Homo sapiens		h	2.961		Severe renal impairment		7			false
8744	9773		ADULT	6869	350.39	PENICILLIN V	PENICILLIN V	CC1(C)S[C@@H]2[C@H](NC(=O)COC3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O	PLASMA	Z61I075U2W							6		t	μg × h/mL	8.23		μg/mL	5.73			RECOMMENDED	mg	500		SINGLE	FASTED				https://link.springer.com/article/10.2165/00003088-197601040-00004	20	UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/809408/	Homo sapiens		h	2							false
8745	9779		ADULT	16720766	443.519	PEVONEDISTAT	PEVONEDISTAT	NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)N2C=CC3=C2N=CN=C3N[C@H]4CCC5=C4C=CC=C5	PLASMA	S3AZD8D215							24		t	ng × h/mL	3857		ng/mL	1173			UNKNOWN	mg/m²	78		MULTIPLE	UNKNOWN		week	3			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25733005	Homo sapiens				Pevonedistat was administered via a 60-min intravenous infusion on days 1, 3 and 5 every 21-days; median of 2 (range 1–19) cycles.			4	PEVONEDISTAT		false
8746	9779		ADULT	16720766	443.519	PEVONEDISTAT	PEVONEDISTAT	NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)N2C=CC3=C2N=CN=C3N[C@H]4CCC5=C4C=CC=C5	PLASMA	S3AZD8D215							24		t	ng × h/mL	2506		ng/mL	648			MAX TOLERATED	mg/m²	59		MULTIPLE	UNKNOWN		week	3			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25733005	Homo sapiens				Pevonedistat was administered via a 60-min intravenous infusion on days 1, 3 and 5 every 21-days; median of 2 (range 1–19) cycles.			6	PEVONEDISTAT		false
8747	9779		ADULT	16720766	443.519	PEVONEDISTAT	PEVONEDISTAT	NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)N2C=CC3=C2N=CN=C3N[C@H]4CCC5=C4C=CC=C5	PLASMA	S3AZD8D215							24		t	ng × h/mL	3869		ng/mL	1212			MAX TOLERATED	mg/m²	83		MULTIPLE	UNKNOWN		week	2			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25733005	Homo sapiens		h	12	Pevonedistat was administered via a 60-min intravenous infusion on days 1, 4, 8 and 11 every 21-days, median of 2 (range 1–13) cycles.			17	PEVONEDISTAT		false
8748	9779		ADULT	16720766	443.519	PEVONEDISTAT	PEVONEDISTAT	NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)N2C=CC3=C2N=CN=C3N[C@H]4CCC5=C4C=CC=C5	PLASMA	S3AZD8D215									∞	ng × h/mL	8932		ng/mL	2452			UNKNOWN	mg/m²	157		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27056178	Homo sapiens		h	10.1	Patients received pevonedistat as 1 h intravenous infusions on Days 1, 8, and 15 of 21-day cycles; the median number of treatment cycles of pevonedistat administered was 2 (range 1–11)			10	PEVONEDISTAT		false
8749	9779		ADULT	16720766	443.519	PEVONEDISTAT	PEVONEDISTAT	NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)N2C=CC3=C2N=CN=C3N[C@H]4CCC5=C4C=CC=C5	PLASMA	S3AZD8D215									∞	ng × h/mL	12300		ng/mL	3591			MAX TOLERATED	mg/m²	209		MULTIPLE	UNKNOWN		week	2			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27056178	Homo sapiens		h	10.4	Patients received pevonedistat as 1 h intravenous infusions on Days 1, 4, 8, and 11 of 21-day cycles.			11	PEVONEDISTAT		false
8750	9780		ADULT	24765037	556.6305	PEXMETINIB	PEXMETINIB	CC1=CC=C(C=C1)N2N=C(C=C2NC(=O)NCC3=C(OC4=CC5=C(C=C4)N(CCO)N=C5)C=CC(F)=C3)C(C)(C)C	PLASMA	3750D0U8B5									∞	μg × h/mL	4.22		μg/mL	0.37			RECOMMENDED	mg	400		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26491375	Homo sapiens		h	14.2							false
8751	9787		ADULT	56599306	541.022	PILARALISIB	PILARALISIB	COC1=CC(NC2=NC3=C(C=CC=C3)N=C2NS(=O)(=O)C4=CC=CC(NC(=O)C(C)(C)N)=C4)=C(Cl)C=C1	PLASMA	60ES45KTMK							24		t	ng × h/mL	2060000		ng/mL	95200			MAX TOLERATED	mg	600		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/24166903	Homo sapiens		h	88							false
8752	9794		ADULT	9948102	295.847	PITOLISANT	PITOLISANT	ClC1=CC=C(CCCOCCCN2CCCCC2)C=C1	SERUM	4BC83L4PIY									?	ng × h/mL	812		ng/mL	73			RECOMMENDED	mg	35.6		STEADY-STATE	UNKNOWN		day	1	Serum protein binding is approximately 91% to 96%.	6.5	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211150s000lbl.pdf	Homo sapiens		h	20							false
8753	9825		UNKNOWN	3034034	324.4168	QUININE	Quinine	COC1=CC2=C(C=C1)N=CC=C2[C@@H](O)[C@@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C	PLASMA	A7V27PHC7A							12		t	μg × h/mL	73		μg/mL	8.4			UNKNOWN	mg/kg	10		SINGLE	UNKNOWN				During active malarial infection, protein binding of quinine is increased to 78 to 95%		UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021799lbl.pdf	Homo sapiens										false
8754	9825		UNKNOWN	3034034	324.4	Quinine	Quinine	COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O	PLASMA	A7V27PHC7A							12		t	μg × h/mL	28		μg/mL	3.2			UNKNOWN	mg/kg	8.7		SINGLE	UNKNOWN				Quinine is moderately protein-bound in blood in healthy subjects, ranging from 69 to 92%.		HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021799lbl.pdf	Homo sapiens										false
8755	9825		CHILD	3034034	324.4168	QUININE	Quinine	COC1=CC2=C(C=C1)N=CC=C2[C@@H](O)[C@@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C	SERUM	A7V27PHC7A							12		t	μg × h/mL	90.5		μg/mL	9.7			UNKNOWN	mg/m²	300		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://www.sciencedirect.com/science/article/abs/pii/S0022347685806922	Homo sapiens		h	12.5							false
8756	9825		CHILD	3034034	324.4168	QUININE	Quinine	COC1=CC2=C(C=C1)N=CC=C2[C@@H](O)[C@@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C	SERUM	A7V27PHC7A							12		t	μg × h/mL	87.2		μg/mL	10.6			UNKNOWN	mg/m²	300		SINGLE	UNKNOWN						UNHEALTHY	Intramuscular	UNKNOWN	EXPERIMENT	https://www.sciencedirect.com/science/article/abs/pii/S0022347685806922	Homo sapiens		h	8.4							false
8757	9825		CHILD	3034034	324.4168	QUININE	Quinine	COC1=CC2=C(C=C1)N=CC=C2[C@@H](O)[C@@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C	SERUM	A7V27PHC7A							12		t	μg × h/mL	95.4		μg/mL	10.3			UNKNOWN	mg/m²	300		SINGLE	UNKNOWN						UNHEALTHY	Intragastric	UNKNOWN	EXPERIMENT	https://www.sciencedirect.com/science/article/abs/pii/S0022347685806922	Homo sapiens		h	13.1							false
8758	9825		CHILD	3034034	324.4168	QUININE	Quinine	COC1=CC2=C(C=C1)N=CC=C2[C@@H](O)[C@@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C	SERUM	A7V27PHC7A													μg/mL	11.3			UNKNOWN	mg/m²	300		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Intramuscular	UNKNOWN	EXPERIMENT	https://www.sciencedirect.com/science/article/abs/pii/S0022347685806922	Homo sapiens		h	9.8							false
8759	9836		ADULT	9294	165.2322	EPHEDRINE	EPHEDRINE	CN[C@@H](C)[C@H](O)C1=CC=CC=C1	PLASMA	GN83C131XS									∞	ng × h/mL	751		ng/mL	79.4			UNKNOWN	mg	22		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/973934/	Homo sapiens		h	6.75							false
8760	9849		ADULT	25066467	553.5868	REBASTINIB	rebastinib	CNC(=O)C1=NC=CC(OC2=CC(F)=C(NC(=O)NC3=CC(=NN3C4=CC5=C(C=C4)N=CC=C5)C(C)(C)C)C=C2)=C1	PLASMA	75017Q6I97							4		t	ng × h/mL	528		ng/mL	229			UNKNOWN	mg	300		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27927766	Homo sapiens				powder-in-capsule			1	rebastinib		false
8761	9849		ADULT	25066467	553.5868	REBASTINIB	rebastinib	CNC(=O)C1=NC=CC(OC2=CC(F)=C(NC(=O)NC3=CC(=NN3C4=CC5=C(C=C4)N=CC=C5)C(C)(C)C)C=C2)=C1	PLASMA	75017Q6I97							10		t	ng × h/mL	805		ng/mL	218			UNKNOWN	mg	600		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27927766	Homo sapiens				powder-in-capsule			5	rebastinib		false
8762	9849		ADULT	25066467	553.5868	REBASTINIB	rebastinib	CNC(=O)C1=NC=CC(OC2=CC(F)=C(NC(=O)NC3=CC(=NN3C4=CC5=C(C=C4)N=CC=C5)C(C)(C)C)C=C2)=C1	PLASMA	75017Q6I97							10		t	ng × h/mL	554		ng/mL	114			UNKNOWN	mg	100		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27927766	Homo sapiens				tablet			9	rebastinib		false
8763	9849		ADULT	25066467	553.5868	REBASTINIB	rebastinib	CNC(=O)C1=NC=CC(OC2=CC(F)=C(NC(=O)NC3=CC(=NN3C4=CC5=C(C=C4)N=CC=C5)C(C)(C)C)C=C2)=C1	PLASMA	75017Q6I97							10		t	ng × h/mL	786		ng/mL	308			MAX TOLERATED	mg	150		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27927766	Homo sapiens				tablet			28	rebastinib		false
8764	9849		ADULT	25066467	553.5868	REBASTINIB	rebastinib	CNC(=O)C1=NC=CC(OC2=CC(F)=C(NC(=O)NC3=CC(=NN3C4=CC5=C(C=C4)N=CC=C5)C(C)(C)C)C=C2)=C1	PLASMA	75017Q6I97							10		t	ng × h/mL	348		ng/mL	67			UNKNOWN	mg	114		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27927766	Homo sapiens				powder-in-capsule			1	rebastinib		false
8765	9849		ADULT	25066467	553.5868	REBASTINIB	rebastinib	CNC(=O)C1=NC=CC(OC2=CC(F)=C(NC(=O)NC3=CC(=NN3C4=CC5=C(C=C4)N=CC=C5)C(C)(C)C)C=C2)=C1	PLASMA	75017Q6I97							10		t	ng × h/mL	966		ng/mL	284			UNKNOWN	mg	1200		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27927766	Homo sapiens				powder-in-capsule			3	rebastinib		false
8766	9849		ADULT	25066467	553.5868	REBASTINIB	rebastinib	CNC(=O)C1=NC=CC(OC2=CC(F)=C(NC(=O)NC3=CC(=NN3C4=CC5=C(C=C4)N=CC=C5)C(C)(C)C)C=C2)=C1	PLASMA	75017Q6I97							10		t	ng × h/mL	1180		ng/mL	377			UNKNOWN	mg	200		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27927766	Homo sapiens				tablet			4	rebastinib		false
8767	9858		ADULT	16135625	1411.6274	RIMIDUCID	RIMIDUCID	CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCC2=CC(OC)=C(OC)C=C2)C3=CC=CC(OCC(=O)NCCNC(=O)COC4=CC=CC(=C4)[C@@H](CCC5=CC(OC)=C(OC)C=C5)OC(=O)[C@@H]6CCCCN6C(=O)[C@@H](CC)C7=CC(OC)=C(OC)C(OC)=C7)=C3)C8=CC(OC)=C(OC)C(OC)=C8	PLASMA	H564L1W5J2									∞	ng × h/mL	2972		ng/mL	1273			UNKNOWN	mg/kg	1		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11504275	Homo sapiens		h	12	continuous  2-hour  intravenous  infusion			4	RIMIDUCID		false
8768	9886		ADULT	108059	370.4819	SEGESTERONE ACETATE	segesterone acetate	CC(=O)O[C@]1(C(C)=O)C(=C)C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C	SERUM	9AMX4Q13CC	5757		ESTRADIOL	estradiol	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@H]2O	4TI98Z838E	72		t	pg × h/mL	38685.7		pg/mL	942.9			UNKNOWN	μg	200		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Vaginal	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29409834/	Homo sapiens										true
8769	9886		ADULT	108059	370.4819	SEGESTERONE ACETATE	Segesterone Acetate	CC(=O)O[C@]1(C(C)=O)C(=C)C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C	SERUM	9AMX4Q13CC	5991		ETHINYL ESTRADIOL	Ethinyl Estradiol	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@]2(O)C#C	423D2T571U	24		t	ng × h/mL	15		pg/mL	1147			RECOMMENDED	mg	0.15		STEADY-STATE	UNKNOWN		day	1	Segesterone Acetate is approximately 95% bound to human serum proteins.	5	HEALTHY	Vaginal	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf	Homo sapiens		h	4.5							true
8770	9886		ADULT	108059	370.4819	SEGESTERONE ACETATE	Segesterone Acetate	CC(=O)O[C@]1(C(C)=O)C(=C)C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C	SERUM	9AMX4Q13CC	5991		ETHINYL ESTRADIOL	ETHINYL ESTRADIOL	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@]2(O)C#C	423D2T571U	24		t	ng × h/mL	3.9		pg/mL	294			RECOMMENDED	mg	0.15		STEADY-STATE	UNKNOWN		day	1	Segesterone Acetate is approximately 95% bound to human serum proteins.	5	HEALTHY	Vaginal	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf	Homo sapiens		h	4.5							true
8771	9887		ADULT	56928390	482.845	SELETALISIB	seletalisib	[O-][N+]1=CC=CC(=C1)C2=NC3=C(Cl)C=CC=C3C=C2[C@@H](NC4=NC=NC5=CC=CN=C45)C(F)(F)F	PLASMA	64CW205BDD									∞	ng × h/mL	17252		ng/mL	690.8			UNKNOWN	mg	45		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/28160012	Homo sapiens		h	22.4							false
8772	9887		ADULT	56928390	482.845	SELETALISIB	SELETALISIB	[O-][N+]1=CC=CC(=C1)C2=NC3=C(Cl)C=CC=C3C=C2[C@@H](NC4=NC=NC5=CC=CN=C45)C(F)(F)F	PLASMA	64CW205BDD							24		t	ng × h/mL	16963		ng/mL	1114			UNKNOWN	mg	45		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/28160012	Homo sapiens		h	28.5							false
8773	9888		ADULT	9913767	496.622	SELEXIPAG	SELEXIPAG	CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)C1=NC(C2=CC=CC=C2)=C(N=C1)C3=CC=CC=C3	PLASMA	5EXC0E384L									∞	ng × h/mL	4.61		ng/mL	2.2			UNKNOWN	μg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25850750	Homo sapiens		h	0.7							false
8774	9888		ADULT	9913767	496.622	SELEXIPAG	SELEXIPAG	CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)C1=NC(C2=CC=CC=C2)=C(N=C1)C3=CC=CC=C3	PLASMA	5EXC0E384L									∞	ng × h/mL	6.77		ng/mL	3.4			UNKNOWN	μg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25850750	Homo sapiens		h	0.8							false
8775	9888		ADULT	9913767	496.622	SELEXIPAG	SELEXIPAG	CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)C1=NC(C2=CC=CC=C2)=C(N=C1)C3=CC=CC=C3	PLASMA	5EXC0E384L									∞	ng × h/mL	12.35		ng/mL	5.98			UNKNOWN	μg	400		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25850750	Homo sapiens		h	1							false
8776	9888		ADULT	9913767	496.622	SELEXIPAG	SELEXIPAG	CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)C1=NC(C2=CC=CC=C2)=C(N=C1)C3=CC=CC=C3	PLASMA	5EXC0E384L									∞	ng × h/mL	23.27		ng/mL	11.19			UNKNOWN	μg	600		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25850750	Homo sapiens		h	1.9							false
8777	9888		ADULT	9913767	496.622	SELEXIPAG	SELEXIPAG	CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)C1=NC(C2=CC=CC=C2)=C(N=C1)C3=CC=CC=C3	PLASMA	5EXC0E384L									∞	ng × h/mL	24.97		ng/mL	11.53			UNKNOWN	μg	800		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25850750	Homo sapiens		h	2.3							false
8778	9888		ADULT	9913767	496.622	SELEXIPAG	SELEXIPAG	CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)C1=NC(C2=CC=CC=C2)=C(N=C1)C3=CC=CC=C3	PLASMA	5EXC0E384L							12		t	ng × h/mL	5.38		ng/mL	1.85			UNKNOWN	μg	200		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25850750	Homo sapiens		h	1.14							false
8779	9888		ADULT	9913767	496.622	SELEXIPAG	SELEXIPAG	CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)C1=NC(C2=CC=CC=C2)=C(N=C1)C3=CC=CC=C3	PLASMA	5EXC0E384L							12		t	ng × h/mL	9.7		ng/mL	4.12			UNKNOWN	μg	400		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25850750	Homo sapiens		h	1.41							false
8780	9888		ADULT	9913767	496.622	SELEXIPAG	SELEXIPAG	CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)C1=NC(C2=CC=CC=C2)=C(N=C1)C3=CC=CC=C3	PLASMA	5EXC0E384L							12		t	ng × h/mL	13.78		ng/mL	5.29			UNKNOWN	μg	600		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25850750	Homo sapiens		h	1.24							false
8781	9888		UNKNOWN	9913767	496.622	SELEXIPAG	SELEXIPAG	CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)C1=NC(C2=CC=CC=C2)=C(N=C1)C3=CC=CC=C3	PLASMA	5EXC0E384L																						UNKNOWN				Selexipag and its active metabolite are highly bound to plasma proteins (approximately 99% in total and to the same extent to albumin and alpha1-acid glycoprotein).	1	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/207947s007lbl.pdf	Homo sapiens										false
8782	9889		ADULT	68736	223.1635	SELFOTEL	SELFOTEL	OC(=O)[C@@H]1C[C@H](CP(O)(O)=O)CCN1	PLASMA	4VGJ4A41L2									?	ng × h/mL	31622		ng/mL	20676			UNKNOWN	mg/kg	2		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7709405	Homo sapiens		h	2				6	SELFOTEL		false
8783	9890		UNKNOWN	71245288	445.4921	SELONSERTIB	SELONSERTIB	CC(C)N1C=NN=C1C2=CC=CC(NC(=O)C3=CC(N4C=NC(=C4)C5CC5)=C(C)C=C3F)=N2	PLASMA	NS3988A2TC																						UNKNOWN				the free fraction of GS-4997 in human plasma is 12%.	12	UNKNOWN		UNKNOWN	OTHER GOV'T	https://clinicaltrials.gov/ProvidedDocs/31/NCT02854631/Prot_000.pdf	Homo sapiens										false
8784	9892		ADULT	10126189	363.3899	SEPANTRONIUM	SEPANTRONIUM	COCC[N ]1=C(C)N(CC2=NC=CN=C2)C3=C1C(=O)C4=C(C=CC=C4)C3=O	PLASMA	UZ77T1VFBM									∞	ng × h/mL	1439		ng/mL	10.7			MAX TOLERATED	mg/m²	4.8		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18824702	Homo sapiens		h	26.3	168-hour continuous intravenous infusion			25	Sepantronium bromide		false
8785	9895		ADULT	11609586	328.4103	SERDEMETAN	SERDEMETAN	C(CC1=CNC2=C1C=CC=C2)NC3=CC=C(NC4=CC=NC=C4)C=C3	PLASMA	ID6YB4W3V8							24		t	μg × h/mL	43		ng/mL	2330			UNKNOWN	mg	350		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/21831953	Homo sapiens		h	16							false
8786	9933		UNKNOWN	49848070	512.502	TALADEGIB	TALADEGIB	CN(C1CCN(CC1)C2=NN=C(C3=CC=NN3C)C4=CC=CC=C24)C(=O)C5=C(C=C(F)C=C5)C(F)(F)F	PLASMA	QY8BWX1LJ5																						UNKNOWN				The mean percentages bound were 94.4% for taladegib and 8.2% for LSN3185556.	5.6	UNKNOWN		UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422158/	Homo sapiens										false
8787	9933		ADULT	49848070	512.502	TALADEGIB	taladegib	CN(C1CCN(CC1)C2=NN=C(C3=CC=NN3C)C4=CC=CC=C24)C(=O)C5=C(C=C(F)C=C5)C(F)(F)F	PLASMA	QY8BWX1LJ5							24		t	μg × h/mL	43.1		μg/mL	3.84			UNKNOWN	mg	400		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/29453627	Homo sapiens		h	12.3							false
8788	9933		ADULT	49848070	512.502	TALADEGIB	TALADEGIB	CN(C1CCN(CC1)C2=NN=C(C3=CC=NN3C)C4=CC=CC=C24)C(=O)C5=C(C=C(F)C=C5)C(F)(F)F	PLASMA	QY8BWX1LJ5							24		t	μg × h/mL	13.7		μg/mL	9.08			UNKNOWN	mg	400		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/29453627	Homo sapiens		h	13.7							false
8789	9940		ADULT		448.4415	TANZISERTIB	tanzisertib	O[C@H]1CC[C@@H](CC1)NC2=NC3=C(C=N2)N=C(NC4=C(F)C=C(F)C=C4F)N3[C@H]5CCOC5	PLASMA	M5O06306UO									?	ng × eq × h/g	15827		ng × eq/g	1505			UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25482583	Homo sapiens		h	13				6	tanzisertib		false
8790	9941		ADULT	11226090	515.955	TARANABANT	Taranabant	C[C@H](NC(=O)C(C)(C)OC1=NC=C(C=C1)C(F)(F)F)[C@@H](CC2=CC=C(Cl)C=C2)C3=CC(=CC=C3)C#N	PLASMA	X9U622S114							24		t	nM × h	265.2		nM	49.99			UNKNOWN	mg	5		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18508950	Homo sapiens		h	90.5				12	Taranabant		false
8791	9941		ADULT	11226090	515.955	TARANABANT	Taranabant	C[C@H](NC(=O)C(C)(C)OC1=NC=C(C=C1)C(F)(F)F)[C@@H](CC2=CC=C(Cl)C=C2)C3=CC(=CC=C3)C#N	PLASMA	X9U622S114							24		t	nM × h	806.3		nM	147.55			UNKNOWN	mg	25		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18508950	Homo sapiens		h	103.6				12	Taranabant		false
8792	9941		ADULT	11226090	515.955	TARANABANT	Taranabant	C[C@H](NC(=O)C(C)(C)OC1=NC=C(C=C1)C(F)(F)F)[C@@H](CC2=CC=C(Cl)C=C2)C3=CC(=CC=C3)C#N	PLASMA	X9U622S114							24		t	nM × h	416.4		nM	85.62			UNKNOWN	mg	10		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18508950	Homo sapiens		h	97.4				12	Taranabant		false
8793	9941		ADULT	11226090	515.955	TARANABANT	Taranabant	C[C@H](NC(=O)C(C)(C)OC1=NC=C(C=C1)C(F)(F)F)[C@@H](CC2=CC=C(Cl)C=C2)C3=CC(=CC=C3)C#N	PLASMA	X9U622S114							24		t	nM × h	298.3		nM	58.24			UNKNOWN	mg	7.5		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18508950	Homo sapiens		h	93.3				12	Taranabant		false
8794	9944		ADULT	16124688	376.3292	TECOVIRIMAT	TECOVIRIMAT	FC(F)(F)C1=CC=C(C=C1)C(=O)NN2C(=O)[C@H]3[C@H]([C@H]4C=C[C@@H]3[C@@H]5C[C@H]45)C2=O	PLASMA	F925RR824R							24		t	ng × h/mL	25876		ng/mL	1591			RECOMMENDED	mg	600		SINGLE	FED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29972742/	Homo sapiens										false
8795	9944		ADULT	16124688	376.3292	TECOVIRIMAT	TECOVIRIMAT	FC(F)(F)C1=CC=C(C=C1)C(=O)NN2C(=O)[C@H]3[C@H]([C@H]4C=C[C@@H]3[C@@H]5C[C@H]45)C2=O	PLASMA	F925RR824R							24		t	ng × h/mL	30632		ng/mL	2209			RECOMMENDED	mg	600		STEADY-STATE	FED		day	2			HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29972742/	Homo sapiens		h	23							false
8796	9944		ADULT	16124688	376.3292	TECOVIRIMAT	TECOVIRIMAT	FC(F)(F)C1=CC=C(C=C1)C(=O)NN2C(=O)[C@H]3[C@H]([C@H]4C=C[C@@H]3[C@@H]5C[C@H]45)C2=O	PLASMA	F925RR824R							24		t	ng × h/mL	28791		ng/mL	2106			RECOMMENDED	mg	600		STEADY-STATE	UNKNOWN		day	2	77-82 % bound to human plasma proteins.	20.5	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208627s000lbl.pdf	Homo sapiens		h	20							false
8797	9951		ADULT	11319053	566.523	TELCAGEPANT	Telcagepant	FC1=C(F)C(=CC=C1)[C@@H]2CC[C@@H](NC(=O)N3CCC(CC3)N4C(=O)NC5=C4C=CC=N5)C(=O)N(CC(F)(F)F)C2	PLASMA	D42O649ALL							24		t	μM × h	46.65		μM	8.82			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20173082	Homo sapiens		h	4.7				6	Telcagepant		false
8798	9951		ADULT	11319053	566.523	TELCAGEPANT	TELCAGEPANT	FC1=C(F)C(=CC=C1)[C@@H]2CC[C@@H](NC(=O)N3CCC(CC3)N4C(=O)NC5=C4C=CC=N5)C(=O)N(CC(F)(F)F)C2	PLASMA	D42O649ALL							24		t	μM × h	35.16		μM	7.56			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20173082	Homo sapiens		h	6.2				6	TELCAGEPANT		false
8799	9951		ADULT	11319053	566.523	TELCAGEPANT	TELCAGEPANT	FC1=C(F)C(=CC=C1)[C@@H]2CC[C@@H](NC(=O)N3CCC(CC3)N4C(=O)NC5=C4C=CC=N5)C(=O)N(CC(F)(F)F)C2	PLASMA	D42O649ALL							24		t	μM × h	20.08		μM	4.07			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20173082	Homo sapiens		h	5.3				6	TELCAGEPANT		false
8800	9951		ADULT	11319053	566.523	TELCAGEPANT	Telcagepant	FC1=C(F)C(=CC=C1)[C@@H]2CC[C@@H](NC(=O)N3CCC(CC3)N4C(=O)NC5=C4C=CC=N5)C(=O)N(CC(F)(F)F)C2	PLASMA	D42O649ALL							24		t	μM × h	32.47		μM	5.64			UNKNOWN	mg	200		STEADY-STATE	FASTED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20173082	Homo sapiens		h	6.4				6	TELCAGEPANT		false
8801	9951		ADULT	11319053	566.523	TELCAGEPANT	TELCAGEPANT	FC1=C(F)C(=CC=C1)[C@@H]2CC[C@@H](NC(=O)N3CCC(CC3)N4C(=O)NC5=C4C=CC=N5)C(=O)N(CC(F)(F)F)C2	PLASMA	D42O649ALL							24		t	μM × h	35.16		μM	7.56			UNKNOWN	mg	300		STEADY-STATE	FASTED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20173082	Homo sapiens		h	6.2				6	TELCAGEPANT		false
8802	9951		ADULT	11319053	566.523	TELCAGEPANT	TELCAGEPANT	FC1=C(F)C(=CC=C1)[C@@H]2CC[C@@H](NC(=O)N3CCC(CC3)N4C(=O)NC5=C4C=CC=N5)C(=O)N(CC(F)(F)F)C2	PLASMA	D42O649ALL							24		t	μM × h	103.86		μM	14.45			UNKNOWN	mg	400		STEADY-STATE	FASTED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20173082	Homo sapiens		h	6				6	TELCAGEPANT		false
8803	9956		ADULT	25171648	492.5716	TEPOTINIB	TEPOTINIB	CN1CCC(COC2=CN=C(N=C2)C3=CC(CN4N=C(C=CC4=O)C5=CC(=CC=C5)C#N)=CC=C3)CC1	PLASMA	1IJV77EI07							24		t	ng × h/mL	849		ng/mL	57			UNKNOWN	mg	30		SINGLE	FED						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31822497/	Homo sapiens					cancer		3	TEPOTINIB		false
8804	9956		ADULT	25171648	492.5716	TEPOTINIB	TEPOTINIB	CN1CCC(COC2=CN=C(N=C2)C3=CC(CN4N=C(C=CC4=O)C5=CC(=CC=C5)C#N)=CC=C3)CC1	PLASMA	1IJV77EI07							24		t	ng × h/mL	5918		ng/mL	330			RP2D	mg	500		SINGLE	FED						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31822497/	Homo sapiens					cancer		19	TEPOTINIB		false
8805	9956		ADULT	25171648	492.5716	TEPOTINIB	TEPOTINIB	CN1CCC(COC2=CN=C(N=C2)C3=CC(CN4N=C(C=CC4=O)C5=CC(=CC=C5)C#N)=CC=C3)CC1	PLASMA	1IJV77EI07							24		t	ng × h/mL	15542		ng/mL	863			HIGHEST STUDIED	mg	1400		SINGLE	FED						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31822497/	Homo sapiens					cancer		6	TEPOTINIB		false
8806	9956		ADULT	25171648	492.5716	TEPOTINIB	TEPOTINIB	CN1CCC(COC2=CN=C(N=C2)C3=CC(CN4N=C(C=CC4=O)C5=CC(=CC=C5)C#N)=CC=C3)CC1	PLASMA	1IJV77EI07							24		t	ng × h/mL	2267		ng/mL	113			UNKNOWN	mg	30		STEADY-STATE	FED		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31822497/	Homo sapiens				14 days dosing	cancer		2	TEPOTINIB		false
8807	9956		ADULT	25171648	492.5716	TEPOTINIB	TEPOTINIB	CN1CCC(COC2=CN=C(N=C2)C3=CC(CN4N=C(C=CC4=O)C5=CC(=CC=C5)C#N)=CC=C3)CC1	PLASMA	1IJV77EI07							24		t	ng × h/mL	20169		ng/mL	943			RP2D	mg	500		STEADY-STATE	FED		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31822497/	Homo sapiens				14 days dosing	cancer		17	TEPOTINIB		false
8808	9956		ADULT	25171648	492.5716	TEPOTINIB	TEPOTINIB	CN1CCC(COC2=CN=C(N=C2)C3=CC(CN4N=C(C=CC4=O)C5=CC(=CC=C5)C#N)=CC=C3)CC1	PLASMA	1IJV77EI07							24		t	ng × h/mL	39284		ng/mL	1805			HIGHEST STUDIED	mg	1400		STEADY-STATE	FED		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31822497/	Homo sapiens				14 days dosing	cancer		4	TEPOTINIB		false
8809	9956		ADULT	25171648	492.5716	TEPOTINIB	TEPOTINIB	CN1CCC(COC2=CN=C(N=C2)C3=CC(CN4N=C(C=CC4=O)C5=CC(=CC=C5)C#N)=CC=C3)CC1	PLASMA	1IJV77EI07							48		t	ng × h/mL	3032		ng/mL	89			UNKNOWN	mg	60		MULTIPLE	FED		week	3			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31822497/	Homo sapiens				19 days dosing	cancer		5	TEPOTINIB		false
8810	9956		ADULT	25171648	492.5716	TEPOTINIB	TEPOTINIB	CN1CCC(COC2=CN=C(N=C2)C3=CC(CN4N=C(C=CC4=O)C5=CC(=CC=C5)C#N)=CC=C3)CC1	PLASMA	1IJV77EI07							48		t	ng × h/mL	5306		ng/mL	178			UNKNOWN	mg	130		MULTIPLE	FED		week	3			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31822497/	Homo sapiens				19 days dosing	cancer		6	TEPOTINIB		false
8811	9956		ADULT	25171648	492.5716	TEPOTINIB	TEPOTINIB	CN1CCC(COC2=CN=C(N=C2)C3=CC(CN4N=C(C=CC4=O)C5=CC(=CC=C5)C#N)=CC=C3)CC1	PLASMA	1IJV77EI07							48		t	ng × h/mL	27760		ng/mL	722			HIGHEST STUDIED	mg	315		MULTIPLE	FED		week	3			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31822497/	Homo sapiens				19 days dosing	cancer		6	TEPOTINIB		false
8812	9956		ADULT	25171648	492.5716	TEPOTINIB	TEPOTINIB	CN1CCC(COC2=CN=C(N=C2)C3=CC(CN4N=C(C=CC4=O)C5=CC(=CC=C5)C#N)=CC=C3)CC1	PLASMA	1IJV77EI07							24		t	ng × h/mL	5412.7		ng/mL	301.3			UNKNOWN	mg	300		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32328660/	Homo sapiens					solid tumors		3	TEPOTINIB		false
8813	9956		ADULT	25171648	492.5716	TEPOTINIB	TEPOTINIB	CN1CCC(COC2=CN=C(N=C2)C3=CC(CN4N=C(C=CC4=O)C5=CC(=CC=C5)C#N)=CC=C3)CC1	PLASMA	1IJV77EI07							24		t	ng × h/mL	8235		ng/mL	442.4			HIGHEST STUDIED	mg	500		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32328660/	Homo sapiens					solid tumors		6	TEPOTINIB		false
8814	9956		ADULT	25171648	492.5716	TEPOTINIB	TEPOTINIB	CN1CCC(COC2=CN=C(N=C2)C3=CC(CN4N=C(C=CC4=O)C5=CC(=CC=C5)C#N)=CC=C3)CC1	PLASMA	1IJV77EI07							24		t	ng × h/mL	4060.8		ng/mL	244.4			UNKNOWN	mg	215		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32328660/	Homo sapiens					solid tumors		3	TEPOTINIB		false
8815	9956		ADULT	25171648	492.5716	TEPOTINIB	TEPOTINIB	CN1CCC(COC2=CN=C(N=C2)C3=CC(CN4N=C(C=CC4=O)C5=CC(=CC=C5)C#N)=CC=C3)CC1	PLASMA	1IJV77EI07							24		?	ng × h/mL	16088.6		ng/mL	807.5			UNKNOWN	mg	215		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32328660/	Homo sapiens				14 days dosing	solid tumors		3	TEPOTINIB		false
8816	9956		ADULT	25171648	492.5716	TEPOTINIB	TEPOTINIB	CN1CCC(COC2=CN=C(N=C2)C3=CC(CN4N=C(C=CC4=O)C5=CC(=CC=C5)C#N)=CC=C3)CC1	PLASMA	1IJV77EI07							24		?	ng × h/mL	13313.4		ng/mL	610.1			UNKNOWN	mg	300		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32328660/	Homo sapiens				14 days dosing	solid tumors		3	TEPOTINIB		false
8817	9956		ADULT	25171648	492.5716	TEPOTINIB	TEPOTINIB	CN1CCC(COC2=CN=C(N=C2)C3=CC(CN4N=C(C=CC4=O)C5=CC(=CC=C5)C#N)=CC=C3)CC1	PLASMA	1IJV77EI07							24		?	ng × h/mL	21509		ng/mL	996.8			HIGHEST STUDIED	mg	500		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32328660/	Homo sapiens				14 days dosing	solid tumors		6	TEPOTINIB		false
8818	9956		ADULT	25171648	492.5716	TEPOTINIB	TEPOTINIB	CN1CCC(COC2=CN=C(N=C2)C3=CC(CN4N=C(C=CC4=O)C5=CC(=CC=C5)C#N)=CC=C3)CC1	UNKNOWN	1IJV77EI07							24		t	ng × h/mL	27438		ng/mL	1291			RECOMMENDED	mg	450		STEADY-STATE	FED		day	1		2	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214096s000lbl.pdf	Homo sapiens		h	32		cancer			TEPOTINIB		false
8819	9990		ADULT	11518241	459.5766	TRIFAROTENE	TRIFAROTENE	CC(C)(C)C1=C(C=CC(=C1)C2=C(OCCO)C=CC(=C2)C3=CC=C(C=C3)C(O)=O)N4CCCC4	PLASMA								24		t	pg × h/mL	118		pg/mL	10.8			UNKNOWN	mg	200		STEADY-STATE	UNKNOWN		day	1	Trifarotene has high protein binding (>99%).		UNHEALTHY	Topical	UNKNOWN	OTHER GOV'T	https://www.fda.gov/media/132145/download	Homo sapiens		h	3							false
8820	9990		ADOLESCENT	11518241	459.5766	TRIFAROTENE	TRIFAROTENE	CC(C)(C)C1=C(C=CC(=C1)C2=C(OCCO)C=CC(=C2)C3=CC=C(C=C3)C(O)=O)N4CCCC4	PLASMA								24		t	pg × h/mL	137		pg/mL	12			UNKNOWN	mg	200		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Topical	UNKNOWN	OTHER GOV'T	https://www.fda.gov/media/132145/download	Homo sapiens										false
8821	9997			51039094	480.5212	TUCATINIB	tucatinib	CC1=C(OC2=CC3=NC=NN3C=C2)C=CC(NC4=NC=NC5=CC=C(NC6=NC(C)(C)CO6)C=C45)=C1	PLASMA	234248D0HH																										The plasma protein binding was 97.1% at clinically relevant concentrations.	2.9				DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213411s000lbl.pdf	Homo sapiens										false
8822	9997		ADULT	51039094	480.5212	TUCATINIB	CC1=C(OC2=CC3=NC=NN3C=C2)C=CC(NC4=NC=NC5=C4C=C(NC6=NC(C)(C)CO6)C=C5)=C1	CC1=C(OC2=CC3=NC=NN3C=C2)C=CC(NC4=NC=NC5=C4C=C(NC6=NC(C)(C)CO6)C=C5)=C1	PLASMA	234248D0HH							6		t	ng × h/mL	2920		ng/mL	790			RECOMMENDED	mg	300		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/29955792	Homo sapiens		h	5.5							false
8823	10003		UNKNOWN	11719003	433.331	ULIXERTINIB	ULIXERTINIB	CC(C)NC1=NC=C(Cl)C(=C1)C2=CNC(=C2)C(=O)N[C@H](CO)C3=CC(Cl)=CC=C3	PLASMA	16ZDH50O1U																						UNKNOWN				In addition, ulixertinib is highly protein bound in multiple species, including human (99.9–100%).	0.05	UNKNOWN		UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973962/	Homo sapiens										false
8824	10003		ADULT	11719003	433.331	ULIXERTINIB	ULIXERTINIB	CC(C)NC1=NC=C(Cl)C(=C1)C2=CNC(=C2)C(=O)N[C@H](CO)C3=CC(Cl)=CC=C3	PLASMA	16ZDH50O1U							12		t	μg × h/mL	19.93		μg/mL	2.12			MAX TOLERATED	mg	600		STEADY-STATE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/29247021	Homo sapiens										false
8825	10005		ADULT	131411|28446253	477.415	UMIFENOVIR	Umifenovir	CCOC(=O)C1=C(CSC2=CC=CC=C2)N(C)C3=C1C(CN(C)C)=C(O)C(Br)=C3	PLASMA	93M09WW4RU									∞	ng × h/mL	2203		ng/mL	467			UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23357765/	Homo sapiens		h	15.7				4			false
8826	10005		ADULT	131411|28446253	477.415	UMIFENOVIR	Umifenovir	CCOC(=O)C1=C(CSC2=CC=CC=C2)N(C)C3=C1C(CN(C)C)=C(O)C(Br)=C3	PLASMA	93M09WW4RU									?	mg × day/L	5.81		mg/L	1.24			UNKNOWN	g	0.4		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23391367/	Homo sapiens							12			false
8827	10005		ADULT	131411|28446253	477.415	UMIFENOVIR	Umifenovir	CCOC(=O)C1=C(CSC2=CC=CC=C2)N(C)C3=C1C(CN(C)C)=C(O)C(Br)=C3	PLASMA	93M09WW4RU									?	mg × day/L	3.27		mg/L	0.7			UNKNOWN	g	0.2		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23391367/	Homo sapiens							12			false
8828	10005		ADULT	131411|28446253	477.415	UMIFENOVIR	Umifenovir	CCOC(=O)C1=C(CSC2=CC=CC=C2)N(C)C3=C1C(CN(C)C)=C(O)C(Br)=C3	PLASMA	93M09WW4RU									?	mg × day/L	12.72		mg/L	2.16			UNKNOWN	g	0.8		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23391367/	Homo sapiens							12			false
8829	10009		ADULT	56649692	297.135	VABORBACTAM	VABORBACTAM	OB1O[C@H](CC(O)=O)CC[C@@H]1NC(=O)CC2=CC=CS2	PLASMA	1C75676F8V									∞	μg × h/mL	16.6		μg/mL	5.03			UNKNOWN	mg	250		SINGLE	UNKNOWN				The average serum protein binding level across the range studied was 33%. The protein binding levels were similar at all concentrations tested (1, 5, 15, and 50 ug/ml).	67	HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27527080	Homo sapiens		h	1.17							false
8830	10009		ADULT	56649692	297.135	VABORBACTAM	VABORBACTAM	OB1O[C@H](CC(O)=O)CC[C@@H]1NC(=O)CC2=CC=CS2	PLASMA	1C75676F8V									∞	μg × h/mL	35.6		μg/mL	9.97			UNKNOWN	mg	500		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27527080	Homo sapiens		h	1.35							false
8831	10009		ADULT	56649692	297.135	VABORBACTAM	VABORBACTAM	OB1O[C@H](CC(O)=O)CC[C@@H]1NC(=O)CC2=CC=CS2	PLASMA	1C75676F8V									∞	μg × h/mL	51.8		μg/mL	15.3			UNKNOWN	mg	750		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27527080	Homo sapiens		h	1.24							false
8832	10009		ADULT	56649692	297.135	VABORBACTAM	VABORBACTAM	OB1O[C@H](CC(O)=O)CC[C@@H]1NC(=O)CC2=CC=CS2	PLASMA	1C75676F8V									∞	μg × h/mL	79.3		μg/mL	21.8			UNKNOWN	mg	1000		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27527080	Homo sapiens		h	1.41							false
8833	10009		ADULT	56649692	297.135	VABORBACTAM	VABORBACTAM	OB1O[C@H](CC(O)=O)CC[C@@H]1NC(=O)CC2=CC=CS2	PLASMA	1C75676F8V									∞	μg × h/mL	100		μg/mL	27.8			UNKNOWN	mg	1250		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27527080	Homo sapiens		h	1.32							false
8834	10009		ADULT	56649692	297.135	VABORBACTAM	VABORBACTAM	OB1O[C@H](CC(O)=O)CC[C@@H]1NC(=O)CC2=CC=CS2	PLASMA	1C75676F8V									∞	μg × h/mL	114		μg/mL	32.9			UNKNOWN	mg	1500		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27527080	Homo sapiens		h	1.4							false
8835	10009		ADULT	56649692	297.135	VABORBACTAM	VABORBACTAM	OB1O[C@H](CC(O)=O)CC[C@@H]1NC(=O)CC2=CC=CS2	PLASMA	1C75676F8V									∞	μg × h/mL	144		μg/mL	41.6			RECOMMENDED	mg	2000		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27527080	Homo sapiens		h	1.51							false
8836	10009		ADULT	56649692	297.135	VABORBACTAM	VABORBACTAM	OB1O[C@H](CC(O)=O)CC[C@@H]1NC(=O)CC2=CC=CS2	PLASMA	1C75676F8V									?	μg × h/mL	16.3		μg/mL	4.81			UNKNOWN	mg	250		MULTIPLE	UNKNOWN		day	3			HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27527080	Homo sapiens		h	1.17							false
8837	10009		ADULT	56649692	297.135	VABORBACTAM	VABORBACTAM	OB1O[C@H](CC(O)=O)CC[C@@H]1NC(=O)CC2=CC=CS2	PLASMA	1C75676F8V									?	μg × h/mL	74.6		μg/mL	21.3			UNKNOWN	mg	1000		MULTIPLE	UNKNOWN		day	3			HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27527080	Homo sapiens		h	1.43							false
8838	10009		ADULT	56649692	297.135	VABORBACTAM	VABORBACTAM	OB1O[C@H](CC(O)=O)CC[C@@H]1NC(=O)CC2=CC=CS2	PLASMA	1C75676F8V									?	μg × h/mL	118		μg/mL	33.4			UNKNOWN	mg	1500		MULTIPLE	UNKNOWN		day	3			HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27527080	Homo sapiens		h	1.65							false
8839	10009		ADULT	56649692	297.135	VABORBACTAM	VABORBACTAM	OB1O[C@H](CC(O)=O)CC[C@@H]1NC(=O)CC2=CC=CS2	PLASMA	1C75676F8V									?	μg × h/mL	145		μg/mL	40.9			RECOMMENDED	mg	2000		MULTIPLE	UNKNOWN		day	3			HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27527080	Homo sapiens		h	1.66							false
8840	10010		ADULT	123964	282.2907	VADIMEZAN	VADIMEZAN	CC1=C(C)C2=C(C=C1)C(=O)C3=C(O2)C(CC(O)=O)=CC=C3	PLASMA	0829J8133H									?	μM × h	7640		μM	1290			MAX TOLERATED	mg/m²	3700		SINGLE	UNKNOWN		week	1	At doses of up to 320 mg/m2, DMXAA was more than 99% plasma protein bound. At higher doses, the percentage of free drug increased, with a mean value of 4.2  /-1.4% above 1000 uM ; at higher doses the percent free drug increased to a maximum of 6.9% at 4900 mg/m2.	4.2	UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12698178	Homo sapiens		h	8.1				3	VADIMEZAN		false
8841	10010		ADULT	123964	282.2907	VADIMEZAN	VADIMEZAN	CC1=C(C)C2=C(C=C1)C(=O)C3=C(O2)C(CC(O)=O)=CC=C3	PLASMA	0829J8133H									?	μM × h	12400		μM	1910			UNKNOWN	μmol/kg	4900		MULTIPLE	UNKNOWN		3 weeks	1	5,6-Dimethylxanthenone-4-acetic acid was highly protein-bound  (>99%)  at  doses up to 650 mg/m2  but  saturation of protein binding at higher doses occurred in both this trial and in vitro studies, with free plasma DMXAA reliably exceeding 1% at total drug concentrations in excess of 500 uM and the plasma percent free drug fraction rose as high as 20%	20	UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17021822	Homo sapiens		h	8.73	5,6-Dimethylxanthenone-4-acetic acid was administered  intravenously  in  a  minimum  volumeof  100 ml  of  normal  saline over 20 min every 3 weeks.			3	VADIMEZAN		false
8842	10018		UNKNOWN	71492799	442.3179	VERDINEXOR	VERDINEXOR	FC(F)(F)C1=CC(=CC(=C1)C2=NN(C=N2)\\C=C/C(=O)NNC3=NC=CC=C3)C(F)(F)F	SERUM	85Q03215IW																						UNKNOWN				Serum protein binding of verdinexor in humans is 98.4%	1.6	UNKNOWN		UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192554/	Homo sapiens										false
8843	10029		UNKNOWN	67409219	469.838	VORUCICLIB	VORUCICLIB	CN1CC[C@H]([C@@H]1CO)C2=C3OC(=CC(=O)C3=C(O)C=C2O)C4=C(Cl)C=C(C=C4)C(F)(F)F	UNKNOWN	W66XP666AM	42611257		VEMURAFENIB	Vemurafenib	CCCS(=O)(=O)NC1=C(F)C(C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(Cl)C=C4)=C(F)C=C1	207SMY3FQT	24		t	ng × h/mL	14451		ng/mL	796			UNKNOWN	mg	15		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://ascopubs.org/doi/10.1200/jco.2015.33.15_suppl.9076	Homo sapiens										true
8844	10030		ADULT	89921642	868.934	VOXILAPREVIR	VOXILAPREVIR	CC[C@@H]1[C@@H]2CN([C@@H]1C(=O)N[C@@]3(C[C@H]3C(F)F)C(=O)NS(=O)(=O)C4(C)CC4)C(=O)[C@@H](NC(=O)O[C@@H]5C[C@H]5CCCCC(F)(F)C6=NC7=C(C=C(OC)C=C7)N=C6O2)C(C)(C)C	PLASMA	0570F37359							24		t	ng × h/mL	183.3		ng/mL	28.6			UNKNOWN	mg	50		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26957110	Homo sapiens		h	11.87							false
8845	10030		ADULT	89921642	868.934	VOXILAPREVIR	VOXILAPREVIR	CC[C@@H]1[C@@H]2CN([C@@H]1C(=O)N[C@@]3(C[C@H]3C(F)F)C(=O)NS(=O)(=O)C4(C)CC4)C(=O)[C@@H](NC(=O)O[C@@H]5C[C@H]5CCCCC(F)(F)C6=NC7=C(C=C(OC)C=C7)N=C6O2)C(C)(C)C	PLASMA	0570F37359							24		t	ng × h/mL	479.2		ng/mL	70.4			RECOMMENDED	mg	100		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26957110	Homo sapiens		h	11.18							false
8846	10030		ADULT	89921642	868.934	VOXILAPREVIR	VOXILAPREVIR	CC[C@@H]1[C@@H]2CN([C@@H]1C(=O)N[C@@]3(C[C@H]3C(F)F)C(=O)NS(=O)(=O)C4(C)CC4)C(=O)[C@@H](NC(=O)O[C@@H]5C[C@H]5CCCCC(F)(F)C6=NC7=C(C=C(OC)C=C7)N=C6O2)C(C)(C)C	PLASMA	0570F37359							24		t	ng × h/mL	1227		ng/mL	156.7			UNKNOWN	mg	300		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26957110	Homo sapiens		h	9.8							false
8847	10030		ADULT	89921642	868.934	VOXILAPREVIR	VOXILAPREVIR	CC[C@@H]1[C@@H]2CN([C@@H]1C(=O)N[C@@]3(C[C@H]3C(F)F)C(=O)NS(=O)(=O)C4(C)CC4)C(=O)[C@@H](NC(=O)O[C@@H]5C[C@H]5CCCCC(F)(F)C6=NC7=C(C=C(OC)C=C7)N=C6O2)C(C)(C)C	PLASMA	0570F37359							24		t	ng × h/mL	372.3		ng/mL	39.8			UNKNOWN	mg	50		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26957110	Homo sapiens		h	39.71							false
8848	10030		ADULT	89921642	868.934	VOXILAPREVIR	VOXILAPREVIR	CC[C@@H]1[C@@H]2CN([C@@H]1C(=O)N[C@@]3(C[C@H]3C(F)F)C(=O)NS(=O)(=O)C4(C)CC4)C(=O)[C@@H](NC(=O)O[C@@H]5C[C@H]5CCCCC(F)(F)C6=NC7=C(C=C(OC)C=C7)N=C6O2)C(C)(C)C	PLASMA	0570F37359							24		t	ng × h/mL	1357.6		ng/mL	155.1			RECOMMENDED	mg	100		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26957110	Homo sapiens		h	37.28							false
8849	10030		ADULT	89921642	868.934	VOXILAPREVIR	VOXILAPREVIR	CC[C@@H]1[C@@H]2CN([C@@H]1C(=O)N[C@@]3(C[C@H]3C(F)F)C(=O)NS(=O)(=O)C4(C)CC4)C(=O)[C@@H](NC(=O)O[C@@H]5C[C@H]5CCCCC(F)(F)C6=NC7=C(C=C(OC)C=C7)N=C6O2)C(C)(C)C	PLASMA	0570F37359							24		t	ng × h/mL	3926.9		ng/mL	413.8			UNKNOWN	mg	300		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26957110	Homo sapiens		h	30.33							false
8850	10030		UNKNOWN	89921642	868.934	VOXILAPREVIR	VOXILAPREVIR	CC[C@@H]1[C@@H]2CN([C@@H]1C(=O)N[C@@]3(C[C@H]3C(F)F)C(=O)NS(=O)(=O)C4(C)CC4)C(=O)[C@@H](NC(=O)O[C@@H]5C[C@H]5CCCCC(F)(F)C6=NC7=C(C=C(OC)C=C7)N=C6O2)C(C)(C)C	PLASMA	0570F37359																	UNKNOWN				UNKNOWN	UNKNOWN				% Bound to human plasma proteins is >99.	1	UNKNOWN	UNKNOWN	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209195s003lbl.pdf	Homo sapiens										false
8851	10031		ADULT	16123056	270.2899	VOXTALISIB	VOXTALISIB	CCN1C(=O)C(=CC2=C1N=C(N)N=C2C)C3=CC=NN3	PLASMA	CVL1685GPH									?	ng × h/mL	1410		ng/mL	341			MAX TOLERATED	mg	40		STEADY-STATE	UNKNOWN		day	2	geom. means		UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28417284	Homo sapiens		h	2.29	Cycle 1, Day 28			5	VOXTALISIB		false
8852	10031		ADULT	16123056	270.2899	VOXTALISIB	VOXTALISIB	CCN1C(=O)C(=CC2=C1N=C(N)N=C2C)C3=CC=NN3	PLASMA	CVL1685GPH									?	ng × h/mL	1680		ng/mL	375			UNKNOWN	mg	50		STEADY-STATE	UNKNOWN		day	2	geom. means		UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28417284	Homo sapiens		h	4.2	Cycle 1, Day 28			5	VOXTALISIB		false
8853	10031		ADULT	16123056	270.2899	VOXTALISIB	VOXTALISIB	CCN1C(=O)C(=CC2=C1N=C(N)N=C2C)C3=CC=NN3	PLASMA	CVL1685GPH							24		t	ng × h/mL	2640		ng/mL	485			UNKNOWN	mg	70		SINGLE	UNKNOWN				geom. means		UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28417284	Homo sapiens		h	4.55	Cycle 1, Day 1			12	VOXTALISIB		false
8854	10031		ADULT	16123056	270.2899	VOXTALISIB	VOXTALISIB	CCN1C(=O)C(=CC2=C1N=C(N)N=C2C)C3=CC=NN3	PLASMA	CVL1685GPH									?	ng × h/mL	2160		ng/mL	403			UNKNOWN	mg	70		STEADY-STATE	UNKNOWN		day	1	geom. means		UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28417284	Homo sapiens		h	3.04	Cycle 1, Day 28			3	VOXTALISIB		false
8855	10031		ADULT	16123056	270.2899	VOXTALISIB	VOXTALISIB	CCN1C(=O)C(=CC2=C1N=C(N)N=C2C)C3=CC=NN3	PLASMA	CVL1685GPH									?	ng × h/mL	2060		ng/mL	351			MAX TOLERATED	mg	60		MULTIPLE	UNKNOWN		day	1	geom. means		UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28417284	Homo sapiens		h	3.8	Cycle 1, Day 28			12	VOXTALISIB		false
8856	10031		ADULT	16123056	270.2899	VOXTALISIB	VOXTALISIB	CCN1C(=O)C(=CC2=C1N=C(N)N=C2C)C3=CC=NN3	PLASMA	CVL1685GPH							24		t	ng × h/mL	1510		ng/mL	282			MAX TOLERATED	mg	60		SINGLE	UNKNOWN				geom. means		UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28417284	Homo sapiens		h	3.5	Cycle 1, Day 1			17	VOXTALISIB		false
8857	10031		ADULT	16123056	270.2899	VOXTALISIB	VOXTALISIB	CCN1C(=O)C(=CC2=C1N=C(N)N=C2C)C3=CC=NN3	PLASMA	CVL1685GPH							24		t	ng × h/mL	1410		ng/mL	322			UNKNOWN	mg	50		SINGLE	UNKNOWN				geom. means		UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28417284	Homo sapiens		h	4.33	Cycle 1, Day 1			7	VOXTALISIB		false
8858	10031		ADULT	16123056	270.2899	VOXTALISIB	VOXTALISIB	CCN1C(=O)C(=CC2=C1N=C(N)N=C2C)C3=CC=NN3	PLASMA	CVL1685GPH							24		t	ng × h/mL	1680		ng/mL	321			MAX TOLERATED	mg	40		SINGLE	UNKNOWN				geom. means		UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28417284	Homo sapiens		h	2.72	Cycle 1, Day 1			6	VOXTALISIB		false
8859	10031		UNKNOWN	16123056	270.2899	VOXTALISIB	VOXTALISIB	CCN1C(=O)C(=CC2=C1N=C(N)N=C2C)C3=CC=NN3	PLASMA	CVL1685GPH																						UNKNOWN				Fraction unbound (human), XL765, 0.14	14	UNKNOWN		UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6597235/	Homo sapiens										false
8860	10031		ADULT	16123056	270.2899	VOXTALISIB	VOXTALISIB	CCN1C(=O)C(=CC2=C1N=C(N)N=C2C)C3=CC=NN3	PLASMA	CVL1685GPH							24		t	ng × h/mL	1510		ng/mL	282			MAX TOLERATED	mg	60		SINGLE	UNKNOWN				geom. means		UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/28417284	Homo sapiens		h	3.5	Cycle 1, day 1			17			false
8861	10031		ADULT	16123056	270.2899	VOXTALISIB	VOXTALISIB	CCN1C(=O)C(=CC2=C1N=C(N)N=C2C)C3=CC=NN3	PLASMA	CVL1685GPH							24		t	ng × h/mL	1680		ng/mL	321			MAX TOLERATED	mg	40		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/28417284	Homo sapiens		h	2.72	Cycle 1, Day 1			6			false
8862	10052			49806720	482.6166	ALECTINIB	ALECTINIB	CCC1=C(C=C2C(=C1)C(=O)C3=C(NC4=C3C=CC(=C4)C#N)C2(C)C)N5CCC(CC5)N6CCOCC6	PLASMA	LIJ4CT1Z3Y													ng/mL	107				mg	300		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02621047	Homo sapiens										false
8863	10052			49806720	482.6166	ALECTINIB	ALECTINIB	CCC1=C(C=C2C(=C1)C(=O)C3=C(NC4=C3C=CC(=C4)C#N)C2(C)C)N5CCC(CC5)N6CCOCC6	PLASMA	LIJ4CT1Z3Y									∞	ng × h/mL	2920							mg	300		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02621047	Homo sapiens										false
8864	10052			49806720	482.6166	ALECTINIB	ALECTINIB	CCC1=C(C=C2C(=C1)C(=O)C3=C(NC4=C3C=CC(=C4)C#N)C2(C)C)N5CCC(CC5)N6CCOCC6	PLASMA	LIJ4CT1Z3Y							240		t	ng × h/mL	2820							mg	300		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02621047	Homo sapiens										false
8865	10052			49806720	482.6166	ALECTINIB	ALECTINIB	CCC1=C(C=C2C(=C1)C(=O)C3=C(NC4=C3C=CC(=C4)C#N)C2(C)C)N5CCC(CC5)N6CCOCC6	PLASMA	LIJ4CT1Z3Y																		mg	300		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02621047	Homo sapiens		h	26.1							false
8866	10052			49806720	482.6166	ALECTINIB	ALECTINIB	CCC1=C(C=C2C(=C1)C(=O)C3=C(NC4=C3C=CC(=C4)C#N)C2(C)C)N5CCC(CC5)N6CCOCC6	PLASMA	LIJ4CT1Z3Y													ng/mL	85.5				mg	300		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02621047	Homo sapiens										false
8867	10052			49806720	482.6166	ALECTINIB	ALECTINIB	CCC1=C(C=C2C(=C1)C(=O)C3=C(NC4=C3C=CC(=C4)C#N)C2(C)C)N5CCC(CC5)N6CCOCC6	PLASMA	LIJ4CT1Z3Y									∞	ng × h/mL	3850							mg	300		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02621047	Homo sapiens										false
8868	10052			49806720	482.6166	ALECTINIB	ALECTINIB	CCC1=C(C=C2C(=C1)C(=O)C3=C(NC4=C3C=CC(=C4)C#N)C2(C)C)N5CCC(CC5)N6CCOCC6	PLASMA	LIJ4CT1Z3Y							240		t	ng × h/mL	3710							mg	300		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02621047	Homo sapiens										false
8869	10052			49806720	482.6166	ALECTINIB	ALECTINIB	CCC1=C(C=C2C(=C1)C(=O)C3=C(NC4=C3C=CC(=C4)C#N)C2(C)C)N5CCC(CC5)N6CCOCC6	PLASMA	LIJ4CT1Z3Y																		mg	300		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02621047	Homo sapiens		h	39.3							false
8870	10052			66835300	456.5793	ALECTINIB metabolite M4	ALECTINIB metabolite M4	CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N5CCC(CC5)NCCO	PLASMA	6L7WLR552I									∞	ng × h/mL	583		ng/mL	19.3				mg	300		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02621047	Homo sapiens		h	24.5							false
8871	10052			66835300	456.5793	ALECTINIB metabolite M4	ALECTINIB metabolite M4	CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N5CCC(CC5)NCCO	PLASMA	6L7WLR552I									∞	ng × h/mL	465		ng/mL	17.5				mg	300		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02621047	Homo sapiens		h	30.5							false
8872	10052			49806720	482.6166	ALECTINIB	ALECTINIB	CCC1=C(C=C2C(=C1)C(=O)C3=C(NC4=C3C=CC(=C4)C#N)C2(C)C)N5CCC(CC5)N6CCOCC6	PLASMA	LIJ4CT1Z3Y							12		t	ng × h/mL	1590		ng/mL	255				mg	600		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02838420	Homo sapiens										false
8873	10052			66835300	456.5793	ALECTINIB metabolite M4	ALECTINIB metabolite M4	CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N5CCC(CC5)NCCO	PLASMA	6L7WLR552I							12		t	ng × h/mL	471		ng/mL	71.4				mg	600		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02838420	Homo sapiens										false
8874	10052			49806720	482.6166	ALECTINIB	ALECTINIB	CCC1=C(C=C2C(=C1)C(=O)C3=C(NC4=C3C=CC(=C4)C#N)C2(C)C)N5CCC(CC5)N6CCOCC6	PLASMA	LIJ4CT1Z3Y							12		t	ng × h/mL	7760		ng/mL	861				mg	600		STEADY-STATE			day	2			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02838420	Homo sapiens										false
8875	10052			66835300	456.5793	ALECTINIB metabolite M4	ALECTINIB metabolite M4	CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N5CCC(CC5)NCCO	PLASMA	6L7WLR552I							12		t	ng × h/mL	2890		ng/mL	306				mg	600		STEADY-STATE			day	2			UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02838420	Homo sapiens										false
8876	10052		ADULT	49806720	482.6166	ALECTINIB	CCC1=CC2=C(C=C1N3CCC(CC3)N4CCOCC4)C(C)(C)C5=C(C6=CC=C(C=C6N5)C#N)C2=O	CCC1=CC2=C(C=C1N3CCC(CC3)N4CCOCC4)C(C)(C)C5=C(C6=CC=C(C=C6N5)C#N)C2=O	PLASMA	LIJ4CT1Z3Y							12		t	ng × h/mL	7430		ng/mL	665			RECOMMENDED	mg	600		STEADY-STATE	UNKNOWN		day	2	also confirmed here https://www.tga.gov.au/sites/default/files/auspar-alectinib-hydrochloride-171127.pdf	1	UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208434s003lbl.pdf	Homo sapiens		h	33							false
8877	10052		ADULT	49806720	482.6166	ALECTINIB	ALECTINIB	CCC1=C(C=C2C(=C1)C(=O)C3=C(NC4=C3C=CC(=C4)C#N)C2(C)C)N5CCC(CC5)N6CCOCC6	PLASMA	LIJ4CT1Z3Y									∞	ng × h/mL	2790		ng/mL	181			RECOMMENDED	mg	600		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208434Orig1s000ClinPharmR.pdf	Homo sapiens		h	32							false
8878	10053		ADULT	11978813	433.566	BREXPIPRAZOLE	BREXPIPRAZOLE	O=C1NC2=C(C=C1)C=CC(OCCCCN3CCN(CC3)C4=CC=CC5=C4C=CS5)=C2	PLASMA	2J3YBM1K8C							24		t	ng × h/mL	537		ng/mL	29.3			UNKNOWN	mg	1		MULTIPLE	FED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28750151	Homo sapiens		h	91.9							false
8879	10053		ADULT	11978813	433.566	BREXPIPRAZOLE	BREXPIPRAZOLE	O=C1NC2=C(C=C1)C=CC(OCCCCN3CCN(CC3)C4=CC=CC5=C4C=CS5)=C2	PLASMA	2J3YBM1K8C							24		t	ng × h/mL	3238		ng/mL	165			UNKNOWN	mg	4		MULTIPLE	FED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28750151	Homo sapiens		h	70.6							false
8880	10053		ADULT	11978813	433.566	BREXPIPRAZOLE	BREXPIPRAZOLE	O=C1NC2=C(C=C1)C=CC(OCCCCN3CCN(CC3)C4=CC=CC5=C4C=CS5)=C2	PLASMA	2J3YBM1K8C							24		t	ng × h/mL	3738		ng/mL	206			UNKNOWN	mg	6		MULTIPLE	FED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28750151	Homo sapiens		h	51.9							false
8881	10053		UNKNOWN	11978813	433.566	BREXPIPRAZOLE	BREXPIPRAZOLE	O=C1NC2=C(C=C1)C=CC(OCCCCN3CCN(CC3)C4=CC=CC5=C4C=CS5)=C2	PLASMA	2J3YBM1K8C																	UNKNOWN				UNKNOWN	UNKNOWN				Brexpiprazole is highly protein bound in plasma (greater than 99%) to serum albumin and α1­-acid glycoprotein, and its protein binding is not affected by renal or hepatic impairment.	1	UNKNOWN	UNKNOWN	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/205422s005lbl.pdf	Homo sapiens										false
8882	10056		ADULT	16222096	531.31	COBIMETINIB	COBIMETINIB	OC1(CN(C1)C(=O)C2=CC=C(F)C(F)=C2NC3=CC=C(I)C=C3F)[C@@H]4CCCCN4	PLASMA	ER29L26N1X							576		t	ng × h/mL	498							mg	10		SINGLE	FASTED						UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02300025	Homo sapiens		h	95.2							false
8883	10056		ADULT	16222096	531.31	COBIMETINIB	COBIMETINIB	OC1(CN(C1)C(=O)C2=CC=C(F)C(F)=C2NC3=CC=C(I)C=C3F)[C@@H]4CCCCN4	PLASMA	ER29L26N1X							576		t	ng × h/mL	539							mg	10		SINGLE	FASTED						UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02300025	Homo sapiens		h	104							false
8884	10056		ADULT	16222096	531.31	COBIMETINIB	COBIMETINIB	OC1(CN(C1)C(=O)C2=CC=C(F)C(F)=C2NC3=CC=C(I)C=C3F)[C@@H]4CCCCN4	PLASMA	ER29L26N1X							576		t	ng × h/mL	268							mg	10		SINGLE	FASTED						UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02300025	Homo sapiens		h	143							false
8885	10056		ADULT	16222096	531.31	COBIMETINIB	COBIMETINIB	OC1(CN(C1)C(=O)C2=CC=C(F)C(F)=C2NC3=CC=C(I)C=C3F)[C@@H]4CCCCN4	PLASMA	ER29L26N1X							24		t	ng × h/mL	4340		ng/mL	273			DEFINED DAILY	mg	60		STEADY-STATE	UNKNOWN		day	1	Cobimetinib is 95% bound to human plasma proteins in vitro, independent of drug concentration. (PK1 ref). More detais could be retrieved from https://www.ema.europa.eu/en/documents/assessment-report/cotellic-epar-public-assessment-report_en.pdf (results of in vitro distribution studies for unbound and bound plasma proteins are shown in Table 7: Cobimetinib Concentration 1 uM - Percent Unbound [14C]Cobimetinib - 5.19; Cobimetinib Concentration 5 uM - Percent Unbound [14C]Cobimetinib - 6.47; Cobimetinib Concentration 10 uM - Percent Unbound [14C]Cobimetinib - 5.83	5	UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206192s002lbl.pdf	Homo sapiens		h	44							false
8886	10057		CHILD	9887712	408.873	DAPAGLIFLOZIN	DAPAGLIFLOZIN	CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C=C1	PLASMA	1ULL0QJ8UC													ng/mL	118				mg	10		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01525238	Homo sapiens										false
8887	10057		CHILD	9887712	408.873	DAPAGLIFLOZIN	DAPAGLIFLOZIN	CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C=C1	PLASMA	1ULL0QJ8UC									∞	ng × h/mL	427							mg	10		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01525238	Homo sapiens										false
8888	10057		CHILD	9887712	408.873	DAPAGLIFLOZIN	DAPAGLIFLOZIN	CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C=C1	PLASMA	1ULL0QJ8UC							48		t	ng × h/mL	418							mg	10		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01525238	Homo sapiens										false
8889	10057		CHILD	91617971	585	DAPAGLIFLOZIN 3-O-Glucuronide	DAPAGLIFLOZIN 3-O-Glucuronide	CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)OC4C(C(C(C(O4)C(=O)O)O)O)O)O)Cl	PLASMA	X42P3B148J													ng/mL	154				mg	10		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01525238	Homo sapiens										false
8890	10057		CHILD	91617971	585	DAPAGLIFLOZIN 3-O-Glucuronide	DAPAGLIFLOZIN 3-O-Glucuronide	CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)OC4C(C(C(C(O4)C(=O)O)O)O)O)O)Cl	PLASMA	X42P3B148J									∞	ng × h/mL	658							mg	10		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01525238	Homo sapiens										false
8891	10057		CHILD	91617971	585	DAPAGLIFLOZIN 3-O-Glucuronide	DAPAGLIFLOZIN 3-O-Glucuronide	CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)OC4C(C(C(C(O4)C(=O)O)O)O)O)O)Cl	PLASMA	X42P3B148J							48		t	ng × h/mL	612							mg	10		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01525238	Homo sapiens										false
8892	10057		CHILD	9887712	408.873	DAPAGLIFLOZIN	DAPAGLIFLOZIN	CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C=C1	PLASMA	1ULL0QJ8UC													ng/mL	24.8				mg	2.5		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01525238	Homo sapiens										false
8893	10057		CHILD	9887712	408.873	DAPAGLIFLOZIN	DAPAGLIFLOZIN	CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C=C1	PLASMA	1ULL0QJ8UC									∞	ng × h/mL	101							mg	2.5		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01525238	Homo sapiens										false
8894	10057		CHILD	9887712	408.873	DAPAGLIFLOZIN	DAPAGLIFLOZIN	CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C=C1	PLASMA	1ULL0QJ8UC							48		t	ng × h/mL	92.3							mg	2.5		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01525238	Homo sapiens										false
8895	10057		CHILD	91617971	585	DAPAGLIFLOZIN 3-O-Glucuronide	DAPAGLIFLOZIN 3-O-Glucuronide	CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)OC4C(C(C(C(O4)C(=O)O)O)O)O)O)Cl	PLASMA	X42P3B148J													ng/mL	24.6				mg	2.5		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01525238	Homo sapiens										false
8896	10057		CHILD	91617971	585	DAPAGLIFLOZIN 3-O-Glucuronide	DAPAGLIFLOZIN 3-O-Glucuronide	CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)OC4C(C(C(C(O4)C(=O)O)O)O)O)O)Cl	PLASMA	X42P3B148J									∞	ng × h/mL	105							mg	2.5		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01525238	Homo sapiens										false
8897	10057		CHILD	91617971	585	DAPAGLIFLOZIN 3-O-Glucuronide	DAPAGLIFLOZIN 3-O-Glucuronide	CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)OC4C(C(C(C(O4)C(=O)O)O)O)O)O)Cl	PLASMA	X42P3B148J							48		t	ng × h/mL	95.8							mg	2.5		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01525238	Homo sapiens										false
8898	10057		CHILD	9887712	408.873	DAPAGLIFLOZIN	DAPAGLIFLOZIN	CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C=C1	PLASMA	1ULL0QJ8UC													ng/mL	48.4				mg	5		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01525238	Homo sapiens										false
8899	10057		CHILD	9887712	408.873	DAPAGLIFLOZIN	DAPAGLIFLOZIN	CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C=C1	PLASMA	1ULL0QJ8UC									∞	ng × h/mL	199							mg	5		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01525238	Homo sapiens										false
8900	10057		CHILD	9887712	408.873	DAPAGLIFLOZIN	DAPAGLIFLOZIN	CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C=C1	PLASMA	1ULL0QJ8UC							48		t	ng × h/mL	189							mg	5		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01525238	Homo sapiens										false
8901	10057		CHILD	91617971	585	DAPAGLIFLOZIN 3-O-Glucuronide	DAPAGLIFLOZIN 3-O-Glucuronide	CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)OC4C(C(C(C(O4)C(=O)O)O)O)O)O)Cl	PLASMA	X42P3B148J													ng/mL	49				mg	5		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01525238	Homo sapiens										false
8902	10057		CHILD	91617971	585	DAPAGLIFLOZIN 3-O-Glucuronide	DAPAGLIFLOZIN 3-O-Glucuronide	CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)OC4C(C(C(C(O4)C(=O)O)O)O)O)O)Cl	PLASMA	X42P3B148J									∞	ng × h/mL	232							mg	5		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01525238	Homo sapiens										false
8903	10057		CHILD	91617971	585	DAPAGLIFLOZIN 3-O-Glucuronide	DAPAGLIFLOZIN 3-O-Glucuronide	CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)OC4C(C(C(C(O4)C(=O)O)O)O)O)O)Cl	PLASMA	X42P3B148J							48		t	ng × h/mL	208							mg	5		SINGLE							UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT01525238	Homo sapiens										false
8904	10057		UNKNOWN	9887712	408.873	DAPAGLIFLOZIN	DAPAGLIFLOZIN	CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C=C1	PLASMA	1ULL0QJ8UC									∞	ng × h/mL	368		ng/mL	116			RECOMMENDED	mg	10		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	REVIEW	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000ClinPharmR.pdf	Homo sapiens		h	3							false
8905	10057		UNKNOWN	9887712	408.873	DAPAGLIFLOZIN	DAPAGLIFLOZIN	CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C=C1	PLASMA	1ULL0QJ8UC							24		t	ng × h/mL	506		ng/mL	119			RECOMMENDED	mg	10		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	UNKNOWN	REVIEW	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000ClinPharmR.pdf	Homo sapiens		h	15.77							false
8906	10058		ADULT	44610678	720.259	EDOXABAN TOSYLATE	EDOXABAN TOSYLATE	CC1=CC=C(C=C1)S(O)(=O)=O.CN(C)C(=O)[C@H]2CC[C@H](NC(=O)C(=O)NC3=NC=C(Cl)C=C3)[C@@H](C2)NC(=O)C4=NC5=C(CN(C)CC5)S4	PLASMA	32W99UE810									∞	ng × h/mL	259		ng/mL	33.5			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20081065	Homo sapiens		h	5.79							false
8907	10058		ADULT	44610678	720.259	EDOXABAN TOSYLATE	EDOXABAN TOSYLATE	CC1=CC=C(C=C1)S(O)(=O)=O.CN(C)C(=O)[C@H]2CC[C@H](NC(=O)C(=O)NC3=NC=C(Cl)C=C3)[C@@H](C2)NC(=O)C4=NC5=C(CN(C)CC5)S4	PLASMA	32W99UE810									∞	ng × h/mL	993		ng/mL	152			RECOMMENDED	mg	30		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20081065	Homo sapiens		h	8.92							false
8908	10058		ADULT	44610678	720.259	EDOXABAN TOSYLATE	EDOXABAN TOSYLATE	CC1=CC=C(C=C1)S(O)(=O)=O.CN(C)C(=O)[C@H]2CC[C@H](NC(=O)C(=O)NC3=NC=C(Cl)C=C3)[C@@H](C2)NC(=O)C4=NC5=C(CN(C)CC5)S4	PLASMA	32W99UE810									∞	ng × h/mL	1779		ng/mL	302			RECOMMENDED	mg	60		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20081065	Homo sapiens		h	8.9							false
8909	10058		ADULT	44610678	720.259	EDOXABAN TOSYLATE	EDOXABAN TOSYLATE	CC1=CC=C(C=C1)S(O)(=O)=O.CN(C)C(=O)[C@H]2CC[C@H](NC(=O)C(=O)NC3=NC=C(Cl)C=C3)[C@@H](C2)NC(=O)C4=NC5=C(CN(C)CC5)S4	PLASMA	32W99UE810									∞	ng × h/mL	2680		ng/mL	375			UNKNOWN	mg	90		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20081065	Homo sapiens		h	9.3							false
8910	10058		ADULT	44610678	720.259	EDOXABAN TOSYLATE	EDOXABAN TOSYLATE	CC1=CC=C(C=C1)S(O)(=O)=O.CN(C)C(=O)[C@H]2CC[C@H](NC(=O)C(=O)NC3=NC=C(Cl)C=C3)[C@@H](C2)NC(=O)C4=NC5=C(CN(C)CC5)S4	PLASMA	32W99UE810									∞	ng × h/mL	2789		ng/mL	409			UNKNOWN	mg	120		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20081065	Homo sapiens		h	8.56							false
8911	10058		ADULT	44610678	720.259	EDOXABAN TOSYLATE	EDOXABAN TOSYLATE	CC1=CC=C(C=C1)S(O)(=O)=O.CN(C)C(=O)[C@H]2CC[C@H](NC(=O)C(=O)NC3=NC=C(Cl)C=C3)[C@@H](C2)NC(=O)C4=NC5=C(CN(C)CC5)S4	PLASMA	32W99UE810									∞	ng × h/mL	4322		ng/mL	487			UNKNOWN	mg	150		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20081065	Homo sapiens		h	10.7							false
8912	10058		ADULT	44610678	720.259	EDOXABAN TOSYLATE	EDOXABAN TOSYLATE	CC1=CC=C(C=C1)S(O)(=O)=O.CN(C)C(=O)[C@H]2CC[C@H](NC(=O)C(=O)NC3=NC=C(Cl)C=C3)[C@@H](C2)NC(=O)C4=NC5=C(CN(C)CC5)S4	PLASMA	32W99UE810									?	ng × h/mL	2806		ng/mL	507			UNKNOWN	mg	90		MULTIPLE	FED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20081065	Homo sapiens		h	9.2							false
8913	10058		ADULT	44610678	720.259	EDOXABAN TOSYLATE	EDOXABAN TOSYLATE	CC1=CC=C(C=C1)S(O)(=O)=O.CN(C)C(=O)[C@H]2CC[C@H](NC(=O)C(=O)NC3=NC=C(Cl)C=C3)[C@@H](C2)NC(=O)C4=NC5=C(CN(C)CC5)S4	PLASMA	32W99UE810									?	ng × h/mL	1805		ng/mL	305			UNKNOWN	mg	60		MULTIPLE	FED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20081065	Homo sapiens		h	9.44							false
8914	10058		ADULT	44610678	720.259	EDOXABAN TOSYLATE	EDOXABAN TOSYLATE	CC1=CC=C(C=C1)S(O)(=O)=O.CN(C)C(=O)[C@H]2CC[C@H](NC(=O)C(=O)NC3=NC=C(Cl)C=C3)[C@@H](C2)NC(=O)C4=NC5=C(CN(C)CC5)S4	PLASMA	32W99UE810									?	ng × h/mL	3682		ng/mL	649			UNKNOWN	mg	120		MULTIPLE	FED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20081065	Homo sapiens		h	9.75							false
8915	10058		ADULT	44610678	720.259	EDOXABAN TOSYLATE	EDOXABAN TOSYLATE	CC1=CC=C(C=C1)S(O)(=O)=O.CN(C)C(=O)[C@H]2CC[C@H](NC(=O)C(=O)NC3=NC=C(Cl)C=C3)[C@@H](C2)NC(=O)C4=NC5=C(CN(C)CC5)S4	PLASMA	32W99UE810									∞	ng × h/mL	1781		ng/mL	312			RECOMMENDED	mg	60		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20081065	Homo sapiens		h	9.75							false
8916	10058		UNKNOWN	44610678	720.259	EDOXABAN TOSYLATE	EDOXABAN TOSYLATE	CC1=CC=C(C=C1)S(O)(=O)=O.CN(C)C(=O)[C@H]2CC[C@H](NC(=O)C(=O)NC3=NC=C(Cl)C=C3)[C@@H](C2)NC(=O)C4=NC5=C(CN(C)CC5)S4	PLASMA	32W99UE810																	UNKNOWN				UNKNOWN	UNKNOWN				In vitro plasma protein binding is approximately 55%.	45	UNKNOWN	UNKNOWN	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206316s016lbl.pdf	Homo sapiens										false
8917	10059		ADULT	6918141	490.715	ELDECALCITOL	Eldecalcitol	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\\C(CCC[C@]12C)=C\\C=C3\\C[C@@H](O)[C@@H](OCCCO)[C@H](O)C3=C	SERUM	I2JP8UE90H									∞	pg × h/mL	6560.7		pg/mL	99.83			DEFINED DAILY	μg	0.75		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/450045_3112006M1022_1_010_1F.pdf#page=25 | https://www.pmda.go.jp/drugs/2011/P201100025/450045000_22300AMX00416_K100_1.pdf#page=349	Homo sapiens		h	52.99				32			false
8918	10059		ADULT	6918141	490.715	ELDECALCITOL	Eldecalcitol	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\\C(CCC[C@]12C)=C\\C=C3\\C[C@@H](O)[C@@H](OCCCO)[C@H](O)C3=C	SERUM	I2JP8UE90H							24		t	pg × h/mL	1368		pg/mL	80.9			DEFINED DAILY	μg	0.75		MULTIPLE	FED		day	1	n=9 for AUC and t1/2		HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/450045_3112006M1022_1_010_1F.pdf#page=25 | https://www.pmda.go.jp/drugs/2011/P201100025/450045000_22300AMX00416_K100_1.pdf#page=418	Homo sapiens		h	48.4	1st dose			10			false
8919	10059		ADULT	6918141	490.715	ELDECALCITOL	Eldecalcitol	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\\C(CCC[C@]12C)=C\\C=C3\\C[C@@H](O)[C@@H](OCCCO)[C@H](O)C3=C	SERUM	I2JP8UE90H							24		t	pg × h/mL	4964		pg/mL	243.5			DEFINED DAILY	μg	0.75		STEADY-STATE	FED		day	1	n=9 for AUC and t1/2		HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/450045_3112006M1022_1_010_1F.pdf#page=25 | https://www.pmda.go.jp/drugs/2011/P201100025/450045000_22300AMX00416_K100_1.pdf#page=418	Homo sapiens		h	48.7	14th dose			10			false
8920	10059		ADULT	6918141	490.715	ELDECALCITOL	Eldecalcitol	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\\C(CCC[C@]12C)=C\\C=C3\\C[C@@H](O)[C@@H](OCCCO)[C@H](O)C3=C	SERUM	I2JP8UE90H									∞	pg × h/mL	6977.4		pg/mL	95.37			DEFINED DAILY	μg	0.75		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2011/P201100025/450045000_22300AMX00416_A100_1.pdf#page=34 | https://www.pmda.go.jp/drugs/2011/P201100025/450045000_22300AMX00416_K100_1.pdf#page=351	Homo sapiens		h	56.89				15			false
8921	10059		ADULT	6918141	490.715	ELDECALCITOL	Eldecalcitol	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\\C(CCC[C@]12C)=C\\C=C3\\C[C@@H](O)[C@@H](OCCCO)[C@H](O)C3=C	SERUM	I2JP8UE90H									∞	pg × h/mL	6956.2		pg/mL	100.42			DEFINED DAILY	μg	0.75		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2011/P201100025/450045000_22300AMX00416_A100_1.pdf#page=34 | https://www.pmda.go.jp/drugs/2011/P201100025/450045000_22300AMX00416_K100_1.pdf#page=351	Homo sapiens		h	55.84				15			false
8922	10059			6918141	490.715	ELDECALCITOL	Eldecalcitol	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\\C(CCC[C@]12C)=C\\C=C3\\C[C@@H](O)[C@@H](OCCCO)[C@H](O)C3=C	SERUM	I2JP8UE90H																										Human serum protein binding (ultrafiltration): 96.2% (1ng/mL), 95.1% (10ng/mL), 94.2% (100ng/mL)	3.8				OTHER GOV'T	https://www.pmda.go.jp/drugs/2011/P201100025/450045000_22300AMX00416_A100_1.pdf#page=36 | https://www.pmda.go.jp/drugs/2011/P201100025/450045000_22300AMX00416_I100_1.pdf#page=49	Homo sapiens										false
8923	10059		ADULT	6918141	490.715	ELDECALCITOL	Eldecalcitol	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\\C(CCC[C@]12C)=C\\C=C3\\C[C@@H](O)[C@@H](OCCCO)[C@H](O)C3=C	SERUM	I2JP8UE90H							24		t	pg × h/mL	8496		pg/mL	407.9			UNKNOWN	μg	1		MULTIPLE	FED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2011/P201100025/450045000_22300AMX00416_A100_1.pdf#page=37 | https://www.pmda.go.jp/drugs/2011/P201100025/450045000_22300AMX00416_A100_1.pdf#page=38 | https://www.pmda.go.jp/drugs/2011/P201100025/450045000_22300AMX00416_K100_1.pdf#page=390	Homo sapiens		h	54.3	Day 15			6			false
8924	10059		ADULT	6918141	490.715	ELDECALCITOL	Eldecalcitol	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\\C(CCC[C@]12C)=C\\C=C3\\C[C@@H](O)[C@@H](OCCCO)[C@H](O)C3=C	SERUM	I2JP8UE90H													pg/mL	30.6			UNKNOWN	μg	0.25		MULTIPLE	FED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2011/P201100025/450045000_22300AMX00416_A100_1.pdf#page=37 | https://www.pmda.go.jp/drugs/2011/P201100025/450045000_22300AMX00416_A100_1.pdf#page=38 |https://www.pmda.go.jp/drugs/2011/P201100025/450045000_22300AMX00416_K100_1.pdf#page=390	Homo sapiens				Day 1			6			false
8925	10059		ADULT	6918141	490.715	ELDECALCITOL	Eldecalcitol	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\\C(CCC[C@]12C)=C\\C=C3\\C[C@@H](O)[C@@H](OCCCO)[C@H](O)C3=C	SERUM	I2JP8UE90H													pg/mL	30.6			UNKNOWN	μg	0.1		STEADY-STATE	FED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2011/P201100025/450045000_22300AMX00416_A100_1.pdf#page=37 | https://www.pmda.go.jp/drugs/2011/P201100025/450045000_22300AMX00416_A100_1.pdf#page=38 |https://www.pmda.go.jp/drugs/2011/P201100025/450045000_22300AMX00416_K100_1.pdf#page=390	Homo sapiens				Day 15			6			false
8926	10059		ADULT	6918141	490.715	ELDECALCITOL	Eldecalcitol	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\\C(CCC[C@]12C)=C\\C=C3\\C[C@@H](O)[C@@H](OCCCO)[C@H](O)C3=C	SERUM	I2JP8UE90H													pg/mL	61			RECOMMENDED	μg	0.5		MULTIPLE	FED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2011/P201100025/450045000_22300AMX00416_A100_1.pdf#page=37 | https://www.pmda.go.jp/drugs/2011/P201100025/450045000_22300AMX00416_A100_1.pdf#page=38 |https://www.pmda.go.jp/drugs/2011/P201100025/450045000_22300AMX00416_K100_1.pdf#page=390	Homo sapiens				Day 1			6			false
8927	10059		ADULT	6918141	490.715	ELDECALCITOL	Eldecalcitol	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\\C(CCC[C@]12C)=C\\C=C3\\C[C@@H](O)[C@@H](OCCCO)[C@H](O)C3=C	SERUM	I2JP8UE90H													pg/mL	115.5			UNKNOWN	μg	1		MULTIPLE	FED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2011/P201100025/450045000_22300AMX00416_A100_1.pdf#page=37 | https://www.pmda.go.jp/drugs/2011/P201100025/450045000_22300AMX00416_A100_1.pdf#page=38 |https://www.pmda.go.jp/drugs/2011/P201100025/450045000_22300AMX00416_K100_1.pdf#page=390	Homo sapiens				Day 1			6			false
8928	10059		ADULT	6918141	490.715	ELDECALCITOL	Eldecalcitol	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\\C(CCC[C@]12C)=C\\C=C3\\C[C@@H](O)[C@@H](OCCCO)[C@H](O)C3=C	SERUM	I2JP8UE90H							24		t	pg × h/mL	778		pg/mL	37.9			UNKNOWN	μg	0.1		MULTIPLE	FED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2011/P201100025/450045000_22300AMX00416_A100_1.pdf#page=37 | https://www.pmda.go.jp/drugs/2011/P201100025/450045000_22300AMX00416_A100_1.pdf#page=38 |https://www.pmda.go.jp/drugs/2011/P201100025/450045000_22300AMX00416_K100_1.pdf#page=390	Homo sapiens				Day 15			6			false
8929	10059		ADULT	6918141	490.715	ELDECALCITOL	Eldecalcitol	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\\C(CCC[C@]12C)=C\\C=C3\\C[C@@H](O)[C@@H](OCCCO)[C@H](O)C3=C	SERUM	I2JP8UE90H							24		t	pg × h/mL	2180		pg/mL	107.9			UNKNOWN	μg	0.25		MULTIPLE	FED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2011/P201100025/450045000_22300AMX00416_A100_1.pdf#page=37 | https://www.pmda.go.jp/drugs/2011/P201100025/450045000_22300AMX00416_A100_1.pdf#page=38 |https://www.pmda.go.jp/drugs/2011/P201100025/450045000_22300AMX00416_K100_1.pdf#page=390	Homo sapiens		h	55.1	Day 15			6			false
8930	10059		ADULT	6918141	490.715	ELDECALCITOL	Eldecalcitol	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\\C(CCC[C@]12C)=C\\C=C3\\C[C@@H](O)[C@@H](OCCCO)[C@H](O)C3=C	SERUM	I2JP8UE90H							24		t	pg × h/mL	3988		pg/mL	195.4			RECOMMENDED	μg	0.5		MULTIPLE	FED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2011/P201100025/450045000_22300AMX00416_A100_1.pdf#page=37 | https://www.pmda.go.jp/drugs/2011/P201100025/450045000_22300AMX00416_A100_1.pdf#page=38 |https://www.pmda.go.jp/drugs/2011/P201100025/450045000_22300AMX00416_K100_1.pdf#page=390	Homo sapiens		h	51.9	Day 15			6			false
8931	10059		ADULT	6918141	490.715	ELDECALCITOL	Eldecalcitol	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\\C(CCC[C@]12C)=C\\C=C3\\C[C@@H](O)[C@@H](OCCCO)[C@H](O)C3=C	SERUM	I2JP8UE90H									?	pg × h/mL	2086.6		pg/mL	61.3			RECOMMENDED	μg	0.5		SINGLE	FASTED				n=4 for AUC		HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2011/P201100025/450045000_22300AMX00416_A100_1.pdf#page=37 | https://www.pmda.go.jp/drugs/2011/P201100025/450045000_22300AMX00416_K100_1.pdf#page=380	Homo sapiens							6			false
8932	10059		ADULT	6918141	490.715	ELDECALCITOL	Eldecalcitol	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\\C(CCC[C@]12C)=C\\C=C3\\C[C@@H](O)[C@@H](OCCCO)[C@H](O)C3=C	SERUM	I2JP8UE90H									?	pg × h/mL	4545.1		pg/mL	104.3			UNKNOWN	μg	1		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2011/P201100025/450045000_22300AMX00416_A100_1.pdf#page=37 | https://www.pmda.go.jp/drugs/2011/P201100025/450045000_22300AMX00416_K100_1.pdf#page=380	Homo sapiens		h	52.5				6			false
8933	10059		ADULT	6918141	490.715	ELDECALCITOL	Eldecalcitol	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\\C(CCC[C@]12C)=C\\C=C3\\C[C@@H](O)[C@@H](OCCCO)[C@H](O)C3=C	SERUM	I2JP8UE90H									∞	pg × h/mL	5996.1		pg/mL	99.66			DEFINED DAILY	μg	0.75		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2011/P201100025/450045000_22300AMX00416_A100_1.pdf#page=40 | https://www.pmda.go.jp/drugs/2011/P201100025/450045000_22300AMX00416_K100_1.pdf#page=404	Homo sapiens		h	48.03		Mild hepatic impairment (Child-Pugh A)		8			false
8934	10059		ADULT	6918141	490.715	ELDECALCITOL	Eldecalcitol	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\\C(CCC[C@]12C)=C\\C=C3\\C[C@@H](O)[C@@H](OCCCO)[C@H](O)C3=C	SERUM	I2JP8UE90H									∞	pg × h/mL	5076.8		pg/mL	73.85			DEFINED DAILY	μg	0.75		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2011/P201100025/450045000_22300AMX00416_A100_1.pdf#page=40 | https://www.pmda.go.jp/drugs/2011/P201100025/450045000_22300AMX00416_K100_1.pdf#page=404	Homo sapiens		h	45.88		Moderate hepatic impairment (Child-Pugh B)		2			false
8935	10061		UNKNOWN	9823820	426.853	LENVATINIB	LENVATINIB	COC1=C(C=C2C(OC3=CC(Cl)=C(NC(=O)NC4CC4)C=C3)=CC=NC2=C1)C(N)=O	PLASMA	EE083865G2																						UNKNOWN				In vitro binding of lenvatinib to human plasma proteins ranged from 98% to 99% at concentrations of 0.3 to 30 μg/mL.	1.5	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206947s007lbl.pdf	Homo sapiens										false
8936	10061		ADULT	9823820	426.10947	LENVATINIB	LENVATINIB	COC1=C(C=C2C(OC3=CC(Cl)=C(NC(=O)NC4CC4)C=C3)=CC=NC2=C1)C(N)=O	PLASMA	EE083865G2									∞	ng × h/mL	3010		ng/mL	325			DEFINED DAILY	mg	2		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.ema.europa.eu/en/documents/assessment-report/lenvima-epar-public-assessment-report_en.pdf	Homo sapiens		h	28							false
8937	10062		ADULT	688272	341.426	LEVOSULPIRIDE	Levosulpiride	CCN1CCC[C@H]1CNC(=O)C2=C(OC)C=CC(=C2)S(N)(=O)=O	PLASMA	JTG7R315LK									∞	ng × h/mL	874		ng/mL	73			UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19488984/	Homo sapiens		h	8.77				24			false
8938	10062		ADULT	688272	341.426	LEVOSULPIRIDE	Levosulpiride	CCN1CCC[C@H]1CNC(=O)C2=C(OC)C=CC(=C2)S(N)(=O)=O	PLASMA	JTG7R315LK							36		t	ng × h/mL	2146		ng/mL	539			UNKNOWN	mg	25		MULTIPLE	UNKNOWN		day	2			HEALTHY	Intramuscular	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26579410/	Homo sapiens		h	7.6	Day 5 PK			12			false
8939	10062		ADULT	688272	341.426	LEVOSULPIRIDE	Levosulpiride	CCN1CCC[C@H]1CNC(=O)C2=C(OC)C=CC(=C2)S(N)(=O)=O	PLASMA	JTG7R315LK							36		t	ng × h/mL	3478		ng/mL	823			UNKNOWN	mg	50		SINGLE	FED						HEALTHY	Intramuscular	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26579410/	Homo sapiens		h	6.8				12			false
8940	10062		ADULT	688272	341.426	LEVOSULPIRIDE	Levosulpiride	CCN1CCC[C@H]1CNC(=O)C2=C(OC)C=CC(=C2)S(N)(=O)=O	PLASMA	JTG7R315LK							36		t	ng × h/mL	1724		ng/mL	441			UNKNOWN	mg	25		SINGLE	FED						HEALTHY	Intramuscular	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26579410/	Homo sapiens		h	7				12			false
8941	10062			688272	341.426	LEVOSULPIRIDE	Levosulpiride	CCN1CCC[C@H]1CNC(=O)C2=C(OC)C=CC(=C2)S(N)(=O)=O	PLASMA	JTG7R315LK																										In human plasma, 14% is bound over a concentration range of 1 to 50 pg/ml.	86				REVIEW	https://pubmed.ncbi.nlm.nih.gov/7596959/	Homo sapiens										false
8942	10065		ADULT	46209133	398.428	OMARIGLIPTIN	Omarigliptin	CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]3CO[C@@H]([C@@H](N)C3)C4=C(F)C=CC(F)=C4	PLASMA	CVP59Q4JE1							168		t	μM × h	23		nM	523			RECOMMENDED	mg	25		SINGLE	HIGH-FAT						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=26 | https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=37	Homo sapiens		h	46				14			false
8943	10065		ADULT	46209133	398.428	OMARIGLIPTIN	Omarigliptin	CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]3CO[C@@H]([C@@H](N)C3)C4=C(F)C=CC(F)=C4	PLASMA	CVP59Q4JE1							168		t	μM × h	22.7		nM	549			RECOMMENDED	mg	25		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=26 | https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=37	Homo sapiens		h	46.8				14			false
8944	10065			46209133	398.428	OMARIGLIPTIN	Omarigliptin	CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]3CO[C@@H]([C@@H](N)C3)C4=C(F)C=CC(F)=C4	PLASMA	CVP59Q4JE1																										Human plasma protein Fu (equilibrium dialysis): 25% (1nM), 36% (5nM), 43% (10nM), 56% (25nM),64% (50nM), 71% (100nM), 76% (250, 1000nM)	24				OTHER GOV'T	https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=27 | https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_I100_1.pdf#page=21	Homo sapiens										false
8945	10065		ADULT	46209133	398.428	OMARIGLIPTIN	Omarigliptin	CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]3CO[C@@H]([C@@H](N)C3)C4=C(F)C=CC(F)=C4	PLASMA	CVP59Q4JE1							168		t	μM × h	5.34		nM	141.51			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=29 | https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=51	Homo sapiens		h	66.65		Japanese subjects		6			false
8946	10065		ADULT	46209133	398.428	OMARIGLIPTIN	Omarigliptin	CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]3CO[C@@H]([C@@H](N)C3)C4=C(F)C=CC(F)=C4	PLASMA	CVP59Q4JE1							168		t	μM × h	23.81		nM	749.54			RECOMMENDED	mg	25		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=29 | https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=51	Homo sapiens		h	38.89		Japanese subjects		6			false
8947	10065		ADULT	46209133	398.428	OMARIGLIPTIN	Omarigliptin	CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]3CO[C@@H]([C@@H](N)C3)C4=C(F)C=CC(F)=C4	PLASMA	CVP59Q4JE1							168		t	μM × h	9.07		nM	297.84			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=29 | https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=51	Homo sapiens		h	49.91		Japanese subjects		6			false
8948	10065		ADULT	46209133	398.428	OMARIGLIPTIN	Omarigliptin	CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]3CO[C@@H]([C@@H](N)C3)C4=C(F)C=CC(F)=C4	PLASMA	CVP59Q4JE1							168		t	μM × h	94.63		nM	2709.59			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=29 | https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=51	Homo sapiens		h	43.41		Japanese subjects		6			false
8949	10065		ADULT	46209133	398.428	OMARIGLIPTIN	Omarigliptin	CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]3CO[C@@H]([C@@H](N)C3)C4=C(F)C=CC(F)=C4	PLASMA	CVP59Q4JE1							168		t	μM × h	48.66		nM	1712.32			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=29 | https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=51	Homo sapiens		h	33.43		Japanese subjects		6			false
8950	10065		ADULT	46209133	398.428	OMARIGLIPTIN	Omarigliptin	CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]3CO[C@@H]([C@@H](N)C3)C4=C(F)C=CC(F)=C4	PLASMA	CVP59Q4JE1							168		t	μM × h	8.75		nM	223.03			UNKNOWN	mg	10		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=29 | https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=51	Homo sapiens		h	89.45		Japanese subjects		6			false
8951	10065		ADULT	46209133	398.428	OMARIGLIPTIN	Omarigliptin	CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]3CO[C@@H]([C@@H](N)C3)C4=C(F)C=CC(F)=C4	PLASMA	CVP59Q4JE1							168		t	μM × h	40.32		nM	1083.59			UNKNOWN	mg	50		MULTIPLE	FASTED		week	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=30 | https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=52	Homo sapiens				Day 1	Japanese subjects		6			false
8952	10065		ADULT	46209133	398.428	OMARIGLIPTIN	Omarigliptin	CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]3CO[C@@H]([C@@H](N)C3)C4=C(F)C=CC(F)=C4	PLASMA	CVP59Q4JE1							168		t	μM × h	41.56		nM	1305.97			UNKNOWN	mg	50		MULTIPLE	FASTED		week	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=30 | https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=52	Homo sapiens		h	73.73	Day 15	Japanese subjects		5			false
8953	10065		ADULT	46209133	398.428	OMARIGLIPTIN	Omarigliptin	CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]3CO[C@@H]([C@@H](N)C3)C4=C(F)C=CC(F)=C4	PLASMA	CVP59Q4JE1							168		t	μM × h	1.03		nM	15.66			UNKNOWN	mg	1		MULTIPLE	FASTED		week	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=30 | https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=52	Homo sapiens				Day 1	Japanese subjects		6			false
8954	10065		ADULT	46209133	398.428	OMARIGLIPTIN	Omarigliptin	CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]3CO[C@@H]([C@@H](N)C3)C4=C(F)C=CC(F)=C4	PLASMA	CVP59Q4JE1							168		t	μM × h	1.4		nM	21.25			UNKNOWN	mg	1		MULTIPLE	FASTED		week	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=30 | https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=52	Homo sapiens		h	144.88	Day 15	Japanese subjects		4			false
8955	10065		ADULT	46209133	398.428	OMARIGLIPTIN	Omarigliptin	CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]3CO[C@@H]([C@@H](N)C3)C4=C(F)C=CC(F)=C4	PLASMA	CVP59Q4JE1							168		t	μM × h	8.92		nM	236.65			UNKNOWN	mg	10		MULTIPLE	FASTED		week	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=30 | https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=52	Homo sapiens				Day 1	Japanese subjects		6			false
8956	10065		ADULT	46209133	398.428	OMARIGLIPTIN	Omarigliptin	CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]3CO[C@@H]([C@@H](N)C3)C4=C(F)C=CC(F)=C4	PLASMA	CVP59Q4JE1							168		t	μM × h	9.75		nM	278.21			RECOMMENDED	mg	10		MULTIPLE	FASTED		week	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=30 | https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=52	Homo sapiens		h	143.52	Day 15	Japanese subjects		6			false
8957	10065		ADULT	46209133	398.428	OMARIGLIPTIN	Omarigliptin	CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]3CO[C@@H]([C@@H](N)C3)C4=C(F)C=CC(F)=C4	PLASMA	CVP59Q4JE1							168		t	μM × h	21.19		nM	802.6			RECOMMENDED	mg	25		MULTIPLE	FASTED		week	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=30 | https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=52	Homo sapiens				Day 1	Japanese subjects		6			false
8958	10065		ADULT	46209133	398.428	OMARIGLIPTIN	Omarigliptin	CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]3CO[C@@H]([C@@H](N)C3)C4=C(F)C=CC(F)=C4	PLASMA	CVP59Q4JE1							168		t	μM × h	22.31		nM	700.63			UNKNOWN	mg	25		MULTIPLE	FASTED		week	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=30 | https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=52	Homo sapiens		h	82.48	Day 15	Japanese subjects		6			false
8959	10065		ADULT	46209133	398.428	OMARIGLIPTIN	Omarigliptin	CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]3CO[C@@H]([C@@H](N)C3)C4=C(F)C=CC(F)=C4	PLASMA	CVP59Q4JE1									?	μM × h	0.147		nM	6.45			UNKNOWN	mg	0.5		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=32 | https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=69	Homo sapiens							6			false
8960	10065		ADULT	46209133	398.428	OMARIGLIPTIN	Omarigliptin	CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]3CO[C@@H]([C@@H](N)C3)C4=C(F)C=CC(F)=C4	PLASMA	CVP59Q4JE1							168		t	μM × h	1.2		nM	20.7			UNKNOWN	mg	1.5		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=32 | https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=69	Homo sapiens		h	93.3				6			false
8961	10065		ADULT	46209133	398.428	OMARIGLIPTIN	Omarigliptin	CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]3CO[C@@H]([C@@H](N)C3)C4=C(F)C=CC(F)=C4	PLASMA	CVP59Q4JE1							168		t	μM × h	4.13		nM	88.2			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=32 | https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=69	Homo sapiens		h	115.94				6			false
8962	10065		ADULT	46209133	398.428	OMARIGLIPTIN	Omarigliptin	CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]3CO[C@@H]([C@@H](N)C3)C4=C(F)C=CC(F)=C4	PLASMA	CVP59Q4JE1							168		t	μM × h	10.6		nM	219			UNKNOWN	mg	12.5		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=32 | https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=69	Homo sapiens		h	68.88				6			false
8963	10065		ADULT	46209133	398.428	OMARIGLIPTIN	Omarigliptin	CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]3CO[C@@H]([C@@H](N)C3)C4=C(F)C=CC(F)=C4	PLASMA	CVP59Q4JE1							168		t	μM × h	20.9		nM	484			UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=32 | https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=69	Homo sapiens		h	49.52				6			false
8964	10065		ADULT	46209133	398.428	OMARIGLIPTIN	Omarigliptin	CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]3CO[C@@H]([C@@H](N)C3)C4=C(F)C=CC(F)=C4	PLASMA	CVP59Q4JE1							168		t	μM × h	39.4		nM	904			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=32 | https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=69	Homo sapiens		h	47.65				6			false
8965	10065		ADULT	46209133	398.428	OMARIGLIPTIN	Omarigliptin	CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]3CO[C@@H]([C@@H](N)C3)C4=C(F)C=CC(F)=C4	PLASMA	CVP59Q4JE1							168		t	μM × h	82.5		nM	2210			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=32 | https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=69	Homo sapiens		h	42.62				6			false
8966	10065		ADULT	46209133	398.428	OMARIGLIPTIN	Omarigliptin	CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]3CO[C@@H]([C@@H](N)C3)C4=C(F)C=CC(F)=C4	PLASMA	CVP59Q4JE1							168		t	μM × h	155		nM	3850			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=32 | https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=69	Homo sapiens		h	45.19				6			false
8967	10065		ADULT	46209133	398.428	OMARIGLIPTIN	Omarigliptin	CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]3CO[C@@H]([C@@H](N)C3)C4=C(F)C=CC(F)=C4	PLASMA	CVP59Q4JE1							168		t	μM × h	323		nM	9290			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=32 | https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=69	Homo sapiens		h	42.45				12			false
8968	10065		ADULT	46209133	398.428	OMARIGLIPTIN	Omarigliptin	CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]3CO[C@@H]([C@@H](N)C3)C4=C(F)C=CC(F)=C4	PLASMA	CVP59Q4JE1							168		t	μM × h	9.59		nM	206			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=32 | https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=70	Homo sapiens		h	119.59				6			false
8969	10065		ADULT	46209133	398.428	OMARIGLIPTIN	Omarigliptin	CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]3CO[C@@H]([C@@H](N)C3)C4=C(F)C=CC(F)=C4	PLASMA	CVP59Q4JE1							168		t	μM × h	9.99		nM	195			UNKNOWN	mg	10		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=32 | https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=70	Homo sapiens		h	98.22				6			false
8970	10065		ADULT	46209133	398.428	OMARIGLIPTIN	Omarigliptin	CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]3CO[C@@H]([C@@H](N)C3)C4=C(F)C=CC(F)=C4	PLASMA	CVP59Q4JE1							168		t	μM × h	8.76		nM	195			UNKNOWN	mg	10		MULTIPLE	FASTED		week	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=33 | https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=79	Homo sapiens		h	83.18	Day 15			6			false
8971	10065		ADULT	46209133	398.428	OMARIGLIPTIN	Omarigliptin	CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]3CO[C@@H]([C@@H](N)C3)C4=C(F)C=CC(F)=C4	PLASMA	CVP59Q4JE1							168		t	μM × h	7.37		nM	184			UNKNOWN	mg	10		MULTIPLE	FASTED		week	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=33 | https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=79	Homo sapiens				Day 1			6			false
8972	10065		ADULT	46209133	398.428	OMARIGLIPTIN	Omarigliptin	CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]3CO[C@@H]([C@@H](N)C3)C4=C(F)C=CC(F)=C4	PLASMA	CVP59Q4JE1							168		t	μM × h	22		nM	610			RECOMMENDED	mg	25		MULTIPLE	FASTED		week	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=33 | https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=79	Homo sapiens				Day 1			6			false
8973	10065		ADULT	46209133	398.428	OMARIGLIPTIN	Omarigliptin	CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]3CO[C@@H]([C@@H](N)C3)C4=C(F)C=CC(F)=C4	PLASMA	CVP59Q4JE1							168		t	μM × h	22		nM	565			RECOMMENDED	mg	25		MULTIPLE	FASTED		week	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=33 | https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=79	Homo sapiens		h	66.74	Day 15			6			false
8974	10065		ADULT	46209133	398.428	OMARIGLIPTIN	Omarigliptin	CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]3CO[C@@H]([C@@H](N)C3)C4=C(F)C=CC(F)=C4	PLASMA	CVP59Q4JE1							168		t	μM × h	40.7		nM	988			RECOMMENDED	mg	50		MULTIPLE	FASTED		week	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=33 | https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=79	Homo sapiens				Day 1			6			false
8975	10065		ADULT	46209133	398.428	OMARIGLIPTIN	Omarigliptin	CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]3CO[C@@H]([C@@H](N)C3)C4=C(F)C=CC(F)=C4	PLASMA	CVP59Q4JE1							168		t	μM × h	47.8		nM	1080			RECOMMENDED	mg	50		MULTIPLE	FASTED		week	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=33 | https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=79	Homo sapiens		h	48.3	Day 15			6			false
8976	10065		ADULT	46209133	398.428	OMARIGLIPTIN	Omarigliptin	CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]3CO[C@@H]([C@@H](N)C3)C4=C(F)C=CC(F)=C4	PLASMA	CVP59Q4JE1							168		t	μM × h	82.3		nM	2320			RECOMMENDED	mg	100		MULTIPLE	FASTED		week	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=33 | https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=79	Homo sapiens				Day 1			6			false
8977	10065		ADULT	46209133	398.428	OMARIGLIPTIN	Omarigliptin	CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]3CO[C@@H]([C@@H](N)C3)C4=C(F)C=CC(F)=C4	PLASMA	CVP59Q4JE1							168		t	μM × h	87.8		nM	2400			RECOMMENDED	mg	100		MULTIPLE	FASTED		week	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=33 | https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=79	Homo sapiens		h	41.74	Day 15			6			false
8978	10065		ADULT	46209133	398.428	OMARIGLIPTIN	Omarigliptin	CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]3CO[C@@H]([C@@H](N)C3)C4=C(F)C=CC(F)=C4	PLASMA	CVP59Q4JE1							168		t	nM × h	3055		nM	60.4			UNKNOWN	mg	3		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=36	Homo sapiens		h	148		Mild renal impairment		6			false
8979	10065		ADULT	46209133	398.428	OMARIGLIPTIN	Omarigliptin	CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]3CO[C@@H]([C@@H](N)C3)C4=C(F)C=CC(F)=C4	PLASMA	CVP59Q4JE1							168		t	nM × h	3675		nM	61.4			UNKNOWN	mg	3		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=36	Homo sapiens		h	156		Moderate renal impairment		6			false
8980	10065		ADULT	46209133	398.428	OMARIGLIPTIN	Omarigliptin	CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]3CO[C@@H]([C@@H](N)C3)C4=C(F)C=CC(F)=C4	PLASMA	CVP59Q4JE1							168		t	nM × h	3580		nM	48.7			UNKNOWN	mg	3		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=36	Homo sapiens		h	160		Severe renal impairment		6			false
8981	10065		ADULT	46209133	398.428	OMARIGLIPTIN	Omarigliptin	CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]3CO[C@@H]([C@@H](N)C3)C4=C(F)C=CC(F)=C4	PLASMA	CVP59Q4JE1							168		t	nM × h	3352		nM	41.4			UNKNOWN	mg	3		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=36	Homo sapiens		h	215		ESRD, administered right after hemodialysis		6			false
8982	10065		ADULT	46209133	398.428	OMARIGLIPTIN	Omarigliptin	CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]3CO[C@@H]([C@@H](N)C3)C4=C(F)C=CC(F)=C4	PLASMA	CVP59Q4JE1							168		t	nM × h	3151		nM	41			UNKNOWN	mg	3		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=36	Homo sapiens		h	264		ESRD, administered 2-h prior to hemodialysis		6			false
8983	10065		ADULT	46209133	398.428	OMARIGLIPTIN	Omarigliptin	CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]3CO[C@@H]([C@@H](N)C3)C4=C(F)C=CC(F)=C4	PLASMA	CVP59Q4JE1							168		t	nM × h	2432		nM	56.1			UNKNOWN	mg	3		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=36	Homo sapiens		h	163		Normal renal function		7			false
8984	10065		ADULT	46209133	398.428	OMARIGLIPTIN	Omarigliptin	CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]3CO[C@@H]([C@@H](N)C3)C4=C(F)C=CC(F)=C4	PLASMA	CVP59Q4JE1							168		t	μM × h	22.4		nM	572			RECOMMENDED	mg	25		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=38 | https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=125	Homo sapiens		h	34.6		Moderate hepatic impairment		8			false
8985	10065		ADULT	46209133	398.428	OMARIGLIPTIN	Omarigliptin	CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]3CO[C@@H]([C@@H](N)C3)C4=C(F)C=CC(F)=C4	PLASMA	CVP59Q4JE1							168		t	μM × h	23.8		nM	554			RECOMMENDED	mg	25		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_A100_2.pdf#page=38 | https://www.pmda.go.jp/drugs/2015/P20151007002/170050000_22700AMX01014000_K108_1.pdf#page=125	Homo sapiens		h	34.5		Normal hepatic function		8			false
8986	10066		UNKNOWN	71496458	499.6073	OSIMERTINIB	OSIMERTINIB	COC1=C(NC2=NC=CC(=N2)C3=CN(C)C4=C3C=CC=C4)C=C(NC(=O)C=C)C(=C1)N(C)CCN(C)C	PLASMA	3C06JJ0Z2O																						UNKNOWN				Plasma protein binding of osimertinib was 95%.	5	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208065s008lbl.pdf	Homo sapiens										false
8987	10066		ADULT	71496458	499.2696	OSIMERTINIB	OSIMERTINIB	COC1=C(NC2=NC=CC(=N2)C3=CN(C)C4=C3C=CC=C4)C=C(NC(=O)C=C)C(=C1)N(C)CCN(C)C	PLASMA	3C06JJ0Z2O									∞	nM × h	12670		nM	660.7			DEFINED DAILY	mg	80		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891183/pdf/CAS-109-1177.pdf	Homo sapiens										false
8988	10066		ADULT	71496458	499.2696	OSIMERTINIB	OSIMERTINIB	COC1=C(NC2=NC=CC(=N2)C3=CN(C)C4=C3C=CC=C4)C=C(NC(=O)C=C)C(=C1)N(C)CCN(C)C	PLASMA	3C06JJ0Z2O									∞	nM × h	6770		nM	118			DEFINED DAILY	mg	80		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/29683562	Homo sapiens		h	59.7							false
8989	10067		ADULT	5330286	447.5	PALBOCICLIB	PALBOCICLIB	CC(=O)C1=C(C)C2=CN=C(NC3=CC=C(C=N3)N4CCNCC4)N=C2N(C5CCCC5)C1=O	PLASMA	G9ZF61LE7G									∞	ng × h/mL	2483		ng/mL	104.1			RECOMMENDED	mg	125		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26991823	Homo sapiens		h	23.9							false
8990	10068		UNKNOWN	6918837	349.4262	PANOBINOSTAT	PANOBINOSTAT	CC1=C(CCNCC2=CC=C(\\C=C\\C(=O)NO)C=C2)C3=C(N1)C=CC=C3	PLASMA	9647FM7Y3Z																						UNKNOWN				Panobinostat is approximately 90% bound to human plasma proteins in vitro and is independent of concentration.	10	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205353s000lbl.pdf	Homo sapiens										false
8991	10068		ADULT	6918837	349.17902	PANOBINOSTAT	PANOBINOSTAT	CC1=C(CCNCC2=CC=C(\\C=C\\C(=O)NO)C=C2)C3=C(N1)C=CC=C3	PLASMA	9647FM7Y3Z	387447		BORTEZOMIB	bortezomib	CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)B(O)O	69G8BD63PP	24		t	ng × h/mL	95.2		ng/mL	15.3			UNKNOWN	mg	20		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	REVIEW	https://www.ncbi.nlm.nih.gov/pubmed/27226420	Homo sapiens		h	16.7							true
8992	10069		ADULT	10311306	500.4766	ROLAPITANT	C[C@@H](OC[C@]1(CC[C@]2(CCC(=O)N2)CN1)C3=CC=CC=C3)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F	C[C@@H](OC[C@]1(CC[C@]2(CCC(=O)N2)CN1)C3=CC=CC=C3)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F	PLASMA	NLE429IZUC													ng/mL	968			RECOMMENDED	mg	180		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208399s000lbl.pdf	Homo sapiens		h	183							false
8993	10069		ADULT	10311306	500.4766	ROLAPITANT	C[C@@H](OC[C@]1(CC[C@]2(CCC(=O)N2)CN1)C3=CC=CC=C3)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F	C[C@@H](OC[C@]1(CC[C@]2(CCC(=O)N2)CN1)C3=CC=CC=C3)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F	PLASMA	NLE429IZUC									∞	ng × h/mL	118019.42		ng/mL	967.69			RECOMMENDED	mg	180		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/28906561	Homo sapiens										false
8994	10070		UNKNOWN	24775005	485.4981	SONIDEGIB	SONIDEGIB	C[C@H]1CN(C[C@@H](C)O1)C2=NC=C(NC(=O)C3=C(C)C(=CC=C3)C4=CC=C(OC(F)(F)F)C=C4)C=C2	PLASMA	0RLU3VTK5M							24		t	μg × h/mL	22		ng/mL	1030			RECOMMENDED	mg	200		STEADY-STATE	UNKNOWN		day	1	Sonidegib was highly bound to human plasma proteins in vitro (>97%) and the binding was concentration independent.	3	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205266Orig1s000lbl.pdf	Homo sapiens		day	28							false
8995	10070		UNKNOWN	24775005	485.4981	SONIDEGIB	SONIDEGIB	C[C@H]1CN(C[C@@H](C)O1)C2=NC=C(NC(=O)C3=C(C)C(=CC=C3)C4=CC=C(OC(F)(F)F)C=C4)C=C2	PLASMA																							UNKNOWN				This could be seen as an advantage for taladegib over vismodegib, which experienced saturable binding to α−1-acid glycoprotein (19), and sonidegib, which is highly bound (over 99%) to plasma protein (20).	1	UNKNOWN		UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422158/	Homo sapiens										false
8996	10071		ADULT	24970412	503.33	TAFAMIDIS MEGLUMINE	Tafamidis Meglumine	CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC(=O)C1=CC=C2N=C(OC2=C1)C3=CC(Cl)=CC(Cl)=C3	PLASMA	ZU7CF08A1A									?	μg × h/mL	60.39		μg/mL	3			MIN EFFICACIOUS	mg	20		STEADY-STATE	UNKNOWN		day	1	Tafamidis is highly protein bound (>99%) in plasma.	1	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.pfizer.ca/sites/default/files/202002/Vyndaqel_PM_228368_20Jan2020_EN.pdf	Homo sapiens		h	57							false
8997	10071		ADULT	24970412	503.33	TAFAMIDIS MEGLUMINE	Tafamidis Meglumine	CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC(=O)C1=CC=C2N=C(OC2=C1)C3=CC(Cl)=CC(Cl)=C3	PLASMA	ZU7CF08A1A									?	μg × h/mL	241.5		μg/mL	11.99			RECOMMENDED	mg	80		STEADY-STATE	UNKNOWN		day	1	Tafamidis is highly protein bound (>99%) in plasma.	1	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.pfizer.ca/sites/default/files/202002/Vyndaqel_PM_228368_20Jan2020_EN.pdf	Homo sapiens		h	57							false
8998	10073		ADULT	5288320	248.2428	TOPIROXOSTAT	Topiroxostat	N#CC1=NC=CC(=C1)C2=NNC(=N2)C3=CC=NC=C3	PLASMA	0J877412JV									∞	ng × h/mL	838.8		ng/mL	375.8			UNKNOWN	mg	60		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300069/670242000_22500AMX00987000_A100_2.pdf#page=29	Homo sapiens		h	6.7				11			false
8999	10073		ADULT	5288320	248.2428	TOPIROXOSTAT	Topiroxostat	N#CC1=NC=CC(=C1)C2=NNC(=N2)C3=CC=NC=C3	PLASMA	0J877412JV									∞	ng × h/mL	793.5		ng/mL	579.3			UNKNOWN	mg	60		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300069/670242000_22500AMX00987000_A100_2.pdf#page=29	Homo sapiens		h	10.9				11			false
9000	10073			5288320	248.2428	TOPIROXOSTAT	Topiroxostat	N#CC1=NC=CC(=C1)C2=NNC(=N2)C3=CC=NC=C3	PLASMA	0J877412JV																										Human plasma protein binding: >97.5% (20ng/mL), 98.8% (200ng/mL), 98.4% (2000ng/mL); ultrafiltration	1.2				OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300069/670242000_22500AMX00987000_A100_2.pdf#page=31	Homo sapiens										false
9001	10073		ADULT	5288320	248.2428	TOPIROXOSTAT	Topiroxostat	N#CC1=NC=CC(=C1)C2=NNC(=N2)C3=CC=NC=C3	PLASMA	0J877412JV									∞	ng × h/mL	1278.6		ng/mL	755.2			UNKNOWN	mg	80		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300069/670242000_22500AMX00987000_A100_2.pdf#page=32	Homo sapiens		h	5.1				6			false
9002	10073		ADULT	5288320	248.2428	TOPIROXOSTAT	Topiroxostat	N#CC1=NC=CC(=C1)C2=NNC(=N2)C3=CC=NC=C3	PLASMA	0J877412JV									∞	ng × h/mL	499.1		ng/mL	288.7			UNKNOWN	mg	40		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300069/670242000_22500AMX00987000_A100_2.pdf#page=32	Homo sapiens		h	5.2				6			false
9003	10073		ADULT	5288320	248.2428	TOPIROXOSTAT	Topiroxostat	N#CC1=NC=CC(=C1)C2=NNC(=N2)C3=CC=NC=C3	PLASMA	0J877412JV									∞	ng × h/mL	225.4		ng/mL	229.9			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300069/670242000_22500AMX00987000_A100_2.pdf#page=32	Homo sapiens		h	5				6			false
9004	10073		ADULT	5288320	248.2428	TOPIROXOSTAT	Topiroxostat	N#CC1=NC=CC(=C1)C2=NNC(=N2)C3=CC=NC=C3	PLASMA	0J877412JV									∞	ng × h/mL	2366.7		ng/mL	1318.4			UNKNOWN	mg	120		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300069/670242000_22500AMX00987000_A100_2.pdf#page=32	Homo sapiens		h	4.6				6			false
9005	10073		ADULT	5288320	248.2428	TOPIROXOSTAT	Topiroxostat	N#CC1=NC=CC(=C1)C2=NNC(=N2)C3=CC=NC=C3	PLASMA	0J877412JV									∞	ng × h/mL	1206.6		ng/mL	822.3			UNKNOWN	mg	80		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300069/670242000_22500AMX00987000_A100_2.pdf#page=32	Homo sapiens		h	5.2				6			false
9006	10073		ADULT	5288320	248.2428	TOPIROXOSTAT	Topiroxostat	N#CC1=NC=CC(=C1)C2=NNC(=N2)C3=CC=NC=C3	PLASMA	0J877412JV									∞	ng × h/mL	580.2		ng/mL	469.4			UNKNOWN	mg	40		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300069/670242000_22500AMX00987000_A100_2.pdf#page=32	Homo sapiens		h	7.5				6			false
9007	10073		ADULT	5288320	248.2428	TOPIROXOSTAT	Topiroxostat	N#CC1=NC=CC(=C1)C2=NNC(=N2)C3=CC=NC=C3	PLASMA	0J877412JV									∞	ng × h/mL	2838.2		ng/mL	1773.5			UNKNOWN	mg	180		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300069/670242000_22500AMX00987000_A100_2.pdf#page=32	Homo sapiens		h	7.1				6			false
9008	10073		ADULT	5288320	248.2428	TOPIROXOSTAT	Topiroxostat	N#CC1=NC=CC(=C1)C2=NNC(=N2)C3=CC=NC=C3	PLASMA	0J877412JV							24		t	ng × h/mL	944.3		ng/mL	466.8			UNKNOWN	mg	80		MULTIPLE	FED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300069/670242000_22500AMX00987000_A100_2.pdf#page=34	Homo sapiens		h	6.9	Day 1			6			false
9009	10073		ADULT	5288320	248.2428	TOPIROXOSTAT	Topiroxostat	N#CC1=NC=CC(=C1)C2=NNC(=N2)C3=CC=NC=C3	PLASMA	0J877412JV							12		t	ng × h/mL	443.9		ng/mL	172.9			UNKNOWN	mg	80		MULTIPLE	FED		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300069/670242000_22500AMX00987000_A100_2.pdf#page=34	Homo sapiens		h	6.2	Day 7			6			false
9010	10073		ADULT	5288320	248.2428	TOPIROXOSTAT	Topiroxostat	N#CC1=NC=CC(=C1)C2=NNC(=N2)C3=CC=NC=C3	PLASMA	0J877412JV							24		t	ng × h/mL	964.3		ng/mL	501.9			UNKNOWN	mg	80		MULTIPLE	FED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300069/670242000_22500AMX00987000_A100_2.pdf#page=34	Homo sapiens		h	6.9	Day 7			6			false
9011	10073		ADULT	5288320	248.2428	TOPIROXOSTAT	Topiroxostat	N#CC1=NC=CC(=C1)C2=NNC(=N2)C3=CC=NC=C3	PLASMA	0J877412JV							12		t	ng × h/mL	1137.1		ng/mL	608.5			UNKNOWN	mg	160		MULTIPLE	FED		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300069/670242000_22500AMX00987000_A100_2.pdf#page=34	Homo sapiens		h	8	Day 7			6			false
9012	10073		ADULT	5288320	248.2428	TOPIROXOSTAT	Topiroxostat	N#CC1=NC=CC(=C1)C2=NNC(=N2)C3=CC=NC=C3	PLASMA	0J877412JV							12		t	ng × h/mL	1044.4		ng/mL	552.8			UNKNOWN	mg	160		MULTIPLE	FED		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300069/670242000_22500AMX00987000_A100_2.pdf#page=34	Homo sapiens		h	5.9	Day 1			6			false
9013	10073		ADULT	5288320	248.2428	TOPIROXOSTAT	Topiroxostat	N#CC1=NC=CC(=C1)C2=NNC(=N2)C3=CC=NC=C3	PLASMA	0J877412JV							12		t	ng × h/mL	419.8		ng/mL	208.7			UNKNOWN	mg	80		MULTIPLE	FED		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300069/670242000_22500AMX00987000_A100_2.pdf#page=34	Homo sapiens		h	4.3	Day 1			6			false
9014	10073		ADULT	5288320	248.2428	TOPIROXOSTAT	Topiroxostat	N#CC1=NC=CC(=C1)C2=NNC(=N2)C3=CC=NC=C3	PLASMA	0J877412JV									∞	ng × h/mL	1161.5		ng/mL	740.3			UNKNOWN	mg	80		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300069/670242000_22500AMX00987000_A100_2.pdf#page=36	Homo sapiens		h	8.4		Normal renal function		6			false
9015	10073		ADULT	5288320	248.2428	TOPIROXOSTAT	Topiroxostat	N#CC1=NC=CC(=C1)C2=NNC(=N2)C3=CC=NC=C3	PLASMA	0J877412JV									∞	ng × h/mL	1372.7		ng/mL	806.7			UNKNOWN	mg	80		SINGLE	FASTED						UNHEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300069/670242000_22500AMX00987000_A100_2.pdf#page=36	Homo sapiens		h	6.7		Mild renal impairment		5			false
9016	10073		ADULT	5288320	248.2428	TOPIROXOSTAT	Topiroxostat	N#CC1=NC=CC(=C1)C2=NNC(=N2)C3=CC=NC=C3	PLASMA	0J877412JV									∞	ng × h/mL	1426.6		ng/mL	713.2			UNKNOWN	mg	80		SINGLE	FASTED						UNHEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300069/670242000_22500AMX00987000_A100_2.pdf#page=36	Homo sapiens		h	7.2		Moderate renal impairment		6			false
9017	10073		ADULT	5288320	248.2428	TOPIROXOSTAT	Topiroxostat	N#CC1=NC=CC(=C1)C2=NNC(=N2)C3=CC=NC=C3	PLASMA	0J877412JV									∞	ng × h/mL	1264		ng/mL	969.1			UNKNOWN	mg	80		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300069/670242000_22500AMX00987000_A100_2.pdf#page=37	Homo sapiens		h	7.3		Young subjects (23~34 y)		6			false
9018	10073		ADULT	5288320	248.2428	TOPIROXOSTAT	Topiroxostat	N#CC1=NC=CC(=C1)C2=NNC(=N2)C3=CC=NC=C3	PLASMA	0J877412JV									∞	ng × h/mL	1213.8		ng/mL	741.1			UNKNOWN	mg	80		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300069/670242000_22500AMX00987000_A100_2.pdf#page=37	Homo sapiens		h	6.9		Elderly subjects (67~74 y)		6			false
9019	10073		ADULT	5288320	248.2428	TOPIROXOSTAT	Topiroxostat	N#CC1=NC=CC(=C1)C2=NNC(=N2)C3=CC=NC=C3	PLASMA	0J877412JV									∞	ng × h/mL	1523.5		ng/mL	719			UNKNOWN	mg	80		SINGLE	FASTED						HEALTHY	Oral	FEMALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300069/670242000_22500AMX00987000_A100_2.pdf#page=38	Homo sapiens		h	8.2		Elderly female subjects (66~75 y)		6			false
9020	10075		ADULT	6918537	303.3993	VILDAGLIPTIN	Vildagliptin	OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N4CCC[C@H]4C#N	PLASMA	I6B4B2U96P									?	ng × h/mL	13420		ng/mL	2860			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.info.pmda.go.jp/go/interview/1/300242_3969011F1020_1_EQA_1F.pdf#page=36	Homo sapiens		h	5.29				6			false
9021	10075		ADULT	6918537	303.3993	VILDAGLIPTIN	Vildagliptin	OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N4CCC[C@H]4C#N	PLASMA	I6B4B2U96P									?	ng × h/mL	2968		ng/mL	671			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.info.pmda.go.jp/go/interview/1/300242_3969011F1020_1_EQA_1F.pdf#page=36	Homo sapiens		h	2.1				6			false
9022	10075		ADULT	6918537	303.3993	VILDAGLIPTIN	Vildagliptin	OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N4CCC[C@H]4C#N	PLASMA	I6B4B2U96P									?	ng × h/mL	1139		ng/mL	272			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.info.pmda.go.jp/go/interview/1/300242_3969011F1020_1_EQA_1F.pdf#page=36	Homo sapiens		h	1.77				6			false
9023	10075		ADULT	6918537	303.3993	VILDAGLIPTIN	Vildagliptin	OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N4CCC[C@H]4C#N	PLASMA	I6B4B2U96P									?	ng × h/mL	6857		ng/mL	1959			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.info.pmda.go.jp/go/interview/1/300242_3969011F1020_1_EQA_1F.pdf#page=36	Homo sapiens		h	2				6			false
9024	10075		ADULT	6918537	303.3993	VILDAGLIPTIN	Vildagliptin	OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N4CCC[C@H]4C#N	PLASMA	I6B4B2U96P									?	ng × h/mL	545		ng/mL	162			UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.info.pmda.go.jp/go/interview/1/300242_3969011F1020_1_EQA_1F.pdf#page=36	Homo sapiens		h	1.54		n=5 for AUC and t1/2		6			false
9025	10075		ADULT	6918537	303.3993	VILDAGLIPTIN		OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N4CCC[C@H]4C#N	PLASMA	I6B4B2U96P							12		t	ng × h/mL	1480		ng/mL	524			RECOMMENDED	mg	50		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.info.pmda.go.jp/go/interview/1/300242_3969011F1020_1_EQA_1F.pdf#page=37	Homo sapiens		h	1.78	Day 1	type-2 diabetes, dosing-30 min before breakfast/dinner		16			false
9026	10075		ADULT	6918537	303.3993	VILDAGLIPTIN		OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N4CCC[C@H]4C#N	PLASMA	I6B4B2U96P							12		t	ng × h/mL	1490		ng/mL	415			RECOMMENDED	mg	50		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.info.pmda.go.jp/go/interview/1/300242_3969011F1020_1_EQA_1F.pdf#page=37	Homo sapiens		h	2.41	Day 7	type-2 diabetes, dosing-30 min before breakfast/dinner		16			false
9027	10075		ADULT	6918537	303.3993	VILDAGLIPTIN		OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N4CCC[C@H]4C#N	PLASMA	I6B4B2U96P							12		?	ng × h/mL	2500		ng/mL	538			DEFINED DAILY	mg	100		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.info.pmda.go.jp/go/interview/1/300242_3969011F1020_1_EQA_1F.pdf#page=37	Homo sapiens		h	2.1				24			false
9028	10075		ADULT	6918537	303.3993	VILDAGLIPTIN		OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N4CCC[C@H]4C#N	PLASMA	I6B4B2U96P							12		?	ng × h/mL	2215		ng/mL	431			DEFINED DAILY	mg	100		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.info.pmda.go.jp/go/interview/1/300242_3969011F1020_1_EQA_1F.pdf#page=37	Homo sapiens		h	2.9				24			false
9029	10075			6918537	303.3993	VILDAGLIPTIN		OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N4CCC[C@H]4C#N	PLASMA	I6B4B2U96P							12																			Human plasma protein binding: 9.3% (10~10000ng/mL, ultrafiltration)	90.7				EXPERIMENT	https://www.info.pmda.go.jp/go/interview/1/300242_3969011F1020_1_EQA_1F.pdf#page=40	Homo sapiens										false
9030	10075		ADULT	6918537	303.3993	VILDAGLIPTIN		OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N4CCC[C@H]4C#N	PLASMA	I6B4B2U96P									?	ng × h/mL	2567		ng/mL	675			HIGHEST STUDIED	mg	100		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2010/P201000008/30024200_22200AMX00233_A100_5.pdf#page=50 | https://pubmed.ncbi.nlm.nih.gov/17486328/	Homo sapiens		h	2				6			false
9031	10075		ADULT	6918537	303.3993	VILDAGLIPTIN		OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N4CCC[C@H]4C#N	PLASMA	I6B4B2U96P									?	ng × h/mL	2076		ng/mL	497			HIGHEST STUDIED	mg	100		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2010/P201000008/30024200_22200AMX00233_A100_5.pdf#page=50 | https://pubmed.ncbi.nlm.nih.gov/17486328/	Homo sapiens		h	4.9		Mild hepatic impairment		6			false
9032	10075		ADULT	6918537	303.3993	VILDAGLIPTIN		OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N4CCC[C@H]4C#N	PLASMA	I6B4B2U96P									?	ng × h/mL	2411		ng/mL	512			HIGHEST STUDIED	mg	100		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2010/P201000008/30024200_22200AMX00233_A100_5.pdf#page=50 | https://pubmed.ncbi.nlm.nih.gov/17486328/	Homo sapiens		h	3.1		Moderate hepatic impairment		6			false
9033	10075		ADULT	6918537	303.3993	VILDAGLIPTIN		OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N4CCC[C@H]4C#N	PLASMA	I6B4B2U96P									?	ng × h/mL	3322		ng/mL	632			HIGHEST STUDIED	mg	100		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2010/P201000008/30024200_22200AMX00233_A100_5.pdf#page=50 | https://pubmed.ncbi.nlm.nih.gov/17486328/	Homo sapiens		h	2.4		Severe hepatic impairment		4			false
9034	10079		ADULT	128878|135678104	243.326	2-IMINOBIOTIN	2-IMINOBIOTIN	OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=N)N[C@H]12	PLASMA	HXH71NRQ5C							4		∞	ng × h/mL	16448		ng/mL	22541			MAX TOLERATED	mg/kg	6		MULTIPLE	UNKNOWN		day	6			HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31625480	Homo sapiens		h	2.12	6 mg/kg 2-IB over 15 min in 5% Captisol			6	2-IMINOBIOTIN		false
9035	10079		ADULT	128878|135678104	243.326	2-IMINOBIOTIN	2-IMINOBIOTIN	OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=N)N[C@H]12	PLASMA	HXH71NRQ5C									∞	ng × h/mL	1528		ng/mL	1808			UNKNOWN	mg/kg	0.6		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31625480	Homo sapiens		h	1.48	0.6 mg/kg in 15 min			2	2-IMINOBIOTIN		false
9036	10079		ADULT	128878|135678104	243.326	2-IMINOBIOTIN	2-IMINOBIOTIN	OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=N)N[C@H]12	PLASMA	HXH71NRQ5C							4		∞	ng × h/mL	39956		ng/mL	34175			UNKNOWN	mg/kg	12		MULTIPLE	UNKNOWN		day	6			HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31625480	Homo sapiens		h	2.37	12 mg/kg 2-IB over 30 min in 5% Captisol			6	2-IMINOBIOTIN		false
9037	10081		ADULT	72271	482.5304	7-HYDROXYSTAUROSPORINE	7-HYDROXYSTAUROSPORINE	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N3C4=C(C=CC=C4)C5=C3C6=C(C7=C(C=CC=C7)N26)C8=C5[C@@H](O)NC8=O	PLASMA	7BU5H4V94A									∞	μM × h	24510		μM	36.8			UNKNOWN	mg/m²	53		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11304786	Homo sapiens		h	559	72-hour continuous intravenous infusion			9	7-HYDROXYSTAUROSPORINE		false
9038	10081		ADULT	72271	482.5304	7-HYDROXYSTAUROSPORINE	7-HYDROXYSTAUROSPORINE	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N3C4=C(C=CC=C4)C5=C3C6=C(C7=C(C=CC=C7)N26)C8=C5[C@@H](O)NC8=O	PLASMA	7BU5H4V94A									∞	μM × h	21212		μM	36.4			RP2D	mg/m²	42.5		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11304786	Homo sapiens		h	618	72-hour continuous intravenous infusion			10	7-HYDROXYSTAUROSPORINE		false
9039	10081		ADULT	72271	482.5304	7-HYDROXYSTAUROSPORINE	7-HYDROXYSTAUROSPORINE	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N3C4=C(C=CC=C4)C5=C3C6=C(C7=C(C=CC=C7)N26)C8=C5[C@@H](O)NC8=O	PLASMA	7BU5H4V94A									?	mg × h/L	26140		mg/L	19.1			UNKNOWN	mg/m²	53		MULTIPLE	UNKNOWN		day	1		0.829	UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15501960	Homo sapiens		h	509	72-hour i.v. infusion			8	7-HYDROXYSTAUROSPORINE		false
9040	10081		ADULT	72271	482.5304	7-HYDROXYSTAUROSPORINE	7-HYDROXYSTAUROSPORINE	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N3C4=C(C=CC=C4)C5=C3C6=C(C7=C(C=CC=C7)N26)C8=C5[C@@H](O)NC8=O	PLASMA	7BU5H4V94A	60838	586.678	IRINOTECAN	irinotecan	CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC5=CC=C(OC(=O)N6CCC(CC6)N7CCCCC7)C=C15	7673326042			?	μM × h	10157		μM	31.8			MAX TOLERATED	mg/m²	70		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17429623	Homo sapiens		h	280.6	3-h infusion		irinotecan IV over 90 min	5	7-HYDROXYSTAUROSPORINE		true
9041	10081		ADULT	72271	482.5304	7-HYDROXYSTAUROSPORINE	7-HYDROXYSTAUROSPORINE	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N3C4=C(C=CC=C4)C5=C3C6=C(C7=C(C=CC=C7)N26)C8=C5[C@@H](O)NC8=O	PLASMA	7BU5H4V94A	60838	586.678	IRINOTECAN	irinotecan	CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC5=CC=C(OC(=O)N6CCC(CC6)N7CCCCC7)C=C15	7673326042			?	μM × h	12526		μM	31.6			UNKNOWN	mg/m²	90		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17429623	Homo sapiens		h	341.4	3-h infusion		irinotecan IV over 90 min	4	7-HYDROXYSTAUROSPORINE		true
9042	10083		ADULT	11749858	397.4244	ABEXINOSTAT	ABEXINOSTAT	CN(C)CC1=C(OC2=C1C=CC=C2)C(=O)NCCOC3=CC=C(C=C3)C(=O)NO	BLOOD	IYO470654U							24		t	ng × h/mL	1130		ng/mL	277			UNKNOWN	mg	120		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/27911138	Homo sapiens										false
9043	10087		ADULT	46843057	427.323	AFURESERTIB	afuresertib	CN1N=CC(Cl)=C1C2=C(Cl)SC(=C2)C(=O)N[C@H](CN)CC3=CC(F)=CC=C3	PLASMA	8739X25QI3							24		t	ng × h/mL	6782		ng/mL	554			UNKNOWN	mg	100		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25075128/	Homo sapiens							8	afuresertib		false
9044	10087		ADULT	46843057	427.323	AFURESERTIB	afuresertib	CN1N=CC(Cl)=C1C2=C(Cl)SC(=C2)C(=O)N[C@H](CN)CC3=CC(F)=CC=C3	PLASMA	8739X25QI3							24		t	ng × h/mL	7405		ng/mL	531			MAX TOLERATED	mg	125		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25075128/	Homo sapiens							8	afuresertib		false
9045	10087		ADULT	46843057	427.323	AFURESERTIB	afuresertib	CN1N=CC(Cl)=C1C2=C(Cl)SC(=C2)C(=O)N[C@H](CN)CC3=CC(F)=CC=C3	PLASMA	8739X25QI3							24		t	ng × h/mL	13425		ng/mL	949			HIGHEST STUDIED	mg	150		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25075128/	Homo sapiens							8	afuresertib		false
9046	10088		ADULT	24771867	518.924	ALISERTIB	ALISERTIB	COC1=C(C=CC(NC2=NC3=C(CN=C(C4=CC(Cl)=CC=C34)C5=C(OC)C=CC=C5F)C=N2)=C1)C(O)=O	PLASMA	T66ES73M18									∞	ng × h/mL	23386		ng/mL	1253			UNKNOWN	mg	50		SINGLE	UNKNOWN				Alisertib was approximately 99% protein bound in all hepatic function groups.	1	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/30985952	Homo sapiens		h	22.8							false
9047	10093		ADULT	135398495	381.4316	AT-9283	AT-9283	O=C(NC1CC1)NC2=CNN=C2C3=NC4=CC(CN5CCOCC5)=CC=C4N3	PLASMA	XAV9KYN9WL									∞	ng × h/mL	1200		ng/mL	19.1			UNKNOWN	mg/m²	6		MULTIPLE	UNKNOWN		hour	72			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22015452	Homo sapiens		h	7.6				3	AT-9283		false
9048	10093		ADULT	135398495	381.4316	AT-9283	AT-9283	O=C(NC1CC1)NC2=CNN=C2C3=NC4=CC(CN5CCOCC5)=CC=C4N3	PLASMA	XAV9KYN9WL									∞	ng × h/mL	2910		ng/mL	42.9			UNKNOWN	mg/m²	13		MULTIPLE	UNKNOWN		hour	72			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22015452	Homo sapiens		h	7.5				6	AT-9283		false
9049	10093		ADULT	135398495	381.4316	AT-9283	AT-9283	O=C(NC1CC1)NC2=CNN=C2C3=NC4=CC(CN5CCOCC5)=CC=C4N3	PLASMA	XAV9KYN9WL									∞	ng × h/mL	1720		ng/mL	25.4			UNKNOWN	mg/m²	9		MULTIPLE	UNKNOWN		hour	72			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22015452	Homo sapiens		h	7.8				7	AT-9283		false
9050	10093		ADULT	135398495	381.4316	AT-9283	AT-9283	O=C(NC1CC1)NC2=CNN=C2C3=NC4=CC(CN5CCOCC5)=CC=C4N3	PLASMA	XAV9KYN9WL									∞	ng × h/mL	278		ng/mL	4.7			UNKNOWN	mg/m²	1.5		MULTIPLE	UNKNOWN		hour	72			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22015452	Homo sapiens		h	13.4				3	AT-9283		false
9051	10093		CHILD	135398495	381.4316	AT-9283	AT-9283	O=C(NC1CC1)NC2=CNN=C2C3=NC4=CC(CN5CCOCC5)=CC=C4N3	PLASMA	XAV9KYN9WL									?	ng × h/mL	38254						MAX TOLERATED	mg	500		MULTIPLE	UNKNOWN		hour	72			UNHEALTHY	Intravenous	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/28177130	Homo sapiens							7	AT-9283		false
9052	10093		ADULT	135398495	381.4316	AT-9283	AT-9283	O=C(NC1CC1)NC2=CNN=C2C3=NC4=CC(CN5CCOCC5)=CC=C4N3	PLASMA	XAV9KYN9WL									?	ng × h/mL	20956						MAX TOLERATED	mg	567		MULTIPLE	UNKNOWN		hour	72			UNHEALTHY	Intravenous	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/28177130	Homo sapiens							24	AT-9283		false
9053	10093		ADULT	135398495	381.4316	AT-9283	AT-9283	O=C(NC1CC1)NC2=CNN=C2C3=NC4=CC(CN5CCOCC5)=CC=C4N3	PLASMA	XAV9KYN9WL									?	ng × h/mL	1653						MAX TOLERATED	mg	51.3		MULTIPLE	UNKNOWN		hour	72			UNHEALTHY	Intravenous	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/28177130	Homo sapiens							29	AT-9283		false
9054	10093		CHILD	135398495	381.4316	AT-9283	AT-9283	O=C(NC1CC1)NC2=CNN=C2C3=NC4=CC(CN5CCOCC5)=CC=C4N3	PLASMA	XAV9KYN9WL									?	ng × h/mL	2984						MAX TOLERATED	mg	67.7		MULTIPLE	UNKNOWN		hour	72			UNHEALTHY	Intravenous	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/28177130	Homo sapiens							32	AT-9283		false
9055	10094		ADULT	11292191	388.868	AZD-1981	AZD-1981	CC(=O)NC1=CC=CC2=C1C(SC3=CC=C(Cl)C=C3)=C(C)N2CC(O)=O	PLASMA	2AD53WQ2CX									?	nM × h	18900		nM	9030			UNKNOWN	mg	400		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27558866	Homo sapiens							3	AZD-1981		false
9056	10096		ADULT	51039095	463.5719	AZD-4547	AZD-4547	COC1=CC(OC)=CC(CCC2=CC(NC(=O)C3=CC=C(C=C3)N4C[C@H](C)N[C@H](C)C4)=NN2)=C1	PLASMA	2167OG1EKJ									?	ng × h/mL	4134		ng/mL	302.9			UNKNOWN	mg	160		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28070720	Homo sapiens							15	AZD-4547		false
9057	10096		ADULT	51039095	463.5719	AZD-4547	AZD-4547	COC1=CC(OC)=CC(CCC2=CC(NC(=O)C3=CC=C(C=C3)N4C[C@H](C)N[C@H](C)C4)=NN2)=C1	PLASMA	2167OG1EKJ									?	ng × h/mL	3417		ng/mL	216.2			UNKNOWN	mg	160		SINGLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28070720	Homo sapiens		h	27.96				15	AZD-4547		false
9058	10096		ADULT	51039095	463.5719	AZD-4547	AZD-4547	COC1=CC(OC)=CC(CCC2=CC(NC(=O)C3=CC=C(C=C3)N4C[C@H](C)N[C@H](C)C4)=NN2)=C1	PLASMA	2167OG1EKJ									?	ng × h/mL	2072		ng/mL	215.8			UNKNOWN	mg	120		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28070720	Homo sapiens							6	AZD-4547		false
9059	10096		ADULT	51039095	463.5719	AZD-4547	COC1=CC(OC)=CC(CCC2=CC(NC(=O)C3=CC=C(C=C3)N4C[C@H](C)N[C@H](C)C4)=NN2)=C1	COC1=CC(OC)=CC(CCC2=CC(NC(=O)C3=CC=C(C=C3)N4C[C@H](C)N[C@H](C)C4)=NN2)=C1	PLASMA	2167OG1EKJ									∞	ng × h/mL	1539		ng/mL	88.41			RECOMMENDED	mg	80		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/28070720	Homo sapiens		h	28.82							false
9060	10099		ADULT	11387605	576.6153	BAFETINIB	BAFETINIB	CN(C)[C@H]1CCN(CC2=C(C=C(C=C2)C(=O)NC3=CC(NC4=NC(=CC=N4)C5=CN=CN=C5)=C(C)C=C3)C(F)(F)F)C1	PLASMA	NVW4Z03I9B							12		t	ng × h/mL	1000		ng/mL	164			UNKNOWN	mg	360		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23380277	Homo sapiens							1	BAFETINIB		false
9061	10099		ADULT	11387605	576.6153	BAFETINIB	BAFETINIB	CN(C)[C@H]1CCN(CC2=C(C=C(C=C2)C(=O)NC3=CC(NC4=NC(=CC=N4)C5=CN=CN=C5)=C(C)C=C3)C(F)(F)F)C1	PLASMA	NVW4Z03I9B							12		t	ng × h/mL	522		ng/mL	129			UNKNOWN	mg	360		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23380277	Homo sapiens							1	BAFETINIB		false
9062	10099		ADULT	11387605	576.6	BAFETINIB	BAFETINIB	CN(C)[C@H]1CCN(CC2=CC=C(C=C2C(F)(F)F)C(=O)NC3=CC=C(C)C(NC4=NC=C(C=N4)C5=CN=CN=C5)=C3)C1	PLASMA	NVW4Z03I9B													ng/mL	487			MAX TOLERATED	mg	240		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/20310049	Homo sapiens		h	1.99							false
9063	10099		ADULT	11387605	576.6	BAFETINIB	BAFETINIB	CN(C)[C@H]1CCN(CC2=CC=C(C=C2C(F)(F)F)C(=O)NC3=CC=C(C)C(NC4=NC=C(C=N4)C5=CN=CN=C5)=C3)C1	PLASMA	NVW4Z03I9B							12		t	ng × h/mL	544		ng/mL	109			MAX TOLERATED	mg	240		SINGLE	FASTED				Cmax and AUC geom averaged over 5 patients		UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/23380277	Homo sapiens							5			false
9064	10100		ADULT	11497983	587.5	BARASERTIB	BARASERTIB	CCN(CCO)CCCOC1=CC2=C(C=C1)C(NC3=NNC(CC(=O)NC4=CC(F)=CC=C4)=C3)=NC=N2	PLASMA	29P8LWS24N									?	ng × h/mL	9470		ng/mL	74.2			MAX TOLERATED	mg	1200		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/21565405	Homo sapiens										false
9065	10100		ADULT	11497983	587.5	BARASERTIB	BARASERTIB	CCN(CCO)CCCOC1=CC2=C(C=C1)C(NC3=NNC(CC(=O)NC4=CC(F)=CC=C4)=C3)=NC=N2	PLASMA	29P8LWS24N									∞	ng × h/mL	4054		ng/mL	1484			MAX TOLERATED	mg	220		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/22661287	Homo sapiens		h	2.16							false
9066	10101		ADULT	400769	505.6881	BARDOXOLONE METHYL	BARDOXOLONE METHYL	COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]3C(=O)C=C4[C@@]5(C)C=C(C#N)C(=O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)CC2	PLASMA	CEG1Q6OGU1							24		t	ng × h/mL	20370		ng/mL	24.7			MAX TOLERATED	mg	900		STEADY-STATE	FED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/22634319	Homo sapiens		h	39							false
9067	10103		ADULT		584.8262	BEVIRIMAT	BEVIRIMAT	CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O	PLASMA	S125DW66N8							240		t	μg × h/mL	599.5		μg/mL	31.6			UNKNOWN	mg	100		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17596104	Homo sapiens		h	56.3				6	BEVIRIMAT		false
9068	10103		ADULT		584.8262	BEVIRIMAT	BEVIRIMAT	CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O	PLASMA	S125DW66N8							240		t	μg × h/mL	827.9		μg/mL	43.7			UNKNOWN	mg	150		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17596104	Homo sapiens		h	61.2				6	BEVIRIMAT		false
9069	10103		ADULT		584.8262	BEVIRIMAT	BEVIRIMAT	CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O	PLASMA	S125DW66N8							240		t	μg × h/mL	1113.7		μg/mL	58			UNKNOWN	mg	200		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17596104	Homo sapiens		h	62.1				6	BEVIRIMAT		false
9070	10103		ADULT		584.8262	BEVIRIMAT	BEVIRIMAT	CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O	PLASMA	S125DW66N8							24		t	μg × h/mL	88.2		μg/mL	6			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17596104	Homo sapiens							6	BEVIRIMAT		false
9071	10103		ADULT		584.8262	BEVIRIMAT	BEVIRIMAT	CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O	PLASMA	S125DW66N8							240		t	μg × h/mL	156.5		μg/mL	8			UNKNOWN	mg	25		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17596104	Homo sapiens		h	1.75				6	BEVIRIMAT		false
9072	10103		ADULT		584.8262	BEVIRIMAT	BEVIRIMAT	CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O	PLASMA	S125DW66N8							24		t	μg × h/mL	180.9		μg/mL	11.9			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17596104	Homo sapiens							6	BEVIRIMAT		false
9073	10103		ADULT		584.8262	BEVIRIMAT	BEVIRIMAT	CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O	PLASMA	S125DW66N8							24		t	μg × h/mL	382.9		μg/mL	25.1			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17596104	Homo sapiens							6	BEVIRIMAT		false
9074	10104		ADULT	11364421	521.6544	BI-2536	BI-2536	CC[C@H]1N(C2CCCC2)C3=C(C=NC(NC4=C(OC)C=C(C=C4)C(=O)NC5CCN(C)CC5)=N3)N(C)C1=O	PLASMA	4LJG22T9C6									∞	ng × h/mL	3100		ng/mL	921			UNKNOWN	mg	250		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18955456	Homo sapiens		h	15.9				6	BI-2536		false
9075	10104		ADULT	11364421	521.6544	BI-2536	BI-2536	CC[C@H]1N(C2CCCC2)C3=C(C=NC(NC4=C(OC)C=C(C=C4)C(=O)NC5CCN(C)CC5)=N3)N(C)C1=O	PLASMA	4LJG22T9C6							24		∞	ng × h/mL	2480		mg/mL	840			MAX TOLERATED	mg	200		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18955456	Homo sapiens		h	15.4				24	BI-2536		false
9076	10104		ADULT	11364421	521.6544	BI-2536	BI-2536	CC[C@H]1N(C2CCCC2)C3=C(C=NC(NC4=C(OC)C=C(C=C4)C(=O)NC5CCN(C)CC5)=N3)N(C)C1=O	PLASMA	4LJG22T9C6	446556|5288715|135410875	427.4106	PEMETREXED	pemetrexed	NC1=NC2=C(C(CCC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CN2)C(=O)N1	04Q9AIZ7NO			∞	ng × h/mL	3920		ng/mL	1370			MAX TOLERATED	mg	300		MULTIPLE	UNKNOWN		3 weeks	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22658814	Homo sapiens		h	36.3				10	BI-2536		true
9077	10104		ADULT	11364421	521.6544	BI-2536	BI-2536	CC[C@H]1N(C2CCCC2)C3=C(C=NC(NC4=C(OC)C=C(C=C4)C(=O)NC5CCN(C)CC5)=N3)N(C)C1=O	PLASMA	4LJG22T9C6	446556|5288715|135410875	427.4106	PEMETREXED	pemetrexed	NC1=NC2=C(C(CCC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CN2)C(=O)N1	04Q9AIZ7NO			∞	ng × h/mL	4120		ng/mL	1250			UNKNOWN	mg	325		MULTIPLE	UNKNOWN		3 weeks	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22658814	Homo sapiens		h	32.8				3	BI-2536		true
9078	10104		ADULT	11364421	521.6544	BI-2536	BI-2536	CC[C@H]1N(C2CCCC2)C3=C(C=NC(NC4=C(OC)C=C(C=C4)C(=O)NC5CCN(C)CC5)=N3)N(C)C1=O	PLASMA	4LJG22T9C6							24		t	ng × h/mL	509		ng/mL	215			MAX TOLERATED	mg	60		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/22328845	Homo sapiens		h	9.17							false
9079	10104		ADULT	11364421	521.6544	BI-2536	BI-2536	CC[C@H]1N(C2CCCC2)C3=C(C=NC(NC4=C(OC)C=C(C=C4)C(=O)NC5CCN(C)CC5)=N3)N(C)C1=O	PLASMA	4LJG22T9C6							24		t	ng × h/mL	921		ng/mL	288			MAX TOLERATED	mg	60		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/22328845	Homo sapiens		h	38.9							false
9080	10105		ADULT	49836020	806.9408	BIRINAPANT	BIRINAPANT	CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1CC2=C(NC3=C2C=CC(F)=C3)C4=C(C[C@@H]5C[C@H](O)CN5C(=O)[C@H](CC)NC(=O)[C@H](C)NC)C6=C(N4)C=C(F)C=C6	BLOOD	6O4Z07B57R									∞	ng × h/mL	4648.4		ng/mL	3995			MAX TOLERATED	mg/m²	47		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26333381	Homo sapiens		h	24.5							false
9081	10109		ADULT	11349170	368.4329	BMS-690514	BMS-690514	COC1=CC(NC2=NC=NN3C=CC(CN4CC[C@@H](N)[C@H](O)C4)=C23)=CC=C1	PLASMA	VKU5X213Q7							24		t	ng × h/mL	1205.81		ng/mL	203.77			MAX TOLERATED	mg	200		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/22878519	Homo sapiens										false
9082	10109		ADULT	11349170	368.4329	BMS-690514	BMS-690514	COC1=CC(NC2=NC=NN3C=CC(CN4CC[C@@H](N)[C@H](O)C4)=C23)=CC=C1	PLASMA	VKU5X213Q7							24		t	ng × h/mL	1349.77		ng/mL	207.8			MAX TOLERATED	mg	200		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/22878519	Homo sapiens		h	12.17							false
9083	10113		ADULT	15984937	424.5541	CAMICINAL	camicinal	C[C@H]1CN(CC2=CC=C(CC(=O)N3CCC(CC3)NC4=CC(F)=CC=C4)C=C2)CCN1	PLASMA	3C8348951H									∞	ng × h/mL	16774.2		ng/mL	1124.9			UNKNOWN	mg	125		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26924243	Homo sapiens							6	camicinal		false
9084	10113		ADULT	15984937	424.5541	CAMICINAL	camicinal	C[C@H]1CN(CC2=CC=C(CC(=O)N3CCC(CC3)NC4=CC(F)=CC=C4)C=C2)CCN1	PLASMA	3C8348951H									∞	ng × h/mL	6193.8		ng/mL	488			UNKNOWN	mg	50		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26924243	Homo sapiens							7	camicinal		false
9085	10113		ADULT	15984937	424.5541	CAMICINAL	camicinal	C[C@H]1CN(CC2=CC=C(CC(=O)N3CCC(CC3)NC4=CC(F)=CC=C4)C=C2)CCN1	PLASMA	3C8348951H									∞	ng × h/mL	4103.1		ng/mL	288.3			UNKNOWN	mg	25		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26924243	Homo sapiens							7	camicinal		false
9086	10115		ADULT	25145656	412.4191	CAPMATINIB	CNC(=O)C1=CC=C(C=C1F)C2=NN3C(CC4=CC=C5N=CC=CC5=C4)=CN=C3N=C2	CNC(=O)C1=CC=C(C=C1F)C2=NN3C(CC4=CC=C5N=CC=CC5=C4)=CN=C3N=C2	PLASMA	TY34L4F9OZ							12		t	ng × h/mL	26300		ng/mL	6450			NOAEL	mg	400		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/30724423	Homo sapiens		h	2.7							false
9087	10119		ADULT	9996409	325.162	CHF-5074	CHF5074	OC(=O)C1(CC1)C2=CC(F)=C(C=C2)C3=CC=C(Cl)C(Cl)=C3	PLASMA	C35RF1MWQZ							24		t	μM × h	621		μM	56.3			UNKNOWN	mg	200		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22922591/	Homo sapiens		h	31.8				12	CHF5074		false
9088	10119		ADULT	9996409	325.162	CHF-5074	CHF5074	OC(=O)C1(CC1)C2=CC(F)=C(C=C2)C3=CC=C(Cl)C(Cl)=C3	PLASMA	C35RF1MWQZ							24		t	μM × h	948		μM	88.7			UNKNOWN	mg	400		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22922591/	Homo sapiens		h	31.8				12	CHF5074		false
9089	10119		ADULT	9996409	325.162	CHF-5074	CHF5074	OC(=O)C1(CC1)C2=CC(F)=C(C=C2)C3=CC=C(Cl)C(Cl)=C3	PLASMA	C35RF1MWQZ							24		t	μM × h	1530		μM	151			UNKNOWN	mg	600		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22922591/	Homo sapiens		h	25.3				12	CHF5074		false
9090	10122		ADULT	9811611	532.402	CP-547632	CP-547632	NC(=O)C1=C(NC(=O)NCCCCN2CCCC2)SN=C1OCC3=C(F)C=C(Br)C=C3F	PLASMA	W1B375O5M2									∞	ng × h/mL	10900		ng/mL	216			UNKNOWN	mg	250		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17031646	Homo sapiens		h	32.1				5	CP-547632		false
9091	10122		ADULT	9811611	532.402	CP-547632	CP-547632	NC(=O)C1=C(NC(=O)NCCCCN2CCCC2)SN=C1OCC3=C(F)C=C(Br)C=C3F	PLASMA	W1B375O5M2							24		t	ng × h/mL	7680		ng/mL	394			UNKNOWN	mg	250		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17031646	Homo sapiens							3	CP-547632		false
9092	10122		ADULT	9811611	532.402	CP-547632	CP-547632	NC(=O)C1=C(NC(=O)NCCCCN2CCCC2)SN=C1OCC3=C(F)C=C(Br)C=C3F	PLASMA	W1B375O5M2							24		∞	ng × h/mL	5180		ng/mL	142			MAX TOLERATED	mg	200		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17031646	Homo sapiens		h	31.5				8	CP-547632		false
9093	10122		ADULT	9811611	532.402	CP-547632	CP-547632	NC(=O)C1=C(NC(=O)NCCCCN2CCCC2)SN=C1OCC3=C(F)C=C(Br)C=C3F	PLASMA	W1B375O5M2							24		t	ng × h/mL	5650		ng/mL	312			MAX TOLERATED	mg	200		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17031646	Homo sapiens							16	CP-547632		false
9094	10123		ADULT	10366136	443.5	CRENOLANIB	CRENOLANIB	CC6(COC1=CC2=C(C=C1)N(C=N2)C3=NC4=C(C=CC=C4C=C3)N5CCC(N)CC5)COC6	PLASMA	LQF7I567TQ							72		t	ng × h/mL	4610		ng/mL	579			MAX TOLERATED	mg	200		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/19738123	Homo sapiens		h	13.4							false
9095	10124		ADULT	969516	368.3799	CURCUMIN	CURCUMIN	COC1=CC(=CC=C1O)\\C=C\\C(=O)CC(=O)\\C=C\\C2=CC=C(O)C(OC)=C2	PLASMA	IT942ZTH98							24		t	ng × h/mL	1360		ng/mL	87.7			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30666922/	Homo sapiens		h	6.01				6	CURCUMIN		false
9096	10125		ADULT	11977753	469.5365	DACTOLISIB	DACTOLISIB	CN1C(=O)N(C2=C3C=C(C=CC3=NC=C12)C4=CN=C5C=CC=CC5=C4)C6=CC=C(C=C6)C(C)(C)C#N	PLASMA	RUJ6Z9Y0DT	134551073		EVEROLIMUS	everolimus	CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO	9HW64Q8G6G			∞	ng × h/mL	468.5		ng/mL	45.2			UNKNOWN	mg	200		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/28357727	Homo sapiens		h	3.2							true
9097	10125		ADULT	11977753	469.5365	DACTOLISIB	DACTOLISIB	CN1C(=O)N(C2=C3C=C(C=CC3=NC=C12)C4=CN=C5C=CC=CC5=C4)C6=CC=C(C=C6)C(C)(C)C#N	PLASMA	RUJ6Z9Y0DT	134551073		EVEROLIMUS	Everolimus	CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO	9HW64Q8G6G			∞	ng × h/mL	830.8		ng/mL	101.8			UNKNOWN	mg	400		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/28357727	Homo sapiens		h	8.6							true
9098	10125		ADULT	11977753	469.5365	DACTOLISIB	DACTOLISIB	CN1C(=O)N(C2=C3C=C(C=CC3=NC=C12)C4=CN=C5C=CC=CC5=C4)C6=CC=C(C=C6)C(C)(C)C#N	PLASMA	RUJ6Z9Y0DT	134551073		EVEROLIMUS	Everolimus	CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO	9HW64Q8G6G			∞	ng × h/mL	2167.3		ng/mL	243			UNKNOWN	mg	800		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/28357727	Homo sapiens		h	5.9							true
9099	10127		ADULT	11442891	474.5548	DANUSERTIB	DANUSERTIB	CO[C@@H](C(=O)N1CC2=C(C1)C(NC(=O)C3=CC=C(C=C3)N4CCN(C)CC4)=NN2)C5=CC=CC=C5	PLASMA	M3X659D0FY									∞	μM × h	49.3		μM	6.31			UNKNOWN	mg/m²	400		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/19770380	Homo sapiens		h	37.7							false
9100	10131		ADULT		308.3776	DERENOFYLLINE	DERENOFYLLINE	O[C@H]1CC[C@@H](CC1)NC2=NC(=NC3=C2C=CN3)C4=CC=CC=C4	PLASMA	O1Q96UZ63W																	UNKNOWN	mg	15		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19919976	Homo sapiens		h	2.13				22	DERENOFYLLINE		false
9101	10131		ADULT	9953065	308.3776	DERENOFYLLINE	DERENOFYLLINE	O[C@H]1CC[C@@H](CC1)NC2=NC(=NC3=C2C=CN3)C4=CC=CC=C4	PLASMA	O1Q96UZ63W																	INVESTIGATIONAL	mg	15		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/19919976	Homo sapiens		h	2.13							false
9102	10135		ADULT	44557636	265.285	DIPRAGLURANT	Dipraglurant	FC1=CN2C=C(CCC#CC3=NC=CC=C3)N=C2C=C1	PLASMA	CV8JZR21A1									?	ng × h/mL	2009.8		ng/mL	1521			MAX DAILY	mg	300		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27214664	Homo sapiens		h	0.65				49	Dipraglurant		false
9103	10135		ADULT	44557636	265.285	DIPRAGLURANT	Dipraglurant	FC1=CN2C=C(CCC#CC3=NC=CC=C3)N=C2C=C1	PLASMA	CV8JZR21A1							3		?	ng × h/mL	858.9		ng/mL	679.6			UNKNOWN	mg	50		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27214664	Homo sapiens		h	0.56				51	Dipraglurant		false
9104	10135		ADULT	44557636	265.285	DIPRAGLURANT	Dipraglurant	FC1=CN2C=C(CCC#CC3=NC=CC=C3)N=C2C=C1	PLASMA	CV8JZR21A1									?	ng × h/mL	1760.6		ng/mL	1320.6			UNKNOWN	mg	100		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27214664	Homo sapiens		h	0.67				50	Dipraglurant		false
9105	10137		ADULT	122335	341.4009	EFAPROXIRAL	Efaproxiral	CC1=CC(NC(=O)CC2=CC=C(OC(C)(C)C(O)=O)C=C2)=CC(C)=C1	RED BLOOD CELLS	J81E81G364													μg/mL	333			UNKNOWN	mg/kg	75		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11240256/	Homo sapiens		h	4.1				6			false
9106	10137		ADULT	122335	341.4009	EFAPROXIRAL	Efaproxiral	CC1=CC(NC(=O)CC2=CC=C(OC(C)(C)C(O)=O)C=C2)=CC(C)=C1	RED BLOOD CELLS	J81E81G364													μg/mL	459			UNKNOWN	mg/kg	100		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11240256/	Homo sapiens		h	5				11			false
9107	10140		ADULT	12000240	569.5021	EMRICASAN	EMRICASAN	C[C@H](NC(=O)C(=O)NC1=C(C=CC=C1)C(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)COC2=C(F)C(F)=CC(F)=C2F	PLASMA	P0GMS9N47Q							8		t	ng × h/mL	275		ng/mL	84.4			UNKNOWN	mg	5		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/30302038	Homo sapiens		h	2.96	Day 1						false
9108	10140		ADULT	12000240	569.5021	EMRICASAN	EMRICASAN	C[C@H](NC(=O)C(=O)NC1=C(C=CC=C1)C(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)COC2=C(F)C(F)=CC(F)=C2F	PLASMA	P0GMS9N47Q							8		t	ng × h/mL	2441		ng/mL	696			UNKNOWN	mg	50		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/30302038	Homo sapiens				Day 1						false
9109	10142		ADULT	59473233	411.5	ENTOSPLETINIB	ENTOSPLETINIB	C1CN(CCO1)C2=CC=C(NC3=NC(=CN4C=CN=C34)C5=CC6=C(C=NN6)C=C5)C=C2	PLASMA	6I3O3W6O3B									∞	ng × h/mL	4248.7		ng/mL	534.5			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/27785737	Homo sapiens		h	9.51							false
9110	10144		ADULT	10286159	282.3	ERTEBEREL	ERTEBEREL	OC1=CC=C(C=C1)[C@@H]2OC3=C(C=C(O)C=C3)[C@@H]4CCC[C@H]24	PLASMA	2ZUL6758TZ									∞	ng × h/mL	206		ng/mL	24.8			UNKNOWN	mg	250		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/27136911	Homo sapiens		h	17.1							false
9111	10147		ADULT		501.6	TLK236	TLK236	CCOC(=O)C(C1=CC=CC=C1)NC(=O)C(CSCC2=CC=CC=C2)NC(=O)CCC(C(=O)O)N	PLASMA														μg/mL	9			UNKNOWN	mg	6000		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/19398716	Homo sapiens		h	3							false
9112	10148		ADULT	49831257	425.504	FILGOTINIB	FILGOTINIB	O=C(NC1=NN2C(C=CC=C2C3=CC=C(CN4CCS(=O)(=O)CC4)C=C3)=N1)C5CC5	PLASMA	3XVL385Q0M																						UNKNOWN				Protein bindings of FIL and its metabolite (fu: 41%–44% and 55%–61%, respectively) were unchanged in subjects with moderate HI.	42.5	UNHEALTHY		UNKNOWN	EXPERIMENT	https://ard.bmj.com/content/78/Suppl_2/331.1	Homo sapiens										false
9113	10148		ADULT	49831257	425.504	FILGOTINIB	FILGOTINIB	O=C(NC1=NN2C(C=CC=C2C3=CC=C(CN4CCS(=O)(=O)CC4)C=C3)=N1)C5CC5	PLASMA	3XVL385Q0M									?	ng × h/mL	10200		ng/mL	2580			UNKNOWN	mg	450		MULTIPLE	FED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25681059	Homo sapiens		h	7.09				6	FILGOTINIB		false
9114	10148		ADULT	49831257	425.504	FILGOTINIB	FILGOTINIB	O=C(NC1=NN2C(C=CC=C2C3=CC=C(CN4CCS(=O)(=O)CC4)C=C3)=N1)C5CC5	PLASMA	3XVL385Q0M									∞	ng × h/mL	4844		ng/mL	1160			UNKNOWN	mg	200		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25681059	Homo sapiens		h	5.68				6	FILGOTINIB		false
9115	10148		ADULT	49831257	425.504	FILGOTINIB	FILGOTINIB	O=C(NC1=NN2C(C=CC=C2C3=CC=C(CN4CCS(=O)(=O)CC4)C=C3)=N1)C5CC5	PLASMA	3XVL385Q0M									?	μg × h/mL	16.3		μg/mL	4.42			UNKNOWN	mg	450		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31797578	Homo sapiens							47	FILGOTINIB		false
9116	10148		ADULT	49831257	425.504	FILGOTINIB	FILGOTINIB	O=C(NC1=NN2C(C=CC=C2C3=CC=C(CN4CCS(=O)(=O)CC4)C=C3)=N1)C5CC5	PLASMA	3XVL385Q0M									∞	ng × h/mL	1743		ng/mL	565			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/25681059	Homo sapiens		h	4.91							false
9117	10148		ADULT	49831257	425.504	FILGOTINIB	FILGOTINIB	O=C(NC1=NN2C(C=CC=C2C3=CC=C(CN4CCS(=O)(=O)CC4)C=C3)=N1)C5CC5	PLASMA	3XVL385Q0M							24		t	ng × h/mL	2380		ng/mL	556			UNKNOWN	mg	100		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/25681059	Homo sapiens		h	5.87							false
9118	10153		ADULT	42642645	632.7	FORETINIB	FORETINIB	COC1=CC2=C(C=C1OCCCN3CCOCC3)N=CC=C2OC4=CC=C(NC(=O)C5(CC5)C(=O)NC6=CC=C(F)C=C6)C=C4F	PLASMA	81FH7VK1C4							24		t	ng × h/mL	1300		ng/mL	90.5			MAX TOLERATED	mg/kg	3.6		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/20472683	Homo sapiens		h	36.2							false
9119	10153		ADULT	42642645	632.7	FORETINIB	FORETINIB	COC1=CC2=C(C=C1OCCCN3CCOCC3)N=CC=C2OC4=CC=C(NC(=O)C5(CC5)C(=O)NC6=CC=C(F)C=C6)C=C4F	PLASMA	81FH7VK1C4							24		t	ng × h/mL	303		ng/mL	24.5			MAX TOLERATED	mg	80		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/23054208	Homo sapiens										false
9120	10155		ADULT	46213929	469.942	GANDOTINIB	GANDOTINIB	CC1=CC(NC2=NN3C(CC4=C(F)C=C(Cl)C=C4)=C(C)N=C3C(CN5CCOCC5)=C2)=NN1	PLASMA	ANC71R916O							8		t	ng × h/mL	753		ng/mL	154			MAX TOLERATED	mg	120		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28934680	Homo sapiens		h	5.82							false
9121	10156		UNKNOWN	9892860|135536943	519.617	GISADENAFIL	GISADENAFIL	CCOC1=C(C=C(C=N1)S(=O)(=O)N2CCN(CC)CC2)C3=NC4=C(CC)N(CCOC)N=C4C(=O)N3	PLASMA	S6G4R7DI1C																	UNKNOWN				UNKNOWN	UNKNOWN				Human plasma protein binding (fup) (%) - 66	34	UNKNOWN	UNKNOWN	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21451120	Homo sapiens								GISADENAFIL		false
9122	10156		ADULT	9892860|135536943	519.617	GISADENAFIL	GISADENAFIL	CCOC1=C(C=C(C=N1)S(=O)(=O)N2CCN(CC)CC2)C3=NC4=C(CC)N(CCOC)N=C4C(=O)N3	PLASMA	S6G4R7DI1C									?	ng × h/mL	95.2		ng/mL	204.8			UNKNOWN	mg/kg	1.43		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22100260	Homo sapiens								GISADENAFIL		false
9123	10156		ADULT	9892860|135536943	519.617	GISADENAFIL	GISADENAFIL	CCOC1=C(C=C(C=N1)S(=O)(=O)N2CCN(CC)CC2)C3=NC4=C(CC)N(CCOC)N=C4C(=O)N3	PLASMA	S6G4R7DI1C																	UNKNOWN	mg/kg	0.43		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22100260	Homo sapiens		h	2.6					GISADENAFIL		false
9124	10157		ADULT	9804992	421.4889	GIVINOSTAT	CCN(CC)CC1=CC2=C(C=C1)C=C(COC(=O)NC3=CC=C(C=C3)C(=O)NO)C=C2	CCN(CC)CC1=CC2=C(C=C1)C=C(COC(=O)NC3=CC=C(C=C3)C(=O)NO)C=C2	PLASMA	5P60F84FBH							24		t	ng × h/mL	3543		ng/mL	542			INVESTIGATIONAL	mg	600		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/21365126	Homo sapiens		h	5.3							false
9125	10158		ADULT	25166913	374.4	GLASDEGIB	GLASDEGIB	CN1CC[C@H](C[C@@H]1C2=NC3=CC=CC=C3N2)NC(=O)NC4=CC=C(C=C4)C#N	PLASMA	K673DMO5H9									?	ng × h/mL	17210		ng/mL	1252			RECOMMENDED	mg	100		MULTIPLE	UNKNOWN		day	1	Glasdegib is 91% bound to human plasma proteins in vitro.	9	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210656s000lbl.pdf	Homo sapiens		h	17.4							false
9126	10167		ADULT	11395145	389.422	INDEGLITAZAR	INDEGLITAZAR	COC1=CC=C(C=C1)S(=O)(=O)N2C=C(CCC(O)=O)C3=C2C=CC(OC)=C3	PLASMA	JMC809G4ZH									∞	ng × h/mL	141900		ng/mL	8517			UNKNOWN	mg/kg	4		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19116277	Homo sapiens		h	21.3					INDEGLITAZAR		false
9127	10170			53235510	560.475	INFIGRATINIB	INFIGRATINIB	CCN1CCN(CC1)C2=CC=C(NC3=NC=NC(=C3)N(C)C(=O)NC4=C(Cl)C(OC)=CC(OC)=C4Cl)C=C2	PLASMA	A4055ME1VK																										The compound is highly bound to plasma proteins (~ 98%)	2				EXPERIMENT	https://clinicaltrials.gov/ProvidedDocs/91/NCT02706691/Prot_SAP_000.pdf	Homo sapiens										false
9128	10170		ADULT	53235510	560.475	INFIGRATINIB	INFIGRATINIB	CCN1CCN(CC1)C2=CC=C(NC3=NC=NC(=C3)N(C)C(=O)NC4=C(Cl)C(OC)=CC(OC)=C4Cl)C=C2	PLASMA	A4055ME1VK							24		t	ng × h/mL	3183.3		ng/mL	244			RECOMMENDED	mg	125		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27870574	Homo sapiens		h	11.55							false
9129	10173		ADULT	5287541	309.338	IROSUSTAT	irosustat	NS(=O)(=O)OC1=CC=C2C(OC(=O)C3=C2CCCCC3)=C1	PLASMA	366037O6O7									?	ng × h/mL	121		ng/mL	10.44			UNKNOWN	mg	5		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23797179	Homo sapiens							7	irosustat		false
9130	10173		ADULT	5287541	309.338	IROSUSTAT	irosustat	NS(=O)(=O)OC1=CC=C2C(OC(=O)C3=C2CCCCC3)=C1	PLASMA	366037O6O7									?	ng × h/mL	681.2		ng/mL	72.3			UNKNOWN	mg	40		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23797179	Homo sapiens							13	irosustat		false
9131	10173		ADULT	5287541	309.338	IROSUSTAT	irosustat	NS(=O)(=O)OC1=CC=C2C(OC(=O)C3=C2CCCCC3)=C1	PLASMA	366037O6O7									?	ng × h/mL	1229		ng/mL	159.4			MAX TOLERATED	mg	80		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23797179	Homo sapiens							6	irosustat		false
9132	10173		ADULT	5287541	309.338	IROSUSTAT	irosustat	NS(=O)(=O)OC1=CC=C2C(OC(=O)C3=C2CCCCC3)=C1	PLASMA	366037O6O7									?	ng × h/mL	26.86		ng/mL	1.94			UNKNOWN	mg	1		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23797179	Homo sapiens							3	irosustat		false
9133	10173		ADULT	5287541	309.338	IROSUSTAT	irosustat	NS(=O)(=O)OC1=CC=C2C(OC(=O)C3=C2CCCCC3)=C1	PLASMA	366037O6O7									?	ng × h/mL	432.2		ng/mL	33.31			UNKNOWN	mg	20		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23797179	Homo sapiens							6	irosustat		false
9134	10176		ADULT	216453|91981405	442.341	L-778123	L-778,123	Cl.ClC1=CC(=CC=C1)N2CCN(CC3=CN=CN3CC4=CC=C(C=C4)C#N)CC2=O	BLOOD	2A2059P49U									?	μM × h	472.5		μM	2.8			UNKNOWN	mg/m²	140		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11751480	Homo sapiens		h	2.6				3	L-778,123		false
9135	10176		ADULT	216453|91981405	442.341	L-778123	L-778123	Cl.ClC1=CC(=CC=C1)N2CCN(CC3=CN=CN3CC4=CC=C(C=C4)C#N)CC2=O	BLOOD	2A2059P49U									?	μM × h	134.4		μM	0.79			UNKNOWN	mg/m²	35		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11751480	Homo sapiens		h	3.2				3	L-778123		false
9136	10176		ADULT	216453|91981405	442.341	L-778123	L-778,123	Cl.ClC1=CC(=CC=C1)N2CCN(CC3=CN=CN3CC4=CC=C(C=C4)C#N)CC2=O	BLOOD	2A2059P49U									?	μM × h	1310.7		μM	8.09			UNKNOWN	mg/m²	560		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11751480	Homo sapiens		h	2.6				5	L-778,123		false
9137	10176		ADULT	216453|91981405	442.341	L-778123	L-778,123	Cl.ClC1=CC(=CC=C1)N2CCN(CC3=CN=CN3CC4=CC=C(C=C4)C#N)CC2=O	BLOOD	2A2059P49U									?	μM × h	3179.5		μM	18.1			UNKNOWN	mg/m²	1120		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11751480	Homo sapiens		h	2.7				3	L-778,123		false
9138	10177		ADULT	24737642	500.629	LCL-161	LCL-161	CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N2CCC[C@H]2C3=NC(=CS3)C(=O)C4=CC=C(F)C=C4	PLASMA	6TNS415Y3P									∞	ng × h/mL	32081		ng/mL	2350			RP2D	mg	1800		SINGLE	UNKNOWN		week	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25113756	Homo sapiens		h	6.9	cycle 1 day 1			15	LCL-161		false
9139	10177		ADULT	24737642	500.629	LCL-161	CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N2CCC[C@H]2C3=NC(=CS3)C(=O)C4=CC=C(F)C=C4	CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N2CCC[C@H]2C3=NC(=CS3)C(=O)C4=CC=C(F)C=C4	PLASMA	6TNS415Y3P									∞	ng × h/mL	32081		ng/mL	2350			RECOMMENDED	mg	1800		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/25113756	Homo sapiens		h	6.9							false
9140	10179		ADULT		421.4937	LINSITINIB	LINSITINIB	C[C@@]1(O)C[C@@H](C1)C2=NC(=C3N2C=CN=C3N)C4=CC=C5C=CC(=NC5=C4)C6=CC=CC=C6	PLASMA	15A52GPT8T									∞	ng × h/mL	9475		ng/mL	1705			MAX TOLERATED	mg	150		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/25212606	Homo sapiens		h	2.93							false
9141	10179		ADULT		421.4937	LINSITINIB	LINSITINIB	C[C@@]1(O)C[C@@H](C1)C2=NC(=C3N2C=CN=C3N)C4=CC=C5C=CC(=NC5=C4)C6=CC=CC=C6	PLASMA	15A52GPT8T									∞	ng × h/mL	24747		ng/mL	3110			MAX TOLERATED	mg	150		STEADY-STATE	FED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/25212606	Homo sapiens		h	5.03							false
9142	10179		ADULT		421.4937	LINSITINIB	LINSITINIB	C[C@@]1(O)C[C@@H](C1)C2=NC(=C3N2C=CN=C3N)C4=CC=C5C=CC(=NC5=C4)C6=CC=CC=C6	PLASMA	15A52GPT8T							12		t	ng × h/mL	17906		ng/mL	2580			MAX TOLERATED	mg	150		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26831715	Homo sapiens										false
9143	10180		ADULT	71731823	406.413	LORLATINIB	LORLATINIB	C[C@H]1OC2=CC(=CN=C2N)C3=C(C#N)N(C)N=C3CN(C)C(=O)C4=C1C=C(F)C=C4	PLASMA	OSP71S83EU							24		t	ng × h/mL	5650		ng/mL	577			RECOMMENDED	mg	100		STEADY-STATE	UNKNOWN		day	1	In vitro, lorlatinib was 66% bound to plasma proteins at a concentration of 2.4 µM.	34	UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdf	Homo sapiens		h	24							false
9144	10181			25031915	443.4944	LUCITANIB	LUCITANIB	CNC(=O)C1=C2C=CC(OC3=C4C=C(OC)C(OCC5(N)CC5)=CC4=NC=C3)=CC2=CC=C1	PLASMA	PP449XA4BH																										The concentration of the free drug resulted 2.3 ng/ml and the protein binding >99%	1				EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/22012670	Homo sapiens										false
9145	10183		ADULT	46944259	444.314	LY-2874455	LY2874455	C[C@@H](OC1=CC2=C(NN=C2\\C=C\\C3=CN(CCO)N=C3)C=C1)C4=C(Cl)C=NC=C4Cl	PLASMA	E9M363811V									∞	ng × h/mL	325		ng/mL	59.9			UNKNOWN	mg	36		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28589492/	Homo sapiens				18 mg BID			6	LY2874455		false
9146	10183		ADULT	46944259	444.314	LY-2874455	LY2874455	C[C@@H](OC1=CC2=C(NN=C2\\C=C\\C3=CN(CCO)N=C3)C=C1)C4=C(Cl)C=NC=C4Cl	PLASMA	E9M363811V									?	ng × h/mL	32.7		ng/mL	6.25			UNKNOWN	mg	2		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28589492/	Homo sapiens							3	LY2874455		false
9147	10183		ADULT	46944259	444.314	LY-2874455	LY2874455	C[C@@H](OC1=CC2=C(NN=C2\\C=C\\C3=CN(CCO)N=C3)C=C1)C4=C(Cl)C=NC=C4Cl	PLASMA	E9M363811V							12		t	ng × h/mL	171		ng/mL	29.9			RECOMMENDED	mg	32		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28589492/	Homo sapiens				16 mg BID			3	LY2874455		false
9148	10183		ADULT	46944259	444.314	LY-2874455	LY2874455	C[C@@H](OC1=CC2=C(NN=C2\\C=C\\C3=CN(CCO)N=C3)C=C1)C4=C(Cl)C=NC=C4Cl	PLASMA	E9M363811V							12		t	ng × h/mL	140		ng/mL	35.5			UNKNOWN	mg	20		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28589492/	Homo sapiens				10 mg BID			3	LY2874455		false
9149	10183		ADULT	46944259	444.314	LY-2874455	LY2874455	C[C@@H](OC1=CC2=C(NN=C2\\C=C\\C3=CN(CCO)N=C3)C=C1)C4=C(Cl)C=NC=C4Cl	PLASMA	E9M363811V							12		t	ng × h/mL	532		ng/mL	107			HIGHEST STUDIED	mg	48		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28589492/	Homo sapiens				24 mg BID			3	LY2874455		false
9150	10183		ADULT	46944259	444.314	LY-2874455	LY2874455	C[C@@H](OC1=CC2=C(NN=C2\\C=C\\C3=CN(CCO)N=C3)C=C1)C4=C(Cl)C=NC=C4Cl	PLASMA	E9M363811V									?	pg × h/mL	224		ng/mL	38.4			UNKNOWN	mg	10		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28589492/	Homo sapiens							3	LY2874455		false
9151	10183		ADULT	46944259	444.314	LY-2874455	LY-2874455	C[C@@H](OC1=CC2=C(NN=C2\\C=C\\C3=CN(CCO)N=C3)C=C1)C4=C(Cl)C=NC=C4Cl	BLOOD	E9M363811V									?	ng × h/mL	171		ng/mL	29.9			RECOMMENDED	mg	16		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/28589492	Homo sapiens										false
9152	10183		ADULT	46944259	444.314	LY-2874455	LY-2874455	C[C@@H](OC1=CC2=C(NN=C2\\C=C\\C3=CN(CCO)N=C3)C=C1)C4=C(Cl)C=NC=C4Cl	BLOOD	E9M363811V									?	ng × h/mL	380		ng/mL	91.9			MAX TOLERATED	mg	10		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/28589492	Homo sapiens										false
9153	10188			16718576	460.5746	MILCICLIB	Milciclib	CNC(=O)C1=NN(C)C2=C1C(C)(C)CC3=C2N=C(NC4=CC=C(C=C4)N5CCN(C)CC5)N=C3	PLASMA	688000M8S8																										The in vitro plasma protein binding ranged from 78 to 90%, depending on the species.	16				OTHER GOV'T	https://clinicaltrials.gov/ProvidedDocs/91/NCT01301391/Prot_000.pdf	Homo sapiens										false
9154	10188		ADULT	16718576	460.5746	MILCICLIB	CNC(=O)C1=NN(C)C2=C1C(C)(C)CC3=CN=C(NC4=CC=C(C=C4)N5CCN(C)CC5)N=C23	CNC(=O)C1=NN(C)C2=C1C(C)(C)CC3=CN=C(NC4=CC=C(C=C4)N5CCN(C)CC5)N=C23	PLASMA	688000M8S8							24		t	μM × h	25		μM	1.5			RECOMMENDED	mg	150		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/22160853	Homo sapiens		h	33.1							false
9155	10191		UNKNOWN	24856436	500.5954	MK-1775	MK-1775	CN1CCN(CC1)C2=CC=C(NC3=NC4=C(C=N3)C(=O)N(CC=C)N4C5=CC=CC(=N5)C(C)(C)O)C=C2	PLASMA	K2T6HJX3I3																						UNKNOWN				AZD1775 has physicochemical properties that are relatively favorable for brain penetration, i.e., molecular weight of 501.2 Da, octanol-water partition coefficient (logP) of 2.8, and fraction unbound of ~0.2 in human plasma.	20	UNKNOWN		UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6863148/	Homo sapiens										false
9156	10191		ADULT	24856436	500.5954	MK-1775	MK-1775	CN1CCN(CC1)C2=CC=C(NC3=NC4=C(C=N3)C(=O)N(CC=C)N4C5=CC=CC(=N5)C(C)(C)O)C=C2	PLASMA	K2T6HJX3I3							8		t	nM × h	3990		nM	740			MAX TOLERATED	mg	225		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/25964244	Homo sapiens										false
9157	10192		ADULT	67254077	443.928	MK-2206	MK-2206	Cl.NC1(CCC1)C2=CC=C(C=C2)C3=C(C=C4C5=NNC(=O)N5C=CC4=N3)C6=CC=CC=C6	PLASMA	4HA45S22ZZ							48		t	nM × h	1820		nM	66.4			MAX TOLERATED	mg	60		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22025163	Homo sapiens							20	MK-2206		false
9158	10192		ADULT	67254077	443.928	MK-2206	MK-2206	Cl.NC1(CCC1)C2=CC=C(C=C2)C3=C(C=C4C5=NNC(=O)N5C=CC4=N3)C6=CC=CC=C6	PLASMA	4HA45S22ZZ							48		t	nM × h	7970		nM	232			UNKNOWN	mg	90		MULTIPLE	FASTED		2 days	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22025163	Homo sapiens		h	66.2	day 27			7	MK-2206		false
9159	10192		ADULT	67254077	443.928	MK-2206	MK-2206	Cl.NC1(CCC1)C2=CC=C(C=C2)C3=C(C=C4C5=NNC(=O)N5C=CC4=N3)C6=CC=CC=C6	PLASMA	4HA45S22ZZ							48		t	nM × h	5860		nM	163			MAX TOLERATED	mg	60		MULTIPLE	FASTED		2 days	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22025163	Homo sapiens		h	71.3	day 27			20	MK-2206		false
9160	10192		ADULT	67254077	443.928	MK-2206	MK-2206	Cl.NC1(CCC1)C2=CC=C(C=C2)C3=C(C=C4C5=NNC(=O)N5C=CC4=N3)C6=CC=CC=C6	PLASMA	4HA45S22ZZ							48		t	nM × h	3950		nM	132			UNKNOWN	mg	90		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22025163	Homo sapiens							7	MK-2206		false
9161	10192		ADULT	67254077	443.928	MK-2206	MK-2206	Cl.NC1(CCC1)C2=CC=C(C=C2)C3=C(C=C4C5=NNC(=O)N5C=CC4=N3)C6=CC=CC=C6	PLASMA	4HA45S22ZZ							168		t	nM × h	23500		nM	345			MAX TOLERATED	mg	200		MULTIPLE	FASTED		week	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25239610	Homo sapiens		h	75.1				17	MK-2206		false
9162	10192		ADULT	67254077	443.928	MK-2206	MK-2206	Cl.NC1(CCC1)C2=CC=C(C=C2)C3=C(C=C4C5=NNC(=O)N5C=CC4=N3)C6=CC=CC=C6	PLASMA	4HA45S22ZZ							168		t	nM × h	27700		nM	466			UNKNOWN	mg	300		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25239610	Homo sapiens							3	MK-2206		false
9163	10192		ADULT	67254077	443.928	MK-2206	MK-2206	Cl.NC1(CCC1)C2=CC=C(C=C2)C3=C(C=C4C5=NNC(=O)N5C=CC4=N3)C6=CC=CC=C6	PLASMA	4HA45S22ZZ							168		t	nM × h	16400		nM	264			MAX TOLERATED	mg	200		SINGLE	FASTED		week	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25239610	Homo sapiens							17	MK-2206		false
9164	10192		ADULT	67254077	443.928	MK-2206	MK-2206	Cl.NC1(CCC1)C2=CC=C(C=C2)C3=C(C=C4C5=NNC(=O)N5C=CC4=N3)C6=CC=CC=C6	PLASMA	4HA45S22ZZ							48		t	nM × h	2720		nM	95.9			MAX TOLERATED	mg	60		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26104654	Homo sapiens		h	71.8							false
9165	10193		ADULT	9865515	396.4445	MOCETINOSTAT	MOCETINOSTAT	NC1=C(NC(=O)C2=CC=C(CNC3=NC(=CC=N3)C4=CN=CC=C4)C=C2)C=CC=C1	PLASMA	A6GWB8T96J							24		t	ng × h/mL	1000		ng/mL	161			UNKNOWN	mg/m²	60		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/18495956	Homo sapiens		h	10.9							false
9166	10194		ADULT	59603622	314.3027	MOLIDUSTAT	MOLIDUSTAT	O=C1N(NC=C1N2C=CN=N2)C3=NC=NC(=C3)N4CCOCC4	BLOOD	9JH486CZ13									∞	μg × h/L	2960		μg/L	1920			UNKNOWN	mg	150		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/31919558	Homo sapiens		h	11.9							false
9167	10196		ADULT	10170574|102495492	1079.302	NASTORAZEPIDE CALCIUM	Z-360	[Ca  ].CC(C)(C)C(=O)CN1C2=C(C=CC=C2)N(C[C@@H](NC(=O)NC3=CC(=CC=C3)C([O-])=O)C1=O)C4CCCCC4.CC(C)(C)C(=O)CN5C6=C(C=CC=C6)N(C[C@@H](NC(=O)NC7=CC(=CC=C7)C([O-])=O)C5=O)C8CCCCC8	PLASMA	GZ3I1DMI8Q									∞	ng × h/mL	18600		ng/mL	4434			UNKNOWN	mg	120		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20006921/	Homo sapiens		h	4.17				9	Z-360		false
9168	10196		ADULT	10170574|102495492	1079.302	NASTORAZEPIDE CALCIUM	Z-360	[Ca  ].CC(C)(C)C(=O)CN1C2=C(C=CC=C2)N(C[C@@H](NC(=O)NC3=CC(=CC=C3)C([O-])=O)C1=O)C4CCCCC4.CC(C)(C)C(=O)CN5C6=C(C=CC=C6)N(C[C@@H](NC(=O)NC7=CC(=CC=C7)C([O-])=O)C5=O)C8CCCCC8	PLASMA	GZ3I1DMI8Q									∞	ng × h/mL	24030		ng/mL	6756			HIGHEST STUDIED	mg	240		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20006921/	Homo sapiens		h	5.5				11	Z-360		false
9169	10198		ADULT	24978538	974.613	NAVITOCLAX	NAVITOCLAX	CC1(C)CCC(=C(CN2CCN(CC2)C3=CC=C(C=C3)C(=O)NS(=O)(=O)C4=CC(=C(N[C@H](CCN5CCOCC5)CSC6=CC=CC=C6)C=C4)S(=O)(=O)C(F)(F)F)C1)C7=CC=C(Cl)C=C7	PLASMA	XKJ5VVK2WD									∞	μg × h/mL	66.5		μg/mL	6.75			UNKNOWN	mg	250		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/21094089	Homo sapiens		h	13.8							false
9170	10204		ADULT	10173280	418.5313	PALOSURAN	palosuran	CC1=NC2=C(C=CC=C2)C(NC(=O)NCCN3CCC(O)(CC4=CC=CC=C4)CC3)=C1	PLASMA	ULD9ZKE457									?	ng × h/mL	433		ng/mL	135			UNKNOWN	mg	125		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16952491/	Homo sapiens					Corrected creatinine clearance >50 mL*min-1*1.73 m2		9	palosuran		false
9171	10204		ADULT	10173280	418.5313	PALOSURAN	palosuran	CC1=NC2=C(C=CC=C2)C(NC(=O)NCCN3CCC(O)(CC4=CC=CC=C4)CC3)=C1	PLASMA	ULD9ZKE457									?	ng × h/mL	429		ng/mL	107			UNKNOWN	mg	125		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16952491/	Homo sapiens					Corrected creatinine clearance <50 mL*min-1*1.73 m2		10	palosuran		false
9172	10204		ADULT	10173280	418.5313	PALOSURAN	palosuran	CC1=NC2=C(C=CC=C2)C(NC(=O)NCCN3CCC(O)(CC4=CC=CC=C4)CC3)=C1	PLASMA	ULD9ZKE457							12		t	ng × h/mL	34.2		ng/mL	11.5			UNKNOWN	mg	25		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30384375/	Homo sapiens							6	palosuran		false
9173	10204		ADULT	10173280	418.5313	PALOSURAN	palosuran	CC1=NC2=C(C=CC=C2)C(NC(=O)NCCN3CCC(O)(CC4=CC=CC=C4)CC3)=C1	PLASMA	ULD9ZKE457							12		t	ng × h/mL	1429		ng/mL	431			UNKNOWN	mg	125		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30384375/	Homo sapiens		h	29.9				6	palosuran		false
9174	10204		ADULT	10173280	418.5313	PALOSURAN	palosuran	CC1=NC2=C(C=CC=C2)C(NC(=O)NCCN3CCC(O)(CC4=CC=CC=C4)CC3)=C1	PLASMA	ULD9ZKE457							12		t	ng × h/mL	735		ng/mL	196			UNKNOWN	mg	125		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30384375/	Homo sapiens							6	palosuran		false
9175	10204		ADULT	10173280	418.5313	PALOSURAN	palosuran	CC1=NC2=C(C=CC=C2)C(NC(=O)NCCN3CCC(O)(CC4=CC=CC=C4)CC3)=C1	PLASMA	ULD9ZKE457							12		t	ng × h/mL	3350		ng/mL	1069			UNKNOWN	mg	500		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30384375/	Homo sapiens							6	palosuran		false
9176	10204		ADULT	10173280	418.5313	PALOSURAN	palosuran	CC1=NC2=C(C=CC=C2)C(NC(=O)NCCN3CCC(O)(CC4=CC=CC=C4)CC3)=C1	PLASMA	ULD9ZKE457							12		t	ng × h/mL	84.1		ng/mL	21.5			UNKNOWN	mg	25		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30384375/	Homo sapiens		h	21.1				6	palosuran		false
9177	10204		ADULT	10173280	418.5313	PALOSURAN	palosuran	CC1=NC2=C(C=CC=C2)C(NC(=O)NCCN3CCC(O)(CC4=CC=CC=C4)CC3)=C1	PLASMA	ULD9ZKE457							12		t	ng × h/mL	9216		ng/mL	1615			UNKNOWN	mg	500		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30384375/	Homo sapiens		h	23.2				6	palosuran		false
9178	10205		ADULT	10295295	414.5393	PALOVAROTENE	PALOVAROTENE	CC1(C)CCC(C)(C)C2=CC(\\C=C\\C3=CC=C(C=C3)C(O)=O)=C(CN4C=CC=N4)C=C12	PLASMA	28K6I5M16G									?	ng × h/mL	57.7		ng/mL	10.3			UNKNOWN	mg	1		MULTIPLE	FED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17324249	Homo sapiens				10 patients received 1 mg of R667 once daily for 14–16 days.			10	PALOVAROTENE		false
9179	10206		ADULT	6445562	467.9	PELITINIB	PELITINIB	CCOC1=C(NC(=O)\\C=C\\CN(C)C)C=C2C(=C1)N=CC(C#N)=C2NC3=CC(Cl)=C(F)C=C3	PLASMA	X5DWL380Z6							24		t	ng × h/mL	815		ng/mL	45.1			MAX TOLERATED	mg	75		MULTIPLE	FED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/16710023	Homo sapiens		h	21.7							false
9180	10208		ADULT	24771824	455.4324	PF-04457845	PF-04457845	FC(F)(F)C1=CN=C(OC2=CC(C=C3CCN(CC3)C(=O)NC4=NN=CC=C4)=CC=C2)C=C1	PLASMA	H4C81M8YYW									∞	ng × h/mL	6048		ng/mL	442			UNKNOWN	mg	40		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22044402	Homo sapiens		h	22.8				9			false
9181	10208		ADULT	24771824	455.4324	PF-04457845	PF-04457845	FC(F)(F)C1=CN=C(OC2=CC(C=C3CCN(CC3)C(=O)NC4=NN=CC=C4)=CC=C2)C=C1	PLASMA	H4C81M8YYW									t	ng × h/mL	1420		ng/mL	129			UNKNOWN	mg	8		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22044402	Homo sapiens		h	21.9	14 days			8			false
9182	10208		ADULT	24771824	455.4324	PF-04457845	PF-04457845	FC(F)(F)C1=CN=C(OC2=CC(C=C3CCN(CC3)C(=O)NC4=NN=CC=C4)=CC=C2)C=C1	PLASMA	H4C81M8YYW									∞	ng × h/mL	6048		ng/mL	442			UNKNOWN	mg	40		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/22044402	Homo sapiens		h	22.8							false
9183	10209		ADULT	11581936	392.4525	PF-2545920	PF-2545920	CN1C=C(C(=N1)C2=CC=C(OCC3=NC4=C(C=CC=C4)C=C3)C=C2)C5=CC=NC=C5	SERUM	R9Y8EY0G42													ng/mL	202			UNKNOWN	mg	30		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28122201	Homo sapiens							1	PF-2545920		false
9184	10209		ADULT	11610553	378.4	PF-1001252	PF-1001252	C1=CC=C2C(=C1)C=CC(=N2)COC3=CC=C(C=C3)C4=C(C=NN4)C5=CC=NC=C5	SERUM														ng/mL	8.6			UNKNOWN	mg	10		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28122201	Homo sapiens							3	PF-02545920		false
9185	10209		ADULT	11610553	378.4	PF-1001252	PF-1001252	C1=CC=C2C(=C1)C=CC(=N2)COC3=CC=C(C=C3)C4=C(C=NN4)C5=CC=NC=C5	SERUM														ng/mL	21.6			UNKNOWN	mg	30		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28122201	Homo sapiens							1	PF-02545920		false
9186	10209		ADULT	11581936	392.4525	PF-2545920	PF-2545920	CN1C=C(C(=N1)C2=CC=C(OCC3=NC4=C(C=CC=C4)C=C3)C=C2)C5=CC=NC=C5	SERUM	R9Y8EY0G42													ng/mL	40.4			UNKNOWN	mg	10		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28122201	Homo sapiens							3	PF-02545920		false
9187	10209		ADULT	11610553	378.4	PF-1001252	PF-1001252	C1=CC=C2C(=C1)C=CC(=N2)COC3=CC=C(C=C3)C4=C(C=NN4)C5=CC=NC=C5	SERUM														ng/mL	22.1			UNKNOWN	mg	20		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28122201	Homo sapiens							4	PF-02545920		false
9188	10209		ADULT	11581936	392.4525	PF-2545920	PF-2545920	CN1C=C(C(=N1)C2=CC=C(OCC3=NC4=C(C=CC=C4)C=C3)C=C2)C5=CC=NC=C5	SERUM	R9Y8EY0G42													ng/mL	104			UNKNOWN	mg	20		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28122201	Homo sapiens							4	PF-02545920		false
9189	10212		ADULT	72435	414.4053	PICROPODOPHYLLIN	AXL1717	COC1=CC(=CC(OC)=C1OC)[C@H]2[C@H]3[C@H](COC3=O)[C@@H](O)C4=C2C=C5OCOC5=C4	PLASMA	0F35AOI227							12		t	nM × h	3142		nM	652			UNKNOWN	mg	520		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26161618/	Homo sapiens							23	AXL1717		false
9190	10212		ADULT	72435	414.4053	PICROPODOPHYLLIN	AXL1717	COC1=CC(=CC(OC)=C1OC)[C@H]2[C@H]3[C@H](COC3=O)[C@@H](O)C4=C2C=C5OCOC5=C4	PLASMA	0F35AOI227							12		t	nM × h	1877		nM	448			RECOMMENDED	mg	390		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26161618/	Homo sapiens							14	AXL1717		false
9191	10212		ADULT	72435	414.4053	PICROPODOPHYLLIN	AXL1717	COC1=CC(=CC(OC)=C1OC)[C@H]2[C@H]3[C@H](COC3=O)[C@@H](O)C4=C2C=C5OCOC5=C4	PLASMA	0F35AOI227							12		t	nM × h	9982		nM	1783			RECOMMENDED	mg	390		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26161618/	Homo sapiens				Day 14			10	AXL1717		false
9192	10212		ADULT	72435	414.4053	PICROPODOPHYLLIN	AXL1717	COC1=CC(=CC(OC)=C1OC)[C@H]2[C@H]3[C@H](COC3=O)[C@@H](O)C4=C2C=C5OCOC5=C4	PLASMA	0F35AOI227							12		t	nM × h	13079		nM	2391			HIGHEST STUDIED	mg	520		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26161618/	Homo sapiens				Day 14			7	AXL1717		false
9193	10213		ADULT	17755052	513.636	PICTILISIB	PICTILISIB	CS(=O)(=O)N1CCN(CC2=CC3=C(S2)C(=NC(=N3)C4=C5C=NNC5=CC=C4)N6CCOCC6)CC1	PLASMA	ICY00EMP8P									∞	μM × h	19.4		μM	1.52			MAX TOLERATED	mg	330		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/25370471	Homo sapiens		h	15.7							false
9194	10215		ADULT	25127713	491.342	POZIOTINIB	POZIOTINIB	COC1=C(OC2CCN(CC2)C(=O)C=C)C=C3C(NC4=C(F)C(Cl)=C(Cl)C=C4)=NC=NC3=C1	PLASMA	OEI6OOU6IK									?	ng × h/mL	0.989		ng/mL	0.869			UNKNOWN	mg	32		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/25377158	Homo sapiens										false
9195	10216		UNKNOWN	49855250	358.4778	PRACINOSTAT	PRACINOSTAT	CCCCC1=NC2=C(C=CC(\\C=C\\C(=O)NO)=C2)N1CCN(CC)CC	PLASMA	GPO2JN4UON																						UNKNOWN				Plasma protein binding in mouse, rat, dog, and human ranged between ∼84 and 94%	11	UNKNOWN		UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/21873472	Homo sapiens										false
9196	10216		ADULT	49855250	358.5	PRACINOSTAT	PRACINOSTAT	CCCCC1=NC2=CC(\\C=C\\C(=O)NO)=CC=C2N1CCN(CC)CC	PLASMA	GPO2JN4UON									∞	ng × h/mL	1356		ng/mL	202			MAX TOLERATED	mg	120		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/28841236	Homo sapiens		h	10.8							false
9197	10218		ADULT	11955855	436.303	RABUSERTIB	RABUSERTIB	CC1=CN=C(NC(=O)NC2=CC(Br)=C(C)C=C2OC[C@@H]3CNCCO3)C=N1	PLASMA	3S9L1NU6U7									∞	ng × h/mL	38000		ng/mL	3430			RECOMMENDED	mg/m²	150		MULTIPLE	UNKNOWN		3 weeks	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/27350064	Homo sapiens		h	14.4							false
9198	10221			44182295	572.337	REFAMETINIB	REFAMETINIB	COC1=C(NS(=O)(=O)C2(C[C@H](O)CO)CC2)C(NC3=C(F)C=C(I)C=C3)=C(F)C(F)=C1	PLASMA	JPX07AFM0N																										Mouse and human plasma protein binding of RDEA119 is 99.6% and 99.8%, respectively	0.2				EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/19706763	Homo sapiens										false
9199	10221		ADULT	44182295	572.337	REFAMETINIB	REFAMETINIB	COC1=C(NS(=O)(=O)C2(C[C@H](O)CO)CC2)C(NC3=C(F)C=C(I)C=C3)=C(F)C(F)=C1	PLASMA	JPX07AFM0N							24		t	ng × h/mL	17975		ng/mL	1442			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/23434733	Homo sapiens		h	12							false
9200	10223		UNKNOWN	10348973	623.63	RELUGOLIX	Relugolix	CONC(=O)NC1=CC=C(C=C1)C2=C(CN(C)C)C3=C(S2)N(CC4=C(F)C=CC=C4F)C(=O)N(C3=O)C5=NN=C(OC)C=C5	PLASMA	P76B05O5V6																						UNKNOWN				Human plasma protein binding: 68% to 71%	32	UNKNOWN		UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda#page=48_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=6	Homo sapiens										false
9201	10223		ADULT	10348973	623.63	RELUGOLIX	Relugolix	CONC(=O)NC1=CC=C(C=C1)C2=C(CN(C)C)C3=C(S2)N(CC4=C(F)C=CC=C4F)C(=O)N(C3=O)C5=NN=C(OC)C=C5	PLASMA	P76B05O5V6	5757	272.382	ESTRADIOL	estradiol	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@H]2O	4TI98Z838E			∞	ng × h/mL	198.1		ng/mL	26			RECOMMENDED	mg	40		SINGLE	FASTED						HEALTHY	Oral	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214846s000lbl.pdf#page=19 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=6	Homo sapiens					Postmenopausal women	1 mg   norethindrone acetate 0.5 mg				true
9202	10223		ADULT	10348973	623.63	RELUGOLIX	Relugolix	CONC(=O)NC1=CC=C(C=C1)C2=C(CN(C)C)C3=C(S2)N(CC4=C(F)C=CC=C4F)C(=O)N(C3=O)C5=NN=C(OC)C=C5	PLASMA	P76B05O5V6									∞	ng × h/mL	0.97		ng/mL	0.12			UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Oral	FEMALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=29	Homo sapiens		h	6.6		Healthy premenopausal women		10			false
9203	10223		ADULT	10348973	623.63	RELUGOLIX	Relugolix	CONC(=O)NC1=CC=C(C=C1)C2=C(CN(C)C)C3=C(S2)N(CC4=C(F)C=CC=C4F)C(=O)N(C3=O)C5=NN=C(OC)C=C5	PLASMA	P76B05O5V6									∞	ng × h/mL	8.44		ng/mL	0.56			UNKNOWN	mg	5		SINGLE	FASTED						HEALTHY	Oral	FEMALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=29	Homo sapiens		h	14.18		Healthy premenopausal women		10			false
9204	10223		ADULT	10348973	623.63	RELUGOLIX	Relugolix	CONC(=O)NC1=CC=C(C=C1)C2=C(CN(C)C)C3=C(S2)N(CC4=C(F)C=CC=C4F)C(=O)N(C3=O)C5=NN=C(OC)C=C5	PLASMA	P76B05O5V6									∞	ng × h/mL	45.25		ng/mL	3.74			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	FEMALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=29	Homo sapiens		h	16.23		Healthy premenopausal women		10			false
9205	10223		ADULT	10348973	623.63	RELUGOLIX	Relugolix	CONC(=O)NC1=CC=C(C=C1)C2=C(CN(C)C)C3=C(S2)N(CC4=C(F)C=CC=C4F)C(=O)N(C3=O)C5=NN=C(OC)C=C5	PLASMA	P76B05O5V6									∞	ng × h/mL	107.67		ng/mL	9.46			RECOMMENDED	mg	40		SINGLE	FASTED						HEALTHY	Oral	FEMALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=29	Homo sapiens		h	16.49		Healthy premenopausal women		10			false
9206	10223		ADULT	10348973	623.63	RELUGOLIX	Relugolix	CONC(=O)NC1=CC=C(C=C1)C2=C(CN(C)C)C3=C(S2)N(CC4=C(F)C=CC=C4F)C(=O)N(C3=O)C5=NN=C(OC)C=C5	PLASMA	P76B05O5V6									∞	ng × h/mL	293.45		ng/mL	32.9			UNKNOWN	mg	80		SINGLE	FASTED						HEALTHY	Oral	FEMALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=29	Homo sapiens		h	15.64		Healthy premenopausal women		10			false
9207	10223		ADULT	10348973	623.63	RELUGOLIX	Relugolix	CONC(=O)NC1=CC=C(C=C1)C2=C(CN(C)C)C3=C(S2)N(CC4=C(F)C=CC=C4F)C(=O)N(C3=O)C5=NN=C(OC)C=C5	PLASMA	P76B05O5V6									∞	ng × h/mL	18.05		ng/mL	1.61			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	FEMALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=29	Homo sapiens		h	15.15		Healthy premenopausal women		10			false
9208	10223		ADULT	10348973	623.63	RELUGOLIX	Relugolix	CONC(=O)NC1=CC=C(C=C1)C2=C(CN(C)C)C3=C(S2)N(CC4=C(F)C=CC=C4F)C(=O)N(C3=O)C5=NN=C(OC)C=C5	PLASMA	P76B05O5V6							24		t	ng × h/mL	35.34		ng/mL	1.34			UNKNOWN	mg	10		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=30	Homo sapiens				Day 1 PK	Healthy premenopausal women		9			false
9209	10223		ADULT	10348973	623.63	RELUGOLIX	Relugolix	CONC(=O)NC1=CC=C(C=C1)C2=C(CN(C)C)C3=C(S2)N(CC4=C(F)C=CC=C4F)C(=O)N(C3=O)C5=NN=C(OC)C=C5	PLASMA	P76B05O5V6							24		t	ng × h/mL	18.16		ng/mL	5.06			UNKNOWN	mg	20		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=30	Homo sapiens				Day 1 PK	Healthy premenopausal women		9			false
9210	10223		ADULT	10348973	623.63	RELUGOLIX	Relugolix	CONC(=O)NC1=CC=C(C=C1)C2=C(CN(C)C)C3=C(S2)N(CC4=C(F)C=CC=C4F)C(=O)N(C3=O)C5=NN=C(OC)C=C5	PLASMA	P76B05O5V6							24		t	ng × h/mL	58.65		ng/mL	19			RECOMMENDED	mg	40		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=30	Homo sapiens				Day 1 PK	Healthy premenopausal women		9			false
9211	10223		ADULT	10348973	623.63	RELUGOLIX	Relugolix	CONC(=O)NC1=CC=C(C=C1)C2=C(CN(C)C)C3=C(S2)N(CC4=C(F)C=CC=C4F)C(=O)N(C3=O)C5=NN=C(OC)C=C5	PLASMA	P76B05O5V6							24		t	ng × h/mL	19.6		ng/mL	2.05			UNKNOWN	mg	10		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=30	Homo sapiens				Day 14 PK	Healthy premenopausal women		9			false
9212	10223		ADULT	10348973	623.63	RELUGOLIX	Relugolix	CONC(=O)NC1=CC=C(C=C1)C2=C(CN(C)C)C3=C(S2)N(CC4=C(F)C=CC=C4F)C(=O)N(C3=O)C5=NN=C(OC)C=C5	PLASMA	P76B05O5V6							24		t	ng × h/mL	58.68		ng/mL	8.2			UNKNOWN	mg	20		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=30	Homo sapiens				Day 14 PK	Healthy premenopausal women		9			false
9213	10223		ADULT	10348973	623.63	RELUGOLIX	Relugolix	CONC(=O)NC1=CC=C(C=C1)C2=C(CN(C)C)C3=C(S2)N(CC4=C(F)C=CC=C4F)C(=O)N(C3=O)C5=NN=C(OC)C=C5	PLASMA	P76B05O5V6							24		t	ng × h/mL	119.04		ng/mL	21.8			RECOMMENDED	mg	40		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=30	Homo sapiens				Day 14 PK	Healthy premenopausal women		9			false
9214	10223		ADULT	10348973	623.63	RELUGOLIX	Relugolix	CONC(=O)NC1=CC=C(C=C1)C2=C(CN(C)C)C3=C(S2)N(CC4=C(F)C=CC=C4F)C(=O)N(C3=O)C5=NN=C(OC)C=C5	PLASMA	P76B05O5V6	5757	272.382	ESTRADIOL	estradiol	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@H]2O	4TI98Z838E			∞	ng × h/mL	104.6		ng/mL	8.884			RECOMMENDED	mg	40		SINGLE	FED						HEALTHY	Oral	FEMALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=38	Homo sapiens						1 mg   Norethindrone acetate 0.5 mg	23			true
9215	10223		ADULT	10348973	623.63	RELUGOLIX	Relugolix	CONC(=O)NC1=CC=C(C=C1)C2=C(CN(C)C)C3=C(S2)N(CC4=C(F)C=CC=C4F)C(=O)N(C3=O)C5=NN=C(OC)C=C5	PLASMA	P76B05O5V6	5757	272.382	ESTRADIOL	estradiol	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@H]2O	4TI98Z838E			∞	ng × h/mL	168.5		ng/mL	19.59			RECOMMENDED	mg	40		SINGLE	FASTED						HEALTHY	Oral	FEMALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=38	Homo sapiens						1 mg   Norethindrone acetate 0.5 mg	23			true
9216	10223		ADULT	10348973	623.63	RELUGOLIX	Relugolix	CONC(=O)NC1=CC=C(C=C1)C2=C(CN(C)C)C3=C(S2)N(CC4=C(F)C=CC=C4F)C(=O)N(C3=O)C5=NN=C(OC)C=C5	PLASMA	P76B05O5V6									∞	ng × h/mL	123		ng/mL	12.5			RECOMMENDED	mg	40		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=48	Homo sapiens					Normal hepatic function, n=7 for AUCinf		8			false
9217	10223		ADULT	10348973	623.63	RELUGOLIX	Relugolix	CONC(=O)NC1=CC=C(C=C1)C2=C(CN(C)C)C3=C(S2)N(CC4=C(F)C=CC=C4F)C(=O)N(C3=O)C5=NN=C(OC)C=C5	PLASMA	P76B05O5V6									∞	ng × h/mL	84.1		ng/mL	9.43			RECOMMENDED	mg	40		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=48	Homo sapiens					Mild hepatic impairment		8			false
9218	10223		ADULT	10348973	623.63	RELUGOLIX	Relugolix	CONC(=O)NC1=CC=C(C=C1)C2=C(CN(C)C)C3=C(S2)N(CC4=C(F)C=CC=C4F)C(=O)N(C3=O)C5=NN=C(OC)C=C5	PLASMA	P76B05O5V6									∞	ng × h/mL	116		ng/mL	14.6			RECOMMENDED	mg	40		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=48	Homo sapiens					Moderate hepatic impairment		8			false
9219	10223		ADULT	10348973	623.63	RELUGOLIX	Relugolix	CONC(=O)NC1=CC=C(C=C1)C2=C(CN(C)C)C3=C(S2)N(CC4=C(F)C=CC=C4F)C(=O)N(C3=O)C5=NN=C(OC)C=C5	PLASMA	P76B05O5V6									∞	ng × h/mL	93.4		ng/mL	11.65			RECOMMENDED	mg	40		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=49	Homo sapiens					Normal renal function		12			false
9220	10223		ADULT	10348973	623.63	RELUGOLIX	Relugolix	CONC(=O)NC1=CC=C(C=C1)C2=C(CN(C)C)C3=C(S2)N(CC4=C(F)C=CC=C4F)C(=O)N(C3=O)C5=NN=C(OC)C=C5	PLASMA	P76B05O5V6									∞	ng × h/mL	144.6		ng/mL	20.92			RECOMMENDED	mg	40		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=49	Homo sapiens					Moderate renal impairment		12			false
9221	10223		ADULT	10348973	623.63	RELUGOLIX	Relugolix	CONC(=O)NC1=CC=C(C=C1)C2=C(CN(C)C)C3=C(S2)N(CC4=C(F)C=CC=C4F)C(=O)N(C3=O)C5=NN=C(OC)C=C5	PLASMA	P76B05O5V6									∞	ng × h/mL	109		ng/mL	14			RECOMMENDED	mg	40		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=50	Homo sapiens					Normal renal function, n=7 for AUCinf		8			false
9222	10223		ADULT	10348973	623.63	RELUGOLIX	Relugolix	CONC(=O)NC1=CC=C(C=C1)C2=C(CN(C)C)C3=C(S2)N(CC4=C(F)C=CC=C4F)C(=O)N(C3=O)C5=NN=C(OC)C=C5	PLASMA	P76B05O5V6									∞	ng × h/mL	163		ng/mL	15.4			RECOMMENDED	mg	40		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf#page=50	Homo sapiens					Severe renal impairment (no dialysis)		8			false
9223	10226		ADULT	53340666	433.5029	RICOLINOSTAT	RICOLINOSTAT	ONC(=O)CCCCCCNC(=O)C1=CN=C(N=C1)N(C2=CC=CC=C2)C3=CC=CC=C3	PLASMA	WKT909C62B							6		t	ng × h/mL	1489		ng/mL	821			RECOMMENDED	mg	160		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/27646843	Homo sapiens		h	2.88							false
9224	10229		ADULT	49867930	469.4045	RG-4733	RO4929097	CC(C)(C(=O)NCC(F)(F)C(F)(F)F)C(=O)N[C@H]1C2=C(C=CC=C2)C3=C(NC1=O)C=CC=C3	PLASMA	KK8645V7LE							24		t	nM × h	6034.5		nM	498.1			UNKNOWN	mg	20		SINGLE	UNKNOWN					1.2	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22351688	Homo sapiens		h	24.5				8	RO4929097		false
9225	10231		ADULT	5469318	358.5	SALIRASIB	SALIRASIB	CC(C)=CCC\\C(C)=C\\CC\\C(C)=C\\CSC1=C(C=CC=C1)C(O)=O	PLASMA	MZH0OM550M									∞	ng × h/mL	26900		ng/mL	4990			UNKNOWN	mg	1000		SINGLE	FED						UNHEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/29992354	Homo sapiens		h	9.11				3			false
9226	10231		ADULT	5469318	358.5	SALIRASIB	SALIRASIB	CC(C)=CCC\\C(C)=C\\CC\\C(C)=C\\CSC1=C(C=CC=C1)C(O)=O	PLASMA	MZH0OM550M							12		t	ng × h/mL	4610		ng/mL	1180			UNKNOWN	mg	100		MULTIPLE	FED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/29992354	Homo sapiens				Day 21			2			false
9227	10231		ADULT	5469318	358.5	SALIRASIB	SALIRASIB	CC(C)=CCC\\C(C)=C\\CC\\C(C)=C\\CSC1=C(C=CC=C1)C(O)=O	PLASMA	MZH0OM550M									∞	ng × h/mL	20300		ng/mL	3630			UNKNOWN	mg	400		SINGLE	FED						UNHEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/29992354	Homo sapiens		h	4				3			false
9228	10231		ADULT	5469318	358.5	SALIRASIB	SALIRASIB	CC(C)=CCC\\C(C)=C\\CC\\C(C)=C\\CSC1=C(C=CC=C1)C(O)=O	PLASMA	MZH0OM550M							12		t	ng × h/mL	14800		ng/mL	3250			UNKNOWN	mg	400		MULTIPLE	FED		day	2			UNHEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/29992354	Homo sapiens				Day 21			3			false
9229	10231		ADULT	5469318	358.5	SALIRASIB	SALIRASIB	CC(C)=CCC\\C(C)=C\\CC\\C(C)=C\\CSC1=C(C=CC=C1)C(O)=O	PLASMA	MZH0OM550M							12		t	ng × h/mL	16300		ng/mL	3840			UNKNOWN	mg	800		MULTIPLE	FED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/29992354	Homo sapiens				Day 21			6			false
9230	10231		ADULT	5469318	358.5	SALIRASIB	SALIRASIB	CC(C)=CCC\\C(C)=C\\CC\\C(C)=C\\CSC1=C(C=CC=C1)C(O)=O	PLASMA	MZH0OM550M							12		t	ng × h/mL	10500		ng/mL	2610			UNKNOWN	mg	200		MULTIPLE	FED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/29992354	Homo sapiens				Day 21			3			false
9231	10231		ADULT	5469318	358.5	SALIRASIB	SALIRASIB	CC(C)=CCC\\C(C)=C\\CC\\C(C)=C\\CSC1=C(C=CC=C1)C(O)=O	PLASMA	MZH0OM550M							12		t	ng × h/mL	15700		ng/mL	2630			UNKNOWN	mg	1000		MULTIPLE	FED		day	2			UNHEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/29992354	Homo sapiens							3			false
9232	10231		ADULT	5469318	358.5	SALIRASIB	SALIRASIB	CC(C)=CCC\\C(C)=C\\CC\\C(C)=C\\CSC1=C(C=CC=C1)C(O)=O	PLASMA	MZH0OM550M									∞	ng × h/mL	11400		ng/mL	2830			UNKNOWN	mg	200		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/29992354	Homo sapiens		h	4.16				3			false
9233	10231		ADULT	5469318	358.5	SALIRASIB	SALIRASIB	CC(C)=CCC\\C(C)=C\\CC\\C(C)=C\\CSC1=C(C=CC=C1)C(O)=O	PLASMA	MZH0OM550M									∞	ng × h/mL	26600		ng/mL	4790			UNKNOWN	mg	800		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/29992354	Homo sapiens		h	3.67				6			false
9234	10231		ADULT	5469318	358.5	SALIRASIB	SALIRASIB	CC(C)=CCC\\C(C)=C\\CC\\C(C)=C\\CSC1=C(C=CC=C1)C(O)=O	PLASMA	MZH0OM550M									∞	ng × h/mL	4970		ng/mL	1340			UNKNOWN	mg	100		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/29992354	Homo sapiens		h	3.81				3			false
9235	10232		ADULT	45375953	309.33	SAPANISERTIB	SAPANISERTIB	CC(C)N1N=C(C2=C(N)N=CN=C12)C3=CC4=C(OC(N)=N4)C=C3	PLASMA	JGH0DF1U03									∞	ng × h/mL	369.2		ng/mL	36.4			UNKNOWN	mg	4		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/29464110	Homo sapiens		h	8.3							false
9236	10232			45375953	309.3259	SAPANISERTIB	SAPANISERTIB	CC(C)N1N=C(C2=C1N=CN=C2N)C3=CC4=C(OC(N)=N4)C=C3	PLASMA	JGH0DF1U03																										Human Fu (plasma) = 0.18	18				EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/30222978	Homo sapiens										false
9237	10233		ADULT	11488320	473.9	SAPITINIB	SAPITINIB	CNC(=O)CN1CCC(CC1)OC2=C(OC)C=C3N=CN=C(NC4=C(F)C(Cl)=CC=C4)C3=C2	PLASMA	3499328002									∞	ng × h/mL	8049		ng/mL	1345			MAX TOLERATED	mg	240		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/23589215	Homo sapiens		h	10							false
9238	10234		ADULT	10302451	542.026	SARACATINIB	SARACATINIB	CN1CCN(CCOC2=CC(OC3CCOCC3)=C4C(NC5=C6OCOC6=CC=C5Cl)=NC=NC4=C2)CC1	PLASMA	9KD24QGH76							24		t	ng × h/mL	1653		ng/mL	149			UNKNOWN	mg	175		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/20805299	Homo sapiens		h	39							false
9239	10235		ADULT	9910486	429.234	SB-705498	SB-705498	FC(F)(F)C1=CN=C(C=C1)N2CC[C@H](C2)NC(=O)NC3=C(Br)C=CC=C3	PLASMA	T74V9O0Y2W							24		∞	μg × h/mL	42.3		μg/mL	1.18			UNKNOWN	mg	400		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17659837	Homo sapiens		h	54.1				19			false
9240	10235		ADULT	9910486	429.234	SB-705498	SB-705498	FC(F)(F)C1=CN=C(C=C1)N2CC[C@H](C2)NC(=O)NC3=C(Br)C=CC=C3	PLASMA	T74V9O0Y2W							24		t	ng × h/mL	3416.3		ng/mL	196.3			UNKNOWN	mg	12		MULTIPLE	UNKNOWN		day	2			HEALTHY	Nasal	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23909699	Homo sapiens				14 days			10			false
9241	10235		ADULT	9910486	429.234	SB-705498	SB-705498	FC(F)(F)C1=CN=C(C=C1)N2CC[C@H](C2)NC(=O)NC3=C(Br)C=CC=C3	PLASMA	T74V9O0Y2W									?	ng × h/mL	903.6		ng/mL	86.4			UNKNOWN	mg	12		SINGLE	UNKNOWN						HEALTHY	Nasal	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23909699	Homo sapiens							12			false
9242	10238		ADULT	160355	354.4493	SELICICLIB	SELICICLIB	CC[C@H](CO)NC1=NC2=C(N=CN2C(C)C)C(NCC3=CC=CC=C3)=N1	PLASMA	0ES1C2KQ94							24		t	μg × h/mL	24.73		μg/mL	3.76			MAX TOLERATED	mg	1600		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/20822897	Homo sapiens		h	3.11							false
9243	10239		ADULT	5113032	248.708	SELISISTAT	SELISISTAT	NC(=O)C1CCCC2=C1NC3=C2C=C(Cl)C=C3	PLASMA	L19ECD5014									∞	μM × h	319		μM	26.6			UNKNOWN	mg	600		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/25223836	Homo sapiens		h	6.12							false
9244	10242		ADULT	10257882	592.749	SPARSENTAN	SPARSENTAN	CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC(COCC)=C(C=C3)C4=C(C=CC=C4)S(=O)(=O)NC5=NOC(C)=C5C	PLASMA	9242RO5URM									?	μg × h/mL	63.6		μg/mL	6.47			RECOMMENDED	mg	400		STEADY-STATE	UNKNOWN		day	1	Sparsentan is >99% bound to human plasma proteins.	1	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216403s000lbl.pdf	Homo sapiens		h	9.6					SPARSENTAN		false
9245	10242		ADULT	10257882	592.749	SPARSENTAN	SPARSENTAN	CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC(COCC)=C(C=C3)C4=C(C=CC=C4)S(=O)(=O)NC5=NOC(C)=C5C	PLASMA	9242RO5URM									?	μg × h/mL	83		μg/mL	6.97			RECOMMENDED	mg	400		SINGLE	UNKNOWN				Sparsentan is >99% bound to human plasma proteins.	1	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216403s000lbl.pdf	Homo sapiens								SPARSENTAN		false
9246	10243		ADULT	59174488	423.4402	SPEBRUTINIB	SPEBRUTINIB	COCCOC1=CC=C(NC2=NC(NC3=CC(NC(=O)C=C)=CC=C3)=C(F)C=N2)C=C1	PLASMA	DRU6NG543J							24		t	ng × h/mL	7972		ng/mL	1851			UNKNOWN	mg	750		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/27151992	Homo sapiens										false
9247	10243		ADULT	59174488	423.4402	SPEBRUTINIB	SPEBRUTINIB	COCCOC1=CC=C(NC2=NC(NC3=CC(NC(=O)C=C)=CC=C3)=C(F)C=N2)C=C1	PLASMA	DRU6NG543J																	UNKNOWN	mg	200		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/28543084	Homo sapiens		h	2.8							false
9248	10246		ADULT	54682876	406.3552	TASQUINIMOD	Tasquinimod	COC1=CC=CC2=C1C(O)=C(C(=O)N(C)C3=CC=C(C=C3)C(F)(F)F)C(=O)N2C	PLASMA	756U07KN1R									?	μM × h	4.8		μM	0.26			MAX TOLERATED	mg	0.5		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19755981/	Homo sapiens		h	40				17	Tasquinimod		false
9249	10247		ADULT	66558664	572.7376	TAZEMETOSTAT	TAZEMETOSTAT	CCN(C1CCOCC1)C2=C(C)C(=CC(=C2)C3=CC=C(CN4CCOCC4)C=C3)C(=O)NCC5=C(C)C=C(C)NC5=O	PLASMA	Q40W93WPE1							12		t	ng × h/mL	4630		ng/mL	818			RECOMMENDED	mg	800		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	UNKNOWN	REVIEW	https://patents.google.com/patent/WO2017079757A1	Homo sapiens										false
9250	10247		ADULT	66558664	572.7376	TAZEMETOSTAT	Tazemetostat	CCN(C1CCOCC1)C2=C(C)C(=CC(=C2)C3=CC=C(CN4CCOCC4)C=C3)C(=O)NCC5=C(C)C=C(C)NC5=O	PLASMA	Q40W93WPE1							12		t	ng × h/mL	3340		ng/mL	829			RECOMMENDED	mg	800		STEADY-STATE	UNKNOWN		day	2	Tazemetostat is 88% bound to human plasma proteins in vitro.	12	UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211723s000lbl.pdf	Homo sapiens		h	3.1							false
9251	10250		ADULT	6711805	401.882	TNP-470	TNP-470	CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]3(C)O[C@@H]3CC=C(C)C)OC(=O)NC(=O)CCl	PLASMA	X47GR46481									?	ng × h/mL	1459		ng/mL	490			UNKNOWN	mg/m²	235		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10473076	Homo sapiens		min	2	TNP-470 was administered by a 4-h i.v. infusion once a week			6	TNP-470		false
9252	10250		ADULT	6711805	401.882	TNP-470	TNP-470	CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]3(C)O[C@@H]3CC=C(C)C)OC(=O)NC(=O)CCl	PLASMA	X47GR46481									?	ng × h/mL	1239		ng/mL	498			MAX TOLERATED	mg/m²	177		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10473076	Homo sapiens		min	3	TNP-470 was administered by a 4-h i.v. infusion once a week			12	TNP-470		false
9253	10254		ADULT	51042438	429.248	UPROSERTIB	UPROSERTIB	CN1N=CC(Cl)=C1C2=C(Cl)OC(=C2)C(=O)N[C@H](CN)CC3=CC(F)=C(F)C=C3	BLOOD	ZXM835LQ5E							24		t	ng × h/mL	1262		ng/mL	94.6			RECOMMENDED	mg	75		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/29611022	Homo sapiens										false
9254	10258		ADULT	25262792	462.5441	VISTUSERTIB	CNC(=O)C1=CC=CC(=C1)C2=CC=C3C(N=C(N=C3N4CCOC[C@@H]4C)N5CCOC[C@@H]5C)=N2	CNC(=O)C1=CC=CC(=C1)C2=CC=C3C(N=C(N=C3N4CCOC[C@@H]4C)N5CCOC[C@@H]5C)=N2	PLASMA	0BSC3P4H5X							12		t	ng × h/mL	2821		ng/mL	926			INVESTIGATIONAL	mg	50		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.2571	Homo sapiens		h	3							false
9255	10258			25262792	462.5441	VISTUSERTIB	VISTUSERTIB	CNC(=O)C1=CC=CC(=C1)C2=CC=C3C(N=C(N=C3N4CCOC[C@@H]4C)N5CCOC[C@@H]5C)=N2	PLASMA	0BSC3P4H5X																										fu (Human) = 0.05	5				EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/23375793	Homo sapiens										false
9256	10260		ADULT	9910224	424.433	ZIBOTENTAN	ZIBOTENTAN	COC1=C(NS(=O)(=O)C2=C(N=CC=C2)C3=CC=C(C=C3)C4=NN=CO4)N=CC(C)=N1	PLASMA	8054MM4902							24		t	ng × h/mL	12298		ng/mL	1165.07			UNKNOWN	mg	22.5		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/19763400	Homo sapiens		h	9.24							false
9257	10263		ADULT	16154396|16197727|44285019|57514683|91898441	1646.8452	AFAMELANOTIDE	AFAMELANOTIDE	CCCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC2=CNC=N2)C(=O)N[C@H](CC3=CC=CC=C3)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC4=CNC5=CC=CC=C45)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N6CCC[C@H]6C(=O)N[C@@H](C(C)C)C(N)=O	PLASMA	QW68W3J66U									∞	ng × h/mL	138.9		ng/mL	3.7			RECOMMENDED	mg	16		SINGLE	UNKNOWN						HEALTHY	Subcutaneous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf	Homo sapiens		h	15							false
9258	10264		ADULT	10274777	437.508	ALEGLITAZAR	Aleglitazar	CO[C@@H](CC1=C2SC=CC2=C(OCCC3=C(C)OC(=N3)C4=CC=CC=C4)C=C1)C(O)=O	PLASMA	41T4OAG59U							24		t	ng × h/mL	26		ng/mL	3.05			UNKNOWN	μg	50		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20336066/	Homo sapiens		h	7.77				8	Aleglitazar		false
9259	10264		ADULT	10274777	437.508	ALEGLITAZAR	Aleglitazar	CO[C@@H](CC1=C2SC=CC2=C(OCCC3=C(C)OC(=N3)C4=CC=CC=C4)C=C1)C(O)=O	PLASMA	41T4OAG59U							24		t	ng × h/mL	141		ng/mL	16.8			UNKNOWN	μg	300		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20336066/	Homo sapiens		h	11.9				9	Aleglitazar		false
9260	10264		ADULT	10274777	437.508	ALEGLITAZAR	Aleglitazar	CO[C@@H](CC1=C2SC=CC2=C(OCCC3=C(C)OC(=N3)C4=CC=CC=C4)C=C1)C(O)=O	PLASMA	41T4OAG59U							24		t	ng × h/mL	402		ng/mL	49.2			HIGHEST STUDIED	μg	900		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20336066/	Homo sapiens		h	16.4				10	Aleglitazar		false
9261	10264		ADULT	10274777	437.508	ALEGLITAZAR	Aleglitazar	CO[C@@H](CC1=C2SC=CC2=C(OCCC3=C(C)OC(=N3)C4=CC=CC=C4)C=C1)C(O)=O	PLASMA	41T4OAG59U							24		t	ng × h/mL	8.66		ng/mL	1.1			UNKNOWN	μg	20		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20336066/	Homo sapiens		h	6.04				8	Aleglitazar		false
9262	10264		ADULT	10274777	437.508	ALEGLITAZAR	Aleglitazar	CO[C@@H](CC1=C2SC=CC2=C(OCCC3=C(C)OC(=N3)C4=CC=CC=C4)C=C1)C(O)=O	PLASMA	41T4OAG59U							24		t	ng × h/mL	204		ng/mL	28.9			UNKNOWN	μg	600		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20336066/	Homo sapiens		h	13.4				10	Aleglitazar		false
9263	10264		ADULT	10274777	437.508	ALEGLITAZAR	Aleglitazar	CO[C@@H](CC1=C2SC=CC2=C(OCCC3=C(C)OC(=N3)C4=CC=CC=C4)C=C1)C(O)=O	PLASMA	41T4OAG59U							24		t	ng × h/mL	41.8		ng/mL	5.91			UNKNOWN	μg	100		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20336066/	Homo sapiens		h	8.2				8	Aleglitazar		false
9264	10266		ADULT	23727689	512.5632	ALMOREXANT	almorexant	CNC(=O)[C@H](N1CCC2=C(C=C(OC)C(OC)=C2)[C@@H]1CCC3=CC=C(C=C3)C(F)(F)F)C4=CC=CC=C4	PLASMA	9KCW39P2EI									∞	ng × h/mL	362		ng/mL	111			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20376002	Homo sapiens		h	13.1				6	almorexant		false
9265	10266		ADULT	23727689	512.5632	ALMOREXANT	almorexant	CNC(=O)[C@H](N1CCC2=C(C=C(OC)C(OC)=C2)[C@@H]1CCC3=CC=C(C=C3)C(F)(F)F)C4=CC=CC=C4	PLASMA	9KCW39P2EI									∞	ng × h/mL	1910		ng/mL	291			HIGHEST STUDIED	mg	1000		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20376002	Homo sapiens		h	19				6	almorexant		false
9266	10266		ADULT	23727689	512.5632	ALMOREXANT	almorexant	CNC(=O)[C@H](N1CCC2=C(C=C(OC)C(OC)=C2)[C@@H]1CCC3=CC=C(C=C3)C(F)(F)F)C4=CC=CC=C4	PLASMA	9KCW39P2EI									∞	ng × h/mL	638		ng/mL	115			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20376002	Homo sapiens		h	15.1				6	almorexant		false
9267	10267		ADULT	71587812	491.562	ALVELESTAT	ALVELESTAT	CN1N=CC=C1C2=C(C)N(C(=O)C(=C2)C(=O)NCC3=NC=C(C=C3)S(C)(=O)=O)C4=CC=CC(C)=C4	PLASMA	6Y5629322X													nM	621.7			UNKNOWN	mg	60		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22458939	Homo sapiens							202	ALVELESTAT		false
9268	10268		ADULT	99719309	616.7455	ALVESPIMYCIN	ALVESPIMYCIN	CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\\C(C)=C\\C=C[C@H](OC)[C@@H](OC(N)=O)\\C(C)=C\\[C@H](C)[C@H]1O)C2=O	BLOOD	001L2FE0M3									∞	ng × h/mL	2224		ng/mL	683.36			RECOMMENDED	mg/m²	24		MULTIPLE	UNKNOWN		week	2			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/20111068	Homo sapiens		h	21.49							false
9269	10269		ADULT	2206	188.2258	ANTIPYRINE	antipyrine	CN1N(C(=O)C=C1C)C2=CC=CC=C2	PLASMA	T3CHA1B51H																	UNKNOWN	mg/kg	18		SINGLE	UNKNOWN					0.97	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1164816/	Homo sapiens		h	12.7				12			false
9270	10269		ADULT	2206	188.2258	ANTIPYRINE	antipyrine	CN1N(C(=O)C=C1C)C2=CC=CC=C2	PLASMA	T3CHA1B51H																	UNKNOWN	g	1		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1164824/	Homo sapiens		h	13.8				307			false
9271	10273		ADULT	46883536	520.885	AVAGACESTAT	AVAGACESTAT	NC(=O)[C@@H](CCC(F)(F)F)N(CC1=C(F)C=C(C=C1)C2=NOC=N2)S(=O)(=O)C3=CC=C(Cl)C=C3	PLASMA	TQ44WWY45Q									∞	ng × h/mL	36671		ng/mL	3001			UNKNOWN	mg	800		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22381714	Homo sapiens		h	41				6	AVAGACESTAT		false
9272	10276		ADULT	400010	491.6615	BARDOXOLONE	Bardoxolone	CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C4[C@@]5(C)C=C(C#N)C(=O)C(C)(C)[C@@H]5CC[C@@]34C)C(O)=O	PLASMA	7HT68L8941							24		t	ng × h/mL	24411		ng/mL	28.8			UNKNOWN	mg	1300		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22634319	Homo sapiens		h	34				5	Bardoxolone methyl		false
9273	10276		ADULT	400010	491.6615	BARDOXOLONE	Bardoxolone	CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C4[C@@]5(C)C=C(C#N)C(=O)C(C)(C)[C@@H]5CC[C@@]34C)C(O)=O	PLASMA	7HT68L8941							24		t	ng × h/mL	20370		ng/mL	24.7			MAX TOLERATED	mg	900		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22634319	Homo sapiens		h	39				19	Bardoxolone methyl		false
9274	10278		UNKNOWN	24946690	543.455	BITOPERTIN	BITOPERTIN	C[C@H](OC1=C(C=C(C=C1)S(C)(=O)=O)C(=O)N2CCN(CC2)C3=NC=C(C=C3F)C(F)(F)F)C(F)(F)F	PLASMA	Q8L6AN59YY																	UNKNOWN				UNKNOWN	UNKNOWN				The plasma protein binding was high in the two preclinical species (97%) and in human (98%).	2	UNKNOWN	UNKNOWN	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20491477	Homo sapiens								BITOPERTIN		false
9275	10278		ADULT	24946690	543.455	BITOPERTIN	BITOPERTIN	C[C@H](OC1=C(C=C(C=C1)S(C)(=O)=O)C(=O)N2CCN(CC2)C3=NC=C(C=C3F)C(F)(F)F)C(F)(F)F	PLASMA	Q8L6AN59YY									∞	ng × h/mL	6570		ng/mL	214			UNKNOWN	mg	30		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26341813	Homo sapiens		h	44.2				11	BITOPERTIN		false
9276	10278		ADULT	24946690	543.455	BITOPERTIN	BITOPERTIN	C[C@H](OC1=C(C=C(C=C1)S(C)(=O)=O)C(=O)N2CCN(CC2)C3=NC=C(C=C3F)C(F)(F)F)C(F)(F)F	PLASMA	Q8L6AN59YY							312		t	ng × h/mL	2300		ng/mL	76.5			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26341813	Homo sapiens		h	52.7				11	BITOPERTIN		false
9277	10280		ADULT		463.872	CARIPRAZINE HYDROCHLORIDE	CARIPRAZINE HYDROCHLORIDE	Cl.CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C3=CC=CC(Cl)=C3Cl)CC1	PLASMA	KQD7C255YG							24		t	ng × h/mL	156		ng/mL	10.2			UNKNOWN	mg	3		MULTIPLE	FED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26834462	Homo sapiens		h	68.4							false
9278	10280		ADULT		463.872	CARIPRAZINE HYDROCHLORIDE	CARIPRAZINE HYDROCHLORIDE	Cl.CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C3=CC=CC(Cl)=C3Cl)CC1	PLASMA	KQD7C255YG							24		t	ng × h/mL	358		ng/mL	22.7			UNKNOWN	mg	6		MULTIPLE	FED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26834462	Homo sapiens		h	44.3							false
9279	10280		ADULT		463.872	CARIPRAZINE HYDROCHLORIDE	CARIPRAZINE HYDROCHLORIDE	Cl.CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C3=CC=CC(Cl)=C3Cl)CC1	PLASMA	KQD7C255YG							24		t	ng × h/mL	466		ng/mL	28.8			UNKNOWN	mg	9		MULTIPLE	FED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26834462	Homo sapiens		h	31.6							false
9280	10280		UNKNOWN		463.872	CARIPRAZINE HYDROCHLORIDE	CARIPRAZINE HYDROCHLORIDE	Cl.CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C3=CC=CC(Cl)=C3Cl)CC1	PLASMA	KQD7C255YG																	UNKNOWN				UNKNOWN	UNKNOWN				Cariprazine and its major active metabolites are highly bound (91 to 97%) to plasma proteins.	9	UNKNOWN	UNKNOWN	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/204370s006lbl.pdf	Homo sapiens										false
9281	10282		ADULT	9933475	450.5053	CEDIRANIB	Cediranib	COC1=C(OCCCN2CCCC2)C=C3N=CN=C(OC4=C(F)C5=C(NC(C)=C5)C=C4)C3=C1	PLASMA	NQU9IPY4K9							24		t	ng × h/mL	25.1		ng/mL	2.33			UNKNOWN	mg	1		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17458505/	Homo sapiens				Day 21	Patients with advanced prostate adenocarcinoma		3			false
9282	10282		ADULT	9933475	450.5053	CEDIRANIB	Cediranib	COC1=C(OCCCN2CCCC2)C=C3N=CN=C(OC4=C(F)C5=C(NC(C)=C5)C=C4)C3=C1	PLASMA	NQU9IPY4K9							24		t	ng × h/mL	15.5		ng/mL	1.36			UNKNOWN	mg	1		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17458505/	Homo sapiens				Day 1	Patients with advanced prostate adenocarcinoma		3			false
9283	10282		ADULT	9933475	450.5053	CEDIRANIB	Cediranib	COC1=C(OCCCN2CCCC2)C=C3N=CN=C(OC4=C(F)C5=C(NC(C)=C5)C=C4)C3=C1	PLASMA	NQU9IPY4K9							24		t	ng × h/mL	97.4		ng/mL	6.78			UNKNOWN	mg	5		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17458505/	Homo sapiens				Day 1	Patients with advanced prostate adenocarcinoma		3			false
9284	10282		ADULT	9933475	450.5053	CEDIRANIB	Cediranib	COC1=C(OCCCN2CCCC2)C=C3N=CN=C(OC4=C(F)C5=C(NC(C)=C5)C=C4)C3=C1	PLASMA	NQU9IPY4K9							24		t	ng × h/mL	34.9		ng/mL	3.02			UNKNOWN	mg	2.5		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17458505/	Homo sapiens				Day 1	Patients with advanced prostate adenocarcinoma		3			false
9285	10282		ADULT	9933475	450.5053	CEDIRANIB	Cediranib	COC1=C(OCCCN2CCCC2)C=C3N=CN=C(OC4=C(F)C5=C(NC(C)=C5)C=C4)C3=C1	PLASMA	NQU9IPY4K9							24		t	ng × h/mL	309		ng/mL	25.7			UNKNOWN	mg	20		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17458505/	Homo sapiens				Day 1	Patients with advanced prostate adenocarcinoma		9			false
9286	10282		ADULT	9933475	450.5053	CEDIRANIB	Cediranib	COC1=C(OCCCN2CCCC2)C=C3N=CN=C(OC4=C(F)C5=C(NC(C)=C5)C=C4)C3=C1	PLASMA	NQU9IPY4K9							24		t	ng × h/mL	302		ng/mL	25.8			UNKNOWN	mg	10		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17458505/	Homo sapiens				Day 1	Patients with advanced prostate adenocarcinoma		3			false
9287	10282		ADULT	9933475	450.5053	CEDIRANIB	Cediranib	COC1=C(OCCCN2CCCC2)C=C3N=CN=C(OC4=C(F)C5=C(NC(C)=C5)C=C4)C3=C1	PLASMA	NQU9IPY4K9							24		t	ng × h/mL	565		ng/mL	52.6			UNKNOWN	mg	30		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17458505/	Homo sapiens				Day 1	Patients with advanced prostate adenocarcinoma		4			false
9288	10282		ADULT	9933475	450.5053	CEDIRANIB	Cediranib	COC1=C(OCCCN2CCCC2)C=C3N=CN=C(OC4=C(F)C5=C(NC(C)=C5)C=C4)C3=C1	PLASMA	NQU9IPY4K9							24		t	ng × h/mL	95.3		ng/mL	5.28			UNKNOWN	mg	2.5		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17458505/	Homo sapiens				Day 21	Patients with advanced prostate adenocarcinoma		1			false
9289	10282		ADULT	9933475	450.5053	CEDIRANIB	Cediranib	COC1=C(OCCCN2CCCC2)C=C3N=CN=C(OC4=C(F)C5=C(NC(C)=C5)C=C4)C3=C1	PLASMA	NQU9IPY4K9							24		t	ng × h/mL	226		ng/mL	17.3			UNKNOWN	mg	5		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17458505/	Homo sapiens				Day 21	Patients with advanced prostate adenocarcinoma		3			false
9290	10282		ADULT	9933475	450.5053	CEDIRANIB	Cediranib	COC1=C(OCCCN2CCCC2)C=C3N=CN=C(OC4=C(F)C5=C(NC(C)=C5)C=C4)C3=C1	PLASMA	NQU9IPY4K9							24		t	ng × h/mL	316		ng/mL	18.8			UNKNOWN	mg	10		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17458505/	Homo sapiens				Day 21	Patients with advanced prostate adenocarcinoma		2			false
9291	10282		ADULT	9933475	450.5053	CEDIRANIB	Cediranib	COC1=C(OCCCN2CCCC2)C=C3N=CN=C(OC4=C(F)C5=C(NC(C)=C5)C=C4)C3=C1	PLASMA	NQU9IPY4K9							24		t	ng × h/mL	559		ng/mL	40.4			MAX TOLERATED	mg	20		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17458505/	Homo sapiens				Day 21	Patients with advanced prostate adenocarcinoma		6			false
9292	10282		ADULT	9933475	450.5053	CEDIRANIB	Cediranib	COC1=C(OCCCN2CCCC2)C=C3N=CN=C(OC4=C(F)C5=C(NC(C)=C5)C=C4)C3=C1	PLASMA	NQU9IPY4K9									?	ng × h/mL	1920		ng/mL	87.3			UNKNOWN	mg	45		SINGLE	FED				n=30 for AUC		UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21120480/	Homo sapiens					Patients with advanced solid tumors		31			false
9293	10282		ADULT	9933475	450.5053	CEDIRANIB	Cediranib	COC1=C(OCCCN2CCCC2)C=C3N=CN=C(OC4=C(F)C5=C(NC(C)=C5)C=C4)C3=C1	PLASMA	NQU9IPY4K9									?	ng × h/mL	2392		ng/mL	127.9			UNKNOWN	mg	45		SINGLE	FASTED				n=32 for AUC		UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21120480/	Homo sapiens					Patients with advanced solid tumors		33			false
9294	10282		ADULT	9933475	450.5053	CEDIRANIB	Cediranib	COC1=C(OCCCN2CCCC2)C=C3N=CN=C(OC4=C(F)C5=C(NC(C)=C5)C=C4)C3=C1	PLASMA	NQU9IPY4K9									∞	ng × h/mL	2005		ng/mL	118			UNKNOWN	mg	45		SINGLE	UNKNOWN				n=16 for AUC		UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23197081/	Homo sapiens		h	19.7		Patients with normal hepatic function of mild hepatic impairment (bilirubin =< 1.5 x  ULRR)		18			false
9295	10282		ADULT	9933475	450.5053	CEDIRANIB	Cediranib	COC1=C(OCCCN2CCCC2)C=C3N=CN=C(OC4=C(F)C5=C(NC(C)=C5)C=C4)C3=C1	PLASMA	NQU9IPY4K9							24		t	ng × h/mL	1213		ng/mL	96			UNKNOWN	mg	30		STEADY-STATE	UNKNOWN		day	1	n=12 for AUC		UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23197081/	Homo sapiens				21-day administration	Patients with normal hepatic function or mild hepatic impairment (bilirubin =< 1.5 x ULRR)		16			false
9296	10282		ADULT	9933475	450.5053	CEDIRANIB	Cediranib	COC1=C(OCCCN2CCCC2)C=C3N=CN=C(OC4=C(F)C5=C(NC(C)=C5)C=C4)C3=C1	PLASMA	NQU9IPY4K9							24		t	ng × h/mL	1106		ng/mL	88.9			UNKNOWN	mg	30		STEADY-STATE	UNKNOWN		day	1	n=16 for AUC		UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23197081/	Homo sapiens				21-day administration	Patients with mild hepatic impairment (Child-Pugh (score 5-6))		20			false
9297	10282		ADULT	9933475	450.5053	CEDIRANIB	Cediranib	COC1=C(OCCCN2CCCC2)C=C3N=CN=C(OC4=C(F)C5=C(NC(C)=C5)C=C4)C3=C1	PLASMA	NQU9IPY4K9									∞	ng × h/mL	2238		ng/mL	113			UNKNOWN	mg	45		SINGLE	UNKNOWN				n=11 for AUC		UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23197081/	Homo sapiens		h	25.6		Patients with moderate hepatic impairment (bilirubin levels of >1.5 and =< 3  X ULRR)		12			false
9298	10282		ADULT	9933475	450.5053	CEDIRANIB	Cediranib	COC1=C(OCCCN2CCCC2)C=C3N=CN=C(OC4=C(F)C5=C(NC(C)=C5)C=C4)C3=C1	PLASMA	NQU9IPY4K9									∞	ng × h/mL	1857		ng/mL	115			UNKNOWN	mg	45		SINGLE	UNKNOWN				n=20 for AUC		UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23197081/	Homo sapiens					Patients with mild hepatic impairment (Child-Pugh (score 5-6))		23			false
9299	10282		ADULT	9933475	450.5053	CEDIRANIB	Cediranib	COC1=C(OCCCN2CCCC2)C=C3N=CN=C(OC4=C(F)C5=C(NC(C)=C5)C=C4)C3=C1	PLASMA	NQU9IPY4K9									∞	ng × h/mL	1248		ng/mL	47			UNKNOWN	mg	45		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23197081/	Homo sapiens					Patients with severe hepatic impairment (Child-Pugh (score 10-15))		1			false
9300	10282		ADULT	9933475	450.5053	CEDIRANIB	Cediranib	COC1=C(OCCCN2CCCC2)C=C3N=CN=C(OC4=C(F)C5=C(NC(C)=C5)C=C4)C3=C1	PLASMA	NQU9IPY4K9									∞	ng × h/mL	3427		ng/mL	138			UNKNOWN	mg	45		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23197081/	Homo sapiens					Patients with moderate hepatic impairment (Child-Pugh (score 7-9))		6			false
9301	10282		ADULT	9933475	450.5053	CEDIRANIB	Cediranib	COC1=C(OCCCN2CCCC2)C=C3N=CN=C(OC4=C(F)C5=C(NC(C)=C5)C=C4)C3=C1	PLASMA	NQU9IPY4K9							24		t	ng × h/mL	958.1		ng/mL	72			UNKNOWN	mg	30		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23197081/	Homo sapiens				21-day administration	Patients with moderate hepatic impairment (Child-Pugh (score 7-9))		3			false
9302	10282		ADULT	9933475	450.5053	CEDIRANIB	Cediranib	COC1=C(OCCCN2CCCC2)C=C3N=CN=C(OC4=C(F)C5=C(NC(C)=C5)C=C4)C3=C1	PLASMA	NQU9IPY4K9							24		t	ng × h/mL	877		ng/mL	64.2			UNKNOWN	mg	30		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23197081/	Homo sapiens				21-day administration	Patients with moderate hepatic impairment (bilirubin levels of >1.5 and =< 3 x ULRR)		8			false
9303	10282		ADULT	9933475	450.5053	CEDIRANIB	Cediranib	COC1=C(OCCCN2CCCC2)C=C3N=CN=C(OC4=C(F)C5=C(NC(C)=C5)C=C4)C3=C1	PLASMA	NQU9IPY4K9							24		t	ng × h/mL	805		ng/mL	42.2			UNKNOWN	mg	30		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23197081/	Homo sapiens				21-day administration	Patients with severe hepatic impairment (Child-Pugh (score 10-15))		1			false
9304	10282			9933475	450.5053	CEDIRANIB	Cediranib	COC1=C(OCCCN2CCCC2)C=C3N=CN=C(OC4=C(F)C5=C(NC(C)=C5)C=C4)C3=C1	PLASMA	NQU9IPY4K9																										Human plasma protein binding: 95.4% (30-10000ng/mL)	4.6				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27943222/	Homo sapiens										false
9305	10282		ADULT	9933475	450.5053	CEDIRANIB	Cediranib	COC1=C(OCCCN2CCCC2)C=C3N=CN=C(OC4=C(F)C5=C(NC(C)=C5)C=C4)C3=C1	PLASMA	NQU9IPY4K9									∞	ng × h/mL	457		ng/mL	24.8			UNKNOWN	mg	10		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27943222/ | https://pubmed.ncbi.nlm.nih.gov/17634482/	Homo sapiens		h	18.8		Patients with advanced solid tumours		4			false
9306	10282		ADULT	9933475	450.5053	CEDIRANIB	Cediranib	COC1=C(OCCCN2CCCC2)C=C3N=CN=C(OC4=C(F)C5=C(NC(C)=C5)C=C4)C3=C1	PLASMA	NQU9IPY4K9									∞	ng × h/mL	87.1		ng/mL	5.1			UNKNOWN	mg	2.5		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27943222/ | https://pubmed.ncbi.nlm.nih.gov/17634482/	Homo sapiens		h	16.5		Patients with advanced solid tumours		3			false
9307	10282		ADULT	9933475	450.5053	CEDIRANIB	Cediranib	COC1=C(OCCCN2CCCC2)C=C3N=CN=C(OC4=C(F)C5=C(NC(C)=C5)C=C4)C3=C1	PLASMA	NQU9IPY4K9									∞	ng × h/mL	865		ng/mL	45.7			UNKNOWN	mg	20		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27943222/ | https://pubmed.ncbi.nlm.nih.gov/17634482/	Homo sapiens		h	21.7		Patients with advanced solid tumours		3			false
9308	10282		ADULT	9933475	450.5053	CEDIRANIB	Cediranib	COC1=C(OCCCN2CCCC2)C=C3N=CN=C(OC4=C(F)C5=C(NC(C)=C5)C=C4)C3=C1	PLASMA	NQU9IPY4K9									∞	ng × h/mL	1190		ng/mL	73.1			UNKNOWN	mg	30		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27943222/ | https://pubmed.ncbi.nlm.nih.gov/17634482/	Homo sapiens		h	19.7		Patients with advanced solid tumours		5			false
9309	10282		ADULT	9933475	450.5053	CEDIRANIB	Cediranib	COC1=C(OCCCN2CCCC2)C=C3N=CN=C(OC4=C(F)C5=C(NC(C)=C5)C=C4)C3=C1	PLASMA	NQU9IPY4K9									∞	ng × h/mL	15.6		ng/mL	1.02			UNKNOWN	mg	0.5		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27943222/ | https://pubmed.ncbi.nlm.nih.gov/17634482/	Homo sapiens		h	16.6		Patients with advanced solid tumours		3			false
9310	10282		ADULT	9933475	450.5053	CEDIRANIB	Cediranib	COC1=C(OCCCN2CCCC2)C=C3N=CN=C(OC4=C(F)C5=C(NC(C)=C5)C=C4)C3=C1	PLASMA	NQU9IPY4K9									∞	ng × h/mL	32.3		ng/mL	1.9			UNKNOWN	mg	1		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27943222/ | https://pubmed.ncbi.nlm.nih.gov/17634482/	Homo sapiens		h	22.2		Patients with advanced solid tumours		3			false
9311	10282		ADULT	9933475	450.5053	CEDIRANIB	Cediranib	COC1=C(OCCCN2CCCC2)C=C3N=CN=C(OC4=C(F)C5=C(NC(C)=C5)C=C4)C3=C1	PLASMA	NQU9IPY4K9									∞	ng × h/mL	2190		ng/mL	96.9			UNKNOWN	mg	45		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27943222/ | https://pubmed.ncbi.nlm.nih.gov/17634482/	Homo sapiens		h	25.7		Patients with advanced solid tumours		4			false
9312	10282		ADULT	9933475	450.5053	CEDIRANIB	Cediranib	COC1=C(OCCCN2CCCC2)C=C3N=CN=C(OC4=C(F)C5=C(NC(C)=C5)C=C4)C3=C1	PLASMA	NQU9IPY4K9									∞	ng × h/mL	117		ng/mL	7.02			UNKNOWN	mg	5		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27943222/ | https://pubmed.ncbi.nlm.nih.gov/17634482/	Homo sapiens		h	25.6		Patients with advanced solid tumours		3			false
9313	10282		ADULT	9933475	450.5053	CEDIRANIB	Cediranib	COC1=C(OCCCN2CCCC2)C=C3N=CN=C(OC4=C(F)C5=C(NC(C)=C5)C=C4)C3=C1	PLASMA	NQU9IPY4K9							24		t	ng × h/mL	17.3		ng/mL	1.39			UNKNOWN	mg	0.5		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27943222/ | https://pubmed.ncbi.nlm.nih.gov/17634482/	Homo sapiens					Patients with advanced solid tumours		3			false
9314	10282		ADULT	9933475	450.5053	CEDIRANIB	Cediranib	COC1=C(OCCCN2CCCC2)C=C3N=CN=C(OC4=C(F)C5=C(NC(C)=C5)C=C4)C3=C1	PLASMA	NQU9IPY4K9									∞	ng × h/mL	3590		ng/mL	217			UNKNOWN	mg	60		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27943222/ | https://pubmed.ncbi.nlm.nih.gov/17634482/	Homo sapiens		h	27.2		Patients with advanced solid tumours		8			false
9315	10282		ADULT	9933475	450.5053	CEDIRANIB	Cediranib	COC1=C(OCCCN2CCCC2)C=C3N=CN=C(OC4=C(F)C5=C(NC(C)=C5)C=C4)C3=C1	PLASMA	NQU9IPY4K9							24		t	ng × h/mL	1860		ng/mL	170			UNKNOWN	mg	60		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27943222/ | https://pubmed.ncbi.nlm.nih.gov/17634482/	Homo sapiens					Patients with advanced solid tumours		4			false
9316	10282		ADULT	9933475	450.5053	CEDIRANIB	Cediranib	COC1=C(OCCCN2CCCC2)C=C3N=CN=C(OC4=C(F)C5=C(NC(C)=C5)C=C4)C3=C1	PLASMA	NQU9IPY4K9							24		t	ng × h/mL	102		ng/mL	9.37			UNKNOWN	mg	2.5		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27943222/ | https://pubmed.ncbi.nlm.nih.gov/17634482/	Homo sapiens					Patients with advanced solid tumours		1			false
9317	10282		ADULT	9933475	450.5053	CEDIRANIB	Cediranib	COC1=C(OCCCN2CCCC2)C=C3N=CN=C(OC4=C(F)C5=C(NC(C)=C5)C=C4)C3=C1	PLASMA	NQU9IPY4K9							24		t	ng × h/mL	24.3		ng/mL	1.79			UNKNOWN	mg	1		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27943222/ | https://pubmed.ncbi.nlm.nih.gov/17634482/	Homo sapiens					Patients with advanced solid tumours		2			false
9318	10282		ADULT	9933475	450.5053	CEDIRANIB	Cediranib	COC1=C(OCCCN2CCCC2)C=C3N=CN=C(OC4=C(F)C5=C(NC(C)=C5)C=C4)C3=C1	PLASMA	NQU9IPY4K9							24		t	ng × h/mL	196		ng/mL	13.4			UNKNOWN	mg	5		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27943222/ | https://pubmed.ncbi.nlm.nih.gov/17634482/	Homo sapiens					Patients with advanced solid tumours		2			false
9319	10282		ADULT	9933475	450.5053	CEDIRANIB	Cediranib	COC1=C(OCCCN2CCCC2)C=C3N=CN=C(OC4=C(F)C5=C(NC(C)=C5)C=C4)C3=C1	PLASMA	NQU9IPY4K9							24		t	ng × h/mL	502		ng/mL	42.8			UNKNOWN	mg	10		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27943222/ | https://pubmed.ncbi.nlm.nih.gov/17634482/	Homo sapiens					Patients with advanced solid tumours		1			false
9320	10282		ADULT	9933475	450.5053	CEDIRANIB	Cediranib	COC1=C(OCCCN2CCCC2)C=C3N=CN=C(OC4=C(F)C5=C(NC(C)=C5)C=C4)C3=C1	PLASMA	NQU9IPY4K9							24		t	ng × h/mL	774		ng/mL	66.6			UNKNOWN	mg	20		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27943222/ | https://pubmed.ncbi.nlm.nih.gov/17634482/	Homo sapiens					Patients with advanced solid tumours		11			false
9321	10282		ADULT	9933475	450.5053	CEDIRANIB	Cediranib	COC1=C(OCCCN2CCCC2)C=C3N=CN=C(OC4=C(F)C5=C(NC(C)=C5)C=C4)C3=C1	PLASMA	NQU9IPY4K9							24		t	ng × h/mL	741		ng/mL	69.6			UNKNOWN	mg	30		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27943222/ | https://pubmed.ncbi.nlm.nih.gov/17634482/	Homo sapiens					Patients with advanced solid tumours		12			false
9322	10282		ADULT	9933475	450.5053	CEDIRANIB	Cediranib	COC1=C(OCCCN2CCCC2)C=C3N=CN=C(OC4=C(F)C5=C(NC(C)=C5)C=C4)C3=C1	PLASMA	NQU9IPY4K9							24		t	ng × h/mL	1060		ng/mL	73.9			UNKNOWN	mg	45		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27943222/ | https://pubmed.ncbi.nlm.nih.gov/17634482/	Homo sapiens					Patients with advanced solid tumours		6			false
9323	10288		ADULT	73442840	323.4596	DEUTETRABENAZINE	DEUTETRABENAZINE	[2H]C([2H])([2H])OC1=C(OC([2H])([2H])[2H])C=C2[C@@H]3CC(=O)[C@@H](CC(C)C)CN3CCC2=C1	PLASMA	P341G6W9NB							5		t	ng × h/mL	0.26		ng/mL	0.3			UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32155315	Homo sapiens										false
9324	10295		UNKNOWN	71511839	1048.251	ETELCALCETIDE	ETELCALCETIDE	C[C@@H](NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](C)NC(=O)[C@@H](CSSC[C@H](N)C(O)=O)NC(C)=O)C(=O)N[C@H](CCCNC(N)=N)C(N)=O	PLASMA	60ME133FJB																	UNKNOWN				UNKNOWN	UNKNOWN				The degree of plasma protein binding was relatively consistent across species, averaging 88, 95, 84 and 89% in human, rat, dog and horse plasma, respectively.	12	UNKNOWN	UNKNOWN	UNKNOWN	REVIEW	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208325Orig1s000PharmR.pdf	Homo sapiens										false
9325	10295		ADOLESCENT	71511839	1048.251	ETELCALCETIDE	ETELCALCETIDE	C[C@@H](NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](C)NC(=O)[C@@H](CSSC[C@H](N)C(O)=O)NC(C)=O)C(=O)N[C@H](CCCNC(N)=N)C(N)=O	PLASMA	60ME133FJB									∞	ng × h/mL	2700		ng/mL	67			RECOMMENDED	mg/kg	0.035		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.ema.europa.eu/en/documents/variation-report/parsabiv-h-c-3995-p46-002-epar-assessment-report_en.pdf	Homo sapiens		day	5.67							false
9326	10295		CHILD	71511839	1048.251	ETELCALCETIDE	ETELCALCETIDE	C[C@@H](NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](C)NC(=O)[C@@H](CSSC[C@H](N)C(O)=O)NC(C)=O)C(=O)N[C@H](CCCNC(N)=N)C(N)=O	PLASMA	60ME133FJB									∞	ng × h/mL	955		ng/mL	31.4			RECOMMENDED	mg/kg	0.035		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.ema.europa.eu/en/documents/variation-report/parsabiv-h-c-3995-p46-002-epar-assessment-report_en.pdf	Homo sapiens		h	5.85							false
9327	10297		ADULT	57339446	1067.266	FASIGLIFAM HEMIHYDRATE	TAK-875	O.CC1=CC(OCCCS(C)(=O)=O)=CC(C)=C1C2=CC(COC3=CC4=C(C=C3)[C@H](CC(O)=O)CO4)=CC=C2.CC5=CC(OCCCS(C)(=O)=O)=CC(C)=C5C6=CC(COC7=CC8=C(C=C7)[C@H](CC(O)=O)CO8)=CC=C6	PLASMA	8LDT91CH8A							24		t	μg × h/mL	230		μg/mL	17.6			UNKNOWN	mg	400		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22669289	Homo sapiens							9	TAK-875		false
9328	10297		ADULT	57339446	1067.266	FASIGLIFAM HEMIHYDRATE	TAK-875	O.CC1=CC(OCCCS(C)(=O)=O)=CC(C)=C1C2=CC(COC3=CC4=C(C=C3)[C@H](CC(O)=O)CO4)=CC=C2.CC5=CC(OCCCS(C)(=O)=O)=CC(C)=C5C6=CC(COC7=CC8=C(C=C7)[C@H](CC(O)=O)CO8)=CC=C6	PLASMA	8LDT91CH8A							24		t	μg × h/mL	235.5		μg/mL	13			UNKNOWN	mg	100		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22669289	Homo sapiens		h	45.8				9	TAK-875		false
9329	10297		ADULT	57339446	1067.266	FASIGLIFAM HEMIHYDRATE	TAK-875	O.CC1=CC(OCCCS(C)(=O)=O)=CC(C)=C1C2=CC(COC3=CC4=C(C=C3)[C@H](CC(O)=O)CO4)=CC=C2.CC5=CC(OCCCS(C)(=O)=O)=CC(C)=C5C6=CC(COC7=CC8=C(C=C7)[C@H](CC(O)=O)CO8)=CC=C6	PLASMA	8LDT91CH8A							24		t	μg × h/mL	13.7		μg/mL	1			UNKNOWN	mg	25		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22669289	Homo sapiens							9	TAK-875		false
9330	10297		ADULT	57339446	1067.266	FASIGLIFAM HEMIHYDRATE	TAK-875	O.CC1=CC(OCCCS(C)(=O)=O)=CC(C)=C1C2=CC(COC3=CC4=C(C=C3)[C@H](CC(O)=O)CO4)=CC=C2.CC5=CC(OCCCS(C)(=O)=O)=CC(C)=C5C6=CC(COC7=CC8=C(C=C7)[C@H](CC(O)=O)CO8)=CC=C6	PLASMA	8LDT91CH8A							24		t	nmol × h/mL	40.3		μg/mL	2.3			UNKNOWN	mg	25		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22669289	Homo sapiens		h	44.7				8	TAK-875		false
9331	10297		ADULT	57339446	1067.266	FASIGLIFAM HEMIHYDRATE	TAK-875	O.CC1=CC(OCCCS(C)(=O)=O)=CC(C)=C1C2=CC(COC3=CC4=C(C=C3)[C@H](CC(O)=O)CO4)=CC=C2.CC5=CC(OCCCS(C)(=O)=O)=CC(C)=C5C6=CC(COC7=CC8=C(C=C7)[C@H](CC(O)=O)CO8)=CC=C6	PLASMA	8LDT91CH8A							24		t	μg × h/mL	549.9		μg/mL	30.8			UNKNOWN	mg	400		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22669289	Homo sapiens		h	31.5				8	TAK-875		false
9332	10297		ADULT	57339446	1067.266	FASIGLIFAM HEMIHYDRATE	TAK-875	O.CC1=CC(OCCCS(C)(=O)=O)=CC(C)=C1C2=CC(COC3=CC4=C(C=C3)[C@H](CC(O)=O)CO4)=CC=C2.CC5=CC(OCCCS(C)(=O)=O)=CC(C)=C5C6=CC(COC7=CC8=C(C=C7)[C@H](CC(O)=O)CO8)=CC=C6	PLASMA	8LDT91CH8A							24		t	μg × h/mL	71.2		μg/mL	5.5			UNKNOWN	mg	100		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22669289	Homo sapiens							9	TAK-875		false
9333	10298		ADULT	16722836	524.678	FEDRATINIB	fedratinib	CC1=C(NC2=CC(=CC=C2)S(=O)(=O)NC(C)(C)C)N=C(NC3=CC=C(OCCN4CCCC4)C=C3)N=C1	PLASMA	6L1XP550I6							24		t	ng × h/mL	17800		ng/mL	1760			MAX TOLERATED	mg	680		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24165976	Homo sapiens		h	62.1							false
9334	10298		ADULT	16722836	524.678	FEDRATINIB	FEDRATINIB	CC1=C(NC2=CC(=CC=C2)S(=O)(=O)NC(C)(C)C)N=C(NC3=CC=C(OCCN4CCCC4)C=C3)N=C1	PLASMA	6L1XP550I6							24		t	ng × h/mL	26870		ng/mL	1804			RECOMMENDED	mg	400		STEADY-STATE	UNKNOWN		day	1	Fedratinib is 92% or greater bound to human plasma proteins.	8	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf	Homo sapiens		h	41							false
9335	10298		ADULT	16722836	524.678	FEDRATINIB	FEDRATINIB	CC1=C(NC2=CC(=CC=C2)S(=O)(=O)NC(C)(C)C)N=C(NC3=CC=C(OCCN4CCCC4)C=C3)N=C1	PLASMA	6L1XP550I6									?	ng × h/mL	38712		ng/mL	2539			UNKNOWN	mg	500		STEADY-STATE	UNKNOWN		day	1	Plasma protein binding was 92-98%	2	UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212327Orig1s000MultidisciplineR.pdf	Homo sapiens										false
9336	10298		UNKNOWN	16722836	524.678	FEDRATINIB	FEDRATINIB	CC1=C(NC2=CC(=CC=C2)S(=O)(=O)NC(C)(C)C)N=C(NC3=CC=C(OCCN4CCCC4)C=C3)N=C1	PLASMA	6L1XP550I6																						UNKNOWN				Fedratinib was bound by 92% or greater to human plasma proteins in vitro.	8	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212327Orig1s000MultidisciplineR.pdf	Homo sapiens										false
9337	10299		ADULT	10090485	369.4192	GALUNISERTIB	galunisertib	CC1=NC(=CC=C1)C2=NN3CCCC3=C2C4=C5C=C(C=CC5=NC=C4)C(N)=O	PLASMA	3OKH1W5LZE									∞	ng × h/mL	3730		ng/mL	990			RECOMMENDED	mg	300		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/25529192	Homo sapiens		h	8							false
9338	10299		UNKNOWN	10090485	369.4192	GALUNISERTIB	GALUNISERTIB	CC1=NC(=CC=C1)C2=NN3CCCC3=C2C4=C5C=C(C=CC5=NC=C4)C(N)=O	PLASMA	3OKH1W5LZE																						UNKNOWN				fu,p 0.36 (unitless). Measurement by equilibrium dialysis technique.	36	UNKNOWN		UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/28436712	Homo sapiens										false
9339	10300		ADULT	44516953	615.7	GEDATOLISIB	GEDATOLISIB	CN(C)C1CCN(CC1)C(=O)C2=CC=C(NC(=O)NC3=CC=C(C=C3)C4=NC(=NC(=N4)N5CCOCC5)N6CCOCC6)C=C2	PLASMA	96265TNH2R									∞	ng × h/mL	8647		ng/mL	6558			UNKNOWN	mg	89		SINGLE	FASTED				unbound plasma fraction [fup] = 0.017; blood‐to‐plasma ratio [BPR] = 0.87; unbound hepatocyte fraction [fuhep] = 0.21	1.7	HEALTHY	Intravenous	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/30256541	Homo sapiens		h	36.92							false
9340	10303		ADULT	16118392	633.6882	GOLVATINIB	GOLVATINIB	CN1CCN(CC1)C2CCN(CC2)C(=O)NC3=NC=CC(OC4=CC(F)=C(NC(=O)C5(CC5)C(=O)NC6=CC=C(F)C=C6)C=C4)=C3	PLASMA	516Z3YP58E									?	ng × h/mL	171000						MAX TOLERATED	mg	400		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25278451	Homo sapiens		h	45				6	GOLVATINIB		false
9341	10303		ADULT	16118392	633.6882	GOLVATINIB	GOLVATINIB	CN1CCN(CC1)C2CCN(CC2)C(=O)NC3=NC=CC(OC4=CC(F)=C(NC(=O)C5(CC5)C(=O)NC6=CC=C(F)C=C6)C=C4)=C3	PLASMA	516Z3YP58E							24		t	ng × h/mL	171000		ng/mL	9730			UNKNOWN	mg	400		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/25278451	Homo sapiens		h	45							false
9342	10307		ADULT	25183872	361.029	IXAZOMIB	IXAZOMIB	CC(C)C[C@H](NC(=O)CNC(=O)C1=C(Cl)C=CC(Cl)=C1)B(O)O	PLASMA	71050168A2							72		t	ng × h/mL	60.9							mg/m²	0.25		MULTIPLE			3 days	1			UNHEALTHY	Intravenous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00830869	Homo sapiens										false
9343	10307		ADULT	25183872	361.029	IXAZOMIB	IXAZOMIB	CC(C)C[C@H](NC(=O)CNC(=O)C1=C(Cl)C=CC(Cl)=C1)B(O)O	PLASMA	71050168A2							72		t	ng × h/mL	301							mg/m²	0.5		MULTIPLE			3 days	1			UNHEALTHY	Intravenous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00830869	Homo sapiens										false
9344	10307		ADULT	25183872	361.029	IXAZOMIB	IXAZOMIB	CC(C)C[C@H](NC(=O)CNC(=O)C1=C(Cl)C=CC(Cl)=C1)B(O)O	PLASMA	71050168A2							72		t	ng × h/mL	579.91							mg/m²	1		MULTIPLE			3 days	1			UNHEALTHY	Intravenous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00830869	Homo sapiens		h	171.9							false
9345	10307		ADULT	25183872	361.029	IXAZOMIB	IXAZOMIB	CC(C)C[C@H](NC(=O)CNC(=O)C1=C(Cl)C=CC(Cl)=C1)B(O)O	PLASMA	71050168A2							72		t	ng × h/mL	1161.92							mg/m²	1.33		MULTIPLE			3 days	1			UNHEALTHY	Intravenous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00830869	Homo sapiens		h	144.69							false
9346	10307		ADULT	25183872	361.029	IXAZOMIB	IXAZOMIB	CC(C)C[C@H](NC(=O)CNC(=O)C1=C(Cl)C=CC(Cl)=C1)B(O)O	PLASMA	71050168A2							72		t	ng × h/mL	1542.64							mg/m²	1.76		MULTIPLE			3 days	1			UNHEALTHY	Intravenous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00830869	Homo sapiens		h	104.84							false
9347	10307		ADULT	25183872	361.029	IXAZOMIB	IXAZOMIB	CC(C)C[C@H](NC(=O)CNC(=O)C1=C(Cl)C=CC(Cl)=C1)B(O)O	PLASMA	71050168A2							72		t	ng × h/mL	3800							mg/m²	2.34		MULTIPLE			3 days	1			UNHEALTHY	Intravenous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00830869	Homo sapiens		h	90.8							false
9348	10307		ADULT	25183872	361.029	IXAZOMIB	IXAZOMIB	CC(C)C[C@H](NC(=O)CNC(=O)C1=C(Cl)C=CC(Cl)=C1)B(O)O	PLASMA	71050168A2							72		t	ng × h/mL	91.6							mg/m²	0.5		SINGLE							UNHEALTHY	Intravenous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00830869	Homo sapiens										false
9349	10307		ADULT	25183872	361.029	IXAZOMIB	IXAZOMIB	CC(C)C[C@H](NC(=O)CNC(=O)C1=C(Cl)C=CC(Cl)=C1)B(O)O	PLASMA	71050168A2							72		t	ng × h/mL	191.87							mg/m²	1		SINGLE							UNHEALTHY	Intravenous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00830869	Homo sapiens										false
9350	10307		ADULT	25183872	361.029	IXAZOMIB	IXAZOMIB	CC(C)C[C@H](NC(=O)CNC(=O)C1=C(Cl)C=CC(Cl)=C1)B(O)O	PLASMA	71050168A2							72		t	ng × h/mL	391.46							mg/m²	1.33		SINGLE							UNHEALTHY	Intravenous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00830869	Homo sapiens										false
9351	10307		ADULT	25183872	361.029	IXAZOMIB	IXAZOMIB	CC(C)C[C@H](NC(=O)CNC(=O)C1=C(Cl)C=CC(Cl)=C1)B(O)O	PLASMA	71050168A2							72		t	ng × h/mL	522.74							mg/m²	1.76		SINGLE							UNHEALTHY	Intravenous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00830869	Homo sapiens										false
9352	10307		ADULT	25183872	361.029	IXAZOMIB	IXAZOMIB	CC(C)C[C@H](NC(=O)CNC(=O)C1=C(Cl)C=CC(Cl)=C1)B(O)O	PLASMA	71050168A2							72		t	ng × h/mL	620							mg/m²	2.34		SINGLE							UNHEALTHY	Intravenous		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT00830869	Homo sapiens										false
9353	10307		ADULT	25183872	361.029	IXAZOMIB	IXAZOMIB	CC(C)C[C@H](NC(=O)CNC(=O)C1=C(Cl)C=CC(Cl)=C1)B(O)O	PLASMA	71050168A2							216		t	ng × h/mL	1470		ng/mL	77			RECOMMENDED	mg	4		MULTIPLE	FASTED		2 weeks	3			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26872892/	Homo sapiens										false
9354	10307		ADULT		361.029	IXAZOMIB	Ixazomib	CC(C)C[C@H](NC(=O)CNC(=O)C1=C(Cl)C=CC(Cl)=C1)B(O)O	PLASMA	71050168A2							216		t	ng × h/mL	999		ng/mL	22.8			RECOMMENDED	mg	4		MULTIPLE	HIGH-FAT		2 weeks	3			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26872892/	Homo sapiens										false
9355	10307		ADULT	25183872	361.029	IXAZOMIB	IXAZOMIB	CC(C)C[C@H](NC(=O)CNC(=O)C1=C(Cl)C=CC(Cl)=C1)B(O)O	PLASMA	71050168A2									?	ng × h/mL	575		ng/mL	25.8			UNKNOWN	mg	3		SINGLE	FASTED				In vitro protein binding was assessed by rapid equilibrium dialysis	1	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27196567/	Homo sapiens										false
9356	10307		UNKNOWN	25183872	361.029	IXAZOMIB	Ixazomib	CC(C)C[C@H](NC(=O)CNC(=O)C1=C(Cl)C=CC(Cl)=C1)B(O)O	PLASMA	71050168A2																	UNKNOWN				MULTIPLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28290121/	Homo sapiens		day	9.5							false
9357	10312		ADULT	60182	461.379	LOXIGLUMIDE	LOXIGLUMIDE	CCCCCN(CCCOC)C(=O)C(CCC(O)=O)NC(=O)C1=CC(Cl)=C(Cl)C=C1	PLASMA	77MPX3N42I									?	mg × h/L	109.8		mg/L	12.7			UNKNOWN	mg	400		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2619779	Homo sapiens				7 days			6	LOXIGLUMIDE		false
9358	10312		ADULT	60182	461.379	LOXIGLUMIDE	LOXIGLUMIDE	CCCCCN(CCCOC)C(=O)C(CCC(O)=O)NC(=O)C1=CC(Cl)=C(Cl)C=C1	PLASMA	77MPX3N42I									?	mg × h/L	60.6		mg/L	11.9			UNKNOWN	mg	400		SINGLE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2619779	Homo sapiens							6	LOXIGLUMIDE		false
9359	10316		ADULT	11250029|130406582	569.6508	ELUXADOLINE	ELUXADOLINE	COC1=C(C=C(CN([C@@H](C)C2=NC(=CN2)C3=CC=CC=C3)C(=O)[C@@H](N)CC4=C(C)C=C(C=C4C)C(N)=O)C=C1)C(O)=O	PLASMA	45TPJ4MBQ1									∞	ng × h/mL	237.2		ng/mL	58.8			UNKNOWN	mg	100		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28719721	Homo sapiens		h	5.9		Severe Hepatic Impairment					false
9360	10316		ADULT	11250029|130406582	569.6508	ELUXADOLINE	ELUXADOLINE	COC1=C(C=C(CN([C@@H](C)C2=NC(=CN2)C3=CC=CC=C3)C(=O)[C@@H](N)CC4=C(C)C=C(C=C4C)C(N)=O)C=C1)C(O)=O	PLASMA	45TPJ4MBQ1									∞	ng × h/mL	104.8		ng/mL	29.9			UNKNOWN	mg	100		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28719721	Homo sapiens		h	21.8		Moderate Hepatic Impairment					false
9361	10316		ADULT	11250029|130406582	569.6508	ELUXADOLINE	ELUXADOLINE	COC1=C(C=C(CN([C@@H](C)C2=NC(=CN2)C3=CC=CC=C3)C(=O)[C@@H](N)CC4=C(C)C=C(C=C4C)C(N)=O)C=C1)C(O)=O	PLASMA	45TPJ4MBQ1									∞	ng × h/mL	22.1		ng/mL	4.1			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28719721	Homo sapiens		h	4.4							false
9362	10316		ADULT	11250029|130406582	569.6508	ELUXADOLINE	ELUXADOLINE	COC1=C(C=C(CN([C@@H](C)C2=NC(=CN2)C3=CC=CC=C3)C(=O)[C@@H](N)CC4=C(C)C=C(C=C4C)C(N)=O)C=C1)C(O)=O	PLASMA	45TPJ4MBQ1									∞	ng × h/mL	268.1		ng/mL	27.6			UNKNOWN	mg	100		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28719721	Homo sapiens		h	14.4		Mild Hepatic Impairment					false
9363	10316		UNKNOWN	11250029|130406582	569.6508	ELUXADOLINE	ELUXADOLINE	COC1=C(C=C(CN([C@@H](C)C2=NC(=CN2)C3=CC=CC=C3)C(=O)[C@@H](N)CC4=C(C)C=C(C=C4C)C(N)=O)C=C1)C(O)=O	PLASMA	45TPJ4MBQ1																	UNKNOWN				UNKNOWN	UNKNOWN				Plasma protein binding of eluxadoline was 81%.	19	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206940s007lbl.pdf	Homo sapiens										false
9364	10317		ADULT	135273516	1001.1412	PNU166148	MURELETECAN		PLASMA	TTJ03QI76T							96		t	μg × h/mL	4712		μg/mL	94			UNKNOWN	mg/m²	130		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12237769	Homo sapiens							3	MURELETECAN		false
9365	10317		ADULT	135273516	1001.1412	PNU166148	MURELETECAN		PLASMA	TTJ03QI76T									∞	μg × h/mL	8661		μg/mL	56			MAX TOLERATED	mg/m²	68		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12237769	Homo sapiens		day	7.9				3	MURELETECAN		false
9366	10317		ADULT	135273516	1001.1412	PNU166148	MURELETECAN		PLASMA	TTJ03QI76T									∞	μg × h/mL	9305.3						UNKNOWN	mg/m²	200		MULTIPLE	UNKNOWN		4 weeks	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15187995	Homo sapiens		h	237	30-min infusion once every 4 weeks			8	MURELETECAN		false
9367	10317		ADULT	135273516	1001.1412	PNU166148	MURELETECAN		PLASMA	TTJ03QI76T									∞	μg × h/mL	10667.5						UNKNOWN	mg/m²	240		MULTIPLE	UNKNOWN		4 weeks	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15187995	Homo sapiens		h	155	30-min infusion once every 4 weeks			2	MURELETECAN		false
9368	10319		ADULT	449035	299.3245	NIRAXOSTAT	NIRAXOSTAT	CC(C)(C)COC1=C(C=C(C=C1)N2C=C(C=N2)C(O)=O)C#N	PLASMA	246FR6022S							71		t	μg × h/mL	16.6		μg/mL	0.92			UNKNOWN	mg	20		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15571214	Homo sapiens		h	29.8					Y-700		false
9369	10319		ADULT	449035	299.3245	NIRAXOSTAT	NIRAXOSTAT	CC(C)(C)COC1=C(C=C(C=C1)N2C=C(C=N2)C(O)=O)C#N	PLASMA	246FR6022S							71		t	μg × h/mL	106.3		μg/mL	5.54			MAX DAILY	mg	80		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15571214	Homo sapiens		h	27.6					Y-700		false
9370	10319		ADULT	449035	299.3245	NIRAXOSTAT	NIRAXOSTAT	CC(C)(C)COC1=C(C=C(C=C1)N2C=C(C=N2)C(O)=O)C#N	PLASMA	246FR6022S							71		t	μg × h/mL	5.5		μg/mL	0.24			UNKNOWN	mg	5		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15571214	Homo sapiens		h	40.2					Y-700		false
9371	10320		UNKNOWN	447715	420.6252	OBETICHOLIC ACID	OBETICHOLIC ACID	CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCC(O)=O)[C@@]3(C)CC[C@@H]2[C@@]4(C)CC[C@@H](O)C[C@@H]14	PLASMA	0462Z4S4OZ																						UNKNOWN				Human plasma protein binding of obeticholic acid and its conjugates is greater than 99%	1	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207999s003lbl.pdf	Homo sapiens										false
9372	10320		ADULT	447715	420.6252	OBETICHOLIC ACID	OBETICHOLIC ACID	CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCC(O)=O)[C@@]3(C)CC[C@@H]2[C@@]4(C)CC[C@@H](O)C[C@@H]14	PLASMA	0462Z4S4OZ							24		t	ng × h/mL	747		ng/mL	68.3			DEFINED DAILY	mg	10		SINGLE	FASTED						UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.ema.europa.eu/en/documents/assessment-report/ocaliva-epar-public-assessment-report_en.pdf	Homo sapiens										false
9373	10321		ADULT	6918509	869.645	OLCEGEPANT	OLCEGEPANT	NCCCC[C@H](NC(=O)[C@@H](CC1=CC(Br)=C(O)C(Br)=C1)NC(=O)N2CCC(CC2)N3CC4=C(NC3=O)C=CC=C4)C(=O)N5CCN(CC5)C6=CC=NC=C6	PLASMA	WOA5J8TX6M									∞	ng × h/mL	842		ng/mL	1090			UNKNOWN	mg	10		SINGLE	FED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15265053	Homo sapiens		h	2.37				6			false
9374	10322		ADULT	25067547	532.609	OPROZOMIB	OPROZOMIB	COC[C@H](NC(=O)[C@H](COC)NC(=O)C1=CN=C(C)S1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)[C@@]3(C)CO3	PLASMA	MZ37792Y8J									?	ng × h/mL	1070		ng/mL	760			MAX TOLERATED	mg	150		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26924128	Homo sapiens		h	0.843							false
9375	10323		ADULT	5329099	310.3471	ORANTINIB	ORANTINIB	CC1=C(CCC(O)=O)C(C)=C(N1)\\C=C2/C(=O)NC3=C2C=CC=C3	PLASMA	9RL37ZZ665									?	μg × h/mL	16.6		μg/mL	3			UNKNOWN	mg/m²	200		MULTIPLE	FED		day	1			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/15292716	Homo sapiens		h	5.5							false
9376	10323		ADULT	5329099	310.3471	ORANTINIB	ORANTINIB	CC1=C(CCC(O)=O)C(C)=C(N1)\\C=C2/C(=O)NC3=C2C=CC=C3	PLASMA	9RL37ZZ665																						FED				SU006668 avidly bound to human plasma, most likely to albumin, for more than 99%	1	UNHEALTHY		UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/16406576	Homo sapiens										false
9377	10324		ADULT	23643975	438.301	RIVICICLIB HYDROCHLORIDE	P-276-00	Cl.CN1CC[C@H]([C@@H]1CO)C2=C3OC(=CC(=O)C3=C(O)C=C2O)C4=C(Cl)C=CC=C4	PLASMA	DRP53ZDY6H									?	ng × h/mL	5158.09		ng/mL	1818.96			UNKNOWN	mg/m²	94.5		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://cancerres.aacrjournals.org/content/68/9_Supplement/5079	Homo sapiens		h	6.22				3	P-276-00		false
9378	10325		ADULT	46216796	472.6	PACRITINIB	PACRITINIB	C(CN1CCCC1)OC2=C3COC\\C=C\\COCC4=CC=CC(=C4)C5=NC(NC=C5)=NC(C=C2)=C3	PLASMA	G22N65IL3O							24		t	μg × h/mL	29		μg/mL	2			UNKNOWN	mg	600		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/25600203	Homo sapiens		h	25							false
9379	10325		ADULT	46216796	472.6	PACRITINIB	PACRITINIB	C(CN1CCCC1)OC2=C3COC\\C=C\\COCC4=CC=CC(=C4)C5=NC(NC=C5)=NC(C=C2)=C3	PLASMA	G22N65IL3O							24		t	μg × h/mL	161.3		μg/mL	9.2			MAX TOLERATED	mg	600		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/27931243 | https://www.ctibiopharma.com/wp-content/uploads/pac_eha2_june2013.pdf	Homo sapiens										false
9380	10328		ADULT	123683	510.2857	PICLIDENOSON	CF101	CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)N2C=NC3=C2N=CN=C3NCC4=CC(I)=CC=C4	PLASMA	30679UMI0N							12		t	ng × h/mL	601		ng/mL	79.5			UNKNOWN	mg	5		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15516022	Homo sapiens		h	9.39				5	CF101		false
9381	10328		ADULT	123683	510.2857	PICLIDENOSON	CF101	CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)N2C=NC3=C2N=CN=C3NCC4=CC(I)=CC=C4	PLASMA	30679UMI0N							12		t	ng × h/mL	242.4		ng/mL	30.9			UNKNOWN	mg	2		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15516022	Homo sapiens		h	9.83				5	CF101		false
9382	10328		ADULT	123683	510.2857	PICLIDENOSON	CF101	CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)N2C=NC3=C2N=CN=C3NCC4=CC(I)=CC=C4	PLASMA	30679UMI0N							12		t	ng × h/mL	341.6		ng/mL	49			UNKNOWN	mg	3		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15516022	Homo sapiens		h	9.25				5	CF101		false
9383	10328		ADULT	123683	510.2857	PICLIDENOSON	CF101	CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)N2C=NC3=C2N=CN=C3NCC4=CC(I)=CC=C4	PLASMA	30679UMI0N							12		t	ng × h/mL	458.3		ng/mL	58.1			UNKNOWN	mg	4		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15516022	Homo sapiens		h	8.93				5	CF101		false
9384	10329		ADULT	131706746	1005.1964	PIMAVANSERIN TARTRATE	PIMAVANSERIN TARTRATE	O[C@@H]([C@@H](O)C(O)=O)C(O)=O.CC(C)COC1=CC=C(CNC(=O)N(CC2=CC=C(F)C=C2)C3CCN(C)CC3)C=C1.CC(C)COC4=CC=C(CNC(=O)N(CC5=CC=C(F)C=C5)C6CCN(C)CC6)C=C4	PLASMA	NA83F1SJSR									∞	ng × h/mL	706		ng/mL	9.2			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17473118	Homo sapiens		h	57							false
9385	10329		ADULT	131706746	1005.1964	PIMAVANSERIN TARTRATE	PIMAVANSERIN TARTRATE	O[C@@H]([C@@H](O)C(O)=O)C(O)=O.CC(C)COC1=CC=C(CNC(=O)N(CC2=CC=C(F)C=C2)C3CCN(C)CC3)C=C1.CC(C)COC4=CC=C(CNC(=O)N(CC5=CC=C(F)C=C5)C6CCN(C)CC6)C=C4	PLASMA	NA83F1SJSR									∞	ng × h/mL	1315		ng/mL	20.3			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17473118	Homo sapiens		h	53							false
9386	10329		ADULT	131706746	1005.1964	PIMAVANSERIN TARTRATE	PIMAVANSERIN TARTRATE	O[C@@H]([C@@H](O)C(O)=O)C(O)=O.CC(C)COC1=CC=C(CNC(=O)N(CC2=CC=C(F)C=C2)C3CCN(C)CC3)C=C1.CC(C)COC4=CC=C(CNC(=O)N(CC5=CC=C(F)C=C5)C6CCN(C)CC6)C=C4	PLASMA	NA83F1SJSR									∞	ng × h/mL	3742		ng/mL	49.7			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Nasogastric	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17473118	Homo sapiens		h	58.3							false
9387	10329		ADULT	131706746	1005.1964	PIMAVANSERIN TARTRATE	PIMAVANSERIN TARTRATE	O[C@@H]([C@@H](O)C(O)=O)C(O)=O.CC(C)COC1=CC=C(CNC(=O)N(CC2=CC=C(F)C=C2)C3CCN(C)CC3)C=C1.CC(C)COC4=CC=C(CNC(=O)N(CC5=CC=C(F)C=C5)C6CCN(C)CC6)C=C4	PLASMA	NA83F1SJSR									∞	ng × h/mL	7335		ng/mL	111.3			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Nasogastric	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17473118	Homo sapiens		h	55.4							false
9388	10329		ADULT	131706746	1005.1964	PIMAVANSERIN TARTRATE	PIMAVANSERIN TARTRATE	O[C@@H]([C@@H](O)C(O)=O)C(O)=O.CC(C)COC1=CC=C(CNC(=O)N(CC2=CC=C(F)C=C2)C3CCN(C)CC3)C=C1.CC(C)COC4=CC=C(CNC(=O)N(CC5=CC=C(F)C=C5)C6CCN(C)CC6)C=C4	PLASMA	NA83F1SJSR									∞	ng × h/mL	10798		ng/mL	151.8			UNKNOWN	mg	300		SINGLE	FASTED				Pimavanserin was highly protein bound (93.57%-96.80%).	3.2	HEALTHY	Nasogastric	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17473118	Homo sapiens		h	53.5							false
9389	10329		ADULT	131706746	1005.1964	PIMAVANSERIN TARTRATE	PIMAVANSERIN TARTRATE	O[C@@H]([C@@H](O)C(O)=O)C(O)=O.CC(C)COC1=CC=C(CNC(=O)N(CC2=CC=C(F)C=C2)C3CCN(C)CC3)C=C1.CC(C)COC4=CC=C(CNC(=O)N(CC5=CC=C(F)C=C5)C6CCN(C)CC6)C=C4	PLASMA	NA83F1SJSR									∞	ng × h/mL	1838.7		ng/mL	92.9			UNKNOWN	mg	50		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17473118	Homo sapiens		h	54.6							false
9390	10329		ADULT	131706746	1005.1964	PIMAVANSERIN TARTRATE	PIMAVANSERIN TARTRATE	O[C@@H]([C@@H](O)C(O)=O)C(O)=O.CC(C)COC1=CC=C(CNC(=O)N(CC2=CC=C(F)C=C2)C3CCN(C)CC3)C=C1.CC(C)COC4=CC=C(CNC(=O)N(CC5=CC=C(F)C=C5)C6CCN(C)CC6)C=C4	PLASMA	NA83F1SJSR									∞	ng × h/mL	3804.6		ng/mL	193.4			UNKNOWN	mg	100		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17473118	Homo sapiens		h	60.1							false
9391	10329		ADULT	131706746	1005.1964	PIMAVANSERIN TARTRATE	PIMAVANSERIN TARTRATE	O[C@@H]([C@@H](O)C(O)=O)C(O)=O.CC(C)COC1=CC=C(CNC(=O)N(CC2=CC=C(F)C=C2)C3CCN(C)CC3)C=C1.CC(C)COC4=CC=C(CNC(=O)N(CC5=CC=C(F)C=C5)C6CCN(C)CC6)C=C4	PLASMA	NA83F1SJSR									∞	ng × h/mL	4680.3		ng/mL	247.5			UNKNOWN	mg	150		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17473118	Homo sapiens		h	48							false
9392	10330		UNKNOWN	57345410	562.7063	PINOMETOSTAT	PINOMETOSTAT	CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)N2C=NC3=C2N=CN=C3N)[C@@H]4C[C@H](CCC5=NC6=C(N5)C=CC(=C6)C(C)(C)C)C4	PLASMA	8V9YR09EF3																	UNKNOWN				UNKNOWN	UNKNOWN				[14C]EPZ-5676 concentration =1uM	4	UNKNOWN	UNKNOWN	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27160567	Homo sapiens								PINOMETOSTAT		false
9393	10332		ADULT	10117987	503.5563	PRELADENANT	preladenant	COCCOC1=CC=C(C=C1)N2CCN(CCN3N=CC4=C3N=C(N)N5N=C(N=C45)C6=CC=CO6)CC2	PLASMA	950O97NUPO							24		t	ng × h/mL	696		ng/mL	254			UNKNOWN	mg	25		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22676397	Homo sapiens		h	3.66				9	preladenant		false
9394	10332		ADULT	10117987	503.5563	PRELADENANT	preladenant	COCCOC1=CC=C(C=C1)N2CCN(CCN3N=CC4=C3N=C(N)N5N=C(N=C45)C6=CC=CO6)CC2	PLASMA	950O97NUPO							24		t	ng × h/mL	260		ng/mL	90.8			UNKNOWN	mg	10		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22676397	Homo sapiens		h	2.64				9	preladenant		false
9395	10332		ADULT	10117987	503.5563	PRELADENANT	preladenant	COCCOC1=CC=C(C=C1)N2CCN(CCN3N=CC4=C3N=C(N)N5N=C(N=C45)C6=CC=CO6)CC2	PLASMA	950O97NUPO							24		t	ng × h/mL	3312		ng/mL	857			UNKNOWN	mg	200		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22676397	Homo sapiens		h	16.6				9	preladenant		false
9396	10332		ADULT	10117987	503.5563	PRELADENANT	preladenant	COCCOC1=CC=C(C=C1)N2CCN(CCN3N=CC4=C3N=C(N)N5N=C(N=C45)C6=CC=CO6)CC2	PLASMA	950O97NUPO							24		t	ng × h/mL	3339		ng/mL	846			UNKNOWN	mg	100		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22676397	Homo sapiens		h	15.3				9	preladenant		false
9397	10332		ADULT	10117987	503.5563	PRELADENANT	preladenant	COCCOC1=CC=C(C=C1)N2CCN(CCN3N=CC4=C3N=C(N)N5N=C(N=C45)C6=CC=CO6)CC2	PLASMA	950O97NUPO							24		t	ng × h/mL	2266		ng/mL	478			UNKNOWN	mg	50		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22676397	Homo sapiens		h	12.3				9	preladenant		false
9398	10336		ADULT	11539025	420.5257	RALIMETINIB	ralimetinib	CC(C)(C)CN1C(N)=NC2=C1N=C(C=C2)C3=C(NC(=N3)C(C)(C)C)C4=CC=C(F)C=C4	PLASMA	73I34XW4HD							24		t	ng × h/mL	7490		ng/mL	574			UNKNOWN	mg	160		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26581242	Homo sapiens		h	86.8	tablet			3	ralimetinib		false
9399	10336		ADULT	11539025	420.5257	RALIMETINIB	ralimetinib	CC(C)(C)CN1C(N)=NC2=C1N=C(C=C2)C3=C(NC(=N3)C(C)(C)C)C4=CC=C(F)C=C4	PLASMA	73I34XW4HD													ng/mL	963			UNKNOWN	mg	200		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26581242	Homo sapiens				tablet			3	ralimetinib		false
9400	10336		ADULT	11539025	420.5257	RALIMETINIB	ralimetinib	CC(C)(C)CN1C(N)=NC2=C1N=C(C=C2)C3=C(NC(=N3)C(C)(C)C)C4=CC=C(F)C=C4	PLASMA	73I34XW4HD							24		t	ng × h/mL	26200		ng/mL	2230			UNKNOWN	mg	420		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26581242	Homo sapiens		h	77.4	tablet			13	ralimetinib		false
9401	10336		ADULT	11539025	420.5257	RALIMETINIB	ralimetinib	CC(C)(C)CN1C(N)=NC2=C1N=C(C=C2)C3=C(NC(=N3)C(C)(C)C)C4=CC=C(F)C=C4	PLASMA	73I34XW4HD							24		t	ng × h/mL	17900		ng/mL	1400			MAX TOLERATED	mg	300		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26581242	Homo sapiens		h	92.6	tablet			9	ralimetinib		false
9402	10336		ADULT	11539025	420.5257	RALIMETINIB	ralimetinib	CC(C)(C)CN1C(N)=NC2=C1N=C(C=C2)C3=C(NC(=N3)C(C)(C)C)C4=CC=C(F)C=C4	PLASMA	73I34XW4HD							24		t	ng × h/mL	40500		ng/mL	3060			HIGHEST STUDIED	mg	560		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26581242	Homo sapiens		h	193	tablet			1	ralimetinib		false
9403	10341		ADULT	57335384	555.5515	ROCILETINIB	Rociletinib	COC1=C(NC2=NC(NC3=CC(NC(=O)C=C)=CC=C3)=C(C=N2)C(F)(F)F)C=CC(=C1)N4CCN(CC4)C(C)=O	PLASMA	72AH61702G							24		t	μg × h/mL	8.85		μg/mL	1.8			UNKNOWN	mg	450		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25923550/	Homo sapiens		h	3.7				3	Rociletinib free base		false
9404	10341		ADULT	57335384	555.5515	ROCILETINIB	Rociletinib	COC1=C(NC2=NC(NC3=CC(NC(=O)C=C)=CC=C3)=C(C=N2)C(F)(F)F)C=CC(=C1)N4CCN(CC4)C(C)=O	PLASMA	72AH61702G							24		t	μg × h/mL	8.37		μg/mL	1.29			UNKNOWN	mg	300		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25923550/	Homo sapiens		h	4.6				3	Rociletinib free base		false
9405	10341		ADULT	57335384	555.5515	ROCILETINIB	Rociletinib	COC1=C(NC2=NC(NC3=CC(NC(=O)C=C)=CC=C3)=C(C=N2)C(F)(F)F)C=CC(=C1)N4CCN(CC4)C(C)=O	PLASMA	72AH61702G							24		t	μg × h/mL	2.9		μg/mL	0.537			UNKNOWN	mg	150		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25923550/	Homo sapiens		h	4.8				9	Rociletinib free base		false
9406	10341		ADULT	57335384	555.5515	ROCILETINIB	Rociletinib	COC1=C(NC2=NC(NC3=CC(NC(=O)C=C)=CC=C3)=C(C=N2)C(F)(F)F)C=CC(=C1)N4CCN(CC4)C(C)=O	PLASMA	72AH61702G							24		t	μg × h/mL	3.34		μg/mL	0.533			UNKNOWN	mg	200		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25923550/	Homo sapiens		h	3.48				3	Rociletinib free base		false
9407	10341		ADULT	57335384	555.5515	ROCILETINIB	Rociletinib	COC1=C(NC2=NC(NC3=CC(NC(=O)C=C)=CC=C3)=C(C=N2)C(F)(F)F)C=CC(=C1)N4CCN(CC4)C(C)=O	PLASMA	72AH61702G							24		t	μg × h/mL	5.84		μg/mL	0.969			UNKNOWN	mg	600		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25923550/	Homo sapiens		h	4.4				3	Rociletinib free base		false
9408	10341		ADULT	57335384	555.5515	ROCILETINIB	Rociletinib	COC1=C(NC2=NC(NC3=CC(NC(=O)C=C)=CC=C3)=C(C=N2)C(F)(F)F)C=CC(=C1)N4CCN(CC4)C(C)=O	PLASMA	72AH61702G							24		t	μg × h/mL	13.3		μg/mL	2.47			UNKNOWN	mg	900		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25923550/	Homo sapiens		h	3.5				3	Rociletinib free base		false
9409	10341		ADULT	57335384	555.5515	ROCILETINIB	Rociletinib	COC1=C(NC2=NC(NC3=CC(NC(=O)C=C)=CC=C3)=C(C=N2)C(F)(F)F)C=CC(=C1)N4CCN(CC4)C(C)=O	PLASMA	72AH61702G							24		t	μg × h/mL	5.74		μg/mL	0.574			UNKNOWN	mg	100		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25923550/	Homo sapiens		h	3				3	Rociletinib free base		false
9410	10341		ADULT	57335384	555.5515	ROCILETINIB	Rociletinib	COC1=C(NC2=NC(NC3=CC(NC(=O)C=C)=CC=C3)=C(C=N2)C(F)(F)F)C=CC(=C1)N4CCN(CC4)C(C)=O	PLASMA	72AH61702G							24		t	μg × h/mL	8.47		μg/mL	0.706			UNKNOWN	mg	300		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25923550/	Homo sapiens		h	3.5				3	Rociletinib free base		false
9411	10341		ADULT	57335384	555.5515	ROCILETINIB	Rociletinib	COC1=C(NC2=NC(NC3=CC(NC(=O)C=C)=CC=C3)=C(C=N2)C(F)(F)F)C=CC(=C1)N4CCN(CC4)C(C)=O	PLASMA	72AH61702G							24		t	μg × h/mL	20.4		μg/mL	1.68			UNKNOWN	mg	600		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25923550/	Homo sapiens		h	3.6				5	Rociletinib free base		false
9412	10341		ADULT	57335384	555.5515	ROCILETINIB	Rociletinib	COC1=C(NC2=NC(NC3=CC(NC(=O)C=C)=CC=C3)=C(C=N2)C(F)(F)F)C=CC(=C1)N4CCN(CC4)C(C)=O	PLASMA	72AH61702G							24		t	μg × h/mL	16		μg/mL	1.65			UNKNOWN	mg	900		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25923550/	Homo sapiens		h	2.8				19	Rociletinib free base		false
9413	10341		ADULT	57335384	555.5515	ROCILETINIB	Rociletinib	COC1=C(NC2=NC(NC3=CC(NC(=O)C=C)=CC=C3)=C(C=N2)C(F)(F)F)C=CC(=C1)N4CCN(CC4)C(C)=O	PLASMA	72AH61702G							24						μg/mL	0.704			UNKNOWN	mg	400		MULTIPLE	FASTED		day	3			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25923550/	Homo sapiens							3	Rociletinib free base		false
9414	10341		ADULT	57335384	555.5515	ROCILETINIB	Rociletinib	COC1=C(NC2=NC(NC3=CC(NC(=O)C=C)=CC=C3)=C(C=N2)C(F)(F)F)C=CC(=C1)N4CCN(CC4)C(C)=O	PLASMA	72AH61702G							24		t	μg × h/mL	23.4		μg/mL	2.41			UNKNOWN	mg	500		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25923550/	Homo sapiens		h	2.7		including 10 patients transitioned from free base to HBr		24	Rociletinib HBR (expressed as mg FB)		false
9415	10341		ADULT	57335384	555.5515	ROCILETINIB	Rociletinib	COC1=C(NC2=NC(NC3=CC(NC(=O)C=C)=CC=C3)=C(C=N2)C(F)(F)F)C=CC(=C1)N4CCN(CC4)C(C)=O	PLASMA	72AH61702G							24		t	μg × h/mL	36.6		μg/mL	3.31			UNKNOWN	mg	625		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25923550/	Homo sapiens		h	3.5				15	Rociletinib HBR (expressed as mg FB)		false
9416	10341		ADULT	57335384	555.5515	ROCILETINIB	Rociletinib	COC1=C(NC2=NC(NC3=CC(NC(=O)C=C)=CC=C3)=C(C=N2)C(F)(F)F)C=CC(=C1)N4CCN(CC4)C(C)=O	PLASMA	72AH61702G							24		t	μg × h/mL	19.4		μg/mL	1.82			UNKNOWN	mg	750		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25923550/	Homo sapiens		h	2.8				9	Rociletinib HBR (expressed as mg FB)		false
9417	10341		ADULT	57335384	555.5515	ROCILETINIB	Rociletinib	COC1=C(NC2=NC(NC3=CC(NC(=O)C=C)=CC=C3)=C(C=N2)C(F)(F)F)C=CC(=C1)N4CCN(CC4)C(C)=O	PLASMA	72AH61702G							24		t	μg × h/mL	50.1		μg/mL	4.25			UNKNOWN	mg	1000		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25923550/	Homo sapiens		h	3.4				6	Rociletinib HBR (expressed as mg FB)		false
9418	10342		ADULT		411.4908	SACUBITRIL	Sacubitril	CCOC(=O)[C@H](C)C[C@@H](CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(O)=O	PLASMA	17ERJ0MKGI	60846		VALSARTAN	valsartan	CCCCC(=O)N(CC1=CC=C(C=C1)C2=C(C=CC=C2)C3=NN=NN3)[C@@H](C(C)C)C(O)=O	80M03YXJ7I	12		t	ng × h/mL	1537		ng/mL	1229			UNKNOWN	mg	100		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26990595/	Homo sapiens										true
9419	10342		ADULT		411.4908	SACUBITRIL	Sacubitril	CCOC(=O)[C@H](C)C[C@@H](CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(O)=O	PLASMA	17ERJ0MKGI	60846		VALSARTAN	Valsartan	CCCCC(=O)N(CC1=CC=C(C=C1)C2=C(C=CC=C2)C3=NN=NN3)[C@@H](C(C)C)C(O)=O	80M03YXJ7I	12		t	ng × h/mL	3153		ng/mL	2408			UNKNOWN	mg	200		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26990595/	Homo sapiens		h	3.9							true
9420	10342		ADULT	10430040	383.4376	SACUBITRILAT	SACUBITRILAT	C[C@H](C[C@@H](CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(O)=O)C(O)=O	PLASMA	SPI5PBF81S	60846		VALSARTAN	Valsartan	CCCCC(=O)N(CC1=CC=C(C=C1)C2=C(C=CC=C2)C3=NN=NN3)[C@@H](C(C)C)C(O)=O	80M03YXJ7I	12		t	ng × h/mL	82633		ng/mL	9103			UNKNOWN	mg	100		STEADY-STATE	UNKNOWN		day	2			UNKNOWN	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26990595/	Homo sapiens										true
9421	10342		ADULT	10430040	383.4376	SACUBITRILAT	SACUBITRILAT	C[C@H](C[C@@H](CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(O)=O)C(O)=O	PLASMA	SPI5PBF81S	60846		VALSARTAN	Valsartan	CCCCC(=O)N(CC1=CC=C(C=C1)C2=C(C=CC=C2)C3=NN=NN3)[C@@H](C(C)C)C(O)=O	80M03YXJ7I	12		t	ng × h/mL	147111		ng/mL	16345			UNKNOWN	mg	200		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26990595/	Homo sapiens		h	18.4							true
9422	10344		ADULT	9843750	361.4354	SEMAGACESTAT	SEMAGACESTAT	CC(C)[C@H](O)C(=O)N[C@@H](C)C(=O)N[C@H]1C2=C(CCN(C)C1=O)C=CC=C2	CEREBROSPINAL FLUID	3YN0602W4W													ng/mL	327			UNKNOWN	mg	280		SINGLE							HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19360898	Homo sapiens		h	3.04				5	SEMAGACESTAT		false
9423	10344		ADULT	9843750	361.4354	SEMAGACESTAT	SEMAGACESTAT	CC(C)[C@H](O)C(=O)N[C@@H](C)C(=O)N[C@H]1C2=C(CCN(C)C1=O)C=CC=C2	PLASMA	3YN0602W4W									∞	ng × h/mL	7710		ng/mL	2200			UNKNOWN	mg	140		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21724950	Homo sapiens		h	2.3				25	SEMAGACESTAT		false
9424	10344		ADULT	9843750	361.4354	SEMAGACESTAT	SEMAGACESTAT	CC(C)[C@H](O)C(=O)N[C@@H](C)C(=O)N[C@H]1C2=C(CCN(C)C1=O)C=CC=C2	PLASMA	3YN0602W4W									∞	ng × h/mL	7850		ng/mL	1860			UNKNOWN	mg	140		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21724950	Homo sapiens		h	2.3				26	SEMAGACESTAT		false
9425	10345		ADULT	216327	323.336	SENICAPOC	Senicapoc	NC(=O)C(C1=CC=CC=C1)(C2=CC=C(F)C=C2)C3=CC=C(F)C=C3	PLASMA	TS6G201A6Q									∞	ng × h/mL	11826		ng/mL	59.1			UNKNOWN	mg	50		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17064199	Homo sapiens		h	369.5				9	ICA-17043		false
9426	10345		ADULT	216327	323.336	SENICAPOC	SENICAPOC	NC(=O)C(C1=CC=CC=C1)(C2=CC=C(F)C=C2)C3=CC=C(F)C=C3	PLASMA	TS6G201A6Q									∞	ng × h/mL	30675.7		ng/mL	109.1			UNKNOWN	mg	150		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17064199	Homo sapiens		h	296.7				6	ICA-17043		false
9427	10345		ADULT	216327	323.336	SENICAPOC	SENICAPOC	NC(=O)C(C1=CC=CC=C1)(C2=CC=C(F)C=C2)C3=CC=C(F)C=C3	PLASMA	TS6G201A6Q									∞	ng × h/mL	19696.5		ng/mL	108.7			UNKNOWN	mg	100		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17064199	Homo sapiens		h	219.3				6	ICA-17043		false
9428	10346		ADULT	24748573	349.77	SILMITASERTIB	SILMITASERTIB	OC(=O)C1=CC2=C(C=C1)C3=CN=CC=C3C(NC4=CC=CC(Cl)=C4)=N2	PLASMA	C6RWP0N0L2							12		t	μg × h/mL	11.4		μg/mL	14.8			UNKNOWN	mg/kg	1.6		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	http://www.imedpub.com/articles/phase-i-study-of-cigb300-administeredintravenously-in-patients-with-relapsedrefractory-solid-tumors.pdf	Homo sapiens		h	0.75							false
9429	10348		ADULT	10296883	438.4812	SOTRASTAURIN	SOTRASTAURIN	CN1CCN(CC1)C2=NC(C3=C(C(=O)NC3=O)C4=CNC5=C4C=CC=C5)=C6C=CC=CC6=N2	PLASMA	7I279E1NZ8			TACROLIMUS	tacrolimus	O.CO[C@@H]1C[C@@H](CC[C@H]1O)\\C=C(/C)[C@H]2OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@H](C[C@@H](C)C\\C(C)=C\\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)OC	WM0HAQ4WNM	24		t	μg × h/mL	12.9		μg/mL	1.8			RECOMMENDED	mg	200		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/20137762	Homo sapiens		h	5.9							true
9430	10350		ADULT	3038522	562.703	TANDUTINIB	TANDUTINIB	COC1=C(OCCCN2CCCCC2)C=C3N=CN=C(N4CCN(CC4)C(=O)NC5=CC=C(OC(C)C)C=C5)C3=C1	PLASMA	E1IO3ICJ9A									?	ng × h/mL	8193		ng/mL	1285			UNKNOWN	mg	700		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27663390	Homo sapiens		h	13.2				3	TANDUTINIB		false
9431	10350		ADULT	3038522	562.703	TANDUTINIB	TANDUTINIB	COC1=C(OCCCN2CCCCC2)C=C3N=CN=C(N4CCN(CC4)C(=O)NC5=CC=C(OC(C)C)C=C5)C3=C1	PLASMA	E1IO3ICJ9A									?	ng × h/mL	4659		ng/mL	486			MAX TOLERATED	mg	600		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27663390	Homo sapiens		h	10.4				31	TANDUTINIB		false
9432	10352		ADULT	92337	244.2609	TARENFLURBIL	R-flurbiprofen	C[C@@H](C(O)=O)C1=CC(F)=C(C=C1)C2=CC=CC=C2	PLASMA	501W00OOWA									∞	μg × h/mL	173		μg/mL	20.3			UNKNOWN	mg	200		MULTIPLE	FASTED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18090435	Homo sapiens		h	2.17				12	R-flurbiprofen		false
9433	10352		ADULT	92337	244.2609	TARENFLURBIL	R-flurbiprofen	C[C@@H](C(O)=O)C1=CC(F)=C(C=C1)C2=CC=CC=C2	PLASMA	501W00OOWA									∞	μg × h/mL	546		μg/mL	45			UNKNOWN	mg	800		MULTIPLE	FASTED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18090435	Homo sapiens		h	7.61				12	R-flurbiprofen		false
9434	10352		ADULT	92337	244.2609	TARENFLURBIL	R-flurbiprofen	C[C@@H](C(O)=O)C1=CC(F)=C(C=C1)C2=CC=CC=C2	PLASMA	501W00OOWA									∞	μg × h/mL	465		μg/mL	38.6			UNKNOWN	mg	400		MULTIPLE	FASTED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18090435	Homo sapiens		h	6.88				12	R-flurbiprofen		false
9435	10353		ADULT	3075702	198.649	TEBANICLINE	TEBANICLINE	ClC1=CC=C(OC[C@H]2CCN2)C=N1	PLASMA	9KX8NKV538							12		t	ng × h/mL	22.9		ng/mL	2.5			UNKNOWN	μg	300		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19632048	Homo sapiens				Day 49 ± 3			2	TEBANICLINE		false
9436	10353		ADULT	3075702	198.649	TEBANICLINE	TEBANICLINE	ClC1=CC=C(OC[C@H]2CCN2)C=N1	PLASMA	9KX8NKV538							12		t	ng × h/mL	25		ng/mL	2.73			UNKNOWN	μg	300		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19632048	Homo sapiens				Day 14 ± 3			4	TEBANICLINE		false
9437	10358		ADULT	9903778|44306451	279.123	TIPIRACIL HYDROCHLORIDE	TIPIRACIL HYDROCHLORIDE	Cl.ClC1=C(CN2CCCC2=N)NC(=O)NC1=O	PLASMA	4H59KLQ0A4	6256		TRIFLURIDINE	TRIFLURIDINE	OC[C@H]1O[C@H](C[C@@H]1O)N2C=C(C(=O)NC2=O)C(F)(F)F	RMW9V5RW38	10		t	ng × h/mL	234		ng/mL	44.1			UNKNOWN	mg/m²	30		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22735906	Homo sapiens		h	2.89							true
9438	10358		ADULT	9903778|44306451	279.123	TIPIRACIL HYDROCHLORIDE	TIPIRACIL HYDROCHLORIDE	Cl.ClC1=C(CN2CCCC2=N)NC(=O)NC1=O	PLASMA	4H59KLQ0A4	6256		TRIFLURIDINE	TRIFLURIDINE	OC[C@H]1O[C@H](C[C@@H]1O)N2C=C(C(=O)NC2=O)C(F)(F)F	RMW9V5RW38	10		t	ng × h/mL	161		ng/mL	41.8			UNKNOWN	mg/m²	40		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22735906	Homo sapiens		h	1.82							true
9439	10358		ADULT	9903778|44306451	279.123	TIPIRACIL HYDROCHLORIDE	TIPIRACIL HYDROCHLORIDE	Cl.ClC1=C(CN2CCCC2=N)NC(=O)NC1=O	PLASMA	4H59KLQ0A4	6256		TRIFLURIDINE	TRIFLURIDINE	OC[C@H]1O[C@H](C[C@@H]1O)N2C=C(C(=O)NC2=O)C(F)(F)F	RMW9V5RW38	10		t	ng × h/mL	300		ng/mL	50.2			UNKNOWN	mg/m²	50		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22735906	Homo sapiens		h	4.01							true
9440	10358		ADULT	9903778|44306451	279.123	TIPIRACIL HYDROCHLORIDE	TIPIRACIL HYDROCHLORIDE	Cl.ClC1=C(CN2CCCC2=N)NC(=O)NC1=O	PLASMA	4H59KLQ0A4	6256		TRIFLURIDINE	TRIFLURIDINE	OC[C@H]1O[C@H](C[C@@H]1O)N2C=C(C(=O)NC2=O)C(F)(F)F	RMW9V5RW38	10		t	ng × h/mL	447		ng/mL	99.6			UNKNOWN	mg/m²	60		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22735906	Homo sapiens		h	2.21							true
9441	10358		ADULT	9903778|44306451	279.123	TIPIRACIL HYDROCHLORIDE	TIPIRACIL HYDROCHLORIDE	Cl.ClC1=C(CN2CCCC2=N)NC(=O)NC1=O	PLASMA	4H59KLQ0A4	6256		TRIFLURIDINE	TRIFLURIDINE	OC[C@H]1O[C@H](C[C@@H]1O)N2C=C(C(=O)NC2=O)C(F)(F)F	RMW9V5RW38	10		t	ng × h/mL	317		ng/mL	70			UNKNOWN	mg/m²	70		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22735906	Homo sapiens		h	2.37							true
9442	10358		UNKNOWN	9903778|44306451	279.123	TIPIRACIL HYDROCHLORIDE	TIPIRACIL HYDROCHLORIDE	Cl.ClC1=C(CN2CCCC2=N)NC(=O)NC1=O	PLASMA	4H59KLQ0A4																	RECOMMENDED	mg/m²	35		STEADY-STATE	UNKNOWN		day	2	Plasma protein binding of tipiracil is below 8%.	92	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/207981s009lbl.pdf	Homo sapiens		h	2.4							false
9443	10362		ADULT	49846579	868.439	VENETOCLAX	venetoclax	CC1(C)CCC(CN2CCN(CC2)C3=CC(OC4=CC5=C(NC=C5)N=C4)=C(C=C3)C(=O)NS(=O)(=O)C6=CC(=C(NCC7CCOCC7)C=C6)[N+]([O-])=O)=C(C1)C8=CC=C(Cl)C=C8	PLASMA	N54AIC43PW									∞	μg × h/mL	30.2		μg/mL	1.43			UNKNOWN	mg	400		MULTIPLE	HIGH-FAT		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27558232	Homo sapiens		h	14.1							false
9444	10362		ADULT	49846579	868.439	VENETOCLAX	VENETOCLAX	CC1(C)CCC(CN2CCN(CC2)C3=CC(OC4=CC5=C(NC=C5)N=C4)=C(C=C3)C(=O)NS(=O)(=O)C6=CC(=C(NCC7CCOCC7)C=C6)[N+]([O-])=O)=C(C1)C8=CC=C(Cl)C=C8	PLASMA	N54AIC43PW							24		t	μg × h/mL	32.8		μg/mL	2.1			UNKNOWN	mg	400		STEADY-STATE	LOW-FAT		day	1	Venetoclax is highly bound to human plasma protein with unbound fraction in plasma <0.01 across a concentration range of 1-30 µM (0.87-26 µg/mL).	1	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208573s000lbl.pdf	Homo sapiens										false
9445	10363		ADULT	3009355	533.6288	VICRIVIROC	vicriviroc	COC[C@H](N1CCN(C[C@@H]1C)C2(C)CCN(CC2)C(=O)C3=C(C)N=CN=C3C)C4=CC=C(C=C4)C(F)(F)F	PLASMA	TL515DW4QS							12		t	ng × h/mL	1060		ng/mL	149			UNKNOWN	mg	20.5		STEADY-STATE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17545705	Homo sapiens		h	29				12	vicriviroc		false
9446	10363		ADULT	3009355	533.6288	VICRIVIROC	vicriviroc	COC[C@H](N1CCN(C[C@@H]1C)C2(C)CCN(CC2)C(=O)C3=C(C)N=CN=C3C)C4=CC=C(C=C4)C(F)(F)F	PLASMA	TL515DW4QS							12		t	ng × h/mL	2290		ng/mL	342			UNKNOWN	mg	41.1		STEADY-STATE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17545705	Homo sapiens		h	28				11	vicriviroc		false
9447	10363		ADULT	3009355	533.6288	VICRIVIROC	vicriviroc	COC[C@H](N1CCN(C[C@@H]1C)C2(C)CCN(CC2)C(=O)C3=C(C)N=CN=C3C)C4=CC=C(C=C4)C(F)(F)F	PLASMA	TL515DW4QS							12		t	ng × h/mL	424		ng/mL	65			UNKNOWN	mg	8.2		STEADY-STATE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17545705	Homo sapiens		h	33				11	vicriviroc		false
9448	10363		ADULT	3009355	533.6288	VICRIVIROC	Vicriviroc	COC[C@H](N1CCN(C[C@@H]1C)C2(C)CCN(CC2)C(=O)C3=C(C)N=CN=C3C)C4=CC=C(C=C4)C(F)(F)F	PLASMA	TL515DW4QS									?	ng × h/mL	2502		ng/mL	131			UNKNOWN	mg	10		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20071999	Homo sapiens							29	Vicriviroc		false
9449	10363		ADULT	3009355	533.6288	VICRIVIROC	Vicriviroc	COC[C@H](N1CCN(C[C@@H]1C)C2(C)CCN(CC2)C(=O)C3=C(C)N=CN=C3C)C4=CC=C(C=C4)C(F)(F)F	PLASMA	TL515DW4QS									?	ng × h/mL	3390		ng/mL	181			UNKNOWN	mg	15		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20071999	Homo sapiens							29	Vicriviroc		false
9450	10363		ADULT	3009355	533.6288	VICRIVIROC	Vicriviroc	COC[C@H](N1CCN(C[C@@H]1C)C2(C)CCN(CC2)C(=O)C3=C(C)N=CN=C3C)C4=CC=C(C=C4)C(F)(F)F	PLASMA	TL515DW4QS									?	ng × h/mL	1172		ng/mL	63			UNKNOWN	mg	5		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20071999	Homo sapiens							28	Vicriviroc		false
9451	10366		ADULT	3086674	427.2847	IOFLUPANE I-123	Ioflupane I 123	COC(=O)[C@@H]1[C@H]2CC[C@@H](C[C@@H]1C3=CC=C([123I])C=C3)N2CCCF	BLOOD	3MM99T8R5Q																						UNKNOWN				Human plasma protein Fu = 6.5% (0.25, 1.25nmol/L)	6.5	HEALTHY		MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300132/530359000_22500AMX01807000_A100_1.pdf#page=17 | https://www.pmda.go.jp/drugs/2013/P201300132/530359000_22500AMX01807_K101_1.pdf#page=31	Homo sapiens					Japanese subjects		12			false
9452	10374		ADULT	123935|7014883	217.2224	ALANYL GLUTAMINE	ALANYL GLUTAMINE	C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(O)=O	PLASMA	U5JDO2770Z													μM	652			UNKNOWN	g/kg	0.5		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16049639/	Homo sapiens		h	0.26	4 hours infusion			10	ALANYL GLUTAMINE		false
9453	10379		ADULT	9821754	390.3408	BICYCLOL	BICYCLOL	COC(=O)C1=CC(OC)=C2OCOC2=C1C3=C4OCOC4=C(OC)C=C3CO	PLASMA	9734122TH2									∞	ng × h/mL	889.893		ng/mL	122			UNKNOWN	mg	50		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31322745/	Homo sapiens		h	8.109				6	BICYCLOL		false
9454	10380		ADULT	108213	418.3509	BIFENDATE	Bifendate	COC(=O)C1=CC(OC)=C2OCOC2=C1C3=C4OCOC4=C(OC)C=C3C(=O)OC	PLASMA	0G32E321W1									∞	ng × h/mL	3191.2		ng/mL	209.4			UNKNOWN	mg	15		MULTIPLE	FASTED		day	3			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19845435/	Homo sapiens		h	10.6				16			false
9455	10393		ADULT	4594	345.416	ESOMEPRAZOLE	ESOMEPRAZOLE	COC1=CC2=C(NC(=N2)[S+]([O-])CC3=C(C)C(OC)=C(C)C=N3)C=C1	PLASMA	N3PA6559FT									?	μM × h	16.2		μM	7.5			RECOMMENDED	mg	40		MULTIPLE	UNKNOWN		day	1			HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021689Orig1s034lbl.pdf	Homo sapiens		h	1.4							false
9456	10400		ADULT		0	INDENOLOL	Indenolol		PLASMA	3MZM7RWW00									∞	ng × h/mL	303.44		ng/mL	31.54			RECOMMENDED	mg	120		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://doi.org/10.1002/j.1552-4604.1985.tb02851.x	Homo sapiens		h	4.65	Day 14	moderate hypertensive patients		5	Indenolol		false
9457	10400		ADULT		0	INDENOLOL HYDROCHLORIDE	INDENOLOL HYDROCHLORIDE		PLASMA	2VLW0IV0ZQ									∞	ng × h/mL	191.59		ng/mL	22.97			RECOMMENDED	mg	60		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://doi.org/10.1002/j.1552-4604.1985.tb02851.x	Homo sapiens		h	4.06	Day 1	Mild Hypertensive Patients		5	Indenolol		false
9458	10400		ADULT		0	INDENOLOL HYDROCHLORIDE	INDENOLOL HYDROCHLORIDE		PLASMA	2VLW0IV0ZQ									∞	ng × h/mL	174.68		ng/mL	22.99			RECOMMENDED	mg	60		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://doi.org/10.1002/j.1552-4604.1985.tb02851.x	Homo sapiens		h	3.55	Day 14	mild hypertensive patients		5	Indenolol		false
9459	10400		ADULT		0	INDENOLOL HYDROCHLORIDE	INDENOLOL HYDROCHLORIDE		PLASMA	2VLW0IV0ZQ									∞	ng × h/mL	363.48		ng/mL	39.56			RECOMMENDED	mg	120		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://doi.org/10.1002/j.1552-4604.1985.tb02851.x	Homo sapiens		h	3.76	Day 1	moderate hypertensive patients		5	Indenolol		false
9460	10404		ADULT	10453870	404.452	IPRAGLIFLOZIN	Ipragliflozin	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C2=CC(CC3=CC4=C(S3)C=CC=C4)=C(F)C=C2	PLASMA	3N2N8OOR7X									∞	ng × h/mL	27298.54		ng/mL	3421.41			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009_K100_1.pdf#page=35 | https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009_K101_1.pdf#pag=50 | https://pubmed.ncbi.nlm.nih.gov/25316572/	Homo sapiens		h	10.34				6			false
9461	10404		ADULT	10453870	404.452	IPRAGLIFLOZIN	Ipragliflozin	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C2=CC(CC3=CC4=C(S3)C=CC=C4)=C(F)C=C2	PLASMA	3N2N8OOR7X									∞	ng × h/mL	58.94		ng/mL	17.89			UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009_K100_1.pdf#page=35 | https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009_K101_1.pdf#pag=50 | https://pubmed.ncbi.nlm.nih.gov/25316572/	Homo sapiens		h	4.35				6			false
9462	10404		ADULT	10453870	404.452	IPRAGLIFLOZIN	Ipragliflozin	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C2=CC(CC3=CC4=C(S3)C=CC=C4)=C(F)C=C2	PLASMA	3N2N8OOR7X									∞	ng × h/mL	244.64		ng/mL	53.72			UNKNOWN	mg	3		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009_K100_1.pdf#page=35 | https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009_K101_1.pdf#pag=50 | https://pubmed.ncbi.nlm.nih.gov/25316572/	Homo sapiens		h	10.01				6			false
9463	10404		ADULT	10453870	404.452	IPRAGLIFLOZIN	Ipragliflozin	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C2=CC(CC3=CC4=C(S3)C=CC=C4)=C(F)C=C2	PLASMA	3N2N8OOR7X									∞	ng × h/mL	855.06		ng/mL	174.34			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009_K100_1.pdf#page=35 | https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009_K101_1.pdf#pag=50 | https://pubmed.ncbi.nlm.nih.gov/25316572/	Homo sapiens		h	13.34				6			false
9464	10404		ADULT	10453870	404.452	IPRAGLIFLOZIN	Ipragliflozin	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C2=CC(CC3=CC4=C(S3)C=CC=C4)=C(F)C=C2	PLASMA	3N2N8OOR7X									∞	ng × h/mL	2895.83		ng/mL	523.63			UNKNOWN	mg	30		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009_K100_1.pdf#page=35 | https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009_K101_1.pdf#pag=50 | https://pubmed.ncbi.nlm.nih.gov/25316572/	Homo sapiens		h	12.43				6			false
9465	10404		ADULT	10453870	404.452	IPRAGLIFLOZIN	Ipragliflozin	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C2=CC(CC3=CC4=C(S3)C=CC=C4)=C(F)C=C2	PLASMA	3N2N8OOR7X									∞	ng × h/mL	9696.47		ng/mL	1392.39			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009_K100_1.pdf#page=35 | https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009_K101_1.pdf#pag=50 | https://pubmed.ncbi.nlm.nih.gov/25316572/	Homo sapiens		h	11.71				6			false
9466	10404		ADULT	10453870	404.452	IPRAGLIFLOZIN	Ipragliflozin	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C2=CC(CC3=CC4=C(S3)C=CC=C4)=C(F)C=C2	PLASMA	3N2N8OOR7X							24		t	ng × h/mL	1894.04		ng/mL	398.05			UNKNOWN	mg	20		STEADY-STATE	FED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009_K100_1.pdf#page=36 | https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009_K101_1.pdf#pag=55 | https://pubmed.ncbi.nlm.nih.gov/25316572/	Homo sapiens		h	13.93	Day 7			8			false
9467	10404		ADULT	10453870	404.452	IPRAGLIFLOZIN	Ipragliflozin	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C2=CC(CC3=CC4=C(S3)C=CC=C4)=C(F)C=C2	PLASMA	3N2N8OOR7X							24		t	ng × h/mL	4693.11		ng/mL	975.53			UNKNOWN	mg	50		STEADY-STATE	FED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009_K100_1.pdf#page=36 | https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009_K101_1.pdf#pag=55 | https://pubmed.ncbi.nlm.nih.gov/25316572/	Homo sapiens		h	11.24	Day 7			8			false
9468	10404		ADULT	10453870	404.452	IPRAGLIFLOZIN	Ipragliflozin	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C2=CC(CC3=CC4=C(S3)C=CC=C4)=C(F)C=C2	PLASMA	3N2N8OOR7X							24		t	ng × h/mL	9113.99		ng/mL	1731.61			UNKNOWN	mg	100		STEADY-STATE	FED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009_K100_1.pdf#page=36 | https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009_K101_1.pdf#pag=55 | https://pubmed.ncbi.nlm.nih.gov/25316572/	Homo sapiens		h	15.36	Day 7			8			false
9469	10404		ADULT	10453870	404.452	IPRAGLIFLOZIN	Ipragliflozin	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C2=CC(CC3=CC4=C(S3)C=CC=C4)=C(F)C=C2	PLASMA	3N2N8OOR7X									∞	ng × h/mL	5490.74		ng/mL	1464.17			RECOMMENDED	mg	50		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009000_A100_1.pdf#page=32 | https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009_K101_1.pdf#page=17	Homo sapiens		h	16.9		Administered 5 min before breakfast		30			false
9470	10404		ADULT	10453870	404.452	IPRAGLIFLOZIN	Ipragliflozin	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C2=CC(CC3=CC4=C(S3)C=CC=C4)=C(F)C=C2	PLASMA	3N2N8OOR7X									∞	ng × h/mL	5291.35		ng/mL	976.32			RECOMMENDED	mg	50		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009000_A100_1.pdf#page=32 | https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009_K101_1.pdf#page=17	Homo sapiens		h	17				30			false
9471	10404		ADULT	10453870	404.452	IPRAGLIFLOZIN	Ipragliflozin	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C2=CC(CC3=CC4=C(S3)C=CC=C4)=C(F)C=C2	PLASMA	3N2N8OOR7X									∞	ng × h/mL	5238.53		ng/mL	1174.67			RECOMMENDED	mg	50		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009000_A100_1.pdf#page=32 | https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009_K101_1.pdf#page=17	Homo sapiens		h	13.67				30			false
9472	10404			10453870	404.452	IPRAGLIFLOZIN	Ipragliflozin	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C2=CC(CC3=CC4=C(S3)C=CC=C4)=C(F)C=C2	PLASMA	3N2N8OOR7X																										The plasma protein binding of 14C-ipragliflozin (0.05–200 μg/mL) was almost constant within the concentration range examined, from 94.6 to 96.5 %. The main plasma binding protein was albumin. ultrafiltration	3.5				OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009000_A100_1.pdf#page=33 | https://pubmed.ncbi.nlm.nih.gov/25316572/	Homo sapiens										false
9473	10404		ADULT	10453870	404.452	IPRAGLIFLOZIN	Ipragliflozin	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C2=CC(CC3=CC4=C(S3)C=CC=C4)=C(F)C=C2	PLASMA	3N2N8OOR7X									∞	ng × h/mL	8519.799		ng/mL	1260.674			MAX DAILY	mg	100		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009000_A100_1.pdf#page=39 | https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009_K101_1.pdf#page=145	Homo sapiens		h	15.046	Day 1	Young subjects (21~44 y), administered 5 min before breakfast		12			false
9474	10404		ADULT	10453870	404.452	IPRAGLIFLOZIN	Ipragliflozin	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C2=CC(CC3=CC4=C(S3)C=CC=C4)=C(F)C=C2	PLASMA	3N2N8OOR7X									∞	ng × h/mL	9844.079		ng/mL	1690.752			MAX DAILY	mg	100		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009000_A100_1.pdf#page=39 | https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009_K101_1.pdf#page=145	Homo sapiens		h	17.93	Day 1	Young subjects (21~44 y), administered 5 min before breakfast		12			false
9475	10404		ADULT	10453870	404.452	IPRAGLIFLOZIN	Ipragliflozin	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C2=CC(CC3=CC4=C(S3)C=CC=C4)=C(F)C=C2	PLASMA	3N2N8OOR7X									∞	ng × h/mL	10325.042		ng/mL	1491.293			MAX DAILY	mg	100		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009000_A100_1.pdf#page=39 | https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009_K101_1.pdf#page=145	Homo sapiens		h	15.234	Day 1	Elderly subjects (65~81 y), administered 5 min before breakfast		12			false
9476	10404		ADULT	10453870	404.452	IPRAGLIFLOZIN	Ipragliflozin	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C2=CC(CC3=CC4=C(S3)C=CC=C4)=C(F)C=C2	PLASMA	3N2N8OOR7X									∞	ng × h/mL	13772.018		ng/mL	1975.718			MAX DAILY	mg	100		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009000_A100_1.pdf#page=39 | https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009_K101_1.pdf#page=145	Homo sapiens		h	15.568	Day 1	Elderly subjects (65~81 y), administered 5 min before breakfast		13			false
9477	10404		ADULT	10453870	404.452	IPRAGLIFLOZIN	Ipragliflozin	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C2=CC(CC3=CC4=C(S3)C=CC=C4)=C(F)C=C2	PLASMA	3N2N8OOR7X							24		t	ng × h/mL	8231.224		ng/mL	1592.925			MAX DAILY	mg	100		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009000_A100_1.pdf#page=39 | https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009_K101_1.pdf#page=147	Homo sapiens		h	16.717	Day 18	Young subjects (21~44 y), administered 5 min before breakfast		12			false
9478	10404		ADULT	10453870	404.452	IPRAGLIFLOZIN	Ipragliflozin	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C2=CC(CC3=CC4=C(S3)C=CC=C4)=C(F)C=C2	PLASMA	3N2N8OOR7X							24		t	ng × h/mL	9582.693		ng/mL	1676.536			MAX DAILY	mg	100		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	FEMALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009000_A100_1.pdf#page=39 | https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009_K101_1.pdf#page=147	Homo sapiens		h	23.654	Day 18	Young subjects (21~44 y), administered 5 min before breakfast		10			false
9479	10404		ADULT	10453870	404.452	IPRAGLIFLOZIN	Ipragliflozin	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C2=CC(CC3=CC4=C(S3)C=CC=C4)=C(F)C=C2	PLASMA	3N2N8OOR7X							24		t	ng × h/mL	10050.118		ng/mL	1584.996			MAX DAILY	mg	100		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009000_A100_1.pdf#page=39 | https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009_K101_1.pdf#page=147	Homo sapiens		h	16.798	Day 18	Elderly subjects (65~81 y), administered 5 min before breakfast		12			false
9480	10404		ADULT	10453870	404.452	IPRAGLIFLOZIN	Ipragliflozin	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C2=CC(CC3=CC4=C(S3)C=CC=C4)=C(F)C=C2	PLASMA	3N2N8OOR7X							24		t	ng × h/mL	14027.041		ng/mL	2124.083			MAX DAILY	mg	100		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	FEMALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009000_A100_1.pdf#page=39 | https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009_K101_1.pdf#page=147	Homo sapiens		h	20.292	Day 18	Elderly subjects (65~81 y), administered 5 min before breakfast		12			false
9481	10404		ADULT	10453870	404.452	IPRAGLIFLOZIN	Ipragliflozin	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C2=CC(CC3=CC4=C(S3)C=CC=C4)=C(F)C=C2	PLASMA	3N2N8OOR7X									∞	ng × h/mL	4821.35		mg/mL	1044.74			RECOMMENDED	mg	50		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009000_A100_1.pdf#page=40 | https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009_K101_1.pdf#page=170	Homo sapiens		h	14.97		Type-2 diabetes with normal renal function		8			false
9482	10404		ADULT	10453870	404.452	IPRAGLIFLOZIN	Ipragliflozin	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C2=CC(CC3=CC4=C(S3)C=CC=C4)=C(F)C=C2	PLASMA	3N2N8OOR7X									∞	ng × h/mL	4482.28		mg/mL	1088.77			RECOMMENDED	mg	50		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009000_A100_1.pdf#page=40 | https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009_K101_1.pdf#page=170	Homo sapiens		h	15.37		Type-2 diabetes with mild renal impairment		9			false
9483	10404		ADULT	10453870	404.452	IPRAGLIFLOZIN	Ipragliflozin	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C2=CC(CC3=CC4=C(S3)C=CC=C4)=C(F)C=C2	PLASMA	3N2N8OOR7X									∞	ng × h/mL	5947.6		mg/mL	1160.97			RECOMMENDED	mg	50		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009000_A100_1.pdf#page=40 | https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009_K101_1.pdf#page=170	Homo sapiens		h	17.08		Type-2 diabetes with moderate renal impairment		8			false
9484	10404		ADULT	10453870	404.452	IPRAGLIFLOZIN	Ipragliflozin	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C2=CC(CC3=CC4=C(S3)C=CC=C4)=C(F)C=C2	PLASMA	3N2N8OOR7X									∞	ng × h/mL	12687.14		ng/mL	1576.08			MAX DAILY	mg	100		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009000_A100_1.pdf#page=42 | https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009_K101_1.pdf#page=198	Homo sapiens		h	21.22		Type-2 diabetes with severe renal impairment, non-Japanese		8			false
9485	10404		ADULT	10453870	404.452	IPRAGLIFLOZIN	Ipragliflozin	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C2=CC(CC3=CC4=C(S3)C=CC=C4)=C(F)C=C2	PLASMA	3N2N8OOR7X									∞	ng × h/mL	12103.73		ng/mL	1448.14			MAX DAILY	mg	100		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009000_A100_1.pdf#page=42 | https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009_K101_1.pdf#page=198	Homo sapiens		h	20.76		Type-2 diabetes with moderate renal impairment, non-Japanese		8			false
9486	10404		ADULT	10453870	404.452	IPRAGLIFLOZIN	Ipragliflozin	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C2=CC(CC3=CC4=C(S3)C=CC=C4)=C(F)C=C2	PLASMA	3N2N8OOR7X									∞	ng × h/mL	7325.78		ng/mL	1277.19			MAX DAILY	mg	100		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009000_A100_1.pdf#page=42 | https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009_K101_1.pdf#page=198	Homo sapiens		h	15.18		non-Japanese		8			false
9487	10404		ADULT	10453870	404.452	IPRAGLIFLOZIN	Ipragliflozin	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C2=CC(CC3=CC4=C(S3)C=CC=C4)=C(F)C=C2	PLASMA	3N2N8OOR7X									∞	ng × h/mL	8240.8		ng/mL	1456.05			MAX DAILY	mg	100		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009000_A100_1.pdf#page=42 | https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009_K101_1.pdf#page=198	Homo sapiens		h	19.16		Type-2 diabetes with normal renal function, non-Japanese		8			false
9488	10404		ADULT	10453870	404.452	IPRAGLIFLOZIN	Ipragliflozin	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C2=CC(CC3=CC4=C(S3)C=CC=C4)=C(F)C=C2	PLASMA	3N2N8OOR7X									∞	ng × h/mL	10506.14		ng/mL	1625.63			MAX DAILY	mg	100		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009000_A100_1.pdf#page=42 | https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009_K101_1.pdf#page=198	Homo sapiens		h	20.56		Type-2 diabetes with mild renal impairment, non-Japanese		8			false
9489	10404		ADULT	10453870	404.452	IPRAGLIFLOZIN	Ipragliflozin	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C2=CC(CC3=CC4=C(S3)C=CC=C4)=C(F)C=C2	PLASMA	3N2N8OOR7X									∞	ng × h/mL	9103.55		ng/mL	1397.58			MAX DAILY	mg	100		SINGLE	FASTED				n=7 for AUC and t1/2		HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009000_A100_1.pdf#page=43 | https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009_K102_1.pdf#page=13	Homo sapiens		h	16.18				8			false
9490	10404		ADULT	10453870	404.452	IPRAGLIFLOZIN	Ipragliflozin	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C2=CC(CC3=CC4=C(S3)C=CC=C4)=C(F)C=C2	PLASMA	3N2N8OOR7X									∞	ng × h/mL	11814.32		ng/mL	1761.06			MAX DAILY	mg	100		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009000_A100_1.pdf#page=43 | https://www.pmda.go.jp/drugs/2013/P201300172/800126000_22600AMX00009_K102_1.pdf#page=13	Homo sapiens		h	15.78		Moderate hepatic impairment		8			false
9491	10406		ADULT	3830	215.2114	KINETIN	Kinetin	C(NC1=C2N=CNC2=NC=N1)C3=CC=CO3	PLASMA	P39Y9652YJ									?	ng × h/mL	2778.75		ng/mL	806			UNKNOWN	mg/kg	3.35		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19033881/	Homo sapiens		h	0.65	8-day administration	Familial dysautonomia patients (carriers of the common IVS20 6T>C FD mutation)		5			false
9492	10406		ADULT	3830	215.2114	KINETIN	Kinetin	C(NC1=C2N=CNC2=NC=N1)C3=CC=CO3	PLASMA	P39Y9652YJ									?	ng × h/mL	2622.25		ng/mL	728			UNKNOWN	mg/kg	6.7		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19033881/	Homo sapiens		h	0.65	8-day administration	Familial dysautonomia patients (carriers of the common IVS20 6T>C FD mutation)		5			false
9493	10406		ADULT	3830	215.2114	KINETIN	Kinetin	C(NC1=C2N=CNC2=NC=N1)C3=CC=CO3	PLASMA	P39Y9652YJ									?	ng × h/mL	10500.25		ng/mL	1787			UNKNOWN	mg/kg	11.1		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19033881/	Homo sapiens		h	0.6	8-day administration	Familial dysautonomia patients (carriers of the common IVS20 6T>C FD mutation)		5			false
9494	10406		ADULT	3830	215.2114	KINETIN	Kinetin	C(NC1=C2N=CNC2=NC=N1)C3=CC=CO3	PLASMA	P39Y9652YJ									?	ng × h/mL	18660.5		ng/mL	2760			UNKNOWN	mg/kg	16.8		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19033881/	Homo sapiens		h	0.86	8-day administration	Familial dysautonomia patients (carriers of the common IVS20 6T>C FD mutation)		7			false
9495	10406			3830	215.2114	KINETIN	Kinetin	C(NC1=C2N=CNC2=NC=N1)C3=CC=CO3	PLASMA	P39Y9652YJ																										Human plasma protein binding: about 69% (directly read from Fig. 7), equilibrium dialysis	31				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19033881/	Homo sapiens										false
9496	10406		ADULT	3830	215.2114	KINETIN	Kinetin	C(NC1=C2N=CNC2=NC=N1)C3=CC=CO3	PLASMA	P39Y9652YJ									?	ng × h/mL	26783.65		ng/mL	5050			UNKNOWN	mg/kg	23.5		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19033881/	Homo sapiens		h	2	8-day administration	Familial dysautonomia patients (carriers of the common IVS20 6T>C FD mutation)		7			false
9497	10406		ADULT	3830	215.2114	KINETIN	Kinetin	C(NC1=C2N=CNC2=NC=N1)C3=CC=CO3	PLASMA	P39Y9652YJ									?	ng × h/mL	26854		ng/mL	5135			UNKNOWN	mg/kg	23.5		MULTIPLE	FED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19033881/	Homo sapiens		h	2.09	8-day administration	Familial dysautonomia patients (carriers of the common IVS20 6T>C FD mutation)		5			false
9498	10409		ADULT	115198	298.2918	METADOXINE	METADOXINE	OC(=O)[C@@H]1CCC(=O)N1.CC2=NC=C(CO)C(CO)=C2O	PLASMA	EJQ7M98H5J									∞	mg × h/L	26.22		mg/L	8.61			UNKNOWN	mg	900		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17335665/	Homo sapiens		h	0.85				10	METADOXINE		false
9499	10409		ADULT	115198	298.2918	METADOXINE	METADOXINE	OC(=O)[C@@H]1CCC(=O)N1.CC2=NC=C(CO)C(CO)=C2O	PLASMA	EJQ7M98H5J									∞	mg × h/L	23.43		mg/L	7.61			UNKNOWN	mg	900		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17335665/	Homo sapiens		h	0.77				10	METADOXINE		false
9500	10723		ADULT	72327	260.22	FMAU	FMAU		PLASMA	37F7D05ANB													ng/mL	2.1			UNKNOWN	mg/m²	50		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22410089	Homo sapiens							3	FAU		false
9501	10723		ADULT	3007908	246.1924	1-(2-DEOXY-2-FLUORO-.BETA.-D-ARABINOFURANOSYL)URACIL	FAU	OC[C@H]1O[C@H]([C@@H](F)[C@@H]1O)N2C=CC(=O)NC2=O	PLASMA	K7386OMP29													ng/mL	1479			UNKNOWN	mg/m²	50		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22410089	Homo sapiens							3	1-(2-DEOXY-2-FLUORO-β-D-ARABINOFURANOSYL)URACIL		false
9502	10723		ADULT	3007908	246.1924	1-(2-DEOXY-2-FLUORO-.BETA.-D-ARABINOFURANOSYL)URACIL	FAU	OC[C@H]1O[C@H]([C@@H](F)[C@@H]1O)N2C=CC(=O)NC2=O	PLASMA	K7386OMP29													ng/mL	1152			UNKNOWN	mg/m²	50		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22410089	Homo sapiens							3	FAU		false
9503	10723		ADULT	72327	260.22	FMAU	FMAU	CC1=CN(C(=O)NC1=O)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)F	PLASMA	37F7D05ANB													ng/mL	4.1			UNKNOWN	mg/m²	50		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22410089	Homo sapiens							3	FAU		false
9504	17717		ADULT		104.1	(R)-3-Hydroxybutyric acid	D-beta-hydroxybutyrate	C[C@H](CC(=O)O)O	PLASMA										∞	mM × h	1.09		mM	0.28			UNKNOWN	mg/kg	140		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22561291/	Homo sapiens		h	1.61	given to subjects as a constituent of meal replacement milkshake beverages			6	(R)-3-hydroxybutyl (R)-3-hydroxybutyrate		false
9505	17717		ADULT		104.1	(R)-3-Hydroxybutyric acid	D-beta-hydroxybutyrate	C[C@H](CC(=O)O)O	PLASMA										∞	mM × h	13		mM	3.3			UNKNOWN	mg/kg	714		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22561291/	Homo sapiens		h	0.77	given to subjects as a constituent of meal replacement milkshake beverages			6	(R)-3-hydroxybutyl (R)-3-hydroxybutyrate		false
9506	17717		ADULT		104.1	(R)-3-Hydroxybutyric acid	D-beta-hydroxybutyrate	C[C@H](CC(=O)O)O	PLASMA										∞	mM × h	4		mM	1			UNKNOWN	mg/kg	357		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22561291/	Homo sapiens		h	3.06	given to subjects as a constituent of meal replacement milkshake beverages			6	(R)-3-hydroxybutyl (R)-3-hydroxybutyrate		false
9507	17717		ADULT	6971017	101.0807	[NO STEREO] ACETOACETIC ACID	acetoacetate	CC(=O)CC([O-])=O	PLASMA	[NO STEREO] 4ZI204Y1MC									∞	mM × h	7.8		mM	1.19			UNKNOWN	mg/kg	714		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22561291/	Homo sapiens		h	10.47	given to subjects as a constituent of meal replacement milkshake beverages			6	(R)-3-hydroxybutyl (R)-3-hydroxybutyrate		false
9508	17717		ADULT	6971017	101.0807	[NO STEREO] ACETOACETIC ACID	acetoacetate	CC(=O)CC([O-])=O	PLASMA	[NO STEREO] 4ZI204Y1MC									∞	mM × h	4.19		mM	0.54			UNKNOWN	mg/kg	357		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22561291/	Homo sapiens		h	8.23	given to subjects as a constituent of meal replacement milkshake beverages			6	(R)-3-hydroxybutyl (R)-3-hydroxybutyrate		false
9509	17717		ADULT		101.0807	[NO STEREO] ACETOACETIC ACID	acetoacetate	CC(=O)CC([O-])=O	PLASMA	[NO STEREO] 4ZI204Y1MC									∞	mM × h	2.06		mM	0.23			UNKNOWN	mg/kg	140		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22561291/	Homo sapiens		h	14.29	given to subjects as a constituent of meal replacement milkshake beverages			6	(R)-3-hydroxybutyl (R)-3-hydroxybutyrate		false
9510	18005		ADULT	14113|74441225	179.2157	4-AMINO-3-PHENYLBUTYRIC ACID	Phenibut	NCC(CC(O)=O)C1=CC=CC=C1	PLASMA	T2M58D6LA8																	UNKNOWN	mg	250		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/26693960/ | https://pubmed.ncbi.nlm.nih.gov/11830761/	Homo sapiens		h	5.3							false
9511	19004		ADULT	15985904	447.51	4SC-202	4SC-202	CN1C=C(C=N1)C2=CC=C(C=C2)S(=O)(=O)N3C=CC(\\C=C\\C(=O)NC4=C(N)C=CC=C4)=C3	PLASMA	264ARM7UXX																	RECOMMENDED	mg	200		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26357940/	Homo sapiens		h	146					4SC-202		false
9512	20304		ADULT	64999	794.9813	A-77003	A-77003	CC(C)[C@H](NC(=O)N(C)CC1=NC=CC=C1)C(=O)N[C@@H](CC2=CC=CC=C2)[C@H](O)[C@H](O)[C@H](CC3=CC=CC=C3)NC(=O)[C@@H](NC(=O)N(C)CC4=NC=CC=C4)C(C)C	PLASMA	BER06U740R													μg/mL	0.358			UNKNOWN	mg/kg/h	0.28		MULTIPLE	UNKNOWN		day	24			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7492104/	Homo sapiens		min	20	24-h infusion period			9	A77003		false
9513	20304		ADULT	64999	794.9813	A-77003	A-77003	CC(C)[C@H](NC(=O)N(C)CC1=NC=CC=C1)C(=O)N[C@@H](CC2=CC=CC=C2)[C@H](O)[C@H](O)[C@H](CC3=CC=CC=C3)NC(=O)[C@@H](NC(=O)N(C)CC4=NC=CC=C4)C(C)C	PLASMA	BER06U740R													μg/mL	0.143			UNKNOWN	mg/kg/h	0.07		MULTIPLE	UNKNOWN		day	24			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7492104/	Homo sapiens				24-h infusion period			5	A77003		false
9514	20304		ADULT	64999	794.9813	A-77003	A-77003	CC(C)[C@H](NC(=O)N(C)CC1=NC=CC=C1)C(=O)N[C@@H](CC2=CC=CC=C2)[C@H](O)[C@H](O)[C@H](CC3=CC=CC=C3)NC(=O)[C@@H](NC(=O)N(C)CC4=NC=CC=C4)C(C)C	PLASMA	BER06U740R													μg/mL	0.174			UNKNOWN	mg/kg/h	0.14		MULTIPLE	UNKNOWN		day	24			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7492104/	Homo sapiens				24-h infusion period			5	A77003		false
9515	20515		ADULT	5330	280.303	SULFAMETHOXYPYRIDAZINE	sulfamethoxypyridazine	COC1=NN=C(NS(=O)(=O)C2=CC=C(N)C=C2)C=C1	BLOOD	T034E4NS2Z													mg/dL	3.4			RECOMMENDED	g	1		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/13533417/	Homo sapiens										false
9516	20515		CHILD		280.303	SULFAMETHOXYPYRIDAZINE	sulfamethoxypyridazine	COC1=NN=C(NS(=O)(=O)C2=CC=C(N)C=C2)C=C1	BLOOD	T034E4NS2Z													mg/dL	5			RECOMMENDED	mg/kg	30		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/13533417/	Homo sapiens										false
9517	20538		ADULT	12035	163.2	ACETYLCYSTEINE	ACETYLCYSTEINE	CC(=O)NC(CS)C(O)=O	PLASMA	WYQ7N0BPYC									∞	μg × h/mL	186		μg/mL	26.5			RECOMMENDED	g	11		SINGLE	UNKNOWN				The protein binding for acetylcysteine ranges from 66% to 87 %	23.5	HEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207916s003lbl.pdf	Homo sapiens		h	18.1							false
9518	20538		UNKNOWN	12035	163.195	ACETYLCYSTEINE	ACETYLCYSTEINE	CC(=O)N[C@@H](CS)C(O)=O	PLASMA	WYQ7N0BPYC													mg/L	3.47			UNKNOWN	mg	400		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/2029805	Homo sapiens										false
9519	20538		UNKNOWN	12035	163.195	ACETYLCYSTEINE	ACETYLCYSTEINE	CC(=O)N[C@@H](CS)C(O)=O	PLASMA	WYQ7N0BPYC													mg/L	0.68			UNKNOWN	mg	200		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/2029805	Homo sapiens										false
9520	20538		UNKNOWN	12035	163.195	ACETYLCYSTEINE	ACETYLCYSTEINE	CC(=O)N[C@@H](CS)C(O)=O	PLASMA	WYQ7N0BPYC													mg/L	2.57			UNKNOWN	mg	600		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/2029805	Homo sapiens										false
9521	20538		ADULT	12035	163.195	ACETYLCYSTEINE	ACETYLCYSTEINE	CC(=O)N[C@@H](CS)C(O)=O	PLASMA	WYQ7N0BPYC																	UNKNOWN	mg	600		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/3803419	Homo sapiens		h	2.27							false
9522	20722		ADULT	9916058	570.685	ADH-1	ADH-1	CC(C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(N)=O)NC(C)=O	PLASMA	B058ME29VU									∞	μg × h/mL	58.8		μg/mL	40.9			UNKNOWN	mg/m²	300		MULTIPLE	UNKNOWN		4 weeks	3			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19190075	Homo sapiens		h	2				4	ADH-1		false
9523	20722		ADULT	9916058	570.685	ADH-1	ADH-1	CC(C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(N)=O)NC(C)=O	PLASMA	B058ME29VU									∞	ng × h/mL	102.5		μg/mL	60.7			UNKNOWN	mg/m²	600		MULTIPLE	UNKNOWN		4 weeks	3			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19190075	Homo sapiens		h	2.16				5	ADH-1		false
9524	20722		ADULT	9916058	570.685	ADH-1	ADH-1	CC(C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(N)=O)NC(C)=O	PLASMA	B058ME29VU									∞	μg × h/mL	167.7		μg/mL	141.5			UNKNOWN	mg/m²	1200		MULTIPLE	UNKNOWN		4 weeks	3			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19190075	Homo sapiens		h	1.35				3	ADH-1		false
9525	20722		ADULT	9916058	570.685	ADH-1	ADH-1	CC(C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(N)=O)NC(C)=O	PLASMA	B058ME29VU									∞	μg × h/mL	398.8		μg/mL	225			UNKNOWN	mg/m²	2400		MULTIPLE	UNKNOWN		4 weeks	3			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19190075	Homo sapiens		h	1.92				3	ADH-1		false
9526	20842		ADULT	25017411	407.4375	ANLOTINIB	Anlotinib	COC1=CC2=C(OC3=C(F)C4=C(NC(C)=C4)C=C3)C=CN=C2C=C1OCC5(N)CC5	PLASMA	GKF8S4C432									∞	ng × h/mL	687		ng/mL	5.8			UNKNOWN	mg	5		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27716285/	Homo sapiens		h	102		Patients with advanced refractory solid tumors		1			false
9527	20842		ADULT	25017411	407.4375	ANLOTINIB	Anlotinib	COC1=CC2=C(OC3=C(F)C4=C(NC(C)=C4)C=C3)C=CN=C2C=C1OCC5(N)CC5	PLASMA	GKF8S4C432									∞	ng × h/mL	562		ng/mL	5.8			UNKNOWN	mg	10		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27716285/	Homo sapiens		h	95		Patients with advanced refractory solid tumors		4			false
9528	20842		ADULT	25017411	407.4375	ANLOTINIB	Anlotinib	COC1=CC2=C(OC3=C(F)C4=C(NC(C)=C4)C=C3)C=CN=C2C=C1OCC5(N)CC5	PLASMA	GKF8S4C432									∞	ng × h/mL	1066		ng/mL	10.5			UNKNOWN	mg	12		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27716285/	Homo sapiens		h	116		Patients with advanced refractory solid tumors		11			false
9529	20842		ADULT	25017411	407.4375	ANLOTINIB	Anlotinib	COC1=CC2=C(OC3=C(F)C4=C(NC(C)=C4)C=C3)C=CN=C2C=C1OCC5(N)CC5	PLASMA	GKF8S4C432									∞	ng × h/mL	1585		ng/mL	15.8			UNKNOWN	mg	16		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27716285/	Homo sapiens		h	98		Patients with advanced refractory solid tumors		11			false
9530	20842			25017411	407.4375	ANLOTINIB	Anlotinib	COC1=CC2=C(OC3=C(F)C4=C(NC(C)=C4)C=C3)C=CN=C2C=C1OCC5(N)CC5	PLASMA	GKF8S4C432																										Human plasma protein binding: 92.1% (equilibrium dialysis)	7.9				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29620050/	Homo sapiens										false
9531	21096		ADULT	15130	353.4977	LEVOMETHADYL ACETATE	LEVOMETHADYL ACETATE	CC[C@H](OC(C)=O)C(C[C@H](C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2	PLASMA	R3B637Y991							48		t	ng × h/mL	2995		ng/mL	188			UNKNOWN	mg	80		STEADY-STATE	UNKNOWN		2 days	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15380290	Homo sapiens										false
9532	21096		ADULT	15129	339.4712	NORACYMETHADOL	noracetylmethadol	CCC(OC(C)=O)C(CC(C)NC)(C1=CC=CC=C1)C2=CC=CC=C2	PLASMA	KU5U13XY7J							48		t	ng × h/mL	6056		ng/mL	184			UNKNOWN	mg	80		STEADY-STATE	UNKNOWN		2 days	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15380290	Homo sapiens										false
9533	21096		ADULT	12341793	325.4	Dinoracetylmethadol	dinoracetylmethadol		PLASMA								48		t	ng × h/mL	5892		ng/mL	139			UNKNOWN	mg	80		STEADY-STATE	UNKNOWN		2 days	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15380290	Homo sapiens										false
9534	21284		ADULT	9938965	619.6	AMG-487 metabolite M1	AMG-487 metabolite M1		PLASMA	FN2HYI3FM5							24		t	μM × h	3.6		μM	0.62			UNKNOWN	mg	100		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19088267/	Homo sapiens				Day 7			4	AMG 487		false
9535	21284		ADULT	9938965	619.6	AMG-487 metabolite M1	AMG-487 metabolite M1		PLASMA	FN2HYI3FM5							24		t	μM × h	15		μM	1.3			HIGHEST STUDIED	mg	250		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19088267/	Homo sapiens				Day 7			5	AMG 487		false
9536	21284		ADULT	24957182	603.591	AMG-487	AMG-487	CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2[C@@H](C)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(OC(F)(F)F)C=C5	PLASMA	355CGR2CBL							24		t	μM × h	3.3		μM	0.43			UNKNOWN	mg	100		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19088267/	Homo sapiens				Day 7			4	AMG 487		false
9537	21284		ADULT	24957182	603.591	AMG-487	AMG-487	CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2[C@@H](C)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(OC(F)(F)F)C=C5	PLASMA	355CGR2CBL							24		t	μM × h	27		μM	2.8			HIGHEST STUDIED	mg	250		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19088267/	Homo sapiens				Day 7			5	AMG 487		false
9538	21284		ADULT	9938965	619.6	AMG-487 metabolite M1	AMG-487 metabolite M1		PLASMA	FN2HYI3FM5							24		t	μM × h	0.52		μM	0.11			UNKNOWN	mg	25		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19088267/	Homo sapiens		h	9	Day 7			8	AMG 487		false
9539	21284		ADULT	24957182	603.591	AMG-487	AMG-487	CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2[C@@H](C)N(CC4=CN=CC=C4)C(=O)CC5=CC=C(OC(F)(F)F)C=C5	PLASMA	355CGR2CBL							24		t	μM × h	0.28		μM	0.052			UNKNOWN	mg	25		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19088267/	Homo sapiens		h	9.7	Day 7			8	AMG 487		false
9540	21551		ADULT	25194	353.845	AMOPYROQUINE	AMOPYROQUINE	OC1=CC=C(NC2=C3C=CC(Cl)=CC3=NC=C2)C=C1CN4CCCC4	PLASMA	SV6L22Y9QF							24		t	μg × min/mL	40		nM	800			UNKNOWN	mg/kg	6		MULTIPLE	UNKNOWN		day	1			HEALTHY	Intramuscular	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7706177/	Homo sapiens		h	18.3							false
9541	21634		ADULT	5318517	350.4492	ANDROGRAPHOLIDE	ANDROGRAPHOLIDE	C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H](C\\C=C3/[C@H](O)COC3=O)C(=C)CC[C@H]12	PLASMA	410105JHGR									∞	ng × h/mL	1294		ng/mL	141.7			UNKNOWN	mg	20		SINGLE	FASTED				55 % of the andrographolide is bound with human blood plasma proteins.	45	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11081986	Homo sapiens		h	3.94				16	ANDROGRAPHOLIDE		false
9542	21842		UNKNOWN	2214	166.1739	APOCYNIN	APOCYNIN	COC1=C(O)C=CC(=C1)C(C)=O	PLASMA	B6J7B9UDTR																						UNKNOWN				Plasma protein binding of apocynin in human plasma - 73.34% (300 ng/mL)	26.7	UNKNOWN		UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25682338/	Homo sapiens										false
9543	21851		ADULT	52918385	199.2469	APR-246	APR-246	COCC1(CO)N2CCC(CC2)C1=O	PLASMA	Z41TGB4080							24		t	μg × h/mL	347		μg/mL	57.1			MAX TOLERATED	mg/kg	60		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22965953	Homo sapiens		h	3.56	First Dose. Note that AUC and Cmax units reported in table 3 are most likely incorrect and should be ug/mL and ug*h/mL, according to Fig. 1			6	APR-246		false
9544	21851		ADULT	52918385	199.2469	APR-246	APR-246	COCC1(CO)N2CCC(CC2)C1=O	PLASMA	Z41TGB4080							24		t	μg × h/mL	356		μg/mL	55.4			MAX TOLERATED	mg/kg	60		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22965953	Homo sapiens		h	3.71	APR-246 was given intravenously as a 2-hour infusion once per day for 4 consecutive days; last dose.  Note that AUC and Cmax units reported in table 3 are most likely incorrect and should be ug/mL and ug*h/mL, according to Fig. 1			6	APR-246		false
9545	21851		ADULT	52918385	199.2469	APR-246	APR-246	COCC1(CO)N2CCC(CC2)C1=O	PLASMA	Z41TGB4080							24		t	μg × h/mL	584		μg/mL	82.6			UNKNOWN	mg/kg	90		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22965953	Homo sapiens		h	4.71	First Dose. Note that AUC and Cmax units reported in table 3 are most likely incorrect and should be ug/mL and ug*h/mL, according to Fig. 1			3	APR-246		false
9546	21859		ADULT	11960271	367.4	APTO-253	APTO-253		SERUM	WB59MRW00U													ng/mL	1190			RECOMMENDED	mg/m²	229		SINGLE	UNKNOWN						UNKNOWN	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26268924	Homo sapiens							4			false
9547	21868		ADULT	6918848	312.363	AR-42	AR-42	CC(C)[C@H](C(=O)NC1=CC=C(C=C1)C(=O)NO)C2=CC=CC=C2	PLASMA	E0GG29V0AQ									?	μM × h	27.6		μM	3.25			UNKNOWN	mg	80		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://ashpublications.org/blood/article/120/21/2955/102418/Phase-I-Study-of-AR-42-in-Relapsed-Multiple	Homo sapiens										false
9548	22065		ADULT	25134326	580.745	ASP-3026	ASP-3026	COC1=C(NC2=NC=NC(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=CC(=C1)N4CCC(CC4)N5CCN(C)CC5	PLASMA	HP4L6MXF10							24		t	ng × h/mL	11746		ng/mL	961			MAX TOLERATED	mg	525		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26966027	Homo sapiens							16	ASP-3026		false
9549	22065		ADULT	25134326	580.745	ASP-3026	ASP-3026	COC1=C(NC2=NC=NC(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=CC(=C1)N4CCC(CC4)N5CCN(C)CC5	PLASMA	HP4L6MXF10							24		t	ng × h/mL	19993		ng/mL	1331			MAX TOLERATED	mg	525		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26966027	Homo sapiens		h	24.9	day 28			15	ASP-3026		false
9550	22065		ADULT	25134326	580.745	ASP-3026	ASP-3026	COC1=C(NC2=NC=NC(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=CC(=C1)N4CCC(CC4)N5CCN(C)CC5	PLASMA	HP4L6MXF10							24		t	ng × h/mL	21796		ng/mL	1633			UNKNOWN	mg	800		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26966027	Homo sapiens							3	ASP-3026		false
9551	22065		ADULT	25134326	580.745	ASP-3026	ASP-3026	COC1=C(NC2=NC=NC(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=CC(=C1)N4CCC(CC4)N5CCN(C)CC5	PLASMA	HP4L6MXF10							24		t	ng × h/mL	78081		ng/mL	4854			UNKNOWN	mg	800		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26966027	Homo sapiens		h	37.9	day 28			1	ASP-3026		false
9552	22117		ADULT	24905401	313.781	AT-13148	AT-13148	NC[C@@](O)(C1=CC=C(Cl)C=C1)C2=CC=C(C=C2)C3=CNN=C3	PLASMA	A49037RP1E													nM	50			UNKNOWN	mg	20		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://ascopubs.org/doi/abs/10.1200/jco.2014.32.15_suppl.2554	Homo sapiens		h	24					AT13148		false
9553	22117		ADULT	24905401	313.781	AT-13148	AT-13148	NC[C@@](O)(C1=CC=C(Cl)C=C1)C2=CC=C(C=C2)C3=CNN=C3	PLASMA	A49037RP1E													nM	50			UNKNOWN	mg	20		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://ascopubs.org/doi/abs/10.1200/jco.2014.32.15_suppl.2554	Homo sapiens		h	24							false
9554	22117		ADULT		313.781	AT-13148	AT-13148	NC[C@@](O)(C1=CC=C(Cl)C=C1)C2=CC=C(C=C2)C3=CNN=C3	PLASMA	A49037RP1E									∞	nM × h	20000		nM	400			MAX TOLERATED	mg	180		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32616501	Homo sapiens		h	40				55	AT13148		false
9555	22117		ADULT	24905401	313.781	AT-13148	AT-13148	NC[C@@](O)(C1=CC=C(Cl)C=C1)C2=CC=C(C=C2)C3=CNN=C3	PLASMA	A49037RP1E									∞	nM × h	20000		nM	400			UNKNOWN	mg	160		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32616501	Homo sapiens		h	40				56	AT13148		false
9556	22117		ADULT		313.781	AT-13148	AT-13148	NC[C@@](O)(C1=CC=C(Cl)C=C1)C2=CC=C(C=C2)C3=CNN=C3	PLASMA	A49037RP1E									∞	nM × h	900		nM	20			UNKNOWN	mg	5		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32616501	Homo sapiens		h	60				56	AT13148		false
9557	22117		ADULT	24905401	313.781	AT-13148	AT-13148	NC[C@@](O)(C1=CC=C(Cl)C=C1)C2=CC=C(C=C2)C3=CNN=C3	PLASMA	A49037RP1E									∞	nM × h	2100		nM	120			UNKNOWN	mg	40		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32616501	Homo sapiens		h	15				57	AT13148		false
9558	22117		ADULT	24905401	313.781	AT-13148	AT-13148	NC[C@@](O)(C1=CC=C(Cl)C=C1)C2=CC=C(C=C2)C3=CNN=C3	PLASMA	A49037RP1E									∞	nM × h	40000		nM	700			UNKNOWN	mg	300		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32616501	Homo sapiens		h	60				56	AT13148		false
9559	22186		ADULT	5281157	299.2781	AVENANTHRAMIDE A	AVENANTHRAMIDE A	OC(=O)C1=C(NC(=O)\\C=C\\C2=CC=C(O)C=C2)C=CC(O)=C1	PLASMA	G1I8LE060C									?	nM × h	1501		nM	374.6			UNKNOWN	μmol	154		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17513394/	Homo sapiens		h	2	1 g avenanthramide-enriched mixture (AEM) extracted from oats, concentrations of the 3 major components, AV-A, AV-B, and AV-C in the AEM were 154, 109, and 117 mmol/g.			6	AVENANTHRAMIDE A		false
9560	22186		ADULT	5281157	299.2781	AVENANTHRAMIDE A	AVENANTHRAMIDE A	OC(=O)C1=C(NC(=O)\\C=C\\C2=CC=C(O)C=C2)C=CC(O)=C1	PLASMA	G1I8LE060C									?	nM × h	394		nM	112.9			UNKNOWN	μmol	77		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17513394/	Homo sapiens		h	1.5	1 g avenanthramide-enriched mixture (AEM) extracted from oats, concentrations of the 3 major components, AV-A, AV-B, and AV-C in the AEM were 154, 109, and 117 mmol/g.			6	AVENANTHRAMIDE A		false
9561	22196		ADULT	16005981	388.247	AVL-3288	AVL-3288	CC1=NOC(=C1)C(=CNC2=CC=C(Cl)C=C2)C(=O)NC3=CC=C(Cl)C=C3	BLOOD	VA80VAX4WF									?	ng × h/mL	1488		ng/mL	239			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28196430	Homo sapiens		h	1.54				6			false
9562	22196		ADULT	16005981	388.247	AVL-3288	AVL-3288	CC1=NOC(=C1)C(=CNC2=CC=C(Cl)C=C2)C(=O)NC3=CC=C(Cl)C=C3	BLOOD	VA80VAX4WF									?	ng × h/mL	385		ng/mL	79.3			UNKNOWN	mg	3		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28196430	Homo sapiens		h	3.7				6			false
9563	22196		ADULT	16005981	388.247	AVL-3288	AVL-3288	CC1=NOC(=C1)C(=CNC2=CC=C(Cl)C=C2)C(=O)NC3=CC=C(Cl)C=C3	BLOOD	VA80VAX4WF									?	ng × h/mL	4231		ng/mL	310.73			UNKNOWN	mg	30		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28196430	Homo sapiens		h	2.77				6			false
9564	22255		ADULT	16041426	381.816	AZD-2066	AZD-2066	C[C@@H](OC1=NN=C(N1C)C2=CC=NC=C2)C3=NOC(=C3)C4=CC(Cl)=CC=C4	BLOOD	MQ908Y1ZB2													nM	6			UNKNOWN	mg	13		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22469098	Homo sapiens							13			false
9565	22269		ADULT	16666708	461.2268	AZD-8330	AZD-8330	CN1C(=O)C(C)=CC(C(=O)NOCCO)=C1NC2=C(F)C=C(I)C=C2	PLASMA	G4990BOZ66									∞	ng × h/mL	186		ng/mL	69.3			MAX TOLERATED	mg	20		SINGLE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23433846	Homo sapiens		h	3.8	day 1			9	AZD-8330		false
9566	22269		ADULT	16666708	461.2268	AZD-8330	AZD-8330	CN1C(=O)C(C)=CC(C(=O)NOCCO)=C1NC2=C(F)C=C(I)C=C2	PLASMA	G4990BOZ66							24		t	ng × h/mL	252.9		ng/mL	113.5			MAX TOLERATED	mg	20		MULTIPLE	FASTED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23433846	Homo sapiens				day 15			7	AZD-8330		false
9567	22269		ADULT	16666708	461.2268	AZD-8330	AZD-8330	CN1C(=O)C(C)=CC(C(=O)NOCCO)=C1NC2=C(F)C=C(I)C=C2	PLASMA	G4990BOZ66									∞	ng × h/mL	329.8		ng/mL	160			UNKNOWN	mg	60		SINGLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23433846	Homo sapiens		h	14.7				3	AZD-8330		false
9568	22269		ADULT	16666708	461.2268	AZD-8330	AZD-8330	CN1C(=O)C(C)=CC(C(=O)NOCCO)=C1NC2=C(F)C=C(I)C=C2	PLASMA	G4990BOZ66							24		t	ng × h/mL	351.1		ng/mL	160			UNKNOWN	mg	60		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23433846	Homo sapiens				day 15			3	AZD-8330		false
9569	22275		ADULT	2267	381.898	AZELASTINE	Azelastine	CN1CCCC(CC1)N2N=C(CC3=CC=C(Cl)C=C3)C4=CC=CC=C4C2=O	PLASMA	ZQI909440X									∞	pg × h/mL	5122		pg/mL	200			UNKNOWN	μg	548		SINGLE	FASTED						HEALTHY	Nasal	MALE	OTHER GOV'T	https://mhraproducts4853.blob.core.windows.net/docs/e1797a8f2c2b38487c21ccb8946319d339761af5#page=23	Homo sapiens				137 μg/spray x 4 sprays						false
9570	22275		ADULT	162558	367.872	DESMETHYLAZELASTINE	Desmethylazelastine	ClC1=CC=C(CC2=NN(C3CCCNCC3)C(=O)C4=C2C=CC=C4)C=C1	PLASMA	8W9SOB28Q4									∞	pg × h/mL	2131		pg/mL	23			UNKNOWN	μg	548		SINGLE	FASTED						HEALTHY	Nasal	MALE	OTHER GOV'T	https://mhraproducts4853.blob.core.windows.net/docs/e1797a8f2c2b38487c21ccb8946319d339761af5#page=23	Homo sapiens				137 μg/spray x 4 sprays						false
9571	22275		ADULT	2267	381.898	AZELASTINE	Azelastine	CN1CCCC(CC1)N2N=C(CC3=CC=C(Cl)C=C3)C4=CC=CC=C4C2=O	PLASMA	ZQI909440X									∞	pg × h/mL	9312		pg/mL	409			UNKNOWN	μg	822		SINGLE	FASTED						HEALTHY	Nasal	MALE	OTHER GOV'T	https://mhraproducts4853.blob.core.windows.net/docs/e1797a8f2c2b38487c21ccb8946319d339761af5#page=23	Homo sapiens				205.5 μg/spray x 4 sprays						false
9572	22275		ADULT	162558	367.872	DESMETHYLAZELASTINE	Desmethylazelastine	ClC1=CC=C(CC2=NN(C3CCCNCC3)C(=O)C4=C2C=CC=C4)C=C1	PLASMA	8W9SOB28Q4									∞	pg × h/mL	3824		pg/mL	38			UNKNOWN	μg	822		SINGLE	FASTED						HEALTHY	Nasal	MALE	OTHER GOV'T	https://mhraproducts4853.blob.core.windows.net/docs/e1797a8f2c2b38487c21ccb8946319d339761af5#page=23	Homo sapiens				205.5 μg/spray x 4 sprays						false
9573	22275		ADULT	2267	381.898	AZELASTINE	Azelastine	CN1CCCC(CC1)N2N=C(CC3=CC=C(Cl)C=C3)C4=CC=CC=C4C2=O	PLASMA	ZQI909440X									∞	pg × h/mL	6122		pg/mL	235			UNKNOWN	μg	548		SINGLE	FASTED						HEALTHY	Nasal	MALE	OTHER GOV'T	https://mhraproducts4853.blob.core.windows.net/docs/e1797a8f2c2b38487c21ccb8946319d339761af5#page=23	Homo sapiens				137 μg/spray x 4 sprays						false
9574	22275		ADULT	162558	367.872	DESMETHYLAZELASTINE	Desmethylazelastine	ClC1=CC=C(CC2=NN(C3CCCNCC3)C(=O)C4=C2C=CC=C4)C=C1	PLASMA	8W9SOB28Q4									∞	pg × h/mL	2615		pg/mL	24			UNKNOWN	μg	548		SINGLE	FASTED						HEALTHY	Nasal	MALE	OTHER GOV'T	https://mhraproducts4853.blob.core.windows.net/docs/e1797a8f2c2b38487c21ccb8946319d339761af5#page=23	Homo sapiens				137 μg/spray x 4 sprays						false
9575	22275		ADULT	2267	381.898	AZELASTINE	Azelastine	CN1CCCC(CC1)N2N=C(CC3=CC=C(Cl)C=C3)C4=CC=CC=C4C2=O	PLASMA	ZQI909440X									∞	ng × h/mL	28.24		ng/mL	1.1			UNKNOWN	mg	2		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23675185/	Homo sapiens		h	21.4				23			false
9576	22275			2267	381.898	AZELASTINE	Azelastine	CN1CCCC(CC1)N2N=C(CC3=CC=C(Cl)C=C3)C4=CC=CC=C4C2=O	PLASMA	ZQI909440X																										Human plasma protein binding: 80~84%	16				OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/170033_4490004F1021_1_010_1F.pdf#page=22	Homo sapiens										false
9577	22275		ADULT	2267	381.898	AZELASTINE	Azelastine	CN1CCCC(CC1)N2N=C(CC3=CC=C(Cl)C=C3)C4=CC=CC=C4C2=O	PLASMA	ZQI909440X							48		t	ng × h/mL	12.17		ng/mL	0.55			DEFINED DAILY	mg	1		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400813_4490004F1080_1_006_1F.pdf#page=18	Homo sapiens		h	17.3				14			false
9578	22275		ADULT	2267	381.898	AZELASTINE	Azelastine	CN1CCCC(CC1)N2N=C(CC3=CC=C(Cl)C=C3)C4=CC=CC=C4C2=O	PLASMA	ZQI909440X							55		t	ng × h/mL	38.6		ng/mL	2.6			UNKNOWN	mg	4		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.info.pmda.go.jp/go/interview/1/400813_4490004F1080_1_006_1F.pdf#page=19	Homo sapiens		h	18.1				14			false
9579	22275		ADULT	2267	381.898	AZELASTINE	Azelastine	CN1CCCC(CC1)N2N=C(CC3=CC=C(Cl)C=C3)C4=CC=CC=C4C2=O	PLASMA	ZQI909440X													ng/mL	0.26			UNKNOWN	mg	0.28		MULTIPLE	UNKNOWN		day	2			UNKNOWN	Nasal	UNKNOWN	OTHER	https://www.medicines.org.uk/emc/product/1623/smpc#PHARMACOKINETIC_PROPS	Homo sapiens				Dose: 0.14mg/each nostril x 2						false
9580	22275			2267	381.898	AZELASTINE	Azelastine	CN1CCCC(CC1)N2N=C(CC3=CC=C(Cl)C=C3)C4=CC=CC=C4C2=O	PLASMA	ZQI909440X																										The level of protein binding is low (80-95%, a level too low to give concern over drug displacement reactions).	5				OTHER	https://www.medicines.org.uk/emc/product/1623/smpc#PHARMACOKINETIC_PROPS	Homo sapiens										false
9581	22275		ADULT	162558	367.872	DESMETHYLAZELASTINE	Desmethylazelastine	ClC1=CC=C(CC2=NN(C3CCCNCC3)C(=O)C4=C2C=CC=C4)C=C1	PLASMA	8W9SOB28Q4													ng/mL	0.12			UNKNOWN	mg	0.28		MULTIPLE	UNKNOWN		day	2	Cmax=<0.12 ng/mL		UNKNOWN	Nasal	UNKNOWN	OTHER	https://www.medicines.org.uk/emc/product/1623/smpc#PHARMACOKINETIC_PROPS	Homo sapiens				Dose: 0.14mg/each nostril x 2						false
9582	22275		ADULT	2267	381.898	AZELASTINE	Azelastine	CN1CCCC(CC1)N2N=C(CC3=CC=C(Cl)C=C3)C4=CC=CC=C4C2=O	PLASMA	ZQI909440X													ng/mL	3.9			UNKNOWN	mg	2.2		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	UNKNOWN	OTHER	https://www.medicines.org.uk/emc/product/1623/smpc#PHARMACOKINETIC_PROPS	Homo sapiens		h	20		Patients with allergic rhinitis					false
9583	22275		ADULT	162558	367.872	DESMETHYLAZELASTINE	Desmethylazelastine	ClC1=CC=C(CC2=NN(C3CCCNCC3)C(=O)C4=C2C=CC=C4)C=C1	PLASMA	8W9SOB28Q4													ng/mL	1.86			UNKNOWN	mg	2.2		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	UNKNOWN	OTHER	https://www.medicines.org.uk/emc/product/1623/smpc#PHARMACOKINETIC_PROPS	Homo sapiens		h	45		Patients with allergic rhinitis					false
9584	22275			2267	381.898	AZELASTINE	Azelastine	CN1CCCC(CC1)N2N=C(CC3=CC=C(Cl)C=C3)C4=CC=CC=C4C2=O	PLASMA	ZQI909440X																										Protein binding of azelastine is approximately 88%.	12				OTHER	https://www.pdr.net/drug-summary/Astepro-azelastine-hydrochloride-994#15	Homo sapiens										false
9585	22277		ADULT	9873077	582.6463	AZELNIDIPINE, (R)-	AZELNIDIPINE, (R)-	CC(C)OC(=O)C1=C(C)NC(N)=C([C@@H]1C2=CC(=CC=C2)[N ]([O-])=O)C(=O)OC3CN(C3)C(C4=CC=CC=C4)C5=CC=CC=C5	PLASMA	0089IC5K88							24		t	ng × h/mL	26.97		ng/mL	4.1			UNKNOWN	mg	16		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17350354/	Homo sapiens		h	4.39				5	AZELNIDIPINE		false
9586	22278		ADULT	45107611	582.6463	AZELNIDIPINE, (S)-	AZELNIDIPINE, (S)-	CC(C)OC(=O)C1=C(C)NC(N)=C([C@H]1C2=CC(=CC=C2)[N ]([O-])=O)C(=O)OC3CN(C3)C(C4=CC=CC=C4)C5=CC=CC=C5	PLASMA	368RN01P1M							24		t	ng × h/mL	21.34		ng/mL	3.6			UNKNOWN	mg	16		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17350354/	Homo sapiens		h	3.72				5	AZELNIDIPINE		false
9587	22342		ADULT	5281605	270.2369	BAICALEIN	Baicalein	OC1=CC2=C(C(=O)C=C(O2)C3=CC=CC=C3)C(O)=C1O	PLASMA	49QAH60606									∞	ng × h/mL	598.4		ng/mL	65.171			HIGHEST STUDIED	mg	800		STEADY-STATE	FASTED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27352310	Homo sapiens		h	11.09	chewable tablets			8	Baicalein		false
9588	22342		ADULT	5281605	270.2369	BAICALEIN	baicalein	OC1=CC2=C(C(=O)C=C(O2)C3=CC=CC=C3)C(O)=C1O	PLASMA	49QAH60606									∞	ng × h/mL	169		ng/mL	17.61			UNKNOWN	mg	200		STEADY-STATE	FASTED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27352310	Homo sapiens		h	8.8	chewable tablets			9	baicalein		false
9589	22342		ADULT	5281605	270.2369	BAICALEIN	baicalein	OC1=CC2=C(C(=O)C=C(O2)C3=CC=CC=C3)C(O)=C1O	PLASMA	49QAH60606									∞	ng × h/mL	332.9		ng/mL	31.723			UNKNOWN	mg	400		STEADY-STATE	FASTED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27352310	Homo sapiens		h	12.53	chewable tablets			10	Baicalein		false
9590	22342		ADULT	5281605	270.2369	BAICALEIN	baicalein	OC1=CC2=C(C(=O)C=C(O2)C3=CC=CC=C3)C(O)=C1O	PLASMA	49QAH60606									∞	ng × h/mL	12580.06		ng/mL	1322.5			HIGHEST STUDIED	mg	600		STEADY-STATE	FASTED		day	3			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/34156161	Homo sapiens				baicalein tablet or placebo once daily on day 1 and day 10, 3 times daily on days 4– 9			10	baicalein		false
9591	22342		ADULT	64982	446.361	BAICALIN	Baicalin	O[C@H]1[C@H](OC2=CC3=C(C(=O)C=C(O3)C4=CC=CC=C4)C(O)=C2O)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O	PLASMA	347Q89U4M5									∞	ng × h/mL	10175.14		ng/mL	1508.45			HIGHEST STUDIED	mg	600		STEADY-STATE	FASTED		day	3			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/34156161	Homo sapiens				baicalein tablet or placebo once daily on day 1 and day 10, 3 times daily on days 4– 9			10	Baicalein		false
9592	22343		UNKNOWN	64982	446.361	BAICALIN	Baicalin	O[C@H]1[C@H](OC2=CC3=C(C(=O)C=C(O3)C4=CC=CC=C4)C(O)=C2O)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O	PLASMA	347Q89U4M5																						UNKNOWN				The protein binding of baicalin in human plasma decreased as the  total analyte concentration increased, and the plasma protein binding was in the range 86–92% over all concentrations  studied.	11	UNKNOWN		UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16708379	Homo sapiens										false
9593	22343		ADULT	64982	446.361	BAICALIN	BAICALIN	O[C@H]1[C@H](OC2=CC3=C(C(=O)C=C(O3)C4=CC=CC=C4)C(O)=C2O)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O	PLASMA	347Q89U4M5									∞	ng × h/mL	11961.53		ng/mL	1847.21			UNKNOWN	mg	2800		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25219601	Homo sapiens		h	9.65				6			false
9594	22492		ADULT	10445549	265.27	Galidesivir	Galidesivir		PLASMA	OLF97F86A7									∞	ng × h/mL	21160		ng/mL	5540			UNKNOWN	mg/kg	5		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://clinicaltrials.gov/ct2/show/results/NCT03800173	Homo sapiens							6	Galidesivir		false
9595	22492		ADULT	10445549	265.27	Galidesivir	Galidesivir		PLASMA	OLF97F86A7									∞	ng × h/mL	37080		ng/mL	10300			UNKNOWN	mg/kg	10		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://clinicaltrials.gov/ct2/show/results/NCT03800173	Homo sapiens							6	Galidesivir		false
9596	22492		ADULT	10445549	265.27	Galidesivir	Galidesivir		PLASMA	OLF97F86A7									∞	ng × h/mL	65860		ng/mL	17730			UNKNOWN	mg/kg	15		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://clinicaltrials.gov/ct2/show/results/NCT03800173	Homo sapiens							6	Galidesivir		false
9597	22492		ADULT	10445549	265.27	Galidesivir	Galidesivir		PLASMA	OLF97F86A7									∞	ng × h/mL	81230		ng/mL	20490			HIGHEST STUDIED	mg/kg	20		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://clinicaltrials.gov/ct2/show/results/NCT03800173	Homo sapiens							6	Galidesivir		false
9598	22513		ADULT	62965	464.979	BECLOMETHASONE 17-MONOPROPIONATE	BECLOMETHASONE 17-MONOPROPIONATE	CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C)C(=O)CO	PLASMA	5BGA9FD55H									∞	ng × h/mL	4.985		ng/mL	1.419			UNKNOWN	μg	100		MULTIPLE	UNKNOWN		day	4			UNHEALTHY	Respiratory	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12107606/	Homo sapiens		h	2.8							false
9599	22924		ADULT	2355	216.1895	BERGAPTEN	Bergapten	COC1=C2C=COC2=CC3=C1C=CC(=O)O3	SERUM	4FVK84C92X									?	ng × h/mL	1754		ng/mL	82			UNKNOWN	mg/kg	1.2		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1981428/	Homo sapiens				Morning administration			8			false
9600	22924		ADULT	2355	216.1895	BERGAPTEN	Bergapten	COC1=C2C=COC2=CC3=C1C=CC(=O)O3	SERUM	4FVK84C92X									?	ng × h/mL	1757		ng/mL	89			UNKNOWN	mg/kg	1.2		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1981428/	Homo sapiens				Afternoon administration			8			false
9601	22924		ADULT	2355	216.1895	BERGAPTEN	Bergapten	COC1=C2C=COC2=CC3=C1C=CC(=O)O3	SERUM	4FVK84C92X									?	ng × h/mL	3282		ng/mL	175			UNKNOWN	mg/kg	1.2		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1981428/	Homo sapiens				Evening administration			8			false
9602	22924		ADULT	2355	216.1895	BERGAPTEN	Bergapten	COC1=C2C=COC2=CC3=C1C=CC(=O)O3	SERUM	4FVK84C92X							5		t	μg × h/L	276		μg/L	108			UNKNOWN	mg/kg	1.2		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3994922/	Homo sapiens				Tablets	psoriasis patients		7			false
9603	22924		ADULT	2355	216.1895	BERGAPTEN	Bergapten	COC1=C2C=COC2=CC3=C1C=CC(=O)O3	SERUM	4FVK84C92X							5		t	μg × h/L	942		μg/L	322			UNKNOWN	mg/kg	1.2		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3994922/	Homo sapiens				Capsules	psoriasis patients		7			false
9604	22994		ADULT	6093355	307.4278	BETAXOLOL, (R)-	Betaxolol, (R)-	CC(C)NC[C@@H](O)COC1=CC=C(CCOCC2CC2)C=C1	BLOOD	759O83814X									?	μg × h/mL	314						UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1865331/	Homo sapiens							12	Betaxolol hydrochloride		false
9605	22994		ADULT	6093355	307.4278	BETAXOLOL, (R)-	Betaxolol, (R)-	CC(C)NC[C@@H](O)COC1=CC=C(CCOCC2CC2)C=C1	BLOOD	759O83814X									?	μg × h/mL	1077		ng/mL	41			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1865331/	Homo sapiens							12	Betaxolol hydrochloride		false
9606	22994		ADULT	2369	307.4278	BETAXOLOL	Betaxolol	CC(C)NCC(O)COC1=CC=C(CCOCC2CC2)C=C1	BLOOD	O0ZR1R6RZ2									?	ng × h/mL	692		ng/mL	48.5			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2879735/	Homo sapiens		h	16.4				8			false
9607	22994		ADULT	2369	307.4278	BETAXOLOL	Betaxolol	CC(C)NCC(O)COC1=CC=C(CCOCC2CC2)C=C1	BLOOD	O0ZR1R6RZ2									?	ng × h/mL	1033		ng/mL	42.6			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2879735/	Homo sapiens		h	16.8				8			false
9608	22994			2369	307.4278	BETAXOLOL	Betaxolol	CC(C)NCC(O)COC1=CC=C(CCOCC2CC2)C=C1	PLASMA	O0ZR1R6RZ2																										Human plasma protein binding: 49% (equilibrium dialysis)	51				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2892848/	Homo sapiens										false
9609	23017		ADULT	45270144	501.5008	BI-671800	BI 671800	CN(C)C1=NC(CC2=CC=C(NC(=O)C3=CC=C(C=C3)C(F)(F)F)C=C2)=NC(N(C)C)=C1CC(O)=O	PLASMA	721F767LHB							12		t	ng × h/mL	32500		ng/mL	7600			UNKNOWN	mg	400		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.mystudywindow.com/trial/completed/253367/1268-0059	Homo sapiens		h	15.2				22	BI 671800		false
9610	23017		ADULT	45270144	501.5008	BI-671800	BI 671800	CN(C)C1=NC(CC2=CC=C(NC(=O)C3=CC=C(C=C3)C(F)(F)F)C=C2)=NC(N(C)C)=C1CC(O)=O	PLASMA	721F767LHB							12		t	ng × h/mL	19100		ng/mL	4780			UNKNOWN	mg	200		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.mystudywindow.com/trial/completed/253367/1268-0059	Homo sapiens		h	9.05				22	BI 671800		false
9611	23067		ADULT	73581	326.2986	BILOBALIDE	BILOBALIDE	CC(C)(C)[C@]1(O)C[C@@H]2OC(=O)C[C@@]23C(=O)O[C@@H]4OC(=O)[C@H](O)[C@]134	PLASMA	M81D2O8H7U	9909368|65243	408.3992|424.4	GINKGOLIDE A|ginkgolide B	ginkgolide A|ginkgolide   B	C[C@@H]1C(=O)O[C@H]2C[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]36[C@@H](O)C(=O)O[C@H]6O[C@@]4(C(=O)O5)[C@@]12O|CC1C(=O)OC2C1(C34C(=O)OC5C3(C2O)C6(C(C5)C(C)(C)C)C(C(=O)OC6O4)O)O	TAZ2DPR77B			?	ng × h/mL	29.38		ng/mL	11.16			UNKNOWN	μg	1974.96		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20041430	Homo sapiens		h	2.52	One Ginkgo fresh plant extract tablet contained 493.74 μg bilobalide,  220.38 μg ginkgolide A and 131.14 μg ginkgolide   B; single oral dose of 4 Ginkgo fresh plant extract tablets			8	BILOBALIDE		true
9612	23295		ADULT	2405	325.443	BISOPROLOL	BISOPROLOL	CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1	PLASMA	Y41JS2NL6U							24		t	μg × h/L	661		μg/L	52			UNKNOWN	mg	10		STEADY-STATE	UNKNOWN		day	1		70	HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2887325/	Homo sapiens		h	10							false
9613	23295		ADULT	2405	325.443	BISOPROLOL	BISOPROLOL	CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1	PLASMA	Y41JS2NL6U									?	ng × h/mL	609.8		ng/mL	40.37			UNKNOWN	mg	10		SINGLE	FASTED					70	HEALTHY	Oral	MALE	DRUG LABEL	https://www.sandoz.ca/sites/www.sandoz.ca/files/Bisoprolol_TAB_Monograph.pdf	Homo sapiens		h	11.07							false
9614	23835			7184	194.2271	BUTYLPARABEN	Butylparaben	CCCCOC(=O)C1=CC=C(O)C=C1	PLASMA	3QPI1U3FV8																										Plasma protein binding: 96.29% (untrafiltration)	3.71				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33188879/	Homo sapiens										false
9615	24001		ADULT	7965	99.1741	CYCLOHEXYLAMINE	cyclohexylamine	NC1CCCCC1	PLASMA	I6GH4W7AEG							8		t	ng × h/mL	1912		ng/mL	400			UNKNOWN	g	2.2		STEADY-STATE	UNKNOWN		day	3			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1379387/	Homo sapiens		h	4							false
9616	24093		UNKNOWN	338|118212070	138.1207	SALICYLIC ACID	salicylic acid	OC(=O)C1=C(O)C=CC=C1	SERUM	O414PZ4LPZ																						UNKNOWN				HSA (0.58 mcmol/mL), salicylic acid (0.65 to 0.86 mcmol/mL), equilibrium dialysis, 5 deg C, HSA binding - 83 to 91%	9	UNKNOWN		UNKNOWN	EXPERIMENT	https://pdfs.semanticscholar.org/6ff0/f6e7debaa3ce547a6f35b57d8a2c368b0357.pdf	Homo sapiens										false
9617	24093		ADULT	338|118212070	138.1207	SALICYLIC ACID	salicylic acid	OC(=O)C1=C(O)C=CC=C1	PLASMA	O414PZ4LPZ									∞	μg × h/L	4225		μg/L	525			RECOMMENDED	%	2		STEADY-STATE	FASTED		day	1			HEALTHY	Topical	FEMALE	EXPERIMENT	https://www.sciencedirect.com/science/article/pii/S0022354915503596	Homo sapiens		h	7.62							false
9618	24093		ADULT	338|118212070	138.1207	SALICYLIC ACID	salicylic acid	OC(=O)C1=C(O)C=CC=C1	PLASMA	O414PZ4LPZ									∞	μg × h/L	22010		μg/L	5282			RECOMMENDED	mg	81		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE	EXPERIMENT	https://www.sciencedirect.com/science/article/pii/S0022354915503596	Homo sapiens		h	2.62							false
9619	24093		ADULT	338|118212070	138.1207	SALICYLIC ACID	salicylic acid	OC(=O)C1=C(O)C=CC=C1	PLASMA	O414PZ4LPZ									∞	μg × h/mL	6.3944		μg/mL	0.814			RECOMMENDED	%	30		SINGLE	FASTED						HEALTHY	Topical	FEMALE / MALE	EXPERIMENT	https://www.sciencedirect.com/science/article/pii/S0022354916325199	Homo sapiens		h	3.82							false
9620	24093		ADULT	338|118212070	138.1207	SALICYLIC ACID	salicylic acid	OC(=O)C1=C(O)C=CC=C1	PLASMA	O414PZ4LPZ									∞	μg × h/mL	319.9		μg/mL	56.4			RECOMMENDED	mg	650		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.sciencedirect.com/science/article/pii/S0022354916325199	Homo sapiens		h	2.23							false
9621	24149		ADULT	2537	152.2334	[NO STEREO] CAMPHOR, (-)-|[NO STEREO] CAMPHOR (SYNTHETIC)|[NO STEREO] CAMPHOR (NATURAL)	CAMPHOR	CC1(C)C2CCC1(C)C(=O)C2	PLASMA	[NO STEREO] 213N3S8275|[NO STEREO] 5TJD82A1ET|[NO STEREO] N20HL7Q941	1254		MENTHOL, UNSPECIFIED FORM	menthol	CC(C)C1CCC(C)CC1O	L7T10EIP3A	12		t	ng × h/mL	302		ng/mL	41			UNKNOWN	mg	374.4		SINGLE	UNKNOWN						HEALTHY	Topical	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15342616/	Homo sapiens		h	6.5							true
9622	24251		ADULT	44093|12851888	217.285	CAPTOPRIL	CAPTOPRIL	C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O	PLASMA	9G64RSX1XD																	UNKNOWN	mg	5		SINGLE	UNKNOWN				At 0.5 and 2.0 hr after dosing, an average of 23.0% and 30.6% in plasma, respectively, was bound to proteins	69.4	HEALTHY	Oral	MALE	EXPERIMENT	https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt1978231107	Homo sapiens										false
9623	24251		ADULT	44093|12851888	217.285	CAPTOPRIL	CAPTOPRIL	C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O	BLOOD	9G64RSX1XD									?	μg × h/L	1235		μg/L	878			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/3292102/	Homo sapiens										false
9624	24251		ADULT	44093|12851888	217.285	CAPTOPRIL	CAPTOPRIL	C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O	BLOOD	9G64RSX1XD									?	μg × h/L	1197		μg/L	824			UNKNOWN	mg	100		MULTIPLE	UNKNOWN		day	3			HEALTHY	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/3292102/	Homo sapiens										false
9625	24251		ADULT	44093|12851888	217.285	CAPTOPRIL	captopril	C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O	BLOOD	9G64RSX1XD									∞	μg × h/L/(mg dose)	20.1						UNKNOWN	mg	2.5		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/3292102/	Homo sapiens										false
9626	24251		ADULT	44093|12851888	217.285	CAPTOPRIL	captopril	C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O	BLOOD	9G64RSX1XD									∞	μg × h/L/(mg dose)	21						UNKNOWN	mg	5		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/3292102/	Homo sapiens		h	2.2							false
9627	24251		ADULT	44093|12851888	217.285	CAPTOPRIL	captopril	C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O	BLOOD	9G64RSX1XD									∞	μg × h/L/(mg dose)	20.5						UNKNOWN	mg	10		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/3292102/	Homo sapiens		h	2.1							false
9628	24251		ADULT	44093|12851888	217.285	CAPTOPRIL	CAPTOPRIL	C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O	PLASMA	9G64RSX1XD													μg/mL	1.31			UNKNOWN	mg/kg	1		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6324834/	Homo sapiens		h	0.66							false
9629	24251		ADULT	44093|12851888	217.285	CAPTOPRIL	captopril	C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O	BLOOD	9G64RSX1XD							48		t	ng × h/mL	1150		ng/mL	800			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6989546/	Homo sapiens										false
9630	24251		ADULT	10002934	432.555	CAPTOPRIL DISULFIDE	CAPTOPRIL DISULFIDE	C[C@H](CSSC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O)C(=O)N2CCC[C@H]2C(O)=O	BLOOD	Y21D2C2453							48		t	ng × h/mL	260		ng/mL	230			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6989546/	Homo sapiens										false
9631	24461		ADULT	5362065	453.45	CEFIXIME ANHYDROUS	CEFIXIME ANHYDROUS	NC1=NC(=CS1)C(=N\\OCC(O)=O)\\C(=O)N[C@H]2[C@H]3SCC(C=C)=C(N3C2=O)C(O)=O	SERUM	XZ7BG04GJX									?	mg × h/L	34.9		mg/L	4.74			DEFINED DAILY	mg	400		STEADY-STATE	UNKNOWN		day	1	Serum protein binding is concentration independent with a bound fraction of approximately 65%.	35	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202091s005,203195s006lbl.pdf	Homo sapiens		h	3.5							false
9632	24466		ADULT	5742673	455.465	CEFOTAXIME	CEFOTAXIME	CO\\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(C)=O)=C(N2C1=O)C(O)=O)C3=CSC(N)=N3	PLASMA	N2GI8B1GK7									?	μg × h/mL	104		μg/mL	40.8			UNKNOWN	g	0.5		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6275776/	Homo sapiens		h	0.72							false
9633	24470		ADULT	6536864|73415797|131673973	636.652	CEFTAZIDIME	ceftazidime	[H+].O.O.O.O.O.CC(C)(O\\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[N+]3=CC=CC=C3)=C(N2C1=O)C([O-])=O)C4=CSC(N)=N4)C([O-])=O	SERUM	9M416Z9QNR									?	μg × h/mL	285						DEFINED DAILY	mg/kg	25		MULTIPLE	UNKNOWN		day	3			HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2088186	Homo sapiens		min	9.6							false
9634	24470		ADULT	6536864|73415797|131673973	636.652	CEFTAZIDIME	CEFTAZIDIME	[H+].O.O.O.O.O.CC(C)(O\\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[N+]3=CC=CC=C3)=C(N2C1=O)C([O-])=O)C4=CSC(N)=N4)C([O-])=O	SERUM	9M416Z9QNR									?	μg × h/mL	21.3						DEFINED DAILY	mg/kg	75	infusion, 24 hour	OTHER	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2088186	Homo sapiens										false
9635	24470		ADULT	6536864|73415797|131673973	636.652	CEFTAZIDIME	CEFTAZIDIME	[H+].O.O.O.O.O.CC(C)(O\\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[N+]3=CC=CC=C3)=C(N2C1=O)C([O-])=O)C4=CSC(N)=N4)C([O-])=O	UNKNOWN	9M416Z9QNR									?	μg × h/mL	18						DEFINED DAILY	mg/kg	75	infusion, 24 hour	OTHER	UNKNOWN		day	1			HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2088186	Homo sapiens										false
9636	24472		ADULT	5479530	554.58	CEFTRIAXONE	CEFTRIAXONE	CO\\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC3=NC(=O)C(=O)NN3C)=C(N2C1=O)C(O)=O)C4=CSC(N)=N4	PLASMA	75J73V1629							24		t	μg × h/mL	478		μg/mL	82			RECOMMENDED	g	0.5		SINGLE	UNKNOWN				Ceftriaxone is reversibly bound to human plasma proteins, and the binding decreased from a value of 95% bound at plasma concentrations of <25 µg/mL to a value of 85% bound at 300 µg/mL	5	HEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/050585s068lbl.pdf	Homo sapiens		h	8.7							false
9637	24729		ADULT	8259	149.404	2,2,2-TRICHLOROETHANOL	trichloroethanol	OCC(Cl)(Cl)Cl	PLASMA	AW835AJ62N													ng/mL	6131			RECOMMENDED	mg	500		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9522024/	Homo sapiens		h	9.75							false
9638	24729		ADULT	8259	149.404	2,2,2-TRICHLOROETHANOL	trichloroethanol	OCC(Cl)(Cl)Cl	PLASMA	AW835AJ62N													ng/mL	2993			RECOMMENDED	mg	250		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9522024/	Homo sapiens		h	9.75							false
9639	24729		ADULT	6421|23223116	163.387	TRICHLOROACETIC ACID	Trichloroacetic acid	OC(=O)C(Cl)(Cl)Cl	PLASMA	5V2JDO056X																	RECOMMENDED	mg	500		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9522024/	Homo sapiens		h	91.5							false
9640	24751		ADULT	3084599	450.143	CHLORAZEPAM	CHLORAZEPAM	OC(O)C(Cl)(Cl)Cl.CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C3=CC=CC=C3	PLASMA	R14J9HX8JT							48		t	ng × h/mL	242		ng/mL	10.4			UNKNOWN	mg	2		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4828698/	Homo sapiens		h	26.4							false
9641	24835		ADULT	1794427	354.3087	CHLOROGENIC ACID	CHLOROGENIC ACID	O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\\C=C\\C2=CC=C(O)C(O)=C2)[C@@H]1O)C(O)=O	PLASMA	318ADP12RI	155900002	515.703	TAUROCHOLIC ACID	taurocholic acid	C[C@H](CCC(=O)NCCS(O)(=O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C	5E090O0G3Z	6		t	ng × h/mL	1.782		ng/mL	0.6637			UNKNOWN	mg	3.64		STEADY-STATE	FASTED		day	3			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27114321	Homo sapiens		h	1.4	2.4g SBTs (equivalent to 3.64 mg CGA and 18.48 mg TCA). Note that reported AUC units (ng*h/L) are most likely incorrect and should read ng*h/mL			12	CHLOROGENIC ACID		true
9642	24835		ADULT	1794427	354.3087	CHLOROGENIC ACID	CHLOROGENIC ACID	O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\\C=C\\C2=CC=C(O)C(O)=C2)[C@@H]1O)C(O)=O	PLASMA	318ADP12RI	155900002	515.703	TAUROCHOLIC ACID	taurocholic acid	C[C@H](CCC(=O)NCCS(O)(=O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C	5E090O0G3Z	6		t	ng × h/mL	1.135		ng/mL	0.7638			UNKNOWN	mg	3.64		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27114321	Homo sapiens		h	1.3	2.4g SBTs (equivalent to 3.64 mg CGA and 18.48 mg TCA). . Note that reported AUC units (ng*h/L) are most likely incorrect and should read ng*h/mL			12	CHLOROGENIC ACID		true
9643	24835		ADULT	1794427	354.3087	CHLOROGENIC ACID	CHLOROGENIC ACID	O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\\C=C\\C2=CC=C(O)C(O)=C2)[C@@H]1O)C(O)=O	PLASMA	318ADP12RI									∞	ng × h/mL	6124		ng/mL	2376			UNKNOWN	mg/kg	3		SINGLE	UNKNOWN						UNHEALTHY	Intramuscular	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31541942	Homo sapiens		h	1				3	CHLOROGENIC ACID		false
9644	24835		ADULT	1794427	354.3087	CHLOROGENIC ACID	CHLOROGENIC ACID	O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\\C=C\\C2=CC=C(O)C(O)=C2)[C@@H]1O)C(O)=O	PLASMA	318ADP12RI									∞	ng × h/mL	7199		ng/mL	2914			UNKNOWN	mg/kg	3		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intramuscular	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31541942	Homo sapiens		h	1.2				3	CHLOROGENIC ACID		false
9645	25061		ADULT	148198	371.864	CHS-828	CHS-828	ClC1=CC=C(OCCCCCCNC(NC2=CC=NC=C2)=NC#N)C=C1	PLASMA	8LAP87DNSZ									∞	ng × h/mL	54529		ng/mL	3999			MAX TOLERATED	mg	500		MULTIPLE	FASTED		3 weeks	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15763645	Homo sapiens		h	7.9				3			false
9646	25061		ADULT	148198	371.864	CHS-828	CHS-828	ClC1=CC=C(OCCCCCCNC(NC2=CC=NC=C2)=NC#N)C=C1	PLASMA	8LAP87DNSZ									∞	ng × h/mL	16063		ng/mL	1723			RECOMMENDED	mg	420		MULTIPLE	FASTED		3 weeks	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15763645	Homo sapiens		h	6.1	recommended dose for phase II studies			7			false
9647	25077		ADULT	198692|74764571	509.869	CI-966	CI-966	Cl.OC(=O)C1=CCCN(CCOC(C2=CC=C(C=C2)C(F)(F)F)C3=CC=C(C=C3)C(F)(F)F)C1	PLASMA	MGZ24EM59L									∞	μg × h/mL	4.66		μg/mL	0.28			UNKNOWN	mg	10		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://onlinelibrary.wiley.com/doi/10.1002/ddr.430210309	Homo sapiens		h	12.2				2	CI-966		false
9648	25077		ADULT	198692|74764571	509.869	CI-966	CI-966	Cl.OC(=O)C1=CCCN(CCOC(C2=CC=C(C=C2)C(F)(F)F)C3=CC=C(C=C3)C(F)(F)F)C1	PLASMA	MGZ24EM59L									∞	μg × h/mL	2.8		μg/mL	0.09			UNKNOWN	mg	5		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://onlinelibrary.wiley.com/doi/10.1002/ddr.430210309	Homo sapiens		h	20.2				2	CI-966		false
9649	25077		ADULT	198692|74764571	509.869	CI-966	CI-966	Cl.OC(=O)C1=CCCN(CCOC(C2=CC=C(C=C2)C(F)(F)F)C3=CC=C(C=C3)C(F)(F)F)C1	PLASMA	MGZ24EM59L									∞	μg × h/mL	13.6		μg/mL	0.5			UNKNOWN	mg	25		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://onlinelibrary.wiley.com/doi/10.1002/ddr.430210309	Homo sapiens		h	21.4				2	CI-966		false
9650	25077		ADULT	198692|74764571	509.869	CI-966	CI-966	Cl.OC(=O)C1=CCCN(CCOC(C2=CC=C(C=C2)C(F)(F)F)C3=CC=C(C=C3)C(F)(F)F)C1	PLASMA	MGZ24EM59L													μg/mL	1.2			HIGHEST STUDIED	mg	50		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE	EXPERIMENT	https://onlinelibrary.wiley.com/doi/10.1002/ddr.430210309	Homo sapiens		h	15.7				2	CI-966		false
9651	25132		ADULT	90454	294.3908	CINCHONINE	CINCHONINE	O[C@H]([C@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)C3=C4C=CC=CC4=NC=C3	SERUM	V43X79NZCD	31703		DOXORUBICIN	DOXORUBICIN	COC1=CC=CC2=C1C(=O)C3=C(C2=O)C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O)C(=O)CO	80168379AG			∞	μg × h/mL	22.1						UNKNOWN	mg/kg	15	infusion, 2 days	OTHER	UNKNOWN		4 weeks	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11187897	Homo sapiens		h	2.98							true
9652	25132		ADULT	90454	294.3908	CINCHONINE	CINCHONINE	O[C@H]([C@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)C3=C4C=CC=CC4=NC=C3	SERUM	V43X79NZCD	31703		DOXORUBICIN	DOXORUBICIN	COC1=CC=CC2=C1C(=O)C3=C(C2=O)C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O)C(=O)CO	80168379AG			∞	μg × h/mL	13.4						UNKNOWN	mg/kg	20	infusion, 2 days	OTHER	UNKNOWN		4 weeks	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11187897	Homo sapiens		h	1.41							true
9653	25132		ADULT	90454	294.3908	CINCHONINE	CINCHONINE	O[C@H]([C@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)C3=C4C=CC=CC4=NC=C3	SERUM	V43X79NZCD	31703		DOXORUBICIN	DOXORUBICIN	COC1=CC=CC2=C1C(=O)C3=C(C2=O)C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O)C(=O)CO	80168379AG			∞	μg × h/mL	29.3						UNKNOWN	mg/kg	25	infusion, 2 days	OTHER	UNKNOWN		4 weeks	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11187897	Homo sapiens		h	2.19							true
9654	25132		ADULT	90454	294.3908	CINCHONINE	CINCHONINE	O[C@H]([C@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)C3=C4C=CC=CC4=NC=C3	SERUM	V43X79NZCD	31703		DOXORUBICIN	DOXORUBICIN	COC1=CC=CC2=C1C(=O)C3=C(C2=O)C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O)C(=O)CO	80168379AG			∞	μg × h/mL	23.1						UNKNOWN	mg/kg	30	infusion, 2 days	OTHER	UNKNOWN		4 weeks	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11187897	Homo sapiens		h	1.65							true
9655	25132		ADULT	90454	294.3908	CINCHONINE	CINCHONINE	O[C@H]([C@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)C3=C4C=CC=CC4=NC=C3	SERUM	V43X79NZCD									∞	μg × h/mL	35.1						UNKNOWN	mg/kg	35	infusion, 2 days	OTHER	UNKNOWN		4 weeks	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11187897	Homo sapiens		h	3.51							false
9656	25132		ADULT	90454	294.3908	CINCHONINE	CINCHONINE	O[C@H]([C@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)C3=C4C=CC=CC4=NC=C3	PLASMA	V43X79NZCD	3034034		QUININE	QUININE	COC1=CC2=C(C=C1)N=CC=C2[C@@H](O)[C@@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C	A7V27PHC7A							ng/mL	420			UNKNOWN	mg	133		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1298088	Homo sapiens		h	3.8							true
9657	25132		ADULT	90454	294.3908	CINCHONINE	CINCHONINE	O[C@H]([C@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)C3=C4C=CC=CC4=NC=C3	PLASMA	V43X79NZCD	3034034		QUININE	QUININE	COC1=CC2=C(C=C1)N=CC=C2[C@@H](O)[C@@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C	A7V27PHC7A							ng/mL	2120			UNKNOWN	mg	200		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1298088	Homo sapiens										true
9658	25132		ADULT	90454	294.3908	CINCHONINE	CINCHONINE	O[C@H]([C@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)C3=C4C=CC=CC4=NC=C3	PLASMA	V43X79NZCD																	UNKNOWN	g	3		MULTIPLE	UNKNOWN		day	1	At a plasma drug concentration of 2 mgm per liter and a plasma albumin content of 4 grams per 100 ml, 60% of cinchonine is bound.	40	HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16695641	Homo sapiens										false
9659	25327		UNKNOWN	135398737	326.823	CLOZAPINE	CLOZAPINE	CN1CCN(CC1)C2=NC3=C(NC4=CC=CC=C24)C=CC(Cl)=C3	PLASMA	J60AR2IKIC													ng/mL	319			DEFINED DAILY	mg	100		STEADY-STATE	UNKNOWN		day	2	Clozapine is approximately 97% bound to serum proteins.	3	UNKNOWN	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019758s073lbl.pdf	Homo sapiens		h	12							false
9660	25327		ADULT	135398737	326.823	CLOZAPINE	CLOZAPINE	CN1CCN(CC1)C2=NC3=C(NC4=CC=CC=C24)C=CC(Cl)=C3	PLASMA	J60AR2IKIC									∞	nM × h	1348		nM	98			RECOMMENDED	mg	12.5		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/10606838	Homo sapiens		h	18.6							false
9661	25531		ADULT	101301	369.4541	CORYDALINE	CORYDALINE	COC1=CC2=C(C=C1OC)[C@H]3[C@@H](C)C4=C(CN3CC2)C(OC)=C(OC)C=C4	PLASMA	08N392L8VX							8		t	μg × min/mL	276		ng/mL	2370			UNKNOWN	mg/kg	4.5		SINGLE	FASTED				The plasma protein binding value of corydaline in female rats was\n95.7% (free fraction of 4.34%)	4.34	HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24216274	Homo sapiens		min	324				8	CORYDALINE		false
9662	25624		UNKNOWN	57389999	365.813	CPI-0610	CC1=NOC2=C1C3=CC=CC=C3C(=N[C@H]2CC(N)=O)C4=CC=C(Cl)C=C4	CC1=NOC2=C1C3=CC=CC=C3C(=N[C@H]2CC(N)=O)C4=CC=C(Cl)C=C4	PLASMA	U4017GUQ06																	INVESTIGATIONAL	mg	230		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://ashpublications.org/blood/article/126/23/1491/134890/BET-Inhibitor-CPI-0610-Is-Well-Tolerated-and	Homo sapiens		h	10.7							false
9663	25624		ADULT	57389999	365.8	CPI-0610	CPI-0610		PLASMA	U4017GUQ06							24		t	μM × h	49		μM	5.9			UNKNOWN	mg	300		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26815195	Homo sapiens		h	23	14 days				CPI-0610		false
9664	25624		UNKNOWN	57389999	365.813	CPI-0610	CC1=NOC2=C1C3=CC=CC=C3C(=N[C@H]2CC(N)=O)C4=CC=C(Cl)C=C4	CC1=NOC2=C1C3=CC=CC=C3C(=N[C@H]2CC(N)=O)C4=CC=C(Cl)C=C4	PLASMA	U4017GUQ06							24		t	μM × h	49		μM	5.9			INVESTIGATIONAL	mg	300		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26815195	Homo sapiens		h	23							false
9665	25673		ADULT	16744283	513.246	CRS-3123	CRS3123	BrC1=CC(Br)=C2OCC[C@@H](NCCCNC3=CC(=O)C4=C(N3)C=CS4)C2=C1	PLASMA	2P987FW4E8							12		t	ng × h/mL	3560		ng/mL	654			UNKNOWN	mg	600		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31685472	Homo sapiens		h	5				8	CRS3123		false
9666	25673		ADULT	16744283	513.246	CRS-3123	CRS3123	BrC1=CC(Br)=C2OCC[C@@H](NCCCNC3=CC(=O)C4=C(N3)C=CS4)C2=C1	PLASMA	2P987FW4E8							12		t	ng × h/mL	2340		ng/mL	507			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31685472	Homo sapiens		h	3.6				8	CRS3123		false
9667	25673		ADULT	16744283	513.246	CRS-3123	CRS3123	BrC1=CC(Br)=C2OCC[C@@H](NCCCNC3=CC(=O)C4=C(N3)C=CS4)C2=C1	PLASMA	2P987FW4E8							12		t	ng × h/mL	1550		ng/mL	352			UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31685472	Homo sapiens		h	3				8	CRS3123		false
9668	25673		ADULT	16744283	513.246	CRS-3123	CRS3123	BrC1=CC(Br)=C2OCC[C@@H](NCCCNC3=CC(=O)C4=C(N3)C=CS4)C2=C1	PLASMA	2P987FW4E8									?	ng × h/mL	2500		ng/mL	470			UNKNOWN	mg	200		STEADY-STATE	FASTED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31685472	Homo sapiens		h	4.6				8	CRS3123		false
9669	25673		ADULT	16744283	513.246	CRS-3123	CRS3123	BrC1=CC(Br)=C2OCC[C@@H](NCCCNC3=CC(=O)C4=C(N3)C=CS4)C2=C1	PLASMA	2P987FW4E8							12		t	ng × h/mL	4030		ng/mL	731			UNKNOWN	mg	600		STEADY-STATE	FASTED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31685472	Homo sapiens		h	6.1				8	CRS3123		false
9670	25673		ADULT	16744283	513.246	CRS-3123	CRS3123	BrC1=CC(Br)=C2OCC[C@@H](NCCCNC3=CC(=O)C4=C(N3)C=CS4)C2=C1	PLASMA	2P987FW4E8									?	ng × h/mL	3200		ng/mL	615			UNKNOWN	mg	400		STEADY-STATE	FASTED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31685472	Homo sapiens		h	5				8	CRS3123		false
9671	25718		ADULT	24756910	434.4876	CUDC-101	CUDC-101	COC1=C(OCCCCCCC(=O)NO)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1	PLASMA	1A7Y9MP123									∞	mg × h/L	10.6		mg/L	8.83			UNKNOWN	mg	300		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25107918	Homo sapiens		h	6.3				4	CUDC-101		false
9672	25718		ADULT	24756910	434.4876	CUDC-101	CUDC-101	COC1=C(OCCCCCCC(=O)NO)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1	PLASMA	1A7Y9MP123									∞	mg × h/L	9.99		mg/L	9.23			MAX TOLERATED	mg	275		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25107918	Homo sapiens		h	4.4				6	CUDC-101		false
9673	25719		ADULT	44156921	442.5776	CUDC-305		CN(C)c1cc2OCOc2cc1Sc3nc4c(N)nccc4n3CCNCC(C)(C)C	PLASMA	0V278OKN9G									∞	ng × h/mL	28.1		ng/mL	4.96			UNKNOWN	mg	50		MULTIPLE	FASTED		2 days	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25646368/	Homo sapiens		h	3.26				3			false
9674	25719		ADULT	44156921	442.5776	CUDC-305		CN(C)c1cc2OCOc2cc1Sc3nc4c(N)nccc4n3CCNCC(C)(C)C	PLASMA	0V278OKN9G									∞	ng × h/mL	81.7		ng/mL	27.12			UNKNOWN	mg	100		MULTIPLE	FASTED		2 days	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25646368/	Homo sapiens		h	4.56				3			false
9675	25719		ADULT	44156921	442.5776	CUDC-305		CN(C)c1cc2OCOc2cc1Sc3nc4c(N)nccc4n3CCNCC(C)(C)C	PLASMA	0V278OKN9G									∞	ng × h/mL	137.4		ng/mL	26.14			UNKNOWN	mg	200		MULTIPLE	FASTED		2 days	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25646368/	Homo sapiens		h	8.9				2			false
9676	25719		ADULT	44156921	442.5776	CUDC-305		CN(C)c1cc2OCOc2cc1Sc3nc4c(N)nccc4n3CCNCC(C)(C)C	PLASMA	0V278OKN9G									∞	ng × h/mL	466.4		ng/mL	62.45			UNKNOWN	mg	400		MULTIPLE	FASTED		2 days	1			UNHEALTHY	Oral		EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25646368/	Homo sapiens		h	15.6				4			false
9677	25719		ADULT	44156921	442.5776	CUDC-305		CN(C)c1cc2OCOc2cc1Sc3nc4c(N)nccc4n3CCNCC(C)(C)C	PLASMA	0V278OKN9G									∞	ng × h/mL	609.4		ng/mL	93.37			UNKNOWN	mg	800		MULTIPLE	FASTED		2 days	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25646368/	Homo sapiens		h	13.6				3			false
9678	25719		ADULT	44156921	442.5776	CUDC-305		CN(C)c1cc2OCOc2cc1Sc3nc4c(N)nccc4n3CCNCC(C)(C)C	PLASMA	0V278OKN9G									∞	ng × h/mL	1137		ng/mL	130.7			MAX TOLERATED	mg	1600		MULTIPLE	FASTED		2 days	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25646368/	Homo sapiens		h	11.5				5			false
9679	25719		ADULT	44156921	442.5776	CUDC-305		CN(C)c1cc2OCOc2cc1Sc3nc4c(N)nccc4n3CCNCC(C)(C)C	PLASMA	0V278OKN9G									∞	ng × h/mL	711.3		ng/mL	82.7			UNKNOWN	mg	800		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25646368/	Homo sapiens		h	9.6				3			false
9680	25719		ADULT	44156921	442.5776	CUDC-305		CN(C)c1cc2OCOc2cc1Sc3nc4c(N)nccc4n3CCNCC(C)(C)C	PLASMA	0V278OKN9G									∞	ng × h/mL	44.03		ng/mL	3.85			UNKNOWN	mg	50		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25646368/	Homo sapiens		h	3.95				3			false
9681	25719		ADULT	44156921	442.5776	CUDC-305		CN(C)c1cc2OCOc2cc1Sc3nc4c(N)nccc4n3CCNCC(C)(C)C	PLASMA	0V278OKN9G									∞	ng × h/mL	27.88		ng/mL	9.93			UNKNOWN	mg	100		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25646368/	Homo sapiens		h	2.4				3			false
9682	25719		ADULT	44156921	442.5776	CUDC-305		CN(C)c1cc2OCOc2cc1Sc3nc4c(N)nccc4n3CCNCC(C)(C)C	PLASMA	0V278OKN9G									∞	ng × h/mL	62.62		ng/mL	18.3			UNKNOWN	mg	200		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25646368/	Homo sapiens		h	6.26				4			false
9683	25719		ADULT	44156921	442.5776	CUDC-305		CN(C)c1cc2OCOc2cc1Sc3nc4c(N)nccc4n3CCNCC(C)(C)C	PLASMA	0V278OKN9G									∞	ng × h/mL	765.7		ng/mL	105.4			RECOMMENDED	mg	1000		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25646368/	Homo sapiens		h	9.83	Day 1			39			false
9684	25719		ADULT	44156921	442.5776	CUDC-305		CN(C)c1cc2OCOc2cc1Sc3nc4c(N)nccc4n3CCNCC(C)(C)C	PLASMA	0V278OKN9G									∞	ng × h/mL	362.4		ng/mL	81.35			UNKNOWN	mg	400		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25646368/	Homo sapiens		h	8.38				3			false
9685	25719		ADULT	44156921	442.5776	CUDC-305		CN(C)c1cc2OCOc2cc1Sc3nc4c(N)nccc4n3CCNCC(C)(C)C	PLASMA	0V278OKN9G									∞	ng × h/mL	1181		ng/mL	178.4			RECOMMENDED	mg	1000		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25646368/	Homo sapiens		h	9.05	Day 29			21			false
9686	25719		ADULT	44156921	442.5776	CUDC-305		CN(C)c1cc2OCOc2cc1Sc3nc4c(N)nccc4n3CCNCC(C)(C)C	PLASMA	0V278OKN9G									∞	ng × h/mL	1012		ng/mL	122			MAX TOLERATED	mg	1600		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25646368/	Homo sapiens		h	7.43				3			false
9687	25720		ADULT	54575456	508.553	CUDC-907	COC1=CC=C(C=N1)C2=NC3=C(SC(CN(C)C4=NC=C(C=N4)C(=O)NO)=C3)C(=N2)N5CCOCC5	COC1=CC=C(C=N1)C2=NC3=C(SC(CN(C)C4=NC=C(C=N4)C(=O)NO)=C3)C(=N2)N5CCOCC5	PLASMA	3S9RX35S5X							24		t	ng × h/mL	24.5		ng/mL	9.19			RECOMMENDED	mg	60		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/28860342	Homo sapiens		h	3.89							false
9688	25845		ADULT	25257557	513.614	CX-5461	CX-5461	CN1CCCN(CC1)C2=NC3=C(C=C2)C(=O)C(C(=O)NCC4=CN=C(C)C=N4)=C5SC6=C(C=CC=C6)N35	PLASMA	3R4C5YLB9I									∞	ng × h/mL	17943		ng/mL	1707			MAX TOLERATED	mg/m²	170		MULTIPLE	UNKNOWN		3 weeks	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31092402	Homo sapiens		h	45.5				3	CX-5461		false
9689	25845		ADULT	25257557	513.614	CX-5461	CX-5461	CN1CCCN(CC1)C2=NC3=C(C=C2)C(=O)C(C(=O)NCC4=CN=C(C)C=N4)=C5SC6=C(C=CC=C6)N35	PLASMA	3R4C5YLB9I									∞	ng × h/mL	28612		ng/mL	1358			UNKNOWN	mg/m²	250		MULTIPLE	UNKNOWN		3 weeks	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31092402	Homo sapiens		h	83.3				2	CX-5461		false
9690	26044		ADULT	260439	402.6562	CYCLOVIROBUXINE D	CYCLOVIROBUXINE D	CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](NC)C4(C)C	PLASMA	51GY352868									∞	ng × h/mL	47.22		ng/mL	6.1			UNKNOWN	mg	2		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16765010	Homo sapiens		h	27.51				16	CYCLOVIROBUXINE D		false
9691	26558		UNKNOWN	71532123	442.3956	DCFPYL	DCFPYL	OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)C1=CC=C(F)N=C1)C(O)=O)C(O)=O	PLASMA	82VH67YON8																	UNKNOWN	MBq	333		SINGLE	UNKNOWN						UNKNOWN	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214793s000lbl.pdf#page=7	Homo sapiens		h	3.47	Piflufolastat F-18						false
9692	26583		ADULT	66555680	356.3806	DEBIO-1347	Debio-1347	CC1=NC2=C(N1)C=C(C=C2)N3N=CC(C(=O)C4=CC5=C(N4)C=CC=C5)=C3N	PLASMA	NR9ZYH80Z8									?	ng × h/mL	44185		ng/mL	2729			HIGHEST STUDIED	mg	150		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30745300/	Homo sapiens				tablet			3	Debio 1347		false
9693	26583		ADULT	66555680	356.3806	DEBIO-1347	Debio-1347	CC1=NC2=C(N1)C=C(C=C2)N3N=CC(C(=O)C4=CC5=C(N4)C=CC=C5)=C3N	PLASMA	NR9ZYH80Z8									?	ng × h/mL	973		ng/mL	114			UNKNOWN	mg	10		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30745300/	Homo sapiens				capsule			2	Debio 1347		false
9694	26583		ADULT	66555680	356.3806	DEBIO-1347	Debio-1347	CC1=NC2=C(N1)C=C(C=C2)N3N=CC(C(=O)C4=CC5=C(N4)C=CC=C5)=C3N	PLASMA	NR9ZYH80Z8									?	ng × h/mL	3551		ng/mL	425			UNKNOWN	mg	30		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30745300/	Homo sapiens				capsule			4	Debio 1347		false
9695	26583		ADULT	66555680	356.3806	DEBIO-1347	Debio-1347	CC1=NC2=C(N1)C=C(C=C2)N3N=CC(C(=O)C4=CC5=C(N4)C=CC=C5)=C3N	PLASMA	NR9ZYH80Z8									?	ng × h/mL	14744		ng/mL	1125			UNKNOWN	mg	60		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30745300/	Homo sapiens				tablet			6	Debio 1347		false
9696	26583		ADULT	66555680	356.3806	DEBIO-1347	Debio-1347	CC1=NC2=C(N1)C=C(C=C2)N3N=CC(C(=O)C4=CC5=C(N4)C=CC=C5)=C3N	PLASMA	NR9ZYH80Z8									?				ng/mL	1373			UNKNOWN	mg	110		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30745300/	Homo sapiens				tablet			2	Debio 1347		false
9697	26583		ADULT	66555680	356.3806	DEBIO-1347	Debio-1347	CC1=NC2=C(N1)C=C(C=C2)N3N=CC(C(=O)C4=CC5=C(N4)C=CC=C5)=C3N	PLASMA	NR9ZYH80Z8									?	ng × h/mL	4700		ng/mL	469			UNKNOWN	mg	40		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30745300/	Homo sapiens				capsule			4	Debio 1347		false
9698	26583		ADULT	66555680	356.3806	DEBIO-1347	Debio-1347	CC1=NC2=C(N1)C=C(C=C2)N3N=CC(C(=O)C4=CC5=C(N4)C=CC=C5)=C3N	PLASMA	NR9ZYH80Z8									?	ng × h/mL	41994		ng/mL	2486			UNKNOWN	mg	80		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30745300/	Homo sapiens				tablet			6	Debio 1347		false
9699	26583		ADULT	66555680	356.3806	DEBIO-1347	Debio-1347	CC1=NC2=C(N1)C=C(C=C2)N3N=CC(C(=O)C4=CC5=C(N4)C=CC=C5)=C3N	PLASMA	NR9ZYH80Z8									?	ng × h/mL	9567		ng/mL	881			UNKNOWN	mg	40		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30745300/	Homo sapiens				tablet			4	Debio 1347		false
9700	26583		ADULT	66555680	356.3806	DEBIO-1347	Debio-1347	CC1=NC2=C(N1)C=C(C=C2)N3N=CC(C(=O)C4=CC5=C(N4)C=CC=C5)=C3N	PLASMA	NR9ZYH80Z8									t	ng × h/mL	3910		ng/mL	291			UNKNOWN	mg	20		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30745300/	Homo sapiens				capsule			5	Debio 1347		false
9701	26730		ADULT	40585	505.199	DELTAMETHRIN	Deltamethrin	CC1(C)[C@@H](C=C(Br)Br)[C@H]1C(=O)O[C@H](C#N)C2=CC(OC3=CC=CC=C3)=CC=C2	PLASMA	2JTS8R821G																						UNKNOWN				Human plasma protein Fu=~10% (organic solvent extraction)	10	UNKNOWN		UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26571224/	Homo sapiens										false
9702	26781		ADULT	91272	387.5208	DEOXYSPERGUALIN	deoxyspergualin	NCCCNCCCCNC(=O)[C@H](O)NC(=O)CCCCCCNC(N)=N	PLASMA	57F9XM233R									?	μM × h	836						UNKNOWN	mg/m²	1140		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2039989/	Homo sapiens		min	24.1	mg/m2/day for 5 days by continuous i.v. infusion			3	deoxyspergualin		false
9703	26781		ADULT	91272	387.5208	DEOXYSPERGUALIN	deoxyspergualin	NCCCNCCCCNC(=O)[C@H](O)NC(=O)CCCCCCNC(N)=N	PLASMA	57F9XM233R									?	μM × h	247						UNKNOWN	mg/m²	560		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2039989/	Homo sapiens		min	16.7				3	deoxyspergualin		false
9704	26781		ADULT	91272	387.5208	DEOXYSPERGUALIN	deoxyspergualin	NCCCNCCCCNC(=O)[C@H](O)NC(=O)CCCCCCNC(N)=N	PLASMA	57F9XM233R									?	μM × h	114						UNKNOWN	mg/m²	264		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2039989/	Homo sapiens		min	5.6	mg/m2/day for 5 days by continuous i.v. infusion			2	deoxyspergualin		false
9705	26781		ADULT	91272	387.5208	DEOXYSPERGUALIN	deoxyspergualin	NCCCNCCCCNC(=O)[C@H](O)NC(=O)CCCCCCNC(N)=N	PLASMA	57F9XM233R									?	μM × h	1164		μM	11.1			HIGHEST STUDIED	mg/m²	2160		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2039989/	Homo sapiens		h	30.8	mg/m2/day for 5 days by continuous i.v. infusion			3	deoxyspergualin		false
9706	26781		UNKNOWN	91272	387.5208	DEOXYSPERGUALIN	deoxyspergualin	NCCCNCCCCNC(=O)[C@H](O)NC(=O)CCCCCCNC(N)=N	PLASMA	57F9XM233R									?	μM × h	260						UNKNOWN	mg/m²	400		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2039989/	Homo sapiens		min	37	mg/m2/day for 5 days by continuous i.v. infusion			1	deoxyspergualin		false
9707	26781		ADULT	91272	387.5208	DEOXYSPERGUALIN	deoxyspergualin	NCCCNCCCCNC(=O)[C@H](O)NC(=O)CCCCCCNC(N)=N	PLASMA	57F9XM233R									?	μM × h	72						UNKNOWN	mg/m²	160		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2039989/	Homo sapiens		min	7	mg/m2/day for 5 days by continuous i.v. infusion			3	deoxyspergualin		false
9708	26781		ADULT	91272	387.5208	DEOXYSPERGUALIN	deoxyspergualin	NCCCNCCCCNC(=O)[C@H](O)NC(=O)CCCCCCNC(N)=N	PLASMA	57F9XM233R									?	μM × h	280						UNKNOWN	mg/m²	720		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2039989/	Homo sapiens		min	10	mg/m2/day for 5 days by continuous i.v. infusion			4	deoxyspergualin		false
9709	26781		ADULT	91272	387.5208	DEOXYSPERGUALIN	deoxyspergualin	NCCCNCCCCNC(=O)[C@H](O)NC(=O)CCCCCCNC(N)=N	PLASMA	57F9XM233R									?	μM × h	32		μM	0.25			UNKNOWN	mg/m²	80		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2039989/	Homo sapiens		min	22	mg/m2/day for 5 days by continuous i.v. infusion			2	deoxyspergualin		false
9710	26781		ADULT	91272	387.5208	DEOXYSPERGUALIN	deoxyspergualin	NCCCNCCCCNC(=O)[C@H](O)NC(=O)CCCCCCNC(N)=N	PLASMA	57F9XM233R									?	μM × h	534						UNKNOWN	mg/m²	960		UNKNOWN	UNKNOWN		day	1			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2039989/	Homo sapiens		h	12.3	mg/m2/day for 5 days by continuous i.v. infusion			4	deoxyspergualin		false
9711	26949		ADULT	107778	386.5674	DEXANABINOL	Dexanabinol	CCCCCCC(C)(C)C1=CC2=C([C@H]3CC(CO)=CC[C@@H]3C(C)(C)O2)C(O)=C1	PLASMA	R6VT8U5372							4		t	ng × h/mL	881		ng/mL	387			UNKNOWN	mg/kg	4		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33615223	Homo sapiens		h	1.7				3	Dexanabinol		false
9712	26949		ADULT	107778	386.5674	DEXANABINOL	Dexanabinol	CCCCCCC(C)(C)C1=CC2=C([C@H]3CC(CO)=CC[C@@H]3C(C)(C)O2)C(O)=C1	PLASMA	R6VT8U5372							4		t	ng × h/mL	475		ng/mL	204			UNKNOWN	mg/kg	2		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33615223	Homo sapiens		h	2.2				3	Dexanabinol		false
9713	26949		ADULT	107778	386.5674	DEXANABINOL	Dexanabinol	CCCCCCC(C)(C)C1=CC2=C([C@H]3CC(CO)=CC[C@@H]3C(C)(C)O2)C(O)=C1	PLASMA	R6VT8U5372							4		t	ng × h/mL	5750		ng/mL	2885			UNKNOWN	mg/kg	16		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33615223	Homo sapiens		h	1.8				3	Dexanabinol		false
9714	26949		ADULT	107778	386.5674	DEXANABINOL	Dexanabinol	CCCCCCC(C)(C)C1=CC2=C([C@H]3CC(CO)=CC[C@@H]3C(C)(C)O2)C(O)=C1	PLASMA	R6VT8U5372							4		t	ng × h/mL	10800		ng/mL	4226			UNKNOWN	mg/kg	24		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33615223	Homo sapiens		h	3.4				3	Dexanabinol		false
9715	26949		ADULT	107778	386.5674	DEXANABINOL	Dexanabinol	CCCCCCC(C)(C)C1=CC2=C([C@H]3CC(CO)=CC[C@@H]3C(C)(C)O2)C(O)=C1	PLASMA	R6VT8U5372							4		t	ng × h/mL	1890		ng/mL	813			UNKNOWN	mg/kg	8		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33615223	Homo sapiens		h	2.3				3	Dexanabinol		false
9716	26949		ADULT	107778	386.5674	DEXANABINOL	Dexanabinol	CCCCCCC(C)(C)C1=CC2=C([C@H]3CC(CO)=CC[C@@H]3C(C)(C)O2)C(O)=C1	PLASMA	R6VT8U5372							4		t	ng × h/mL	15400		ng/mL	7018			RECOMMENDED	mg/kg	28		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33615223	Homo sapiens		h	1.7				3	Dexanabinol		false
9717	26949		ADULT	107778	386.5674	DEXANABINOL	Dexanabinol	CCCCCCC(C)(C)C1=CC2=C([C@H]3CC(CO)=CC[C@@H]3C(C)(C)O2)C(O)=C1	PLASMA	R6VT8U5372							4		t	ng × h/mL	38300		ng/mL	20139			HIGHEST STUDIED	mg/kg	36		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33615223	Homo sapiens		h	2				8	Dexanabinol		false
9718	27336		ADULT	3045	169.1348	DIDOX	DIDOX	ONC(=O)C1=CC=C(O)C(O)=C1	PLASMA	L106XFV0RQ									∞	μg × h/mL	8		μg/mL	1.7			UNKNOWN	mg/m²	265		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25698442	Homo sapiens		h	13.8				7	DIDOX		false
9719	27846			21855	292.418	DIMETHINDENE	Dimethindene	CC(C1=C(CCN(C)C)CC2=C1C=CC=C2)C3=CC=CC=N3	PLASMA	661FH77Z3P																										Human plasma protein binding (capillary electrophoresis): 83%	17				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17339039/	Homo sapiens										false
9720	28424		ADULT	2266|19347555	188.2209	AZELAIC ACID	Azelaic acid	OC(=O)CCCCCCCC(O)=O	PLASMA	F2VW3D43YT									?	ng × h/mL	613		ng/mL	112			UNKNOWN	g	1		SINGLE	UNKNOWN						HEALTHY	Topical	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020428Orig1s000rev.pdf	Homo sapiens		h	12							false
9721	28424		ADULT	2266|19347555	188.2209	AZELAIC ACID	azelaic acid	OC(=O)CCCCCCCC(O)=O	PLASMA	F2VW3D43YT									?	ng × h/mL	686		ng/mL	136			UNKNOWN	g	1		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Topical	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020428Orig1s000rev.pdf	Homo sapiens										false
9722	28748		ADULT	11680542	264.579	DOV-216303	DOV-216303	Cl.ClC1=C(Cl)C=C(C=C1)[C@@]23C[C@@H]2CNC3	PLASMA	06S4712H0T									∞	ng × h/mL	154		ng/mL	37.4			UNKNOWN	mg	5		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15545306/	Homo sapiens		h	3.4				7	DOV 216,303		false
9723	28748		ADULT	11680542	264.579	DOV-216303	DOV 216,303	Cl.ClC1=C(Cl)C=C(C=C1)[C@@]23C[C@@H]2CNC3	PLASMA	06S4712H0T									∞	ng × h/mL	3300		ng/mL	712			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15545306/	Homo sapiens		h	4				7	DOV 216,303		false
9724	28748		ADULT	11680542	264.579	DOV-216303	DOV 216,303	Cl.ClC1=C(Cl)C=C(C=C1)[C@@]23C[C@@H]2CNC3	PLASMA	06S4712H0T									∞	ng × h/mL	911		ng/mL	191			UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15545306/	Homo sapiens		h	3.6				7	DOV 216,303		false
9725	28748		ADULT	11680542	264.579	DOV-216303	DOV 216,303	Cl.ClC1=C(Cl)C=C(C=C1)[C@@]23C[C@@H]2CNC3	PLASMA	06S4712H0T							24		t	ng × h/mL	2200		ng/mL	214			UNKNOWN	mg	25		MULTIPLE	FASTED		day	3			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15545306/	Homo sapiens							7	DOV 216,303		false
9726	28748		ADULT	11680542	264.579	DOV-216303	DOV 216,303	Cl.ClC1=C(Cl)C=C(C=C1)[C@@]23C[C@@H]2CNC3	PLASMA	06S4712H0T									∞	ng × h/mL	5520		ng/mL	1220			HIGHEST STUDIED	mg	150		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15545306/	Homo sapiens		h	4.4				7	DOV 216,303		false
9727	28748		ADULT	11680542	264.579	DOV-216303	DOV 216,303	Cl.ClC1=C(Cl)C=C(C=C1)[C@@]23C[C@@H]2CNC3	PLASMA	06S4712H0T									∞	ng × h/mL	2460		ng/mL	493			UNKNOWN	mg	50		MULTIPLE	FASTED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15545306/	Homo sapiens							7	DOV 216,303		false
9728	28748		ADULT	11680542	264.579	DOV-216303	DOV 216,303	Cl.ClC1=C(Cl)C=C(C=C1)[C@@]23C[C@@H]2CNC3	PLASMA	06S4712H0T							24		t	ng × h/mL	902		ng/mL	162			UNKNOWN	mg	25		MULTIPLE	FASTED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15545306/	Homo sapiens							7	DOV 216,303		false
9729	28763		ADULT		462.4498	DOXYCYCLINE	DOXYCYCLINE	O.C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C2C(=O)C4=C1C=CC=C4O	PLASMA	N12000U13O							24		t	μg × h/mL	32		μg/mL	3.17			RECOMMENDED	mg	200		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/15793155	Homo sapiens		h	10.5							false
9730	28828		ADULT	25267262|135565981	317.3446	E-7449	E-7449	O=C1NN=C2NC(CN3CC4=C(C3)C=CC=C4)=NC5=C2C1=CC=C5	PLASMA	9X5A2QIA7C									∞	ng × h/mL	9660		ng/mL	2230			MAX TOLERATED	mg	600		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32523090	Homo sapiens		h	5.05				6	E-7449		false
9731	28828		ADULT	25267262|135565981	317.3446	E-7449	E-7449	O=C1NN=C2NC(CN3CC4=C(C3)C=CC=C4)=NC5=C2C1=CC=C5	PLASMA	9X5A2QIA7C							24		t	ng × h/mL	11300		ng/mL	4430			UNKNOWN	mg	800		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32523090	Homo sapiens		h	9.45				6	E-7449		false
9732	28828		ADULT	25267262|135565981	317.3446	E-7449	E-7449	O=C1NN=C2NC(CN3CC4=C(C3)C=CC=C4)=NC5=C2C1=CC=C5	PLASMA	9X5A2QIA7C									∞	ng × h/mL	3240		ng/mL	1130			UNKNOWN	mg	400		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32523090	Homo sapiens		h	4.16				3	E-7449		false
9733	28828		ADULT	25267262|135565981	317.3446	E-7449	E-7449	O=C1NN=C2NC(CN3CC4=C(C3)C=CC=C4)=NC5=C2C1=CC=C5	PLASMA	9X5A2QIA7C							24		t	ng × h/mL	7930		ng/mL	2250			UNKNOWN	mg	600		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32523090	Homo sapiens		h	7.17				8	E-7449		false
9734	28828		ADULT	25267262|135565981	317.3446	E-7449	E-7449	O=C1NN=C2NC(CN3CC4=C(C3)C=CC=C4)=NC5=C2C1=CC=C5	PLASMA	9X5A2QIA7C							24		t	ng × h/mL	4690		ng/mL	999			UNKNOWN	mg	400		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32523090	Homo sapiens		h	8.62				4	E-7449		false
9735	28828		ADULT	25267262|135565981	317.3446	E-7449	E-7449	O=C1NN=C2NC(CN3CC4=C(C3)C=CC=C4)=NC5=C2C1=CC=C5	PLASMA	9X5A2QIA7C									∞	ng × h/mL	12000		ng/mL	4120			UNKNOWN	mg	800		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32523090	Homo sapiens		h	6.44				5	E-7449		false
9736	28832		ADULT	16202132	718.96	E7107	E7107	CC[C@H](O)[C@@H](C)[C@H]1O[C@@H]1C[C@@](C)(O)\\C=C\\C=C(/C)[C@H]2OC(=O)C[C@H](O)CC[C@@](C)(O)[C@@H](OC(=O)N3CCN(CC3)C4CCCCCC4)\\C=C\\[C@@H]2C	PLASMA	R60DZX1E2N									∞	ng × h/mL	34.6		ng/mL	28.5			MAX TOLERATED	mg/m²	4		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23983259	Homo sapiens		h	8				17			false
9737	28832		ADULT	16202132	718.96	E7107	E7107	CC[C@H](O)[C@@H](C)[C@H]1O[C@@H]1C[C@@](C)(O)\\C=C\\C=C(/C)[C@H]2OC(=O)C[C@H](O)CC[C@@](C)(O)[C@@H](OC(=O)N3CCN(CC3)C4CCCCCC4)\\C=C\\[C@@H]2C	PLASMA	R60DZX1E2N									∞	ng × h/mL	37.1		ng/mL	260			MAX TOLERATED	mg/m²	4		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23983259	Homo sapiens		h	9.2				15			false
9738	28885		ADULT	3009	182.17	EFLORNITHINE	EFLORNITHINE	NCCCC(N)(C(F)F)C(O)=O	PLASMA	ZQN1G5V6SR									∞	μM × h	4430		μM	484			RECOMMENDED	mg/kg	100		STEADY-STATE	UNKNOWN		day	4			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/15141331	Homo sapiens		h	10.6							false
9739	28908			108059	370.4819	SEGESTERONE ACETATE	Elcometrine	CC(=O)O[C@]1(C(C)=O)C(=C)C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C	SERUM	9AMX4Q13CC																										up to 13 % non-protein bound in serum	13				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2272183/	Homo sapiens										false
9740	28908		ADULT	108059	370.4819	SEGESTERONE ACETATE	Elcometrine	CC(=O)O[C@]1(C(C)=O)C(=C)C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C	PLASMA	9AMX4Q13CC													pg/mL	875			UNKNOWN	mg	22		SINGLE	UNKNOWN						HEALTHY	Vaginal	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/6509989/	Homo sapiens		h	11.25	Vginal ring, 48-h treatment			2			false
9741	28908		ADULT	108059	370.4819	SEGESTERONE ACETATE	Elcometrine	CC(=O)O[C@]1(C(C)=O)C(=C)C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C	PLASMA	9AMX4Q13CC									?	nM × min	323						UNKNOWN	μg	100		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8131396/	Homo sapiens		min	158				4			false
9742	28908		ADULT	108059	370.4819	SEGESTERONE ACETATE	Elcometrine	CC(=O)O[C@]1(C(C)=O)C(=C)C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C	PLASMA	9AMX4Q13CC									?	nM × min	26		nM	0.423			UNKNOWN	μg	100		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8131396/	Homo sapiens		min	60				4			false
9743	28981		ADULT	10090750	373.4874	ENDOXIFEN	ENDOXIFEN	CC\\C(=C(/C1=CC=C(O)C=C1)C2=CC=C(OCCNC)C=C2)C3=CC=CC=C3	PLASMA	46AF8680RC									∞	ng × h/mL	801		ng/mL	15.1			UNKNOWN	mg	4		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20981001	Homo sapiens		h	52.1				8	Endoxifen citrate		false
9744	28981		ADULT	10090750	373.4874	ENDOXIFEN	ENDOXIFEN	CC\\C(=C(/C1=CC=C(O)C=C1)C2=CC=C(OCCNC)C=C2)C3=CC=CC=C3	PLASMA	46AF8680RC							24		t	μg × h/mL	37.9		ng/mL	1874			UNKNOWN	mg	160		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28854070	Homo sapiens				day 28			3	Z-endoxifen hydrochloride		false
9745	28981		ADULT	10090750	373.4874	ENDOXIFEN	ENDOXIFEN	CC\\C(=C(/C1=CC=C(O)C=C1)C2=CC=C(OCCNC)C=C2)C3=CC=CC=C3	PLASMA	46AF8680RC							24		t	μg × h/mL	9.81		ng/mL	635			UNKNOWN	mg	160		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28854070	Homo sapiens		h	54.6	day 1			3	Z-endoxifen hydrochloride		false
9746	28981		ADULT	3035980	373.4874	ENDOXIFEN, (E)-	CC\\C(=C(\\C1=CC=C(O)C=C1)C2=CC=C(OCCNC)C=C2)C3=CC=CC=C3	CC\\C(=C(\\C1=CC=C(O)C=C1)C2=CC=C(OCCNC)C=C2)C3=CC=CC=C3	PLASMA	HB2U71MNOT									∞	ng × h/mL	801		ng/mL	15.1			INVESTIGATIONAL	mg	4		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/20981001	Homo sapiens		h	52.1							false
9747	28981		ADULT	3035980	373.4874	ENDOXIFEN, (E)-	CC\\C(=C(\\C1=CC=C(O)C=C1)C2=CC=C(OCCNC)C=C2)C3=CC=CC=C3	CC\\C(=C(\\C1=CC=C(O)C=C1)C2=CC=C(OCCNC)C=C2)C3=CC=CC=C3	PLASMA	HB2U71MNOT							336		t	ng × h/mL	8.46						INVESTIGATIONAL	mg	4		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/27346789	Homo sapiens		h	52.05							false
9748	29027		ADULT	72276	290.2681	EPICATECHIN	EPICATECHIN	O[C@@H]1CC2=C(O[C@@H]1C3=CC=C(O)C(O)=C3)C=C(O)C=C2O	PLASMA	34PHS7TU43							6		t	μg × h/L	21.67		μg/L	5.5			UNKNOWN	mg	50		MULTIPLE	FASTED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25598082	Homo sapiens				day 1			8	EPICATECHIN		false
9749	29027		ADULT	72276	290.2681	EPICATECHIN	EPICATECHIN	O[C@@H]1CC2=C(O[C@@H]1C3=CC=C(O)C(O)=C3)C=C(O)C=C2O	PLASMA	34PHS7TU43							6		t	μg × h/L	10.3		μg/L	3.9			UNKNOWN	mg	50		MULTIPLE	FASTED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25598082	Homo sapiens				day 5			8	EPICATECHIN		false
9750	29027		ADULT	72276	290.2681	EPICATECHIN	EPICATECHIN	O[C@@H]1CC2=C(O[C@@H]1C3=CC=C(O)C(O)=C3)C=C(O)C=C2O	PLASMA	34PHS7TU43									∞	μg × h/L	122.4		μg/L	34.5			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25598082	Homo sapiens		h	2.5				3	EPICATECHIN		false
9751	29254		ADULT	107841	413.533	ETHACIZINE	ETHACIZINE	CCOC(=O)NC1=CC=C2SC3=C(C=CC=C3)N(C(=O)CCN(CC)CC)C2=C1	PLASMA	FE5SPV1Z6G									∞	ng × h/mL	571.6		ng/mL	63.7			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32146624/	Homo sapiens		h	6.7				9	ETHACIZINE		false
9752	29493		ADULT	445858	194.184	FERULIC ACID	FERULIC ACID	COC1=C(O)C=CC(\\C=C\\C(O)=O)=C1	PLASMA	AVM951ZWST									∞	nmol × h/mL	1.97		nmol/mL	2.47			DEFINED DAILY	mg	50		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17049197/	Homo sapiens		h	0.69	Reference capsules			20	SODIUM FERULATE		false
9753	29493		ADULT	445858	194.184	FERULIC ACID	FERULIC ACID	COC1=C(O)C=CC(\\C=C\\C(O)=O)=C1	PLASMA	AVM951ZWST									∞	nmol × h/mL	1.9		nmol/mL	2.45			DEFINED DAILY	mg	50		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17049197/	Homo sapiens		h	0.7	Test capsules			20	SODIUM FERULATE		false
9754	29496		ADULT	5358902	144.1253	ETHYL FUMARATE	Ethyl fumarate	CCOC(=O)\\C=C\\C(O)=O	PLASMA	Y3W849NG2N	5369209	130.0987	MONOMETHYL FUMARATE	Monomethyl fumarate	COC(=O)\\C=C\\C(O)=O	45IUB1PX8R			∞	μg × min/mL	63.6		μM	5.2			UNKNOWN	mg	190		SINGLE	FASTED						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20574745/	Homo sapiens		h	25.4		psoriasis patients	240mg	3			true
9755	29794		ADULT	667484	244.289	ETOMIDATE	ETOMIDATE	CCOC(=O)C1=CN=CN1[C@H](C)C2=CC=CC=C2	PLASMA	Z22628B598									?	ng × min/mL	3263		ng/mL	87			RECOMMENDED	mg	25		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9447861/	Homo sapiens		min	75							false
9756	29864		ADULT	3325|5353622|5702160	337.445	FAMOTIDINE	FAMOTIDINE	NC(=N)NC1=NC(CSCCC(=N)NS(N)(=O)=O)=CS1	PLASMA	5QZO15J2Z8							10		t	ng × h/mL	424		ng/mL	73			RECOMMENDED	mg	20		SINGLE	UNKNOWN				Fifteen to 20% of famotidine in plasma is protein bound.	82.5	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019462s039lbl.pdf	Homo sapiens		h	3							false
9757	30199		ADULT	46848036	562.5888	FLUMATINIB	Flumatinib	CN1CCN(CC2=C(C=C(C=C2)C(=O)NC3=CN=C(C)C(NC4=NC(=CC=N4)C5=CN=CC=C5)=C3)C(F)(F)F)CC1	PLASMA	R4009Y24AI									∞	ng × h/mL	847		ng/mL	50.7			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32757049/	Homo sapiens		h	13.3				11	Flumatinib mesylate		false
9758	30199		ADULT	46848036	562.5888	FLUMATINIB	Flumatinib	CN1CCN(CC2=C(C=C(C=C2)C(=O)NC3=CN=C(C)C(NC4=NC(=CC=N4)C5=CN=CC=C5)=C3)C(F)(F)F)CC1	PLASMA	R4009Y24AI									∞	ng × h/mL	1277		ng/mL	132			UNKNOWN	mg	400		SINGLE	HIGH-FAT						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32757049/	Homo sapiens		h	15.5				12	Flumatinib mesylate		false
9759	30199		ADULT	60202757	548.5622	N-DESMETHYL FLUMATINIB		Cc1ncc(NC(=O)c2ccc(CN3CCNCC3)c(c2)C(F)(F)F)cc1Nc4nccc(n4)c5cccnc5	PLASMA	U342756MZ6									∞	ng × h/mL	243		ng/mL	27.2			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32757049/	Homo sapiens		h	22.8				11	Flumatinib mesylate		false
9760	30199		ADULT	60202757	548.5622	N-DESMETHYL FLUMATINIB		Cc1ncc(NC(=O)c2ccc(CN3CCNCC3)c(c2)C(F)(F)F)cc1Nc4nccc(n4)c5cccnc5	PLASMA	U342756MZ6									∞	ng × h/mL	390		ng/mL	54.7			UNKNOWN	mg	400		SINGLE	HIGH-FAT						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32757049/	Homo sapiens		h	24.4				12	Flumatinib mesylate		false
9761	30219		ADULT	6215	452.5	FLUOCINOLONE ACETONIDE	FLUOCINOLONE ACETONIDE	CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO	PLASMA	0CD5FD6S2M									∞	ng × h/mL	354.8		ng/mL	54			UNKNOWN	mg	0.8		SINGLE	UNKNOWN						HEALTHY	Topical	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/1874579	Homo sapiens		h	14.8							false
9762	30356		CHILD	9560989	434.4068	FLUVOXAMINE MALEATE	FLUVOXAMINE MALEATE	OC(=O)\\C=C/C(O)=O.COCCCC\\C(C1=CC=C(C=C1)C(F)(F)F)=N/OCCN	PLASMA	5LGN83G74V							12		t	ng × h/mL/kg	155.1		ng/mL/kg	14.8			RECOMMENDED	mg	100		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf	Homo sapiens							10			false
9763	30356		ADULT	9560989	434.4068	FLUVOXAMINE MALEATE	FLUVOXAMINE MALEATE	OC(=O)\\C=C/C(O)=O.COCCCC\\C(C1=CC=C(C=C1)C(F)(F)F)=N/OCCN	PLASMA	5LGN83G74V							12		t	ng × h/mL/kg	59.4		ng/mL/kg	5.7			RECOMMENDED	mg	150		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf	Homo sapiens							16			false
9764	30356		ADOLESCENT	9560989	434.4068	FLUVOXAMINE MALEATE	FLUVOXAMINE MALEATE	OC(=O)\\C=C/C(O)=O.COCCCC\\C(C1=CC=C(C=C1)C(F)(F)F)=N/OCCN	PLASMA	5LGN83G74V							12		t	ng × h/mL/kg	43.9		ng/mL/kg	4.2			RECOMMENDED	mg	100		STEADY-STATE	UNKNOWN		day	2		20	UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf	Homo sapiens		h	15.6				17			false
9765	30356		ADOLESCENT	9560989	434.4068	FLUVOXAMINE MALEATE	FLUVOXAMINE MALEATE	OC(=O)\\C=C/C(O)=O.COCCCC\\C(C1=CC=C(C=C1)C(F)(F)F)=N/OCCN	PLASMA	5LGN83G74V							12		t	ng × h/mL/kg	69.6		ng/mL/kg	6.7			RECOMMENDED	mg	150		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf	Homo sapiens							13			false
9766	30642		ADULT	115067	286.2778	GASTRODIN	Gastrodin	OC[C@H]1O[C@@H](OC2=CC=C(CO)C=C2)[C@H](O)[C@@H](O)[C@@H]1O	PLASMA	5YS9U2W3RQ									∞	ng × h/mL	7210.26		ng/mL	1484.55			UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20542476/	Homo sapiens		h	6.06				18			false
9767	30649		ADULT	42642654	456.21	GDC-0623	OCCONC(=O)C1=C(NC2=CC=C(I)C=C2F)N3C=NC=C3C=C1	OCCONC(=O)C1=C(NC2=CC=C(I)C=C2F)N3C=NC=C3C=C1	PLASMA	HW67545I4Q																	MAX TOLERATED	mg	120		SINGLE	FASTED						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://mct.aacrjournals.org/content/12/11_Supplement/B75	Homo sapiens		h	5							false
9768	30651		UNKNOWN	71600094	564.699	GDC-0917	GDC-0917	CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N2CCC[C@H]2C(=O)NC3=C(N=C(S3)C4=NC=CO4)C5=CC=CC=C5	PLASMA	KWH46ZDG32																						UNKNOWN					15	UNKNOWN		UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24041744	Homo sapiens								GDC-0917		false
9769	30651		ADULT	71600094	564.699	GDC-0917	GDC-0917	CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N2CCC[C@H]2C(=O)NC3=C(N=C(S3)C4=NC=CO4)C5=CC=CC=C5	PLASMA	KWH46ZDG32							24		t	ng × day/mL	7000		ng/mL	957			UNKNOWN	mg	600		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27076626	Homo sapiens							3	GDC-0917		false
9770	30651		ADULT	71600094	564.699	GDC-0917	GDC-0917	CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N2CCC[C@H]2C(=O)NC3=C(N=C(S3)C4=NC=CO4)C5=CC=CC=C5	PLASMA	KWH46ZDG32									∞	ng × day/mL	5320		ng/mL	744			UNKNOWN	mg	600		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27076626	Homo sapiens		h	5.62				3	GDC-0917		false
9771	30652		ADULT	71727581	440.9	Ravoxertinib	GDC-0994		PLASMA	R6AXV96CRH							24		t	μM × h	62		μM	3.68			UNKNOWN	mg	200		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31848189/	Homo sapiens							3	GDC-0994		false
9772	30652		ADULT	71727581	440.9	Ravoxertinib	GDC-0994		PLASMA	R6AXV96CRH							24		t	μM × h	88.9		μM	5.17			RECOMMENDED	mg	400		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31848189/	Homo sapiens							6	GDC-0994		false
9773	30652		ADULT	71727581	440.9	Ravoxertinib			PLASMA	R6AXV96CRH							24		t	μM × h	27.7		μM	1.88			UNKNOWN	mg	100		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31848189/	Homo sapiens							3	GDC-0994		false
9774	30652		ADULT	71727581	440.9	Ravoxertinib	GDC-0994		PLASMA	R6AXV96CRH							24		t	μM × h	26.8		μM	1.66			UNKNOWN	mg	50		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31848189/	Homo sapiens							4	GDC-0994		false
9775	30741		ADULT	11539477	441.5233	GGTI-2418	GGTI-2418	CC(C)C[C@H](NC(=O)N1CCN(CC2=C(C)N=CN2)C(=O)[C@@H]1CC3=CC=CC=C3)C(O)=O	PLASMA	M67G28K74K									?	μg × h/mL	180		μg/mL	160			UNKNOWN	mg/m²	1050		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31372813/	Homo sapiens		h	1.1				1	GGTI-2418		false
9776	30741		ADULT	11539477	441.5233	GGTI-2418	GGTI-2418	CC(C)C[C@H](NC(=O)N1CCN(CC2=C(C)N=CN2)C(=O)[C@@H]1CC3=CC=CC=C3)C(O)=O	PLASMA	M67G28K74K									?	μg × h/mL	16.2		μg/mL	19			UNKNOWN	mg/m²	330		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31372813/	Homo sapiens		h	1.3	administered as a 30-min IV infusion on days 1–5 of each 21-day cycle			1	GGTI-2418		false
9777	30741		ADULT	11539477	441.5233	GGTI-2418	GGTI-2418	CC(C)C[C@H](NC(=O)N1CCN(CC2=C(C)N=CN2)C(=O)[C@@H]1CC3=CC=CC=C3)C(O)=O	PLASMA	M67G28K74K									?	μg × h/mL	462		μg/mL	209			MAX TOLERATED	mg/m²	2060		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31372813/	Homo sapiens		h	0.99				6	GGTI-2418		false
9778	30741		ADULT	11539477	441.5233	GGTI-2418	GGTI-2418	CC(C)C[C@H](NC(=O)N1CCN(CC2=C(C)N=CN2)C(=O)[C@@H]1CC3=CC=CC=C3)C(O)=O	PLASMA	M67G28K74K									?	μg × h/mL	36.3		μg/mL	56.1			UNKNOWN	mg/m²	500		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31372813/	Homo sapiens		h	1				1	GGTI-2418		false
9779	30741		ADULT	11539477	441.5233	GGTI-2418	GGTI-2418	CC(C)C[C@H](NC(=O)N1CCN(CC2=C(C)N=CN2)C(=O)[C@@H]1CC3=CC=CC=C3)C(O)=O	PLASMA	M67G28K74K									?	μg × h/mL	186		μg/mL	117			UNKNOWN	mg/m²	750		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31372813/	Homo sapiens		h	1.1	administered as a 30-min IV infusion on days 1–5 of each 21-day cycle			2	GGTI-2418		false
9780	30741		ADULT	11539477	441.5233	GGTI-2418	GGTI-2418	CC(C)C[C@H](NC(=O)N1CCN(CC2=C(C)N=CN2)C(=O)[C@@H]1CC3=CC=CC=C3)C(O)=O	PLASMA	M67G28K74K									?	μg × h/mL	320		μg/mL	226			UNKNOWN	mg/m²	1470		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31372813/	Homo sapiens		h	1.1	administered as a 30-min IV infusion on days 1–5 of each 21-day cycle			1	GGTI-2418		false
9781	30741		ADULT	11539477	441.5233	GGTI-2418	GGTI-2418		PLASMA	M67G28K74K									?	μg × h/mL	21.9		μg/mL	26.8			UNKNOWN	mg/m²	200		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31372813/	Homo sapiens		h	1.4	administered as a 30-min IV infusion on days 1–5 of each 21-day cycle			1	GGTI-2418		false
9782	30741		ADULT	11539477	441.5233	GGTI-2418	GGTI-2418	CC(C)C[C@H](NC(=O)N1CCN(CC2=C(C)N=CN2)C(=O)[C@@H]1CC3=CC=CC=C3)C(O)=O	PLASMA	M67G28K74K									?	μg × h/mL	126		μg/mL	93.7			UNKNOWN	mg/m²	750		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31372813/	Homo sapiens		h	1.1				2	GGTI-2418		false
9783	30741		ADULT	11539477	441.5233	GGTI-2418	GGTI-2418	CC(C)C[C@H](NC(=O)N1CCN(CC2=C(C)N=CN2)C(=O)[C@@H]1CC3=CC=CC=C3)C(O)=O	PLASMA	M67G28K74K									?	μg × h/mL	15.2		μg/mL	18.5			UNKNOWN	mg/m²	200		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31372813/	Homo sapiens		h	1.1				1	GGTI-2418		false
9784	30750		ADULT		424.3986	GINKGOLIDE B	Ginkgolide B	C[C@@H]1C(=O)O[C@H]2[C@@H](O)[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]36[C@@H](O)C(=O)O[C@H]6O[C@@]4(C(=O)O5)[C@@]12O	PLASMA	DF149B9460									?	ng × h/mL	82.77		ng/mL	9.99			UNKNOWN	μg	836.46		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20041430/	Homo sapiens		h	3.57	3 tablets containing Ginkgolide B 836.46 μg			8	EGb 761TM		false
9785	30750		ADULT		424.3986	GINKGOLIDE B	Ginkgolide B	C[C@@H]1C(=O)O[C@H]2[C@@H](O)[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]36[C@@H](O)C(=O)O[C@H]6O[C@@]4(C(=O)O5)[C@@]12O	PLASMA	DF149B9460									?	ng × h/mL	16.36		ng/mL	4.18			UNKNOWN	μg	524.56		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20041430/	Homo sapiens		h	3.24	4 tablets containing Ginkgolide B 524.56 μg			8	Ginkgo fresh plant extract tablets		false
9786	30750		ADULT		424.3986	GINKGOLIDE B	Ginkgolide B	C[C@@H]1C(=O)O[C@H]2[C@@H](O)[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]36[C@@H](O)C(=O)O[C@H]6O[C@@]4(C(=O)O5)[C@@]12O	PLASMA	DF149B9460									?	ng × h/mL	7.75		ng/mL	1.73			UNKNOWN	μg	147.45		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20041430/	Homo sapiens		h	2.34	90 drops, 2.73 mL, GeriaforceTM contains Ginkgolide B 147.45 μg			8	GeriaforceTM tincture		false
9787	30759		ADULT	10798271	205.2099	ZENUZOLAC		OC(=O)CC1CC(=NO1)c2ccccc2	PLASMA	AKT814N13R									∞	μg × h/mL	4.9		μg/mL	1.07			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27138022/	Homo sapiens		h	5.1				6			false
9788	30759		ADULT	10798271	205.2099	ZENUZOLAC		OC(=O)CC1CC(=NO1)c2ccccc2	PLASMA	AKT814N13R									∞	μg × h/mL	88.5		μg/mL	9.83			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27138022/	Homo sapiens		h	9.1				6			false
9789	30759		ADULT	10798271	205.2099	ZENUZOLAC		OC(=O)CC1CC(=NO1)c2ccccc2	PLASMA	AKT814N13R									∞	μg × h/mL	115.6		μg/mL	16.56			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27138022/	Homo sapiens		h	7.7				6			false
9790	30759		ADULT	10798271	205.2099	ZENUZOLAC		OC(=O)CC1CC(=NO1)c2ccccc2	PLASMA	AKT814N13R									∞	μg × h/mL	0.5		μg/mL	0.05			UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27138022/	Homo sapiens		h	7.4				6			false
9791	30759		ADULT	10798271	205.2099	ZENUZOLAC		OC(=O)CC1CC(=NO1)c2ccccc2	PLASMA	AKT814N13R									∞	μg × h/mL	172.5		μg/mL	24.6			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27138022/	Homo sapiens		h	6.8				6			false
9792	30759		ADULT	10798271	205.2099	ZENUZOLAC		OC(=O)CC1CC(=NO1)c2ccccc2	PLASMA	AKT814N13R									∞	μg × h/mL	361.2		μg/mL	44.14			UNKNOWN	mg	800		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27138022/	Homo sapiens		h	8.5				6			false
9793	30759		ADULT	10798271	205.2099	ZENUZOLAC		OC(=O)CC1CC(=NO1)c2ccccc2	PLASMA	AKT814N13R									∞	μg × h/mL	40.2		μg/mL	6.63			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27138022/	Homo sapiens		h	6.1				6			false
9794	30759		ADULT	10798271	205.2099	ZENUZOLAC		OC(=O)CC1CC(=NO1)c2ccccc2	PLASMA	AKT814N13R									∞	μg × h/mL	56.8		μg/mL	4.66			UNKNOWN	mg	100		SINGLE	HIGH-FAT						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27138022/	Homo sapiens		h	6.5				6			false
9795	30759		ADULT	10798271	205.2099	ZENUZOLAC		OC(=O)CC1CC(=NO1)c2ccccc2	PLASMA	AKT814N13R							24		t	μg × h/mL	18.53		μg/mL	3.69			UNKNOWN	mg	40		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27138022/	Homo sapiens		h	7.73	Day 1			8			false
9796	30759		ADULT	10798271	205.2099	ZENUZOLAC		OC(=O)CC1CC(=NO1)c2ccccc2	PLASMA	AKT814N13R							24		t	μg × h/mL	13.18		μg/mL	3.13			UNKNOWN	mg	40		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27138022/	Homo sapiens		h	8.07	Day 5			8			false
9797	30759		ADULT	10798271	205.2099	ZENUZOLAC		OC(=O)CC1CC(=NO1)c2ccccc2	PLASMA	AKT814N13R							24		t	μg × h/mL	31.9		μg/mL	7.87			UNKNOWN	mg	100		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27138022/	Homo sapiens		h	11.23	Day 1			8			false
9798	30759		ADULT	10798271	205.2099	ZENUZOLAC		OC(=O)CC1CC(=NO1)c2ccccc2	PLASMA	AKT814N13R							24		t	μg × h/mL	25.62		μg/mL	6.89			UNKNOWN	mg	100		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27138022/	Homo sapiens		h	8.53	Day 5			8			false
9799	30759		ADULT	10798271	205.2099	ZENUZOLAC		OC(=O)CC1CC(=NO1)c2ccccc2	PLASMA	AKT814N13R							24		t	μg × h/mL	90.58		μg/mL	16.58			UNKNOWN	mg	200		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27138022/	Homo sapiens		h	8.67	Day 1			8			false
9800	30759		ADULT	10798271	205.2099	ZENUZOLAC		OC(=O)CC1CC(=NO1)c2ccccc2	PLASMA	AKT814N13R							24		t	μg × h/mL	78.63		μg/mL	14.62			UNKNOWN	mg	200		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27138022/	Homo sapiens		h	9.87	Day 5			8			false
9801	30759		ADULT	10798271	205.2099	ZENUZOLAC		OC(=O)CC1CC(=NO1)c2ccccc2	PLASMA	AKT814N13R							12		t	μg × h/mL	59.74		μg/mL	13.46			UNKNOWN	mg	200		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27138022/	Homo sapiens				Day 1			8			false
9802	30759		ADULT	10798271	205.2099	ZENUZOLAC		OC(=O)CC1CC(=NO1)c2ccccc2	PLASMA	AKT814N13R							12		t	μg × h/mL	88.53		μg/mL	17.48			UNKNOWN	mg	200		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27138022/	Homo sapiens		h	10.84	Day 5			8			false
9803	30872		ADULT	12211	137.0914	GLYCERYL 1-NITRATE	GLYCERYL 1-NITRATE	OCC(O)CO[N ]([O-])=O	PLASMA	212452MD4J									∞	ng × h/mL	2840		ng/mL	638			UNKNOWN	mg	40		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3100313	Homo sapiens		h	2.56				12	GLYCERYL 1-NITRATE		false
9804	30872		ADULT	12211	137.0914	GLYCERYL 1-NITRATE	GLYCERYL 1-NITRATE	OCC(O)CO[N ]([O-])=O	PLASMA	212452MD4J													ng/mL	307			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3105569	Homo sapiens		h	2.58				10	GLYCERYL 1-NITRATE		false
9805	30872		ADULT	12211	137.0914	GLYCERYL 1-NITRATE	GLYCERYL 1-NITRATE	OCC(O)CO[N ]([O-])=O	PLASMA	212452MD4J													ng/mL	324			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3105569	Homo sapiens		h	2.5				10	GLYCERYL 1-NITRATE		false
9806	31001		ADULT	187808	446.4041	GLYCITIN	GLYCITIN	COC1=C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C3OC=C(C(=O)C3=C1)C4=CC=C(O)C=C4	PLASMA	G2S44P62XC													ng/mL	200			UNKNOWN	mg	25		SINGLE	UNKNOWN						UNKNOWN	Oral	MALE	OTHER	https://efsa.onlinelibrary.wiley.com/doi/pdf/10.2903/j.efsa.2015.4246	Homo sapiens							1	GLYCITIN		false
9807	31147		ADULT	139292198	411.28	GS-566500	GS-566500		PLASMA								24		t	ng × h/mL	105.7		ng/mL	29.1			UNKNOWN	mg	200		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23263000/	Homo sapiens		h	3.3				8	GS-9851		false
9808	31147		ADULT	11311503	260.219	RO-2433	GS-331007	C[C@@]1(F)[C@H](O)[C@@H](CO)O[C@H]1N2C=CC(=O)NC2=O	PLASMA	44V7045CXS							24		t	ng × h/mL	3554.4		ng/mL	340.4			HIGHEST STUDIED	mg	400		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23263000/	Homo sapiens		h	17.9				8	GS-9851		false
9809	31147		ADULT	11311503	260.219	RO-2433	GS-331007	C[C@@]1(F)[C@H](O)[C@@H](CO)O[C@H]1N2C=CC(=O)NC2=O	PLASMA	44V7045CXS							24		t	ng × h/mL	2947.7		ng/mL	336.6			UNKNOWN	mg	200		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23263000/	Homo sapiens		h	7.2				8	GS-9851		false
9810	31147		ADULT	139292198	411.28	GS-566500	GS-566500		PLASMA								24		t	ng × h/mL	91.5		ng/mL	32.8			UNKNOWN	mg	100		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23263000/	Homo sapiens		h	2.3				7	GS-9851		false
9811	31147		ADULT	45375806	529.4525	PSI-7851	GS-9851	CC(C)OC(=O)[C@H](C)NP(=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC3=CC=CC=C3	PLASMA	3S5S1851OV							24		t	ng × h/mL	35.1		ng/mL	21.5			UNKNOWN	mg	50		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23263000/	Homo sapiens		h	1				7	GS-9851		false
9812	31147		ADULT	11311503	260.219	RO-2433	GS-331007	C[C@@]1(F)[C@H](O)[C@@H](CO)O[C@H]1N2C=CC(=O)NC2=O	PLASMA	44V7045CXS							24		t	ng × h/mL	951.5		ng/mL	117.7			UNKNOWN	mg	50		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23263000/	Homo sapiens		h	6				7	GS-9851		false
9813	31147		ADULT	45375806	529.4525	PSI-7851	GS-9851	CC(C)OC(=O)[C@H](C)NP(=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC3=CC=CC=C3	PLASMA	3S5S1851OV							24		t	ng × h/mL	113.2		ng/mL	81			UNKNOWN	mg	100		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23263000/	Homo sapiens		h	1				8	GS-9851		false
9814	31147		ADULT	139292198	411.28	GS-566500	GS-566500		PLASMA								24		t	ng × h/mL	21.3		ng/mL	13.3			UNKNOWN	mg	50		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23263000/	Homo sapiens							4	GS-9851		false
9815	31147		ADULT	11311503	260.219	RO-2433	GS-331007	C[C@@]1(F)[C@H](O)[C@@H](CO)O[C@H]1N2C=CC(=O)NC2=O	PLASMA	44V7045CXS							24		t	ng × h/mL	1719.9		ng/mL	218.9			UNKNOWN	mg	100		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23263000/	Homo sapiens		h	10.3				8	GS-9851		false
9816	31147		ADULT	45375806	529.4525	PSI-7851	GS-9851	CC(C)OC(=O)[C@H](C)NP(=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC3=CC=CC=C3	PLASMA	3S5S1851OV							24		t	ng × h/mL	191.5		ng/mL	81.69			HIGHEST STUDIED	mg	400		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23263000/	Homo sapiens		h	1				8	GS-9851		false
9817	31147		ADULT	139292198	411.28	GS-566500	GS-566500		PLASMA								24		t	ng × h/mL	215		ng/mL	46.2			HIGHEST STUDIED	mg	400		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23263000/	Homo sapiens		h	3.7				8	GS-9851		false
9818	31147		ADULT	45375806	529.4525	PSI-7851	GS-9851	CC(C)OC(=O)[C@H](C)NP(=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC3=CC=CC=C3	PLASMA	3S5S1851OV							24		t	ng × h/mL	159.7		ng/mL	77.1			UNKNOWN	mg	200		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23263000/	Homo sapiens		h	1.3				8	GS-9851		false
9819	31161		ADULT	59448236	447.4568	GSK-2256294	GSK-2256294	CNC1=NC(C)=NC(N[C@H]2CCC[C@H](C2)C(=O)NCC3=C(C=C(C=C3)C#N)C(F)(F)F)=N1	PLASMA	L33EX3XR0T							24		t	ng × h/mL	5267		ng/mL	559			UNKNOWN	mg	10		SINGLE	UNKNOWN						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26620151	Homo sapiens		h	42.7				13	GSK-2256294		false
9820	31161		ADULT	59448236	447.4568	GSK-2256294	GSK-2256294	CNC1=NC(C)=NC(N[C@H]2CCC[C@H](C2)C(=O)NCC3=C(C=C(C=C3)C#N)C(F)(F)F)=N1	PLASMA	L33EX3XR0T							24		t	ng × h/mL	2741		ng/mL	321			UNKNOWN	mg	6		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26620151	Homo sapiens		h	25				14	GSK2256294		false
9821	31161		ADULT	59448236	447.4568	GSK-2256294	GSK-2256294	CNC1=NC(C)=NC(N[C@H]2CCC[C@H](C2)C(=O)NCC3=C(C=C(C=C3)C#N)C(F)(F)F)=N1	PLASMA	L33EX3XR0T							24		t	ng × h/mL	6680		ng/mL	836			UNKNOWN	mg	12		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26620151	Homo sapiens		h	19.3				14	GSK-2256294		false
9822	31161		ADULT	59448236	447.4568	GSK-2256294	GSK-2256294	CNC1=NC(C)=NC(N[C@H]2CCC[C@H](C2)C(=O)NCC3=C(C=C(C=C3)C#N)C(F)(F)F)=N1	PLASMA	L33EX3XR0T							24		t	ng × h/mL	15774		ng/mL	1455			UNKNOWN	mg	18		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26620151	Homo sapiens							27	GSK-2256294		false
9823	31161		ADULT	59448236	447.4568	GSK-2256294	GSK-2256294	CNC1=NC(C)=NC(N[C@H]2CCC[C@H](C2)C(=O)NCC3=C(C=C(C=C3)C#N)C(F)(F)F)=N1	PLASMA	L33EX3XR0T							24		t	ng × h/mL	11464		ng/mL	1223			UNKNOWN	mg	20		SINGLE	UNKNOWN						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26620151	Homo sapiens		h	41.4				13	GSK-2256294		false
9824	31161		ADULT	59448236	447.4568	GSK-2256294	GSK-2256294	CNC1=NC(C)=NC(N[C@H]2CCC[C@H](C2)C(=O)NCC3=C(C=C(C=C3)C#N)C(F)(F)F)=N1	PLASMA	L33EX3XR0T							24		t	ng × h/mL	5801		ng/mL	689			UNKNOWN	mg	6		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26620151	Homo sapiens							23	GSK-2256294		false
9825	31164		ADULT	56949517	433.4236	GSK-2636771	GSK-2636771	CC1=NC2=C(C=C(C=C2C(O)=O)N3CCOCC3)N1CC4=CC=CC(=C4C)C(F)(F)F	PLASMA	DW94IAT0LS							24		t	ng × h/mL	67051		ng/mL	5493			MAX TOLERATED	mg	400		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28645941	Homo sapiens		h	23.2							false
9826	31164		ADULT	56949517	433.4236	GSK-2636771	GSK-2636771	CC1=NC2=C(C=C(C=C2C(O)=O)N3CCOCC3)N1CC4=CC=CC(=C4C)C(F)(F)F	PLASMA	DW94IAT0LS									∞	ng × h/mL	190798		ng/mL	7221			UNKNOWN	mg	500		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28645941	Homo sapiens		h	23				4	GSK-2636771		false
9827	31164		ADULT	56949517	433.4236	GSK-2636771	GSK-2636771	CC1=NC2=C(C=C(C=C2C(O)=O)N3CCOCC3)N1CC4=CC=CC(=C4C)C(F)(F)F	PLASMA	DW94IAT0LS									∞	ng × h/mL	161874		ng/mL	5493			RP2D	mg	400		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28645941	Homo sapiens		h	23.2				6	GSK-2636771		false
9828	31164		ADULT	56949517	433.4236	GSK-2636771	GSK-2636771	CC1=NC2=C(C=C(C=C2C(O)=O)N3CCOCC3)N1CC4=CC=CC(=C4C)C(F)(F)F	PLASMA	DW94IAT0LS									?	ng × h/mL	205014		ng/mL	15078			RP2D	mg	400		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28645941	Homo sapiens							6	GSK-2636771		false
9829	31164		ADULT	56949517	433.4236	GSK-2636771	GSK-2636771	CC1=NC2=C(C=C(C=C2C(O)=O)N3CCOCC3)N1CC4=CC=CC(=C4C)C(F)(F)F	PLASMA	DW94IAT0LS									?	ng × h/mL	485325		ng/mL	29530			UNKNOWN	mg	500		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28645941	Homo sapiens							2	GSK-2636771		false
9830	31167			66571643	364.4806	GSK-2879552	GSK-2879552	OC(=O)C1=CC=C(CN2CCC(CN[C@@H]3C[C@H]3C4=CC=CC=C4)CC2)C=C1	PLASMA	GT77Z6Y09Z																										In vitro, GSK2879552 binding to plasma proteins varied between species and was around 64% in mice, 81% in rats, 42% in dogs and 55% in human at a concentration of 0.02 uM (~8 ng/mL).	45				EXPERIMENT	https://clinicaltrials.gov/ProvidedDocs/12/NCT02177812/Prot_000.pdf	Homo sapiens										false
9831	31167		ADULT	66571643	364.4806	GSK-2879552	GSK-2879552	OC(=O)C1=CC=C(CN2CCC(CN[C@@H]3C[C@H]3C4=CC=CC=C4)CC2)C=C1	BLOOD	GT77Z6Y09Z							24		t	ng × h/mL	10.4		ng/mL	3.8			UNKNOWN	mg	0.25		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/31260835	Homo sapiens		h	16.9							false
9832	31167		ADULT	66571643	364.4806	GSK-2879552	GSK-2879552	OC(=O)C1=CC=C(CN2CCC(CN[C@@H]3C[C@H]3C4=CC=CC=C4)CC2)C=C1	BLOOD	GT77Z6Y09Z							24		t	ng × h/mL	159		ng/mL	22			UNKNOWN	mg	3		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/31260835	Homo sapiens		h	15.4							false
9833	31383		ADULT	6604443	367.4	(R)-BAMBUTEROL	(R)-BAMBUTEROL		PLASMA	U44CBZ5I3E													ng/L	149.2			UNKNOWN	mg	2.5		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26137575/	Homo sapiens							10	R-bambuterol		false
9834	31383		ADULT	6604443	367.4	(R)-BAMBUTEROL			PLASMA	U44CBZ5I3E													ng/L	419.4			UNKNOWN	mg	5		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26137575/	Homo sapiens							10	(R)-BAMBUTEROL		false
9835	31383		ADULT	6604443	367.4	(R)-BAMBUTEROL			PLASMA	U44CBZ5I3E													ng/L	1136			MAX DAILY	mg	10		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26137575/	Homo sapiens							10	(R)-BAMBUTEROL		false
9836	31674		ADULT	114840	271.3111	HIGENAMINE	HIGENAMINE	OC1=CC=C(CC2NCCC3=C2C=C(O)C(O)=C3)C=C1	PLASMA	TBV5O16GAP									∞	ng × h/mL	5.39		μg/L	31.3			UNKNOWN	μg/kg	22.5		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23085737/	Homo sapiens		h	0.133	subjects received continuous, intravenous infusion of higenamine at gradually escalating doses of 0.5, 1.0, 2.0 and 4.0\nµg/kg/min, each of which was given for 3 min			10	HIGENAMINE  HYDROCHLORIDE		false
9837	31699		ADULT	11399764	688.7284	HM-30181	HM-30181	COC1=CC(NC(=O)C2=CC(=O)C3=C(O2)C=CC=C3)=C(C=C1OC)C4=NN(N=N4)C5=CC=C(CCN6CCC7=CC(OC)=C(OC)C=C7C6)C=C5	PLASMA	K4I4I996O4									?	μg × h/L	233.1		μg/L	13.4			UNKNOWN	mg	180		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22284902/	Homo sapiens		h	215.2				8	HM30181		false
9838	31699		ADULT	11399764	688.7284	HM-30181	HM-30181	COC1=CC(NC(=O)C2=CC(=O)C3=C(O2)C=CC=C3)=C(C=C1OC)C4=NN(N=N4)C5=CC=C(CCN6CCC7=CC(OC)=C(OC)C=C7C6)C=C5	PLASMA	K4I4I996O4									∞	μg × h/L	697		μg/L	4			UNKNOWN	mg	360		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22284902/	Homo sapiens		h	169.3				8	HM30181		false
9839	31699		ADULT	11399764	688.7284	HM-30181	HM-30181	COC1=CC(NC(=O)C2=CC(=O)C3=C(O2)C=CC=C3)=C(C=C1OC)C4=NN(N=N4)C5=CC=C(CCN6CCC7=CC(OC)=C(OC)C=C7C6)C=C5	PLASMA	K4I4I996O4									∞	μg × h/L	556.8		μg/L	5.2			UNKNOWN	mg	600		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22284902/	Homo sapiens		h	75.7				8	HM30181		false
9840	31699		ADULT	11399764	688.7284	HM-30181	HM-30181	COC1=CC(NC(=O)C2=CC(=O)C3=C(O2)C=CC=C3)=C(C=C1OC)C4=NN(N=N4)C5=CC=C(CCN6CCC7=CC(OC)=C(OC)C=C7C6)C=C5	PLASMA	K4I4I996O4									?	μg × h/L	262.3		μg/L	16.2			UNKNOWN	mg	60		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22284902/	Homo sapiens		h	153.5				8	HM30181		false
9841	31699		ADULT	11399764	688.7284	HM-30181	HM-30181	COC1=CC(NC(=O)C2=CC(=O)C3=C(O2)C=CC=C3)=C(C=C1OC)C4=NN(N=N4)C5=CC=C(CCN6CCC7=CC(OC)=C(OC)C=C7C6)C=C5	PLASMA	K4I4I996O4									?	μg × h/L	233.1		μg/L	22.5			HIGHEST STUDIED	mg	360		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22284902/	Homo sapiens		h	198				8	HM30181		false
9842	31699		ADULT	11399764	688.7284	HM-30181	HM-30181	COC1=CC(NC(=O)C2=CC(=O)C3=C(O2)C=CC=C3)=C(C=C1OC)C4=NN(N=N4)C5=CC=C(CCN6CCC7=CC(OC)=C(OC)C=C7C6)C=C5	PLASMA	K4I4I996O4									∞	μg × h/L	1112.8		μg/L	6.6			HIGHEST STUDIED	mg	900		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22284902/	Homo sapiens		h	122.8				8	HM30181		false
9843	31756		ADULT	46216556	379.3876	HSP-990	HSP-990	COC1=CC=CC(=N1)C2=C(C=CC(F)=C2)[C@H]3CC4=C(C(=O)N3)C(C)=NC(N)=N4	PLASMA	E0WBA7B62L									∞	ng × h/mL	10108		ng/mL	496			MAX TOLERATED	mg	50		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25625276	Homo sapiens		h	20.2				22	HSP-990		false
9844	31756		ADULT	46216556	379.3876	HSP-990	HSP-990	COC1=CC=CC(=N1)C2=C(C=CC(F)=C2)[C@H]3CC4=C(C(=O)N3)C(C)=NC(N)=N4	PLASMA	E0WBA7B62L									∞	ng × h/mL	9712		ng/mL	700			UNKNOWN	mg	60		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25625276	Homo sapiens		h	17.6				5	HSP-990		false
9845	31798		ADULT	5284569	299.3642	HYDROCODONE	HYDROCODONE	COC1=CC=C2C[C@@H]3[C@@H]4CCC(=O)[C@@H]5OC1=C2[C@]45CCN3C	PLASMA	6YKS4Y3WQ7									∞	ng × h/mL	269		ng/mL	13			RECOMMENDED	mg	15		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27138027/	Homo sapiens		h	10.5		Moderate Hepatic Impairment		8			false
9846	31798		ADULT	5284569	299.3642	HYDROCODONE	HYDROCODONE	COC1=CC=C2C[C@@H]3[C@@H]4CCC(=O)[C@@H]5OC1=C2[C@]45CCN3C	PLASMA	6YKS4Y3WQ7									∞	ng × h/mL	155		ng/mL	10.1			RECOMMENDED	mg	15		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27138027/	Homo sapiens		h	10.2		Normal hepatic function		8	Hydrocodone Extended Release		false
9847	31798		ADULT	5284569	299.3642	HYDROCODONE	HYDROCODONE	COC1=CC=C2C[C@@H]3[C@@H]4CCC(=O)[C@@H]5OC1=C2[C@]45CCN3C	PLASMA	6YKS4Y3WQ7													ng/mL	23.6			RECOMMENDED	mg	10		SINGLE	FASTED				As most agents in the 5-ring morphinan group of semi-synthetic opioids bind plasma protein to a similar degree (range 19% [hydromorphone] to 45% [oxycodone]), hydrocodone is expected to fall within this range.	55	HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/005213s039lbl.pdf	Homo sapiens		h	4							false
9848	31800		ADULT	5754	362.4599	HYDROCORTISONE	HYDROCORTISONE	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO	PLASMA	WI4X0X7BPJ									?	ng × h/mL	1175						UNKNOWN	mg	20		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2050835	Homo sapiens		h	1.66							false
9849	31800		ADULT	5754	362.4599	HYDROCORTISONE	HYDROCORTISONE	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO	PLASMA	WI4X0X7BPJ									?	ng × h/mL	1162		ng/mL	258			UNKNOWN	mg	20		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2050835	Homo sapiens		h	1.82							false
9850	31800		ADULT	5754	362.4599	HYDROCORTISONE	HYDROCORTISONE	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO	PLASMA	WI4X0X7BPJ																	UNKNOWN				UNKNOWN	UNKNOWN				90% or more of circulating hydrocortisone is reversibly bound to protein. The binding is accounted for by two protein fractions. One, corticosteroid-binding globulin is a glycoprotein; the other is albumin.	10	HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213876s000lbl.pdf	Homo sapiens		h	1.5							false
9851	31831		UNKNOWN	5462347|25058198	321.799	HYDROMORPHONE HYDROCHLORIDE	HYDROMORPHONE HYDROCHLORIDE	Cl.CN1CC[C@@]23[C@H]4OC5=C2C(C[C@@H]1[C@@H]3CCC4=O)=CC=C5O	PLASMA	L960UP2KRW									?	ng × h/mL	23.7		ng/mL	5.5			UNKNOWN	mg	8		SINGLE	UNKNOWN				At therapeutic plasma levels, hydromorphone is approximately 8 to 19% bound to plasma proteins.	81	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019891s028,019892s035lbl.pdf	Homo sapiens		h	2.6							false
9852	31834		ADULT	91503	326.4326	HYDROQUINIDINE	HYDROQUINIDINE	CC[C@H]1C[N@@]2CC[C@H]1C[C@@H]2[C@@H](O)C3=C4C=C(OC)C=CC4=NC=C3	UNKNOWN	8P68XPY4HG													mg/L	0.74			UNKNOWN	mg	300		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7095920/	Homo sapiens				tablet	heart disease		12	HYDROQUINIDINE HYDROCHLORIDE		false
9853	31834		ADULT	91503	326.4326	HYDROQUINIDINE	HYDROQUINIDINE	CC[C@H]1C[N@@]2CC[C@H]1C[C@@H]2[C@@H](O)C3=C4C=C(OC)C=CC4=NC=C3	UNKNOWN	8P68XPY4HG													mg/L	0.55			UNKNOWN	mg	500		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7095920/	Homo sapiens				sustained-release capsule	heart disease		12	HYDROQUINIDINE HYDROCHLORIDE		false
9854	31834		ADULT	91503	326.4326	HYDROQUINIDINE	HYDROQUINIDINE	CC[C@H]1C[N@@]2CC[C@H]1C[C@@H]2[C@@H](O)C3=C4C=C(OC)C=CC4=NC=C3	UNKNOWN	8P68XPY4HG																	UNKNOWN	mg	300		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7095920/	Homo sapiens		h	10.8		heart disease		12	HYDROQUINIDINE GLUCONATE		false
9855	31836		ADULT	121515	326.4326	HYDROQUININE	Hydroquinine	CC[C@H]1C[N@@]2CC[C@H]1C[C@H]2[C@H](O)C3=C4C=C(OC)C=CC4=NC=C3	SERUM	31J3Q51T6L							24		t	mg × h/L	29.7		mg/L	2.43			UNKNOWN	mg	300		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10952483/	Homo sapiens		h	10.9		Muscle cramp patients		16	Hydroquinine hydrobromide (214mg free base)		false
9856	32062		ADULT	6603887	204.2252	IDAZOXAN, (-)-	IDAZOXAN, (-)-	C1CN=C(N1)[C@@H]2COC3=C(O2)C=CC=C3	PLASMA	4M0GQ8Z17B									∞	ng × h/mL	43		ng/mL	10.2			UNKNOWN	mg	10		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	PATENT	https://patentimages.storage.googleapis.com/e4/98/6f/0a784c47c94176/US8476307.pdf	Homo sapiens		h	3.1					IDAZOXAN, (-)-		false
9857	32063		ADULT	12866829	204.22	(S)-Idazoxan	IDAZOXAN, ( )-	C1CN=C(N1)C2COC3=CC=CC=C3O2	PLASMA	TVQ8F94ARF									∞	ng × h/mL	27		ng/mL	7.2			UNKNOWN	mg	10		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	PATENT	https://patentimages.storage.googleapis.com/e4/98/6f/0a784c47c94176/US8476307.pdf	Homo sapiens		h	7.8					IDAZOXAN, ( )-		false
9858	32145			64973	227.194	DEXELVUCITABINE		NC1=NC(=O)N(C=C1F)[C@@H]2O[C@H](CO)C=C2	SERUM	KU8SPJ271W																										DPC 817 is scarcely bound by plasma proteins: the free fraction in human serum was determined to be 96%. (equilibrium dialysis)	4				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11959574/	Homo sapiens										false
9859	32166		ADULT	11519397	459.4507	INDIMITECAN	INDIMITECAN	COC1=C(OC)C=C2C(=O)N(CCCN3C=CN=C3)C4=C(C(=O)C5=CC6=C(OCO6)C=C45)C2=C1	PLASMA	V5T7S4HP8A							24		t	μg × h/mL	14.7		μg/mL	1.65			UNKNOWN	mg/m²	80		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5199138/	Homo sapiens		h	50							false
9860	32199		ADULT		295.3325	INDOBUFEN, (S)-	S-indobufen	CC[C@H](C(O)=O)C1=CC=C(C=C1)N2CC3=C(C=CC=C3)C2=O	SERUM	58LEO57GJB	189556	295.3	(-)-Indobufen	R-indobufen	CC[C@H](C1=CC=C(C=C1)N2CC3=CC=CC=C3C2=O)C(=O)O				∞	mg × h/L	78.1		mg/L	9.4			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10602265	Homo sapiens		h	4.8	Indobufen Jelfa tablet			10	racemic indobufen		true
9861	32199		ADULT	44562	295.3325	INDOBUFEN, (S)-	S-indobufen	CC[C@H](C(O)=O)C1=CC=C(C=C1)N2CC3=C(C=CC=C3)C2=O	SERUM	58LEO57GJB	189556	295.3	(-)-Indobufen	R-indobufen	CC[C@H](C1=CC=C(C=C1)N2CC3=CC=CC=C3C2=O)C(=O)O				∞	mg × h/L	71.7		mg/L	12.5			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10602265	Homo sapiens		h	3.1	Ibustrin tablet			10	racemic indobufen		true
9862	32199		ADULT		295.3325	INDOBUFEN, (S)-	S-indobufen	CC[C@H](C(O)=O)C1=CC=C(C=C1)N2CC3=C(C=CC=C3)C2=O	SERUM	58LEO57GJB	189556	295.3	(-)-Indobufen	R-indobufen	CC[C@H](C1=CC=C(C=C1)N2CC3=CC=CC=C3C2=O)C(=O)O				∞	mg × h/L	65.2		mg/L	12.2			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Intramuscular	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10602265	Homo sapiens		h	3.5	Ibustrin i.m. injection			10	racemic indobufen		true
9863	32199		ADULT		295.3325	INDOBUFEN, (S)-	S-indobufen	CC[C@H](C(O)=O)C1=CC=C(C=C1)N2CC3=C(C=CC=C3)C2=O	SERUM		189556	295.3	(-)-Indobufen	R-indobufen	CC[C@H](C1=CC=C(C=C1)N2CC3=CC=CC=C3C2=O)C(=O)O				∞	mg × h/L	59		mg/L	11.4			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Intramuscular	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10602265	Homo sapiens		h	3.3	Indobufen Jelfa i.m. injection			10	racemic indobufen		true
9864	32199		ADULT	44562	295.3325	INDOBUFEN, (S)-	S-indobufen	CC[C@H](C(O)=O)C1=CC=C(C=C1)N2CC3=C(C=CC=C3)C2=O	SERUM	58LEO57GJB	189556	295.3	(-)-Indobufen	R-indobufen	CC[C@H](C1=CC=C(C=C1)N2CC3=CC=CC=C3C2=O)C(=O)O												UNKNOWN	mg	100		MULTIPLE	UNKNOWN		day	2		1	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12237835/	Homo sapiens					Patients with obliterative atherosclerosis		3	racemic indobufen		true
9865	32199		ADULT	44562	295.3325	INDOBUFEN, (S)-	S-indobufen	CC[C@H](C(O)=O)C1=CC=C(C=C1)N2CC3=C(C=CC=C3)C2=O	PLASMA	58LEO57GJB	189556	295.3	(-)-Indobufen	R-indobufen	CC[C@H](C1=CC=C(C=C1)N2CC3=CC=CC=C3C2=O)C(=O)O								μg/mL	7.93			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1596290/	Homo sapiens		h	6.21				12	racemic indobufen		true
9866	32216		ADULT	11533060	478.4938	INDOTECAN	INDOTECAN	COC1=C(OC)C=C2C(=O)N(CCCN3CCOCC3)C4=C(C(=O)C5=CC6=C(OCO6)C=C45)C2=C1	PLASMA	BTA69L5M8D							24		t	μg × h/mL	14.7		μg/mL	1.65			UNKNOWN	mg/m²	80		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27169793	Homo sapiens				Indotecan was administered intravenously through a central line over 1 hour for the daily schedule (days 1–5, followed by 23 days without drug in 28-day cycles)			3	INDOTECAN		false
9867	32216		ADULT	11533060	478.4938	INDOTECAN	INDOTECAN	COC1=C(OC)C=C2C(=O)N(CCCN3CCOCC3)C4=C(C(=O)C5=CC6=C(OCO6)C=C45)C2=C1	PLASMA	BTA69L5M8D									∞	μg × h/mL	88.6		μg/mL	1.69			MAX TOLERATED	mg/m²	90		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27169793	Homo sapiens		h	74	weekly regimen			8	INDOTECAN		false
9868	32216		ADULT	11533060	478.4938	INDOTECAN	INDOTECAN	COC1=C(OC)C=C2C(=O)N(CCCN3CCOCC3)C4=C(C(=O)C5=CC6=C(OCO6)C=C45)C2=C1	PLASMA	BTA69L5M8D									∞	μg × h/mL	70.8		μg/mL	1.93			UNKNOWN	mg/m²	135		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27169793	Homo sapiens		h	50	weekly regimen			7	INDOTECAN		false
9869	32216		ADULT	11533060	478.4938	INDOTECAN	INDOTECAN	COC1=C(OC)C=C2C(=O)N(CCCN3CCOCC3)C4=C(C(=O)C5=CC6=C(OCO6)C=C45)C2=C1	PLASMA	BTA69L5M8D							24		t	μg × h/mL	12.8		μg/mL	1.61			MAX TOLERATED	mg/m²	60		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27169793	Homo sapiens				Indotecan was administered intravenously through a central line over 1 hour for the daily schedule (days 1–5, followed by 23 days without drug in 28-day cycles)			6	INDOTECAN		false
9870	32216		ADULT	11533060	478.4938	INDOTECAN	LMP400	COC1=C(OC)C=C2C(=O)N(CCCN3CCOCC3)C4=C(C(=O)C5=CC6=C(OCO6)C=C45)C2=C1	PLASMA	BTA69L5M8D							24		t	μg × h/mL	14.7		μg/mL	1.65			UNKNOWN	mg/m²	80		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/27169793	Homo sapiens		h	50							false
9871	32307		ADULT		545.18	IOWH-032	IOWH-032	OC1=C(Br)C=C(C=C1Br)C2=NOC(=N2)C(=O)NCC3=CC=C(OC4=CC=CC=C4)C=C3	PLASMA	8Y3GDT6YWV									∞	ng × h/mL	6250		ng/mL	482			UNKNOWN	mg	300		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	OTHER	https://path.azureedge.net/media/documents/DD_ddw_pstr.pdf	Homo sapiens		h	8.2							false
9872	32307		ADULT	135565181	545.18	IOWH-032	IOWH-032	OC1=C(Br)C=C(C=C1Br)C2=NOC(=N2)C(=O)NCC3=CC=C(OC4=CC=CC=C4)C=C3	PLASMA	8Y3GDT6YWV									∞	ng × h/mL	22700		ng/mL	1280			UNKNOWN	mg	300		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER	https://path.azureedge.net/media/documents/DD_ddw_pstr.pdf	Homo sapiens		h	8.5							false
9873	32308		ADULT	3742	1268.8792	IOXAGLIC ACID	ioxaglate	CNC(=O)C1=C(I)C(N(C)C(C)=O)=C(I)C(C(=O)NCC(=O)NC2=C(I)C(C(O)=O)=C(I)C(C(=O)NCCO)=C2I)=C1I	PLASMA	Z40X7EI2AF													μg/mL	2100			RECOMMENDED	g	26.663		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018905s025lbl.pdf	Homo sapiens		min	92							false
9874	32789		ADULT	5280343	302.2357	QUERCETIN	Quercetin	OC1=CC2=C(C(O)=C1)C(=O)C(O)=C(O2)C3=CC=C(O)C(O)=C3	PLASMA	9IKM0I5T1E							24		t	μM × h	15						UNKNOWN	mg	500		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://clinicaltrials.gov/ct2/show/results/NCT01722669	Homo sapiens							5	Isoquercetin		false
9875	32949		ADULT	46911863	377.3502	JNJ-38877605	JNJ-38877605	CN1C=C(C=N1)C2=NN3C(C=C2)=NN=C3C(F)(F)C4=CC5=C(C=C4)N=CC=C5	PLASMA	15UDG410PN							24		t	ng × h/mL	937		ng/mL	416			UNKNOWN	mg	60		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25745036	Homo sapiens		h	1.6				4			false
9876	32949		ADULT	46911863	377.3502	JNJ-38877605	JNJ-38877605	CN1C=C(C=N1)C2=NN3C(C=C2)=NN=C3C(F)(F)C4=CC5=C(C=C4)N=CC=C5	PLASMA	15UDG410PN							24		t	ng × h/mL	523		ng/mL	177			UNKNOWN	mg	20		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25745036	Homo sapiens				day 21			2			false
9877	32949		ADULT	46911863	377.3502	JNJ-38877605	JNJ-38877605	CN1C=C(C=N1)C2=NN3C(C=C2)=NN=C3C(F)(F)C4=CC5=C(C=C4)N=CC=C5	BLOOD	15UDG410PN							24		t	ng × h/mL	937		ng/mL	416			MAX TOLERATED	mg	60		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/25745036	Homo sapiens		h	1.6							false
9878	33041		ADULT	101244291	246.26	p-Hydroxykavain		COC1=CC(=O)OC(C1)/C=C/C2=CC=C(C=C2)O	SERUM	W1ES06373M									∞	ng × h/mL	64.8		ng/mL	41			UNKNOWN	mg	800		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12726850/	Homo sapiens		h	0.71							false
9879	33041		ADULT	5281565	230.2592	KAVAIN	Kavain	COC1=CC(=O)O[C@H](C1)\\C=C\\C2=CC=CC=C2	PLASMA	W1ES06373M													ng/mL	18			UNKNOWN	mg	200		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12726850/	Homo sapiens		h	9							false
9880	33041		ADULT	5281565	230.2592	KAVAIN	Kavain	COC1=CC(=O)O[C@H](C1)\\C=C\\C2=CC=CC=C2	SERUM	W1ES06373M													ng/mL	40			UNKNOWN	mg	800		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12726850/	Homo sapiens										false
9881	33115		ADULT	23116321	611.123	KW-2478	KW-2478	Cl.CCC1=C(CC(=O)N(CCOC)CCOC)C(C(=O)C2=CC(OC)=C(OCCN3CCOCC3)C=C2)=C(O)C=C1O	PLASMA	E628ZH6U2C									∞	ng × h/mL	992		ng/mL	645			UNKNOWN	mg/m²	14		SINGLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28873084	Homo sapiens		h	6.05				3	KW-2478		false
9882	33115		ADULT	23116321	611.123	KW-2478	KW-2478	Cl.CCC1=C(CC(=O)N(CCOC)CCOC)C(C(=O)C2=CC(OC)=C(OCCN3CCOCC3)C=C2)=C(O)C=C1O	PLASMA	E628ZH6U2C									∞	ng × h/mL	11501		ng/mL	6838			UNKNOWN	mg/m²	176		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28873084	Homo sapiens		h	5.43				6			false
9883	33115		ADULT	23116321	611.123	KW-2478	KW-2478	Cl.CCC1=C(CC(=O)N(CCOC)CCOC)C(C(=O)C2=CC(OC)=C(OCCN3CCOCC3)C=C2)=C(O)C=C1O	PLASMA	E628ZH6U2C									∞	ng × h/mL	7876		ng/mL	5410			UNKNOWN	mg/m²	132		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28873084	Homo sapiens		h	5.71				6			false
9884	33115		ADULT	23116321	611.123	KW-2478	KW-2478	Cl.CCC1=C(CC(=O)N(CCOC)CCOC)C(C(=O)C2=CC(OC)=C(OCCN3CCOCC3)C=C2)=C(O)C=C1O	PLASMA	E628ZH6U2C									∞	ng × h/mL	3197		ng/mL	2620			UNKNOWN	mg/m²	71		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28873084	Homo sapiens		h	6.29				3			false
9885	33115		ADULT	23116321	611.123	KW-2478	KW-2478	Cl.CCC1=C(CC(=O)N(CCOC)CCOC)C(C(=O)C2=CC(OC)=C(OCCN3CCOCC3)C=C2)=C(O)C=C1O	PLASMA	E628ZH6U2C									∞	ng × h/mL	2758		ng/mL	1990			UNKNOWN	mg/m²	47		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28873084	Homo sapiens		h	6.6				3			false
9886	33464		ADULT	15150|443893|5282143|78759347|135403647|135883785	511.501	LEUCOVORIN CALCIUM	LEUCOVORIN CALCIUM	[Ca++].NC1=NC(=O)C2=C(NCC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)N2C=O)N1	PLASMA	RPR1R4C0P4	3385|5281053		FLUOROURACIL	FLUOROURACIL	FC1=CNC(=O)NC1=O	U3P01618RT			?	mM × min	71		μM	96			UNKNOWN	mg/m²	500	infusion, 2 hour	OTHER	UNKNOWN		week	1			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3260621	Homo sapiens		h	8							true
9887	33464		ADULT	15150|443893|5282143|78759347|135403647|135883785	511.501	LEUCOVORIN CALCIUM	LEUCOVORIN CALCIUM	[Ca++].NC1=NC(=O)C2=C(NCC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)N2C=O)N1	PLASMA	RPR1R4C0P4	3385|5281053		FLUOROURACIL	FLUOROURACIL	FC1=CNC(=O)NC1=O	U3P01618RT			?	mM × min	364		μM	51			UNKNOWN	mg/m²	500	infusion, 120 hour	OTHER	UNKNOWN		5 weeks	1			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/3260621	Homo sapiens										true
9888	33464		ADULT	15150|443893|5282143|78759347|135403647|135883785	511.501	LEUCOVORIN CALCIUM	LEUCOVORIN CALCIUM	[Ca++].NC1=NC(=O)C2=C(NCC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)N2C=O)N1	PLASMA	RPR1R4C0P4							24		t	mg × h/mL	1810		ng/mL	391			UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8405015	Homo sapiens										false
9889	33502		ADULT	460516	244.2047	LEVOVIRIN	levovirin	NC(=O)C1=NN(C=N1)[C@H]2O[C@@H](CO)[C@H](O)[C@@H]2O	PLASMA	ZGF0S6S33Q									∞	μg × h/mL	193.1		μg/mL	19.62			UNKNOWN	mg	1500		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15831782/	Homo sapiens		h	9.9				6	levovirin valinate		false
9890	33502		ADULT	460516	244.2047	LEVOVIRIN	levovirin	NC(=O)C1=NN(C=N1)[C@H]2O[C@@H](CO)[C@H](O)[C@@H]2O	PLASMA	ZGF0S6S33Q									∞	μg × h/mL	1.68		μg/mL	0.66			UNKNOWN	mg	3000		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15831782/	Homo sapiens		h	0.8				6	levovirin valinate		false
9891	33502		ADULT	460516	244.2047	LEVOVIRIN	levovirin	NC(=O)C1=NN(C=N1)[C@H]2O[C@@H](CO)[C@H](O)[C@@H]2O	PLASMA	ZGF0S6S33Q									∞	μg × h/mL	98		μg/mL	13.65			UNKNOWN	mg	750		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15831782/	Homo sapiens		h	15.1				6	levovirin valinate		false
9892	33502		ADULT	460516	244.2047	LEVOVIRIN	levovirin	NC(=O)C1=NN(C=N1)[C@H]2O[C@@H](CO)[C@H](O)[C@@H]2O	PLASMA	ZGF0S6S33Q									∞	μg × h/mL	275.7		μg/mL	28.22			UNKNOWN	mg	1500		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15831782/	Homo sapiens		h	21.1				6	levovirin valinate		false
9893	33502		ADULT	460516	244.2047	LEVOVIRIN	levovirin	NC(=O)C1=NN(C=N1)[C@H]2O[C@@H](CO)[C@H](O)[C@@H]2O	PLASMA	ZGF0S6S33Q									∞	μg × h/mL	2.09		μg/mL	0.89			UNKNOWN	mg	3000		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15831782/	Homo sapiens		h	0.65				6	levovirin valinate		false
9894	33502		ADULT	460516	244.2047	LEVOVIRIN	levovirin	NC(=O)C1=NN(C=N1)[C@H]2O[C@@H](CO)[C@H](O)[C@@H]2O	PLASMA	ZGF0S6S33Q									∞	μg × h/mL	94.5		μg/mL	10.02			UNKNOWN	mg	750		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15831782/	Homo sapiens		h	7.7				5	levovirin valinate		false
9895	33502		ADULT	460516	244.2047	LEVOVIRIN	levovirin	NC(=O)C1=NN(C=N1)[C@H]2O[C@@H](CO)[C@H](O)[C@@H]2O	PLASMA	ZGF0S6S33Q									∞	μg × h/mL	371.7		μg/mL	35.13			HIGHEST STUDIED	mg	3000		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15831782/	Homo sapiens		h	8.5				6	levovirin valinate		false
9896	33538			184459	234.1895	LIGUSTRAZINE PHOSPHATE	tetramethylpyrazine phosphate	OP(O)(O)=O.CC1=NC(C)=C(C)N=C1C	PLASMA	R880OY6N6S																											34.15				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21213541/	Homo sapiens								tetramethylpyrazine phosphate		false
9897	33538		ADULT	14296	136.1943	LIGUSTRAZINE	tetramethylpyrazine	CC1=NC(C)=C(C)N=C1C	PLASMA	V80F4IA5XG									∞	ng × h/mL	2715.6		ng/mL	1284.26			UNKNOWN	mg	108		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23514701/	Homo sapiens		h	1.49	Dose (108 mg) refers to tetramethylpyrazine free base.			20	2,3,5,6-tetramethylpyrazine phosphate		false
9898	33538		ADULT	14296	136.1943	LIGUSTRAZINE	tetramethylpyrazine	CC1=NC(C)=C(C)N=C1C	PLASMA	V80F4IA5XG									∞	ng × h/mL	3313.58		ng/mL	309.2			UNKNOWN	mg	250		SINGLE	FASTED						HEALTHY	Transdermal	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23514701/	Homo sapiens				Dose (250 mg) refers to tetramethylpyrazine free base.			20	2,3,5,6-tetramethylpyrazine phosphate		false
9899	33538		ADULT	14296	136.1943	LIGUSTRAZINE	tetramethylpyrazine	CC1=NC(C)=C(C)N=C1C	PLASMA	V80F4IA5XG										ng × h/mL	3753.91		ng/mL	326.13			UNKNOWN	mg	250		MULTIPLE			day	1	AUC was for steady-state, referring to AUC within the interval between administrations in the multiple-dose study.		HEALTHY	Transdermal	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23514701/	Homo sapiens				Dose (250 mg) refers to tetramethylpyrazine free base.			20	2,3,5,6-tetramethylpyrazine phosphate		false
9900	33538		ADULT	14296	136.1943	LIGUSTRAZINE	tetramethylpyrazine	CC1=NC(C)=C(C)N=C1C	PLASMA	V80F4IA5XG										ng × h/mL	1187.89		ng/mL	613.44			UNKNOWN	mg	54		MULTIPLE			day	3	AUC was for steady-state, referring to AUC within the interval between administrations in the multiple-dose study.		HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23514701/	Homo sapiens		h	1.61	Dose (54 mg) refers to tetramethylpyrazine free base.			20	2,3,5,6-tetramethylpyrazine phosphate		false
9901	33538		ADULT	184459	234.1895	LIGUSTRAZINE PHOSPHATE	tetramethylpyrazine phosphate	OP(O)(O)=O.CC1=NC(C)=C(C)N=C1C	PLASMA	R880OY6N6S									∞	ng × h/mL	1786.29		ng/mL	1109.78			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29882510/	Homo sapiens		h	1.69				20	tetramethylpyrazine phosphate		false
9902	33779		ADULT	46200994	1439.7914	LTX-315	LTX-315	NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC3=CNC4=C3C=CC=C4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC5=CNC6=C5C=CC=C6)C(=O)N[C@@H](C(C7=CC=CC=C7)C8=CC=CC=C8)C(=O)N[C@@H](CCCCN)C(N)=O	PLASMA	75FBL12IZ7									?	ng × h/mL	28		ng/mL	95			UNKNOWN	mg	4		MULTIPLE	UNKNOWN		week	3			UNHEALTHY	Intralesional	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33542073	Homo sapiens							3	LTX-315		false
9903	33779		ADULT	46200994	1439.7914	LTX-315	LTX-315	NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC3=CNC4=C3C=CC=C4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC5=CNC6=C5C=CC=C6)C(=O)N[C@@H](C(C7=CC=CC=C7)C8=CC=CC=C8)C(=O)N[C@@H](CCCCN)C(N)=O	PLASMA	75FBL12IZ7									?	ng × h/mL	49		ng/mL	427			UNKNOWN	mg	6		MULTIPLE	UNKNOWN		week	3			UNHEALTHY	Intralesional	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33542073	Homo sapiens								LTX-315		false
9904	33779		ADULT	46200994	1439.7914	LTX-315	LTX-315	NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC3=CNC4=C3C=CC=C4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC5=CNC6=C5C=CC=C6)C(=O)N[C@@H](C(C7=CC=CC=C7)C8=CC=CC=C8)C(=O)N[C@@H](CCCCN)C(N)=O	PLASMA	75FBL12IZ7									?	ng × h/mL	6		ng/mL	24			UNKNOWN	mg	2		MULTIPLE	UNKNOWN		week	3			UNHEALTHY	Intralesional	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33542073	Homo sapiens							3	LTX-315		false
9905	33779		UNKNOWN	46200994	1439.7914	LTX-315	LTX-315	NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC3=CNC4=C3C=CC=C4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC5=CNC6=C5C=CC=C6)C(=O)N[C@@H](C(C7=CC=CC=C7)C8=CC=CC=C8)C(=O)N[C@@H](CCCCN)C(N)=O	PLASMA	75FBL12IZ7									?	ng × h/mL	617		ng/mL	389			UNKNOWN	mg	7		MULTIPLE	UNKNOWN		week	3			UNHEALTHY	Intralesional	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33542073	Homo sapiens							4	LTX-315		false
9906	33789		ADULT		528.9	LUMEFANTRINE			PLASMA										∞	ng × h/mL	356		μg/mL	6.2			UNKNOWN	mg	480		MULTIPLE	FASTED		day	1	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022268s021lbl.pdf	0.3	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10681341/	Homo sapiens		h	6.1							false
9907	33839		ADULT	9871558	264.1829	2',2'-DIFLUORODEOXYURIDINE	2\',2\'-difluorodeoxyuridine	OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)C(F)(F)[C@@H]1O	PLASMA	Y30D8SIL1I	176870	393.4357	ERLOTINIB	Erlotinib	COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1	J4T82NDH7E	24		t	ng × h/mL	4008		ng/mL	192			UNKNOWN	mg	20		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21753156/	Homo sapiens				Day 1	Patients with advanced solid tumors		2			true
9908	33839		ADULT	9871558	264.1829	2',2'-DIFLUORODEOXYURIDINE	2\',2\'-difluorodeoxyuridine	OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)C(F)(F)[C@@H]1O	PLASMA	Y30D8SIL1I	176870	393.4357	ERLOTINIB	Erlotinib	COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1	J4T82NDH7E	24		t	ng × h/mL	3169		ng/mL	160			UNKNOWN	mg	20		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21753156/	Homo sapiens				Day 1	Patients with advanced solid tumors		3			true
9909	33839		ADULT	9871558	264.1829	2',2'-DIFLUORODEOXYURIDINE	2\',2\'-difluorodeoxyuridine	OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)C(F)(F)[C@@H]1O	PLASMA	Y30D8SIL1I	176870	393.4357	ERLOTINIB	Erlotinib	COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1	J4T82NDH7E	24		t	ng × h/mL	5705		ng/mL	262			UNKNOWN	mg	30		MULTIPLE	UNKNOWN		day	1	n=1 for AUC		UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21753156/	Homo sapiens				Day 1	Patients with advanced solid tumors		3			true
9910	33839		ADULT	9871558	264.1829	2',2'-DIFLUORODEOXYURIDINE	2\',2\'-difluorodeoxyuridine	OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)C(F)(F)[C@@H]1O	PLASMA	Y30D8SIL1I	176870	393.4357	ERLOTINIB	Erlotinib	COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1	J4T82NDH7E	24		t	ng × h/mL	5853		ng/mL	296			UNKNOWN	mg	40		MULTIPLE	UNKNOWN		day	1	n=15 for AUC		UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21753156/	Homo sapiens				Day 1	Patients with advanced solid tumors		19			true
9911	33839		ADULT	9871558	264.1829	2',2'-DIFLUORODEOXYURIDINE	2\',2\'-difluorodeoxyuridine	OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)C(F)(F)[C@@H]1O	PLASMA	Y30D8SIL1I	176870	393.4357	ERLOTINIB	Erlotinib	COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1	J4T82NDH7E	24		t	ng × h/mL	7093		ng/mL	320			UNKNOWN	mg	40		MULTIPLE	UNKNOWN		day	1	n=5 for AUC		UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21753156/	Homo sapiens				Day 1	Patients with advanced solid tumors		6			true
9912	33839		ADULT	9871558	264.1829	2',2'-DIFLUORODEOXYURIDINE	2\',2\'-difluorodeoxyuridine	OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)C(F)(F)[C@@H]1O	PLASMA	Y30D8SIL1I	176870	393.4357	ERLOTINIB	Erlotinib	COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1	J4T82NDH7E	24		t	ng × h/mL	5753		ng/mL	363			UNKNOWN	mg	50		MULTIPLE	UNKNOWN		day	1	n=3 for AUC		UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21753156/	Homo sapiens				Day 1	Patients with advanced solid tumors		5			true
9913	33839		ADULT	9871558	264.1829	2',2'-DIFLUORODEOXYURIDINE	2\',2\'-difluorodeoxyuridine	OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)C(F)(F)[C@@H]1O	PLASMA	Y30D8SIL1I	176870	393.4357	ERLOTINIB	Erlotinib	COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1	J4T82NDH7E	24		t	ng × h/mL	3338		ng/mL	152			UNKNOWN	mg	5		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21753156/	Homo sapiens		h	89.3	Day 14	Patients with advanced solid tumors		5			true
9914	33839		ADULT	9871558	264.1829	2',2'-DIFLUORODEOXYURIDINE	2\',2\'-difluorodeoxyuridine	OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)C(F)(F)[C@@H]1O	PLASMA	Y30D8SIL1I	176870	393.4357	ERLOTINIB	Erlotinib	COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1	J4T82NDH7E	24		t	ng × h/mL	9355		ng/mL	401			UNKNOWN	mg	10		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21753156/	Homo sapiens		h	151	Day 14	Patients with advanced solid tumors		1			true
9915	33839		ADULT	9871558	264.1829	2',2'-DIFLUORODEOXYURIDINE	2\',2\'-difluorodeoxyuridine	OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)C(F)(F)[C@@H]1O	PLASMA	Y30D8SIL1I	176870	393.4357	ERLOTINIB	Erlotinib	COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1	J4T82NDH7E	24		t	ng × h/mL	17066		ng/mL	767			UNKNOWN	mg	20		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21753156/	Homo sapiens		h	89.2	Day 14	Patients with advanced solid tumors		3			true
9916	33839		ADULT	9871558	264.1829	2',2'-DIFLUORODEOXYURIDINE	2\',2\'-difluorodeoxyuridine	OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)C(F)(F)[C@@H]1O	PLASMA	Y30D8SIL1I	176870	393.4357	ERLOTINIB	Erlotinib	COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1	J4T82NDH7E	24		t	ng × h/mL	18438		ng/mL	873			UNKNOWN	mg	20		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21753156/	Homo sapiens		h	105	Day 14	Patients with advanced solid tumors		3			true
9917	33839		ADULT	9871558	264.1829	2',2'-DIFLUORODEOXYURIDINE	2\',2\'-difluorodeoxyuridine	OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)C(F)(F)[C@@H]1O	PLASMA	Y30D8SIL1I	176870	393.4357	ERLOTINIB	Erlotinib	COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1	J4T82NDH7E	24		t	ng × h/mL	22254		ng/mL	1034			UNKNOWN	mg	30		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21753156/	Homo sapiens		h	71	Day 14	Patients with advanced solid tumors		3			true
9918	33839		ADULT	9871558	264.1829	2',2'-DIFLUORODEOXYURIDINE	2\',2\'-difluorodeoxyuridine	OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)C(F)(F)[C@@H]1O	PLASMA	Y30D8SIL1I	176870	393.4357	ERLOTINIB	Erlotinib	COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1	J4T82NDH7E	24		t	ng × h/mL	28264		ng/mL	1295			UNKNOWN	mg	40		MULTIPLE	UNKNOWN		day	1	n=4 for AUC		UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21753156/	Homo sapiens		h	85.1	Day 14	Patients with advanced solid tumors		5			true
9919	33839		ADULT	9871558	264.1829	2',2'-DIFLUORODEOXYURIDINE	2\',2\'-difluorodeoxyuridine	OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)C(F)(F)[C@@H]1O	PLASMA	Y30D8SIL1I	176870	393.4357	ERLOTINIB	Erlotinib	COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1	J4T82NDH7E	24		t	ng × h/mL	21055		ng/mL	977			UNKNOWN	mg	40		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21753156/	Homo sapiens		h	78.2	Day 14	Patients with advanced solid tumors		4			true
9920	33839		ADULT	9871558	264.1829	2',2'-DIFLUORODEOXYURIDINE	2\',2\'-difluorodeoxyuridine	OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)C(F)(F)[C@@H]1O	PLASMA	Y30D8SIL1I	176870	393.4357	ERLOTINIB	Erlotinib	COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1	J4T82NDH7E	24		t	ng × h/mL	32477		ng/mL	1292			UNKNOWN	mg	50		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21753156/	Homo sapiens		h	92	Day 14	Patients with advanced solid tumors		3			true
9921	33839		ADULT	11646777	389.3943	LY-2334737	LY-2334737	CCCC(CCC)C(=O)NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	YLR364XYSA									∞	ng × h/mL	20		ng/mL	5.3			UNKNOWN	mg	5		MULTIPLE	UNKNOWN		day	1	n=6 for t1/2 and AUC		UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21753156/	Homo sapiens		h	1.6	Day 1	Patients with advanced solid tumors		7			false
9922	33839		ADULT	11646777	389.3943	LY-2334737	LY-2334737	CCCC(CCC)C(=O)NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	YLR364XYSA									∞	ng × h/mL	88		ng/mL	39.3			UNKNOWN	mg	20		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21753156/	Homo sapiens		h	2.6	Day 1	Patients with advanced solid tumors		2			false
9923	33839		ADULT	11646777	389.3943	LY-2334737	LY-2334737	CCCC(CCC)C(=O)NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	YLR364XYSA									∞	ng × h/mL	52		ng/mL	11.6			UNKNOWN	mg	10		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21753156/	Homo sapiens		h	2.4	Day 1	Patients with advanced solid tumors		4			false
9924	33839		ADULT	11646777	389.3943	LY-2334737	LY-2334737	CCCC(CCC)C(=O)NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	YLR364XYSA	176870	393.4357	ERLOTINIB	Erlotinib	COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1	J4T82NDH7E			∞	ng × h/mL	132		ng/mL	34.6			UNKNOWN	mg	20		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21753156/	Homo sapiens		h	5.2	Day 1	Patients with advanced solid tumors		3			true
9925	33839		ADULT	11646777	389.3943	LY-2334737	LY-2334737	CCCC(CCC)C(=O)NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA		176870	393.4357	ERLOTINIB	Erlotinib	COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1	J4T82NDH7E			∞	ng × h/mL	126		ng/mL	44.3			UNKNOWN	mg	30		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21753156/	Homo sapiens		h	3.4	Day 1	Patients with advanced solid tumors		3			true
9926	33839		ADULT	11646777	389.3943	LY-2334737	LY-2334737	CCCC(CCC)C(=O)NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	YLR364XYSA	176870	393.4357	ERLOTINIB	Erlotinib	COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1	J4T82NDH7E			∞	ng × h/mL	140		ng/mL	47.3			UNKNOWN	mg	40		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21753156/	Homo sapiens		h	3	Day 1	Patients with advanced solid tumors		19			true
9927	33839		ADULT	11646777	389.3943	LY-2334737	LY-2334737	CCCC(CCC)C(=O)NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	YLR364XYSA	176870	393.4357	ERLOTINIB	Erlotinib	COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1	J4T82NDH7E			∞	ng × h/mL	170		ng/mL	60			UNKNOWN	mg	40		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21753156/	Homo sapiens		h	2	Day 1	Patients with advanced solid tumors		6			true
9928	33839		ADULT	11646777	389.3943	LY-2334737	LY-2334737	CCCC(CCC)C(=O)NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	YLR364XYSA	176870	393.4357	ERLOTINIB	Erlotinib	COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1	J4T82NDH7E			∞	ng × h/mL	173		ng/mL	71.3			UNKNOWN	mg	50		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21753156/	Homo sapiens		h	3.2	Day 1	Patients with advanced solid tumors		5			true
9929	33839		ADULT	11646777	389.3943	LY-2334737	LY-2334737	CCCC(CCC)C(=O)NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	YLR364XYSA	176870	393.4357	ERLOTINIB	Erlotinib	COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1	J4T82NDH7E			∞	ng × h/mL	17		ng/mL	5			UNKNOWN	mg	5		MULTIPLE	UNKNOWN		day	1	n-4 for t1/2 and AUC		UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21753156/	Homo sapiens		h	1.5	Day 14	Patients with advanced solid tumors		5			true
9930	33839		ADULT	11646777	389.3943	LY-2334737	LY-2334737	CCCC(CCC)C(=O)NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	YLR364XYSA	176870	393.4357	ERLOTINIB	Erlotinib	COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1	J4T82NDH7E			∞	ng × h/mL	80		ng/mL	4			UNKNOWN	mg	10		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21753156/	Homo sapiens				Day 14	Patients with advanced solid tumors		2			true
9931	33839		ADULT	11646777	389.3943	LY-2334737	LY-2334737	CCCC(CCC)C(=O)NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	YLR364XYSA	176870	393.4357	ERLOTINIB	Erlotinib	COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1	J4T82NDH7E			∞	ng × h/mL	81		ng/mL	20.7			UNKNOWN	mg	20		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21753156/	Homo sapiens		h	5.5	Day 14	Patients with advanced solid tumors		3			true
9932	33839		ADULT	11646777	389.3943	LY-2334737	LY-2334737	CCCC(CCC)C(=O)NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	YLR364XYSA	176870	393.4357	ERLOTINIB	Erlotinib	COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1	J4T82NDH7E			∞	ng × h/mL	172		ng/mL	51.5			UNKNOWN	mg	20		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21753156/	Homo sapiens		h	11.3	Day 14	Patients with advanced solid tumors		3			true
9933	33839		ADULT	11646777	389.3943	LY-2334737	LY-2334737	CCCC(CCC)C(=O)NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	YLR364XYSA	176870	393.4357	ERLOTINIB	Erlotinib	COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1	J4T82NDH7E			∞	ng × h/mL	208		ng/mL	85.6			UNKNOWN	mg	30		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21753156/	Homo sapiens		h	4	Day 14	Patients with advanced solid tumors		3			true
9934	33839		ADULT	11646777	389.3943	LY-2334737	LY-2334737	CCCC(CCC)C(=O)NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	YLR364XYSA	176870	393.4357	ERLOTINIB	Erlotinib	COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1	J4T82NDH7E			∞	ng × h/mL	244		ng/mL	44.7			UNKNOWN	mg	40		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21753156/	Homo sapiens		h	11.4	Day 14	Patients with advanced solid tumors		5			true
9935	33839		ADULT	11646777	389.3943	LY-2334737	LY-2334737	CCCC(CCC)C(=O)NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	YLR364XYSA	176870	393.4357	ERLOTINIB	Erlotinib	COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1	J4T82NDH7E			∞	ng × h/mL	189		ng/mL	43.8			UNKNOWN	mg	40		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21753156/	Homo sapiens		h	3.4	Day 14	Patients with advanced solid tumors		4			true
9936	33839		ADULT	11646777	389.3943	LY-2334737	LY-2334737	CCCC(CCC)C(=O)NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	YLR364XYSA	176870	393.4357	ERLOTINIB	Erlotinib	COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1	J4T82NDH7E			∞	ng × h/mL	340		ng/mL	61.2			UNKNOWN	mg	50		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21753156/	Homo sapiens		h	5.2	Day 14	Patients with advanced solid tumors		3			true
9937	33839		ADULT	60750	263.1981	GEMCITABINE	Gemcitabine	NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	B76N6SBZ8R	176870	393.4357	ERLOTINIB	Erlotinib	COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1	J4T82NDH7E							ng/mL	0.6			UNKNOWN	mg	5		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21753156/	Homo sapiens				Day 1	Patients with advanced solid tumors		7			true
9938	33839		ADULT	60750	263.1981	GEMCITABINE	Gemcitabine	NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	B76N6SBZ8R	176870	393.4357	ERLOTINIB	Erlotinib	COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1	J4T82NDH7E			∞	ng × h/mL	6.7		ng/mL	1.37			UNKNOWN	mg	10		MULTIPLE	UNKNOWN		day	1	n=1 for t1/2 and AUC		UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21753156/	Homo sapiens		h	2.8	Day 1	Patients with advanced solid tumors		4			true
9939	33839		ADULT	60750	263.1981	GEMCITABINE	Gemcitabine	NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	B76N6SBZ8R	176870	393.4357	ERLOTINIB	Erlotinib	COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1	J4T82NDH7E			∞	ng × h/mL	9.9		ng/mL	3.2			UNKNOWN	mg	20		MULTIPLE	UNKNOWN		day	1	n=1 for t1/2 and AUC		UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21753156/	Homo sapiens		h	1.1	Day 1	Patients with advanced solid tumors		2			true
9940	33839		ADULT	60750	263.1981	GEMCITABINE	Gemcitabine	NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	B76N6SBZ8R	176870	393.4357	ERLOTINIB	Erlotinib	COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1	J4T82NDH7E			∞	ng × h/mL	9		ng/mL	2			UNKNOWN	mg	20		MULTIPLE	UNKNOWN		day	1	n=2 for t1/2 and AUC		UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21753156/	Homo sapiens		h	2.1	Day 1	Patients with advanced solid tumors		3			true
9941	33839		ADULT	60750	263.1981	GEMCITABINE	Gemcitabine	NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	B76N6SBZ8R	176870	393.4357	ERLOTINIB	Erlotinib	COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1	J4T82NDH7E			∞	ng × h/mL	16		ng/mL	5.25			UNKNOWN	mg	30		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21753156/	Homo sapiens		h	2.1	Day 1	Patients with advanced solid tumors		3			true
9942	33839		ADULT	60750	263.1981	GEMCITABINE	Gemcitabine	NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	B76N6SBZ8R	176870	393.4357	ERLOTINIB	Erlotinib	COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1	J4T82NDH7E			∞	ng × h/mL	17.4		ng/mL	5.32			UNKNOWN	mg	40		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21753156/	Homo sapiens		h	1.9	Day 1	Patients with advanced solid tumors		19			true
9943	33839		ADULT	60750	263.1981	GEMCITABINE	Gemcitabine	NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	B76N6SBZ8R	176870	393.4357	ERLOTINIB	Erlotinib	COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1	J4T82NDH7E			∞	ng × h/mL	27.9		ng/mL	6.45			UNKNOWN	mg	40		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21753156/	Homo sapiens		h	1.6	Day 1	Patients with advanced solid tumors		6			true
9944	33839		ADULT	60750	263.1981	GEMCITABINE	Gemcitabine	NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	B76N6SBZ8R	176870	393.4357	ERLOTINIB	Erlotinib	COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1	J4T82NDH7E			∞	ng × h/mL	26.6		ng/mL	11.1			UNKNOWN	mg	50		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21753156/	Homo sapiens		h	1.7	Day 1	Patients with advanced solid tumors		5			true
9945	33839		ADULT	60750	263.1981	GEMCITABINE	Gemcitabine	NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	B76N6SBZ8R	176870	393.4357	ERLOTINIB	Erlotinib	COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1	J4T82NDH7E							ng/mL	0.62			UNKNOWN	mg	5		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21753156/	Homo sapiens				Day 14	Patients with advanced solid tumors		4			true
9946	33839		ADULT	60750	263.1981	GEMCITABINE	Gemcitabine	NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	B76N6SBZ8R	176870	393.4357	ERLOTINIB	Erlotinib	COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1	J4T82NDH7E							ng/mL	0.4			UNKNOWN	mg	10		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21753156/	Homo sapiens				Day 14	Patients with advanced solid tumors		1			true
9947	33839		ADULT	60750	263.1981	GEMCITABINE	Gemcitabine	NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	B76N6SBZ8R	176870	393.4357	ERLOTINIB	Erlotinib	COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1	J4T82NDH7E							ng/mL	1.56			UNKNOWN	mg	20		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21753156/	Homo sapiens				Day 14	Patients with advanced solid tumors		2			true
9948	33839		ADULT	60750	263.1981	GEMCITABINE	Gemcitabine	NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	B76N6SBZ8R	176870	393.4357	ERLOTINIB	Erlotinib	COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1	J4T82NDH7E			∞	ng × h/mL	10.8		ng/mL	3.66			UNKNOWN	mg	20		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21753156/	Homo sapiens		h	1.7	Day 14	Patients with advanced solid tumors		3			true
9949	33839		ADULT	60750	263.1981	GEMCITABINE	Gemcitabine	NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	B76N6SBZ8R	176870	393.4357	ERLOTINIB	Erlotinib	COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1	J4T82NDH7E			∞	ng × h/mL	25.1		ng/mL	7.97			UNKNOWN	mg	30		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21753156/	Homo sapiens		h	3.7	Day 14	Patients with advanced solid tumors		3			true
9950	33839		ADULT	60750	263.1981	GEMCITABINE	Gemcitabine	NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	B76N6SBZ8R	176870	393.4357	ERLOTINIB	Erlotinib	COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1	J4T82NDH7E			∞	ng × h/mL	37		ng/mL	5.02			UNKNOWN	mg	50		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21753156/	Homo sapiens		h	3.6	Day 14	Patients with advanced solid tumors		3			true
9951	33839		ADULT	60750	263.1981	GEMCITABINE	Gemcitabine	NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	B76N6SBZ8R	176870	393.4357	ERLOTINIB	Erlotinib	COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1	J4T82NDH7E			∞	ng × h/mL	35.9		ng/mL	4.41			UNKNOWN	mg	40		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21753156/	Homo sapiens		h	8.7	Day 14	Patients with advanced solid tumors		5			true
9952	33839		ADULT	60750	263.1981	GEMCITABINE	Gemcitabine	NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	B76N6SBZ8R	176870	393.4357	ERLOTINIB	Erlotinib	COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1	J4T82NDH7E			∞	ng × h/mL	29.1		ng/mL	4.09			UNKNOWN	mg	40		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21753156/	Homo sapiens		h	4.8	Day 14	Patients with advanced solid tumors		4			true
9953	33839		ADULT	9871558	264.1829	2',2'-DIFLUORODEOXYURIDINE	2\',2\'-difluorodeoxyuridine	OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)C(F)(F)[C@@H]1O	PLASMA	Y30D8SIL1I	176870	393.4357	ERLOTINIB	Erlotinib	COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1	J4T82NDH7E	24		t	ng × h/mL	1463		ng/mL	61			UNKNOWN	mg	5		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21753156/	Homo sapiens				Day 1	Patients with advanced solid tumors		7			true
9954	33839		ADULT	9871558	264.1829	2',2'-DIFLUORODEOXYURIDINE	2\',2\'-difluorodeoxyuridine	OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)C(F)(F)[C@@H]1O	PLASMA	Y30D8SIL1I	176870	393.4357	ERLOTINIB	Erlotinib	COCCOC1=C(OCCOC)C=C2C(NC3=CC(=CC=C3)C#C)=NC=NC2=C1	J4T82NDH7E	24		t	ng × h/mL	2511		ng/mL	121			UNKNOWN	mg	10		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21753156/	Homo sapiens				Day 1	Patients with advanced solid tumors		4			true
9955	33839		ADULT	9871558	264.1829	2',2'-DIFLUORODEOXYURIDINE	2\',2\'-difluorodeoxyuridine	OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)C(F)(F)[C@@H]1O	PLASMA	Y30D8SIL1I							48		t	ng × h/mL	38000		ng/mL	1050			UNKNOWN	mg	80		STEADY-STATE	UNKNOWN		2 days	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens		h	61.6	Day 21	patients with solid tumors		3			false
9956	33839		ADULT	9871558	264.1829	2',2'-DIFLUORODEOXYURIDINE	2\',2\'-difluorodeoxyuridine	OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)C(F)(F)[C@@H]1O	PLASMA	Y30D8SIL1I							48		t	ng × h/mL	51500		ng/mL	1390			UNKNOWN	mg	90		STEADY-STATE	UNKNOWN		2 days	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens		h	87.4	Day 21	patients with solid tumors		13			false
9957	33839		ADULT	9871558	264.1829	2',2'-DIFLUORODEOXYURIDINE	2\',2\'-difluorodeoxyuridine	OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)C(F)(F)[C@@H]1O	PLASMA	Y30D8SIL1I							48		t	ng × h/mL	57400		ng/mL	1360			UNKNOWN	mg	100		STEADY-STATE	UNKNOWN		2 days	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens		h	84.6	Day 21	patients with solid tumors		3			false
9958	33839		ADULT	11646777	389.3943	LY-2334737	LY-2334737	CCCC(CCC)C(=O)NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	YLR364XYSA							24		t	ng × h/mL	227		ng/mL	48.8			UNKNOWN	mg	40		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens		h	3.29	Day 21	patients with solid tumors		3			false
9959	33839		ADULT	11646777	389.3943	LY-2334737	LY-2334737	CCCC(CCC)C(=O)NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	YLR364XYSA							24		t	ng × h/mL	233		ng/mL	37.9			UNKNOWN	mg	50		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens		h	3.73	Day 21	patients with solid tumors		3			false
9960	33839		ADULT	11646777	389.3943	LY-2334737	LY-2334737	CCCC(CCC)C(=O)NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	YLR364XYSA							24		t	ng × h/mL	445		ng/mL	106			UNKNOWN	mg	60		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens		h	4.42	Day 21	patients with solid tumors		5			false
9961	33839		ADULT	11646777	389.3943	LY-2334737	LY-2334737	CCCC(CCC)C(=O)NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	YLR364XYSA							24		t	ng × h/mL	620		ng/mL	108			UNKNOWN	mg	70		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens		h	8.63	Day 21	patients with solid tumors		2			false
9962	33839		ADULT	11646777	389.3943	LY-2334737	LY-2334737	CCCC(CCC)C(=O)NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	YLR364XYSA							24		t	ng × h/mL	392		ng/mL	74.4			UNKNOWN	mg	80		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens		h	3.86	Day 21	patients with solid tumors		5			false
9963	33839		ADULT	11646777	389.3943	LY-2334737	LY-2334737	CCCC(CCC)C(=O)NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	YLR364XYSA							24		t	ng × h/mL	580		ng/mL	137			UNKNOWN	mg	90		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens		h	4.63	Day 21	patients with solid tumors		3			false
9964	33839		ADULT	60750	263.1981	GEMCITABINE	Gemcitabine	NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	B76N6SBZ8R							24		t	ng × h/mL	38.6		ng/mL	5.8			UNKNOWN	mg	40		STEADY-STATE	UNKNOWN		day	1	n=1 for AUC		UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens				Day 21	patients with solid tumors		3			false
9965	33839		ADULT	60750	263.1981	GEMCITABINE	Gemcitabine	NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	B76N6SBZ8R							24		t	ng × h/mL	27.8		ng/mL	4.1			UNKNOWN	mg	50		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens				Day 21	patients with solid tumors		3			false
9966	33839		ADULT	60750	263.1981	GEMCITABINE	Gemcitabine	NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	B76N6SBZ8R							24		t	ng × h/mL	28.9		ng/mL	7			UNKNOWN	mg	60		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens				Day 21	patients with solid tumors		5			false
9967	33839		ADULT	60750	263.1981	GEMCITABINE	Gemcitabine	NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	B76N6SBZ8R							24		t	ng × h/mL	74.8		ng/mL	7			UNKNOWN	mg	70		STEADY-STATE	UNKNOWN		day	1	n=1 for AUC		UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens				Day 21	patients with solid tumors		2			false
9968	33839		ADULT	60750	263.1981	GEMCITABINE	Gemcitabine	NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	B76N6SBZ8R							24		t	ng × h/mL	45		ng/mL	6.9			UNKNOWN	mg	80		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens				Day 21	patients with solid tumors		5			false
9969	33839		ADULT	60750	263.1981	GEMCITABINE	Gemcitabine	NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	B76N6SBZ8R							24		t	ng × h/mL	119		ng/mL	16.7			UNKNOWN	mg	90		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens				Day 21	patients with solid tumors		3			false
9970	33839		ADULT	9871558	264.1829	2',2'-DIFLUORODEOXYURIDINE	2\',2\'-difluorodeoxyuridine	OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)C(F)(F)[C@@H]1O	PLASMA	Y30D8SIL1I							24		t	ng × h/mL	29300		ng/mL	1450			UNKNOWN	mg	40		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens		h	107	Day 21	patients with solid tumors		3			false
9971	33839		ADULT	11646777	389.3943	LY-2334737	LY-2334737	CCCC(CCC)C(=O)NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	YLR364XYSA									∞	ng × h/mL	159		ng/mL	50			UNKNOWN	mg	40		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens		h	3.2		patients with solid tumors		6			false
9972	33839		ADULT	9871558	264.1829	2',2'-DIFLUORODEOXYURIDINE	2\',2\'-difluorodeoxyuridine	OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)C(F)(F)[C@@H]1O	PLASMA	Y30D8SIL1I							24		t	ng × h/mL	32200		ng/mL	1670			UNKNOWN	mg	50		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens		h	121	Day 21	patients with solid tumors		3			false
9973	33839		ADULT	11646777	389.3943	LY-2334737	LY-2334737	CCCC(CCC)C(=O)NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	YLR364XYSA									∞	ng × h/mL	207		ng/mL	72.2			UNKNOWN	mg	50		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens		h	3.4		patients with solid tumors		5			false
9974	33839		ADULT	11646777	389.3943	LY-2334737	LY-2334737	CCCC(CCC)C(=O)NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	YLR364XYSA									∞	ng × h/mL	292		ng/mL	98.2			UNKNOWN	mg	60		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens		h	3.31		patients with solid tumors		10			false
9975	33839		ADULT	9871558	264.1829	2',2'-DIFLUORODEOXYURIDINE	2\',2\'-difluorodeoxyuridine	OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)C(F)(F)[C@@H]1O	PLASMA	Y30D8SIL1I							24		t	ng × h/mL	35700		ng/mL	1650			UNKNOWN	mg	60		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens		h	85.4	Day 21	patients with solid tumors		5			false
9976	33839		ADULT	9871558	264.1829	2',2'-DIFLUORODEOXYURIDINE	2\',2\'-difluorodeoxyuridine	OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)C(F)(F)[C@@H]1O	PLASMA	Y30D8SIL1I							24		t	ng × h/mL	37100		ng/mL	1690			UNKNOWN	mg	70		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens		h	87.3	Day 21	patients with solid tumors		2			false
9977	33839		ADULT	11646777	389.3943	LY-2334737	LY-2334737	CCCC(CCC)C(=O)NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	YLR364XYSA									∞	ng × h/mL	294		ng/mL	106.9			UNKNOWN	mg	70		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens		h	3.28		patients with solid tumors		5			false
9978	33839		ADULT	11646777	389.3943	LY-2334737	LY-2334737	CCCC(CCC)C(=O)NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	YLR364XYSA									∞	ng × h/mL	247		ng/mL	69.2			UNKNOWN	mg	80		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens		h	3.2		patients with solid tumors		10			false
9979	33839		ADULT	9871558	264.1829	2',2'-DIFLUORODEOXYURIDINE	2\',2\'-difluorodeoxyuridine	OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)C(F)(F)[C@@H]1O	PLASMA	Y30D8SIL1I							24		t	ng × h/mL	35600		ng/mL	1680			UNKNOWN	mg	80		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens		h	78.3	Day 21	patients with solid tumors		5			false
9980	33839		ADULT	11646777	389.3943	LY-2334737	LY-2334737	CCCC(CCC)C(=O)NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	YLR364XYSA									∞	ng × h/mL	466		ng/mL	168.3			UNKNOWN	mg	90		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens		h	3.8		patients with solid tumors		21			false
9981	33839		ADULT	9871558	264.1829	2',2'-DIFLUORODEOXYURIDINE	2\',2\'-difluorodeoxyuridine	OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)C(F)(F)[C@@H]1O	PLASMA	Y30D8SIL1I							24		t	ng × h/mL	39900		ng/mL	1940			UNKNOWN	mg	90		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens		h	65.7	Day 21	patients with solid tumors		3			false
9982	33839		ADULT	11646777	389.3943	LY-2334737	LY-2334737	CCCC(CCC)C(=O)NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	YLR364XYSA									∞	ng × h/mL	421		ng/mL	105			UNKNOWN	mg	100		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens		h	3.9		patients with solid tumors		8			false
9983	33839		ADULT	60750	263.1981	GEMCITABINE	Gemcitabine	NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	B76N6SBZ8R									∞	ng × h/mL	21.4		ng/mL	7.72			UNKNOWN	mg	50		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens		h	2.1		patients with solid tumors		5			false
9984	33839		ADULT	60750	263.1981	GEMCITABINE	Gemcitabine	NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	B76N6SBZ8R									∞	ng × h/mL	28.3		ng/mL	9.5			UNKNOWN	mg	60		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens		h	1.96		patients with solid tumors		10			false
9985	33839		ADULT	60750	263.1981	GEMCITABINE	Gemcitabine	NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	B76N6SBZ8R									∞	ng × h/mL	50.8		ng/mL	16			UNKNOWN	mg	90		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens		h	2.72		patients with solid tumors		21			false
9986	33839		ADULT	60750	263.1981	GEMCITABINE	Gemcitabine	NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	B76N6SBZ8R									∞	ng × h/mL	59.9		ng/mL	12.1			UNKNOWN	mg	100		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens		h	3.66		patients with solid tumors		7			false
9987	33839		ADULT	11646777	389.3943	LY-2334737	LY-2334737	CCCC(CCC)C(=O)NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	YLR364XYSA							48		t	ng × h/mL	219		ng/mL	68.4			UNKNOWN	mg	40		STEADY-STATE	UNKNOWN		2 days	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens		h	4.8	Day 21	patients with solid tumors		3			false
9988	33839		ADULT	11646777	389.3943	LY-2334737	LY-2334737	CCCC(CCC)C(=O)NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	YLR364XYSA							48		t	ng × h/mL	364		ng/mL	110			UNKNOWN	mg	50		STEADY-STATE	UNKNOWN		2 days	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens		h	6	Day 21	patients with solid tumors		2			false
9989	33839		ADULT	11646777	389.3943	LY-2334737	LY-2334737	CCCC(CCC)C(=O)NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	YLR364XYSA							48		t	ng × h/mL	188		ng/mL	35.7			UNKNOWN	mg	60		STEADY-STATE	UNKNOWN		2 days	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens		h	3.9	Day 21	patients with solid tumors		3			false
9990	33839		ADULT	11646777	389.3943	LY-2334737	LY-2334737	CCCC(CCC)C(=O)NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	YLR364XYSA							48		t	ng × h/mL	341		ng/mL	61.5			UNKNOWN	mg	80		STEADY-STATE	UNKNOWN		2 days	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens		h	6.1	Day 21	patients with solid tumors		3			false
9991	33839		ADULT	11646777	389.3943	LY-2334737	LY-2334737	CCCC(CCC)C(=O)NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	YLR364XYSA							48		t	ng × h/mL	318		ng/mL	93.1			UNKNOWN	mg	70		STEADY-STATE	UNKNOWN		2 days	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens		h	3.8	Day 21	patients with solid tumors		2			false
9992	33839		ADULT	11646777	389.3943	LY-2334737	LY-2334737	CCCC(CCC)C(=O)NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	YLR364XYSA							48		t	ng × h/mL	525		ng/mL	126			UNKNOWN	mg	90		STEADY-STATE	UNKNOWN		2 days	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens		h	6.2	Day 21	patients with solid tumors		13			false
9993	33839		ADULT	11646777	389.3943	LY-2334737	LY-2334737	CCCC(CCC)C(=O)NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	YLR364XYSA							48		t	ng × h/mL	647		ng/mL	147			UNKNOWN	mg	100		STEADY-STATE	UNKNOWN		2 days	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens		h	4.6	Day 21	patients with solid tumors		3			false
9994	33839		ADULT	60750	263.1981	GEMCITABINE	Gemcitabine	NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	B76N6SBZ8R									∞	ng × h/mL	17.3		ng/mL	6.07			UNKNOWN	mg	40		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens		h	2.22		patients with solid tumors		6			false
9995	33839		ADULT	60750	263.1981	GEMCITABINE	Gemcitabine	NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	B76N6SBZ8R									∞	ng × h/mL	35.5		ng/mL	11.4			UNKNOWN	mg	70		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens		h	1.91		patients with solid tumors		5			false
9996	33839		ADULT	60750	263.1981	GEMCITABINE	Gemcitabine	NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	B76N6SBZ8R									∞	ng × h/mL	25		ng/mL	7.2			UNKNOWN	mg	80		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens		h	1.9		patients with solid tumors		10			false
9997	33839		ADULT	60750	263.1981	GEMCITABINE	Gemcitabine	NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	B76N6SBZ8R							48		t	ng × h/mL	12.5		ng/mL	3.6			UNKNOWN	mg	40		STEADY-STATE	UNKNOWN		2 days	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens				Day 21	patients with solid tumors		3			false
9998	33839		ADULT	60750	263.1981	GEMCITABINE	Gemcitabine	NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	B76N6SBZ8R							48		t	ng × h/mL	26.6		ng/mL	8.2			UNKNOWN	mg	50		STEADY-STATE	UNKNOWN		2 days	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens				Day 21	patients with solid tumors		2			false
9999	33839		ADULT	60750	263.1981	GEMCITABINE	Gemcitabine	NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	B76N6SBZ8R							48		t	ng × h/mL	31.1		ng/mL	3.9			UNKNOWN	mg	60		STEADY-STATE	UNKNOWN		2 days	1	n=1 for AUC		UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens				Day 21	patients with solid tumors		3			false
10000	33839		ADULT	60750	263.1981	GEMCITABINE	Gemcitabine	NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	B76N6SBZ8R							48		t	ng × h/mL	35.7		ng/mL	11.3			UNKNOWN	mg	70		STEADY-STATE	UNKNOWN		2 days	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens				Day 21	patients with solid tumors		2			false
10001	33839		ADULT	60750	263.1981	GEMCITABINE	Gemcitabine	NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	B76N6SBZ8R							48		t	ng × h/mL	53.4		ng/mL	10.9			UNKNOWN	mg	80		STEADY-STATE	UNKNOWN		2 days	1	n=1 for AUC		UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens				Day 21	patients with solid tumors		3			false
10002	33839		ADULT	60750	263.1981	GEMCITABINE	Gemcitabine	NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	B76N6SBZ8R							48		t	ng × h/mL	59.6		ng/mL	10.2			UNKNOWN	mg	90		STEADY-STATE	UNKNOWN		2 days	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens				Day 21	patients with solid tumors		13			false
10003	33839		ADULT	60750	263.1981	GEMCITABINE	Gemcitabine	NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	PLASMA	B76N6SBZ8R							48		t	ng × h/mL	55.6		ng/mL	10.9			UNKNOWN	mg	100		STEADY-STATE	UNKNOWN		2 days	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens				Day 21	patients with solid tumors		3			false
10004	33839		ADULT	9871558	264.1829	2',2'-DIFLUORODEOXYURIDINE	2\',2\'-difluorodeoxyuridine	OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)C(F)(F)[C@@H]1O	PLASMA	Y30D8SIL1I							48		t	ng × h/mL	41000		ng/mL	1060			UNKNOWN	mg	40		STEADY-STATE	UNKNOWN		2 days	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens		h	102	Day 21	patients with solid tumors		3			false
10005	33839		ADULT	9871558	264.1829	2',2'-DIFLUORODEOXYURIDINE	2\',2\'-difluorodeoxyuridine	OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)C(F)(F)[C@@H]1O	PLASMA	Y30D8SIL1I							48		t	ng × h/mL	38700		ng/mL	992			UNKNOWN	mg	50		STEADY-STATE	UNKNOWN		2 days	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens		h	95.5	Day 21	patients with solid tumors		2			false
10006	33839		ADULT	9871558	264.1829	2',2'-DIFLUORODEOXYURIDINE	2\',2\'-difluorodeoxyuridine	OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)C(F)(F)[C@@H]1O	PLASMA	Y30D8SIL1I							48		t	ng × h/mL	46800		ng/mL	1120			UNKNOWN	mg	60		STEADY-STATE	UNKNOWN		2 days	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens		h	90.8	Day 21	patients with solid tumors		3			false
10007	33839		ADULT	9871558	264.1829	2',2'-DIFLUORODEOXYURIDINE	2\',2\'-difluorodeoxyuridine	OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)C(F)(F)[C@@H]1O	PLASMA	Y30D8SIL1I							48		t	ng × h/mL	49300		ng/mL	1330			UNKNOWN	mg	70		STEADY-STATE	UNKNOWN		2 days	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens		h	95.8	Day 21	patients with solid tumors		2			false
10008	33850		UNKNOWN	57519748	406.4775	LY-3023414	LY-3023414	CO[C@@H](C)CN1C(=O)N(C)C2=CN=C3C=CC(=CC3=C12)C4=CN=CC(=C4)C(C)(C)O	PLASMA	C88817F47Y																						UNKNOWN				LY3023414 was moderately bound to plasma proteins, with an ex vivo mean unbound fraction of 40% in rat plasma and 17% in human plasma.	17	UNKNOWN		UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/27439478	Homo sapiens										false
10009	33850		ADULT	57519748	406.4775	LY-3023414	CO[C@@H](C)CN1C(=O)N(C)C2=C1C3=CC(=CC=C3N=C2)C4=CC(=CN=C4)C(C)(C)O	CO[C@@H](C)CN1C(=O)N(C)C2=C1C3=CC(=CC=C3N=C2)C4=CC(=CN=C4)C(C)(C)O	BLOOD	C88817F47Y									∞	ng × h/mL	3670		ng/mL	941			RECOMMENDED	mg	200		STEADY-STATE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/29636360	Homo sapiens		h	1.9							false
10010	33851		ADULT	71236992	464.4376	LY-3039478	LY3039478	C[C@H](NC(=O)CCC(F)(F)F)C(=O)N[C@H]1C2=C(C=CC=C2)C3=C(N=CC=C3)N(CCO)C1=O	PLASMA	923X28214S							48		t	ng × h/mL	3900		ng/mL	770			HIGHEST STUDIED	mg	100		MULTIPLE	UNKNOWN		week	3			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30060061/	Homo sapiens		h	5.39				5	LY3039478		false
10011	33851		ADULT	71236992	464.4376	LY-3039478	LY3039478	C[C@H](NC(=O)CCC(F)(F)F)C(=O)N[C@H]1C2=C(C=CC=C2)C3=C(N=CC=C3)N(CCO)C1=O	PLASMA	923X28214S							48		t	ng × h/mL	3220		ng/mL	522			UNKNOWN	mg	45		MULTIPLE	UNKNOWN		week	3			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30060061/	Homo sapiens		h	5.74				5	LY3039478		false
10012	33851		ADULT	71236992	464.4376	LY-3039478	LY3039478	C[C@H](NC(=O)CCC(F)(F)F)C(=O)N[C@H]1C2=C(C=CC=C2)C3=C(N=CC=C3)N(CCO)C1=O	PLASMA	923X28214S							48		t	ng × h/mL	1170		ng/mL	175			UNKNOWN	mg	20		MULTIPLE	UNKNOWN		week	3			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30060061/	Homo sapiens		h	5.76				6	LY3039478		false
10013	33851		ADULT	71236992	464.4376	LY-3039478	LY3039478	C[C@H](NC(=O)CCC(F)(F)F)C(=O)N[C@H]1C2=C(C=CC=C2)C3=C(N=CC=C3)N(CCO)C1=O	PLASMA	923X28214S							48		t	ng × h/mL	3350		ng/mL	444			MAX TOLERATED	mg	75		MULTIPLE	UNKNOWN		week	3			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30060061/	Homo sapiens		h	5.19				4	LY3039478		false
10014	33851		ADULT	71236992	464.4376	LY-3039478	LY3039478	C[C@H](NC(=O)CCC(F)(F)F)C(=O)N[C@H]1C2=C(C=CC=C2)C3=C(N=CC=C3)N(CCO)C1=O	PLASMA	923X28214S									∞	ng × h/mL	711		ng/mL	158			UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30539232/	Homo sapiens		h	5.63				10	crenigacestat		false
10015	33851		ADULT	71236992	464.4376	LY-3039478	LY3039478	C[C@H](NC(=O)CCC(F)(F)F)C(=O)N[C@H]1C2=C(C=CC=C2)C3=C(N=CC=C3)N(CCO)C1=O	PLASMA	923X28214S									∞	ng × h/mL	1400		ng/mL	296			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30539232/	Homo sapiens		h	5.47				9	crenigacestat		false
10016	33851		ADULT	71236992	464.4376	LY-3039478	LY3039478	C[C@H](NC(=O)CCC(F)(F)F)C(=O)N[C@H]1C2=C(C=CC=C2)C3=C(N=CC=C3)N(CCO)C1=O	PLASMA	923X28214S									∞	ng × h/mL	2090		ng/mL	461			UNKNOWN	mg	75		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30539232/	Homo sapiens		h	5.71				10	crenigacestat		false
10017	34187		ADULT	11249520	528.89	MALVIDIN 3-GLUCOSIDE	MALVIDIN 3-GLUCOSIDE	[Cl-].COC1=CC(=CC(OC)=C1O)C2=[O ]C3=C(C=C2O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(O)=CC(O)=C3	PLASMA	B34F52D7NB									?	nM × h	288		nM	1.38			UNKNOWN	mg	68.6		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11697443/	Homo sapiens							6	MALVIDIN 3-GLUCOSIDE		false
10018	34252		ADULT	5281647	422.3396	MANGIFERIN	mangiferin	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C2=C(O)C3=C(OC4=CC(O)=C(O)C=C4C3=O)C=C2O	PLASMA	1M84LD0UMD									∞	ng × h/mL	167.9		ng/mL	19.94			UNKNOWN	g	0.2		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26434292/	Homo sapiens		h	4.47				7	mangiferin		false
10019	34252		ADULT	5281647	422.3396	MANGIFERIN	mangiferin	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C2=C(O)C3=C(OC4=CC(O)=C(O)C=C4C3=O)C=C2O	PLASMA	1M84LD0UMD									∞	ng × h/mL	415.14		ng/mL	38.64			UNKNOWN	g	0.9		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26434292/	Homo sapiens		h	7.85				7	mangiferin		false
10020	34252		ADULT	5281647	422.3396	MANGIFERIN	mangiferin	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C2=C(O)C3=C(OC4=CC(O)=C(O)C=C4C3=O)C=C2O	PLASMA	1M84LD0UMD									∞	ng × h/mL	269.35		ng/mL	34.7			UNKNOWN	g	0.3		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26434292/	Homo sapiens		h	8.8				7	mangiferin		false
10021	34280		ADULT	91466	248.3639	MATRINE	Matrine	O=C1CCC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34	PLASMA	N390W430AC									∞	ng × h/mL	6375		ng/mL	603.3			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19726245/	Homo sapiens		h	8.7				9	Matrine		false
10022	34280		ADULT	91466	248.3639	MATRINE	Matrine	O=C1CCC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34	PLASMA	N390W430AC									∞	ng × h/mL	20316		ng/mL	2384.4			HIGHEST STUDIED	mg	400		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19726245/	Homo sapiens		h	7.8				9	Matrine		false
10023	34280		ADULT	91466	248.3639	MATRINE	Matrine	O=C1CCC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34	PLASMA	N390W430AC									∞	ng × h/mL	13047		ng/mL	1207.3			UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19726245/	Homo sapiens		h	8.3				9	Matrine		false
10024	34353		ADULT	4034	390.948	MECLIZINE	MECLIZINE	CC1=CC=CC(CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(Cl)C=C4)=C1	PLASMA	3L5TQ84570									∞	ng × h/mL	564.03		ng/mL	99.43			RECOMMENDED	mg	25		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21903894/	Homo sapiens		h	5.24							false
10025	34661		ADULT	10836	149.2328	METHAMPHETAMINE	METHAMPHETAMINE	CN[C@@H](C)CC1=CC=CC=C1	PLASMA	44RAL3456C									∞	ng × h/mL	330		ng/mL	19.8			UNKNOWN	mg/kg	0.125		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1362938/	Homo sapiens		h	8.46							false
10026	34736		ADULT	4113	47.0565	METHOXYAMINE	METHOXYAMINE	CON	PLASMA	9TZH4WY30J									∞	ng × h/mL	3105		ng/mL	247			UNKNOWN	mg/m²	100		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23054206	Homo sapiens		h	25	Cycle 1 Day 4			5	METHOXYAMINE		false
10027	34736		ADULT	4113	47.0565	METHOXYAMINE	METHOXYAMINE	CON	PLASMA	9TZH4WY30J									∞	ng × h/mL	5812		ng/mL	327			MAX TOLERATED	mg/m²	60		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23054206	Homo sapiens		h	26.9	Cycle 1 Day 4			3	METHOXYAMINE		false
10028	34736		ADULT	4113	47.0565	METHOXYAMINE	METHOXYAMINE	CON	PLASMA	9TZH4WY30J									∞	ng × h/mL	2312		ng/mL	152			UNKNOWN	mg/m²	100		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23054206	Homo sapiens		h	26.8	Cycle 1 Day 1			5	METHOXYAMINE		false
10029	34736		ADULT		47.0565	METHOXYAMINE	METHOXYAMINE	CON	PLASMA	9TZH4WY30J									∞	ng × h/mL	287		ng/mL	19.7			UNKNOWN	mg/m²	15		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23054206	Homo sapiens		h	37.3	Cycle 1 Day 1			3	METHOXYAMINE		false
10030	34736		ADULT	4113	47.0565	METHOXYAMINE	METHOXYAMINE	CON	PLASMA	9TZH4WY30J									∞	ng × h/mL	1041		ng/mL	64.3			UNKNOWN	mg/m²	30		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23054206	Homo sapiens		h	21.8	Cycle 1 Day 1			6	METHOXYAMINE		false
10031	34736		ADULT	4113	47.0565	METHOXYAMINE	METHOXYAMINE	CON	PLASMA	9TZH4WY30J									∞	ng × h/mL	1991		ng/mL	119			MAX TOLERATED	mg/m²	60		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23054206	Homo sapiens		h	21.9	Cycle 1 Day 1			3	METHOXYAMINE		false
10032	34736		ADULT	4113	47.0565	METHOXYAMINE	METHOXYAMINE	CON	PLASMA	9TZH4WY30J									∞	ng × h/mL	1960		ng/mL	126			UNKNOWN	mg/m²	30		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23054206	Homo sapiens		h	30.9	Cycle 1 Day 4			6	METHOXYAMINE		false
10033	34736		ADULT	4113	47.0565	METHOXYAMINE	METHOXYAMINE	CON	PLASMA	9TZH4WY30J									∞	ng × h/mL	1136		ng/mL	68.1			UNKNOWN	mg/m²	15		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23054206	Homo sapiens		h	41.5	Cycle 1 Day 4			3	METHOXYAMINE		false
10034	35337		ADULT	25212148	629.7	Sitravatinib	MG-516	COCCNCC1=CN=C(C=C1)C2=CC3=NC=CC(=C3S2)OC4=C(C=C(C=C4)NC(=O)C5(CC5)C(=O)NC6=CC=C(C=C6)F)F	PLASMA	CWG62Q1VTB													ng/mL	21			UNKNOWN	mg	120		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	OTHER	https://www.mirati.com/wp-content/uploads/Mirati-516-003-SITC-2019-Final-Slides-web.pdf	Homo sapiens							33	MG-516		false
10035	35337		ADULT	25212148	629.7	Sitravatinib	MG-516	COCCNCC1=CN=C(C=C1)C2=CC3=NC=CC(=C3S2)OC4=C(C=C(C=C4)NC(=O)C5(CC5)C(=O)NC6=CC=C(C=C6)F)F	PLASMA	CWG62Q1VTB													ng/mL	72.5			UNKNOWN	mg	120		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	OTHER	https://www.mirati.com/wp-content/uploads/Mirati-516-003-SITC-2019-Final-Slides-web.pdf	Homo sapiens							33	MG-516		false
10036	35399		ADULT	11491176	406.4097	MK-0557	MK-0557	FC1=CC=CC=C1N2C=CC(NC(=O)[C@H]3CC[C@@]4(CC3)OC(=O)C5=CC=NC=C45)=N2	PLASMA	HVE36P8422									∞	μM × h	2.8		μM	0.07			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17011500	Homo sapiens		h	19				6			false
10037	35399		ADULT	11491176	406.409	MK-055	MK-0557	FC1=CC=CC=C1N2C=CC(NC(=O)[C@H]3CC[C@@]4(CC3)OC(=O)C5=CC=NC=C45)=N2	PLASMA	HVE36P842									∞	μM × h	62.8		μM	1.13			UNKNOWN	mg	750		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17011500	Homo sapiens		h	30				6			false
10038	35399		ADULT		406.4097	MK-0557	MK-0557	FC1=CC=CC=C1N2C=CC(NC(=O)[C@H]3CC[C@@]4(CC3)OC(=O)C5=CC=NC=C45)=N2	PLASMA	HVE36P8422									∞	μM × h	62.8		μM	1.13			UNKNOWN	mg	750		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/17011500	Homo sapiens		h	30							false
10039	35409		ADULT	54698642	461.874	MK-2048	MK-2048	CCN1C[C@H](C)N2C(=C(O)C3=C2C(=NN(CC4=CC(Cl)=C(F)C=C4)C3=O)C(=O)NC)C1=O	PLASMA	LJ8U884TM5									?	pg × h/mL	277172		pg/mL	728			UNKNOWN	mg	30		STEADY-STATE	UNKNOWN		4 weeks	1			HEALTHY	Vaginal	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30289435	Homo sapiens		h	3	MK-2048 VR contains 30 mg of MK-2048, 28 days of continuous use			12	MK-2048		false
10040	35411		UNKNOWN	25019940	557.5905	MK-3207	MK-3207	FC1=CC(=CC(F)=C1)[C@@H]2CNC3(CCCC3)C(=O)N2CC(=O)NC4=CC5=C(C[C@]6(C5)C(=O)NC7=NC=CC=C67)C=C4	PLASMA	5C44M1QYCC																						UNKNOWN					9.4	UNKNOWN		UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24900170	Homo sapiens										false
10041	35430		ADULT	71715374	519.5	TAK-243	MLN-7243		PLASMA	V9GGV0YCDI									∞	ng × h/mL	752.152						UNKNOWN	mg	12		MULTIPLE	UNKNOWN		week	2			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://clinicaltrials.gov/ct2/show/results/NCT02045095	Homo sapiens		h	27.446	10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle			1	TAK-243		false
10042	35430		ADULT	71715374	519.5	TAK-243	MLN-7243		PLASMA	V9GGV0YCDI									∞	ng × h/mL	179.726						UNKNOWN	mg	4		MULTIPLE	UNKNOWN		week	2			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://clinicaltrials.gov/ct2/show/results/NCT02045095	Homo sapiens		h	5.572	10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle			1	TAK-243		false
10043	35430		ADULT	71715374	519.5	TAK-243	MLN-7243		PLASMA	V9GGV0YCDI									∞	ng × h/mL	509.785						UNKNOWN	mg	8		MULTIPLE	UNKNOWN		week	2			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://clinicaltrials.gov/ct2/show/results/NCT02045095	Homo sapiens		h	15.212	10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle			1	TAK-243		false
10044	35430		ADULT	71715374	519.5	TAK-243	MLN-7243		PLASMA	V9GGV0YCDI									∞	ng × h/mL	864.533						HIGHEST STUDIED	mg	18		MULTIPLE	UNKNOWN		week	2			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://clinicaltrials.gov/ct2/show/results/NCT02045095	Homo sapiens		h	9.873	10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle			3	TAK-243		false
10045	36941		ADULT	9851774	605.942	NAPHTHOQUINE PHOSPHATE	NAPHTHOQUINE PHOSPHATE	OP(O)(O)=O.OP(O)(O)=O.CC(C)(C)NCC1=C(O)C2=C(CCCC2)C(NC3=C4C=CC(Cl)=CC4=NC=C3)=C1	PLASMA	M6M6AP4KAH	68827	282.3322	ARTEMISININ	Artemisinin	C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4	9RMU91N5K2			?	μg × h/L	1875		μg/L	59.8			UNKNOWN	mg	600		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20197487/	Homo sapiens		h	233.3			combination consisting of naphthoquine phosphate and\nartemisinin with a ratio of 1:2.5 (600mg:1500mg).	10	NAPHTHOQUINE PHOSPHATE		true
10046	36941		ADULT	9851774	605.942	NAPHTHOQUINE PHOSPHATE	NAPHTHOQUINE PHOSPHATE	OP(O)(O)=O.OP(O)(O)=O.CC(C)(C)NCC1=C(O)C2=C(CCCC2)C(NC3=C4C=CC(Cl)=CC4=NC=C3)=C1	PLASMA	M6M6AP4KAH									?	μg × h/L	424		μg/L	13.4			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20197487/	Homo sapiens		h	298.6				10	NAPHTHOQUINE PHOSPHATE		false
10047	36941		ADULT	9851774	605.942	NAPHTHOQUINE PHOSPHATE	NAPHTHOQUINE PHOSPHATE	OP(O)(O)=O.OP(O)(O)=O.CC(C)(C)NCC1=C(O)C2=C(CCCC2)C(NC3=C4C=CC(Cl)=CC4=NC=C3)=C1	PLASMA	M6M6AP4KAH	68827	282.3322	ARTEMISININ	Artemisinin	C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4	9RMU91N5K2			?	μg × h/L	446		μg/L	12.8			UNKNOWN	mg	400		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20197487/	Homo sapiens		h	156.4			combination consisting of naphthoquine phosphate and\nartemisinin with a ratio of 1:2.5 (400mg:1000mg).	10	NAPHTHOQUINE PHOSPHATE		true
10048	36941		ADULT	9851774	605.942	NAPHTHOQUINE PHOSPHATE	NAPHTHOQUINE PHOSPHATE	OP(O)(O)=O.OP(O)(O)=O.CC(C)(C)NCC1=C(O)C2=C(CCCC2)C(NC3=C4C=CC(Cl)=CC4=NC=C3)=C1	PLASMA	M6M6AP4KAH	68827	282.3322	ARTEMISININ	Artemisinin	C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4	9RMU91N5K2			?	μg × h/L	480		μg/L	11.4			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20197487/	Homo sapiens		h	256.4			combination consisting of naphthoquine phosphate and\nartemisinin with a ratio of 1:2.5 (200mg:500mg).	10	NAPHTHOQUINE PHOSPHATE		true
10049	36941		ADULT	9851774	605.942	NAPHTHOQUINE PHOSPHATE	NAPHTHOQUINE PHOSPHATE	OP(O)(O)=O.OP(O)(O)=O.CC(C)(C)NCC1=C(O)C2=C(CCCC2)C(NC3=C4C=CC(Cl)=CC4=NC=C3)=C1	PLASMA	M6M6AP4KAH	68827	282.3322	ARTEMISININ	Artemisinin	C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4	9RMU91N5K2			?	μg × h/L	955		μg/L	27.4			UNKNOWN	mg	400		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20197487/	Homo sapiens		h	276.4			combination consisting of naphthoquine phosphate and\nartemisinin with a ratio of 1:2.5 (400mg:1000mg).	10	NAPHTHOQUINE PHOSPHATE		true
10050	36973		ADULT	11513816	169.13	NCX 4015	NCX 4015	Oc1cccc(CO[N](=O)O)c1	PLASMA										∞	ng × h/mL	784.85		ng/mL	161.94			UNKNOWN	mg	1600		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15063462	Homo sapiens		h	3.1				8			false
10051	37453		ADULT	73777259	386.5	ONC201	NSC-350625		PLASMA	9U35A31JAI									?	μg × h/mL	37.7		μg/mL	3.6			RECOMMENDED	mg	625		MULTIPLE	UNKNOWN		3 weeks	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28331050/	Homo sapiens		h	11.3				24	ONC201		false
10052	37458		ADULT	50922681	366.4998	NSI-189	NSI-189	CC(C)CCNC1=NC=CC=C1C(=O)N2CCN(CC3=CC=CC=C3)CC2	PLASMA	YVE9U408ZL							24		t	ng × h/mL	2791						UNKNOWN	mg	40		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26643541	Homo sapiens		h	20.5				6	NSI-189		false
10053	37458		ADULT	50922681	366.4998	NSI-189	NSI-189	CC(C)CCNC1=NC=CC=C1C(=O)N2CCN(CC3=CC=CC=C3)CC2	PLASMA	YVE9U408ZL							24		t	ng × h/mL	1144						UNKNOWN	mg	40		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26643541	Homo sapiens		h	17.4				6	NSI-189		false
10054	37458		ADULT	50922681	366.4998	NSI-189	NSI-189	CC(C)CCNC1=NC=CC=C1C(=O)N2CCN(CC3=CC=CC=C3)CC2	PLASMA	YVE9U408ZL							24		t	ng × h/mL	4384						UNKNOWN	mg	40		MULTIPLE	UNKNOWN		day	3			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26643541	Homo sapiens		h	18.6				6	NSI-189		false
10055	37797		ADULT	67171867	398.846	ODM-201	C[C@@H](CN1C=CC(=N1)C2=CC(Cl)=C(C=C2)C#N)NC(=O)C3=NNC(=C3)C(C)O	C[C@@H](CN1C=CC(=N1)C2=CC(Cl)=C(C=C2)C#N)NC(=O)C3=NNC(=C3)C(C)O	PLASMA	X05U0N2RCO							12		t	μg × h/mL	52.82		mg/L	4.79			RECOMMENDED	mg	600		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf	Homo sapiens		h	20							false
10056	37826		ADULT	158150	312.4	alpha-arteether	ARTEETHER		PLASMA	R6TF0B136Q									∞	μg × h/L	1303.09		μg/L	60.72			UNKNOWN	mg	45		SINGLE	UNKNOWN						HEALTHY	Intramuscular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16231969/	Homo sapiens		h	13.24	150 mg individual dose of the arteether formulation containing α- and β-isomers in a 30 : 70 ratio.			13	arteether		false
10057	38473		ADULT	10091392	383.527	ORG-28611	ORG-28611	COC1=CC=CC2=C1N(CC3CCCCC3)C=C2C(=O)N4CCN(C)[C@@H](C)C4	BLOOD	1U7V49NTQG													ng/mL	24			UNKNOWN	μg/kg	3		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18635703	Homo sapiens				intravenous bolus			21	ORG-28611		false
10058	38523		ADULT		406.4378	OSI-027	OSI-027	COC1=CC=CC2=C1NC(=C2)C3=C4N(N=CN=C4N)C(=N3)[C@H]5CC[C@@H](CC5)C(O)=O	PLASMA	25MKH1SZ0M									∞	ng × h/mL	46250		ng/mL	3040			UNKNOWN	mg	50		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27002938	Homo sapiens		h	10.3				3			false
10059	38523		ADULT		406.4378	OSI-027	OSI-027	COC1=CC=CC2=C1NC(=C2)C3=C4N(N=CN=C4N)C(=N3)[C@H]5CC[C@@H](CC5)C(O)=O	PLASMA	25MKH1SZ0M									∞	ng × h/mL	125278		ng/mL	8780			UNKNOWN	mg	240		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27002938	Homo sapiens		h	13.8				15			false
10060	38523		ADULT		406.4378	OSI-027	OSI-027	COC1=CC=CC2=C1NC(=C2)C3=C4N(N=CN=C4N)C(=N3)[C@H]5CC[C@@H](CC5)C(O)=O	PLASMA	25MKH1SZ0M							24		t	ng × h/mL	105663		ng/mL	11007			UNKNOWN	mg	160		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27002938	Homo sapiens		h	11.9	day 3			5			false
10061	38523		ADULT		406.4378	OSI-027	OSI-027	COC1=CC=CC2=C1NC(=C2)C3=C4N(N=CN=C4N)C(=N3)[C@H]5CC[C@@H](CC5)C(O)=O	PLASMA	25MKH1SZ0M									∞	ng × h/mL	131223		ng/mL	9329			UNKNOWN	mg	160		SINGLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27002938	Homo sapiens		h	10.3	once daily for three consecutive days every week			5			false
10062	38523		ADULT		406.4378	OSI-027	OSI-027	COC1=CC=CC2=C1NC(=C2)C3=C4N(N=CN=C4N)C(=N3)[C@H]5CC[C@@H](CC5)C(O)=O	PLASMA	25MKH1SZ0M									∞	ng × h/mL	17246		ng/mL	1110			UNKNOWN	mg	50		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27002938	Homo sapiens				day 22			1			false
10063	38525		ADULT	9868037	443.442	OSI-930	OSI-930	FC(F)(F)OC1=CC=C(NC(=O)C2=C(NCC3=CC=NC4=C3C=CC=C4)C=CS2)C=C1	PLASMA	G1PEG5Q9Y2									?	μg × h/mL	5.76		μg/mL	1.01			MAX TOLERATED	mg	500		MULTIPLE	FED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23403628	Homo sapiens		h	7.11				21	OSI-930		false
10064	38525		ADULT	9868037	443.442	OSI-930	OSI-930	FC(F)(F)OC1=CC=C(NC(=O)C2=C(NCC3=CC=NC4=C3C=CC=C4)C=CS2)C=C1	PLASMA	G1PEG5Q9Y2									?	μg × h/mL	11.9		μg/mL	2.03			UNKNOWN	mg	600		MULTIPLE	FED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23403628	Homo sapiens		h	5.39				6	OSI-930		false
10065	38525		ADULT	9868037	443.442	OSI-930	OSI-930	FC(F)(F)OC1=CC=C(NC(=O)C2=C(NCC3=CC=NC4=C3C=CC=C4)C=CS2)C=C1	PLASMA	G1PEG5Q9Y2									?	μg × h/mL	13		μg/mL	1.07			UNKNOWN	mg	1600		MULTIPLE	FED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23403628	Homo sapiens		h	12.6				3	OSI-930		false
10066	38608		ADULT	72390	147.152	OXOTHIAZOLIDINECARBOXYLIC ACID	OXOTHIAZOLIDINECARBOXYLIC ACID	OC(=O)[C@@H]1CSC(=O)N1	PLASMA	X7063P804E									?	nmol × h/mL	88		nmol/mL	105			UNKNOWN	mg	500		SINGLE	FASTED						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9590463	Homo sapiens							37	OXOTHIAZOLIDINECARBOXYLIC ACID		false
10067	38608		ADULT	72390	147.152	OXOTHIAZOLIDINECARBOXYLIC ACID	OXOTHIAZOLIDINECARBOXYLIC ACID	OC(=O)[C@@H]1CSC(=O)N1	PLASMA	X7063P804E									?	nmol × h/mL	428		nmol/mL	242			UNKNOWN	mg	1500		SINGLE	FASTED						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9590463	Homo sapiens							37	OXOTHIAZOLIDINECARBOXYLIC ACID		false
10068	38608		ADULT	72390	147.152	OXOTHIAZOLIDINECARBOXYLIC ACID	OXOTHIAZOLIDINECARBOXYLIC ACID	OC(=O)[C@@H]1CSC(=O)N1	PLASMA	X7063P804E									?	nmol × h/mL	4063		nmol/mL	734			UNKNOWN	mg	4500		SINGLE	FASTED						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9590463	Homo sapiens							37	OXOTHIAZOLIDINECARBOXYLIC ACID		false
10069	38624		ADULT	24864132	264.3633	OXYMATRINE	Oxymatrine	[O-][N@ ]12CCC[C@H]3CN4[C@H](CCCC4=O)[C@@H](CCC1)[C@@H]23	PLASMA	85U4C366QS									∞	ng × h/mL	20436		ng/mL	20519			UNKNOWN	mg	600		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16500065/	Homo sapiens		h	2.17				10			false
10070	38624		ADULT	91466	248.3639	MATRINE	Matrine	O=C1CCC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34	PLASMA	N390W430AC									∞	ng × h/mL	3841		ng/mL	247			UNKNOWN	mg	600		SINGLE	FASTED						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16500065/	Homo sapiens		h	9.43				10			false
10071	38624		ADULT	24864132	264.3633	OXYMATRINE	Oxymatrine	[O-][N@ ]12CCC[C@H]3CN4[C@H](CCCC4=O)[C@@H](CCC1)[C@@H]23	PLASMA	85U4C366QS									∞	ng × h/mL	1431.53		ng/mL	392.33			UNKNOWN	mg	300		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18647475/	Homo sapiens		h	2				18			false
10072	38624		ADULT	24864132	264.3633	OXYMATRINE	Oxymatrine	[O-][N@ ]12CCC[C@H]3CN4[C@H](CCCC4=O)[C@@H](CCC1)[C@@H]23	PLASMA	85U4C366QS									∞	ng × h/mL	1205		ng/mL	364.5			UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23747322/	Homo sapiens		h	2.87	Oral solution			6			false
10073	38624		ADULT	91466	248.3639	MATRINE	Matrine	O=C1CCC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34	PLASMA	N390W430AC									∞	ng × h/mL	30470		ng/mL	2057			UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23747322/	Homo sapiens		h	7	Oral solution			6			false
10074	39035		ADULT	6473881	248.3175	PARTHENOLIDE	Parthenolide	C\\C1=C/CC[C@@]2(C)O[C@H]2[C@H]3OC(=O)C(=C)[C@@H]3CC1	PLASMA	2RDB26I5ZB																						UNKNOWN				Human plasma protein binding: 81.9% (200μM)	8.1	HEALTHY		FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15114499/	Homo sapiens							7			false
10075	39159		ADULT	5904	334.39	PENICILLIN G	penicillin g	CC1(C)S[C@@H]2[C@H](NC(=O)CC3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O	PLASMA	Q42T66VG0C													unit/mL	0.138			DEFINED DAILY	unit	100000		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/14880731/	Homo sapiens										false
10076	39159		ADULT	5904	334.39	PENICILLIN G	penicillin G	CC1(C)S[C@@H]2[C@H](NC(=O)CC3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O	PLASMA	Q42T66VG0C													unit/mL	0.142			DEFINED DAILY	unit	100000		MULTIPLE	FED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/14880731/	Homo sapiens										false
10077	39162		NEWBORN	5904	334.39	PENICILLIN G	PENICILLIN G	CC1(C)S[C@@H]2[C@H](NC(=O)CC3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O	PLASMA	Q42T66VG0C							12		t	μg × min/mL	23360.2		μg/mL	145.5			RECOMMENDED	mg/kg	30		MULTIPLE	UNKNOWN		day	2	https://pubmed.ncbi.nlm.nih.gov/797501/	40	UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17371819/	Homo sapiens		h	3.8							false
10078	39385		ADULT	1256	166.22	perillic acid	perillic acid		PLASMA	PKS69DU4ZQ							6		t	μM × h	1248		μM	539			UNKNOWN	mg/m²	2000		MULTIPLE	UNKNOWN		day	4			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15205914	Homo sapiens							15	PERILLYL ALCOHOL		false
10079	39385		ADULT	1256	166.22	perillic acid	perillic acid		PLASMA	PKS69DU4ZQ							6		t	μM × h	2115		μM	604			UNKNOWN	mg/m²	2000		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15205914	Homo sapiens		h	1.2				15	Perillyl alcohol		false
10080	39385		ADULT	381256	168.23	dihydroperillic acid	dihydroperillic acid	CC(=C)C1CCC(CC1)C(=O)O	PLASMA								6		t	μM × h	235		μM	48			UNKNOWN	mg/m²	2000		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15205914	Homo sapiens		h	2.8				15	Perillyl alcohol		false
10081	39385		ADULT	381256	168.23	dihydroperillic acid	dihydroperillic acid	CC(=C)C1CCC(CC1)C(=O)O	PLASMA								88		t	μM × h	6		μM	26			UNKNOWN	mg/m²	1200		MULTIPLE	UNKNOWN		day	4			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15205914	Homo sapiens							15	Perillyl alcohol		false
10082	39385		ADULT	381256	168.23	dihydroperillic acid	dihydroperillic acid	CC(=C)C1CCC(CC1)C(=O)O	PLASMA								6		t	μM × h	208		μM	44			UNKNOWN	mg/m²	2000		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15205914	Homo sapiens		h	1.7				15	Perillyl alcohol		false
10083	39385		ADULT	381256	168.23	dihydroperillic acid	dihydroperillic acid	CC(=C)C1CCC(CC1)C(=O)O	PLASMA								6		t	μM × h	57		μM	15			UNKNOWN	mg/m²	1600		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15205914	Homo sapiens		h	1.9				15	Perillyl alcohol		false
10084	39385		ADULT	1256	166.22	perillic acid	perillic acid		PLASMA	PKS69DU4ZQ							6		t	μM × h	766		μM	327			UNKNOWN	mg/m²	1600		MULTIPLE	UNKNOWN		day	4			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15205914	Homo sapiens							15	Perillyl alcohol		false
10085	39385		ADULT	1256	166.22	perillic acid	perillic acid		PLASMA	PKS69DU4ZQ							6		t	μM × h	1314		μM	442			UNKNOWN	mg	1600		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15205914	Homo sapiens		h	0.9				15	Perillyl alcohol		false
10086	39385		ADULT	1256	166.22	perillic acid	perillic acid		PLASMA	PKS69DU4ZQ							6		t	μM × h	2004		μM	600			UNKNOWN	mg/m²	2000		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15205914	Homo sapiens		h	0.9				15	Perillyl alcohol		false
10087	39385		ADULT	1256	166.22	perillic acid	Perillic acid		PLASMA	PKS69DU4ZQ							6		t	μM × h	472		μM	225			UNKNOWN	mg/m²	1200		MULTIPLE	UNKNOWN		day	4			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15205914	Homo sapiens							15	Perillyl alcohol		false
10088	39385		ADULT	1256	166.22	perillic acid	perillic acid		PLASMA	PKS69DU4ZQ							6		t	μM × h	871		μM	306			UNKNOWN	mg/m²	1600		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15205914	Homo sapiens		h	1.4				15	Perillyl alcohol		false
10089	39385		ADULT	381256	168.23	dihydroperillic acid	dihydroperillic acid	CC(=C)C1CCC(CC1)C(=O)O	PLASMA								6		t	μM × h	72		μM	24			UNKNOWN	mg/m²	1200		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15205914	Homo sapiens		h	1				15	Perillyl alcohol		false
10090	39385		ADULT	1256	166.22	perillic acid	perillic acid		PLASMA	PKS69DU4ZQ							6		t	μM × h	813		μM	311			UNKNOWN	mg/m²	1200		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15205914	Homo sapiens		h	0.6				15	Perillyl alcohol		false
10091	39385		ADULT	1256	166.22	perillic acid	perillic acid		PLASMA	PKS69DU4ZQ							6		t	μM × h	663		μM	203			UNKNOWN	mg/m²	1200		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15205914	Homo sapiens		h	0.6				8	Perillyl alcohol		false
10092	39385		ADULT	381256	168.23	Dihydroperillic acid	dihydroperillic acid	CC(=C)C1CCC(CC1)C(=O)O	PLASMA								6		t	μM × h	89		μM	22			UNKNOWN	mg/m²	1600		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15205914	Homo sapiens		h	1.1				15	Perillyl alcohol		false
10093	39385		ADULT	381256	168.23	Dihydroperillic acid	Dihydroperillic acid	CC(=C)C1CCC(CC1)C(=O)O	PLASMA								6		t	μM × h	77		μM	26			UNKNOWN	mg/m²	1600		MULTIPLE	UNKNOWN		day	4			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15205914	Homo sapiens							15	Perillyl alcohol		false
10094	39385		ADULT	381256	168.23	dihydroperillic acid	dihydroperillic acid	CC(=C)C1CCC(CC1)C(=O)O	PLASMA								6		t	μM × h	228		μM	66			UNKNOWN	mg/m²	200		MULTIPLE	UNKNOWN		day	4			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15205914	Homo sapiens							15	Perillyl alcohol		false
10095	39385		ADULT	381256	168.23	dihydroperillic acid	dihydroperillic acid	CC(=C)C1CCC(CC1)C(=O)O	PLASMA								6		t	μM × h	77		μM	22			UNKNOWN	mg/m²	1200		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15205914	Homo sapiens		h	1				15	Perillyl alcohol		false
10096	39388		ADULT	72022	340.4146	PERINDOPRILAT	PERINDOPRILAT	CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(O)=O	PLASMA	2UV6ZNQ92K							24		t	ng × h/mL	52		ng/mL	3.8			RECOMMENDED	mg	2.5		STEADY-STATE	FASTED		day	1	Plasma protein binding of perindoprilat is low (10 to 35%), the binding is concentration dependent due to the saturable binding of perindoprilat to the circulating angiotensin-converting enzyme.		HEALTHY	Oral	UNKNOWN	OTHER	https://pdf.hres.ca/dpd_pm/00044188.PDF	Homo sapiens										false
10097	39388		ADULT	107807|40466996	368.4678	PERINDOPRIL	PERINDOPRIL	CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC	PLASMA	Y5GMK36KGY							24		t	ng × h/mL	17		ng/mL	15			RECOMMENDED	mg	2.5		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	UNKNOWN	OTHER	https://pdf.hres.ca/dpd_pm/00044188.PDF	Homo sapiens		h	0.42							false
10098	39388		ADULT	72022	340.4146	PERINDOPRILAT	PERINDOPRILAT	CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(O)=O	PLASMA	2UV6ZNQ92K							24		t	ng × h/mL	81		ng/mL	8.3			RECOMMENDED	mg	5		STEADY-STATE	FASTED		day	1	Plasma protein binding of perindoprilat is low (10 to 35%), the binding is concentration dependent due to the saturable binding of perindoprilat to the circulating angiotensin-converting enzyme.		HEALTHY	Oral	UNKNOWN	OTHER	https://pdf.hres.ca/dpd_pm/00044188.PDF	Homo sapiens										false
10099	39388		ADULT	107807|40466996	368.4678	PERINDOPRIL	PERINDOPRIL	CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC	PLASMA	Y5GMK36KGY							24		t	ng × h/mL	34		ng/mL	26			RECOMMENDED	mg	5		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	UNKNOWN	OTHER	https://pdf.hres.ca/dpd_pm/00044188.PDF	Homo sapiens		h	0.45							false
10100	39388		ADULT	72022	340.4146	PERINDOPRILAT	PERINDOPRILAT	CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(O)=O	PLASMA	2UV6ZNQ92K							24		t	ng × h/mL	127		ng/mL	16			RECOMMENDED	mg	10		STEADY-STATE	FASTED		day	1	Plasma protein binding of perindoprilat is low (10 to 35%), the binding is concentration dependent due to the saturable binding of perindoprilat to the circulating angiotensin-converting enzyme.		HEALTHY	Oral	UNKNOWN	OTHER	https://pdf.hres.ca/dpd_pm/00044188.PDF	Homo sapiens										false
10101	39388		ADULT	107807|40466996	368.4678	PERINDOPRIL	PERINDOPRIL	CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC	PLASMA	Y5GMK36KGY							24		t	ng × h/mL	69		ng/mL	61			RECOMMENDED	mg	10		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	UNKNOWN	OTHER	https://pdf.hres.ca/dpd_pm/00044188.PDF	Homo sapiens		h	0.42							false
10102	39390		ADULT	107807|40466996	368.4678	PERINDOPRIL	PERINDOPRIL	CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC	PLASMA	Y5GMK36KGY									∞	ng × h/mL	130		ng/mL	83.83			UNKNOWN	mg	4		SINGLE	FASTED				Approximately 60 % of circulating perindopril is bound to plasma proteins	40	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21650082	Homo sapiens		h	1.05							false
10103	39390		ADULT	72022	340.4146	PERINDOPRILAT	PERINDOPRILAT	CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(O)=O	PLASMA	2UV6ZNQ92K									∞	ng × h/mL	170.61		ng/mL	3.54			UNKNOWN	mg	4		SINGLE	FASTED				Only 10 to 20 % of perindoprilat is bound is bound to plasma proteins	80	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21650082	Homo sapiens		h	38.01							false
10104	39411		UNKNOWN	40326	391.288	PERMETHRIN	PERMETHRIN	CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC2=CC=CC(OC3=CC=CC=C3)=C2	PLASMA	509F88P9SZ																						UNKNOWN					10	UNKNOWN		UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31248885	Homo sapiens										false
10105	39411		ADULT	40326	391.288	PERMETHRIN	permethrin	CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC2=CC=CC(OC3=CC=CC=C3)=C2	SERUM	509F88P9SZ													ng/mL	868			UNKNOWN	g	143		SINGLE	UNKNOWN						UNHEALTHY	Oral	MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/9541045	Homo sapiens										false
10106	39411		ADULT	40326	391.288	PERMETHRIN	permethrin	CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC2=CC=CC(OC3=CC=CC=C3)=C2	SERUM	509F88P9SZ							24		t	μg × h/mL	2.73		ng/mL	253			UNKNOWN	g	143		SINGLE	UNKNOWN						UNHEALTHY	Oral	MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/9541045	Homo sapiens		h	5.08							false
10107	39411		ADULT	40326	391.288	PERMETHRIN	permethrin	CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC2=CC=CC(OC3=CC=CC=C3)=C2	SERUM	509F88P9SZ							24		t	μg × h/mL	6.26		ng/mL	615			UNKNOWN	g	143		SINGLE	UNKNOWN						UNHEALTHY	Oral	MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/9541045	Homo sapiens		h	4.82							false
10108	39468		ADULT	51346455	474.4788	PF-03814735	PF-03814735	CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1C3=CC(NC4=NC(NC5CCC5)=C(C=N4)C(F)(F)F)=CC=C23	PLASMA	6V5T4O5758									∞	μg × h/mL	64.4		μg/mL	2.81			MAX TOLERATED	mg	80		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21852114	Homo sapiens		h	20.9				15			false
10109	39468		ADULT	51346455	474.4788	PF-03814735	PF-03814735	CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1C3=CC(NC4=NC(NC5CCC5)=C(C=N4)C(F)(F)F)=CC=C23	PLASMA	6V5T4O5758									?	μg × h/mL	58		μg/mL	4.11			UNKNOWN	mg	100		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21852114	Homo sapiens				5 days			7			false
10110	39468		ADULT	51346455	474.4788	PF-03814735	PF-03814735	CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1C3=CC(NC4=NC(NC5CCC5)=C(C=N4)C(F)(F)F)=CC=C23	PLASMA	6V5T4O5758									?	μg × h/mL	49.3		μg/mL	3.77			MAX TOLERATED	mg	80		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21852114	Homo sapiens				day 4			15			false
10111	39468		ADULT	51346455	474.4788	PF-03814735	PF-03814735	CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1C3=CC(NC4=NC(NC5CCC5)=C(C=N4)C(F)(F)F)=CC=C23	PLASMA	6V5T4O5758									?	μg × h/mL	37.2		μg/mL	2.79			MAX TOLERATED	mg	50		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21852114	Homo sapiens				day 9			13			false
10112	39468		ADULT	51346455	474.4788	PF-03814735	PF-03814735	CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1C3=CC(NC4=NC(NC5CCC5)=C(C=N4)C(F)(F)F)=CC=C23	PLASMA	6V5T4O5758									∞	μg × h/mL	84.8		μg/mL	3.49			UNKNOWN	mg	100		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21852114	Homo sapiens		h	21.2				7			false
10113	39473		ADULT	17754438	372.3833	PF-04217903	PF-04217903	OCCN1C=C(C=N1)C2=NC3=C(N=NN3CC4=CC5=CC=CN=C5C=C4)N=C2	PLASMA	CYJ9ATV1IJ									∞	μg × h/mL	0.81		μg/mL	0.24			UNKNOWN	mg	30		SINGLE	UNKNOWN					16.4	HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21098644	Homo sapiens		h	6.6				6	PF-04217903		false
10114	39476		ADULT	135564558	395.4582	PF-04447943	PF-04447943	C[C@@H]1CN(CC2=NC=CC=N2)C[C@H]1C3=NC4=C(C=NN4C5CCOCC5)C(=O)N3	PLASMA	7N969W8Y4O							12		t	ng × h/mL	1170		ng/mL	248.2			UNKNOWN	mg	25		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30597771	Homo sapiens							15	PF-04447943		false
10115	39476		ADULT	135564558	395.4582	PF-04447943	PF-04447943	C[C@@H]1CN(CC2=NC=CC=N2)C[C@H]1C3=NC4=C(C=NN4C5CCOCC5)C(=O)N3	PLASMA	7N969W8Y4O							12		t	ng × h/mL	242		ng/mL	45.8			UNKNOWN	mg	5		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30597771	Homo sapiens							7	PF-04447943		false
10116	39483		ADULT	46181428	396.3637	PF-04991532	PF-04991532	OC(=O)C1=CC=C(NC(=O)[C@H](CC2CCCC2)N3C=NC(=C3)C(F)(F)F)N=C1	PLASMA	AJ212MS2O2									∞	ng × h/mL	3669		ng/mL	1436			UNKNOWN	mg	450		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30747552	Homo sapiens		h	1898				3			false
10117	39502		ADULT	23725123	350.394	PF-915275	PF-915275	NC1=CC=CC(NS(=O)(=O)C2=CC=C(C=C2)C3=CC=C(C=C3)C#N)=N1	PLASMA	388927163B							24		t	ng × h/mL	7392		ng/mL	480			UNKNOWN	mg	10		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17986636/	Homo sapiens		h	23.1				9	PF-00915275		false
10118	39502		ADULT	23725123	350.394	PF-915275	PF-915275	NC1=CC=CC(NS(=O)(=O)C2=CC=C(C=C2)C3=CC=C(C=C3)C#N)=N1	PLASMA	388927163B							24		t	ng × h/mL	318		ng/mL	18.8			UNKNOWN	mg	0.3		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17986636/	Homo sapiens		h	30.4				9	PF-00915275		false
10119	39502		ADULT	23725123	350.394	PF-915275	PF-915275	NC1=CC=CC(NS(=O)(=O)C2=CC=C(C=C2)C3=CC=C(C=C3)C#N)=N1	PLASMA	388927163B							24		t	ng × h/mL	1047		ng/mL	61			UNKNOWN	mg	1		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17986636/	Homo sapiens		h	32.3				11	PF-00915275		false
10120	39502		ADULT	23725123	350.394	PF-915275	PF-915275	NC1=CC=CC(NS(=O)(=O)C2=CC=C(C=C2)C3=CC=C(C=C3)C#N)=N1	PLASMA	388927163B							24		t	ng × h/mL	3366		ng/mL	202			UNKNOWN	mg	3		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17986636/	Homo sapiens		h	30.9				9	PF-00915275		false
10121	39502		ADULT	23725123	350.394	PF-915275	PF-915275	NC1=CC=CC(NS(=O)(=O)C2=CC=C(C=C2)C3=CC=C(C=C3)C#N)=N1	PLASMA	388927163B							24		t	ng × h/mL	16344		ng/mL	956			HIGHEST STUDIED	mg	15		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17986636/	Homo sapiens		h	31.8				9	PF-00915275		false
10122	39509		ADULT	46191454	361.4817	PHA-793887	PHA-793887	CC(C)CC(=O)NC1=NNC2=C1CN(C(=O)C3CCN(C)CC3)C2(C)C	PLASMA	MKS45S912B									∞	μM × h	13.072		μM	5.807			UNKNOWN	mg/m²	66		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21368575	Homo sapiens		h	7.247				3			false
10123	39509		ADULT	46191454	361.4817	PHA-793887	PHA-793887	CC(C)CC(=O)NC1=NNC2=C1CN(C(=O)C3CCN(C)CC3)C2(C)C	PLASMA	MKS45S912B									∞	μM × h	10.148		μM	3.607			UNKNOWN	mg/m²	44		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21368575	Homo sapiens		h	9.177				9			false
10124	39531		UNKNOWN	40113	349.61	PHENAZEPAM	Phenazepam	ClC1=C(C=CC=C1)C2=NCC(=O)NC3=CC=C(Br)C=C23	UNKNOWN	3DSB43090Z																	UNKNOWN	mg	3		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/26408390/	Homo sapiens		h	103	Dose: 3-5mg			6			false
10125	39531		UNKNOWN	40113	349.61	PHENAZEPAM	Phenazepam	ClC1=C(C=CC=C1)C2=NCC(=O)NC3=CC=C(Br)C=C23	UNKNOWN	3DSB43090Z																	UNKNOWN	mg	2		SINGLE	UNKNOWN						UNKNOWN	Intravenous	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/26408390/	Homo sapiens		h	14.9				6			false
10126	39531		UNKNOWN	40113	349.61	PHENAZEPAM	Phenazepam	ClC1=C(C=CC=C1)C2=NCC(=O)NC3=CC=C(Br)C=C23	UNKNOWN	3DSB43090Z																	UNKNOWN	mg	2		SINGLE	UNKNOWN						UNKNOWN	Intramuscular	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/26408390/	Homo sapiens		h	15.6				6			false
10127	39531		UNKNOWN	40113	349.61	PHENAZEPAM	Phenazepam	ClC1=C(C=CC=C1)C2=NCC(=O)NC3=CC=C(Br)C=C23	PLASMA	3DSB43090Z																						UNKNOWN				Human plasma protein binding: 98.3%, equilibrium dialysis	1.7	UNKNOWN		FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29582576/	Homo sapiens							6			false
10128	39531		ADULT	40113	349.61	PHENAZEPAM	Phenazepam	ClC1=C(C=CC=C1)C2=NCC(=O)NC3=CC=C(Br)C=C23	BLOOD	3DSB43090Z									?	μg × min/mL	112		μg/mL	0.024			UNKNOWN	mg	3		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7173273/ | https://pubmed.ncbi.nlm.nih.gov/26408390/	Homo sapiens		h	60				1			false
10129	39531		ADULT	40113	349.61	PHENAZEPAM	Phenazepam	ClC1=C(C=CC=C1)C2=NCC(=O)NC3=CC=C(Br)C=C23	BLOOD	3DSB43090Z									?	μg × min/mL	208		μg/mL	0.038			UNKNOWN	mg	5		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7173273/ | https://pubmed.ncbi.nlm.nih.gov/26408390/	Homo sapiens		h	60				1			false
10130	39758		CHILD	587|5359254|9548602	211.1131	PHOSPHOCREATINE	PHOSPHOCREATINE	CN(CC(O)=O)C(=N)NP(O)(O)=O	PLASMA	020IUV4N33									∞	μg × h/mL	17.16		μg/mL	47.34			UNKNOWN	g	2		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31013362/	Homo sapiens		h	0.24		viral myocarditis		6	PHOSPHOCREATINE DISODIUM		false
10131	39758		CHILD	586|59098743	131.1332	CREATINE	CREATINE	CN(CC(O)=O)C(N)=N	PLASMA	MU72812GK0									∞	μg × h/mL	79.01		μg/mL	59.29			UNKNOWN	g	2		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31013362/	Homo sapiens		h	0.83		viral myocarditis		6	PHOSPHOCREATINE DISODIUM		false
10132	39837		ADULT		450.6957	PHYTONADIONE	PHYTONADIONE		PLASMA	A034SE7857							12		t	ng × h/mL	146		ng/mL	32.5			RECOMMENDED	mg	5		SINGLE	FED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28107923/	Homo sapiens		h	4							false
10133	39846		ADULT	60608	208.2139	PICAMILON	PICAMILON	OC(=O)CCCNC(=O)C1=CC=CN=C1	PLASMA	0S5N9SEK4N									∞	ng × h/mL	1106		ng/mL	667			UNKNOWN	mg	50		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20359966/	Homo sapiens		h	1.46				10	PICAMILON		false
10134	39846		ADULT	60608	208.2139	PICAMILON	PICAMILON	OC(=O)CCCNC(=O)C1=CC=CN=C1	PLASMA	0S5N9SEK4N									∞	ng × h/mL	2230		ng/mL	1551			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20359966/	Homo sapiens		h	1.46				10	PICAMILON		false
10135	39846		ADULT	60608	208.2139	PICAMILON	PICAMILON	OC(=O)CCCNC(=O)C1=CC=CN=C1	PLASMA	0S5N9SEK4N									∞	ng × h/mL	4284		ng/mL	2971			UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20359966/	Homo sapiens		h	1.46				10	PICAMILON		false
10136	39864		ADULT	4814	376.4085	PICOTAMIDE	Picotamide	COC1=C(C=C(C=C1)C(=O)NCC2=CN=CC=C2)C(=O)NCC3=CN=CC=C3	PLASMA	654G2VCI4Q													μg/mL	2.02			UNKNOWN	mg	300		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1400771/	Homo sapiens							4			false
10137	40105		ADULT	9845148	422.52	PNU-142633	PNU-142633	CNC(=O)C1=CC2=C(C=C1)[C@H](CCN3CCN(CC3)C4=CC=C(C=C4)C(N)=O)OCC2	PLASMA	B54P1BQ73L													ng/mL	141			UNKNOWN	mg	50		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11595000	Homo sapiens							34	PNU-142633		false
10138	40782		ADULT		809.9366	PROTOVERATRINE B	PROTOVERATRINE B	CC[C@@H](C)C(=O)O[C@H]1[C@H](O)[C@H]2[C@@H](CN3C[C@@H](C)CC[C@H]3[C@@]2(C)O)[C@@H]4C[C@@]56O[C@@]7(O)[C@@H]([C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@H]5[C@]14O)[C@]6(C)CC[C@@H]7OC(=O)[C@](C)(O)[C@@H](C)O	PLASMA	AK816144R9													pg/mL	402			UNKNOWN	mg	0.5		SINGLE	UNKNOWN						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19021933/	Homo sapiens										false
10139	40814		ADULT	5281751	520.4426	PSEUDOHYPERICIN	Pseudohypericin	CC1=C2C3=C4C(C(=O)C5=C(O)C=C(O)C6=C5C4=C7C2=C(C(O)=C1)C(=O)C8=C(O)C=C(O)C6=C78)=C(O)C=C3CO	PLASMA	MQ0U4663ZO									?	ng × min/mL	1900		ng/mL	2.7			UNKNOWN	μg	526		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7857509	Homo sapiens		h	16.3				4			false
10140	40814		ADULT	5281751	520.4426	PSEUDOHYPERICIN	Pseudohypericin	CC1=C2C3=C4C(C(=O)C5=C(O)C=C(O)C6=C5C4=C7C2=C(C(O)=C1)C(=O)C8=C(O)C=C(O)C6=C78)=C(O)C=C3CO	PLASMA	MQ0U4663ZO									?	ng × min/mL	19910		ng/mL	30.6			UNKNOWN	μg	3156		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7857509	Homo sapiens		h	22.8				4			false
10141	40814		ADULT	5281751	520.4426	PSEUDOHYPERICIN	pseudohypericin	CC1=C2C3=C4C(C(=O)C5=C(O)C=C(O)C6=C5C4=C7C2=C(C(O)=C1)C(=O)C8=C(O)C=C(O)C6=C78)=C(O)C=C3CO	PLASMA	MQ0U4663ZO									?	ng × min/mL	7130		ng/mL	11.7			UNKNOWN	μg	1578		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7857509	Homo sapiens		h	36				3			false
10142	40862		ADULT	9549213	512.368	PU-H71	PU-H71	CC(C)NCCCN1C(SC2=C(I)C=C3OCOC3=C2)=NC4=C1N=CN=C4N	PLASMA	06IVK87M04									∞	μM × min	1007		μM	5.7			UNKNOWN	mg/m²	80		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28808818/	Homo sapiens		h	6.7				2	PU-H71		false
10143	40862		ADULT	9549213	512.368	PU-H71	PU-H71	CC(C)NCCCN1C(SC2=C(I)C=C3OCOC3=C2)=NC4=C1N=CN=C4N	PLASMA	06IVK87M04									∞	μM × min	2477		μM	8			UNKNOWN	mg/m²	200		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28808818/	Homo sapiens		h	7.1				2	PU-H71		false
10144	40862		ADULT	9549213	512.368	PU-H71	PU-H71	CC(C)NCCCN1C(SC2=C(I)C=C3OCOC3=C2)=NC4=C1N=CN=C4N	PLASMA	06IVK87M04									∞	μM × min	3905		μM	74.7			UNKNOWN	mg/m²	40		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28808818/	Homo sapiens		h	9.2				1	PU-H71		false
10145	40862		ADULT	9549213	512.368	PU-H71	PU-H71	CC(C)NCCCN1C(SC2=C(I)C=C3OCOC3=C2)=NC4=C1N=CN=C4N	PLASMA	06IVK87M04									∞	μM × min	1375		μM	7.3			UNKNOWN	mg/m²	110		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28808818/	Homo sapiens		h	7.6				3	PU-H71		false
10146	40862		ADULT	9549213	512.368	PU-H71	PU-H71	CC(C)NCCCN1C(SC2=C(I)C=C3OCOC3=C2)=NC4=C1N=CN=C4N	PLASMA	06IVK87M04									∞	μM × min	10815		μM	17.3			UNKNOWN	mg/m²	354		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28808818/	Homo sapiens		h	11.5				3	PU-H71		false
10147	40862		ADULT	9549213	512.368	PU-H71	PU-H71	CC(C)NCCCN1C(SC2=C(I)C=C3OCOC3=C2)=NC4=C1N=CN=C4N	PLASMA	06IVK87M04									∞	μM × min	31		μM	0.2			UNKNOWN	mg/m²	10		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28808818/	Homo sapiens		h	2.7				1	PU-H71		false
10148	40862		ADULT	9549213	512.368	PU-H71	PU-H71	CC(C)NCCCN1C(SC2=C(I)C=C3OCOC3=C2)=NC4=C1N=CN=C4N	PLASMA	06IVK87M04									∞	μM × min	12151		μM	33.7			HIGHEST STUDIED	mg/m²	470		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28808818/	Homo sapiens		h	10.8				1	PU-H71		false
10149	41113		ADULT	3034034	324.4168	QUININE	QUININE	COC1=CC2=C(C=C1)N=CC=C2[C@@H](O)[C@@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C	PLASMA	A7V27PHC7A							12		t	μg × h/mL	28		μg/mL	3.2			RECOMMENDED	mg/kg	8.7		SINGLE	UNKNOWN				Quinine is moderately protein-bound in blood in healthy subjects, ranging from 69 to 92%.	8	HEALTHY	Oral	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021799s029lbl.pdf	Homo sapiens		h	12.5							false
10150	41427		ADULT	11548630	565.2816	RO-4987655	RO-4987655	OCCONC(=O)C1=CC(CN2OCCCC2=O)=C(F)C(F)=C1NC3=CC=C(I)C=C3F	PLASMA	I3733P75ML							12		t	ng × h/mL	2638		ng/mL	399			UNKNOWN	mg	10.5		STEADY-STATE	FED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22767668	Homo sapiens		h	8.1	day 15			2	RO-4987655		false
10151	41427		ADULT	11548630	565.2816	RO-4987655	RO-4987655	OCCONC(=O)C1=CC(CN2OCCCC2=O)=C(F)C(F)=C1NC3=CC=C(I)C=C3F	PLASMA	I3733P75ML							12		t	ng × h/mL	2282		ng/mL	601			MAX TOLERATED	mg	10.5		MULTIPLE	FED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22767668	Homo sapiens		h	3.7	day 1			4	RO-4987655		false
10152	41427		ADULT	11548630	565.2816	RO-4987655	RO-4987655	OCCONC(=O)C1=CC(CN2OCCCC2=O)=C(F)C(F)=C1NC3=CC=C(I)C=C3F	PLASMA	I3733P75ML							12		t	ng × h/mL	2577		ng/mL	530			MAX TOLERATED	mg	8.5		STEADY-STATE	FED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22767668	Homo sapiens		h	8	day 15			9	RO-4987655		false
10153	41427		ADULT	11548630	565.2816	RO-4987655	RO-4987655	OCCONC(=O)C1=CC(CN2OCCCC2=O)=C(F)C(F)=C1NC3=CC=C(I)C=C3F	PLASMA	I3733P75ML							12		t	ng × h/mL	1660		ng/mL	425			MAX TOLERATED	mg	8.5		MULTIPLE	FED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22767668	Homo sapiens		h	3.4	day 1			9	RO-4987655		false
10154	41431		ADULT	57406853	727.783	RO-5045337	RO-5045337	CCOC1=C(C=CC(=C1)C(C)(C)C)C2=N[C@@](C)(C3=CC=C(Cl)C=C3)[C@](C)(N2C(=O)N4CCN(CCCS(C)(=O)=O)CC4)C5=CC=C(Cl)C=C5	PLASMA	Q8MI0X869M							24		t	ng × h/mL	89972.3		ng/mL	5646.7			UNKNOWN	mg/m²	1920		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26459177	Homo sapiens		h	17.2				3	RO-5045337		false
10155	41431		ADULT	57406853	727.783	RO-5045337	RO-5045337	CCOC1=C(C=CC(=C1)C(C)(C)C)C2=N[C@@](C)(C3=CC=C(Cl)C=C3)[C@](C)(N2C(=O)N4CCN(CCCS(C)(=O)=O)CC4)C5=CC=C(Cl)C=C5	PLASMA	Q8MI0X869M							24		t	ng × h/mL	125264.1		ng/mL	6500			UNKNOWN	mg	1000		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26459177	Homo sapiens		h	38.8				5	RO-5045337		false
10156	41431		ADULT	57406853	727.783	RO-5045337	RO-5045337	CCOC1=C(C=CC(=C1)C(C)(C)C)C2=N[C@@](C)(C3=CC=C(Cl)C=C3)[C@](C)(N2C(=O)N4CCN(CCCS(C)(=O)=O)CC4)C5=CC=C(Cl)C=C5	PLASMA	Q8MI0X869M							24		t	ng × h/mL	88065.4		ng/mL	4611.7			UNKNOWN	mg/m²	1215		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26459177	Homo sapiens		h	31.7				3	RO-5045337		false
10157	41431		ADULT	57406853	727.783	RO-5045337	RO-5045337	CCOC1=C(C=CC(=C1)C(C)(C)C)C2=N[C@@](C)(C3=CC=C(Cl)C=C3)[C@](C)(N2C(=O)N4CCN(CCCS(C)(=O)=O)CC4)C5=CC=C(Cl)C=C5	PLASMA	Q8MI0X869M							24		t	ng × h/mL	100944.3		ng/mL	5544.3			UNKNOWN	mg/m²	810		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26459177	Homo sapiens		h	36				7	RO-5045337		false
10158	41431		ADULT	57406853	727.783	RO-5045337	RO-5045337	CCOC1=C(C=CC(=C1)C(C)(C)C)C2=N[C@@](C)(C3=CC=C(Cl)C=C3)[C@](C)(N2C(=O)N4CCN(CCCS(C)(=O)=O)CC4)C5=CC=C(Cl)C=C5	PLASMA	Q8MI0X869M							24		t	ng × h/mL	46137.4		ng/mL	2518.7			UNKNOWN	mg/m²	405		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26459177	Homo sapiens		h	55				7	RO-5045337		false
10159	41431		ADULT	57406853	727.783	RO-5045337	RO-5045337	CCOC1=C(C=CC(=C1)C(C)(C)C)C2=N[C@@](C)(C3=CC=C(Cl)C=C3)[C@](C)(N2C(=O)N4CCN(CCCS(C)(=O)=O)CC4)C5=CC=C(Cl)C=C5	PLASMA	Q8MI0X869M							24		t	ng × h/mL	48023.1		ng/mL	3393			UNKNOWN	mg/m²	1215		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26459177	Homo sapiens		h	41				4	RO-5045337		false
10160	41431		ADULT	57406853	727.783	RO-5045337	RO-5045337	CCOC1=C(C=CC(=C1)C(C)(C)C)C2=N[C@@](C)(C3=CC=C(Cl)C=C3)[C@](C)(N2C(=O)N4CCN(CCCS(C)(=O)=O)CC4)C5=CC=C(Cl)C=C5	PLASMA	Q8MI0X869M							24		t	ng × h/mL	175528.9		ng/mL	8943			MAX TOLERATED	mg	1500		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26459177	Homo sapiens		h	41.1				30	RO-5045337		false
10161	41431		ADULT	57406853	727.783	RO-5045337	RO-5045337	CCOC1=C(C=CC(=C1)C(C)(C)C)C2=N[C@@](C)(C3=CC=C(Cl)C=C3)[C@](C)(N2C(=O)N4CCN(CCCS(C)(=O)=O)CC4)C5=CC=C(Cl)C=C5	PLASMA	Q8MI0X869M							24		t	ng × h/mL	67635.3		ng/mL	4227.5			UNKNOWN	mg/m²	540		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26459177	Homo sapiens		h	36.3				4	RO-5045337		false
10162	41431		ADULT	57406853	727.783	RO-5045337	RO-5045337	CCOC1=C(C=CC(=C1)C(C)(C)C)C2=N[C@@](C)(C3=CC=C(Cl)C=C3)[C@](C)(N2C(=O)N4CCN(CCCS(C)(=O)=O)CC4)C5=CC=C(Cl)C=C5	PLASMA	Q8MI0X869M							24		t	ng × h/mL	49082.4		ng/mL	3075			UNKNOWN	mg/m²	360		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26459177	Homo sapiens		h	22.7				2	RO-5045337		false
10163	41431		ADULT	57406853	727.783	RO-5045337	RO-5045337	CCOC1=C(C=CC(=C1)C(C)(C)C)C2=N[C@@](C)(C3=CC=C(Cl)C=C3)[C@](C)(N2C(=O)N4CCN(CCCS(C)(=O)=O)CC4)C5=CC=C(Cl)C=C5	PLASMA	Q8MI0X869M							24		t	ng × h/mL	18842.6		ng/mL	1080			UNKNOWN	mg/m²	45		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26459177	Homo sapiens		h	96.2				3	RO-5045337		false
10164	41431		ADULT	57406853	727.783	RO-5045337	RO-5045337	CCOC1=C(C=CC(=C1)C(C)(C)C)C2=N[C@@](C)(C3=CC=C(Cl)C=C3)[C@](C)(N2C(=O)N4CCN(CCCS(C)(=O)=O)CC4)C5=CC=C(Cl)C=C5	PLASMA	Q8MI0X869M							24		t	ng × h/mL	7859.2		ng/mL	442.7			UNKNOWN	mg/m²	30		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26459177	Homo sapiens		h	61.9				3	RO-5045337		false
10165	41431		ADULT	57406853	727.783	RO-5045337	RO-5045337	CCOC1=C(C=CC(=C1)C(C)(C)C)C2=N[C@@](C)(C3=CC=C(Cl)C=C3)[C@](C)(N2C(=O)N4CCN(CCCS(C)(=O)=O)CC4)C5=CC=C(Cl)C=C5	PLASMA	Q8MI0X869M							24		t	ng × h/mL	1597.2		ng/mL	112.3			UNKNOWN	mg/m²	20		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26459177	Homo sapiens		h	58.4				4	RO-5045337		false
10166	41431		ADULT	57406853	727.783	RO-5045337	RO-5045337	CCOC1=C(C=CC(=C1)C(C)(C)C)C2=N[C@@](C)(C3=CC=C(Cl)C=C3)[C@](C)(N2C(=O)N4CCN(CCCS(C)(=O)=O)CC4)C5=CC=C(Cl)C=C5	PLASMA	Q8MI0X869M							24		t	ng × h/mL	67189.8		ng/mL	4074			UNKNOWN	mg/m²	810		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26459177	Homo sapiens		h	23.7				5	RO-5045337		false
10167	41461		ADULT	5281792	360.3148	ROSMARINIC ACID	rosmarinic acid	OC(=O)[C@@H](CC1=CC=C(O)C(O)=C1)OC(=O)\\C=C\\C2=CC(O)=C(O)C=C2	SERUM	MQE6XG29YI							48		t	nM × h	354.88		nM	72.22			UNKNOWN	mg	250		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25978046/	Homo sapiens				Melissa officinalis extract containing 250 mg rosmarinic acid			6			false
10168	41461		ADULT	5281792	360.3148	ROSMARINIC ACID	rosmarinic acid	OC(=O)[C@@H](CC1=CC=C(O)C(O)=C1)OC(=O)\\C=C\\C2=CC(O)=C(O)C=C2	SERUM	MQE6XG29YI							48		t	nM × h	945.03		nM	142.2			UNKNOWN	mg	500		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25978046/	Homo sapiens				Melissa officinalis extract containing 500 mg rosmarinic acid			6			false
10169	41461		ADULT	5281792	360.3148	ROSMARINIC ACID	rosmarinic acid	OC(=O)[C@@H](CC1=CC=C(O)C(O)=C1)OC(=O)\\C=C\\C2=CC(O)=C(O)C=C2	SERUM	MQE6XG29YI							48		t	nM × h	832.13		nM	162.2			UNKNOWN	mg	500		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25978046/	Homo sapiens				Melissa officinalis extract containing 500 mg rosmarinic acid			6			false
10170	41631		ADULT	338|118212070	138.1207	SALICYLIC ACID	SALICYLIC ACID	OC(=O)C1=C(O)C=CC=C1	SERUM	O414PZ4LPZ									?	μM × h	99						UNKNOWN	mg	240		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11599656	Homo sapiens		h	2.45							false
10171	41631		ADULT	10253	195.1721	N-SALICYLOYLGLYCINE	N-SALICYLOYLGLYCINE	OC(=O)CNC(=O)C1=C(O)C=CC=C1	SERUM	5BR3P7J05U									?	μM × h	10.7						UNKNOWN	mg	240		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11599656	Homo sapiens										false
10172	41631		ADULT	3469	154.1201	GENTISIC ACID	GENTISIC ACID	OC(=O)C1=CC(O)=CC=C1O	SERUM	VP36V95O3T									?	μM × h	4.9						UNKNOWN	mg	240		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11599656	Homo sapiens										false
10173	41695		ADULT	53476877	562.503	SAR-405838	SAR-405838	CC(C)(C)C[C@@H]1N[C@H]([C@H](C2=CC=CC(Cl)=C2F)[C@]13C(=O)NC4=CC(Cl)=CC=C34)C(=O)N[C@H]5CC[C@H](O)CC5	PLASMA	8570LZ3RCA							24		t	ng × h/mL	32300		ng/mL	2170			UNKNOWN	mg	400		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28324749	Homo sapiens		h	18.5				7	SAR-405838		false
10174	41695		ADULT	53476877	562.503	SAR-405838	SAR-405838	CC(C)(C)C[C@@H]1N[C@H]([C@H](C2=CC=CC(Cl)=C2F)[C@]13C(=O)NC4=CC(Cl)=CC=C34)C(=O)N[C@H]5CC[C@H](O)CC5	PLASMA	8570LZ3RCA							24		t	ng × h/mL	78000		ng/mL	4590			UNKNOWN	mg	1800		MULTIPLE	FED		week	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28324749	Homo sapiens							6	SAR-405838		false
10175	41695		ADULT	53476877	562.503	SAR-405838	SAR-405838	CC(C)(C)C[C@@H]1N[C@H]([C@H](C2=CC=CC(Cl)=C2F)[C@]13C(=O)NC4=CC(Cl)=CC=C34)C(=O)N[C@H]5CC[C@H](O)CC5	PLASMA	8570LZ3RCA							24		t	ng × h/mL	13000		ng/mL	1510			MAX TOLERATED	mg	300		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28324749	Homo sapiens		h	17				21	SAR-405838		false
10176	41699		ADULT	1088|7311726	89.0932	SARCOSINE	sarcosine	CNCC(O)=O	SERUM	Z711V88R5F																	UNKNOWN	g	4		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25841105/	Homo sapiens		h	1				17	sarcosine		false
10177	41911		ADULT	46917407	342	( )-sesamin monocatechol			PLASMA	F8YB79JA5A									∞	ng × h/mL	819		ng/mL	187			UNKNOWN	mg	25		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24014208/	Homo sapiens		h	2.4	a mixture of sesamin and episesamin (sesamin/episesamin = 1/1)			10	SESAMIN		false
10178	41911		ADULT	46881231	330	( )-sesamin dicatechol			PLASMA	Y5Y6335JEF									∞	ng × h/mL	49.6		ng/mL	10.4			UNKNOWN	mg	25		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24014208/	Homo sapiens		h	2.9	a mixture of sesamin and episesamin (sesamin/episesamin = 1/1)			10	SESAMIN		false
10179	41911		ADULT	72307	354.3533	SESAMIN	sesamin	C1OC2=CC=C(C=C2O1)[C@H]3OC[C@H]4[C@@H]3CO[C@@H]4C5=CC6=C(OCO6)C=C5	PLASMA	S7946O4P76									?	ng × h/mL	17.3		ng/mL	2.9			UNKNOWN	mg	25		MULTIPLE	FED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24014208/	Homo sapiens				a mixture of sesamin and episesamin (sesamin/episesamin = 1/1)			10	SESAMIN		false
10180	41911		ADULT	72307	354.3533	SESAMIN	SESAMIN	C1OC2=CC=C(C=C2O1)[C@H]3OC[C@H]4[C@@H]3CO[C@@H]4C5=CC6=C(OCO6)C=C5	PLASMA	S7946O4P76									?	ng × h/mL	10.6		ng/mL	2.69			UNKNOWN	mg	25		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24014208/	Homo sapiens				a mixture of sesamin and episesamin (sesamin/episesamin = 1/1)			10	SESAMIN		false
10181	42037		ADULT	24772860	464.4807	SNX-2112	SNX-2112	CC1(C)CC2=C(C(=NN2C3=CC=C(C(N)=O)C(N[C@H]4CC[C@H](O)CC4)=C3)C(F)(F)F)C(=O)C1	PLASMA	10C9P3FFOW							48		t	ng × h/mL	9990		ng/mL	1210			UNKNOWN	mg/m²	100		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25262379	Homo sapiens		h	10.5							false
10182	42037		ADULT		464.4807	SNX-2112	SNX-2112	CC1(C)CC2=C(C(=NN2C3=CC=C(C(N)=O)C(N[C@H]4CC[C@H](O)CC4)=C3)C(F)(F)F)C(=O)C1	PLASMA	10C9P3FFOW									?	ng × h/mL	6610		ng/mL	460			UNKNOWN	mg/m²	21.28		STEADY-STATE	UNKNOWN		2 days	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25262379	Homo sapiens		h	16.8				3	SNX-5422		false
10183	42037		ADULT		464.4807	SNX-2112	SNX-2112	CC1(C)CC2=C(C(=NN2C3=CC=C(C(N)=O)C(N[C@H]4CC[C@H](O)CC4)=C3)C(F)(F)F)C(=O)C1	PLASMA	10C9P3FFOW									?	ng × h/mL	6010		ng/mL	770			UNKNOWN	mg/m²	56		STEADY-STATE	UNKNOWN		2 days	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25262379	Homo sapiens		h	10.9				3	SNX-5422		false
10184	42037		ADULT		464.4807	SNX-2112	SNX-2112	CC1(C)CC2=C(C(=NN2C3=CC=C(C(N)=O)C(N[C@H]4CC[C@H](O)CC4)=C3)C(F)(F)F)C(=O)C1	PLASMA	10C9P3FFOW									?	ng × h/mL	10500		ng/mL	1220			MAX TOLERATED	mg/m²	100		STEADY-STATE	UNKNOWN		2 days	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25262379	Homo sapiens		h	10.2				9	SNX-5422		false
10185	42037		ADULT		464.4807	SNX-2112	SNX-2112	CC1(C)CC2=C(C(=NN2C3=CC=C(C(N)=O)C(N[C@H]4CC[C@H](O)CC4)=C3)C(F)(F)F)C(=O)C1	PLASMA	10C9P3FFOW									?	ng × h/mL	3950		ng/mL	579			UNKNOWN	mg/m²	50		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25262379	Homo sapiens		h	11.1				6	SNX-5422		false
10186	42037		ADULT		464.4807	SNX-2112	SNX-2112	CC1(C)CC2=C(C(=NN2C3=CC=C(C(N)=O)C(N[C@H]4CC[C@H](O)CC4)=C3)C(F)(F)F)C(=O)C1	PLASMA	10C9P3FFOW									?	ng × h/mL	5770		mg/mL	723			MAX TOLERATED	mg/m²	67		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25262379	Homo sapiens		h	9.8				4	SNX-5422		false
10187	42275		NEWBORN	2797	214.646	CLOFIBRIC ACID	CLOFIBRIC ACID	CC(C)(OC1=CC=C(Cl)C=C1)C(O)=O	PLASMA	53PF01Q249									∞	μg × h/mL	30649		μg/mL	216			UNKNOWN	mg/kg	100		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7550835/	Homo sapiens		h	103.1							false
10188	42436		UNKNOWN	338|118212070	138.1207	SALICYLIC ACID	SALICYLIC ACID	OC(=O)C1=C(O)C=CC=C1	PLASMA	O414PZ4LPZ																	UNKNOWN	mg	500		SINGLE	UNKNOWN						UNKNOWN	Intravenous	MALE	EXPERIMENT	https://www.sciencedirect.com/science/article/abs/pii/S0022354915364558	Homo sapiens		min	238							false
10189	42775		UNKNOWN	25108829	516.638	SRT-2104	SRT-2104	CC1=C(SC(=N1)C2=CN=CC=C2)C(=O)NC3=C(C=CC=C3)C4=CN5C(CN6CCOCC6)=CSC5=N4	PLASMA	4521NR0J09							24		t	ng × h/mL	13997		ng/mL	1874			UNKNOWN	g	2		MULTIPLE	FED		day	1			HEALTHY	Oral	MALE	REVIEW	https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0142081.s003&type=supplementary	Homo sapiens							10			false
10190	42775		UNKNOWN	25108829	516.638	SRT-2104	SRT-2104	CC1=C(SC(=N1)C2=CN=CC=C2)C(=O)NC3=C(C=CC=C3)C4=CN5C(CN6CCOCC6)=CSC5=N4	PLASMA	4521NR0J09																	UNKNOWN	μg	100		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	REVIEW	https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0142081.s003&type=supplementary	Homo sapiens		h	23.7							false
10191	42775		UNKNOWN	25108829	516.638	SRT-2104	SRT-2104	CC1=C(SC(=N1)C2=CN=CC=C2)C(=O)NC3=C(C=CC=C3)C4=CN5C(CN6CCOCC6)=CSC5=N4	PLASMA	4521NR0J09																	UNKNOWN	mg	250		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	REVIEW	https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0142081.s003&type=supplementary	Homo sapiens		h	25.5							false
10192	42775		ADULT	25108829	516.638	SRT-2104	SRT-2104	CC1=C(SC(=N1)C2=CN=CC=C2)C(=O)NC3=C(C=CC=C3)C4=CN5C(CN6CCOCC6)=CSC5=N4	PLASMA	4521NR0J09							24		t	ng × h/mL	1573		ng/mL	261.2			UNKNOWN	g	3		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22616762	Homo sapiens		h	14.6	7 days			4			false
10193	42775		ADULT	25108829	516.638	SRT-2104	SRT-2104	CC1=C(SC(=N1)C2=CN=CC=C2)C(=O)NC3=C(C=CC=C3)C4=CN5C(CN6CCOCC6)=CSC5=N4	PLASMA	4521NR0J09							24		t	ng × h/mL	3665		ng/mL	536.8			UNKNOWN	g	2		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22616762	Homo sapiens		h	14.2	7 days			4			false
10194	42775		ADULT		516.638	SRT-2104	SRT-2104	CC1=C(SC(=N1)C2=CN=CC=C2)C(=O)NC3=C(C=CC=C3)C4=CN5C(CN6CCOCC6)=CSC5=N4	PLASMA	4521NR0J09							24		t	ng × h/mL	3087		ng/mL	452.7			UNKNOWN	g	1		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22616762	Homo sapiens		h	17.7	7 days			4			false
10195	42775		ADULT		516.638	SRT-2104	SRT-2104	CC1=C(SC(=N1)C2=CN=CC=C2)C(=O)NC3=C(C=CC=C3)C4=CN5C(CN6CCOCC6)=CSC5=N4	PLASMA	4521NR0J09							24		t	ng × h/mL	1878		ng/mL	293.3			UNKNOWN	g	0.5		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22616762	Homo sapiens		h	20	7 days			4			false
10196	42775		ADULT		516.638	SRT-2104	SRT-2104	CC1=C(SC(=N1)C2=CN=CC=C2)C(=O)NC3=C(C=CC=C3)C4=CN5C(CN6CCOCC6)=CSC5=N4	PLASMA	4521NR0J09							24		t	ng × h/mL	1191		ng/mL	218.7			UNKNOWN	g	0.25		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22616762	Homo sapiens		h	21.6	7 days			4			false
10197	42775		ADULT		516.638	SRT-2104	SRT-2104	CC1=C(SC(=N1)C2=CN=CC=C2)C(=O)NC3=C(C=CC=C3)C4=CN5C(CN6CCOCC6)=CSC5=N4	PLASMA								24		t	ng × h/mL	602		ng/mL	127.3			UNKNOWN	g	0.1		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22616762	Homo sapiens		h	12.1	7 days			4			false
10198	42775		ADULT		516.638	SRT-2104	SRT-2104	CC1=C(SC(=N1)C2=CN=CC=C2)C(=O)NC3=C(C=CC=C3)C4=CN5C(CN6CCOCC6)=CSC5=N4	PLASMA								24		t	ng × h/mL	247		ng/mL	50.1			UNKNOWN	g	0.03		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22616762	Homo sapiens		h	12.7	7 days			4			false
10199	42994		ADULT	23955	87.62	STRONTIUM	STRONTIUM	[Sr]	PLASMA	YZS2RPE8LE									∞	μg × h/mL	47.8		μg/mL	2.6			UNKNOWN	mg	170		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	PATENT	https://patentimages.storage.googleapis.com/2d/ec/d1/45148c1fe099d4/US20200016101A1.pdf	Homo sapiens		h	12.3							false
10200	43229		ADULT	11620908	547.957	TAK-285	TAK-285	CC(C)(O)CC(=O)NCCN1C=CC2=C1C(NC3=CC(Cl)=C(OC4=CC(=CC=C4)C(F)(F)F)C=C3)=NC=N2	PLASMA	70CCB438L6									?	ng × h/mL	30900		ng/mL	3700			MAX TOLERATED	mg	300		MULTIPLE			day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22240796	Homo sapiens		h	8.25				3	TAK-285		false
10201	43285		ADULT	73774610	648.635	TD-139	TD139	OC[C@H]1O[C@@H](S[C@@H]2O[C@H](CO)[C@H](O)[C@@H]([C@H]2O)N3C=C(N=N3)C4=CC(F)=CC=C4)[C@H](O)[C@H]([C@H]1O)N5C=C(N=N5)C6=CC=CC(F)=C6	BLOOD	60Y0GUO72B																	UNKNOWN	mg	10		MULTIPLE	UNKNOWN		day	1			UNKNOWN	Respiratory	UNKNOWN	EXPERIMENT	https://www.atsjournals.org/doi/pdf/10.1164/ajrccm-conference.2017.195.1_MeetingAbstracts.A7560	Homo sapiens		h	7				24	TD139		false
10202	43365		ADULT	21146529	305.2276	TENOFOVIR	Tenofovir	O.C[C@H](CN1C=NC2=C1N=CN=C2N)OCP(O)(O)=O	SERUM	99YXE507IL									?	ng × h/mL	3324		ng/mL	326			RECOMMENDED	mg	245		MULTIPLE	FED		day	1	In vitro protein binding of tenofovir to plasma or serum protein was less than 0.7 and 7.2%, respectively, over the tenofovir concentration range 0.01 to 25 µg/ml.	99.3	UNHEALTHY	Oral	UNKNOWN	OTHER	https://www.medicines.org.uk/emc/product/8138/smpc#PRODUCTINFO	Homo sapiens		h	18		HIV patients					false
10203	43589		ADULT	114924	288.489	TETRADECYLTHIOACETIC ACID	Tetradecylthioacetic acid	CCCCCCCCCCCCCCSCC(O)=O	SERUM	7ZU5I25S2O													mg/L	9			UNKNOWN	mg	600		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18427285	Homo sapiens							6	Tetradecylthioacetic acid		false
10204	43589		ADULT	114924	288.489	TETRADECYLTHIOACETIC ACID	Tetradecylthioacetic acid	CCCCCCCCCCCCCCSCC(O)=O	SERUM	7ZU5I25S2O													mg/L	14			UNKNOWN	mg	1000		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18427285	Homo sapiens							6	Tetradecylthioacetic acid		false
10205	43589		ADULT	114924	288.489	TETRADECYLTHIOACETIC ACID	Tetradecylthioacetic acid	CCCCCCCCCCCCCCSCC(O)=O	SERUM	7ZU5I25S2O													mg/L	2.9			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18427285	Homo sapiens							6			false
10206	43589		ADULT	114924	288.489	TETRADECYLTHIOACETIC ACID	Tetradecylthioacetic acid	CCCCCCCCCCCCCCSCC(O)=O	SERUM	7ZU5I25S2O													mg/L	11.5			UNKNOWN	mg	600		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18427285	Homo sapiens							6			false
10207	43589		ADULT	114924	288.489	TETRADECYLTHIOACETIC ACID	Tetradecylthioacetic acid	CCCCCCCCCCCCCCSCC(O)=O	SERUM	7ZU5I25S2O													mg/L	4			UNKNOWN	mg	200		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18427285	Homo sapiens							6	Tetradecylthioacetic acid		false
10208	43589		ADULT	114924	288.489	TETRADECYLTHIOACETIC ACID	Tetradecylthioacetic acid	CCCCCCCCCCCCCCSCC(O)=O	SERUM	7ZU5I25S2O													mg/L	11			UNKNOWN	mg	1000		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18427285	Homo sapiens							6			false
10209	43651		ADULT	72301	355.4275	TETRAHYDROPALMATINE	TETRAHYDROPALMATINE	COC1=CC2=C(C=C1OC)[C@@H]3CC4=C(CN3CC2)C(OC)=C(OC)C=C4	PLASMA	3X69CO5I79									∞	ng × h/mL	396.1		ng/mL	42.8			UNKNOWN	mg	30		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27363313	Homo sapiens		h	13.3				9	TETRAHYDROPALMATINE		false
10210	43705		ADULT	73078	622.7499	TETRANDRINE	Tetrandrine	COC1=CC2=C3C=C1OC4=C5[C@H](CC6=CC(OC7=CC=C(C[C@@H]3N(C)CC2)C=C7)=C(OC)C=C6)N(C)CCC5=CC(OC)=C4OC	PLASMA	29EX23D5AJ									∞	ng × h/mL	1554.16		ng/mL	67.26			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29100757/	Homo sapiens		h	22.34				6			false
10211	43705		ADULT	275182	608.7233	BERBAMINE	Berbamine	COC1=CC2=C3C=C1OC4=C5[C@@H](CC6=CC(OC7=CC=C(C[C@@H]3N(C)CC2)C=C7)=C(O)C=C6)N(C)CCC5=CC(OC)=C4OC	PLASMA	V5KM4XJ0WM									∞	ng × h/mL	756.73		ng/mL	33.24			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29100757/	Homo sapiens		h	39.25				6			false
10212	43761		ADULT	92142	258.2295	THALIDOMIDE, (S)-	THALIDOMIDE, (-)-	O=C1N([C@H]2CCC(=O)NC2=O)C(=O)C3=C1C=CC=C3	BLOOD	TG87FSR590									?	μg × h/mL	2.75		μg/mL	0.93			UNKNOWN	mg	50		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10933131/	Homo sapiens							6	THALIDOMIDE, (-)-		false
10213	43761		ADULT	75792	258.2295	THALIDOMIDE, (R)-	THALIDOMIDE, (R)-	O=C1N([C@@H]2CCC(=O)NC2=O)C(=O)C3=C1C=CC=C3	BLOOD	QN61H68KLK									?	μg × h/mL	2.42		μg/mL	0.23			UNKNOWN	mg	50		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10933131/	Homo sapiens							6	THALIDOMIDE, (-)-		false
10214	43761		ADULT	92142	258.2295	THALIDOMIDE, (S)-	THALIDOMIDE, (-)-	O=C1N([C@H]2CCC(=O)NC2=O)C(=O)C3=C1C=CC=C3	BLOOD	TG87FSR590									∞	μg × h/mL	3.9						UNKNOWN	mg/kg	1		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7702998/	Homo sapiens		h	4.8				6	THALIDOMIDE, (-)-		false
10215	43761		ADULT	75792	258.2295	THALIDOMIDE, (R)-	THALIDOMIDE, (R)-	O=C1N([C@@H]2CCC(=O)NC2=O)C(=O)C3=C1C=CC=C3	BLOOD	QN61H68KLK									∞	μg × h/mL	2.9						UNKNOWN	mg/kg	1		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/7702998/	Homo sapiens							6	THALIDOMIDE, (-)-		false
10216	43770		ADULT	439378|25201220	174.1977	THEANINE	L-theanine	CCNC(=O)CC[C@H](N)C(O)=O	PLASMA	8021PR16QO									?	μM × h	57.1		μM	24.3			UNKNOWN	mg	100		SINGLE	FASTED				AUC and Cmax were corrected to a body weight of 70 kg.		HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23096008/	Homo sapiens		h	1.2		nonsmokers		12	L-Theanine		false
10217	43770		ADULT	6341	45.0837	ETHYLAMINE	ethylamine	CCN	PLASMA	YG6MGA6AT5									?	μM × h	101		μM	6.1			UNKNOWN	mg	100		SINGLE	FASTED				AUC and Cmax were corrected to a body weight of 70 kg.		HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23096008/	Homo sapiens					nonsmokers		12	L-Theanine		false
10218	43770		ADULT	33032|44272391|88747398	147.1293	GLUTAMIC ACID	glutamic acid	N[C@@H](CCC(O)=O)C(O)=O	RED BLOOD CELLS	3KX376GY7L									?	μM × h	276		μM	43.1			UNKNOWN	mg	100		SINGLE	FASTED				AUC and Cmax were corrected to a body weight of 70 kg.		HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23096008/	Homo sapiens					nonsmokers		12	L-Theanine		false
10219	43770		ADULT	33032|44272391|88747398	147.1293	GLUTAMIC ACID	glutamic acid	N[C@@H](CCC(O)=O)C(O)=O	PLASMA	3KX376GY7L									?	μM × h	38.9		μM	12.9			UNKNOWN	mg	100		SINGLE	FASTED				AUC and Cmax were corrected to a body weight of 70 kg.		HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23096008/	Homo sapiens					nonsmokers		12	L-Theanine		false
10220	43770		ADULT	439378|25201220	174.1977	THEANINE	L-theanine	CCNC(=O)CC[C@H](N)C(O)=O	RED BLOOD CELLS	8021PR16QO									?	μM × h	50.5		μM	2.8			UNKNOWN	mg	100		SINGLE	FASTED				AUC and Cmax were corrected to a body weight of 70 kg.		HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23096008/	Homo sapiens					nonsmokers		12	L-Theanine		false
10221	43877		ADULT	6112	206.326	THIOCTIC ACID, ( )-	Lipoic acid	OC(=O)CCCC[C@@H]1CCSS1	PLASMA	VLL71EBS9Z									?	ng × h/mL	110.23		ng/mL	71.78			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10072479/	Homo sapiens		h	0.5				15	rac-Thioctic acid		false
10222	43877		ADULT	445125	206.326	THIOCTIC ACID, (-)-	Thioctic acid, (-)-	OC(=O)CCCC[C@H]1CCSS1	PLASMA	J2Y905FQ57									?	ng × h/mL	65.51		ng/mL	42.74			UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10072479/	Homo sapiens		h	0.56				15	rac-Thioctic acid		false
10223	43877		ADULT	6112	206.326	THIOCTIC ACID, ( )-	Lipoic acid	OC(=O)CCCC[C@@H]1CCSS1	PLASMA	VLL71EBS9Z									?	ng × h/mL	261.73		ng/mL	302.98			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10072479/	Homo sapiens		h	0.5				15	rac-Thioctic acid		false
10224	43877		ADULT	445125	206.326	THIOCTIC ACID, (-)-	Thioctic acid, (-)-	OC(=O)CCCC[C@H]1CCSS1	PLASMA	J2Y905FQ57									?	ng × h/mL	147.89		ng/mL	182.23			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10072479/	Homo sapiens		h	0.47				15	rac-Thioctic acid		false
10225	43877		ADULT	6112	206.326	THIOCTIC ACID, ( )-	Lipoic acid	OC(=O)CCCC[C@@H]1CCSS1	PLASMA	VLL71EBS9Z									?	ng × h/mL	506.77		ng/mL	429.28			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10072479/	Homo sapiens		h	0.67				15	rac-Thioctic acid		false
10226	43877		ADULT	445125	206.326	THIOCTIC ACID, (-)-	Thioctic acid, (-)-	OC(=O)CCCC[C@H]1CCSS1	PLASMA	J2Y905FQ57									?	ng × h/mL	282.67		ng/mL	231.27			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10072479/	Homo sapiens		h	0.69				15	rac-Thioctic acid		false
10227	43877		ADULT	6112	206.326	THIOCTIC ACID, ( )-	Lipoic acid	OC(=O)CCCC[C@@H]1CCSS1	PLASMA	VLL71EBS9Z									?	ng × h/mL	752.76		ng/mL	473.74			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10072479/	Homo sapiens		h	0.58				15	rac-Thioctic acid		false
10228	43877		ADULT	445125	206.326	THIOCTIC ACID, (-)-	Thioctic acid, (-)-	OC(=O)CCCC[C@H]1CCSS1	PLASMA	J2Y905FQ57									?	ng × h/mL	393.69		ng/mL	235.08			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10072479/	Homo sapiens		h	0.6				15	rac-Thioctic acid		false
10229	43877		ADULT	6112	206.326	THIOCTIC ACID, ( )-	Lipoic acid	OC(=O)CCCC[C@@H]1CCSS1	PLASMA	VLL71EBS9Z									?	ng × h/mL	1814.81		ng/mL	1135.1			UNKNOWN	mg	600		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10072479/	Homo sapiens		h	0.6				15	rac-Thioctic acid		false
10230	43877		ADULT	445125	206.326	THIOCTIC ACID, (-)-	Thioctic acid, (-)-	OC(=O)CCCC[C@H]1CCSS1	PLASMA	J2Y905FQ57									?	ng × h/mL	929.34		ng/mL	591.33			UNKNOWN	mg	600		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10072479/	Homo sapiens		h	0.64				15	rac-Thioctic acid		false
10231	43877		ADULT	6112	206.326	THIOCTIC ACID, ( )-	Lipoic acid	OC(=O)CCCC[C@@H]1CCSS1	PLASMA	VLL71EBS9Z									?	ng × h/mL	2518		ng/mL	2654			UNKNOWN	mg	600		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8858282/	Homo sapiens							12			false
10232	43877		ADULT	6112	206.326	THIOCTIC ACID, ( )-	Lipoic acid	OC(=O)CCCC[C@@H]1CCSS1	PLASMA	VLL71EBS9Z									?	ng × h/mL	1926		ng/mL	1735			UNKNOWN	mg	600		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8858282/	Homo sapiens							12			false
10233	43877		ADULT	445125	206.326	THIOCTIC ACID, (-)-	Thioctic acid, (-)-	OC(=O)CCCC[C@H]1CCSS1	PLASMA	J2Y905FQ57									?	ng × h/mL	1361		ng/mL	1415			UNKNOWN	mg	600		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8858282/	Homo sapiens							12			false
10234	43877		ADULT	445125	206.326	THIOCTIC ACID, (-)-	Thioctic acid, (-)-	OC(=O)CCCC[C@H]1CCSS1	PLASMA	J2Y905FQ57									?	ng × h/mL	1134		ng/mL	1003			UNKNOWN	mg	600		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8858282/	Homo sapiens							12			false
10235	43999		ADULT	5789	242.2286	THYMIDINE	THYMIDINE	CC1=CN([C@H]2C[C@H](O)[C@@H](CO)O2)C(=O)NC1=O	PLASMA	VC2W18DGKR	10339178	371.254	CARBOPLATIN	Carboplatin	N.N.[Pt  ].[O-]C(=O)C1(CCC1)C([O-])=O	BG3F62OND5											UNKNOWN	mg/m²	75		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/10561372	Homo sapiens		min	120	24-hour infusion		Carboplatin was administered over 20 minutes at hour 20 of the 24-hour thymidine infusion	23	THYMIDINE		true
10236	44033		ADULT	60937	318.608	TILUDRONIC ACID	TILUDRONIC ACID	OP(O)(=O)C(SC1=CC=C(Cl)C=C1)P(O)(O)=O	PLASMA	6PNS59HP4Y							24		t	mg × h/L	10.3		mg/L	1.1			UNKNOWN	mg	200		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8911885	Homo sapiens										false
10237	44033		ADULT	60937	318.608	TILUDRONIC ACID	TILUDRONIC ACID	OP(O)(=O)C(SC1=CC=C(Cl)C=C1)P(O)(O)=O	PLASMA	6PNS59HP4Y							24		t	mg × h/L	25		mg/L	2.3			UNKNOWN	mg	400		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8911885	Homo sapiens		h	78							false
10238	44033		ADULT	60937	318.608	TILUDRONIC ACID	TILUDRONIC ACID	OP(O)(=O)C(SC1=CC=C(Cl)C=C1)P(O)(O)=O	PLASMA	6PNS59HP4Y							24		t	mg × h/L	46.8		mg/L	4.7			UNKNOWN	mg	600		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8911885	Homo sapiens		h	65.7							false
10239	44033		ADULT	60937	318.608	TILUDRONIC ACID	TILUDRONIC ACID	OP(O)(=O)C(SC1=CC=C(Cl)C=C1)P(O)(O)=O	PLASMA	6PNS59HP4Y							24		t	mg × h/L	80		mg/L	7.8			UNKNOWN	mg	800		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8911885	Homo sapiens		h	72							false
10240	44096		ADULT	5282350	396.6053	.DELTA.-TOCOTRIENOL	delta-tocotrienol	CC(C)=CCC\\C(C)=C\\CC\\C(C)=C\\CC[C@]1(C)CCC2=CC(O)=CC(C)=C2O1	PLASMA	1SRB74OWSI									∞	ng × h/mL	5904.6		ng/mL	1419.6			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27278668/	Homo sapiens		h	1.7				3	delta-tocotrienol		false
10241	44096		ADULT	5282350	396.6053	.DELTA.-TOCOTRIENOL	delta-tocotrienol	CC(C)=CCC\\C(C)=C\\CC\\C(C)=C\\CC[C@]1(C)CCC2=CC(O)=CC(C)=C2O1	PLASMA	1SRB74OWSI									∞	ng × h/mL	10798.9		ng/mL	1818.1			UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27278668/	Homo sapiens		h	2.3				3	delta-tocotrienol		false
10242	44096		ADULT		396.6053	.DELTA.-TOCOTRIENOL	delta-tocotrienol	CC(C)=CCC\\C(C)=C\\CC\\C(C)=C\\CC[C@]1(C)CCC2=CC(O)=CC(C)=C2O1	PLASMA	1SRB74OWSI									∞	ng × h/mL	6549.3		ng/mL	795.6			UNKNOWN	mg	400		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27278668/	Homo sapiens		h	4.5				3	delta-tocotrienol		false
10243	44096		ADULT		396.6053	.DELTA.-TOCOTRIENOL	delta-tocotrienol	CC(C)=CCC\\C(C)=C\\CC\\C(C)=C\\CC[C@]1(C)CCC2=CC(O)=CC(C)=C2O1	PLASMA	1SRB74OWSI									∞	ng × h/mL	29923.4		ng/mL	3742.6			UNKNOWN	mg	800		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27278668/	Homo sapiens		h	4.5				3	delta-tocotrienol		false
10244	44096		ADULT		396.6053	.DELTA.-TOCOTRIENOL	delta-tocotrienol	CC(C)=CCC\\C(C)=C\\CC\\C(C)=C\\CC[C@]1(C)CCC2=CC(O)=CC(C)=C2O1	PLASMA	1SRB74OWSI									∞	ng × h/mL	11490.6		ng/mL	1272.4			UNKNOWN	mg	1600		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27278668/	Homo sapiens		h	2.4				3	delta-tocotrienol		false
10245	44096		ADULT		396.6053	.DELTA.-TOCOTRIENOL	delta-tocotrienol	CC(C)=CCC\\C(C)=C\\CC\\C(C)=C\\CC[C@]1(C)CCC2=CC(O)=CC(C)=C2O1	PLASMA	1SRB74OWSI							12		t	ng × h/mL	1987.7		ng/mL	493.3			UNKNOWN	mg	100		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27278668/	Homo sapiens		h	3.8				3	delta-tocotrienol		false
10246	44096		ADULT		396.6053	.DELTA.-TOCOTRIENOL	delta-tocotrienol	CC(C)=CCC\\C(C)=C\\CC\\C(C)=C\\CC[C@]1(C)CCC2=CC(O)=CC(C)=C2O1	PLASMA	1SRB74OWSI							12		t	ng × h/mL	5083.1		ng/mL	1026.8			UNKNOWN	mg	200		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27278668/	Homo sapiens		h	2.1				3	delta-tocotrienol		false
10247	44096		ADULT		396.6053	.DELTA.-TOCOTRIENOL	delta-tocotrienol	CC(C)=CCC\\C(C)=C\\CC\\C(C)=C\\CC[C@]1(C)CCC2=CC(O)=CC(C)=C2O1	PLASMA	1SRB74OWSI							12		t	ng × h/mL	7458.5		ng/mL	1320.3			UNKNOWN	mg	400		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27278668/	Homo sapiens		h	2.3				3	delta-tocotrienol		false
10248	44096		ADULT		396.6053	.DELTA.-TOCOTRIENOL	delta-tocotrienol	CC(C)=CCC\\C(C)=C\\CC\\C(C)=C\\CC[C@]1(C)CCC2=CC(O)=CC(C)=C2O1	PLASMA	1SRB74OWSI							12		t	ng × h/mL	8764.4		ng/mL	1299.9			UNKNOWN	mg	800		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27278668/	Homo sapiens		h	3				3	delta-tocotrienol		false
10249	44096		ADULT		396.6053	.DELTA.-TOCOTRIENOL	delta-tocotrienol	CC(C)=CCC\\C(C)=C\\CC\\C(C)=C\\CC[C@]1(C)CCC2=CC(O)=CC(C)=C2O1	PLASMA	1SRB74OWSI							12		t	ng × h/mL	22171.2		ng/mL	3746			UNKNOWN	mg	1600		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27278668/	Homo sapiens		h	6.9				3	delta-tocotrienol		false
10250	44414		ADULT	8471	101.19	Triethylamine	Triethylamine	CCN(CC)CC	PLASMA	VOU728O6AY									∞	μM × h	5.46		μM	1.17			UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.sciencedirect.com/science/article/abs/pii/0041008X89903001	Homo sapiens		h	2.9							false
10251	44414		ADULT	8471	101.19	TRIETHYLAMINE	triethylamine	CCN(CC)CC	PLASMA	VOU728O6AY									∞	μM × h	3.81						UNKNOWN	μmol	137		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://www.sciencedirect.com/science/article/abs/pii/0041008X89903001	Homo sapiens		h	3.7							false
10252	44576		ADULT	453131|28248405	343.3737	TRIMETHYLCOLCHICINIC ACID	TRIMETHYLCOLCHICINIC ACID	COC1=C(OC)C(OC)=C2C(CC[C@H](N)C3=CC(=O)C(O)=CC=C23)=C1	PLASMA	333BVY614O									?	μg × h/L	737						UNKNOWN	mg	10		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	MALE	EXPERIMENT	https://onlinelibrary.wiley.com/doi/abs/10.1046/j.1525-1411.1999.14010.x	Homo sapiens		h	10.7	5 mg/m2/day for 4 or 5 days every 3 weeks			18	TRIMETHYLCOLCHICINIC ACID		false
10253	44576		ADULT	453131|28248405	343.3737	TRIMETHYLCOLCHICINIC ACID	TRIMETHYLCOLCHICINIC ACID	COC1=C(OC)C(OC)=C2C(CC[C@H](N)C3=CC(=O)C(O)=CC=C23)=C1	PLASMA	333BVY614O									?	μg × h/L	490		μg/L	30			UNKNOWN	mg/m²	7		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/2208579	Homo sapiens		h	9.5	day 5			1	TRIMETHYLCOLCHICINIC ACID		false
10254	44904		ADULT	16048966	326.3498	UNBS-5162	UNBS-5162	CN(C)CCN1C(=O)C2=CC(NC(N)=O)=CC3=CC=CC(C1=O)=C23	PLASMA	JY9JF7D78N									?	ng × h/mL	12786		ng/mL	5913.7			UNKNOWN	mg/m²	234		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23053399	Homo sapiens		h	7.94	intravenous (IV) infusion over 1 h weekly for 3 weeks followed by 1 week of no treatment			3	UNBS-5162		false
10255	44964		ADULT	5639	387.476	URAPIDIL	Urapidil	COC1=C(C=CC=C1)N2CCN(CCCNC3=CC(=O)N(C)C(=O)N3C)CC2	PLASMA	A78GF17HJS									∞	ng × h/mL	6374.4837		ng/mL	1005.6091			UNKNOWN	mg	60		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://innovareacademics.in/journals/index.php/ijpps/article/view/2902	Homo sapiens		h	4.6332				10	Urapidil		false
10256	44964		ADULT	5639	387.476	URAPIDIL	Urapidil	COC1=C(C=CC=C1)N2CCN(CCCNC3=CC(=O)N(C)C(=O)N3C)CC2	PLASMA	A78GF17HJS									∞	ng × h/mL	6084.7484		ng/mL	976.0297			UNKNOWN	mg	60		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://innovareacademics.in/journals/index.php/ijpps/article/view/2902	Homo sapiens		h	4.1779				9	Urapidil		false
10257	44964			5639	387.476	URAPIDIL	Urapidil	COC1=C(C=CC=C1)N2CCN(CCCNC3=CC(=O)N(C)C(=O)N3C)CC2	PLASMA	A78GF17HJS																										Human plasma protein binding: 75.3% (equilibrium dialysis)	24.7				EXPERIMENT	https://link.springer.com/article/10.2165/00003495-198938060-00005	Homo sapiens										false
10258	44964		ADULT	5639	387.476	URAPIDIL	Urapidil	COC1=C(C=CC=C1)N2CCN(CCCNC3=CC(=O)N(C)C(=O)N3C)CC2	PLASMA	A78GF17HJS									∞	ng × h/mL	2838		ng/mL	460			UNKNOWN	mg	25		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23463771/	Homo sapiens		h	1.83				8	Urapidil		false
10259	44991		ADULT	64945	456.7003	URSOLIC ACID	ursolic acid	C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O	PLASMA	P3M2575F3F							16		∞	ng × h/mL	4834		ng/mL	1211			UNKNOWN	mg/m²	74		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23319864	Homo sapiens		h	4				8	ursolic acid		false
10260	44991		ADULT	64945	456.7003	URSOLIC ACID	ursolic acid	C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O	PLASMA	P3M2575F3F							16		t	ng × h/mL	9696		ng/mL	3457			UNKNOWN	mg/m²	98		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23319864	Homo sapiens		h	3.9				8	ursolic acid		false
10261	44991		ADULT	64945	456.7003	URSOLIC ACID	ursolic acid	C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O	PLASMA	P3M2575F3F							16		t	ng × h/mL	7175		ng/mL	2865			UNKNOWN	mg/m²	74		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23319864	Homo sapiens		h	4.46				8	ursolic acid		false
10262	44991		ADULT	64945	456.7003	URSOLIC ACID	ursolic acid	C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O	PLASMA	P3M2575F3F							16		t	ng × h/mL	4203		μg/mL	1835			UNKNOWN	mg/m²	37		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23319864	Homo sapiens		h	4.59				8	ursolic acid		false
10263	45220		ADULT	6410104	317.3479	VLX-600	VLX-600	C\\C(=N/NC1=NC2=C(N=N1)C3=CC=CC(C)=C3N2)C4=NC=CC=C4	PLASMA	YZO6DG19MG									∞	ng × h/mL	4100		ng/mL	630			UNKNOWN	mg	60		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30460505	Homo sapiens		h	9.3							false
10264	45237		ADULT	16126898	525.081	VTP-27999	VTP-27999	CN[C@H](CNC(=O)N1CCC[C@H](C1)[C@@H](OCCNC(=O)OC)C2=CC(Cl)=CC=C2)C[C@H]3CCCOC3	PLASMA	254XY8NV84							24		t	ng × h/mL	13663		ng/mL	1736			UNKNOWN	mg	600		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24470465	Homo sapiens		h	23.8	10 days			6			false
10265	45237		ADULT	16126898	525.081	VTP-27999	VTP-27999	CN[C@H](CNC(=O)N1CCC[C@H](C1)[C@@H](OCCNC(=O)OC)C2=CC(Cl)=CC=C2)C[C@H]3CCCOC3	PLASMA	254XY8NV84							24		t	ng × h/mL	8466		ng/mL	1207			UNKNOWN	mg	600		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24470465	Homo sapiens							6			false
10266	45290		ADULT	56960447	547.409	X-396	X-396	C[C@@H](OC1=C(N)N=NC(=C1)C(=O)NC2=CC=C(C=C2)C(=O)N3CCN(C)CC3)C4=C(Cl)C(F)=CC=C4Cl	PLASMA	7DR7JMB8BH									∞	ng × h/mL	5530		ng/mL	318			RECOMMENDED	mg	225		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29563138/	Homo sapiens		h	33.2				10	Ensartinib		false
10267	45290		ADULT	56960447	547.409	X-396	X-396	C[C@@H](OC1=C(N)N=NC(=C1)C(=O)NC2=CC=C(C=C2)C(=O)N3CCN(C)CC3)C4=C(Cl)C(F)=CC=C4Cl	PLASMA	7DR7JMB8BH									∞	ng × h/mL	5330		ng/mL	311			RECOMMENDED	mg	225		MULTIPLE	FED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29563138/	Homo sapiens		h	37.7				8	Ensartinib		false
10268	45290		ADULT	56960447	547.409	X-396	X-396	C[C@@H](OC1=C(N)N=NC(=C1)C(=O)NC2=CC=C(C=C2)C(=O)N3CCN(C)CC3)C4=C(Cl)C(F)=CC=C4Cl	PLASMA	7DR7JMB8BH									∞	ng × h/mL	3827		ng/mL	212			UNKNOWN	mg	200		SINGLE	FASTED				the plasma protein binding rate was 91.55%, so the free concentration was relatively low.	8.45	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33044566/	Homo sapiens		h	18.3				6	Ensartinib		false
10269	45300		ADULT	639665	354.3964	XANTHOHUMOL	XANTHOHUMOL	COC1=C(C(=O)\\C=C\\C2=CC=C(O)C=C2)C(O)=C(CC=C(C)C)C(O)=C1	PLASMA	T4467YT1NT									∞	μg × h/L	286.99		μg/L	63			UNKNOWN	mg	60		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24038952	Homo sapiens		h	20				6	XANTHOHUMOL		false
10270	45300		ADULT	639665	354.3964	XANTHOHUMOL	XANTHOHUMOL	COC1=C(C(=O)\\C=C\\C2=CC=C(O)C=C2)C(O)=C(CC=C(C)C)C(O)=C1	PLASMA	T4467YT1NT									∞	μg × h/L	996		μg/L	178			UNKNOWN	mg	180		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24038952	Homo sapiens		h	19				9	XANTHOHUMOL		false
10271	45300		ADULT	639665	354.3964	XANTHOHUMOL	XANTHOHUMOL	COC1=C(C(=O)\\C=C\\C2=CC=C(O)C=C2)C(O)=C(CC=C(C)C)C(O)=C1	PLASMA	T4467YT1NT									∞	μg × h/L	712		μg/L	83			UNKNOWN	mg	180		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24038952	Homo sapiens		h	16				8	XANTHOHUMOL		false
10272	45300		ADULT	639665	354.3964	XANTHOHUMOL	XANTHOHUMOL	COC1=C(C(=O)\\C=C\\C2=CC=C(O)C=C2)C(O)=C(CC=C(C)C)C(O)=C1	PLASMA	T4467YT1NT									∞	μg × h/L	354		μg/L	70			UNKNOWN	mg	60		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24038952	Homo sapiens		h	19				7	XANTHOHUMOL		false
10273	45300		ADULT	513197	354.4	isoxanthohumol	Isoxanthohumol	CC(=CCC1=C2C(=C(C=C1O)OC)C(=O)CC(O2)C3=CC=C(C=C3)O)C	PLASMA										∞	μg × h/L	511		μg/L	25			UNKNOWN	mg	180		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24038952	Homo sapiens		h	22				8	XANTHOHUMOL		false
10274	45300		ADULT	513197	354.4	isoxanthohumol	isoxanthohumol		PLASMA										∞	μg × h/L	216		μg/L	9.7			UNKNOWN	mg	60		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24038952	Homo sapiens		h	21.6				6	XANTHOHUMOL		false
10275	45300		ADULT	513197	354.4	Isoxanthohumol	Isoxanthohumol	CC(=CCC1=C2C(=C(C=C1O)OC)C(=O)CC(O2)C3=CC=C(C=C3)O)C	PLASMA										∞	μg × h/L	342		μg/L	9.3			UNKNOWN	mg	60		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24038952	Homo sapiens		h	30				7	XANTHOHUMOL		false
10276	45300		ADULT	513197	354.4	isoxanthohumol	Isoxanthohumol		PLASMA										∞	μg × h/L	982		μg/L	37			UNKNOWN	mg	180		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24038952	Homo sapiens		h	24				9	XANTHOHUMOL		false
10277	45324		ADULT	148182|23675947	366.731	XK-469	XK-469	[Na ].CC(OC1=CC=C(OC2=NC3=CC(Cl)=CC=C3N=C2)C=C1)C([O-])=O	PLASMA	G6S5600O0D							24		t	μg × h/mL	2312		μg/mL	152			MAX TOLERATED	mg/m²	260		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17103044	Homo sapiens		h	53.9	XK-469 was administered as a 5 or 20 min IV infusion on days 1-5 every 21 days. Pharmacokinetics (PK) were conducted in cycles 1-3. Day 4			6	XK-469		false
10278	45324		ADULT	148182|23675947	366.731	XK-469	XK-469	[Na ].CC(OC1=CC=C(OC2=NC3=CC(Cl)=CC=C3N=C2)C=C1)C([O-])=O	PLASMA	G6S5600O0D							24		t	μg × h/mL	955		μg/mL	84.6			MAX TOLERATED	mg	260		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17103044	Homo sapiens							6	XK-469		false
10279	45324		ADULT	148182|23675947	366.731	XK-469	XK-469	[Na ].CC(OC1=CC=C(OC2=NC3=CC(Cl)=CC=C3N=C2)C=C1)C([O-])=O	PLASMA	G6S5600O0D																	UNKNOWN				UNKNOWN	UNKNOWN				Protein binding = 99.3% at 50 ug/ml	0.7	HEALTHY	UNKNOWN	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17103044	Homo sapiens							4	XK-469		false
10280	45324		ADULT	148182|23675947	366.731	XK-469	XK-469	[Na ].CC(OC1=CC=C(OC2=NC3=CC(Cl)=CC=C3N=C2)C=C1)C([O-])=O	PLASMA	G6S5600O0D									∞	μg × h/mL	14863		μg/mL	264			UNKNOWN	mg	2750		MULTIPLE	UNKNOWN		week	3			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18425419	Homo sapiens		h	55	XK-469 was given intravenously over 30 to 60 min on days 1, 3, and 5 of a 21 day cycle			14	XK-469		false
10281	45324		ADULT	148182|23675947	366.731	XK-469	XK-469	[Na ].CC(OC1=CC=C(OC2=NC3=CC(Cl)=CC=C3N=C2)C=C1)C([O-])=O	PLASMA	G6S5600O0D									∞	μg × h/mL	9150		μg/mL	211			RP2D	mg	1750		MULTIPLE	UNKNOWN		week	3			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18425419	Homo sapiens		h	45	XK-469 was given intravenously over 30 to 60 min on days 1, 3, and 5 of a 21 day cycle			12	XK-469		false
10282	45325		ADULT	11957724|15978058	366.731	XK-469, (R)-	XK-469, (R)-	[Na ].C[C@@H](OC1=CC=C(OC2=NC3=C(C=CC(Cl)=C3)N=C2)C=C1)C([O-])=O	PLASMA	4YM76775EY									∞	μg × h/mL	16.445		μg/mL	292.3			UNKNOWN	mg	3200		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18650079	Homo sapiens		h	49				5			false
10283	45325		ADULT	11957724|15978058	366.731	XK-469, (R)-	XK-469, (R)-	[Na ].C[C@@H](OC1=CC=C(OC2=NC3=C(C=CC(Cl)=C3)N=C2)C=C1)C([O-])=O	PLASMA	4YM76775EY									∞	μg × h/mL	7.903		μg/mL	146.3			UNKNOWN	mg	1100		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18650079	Homo sapiens		h	55				20			false
10284	45325		ADULT	11957724|15978058	366.731	XK-469, (R)-	XK-469, (R)-	[Na ].C[C@@H](OC1=CC=C(OC2=NC3=C(C=CC(Cl)=C3)N=C2)C=C1)C([O-])=O	PLASMA	4YM76775EY									∞	μg × h/mL	1.285		μg/mL	27.9			UNKNOWN	mg	240		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18650079	Homo sapiens		h	56				4			false
10285	45325		ADULT	11957724|15978058	366.731	XK-469, (R)-	XK-469, (R)-	[Na ].C[C@@H](OC1=CC=C(OC2=NC3=C(C=CC(Cl)=C3)N=C2)C=C1)C([O-])=O	PLASMA	4YM76775EY									∞	μg × h/mL	162		μg/mL	4.1			UNKNOWN	mg	30		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18650079	Homo sapiens		h	57				2			false
10286	45325		ADULT	11957724|15978058	366.731	XK-469, (R)-	XK-469, (R)-	[Na ].C[C@@H](OC1=CC=C(OC2=NC3=C(C=CC(Cl)=C3)N=C2)C=C1)C([O-])=O	PLASMA	4YM76775EY									∞	μg × h/mL	347		μg/mL	14.3			UNKNOWN	mg	120		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18650079	Homo sapiens		h	30				1			false
10287	45325		ADULT	11957724|15978058	366.731	XK-469, (R)-	XK-469, (R)-	[Na ].C[C@@H](OC1=CC=C(OC2=NC3=C(C=CC(Cl)=C3)N=C2)C=C1)C([O-])=O	PLASMA	4YM76775EY									∞	μg × h/mL	5.161		μg/mL	105.1			UNKNOWN	mg	850		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18650079	Homo sapiens		h	43				7			false
10288	45325		ADULT	11957724|15978058	366.731	XK-469, (R)-	XK-469, (R)-	[Na ].C[C@@H](OC1=CC=C(OC2=NC3=C(C=CC(Cl)=C3)N=C2)C=C1)C([O-])=O	PLASMA	4YM76775EY									∞	μg × h/mL	16.473		μg/mL	173.1			UNKNOWN	mg	1400		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18650079	Homo sapiens		h	107				1			false
10289	45325		ADULT	11957724|15978058	366.731	XK-469, (R)-	XK-469, (R)-	[Na ].C[C@@H](OC1=CC=C(OC2=NC3=C(C=CC(Cl)=C3)N=C2)C=C1)C([O-])=O	PLASMA	4YM76775EY									∞	μg × h/mL	11.204		μg/mL	247.6			UNKNOWN	mg	2000		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18650079	Homo sapiens		h	47				3			false
10290	45325		ADULT	11957724|15978058	366.731	XK-469, (R)-	XK-469, (R)-	[Na ].C[C@@H](OC1=CC=C(OC2=NC3=C(C=CC(Cl)=C3)N=C2)C=C1)C([O-])=O	PLASMA	4YM76775EY									∞	μg × h/mL	13.905		μg/mL	293.9			UNKNOWN	mg	2500		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18650079	Homo sapiens		h	42				14			false
10291	45398		ADULT	5280899	568.8714	ZEAXANTHIN	Zeaxanthin	CC(\\C=C\\C=C(C)\\C=C\\C1=C(C)C[C@@H](O)CC1(C)C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C2=C(C)C[C@@H](O)CC2(C)C	PLASMA	CV0IB81ORO	5281243	568.8714	LUTEIN	Lutein	CC(\\C=C\\C=C(C)\\C=C\\[C@H]1C(C)=C[C@H](O)CC1(C)C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C2=C(C)C[C@@H](O)CC2(C)C	X72A60C9MT	24		t	μM × h	0.655		μM	0.033			UNKNOWN	μmol	0.58		MULTIPLE	FED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16002805/	Homo sapiens				Day 42		6.703 μmol/d	8			true
10292	45398		ADULT	5280899	568.8714	ZEAXANTHIN	Zeaxanthin	CC(\\C=C\\C=C(C)\\C=C\\C1=C(C)C[C@@H](O)CC1(C)C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C2=C(C)C[C@@H](O)CC2(C)C	PLASMA	CV0IB81ORO	5281243	568.8714	LUTEIN	Lutein	CC(\\C=C\\C=C(C)\\C=C\\[C@H]1C(C)=C[C@H](O)CC1(C)C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C2=C(C)C[C@@H](O)CC2(C)C	X72A60C9MT	24		t	μM × h	2.476		μM	0.113			UNKNOWN	μmol	2.31		MULTIPLE	FED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16002805/	Homo sapiens		day	5.51	Day 42		33.513 μmol/d	8			true
10293	45584		ADULT	1548955	405.96	ZUCLOMIPHENE	Zuclomiphene	CCN(CC)CCOC1=CC=C(C=C1)C(=C(/Cl)C2=CC=CC=C2)\\C3=CC=CC=C3	PLASMA	3JU1DU3652									?	ng × h/mL	1289		ng/mL	15			UNKNOWN	mg	50		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19033451/	Homo sapiens					PCOS patients		9	Clomiphene citrate		false
10294	45742		ADULT	11256560	348.4	ABT-102	ABT-102	CC(C)(C)C1=CC2=C(C=C1)C(CC2)NC(=O)NC3=CC=CC4=C3C=NN4	PLASMA	J0YBN3USJN							24		t	ng × h/mL	487		ng/mL	31.6			UNKNOWN	mg	8		MULTIPLE	FED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21566201	Homo sapiens		h	10	7 days			6			false
10295	45742		ADULT	11256560	348.4	ABT-102	ABT-102	CC(C)(C)C1=CC2=C(C=C1)C(CC2)NC(=O)NC3=CC=CC4=C3C=NN4	PLASMA	J0YBN3USJN									∞	ng × h/mL	1180		ng/mL	73.4			UNKNOWN	mg	40		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21566201	Homo sapiens		h	11				6			false
10296	45831		ADULT	49763030	164.16	MK-1903	MK-1903	C1C2C1C3=C(C2)C(=NN3)C(=O)O	PLASMA	62N05GRI0P									t	nM × h	119.2		nM	49.8			MAX TOLERATED	mg	200		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22435740	Homo sapiens		h	4.6				6			false
10297	45831		ADULT	49763030	164.16	MK-1903	MK-1903	C1C2C1C3=C(C2)C(=NN3)C(=O)O	PLASMA	62N05GRI0P									?	nM × h	113.7		nM	56.3			MAX TOLERATED	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22435740	Homo sapiens							6			false
10298	45831		ADULT	49763030	164.16	MK-1903	MK-1903	C1C2C1C3=C(C2)C(=NN3)C(=O)O	PLASMA	62N05GRI0P									?	nM × h	87.9		nM	44.9			UNKNOWN	mg	150		MULTIPLE	UNKNOWN		day	3			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22435740	Homo sapiens		h	11	A dose of 150 mg TID was selected for future human clinical trials.			6			false
10299	45889		ADULT	46893585	519.6	AZD-3514	AZD-3514	CC(=O)N1CCN(CC1)CCOC2=CC=C(C=C2)C3CCN(CC3)C4=NN5C(=NN=C5C(F)(F)F)CC4	PLASMA	127DSS8X7J									?	ng × h/mL	36890		ng/mL	9750			UNKNOWN	mg	1000		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25920479	Homo sapiens							9	AZD-3514		false
10300	45909		UNKNOWN	49836057	436.3	TBA-354	TBA-354	C1C(COC2=NC(=CN21)[N ](=O)[O-])OCC3=CN=C(C=C3)C4=CC=C(C=C4)OC(F)(F)F	PLASMA	911T37M2WY																	UNKNOWN				UNKNOWN	UNKNOWN				TBA-354 exhibits moderate to high protein binding at 10 uM with mean plasma protein binding values in human, monkey, dog, rat, and mouse plasma of 96.5%, 94.6%, 96.2%, 95.9%, and 92.6%, respectively.	3.5	UNKNOWN	UNKNOWN	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25331696	Homo sapiens								TBA-354		false
10301	45918		ADULT	46202416	431.4125	AZD-3839	AZD-3839	NC1=N[C@@](C2=C1C(F)=CC=C2)(C3=CC(=CC=C3)C4=CN=CN=C4)C5=CC(=NC=C5)C(F)F	PLASMA	I8ID590133													nM	3400			UNKNOWN	mg	300		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24917547	Homo sapiens								AZD-3839		false
10302	45918		ADULT	46202416	431.4125	AZD-3839	AZD-3839	NC1=N[C@@](C2=C1C(F)=CC=C2)(C3=CC(=CC=C3)C4=CN=CN=C4)C5=CC(=NC=C5)C(F)F	PLASMA	I8ID590133													nM	3807			UNKNOWN	mg	300		SINGLE	UNKNOWN					3.6	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27129013	Homo sapiens								AZD-3839		false
10303	45929		ADULT	40924317	388.5	ACT-462206	ACT-462206	CC1=CC(=CC(=C1)NC(=O)C2CCCN2S(=O)(=O)C3=CC=C(C=C3)OC)C	PLASMA	64ONO62P28									∞	ng × h/mL	27975		ng/mL	891			UNKNOWN	mg	1500		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24691844	Homo sapiens		h	11.1				6			false
10304	45939		ADULT	67475270	484.5	LY-3000328	LY-3000328	CNC(=O)OC1COC2=C(C1NC(=O)C3=CC=C(C=C3)F)C=C(C=C2)N4CCN(CC4)C5COC5	PLASMA	1210T8CX6K									∞	ng × h/mL	24900		ng/mL	3870			UNKNOWN	mg	300		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25039273	Homo sapiens		h	5.96				6			false
10305	45956		ADULT	67501411	454.5	TAS-116	TAS-116	CCC1=C(C=CC(=C1)C(=O)N)N2C3=NC=CC(=C3C(=N2)C(C)C)N4C=C(N=C4)C5=CN(N=C5)C	PLASMA	PLO044MUDZ									∞	ng × h/mL	47365		ng/mL	3097			MAX TOLERATED	mg/m²	210.7		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30679388	Homo sapiens		h	13.32	day 1			6	TAS-116		false
10306	45956		ADULT	67501411	454.5	TAS-116	TAS-116	CCC1=C(C=CC(=C1)C(=O)N)N2C3=NC=CC(=C3C(=N2)C(C)C)N4C=C(N=C4)C5=CN(N=C5)C	PLASMA	PLO044MUDZ									∞	ng × h/mL	36779		ng/mL	2587			MAX TOLERATED	mg/m²	107.5		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30679388	Homo sapiens		h	13.21	day 1			6	TAS-116		false
10307	45956		ADULT	67501411	454.5	TAS-116	TAS-116	CCC1=C(C=CC(=C1)C(=O)N)N2C3=NC=CC(=C3C(=N2)C(C)C)N4C=C(N=C4)C5=CN(N=C5)C	PLASMA	PLO044MUDZ									?	ng × h/mL	38923		ng/mL	3080			MAX TOLERATED	mg/m²	107.5		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30679388	Homo sapiens		h	12.76	day 8			6	TAS-116		false
10308	45956		ADULT	67501411	454.5	TAS-116	TAS-116	CCC1=C(C=CC(=C1)C(=O)N)N2C3=NC=CC(=C3C(=N2)C(C)C)N4C=C(N=C4)C5=CN(N=C5)C	PLASMA	PLO044MUDZ									?	ng × h/mL	33090		ng/mL	2756			MAX TOLERATED	mg/m²	210.7		MULTIPLE	UNKNOWN		2 days	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30679388	Homo sapiens		h	9.91	day 15			6	TAS-116		false
10309	45957		ADULT	58573469	568.6	AMG-232	AMG 232		PLASMA	7R7G6EH5UL							24		t	ng × h/mL	5690		ng/mL	1030			UNKNOWN	mg	240		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/31359240	Homo sapiens										false
10310	45957		ADULT	58573469	568.6	AMG-232	AMG-232		PLASMA	7R7G6EH5UL							24		t	ng × h/mL	18800		ng/mL	2630			UNKNOWN	mg	480		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/31359240	Homo sapiens										false
10311	45967		ADULT		397.4708	CC-223	CC-223	CO[C@H]1CC[C@@H](CC1)N2C(=O)CNC3=NC=C(N=C23)C4=CC=C(N=C4)C(C)(C)O	PLASMA	I8RA3543SY							24		t	ng × h/mL	2031		ng/mL	319			UNKNOWN	mg	60		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26177599	Homo sapiens		h	5.64							false
10312	45972		ADULT	86291103	415.4197	TENALISIB	Tenalisib	CC[C@H](NC1=C2N=CNC2=NC=N1)C3=C(C(=O)C4=C(O3)C=CC=C4)C5=CC(F)=CC=C5	PLASMA	2261HH611H									∞	ng × h/mL	16214.14		ng/mL	4508.55			UNKNOWN	mg	400		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31761713/	Homo sapiens		h	3.89	capsules			2	Tenalisib		false
10313	45972		ADULT	86291103	415.4197	TENALISIB	Tenalisib	CC[C@H](NC1=C2N=CNC2=NC=N1)C3=C(C(=O)C4=C(O3)C=CC=C4)C5=CC(F)=CC=C5	PLASMA	2261HH611H									?	ng × h/mL	37313.58		ng/mL	5692.04			HIGHEST STUDIED	mg	800		STEADY-STATE	UNKNOWN		day	3			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31761713/	Homo sapiens							3	Tenalisib		false
10314	45972		ADULT	86291103	415.4197	TENALISIB	Tenalisib	CC[C@H](NC1=C2N=CNC2=NC=N1)C3=C(C(=O)C4=C(O3)C=CC=C4)C5=CC(F)=CC=C5	PLASMA	2261HH611H									∞	ng × h/mL	26627.57		ng/mL	3510.58			UNKNOWN	mg	600		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31761713/	Homo sapiens		h	5.09	tablets			3	Tenalisib		false
10315	45972		ADULT	86291103	415.4197	TENALISIB	Tenalisib	CC[C@H](NC1=C2N=CNC2=NC=N1)C3=C(C(=O)C4=C(O3)C=CC=C4)C5=CC(F)=CC=C5	PLASMA	2261HH611H									∞	ng × h/mL	21261.13		ng/mL	5777.7			HIGHEST STUDIED	mg	1200		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31761713/	Homo sapiens		h	4.8	tablets			3	Tenalisib		false
10316	45972		ADULT	86291103	415.4197	TENALISIB	Tenalisib	CC[C@H](NC1=C2N=CNC2=NC=N1)C3=C(C(=O)C4=C(O3)C=CC=C4)C5=CC(F)=CC=C5	PLASMA	2261HH611H									∞	ng × h/mL	5173.3		ng/mL	1383.32			UNKNOWN	mg	200		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31761713/	Homo sapiens		h	2.51	capsules			3	Tenalisib		false
10317	45972		ADULT	86291103	415.4197	TENALISIB	Tenalisib	CC[C@H](NC1=C2N=CNC2=NC=N1)C3=C(C(=O)C4=C(O3)C=CC=C4)C5=CC(F)=CC=C5	PLASMA	2261HH611H									∞	ng × h/mL	8268.96		ng/mL	1525.5			UNKNOWN	mg	200		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31761713/	Homo sapiens		h	3.33	tablets			3	Tenalisib		false
10318	45972		ADULT	86291103	415.4197	TENALISIB	Tenalisib	CC[C@H](NC1=C2N=CNC2=NC=N1)C3=C(C(=O)C4=C(O3)C=CC=C4)C5=CC(F)=CC=C5	PLASMA	2261HH611H									?	ng × h/mL	22282.67		ng/mL	3100.66			UNKNOWN	mg	600		STEADY-STATE	UNKNOWN		day	3			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31761713/	Homo sapiens				tablets			3	Tenalisib		false
10319	45972		ADULT	86291103	415.4197	TENALISIB	Tenalisib	CC[C@H](NC1=C2N=CNC2=NC=N1)C3=C(C(=O)C4=C(O3)C=CC=C4)C5=CC(F)=CC=C5	PLASMA	2261HH611H									∞	ng × h/mL	25631.93		ng/mL	3521.29			UNKNOWN	mg	800		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31761713/	Homo sapiens		h	4.49	tablets			3	Tenalisib		false
10320	45976		ADULT	58298318	336.3512	CC-115	CC-115	CCN1C(=O)CNC2=NC=C(N=C12)C3=C(C)N=C(C=C3)C4=NN=CN4	PLASMA	FII75TFH5L							24		t	ng × h/mL	1716		ng/mL	173			MAX TOLERATED	mg	25		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31853198	Homo sapiens		h	7.9				7	CC-115		false
10321	45976		ADULT	58298318	336.3512	CC-115	CC-115	CCN1C(=O)CNC2=NC=C(N=C12)C3=C(C)N=C(C=C3)C4=NN=CN4	PLASMA	FII75TFH5L							24		t	ng × h/mL	1573		ng/mL	198			MAX TOLERATED	mg	25		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31853198	Homo sapiens							5	CC-115		false
10322	45976		ADULT	58298318	336.3512	CC-115	CC-115	CCN1C(=O)CNC2=NC=C(N=C12)C3=C(C)N=C(C=C3)C4=NN=CN4	PLASMA	FII75TFH5L							24		t	ng × h/mL	2055.99		ng/mL	162			UNKNOWN	mg	15		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31853198	Homo sapiens							5	CC-115		false
10323	45976		ADULT	58298318	336.3512	CC-115	CC-115	CCN1C(=O)CNC2=NC=C(N=C12)C3=C(C)N=C(C=C3)C4=NN=CN4	PLASMA	FII75TFH5L							24		t	ng × h/mL	2650		ng/mL	244			UNKNOWN	mg	40		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31853198	Homo sapiens							4	CC-115		false
10324	45976		ADULT	58298318	336.3512	CC-115	CC-115	CCN1C(=O)CNC2=NC=C(N=C12)C3=C(C)N=C(C=C3)C4=NN=CN4	PLASMA	FII75TFH5L							24		t	ng × h/mL	766		ng/mL	75.2			MAX TOLERATED	mg	10		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31853198	Homo sapiens							7	CC-115		false
10325	45976		ADULT	58298318	336.3512	CC-115	CC-115	CCN1C(=O)CNC2=NC=C(N=C12)C3=C(C)N=C(C=C3)C4=NN=CN4	PLASMA	FII75TFH5L									∞	ng × h/mL	625		ng/mL	88.7			UNKNOWN	mg	16		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31853198	Homo sapiens		h	7.14				6			false
10326	45976		ADULT	58298318	336.3512	CC-115	CC-115	CCN1C(=O)CNC2=NC=C(N=C12)C3=C(C)N=C(C=C3)C4=NN=CN4	PLASMA	FII75TFH5L							24		t	ng × h/mL	622		ng/mL	51.8			MAX TOLERATED	mg	10		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31853198	Homo sapiens		h	3.98	1 day			6	CC-115		false
10327	45976		ADULT	58298318	336.3512	CC-115	CC-115	CCN1C(=O)CNC2=NC=C(N=C12)C3=C(C)N=C(C=C3)C4=NN=CN4	PLASMA	FII75TFH5L							24		t	ng × h/mL	286		ng/mL	40.9			UNKNOWN	mg	8		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31853198	Homo sapiens							7	CC-115		false
10328	45976		ADULT	58298318	336.3512	CC-115	CC-115	CCN1C(=O)CNC2=NC=C(N=C12)C3=C(C)N=C(C=C3)C4=NN=CN4	PLASMA	FII75TFH5L							24		t	ng × h/mL	1095		ng/mL	118			UNKNOWN	mg	16		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31853198	Homo sapiens							8	CC-115		false
10329	45997		ADULT	78323434	587.7	E-7090	E-7090	CNC(=O)N1C=CC2=CC(=C(C=C21)OCCOC)OC3=CC(=NC=C3)NC(=O)C4=CC=C(C=C4)C5CCN(CC5)CCO	PLASMA	TN7CUD1NGA									∞	ng × h/mL	4050		ng/mL	227			RP2D	mg	140		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31797489	Homo sapiens		h	27				3	E-7090		false
10330	45997		ADULT	78323434	587.7	E-7090	E-7090	CNC(=O)N1C=CC2=CC(=C(C=C21)OCCOC)OC3=CC(=NC=C3)NC(=O)C4=CC=C(C=C4)C5CCN(CC5)CCO	PLASMA	TN7CUD1NGA									?	ng × h/mL	4700		ng/mL	372			RP2D	mg	140		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31797489	Homo sapiens							3	E-7090		false
10331	45997		ADULT	78323434	587.7	E-7090	E-7090	CNC(=O)N1C=CC2=CC(=C(C=C21)OCCOC)OC3=CC(=NC=C3)NC(=O)C4=CC=C(C=C4)C5CCN(CC5)CCO	PLASMA	TN7CUD1NGA									?	ng × h/mL	3860		ng/mL	337			UNKNOWN	mg	180		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31797489	Homo sapiens							3	E-7090		false
10332	45997		ADULT	78323434	587.7	E-7090	E-7090	CNC(=O)N1C=CC2=CC(=C(C=C21)OCCOC)OC3=CC(=NC=C3)NC(=O)C4=CC=C(C=C4)C5CCN(CC5)CCO	PLASMA	TN7CUD1NGA									∞	ng × h/mL	1120		ng/mL	86			UNKNOWN	mg	100		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31797489	Homo sapiens		h	15				3	E-7090		false
10333	45997		ADULT	78323434	587.7	E-7090	E-7090	CNC(=O)N1C=CC2=CC(=C(C=C21)OCCOC)OC3=CC(=NC=C3)NC(=O)C4=CC=C(C=C4)C5CCN(CC5)CCO	PLASMA	TN7CUD1NGA									∞	ng × h/mL	554		ng/mL	39			UNKNOWN	mg	60		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31797489	Homo sapiens		h	23				3	E-7090		false
10334	45997		ADULT		587.7	E-7090	E-7090	CNC(=O)N1C=CC2=CC(=C(C=C21)OCCOC)OC3=CC(=NC=C3)NC(=O)C4=CC=C(C=C4)C5CCN(CC5)CCO	PLASMA	TN7CUD1NGA									∞	ng × h/mL	239		ng/mL	28			UNKNOWN	mg	30		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31797489	Homo sapiens		h	23				2	E-7090		false
10335	45997		ADULT	78323434	587.7	E-7090	E-7090	CNC(=O)N1C=CC2=CC(=C(C=C21)OCCOC)OC3=CC(=NC=C3)NC(=O)C4=CC=C(C=C4)C5CCN(CC5)CCO	PLASMA	TN7CUD1NGA									?	ng × h/mL	1340		ng/mL	116			UNKNOWN	mg	100		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31797489	Homo sapiens							3	E-7090		false
10336	45997		ADULT		587.7	E-7090	E-7090	CNC(=O)N1C=CC2=CC(=C(C=C21)OCCOC)OC3=CC(=NC=C3)NC(=O)C4=CC=C(C=C4)C5CCN(CC5)CCO	PLASMA	TN7CUD1NGA									?	ng × h/mL	507		ng/mL	51			UNKNOWN	mg	60		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31797489	Homo sapiens							3	E-7090		false
10337	45997		ADULT		587.7	E-7090	E-7090	CNC(=O)N1C=CC2=CC(=C(C=C21)OCCOC)OC3=CC(=NC=C3)NC(=O)C4=CC=C(C=C4)C5CCN(CC5)CCO	PLASMA	TN7CUD1NGA									?	ng × h/mL	162		ng/mL	13			UNKNOWN	mg	30		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31797489	Homo sapiens							2	E-7090		false
10338	45997		ADULT	78323434	587.7	E-7090	E-7090	CNC(=O)N1C=CC2=CC(=C(C=C21)OCCOC)OC3=CC(=NC=C3)NC(=O)C4=CC=C(C=C4)C5CCN(CC5)CCO	PLASMA	TN7CUD1NGA									∞	ng × h/mL	2610		ng/mL	154			UNKNOWN	mg	180		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31797489	Homo sapiens		h	24				3	E-7090		false
10339	46009		ADULT	91668194	415.42	PF-06747775	PF-06747775	CN1C=C(C(=N1)OC)NC2=C3C(=NC(=N2)N4C[C@H]([C@@H](C4)F)NC(=O)C=C)N(C=N3)C	PLASMA	YXX2180047																	UNKNOWN	mg	600		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	UNKNOWN	FEMALE / MALE	EXPERIMENT	https://www.jto.org/article/S1556-0864(16)32909-4/pdf	Homo sapiens		h	30							false
10340	46019		ADULT	12136798	390.4103	CHIDAMIDE	Chidamide	NC1=C(NC(=O)C2=CC=C(CNC(=O)\\C=C\\C3=CC=CN=C3)C=C2)C=CC(F)=C1	PLASMA	87CIC980Y0									∞	ng × h/mL	1911		ng/mL	140.3			RECOMMENDED	mg	25		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30700929/	Homo sapiens		h	18.3							false
10341	46019		ADULT	12136798	390.4103	CHIDAMIDE	Chidamide	NC1=C(NC(=O)C2=CC=C(CNC(=O)\\C=C\\C3=CC=CN=C3)C=C2)C=CC(F)=C1	PLASMA	87CIC980Y0	60198		EXEMESTANE	exemestane	C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O	NY22HMQ4BX			∞	ng × h/mL	84.1		ng/mL	31.4			RECOMMENDED	mg	25		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30700929/	Homo sapiens		h	5.4							true
10342	46021		ADULT	2913	287.3981	CYPROHEPTADINE	CN1CCC(CC1)=C2C3=C(C=CC=C3)C=CC4=C2C=CC=C4	CN1CCC(CC1)=C2C3=C(C=CC=C3)C=CC4=C2C=CC=C4	PLASMA	2YHB6175DO	91820207		COBAMAMIDE	COBAMAMIDE	C[C@@H]1CNC(=O)CC[C@]2(C)[C@@H](CC(N)=O)C3[N-]4C2=C(C)C5=[N]6C(=CC7=[N]8C(=C(C)C9=[N]([C@]3(C)[C@@](C)(CC(N)=O)[C@@H]9CCC(N)=O)[Co+3]468([C-][C@H]%10O[C@H]([C@@H](O)[C@@H]%10O)N%11C=NC%12=C%11N=CN=C%12N)[N]%13=C[N@@]([C@H]%14O[C@H](CO)[C@@H](OP([O-])(=O)O1)[C@H]%14O)C%15=C%13C=C(C)C(C)=C%15)[C@@](C)(CC(N)=O)[C@@H]7CCC(N)=O)C(C)(C)[C@@H]5CCC(N)=O	F0R1QK73KB			∞	ng × h/mL	40.82		ng/mL	1.25			UNKNOWN	mg	4		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/21432861	Homo sapiens		h	38.21							true
10343	46022			10235	190.2417	CYTISINE	cytisine	O=C1C=CC=C2[C@H]3CNC[C@H](C3)CN12	PLASMA	53S5U404NU																										Human Funbound was predicted by allometric scaling of rat pharmacokinetic data.	64				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20331614/	Homo sapiens										false
10344	46022		ADULT	10235	190.2417	CYTISINE	cytisine	O=C1C=CC=C2[C@H]3CNC[C@H](C3)CN12	PLASMA	53S5U404NU							24		t	ng × h/mL	81.9		ng/mL	12.1			UNKNOWN	mg	1.5		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30526213/	Homo sapiens		h	4.4		Smokers, at least 10 cigarettes a day		6			false
10345	46022		ADULT	10235	190.2417	CYTISINE	cytisine	O=C1C=CC=C2[C@H]3CNC[C@H](C3)CN12	PLASMA	53S5U404NU							24		t	ng × h/mL	181.9		ng/mL	27.8			UNKNOWN	mg	3		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30526213/	Homo sapiens		h	4.4		Smokers, at least 10 cigarettes a day		6			false
10346	46022		ADULT	10235	190.2417	CYTISINE	cytisine	O=C1C=CC=C2[C@H]3CNC[C@H](C3)CN12	PLASMA	53S5U404NU							24		t	ng × h/mL	254.5		ng/mL	43.1			UNKNOWN	mg	4.5		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30526213/	Homo sapiens		h	3.9		Smokers, at least 10 cigarettes a day		6			false
10347	46110		ADULT	66414	302.4079	2-METHOXYESTRADIOL	2-METHOXYESTRADIOL	COC1=CC2=C(CC[C@H]3[C@@H]4CC[C@H](O)[C@@]4(C)CC[C@H]23)C=C1O	PLASMA	6I2QW73SR5																						UNKNOWN				The time to equilibrium was approximately 24 h and the mean unbound fraction of 2ME2 (fu) over the observed concentration range in plasma of patients receiving 2ME2 orally was 0.019±0.0043. The mean fu was 0.027±0.0019 in plasma of healthy human volunteers.	2.7	HEALTHY		UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/?term=16940808	Homo sapiens										false
10348	46110		ADULT	66414	302.4079	2-METHOXYESTRADIOL	2-METHOXYESTRADIOL	COC1=CC2=C(CC[C@H]3[C@@H]4CC[C@H](O)[C@@]4(C)CC[C@H]23)C=C1O	PLASMA	6I2QW73SR5							24		t	ng × h/mL	46.2		ng/mL	3.9			UNKNOWN	mg	200		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/16969706	Homo sapiens		h	10							false
10349	46180		ADULT	135424953	271.636	4-AMINO-N-(3-CHLORO-4-FLUOROPHENYL)-N'-HYDROXY-1,2,5-OXADIAZOLE-3-CARBOXIMIDAMIDE	4-AMINO-N-(3-CHLORO-4-FLUOROPHENYL)-N\'-HYDROXY-1,2,5-OXADIAZOLE-3-CARBOXIMIDAMIDE	NC1=NON=C1\\C(NO)=N\\C2=CC=C(F)C(Cl)=C2	PLASMA	2HR315841W									?	μM × h	35.8		μM	6.23			UNKNOWN	mg	700		STEADY-STATE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28053021	Homo sapiens		h	3	Day 15			4	4-AMINO-N-(3-CHLORO-4-FLUOROPHENYL)-N'-HYDROXY-1,2,5-OXADIAZOLE-3-CARBOXIMIDAMIDE		false
10350	46260		ADULT	15604015	380.91	ABC-294640	ABC-294640	ClC1=CC=C(C=C1)C23CC4CC(CC(C4)(C2)C(=O)NCC5=CC=NC=C5)C3	PLASMA	DRG21OQ517									?	μg × h/mL	50.84		μg/mL	5.16			MAX TOLERATED	mg	500		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28420720	Homo sapiens		h	10							false
10351	46260		ADULT	15604015	380.91	ABC-294640	ABC-294640	ClC1=CC=C(C=C1)C23CC4CC(CC(C4)(C2)C(=O)NCC5=CC=NC=C5)C3	BLOOD	DRG21OQ517									∞	μg × h/mL	40.7		μg/mL	5.16			RECOMMENDED	mg	500		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/28420720	Homo sapiens										false
10352	46260		ADULT	15604015	380.91	ABC-294640	ABC-294640	ClC1=CC=C(C=C1)C23CC4CC(CC(C4)(C2)C(=O)NCC5=CC=NC=C5)C3	BLOOD	DRG21OQ517									∞	μg × h/mL	15.23		μg/mL	2.68			UNKNOWN	mg	250		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/28420720	Homo sapiens										false
10353	46291		ADULT	10297043	440.5832	AEE-788	AEE-788	CCN1CCN(CC2=CC=C(C=C2)C3=CC4=C(N3)N=CN=C4N[C@H](C)C5=CC=CC=C5)CC1	PLASMA	F9JLR95I3I							24		t	ng × h/mL	4300.5		ng/mL	234.3			UNKNOWN	mg	550		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22392572	Homo sapiens							4	AEE-788		false
10354	46291		ADULT	10297043	440.5832	AEE-788	AEE-788	CCN1CCN(CC2=CC=C(C=C2)C3=CC4=C(N3)N=CN=C4N[C@H](C)C5=CC=CC=C5)CC1	PLASMA	F9JLR95I3I							24		t	ng × h/mL	3005		ng/mL	147.7			UNKNOWN	mg	450		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22392572	Homo sapiens							4	AEE-788		false
10355	46291		ADULT	10297043	440.5832	AEE-788	AEE-788	CCN1CCN(CC2=CC=C(C=C2)C3=CC4=C(N3)N=CN=C4N[C@H](C)C5=CC=CC=C5)CC1	PLASMA	F9JLR95I3I							24		t	ng × h/mL	1154		ng/mL	77.1			UNKNOWN	mg	400		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22392572	Homo sapiens							3	AEE-788		false
10356	46291		ADULT	10297043	440.5832	AEE-788	AEE-788	CCN1CCN(CC2=CC=C(C=C2)C3=CC4=C(N3)N=CN=C4N[C@H](C)C5=CC=CC=C5)CC1	PLASMA	F9JLR95I3I							24		t	ng × h/mL	189		ng/mL	8.2			UNKNOWN	mg	200		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22392572	Homo sapiens							1	AEE-788		false
10357	46291		ADULT	10297043	440.5832	AEE-788	AEE-788	CCN1CCN(CC2=CC=C(C=C2)C3=CC4=C(N3)N=CN=C4N[C@H](C)C5=CC=CC=C5)CC1	PLASMA	F9JLR95I3I							24		t	ng × h/mL	1438		ng/mL	74.5			UNKNOWN	mg	250		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22392572	Homo sapiens							5	AEE-788		false
10358	46291		ADULT	10297043	440.5832	AEE-788	AEE-788	CCN1CCN(CC2=CC=C(C=C2)C3=CC4=C(N3)N=CN=C4N[C@H](C)C5=CC=CC=C5)CC1	PLASMA	F9JLR95I3I							24		t	ng × h/mL	168		ng/mL	12.7			UNKNOWN	mg	100		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22392572	Homo sapiens							2	AEE-788		false
10359	46291		ADULT	10297043	440.5832	AEE-788	AEE-788	CCN1CCN(CC2=CC=C(C=C2)C3=CC4=C(N3)N=CN=C4N[C@H](C)C5=CC=CC=C5)CC1	PLASMA	F9JLR95I3I							24		t	ng × h/mL	82		ng/mL	7.7			UNKNOWN	mg	50		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22392572	Homo sapiens							1	AEE-788		false
10360	46291		ADULT	10297043	440.5832	AEE-788	AEE-788	CCN1CCN(CC2=CC=C(C=C2)C3=CC4=C(N3)N=CN=C4N[C@H](C)C5=CC=CC=C5)CC1	PLASMA	F9JLR95I3I	134551073		EVEROLIMUS	RAD001	CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO	9HW64Q8G6G	24		t	ng × h/mL	710						UNKNOWN	mg	200		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/21984222	Homo sapiens										true
10361	46310		ADULT	11256587	349.4726	AMD-070	AMD-070	NCCCCN(CC1=NC2=C(N1)C=CC=C2)[C@H]3CCCC4=CC=CN=C34	PLASMA	0G9LGB5O2W							24		t	ng × h/mL	8060		ng/mL	2260			UNKNOWN	mg	400		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32870250	Homo sapiens							3	AMD-070		false
10362	46310		ADULT	11256587	349.4726	AMD-070	AMD-070	NCCCCN(CC1=NC2=C(N1)C=CC=C2)[C@H]3CCCC4=CC=CN=C34	PLASMA	0G9LGB5O2W							24		t	ng × h/mL	9500		ng/mL	2430			UNKNOWN	mg	300		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32870250	Homo sapiens							6	AMD-070		false
10363	46310		ADULT	11256587	349.4726	AMD-070	AMD-070	NCCCCN(CC1=NC2=C(N1)C=CC=C2)[C@H]3CCCC4=CC=CN=C34	PLASMA	0G9LGB5O2W							24		t	ng × h/mL	1680		ng/mL	633			UNKNOWN	mg	150		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32870250	Homo sapiens							2	AMD-070		false
10364	46310		ADULT	11256587	349.4726	AMD-070	AMD-070	NCCCCN(CC1=NC2=C(N1)C=CC=C2)[C@H]3CCCC4=CC=CN=C34	PLASMA	0G9LGB5O2W							24		t	ng × h/mL	3830		ng/mL	956			UNKNOWN	mg	200		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32870250	Homo sapiens							3	AMD-070		false
10365	46310		ADULT	11256587	349.4726	AMD-070	AMD-070	NCCCCN(CC1=NC2=C(N1)C=CC=C2)[C@H]3CCCC4=CC=CN=C34	PLASMA	0G9LGB5O2W							24		t	ng × h/mL	1089.99		ng/mL	514			UNKNOWN	mg	100		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32870250	Homo sapiens							4	AMD-070		false
10366	46310		ADULT	11256587	349.4726	AMD-070	AMD-070	NCCCCN(CC1=NC2=C(N1)C=CC=C2)[C@H]3CCCC4=CC=CN=C34	PLASMA	0G9LGB5O2W							24		t	ng × h/mL	262		ng/mL	117			UNKNOWN	mg	20		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32870250	Homo sapiens							2	Mavorixafor		false
10367	46311		ADULT	24864821	383.4027	AMG-208	AMG-208	COC1=CC2=C(C=C1)C(OCC3=NN=C4C=CC(=NN34)C5=CC=CC=C5)=CC=N2	PLASMA	Y2SR66P7VM							24		t	μg × h/mL	245		μg/mL	18.4			UNKNOWN	mg	400		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26155941	Homo sapiens		h	45.05	Patients received AMG 208 orally on days 1 and days 4-28 once daily.			11	AMG-208		false
10368	46311		ADULT	24864821	383.4027	AMG-208	AMG-208	COC1=CC2=C(C=C1)C(OCC3=NN=C4C=CC(=NN34)C5=CC=CC=C5)=CC=N2	PLASMA	Y2SR66P7VM							24		t	μg × h/mL	245		μg/mL	18.4			UNKNOWN	mg	400		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/26155941	Homo sapiens										false
10369	46312		ADULT	16007367	430.403	AMG-517	AMG-517	CC(=O)NC1=NC2=C(S1)C=CC=C2OC3=NC=NC(=C3)C4=CC=C(C=C4)C(F)(F)F	PLASMA	172V4FBZ75													ng/mL	211			HIGHEST STUDIED	mg	25		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18337008/	Homo sapiens							7	AMG-517		false
10370	46312		ADULT	16007367	430.403	AMG-517	AMG-517	CC(=O)NC1=NC2=C(S1)C=CC=C2OC3=NC=NC(=C3)C4=CC=C(C=C4)C(F)(F)F	PLASMA	172V4FBZ75													ng/mL	105			UNKNOWN	mg	5		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18337008/	Homo sapiens							6	AMG-517		false
10371	46312		ADULT	16007367	430.403	AMG-517	AMG-517	CC(=O)NC1=NC2=C(S1)C=CC=C2OC3=NC=NC(=C3)C4=CC=C(C=C4)C(F)(F)F	PLASMA	172V4FBZ75													ng/mL	45.2			UNKNOWN	mg	2		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18337008/	Homo sapiens							5	AMG-517		false
10372	46312		ADULT	16007367	430.403	AMG-517	AMG-517	CC(=O)NC1=NC2=C(S1)C=CC=C2OC3=NC=NC(=C3)C4=CC=C(C=C4)C(F)(F)F	PLASMA	172V4FBZ75													ng/mL	199			HIGHEST STUDIED	mg	10		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18337008/	Homo sapiens							6	AMG-517		false
10373	46315		ADULT	24856041	503.578	AMG-900	AMG-900	CC1=CSC(=C1)C2=NN=C(NC3=CC=C(OC4=NC=CC=C4C5=NC(N)=NC=C5)C=C3)C6=CC=CC=C26	PLASMA	9R2G075611							4		t	ng × h/mL	10200		ng/mL	3670			UNKNOWN	mg	100		SINGLE	FASTED						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28370201	Homo sapiens							1	AMG-900		false
10374	46315		ADULT	24856041	503.578	AMG-900	AMG-900	CC1=CSC(=C1)C2=NN=C(NC3=CC=C(OC4=NC=CC=C4C5=NC(N)=NC=C5)C=C3)C6=CC=CC=C26	PLASMA	9R2G075611							4		t	ng × h/mL	2740		ng/mL	951			MAX TOLERATED	mg	25		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28370201	Homo sapiens							3	AMG-900		false
10375	46331		ADULT	10027278	460.4505	AR-12	AR-12	NCC(=O)NC1=CC=C(C=C1)N2N=C(C=C2C3=CC4=C(C=C3)C5=C(C=CC=C5)C=C4)C(F)(F)F	PLASMA	EX3O2Q61UV													μM	2			RP2D	mg	800		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25103559	Homo sapiens							-1	AR-12		false
10376	46342		UNKNOWN	25173585	561.7149	AT-406	AT-406	CN[C@@H](C)C(=O)N[C@H]1CN(CC[C@H]2CC[C@H](N2C1=O)C(=O)NCC3=C(C=CC=C3)C4=CC=CC=C4)C(=O)CC(C)C	PLASMA	N65WC8PXDD																						UNKNOWN				The calculated unbound fraction in plasma (fup) at 1 μg/ml is 0.185 and at 5 μg/ml is 0.195, and the average of 0.19 was used in further studies.	19	UNKNOWN		UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/23813446/	Homo sapiens										false
10377	46342		ADULT	25022340	561.7149	AT-406	CN[C@@H](C)C(=O)N[C@H]1CN(CC[C@H]2CC[C@H](N2C1=O)C(=O)NC(C3=CC=CC=C3)C4=CC=CC=C4)C(=O)CC(C)C	CN[C@@H](C)C(=O)N[C@H]1CN(CC[C@H]2CC[C@H](N2C1=O)C(=O)NC(C3=CC=CC=C3)C4=CC=CC=C4)C(=O)CC(C)C	PLASMA	N65WC8PXDD									∞	ng × h/mL	47000		ng/mL	10300			UNKNOWN	mg	900		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/25716544	Homo sapiens		h	3.15							false
10378	46343		ADULT	11338033	382.244	AT-7519	AT-7519	ClC1=CC=CC(Cl)=C1C(=O)NC2=CNN=C2C(=O)NC3CCNCC3	PLASMA	X1BF92PW9T													ng/mL	591			RP2D	mg/m²	27		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25393368	Homo sapiens		h	13.1	day 1, cycle 1			15	AT-7519		false
10379	46343		ADULT	11338033	382.244	AT-7519	AT-7519	ClC1=CC=CC(Cl)=C1C(=O)NC2=CNN=C2C(=O)NC3CCNCC3	PLASMA	X1BF92PW9T	11955716	409.5212	ONALESPIB	Onalespib	CC(C)C1=C(O)C=C(O)C(=C1)C(=O)N2CC3=C(C2)C=C(CN4CCN(C)CC4)C=C3	Q7Y33N57ZZ			?	ng × h/mL	2449		ng/mL	508.7			MAX TOLERATED	mg/m²	21		MULTIPLE	UNKNOWN		week	2			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33095286	Homo sapiens		h	10.7	1-h intravenous infusion twice weekly (days 1, 4, 8, and 11) every 21 days; day 11		onalespib 80 mg/m2 IV	11	AT-7519		true
10380	46343		ADULT	11338033	382.244	AT-7519	AT-7519	ClC1=CC=CC(Cl)=C1C(=O)NC2=CNN=C2C(=O)NC3CCNCC3	PLASMA	X1BF92PW9T	11955716	409.5212	ONALESPIB	Onalespib	CC(C)C1=C(O)C=C(O)C(=C1)C(=O)N2CC3=C(C2)C=C(CN4CCN(C)CC4)C=C3	Q7Y33N57ZZ			?	ng × h/mL	2300		ng/mL	459.3			MAX TOLERATED	mg/m²	21		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33095286	Homo sapiens		h	11.1	day 1		onalespib 80 mg/m2 IV	16	AT-7519		true
10381	46343		ADULT	11338033	382.2	AT-7519	AT-7519	ClC1=CC=CC(Cl)=C1C(=O)NC2=CNN=C2C(=O)NC3CCNCC3	PLASMA	X1BF92PW9T													ng/mL	591			RECOMMENDED	mg/m²	27		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/25393368	Homo sapiens		h	13.1							false
10382	46353		ADULT	135564570	334.4	AZD-1080	AZ-1080	C1COCCN1CC2=CN=C(C=C2)C3=C(NC4=C3C=C(C=C4)C#N)O	PLASMA	0TII45R8IJ													nM	86			UNKNOWN	mg	15		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23410232	Homo sapiens		h	20				6	AZ-1080		false
10383	46359		ADULT	58423153	379.475	AZD-1208	AZD-1208	N[C@@H]1CCCN(C1)C2=C(C=CC=C2\\C=C3/SC(=O)NC3=O)C4=CC=CC=C4	PLASMA	S98NFM1378							24		t	ng × h/mL	75000		ng/mL	3844			MAX TOLERATED	mg	800		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/29765150	Homo sapiens		h	37.2							false
10384	46367		ADULT	16747683	371.5	AZD-5438	AZD-5438		PLASMA	276Z913G29							5		t	ng × h/mL	58.7		ng/mL	24.2			UNKNOWN	mg	2.5		STEADY-STATE	UNKNOWN		day	4			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19825886/	Homo sapiens							3	AZD5438		false
10385	46367		ADULT	276Z913G29	371.5	AZD-5438	AZD-5438		PLASMA	276Z913G29							5		t	ng × h/mL	62.2		ng/mL	27.7			UNKNOWN	mg	5		STEADY-STATE	UNKNOWN		day	4			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19825886/	Homo sapiens							3	AZD5438		false
10386	46367		ADULT	16747683	371.5	AZD-5438	AZD-5438		PLASMA	276Z913G29									t	ng × h/mL	411.1		ng/mL	150			UNKNOWN	mg	10		STEADY-STATE	UNKNOWN		day	4			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19825886/	Homo sapiens							2	AZD5438		false
10387	46367		ADULT	16747683	371.5	AZD-5438	AZD5438		PLASMA	276Z913G29							5		t	ng × h/mL	245		ng/mL	85.5			HIGHEST STUDIED	mg	40		STEADY-STATE	UNKNOWN		day	4			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19825886/	Homo sapiens							1	AZD5438		false
10388	46367		ADULT	16747683	371.5	AZD-5438	AZD-5438		PLASMA	276Z913G29							5		t	ng × h/mL	392		ng/mL	155			UNKNOWN	mg	20		STEADY-STATE	UNKNOWN		day	4			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19825886/	Homo sapiens							3	AZD5438		false
10389	46373		ADULT	42636350	367.4	AZD-7687	AZD-7687		PLASMA	6QTJ9P2NYT									?	μM × h	43		μM	3.5			UNKNOWN	mg	20		SINGLE	HIGH-FAT						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22950654	Homo sapiens							6	AZD-7687		false
10390	46373		ADULT	42636350	367.4	AZD-7687	AZD-7687		PLASMA	6QTJ9P2NYT									?	μM × h	33		μM	2.9			UNKNOWN	mg	20		SINGLE	LOW-FAT						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22950654	Homo sapiens							6	AZD-7687		false
10391	46373		ADULT	42636350	367.4	AZD-7687	AZD-7687		PLASMA	6QTJ9P2NYT									?	μM × h	110		μM	12			UNKNOWN	mg	60		SINGLE	LOW-FAT						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22950654	Homo sapiens							6	AZD-7687		false
10392	46373		ADULT	42636350	367.4	AZD-7687	AZD-7687		PLASMA	6QTJ9P2NYT									?	μM × h	11		μM	0.96			UNKNOWN	mg	5		SINGLE	LOW-FAT						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22950654	Homo sapiens							6	AZD-7687		false
10393	46373		ADULT	42636350	367.4	AZD-7687	AZD-7687		PLASMA	6QTJ9P2NYT									?	μM × h	19		μM	1.9			UNKNOWN	mg	10		SINGLE	HIGH-FAT						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22950654	Homo sapiens							6	AZD-7687		false
10394	46373		ADULT	42636350	367.4	AZD-7687	AZD-7687		PLASMA	6QTJ9P2NYT									?	μM × h	11		μM	0.92			UNKNOWN	mg	5		SINGLE	HIGH-FAT						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22950654	Homo sapiens							6	AZD-7687		false
10395	46373		ADULT	42636350	367.4	AZD-7687	AZD-7687		PLASMA	6QTJ9P2NYT									?	μM × h	18		μM	1.6			UNKNOWN	mg	10		SINGLE	LOW-FAT						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22950654	Homo sapiens							6	AZD-7687		false
10396	46374		ADULT	11152667	362.422	AZD-7762	AZD-7762	NC(=O)NC1=C(SC(=C1)C2=CC=CC(F)=C2)C(=O)N[C@H]3CCCNC3	PLASMA	5D822Y3L1H									?	μg × h/L	1361.2		μg/L	383			UNKNOWN	mg	30		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23892959	Homo sapiens		h	16.2				8	AZD-7762		false
10397	46374		ADULT	11152667	362.422	AZD-7762	AZD-7762	NC(=O)NC1=C(SC(=C1)C2=CC=CC(F)=C2)C(=O)N[C@H]3CCCNC3	PLASMA	5D822Y3L1H	60750	263.1981	GEMCITABINE	gemcitabine	NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F	B76N6SBZ8R			?	μg × h/L	996.9		μg/L	247			MAX TOLERATED	mg	21		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23892959	Homo sapiens		h	15.6			1000 mg/m(2)	6	AZD-7762		true
10398	46374		ADULT	11152667	362.422	AZD-7762	AZD-7762	NC(=O)NC1=C(SC(=C1)C2=CC=CC(F)=C2)C(=O)N[C@H]3CCCNC3	PLASMA	5D822Y3L1H									?	μg × h/L	818		μg/L	221			UNKNOWN	mg	21		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23892959	Homo sapiens		h	16.1				6	AZD-7762		false
10399	46375		ADULT	25262965	465.5447	AZD-8055	AZD8055	COC1=C(CO)C=C(C=C1)C2=CC=C3C(=N2)N=C(N=C3N4CCOC[C@@H]4C)N5CCOC[C@@H]5C	PLASMA	970JJ37FPW									∞	ng × h/mL	294		ng/mL	177			UNKNOWN	mg	120		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22935583	Homo sapiens		h	3.14				10	AZD8055		false
10400	46375		ADULT	25262965	465.5447	AZD-8055	AZD8055	COC1=C(CO)C=C(C=C1)C2=CC=C3C(=N2)N=C(N=C3N4CCOC[C@@H]4C)N5CCOC[C@@H]5C	PLASMA	970JJ37FPW									∞	ng × h/mL	134		ng/mL	70.1			MAX TOLERATED	mg	90		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22935583	Homo sapiens		h	2.36				11	AZD8055		false
10401	46375		ADULT	25262965	465.5447	AZD-8055	AZD8055	COC1=C(CO)C=C(C=C1)C2=CC=C3C(=N2)N=C(N=C3N4CCOC[C@@H]4C)N5CCOC[C@@H]5C	PLASMA	970JJ37FPW									?	ng × h/mL	501		ng/mL	355			UNKNOWN	mg	120		STEADY-STATE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22935583	Homo sapiens		h	2.45				10	AZD8055		false
10402	46375		ADULT	25262965	465.5447	AZD-8055	AZD8055	COC1=C(CO)C=C(C=C1)C2=CC=C3C(=N2)N=C(N=C3N4CCOC[C@@H]4C)N5CCOC[C@@H]5C	PLASMA	970JJ37FPW									?	ng × h/mL	122		ng/mL	70			MAX TOLERATED	mg	90		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22935583	Homo sapiens		h	2.63				11	AZD8055		false
10403	46397		ADULT	44420198	456.7003	BETULINIC ACID	BETULINIC ACID	CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O	PLASMA	4G6A18707N									?	μg × h/mL	1113.7		μg/mL	25.1			UNKNOWN	mg	200		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17596104	Homo sapiens		h	62.1	day 10			6	BETULINIC ACID		false
10404	46397		ADULT	44420198	456.7003	BETULINIC ACID	BETULINIC ACID	CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O	PLASMA	4G6A18707N							24		t	μg × h/mL	382.9		μg/mL	25.1			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17596104	Homo sapiens				day 1			6	BETULINIC ACID		false
10405	46400		ADULT	57336745	650.6045	BGT-226 MALEATE	BGT226	OC(=O)\\C=C/C(O)=O.COC1=NC=C(C=C1)C2=CC3=C(C=C2)N=CC4=C3N(C(=O)N4C)C5=CC(=C(C=C5)N6CCNCC6)C(F)(F)F	PLASMA	4YG62LG876							48		t	ng × h/mL	32.86		ng/mL	2.5			UNKNOWN	mg	80		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22357447	Homo sapiens		h	7.61				9	BGT226		false
10406	46400		ADULT	57336745	650.6045	BGT-226 MALEATE	BGT-226	OC(=O)\\C=C/C(O)=O.COC1=NC=C(C=C1)C2=CC3=C(C=C2)N=CC4=C3N(C(=O)N4C)C5=CC(=C(C=C5)N6CCNCC6)C(F)(F)F	PLASMA	4YG62LG876							48		t	ng × h/mL	78.75		ng/mL	5.21			MAX TOLERATED	mg	125		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22357447	Homo sapiens		h	8.62				11	BGT-226		false
10407	46400		ADULT	57336745	650.6045	BGT-226 MALEATE	BGT-226	OC(=O)\\C=C/C(O)=O.COC1=NC=C(C=C1)C2=CC3=C(C=C2)N=CC4=C3N(C(=O)N4C)C5=CC(=C(C=C5)N6CCNCC6)C(F)(F)F	PLASMA	4YG62LG876							48		t	ng × h/mL	26.97		ng/mL	2.45			RECOMMENDED	mg	100		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22357447	Homo sapiens		h	8.61				13	BGT-226		false
10408	46404		ADULT	57471941	393.4	PRT062607	BIIB-057	C1CCC(C(C1)N)NC2=NC=C(C(=N2)NC3=CC=C(C=C3)N4N=CC=N4)C(=O)N	PLASMA	K9C42672RH									?	ng × h/mL	22300		ng/mL	996			UNKNOWN	mg	400		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27406873	Homo sapiens		h	65.1				6	BIIB-057		false
10409	46404		ADULT	57471941	393.4	PRT062607	BIIB-057	C1CCC(C(C1)N)NC2=NC=C(C(=N2)NC3=CC=C(C=C3)N4N=CC=N4)C(=O)N	PLASMA	K9C42672RH							24		t	ng × h/mL	8487		ng/mL	557			UNKNOWN	mg	110		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27406873	Homo sapiens		h	75.3	day 10			6	BIIB-057		false
10410	46419		ADULT	10437018	530.5535	BMS-599626	BMS-599626	CC1=C2N(C=C1NC(=O)OC[C@@H]3COCCN3)N=CN=C2NC4=CC5=C(C=C4)N(CC6=CC(F)=CC=C6)N=C5	PLASMA	2252724U5N									∞	ng × h/mL	8300		ng/mL	377			UNKNOWN	mg	100		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://ascopubs.org/doi/abs/10.1200/jco.2005.23.16_suppl.3152	Homo sapiens		h	20	PK data on day 21st			7	BMS-599626		false
10411	46419		ADULT	10437018	530.5535	BMS-599626	BMS-599626	CC1=C2N(C=C1NC(=O)OC[C@@H]3COCCN3)N=CN=C2NC4=CC5=C(C=C4)N(CC6=CC(F)=CC=C6)N=C5	PLASMA	2252724U5N									∞	ng × h/mL	2610		ng/mL	120			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://ascopubs.org/doi/abs/10.1200/jco.2005.23.16_suppl.3152	Homo sapiens							6	BMS-599626		false
10412	46419		ADULT	10437018	530.5535	BMS-599626	BMS-599626	CC1=C2N(C=C1NC(=O)OC[C@@H]3COCCN3)N=CN=C2NC4=CC5=C(C=C4)N(CC6=CC(F)=CC=C6)N=C5	PLASMA	2252724U5N									∞	ng × h/mL	2920		ng/mL	162			UNKNOWN	mg	100		SINGLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://ascopubs.org/doi/abs/10.1200/jco.2005.23.16_suppl.3152	Homo sapiens							3	BMS-599626		false
10413	46422		ADULT	50922691	432.5214	BMS-911543	BMS-911543	CCN1C(=CC2=C1N=C(NC3=NN(C)C(C)=C3)C4=C2N(C)C=N4)C(=O)N(C5CC5)C6CC6	PLASMA	7N03P021J8																	UNKNOWN	mg	240		SINGLE	UNKNOWN					2	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26225254	Homo sapiens		h	4.9					BMS-911543		false
10414	46482		ADULT	49784945	377.421	CH-5132799	CH5132799	CS(=O)(=O)N1CCC2=C(N=C(N=C12)N3CCOCC3)C4=CN=C(N)N=C4	PLASMA	JCL936W835							24		t	ng × h/mL	159		ng/mL	46.3			UNKNOWN	mg	8		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25231405/	Homo sapiens							2	CH5132799		false
10415	46482		ADULT	49784945	377.421	CH-5132799	CH5132799	CS(=O)(=O)N1CCC2=C(N=C(N=C12)N3CCOCC3)C4=CN=C(N)N=C4	PLASMA	JCL936W835							24		t	ng × h/mL	48.8		ng/mL	9.92			UNKNOWN	mg	2		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25231405/	Homo sapiens							2	CH5132799		false
10416	46482		ADULT	49784945	377.421	CH-5132799	CH5132799	CS(=O)(=O)N1CCC2=C(N=C(N=C12)N3CCOCC3)C4=CN=C(N)N=C4	PLASMA	JCL936W835							12		t	ng × h/mL	1550		ng/mL	175			MAX TOLERATED	mg	48		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25231405/	Homo sapiens							5	CH5132799		false
10417	46482		ADULT	49784945	377.421	CH-5132799	CH5132799	CS(=O)(=O)N1CCC2=C(N=C(N=C12)N3CCOCC3)C4=CN=C(N)N=C4	PLASMA	JCL936W835							12		t	ng × h/mL	5940		ng/mL	331			UNKNOWN	mg	56		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25231405/	Homo sapiens							3	CH5132799		false
10418	46482		ADULT	49784945	377.421	CH-5132799	CH5132799	CS(=O)(=O)N1CCC2=C(N=C(N=C12)N3CCOCC3)C4=CN=C(N)N=C4	PLASMA	JCL936W835							24		t	ng × h/mL	961		ng/mL	103			HIGHEST STUDIED	mg	96		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25231405/	Homo sapiens							3	CH5132799		false
10419	46482		ADULT	49784945	377.421	CH-5132799	CH5132799	CS(=O)(=O)N1CCC2=C(N=C(N=C12)N3CCOCC3)C4=CN=C(N)N=C4	PLASMA	JCL936W835							24		t	ng × h/mL	1740		ng/mL	345			UNKNOWN	mg	32		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25231405/	Homo sapiens							3	CH5132799		false
10420	46482		ADULT	49784945	377.421	CH-5132799	CH5132799	CS(=O)(=O)N1CCC2=C(N=C(N=C12)N3CCOCC3)C4=CN=C(N)N=C4	PLASMA	JCL936W835							24		t	ng × h/mL	748		ng/mL	184			UNKNOWN	mg	56		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25231405/	Homo sapiens							3	CH5132799		false
10421	46482		ADULT	49784945	377.421	CH-5132799	CH5132799	CS(=O)(=O)N1CCC2=C(N=C(N=C12)N3CCOCC3)C4=CN=C(N)N=C4	PLASMA	JCL936W835							12		t	ng × h/mL	5580		ng/mL	631			HIGHEST STUDIED	mg	72		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25231405/	Homo sapiens							1	CH5132799		false
10422	46495		ADULT	10112191	409.55	PD-0184264	PD0184264	C1=CC(=C(C=C1I)Cl)NC2=C(C=CC(=C2F)F)C(=O)O	PLASMA										?	ng × h/mL	114000		ng/mL	11700			MAX TOLERATED	mg	800		STEADY-STATE	FED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16009947	Homo sapiens		h	20.9				13	CI-1040		false
10423	46495		ADULT	10112191	409.55	PD0184264	PD0184264	C1=CC(=C(C=C1I)Cl)NC2=C(C=CC(=C2F)F)C(=O)O	PLASMA										?	ng × h/mL	127000		ng/mL	18000			UNKNOWN	mg	800		STEADY-STATE	FED		day	3			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16009947	Homo sapiens							7	CI-1040		false
10424	46495		ADULT	10112191	409.55	PD0184264	PD0184264	C1=CC(=C(C=C1I)Cl)NC2=C(C=CC(=C2F)F)C(=O)O	PLASMA										?	ng × h/mL	78100		ng/mL	4420			UNKNOWN	mg	1600		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16009947	Homo sapiens							13	CI-1040		false
10425	46507		ADULT	5351344	316.3484	COMBRESTATIN A4	COMBRESTATIN A4	COC1=CC(\\C=C/C2=CC(O)=C(OC)C=C2)=CC(OC)=C1OC	PLASMA	16U6OP69RQ									?	μM × h	19.69		μM	24.42			UNKNOWN	mg/m²	84.98		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21276042	Homo sapiens		h	0.46				2	COMBRESTATIN A4		false
10426	46521		ADULT	9874913	469.535	CP-724714	CP-724714	COCC(=O)NC\\C=C\\C1=CC=C2N=CN=C(NC3=CC(C)=C(OC4=CN=C(C)C=C4)C=C3)C2=C1	PLASMA	I05QZ0S4V3									?	ng × h/mL	14900		ng/mL	4940			UNKNOWN	mg	400		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17317835	Homo sapiens							3	CP-724714		false
10427	46521		ADULT	9874913	469.535	CP-724714	CP-724714	COCC(=O)NC\\C=C\\C1=CC=C2N=CN=C(NC3=CC(C)=C(OC4=CN=C(C)C=C4)C=C3)C2=C1	PLASMA	I05QZ0S4V3									?	ng × h/mL	11900		ng/mL	4900			UNKNOWN	mg	400		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17317835	Homo sapiens		h	4.34	day 1			5	CP-724714		false
10428	46521		ADULT	9874913	469.535	CP-724714	CP-724714	COCC(=O)NC\\C=C\\C1=CC=C2N=CN=C(NC3=CC(C)=C(OC4=CN=C(C)C=C4)C=C3)C2=C1	PLASMA	I05QZ0S4V3									?	ng × h/mL	9300		ng/mL	3660			RP2D	mg	250		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17317835	Homo sapiens							10	CP-724714		false
10429	46521		ADULT	9874913	469.535	CP-724714	CP-724714	COCC(=O)NC\\C=C\\C1=CC=C2N=CN=C(NC3=CC(C)=C(OC4=CN=C(C)C=C4)C=C3)C2=C1	PLASMA	I05QZ0S4V3									?	ng × h/mL	7360		ng/mL	2740			RP2D	mg	250		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17317835	Homo sapiens		h	4.8	day 1			15	CP-724714		false
10430	46521		ADULT	9874913	469.535	CP-724714	CP-724714	COCC(=O)NC\\C=C\\C1=CC=C2N=CN=C(NC3=CC(C)=C(OC4=CN=C(C)C=C4)C=C3)C2=C1	PLASMA	I05QZ0S4V3									?	ng × h/mL	14900		ng/mL	4940			UNKNOWN	mg	400		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17805538	Homo sapiens				Day 1 of Cycle 2; 21-day cycles			3	CP-724714		false
10431	46521		ADULT	9874913	469.535	CP-724714	CP-724714	COCC(=O)NC\\C=C\\C1=CC=C2N=CN=C(NC3=CC(C)=C(OC4=CN=C(C)C=C4)C=C3)C2=C1	PLASMA	I05QZ0S4V3									?	ng × h/mL	11900		ng/mL	4900			UNKNOWN	mg	400		SINGLE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17805538	Homo sapiens		h	4.34				5	CP-724714		false
10432	46521		ADULT	9874913	469.5	CP-724714	CP-724714	COCC(=O)NC\\C=C\\C1=CC=C2N=CN=C(NC3=CC=C(OC4=CN=C(C)C=C4)C(C)=C3)C2=C1	PLASMA	I05QZ0S4V3							48		t	ng × h/mL	7720		ng/mL	3990			UNKNOWN	mg	250		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/17805538	Homo sapiens		h	4.8							false
10433	46607		ADULT	65064	458.4	Epigallocatechin gallate	Epigallocatechin gallate		SERUM	BQM438CTEL									?	μg × min/mL	161.4		ng/mL	438.5			UNKNOWN	mg	800		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11205489/	Homo sapiens		min	114				5	epigallocatechin gallate		false
10434	46607		ADULT	65064	458.4	Epigallocatechin gallate	Epigallocatechin gallate	Oc1cc(O[C@@H]([C@@H](C2)OC(c(cc3O)cc(O)c3O)=O)c(cc3O)cc(O)c3O)c2c(O)c1	PLASMA	BQM438CTEL									?	μg × min/mL	22.5		ng/mL	73.7			UNKNOWN	mg	200		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11205489/	Homo sapiens		min	118				5	epigallocatechin gallate		false
10435	46607		ADULT	65064	458.4	Epigallocatechin gallate	Epigallocatechin gallate		SERUM	BQM438CTEL									?	μg × min/mL	101.9		ng/mL	169.1			UNKNOWN	mg	600		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11205489/	Homo sapiens		min	183.7				5	epigallocatechin gallate		false
10436	46607		ADULT	65064	458.4	Epigallocatechin gallate	Epigallocatechin gallate		SERUM	BQM438CTEL									?	μg × min/mL	35.4		ng/mL	111.8			UNKNOWN	mg	400		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/11205489/	Homo sapiens		min	162.3				5	epigallocatechin gallate		false
10437	46609		ADULT	447865	491.683	EPOTHILONE D	Epothilone D	C[C@H]1CCCC(C)=CC[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\\C)=C\\C2=CSC(C)=N2	PLASMA	T0358E0YUF							99		t	μg × h/L	9451.7		ng/mL	2737.2			UNKNOWN	mg/m²	125		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19775943	Homo sapiens		h	15				6	EPOTHILONE D		false
10438	46609		ADULT		509698	epothilone D hydrolytic metabolite		C[C@@H](CCC\\C(=C/C[C@H](O)\\C(=C\\c1csc(C)n1)\\C)\\C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O	PLASMA								99		t	μg × h/L	16928.2		ng/mL	3001.6			UNKNOWN	mg/m²	125		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19775943	Homo sapiens		h	23.2				6	EPOTHILONE D		false
10439	46609		ADULT	447865	491.683	EPOTHILONE D	Epothilone D	C[C@H]1CCCC(C)=CC[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\\C)=C\\C2=CSC(C)=N2	PLASMA	T0358E0YUF									?	ng × h/mL	12093		ng/mL	4037			MAX TOLERATED	mg/m²	100		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22072399	Homo sapiens		h	9.1				10	KOS-862 (Epothilone D)		false
10440	46629		ADULT	54766013	399.4	Vactosertib	EW-7197	CC1=NC(=CC=C1)C2=C(N=C(N2)CNC3=CC=CC=C3F)C4=CN5C(=NC=N5)C=C4	PLASMA	6T4O391P5Y									?	μg × h/mL	6.29		μg/mL	1.31			UNKNOWN	mg	340		SINGLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31300967	Homo sapiens		h	3.9				4	EW-7197		false
10441	46629		ADULT	54766013	399.4	Vactosertib	EW-7197	CC1=NC(=CC=C1)C2=C(N=C(N2)CNC3=CC=CC=C3F)C4=CN5C(=NC=N5)C=C4	PLASMA	6T4O391P5Y									?	μg × h/mL	8.02		μg/mL	2.05			UNKNOWN	mg	340		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31300967	Homo sapiens		h	7.4	day 5			4	EW-7197		false
10442	46641		ADULT	6914666	280.664	FG-2216	FG-2216	OC(=O)CNC(=O)C1=C(O)C2=C(C=CC=C2)C(Cl)=N1	PLASMA	RU921DS4Z5							24		t	μg × h/mL	3660		μg/mL	179			INVESTIGATIONAL	mg/kg	20		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/21115615	Homo sapiens		h	15.7							false
10443	46663		ADULT	46940575	498.641	GDC-0152	CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N2CCC[C@H]2C(=O)NC3=C(N=NS3)C4=CC=CC=C4	CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N2CCC[C@H]2C(=O)NC3=C(N=NS3)C4=CC=CC=C4	PLASMA	4KW1M48SHS									∞	ng × h/mL	2580						UNKNOWN	mg/kg	1.06		MULTIPLE	UNKNOWN		2 weeks	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://s3.amazonaws.com/academia.edu.documents/51710461/s1359-6349_2810_2972101-720170208-6556-1tprdp9.pdf?response-content-disposition=inline%3B%20filename%3D394_A_phase_I_dose_escalation_and_pharma.pdf&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIAIWOWYYGZ2Y53UL3A%2F20200207%2Fus-east-1%2Fs3%2Faws4_request&X-Amz-Date=20200207T150708Z&X-Amz-Expires=3600&X-Amz-SignedHeaders=host&X-Amz-Signature=420ef251858231778599fc07711626029b17da7589c9d3483b879202b559b848	Homo sapiens		h	4							false
10444	46668		ADULT	442793	294.3859	GINGEROL	6-gingerol	CCCCC[C@H](O)CC(=O)CCC1=CC(OC)=C(O)C=C1	PLASMA	925QK2Z900									?	μg × h/mL	75.6		μg/mL	1.69			UNKNOWN	mg	32.25		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18708382/	Homo sapiens				Dose = 1500 mg. 250 mg capsule of ginger extract contained 5.38 mg (2.15%) 6-gingerol			3	6-gingerol		false
10445	46668		ADULT	442793	294.3859	GINGEROL	6-gingerol	CCCCC[C@H](O)CC(=O)CCC1=CC(OC)=C(O)C=C1	PLASMA	925QK2Z900									?	μg × h/mL	12.6		μg/mL	0.4			UNKNOWN	mg	21.5		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18708382/	Homo sapiens				Dose = 1000 mg. 250 mg capsule of ginger extract contained 5.38 mg (2.15%) 6-gingerol			7	6-gingerol		false
10446	46668		ADULT	442793	294.3859	GINGEROL	6-gingerol	CCCCC[C@H](O)CC(=O)CCC1=CC(OC)=C(O)C=C1	PLASMA	925QK2Z900									?	μg × h/mL	65.6		μg/mL	0.85			UNKNOWN	mg	43		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18708382/	Homo sapiens		min	110	Dose = 2000 mg. 250 mg capsule of ginger extract contained 5.38 mg (2.15%) 6-gingerol			8	6-gingerol		false
10447	46682		ADULT	763|3946848|4546993	117.1066	GLYCOCYAMINE	GLYCOCYAMINE	NC(=N)NCC(O)=O	PLASMA	GO52O1A04E									∞	μM × h	531.4		μM	151.3			UNKNOWN	g	2.4		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25622538/	Homo sapiens		h	1.74							false
10448	46692		ADULT	46885626	507.6	GSK-1070916A	CCN1C=C(C(=N1)C2=CC=C(NC(=O)N(C)C)C=C2)C3=C4C=C(NC4=NC=C3)C5=CC=CC(CN(C)C)=C5	CCN1C=C(C(=N1)C2=CC=C(NC(=O)N(C)C)C=C2)C3=C4C=C(NC4=NC=C3)C5=CC=CC(CN(C)C)=C5	PLASMA	8VLB51V7HO																	MAX TOLERATED	mg/m²	85		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://ascopubs.org/doi/abs/10.1200/jco.2013.31.15_suppl.2525	Homo sapiens		h	8.98							false
10449	46695		ADULT	15983966	543.604	GSK-461364	GSK-461364	C[C@@H](OC1=C(SC(=C1)N2C=NC3=C2C=C(CN4CCN(C)CC4)C=C3)C(N)=O)C5=C(C=CC=C5)C(F)(F)F	PLASMA	8QO27TK6Q4									∞	ng × h/mL	2953		ng/mL	411			MAX TOLERATED	mg	225		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21459796/	Homo sapiens		h	8.99				7	GSK461364		false
10450	46695		ADULT	15983966	543.604	GSK-461364	GSK-461364	C[C@@H](OC1=C(SC(=C1)N2C=NC3=C2C=C(CN4CCN(C)CC4)C=C3)C(N)=O)C5=C(C=CC=C5)C(F)(F)F	PLASMA	8QO27TK6Q4									∞	ng × h/mL	1369		ng/mL	139			UNKNOWN	mg	100		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21459796/	Homo sapiens		h	12.9				3	GSK461364		false
10451	46695		ADULT	15983966	543.604	GSK-461364	GSK-461364	C[C@@H](OC1=C(SC(=C1)N2C=NC3=C2C=C(CN4CCN(C)CC4)C=C3)C(N)=O)C5=C(C=CC=C5)C(F)(F)F	PLASMA	8QO27TK6Q4									∞	ng × h/mL	665		ng/mL	61.2			UNKNOWN	mg	50		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21459796/	Homo sapiens		h	13.1				2	GSK461364		false
10452	46695		ADULT	15983966	543.604	GSK-461364	GSK-461364	C[C@@H](OC1=C(SC(=C1)N2C=NC3=C2C=C(CN4CCN(C)CC4)C=C3)C(N)=O)C5=C(C=CC=C5)C(F)(F)F	PLASMA	8QO27TK6Q4									∞	ng × h/mL	1362		ng/mL	149			UNKNOWN	mg	150		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21459796/	Homo sapiens		h	9.61				2	GSK461364		false
10453	46695		ADULT	15983966	543.604	GSK-461364	GSK-461364	C[C@@H](OC1=C(SC(=C1)N2C=NC3=C2C=C(CN4CCN(C)CC4)C=C3)C(N)=O)C5=C(C=CC=C5)C(F)(F)F	PLASMA	8QO27TK6Q4							24		t	ng × h/mL	980		ng/mL	120			MAX TOLERATED	mg	75		MULTIPLE	UNKNOWN		week	2			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21459796/	Homo sapiens		h	12.7				5	GSK461364		false
10454	46695		ADULT	15983966	543.604	GSK-461364	GSK-461364	C[C@@H](OC1=C(SC(=C1)N2C=NC3=C2C=C(CN4CCN(C)CC4)C=C3)C(N)=O)C5=C(C=CC=C5)C(F)(F)F	PLASMA	8QO27TK6Q4									∞	ng × h/mL	3774		ng/mL	456			HIGHEST STUDIED	mg	300		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21459796/	Homo sapiens		h	9.18				7	GSK461364		false
10455	46696		ADULT	46943432	423.895	GSK-525762	GSK-525762	CCNC(=O)C[C@@H]1N=C(C2=CC=C(Cl)C=C2)C3=C(C=CC(OC)=C3)N4C(C)=NN=C14	PLASMA	5QIO6SRZ2R							24		t	ng × h/mL	3818.5		ng/mL	918.6			UNKNOWN	mg	100		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32328561	Homo sapiens		h	3.82				6	GSK-525762		false
10456	46696		ADULT	46943432	423.895	GSK-525762	GSK-525762	CCNC(=O)C[C@@H]1N=C(C2=CC=C(Cl)C=C2)C3=C(C=CC(OC)=C3)N4C(C)=NN=C14	PLASMA	5QIO6SRZ2R									∞	ng × h/mL	7294.6		ng/mL	1080.5			UNKNOWN	mg	100		SINGLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32328561	Homo sapiens		h	6.2				9	GSK-525762		false
10457	46757		ADULT	22024915	391.1532	ICOTINIB	C#CC1=CC(NC2=NC=NC3=C2C=C4OCCOCCOCCOC4=C3)=CC=C1	C#CC1=CC(NC2=NC=NC3=CC4=C(OCCOCCOCCO4)C=C23)=CC=C1	PLASMA	9G6U5L461Q									∞	mg × h/L	3.22		mg/L	0.728			UNKNOWN	mg	100		SINGLE	FASTED				Human protein binding was estimated to be 98.5 % based on an in vitro human plasma binding study	1.5	HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/24488324	Homo sapiens		h	6.02							false
10458	46807		ADULT	5280863	286.2363	KAEMPFEROL	KAEMPFEROL	OC1=CC=C(C=C1)C2=C(O)C(=O)C3=C(O2)C=C(O)C=C3O	PLASMA	731P2LE49E									∞	mg × h/L	17.72		μg/mL	1.43			UNKNOWN	mg/kg	6		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26051640	Homo sapiens		h	5.11				6	KAEMPFEROL		false
10459	46818		ADULT	11427553	332.4	KW-2449	KW-2449	C1CN(CCN1)C(=O)C2=CC=C(C=C2)/C=C/C3=NNC4=CC=CC=C43	PLASMA	2D9N67F58G									?	ng × h/mL	821		ng/mL	180			UNKNOWN	mg/kg	1		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28751116	Homo sapiens		h	2.93					KW-2449		false
10460	46818		UNKNOWN	11267995	346.4	4-[4-[(E)-2-(1H-Indazol-3-yl)ethenyl]benzoyl]piperazin-2-one		C1CN(CC(=O)N1)C(=O)C2=CC=C(C=C2)/C=C/C3=NNC4=CC=CC=C43	PLASMA										t	ng × h/mL	8540		ng/mL	1190			UNKNOWN	mg/kg	1		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28751116	Homo sapiens		h	2.65					KW-2449		false
10461	46824		ADULT	5311201	398.4571	L-365260	L-365260	CN1C2=C(C=CC=C2)C(=N[C@@H](NC(=O)NC3=CC=CC(C)=C3)C1=O)C4=CC=CC=C4	PLASMA	370JHF4586									∞	ng × h/mL	2807.9		ng/mL	503.2			UNKNOWN	mg	50		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8728342	Homo sapiens		h	11.13				8	L-365260		false
10462	46824		ADULT	5311201	398.4571	L-365260	L-365260	CN1C2=C(C=CC=C2)C(=N[C@@H](NC(=O)NC3=CC=CC(C)=C3)C1=O)C4=CC=CC=C4	PLASMA	370JHF4586									∞	ng × h/mL	2287		ng/mL	269.6			UNKNOWN	mg	25		MULTIPLE	UNKNOWN		day	4			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8728342	Homo sapiens		h	9.9	day 11			8	L-365260		false
10463	46824		ADULT	5311201	398.4571	L-365260	L-365260	CN1C2=C(C=CC=C2)C(=N[C@@H](NC(=O)NC3=CC=CC(C)=C3)C1=O)C4=CC=CC=C4	PLASMA	370JHF4586							6		t	ng × h/mL	846.7		ng/mL	294.6			UNKNOWN	mg	25		SINGLE	UNKNOWN		day	4			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/8728342	Homo sapiens				day 1			8	L-365260		false
10464	46829		ADOLESCENT	6918451	362.3455	L-822179	L-822179	CN1C=C(COC2=NN3C(=NN=C3C4=C2C=CC=C4)C5=NOC(C)=C5)N=N1	PLASMA	1M7NI1A92L													ng/mL	28			UNKNOWN	mg	6		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/19770002/	Homo sapiens		h	2.5				8	α5IA		false
10465	46829		ADOLESCENT	6918451	362.3455	L-822179	L-822179	CN1C=C(COC2=NN3C(=NN=C3C4=C2C=CC=C4)C5=NOC(C)=C5)N=N1	PLASMA	1M7NI1A92L							6		t	ng × h/mL	46						UNKNOWN	mg	2		MULTIPLE	UNKNOWN		day	4			HEALTHY	Oral	MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/19770002/	Homo sapiens				Multiple doses of α5IA administered as a single dose on Day 1 followed by 13 days of dosing either every 6 h (2-mg tablet) or 8 h (4-and 6-mg tablet)			11	α5IA		false
10466	46829		ADOLESCENT	6918451	362.3455	L-822179	L-822179	CN1C=C(COC2=NN3C(=NN=C3C4=C2C=CC=C4)C5=NOC(C)=C5)N=N1	PLASMA	1M7NI1A92L							6		t	ng × h/mL	80						UNKNOWN	mg	4		MULTIPLE	UNKNOWN		day	3			HEALTHY	Oral	MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/19770002/	Homo sapiens				Multiple doses of α5IA administered as a single dose on Day 1 followed by 13 days of dosing either every 6 h (2-mg tablet) or 8 h (4-and 6-mg tablet)			8	α5IA		false
10467	46829		ADULT	6918451	362.3455	L-822179	L-822179	CN1C=C(COC2=NN3C(=NN=C3C4=C2C=CC=C4)C5=NOC(C)=C5)N=N1	PLASMA	1M7NI1A92L							6		t	ng × h/mL	168						UNKNOWN	mg	6		MULTIPLE	UNKNOWN		day	3			HEALTHY	Oral	MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/19770002/	Homo sapiens				Multiple doses of α5IA administered as a single dose on Day 1 followed by 13 days of dosing either every 6 h (2-mg tablet) or 8 h (4-and 6-mg tablet)			7	α5IA		false
10468	46829		ADOLESCENT	6918451	362.3455	L-822179	L-822179	CN1C=C(COC2=NN3C(=NN=C3C4=C2C=CC=C4)C5=NOC(C)=C5)N=N1	PLASMA	1M7NI1A92L													ng/mL	16			UNKNOWN	mg	4		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/19770002/	Homo sapiens		h	2				8	α5IA		false
10469	46829		ADOLESCENT	6918451	362.3455	L-822179	L-822179	CN1C=C(COC2=NN3C(=NN=C3C4=C2C=CC=C4)C5=NOC(C)=C5)N=N1	PLASMA	1M7NI1A92L													ng/mL	8.8			UNKNOWN	mg	2		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	REVIEW	https://pubmed.ncbi.nlm.nih.gov/19770002/	Homo sapiens		h	2.2				8	α5IA		false
10470	46839		ADULT	6441636	390.5131	LATANOPROST ACID	LATANOPROST ACID	O[C@H](CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\\C=C/CCCC(O)=O)CCC2=CC=CC=C2	PLASMA	EJ85341990									?	ng × h/mL	7.15						UNKNOWN	μg/kg bw	3		SINGLE	UNKNOWN						HEALTHY	Intravenous	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12204697/	Homo sapiens		min	16.6							false
10471	46839		ADULT	6441636	390.5131	LATANOPROST ACID	LATANOPROST ACID	O[C@H](CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\\C=C/CCCC(O)=O)CCC2=CC=CC=C2	PLASMA	EJ85341990									?	pg × h/mL	34		pg/mL	53			UNKNOWN	μg	1.5		SINGLE	UNKNOWN						HEALTHY	Ocular	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/12204697/	Homo sapiens		min	17							false
10472	46860		ADULT	64727	422.5549	LOVASTATIN ACID	LOVASTATIN ACID	CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12	PLASMA	5CLV35Y90C							12		t	ng × h/mL	76.9		ng/mL	17.6			UNKNOWN	mg	80		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9585793	Homo sapiens		h	2.5							false
10473	46860		ADULT	64727	422.5549	LOVASTATIN ACID	LOVASTATIN ACID	CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12	PLASMA	5CLV35Y90C							24		t	ng × h/mL	83		ng/mL	11.9			RECOMMENDED	mg	40		STEADY-STATE	UNKNOWN		day	1	Both lovastatin and its β-hydroxyacid metabolite are highly bound (>95%) to human plasma proteins	5	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021316s028lbl.pdf	Homo sapiens										false
10474	46864		ADULT	10029385	512.5349	LY-2090314	LY-2090314	FC1=CC2=C3N(CCN(CC3=C1)C(=O)N4CCCCC4)C=C2C5=C(C(=O)NC5=O)C6=CN=C7C=CC=CN67	PLASMA	822M3GYM67	446556|5288715|135410875	427.4106|\t371.25	PEMETREXED|carboplatin	pemetrexed|carboplatin	NC1=NC2=C(C(CCC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CN2)C(=O)N1|C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt 2]	04Q9AIZ7NO|BG3F62OND5			∞	ng × h/mL	976		ng/mL	603			MAX TOLERATED	mg	40		SINGLE	UNKNOWN		day	1		1	UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23305709	Homo sapiens		h	3.15				11	LY-2090314		true
10475	46864		ADULT	10029385	512.5349	LY-2090314	LY-2090314	FC1=CC2=C3N(CCN(CC3=C1)C(=O)N4CCCCC4)C=C2C5=C(C(=O)NC5=O)C6=CN=C7C=CC=CN67	PLASMA	822M3GYM67	446556|5288715|135410875	427.4106|\t371.25	PEMETREXED|carboplatin	pemetrexed|carboplatin	NC1=NC2=C(C(CCC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CN2)C(=O)N1|C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt 2]	04Q9AIZ7NO|BG3F62OND5			∞	ng × h/mL	3310		ng/mL	1700			UNKNOWN	mg	120		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23305709	Homo sapiens		h	2.97				3	LY-2090314		true
10476	46864		UNKNOWN	10029385	512.5349	LY-2090314	LY-2090314	FC1=CC2=C3N(CCN(CC3=C1)C(=O)N4CCCCC4)C=C2C5=C(C(=O)NC5=O)C6=CN=C7C=CC=CN67	PLASMA	822M3GYM67									∞	ng × h/mL	3310		ng/mL	1700			UNKNOWN	mg	120		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/23305709	Homo sapiens		h	2.97							false
10477	46865		ADULT		445.4161	LY-2584702	LY2584702	CN1C=C(N=C1C2CCN(CC2)C3=NC=NC4=C3C=NN4)C5=CC(=C(F)C=C5)C(F)(F)F	BLOOD	I4965C6W4O							24		t	ng × h/mL	4470.57		ng/mL	841.58			UNKNOWN	mg	50		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24440085	Homo sapiens										false
10478	46865		ADULT		445.4161	LY-2584702	LY2584702	CN1C=C(N=C1C2CCN(CC2)C3=NC=NC4=C3C=NN4)C5=CC(=C(F)C=C5)C(F)(F)F	BLOOD	I4965C6W4O							24		∞	ng × h/mL	30897		ng/mL	1843			UNKNOWN	mg	300		SINGLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24440085	Homo sapiens		h	3.42							false
10479	46865		ADULT	25118925	445.4161	LY-2584702	LY-2584702	CN1C=C(N=C1C2CCN(CC2)C3=NC=NC4=C3C=NN4)C5=CC(=C(F)C=C5)C(F)(F)F	BLOOD	I4965C6W4O							24		t	ng × h/mL	6106.05		ng/mL	1518.04			UNKNOWN	mg	100		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24440085	Homo sapiens										false
10480	46865		ADULT	25118925	445.4161	LY-2584702	LY2584702	CN1C=C(N=C1C2CCN(CC2)C3=NC=NC4=C3C=NN4)C5=CC(=C(F)C=C5)C(F)(F)F	BLOOD	I4965C6W4O							24		t	ng × h/mL	13718.79		ng/mL	2529.26			UNKNOWN	mg	100		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24440085	Homo sapiens										false
10481	46913		ADULT	11159621	176.1786	MK-0354	MK-0354	C1CC2=C(C1)C(=NN2)C3=NN=NN3	PLASMA	4U62D8JYIQ									?	μM × h	766		μM	373			UNKNOWN	mg	3600		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21291763	Homo sapiens		h	9.1				6			false
10482	46913		ADULT	11159621	176.1786	MK-0354	MK-0354	C1CC2=C(C1)C(=NN2)C3=NN=NN3	PLASMA	4U62D8JYIQ									?	μM × h	731		μM	351			UNKNOWN	mg	3600		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21291763	Homo sapiens		h	7.7				6			false
10483	46913		ADULT	11159621	176.1786	MK-0354	MK-0354	C1CC2=C(C1)C(=NN2)C3=NN=NN3	PLASMA	4U62D8JYIQ									?	μM × h	392		μM	147			UNKNOWN	mg	1800		MULTIPLE	FED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21291763	Homo sapiens		h	10.4				6			false
10484	46913		ADULT	11159621	176.1786	MK-0354	MK-0354	C1CC2=C(C1)C(=NN2)C3=NN=NN3	PLASMA	4U62D8JYIQ									?	μM × h	487		μM	235			UNKNOWN	mg	1800		MULTIPLE	FASTED		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21291763	Homo sapiens		h	9.9				6			false
10485	46916		ADULT	44137946	495.551	MK-2461	MK-2461	CN(C[C@@H]1COCCO1)S(=O)(=O)NC2=CC3=C(C=C2)C=CC4=NC=C(C=C4C3=O)C5=CN(C)N=C5	PLASMA	4200RD53XF																	INVESTIGATIONAL	mg	60		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://ascopubs.org/doi/abs/10.1200/jco.2008.26.15_suppl.14657	Homo sapiens		h	6.3							false
10486	46918		ADULT		461.937	MK-5108	MK-5108	OC(=O)[C@@]3(CC1=NC(NC2=NC=CS2)=CC=C1)CC[C@@H](CC3)OC4=CC=CC(Cl)=C4F	PLASMA	H8J407531S							12		t	μM × h	31.2		μM	4.8			UNKNOWN	mg	200		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26620496	Homo sapiens		h	9.3	Dose 4			3	MK-5108		false
10487	46918		ADULT		461.937	MK-5108	MK-5108	OC(=O)[C@@]3(CC1=NC(NC2=NC=CS2)=CC=C1)CC[C@@H](CC3)OC4=CC=CC(Cl)=C4F	PLASMA	H8J407531S							12		t	μM × h	115.9		μM	25			UNKNOWN	mg	1200		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26620496	Homo sapiens		h	8.3	Dose 4			3	MK-5108		false
10488	46918		ADULT		461.937	MK-5108	MK-5108	OC(=O)[C@@]3(CC1=NC(NC2=NC=CS2)=CC=C1)CC[C@@H](CC3)OC4=CC=CC(Cl)=C4F	PLASMA	H8J407531S							12		t	μM × h	130.7		μM	28.9			UNKNOWN	mg	1500		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26620496	Homo sapiens		h	11.4	Dose 4			3	MK-5108		false
10489	46918		ADULT		461.937	MK-5108	MK-5108	OC(=O)[C@@]3(CC1=NC(NC2=NC=CS2)=CC=C1)CC[C@@H](CC3)OC4=CC=CC(Cl)=C4F	PLASMA	H8J407531S							12		t	μM × h	234.4		μM	50.2			HIGHEST STUDIED	mg	1800		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26620496	Homo sapiens		h	6.6	Dose 4			3	MK-5108		false
10490	46918		UNKNOWN		461.937	MK-5108	MK-5108	OC(=O)[C@@]3(CC1=NC(NC2=NC=CS2)=CC=C1)CC[C@@H](CC3)OC4=CC=CC(Cl)=C4F	PLASMA	H8J407531S							12		t	μM × h	95.5		μM	20			UNKNOWN	mg	800		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26620496	Homo sapiens		h	11.1	Dose 4			3	MK-5108		false
10491	46918		ADULT		461.937	MK-5108	MK-5108	OC(=O)[C@@]3(CC1=NC(NC2=NC=CS2)=CC=C1)CC[C@@H](CC3)OC4=CC=CC(Cl)=C4F	PLASMA	H8J407531S							12		t	μM × h	75.7		μM	11			UNKNOWN	mg	400		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26620496	Homo sapiens		h	8.7	Dose 4			3	MK-5108		false
10492	46923		ADULT	11712649	476.862	MLN8054	MLN8054	OC(=O)C1=CC=C(NC2=NC3=C(CN=C(C4=CC(Cl)=CC=C34)C5=C(F)C=CC=C5F)C=N2)C=C1	PLASMA	BX854EHD63							24		t	nM × h	10109		nM	2129			UNKNOWN	mg	20		MULTIPLE	FASTED		day	4			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20607239	Homo sapiens				day 7			3	MLN8054		false
10493	46923		ADULT	11712649	476.862	MLN8054	MLN8054	OC(=O)C1=CC=C(NC2=NC3=C(CN=C(C4=CC(Cl)=CC=C34)C5=C(F)C=CC=C5F)C=N2)C=C1	PLASMA	BX854EHD63	10657292	233.3062	METHYLPHENIDATE	Methylphenidate	COC(=O)[C@H]([C@@H]1CCCCN1)C2=CC=CC=C2	207ZZ9QZ49	24		t	nM × h	13203		nM	2642			MAX TOLERATED	mg	15		MULTIPLE	FASTED		day	4	day 14		UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20607239	Homo sapiens							3	MLN8054		true
10494	47044		ADULT	9826528	482.193	PD-0325901	PD-0325901	OC[C@@H](O)CONC(=O)C1=CC=C(F)C(F)=C1NC2=CC=C(I)C=C2F	PLASMA	86K0J5AK6M							24		t	ng × h/mL	94.6		ng/mL	19.9			UNKNOWN	mg	1		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://clincancerres.aacrjournals.org/content/16/6/1924.full-text.pdf	Homo sapiens		h	18							false
10495	47044		ADULT	9826528	482.193	PD-0325901	PD-0325901	OC[C@@H](O)CONC(=O)C1=CC=C(F)C(F)=C1NC2=CC=C(I)C=C2F	PLASMA	86K0J5AK6M									?	ng × h/mL	2840		ng/mL	706			UNKNOWN	mg	15		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20215549/	Homo sapiens		h	8.7	intermittent (3 wk on treatment/1 wk off)			3	PD-0325901		false
10496	47044		ADULT	9826528	482.193	PD-0325901	PD-0325901	OC[C@@H](O)CONC(=O)C1=CC=C(F)C(F)=C1NC2=CC=C(I)C=C2F	PLASMA	86K0J5AK6M									?	ng × h/mL	6215		ng/mL	1640			UNKNOWN	mg	30		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20215549/	Homo sapiens		h	4.7	intermittent (3 wk on treatment/1 wk off)			2	PD-0325901		false
10497	47044		ADULT	9826528	482.193	PD-0325901	PD-0325901	OC[C@@H](O)CONC(=O)C1=CC=C(F)C(F)=C1NC2=CC=C(I)C=C2F	PLASMA	86K0J5AK6M									?	ng × h/mL	691		ng/mL	198			UNKNOWN	mg	4		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20215549/	Homo sapiens		h	5.5	intermittent (3 wk on treatment/1 wk off)			2	PD-0325901		false
10498	47044		ADULT	9826528	482.193	PD-0325901	PD-0325901	OC[C@@H](O)CONC(=O)C1=CC=C(F)C(F)=C1NC2=CC=C(I)C=C2F	PLASMA	86K0J5AK6M									?	ng × h/mL	3062		ng/mL	839			MAX TOLERATED	mg	15		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20215549/	Homo sapiens		h	5.2	continuous			6	PD-0325901		false
10499	47044		ADULT	9826528	482.193	PD-0325901	PD-0325901	OC[C@@H](O)CONC(=O)C1=CC=C(F)C(F)=C1NC2=CC=C(I)C=C2F	PLASMA	86K0J5AK6M									?	ng × h/mL	3497		ng/mL	766			UNKNOWN	mg	20		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20215549/	Homo sapiens		h	7.7	intermittent (3 wk on treatment/1 wk off)			6	PD-0325901		false
10500	47044		ADULT	9826528	482.193	PD-0325901	PD-0325901	OC[C@@H](O)CONC(=O)C1=CC=C(F)C(F)=C1NC2=CC=C(I)C=C2F	PLASMA	86K0J5AK6M									?	ng × h/mL	3235		ng/mL	972			UNKNOWN	mg	20		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20215549/	Homo sapiens		h	4.6	continuous [daily (QD)]			6	PD-0325901		false
10501	47044		ADULT	9826528	482.193	PD-0325901	PD-0325901	OC[C@@H](O)CONC(=O)C1=CC=C(F)C(F)=C1NC2=CC=C(I)C=C2F	PLASMA	86K0J5AK6M									?	ng × h/mL	1784		ng/mL	462			UNKNOWN	mg	10		MULTIPLE	FASTED		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20215549/	Homo sapiens		h	7.28	continuous [daily (QD)]			6	PD-0325901		false
10502	47056		ADULT	25033539	425.4809	PF-04691502	PF-04691502	COC1=CC=C(C=N1)C2=CC3=C(C)N=C(N)N=C3N([C@H]4CC[C@@H](CC4)OCCO)C2=O	PLASMA	4W39NS61KI							24		t	ng × h/mL	1287		ng/mL	102.3			MAX TOLERATED	mg	8		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24395457	Homo sapiens		h	9				20			false
10503	47056		ADULT	25033539	425.4809	PF-04691502	PF-04691502	COC1=CC=C(C=N1)C2=CC3=C(C)N=C(N)N=C3N([C@H]4CC[C@@H](CC4)OCCO)C2=O	PLASMA	4W39NS61KI							24		t	ng × h/mL	809.3		ng/mL	66.4			MAX TOLERATED	mg	8		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/24395457	Homo sapiens		h	13.8							false
10504	47061		ADULT	9930121	271.3144	PHA-543613	PHA-543613	O=C(N[C@H]1CN2CCC1CC2)C3=CC4=C(OC=C4)C=N3	PLASMA	R36R9KVD6Y							12		t	ng × h/mL	1140		ng/mL	151			UNKNOWN	mg	40		SINGLE	FASTED					81	HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/17446264	Homo sapiens		h	8.78				4	PHA-543613		false
10505	47061		ADULT	9930121	271.3144	PHA-543613	PHA-543613	O=C(N[C@H]1CN2CCC1CC2)C3=CC4=C(OC=C4)C=N3	PLASMA	R36R9KVD6Y							12		t	ng × h/mL	1630		ng/mL	212			UNKNOWN	mg	40		SINGLE	FASTED					81	HEALTHY	Oral	FEMALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/17446264	Homo sapiens		h	11.8				4	PHA-543613		false
10506	47131		ADULT	445154	228.2433	RESVERATROL	Resveratrol	OC1=CC=C(\\C=C\\C2=CC(O)=CC(O)=C2)C=C1	PLASMA	Q369O8926L							12		t	ng × h/mL	3558		ng/mL	1274			UNKNOWN	mg	2000		MULTIPLE	FED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20528005/	Homo sapiens		h	2.4		Days 1-7: Standard breakfast, Day 8: High-fat breakfast		8			false
10507	47131		ADULT	445154	228.2433	RESVERATROL	Resveratrol	OC1=CC=C(\\C=C\\C2=CC(O)=CC(O)=C2)C=C1	PLASMA	Q369O8926L							12		t	ng × h/mL	1966		ng/mL	689			UNKNOWN	mg	2000		MULTIPLE	HIGH-FAT		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20528005/	Homo sapiens		h	2.5	Day 8	Days 1-7: Standard breakfast, Day 8: High-fat breakfast		8			false
10508	47131		ADULT	445154	228.2433	RESVERATROL	Resveratrol	OC1=CC=C(\\C=C\\C2=CC(O)=CC(O)=C2)C=C1	PLASMA	Q369O8926L	5280343	302.2357	QUERCETIN	Quercetin	OC1=CC2=C(C(O)=C1)C(=O)C(O)=C(O2)C3=CC=C(O)C(O)=C3	9IKM0I5T1E	12		t	ng × h/mL	4025		ng/mL	1272			UNKNOWN	mg	2000		MULTIPLE	FED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20528005/	Homo sapiens		h	2.2	Day 7	Days 1-7: Standard breakfast, Day 8: High-fat breakfast	500mg BID	8			true
10509	47131		ADULT	445154	228.2433	RESVERATROL	Resveratrol	OC1=CC=C(\\C=C\\C2=CC(O)=CC(O)=C2)C=C1	PLASMA	Q369O8926L	5280343	302.2357	QUERCETIN	Quercetin	OC1=CC2=C(C(O)=C1)C(=O)C(O)=C(O2)C3=CC=C(O)C(O)=C3	9IKM0I5T1E	12		t	ng × h/mL	3800		ng/mL	1296			UNKNOWN	mg	2000		MULTIPLE	FED		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20528005/	Homo sapiens		h	2.1	Day 8	Days 1-7: Standard breakfast, Day 8: High-fat breakfast	500mg BID and 5% ethanol (100 mL) on Day 8	8			true
10510	47131		ADULT	445154	228.2433	RESVERATROL	Resveratrol	OC1=CC=C(\\C=C\\C2=CC(O)=CC(O)=C2)C=C1	PLASMA	Q369O8926L																						UNKNOWN				Human plasma protein binding (ultrafiltration): 98.3% (98.2% (5μg/mL), 98.5% (12,.5μg/mL), 98.2% (25%))	1.7	HEALTHY		FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25224342/	Homo sapiens										false
10511	47134		ADULT	56654642	339.4314	RG-2833	RG-2833	CC1=CC=C(C=C1)C(=O)NCCCCCC(=O)NC2=C(N)C=CC=C2	PLASMA	17V14R89EU									∞	ng × h/mL	7758		ng/mL	1975			UNKNOWN	mg	30		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25159818/	Homo sapiens		h	8.2				2	RG-2833		false
10512	47134		ADULT	56654642	339.4314	RG-2833	RG-2833	CC1=CC=C(C=C1)C(=O)NCCCCCC(=O)NC2=C(N)C=CC=C2	PLASMA	17V14R89EU									∞	ng × h/mL	9715		ng/mL	2563			UNKNOWN	mg	60		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25159818/	Homo sapiens		h	8.43				3	RG-2833		false
10513	47134		ADULT	56654642	339.4314	RG-2833	RG-2833	CC1=CC=C(C=C1)C(=O)NCCCCCC(=O)NC2=C(N)C=CC=C2	PLASMA	17V14R89EU									∞	ng × h/mL	35058		ng/mL	10930			UNKNOWN	mg	180		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25159818/	Homo sapiens		h	7.07				5	RG-2833		false
10514	47134		ADULT	56654642	339.4314	RG-2833	RG-2833	CC1=CC=C(C=C1)C(=O)NCCCCCC(=O)NC2=C(N)C=CC=C2	PLASMA	17V14R89EU									∞	ng × h/mL	39569		ng/mL	7154			UNKNOWN	mg	240		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25159818/	Homo sapiens		h	8.56				5	RG-2833		false
10515	47134		ADULT	56654642	339.4314	RG-2833	RG-2833	CC1=CC=C(C=C1)C(=O)NCCCCCC(=O)NC2=C(N)C=CC=C2	PLASMA	17V14R89EU									∞	ng × h/mL	21973		ng/mL	6474			UNKNOWN	mg	120		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25159818/	Homo sapiens		h	10.1				5	RG-2833		false
10516	47135		ADULT	11285001	618.555	RGB-286638	RGB-286638	Cl.Cl.COCCN1CCN(CC2=CC=C(C=C2)C3=NNC4=C3C(=O)C5=C4C=CC=C5NC(=O)NN6CCOCC6)CC1	PLASMA	478ZV54680							24		t	μg × h/mL	275						UNKNOWN	mg	20		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25024258/	Homo sapiens		h	8.35	RGB-286638 was administered i.v. more than 60 minutes on days 1 to 5 of a 4-weekly cycle.			3	RGB-286638		false
10517	47135		ADULT	11285001	618.555	RGB-286638	RGB-286638	Cl.Cl.COCCN1CCN(CC2=CC=C(C=C2)C3=NNC4=C3C(=O)C5=C4C=CC=C5NC(=O)NN6CCOCC6)CC1	PLASMA	478ZV54680							24		t	μg × h/mL	1297						UNKNOWN	mg	80		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25024258/	Homo sapiens		h	9.1	RGB-286638 was administered i.v. more than 60 minutes on days 1 to 5 of a 4-weekly cycle.			6	RGB-286638		false
10518	47135		ADULT	11285001	618.555	RGB-286638	RGB-286638	Cl.Cl.COCCN1CCN(CC2=CC=C(C=C2)C3=NNC4=C3C(=O)C5=C4C=CC=C5NC(=O)NN6CCOCC6)CC1	PLASMA	478ZV54680							24		t	μg × h/mL	2307						HIGHEST STUDIED	mg	160		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25024258/	Homo sapiens		h	7.87	RGB-286638 was administered i.v. more than 60 minutes on days 1 to 5 of a 4-weekly cycle.			4	RGB-286638		false
10519	47135		ADULT	11285001	618.555	RGB-286638	RGB-286638	Cl.Cl.COCCN1CCN(CC2=CC=C(C=C2)C3=NNC4=C3C(=O)C5=C4C=CC=C5NC(=O)NN6CCOCC6)CC1	PLASMA	478ZV54680							24		t	μg × h/mL	2026						MAX TOLERATED	mg	120		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25024258/	Homo sapiens		h	9.3	RGB-286638 was administered i.v. more than 60 minutes on days 1 to 5 of a 4-weekly cycle.			7	RGB-286638		false
10520	47161		ADULT	128563	432.4636	SALVINORIN A	SALVINORIN A	COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]3C(=O)O[C@@H](C[C@]23C)C4=COC=C4	PLASMA	T56W91NG6J									∞	ng × h/mL	371.14		ng/mL	31.25			UNKNOWN	mg	1		SINGLE	UNKNOWN						HEALTHY	Respiratory	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26874330	Homo sapiens		h	49.21				12	SALVINORIN A		false
10521	47180		ADULT		180.1559	SCYLLO-INOSITOL	Scyllo-Inositol	O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O	PLASMA	1VS4X81277									?	μg × h/mL	277		μg/mL	39.8			UNKNOWN	mg	1000		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27121673/	Homo sapiens		h	62.6	2000 mg ELND005 were administered with water as four 500 mg capsules twice a day for 10 days			8	ELND005		false
10522	47180		ADULT		180.1559	SCYLLO-INOSITOL	Scyllo-Inositol	O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O	PLASMA	1VS4X81277									?	μg × h/mL	98.9		μg/mL	17.2			UNKNOWN	mg	2000		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27121673/	Homo sapiens							8	ELND005		false
10523	47180		ADULT		180.1559	SCYLLO-INOSITOL	Scyllo-Inositol	O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O	CEREBROSPINAL FLUID	1VS4X81277									?	μg × h/mL	49.4		μg/mL	6.5			UNKNOWN	mg	2000		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27121673/	Homo sapiens							8	ELND005		false
10524	47180		ADULT		180.1559	SCYLLO-INOSITOL	Scyllo-Inositol	O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O	CEREBROSPINAL FLUID	1VS4X81277									?	μg × h/mL	153		μg/mL	13.7			UNKNOWN	mg	1000		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27121673/	Homo sapiens		h	26.2	2000 mg ELND005 were administered with water as four 500 mg capsules twice a day for 10 days			8	ELND005		false
10525	47191		UNKNOWN	3025986	380.528	SNS-032	SNS-032	CC(C)(C)C1=CN=C(CSC2=CN=C(NC(=O)C3CCNCC3)S2)O1	SERUM	9979I93686																	UNKNOWN				UNKNOWN	UNKNOWN					37	UNKNOWN	UNKNOWN	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15027863	Homo sapiens								SNS-032		false
10526	47191		ADULT	3025986	380.528	SNS-032	SNS-032	CC(C)(C)C1=CN=C(CSC2=CN=C(NC(=O)C3CCNCC3)S2)O1	PLASMA	9979I93686									∞	μg × h/mL	0.553		μg/mL	0.287			UNKNOWN	mg/m²	16		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17938863	Homo sapiens		h	9.1	1-h intravenous infusion			4	SNS-032		false
10527	47191		ADULT	3025986	380.528	SNS-032	SNS-032	CC(C)(C)C1=CN=C(CSC2=CN=C(NC(=O)C3CCNCC3)S2)O1	PLASMA	9979I93686									?	μg × h/mL	0.052		μg/mL	0.017			UNKNOWN	mg/m²	16		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17938863	Homo sapiens		h	8.5				3	SNS-032		false
10528	47198		ADULT	5274428	330.5505	SQ-109	SQ-109	CC(C)=CCC\\C(C)=C\\CNCCNC1C2CC3CC(C2)CC1C3	PLASMA	9AU7XUV31A							24		t	ng × h/mL	240.8		ng/mL	39.1			UNKNOWN	mg	300		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25630641	Homo sapiens				day 7			14	SQ-109		false
10529	47198		ADULT	5274428	330.5505	SQ-109	SQ-109	CC(C)=CCC\\C(C)=C\\CNCCNC1C2CC3CC(C2)CC1C3	PLASMA	9AU7XUV31A							24		t	ng × h/mL	183.7		ng/mL	43.3			UNKNOWN	mg	300		SINGLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25630641	Homo sapiens				day 1			14	SQ-109		false
10530	47198		ADULT	5274428	330.5505	SQ-109	SQ-109	CC(C)=CCC\\C(C)=C\\CNCCNC1C2CC3CC(C2)CC1C3	PLASMA	9AU7XUV31A							24		t	ng × h/mL	268.5		ng/mL	45.9			UNKNOWN	mg	300		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25630641	Homo sapiens				day 14			14	SQ-109		false
10531	47207		ADULT	10138259	442.4833	SU-14813	SU-14813	CC1=C(C(=O)NC[C@H](O)CN2CCOCC2)C(C)=C(N1)\\C=C3/C(=O)NC4=C3C=C(F)C=C4	PLASMA	ZZ6VH5MZ17									?	ng × h/mL	2701		ng/mL	253			MAX TOLERATED	mg	200		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20605934	Homo sapiens		h	19.1				6	SU-14813		false
10532	47207		ADULT	10138259	442.4833	SU-14813	SU-14813	CC1=C(C(=O)NC[C@H](O)CN2CCOCC2)C(C)=C(N1)\\C=C3/C(=O)NC4=C3C=C(F)C=C4	PLASMA	ZZ6VH5MZ17									?	ng × h/mL	8007		ng/mL	558			MAX TOLERATED	mg	200		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20605934	Homo sapiens		h	28.4	once-daily SU14813, for 4 weeks followed by 1 week off treatment (schedule 4/1)			5	SU-14813		false
10533	47207		ADULT	10138259	442.4833	SU-14813	SU-14813	CC1=C(C(=O)NC[C@H](O)CN2CCOCC2)C(C)=C(N1)\\C=C3/C(=O)NC4=C3C=C(F)C=C4	PLASMA	ZZ6VH5MZ17									?	ng × h/mL	2878		ng/mL	255			MAX TOLERATED	mg	100		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20605934	Homo sapiens		h	12.7	continuous daily dosing			6	SU-14813		false
10534	47207		ADULT	10138259	442.4833	SU-14813	SU-14813	CC1=C(C(=O)NC[C@H](O)CN2CCOCC2)C(C)=C(N1)\\C=C3/C(=O)NC4=C3C=C(F)C=C4	PLASMA	ZZ6VH5MZ17									?	ng × h/mL	1778		ng/mL	171			MAX TOLERATED	mg	100		SINGLE	FASTED			1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20605934	Homo sapiens		h	13.2				6	SU-14813		false
10535	47270		UNKNOWN	9833519	777.8713	UK-432097	UK-432097	CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)N2C=NC3=C2N=C(N=C3NCC(C4=CC=CC=C4)C5=CC=CC=C5)C(=O)NCCNC(=O)NC6CCN(CC6)C7=NC=CC=C7	BLOOD	8L3OAJ1R5A																	UNKNOWN				UNKNOWN	UNKNOWN					1.6	UNKNOWN	UNKNOWN	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22077102	Homo sapiens								UK-432097		false
10536	47270		ADULT	9833519	777.8713	UK-432097	UK-432097	CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)N2C=NC3=C2N=C(N=C3NCC(C4=CC=CC=C4)C5=CC=CC=C5)C(=O)NCCNC(=O)NC6CCN(CC6)C7=NC=CC=C7	PLASMA	8L3OAJ1R5A													pg/mL	50			UNKNOWN	μg	4500		SINGLE	UNKNOWN						HEALTHY	Respiratory	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22077102	Homo sapiens								UK-432097		false
10537	47286		ADULT	51001932	460.5315	TASELISIB	TASELISIB	CC(C)N1N=C(C)N=C1C2=CN3CCOC4=C(C=CC(=C4)C5=CN(N=C5)C(C)(C)C(N)=O)C3=N2	PLASMA	L08J2O299M							24		t	μM × h	2.26		μM	0.134			UNKNOWN	mg	16		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/28331003	Homo sapiens		h	39.7							false
10538	47287		ADULT	59472121	463.552	VX-970	VX-970	CNCC1=CC=C(C=C1)C2=NOC(=C2)C3=C(N)N=CC(=N3)C4=CC=C(C=C4)S(=O)(=O)C(C)C	PLASMA	L423PRV3V3									∞	ng × h/mL	14900		ng/mL	4410			UNKNOWN	mg/m²	480		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32568634	Homo sapiens		h	21.2	Cycle 1, day 1			6	VX-970		false
10539	47287		ADULT	59472121	463.552	VX-970	VX-970	CNCC1=CC=C(C=C1)C2=NOC(=C2)C3=C(N)N=CC(=N3)C4=CC=C(C=C4)S(=O)(=O)C(C)C	PLASMA	L423PRV3V3									∞	ng × h/mL	8270		ng/mL	1520			RP2D	mg/m²	240		SINGLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32568634	Homo sapiens		h	17.9	Cycle 1, day 1			6	VX-970		false
10540	47321		ADULT	444499|5288627|135409409	266.2533	FORODESINE	FORODESINE	OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)C2=CNC3=C2N=CNC3=O	PLASMA	426X066ELK							24		t	ng × h/mL	4596		ng/mL	328			HIGHEST STUDIED	mg	300		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22448814/	Homo sapiens		h	14.4				5	BCX1777		false
10541	47321		ADULT	444499|5288627|135409409	266.2533	FORODESINE	FORODESINE	OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)C2=CNC3=C2N=CNC3=O	PLASMA	426X066ELK									?	ng × h/mL	2730		ng/mL	216.5			UNKNOWN	mg	100		STEADY-STATE	FED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22448814/	Homo sapiens							5	BCX1777		false
10542	47321		ADULT	444499|5288627|135409409	266.2533	FORODESINE	FORODESINE	OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)C2=CNC3=C2N=CNC3=O	PLASMA	426X066ELK									?	ng × h/mL	5587		ng/mL	421.6			HIGHEST STUDIED	mg	300		STEADY-STATE	FED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22448814/	Homo sapiens							5	BCX1777		false
10543	47321		ADULT	444499|5288627|135409409	266.2533	FORODESINE	forodesine	OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)C2=CNC3=C2N=CNC3=O	PLASMA	426X066ELK							24		t	ng × h/mL	1948		ng/mL	139.2			UNKNOWN	mg	100		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22448814/	Homo sapiens		h	13				5	BCX1777		false
10544	47321		ADULT	444499|5288627|135409409	266.2533	FORODESINE	FORODESINE	OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)C2=CNC3=C2N=CNC3=O	PLASMA	426X066ELK									?	ng × h/mL	6303		ng/mL	499			UNKNOWN	mg	200		STEADY-STATE	FED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22448814/	Homo sapiens							3	BCX1777		false
10545	47321		ADULT	444499|5288627|135409409	266.2533	FORODESINE	FORODESINE	OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)C2=CNC3=C2N=CNC3=O	PLASMA	426X066ELK							24		t	ng × h/mL	4608		ng/mL	335.3			UNKNOWN	mg	200		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22448814/	Homo sapiens		h	14.1				3	BCX1777		false
10546	47344		ADULT	25181472	619.705	Glesatinib	COCCNCC1=CN=C(C=C1)C2=CC3=NC=CC(OC4=C(F)C=C(NC(=S)NC(=O)CC5=CC=C(F)C=C5)C=C4)=C3S2	COCCNCC1=CN=C(C=C1)C2=CC3=NC=CC(OC4=C(F)C=C(NC(=S)NC(=O)CC5=CC=C(F)C=C5)C=C4)=C3S2	PLASMA	7Q29OXD98N									∞	ng × h/mL	816		ng/mL	29.8			INVESTIGATIONAL	mg/m²	24		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://ascopubs.org/doi/abs/10.1200/jco.2009.27.15_suppl.e14525	Homo sapiens		h	22.4							false
10547	47345		UNKNOWN	71657455	582.961	IVOSIDENIB	IVOSIDENIB	FC1=CC(=CN=C1)N([C@H](C(=O)NC2CC(F)(F)C2)C3=C(Cl)C=CC=C3)C(=O)[C@@H]4CCC(=O)N4C5=NC=CC(=C5)C#N	PLASMA	Q2PCN8MAM6																						UNKNOWN				Protein binding of ivosidenib ranges from 92 to 96% in vitro.	6	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf	Homo sapiens										false
10548	47345		ADULT	71657455	583	IVOSIDENIB	IVOSIDENIB	FC1=CN=CC(=C1)N([C@H](C(=O)NC2CC(F)(F)C2)C3=C(Cl)C=CC=C3)C(=O)[C@@H]4CCC(=O)N4C5=NC=CC(=C5)C#N	PLASMA	Q2PCN8MAM6							72		t	ng × h/mL	112490		ng/mL	3657			RECOMMENDED	mg	500		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/31028664	Homo sapiens		h	64.3							false
10549	47346		ADULT	11326715	389.328	ENOBOSARM	MK-2866	C[C@](O)(COC1=CC=C(C=C1)C#N)C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F	PLASMA	O3571H3R8N									∞	ng × h/mL	779.5		ng/mL	57.6			UNKNOWN	mg	3		SINGLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27105861	Homo sapiens		h	22				12	MK-2866		false
10550	47355		ADULT	78357816	399.3395	SEVITERONEL	SEVITERONEL	CC(C)[C@@](O)(C1=CN=NN1)C2=CC3=C(C=C2)C=C(OC(F)F)C(OC(F)F)=C3	PLASMA	8S5OIN36X4									∞	ng × h/mL	31124		ng/mL	4506			RP2D	mg	450		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29744674	Homo sapiens		h	6.4				7	SEVITERONEL		false
10551	47355		ADULT	78357816	399.3395	SEVITERONEL	SEVITERONEL	CC(C)[C@@](O)(C1=CN=NN1)C2=CC3=C(C=C2)C=C(OC(F)F)C(OC(F)F)=C3	PLASMA	8S5OIN36X4									∞	ng × h/mL	84558		ng/mL	7822			UNKNOWN	mg	750		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29744674	Homo sapiens		h	6.8				6	SEVITERONEL		false
10552	47355		ADULT	78357816	399.3395	SEVITERONEL	SEVITERONEL	CC(C)[C@@](O)(C1=CN=NN1)C2=CC3=C(C=C2)C=C(OC(F)F)C(OC(F)F)=C3	PLASMA	8S5OIN36X4							24		t	ng × h/mL	79824		ng/mL	5600			UNKNOWN	mg	900		SINGLE	UNKNOWN						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30012563	Homo sapiens							1	SEVITERONEL		false
10553	47355		ADULT	78357816	399.3395	SEVITERONEL	SEVITERONEL	CC(C)[C@@](O)(C1=CN=NN1)C2=CC3=C(C=C2)C=C(OC(F)F)C(OC(F)F)=C3	PLASMA	8S5OIN36X4									?	mg × h/L	63.5		mg/L	5.65			UNKNOWN	mg	750		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32327394	Homo sapiens		h	18.3	Cycle 2 day 2			1	SEVITERONEL		false
10554	47355		ADULT	78357816	399.3395	SEVITERONEL	SEVITERONEL	CC(C)[C@@](O)(C1=CN=NN1)C2=CC3=C(C=C2)C=C(OC(F)F)C(OC(F)F)=C3	PLASMA	8S5OIN36X4									∞	mg × h/L	44.2		mg/L	5.11			UNKNOWN	mg	750		SINGLE	UNKNOWN						UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32327394	Homo sapiens		h	10.5	Cycle 1 day 1			3	SEVITERONEL		false
10555	47367		ADULT	25227436	428.915	AZD-5363	AZD-5363	NC1(CCN(CC1)C2=NC=NC3=C2C=CN3)C(=O)N[C@@H](CCO)C4=CC=C(Cl)C=C4	PLASMA	WFR23M21IE									?	ng × h/mL	7952		ng/mL	1426			UNKNOWN	mg	480		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29066505	Homo sapiens		h	10							false
10556	47370		CHILD	6851740	517.062	ISPINESIB	ISPINESIB	CC(C)[C@@H](N(CCCN)C(=O)C1=CC=C(C)C=C1)C2=NC3=C(C=CC(Cl)=C3)C(=O)N2CC4=CC=CC=C4	PLASMA	BKT5F9C2NI									∞	ng × h/mL	3811		ng/mL	281			MAX TOLERATED	mg/m²	9		SINGLE	UNKNOWN				Percent protein binding in humans ranges from 81.1% to 96.2% (mean, 90.5%).	9.5	UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/20712019	Homo sapiens		h	33							false
10557	47370		ADULT	6851740	517.062	ISPINESIB	ISPINESIB	CC(C)[C@@H](N(CCCN)C(=O)C1=CC=C(C)C=C1)C2=NC3=C(C=CC(Cl)=C3)C(=O)N2CC4=CC=CC=C4	PLASMA	BKT5F9C2NI							1		t	ng × h/mL	349						UNKNOWN	mg/m²	10		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/22123335	Homo sapiens										false
10558	47382		ADULT	57990869	444.5288	XL-019	XL019	O=C(NC1=CC=C(C=C1)C2=NC(NC3=CC=C(C=C3)N4CCOCC4)=NC=C2)[C@@H]5CCCN5	PLASMA	4L1AM42NVA																	HIGHEST STUDIED	mg	300		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24374145/	Homo sapiens		h	21	orally on days 1–21 of a 28-day cycle.			6	XL019		false
10559	47383		ADULT	15983988	357.3821	TRELAGLIPTIN	TRELAGLIPTIN	CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC3=C(C=CC(F)=C3)C#N)C1=O	PLASMA	Q836OWG55H							168		t	ng × h/mL	1490.9		ng/mL	129.8			UNKNOWN	mg	25		SINGLE	FED				Protein binding of trelagliptin was 22.1% to 27.6%, showing a low protein binding in human plasma.	75.15	HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/files/000213963.pdf	Homo sapiens		h	50.4		30 minutes before the start of breakfast		10	TRELAGLIPTIN		false
10560	47383		ADULT	15983988	357.3821	TRELAGLIPTIN	TRELAGLIPTIN	CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC3=C(C=CC(F)=C3)C#N)C1=O	PLASMA	Q836OWG55H							168		t	ng × h/mL	6365.2		ng/mL	541.4			UNKNOWN	mg	100		SINGLE	FASTED				Protein binding of trelagliptin was 22.1% to 27.6%, showing a low protein binding in human plasma.	75.15	HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/files/000213963.pdf	Homo sapiens		h	60				10	TRELAGLIPTIN		false
10561	47383		ADULT	15983988	357.3821	TRELAGLIPTIN	TRELAGLIPTIN	CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC3=C(C=CC(F)=C3)C#N)C1=O	PLASMA	Q836OWG55H							168		?	ng × h/mL	10094.86		ng/mL	1388.63			UNKNOWN	mg	200		MULTIPLE	FED		day	1	Protein binding of trelagliptin was 22.1% to 27.6%, showing a low protein binding in human plasma.	75.15	HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/files/000213963.pdf	Homo sapiens		h	32.51	Day 14	30 minutes before the start of breakfast		9	TRELAGLIPTIN		false
10562	47383		ADULT	15983988	357.3821	TRELAGLIPTIN	TRELAGLIPTIN	CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC3=C(C=CC(F)=C3)C#N)C1=O	PLASMA	Q836OWG55H							168		t	ng × h/mL	466.5		ng/mL	25.3			UNKNOWN	mg	6.25		SINGLE	FED				Protein binding of trelagliptin was 22.1% to 27.6%, showing a low protein binding in human plasma.	75.15	HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/files/000213963.pdf	Homo sapiens		h	43.2		30 minutes before the start of breakfast		10	TRELAGLIPTIN		false
10563	47383		ADULT	15983988	357.3821	TRELAGLIPTIN	TRELAGLIPTIN	CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC3=C(C=CC(F)=C3)C#N)C1=O	PLASMA	Q836OWG55H							168		t	ng × h/mL	25046.6		ng/mL	3334.9			UNKNOWN	mg	400		SINGLE	FED				Protein binding of trelagliptin was 22.1% to 27.6%, showing a low protein binding in human plasma.	75.15	HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/files/000213963.pdf	Homo sapiens		h	46.1		30 minutes before the start of breakfast		7	TRELAGLIPTIN		false
10564	47383		ADULT	15983988	357.3821	TRELAGLIPTIN	TRELAGLIPTIN	CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC3=C(C=CC(F)=C3)C#N)C1=O	PLASMA	Q836OWG55H							168		?	ng × h/mL	5292.95		ng/mL	602.63			UNKNOWN	mg	100		MULTIPLE	FED		day	1	Protein binding of trelagliptin was 22.1% to 27.6%, showing a low protein binding in human plasma.	75.15	HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/files/000213963.pdf	Homo sapiens		h	35.12	Day 14	30 minutes before the start of breakfast		9	TRELAGLIPTIN		false
10565	47383		ADULT	15983988	357.3821	TRELAGLIPTIN	TRELAGLIPTIN	CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC3=C(C=CC(F)=C3)C#N)C1=O	PLASMA	Q836OWG55H							168		t	ng × h/mL	49416.5		ng/mL	7108.3			HIGHEST STUDIED	mg	800		SINGLE	FED				Protein binding of trelagliptin was 22.1% to 27.6%, showing a low protein binding in human plasma.	75.15	HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/files/000213963.pdf	Homo sapiens		h	39		30 minutes before the start of breakfast		10	TRELAGLIPTIN		false
10566	47383		ADULT	15983988	357.3821	TRELAGLIPTIN	TRELAGLIPTIN	CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC3=C(C=CC(F)=C3)C#N)C1=O	PLASMA	Q836OWG55H							168		t	ng × h/mL	6431.4		ng/mL	619.4			UNKNOWN	mg	100		SINGLE	FED				Protein binding of trelagliptin was 22.1% to 27.6%, showing a low protein binding in human plasma.	75.15	HEALTHY	Oral	MALE	OTHER GOV'T	https://www.pmda.go.jp/files/000213963.pdf	Homo sapiens		h	54.3		30 minutes before the start of breakfast		10	TRELAGLIPTIN		false
10567	47387		ADULT	443873	513.07	TEMOCAPRIL HYDROCHLORIDE	TEMOCAPRIL HCL	Cl.CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CS[C@@H](CN(CC(O)=O)C2=O)C3=CC=CS3	PLASMA	8G820I95VP									?	ng × h/mL	141		ng/mL	136			UNKNOWN	mg	20		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9803985/	Homo sapiens		h	1.5				18	TEMOCAPRIL HCL		false
10568	47387		ADULT	443873	513.07	TEMOCAPRIL HYDROCHLORIDE	TEMOCAPRIL HCL	Cl.CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CS[C@@H](CN(CC(O)=O)C2=O)C3=CC=CS3	PLASMA	8G820I95VP									?	ng × h/mL	140		ng/mL	139			UNKNOWN	mg	20		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/9803985/	Homo sapiens		h	1.6				18	TEMOCAPRIL HCL		false
10569	47398			71353	305.4134	DAPOXETINE	Dapoxetine	CN(C)[C@@H](CCOC1=C2C=CC=CC2=CC=C1)C3=CC=CC=C3	PLASMA	GB2433A4M3																										Human plasma protein binding: 99%	1				REVIEW	https://pubmed.ncbi.nlm.nih.gov/16430636/ | https://pubmed.ncbi.nlm.nih.gov/32485631/	Homo sapiens										false
10570	47398		ADULT	71353	305.4134	DAPOXETINE	Dapoxetine	CN(C)[C@@H](CCOC1=C2C=CC=CC2=CC=C1)C3=CC=CC=C3	PLASMA	GB2433A4M3							24		t	ng × h/mL	1110		ng/mL	297			UNKNOWN	mg	30		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16490806/	Homo sapiens		h	18.7	Day 1			37			false
10571	47398		ADULT	71353	305.4134	DAPOXETINE	Dapoxetine	CN(C)[C@@H](CCOC1=C2C=CC=CC2=CC=C1)C3=CC=CC=C3	PLASMA	GB2433A4M3							24		t	ng × h/mL	1550		ng/mL	349			UNKNOWN	mg	30		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16490806/	Homo sapiens				Day 9 (no doses on Days 2 and 3)			37			false
10572	47398		ADULT	71353	305.4134	DAPOXETINE	Dapoxetine	CN(C)[C@@H](CCOC1=C2C=CC=CC2=CC=C1)C3=CC=CC=C3	PLASMA	GB2433A4M3							24		t	ng × h/mL	2070		ng/mL	498			UNKNOWN	mg	60		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16490806/	Homo sapiens		h	21.9	Day 1			37			false
10573	47398		ADULT	71353	305.4134	DAPOXETINE	Dapoxetine	CN(C)[C@@H](CCOC1=C2C=CC=CC2=CC=C1)C3=CC=CC=C3	PLASMA	GB2433A4M3							24		t	ng × h/mL	2950		ng/mL	596			UNKNOWN	mg	60		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16490806/	Homo sapiens				Day 9 (no doses on Days 2 and 3)			37			false
10574	47398		ADULT	71353	305.4134	DAPOXETINE	Dapoxetine	CN(C)[C@@H](CCOC1=C2C=CC=CC2=CC=C1)C3=CC=CC=C3	PLASMA	GB2433A4M3									∞	ng × h/mL	2040		ng/mL	338			UNKNOWN	mg	60		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16920897/	Homo sapiens		h	17.8		Young subjects (18-43 y)		18			false
10575	47398		ADULT	71353	305.4134	DAPOXETINE	Dapoxetine	CN(C)[C@@H](CCOC1=C2C=CC=CC2=CC=C1)C3=CC=CC=C3	PLASMA	GB2433A4M3									∞	ng × h/mL	2280		ng/mL	310			UNKNOWN	mg	60		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16920897/	Homo sapiens		h	26		Elderly subjects (65-77 y)		18			false
10576	47398		ADULT	71353	305.4134	DAPOXETINE	Dapoxetine	CN(C)[C@@H](CCOC1=C2C=CC=CC2=CC=C1)C3=CC=CC=C3	PLASMA	GB2433A4M3									∞	ng × h/mL	2190		ng/mL	443			UNKNOWN	mg	60		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16920897/	Homo sapiens		h	16.3				27			false
10577	47398		ADULT	71353	305.4134	DAPOXETINE	Dapoxetine	CN(C)[C@@H](CCOC1=C2C=CC=CC2=CC=C1)C3=CC=CC=C3	PLASMA	GB2433A4M3									∞	ng × h/mL	2450		ng/mL	398			UNKNOWN	mg	60		SINGLE	HIGH-FAT						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16920897/	Homo sapiens		h	17.8				27			false
10578	47398		ADULT	71353	305.4134	DAPOXETINE	Dapoxetine	CN(C)[C@@H](CCOC1=C2C=CC=CC2=CC=C1)C3=CC=CC=C3	PLASMA	GB2433A4M3									∞	ng × h/mL	1078		ng/mL	204			UNKNOWN	mg	30		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20097934/	Homo sapiens		h	15	Day 1	Chinese subjects		12			false
10579	47398		ADULT	71353	305.4134	DAPOXETINE	Dapoxetine	CN(C)[C@@H](CCOC1=C2C=CC=CC2=CC=C1)C3=CC=CC=C3	PLASMA	GB2433A4M3									∞	ng × h/mL	1162		ng/mL	259			UNKNOWN	mg	30		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20097934/	Homo sapiens		h	14.8	Day 1	Japanese subjects		44			false
10580	47398		ADULT	71353	305.4134	DAPOXETINE	Dapoxetine	CN(C)[C@@H](CCOC1=C2C=CC=CC2=CC=C1)C3=CC=CC=C3	PLASMA	GB2433A4M3							24		t	ng × h/mL	1028		ng/mL	252			UNKNOWN	mg	30		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20097934/	Homo sapiens		h	15.7	Day 9 (no doses on Days 2 and 3)	Caucasian subjects		44			false
10581	47398		ADULT	71353	305.4134	DAPOXETINE	Dapoxetine	CN(C)[C@@H](CCOC1=C2C=CC=CC2=CC=C1)C3=CC=CC=C3	PLASMA	GB2433A4M3									∞	ng × h/mL	1792		ng/mL	403			UNKNOWN	mg	60		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20097934/	Homo sapiens		h	13.9	Day 1	Caucasian subjects		43			false
10582	47398		ADULT	71353	305.4134	DAPOXETINE	Dapoxetine	CN(C)[C@@H](CCOC1=C2C=CC=CC2=CC=C1)C3=CC=CC=C3	PLASMA	GB2433A4M3							24		t	ng × h/mL	2238		ng/mL	488			UNKNOWN	mg	60		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20097934/	Homo sapiens		h	17.2	Day 9 (no doses on Days 2 and 3)	Japanese subjects		44			false
10583	47398		ADULT	71353	305.4134	DAPOXETINE	Dapoxetine	CN(C)[C@@H](CCOC1=C2C=CC=CC2=CC=C1)C3=CC=CC=C3	PLASMA	GB2433A4M3							24		t	ng × h/mL	1954		ng/mL	439			UNKNOWN	mg	60		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20097934/	Homo sapiens		h	16.2	Day 9 (no doses on Days 2 and 3)	Caucasian subjects		43			false
10584	47398		ADULT	71353	305.4134	DAPOXETINE	Dapoxetine	CN(C)[C@@H](CCOC1=C2C=CC=CC2=CC=C1)C3=CC=CC=C3	PLASMA	GB2433A4M3									∞	ng × h/mL	2251		ng/mL	421			UNKNOWN	mg	60		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20097934/	Homo sapiens		h	15.3	Day 1	Japanese subjects		44			false
10585	47398		ADULT	71353	305.4134	DAPOXETINE	Dapoxetine	CN(C)[C@@H](CCOC1=C2C=CC=CC2=CC=C1)C3=CC=CC=C3	PLASMA	GB2433A4M3									∞	ng × h/mL	980		ng/mL	241			UNKNOWN	mg	30		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20097934/	Homo sapiens		h	14	Day 1	Caucasian subjects		44			false
10586	47398		ADULT	71353	305.4134	DAPOXETINE	Dapoxetine	CN(C)[C@@H](CCOC1=C2C=CC=CC2=CC=C1)C3=CC=CC=C3	PLASMA	GB2433A4M3									∞	ng × h/mL	2022		ng/mL	396			UNKNOWN	mg	60		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20097934/	Homo sapiens		h	15.4	Day 1	Chinese subjects		12			false
10587	47398		ADULT	71353	305.4134	DAPOXETINE	Dapoxetine	CN(C)[C@@H](CCOC1=C2C=CC=CC2=CC=C1)C3=CC=CC=C3	PLASMA	GB2433A4M3							24		t	ng × h/mL	1200		ng/mL	272			UNKNOWN	mg	30		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20097934/	Homo sapiens		h	16.6	Day 1	Japanese subjects		44			false
10588	47398		ADULT	71353	305.4134	DAPOXETINE	Dapoxetine	CN(C)[C@@H](CCOC1=C2C=CC=CC2=CC=C1)C3=CC=CC=C3	PLASMA	GB2433A4M3									∞	ng × h/mL	1179		ng/mL	269			UNKNOWN	mg	30		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33528113/	Homo sapiens		h	16.1				39			false
10589	47398		ADULT	71353	305.4134	DAPOXETINE	Dapoxetine	CN(C)[C@@H](CCOC1=C2C=CC=CC2=CC=C1)C3=CC=CC=C3	PLASMA	GB2433A4M3									∞	ng × h/mL	1531		ng/mL	261			UNKNOWN	mg	30		SINGLE	HIGH-FAT						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33528113/	Homo sapiens		h	15.7				39			false
10590	47398		ADULT	71353	305.4134	DAPOXETINE	Dapoxetine	CN(C)[C@@H](CCOC1=C2C=CC=CC2=CC=C1)C3=CC=CC=C3	PLASMA	GB2433A4M3									∞	ng × h/mL	2626		ng/mL	369			UNKNOWN	mg	60		SINGLE	HIGH-FAT						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33528113/	Homo sapiens		h	15.2				31			false
10591	47398		ADULT	71353	305.4134	DAPOXETINE	Dapoxetine	CN(C)[C@@H](CCOC1=C2C=CC=CC2=CC=C1)C3=CC=CC=C3	PLASMA	GB2433A4M3									∞	ng × h/mL	2532		ng/mL	413			UNKNOWN	mg	60		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33528113/	Homo sapiens		h	18.5				35			false
10592	47415		ADULT	11494412	369.4	TIVANTINIB	TIVANTINIB	O=C1NC(=O)[C@H]([C@@H]1C2=CNC3=C2C=CC=C3)C4=CN5CCCC6=CC=CC4=C56	PLASMA	PJ4H73IL17							24		t	ng × h/mL	13297		ng/mL	2051			UNKNOWN	mg	120		STEADY-STATE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/21976535	Homo sapiens		h	2.7							false
10593	47417		UNKNOWN	25254071	498.601	APITOLISIB	GDC-0980	C[C@H](O)C(=O)N1CCN(CC2=C(C)C3=C(S2)C(=NC(=N3)C4=CN=C(N)N=C4)N5CCOCC5)CC1	PLASMA	1C854K1MIJ																						UNKNOWN				Free [14C] GDC-0980: 39 -45%, over concentrations 1-40 uM	42	UNKNOWN		UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/22696419	Homo sapiens										false
10594	47417		ADULT	25254071	498.6	Apitolisib	C[C@H](O)C(=O)N1CCN(CC2=C(C)C3=C(S2)C(=NC(=N3)C4=CN=C(N)N=C4)N5CCOCC5)CC1	C[C@H](O)C(=O)N1CCN(CC2=C(C)C3=C(S2)C(=NC(=N3)C4=CN=C(N)N=C4)N5CCOCC5)CC1	PLASMA	1C854K1MIJ									∞	ng × h/mL	108		ng/mL	11.1			UNKNOWN	mg	2		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/25165011	Homo sapiens		h	13.1							false
10595	47418		ADULT	24788740	457.996	IPATASERTIB	CC(C)NC[C@@H](C(=O)N1CCN(CC1)C2=C3[C@H](C)C[C@@H](O)C3=NC=N2)C4=CC=C(Cl)C=C4	CC(C)NC[C@@H](C(=O)N1CCN(CC1)C2=C3[C@H](C)C[C@@H](O)C3=NC=N2)C4=CC=C(Cl)C=C4	PLASMA	524Y3IB4HQ							24		t	ng × h/mL	5930		ng/mL	953			MAX TOLERATED	mg	600		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/31227862	Homo sapiens		h	21.5							false
10596	47418		ADULT	24788740	457.996	IPATASERTIB	CC(C)NC[C@@H](C(=O)N1CCN(CC1)C2=C3[C@H](C)C[C@@H](O)C3=NC=N2)C4=CC=C(Cl)C=C4	CC(C)NC[C@@H](C(=O)N1CCN(CC1)C2=C3[C@H](C)C[C@@H](O)C3=NC=N2)C4=CC=C(Cl)C=C4	PLASMA	524Y3IB4HQ							24		t	ng × h/mL	6510		ng/mL	973			MAX TOLERATED	mg	600		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/31227862	Homo sapiens		h	8.06							false
10597	47448		CHILD	135742018	428.4	AZILSARTAN Metabolite M-II	AZILSARTAN Metabolite M-II	C1=CC=C(C(=C1)C2=CC=C(C=C2)CN3C4=C(C=CC=C4NC3=O)C(=O)O)C5=NOC(=O)N5	PLASMA								24		t	ng × h/mL	1986.5		ng/mL	227.7				mg	5		SINGLE	FED						UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02451150	Homo sapiens										false
10598	47448		CHILD	9825285|135415867	456.4501	AZILSARTAN	AZILSARTAN	CCOC1=NC2=C(N1CC3=CC=C(C=C3)C4=C(C=CC=C4)C5=NOC(=O)N5)C(=CC=C2)C(O)=O	PLASMA	F9NUX55P23							24		t	ng × h/mL	6350.3		ng/mL	888.3				mg	5		SINGLE	FED						UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02451150	Homo sapiens										false
10599	47448		CHILD	101102054	414.5	AZILSARTAN Metabolite M-I	AZILSARTAN Metabolite M-I	CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(N)=N	PLASMA								24		t	ng × h/mL	1592.7		ng/mL	191.3				mg	5		SINGLE	FED						UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02451150	Homo sapiens										false
10600	47448		CHILD	101102054	414.5	AZILSARTAN Metabolite M-I	AZILSARTAN Metabolite M-I	CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(N)=N	PLASMA								24		t	ng × h/mL	1420.5		ng/mL	141.3				mg	10		SINGLE	FED						UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02451150	Homo sapiens										false
10601	47448		CHILD	135742018	428.4	AZILSARTAN Metabolite M-II	AZILSARTAN Metabolite M-II	C1=CC=C(C(=C1)C2=CC=C(C=C2)CN3C4=C(C=CC=C4NC3=O)C(=O)O)C5=NOC(=O)N5	PLASMA								24		t	ng × h/mL	3526		ng/mL	179.3				mg	10		SINGLE	FED						UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02451150	Homo sapiens										false
10602	47448		CHILD	9825285|135415867	456.4501	AZILSARTAN	AZILSARTAN	CCOC1=NC2=C(N1CC3=CC=C(C=C3)C4=C(C=CC=C4)C5=NOC(=O)N5)C(=CC=C2)C(O)=O	PLASMA	F9NUX55P23							24		t	ng × h/mL	6871.7		ng/mL	831.3				mg	10		SINGLE	FED						UNHEALTHY	Oral		EXPERIMENT	https://clinicaltrials.gov/ct2/show/NCT02451150	Homo sapiens										false
10603	47448		ADULT	135415867	456.4	Azilsartan		CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NOC(=O)N5)C(=O)O	PLASMA				Chlorthalidone	Chlorthalidone					∞	ng × h/mL	46688.2		ng/mL	5355.71			RECOMMENDED	mg	80		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27514506/	Homo sapiens		h	12.1							true
10604	47448		UNKNOWN	135415867	456.4	Azilsartan	CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NOC(=O)N5)C(=O)O	CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NOC(=O)N5)C(=O)O	PLASMA																		UNKNOWN	mg	80		UNKNOWN	UNKNOWN		day	1	Azilsartan is highly bound to human plasma proteins (>99%), mainly serum albumin	1	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/200796s012lbl.pdf	Homo sapiens										false
10605	47453		ADULT	667528	287.3535	ETODOLAC, (R)-	ETODOLAC, (R)-	CCC1=C2NC3=C(CCO[C@]3(CC)CC(O)=O)C2=CC=C1	PLASMA	Y1RAH31T6K									?	μg × h/mL	768.7		μg/mL	106.4			UNKNOWN	mg	2400		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18094935	Homo sapiens		h	4.94				3	ETODOLAC, (R)-		false
10606	47453		ADULT	667528	287.3535	ETODOLAC, (R)-	ETODOLAC, (R)-	CCC1=C2NC3=C(CCO[C@]3(CC)CC(O)=O)C2=CC=C1	PLASMA	Y1RAH31T6K									?	μg × h/mL	543.3		μg/mL	85.1			MAX TOLERATED	mg	1200		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18094935	Homo sapiens		h	5.76				5	ETODOLAC, (R)-		false
10607	47480		ADULT	11653580	370.3378	[NO STEREO] TEDIZOLID	CN1N=C(N=N1)C2=NC=C(C=C2)C3=C(C=C(C=C3)N4CC(OC4=O)CO)F	CN1N=NC(=N1)C2=NC=C(C=C2)C3=C(F)C=C(C=C3)N4CC(CO)OC4=O	PLASMA	[NO STEREO] 97HLQ82NGL							24		t	μg × h/mL	25.6		μg/mL	2.2			RECOMMENDED	mg	200		STEADY-STATE	UNKNOWN		day	1		20	UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205435s000lbl.pdf	Homo sapiens		h	12							false
10608	47480		ADULT	11653580	370.3378	[NO STEREO] TEDIZOLID	CN1N=C(N=N1)C2=NC=C(C=C2)C3=C(C=C(C=C3)N4CC(OC4=O)CO)F	CN1N=NC(=N1)C2=NC=C(C=C2)C3=C(F)C=C(C=C3)N4CC(CO)OC4=O	PLASMA	[NO STEREO] 97HLQ82NGL							24		t	μg × h/mL	29.2		μg/mL	3			RECOMMENDED	mg	200		STEADY-STATE	UNKNOWN		day	1		20	UNHEALTHY	Intravenous	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205435s000lbl.pdf	Homo sapiens		h	12							false
10609	47480		ADULT	11653580	370.3378	[NO STEREO] TEDIZOLID	CN1N=C(N=N1)C2=NC=C(C=C2)C3=C(C=C(C=C3)N4CC(OC4=O)CO)F	CN1N=NC(=N1)C2=NC=C(C=C2)C3=C(F)C=C(C=C3)N4CC(CO)OC4=O	PLASMA	[NO STEREO] 97HLQ82NGL							24		t	μg × h/mL	23.8		μg/mL	2			RECOMMENDED	mg	200		SINGLE	UNKNOWN					20	UNHEALTHY	Oral	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205435s000lbl.pdf	Homo sapiens		h	12							false
10610	47480		ADULT	11653580	370.3378	[NO STEREO] TEDIZOLID	CN1N=C(N=N1)C2=NC=C(C=C2)C3=C(C=C(C=C3)N4CC(OC4=O)CO)F	CN1N=NC(=N1)C2=NC=C(C=C2)C3=C(F)C=C(C=C3)N4CC(CO)OC4=O	PLASMA	[NO STEREO] 97HLQ82NGL							24		t	μg × h/mL	26.6		μg/mL	2.3			RECOMMENDED	mg	200		SINGLE	UNKNOWN					20	UNHEALTHY	Intravenous	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205435s000lbl.pdf	Homo sapiens		h	12							false
10611	47493		ADULT	46224413	489.6441	NIROGACESTAT	NIROGACESTAT	CCC[C@H](N[C@H]1CCC2=C(C1)C(F)=CC(F)=C2)C(=O)NC3=CN(C=N3)C(C)(C)CNCC(C)(C)C	PLASMA	QZ62892OFJ													ng/mL	963			MAX TOLERATED	mg	100		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27906684	Homo sapiens								NIROGACESTAT		false
10612	47498		ADULT	44247568	337.4155	E-52862	E-52862	CC1=CC(OCCN2CCOCC2)=NN1C3=CC4=C(C=CC=C4)C=C3	PLASMA	ZW18DSD1H4									∞	ng × h/mL	155911		ng/mL	5580.1			UNKNOWN	mg	800		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26291080	Homo sapiens		h	41.5				31	E-52862		false
10613	47518			9819382	341.487	DESFESOTERODINE	Desfesoterodine	CC(C)N(CC[C@H](C1=CC=CC=C1)C2=C(O)C=CC(CO)=C2)C(C)C	PLASMA	YU871O78GR																										Plasma protein binding of the active metabolite is low (approximately 50%).	50				DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022030s019lbl.pdf#page=16	Homo sapiens										false
10614	47518		ADULT	9819382	341.487	DESFESOTERODINE	5-hydroxymethyltolterodine	CC(C)N(CC[C@H](C1=CC=CC=C1)C2=C(O)C=CC(CO)=C2)C(C)C	PLASMA	YU871O78GR									?	ng × h/mL	24.461		ng/mL	2.464			DEFINED DAILY	mg	4		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022030s000_ClinPharmR.pdf#page=23	Homo sapiens		h	9.671		Healthy Japanese males		8			false
10615	47518		ADULT	9819382	341.487	DESFESOTERODINE	Desfesoterodine	CC(C)N(CC[C@H](C1=CC=CC=C1)C2=C(O)C=CC(CO)=C2)C(C)C	PLASMA	YU871O78GR									?	ng × h/mL	53.715		ng/mL	5.519			MAX DAILY	mg	8		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022030s000_ClinPharmR.pdf#page=23	Homo sapiens		h	9.37		Healthy Japanese males		8			false
10616	47518		ADULT	9819382	341.487	DESFESOTERODINE	Desfesoterodine	CC(C)N(CC[C@H](C1=CC=CC=C1)C2=C(O)C=CC(CO)=C2)C(C)C	PLASMA	YU871O78GR									?	ng × h/mL	111.091		ng/mL	10.863			HIGHEST STUDIED	mg	16		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022030s000_ClinPharmR.pdf#page=23	Homo sapiens		h	7.58		Healthy Japanese males		8			false
10617	47518		ADULT	9819382	341.487	DESFESOTERODINE	Desfesoterodine	CC(C)N(CC[C@H](C1=CC=CC=C1)C2=C(O)C=CC(CO)=C2)C(C)C	PLASMA	YU871O78GR							24		t	ng × h/mL	32.8		ng/mL	3.59			MAX DAILY	mg	8		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022030s000_ClinPharmR.pdf#page=25	Homo sapiens		h	4.86		Healthy Japanese males		8			false
10618	47518		ADULT	9819382	341.487	DESFESOTERODINE	Desfesoterodine	CC(C)N(CC[C@H](C1=CC=CC=C1)C2=C(O)C=CC(CO)=C2)C(C)C	PLASMA	YU871O78GR							24		t	ng × h/mL	19.9		ng/mL	1.96			DEFINED DAILY	mg	4		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022030s000_ClinPharmR.pdf#page=25	Homo sapiens		h	8.13	Day 1	Healthy Japanese males		8			false
10619	47518		ADULT	9819382	341.487	DESFESOTERODINE	Desfesoterodine	CC(C)N(CC[C@H](C1=CC=CC=C1)C2=C(O)C=CC(CO)=C2)C(C)C	PLASMA	YU871O78GR							244		t	ng × h/mL	26.9		ng/mL	2.89			MAX DAILY	mg	8		SINGLE	FASTED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022030s000_ClinPharmR.pdf#page=25	Homo sapiens		h	6.86	Day 1			8			false
10620	47518		ADULT	9819382	341.487	DESFESOTERODINE	Desfesoterodine	CC(C)N(CC[C@H](C1=CC=CC=C1)C2=C(O)C=CC(CO)=C2)C(C)C	PLASMA	YU871O78GR							24		t	ng × h/mL	23.4		ng/mL	2.32			DEFINED DAILY	mg	4		MULTIPLE	FASTED		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022030s000_ClinPharmR.pdf#page=25	Homo sapiens		h	5.13	Day 5	Healthy Japanese males		8			false
10621	47534		ADULT	70693519	487.954	DACOMITINIB	DACOMITINIB	O.COC1=C(NC(=O)\\C=C\\CN2CCCCC2)C=C3C(NC4=CC(Cl)=C(F)C=C4)=NC=NC3=C1	PLASMA	5092U85G58							24		t	ng × h/mL	2213		ng/mL	108			RECOMMENDED	mg	45		STEADY-STATE	UNKNOWN		day	1	In vitro binding of dacomitinib to human plasma proteins is approximately 98% and is independent of drug concentrations from 250 ng/mL to 1000 ng/mL.	2	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf	Homo sapiens		h	70							false
10622	47534		ADULT	70693519	487.954	DACOMITINIB	DACOMITINIB	O.COC1=C(NC(=O)\\C=C\\CN2CCCCC2)C=C3C(NC4=CC(Cl)=C(F)C=C4)=NC=NC3=C1	PLASMA	5092U85G58							24		t	ng × h/mL	1720		ng/mL	105			MAX DAILY	mg	60		STEADY-STATE	UNKNOWN		day	1	The protein binding of dacomitinib in human plasma averaged 98% at both in vitro concentrations of 250 ng/mL and 1000 ng/mL.	2	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211288Orig1s000MultidisciplineR.pdf	Homo sapiens										false
10623	47535		ADULT		525.5569	ENMD-2076	ENMD-2076	O[C@@H]([C@@H](O)C(O)=O)C(O)=O.CN1CCN(CC1)C2=CC(NC3=NNC(C)=C3)=NC(\\C=C\\C4=CC=CC=C4)=N2	PLASMA	KXQ762CQTH									∞	μg × h/mL	14.66		ng/mL	233			UNKNOWN	mg/m²	80		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21131552/	Homo sapiens		h	51				3	ENMD-2076		false
10624	47535		ADULT		525.5569	ENMD-2076	ENMD-2076	O[C@@H]([C@@H](O)C(O)=O)C(O)=O.CN1CCN(CC1)C2=CC(NC3=NNC(C)=C3)=NC(\\C=C\\C4=CC=CC=C4)=N2	PLASMA	KXQ762CQTH									∞	μg × h/mL	16.74		ng/mL	314			UNKNOWN	mg/m²	120		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21131552/	Homo sapiens		h	44.9				3	ENMD-2076		false
10625	47535		ADULT		525.5569	ENMD-2076	ENMD-2076	O[C@@H]([C@@H](O)C(O)=O)C(O)=O.CN1CCN(CC1)C2=CC(NC3=NNC(C)=C3)=NC(\\C=C\\C4=CC=CC=C4)=N2	PLASMA	KXQ762CQTH									∞	μg × h/mL	34.6		ng/mL	558			MAX TOLERATED	mg/m²	160		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21131552/	Homo sapiens		h	46.1				5	ENMD-2076		false
10626	47535		ADULT		525.5569	ENMD-2076	ENMD-2076	O[C@@H]([C@@H](O)C(O)=O)C(O)=O.CN1CCN(CC1)C2=CC(NC3=NNC(C)=C3)=NC(\\C=C\\C4=CC=CC=C4)=N2	PLASMA	KXQ762CQTH									∞	μg × h/mL	15.26		ng/mL	218			UNKNOWN	mg/m²	60		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21131552/	Homo sapiens		h	53.1				6	ENMD-2076		false
10627	47535		ADULT		525.5569	ENMD-2076	ENMD-2076	O[C@@H]([C@@H](O)C(O)=O)C(O)=O.CN1CCN(CC1)C2=CC(NC3=NNC(C)=C3)=NC(\\C=C\\C4=CC=CC=C4)=N2	PLASMA	KXQ762CQTH									∞	μg × h/mL	34.5		ng/mL	557			HIGHEST STUDIED	mg/m²	200		MULTIPLE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21131552/	Homo sapiens		h	47.6				4	ENMD-2076		false
10628	47540		ADULT	10341154	404.3178	VX-702	VX-702	NC(=O)N(C1=NC(=C(C=C1)C(N)=O)C2=C(F)C=C(F)C=C2)C3=C(F)C=CC=C3F	PLASMA	527E7SK68P							24		t	ng × h/mL	2188.7		ng/mL	130			UNKNOWN	mg	5		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/19404957	Homo sapiens							103			false
10629	47540		ADULT	10341154	404.3178	VX-702	VX-702	NC(=O)N(C1=NC(=C(C=C1)C(N)=O)C2=C(F)C=C(F)C=C2)C3=C(F)C=CC=C3F	PLASMA	527E7SK68P							24		t	ng × h/mL	4022.6		ng/mL	234.5			UNKNOWN	mg	10		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/19404957	Homo sapiens							104			false
10630	47560		ADULT	10114	470.6838	ENOXOLONE	CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]3(C)[C@@H]2C(=O)C=C4[C@@H]5C[C@](C)(CC[C@]5(C)CC[C@@]34C)C(O)=O	CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]3(C)[C@@H]2C(=O)C=C4[C@@H]5C[C@](C)(CC[C@]5(C)CC[C@@]34C)C(O)=O	PLASMA	P540XA09DR									∞	ng × h/mL	1396.97		ng/mL	103.89			UNKNOWN	mg	150		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/18452416	Homo sapiens		h	9.46							false
10631	47561		ADULT	5511	245.3599	TOLPERISONE	Tolperisone	CC(CN1CCCCC1)C(=O)C2=CC=C(C)C=C2	PLASMA	F5EOM0LD8E									?	ng × h/mL	516		ng/mL	297.6			UNKNOWN	mg	450		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16681042/	Homo sapiens		h	1.14				8	Tolperisone HCl		false
10632	47561		ADULT	5511	245.3599	TOLPERISONE	Tolperisone	CC(CN1CCCCC1)C(=O)C2=CC=C(C)C=C2	PLASMA	F5EOM0LD8E							12		t	ng × h/mL	111.2		ng/mL	64.1			UNKNOWN	mg	150		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/23217307/	Homo sapiens		h	3.3				14	Mydocalm (tolperisone hydrochloride)		false
10633	47561		ADULT	5511	245.3599	TOLPERISONE	Tolperisone	CC(CN1CCCCC1)C(=O)C2=CC=C(C)C=C2	PLASMA	F5EOM0LD8E									∞	ng × h/mL	151.92		ng/mL	90.88			UNKNOWN	mg	150		SINGLE	FASTED				Median values: Cmax=64.71 ng/mL, AUCinf=85.69 ng x h/mL, t1/2=2.32 h		HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25953735/	Homo sapiens		h	2.7		Whole study group		28	Mydocalm Forte		false
10634	47561		ADULT	5511	245.3599	TOLPERISONE	Tolperisone	CC(CN1CCCCC1)C(=O)C2=CC=C(C)C=C2	PLASMA	F5EOM0LD8E									∞	ng × h/mL	682.03		ng/mL	229.47			UNKNOWN	mg	150		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25953735/	Homo sapiens		h	2.66		CYP2D6 Poor Metabolizer (PM), CYP2D6*4/*4		1	Mydocalm Forte		false
10635	47561		ADULT	5511	245.3599	TOLPERISONE	Tolperisone	CC(CN1CCCCC1)C(=O)C2=CC=C(C)C=C2	PLASMA	F5EOM0LD8E									∞	ng × h/mL	81.09		ng/mL	54			UNKNOWN	mg	150		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25953735/	Homo sapiens		h	2.91		CYP2D6 Extensive Metabolizer (EM), CYP2D6*1/*1		15	Mydocalm Forte		false
10636	47561		ADULT	5511	245.3599	TOLPERISONE	Tolperisone	CC(CN1CCCCC1)C(=O)C2=CC=C(C)C=C2	PLASMA	F5EOM0LD8E									∞	ng × h/mL	170.2		ng/mL	98.85			UNKNOWN	mg	150		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25953735/	Homo sapiens		h	2.33		CYP2D6 Intermediate Metabolizer (IM), CYP2D6*1/*4		9	Mydocalm Forte		false
10637	47561		ADULT	5511	245.3599	TOLPERISONE	Tolperisone	CC(CN1CCCCC1)C(=O)C2=CC=C(C)C=C2	PLASMA	F5EOM0LD8E									∞	ng × h/mL	274.6		ng/mL	205.2			UNKNOWN	mg	150		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25953735/	Homo sapiens		h	2.82		CYP2D6 Intermediate Metabolizer (IM), CYP2D6*1/*5		3	Mydocalm Forte		false
10638	47561		ADULT	5511	245.3599	TOLPERISONE	Tolperisone	CC(CN1CCCCC1)C(=O)C2=CC=C(C)C=C2	PLASMA	F5EOM0LD8E									∞	ng × h/mL	101.11		ng/mL	70.89			UNKNOWN	mg	150		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25953735/	Homo sapiens		h	2.84		CYP2C19 Extensive Metabolizer (EM), CYP2C19*1/*1		18	Mydocalm Forte		false
10639	47561		ADULT	5511	245.3599	TOLPERISONE	Tolperisone	CC(CN1CCCCC1)C(=O)C2=CC=C(C)C=C2	PLASMA	F5EOM0LD8E									∞	ng × h/mL	194.63		ng/mL	115.44			UNKNOWN	mg	150		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25953735/	Homo sapiens		h	2.44		CYP2C19 Extensive Metabolizer (EM), CYP2C19*1/*2		9	Mydocalm Forte		false
10640	47593		UNKNOWN	5743	392.4611	DEXAMETHASONE	Dexamethasone	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO	PLASMA	7S5I7G3JQL																	UNKNOWN				UNKNOWN	UNKNOWN					32	UNKNOWN	Intravenous	UNKNOWN	REVIEW	https://pubmed.ncbi.nlm.nih.gov/30115648/	Homo sapiens								Dexamethasone		false
10641	47594		ADULT	6279	386.5244	MEDROXYPROGESTERONE ACETATE	MEDROXYPROGESTERONE ACETATE	C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]4(C)CCC(=O)C=C14	PLASMA	C2QI4IOI2G									∞	ng × h/mL	6.01		ng/mL	0.71			RECOMMENDED	mg	10		STEADY-STATE	FASTED		day	1	MPA is approximately 90% protein bound, primarily to albumin	10	HEALTHY	Oral	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/011839s071lbl.pdf	Homo sapiens		h	16.6							false
10642	47595			5755	360.444	PREDNISOLONE	Prednisolone	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO	PLASMA	9PHQ9Y1OLM																										Prednisolone is eliminated from the plasma with a half-life of 2-4 hours; however, the biological half-life is 18-36 hours.					OTHER	https://www.pdr.net/drug-summary/Omnipred-prednisolone-acetate-1102.1749#15	Homo sapiens		h	4							false
10643	47595			5755	360.444	PREDNISOLONE	Prednisolone	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO	PLASMA	9PHQ9Y1OLM																										The circulating drug is 70-90% bound to plasma proteins.	10				OTHER	https://www.pdr.net/drug-summary/Omnipred-prednisolone-acetate-1102.1749#15	Homo sapiens										false
10644	47595		UNKNOWN	5755	360.444	PREDNISOLONE	Prednisolone	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO	BLOOD	9PHQ9Y1OLM													ng/mL	14.43			UNKNOWN	mg	40		SINGLE	UNKNOWN						UNKNOWN	Intramuscular	UNKNOWN	DRUG LABEL	https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/672212_2456402C1044_3_03#page=4	Homo sapiens										false
10645	47647		ADULT	46898058	592.1	GSK-923295	GSK-923295		PLASMA	072702W9QD									∞	ng × h/mL	14700		ng/mL	7120			MAX TOLERATED	mg/m²	190		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22020315/	Homo sapiens		h	8.16	1-h intravenous administration of GSK923295, once weekly for three consecutive weeks, repeated every 4 weeks			6	GSK923295		false
10646	47647		ADULT	46898058	592.1	GSK-923295	GSK-923295		PLASMA	072702W9QD									∞	ng × h/mL	541		ng/mL	305			UNKNOWN	mg/m²	10		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22020315/	Homo sapiens		h	6.04	1-h intravenous administration of GSK923295, once weekly for three consecutive weeks, repeated every 4 weeks			2	GSK923295		false
10647	47647		ADULT	46898058	592.1	GSK-923295	GSK-923295		PLASMA	072702W9QD									∞	ng × h/mL	4700		ng/mL	2230			UNKNOWN	mg/m²	80		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22020315/	Homo sapiens		h	9.23	1-h intravenous administration of GSK923295, once weekly for three consecutive weeks, repeated every 4 weeks			6	GSK923295		false
10648	47647		ADULT	46898058	592.1	GSK-923295	GSK-923295		PLASMA	072702W9QD									∞	ng × h/mL	4110		ng/mL	2020			UNKNOWN	mg/m²	40		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22020315/	Homo sapiens		h	10.7	1-h intravenous administration of GSK923295, once weekly for three consecutive weeks, repeated every 4 weeks			2	GSK923295		false
10649	47647		ADULT	46898058	592.1	GSK-923295	GSK-923295		PLASMA	072702W9QD									∞	ng × h/mL	14600		ng/mL	7340			UNKNOWN	mg/m²	140		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22020315/	Homo sapiens		h	10.3	1-h intravenous administration of GSK923295, once weekly for three consecutive weeks, repeated every 4 weeks			5	GSK923295		false
10650	47647		ADULT	46898058	592.1	GSK-923295	GSK-923295		PLASMA	072702W9QD									∞	ng × h/mL	19600		ng/mL	8240			HIGHEST STUDIED	mg/m²	250		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22020315/	Homo sapiens		h	11.6	1-h intravenous administration of GSK923295, once weekly for three consecutive weeks, repeated every 4 weeks			7	GSK923295		false
10651	47662		ADULT	68210102	526.6812	GSK-2816126		CC[C@H](C)n1cc(C)c2c(cc(cc12)c3ccc(nc3)N4CCNCC4)C(=O)NCC5=C(C)C=C(C)NC5=O	PLASMA	W4OGW9QZ97													μg/mL	1.4			UNKNOWN	mg	200		MULTIPLE	UNKNOWN		week	2			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31471312/	Homo sapiens				Day 1	Patients with solid tumors or B-cell lymphomas with no available standard treatment regimen		1			false
10652	47662		ADULT	68210102	526.6812	GSK-2816126		CC[C@H](C)n1cc(C)c2c(cc(cc12)c3ccc(nc3)N4CCNCC4)C(=O)NCC5=C(C)C=C(C)NC5=O	PLASMA	W4OGW9QZ97													μg/mL	1.5			UNKNOWN	mg	200		MULTIPLE	UNKNOWN		week	2			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31471312/	Homo sapiens				Day 15	Patients with solid tumors or B-cell lymphomas with no available standard treatment regimen		1			false
10653	47662		ADULT	68210102	526.6812	GSK-2816126		CC[C@H](C)n1cc(C)c2c(cc(cc12)c3ccc(nc3)N4CCNCC4)C(=O)NCC5=C(C)C=C(C)NC5=O	PLASMA	W4OGW9QZ97									∞	μg × h/mL	13.2		μg/mL	4			UNKNOWN	mg	400		MULTIPLE	UNKNOWN		week	2			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31471312/	Homo sapiens		h	49.1	Day 1	Patients with solid tumors or B-cell lymphomas with no available standard treatment regimen		1			false
10654	47662		ADULT	68210102	526.6812	GSK-2816126		CC[C@H](C)n1cc(C)c2c(cc(cc12)c3ccc(nc3)N4CCNCC4)C(=O)NCC5=C(C)C=C(C)NC5=O	PLASMA	W4OGW9QZ97									∞	μg × h/mL	14.8		μg/mL	3.5			UNKNOWN	mg	400		MULTIPLE	UNKNOWN		week	2			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31471312/	Homo sapiens		h	39.7	Day 15	Patients with solid tumors or B-cell lymphomas with no available standard treatment regimen		1			false
10655	47662		ADULT	68210102	526.6812	GSK-2816126		CC[C@H](C)n1cc(C)c2c(cc(cc12)c3ccc(nc3)N4CCNCC4)C(=O)NCC5=C(C)C=C(C)NC5=O	PLASMA	W4OGW9QZ97									∞	μg × h/mL	26.4		μg/mL	7.31			UNKNOWN	mg	800		MULTIPLE	UNKNOWN		week	2			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31471312/	Homo sapiens		h	26.5	Day 1	Patients with solid tumors or B-cell lymphomas with no available standard treatment regimen		3			false
10656	47662		ADULT	68210102	526.6812	GSK-2816126		CC[C@H](C)n1cc(C)c2c(cc(cc12)c3ccc(nc3)N4CCNCC4)C(=O)NCC5=C(C)C=C(C)NC5=O	PLASMA	W4OGW9QZ97									∞	μg × h/mL	33.3		μg/mL	7.46			UNKNOWN	mg	800		MULTIPLE	UNKNOWN		week	2	n=2 for AUC and t1/2		UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31471312/	Homo sapiens		h	27.35	Day 15	Patients with solid tumors or B-cell lymphomas with no available standard treatment regimen		3			false
10657	47662		ADULT	68210102	526.6812	GSK-2816126		CC[C@H](C)n1cc(C)c2c(cc(cc12)c3ccc(nc3)N4CCNCC4)C(=O)NCC5=C(C)C=C(C)NC5=O	PLASMA	W4OGW9QZ97									∞	μg × h/mL	60.9		μg/mL	10.9			UNKNOWN	mg	1200		MULTIPLE	UNKNOWN		week	2	n=1 for AUC and t1/2		UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31471312/	Homo sapiens		h	14.1	Day 1	Patients with solid tumors or B-cell lymphomas with no available standard treatment regimen		4			false
10658	47662		ADULT	68210102	526.6812	GSK-2816126		CC[C@H](C)n1cc(C)c2c(cc(cc12)c3ccc(nc3)N4CCNCC4)C(=O)NCC5=C(C)C=C(C)NC5=O	PLASMA	W4OGW9QZ97									∞	μg × h/mL	1.33		μg/mL	0.42			UNKNOWN	mg	50		MULTIPLE	UNKNOWN		week	2			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31471312/	Homo sapiens		h	7.62	Day 1	Patients with solid tumors or B-cell lymphomas with no available standard treatment regimen		2			false
10659	47662		ADULT	68210102	526.6812	GSK-2816126		CC[C@H](C)n1cc(C)c2c(cc(cc12)c3ccc(nc3)N4CCNCC4)C(=O)NCC5=C(C)C=C(C)NC5=O	PLASMA	W4OGW9QZ97									∞	μg × h/mL	60.2		μg/mL	11.6			UNKNOWN	mg	1200		MULTIPLE	UNKNOWN		week	2	n=1 for AUC		UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31471312/	Homo sapiens		h	27.3	Day 15	Patients with solid tumors or B-cell lymphomas with no available standard treatment regimen		4			false
10660	47662		ADULT	68210102	526.6812	GSK-2816126		CC[C@H](C)n1cc(C)c2c(cc(cc12)c3ccc(nc3)N4CCNCC4)C(=O)NCC5=C(C)C=C(C)NC5=O	PLASMA	W4OGW9QZ97									∞	μg × h/mL	51.2		μg/mL	13			UNKNOWN	mg	1800		MULTIPLE	UNKNOWN		week	2			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31471312/	Homo sapiens		h	31.8	Day 1	Patients with solid tumors or B-cell lymphomas with no available standard treatment regimen		10			false
10661	47662		ADULT	68210102	526.6812	GSK-2816126		CC[C@H](C)n1cc(C)c2c(cc(cc12)c3ccc(nc3)N4CCNCC4)C(=O)NCC5=C(C)C=C(C)NC5=O	PLASMA	W4OGW9QZ97									∞	μg × h/mL	81.7		μg/mL	14.2			UNKNOWN	mg	1800		MULTIPLE	UNKNOWN		week	2			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31471312/	Homo sapiens		h	29.88	Day 15	Patients with solid tumors or B-cell lymphomas with no available standard treatment regimen		9			false
10662	47662		ADULT	68210102	526.6812	GSK-2816126		CC[C@H](C)n1cc(C)c2c(cc(cc12)c3ccc(nc3)N4CCNCC4)C(=O)NCC5=C(C)C=C(C)NC5=O	PLASMA	W4OGW9QZ97									∞	μg × h/mL	102		μg/mL	22.3			UNKNOWN	mg	2400		MULTIPLE	UNKNOWN		week	2	n=10 for AUC and t1/2		UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31471312/	Homo sapiens		h	33.7	Day 1	Patients with solid tumors or B-cell lymphomas with no available standard treatment regimen		12			false
10663	47662		ADULT	68210102	526.6812	GSK-2816126		CC[C@H](C)n1cc(C)c2c(cc(cc12)c3ccc(nc3)N4CCNCC4)C(=O)NCC5=C(C)C=C(C)NC5=O	PLASMA	W4OGW9QZ97													μg/mL	1.1			UNKNOWN	mg	100		MULTIPLE	UNKNOWN		week	2			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31471312/	Homo sapiens				Day 1	Patients with solid tumors or B-cell lymphomas with no available standard treatment regimen		1			false
10664	47662		ADULT	68210102	526.6812	GSK-2816126		CC[C@H](C)n1cc(C)c2c(cc(cc12)c3ccc(nc3)N4CCNCC4)C(=O)NCC5=C(C)C=C(C)NC5=O	PLASMA	W4OGW9QZ97									∞	μg × h/mL	123		μg/mL	21.6			UNKNOWN	mg	2400		MULTIPLE	UNKNOWN		week	2			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31471312/	Homo sapiens		h	22.75	Day 15	Patients with solid tumors or B-cell lymphomas with no available standard treatment regimen		11			false
10665	47662		ADULT	68210102	526.6812	GSK-2816126		CC[C@H](C)n1cc(C)c2c(cc(cc12)c3ccc(nc3)N4CCNCC4)C(=O)NCC5=C(C)C=C(C)NC5=O	PLASMA	W4OGW9QZ97									∞	μg × h/mL	103		μg/mL	23.8			UNKNOWN	mg	3000		MULTIPLE	UNKNOWN		week	2			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31471312/	Homo sapiens		h	22.5	Day 1	Patients with solid tumors or B-cell lymphomas with no available standard treatment regimen		7			false
10666	47662		ADULT	68210102	526.6812	GSK-2816126		CC[C@H](C)n1cc(C)c2c(cc(cc12)c3ccc(nc3)N4CCNCC4)C(=O)NCC5=C(C)C=C(C)NC5=O	PLASMA	W4OGW9QZ97									∞	μg × h/mL	183		μg/mL	30.5			UNKNOWN	mg	3000		MULTIPLE	UNKNOWN		week	2			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31471312/	Homo sapiens		h	27.25	Day 15	Patients with solid tumors or B-cell lymphomas with no available standard treatment regimen		4			false
10667	47662		ADULT	68210102	526.6812	GSK-2816126		CC[C@H](C)n1cc(C)c2c(cc(cc12)c3ccc(nc3)N4CCNCC4)C(=O)NCC5=C(C)C=C(C)NC5=O	PLASMA	W4OGW9QZ97									∞	μg × h/mL	7		μg/mL	1			UNKNOWN	mg	100		MULTIPLE	UNKNOWN		week	2			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31471312/	Homo sapiens		h	36.8	Day 15	Patients with solid tumors or B-cell lymphomas with no available standard treatment regimen		1			false
10668	47662		ADULT	68210102	526.6812	GSK-2816126		CC[C@H](C)n1cc(C)c2c(cc(cc12)c3ccc(nc3)N4CCNCC4)C(=O)NCC5=C(C)C=C(C)NC5=O	PLASMA	W4OGW9QZ97									∞	μg × h/mL	3.9		μg/mL	0.5			UNKNOWN	mg	50		MULTIPLE	UNKNOWN		week	2			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31471312/	Homo sapiens		h	46.5	Day 15	Patients with solid tumors or B-cell lymphomas with no available standard treatment regimen		1			false
10669	47666		ADULT	46832368	559.807	LY-2608204	LY2608204	O=C(NC1=NC=C(SCCN2CCCC2)S1)[C@@]3(C[C@H]3C4CCCCC4)C5=CC=C(C=C5)S(=O)(=O)C6CC6	PLASMA	5A0L003HEY									?	ng × h/mL	6028.2		ng/mL	342			UNKNOWN	mg	240		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33125674/	Homo sapiens							6	Globalagliatin		false
10670	47666		ADULT	46832368	559.807	LY-2608204	LY2608204	O=C(NC1=NC=C(SCCN2CCCC2)S1)[C@@]3(C[C@H]3C4CCCCC4)C5=CC=C(C=C5)S(=O)(=O)C6CC6	PLASMA	5A0L003HEY									?	ng × h/mL	9218.38		ng/mL	471.5			HIGHEST STUDIED	mg	320		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33125674/	Homo sapiens							6	Globalagliatin		false
10671	47666		ADULT	46832368	559.807	LY-2608204	LY2608204	O=C(NC1=NC=C(SCCN2CCCC2)S1)[C@@]3(C[C@H]3C4CCCCC4)C5=CC=C(C=C5)S(=O)(=O)C6CC6	PLASMA	5A0L003HEY							24		t	ng × h/mL	369.71		ng/mL	29.36			UNKNOWN	mg	80		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33125674/	Homo sapiens							9	Globalagliatin		false
10672	47666		ADULT	46832368	559.807	LY-2608204	LY2608204	O=C(NC1=NC=C(SCCN2CCCC2)S1)[C@@]3(C[C@H]3C4CCCCC4)C5=CC=C(C=C5)S(=O)(=O)C6CC6	PLASMA	5A0L003HEY									?	ng × h/mL	3036.75		ng/mL	183.88			UNKNOWN	mg	160		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33125674/	Homo sapiens							8	Globalagliatin		false
10673	47666		ADULT	46832368	559.807	LY-2608204	LY2608204	O=C(NC1=NC=C(SCCN2CCCC2)S1)[C@@]3(C[C@H]3C4CCCCC4)C5=CC=C(C=C5)S(=O)(=O)C6CC6	PLASMA	5A0L003HEY									?	ng × h/mL	1009.35		ng/mL	69.43			UNKNOWN	mg	80		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33125674/	Homo sapiens							9	Globalagliatin		false
10674	47676		ADULT	24739943	448.9	ALLITINIB	ALLITINIB		PLASMA	CX0M5RO7CY							24		t	ng × h/mL	1150		ng/mL	69.6			UNKNOWN	mg	800		SINGLE	FASTED						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24612546/	Homo sapiens		h	5.56		advanced solid tumors. TID cohort.		13	ALLITINIB		false
10675	47676		ADULT	24739943	448.9	ALLITINIB	ALLITINIB		PLASMA	CX0M5RO7CY							24		t	ng × h/mL	913		ng/mL	43.5			UNKNOWN	mg	800		STEADY-STATE	FASTED		day	3			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24612546/	Homo sapiens		h	4.88	21 days dosing	advanced solid tumors.		13	ALLITINIB		false
10676	47676		ADULT	24739943	448.9	ALLITINIB	ALLITINIB		PLASMA	CX0M5RO7CY							24		t	ng × h/mL	1030		ng/mL	67.3			UNKNOWN	mg	1000		STEADY-STATE	FASTED		day	3			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24612546/	Homo sapiens		h	6.23	21 days dosing	advanced solid tumors.		9	ALLITINIB		false
10677	47676		ADULT	24739943	448.9	ALLITINIB	ALLITINIB		PLASMA	CX0M5RO7CY							24		t	ng × h/mL	1130		ng/mL	47.3			UNKNOWN	mg	1000		SINGLE	FASTED						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24612546/	Homo sapiens		h	4.4		advanced solid tumors. TID cohort.		9	ALLITINIB		false
10678	47676		ADULT	24739943	448.9	ALLITINIB	ALLITINIB		PLASMA	CX0M5RO7CY							24		t	ng × h/mL	2780		ng/mL	61.9			UNKNOWN	mg	1200		SINGLE	FASTED						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24612546/	Homo sapiens		h	5.13		advanced solid tumors. TID cohort.		2	ALLITINIB		false
10679	47676		ADULT	24739943	448.9	ALLITINIB	ALLITINIB		PLASMA	CX0M5RO7CY							24		t	ng × h/mL	1060		ng/mL	73.4			UNKNOWN	mg	1200		STEADY-STATE	FASTED		day	3			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24612546/	Homo sapiens		h	7.57	21 days dosing	advanced solid tumors.		2	ALLITINIB		false
10680	47676		ADULT	24739943	448.9	ALLITINIB	ALLITINIB		PLASMA	CX0M5RO7CY							24		t	ng × h/mL	313		ng/mL	70.7			UNKNOWN	mg	400		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24612546/	Homo sapiens		h	5.74	21 days dosing	advanced solid tumors.		1	ALLITINIB		false
10681	47676		ADULT	24739943	448.9	ALLITINIB	ALLITINIB		PLASMA	CX0M5RO7CY							24		t	ng × h/mL	314		ng/mL	65.1			UNKNOWN	mg	800		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24612546/	Homo sapiens		h	6.87	21 days dosing	advanced solid tumors.		3	ALLITINIB		false
10682	47676		ADULT	24739943	448.9	ALLITINIB	ALLITINIB		PLASMA	CX0M5RO7CY							24		t	ng × h/mL	630		ng/mL	50			UNKNOWN	mg	800		SINGLE	FASTED						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24612546/	Homo sapiens		h	3.67		advanced solid tumors. BID cohort.		3	ALLITINIB		false
10683	47676		ADULT	24739943	448.9	ALLITINIB	ALLITINIB		PLASMA	CX0M5RO7CY							24		t	ng × h/mL	379		ng/mL	24.2			UNKNOWN	mg	600		STEADY-STATE	FASTED		day	2			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24612546/	Homo sapiens		h	4.56	21 days dosing	advanced solid tumors.		3	ALLITINIB		false
10684	47676		ADULT	24739943	448.9	ALLITINIB	ALLITINIB		PLASMA	CX0M5RO7CY									∞	ng × h/mL	331		ng/mL	70.3			UNKNOWN	mg	1000		SINGLE	FASTED						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24612546/	Homo sapiens		h	6.99		advanced solid tumors		12	ALLITINIB		false
10685	47676		ADULT	24739943	448.9	ALLITINIB	ALLITINIB		PLASMA	CX0M5RO7CY							24		t	ng × h/mL	742		ng/mL	48.3			UNKNOWN	mg	800		STEADY-STATE	FASTED		day	2			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24612546/	Homo sapiens		h	3.33	21 days dosing	advanced solid tumors.		3	ALLITINIB		false
10686	47676		ADULT	24739943	448.9	ALLITINIB	ALLITINIB		PLASMA	CX0M5RO7CY							24		t	ng × h/mL	534		ng/mL	61			UNKNOWN	mg	1200		STEADY-STATE	FASTED		day	2			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24612546/	Homo sapiens		h	5.9	21 days dosing	advanced solid tumors.		3	ALLITINIB		false
10687	47676		ADULT	24739943	448.9	ALLITINIB	ALLITINIB		PLASMA	CX0M5RO7CY							24		t	ng × h/mL	924		ng/mL	93.2			UNKNOWN	mg	1000		STEADY-STATE	FASTED		day	2			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24612546/	Homo sapiens		h	5.59	21 days dosing	advanced solid tumors.		5	ALLITINIB		false
10688	47676		ADULT	24739943	448.9	ALLITINIB	ALLITINIB		PLASMA	CX0M5RO7CY									∞	ng × h/mL	814		ng/mL	139			UNKNOWN	mg	1000		SINGLE	HIGH-FAT						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24612546/	Homo sapiens		h	4.19		advanced solid tumors		12	ALLITINIB		false
10689	47676		ADULT	24739943	448.9	ALLITINIB	ALLITINIB		PLASMA	CX0M5RO7CY							24		t	ng × h/mL	696		ng/mL	75			UNKNOWN	mg	1000		SINGLE	FASTED						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24612546/	Homo sapiens		h	4.24		advanced solid tumors. BID cohort.		5	ALLITINIB		false
10690	47676		ADULT	24739943	448.9	ALLITINIB	ALLITINIB		PLASMA	CX0M5RO7CY							24		t	ng × h/mL	116		ng/mL	22.6			UNKNOWN	mg	400		SINGLE	FASTED						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24612546/	Homo sapiens		h	4.66		advanced solid tumors. QD cohort.		1	ALLITINIB		false
10691	47676		ADULT	24739943	448.9	ALLITINIB	ALLITINIB		PLASMA	CX0M5RO7CY							24		t	ng × h/mL	1030		ng/mL	50.9			UNKNOWN	mg	1200		SINGLE	FASTED						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24612546/	Homo sapiens		h	3.66		advanced solid tumors. BID cohort.		3	ALLITINIB		false
10692	47676		ADULT	24739943	448.9	ALLITINIB	ALLITINIB		PLASMA	CX0M5RO7CY							24		t	ng × h/mL	853		ng/mL	59			HIGHEST STUDIED	mg	1500		STEADY-STATE	FASTED		day	2			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24612546/	Homo sapiens		h	3.94	21 days dosing	advanced solid tumors.		5	ALLITINIB		false
10693	47676		ADULT	24739943	448.9	ALLITINIB	ALLITINIB		PLASMA	CX0M5RO7CY							24		t	ng × h/mL	201		ng/mL	67.7			UNKNOWN	mg	800		SINGLE	FASTED						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24612546/	Homo sapiens		h	4.5		advanced solid tumors. QD cohort.		3	ALLITINIB		false
10694	47676		ADULT	24739943	448.9	ALLITINIB	ALLITINIB		PLASMA	CX0M5RO7CY							24		t	ng × h/mL	997		ng/mL	57.1			HIGHEST STUDIED	mg	1500		SINGLE	FASTED						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24612546/	Homo sapiens		h	3.48		advanced solid tumors. BID cohort.		5	ALLITINIB		false
10695	47676		ADULT	24739943	448.9	ALLITINIB	ALLITINIB		PLASMA	CX0M5RO7CY							24		t	ng × h/mL	780		ng/mL	37.7			UNKNOWN	mg	600		STEADY-STATE	FASTED		day	3			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24612546/	Homo sapiens		h	5.38	21 days dosing	advanced solid tumors.		8	ALLITINIB		false
10696	47676		ADULT	24739943	448.9	ALLITINIB	ALLITINIB		PLASMA	CX0M5RO7CY							24		t	ng × h/mL	735		ng/mL	33.8			UNKNOWN	mg	600		SINGLE	FASTED						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24612546/	Homo sapiens		h	4.84		advanced solid tumors. TID cohort.		8	ALLITINIB		false
10697	47676		ADULT	24739943	448.9	ALLITINIB	ALLITINIB		PLASMA	CX0M5RO7CY							24		t	ng × h/mL	350		ng/mL	15.3			UNKNOWN	mg	600		SINGLE	FASTED						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24612546/	Homo sapiens		h	3.58		advanced solid tumors. BID cohort.		3	ALLITINIB		false
10698	47698		ADULT	49867937	553.5	SB743921	SB743921	CC1=CC=C(C=C1)C(=O)N(CCCN)C(C2=C(C(=O)C3=C(O2)C=C(C=C3)Cl)CC4=CC=CC=C4)C(C)C.Cl	PLASMA	2YW6FB68GM							7264		t	ng × h/mL	3776		ng/mL	803			HIGHEST STUDIED	mg/m²	8		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20461380/	Homo sapiens		h	30.3				6	SB743921		false
10699	47698		ADULT	49867937	553.5	SB743921	SB743921	CC1=CC=C(C=C1)C(=O)N(CCCN)C(C2=C(C(=O)C3=C(O2)C=C(C=C3)Cl)CC4=CC=CC=C4)C(C)C.Cl	PLASMA	2YW6FB68GM							5378		t	ng × h/mL	3776		ng/mL	607			UNKNOWN	mg/m²	5		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20461380/	Homo sapiens		h	36.8				6	SB743921		false
10700	47698		ADULT	49867937	553.5	SB743921	SB743921	CC1=CC=C(C=C1)C(=O)N(CCCN)C(C2=C(C(=O)C3=C(O2)C=C(C=C3)Cl)CC4=CC=CC=C4)C(C)C.Cl	PLASMA	2YW6FB68GM							48		t	ng × h/mL	1706		ng/mL	233			UNKNOWN	mg/m²	2		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20461380/	Homo sapiens		h	31.1				2	SB743921		false
10701	47698		ADULT	49867937	553.5	SB743921	SB743921	CC1=CC=C(C=C1)C(=O)N(CCCN)C(C2=C(C(=O)C3=C(O2)C=C(C=C3)Cl)CC4=CC=CC=C4)C(C)C.Cl	PLASMA	2YW6FB68GM							48		t	ng × h/mL	3776		ng/mL	489			MAX TOLERATED	mg/m²	4		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20461380/	Homo sapiens		h	28				26	SB743921		false
10702	47698		ADULT	49867937	553.5	SB743921	SB743921	CC1=CC=C(C=C1)C(=O)N(CCCN)C(C2=C(C(=O)C3=C(O2)C=C(C=C3)Cl)CC4=CC=CC=C4)C(C)C.Cl	PLASMA	2YW6FB68GM							5421		t	ng × h/mL	3776		ng/mL	817			UNKNOWN	mg/m²	6		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/20461380/	Homo sapiens		h	33.7				3	SB743921		false
10703	47978		ADULT	57662985	473.5683	BMS-833923	CC1=C(C=C(C=C1)CNC)NC(=O)C2=CC=C(C=C2)NC3=NC4=CC=CC=C4C(=N3)C5=CC=CC=C5	CNCC1=CC(NC(=O)C2=CC=C(NC3=NC4=CC=CC=C4C(=N3)C5=CC=CC=C5)C=C2)=C(C)C=C1	PLASMA														ng/mL	102			UNKNOWN	mg	120		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://mct.aacrjournals.org/content/8/12_Supplement/A55.short	Homo sapiens		day	7							false
10704	48062		ADULT	9820874	373.4	CP-615,003	CP 615003		PLASMA	F8CYO0R7I1							12		t	ng × h/mL	1052		ng/mL	173			UNKNOWN	mg	100		STEADY-STATE	UNKNOWN		day	2	Ex Vivo Plasma fu 0.233		HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17470526/	Homo sapiens								CP-615,003		false
10705	48062		ADULT	23628192	332.33	CP-900,725	CP-900,725	C1CC2=C(C(=O)C1)C(=CN2)C(=O)NC3=CC(=C(C=C3)OCCO)F	PLASMA								12		t	ng × h/mL	277		ng/mL	34.6			UNKNOWN	mg	100		STEADY-STATE	UNKNOWN		day	2	Ex Vivo Plasma fu 0.148		HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/17470526/	Homo sapiens								CP-615,003		false
10706	48273		ADULT	9809368	627.7	HMR 1031	HMR 1031		PLASMA	RNM7WQO98Y									∞	ng × h/mL	11.18		ng/mL	2.25			UNKNOWN	mg	3		SINGLE	UNKNOWN						HEALTHY	Respiratory	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/14999362/	Homo sapiens		h	2.39	delivered from the Pari LC Star nebulizer			12	HMR 1031		false
10707	48273		ADULT	9809368	627.7	HMR 1031	HMR 1031		PLASMA	RNM7WQO98Y									∞	ng × h/mL	16.43		ng/mL	4.26			UNKNOWN	mg	3		SINGLE	UNKNOWN						HEALTHY	Respiratory	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/14999362/	Homo sapiens		h	2.34				12	HMR 1031		false
10708	48475		ADULT	11644726	270.285	MORINIDAZOLE	Morinidazole	Cc1ncc([N ](=O)[O-])n1CC(O)CN2CCOCC2	PLASMA	TUPWG40JAL									?	μg × h/mL	60.8		μg/mL	10.8			UNKNOWN	mg	500		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24820074/	Homo sapiens		h	5.5							false
10709	48475		ADULT	11644726	270.285	MORINIDAZOLE	Morinidazole	Cc1ncc([N ](=O)[O-])n1CC(O)CN2CCOCC2	PLASMA	TUPWG40JAL									?	μg × h/mL	89.5		μg/mL	11.2			UNKNOWN	mg	500		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24820074/	Homo sapiens		h	7.4		Patients with severe renal impairment					false
10710	48475		ADULT	11644726	270.285	MORINIDAZOLE	Morinidazole	Cc1ncc([N ](=O)[O-])n1CC(O)CN2CCOCC2	PLASMA	TUPWG40JAL																	UNKNOWN	mg	500		SINGLE	UNKNOWN				Fu=72.8% (200ng/mL), 77.9% (2000ng/mL), 76.9% (10000ng/mL); ultrafiltration	72.8	UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/24820074/	Homo sapiens					Patients with severe renal impairment					false
10711	48475		ADULT	11644726	270.285	MORINIDAZOLE	Morinidazole	Cc1ncc([N ](=O)[O-])n1CC(O)CN2CCOCC2	PLASMA	TUPWG40JAL									∞	ng × h/mL	76830.62		ng/mL	12514.09			UNKNOWN	mg	500		SINGLE	FASTED						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32152080/	Homo sapiens		h	5.94				15			false
10712	48567		ADULT	71543365	230.3486	ORY-1001	NC1CCC(CC1)N[C@@H]2C[C@H]2C3=CC=CC=C3	NC1CCC(CC1)N[C@@H]2C[C@H]2C3=CC=CC=C3	PLASMA	G02YXY861Q							24		t	pg × h/mL	181.7		pg/mL	13.1			RECOMMENDED	μg/m²	140		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://ashpublications.org/blood/article/128/22/4060/113698/Safety-Phamacokinetics-PK-Pharmacodynamics-PD-and	Homo sapiens										false
10713	48569		ADULT	10466781	239.34	N-Depropyl-(-)-osu 6162			PLASMA	WA0BU02HD7									∞	μM × h	12.53		μM	1.1			HIGHEST STUDIED	mg	200		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/14973308/	Homo sapiens		h	5.37				6	PNU-96391		false
10714	48569		ADULT	10466781	239.34	N-Depropyl-(-)-osu 6162	PNU-100014		PLASMA	WA0BU02HD7  WA0BU02HD7									∞	μM × h	2.27		μM	0.245			UNKNOWN	mg	30		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/14973308/	Homo sapiens		h	5.89				6	PNU-96391		false
10715	48569		ADULT	10466781	239.34	N-Depropyl-(-)-osu 6162	PNU-100014		PLASMA	WA0BU02HD7									∞	μM × h	6.18		μM	0.543			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/14973308/	Homo sapiens		h	5.32				6	PNU-96391		false
10716	48569		ADULT	10466781	239.34	N-Depropyl-(-)-osu 6162	PNU-100014		PLASMA	WA0BU02HD7									∞	μM × h	0.24		μM	0.0178			UNKNOWN	mg	3		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/14973308/	Homo sapiens		h	7.94				6	PNU-96391		false
10717	48569		ADULT	9795741	281.4	OSU-6162	OSU 6162		PLASMA	0D21EQAQQA									∞	μM × h	14.8		μM	2.19			HIGHEST STUDIED	mg	200		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/14973308/	Homo sapiens		h	3.66				6	PNU-96391		false
10718	48569		ADULT	9795741	281.4	OSU-6162	OSU 6162		PLASMA	0D21EQAQQA									∞	μM × h	6.87		μM	1.2			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/14973308/	Homo sapiens		h	3.39				6	PNU-96391		false
10719	48569		ADULT	9795741	281.4	OSU-6162	PNU-96391		PLASMA	0D21EQAQQA									∞	μM × h	0.223		μM	0.038			UNKNOWN	mg	3		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/14973308/	Homo sapiens		h	3.77				6	PNU-96391		false
10720	48569		ADULT	9795741	281.4	OSU-6162	OSU-6162		PLASMA	0D21EQAQQA									∞	μM × h	1.69		μM	0.372			UNKNOWN	mg	30		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/14973308/	Homo sapiens		h	3.33				6	PNU-96391		false
10721	48571		ADULT	9936746	492	Birabresib	OTX015	CC1=C(SC2=C1C(=NC(C3=NN=C(N32)C)CC(=O)NC4=CC=C(C=C4)O)C5=CC=C(C=C5)Cl)C	PLASMA	X40LKS49S3							24		t	μg × h/L	13921		μg/L	1292			UNKNOWN	mg	160		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/26341814	Homo sapiens		h	5.48				5	OTX015		false
10722	48571		ADULT	9936746	492	Birabresib	OTX015	CC1=C(SC2=C1C(=NC(C3=NN=C(N32)C)CC(=O)NC4=CC=C(C=C4)O)C5=CC=C(C=C5)Cl)C	PLASMA	X40LKS49S3							24		t	μg × h/L	14090		nM	2627			UNKNOWN	mg	160		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27063977	Homo sapiens							5	OTX015		false
10723	48582		ADULT	117779453	610.6	PAK4-IN-1	PAK4-IN-1	C1CN(CCC1(F)F)C(=O)C2=CC=C(C=C2)C3=CC(=C4C(=C3)C=C(O4)CNC(=O)C=CC5=CN=C(C=C5)N)C6=CC=C(C=C6)F	PLASMA	9T56TV18X7									∞	ng × h/mL	53430		ng/mL	1550			UNKNOWN	mg	40		MULTIPLE	UNKNOWN		week	3			UNHEALTHY	Oral	FEMALE / MALE	OTHER	https://www.karyopharm.com/wp-content/uploads/2019/02/KPT-9274-Poster-ESMO-2017-FINAL-1.pdf	Homo sapiens				day 24			7	PAK4-IN-1		false
10724	48582		ADULT	117779453	610.6	PAK4-IN-1	PAK4-IN-1	C1CN(CCC1(F)F)C(=O)C2=CC=C(C=C2)C3=CC(=C4C(=C3)C=C(O4)CNC(=O)C=CC5=CN=C(C=C5)N)C6=CC=C(C=C6)F	PLASMA	9T56TV18X7									∞	ng × h/mL	18709		ng/mL	565			UNKNOWN	mg	40		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	OTHER	https://www.karyopharm.com/wp-content/uploads/2019/02/KPT-9274-Poster-ESMO-2017-FINAL-1.pdf	Homo sapiens							7	PAK4-IN-1		false
10725	48646		ADULT	6918403	330.4	PKI-166	PKI-166		PLASMA	9RIE5HW38P							24		t	ng × h/mL	3555		ng/mL	403			UNKNOWN	mg	400		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16203782/	Homo sapiens		h	7.2	once daily for 2 weeks every 4 weeks			3	PKI166		false
10726	48646		ADULT	6918403	330.4	PKI-166	PKI-166		PLASMA	9RIE5HW38P							24		t	ng × h/mL	13727		ng/mL	1319			MAX TOLERATED	mg	750		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16203782/	Homo sapiens		h	16.1	once daily for 2 weeks every 4 weeks			7	PKI166		false
10727	48646		ADULT	6918403	330.4	PKI-166	PKI-166		PLASMA	9RIE5HW38P							24		t	ng × h/mL	3334		ng/mL	273			UNKNOWN	mg	50		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16203782/	Homo sapiens				once daily for 2 weeks every 4 weeks			8	PKI166		false
10728	48646		ADULT	6918403	330.4	PKI-166	PKI-166		PLASMA	9RIE5HW38P							24		t	ng × h/mL	18853		ng/mL	2159			HIGHEST STUDIED	mg	900		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/16203782/	Homo sapiens		h	16.2	once daily for 2 weeks every 4 weeks			4	PKI166		false
10729	48647			59634741	450.5604	MITAPIVAT		O=C(N1CCN(CC2CC2)CC1)c3ccc(NS(=O)(=O)c4cccc5cccnc45)cc3	PLASMA	2WTV10SIKH																										Human plasma protein binding: 97.7% (0.2, 1.0, and 10 microM)	2.3				OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/216196Orig1s000IntegratedR.pdf#page=165 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/216196Orig1s000IntegratedR.pdf#page=141	Homo sapiens										false
10730	48647		ADULT	59634741	450.5604	MITAPIVAT		O=C(N1CCN(CC2CC2)CC1)c3ccc(NS(=O)(=O)c4cccc5cccnc45)cc3	PLASMA	2WTV10SIKH									?	ng × h/mL	440		ng/mL	131			UNKNOWN	mg	5		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/216196Orig1s000IntegratedR.pdf#page=198	Homo sapiens				popPK	Healthy and Patients					false
10731	48647		ADULT	59634741	450.5604	MITAPIVAT		O=C(N1CCN(CC2CC2)CC1)c3ccc(NS(=O)(=O)c4cccc5cccnc45)cc3	PLASMA	2WTV10SIKH									?	ng × h/mL	1582		ng/mL	499			UNKNOWN	mg	20		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/216196Orig1s000IntegratedR.pdf#page=198	Homo sapiens				popPK	Healthy and Patients					false
10732	48647		ADULT	59634741	450.5604	MITAPIVAT		O=C(N1CCN(CC2CC2)CC1)c3ccc(NS(=O)(=O)c4cccc5cccnc45)cc3	PLASMA	2WTV10SIKH									?	ng × h/mL	3482		ng/mL	1178			UNKNOWN	mg	50		STEADY-STATE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/216196Orig1s000IntegratedR.pdf#page=198	Homo sapiens				popPK	Healthy and Patients					false
10733	48647		ADULT	59634741	450.5604	MITAPIVAT		O=C(N1CCN(CC2CC2)CC1)c3ccc(NS(=O)(=O)c4cccc5cccnc45)cc3	PLASMA	2WTV10SIKH									?	ng × h/mL	304		ng/mL	76			UNKNOWN	mg	5		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/216196Orig1s000IntegratedR.pdf#page=215	Homo sapiens										false
10734	48647		ADULT	59634741	450.5604	MITAPIVAT		O=C(N1CCN(CC2CC2)CC1)c3ccc(NS(=O)(=O)c4cccc5cccnc45)cc3	PLASMA	2WTV10SIKH									?	ng × h/mL	4007		ng/mL	1005			UNKNOWN	mg	50		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/216196Orig1s000IntegratedR.pdf#page=215	Homo sapiens										false
10735	48647		ADULT	59634741	450.5604	MITAPIVAT		O=C(N1CCN(CC2CC2)CC1)c3ccc(NS(=O)(=O)c4cccc5cccnc45)cc3	PLASMA	2WTV10SIKH									?	ng × h/mL	15642		ng/mL	4425			UNKNOWN	mg	200		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/216196Orig1s000IntegratedR.pdf#page=215	Homo sapiens										false
10736	48647		ADULT	59634741	450.5604	MITAPIVAT		O=C(N1CCN(CC2CC2)CC1)c3ccc(NS(=O)(=O)c4cccc5cccnc45)cc3	PLASMA	2WTV10SIKH									?	ng × h/mL	778		ng/mL	248			UNKNOWN	mg	15		MULTIPLE	UNKNOWN		day	2			UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/216196Orig1s000IntegratedR.pdf#page=215	Homo sapiens				Day 1						false
10737	48647		ADULT	59634741	450.5604	MITAPIVAT		O=C(N1CCN(CC2CC2)CC1)c3ccc(NS(=O)(=O)c4cccc5cccnc45)cc3	PLASMA	2WTV10SIKH									?	ng × h/mL	938		ng/mL	255			UNKNOWN	mg	15		MULTIPLE	UNKNOWN		day	2			UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/216196Orig1s000IntegratedR.pdf#page=215	Homo sapiens				Day 14						false
10738	48647		ADULT	59634741	450.5604	MITAPIVAT		O=C(N1CCN(CC2CC2)CC1)c3ccc(NS(=O)(=O)c4cccc5cccnc45)cc3	PLASMA	2WTV10SIKH									?	ng × h/mL	3279		ng/mL	1287			UNKNOWN	mg	60		MULTIPLE	UNKNOWN		day	2			UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/216196Orig1s000IntegratedR.pdf#page=215	Homo sapiens				Day 1						false
10739	48647		ADULT	59634741	450.5604	MITAPIVAT		O=C(N1CCN(CC2CC2)CC1)c3ccc(NS(=O)(=O)c4cccc5cccnc45)cc3	PLASMA	2WTV10SIKH									?	ng × h/mL	3358		ng/mL	1322			UNKNOWN	mg	60		MULTIPLE	UNKNOWN		day	2			UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/216196Orig1s000IntegratedR.pdf#page=215	Homo sapiens				Day 14						false
10740	48647		ADULT	59634741	450.5604	MITAPIVAT		O=C(N1CCN(CC2CC2)CC1)c3ccc(NS(=O)(=O)c4cccc5cccnc45)cc3	PLASMA	2WTV10SIKH									?	ng × h/mL	10034		ng/mL	2806			UNKNOWN	mg	120		MULTIPLE	UNKNOWN		day	1			UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/216196Orig1s000IntegratedR.pdf#page=215	Homo sapiens				Day 1						false
10741	48647		ADULT	59634741	450.5604	MITAPIVAT		O=C(N1CCN(CC2CC2)CC1)c3ccc(NS(=O)(=O)c4cccc5cccnc45)cc3	PLASMA	2WTV10SIKH									?	ng × h/mL	8461		ng/mL	2094			UNKNOWN	mg	120		MULTIPLE	UNKNOWN		day	1			UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/216196Orig1s000IntegratedR.pdf#page=215	Homo sapiens				Day 14						false
10742	48647		ADULT	59634741	450.5604	MITAPIVAT		O=C(N1CCN(CC2CC2)CC1)c3ccc(NS(=O)(=O)c4cccc5cccnc45)cc3	PLASMA	2WTV10SIKH									?	ng × h/mL	3162		ng/mL	1033			UNKNOWN	mg	50		MULTIPLE	UNKNOWN		day	2			UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/216196Orig1s000IntegratedR.pdf#page=215	Homo sapiens				Day 84						false
10743	48647		ADULT	59634741	450.5604	MITAPIVAT		O=C(N1CCN(CC2CC2)CC1)c3ccc(NS(=O)(=O)c4cccc5cccnc45)cc3	PLASMA	2WTV10SIKH									?	ng × h/mL	2628		ng/mL	938			UNKNOWN	mg	50		MULTIPLE	UNKNOWN		day	2			UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/216196Orig1s000IntegratedR.pdf#page=215	Homo sapiens				Day 168						false
10744	48647		ADULT	59634741	450.5604	MITAPIVAT		O=C(N1CCN(CC2CC2)CC1)c3ccc(NS(=O)(=O)c4cccc5cccnc45)cc3	PLASMA	2WTV10SIKH							12		t	ng × h/mL	450.4		ng/mL	101.2			UNKNOWN	mg	5		STEADY-STATE	UNKNOWN		day	2	t1/2=3 to 5 h		UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/216196Orig1s000IntegratedR.pdf#page=35 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/216196Orig1s000IntegratedR.pdf#page=37	Homo sapiens		h	5							false
10745	48647		ADULT	59634741	450.5604	MITAPIVAT		O=C(N1CCN(CC2CC2)CC1)c3ccc(NS(=O)(=O)c4cccc5cccnc45)cc3	PLASMA	2WTV10SIKH							12		t	ng × h/mL	1623.8		ng/mL	389.9			UNKNOWN	mg	20		STEADY-STATE	UNKNOWN		day	2	t1/2=3 to 5 h		UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/216196Orig1s000IntegratedR.pdf#page=35 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/216196Orig1s000IntegratedR.pdf#page=37	Homo sapiens		h	5							false
10746	48647		ADULT	59634741	450.5604	MITAPIVAT		O=C(N1CCN(CC2CC2)CC1)c3ccc(NS(=O)(=O)c4cccc5cccnc45)cc3	PLASMA	2WTV10SIKH							12		t	ng × h/mL	3591.4		ng/mL	935.2			RECOMMENDED	mg	50		STEADY-STATE	UNKNOWN		day	2	t1/2=3 to 5 h		UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/216196Orig1s000IntegratedR.pdf#page=35 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/216196Orig1s000IntegratedR.pdf#page=37	Homo sapiens		h	5							false
10747	48659		ADULT	656804	460.5168	PREDNISOLONE HEMISUCCINATE	Prednisolone hemisuccinate	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)COC(=O)CCC(O)=O	PLASMA	G7080T74ON									∞	μg × h/mL	0.025						UNKNOWN	mg	1200		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4084667/	Homo sapiens		min	25				9			false
10748	48659		ADULT	656804	460.5168	PREDNISOLONE HEMISUCCINATE	Prednisolone hemisuccinate	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)COC(=O)CCC(O)=O	PLASMA	G7080T74ON									∞	μg × h/mL	0.0173						UNKNOWN	mg	75		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4084667/	Homo sapiens		min	18				7			false
10749	48659		ADULT	5755	360.444	PREDNISOLONE	Prednisolone	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO	PLASMA	9PHQ9Y1OLM									∞	μg × h/mL	0.085						UNKNOWN	mg	1200		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4084667/	Homo sapiens		h	3.7				9			false
10750	48659		ADULT	5755	360.444	PREDNISOLONE	Prednisolone	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO	PLASMA	9PHQ9Y1OLM									∞	μg × h/mL	0.0601						UNKNOWN	mg	75		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4084667/	Homo sapiens		h	3.5				7			false
10751	48659		ADULT	5755	360.444	PREDNISOLONE	Prednisolone	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO	PLASMA	9PHQ9Y1OLM																	UNKNOWN	mg	75		SINGLE	UNKNOWN				Fb=0.62 (60min), 0.64 (90min), 0.68 (120min), 0.77 (120min)	23	HEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/4084667/	Homo sapiens							7			false
10752	48791		ADULT	135511704	355.406	SP-420		COCCOCCOc1ccc(C2=N[C@](C)(CS2)C(=O)O)c(O)c1	PLASMA	WBX54NZ436							24		t	ng × h/mL	151446		ng/mL	46767			UNKNOWN	mg/kg	24		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28940308/	Homo sapiens				Day 7			6			false
10753	48791		ADULT	135511704	355.406	SP-420		COCCOCCOc1ccc(C2=N[C@](C)(CS2)C(=O)O)c(O)c1	PLASMA	WBX54NZ436							12		t	ng × h/mL	81642		ng/mL	23450			UNKNOWN	mg/kg	9		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28940308/	Homo sapiens				Day 7			6			false
10754	48791		ADULT	135511704	355.406	SP-420		COCCOCCOc1ccc(C2=N[C@](C)(CS2)C(=O)O)c(O)c1	PLASMA	WBX54NZ436							24		t	ng × h/mL	28690		ng/mL	9900			UNKNOWN	mg/kg	3		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28940308/	Homo sapiens				Day 7			3			false
10755	48791		ADULT	135511704	355.406	SP-420		COCCOCCOc1ccc(C2=N[C@](C)(CS2)C(=O)O)c(O)c1	PLASMA	WBX54NZ436							24		t	ng × h/mL	13810		ng/mL	4933			UNKNOWN	mg/kg	1.5		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28940308/	Homo sapiens				Day 7			3			false
10756	48791		ADULT	135511704	355.406	SP-420		COCCOCCOc1ccc(C2=N[C@](C)(CS2)C(=O)O)c(O)c1	PLASMA	WBX54NZ436							24		t	ng × h/mL	32117		ng/mL	11987			UNKNOWN	mg/kg	6		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28940308/	Homo sapiens				Day 7			3			false
10757	48791		ADULT	135511704	355.406	SP-420		COCCOCCOc1ccc(C2=N[C@](C)(CS2)C(=O)O)c(O)c1	PLASMA	WBX54NZ436							24		t	ng × h/mL	84056		ng/mL	25633			UNKNOWN	mg/kg	12		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28940308/	Homo sapiens				Day 7			3			false
10758	49024		ADULT	9799417	368.4676	CB-13	CB-13	CCCCCOC1=C2C=CC=CC2=C(C=C1)C(=O)C3=C4C=CC=CC4=CC=C3	PLASMA	9XRJ6055XT									∞	ng × h/mL	1362		ng/mL	138.1			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19144772/	Homo sapiens		h	21.3				6	CB-13		false
10759	49024		ADULT	9799417	368.4676	CB-13	CB-13	CCCCCOC1=C2C=CC=CC2=C(C=C1)C(=O)C3=C4C=CC=CC4=CC=C3	PLASMA	9XRJ6055XT									∞	ng × h/mL	3128		ng/mL	278.2			UNKNOWN	mg	40		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19144772/	Homo sapiens		h	54.8				6	CB-13		false
10760	49024		ADULT	9799417	368.4676	CB-13	CB-13	CCCCCOC1=C2C=CC=CC2=C(C=C1)C(=O)C3=C4C=CC=CC4=CC=C3	PLASMA	9XRJ6055XT									∞	ng × h/mL	4966		ng/mL	481.5			UNKNOWN	mg	80		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/19144772/	Homo sapiens		h	35.5				6	CB-13		false
10761	49025		ADULT	66571548	479.919	PF-06273340	PF-06273340	CC(C)(CO)N1C=C(C(=O)C2=CN=CC(NC(=O)CC3=NC=C(Cl)C=C3)=C2)C4=C1N=C(N)N=C4	PLASMA	I136775ABW									?	ng × h/mL	3630		ng/mL	1396			UNKNOWN	mg	400		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29178434	Homo sapiens							19			false
10762	49026		ADULT	54758501	486.589	OLMUTINIB	Olmutinib	CN1CCN(CC1)C2=CC=C(NC3=NC4=C(SC=C4)C(OC5=CC(NC(=O)C=C)=CC=C5)=N3)C=C2	PLASMA	CHL9B67L95							48		t	ng × h/mL	12322		ng/mL	932			UNKNOWN	mg	100		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	http://www.hanmipharm.com/ehanmi/img/rnd/2013_WCLC_(HM61713).pdf	Homo sapiens		h	9		non-small cell lung cancer (NSCLC) patients		6			false
10763	49026		ADULT	54758501	486.589	OLMUTINIB	Olmutinib	CN1CCN(CC1)C2=CC=C(NC3=NC4=C(SC=C4)C(OC5=CC(NC(=O)C=C)=CC=C5)=N3)C=C2	PLASMA	CHL9B67L95							48		t	ng × h/mL	3574		ng/mL	267			UNKNOWN	mg	50		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	http://www.hanmipharm.com/ehanmi/img/rnd/2013_WCLC_(HM61713).pdf	Homo sapiens		h	11.3		non-small cell lung cancer (NSCLC) patients		3			false
10764	49026		ADULT	54758501	486.589	OLMUTINIB	Olmutinib	CN1CCN(CC1)C2=CC=C(NC3=NC4=C(SC=C4)C(OC5=CC(NC(=O)C=C)=CC=C5)=N3)C=C2	PLASMA	CHL9B67L95							48		t	ng × h/mL	9105		ng/mL	845			UNKNOWN	mg	75		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	http://www.hanmipharm.com/ehanmi/img/rnd/2013_WCLC_(HM61713).pdf	Homo sapiens		h	8.2		non-small cell lung cancer (NSCLC) patients		4			false
10765	49026		ADULT	54758501	486.589	OLMUTINIB	Olmutinib	CN1CCN(CC1)C2=CC=C(NC3=NC4=C(SC=C4)C(OC5=CC(NC(=O)C=C)=CC=C5)=N3)C=C2	PLASMA	CHL9B67L95							48		t	ng × h/mL	15537		ng/mL	1226			UNKNOWN	mg	150		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	http://www.hanmipharm.com/ehanmi/img/rnd/2013_WCLC_(HM61713).pdf	Homo sapiens		h	8.6		non-small cell lung cancer (NSCLC) patients		3			false
10766	49026		ADULT	54758501	486.589	OLMUTINIB	Olmutinib	CN1CCN(CC1)C2=CC=C(NC3=NC4=C(SC=C4)C(OC5=CC(NC(=O)C=C)=CC=C5)=N3)C=C2	PLASMA	CHL9B67L95							48		t	ng × h/mL	28339		ng/mL	2043			UNKNOWN	mg	250		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	http://www.hanmipharm.com/ehanmi/img/rnd/2013_WCLC_(HM61713).pdf	Homo sapiens		h	8.6		non-small cell lung cancer (NSCLC) patients		4			false
10767	49026		ADULT	54758501	486.589	OLMUTINIB	Olmutinib	CN1CCN(CC1)C2=CC=C(NC3=NC4=C(SC=C4)C(OC5=CC(NC(=O)C=C)=CC=C5)=N3)C=C2	PLASMA	CHL9B67L95							48		t	ng × h/mL	36618		ng/mL	2565			UNKNOWN	mg	200		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	http://www.hanmipharm.com/ehanmi/img/rnd/2013_WCLC_(HM61713).pdf	Homo sapiens		h	9.4		non-small cell lung cancer (NSCLC) patients		3			false
10768	49026		ADULT	54758501	486.589	OLMUTINIB	Olmutinib	CN1CCN(CC1)C2=CC=C(NC3=NC4=C(SC=C4)C(OC5=CC(NC(=O)C=C)=CC=C5)=N3)C=C2	PLASMA	CHL9B67L95							48		t	ng × h/mL	42198		ng/mL	2432			UNKNOWN	mg	300		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	http://www.hanmipharm.com/ehanmi/img/rnd/2013_WCLC_(HM61713).pdf	Homo sapiens		h	11.3		non-small cell lung cancer (NSCLC) patients		6			false
10769	49026		ADULT	54758501	486.589	OLMUTINIB	Olmutinib	CN1CCN(CC1)C2=CC=C(NC3=NC4=C(SC=C4)C(OC5=CC(NC(=O)C=C)=CC=C5)=N3)C=C2	PLASMA	CHL9B67L95									∞	ng × h/mL	7483.4		ng/mL	982.1			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31125491/	Homo sapiens		h	4.8		Caucasian subjects		8			false
10770	49026		ADULT	54758501	486.589	OLMUTINIB	Olmutinib	CN1CCN(CC1)C2=CC=C(NC3=NC4=C(SC=C4)C(OC5=CC(NC(=O)C=C)=CC=C5)=N3)C=C2	PLASMA	CHL9B67L95									∞	ng × h/mL	13882.2		ng/mL	1495.7			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31125491/	Homo sapiens		h	5.6		Caucasian subjects		8			false
10771	49026		ADULT	54758501	486.589	OLMUTINIB	Olmutinib	CN1CCN(CC1)C2=CC=C(NC3=NC4=C(SC=C4)C(OC5=CC(NC(=O)C=C)=CC=C5)=N3)C=C2	PLASMA	CHL9B67L95									∞	ng × h/mL	8439.8		ng/mL	941.3			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31125491/	Homo sapiens		h	6		Korean, Japanese, and Caucasian subjects		24			false
10772	49026		ADULT	54758501	486.589	OLMUTINIB	Olmutinib	CN1CCN(CC1)C2=CC=C(NC3=NC4=C(SC=C4)C(OC5=CC(NC(=O)C=C)=CC=C5)=N3)C=C2	PLASMA	CHL9B67L95									∞	ng × h/mL	12566.4		ng/mL	1327.2			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31125491/	Homo sapiens		h	5.8		Korean, Japanese, and Caucasian subjects		24			false
10773	49026			54758501	486.589	OLMUTINIB	Olmutinib	CN1CCN(CC1)C2=CC=C(NC3=NC4=C(SC=C4)C(OC5=CC(NC(=O)C=C)=CC=C5)=N3)C=C2	PLASMA	CHL9B67L95																										The in vitro plasma protein binding was high to very high in all species with 99.8% in human plasma.	0.2				EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31125491/	Homo sapiens										false
10774	49026		ADULT	54758501	486.589	OLMUTINIB	Olmutinib	CN1CCN(CC1)C2=CC=C(NC3=NC4=C(SC=C4)C(OC5=CC(NC(=O)C=C)=CC=C5)=N3)C=C2	PLASMA	CHL9B67L95									∞	ng × h/mL	3889.1		ng/mL	441.4			UNKNOWN	mg	100		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31125491/	Homo sapiens		h	5		Korean subjects		8			false
10775	49026		ADULT	54758501	486.589	OLMUTINIB	Olmutinib	CN1CCN(CC1)C2=CC=C(NC3=NC4=C(SC=C4)C(OC5=CC(NC(=O)C=C)=CC=C5)=N3)C=C2	PLASMA	CHL9B67L95									∞	ng × h/mL	9383.2		ng/mL	931			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31125491/	Homo sapiens		h	7.4		Korean subjects		8			false
10776	49026		ADULT	54758501	486.589	OLMUTINIB	Olmutinib	CN1CCN(CC1)C2=CC=C(NC3=NC4=C(SC=C4)C(OC5=CC(NC(=O)C=C)=CC=C5)=N3)C=C2	PLASMA	CHL9B67L95									∞	ng × h/mL	12766.4		ng/mL	1322.7			UNKNOWN	mg	300		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31125491/	Homo sapiens		h	5.7		Korean subjects		8			false
10777	49026		ADULT	54758501	486.589	OLMUTINIB	Olmutinib	CN1CCN(CC1)C2=CC=C(NC3=NC4=C(SC=C4)C(OC5=CC(NC(=O)C=C)=CC=C5)=N3)C=C2	PLASMA	CHL9B67L95									∞	ng × h/mL	10792.7		ng/mL	1089.2			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31125491/	Homo sapiens		h	5.7		Korean subjects		8			false
10778	49026		ADULT	54758501	486.589	OLMUTINIB	Olmutinib	CN1CCN(CC1)C2=CC=C(NC3=NC4=C(SC=C4)C(OC5=CC(NC(=O)C=C)=CC=C5)=N3)C=C2	PLASMA	CHL9B67L95									∞	ng × h/mL	8452.8		ng/mL	910.8			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31125491/	Homo sapiens		h	6		Japanese subjects		8			false
10779	49026		ADULT	54758501	486.589	OLMUTINIB	Olmutinib	CN1CCN(CC1)C2=CC=C(NC3=NC4=C(SC=C4)C(OC5=CC(NC(=O)C=C)=CC=C5)=N3)C=C2	PLASMA	CHL9B67L95									∞	ng × h/mL	13024.3		ng/mL	1396.7			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31125491/	Homo sapiens		h	6.1		Japanese subjects		8			false
10780	49027		ADULT	91270|40466988	498.5681	MOEXIPRIL	MOEXIPRIL	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CC3=C(C[C@H]2C(O)=O)C=C(OC)C(OC)=C3	PLASMA	WT87C52TJZ							24		t	ng × h/mL	328		ng/mL	154			UNKNOWN	mg	15		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1527-3466.1995.tb00304.x	Homo sapiens					cirrhotic					false
10781	49027		ADULT	55331	470.5149	MOEXIPRILAT	MOEXIPRILAT	COC1=CC2=C(CN([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC3=CC=CC=C3)C(O)=O)C=C1OC	PLASMA	H3753190JS							24		t	ng × h/mL	136		ng/mL	48			UNKNOWN	mg	30		MULTIPLE	UNKNOWN		day	1	Protein binding of moexiprilat was about 70%	30	HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1527-3466.1995.tb00304.x	Homo sapiens		h	10							false
10782	49027		ADULT	55331	470.5149	MOEXIPRILAT	MOEXIPRILAT	COC1=CC2=C(CN([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC3=CC=CC=C3)C(O)=O)C=C1OC	PLASMA	H3753190JS							24		t	ng × h/mL	98		ng/mL	16			UNKNOWN	mg	15		MULTIPLE	UNKNOWN		day	1	Protein binding of moexiprilat was about 70%	30	UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1527-3466.1995.tb00304.x	Homo sapiens					cirrhotic					false
10783	49027		ADULT	91270|40466988	498.5681	MOEXIPRIL	MOEXIPRIL	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CC3=C(C[C@H]2C(O)=O)C=C(OC)C(OC)=C3	PLASMA	WT87C52TJZ							24		t	ng × h/mL	320		ng/mL	194			UNKNOWN	mg	30		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1527-3466.1995.tb00304.x	Homo sapiens										false
10784	49030		ADULT	71667668	562.7063	NAQUOTINIB	NAQUOTINIB	CCC1=NC(C(N)=O)=C(NC2=CC=C(C=C2)N3CCC(CC3)N4CCN(C)CC4)N=C1O[C@@H]5CCN(C5)C(=O)C=C	PLASMA	47DD4548PB							24		t	ng × h/mL	34600		ng/mL	2790			MAX TOLERATED	mg	400		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/29972716	Homo sapiens		h	12.9							false
10785	49033		ADULT	70817911	383.4	BAY-1125976	BAY-1125976		PLASMA	ZL7A1UM87X							48		?	μg × h/L	363		μg/L	37.7			MAX TOLERATED	mg	80		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31835495	Homo sapiens							13	BAY-1125976		false
10786	49033		ADULT	70817911	383.4	BAY-1125976	BAY-1125976		PLASMA	ZL7A1UM87X							48		t	μg × h/L	165		μg/L	28.8			UNKNOWN	mg	80		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31835495	Homo sapiens							3	BAY-1125976		false
10787	49033		ADULT	70817911	383.4	BAY-1125976	BAY-1125976		PLASMA	ZL7A1UM87X									?	μg × h/L	94		μg/L	18			UNKNOWN	mg	40		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31835495	Homo sapiens							3	BAY-1125976		false
10788	49033		ADULT	70817911	383.4	BAY-1125976	BAY-1125976		PLASMA	ZL7A1UM87X									?	μg × h/L	177		μg/L	33.4			MAX TOLERATED	mg	60		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31835495	Homo sapiens							15	BAY-1125976		false
10789	49033		ADULT	70817911	383.4	BAY-1125976	BAY-1125976		PLASMA	ZL7A1UM87X									?	μg × h/L	127		μg/L	9.21			UNKNOWN	mg	40		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31835495	Homo sapiens							4	BAY-1125976		false
10790	49033		ADULT	70817911	383.4	BAY-1125976	BAY-1125976		PLASMA	L7A1UM87X									?	μg × h/L	294		μg/L	44.5			UNKNOWN	mg	120		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31835495	Homo sapiens							6	BAY-1125976		false
10791	49033		ADULT	70817911	383.4	BAY-1125976	BAY-1125976		PLASMA	ZL7A1UM87X							48		t	μg × h/L	192		μg/L	21.1			UNKNOWN	mg	80		SINGLE	FED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/31835495	Homo sapiens							3	BAY-1125976		false
10792	49034		ADULT	118023034	498.558	AVAPRITINIB	C[C@](C1=CC=C(C=C1)F)(C2=CN=C(N=C2)N3CCN(CC3)C4=NC=NN5C4=CC(=C5)C6=CN(N=C6)C)N	CN1C=C(C=N1)C2=CN3N=CN=C(N4CCN(CC4)C5=NC=C(C=N5)[C@@](C)(N)C6=CC=C(F)C=C6)C3=C2	PLASMA	513P80B4YJ							24		t	ng × h/mL	15400		ng/mL	813			RECOMMENDED	mg	300		STEADY-STATE	FASTED		day	1			UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212608s000lbl.pdf	Homo sapiens		h	57							false
10793	49036		ADULT	23063810	232.21	PF-06840002	PF-06840002	C1[C@@H](C(=O)NC1=O)C2=CNC3=C2C=C(C=C3)F	PLASMA								12		t	ng × h/mL	20410		ng/mL	2474			UNKNOWN	mg	500		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32436060/	Homo sapiens		h	2.885	PF-06840003 is a racemic mixture of active (PF-06840002) and inactive (PF06840001) enantiomers that spontaneously epimerize to each other in plasma			8	PF-06840003		false
10794	49036		ADULT	118512017	232.21	PF-06840002	PF-06840002	C1[C@@H](C(=O)NC1=O)C2=CNC3=C2C=C(C=C3)F	PLASMA								24		t	ng × h/mL	6115		ng/mL	623			UNKNOWN	mg	125		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32436060/	Homo sapiens		h	5.58	PF-06840003 is a racemic mixture of active (PF-06840002) and inactive (PF06840001) enantiomers that spontaneously epimerize to each other in plasma			2	PF-06840003		false
10795	49036		ADULT	23063810	232.21	PF-06840002	PF-06840002	C1[C@@H](C(=O)NC1=O)C2=CNC3=C2C=C(C=C3)F	PLASMA								12		t	ng × h/mL	12730		ng/mL	1763			UNKNOWN	mg	250		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32436060/	Homo sapiens		h	2.68	PF-06840003 is a racemic mixture of active (PF-06840002) and inactive (PF06840001) enantiomers that spontaneously epimerize to each other in plasma			3	PF-06840003		false
10796	49036		ADULT	118512017	232.21	PF-06840002	PF-06840002	C1[C@@H](C(=O)NC1=O)C2=CNC3=C2C=C(C=C3)F	PLASMA								24		t	ng × h/mL	6680		ng/mL	779.3			UNKNOWN	mg	250		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/32436060/	Homo sapiens		h	2.9	PF-06840003 is a racemic mixture of active (PF-06840002) and inactive (PF06840001) enantiomers that spontaneously epimerize to each other in plasma			4	PF-06840003		false
10797	49038		ADULT	46834118	468.5652	DERAZANTINIB	COCCNCCC1=CC(NC2=NC=C3C[C@@H](C4=CC=CC=C4F)C5=CC=CC=C5C3=N2)=CC=C1	COCCNCCC1=CC(NC2=NC=C3C[C@@H](C4=CC=CC=C4F)C5=CC=CC=C5C3=N2)=CC=C1	PLASMA								24		t	ng × h/mL	1940.87		ng/mL	164.2			RECOMMENDED	mg	300		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/28972963	Homo sapiens		day	5							false
10798	49038		ADULT	46834118	468.5652	DERAZANTINIB	COCCNCCC1=CC(NC2=NC=C3C[C@@H](C4=CC=CC=C4F)C5=CC=CC=C5C3=N2)=CC=C1	COCCNCCC1=CC(NC2=NC=C3C[C@@H](C4=CC=CC=C4F)C5=CC=CC=C5C3=N2)=CC=C1	PLASMA								24		t	ng × h/mL	20339.47		ng/mL	963.1			RECOMMENDED	mg	300		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/28972963	Homo sapiens		day	5							false
10799	49040		ADULT	70798655	363.37	SERABELISIB	NC1=NC2=C(O1)C=CC(=C2)C3=CN4C(=CN=C4C=C3)C(=O)N5CCOCC5	NC1=NC2=C(O1)C=CC(=C2)C3=CN4C(=CN=C4C=C3)C(=O)N5CCOCC5	PLASMA										∞	ng × h/mL	119000		ng/mL	7860			RECOMMENDED	mg	900		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/28490463	Homo sapiens		h	10.3							false
10800	49041		ADULT	78323835	323.42	PF-04965842	PF-04965842	CCCS(=O)(=O)NC1CC(C1)N(C)C2=NC=NC3=C2C=CN3	PLASMA	73SM5SF3OR									∞	ng × h/mL	23740		ng/mL	3712			UNKNOWN	mg	800		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29672897	Homo sapiens		h	4.88				16	PF-04965842		false
10801	49041		ADULT	78323835	323.42	PF-04965842	PF-04965842	CCCS(=O)(=O)NC1CC(C1)N(C)C2=NC=NC3=C2C=CN3	PLASMA	73SM5SF3OR									?	ng × h/mL	18230		ng/mL	3334			UNKNOWN	mg	400		MULTIPLE	FASTED		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29672897	Homo sapiens		h	4.85				8	PF-04965842		false
10802	49237		ADULT	117761397	273.3341	MAVACAMTEN		CC(C)N1C(=O)NC(=CC1=O)N[C@@H](C)c2ccccc2	PLASMA	QX45B99R3J									∞	ng × h/mL	43520		ng/mL	509			UNKNOWN	mg	15		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214998Orig1s000ClinPharmR.pdf#page=40	Homo sapiens					CYP2C19 poor metabolizer (PM)		8			false
10803	49237		ADULT	117761397	273.3341	MAVACAMTEN		CC(C)N1C(=O)NC(=CC1=O)N[C@@H](C)c2ccccc2	PLASMA	QX45B99R3J									∞	ng × h/mL	14130		ng/mL	397			UNKNOWN	mg	15		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214998Orig1s000ClinPharmR.pdf#page=40	Homo sapiens					CYP2C19 normal metabolizer (NM)		8			false
10804	49237		ADULT	117761397	273.3341	MAVACAMTEN		CC(C)N1C(=O)NC(=CC1=O)N[C@@H](C)c2ccccc2	PLASMA	QX45B99R3J									∞	ng × h/mL	19700		ng/mL	426			UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214998Orig1s000ClinPharmR.pdf#page=41	Homo sapiens					Normal hepatic function (matched control of Moderate hepatic impairment group)		8			false
10805	49237		ADULT	117761397	273.3341	MAVACAMTEN		CC(C)N1C(=O)NC(=CC1=O)N[C@@H](C)c2ccccc2	PLASMA	QX45B99R3J									∞	ng × h/mL	18200		ng/mL	534			UNKNOWN	mg	25		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214998Orig1s000ClinPharmR.pdf#page=41	Homo sapiens					Normal hepatic function (matched control of Mild hepatic impairment group)		8			false
10806	49237		ADULT	117761397	273.3341	MAVACAMTEN		CC(C)N1C(=O)NC(=CC1=O)N[C@@H](C)c2ccccc2	PLASMA	QX45B99R3J									∞	ng × h/mL	32800		ng/mL	468			UNKNOWN	mg	25		SINGLE	FASTED						UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214998Orig1s000ClinPharmR.pdf#page=41	Homo sapiens					Moderate hepatic impairment; n=4 for AUCinf		8			false
10807	49237		ADULT	117761397	273.3341	MAVACAMTEN		CC(C)N1C(=O)NC(=CC1=O)N[C@@H](C)c2ccccc2	PLASMA	QX45B99R3J									∞	ng × h/mL	71000		ng/mL	596			UNKNOWN	mg	25		SINGLE	FASTED						UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214998Orig1s000ClinPharmR.pdf#page=41	Homo sapiens					Mild hepatic impairment; n=4 for AUCinf		8			false
10808	49237		ADULT	117761397	273.3341	MAVACAMTEN		CC(C)N1C(=O)NC(=CC1=O)N[C@@H](C)c2ccccc2	PLASMA	QX45B99R3J									∞	ng × h/mL	10690		ng/mL	341.1			UNKNOWN	mg	15		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214998Orig1s000ClinPharmR.pdf#page=50	Homo sapiens							16			false
10809	49237		ADULT	117761397	273.3341	MAVACAMTEN		CC(C)N1C(=O)NC(=CC1=O)N[C@@H](C)c2ccccc2	PLASMA	QX45B99R3J									∞	ng × h/mL	9395		ng/mL	153			UNKNOWN	mg	15		SINGLE	HIGH-FAT						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214998Orig1s000ClinPharmR.pdf#page=50	Homo sapiens							16			false
10810	49237		ADULT	117761397	273.3341	MAVACAMTEN		CC(C)N1C(=O)NC(=CC1=O)N[C@@H](C)c2ccccc2	PLASMA	QX45B99R3J									∞	ng × h/mL	12530		ng/mL	333.2			UNKNOWN	mg	15		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214998Orig1s000ClinPharmR.pdf#page=81	Homo sapiens		h	192.7		CYP2C19 NM					false
10811	49237		ADULT	117761397	273.3341	MAVACAMTEN		CC(C)N1C(=O)NC(=CC1=O)N[C@@H](C)c2ccccc2	PLASMA	QX45B99R3J									?	ng × h/mL	17370		ng/mL	504			UNKNOWN	mg	25		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214998Orig1s000ClinPharmR.pdf#page=81	Homo sapiens		h	141		CYP2C19 NM, Japanese					false
10812	49237		ADULT	117761397	273.3341	MAVACAMTEN		CC(C)N1C(=O)NC(=CC1=O)N[C@@H](C)c2ccccc2	PLASMA	QX45B99R3J									?	ng × h/mL	42800		ng/mL	490			UNKNOWN	mg	15		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214998Orig1s000ClinPharmR.pdf#page=81	Homo sapiens		h	553		CYP2C19 PM					false
10813	49237		ADULT	117761397	273.3341	MAVACAMTEN		CC(C)N1C(=O)NC(=CC1=O)N[C@@H](C)c2ccccc2	PLASMA	QX45B99R3J									?	ng × h/mL	12530		ng/mL	333			UNKNOWN	mg	15		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214998Orig1s000ClinPharmR.pdf#page=81	Homo sapiens		h	193		CYP2C19 NM					false
10814	49237		ADULT	117761397	273.3341	MAVACAMTEN		CC(C)N1C(=O)NC(=CC1=O)N[C@@H](C)c2ccccc2	PLASMA	QX45B99R3J									?	ng × h/mL	19280		ng/mL	516			UNKNOWN	mg	25		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214998Orig1s000ClinPharmR.pdf#page=81	Homo sapiens		h	144		CYP2C19 NM, Caucasian					false
10815	49237		ADULT	117761397	273.3341	MAVACAMTEN		CC(C)N1C(=O)NC(=CC1=O)N[C@@H](C)c2ccccc2	PLASMA	QX45B99R3J									?	ng × h/mL	2768		ng/mL	391			UNKNOWN	mg	15		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214998Orig1s000ClinPharmR.pdf#page=81	Homo sapiens				Day 1 PK	CYP2C19 NM					false
10816	49237		ADULT	117761397	273.3341	MAVACAMTEN		CC(C)N1C(=O)NC(=CC1=O)N[C@@H](C)c2ccccc2	PLASMA	QX45B99R3J									?	ng × h/mL	15410		ng/mL	289			UNKNOWN	mg	15		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214998Orig1s000ClinPharmR.pdf#page=81	Homo sapiens		h	216		CYP2C19 NM, Japanese					false
10817	49237		ADULT	117761397	273.3341	MAVACAMTEN		CC(C)N1C(=O)NC(=CC1=O)N[C@@H](C)c2ccccc2	PLASMA	QX45B99R3J									∞	ng × h/mL	42800		ng/mL	489.9			UNKNOWN	mg	15		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214998Orig1s000ClinPharmR.pdf#page=81	Homo sapiens		h	552.8		CYP2C19 PM					false
10818	49237		ADULT	117761397	273.3341	MAVACAMTEN		CC(C)N1C(=O)NC(=CC1=O)N[C@@H](C)c2ccccc2	PLASMA	QX45B99R3J									?	ng × h/mL	8313		ng/mL	596			UNKNOWN	mg	15		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214998Orig1s000ClinPharmR.pdf#page=81	Homo sapiens				Day 15 PK	CYP2C19 NM					false
10819	49237		ADULT	117761397	273.3341	MAVACAMTEN		CC(C)N1C(=O)NC(=CC1=O)N[C@@H](C)c2ccccc2	PLASMA	QX45B99R3J							24		t	ng × h/mL	32990		ng/mL	894			UNKNOWN	mg	48		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214998Orig1s000ClinPharmR.pdf#page=82	Homo sapiens										false
10820	49237		ADULT	117761397	273.3341	MAVACAMTEN		CC(C)N1C(=O)NC(=CC1=O)N[C@@H](C)c2ccccc2	PLASMA	QX45B99R3J							24		t	ng × h/mL	296		ng/mL	20.9			UNKNOWN	mg	1		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214998Orig1s000ClinPharmR.pdf#page=82	Homo sapiens										false
10821	49237		ADULT	117761397	273.3341	MAVACAMTEN		CC(C)N1C(=O)NC(=CC1=O)N[C@@H](C)c2ccccc2	PLASMA	QX45B99R3J							24		t	ng × h/mL	1368		ng/mL	62			UNKNOWN	mg	2		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214998Orig1s000ClinPharmR.pdf#page=82	Homo sapiens										false
10822	49237		ADULT	117761397	273.3341	MAVACAMTEN		CC(C)N1C(=O)NC(=CC1=O)N[C@@H](C)c2ccccc2	PLASMA	QX45B99R3J							24		t	ng × h/mL	3245		ng/mL	101			UNKNOWN	mg	6		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214998Orig1s000ClinPharmR.pdf#page=82	Homo sapiens										false
10823	49237		ADULT	117761397	273.3341	MAVACAMTEN		CC(C)N1C(=O)NC(=CC1=O)N[C@@H](C)c2ccccc2	PLASMA	QX45B99R3J							24		t	ng × h/mL	5333		ng/mL	204			UNKNOWN	mg	12		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214998Orig1s000ClinPharmR.pdf#page=82	Homo sapiens										false
10824	49237		ADULT	117761397	273.3341	MAVACAMTEN		CC(C)N1C(=O)NC(=CC1=O)N[C@@H](C)c2ccccc2	PLASMA	QX45B99R3J							24		t	ng × h/mL	14555		ng/mL	492			UNKNOWN	mg	24		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214998Orig1s000ClinPharmR.pdf#page=82	Homo sapiens										false
10825	49237		UNKNOWN	117761397	273.3341	MAVACAMTEN		CC(C)N1C(=O)NC(=CC1=O)N[C@@H](C)c2ccccc2	PLASMA	QX45B99R3J																						UNKNOWN				Human plasma protein binding: 93.1% (92.9% (0.2mcM), 93.3% (1mcM), 93.1% (10mcM))	6.9	UNKNOWN		UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214998Orig1s000PharmR.pdf#page=99	Homo sapiens										false
10826	49291		ADULT		319.4	NBI-98782	NBI-98782		PLASMA	IFRYDMLSGE									∞	ng × h/mL	9.22		ng/mL	0.19			UNKNOWN	mg	1		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28839339/	Homo sapiens		h	32							false
10827	49291		ADULT		319.4	NBI-98782			PLASMA	IFRYDMLSGE									∞	ng × h/mL	1150		ng/mL	31.7			DEFINED DAILY	mg	75		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28839339/	Homo sapiens		h	21							false
10828	49291		ADULT		319.4	NBI-98782			PLASMA	IFRYDMLSGE									∞	ng × h/mL	1840		ng/mL	56.2			UNKNOWN	mg	150		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28839339/	Homo sapiens		h	19							false
10829	49291		ADULT		319.4	NBI-98782			PLASMA	IFRYDMLSGE							24		t	ng × h/mL	630		ng/mL	35.1			UNKNOWN	mg	50		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28839339/	Homo sapiens		h	21							false
10830	49291		ADULT		319.4	NBI-98782			PLASMA	IFRYDMLSGE							24		t	ng × h/mL	1110		ng/mL	64			MAX TOLERATED	mg	100		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/28839339/	Homo sapiens		h	19							false
10831	49291		ADULT		319.4	NBI-98782	NBI-98782		UNKNOWN	IFRYDMLSGE							24		t	ng × h/mL	695		ng/mL	39.4			RECOMMENDED	mg	80		STEADY-STATE	UNKNOWN		day	1	Plasma Protein Binding ~64%	36	HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209241oirg1s000clinpharmr.pdf	Homo sapiens		h	18.5							false
10832	49345		ADULT		146648.64	PEMBROLIZUMAB	PEMBROLIZUMAB		SERUM										∞	μg × day/mL	212		μg/mL	16.4			RECOMMENDED	mg/kg	1		STEADY-STATE	UNKNOWN		2 weeks	1			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25977344/	Homo sapiens		day	14.1							false
10833	49345		ADULT		146648.64	PEMBROLIZUMAB	PEMBROLIZUMAB		SERUM										∞	μg × day/mL	1530		μg/mL	107			RECOMMENDED	mg/kg	3		STEADY-STATE	UNKNOWN		2 weeks	1			UNKNOWN	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25977344/	Homo sapiens		day	21.6							false
10834	49345		ADULT		146648.64	PEMBROLIZUMAB	PEMBROLIZUMAB		SERUM										∞	μg × day/mL	2150		μg/mL	256			RECOMMENDED	mg/kg	10		STEADY-STATE	UNKNOWN		2 weeks	1			UNHEALTHY	Intravenous	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/25977344/	Homo sapiens		day	17.7							false
10835	49365		ADULT	5369209	130.0987	MONOMETHYL FUMARATE	COC(=O)C=CC(=O)O	COC(=O)C=CC(O)=O	PLASMA	45IUB1PX8R									?	mg × h/L	8.21		mg/L	1.87			RECOMMENDED	mg	240		MULTIPLE	FED		day	2		64	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204063lbl.pdf	Homo sapiens		h	1							false
10836	49587		ADULT		137909.27	TRASTUZUMAB	TRASTUZUMAB		SERUM										∞	μg × h/mL	35890		μg/mL	153			RECOMMENDED	mg/kg	6		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/27368117/	Homo sapiens		h	198							false
10837	49587		ADULT		137909.27	TRASTUZUMAB	TRASTUZUMAB		SERUM														μg/mL	377			MAX DAILY	mg	500		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103792s5256lbl.pdf	Homo sapiens		day	12							false
10838	49587		ADULT		137909.27	TRASTUZUMAB	TRASTUZUMAB		SERUM																		RECOMMENDED	mg	10		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103792s5256lbl.pdf	Homo sapiens		day	2							false
10839	49587		ADULT		137909.27	TRASTUZUMAB	TRASTUZUMAB		SERUM														μg/mL	123			RECOMMENDED	mg/kg	4		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Intravenous	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103792s5256lbl.pdf	Homo sapiens		day	6							false
10840	49587		ADULT		137909.27	TRASTUZUMAB	TRASTUZUMAB		SERUM														μg/mL	216			RECOMMENDED	mg/kg	8		MULTIPLE	UNKNOWN		week	1			UNKNOWN	Intravenous	FEMALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103792s5256lbl.pdf	Homo sapiens		day	16							false
10841	50379		ADULT		194.23	SOLRIAMFETOL	SOLRIAMFETOL		PLASMA	939U7C91AI									∞	ng × h/mL	5273		ng/mL	499			RECOMMENDED	mg	75		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30865315/	Homo sapiens		h	7.6							false
10842	50435		ADULT	5362471	317.3795	CODEINE	CODEINE	O.COC1=CC=C2C[C@@H]3[C@@H]4C=C[C@H](O)[C@@H]5OC1=C2[C@]45CCN3C	PLASMA	Q830PW7520									∞	μM × h	0.61		ng/mL	66.9			RECOMMENDED	mg	30		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/1391681/	Homo sapiens		h	1.47							false
10843	50435		ADULT	5362471	317.3795	CODEINE	CODEINE	O.COC1=CC=C2C[C@@H]3[C@@H]4C=C[C@H](O)[C@@H]5OC1=C2[C@]45CCN3C	PLASMA	Q830PW7520																	RECOMMENDED	mg	15		SINGLE	UNKNOWN				Codeine has low plasma protein binding with about 7-25% of codeine bound to plasma proteins.	75	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022402s000lbl.pdf	Homo sapiens										false
10844	50594		ADULT		337.4	VOXELOTOR	VOXELOTOR		RED BLOOD CELLS	3ZO554A4Q8									∞	μg × h/mL	15800		μg/mL	136			UNKNOWN	mg	1000		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30743314/	Homo sapiens		h	61.1							false
10845	50594		ADULT		337.4	VOXELOTOR	VOXELOTOR		PLASMA										∞	μg × h/mL	166		μg/mL	2.21			UNKNOWN	mg	1000		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30743314/	Homo sapiens										false
10846	50594		ADULT		337.4	VOXELOTOR	VOXELOTOR		RED BLOOD CELLS	3ZO554A4Q8									∞	μg × h/mL	10000		μg/mL	146			UNKNOWN	mg	1000		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30743314/	Homo sapiens		h	49.7							false
10847	50594		ADULT		337.4	VOXELOTOR			PLASMA	3ZO554A4Q8									∞	μg × h/mL	134		μg/mL	2.94			UNKNOWN	mg	1000		SINGLE	FASTED						UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30743314/	Homo sapiens										false
10848	50594		ADULT		337.4	VOXELOTOR			RED BLOOD CELLS	3ZO554A4Q8							24		t	μg × h/mL	4950		μg/mL	225			UNKNOWN	mg	300		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30743314/	Homo sapiens		h	80.3							false
10849	50594		ADULT		337.4	VOXELOTOR			PLASMA	3ZO554A4Q8							24		t	μg × h/mL	56.6		μg/mL	2.91			UNKNOWN	mg	300		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30743314/	Homo sapiens										false
10850	50594		ADULT		337.4	VOXELOTOR			RED BLOOD CELLS	3ZO554A4Q8							24		t	μg × h/mL	14000		μg/mL	688			UNKNOWN	mg	900		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30743314/	Homo sapiens		h	85.1							false
10851	50594		ADULT		337.4	VOXELOTOR			PLASMA	3ZO554A4Q8							24		t	μg × h/mL	215		μg/mL	11.4			UNKNOWN	mg	900		STEADY-STATE	FASTED		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30743314/	Homo sapiens										false
10852	50879		ADULT	72950888	571.5566	UMBRALISIB	UMBRALISIB	CC(C)Oc1ccc(cc1F)c2nn([C@@H](C)C3=C(C(=O)c4cc(F)ccc4O3)c5cccc(F)c5)c6ncnc(N)c26	PLASMA	38073MQB2A							24		t	ng × h/mL	14200		ng/mL	1830			DEFINED DAILY	mg	800		SINGLE	FED						UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213176Orig1Orig2s000MultidisciplineR.pdf#page=209	Homo sapiens					Phase 1, subjects with relapsed or refractory hematologic malignancies					false
10853	50879		ADULT	72950888	571.5566	UMBRALISIB	UMBRALISIB	CC(C)Oc1ccc(cc1F)c2nn([C@@H](C)C3=C(C(=O)c4cc(F)ccc4O3)c5cccc(F)c5)c6ncnc(N)c26	PLASMA	38073MQB2A							24		t	ng × h/mL	8830		ng/mL	750			UNKNOWN	mg	400		SINGLE	FED						UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213176Orig1Orig2s000MultidisciplineR.pdf#page=209	Homo sapiens					Phase 1, subjects with relapsed or refractory hematologic malignancies					false
10854	50879		ADULT	72950888	571.5566	UMBRALISIB	UMBRALISIB	CC(C)Oc1ccc(cc1F)c2nn([C@@H](C)C3=C(C(=O)c4cc(F)ccc4O3)c5cccc(F)c5)c6ncnc(N)c26	PLASMA	38073MQB2A							24		t	ng × h/mL	20700		ng/mL	1680			UNKNOWN	mg	1000		SINGLE	FED						UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213176Orig1Orig2s000MultidisciplineR.pdf#page=209	Homo sapiens					Phase 1, subjects with relapsed or refractory hematologic malignancies					false
10855	50879		ADULT	72950888	571.5566	UMBRALISIB	UMBRALISIB	CC(C)Oc1ccc(cc1F)c2nn([C@@H](C)C3=C(C(=O)c4cc(F)ccc4O3)c5cccc(F)c5)c6ncnc(N)c26	PLASMA	38073MQB2A																	DEFINED DAILY	mg	800		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213176Orig1Orig2s000MultidisciplineR.pdf#page=72	Homo sapiens		h	110							false
10856	50879		UNKNOWN	72950888	571.5566	UMBRALISIB	UMBRALISIB	CC(C)Oc1ccc(cc1F)c2nn([C@@H](C)C3=C(C(=O)c4cc(F)ccc4O3)c5cccc(F)c5)c6ncnc(N)c26	PLASMA	38073MQB2A																						UNKNOWN				Plasma protein binding: 99.7-99.8%	0.2	UNKNOWN		UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213176Orig1Orig2s000MultidisciplineR.pdf#page=72	Homo sapiens										false
10857	50879		ADULT	72950888	571.5566	UMBRALISIB	UMBRALISIB	CC(C)Oc1ccc(cc1F)c2nn([C@@H](C)C3=C(C(=O)c4cc(F)ccc4O3)c5cccc(F)c5)c6ncnc(N)c26	PLASMA	38073MQB2A																	DEFINED DAILY	mg	800		SINGLE	UNKNOWN						UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213176Orig1Orig2s000MultidisciplineR.pdf#page=72	Homo sapiens		h	91		Patients with hematological malignancies					false
10858	51481		ADULT	10151715	460.5	APREMILAST, (+/-)-	CCOC1=C(C=CC(=C1)C(CS(=O)(=O)C)N2C(=O)C3=C(C2=O)C(=CC=C3)NC(=O)C)OC	CCOC1=C(OC)C=CC(=C1)C(CS(C)(=O)=O)N2C(=O)C3=C(C2=O)C(NC(C)=O)=CC=C3	PLASMA	N5UK68MGDZ									∞	ng × eq × h/mL	6632		ng × eq/mL	527			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/21859393/	Homo sapiens		h	50.4							false
10859	51481		ADULT	11561674	460.5	APREMILAST	Apremilast	CCOC1=C(OC)C=CC(=C1)[C@@H](CS(C)(=O)=O)N2C(=O)C3=C(C2=O)C(NC(C)=O)=CC=C3	PLASMA	UP7QBP99PN							8		t	ng × h/mL	1008		ng/mL	208			RECOMMENDED	mg	10		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22748702/	Homo sapiens										false
10860	51481		ADULT	11561674	460.5	APREMILAST	Apremilast	CCOC1=C(OC)C=CC(=C1)[C@@H](CS(C)(=O)=O)N2C(=O)C3=C(C2=O)C(NC(C)=O)=CC=C3	PLASMA	UP7QBP99PN							8		t	ng × h/mL	1591		ng/mL	298			RECOMMENDED	mg	20		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22748702/	Homo sapiens										false
10861	51481		ADULT	11561674	460.5	APREMILAST	Apremilast	CCOC1=C(OC)C=CC(=C1)[C@@H](CS(C)(=O)=O)N2C(=O)C3=C(C2=O)C(NC(C)=O)=CC=C3	PLASMA	UP7QBP99PN							8		t	ng × h/mL	3467		ng/mL	637			RECOMMENDED	mg	30		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22748702/	Homo sapiens										false
10862	51481		ADULT	10151715	460.5	APREMILAST, (+/-)-	CCOC1=C(C=CC(=C1)C(CS(=O)(=O)C)N2C(=O)C3=C(C2=O)C(=CC=C3)NC(=O)C)OC	CCOC1=C(OC)C=CC(=C1)C(CS(C)(=O)=O)N2C(=O)C3=C(C2=O)C(NC(C)=O)=CC=C3	PLASMA	N5UK68MGDZ																	UNKNOWN				UNKNOWN	UNKNOWN		UNKNOWN			32	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205437s006lbl.pdf	Homo sapiens		h	7.5							false
10863	51767		NEWBORN	441129|139053447	437.508	MEROPENEM	meropenem	O.O.O.C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)=C(N2C1=O)C(O)=O	UNKNOWN	FV9J3JU8B1							24		t	μg × h/mL	445		μg/mL	44.9			UNKNOWN	mg/kg	20	infusion, 30 min	OTHER	UNKNOWN		day	3			UNHEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/050706s041lbl.pdf	Homo sapiens		h	2.33							false
10864	51767		NEWBORN	441129|139053447	437.508	MEROPENEM	MEROPENEM	O.O.O.C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)=C(N2C1=O)C(O)=O	UNKNOWN	FV9J3JU8B1							24		t	μg × h/mL	444		μg/mL	61			UNKNOWN	mg/kg	30	infusion, 30 min	OTHER	UNKNOWN		day	3			UNHEALTHY	Intravenous	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/050706s041lbl.pdf	Homo sapiens		h	1.58							false
10865	51848		ADULT	5362118	441.5185	LISINOPRIL	LISINOPRIL	O.O.NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N2CCC[C@H]2C(O)=O	PLASMA	E7199S1YWR									∞	ng × h/mL	1264.94		ng/mL	95.62			RECOMMENDED	mg	20		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/14979604	Homo sapiens		h	6.554							false
10866	51848		ADULT	5362118	441.5185	LISINOPRIL	LISINOPRIL	O.O.NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N2CCC[C@H]2C(O)=O	PLASMA	E7199S1YWR									∞	ng × h/mL	906.97		ng/mL	61.11			RECOMMENDED	mg	10		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/18368945	Homo sapiens		h	10.03							false
10867	51848		UNKNOWN	5362118	441.5185	LISINOPRIL	lisinopril	O.O.NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N2CCC[C@H]2C(O)=O	SERUM	E7199S1YWR																						UNKNOWN				Lisinopril does not appear to be bound to serum proteins	100	UNKNOWN		UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019777s054lbl.pdf	Homo sapiens										false
10868	51905		ADULT	104865	551.614	BOSENTAN ANHYDROUS	BOSENTAN ANHYDROUS	COC1=C(OC2=C(OCCO)N=C(N=C2NS(=O)(=O)C3=CC=C(C=C3)C(C)(C)C)C4=NC=CC=N4)C=CC=C1	PLASMA	XUL93R30K2									∞	mg × h/L	0.96		mg/L	0.12			UNKNOWN	mg	10		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15568889	Homo sapiens		h	4							false
10869	51905		ADULT	104865	551.614	BOSENTAN ANHYDROUS	BOSENTAN ANHYDROUS	COC1=C(OC2=C(OCCO)N=C(N=C2NS(=O)(=O)C3=CC=C(C=C3)C(C)(C)C)C4=NC=CC=N4)C=CC=C1	PLASMA	XUL93R30K2									∞	mg × h/L	7.37		mg/L	1.56			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15568889	Homo sapiens		h	4.8							false
10870	51905		ADULT	104865	551.614	BOSENTAN ANHYDROUS	BOSENTAN ANHYDROUS	COC1=C(OC2=C(OCCO)N=C(N=C2NS(=O)(=O)C3=CC=C(C=C3)C(C)(C)C)C4=NC=CC=N4)C=CC=C1	PLASMA	XUL93R30K2									∞	mg × h/L	17.4		mg/L	4.62			UNKNOWN	mg	300		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15568889	Homo sapiens		h	4.8							false
10871	51905		ADULT	104865	551.614	BOSENTAN ANHYDROUS	BOSENTAN ANHYDROUS	COC1=C(OC2=C(OCCO)N=C(N=C2NS(=O)(=O)C3=CC=C(C=C3)C(C)(C)C)C4=NC=CC=N4)C=CC=C1	PLASMA	XUL93R30K2									∞	mg × h/L	40.3		mg/L	9.49			UNKNOWN	mg	600		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15568889	Homo sapiens		h	5.1							false
10872	51905		ADULT	104865	551.614	BOSENTAN ANHYDROUS	BOSENTAN ANHYDROUS	COC1=C(OC2=C(OCCO)N=C(N=C2NS(=O)(=O)C3=CC=C(C=C3)C(C)(C)C)C4=NC=CC=N4)C=CC=C1	PLASMA	XUL93R30K2									∞	mg × h/L	56.3		mg/L	13			UNKNOWN	mg	1200		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15568889	Homo sapiens		h	7.1							false
10873	51905		ADULT	104865	551.614	BOSENTAN ANHYDROUS	BOSENTAN ANHYDROUS	COC1=C(OC2=C(OCCO)N=C(N=C2NS(=O)(=O)C3=CC=C(C=C3)C(C)(C)C)C4=NC=CC=N4)C=CC=C1	PLASMA	XUL93R30K2									∞	mg × h/L	77.3		mg/L	16.5			UNKNOWN	mg	2400		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15568889	Homo sapiens		h	6.7							false
10874	51905		ADULT	104865	551.614	BOSENTAN ANHYDROUS	BOSENTAN ANHYDROUS	COC1=C(OC2=C(OCCO)N=C(N=C2NS(=O)(=O)C3=CC=C(C=C3)C(C)(C)C)C4=NC=CC=N4)C=CC=C1	PLASMA	XUL93R30K2									∞	mg × h/L	3.38		mg/L	0.69			UNKNOWN	mg	100		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15568889	Homo sapiens		h	4.6							false
10875	51905		ADULT	104865	551.614	BOSENTAN ANHYDROUS	BOSENTAN ANHYDROUS	COC1=C(OC2=C(OCCO)N=C(N=C2NS(=O)(=O)C3=CC=C(C=C3)C(C)(C)C)C4=NC=CC=N4)C=CC=C1	PLASMA	XUL93R30K2									∞	mg × h/L	6.97		mg/L	1.8			UNKNOWN	mg	200		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15568889	Homo sapiens		h	6.3							false
10876	51905		ADULT	104865	551.614	BOSENTAN ANHYDROUS	BOSENTAN ANHYDROUS	COC1=C(OC2=C(OCCO)N=C(N=C2NS(=O)(=O)C3=CC=C(C=C3)C(C)(C)C)C4=NC=CC=N4)C=CC=C1	PLASMA	XUL93R30K2									∞	mg × h/L	13.9		mg/L	3.21			UNKNOWN	mg	500		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15568889	Homo sapiens		h	6.8							false
10877	51905		ADULT	104865	551.614	BOSENTAN ANHYDROUS	BOSENTAN ANHYDROUS	COC1=C(OC2=C(OCCO)N=C(N=C2NS(=O)(=O)C3=CC=C(C=C3)C(C)(C)C)C4=NC=CC=N4)C=CC=C1	PLASMA	XUL93R30K2									∞	mg × h/L	12.9		mg/L	2.69			UNKNOWN	mg	1000		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15568889	Homo sapiens		h	19							false
10878	51905		ADULT	104865	551.614	BOSENTAN ANHYDROUS	BOSENTAN ANHYDROUS	COC1=C(OC2=C(OCCO)N=C(N=C2NS(=O)(=O)C3=CC=C(C=C3)C(C)(C)C)C4=NC=CC=N4)C=CC=C1	PLASMA	XUL93R30K2									∞	mg × h/L	2.81		mg/L	0.46			UNKNOWN	mg	30		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15568889	Homo sapiens		h	4.3							false
10879	51905		ADULT	104865	551.614	BOSENTAN ANHYDROUS	BOSENTAN ANHYDROUS	COC1=C(OC2=C(OCCO)N=C(N=C2NS(=O)(=O)C3=CC=C(C=C3)C(C)(C)C)C4=NC=CC=N4)C=CC=C1	PLASMA	XUL93R30K2									∞	mg × h/mL	0.26		mg/L	0.034			UNKNOWN	mg	3		SINGLE	UNKNOWN				High binding to plasma proteins was reported at bosentan concentrations up to 20 mg/L, both in vitro and ex vivo. The fraction bound was approximately 98% and binding was almost entirely to albumin	2	HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/15568889/	Homo sapiens		h	3.6							false
10880	51945		UNKNOWN	9865442	394.889	LOTEPREDNOL	LOTEPREDNOL	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)OCCl	PLASMA	Z8CBU6KR16																						UNKNOWN				Moreover, deactivation in plasma and strong protein binding (around 98%) minimize the adverse effects of LE and ED in the systemic circulation.	2	UNKNOWN		UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/28017774	Homo sapiens										false
10881	52444		UNKNOWN	3639	297.7	Hydrochlorothiazide	Hydrochlorothiazide	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1	PLASMA	0J48LPH2TH													ng/mL	490			DEFINED DAILY	mg	100		SINGLE	UNKNOWN				Binding to serum proteins has been reported to be approximately 40% to 68%.	46	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020504s018lbl.pdf	Homo sapiens		h	14.8							false
10882	52444		UNKNOWN	3639	297.7	Hydrochlorothiazide	Hydrochlorothiazide	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1	PLASMA	0J48LPH2TH													ng/mL	70			DEFINED DAILY	mg	12.5		STEADY-STATE	UNKNOWN		day	1			UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020504s018lbl.pdf	Homo sapiens										false
10883	52704		ADULT	4725|5281036|135398748	253.2578	PENCICLOVIR	penciclovir	NC1=NC2=C(N=CN2CCC(CO)CO)C(=O)N1	PLASMA	359HUE8FJC									?	μg × h/mL	12.1		μg/mL	4			UNKNOWN	mg	500		SINGLE	UNKNOWN						UNHEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020363s050lbl.pdf	Homo sapiens										false
10884	52704		ADULT	4725|5281036|135398748	253.2578	PENCICLOVIR	Penciclovir	NC1=NC2=C(N=CN2CCC(CO)CO)C(=O)N1	PLASMA	359HUE8FJC									∞	μg × h/mL	17.9		μg/mL	6.6			UNKNOWN	mg	1000		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020363s050lbl.pdf	Homo sapiens										false
10885	52704		ADULT	4725|5281036|135398748	253.2578	PENCICLOVIR	Penciclovir	NC1=NC2=C(N=CN2CCC(CO)CO)C(=O)N1	PLASMA	359HUE8FJC									∞	μg × h/mL	4.48		μg/mL	1.6			UNKNOWN	mg	250		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020363s050lbl.pdf	Homo sapiens										false
10886	52704		ADULT	4725|5281036|135398748	253.2578	PENCICLOVIR	penciclovir	NC1=NC2=C(N=CN2CCC(CO)CO)C(=O)N1	PLASMA	359HUE8FJC									∞	μg × h/mL	2.24		μg/mL	0.8			UNKNOWN	mg	125		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020363s050lbl.pdf	Homo sapiens										false
10887	52704		ADULT	4725|5281036|135398748	253.2578	PENCICLOVIR	Penciclovir	NC1=NC2=C(N=CN2CCC(CO)CO)C(=O)N1	PLASMA	359HUE8FJC									∞	μg × h/mL	8.95		μg/mL	3.3			UNKNOWN	mg	500		SINGLE	UNKNOWN				Penciclovir is less than 20% bound to plasma proteins over the concentration range of 0.1 to 20 mcg/mL.	80	HEALTHY	Oral	MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020363s050lbl.pdf	Homo sapiens		h	2.3							false
10888	53096		ADULT	11808	259.06	BROMOTHEOPHYLLINE	BROMOTHEOPHYLLINE	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O	PLASMA	FZG87K1MQ6	1983		ACETAMINOPHEN	paracetamol	CC(=O)NC1=CC=C(O)C=C1	362O9ITL9D			∞	ng × h/mL	46210.49		ng/mL	3685.6			RECOMMENDED	mg	25		SINGLE	FASTED						HEALTHY	Oral	FEMALE	EXPERIMENT	http://www.annexpublishers.co/full-text/JBS/3101/Bioanalytical-Method-for-Pamabrom-Determined-As-8-Bromotheophylline-and-its-Application-to-a-Pharmacokinetic-Study.php	Homo sapiens		h	21.35							true
10889	53802		UNKNOWN	44093|12851888	217.285	CAPTOPRIL	captopril	C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O	PLASMA	9G64RSX1XD																	UNKNOWN	mg	50		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/3899460	Homo sapiens		h	1.9							false
10890	58468		ADULT	138108296	389.4024	BREPOCITINIB	BREPOCITINIB	CN1C=C(NC2=NC=CC(=N2)N3CC4CCC(C3)N4C(=O)C5CC5(F)F)C=N1	PLASMA	3X8387Q25N									?	ng × h/mL	16180		ng/mL	2091			UNKNOWN	mg	175		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29266308	Homo sapiens		h	7.5	Day 10			4	[(1S)-2,2-DIFLUOROCYCLOPROPYL][(1R,5S)-3-{2-[(1-METHYL-1H-PYRAZOL-4-YL)AMINO]-4-PYRIMIDINYL}-3,8-DIAZABICYCLO[3.2.1]OCT-8-YL]METHANONE		false
10891	58489		ADULT	9847629	472.5325	LANINAMIVIR OCTANOATE	Laninamivir octanoate	CCCCCCCC(=O)OC[C@@H](O)[C@@H](OC)[C@@H]1OC(=C[C@H](NC(N)=N)[C@H]1NC(C)=O)C(O)=O	PLASMA	E026V904RL									?	μg × h/mL	0.705		μg/mL	0.162			UNKNOWN	mg	40		SINGLE	UNKNOWN				The plasma protein binding of laninamivir was <0.1%	99.9	HEALTHY	Respiratory	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/22526307/	Homo sapiens		h	2.6				5	Laninamivir octanoate		false
10892	58489		ADULT	9847629	472.5325	LANINAMIVIR OCTANOATE	LANINAMIVIR OCTANOATE	CCCCCCCC(=O)OC[C@@H](O)[C@@H](OC)[C@@H]1OC(=C[C@H](NC(N)=N)[C@H]1NC(C)=O)C(O)=O	PLASMA	E026V904RL									∞	ng × h/mL	193.1		ng/mL	40.2			UNKNOWN	mg	40		SINGLE	FASTED				The plasma protein binding of laninamivir was less than 0.1%	99.9	HEALTHY	Respiratory	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29061751/	Homo sapiens		h	1.84				8	LANINAMIVIR OCTANOATE		false
10893	58489		ADULT	9847629	472.5325	LANINAMIVIR OCTANOATE	LANINAMIVIR OCTANOATE	CCCCCCCC(=O)OC[C@@H](O)[C@@H](OC)[C@@H]1OC(=C[C@H](NC(N)=N)[C@H]1NC(C)=O)C(O)=O	PLASMA	E026V904RL									∞	ng × h/mL	325.3		ng/mL	55.9			UNKNOWN	mg	80		SINGLE	FASTED				The plasma protein binding of laninamivir was less than 0.1%	99.9	HEALTHY	Respiratory	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29061751/	Homo sapiens		h	3.11				8	LANINAMIVIR OCTANOATE		false
10894	58489		ADULT	9847629	472.5325	LANINAMIVIR OCTANOATE	LANINAMIVIR OCTANOATE	CCCCCCCC(=O)OC[C@@H](O)[C@@H](OC)[C@@H]1OC(=C[C@H](NC(N)=N)[C@H]1NC(C)=O)C(O)=O	PLASMA	E026V904RL									∞	ng × h/mL	485.2		ng/mL	77.1			RECOMMENDED	mg	160		SINGLE	FASTED				The plasma protein binding of laninamivir was less than 0.1%	99.9	HEALTHY	Respiratory	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29061751/	Homo sapiens		h	4.01				8	LANINAMIVIR OCTANOATE		false
10895	58489		ADULT	9847629	472.5325	LANINAMIVIR OCTANOATE	LANINAMIVIR OCTANOATE	CCCCCCCC(=O)OC[C@@H](O)[C@@H](OC)[C@@H]1OC(=C[C@H](NC(N)=N)[C@H]1NC(C)=O)C(O)=O	PLASMA	E026V904RL									∞	ng × h/mL	1102		ng/mL	134.8			UNKNOWN	mg	240		SINGLE	FASTED				The plasma protein binding of laninamivir was less than 0.1%	99.9	HEALTHY	Respiratory	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29061751/	Homo sapiens		h	34.1				8	LANINAMIVIR OCTANOATE		false
10896	58489		ADULT	9847629	472.5325	LANINAMIVIR OCTANOATE	LANINAMIVIR OCTANOATE	CCCCCCCC(=O)OC[C@@H](O)[C@@H](OC)[C@@H]1OC(=C[C@H](NC(N)=N)[C@H]1NC(C)=O)C(O)=O	PLASMA	E026V904RL									∞	ng × h/mL	1504		ng/mL	193.9			HIGHEST STUDIED	mg	320		SINGLE	FASTED				The plasma protein binding of laninamivir was less than 0.1%	99.9	HEALTHY	Respiratory	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29061751/	Homo sapiens		h	55.1				8	LANINAMIVIR OCTANOATE		false
10897	58489		ADULT	502272	346.3364	LANINAMIVIR	LANINAMIVIR	CO[C@H]([C@H](O)CO)[C@@H]1OC(=C[C@H](NC(N)=N)[C@H]1NC(C)=O)C(O)=O	PLASMA	B408IW3GL5									∞	ng × h/mL	5059		ng/mL	54.8			HIGHEST STUDIED	mg	320		SINGLE	FASTED				The plasma protein binding of laninamivir was less than 0.1%	99.9	HEALTHY	Respiratory	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29061751/	Homo sapiens		h	165.8				8	LANINAMIVIR OCTANOATE		false
10898	58489		ADULT	502272	346.3364	LANINAMIVIR	LANINAMIVIR	CO[C@H]([C@H](O)CO)[C@@H]1OC(=C[C@H](NC(N)=N)[C@H]1NC(C)=O)C(O)=O	PLASMA	B408IW3GL5									∞	ng × h/mL	3164		ng/mL	40			UNKNOWN	mg	240		SINGLE	FASTED				The plasma protein binding of laninamivir was less than 0.1%	99.9	HEALTHY	Respiratory	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29061751/	Homo sapiens		h	144.6				8	LANINAMIVIR OCTANOATE		false
10899	58489		ADULT	502272	346.3364	LANINAMIVIR	LANINAMIVIR	CO[C@H]([C@H](O)CO)[C@@H]1OC(=C[C@H](NC(N)=N)[C@H]1NC(C)=O)C(O)=O	PLASMA	B408IW3GL5									∞	ng × h/mL	1629		ng/mL	26.6			RECOMMENDED	mg	160		SINGLE	FASTED				The plasma protein binding of laninamivir was less than 0.1%	99.9	HEALTHY	Respiratory	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29061751/	Homo sapiens		h	115.6				8	LANINAMIVIR OCTANOATE		false
10900	58489		ADULT	502272	346.3364	LANINAMIVIR	LANINAMIVIR	CO[C@H]([C@H](O)CO)[C@@H]1OC(=C[C@H](NC(N)=N)[C@H]1NC(C)=O)C(O)=O	PLASMA	B408IW3GL5									∞	ng × h/mL	810.9		ng/mL	14.3			UNKNOWN	mg	80		SINGLE	FASTED				The plasma protein binding of laninamivir was less than 0.1%	99.9	HEALTHY	Respiratory	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29061751/	Homo sapiens		h	95				8	LANINAMIVIR OCTANOATE		false
10901	58489		ADULT	502272	346.3364	LANINAMIVIR	LANINAMIVIR	CO[C@H]([C@H](O)CO)[C@@H]1OC(=C[C@H](NC(N)=N)[C@H]1NC(C)=O)C(O)=O	PLASMA	B408IW3GL5									∞	ng × h/mL	371.1		ng/mL	10.8			UNKNOWN	mg	40		SINGLE	FASTED				The plasma protein binding of laninamivir was less than 0.1%	99.9	HEALTHY	Respiratory	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/29061751/	Homo sapiens		h	58.3				8	LANINAMIVIR OCTANOATE		false
10902	58492		ADULT	5755	360.4	PREDNISOLONE	PREDNISOLONE	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C	PLASMA	8B2807733D									∞	ng × h/mL	2408.1		ng/mL	420.91			RECOMMENDED	mg	30		SINGLE	FASTED				Prednisolone is 70-90% protein-bound in the plasma and the volume of distribution is reported as 0.22 - 0.7 L/kg	20	HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021959s004lbl.pdf	Homo sapiens		h	2.6							false
10903	58532		ADULT	71621331	418.4	FUTIBATINIB	FUTIBATINIB	COC1=CC(=CC(=C1)C#CC2=NN(C3=NC=NC(=C23)N)C4CCN(C4)C(=O)C=C)OC	PLASMA	4B93MGE4AL									∞	ng × h/mL	592.9		ng/mL	96.2			RECOMMENDED	mg	20		SINGLE	FED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/36382853/	Homo sapiens		h	2.5				16	FUTIBATINIB		false
10904	58532		ADULT	71621331	418.4	FUTIBATINIB	FUTIBATINIB	COC1=CC(=CC(=C1)C#CC2=NN(C3=NC=NC(=C23)N)C4CCN(C4)C(=O)C=C)OC	PLASMA	4B93MGE4AL									∞	ng × h/mL	673.8		ng/mL	163.6			RECOMMENDED	mg	20		SINGLE	FASTED						HEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/36382853/	Homo sapiens		h	2.6				16	FUTIBATINIB		false
10905	58532		ADULT	71621331	418.4	FUTIBATINIB	FUTIBATINIB	COC1=CC(=CC(=C1)C#CC2=NN(C3=NC=NC(=C23)N)C4CCN(C4)C(=O)C=C)OC	PLASMA	4B93MGE4AL									?	ng × h/mL	790		ng/mL	144			RECOMMENDED	mg	20		STEADY-STATE	UNKNOWN		day	1	Futibatinib is 95% bound to human plasma protein at 0.2 to 5 µmol/L in vitro, primarily to albumin and α1-acid glycoprotein.	5	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf	Homo sapiens		h	2.9					FUTIBATINIB		false
10906	58596		ADULT	21302490	393.497	LUMATEPERONE	LUMATEPERONE	CN1CCN2[C@H]3CCN(CCCC(=O)C4=CC=C(F)C=C4)C[C@H]3C5=C2C1=CC=C5	PLASMA	70BSQ12069									?	ng × h/mL	64.2		ng/mL	19.7			RECOMMENDED	mg	42		STEADY-STATE	UNKNOWN		day	1	Plasma protein binding: > 90%. Absolute bioavailability: ~ 4.4%	4.4	UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/209500Orig1s000MultidisciplineR.pdf	Homo sapiens		h	3.1							false
10907	59512		UNKNOWN		487.5	PEMIGATINIB	PEMIGATINIB		PLASMA	Y6BX7BL23K							24		t	nM × h	2620		nM	236			RECOMMENDED	mg	13.5		STEADY-STATE	UNKNOWN		day	1			UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf	Homo sapiens		h	15.4							false
10908	59513		UNKNOWN	25267009	268.21	CEDAZURIDINE	CEDAZURIDINE	C1CN(C(=O)N[C@@H]1O)[C@H]2C([C@@H]([C@H](O2)CO)O)(F)F	PLASMA	39IS23Q1EW	451668		DECITABINE	Decitabine	NC1=NC(=O)N(C=N1)[C@H]2C[C@H](O)[C@@H](CO)O2	776B62CQ27	24		t	ng × h/mL	2950		ng/mL	371			RECOMMENDED	mg	100		STEADY-STATE	FASTED		day	1		20	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212576s000lbl.pdf	Homo sapiens		h	6.7							true
10909	59514		ADULT	134436906	525.6015	SELPERCATINIB	CC(C)(COC1=CN2C(=C(C=N2)C#N)C(=C1)C3=CN=C(C=C3)N4CC5CC(C4)N5CC6=CN=C(C=C6)OC)O	COC1=NC=C(CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(OCC(C)(C)O)=CN6N=CC(C#N)=C56)C=C1	PLASMA	CEGM9YBNGD							24		t	ng × h/mL	10000						INVESTIGATIONAL	mg	80		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pdfs.semanticscholar.org/cfc8/3d2a1480f8c2009538a722390a58679b3f6b.pdf	Homo sapiens										false
10910	59515		ADULT	135905454	471.5509	ZANUBRUTINIB	C=CC(=O)N1CCC(CC1)C2CCNC3=C(C(=NN23)C4=CC=C(C=C4)OC5=CC=CC=C5)C(=O)N	NC(=O)C1=C2NCCC(C3CCN(CC3)C(=O)C=C)N2N=C1C4=CC=C(OC5=CC=CC=C5)C=C4	PLASMA	AG9MHG098Z									?	ng × h/mL	2180		ng/mL	543			RECOMMENDED	mg	320		STEADY-STATE	UNKNOWN		day	1	The plasma protein binding of zanubrutinib is approximately 94%	6	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213217s000lbl.pdf	Homo sapiens		h	4							false
10911	59515		ADULT	135565884	471.5509	ZANUBRUTINIB	ZANUBRUTINIB	NC(=O)C1=C2NCC[C@@H](C3CCN(CC3)C(=O)C=C)N2N=C1C4=CC=C(OC5=CC=CC=C5)C=C4	PLASMA										∞	ng × h/mL	1405		ng/mL	346			RECOMMENDED	mg	160		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://www.ncbi.nlm.nih.gov/pubmed/31340982	Homo sapiens		h	3.31							false
10912	59516		ADULT		483.5	BALOXAVIR	BALOXAVIR		PLASMA	4G86Y4JT3F									∞	ng × h/mL	6669		ng/mL	123			RECOMMENDED	mg	40		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30288682/	Homo sapiens		h	85.9							false
10913	59516		ADULT		483.5	BALOXAVIR			PLASMA	4G86Y4JT3F									∞	ng × h/mL	11970		ng/mL	253			RECOMMENDED	mg	80		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30288682/	Homo sapiens		h	75.9							false
10914	59516		ADULT		483.5	BALOXAVIR			PLASMA	4G86Y4JT3F									∞	ng × h/mL	3867		ng/mL	49.1			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30288682/	Homo sapiens		h	104							false
10915	59516		ADULT		483.5	BALOXAVIR			PLASMA	4G86Y4JT3F									∞	ng × h/mL	2429		ng/mL	25.7			UNKNOWN	mg	20		SINGLE	FED						HEALTHY	Oral	MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/30288682/	Homo sapiens		h	114							false
10916	59516		ADULT		483.5	BALOXAVIR	BALOXAVIR		PLASMA	4G86Y4JT3F									∞	ng × h/mL	6160		ng/mL	96.4			RECOMMENDED	mg	40		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210854s000lbl.pdf	Homo sapiens		h	79.1							false
10917	59516		ADULT		483.5	BALOXAVIR			PLASMA	4G86Y4JT3F									∞	ng × h/mL	8009		ng/mL	107			RECOMMENDED	mg	80		SINGLE	UNKNOWN						HEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210854s000lbl.pdf	Homo sapiens		h	79.1							false
10918	59517		ADULT		542.712	FR-135313			PLASMA										∞	ng × h/mL	1549		ng/mL	377			RECOMMENDED	mg/m²	14		MULTIPLE	UNKNOWN		4 weeks	3	Romidepsin is highly protein bound in plasma (92% to 94%) over the concentration range of 50 ng/mL to 1000 ng/mL with α1-acid-glycoprotein (AAG) being the principal binding protein.	6	UNHEALTHY	Intravenous	FEMALE / MALE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022393s015lbl.pdf	Homo sapiens		h	3							false
10919	59519		ADULT	71365	330.423	ALMECILLIN	ALMECILLIN	CC1(C)S[C@@H]2[C@H](NC(=O)CSCC=C)C(=O)N2[C@H]1C(O)=O	BLOOD	6246WH0S1O							4		t	ng × h/mL	600		ng/mL	250			RECOMMENDED	mg	125		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/14856987/	Homo sapiens		h	1							false
10920	59532		ADULT	5369209	130.0987	MONOMETHYL FUMARATE	Monomethyl fumarate	COC(=O)\\C=C\\C(O)=O	PLASMA	45IUB1PX8R									?	mg × h/L	8.32		mg/L	2.11			RECOMMENDED	mg	462		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211855s000lbl.pdf	Homo sapiens					Patients with Multiple sclerosis					false
10921	59532		ADULT	5369209	130.0987	MONOMETHYL FUMARATE	Monomethyl fumarate	COC(=O)\\C=C\\C(O)=O	PLASMA	45IUB1PX8R									∞	μg × h/mL	3.57		μg/mL	1.57			RECOMMENDED	mg	462		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211855Orig1s000ClinPharmR.pdf#page=10	Homo sapiens							35			false
10922	59532		ADULT	5369209	130.0987	MONOMETHYL FUMARATE	Monomethyl fumarate	COC(=O)\\C=C\\C(O)=O	PLASMA	45IUB1PX8R									∞	μg × h/mL	4.879						RECOMMENDED	mg	462		SINGLE	FED						UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211855Orig1s000ClinPharmR.pdf#page=12	Homo sapiens					Mild renal impairment, Provided a standardized light snack 2 hours prior to dosing		5			false
10923	59532		ADULT	5369209	130.0987	MONOMETHYL FUMARATE	Monomethyl fumarate	COC(=O)\\C=C\\C(O)=O	PLASMA	45IUB1PX8R									∞	μg × h/mL	3.336						RECOMMENDED	mg	462		SINGLE	FED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211855Orig1s000ClinPharmR.pdf#page=12	Homo sapiens					Normal renal function, Provided a standardized light snack 2 hours prior to dosing		5			false
10924	59532		ADULT	5369209	130.0987	MONOMETHYL FUMARATE	Monomethyl fumarate	COC(=O)\\C=C\\C(O)=O	PLASMA	45IUB1PX8R									∞	μg × h/mL	4.939						RECOMMENDED	mg	462		SINGLE	FED						UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211855Orig1s000ClinPharmR.pdf#page=12	Homo sapiens					Moderate renal impairment, Provided a standardized light snack 2 hours prior to dosing		6			false
10925	59532		ADULT	5369209	130.0987	MONOMETHYL FUMARATE	Monomethyl fumarate	COC(=O)\\C=C\\C(O)=O	PLASMA	45IUB1PX8R									∞	μg × h/mL	4.743						RECOMMENDED	mg	462		SINGLE	FED						UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211855Orig1s000ClinPharmR.pdf#page=12	Homo sapiens					Severe renal impairment, Provided a standardized light snack 2 hours prior to dosing		6			false
10926	59532		ADULT	5369209	130.0987	MONOMETHYL FUMARATE	Monomethyl fumarate	COC(=O)\\C=C\\C(O)=O	PLASMA	45IUB1PX8R									∞	μg × h/mL	2.83		μg/mL	0.88			RECOMMENDED	mg	462		SINGLE	HIGH-FAT						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211855Orig1s000ClinPharmR.pdf#page=15	Homo sapiens					n=25 for AUCinf		42			false
10927	59532		ADULT	5369209	130.0987	MONOMETHYL FUMARATE	Monomethyl fumarate	COC(=O)\\C=C\\C(O)=O	PLASMA	45IUB1PX8R									∞	μg × h/mL	3.09		μg/mL	1.63			RECOMMENDED	mg	462		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211855Orig1s000ClinPharmR.pdf#page=20	Homo sapiens										false
10928	59532		ADULT	5369209	130.0987	MONOMETHYL FUMARATE	Monomethyl fumarate	COC(=O)\\C=C\\C(O)=O	PLASMA	45IUB1PX8R									?	μg × h/mL	2.5		μg/mL	0.955			RECOMMENDED	mg	462		SINGLE	HIGH-FAT						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211855Orig1s000ClinPharmR.pdf#page=21	Homo sapiens										false
10929	59532		ADULT	5369209	130.0987	MONOMETHYL FUMARATE	Monomethyl fumarate	COC(=O)\\C=C\\C(O)=O	PLASMA	45IUB1PX8R	702	46.0684	ALCOHOL	ethanol	CCO	3K9958V90M							μg/mL	0.9			UNKNOWN	mg	462		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211855Orig1s000ClinPharmR.pdf#page=23	Homo sapiens						5% v/v ethanol, 240 mL	30			true
10930	59532		ADULT	5369209	130.0987	MONOMETHYL FUMARATE	Monomethyl fumarate	COC(=O)\\C=C\\C(O)=O	PLASMA	45IUB1PX8R	702	46.0684	ALCOHOL	Ethanol	CCO	3K9958V90M							μg/mL	1			UNKNOWN	mg	462		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211855Orig1s000ClinPharmR.pdf#page=23	Homo sapiens						5% v/v ethanol, 240 mL	30			true
10931	59532		ADULT	5369209	130.0987	MONOMETHYL FUMARATE	Monomethyl fumarate	COC(=O)\\C=C\\C(O)=O	PLASMA	45IUB1PX8R	702	46.0684	ALCOHOL	Ethanol	CCO	3K9958V90M							μg/mL	0.6			UNKNOWN	mg	462		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211855Orig1s000ClinPharmR.pdf#page=23	Homo sapiens						40% v/v ethanol, 240 mL	30			true
10932	59532			5369209	130.0987	MONOMETHYL FUMARATE	Monomethyl fumarate	COC(=O)\\C=C\\C(O)=O	PLASMA	45IUB1PX8R																										Human plasma protein binding (Monomethyl fumarate): 75%	75				OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211855Orig1s000ClinPharmR.pdf#page=8	Homo sapiens										false
10933	59532		ADULT	5369209	130.0987	MONOMETHYL FUMARATE	Monomethyl fumarate	COC(=O)\\C=C\\C(O)=O	PLASMA	45IUB1PX8R																	UNKNOWN				SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211855Orig1s000ClinPharmR.pdf#page=8	Homo sapiens		h	1							false
10934	59533		ADULT	137528262	562.5684	BEROTRALSTAT	C1CC1CNC(C2=CC(=C(C=C2)F)NC(=O)C3=CC(=NN3C4=CC=CC(=C4)CN)C(F)(F)F)C5=CC=CC(=C5)C#N	NCc1cccc(c1)n2nc(cc2C(=O)Nc3cc(ccc3F)[C@H](NCC4CC4)c5cccc(c5)C#N)C(F)(F)F	PLASMA	XZA0KB1BDQ									?	ng × h/mL	2770		ng/mL	158			UNKNOWN	mg	150		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214094Orig1s000MultidisciplineR.pdf#page=52	Homo sapiens										false
10935	59533		ADULT	XZA0KB1BDQ	562.5684	BEROTRALSTAT	C1CC1CNC(C2=CC(=C(C=C2)F)NC(=O)C3=CC(=NN3C4=CC=CC(=C4)CN)C(F)(F)F)C5=CC=CC(=C5)C#N	NCc1cccc(c1)n2nc(cc2C(=O)Nc3cc(ccc3F)[C@H](NCC4CC4)c5cccc(c5)C#N)C(F)(F)F	PLASMA	XZA0KB1BDQ									?	ng × h/mL	1600		ng/mL	97.8			UNKNOWN	mg	110		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214094Orig1s000MultidisciplineR.pdf#page=52	Homo sapiens										false
10936	59533		UNKNOWN	137528262	562.5684	BEROTRALSTAT		NCc1cccc(c1)n2nc(cc2C(=O)Nc3cc(ccc3F)[C@H](NCC4CC4)c5cccc(c5)C#N)C(F)(F)F	PLASMA	XZA0KB1BDQ																	UNKNOWN				SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214094Orig1s000MultidisciplineR.pdf#page=52	Homo sapiens		h	93							false
10937	59533		UNKNOWN	137528262	562.5684	BEROTRALSTAT		NCc1cccc(c1)n2nc(cc2C(=O)Nc3cc(ccc3F)[C@H](NCC4CC4)c5cccc(c5)C#N)C(F)(F)F	PLASMA	XZA0KB1BDQ																	UNKNOWN	mg	300		SINGLE	UNKNOWN				Human plasma protein binding: 99%; Blood-to-plasma ratio: 0.92	1	UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214094Orig1s000MultidisciplineR.pdf#page=52 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214094Orig1s000MultidisciplineR.pdf#page=56	Homo sapiens										false
10938	59533		ADULT	137528262	562.5684	BEROTRALSTAT		NCc1cccc(c1)n2nc(cc2C(=O)Nc3cc(ccc3F)[C@H](NCC4CC4)c5cccc(c5)C#N)C(F)(F)F	PLASMA	XZA0KB1BDQ									∞	ng × h/L	850		ng/mL	57.9			RECOMMENDED	mg	150		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214094Orig1s000MultidisciplineR.pdf#page=62	Homo sapiens					Severe hepatic impairment		6			false
10939	59533		ADULT	137528262	562.5684	BEROTRALSTAT		NCc1cccc(c1)n2nc(cc2C(=O)Nc3cc(ccc3F)[C@H](NCC4CC4)c5cccc(c5)C#N)C(F)(F)F	PLASMA	XZA0KB1BDQ									∞	ng × h/L	907		ng/mL	45.5			RECOMMENDED	mg	150		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214094Orig1s000MultidisciplineR.pdf#page=62	Homo sapiens					Normal hepatic function		6			false
10940	59533		ADULT	137528262	562.5684	BEROTRALSTAT		NCc1cccc(c1)n2nc(cc2C(=O)Nc3cc(ccc3F)[C@H](NCC4CC4)c5cccc(c5)C#N)C(F)(F)F	PLASMA	XZA0KB1BDQ									∞	ng × h/L	945		ng/mL	45.9			RECOMMENDED	mg	150		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214094Orig1s000MultidisciplineR.pdf#page=62	Homo sapiens					Mild hepatic impairment		6			false
10941	59533		ADULT	137528262	562.5684	BEROTRALSTAT		NCc1cccc(c1)n2nc(cc2C(=O)Nc3cc(ccc3F)[C@H](NCC4CC4)c5cccc(c5)C#N)C(F)(F)F	PLASMA	XZA0KB1BDQ									∞	ng × h/L	1250		ng/mL	68.3			RECOMMENDED	mg	150		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214094Orig1s000MultidisciplineR.pdf#page=62	Homo sapiens					Combined moderate/severe hepatic impairment		6			false
10942	59533		ADULT	137528262	562.5684	BEROTRALSTAT		NCc1cccc(c1)n2nc(cc2C(=O)Nc3cc(ccc3F)[C@H](NCC4CC4)c5cccc(c5)C#N)C(F)(F)F	PLASMA	XZA0KB1BDQ									∞	ng × h/L	1620		ng/mL	80.5			RECOMMENDED	mg	150		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214094Orig1s000MultidisciplineR.pdf#page=62	Homo sapiens					Moderate hepatic impairment		6			false
10943	59533		ADULT	137528262	562.5684	BEROTRALSTAT		NCc1cccc(c1)n2nc(cc2C(=O)Nc3cc(ccc3F)[C@H](NCC4CC4)c5cccc(c5)C#N)C(F)(F)F	PLASMA	XZA0KB1BDQ									∞	ng × h/L	2063		ng/mL	89			UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214094Orig1s000MultidisciplineR.pdf#page=64	Homo sapiens					Normal renal function		7			false
10944	59533		ADULT	137528262	562.5684	BEROTRALSTAT		NCc1cccc(c1)n2nc(cc2C(=O)Nc3cc(ccc3F)[C@H](NCC4CC4)c5cccc(c5)C#N)C(F)(F)F	PLASMA	XZA0KB1BDQ									∞	ng × h/L	2252		ng/mL	130			UNKNOWN	mg	200		SINGLE	UNKNOWN						UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214094Orig1s000MultidisciplineR.pdf#page=64	Homo sapiens					Severe renal impairment (CLcr < 30 mL/min)		6			false
10945	59534		ADULT	68029831	446.556	TRILACICLIB		CN1CCN(CC1)c2ccc(Nc3ncc4cc5C(=O)NCC6(CCCCC6)n5c4n3)nc2	PLASMA	U6072DO9XG	60700	421.4458	TOPOTECAN	Topotecan	CC[C@@]1(O)C(=O)OCC2=C1C=C3N(CC4=CC5=C(C=CC(O)=C5CN(C)C)N=C34)C2=O	7M7YKX2N15	24		t	ng × h/mL	2320		ng/mL	1060			UNKNOWN	mg/m²	200		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33595690/ | https://static-content.springer.com/esm/art%3A10.1007%2Fs00280-021-04239-9/MediaObjects/280_2021_4239_MOESM1_ESM.pdf#page=10	Homo sapiens		h	8.57	Cycle 1 Day 4	Patients with previously treated ES-SCLC	on Days 1-5	9			true
10946	59534		ADULT	68029831	446.556	TRILACICLIB		CN1CCN(CC1)c2ccc(Nc3ncc4cc5C(=O)NCC6(CCCCC6)n5c4n3)nc2	PLASMA	U6072DO9XG	60700	421.4458	TOPOTECAN	Topotecan	CC[C@@]1(O)C(=O)OCC2=C1C=C3N(CC4=CC5=C(C=CC(O)=C5CN(C)C)N=C34)C2=O	7M7YKX2N15	24		t	ng × h/mL	2880		ng/mL	1220			UNKNOWN	mg/m²	240		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33595690/ | https://static-content.springer.com/esm/art%3A10.1007%2Fs00280-021-04239-9/MediaObjects/280_2021_4239_MOESM1_ESM.pdf#page=10	Homo sapiens		h	8.09	Cycle 1 Day 4	Patients with previously treated ES-SCLC	on Days 1-5	15			true
10947	59534		ADULT	68029831	446.556	TRILACICLIB		CN1CCN(CC1)c2ccc(Nc3ncc4cc5C(=O)NCC6(CCCCC6)n5c4n3)nc2	PLASMA	U6072DO9XG	60700	421.4458	TOPOTECAN	Topotecan	CC[C@@]1(O)C(=O)OCC2=C1C=C3N(CC4=CC5=C(C=CC(O)=C5CN(C)C)N=C34)C2=O	7M7YKX2N15			∞	ng × h/mL	2910		ng/mL	1270			UNKNOWN	mg/m²	240		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33595690/ | https://static-content.springer.com/esm/art%3A10.1007%2Fs00280-021-04239-9/MediaObjects/280_2021_4239_MOESM1_ESM.pdf#page=10	Homo sapiens		h	6.79	Cycle 1 Day 1	Patients with previously treated ES-SCLC	on Days 1-5	14			true
10948	59534		ADULT	68029831	446.556	TRILACICLIB		CN1CCN(CC1)c2ccc(Nc3ncc4cc5C(=O)NCC6(CCCCC6)n5c4n3)nc2	PLASMA	U6072DO9XG	60700	421.4458	TOPOTECAN	Topotecan	CC[C@@]1(O)C(=O)OCC2=C1C=C3N(CC4=CC5=C(C=CC(O)=C5CN(C)C)N=C34)C2=O	7M7YKX2N15			∞	ng × h/mL	3490		ng/mL	1110			UNKNOWN	mg/m²	280		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33595690/ | https://static-content.springer.com/esm/art%3A10.1007%2Fs00280-021-04239-9/MediaObjects/280_2021_4239_MOESM1_ESM.pdf#page=10	Homo sapiens		h	7.38	Cycle 1 Day 1	Patients with previously treated ES-SCLC	on Days 1-5	7			true
10949	59534		ADULT	68029831	446.556	TRILACICLIB		CN1CCN(CC1)c2ccc(Nc3ncc4cc5C(=O)NCC6(CCCCC6)n5c4n3)nc2	PLASMA	U6072DO9XG	60700	421.4458	TOPOTECAN	Topotecan	CC[C@@]1(O)C(=O)OCC2=C1C=C3N(CC4=CC5=C(C=CC(O)=C5CN(C)C)N=C34)C2=O	7M7YKX2N15			∞	ng × h/mL	4520		ng/mL	2220			UNKNOWN	mg/m²	280		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33595690/ | https://static-content.springer.com/esm/art%3A10.1007%2Fs00280-021-04239-9/MediaObjects/280_2021_4239_MOESM1_ESM.pdf#page=10	Homo sapiens		h	8.54	Cycle 1 Day 4	Patients with previously treated ES-SCLC	on Days 1-5	7			true
10950	59534		ADULT	68029831	446.556	TRILACICLIB		CN1CCN(CC1)c2ccc(Nc3ncc4cc5C(=O)NCC6(CCCCC6)n5c4n3)nc2	PLASMA	U6072DO9XG									∞	ng × h/mL	66.6		ng/mL	50.4			UNKNOWN	mg/m²	6		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33595690/ | https://static-content.springer.com/esm/art%3A10.1007%2Fs00280-021-04239-9/MediaObjects/280_2021_4239_MOESM1_ESM.pdf#page=9	Homo sapiens		h	5.32				3			false
10951	59534		ADULT	68029831	446.556	TRILACICLIB		CN1CCN(CC1)c2ccc(Nc3ncc4cc5C(=O)NCC6(CCCCC6)n5c4n3)nc2	PLASMA	U6072DO9XG									∞	ng × h/mL	143		ng/mL	119			UNKNOWN	mg/m²	12		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33595690/ | https://static-content.springer.com/esm/art%3A10.1007%2Fs00280-021-04239-9/MediaObjects/280_2021_4239_MOESM1_ESM.pdf#page=9	Homo sapiens		h	7.62				3			false
10952	59534		ADULT	68029831	446.556	TRILACICLIB		CN1CCN(CC1)c2ccc(Nc3ncc4cc5C(=O)NCC6(CCCCC6)n5c4n3)nc2	PLASMA	U6072DO9XG									∞	ng × h/mL	518		ng/mL	224			UNKNOWN	mg/m²	49		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33595690/ | https://static-content.springer.com/esm/art%3A10.1007%2Fs00280-021-04239-9/MediaObjects/280_2021_4239_MOESM1_ESM.pdf#page=9	Homo sapiens		h	12.9				3			false
10953	59534		ADULT	68029831	446.556	TRILACICLIB		CN1CCN(CC1)c2ccc(Nc3ncc4cc5C(=O)NCC6(CCCCC6)n5c4n3)nc2	PLASMA	U6072DO9XG									∞	ng × h/mL	279		ng/mL	255			UNKNOWN	mg/m²	24		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33595690/ | https://static-content.springer.com/esm/art%3A10.1007%2Fs00280-021-04239-9/MediaObjects/280_2021_4239_MOESM1_ESM.pdf#page=9	Homo sapiens		h	9.28				3			false
10954	59534		ADULT	68029831	446.556	TRILACICLIB		CN1CCN(CC1)c2ccc(Nc3ncc4cc5C(=O)NCC6(CCCCC6)n5c4n3)nc2	PLASMA	U6072DO9XG									∞	ng × h/mL	1341		ng/mL	910			UNKNOWN	mg/m²	96		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33595690/ | https://static-content.springer.com/esm/art%3A10.1007%2Fs00280-021-04239-9/MediaObjects/280_2021_4239_MOESM1_ESM.pdf#page=9	Homo sapiens		h	14.7				6			false
10955	59534		ADULT	68029831	446.556	TRILACICLIB		CN1CCN(CC1)c2ccc(Nc3ncc4cc5C(=O)NCC6(CCCCC6)n5c4n3)nc2	PLASMA	U6072DO9XG									∞	ng × h/mL	1341		ng/mL	910			UNKNOWN	mg/m²	96		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33595690/ | https://static-content.springer.com/esm/art%3A10.1007%2Fs00280-021-04239-9/MediaObjects/280_2021_4239_MOESM1_ESM.pdf#page=9	Homo sapiens		h	14.7				6			false
10956	59534		ADULT	68029831	446.556	TRILACICLIB		CN1CCN(CC1)c2ccc(Nc3ncc4cc5C(=O)NCC6(CCCCC6)n5c4n3)nc2	PLASMA	U6072DO9XG									∞	ng × h/mL	3106		ng/mL	1969			UNKNOWN	mg/m²	192		SINGLE	UNKNOWN						HEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33595690/ | https://static-content.springer.com/esm/art%3A10.1007%2Fs00280-021-04239-9/MediaObjects/280_2021_4239_MOESM1_ESM.pdf#page=9	Homo sapiens		h	14.5				6			false
10957	59534		ADULT	68029831	446.556	TRILACICLIB		CN1CCN(CC1)c2ccc(Nc3ncc4cc5C(=O)NCC6(CCCCC6)n5c4n3)nc2	PLASMA	U6072DO9XG	60700	421.4458	TOPOTECAN	Topotecan	CC[C@@]1(O)C(=O)OCC2=C1C=C3N(CC4=CC5=C(C=CC(O)=C5CN(C)C)N=C34)C2=O	7M7YKX2N15			∞	ng × h/mL	2410		ng/mL	1200			UNKNOWN	mg/m²	200		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Intravenous	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33595690/ | https://static-content.springer.com/esm/art%3A10.1007%2Fs00280-021-04239-9/MediaObjects/280_2021_4239_MOESM1_ESM.pdf#page=9	Homo sapiens		h	6.92	Cycle 1 Day 1	Patients with previously treated ES-SCLC	on Days 1-5	10			true
10958	59534		UNKNOWN	68029831	446.556	TRILACICLIB		CN1CCN(CC1)c2ccc(Nc3ncc4cc5C(=O)NCC6(CCCCC6)n5c4n3)nc2	PLASMA	U6072DO9XG									?	ng × h/mL	2730		ng/mL	1270			RECOMMENDED	mg/m²	240		SINGLE	UNKNOWN						UNKNOWN	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214200Orig1s000ClinPharmR.pdf#page=11	Homo sapiens										false
10959	59534		ADULT	68029831	446.556	TRILACICLIB		CN1CCN(CC1)c2ccc(Nc3ncc4cc5C(=O)NCC6(CCCCC6)n5c4n3)nc2	PLASMA	U6072DO9XG									∞	ng × h/mL	2969		ng/mL	1020			RECOMMENDED	mg/m²	240		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214200Orig1s000ClinPharmR.pdf#page=24	Homo sapiens					non-Japanese					false
10960	59534		ADULT	68029831	446.556	TRILACICLIB		CN1CCN(CC1)c2ccc(Nc3ncc4cc5C(=O)NCC6(CCCCC6)n5c4n3)nc2	PLASMA	U6072DO9XG									∞	ng × h/mL	3922		ng/mL	2457			RECOMMENDED	mg/m²	240		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214200Orig1s000ClinPharmR.pdf#page=24	Homo sapiens					Japanese					false
10961	59534		UNKNOWN	68029831	446.556	TRILACICLIB		CN1CCN(CC1)c2ccc(Nc3ncc4cc5C(=O)NCC6(CCCCC6)n5c4n3)nc2	PLASMA	U6072DO9XG																					SINGLE	UNKNOWN						UNKNOWN	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214200Orig1s000ClinPharmR.pdf#page=7	Homo sapiens		h	14							false
10962	59534		UNKNOWN	68029831	446.556	TRILACICLIB		CN1CCN(CC1)c2ccc(Nc3ncc4cc5C(=O)NCC6(CCCCC6)n5c4n3)nc2	PLASMA	U6072DO9XG																						UNKNOWN				Human plasma protein binding (equilibrium dialysis): 69.6% (50ng/mL), 71.7% (750ng/mL), 69.6% (20000ng/mL)	28.3	UNKNOWN		UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214200Orig1s000PharmR.pdf#page=35	Homo sapiens										false
10963	59535		ADULT	126961379	3381.6418	DASIGLUCAGON		CC(C)C[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)C(C)(C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc5ccc(O)cc5)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc6ccccc6)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc7c[nH]cn7)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)O	PLASMA	AD4J2O47FQ													pg/mL	5107			UNKNOWN	mg	0.6		SINGLE	UNKNOWN						UNHEALTHY	Subcutaneous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214231Orig1s000ClinPharmR.pdf#page=7	Homo sapiens		min	30		Patients with T1DM					false
10964	59536		ADULT	46871657	730.0443	IBREXAFUNGERP		CC(C)[C@@H](C)[C@@]1(C)CC[C@]2(C)[C@H]3CC[C@H]4[C@@]5(C)COC[C@@]4(C[C@H]([C@@H]5OC[C@](C)(N)C(C)(C)C)n6ncnc6c7ccncc7)C3=CC[C@@]2(C)[C@@H]1C(=O)O	PLASMA	A92JFM5XNU									∞	μM × h	0.26		nM	12.75			UNKNOWN	mg	20		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214900Orig1s000MultidisciplineR.pdf#page=179	Homo sapiens		h	16.4				6			false
10965	59536		ADULT	46871657	730.0443	IBREXAFUNGERP		CC(C)[C@@H](C)[C@@]1(C)CC[C@]2(C)[C@H]3CC[C@H]4[C@@]5(C)COC[C@@]4(C[C@H]([C@@H]5OC[C@](C)(N)C(C)(C)C)n6ncnc6c7ccncc7)C3=CC[C@@]2(C)[C@@H]1C(=O)O	PLASMA	A92JFM5XNU									∞	μM × h	3.27		nM	167.86			UNKNOWN	mg	150		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214900Orig1s000MultidisciplineR.pdf#page=179	Homo sapiens		h	19.7				6			false
10966	59536		ADULT	46871657	730.0443	IBREXAFUNGERP		CC(C)[C@@H](C)[C@@]1(C)CC[C@]2(C)[C@H]3CC[C@H]4[C@@]5(C)COC[C@@]4(C[C@H]([C@@H]5OC[C@](C)(N)C(C)(C)C)n6ncnc6c7ccncc7)C3=CC[C@@]2(C)[C@@H]1C(=O)O	PLASMA	A92JFM5XNU									∞	μM × h	17.97		nM	875.86			DEFINED DAILY	mg	600		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214900Orig1s000MultidisciplineR.pdf#page=179	Homo sapiens		h	18.7				7			false
10967	59536		ADULT	46871657	730.0443	IBREXAFUNGERP		CC(C)[C@@H](C)[C@@]1(C)CC[C@]2(C)[C@H]3CC[C@H]4[C@@]5(C)COC[C@@]4(C[C@H]([C@@H]5OC[C@](C)(N)C(C)(C)C)n6ncnc6c7ccncc7)C3=CC[C@@]2(C)[C@@H]1C(=O)O	PLASMA	A92JFM5XNU									∞	μM × h	51.6		nM	2085.4			UNKNOWN	mg	1600		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214900Orig1s000MultidisciplineR.pdf#page=179	Homo sapiens		h	20.9				5			false
10968	59536		ADULT	46871657	730.0443	IBREXAFUNGERP		CC(C)[C@@H](C)[C@@]1(C)CC[C@]2(C)[C@H]3CC[C@H]4[C@@]5(C)COC[C@@]4(C[C@H]([C@@H]5OC[C@](C)(N)C(C)(C)C)n6ncnc6c7ccncc7)C3=CC[C@@]2(C)[C@@H]1C(=O)O	PLASMA	A92JFM5XNU									∞	μM × h	0.15		nM	6.13			UNKNOWN	mg	10		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214900Orig1s000MultidisciplineR.pdf#page=179	Homo sapiens		h	21				6			false
10969	59536		ADULT	46871657	730.0443	IBREXAFUNGERP		CC(C)[C@@H](C)[C@@]1(C)CC[C@]2(C)[C@H]3CC[C@H]4[C@@]5(C)COC[C@@]4(C[C@H]([C@@H]5OC[C@](C)(N)C(C)(C)C)n6ncnc6c7ccncc7)C3=CC[C@@]2(C)[C@@H]1C(=O)O	PLASMA	A92JFM5XNU									∞	μM × h	0.62		nM	30.87			UNKNOWN	mg	40		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214900Orig1s000MultidisciplineR.pdf#page=179	Homo sapiens		h	17.8				6			false
10970	59536		ADULT	46871657	730.0443	IBREXAFUNGERP		CC(C)[C@@H](C)[C@@]1(C)CC[C@]2(C)[C@H]3CC[C@H]4[C@@]5(C)COC[C@@]4(C[C@H]([C@@H]5OC[C@](C)(N)C(C)(C)C)n6ncnc6c7ccncc7)C3=CC[C@@]2(C)[C@@H]1C(=O)O	PLASMA	A92JFM5XNU									∞	μM × h	1.33		nM	60.24			UNKNOWN	mg	80		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214900Orig1s000MultidisciplineR.pdf#page=179	Homo sapiens		h	21.1				6			false
10971	59536		ADULT	46871657	730.0443	IBREXAFUNGERP		CC(C)[C@@H](C)[C@@]1(C)CC[C@]2(C)[C@H]3CC[C@H]4[C@@]5(C)COC[C@@]4(C[C@H]([C@@H]5OC[C@](C)(N)C(C)(C)C)n6ncnc6c7ccncc7)C3=CC[C@@]2(C)[C@@H]1C(=O)O	PLASMA	A92JFM5XNU									∞	μM × h	20.07		nM	895.6			UNKNOWN	mg	800		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214900Orig1s000MultidisciplineR.pdf#page=179	Homo sapiens		h	19.3				6			false
10972	59536		ADULT	46871657	730.0443	IBREXAFUNGERP		CC(C)[C@@H](C)[C@@]1(C)CC[C@]2(C)[C@H]3CC[C@H]4[C@@]5(C)COC[C@@]4(C[C@H]([C@@H]5OC[C@](C)(N)C(C)(C)C)n6ncnc6c7ccncc7)C3=CC[C@@]2(C)[C@@H]1C(=O)O	PLASMA	A92JFM5XNU									∞	μM × h	1.7		nM	71.93			UNKNOWN	mg	80		SINGLE	HIGH-FAT						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214900Orig1s000MultidisciplineR.pdf#page=179	Homo sapiens		h	19.9				6			false
10973	59536		ADULT	46871657	730.0443	IBREXAFUNGERP		CC(C)[C@@H](C)[C@@]1(C)CC[C@]2(C)[C@H]3CC[C@H]4[C@@]5(C)COC[C@@]4(C[C@H]([C@@H]5OC[C@](C)(N)C(C)(C)C)n6ncnc6c7ccncc7)C3=CC[C@@]2(C)[C@@H]1C(=O)O	PLASMA	A92JFM5XNU									∞	μM × h	3.27		nM	349.15			UNKNOWN	mg	300		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214900Orig1s000MultidisciplineR.pdf#page=179	Homo sapiens		h	20.5				6			false
10974	59536		ADULT	46871657	730.0443	IBREXAFUNGERP		CC(C)[C@@H](C)[C@@]1(C)CC[C@]2(C)[C@H]3CC[C@H]4[C@@]5(C)COC[C@@]4(C[C@H]([C@@H]5OC[C@](C)(N)C(C)(C)C)n6ncnc6c7ccncc7)C3=CC[C@@]2(C)[C@@H]1C(=O)O	PLASMA	A92JFM5XNU							24		t	μM × h	3.82		nM	308.6			UNKNOWN	mg	300		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214900Orig1s000MultidisciplineR.pdf#page=180	Homo sapiens		h	13.3	Day 1			6			false
10975	59536		ADULT	46871657	730.0443	IBREXAFUNGERP		CC(C)[C@@H](C)[C@@]1(C)CC[C@]2(C)[C@H]3CC[C@H]4[C@@]5(C)COC[C@@]4(C[C@H]([C@@H]5OC[C@](C)(N)C(C)(C)C)n6ncnc6c7ccncc7)C3=CC[C@@]2(C)[C@@H]1C(=O)O	PLASMA	A92JFM5XNU							24		t	μM × h	9.01		nM	553.7			UNKNOWN	mg	300		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214900Orig1s000MultidisciplineR.pdf#page=180	Homo sapiens		h	24.7	Day 10			6			false
10976	59536		ADULT	46871657	730.0443	IBREXAFUNGERP		CC(C)[C@@H](C)[C@@]1(C)CC[C@]2(C)[C@H]3CC[C@H]4[C@@]5(C)COC[C@@]4(C[C@H]([C@@H]5OC[C@](C)(N)C(C)(C)C)n6ncnc6c7ccncc7)C3=CC[C@@]2(C)[C@@H]1C(=O)O	PLASMA	A92JFM5XNU							24		t	μM × h	9.38		nM	705.9			DEFINED DAILY	mg	600		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214900Orig1s000MultidisciplineR.pdf#page=180	Homo sapiens		h	14.6	Day 1			6			false
10977	59536		ADULT	46871657	730.0443	IBREXAFUNGERP		CC(C)[C@@H](C)[C@@]1(C)CC[C@]2(C)[C@H]3CC[C@H]4[C@@]5(C)COC[C@@]4(C[C@H]([C@@H]5OC[C@](C)(N)C(C)(C)C)n6ncnc6c7ccncc7)C3=CC[C@@]2(C)[C@@H]1C(=O)O	PLASMA	A92JFM5XNU							24		t	μM × h	21.11		nM	1272			DEFINED DAILY	mg	600		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214900Orig1s000MultidisciplineR.pdf#page=180	Homo sapiens		h	28.9	Day 10			6			false
10978	59536		ADULT	46871657	730.0443	IBREXAFUNGERP		CC(C)[C@@H](C)[C@@]1(C)CC[C@]2(C)[C@H]3CC[C@H]4[C@@]5(C)COC[C@@]4(C[C@H]([C@@H]5OC[C@](C)(N)C(C)(C)C)n6ncnc6c7ccncc7)C3=CC[C@@]2(C)[C@@H]1C(=O)O	PLASMA	A92JFM5XNU							24		t	μM × h	12.53		nM	1024			UNKNOWN	mg	800		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214900Orig1s000MultidisciplineR.pdf#page=180	Homo sapiens		h	11.3	Day 1			6			false
10979	59536		ADULT	46871657	730.0443	IBREXAFUNGERP		CC(C)[C@@H](C)[C@@]1(C)CC[C@]2(C)[C@H]3CC[C@H]4[C@@]5(C)COC[C@@]4(C[C@H]([C@@H]5OC[C@](C)(N)C(C)(C)C)n6ncnc6c7ccncc7)C3=CC[C@@]2(C)[C@@H]1C(=O)O	PLASMA	A92JFM5XNU							24		t	μM × h	26.38		nM	1609			UNKNOWN	mg	800		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214900Orig1s000MultidisciplineR.pdf#page=180	Homo sapiens		h	32.3	Day 10			6			false
10980	59536		ADULT	46871657	730.0443	IBREXAFUNGERP		CC(C)[C@@H](C)[C@@]1(C)CC[C@]2(C)[C@H]3CC[C@H]4[C@@]5(C)COC[C@@]4(C[C@H]([C@@H]5OC[C@](C)(N)C(C)(C)C)n6ncnc6c7ccncc7)C3=CC[C@@]2(C)[C@@H]1C(=O)O	PLASMA	A92JFM5XNU							24		t	μM × h	13.75		nM	1112			UNKNOWN	mg	800		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214900Orig1s000MultidisciplineR.pdf#page=180	Homo sapiens		h	14.3	Day 1 (28-day treatment)			5			false
10981	59536		ADULT	46871657	730.0443	IBREXAFUNGERP		CC(C)[C@@H](C)[C@@]1(C)CC[C@]2(C)[C@H]3CC[C@H]4[C@@]5(C)COC[C@@]4(C[C@H]([C@@H]5OC[C@](C)(N)C(C)(C)C)n6ncnc6c7ccncc7)C3=CC[C@@]2(C)[C@@H]1C(=O)O	PLASMA	A92JFM5XNU							24		t	μM × h	45.85		nM	2634			UNKNOWN	mg	800		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214900Orig1s000MultidisciplineR.pdf#page=180	Homo sapiens		h	22.6	Day 26 (28-day treatment)			5			false
10982	59536		ADULT	46871657	730.0443	IBREXAFUNGERP		CC(C)[C@@H](C)[C@@]1(C)CC[C@]2(C)[C@H]3CC[C@H]4[C@@]5(C)COC[C@@]4(C[C@H]([C@@H]5OC[C@](C)(N)C(C)(C)C)n6ncnc6c7ccncc7)C3=CC[C@@]2(C)[C@@H]1C(=O)O	PLASMA	A92JFM5XNU							12		t	ng × h/mL	6283		ng/mL	724.1			UNKNOWN	mg	750		MULTIPLE	UNKNOWN		day	2			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214900Orig1s000MultidisciplineR.pdf#page=182	Homo sapiens				Day 1 (750mg BID on Days 1 and 2)			16			false
10983	59536		ADULT	46871657	730.0443	IBREXAFUNGERP		CC(C)[C@@H](C)[C@@]1(C)CC[C@]2(C)[C@H]3CC[C@H]4[C@@]5(C)COC[C@@]4(C[C@H]([C@@H]5OC[C@](C)(N)C(C)(C)C)n6ncnc6c7ccncc7)C3=CC[C@@]2(C)[C@@H]1C(=O)O	PLASMA	A92JFM5XNU							12		t	ng × h/mL	15630		ng/mL	1497			UNKNOWN	mg	750		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214900Orig1s000MultidisciplineR.pdf#page=182	Homo sapiens		h	41.071	Day 7 (750mg QD on Days 3 trough 7)			16			false
10984	59536		ADULT	46871657	730.0443	IBREXAFUNGERP		CC(C)[C@@H](C)[C@@]1(C)CC[C@]2(C)[C@H]3CC[C@H]4[C@@]5(C)COC[C@@]4(C[C@H]([C@@H]5OC[C@](C)(N)C(C)(C)C)n6ncnc6c7ccncc7)C3=CC[C@@]2(C)[C@@H]1C(=O)O	PLASMA	A92JFM5XNU							24		t	μM × h	20.75		nM	1542			UNKNOWN	mg	600		MULTIPLE	UNKNOWN		day	3			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214900Orig1s000MultidisciplineR.pdf#page=183	Homo sapiens				Day 1 (600mg TID on Day 1, loading dose, 500mg QD on Days 2 through 7)			6			false
10985	59536		ADULT	46871657	730.0443	IBREXAFUNGERP		CC(C)[C@@H](C)[C@@]1(C)CC[C@]2(C)[C@H]3CC[C@H]4[C@@]5(C)COC[C@@]4(C[C@H]([C@@H]5OC[C@](C)(N)C(C)(C)C)n6ncnc6c7ccncc7)C3=CC[C@@]2(C)[C@@H]1C(=O)O	PLASMA	A92JFM5XNU							24		t	μM × h	20.95		nM	1196			UNKNOWN	mg	500		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214900Orig1s000MultidisciplineR.pdf#page=183	Homo sapiens		h	19.3	Day 3 (600mg TID on Day 1, loading dose, 500mg QD on Days 2 through 7)			6			false
10986	59536		ADULT	46871657	730.0443	IBREXAFUNGERP		CC(C)[C@@H](C)[C@@]1(C)CC[C@]2(C)[C@H]3CC[C@H]4[C@@]5(C)COC[C@@]4(C[C@H]([C@@H]5OC[C@](C)(N)C(C)(C)C)n6ncnc6c7ccncc7)C3=CC[C@@]2(C)[C@@H]1C(=O)O	PLASMA	A92JFM5XNU							24		t	μM × h	16.11		nM	959			UNKNOWN	mg	500		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214900Orig1s000MultidisciplineR.pdf#page=183	Homo sapiens		h	25.6	Day 7 (600mg TID on Day 1, loading dose, 500mg QD on Days 2 through 7)			6			false
10987	59536		UNKNOWN	46871657	730.0443	IBREXAFUNGERP		CC(C)[C@@H](C)[C@@]1(C)CC[C@]2(C)[C@H]3CC[C@H]4[C@@]5(C)COC[C@@]4(C[C@H]([C@@H]5OC[C@](C)(N)C(C)(C)C)n6ncnc6c7ccncc7)C3=CC[C@@]2(C)[C@@H]1C(=O)O	PLASMA	A92JFM5XNU																										Human plasma protein binding (equilibrium dialysis): 99.8 (Fu: 0.210)% (0.1ng/mL), 99.8 (Fu: 0.247)% (0.5ng/mL), 99.8 (Fu: 0.187)% (1ng/mL), 99.6 (Fu: 0.410)% (5ng/mL), and 99.6 (Fu: 0.397)% (10ng/mL)	0.187			UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214900Orig1s000MultidisciplineR.pdf#page=186	Homo sapiens										false
10988	59536		ADULT	46871657	730.0443	IBREXAFUNGERP		CC(C)[C@@H](C)[C@@]1(C)CC[C@]2(C)[C@H]3CC[C@H]4[C@@]5(C)COC[C@@]4(C[C@H]([C@@H]5OC[C@](C)(N)C(C)(C)C)n6ncnc6c7ccncc7)C3=CC[C@@]2(C)[C@@H]1C(=O)O	PLASMA	A92JFM5XNU																	UNKNOWN	mg	300		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214900Orig1s000MultidisciplineR.pdf#page=80	Homo sapiens		h	20				6	Ibrexafungerp salt form equivalent to 300mg free drug		false
10989	59536		ADULT	46871657	730.0443	IBREXAFUNGERP		CC(C)[C@@H](C)[C@@]1(C)CC[C@]2(C)[C@H]3CC[C@H]4[C@@]5(C)COC[C@@]4(C[C@H]([C@@H]5OC[C@](C)(N)C(C)(C)C)n6ncnc6c7ccncc7)C3=CC[C@@]2(C)[C@@H]1C(=O)O	PLASMA	A92JFM5XNU									∞	nM × h	7997		nM	318			UNKNOWN	mg	600		SINGLE	FED				Dose Normalized (AUCinf and Cmax/300mg Dose)		HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214900Orig1s000MultidisciplineR.pdf#page=84	Homo sapiens							9	Ibrexafungerp citrate form equivalent to 300mg free drug		false
10990	59536		ADULT	46871657	730.0443	IBREXAFUNGERP		CC(C)[C@@H](C)[C@@]1(C)CC[C@]2(C)[C@H]3CC[C@H]4[C@@]5(C)COC[C@@]4(C[C@H]([C@@H]5OC[C@](C)(N)C(C)(C)C)n6ncnc6c7ccncc7)C3=CC[C@@]2(C)[C@@H]1C(=O)O	PLASMA	A92JFM5XNU									∞	nM × h	11052		nM	420.6			UNKNOWN	mg	300		SINGLE	FED				Dose Normalized (AUCinf and Cmax/300mg Dose)		HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214900Orig1s000MultidisciplineR.pdf#page=84	Homo sapiens							9	Ibrexafungerp citrate form equivalent to 300mg free drug		false
10991	59536		ADULT	46871657	730.0443	IBREXAFUNGERP		CC(C)[C@@H](C)[C@@]1(C)CC[C@]2(C)[C@H]3CC[C@H]4[C@@]5(C)COC[C@@]4(C[C@H]([C@@H]5OC[C@](C)(N)C(C)(C)C)n6ncnc6c7ccncc7)C3=CC[C@@]2(C)[C@@H]1C(=O)O	PLASMA	A92JFM5XNU									∞	nM × h	795.1		nM	36.13			UNKNOWN	mg	600		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214900Orig1s000MultidisciplineR.pdf#page=87 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214900Orig1s000MultidisciplineR.pdf#page=200	Homo sapiens		h	20.3				12	Ibrexafungerp citrate form equivalent to 300mg free drug		false
10992	59537		ADULT	39HBQ4A67L	585.6966	MOBOCERTINIB		COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc2ncc(C(=O)OC(C)C)c(n2)c3cn(C)c4ccccc34	PLASMA	39HBQ4A67L																	UNKNOWN				STEADY-STATE	UNKNOWN		day	1			UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215310s000lbl.pdf#page=14	Homo sapiens		h	18							false
10993	59537		ADULT	118607832	585.6966	MOBOCERTINIB		COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc2ncc(C(=O)OC(C)C)c(n2)c3cn(C)c4ccccc34	PLASMA	39HBQ4A67L							24		t	ng × h/mL	28.3		ng/mL	2.27			UNKNOWN	mg	5		MULTIPLE	UNKNOWN		day	1			UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215310Orig1s000MultidisciplineR.pdf#page=274	Homo sapiens				Day 1			4			false
10994	59537		ADULT	118607832	585.6966	MOBOCERTINIB		COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc2ncc(C(=O)OC(C)C)c(n2)c3cn(C)c4ccccc34	PLASMA	39HBQ4A67L							24		t	ng × h/mL	36		ng/mL	2.15			UNKNOWN	mg	5		MULTIPLE	UNKNOWN		day	1			UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215310Orig1s000MultidisciplineR.pdf#page=274	Homo sapiens				Day 29			2			false
10995	59537		ADULT	118607832	585.6966	MOBOCERTINIB		COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc2ncc(C(=O)OC(C)C)c(n2)c3cn(C)c4ccccc34	PLASMA	39HBQ4A67L							24		t	ng × h/mL	62.3		ng/mL	5.37			UNKNOWN	mg	10		MULTIPLE	UNKNOWN		day	1			UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215310Orig1s000MultidisciplineR.pdf#page=274	Homo sapiens				Day 1			5			false
10996	59537		ADULT	118607832	585.6966	MOBOCERTINIB		COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc2ncc(C(=O)OC(C)C)c(n2)c3cn(C)c4ccccc34	PLASMA	39HBQ4A67L							24		t	ng × h/mL	99.8		ng/mL	5.77			UNKNOWN	mg	10		MULTIPLE	UNKNOWN		day	1			UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215310Orig1s000MultidisciplineR.pdf#page=274	Homo sapiens				Day 29			2			false
10997	59537		ADULT	118607832	585.6966	MOBOCERTINIB		COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc2ncc(C(=O)OC(C)C)c(n2)c3cn(C)c4ccccc34	PLASMA	39HBQ4A67L							24		t	ng × h/mL	99.2		ng/mL	8.79			UNKNOWN	mg	20		MULTIPLE	UNKNOWN		day	1			UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215310Orig1s000MultidisciplineR.pdf#page=274	Homo sapiens				Day 1			5			false
10998	59537		ADULT	118607832	585.6966	MOBOCERTINIB		COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc2ncc(C(=O)OC(C)C)c(n2)c3cn(C)c4ccccc34	PLASMA	39HBQ4A67L							24		t	ng × h/mL	105		ng/mL	7.7			UNKNOWN	mg	20		MULTIPLE	UNKNOWN		day	1			UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215310Orig1s000MultidisciplineR.pdf#page=275	Homo sapiens				Day 29			4			false
10999	59537		ADULT	118607832	585.6966	MOBOCERTINIB		COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc2ncc(C(=O)OC(C)C)c(n2)c3cn(C)c4ccccc34	PLASMA	39HBQ4A67L							24		t	ng × h/mL	250		ng/mL	20.2			UNKNOWN	mg	40		MULTIPLE	UNKNOWN		day	1			UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215310Orig1s000MultidisciplineR.pdf#page=275	Homo sapiens				Day 1			6			false
11000	59537		ADULT	118607832	585.6966	MOBOCERTINIB		COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc2ncc(C(=O)OC(C)C)c(n2)c3cn(C)c4ccccc34	PLASMA	39HBQ4A67L							24		t	ng × h/mL	295		ng/mL	19.3			UNKNOWN	mg	40		MULTIPLE	UNKNOWN		day	1			UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215310Orig1s000MultidisciplineR.pdf#page=275	Homo sapiens				Day 29			4			false
11001	59537		ADULT	118607832	585.6966	MOBOCERTINIB		COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc2ncc(C(=O)OC(C)C)c(n2)c3cn(C)c4ccccc34	PLASMA	39HBQ4A67L							24		t	ng × h/mL	386		ng/mL	33.3			UNKNOWN	mg	80		MULTIPLE	UNKNOWN		day	1			UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215310Orig1s000MultidisciplineR.pdf#page=275	Homo sapiens				Day 1			7			false
11002	59537		ADULT	118607832	585.6966	MOBOCERTINIB		COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc2ncc(C(=O)OC(C)C)c(n2)c3cn(C)c4ccccc34	PLASMA	39HBQ4A67L							24		t	ng × h/mL	321		ng/mL	22.4			UNKNOWN	mg	80		MULTIPLE	UNKNOWN		day	1			UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215310Orig1s000MultidisciplineR.pdf#page=275	Homo sapiens				Day 29			3			false
11003	59537		ADULT	118607832	585.6966	MOBOCERTINIB		COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc2ncc(C(=O)OC(C)C)c(n2)c3cn(C)c4ccccc34	PLASMA	39HBQ4A67L							24		t	ng × h/mL	599		ng/mL	49.3			UNKNOWN	mg	120		MULTIPLE	UNKNOWN		day	1			UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215310Orig1s000MultidisciplineR.pdf#page=275	Homo sapiens				Day 1			26			false
11004	59537		ADULT	118607832	585.6966	MOBOCERTINIB		COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc2ncc(C(=O)OC(C)C)c(n2)c3cn(C)c4ccccc34	PLASMA	39HBQ4A67L							24		t	ng × h/mL	772		ng/mL	52.9			UNKNOWN	mg	120		MULTIPLE	UNKNOWN		day	1			UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215310Orig1s000MultidisciplineR.pdf#page=275	Homo sapiens				Day 29			14			false
11005	59537		ADULT	118607832	585.6966	MOBOCERTINIB		COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc2ncc(C(=O)OC(C)C)c(n2)c3cn(C)c4ccccc34	PLASMA	39HBQ4A67L							24		t	ng × h/mL	1055		ng/mL	86.9			UNKNOWN	mg	180		MULTIPLE	UNKNOWN		day	1			UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215310Orig1s000MultidisciplineR.pdf#page=275	Homo sapiens				Day 1			4			false
11006	59537		ADULT	118607832	585.6966	MOBOCERTINIB		COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc2ncc(C(=O)OC(C)C)c(n2)c3cn(C)c4ccccc34	PLASMA	39HBQ4A67L							24		t	ng × h/mL	768		ng/mL	64.8			UNKNOWN	mg	180		MULTIPLE	UNKNOWN		day	1			UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215310Orig1s000MultidisciplineR.pdf#page=275	Homo sapiens				Day 29			1			false
11007	59537		ADULT	118607832	585.6966	MOBOCERTINIB		COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc2ncc(C(=O)OC(C)C)c(n2)c3cn(C)c4ccccc34	PLASMA	39HBQ4A67L									∞	ng × h/mL	58.3		ng/mL	17			UNKNOWN	mg	180		MULTIPLE	UNKNOWN		day	1			UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215310Orig1s000MultidisciplineR.pdf#page=282	Homo sapiens				Day 29						false
11008	59537			118607832	585.6966	MOBOCERTINIB		COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc2ncc(C(=O)OC(C)C)c(n2)c3cn(C)c4ccccc34	PLASMA	39HBQ4A67L																										Human plasma protein binding: 99.3%	0.7				OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215310Orig1s000MultidisciplineR.pdf#page=57	Homo sapiens										false
11009	59538		ADULT	91801202	450.9207	DARIDOREXANT		COc1ccc(c(c1)C(=O)N2CCC[C@@]2(C)c3nc4c(C)c(Cl)ccc4[nH]3)n5nccn5	PLASMA	LMQ24G57E9							24		t	ng × h/mL	2568		ng/mL	632			RECOMMENDED	mg	25		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214985Orig1s000IntegratedR.pdf#page=234	Homo sapiens		h	6.1				6			false
11010	59538		ADULT	91801202	450.9207	DARIDOREXANT		COc1ccc(c(c1)C(=O)N2CCC[C@@]2(C)c3nc4c(C)c(Cl)ccc4[nH]3)n5nccn5	PLASMA	LMQ24G57E9							24		t	ng × h/mL	6947		ng/mL	1231			RECOMMENDED	mg	50		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214985Orig1s000IntegratedR.pdf#page=234	Homo sapiens		h	5.9				6			false
11011	59538		ADULT	91801202	450.9207	DARIDOREXANT		COc1ccc(c(c1)C(=O)N2CCC[C@@]2(C)c3nc4c(C)c(Cl)ccc4[nH]3)n5nccn5	PLASMA	LMQ24G57E9							24		t	ng × h/mL	10998		ng/mL	1557			UNKNOWN	mg	100		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214985Orig1s000IntegratedR.pdf#page=234	Homo sapiens		h	7.5				6			false
11012	59538		ADULT	91801202	450.9207	DARIDOREXANT		COc1ccc(c(c1)C(=O)N2CCC[C@@]2(C)c3nc4c(C)c(Cl)ccc4[nH]3)n5nccn5	PLASMA	LMQ24G57E9							24		t	ng × h/mL	17864		ng/mL	1869			UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214985Orig1s000IntegratedR.pdf#page=234	Homo sapiens		h	8.8				6			false
11013	59538		ADULT	91801202	450.9207	DARIDOREXANT		COc1ccc(c(c1)C(=O)N2CCC[C@@]2(C)c3nc4c(C)c(Cl)ccc4[nH]3)n5nccn5	PLASMA	LMQ24G57E9							24		t	ng × h/mL	894		ng/mL	160			UNKNOWN	mg	5		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214985Orig1s000IntegratedR.pdf#page=234	Homo sapiens		h	6.5				6			false
11014	59538		ADULT	91801202	450.9207	DARIDOREXANT		COc1ccc(c(c1)C(=O)N2CCC[C@@]2(C)c3nc4c(C)c(Cl)ccc4[nH]3)n5nccn5	PLASMA	LMQ24G57E9							24		t	ng × h/mL	1156		ng/mL	256			UNKNOWN	mg	10		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214985Orig1s000IntegratedR.pdf#page=235	Homo sapiens		h	5.9	Day 1			8			false
11015	59538		ADULT	91801202	450.9207	DARIDOREXANT		COc1ccc(c(c1)C(=O)N2CCC[C@@]2(C)c3nc4c(C)c(Cl)ccc4[nH]3)n5nccn5	PLASMA	LMQ24G57E9							24		t	ng × h/mL	1293		ng/mL	280			UNKNOWN	mg	10		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214985Orig1s000IntegratedR.pdf#page=235	Homo sapiens		h	5.6	Day 5			8			false
11016	59538		ADULT	91801202	450.9207	DARIDOREXANT		COc1ccc(c(c1)C(=O)N2CCC[C@@]2(C)c3nc4c(C)c(Cl)ccc4[nH]3)n5nccn5	PLASMA	LMQ24G57E9							24		t	ng × h/mL	3502		ng/mL	614			UNKNOWN	mg	25		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214985Orig1s000IntegratedR.pdf#page=235	Homo sapiens		h	5.9	Day 1			8			false
11017	59538		ADULT	91801202	450.9207	DARIDOREXANT		COc1ccc(c(c1)C(=O)N2CCC[C@@]2(C)c3nc4c(C)c(Cl)ccc4[nH]3)n5nccn5	PLASMA	LMQ24G57E9							24		t	ng × h/mL	3805		ng/mL	616			UNKNOWN	mg	25		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214985Orig1s000IntegratedR.pdf#page=235	Homo sapiens		h	6.7	Day 5			8			false
11018	59538		ADULT	91801202	450.9207	DARIDOREXANT		COc1ccc(c(c1)C(=O)N2CCC[C@@]2(C)c3nc4c(C)c(Cl)ccc4[nH]3)n5nccn5	PLASMA	LMQ24G57E9							24		t	ng × h/mL	8583		ng/mL	1225			UNKNOWN	mg	75		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214985Orig1s000IntegratedR.pdf#page=235	Homo sapiens		h	9.2	Day 1			7			false
11019	59538		ADULT	91801202	450.9207	DARIDOREXANT		COc1ccc(c(c1)C(=O)N2CCC[C@@]2(C)c3nc4c(C)c(Cl)ccc4[nH]3)n5nccn5	PLASMA	LMQ24G57E9							24		t	ng × h/mL	8940		ng/mL	1308			UNKNOWN	mg	75		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214985Orig1s000IntegratedR.pdf#page=235	Homo sapiens		h	8.5	Day 5			7			false
11020	59538			91801202	450.9207	DARIDOREXANT		COc1ccc(c(c1)C(=O)N2CCC[C@@]2(C)c3nc4c(C)c(Cl)ccc4[nH]3)n5nccn5	PLASMA	LMQ24G57E9																										Human plasma protein binding: 99.7%	0.3				OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214985Orig1s000IntegratedR.pdf#page=45 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214985Orig1s000IntegratedR.pdf#page=169	Homo sapiens										false
11021	59539		ADULT	10153627	740.9382	ODEVIXIBAT		CCCCC1(CCCC)CN(c2ccccc2)c3cc(SC)c(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(=O)O)c4ccc(O)cc4)cc3S(=O)(=O)N1	PLASMA	2W150K0UUC							24		t	ng × h/mL	2.19		ng/mL	0.47			UNKNOWN	mg	7.2		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215498Orig1s000IntegratedR.pdf#page=39	Homo sapiens							21			false
11022	59539		ADULT	10153627	740.9382	ODEVIXIBAT		CCCCC1(CCCC)CN(c2ccccc2)c3cc(SC)c(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(=O)O)c4ccc(O)cc4)cc3S(=O)(=O)N1	PLASMA	2W150K0UUC							24		t	ng × h/mL	2.94		ng/mL	0.61			UNKNOWN	mg	9.6		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215498Orig1s000IntegratedR.pdf#page=39	Homo sapiens							17			false
11023	59539		ADULT	10153627	740.9382	ODEVIXIBAT		CCCCC1(CCCC)CN(c2ccccc2)c3cc(SC)c(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(=O)O)c4ccc(O)cc4)cc3S(=O)(=O)N1	PLASMA	2W150K0UUC	4192	325.767	MIDAZOLAM	Midazolam	CC1=NC=C2CN=C(C3=C(F)C=CC=C3)C4=C(C=CC(Cl)=C4)N12	R60L0SM5BC	24		t	ng × h/mL	2.66		ng/mL	0.53			UNKNOWN	mg	7.2		MULTIPLE	FASTED		day	1			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215498Orig1s000IntegratedR.pdf#page=39	Homo sapiens							20			true
11024	59539			10153627	740.9382	ODEVIXIBAT		CCCCC1(CCCC)CN(c2ccccc2)c3cc(SC)c(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(=O)O)c4ccc(O)cc4)cc3S(=O)(=O)N1	PLASMA	2W150K0UUC																										Human plasma protein binding (equilibrium dialysis): >99.7% (>99.7% (4 microM), >99.97% (40 microM))	0.3				OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215498Orig1s000IntegratedR.pdf#page=41 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215498Orig1s000IntegratedR.pdf#page=170	Homo sapiens										false
11025	59540		ADULT	134587348	597.6596	ELEXACAFTOR		C[C@@H]1CN(c2nc(ccc2C(=O)NS(=O)(=O)c3cn(C)nc3C)n4ccc(OCC(C)(C)C(F)(F)F)n4)C(C)(C)C1	PLASMA	RRN67GMB0V	46199646	520.4976	TEZACAFTOR	Tezacaftor	CC(C)(CO)C1=CC2=C(C=C(F)C(NC(=O)C3(CC3)C4=CC5=C(OC(F)(F)O5)C=C4)=C2)N1C[C@@H](O)CO	8RW88Y506K			∞	μg × h/mL	107		μg/mL	3.03			UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212273Orig1s000MultidisciplineR.pdf#page=186	Homo sapiens		h	20.31			and ivacaftor	6			true
11026	59540		ADULT	134587348	597.6596	ELEXACAFTOR		C[C@@H]1CN(c2nc(ccc2C(=O)NS(=O)(=O)c3cn(C)nc3C)n4ccc(OCC(C)(C)C(F)(F)F)n4)C(C)(C)C1	PLASMA	RRN67GMB0V	46199646	520.4976	TEZACAFTOR	Tezacaftor	CC(C)(CO)C1=CC2=C(C=C(F)C(NC(=O)C3(CC3)C4=CC5=C(OC(F)(F)O5)C=C4)=C2)N1C[C@@H](O)CO	8RW88Y506K			∞	μg × h/mL	32.6		μg/mL	1.03			UNKNOWN	mg	60		SINGLE	FED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212273Orig1s000MultidisciplineR.pdf#page=192	Homo sapiens		h	18.6			and ivacaftor	6			true
11027	59540		ADULT	134587348	597.6596	ELEXACAFTOR		C[C@@H]1CN(c2nc(ccc2C(=O)NS(=O)(=O)c3cn(C)nc3C)n4ccc(OCC(C)(C)C(F)(F)F)n4)C(C)(C)C1	PLASMA	RRN67GMB0V	46199646	520.4976	TEZACAFTOR	Tezacaftor	CC(C)(CO)C1=CC2=C(C=C(F)C(NC(=O)C3(CC3)C4=CC5=C(OC(F)(F)O5)C=C4)=C2)N1C[C@@H](O)CO	8RW88Y506K			∞	μg × h/mL	94.6		μg/mL	2.54			UNKNOWN	mg	120		SINGLE	FED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212273Orig1s000MultidisciplineR.pdf#page=192	Homo sapiens		h	23.5			and ivacaftor	6			true
11028	59540		ADULT	134587348	597.6596	ELEXACAFTOR		C[C@@H]1CN(c2nc(ccc2C(=O)NS(=O)(=O)c3cn(C)nc3C)n4ccc(OCC(C)(C)C(F)(F)F)n4)C(C)(C)C1	PLASMA	RRN67GMB0V	46199646	520.4976	TEZACAFTOR	Tezacaftor	CC(C)(CO)C1=CC2=C(C=C(F)C(NC(=O)C3(CC3)C4=CC5=C(OC(F)(F)O5)C=C4)=C2)N1C[C@@H](O)CO	8RW88Y506K			∞	μg × h/mL	131		μg/mL	4.7			UNKNOWN	mg	240		SINGLE	FED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212273Orig1s000MultidisciplineR.pdf#page=192	Homo sapiens		h	16.5			and ivacaftor	6			true
11029	59540		ADULT	134587348	597.6596	ELEXACAFTOR		C[C@@H]1CN(c2nc(ccc2C(=O)NS(=O)(=O)c3cn(C)nc3C)n4ccc(OCC(C)(C)C(F)(F)F)n4)C(C)(C)C1	PLASMA	RRN67GMB0V	46199646	520.4976	TEZACAFTOR	Tezacaftor	CC(C)(CO)C1=CC2=C(C=C(F)C(NC(=O)C3(CC3)C4=CC5=C(OC(F)(F)O5)C=C4)=C2)N1C[C@@H](O)CO	8RW88Y506K			∞	μg × h/mL	290		μg/mL	7.17			UNKNOWN	mg	360		SINGLE	FED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212273Orig1s000MultidisciplineR.pdf#page=192	Homo sapiens		h	21.5			and ivacaftor	6			true
11030	59540		ADULT	134587348	597.6596	ELEXACAFTOR		C[C@@H]1CN(c2nc(ccc2C(=O)NS(=O)(=O)c3cn(C)nc3C)n4ccc(OCC(C)(C)C(F)(F)F)n4)C(C)(C)C1	PLASMA	RRN67GMB0V	46199646	520.4976	TEZACAFTOR	Tezacaftor	CC(C)(CO)C1=CC2=C(C=C(F)C(NC(=O)C3(CC3)C4=CC5=C(OC(F)(F)O5)C=C4)=C2)N1C[C@@H](O)CO	8RW88Y506K			∞	μg × h/mL	12.8		μg/mL	0.407			UNKNOWN	mg	20		SINGLE	FED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212273Orig1s000MultidisciplineR.pdf#page=192	Homo sapiens		h	20.7			and ivacaftor	6			true
11031	59540		ADULT	134587348	597.6596	ELEXACAFTOR		C[C@@H]1CN(c2nc(ccc2C(=O)NS(=O)(=O)c3cn(C)nc3C)n4ccc(OCC(C)(C)C(F)(F)F)n4)C(C)(C)C1	PLASMA	RRN67GMB0V	46199646	520.4976	TEZACAFTOR	Tezacaftor	CC(C)(CO)C1=CC2=C(C=C(F)C(NC(=O)C3(CC3)C4=CC5=C(OC(F)(F)O5)C=C4)=C2)N1C[C@@H](O)CO	8RW88Y506K			∞	μg × h/mL	14.5		μg/mL	0.761			UNKNOWN	mg	20		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212273Orig1s000MultidisciplineR.pdf#page=193	Homo sapiens		h	20.8			and ivacaftor	7			true
11032	59540		ADULT	134587348	597.6596	ELEXACAFTOR		C[C@@H]1CN(c2nc(ccc2C(=O)NS(=O)(=O)c3cn(C)nc3C)n4ccc(OCC(C)(C)C(F)(F)F)n4)C(C)(C)C1	PLASMA	RRN67GMB0V	46199646	520.4976	TEZACAFTOR	Tezacaftor	CC(C)(CO)C1=CC2=C(C=C(F)C(NC(=O)C3(CC3)C4=CC5=C(OC(F)(F)O5)C=C4)=C2)N1C[C@@H](O)CO	8RW88Y506K	24		t	μg × h/mL	18.2		μg/mL	1.2			UNKNOWN	mg	60		MULTIPLE	FED		day	1			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212273Orig1s000MultidisciplineR.pdf#page=196	Homo sapiens				Day 1		and ivacaftor	6			true
11033	59540		ADULT	134587348	597.6596	ELEXACAFTOR		C[C@@H]1CN(c2nc(ccc2C(=O)NS(=O)(=O)c3cn(C)nc3C)n4ccc(OCC(C)(C)C(F)(F)F)n4)C(C)(C)C1	PLASMA	RRN67GMB0V	46199646	520.4976	TEZACAFTOR	Tezacaftor	CC(C)(CO)C1=CC2=C(C=C(F)C(NC(=O)C3(CC3)C4=CC5=C(OC(F)(F)O5)C=C4)=C2)N1C[C@@H](O)CO	8RW88Y506K	24		t	μg × h/mL	36.9		μg/mL	2.15			UNKNOWN	mg	60		MULTIPLE	FED		day	1			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212273Orig1s000MultidisciplineR.pdf#page=196	Homo sapiens		h	17.6	Day 10		and ivacaftor	6			true
11034	59540		ADULT	134587348	597.6596	ELEXACAFTOR		C[C@@H]1CN(c2nc(ccc2C(=O)NS(=O)(=O)c3cn(C)nc3C)n4ccc(OCC(C)(C)C(F)(F)F)n4)C(C)(C)C1	PLASMA	RRN67GMB0V	46199646	520.4976	TEZACAFTOR	Tezacaftor	CC(C)(CO)C1=CC2=C(C=C(F)C(NC(=O)C3(CC3)C4=CC5=C(OC(F)(F)O5)C=C4)=C2)N1C[C@@H](O)CO	8RW88Y506K	24		t	μg × h/mL	42.8		μg/mL	2.89			UNKNOWN	mg	120		MULTIPLE	FED		day	1			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212273Orig1s000MultidisciplineR.pdf#page=196	Homo sapiens				Day 1		and ivacaftor	6			true
11035	59540		ADULT	134587348	597.6596	ELEXACAFTOR		C[C@@H]1CN(c2nc(ccc2C(=O)NS(=O)(=O)c3cn(C)nc3C)n4ccc(OCC(C)(C)C(F)(F)F)n4)C(C)(C)C1	PLASMA	RRN67GMB0V	46199646	520.4976	TEZACAFTOR	Tezacaftor	CC(C)(CO)C1=CC2=C(C=C(F)C(NC(=O)C3(CC3)C4=CC5=C(OC(F)(F)O5)C=C4)=C2)N1C[C@@H](O)CO	8RW88Y506K	24		t	μg × h/mL	103		μg/mL	6.03			UNKNOWN	mg	120		MULTIPLE	FED		day	1			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212273Orig1s000MultidisciplineR.pdf#page=196	Homo sapiens		h	20.4	Day 10		and ivacaftor	6			true
11036	59540		ADULT	134587348	597.6596	ELEXACAFTOR		C[C@@H]1CN(c2nc(ccc2C(=O)NS(=O)(=O)c3cn(C)nc3C)n4ccc(OCC(C)(C)C(F)(F)F)n4)C(C)(C)C1	PLASMA	RRN67GMB0V	46199646	520.4976	TEZACAFTOR	Tezacaftor	CC(C)(CO)C1=CC2=C(C=C(F)C(NC(=O)C3(CC3)C4=CC5=C(OC(F)(F)O5)C=C4)=C2)N1C[C@@H](O)CO	8RW88Y506K	24		t	μg × h/mL	61.6		μg/mL	3.81			UNKNOWN	mg	240		MULTIPLE	FED		day	1			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212273Orig1s000MultidisciplineR.pdf#page=196	Homo sapiens				Day 1		and ivacaftor	6			true
11037	59540		ADULT	134587348	597.6596	ELEXACAFTOR		C[C@@H]1CN(c2nc(ccc2C(=O)NS(=O)(=O)c3cn(C)nc3C)n4ccc(OCC(C)(C)C(F)(F)F)n4)C(C)(C)C1	PLASMA	RRN67GMB0V	46199646	520.4976	TEZACAFTOR	Tezacaftor	CC(C)(CO)C1=CC2=C(C=C(F)C(NC(=O)C3(CC3)C4=CC5=C(OC(F)(F)O5)C=C4)=C2)N1C[C@@H](O)CO	8RW88Y506K	24		t	μg × h/mL	214		μg/mL	11.8			UNKNOWN	mg	240		MULTIPLE	FED		day	1			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212273Orig1s000MultidisciplineR.pdf#page=196	Homo sapiens		h	27.9	Day 10		and ivacaftor	6			true
11038	59540		ADULT	134587348	597.6596	ELEXACAFTOR		C[C@@H]1CN(c2nc(ccc2C(=O)NS(=O)(=O)c3cn(C)nc3C)n4ccc(OCC(C)(C)C(F)(F)F)n4)C(C)(C)C1	PLASMA	RRN67GMB0V	46199646	520.4976	TEZACAFTOR	Tezacaftor	CC(C)(CO)C1=CC2=C(C=C(F)C(NC(=O)C3(CC3)C4=CC5=C(OC(F)(F)O5)C=C4)=C2)N1C[C@@H](O)CO	8RW88Y506K	24		t	μg × h/mL	123		μg/mL	11.6			UNKNOWN	mg	340		MULTIPLE	FED		day	1			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212273Orig1s000MultidisciplineR.pdf#page=196	Homo sapiens				Day 1		and ivacaftor	6			true
11039	59540		ADULT	134587348	597.6596	ELEXACAFTOR		C[C@@H]1CN(c2nc(ccc2C(=O)NS(=O)(=O)c3cn(C)nc3C)n4ccc(OCC(C)(C)C(F)(F)F)n4)C(C)(C)C1	PLASMA	RRN67GMB0V	46199646	520.4976	TEZACAFTOR	Tezacaftor	CC(C)(CO)C1=CC2=C(C=C(F)C(NC(=O)C3(CC3)C4=CC5=C(OC(F)(F)O5)C=C4)=C2)N1C[C@@H](O)CO	8RW88Y506K	24		t	μg × h/mL	355		μg/mL	18.8			UNKNOWN	mg	340		MULTIPLE	FED		day	1			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212273Orig1s000MultidisciplineR.pdf#page=196	Homo sapiens		h	23.9	Day 10		and ivacaftor	6			true
11040	59540		ADULT	134587348	597.6596	ELEXACAFTOR		C[C@@H]1CN(c2nc(ccc2C(=O)NS(=O)(=O)c3cn(C)nc3C)n4ccc(OCC(C)(C)C(F)(F)F)n4)C(C)(C)C1	PLASMA	RRN67GMB0V	46199646	520.4976	TEZACAFTOR	Tezacaftor	CC(C)(CO)C1=CC2=C(C=C(F)C(NC(=O)C3(CC3)C4=CC5=C(OC(F)(F)O5)C=C4)=C2)N1C[C@@H](O)CO	8RW88Y506K	24		t	μg × h/mL	186		μg/mL	9.99			UNKNOWN	mg	200		MULTIPLE	FED		day	1			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212273Orig1s000MultidisciplineR.pdf#page=200	Homo sapiens				Day 1		and ivacaftor	32			true
11041	59540		ADULT	134587348	597.6596	ELEXACAFTOR		C[C@@H]1CN(c2nc(ccc2C(=O)NS(=O)(=O)c3cn(C)nc3C)n4ccc(OCC(C)(C)C(F)(F)F)n4)C(C)(C)C1	PLASMA	RRN67GMB0V	46199646	520.4976	TEZACAFTOR	Tezacaftor	CC(C)(CO)C1=CC2=C(C=C(F)C(NC(=O)C3(CC3)C4=CC5=C(OC(F)(F)O5)C=C4)=C2)N1C[C@@H](O)CO	8RW88Y506K	24		t	μg × h/mL	395		μg/mL	20.9			UNKNOWN	mg	400		MULTIPLE	FED		day	1			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212273Orig1s000MultidisciplineR.pdf#page=200	Homo sapiens				Day 1		and ivacaftor	31			true
11042	59540			134587348	597.6596	ELEXACAFTOR		C[C@@H]1CN(c2nc(ccc2C(=O)NS(=O)(=O)c3cn(C)nc3C)n4ccc(OCC(C)(C)C(F)(F)F)n4)C(C)(C)C1	PLASMA	RRN67GMB0V																										Human plasma protein binding: 99.63%	0.007				OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212273Orig1s000MultidisciplineR.pdf#page=40	Homo sapiens										false
11043	59540		UNKNOWN	134587348	597.6596	ELEXACAFTOR		C[C@@H]1CN(c2nc(ccc2C(=O)NS(=O)(=O)c3cn(C)nc3C)n4ccc(OCC(C)(C)C(F)(F)F)n4)C(C)(C)C1	PLASMA	RRN67GMB0V																	UNKNOWN	mg	200		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212273Orig1s000MultidisciplineR.pdf#page=54	Homo sapiens		h	24.7							false
11044	59540		ADULT	134587348	597.6596	ELEXACAFTOR		C[C@@H]1CN(c2nc(ccc2C(=O)NS(=O)(=O)c3cn(C)nc3C)n4ccc(OCC(C)(C)C(F)(F)F)n4)C(C)(C)C1	PLASMA	RRN67GMB0V	46199646	520.4976	TEZACAFTOR	Tezacaftor	CC(C)(CO)C1=CC2=C(C=C(F)C(NC(=O)C3(CC3)C4=CC5=C(OC(F)(F)O5)C=C4)=C2)N1C[C@@H](O)CO	8RW88Y506K			∞	μg × h/mL	99		μg/mL	1.07			UNKNOWN	mg	200		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212273Orig1s000MultidisciplineR.pdf#page=60 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212273Orig1s000MultidisciplineR.pdf#page=210	Homo sapiens		h	32.8			and ivacaftor	15			true
11045	59540		ADULT	134587348	597.6596	ELEXACAFTOR		C[C@@H]1CN(c2nc(ccc2C(=O)NS(=O)(=O)c3cn(C)nc3C)n4ccc(OCC(C)(C)C(F)(F)F)n4)C(C)(C)C1	PLASMA	RRN67GMB0V	46199646	520.4976	TEZACAFTOR	Tezacaftor	CC(C)(CO)C1=CC2=C(C=C(F)C(NC(=O)C3(CC3)C4=CC5=C(OC(F)(F)O5)C=C4)=C2)N1C[C@@H](O)CO	8RW88Y506K			∞	μg × h/mL	117		μg/mL	2.46			UNKNOWN	mg	200		SINGLE	LOW-FAT						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212273Orig1s000MultidisciplineR.pdf#page=60 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212273Orig1s000MultidisciplineR.pdf#page=210	Homo sapiens		h	23.1			and ivacaftor	15			true
11046	59540		ADULT	134587348	597.6596	ELEXACAFTOR		C[C@@H]1CN(c2nc(ccc2C(=O)NS(=O)(=O)c3cn(C)nc3C)n4ccc(OCC(C)(C)C(F)(F)F)n4)C(C)(C)C1	PLASMA	RRN67GMB0V	46199646	520.4976	TEZACAFTOR	Tezacaftor	CC(C)(CO)C1=CC2=C(C=C(F)C(NC(=O)C3(CC3)C4=CC5=C(OC(F)(F)O5)C=C4)=C2)N1C[C@@H](O)CO	8RW88Y506K			∞	μg × h/mL	152		μg/mL	4.01			UNKNOWN	mg	200		SINGLE	FED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212273Orig1s000MultidisciplineR.pdf#page=60 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212273Orig1s000MultidisciplineR.pdf#page=210	Homo sapiens		h	22.5		Moderate-fat meal	and ivacaftor	15			true
11047	59540		CHILD	134587348	597.6596	ELEXACAFTOR		C[C@@H]1CN(c2nc(ccc2C(=O)NS(=O)(=O)c3cn(C)nc3C)n4ccc(OCC(C)(C)C(F)(F)F)n4)C(C)(C)C1	PLASMA	RRN67GMB0V	46199646	520.4976	TEZACAFTOR	Tezacaftor	CC(C)(CO)C1=CC2=C(C=C(F)C(NC(=O)C3(CC3)C4=CC5=C(OC(F)(F)O5)C=C4)=C2)N1C[C@@H](O)CO	8RW88Y506K	24		t	ng × h/mL	149000		ng/mL	8400			UNKNOWN	mg	200		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212273Orig1s000MultidisciplineR.pdf#page=69	Homo sapiens				24-week treatment	Pediatric (12 to <18 yr) patients with CF	and ivacaftor				true
11048	59540		CHILD	134587348	597.6596	ELEXACAFTOR		C[C@@H]1CN(c2nc(ccc2C(=O)NS(=O)(=O)c3cn(C)nc3C)n4ccc(OCC(C)(C)C(F)(F)F)n4)C(C)(C)C1	PLASMA	RRN67GMB0V	46199646	520.4976	TEZACAFTOR	Tezacaftor	CC(C)(CO)C1=CC2=C(C=C(F)C(NC(=O)C3(CC3)C4=CC5=C(OC(F)(F)O5)C=C4)=C2)N1C[C@@H](O)CO	8RW88Y506K	24		t	ng × h/mL	167000		ng/mL	8770			UNKNOWN	mg	200		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212273Orig1s000MultidisciplineR.pdf#page=69	Homo sapiens				24-week treatment	Adolescent (>=18 yr) patients with CF	and ivacaftor				true
11049	59541		ADULT	118513932	401.4717	RISDIPLAM		Cc1cn2nc(cc(C)c2n1)C3=CC(=O)N4C=C(C=CC4=N3)N5CCNC6(CC6)C5	PLASMA	76RS4S2ET1							24		t	ng × h/mL	1440		ng/mL	73.3			UNKNOWN	mg	5		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213535Orig1s000ClinPharmR.pdf#page=15	Homo sapiens					Patients with Type 1, 2, or 3 SMA, 21 (14-53) yr		12			false
11050	59541		CHILD	118513932	401.4717	RISDIPLAM		Cc1cn2nc(cc(C)c2n1)C3=CC(=O)N4C=C(C=CC4=N3)N5CCNC6(CC6)C5	PLASMA	76RS4S2ET1							24		t	ng × h/mL	2286		ng/mL	178			UNKNOWN	mg/kg	0.25		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213535Orig1s000ClinPharmR.pdf#page=15	Homo sapiens					Patients with Type 2 and Type 3 SMA (ambulant and non-ambulant), 4.8 (3.2-11) yr		28			false
11051	59541		CHILD	118513932	401.4717	RISDIPLAM		Cc1cn2nc(cc(C)c2n1)C3=CC(=O)N4C=C(C=CC4=N3)N5CCNC6(CC6)C5	PLASMA	76RS4S2ET1							24		t	ng × h/mL	1943		ng/mL	134			UNKNOWN	mg	5		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213535Orig1s000ClinPharmR.pdf#page=15	Homo sapiens					Patients with Type 2 and Type 3 SMA (ambulant and non-ambulant), 12.8 (4.9-26.4) yr		89			false
11052	59541		NEWBORN	118513932	401.4717	RISDIPLAM		Cc1cn2nc(cc(C)c2n1)C3=CC(=O)N4C=C(C=CC4=N3)N5CCNC6(CC6)C5	PLASMA	76RS4S2ET1							24		t	ng × h/mL	1060		ng/mL	60			UNKNOWN	mg/kg	0.08		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213535Orig1s000ClinPharmR.pdf#page=15	Homo sapiens					Infant patients with Type 1 SMA , 0.54 (0.45-1.4) yr		4			false
11053	59541		NEWBORN	118513932	401.4717	RISDIPLAM		Cc1cn2nc(cc(C)c2n1)C3=CC(=O)N4C=C(C=CC4=N3)N5CCNC6(CC6)C5	PLASMA	76RS4S2ET1							24		t	ng × h/mL	1930		ng/mL	117			UNKNOWN	mg/kg	0.2		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213535Orig1s000ClinPharmR.pdf#page=15	Homo sapiens					Infant patients with Type 1 SMA , 1.1 (0.37-2.1) yr		53			false
11054	59541		CHILD	118513932	401.4717	RISDIPLAM		Cc1cn2nc(cc(C)c2n1)C3=CC(=O)N4C=C(C=CC4=N3)N5CCNC6(CC6)C5	PLASMA	76RS4S2ET1							24		t	ng × h/mL	1770		ng/mL	114			UNKNOWN	mg/kg	0.25		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213535Orig1s000ClinPharmR.pdf#page=15	Homo sapiens					Infant patients with Type 1 SMA , 2.6 (2.1-2.7) yr		5			false
11055	59541		ADULT	118513932	401.4717	RISDIPLAM		Cc1cn2nc(cc(C)c2n1)C3=CC(=O)N4C=C(C=CC4=N3)N5CCNC6(CC6)C5	PLASMA	76RS4S2ET1									∞	ng × h/mL	86.7		ng/mL	2.82			UNKNOWN	mg	0.6		SINGLE	UNKNOWN						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213535Orig1s000ClinPharmR.pdf#page=20	Homo sapiens		h	24.8				3			false
11056	59541		ADULT	118513932	401.4717	RISDIPLAM		Cc1cn2nc(cc(C)c2n1)C3=CC(=O)N4C=C(C=CC4=N3)N5CCNC6(CC6)C5	PLASMA	76RS4S2ET1									∞	ng × h/mL	294		ng/mL	8.33			UNKNOWN	mg	2		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213535Orig1s000ClinPharmR.pdf#page=20	Homo sapiens		h	40.1				3			false
11057	59541		ADULT	118513932	401.4717	RISDIPLAM		Cc1cn2nc(cc(C)c2n1)C3=CC(=O)N4C=C(C=CC4=N3)N5CCNC6(CC6)C5	PLASMA	76RS4S2ET1									∞	ng × h/mL	1080		ng/mL	24.5			UNKNOWN	mg	6		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213535Orig1s000ClinPharmR.pdf#page=20	Homo sapiens		h	47.7				3			false
11058	59541		ADULT	118513932	401.4717	RISDIPLAM		Cc1cn2nc(cc(C)c2n1)C3=CC(=O)N4C=C(C=CC4=N3)N5CCNC6(CC6)C5	PLASMA	76RS4S2ET1									∞	ng × h/mL	3290		ng/mL	93.2			UNKNOWN	mg	18		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213535Orig1s000ClinPharmR.pdf#page=20	Homo sapiens		h	68.7		n=5 for AUC and T1/2		6			false
11059	59541		ADULT	118513932	401.4717	RISDIPLAM		Cc1cn2nc(cc(C)c2n1)C3=CC(=O)N4C=C(C=CC4=N3)N5CCNC6(CC6)C5	PLASMA	76RS4S2ET1									∞	ng × h/mL	1080		ng/mL	24.5			UNKNOWN	mg	6		SINGLE	FASTED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213535Orig1s000ClinPharmR.pdf#page=21	Homo sapiens		h	68.7				3			false
11060	59541		ADULT	118513932	401.4717	RISDIPLAM		Cc1cn2nc(cc(C)c2n1)C3=CC(=O)N4C=C(C=CC4=N3)N5CCNC6(CC6)C5	PLASMA	76RS4S2ET1									∞	ng × h/mL	1010		ng/mL	24.8			UNKNOWN	mg	6		SINGLE	FED						HEALTHY	Oral	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213535Orig1s000ClinPharmR.pdf#page=21	Homo sapiens							3			false
11061	59541		ADULT	118513932	401.4717	RISDIPLAM		Cc1cn2nc(cc(C)c2n1)C3=CC(=O)N4C=C(C=CC4=N3)N5CCNC6(CC6)C5	PLASMA	76RS4S2ET1							24		t	ng × h/mL	404		ng/mL	25.9			UNKNOWN	mg	5		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213535Orig1s000ClinPharmR.pdf#page=25	Homo sapiens				Day 1			8			false
11062	59541		ADULT	118513932	401.4717	RISDIPLAM		Cc1cn2nc(cc(C)c2n1)C3=CC(=O)N4C=C(C=CC4=N3)N5CCNC6(CC6)C5	PLASMA	76RS4S2ET1							24		t	ng × h/mL	1250		ng/mL	78.6			UNKNOWN	mg	5		STEADY-STATE	UNKNOWN		day	1			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213535Orig1s000ClinPharmR.pdf#page=25	Homo sapiens				Day 14			8			false
11063	59541		ADULT	118513932	401.4717	RISDIPLAM		Cc1cn2nc(cc(C)c2n1)C3=CC(=O)N4C=C(C=CC4=N3)N5CCNC6(CC6)C5	PLASMA	76RS4S2ET1							24		t	ng × h/mL	613		ng/mL	42.6			UNKNOWN	mg	8		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213535Orig1s000ClinPharmR.pdf#page=25	Homo sapiens				Day 1			27			false
11064	59541		ADULT	118513932	401.4717	RISDIPLAM		Cc1cn2nc(cc(C)c2n1)C3=CC(=O)N4C=C(C=CC4=N3)N5CCNC6(CC6)C5	PLASMA	76RS4S2ET1							24		t	ng × h/mL	1730		ng/mL	113			UNKNOWN	mg	8		MULTIPLE	UNKNOWN		day	1			HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213535Orig1s000ClinPharmR.pdf#page=25	Homo sapiens				Day 14			27			false
11065	59541			118513932	401.4717	RISDIPLAM		Cc1cn2nc(cc(C)c2n1)C3=CC(=O)N4C=C(C=CC4=N3)N5CCNC6(CC6)C5	PLASMA	76RS4S2ET1																										Human plasma protein binding: 89%	11				OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213535Orig1s000PharmR.pdf#page=5 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213535Orig1s000ClinPharmR.pdf#page=10	Homo sapiens										false
11066	59542		ADULT	129073603	533.6088	PRALSETINIB		CO[C@@]1(CC[C@H](CC1)c2nc(C)cc(Nc3cc(C)[nH]n3)n2)C(=O)N[C@@H](C)c4ccc(nc4)n5cc(F)cn5	PLASMA	1WPE73O1WV							24		t	ng × h/mL	36700		ng/mL	2470			UNKNOWN	mg	400		STEADY-STATE	FASTED		day	1			UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213721s005lbl.pdf#page=20	Homo sapiens		h	20							false
11067	59542		ADULT	129073603	533.6088	PRALSETINIB		CO[C@@]1(CC[C@H](CC1)c2nc(C)cc(Nc3cc(C)[nH]n3)n2)C(=O)N[C@@H](C)c4ccc(nc4)n5cc(F)cn5	PLASMA	1WPE73O1WV																	UNKNOWN				SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213721s005lbl.pdf#page=20	Homo sapiens		h	15.7							false
11068	59542			129073603	533.6088	PRALSETINIB		CO[C@@]1(CC[C@H](CC1)c2nc(C)cc(Nc3cc(C)[nH]n3)n2)C(=O)N[C@@H](C)c4ccc(nc4)n5cc(F)cn5	PLASMA	1WPE73O1WV																										Human plasma protein binding: 97.1% (1 and 10 microM)	2.9				OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213721Orig1s000MultidisciplineR.pdf#page=57	Homo sapiens										false
11069	59543		ADULT	121304016	602.5815	REMDESIVIR		CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@](C#N)([C@H](O)[C@@H]1O)c2ccc3c(N)ncnn23)Oc4ccccc4	PLASMA	3QKI37EEHE																	UNKNOWN	mg	150		SINGLE	UNKNOWN						UNKNOWN	Intravenous	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214787Orig1s000ClinpharmR.pdf#page=31	Homo sapiens		h	1				8			false
11070	59543		ADULT	121304016	602.5815	REMDESIVIR		CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@](C#N)([C@H](O)[C@@H]1O)c2ccc3c(N)ncnn23)Oc4ccccc4	PLASMA	3QKI37EEHE																	UNKNOWN	mg	150		SINGLE	UNKNOWN						UNKNOWN	Intravenous	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214787Orig1s000ClinpharmR.pdf#page=31	Homo sapiens		h	1				8			false
11071	59543		ADULT	121304016	602.5815	REMDESIVIR		CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@](C#N)([C@H](O)[C@@H]1O)c2ccc3c(N)ncnn23)Oc4ccccc4	PLASMA	3QKI37EEHE							24		t	ng × h/mL	2862.5		ng/mL	4377.9			UNKNOWN	mg	200		MULTIPLE	UNKNOWN		day	1			HEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214787Orig1s000ClinpharmR.pdf#page=37 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214787Orig1s000ClinpharmR.pdf#page=45	Homo sapiens		h	0.9	Day 1 (200 mg IV on day 1 and 100 mg daily on days 2-5 (cohort 1) or days 2-10 (cohort 2))			28			false
11072	59543		ADULT	121304016	602.5815	REMDESIVIR		CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@](C#N)([C@H](O)[C@@H]1O)c2ccc3c(N)ncnn23)Oc4ccccc4	PLASMA	3QKI37EEHE							24		t	ng × h/mL	1585.3		ng/mL	2228.8			UNKNOWN	mg	100		MULTIPLE	UNKNOWN		day	1			HEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214787Orig1s000ClinpharmR.pdf#page=37 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214787Orig1s000ClinpharmR.pdf#page=45	Homo sapiens		h	0.96	Days 5 or 10 (200 mg IV on day 1 and 100 mg daily on days 2-5 (cohort 1) or days 2-10 (cohort 2))	n=25 for AUCtau and t1/2		26			false
11073	59543		ADULT	121304016	602.5815	REMDESIVIR		CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@](C#N)([C@H](O)[C@@H]1O)c2ccc3c(N)ncnn23)Oc4ccccc4	PLASMA	3QKI37EEHE							24		t	ng × h/mL	1579.3		ng/mL	2335			UNKNOWN	mg	100		MULTIPLE	UNKNOWN		day	1			HEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214787Orig1s000ClinpharmR.pdf#page=64	Homo sapiens				Days 5 (200 mg IV on day 1 and 100 mg daily on days 2-5 (cohort 1))						false
11074	59543		ADOLESCENT	121304016	602.5815	REMDESIVIR		CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@](C#N)([C@H](O)[C@@H]1O)c2ccc3c(N)ncnn23)Oc4ccccc4	PLASMA	3QKI37EEHE							24		t	ng × h/mL	3106.47		ng/mL	5002.68			UNKNOWN	mg	200		MULTIPLE	UNKNOWN		day	1			HEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214787Orig1s000ClinpharmR.pdf#page=64	Homo sapiens				Days 1 (200 mg IV on day 1 and 100 mg daily on days 2-5 (cohort 1))	>=12 years of age with body weight >= 40 kg					false
11075	59543		ADOLESCENT	121304016	602.5815	REMDESIVIR		CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@](C#N)([C@H](O)[C@@H]1O)c2ccc3c(N)ncnn23)Oc4ccccc4	PLASMA	3QKI37EEHE							24		t	ng × h/mL	1553.48		ng/mL	2499.88			UNKNOWN	mg	100		MULTIPLE	UNKNOWN		day	1			HEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214787Orig1s000ClinpharmR.pdf#page=64	Homo sapiens				Days 5 (200 mg IV on day 1 and 100 mg daily on days 2-5 (cohort 1))	>=12 years of age with body weight >= 40 kg					false
11076	59543		ADULT	121304016	602.5815	REMDESIVIR		CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@](C#N)([C@H](O)[C@@H]1O)c2ccc3c(N)ncnn23)Oc4ccccc4	PLASMA	3QKI37EEHE							24		t	ng × h/mL	2782.7		ng/mL	4190			UNKNOWN	mg	200		MULTIPLE	UNKNOWN		day	1			HEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214787Orig1s000ClinpharmR.pdf#page=64	Homo sapiens				Days 1 (200 mg IV on day 1 and 100 mg daily on days 2-5 (cohort 1))			28			false
11077	59543			121304016	602.5815	REMDESIVIR		CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@](C#N)([C@H](O)[C@@H]1O)c2ccc3c(N)ncnn23)Oc4ccccc4	PLASMA	3QKI37EEHE																										(equilibrium dialysis, 2 microM); Fu=6.5% (1 microM), 7.4% (10 microM) (equilibrium dialysis)	12.1				OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214787Orig1s000PharmR.pdf#page=18 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214787Orig1s000ClinpharmR.pdf#page=48	Homo sapiens										false
11078	59544		ADULT		43500	PEGCETACOPLAN			PLASMA	TO3JYR3BOU									∞	μg × h/mL	2611		μg/mL	5.8			UNKNOWN	mg	45		SINGLE	UNKNOWN						HEALTHY	Subcutaneous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215014Orig1s000IntegratedR.pdf#page=113	Homo sapiens		h	194				4			false
11079	59544		ADULT		43500	PEGCETACOPLAN			PLASMA	TO3JYR3BOU									∞	μg × h/mL	8096		μg/mL	24			UNKNOWN	mg	90		SINGLE	UNKNOWN						HEALTHY	Subcutaneous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215014Orig1s000IntegratedR.pdf#page=113	Homo sapiens		h	223				4			false
11080	59544		ADULT		43500	PEGCETACOPLAN			PLASMA	TO3JYR3BOU									∞	μg × h/mL	13520		μg/mL	31			UNKNOWN	mg	180		SINGLE	UNKNOWN						HEALTHY	Subcutaneous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215014Orig1s000IntegratedR.pdf#page=113	Homo sapiens		h	211				4			false
11081	59544		ADULT		43500	PEGCETACOPLAN			PLASMA	TO3JYR3BOU									∞	μg × h/mL	28930		μg/mL	72			UNKNOWN	mg	360		SINGLE	UNKNOWN						HEALTHY	Subcutaneous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215014Orig1s000IntegratedR.pdf#page=113	Homo sapiens		h	203				4			false
11082	59544		ADULT		43500	PEGCETACOPLAN			PLASMA	TO3JYR3BOU									∞	μg × h/mL	59040		μg/mL	139			UNKNOWN	mg	720		SINGLE	UNKNOWN						HEALTHY	Subcutaneous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215014Orig1s000IntegratedR.pdf#page=113	Homo sapiens		h	235				4			false
11083	59544		ADULT		43500	PEGCETACOPLAN			PLASMA	TO3JYR3BOU									∞	μg × h/mL	97320		μg/mL	249			UNKNOWN	mg	1440		SINGLE	UNKNOWN						HEALTHY	Subcutaneous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215014Orig1s000IntegratedR.pdf#page=113	Homo sapiens		h	209				4			false
11084	59544		ADULT		43500	PEGCETACOPLAN			PLASMA	TO3JYR3BOU									∞	μg × h/mL	16040		μg/mL	59.88			UNKNOWN	mg	200		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215014Orig1s000IntegratedR.pdf#page=115	Homo sapiens		h	201				4			false
11085	59544		ADULT		43500	PEGCETACOPLAN			PLASMA	TO3JYR3BOU									∞	μg × h/mL	51270		μg/mL	193			UNKNOWN	mg	600		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215014Orig1s000IntegratedR.pdf#page=115	Homo sapiens		h	222				4			false
11086	59544		ADULT		43500	PEGCETACOPLAN			PLASMA	TO3JYR3BOU									∞	μg × h/mL	117000		μg/mL	562.2			UNKNOWN	mg	1500		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215014Orig1s000IntegratedR.pdf#page=115	Homo sapiens		h	205				4			false
11087	59544		ADULT		43500	PEGCETACOPLAN			PLASMA	TO3JYR3BOU									∞	μg × h/mL	174000		μg/mL	701			UNKNOWN	mg	2300		SINGLE	UNKNOWN						HEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215014Orig1s000IntegratedR.pdf#page=115	Homo sapiens		h	285				3			false
11088	59544		ADULT		43500	PEGCETACOPLAN			PLASMA	TO3JYR3BOU									∞	μg × h/mL	9.89		μg/mL	3.67			UNKNOWN	mg	270		SINGLE	UNKNOWN						HEALTHY	Subcutaneous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215014Orig1s000IntegratedR.pdf#page=116	Homo sapiens					Normal renal function		8			false
11089	59544		ADULT		43500	PEGCETACOPLAN			PLASMA	TO3JYR3BOU									∞	μg × h/mL	9.8		μg/mL	3.67			UNKNOWN	mg	270		SINGLE	UNKNOWN						UNHEALTHY	Subcutaneous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215014Orig1s000IntegratedR.pdf#page=116	Homo sapiens					Severe renal impairment		8			false
11090	59544		ADULT		43500	PEGCETACOPLAN			PLASMA	TO3JYR3BOU													μg/mL	628.8			UNKNOWN	mg	360		MULTIPLE	UNKNOWN		day	1			HEALTHY	Subcutaneous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215014Orig1s000IntegratedR.pdf#page=118	Homo sapiens		h	206.1	Day 28			4			false
11091	59544		ADULT		43500	PEGCETACOPLAN			PLASMA	TO3JYR3BOU													μg/mL	749.3			UNKNOWN	mg	1300		MULTIPLE	UNKNOWN		week	2			HEALTHY	Subcutaneous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215014Orig1s000IntegratedR.pdf#page=118	Homo sapiens		h	221.9	Day 28			4			false
11092	59544		ADULT		43500	PEGCETACOPLAN			PLASMA	TO3JYR3BOU													μg/mL	856			UNKNOWN	mg	2600		MULTIPLE	UNKNOWN		week	1			HEALTHY	Subcutaneous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215014Orig1s000IntegratedR.pdf#page=118	Homo sapiens		h	221.9	Day 28			3			false
11093	59544		ADULT		43500	PEGCETACOPLAN			PLASMA	TO3JYR3BOU													μg/mL	685.2			UNKNOWN	mg	1080		MULTIPLE	UNKNOWN		week	2			HEALTHY	Subcutaneous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215014Orig1s000IntegratedR.pdf#page=118	Homo sapiens		h	226.3	Day 28			16			false
11094	59544		ADULT		43500	PEGCETACOPLAN			PLASMA	TO3JYR3BOU													μg/mL	726			UNKNOWN	mg	1080		MULTIPLE	UNKNOWN		week	2			HEALTHY	Subcutaneous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215014Orig1s000IntegratedR.pdf#page=118	Homo sapiens		h	243.8	Day 28 (using a wearable infuser)			6			false
11095	59544		ADULT		43500	PEGCETACOPLAN			PLASMA	TO3JYR3BOU																	UNKNOWN				UNKNOWN	UNKNOWN						UNHEALTHY	Subcutaneous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215014Orig1s000IntegratedR.pdf#page=33	Homo sapiens		day	8		Patients with PNH					false
11096	59545		ADULT	137278711	560.5944	SOTORASIB		CC(C)c1nccc(C)c1N2C(=O)N=C(N3CCN(C[C@@H]3C)C(=O)C=C)c4cc(F)c(nc24)c5c(O)cccc5F	PLASMA	2B2VM6UC8G										ng × h/mL	28700		ng/mL	6690			RECOMMENDED	mg	960		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf#page=255	Homo sapiens										false
11097	59545		ADULT	137278711	560.5944	SOTORASIB		CC(C)c1nccc(C)c1N2C(=O)N=C(N3CCN(C[C@@H]3C)C(=O)C=C)c4cc(F)c(nc24)c5c(O)cccc5F	PLASMA	2B2VM6UC8G										ng × h/mL	31500		ng/mL	7880			RECOMMENDED	mg	960		SINGLE	FASTED						HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf#page=255	Homo sapiens										false
11098	59545		ADULT	137278711	560.5944	SOTORASIB		CC(C)c1nccc(C)c1N2C(=O)N=C(N3CCN(C[C@@H]3C)C(=O)C=C)c4cc(F)c(nc24)c5c(O)cccc5F	PLASMA	2B2VM6UC8G										ng × h/mL	81500		ng/mL	8320			RECOMMENDED	mg	960		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf#page=255	Homo sapiens				Day 1	Patients					false
11099	59545		ADULT	137278711	560.5944	SOTORASIB		CC(C)c1nccc(C)c1N2C(=O)N=C(N3CCN(C[C@@H]3C)C(=O)C=C)c4cc(F)c(nc24)c5c(O)cccc5F	PLASMA	2B2VM6UC8G										ng × h/mL	43900		ng/mL	7180			RECOMMENDED	mg	960		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf#page=255	Homo sapiens				Day 8	Patients					false
11100	59545			137278711	560.5944	SOTORASIB		CC(C)c1nccc(C)c1N2C(=O)N=C(N3CCN(C[C@@H]3C)C(=O)C=C)c4cc(F)c(nc24)c5c(O)cccc5F	PLASMA	2B2VM6UC8G																										Fu=8.6% to 15% (0.25 to 25 microM)	11.2				OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf#page=58 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf#page=89	Homo sapiens										false
11101	59545		ADULT	137278711	560.5944	SOTORASIB		CC(C)c1nccc(C)c1N2C(=O)N=C(N3CCN(C[C@@H]3C)C(=O)C=C)c4cc(F)c(nc24)c5c(O)cccc5F	PLASMA	2B2VM6UC8G							24		t	μg × h/mL	32.4		μg/mL	5.39			RECOMMENDED	mg	960		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf#page=94	Homo sapiens		h	5.07	Day 8	Subjects with KRAS G12C-mutated advanced solid tumors		24			false
11102	59545		ADULT	137278711	560.5944	SOTORASIB		CC(C)c1nccc(C)c1N2C(=O)N=C(N3CCN(C[C@@H]3C)C(=O)C=C)c4cc(F)c(nc24)c5c(O)cccc5F	PLASMA	2B2VM6UC8G							24		t	μg × h/mL	31.7		μg/mL	6.44			RECOMMENDED	mg	180		STEADY-STATE	FASTED		day	1			UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf#page=94 | https://pubmed.ncbi.nlm.nih.gov/34903582/	Homo sapiens		h	5.13	Day 8	Subjects with KRAS G12C-mutated advanced solid tumors		6			false
11103	59545		ADULT	137278711	560.5944	SOTORASIB		CC(C)c1nccc(C)c1N2C(=O)N=C(N3CCN(C[C@@H]3C)C(=O)C=C)c4cc(F)c(nc24)c5c(O)cccc5F	PLASMA	2B2VM6UC8G							24		t	μg × h/mL	38.9		μg/mL	6.31			RECOMMENDED	mg	360		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf#page=94 | https://pubmed.ncbi.nlm.nih.gov/34903582/	Homo sapiens		h	5.53	Day 8	Subjects with KRAS G12C-mutated advanced solid tumors		24			false
11104	59545		ADULT	137278711	560.5944	SOTORASIB		CC(C)c1nccc(C)c1N2C(=O)N=C(N3CCN(C[C@@H]3C)C(=O)C=C)c4cc(F)c(nc24)c5c(O)cccc5F	PLASMA	2B2VM6UC8G							24		t	μg × h/mL	42.1		μg/mL	5.45			RECOMMENDED	mg	720		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf#page=94 | https://pubmed.ncbi.nlm.nih.gov/34903582/	Homo sapiens		h	4.75	Day 8	Subjects with KRAS G12C-mutated advanced solid tumors		11			false
11105	59546		ADULT	117947097	383.3417	BELZUTIFAN		CS(=O)(=O)c1ccc(Oc2cc(F)cc(c2)C#N)c3[C@@H](F)[C@@H](F)[C@@H](O)c13	PLASMA	7K28NB895L							24		t	ng × h/mL	1530.59		ng/mL	172.9			UNKNOWN	mg	20		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33888901/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128828/#SD1	Homo sapiens		h	11.17	Week 1	Patients with advanced solid tumors		6			false
11106	59546		ADULT	117947097	383.3417	BELZUTIFAN		CS(=O)(=O)c1ccc(Oc2cc(F)cc(c2)C#N)c3[C@@H](F)[C@@H](F)[C@@H](O)c13	PLASMA	7K28NB895L							24		t	ng × h/mL	5396.19		ng/mL	572			UNKNOWN	mg	40		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33888901/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128828/#SD1	Homo sapiens		h	16.52	Week 1	Patients with advanced solid tumors		6			false
11107	59546		ADULT	117947097	383.3417	BELZUTIFAN		CS(=O)(=O)c1ccc(Oc2cc(F)cc(c2)C#N)c3[C@@H](F)[C@@H](F)[C@@H](O)c13	PLASMA	7K28NB895L							24		t	ng × h/mL	12513		ng/mL	1240.67			UNKNOWN	mg	80		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33888901/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128828/#SD1	Homo sapiens		h	20.28	Week 1	Patients with advanced solid tumors		6			false
11108	59546		ADULT	117947097	383.3417	BELZUTIFAN		CS(=O)(=O)c1ccc(Oc2cc(F)cc(c2)C#N)c3[C@@H](F)[C@@H](F)[C@@H](O)c13	PLASMA	7K28NB895L							24		t	ng × h/mL	14559.56		ng/mL	1346			UNKNOWN	mg	120		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33888901/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128828/#SD1	Homo sapiens		h	16.84	Week 1	Patients with advanced solid tumors		58			false
11109	59546		ADULT	117947097	383.3417	BELZUTIFAN		CS(=O)(=O)c1ccc(Oc2cc(F)cc(c2)C#N)c3[C@@H](F)[C@@H](F)[C@@H](O)c13	PLASMA	7K28NB895L							24		t	ng × h/mL	16851.51		ng/mL	2042			UNKNOWN	mg	160		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33888901/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128828/#SD1	Homo sapiens		h	13.09	Week 1	Patients with advanced solid tumors		6			false
11110	59546		ADULT	117947097	383.3417	BELZUTIFAN		CS(=O)(=O)c1ccc(Oc2cc(F)cc(c2)C#N)c3[C@@H](F)[C@@H](F)[C@@H](O)c13	PLASMA	7K28NB895L							24		t	ng × h/mL	24767.93		ng/mL	2540			UNKNOWN	mg	240		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33888901/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128828/#SD1	Homo sapiens		h	14.34	Week 1	Patients with advanced solid tumors		7			false
11111	59546		ADULT	117947097	383.3417	BELZUTIFAN		CS(=O)(=O)c1ccc(Oc2cc(F)cc(c2)C#N)c3[C@@H](F)[C@@H](F)[C@@H](O)c13	PLASMA	7K28NB895L							12		t	ng × h/mL	8846.05		ng/mL	1277			UNKNOWN	mg	120		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33888901/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128828/#SD1	Homo sapiens		h	13.49	Week 1	Patients with advanced solid tumors		6			false
11112	59546		ADULT	117947097	383.3417	BELZUTIFAN		CS(=O)(=O)c1ccc(Oc2cc(F)cc(c2)C#N)c3[C@@H](F)[C@@H](F)[C@@H](O)c13	PLASMA	7K28NB895L							24		t	ng × h/mL	2170.64		ng/mL	245.2			UNKNOWN	mg	20		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33888901/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128828/#SD1	Homo sapiens		h	12.87	Week 3	Patients with advanced solid tumors		6			false
11113	59546		ADULT	117947097	383.3417	BELZUTIFAN		CS(=O)(=O)c1ccc(Oc2cc(F)cc(c2)C#N)c3[C@@H](F)[C@@H](F)[C@@H](O)c13	PLASMA	7K28NB895L							24		t	ng × h/mL	7136.85		ng/mL	540.8			UNKNOWN	mg	40		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33888901/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128828/#SD1	Homo sapiens		h	18.52	Week 3	Patients with advanced solid tumors		6			false
11114	59546		ADULT	117947097	383.3417	BELZUTIFAN		CS(=O)(=O)c1ccc(Oc2cc(F)cc(c2)C#N)c3[C@@H](F)[C@@H](F)[C@@H](O)c13	PLASMA	7K28NB895L							24		t	ng × h/mL	18369.47		ng/mL	1402.5			UNKNOWN	mg	80		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33888901/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128828/#SD1	Homo sapiens		h	21.48	Week 3	Patients with advanced solid tumors		6			false
11115	59546		ADULT	117947097	383.3417	BELZUTIFAN		CS(=O)(=O)c1ccc(Oc2cc(F)cc(c2)C#N)c3[C@@H](F)[C@@H](F)[C@@H](O)c13	PLASMA	7K28NB895L							24		t	ng × h/mL	21046.06		ng/mL	1791.98			UNKNOWN	mg	120		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33888901/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128828/#SD1	Homo sapiens		h	15.95	Week 3	Patients with advanced solid tumors		58			false
11116	59546		ADULT	117947097	383.3417	BELZUTIFAN		CS(=O)(=O)c1ccc(Oc2cc(F)cc(c2)C#N)c3[C@@H](F)[C@@H](F)[C@@H](O)c13	PLASMA	7K28NB895L							24		t	ng × h/mL	22271.92		ng/mL	2041.67			UNKNOWN	mg	160		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33888901/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128828/#SD1	Homo sapiens		h	13.18	Week 3	Patients with advanced solid tumors		6			false
11117	59546		ADULT	117947097	383.3417	BELZUTIFAN		CS(=O)(=O)c1ccc(Oc2cc(F)cc(c2)C#N)c3[C@@H](F)[C@@H](F)[C@@H](O)c13	PLASMA	7K28NB895L							24		t	ng × h/mL	27874.67		ng/mL	2671.67			UNKNOWN	mg	240		MULTIPLE	UNKNOWN		day	1			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33888901/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128828/#SD1	Homo sapiens		h	13.88	Week 3	Patients with advanced solid tumors		7			false
11118	59546		ADULT	117947097	383.3417	BELZUTIFAN		CS(=O)(=O)c1ccc(Oc2cc(F)cc(c2)C#N)c3[C@@H](F)[C@@H](F)[C@@H](O)c13	PLASMA	7K28NB895L							12		t	ng × h/mL	22256.03		ng/mL	2672			UNKNOWN	mg	120		MULTIPLE	UNKNOWN		day	2			UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/33888901/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128828/#SD1	Homo sapiens		h	14.11	Week 3	Patients with advanced solid tumors		6			false
11119	59546		ADULT	117947097	383.3417	BELZUTIFAN		CS(=O)(=O)c1ccc(Oc2cc(F)cc(c2)C#N)c3[C@@H](F)[C@@H](F)[C@@H](O)c13	PLASMA	7K28NB895L							24		t	μg × h/mL	16.7		μg/mL	1.3			UNKNOWN	mg	120		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215383s000lbl.pdf#page=9	Homo sapiens		h	14		Patients with VHL disease-associated RCC					false
11120	59546		ADULT	117947097	383.3417	BELZUTIFAN		CS(=O)(=O)c1ccc(Oc2cc(F)cc(c2)C#N)c3[C@@H](F)[C@@H](F)[C@@H](O)c13	PLASMA	7K28NB895L									∞	μg × h/mL	15		ng/mL	665			UNKNOWN	mg	40		SINGLE	UNKNOWN						UNKNOWN	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215383Orig1s000MultidisciplineR.pdf#page=244	Homo sapiens					Japanese subjects					false
11121	59546			117947097	383.3417	BELZUTIFAN		CS(=O)(=O)c1ccc(Oc2cc(F)cc(c2)C#N)c3[C@@H](F)[C@@H](F)[C@@H](O)c13	PLASMA	7K28NB895L																										Human plasma protein binding: 45%	55				OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215383Orig1s000MultidisciplineR.pdf#page=41 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215383Orig1s000MultidisciplineR.pdf#page=80	Homo sapiens										false
11122	59547		ADULT	72163100	603.5207	ATOGEPANT		C[C@@H]1[C@@H](C[C@H](NC(=O)c2cnc3C[C@]4(Cc3c2)C(=O)Nc5ncccc45)C(=O)N1CC(F)(F)F)c6c(F)ccc(F)c6F	PLASMA	7CRV8RR151									∞	ng × h/mL	2633.43		ng/mL	538.55			RECOMMENDED	mg	60		SINGLE	FASTED				Human plasma protein binding: 98.21% (2 hr)	1.79	HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215206Orig1s000IntegratedR.pdf#page=164 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215206Orig1s000IntegratedR.pdf#page=218	Homo sapiens		h	9.4		Normal hepatic function		8			false
11123	59547		ADULT	72163100	603.5207	ATOGEPANT		C[C@@H]1[C@@H](C[C@H](NC(=O)c2cnc3C[C@]4(Cc3c2)C(=O)Nc5ncccc45)C(=O)N1CC(F)(F)F)c6c(F)ccc(F)c6F	PLASMA	7CRV8RR151									∞	ng × h/mL	3273.58		ng/mL	586.89			RECOMMENDED	mg	60		SINGLE	FASTED				Human plasma protein binding: 97.36% (2 hr)	2.64	HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215206Orig1s000IntegratedR.pdf#page=164 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215206Orig1s000IntegratedR.pdf#page=218	Homo sapiens		h	8.7		Mild hepatic impairment		8			false
11124	59547		ADULT	72163100	603.5207	ATOGEPANT		C[C@@H]1[C@@H](C[C@H](NC(=O)c2cnc3C[C@]4(Cc3c2)C(=O)Nc5ncccc45)C(=O)N1CC(F)(F)F)c6c(F)ccc(F)c6F	PLASMA	7CRV8RR151									∞	ng × h/mL	3028.57		ng/mL	474.85			RECOMMENDED	mg	60		SINGLE	FASTED				Human plasma protein binding: 97.05% (2 hr)	2.95	HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215206Orig1s000IntegratedR.pdf#page=164 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215206Orig1s000IntegratedR.pdf#page=218	Homo sapiens		h	11.9		Moderate hepatic impairment		8			false
11125	59547		ADULT	72163100	603.5207	ATOGEPANT		C[C@@H]1[C@@H](C[C@H](NC(=O)c2cnc3C[C@]4(Cc3c2)C(=O)Nc5ncccc45)C(=O)N1CC(F)(F)F)c6c(F)ccc(F)c6F	PLASMA	7CRV8RR151									∞	ng × h/mL	3633.22		ng/mL	515.45			RECOMMENDED	mg	60		SINGLE	FASTED				Human plasma protein binding: 95.34% (2 hr)	4.66	HEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215206Orig1s000IntegratedR.pdf#page=164 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215206Orig1s000IntegratedR.pdf#page=218	Homo sapiens		h	7.54		Severe hepatic impairment		8			false
11126	59547		ADULT	72163100	603.5207	ATOGEPANT		C[C@@H]1[C@@H](C[C@H](NC(=O)c2cnc3C[C@]4(Cc3c2)C(=O)Nc5ncccc45)C(=O)N1CC(F)(F)F)c6c(F)ccc(F)c6F	PLASMA	7CRV8RR151							24		t	ng × h/mL	525		ng/mL	81.7			RECOMMENDED	mg	10		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215206Orig1s000IntegratedR.pdf#page=31	Homo sapiens				popPK	Patients with episodic migraines dosed with or without food					false
11127	59547		ADULT	72163100	603.5207	ATOGEPANT		C[C@@H]1[C@@H](C[C@H](NC(=O)c2cnc3C[C@]4(Cc3c2)C(=O)Nc5ncccc45)C(=O)N1CC(F)(F)F)c6c(F)ccc(F)c6F	PLASMA	7CRV8RR151							24		t	ng × h/mL	1830		ng/mL	271			RECOMMENDED	mg	30		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215206Orig1s000IntegratedR.pdf#page=31	Homo sapiens				popPK	Patients with episodic migraines dosed with or without food					false
11128	59547		ADULT	72163100	603.5207	ATOGEPANT		C[C@@H]1[C@@H](C[C@H](NC(=O)c2cnc3C[C@]4(Cc3c2)C(=O)Nc5ncccc45)C(=O)N1CC(F)(F)F)c6c(F)ccc(F)c6F	PLASMA	7CRV8RR151							24		t	ng × h/mL	3740		ng/mL	561			RECOMMENDED	mg	60		STEADY-STATE	UNKNOWN		day	1			UNHEALTHY	Oral	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215206Orig1s000IntegratedR.pdf#page=31	Homo sapiens				popPK	Patients with episodic migraines dosed with or without food					false
11129	59547			72163100	603.5207	ATOGEPANT		C[C@@H]1[C@@H](C[C@H](NC(=O)c2cnc3C[C@]4(Cc3c2)C(=O)Nc5ncccc45)C(=O)N1CC(F)(F)F)c6c(F)ccc(F)c6F	PLASMA	7CRV8RR151																										Human plasma protein binding: 95% (0.1 to 10 microM)	5				OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215206Orig1s000IntegratedR.pdf#page=32 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215206Orig1s000IntegratedR.pdf#page=158	Homo sapiens										false
11130	59548		ADULT	156588324	4813	TIRZEPATIDE		CCC(C)C(C(=O)NC(C)C(=O)NC(CCC(=O)N)C(=O)NC(CCCCN)C(=O)NC(C)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NCC(=O)NCC(=O)N4CCCC4C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N5CCCC5C(=O)N6CCCC6C(=O)N7CCCC7C(=O)NC(CO)C(=O)N)NC(=O)C(CCCCNC(=O)CCCCCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCOCCOCC(=O)NCCOCCOCC(=O)O)C(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C)(C)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(CC8=CC=C(C=C8)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC9=CC=CC=C9)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC1=CC=C(C=C1)O)N	PLASMA	OYN3CCI6QE									∞	ng × h/mL	53200		ng/mL	231			RECOMMENDED	mg	2.5		SINGLE	UNKNOWN						HEALTHY	Subcutaneous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215866Orig1s000ClinPharmR.pdf#page=19	Homo sapiens		h	120				6			false
11131	59548		ADULT	156588324	4813	TIRZEPATIDE		CCC(C)C(C(=O)NC(C)C(=O)NC(CCC(=O)N)C(=O)NC(CCCCN)C(=O)NC(C)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NCC(=O)NCC(=O)N4CCCC4C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N5CCCC5C(=O)N6CCCC6C(=O)N7CCCC7C(=O)NC(CO)C(=O)N)NC(=O)C(CCCCNC(=O)CCCCCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCOCCOCC(=O)NCCOCCOCC(=O)O)C(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C)(C)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(CC8=CC=C(C=C8)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC9=CC=CC=C9)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC1=CC=C(C=C1)O)N	PLASMA	OYN3CCI6QE							168		t	ng × h/mL	10600		ng/mL	77.8			UNKNOWN	mg	0.5		MULTIPLE	UNKNOWN		week	1			HEALTHY	Subcutaneous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215866Orig1s000ClinPharmR.pdf#page=19	Homo sapiens		h	152	Day 22			4			false
11132	59548		ADULT	156588324	4813	TIRZEPATIDE		CCC(C)C(C(=O)NC(C)C(=O)NC(CCC(=O)N)C(=O)NC(CCCCN)C(=O)NC(C)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NCC(=O)NCC(=O)N4CCCC4C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N5CCCC5C(=O)N6CCCC6C(=O)N7CCCC7C(=O)NC(CO)C(=O)N)NC(=O)C(CCCCNC(=O)CCCCCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCOCCOCC(=O)NCCOCCOCC(=O)O)C(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C)(C)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(CC8=CC=C(C=C8)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC9=CC=CC=C9)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC1=CC=C(C=C1)O)N	PLASMA	OYN3CCI6QE									∞	ng × h/mL	22600		ng/mL	108			UNKNOWN	mg	1		SINGLE	UNKNOWN						HEALTHY	Subcutaneous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215866Orig1s000ClinPharmR.pdf#page=19	Homo sapiens		h	108				5			false
11133	59548		ADULT	156588324	4813	TIRZEPATIDE		CCC(C)C(C(=O)NC(C)C(=O)NC(CCC(=O)N)C(=O)NC(CCCCN)C(=O)NC(C)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NCC(=O)NCC(=O)N4CCCC4C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N5CCCC5C(=O)N6CCCC6C(=O)N7CCCC7C(=O)NC(CO)C(=O)N)NC(=O)C(CCCCNC(=O)CCCCCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCOCCOCC(=O)NCCOCCOCC(=O)O)C(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C)(C)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(CC8=CC=C(C=C8)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC9=CC=CC=C9)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC1=CC=C(C=C1)O)N	PLASMA	OYN3CCI6QE									∞	ng × h/mL	90500		ng/mL	397			UNKNOWN	mg	5		SINGLE	UNKNOWN						HEALTHY	Subcutaneous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215866Orig1s000ClinPharmR.pdf#page=19	Homo sapiens		h	123				5			false
11134	59548		ADULT	156588324	4813	TIRZEPATIDE		CCC(C)C(C(=O)NC(C)C(=O)NC(CCC(=O)N)C(=O)NC(CCCCN)C(=O)NC(C)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NCC(=O)NCC(=O)N4CCCC4C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N5CCCC5C(=O)N6CCCC6C(=O)N7CCCC7C(=O)NC(CO)C(=O)N)NC(=O)C(CCCCNC(=O)CCCCCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCOCCOCC(=O)NCCOCCOCC(=O)O)C(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C)(C)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(CC8=CC=C(C=C8)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC9=CC=CC=C9)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC1=CC=C(C=C1)O)N	PLASMA	OYN3CCI6QE							168		t	ng × h/mL	24800		ng/mL	198			UNKNOWN	mg	1.5		MULTIPLE	UNKNOWN		week	1			HEALTHY	Subcutaneous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215866Orig1s000ClinPharmR.pdf#page=19	Homo sapiens		h	113	Day 22			5			false
11135	59548		ADULT	156588324	4813	TIRZEPATIDE		CCC(C)C(C(=O)NC(C)C(=O)NC(CCC(=O)N)C(=O)NC(CCCCN)C(=O)NC(C)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NCC(=O)NCC(=O)N4CCCC4C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N5CCCC5C(=O)N6CCCC6C(=O)N7CCCC7C(=O)NC(CO)C(=O)N)NC(=O)C(CCCCNC(=O)CCCCCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCOCCOCC(=O)NCCOCCOCC(=O)O)C(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C)(C)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(CC8=CC=C(C=C8)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC9=CC=CC=C9)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC1=CC=C(C=C1)O)N	PLASMA	OYN3CCI6QE									∞	ng × h/mL	169000		ng/mL	874			UNKNOWN	mg	8		SINGLE	UNKNOWN						HEALTHY	Subcutaneous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215866Orig1s000ClinPharmR.pdf#page=19	Homo sapiens		h	111				7			false
11136	59548		ADULT	156588324	4813	TIRZEPATIDE		CCC(C)C(C(=O)NC(C)C(=O)NC(CCC(=O)N)C(=O)NC(CCCCN)C(=O)NC(C)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NCC(=O)NCC(=O)N4CCCC4C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N5CCCC5C(=O)N6CCCC6C(=O)N7CCCC7C(=O)NC(CO)C(=O)N)NC(=O)C(CCCCNC(=O)CCCCCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCOCCOCC(=O)NCCOCCOCC(=O)O)C(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C)(C)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(CC8=CC=C(C=C8)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC9=CC=CC=C9)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC1=CC=C(C=C1)O)N	PLASMA	OYN3CCI6QE							168		t	ng × h/mL	103000		ng/mL	884			UNKNOWN	mg	4.5		MULTIPLE	UNKNOWN		week	1			HEALTHY	Subcutaneous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215866Orig1s000ClinPharmR.pdf#page=19	Homo sapiens		h	132	Day 22			6			false
11137	59548		ADULT	156588324	4813	TIRZEPATIDE		CCC(C)C(C(=O)NC(C)C(=O)NC(CCC(=O)N)C(=O)NC(CCCCN)C(=O)NC(C)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NCC(=O)NCC(=O)N4CCCC4C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N5CCCC5C(=O)N6CCCC6C(=O)N7CCCC7C(=O)NC(CO)C(=O)N)NC(=O)C(CCCCNC(=O)CCCCCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCOCCOCC(=O)NCCOCCOCC(=O)O)C(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C)(C)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(CC8=CC=C(C=C8)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC9=CC=CC=C9)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC1=CC=C(C=C1)O)N	PLASMA	OYN3CCI6QE							168		t	ng × h/mL	198000		ng/mL	1510			UNKNOWN	mg	5		MULTIPLE	UNKNOWN		week	1			HEALTHY	Subcutaneous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215866Orig1s000ClinPharmR.pdf#page=19	Homo sapiens		h	126	Day 22 (Day 1 and 8: 5mg; Day 15: 8mg; Day 22: 10mg)			4			false
11138	59548		ADULT	156588324	4813	TIRZEPATIDE		CCC(C)C(C(=O)NC(C)C(=O)NC(CCC(=O)N)C(=O)NC(CCCCN)C(=O)NC(C)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NCC(=O)NCC(=O)N4CCCC4C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N5CCCC5C(=O)N6CCCC6C(=O)N7CCCC7C(=O)NC(CO)C(=O)N)NC(=O)C(CCCCNC(=O)CCCCCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCOCCOCC(=O)NCCOCCOCC(=O)O)C(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C)(C)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(CC8=CC=C(C=C8)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC9=CC=CC=C9)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC1=CC=C(C=C1)O)N	PLASMA	OYN3CCI6QE									∞	ng × h/mL	12000		ng/mL	57.7			UNKNOWN	mg	0.5		SINGLE	UNKNOWN						HEALTHY	Subcutaneous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215866Orig1s000ClinPharmR.pdf#page=19	Homo sapiens		h	124				12			false
11139	59548		ADULT	156588324	4813	TIRZEPATIDE		CCC(C)C(C(=O)NC(C)C(=O)NC(CCC(=O)N)C(=O)NC(CCCCN)C(=O)NC(C)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NCC(=O)NCC(=O)N4CCCC4C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N5CCCC5C(=O)N6CCCC6C(=O)N7CCCC7C(=O)NC(CO)C(=O)N)NC(=O)C(CCCCNC(=O)CCCCCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCOCCOCC(=O)NCCOCCOCC(=O)O)C(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C)(C)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(CC8=CC=C(C=C8)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC9=CC=CC=C9)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC1=CC=C(C=C1)O)N	PLASMA	OYN3CCI6QE									∞	ng × h/mL	5760		ng/mL	26			UNKNOWN	mg	0.25		SINGLE	UNKNOWN						HEALTHY	Subcutaneous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215866Orig1s000ClinPharmR.pdf#page=19	Homo sapiens		h	116				6			false
11140	59548		ADULT	156588324	4813	TIRZEPATIDE		CCC(C)C(C(=O)NC(C)C(=O)NC(CCC(=O)N)C(=O)NC(CCCCN)C(=O)NC(C)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NCC(=O)NCC(=O)N4CCCC4C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N5CCCC5C(=O)N6CCCC6C(=O)N7CCCC7C(=O)NC(CO)C(=O)N)NC(=O)C(CCCCNC(=O)CCCCCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCOCCOCC(=O)NCCOCCOCC(=O)O)C(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C)(C)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(CC8=CC=C(C=C8)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC9=CC=CC=C9)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC1=CC=C(C=C1)O)N	PLASMA	OYN3CCI6QE							168		t	ng × h/mL	7200		ng/mL	54.6			UNKNOWN	mg	0.5		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Subcutaneous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215866Orig1s000ClinPharmR.pdf#page=20	Homo sapiens		h	120	Day 22	Patients with T2DM		9			false
11141	59548		ADULT	156588324	4813	TIRZEPATIDE		CCC(C)C(C(=O)NC(C)C(=O)NC(CCC(=O)N)C(=O)NC(CCCCN)C(=O)NC(C)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NCC(=O)NCC(=O)N4CCCC4C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N5CCCC5C(=O)N6CCCC6C(=O)N7CCCC7C(=O)NC(CO)C(=O)N)NC(=O)C(CCCCNC(=O)CCCCCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCOCCOCC(=O)NCCOCCOCC(=O)O)C(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C)(C)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(CC8=CC=C(C=C8)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC9=CC=CC=C9)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC1=CC=C(C=C1)O)N	PLASMA	OYN3CCI6QE							168		t	ng × h/mL	81900		ng/mL	614			UNKNOWN	mg	5		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Subcutaneous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215866Orig1s000ClinPharmR.pdf#page=20	Homo sapiens		h	114	Day 22	Patients with T2DM		6			false
11142	59548		ADULT	156588324	4813	TIRZEPATIDE		CCC(C)C(C(=O)NC(C)C(=O)NC(CCC(=O)N)C(=O)NC(CCCCN)C(=O)NC(C)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NCC(=O)NCC(=O)N4CCCC4C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N5CCCC5C(=O)N6CCCC6C(=O)N7CCCC7C(=O)NC(CO)C(=O)N)NC(=O)C(CCCCNC(=O)CCCCCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCOCCOCC(=O)NCCOCCOCC(=O)O)C(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C)(C)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(CC8=CC=C(C=C8)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC9=CC=CC=C9)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC1=CC=C(C=C1)O)N	PLASMA	OYN3CCI6QE							168		t	ng × h/mL	131000		ng/mL	1030			UNKNOWN	mg	5		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Subcutaneous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215866Orig1s000ClinPharmR.pdf#page=20	Homo sapiens		h	115	Day 22 (5.0/5.0/10.0/10.0 mg)	Patients with T2DM		12			false
11143	59548		ADULT	156588324	4813	TIRZEPATIDE		CCC(C)C(C(=O)NC(C)C(=O)NC(CCC(=O)N)C(=O)NC(CCCCN)C(=O)NC(C)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NCC(=O)NCC(=O)N4CCCC4C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N5CCCC5C(=O)N6CCCC6C(=O)N7CCCC7C(=O)NC(CO)C(=O)N)NC(=O)C(CCCCNC(=O)CCCCCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCOCCOCC(=O)NCCOCCOCC(=O)O)C(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C)(C)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(CC8=CC=C(C=C8)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC9=CC=CC=C9)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC1=CC=C(C=C1)O)N	PLASMA	OYN3CCI6QE							168		t	ng × h/mL	164000		ng/mL	1250			UNKNOWN	mg	5		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Subcutaneous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215866Orig1s000ClinPharmR.pdf#page=20	Homo sapiens		h	104	Day 22 (5.0/5.0/10.0/15.0 mg)	Patients with T2DM		10			false
11144	59548		ADULT	156588324	4813	TIRZEPATIDE		CCC(C)C(C(=O)NC(C)C(=O)NC(CCC(=O)N)C(=O)NC(CCCCN)C(=O)NC(C)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NCC(=O)NCC(=O)N4CCCC4C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N5CCCC5C(=O)N6CCCC6C(=O)N7CCCC7C(=O)NC(CO)C(=O)N)NC(=O)C(CCCCNC(=O)CCCCCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCOCCOCC(=O)NCCOCCOCC(=O)O)C(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C)(C)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(CC8=CC=C(C=C8)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC9=CC=CC=C9)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC1=CC=C(C=C1)O)N	PLASMA	OYN3CCI6QE							168		t	ng × h/mL	192000		ng/mL	1520			UNKNOWN	mg	2.5		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Subcutaneous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215866Orig1s000ClinPharmR.pdf#page=23	Homo sapiens		h	135	Day 50 (2.5mg Weeks 1 to 2; 5mg Weeks 3 to 4; 10mg Weeks 5 to 8)	Japanese patients with T2DM		11			false
11145	59548		ADULT	156588324	4813	TIRZEPATIDE		CCC(C)C(C(=O)NC(C)C(=O)NC(CCC(=O)N)C(=O)NC(CCCCN)C(=O)NC(C)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NCC(=O)NCC(=O)N4CCCC4C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N5CCCC5C(=O)N6CCCC6C(=O)N7CCCC7C(=O)NC(CO)C(=O)N)NC(=O)C(CCCCNC(=O)CCCCCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCOCCOCC(=O)NCCOCCOCC(=O)O)C(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C)(C)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(CC8=CC=C(C=C8)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC9=CC=CC=C9)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC1=CC=C(C=C1)O)N	PLASMA	OYN3CCI6QE							168		t	ng × h/mL	285000		ng/mL	2270			UNKNOWN	mg	5		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Subcutaneous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215866Orig1s000ClinPharmR.pdf#page=23	Homo sapiens		h	121	Day 50 (5mg Weeks 1 to 2; 10mg Weeks 3 to 6; 15mg Weeks 7 to 8)	Japanese patients with T2DM		12			false
11146	59548		ADULT	156588324	4813	TIRZEPATIDE		CCC(C)C(C(=O)NC(C)C(=O)NC(CCC(=O)N)C(=O)NC(CCCCN)C(=O)NC(C)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NCC(=O)NCC(=O)N4CCCC4C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N5CCCC5C(=O)N6CCCC6C(=O)N7CCCC7C(=O)NC(CO)C(=O)N)NC(=O)C(CCCCNC(=O)CCCCCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCOCCOCC(=O)NCCOCCOCC(=O)O)C(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C)(C)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(CC8=CC=C(C=C8)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC9=CC=CC=C9)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC1=CC=C(C=C1)O)N	PLASMA	OYN3CCI6QE							168		t	ng × h/mL	104000		ng/mL	838			UNKNOWN	mg	5		MULTIPLE	UNKNOWN		week	1			UNHEALTHY	Subcutaneous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215866Orig1s000ClinPharmR.pdf#page=23	Homo sapiens		h	127	Day 50	Japanese patients with T2DM		11			false
11147	59548		ADULT	156588324	4813	TIRZEPATIDE		CCC(C)C(C(=O)NC(C)C(=O)NC(CCC(=O)N)C(=O)NC(CCCCN)C(=O)NC(C)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NCC(=O)NCC(=O)N4CCCC4C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N5CCCC5C(=O)N6CCCC6C(=O)N7CCCC7C(=O)NC(CO)C(=O)N)NC(=O)C(CCCCNC(=O)CCCCCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCOCCOCC(=O)NCCOCCOCC(=O)O)C(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C)(C)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(CC8=CC=C(C=C8)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC9=CC=CC=C9)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC1=CC=C(C=C1)O)N	PLASMA	OYN3CCI6QE							168		t	ng × h/mL	68900		ng/mL	663			UNKNOWN	mg	5		MULTIPLE	UNKNOWN		week	1			HEALTHY	Subcutaneous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215866Orig1s000ClinPharmR.pdf#page=26	Homo sapiens				Day 1 (5mg Weeks 1 to 2, 7.5mg Week 3, 10mg Week 10)			12			false
11148	59548		ADULT	156588324	4813	TIRZEPATIDE		CCC(C)C(C(=O)NC(C)C(=O)NC(CCC(=O)N)C(=O)NC(CCCCN)C(=O)NC(C)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NCC(=O)NCC(=O)N4CCCC4C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N5CCCC5C(=O)N6CCCC6C(=O)N7CCCC7C(=O)NC(CO)C(=O)N)NC(=O)C(CCCCNC(=O)CCCCCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCOCCOCC(=O)NCCOCCOCC(=O)O)C(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C)(C)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(CC8=CC=C(C=C8)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC9=CC=CC=C9)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC1=CC=C(C=C1)O)N	PLASMA	OYN3CCI6QE							168		t	ng × h/mL	149000		ng/mL	1270			UNKNOWN	mg	7.5		MULTIPLE	UNKNOWN		week	1			HEALTHY	Subcutaneous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215866Orig1s000ClinPharmR.pdf#page=26	Homo sapiens				Day 15 (5mg Weeks 1 to 2, 7.5mg Week 3, 10mg Week 10)			12			false
11149	59548		ADULT	156588324	4813	TIRZEPATIDE		CCC(C)C(C(=O)NC(C)C(=O)NC(CCC(=O)N)C(=O)NC(CCCCN)C(=O)NC(C)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NCC(=O)NCC(=O)N4CCCC4C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N5CCCC5C(=O)N6CCCC6C(=O)N7CCCC7C(=O)NC(CO)C(=O)N)NC(=O)C(CCCCNC(=O)CCCCCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCOCCOCC(=O)NCCOCCOCC(=O)O)C(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C)(C)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(CC8=CC=C(C=C8)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC9=CC=CC=C9)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC1=CC=C(C=C1)O)N	PLASMA	OYN3CCI6QE													ng/mL	1900			UNKNOWN	mg	10		MULTIPLE	UNKNOWN		week	1			HEALTHY	Subcutaneous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215866Orig1s000ClinPharmR.pdf#page=26	Homo sapiens				Day 22 (5mg Weeks 1 to 2, 7.5mg Week 3, 10mg Week 10)			11			false
11150	59548		UNKNOWN	156588324	4813	TIRZEPATIDE		CCC(C)C(C(=O)NC(C)C(=O)NC(CCC(=O)N)C(=O)NC(CCCCN)C(=O)NC(C)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NCC(=O)NCC(=O)N4CCCC4C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N5CCCC5C(=O)N6CCCC6C(=O)N7CCCC7C(=O)NC(CO)C(=O)N)NC(=O)C(CCCCNC(=O)CCCCCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCOCCOCC(=O)NCCOCCOCC(=O)O)C(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C)(C)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(CC8=CC=C(C=C8)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC9=CC=CC=C9)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC1=CC=C(C=C1)O)N	PLASMA	OYN3CCI6QE																	UNKNOWN	mg	5		SINGLE	UNKNOWN						UNHEALTHY	Subcutaneous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215866Orig1s000ClinPharmR.pdf#page=4 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215866Orig1s000ClinPharmR.pdf#page=9	Homo sapiens		day	5		Patients with T2DM					false
11151	59548		ADULT	156588324	4813	TIRZEPATIDE		CCC(C)C(C(=O)NC(C)C(=O)NC(CCC(=O)N)C(=O)NC(CCCCN)C(=O)NC(C)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NCC(=O)NCC(=O)N4CCCC4C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N5CCCC5C(=O)N6CCCC6C(=O)N7CCCC7C(=O)NC(CO)C(=O)N)NC(=O)C(CCCCNC(=O)CCCCCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCOCCOCC(=O)NCCOCCOCC(=O)O)C(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C)(C)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(CC8=CC=C(C=C8)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC9=CC=CC=C9)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC1=CC=C(C=C1)O)N	PLASMA	OYN3CCI6QE									?	ng × h/mL	83300		ng/mL	664			UNKNOWN	mg	5		STEADY-STATE	UNKNOWN		week	1			UNHEALTHY	Subcutaneous	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215866Orig1s000ClinPharmR.pdf#page=9	Homo sapiens				popPK	Patients with T2DM					false
11152	59548		ADULT	156588324	4813	TIRZEPATIDE		CCC(C)C(C(=O)NC(C)C(=O)NC(CCC(=O)N)C(=O)NC(CCCCN)C(=O)NC(C)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NCC(=O)NCC(=O)N4CCCC4C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N5CCCC5C(=O)N6CCCC6C(=O)N7CCCC7C(=O)NC(CO)C(=O)N)NC(=O)C(CCCCNC(=O)CCCCCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCOCCOCC(=O)NCCOCCOCC(=O)O)C(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C)(C)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(CC8=CC=C(C=C8)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC9=CC=CC=C9)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC1=CC=C(C=C1)O)N	PLASMA	OYN3CCI6QE									?	ng × h/mL	168000		ng/mL	1340			UNKNOWN	mg	10		STEADY-STATE	UNKNOWN		week	1			UNHEALTHY	Subcutaneous	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215866Orig1s000ClinPharmR.pdf#page=9	Homo sapiens				popPK	Patients with T2DM					false
11153	59548		ADULT	156588324	4813	TIRZEPATIDE		CCC(C)C(C(=O)NC(C)C(=O)NC(CCC(=O)N)C(=O)NC(CCCCN)C(=O)NC(C)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NCC(=O)NCC(=O)N4CCCC4C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N5CCCC5C(=O)N6CCCC6C(=O)N7CCCC7C(=O)NC(CO)C(=O)N)NC(=O)C(CCCCNC(=O)CCCCCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCOCCOCC(=O)NCCOCCOCC(=O)O)C(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C)(C)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(CC8=CC=C(C=C8)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC9=CC=CC=C9)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC1=CC=C(C=C1)O)N	PLASMA	OYN3CCI6QE									?	ng × h/mL	250000		ng/mL	1990			UNKNOWN	mg	15		STEADY-STATE	UNKNOWN		week	1			UNHEALTHY	Subcutaneous	FEMALE / MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215866Orig1s000ClinPharmR.pdf#page=9	Homo sapiens				popPK	Patients with T2DM					false
11154	59548			156588324	4813	TIRZEPATIDE		CCC(C)C(C(=O)NC(C)C(=O)NC(CCC(=O)N)C(=O)NC(CCCCN)C(=O)NC(C)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NCC(=O)NCC(=O)N4CCCC4C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N5CCCC5C(=O)N6CCCC6C(=O)N7CCCC7C(=O)NC(CO)C(=O)N)NC(=O)C(CCCCNC(=O)CCCCCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCOCCOCC(=O)NCCOCCOCC(=O)O)C(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C)(C)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(CC8=CC=C(C=C8)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC9=CC=CC=C9)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC1=CC=C(C=C1)O)N	PLASMA	OYN3CCI6QE																										Human plasma protein binding (florescence polarization (fp) method): 99.06% (98.64% to 99.30%)	0.94				OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215866Orig1s000PharmR.pdf#page=28 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215866Orig1s000ClinPharmR.pdf#page=34	Homo sapiens										false
11155	59549		ADULT	16223405	970.1	Gadopiclenol	Gadopiclenol	C1CN(CC2=NC(=CC=C2)CN(CCN1C(CCC(=O)NCC(CO)O)C(=O)[O-])C(CCC(=O)NCC(CO)O)C(=O)[O-])C(CCC(=O)NCC(CO)O)C(=O)[O-].[Gd 3]	PLASMA	S276568KOY									∞	μg × h/mL	1113						RECOMMENDED	mmol/kg	0.1		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/216986Orig1s000MultidisciplineR.pdf#page=101 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216986s000lbl.pdf#page=11	Homo sapiens		h	1.9		Normal renal function (eGFR >=90 mL/min)		8			false
11156	59549		ADULT	16223405	970.1	Gadopiclenol	Gadopiclenol	C1CN(CC2=NC(=CC=C2)CN(CCN1C(CCC(=O)NCC(CO)O)C(=O)[O-])C(CCC(=O)NCC(CO)O)C(=O)[O-])C(CCC(=O)NCC(CO)O)C(=O)[O-].[Gd 3]	PLASMA	S276568KOY									∞	μg × h/mL	1711						RECOMMENDED	mmol/kg	0.1		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/216986Orig1s000MultidisciplineR.pdf#page=101 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216986s000lbl.pdf#page=11	Homo sapiens		h	3.3		Mild renal impairment (eGFR 60 to <90 mL/min)		8			false
11157	59549		ADULT	16223405	970.1	Gadopiclenol	Gadopiclenol	C1CN(CC2=NC(=CC=C2)CN(CCN1C(CCC(=O)NCC(CO)O)C(=O)[O-])C(CCC(=O)NCC(CO)O)C(=O)[O-])C(CCC(=O)NCC(CO)O)C(=O)[O-].[Gd 3]	PLASMA	S276568KOY									∞	μg × h/mL	2759						RECOMMENDED	mmol/kg	0.1		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/216986Orig1s000MultidisciplineR.pdf#page=101 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216986s000lbl.pdf#page=11	Homo sapiens		h	3.8		Moderate renal impairment (eGFR 30 to <60 mL/min)		8			false
11158	59549		ADULT	16223405	970.1	Gadopiclenol	Gadopiclenol	C1CN(CC2=NC(=CC=C2)CN(CCN1C(CCC(=O)NCC(CO)O)C(=O)[O-])C(CCC(=O)NCC(CO)O)C(=O)[O-])C(CCC(=O)NCC(CO)O)C(=O)[O-].[Gd 3]	PLASMA	S276568KOY									∞	μg × h/mL	9671						RECOMMENDED	mmol/kg	0.1		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/216986Orig1s000MultidisciplineR.pdf#page=101 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216986s000lbl.pdf#page=11	Homo sapiens		h	11.7		Severe renal impairment (eGFR <30 mL/min)		8			false
11159	59549		UNKNOWN	16223405	970.1	Gadopiclenol	Gadopiclenol	C1CN(CC2=NC(=CC=C2)CN(CCN1C(CCC(=O)NCC(CO)O)C(=O)[O-])C(CCC(=O)NCC(CO)O)C(=O)[O-])C(CCC(=O)NCC(CO)O)C(=O)[O-].[Gd 3]	PLASMA	S276568KOY									∞	μg × h/mL	569		μg/mL	525			RECOMMENDED	mmol/kg	0.05		SINGLE	UNKNOWN				Protein binding of gadopiclenol is ≤1.8% at clinically relevant concentrations.	98.2	HEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/216986Orig1s000MultidisciplineR.pdf#page=93 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/216986Orig1s000MultidisciplineR.pdf#page=97	Homo sapiens		h	1.5				6			false
11160	59549		ADOLESCENT	16223405	970.1	Gadopiclenol	Gadopiclenol	C1CN(CC2=NC(=CC=C2)CN(CCN1C(CCC(=O)NCC(CO)O)C(=O)[O-])C(CCC(=O)NCC(CO)O)C(=O)[O-])C(CCC(=O)NCC(CO)O)C(=O)[O-].[Gd 3]	PLASMA	S276568KOY									∞	μg × h/mL	582						RECOMMENDED	mmol/kg	0.05		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/216986Orig1s000MultidisciplineR.pdf#page=99 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216986s000lbl.pdf#page=11	Homo sapiens		h	1.77		12-17 years		19			false
11161	59549		ADULT	16223405	970.1	Gadopiclenol	Gadopiclenol	C1CN(CC2=NC(=CC=C2)CN(CCN1C(CCC(=O)NCC(CO)O)C(=O)[O-])C(CCC(=O)NCC(CO)O)C(=O)[O-])C(CCC(=O)NCC(CO)O)C(=O)[O-].[Gd 3]	PLASMA	S276568KOY									∞	μg × h/mL	590						RECOMMENDED	mmol/kg	0.05		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/216986Orig1s000MultidisciplineR.pdf#page=99 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216986s000lbl.pdf#page=11	Homo sapiens		h	1.82		> 18 years		46			false
11162	59549		CHILD	16223405	970.1	Gadopiclenol	Gadopiclenol	C1CN(CC2=NC(=CC=C2)CN(CCN1C(CCC(=O)NCC(CO)O)C(=O)[O-])C(CCC(=O)NCC(CO)O)C(=O)[O-])C(CCC(=O)NCC(CO)O)C(=O)[O-].[Gd 3]	PLASMA	S276568KOY									∞	μg × h/mL	478						RECOMMENDED	mmol/kg	0.05		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/216986Orig1s000MultidisciplineR.pdf#page=99 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216986s000lbl.pdf#page=11	Homo sapiens		h	1.48		7-11 years		19			false
11163	59549		CHILD	16223405	970.1	Gadopiclenol	Gadopiclenol	C1CN(CC2=NC(=CC=C2)CN(CCN1C(CCC(=O)NCC(CO)O)C(=O)[O-])C(CCC(=O)NCC(CO)O)C(=O)[O-])C(CCC(=O)NCC(CO)O)C(=O)[O-].[Gd 3]	PLASMA	S276568KOY									∞	μg × h/mL	403						RECOMMENDED	mmol/kg	0.05		SINGLE	UNKNOWN						UNHEALTHY	Intravenous	UNKNOWN	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/216986Orig1s000MultidisciplineR.pdf#page=99 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216986s000lbl.pdf#page=11	Homo sapiens		h	1.29		2-6 years		19			false
11164	59550		ADULT	44230999	520.6	OMIDENEPAG ISOPROPYL	OMIDENEPAG ISOPROPYL	CC(C)OC(=O)CNC1=CC=CC(=N1)CN(CC2=CC=C(C=C2)N3C=CC=N3)S(=O)(=O)C4=CN=CC=C4	PLASMA	G0G0H52U6K									∞	pmol × h/mL	21.54		pg/mL	34.36			UNKNOWN	drop	1		MULTIPLE	UNKNOWN		day	1	Binding is independent of concentration between 2.5 and 20 ng/mL. equilibrium dialysis	2.2	HEALTHY	Ocular	MALE	OTHER GOV'T	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215092Orig1s000ClinPharmR.pdf#page=7 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215092Orig1s000ClinPharmR.pdf#page=15 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215092Orig1s000ClinPharmR.pdf#page=21	Homo sapiens		h	0.449	0.0025% ophthalmic solution, 1 drop into both eyes for 7 days	7 Japanese and 7 Caucasian, administered at 9:00 am		14			false
11165	59551		ADULT	138611145	604.1	Adagrasib	Adagrasib	CN1CCCC1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)C(=N2)N6CCN(C(C6)CC#N)C(=O)C(=C)F	PLASMA	8EOO6HQF8Y									∞	ng × h/mL	37139		ng/mL	984			RECOMMENDED	mg	600		SINGLE	FASTED				Human plasma protein binding of adagrasib is approximately 98% in vitro. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340s000lbl.pdf	2	UNHEALTHY	Oral	UNKNOWN	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/35167329/	Homo sapiens		h	23				1	ADAGRASIB		false
11166	59551		ADULT	138611145	604.1	Adagrasib	Adagrasib	CN1CCCC1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)C(=N2)N6CCN(C(C6)CC#N)C(=O)C(=C)F	PLASMA	8EOO6HQF8Y									?	ng × h/mL	31600		ng/mL	3253			RECOMMENDED	mg	600		STEADY-STATE	FASTED		day	2	Human plasma protein binding of adagrasib is approximately 98% in vitro. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340s000lbl.pdf	2	UNHEALTHY	Oral	FEMALE / MALE	EXPERIMENT	https://pubmed.ncbi.nlm.nih.gov/35167329/	Homo sapiens							7	ADAGRASIB		false
11167	59552		ADULT	118955396	354.8	OLUTASIDENIB	OLUTASIDENIB	CC(C1=CC2=C(C=CC(=C2)Cl)NC1=O)NC3=CC=C(N(C3=O)C)C#N	PLASMA	0T4IMT8S5Z							12		t	ng × h/mL	43050		ng/mL	3573			RECOMMENDED	mg	150		STEADY-STATE	UNKNOWN		day	2	The plasma protein binding of olutasidenib is approximately 93%.	7	UNHEALTHY	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf	Homo sapiens		h	67					OLUTASIDENIB		false
11168	59553		ADULT	133082658	1156.356	LENACAPAVIR	LENACAPAVIR	CCC(C)C(NC(=O)C(NC(=O)C(C)NC(=O)C1CCCN1C(=O)C(C)NC(=O)C(CS)NC(=O)C(C)NC(=O)C(CC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(N)CC(C)C)C(C)C)C(=O)NC(CCCNC(N)=N)C(O)=O	PLASMA	A9A0O6FB4H									∞	ng × h/mL	9220		ng/mL	26.8			UNKNOWN	mg	300		SINGLE	UNKNOWN				Plasma protein binding, % 99.8	0.2	HEALTHY	Oral	FEMALE / MALE	OTHER	https://www.hivandmore.de/kongresse/croi2021/slides/gilead/Jogiraju_LEN-PK-in-Hepatic-Impairment_CROI-2021_Poster-1315_Final.pdf	Homo sapiens		h	314				10	LENACAPAVIR		false
11169	59554		ADULT	129269915	479.4	PIRTOBRUTINIB	PIRTOBRUTINIB	CC(C(F)(F)F)N1C(=C(C(=N1)C2=CC=C(C=C2)CNC(=O)C3=C(C=CC(=C3)F)OC)C(=O)N)N	PLASMA	JNA39I7ZVB									?	ng × h/mL	91300		ng/mL	6460			RECOMMENDED	mg	200		STEADY-STATE	UNKNOWN		day	1	Human protein binding of pirtobrutinib is 96%\nand is independent of concentration in vitro.	4	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216059Orig1s000Corrected_lbl.pdf	Homo sapiens		h	19					PIRTOBRUTINIB		false
11170	59554		ADULT	129269915	479.4	PIRTOBRUTINIB	PIRTOBRUTINIB	CC(C(F)(F)F)N1C(=C(C(=N1)C2=CC=C(C=C2)CNC(=O)C3=C(C=CC(=C3)F)OC)C(=O)N)N	PLASMA	JNA39I7ZVB							24		t	ng × h/mL	81800		ng/mL	3670			RECOMMENDED	mg	200		SINGLE	UNKNOWN				Human protein binding of pirtobrutinib is 96%\nand is independent of concentration in vitro.	4	UNKNOWN	Oral	UNKNOWN	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216059Orig1s000Corrected_lbl.pdf	Homo sapiens		h	19					PIRTOBRUTINIB		false
